<SEC-DOCUMENT>0001628280-22-008842.txt : 20220408
<SEC-HEADER>0001628280-22-008842.hdr.sgml : 20220408
<ACCEPTANCE-DATETIME>20220408170628
ACCESSION NUMBER:		0001628280-22-008842
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		166
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220408
DATE AS OF CHANGE:		20220408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		22817787

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>nbx-20211231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a,d:377d9717844147e799376babda10462f--><html xmlns:nbx="http://nanobiotix.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV8zLTEtMS0xLTExOTk5_1dda997e-375e-4d4e-9d67-b5330f3c7f78">0001760854</ix:nonNumeric><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV80LTEtMS0xLTExOTk5_bbe421ef-295e-4355-9fbc-d40c1018f705">2021</ix:nonNumeric><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV81LTEtMS0xLTExOTk5_b4f6ecbb-c5e3-4bb1-86ae-1b2843116d39">FY</ix:nonNumeric><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV82LTEtMS0xLTExOTk5_a6f32501-1ca2-4bd9-8f54-2bfe222b12d9">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:NoTradingSymbolFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV83LTEtMS0xLTgwMTUy_64867d8a-0129-4f1f-aa8f-bfb5118d230f">TRUE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="if17a2f2e90aa4abfa844349f8bbeffdd_D20210420-20210420" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NDI_b6d1ab61-248d-489f-b8db-8ba6f3e01cd0">.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id8d3dbb65e224379b7a93e55ca7be0c4_D20210420-20210420" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NTc_d8adfe99-3e02-48e9-9c69-e1e3dbc80b5b">.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if2dd11d82dad4017b9e787f657b62484_D20210420-20210420" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NzI_d1597e81-3e58-49ac-b721-28d4a5009159">.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9ca1834853e14961be45fc7a1f5a71d2_D20200311-20200311" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzY0_d9b20358-8953-4463-9179-9d7adb90635b">.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3980c93822e74e5291bc063308f06aee_D20200311-20200311" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzEzMw_2ef548ad-5852-4638-8e16-835d4d6b527d">.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3b902764e68a4c7ca60c0b4162e645fd_D20200311-20200311" decimals="4" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzIxMQ_06992599-c9eb-46ca-a946-bf14f87f19af">.3333</ix:nonFraction><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DefinedBenefitObligationPayablePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzk_e3c5a367-0c4d-4262-b3f1-35ea622dad92">P5Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i0e5a3763fc65486f85e8d7953a8d5b82_D20200317-20200317" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzEz_3bc3b12d-83c6-4365-8b9c-0ddaa7d9e357">0.13</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie13f58ebae684d3a9931caa0b61af23e_D20200317-20200317" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzE5_5a737926-08c9-4448-b678-9588fb8ad5dd">0.07</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0NjM_3528a10d-8dc7-41af-9286-357ec34972e5">0.38</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0NTU_f4629138-ffe6-4e7f-a972-88b7a840dd85">0.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1NDY_77cd5865-102b-4753-89dd-1a6200edff3a">0.28</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0OTc_17f17278-681c-4b4a-9d47-5f87085e2fea">0.35</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621" decimals="3" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1MTI_7d366768-49b0-4a41-b3e1-48475e35e611">0.3</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1NjE_b5a1c3ca-69f3-4049-bbd8-47de4850cb2b">0.26</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if631599c27df453a8c0ab011671a4c75_D20200311-20200311" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMy_cfc2bd88-f5f7-4ec5-bd34-decad6d14f85">0.74</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib1ee66f5e8304133a7dea90f9c6c7899_D20200311-20200311" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzM4_532341f7-df2a-4a08-93aa-46f7d933d173">0.69</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic9fa057bcb1a4c2e9c49ddc99225a69e_D20210420-20210420" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODMzOTY_1dbd6775-0578-4491-8c93-d78c2d2d8037">0.63</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i61ac332477d243c19cdd74fe9fc3ff31_D20210420-20210420" decimals="4" sign="-" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0MTE_5f8c6b5a-dd56-4360-86b2-e989dff768d4">0.59</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">nbx:AmericanDepositorySharesNASDAQStockMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ef069d6d904f1cbf20114a97bea67a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ief56ec2bd42a44a6a729bc2731655345_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120ec80e331e46b4a8d8c2e900c322ce_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9dafc6f49b842eab8640526d732bb38_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086600f2d4fd4f29b9e0175fa9980649_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215f01165ded46dda75650b910df1253_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5767bd39bba43819d6569d194f2f1d6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb077c12bc264a7ab30586528053d5b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9373d1667a940b68a4392136b2737e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec4369f4c7649dba76e50278de42760_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2f48357d7645e5a28e6091cc904770_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib450eccc21d24368a1877065c5e022e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b268f53590247bcb64f8ce92ed3144d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91c813e0c574310a2f8c983ce2042ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58665d50b9245cbb263201dd383577d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05eefb483e484cf597b3e3872a255374_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aad128401e440c58786e8375faef035_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4b95efdee94328b574c4dd5a972a78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia680b82130144ad9af8419938ca05856_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e365c4a4f144b5e87711257c20e4830_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e4260d8f2204ff1897746ec6304ec1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da366d77c294b75876c03db3346763e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead84a7b542a49db9faee4780fc37284_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0283091d6704f18a2ff733acf943ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida63773549fb469180532f7bff7a9b6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d7277ffa0b489fa8a0f3ad5aa861e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i919a1afd086a4da19822485db27af8c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if46cc205e82045279e50f91253f8ea1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fbf747738f94b4484ec6e4bf65b8025_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4221b386b8a41008368fa79a2422241_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4324070196a42ce81514023ff835c69_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="study"><xbrli:measure>nbx:study</xbrli:measure></xbrli:unit><xbrli:context id="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf991456c15f4bd0beed8a02658e4984_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="parent_entity"><xbrli:measure>nbx:parent_entity</xbrli:measure></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>nbx:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b5f453227ff4a7692568ee182571454_I20120831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0383e3a745c6410a8ad6434d35604d24_D20120801-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-08-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib667123634854784a7a53e8925b6cdd7_D20210301-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66ef1f72fe74f22bed3a4ecb3ee2669_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08b49a302c4409797ed3baba0f7a8e2_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9f4e02188e458a98c73d7d32919183_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3f097755a84ae28952d3b990109fcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730862d53f524fd48823ccef1c727d85_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019a762512c74bd995f218b15c627c60_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0738eac499e4251a6854800b581173f_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>nbx:patient</xbrli:measure></xbrli:unit><xbrli:context id="ie86596994b614e61888621f5f63b3d95_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-03</xbrli:startDate><xbrli:endDate>2020-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i924453673b444fda9c3c28b015994d6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe58517db324e8ab08832232c673117_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e879f68f73480b92b03ede2c9ea8b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia618a699065e48f1b3d3352fbfb17118_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa32daece2d40c39f286dbb440ed1a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68188d7927a49d199519c9b6b2e7235_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e7f92a2efb4119907ab206e3174d4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4e681a419c4d16b32f5518228877ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b9b382940d4e8fa4efbc37ae851522_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7046c37f9b34feca0220aebcdc2b9d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c5ada34f4342ffbb24c0ed227de3b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00d268a8bc3d448db012d4136f9d9326_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3d1f32ff2c425093e40400c4b37239_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22135b3300e048769f42cc9088154762_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661079bae5984baa83e48cf8bf2e0ca0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3447f0049044af6945782db9521890b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643b965508bf43d4a88c27237bc3b7fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02245261c2374bc991f32f8bc9d1afd3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2713ac30115344d4be481a055affe757_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc87ab6886c14a47b7ebba0f7a2fe2cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd5dc377e504702bf04bf3db9a706ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857b522132a0476eb6dce6d1596820d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fc3134a84e4b788c49a537b36f4ea2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383069cd64164d36bf3be6f4fe694362_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45392436feb24c1ca988401841003b83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f0187d0a71420b849fd1c9efa74737_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740f5b7742a3429183c226bf413db5e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec3261b213d45b7859dea5fb22ef918_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3891cbb9d139409f926550e2d536f939_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081e0c1a8c8c4accb7e935ac897dcf77_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c487a257944224b5d370f39d0697cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia058d7b209a54f6fbe029cc8f59f7699_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada2ffdf9e7841edb4e55be9d4d3d033_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbefaf925c74b24a9922616c74a0553_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd3865bd72e4c6dabd994b9080949fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992fc55410f2432f87fb2d95d37cf5c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd26e64de5444c1f98cc675c204144c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d2744884e34de08bb1bf0f018e8367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifed0297807f94baea1c5c2d340771ee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c91a06314d44bbbde5e2e5d56195e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8472a834d7c6410ea1e767fc3c34d64b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i680d6b18b0404cd387ee4220cef45346_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc67e0cf8262400995ad31c3fea9c892_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6598955ac8a492fa0a7949b58b5e311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2612520a1a2840a7a26c63194c557e76_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f8b941671b4fc5b254babe62d0b548_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fe0f143f954dc68e1ffd022dae5517_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbf6a969f3a946aeb176967ed73299f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5e055bdd934a89b887335915deb655_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065694e284ad457594585f67d682acd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79cd2925606d4aafab7f52373500d486_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb76dbf343af4ef7a2d493513ebc63dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94439a4b662842c2acd86680522e2018_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81a7b8866e64bb5ab7ac45083f0107d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13580af0c9c0455c808971d25d9c62f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170ffb1f1c9a464dac427c1aae8b927a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b3ae8877e44bcea3e5d515c0c8b8d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb66730c4b2d424b843abc92b234a808_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26b0bf7b703446948688e7ad02d72cc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie783ca6ccd7146eab501b3c72da67598_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf55c96a01274951b50be727c673d9f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa642340f4542e7a93116c893889a2f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbdff15c03e7404a98464181c8e1cedd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa22cbb09f04242898c09c6ea3dc0bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3866b055ff984a8f95514cf68bf892bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic272971549af47d782e5f60383a7ecae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105222fe76b34ab481e711fb628a0ce9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf7ac359e404a6e813c1c0ebe727df5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb9257083bde4c48b34295c66106f1c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e0a92dd7344b67b577f12968b769f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c8eab481334a328766007df5fec6db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab30071042b444a9fac05b56e56f51c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20937f10c0074df48fcf6aae22f3d9fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260064a22ba34ca4a69fe812eb47df77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i910c9a241c624e01900913f0b0bdef46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i811a11b85e114a59b32992557918554f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease_contract"><xbrli:measure>nbx:lease_contract</xbrli:measure></xbrli:unit><xbrli:context id="ia7a4c79360f041e5886fda1753c164ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractOberkampfStreetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e3193487544206a16d163e6d8f920a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractFaubourgSaintAntoineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a5d032d32a4c5aa0906fe6968d960c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractAlfortvilleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8540a5ebd94096aee7b210cb09c5da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractParkingVillejuifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353ed3a135f54c7a972415594cd58a8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractWattigniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46249c3026ff4190a1f98baf898f61d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04209b08bf44c238d4f342e917d80c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbdf51ff17642c88fe93c80600f8cb4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694c290810ce4cc9842fae0c52f55511_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752591c410134e60bdd79d9b16eff052_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2c65d93df14f99b81bd99646ea83fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df395790ebc462db44260a48f7af4f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e942c5d9cf5421e8899afaab5b13ae1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937f4bc37d82433796fe6b3c4ec0ccb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589f8e8059664ca486811bb10b3d5162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b861ae5f68a416d8f8db4e710c14707_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b8abb72e0b4536a6fe80c714c03c32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a5ffbbe08f4f37926998b489baeab7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d57836a46444b38c01d05737626c40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75abd63d3d554d209254ec0fe3788db5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa06ae2654e494ca242be8b5638282c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6259fe63f29c47ceb1ee63617d3f873e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897163af67de42779bade9156e460371_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab0221939eca477097e1a9493a0df475_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6584aaa34740b0aea5f3a15d522bf5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b95576d1404490b4202945e6c02016_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc4df3987ae442da01b94c5efbf38f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0a8e1adc2f4d8daeb375e78b79e118_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2018TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea5a1f000274c7aa5aec8d463a011bd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2019TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3549effa38bf42068215a5f6e7f44599_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2019TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3d9c879e064e8595cbe98b04ca6d30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3f9bb9f0f14b24babfb6bd054d8acf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92e58618b784d11b24590f639ec3c5c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bd304d054954aa8889e0379a055b796_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-06</xbrli:startDate><xbrli:endDate>2020-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d2b59cd3394eb38b1112a6d40ba562_D20200306-20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-06</xbrli:startDate><xbrli:endDate>2020-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfcb03f93ca547db9f9c30453f57d130_D20200624-20200624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-24</xbrli:startDate><xbrli:endDate>2020-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd06ab95cb464cf7ab36d088f33b9b5c_D20200626-20200626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-26</xbrli:startDate><xbrli:endDate>2020-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibccb3f7b5d984a47977843563136cbfd_D20200629-20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1db8fdf89004094a84398a37852bd32_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5449b75fc7d4fbda4157cb2026ec2f5_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-28</xbrli:startDate><xbrli:endDate>2020-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-28</xbrli:startDate><xbrli:endDate>2020-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263948c1f81b493eb8cca425bcebfa1d_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61be2d4b393849cc9560e858d770a26c_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c448e8551854ba3817ac8e0588ff235_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e354131ae34438ad0ee61bab49371d_D20201216-20201216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-16</xbrli:startDate><xbrli:endDate>2020-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c6af94c36742b38cd4e03676b70d2e_D20201218-20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-18</xbrli:startDate><xbrli:endDate>2020-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-18</xbrli:startDate><xbrli:endDate>2020-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d5fe1d4b1c4217af0247979f91d136_D20201218-20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-18</xbrli:startDate><xbrli:endDate>2020-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-18</xbrli:startDate><xbrli:endDate>2020-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de9f777ee344fac809f90733d665d63_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b881b34146431e87bbf66200b0999b_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc02833837f240adba65b3984741f75d_D20210531-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-31</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9ad81b51bf4c808adb6b86c14e2b1b_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:InitialPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4304c8534859424ebd1d4888fc19dd31_D20190409-20190409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-09</xbrli:startDate><xbrli:endDate>2019-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a906e28a874a89ade36d6366ebe2af_D20190409-20190409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-09</xbrli:startDate><xbrli:endDate>2019-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57fc815199246ce8209d327ed4e9354_D20190409-20190409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-09</xbrli:startDate><xbrli:endDate>2019-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-18</xbrli:startDate><xbrli:endDate>2012-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294a61301bf542ec867f89a9f95e7c74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0205324a5c7d4615881636c0201fd64e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-08-28</xbrli:startDate><xbrli:endDate>2013-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5575b3f42d764a5dbad1316d83a15f52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-16</xbrli:startDate><xbrli:endDate>2014-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6164f9d60bc2408f8040f375730909e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650e54c23e864e5a9837d51c41b31a11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4bbee7b8464e3bbabeace3aa802581_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie08726f70e014e668fe8d3b22f627e3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7c12d22fc24156bb81feb9babf660b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib015ff2793a347eea190254523e266cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd0d6bab50d405cafa491285cc4f581_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c71468be56c45e99adce81f572af018_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic30eabe785c742e8b11a208b390d5b0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58d6cd769d14890874fc2f862b4fd1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7fa7d04b56046148c18d80e87276dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6315b11bee49a48773726a45aedbb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4574c0827bd436bb79456dc0389b57c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d9ddb730e24052933a829799eaa5b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218535f19cea498592b94ff4a7972768_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6119076476e4da0bce1c4d855f1ae02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddede090f4d14469a738de2cd2066a57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a7c7c748674e5b922e368dcd8635b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dd60f3a2d649f8b0d32174a89ec727_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec3ff678f124faa9cff8cf3e429be81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>nbx:employee</xbrli:measure></xbrli:unit><xbrli:context id="i0dce03cc95974732b21be1bff36d224d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerExecutiveBoardMembersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-04</xbrli:startDate><xbrli:endDate>2012-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-04-10</xbrli:startDate><xbrli:endDate>2013-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510cfe19450a4049be49e84fad36335a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80ebbb46eb64299bfbf12da7eb08344_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-16</xbrli:startDate><xbrli:endDate>2014-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd5c20435184561a25fd67367fe177e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287ca2164109487e803ea58119f85b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd30db4dc68e4dcd81aa001f304ccf02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444894e06ef84e86916f0f43636239a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873a0cd9fb8c4033a253afbd56030396_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ea1268150748fba93569448532c0ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15cc4f8cfe94884af5dec143cec0074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie729c807456a4342ae1d1ec7e0b01004_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac18bcb7a8e547b58905c1c5db99010c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic202005056b44f91afe160b576641e45_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe646b429ac44edb9d5b3c79beecffdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd6514681b0542d6ad81d4e87b9026b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ec3b243e08547a7a32d94cc27e3f446_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1112922487994275ba7f128834f46d02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93dc071a53df4b658e48104f724a4d81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82aea750feb9452ea792b03a00878392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c32baad1d584e179d05334758196e37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie220c08e5abd4acc97a8dc56ed476133_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185c5465e4f54321893449f2ed13c945_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035962ed0e9a4ed88c5d0e27de65b632_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ec46661f19e44898198a21b96fcd9e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia215c2b217c345f5a90b27a71eb9f095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a196703767045b4aeaf86e08026e973_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffce4cb7839e46bf9d2e020d8104e671_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef0655661e64102ad08b456cde29404_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f2458d1e5f4672ac966ade528e91b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35f615a359f04a498a53989136de928e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d97c2e219d4ae29053a4b79902220a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590691d490654f4a9b933f3df5ec0da8_D20200317-20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb4ec8843e44af1897cc09338a3eca3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084aeefdb60241db94c5f459f1acd1e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525d2a7385a042e2ab94b0f0b95ba373_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84c12e1bb5740c281fb000429621cde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia368008e38064499b91b8e7a2b6fc5e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968789d68e624749aec48577df75436b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1ece5200db4069abd23c1d44f99b24_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243c3f4181bd408d943852138fc86c46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d44db1d1fd485190ead9f20de4e21d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d936b0e4f0c4c87887a0435daa8724b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i365d674525a9479c8b26b35aa085cdbe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b4ed0b8dd1a49078d6c857b4f238367_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637bf676e3a04e68824daeb6b1575335_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i459ca9e3f16d4cd781dff0c62bdaf84a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic842508dfcc549caa3953140c12e7710_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579df336feef41d99666585cbbcc7e99_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09df6772a877464aaef8a472647e85c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ac1b9334ed440281d6eb50aa0804a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bedcd322874e948f08ed1dc1e2b254_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4483ef3c39a64c83b928490f95c78902_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b320a95d374a8ba1b1f5bfe078d26f_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86beff482d940c8b3f9b44ae18afb4a_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AInReplacementOfBSA2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2fe9c5747a478cafb0068a92d9a750_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i623d044c980a4fe9b59d0cf0c4357c46_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ba274c2f734a61a9cb2f4453142924_I20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca2359b6d7e4ffaabb4dff17cf89642_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd4d704ab87433eaab118942f97873a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc086387801445bbd7de462f336e65f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f5a42a1d914ed8aded2558448aef2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3ccd35f2ba46f3b213016bd228158b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff05550398184321955321fa5e96e1e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efe15242bc44621ad8fa904a5ae89df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aea800177684b0784cf738a4f290854_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff82164675b4db0ae05af2af10c6d6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-24</xbrli:startDate><xbrli:endDate>2019-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc595b28b04c43efa8c9724856fa5a57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f34aacd8914d92858087d804274e6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534aabb6b4774e578e1faec31a145c88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5392b89aa5e4f9f80dabd7f2b3a9a2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652de3ad86c34c4db4db1a382b545fa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f5317d31b44749b1f183f90bf871b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d069488ce3f445a8572023fb43124a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e72259f766468696e8950f2f900687_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3beab101ac5944d8996b39264b8500e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb46e1a795c49bcb05fc8d3200315fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa9412e0984488299213d105f5179a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956533d5e0a2448295b775623b2026d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4ccf47be0e4bbd9bb2d8faab31cb87_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abb27847f02467bacf8dcdc5928b771_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354033aa64f342da8206f231dd7c8d2d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic71ae7b3a2ec44fe93b98d0ab5cc918a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d97220fa46f480eb51782483039e25d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095127a75d214c5f8b6280cf3229e623_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eba6313515d4559a36c492791143e24_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91936820e19b4923b898ad1557219659_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8343c910974c02b4c1483f76998841_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromFirstYearOfGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1755b173a3d34e8499dc5ce10a9bec9c_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromSecondYearOfGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa42a50048a45a9a9d4dbf0fc6f444f_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromThirdYearOfGrantDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475209eaa2224a61a801471a000eda08_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd940520765e4ad5b9784e162babba1b_I20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantLaurentLevyAndBartVanRhijnMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28c239f39194bb4b639651e62839a6e_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:MembersOfTheExecutiveBoardAndAlainDostieMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e429614d77462f852336283afd726b_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e0b829dfdd4803b7abd6510fa5d82f_I20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerExecutiveBoardMembersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954049ede5c54ffaa561a7d9cfab1443_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd83d8297074b52a62595e69d21c63a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i618e2a4f0714405d93ca3cb13691d6ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd068ca5156440caa5babda88800ff1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34704d55c6ee4757afcef3b7be3465b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i438c89d9de71485fa265416e30bb0e74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib866094a2bed45fbb12978a62862e821_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca07aabfb0141ccb67f650409efd173_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15a8434290bb4198a83ded0ca18c27a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0979101cec4474688543efa006ec62d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d6f1511d6e44e78b354c3721b5d10d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d6ad9db19141c78c82ca8829ef8a66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8ccb113d1241d8bfccb1356614de26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c10d2422b545efaf4328d5268483f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09f2bb3b6114c268acacc4f0ebce171_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140d20eec52d43de90b683cedaafe648_I20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaafc498a94374f9f8c4d0dda5b2e6397_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f28affaf7bb40ce8972d14b1c1f055b_I20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020AndAGA2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49ffd5f6a8a43efaa547e2eb3e46420_D20191024-20191024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-24</xbrli:startDate><xbrli:endDate>2019-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bf73603bb74c11877603a93c8fee52_D20210317-20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0906164d3245eca6340ec305f7b4bf_D20210401-20210401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa39e4659a8045229764c592849e2e2d_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabb0dddb8454f87a533b1f04427ec7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if17a2f2e90aa4abfa844349f8bbeffdd_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d3dbb65e224379b7a93e55ca7be0c4_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2dd11d82dad4017b9e787f657b62484_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca1834853e14961be45fc7a1f5a71d2_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3980c93822e74e5291bc063308f06aee_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b902764e68a4c7ca60c0b4162e645fd_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b309086b1c64082bcccc5093b2b7923_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c815a380ae74027ad90d5faa79e3d8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00cc8afb53664ed8b93b3511d260adb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9770c3638b9e47bf84c5dfee8735850b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9d433b2a87420884917078664d7f8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c7c68e80ad24f5093d192fa5626429e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38ca1b371aa43d5a00e50015286da3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a92c12751c43379ad3872883245ab6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee51e9d440a047eebd1e8bf2e351748c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib657a40efdff4a8abe6d4859411ae9a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7799f346c5b4b37b8b69785c49cf119_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec1a6d0e59f4fa0a6f189b7aa6224ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b79b0b3f6a5401baa1cee18c3d6fedb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a2056a247c446a399326de355e4dd00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31eefc648a754106ba154cff1e338702_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id481c669f10348a6bb361ea9989abe14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8df14f2f9d420ca23cd6a4dbaf06f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff4e8698b934f5ca052b72aca594ec8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9f94f4d137434787ce8c4eaa14426e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d81d56997d4d9c87371cf48ed31342_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00fb905b6ac2460fbb950029daa312f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fe37bb0cdf444b83b46778e2b4506e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f0c77f0c744ce19a75d7d15fcb5f32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonExecutiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie314f470deb843f992c5a952cdab570c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f003eaa769045d399df6708982c5689_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonExecutiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc5ff1dff994b4eb048694b27359b44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e19e74602b46bfa5b381e3de4fca06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice82a034b6964d1d92ad1d346d346b3c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3979f010ce54acda1438941b43765cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb22c0964cc746dd82cf9597bde3d98d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i860acbbc413c411d9552c930dd50330e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c9105496ee4b008bc01ccddf108a3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6063d413a70f4e42ab228ca05274873e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26c49ada5ea49f6925b076f04f65999_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9f36c6b44349068238dd8813d5bb59_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f90ba5db684b64a31830ebf03467df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e7d5a08503c4c58999df6bf6e4c20d4_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>nbx:tranche</xbrli:measure></xbrli:unit><xbrli:context id="icdb43c79419c4ae4a549589fcd0ea3d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677dc547692443839295f53c6d89dbdd_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e96e3484ed74cb680b4ae9eab1f7e13_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a077384c26495caae329e040555472_D20200710-20200710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0602bff51649496c9da805f828e74529_I20200710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="quarterly_instalment"><xbrli:measure>nbx:quarterly_instalment</xbrli:measure></xbrli:unit><xbrli:context id="i0110777e52b3473f8b462de884b09e80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a151e2334941ad93f623e660566efd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae65f3974804742b4ab99567efade16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7917ccaea2634af4a65d44c4873dfc76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba645486aa240169be18398fc400965_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2608a211d394427a2eb417f85f7c460_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce52155b2714380bea43bb9d5364790_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d080d4ae22f49209fad3088f5cd1717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia690845ba75d4a2d9817787693b33552_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3325ccb1e560443f9ddb6eddf043414a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaca493780d654d98a11eee83335034c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i501dadac2baa4da2b169943189296894_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i166567b173294d53b3207d7758ed8744_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6fda04984b54ecd9c6ae4c8f6433521_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f6c485623c34a36a0a0c935c03af6b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b283275fffa429aa785167b228d13d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00db9d1206a4981b2ae432d997b3bfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b69bb03edc48d388d2b08bd8342672_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f3c9741ef74beea34a7372eea88c9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06da0291c1964865b0bee57ea7df6660_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ac85adcce64257b4ab0b5899397068_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9db631ab0a946ffa6c39533461876b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id83ab7ac51814807be706998f4cc09e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea99a9d2ede149058f2638ecfe804933_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e7563cfe4f4e48bdebe1cd3babc08c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa2ca3eec9341eea4ebbd1e22088ba8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c4fa6093f8a43df81a2388bcd182126_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9daf524aa9d74916971b8de78a30e4c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i127de2da61e64e78845c4c06ce48cee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66337c960fa942618f0543d1c09dfea5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03fc764f222342e8a738cfe4737267f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74e0b22ef5ef4129b1e88005177dcf0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a2318ff64a450380b9438374b59d05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id119775bd1424312ac886a611fd9da80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5226cc30782848c99b13dc241995afe3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a94562c5153457ab46aec435a38bf16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72f0771e7134f64a254bb97d9bc45bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59396251fd945158fa1538f914cc4b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2295671454b14d6d91210a5944d6c07b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbfecf36047400ead3aea1bcc9b8a13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124ed568f8a24aa78e3ff34558ad81c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7191a356d1c64bd49a626a0c200e1eaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69512fc2f0d34eb4b0cf656265fa6930_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024c28063f484f59b11cb851e436a1c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1502f4415f84bc0ad1e2d41b2f6944f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i836bec40340a45258bbea36837952d12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03054a03855b4b37a9b8768c06f2bd7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf7bec92f924353b5d3c40835d5e6fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a60e1d925a45289d5b33cdd832c02e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3e0b6ca2a945ed8c4fb13c8274f2cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2369a7d63f7d4af9aaccfee568c13c3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d3c34726ac4988b595b25c132f4bcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8604d938eea43d1ad397edac29826f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9f7ca1927d4697a4fe081256782a2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38f8669a4be407cab008b29e2b85d90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db0464e08894c07a24540e1493e87e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abc10eb5d6945cb92399dbc699bfb72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cfdfc0910e47f6becde04d1178f72d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce13eb6ddc140849ea104ec96d8f749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied1dea9b89304c059d54ab720191a5d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1eac451531248ea959e4a652e5278e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="borrowing"><xbrli:measure>nbx:borrowing</xbrli:measure></xbrli:unit><xbrli:context id="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a681b206df4511b7799f7f5af81474_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf95cc261a574c20bb75916fc307fd2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e92157b10524c51b91a421eb6a8c483_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:ICONPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c320981631448bb18db0fd12c61f50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id999c1e7e2574135a234b087144a61d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2547d3f63dd142aebf5856fb5e8585d9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e4d5d5fad3437283d2114e123c9052_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c4b87a005448a6af125cf0d25e3ca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0503316bb634a33b147e9bd8ec248d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3893bd24e354c778100e28facefe020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d08cfa6357540d1ad2a166b19c12357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c39078fac4b4979aea00def2bcbb7e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50df0717ba78443aa1b28f71669529c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7f775ffe9b4f938e53f99295d0dd49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2445eebc99b4373b2eb31de5002f587_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4882dee440d4a6786f1a85711a2f076_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d0f6bcf35c4bf6a5b350b635b2cf61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f6b64bccba4b65be62a02815fcc7d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4dd7cc1b414385a787daf2198eed07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a633ef24e1c46b0a69bcaf4403e72ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14898c15ca2947e18832b9287191cc4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i844f8507f9df4617831e6d34785b0ce7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4b0a0a486794f239a3054bc37c245ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62783c3667b540b998e0995fce469eb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4e939bfe23c45adaf30417def90ead9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de0719450484ecc8171d036b10ef5e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac2ec9156e94f5b90790097f4f6f9e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0f98e9c5bf49a7a5c86be5e8e9f97e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963e0d114bd6453f9f66f58da5eff1cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005555f4e921493c8254695ac286ae81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcca9167f6249298283face31cd7f47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f20ea2133e94954bd0a8f66c6e3cc78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4486c4d182429aa433718272dbe53b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf161735ab842849b194cad877786e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e283091672405988eeb41d8577edbe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-15</xbrli:startDate><xbrli:endDate>2021-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16897dad579b4f4b86092bda744f7b49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923e1965fdfa48cb90e163414c18dcc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0280ecfc6a714e849f5cba16bb5df0e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66824b4e473b46179fd1ef1f2f501a12_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib221c9ab85f1428998e5bd37d6eadcba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1b70eaca444c0098a66c5e8a9832bc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9df4ab9cfd314a1baaac83e76837eb48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3840527069c4348acc9ab3731676a5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302b2241ee6d4e209916d02969566345_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90622151f5e4db4a3a49e27eba46371_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9557dec5d8804e348756bbd9f050ae89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62e1ab97b0f340d2806afa0a17c159aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835b7224a73b4426b167298dea1d3004_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i408716a3b82f46e08e6b6d3596e1b7c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14b8fcd297d44c2b25d620752b4cc83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="factor"><xbrli:measure>nbx:factor</xbrli:measure></xbrli:unit><xbrli:context id="iff6c0684a6ed4d3e8d05a4ad259e7b4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08cbc41147294b6ea9fed577e2d2ba27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcca4f14254e4036b189591f841d06e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0017336596444f75835cadbb51aedd4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>nbx:plan</xbrli:measure></xbrli:unit><xbrli:context id="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e4592fbfd14066969841772071af84_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id607143fbf804fcb95f3a7824923bd6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b60bdf71454ad2b8b8f960988c0487_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i189db34738f54105b56656b53ef3d1c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d417b93bee43c780915df01c38d487_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabf9bb1fb1a49fbb1705b814228871c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0da65f2ab874878b39ebf2ec076918d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i712e048fe4d145e490466b4059621db8_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i792610cd47d74497aa1f7ab82c8af31f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-04</xbrli:startDate><xbrli:endDate>2012-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131da624a9f34a0ea29bf0fb2176cb5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6efed0beb6459b810d1467e0c1183b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9862c8deb0544ba80cef9d729d58100_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-18</xbrli:startDate><xbrli:endDate>2012-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2919f18751144b78569c4161f2e947a_D20121218-20121218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-18</xbrli:startDate><xbrli:endDate>2012-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59ef69bbeb80421eb92fd0f71ad1d8e4_D20121218-20121218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-18</xbrli:startDate><xbrli:endDate>2012-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5b8beea7b64bb286271b8eb038177b_D20121218-20121218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-18</xbrli:startDate><xbrli:endDate>2012-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47716d92fe342deb87045fda3d7f2c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-04-10</xbrli:startDate><xbrli:endDate>2013-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a43074ca66449b4b97de195d8ec4408_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib461318901ed4fe7a3b3fd7d2eb455e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfbec539f6234dc4ac97bed76d788c2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6ba050064a421289ccace20cb9938f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529aac24770b44a3a7b925fc089a42f7_D20140916-20140916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-16</xbrli:startDate><xbrli:endDate>2014-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea55eafbda0d41bfa15182895fad5428_D20140916-20140916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-16</xbrli:startDate><xbrli:endDate>2014-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb6b9590e1084b969feeba3744fac7fa_D20140916-20140916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-09-16</xbrli:startDate><xbrli:endDate>2014-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d028643a8ae49cb91443fcb6667aff4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cfb0e0616fc451db5120b69a2855aef_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae0ae0f0de24a7a8c7909960e7edc97_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d2e2aabd79424b9ff15157a58c2098_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a361874f01d45dfb381dace0aaa6dca_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3149d9f29e6948679668c8902a58d1d1_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6508d90ca7934d8a8c8c500934137220_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c141fe66774426ab927cbccd1a4268_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cedf3438b9b490a99a1bdf2d42f0411_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9cdfe23729475a93bb7b74d4885975_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4b9ce0de6e4e6eb552cbf8fa6227a2_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f5242dc069c466caf5e1c7529c26b46_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7e511fc9c144a38119eb439ec44e9f_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207651a4998445daab53f905e5da87aa_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0567406eef544202ac9f21ae3e4dedaf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2278b3270e54cd99a22052840e92c05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91baa8cdfc354286a5178aa94929c1b0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f6266a6261424cb3701521e5a643bb_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39b343cc43b1488fbabbaadbf30a57c5_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia126f4a85d5f4a6c89bd72f4726e6886_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4349ffd9c31d4d72afb2c3d5558ef0ff_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if88984bd12b3495c88bd5037ff1a7d37_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a26e567a53c4044a0c3a2ccdad0fc3f_D20150610-20150610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-10</xbrli:startDate><xbrli:endDate>2015-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1b746c0ab7b412ca2b2dcbaaa72a86a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7662da67c64289867d340b367149ab_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4d7149ad404f968cc08e4aef7c0075_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b964e599c664b8cab5e656560b104ce_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a861384c2b240cc81036e74e3cc65b5_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774ea0f18ade47cc86a9a59b81faa563_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2fc173db3ba4df1afee089ed2af09e3_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b41add39c641428eeb18e53a36b901_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf0cda381de45b4a117fd8996ba9e9d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847617a0623e4f41a7bb7506d0ec32e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329a6fa2c67c4bac97fd56ac1b9a7dfb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id634b4f13485463ab1d7a2134ff28cf9_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0299ef3d2b54641bfbea01d292269b4_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8dd4ad27014b778bbf05ed702bbdc5_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813aa1603ff64691b4654fe399d47cc0_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0363e72665149cf92fa348abb499297_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8f32dfa54044567a9386587ef6bf4fd_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e6fe4ace1c746f6a6dfb0b6c92cabd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c0ec932c6f41ba9b4f8939121b36b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5763ec171d43428a511bc2c311c914_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0a7ff6bb25f4c1ab55f70225cff85dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1544d3f2c5e499b98da7226782ca2be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03089c18f63c4ac8a3762b696eec3b39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icefaa359b31741c8b95cb9bf016ef953_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa4bf2f58fa428f93dd6a7a167a2f65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ae9590b9fe34d0fb673e82af470816c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bc4af9395b4f90b4d7b6e26b0c54be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702ec3ead1cd4f79b60cc12b87ee7e11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0befb495f44c12ba65c30bf98111ac_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c574e42a78453ca42bf37f9baff97a_D20150210-20150210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-10</xbrli:startDate><xbrli:endDate>2015-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7eb6413b784b03bfd43acb963cb132_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473116fa095c422aba3d6c699591faec_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if70f79e4689d4c54bb89ab61ff89be6b_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dd5d3865134117a9b633b2f3f00560_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1d34c3fdac49f49c878cd386025fdf_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc916f578f474fecb4f9f2502dbc7c53_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8b1058bf864a27b1cf4a2fe6482f13_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4f2071f6814b1e98aebb47c96b9621_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic807dce5e3d345bcbc42d29872af83fb_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i985db50e042a4e9c97fffbb93177626a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2749bb6daaa74679a776487c8f281567_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207347ba76db4b1193a91409ae7c99f1_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d07ad7bcbd0459cbefcedfd8f8f334d_D20150625-20150625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-25</xbrli:startDate><xbrli:endDate>2015-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0d58d5db0f4384894e4a99e7d095a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e6b9424288f466c8a47cebae0ec48a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9a5316762943d8affcd949d696ec10_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433bcdf7285544c9bc5810b1f42b26a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3ff9b9323446e5971e03c82d1e528a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34873da26ebb48f083c0f122691b5ad1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie75d48a141ae4d8fad1403660910f20d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aabc8c23a414a9db5e4f5a8bc2f1f48_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15526fdee1e4d91b1d5060f8b0f7568_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48621182e8c349318f629a81af122a57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d75b447af424ab48bcfec52ab34781a_D20180727-20180727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f33f50e592545199d2ce53e53f832e8_D20180727-20180727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-27</xbrli:startDate><xbrli:endDate>2018-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62055563f69f41f7a159c6147a4b0329_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b752f6985348a1aa563e64204c8eb8_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cecda26bbe64fd28d73f2e4da6b44d3_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9710c7a719da4648bd568199fecfdacd_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e94260ccc24cbe9513a3b50f37537a_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf10e5b531374a0e9d6f2b724723372e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf550bcce0b41ffa51ebe138b5a4a4b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6007079e0504a6db30cf3d75e896d43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96cf2e24893f48c0896bad782974579f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4ca2c02a4834134bc70d6a0b83f4207_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b41d660ccf4571b36b582d24ff5ff6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee4337742624978b8797907bce374b5_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2d89fd172a24e52a024851b281acab3_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca7f4263bac419496f22afb16380f23_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae657f1c9494ab7bdb98d4f741e4ce0_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="ic968a488e1214d2d8c4c849a19ca99b6_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaea4d6cd48f4720982f886453404978_D20160202-20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-02</xbrli:startDate><xbrli:endDate>2016-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c58f2d20a0a4f05982535c1b79a1d17_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5376aaec1d46476289ea3b5ba880bbca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i600323d428624ba1bb39688b7d1835c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e9a19f5187490e9f895ee7d396fa92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f126d516ed4651b3e072805f960c62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e278299ecb14d3b90fa008334cbd38d_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d3653f8d5c496bb69df2a4c27ce1c8_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b78d4a9e1549888d151cde77a2ef7a_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aadf58558ae4edfbdbd94aeefe4c495_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55c037dd3314b7f8276f447908d4668_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9512072caa04e9ba888206ac0507aad_D20161103-20161103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-03</xbrli:startDate><xbrli:endDate>2016-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3fb2391fd144d51a52e3aa90706b6f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fcc7ccd6a81428d9ed0e09d57d5a084_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d85d406740e405b90ed84914b379490_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3527d165f9d4cd5aa38b20a8500d946_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa4fccf9efb24a25859f2060793c20e4_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d0968247324343b41e1174b2637006_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fd7c980ffd4542aa22782c5e050c9d_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368408c4bd784fc5bacc7ae16ca08d7b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ac6393cd9348b8823b3228b7eee05a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-07</xbrli:startDate><xbrli:endDate>2017-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5101486495a4ef5bd91b420accb232e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b377dbf1f5453dbe7f2e047889e4ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b885452a1484ddd888ac4daf4dd2ef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ceeee7f4fc47d5b756fb41d517c7f5_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d4aa90997f4e6c8c19980dc74f6f5c_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5d8be3215b43c697cda5e740dce757_D20180306-20180306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-06</xbrli:startDate><xbrli:endDate>2018-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb23c53c4def4af9ac2648225e92fe29_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ca631b3e9147edadb169085675ab89_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198c812116bc40eba4d502226fd16032_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394793f80d274291b22ad542c6d2abd0_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dda9fb982e1491e90a9fcf99f478e19_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5200a128866a420b84b1e760ddad6401_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ced96080c741eb86c560c4806b4bac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6f2878993e468fa6f8eb36906b91de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f36fa16350140b9b69fe1134da42b69_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c93a64b4574a449d4ad5addda19ec0_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73558c5663be437689199c827a5964f1_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i276bc4fd1a094b3088274297dda73e5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b03d50b925f4ccb87f9715164ee45dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie14e3a19e1d44a86a04438f03dbba7fc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d2e17f384646f2a195144983cd8b67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623bf93a1859415a8a96f48101b40599_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bd49a836ca4a4cb9e32546a222901f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1059b42ec64434bd92678ec7a69180_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0277fbafbb433c94c83dbacd512259_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da41881e01c4b918d3d6023763371d5_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae10134a55c4ec0bfa8de540a4fa154_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4fab534e274a858c234a1f5128ae78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954ef2ab820e48b5b6d82b3be204467e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-21</xbrli:startDate><xbrli:endDate>2021-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia03d50617eac462d8a56b671789e4d10_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab950c0a8e24aae8bb9c60287630006_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b51e3ab383942a5aa13a3c61bfd07b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d1dc40ee294a4eb862a754e1a7b7a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6244d605e7d349cd88cc8c11756f1c6c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3d45ed49f246078f98c1da6b744503_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43664a271eab453f8088849ba1fb58f7_D20190329-20190329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-29</xbrli:startDate><xbrli:endDate>2019-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb041ec28cd441c8a5a4283ac0d8d07d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f726d12be094192a3269413d8216aaf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdea060a980d42ec8049515011a575c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6340f94bc5146cd810b425747377b1d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5a3763fc65486f85e8d7953a8d5b82_D20200317-20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13f58ebae684d3a9931caa0b61af23e_D20200317-20200317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-17</xbrli:startDate><xbrli:endDate>2020-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if631599c27df453a8c0ab011671a4c75_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ee66f5e8304133a7dea90f9c6c7899_D20200311-20200311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-11</xbrli:startDate><xbrli:endDate>2020-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9fa057bcb1a4c2e9c49ddc99225a69e_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ac332477d243c19cdd74fe9fc3ff31_D20210420-20210420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-20</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7abdd665664906840a18afc4669ef7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6010c7ae114b0cbe67c4bf3c2b2d79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8972928b2f3477aa4ff40a52480c1a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095137ac480d4189b8d3e9c4120fed6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbaf4b30ae8c4e248d5a4b78dcced4ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb2c3901cc8428a999595204c3b6eb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28327906e6194ba78e2313551bf12bd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d12dbc4d05a4a798e08dead85d18b91_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9f1e5116224a2e8a73cd903766f102_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c1e08d0df7b47f394f08a0c2faeffba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e5c44a32c64f1d93ae818113e1b5ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i958be4f23f454d25a7eb235f2588e9a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7d1edd94224299addbda5de426a08d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06cb4ce5915c4e4d828fd72b9468368d_D20190101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b267957c564e22a8fe73487217730b_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae5cf18bb21492a86c074c63258fe60_I20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7bf6f87d6c4461a273858821e7fb90_D20220311-20220311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001760854</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i377d9717844147e799376babda10462f_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:80%">____________________________________________________________________________________________________________________________________________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk4_7219d0c2-b2ee-4b1e-9edf-ad25bb356950">20-F</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________ </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#242424;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8xLTAtMS0xLTExOTk5_76ada55c-22a7-4211-a212-c03d36f6cd87">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#242424;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTAtMS0xLTExOTk5_4dec6b62-03b8-4a5f-89be-01f081cfeb22">x</ix:nonNumeric><br/></span><span style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/><br/><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for the fiscal year ended <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTEtMS0xLTExOTk5L3RleHRyZWdpb246YTQ3NTY2NTAzMjUxNDQ5YjgyNjczOTM4NGZiNmJjMThfMjE5OTAyMzI1NTc5Mg_603e3f6c-c540-4b11-8f74-786029e60493"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTEtMS0xLTExOTk5L3RleHRyZWdpb246YTQ3NTY2NTAzMjUxNDQ5YjgyNjczOTM4NGZiNmJjMThfMjE5OTAyMzI1NTc5Mg_ed1d81a5-6578-4090-825e-add257b7d640">December, 31</ix:nonNumeric> 2021</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#242424;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8zLTAtMS0xLTExOTk5_3b4cece5-ffaa-434f-9ad1-738a86e068dc">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for the transition period from __________ to __________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#242424;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV80LTAtMS0xLTExOTk5_73ea32d0-61b3-4957-b278-7f8cfd5850f3">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of event requiring this shell company report __________</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA5_281546a2-3afc-48a2-90db-bd85403239b1">001-39777</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:17pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzEx_af4d249d-af2d-401e-ae77-d69093e34186">NANOBIOTIX S.A.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njkz_1dbb6e45-f2b6-4e50-a521-cccf8b75153a">France</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix S.A.</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAw_4d838404-1a51-4ae6-83f5-90dd158c24eb">60 rue de Wattignies</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV81ODY_9b09a36f-6d38-4229-9cc3-656aa506c286">75012</ix:nonNumeric> <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njkx_bd9dc867-07d8-46b6-9b4c-0e4407829965">Paris</ix:nonNumeric>, <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAx_46208eab-51b9-4df2-9210-947fb74f8987">France</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:ContactPersonnelName" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA2_b22a3992-d951-428e-a30b-096ee26b1eb6">Mr. Bart van Rhijn</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nanobiotix S.A.</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA3_b22ff745-31c9-4938-9d2f-4d31c80f2302">60 rue de Wattignies</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV83Mjg_62b6f154-b6ef-4d9a-bc29-ece446f3bed7">75012</ix:nonNumeric> <ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk0_0b34cb4a-f76e-479f-a126-79e1ac402637">Paris</ix:nonNumeric>, <ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzEz_40f1f669-55fc-4da7-b81c-14dd2b2af960">France</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tel: +<ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV83NTE_8a909b34-954c-4e20-b270-cd4a65006420">33</ix:nonNumeric> <ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA4_8a771207-c837-497f-ab8c-a26f85fb7474">(0)1 40 26 04 70</ix:nonNumeric>, Fax: +<ix:nonNumeric contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231" name="dei:ContactPersonnelFaxNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk1_43ca0425-535e-4e4c-9123-6f282ec224d0">33 (0)1 40 26 04 44</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section 12(b) of the Act:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.422%"><tr><td style="width:1.0%"></td><td style="width:20.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTAtMS0xLTExOTk5_f7e1c218-64d8-4d3d-a124-6cd05a03e0bb">American depositary shares, each representing one ordinary share, nominal value &#8364;0.03 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTItMS0xLTExOTk5_ff5c2248-3016-4b2a-9904-4b96234fc2cb">NBTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTQtMS0xLTExOTk5_f6a8bbc3-6c14-4b91-8a3d-4f94b3f78f05">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18yLTAtMS0xLTExOTk5L3RleHRyZWdpb246YjhjZmU2NzUzZmMyNGZkMWI0MDNlNzAzZDJkMGZjOTVfMjE5OTAyMzI1NTY0OQ_73dd2852-eac9-4c86-a897-323aef20240a">Ordinary shares, nominal value &#8364;0.03 per share</ix:nonNumeric>*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18yLTQtMS0xLTExOTk5L3RleHRyZWdpb246NGQwMjRmM2I2YjQwNGFmN2JlMjRlNWM3NmIzYTBjMWNfMjE5OTAyMzI1NTYxMQ_90d967e0-5e92-47d0-b18c-7152f1e5b4da">The Nasdaq Stock Market LLC</ix:nonNumeric>*</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Not for trading, but only in connection with the registration of the American Depositary Shares.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">None</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">None</span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Indicate the number of outstanding shares of each of the issuer&#8217;s class of capital or common stock as of the close of the period covered by the annual report.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares, nominal value &#8364;0.03 per share: <ix:nonFraction unitRef="shares" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV8xNDkx_56ef539f-5e62-4dce-91fd-a7878d5748c5">34,825,872</ix:nonFraction> as of December 31, 2021</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.          Yes &#9744;      <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAy_3162ef92-89b2-4128-b10a-02b80cbabfa3">No</ix:nonNumeric> &#9746;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If this report is an annual or transition report, indicate by check mark, if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes &#9744; <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE1_a58679d5-0be3-4096-8b11-0d075371e748">No</ix:nonNumeric> &#9746;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Note &#8211; Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk2_7032f30d-4e97-4f40-9c1c-9f63b9a6f47b">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAz_54a6c375-afb0-4267-bd48-803a3f881a69">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:127%">Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Large accelerated filer &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV84Nzk2MDkzMDI3MDQw_b27bcf83-956e-41e5-8405-e52b17c51118">Accelerated filer</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  &#9746;</span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-accelerated filer &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Emerging Growth Company <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV84Nzk2MDkzMDI5Mzg2_49b96337-fda6-4d55-9cb8-17c9a938f820">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards &#8224; provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE2_5be76fd8-d61c-4a39-a47b-ac3971bc9282">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE3_7ac9a61e-b496-44a2-ba73-cf4cbf5385cc">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.426%"><tr><td style="width:1.0%"></td><td style="width:14.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. GAAP &#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:DocumentAccountingStandard" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6OGQ3YzE1YjhiMzcyNDYzYTk3NWRmMDZkYTRkZTkyOGMvdGFibGVyYW5nZTo4ZDdjMTViOGIzNzI0NjNhOTc1ZGYwNmRhNGRlOTI4Y18wLTEtMS0xLTExOTk5L3RleHRyZWdpb246YmYyYjJhMzE4MWMyNDlhMTkzYzVhNWQ1ZDY2YTBlZjJfMjE5OTAyMzI1NTcwOA_e5b48859-1c39-411b-b897-e937e5550a03">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board  &#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other  &#9744;</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow: Item 17 &#9744; Item 18 &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV8zMTg4NTgzNzIxMjY4NA_09a4baab-4e1e-43c9-861a-d0c20d2a44ed">&#9746;</ix:nonNumeric></span></div><div style="text-indent:0.15pt"><span><br/></span></div><div style="text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.Yes &#9744; No &#9744;</span></div><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%">______________________________________________________________________________________________</span></div><div><span style="color:#242424;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%">______________________________________________________________________________________________</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i377d9717844147e799376babda10462f_7"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_10">INTRODUCTION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_13">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_19">Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_22">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_22">Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Item 3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Key Information</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_1814">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_28">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_28">Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_28">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_31">Item 4a.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_31">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_31">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_34">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_34">Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_34">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_37">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_37">Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_37">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_40">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_40">Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_40">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_43">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_43">Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_43">127</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_46">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_46">The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_46">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_49">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_49">Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_49">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_52">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_52">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_52">139</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_55">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_55">Description of Securities Other than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_55">140</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_58">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_58">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_61">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_61">Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_61">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_64">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_64">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_64">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_67">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_67">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_67">143</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_70">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_70">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_70">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_73">Item 16A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_73">Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_73">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_76">Item 16B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_76">Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_76">144</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_79">Item 16C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_79">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_79">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_82">Item 16D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_82">Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_82">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_85">Item 16E.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_85">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_85">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_88">Item 16F.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_88">Change in Registrant&#8217;s Certifying Accountant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_88">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_91">Item 16G.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_91">Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_91">146</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_94">Item 16H.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_94">Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_94">146</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_2043">Item 16</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_2043">I</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_2043">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_2043">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_2043">146</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_97">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_97">147</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_100">Item 17.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_100">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_100">147</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_103">Item 18.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_103">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_103">147</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_106">Item 19.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_106">147</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_109">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i377d9717844147e799376babda10462f_10"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise indicated or the context otherwise requires, references in this Annual Report to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Nanobiotix&#8221;, the &#8220;Company&#8221;, or the &#8220;Group&#8221; refer to Nanobiotix S.A. and its consolidated subsidiaries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We were incorporated as a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> on March 4, 2003. We are registered at the Paris </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Registre du Commerce et des Soci&#233;t&#233;s</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> under the number 447 521 600 00034. Our principal executive offices are located at 60, rue de Wattignies, 75012 Paris, France, and our telephone number is +33 1 40 26 04 70. Our agent for service of process in the United States is our U.S. subsidiary, Nanobiotix Corporation located at 210 Broadway, Cambridge, Massachusetts 02139. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our ordinary shares, nominal value &#8364;0.03 per share (&#8220;ordinary shares&#8221;) began trading on the regulated market of Euronext in Paris in October 2012. Our American Depositary Shares, each representing one ordinary share, began trading on the Nasdaq Global Select Market on December 11, 2020. Throughout this Annual Report, references to ADSs mean American Depository Shares or ordinary shares represented by ADSs, as the case may be. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We maintain a website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">http://www.nanobiotix.com/en/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website or any other website cited in this Annual Report is not a part of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our audited consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;). Our audited consolidated financial statements are presented in euros and, unless otherwise specified, all monetary amounts presented in this Annual Report are in euros. All references in this Annual Report to &#8220;$,&#8221; &#8220;dollars&#8221; and &#8220;USD&#8221; mean U.S. dollars and all references to all references to &#8220;&#8364;&#8221; and &#8220;euros&#8221; mean euros.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trademarks and Service Marks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We own various trademark registrations and applications, and unregistered trademarks and service marks. &#8220;Nanobiotix,&#8221; &#8220;NBTX&#8221; (including, among others, referring to NBTXR3), the Nanobiotix logo and other trademarks or service marks of Nanobiotix S.A. appearing in this Annual Report are the property of Nanobiotix S.A. or its subsidiaries. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report are listed without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this Annual Report are the property of their respective owners. We do not intend to use or display other companies&#8217; trademarks and trade names to imply any relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i377d9717844147e799376babda10462f_13"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This Annual Report contains &#8220;forward-looking statements&#8221; within the meaning of applicable federal securities laws, including the Private Securities Litigation Reform Act of 1995. All statements other than present and historical facts and conditions contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this Annual Report, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or the negative of these and similar expressions identify forward-looking statements. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under &#8220;Item 3D. Risk Factors&#8221; in this Annual Report. These risks and uncertainties include factors relating to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to successfully develop and commercialize NBTXR3;   </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">          </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to expand our product pipeline by developing and commercializing NBTXR3 in additional indications, including in combination with chemotherapies or I-O treatment;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to compete with institutions with greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the completion of applicable pre-marketing regulatory requirements and/or our ability to maintain regulatory approvals and certifications for our products and product candidates and the rate and degree of market acceptance of our product candidates, including NBTXR3;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">regulatory developments in the United States, the EU, and other countries;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the effects of the COVID-19 pandemic on our business operations and clinical development timelines and plans;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, including those trials to be conducted under our collaboration with MD Anderson;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the expected timeline of our clinical trial completion, including our ability, and the ability of third party collaborators, to successfully conduct, supervise and monitor clinical trials for our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to obtain raw resources and maintain and operate our facilities to manufacture our product candidates;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to manufacture, market and distribute our products upon successful completion of applicable pre-marketing regulatory requirements, specifically NBTXR3;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to achieve the commercialization goals for NBTXR3; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to enter into effective collaborations on attractive terms and to successfully resolve disputes, if any, under existing and future collaboration agreements;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to obtain funding for our operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to attract and retain key management and other qualified personnel;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our global operations and exposure to global markets;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to protect and maintain our intellectual property rights, manufacturing know-how and proprietary technologies and our ability to operate our business without infringing upon the intellectual property rights and proprietary technologies of third parties;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to effectively deploy the proceeds from our Global Offering (as defined herein);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">future revenue, expenses, capital expenditures, capital requirements and performance of our publicly traded equity securities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our status as a foreign private issuer and emerging growth company and the reduced disclosure requirements associated with maintaining these statuses; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">other risks and uncertainties, including those listed under &#8220;Item 3D. Risk Factors.&#8221;</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">You should read this Annual Report and the documents that we reference in this Annual Report and have filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Market, Industry and Other Data</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise indicated, information contained in this Annual Report concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size estimates, is based on information from independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe the market opportunity information included in this Annual Report is generally reliable and is based on reasonable assumptions, such data involves risks and uncertainties and are subject to change based on various factors, including those discussed under &#8220;Item 3D. Risk Factors.&#8221; </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i377d9717844147e799376babda10462f_16"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">PART I</span></div><div style="text-align:center"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_19"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 1.&#160;&#160;&#160;&#160;IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_22"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 2.&#160;&#160;&#160;&#160;OFFER STATISTICS AND EXPECTED TIMETABLE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1814"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 3.&#160;&#160;&#160;&#160;KEY INFORMATION </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_498"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A.[Reserved] </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_505"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Capitalization and Indebtedness </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_512"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Reasons for the Offer and Use of Proceeds </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_518"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our business and our industry are subject to significant risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report, including our audited consolidated financial statements and related notes. This Annual Report also includes forward-looking statements that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_534"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Summary of Key Risks </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Our Business</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our operating history, which has focused primarily on research and development and advancing the clinical trial program for NBTXR3, makes it difficult to assess our future prospects.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We have not generated significant revenues and have incurred significant operating losses since our inception. While the amount of our future net losses will depend, in part, on the amount of our future operating expenses and our ability to obtain funding, we anticipate that we will continue to incur significant losses for the foreseeable future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Because each of our ongoing and contemplated clinical trials involves NBTXR3, we are heavily dependent on the successful development and commercialization of this lead product candidate.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We face significant competition in our discovery, development and commercialization activities from competitors who may have significantly greater resources than we do.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">The extent to which the COVID-19 pandemic and resulting deterioration of worldwide economic conditions adversely impacts our business, financial condition, and operating results will depend on future developments, which are difficult to predict.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We will require additional funding, which may not be available on acceptable terms or at all, and certain financing instruments&#8212;such as the finance contract for the EIB loan (as defined herein)&#8212;may impose certain restrictions on the operation of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to the Development of Our Product Candidates</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our product candidates must undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable and for which there is a high risk of failure, and which are susceptible under a variety of circumstances to additional costs, delays, suspensions and terminations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We rely on third parties to assist in our discovery, development, commercialization and manufacturing of our product candidates and issues relating to such third parties, or their activities, could result in additional costs and delays and hinder our research, development and commercialization prospects.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">In connection with collaboration agreements with third parties for the development and commercialization of our product candidates, we may be unable to identify suitable collaboration partners, and once a collaboration partner is secured, we have limited control over the attention that our commercialization partner devotes to our product candidates.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Obtaining Regulatory Approval or Certification for Our Product Candidates</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our business is governed by a rigorous, complex and evolving regulatory framework, including stringent clinical trial regulations, pre-marketing regulatory requirements, pricing, reimbursement and cost-containment regulations, and rigorous ongoing regulation of approved products. This regulatory framework results in significant compliance costs, makes the development and approval of our product candidates time intensive and unpredictable, and may reduce the ultimate economic value and prospects for our product candidates.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">A Fast Track or Breakthrough Therapy designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to the Production and Manufacturing of Our Product Candidates</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Because we depend on third parties for the supply of various materials that are necessary to produce our product candidates for clinical trials, the loss of key suppliers, the unavailability of raw materials, or disruptions in manufacturing processes could increase production costs or result in delays in our product development.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our and our subcontractors&#8217; manufacturing facilities are subject to significant government regulations and approvals and any compliance failures could lead to significant delays in the availability of products for commercial sale or clinical trials, may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications or the completion of pre-marketing certification procedures, as applicable, for our products.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Even if we successfully complete clinical trials for certain of our product candidates, those candidates may not be commercialized or achieve commercial success for a variety of reasons, including a lack of acceptance by the medical community, the imposition of post-marketing regulatory restrictions, the costs and burdens associated with post-marketing regulatory requirements, or unanticipated problems with our products following regulatory approval.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If we are unable to establish sales, marketing and distribution capabilities for our product candidates, we may not be successful in commercializing those product candidates if and when they are approved or duly CE marked.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Human Capital Management</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We may encounter difficulties in managing our development and expansion, including challenges associated with our ability to attract and retain executive management and supervisory board members as a U.S. public company.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our business could be harmed if we lose key management personnel on whom we depend or if we cannot attract and retain other qualified personnel.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Operational Compliance and Risk Management</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We use hazardous chemicals in our business, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming and costly.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">The risk of product liability claims is inherent in the development and commercialization of therapeutic products, and product liability or other lawsuits could divert management and financial resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We are subject to extensive healthcare laws and regulations impacting, among other things, our research and proposed sales, marketing and education programs of product candidates that successfully complete applicable pre-marketing regulatory requirements, and which may require substantial compliance efforts. Any regulatory compliance failures could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Intellectual Property</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Because our commercial success depends, in part, on obtaining and maintaining proprietary rights to our and our licensors&#8217; intellectual property, our ability to compete may decline if we fail to obtain protection for our products, product candidates, processes and technologies or do not adequately protect our intellectual property.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our competitive position may be adversely impacted as a result of a variety of factors, including potentially adverse determinations of complex legal and factual questions involved in patents and patent applications or insufficiently long patent lifespans in one or more jurisdictions where we obtain intellectual property protection.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Because it is cost prohibitive to seek intellectual property protection on a global basis, our intellectual property protection in certain jurisdictions many not be as robust as in the United States, which may adversely impact our competitive position.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Third parties may assert ownership or commercial rights to inventions we develop or otherwise regard as our own, or assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">A dispute concerning the infringement or misappropriation of our intellectual property rights or the intellectual property rights of others could be time-consuming and costly, and an unfavorable outcome could harm our business.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to the Ownership of Our Ordinary Shares and ADSs</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We do not currently intend to pay dividends on our securities, and under French law may be limited in our ability to do so in the future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Holders of ADSs will not be directly holding our ordinary shares and may be subject to limitations on the transfer of their ADSs and certain voting and withdrawal rights of the underlying ordinary shares as well as limitations on their ability to exercise preferential subscription rights or receive share dividends.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to us will make our ADSs less attractive to investors.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiffs in any such action.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Risks Related to Our Status as a Non-U.S. Company</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and the Nasdaq&#8217;s corporate governance standards. We expect to follow certain home country practices in relation to certain corporate governance matters, which may afford less protection than would be provided if we fully complied with the Nasdaq requirements.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our By-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If we are determined to be a PFIC for any taxable year, there may be adverse U.S. federal income tax consequences to U.S. holders.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">Our international operations may be exposed to foreign exchange risks, U.S. federal income tax risks, and additional risks, and our exposure to these risks will increase as our business continues to expand.</span></div><div style="padding-left:36pt"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_542"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our operating history makes it difficult to assess our future prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our operating history has been focused primarily on research and development and the advancement of the clinical trial program for our lead product candidate, NBTXR3. A key element of our strategy is to use and expand our proprietary technology to continue to develop our innovative product candidates designed to enhance the efficacy of radiotherapy and to progress these candidates through clinical development for the treatment of a wide variety of cancers, including STS, head and neck cancers, liver cancers, prostate cancer and rectal cancer. The nanotechnology underlying our product candidates, specifically the use of nano-sized radiation enhancers as a cancer treatment method, is novel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Although in April 2019, we successfully completed the applicable conformity assessment procedure for affixing the CE marking to our NBTXR3 device for the treatment of locally advanced STS, enabling commercialization of the product in the European Union (the &#8220;EU&#8221;) for such indication, we have not yet commercialized the product nor generated any revenues from the sale of any approved products and we may ultimately not be able to generate substantial revenue from the commercialization of approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We have encountered, and will continue to encounter, risks and difficulties frequently encountered by growing companies in new and rapidly evolving fields, particularly as we seek to utilize nanotechnology to provide solutions to unmet therapeutic needs in oncology. Consequently, the ability to predict our future operating results or business prospects is more limited than if we had a portfolio of approved products on the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We may not be able to fully implement or execute on our commercial strategy or realize, in whole or in part or within our expected time frames, the anticipated benefits of our growth strategies. You should consider our business and prospects in light of the risks and difficulties we face as a growing company focused primarily on the development and advancement of clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We have incurred significant losses and anticipate that we will continue to incur significant losses for the foreseeable future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We have not generated significant revenues and have incurred significant operating losses since our inception. To date, our limited revenues and other income have been derived primarily from payments under our license and collaboration agreement with PharmaEngine, which terminated in March 2021 (see item 4B. Business overview - our collaboration agreements&#8221; for additional details), and research tax credits. We have not generated revenues to date from product sales or royalties, and we do not expect to generate significant revenues from product sales or royalties unless and until our product candidates are successfully commercialized following regulatory approval. We incurred net losses of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8364;47.0 million for the year ended December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">. The amount of our future net losses will depend, in part, on the amount of our future operating expenses and the pace at which they are incurred and our ability to obtain funding through our commercialization activities, through equity or debt financings or through research grants or collaborative partnerships. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As of December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">, our losses are primarily attributable to expenditures committed to developing our nanotechnology and our clinical and preclinical programs. We expect to continue to incur significant expenses and losses for the foreseeable future. We anticipate that such expenses and capital requirements will increase substantially as we:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">continue our preclinical and clinical programs currently in progress;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">expand the scope of our current clinical trials and commence new clinical trials to research new oncological applications for our nanotechnology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">expand our manufacturing capabilities for the production of our product candidates and maintain compliance with applicable manufacturing regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">seek regulatory and marketing approvals, or initiate the necessary conformity assessment procedures, as applicable, for our product candidates that successfully complete clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may successfully complete applicable pre-marketing regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">advance our research and development efforts, which may include the acquisition of new technologies, products or licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">maintain, protect and expand our intellectual property portfolio; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">attract new and retain existing skilled personnel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The net losses we incur may fluctuate significantly from year-to-year such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular period or periods, our operating results could be below the expectations of securities analysts or investors, which could cause the price of our ordinary shares and ADSs to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We are heavily dependent on the successful development and commercialization of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our business and future success depends heavily on our ability to develop and commercialize our lead product candidate, NBTXR3, for indications for which there is an attractive market opportunity, and to satisfy the necessary regulatory requirements for its marketing and sale. Our development programs of NBTXR3 for the treatment of different cancer indications are at varying stages. Because each of our ongoing and contemplated trials involves NBTXR3, if one of these preclinical or clinical trials reveals safety and/or therapeutic efficacy issues, the validity of our nanotechnology platform itself could be questioned, which could potentially require additional time and investment in research and development to attempt to remedy the issues identified. The development of each application of NBTXR3 could subsequently be impacted, potentially having a significant negative impact on our business prospects, financial situation and anticipated growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Although we successfully completed the applicable conformity assessment procedure for affixing the CE marking to our NBTXR3 device for the treatment of locally advanced STS, enabling the commercialization of the product in the EU for such indication, NBTXR3 remains in clinical development for other indications, and we cannot be certain that NBTXR3 will receive regulatory approval or successfully complete the necessary conformity assessment procedures, as applicable, or be successfully commercialized, for any additional cancer indications, even if we successfully complete applicable pre-marketing regulatory requirements. Any failure or delay in the development or commercialization of NBTXR3 could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We face competition and our competitors may have significantly greater financial, technical and other resources than we do, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The development of treatments for cancer is subject to rapid technological change. Many companies, academic research institutions, governmental agencies and public and private research institutions are pursuing the development of medicinal products, devices and other therapies that target the same conditions that we are targeting, including in some cases in the same patient populations that we are targeting. Certain companies are developing treatments to increase sensitivities of tumors to radiation and other sources of energy. Like us, these companies are pursuing various technologies that involve substances that work to destroy tumor cells from the inside without causing additional damage to surrounding healthy tissues. Any product candidates that we develop and commercialize may compete with existing therapies, as well as new therapies that may become available in the future, including therapies with a mode of action similar to that of NBTXR3.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Many of our competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. These competitors also compete with us in recruiting and retaining qualified research and development and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with more established companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The key competitive factors affecting the success of NBTXR3 and any other product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price and the availability of reimbursement from government and other third-party payors. We must also protect our proprietary technology used in the development of our product candidates. Our commercial opportunity could be reduced if our competitors develop and commercialize products that are more effective or demonstrate a more favorable safety profile than any products that we may develop. Similarly, our commercial opportunity could be reduced if we fail to protect or to enforce our intellectual property rights successfully against third parties who infringe our patents or our licensors&#8217; patents, or if competitors design around our patent claims or our licensors&#8217; patent claims to produce competitive products, product candidates, processes and technologies that fall outside of the scope of our or our licensors&#8217; patents. Our competitors may also successfully complete applicable pre-marketing regulatory requirements for their products more rapidly than us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The extent to which the COVID-19 pandemic and resulting deterioration of worldwide economic conditions adversely impacts our business, financial condition, and operating results will depend on future developments, which are difficult to predict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In December 2019, a new strain of coronavirus, SARS-CoV-2, identified as the cause of coronavirus disease 2019 (COVID-19), emerged. Since then, SARS-CoV-2 and the resulting disease COVID-19 has spread to many countries, including each of the countries in which our clinical trials are planned or ongoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a result of the COVID-19 pandemic, governmental authorities have implemented and are continuing to implement numerous and rapidly evolving measures to try to contain the virus, such as travel bans and restrictions, limits on gatherings, quarantines, shelter-in-place orders, and business shutdowns. In response to the COVID-19 pandemic and in accordance with governmental orders, we have also modified our business practices and implemented proactive measures to protect the health and safety of employees, including restricting employee travel, requiring remote work arrangements for non-laboratory employees, implementing social distancing and enhanced sanitary measures in our facilities, and cancelling attendance at in-person events and conferences. Many of the suppliers and service providers on whom we rely have made similar modifications. There is no certainty that such measures will be sufficient to mitigate the risks posed by, or the impacts and disruptions of, the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a result of the COVID-19 pandemic, we have experienced, and expect to continue to experience, disruptions and adverse impacts to our business, including delays in certain clinical trial activities. Although the ultimate impact of the COVID-19 pandemic on our business is not determinable at this stage, the operational and functional impacts of the COVID-19 pandemic could be material, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Disruptions, interruptions or delays of our clinical trial activities, whether conducted by us or in collaboration with our partners (such as MD Anderson), due in particular to delays or difficulties in recruiting patients, challenges from quarantines, site closures, supply chain interruptions, limitations or redirection of human or material resources normally allocated to these clinical trials, interruptions in data collection, monitoring and/or processing, more limited access to physicians, delays in receiving, or shortages of, the supplies and materials necessary for the performance of clinical trials, or travel restrictions imposed or recommended by local authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Changes in local regulations due to the measures taken in response to the COVID-19 pandemic, which could require us to modify the conditions of our clinical trials, potentially resulting in unforeseen costs or the interruption of our trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Delays in obtaining from regulatory authorities the approvals required to launch our contemplated clinical trials, as well as delays in the necessary interactions with local authorities or other important organizations and third-party partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Overall reduced operational productivity, including interruptions to our research and development activity, resulting from challenges associated with remote work arrangements and limited resources available to employees working remotely; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Challenges in accessing, in a timely manner or on acceptable terms, financing opportunities as a result of dislocations in the capital markets, liquidity constraints on potential commercial partners, and general disruptions to global and regional economies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">While recruitment and monitoring in our clinical trials have slowed due to the pandemic and based on current circumstances, we expect that the receipt and reporting of data in head and neck cancer and immuno-oncology (&#8220;I-O&#8221;) clinical trials that were underway prior to the pandemic will generally proceed as planned based on the number of patients that had already been recruited. We anticipate that, as a result of the disruptions of the COVID-19 pandemic, protocol development and review processes and enrollment in trials not yet in progress are likely to be </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">delayed or to progress more slowly than originally anticipated. Moreover, given recruitment barriers, we expect delays in launching these trials even after regulatory clearance to proceed is obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The degree to which COVID-19 ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the severity, duration and geographic spread of the outbreak, potential resurgence events and the emergence of additional variant strains, the effectiveness of available vaccines (including with respect to emerging variants of COVID-19) and the effective distribution thereof, as well as the global, national and regional actions to contain the virus and address its impact. The resumption of normal business operations after interruptions caused by COVID-19 may be delayed or constrained by lingering effects of COVID-19 on us or our suppliers and third-party service providers, respectively. Even after the COVID-19 outbreak has subsided, we may experience material and adverse impacts as a result of the global economic impact of the COVID-19 outbreak.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The impact of COVID-19 may also exacerbate other risks discussed in this Annual Report, any of which could have a material effect on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Due to our limited resources and access to capital, our decisions to prioritize development of certain product candidates or certain indications to pursue with the product candidates that we are developing may adversely affect our business prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. In addition, for product candidates under development, such as NBTXR3, we must decide for which indications we intend to develop the product candidate for treatment. As such, we are currently primarily focused on the development of NBTXR3, particularly for the treatment of patients with locally advanced head and neck cancers, while also evaluating other indications and building out a</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">robust immuno-oncology program. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular product candidates, oncological indications or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from other more promising opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties with respect to some of our product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the field of cancer treatment, our business prospects could be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We will require additional funding, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The process of developing our product candidates is expensive, lengthy and risky. We expect our research and development expenses to increase substantially as we continue to develop NBTXR3 through our clinical development programs and identify new product candidates for development. Further, as a result of our increasing commercialization efforts with respect to NBTXR3 and the costs of operating as a U.S. public company, our selling, general and administrative expenses will increase significantly in the next several years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As of December 31, 2021, we had cash and cash equivalents of &#8364;83.9 million. We believe our cash and cash equivalents will be sufficient to fund our operations through the second quarter of 2023. However, in order to continue our ongoing research and development efforts, pursue regulatory approval and certification, and advance our commercialization efforts, we will require substantial additional funding. Also, our operating plan, including our product candidate development plans, may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other strategic alliances and licensing arrangements, or a combination of these approaches.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">To the extent that we raise additional capital through the sale of additional equity or convertible securities, holders of our ordinary shares and ADSs will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Debt financing, if available, would result in increased fixed payment obligations and a portion of our operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. In addition, debt financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends. To the extent that we raise additional funds through arrangements with research and development partners or otherwise, we may be required to relinquish some of our technologies, product candidates or revenue streams, license our technologies or product candidates on unfavorable terms, or otherwise agree to terms unfavorable to us. Any additional fundraising efforts may divert our management&#8217;s attention from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of specific strategic considerations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we are unable to obtain funding on a timely basis, our growth prospects could be impaired, the price of our ordinary shares and ADSs may decline, and we may be required to, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">delay or reduce the number or extent of our preclinical and clinical trials or eliminate them entirely;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">grant licenses to our technology to collaborative partners or third parties; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">enter into new collaboration agreements upon less favorable conditions than we would have been able to obtain under different circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Covenants in the Finance Contract governing the EIB loan impose restrictions on the operation of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The Finance Contract governing our loan from the European Investment Bank, or EIB (the &#8220;EIB loan&#8221;), contains covenants that impose restrictions on the operation of our business. For example, without the approval of the EIB, the restrictions in the Finance Contract limit our and our subsidiaries&#8217; ability, among other things, to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">dispose of any part of our business or assets outside of arm&#8217;s-length ordinary course transactions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">restructure or make substantial changes to the nature of our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">enter into certain merger or consolidation transactions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">dispose of our shareholdings in our material subsidiaries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">pursue acquisitions or investments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">incur any indebtedness in excess of &#8364;1.0 million in the aggregate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">provide guarantees in respect of liabilities or other obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">engage in certain hedging activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">grant security over our assets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">pay dividends or repurchase our shares; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%;padding-left:14.85pt">impair our intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a result of these covenants and restrictions, we are limited in how we conduct our business. Although the restrictions in the Finance Contract contain several exceptions and carve-outs and may be waived by EIB, as a result of the restrictions we may be unable to raise additional financing or pursue new business opportunities that we believe would be beneficial to our business objectives.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_551"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to the Development of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our product candidates must undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In order to obtain requisite regulatory approvals and to successfully complete the necessary conformity assessment procedures, as applicable, we conduct preclinical and clinical programs for our product candidates with the goal of ultimately marketing therapeutic solutions to transform cancer treatments that utilize radiotherapy. NBTXR3, our lead product candidate, is currently being evaluated in a total of eight clinical trials worldwide as a potential treatment in various cancer indications. In January 2019 we announced a collaboration with MD Anderson which provides for approximately 340 patients to be enrolled across multiple clinical trials to be conducted in the United States to evaluate NBTXR3 across several cancer types. Because we are conducting clinical trials for NBTXR3 in multiple cancer indications, an unfavorable outcome in one or more trials may call into question the safety or efficacy in trials with respect to other cancer indications, and potentially undermine the validity of our nanotechnology platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Further, preclinical testing and clinical trials are long, expensive and unpredictable processes that can encounter extensive delays. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. For example, one patient who participated in our clinical trial evaluating NBTXR3 in patients with late-stage cancers died from his cancer before any observation of response to treatment. Although this death was determined to be unrelated to the treatment, such setbacks could cause delays in our clinical trials. It may take several years to complete the preclinical testing and clinical development necessary to commercialize a product candidate, and delays or failure can occur at any stage. The design of a clinical trial can determine whether its results will support approval and certification of a product, as applicable, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An unfavorable outcome in one or more trials would be a major setback for our product candidates and for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more product development programs, which could have a material adverse effect on our business and financial condition and on the value of our ordinary shares or ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In connection with clinical testing and trials, we face a number of risks, including risks that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a product candidate is ineffective, inferior to existing approved treatments, unacceptably toxic, or has unacceptable side effects (both immediate or long-term);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">patients may die or suffer other adverse effects for reasons that may or may not be related to the product candidate being tested;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">extension studies on long-term tolerance could invalidate the use of our product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the results may not confirm the positive results of earlier testing or trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the independent data monitoring committee assigned to review our testing and trials could identify potential flaws in, or recommend against advancement of or adjustments to, any particular trial or trial design; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to establish the safety and efficacy of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The results of preclinical studies do not necessarily predict clinical success, and larger and later-stage clinical trials may not produce the same results as earlier-stage clinical trials. To date, clinical trials of NBTXR3 in certain oncological indications have generated favorable data; however, we may have different enrollment criteria in our future clinical trials and certain clinical trials have only yielded preliminary data. As a result, we may not observe similar results as in our prior clinical trials or in our preliminary data. Frequently, product candidates developed by pharmaceutical, biopharmaceutical and nanomedicine companies have shown promising results in preclinical studies or early clinical trials, but have subsequently suffered significant setbacks or failed in later clinical trials. Further, clinical trials of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We cannot guarantee that our current or future product development efforts will be successful, or completed within our anticipated time frames. If we do not successfully complete preclinical and clinical development, we will be unable to pursue required market authorization to market and sell our product candidates and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before submitting marketing applications to the FDA, or initiating necessary conformity assessment procedures, as applicable. Although there are a large number of drugs and medical devices in development in Europe, the United States and other countries, only a small percentage result in the submission of a marketing application or the initiation of a conformity assessment procedure, even fewer are approved for commercialization, and only a small number achieve widespread physician and consumer acceptance following regulatory approval or successful completion of the conformity assessment procedure, as applicable. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not successfully complete applicable pre-marketing regulatory requirements for any of these product candidates and our business and financial condition will be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Delays, suspensions and terminations in our clinical trials could result in increased costs to us and delay or prevent our ability to generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Human clinical trials are very expensive, time-consuming, and difficult to design, implement and complete. Commencement of our clinical trials for our product candidates may be delayed for a variety of reasons, including delays in:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">demonstrating sufficient preclinical safety and efficacy to obtain regulatory approval to commence a clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">validating test methods to support quality testing of the product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">manufacturing sufficient quantities of the product candidate necessary to conduct clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">determining dosing and clinical trial design; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the relevant oncological indication and the eligibility criteria for the clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The completion of our clinical trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">lack of efficacy of product candidates during clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">adverse events, safety issues or side effects relating to the product candidates or their formulation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">unanticipated events during clinical trials requiring amendments to clinical trial designs or protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">inability to raise additional capital in sufficient amounts to continue funding clinical trials or development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the need to sequence and prioritize clinical trials as opposed to conducting them concomitantly in order to conserve resources;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our inability to enter into collaborations relating to the development and commercialization of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our failure to conduct clinical trials in accordance with regulatory requirements or clinical trial protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our inability to manufacture or obtain from third parties sufficient quantities of product candidates for use in preclinical studies and clinical trials or of raw materials necessary for such manufacture;</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">governmental or regulatory delays and changes in regulatory requirements or policy and guidance from regulatory authorities, including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect to clinical trial results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">delays in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">difficulty in patient monitoring and data collection due to failure of patients to maintain contact after treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">varying interpretations of our data by the Notified Body, FDA and other regulatory agencies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the need to identify alternative clinical trial sites to replace sites originally appointed for activation in Russia and Ukraine, which sites have been suspended in light of the Russian invasion of Ukraine that commenced in February 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Many of these factors could also ultimately lead to the denial of our marketing application or the failure to complete applicable pre-marketing regulatory requirements for NBTXR3, or our other product candidates. If we experience delays, suspensions or terminations in a clinical trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed or such revenues could be reduced or fail to materialize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We rely on third parties to assist in our discovery and development activities, manufacture the nanoparticles used in our product candidates, and conduct our clinical trials and perform data collection and analysis, which could hinder our product development prospects or result in costs and delays that prevent us from successfully commercializing our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We currently, and expect to continue to, depend on collaborations with public and private research institutions, including hospitals, clinics and cancer treatment centers, to conduct some of our development activities. If we are unable to enter into research collaborations with these institutions, or if any one of these institutions fails to work efficiently with us, the research, development or marketing of our product candidates planned as part of the collaboration could be delayed or cancelled. In the event a collaboration agreement is terminated or we become unable to renew the arrangement under acceptable conditions, our discovery and development activities may also be delayed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Further, we depend on our production method, which we developed internally, for the manufacturing of nanoparticles. Although we have trained our third-party manufacturers in the application of our production method (and seek to maintain quality control through, among other things, implementation of a monitoring system), we do not control such third-party manufacturers&#8217; implementation of our production methods. In addition, we cannot provide any assurance that such third-party manufacturers will comply with all necessary safety protocols with respect to the implementation of our production method. Any interruption in the production of nanoparticles using the production method, including due to injuries or safety concerns from the implementation thereof, could significantly compromise our product development efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We rely, or may rely, on medical institutions, clinical investigators and contract collaborators to carry out our clinical trials and to perform data collection and analysis. For example, under our primary collaboration agreement, two NBTXR3 clinical trials are currently being run by MD Anderson, and MD Anderson is expected to serve, pursuant to the terms of the MD Anderson Collaboration Agreement as the sponsor for the remaining several clinical trials we expect to launch as part of this collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the third parties do not devote a sufficient amount of time or effort to our activities or otherwise fail to successfully carry out their contractual duties or to meet regulatory obligations or expected deadlines;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">we replace a third party; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the quality or accuracy of the data obtained by third parties is compromised due to their failure to adhere to clinical protocols, regulatory requirements, or for other reasons.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We rely on a number of third parties for the conduct of clinical trials and data collection and analysis. Third-party performance failures may increase our development costs, delay our ability to obtain regulatory approval or successfully complete pre-marketing certification procedures, and delay or prevent the commercialization of our product candidates. In addition, our third-party agreements usually contain a clause limiting such third party&#8217;s liability, such that we may not be able to obtain full compensation for any losses we may incur in connection with the third party&#8217;s performance failures. Ultimately, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of this responsibility. While we believe that in many cases there are alternative sources to provide these services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs. Further, in the event of a default, bankruptcy or shutdown of, or a dispute with, a third party, we may be unable to enter into a new agreement with another third party on commercially acceptable terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We have entered, and may in the future enter, into collaboration agreements with third parties for the development and commercialization of our product candidates, which may affect our ability to generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We have limited capabilities for product development and may seek to enter into collaborations with third parties for the development and potential commercialization of our product candidates. Should we seek to collaborate with a third party with respect to a prospective development program, we may not be able to locate a suitable collaborator and may not be able to enter into an agreement on commercially reasonable terms or at all. Even if we succeed in securing collaborators for the development and commercialization of our product candidates, such as our existing collaboration arrangements, we have limited control over the amount and timing that our collaborators may dedicate to the development or commercialization of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">These collaborations pose a number of risks, including the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may not have sufficient resources or decide not to devote the necessary resources due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may believe our intellectual property is not valid or is unenforceable or the product candidate infringes on the intellectual property rights of others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may dispute their responsibility to conduct development and commercialization activities pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may decide to pursue a competitive product developed outside of the collaboration arrangement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals or certifications; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">collaborators may delay the development or commercialization of our product candidates in favor of developing or commercializing another party&#8217;s product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Thus, collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We also face competition in seeking out collaborators. If we are unable to secure new collaborations that achieve the collaborator&#8217;s objectives and meet our expectations, we may be unable to advance our product candidates and may not generate meaningful revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">If current or future collaboration partners do not fulfill their obligations, this may cause delays in, or discontinuation of, partner-sponsored clinical trials, reduced revenue potential, and potentially litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our collaboration agreements, and those we may enter into in the future, generally require that our collaboration partners use commercially reasonable efforts to advance the development and/or potential commercialization of our product candidates for certain indications and in specified geographies, typically in accordance with a jointly approved development plan. Such collaboration agreements generally include dispute resolution procedures, which permit both us and our collaboration partners to terminate the collaboration under certain circumstances, including upon any uncured material breach of the agreement. The failure of any collaboration partner to fulfill its obligations under a collaboration agreement may result in delays in clinical trial activities or the discontinuation of clinical trials sponsored and conducted by our collaboration partner, which could limit the geographies in which we are able to effectively develop and commercialize our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Early termination of any collaboration agreement could result in additional costs and the loss of potential revenue opportunities. For example, in March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, we and PharmaEngine mutually agreed to terminate the License and Collaboration agreement that we entered into in August 2012. While we will retain all rights to the development and commercialization of NBTXR3 in the Asia Pacific region, pursuant to a Termination and Release Agreement, we agreed to make payments to PharmaEngine of up to $5 million in total upfront payments upon the completion of various administrative steps in connection with the winding-up of the collaboration, $7.5 million in future payments upon a second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication and to pay royalties to PharmaEngine at low-single digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. In addition, unilateral early termination of any collaboration agreement could result in disputes over intellectual property rights, responsibility for incurred costs or rights with respect to future revenue, which could lead to arbitration, litigation or other dispute resolution mechanisms. Disputes or litigation involving a collaboration partner may make it difficult for us to enter into a new agreement with another third party on commercially acceptable terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i377d9717844147e799376babda10462f_559"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Obtaining Regulatory Approval or Certification for Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our business is governed by a rigorous, complex and evolving regulatory framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The development and commercialization of therapeutic solutions for cancer treatment are governed by a rigorous, complex and evolving global regulatory environment. Regulatory authorities, including the FDA in the United States, have imposed stringent requirements on the amount and types of data required to demonstrate the safety and efficacy of products prior to marketing and sale. Moreover, any products approved for commercialization are reassessed in terms of their patient risk/benefit ratio on a regular basis following initial approval or certification. The late discovery of issues or potential problems which were not detected during development and clinical trials can result in restrictions on sale, the suspension or withdrawal of the product from the market and an increased risk of litigation. Given that extensive global regulation has increased the cost of obtaining and maintaining the necessary marketing authorizations and the cost of successfully completing the necessary conformity assessment procedures, for therapeutic oncology solutions, and therefore may limit the economic value of a new product, the prospects for growth in this field, and for our product candidates, have been reduced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, clinical studies for our product candidates are subject to prior submission requirements to the relevant regulatory authorities of the countries in which the studies will be carried out. For example, in the United States, a clinical study may proceed once the FDA notifies the applicant that the study may proceed or after 30 days if the submission is not placed on hold by the FDA. A negative opinion from such a regulatory authority with respect to any of our clinical development programs could suspend or terminate such programs. Moreover, depending on the information provided to regulatory authorities during a clinical trial pursuant to ongoing reporting requirements, particularly about the occurrence of undesirable side effects, the regulatory authorities could decide to prematurely suspend or terminate the clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">NBTXR3 has been classified as a &#8220;Class III medical device&#8221; in the EU and as a &#8220;drug&#8221; in the United States. Independent certification organizations (&#8220;Notified Bodies&#8221;) designated by the national EU Member States, the FDA in the United States and comparable regulatory authorities in other jurisdictions must approve or certify the conformity of, as applicable, new drug or high risk medical device candidates before they can be commercialized, marketed, promoted or sold in those jurisdictions. We must provide these regulatory authorities with data from preclinical studies and clinical trials that demonstrate that our product candidates are safe and effective for a defined indication before they can be approved or certified for commercial distribution. We must provide data to ensure the strength, quality and purity of the substance and product. We must also assure the regulatory authorities that the characteristics and performance of the clinical batches will be replicated consistently in the commercial batches.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The competent authorities of EU Member States could reconsider the classification of NBTXR3 as a medical device in the EU and decide to reclassify it as a &#8220;drug.&#8221; If our product candidates were to be classified as drugs in the EU, their clinical development would become subject to a different regulatory framework. As a result, the development and commercialization process would be longer and more costly than expected . In an effort to minimize the impact of a potential reclassification of our product candidates, we are designing our clinical development programs so as to generate clinical evidence we believe will constitute a robust scientific basis, irrespective of classification..</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">If our product candidates are not approved for marketing by applicable government authorities or we fail to complete other applicable pre-marketing regulatory requirements, we will be unable to commercialize them.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As of the date of this Annual Report, we are primarily focusing our development and planned commercialization efforts on the EU and the United States. Although we achieved a proof-of-concept in 2019 when we completed the regulatory process for the CE mark of NBTXR3, thereby allowing the product to be commercialized in the 27 EU countries for the treatment of locally advanced STS, we are now prioritizing the development of NBTXR3 in the United States and the EU for the treatment of head and neck cancers. We cannot assure you that NBTXR3, or any of our future product candidates, will receive approval from the FDA or any other regulatory authority, or will successfully complete conformity assessment procedures in the EU. Our April 2019 CE marking for Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%"> does not provide any assurance that additional NBTXR3 product candidates will successfully complete similar regulatory procedures. Even if we successfully complete applicable pre-marketing regulatory requirements for any of our product candidates in a major market such as the United States or the EU, we may never obtain approval or commercialize our products in other major markets, due to varying approval procedures or otherwise, which would limit our ability to realize their full market potential.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Several factors will determine whether we receive FDA approval or whether we successfully complete the conformity assessment procedures in the EU, including, but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to continue to develop our product candidates currently in preliminary clinical phases and to move our products currently in preclinical development phase to a clinical phase or from one clinical phase to the next;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability, or the ability of a contracted third party, to successfully complete the clinical trials required by the set deadlines and with the human, technical and financial resources initially planned.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In the event that we do not successfully complete applicable pre-marketing regulatory requirements for our product candidates established by the applicable authorities or bodies in our target jurisdictions, we will be unable to commercialize such candidates.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Government restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate revenues even if we successfully complete applicable pre-marketing regulatory requirements to market a product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government health administration authorities, private health insurers, health maintenance organizations and other organizations. Third-party payors determine which therapeutic treatments they will cover and establish reimbursement levels. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products and the treatment associated with use of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular therapeutic treatments. Increasingly, third-party payors are requiring that healthcare companies provide them with predetermined discounts from list prices as a condition of coverage, are deploying various techniques to leverage greater discounts in competitive classes, and are challenging the prices charged for therapeutic products. In addition, in the United States, federal programs impose penalties on drug manufacturers in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor and product to product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The continuing efforts of third-party payors to contain or reduce costs of healthcare may negatively affect our commercialization prospects, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to set a price we believe is fair for our products, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to obtain and maintain market acceptance by the medical community and patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to generate revenues and achieve profitability; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the availability of capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We cannot be sure that coverage and reimbursement will be available for any potential product candidate that we may commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we successfully complete applicable pre-marketing regulatory requirements. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we successfully complete applicable pre-marketing regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) has significantly impacted, and will continue to impact, the provision of, and payment for, healthcare. Various provisions of the ACA were designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide healthcare benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support for medical research. With regard to therapeutic products specifically, the ACA, among other things, expanded and increased industry rebates for drugs covered under Medicaid programs and made changes to the coverage requirements under the Medicare prescription drug benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Since its enactment there have been multiple challenges to certain aspects of the ACA and considerable uncertainty remains regarding the implementation and impact of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminated the individual mandate&#8212;a tax penalty for individuals who did not maintain mandated health insurance coverage&#8212;beginning in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition to further legal review of the ACA, U.S. federal and state governments are continuing to focus on the cost of health coverage, health care and pharmaceuticals although future policy or the timing of any changes remains unclear, creating significant risks for the sector. At the federal level, legislation like the Bipartisan Budget Act of 2018 (&#8220;BBA&#8221;) amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, and also increased in 2019 the percentage by which a drug manufacturer must discount the cost of prescription drugs from 50 percent to 70 percent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, both the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012 (the &#8220;ATRA&#8221;), have instituted, among other things, mandatory reductions in Medicare payments to certain providers.We cannot predict  the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts, and there </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">can be no assurance that any such health care reforms will not adversely affect our future business and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. Federal regulatory reform intended to reduce costs of drugs furnished under Medicare and Medicare Advantage plans through utilization management tools, like step therapy, and to increase price transparency for such drugs through the prohibition of gag clauses in pharmacy contracts became effective on January 1, 2020. Since 2017, multiple states enacted and even more states have considered proposed legislation which will require price transparency and reporting of certain manufacturer information. This trend is anticipated to continue, where legislation is expected regarding pricing transparency, marketing, access to drugs and other measures related to pricing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In November 2020, the U.S. Department of Health and Human Services, Office of Inspector General, finalized proposed modifications to the U.S. federal Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, will affect discounts paid by manufacturers to Medicare Part D plans and pharmacy benefit managers working with these organizations. The rule was challenged as arbitrary and capricious under the Administrative Procedure Act. In response, the government agreed to delay the effective date and evaluate the rule adopted by the previous administration. In the interim, the status quo has been restored. In addition to these, new legislative and/or administrative measures and other initiatives to control drug costs could harm our ability to market any product candidates and generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product candidate. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. Additionally, the United States market has been further consolidated by key private payor organizations. For instance, CVS-Aetna and Cigna-ESI mergers highlight the role of integrated payor arrangements, including PBMs, which impacts product access and affordability. Such market consolidation may further impact market pricing in the future (three PBMs now cover over 75% of the market resulting in significant negotiating power for commercial and Medicare Part D plans). Both government and commercial payors are aggressively pursuing and implementing cost containment tools designed to lower plan-level net costs. Further, the United States Congress is expected to continue its focus on pharmaceutical pricing with bipartisan support. Additional legislative focus from state and federal bodies is anticipated. The potential implementation of further pricing practice scrutiny and related cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Moreover, we cannot predict what healthcare reform initiatives may be adopted in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In some foreign countries, the proposed pricing for a therapeutic product must be approved before it may be lawfully marketed. In addition, in some foreign markets, the pricing of therapeutic products is subject to government control and reimbursement may in some cases be unavailable. The requirements governing pricing of therapeutic products vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of therapeutic products for which their national health insurance systems provide reimbursement and to control the prices of therapeutic products for human use. A Member State may approve a specific price for the therapeutic product, may refuse to reimburse a product at the price set by the manufacturer or may instead adopt a system of direct or indirect controls on the profitability of the company placing the therapeutic product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for therapeutic products will allow favorable reimbursement and pricing arrangements for NBTXR3 or any of our other product candidates that may be approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Historically, therapeutic products launched in the EU do not follow price structures of the United States and generally tend to have significantly lower prices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The scope and nature of pricing controls vary country to country, but common themes include the following: reference pricing, systematic price reduction, formularies, volume limitations, patient copayment limitations, and generic substitution. In the United States and internationally, we believe that pricing pressures at multiple levels of government, including third party review of pricing practices, will continue and may increase, which may make it difficult for us to sell our potential product candidates that may be approved in the future at a price acceptable to us or any third parties with whom we may choose to collaborate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Even if we successfully complete applicable pre-marketing regulatory requirements for the commercialization of our product candidates, the terms of approvals or certifications and ongoing regulation of our products may limit how we market our products, which could materially impair our ability to generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Even if we successfully complete applicable pre-marketing regulatory requirements for the commercialization of a product candidate, the resulting approval or certification may carry conditions that limit the market for the product or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can market a product or the patient population that may utilize the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">These restrictions could make it more difficult to market the product effectively. Accordingly, assuming we successfully complete applicable pre-marketing regulatory requirements for the commercialization of any of our product candidates, we will continue to expend time, money and effort in all areas of regulatory compliance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">A Fast Track designation by the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In February 2020, the FDA granted Fast Track designation for NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy. If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for that condition, the product sponsor may apply for FDA Fast Track designation. The FDA has broad discretion whether or not to grant this designation. Even though we have received Fast Track designation for NBTXR3, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw a Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many products that have received Fast Track designation have failed to obtain approval from the FDA.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We do not currently have Breakthrough Therapy designation for any of our product candidates but may seek it in the future. A Breakthrough Therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe, after completing early clinical trials, that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead decide not to grant that designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_569"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to the Production and Manufacturing of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We may not have access to the raw materials and other components necessary for the manufacturing of our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We are dependent on third parties for the supply of various materials that are necessary to produce our product candidates for clinical trials. See &#8220;Item 4B. Business Overview&#8212;Manufacturing.&#8221; Although we have entered into agreements related to the supply of the raw materials used in the manufacturing of our nanoparticles, the supply could be reduced or interrupted at any time. In such case, we may not be able to find other suppliers of acceptable materials in appropriate quantities at an acceptable cost. If we lose key suppliers or the supply of materials is diminished or discontinued, or in the event of a major or international crisis impacting mining or the extraction of minerals in certain regions, we may not be able to continue to develop, manufacture and market our product candidates or products in a timely and competitive manner. In addition, these materials are subject to stringent manufacturing processes and rigorous testing. Delays in the completion and validation of facilities and manufacturing processes of these materials could adversely affect our ability to complete trials and commercialize our products in a cost-effective and timely manner. If we encounter difficulties in the supply of these materials, chemicals or other necessary products, or if we were not able to maintain our supply agreements or establish new supply agreements in the future, or incur increased production costs as a result of any of the foregoing, our product development and our business prospects could be significantly compromised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In November 2017, we opened a new facility to expand our manufacturing capabilities, increase production capacity of NBTXR3 for our clinical trial needs and prepare for potential commercialization. This new facility is located in the Villejuif BioPark, a scientific research and innovation center just outside of Paris, France. We expect that the facility will expand in due course our production capacity with the aim  to produce NBTXR3 for our ongoing clinical trials and our initial commercial phase. However, we have not yet manufactured significant doses of NBTXR3 at this scale and may never be successful in developing manufacturing capabilities sufficient to meet our clinical trial needs. Moreover, we may have more limited access to raw materials and other components necessary for the manufacturing of our product candidates than third-party manufacturers, who may have more established relationships with suppliers, greater financial resources than us, and/or the ability to leverage purchasing scale for more efficient pricing of raw materials. Our manufacturing facilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, regulatory issues and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our manufacturing facilities as well as our subcontractor&#8217;s manufacturing facilities are subject to significant government regulations and approvals. If we or our third-party manufacturers fail to comply with these regulations or maintain these approvals, our business will be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We contract the production of NBTXR3 for use in clinical trials to high-precision manufacturing partners. In addition, in 2017 we expanded our own manufacturing capabilities by opening an internal research and innovation center facility just outside of Paris, France. We and our third-party manufacturers are subject to ongoing regulation and periodic inspection by the national competent authorities of the EU Member States, FDA and other regulatory bodies to ensure current Good Manufacturing Practices (&#8220;cGMP&#8221;) and international organization for standards (&#8220;ISO&#8221;) compliance, as applicable. Any failure to follow and document our or their adherence to such cGMP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical trials, may result in the   termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications or the completion of pre-marketing certification procedures, as applicable, for our products.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Failure to comply with applicable regulations could also result in the FDA or other applicable regulatory authorities taking, or causing to be taken, various actions, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">levying fines and other civil penalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">imposing consent decrees or injunctions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">requiring us to suspend or put on hold one or more of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">suspending or withdrawing regulatory approvals or certifications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">delaying or refusing to approve pending applications or supplements to approved applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">requiring us to suspend manufacturing activities or product sales, imports or exports;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">requiring us to communicate with physicians, hospitals and other stakeholders about concerns related to actual or potential safety, efficacy, and other issues involving our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">ordering or requiring product recalls or seizing products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">imposing operating restrictions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">seeking criminal prosecutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Any of the foregoing actions could be detrimental to our reputation, business, financial condition or operating results. Furthermore, our key suppliers may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, before any products would be considered for marketing in the United States, the EU or elsewhere, our suppliers will have to pass an audit by the applicable regulatory agencies. We are dependent on our suppliers&#8217; cooperation and ability to pass such audits, and the audits and any audit remediation may be costly. Failure to pass such audits by us or any of our suppliers would affect our ability to commercialize our product candidates in the United States, the EU or elsewhere.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_577"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The commercial success of our products is not guaranteed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">To date, we have the right to CE mark, and therefore to commercialize only one of our product candidates, Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">, the brand name for NBTXR3 for the treatment of locally advanced STS. This does not mean any of our other product candidates will receive approval for commercialization or that Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%"> will receive approval for commercialization in any other jurisdictions. In addition, even though we received approval for Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%"> and even if we receive additional approvals to commercialize any of our product candidates in the EU, the United States or elsewhere, we will need to gain the approval of the medical community, care prescribers and third party payors in order to achieve commercial success. Despite the fact that we have successfully completed all the regulatory steps allowing us to commercialize Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%"> in the EU, we have not yet undertaken any commercialization activities. Following evaluation of the results from Study 102 and NANORAY-312, we intend to undertake a strategic review and to determine where we believe we are best positioned to pursue commercialization, including our commercialization strategy with respect to Hensify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:110%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Even if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we are unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable to any alternative treatment methods. We cannot </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">predict the degree of market acceptance of any product candidate that successfully completes applicable pre-marketing regulatory requirements, which will depend on a number of factors, including, but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the perceived therapeutic benefit of the product by care prescribers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the potential occurrence of unanticipated or harmful side effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the ease of integration of the product in current care/treatment processes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the advantages and disadvantages of the product compared to existing or alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the ability of physicians to correctly and effectively administer our product to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the cost of treatment, and coverage and reimbursement policies of third-party payors, including government payors, pertaining to the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ability to educate the medical community about the safety and effectiveness of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">support from the medical community in the oncology field; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the development of one or more competing products for the same oncological indication, including therapies with a mode of action similar to that of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Even if our products are able to improve current therapeutic responses, poor market penetration, resulting from one or more of the factors listed above, could have a negative impact on our business prospects. Other product solutions which directly or indirectly compete with our products could also hinder our development efforts or render our products obsolete. Similarly, to the extent a cancer treatment method is shown to be more effective than, or were to displace, radiotherapy, our business would be adversely affected. Despite our best efforts, we cannot guarantee that the clinical development of our product candidates will result in successful completion of applicable pre-marketing regulatory requirements for commercialization, or that even if we do complete such requirements, that our products will be accepted by the market and experience commercial success.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Even if we successfully complete clinical trials of our product candidates, those candidates may not be commercialized successfully for other reasons.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Even if we successfully complete clinical trials for one or more of our product candidates and complete relevant regulatory requirements, those candidates may not be commercialized for other reasons, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">failing to receive regulatory clearances required to market them as drugs or medical devices, as applicable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">being subject to proprietary rights held by others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">failing to obtain clearance from regulatory authorities for the manufacturing of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">being difficult or expensive to manufacture on a commercial scale;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">having adverse side effects that make their use less desirable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">failing to compete effectively with products or treatments commercialized by competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">failing to show that the long-term benefits of our products exceed their risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">changes to our overall development priorities; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">shifting our commercialization strategy based upon our view that the market no longer supports commercialization of a particular product candidate or for a particular indication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Any of our product candidates for which we obtain authorization for commercialization could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products following approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Any of our product candidates for which we successfully complete applicable pre-marketing regulatory requirements for commercialization, such as CE marking for NBTXR3 for the treatment of locally advanced STS in the EU, as well as the manufacturing processes, post-approval studies and measures, and labeling and promotional activities for such products, among other things, will be subject to continual requirements of and review by the Notified Body and national competent authorities of EU Member States, FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if we successfully complete applicable pre-marketing regulatory requirements for a product candidate, the resulting approval or certification, as applicable, may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including an FDA requirement to implement a risk evaluation and mitigation strategy to ensure that the benefits of a drug product outweigh its risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The FDA, and other regulatory bodies, may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product, such as long term observational studies. The FDA and other U.S. agencies, including the U.S. Department of Justice, closely regulate and monitor the post-approval marketing and promotion of therapeutic products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The national competent authorities of EU Member States and FDA impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not limit the marketing of any of our product candidates to their approved indications, we may be subject to warnings or enforcement action for off-label marketing. Similarly, we cannot promote our products before completion of applicable pre-marketing regulatory requirements. Violation of the </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">U.S. Federal Food, Drug and Cosmetic Act, and other related statutes, may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">If we are unable to establish sales, marketing and distribution capabilities for our product candidates, whether it be an internal infrastructure or an arrangement with a commercial partner, we may not be successful in commercializing those product candidates if and when they are approved or duly CE marked.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We do not currently have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of drug or medical device products. We are currently prioritizing the development of NBTXR3 in the United States and the EU for the treatment of head and neck cancers while also evaluating NBTXR3 in the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">treatment of various other indications and building out a robust immuno-oncology program. At such time as we pursue commercial sales with respect to an approved product candidate, we will have to quickly transition some of our resources and attention to marketing and developing a sales force, either internally or in coordination with strategic partners. We may enter into arrangements with partners for future marketing needs with respect to certain of our products, while also implementing our own sales and marketing organization with respect to other products. Such partners may not attain goals specified in agreements we enter into with them (including, for example, goals related to the timing of product commercialization, amount of sales and payment of milestones and royalties). There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Factors that may inhibit our efforts to commercialize products on our own include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our inability to recruit, train, manage, motivate and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the failure of an adequate number of physicians to adopt any future products as part of treatment; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we were to sell, market and distribute any products that we develop ourselves.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_585"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Human Capital Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As of December 31, 2021, we had 100 full-time employees and we expect to increase our number of employees and expand the scope and location of our operations. To manage our anticipated development, expansion and incurrence of additional expenses, including the development and potential commercialization of our product candidates, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Members of our management team may need to divert a disproportionate amount of their attention away from their day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We depend on key management personnel and attracting and retaining other qualified personnel, and our business could be harmed if we lose key management personnel or cannot attract and retain other qualified personnel.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our success depends to a significant degree upon the technical skills and continued service of certain members of our management team, particularly Laurent Levy, Ph.D., our Chairman of the Executive Board. The loss of the services of any member of our management team could have a material adverse effect on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our success will also depend upon our ability to attract and retain additional qualified management, regulatory, technical, and sales and marketing executives and personnel. The failure to attract, integrate, motivate, and retain additional skilled and qualified personnel could have a material adverse effect on our business. We compete for such personnel against numerous companies, including larger, more established companies with significantly greater </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">financial resources than we possess. In addition, failure to succeed in our product candidates&#8217; development may make it more challenging to recruit and retain qualified personnel. There can be no assurance that we will be successful in attracting or retaining such personnel and the failure to do so could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Being a public company requires significant resources and management attention and may affect our ability to attract and retain executive management and qualified supervisory board members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a public company in both the United States and France, we incur significant legal, accounting and other compliance expenses. In the United States, we are subject to the Exchange Act, including the reporting requirements thereunder, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, certain Nasdaq corporate governance requirements and other applicable securities laws, rules and regulations. Compliance with these laws, rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an emerging growth company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting, and will, in the future, be required to provide an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include this attestation report on internal control over financial reporting issued by our independent registered public accounting firm. When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of complying with Section 404 will significantly increase and management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and results of operations. We may need to hire more employees in the future or engage outside consultants to comply with these requirements, which will further increase our costs and expenses. If we fail to implement the requirements of Section 404 in the required timeframe, we may be subject to sanctions or investigations by regulatory authorities, including the SEC and Nasdaq. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our ADSs could decline, and we could be subject to sanctions or investigations by regulatory authorities. Failure to implement or maintain effective internal control systems required of public companies could also restrict our future access to the capital markets. In addition, enhanced legal and regulatory regimes and heightened standards relating to corporate governance and disclosure for public companies result in increased legal and financial compliance costs and make some activities more time consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with legal requirements or the requirements of the CMS, national competent authorities of EU Member States, FDA and other government regulators, provide accurate information to applicable government authorities, comply with fraud and abuse and other healthcare laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could substantially disrupt our operations.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i377d9717844147e799376babda10462f_593"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Operational Compliance and Risk Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We use hazardous chemicals in our business. Any claims relating to improper handling, storage or disposal of these materials could be time-consuming and costly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our research and development processes involve the controlled storage, handling, use and processing of hazardous materials (notably radioactive substances), including toxins and chemical agents. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and our total assets. EU and U.S. federal, state, local or other foreign laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The risk that we may be sued on product liability claims is inherent in the development and commercialization of therapeutic products. Side effects of, manufacturing defects in, or improper physician administration of, products that we develop could result in the deterioration of a patient&#8217;s condition, injury or even death. For example, our liability could be sought after by patients participating in clinical trials due to unexpected side effects resulting from the administration of our products. Once a product successfully completes applicable pre-marketing regulatory requirements and is commercialized, the likelihood of product liability lawsuits increases. Criminal or civil proceedings might be filed against us by patients, physicians, regulatory authorities, pharmaceutical companies and any other third party using or marketing our products. These actions could include claims resulting from acts by our collaboration partners, potential licensees and subcontractors, over which we have little or no control. These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to limit or forgo further commercialization of the affected products. Any such adverse outcomes in future legal proceedings could also damage our market reputation which could in turn have an adverse effect on our ability to commercialize our products successfully.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We maintain product liability insurance coverage for our clinical trials at levels which we believe are appropriate for our clinical trials. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer. In addition, in the future, we may not be able to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product or other legal or administrative liability claims by us or our collaboration partners, licensees or subcontractors, which could prevent or inhibit the commercial production and sale of any of our product candidates that complete applicable pre-marketing regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We are subject to healthcare laws and regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Healthcare providers, physicians and others will play a primary role in the recommendation, and the incorporation into treatment regimes, of our products, if approved and duly CE-marked. Our business operations in the United States and our arrangements with clinical investigators, healthcare providers, consultants, third-party payors and patients expose us to broadly applicable federal and state fraud and abuse and other healthcare laws. These laws may impact, among other things, our research, proposed sales, marketing and education programs of our product candidates that successfully complete applicable pre-marketing regulatory requirements. Restrictions under applicable U.S. federal, state and foreign healthcare laws and regulations include, but are not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and wilfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by individuals through civil whistleblower or qui tam actions, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes which prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare matters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose certain requirements on covered entities, including certain healthcare providers, health plans and healthcare clearing houses, and their business associates, individuals and entities that perform functions or activities that involve individually identifiable health information on behalf of covered entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the laws and regulations relating to the protection of personal data, and in particular Regulation (EU) 2016/679 of April 27, 2016, or the General Data Protection Regulation (&#8220;GDPR&#8221;), which imposes strict requirements on activities that involve the processing of &#8220;personal data&#8221; (i.e., any information relating to an identified or identifiable natural person), as well as any national implementing law. For example, the GDPR requires the following non-exhaustive requirements: data processing activities must be justified by a legal basis, data subjects must be informed of the characteristics of the processing of their personal data, adequate security measures must be implemented, contractual relationships with data processors and transfers of personal data outside of the EU must be formalized and performed in compliance with data protection rules, data controllers must hold and maintain up to date records of data processing activities, data privacy impact assessments must be performed under certain circumstances, and personal data breaches must be notified. In 2019, a GDPR gap analysis was carried out by external experts on our behalf and we are in the process of implementing the most critical actions suggested to us to be taken;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA, that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i377d9717844147e799376babda10462f_601"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our ability to compete may decline if we do not adequately protect our intellectual property proprietary rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our commercial success depends, in part, on obtaining and maintaining proprietary rights to our and our licensors&#8217; intellectual property as well as successfully defending these rights against third-party challenges. We will only be able to protect our products, product candidates, processes and technologies from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent protection for our products, product candidates, processes and technologies is uncertain due to a number of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">we or our licensors may not have been the first to invent the technology covered by our or their pending patent applications or issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">we cannot be certain that we or our licensors were the first to file patent applications covering our products, product candidates, processes or technologies, as patent applications in the United States and most other countries are confidential for a period of time after filing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">others may independently develop identical, similar or alternative products, product candidates, processes and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the disclosures in our patent applications or our licensors&#8217; patent applications may not be sufficient to meet the statutory requirements for patentability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">any or all of our pending patent applications or our licensors&#8217; pending patent applications may not result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">we or our licensors may not seek or obtain patent protection in countries or jurisdictions that may eventually provide us a significant business opportunity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">any patents issued to us or our licensors may not provide a basis for commercially viable products, product candidates, processes and technologies, may not provide any competitive advantages, or may be successfully challenged by third parties, which may result in our patent claims or our licensors&#8217; patent claims being narrowed, invalidated or held unenforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our or our licensors&#8217; products, product candidates, processes and technologies may not be patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">others may design around our patent claims or our licensors&#8217; patent claims to produce competitive products, product candidates, processes and technologies that fall outside of the scope of our patents or our licensors&#8217; patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">others may identify prior art or other bases upon which to challenge and ultimately invalidate our or our licensors&#8217; patents or otherwise render them unenforceable; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our employees may claim intellectual property rights over, or demand remuneration with respect to, inventions they helped to develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Even if we have or obtain patents covering our products, product candidates, processes and technologies, we may still be barred from making, using and selling our products, product candidates, processes and technologies because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products, product candidates, processes or technologies that are similar or identical to ours. Numerous U.S. and foreign issued patents and pending patent applications owned by others exist in the cancer treatment field in which we are developing products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">These could materially affect our ability to develop and commercialize our product candidates or sell our products if approved. Because patent applications can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our products, product candidates, processes or technologies may infringe. These patent applications may have priority over patent applications filed by us or our licensors. Patent applications in France are only published 18 months after their priority date. In the United States, some patent applications are not published until the grant of the patent itself.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due over the course of several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We or our licensors may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.  If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could harm our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition to patent protection, because we operate in the highly technical field of the development of therapies using nanotechnology, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that our trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. We enter into non-disclosure agreements with our employees, consultants, outside collaborators, sponsored researchers and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may be breached or held unenforceable and may not effectively assign intellectual property rights to us. In particular, such parties may enter into other agreements with third parties and we would have no control over such contractual relationships and how they protect our confidential information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not provide adequate protection for our proprietary information. For example, our security measures may not prevent an employee or consultant with authorized access from misappropriating our trade secrets and providing them to a competitor, and the recourse we have available against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Furthermore, our proprietary information may be independently developed by others in a manner that could prevent legal recourse by us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If any of our confidential or proprietary information, including our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed and our business could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our competitive position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The patent positions of companies developing oncology therapeutic solutions, including pharmaceutical and nanomedicine companies and other actors in our fields of business, can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering therapeutic compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) and foreign patent offices are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated, narrowed or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:110%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">review, or other administrative proceedings in the USPTO. Foreign patents as well may be subject to opposition or comparable proceedings in corresponding foreign patent offices. Challenges to our patents and patent applications or our licensors&#8217; patents and patent applications, if successful, may result in the denial of our patent applications or our licensors&#8217; patent applications or the loss or reduction in their scope. In addition, such interference, reexamination, post-grant review, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:110%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">review, opposition proceedings and other administrative proceedings may be costly and involve the diversion of significant management time. Accordingly, rights under any of our patents or our licensors&#8217; patents may not provide us with sufficient protection against competitive products or processes and any loss, denial or reduction in scope of any of such patents and patent applications may have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Furthermore, even if not challenged, our patents and patent applications or our licensors&#8217; patents and patent applications may not adequately protect our product candidates, processes or technologies or prevent others from designing their products or technology to avoid being covered by our patent claims or our licensors&#8217; patent claims. If the breadth or strength of protection provided by the patents we own or license with respect to our products, product candidates, processes or technologies is threatened, it could dissuade companies from partnering with us to develop, and could threaten our ability to successfully commercialize, our product candidates, processes and technologies. Furthermore, for U.S. patent applications in which claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO in order to determine who was the first to invent any of the subject matter covered by such patent claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use our discoveries or to develop and commercialize our products, product candidates, processes and technologies without providing any notice or compensation to us, or may limit the scope of patent protection that we or our licensors are able to obtain. The laws of some countries do not protect intellectual property rights to the </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we or our licensors fail to obtain and maintain patent protection and trade secret protection of our products, product candidates, processes and technologies, we could lose our competitive advantage and competition we face would increase, potentially reducing revenues and having a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Patents have a limited lifespan. Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. If we or our licensors do not have sufficient patent life to protect our products, processes and technologies, our business and results of operations will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Filing, prosecuting and defending patents on our products, product candidates, processes and technologies in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights are obtained in the United States. Competitors may use our technologies in jurisdictions where we or our licensors do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where we or our licensors have patent protection, but where the ability to enforce our or our licensors&#8217; patent rights is not as strong as in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent such competition. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the federal and state laws in the United States. Patent protection must be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we and our licensors may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to novel therapeutic products or techniques, and the requirements for patentability differ, in varying degrees, from country to country, and the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Such issues may make it difficult for us to stop the infringement, misappropriation or other violation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Accordingly, our and our licensors&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Furthermore, proceedings to enforce our licensors&#8217; and our patent rights and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could put our or our licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us or our licensors. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded to us, if any, may not be commercially meaningful, while the damages and other remedies we may be ordered to pay such third parties may be significant. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Accordingly, our licensors&#8217; and our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Third parties may assert ownership or commercial rights to inventions we develop or otherwise regard as our own.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Third parties may in the future make claims challenging the inventorship or ownership of our or our licensors&#8217; intellectual property. We have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must negotiate certain commercial rights with such collaborators with respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#8217;s materials where required, or if disputes otherwise arise with respect to the intellectual property developed through a collaboration, we may be limited in our ability to capitalize on the full market potential of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and could interfere with our ability to capture the full commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property and associated products, product candidates, processes and technologies, or may lose our rights in that intellectual property. Either outcome could have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We currently employ, and in the future may employ, individuals who were previously employed at universities or other biotechnology, pharmaceutical or nanomedicine companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or damage our reputation. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">A dispute concerning the infringement or misappropriation of our intellectual property rights or the intellectual property rights of others could be time-consuming and costly, and an unfavorable outcome could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">There is significant litigation in the fields of pharmaceutical and medical device development regarding patent and other intellectual property rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our products, product candidates, processes, technologies or activities infringe the intellectual property rights of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If our development activities are found to infringe any such patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs or compositions. In addition, we may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the scope and validity of third-party proprietary rights. If we initiate or threaten patent infringement litigation, such action could provoke third parties to assert claims against us or our licensors or could put our patents at risk of being </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">invalidated or interpreted narrowly. From time to time, we may hire scientific personnel or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling in defending ourselves against these claims could have a negative impact on our cash position. Any legal action against us or our collaborators could lead to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">payment of damages, potentially treble damages, if we are found to have wilfully infringed a party&#8217;s patent rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">us or our collaborators having to enter into license arrangements that may not be available on commercially acceptable terms, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Any of these outcomes could hurt our cash position and financial condition and our ability to develop and commercialize our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names and trademarks, which we need to build name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_609"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Ownership of Our Ordinary Shares and ADSs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The market price of our equity securities may be volatile or may decline regardless of our operating performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The trading price of our ADSs may fluctuate substantially. The trading price of our ADSs depends on a number of factors, including those described in this &#8220;Item 3D. Risk Factors&#8221;, many of which are beyond our control. Such fluctuations in the market price and demand for our ordinary shares or ADSs may occur regardless of, and unrelated to, our actual operating performance, which may limit or prevent holders from readily selling their securities and may otherwise negatively affect the liquidity of our ordinary shares or ADSs. In addition, pharmaceutical, biotechnology and nanomedicine companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We do not currently intend to pay dividends on our securities. In addition, French law may limit the amount of dividends we are able to distribute.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, holders of our ordinary shares are not likely to receive any dividends on such ordinary shares or ADSs for the foreseeable future, and the success of an investment in ordinary shares or ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ordinary shares or ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that the ordinary shares or ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should not purchase our ADSs or ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends is made on the basis of our statutory financial statements prepared and presented in accordance with accounting standards applicable in France. In addition, payment of dividends may subject us to additional taxes under French law. See &#8220;Item 10B. Memorandum and Articles of Association&#8221; for further details on the limitations on our ability to declare and pay dividends. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In addition, exchange rate fluctuations may affect the amount of euros that we are able to distribute, and the amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we declare and pay in euros, if any. These factors could harm the value of the ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Future sales of ordinary shares or ADSs by existing shareholders could depress the market price of our ADSs and ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We believe that additional capital may be needed to continue our planned operations, including conducting our planned clinical trials, manufacturing and commercialization efforts, expanded research and development activities and costs associated with operating as a public company. Sales of additional ordinary shares or ADSs by us, or the perception that these sales could occur, could cause the market price of our ADSs to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If our existing shareholders sell, or indicate an intent to sell, substantial amounts of ordinary shares or ADSs, the trading price of our ADSs and ordinary shares could decline significantly. In addition, such secondary sales may impair our ability to raise capital through the sale of additional equity securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As of December 31, 2021, we had 34,825,872 ordinary shares outstanding. Outstanding shares held by our affiliates, including our supervisory board members and executive board members, may be publicly sold in accordance with the requirements of Rule 144 under the Securities Act, including the volume and manner of sale requirements of that rule. All outstanding ADSs held by non-affiliates may be resold without restriction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Holders of our ADSs may not be able to exercise their right to vote the ordinary shares underlying their ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the provisions of the deposit agreement and not as a direct shareholder. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (1) the notice of the meeting or solicitation of consent or proxy sent by us and (2) a statement as to the manner in which instructions may be given by the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Holders of ADSs may instruct the depositary of their ADSs to vote the ordinary shares underlying their ADSs. Otherwise, Holders of ADSs will not be able to exercise voting rights, unless they withdraw the ordinary shares underlying the ADSs they hold. However, a holder of ADSs may not know about the meeting far enough in advance to withdraw those ordinary shares. If we ask for a holder of ADSs&#8217; instructions, the depositary, upon timely notice from us, will notify him or her of the upcoming vote and arrange to deliver our voting materials to him or her. We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he or she can instruct the depositary to vote his or her ordinary shares or to withdraw his or her ordinary shares so that he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote, and there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she requested.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Holders of ADSs will not be directly holding our ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. French law governs our shareholder rights. The depositary, through the custodian or the custodian&#8217;s nominee, will be the holder of the ordinary shares underlying ADSs held by holders of ADSs. Holders of ADSs will have ADS holder rights. Among other things, ADS holder rights do not provide for double voting rights, which otherwise would be available to holders of ordinary shares held in a shareholders' name for a period of at least two years. The deposit agreement among us, the depositary and holders of ADSs, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of us and the depositary.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive dividends in shares may be limited, which may cause dilution to the holdings of holders of ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">According to French law, if we issue additional securities for cash, current shareholders will have preferential subscription rights for these securities on a pro rata basis unless they waive those rights at an extraordinary meeting of our shareholders (by a two-thirds majority vote) or individually by each shareholder. However, our ADS holders in the United States will not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to holders of ADSs in the United States unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case holders of our ADSs will receive no value for these rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Holders of ADSs in the United States may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">ADSs, which may be evidenced by American Depositary Receipts (&#8220;ADRs&#8221;), are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to a holder of ADSs&#8217; right to cancel his or her ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, a holder of ADSs may not be able to cancel his or her ADSs and withdraw the underlying ordinary shares when he or she owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to us will make our ADSs less attractive to investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. As an emerging growth company, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#8220;emerging growth companies,&#8221; including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We cannot predict if investors will find our ADSs less attractive because we rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile. We intend to take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more; (ii) December 31, 2025; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous three years; and (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Once we cease to be an emerging growth company, we may continue to avail ourselves of the accommodations available to us as a foreign private issuer for so long as we qualify as such.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:110%">We previously identified a material weakness in our internal control over financial reporting. We may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, and as a result, investor confidence in us and the value of our common stock could be materially and adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a public company in the United States, we are required to establish and maintain internal control over financial reporting. Pursuant to Section 404(a) of the Sarbanes-Oxley Act we are required to furnish a report by our management that assesses our internal control over financial reporting as of year-end in our Annual Reports on Form 20-F, commencing with an initial report as of December 31, 2021, which is included in this Annual Report. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Prior to the issuance of our interim financial statements as of and for the six months ended June 30, 2021, a deficiency, which constituted a material weakness in our internal control over financial reporting, was identified. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A material adjustment was made to our interim financial statements as of and for the six months ended June 30, 2021 prior to their issuance which resulted from a deficiency in the controls over the evaluation of certain contracts and the related accounting. The identified deficiency related to the timing of the recognition of expenses associated with new contracts signed with certain contract research organizations for one of our clinical trials. Specifically, we made advance payments that were recorded as expenses of the period instead of prepaid expenses (which in turn inappropriately increased the R&amp;D expenses). Consequently, a material weakness was disclosed in connection with the reporting of our interim financial statements. This material weakness did not result in material adjustments, or restatements, of our audited consolidated financial statements or disclosures for any prior period previously reported by us. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">During the year ended December 31, 2021, we remediated the identified material weakness in internal control over financial reporting identified above. Under the supervision of management and the oversight of our Audit Committee, Under supervision of management and the oversight of our Audit Committee, the Company increased its internal control personnel, strengthened the necessary skills for employees involved in internal control over financial reporting, implemented a more robust data collection system and enhanced reporting processes, including more </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">detailed accounting analyses at time of contract execution next to engaging independent specialists to modernize and perform certain internal control functions.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we are unable to maintain an effective system of internal control over financial reporting, the reliability of our financial reporting, investor confidence in us and the value of our common stock could be materially and adversely affected. In addition, we may discover other control deficiencies in the future, and we cannot assure you that we will not have a material weakness in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiffs in any such action.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders, including holders who acquire ADSs in the secondary market, waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that holders of our ADSs consult legal counsel regarding the jury waiver provision before acquiring ADSs and thereby entering into the deposit agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If holders of our ADSs or any other beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, they may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and the depositary. If a lawsuit is brought against either or both of us and the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have, including results that could be less favorable to the plaintiffs in any such action.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_618"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Risks Related to Our Status as a Non-U.S. Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We are a French company with limited liability. Our corporate affairs are governed by our By-laws and by the laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of our executive board and supervisory board are in many ways different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. For example, in the performance of its duties, our executive board and supervisory board are required by French law to consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in addition to, the interests of our shareholders or holders of ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Further, in accordance with French law, double voting rights automatically attach to each ordinary share of companies listed on a regulated market (such as the regulated market of Euronext in Paris, where our ordinary shares are listed) that is held of record in the name of the same shareholder for a period of at least two years, except as otherwise set forth in a company&#8217;s by-laws. Our By-laws currently do not exclude such double voting rights. See &#8220;Item 6C&#8212;Board Practices&#8212;Corporate Governance Practices&#8221; and &#8220;Item 10B. Memorandum and Articles of Association.&#8221; Ordinary shares held in the form of ADSs are not be eligible for double voting rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">U.S. investors may have difficulty enforcing civil liabilities against our company and supervisory board and senior management and the experts named in this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Certain members of our executive board, supervisory board and senior management and certain experts named in this Annual Report are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. Additionally, it may be difficult to assert U.S. </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">securities law claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a U.S. securities law claim because foreign courts may not be the most appropriate forums in which to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law of the jurisdiction in which the foreign court resides. In particular, there is some doubt as to whether French courts would recognize and enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#8217;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action may be borne by the relevant shareholder or the group of shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The enforceability of any judgment in France will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our By-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Provisions contained in our By-laws and French corporate law could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of French law and our By-laws impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">provisions of French law allowing the owner of 90% of the share capital or voting rights of a public company to force out the minority shareholders following a tender offer made to all shareholders are only applicable to companies listed on a regulated market or a multilateral trading facility in a Member State of the EU or in a state party of the European Economic Area Agreement, including the main French stock exchange, and will therefore be applicable to us only if we continue to dual-list in France;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a merger (i.e., in a French law context, a stock-for-stock exchange after which our company would be dissolved without being liquidated into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the EU would require the approval of our executive board as well as a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a merger of our Company into a company incorporated outside of the EU would require the unanimous approval of our shareholders;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our shareholders have granted and may grant in the future to our executive board broad authorizations to increase our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our shareholders have preferential subscription rights proportional to their shareholding in our company on the issuance by us of any additional shares or securities giving right, immediately or in the future, to new shares for cash or a set-off of cash debts, which rights may only be waived by the extraordinary shareholders&#8217; general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our supervisory board has the right to appoint new members to fill a vacancy created by the resignation or death of a member, subject to the approval by the shareholders of such appointment at the next shareholders&#8217; meeting, which prevents shareholders from having the sole right to fill vacancies on our supervisory board;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the members of our executive board are appointed by our supervisory board and can be removed either by our supervisory board or by the shareholders&#8217; general meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our supervisory board can only be convened by its chairman, by its vice-president, by any two members acting jointly, or, on a reasoned request (e.g. when no board meeting has been held for more than two consecutive months), by (1) members representing at least one-third of the total number of members of our supervisory board or (2) a member of the executive board;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our supervisory board&#8217;s meetings can only be regularly held if at least half of its members attend either physically or by way of videoconference or teleconference, enabling the members&#8217; identification and ensuring their effective participation in the supervisory board&#8217;s decisions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our ordinary shares are nominative or bearer, if the legislation so permits, according to the shareholder&#8217;s choice;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">under French law, (a) any non-French citizen, (b) any French citizen not residing in France, (c) any non-French entity or (d) any French entity controlled by one of the aforementioned persons or entities may have to file a declaration for statistical purposes with the Bank of France (Banque de France) within 20 business days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">particular, such filings are required in connection with investments exceeding &#8364;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. See &#8220;Item 10B. Memorandum and Articles of Association;&#8221;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">under French law, certain investments in any entity governed by French law relating to certain strategic industries (such as research and development in biotechnologies and activities relating to public health) and activities by individuals or entities not French, not resident in France or controlled by entities not French or not resident in France are subject to prior authorization of the Ministry of Economy; see &#8220;Item 10B. Memorandum and Articles of Association;&#8221;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">approval of at least a majority of the votes cast by shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders&#8217; general meeting is required to remove members of the supervisory board with or without cause;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">advance notice is required for nominations to the members of the supervisory board or for proposing matters to be acted upon at a shareholders&#8217; meeting, except that a vote to remove and replace a member of our supervisory board can be proposed at any shareholders&#8217; meeting without notice;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">pursuant to French law, our By-laws, including the sections relating to the number of our supervisory board&#8217;s members and election and removal of a member of the supervisory board from office, may only be modified by a resolution adopted by a two-thirds majority vote of our shareholders present, represented by a proxy or voting by mail at the meeting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">in the event where certain ownership thresholds would be crossed, a number of disclosures should be made by the relevant shareholder and can impose certain obligations; see &#8220;Item 10B. Memorandum and Articles of Association;&#8221; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with the Market Abuse Directive and Regulation dated April 16, 2014.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our business may be exposed to foreign exchange risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We incur some of our expenses, and may in the future derive revenues, in currencies other than the euro. In particular, as we expand our operations and continue to conduct clinical trials in the United States, we will continue to incur expenses in U.S. dollars. As a result, we may be exposed to foreign currency exchange risk as our results of operations and cash flows would be subject to fluctuations in foreign currency exchange rates. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the euro.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Therefore, for example, an increase in the value of the euro against the U.S. dollar could have a negative impact on our revenue and earnings growth as U.S. dollar revenue and earnings, if any, are translated into euros at a reduced value. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows. Our ADSs are quoted in U.S. dollars on the Nasdaq Global Select Market, while our ordinary shares trade in euros on the regulated market of Euronext in Paris. Our financial statements are prepared in euros. Therefore, fluctuations in the exchange rate between the euro and the U.S. dollar will also affect, among other matters, the value of our ordinary shares and ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our international operations involve additional risks, and our exposure to these risks will increase as our business continues to expand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We operate in a number of jurisdictions and intend to continue to expand our global presence. To date, we have focused our development and planned commercialization efforts on the EU and the United States, and to a lesser extent, Asia. International operations are subject to the legal, political, regulatory, and social requirements and economic conditions in the jurisdictions in which they are conducted. Risks inherent to international operations include, but are not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">currency exchange restrictions or costs and exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">exposure to local or regional economic or political instability, war or other armed conflicts, such as the Russian invasion of Ukraine that commenced in February 2022, and other  threatened or actual acts of terrorism and security concerns in general;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">compliance with various laws and regulatory requirements relating to anti-corruption, antitrust or competition, economic sanctions, data content, data protection and privacy, employment and labor laws and health and safety;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">difficulties in attracting and retaining qualified employees in certain international markets, as well as managing staffing and operations due to increased complexity, distance, time zones, language and cultural differences;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">difficulty in enforcing agreements, judgments, and arbitration awards in various legal systems; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">inability to obtain, maintain or enforce our intellectual property rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We believe that our overall success as a global business depends on our ability to succeed in different legal, regulatory, economic, social, and political situations and conditions. We may not be able to develop and implement effective policies and strategies in each jurisdiction where we may conduct operations or do business in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of ADSs and ordinary shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We are a foreign private issuer, as defined in the SEC&#8217;s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act. In addition, our executive board members and supervisory board members are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on the regulated market of Euronext in Paris and expect to file financial reports on an annual basis with the SEC and furnish semi-annual financial information with the SEC, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly reports on Form 10-Q or current report on Form 8-K under the Exchange Act. Accordingly, there will be less publicly available information concerning our company than there would be if we were not a foreign private issuer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">As a foreign private issuer, we are permitted and we expect to follow certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq&#8217;s corporate governance standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq corporate governance standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a foreign private issuer listed on the Nasdaq Global Select Market, we will be subject to Nasdaq&#8217;s corporate governance standards. However, Nasdaq rules provide that foreign private issuers are permitted to follow home country corporate governance practices in lieu of Nasdaq&#8217;s corporate governance standards as long as notification is provided to Nasdaq of the intention to take advantage of such exemptions. Certain corporate governance practices in France, which is our home country, may differ significantly from Nasdaq corporate governance standards. Other than as set forth in this Annual Report, we currently intend to comply with the corporate governance listing standards of Nasdaq to the extent possible under French law. However, we may choose to change such practices to follow additional French home country practices in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">As a result of the accommodations for foreign private issuers, our shareholders may be afforded less protection than they otherwise would have under Nasdaq&#8217;s corporate governance standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see &#8220;Item 6C. Board Practices - Corporate Governance Practices.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June 30, 2022. In the future, we would lose our foreign private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if more than 50% of our securities are held by U.S. residents and more than 50% of our executive board members or supervisory board members are residents or citizens of the United States, we could lose our foreign private issuer status. As of December 31, 2021, approximately 19% of our outstanding ordinary shares are held by U.S. residents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP, rather than IFRS, and modify certain of our policies to comply with corporate governance practices associated with U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described under &#8220;Item 6. Directors, Senior Management and Employees - C. Board Practices - Corporate Governance Practices&#8221; and exemptions from procedural requirements related to the solicitation of proxies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:110%">Although not free from doubt, we do not believe that we were a &#8220;passive foreign investment company&#8221; (&#8220;PFIC&#8221;) for U.S. federal income tax purposes for the taxable year ended December 31, 2021. However, it is not yet known whether we will be a PFIC for the taxable year ending December 31, 2022 or in subsequent taxable years. If we are determined to be a PFIC for any taxable year, there may be adverse U.S. federal income tax consequences to U.S. holders (as defined in the section of this Annual Report titled &#8220;Item 10E. Taxation&#8212;Material U.S. Federal Income Tax Considerations&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">A non-U.S. corporation will be considered a PFIC for any taxable year if either (1) at least 75% of its gross income for such year is passive income or (2) at least 50% of the value of its assets (based on an average of the quarterly values of the assets during such year) is attributable to assets that produce or are held for the production of passive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. In determining whether a foreign corporation is a PFIC, a pro rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. Although not free from doubt, we do not believe that we were a PFIC for the taxable year ended December 31, 2021. However, it is not yet known whether we will be a PFIC for the taxable year ending December 31, 2022 or in subsequent taxable years. The determination of PFIC status is fact-specific, and a separate determination must be made each taxable year as to whether we are a PFIC (after the close of each such taxable year). Our status as a PFIC depends on the composition of our income (including whether reimbursements of certain refundable research tax credits will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets. The value of our assets may be determined in large part by reference to the market value of the ADSs and our ordinary shares, which may fluctuate substantially. Our status as a PFIC may also depend in part upon how quickly we utilize the cash proceeds from our U.S. Offering (and the cash proceeds from other fund-raising activities) in our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we are a PFIC for any taxable year during which a U.S. holder holds ADSs, the U.S. holder may be subject to adverse tax consequences, including (1) the treatment of all or a portion of any gain on disposition as ordinary income, (2) the application of an interest charge with respect to such gain and certain dividends and (3) compliance with certain reporting requirements. Each U.S. holder is strongly urged to consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences. See &#8220;Item 10E. Taxation&#8212;Material U.S. Federal Income Tax Considerations.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Investments in our securities may be subject to prior governmental authorization under the French foreign investment control regime.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Pursuant to the provisions of the French Monetary and Financial Code (code mon&#233;taire et financier), any investment by any non-French citizen, any French citizen not residing in France, any non-French entity or any French entity controlled by one of the aforementioned persons or entities that will result in the relevant investor (a) acquiring control of an entity registered in France, (b) acquiring all or part of a business line of an entity registered in France, or (c) for non-EU or non-EEA investors crossing, directly or indirectly, alone or in concert, a 25% threshold of voting rights in an entity registered in France, in each case, conducting activities in certain strategic industries, such as activities essential to protecting public health as well as biotechnology-related research and development activities, i.e. the industry in which we operate, is subject to the prior authorization of the French Ministry of Economy, which authorization may be conditioned on certain undertakings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">In the context of the ongoing COVID-19 pandemic, the Decree (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:110%">d&#233;cret</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">) n&#176;2020 892 dated July 22, 2020, as amended by the Decree (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:110%">d&#233;cret</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">) n&#176;2020-1729 dated September 28, 2020 and by the Decree (d&#233;cret) n&#176;2021-1758 dated December 22, 2021, has created a new 10% threshold of the voting rights applicable until December 31, 2022 for the non-European investments in listed companies, in addition to the 25% above-mentioned threshold for certain  activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">On November 5, 2020, the French Ministry of Economy informed us that our activities are subject to the above described foreign investment control regime. Therefore, any investor meeting the above criteria willing to acquire all or part of our business with the effect of crossing the applicable share capital thresholds set forth by the French Monetary and Financial Code will have to request this prior governmental authorization before acquiring our ordinary shares or ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We cannot guarantee that such investor will obtain the necessary authorization in due time. The authorization may also be granted subject to conditions that deter a potential purchaser. The existence of such conditions to an investment in our securities could have a negative impact on our ability to raise the funds necessary to our development. In addition, failure to comply with such measures could result in significant consequences for the investor (including the investment to be deemed null and void). Such measures could also delay or discourage a takeover attempt, and we cannot predict whether these measures will result in a lower or more volatile market price of our ADSs or ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">For more details on the French foreign investment control regime see &#8220;Item 10B. Memorandum and Articles of Association.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i377d9717844147e799376babda10462f_626"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We must maintain effective internal control over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could hurt our business, lessen investor confidence and depress the market price of our securities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a U.S. public company, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our disclosure controls and procedures and the effectiveness of our internal control over financial reporting at the end of each fiscal year. Pursuant to Section 404(a) of the Sarbanes-Oxley Act, we are required to furnish an annual report by our management on our internal control over financial reporting, commencing with this Annual Report for the year ended December 31, 2021. The rules governing the standards that must be met for our management to assess our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit and finance committee be advised and regularly updated on management&#8217;s review of internal control over financial reporting.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Our compliance with applicable provisions of Section 404 requires that we incur substantial accounting expense and expend significant management attention and time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. In addition, our independent registered public accounting firm will be required to attest to the effectiveness of our internal controls over financial reporting beginning with our annual report following the date on which we are no longer an emerging growth company, which may extend until December 31, 2025. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">If we fail to staff our accounting and finance function adequately or maintain internal control over financial reporting adequate to meet the requirements of the Sarbanes-Oxley Act, our business and reputation may be harmed. Moreover, if we are not able to comply with the applicable requirements of Section 404 in a timely manner, we may be subject to sanctions or investigations by regulatory authorities, including the SEC and Nasdaq. Furthermore, if we are unable to conclude that our internal control over financial reporting is effective or if deficiencies in our internal control over financial reporting that are deemed to be material weaknesses are identified, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our ADSs could decline, and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities. Failure to implement or maintain effective internal control systems required of public companies could also restrict our access to the capital markets. The occurrence of any of the foregoing would also require additional financial and management resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Our internal computer systems, or those of our third-party subcontractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. If such an event were to occur and cause interruptions in our systems, it could result in a material disruption of our operations. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval, certification and commercialization efforts and significantly increase our costs to recover or reproduce the lost data. In addition, system redundancy may be ineffective or inadequate, and our disaster recovery planning may not be sufficient to cover all eventualities. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities, damage to our reputation, and the further development of our product candidates could be delayed. In addition, we may not have adequate insurance coverage to compensate for any losses associated with such events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Use of social media by third parties may materially and adversely impact our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">There has been a marked increase in the use of social media platforms and similar devices, including weblogs (blogs), social media websites and other forms of Internet-based communications which allow individual access to a broad audience of interested persons. The medical community and care prescribers may value any such readily available information concerning our products or product candidates and may act on such information without further investigation, authentication and without regard to its accuracy. Social media platforms and devices immediately publish the content their subscribers and participants post, often without filters or checks on accuracy of the content posted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">The opportunity for dissemination of information, including inaccurate information, is virtually limitless. Information concerning or affecting us, including information regarding our products, product candidates or proprietary nanotechnology, may be posted by third parties on such platforms and devices at any time. Information posted may be inaccurate and adverse to us, and it may harm our business or reputation. The harm may be immediate without affording us an opportunity for redress or correction. Further, such inaccurate information may require us to engage in a defensive media campaign, which may divert our management&#8217;s attention or result in an increase in our </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">expenses. Such platforms also could be used for the dissemination of trade secret information or compromise of other valuable company assets, any of which could harm our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:110%">We may decide to acquire companies or technologies facilitating access to, or enabling us to access, new therapeutic solutions, new research projects, or new geographical areas, or enabling us to express synergies with our existing operations. If such acquisitions were to become necessary or attractive in the future, we may not be able to identify appropriate targets or make acquisitions under satisfactory conditions, in particular, satisfactory price conditions. In addition, we may be unable to obtain the financing for these acquisitions on favorable terms, which could require us to finance these acquisitions using our existing cash resources that could have been allocated to other purposes, including existing business activities. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure holders of our ordinary shares and ADSs that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_28"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 4.&#160;&#160;&#160;&#160;INFORMATION ON THE COMPANY </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_633"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. History and Development of the Company </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our legal and commercial name is Nanobiotix S.A. We were incorporated as a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> under the laws of the French Republic on March 4, 2003 for a period of 99 years. We are registered at the Paris </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Registre du Commerce et des Soci&#233;t&#233;s</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> under the number 447 521 600. Our principal executive offices are located at 60, rue de Wattignies, 75012 Paris, France, and our telephone number is +33 1 40 26 04 70. Our agent for service of process in the United States is our U.S. subsidiary, Nanobiotix Corporation, located at 210 Broadway, Cambridge, Massachusetts 02139. Our ordinary shares began trading on the regulated market of Euronext in Paris in October 2012. Our ADSs began trading on the Nasdaq Global Select Market on December 11, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We were founded as a spin-off from the State University of New York, Buffalo in 2003. Team members at Nanobiotix, including our founder, Laurent Levy, have nearly two decades of experience developing Nanobiotix&#8217;s technology and we believe we are a pioneer and leader in the field of nanomedicine. We have built an integrated, multidisciplinary team that combines expertise in physics, biology and medicine. Our corporate headquarters and manufacturing facilities are located in Paris, France, with U.S. operations in New York City, New York and Cambridge, Massachusetts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our capital expenditures and additions to intangible assets for the years ended December 31, 2019, 2020 and 2021 together amounted to &#8364;0.9 million, &#8364;0.08 million and &#8364;1.6 million, respectively. These expenditures primarily consisted of the manufacturing line implementation and offices expansion. We expect our capital expenditures to increase in absolute terms in the near term as we continue to advance our research and development programs and grow our operations. We anticipate our capital expenditure in 2022 to be financed from our cash and cash equivalents on hand. Primarily, these capital expenditures will be made in France, where our research and development facilities are currently located.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">http://www.sec.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. We also maintain a website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">http://www.nanobiotix.com/en/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website or any other website cited in this Annual Report is not a part of this Annual Report.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_640"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Business Overview  </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_648"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are a clinical stage  biotechnology company focused on developing first-in-class product candidates that use our proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our lead product candidate, NBTXR3, is an aqueous suspension of functionalized, crystalline hafnium oxide nanoparticles designed for injection directly into a malignant tumor and is activated by radiotherapy (&#8220;RT&#8221;). When exposed to ionizing radiation, NBTXR3 amplifies the localized intratumor killing effect of that radiation and may also prime adaptive immune response and create long-term anti-cancer memory. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues. Given the physical mechanism of action, we believe that NBTXR3 could be developed as a tumor-agnostic treatment targeting all solid tumors that are treated with radiotherapy and across therapeutic combinations, including immune checkpoints inhibitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Radiotherapy, also called radiation therapy, involves the use of X-rays or other high-energy particles or rays to kill cancer cells in tumors. It is among the most common cancer treatments, both as a standalone therapy and in </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">combination with surgery, chemotherapy or biological therapies. In developed countries with access to radiotherapy, approximately 60% of all cancer patients will receive radiotherapy at least once, either alone or as a part of a more complex treatment protocol. Nevertheless, many of these patients still die from the progression of their cancer because, among other reasons, they are not able to receive a high enough radiation dose to completely destroy their tumor without resulting in an unacceptable level of damage to surrounding healthy tissues. We believe that by mitigating these limitations, NBTXR3 may improve the survival rate and quality of life for cancer patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our pioneering approach uses nanophysics to bring a physical mode of action to destroy cancer cells. Unlike traditional chemotherapies or biologics, NBTXR3 has a broadly applicable mechanism of action that we believe to have the potential to be used in the treatment of all solid tumor types in conjunction with radiotherapy. The nanoparticles have a high electron density, which allows a tumor that contains NBTXR3 to absorb more energy than could otherwise be absorbed by the cancer cells alone. This controlled concentration of energy leads to greater localized cancer cell destruction. When exposure to radiation ceases, the nanoparticles return to their inactive, inert state. However, the subsequent effect of improved physical cell destruction may allow for a greater exposition of tumor antigens in the microenvironment. Preclinical data and early data from our ongoing clinical studies both suggest that NBTXR3 activated by radiation therapy may allow for the priming of the immune system. This priming effect, if validated through further clinical testing, may be due to the activation of complex causal mechanisms, referred to as pleiotropic biological pathways, and increased exposition of antigens resulting in the activation of a patient&#8217;s own immune cells to destroy cancer cells in the body. We believe that NBTXR3&#8217;s novel mechanism of action and effect, when activated, on the tumor microenvironment could enable better local control of tumors and may potentially enhance systemic control of tumors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that NBTXR3&#8217;s mode of action could improve outcomes for patient populations across all solid  tumors that may be treated with radiotherapy alone or in combination with other therapeutic agents. These  patient populations represent a significant market opportunity for NBTXR3. Moreover, we believe NBTXR3  could bring new opportunities to patients with cancers that cannot currently be treated with radiotherapy  because of the radiosensitivity, or other characteristics, of the tissues near the tumor. The three most  advanced indications for which we have announced positive clinical trial results are locally advanced STS (for  which we can already legally commercialize NBTXR3 in the EU), locally advanced head and neck cancers (for  which the FDA has granted Fast Track designation for the treatment of elderly patients ineligible for platinum-based chemotherapies, the patient population for our global Phase III clinical trial) and liver cancers.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We achieved a major proof-of-concept milestone for NBTXR3 with the completion of our randomized,  controlled Phase II/III clinical trial in the EU for the treatment of patients with locally advanced STS of the  extremities and trunk wall. Our Phase II/III clinical trial achieved its primary endpoint showing approximately twice as many STS patients who received NBTXR3 plus radiotherapy achieved a pathological complete  response, which is defined as less than 5% residual viable cancer cells in the tumor, compared to patients  who received radiotherapy alone. This difference was statistically significant and served as the basis to obtain  the right to legally commercialize the product in the EU. In April 2019, we completed the regulatory process for  the CE mark of NBTXR3, thereby allowing the product to be commercialized in the 27 EU countries for the  treatment of locally advanced STS of the extremity and chest wall. We are currently preparing to conduct  Study 401 (MS01_1), a post-registrational trial that will continue evaluating the safety and efficacy of NBTXR3, now approved for commercial sale for the treatment of locally advanced STS in the EU under the brand name, Hensify&#174;, and provide patients with access to the product.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are currently prioritizing the development of NBTXR3 in the United States and the EU for the treatment of  patients with locally advanced head and neck cancers ineligible for chemotherapy, which we believe presents  a significant opportunity for NBTXR3 because of the high incidence of these cancers and the significant unmet  medical need for such patients. More than half of locally advanced head and neck cancers include large primary tumors which may invade underlying structures, spread to regional nodes or both. Moreover,  approximately 50% of patients with locally advanced head and neck cancer who are unable to receive  chemotherapy succumb to their cancer within 12 months from the start of radiotherapy. Further, because  treatment of locally advanced forms of head and neck cancer ordinarily requires aggressive, concerted  measures, the subpopulation of elderly patients generally suffers from limited therapeutic options. Accordingly,  we believe NBTXR3 could represent a significant benefit for this patient population with the potential to extend  survival and improve quality of life.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, we concluded an initial dose escalation phase of Study 102 Escalation, our Phase I clinical trial in  elderly patients with locally advanced head and neck cancers who are ineligible for chemotherapy or intolerant  to cetuximab, a patient population that is typically treated with radiotherapy alone. In Study 102 Escalation,  nine out of the 16 evaluable patients who received NBTXR3 plus radiotherapy achieved a complete response  according to RECIST 1.1, the response evaluation criteria in solid tumors, a set of published rules that define  whether tumors in cancer patients have improved, stayed the same or worsened during treatment. Of the  seven patients who received radiation plus the two highest doses of NBTXR3 and who were alive at the 12- month cut-off date, five of seven patients were still alive at 24 months following treatment. Patients who  received NBTXR3 in this trial also have not experienced any serious adverse events associated with  treatment. Based on these encouraging results, we commenced Study 102 Expansion, a Phase I expansion  study to obtain additional preliminary efficacy data.  </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We presented updated clinical results from Study 102 Expansion at the 2021 Annual Meeting of the American  Society for Radiation Oncology (&#8220;ASTRO&#8221;) in October 2021 showing a median Overall Survival (&#8220;mOS&#8221;) of 18.1 months and a median Progression Free Survival of (&#8220;mPFS&#8221;) of 10.6 months in the evaluable population  (n=41), with a cut-off date of September 3, 2021. Investigator-assessed response rates remained consistent with previously  reported results from the dose escalation and dose expansion study, showing a best observed target (injected)  lesion ORR of 85.4%, and a best observed target lesion CRR of 63.4% at a median follow up of 9.5 months. These best observed target lesion response rates include one patient recorded by the principal investigator of  the study as an unconfirmed complete response. NBTXR3 administration remained feasible and well-tolerated. A total of eight Grade 3-4 NBTXR3-related AEs were observed in eight patients, representing 1.3%  of all AEs. Of these AEs related to NBTXR3, five SAEs were observed including dysphagia, sepsis, soft tissue  necrosis, stomatitis, and tumor hemorrhage. One death from sepsis occurred, which the investigator assessed as possibly related to NBTXR3, radiotherapy, and cancer. See &#8220;&#8212;Our Clinical Programs&#8212;Locally Advanced  Head and Neck Cancers&#8212;Dose Expansion Results.&#8221; A review of data as of the February 22, 2022 cut off date from Expansion Study 102 shows median overall survival (mOS) of 23 months in evaluable patients (n=44) demonstrating continued improvement relative to the analysis presented at ASTRO 2021 and consistent with data reported from the dose escalation phase of Study 102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are conducting NANORAY-312, a global Phase III clinical trial for elderly patients with squamous cell carcinoma who are ineligible for platinum-based chemotherapy. The first clinical sites for NANORAY-312 were activated in Europe during the fourth quarter of 2021, with the first patient being randomized in January 2022. We expect activation and enrollment at U.S.sites and Asian sites, through our collaboration partner LianBio, to begin in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Alongside our core NBTXR3 development program, we are also pursuing a robust development program to  study the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across  several solid tumor indications. In recent years, significant attention has been focused on the potential of  immuno-oncology treatments, and in particular, checkpoint inhibitors. Checkpoint inhibitors are a type of  immunotherapy that function to block proteins that stop the immune system from attacking cancer cells. In  doing so, they enable the patient&#8217;s T cells to recognize cancer cells that would otherwise be invisible to  immune attack. However, many tumors exhibit little or no response to checkpoint inhibition (these tumors are  referred to as &#8220;cold&#8221; tumors). Our preclinical and early clinical results suggest that NBTXR3 plus radiotherapy  may prime the immune response, thereby rendering otherwise cold tumors more prone to recognition by the  patient&#8217;s immune system (making them &#8220;hot tumors&#8221;) and therefore potentially more responsive to I-O treatments such as checkpoint inhibitors.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of our checkpoint inhibitor combination development program, we are conducting Study 1100, a Phase  I basket trial for NBTXR3 in combination with the anti-PD-1 checkpoint inhibitors nivolumab (Opdivo) or pembrolizumab (Keytruda) in patients with LRR or R/M HNSCC or with lung or liver metastases from any  primary cancer that is eligible for anti-PD-1 therapy. We presented updated clinical results from Study 1100 at  ASTRO&#8217;s Annual Meeting in October 2021. We believe that these early results suggest that NBTXR3 has the  potential to increase the proportion of patients that respond to immune checkpoint inhibitors, and we have commenced initial discussions with regulatory authorities regarding the potential registration pathway, for this immunotherapy combination. In early 2022, we amended the Study 1100 protocol to add an expansion phase in three cohorts, including two cohorts focused on R/M HNSCC patients that are either na&#239;ve to anti-PD-(L)-1 therapy or resistant to prior anti-PD-(L)-1 therapy and combining other eligible patients with lung and/or liver metastasis from anti-PD-(L)-1 resistant advanced cancers into a third cohort. See &#8220;Business&#8212;Our Clinical Programs&#8212;HNSCC, Lung Metastasis or  Liver Metastasis&#8221; for additional detail. As part of our clinical collaboration with MD Anderson, we plan to  evaluate NBTXR3 in combination with various checkpoint inhibitors (anti-PD-1, anti-PD-L1 and anti-CTLA-4) in  patients across several indications, including inoperable, locally advanced head and neck cancer, R/M  HNSCC, advanced solid tumors, and metastatic lung or liver cancer.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, NBTXR3 has been administered to approximately 300 patients. Given Nanobiotix&#8217;s focus areas, and balanced against the scalable potential of NBTXR3, we have engaged in a strategic collaboration strategy with large and reputable partners to expand development of the product candidate in parallel with our priority development pathways, as discussed under the caption &#8220;&#8212;NBTXR3 Development Pipeline&#8221; below. In 2018 we entered into a broad, comprehensive clinical research collaboration with MD Anderson to sponsor several Phase I and Phase II studies in the United States to evaluate NBTXR3 across tumor types and therapeutic combinations, with a total of approximately 340 patients expected to be enrolled across these clinical trials. Five clinical trials under this collaboration&#8212;a Phase I study in patients with locally advanced or borderline resectable pancreatic cancer, a Phase I study in patients with esophageal cancer, a Phase I study in patients with non-small cell lung cancer and two Phase II studies in patients with head and neck cancer in combination with anti-PD-1&#8212;have commenced enrollment. In May 2021, we entered into a collaboration agreement with LianBio to develop and commercialize NBTXR3 in key countries in Asia, including Mainland China, Taiwan and South Korea, pursuant to which LianBio has undertaken to contribute to enrollment in up to five global registrational studies for NBTXR3. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were founded as a spin-off from the State University of New York, Buffalo in 2003. Team members at  Nanobiotix, including our founder, Laurent Levy have nearly two decades of experience developing Nanobiotix&#8217;s technology and we believe Nanobiotix to be a pioneer and leader in the field of nanomedicine. We have built an integrated, multidisciplinary team that combines expertise in physics, biology and medicine. We believe that its unique expertise in nanotechnology will provide its stakeholders with opportunities to expand its product pipeline and to advance the development of its product candidates, either on its own or in collaboration with third parties. Our corporate headquarters and manufacturing facilities are located in Paris, France, with U.S. operations in New York City, New York and Cambridge, Massachusetts. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_653"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">NBTXR3 Development Pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of nearly two decades of experience developing our technology, and our broad collaboration with MD Anderson, we have a robust development pipeline. The chart below highlights ongoing and planned clinical trials portfolio, including those that are under Nanobiotix&#8217;s collaboration with MD Anderson. Nanobiotix is currently in discussions with MD Anderson to determine the indications for the remaining trials. Additional detail regarding Nanobiotix&#8217;s most advanced clinical trials is provided under the section &#8220;Business&#8212;Our Clinical Programs.&#8221;</span></div><div style="margin-top:12pt"><img src="nbx-20211231_g1.jpg" alt="nbx-20211231_g1.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">*NANORAY-312, a global Phase III clinical trial for elderly patients with locally-advanced head and neck cancer who are ineligible for platinum-based (cisplatin) chemotherapy, is being activated in Europe and the United States initially as a Phase III trial. We activated the first clinical sites for NANORAY-312 in Europe in the fourth quarter of 2021, with the first patient randomized in January 2022. We expect U.S. activation and enrollment at U.S. sites and Asian sites (through LianBio) to begin in 2022. For its evaluation of NANORAY-312, the FDA has accepted the available data from Study 102 Escalation. NBTXR3 for the treatment of locally advanced head and neck cancers received Fast Track designation from the FDA in February 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8224; LianBio has been granted development and commercialization rights for NBTXR3 in key countries in Asia. In addition, certain NBTXR3 clinical trials conducted by our former collaborator, PharmaEngine, are currently being conducted in Asia and are in the process of being concluded or terminated. See &#8220;Business&#8212;Our Collaboration Agreements&#8212;PharmaEngine&#8221; for additional details. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">* Phase I/II Study initiated by former partner, PharmaEngine. In conjunction with the termination of the license and collaboration agreement, PharmaEngine will implement the early termination and wind-down of this clinical trial in accordance with good clinical practice guidelines. The trial will be deemed completed when all enrolled patients have reached &#8220;end-of-study&#8221; and PharmaEngine issues a final study report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The anticipated clinical milestones discussed in the pipeline chart above, and in this Annual Report generally, are subject to the potential impact of the COVID-19 pandemic on Nanobiotix&#8217;s business and may be delayed as a result. The COVID-19 pandemic has caused some delays in the review of data and enrollment in studies. Despite these delays, Nanobiotix&#8217;s overall development plan continues, prioritizing head and neck cancer and immuno-oncology. The COVID-19 pandemic has not negatively impacted our liquidity and/or funding sources. For more information about the ways in which we have been, and may be, impacted by COVID-19, please the section titled &#8220;Risk Factors&#8221;.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i377d9717844147e799376babda10462f_658"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The goal of Nanobiotix is to become a leader in the biotechnology industry, based on the systematic combination of NBTXR3 and radiotherapy, either alone or in further combination with immuno-therapies or chemotherapies, in the treatment of solid tumors. The key elements of this strategy include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;padding-left:14.85pt">Complete the development of, and satisfy applicable EU and U.S. regulatory requirements for, NBTXR3 for the treatment of locally advanced head and neck cancers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Based on encouraging results from Study 102 Escalation, Nanobiotix is conducting Study 102 Expansion to collect additional preliminary efficacy data. Updated clinical results from Study 102 Expansion were presented at ASTRO&#8217;s Annual Meeting in October 2021 showing a mOS of 18.1 months and a mPFS of 10.6 months in the evaluable population (n=41). As of the September 3, 2021 data cut-off, there were 41 evaluable patients in the Study 102 Expansion. Investigator-assessed, response rates remained consistent with previously reported results from the dose escalation and dose expansion study, showing a best observed target (injected) lesion ORR of 85.4%, and a best observed target lesion CRR of 63.4% at a median follow up of 9.5 months. These best observed target lesion response rates include one patient recorded by the principal investigator of the study as an unconfirmed complete response. NBTXR3 administration remained feasible and well-tolerated. A total of eight Grade 3-4 NBTXR3-related AEs were observed in eight patients, representing 1.3% of all AEs. Of these AEs related to NBTXR3, five SAEs were observed including dysphagia, sepsis, soft tissue necrosis, stomatitis and tumor hemorrhage. Of the SAEs, one death from sepsis occurred, which the investigator assessed as possibly related to NBTXR3, radiotherapy, and cancer. See &#8220;Business&#8212;Our Clinical Programs&#8212;Locally Advanced Head and Neck Cancers&#8212;Dose Expansion Results.&#8221; A review of data as of the February 22, 2022 cut off date from Expansion Study 102 shows median overall survival (mOS) of 23 months in evaluable patients (n=44) demonstrating continued improvement relative to the analysis presented at ASTRO 21 and consistent with data reported from the dose escalation phase of Study 102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We commenced NANORAY-312, a global Phase III clinical trial for elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy, randomizing the first patient in January 2022. In the United States, NBTXR3, classified as a drug, was granted Fast Track designation from the FDA in February 2020 for the treatment of locally advanced head and neck cancers, which Nanobiotix believes could allow for expedited clinical development. Nanobiotix expects approximately 500 patients to be enrolled in this global Phase III trial, including up to 100 patients to be enrolled by LianBio. The initial readout will be based on event-driven progression-free survival (&#8220;PFS&#8221;), and the final readout will be based on overall survival (&#8220;OS&#8221;). A futility analysis is expected approximately 18 months after the first patient is randomized, and the interim analysis for PFS superiority is expected approximately 30 months after first patient randomization. The final analysis will report on PFS and OS.</span></div><div style="text-align:justify;text-indent:35.45pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;padding-left:14.85pt">Establish NBTXR3 as a complementary product to immune checkpoint inhibitors.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Nanobiotix is conducting, and continues to further develop a global I-O development program to explore the use of NBTXR3 as a complement to immune checkpoint inhibitors across several solid tumor indications. In preclinical studies, NBTXR3 activated by radiation therapy in combination with immune checkpoint inhibitors demonstrated potential to convert checkpoint inhibitor non-responders into responders, provide better local and systemic control and increase survival. Nanobiotix is conducting Study 1100, a Phase I basket trial of NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in patients with LRR or R/M HNSCC or with lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy. Updated clinical results were presented from ongoing Study 1100 at ASTRO&#8217;s Annual Meeting in October 2021. Nanobiotix believes that these updated results suggest that NBTXR3 could benefit this patient population with the potential to increase the proportion of patients that respond to immune checkpoint inhibitors, and discussions have been initiated  with regulatory authorities regarding the potential registration pathway for this immunotherapy combination. In early 2022, we amended the Study 1100 protocol to add an expansion phase in three cohorts, including two cohorts focused on R/M HNSCC patients that are either na&#239;ve to anti-PD-(L)-1 therapy or resistant to prior anti-PD-(L)-1 therapy and combining other eligible patients with lung and/or liver metastasis from anti-PD-(L)-1 resistant advanced cancers into a third cohort. See &#8220;Business&#8212;Our Clinical Programs&#8212;HNSCC, Lung Metastasis or Liver Metastasis&#8221; for additional detail. In addition, pursuant to its collaboration with MD Anderson, Nanobiotix is planning to evaluate NBTXR3 in combination with various checkpoint inhibitors (anti-PD-1, anti-PD-L1, and anti-CTLA-4) across several cancer indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;padding-left:14.85pt">Expand the opportunity for NBTXR3 as a treatment for solid tumor indications.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Nanobiotix believes that NBTXR3&#8217;s physical mode of action could make it broadly applicable across a multitude of solid tumor indications. In addition to head and neck cancers and STS, Nanobiotix intends to continue to develop and pursue NBTXR3 for other indications, and has already gathered data from clinical trials in liver cancers in the EU, prostate cancer in the United States, and rectal cancer in Taiwan. In December 2018 Nanobiotix entered into a collaboration with MD Anderson as part of which Nanobiotix intends to conduct multiple clinical trials in the United States to evaluate NBTXR3 plus radiotherapy, either alone or in further combination with immuno-therapies or chemotherapies, across several cancer types. If Nanobiotix is able to demonstrate the applicability of NBTXR3 to solid tumor cancers in its current and planned clinical trials, Nanobiotix believes it would be able to increase the addressable patient population of NBTXR3 to </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">encompass a significant portion of the patients who receive radiotherapy as part of their solid tumor cancer treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;padding-left:14.85pt">Complete post-approval trials for NBTXR3 for the treatment of locally advanced STS in the EU.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Following positive results from our Phase II/III clinical trial in April 2019, NBTXR3 became the first ever radioenhancer to have a CE mark, allowing it to be commercialized for the treatment of locally advanced STS under the brand name Hensify&#174;. Nanobiotix is currently preparing a post-marketing Study, (MS01_01 - also referred as Study 401) to continue evaluating acute and long-term safety, feasibility and efficacy in this population.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;padding-left:14.85pt">Build an effective clinical development program and establish a global commercial infrastructure for NBTXR3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Nanobiotix has conducted clinical trials involving multiple therapeutic areas throughout the United States and the EU, in which more than 400 physicians have been involved. In addition, Nanobiotix&#8217;s global medical science liaison team has consulted closely with a number of physicians, hospitals, clinics, and cancer treatment centers in the United States and key European markets to better understand their needs as clinicians and institutions and to tailor NBTXR3 accordingly. Nanobiotix plans to focus our commercialization and marketing efforts for NBTXR3 in Europe and the United States, subject to the grant of any marketing authorization by, among others, health regulatory agencies. Nanobiotix has entered into an agreement with LianBio for the development and potential commercialization of NBTXR3 in key countries in Asia. Nanobiotix retains development and commercialization rights to NBTXR3 in all other geographies, and may develop and commercialize NBTXR3 in other specific regions, independently or through collaboration agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_663"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Current cancer treatment options and limitations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In general, there are four commonly used cancer treatment methods: surgery, radiotherapy, chemotherapy and targeted therapies, in which drugs target specific molecules of the tumor tissue. These treatments may be used individually or in combination with one another.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Surgery remains the primary method for the eradication of solid cancers that are discovered at an early stage. Surgery aims to remove not only the tumor from the body, but also a ring of surrounding healthy tissues (referred to as the surgical margin), to try to ensure that all cancer cells are removed. Surgery may not be a viable option based on a patient&#8217;s health or the characteristics of the patient&#8217;s cancer. For example, when a patient&#8217;s cancer has spread, or metastasized, surgery alone may not be adequate to remove the cancer. When surgery is an option, it is often combined with radiotherapy or chemotherapy either before the surgery, in an effort to try to reduce the size of the tumor so that it is easier to remove with clean margins, or after the surgery, in an effort to eliminate residual cancer cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Radiotherapy is the administration of ionizing radiation, which are high-energy particles or rays such as X-rays, gamma rays, electron beams or protons, to destroy or damage cancer cells by blocking their ability to grow, divide and multiply. Radiotherapy is delivered over a period of several days to several weeks at a specific dose. Typically, patients receive a fraction of the dose per day. The duration and dosage of radiotherapy are based on the standard of care specific to the cancer indication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Radiotherapy is typically measured in grays (&#8216;&#8216;Gy&#8217;&#8217;), a unit of ionizing radiation dose with one Gy representing the absorption of one joule of energy per kilogram. In developed countries with access to radiotherapy, approximately 60% of all cancer patients will receive radiotherapy at least once, either alone or as a part of the more complex treatment protocol.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary growth drivers for the radiotherapy market globally are technological advancements and the associated growing adoption of radiotherapy devices and procedures. Improving the accuracy and precision of the delivery of radiation enhances the efficacy of radiotherapy and reduces the side effects and damage to surrounding healthy tissues, which has led to greater adoption of these techniques by the medical community and more widespread use among cancer patients. Because high-dose radiotherapy can be delivered in a more precise way, it can be used to target tumors that were previously inaccessible, such as brain tumors, thereby opening the radiotherapy market to additional patient populations. In addition, new technologies that require lower doses of radiation to destroy cancer cells can now be used in patients who may previously have been considered too fragile for higher-dose radiation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Despite these technological advancements and the increasing use of radiotherapy in treating cancer, there remain significant limitations to its use. Although radiotherapy is a local approach, it often causes damage to surrounding healthy tissues, and may not be an effective treatment for cancers that have spread, or metastasized. As a result, physicians may decide to withhold radiotherapy, because a high enough dose to kill the tumor cells would create unacceptable damage to surrounding healthy tissues and cause other toxic side effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, the I-O treatment approach has emerged as an option for cancer treatment. The I-O treatment approach is a relatively new approach to fighting cancer that does not directly target the tumor, but instead aims to stimulate and activate the patient&#8217;s own immune system, allowing it to recognize cancer cells and destroy them. I-O treatments </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">have demonstrated efficacy broadly in the treatment of many types of cancer, including among others leukemia, melanoma, lung cancer, prostate cancer, skin cancer, cancer of the digestive system, gynecological cancer and renal cancer. However, not all patients may benefit from I-O therapy. I-O therapy may be ineffective when a patient&#8217;s tumor is &#8220;cold&#8221;, meaning that the cancer either has not been recognized or has not provoked a strong enough response by the patient&#8217;s immune system. The challenge remains to find new ways to turn a cold tumor into a hot tumor&#8212;one that will be responsive to I-O treatment approaches.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_677"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">NBTXR3: Addressing the challenges of radiotherapy and I-O</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have designed NBTXR3 to address limitations inherent in radiotherapy, either alone or in combination with other treatment approaches:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">By amplifying the intratumor killing effect of the radiation dose within cancer cells, NBTXR3 is designed to give a radiation dose greater efficacy.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">By localizing the radiation dose within the tumor, NBTXR3 is designed to enhance the efficacy of radiotherapy without resulting in additional toxicities on the surrounding healthy tissues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">With respect to I-O treatment approaches to fighting cancer, our preclinical and early clinical results suggest that NBTXR3 plus radiotherapy may prime the immune response, thereby rendering otherwise cold tumors more prone to recognition by the patient&#8217;s immune system and therefore potentially more responsive to I-O treatments such as checkpoint inhibitors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_692"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our NBTXR3 technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are exploring the potential for nanotechnologies to provide solutions to unmet therapeutic needs in oncology. Our pioneering approach uses nanophysics to bring a physical mode of action to destroy cancer cells from within. When used in conjunction with radiotherapy, our NBTXR3 nanoparticles increase the absorption of the administered radiation, thereby magnifying and focusing the dose locally within a malignant tumor, but without causing incremental damage to surrounding healthy tissues. In magnifying the effect of the radiation, we believe our NBTXR3 technology improves the benefit-risk ratio of radiotherapy for patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amount of energy that can be deposited in a cell through radiotherapy is a function of the cell&#8217;s ability to absorb the radiation, which depends on the amount and form of energy used and the electron density of the receiving molecules. A cell is primarily composed of water, which has a very low electron density. At an average size of approximately 50 nanometers in diameter, our nanoparticles are directly injected into a malignant tumor prior to standard radiotherapy and can be internalized into the cell through endocytosis to function as radioenhancers. The inert nanoparticles have an inorganic core of crystallized hafnium oxide, which has a high electron density. When exposed to radiation, the high electron density of the nanoparticles allows the cancer cells to absorb more energy than would otherwise be absorbed by the water molecules in the tumor. The high electron density of the nanoparticles is essential for their effective interaction with radiation, while their physical and chemical properties do not cause incremental damage to surrounding healthy tissues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following image is a transmission electron micrograph of a cross-section slice of a tumor with nanoparticles after injection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Clustered 50 nm Nanoparticles in Cytoplasm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g2.jpg" alt="nbx-20211231_g2.jpg" style="height:207px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NBTXR3 is a novel approach to the local treatment of cancer that we believe provides a solution to the basic limitation of radiotherapy - an inability to deliver sufficient amounts of radiation to eradicate the tumor because of the low radiation tolerance of the surrounding healthy tissues. </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following illustration shows a representative increase in the radiation dose absorbed around the NBTXR3 nanoparticles administered into cancer cells. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">NBTXR3 Nanoparticles Amplifying the Effect of Radiation</span></div><div style="text-align:center"><img src="nbx-20211231_g3.jpg" alt="nbx-20211231_g3.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Mode of Action of NBTXR3 Nanoparticles</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">During radiotherapy, the interaction between the radiation and the targeted cell molecules ionizes atoms, freeing electrons from the orbit of the atoms. These electrons dissipate their energy in multiple interactions with surrounding molecules, producing free radicals, which are highly reactive ionized molecules in the cell. These free radicals are primarily responsible for the effectiveness of radiotherapy in causing DNA damage, ultimately leading to cell death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The mode of action of NBTXR3 nanoparticles can be described in four stages:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Stage 1: Activity/Inactivity Principle</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our nanoparticles are inert, meaning that they produce no effect without ionizing radiation. When activated by radiation, a number of phenomena occur. First, the radiation is absorbed by the hafnium oxide core of the nanoparticles. Because the core of the nanoparticle has a significantly higher electron density than water, it can absorb significantly more energy than a tumor cell could without the cluster of nanoparticles. Greater energy absorption generates more electrons, and ultimately more free radicals</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Stage 2: Cell Damage</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The electrons generated in the energy absorption disperse through the cancer cells and dissipate their energy in multiple interactions with surrounding molecules, creating free radicals. The free radicals are highly reactive and tend to destroy the covalent links of the molecules they interact with, such as DNA, RNA and proteins. Specifically, they cause severe and irreparable DNA damage mainly responsible for the lethal effect of ionizing radiation on cells. The free radicals therefore increase the localized cancer cell destruction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Stage 3: Subsequent Action in the Cells</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The destructive effect of free radicals is amplified and localized by the radiation-activated nanoparticles, which generate a controlled concentration of energy within the tumor. Ionizing radiation can be applied to the nanoparticles repeatedly because they return to their inactive, inert state after each exposure to radiation. Multiple courses of radiotherapy can be administered to a tumor that has received a single injection of our nanoparticles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Stage 4: Immune Activation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In our preclinical studies and our early clinical data, the treatment using radiation-activated nanoparticles has also been observed to trigger destruction of metastatic cells due to immunogenic cell death from the activation of the immune system. Based on these observations we believe that our nanoparticles may prime the body&#8217;s immune response, rendering tumors more prone to recognition by a patient&#8217;s immune system. In the illustration below, clusters of NBTXR3 nanoparticles are injected into the cell and, when activated by radiotherapy, cause destruction of cancer cells due to the high energy absorption. This destruction may include structural damage, DNA damage, stress to the cells, immunogenic cell death (a specific form of cell death related to the immune system) and cGAS-STING pathway activation (an immune sensing mechanism). This results in both direct cell death and activation of dendritic cells. Once activated, the dendritic cells trigger additional immune system activation, including the </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">activation of lymphocytes, or white blood cells in the immune system, including T cells such as CD4 (regulatory T cells) and CD8 (cytotoxic T cells). This activation of lymphocytes has the effect of &#8220;priming&#8221; the immune system to be able to better recognize and kill cancer cells.</span></div><div style="text-align:center"><img src="nbx-20211231_g4.jpg" alt="nbx-20211231_g4.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_687"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Overview of NBTXR3</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles, is administered through a single image-guided local injection directly into the tumor prior to radiotherapy. In our clinical trials, the dosage of injected NBTXR3 is based on a percentage of the baseline tumor volume and is determined during the initial phase of the respective clinical trial for different indications. NBTXR3 nanoparticles have a negative-charge surface coating, which allows them to interact with the surface of the tumor and accumulate inside the tumor cells. NBTXR3 is designed to render the targeted tumor more operable or help destroy it completely.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NBTXR3 can easily be incorporated into the current standard of care in radiotherapy. Hospitals and medical facilities where radiotherapy is delivered do not need any new equipment or to otherwise make significant capital investments in new technology in order to treat patients with NBTXR3.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We are currently prioritizing the development of NBTXR3 in the United States and the EU for the treatment of head and neck cancers, although we are also studying, or have studied, NBTXR3 across a broad range of indications, including locally advanced soft tissue sarcoma, primary and secondary liver cancers, prostate cancer, pancreatic cancer, esophageal cancer and non-small cell lung cancer. We believe NBTXR3 has the potential to treat all solid tumors where radiotherapy can be used. We have also observed that NBTXR3 activated by radiotherapy could modulate the antitumor immune response, supporting the rationale for its use as an in situ cancer vaccine, potentially in combination with I-O treatments. With respect to our I-O development program, the initial cancer indications for NBTXR3 in combination with immuno-oncology therapies - and, in particular, checkpoint inhibitor combinations - are head and neck cancers (including recurrent / metastatic head and neck squamous cell carcinoma) as well as lung and liver metastases from any primary cancer eligible for anti-PD-1 therapy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">For certain cancer indications, NBTXR3 can be combined with a gel to create a new formulation, which we refer to as NBTXR3-gel, for direct application in the tumor cavity following surgical removal of the tumor. Potential cancer indications for NBTXR3-gel include certain types of breast cancer, operable lung cancers, vertebral metastases and retroperitoneal STS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i377d9717844147e799376babda10462f_682"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our Clinical Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NBTXR3 has been, and is currently being evaluated in several clinical trials worldwide in various cancer patient populations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In December 2018, we entered into a large-scale comprehensive NBTXR3 clinical collaboration with MD Anderson. The collaboration is expected to support multiple clinical trials with NBTXR3 for use in treating several cancer types&#8212;including head and neck, pancreatic, lung, esophageal cancers&#8212;and is expected to involve approximately 340 patients. The first clinical trial under our collaboration with MD Anderson in patients with locally advanced or borderline resectable pancreatic cancer dosed its first patient in September 2020 while the second clinical trial in patients with esophageal cancer dosed its first patient in January 2021. The third clinical trial under this collaboration for non-small cell lung cancer amenable to re-irradiation was activated in February 2021. The fourth and fifth clinical trials for inoperable LRR HNSCC (I-O program) and R/M HNSCC (I-O program) were activated in March 2021 and April 2021, respectively. The R/M HNSCC clinical trial dosed its first patient in July 2021. Each of these five clinical trials is open and enrolling patients, although two of the trials have experienced slower recruitment and enrollment than planned as a result of the COVID-19 pandemic. The sixth planned clinical trial, in advanced solid tumors with lung or liver metastasis, is in the early stages of the regulatory review process, and the co-development with MD Anderson of additional clinical trials is ongoing. See &#8220;Business&#8212;Our Collaboration Agreements&#8212;Other Collaborations&#8212;NBTXR3 Clinical Collaboration with MD Anderson&#8221; for further detail regarding the terms of the collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In May 2021, we entered into an exclusive license and collaboration agreement with LianBio for the development and commercialization of NBTXR3 in key parts of Asia&#8212;Mainland China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore. LianBio has committed to enrolling patients in the Territory in NANORAY-312 as well as four additional registrational studies that we intend to conduct across indications and therapeutic combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In August 2012, we entered into an exclusive license and collaboration agreement with PharmaEngine for the development and commercialization of NBTXR3 in the Asia Pacific region. In March 2021, we and PharmaEngine mutually agreed to terminate the agreement. Three NBTXR3 clinical trials conducted by PharmaEngine were conducted in Asia and we expect data to be available during 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">See &#8220;Our Collaboration Agreements&#8221; for additional details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Refer to the paragraph titled &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NBTXR3 Development Pipeline</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; above for our ongoing and planned clinical trials, including those being undertaken and contemplated by MD Anderson, our principal collaboration partner</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_711"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Locally advanced soft tissue sarcoma</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Background and Opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Soft tissue sarcomas (&#8220;STSs&#8221;) are rare cancers that develop in different types of soft tissues, including muscles, joint structures, fat, nerves and blood vessels. Although STS can develop at any anatomic site, it occurs in the extremities (arms and legs) in approximately 60% of cases. The American Cancer Society estimates that in 2020 in the United States, approximately 13,130 patients were diagnosed with STS, and approximately 5,350 STS patients died from this cancer. In the EU, over 23,000 patients are diagnosed with STS each year. The National Cancer Institute estimates that the five-year survival rate for STS patients is approximately 65%. Median overall survival for patients with advanced, metastatic STS is estimated to be 18&#8211;19 months. Radiotherapy followed by surgery is part of the typical treatment regimen for patients with non-metastatic advanced, resectable STS of the extremities in Europe.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Achieving local control of the tumor is critical to improving survival rates and reducing the need for limb amputations. Patients with locally advanced STS are high-risk patients and have few therapeutic options capable of achieving local control. Consequently, innovative treatments to improve cancer cell destruction and the feasibility of surgical resection are needed. NBTXR3, when activated by radiotherapy, is designed to enhance the efficacy of radiation both by destroying more tumor cells and rendering the tumor more susceptible to surgical resection, thereby improving patient outcomes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase II/III Trial Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Following the positive results of our Phase I trial described below, we commenced a Phase II/III trial for EU registration (Study 301), which we also refer to as the Act.In.Sarc trial, to measure the anti-tumor activity of preoperative NBTXR3 activated by radiotherapy, as compared to radiotherapy alone, in patients with locally advanced STS. The Act.In.Sarc trial was conducted at more than 30 sites worldwide, including 23 sites in Europe and seven sites in the Asia-Pacific region. The Phase II/III clinical trial was completed outside of Asia in 2018, and the Phase III trial in the Asia-Pacific region was completed by PharmaEngine in the first half of 2021.</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Through the course of the Act.In.Sarc trial, a total of 180 adult patients with locally advanced STS of the extremity or trunk wall were randomized, at a 1:1 ratio, to treatment under one of two arms: (i) single intratumoral injection of NBTXR3 at the recommended dose (10% of the tumor volume), followed by five weeks of radiotherapy (the </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NBTXR3 arm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), or (ii) five weeks of radiotherapy alone (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">control arm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). In both cases, the radiotherapy was followed by surgical resection of the tumor. Of the 180 patients recruited for the trial, 176 were analyzed for the primary endpoint in the intended-to-treat full analysis; three patients were incorrectly diagnosed with STS and one patient was found to be ineligible for pre-operative radiotherapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The primary endpoint of the Phase II/III trial was an increase in the pathological complete response rate of intratumoral injection of NBTXR3 activated by external beam radiation therapy (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">EBRT</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), as compared against EBRT alone. The primary endpoint was evaluated, in accordance with European Organisation for Research and Treatment of Cancer guidelines, by a centralized group of pathologists who were blinded to the arm of treatment. The secondary endpoints were to evaluate the safety profile of NBTXR3 activated by radiotherapy and compare the rate of tumor surgery with R0 margins (meaning no remaining cancer cells could be seen microscopically within a widely accepted margin after resection), the percentage of tumor necrosis/infarction, limb amputation rates and tumor response as measured by RECIST 1.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Pathological complete response rate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The trial achieved its primary endpoint, with 16.1% of patients in the NBTXR3 arm having a pathological complete response (defined as less than 5% of residual viable cancer cells in the tumor) compared to 7.9% of patients in the control arm. The difference was statistically significant, with a p-value of 0.0448. A p-value, or probability value, cited in figures in the Annual Report as &#8220;p&#8221;, is the likelihood of finding the observed, or more extreme, outcome (e.g., a significant difference in terms of response for patients receiving NBTXR3 plus radiotherapy relative to patients receiving radiotherapy alone) when a baseline outcome is assumed to be true (e.g., patients receiving NBTXR3 plus radiotherapy and patients receiving radiotherapy alone both having an equal response). A p-value of less than or equal to 0.05 is generally considered to demonstrate statistical significance, meaning that one would accept the observed outcome as reasonable evidence to not accept the baseline outcome.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, in the subgroup of patients with a higher histology grade (i.e., a more aggressive disease), which represented the majority of patients in the trial, pathological complete response was achieved in four times as many patients in the NBTXR3 arm (17.1%) compared to patients in the control arm (3.9%). The following graph shows the percentage of patients in each arm based on whether they were considered to have Grade 1 or Grade 2/3 tumors. The remaining patients in each arm of the trial had tumors of unknown grade.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g5.jpg" alt="nbx-20211231_g5.jpg" style="height:375px;margin-bottom:5pt;vertical-align:text-bottom;width:430px"/></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><img src="nbx-20211231_g6.jpg" alt="nbx-20211231_g6.jpg" style="height:307px;margin-bottom:5pt;vertical-align:text-bottom;width:422px"/></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patients in the NBTXR3 arm were more likely to have a pathological response (not limited to a complete response). The portion of patients with pathological &#8220;nearly&#8221; complete response (defined as less than 7% of residual viable cancer cells in the tumor) and pathological response with 10% or less of residual viable cancer cells were 24.7% and 34.6%, respectively, in patients in the NBTXR3 arm as compared to 14.8% and 19.8%, respectively, in patients in the control arm</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">R0 resection margin</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The main secondary endpoint of the trial, the rate of tumor surgery with R0 margins, was also met. R0 resection margin was observed in 77% of the patients in the NBTXR3 arm, compared to 64% of patients in the control arm. This difference was statistically significant, with a p-value of 0.0424.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Tumor necrosis/infarction</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on histologic analysis, we observed that the mean percentage of tumor necrosis/infarction achieved was 28.8% for patients in the NBTXR3 arm, compared to 19.2% for patients in the control arm, a difference that was also statistically significant, with a p-value of 0.014.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g7.jpg" alt="nbx-20211231_g7.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:384px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Safety profile similarity between NBTXR3 and control arms</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Similar safety profiles were observed in the NBTXR3 arm and the control arm, including the rate of postsurgical wound complications. NBTXR3 did not impair the patients&#8217; ability to receive the planned dose of radiotherapy (&#8220;RT&#8221; in the table below). In the NBTXR3 arm, 7.9% of patients experienced grade 3-4 acute immune reactions, which were manageable and of short duration. Further, NBTXR3 showed a good local tolerance in patients and did not have any impact on the severity or incidence of radiotherapy-related AEs. The tables below summarize selected contemporaneous safety information gathered as part of the trial, which is the date that was submitted in connection with the regulatory process for the CE mark of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g8.jpg" alt="nbx-20211231_g8.jpg" style="height:501px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trial results were presented in October 2018 at the European Society for Medical Oncology (&#8220;ESMO&#8221;) 2018 Congress and the American Society for Radiation Oncology 60th Annual Meeting and subsequently published online in the peer-reviewed journal The Lancet Oncology in July 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on these trial results, in April 2019, we completed the regulatory process for the CE mark of NBTXR3, thereby allowing the product to be commercialized for the treatment of locally advanced STS of the extremities and trunk wall under the brand name Hensify&#174; in the 27 EU countries. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term patient follow-up is currently ongoing to evaluate the time-to-local / distant recurrence and local / distant recurrence rates at 12 and 24 months. At the 2021 Annual Meeting of ASCO, we reported on long-term safety of NBTXR3 in patients treated in the Act.In.Sarc trial. As evaluated by several patient- and physician-reported methods, the long-term safety evaluation did not identify any negative impact on patient quality of life or long-term morbidity from NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In light of our current development priorities, we do not presently intend to pursue commercialization for NBTXR3 for the treatment of locally advanced STS of the extremities and trunk wall in additional jurisdictions. We are currently preparing a post-registrational trial (Study 401 (MS01_1)) that will continue evaluating the safety and efficacy of </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hensify&#174; and still provide patients with access to the product. Based on the expected timing of discussions with regulatory authorities regarding the planned protocol and impact of the COVID-19 pandemic on clinical development timelines, launch of Study 401 (MS01_1) in Europe is expected in 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Act.in.Sarc trial followed positive results of our initial Phase I trial, which we conducted to evaluate the tolerance and feasibility of increasing doses of NBTXR3 by intratumoral injection, activated by external radiotherapy, in patients with locally advanced STS of the extremity. Through the course of this dose escalation study, we analyzed 22 patients at two sites in France with a single intratumoral injection of NBTXR3 prior to the first radiotherapy session.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase I Trial Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary endpoints of the Phase I trial were to evaluate the feasibility of NBTXR3 intratumoral injection and early dose-limiting toxicities and tolerance of NBTXR3. The secondary endpoints were to evaluate the tumor response to NBTXR3 activated by radiotherapy, measured in terms of the destruction of malignant cells, evaluate the response rate to NBTXR3 activated by radiotherapy by medical imaging and characterize the distribution of NBTXR3 in the body over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Initial data from the Phase I trial confirmed NBTXR3&#8217;s long-term intratumoral bioavailability and an absence of leakage to surrounding healthy tissues. We observed persistence of the nanoparticles in the tumor mass throughout five weeks of radiotherapy, confirming the feasibility of local injection of NBTXR3 and the clinical relevance of a single injection. A single injection was sufficient to achieve long-term intratumoral residence in all histological types and sizes for the sarcomas. No grade three or four adverse events were observed at the recommended dose of 10%. The initial data established feasibility for our NBTXR3 therapeutic approach. As a result, we broadened the target patient population for the trial, amending the research protocol in 2013 to include patients with sarcoma of the trunk wall.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The final Phase I trial results were positive&#8212;on average, we observed 40% shrinkage in treated tumor size and an average pathological response of 73% in tumors known to be treatment-resistant across different sarcoma subtypes, including undifferentiated sarcoma, rhabdomyosarcoma, and synovial sarcoma. Four serious adverse events of pyrexia, abdominal pain, injection-site reaction and post-operative wound complication were deemed to be related to NBTXR3 and two serious adverse events of injection site pain and hypoaesthesia were deemed to be injection related. All patients that participated in the trial underwent complete extended surgical resection of the tumor, which was the therapeutic aim. Complete tumor resection is optimal because it impacts the local recurrence rate and improves prognosis and survival rates. The following graphic depicts shrinkage of the tumor in a representative patient in the trial after five weeks of treatment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g9.jpg" alt="nbx-20211231_g9.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_716"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Locally advanced head and neck cancers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Background and Opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Squamous cell carcinoma of the head and neck cancers constitute more than 95% of head and neck cancers and include cancers of the oral cavity, tongue and oropharynx, a part of the throat, larynx and hypopharynx. These structures play a critical role in a human&#8217;s ability to swallow, eat, breathe and speak. The American Cancer Society estimates that in 2020 in the United States, approximately 53,260 patients will be diagnosed with oral or oropharyngeal cancer and approximately 10,750 patients will die from the cancer. According to 2018 estimates by the Global Cancer Observatory, part of the World Health Organization&#8217;s International Agency for Research on Cancer, around 890,000 patients are diagnosed globally each year with head and neck cancer. The five-year survival rate for patients with oral and oropharyngeal cancer is approximately 65%. These cancers represent a major public health concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cisplatin-based chemotherapy in combination with concomitant definitive radiation is the standard treatment for locally advanced head and neck cancers in both the United States and the EU which cannot be resected or for patients who refuse surgery. However, it is often not an option for elderly or frail patients who are unable to endure </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the physical strain inherent in chemoradiation treatment. The alternative treatment to chemoradiation is cetuximab in combination with radiotherapy, but its efficacy is less well established in elderly patients. These patients are estimated to account for approximately 25% of patients with head and neck cancers. In data presented at the Multidisciplinary Head and Neck Cancers Symposium 2020, elderly patients treated with radiotherapy alone or radiotherapy in combination with cetuximab had a median PFS of 7.3 months. Elderly patients with locally advanced tumors who receive radiation only also generally have limited OS expectancy (median of 12 months following diagnosis, based on our review and sub-group analysis of scientific literature relating to head and neck cancers) and typically experience poor quality of life, as they have limited therapeutic options and a high unmet medical need and are largely underrepresented in existing clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes data from certain published scientific literature relating to head and neck clinical trials evaluating radiotherapy combined with the identified chemotherapies:</span></div><div style="margin-top:12pt;text-align:center"><img src="nbx-20211231_g10.jpg" alt="nbx-20211231_g10.jpg" style="height:720px;margin-bottom:5pt;vertical-align:text-bottom;width:605px"/></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Abbreviations: HPV (human papillomavirus); OPSCC (oropharyngeal squamous cell carcinoma); ECOG (a standardized measure&#8211;ranging from 5 to 0&#8211;of a patient&#8217;s level of functioning in terms of his/her ability to care for him/herself, carry out daily activity and engage in physical ability; a lower score means the patient is better able to function); KPS (a standardized measure&#8211;ranging from 0 to 100&#8211;of a patient's level of functioning in terms of his/her ability to care for himself/herself, carry out daily activity and engage in physical ability; a higher score means the patient is better able to function).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This historical literature is presented solely to illustrate the current market opportunity arising from existing application of the standard treatment&#8212;chemotherapies in combination with concomitant radiation&#8212;for patients with locally advanced head and neck cancers. Because of the unique design of such studies applied to specific patient populations, no comparison with any of our clinical trials is possible and none should be inferred from this background data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase III Registration Trial Design (&#8220;NANORAY-312&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2020, we submitted to the FDA for review the NANORAY-312 protocol for a global Phase III clinical trial in elderly patients with locally-advanced head and neck cancer who are ineligible for platinum-based (cisplatin) chemotherapy. The study is ongoing. First clinical sites for NANORAY-312 were activated in Europe during the fourth quarter of 2021, with the first patient being randomized in January 2022. We expect U.S. sites and Asian sites (through LianBio&#8217;s activities) activation  and enrollment to begin in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The clinical trial will be a controlled randomized (1:1) two-arm  global registration trial including elderly head and neck cancer patients who are ineligible for platinum-based (cisplatin) chemoradiotherapy. Patients in the control arm will receive definitive radiation therapy versus patients in the treatment arm who will receive NBTXR3 activated by definitive radiation therapy. In both arms cetuximab addition would be allowed as per investigator&#8217;s choice. The trial is expected to be conducted at more than 150 sites worldwide and approximately 500 patients will be randomized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary endpoint of the study is the PFS and the key secondary endpoint is the OS. The study is designed to demonstrate a superiority of NBTXR3 activated by radiation therapy over control on PFS with a statistical power of 89%  and on OS with a statistical power of 80% (hazard ratio of at least 0.692 and 0.75 for PFS and OS, respectively). An interim analysis aiming to demonstrate superiority of NBTXR3-containing arm over control on PFS and on OS is planned. In addition, overall response rate, safety and quality of life will be evaluated as secondary endpoints. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A futility analysis is expected at approximately 18 months after the first patient is randomized, the interim analysis for PFS superiority is expected at approximately 30 months  after first patient randomization, and the final analysis at approximately 48 months. In the event of clinically meaningful PFS improvement in the planned interim analysis with no detrimental OS effect having been observed, a submission requesting accelerated approval of NBTXR3 in the United States for this indication will follow (&#8805; 6 months PFS difference). A median PFS of 9 months and median OS of 12 months is expected in the control arm with an expected positive Hazard Ratio (NBTXR3/control) of 0.75 for the NBTXR3 arm. The Hazard Ratio is a measure of the risk of a particular event occurrence in one group compared to another group, over time. For example, a Hazard Ratio of 0.75 indicates that risk of death is reduced by one fourth in the treatment arm as compared to the control arm.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NANORAY-312 will utilize four stratification factors: (i) Investigator&#8217;s choice (cetuximab addition or not), (ii) HPV status (HPV-positive oropharynx versus other), (iii) modified Charlson Comorbidity Index, or mCCI score at screening (2 to 3 versus &#8805; 4) and (iv) region (North America &amp; Western Europe versus Rest of World).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Charlson Comorbidity Index (CCI) measures the burden of disease and predicts mortality in various diseases. The CCI encompasses 19 medical conditions, each weighted according to its impact on mortality. The mCCI further integrates the patient&#8217;s age as an additional scoring information to the CCI.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2020, we received Fast Track designation from the FDA for NBTXR3 in this patient population. Fast Track designation is a process designed to facilitate the development and accelerate the review of treatments for serious conditions and that have the potential to address unmet medical needs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase I (&#8220;Study 102 Escalation&#8221;) and Phase I Expansion (&#8220;Study 102 Expansion&#8221;) Trial Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are conducting a Phase I clinical trial of NBTXR3 activated by intensity-modulated radiation therapy in patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx who are ineligible for cisplatin (the frontline chemotherapy drug for advanced head and neck cancers) or intolerant to cetuximab (a monoclonal antibody used as part of targeted cancer therapy in head and neck cancers). Recommended Phase 2 Dose (&#8220;RP2D&#8221;) has been determined in the Study 102 Escalation. We are in the process of conducting the dose expansion part of the trial at the RP2D. The Study 102 Expansion is being conducted at 20 sites in Europe. In Study 102 Escalation, the administered dosage was escalated, with 19 patients receiving an injection of NBTXR3, followed by intensity-modulated radiation therapy (70Gy in total, or 2Gy per day, five days a week for seven weeks), in accordance with standard medical practice, commencing one to five days after NBTXR3 injection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary endpoint of Study 102 Escalation was to evaluate the safety of NBTXR3 and determine the recommended Phase II dose of NBTXR3 activated by radiotherapy and the primary endpoints of the Study 102 Expansion are to confirm that the recommended dose is safe and to obtain preliminary evidence of efficacy by observing the objective response rate and complete response rate of the primary tumor by imaging according to RECIST 1.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The secondary endpoints of both phases were to evaluate the safety and tolerability of NBTXR3, to evaluate the overall response rate and the complete response rate (based on the RECIST 1.1) of NBTXR3, to evaluate the local and general PFS, assess the feasibility of local administration by intratumoral injection of NBTXR3, and characterize the body kinetics of NBTXR3 administered by intratumoral injection.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the RECIST 1.1 criteria, (i) complete response, or CR, refers to the disappearance of all target lesions, (ii) partial response, or PR, refers to a decrease of at least 30% of target lesions, (iii) overall response, or OR, refers to CR and PR, taken together, (iv) progressive disease, or PD, refers to an increase of at least 20% of target lesions or the appearance of one or more new lesions, (v) stable disease, or SD, refers to a lack of sufficient shrinkage to qualify for PR, but also a lack of sufficient increase to qualify for PD, and (vi) unconfirmed response refers to target lesions that still require a confirmatory scan at a subsequent time point.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Dose Escalation Results</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Phase I Escalation. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We initially presented preliminary efficacy and safety results from Study 102 Escalation in February 2020 at the Multidisciplinary Head and Neck Cancers Symposium. Additional patient follow-up has been conducted through April 2020. NBTXR3 was well tolerated in the trial and the recommended dose was established as equivalent to 22% of tumor volume. Preliminary results included no observed serious side effects or serious adverse events related to NBTXR3 observed, and feasibility of injection at all dose levels (5%, 10%, 15% and 22%) with no leakage to surrounding healthy tissues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following graphic depicts shrinkage of the tumor in a representative patient in the trial over time following treatment. The tumor continued to shrink after the end of treatment, with the patient achieving a complete response at seven months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g11.jpg" alt="nbx-20211231_g11.jpg" style="height:154px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April 2020, nine out of the 16, or 56%, evaluable patients who received the intended dose of NBTXR3 and radiotherapy had achieved a complete response of the injected lesion, according to the RECIST 1.1. Overall complete response (including non-injected lesions) was observed in five of the 16 patients, or 31%, and objective response rate was observed in 11 of the 16 patients, or 68%. Of the seven patients who received the two highest doses of NBTXR3 plus radiotherapy and were alive at the 12-month cut-off date, five patients were still alive at 24 months following treatment. Of the 13 evaluable patients receiving the highest dose levels (therapeutic doses 10%, 15%, and 22%), nine patients, or 69%, achieved a complete response of the injected lesion. Follow up of treated patients remains ongoing. We are encouraged by the preliminary results, and we believe NBTXR3 has the potential to extend survival and improve quality of life in this advanced cancer patient population. The following chart shows </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">follow-up data of the 19 treated patients at the various NBTXR3 dose levels as of the end of April 2020, including the type of cancer, tumor grade, age and human papilloma virus status for each patient.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Patient Follow-up in Study 102 Escalation Locally Advanced Head and Neck Cancers Trial</span></div><div style="margin-top:12pt;text-align:center"><img src="nbx-20211231_g12.jpg" alt="nbx-20211231_g12.jpg" style="height:289px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following chart shows the best observed response from baseline of each of the 16 evaluable patients.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Patients&#8217; Best Response in Study 102 Escalation Locally Advanced Head and Neck Cancers Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g13.jpg" alt="nbx-20211231_g13.jpg" style="height:373px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Dose Expansion Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Phase I Expansion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of January 2022, 56 patients were treated in the expansion cohort of which 44 were confirmed to be evaluable, one additional patient is ongoing but is not yet evaluable. Therefore, patient accrual was completed and recruitment is closed. Ongoing patients on the study will be followed up for safety, response, PFS and OS for a minimum of 12 months after treatment completion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The most recent updated efficacy and safety results from the ongoing Study 102 Expansion were presented at the Annual Meeting of ASTRO in October 2021. As of the September 3, 2021 cut-off date, 54 patients had received NBTXR3 and 41 patients were evaluable for objective tumor response. The expansion cohort utilizes the highest dose level (22%) from Study 102 Escalation in order to potentially strengthen preliminary efficacy data from that initial escalation phase. Evaluability in Study 102 Expansion was determined based on the patient receiving at least 80% of the intended intratumoral dose of NBTXR3, at least 60 Gy of radiotherapy, and the required imaging to assess the target lesion at baseline and at least once post treatment. In the evaluable patient population, the median overall survival was 18.1 months, and the median progression free survival was 10.6 months. Among the 21 patients with best observed overall response of complete response, six patients died for non-oncologic reasons and only one died from disease progression. The median overall survival was not reached at the cut-off date (mean follow up of 16.1 months). Investigator-assessed response rates remained consistent with previously reported results from the dose escalation and dose expansion study, showing the primary tumor objective response rate according to RECIST 1.1, as per investigator assessment, was 85.4% (35 out of 41 patients), consisting of 26 patients with primary tumor complete response (63.4%) and 9 patients with primary tumor partial response (22.0%). The other six patients were considered to have primary tumor stable disease. One patient, identified in the chart below as having stable disease (as noted with a double asterisk), was recorded by the principal investigator on the electronic case report form (&#8220;eCRF&#8221;) as having achieved an unconfirmed complete response of the injected lesion, and we have included this patient in the 63.4% primary tumor complete response rate and the 85.4% primary tumor objective response rate. Because many of the patients are early in their follow-up, there is potential for the rate of complete response to improve with the passage of time, as seen in the dose escalation part. Median follow up as of September 3, 2021 was 9.5 months since administration of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Based on an assessment under the mCCI, the patient population in the Study 102 Expansion is at higher risk of early death than the global elderly head and neck cancer population. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In head and neck cancer, an mCCI &#8805; 4 is correlated with higher risk of death relative to the broader population. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the Study 102 Expansion &#8220;all patients treated&#8221; population (54 patients, including 13 non-evaluable patients), mOS was 14.1 months, and median PFS was 9.4 months. Among the &#8220;all patients treated&#8221; population, 63% of all patients, and nine out of the 13 non-evaluable patients included in the survival analysis, had an mCCI of four or more &#8212; an mCCI score associated with a risk of early death (defined as death within 180 days after initiation of treatment), which is two to three times the prevalence of high mCCI in the overall LA-HNSCC population that has been reported in the literature (Zumsteg ZS, et al. Cancer 2017; 123: 1345-53). Of the 13 non-evaluable patients, two were still pending evaluability assessment and of the 11 remaining, seven had early occurring death (within 180 days after initiation of treatment). In contrast, in evaluable patients the mOS that was reached was 18.1 months as of the September 3, 2021 cut-off, suggesting the observed mOS in all treated patients could be related to the high number of non-evaluable patients and a higher mCCI score observed in this subgroup which may reflect a higher risk for early death as compared to lower mCCI scores.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Among evaluable patients with oropharyngeal head and neck cancer with negative HPV status, objective response rate of the target lesion was 100% (12 out of 12 patients), consisting of eight patients with complete response (66.7%) and four patients with partial response (33.3%). In the subgroup composed of oropharyngeal head and neck cancer patients with positive HPV status, objective response rate, as per investigator&#8217;s assessment, of the target lesion was 100% (10 out of 10 patients) consisting of nine patients with complete response (90%) and one patient with partial response. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Final results might differ from what has been reported at ASTRO&#8217;s Annual Meeting in October 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following chart shows the best observed target lesion response from baseline of each of the 41 evaluable patients as of September 3, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Patients&#8217; Best Observed Target Lesion Response by RECIST 1.1 as per Investigator Assessment in Study 102 Expansion Locally Advanced Head and Neck Cancers Trial (Evaluable Population: N=41)</span></div><div style="margin-top:12pt;text-align:justify"><img src="nbx-20211231_g14.jpg" alt="nbx-20211231_g14.jpg" style="height:372px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following charts show the survival of the 41 evaluable patients and the 54 patients in the "all patients treated&#8221; population as of September 3, 2021. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Kaplan Meier Curve of Survival in Study 102 Expansion Locally Advanced Head and Neck Cancers Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g15.jpg" alt="nbx-20211231_g15.jpg" style="height:259px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Kaplan Meier Curve of Progression Free Survival in Study 102 Expansion Locally Advanced Head and Neck Cancers Trial</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g16.jpg" alt="nbx-20211231_g16.jpg" style="height:257px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NBTXR3 has continued to be well tolerated in Study 102 Expansion. Five SAEs related to NBTXR3 were observed across five patients: one Grade 4 tumor hemorrhage (also related to radiotherapy), one Grade 3 stomatitis (also related to radiotherapy), one Grade 3 soft tissue necrosis (also related to radiotherapy), one Grade 4 dysphagia (also related to radiotherapy) and one Grade 4 sepsis (also related to radiotherapy and disease). Of the SAEs, one death from sepsis occurred, which the investigator assessed as possibly related to NBTXR3, radiotherapy, and cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The AEs and SAEs are set forth in the graph below.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g17.jpg" alt="nbx-20211231_g17.jpg" style="height:332px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A review of data as of the February 22, 2022 cut off date from Expansion Study 102 shows median overall survival (mOS) of 23 months in evaluable patients (n=44) demonstrating continued improvement relative to the analysis presented at ASTRO 21 and consistent with data reported from the dose escalation phase of Study 102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i377d9717844147e799376babda10462f_726"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Immuno-Oncology (&#8220;I-O&#8221;) Program Trials</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In recent years, significant attention has been focused on the potential of I-O treatments to treat cancer patients, and in particular, with the approval of first checkpoint inhibitors anti-CTLA4 (ipilimumab) and anti-PD(L)1 (such as pembrolizumab, nivolumab, durvalumab, or atezolizumab). Checkpoint inhibitors are a type of immunotherapy that function to block proteins that stop the immune system from attacking cancer cells. In doing so, they enable the T cells to recognize cancer cells that would otherwise be invisible to immune attack. However, many cancers, which are often referred to as &#8220;cold&#8221; tumors, exhibit little or no response to checkpoint inhibition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cancer immunotherapy is becoming a major treatment paradigm for a variety of cancers. Although immunotherapy, especially the use of immune checkpoint inhibitors, has achieved clinical success, most cancer patients present resistance to I-O treatments. In fact, published scientific data shows that only 15%-20% of non-small cell lung cancer patients and 13%-22% of head and neck squamous cell carcinoma patients respond to immune checkpoint inhibitors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recently, significant interest has been focused on the possibility of achieving improved response rate across cancers using various therapies in combination with I-O. The figures below show data from a non-exhaustive selection of published scientific literature relating to clinical trials evaluating I-O treatments in combination or alone for the treatment of head and neck cancer in I-O na&#239;ve and I-O non-responder patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Outlook of Best Percentage Change from Baseline in HNSCC Trials </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Literature Data)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">PD-1 Non-Responders (&#8220;NR&#8221;) Trials</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g18.jpg" alt="nbx-20211231_g18.jpg" style="height:289px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><img src="nbx-20211231_g19.jpg" alt="nbx-20211231_g19.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">PD-1 Na&#239;ve Trials</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g20.jpg" alt="nbx-20211231_g20.jpg" style="height:564px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This foregoing historical data survey is presented solely to illustrate the current market opportunity arising from existing application of available I-O treatments&#8212;in combination or alone&#8212;for head and neck cancer patients that are either na&#239;ve or non-responder patients. Because of the unique design of such studies applied to specific patient populations, no comparison with any of our clinical trials is possible and none should be inferred from this background data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Supporting Rationale for I-O Treatment Approach</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that NBTXR3 activated by radiotherapy in combination with immune checkpoint inhibitors has the potential to unlock the potential of I-O treatments by converting checkpoint inhibitor non-responders into responders and is being explored in multiple settings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Our preclinical and early clinical trial results suggest that NBTXR3-enhanced radiotherapy may prime the immune response, thereby rendering otherwise cold tumors more prone to recognition by the patient&#8217;s immune system and therefore more responsive to I-O treatments such as checkpoint inhibitors. This effect is also referred to as causing a &#8220;cold&#8221; tumor to become &#8220;hot.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In preclinical experiments, we observed NBTXR3 activated by radiotherapy kill more cancer cells in vitro than radiotherapy alone, leading to the release of a greater number of tumor-associated antigens. In addition, in in vitro experiments performed on different human cancer cell lines, we observed NBTXR3 activated by radiotherapy enhance the expression of markers of immunogenic cell death, as well as activation of the cGAS-STING pathway (a component of the immune system that detects tumor-derived DNA and generates intrinsic anti-tumor immunity). These results suggest that NBTXR3 activated by radiotherapy could modulate the immunogenicity of the cancer cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also observed NBTXR3 activated by radiotherapy in vivo generate an abscopal effect, which is a reduction of metastases burden outside the irradiated area. This abscopal effect depends on the increase of CD8+ T cell lymphocyte infiltrates (T lymphocytes that work to kill malignant tumor cells) in both treated and untreated tumors, induced by NBTXR3 activated by the radiotherapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In our Phase II/III locally advanced STS clinical trial, based on immunohistochemistry analyses, we observed that NBTXR3 activated by radiotherapy increased the density of CD8+ T cell lymphocytes and also decreased FOXP3+ (Treg) (regulatory T cells that work to suppress immune response) compared to radiotherapy alone in the tumors, while macrophage number remained relatively constant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, researchers from our collaborator, MD Anderson, shared preclinical data in a poster presentation at the American Association of Cancer Research (AACR) Virtual Special Conference on Radiation Science and Medicine. This study examined NBTXR3 activated by radiotherapy in combination with anti-PD-1 along with TIGIT and LAG3 inhibitors in an in vivo anti-PD-1 resistant mouse model (344SQR). The data showed that the combination therapy of NBTXR3 + radiotherapy + anti-PD-1 + anti-LAG3 + anti-TIGIT (Combo therapy) significantly promoted the proliferation activity of CD8+ T cells, improved local and distant tumor control, and increased survival rate. The anti-tumor efficacy of this Combo therapy was heavily dependent on CD4+ and CD8+ T cells. The data showed that the cured mice maintained significantly higher percentages of memory CD4+ and CD8+ T cells, as well as stronger anti-tumor immune activities than control, and the cured mice from the groups treated with the Combo therapy were immune to reinjections of tumor cells. Further, in this preclinical study, the Combo therapy augmented anti-tumor response in both irradiated and unirradiated (abscopal) tumors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Together, these data suggest that NBTXR3 activated by radiotherapy could be able to modulate the anti-tumor immune response and transform the tumor into an in situ vaccine, which prompted the initial development of our I-O program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Development in I-O </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are conducting, and continue to further develop, a global I-O development program to explore the use of NBTXR3 as a complement to immune checkpoint inhibitors across several solid tumor indications. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Study 1100, a Phase I basket trial of NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in patients with R/M HNSCC or with lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy, is ongoing. A clinical study protocol amendment was submitted to the FDA at the start of 2022, to include three expansion cohorts of up to 35 patients each, in order to evaluate the safety and efficacy of the combination in patients with either R/M HNSCC which failed a prior PD-(L)1 treatment (cohort 1), or in R/M HNSCC patients that are PD-1 naive (who have never received I-O treatment before) (cohort 2) or in patients with selected solid tumors (non-HNSCC cohort 3) resistant to prior PD-(L)1 treatment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, pursuant to our collaboration with MD Anderson, we are planning to evaluate NBTXR3 in combination with various other checkpoint inhibitors (anti-PD-1, or anti-PD-L1) across several cancer indications. There are currently three clinical trials contemplated as part of our I-O program under the MD Anderson collaboration. The first two trials are currently enrolling patients, a Phase II trial in the reirradiation setting of NBTXR3 combined with pembrolizumab for inoperable, locoregionally recurrent or second primary HNSCC, and a Phase II trial for NBTXR3 for recurrent/metastatic HNSCC patients with limited PD-L1 expression or refractory to PD-1 blockade on combination with pembrolizumab. The third, a randomized Phase I/II trial for NBTXR3 combined with an anti-PD-1 or PD-L1 +/- RadScopal&#8482; in patients with advanced solid tumors and lung or liver metastases, is in the protocol development stage. We are conducting, and continue to further develop, a global I-O development program to explore the use of NBTXR3 as a complement to immune checkpoint inhibitors across several solid tumor indications. </span></div><div id="i377d9717844147e799376babda10462f_721"></div><div style="margin-top:12pt;padding-left:77.95pt;text-align:justify;text-indent:-77.95pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">I-O Program&#8212;HNSCC, Lung Metastasis or Liver Metastasis</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Phase I Basket Trial Design (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">Study 1100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We initiated a Phase I prospective, multi-center, open-label, non-randomized clinical trial evaluating the safety and efficacy of NBTXR3 activated by radiation therapy combined with anti-PD-1 checkpoint inhibitors (nivolumab or pembrolizumab). The trial is being conducted in two consecutive phases: dose escalation followed by dose expansion. The Dose Escalation part of the trial includes three patient populations: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">patients with locoregional recurrent (LRR) or recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) amenable to irradiation of the head and neck (HN) field that are anti-PD-1 therapy na&#239;ve or nonresponsive to an anti-PD-1 therapy (&#8220;HNSCC Cohort&#8221;),</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">patients with lung metastases from any primary cancer eligible for anti-PD-1 therapy (&#8220;Lung Cohort&#8221;) or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">patients with liver metastases from any primary cancer eligible for anti-PD-1 therapy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Dose Expansion part of the trial has the following treatment cohorts, which were introduced through a protocol amendment in early 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Locoregional recurrent and/or metastatic HNSCC and that are resistant to a prior anti-PD-1/L1 therapy with at least one lesion located in either HN region, lungs or liver, amenable for intratumoral injection and irradiation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Locoregional recurrent and/or metastatic HNSCC na&#239;ve to anti-PD-1/L1 therapy and eligible for an anti-PD-1 therapy with at least one lesion located in either HN region, lungs or liver amenable for intratumoral injection and irradiation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Lung or liver or soft tissue metastases of primary tumor originating from either NSCLC, malignant melanoma, HCC, RCC, urothelial cancer, cervical cancer or TNBC that are resistant to a prior anti-PD-1/L1 therapy and eligible for anti-PD-1 therapy with at least one lesion located in either soft tissue, lungs or liver that could be injected intratumorally and irradiated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trial&#8217;s main objective is to determine the recommended Phase II dose of NBTXR3 activated by radiotherapy in combination with an anti-PD-1. The trial is ongoing and is being conducted at up to 20 sites in the United States; we intend to enroll a total of approximately 141 evaluable patients in the trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The dose escalation phase is based on a classical 3+3 design, meaning that at least three patients will be treated at the initial dose level, with treatment escalated to the next level in the absence of any dose-limiting toxicity occurrences, in order to identify the appropriate dose of NBTXR3 to be injected into the tumor. NBTXR3 doses will be escalated, but the anti-PD-1 antibody dose will remain constant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primary and secondary endpoints will determine the recommended Phase II dose of NBTXR3 activated by radiotherapy and evaluate safety and efficacy, while exploratory endpoints will further characterize the treatment-induced gene expression, including enriched cytokine activity and markers of adaptive immune response and T-cell receptor signaling pathways.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Results </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We presented updated clinical results from ongoing Study 1100 at the 2021 ASTRO Annual Meeting in October 2021. As of the September 3, 2021 cut-off date, 21 patients received NBTXR3 and/or radiotherapy, with 16 patients evaluable for tumor response. Five patients were unevaluable (two patients died with no post-treatment scans, one patient had no post-baseline scan and two patients did not receive at least 80% of NBTXR3).</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The updated results suggest that NBTXR3 administration has been feasible and well-tolerated in all patients currently enrolled in Study 1100. Through the cut-off date, six SAEs were observed which were identified as related to NBTXR3 or the injection procedure in 4 patients, and which included facial paresis, lymphocyte count decrease, weight decrease, hyperglycemia, pneumonitis and soft tissue necrosis. No injection and/or NBTXR3 related AEs of grade 3 or more were reported in the lung metastasis cohort and no injection and/or NBTXR3 related AEs of grade 3 or more were reported at dose level 33%. No injection and/or NBTXR3 related SAE nor death was observed in the lung metastasis and the liver metastasis cohorts. One patient in the HNSCC Cohort died from pneumonitis, approximately 2 months post-NBTXR3 injection, related to anti-PD-1 and possibly related to NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g21.jpg" alt="nbx-20211231_g21.jpg" style="height:183px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regardless of prior anti-PD-1 exposure (i.e., I-O Na&#239;ve and I-O non-responders), in target lesion (injected and non-injected), best objective response rate was 56% and best disease control rate (patients with CR, PR, or SD) was 94%. Best objective overall response rate was 50% and best overall disease control rate was 81%. This preliminary data suggests a correlation between the local and systemic response in both anti-PD-1-na&#239;ve and post-anti-PD-1-failure patients irrespective to the tumor origin in patients receiving NBTXR3 in combination with radiation therapy and anti-PD-1. Details for best observed responses for the 16 evaluable patients currently enrolled in Study 1100 are set forth in the following charts:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;padding-left:77.95pt;text-align:justify;text-indent:-77.95pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Best Observed Target Lesion Response as per Investigator Assessment based on RECIST 1.1</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g22.jpg" alt="nbx-20211231_g22.jpg" style="height:335px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Note: Patient B, that has been previously included in the efficacy population, is now excluded due to a change of evaluability definition. This patient, despite being treated with a lower dose of NBTXR3, had a best objective response of partial response in both all target lesions and overall assessed by RECIST 1.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><img src="nbx-20211231_g23.jpg" alt="nbx-20211231_g23.jpg" style="height:144px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, for three patients who exhibited prior resistance to anti-PD-1, a potential abscopal effect was observed. Specifically, improved control of the disease was observed in two patients (I and L) with highly progressive disease (PD on anti-PD-1 within six months of therapy), where both patients achieved best observed response of stable disease on a non-target, non-irradiated lesion. Reversed resistance was observed in one patient (C) where the patient achieved best observed response of complete response in non-target, non-irradiated lesion. Furthermore, one patient (G) with a liver metastasis from a Stage IV HNSCC with prior secondary resistance, showed a delayed and confirmed response that has deepened over time with a best observed response of complete response, suggesting a potential long term immune response.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the observations with respect to these three patients (I, L and C) may indicate the potential of NBTXR3 in combination with anti-PD-1 checkpoint inhibitors to induce an abscopal effect or, in the case of patient G, a systemic immune response, and support further evaluation of such potential responses, in light of the small number of enrolled patients and because certain local lesions in both the I-O na&#239;ve and I-O non-responder patients potentially received low-dose radiation due to their vicinity to target treatment areas, such data should not be interpreted as statistically significant evidence of any result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The charts below present preliminary response data for Study 1100 in the "all patients treated" population, which comprises 21 patients, including 5 non-evaluable patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:38.97pt;padding-right:38.97pt;text-align:center;text-indent:-77.95pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">All Target Lesions Response per Investigator Assessment Based on RECIST 1.1 </span></div><div style="margin-top:12pt;padding-left:38.97pt;padding-right:38.97pt;text-align:center;text-indent:-77.95pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(All Patients Treated: n=21)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g24.jpg" alt="nbx-20211231_g24.jpg" style="height:413px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g25.jpg" alt="nbx-20211231_g25.jpg" style="height:415px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although Study 1100 data is preliminary and based on a small patient population, we believe these results suggest potential for NBTXR3 activated by radiation therapy to improve treatment outcomes for patients by increasing the proportion of patients that respond to immune checkpoint inhibitors. Recruitment in Study 1100 remains ongoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the 14 anti-PD-1 non-responders included in the &#8220;all patients treated&#8221; population, the following chart provides additional information regarding (i) the time elapsed between prior anti-PD-1 IO treatment and injection with NBTXR3 and (ii) the time elapsed between the NBTXR3 injection and the last survival status, date of last visit, or date of death, as applicable: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="nbx-20211231_g26.jpg" alt="nbx-20211231_g26.jpg" style="height:375px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For this non-responder population, which includes both patients with primary resistance and secondary resistance to anti-PD-1, median time alive, including pre-Study 1100 anti-PD-1 administration and subsequent to enrollment in Study 1100 was 17.02 months.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_749"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Liver cancers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Background and opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to the World Health Organization, liver cancer is currently the fourth most common cause of cancer death in the world and is estimated to have caused over 830,180 deaths in 2020. The American Cancer Society estimated that in 2021 in the United States, 42,230 people would be diagnosed with liver cancer and 30,230 patients would die of the disease. In Europe, an estimated 47,000 patients die of liver cancer each year. The five-year survival rate for patients with localized liver cancer is approximately 31%; once the cancer has spread to other organs or tissues, this survival rate drops to approximately 3%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Two types of liver cancer are hepatocellular carcinoma (&#8220;HCC&#8221;), the most common type of liver cancer, and secondary liver cancer, or liver metastasis, which occurs when cancer from another part of the body spreads to the liver. Surgical resection is often not an option for patients with either HCC or liver metastasis. Moreover, because patients suffering from HCC or liver metastases typically have underlying liver dysfunction and concomitant malignancies, local and systemic treatment options are few in number, with significant limitations. Stereotactic body radiation therapy (&#8220;SBRT&#8221;)&#8212;a high-precision radiation therapy, delivered as high-energy dose fractions&#8212;is a prevalent alternative therapy that has been shown to improve outcomes for these patients, as third-party clinical trials have observed a direct correlation between higher doses of radiation and increased survival rates. However, SBRT dosage is limited due to potential toxicity to surrounding tissues and the need to preserve liver function. Our clinical trial described below evaluated NBTXR3 in patients with liver cancers in need of an alternative treatment, when standard care protocols either could not be used or did not exist. By increasing the absorption of the administered SBRT dose within the tumor itself, without causing additional damage to surrounding healthy tissues, </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and causing more effective tumor destruction, we believe NBTXR3 can improve prognoses for this patient population.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Phase I/II trial design (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Study 103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We completed Phase I of a Phase I/II clinical trial to evaluate the use of NBTXR3 activated by SBRT in liver cancers. The Phase I trial was conducted at six sites in the EU. For this dose escalation phase of the clinical trial, we recruited 23 patients, divided in two subgroups: patients with primary liver cancer (HCC) and patients with secondary liver cancer (liver metastases).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The endpoint of the Phase I part of the trial was to determine the recommended dose of NBTXR3 and to assess early signs of anti-tumor activity. In this portion of the trial, patients received a single intra-lesional injection of NBTXR3, at increasing dose levels, in each case activated by SBRT. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Final data with respect to the Phase I part of Study 103 was presented in October 2020 at the annual meeting of the American Society for Radiation Oncology (ASTRO) and in January 2021 at the annual meeting of the Gastrointestinal Cancers Symposium (ASCO-GI).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Results from the Phase I part of Study 103 showed feasibility of injection at each of the five tested dose levels (10%, 15%, 22%, 33% and 42%) with no leakage to surrounding healthy tissues. One SAE of bile duct stenosis was deemed to be related to NBTXR3 and no dose-limiting toxicities were observed. The recommended Phase II dose (RP2D) has been set at 42%. In 11 patients evaluable for efficacy, early data showed a target lesion objective response rate of 90.9% in evaluable HCC patients and a target lesion objective response rate of 71.4% in evaluable patients with liver metastasis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For HCC patients, preliminary results showed that out of eleven evaluable patients, ten responded at least partially and five of the eleven patients (45.5%) reached complete response. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details for the 11 total HCC patients enrolled in Study 103 are set forth in the following chart:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g27.jpg" alt="nbx-20211231_g27.jpg" style="height:290px;margin-bottom:5pt;vertical-align:text-bottom;width:619px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the metastatic setting, out of the seven patients evaluated for efficacy, five patients presented a partial response and two patients presented stable disease. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe these results suggest meaningful potential to address an unmet medical need in an indication with typically extremely poor prognosis. Although this data is preliminary, it further supports the potential transferability of NBTXR3 across multiple solid tumor indications. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The further development in this indication, including the next steps following Study 103, will be evaluated following the launch of NANORAY-312. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i377d9717844147e799376babda10462f_755"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Pancreatic cancer (MD Anderson acting as sponsor of this Trial)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Background and opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pancreatic cancer is a rare, deadly disease. Worldwide, there were 495,773 new cases in 2020. Given that surgery with R0 resection (i.e., macroscopically complete tumor removal with negative microscopic surgical margins) remains the only hope for long-term survival, clinical trials have investigated various neoadjuvant strategies&#8212;wherein patients receive anti-cancer drugs or radiation prior to surgery&#8212;to increase the surgery-eligible population while also increasing the R0 resection rate. According to the American Cancer Society, for all stages of pancreatic cancer combined, the five-year relative survival rate is 10%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In support of the rationale for neoadjuvant therapy, a retrospective analysis demonstrated a near doubling in OS in pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;) patients who underwent surgery, which was attributed, at least in part, to the increased proportion of borderline resectable pancreatic cancer (&#8220;BRPC&#8221;) patients who became eligible for surgery as a result of neoadjuvant intervention. Importantly, there are also select cases of locally advanced pancreatic cancer (&#8220;LAPC&#8221;) patients being considered for surgical resection based on their response to therapy. Given the poor prognosis of PDAC, therapeutic regimens able to increase the proportion of BRPC and LAPC patients eligible for surgery could improve survival outcomes in this population with unmet need.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase I Trial Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trial is an open-label, single-arm, prospective Phase I study consisting of two parts: (i) dose-escalation to determine the RP2D and (ii) expansion at RP2D. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patient population will include adults (age &#8805; 18 years) with BRPC or LAPC that are radiographically non-metastatic at screening, having received between two to six months of chemotherapy prior to trial enrollment and that have not previously received radiation therapy or surgery for pancreatic cancer. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D. Up to 24 subjects will be enrolled, including a maximum of twelve subjects with LAPC for the dose-finding part. Twelve additional subjects with either LAPC or BRPC will be enrolled for the RP2D expansion. The first patient was dosed in this trial in September 2020. The objectives of the study are the determination of the incidence of dose-limiting toxicity, the maximum tolerated dose and will lead to finding the RP2D.&#8201; </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_760"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Lung cancer (MD Anderson acting as sponsor of this Trial)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Background and opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to the World Health Organization, lung cancer is currently the most common cause of cancer death in the world and is estimated to have caused over 1.7 million deaths in 2020. According to the American Cancer Society, in 2021 it is estimated that there will be approximately 235,760 new cases of lung cancer diagnosed in the United States. It is estimated that in the United States there will be approximately 131,880 deaths from lung cancer in 2021. Non-small cell lung cancer (&#8220;NSCLC&#8221;) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. The five-year relative survival rate for NSCLC at all stages was 25%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase I Trial Design (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Study 2020-0123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">&#8221;)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trial is an open-label, two-cohort, prospective Phase I study consisting of two parts: (i) a radiation therapy safety lead-in, and NBTXR3 activated by radiation therapy dose-finding to determine the RP2D, and (ii) expansion at RP2D with toxicity monitoring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patient population will include adults (age &#8805; 18) with inoperable LRR NSCLC stage IA to IIIC that are radiographically non-metastatic at screening and have previously received definitive radiation therapy. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D. Cohort 1 will evaluate the safety of intensity-modulated radiation therapy (&#8220;IMRT&#8221;) monotherapy in 10 patients using an approach similar to a 3+3 design. If 45 Gy in 15 fractions is deemed safe, cohort 2 will test that regimen with NBTXR3 activated by IMRT. Alternatively, if 45 Gy in 15 fractions is deemed to have excessive toxicity, a 30 Gy in 10 fractions regimen will be used in combination with NBTXR3 in cohort 2. Up to 24 subjects will be enrolled in cohort 2, including a maximum of 12 subjects for the dose-finding part. Twelve additional subjects will be enrolled for the NBTXR3 RP2D expansion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Enrollment for our Phase I clinical trial of NBTXR3 with MD Anderson for patients with lung cancer receiving re-irradiation has commenced. The planned enrollment period is up to three years. The dose levels to be explored are 22% and 33% of baseline gross tumor volume.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i377d9717844147e799376babda10462f_765"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Esophageal cancer (MD Anderson acting as sponsor of this Trial)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Background and opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">According to the World Health Organization, esophageal cancer is currently the sixth most common cause of cancer death in the world and is estimated to have caused 544,076 deaths in 2020. The American Cancer Society estimates that in 2021 in the United States, there will be approximately 19,260 new esophageal cancer cases diagnosed, and approximately 15,530 deaths due to esophageal cancer. Approximately 20% of patients survive esophageal cancer at least five years after diagnoses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Phase I Trial Design (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Study 2020-0122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This trial is an open-label, single-arm, prospective Phase I study consisting of two parts: (i) does-escalation to determine the RP2D of NBTXR3 activated by radiotherapy with concurrent chemotherapy, and (ii) expansion at RP2D with toxicity monitoring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patient population will include adults (age &gt; 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment na&#239;ve and radiographically non-metastatic at screening. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D of NBTXR3 activated by radiation therapy. Up to 24 subjects will be enrolled, including a maximum of 12 subjects for the dose-finding part. Twelve additional subjects will be enrolled for the RP2D expansion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Enrollment has commenced, and the planned enrollment period is 24 months. The first patient was dosed in this trial in January 2021. The objectives of the study  are the determination of dose-limiting toxicity, the maximum tolerated dose and RP2D.&#8201;  </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_777"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Prostate cancer</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Background and opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prostate cancer is the second leading cause of death from cancer and the second-most common form of cancer in the United States in men. The American Cancer Society estimates that in 2021 in the United States, approximately 248,530 people will be diagnosed with prostate cancer and approximately 34,130 patients will die from the disease. Worldwide, there were approximately 1.4 million new cases in 2020. Patient prognosis is good for local and regionalized prostate cancer, but for prostate cancer that has spread to other parts of the body, the five-year survival rate is approximately 31%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Achieving local control is key for treatment of prostate cancer to prevent relapse and subsequent spreading of the disease. Prostate cancer patients typically receive one of two forms of radiotherapy&#8212;EBRT or brachytherapy combined with EBRT. Third-party clinical data has shown that radiotherapy, and specifically the increasing of the radiation dose delivered, significantly improves local control of prostate tumors and reduces recurrence and metastasis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Phase I/II Trial Design (&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%;text-decoration:underline">Study 104</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We initiated a Phase I/II clinical trial of NBTXR3 to evaluate the safety and efficacy of NBTXR3 for the treatment of tumors resulting from prostate cancer. Study 104 enrolled patients with intermediate and high-risk prostate cancer who were eligible to receive one of two radiotherapy standards of care at one site in the United States. One group evaluated NBTXR3 in conjunction with EBRT delivered as intensity-modulated radiation therapy. The second group evaluated NBTXR3 in combination with brachytherapy and EBRT. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The trial administered NBTXR3 to five patients in Phase I. No SAEs were reported by these patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The primary endpoints of the Phase I dose escalation trial were to determine the safety and the recommended doses and early dose-limiting toxicities of NBTXR3 activated by EBRT or by brachytherapy plus EBRT and to assess early signs of anti-tumor activity. The secondary endpoints were to evaluate the dose toxicity and tolerance of NBTXR3, evaluate the complete response rate of NBTXR3, evaluate the local and general PFS time and the OS rate, assess the feasibility of local NBTXR3 administration by intratumoral injection, and evaluate the biochemical failure before activation by intensity-modulated radiation therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have decided to stop this trial as we focus primarily on advancing the development of NBTXR3 for the treatment of locally advanced head and neck cancers. However, we continue to evaluate prostate cancer within the context of our overall development program for NBTXR3 in the treatment of solid tumors.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i377d9717844147e799376babda10462f_786"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">PharmaEngine Trials</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2012, we entered into an exclusive license and collaboration agreement with PharmaEngine for the development and commercialization of NBTXR3 in the Asia-Pacific region. In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, we and PharmaEngine mutually agreed to terminate the agreement. Three NBTXR3 clinical trials (including certain Asia-Pacific sites for the Act.in.Sarc trial) conducted by PharmaEngine in Asia were concluded or terminated, and we retain all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region, pursuant to the terms of a Termination and Release Agreement that we entered into with PharmaEngine in March 2021 (see &#8220;&#8212;Our Collaboration Agreements&#8212;PharmaEngine&#8221; below for additional information).</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_791"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Head and Neck Cancers Treated with Radiotherapy plus Chemotherapy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Trial Design (&#8220;PEP503-HN-1002&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to our contemplated Phase III and ongoing Phase I clinical trials of NBTXR3 in head and neck cancers, PharmaEngine has been conducting a Phase I/II clinical trial of NBTXR3 for patients with head and neck cancers to be treated by radiotherapy plus cisplatin. The primary endpoints of the study were to determine the optimal NBTXR3 dose and to assess the preliminary safety and efficacy of NBTXR3 administered by intratumoral injection in combination with radiotherapy plus chemotherapy. The trial, which is being conducted in Taiwan and was recruiting patients in the Phase I dose escalation part, was expected to treat up to 42 patients. PharmaEngine has implemented the early termination and wind-down of this clinical trial, which will conclude with the issuance of a final study report in accordance with good clinical practice guidelines.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_796"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Rectal Cancer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Trial Design (&#8220;PEP503-RC-1001&#8221;)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PharmaEngine has been conducting an open-label Phase I/II clinical trial of NBTXR3 with radiotherapy in combination with chemotherapy for patients with unresectable rectal cancer. Primary and secondary endpoints were to assess the safety profile and determine the dose-limiting toxicity, evaluate the recommended dosage and assess the anti-tumor activity by evaluating the response rate of NBTXR3 administered by intratumoral injection and activated by external beam radiation, with concurrent chemotherapy treatment in patients with unresectable rectal cancer. The trial, which is being conducted at one site in Taiwan, was expected to treat up to 42 patients. PharmaEngine will implement the early termination and wind-down of this clinical trial, and the trial will be deemed completed when all enrolled patients have reached &#8220;end-of-study&#8221; and PharmaEngine issues a final study report in accordance with good clinical practice guidelines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PharmaEngine presented first clinical results from Study PEP503-RC-1001 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January 2021. Intratumoral injection of NBTXR3 with CCRT was feasible and the product candidate was well tolerated at all dose levels, and no AEs or SAEs associated with NBTXR3 were observed in the study. One dose-limiting toxicity associated with the injection procedure was observed (urinary tract infection with sepsis). The most frequently reported AEs were diarrhea (approximately 45%), leukopenia (approximately 40%), and dermatitis (approximately 25%); however, all were grade one or grade two.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">More than 70% of patients in the study showed objective tumor response after CCRT. Approximately 90% of patients underwent total mesorectal excision (surgery), and 17.6% achieved pathological complete response (pCR). 50% of patients receiving surgery in the study had good tumor regression (tumor regression grade 0 or 1 according to modified Ryan scheme). The RP2D was established for the ongoing Phase II part of the trial at 22% of tumor volume.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i377d9717844147e799376babda10462f_816"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our Preclinical Program for NBTXR3-gel</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are developing NBTXR3-gel, NBTXR3 in a gel formulation, for direct application in the tumor cavity following tumor ablation or resection surgery, before wound closure. As illustrated below, NBTXR3-gel is designed to prepare the surgical site for postoperative radiotherapy (adjuvant treatment) in order to destroy residual cancer cells not removed during surgery.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="nbx-20211231_g28.jpg" alt="nbx-20211231_g28.jpg" style="height:462px;margin-bottom:5pt;vertical-align:text-bottom;width:403px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This unique product candidate has dual aims: effective destruction of cancer cells remaining after surgery and enhancement of tumor cavity radiation by localizing the radiation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The initial cancer indications we are exploring for NBTXR3-gel are certain types of breast cancer, operable lung cancers, vertebral metastases and retroperitoneal STS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Pre-clinical data publication</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2021, Nanobiotix and MD Anderson published in the International Journal of Radiation Oncology, Biology, Physics (Red Journal) preclinical findings of a mouse model study examining the triple combination of NBTXR3 plus radiotherapy plus anti-PD-1.  This preclinical data, which showed that the triple combination significantly delayed the growth of both irradiated and unirradiated tumors in both anti-PD1-sensitive and anti-PD1-resistant lunch cancer models, supports the further exploration of NBTXR3 as a therapeutic option for the treatment of bother primary and metastatic lung cancer and the potential for transforming irradiated tumors into &#8220;self-vaccines.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, we presented preclinical data at the 2021 Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) that showed that in the studies mouse model radiotherapy-activated NBTXR3 increased CD8+ T cell infiltration and modulated the T cell receptor (&#8220;TCR&#8221;) repertoire, as well as marked modulation of immunopeptidome in treated tumor cells. Taken together, these variations support further evaluation of radiotherapy-activated NBTXR3&#8217;s potential to trigger more robust immune priming than radiotherapy alone and further evaluation of CD8+ response and potential abscopal effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i377d9717844147e799376babda10462f_825"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">The Curadigm Platform</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beyond NBTXR3, Nanobiotix is also evaluating several additional potential development programs in nanomedicine. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2019, Nanobiotix formed a wholly-owned subsidiary &#8212; Curadigm SAS &#8212; with the mission of leveraging Nanobiotix&#8217;s expertise and know-how beyond oncology to expand treatment benefits across multiple therapeutic classes by increasing drug bioavailability while decreasing unintended off-target effects, specifically liver toxicity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For most therapeutics today, only a small portion of the medicine administered is effective. After injection, the dose moves through the patient&#8217;s circulatory system within the blood. While a small portion reaches the targeted tissue, the remainder is either cleared from the body or accumulates&#8212;potentially with toxic effect&#8212;in organs such as the liver or spleen.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Leveraging our deep expertise in nanotechnology, Curadigm is developing a nanoparticle, called Nanoprimer, that primes the body for therapeutic treatment. Nanoprimer is based on proprietary technology invented at Nanobiotix and transferred to Curadigm for development and potential commercialization. Injected intravenously prior to a recommended therapeutic, the Nanoprimer has been designed with specific physico-chemical properties that allow it to transiently occupy the liver cells responsible for therapeutic clearance and is intended to prevent rapid clearance, thereby increasing blood bioavailability and subsequent accumulation of therapeutics in the targeted tissues. As a result, a greater portion of the therapeutic treatment remains available for accrual in the target tissue, thereby increasing therapeutic action.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix believes that the Curadigm technology could have broad implications across the healthcare system by increasing the efficacy of therapeutics at their current dose or lowering the necessary dose in order to decrease toxicity and cost and allowing for novel therapeutic approaches and new approaches to drug design. Preclinical in vivo data evaluating Curadigm&#8217;s concept has been generated combining the Nanoprimer with different therapeutic agent families such as small molecules and nucleic acids and has been published in scientific journals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As the Nanoprimer is a combination product candidate that does not alter or modify the therapies it is paired with, we expect that Curadigm will continue to seek partnerships across drug classes-particularly with nucleic acid-based therapies. To support the development of its platform, Curadigm may pursue various funding opportunities, including, without limitation, partnership and collaboration arrangements, licensing opportunities and/or sales of Curadigm securities to third-party investors from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Curadigm Collaboration with Sanofi</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, a research project involving Curadigm&#8217;s Nanoprimer technology was selected for the Sanofi iTech Awards Program for its potential to significantly improve gene therapy development. Curadigm entered into a collaboration agreement with Sanofi that is expected to include direct funding and scientific exchanges. The goal of the project is to establish proof-of-concept for the Nanoprimer as a combination product that could improve treatment outcomes for Sanofi&#8217;s gene therapy product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_831"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Manufacturing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We contract the production of NBTXR3 to high-precision manufacturing partners. Our contracts with these contract manufacturing organizations generally provide that the manufacturing partner may not transfer its rights or sub-contract any of the services covered. . The manufacturing partners are required to perform their obligations in accordance with international professional standards, including the Good Manufacturing Practices guidelines issued by the International Council for Harmonization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2017, we opened a facility to expand our manufacturing capabilities, increase production capacity of NBTXR3 for our clinical trial needs and prepare for potential commercialization. This facility is located in the Villejuif BioPark, a scientific research and innovation center just outside of Paris, France. We expect that the facility will  in due course expand our production capacity with the aim  to produce NBTXR3 for our ongoing clinical trials and our initial commercial phase. Additionally, we have designed our manufacturing process to implement in a timely manner  further set-up of in-house additional production lines.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_837"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commercialization</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have not yet developed commercial infrastructure in either the United States or the EU, and we are in the process of defining our commercialization strategy. We intend to establish a global commercial infrastructure outside the countries in which LianBio will commercialize NBTXR3 by building our own commercial capabilities as well as evaluating partnering opportunities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure, if and when established, will target the community of physicians who are the key specialists in diagnosing and treating the patient populations for which NBTXR3 is being developed. We </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may enter into additional development and commercialization agreements with third parties in select geographic territories for any of our product candidates that successfully complete applicable pre-marketing regulatory requirements in order to optimize sales.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_842"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The development of treatments for cancer is subject to rapid technological change. Many companies, academic research institutions, governmental agencies and public and private research institutions are pursuing the development of medicinal products, devices and other therapies that target the same conditions that we are targeting, including in some cases in the same patient populations that we are targeting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately 60% of all cancer patients undergo radiotherapy at some point during their course of treatment. Current research in radiotherapy focuses primarily on (1) methods to increase sensitivity of tumors to radiation and (2) methods to protect healthy tissues from radiation. In addition, many researchers believe that radiotherapy can enhance the body&#8217;s immune response, thereby making a previously unsusceptible tumor susceptible to vaccines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Companies that are developing treatments to increase sensitivities of tumors to radiation and other sources of energy include MagForce AG, Merck &amp; Co., NH TherAguix, Nanospectra Biosciences, Inc., RiMO Therapeutics and Coordination Pharmaceuticals, Inc. Like us, these companies are pursuing various technologies that involve the delivery of a substance to a tumor that works to destroy the tumor cells without causing additional damage to surrounding healthy tissues. Any product candidates that we or they develop and commercialize may compete with existing therapies, as well as new therapies that may become available in the future, including therapies with a mode of action similar to that of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors. These competitors also compete with us in recruiting and retaining qualified research and development and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with more established companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of NBTXR3 and any other product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price and the availability of reimbursement from government and other third-party payors. We must also protect our proprietary technology used in the development of our product candidates. Our commercial opportunity could be reduced if our competitors develop and commercialize products that are more effective or demonstrate a more favorable safety profile than any products that we may develop. Our competitors may also successfully complete applicable pre-marketing regulatory requirements for their products more rapidly than we do.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_854"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Intellectual property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are innovators in oncology-related nanotechnology. We rely on a combination of patent, trademark, copyright, and trade secret laws in the United States and other jurisdictions to protect our intellectual property rights. No single patent or trademark is material to our business as a whole.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We seek to protect and enhance our proprietary technology, product candidates, inventions and improvements that are commercially important to the development of our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We will also seek to rely on regulatory protection afforded through orphan drug designation, data exclusivity, market exclusivity and patent term extensions where available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To achieve this objective, we maintain a strategic focus on identifying and licensing key patents that provide protection and serve as an optimal platform to enhance our intellectual property and technology base. Our technologies and product candidates are protected by more than 400 issued or pending patents and patent applications in over 23 patent families across the world. We hold key patents and patent applications with respect to the concepts, products and uses of nanoparticles activated by ionizing radiation through NBTXR3 technology and for new applications in nanomedicine. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Summarized below are our material patents and patent applications in our own name:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e0fe3d;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Technology</span></td><td colspan="3" style="background-color:#e0fe3d;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of patent families</span></td><td colspan="3" style="background-color:#e0fe3d;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expiration date for each patent family</span></td><td colspan="3" style="background-color:#e0fe3d;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Countries in which patents are issued</span></td></tr><tr style="height:35pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NanoXray Technology </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Brazil, Canada, China, Eurasia (1 country), Europe (7 countries), Israel, India, Japan, South Korea, Mexico, South Africa, Hong Kong</span></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2031</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States (U.S. continuation granted)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Brazil, Canada, China, Algeria, Eurasia (9 countries), Europe (34 countries), Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, New Zealand, South Africa, Macau, Hong Kong, Singapore</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2031</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States, **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Canada, China, Eurasia (1 country), Europe (22 countries), Indonesia, Israel, India, Japan, South Korea,  Mexico, New Zealand, United States, Singapore, South Africa, Hong Kong, Brazil**</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2032</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">China, Europe (7 countries), Japan</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2032</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Canada, China, Eurasia (1 country), Europe (13 countries), Indonesia, Israel, India, Japan, South Korea, Mexico, New Zealand, Singapore, Ukraine,  South Africa, **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224;&#8224;</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2034</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, China, Europe (36 countries), Indonesia, Japan, Mexico, New Zealand, Israel, Ukraine, United States, Eurasia (1 country), Hong Kong, South Africa, Singapore, South Korea, **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2034</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Canada,  China, Europe (25 countries), Indonesia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, Hong Kong, South Korea, Eurasia (1 country), Ukraine **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2034</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Japan, United States, Europe<br/>(Validated in 7 countries)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2034</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States, Japan, **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224;&#8224;&#8224;</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2036</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Israel, Australia, United States, Ukraine, **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2041</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2041</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other technologies</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2034<br/><br/>2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, Canada, Eurasia (validation in process) , Israel,  India, Indonesia, Mexico, South Korea, Japan, New Zealand, Ukraine, Singapore, South Africa, **, #<br/>United States</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035<br/>2036</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe (23 countries), Japan, <br/>United States, #</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Japan, Europe (Validated in 23 countries), **, #</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Japan, United States, **, #</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2035</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Australia, India, Japan, Mexico, New Zealand, Ukraine, United States, Singapore, About to be granted in Israel, **, #</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2037</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States, **, divisional application filed U.S.</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2037</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States,  **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2037</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;United States, Eurasia (1 country), **</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2038</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2038</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2041</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1)           The NanoXray technology covers, among other things, three product candidates, each of which is based on the same hafnium oxide core. The goal of each of these three product candidates is to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells, without increasing the dose to surrounding healthy tissues. The three product candidates differ in the composition of the nanoparticle coating or formulation, which have been developed for three different modes of administration to cover most oncology applications. The most advanced product candidate in the NanoXray portfolio, and our current focus for development and commercialization, is injectable NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">#             Patent family owned by Curadigm.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*             This expiration year does not take into account supplementary patent protection that could be obtained for some of our patents in the United States, Europe and other countries. Expiration dates for U.S. patents not yet granted may be subject to patent term adjustment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">**           Patent application pending in at least one country/jurisdiction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8224;             Patent family covering the specific composition utilized in NBTXR3 (i.e., composition of matter). This patent family covers the injectable use of metal oxide nanoparticles with a specific density for killing tumor cells, including cancer cells. The injectable use of an efficient dose of NBTXR3 in oncology is covered by this patent family.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8224;&#8224;           Patent family covering the specific composition utilized in injectable NBTXR3 (i.e., composition of matter). This patent family covers the injectable use of metal oxide nanoparticles with a specific density for killing tumor cells and shrinking tumors where a certain number of electrons are delivered to the targeted tumor. The injectable use of an efficient dose of NBTXR3 in oncology is covered by this patent family.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8224;&#8224;&#8224;         Patent family covering the specific composition utilized in NBTXR3 (i.e., composition of matter). This patent family covers the injectable use of NBTXR3 as a therapeutic vaccine used to induce an immune response, including its use in immuno-oncology and its combination with other checkpoint inhibitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to patent protection, we have trademark protection in many countries for our &#8220;Nanobiotix&#8221; name and Nanobiotix logo. We own over 300 trademark registrations and applications related to our products, product candidates, processes and technology worldwide. Trademark registrations are generally granted for a period of ten years and are renewable. We anticipate we will apply for additional patents and trademark registrations in the future as we develop new products, product candidates, processes and technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also rely on trade secrets to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technologies, in part, through confidentiality agreements with our employees, consultants, scientific advisors, contractors and others with access to our proprietary information. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by our competitors.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_849"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our collaboration agreements</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have entered into collaboration agreements in order to enable us to optimize our resources, expedite product development, potentially generate revenue and maintain limited risk exposure outside of Europe.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_863"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">M.D. Anderson Cancer Center of the University of Texas</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On December 21, 2018, we entered into a strategic collaboration agreement with MD Anderson, which was amended and restated in January 2020 and subsequently amended in June 2021. Pursuant to the MD Anderson Collaboration Agreement, we and MD Anderson established a large-scale, comprehensive NBTXR3 clinical collaboration to improve the efficacy of radiotherapy for certain types of cancer. The collaboration initially is expected to support multiple clinical trials conducted by MD Anderson, as sponsor, with NBTXR3 for use in treating several cancer types. We expect to enroll approximately 340 patients across these clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Obligations of the Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the MD Anderson Collaboration Agreement, MD Anderson will provide all necessary personnel, equipment, supplies, facilities and resources for each trial, and we will provide batches of NBTXR3 to be used in the trials. In addition, we have committed to provide financing of approximately $11.0 million for clinical trials during the collaboration. We made an initial $1.0 million payment at the commencement of the collaboration and a second $1.0 million payment on February 3, 2020. Additional payments are processed semi-annually during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are also required to make an additional one-time milestone payment upon (i) the first regulatory approval granted by the FDA for NBTXR3 and (ii) the date on which a specified number of patients have been enrolled in the clinical trials in the United States. The milestone payments increase on an annual basis ranging from $2.2 million to $16.4 million. Accordingly, depending on when the requisite conditions are satisfied, we could be required to pay up to $16.4 million in such milestone payment if the conditions were not satisfied until 2030. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The protocol, schedule, monitoring, termination and replacement of each clinical trial will be determined by mutual agreement between MD Anderson and us, and MD Anderson has granted us certain audit and information rights in connection with the clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have granted MD Anderson a non-exclusive license with respect to NBTXR3 for the conduct of the clinical trials governed by the MD Anderson Collaboration Agreement. We will be the exclusive owner of any right, title or other interest in and to any and all inventions or discoveries made in a trial that incorporates NBTXR3 or any formulation relating to NBTXR3 (though we have agreed to grant MD Anderson a non-exclusive, perpetual irrevocable license to use any such inventions for academic or non-profit research purposes). Other inventions and discoveries made in the course of a trial will be the property of the inventor, Nanobiotix or MD Anderson, as the case may be. Should MD Anderson obtain ownership of any such other invention or discovery, they have agreed to grant us a non-exclusive, royalty-free license, as well as an exclusive option to negotiate an exclusive, royalty-bearing license within a specified time period. Further, we and MD Anderson will be co-owners of the data and clinical results related to the trials, with MD Anderson&#8217;s use of such data limited to academic or non-profit research purposes. MD Anderson possesses a first right to publish and/or publicly disclose data and results of collaboration trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Term and Termination</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MD Anderson Collaboration Agreement will remain in effect until the later of five years or the duration of the clinical trials. Either party may terminate the agreement if the other party commits a material breach that is not cured pursuant to the terms of the agreement within 30 days of notification of the breach. Either party may also terminate a clinical trial in the event of a material breach of the other party&#8217;s obligations, due to health/safety issues related to NBTXR3 or the clinical trial&#8217;s procedures, or if the parties are unable to agree on the designation of the principal investigator or if the principal investigator does not accept the terms of the trial protocol. Termination of the MD Anderson Collaboration Agreement does not affect the conduct of ongoing clinical trials (other than with respect to a termination of a specific trial, as described in the preceding sentence). A clinical trial is automatically terminated in the event of a withdrawal or rejection of requisite regulatory approvals. </span></div><div id="i377d9717844147e799376babda10462f_870"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">LianBio</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 11, 2021, we entered into a strategic License, Development and Commercialization Agreement (the &#8220;LianBio Agreement&#8221;) with LianBio Oncology Limited, a Hong Kong company, for the development and commercialization of NBTXR3, as a product activated by radiotherapy in the field of oncology, in key parts of Asia&#8212;Mainland China, Macau, Hong Kong, Thailand, Taiwan, South Korea and Singapore (collectively, the &#8220;Territory&#8221;). We have granted LianBio an exclusive, royalty-bearing license which includes, subject to certain conditions, the right for LianBio to grant sublicenses to its affiliates and/or third-party subcontractors involved in the development of NBTXR3. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Obligations of the Parties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the LianBio Agreement, LianBio is exclusively responsible for the development and commercialization of NBTXR3 throughout the Territory, except for specified ongoing trials that we will conclude. We are responsible for the manufacturing of NBTXR3 and will be the exclusive supplier of NBTXR3 to LianBio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the LianBio Agreement, LianBio will have to enroll a specified percentage of the worldwide total number of patients in our global Phase III registrational study evaluating NBTXR3 for patients with locally advanced head and neck squamous cell carcinoma (NANORAY-312) and each of four other specified global registrational trials across indications and therapeutic combinations. For NANORAY-312, LianBio is expected to enroll approximately 100 patients based on our current worldwide enrollment expectations. In the event that LianBio does not meet its enrollment undertaking for these trials, LianBio will be responsible for covering certain incremental costs incurred by us as a result. Otherwise, LianBio will fund all development and commercialization expenses in the Territory, and we will fund all development and commercialization expenses in all other geographies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For all non-registrational trials (i.e., Phase I or Phase II trials) undertaken to support the development and approval of NBTXR3, we and LianBio have agreed to provide each other with rights to access all clinical efficacy and safety data. For additional registrational trials, we and LianBio have agreed to provide each other with rights to access all clinical safety data and to provide an opportunity to license and right of reference to efficacy data, subject to certain cost-sharing and/or enrollment undertakings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the LianBio Agreement, LianBio has sole control over commercialization in the Territory and is responsible for all costs and expenses of such commercialization. LianBio, or its affiliates and/or sublicensees, is solely responsible for all communications, filings with, as well as approvals sought from regulatory authorities to obtain all marketing authorizations in relation to NBTXR3 in the Territory. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As consideration for entering into the LianBio Agreement, we received a non-refundable upfront payment from LianBio of $20.0 million in June 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are also eligible to receive up to an aggregate of $220 million in potential contingent, development and commercialization milestone payments. We will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the Territory, subject to downward adjustment based on enrollment incentives and customary country-by-country competition- and intellectual property-related triggers. Royalties will be payable on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last-to-expire valid claim of a licensed patent covering NBTXR3, (ii) the expiration of regulatory exclusivity of NBTXR3, or (iii) the ten-year anniversary of the first commercial sale of NBTXR3. Upon the expiration of the royalty term in a given country, LianBio shall be granted a perpetual, royalty-free, sublicensable license in such country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Responsibility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the LianBio Agreement, the collaboration is implemented under the supervision of a joint steering committee, which will include an equal number of representatives of each party, including one member of senior leadership of each of LianBio and us, and will meet on a regular basis to provide oversight and facilitate information sharing between LianBio and us. In the event of a dispute among representatives at the joint steering committee, the matters shall be escalated to appropriate senior officers of LianBio and us. In the event such senior officers cannot reach an agreement on the matters at hand within a set timeframe, LianBio and we have agreed that one of the parties shall have the final decision-making authority on certain specific matters, without prejudice to any contractual obligations set out under the LianBio Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the LianBio Agreement, LianBio&#8217;s Territory-specific development and regulatory plan and commercialization in the Territory will be conducted pursuant to LianBio&#8217;s Territory-specific plans, which will be subject to periodic updates and joint steering committee review. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We retain the first right to prosecute, maintain and defend, at our expense, all of our licensed patents in the Territory. In the event that we elect not to prosecute or maintain any such patent in the Territory or not to defend a patent in the Territory, we have agreed to notify LianBio, and LianBio shall have the right, but not the obligation, to assume such prosecution, maintenance or defense at its own expense. LianBio shall have the first right to enforce, at its expense, our intellectual property against infringement in the Territory, except where we are enforcing such intellectual property both within and outside the Territory against such infringement. In the event that LianBio elects not to enforce our intellectual property against infringement in the Territory, it has agreed to notify us, and we will have the right to enforce such intellectual property at our expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and LianBio have agreed to customary confidentiality obligations with respect to trade secrets and confidential or proprietary information disclosed in connection with our respective performance under the LianBio Agreement, subject to customary exceptions. We and LianBio have agreed to provide customary indemnification to one another for claims relating to our respective obligations under the LianBio Agreement. LianBio has agreed to maintain a customary liability insurance policy during the term of the LianBio Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">LianBio has undertaken to conduct and ensure that all of its affiliates, sublicensees and subcontractors conduct their business under the LianBio Agreement in accordance with applicable laws and, to the extent applicable with respect to certain development activities, FDA and EU medical device requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and LianBio retain ownership of our respective pre-existing intellectual property. Other inventions and discoveries relating to NBTXR3, made in the course of performing obligations under the LianBio Agreement made solely by us or LianBio, as the case may be, will be owned by the respective inventors. To the extent an invention or discovery relating to NBTXR3 is made by LianBio and us together, such invention and any related patents will be jointly owned by LianBio and us. The rights to file, prosecute and enforce such jointly-owned patents will be determined by mutual agreement through the joint steering committee. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Termination</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless terminated earlier, the LianBio Agreement will remain in effect for so long as royalties are payable under the LianBio Agreement. The LianBio Agreement may be terminated earlier by either party if the other party commits an uncured material breach. In any event where LianBio has a termination right based on a material breach by us, LianBio may elect in lieu of termination to continue the LianBio Agreement, subject to a downward percentage reduction in all milestone and royalty payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Either party may also terminate the agreement in the connection with the occurrence of certain insolvency or bankruptcy events with respect to the other party. LianBio may terminate the agreement following a change in control of us, subject to a specified notice period. We may terminate the agreement under certain circumstances in connection with a change of control of LianBio. We may also terminate the LianBio Agreement in the event that </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">LianBio or its affiliates bring or join any challenge to the validity or enforceability of our patents, subject to certain limited exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Termination of the LianBio Agreement will terminate all rights, licenses and sublicenses under the agreement, subject to our agreement, in certain cases, to negotiate in good faith with sublicensees regarding a potential direct license. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1859"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">PharmaEngine</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2012, we entered into a license and collaboration agreement with PharmaEngine, a Taiwan-based company, for the development and commercialization of NBTXR3 (under the code name PEP503) in several countries in the Asia-Pacific region. Under this agreement, PharmaEngine was responsible for the development (non-clinical and clinical research) and marketing of NBTXR3 across the Asia-Pacific region. In return, PharmaEngine was required to make payments to us based on the achievement of development and commercialization milestones for NBTXR3. We received an upfront payment of $1 million upon signing the agreement and, through December 31, 2020, received $2 million in two interim payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, we and PharmaEngine mutually agreed to terminate the agreement. Accordingly, on March 4, 2021, we and PharmaEngine entered into a Termination and Release Agreement. Under the termination agreement we will retain all rights to the development and commercialization of NBTXR3 in the Asia Pacific region. We have agreed to make total termination payments to PharmaEngine of up to $12.5 million in the aggregate. PharmaEngine was eligible for, and received, a $2.5 million payment from us following the announcement of our collaboration with LianBio for the Asia-Pacific region. During the six months ended June 30, 2021, PharmaEngine also received $4.0 million from us in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PharmaEngine will be eligible to receive from us an additional $1.0 million in administrative fees and a final payment of an additional $5 million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive from us a low-single digit percentage tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the termination agreement, PharmaEngine has re-assigned to us rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_878"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Our research agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have established strategic collaborations with a number of hospitals, clinics and cancer treatment centers in France and abroad. These agreements provide that we may negotiate certain commercial rights with such collaborators with respect to joint inventions or inventions made by our collaborators that arise from the results of the collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the preclinical research agreements for these collaborations, we retain exclusive ownership over any inventions made solely by us. Any invention made solely by a research institution would be owned by the relevant research institution, but would be subject to option to obtain an exclusive license, which would be free for research purposes and royalty-bearing for commercial activities. Inventions made jointly by us and a research institution would be jointly owned. As of December 31, 2021, no inventions under these programs have been made solely by a research institution or jointly by us and a research institution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have entered into an agreement with Institut Gustave Roussy, one of the world&#8217;s leading cancer-research institutes and the largest cancer center in France, for radiobiology research and preclinical development of NBTXR3. Pursuant to the agreement, we conduct studies at Institut Gustave Roussy&#8217;s radiobiology lab to evaluate the antitumor activity of nanoparticles activated by ionizing radiation. We maintain all rights to the products of our studies; however, Institut Gustave Roussy may use the results without charge solely for the purposes of its own academic research.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have also partnered with The University of Texas MD Anderson Cancer Center in Houston, Texas to conduct immunotherapeutic preclinical research in lung cancer, combining NBTXR3 and immune checkpoint inhibitors. This </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research collaboration is distinct from our clinical trial collaboration with MD Anderson and is intended to enable us to generate preclinical data using NBTXR3 activated by radiotherapy plus anti-PD-1 nivolumab (murine version of Opdivo) or other immune checkpoint inhibitors, such as anti-CTLA-4, anti-TIGIT and anti-LAG3.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_886"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Government regulation, product approval and certification</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, in the European Union and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. NBTXR3 and any other therapeutic candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and must complete the conformity assessment procedure with the Notified Body before they may be legally marketed in the EU. In addition, in the European Union, the Group is subject to data protection rules. Finally, the Group&#8217;s activities may be qualified as sensitive activities and thus enter into the scope of the foreign investment control regime in France.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_902"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Regulation in the United States</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_892"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">United States Drug Development Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post approval may subject an applicant to administrative and/or judicial sanctions. FDA sanctions may include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies in accordance with applicable regulations, including good laboratory practice (&#8220;GLP&#8221;) regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable regulations, including current good clinical practice (&#8220;GCP&#8221;) regulations to establish the safety and efficacy of the drug candidate for its proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Submission to the FDA of a new drug application (&#8220;NDA&#8221;) for a new drug product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">A determination by the FDA within 60 days of its receipt of an NDA to accept the submitted NDA for filing and thereafter begin a substantive review of the application;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with cGMP regulations to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">Potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:13.8pt">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Before testing any compounds with potential therapeutic value in humans, the drug candidate goes through a preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The data sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocols for human studies. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period or issues an earlier notice </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">that the clinical trial may proceed. In the case of a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose a clinical hold on a drug candidate at any time before or during clinical trials due to safety concerns or noncompliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that cause us or FDA to suspend or terminate such trial.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board (&#8220;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">IRB</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8221;), at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers issues such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Phase I.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion, the side effects associated with increasing doses, and if possible, to gain early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Phase II.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Phase III.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit/risk ratio of the product and provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase III clinical trials are required by the FDA for approval of an NDA. Phase III clinical trials usually involve several hundred to several thousand participants.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Post-approval studies, or Phase IV clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase IV studies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase I, Phase II and Phase III clinical trials may fail to be completed successfully within any specified period, if at all. The FDA, the IRB or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated checkpoints based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must include developed methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i377d9717844147e799376babda10462f_897"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">FDA Review and Approval Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The application must include negative or ambiguous results of preclinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The FDA reviews the completeness of each NDA submitted before accepting it for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing or refusing to file within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Free Act (&#8220;PDUFA&#8221;), the FDA has ten months from the 60-day filing date in which to complete its initial review of a standard NDA and respond to the applicant, and six months from the 60-day filing date for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The FDA reviews each NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. For novel drug products or drug products which present difficult questions of safety or efficacy, FDA may decide to hold an advisory committee, typically a panel that includes clinicians and other experts, to provide independent advice that will contribute to the quality of the agency's regulatory decision-making and lend credibility to the product review process, including a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with GCP requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase III clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases, patient populations and dosages, or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. For example, the FDA may require Phase IV testing which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also determine that a risk evaluation and </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">mitigation strategy (&#8220;REMS&#8221;) is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS, and the FDA will not approve the NDA without an approved REMS. Depending on FDA&#8217;s evaluation of a drug&#8217;s risks, a REMS may include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution requirements, patient registries and other risk minimization tools. Following approval of an NDA with a REMS, the sponsor is responsible for marketing the drug in compliance with the REMS and must submit periodic REMS assessments to the FDA.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_921"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Post-Approval Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among other requirements, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling (known as &#8220;off-label use&#8221;), limitations on industry sponsored scientific and educational activities, and requirements for promotional activities involving the Internet. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such off-label uses.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The FDA also may require Phase IV testing and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, such as a REMS. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_916"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Coverage and Reimbursement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A pharmaceutical manufacturer&#8217;s ability to commercialize any approved drug product successfully depends in part on the extent to which coverage and adequate reimbursement for such drug product and related treatments will be available from third-party payors, including government health administration authorities, private health insurers, health maintenance organizations and other organizations. Third-party payors determine which drug products and treatments they will cover and establish reimbursement levels. Assuming coverage is obtained for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use a drug product, or agree to treatment using a drug product, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of the drug product and associated treatment. Therefore, coverage and adequate reimbursement is critical to new drug product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for drug products and related treatments. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States.</span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor and product to product. As a result, the coverage determination process is often a time-consuming and costly process that requires pharmaceutical manufacturers to provide scientific and clinical support for the use of its drug products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_911"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Healthcare providers, physicians and others will play a primary role in the recommendation, and the incorporation into treatment regimes, of drug products, if approved. A pharmaceutical manufacturer&#8217;s business operations in the United States and its arrangements with clinical investigators, healthcare providers, consultants, third-party payors and patients expose it to broadly applicable federal and state fraud and abuse and other healthcare laws. These laws may impact, among other things, research, proposed sales, marketing and education programs for product candidates that obtain marketing approval. Restrictions under applicable U.S. federal and state and foreign healthcare laws and regulations include, particularly in the EU, but are not limited to, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, including any kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by individuals through civil whistleblower or qui tam actions, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare matters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose certain requirements on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, and their business associates, individuals and entities that perform functions or activities that involve individually identifiable health information on behalf of covered entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA, that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals, and certain ownership and investment interests held by physicians or their immediate family members; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA, thus complicating compliance efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is costly. It is possible that governmental authorities will conclude that business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If a pharmaceutical manufacturer&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, it may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i377d9717844147e799376babda10462f_941"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Reform</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the United States, the ACA is significantly impacting the provision of, and payment for, healthcare. Various provisions of the ACA were designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide healthcare benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support for medical research. With regard to therapeutic products specifically, the ACA, among other things, expanded and increased industry rebates for drugs covered under Medicaid programs and made changes to the coverage requirements under the Medicare prescription drug benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since its enactment there have been judicial and legislative challenges to certain aspects of the ACA, as well as executive branch efforts to repeal or replace certain aspects of the ACA. Most recently, the executive branch has sought to bolster the ACA through executive order.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; The Further Consolidated Appropriations Act, 2020, signed into law on December 19, 2019, repealed certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the medical device excise tax, and, effective for 2021, the annual fee imposed on certain health insurance providers based on market share. The BBA, among other things, amended the ACA, effective January 1, 2019, to increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, both the Budget Control Act of 2011 and the ATRA have instituted, among other things, mandatory reductions in Medicare payments to certain providers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We cannot predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts, and there can be no assurance that any such health care reforms will not adversely affect our future business and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Additionally, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_936"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Regulation in the EU</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, health products qualify typically as medicinal products or as medical devices. The pre-market requirements applicable to each of these types of products vary significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The demarcation between the definitions of &#8220;medical device&#8221; and &#8220;medicinal product&#8221; can sometimes be blurred, or difficult to draw, for some products referred to as &#8220;borderline products.&#8221; In order to determine whether a product constitutes a medical device or a medicinal product, a number of factors must be taken into account, including the claims regarding the function of the product, the mode of action on the human body and the primary intended purpose of the product. Classification decisions are taken at a national level about individual products. Although these decisions are based on a number of principles that are harmonized across the EU, aiming at a uniform approach to product classification across EU Member States, it is possible that these principles are interpreted differently on a case-by-case basis and that, as a result, a product may be classified as a medicinal product in one Member State and as a medical device in another. The classification of our product, NBTXR3 as a medical device is supported by the conformity assessment procedure applied by the relevant EU Notified Body, which led to the drawing up of the EU Declaration of Conformity, as well as by the opinions released in 2009 and in 2011 by the national competent authorities of Ireland and Spain, respectively. Should national authorities in other EU Member States disagree with such classification, and instead classify our products as medicinal products, our products would </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">be subject to a different regulatory framework, including in particular stringent pre-market authorization requirements that differ significantly from the conformity assessment procedures that are applicable to medical devices.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_952"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">An Evolving Regulatory Framework</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 26, 2021, after a four year transition period, the Medical Devices Regulation (Regulation (EU) 2017/745, the &#8220;MDR&#8221;) became fully applicable and introduced substantial changes to the previous regulatory regime applicable to medical devices (including in particular Directive 93/42/EEC, the &#8220;MDD&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the transitional provisions of the MDR, until May 26, 2021, the certification procedures underlying the CE marking of medical devices could be carried out, at the manufacturer&#8217;s choice, either in accordance with the MDR or in accordance with the MDD. Where a manufacturer elected to perform certification under the MDD - as we did in connection with our NBTXR3 product for the treatment of STS - the related certificates remain valid until May 25, 2024 (for certificates issued prior to May 25, 2017) or May 26, 2024 (for certificates issued on or after May 25, 2017). The medical devices to which these certificates apply may only be sold in the EEA if they continue to comply with the MDD and provided that no significant changes are brought to these devices&#8217; design or intended purpose. Moreover, the manufacturers of those devices that are certified under the MDD have to comply with a number of requirements of the MDR, e.g., those relating to post-market surveillance and vigilance, and they are able to sell such devices only up until May 26, 2025 at the latest. After that date, all devices sold in the EEA will have to be fully compliant with the MDR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the MDR, all devices incorporating or consisting of nanomaterials are classified as Class III if they present a high or medium potential for internal exposure. The MDR introduced higher clinical data requirements for such Class III devices. In particular, manufacturers are generally required to conduct new clinical investigations, subject to certain exceptions. We cannot guarantee that our ongoing trials for our product candidates, including our lead product candidate NBTXR3, will be considered as &#8220;sufficient&#8221; under the MDR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MDR also introduced increased scrutiny of conformity assessments by Notified Bodies for implantable Class III devices. For such devices, the MDR requires that, as part of the conformity assessment procedure, the clinical evaluation assessment report of the concerned Notified Body be submitted to the European Commission for review by an expert panel. The conformity assessment of such devices is further subject to a scrutiny mechanism potentially involving the competent authorities of the EEA, the European Commission, and the Medical Device Coordination Group. Nevertheless, Article 54(2) of the MDR lays out certain exceptions to the need to carry out a clinical evaluation consultation procedure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, under the MDR, manufacturers of Class III devices are subject to a new annual safety reporting requirement called the Periodic Safety Update Report (&#8220;PSUR&#8221;), aimed at capturing the results and conclusions of the analyses of the post-market surveillance data gathered as a result of the manufacturer&#8217;s post market surveillance plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional guidance and legislation further specifying the applicable requirements and obligations under the MDR is expected. We are in the process of assessing the impact of the MDR and associated acts and guidance on our business. Due to these new regulatory requirements, conformity assessment procedures in the EU may experience delays.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_957"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">CE Marking Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As manufacturers of medical devices, in the EU we are required under the MDR to affix a CE mark to our products in order to sell our products in Member States of the EU. The CE mark is a symbol that indicates conformity with the applicable regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Medical Devices in the EU are classified in four different classes (I, IIa, IIb and III) depending on their inherent risk. The MDR includes specific rules on classification of medical devices. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_962"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">EU Development Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For Class III devices, such as NBTXR3, and for implantable devices, it is necessary, save for exceptions, to carry out a clinical investigation to demonstrate that the product complies with the applicable regulatory requirements, including as regards safety and performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any clinical investigation must comply with all relevant legal, ethical and regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clinical investigations must take into account scientific principles underlying the collection of clinical data and be conducted in accordance with the principles of good clinical practice. This means that, for example, all research subjects must have provided their prior informed consent for participation in any clinical investigation.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A clinical investigation can be carried out only if the relevant competent national authorities have approved it and the relevant ethics committee(s) have not issued a negative opinion in relation to it.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MDR specifically requires that, subject to certain conditions, serious adverse events, device deficiencies and related updates be recorded and notified to all competent authorities of the EU Member States in which the clinical investigation is being performed. Termination of a clinical investigation must also be notified to such authorities and be followed by a clinical investigation report, irrespective of the outcome of the investigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MDR specifies conditions required for the collection of data from clinical investigations relating to medical devices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These requirements include rules on informed consent and the protection of vulnerable persons (e.g., persons under 18 years of age, pregnant women and disabled persons).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The conduct of a clinical investigation is subject to EU Member State national laws. For instance, in France, there are specific rules governing the protection of patients (including, for example, regarding regards consent and insurance).</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_967"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Tracking</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MDR introduced a system for the registration of devices and their manufacturers, importers and authorized representatives, and allows EU Member States to also maintain or introduce registration obligations for distributors if they so wish. Moreover, in order to allow identification and to ensure the traceability of devices throughout the supply chain, the MDR requires the establishment of a Unique Device Identification (UDI) system.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_972"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Notified Bodies and Conformity Assessment Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To demonstrate compliance with the applicable regulatory requirements, manufacturers of medical devices must follow a conformity assessment procedure which varies according to the type of medical device and its risk classification. Except for certain Class I devices, a conformity assessment procedure typically requires the intervention of an independent organization accredited to conduct conformity assessments, known as a &#8220;Notified Body.&#8221; Under the conformity assessment procedure we have elected to follow for our products, the Notified Body audits and examines the technical file and the quality system applied to the design, manufacture and final inspection of our products. If we successfully complete the applicable procedure, the Notified Body issues a certificate of conformity. This certificate entitles a manufacturer to affix the CE mark to its medical devices after having also prepared and signed a &#8220;EU declaration of conformity&#8221; indicating that the product meets the applicable regulatory requirements. The certificate of conformity is valid for a maximum of five years, and may be extended on application for a further period not exceeding five years. While we have successfully completed the applicable regulatory procedures for our NBTXR3 product for the treatment of STS, we cannot guarantee that all our product candidates will be equally successful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If we modify substantively our devices we may need to broaden, or re-perform, the certification underlying the CE mark of the modified product. The certificate of conformity can be suspended or withdrawn, e.g., where a Notified Body finds that pertinent regulatory requirements are not met and the manufacturer has not implemented appropriate corrective measures within the time limit set by the Notified Body. The same may be true for any new products that we may develop in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The MDR strengthened the rules on the designation, organization and surveillance of Notified Bodies. These must meet the same high quality standards throughout the EU and have permanent availability of sufficient administrative, technical and scientific personnel as is necessary to carry out their tasks. Notified Bodies must carry out inspections of manufacturers' premises, some of which are unannounced. For certain devices, including Class III implantable devices, Notified Bodies must submit their clinical evaluation assessment report to the European Commission which in turns must submit it to an independent expert panel except for the products which are exempted according to Article 54(2) of the MDR.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_977"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Post-Market Vigilance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Once CE-marked and placed on the EEA market, medical devices are subject to vigilance requirements. In accordance with these requirements, manufacturers must report incidents to the competent authorities and are required to take appropriate &#8220;field safety corrective actions&#8221; to prevent or reduce the risk of serious incidents associated with devices made available on the market. Such actions must also be communicated to users through field safety notices. Manufacturers must equally report statistically significant increases in the frequency of certain incidents by means of trend reports.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to reporting obligations for manufacturers regarding serious incidents and incident trends, the MDR introduced an obligation for EU Member States to encourage and enable healthcare professionals, users and patients to report suspicious incidents at national level.  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_982"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Pricing and Reimbursement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of our products in the EEA will be largely influenced by the outcome of our pricing and reimbursement negotiations with the national authorities of each of the EEA Member States, such as government social security funds. These third-party payors are increasingly limiting coverage and reimbursement for medical products and services. In addition, EEA governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution with cheaper products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or a negative outcome of our reimbursement negotiations could reduce physician usage of our products once approved and have a material adverse effect on our sales, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_987"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Marketing, Advertising and Transparency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the EU, the marketing and advertising of medical devices is subject to both legal and voluntary self-regulatory rules at EU and national level including as regards the strict prohibition of misleading and unfair advertising of medical devices. Moreover, under EU-wide voluntary self-regulatory rules, interactions between medical device manufacturers and healthcare professionals and healthcare organizations &#8211; including in particular any transfers of value that (a) such interactions cannot be misused to influence purchasing decisions through undue or improper advantages and (b) cannot be contingent upon sales transactions, use or recommendation of any specific products. Additional requirements may apply depending on the specific jurisdiction concerned.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finally, increasing transparency requirements are mandated under national legislation and/or self-regulatory codes of conduct. Under these requirements, manufacturers of health products can be required to publicly disclose any transfers of value (whether in kind or in cash) they provide to, e.g., healthcare professionals and healthcare organizations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the above requirements, manufacturers of medical devices are subject to increased monitoring of their promotional activities as well as of their other interactions with healthcare professionals and organizations. Any breach of the applicable rules can result in serious sanctions, including criminal, civil or administrative sanctions depending on the affected jurisdiction.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_992"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Data Protection Rules</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Regulation 2016/679, known as the General Data Protection Regulation, or GDPR, as well as EU Member State national legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These laws impose strict obligations on the processing of personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also, in certain countries, in particular France, the conduct of clinical trials is subject to compliance with specific provisions of the Act No.78-17 of 6 January 1978 on Information Technology, Data Files and Civil Liberties, as amended, and in particular Chapter IX relating to the processing of personal data in the health sector. These provisions require, among others, the filing of compliance undertakings with &#8220;standard methodologies&#8221; adopted by the French Data Protection Authority (the &#8220;CNIL&#8221;), or, if not complying, obtaining a specific authorization from the CNIL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The most common standard methodologies are the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Decision No. 2018-154 of May 3, 2018 concerning the approval of a standard methodology for processing personal data in the context of research in the field of health, which does not require the express consent of the person involved (methodology MR-003);</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Decision No. 2018-153 of May 3, 2018 concerning the approval of a standard methodology for the processing of personal data carried out within the context of research in the field of clinical trials, which requires the express consent of the person involved (standard methodology MR-001);</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In certain specific cases, entities processing health personal data may have to comply with article L1111-8 of the French Public Health Code which imposes certain certifications for the hosting service providers.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i377d9717844147e799376babda10462f_997"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Foreign investment control regime in France</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Over the past few years, the French government has strengthened its foreign investment control regime. Thus, as at the date of this Annual Report, any investment:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.51pt">by (a) any non-French citizen, (b) any French citizen not fiscally residing in France, (c) any non-French entity or (d) any French entity controlled by one of the aforementioned persons or entities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.52pt">that will result in the relevant investor (a) acquiring control of an entity registered in France, (b) acquiring all or part of a business line of an entity registered in France, or (c) for non-EU or non-EEA investors crossing, directly or indirectly, alone or in concert, a 25% threshold of voting rights in an entity registered in France; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:9.53pt">where this entity registered in France is developing activities in certain strategic industries (sensitive sectors or sensitive activities) related to (a) activity likely to prejudice national defense interests, participating in the exercise of official authority or are likely to prejudice public policy and public security (including weapons, double-use items, IT systems, cryptology, date capturing devices, gambling, toxic agents or storage of data), (b) activities relating to essential infrastructure, goods or services (including energy, water, transportation, space, telecom, public health, farm products or media), and (c) research and development activity related to critical technologies (including biotechnology, cybersecurity, artificial intelligence, robotics, additive manufacturing, semiconductors, quantum technologies or energy storage&#8230;) or dual-use items, is subject to the prior authorization of the French Ministry of Economy, which authorization may be conditioned on certain undertakings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in the context of the ongoing COVID-19 pandemic, the Decree (d&#233;cret) n&#176;2020 892 dated July 22, 2020, as amended by the Decree (d&#233;cret) n&#176;2020-1729 dated December 28, 2020 and by the Decree (d&#233;cret) n&#176;2021-1758 dated December 22, 2021, has created a new 10% threshold of the voting rights applicable until December 31, 2022 for the non-European investments (i) in an entity governed by French law and (ii) whose shares are admitted to trading on a regulated market, in addition to the 25% above-mentioned threshold for certain activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On November 5, 2020, the French Ministry of Economy informed us that our activities are subject to the foreign investment control regime described above. Therefore, investments in our Company meeting the above criteria are subject to prior authorization by the French Ministry of Economy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A fast-track procedure shall apply for any non-European investor exceeding this 10% threshold who will have to notify the Minister of Economy who will then have 10 days to decide whether or not the transaction should be subject to further examination.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an investment requiring the prior authorization of the French Minister of Economy is completed without such  authorization having been granted, the French Minister of Economy might direct the relevant investor to  nonetheless (i) submit a request for authorization, (ii) have the previous situation restored at its own expense or (iii) amend the investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the absence of such authorization, the relevant investment shall be deemed null and void. The relevant investor may be found criminally liable and may be sanctioned with a fine not to exceed the greater of the following amounts: (i) twice the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the target company or (iii) &#8364;5 million (for a company) or &#8364;1 million (for a natural person).</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1026"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Regulation in Asia</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We possess the rights to develop and commercialize NBTXR3 in the Asia-Pacific region. We anticipate that the development and commercialization, if any, of NBTXR3 in the Asia-Pacific region would initially target Taiwan, China and Japan.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1035"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Taiwan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In Taiwan, NBTXR3 has been tentatively classified as a drug for regulatory purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">Taiwan Drug Development Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under the Pharmaceutical Affairs Act (the &#8220;PAA&#8221;), the competent authority at central government level is the Taiwan Ministry of Health and Welfare (&#8220;MOHW&#8221;). The Taiwan Food and Drug Administration (&#8220;TFDA&#8221;) under the MOHW is in charge of the administration, inspection and testing of pharmaceutical products (including drugs and medical devices). Companies that plan to import drugs into or manufacture drugs  in Taiwan must receive a prior drug permit license from MOHW and comply with other applicable laws and regulations in Taiwan. Sale of drugs in Taiwan is also subject to applicable laws and regulations. The drug development and marketing process in Taiwan mainly involves </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">preclinical tests, clinical trials, manufacturing and post-market monitoring. The said process is subject to scrutiny and/or approval by the TFDA, such as IND, approval (which must be approved by the TFDA before human clinical trials may begin) and NDA approval. Additionally, according to the PAA, unless otherwise announced by the MOHW, for purposes of pharmaceutical products manufacture, the factory facilities, equipment, organization and personnel, production, quality control, storage, logistics, handling of customer complaints, and other matters requiring compliance shall comply with the Pharmaceutical Good Manufacturing Practice Regulations; the manufacture may only begin after the MOHW has completed its inspection and granted approval and the pharmaceutical products manufacture license has been obtained. After marketing, the pharmaceutical products are still subject to applicable and regulations For instance, with respect to the post-marketing monitoring, a manufacturer or an importer of a new drug defined under the PAA shall collect safety information on drug use available both domestically and abroad during the safety monitoring period; in addition to making report following the Regulations Governing the Reporting of Severe Adverse Reactions of Medicines, such manufacturer or an importer shall also file periodic safety update report to MOHW within the specified time period.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1045"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">People&#8217;s Republic of China</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the People&#8217;s Republic of China (excluding Hong Kong, Macau and Taiwan), no determination has yet been made as to whether NBTXR3 will be classified as a drug or medical device for regulatory purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If NBTXR3 is classified a drug, a market approval is required for its development and commercialization. Extensive data derived from preclinical laboratory tests and studies meeting the requirements of Chinese law are required to support the granting of approval by the National Medical Product Administration (&#8220;NMPA&#8221;) for a new drug product to proceed with clinical trials. If clinical trials sufficiently establish that the product is safe and effective, the NMPA will issue approval for the product to be marketed. Similar to the United States and the EU, the process for obtaining such marketing approval is lengthy, although the Chinese government has recently made efforts to reduce the time required and to streamline the process. After obtaining marketing approval, the marketing approval holder must conduct post-marketing approval studies to closely monitor the use of the product for purposes of reporting its demonstrated safety and efficacy to the NMPA. Further, the marketing approval holder must closely monitor any adverse events or product quality issues, and disclose any such events or issues to the NMPA, as well as potentially to other government agencies and the public. An overseas entity must appoint a domestic agent in assisting it to apply for market approval in China, and the approval holder and its domestic agent will be jointly liable for the aforementioned obligations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If NBTXR3 is classified a medical device, clinical evaluation is required to prove its safety and effectiveness for proceeding with recordation or registration. The clinical evaluation could be clinical trials or analysis on clinical literatures and materials, depending on the product features, clinical risks, existing clinical data and other information.  If it is further classified as a Class I medical device (with low risk level), recordation with the NMPA would suffice and no approval is required. If it is classified as a Class II or III medical device (with moderate or high risk level), registration with the NMPA will be required. Prioritized examination and approval would likely to be granted to an innovative medical device to shorten the timeframe for getting market approval. For overseas recordation/registration holder to import its product into China, it must appoint a domestic agent in assisting it to apply for device recordation/registration in China, and the holder and the domestic agent will be jointly liable for the safety and effectiveness during whole life cycle of a medical device including on quality management, post marketing research and risks management, adverse event monitoring and re-evaluation, product recall systems and other obligations as provided by the Chinese law.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1040"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Japan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In Japan, NBTXR3 is classified as a drug.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Ministry of Health, Labour and Welfare (the &#8220;MHLW&#8221;) regulates drugs and medical devices under the Pharmaceuticals and Medical Devices Act (the &#8220;PMD Act&#8221;) and its implementing regulations. The MHLW delegates part of the oversight to the Pharmaceuticals and Medical Devices Agency (the &#8220;PMDA&#8221;), an independent administrative institution. In order to market a drug or a highly-controlled medical device in Japan, marketing authorization must be obtained in advance. Foreign companies that plan to import drugs or medical devices into Japan must be registered with the MHLW through a separate process. The process for obtaining marketing authorization includes preclinical tests, clinical trials and compliance review of the application for marketing authorization by the PMDA. After marketing authorization is obtained, drugs and medical devices are subject to continuing regulations under the PMD Act. For example, a new drug is subject to periodic reexamination by the MHLW and the marketing authorization holder must continue to collect clinical data during such specified reexamination period. In addition, the marketing authorization holder must report to the MHLW when it learns of new information regarding the efficacy and safety of its product, including occurrences of adverse events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i377d9717844147e799376babda10462f_1057"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Organizational Structure </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix S.A. is a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> organized under the laws of the French Republic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following chart shows our organizational structure as of December 31, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Subsidiary Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Jurisdiction of Organization</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership &amp; Voting Interest Held by Nanobiotix S.A.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix Corp.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Delaware</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% (held directly)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix Germany GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% (held directly)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix Spain S.L.U</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Spain</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% (held directly)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Curadigm S.A.S.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% (held directly)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Curadigm Corp.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Delaware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% (held indirectly through Curadigm S.A.S.)</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nanobiotix also has a Swiss branch (succursale) in Lausanne (Switzerland).</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1063"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Property, Plant and Equipment </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our corporate headquarters is located in Paris, France, where we lease approximately 2,622 square meters of office space. The lease of our Paris headquarters continues through June 30, 2027. Our headquarters, located at 60 rue Wattignies in the 12th arrondissement of Paris, for which we signed a lease on July 1, 2017 for a term of 10 years and an amendment pursuant to which we leased additional space, with retroactive effect from January 1, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Our approximately 1,195 square meter manufacturing facility is located in the Villejuif BioPark, a scientific research and innovation center just outside of Paris, France.  The lease for the facility began on July 1, 2017 for a term of nine years, expiring on June 30, 2029.  The facility, which we opened in November 2017, expanded our potential production capacity with the aim to produce NBTXR3 for our current and contemplated clinical trials and the initial commercial phase. We have designed our manufacturing process to implement in a timely manner further set-up of in-house additional production lines. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We also rent office space in New York City, New York and rent office space for Nanobiotix Corp., our wholly owned U.S. subsidiary, in Cambridge, Massachusetts, in each case on a month-to-month basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have no lease commitments with respect to our foreign subsidiaries, other than lease contracts for vehicles in the United States and Germany.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We believe that our existing facilities are adequate for our near-term needs, and we believe that suitable additional or alternative office and manufacturing space will be available as required in the future on commercially reasonable terms.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_31"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 4a. UNRESOLVED STAFF COMMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_34"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 5.&#160;&#160;&#160;&#160;OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Unless otherwise indicated or the context otherwise requires, references in this Operating and Financial Review and Prospects to &#8220;Nanobiotix,&#8221; or the &#8220;Company&#8221; refer to Nanobiotix S.A. and its consolidated subsidiaries. All references to &#8220;$,&#8221; &#8220;dollars&#8221; and &#8220;USD&#8221; mean U.S. dollars and all references to all references to &#8220;&#8364;&#8221; and &#8220;euros&#8221; mean euros.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our operating and financial review and prospects in conjunction with our audited consolidated financial statements and the related notes thereto included elsewhere in this Annual report. In addition to historical information, the following discussion and analysis contains forward-looking statements that reflect our current plans,estimates, expectations and beliefs and involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Annual Report, particularly in sections titled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i377d9717844147e799376babda10462f_1084"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Financial Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following selected statement of consolidated operations data for the years ended December 31, 2021, 2020 and 2019 and the selected statement of consolidated financial position data as of December 31, 2021 and December 31, 2020 have been derived from our audited consolidated financial statements included elsewhere in this Annual Report. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following summary consolidated financial data for the periods and as of the dates indicated are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and related notes beginning on page F-1 of this Annual Report, as well as the sections titled &#8220;Operating And Financial Review And Prospects&#8221; included elsewhere in this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our historical results for any prior period do not necessarily indicate our results to be expected for any future period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of Euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Statement of consolidated operations data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,647</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(55,226)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(38,941)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(49,320)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(52,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(36,428)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(46,779)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,360&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,580</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,133)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(47,003)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(33,590)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(50,915)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (euros/share)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (euros/share)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:69.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of Euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Statement of consolidated financial position data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Operation Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are a clinical stage biotechnology company focused on developing, first-in-class product candidates that use our proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our lead product candidate NBTXR3, is an aqueous suspension of functionalized, crystalline hafnium oxide nanoparticles designed for injection directly into a malignant tumor and is activated by radiotherapy (&#8220;RT&#8221;). When exposed to ionizing radiation, NBTXR3 amplifies the localized intratumor killing effect of that radiation and may also prime adaptive immune response and create long-term anti-cancer memory. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues. Given the physical mechanism of action, we believe that NBTXR3 could be developed as a tumor-agnostic treatment </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">targeting all solid tumors that are treated with radiotherapy and across therapeutic combinations, including immune checkpoints inhibitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Radiotherapy, also called radiation therapy, involves the use of X-rays or other high-energy particles or rays to kill cancer cells in tumors. It is among the most common cancer treatments, both as a standalone therapy and in combination with surgery, chemotherapy or biological therapies. In developed countries with access to radiotherapy, approximately 60% of all cancer patients will receive radiotherapy at least once, either alone or as a part of a more complex treatment protocol. Nevertheless, many of these patients still die from the progression of their cancer because, among other reasons, they are not able to receive a high enough radiation dose to completely destroy their tumor without resulting in an unacceptable level of damage to surrounding healthy tissues. We believe that by mitigating these limitations, NBTXR3 may improve the survival rate and quality of life for cancer patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our pioneering approach uses nanophysics to bring a physical mode of action to destroy cancer cells. Unlike traditional chemotherapies or biologics, NBTXR3 has a broadly applicable mechanism of action that we believe to have the potential to be used in the treatment of all solid tumor types in conjunction with radiotherapy. The nanoparticles have a high electron density, which allows a tumor that contains NBTXR3 to absorb more energy than could otherwise be absorbed by the cancer cells alone. This controlled concentration of energy leads to greater localized cancer cell destruction. When exposure to radiation ceases, the nanoparticles return to their inactive, inert state. However, the subsequent effect of improved physical cell destruction may allow for a greater exposition of tumor antigens in the microenvironment. Preclinical data and early data from our ongoing clinical studies both suggest that NBTXR3 activated by radiation therapy may allow for the priming of the immune system. This priming effect, if validated through further clinical testing, may be due to the activation of complex causal mechanisms, referred to as pleiotropic biological pathways, and increased exposition of antigens resulting in the activation of a patient&#8217;s own immune cells to destroy cancer cells in the body. We believe that NBTXR3&#8217;s novel mechanism of action and effect, when activated, on the tumor microenvironment could enable better local control of tumors and may potentially enhance systemic control of tumors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, NBTXR3 has been administered to approximately 300 patients. Given our focus areas, and balanced against the scalable potential of NBTXR3, we have engaged in a strategic collaboration strategy with large and reputable partners to expand development of the product candidate in parallel with our priority development pathways, as discussed under the caption &#8220;&#8212;NBTXR3 Development Pipeline&#8221; below. In 2018 we entered into a broad, comprehensive clinical research collaboration with MD Anderson to sponsor several Phase I and Phase II studies in the United States to evaluate NBTXR3 across tumor types and therapeutic combinations, with a total of approximately 340 patients expected to be enrolled across these clinical trials. Five clinical trials under this collaboration&#8212;a Phase I study in patients with locally advanced or borderline resectable pancreatic cancer, a Phase I study in patients with esophageal cancer, a Phase I study in patients with non-small cell lung cancer and two Phase II studies in patients with head and neck cancer in combination with anti-PD-1&#8212;have commenced enrollment. In May 2021, we entered into a collaboration agreement with LianBio to develop and commercialize NBTXR3 in key countries in Asia, including Mainland China, Taiwan and South Korea, pursuant to which LianBio has undertaken to contribute to enrollment in five global registrational studies for NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We were founded as a spin-off from the State University of New York, Buffalo in 2003. Team members at Nanobiotix, including our founder, Laurent Levy, have nearly two decades of experience developing Nanobiotix&#8217;s technology and we believe we are a pioneer and leader in the field of nanomedicine. We have built an integrated, multidisciplinary team that combines expertise in physics, biology and medicine. We believe that our unique expertise in nanotechnology will provide us with opportunities to expand our product pipeline and to advance the development of our product candidates, either on our own or in collaboration with third parties. Our corporate headquarters and manufacturing facilities are located in Paris, France, with U.S. operations in New York City, New York and Cambridge, Massachusetts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, we had cash and cash equivalents of &#8364;83.9 million. See &#8220;&#8212;Liquidity and Capital Resources&#8221; below for additional information. For the years ended December 31, 2021 and 2020, we had </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">de</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">minimis</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">revenue. We have not generated significant revenues to date from product sales or royalties, and we do not expect to generate significant revenues from product sales or royalties unless and until our product candidates are approved for marketing and are successfully commercialized. Historically, we have financed our operations and growth through issuances of new shares, refunds of research tax credits, conditional advances and grants awarded by governmental agencies, as well as bank loans from time to time. From our inception in 2003 through December 31, 2021, we have received more than &#8364;324.4 million in financing in the form of external fundraising, loans and repayable advances. See &#8216;&#8216;&#8212;Liquidity and Capital Resources&#8217;&#8217; below for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since our inception, we have recorded operating losses every year, due primarily to research and development expenses incurred in connection with our efforts to advance our development program for NBTXR3. Our net losses were &#8364;47.0 million, &#8364;33.6 million and &#8364;50.9 million for the years ended December 31, 2021, 2020 and 2019, respectively. Our net losses may fluctuate significantly from year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses and capital requirements will increase substantially in connection with our ongoing activities, as we:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">advance our ongoing clinical trials of NBTXR3;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">initiate and conduct additional planned clinical trials of NBTXR3;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">continue the research and development of other product candidates or other applications of NBTXR3;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">scale-up our manufacturing capabilities to support the launch of additional clinical trials and the commercialization of our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">establish a sales and marketing infrastructure for the commercialization of our product candidates, if approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">hire additional clinical, quality control and scientific personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Until such time that we can generate substantial revenue from product sales, we expect to finance these expenses and our operating activities through our existing liquidity. If we are unable to generate revenue from product sales in accordance with our expected timeframes and in the amounts we expect, or if we otherwise need additional capital to fund our operating activities, we will need to raise additional capital through the issuance of shares, through other equity or debt financings or through collaborations or partnerships with other companies. We may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would otherwise prefer to develop and market ourselves. Failure to secure adequate funding could cause us to cease operations, in part or in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Although it is difficult to predict future liquidity requirements, we expect that our existing cash and cash equivalents as of December 31, 2021 will be sufficient to fund our current operations through the second quarter of 2023. However, this estimate is based on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. In any event, we will need additional capital to pursue preclinical and clinical activities, obtain regulatory approval for, and to commercialize our product candidates. Our ability to successfully transition to profitability will be dependent upon achieving a level of revenues adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We operate in a single operating segment for accounting purposes. The audited consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#8220;IAS&#8221;), as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), as well as interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS-IC&#8221;) and the Standard Interpretations Committee (the &#8220;SIC&#8221;), which application is mandatory as of January 1, 2021. The audited consolidated financial statements are also compliant with IFRS as adopted by the EU.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1079"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">COVID-19 Update</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously reported, while implementing health and safety measures, we have continued to advance our research and development programs. As we continue to actively advance our clinical programs, we remain in close contact with our principal investigators and clinical sites and are assessing the impact of COVID-19 on the expected development timelines and costs of our clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In light of the severity and duration of the COVID-19 pandemic, the focus of healthcare providers and hospitals on addressing COVID-19, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March 18, 2020, we have experienced delays in the enrollment of patients and collection of results from our trials and our preclinical studies. In addition, the ability to conduct patient follow-up is expected to be impacted by the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The exact timing of delays and overall impact of the COVID-19 pandemic to our business, preclinical studies, clinical</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">trials and manufacturing facility is currently unknown, and we are monitoring the pandemic as it continues to rapidly evolve. The overall impact to our business will be dependent on future developments, which are highly uncertain and difficult to predict. See Part II, Item 3D. &#8220;Risk Factor&#8221; of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i377d9717844147e799376babda10462f_1074"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Financial Operations Overview </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1069"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Revenues and Other Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our limited revenues during the years ended December 31, 2021, 2020 and 2019 have been derived mainly from the charging-back of external contract research organization costs that we incurred on behalf of PharmaEngine in connection with development support received as part of our license and collaboration agreement with PharmaEngine. In March 2021, we entered into a Termination and Release agreement, pursuant to which we and PharmaEngine agreed to discontinue our collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Other Income</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our other income consists of grants and subsidies from government agencies and refundable research tax credits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Grants and Subsidies</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have received various grants and other assistance from the government of France and French public authorities, including through Bpifrance (formerly OSEO Innovation), since our inception. The funds are intended to finance our operations or specific projects. Grants and subsidies are recognized in income as the corresponding expenses are incurred and independently of cash flows received.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research Tax Credits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The French tax authorities grant a research tax credit (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria in France (or, since January 1, 2005, other countries in the EU or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that may be used for the payment of their income tax due for the fiscal year in which the expenditures were incurred and during the three fiscal years thereafter. If taxes due are not sufficient to cover the full amount of the tax credit at the end of the three-year period, the difference is repaid in cash to the company by the French tax authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The main characteristics of the research tax credits are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the research tax credits result in a cash inflow to us from the tax authorities, either through an offset against the payment of corporate tax or through a direct payment to us for the portion that remains unused;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">our income tax liability does not limit the amount of the research tax credit, as a company that does not pay any income tax can request direct cash payment of the research tax credit; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the research tax credit is not included in the determination of income tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We apply for the research tax credit for research expenses incurred in each fiscal year and recognize the amounts claimed in the same fiscal year. We have concluded that the research tax credits meet the definition of a government grant as defined in IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, and, as a result, it has been classified as &#8220;Other income&#8221; within operating income in our statements of consolidated operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1098"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our operating expenses are primarily incurred for research and development and selling, general and administrative purposes, for the most part in France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development activities are central to our business. Since our inception, most of our resources have been allocated to research and development. These expenses include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">sub-contracting, collaboration and consultant expenses that primarily consist of the cost of third-party contractors, such as contract research organizations that conduct our non-clinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">employee-related costs for employees in research and development functions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">expenses relating to preclinical studies and clinical trials for NBTXR3;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">manufacturing costs for production of NBTXR3 to support clinical development;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">certain intellectual property expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">expenses relating to regulatory affairs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">expenses relating to the implementation of our quality assurance system.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase in the foreseeable future as we advance the clinical development of NBTXR3.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We cannot determine with certainty the duration and completion costs of the current or planned future clinical trials of our product candidates or if, when, or to what extent we will generate revenue from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may not succeed in achieving regulatory approval for any particular product candidate. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the scope, rate of progress and expense of our ongoing and planned preclinical studies, clinical trials and other research and development activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">clinical trial and early-stage results; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the terms and timing of regulatory approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the expense of filing patent applications and maintaining and enforcing patents and other intellectual property rights and defending against claims or infringements raised by third parties; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the ability to market, commercialize and achieve market acceptance for NBTXR3 or any other product candidate that we may develop in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A change in the outcome of any of these variables with respect to the development of NBTXR3 or any other product candidate that we develop could mean a significant change in the costs and timing associated with the development of NBTXR3 or such other product candidates. For example, if the FDA or other comparable regulatory authority were to require us to conduct preclinical studies and clinical trials beyond those which we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in enrollment in any clinical trials, we could be required to spend significant additional financial resources and time on clinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SG&amp;A expenses mainly comprise administrative payroll costs, overhead costs relating to our headquarters in Paris, and costs such as accounting, legal, human resources, communications and market access activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We anticipate that our SG&amp;A expenses will increase in the future as we increase our headcount to support the expected growth in our research and development activities and the potential commercialization of NBTXR3. We also anticipate increased expenses associated with being a public company in the United States following our initial</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">public offering in December 2020, including costs related to audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq listing and SEC requirements, director and officer insurance premiums, and investor relations costs. In particular, we will need to incur additional accounting expenses to comply with the Sarbanes-Oxley Act of 2002 in the United States, which will require us to test the effectiveness of our internal controls over financial reporting.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Other Operating Income (Loss)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other operating income (loss) relates to payments totalling $6.5&#160;million (&#8364;5.4&#160;million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net Financial Income (Loss)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net financial income (loss) comprises mainly interest income on short-term bank deposits, interest costs primarily on the EIB loan, foreign exchange gains and losses and, since January 1, 2019, the interest costs on leases related to the application of IFRS 16. See Note 12 of our audited consolidated financial statements for additional details regarding the IFRS 16 lease liabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i377d9717844147e799376babda10462f_1104"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Some of the accounting methods and policies used in preparing our financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders&#8217; equity and of our losses could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted. We believe that the most significant management judgments and assumptions in the preparation of our financial statements are named below. For further details, see Notes to our consolidated financial statements. Each of the following is incorporated by</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">reference here:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Revenue Recognition - license and collaboration agreement with PharmaEngine (see Notes 4.1 and 15)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Share-Based Payments (see Notes 3.2 and 17)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Clinical Trial Accruals (see Notes 3.2 and 13.1)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Fair Value of Financial Liabilities &#8211; EIB Loan and associated royalty agreement (see Notes 4.2 and 12).</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1110"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Operating results  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have one operating segment, which is the research and development of product candidates that use proprietary</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">nanotechnology to transform cancer treatment.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1132"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Comparison of the years ended as of December 31, 2021, 2020 and 2019</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our results of operations for the years ended as of December 31, 2021, 2020 and 2019 are summarized in the table below: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues and other income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,647</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,378)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(24,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(55,226)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(38,941)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(49,320)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(52,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(36,428)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(46,779)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,360&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial income (loss)</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,580</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,133)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(47,003)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(33,590)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(50,915)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues and Other Income</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenues and other income increased by 135 thousand, or 5%, from &#8364;2.5 million for the years ended December 31, 2020 to &#8364;2.6 million for the year ended December 31, 2021. For the years ended December 31, 2020 and 2019, the revenues and other income were stable at &#8364;2.5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The components of our revenues and other income are set forth in the table below:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,637</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,462</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,473</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,647</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenues</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All of our revenues for the years ended December 31, 2021, 2020 and 2019 were derived from the chargeback of external contract research organization costs in connection with development support provided to PharmaEngine as part of our license and collaboration agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1122"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Other income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other income remained relatively stable between the year ended December 31, 2021 and the year ended December 31, 2020. The research tax credit increased by &#8364;563 thousand from &#8364;1.9 million for the year ended December 31, 2020 to &#8364;2.5 million for the year ended December 31, 2021, mainly due to an increase in eligible expenditures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The decrease of &#8364;400 thousand in subsidies, from &#8364;526 thousand for the year ended December 31, 2020 to &#8364;126 thousand for the year ended December 31, 2021, is mainly due to the &#8364;312 thousand provided by the French State as part of the &#8216;&#8216;partial unemployment measure&#8217;&#8217; in 2020 (see below). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The decrease in other income for the year ended December 31, 2020 was primarily attributable to the amounts provided by the French State as part of the &#8216;&#8216;partial unemployment measure&#8217;&#8217;, a national plan allowing companies facing economic challenges posed by the COVID-19 pandemic to receive approximately 84% of specific employees&#8217; net salaries from the French State. These subsidies were granted to us and to our subsidiary Curadigm and amounted to &#8364;312 thousand. Subsidies also included the Deep Tech Funding (defined below), &#8364;187 thousand of which was recognized as other income in the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Subsidies increased by &#8364;506 thousand from 2019 to 2020, amounting to &#8364;526 thousand for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1117"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development expenses for the years ended December 31, 2021, 2020 and 2019 are summarized below: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:55.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,734)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,980)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(24,330)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,411)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The total amount of expenses incurred with respect to research and development activities increased by &#8364;6.1 million, or 25.0%, from &#8364;24.3 million for the year ended December 31, 2020 to &#8364;30.4 million for the year ended December 31, 2021. This net increase was mainly due to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Purchases, sub-contracting and other expenses increased by &#8364;6.8 million, or 54% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially our clinical trial NANORAY-312; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease of &#8364;0.7 million, or 6.8%, in payroll costs, which was mainly due to a change in the mix and in the location of research and development staff. As of December 31, 2021, our workforce included 75 research and development staff as compared with a total of 66 as of December 31, 2020; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease of &#8364;79 thousand in depreciation, amortization and provision expenses primarily due to the application of the IFRS 16 standard.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The total amount of expenses incurred with respect to research and development activities decreased by &#8364;6.1 million, or 20.0%, from &#8364;30.4 million for the year ended December 31, 2019 to &#8364;24.3 million for the year ended December 31, 2020. This net decrease was mainly due to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Purchases, sub-contracting and other expenses decreased by &#8364;4.1 million, or 24% for the year ended December 31, 2020 as compared with the same period in 2019. This reflects the Company&#8217;s endeavor to decrease costs while maintaining clinical trials development during the COVID-19 pandemic; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease of &#8364;1.7 million, or 14.4%, in payroll costs, which was mainly due to a decrease of 15 research and development staff for the year ended December 31, 2020 as compared with the same period in 2019. As of December 31, 2020, our workforce included 66 research and development staff as compared with a total of 81 as of December 31, 2019; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease of &#8364;337 thousand in depreciation, amortization and provision expenses primarily due to a &#8364;145 thousand payment related to a provision for disputes for the year ended December 31, 2020, which amount was &#8364;164 thousand for the same period in 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1156"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Selling, General and Administrative (&#8220;SG&amp;A&#8221;) Expenses</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SG&amp;A expenses for the years ended December 31, 2021, 2020 and 2019 are summarized below: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,482)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(19,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14,611)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,909)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our SG&amp;A expenses increased by &#8364;4.8 million, or 33.0%, from &#8364;14.6 million for the year ended December 31, 2020 to &#8364;19.4 million for the year ended December 31, 2021. This was primarily due to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an increase in purchases, fees and other expenses of &#8364;3.1 million or 48.7%. This variation reflects two main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a US public company. The second main impact relates to recruitment expenses; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an increase of &#8364;1.6 million or 20.4% in payroll costs due to a change in the mix and location changes of SG&amp;A staff (more US based employees). At December 31, 2021 we employed 25 SG&amp;A staff as compared with 24 as of December 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation, amortization and provision expenses increased from &#8364;340 thousand in 2020 to &#8364;417 thousand in 2021, primarily due to the to the extension of Villejuif leases.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our SG&amp;A expenses decreased by &#8364;4.3 million, or 22.7%, from &#8364;18.9 million for the year ended December 31, 2019 to &#8364;14.6 million for the year ended December 31, 2020. This was primarily due to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease in purchases, fees and other expenses of &#8364;3.0 million or 31.3% due to our efforts to decrease general and administrative costs in light of the COVID-19 pandemic; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a decrease of &#8364;1.4 million or 15.4% in payroll costs due to a decrease in SG&amp;A staff. At December 31, 2020 we employed 24 SG&amp;A staff as compared with 29 as of December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation, amortization and provision expenses increased from &#8364;270 thousand in 2019 to &#8364;340 thousand in 2020, primarily due to the additional amortization of facility leases in Paris (Oberkampf road and Faubourg Saint Antoine road).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i377d9717844147e799376babda10462f_1151"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Operating Income (Loss)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our operating loss increased by &#8364;16.2 million, or 44.3%, from &#8364;36.5 million for the year ended December 31, 2020 to &#8364;52.6 million for the year ended December 31, 2021. This increase is mainly due to our efforts on our clinical trial development priorities (312 study), along with the expense of &#8364;5.4m pursuant to the termination and release agreement with PharmaEngine.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At December 31, 2021, our workforce totaled 100 employees, which is 10 positions more than the 90 employees for the same period in 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our operating loss decreased by &#8364;10.4 million, or 22.1%, from &#8364;46.8 million for the year ended December 31, 2019 to &#8364;36.4 million for the year ended December 31, 2020. This decrease is mainly due to our efforts to reduce SGA expenses during the COVID-19 pandemic, along with the changes to other income and research and development expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At December 31, 2020, our workforce totaled 90 employees, which is 20 positions less than the 110 employees for the same period in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1146"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Net Financial Income (Loss)      </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">       </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net financial income changed by &#8364;2.7 million, from a &#8364;2.8 million income for the year ended December 31, 2020 to an income of &#8364;5.6 million for the year ended December 31, 2021. The increase was primarily attributable to the  increase in foreign exchange gains as a result of gross proceeds of our global offering, which included our U.S. initial public offering in a US dollar bank account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net financial income changed by &#8364;7.0 million, from a &#8364;4.1 million loss for the year ended December 31, 2019 to an income of &#8364;2.8 million for the year ended December 31, 2020. The increase was primarily attributable to the positive impact of a &#8364;4.8 million decrease in interest costs resulting from our updating of the EIB estimated loan royalties, for the year ended December 31, 2020 compared to a &#8364;4.4 million interest expense for the year ended December 31, 2019, partially offset by a &#8364;1.5 million increase in foreign exchange losses. The increase in foreign exchange losses was driven primarily by our retention of $113.3 million from the gross proceeds of our global offering, which included our U.S. initial public offering in a US dollar bank account. (&#8364;72.0 million as of December 31, 2020), and the impact associated with the closing of a bank account.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1141"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Liquidity and Capital Resources  </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1176"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Introduction</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since our inception, we have consistently generated negative operating cash flows. Historically, we have financed our operations and growth through:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the issuance and sale of ordinary shares, primarily including &#8364;12.1 million in net proceeds from our initial public offering on the Euronext market in Paris in October 2012, &#8364;28.1 million in net proceeds from a private placement capital increase in April 2019, &#8364;18.8 million in net proceeds from a private placement capital increase in July 2020, and $113.3 million (&#8364;93.5 million as of December 10, 2020) in net proceeds from our global offering, including our U.S. initial public offering, in December 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">loans, conditional advances and grants awarded by governmental entities, including:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">our EIB finance contract and royalties agreement granted by the EIB in July 2018, from which we drew (i) the initial tranche of &#8364;16.0 million (repayable in a single installment at maturity) upon satisfying the requisite documentary criteria in October 2018 and (ii) the second tranche of &#8364;14.0 million (repayable in semi-annual installments of principal and interest after a two year grace period) in March 2019 upon achieving the requisite performance criteria (the positive evaluation of the Phase III clinical benefit/risk ratio of NBTXR3 for the treatment of STS by the French notified body covering medical devices, GMED, and the successful identification of the recommended NBTXR3 dosage in our locally advanced head and neck cancers clinical trial).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">a &#8364;2.1 million repayable advance received from Bpifrance in 2013 through France&#8217;s Strategic Industrial Innovation program, an interest-free innovation loan of &#8364;2.0 million from Bpifrance received in September 2016 and a non-dilutive &#8364;1.0 million financing agreement granted in June 2020 as part of Bpifrance&#8217;s Deep Tech program in order to support Curadigm&#8217;s Nanoprimer technology.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">an aggregate of &#8364;10 million in state guaranteed loans (&#8220;Pr&#234;t garanti par l&#8217;Etat&#8221; or &#8220;PGE&#8221;) pursuant to a &#8364;5 million PGE agreement with HSBC France (the &#8220;HSBC PGE Loan&#8221;) in June 2020 and a &#8364;5 million PGE agreement with Bpifrance in July 2020 (the &#8220;Bpifrance PGE Loan&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i377d9717844147e799376babda10462f_1171"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Terms of Our Primary Financing Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1185"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Finance Contract and Royalty Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2018, we and EIB entered into a finance contract and a royalty agreement. The EIB loan is comprised of three potential disbursement tranches, each drawable in the absence of an event of default or prepayment event, subject to our achieving specified documentary and/or performance criteria and making customary representations and warranties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, we drew the initial tranche in October 2018 and the second tranche in March 2019. The terms of the EIB loan provide for a final &#8364;10.0 million third tranche if we satisfy the applicable performance criteria prior to July 26, 2021. The disbursement of the third tranche is dependent on two conditions: (i) obtaining the CE mark for NBTXR3 and achieving the primary endpoint of the pivotal Phase III clinical trial for NBTXR3 in the treatment of locally advanced head and neck cancers and (ii) our raising of new equity financing, which was achieved with our April 2019 capital increase. The deadline for the satisfaction of the requisite performance criteria, which was initially July 26, 2020, was extended to provide an additional year to satisfy the performance conditions and draw the third tranche. If drawn, the third tranche would be repayable in semi-annual installments after a one-year grace period, through the date that is five years after disbursement. As the conditions were not met by July 31, 2021, the Company will not request the final tranche of the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to repayment at maturity (or earlier prepayment), interest on the first tranche shall accrue at the rate of 6% annually, with such interest being capitalized and added to the outstanding principal. Together with the requisite installment of principal, interest on the second tranche (at a 5% fixed rate) and, if disbursed, the third tranche (at a 4% fixed rate) is payable, following the applicable grace period, semi-annually in arrears. The final repayment with respect to each tranche is due five years from the date of its disbursement. Interest on any overdue amounts accrues at an annual rate equal to the higher of the applicable rate plus 2% or EURIBOR plus 2%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We may repay, in whole or in part, any tranche, together with accrued interest upon 30 days prior notice, subject to the payment of a customary prepayment fee. EIB may require us to prepay all outstanding amounts under the EIB loan in connection with certain events, including a substantial reduction in the anticipated cost of our NBTXR3 development program, a prepayment of certain non-EIB financing, certain change of control events, Dr. Laurent Levy ceasing to be our principal executive officer or ceasing hold a specified number of shares, or certain dispositions of assets related to our NBTXR3 development program, in each case, subject to the payment of a customary prepayment fee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB may also require immediate repayment, together with accrued interest and a customary prepayment fee, in connection with the occurrence of any event of default with respect to us or our subsidiaries, including failure to pay any amounts due under the EIB loan, a determination of a material defect in any previously made representation or warranty, any cross-default involving the acceleration or cancellation of an amount equal to at least &#8364;100,000 or pursuant to any other loan from EIB, certain bankruptcy or insolvency events, the occurrence of any material adverse change, or any failure to comply with any other provision under the Finance Contract that remains uncured for 20 business days.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayment fees, if required, are calculated as a percentage of the amount prepaid, which percentage decreases over time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The terms of the EIB loan impose restrictions on us and our subsidiaries that may impact the operation of our business, including, among others, restrictions on (i) the disposition of any part of our business or assets outside of arm&#8217;s length ordinary-course transactions, (ii) restructuring or making any substantial change to the nature of our business, (iii) entering into certain merger or consolidation transactions, (iv) the disposition of our shareholdings in our material subsidiaries, (v) pursuing acquisitions or investments, (vi) incurring any indebtedness in excess of &#8364;1.0 million in the aggregate, (vii) providing guarantees in respect of liabilities or other obligations, (viii) engaging in certain hedging activities, (ix) granting security over our assets, (x) paying dividends or repurchasing our shares, or (xi) impairing our intellectual property rights. Pursuant to these restrictions, we obtained EIB&#8217;s consent to the HSBC PGE Loan (as defined below) and the Bpifrance PGE Loan, which represented an aggregate indebtedness of &#8364;10 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Any of our subsidiaries whose gross revenues, total assets or EBITDA represents at least 5% of our consolidated gross revenues, total assets or EBITDA is required to guarantee our borrowings under the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the royalty agreement, we also committed to pay royalties to EIB calculated on an annual basis for a period of six years beginning on January 1, 2021 and payable with respect to the preceding year on each June 30 during the period from 2022 through 2027. The amount of royalties payable is calculated based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn and indexed on our annual sales turnover.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event that we elect to prepay a tranche of the EIB loan, EIB requires prepayment of the EIB loan in connection with an event of default or other prepayment event under the Finance Contract, or a change of control event occurs following the maturity of the EIB loan, EIB is entitled to request payment of an amount equal to the highest of (i) the net present value of all future royalties, as determined by an independent expert, (ii) the amount required for EIB to realize an internal rate of return of 20% on the EIB loan, and (iii) &#8364;35.0 million. Interest on any overdue amounts accrues at an annual rate equal to 2%.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1206"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PGE Loans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The HSBC PGE Loan is 90% guaranteed by the French State and had an initial 12-month term during which it bore no interest. At the end of this initial term, we (1) paid a guarantee fee equal to 0.25% of the &#8364;5 million principal amount and (2) elected to amortize the principal amount of the loan over a period of five years during which the HSBC PGE Loan will bear interest at a rate of 0.50% per annum for the first two years of amortization and 1% per annum for the third, fourth and fifth year of amortization. The HSBC PGE Loan must be repaid upon the occurrence of customary events of default.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Bpifrance PGE Loan has a six-year term and is 90% guaranteed by the French State. The Bpifrance PGE Loan bears no interest for the first 12-month period but, following such 12-month period and for the subsequent five years, bore an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be repaid in 20 quarterly installments from October 31, 2021 until July 26, 2026. The Bpifrance PGE Loan must be repaid upon the occurrence of customary events of default.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1201"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance Advances and Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except in the event we are unable to commercialize NBTXR3, we have undertaken to repay the total amount of our &#8364;2.1 million advance under the Strategic Industrial Innovation program according to the following schedule: &#8364;0.3 million no later than December 31, 2022, &#8364;0.5 million no later than December 31, 2023, &#8364;0.8 million no later than December 31, 2024 and the remaining balance no later than December 31, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have undertaken to repay the &#8364;2.0 million interest-free innovation loan from 2016 in 16 quarterly installments of &#8364;125 thousand each, beginning in September 2018. Accordingly, we repaid &#8364;0.3 million in 2018 and &#8364;0.5 million in 2019. Due to COVID-19, Bpifrance allowed us to defer two quarterly payments otherwise due in 2020, which will be due, without fees or penalties, at the end of the initial reimbursement period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm&#8217;s &#8364;1.0 million financing agreement under Bpifrance&#8217;s Deep Tech program (the &#8220;Deep Tech Grant&#8221;), which supports Curadigm&#8217;s development of Nanoprimer technology, comprises (i) a &#8364;500 thousand conditional advance, the first &#8364;350 thousand of which was funded at signing and the remainder of which will be funded upon completion of a project related to a nanomedicine therapy, at our request, and (ii) a &#8364;500 thousand grant, the first &#8364;350 thousand of which was funded at signing and the remainder of which will be funded upon completion of a project related to a nanomedicine therapy, at our request. Curadigm received (i) &#8364;350 thousand of the &#8364;500 thousand conditional advance in June 2020, and (ii) &#8364;350 thousand of the &#8364;500 thousand grant, &#8364;187 thousand of which was recognized as revenue in during the year ended December 31, 2020. The conditional advance component of the financing is repayable each quarter, commencing March 31, 2023 and continuing through December 31, 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1196"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Historical Changes in Cash Flows</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below summarizes our cash inflows and outflows for the years ended December 31, 2021, 2020 and 2019: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(29,872)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27,538)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(41,169)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash flows from financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(35,230)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,056</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,109)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i377d9717844147e799376babda10462f_1191"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cash Flows from / used in operating activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our net cash flows used in operating activities was &#8364;29.9 million and &#8364;27.5 million for the years ended December 31, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net cash flows from operating activities for the year ended December 31, 2021 was primarily attributable to:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;11.5 million in changes in working capital mainly composed of operating expenses reflecting the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These funds were partially offset by: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;16.5&#160;million relating to the LianBio upfront payment; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">&#8364;4.9 million of impact of deferred income related to financial liabilities discounting effect.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1224"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cash Flows from / used in investing activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our net cash flows used in investing activities was &#8364;242 thousand for the year ended December 31, 2021 compared to &#8364;112 thousand for the year ended December 31, 2020. The increase of &#8364;130 thousand was due to the fixed asset acquisitions.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1219"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cash Flows from / used in financing activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our net cash flows from financing activities were &#8364;(5.2) million and &#8364;111.8 million for the periods ended December 31, 2021 and 2020, respectively. The decrease of &#8364;116.9 million was primarily attributable to the &#8364;82.9 million of net proceeds, after deducting underwriting commissions and offering expenses, from our U.S. initial public offering in December 2020 and the &#8364;20.0 million of gross proceeds received in July 2020 as a result of a capital increase from a private placement of ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The carrying value and activity of our repayable advances and loans is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:31.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpifrance advance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC<br/>&#8220;PGE&#8221;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance<br/>&#8220;PGE&#8221;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,165</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,746</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38,121</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">974</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">29,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,044</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">42,790</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,533)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">493</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,374</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">300</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,038</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">39,501</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i377d9717844147e799376babda10462f_1237"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Leases liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We adopted IFRS 16 - Leases using the &#8216;&#8216;modified retrospective method&#8217;&#8217; starting on January 1, 2019 and recorded rights of use assets and lease liabilities for the amounts of the discounted lease payments outstanding for the remainder of our leases. The amount of the lease liabilities on initial recognition was &#8364;5.6 million, without impact on future cash payments in connection with the outstanding leases as of January 1, 2019. During the year ended December 31, 2021, net lease liabilities increased by &#8364;0.1 million to &#8364;6.5 million since December 31, 2019. See Note 12.2 of our consolidated financial statements for details regarding the lease liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1232"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Liquidity agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Consistent with customary practices in the French securities market, in 2012 we entered into a liquidity agreement with Gilbert Dupont, an investment company in France, which agreement authorizes Gilbert Dupont to carry out market purchases and sales of our shares on the regulated market of Euronext in Paris in order to provide liquidity for the trading market, such agreement has been amended on November 30, 2018. During the year ended December 31, 2020 and the year ended December 31, 2021, we did not contribute any cash or additional ordinary shares to the liquidity account. The cash and the value of the ordinary shares held in the liquidity account are classified in other non-current financial assets in our statement of consolidated financial position. As of December 31, 2021, a total of 15,456 ordinary shares and &#8364;97 thousand were allocated to the liquidity account with Gilbert Dupont. As of December 31, 2020, a total of 12,970 ordinary shares and &#8364;47 thousand, compared to 15,723 ordinary shares and &#8364;147 thousand as of December 31, 2019, were allocated to the liquidity account with Gilbert Dupont. The liquidity agreement has an automatically renewable term of one year unless otherwise terminated by either party.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1248"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Operating Capital Requirements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Although it is difficult to predict future liquidity requirements, we expect that our existing cash and cash equivalents will be sufficient to fund our current operations through the second quarter of 2023. However, this estimate is based on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. In any event, we will need additional capital to pursue preclinical and clinical activities, obtain regulatory approval for, and to commercialize our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Until we can generate a sufficient amount of revenue from our product candidates, if ever, we expect to finance our operating activities through a combination of equity offerings, debt financings, research tax credits and other government subsidies, and potential milestone payments under third-party collaborations. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our ordinary shares. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our present and future funding requirements will depend on many factors, including, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the size, progress, timing and completion of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the number of potential new product candidates we identify and decide to develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">selling and marketing activities undertaken in connection with the anticipated commercialization of NBTXR3 and any other current or future product candidates and costs involved in the creation of an effective sales and marketing organization; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty payments from our existing or future partnership or collaboration agreements; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the severity, duration and impact of the COVID-19 pandemic, which may continue to adversely impact our business and clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i377d9717844147e799376babda10462f_1243"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Capital Expenditures</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases in software and other intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increases in property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total increases in capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">233</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,444</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 2021, our capital expenditures were comprised primarily of &#8364;73 thousand related to acquisitions of technical equipment and &#8364;53 thousand of new office and IT equipment.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 2020, our capital expenditures were comprised primarily of &#8364;42 thousand related to acquisitions of technical equipment and &#8364;37 thousand of new office and IT equipment.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 2019, our capital expenditures were comprised primarily of &#8364;292 thousand related to the implementation of a new human resources software and of &#8364;815 thousand related to improvements to our new office facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1260"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Research and development, patents and licenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our research and development teams utilize our deep expertise to contribute to the growth of our business. In the</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">years ended December 31, 2021, 2020 and 2019, we incurred expenses &#8364;30.4 million, &#8364;24.3 million and &#8364;30.4 million, respectively, on research and development. For a discussion of our research and development activities, see &#8220;Item 4B - Business Overview&#8221; and &#8220;Item 5A -Operating Results.&#8221;</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1255"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Trend information </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For a discussion of trends, see &#8220;Item 4B. Business Overview,&#8221; &#8220;Item 5A - Operating Results&#8221; and &#8220;Item 5B - Liquidity and Capital Resources.&#8221; Other than as disclosed in these sections, we are not aware of any trends, uncertainties, demands, commitments or events since December 31, 2021 that are reasonably likely to have a material adverse effect on our revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial condition.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1276"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E. Critical Accounting Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_37"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 6.&#160;&#160;&#160;&#160;DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1290"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Directors and Senior Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Corporate Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have a two-tier corporate governance system consisting of an executive board (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">directoire</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), which is responsible for managing the Company and a supervisory board (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conseil de Surveillance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), which oversees the executive board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Executive Board and Supervisory Board Members</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table sets forth information regarding our executive board members and supervisory board members. The address for our supervisory board members and executive board members is 60, rue de Wattignies, 75012 Paris, France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:29.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:96.65pt;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:99.3pt;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Position(s)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Executive Board Members:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Laurent Levy, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">50</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman of the Executive Board and Co-founder (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Principal Executive Officer</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Bart Van Rhijn</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief Financial Officer (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Principal Financial Officer</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ms. Anne-Juliette Hermant</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">47</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chief People Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Supervisory Board Members:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Gary Phillips</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">56</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ms. Anne-Marie Graffin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vice Chairwoman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Alain Herrera, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">71</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Enno Spillner</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Christophe Douat</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">57</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Observer</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following is a brief summary of the business experience of the members of our executive board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Dr. Laurent Levy, Ph.D. </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">is the co-founder of Nanobiotix and has served as our Chairman of the Executive Board since March 2003. He was first appointed as Chairman of the executive board of the Company on May 27, 2004. He has extensive experience in sciences and techniques related to nanotechnologies, a field in which he has worked for more than 10 years. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of a number of concrete applications such as NanoXray, which could open a new method for cancer treatment. Prior to joining Nanobiotix, from 2000 to 2003, he served as consultant for Altran Technologies and worked on the development of applications of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., and Rhodia S.A., as well as for early-stage biotechnology companies. He has served as president of the supervisory board of Valbiotis S.A. (Euronext Paris: ALVAL) since March 2017, as a founding member of the Nanomedicine Translation Advisory Board since June 2014 and as vice chairman of the executive board of the European Technology Platform on Nanomedicine from December 2012 to June 2019. He is the author of more than 35 international scientific publications and communications, has applied for several patents and regularly speaks on the topic of using nanoparticles to fight cancer, including at a recent TEDxParis event. He holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Universit&#233; Paris VI Pierre et Marie Curie) in Paris and from the CEA (Commissariat &#224; l&#8217;&#201;nergie Atomique et aux &#201;nergies Alternatives) and a DEA (advanced studies and diplomas) in Physics of condensed matter from The City of Paris Industrial Physics and Chemistry Higher Educational Institution (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">&#201;cole sup&#233;rieure de physique et de chimie industrielles de la Ville de Paris</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) (UPVI-ESPCI), followed by a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics, SUNY (State University of New York), Buffalo, USA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Mr. Bart Van Rhijn </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer and as an executive board member since June 2021. Mr. Van Rhijn joins Nanobiotix after nearly 3 years as chief financial officer at Servier Pharmaceuticals, LLC (&#8220;Servier US&#8221;), from September 2018 through May 2021. Prior to Servier US, he served as Head of Finance of the US Prescription Business of Galderma from May 2015 through August 2018. Mr. Van Rhijn has also held leadership roles in other prominent organizations in Europe and North America, including Philips, where he has served in Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance positions. Prior to that, Mr. Van Rhijn was a tax consultant at PricewaterhouseCoopers from 1997 to 1999. Mr. Van Rhijn brings 23 years of experience in consultancy, technology, and life sciences industries, including extensive experience in global financial management,</span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">business development and pharmaceutical commercialization. Mr. Van Rhijn received master&#8217;s degrees in Civil Law and Tax Law at Leiden University, The Netherlands, obtained his MBA with honors from Babson&#8217;s Olin School of Management, and his Certified Management Accountant (CMA) certification from the Institute of Management Accounts. In addition, Mr. Van Rhijn serves on the Advisory Board of a Boston-based healthcare start-up, is a venture partner at an emerging technology fund and co-founder of a podcasting hosting and production start-up.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Ms. Anne-Juliette Hermant </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">has served as our Chief People Officer since April 2019 and as an executive board member since July 2019. Ms. Hermant brings over 14 years in talent management and development acquired in different entities at AXA, a multinational firm engaged in global insurance, investment management and other financial services. She worked at AXA Partners from September 2016 to April 2019 as Global Head of Talent, Development, Culture and Corporate Responsibility. Before AXA Partners, Ms. Hermant served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society, from 2007 to 2011. Ms. Hermant holds a Ph. D in French literature from the Ecole Normale Sup&#233;rieure and studied Politics at Sciences Po Paris.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On June 1, 2021, Mr. Bart Van Rhijn succeeded Mr. Philippe Mauberna as the Company's Chief Financial Officer and as a member of the executive board. Mr. Mauberna stepped down from those roles on May 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following is a brief summary of the business experience of the members and observer of our supervisory board.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Dr. Gary Phillip</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">s</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has served as Chairman of our supervisory board since May 2021. Dr. Phillips has over 20 years of experience in the pharmaceutical and healthcare industries, leading commercial operations, clinical medicine, business strategy and development functions. Dr. Phillips serves as the president and chief executive officer of OrphoMed, Inc. in the United States. Before joining OrphoMed in 2018, Dr. Phillips worked with Mallinckrodt Pharmaceuticals, where he had served as Executive Vice President and Chief Strategy Officer since 2013. Prior to that role, he was Head of Global Health &amp; Healthcare Industries at the World Economic Forum, served as President of Reckitt Benckiser Pharmaceuticals North America (now Indivior), and held dual roles as President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch &amp; Lomb. In addition, Dr. Phillips has served in executive roles at Merck Serono, Novartis, and Wyeth. Dr. Phillips earned a B.A. in Biochemistry with Summa Cum Laude and Phi Beta Kappa distinctions from the College of Arts and Sciences at the University of Pennsylvania, an MBA from the Wharton School at the University of Pennsylvania, and an M.D. with Alpha Omega Alpha distinction from the School of Medicine at the University of Pennsylvania. Dr. Phillips maintains an active medical license and practiced as a general medicine clinician/officer in the U.S. Navy, from which he was honorably discharged as a lieutenant commander. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Ms. Anne-Marie Graffin </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">has served as a supervisory board member since 2013, as chairwoman of the appointments and compensation committee since 2017 and as Vice Chairwoman of the supervisory board since July 2017. She has over 20 years of experience in life sciences and pharmaceutical companies. She has served as a non-executive board member of Valneva SE (Nantes, FR &#8211; Vienna, AT) since 2013 and of Sartorius Stedim Biotech SA (Aubagne, FR &#8211; Go&#235;ttingen, Ger) since 2015. Ms. Graffin has expertise in both developing market access strategies and driving biotechnology companies&#8217; growth. She has been a consultant to the pharmaceutical industry since 2011, developing many initiatives within the innovation and startups fields, connecting biotech and medtech startups with major EU venture capital firms and investors. Previously, she was a vice president at Sanofi Pasteur MSD, a European leader in the vaccine field, and acted as a member of the Executive Committee. Prior to working at Sanofi Pasteur MSD, she worked for five years at ROC as international brand manager. Ms. Graffin graduated from ESSEC Business School Paris.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Dr. Alain Herrera, M.D. </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">has served as a supervisory board member since 2013. Dr. Herrera has more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Dr. Herrera currently works at Alain Oncologie Consulting, an oncology consultancy company he started. Previously, Dr. Herrera has served as Head of Corporate Development, Managing Director of PharmaEngine Europe Sarl, as well as the head of the Oncology business at Sanofi-Aventis for 10 years. He also served as Vice President for the Global Oncology Business Strategy and Development from 2007-2008 and Head of the Global Oncology Franchise from 1998-2007. While at Sanofi-Aventis, he contributed to the worldwide registration of Oxaliplatin (Eloxatin</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) and Rasburicase (Fasturtec</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">/Elitek</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), as well as the Gastric and Head &amp; Neck indications for Docetaxel (Taxotere</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">). Prior to Sanofi-Aventis, he served as Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rh&#244;ne Poulenc). Dr. Herrera has also served as a Hematologist Consultant at Antoine Beclere Hospital since 1991.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Mr. Enno Spillner </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">has served as a supervisory board member and chairman of the audit committee since 2014. He has 20 years of experience in the life science industry and currently serves as Chief Financial Officer and Member of the Management Board at German biotech company Evotec SE. From March 2013 until June 2016, he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. From September 2005 to March 2013 he acted as Chief Financial Officer of 4SC AG. Mr. Spillner started his life science industry career as Head of Finance and Managing Partner of the Munich-based biotech venture fund, BioM AG. He was also Managing Director of two portfolio companies, ACTIPAC Biosystems GmbH and Munich innovative Biomaterials GmbH. Prior to moving into the life science field, he was engaged in the media and marketing industry. Mr. Spillner earned his Dipl.-Kaufmann degree (Masters in Business) at the University of Bamberg, Germany.</span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Mr. Christophe Douat </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">serves as a supervisory board observer and is entitled, in this capacity, to attend all meetings of the supervisory board in a non-voting capacity. Mr. Douat previously served as member of the supervisory board from 2011 until 2017 and from 2006 to 2009 when he was the lead investor. He is currently CEO of Medincell (MEDCL, Euronext), a pharmaceutical company that specializes in drug delivery technologies. Mr. Douat worked at the venture capital company Matignon Investissement &amp; Gestion from 2001 to 2009, where he invested in a broad range of companies, and cofounded Matignon Technologies II, one of Europe&#8217;s largest funds specialized in medtech. Mr. Douat is also an alumnus of the Boston Consulting Group. He graduated from &#201;cole des Mines de Paris, an engineering French &#8220;Grande Ecole&#8221;, and holds a master&#8217;s of science in engineering (U.S.A.) and an MBA (Canada).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Family Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">There are no family relationships among any of our executive board members or supervisory board members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Diversity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below provides certain information regarding the Supervisory Board as of the date of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.821%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Supervisory Board Diversity Matrix</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Country of Principal Executive Offices:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">France</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Foreign Private Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Yes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Disclosure Prohibited under Home Country Law</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Total Number of Directors and Board Observers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:41.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Part I: Gender Identity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Part II: Demographic Background</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">LGBTQ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">+</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Did Not Disclose Demographic Background</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We continue to pursue a policy that reflects our commitment to diversity and equality at all levels of the Company. As of the date of this Annual Report, women are represented on both the Supervisory Board and the Executive Board and represent 67% of our total employees.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1296"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Compensation of Supervisory Board and Executive Board Members</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The aggregate compensation paid and benefits in kind granted by us to our current executive board members and supervisory board members, including share-based compensation, for the year ended December 31, 2021 was &#8364;6,846,376. The total amount set aside or accrued to provide pension, retirement or similar benefits was &#8364; 18,025 for the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to the &#8220;say on pay&#8221; regime applicable to companies listed on the regulated market of Euronext in Paris, the payment of compensation (whether fixed, variable or exceptional) attributed for a financial year to any member of the supervisory or executive board is subject to approval at the next ordinary general meeting. All payments of variable or exceptional compensation for the year ended December 31, 2021 detailed below are subject to approval at the annual combined shareholders&#8217; meeting to be held to approve the financial statements for the year ended December, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1382"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Executive Board Compensation</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table sets forth information regarding the compensation earned by our executive board members for service on our executive board during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.236%"><tr><td style="width:1.0%"></td><td style="width:19.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Compensation (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Free Shares (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other Compensation (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total (&#8364;)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Dr. Laurent Levy, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">380,000</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">155,040</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">2,417,400</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">763,920</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">18,025</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">3,734,385</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Ms. Anne-Juliette Hermant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">210,000</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">77,543</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">1,208,700</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">254,640</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">1,750,883</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Mr. Philippe Mauberna</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">101,641</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">25,874</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">0</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">255,000</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">382,515</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Mr. Bart Van Rhijn</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">195,715</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">73,170</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">458,400</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">727,285</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Compensation earned for his corporate office (Chairman of the executive board) that was set by the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Compensation earned under an employment agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects compensation earned for the achievement of specified individual criteria (representing 30% of said bonus), as well as company&#8208;wide, performance criteria (representing 50% of said bonus) and the assessment of individual leadership qualities by the supervisory board (representing the remaining 20%) (together, the &#8220;strategic goals&#8221;). The executive board proposes the strategic goals annually, which are reviewed by the appointments and compensation committee and ultimately approved by the supervisory board. The payment of variable compensation is subject to approval at the annual combined shareholders&#8217; meeting to be held to approve the financial statements for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the valuation of 180,000 free shares granted during the year ended December 31, 2021.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the valuation of 180,000 stock options granted during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects the value of premiums paid for an unemployment insurance policy with the Garantie Sociale des Chefs et Dirigeants d&#8217;Entreprise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects the valuation of 90,000 free shares granted during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the valuation of 60,000 stock options granted during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Mr. Mauberna stepped down as our Chief Financial Officer and executive board member on May 31, 2021, at which time Mr. Van Rhijn was appointed to those roles. See "&#8212;Employment Agreement with Bart Van Rhijn&#8220; below for additional information regarding Mr. Van Rhijn&#8217;s compensation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Compensation earned under an employment agreement covering the six months during which Mr. Mauberna served as an employee of the Company. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the valuation of 1 free share granted during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The Company and Mr. Mauberna mutually agreed to terminate his employment agreement, effective June 30, 2021 and, in this context, entered into a termination agreement on May 19, 2021, the terms of which were approved by the Supervisory Board on April 6, 2021, pursuant to which he was entitled to an exceptional indemnity of &#8364;255,000.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount converted into euros. Compensation earned under an employment agreement covering the seven months during which Mr. Van Rhijn served as a member of the Executive Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(14) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects the valuation of 120,000 stock options granted during the year ended December 31, 2021, which lapsed upon Mr. Mauberna&#8217;s departure from the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">                                                    </span></div><div id="i377d9717844147e799376babda10462f_1377"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Supervisory Board Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate amount of fees of the supervisory board is determined at the shareholders&#8217; annual ordinary general meeting. The supervisory board then divides all or part (at the supervisory board&#8217;s discretion) of this aggregate amount among some or all of its members by a simple majority vote. In addition, the supervisory board may grant exceptional compensation (r&#233;mun&#233;rations exceptionnelles) to individual members on a case-by-case basis for special and temporary assignments. The supervisory board may also authorize the reimbursement of reasonable travel and accommodation expenses, as well as other expenses incurred by its members in the corporate interest. Furthermore supervisory board members may be offered the option of subscribing, under market conditions, for warrants, the issue price of which will be determined on the day of issuance of the warrants on the basis of their characteristics, if necessary with the assistance of an independent expert. Supervisory board members who are employed by us receive separate compensation as officers or employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The members and observers, if any, of the supervisory board are entitled to compensation within the limits of the global annual amount set at the shareholders&#8217; general meeting. The shareholders&#8217; general meeting held on April 28, 2021 set such compensation to an annual aggregate amount of up to &#8364;260,000 for the 2021 financial year and for each subsequent financial year, until a decision to the contrary is made by the shareholders of the Company at an ordinary shareholders' meeting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The supervisory board determines (within the range of limits set in the shareholders&#8217; meeting) the amount awarded to each member and observer, if any, based on the principles described below:</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(i) an amount not exceeding &#8364;63,000 may be granted to the Chairman of the supervisory board;</span></div><div style="padding-left:35.43pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(ii) an amount not exceeding &#8364;35,000 may be granted to each member of the supervisory board (excluding the Chairman but including the observer(s), if any);</span></div><div style="padding-left:35.43pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iii) an additional amount not exceeding &#8364;7,000 may be granted to the chairperson of the appointments and compensation committee; and</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(iv) an additional amount not exceeding  &#8364;15,000 may be granted to the chairperson of the audit committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each of the members and observers, if any, of the supervisory board must attend 80% of all meetings of the supervisory board and committees of the supervisory board, as applicable, in order to receive this compensation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, members and observers, if any, of the supervisory board may receive a compensation for special assignments that may be delegated to them by the supervisory board and that would be the subject of regulated agreements put to the vote at the shareholders&#8217; meeting. The amount of such compensation will be set by the supervisory board based on the nature of the specific assignment entrusted to the concerned member or observer, as applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, travel expenses are reimbursed for each physical attendance upon presentation of an expense report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lastly, the members of the supervisory board may be offered the option of subscribing, under market conditions, for share subscription warrants, the issue price of which will be determined on the day of issuance of the warrants on the basis of their characteristics, if necessary with the assistance of an independent expert.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table sets forth information regarding the compensation earned by our supervisory board members and our supervisory board observer for service on our supervisory board during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:40.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:0.35pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fees earned (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:0.05pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Equity Incentives (&#8364;)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:0.05pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total (&#8364;)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Mr. Laurent Condomine</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">26,250</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">44,303</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">70,553</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Dr. Gary Phillips</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:109%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">36,750</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">36,750</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Ms. Anne-Marie Graffin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">42,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">42,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Dr. Alain Herrera, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">35,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">35,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Mr. Enno Spillner</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">50,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">Mr. Christophe Douat</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">35,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:109%">35,000</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Mr. Laurent Condomine retired from the supervisory board, effective May 25, 2021, at which time Dr. Gary Phillips was appointed as a member of the supervisory board and elected as its chairman. The fees earned cover the period during which Mr. Laurent Condomine was a member of the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Reflects the valuation of 14,431 warrants (BSA) granted during the year ended December 31, 2021, it being specified that Mr. Laurent Condomine paid the Company a total amount of &#8364;42,571.45 for these warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The fees earned cover the period during which Dr. Gary Phillips was a member of the supervisory board </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1372"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Unemployment Insurance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We purchased officer unemployment insurance (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">assurance perte d&#8217;emploi des dirigeants &#8211; GSC</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) for our Chairman of the executive board, Dr. Laurent Levy, for each of the 2019, 2020 and 2021 fiscal years, at an annual cost of &#8364;17,757, &#8364;18,025 and &#8364;18,025, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1878"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Severance Pay</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On May 27, 2004 and July 2, 2013, our supervisory board approved terms for severance pay to be awarded to our Chairman of the executive board, Dr. Laurent Levy. The terms provide that Dr. Levy is entitled to severance pay in either of the following circumstances:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(i) dismissal or non-renewal of executive board membership for any reason other than gross negligence or willful misconduct (&#8220;faute lourde&#8221; as defined under French case law); or</span></div><div style="padding-left:35.43pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(ii) resignation within six months following a change of control (within the meaning of Article L. 233-3 of the French Commercial Code) due to a significant reduction in duties and responsibilities or compensation (including fixed compensation, benefits in kind, variable compensation or severance pay) or transfer of workplace to another country, in each case, without consent.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In such circumstance, as applicable, Dr. Levy is entitled to severance pay in an amount not to exceed the annual gross compensation (fixed and variable) he received during the year preceding the year when his departure occurs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The payment of severance is subject to calculation of the &#8220;average achievement rate,&#8221; which is based on specified performance objectives and is used to calculate the variable compensation received by the payee during the three years preceding departure. If the average achievement rate is less than 50%, no severance is payable, and if the average achievement rate falls between 50% and 100%, severance is payable in full. Any such payment shall include legal indemnities, but exclude compensation due under any non-compete arrangements, subject to certain limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">However, the severance to be paid, together with compensation under any non-compete arrangements that is separately due, may not exceed twice the annual gross compensation received by the payee during the year of resignation, dismissal or non-renewal of executive board membership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No severance payment will be payable if, following resignation, dismissal or non-renewal of executive board membership, Dr. Levy becomes an employee and his duties, responsibilities or compensation have not been reduced nor has he been required to transfer his workplace to another country, in each case, without consent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i377d9717844147e799376babda10462f_2064"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Employment Agreement with Bart Van Rhijn</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have entered into an employment agreement with our Chief Financial Officer and member of our executive board, Mr. Bart Van Rhijn, effective June 1, 2021. Under the employment agreement, Mr. Van Rhijn is entitled to an annual base salary of $380,000 and variable compensation in an amount up to 50% of the annual base salary, depending on the achievement of specified performance objectives. The agreement provides for a 12-month non-compete period following the termination of employment. Mr. Van Rhijn is entitled to compensation during the non-compete period at a rate equal to 80% of his annual base salary and variable compensation. Further, the agreement provides for an exclusivity undertaking during the term of the agreement, and a confidentiality undertaking for the term of the agreement and at all times thereafter. This employment agreement may be terminated by both Mr. Van Rhijn subject to a two-week notice period and by us with or without prior notice.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1362"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Employment Agreement with Anne-Juliette Hermant</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On April 1, 2019, we entered into a permanent employment agreement (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">contrat &#224; dur&#233;e ind&#233;termin&#233;e</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) with our Chief People Officer and member of our executive board, Ms. Anne-Juliette Hermant. Ms. Hermant was entitled to an annual base salary of &#8364;180,000 in 2019, &#8364;200,000 in 2020, and &#8364;210,000 in 2021,and variable compensation in an amount up to 50% of the annual base salary, depending on the achievement of specified performance objectives. The agreement provides for a 12-month non-compete period following the termination of employment. Ms. Hermant is entitled to monthly compensation during the non-compete period of two-thirds of her gross monthly compensation for her last month of service with us. Further, the agreement provides for an exclusivity undertaking during the term of the agreement, and a confidentiality undertaking for the term of the agreement and 10 years thereafter. This employment agreement may be terminated by both Ms. Hermant and us under the conditions provided for by regulation and the collective labor agreement applicable to the employee, and subject to a three-month prior notice.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1367"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Employment Agreement and Termination Agreement with Philippe Mauberna</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On May 23, 2013, we entered into a permanent employment agreement (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">contrat &#224; dur&#233;e ind&#233;termin&#233;e</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), which was amended on April 25, 2019, with our former Chief Financial Officer and member of our executive board, Mr. Philippe Mauberna. Under the employment agreement, Mr. Mauberna was entitled to an annual base salary of &#8364;220,000 in 2018 and variable compensation in an amount up to 50% of the annual base salary, depending on the achievement of specified performance objectives. In 2021, Mr. Mauberna was entitled to an annual base salary of &#8364;242,000 and variable compensation in an amount up to 50% of the annual base salary, depending on the achievement of specified performance objectives. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Mauberna stepped down from his role as chief financial officer and executive board member, effective June 1, 2021. In connection with his departure, Mr. Mauberna and the Company entered into a termination agreement on May 19, 2021, the terms of which were approved by the supervisory board on April 6, 2021. Pursuant to this agreement, Philippe Mauberna is in particular entitled to an exceptional indemnity of &#8364;255,000. He shall also keep the benefit of his 2021 variable compensation (on a pro rata basis), subject however to the achievement of the performance objectives set by the executive board. In addition, the executive board decided to lift, as from June 30, 2021, the continued service condition to which the exercise or definitive acquisition of all incentive instruments held by Philippe Mauberna are subject, notwithstanding the termination of his positions within the Group, and to accelerate the vesting of the OSA 2020 he holds, enabling Philippe Mauberna to exercise all of them. In order to avoid a negative impact on the Company's share price, Philippe Mauberna agreed that the sale of his shares would be restricted. Finally, as from June 30, 2021, Philippe Mauberna was released from his non-compete undertaking.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1357"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Limitations on Liability</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under French law, provisions of our By-laws that limit the liability of directors and officers are ineffective. However, French law allows </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233;s anonymes</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good faith and within their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. Such rules apply to executive and supervisory board members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We expect to maintain customary liability insurance coverage for our supervisory board members and executive board members, including insurance against liability under the Securities Act. We believe that this insurance coverage is necessary to attract qualified supervisory board members and executive board members. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i377d9717844147e799376babda10462f_1352"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Equity Incentives </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We believe that our ability to grant incentive awards is a valuable and necessary compensation tool that allows us to attract and retain the best available personnel for positions of substantial responsibility, provide additional incentives to employees and promote the success of our business. Due to French corporate law and tax considerations, we have historically granted (and may continue to grant in the future) the following equity incentive instruments to our supervisory board members, executive board members, executive officers, employees and other service providers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">founders&#8217; warrants (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">bons de souscription de parts de cr&#233;ateur d&#8217;entreprise</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> or BSPCE), granted only to employees and members of our executive board. We can no longer issue these instruments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">warrants (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">bons de souscription d&#8217;actions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> or BSA), granted only to non-employee supervisory board members and service providers not eligible for either founders&#8217; warrants or stock options;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">restricted stock units (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">actions gratuites</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> or free shares or AGA), generally granted to our employees and corporate officers (including members of the executive board) and the employees and corporate officers of our subsidiaries; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">stock options (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">options de souscription et/ou d&#8217;achat d&#8217;actions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> or OSA), generally granted to the employees of our subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board&#8217;s authority to grant these equity incentive instruments and the aggregate amount authorized to be granted under these instruments must be approved by a two-thirds majority of the votes held by our shareholders present, represented or voting by authorized means, at the relevant extraordinary shareholders&#8217; meeting. Once approved by our shareholders, our executive board can, with the prior approval of the supervisory board, grant warrants (BSA) for up to 18 months, and free shares (the French equivalent of restricted stock units) and stock options for up to 38 months, in each case from the date of the applicable shareholders&#8217; approval. The authority of our executive board to grant equity incentives may be extended or increased only at extraordinary shareholders&#8217; meetings. As a result, we typically request that our shareholders authorize new pools of equity incentive instruments at every annual shareholders&#8217; meeting. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">However, </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">notwithstanding any shareholder authorization, under applicable law we are no longer eligible to issue founders&#8217; warrants (BSPCE).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, founders&#8217; warrants, warrants, employee stock options and free shares were outstanding allowing for the issuance or purchase of an aggregate of 3,006,532 ordinary shares (assuming that such instruments&#8217; vesting conditions are met) at a weighted average exercise price, if any, of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8364;11.47 per ordinary share.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1347"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Founders&#8217; Warrants (BSPCE)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Historically, we have issued founders&#8217; warrants to certain of our employees. However, notwithstanding any shareholder authorization, under applicable law, we can no longer issue founders&#8217; warrants as a result of no longer meeting the criteria to do so. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Founders&#8217; warrants were granted only to our employees who were French tax residents, as they provided favorable tax and social security treatment for French tax residents. Founders&#8217; warrants could have also been granted to our corporate officers having an employee tax status at the time the founders&#8217; warrants were granted. Similar to stock options, founders&#8217; warrants entitle a holder to exercise the warrant for the underlying vested shares at an exercise price per share determined by our executive board and at least equal to the fair market value of an ordinary share on the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1342"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Administration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our shareholders, or pursuant to delegations granted by our shareholders, our executive board, determine, with prior approval of the supervisory board, the recipients of the founders&#8217; warrants, the grant dates, the number and exercise price of the founders&#8217; warrants to be granted, the number of shares issuable upon exercise of the founders&#8217; warrants and certain other terms and conditions of the founders&#8217; warrants, including the period of their exercisability and their vesting schedule. As stated above, we are no longer eligible to issue any further founders&#8217; warrants. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">There is no legal limitation to the size of the founders&#8217; warrant pool. Founders&#8217; warrants are not transferable and may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than by will or by laws of descent or distribution and may be exercised, during the lifetime of the founders&#8217; warrant holder, only by the employee warrant holder.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1337"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Term</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The term of each founders&#8217; warrant is 10 years from the date of grant by the executive board. Any founders&#8217; warrants not exercised by this date will be automatically lapse. In addition, unless otherwise decided by the executive board and the supervisory board, founders&#8217; warrants may be exercised by their holders or assigns six months from (i) the death or disability of the holder or (ii) the termination of the holder from employment or corporate office within the group, failing which the founder&#8217;s warrant will lapse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the executive board decided to lift, the continued service condition to which the exercise of certain founders&#8217; warrants was subject for Mr. Bernd Muehlenweg and Mr. Philippe Mauberna, former members of the executive board, and three of our other employees, notwithstanding the termination of their employment agreements or corporate offices. The executive board also decided to lift for Mr. Muehlenweg, where applicable, the performance conditions to which the exercise of certain founders&#8217; warrants was subject.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1332"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Change in Control</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The terms of the founders&#8217; warrants usually provide that, unless otherwise decided by our supervisory and executive boards, in the event of a merger into another corporation or of the sale by one or several shareholders, acting alone or in concert, of our Company to one or several third parties of a number of shares resulting in a change of control (a &#8220;Liquidity Event&#8221;), the right of holders to exercise outstanding founders&#8217; warrants will be accelerated so that all of such shares may be exercised with effect immediately prior to the completion of the relevant Liquidity Event. Any founders&#8217; warrant not exercised for any reason on or prior to the date of completion of the relevant Liquidity Event will automatically lapse.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the following types of founders&#8217; warrants that we have issued are outstanding:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2012-2</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 08-2013</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 09-2014</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-01</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2015-03</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE 2016</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSPCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 28, 2013</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">December 18, 2012</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">August 28, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSPCE authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSPCE granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">97,200</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">71,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">53,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">126,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">129,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">117,650</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Starting date of the exercise of the BSPCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">August 28, 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 10, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 8, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BSPCE expiry date </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">December 18, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">August 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 10, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Exercise price per BSPCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.63</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;5.92</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;18.68</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;18.57</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;14.46</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;15.93</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Number of shares subscribed as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">333</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSPCEs lapsed or cancelled as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">11,050</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3,200</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">22,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">25,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">28,976</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,150</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of BSPCEs outstanding as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">86,150</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">68,450</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,350</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,567</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,274</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">99,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of shares available for subscription as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">86,150</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">68,450</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,350</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,567</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">38,170</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">99,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">80,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum total number of shares that can be issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">86,150</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">68,450</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,350</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,567</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,274</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">99,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">80,000</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> All such BSPCE can be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The BSPCE 2016-Performance may be exercised as from their date of grant, subject to the achievement of the following targets:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">up to 15% of the BSPCE may be exercised if the number of patients under treatment is at least equal to 200,</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">additional 15% of the BSPCE may be exercised if the number of patients under treatment is at least equal to 300,</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">additional 30% of the BSPCE may be exercised if the number of patients under treatment is at least equal to 400, and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">the balance, i.e., 40% of the BSPCE, may be exercised if the number of patients under treatment is at least equal to 500. As of December 31, 2021, 30% of the BSPCE 2016-Performance can be exercised, it being specified that, on July 23, 2019, the executive board decided to lift the performance conditions to which the exercise of Mr. Bernd Muehlenweg&#8217;s 11,500 BSPCE 2016-Performance was subject. Accordingly, all of Mr. Bernd Muehlenweg&#8217;s BSPCE 2016-Performance may be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> See also &#8220;&#8212;Founders&#8217; Warrants (BSPCE)&#8212;Term&#8221; and &#8220;&#8212;Founders&#8217; Warrants (BSPCE)&#8212;Change in Control.&#8221;</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1327"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Warrants (BSA)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Warrants are typically granted by our executive board to third-party service providers and members of the supervisory board not eligible for either founders&#8217; warrants or stock options. Similar to stock options, warrants entitle a holder to exercise the warrants for the underlying vested shares at an exercise price per share determined by our executive board that is meant to reflect the fair market value of an ordinary share on the date of grant. In addition to such exercise price, warrants are subscribed for at a price determined by the executive board that is meant to reflect the fair market value of the applicable warrants on the grant date.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1322"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Administration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our shareholders, or pursuant to delegations granted by our shareholders, our executive board, with the prior approval of the supervisory board, determine the recipients of the warrants, the grant dates, the number and exercise price of the warrants to be granted, the number of shares issuable upon exercise of the warrants and certain other terms and conditions of the warrants, including the period of their exercisability and their vesting schedule.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">There is no legal limitation to the size of the warrant pool.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1317"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Term</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The term of warrants granted until June 25, 2015 (inclusive), and those granted from July 27, 2018 onwards is 10 years from the date of grant by the Executive Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The term of warrants granted on January 7, 2017 (which lapsed January 7, 2022) and March 6, 2018 is five years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, unless otherwise decided by our supervisory and executive boards, the warrants granted on January 7, 2017 (which lapsed January 7, 2022) must be exercised within six months from (i) the death or disability of the holder or (i) the termination of the holder from employment with us or any of our affiliates during such 10-year period, failing which the BSAs will lapse.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1312"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Change in Control</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The terms of the warrants granted on February 10, 2015 and those granted from January 7, 2017 onwards provide that, unless otherwise decided by our supervisory and executive boards, in the event of a Liquidity Event, the right of any holder to exercise outstanding warrants will be accelerated so that all such warrants may be exercised with effect immediately prior to the completion of the relevant Liquidity Event, subject, if applicable, to continued service by the warrant holder. Any warrant not exercised for any reason on or prior to the date of completion of the relevant Liquidity Event will automatically lapse after this date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The terms of the warrants granted on June 25, 2015 provide their holder with the right to exercise all of his or her warrants in the event of a change of control (i.e., through a merger, a transfer of shares or assets, an operation on share capital or liquidation).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the following types of warrants that we have issued are outstanding:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:18.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 04-2012</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2013</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2014</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-2(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2015-2(b)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2016-Ordinary</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">()</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2016-Performance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> ()</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2016-02</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">()</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 18, 2014</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 4, 2012</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 10, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSA authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">200,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">200,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSA granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">52,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">26,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">64,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,103</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,105</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Starting date of the exercise of the BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">October 23, 2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 30, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BSA expiry date</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 4, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 10, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">September 16, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 10, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise price per BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.37</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;15.01</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Number of shares subscribed as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">22,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of forfeited or cancelled BSAs as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,103</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,105</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSAs outstanding as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">21,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">64,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of shares available for subscription as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Maximum total number of shares that can be issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">21,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">64,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2017</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018-01</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2018-02</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2019-1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2021(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BSA 2021(b)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Date of the shareholders' meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 14, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 14, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 23, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 23, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 11, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">July 27, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 17, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSA authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">116,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">116,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">140,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">650,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">650,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSA granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">48,103</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Starting date of the exercise of the BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">BSA expiry date</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(15)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">July 27, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 17, 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise price per BSA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;15.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.55</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;16.10</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;11.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.47</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.64</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Number of shares subscribed as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of forfeited or cancelled BSAs as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">33,672</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of BSAs outstanding as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14,431</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total number of shares available for subscription as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Maximum total number of shares that can be issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5,820</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">18,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14,431</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All of the BSAs may be exercised, provided that, on the day the BSA is exercised, the relevant holder, when a Supervisory Board member, has attended at least 75% of the Supervisory Board meetings held during the period preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All of the BSAs may be exercised, provided that, on the day the BSA is exercised, (i) the relevant holder, when a Supervisory Board member, has attended at least 75% of the Supervisory Board meetings held during the period preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group (ii) the market value of a Nanobiotix share shall be at least equal to &#8364;40.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All of the BSAs may be exercised, provided that on the day the BSA is exercised, the market value of a Nanobiotix share shall be at least equal to &#8364;50.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All BSAs may be exercised, provided that on the day the BSA is exercised, the market value of a Nanobiotix share shall be at least equal to &#8364;40.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All outstanding BSAs may be exercised, provided that, on the day the BSA is exercised, (i) the relevant holder has attended at least 75% of the Supervisory Board meetings held during the 12-months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group, and (ii) the recommended dose for two out of the three patient cohorts enrolled in Study 1100 has been determined in order to define the next steps of the immuno-oncology development plan, it being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> All BSAs may be exercised, subject to the satisfaction of a performance condition to be acknowledged by the Executive Board, with the prior approval of the Supervisory Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> See also &#8220;&#8212;Warrants (BSA)&#8212;Term&#8221; and &#8220;&#8212;Warrants (BSA)&#8212;Change in Control.&#8221;</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1529"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Stock Options (OSA)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have granted stock options to our employees and the employees of our subsidiaries pursuant to our stock option</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">plans. We currently have two plans, the 2020 Stock Option Plan (&#8220;2020 Plan&#8221;), which was adopted by our executive board on February 9, 2021 and approved by our shareholders during the annual combined shareholders&#8217; meeting held on April 28, 2021 and the 2021 Stock Option Plan ("2021 Plan"), which was adopted by our executive board on June 21, 2021 and shall be submitted to our shareholders for approval during the next annual combined shareholders' meeting. Our executive board has also previously adopted the 2019 Stock Option Plan, the LLY 2019 Plan, the 2018 Stock Option Plan, the 2017 Stock Option Plan and the 2016 Stock Option Plan (collectively, the &#8220;Former Plans&#8221; and together with the 2020 Plan and the 2021 Plan, the &#8220;Stock Option Plans&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock options may be granted to any individual employed by us or our subsidiaries. Stock options may also be granted to the members of our executive board. Incentive stock options may not be granted to holders of 10% or more of our share capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under French law, the maximum number of shares issuable upon the exercise of outstanding stock options may not exceed one-third of the outstanding share capital on a non-diluted basis as of the grant date. Stock options may be granted under the 2020 Plan and the 2021 Plan until 2024.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1524"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Administration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board has the authority to administer and interpret the Stock Option Plans. Subject to the terms and conditions of the Stock Option Plans, our executive board, with the prior approval of the supervisory board, determines the recipients, grant dates, exercise prices, number of ordinary shares underlying and the terms and conditions of the stock options, including their periods of exercisability and their vesting schedules. Our executive board is not required to grant stock options with vesting and exercise terms that are the same for every participant. The term of each stock option granted under the Stock Option Plans is generally 10 years from the grant date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board has the authority to amend and modify stock options outstanding under our Stock Option Plans, including the authority to extend the post-termination exercise period of the options, subject to the written consent of the optionees holding such options, if such amendments or modifications impair the rights of the optionees.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1519"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Options</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Stock Option Plans provide for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and non-statutory Stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These employee stock options are granted pursuant to employee stock option agreements adopted by the executive board. The executive board determines the exercise price for an employee stock option, within the terms and conditions of the applicable Stock Option Plan, provided that the exercise price of an employee stock option generally cannot be less than the per share fair market value of our ordinary shares on the grant date. Employee stock options granted under the Stock Option Plans vest at the rate specified by the executive board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with French Law, our supervisory board decided that the members of our executive board must continue to hold at least 10% of the shares acquired by them upon exercise of the stock options until the termination of their respective term of office.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock options are not transferable (except by succession) and may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner, other than by will or by laws of descent or distribution and may be exercised, during the lifetime of the optionee, only by the optionee.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1514"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Term</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The term of each employee stock option is 10 years from the date of grant or, in the event of death or disability of the optionee during such 10-year period, six months from the date of such death or disability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless a longer period is specified in the notice of grant or otherwise resolved by our executive board, an employee stock option shall remain exercisable by the optionee or his or her assigns, to the extent vested, for six months following an optionee&#8217;s death, disability or termination from continuous employment with us. In the case of an &#8220;Incentive Stock Option&#8221; (as such term is defined in the Stock Option Plan), such period cannot exceed three months following an optionee&#8217;s termination from continuous employment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the stock options granted under the LLY 2019 Plan are not subject to any continuous employment condition nor will they lapse in the event of death or disability of the optionee during the exercise period and six months after the death or disability of the optionee. In addition, the executive board decided to lift, for two of our employees and Mr. Philippe Mauberna, former member of the executive board, the continued service condition to which the exercise of their stock options is subject, notwithstanding the termination of their employment agreement. The executive board also decided to extend the exercise period of the vested stock options of an employee having left the Group by two years. In addition, the executive board decided to accelerate, as from June 30, 2021, the vesting of the OSA 2020 Mr. Philippe Mauberna holds, enabling him to exercise all of them, in the context of his departure from the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1509"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Change in Control</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to the Stock Option Plans, in the event of a Liquidity Event, an optionee&#8217;s right to exercise his or her employee stock options governed by any such plans will be accelerated (subject, if applicable, to a certain stock price being reached) so that the optionee may exercise all vested and unvested employee stock options immediately prior to the completion of the Liquidity Event. Any employee stock option that is not exercised for any reason on or prior to the completion of the Liquidity Event will automatically lapse.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1504"></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">U.S. Tax Limitations on Incentive Stock Options</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The aggregate fair market value, determined at the time of grant, of our ordinary shares issuable under incentive stock options that are exercisable for the first time by an optionee during any calendar year under all of our Stock Option Plans may not exceed $100,000. Employee stock options, or portions thereof, that exceed such limit will generally be treated as non-statutory stock options. No incentive stock option may be granted to any person who, at the time of grant, owns or is deemed to own shares representing more than 10% of our total combined voting power or that of any of our affiliates unless (1) the exercise price is at least 110% of the fair market value of the shares subject to the employee stock option on the date of grant and (2) the term of the incentive stock option does not exceed five years from the date of grant.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the following types of stock options that we have issued are outstanding:</span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:26.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-1 Performance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2016-2</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2017 Ordinary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2018</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2019-1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA LLY 2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 23, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 14, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 23, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 11, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">October 24, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">450,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">526,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">648,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">62,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">37,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Starting date of the exercise of the stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 8, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">October 24, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Stock options expiry date</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:86%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">February 2, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 3, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">January 7, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">October 24, 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Exercise price per stock option</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.05</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;14.26</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;14.97</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;12.87</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;11.08</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Number of shares subscribed as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options lapsed or cancelled as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">3,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">10,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">9,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options outstanding as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">52,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">28,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum number of shares available for subscription as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">120</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">52,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">19,165</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum total number of shares that can be issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">52,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">28,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:38.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 Ordinary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-04 Performance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 Performance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OSA 2021-06 Ordinary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 11, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 28, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 11, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">500,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">850,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">850,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">407,972</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">143,200</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">428,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Starting date of the exercise of the stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 11, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Stock options expiry date</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:86%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 11, 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 21, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Exercise price per stock option</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;12.99</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8364;12.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Number of shares subscribed as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options lapsed or cancelled as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">20,516</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of stock options outstanding as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">387,456</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">93,200</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">398,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum number of shares available for subscription as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">122,738</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum total number of shares that can be issued</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">387,456</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">93,200</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">398,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">60,000</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The OSA 2016-1 Performance may be exercised as from their date of grant, subject to the achievement of the following targets:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">up to 15% of the OSA may be exercised if the number of patients under treatment is at least equal to 200,</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">an additional 15% of the OSA may be exercised if the number of patients under treatment is at least equal to 300,</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">an additional 30% of the OSA may be exercised if the number of patients under treatment is at least equal to 400, and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.52pt">the balance, i.e. 40% of the OSA, may be exercised if the number of patients under treatment is at least equal to 500. As of December 31, 2021, 30% of the OSA 2016-1-Performance, i.e., 120 OSA 2016-1 Performance, can be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">All of the OSA 2016-2 may be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> All of the OSA 2017 Ordinary may be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> All of the OSA 2018 may be exercised.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2019-1 may be exercised as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">up to two-thirds of the OSA 2019-1 as from March 30, 2021; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">the balance, i.e., one-third of the OSA 2019-1 as from March 30, 2022, subject to, for each increment, a continued service condition.</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA LLY 2019 may be exercised under the following conditions:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">10% of the OSA LLY 2019 may be exercised when the market value of a share on the regulated market of Euronext in Paris reaches &#8364;24;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">an additional 10% of the OSA LLY 2019 may be exercised when the market value of a share on the regulated market of Euronext in Paris reaches &#8364;30;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">an additional 40% of the OSA LLY 2019 may be exercised when the market value of a share on the regulated market of Euronext in Paris reaches &#8364;40;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">the balance, i.e. 40% of the OSA LLY 2019 may be exercised when the market value of a share on the regulated market of Euronext in Paris reaches &#8364;60; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">it being specified that, in the event of a Liquidity Event, the performance conditions regarding the price of the Company&#8217;s share price on the regulated market of Euronext in Paris will be automatically waived.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2020 may be exercised as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">up to one-third of the OSA 2020 as from March 11, 2021;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">an additional one-third of the OSA 2020 as from March 11, 2022; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.02pt">the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The exercise of the OSA 2020 granted to members of the executive board and one of our employees was also subject to the achievement of positive results in the 1100 study in 2020. The satisfaction of this performance condition was acknowledged by the executive board, with the approval of the supervisory board, on March 17, 2021.By way of exception, on April 6, 2021, the executive board decided to accelerate the vesting of the 60,000 OSA 2020 granted to Philippe Mauberna, a former member of the executive board, effective June 30, 2021, enabling him to exercise all of them. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2021-04 Ordinary may be exercised as follows:</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; up to one-third of the OSA 2021-04 Ordinary as from April 20, 2022;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional one-third of the OSA 2021-04 Ordinary as from April 20, 2023; and</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; the balance, i.e., one-third of the OSA 2021-04 Ordinary as from April 20, 2024, subject to, for each increment, a continued service condition. In addition, the exercise of the OSA 2021-04 Ordinary granted to members of the executive board is subject to the determination of the recommended dose for two of the three patient cohorts enrolled in Study 1100, in order to be able to define the next stage of the development plan in immuno-oncology before April 20, 2022. The satisfaction of this performance condition shall be acknowledged by the executive board with the approval of the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2021-04 Performance may be exercised under the following conditions:</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify;text-indent:-0.01pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; 10% of the OSA 2021-04 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;24;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify;text-indent:-0.01pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 10% of the OSA 2021-04 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;30;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify;text-indent:-0.01pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 40% of the OSA 2021-04 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;40;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify;text-indent:-0.01pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 40% of the OSA 2021-04 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;60; it being specified that (i) among such OSA 2021-04 Performance that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such OSA 2021-04 Performance as from April 20, 2022, (y) an additional 30% of such OSA 2021-04 Performance as from April 20, 2023, and (z) the balance, i.e., 60% of such OSA 2021-04 Performance as from April 20, 2024 and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. In addition, the exercise of the OSA 2021-04 Performance granted to members of the executive board is subject to the determination of the recommended dose for two of the three patient cohorts enrolled in Study 1100, in order to be able to define the next stage of the development plan in immuno-oncology before April 20, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The satisfaction of this performance condition shall be acknowledged by the executive board with the approval of the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2021-06 Performance may be exercised under the following conditions:</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; 10% of the OSA 2021-06 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;24;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 10% of the OSA 2021-06 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;30;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 40% of the OSA 2021-06 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;40; and</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional 40% of the OSA 2021-06 Performance may be exercised when the market value of a Nanobiotix share on the regulated market of Euronext in Paris reaches &#8364;60, it being specified that (i) among such OSA 2021-06 Performance that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such OSA 2021-06 Performance as from June 21, 2022, (y) an additional 30% of such OSA 2021-06 Performance as from June 21, 2023 and (z) the balance, i.e., 60% of such OSA 2021-06 Performance as from June 21, 2024 and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. The exercise of the OSA 2021-06 Performance is also subject to the determination of the </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">recommended dose for two of the three patient cohorts enrolled in Study 1100, in order to be able to define the next stage of the development plan in immuno-oncology before June 21, 2022. The satisfaction of this performance condition shall be acknowledged by the executive board with the approval of the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The OSA 2021-06 Ordinary may be exercised as follows:</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; up to one-third of the OSA 2021-06 Ordinary as from June 21, 2022;</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; an additional one-third of the OSA 2021-06 Ordinary as from June 21, 2023; and</span></div><div style="margin-top:6pt;padding-left:21.25pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226; the balance, i.e., one-third of the OSA 2021-06 Ordinary as from June 21, 2024, subject to, for each increment, a continued service condition. The exercise of the OSA 2021-06 Ordinary is also subject to the determination of the recommended dose for two of the three patient cohorts enrolled in Study 1100, in order to be able to define the next stage of the development plan in immuno-oncology before June 21, 2022. The satisfaction of this performance condition shall be acknowledged by the executive board with the approval of the supervisory board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> See also &#8220; Stock Options (OSA) Term&#8221; and &#8220;&#8212;Stock Options (OSA)&#8212;Change in Control.&#8221;</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1555"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Free Shares (AGA)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have granted free shares to our employees, employees of our subsidiaries and members of our executive board pursuant to our free share plans (the &#8220;AGA Plans&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Free shares may be granted to any individual employed by us or by any affiliated company under the terms and conditions of an employment contract. Free shares may also be granted to members of our executive board. However, no free shares may be granted to a beneficiary holding more than 10% of our share capital or to a beneficiary who would hold more than 10% of our share capital as a result of such grant.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1550"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Administration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board has the authority to administer and interpret the AGA Plans. Subject to the terms and conditions of the AGA Plans, our executive board, with the prior approval of the supervisory board, determines recipients, dates of grant, the number of free shares to be granted and the terms and conditions of the free shares, including the length of their acquisition period (period starting on the date of grant during which the beneficiary holds a right to acquire shares for free, but does not currently hold any shares) and, as the case may be, holding period (period starting at the end of the acquisition period when the shares are issued and definitively acquired and issued, but may not be transferred) within the limit determined by the shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board has the authority to modify awards outstanding under our AGA Plans, subject to the consent of the beneficiary if such modification is detrimental to him/her, including the authority to release a beneficiary from the continued service condition during the acquisition period after the termination of the employment, on the continued service condition, see also the paragraph &#8220;&#8212;Vesting&#8221;).</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1545"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Vesting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The free shares granted under the AGA Plans will be definitively acquired at the end of the acquisition period as set by our executive board. At the end of the acquisition period, the beneficiary will be the owner of the shares. However, during the holding period (as set by our executive board), if any, the shares may not be sold, transferred or pledged. The sum of the duration of the acquisition and holding periods must be at least two years, in accordance with the provisions of Article L. 225-197-1 of the French Commercial Code.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by our supervisory and executive boards, the AGA 2019-1 granted on March 23, 2019, the AGA 2020 granted on March 11, 2020 and the AGA 2021 granted on April 20, 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2019-1, until March 29, 2021 for French tax residents and March 29, 2022 for foreign tax residents, for the AGA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:1.26pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2020, until March 11, 2022 and for the AGA 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2019-1 or AGA 2020 or AGA 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with the AGA Plans, the executive board decided to lift, for three of our employees and Mr. Philippe Mauberna, a former member of the executive board, the continued service condition to which the definitive acquisition of their AGA 2019-1, as applicable, is subject, notwithstanding the termination of their employment agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by our supervisory and executive boards, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i377d9717844147e799376babda10462f_1579"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Change In Control</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the event of a Liquidity Event, unless otherwise decided by the executive and supervisory board, all of the free shares shall be completely and definitely acquired:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:10.5pt">For French tax residents, (i) if the Liquidity Event occurs before or on the first anniversary date of the grant, on such anniversary date, and (ii) if the change of control occurs after the first anniversary of grant, on the date of completion of the Liquidity Event, it being specified that, in both cases, the relevant free shares will then be subject to a holding period until the second anniversary of the grant.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:10.5pt">For foreign tax residents, if the Liquidity Event occurs before the second anniversary of the grant, on the first anniversary of the grant, it being specified that the relevant free shares will then be subject to a year-long holding period as from their date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the following types of free shares that we have issued are outstanding:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:32.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA<br/>2018-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA<br/>2018-2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA<br/>2019-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA<br/>2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AGA<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Date of the shareholders&#8217; meeting</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">June 14, 2017</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 23, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">May 23, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 11, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">November 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">July 27, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 11, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of free shares authorized</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">526,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">648,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">648,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">650,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">850,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of free shares granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">396,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">438,250</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">362,515</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Date of acquisition (end of the acquisition period)</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:86%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">July 27, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">March 11, 2022</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">April 20, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Duration of the holding period</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:86%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Number of shares acquired as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">340,583</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">369,250</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of free shares lapsed or cancelled as of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">55,667</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">69,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2,003</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Total number of free shares outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">360,512</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:86%">Maximum total number of shares that may be created</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">50,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:5.6pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:115%">360,512</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The AGA 2018-1 granted to French tax residents were definitely acquired on March 6, 2020 and were now subject to a one-year holding period that ended on&#160;&#160;&#160;&#160;March 6, 2021. The AGA 2018-1 granted to foreign tax residents were definitely acquired&#160;&#160;&#160;&#160;on March 6, 2021 and&#160;&#160;&#160;&#160;are not subject   to&#160;&#160;&#160;&#160;any holding period. Hence, as of the date of the Annual&#160;&#160;&#160;&#160;Report, all AGA 2018-1 are definitively acquired and freely transferable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The definitive acquisition of the AGA 2018-1 granted to the members of the executive board was&#160;&#160;&#160;&#160;subject to the achievement of clinical and strategic objectives in the head and neck indication, the completion of which&#160;&#160;&#160;&#160;was recorded by the executive board and the supervisory board on March 15, 2019. On July 23, 2019, the executive board decided that the two-thirds of the AGA  2018-1 granted to Mr. Bernd Muehlenweg, i.e. 28,333 AGA 2018-1 would be definitively acquired on March 6, 2020. The balance, i.e. 14,167 AGA 2018-1, was subject to the conclusion of a clinical trial supply contract before March 6, 2020. As this performance condition was not met, these 14,167 AGA 2018-1 lapsed on March 6, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The AGA 2019-1 granted to French tax residents were definitely acquired on March 29, 2021 and were then subject to a one-year holding period which ended on March 29, 2022. The AGA 2019-1 granted to foreign tax residents would have be definitely acquired on March 29, 2022 and would not have been subject to any holding period. However, the AGA 2019&#8208;1 held by foreign tax residents have lapsed as the beneficiaries left the Company before the end of their acquisition period. The acquisition of the AGA 2019-1 granted to members of our executive board was subject to NBTXR3 receiving the CE mark before June 30, 2019. The satisfaction of this performance condition was acknowledged by the executive board on April 27, 2020, with the prior approval of the supervisory board, on April 6, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The acquisition of the AGA 2020 granted to Ms. Hermant was conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the executive board, with the prior approval of the supervisory board, on March 17, 2021. The AGA 2020 were definitively acquired on March 11, 2022 and are now subject to a one&#8208;year holding period, ending on March 11, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The AGA 2021 granted to members of the executive board are conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in Study 1100 in order to define the next steps of the immuno-oncology development plan before April 20, 2022. The satisfaction of this condition must be acknowledged by the executive board, with the prior approval of the supervisory board, before April 20, 2023. Furthermore, the AGA 2021 will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting April 20, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> See also &#8220;&#8212;Free Shares (AGA)&#8212;Vesting&#8221; and &#8220;&#8212;Free Shares (AGA)&#8212;Change In Control.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i377d9717844147e799376babda10462f_1404"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Board Structure</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our two-tier board structure consists of an executive board and a supervisory board. The roles and functions of each board and the interactions between them are described below.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1414"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Executive Board</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are managed by an executive board under the control of a supervisory board. The members of the executive board determine the broad lines of our business activities and ensure their implementation. Without prejudice to the powers expressly vested in the shareholders&#8217; meetings, and insofar as our By-laws allow, the executive board deals with all matters relating to the conduct of our business. The executive board is vested with the broadest powers to act in all circumstances on our behalf, within the limits of our corporate purpose and subject to the powers granted to the shareholders&#8217; meeting and supervisory board.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board must be composed of between two and seven members. Pursuant to our By-laws, the executive board, in its entirety, is appointed by the supervisory board for a four-year term renewable by the supervisory board. Executive board members may be dismissed at the ordinary general meeting and by the supervisory board. In the case of a vacancy between annual meetings, the supervisory board must within a two-month period appoint a temporary member to fill the vacancy or must change the number of executive board members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We currently have three members of the executive board. The following table sets forth the names of the members of the executive board, the year of their initial appointment as members of the executive board and the expiration date of their current term.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Initial Appointment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Term Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Laurent Levy, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2004</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Bart Van Rhijn</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ms. Anne-Juliette Hermant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2024</span></td></tr></table></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1399"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Supervisory Board</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The members of the supervisory board exercise control over the management of the executive board. The supervisory board operates pursuant to a separate charter adopted by its members on March 18, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On an annual basis, the Supervisory Board intends to review the voting results from our annual shareholders&#8217; meeting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under French law, our supervisory board must be composed of between three and eighteen members. Within this range, the number of members is determined by our shareholders. Further, Euronext Paris gender equality rules require that the number of members of each gender not be less than 40%. However, if the board is composed of eight or less members, the number of members of one gender cannot exceed the number of members of the other by more than two.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Any appointments made in violation of these limitations are null and void. In addition, payment of fees to any member of the board will be suspended until any such violation is remedied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Members of our supervisory board are elected, re-elected and may be removed, with or without cause, at a shareholders general meeting with a simple majority vote of our shareholders. Pursuant to our By-laws, the members of our supervisory board are elected for six-year terms. In accordance with French law, our By-laws also provide that any vacancy on our supervisory board resulting from the death or resignation of a member, provided there are at least three members remaining, may be filled by a majority vote of our members then in office provided that there has been no shareholders meeting since such death or resignation. Members chosen or appointed to fill a vacancy are elected by the supervisory board for the remaining duration of the current term of the replaced member. The appointment must then be ratified at the next shareholders general meeting. In the event the supervisory board would be composed of less than three members as a result of a vacancy, the remaining members shall immediately convene a shareholders general meeting to elect one or several new members so there are at least three members serving on the supervisory board, in accordance with French law. In addition, any appointment made in violation of the gender equality rule described above that is not remedied within six months of such appointment, will be null and void.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We currently have four members of the supervisory board and one observer. The following table sets forth the names of the members and observer of the supervisory board, the year of their initial appointment as members or observer of the supervisory board and the expiration dates of their current term.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year of Initial Appointment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Term Expiration Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Gary Phillips</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ms. Anne-Marie Graffin</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vice Chairwoman</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dr. Alain Herrera, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Enno Spillner</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Member</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mr. Christophe Douat</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Observer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2023</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Mr. Christophe Douat previously served as member of the supervisory board from 2011 until 2017. Since 2017, Mr. Christophe Douat has served as an observer and is entitled to attend all meetings of the supervisory board in a non-voting capacity.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1409"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Supervisory Board Member Independence</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have independent members on our supervisory board, except with respect to our audit committee. Our supervisory board has undertaken a review of the independence of its members and considered whether any member has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from, and provided by, each supervisory board member concerning such member&#8217;s background, employment and affiliations, including family relationships, our supervisory board determined that all of its members qualify as &#8220;independent directors&#8221; as defined under applicable rules of Nasdaq and the independence requirements contemplated by Rule 10A-3 under the Exchange Act. In making these determinations, our supervisory board considered the current and prior relationships that each member has and has had with our company and all other facts and circumstances that our supervisory board deemed relevant in determining their independence, including the beneficial ownership of our ordinary shares by each member and his or her affiliate entities, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Furthermore, the MiddleNext Corporate Governance Code is a reference governance code, as amended in September 2021, published by MiddleNext that is specifically tailored for small and mid-cap companies. Listed companies in France must comply with the corporate governance provisions of general corporate law and may also refer to the recommendations of a reference governance code, such as the MiddleNext Corporate Governance Code. French companies referring to a reference governance code must disclose whether their governance practices deviate from the recommendations set out in such reference code. The MiddleNext Corporate Governance Code sets out the following five criteria to be used to evaluate the independence of supervisory board members, which are characterized by the absence of any significant financial, contractual or family relationship likely to affect a member&#8217;s independence of judgment. Each supervisory board member:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">must not be a salaried employee or corporate officer of us or any of our affiliates and must not have held such a position within the last five years;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">must not be in a significant business relationship with us or any of our affiliates (e.g., client, supplier, competitor, provider, creditor, or banker) and must not have been in such a relationship within the last two years;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">must not be a reference shareholder or hold a significant number of voting rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">must not have close relationships or family ties with any of our corporate officers or reference shareholders; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">must not have been our auditor within the last six years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our supervisory board believes that all of its members are independent under the independence criteria of the MiddleNext Corporate Governance Code.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1455"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Role of the Supervisory Board in Risk Oversight</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our supervisory board is responsible for the oversight of our risk management activities and has delegated to the audit committee the responsibility to assist our supervisory board in this task. The audit committee also monitors our system of disclosure controls and procedures and internal control over financial reporting and reviews contingent financial liabilities. Additionally, the audit committee reviews and discusses with management all reports regarding our enterprise risk management activities, including management&#8217;s assessment of our major risk exposures and the steps taken to monitor and manage those exposures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">While our supervisory board oversees our risk management, our executive board is responsible for our day-to-day risk management processes. Our supervisory board expects our executive board to consider risk and risk management in each business decision and to proactively develop and monitor risk management strategies and </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">processes for day-to-day activities. We believe this division of responsibility is the most effective approach for addressing the risks we face.</span></div><div id="i377d9717844147e799376babda10462f_1450"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Corporate Governance Practices </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a French </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> listed on the regulated market of Euronext in Paris, we are subject to various corporate governance requirements under French law. In addition, as a foreign private issuer listed on the Nasdaq Global Select Market, we are subject to the Nasdaq corporate governance listing standards. However, the Nasdaq listing standards permit foreign private issuers to follow home country corporate governance practices in lieu of the Nasdaq rules, with certain exceptions. Certain corporate governance practices in France may differ significantly from the Nasdaq corporate governance listing standards. For example, neither the corporate laws of France nor our By-laws require that (i) a majority of our directors be independent, (ii) our compensation committee include only independent directors, or (iii) our independent directors hold regularly scheduled meetings at which only independent directors are present. Other than as set forth below, we currently intend to comply with the corporate governance listing standards of Nasdaq to the extent possible under French law. However, we may choose to change such practices to follow home country practices in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Even as a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of the auditor&#8217;s duties, management of complaints made, and selection of consultants. Under Rule 10A-3, if the laws of a foreign private issuer&#8217;s home country require that any such matter be approved by board members or the shareholders of the company, the audit committee&#8217;s responsibilities or powers with respect to such matter may instead be advisory.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under French law, the audit committee may only have an advisory role and the appointment of our statutory auditors, in particular, must be approved by our shareholders at our annual meeting. Therefore, in accordance with Rule 10A-3, our audit committee only has an advisory role with respect to the aforementioned responsibilities. Under French law, an audit committee may have only two members, whereas Nasdaq listing standards require a three-member audit committee. We currently have only two members on our audit committee in accordance with French law. One observer currently attends the audit committee in a non-voting capacity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">French law does not require our independent directors to hold regularly scheduled meetings at which only independent directors are present. We currently follow home country practice in this regard, although, if the independent directors decide to meet in such executive sessions, they may do so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company&#8217;s common voting stock. We follow our French home country practice, rather than complying with this Nasdaq rule. Consistent with French law, our By-laws provide that when first convened, general meetings of shareholders may validly deliberate only if the shareholders present or represented hold at least (1) 20% of the shares entitled to vote in the case of an ordinary general meeting or of an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, or (2) 25% of the shares entitled to vote in the case of any other extraordinary general meeting. If such quorum required by French law is not met, the meeting is adjourned. There is no quorum requirement under French law when an ordinary general meeting or an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium is reconvened, but the reconvened meeting may consider only questions that were on the agenda of the adjourned meeting. When any other extraordinary general meeting is reconvened, the required quorum under French law is 20% of the shares entitled to vote. If a quorum is not met at a reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months. See the section of this Annual Report titled &#8220;Item 10B. Memorandum and Articles of Association.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further, Nasdaq rules require that listed companies have a compensation committee comprised solely of independent directors and that director nominees be selected solely by independent directors. We currently comply with this Nasdaq rule, but may in the future elect to follow French home country practice.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Finally, Nasdaq rules require shareholder approval when a plan or other equity compensation arrangement is established or materially amended. Under French law our shareholders must decide any issuance of equity, as a general matter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">However, we follow our French home country practice and ask our shareholders to delegate their authority to issue incentive equity and define the final terms of any equity compensation plan or arrangements to our executive board. We may, from time to time, ask for our shareholders&#8217; subsequent approval on an equity compensation arrangement in order to obtain advantageous tax treatment or otherwise. In addition, under French law, our executive board must obtain the prior approval of our shareholders before establishing or amending a plan or arrangement that would exceed the limits of the granted delegation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i377d9717844147e799376babda10462f_1440"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Supervisory Board Committees </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our supervisory board has established an audit committee and an appointments and compensation committee, each of which operates pursuant to a separate charter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with French law, committees of our supervisory board will only have an advisory role and can only make recommendations to our supervisory board. As a result, decisions are made by our supervisory board, taking into account non-binding recommendations of the relevant board committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Supervisory Board is carefully monitoring trends and developments with respect to corporate social and environmental responsibility issues, and intends to evaluate the Supervisory Board&#8217;s oversight of the Company with respect to such issues.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1884"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:109%">Audit Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our audit committee monitors the questions relating to the processing and control of accounting and financial information. To this end, it ensures the quality of our internal controls and the reliability of information provided to shareholders and financial markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The duties specifically assigned to the audit committee by our supervisory board include, but are not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">monitoring the financial reporting process;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">monitoring the effectiveness of internal control and risk management systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">monitoring the legal audit of the annual and consolidated accounts of the statutory auditors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making recommendations regarding the selection of our statutory auditors to be appointed by our shareholders, determining their compensation and ensuring their independence;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making recommendations regarding the selection of any accounting firm, other than our statutory auditors, to be appointed for non-audit services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">examining our procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters, as well as for the confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">generally advising the supervisory board and making recommendations with respect to all of the areas above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The audit committee may meet or consult with any member of our executive board and may conduct internal or external due diligence reviews with respect to any matter that may be relevant to the performance of its duties, so long as our supervisory board and the chairman of our executive board are informed in advance. In particular, our audit committee has the right to interview the persons involved in the preparation or control of our financial statements, including our Chief Financial Officer and those persons responsible for significant areas within our financial department.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our audit committee shall be comprised of at least two members from, and appointed by, the supervisory board, after consultation with our appointments and compensation committee. Members shall be independent in accordance with Nasdaq's listing rules and Rule 10A-3 of the Exchange Act as well as the criteria established by the MiddleNext Corporate Governance Code. At least one member shall have specific financial and accounting skills. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Further, under French law an audit committee may only have two members, whereas Nasdaq requires a three-member audit committee. We currently have two members on our audit committee in accordance with French law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Currently, our audit committee is comprised of two members: Mr. Enno Spillner (chairman and independent member) and Dr. Gary Phillips (independent member), and one observer, Mr. Christophe Douat, who attends in a non-voting capacity. Our supervisory board has determined that Mr. Spillner is an &#8220;audit committee financial expert,&#8221; as defined by SEC rules and regulations, and that each member qualifies as financially sophisticated under the Nasdaq listing rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our audit committee met five times in 2021. Mr. Laurent Condomine served on the audit committee for the year 2020 and until his retirement on May 25, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i377d9717844147e799376babda10462f_1435"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:109%">Appointments and Compensation Committee</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our appointments and compensation committee provides recommendations and proposals to our executive and supervisory board members on the composition and compensation policies of our executive and supervisory boards, and also prepares any related reports to be provided by us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The principal duties and responsibilities of our appointments and compensation committee include, but are not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making recommendations on the composition of the executive and supervisory boards and the supervisory board&#8217;s committees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">annually evaluating independence and submitting to our supervisory board a list of its members who may qualify as independent members based on Nasdaq's listing rules and Rule 10A-3 of the Exchange Act as well as the criteria set forth in the MiddleNext Corporate Governance Code;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">establishing a succession plan for our executive officers and assisting our supervisory board in the selection and evaluation of executive and supervisory board members;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">reviewing the main objectives recommended by management regarding the compensation granted to the non-executive officers of the Company, including under free share and stock option plans;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">reviewing equity incentive plans, including free share plans and stock options or stock purchase options, pension and contingency schemes and benefits in kind for non-executive officers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making recommendations to our supervisory board regarding:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">the compensation, pension and contingency schemes, benefits in kind and other various pecuniary rights, including termination, of the members of the executive board. The committee makes recommendations on the amount and structure of executive board member compensation, taking into account strategy, objectives, outcomes, and general market practice, and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">the free share and stock option plans, as well as any similar equity incentive instrument and in particular, the allocation to members of the executive board,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making recommendations to our supervisory board regarding compensation, including equity-based compensation and expense reimbursement, for the members of the supervisory board, taking into account corporate goals and objectives and performance of supervisory board members in light of such goals and objectives;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">preparing and presenting the reports provided for in the supervisory board charter (r&#232;glement int&#233;rieur);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">making any other recommendation that might be requested by our supervisory board regarding compensation; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">generally advising the supervisory board and making recommendations with respect to all of the areas above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our appointments and compensation committee shall be comprised of at least two members from and appointed by the supervisory board. Currently, our appointments and compensation committee is comprised of three members: Ms. Anne-Marie Graffin (chairwoman), Dr. Alain Herrera and Dr. Gary Phillips.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our appointments and compensation committee met four times in 2021. Mr. Laurent Condomine served on the appointments and compensation committee for the year 2020 and until his retirement on May 25, 2021.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1445"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Code of Business Conduct and Ethics </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have adopted a Code of Business Conduct and Ethics (&#8220;Code of Conduct&#8221;) that is applicable to all of our, and our subsidiaries', employees, executive board members and supervisory board members. The Code of Conduct is available on our website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">www.nanobiotix.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. Our supervisory board is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive board members and supervisory board members. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1394"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Employees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, we had 100 full-time employees. Of our full-time employees 74 are engaged in research and development and 37 hold a doctorate in medicine, pharmacy or science. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, 84 of our employees were located in Europe and 16 of our employees were located in the United States. None of our employees is subject to a collective bargaining agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We consider our relationship with our employees to be good. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_2140"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E. Share Ownership</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For information regarding the share ownership of our Supervisory and Executive Board members, see &#8220;Item 6B.Compensation&#8221; and &#8220;Item 7A. Major Shareholders.&#8221;</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i377d9717844147e799376babda10462f_40"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 7.&#160;&#160;&#160;&#160;MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1475"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Major Shareholders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of April 8, 2022 for:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">each of our supervisory board members and executive board members; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">all of our supervisory board members and executive board members as a group.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares that can be acquired within 60 days of April 8, 2022. The percentage ownership information shown in the table is based upon 34,875,872 ordinary shares outstanding as of April 8, 2022. In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of that person, we deemed outstanding ordinary shares subject to founders&#8217; warrants, warrants and stock options held by that person that are immediately exercisable or exercisable within 60 days of April 8, 2022 (and we have assumed no vesting of outstanding free shares). We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Except as otherwise indicated in the footnotes below the table, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares beneficially owned by them, subject to applicable community property laws where applicable. The information is not necessarily indicative of beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The information in the table below is based on information furnished to us or ascertained by us from public filings made by the shareholders in France. Except as otherwise indicated in the table below, addresses of the supervisory board members, executive board members and named beneficial owners are in care of Nanobiotix S.A., 60, rue de Wattignies, 75012 Paris, France.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:73.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Beneficial Owner</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ordinary Shares Beneficially Owned</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:10.55pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:0.1pt;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">5% Shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #231f20;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Entities affiliated with Invus Public Equities, L.P.</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,069,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Caisse des D&#233;p&#244;ts et consignation</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,921,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Baillie Gifford &amp; Co</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,809,326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amiral Gestion</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,750,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Supervisory Board and Executive Board Members:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Laurent Levy, Ph.D.</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,142,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3.28</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Anne-Juliette Hermant</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">81,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Bart Van Rhijn</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Alain Herrera, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Christophe Douat</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Anne-Marie Graffin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gary Phillips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Enno Spillner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">[*]</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All Supervisory Board and Executive Board members as a group (8 persons)</span><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,245,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3.45</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Represents beneficial ownership of less than 1%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Consists of 2,069,034 ordinary shares and 1,000,000 ADSs. Amounts beneficially owned by entities affiliated with  Invus Public Equities, L.P. (&#8220;Invus&#8221;). Amounts beneficially owned by entities affiliated with Invus were reported pursuant to a Schedule 13G amendment filed with the SEC on February 11, 2022 by such entities. The registered office of the entities affiliated with Invus is 750 Lexington Ave., 30th Floor, New York, NY 10022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consists of 1,921,722 ordinary shares</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Consists of 409,836 ordinary shares and 1,400,000 ADSs. Amounts beneficially owned by Baillie Gifford &amp; Co were reported pursuant to a Schedule 13G amendment with the SEC on January 26, 2022 by Baillie Gifford &amp; Co. The address of Baillie Gifford &amp; Co. is Calton Square, 1 Greenside Row, Edinburgh EH1 3AN. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consists of 1,750,624 ordinary shares</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Consists of 936,310 ordinary shares and 205,950 ordinary shares issuable upon exercise of founders&#8217; warrants and stock options.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Consists of 45,000 ordinary shares and 36,000 ordinary shares issuable upon exercise of founders&#8217; warrants and stock options.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consists of 22,500 ordinary shares issuable upon exercise of warrants.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consists of 981,010 ordinary shares and 264,450 ordinary shares issuable upon exercise of founders&#8217; warrants and stock options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, we estimate that approximately 19% respectively of our outstanding ordinary shares were held in the United States.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1481"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Related Party Transactions </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">It is the policy of the supervisory board that in order to mitigate the risk of any actual or perceived conflicts of interest, whenever a matter comes before the supervisory board for its consideration in which a related party supervisory board member has a potential interest, such member shall be recused from participating in any discussions and voting in any decisions on such matter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Agreements with Our Directors and Executive Officers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Director and Executive Officer Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See &#8220;Item 6B. Compensation of Directors and Executive Officers&#8221; for information regarding compensation of directors and executive officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Equity Awards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since January 1, 2022, we have not granted equity awards to certain of our directors and executive officers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See &#8220;Item 7A. Major Shareholders&#8221; for information regarding equity awards to certain of our executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Related-Person Transactions Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have adopted a related-party transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related-party transactions. For purposes of our policy only, a related-party transaction is defined as (1) a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships), in which we and any related parties are, were or will be participants, or otherwise have a direct or indirect interest, in which the amount involved exceeds $120,000, or (2) any agreement or similar transaction under French law which falls within the scope of Article L. 225-86 of the French Commercial Code. For purposes of this policy, a related party is any executive board member, supervisory board member or beneficial owner of more than five percent (5%) of any class of our voting securities, including any of their respective immediate family members and any entity owned or controlled by such persons.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the policy, related-party transactions must be reported to us by the relevant related parties. If a transaction has been identified as a related-party transaction, including any transaction that was not a related-party transaction when originally consummated or any transaction that was not initially identified as a related-party transaction prior to consummation, our management must present information regarding the related-party transaction to our supervisory board for review, consideration and approval or ratification. Certain transactions may be presented to the audit committee, which may make recommendations to the supervisory board on whether the transaction is a related-party transaction; in any case, the related-party transaction will be submitted to our supervisory board for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests in the transaction, direct and indirect, of the related parties, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third-party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each member of our executive board and supervisory board and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-party transactions and to effectuate the terms of the policy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We comply with French law regarding approval of transactions with related parties. In particular, in accordance with articles L. 225-86 et seq. of the French Commercial Code, our executive board informs on an annual basis our supervisory board of any agreement or similar transaction under French law which falls within the scope of Article L. 225-86 of the French Commercial Code entered into during the past fiscal year. Our supervisory board shall review the purpose and financial conditions of these agreements and confirm or deny their classification as current agreements, meaning agreements relating to current operations and entered into under normal conditions. In </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">accordance with Article L. 225-88-2 of the French Commercial Code, we shall disclose on our website information related to any related-party transaction entered into by no later than the day of the relevant transaction's conclusion.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, we have adopted a Code of Business Conduct and Ethics policy. Under this policy, our employees and members of our supervisory and executive boards have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In considering related-party transactions, our supervisory board will take into account the relevant available facts and circumstances including, but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the benefits and perceived benefits to us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the opportunity costs of alternative transactions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the materiality and character of the related party&#8217;s interest;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the actual or apparent conflict of interest of the related party; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The policy requires that, in determining whether to approve, ratify or reject a related-party transaction, our supervisory board must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our supervisory board determines in the good faith exercise of its discretion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All of the transactions referred to above were entered into prior to the adoption of the written related-party transaction policy but all were approved by our supervisory board to the extent required by, and in compliance with, French law.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1603"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Interests of Experts and Counsel </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_43"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 8. FINANCIAL INFORMATION </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1891"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Consolidated Statements and Other Financial Information </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated Financial statements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our audited consolidated financial statements are appended at the end of this Annual Report starting at page F-1, and form a part hereof. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Legal Proceedings </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Dividend Distribution </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our ordinary shares. We do not anticipate paying cash dividends on our equity securities in the foreseeable future and intend to retain all available funds and any future earnings for use in the operation and expansion of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Subject to the requirements of French law and our By-laws, dividends may only be distributed from our distributable profits, plus any amounts held in our available reserves, which are our reserves other than the legal and statutory reserves and the revaluation surplus. The section of this Annual Report titled &#8220;Item 8A. Consolidated Statements and Other Financial Information&#8212;Dividend Distribution&#8221; provides further details on the limitations on our ability to declare and pay dividends. Dividend distributions, if any, will be made in euros and converted into U.S. dollars with respect to the ADSs, as provided in the deposit agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Approval of Dividends.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Pursuant to French law, our executive board may propose a dividend and/or reserve distribution for approval by the shareholders at the annual ordinary general meeting related to the statutory financial statements of Nanobiotix S.A. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Upon recommendation of our executive board, our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when as a result of such distribution our net assets are or would become lower than the amount of the share capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders. The amount of our share capital </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">plus the amount of our legal and other reserves which may not be distributed was equal to $1.1 million on December 31, 2021. Moreover, the statutory accumulated deficit is &#8364;284 million as of December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our executive board may distribute interim dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when the interim balance sheet, established during such year and examined by an auditor, reflects that we have earned distributable profits since the close of the last fiscal year, after recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the By-laws, and including any retained earnings. The amount of such interim dividends may not exceed the amount of the profit so defined. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Distribution of Dividends.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Dividends are distributed to shareholders proportionally to their shareholding interests. In the case of interim dividends, distributions are made to shareholders on the date set by our executive board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders&#8217; meeting or by our executive board in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dividends may be paid in cash or, if the shareholders&#8217; meeting so decides, in kind, provided that all the shareholders receive a whole number of assets of the same nature paid in lieu of cash. Our By-laws provide that, subject to a decision of the shareholders&#8217; meeting taken by ordinary resolution, each shareholder may be given the choice to receive his dividend in cash or in shares. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1898"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Significant Changes </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">None.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 9. THE OFFER AND LISTING </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1931"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Offer and Listing Details </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our ADSs have been listed on Nasdaq Global Select Market under the symbol &#8220;NBTX&#8221; since December 11, 2020. Prior to that date, there was no public trading market for out ADSs. Our ordinary shares have been trading on the regulated market of Euronext in Paris under the symbol &#8220;NANO&#8221; since October 2012. Prior to that date, there was no public trading market for our ADSs or our ordinary shares.  No significant trading suspensions have occurred in the prior three years.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1926"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Plan of Distribution </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1921"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Markets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For information regarding the stock exchanges and regulated markets on which our ADSs and ordinary share are listed, see &#8220;Item 9A. Offer and Listing Details.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1916"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Selling Shareholders </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1911"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E. Dilution </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1906"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">F. Expenses of the Issue </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i377d9717844147e799376babda10462f_49"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 10. ADDITIONAL INFORMATION</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1623"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Share Capital </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1628"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Memorandum and Articles of Association</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1643"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The information set forth in the prospectus dated February 4, 2022 as part of our Registration Statement on Form F-3 (File No. 333-262545), declared effective by the SEC on February 16, 2022, under the headings "Description of Share Capital&#8212;Key Provisions of Our Bylaws and French Law Affecting Our Ordinary Shares," "Description of Share Capital&#8212;Differences in Corporate Law" and "Limitations Affecting Shareholders of a French Company" is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1740"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Listing</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our ADSs are listed on the Nasdaq Global Select Market under the symbol &#8220;NBTX&#8221; and our ordinary shares are listed on the regulated market of Euronext in Paris under the symbol &#8220;NANO.&#8221; </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1767"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Transfer Agent and Registrar</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The transfer agent and registrar for our ADSs is Citibank, N.A. The transfer agent and registrar for our ordinary shares is CIC Securities. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1778"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Material Contracts </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For additional information on our material contracts entered into during the two years immediately preceding the date of the filing of this Annual Report, please refer to &#8220;Item 4B. Business Overview&#8221; and &#8220;Item 7B Related Party Transactions&#8221; of this Annual Report.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1784"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. Exchange Controls </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under current French foreign exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited intermediaries.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1789"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">E. Taxation</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1796"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Material U.S. Federal Income Tax Considerations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following is a discussion of the material U.S. federal income tax consequences of owning and disposing of ADSs. This summary does not address any aspect of U.S. federal non-income tax laws, such as U.S. federal estate and gift tax laws, or state, local or non-U.S. tax laws, and does not purport to be a comprehensive description of all of the U.S. tax considerations that may be relevant to particular holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The discussion applies to you only if you hold the ADSs as capital assets for U.S. federal income tax purposes (generally, for investment). This section does not apply to you if you are a member of a special class of holders subject to special tax rules, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a broker;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a dealer in securities, commodities or foreign currencies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a trader in securities that elects to use a mark-to-market method of accounting for its securities holdings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a bank or other financial institution;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a tax-exempt organization or governmental organization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an insurance company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a regulated investment company or real estate investment trust;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a U.S. expatriate, former U.S. citizen or former long term resident of the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a mutual fund;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an individual retirement or other tax-deferred account;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a holder liable for alternative minimum tax;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a holder that actually or constructively owns 10% or more, by voting power or value, of our stock (including stock represented by ADSs);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a partnership or other pass-through entity for U.S. federal income tax purposes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a holder that holds ADSs as part of a straddle, hedging, constructive sale, conversion or other integrated transaction for U.S. federal income tax purposes; or</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a U.S. holder (as defined below) whose functional currency is not the U.S. dollar.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This section is based on the Internal Revenue Code of 1986, as amended, or (the Code), existing and proposed income tax regulations issued under the Code, legislative history, and judicial and administrative interpretations thereof, all as of the date of this Annual Report. All of the foregoing are subject to change at any time, and any change could be retroactive and could affect the accuracy of this discussion. In addition, the application and interpretation of certain aspects of the passive foreign investment company, or PFIC, rules, referred to below, require the issuance of regulations which in many instances have not been promulgated and which may have retroactive effect. There can be no assurance that any of these regulations will be enacted or promulgated, and if so, the form they will take or the effect that they may have on this discussion. This discussion is not binding on the U.S. Internal Revenue Service, or IRS, or the courts. No ruling has been or will be sought from the IRS with respect to the positions and issues discussed herein, and there can be no assurance that the IRS or a court will not take a different position concerning the U.S. federal income tax consequences of an investment in the ADSs or that any such position would not be sustained.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">YOU SHOULD CONSULT YOUR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF OWNING AND DISPOSING OF THE ADSs IN YOUR PARTICULAR SITUATIONS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">You are a &#8220;U.S. holder&#8221; if you are a beneficial owner of ADSs or are treated for U.S. federal income tax purpose as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a citizen or resident of the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an estate whose income is subject to U.S. federal income tax regardless of its source; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a trust if (1) a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, this discussion is limited to holders who are not resident in France for purposes of the income tax treaty between the United States and France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If a partnership (including for this purpose any entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of the ADSs, the U.S. tax treatment of a partner in the partnership generally will depend on the status of the partner and the activities of the partnership. A holder of the ADSs that is a partnership and partners in such a partnership should consult their own tax advisors concerning the U.S. federal income tax consequences of purchasing, owning and disposing of ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A &#8220;non-U.S. holder&#8221; is a beneficial owner of ADSs that is neither a U.S. holder nor a partnership for U.S. federal income tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Generally, holders of ADSs should be treated for U.S. federal income tax purposes as holding the ordinary shares represented by the ADSs. Accordingly, no gain or loss will be recognized upon an exchange of ordinary shares for ADSs or an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an ADS and the issuer of the security underlying the ADS may be taking actions that are inconsistent with the claiming of foreign tax credits for U.S. holders of ADSs. Accordingly, the credibility of foreign taxes, if any, as described below, could be affected by actions taken by intermediaries in the chain of ownership between the holder of an ADS and the company.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1950"></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:109%">PFIC Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Code provides special rules regarding certain distributions received by U.S. persons with respect to, and sales, exchanges and other dispositions, including pledges, of, shares of stock (including ordinary shares represented by ADSs) in, a PFIC. A non-U.S. corporation will be treated as a PFIC for any taxable year in which either: (1) at least 75% of its gross income is &#8220;passive income&#8221; or (2) at least 50% of its gross assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period) are &#8220;passive assets,&#8221; which generally means that they produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. In determining whether a foreign corporation is a PFIC, a pro rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Although not free from doubt, we do not believe that we were a PFIC for the taxable year ended December 31, 2021. No assurances may be given at this time as to our PFIC status for the taxable year ending December 31, 2022 or subsequent taxable years. Our PFIC status must be determined annually and therefore is subject to change. Because this determination is made annually at the end of each taxable year and is dependent upon a number of factors, some of which are beyond our control, including the amount and nature of our income (including whether </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">reimbursements of certain refundable research tax credits will constitute gross income for purpose of the PFIC income test), as well as on the market valuation of our assets and our spending schedule for our cash balances, and because certain aspects of the PFIC rules are not entirely certain, there can be no assurance that we were not a PFIC, that we are not or will not become a PFIC or that the IRS will agree with our conclusion regarding our PFIC status. If we are not a PFIC during any taxable year in which you hold ADSs, then the remainder of the discussion under &#8220;Taxation&#8212;Material U.S. Federal Income Tax Considerations,&#8221; outside of this &#8220;&#8212;PFIC Considerations&#8221; portion may be relevant to you. U.S. holders should consult their tax advisors as to the applicability of the PFIC rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A U.S. holder that holds ADSs during any taxable year in which we qualify as a PFIC is subject to special tax rules with respect to (a) any gain realized on the sale, exchange or other disposition of the ADSs and (b) any &#8220;excess distribution&#8221; by the corporation to the holder, unless the holder elects to treat the PFIC as a &#8220;qualified electing fund&#8221; (QEF) or makes a &#8220;mark-to-market&#8221; election, each as discussed below. An &#8220;excess distribution&#8221; is that portion of a distribution with respect to ADSs that exceeds 125% of the annual average of such distributions over the preceding three-year period or, if shorter, the U.S. holder&#8217;s holding period for its ADSs. Excess distributions and gains on the sale, exchange or other disposition of ADSs of a corporation which was a PFIC at any time during the U.S. holder&#8217;s holding period are allocated ratably to each day of the U.S. holder&#8217;s holding period. Amounts allocated to the taxable year in which the disposition occurs and amounts allocated to any period in the shareholder&#8217;s holding period before the first day of the first taxable year that the corporation was a PFIC will be taxed as ordinary income (rather than capital gain) earned in the taxable year of the disposition. Amounts allocated to each of the other taxable years in the U.S. holder&#8217;s holding period are not included in gross income for the year of the disposition, but are subject to the highest ordinary income tax rates in effect for individuals or corporations, as applicable, for each such year and the interest charge generally applicable to income tax deficiencies will be imposed on the resulting tax attributable to each year. The tax liability for amounts allocated to years before the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the ADSs cannot be treated as capital, even if a U.S. holder held such ADSs as capital assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If we are a PFIC for any taxable year during which a U.S. holder holds ADSs, then we generally will continue to be treated as a PFIC with respect to the holder for all succeeding years during which such holder holds ADSs, even if we no longer satisfy either the passive income or passive asset tests described above, unless the U.S. holder terminates this deemed PFIC status by making a &#8220;deemed sale&#8221; election. If such election is made, a U.S. holder will be deemed to have sold the ADSs at their fair market value on the last day of the last taxable year for which we were a PFIC, and any gain from such deemed sale would be subject to the excess distribution rules as described above. After the deemed sale election, the ADSs with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If we are or become a PFIC, the excess distribution rules may be avoided if a U.S. holder makes a QEF election effective beginning with the first taxable year in the holder&#8217;s holding period in which we are treated as a PFIC with respect to such holder. A U.S. holder that makes a QEF election with respect to a PFIC is required to include in income its pro rata share of the PFIC&#8217;s ordinary earnings and net capital gain as ordinary income and capital gain, respectively, subject to a separate election to defer payment of taxes, which deferral is subject to an interest charge.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In general, a U.S. holder makes a QEF election by attaching a completed IRS Form 8621 to a timely filed (taking into account any extensions) U.S. federal income tax return for the year beginning with which the QEF election is to be effective. In certain circumstances, a U.S. holder may be able to make a retroactive QEF election. A QEF election can be revoked only with the consent of the IRS. In order for a U.S. holder to make a valid QEF election, the non-U.S. corporation must annually provide or make available to the holder certain information. At this time, we have not determined whether we will provide to U.S. holders the information required to make a valid QEF election and we currently make no undertaking to provide such information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As an alternative to making a QEF election, a U.S. holder may make a &#8220;mark-to-market&#8221; election with respect to its ADSs if the ADSs meet certain minimum trading requirements, as described below. If a U.S. holder makes a valid mark-to-market election for the first taxable year in which such holder holds (or is deemed to hold) ADSs in a corporation and for which such corporation is determined to be a PFIC, such holder generally will not be subject to the PFIC rules described above in respect of its ADSs. Instead, a U.S. holder that makes a mark-to-market election will be required to include in income each year an amount equal to the excess, if any, of the fair market value of the ADSs that the holder owns as of the close of the taxable year over the holder&#8217;s adjusted tax basis in the ADSs. The U.S. holder will be entitled to a deduction for the excess, if any, of the holder&#8217;s adjusted tax basis in the ADSs over the fair market value of the ADSs as of the close of the taxable year; provided, however, that the deduction will be limited to the extent of any net mark-to-market gains with respect to the ADSs included by the U.S. holder under the election for prior taxable years. The U.S. holder&#8217;s basis in the ADSs will be adjusted to reflect the amounts included or deducted pursuant to the election. Amounts included in income pursuant to a mark-to-market election, as well as gain on the sale, exchange or other disposition of the ADSs, will be treated as ordinary income. The deductible portion of any mark-to-market loss, as well as loss on a sale, exchange or other disposition of ADSs to the extent that the amount of such loss does not exceed net mark-to-market gains previously included in income, will be treated as ordinary loss. If a U.S. holder makes a valid mark-to-market election, any distributions made by us in a year in which we are a PFIC would generally be subject to the rules discussed below under &#8220;&#8212;Taxation of Dividends,&#8221; except the lower rate applicable to qualified dividend income would not apply. If we are not a PFIC when a U.S. holder has a mark-to-market election in effect, gain or loss realized by a U.S. holder on the sale of our ADSs will be a </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">capital gain or loss and taxed in the manner described below under &#8220;&#8212;Taxation of Sale, Exchange or other Disposition of ADSs.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The mark-to-market election applies to the taxable year for which the election is made and all subsequent taxable years, unless the ADSs cease to meet applicable trading requirements (described below) or the IRS consents to its revocation. The excess distribution rules generally do not apply to a U.S. holder for taxable years for which a mark-to-market election is in effect. If we are a PFIC for any year in which the U.S. holder owns ADSs but before a mark-to-market election is made, the interest charge rules described above will apply to any mark-to-market gain recognized in the year the election is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A mark-to-mark election is available only if the ADSs are considered &#8220;marketable&#8221; for these purposes. ADSs will be marketable if they are regularly traded on a national securities exchange that is registered with the SEC (such as the Nasdaq Global Select Market) or on a non-U.S. exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. For these purposes, ADSs will be considered regularly traded during any calendar year during which more than a de minimis quantity of the ADSs is traded on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Each U.S. holder should ask its own tax advisor whether a mark-to-market election is available or desirable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If we are a PFIC for any year in which a U.S. holder holds ADSs, such U.S. holder must generally file an IRS Form 8621 annually. A U.S. holder must also provide such other information as may be required by the U.S. Treasury Department if the U.S. holder (1) receives certain direct or indirect distributions from a PFIC, (2) recognizes gain on a direct or indirect disposition of ADSs, or (3) makes certain elections (including a QEF election or a mark-to-market election) reportable on IRS Form 8621.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If we are a PFIC, then under attribution rules, U.S. holders of our ADSs will be deemed to own their proportionate shares of our subsidiaries that are PFICs, if any. It is possible that one or more of our subsidiaries is or will become a PFIC. This determination is made annually at the end of each taxable year and depends upon a number of factors, some of which are beyond our control, including the amount and nature of a subsidiary&#8217;s income, as well as the valuation and nature of a subsidiary&#8217;s assets. In the event that we are a PFIC and we have a subsidiary that is a PFIC, assuming a U.S. holder does not receive from such subsidiary the information that the U.S. holder needs to make a QEF election with respect to such a subsidiary, a U.S. holder generally will be deemed to own a portion of the shares of such lower-tier PFIC and may incur liability for a deferred tax and interest charge if we receive a distribution from, or dispose of all or part of our interest in, or the U.S. holder otherwise is deemed to have disposed of an interest in, the lower-tier PFIC, even though the U.S. holder has not received the proceeds of those distributions or dispositions directly. There is no assurance that we will have timely knowledge of the status of any such lower-tier PFIC, or that we will cause the lower-tier PFIC to provide the required information for a U.S. holder to make and maintain a QEF election with respect to the lower-tier PFIC. In addition, a mark-to-market election generally would not be available with respect to such a lower-tier PFIC and, consequently, if you make a mark-to-market election with respect to our ADSs, you could be subject to the PFIC rules with respect to income of lower-tier PFICs the value of which already had been taken into account indirectly via mark-to-market adjustments. U.S. holders are advised to consult with their tax advisors regarding the tax issues raised by lower-tier PFICs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">U.S. holders are urged to consult their tax advisors as to our status as a PFIC, and, if we are treated as a PFIC, as to the effect on them of, and the reporting requirements with respect to, the PFIC rules and the desirability of making, and the availability of, either a QEF election or a mark-to-market election with respect to our ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Taxation of Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">U.S. Holders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. Subject to the PFIC rules described above under &#8220;&#8212;PFIC Considerations,&#8221; if you are a U.S. holder, you must include in your gross income the gross amount of any distributions of cash or property (other than certain pro rata distributions of ADSs) with respect to ADSs, to the extent the distribution is paid out of our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. A U.S. holder must include the dividend as ordinary income at the time of actual or constructive receipt. Distributions in excess of current and accumulated earnings and profits, as determined for U.S. federal income tax purposes, will be treated as a non-taxable return of capital to the extent of your basis in the ADSs and thereafter as capital gain from the sale or exchange of such ADSs. Notwithstanding the foregoing, we do not intend to maintain calculations of our earnings and profits as determined for U.S. federal income tax purposes. Consequently, distributions generally will be reported as dividend income for U.S. information reporting purposes. The dividend will not be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Subject to the PFIC rules described above under &#8220;&#8212;PFIC Considerations,&#8221; dividends paid by a non-U.S. corporation generally will be taxed at the preferential tax rates applicable to long-term capital gain of non-corporate taxpayers if (a) such non-U.S. corporation is eligible for the benefits of certain U.S. treaties or the dividend is paid by such non-U.S. corporation with respect to stock that is readily tradable on an established securities market in the United </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">States, (b) the U.S. holder receiving such dividend is an individual, estate, or trust, (c) such dividend is paid on shares that have been held by such U.S. holder for at least 61 days during the 121-day period beginning 60 days before the &#8220;ex-dividend date,&#8221; and (d) we are not a PFIC in the year of the dividend or the immediately preceding year. If the requirements of the immediately preceding paragraph are not satisfied, a dividend paid by a non-U.S. corporation to a U.S. holder, including a U.S. holder that is an individual, estate, or trust, generally will be taxed at ordinary income tax rates (and not at the preferential tax rates applicable to long-term capital gains). As discussed above under &#8220;&#8212;PFIC Considerations,&#8221; it is not yet known whether we will be a PFIC for taxable years ending after December 31, 2021. The dividend rules are complex, and each U.S. holder should consult its own tax advisor regarding the dividend rules.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amount of dividend will include any amounts withheld by the Company in respect of French taxes. Subject to applicable limitations, some of which vary depending upon the U.S. holder&#8217;s circumstances and subject to the discussion above regarding concerns expressed by the U.S. Treasury, French income taxes withheld from dividends on ADSs at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. holder&#8217;s U.S. federal income tax liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dividends received generally will be income from non-U.S. sources, which may be relevant in calculating your U.S. foreign tax credit limitation. Such non-U.S. source income generally will be &#8220;passive category income,&#8221; or in certain cases &#8220;general category income&#8221; or &#8220;foreign branch&#8221; income, which is treated separately from other types of income for purposes of computing the foreign tax credit allowable to you. The rules with respect to the foreign tax credit are complex and involve the application of rules that depend upon a U.S. holder&#8217;s particular circumstances. You should consult your own tax advisor to determine the foreign tax credit implications of owning the ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Non-U.S. Holders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. If you are a non-U.S. holder, dividends paid to you generally will not be subject to U.S. income tax unless the dividends are &#8220;effectively connected&#8221; with your conduct of a trade or business within the United States, and the dividends are attributable to a permanent establishment (or in the case of an individual, a fixed place of business) that you maintain in the United States if that is required by an applicable income tax treaty as a condition for subjecting you to U.S. taxation on a net income basis. In such cases you generally will be taxed in the same manner as a U.S. holder (other than with respect to the Medicare Tax described below). If you are a corporate non-U.S. holder, &#8220;effectively connected&#8221; dividends may, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or a lower rate if you are eligible for the benefits of an income tax treaty that provides for a lower rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Taxation of Sale, Exchange or other Disposition of ADSs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">U.S. Holders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. Subject to the PFIC rules described above under &#8220;&#8212;PFIC Considerations,&#8221; if you are a U.S. holder and you sell, exchange or otherwise dispose of your ADSs, you generally will recognize capital gain or loss for U.S. federal income tax purposes equal to the difference between the value of the amount realized and your tax basis in those ADSs. Gain or loss recognized on such a sale, exchange or other disposition of ADSs generally will be long-term capital gain if you have held the ADSs for more than one year. Long-term capital gains of U.S. holders who are individuals (as well as certain trusts and estates) are generally taxed at preferential rates. The gain or loss will generally be income or loss from sources within the United States for foreign tax credit limitation purposes, unless it is attributable to an office or other fixed   place of business outside the United States and certain other conditions are met. Your ability to deduct capital losses is subject to limitations. As discussed above under &#8220;&#8212;PFIC Considerations,&#8221; it is not yet known whether we will be a PFIC for taxable years ending after December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Non-U.S. Holders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. If you are a non-U.S. holder, you will not be subject to U.S. federal income tax on gain recognized on the sale, exchange or other disposition of your ADSs unless:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the gain is &#8220;effectively connected&#8221; with your conduct of a trade or business in the United States, and the gain is attributable to a permanent establishment (or in the case of an individual, a fixed place of business) that you maintain in the United States if that is required by an applicable income tax treaty as a condition for subjecting you to U.S. taxation on a net income basis; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">you are an individual, you are present in the United States for 183 or more days in the taxable year of such sale, exchange or other disposition and certain other conditions are met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the first case, the non-U.S. holder will be taxed in the same manner as a U.S. holder (other than with respect to the Medicare Tax described below). In the second case, the non-U.S. holder will be subject to U.S. federal income tax at a rate of 30% on the amount by which such non-U.S. holder&#8217;s U.S.-source capital gains exceed such non-U.S. holder&#8217;s U.S.-source capital losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If you are a corporate non-U.S. holder, &#8220;effectively connected&#8221; gains that you recognize may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or at a lower rate if you are eligible for the benefits of an income tax treaty that provides for a lower rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Medicare Tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Certain U.S. holders who are individuals, estates or trusts are required to pay a 3.8% Medicare surtax on all or part of that holder&#8217;s &#8220;net investment income,&#8221; which includes, among other items, dividends on, and capital gains from the sale or other taxable disposition of, the ADSs, subject to certain limitations and exceptions. Prospective investors should consult their own tax advisors regarding the effect, if any, of this surtax on their ownership and disposition of the ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Information with Respect to Foreign Financial Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">U</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.S. holders that are individuals (and, to the extent provided in regulations, certain entities) that own &#8220;specified foreign financial assets,&#8221; including possibly the ADSs, with an aggregate value in excess of $50,000 are generally required to file IRS Form 8938 with information regarding such assets. Depending on the circumstances, higher threshold amounts may apply. Specified foreign financial assets include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons, (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties and (iii) interests in non-U.S. entities. If a U.S. holder is subject to this information reporting regime, the failure to timely file IRS Form 8938 may subject the U.S. holder to penalties. In addition to these requirements, U.S. holders may be required to annually file FinCEN Report 114 (Report of Foreign Bank and Financial Accounts) with the U.S. Department of Treasury. Prospective investors are encouraged to consult their own tax advisors with respect to these and other reporting requirements that may apply to their acquisition of the ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Backup Withholding and Information Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In general, information reporting requirements will apply to distributions made on our ADSs within the United States to a non-corporate U.S. holder and to the proceeds from the sale, exchange, redemption or other disposition of ADSs by a non-corporate U.S. holder to or through a U.S. office of a broker. Payments made (and sales or other dispositions effected at an office) outside the U.S. will be subject to information reporting in limited circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, U.S. holders may be subject to backup withholding with respect to dividends on and proceeds from the sale, exchange or other disposition of the ADSs. A paying agent within the United States will be required to withhold at the applicable statutory rate, currently 24%, in respect of any payments of dividends on, and the proceeds from the disposition of, ADSs within the United States to a U.S. holder (other than U.S. holders that are exempt from backup withholding and properly certify their exemption) if the holder fails to furnish its correct taxpayer identification number or otherwise fails to comply with applicable backup withholding requirements. U.S. holders who are required to establish their exempt status generally must provide a properly completed IRS Form W-9.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. holder&#8217;s U.S. federal income tax liability. A U.S. holder generally may obtain a refund of any amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS in a timely manner and furnishing any </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">required information. U.S. holders are advised to consult with their own tax advisors regarding the application of the United States information reporting rules to their particular circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A non-U.S. holder generally may eliminate the requirement for information reporting and backup withholding by providing certification of its non-U.S. status to the payor, under penalties of perjury, on IRS Form W-8BEN or W-8BEN-E, as applicable. You should consult your own tax advisor as to the qualifications for exemption from backup withholding and the procedures for obtaining the exemption.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">The foregoing does not purport to be a complete analysis of the potential tax considerations relating to the ownership and disposition of the ADSs. Prospective investors should consult their own tax advisors as to the particular tax considerations applicable to them relating to the ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local income tax laws or non-income tax laws, non-U.S. tax laws, and any changes in applicable tax laws and any pending or proposed legislation or regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="i377d9717844147e799376babda10462f_1958"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Material French Income Tax Considerations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following describes the material French income tax consequences to U.S. Holders (as defined below for the purposes of this section) of purchasing, owning and disposing of the ADSs and, unless otherwise noted, this discussion is the opinion of Jones Day, our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect to those matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This discussion does not purport to be a complete analysis or listing of all potential tax effects of the acquisition, ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed to be known by investors. All of the following is subject to change. Such changes could apply retroactively and could affect the consequences described below.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2011, France introduced a comprehensive set of new tax rules applicable to French assets that are held by or in foreign trusts. These rules, among other things, provide for the inclusion of trust assets in the settlor&#8217;s net assets for purpose of applying the French real estate wealth tax, for the application of French gift and death duties to French assets held in trust, for a specific tax on capital on the French assets of foreign trusts not already subject to the French real estate wealth tax and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to securities (including ADSs) held in trusts. If securities are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax advisors regarding the specific tax consequences of acquiring, owning and disposing of securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The description of the French income tax and wealth tax consequences set forth below is based on the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital of August 31, 1994 which came into force on December 30, 1995 (as amended by any subsequent protocols, including the protocol of January 13, 2009), and the tax guidelines issued by the French tax authorities in force as of the date hereof, or the Treaty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the purposes of this discussion of French income tax consequences, the term &#8220;U.S. Holder&#8221; means a beneficial owner of ADSs that is (1) an individual who is a U.S. citizen or resident for U.S. federal income tax purposes, (2) a U.S. domestic corporation or certain other entities created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, or (3) otherwise subject to U.S. federal income taxation on a net income basis in respect of ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If a partnership (or any other entity treated as partnership for U.S. federal income tax purposes) holds ADSs, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. If a U.S. Holder is a partner in a partnership that holds ADSs, such holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This discussion applies only to investors that hold our ADSs as capital assets that have the U.S. dollar as their functional currency, that are entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base in France. Certain U.S. Holders (including, but not limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment companies, tax-exempt organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the ADSs pursuant to the exercise of employee share options or otherwise as compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for U.S. federal income tax purposes and persons holding ADSs as a position in a synthetic security, straddle or conversion transaction) may be subject to special rules not discussed below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">U.S. Holders are urged to consult their own tax advisors regarding the tax consequences of the purchase, ownership and disposition of ADSs in light of their particular circumstances, especially with regard to the &#8220;Limitations on Benefits&#8221; provision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Estate and Gift Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In general, a transfer of ADSs by gift or by reason of death of a U.S. Holder that would otherwise be subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November 24, 1978 (as amended by the protocol dated from December 8, 2004), unless the donor or the transferor is domiciled in France at the time of making the gift or at the time of his or her death, or the ADSs were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Financial Transactions Tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to Article 235 ter ZD of the French Tax Code (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Code g&#233;n&#233;ral des imp&#244;ts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), or the FTC, purchases of certain securities issued by a French company, including ADSs, which are listed on a regulated market of the EU or a foreign regulated market formally acknowledged by the AMF (in each case within the meaning of the French Monetary and Financial Code, or the FMFC) are subject in France to a 0.3% tax on financial transactions, or the FTT, provided inter alia that the issuer&#8217;s market capitalization exceeds &#8364;1.0 billion as of December 1 of the year preceding the taxation year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A list of French relevant companies whose market capitalization exceeds &#8364;1.0 billion as of December 1 of the year preceding the taxation year within the meaning of Article 235 ter ZD of the French Tax Code is published annually by the French tax authorities. As of December 1, 2021, our market capitalization did not exceed &#8364;1 billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a result, the ADSs are not currently within the scope of the FTT. Purchases of our ADSs may however become subject to the FTT if our market capitalization exceeds &#8364;1.0 billion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Registration Duties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the case where the FTT is not applicable, (1) transfers of shares issued by a French company which are listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1% if the transfer is evidenced by a written statement (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">acte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) executed either in France or outside France, whereas (2) transfers of shares issued by a French company which are not listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1% notwithstanding the existence of a written statement (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">acte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As ordinary shares of Nanobiotix are listed on the regulated market of Euronext in Paris, which is an organized market within the meaning of the FMFC, their transfer should be subject to uncapped registration duties at the rate of 0.1% subject to the existence of a written agreement (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">acte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Although there is neither case law nor official guidelines published by the French tax authorities on this point, transfers of ADSs should not be subject to the aforementioned 0.1% registration duties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Wealth Tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The French wealth tax (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">imp&#244;t de solidarit&#233; sur la fortune</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) has been repealed by the finance bill for 2018 (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">loi de finances pour 2018</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">) dated December 30, 2017. It used to apply only to individuals and did not generally apply to ADSs held by a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such U.S. Holder did not own directly or indirectly more than 25% of the issuer&#8217;s financial rights and that the ADSs did not form part of the business property of a permanent establishment or fixed base in France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Since January 1, 2018, it has been replaced by a new real estate wealth tax (</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">imp&#244;t sur la fortune immobili&#232;re</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">), which applies only to individuals owning French real estate assets or rights, directly or indirectly through one or more legal entities and whose net taxable assets amount to at least &#8364;1,300,000.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">French real estate wealth tax may only apply to U.S. Holders to the extent the company holds real estate assets that are not allocated to its operational activity, for the fraction of the value of the financial rights representing such assets, and should not generally apply to securities held by an eligible U.S. Holder who is a U.S. resident, as defined pursuant to the provisions of the Treaty, provided that such U.S. Holder does not own directly or indirectly more than 25% of the issuer&#8217;s financial rights.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Taxation of Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dividends paid by a French corporation to non-residents of France are generally subject to French withholding tax at a rate of 25% for corporate bodies or other legal entities or 12.8% for individuals. Dividends paid by a French corporation in a non-cooperative State or territory, as set out in the list referred to in Article 238-0 A of the FTC, other than those mentioned in 2&#176; of 2 bis of the same Article 238-0 A of the FTC, will generally be subject to French withholding tax at a rate of 75%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">However, eligible U.S. Holders, other than individuals subject to the French withholding tax at a rate of 12.8%, entitled to Treaty benefits under the &#8220;Limitation on Benefits&#8221; provision contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be subject to this 25% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate (as described below).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder who is a U.S. resident as defined pursuant to the provisions of the Treaty and whose ownership of the ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. Holder has in France, is generally reduced to 15%, or to 5% if such U.S. Holder is a corporation and owns directly or indirectly at least 10% of the share capital </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">of the issuer; such U.S. Holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates of 15% or 5%, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For U.S. Holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates contained in the &#8220;Limitation on Benefits&#8221; provision of the Treaty, are complex, and certain technical changes were made to these requirements by the protocol of January 13, 2009. U.S. Holders are advised to consult their own tax advisors regarding their eligibility for Treaty benefits in light of their own particular circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the event that dividends are paid by us, dividends paid to an eligible U.S. Holder may immediately be subject to the reduced rates of 5% or 15% provided that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">such holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and providing the depositary with treaty forms (Forms 5000 and 5001); or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the depositary or other financial institution managing the U.S. Holder&#8217;s securities account in the U.S. provides the French paying agent, which will complete Forms 5000 and 5001 (as described above), with a document listing certain information about the U.S. Holder and its ADSs and a certificate whereby the financial institution managing the U.S. Holder&#8217;s securities account in the U.S. takes full responsibility for the accuracy of the information provided in the document.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Otherwise, dividends paid to a U.S. Holder that is a legal person or another legal entity and has not filed Forms 5000 and 5001 before the dividend payment date will be subject to French withholding tax at the rate of 25%, or 75% for any U.S. Holder if paid in a non-cooperative State or territory (as set out in the list referred to in Article 238-0 A of the FTC other than those mentioned in 2&#176; of 2 bis of the same Article 238-0 A of the FTC) (unless the company proves that neither the purpose nor the effect of paying the dividend in that State or territory is that of allowing, with the intent of tax evasion or avoidance, the U.S. Holder to be located in such a State or territory), and then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax authorities with Forms 5000 and 5001 before December 31 of the second calendar year following the year during which the dividend is paid.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Certain qualifying pension funds and certain other tax-exempt entities are subject to the same general filing requirements as other U.S. Holders except that they may have to supply additional documentation evidencing their entitlement to these benefits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Forms 5000 and 5001, together with appropriate instructions, will be provided by the depositary to all U.S. Holders registered with the depositary. The depositary will arrange for the filing with the French tax authorities of all such forms properly completed and executed by U.S. Holders of ADSs and returned to the depositary in sufficient time so that they may be filed with the French tax authorities before the distribution in order to obtain immediately a reduced withholding tax rate. Otherwise, the depositary must withhold tax at the full rate of 25% or 75%, as applicable. In that case, the U.S. Holders may claim a refund from the French tax authorities of the excess withholding tax. Since the withholding tax rate applicable under French domestic law to U.S. Holders who are individuals does not exceed the cap provided in the Treaty (i.e., 15%), the 12.8% rate shall apply, without any reduction provided under the Treaty.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Subject to certain specific conditions, a corporate U.S. Holder which is in a tax loss position for the fiscal year during which the dividend is received may be entitled to a deferral regime and to obtain a withholding tax refund. Furthermore subject to certain conditions, a corporate U.S. Holder may compute the withholding tax on a net basis (i.e., after deduction of expenses) and obtain a partial withholding tax refund.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:109%">Tax on Sale or Other Disposition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a matter of principle, under French tax law, a U.S. Holder should not be subject to any French tax on any capital gain from the sale, exchange, repurchase or redemption by us of ADSs, provided such U.S. Holder is not a French tax resident for French tax purposes and has not held more than 25% of our dividend rights, known as &#8220;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">droits aux b&#233;n&#233;fices sociaux</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8221; at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives (as an exception, a U.S. Holder resident, established or incorporated in a non-cooperative State or territory as set out in the list referred to in Article 238-0 A of the FTC other than those mentioned in 2&#176; of 2 bis of the same Article 238-0 A of the FTC should be subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty and entitled to Treaty benefit will not be subject to French tax on any such capital gain from the sale, exchange, repurchase or redemption by us (other than redemption proceeds which may, under certain circumstances, be partially or fully characterized as dividends under French domestic tax law or administrative guidelines) of ADSs unless such ADSs form part of the business property of a permanent establishment or fixed base that the U.S. Holder has in France. U.S. Holders who own ADSs through U.S. partnerships that are not resident for Treaty purposes are advised to consult their own tax advisors regarding their French tax treatment and their eligibility for Treaty benefits in light of their own particular circumstances. A U.S. Holder that is not a U.S. resident for Treaty purposes or is not entitled to Treaty benefit (and in </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">both cases is not resident, established or incorporated in a non-cooperative State or territory as set out in the list referred to in Article 238-0 A of the FTC other than those mentioned in 2&#176; of 2 bis of the same Article 238-0 A of the FTC) and has held more than 25% of our dividend rights, known as &#8220;</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">droits aux b&#233;n&#233;fices sociaux</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8221; at any time during the preceding five years, either directly or indirectly, and, as relates to individuals, alone or with relatives, will be subject to a levy in France at the rate of the standard corporate income tax (at a rate of 25%), if such U.S. Holder is a legal person, or 12.8%, if such U.S. Holder is an individual.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For a non-French resident entity that holds more than 25% of our dividend rights and may be subject to French tax on capital gains, the Amended Finance Bill for 2021 dated July 19, 2021 (published July 20, 2021) amended the provisions of Article 244 bis B of the FTC in order to comply with European Union (EU) law as French courts have recently ruled that such provisions previously did not comply with European principles and therefore could not be applied by the French tax authorities as the basis for French taxation of foreign shareholders (CE, 14 October 2020, n&#176;421524, AVM International and CAA Versailles, 20 October 2020, n&#176;18VE03012, St&#233; Runa Capital Fund I LP). The Amended Finance Bill for 2021 provides for a refund mechanism allowing an eligible non-French resident corporate investors to claim a refund of the non-resident French capital gains tax to the extent such tax exceeds the amount of the French corporate income tax it would have borne if it had been a French resident. This refund mechanism is available to entities established in (i) an EU Member State or a Member State of the European Economic Area (EEA), other than a non-cooperative State or Territory within the meaning of Article 238-0 A of the FTC that has concluded a tax treaty with France that includes an administrative assistance provision to combat tax fraud and tax evasion (an &#8220;EU/EEA State&#8221;) or (ii) a State, other than a non-cooperative State or Territory that has concluded a tax treaty with France that includes an administrative assistance clause regarding the exchange of information aimed at combating tax fraud and tax evasion (a &#8220;Treaty State&#8221;), provided that the transferor is not effectively involved in the management or control of the entity whose shares are disposed of or redeemed. In addition, the Amended Finance Bill provides that specific collective investment funds established in EU/EEA States or Treaty States are excluded from the scope of the nonresident capital gain tax mentioned above under certain conditions. The recent amendments described above will apply to dispositions and redemptions of shares, and distributions, subject to Section 244 bis B of the FTC, realized as from June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Special rules apply to U.S. Holders who are residents of more than one country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">The discussion above is a summary of the material French tax consequences of an investment in our ADSs and is based upon laws and relevant interpretations thereof in effect as of the date hereof, all of which are subject to change, possibly with retroactive effect. It does not cover all tax matters that may be of importance to a prospective investor. Each prospective investor is urged to consult its own tax advisor about the tax consequences to it of an investment in ADSs in light of the investor&#8217;s own circumstances.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1965"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">F. Dividends and Paying Agents </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1973"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">G. Statement by Experts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1981"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">H. Documents on Display </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We are subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and under those requirements file reports with the SEC. Those reports may be inspected without charge at the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our supervisory and executive board members and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. Nevertheless, we file with the SEC an Annual Report containing financial statements that have been examined and reported on, with and opinion expressed by an independent registered public accounting firm, and we submit quarterly interim consolidated financial data to the SEC under cover of the SEC&#8217;s Form 6-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We maintain a corporate website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">www.nanobiotix.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. We intend to post our Annual Report on our website promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants, such as Nanobiotix, that file electronically with the SEC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">With respect to references made in this Annual Report to any contract or other document of Nanobiotix, such references are not necessarily complete and you should refer to the exhibits attached or incorporated by reference to this Annual Report for copies of the actual contract or document.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_1987"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">I. Subsidiary Information </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_52"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Foreign Currency Exchange Risk </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We use the euro as our functional currency and the substantial majority of our operations are denominated in euros. At this stage in our development, we are exposed to minimal foreign exchange risk due to our low exposure to transactions outside the eurozone in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of the date of this Annual Report, we have not used hedging to protect our business against exchange rate fluctuations. However, a significant increase in business activity in jurisdictions in which currencies other than the euro are used could lead to greater exposure to currency risk. As of December 31, 2021, we recorded foreign exchange gains for an amount of &#8364;6.3 million as a result of USD proceeds from IPO held (see Notes 14 and 18 of our consolidated financial statements). As of December 31, 2020, we recorded foreign exchange losses for an amount of &#8364;1.7 million (see Notes 14 and 18 of our consolidated financial statements). This impact was first arising from retaining $113.3 million of gross proceeds from the IPO on the Nasdaq in a US dollar bank account. After deduction of the transaction costs, this amount was a total of &#8364;84.0 million, net of related transaction expenses. As of December 31, 2020, the proceeds from our initial public offering are still held in US dollars on our current account for a total amount of &#8364;72.0 million and will be used to pay services invoiced in USD. The remaining factors for this increase in foreign exchange risk is the one-off Neuflize account&#8217;s closing. While part the reasons for these foreign exchange losses were related to one-off events, we are currently updating our assessment of this risk for the year 2021 (see Note 14 of our consolidated financial statements). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our exposure to interest rate risk is primarily related to our cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). We had cash and cash equivalents of &#8364;83.9 million as of December 31, 2021, as compared with &#8364;119.15 million as of December 31, 2020, which amounts at each date consisted of bank accounts and short-term deposits. Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated; however, historical fluctuations in interest income have not been significant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In July 2018, we entered into an agreement for the EIB loan under which we may borrow a total of up to &#8364;40 million, divided into three disbursement tranches, two of which were received as of December 31, 2019. The interest rate payable under the loan agreement is a fixed rate based on the applicable disbursement tranche: 6% (payable on maturity), 5% (payable semi-annually) and 4% (payable semi-annually) for the first, second and third tranches, respectively. We also committed, under a royalty agreement entered into in connection with the EIB loan, for a period of six years beginning on January 1, 2021, to pay additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on our annual sales turnover. Any such royalties would be due by June 30 of the year following such sales. In the event the loan is repaid early, or in the event of a change of control after repayment of the loan, the EIB is entitled to request payment of an amount equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than &#8364;35.0 million. As the variable rate of any such royalties due will depend not on the performance of the financial markets, but on our performance, our exposure to interest rate and market risk is deemed low.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On June 18, 2020, Curadigm executed the Deep Tech Funding. The Deep Tech Funding did not have a material impact on our interest rate risk. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On June 22, 2020, the Company entered into a &#8364;5 million PGE with HSBC France (the &#8216;&#8216;HSBC PGE Loan&#8217;&#8217;). The HSBC PGE Loan did not have a material impact on our interest rate risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On July 20, 2020, the Company entered into a &#8364;5 million PGE with BpiFrance (the &#8216;&#8216;BpiFrance PGE Loan&#8217;&#8217;). The BpiFrance PGE Loan did not have a material impact on our interest rate risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the ordinary course of business, we may enter into contractual arrangements to reduce our exposure to interest rate risks. However, we do not believe that a 10% change in current interest rates would have a significant impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Liquidity risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Credit risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers&#8217; high credit rating for other receivables.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_55"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">A. Debt Securities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">B. Warrants and Rights </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">C. Other Securities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">D. American Depositary Shares</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Citibank, N.A., as depositary for our ADSs, registers and delivers ADSs. Each ADS represents one ordinary share deposited with Citibank Europe PLC, located at 388 Greenwich Street, New York, NY 10013 or any successor, as custodian for the depositary. Each ADS will also represent any other securities, cash or other property which may be held by the depositary in respect of the depositary facility. The depositary&#8217;s corporate trust office at which the ADSs will be administered is located at 388 Greenwich Street, New York, New York 10013. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A deposit agreement among us, the depositary and the ADS holders sets out the ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. A copy of the Agreement is incorporated by reference as an exhibit to this Annual Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For additional information on our ADSs, please refer to Exhibit 2.3 &#8220;Description of Securities&#8221; of this Annual Report. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Fees and Charges </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement:</span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:57.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Service</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fees</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS issued</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS cancelled</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS held</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS held</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs to purchase additional ADSs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS held</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs to purchase additional ADSs</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS transferred</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of ADSs (e.g., an issuance of ADS(s) upon a deposit of ordinary shares, upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares pursuant to stock dividends or other free stock distributions or to the exercise of rights to purchase additional ADSs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Up to U.S. 5&#162; per ADS converted</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As an ADS holder you will also be responsible to pay certain charges such as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">taxes (including applicable interest and penalties) and other governmental charges;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">certain cable, telex and facsimile transmission and delivery expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the fees, expenses, spreads, taxes and other charges of the depositary and/or conversion service providers in connection with the conversion of foreign currency, such fees, expenses, spreads, taxes, and other charges to be deducted from the foreign currency;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">any reasonable and customary out-of-pocket expenses incurred in such conversion and/or on behalf of holders and beneficial owners of ADSs in complying with currency exchange control or other governmental requirements; and</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the fees, costs and expenses incurred by the depositary, the custodian, or any nominee in connection with the servicing or delivery of deposited property.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">ADS fees and charges payable upon (1) deposit of ordinary shares against issuance of ADSs and (2) surrender of ADSs for cancellation and withdrawal of ordinary shares are charged to the person to whom the ADSs are delivered (in the case of ADS issuances) and to the person who delivers the ADS, for cancellation (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC or presented to the depositary via DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs or the DTC participant(s) surrendering the ADSs for cancellation, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account(s) of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (1) distributions other than cash and (2) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary agree from time to time.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="i377d9717844147e799376babda10462f_58"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">PART II </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_61"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 13. DEFAULTS, DIVIDENDS ARREARAGES AND DELINQUENCIES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_64"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Initial Public Offering </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On December 15, 2020, we sold 7,300,000 new ordinary shares, including 5,445,000 ADSs, each representing one ordinary share, nominal value &#8364;0.03, in our initial public offering in the United States (the &#8220;U.S. Offering&#8221;) at a price of $13.50 per ADS and 1,855,000 ordinary shares in a concurrent offering of ordinary shares in certain jurisdictions outside of the United States to certain investors (the &#8220;European Offering&#8221; and, together with the U.S. Offering, the &#8220;Global Offering&#8221;) at a corresponding offering price of &#8364;11.14 per ordinary share, for aggregate gross proceeds of $98.6 million. On December 18, 2020, in connection with the exercise by the underwriters of their option to purchase additional shares, we sold an additional 1,095,000 ADSs at the public offering price of $13.50 per ADS resulting in additional gross proceeds of $14.8 million. We incurred aggregate underwriting discounts of $7.9 million and expenses of $5.0 million, resulting in net proceeds to us of $100.4 million. The net proceeds from the Global Offering have been used and are expected to continue to be used as described in the final prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020. No payments were made directly or indirectly to any executive or supervisory board member of ours or to their associates, persons owning ten percent or more of any class of our equity securities, or to any of our affiliates. The offering commenced on December 10, 2020 and did not terminate before all of the securities registered in the registration statement were sold. Jefferies LLC acted as global coordinator and joint book-running manager for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC acted as joint book-running managers for the U.S. Offering. Gilbert Dupont acted as manager for the European Offering.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 15. CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our management, with the participation of our Chairman of the Executive Board (principal executive officer) and our chief financial officer (principal financial officer), has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Annual Report on Form 20-F. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on the foregoing, our Chairman of the Executive Board (principal executive officer) and chief financial officer (principal financial officer) have concluded that, as of December 31, 2021, our disclosure controls and procedures were effective and ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chairman of the Executive Board (principal executive officer) and chief financial officer (principal financial officer), to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified by the SEC&#8217;s rules and forms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management, with the participation of our Chairman of the Executive Board (principal executive officer) and our chief financial officer (principal financial officer), has assessed the effectiveness of internal control over financial reporting as of December 31, 2021. Our management&#8217;s assessment was based on the framework in &#8220;Internal Control Integrated Framework&#8221;, or 2013 framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on that assessment, our management concluded that, as of December 31, 2021, our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes, in accordance with generally accepted accounting principles.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements, and can only provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Changes in Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have made certain changes in internal controls over financial reporting in preparation for the inclusion of our first Section 404 report in this Annual Report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, prior to the issuance of our interim financial statements as of and for the six months ended June 30, 2021, a deficiency, which constituted a material weakness in our internal control over financial reporting, was identified. The material weakness related to the timing of the recognition of expenses associated with new</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">contracts signed with certain contract research organizations for one of our clinical trials. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">During the year ended December 31, 2021, we remediated the identified material weakness in internal control over financial reporting identified above, under the supervision of management and the oversight of our Audit Committee, as described below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%;padding-left:14.85pt">The Company expanded its internal control staffing, with the hiring of an employee with significant expertise in the deployment, maintenance and ongoing monitoring of Sarbanes-Oxley Section 404 controls, and strengthened the applicable skills for employees involved in internal control over financial reporting.<br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8226; &#160;&#160;&#160;&#160;The Company implemented a more robust data collection system, including circularizing the purchase-to-pay process such that a sample of customers are asked to confirm receivables and reinforcing data completeness controls through reliance on management-identified key reports.<br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;At the time contracts are executed, the Company implements a process in which a more detailed accounting analysis is undertaken and the Company&#8217;s accounting personnel create an exhaustive list of all contractual obligations that will have an impact on financial accounts over the life of the agreement.   <br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;  &#160;&#160;&#160;&#160;The Company engaged an independent third-party specialist firm to perform and modernize certain internal audit functions.  Based on this firm&#8217;s specialized expertise and industry knowledge, it provides ongoing process improvements across the Company&#8217;s internal control cycle.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have tested and evaluated the implementation of these new and revised processes and internal controls to ascertain whether they are designed and operating effectively to provide reasonable assurance that they will prevent or detect a material error in our financial statements and have concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Except as noted above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i377d9717844147e799376babda10462f_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16. RESERVED </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_73"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Currently, our audit committee is comprised of two members: Mr. Enno Spillner (chairman) and Mr. Gary Phillips, and one observer, Mr. Christophe Douat, who attends in a non-voting capacity. Our supervisory board has determined that Mr. Spillner is an &#8220;audit committee financial expert,&#8221; as defined by SEC rules and regulations, and that each member qualifies as financially sophisticated under the Nasdaq listing rules. Messrs. Spillner, Phillips and Douat are independent as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of the Nasdaq Stock Market. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_76"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16B. CODE OF ETHICS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">We have adopted a Code of Conduct that is applicable to all of our, and our subsidiaries&#8217;, employees, executive board members and supervisory board members. The Code of Conduct is available on our website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">www.nanobiotix.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. Our supervisory board is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct for employees, executive board members and supervisory board members. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">144</span></div></div></div><div id="i377d9717844147e799376babda10462f_79"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ernst &amp; Young et Autres, or Ernst &amp; Young, has served as our independent registered public accounting firm for 2020 and 2021. Our accountants billed the following fees to us for professional services in each of those fiscal years:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:69.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit Fees</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit-Related Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax Fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All Other Fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">755</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,264</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8220;Audit Fees&#8221; are the aggregate fees billed for the audit of our annual financial statements. This category also includes services that generally the independent accountant provides, such as consents and assistance with and review of documents filed with the SEC.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020 and in 2021, &#8220;Audit Fees&#8221; also includes fees billed for professional services regarding our initial public offering. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8220;Audit-Related Fees&#8221; are the aggregate fees billed for assurance and related services that are reasonably related to the performance of the audit and are not reported under Audit Fees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8220;Tax Fees&#8221; are the aggregate fees billed for professional services rendered by the principal accountant for tax compliance, tax advice and tax planning related services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8220;All Other Fees&#8221; relate to services provided with respect to our registration statement for our Global Offering.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Audit and Non-Audit Services Pre-Approval Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The audit committee has responsibility for appointing, setting compensation of and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the audit committee has adopted a policy governing the pre-approval of all audit and permitted non-audit services performed by our independent registered public accounting firm to ensure that the provision of such services does not impair the independent registered public accounting firm&#8217;s independence from us and our management. Unless a type of service to be provided by our independent registered public accounting firm has received general pre-approval from the audit committee, it requires specific pre-approval by the audit committee. The payment for any proposed services in excess of pre-approved cost levels requires specific pre-approval by the audit committee. All audit and non-audit services rendered by our independent registered public accounting firm in 2021 were pre-approved by the audit committee. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to its pre-approval policy, the audit committee may delegate its authority to pre-approve services to the chairperson of the audit committee. The decisions of the chairperson to grant pre-approvals must be presented to the full audit committee at its next scheduled meeting. The audit committee may not delegate its responsibilities to pre-approve services to the management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The audit committee has considered the non-audit services provided by Ernst &amp; Young as described above and believes that they are compatible with maintaining Ernst &amp; Young&#8217;s independence as our independent registered public accounting firm. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_82"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_85"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_88"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145</span></div></div></div><div id="i377d9717844147e799376babda10462f_91"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a French </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">soci&#233;t&#233; anonyme </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">listed on the regulated market of Euronext in Paris, we are subject to various corporate governance requirements under French law. In addition, as a foreign private issuer listed on the Nasdaq Global Select Market, we will be subject to the Nasdaq corporate governance listing standards. However, the Nasdaq listing standards permit foreign private issuers to follow home country corporate governance practices in lieu of the Nasdaq rules, with certain exceptions. Certain corporate governance practices in France may differ significantly from the Nasdaq corporate governance listing standards. For example, neither the corporate laws of France nor our By-laws require that (i) a majority of our directors be independent, (ii) our compensation committee include only independent directors, or (iii) our independent directors hold regularly scheduled meetings at which only independent directors are present. Other than as set forth below, we currently intend to comply with the corporate governance listing standards of Nasdaq to the extent possible under French law. However, we may choose to change such practices to follow home country practices in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Even as a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit committee composition and responsibilities. Rule 10A-3 provides that the audit committee must have direct responsibility for the nomination, compensation and choice of our auditors, as well as control over the performance of the auditor&#8217;s duties, management of complaints made, and selection of consultants. Under Rule 10A-3, if the laws of a foreign private issuer&#8217;s home country require that any such matter be approved by board members or the shareholders of the company, the audit committee&#8217;s responsibilities or powers with respect to such matter may instead be advisory.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under French law, the audit committee may only have an advisory role and the appointment of our statutory auditors, in particular, must be approved by our shareholders at our annual meeting. Therefore, in accordance with Rule 10A-3, our audit committee will only have an advisory role with respect to the aforementioned responsibilities. Under French law, an audit committee may have only two members, whereas Nasdaq listing standards require a three-member audit committee. We currently intend to have only two members on our audit committee in accordance with French law. French law does not require our independent directors to hold regularly scheduled meetings at which only independent directors are present. We intend to follow home country practice in this regard, although, if the independent directors decide to meet in such executive sessions, they may do so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company&#8217;s common voting stock. We follow our French home country practice, rather than complying with this Nasdaq rule. Consistent with French law, our By-laws provide that when first convened, general meetings of shareholders may validly deliberate only if the shareholders present or represented hold at least (1) 20% of the shares entitled to vote in the case of an ordinary general meeting or of an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium, or (2) 25% of the shares entitled to vote in the case of any other extraordinary general meeting. If such quorum required by French law is not met, the meeting is adjourned. There is no quorum requirement under French law when an ordinary general meeting or an extraordinary general meeting where shareholders are voting on a capital increase by capitalization of reserves, profits or share premium is reconvened, but the reconvened meeting may consider only questions that were on the agenda of the adjourned meeting. When any other extraordinary general meeting is reconvened, the required quorum under French law is 20% of the shares entitled to vote. If a quorum is not met at a reconvened meeting requiring a quorum, then the meeting may be adjourned for a maximum of two months.  Further, Nasdaq rules require that listed companies have a compensation committee comprised solely of independent directors and that director nominees be selected solely by independent directors. We currently comply with this Nasdaq rule, but may in the future elect to follow French home country practice.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Finally, Nasdaq rules require shareholder approval when a plan or other equity compensation arrangement is established or materially amended. Under French law our shareholders must decide any issuance of equity, as a general matter. However, we intend to follow our French home country practice and ask our shareholders to delegate their authority to issue incentive equity and define the final terms of any equity compensation plan or arrangements to our executive board. We may, from time to time, ask for our shareholders&#8217; subsequent approval on an equity compensation arrangement in order to obtain advantageous tax treatment or otherwise. In addition, under French law, our executive board must obtain the prior approval of our shareholders before establishing or amending a plan or arrangement that would exceed the limits of the granted delegation.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_94"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16H. MINE SAFETY DISCLOSURE </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_2043"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="i377d9717844147e799376babda10462f_97"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">PART III</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_100"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 17. FINANCIAL STATEMENTS </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See pages F-1 through F-64 of this Annual Report. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_103"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 18. FINANCIAL STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Not applicable. </span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_106"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ITEM 19. EXHIBITS </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit Index </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following exhibits are filed as part of this Annual Report:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">Number Description of Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">Schedule/Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">File Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:112%;text-decoration:underline">File Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000114036122003895/ny20002455x2_ex3-1.htm">By-laws (</a></span><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000114036122003895/ny20002455x2_ex3-1.htm">statuts</a></span><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000114036122003895/ny20002455x2_ex3-1.htm">) of the registrant (English translation)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">001-39777</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">February 4, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036122003928/ny20002455x1_ex4-2.htm">Deposit Agreement, by and among Nanobiotix S.A. and Citibank, N.A., as Depositary, and the holders and beneficial owners of American Depositary Shares, dated as of December 15, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-262545</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">February 4, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036122003928/ny20002455x1_ex4-2.htm">Form of American Depositary Receipt (included in Exhibit 2.1)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Included in 4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Description of Securities registered under Section 12 of the Exchange Act</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.1&#8224;&#94;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-3.htm">Finance Contract, by and between the European Investment Bank and Nanobiotix S.A., dated as of July 26, 2018 (the &#8220;EIB Finance Contract&#8221;)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-4.htm">Amendment to the EIB Finance Contract, by and between the European Investment Bank and Nanobiotix S.A., dated as of July 20, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.3&#8224;&#94;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-5.htm">Royalty Agreement, by and between the European Investment Bank and Nanobiotix S.A., dated as of July 26, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.4&#8224;&#94;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-6.htm">Amended and Restated Strategic Collaboration Agreement, by and between The University of Texas M.D. Anderson Cancer Center and Nanobiotix S.A., dated as of January 23, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.4.1&#8224;&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Amendment No. 1 to Amended and Restated Strategic Collaboration Agreement, by and between The University of Texas M.D. Anderson Cancer Center and Nanobiotix S.A., dated as of June 4, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.5&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">License, Development and Commercialization Agreement, by and between Nanobiotix S.A. and LianBio Oncology Limited, dated as of May 11, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Summary of HSBC France Loan, by and between HSBC France and Nanobiotix S.A., dated as of June 22, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Summary of Bpifrance Loan, by and between Bpifrance Financement and Nanobiotix S.A., dated as of July 10, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.8*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-7.htm">Summary of BSA Plans</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.9*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-8.htm">Summary of BSPCE Plans</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.10*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-9.htm">2016 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.11*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-10.htm">2016-2 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.12*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-11.htm">2017 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.13*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-12.htm">2018 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.14*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-13.htm">2019 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr></table></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.15*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-14.htm">LLY 2019 Stock Option Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.16*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex10-15.htm">Summary of Free Share Plans</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.17*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000162828021006685/nanobiotix-secifrs20xf2020h.htm">2020 stock option plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">20-F/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">001-39777</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">April 8, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.18*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000162828021006685/nanobiotix-secifrs20xf2020g.htm">Summary of BSA Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">20-F/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">001-39777</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">April 8, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.19*#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000162828021006685/nanobiotix-secifrs20xf2020.htm">Summary of Free share Plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">20-F/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">001-39777</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">April 8, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.20#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1760854/000114036121021717/brhc10025772_ex99-2.htm">2021 stock option plan</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-257239</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">99.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">June 21, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">8.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001760854/000114036120026217/nt10009390x7_ex21-1.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">F-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">333-250707</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">November 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Certification by the Principal Financial Officer pursuant to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Securities Exchange Act Rules 13a-14(a) and 15d-14(a)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Certification by the Principal </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Fi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">nancial</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm"> Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline" href="nanobiotix-secx20xf2021xex.htm">Consent of Ernst &amp; Young et Autres</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The following materials from Nanobiotix S.A.&#8217;s Report<br/>on Form 20&#8208;F formatted in iXBRL (Inline eXtensible<br/>Business Reporting Language): (i) the Statements of<br/>Consolidated Financial Position, (ii) the Statements of<br/>Consolidated Operations, (iii) the Statements of<br/>Consolidated Comprehensive Loss, (iv) the Statements<br/>of Consolidated Changes in Shareholders&#8217; Equity, (v)<br/>the Statements of Consolidated Cash Flows and (vi)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (formatted as Inline<br/>XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed herewith</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Indicates a document previously filed with the SEC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8224; Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#94; Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:30pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></div></div></div><div id="i377d9717844147e799376babda10462f_109"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:86.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.663%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Annual Consolidated Financial Statements for the Years Ended December 31, 2021, 2020 and 2019:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_112">Report of Independent Registered Public Accounting Firm </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_112">- </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_112">PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMDkvZnJhZzpjZGE4NWNhZThiZWE0ZjEzODhjZGI1ZDNmMDMwMmJjOC90YWJsZTpkMjYyN2MyZjI4MTc0OWRkOGI3YjIzZmU0YzFmYWY5ZC90YWJsZXJhbmdlOmQyNjI3YzJmMjgxNzQ5ZGQ4YjdiMjNmZTRjMWZhZjlkXzEtMC0xLTEtMTAxNzk1L3RleHRyZWdpb246YWFmMTdmYmFjOTNjNDM0OWJmMGMxNDcyOTQ4ZTVhMmJfMTY0OTI2NzQ0MjY1OA_45fc76d1-305b-49d0-843f-09a3fe24a496">1704</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_112">F-1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_115">Statements of Consolidated Financial Position as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_115">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_115"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_115">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_115">F-2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">Statements of Consolidated Operations for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118"> and 201</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_118">F-3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">Statements of Consolidated Comprehensive Loss for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121"> and 201</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_121">F-4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">Statements of Consolidated Changes in Shareholders&#8217; Equity for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124"> and 201</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_124">F-5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">Statements of Consolidated Cash Flows for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127"> and 201</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_127">F-6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">Notes to the Audited Consolidated Financial Statements as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">, and for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">1</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">, 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130"> and 201</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_130">F-7</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i377d9717844147e799376babda10462f_112"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To the Supervisory Board and Shareholders of Nanobiotix S.A.,</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Opinion on the Financial Statements </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We have audited the accompanying statements of consolidated financial position of Nanobiotix S.A. (&#8220;the Company&#8221;) as of December 31, 2021 and 2020, and the related statements of consolidated operations, comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its consolidated operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8220;IFRS&#8221;) and in accordance with International Financial Reporting Standards as endorsed by the European Union.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTIvZnJhZzowMTE4MGYwOWQxZGM0MzIwOGUzZDk4NDIyOWUwOTUyOS90ZXh0cmVnaW9uOjAxMTgwZjA5ZDFkYzQzMjA4ZTNkOTg0MjI5ZTA5NTI5XzMxODg1ODM3MjI3Njc5_24fc71aa-297f-4375-9725-e3ea4939fa4f">ERNST &amp; YOUNG et Autres</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We have served as the Company&#8217;s auditor since 2012.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTIvZnJhZzowMTE4MGYwOWQxZGM0MzIwOGUzZDk4NDIyOWUwOTUyOS90ZXh0cmVnaW9uOjAxMTgwZjA5ZDFkYzQzMjA4ZTNkOTg0MjI5ZTA5NTI5XzMxODg1ODM3MjI3Njgw_bf33533f-daff-4e5d-8292-70603561751e">Paris-La D&#233;fense, France</ix:nonNumeric> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">April 8, 2022 </span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i377d9717844147e799376babda10462f_115"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros)</span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:59.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzQtMy0xLTEtMTE5OTk_5c4b6a21-1ee1-4a51-93ee-70810c3b8c16">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzQtNS0xLTEtMTE5OTk_60257f91-fcb8-45cd-aab8-b880a4c44a7a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzUtMy0xLTEtMTE5OTk_1c14da3b-06f5-437f-a883-9f3696014ddc">8,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzUtNS0xLTEtMTE5OTk_4980886d-9fc9-45c6-a587-db74ed11dfb7">8,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzYtMy0xLTEtMTE5OTk_313f9457-f18e-4a42-b666-9782d19ac236">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzYtNS0xLTEtMTE5OTk_29926383-702f-41e2-9d01-d87990e324fb">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzctMy0xLTEtMTE5OTk_163b0901-fac3-48e1-bfcc-10bdcd3a55ef">8,709</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzctNS0xLTEtMTE5OTk_7315f3f5-35ba-404a-8f31-81a3318f7a57">8,782</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzktMy0xLTEtMTE5OTk_5b7a20c1-34da-4b1f-9d60-8102292a4816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzktNS0xLTEtMTE5OTk_a4916f65-6cf2-489b-9f68-27c110ad3f01">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEwLTMtMS0xLTExOTk5_cc6c2d57-ba9e-4b79-9e86-6b45de571a58">9,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEwLTUtMS0xLTExOTk5_f757c235-de2c-45c3-9b8d-ada41c40981f">6,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzExLTMtMS0xLTExOTk5_8c458f5a-c329-47ba-a631-3cf98a09f2b5">83,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzExLTUtMS0xLTExOTk5_5d470d8f-de94-48d9-b113-ede5f17f2361">119,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEyLTMtMS0xLTExOTk5_639e73cd-fb0c-45db-bedf-aa4aec937879">93,060</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEyLTUtMS0xLTExOTk5_e117f349-64fc-4eb3-aaa9-1e9018fc9a58">125,248</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEzLTMtMS0xLTExOTk5_d1123014-6300-49c3-af81-c63e70cc18f1">101,769</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEzLTUtMS0xLTExOTk5_10f39f2b-d8b8-4779-8f96-5116aa40986c">134,030</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.821%"><tr><td style="width:1.0%"></td><td style="width:59.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDER&#8217;S EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzQtMy0xLTEtMTE5OTk_73de1033-6d0b-406f-9563-2e59a50aafd9">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzQtNS0xLTEtMTE5OTk_17e2c251-85d5-41f3-a0bd-6000e9afd4cb">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzUtMy0xLTEtMTE5OTk_9ab460ad-e546-4a42-9336-75d87b9faf38">255,767</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzUtNS0xLTEtMTE5OTk_bd954601-f734-466f-a3bf-43a57349bf41">255,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzYtMy0xLTEtMTE5OTk_b1f72463-8f6e-4b11-bf8c-e6910e0324af">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzYtNS0xLTEtMTE5OTk_75f6be93-587a-42c8-94e9-54ac0c1eff22">555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Treasury shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzctMy0xLTEtMTE5OTk_3152f480-c302-497f-9110-8b51b06f63f7">202</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzctNS0xLTEtMTE5OTk_a067c87f-218a-4a32-95f5-36ef0b0d8e9d">196</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" sign="-" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzgtMy0xLTEtMTE5OTk_6c12337f-56fe-49bb-ac4f-6d428cf08fbe">183,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" sign="-" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzgtNS0xLTEtMTE5OTk_9d6907ed-f46c-44e6-b5f7-86126b441761">153,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" sign="-" name="nbx:NetLossForThePeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzktMy0xLTEtMTE5OTk_dafb1352-5dde-4bcc-a112-1ad0ac045a41">47,003</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" sign="-" name="nbx:NetLossForThePeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzktNS0xLTEtMTE5OTk_063d88d3-eeb4-411b-825d-5427365becde">33,590</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEwLTMtMS0xLTExOTk5_592e6a3f-8997-46c7-a383-d1ff42266061">26,790</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEwLTUtMS0xLTExOTk5_c5472aa4-6ba6-45cb-9870-807af1f3f968">70,468</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEyLTMtMS0xLTExOTk5_f67a4521-629e-454d-85bc-f4ffa12220f6">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEyLTUtMS0xLTExOTk5_50e5ac64-b020-4c98-98b6-d1e90ff6f97c">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEzLTMtMS0xLTExOTk5_4945c2f4-c2b8-4aae-a1a0-82c4a110d458">37,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEzLTUtMS0xLTExOTk5_911cab24-ad63-4ff8-b92a-7c8cdc2710ee">44,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE0LTMtMS0xLTExOTk5_8e635fad-7433-4bd6-a887-9cc03ea310f2">38,134</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE0LTUtMS0xLTExOTk5_706f5f67-3481-4a2a-be94-e353769aadc7">44,522</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE2LTMtMS0xLTExOTk5_96326dcb-492f-47d3-8937-fcbca45f1023">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE2LTUtMS0xLTExOTk5_22656e51-8296-496a-804b-914f82815c3c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE3LTMtMS0xLTExOTk5_19412bb0-77f9-4a62-b738-bcc656dac58d">8,204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE3LTUtMS0xLTExOTk5_9d742a47-7cea-4f51-9e7d-55f71b040f78">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE4LTMtMS0xLTExOTk5_2499ddc5-6b61-4aa2-93f2-aaa3e5bab61c">6,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE4LTUtMS0xLTExOTk5_0fb993d6-90ae-4225-aa65-82965fe343a7">7,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE5LTMtMS0xLTExOTk5_b1d3e4ec-84c9-4173-a39d-80badc997ebe">5,531</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE5LTUtMS0xLTExOTk5_5cc569bc-186b-4792-9a25-259fa0291d5e">7,022</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTMtMS0xLTU2MDcz_7e38b8d7-f67a-4675-9061-fe5fc077cb66">16,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTUtMS0xLTU2MDc1_63b77ef2-8a01-467a-970b-d90e0e667436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTMtMS0xLTExOTk5_2fb68df5-5696-4841-b7c4-06d6e454526e">36,845</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTUtMS0xLTExOTk5_67b6465f-1372-4990-8447-5609bb257d18">19,041</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIxLTMtMS0xLTExOTk5_268f6557-f845-4ca0-81aa-b3fd14a02bb2">101,769</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIxLTUtMS0xLTExOTk5_20b2e5c6-cc1a-4f11-a5b3-e02d633ff2b3">134,030</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these audited consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i377d9717844147e799376babda10462f_118"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">STATEMENTS OF CONSOLIDATED OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros, except per share numbers)</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:44.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues and other income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtMy0xLTEtMTE5OTk_dc1ab5c6-99b4-416f-940f-6847f6908b38">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtNS0xLTEtMTE5OTk_964ff7e5-745d-4186-af97-b8dd09aadf6f">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtNy0xLTEtMTE5OTk_d317ce1c-8805-4868-8e6c-36f3400335fd">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtMy0xLTEtMTE5OTk_09d32c2a-a81c-4e4e-bb6b-8dcdec3e68d6">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtNS0xLTEtMTE5OTk_17f28db1-1196-423b-b98a-fc5e1232d8f0">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtNy0xLTEtMTE5OTk_aa334842-6756-491c-92e3-4cf9c6f7b5ff">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtMy0xLTEtMTE5OTk_4372f900-ea7b-4cb8-8c36-9c79d1f86b94">2,647</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtNS0xLTEtMTE5OTk_7d6024f5-1309-4779-9108-7676943c98fd">2,512</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtNy0xLTEtMTE5OTk_c25dd5d5-9670-4eb9-91e4-f8d4d3578acf">2,541</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtMy0xLTEtMTE5OTk_a0da21ae-91a7-4c0f-90f2-e04156552701">30,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtNS0xLTEtMTE5OTk_af8febf4-30b4-4f6f-bb69-cc06db04d192">24,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtNy0xLTEtMTE5OTk_5aafb4c9-ca62-464a-9d2f-dbf872883a48">30,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctMy0xLTEtMTE5OTk_50d124af-f867-4e35-b212-676af53603c9">19,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctNS0xLTEtMTE5OTk_8a0d3aba-8a63-4c38-b083-77a33662c0fd">14,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctNy0xLTEtMTE5OTk_3a5f583c-d1ba-4601-9277-22cbb9884c5e">18,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtMy0xLTEtNDE5NzE_80f5acb8-197b-4a69-a2d2-bff5737fa99c">5,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNS0xLTEtNDE5NzQ_41e40d66-1d4d-4a08-b9e6-e8d5a6d17dee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNy0xLTEtNDE5NzY_44dbbd63-36ec-471f-9b78-0e93299a95fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtMy0xLTEtMTE5OTk_30c72dc9-2170-4e48-8065-0b45560745e3">55,226</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNS0xLTEtMTE5OTk_6e92b38e-34e7-46cf-a6cf-496e41e6b2a7">38,941</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNy0xLTEtMTE5OTk_828ae11e-13a9-4f9f-b022-651c281155b8">49,320</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktMy0xLTEtMTE5OTk_95492a31-5988-4335-ad9e-51bf3655106d">52,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktNS0xLTEtMTE5OTk_2808e368-3597-466b-bd2e-bdd8f51cd2c2">36,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktNy0xLTEtMTE5OTk_73a75a3d-dc9d-4aa1-a673-715629b8c6d0">46,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTMtMS0xLTExOTk5_d565f462-7718-42cf-9c0a-75dcfb81347e">6,360</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTUtMS0xLTExOTk5_a21c1cb1-b587-41ea-a6e9-2c270bce4a67">201</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTctMS0xLTExOTk5_1dca2eb0-2b93-4e2a-a043-d60ed05df710">837</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTMtMS0xLTExOTk5_ad2f511e-ae95-43e1-8528-7aa2043cfb81">780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTUtMS0xLTExOTk5_009f0be3-2d90-4086-9fe4-52401785b5b7">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTctMS0xLTExOTk5_52fd07df-95c5-4ab0-8196-ffc0643bf122">4,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTMtMS0xLTExOTk5_f0b166d5-2d70-44c9-afa6-12e930827361">5,580</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTUtMS0xLTExOTk5_dfb2da7e-23a5-445f-81ca-6332c726ebfe">2,847</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTctMS0xLTExOTk5_962c21b9-0118-41c3-a5dc-07511ed69f65">4,133</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTMtMS0xLTExOTk5_f3fb85f7-4203-480d-98e3-ed5152c64d60">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTUtMS0xLTExOTk5_4c67dec4-513a-4b95-b325-c11d129a168b">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTctMS0xLTExOTk5_70ca0841-87a0-4de6-856e-70a6e15fa084">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTMtMS0xLTExOTk5_eb83a53d-af7e-4996-b7ba-57f6994dd227">47,003</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTUtMS0xLTExOTk5_e136f06c-665e-4f87-a97e-6e757e78898d">33,590</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTctMS0xLTExOTk5_e51bfa38-f665-4396-8438-8ec219bcd467">50,915</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (euros/share)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTMtMS0xLTExOTk5_559d3ba4-8d2f-4656-b14a-d6c153825f9e">1.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTUtMS0xLTExOTk5_bbae062b-e39e-4dca-8e83-bc290d478f5f">1.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTctMS0xLTExOTk5_1129da95-20bc-4bac-ae22-d9ec7cc8d7cc">2.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (euros/share)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTMtMS0xLTExOTk5_8fb61338-4b1a-4561-8478-f775caf7a8d5">1.35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTUtMS0xLTExOTk5_06466f9c-455f-42c0-af89-78eba7f3eb1a">1.38</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTctMS0xLTExOTk5_030e7e3b-6cc7-47df-89b9-7da068e9e4c4">2.35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes form an integral part of these audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i377d9717844147e799376babda10462f_121"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros)</span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:45.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItMy0xLTEtMTE5OTk_2f853355-adf6-42c9-bcb3-714b187ac4e4">47,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItNS0xLTEtMTE5OTk_2076c25c-c84a-469e-b95d-5e62008923c3">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItNy0xLTEtMTE5OTk_8655ea2f-6f4c-4c6b-9c8e-879e58f9fa82">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial gains and losses on retirement benefit obligations&#160;(IAS 19)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtMy0xLTEtMTE5OTk_e408ab9b-6d29-4534-bbd2-213bf82194bb">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtNS0xLTEtMTE5OTk_9e1150fb-f0f0-45f0-9bfe-5125ef71ea85">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtNy0xLTEtMTE5OTk_8ca670f0-09cc-47c6-8524-57f28b4546bd">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtMy0xLTEtMTE5OTk_3b1bbc83-ce8e-44b5-b9f1-fd832e165aa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtNS0xLTEtMTE5OTk_ea2b10a8-7a53-40dd-9416-3a745271e97d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtNy0xLTEtMTE5OTk_27883b34-6fc5-42d6-9935-5f55daeb32fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive loss that will not be reclassified subsequently to income or loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtMy0xLTEtMTE5OTk_e1583cde-3cab-4943-846b-858f4663ab61">182</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtNS0xLTEtMTE5OTk_82828682-0b53-4a9b-bb08-d8aab8c68458">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtNy0xLTEtMTE5OTk_f415ad59-8d3c-41d0-a8a7-df7e669af8d5">88</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtMy0xLTEtMTE5OTk_500331c9-91bf-411e-a954-2a38b3265a3d">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtNS0xLTEtMTE5OTk_f4e9362e-5056-472f-b07b-eae86c206974">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtNy0xLTEtMTE5OTk_db119ef5-e5fe-4185-a00c-10db4ddec6be">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctMy0xLTEtMTE5OTk_a878edcd-4555-43fb-a3da-a7b15a3cb561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctNS0xLTEtMTE5OTk_f7aa85c3-f558-4843-bed3-8114790ac8d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctNy0xLTEtMTE5OTk_fb320636-84e5-42ef-828a-8a8457734a92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive income that may be reclassified subsequently to income or loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtMy0xLTEtMTE5OTk_f8269794-d6a3-4704-89b1-6a4d9f423ac9">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtNS0xLTEtMTE5OTk_27a63369-1e26-4f65-92e0-bb224a098fc7">125</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtNy0xLTEtMTE5OTk_c633309d-7f6c-48cc-a3ad-fa93f6a12dcc">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktMy0xLTEtMTE5OTk_f0e88a81-e6e4-486b-8b33-e42767e5d881">46,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktNS0xLTEtMTE5OTk_90683383-9e79-483d-805a-face9e2d7ed3">33,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktNy0xLTEtMTE5OTk_9be3be9d-1697-45a1-896a-d13f48c8fbcb">50,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these audited consolidated financial statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i377d9717844147e799376babda10462f_124"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">(Amounts in thousands of euros, except number of shares)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:20.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share capital<br/>Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>&#160;shares </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Premiums </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">related to </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">share capital</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">comprehensive </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">income (loss) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reserve </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">for the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">shareholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">equity</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of January 1, 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ief56ec2bd42a44a6a729bc2731655345_I20181231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTItMS0xLTExOTk5_41854b91-e8dd-498f-9acc-fd77e0fbd636">19,633,373</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ief56ec2bd42a44a6a729bc2731655345_I20181231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTMtMS0xLTExOTk5_7d71070e-ab59-46ba-a3a8-001ab6ef67d6">589</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i120ec80e331e46b4a8d8c2e900c322ce_I20181231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTQtMS0xLTExOTk5_f856a28d-8487-448f-ae8f-3d0e588ebc00">122,799</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib9dafc6f49b842eab8640526d732bb38_I20181231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTUtMS0xLTExOTk5_dbb8a8d3-8aa2-4982-b22f-5fe25c3984a0">381</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i086600f2d4fd4f29b9e0175fa9980649_I20181231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTYtMS0xLTExOTk5_465fec94-7a1b-4111-afac-6326eb45fe45">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i215f01165ded46dda75650b910df1253_I20181231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTctMS0xLTExOTk5_2fa01c80-04f4-47f6-9c41-6cc1c6e42a2f">79,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id5767bd39bba43819d6569d194f2f1d6_I20181231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTgtMS0xLTExOTk5_0f7f013d-51f7-4710-b4aa-3a47fea3202a">30,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifb077c12bc264a7ab30586528053d5b8_I20181231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTktMS0xLTExOTk5_0b9233f7-ae6a-4762-95f6-279f526e182d">14,243</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEzLTgtMS0xLTExOTk5_642d429f-c1fb-45c3-8e7e-9641fc92ec40">50,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEzLTktMS0xLTExOTk5_fc924b51-08a6-4d90-8c42-23e64c8f30d4">50,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE0LTUtMS0xLTExOTk5_14b4a48a-512a-4479-b066-62e76a2d7f55">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE0LTktMS0xLTExOTk5_cd66a73c-d115-4cef-ab63-5103b8b1d6fe">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses (IAS 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE1LTUtMS0xLTExOTk5_5ca1a511-98fd-41a6-82c3-10dc9d9bcca4">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE1LTktMS0xLTExOTk5_cd3af095-bfd3-4e86-a4e9-698060cf5aaf">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTUtMS0xLTExOTk5_0b081a5f-5ab6-4cec-bab5-680b14f4af3d">52</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTgtMS0xLTExOTk5_4f37ffe1-e595-45a3-aebf-481ef5f6771e">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTktMS0xLTExOTk5_5862ea2b-8a9a-4974-bec4-3cc70a67b5cf">50,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231" decimals="-3" sign="-" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTctMS0xLTExOTk5_b916ba93-3cf8-4d63-b497-2071a8093744">30,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTgtMS0xLTExOTk5_cdf783a3-8cad-40d5-b106-8fa420f9e35a">30,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTktMS0xLTExOTk5_85adcc32-9042-48d7-9257-ef4d2123c688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital increase, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTItMS0xLTExOTk5_fdc3882f-677e-441b-a09a-2e8e58a0c59e">2,566,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTMtMS0xLTExOTk5_24391c5f-6b9f-45d3-8ecf-bdb2bf3a68f2">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTQtMS0xLTExOTk5_97f44ee5-d3be-4b82-a842-b10b6c28ab8d">28,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTktMS0xLTExOTk5_02addf01-4764-45e4-9099-a892d2592d44">28,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE exercise</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231" decimals="INF" name="nbx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTItMS0xLTExOTk5_dc77ea11-8178-4bad-8baa-314dda41796a">215,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTMtMS0xLTExOTk5_445627f9-b697-4ced-aa17-e26150086cf8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTQtMS0xLTExOTk5_9da9b3be-9333-4388-9d1d-3be8e66600ce">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTktMS0xLTExOTk5_da86f1fa-3998-415b-afa4-557ffe619646">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subscription of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTQtMS0xLTExOTk5_ecef7aa4-1f52-4f97-9b64-391f8d79e022">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTctMS0xLTExOTk5_81e0b97d-cf09-4cb7-bf19-d821a143d227">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTktMS0xLTExOTk5_c3e60585-7da3-49d7-a0f5-e87c4934855e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based payment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIxLTctMS0xLTExOTk5_ec9035a9-986b-415d-a71e-5f76df01d1fd">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIxLTktMS0xLTExOTk5_b6c22837-88fa-4fb5-80da-53f1f8fcdb71">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib9373d1667a940b68a4392136b2737e8_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIyLTYtMS0xLTExOTk5_c0fd4ef5-8adf-40b8-80a9-a81427b1f887">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIyLTktMS0xLTExOTk5_80c6fe40-232f-4c0a-82eb-27254d13a8cc">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Initial public offering costs offset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIzLTQtMS0xLTExOTk5_2410c027-be2f-485b-ba9e-85e8118bbb5f">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIzLTktMS0xLTExOTk5_04fa9603-7e88-49f8-bc98-39102fcaf888">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTItMS0xLTExOTk5_2c164b02-a344-4731-be32-f49059a9555e">22,415,039</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTMtMS0xLTExOTk5_87956b08-5592-4537-a9a3-a8a29f95d9b1">672</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icec4369f4c7649dba76e50278de42760_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTQtMS0xLTExOTk5_8f5164ee-f68e-4f0e-bac0-ecc46e945e9a">153,139</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5a2f48357d7645e5a28e6091cc904770_I20191231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTUtMS0xLTExOTk5_04e922d5-7f5b-4b59-8265-658293300537">433</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib450eccc21d24368a1877065c5e022e1_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTYtMS0xLTExOTk5_2e86d89c-284b-4005-949f-e586beaba162">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i5b268f53590247bcb64f8ce92ed3144d_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTctMS0xLTExOTk5_9fe9823d-ee66-4675-9517-466781191663">105,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib91c813e0c574310a2f8c983ce2042ad_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTgtMS0xLTExOTk5_b0259920-707a-42cd-b5a6-5b75ec9db3ac">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTktMS0xLTExOTk5_c6414a47-ed46-468b-ac95-1204704dc081">1,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTgtMS0xLTExOTk5_79fc77e3-3d75-45b7-aef6-435a2991d03c">33,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTktMS0xLTExOTk5_4a5c6f0b-8162-4d14-baf6-ef83e4efa5a0">33,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTUtMS0xLTExOTk5_5a17908d-0d28-488d-96b5-f3922bc92969">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTktMS0xLTExOTk5_cca12336-cf32-446d-986b-c51e1ee6a889">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses (IAS 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTUtMS0xLTExOTk5_8c1a6587-8703-4d21-a5b0-5e13cb15b42a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTktMS0xLTExOTk5_5087d1ad-5f7e-4fb5-b71d-e12fe926617a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTUtMS0xLTExOTk5_993ea9ab-25a4-41c8-9f67-fead856faecd">121</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTgtMS0xLTExOTk5_70f5e62d-ea56-4b9d-a913-5ea1e9ea087e">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTktMS0xLTExOTk5_dbb5fab7-6347-4750-bdc0-00ee0b5368a6">33,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231" decimals="-3" sign="-" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTctMS0xLTExOTk5_6ae55812-abdd-45c9-8ff5-4c2e5a06ed44">50,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTgtMS0xLTExOTk5_cc3613bc-b299-4ed5-bb13-ddd0820e281c">50,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTktMS0xLTExOTk5_1d4bd82f-465e-4dae-a700-83f4fd4ce44a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital increase, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTItMS0xLTExOTk5_fea60bff-c3eb-4a57-8d4f-a650e27e4857">12,017,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTMtMS0xLTExOTk5_db826e18-c54a-4126-aada-0e5ae4102e09">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05eefb483e484cf597b3e3872a255374_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTQtMS0xLTExOTk5_330faaa7-53db-4cf5-bd0a-90bef1f7f9af">102,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTctMS0xLTExOTk5_f597b912-52ce-4014-8017-d08726895b39">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTktMS0xLTExOTk5_b912220c-291d-4926-a5b9-acb2998d88bf">102,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subscription of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05eefb483e484cf597b3e3872a255374_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTQtMS0xLTExOTk5_e4a934ab-2996-4984-87e2-1a01a7cddb8c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTktMS0xLTExOTk5_b9eb6ead-b454-495a-97fa-bc9537c63574">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based payment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTctMS0xLTExOTk5_0f3564a5-67ac-47ae-820e-088ddca4bdf7">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTktMS0xLTExOTk5_b1fa7951-9ecd-4d46-aacf-cde98495dc94">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2aad128401e440c58786e8375faef035_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTYtMS0xLTExOTk5_722882f5-1a7b-4484-b15c-2c8324d4190b">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTktMS0xLTExOTk5_a2f58de3-0519-4f7d-90c2-16df98c6db7c">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTItMS0xLTExOTk5_9586508f-4503-4b38-9644-03718735d88c">34,432,122</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTMtMS0xLTExOTk5_271e2117-54cf-423f-b839-55dcaadd0a50">1,033</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTQtMS0xLTExOTk5_4cebb5ae-8d50-4690-85aa-5dd40adac373">255,735</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6b4b95efdee94328b574c4dd5a972a78_I20201231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTUtMS0xLTExOTk5_affe4d73-0114-4ce5-895d-b1d1d5cec3a6">555</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia680b82130144ad9af8419938ca05856_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTYtMS0xLTExOTk5_0f5c0316-1081-4214-ab2b-e227c59a4acf">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i5e365c4a4f144b5e87711257c20e4830_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTctMS0xLTExOTk5_fdfcf86e-4faa-4bc0-b0ea-f525abe1b5b1">153,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4e4260d8f2204ff1897746ec6304ec1a_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTgtMS0xLTExOTk5_967ad1be-a0d2-45fe-b854-ab1a6cdab319">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTktMS0xLTExOTk5_435883da-cb13-483a-b768-cb6f0f4ca559">70,468</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTgtMS0xLTI4ODAw_13ddda2b-8851-49d0-97d1-423238557499">47,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTktMS0xLTI4ODAw_ac1521b4-a1f0-485c-8009-22d13f6414f1">47,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTUtMS0xLTI4ODAw_abcd063b-05a3-4d1b-a531-eea2e38f7bbd">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTktMS0xLTI4ODAw_df08f222-fb38-47ef-acd9-a41f79d2ebe3">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and losses (IAS 19)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTUtMS0xLTI4ODAw_93b0f70a-246b-4fc3-aee7-46d65f98093b">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTktMS0xLTI4ODAw_c661866d-2098-4776-9387-27d2f0559909">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTUtMS0xLTI4ODAw_19066845-fa0f-4699-b578-25b27b1ef211">88</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTgtMS0xLTI4ODAw_09b3e6e5-7d4d-4cb4-a420-c9bcf77a772f">47,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTktMS0xLTI4ODAw_2fed3391-5509-4d55-88f5-02d03881bd42">46,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231" decimals="-3" sign="-" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTctMS0xLTI4ODAw_ee815b16-3680-4b4e-a094-922307943a04">33,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTgtMS0xLTI4ODAw_5683b03e-fae4-4b66-9d75-91413c067765">33,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:AllocationOfPriorPeriodLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTktMS0xLTI4ODAw_684694fe-e3c7-44bd-9fc9-dc46e9f2d3b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Capital increase, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTItMS0xLTI4ODAw_021f8e6d-c8ea-445e-836e-4c3cc1be9835">393,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTMtMS0xLTI4ODAw_4f8244c3-8483-4df9-8388-dfb53c07bdd4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTctMS0xLTI4ODAw_ff0f5291-ce1f-4199-98d2-edff1822e4f3">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTktMS0xLTI4ODAw_79a73fb5-6b27-42a5-a485-455768479593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subscription of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10.3</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTQtMS0xLTI4ODAw_52a30009-1b71-442d-8442-bd6e2e00503f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTctMS0xLTI4ODAw_c623c740-b9e3-40ab-b3b7-f8fdb5150f4e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTktMS0xLTI4ODAw_78cc3a38-2717-4ad4-aa6a-bb07d1a17adc">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share based payment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTctMS0xLTI4ODAw_545ddf8c-42a7-46bd-a860-9225e7da94fc">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTktMS0xLTI4ODAw_447d353b-b6a3-458b-bc5e-9e36b24c8487">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iead84a7b542a49db9faee4780fc37284_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTYtMS0xLTI4ODAw_b42aceb6-e90a-4a6e-af76-bc3faca2db51">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTktMS0xLTI4ODAw_51ef1105-f11c-469b-9271-c0a833d7b9cd">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTItMS0xLTI4ODAw_1fd5596b-c2d0-455b-876e-30656562a00c">34,825,872</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTMtMS0xLTI4ODAw_1092fc97-9eb6-4a2e-aded-140c2d42e98c">1,045</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ida63773549fb469180532f7bff7a9b6b_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTQtMS0xLTI4ODAw_d807f5cd-9829-4a35-aab1-7b7b154467b8">255,767</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i56d7277ffa0b489fa8a0f3ad5aa861e5_I20211231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTUtMS0xLTI4ODAw_d274a360-4d04-46c9-96d6-8765966d727b">643</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTYtMS0xLTI4ODAw_95d23112-b80b-4f3b-baf5-636f30470f31">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i919a1afd086a4da19822485db27af8c0_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTctMS0xLTI4ODAw_c584f937-2604-4ead-908e-846084c386fb">183,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="if46cc205e82045279e50f91253f8ea1e_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTgtMS0xLTI4ODAw_9c04800d-b539-49e0-abcc-0269bd2c38c2">47,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTktMS0xLTI4ODAw_ad4fb02c-7752-4319-9bc6-53d7a2cd8a14">26,790</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these audited consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i377d9717844147e799376babda10462f_127"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">STATEMENTS OF CONSOLIDATED CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">(Amounts in thousands of euros)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:45.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.959%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash flows used in operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtMy0xLTEtMTE5OTk_de03d710-737b-407b-a8d4-e703d8c97ed8">47,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtNS0xLTEtMTE5OTk_04eb5671-6765-429d-baa4-46fc5cd470a2">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtNy0xLTEtMTE5OTk_c71d7c8c-66e2-4761-b114-c9c618f6f2ee">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Elimination of other non-cash, non-operating income and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtMy0xLTEtMTE5OTk_a5f1ea5b-6f3d-4fcb-86c7-f2e804c5bcdc">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtNS0xLTEtMTE5OTk_afd2cd00-9721-40aa-a96a-0c911425b473">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtNy0xLTEtMTE5OTk_be2dc5c7-67d2-446d-ab42-d743bd36eaac">1,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctMy0xLTEtMTE5OTk_3f384908-10b7-4564-9906-81e38f377f22">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctNS0xLTEtMTE5OTk_f2a3011c-903c-40cb-9514-6b1537d6a340">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctNy0xLTEtMTE5OTk_f22bb1f8-6b75-4153-9f1b-285dbaf253fb">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expenses related to share-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtMy0xLTEtMTE5OTk_c1c999a8-9980-4947-b142-6d804822bbf9">3,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtNS0xLTEtMTE5OTk_200e6db2-4b60-4596-9038-292bf71b94c7">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtNy0xLTEtMTE5OTk_1cf213e0-533e-444b-bb2c-a5596a849d68">4,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of net debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktMy0xLTEtMTE5OTk_dbca0659-758f-4930-a777-99ee05bded5a">2,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktNS0xLTEtMTE5OTk_5fd1f072-f553-463d-801f-226c13fcd5e2">2,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktNy0xLTEtMTE5OTk_fcbc2d81-6a16-4987-af10-83ae4eeb9b25">1,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on disposals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTMtMS0xLTExOTk5_8eed1bcf-b5b9-49a2-8ed2-93bed8965340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTUtMS0xLTExOTk5_fc494b07-fd28-42ab-8424-e5c9fcacc595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTctMS0xLTExOTk5_168d5874-9f2d-45c3-a302-608f390ddffd">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering 2018 costs reversal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTMtMS0xLTExOTk5_2e1bbc4e-fb02-4efc-874a-42049a3da75a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTUtMS0xLTExOTk5_95f9c546-c5c6-40fb-af3e-69f90e409b29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTctMS0xLTExOTk5_d627a62f-5502-4422-a88d-02884898ee20">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of deferred income related to financial liabilities discounting effect</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTMtMS0xLTExOTk5_b3b7799b-1453-4c06-a01a-0be91a0b7315">1,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTUtMS0xLTExOTk5_ace728bf-eb6d-45ee-ba04-8fb1bfef4104">6,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTctMS0xLTExOTk5_27263edd-70ff-49da-abf8-d2dfc0db0715">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other charges with no impact on cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTMtMS0xLTExOTk5_049d6af8-467a-492b-a870-de19ad949399">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTUtMS0xLTExOTk5_4436da1e-d186-44b8-9eff-86b12a6eaca5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTctMS0xLTExOTk5_04adc81b-3662-4c33-a1f9-93adefd7e755">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows used in operations, before tax and changes in working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTMtMS0xLTExOTk5_de52d175-c57d-4618-a0b8-77984c2f5332">41,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTUtMS0xLTExOTk5_0a229baf-2340-49a5-988d-19d7b3184ada">33,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTctMS0xLTExOTk5_39ca4592-0ab4-4141-a11a-72fd58f29218">39,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Increase) / Decrease in trade receivables</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTMtMS0xLTExOTk5_35058ba5-725f-4ffa-9152-d285df89bc64">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTUtMS0xLTExOTk5_d820579e-057a-49af-b6f3-7d9d2acf5081">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTctMS0xLTExOTk5_007ac72e-a0cd-449d-b364-d288371ed9f4">85</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decrease in Research tax credit receivable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTMtMS0xLTExOTk5_227f7d7d-e457-46d2-8731-cf6329a6de56">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTUtMS0xLTExOTk5_878681d9-c45b-47ee-8c95-f5cf6a8139b9">5,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTctMS0xLTExOTk5_3454a244-9d9d-4e99-b571-79d30c058bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in other receivables</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTMtMS0xLTExOTk5_3a7625f3-af05-4b14-8d52-28d806feb771">5,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTUtMS0xLTExOTk5_e65f2d9d-6138-44cd-b4a8-f3132b69ee4b">721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTctMS0xLTExOTk5_064ad78a-8d67-434b-8463-d6a2a407a68a">4,640</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase / (Decrease) in trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTMtMS0xLTExOTk5_5b6ce493-9d63-4424-812e-516330416d81">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTUtMS0xLTExOTk5_13402dfe-e548-4bb2-a1fc-4ae650f1e423">995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTctMS0xLTExOTk5_efc622db-89cf-4b2d-9b07-f3d9f01660d1">2,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase / (Decrease) in other current liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTMtMS0xLTExOTk5_17e063e4-c184-49eb-9f1d-db532475f75f">1,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTUtMS0xLTExOTk5_e73aac66-9554-43b7-b108-e1273ee4a20e">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTctMS0xLTExOTk5_ede46322-3886-45b9-b75d-7bd4d90c7484">1,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in deferred income and contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTMtMS0xLTU2NzUz_8131685b-1598-4b9c-a251-1699850ef4c6">16,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTUtMS0xLTU2NzU1_49bcd819-b8d8-433b-b070-4b80313a9b53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTctMS0xLTU2NzU3_0e90f9aa-7473-473e-a077-44089a8672b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in operating working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTMtMS0xLTExOTk5_0cfbf5c9-43bb-43bd-a1ea-e6ac8e14d404">11,540</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTUtMS0xLTExOTk5_3429d743-75b2-4578-ba85-4109c792d21e">5,762</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTctMS0xLTExOTk5_5db3b9ef-9c38-4f2a-adc0-ccbee8756622">1,522</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTMtMS0xLTExOTk5_2ee104fc-1a86-4b35-a822-b990f98e8677">29,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTUtMS0xLTExOTk5_50000d89-4938-48a0-9704-73d47df0afb9">27,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTctMS0xLTExOTk5_1c41f6ef-73bb-4070-a80d-9df379a5b962">41,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTMtMS0xLTExOTk5_ee1cd264-3989-48fc-9051-6e02ed933ec6">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTUtMS0xLTExOTk5_7d2398e6-d444-4741-9ae0-84412e0ae3fe">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTctMS0xLTExOTk5_fe345245-f08e-4a39-abfb-f8c2a2d9cdf6">353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTMtMS0xLTExOTk5_d89f7916-1651-4f04-b39a-5131078b3a7a">228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTUtMS0xLTExOTk5_d501dddb-19b9-431f-b7ca-be36e286321b">96</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTctMS0xLTExOTk5_9bf3dafe-031e-4db8-ae95-99d43f532ee8">1,091</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Addition in non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTMtMS0xLTExOTk5_4f869215-f5d4-4eb2-a527-445d37af9610">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTUtMS0xLTExOTk5_ea6580ea-e49a-4ac4-965c-dd026144816e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTctMS0xLTExOTk5_7d88c156-ea1d-4c62-a6a3-94f54b820d47">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTMtMS0xLTExOTk5_3c1ac336-c8b8-4ea0-bcef-26e92fc03a93">242</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTUtMS0xLTExOTk5_f217207e-0ee0-44ee-94c8-834b621680c2">112</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTctMS0xLTExOTk5_8a353e94-444d-4393-a5e6-1444b2dde020">1,459</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTMtMS0xLTExOTk5_9318a9ad-0c0d-46df-beb5-1e8c6b79cfec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTUtMS0xLTExOTk5_fca821bf-0987-4e7b-b094-8f87d1f97e01">113,650</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTctMS0xLTExOTk5_451b12c9-1800-46b4-b2db-65b46ba6fa7d">29,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants subscription</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ProceedsFromWarrantsSubscription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTMtMS0xLTExOTk5_03cc79db-000e-4d44-99ba-9ae5cd024305">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ProceedsFromWarrantsSubscription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTUtMS0xLTExOTk5_4b3824c5-f1c9-43ab-a74d-040dbd4025b3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:ProceedsFromWarrantsSubscription" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTctMS0xLTExOTk5_02a7038a-e5e6-4ad1-b22a-48322fd3c570">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTMtMS0xLTExOTk5_a6442294-1bbc-4659-8c10-ae7322b9d731">349</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTUtMS0xLTExOTk5_a3de3ac9-a2d3-45a7-b14d-bd6fe5c22d94">10,359</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTctMS0xLTExOTk5_234f42c4-f839-47f1-881e-7383c1a6f35c">1,438</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increase in loans and conditional advances</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTMtMS0xLTExOTk5_a79a366d-db2a-4939-8848-59b37ce0f4b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTUtMS0xLTExOTk5_1b379ce2-ee3b-441c-8b94-9e7737911997">10,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTctMS0xLTExOTk5_a3d966e8-1932-43b6-80a6-ef27e5a3f3e4">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans repayments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTMtMS0xLTExOTk5_c7b0aa29-38dc-4f36-9f38-200e24112d0f">2,833</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTUtMS0xLTExOTk5_a66fe3e3-6fef-4b9b-aa2a-1f2c82c408c8">250</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTctMS0xLTExOTk5_65c5cd36-a33d-4b51-acbf-bd485ce08fcf">500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payment of lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTMtMS0xLTExOTk5_5eaf42a9-1a25-4dea-a83e-a6d04fe6c0b1">909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTUtMS0xLTExOTk5_ad84d45f-da76-4238-845e-f3b3ab9e8751">928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTctMS0xLTExOTk5_fd2aed02-028d-4512-b658-2439cc85d950">1,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTMtMS0xLTExOTk5_b7e3edcb-e4b1-4307-afc3-d8a5ffc37f43">1,132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTUtMS0xLTExOTk5_9ce9ab12-fa91-4f0e-9efb-643f93445021">700</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTctMS0xLTExOTk5_ec3a49c1-0b58-4848-b2f1-38666ea33311">350</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTMtMS0xLTExOTk5_86655f30-8ced-40e2-972c-f5d61f57aea6">5,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTUtMS0xLTExOTk5_ce7375da-5171-4068-ad66-1ccb50baac8f">111,769</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTctMS0xLTExOTk5_08caa502-eee2-4a6f-8a0f-bd2f9c0bf57b">41,489</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rates changes on cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTMtMS0xLTExOTk5_485b1696-d5fd-4e9e-9956-cb353654632d">64</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTUtMS0xLTExOTk5_37fa1356-f494-4c37-9bf7-ca3a349d3cfc">63</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTctMS0xLTExOTk5_5f97fd04-1885-41ed-9b3b-c15ed8d171f0">29</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTMtMS0xLTExOTk5_ae5ae4ca-0d7d-4e9e-9d96-1254b8e9ce32">35,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTUtMS0xLTExOTk5_30c2b3db-4ff8-42e1-b3c0-b9c9e93287da">84,056</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTctMS0xLTExOTk5_fcececa5-367c-4211-9c33-dafd1a9386bf">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTMtMS0xLTExOTk5_8bd4a27e-f00a-4ef9-aab1-518d0521594c">119,151</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTUtMS0xLTExOTk5_a36abcfb-5d9f-4557-a15c-95c50a38d3f5">35,094</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="ifb077c12bc264a7ab30586528053d5b8_I20181231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTctMS0xLTExOTk5_11bd8a17-8242-4d6b-a47b-a9735cef1604">36,203</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTMtMS0xLTExOTk5_9ffe195a-2d05-4b86-aa16-587bc516a2fe">83,921</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTUtMS0xLTExOTk5_37f8ac3b-4575-495c-a4c7-fc5db3e9e587">119,151</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTctMS0xLTExOTk5_96bfdd47-e4b0-4211-9f18-02eb1768943f">35,094</ix:nonFraction></span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these audited consolidated financial statements.</span></div><div style="height:56.69pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i377d9717844147e799376babda10462f_130"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">NOTES TO THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2021 AND 2020, AND FOR THE YEARS ENDED</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">DECEMBER 31, 2021, 2020 AND 2019</span></div><div><span><br/></span></div><div id="i377d9717844147e799376babda10462f_133"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 1. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzc4MjA_942ac4db-97a4-4ca0-8c09-eef1d5d6f3a7" continuedAt="ia54f0f01baa140a6b31899d76b2600f6" escape="true">Company information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia54f0f01baa140a6b31899d76b2600f6" continuedAt="i1bf186763b7946629ecab1eebc864690"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Presentation of the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix S.A. was incorporated in 2003 as a spin-off from the State University of New York (SUNY) in Buffalo. Nanobiotix S.A. (together with its subsidiaries, the &#8220;Company&#8221;), is headquartered in Paris, France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, as well as the utility and efficacy of radiotherapy. Its lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline metallic nanoparticles approximately 50 nanometers (50 billionths of a meter) in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Alongside the Company&#8217;s core NBTXR3 development program, the Company is also pursuing a development program to explore the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across several solid tumor indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company is listed on the Euronext regulated market in Paris (under the ticker symbol &#8220;NANO&#8221;; Code ISIN: FR0011341205, Bloomberg code: NANO:FP) and on the Nasdaq Global Select Market (under the ticker symbol &#8220;NBTX&#8221;).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Significant events of the period</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix and PharmaEngine mutually agree to terminate their collaboration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Termination Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8221;). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $<ix:nonFraction unitRef="usd" contextRef="i5fbf747738f94b4484ec6e4bf65b8025_I20210331" decimals="-5" name="ifrs-full:OnerousContractsProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkwMzM_b4823bda-b465-4adb-a5c2-2b2fe0abbb81">12.5</ix:nonFraction>&#160;million in the aggregate as described below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">PharmaEngine was eligible for and received in March 2021 a $<ix:nonFraction unitRef="usd" contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkxMjA_d3073d99-f4ad-4606-be01-9d8b0159ad05">2.5</ix:nonFraction>&#160;million payment following the announcement of Nanobiotix&#8217;s collaboration with LianBio for the Asia-Pacific region. In May 2021, PharmaEngine received an additional $<ix:nonFraction unitRef="usd" contextRef="ib4221b386b8a41008368fa79a2422241_D20210501-20210531" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkzMDE_88199cd8-4afc-4069-95e0-3ed391d904db">4.0</ix:nonFraction>&#160;million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PharmaEngine will be eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0Njk0ODU_95d3b827-9cc2-49db-a753-d73d92777df4">1.0</ix:nonFraction>&#160;million in administrative fees and a final payment of an additional $<ix:nonFraction unitRef="usd" contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0Njk1NDk_fbe14aab-b58b-4942-87d7-bae601819099">5.0</ix:nonFraction>&#160;million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a <ix:nonNumeric contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" name="nbx:RoyaltiesAgreementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzM4NDgyOTA3Mzk0OTc_9bef500f-9d04-42cf-bffc-bba183de507b">10-year</ix:nonNumeric> period commencing on the corresponding first date of sales in the region. As of December 31, 2021, these future payments were not accrued because the triggering events have not occurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i1bf186763b7946629ecab1eebc864690" continuedAt="i13ddc26d3a2c48e18fe6b79b7bf3260a"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix&#8217;s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in <ix:nonFraction unitRef="study" contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531" decimals="INF" name="nbx:NumberOfGlobalRegistrationalStudiesSupported" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzEyNjM_8f78d38a-9591-4baf-8528-a1a8c18c93f5">five</ix:nonFraction> future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the terms of the agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231" decimals="-6" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzE2Njg_57278a18-51bf-4769-a9ed-a9cd845e11ed">20</ix:nonFraction>&#160;million upfront payment and is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibf991456c15f4bd0beed8a02658e4984_I20210531" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzE3Mzc_28317907-ef10-431f-9f06-fd6502d5e98b">220</ix:nonFraction>&#160;million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (&#8220;the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supervisory Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i13ddc26d3a2c48e18fe6b79b7bf3260a"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.</span></ix:continuation><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i377d9717844147e799376babda10462f_136"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 2. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzgzNzU_7ab62dcc-b141-4b73-ba5c-0073672ddf0c" continuedAt="if9568b498a084704a536874bfe873770" escape="true">General Information, Statement of Compliance and Basis of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if9568b498a084704a536874bfe873770" continuedAt="i95d3f312b5fb45aab0b7c6be503e74da"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:StatementOfIFRSCompliance" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzgzNzY_9da1be2c-af39-481f-b1f9-09779fd58385" continuedAt="i6abda68f50034984b4e52611ec42d71c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">General principles</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders&#8217; equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management&#8217;s supervision and were approved by the Executive Board of the Company (the &#8220;Executive Board&#8221;) and reviewed by the Supervisory Board of the Company (the &#8220;Supervisory Board&#8221;) on March 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (&#8216;&#8216;IFRS&#8217;&#8217;) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company&#8217;s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzE3Njk_aaa07eeb-ed39-415e-8546-4f1d040bd7ed">83,921</ix:nonFraction>&#160;thousand as of December 31, 2021, as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzMyOTg1MzQ5MDQ1NDg_a6aa7da0-7015-406a-9733-bc5406a0b3e8">119,151</ix:nonFraction>&#160;thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements&#8217; publication. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Statement of Compliance and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#8220;IAS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;) as well as interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS-IC&#8221;) and the Standard Interpretations Committee (the &#8220;SIC&#8221;), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Those are available on the European Commission website: </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.15pt">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IFRS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Covid-19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Related rent concession.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of these standards had no impact on the consolidated financial statements of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations early adopted by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. </span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i95d3f312b5fb45aab0b7c6be503e74da"><ix:continuation id="i6abda68f50034984b4e52611ec42d71c"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations not yet applied by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 :</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">IFRS 17 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and related amendments. No impact expected on the financial statements. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 1 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality&#8221;.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 37 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Onerous Contracts - Cost of Fulfilling a Contract. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IFRS 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conceptual framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 8 -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> Definition of an accounting estimate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IAS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Property, Plant and Equipment: Proceeds before Intended Use</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i377d9717844147e799376babda10462f_139"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 3. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzM_1f3a3ee7-e1dd-4932-a194-e3acf9bf33b5" continuedAt="i87e14bb4f5634ea081c1a2a49c37a4fa" escape="true">Consolidation principles and methods</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i87e14bb4f5634ea081c1a2a49c37a4fa" continuedAt="i47cdf77fce444c19a8d60c11db3ed267"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzQ_6ab41ecd-630f-46ff-a515-d5d0048a93ef" continuedAt="i11e45c6c303049289d5faadd222e8b69" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">3.1 Basis of consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 10 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company&#8217;s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting methods of the Company&#8217;s subsidiaries are aligned with those of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $<ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE3Mjc_2d786c22-7499-4e4d-a064-5742070d00ba">1.1326</ix:nonFraction> as of December 31, 2021 and an average of $<ix:nonFraction unitRef="number" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE3NzI_8bf0a7aa-eb2e-4fbc-8414-3717529ac0ae">1.1835</ix:nonFraction> for the year ended December 31, 2021 (source: Banque de France) compared with $<ix:nonFraction unitRef="number" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4NTM_78c2701b-cdac-4a90-be94-ae9865b62ee2">1.2271</ix:nonFraction> and $<ix:nonFraction unitRef="number" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4NjA_48d20211-7b11-4c29-9d4b-27268901f7a4">1.1413</ix:nonFraction>, for 2020 and $<ix:nonFraction unitRef="number" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4Nzc_f48b1e09-c2d1-486f-b79d-f3cfc7d336d6">1.1234</ix:nonFraction> and $<ix:nonFraction unitRef="number" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4ODQ_d65bfaf9-bc4a-4700-b787-3800747cd4cb">1.1196</ix:nonFraction> for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company involves <ix:nonFraction unitRef="parent_entity" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:NumberOfParentEntities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzIxMjc_2773b557-f644-4a35-826a-f2f7f302e4c3">one</ix:nonFraction> parent entity, &#8220;Nanobiotix S.A.,&#8221; and <ix:nonFraction unitRef="subsidiary" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:NumberOfSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzIxNjg_2c10af6d-cde1-4658-af6e-b6a1944297b6">five</ix:nonFraction> wholly owned subsidiaries: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Germany GmbH, incorporated in Germany in October 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Spain S.L.U., incorporated in Spain in December 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="i11e45c6c303049289d5faadd222e8b69">The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.</ix:continuation>  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzU_8d8fb3b8-21d2-4506-80d9-dc862561230a" continuedAt="i6405840c4d994697935cd15051745ce1" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">3.2 Use of judgement, estimates and assumptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Measurement of share-based payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, vesting terms) and market data (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, expected share volatility) (see Note 17).</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i47cdf77fce444c19a8d60c11db3ed267"><ix:continuation id="i6405840c4d994697935cd15051745ce1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred tax assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Clinical trial accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly.  See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 15 for additional detail regarding the Company&#8217;s accounting policies for its additional sources of revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Fair value of financial assets and liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value measurement of the loan granted by European Investment Bank (&#8220;EIB&#8221;) requires the Company to assess the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company&#8217;s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-12</span></div></div></div><div id="i377d9717844147e799376babda10462f_142"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 4. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfSignificantTransactionsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg2Njk_8f380790-4531-4932-b6d4-28f20fb9133e" continuedAt="i91b95b1ba7584707ba45ae22842a8665" escape="true">Significant transactions</ix:nonNumeric></span></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i91b95b1ba7584707ba45ae22842a8665" continuedAt="ifd1bf8fab0974e528d21c9dbb1fe11ae"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.1 LianBio</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In May 2021, Nanobiotix announced a partnership with LianBio Oncology Limited a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in <ix:nonFraction unitRef="study" contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531" decimals="INF" name="nbx:NumberOfGlobalRegistrationalStudiesSupported" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjE5Mjg_1a53a34a-55f7-4f09-a00b-fbc69fa23b9a">five</ix:nonFraction> future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231" decimals="-6" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjIzMjY_5e749e6d-3877-4d5c-8551-d09eae0d63b5">20</ix:nonFraction>&#160;million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibf991456c15f4bd0beed8a02658e4984_I20210531" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjI0NjQ_9c3b5627-a74b-4d6f-94b0-accd0b3a8241">220</ix:nonFraction>&#160;million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 15 Revenues and other income for further details on this new partnership.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.2 PharmaEngine</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In August 2012, the Company entered into an Exclusive License and Collaboration Agreement (as amended in 2014, the &#8216;&#8216;License and Collaboration Agreement&#8217;&#8217;) with PharmaEngine, a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer in Asia. Under the terms of the License and Collaboration Agreement, PharmaEngine will receive the exclusive right to further develop NBTXR3 to obtain regulatory approval, leverage the data generated by the Company&#8217;s development activities and commercialize NBTXR3 in multiple countries throughout the Asia-Pacific region. Under the same Agreement, PharmaEngine is responsible for developing (non-clinical and clinical research) and commercializing NBTXR3 throughout the contractual territory and making certain development and minimum commercial milestone payments to the Company. Key provisions of the License and Collaboration Agreement include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">An exclusive perpetual license granted to PharmaEngine, with the right to sublicense the Company&#8217;s technology in order to exploit or have NBTXR3 exploited and use the Company&#8217;s trademark in connection with the exploitation of NBTXR3 in the contractual territory (with exploitation including among others developing, obtaining and maintaining regulatory approval, commercializing, distributing, promoting and marketing);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The Company&#8217;s commitment to furnish PharmaEngine with know-how necessary and useful to develop and commercialize NBTXR3 in the contractual territory, know-how meaning any results of experimentation and pre-clinical, clinical and non-clinical trial data by providing PharmaEngine with access to an electronic data platform; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The Company&#8217;s commitment to supplying or having supplied PharmaEngine with all quantities of NBTXR3 required and used by PharmaEngine for clinical testing and subsequent commercialization if and when regulatory approvals are obtained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In return, PharmaEngine commits to use commercially reasonable efforts to develop NBTXR3 in the contractual territory at PharmaEngine&#8217;s cost. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the License and Collaboration Agreement, the Company has received and/or is entitled to receive:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A $<ix:nonFraction unitRef="usd" contextRef="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231" decimals="-5" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzIyMTk_1dd02968-e2bd-4769-8696-a397b335e8fc">1.0</ix:nonFraction>&#160;million up-front payment on signature of the contract, fully received in 2012; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments upon the achievement of development milestones, including key stages of product development, first filing for regulatory approval, and first regulatory approval in the contractual territory; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments upon the achievement of commercial milestones based on specified sales thresholds; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Up to double-digit royalties based on net product sales in the Asia-Pacific region; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments for the supply of NBTXR3. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Potential development and commercial milestone payments, including those paid to date, amount to an aggregate of up to $<ix:nonFraction unitRef="usd" contextRef="i4b5f453227ff4a7692568ee182571454_I20120831" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzI4MzM_1a378e71-1928-438b-8501-d5a53fc74796">56</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="ifd1bf8fab0974e528d21c9dbb1fe11ae" continuedAt="i7d6c172823774319879c7ba782631f09"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company and PharmaEngine amended the agreement in October 2014, as part of which PharmaEngine agreed: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To join the global pivotal clinical trial of NBTXR3 for the treatment of Soft Tissue Sarcoma initiated by the Company in the Asia-Pacific area, with each party committing itself to share clinical trial results in order to increase the tested population and to accelerate growth and value creation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To pay the first development milestone ($<ix:nonFraction unitRef="usd" contextRef="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231" decimals="-6" name="nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTM_7d0e162b-5a5c-40e6-a2c7-e83ae6ba3ac5">1</ix:nonFraction>&#160;million, received by the Company in 2014) and share external clinical research organization costs charged to the Company in proportion to its contribution in recruiting the patient population included in the clinical trial; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To pay the development milestone ($<ix:nonFraction unitRef="usd" contextRef="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231" decimals="-6" name="nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzM1NTE_c04441e4-38a8-46f1-947c-181c8fcef2ef">1</ix:nonFraction>&#160;million, received by the Company in 2016) related to the launch of the first Phase II of the pivotal study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i0383e3a745c6410a8ad6434d35604d24_D20120801-20201231" decimals="-5" name="nbx:CollaborationAgreementTotalPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzM2ODA_9bd9f11c-1fbc-43d8-adff-205b66fcb469">3.0</ix:nonFraction>&#160;million has been received since the signature of the License and Collaboration Agreement. The next potential milestone payment under the agreement will become payable only if PharmaEngine files a commercialization authorization of NBTXR3 in their region.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. While both Nanobiotix and PharmaEngine believe in the potential of NBTXR3 to improve treatment outcomes for patients with cancer, the parties have had disagreements regarding the optimal strategy for development in the Asia-Pacific region. As such, after discussion between the two parties, Nanobiotix and PharmaEngine have mutually agreed to discontinue the collaboration. This agreement to terminate the License and Collaboration agreement represents a full resolution of outstanding disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region. See Note 15 for additional detail regarding the accounting policy applied to the License and Collaboration Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, the Company paid a cumulative amount of $<ix:nonFraction unitRef="usd" contextRef="ib667123634854784a7a53e8925b6cdd7_D20210301-20211231" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMDc_57873ea6-ded1-4c3c-997e-36c326f55877">6.5</ix:nonFraction>&#160;million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" decimals="-6" name="nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMjE_30d28939-8481-4448-88b6-33e5c757d7fc">1</ix:nonFraction>&#160;million upon receipt by the Company of certain clinical study reports and of $<ix:nonFraction unitRef="usd" contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" decimals="-6" name="nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMzM_af4eda95-da1d-4f9f-8704-a757240eff62">5</ix:nonFraction>&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a <ix:nonNumeric contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331" name="nbx:RoyaltiesAgreementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwNTI_21d0be1a-946c-42d6-9442-7d1b8c88bc5c">10-year</ix:nonNumeric> period beginning at the date of the first sales in the region. These future payments were not accrued because the triggering events have not occurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.3 Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ie66ef1f72fe74f22bed3a4ecb3ee2669_I20180731" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUwNDI_b136838a-5be1-49a5-b82a-d3eaaf8011ea">40</ix:nonFraction>&#160;million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a first tranche of &#8364;<ix:nonFraction unitRef="eur" contextRef="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUyOTc_bda4f23c-1935-4872-b68b-6ba906137668">16</ix:nonFraction>&#160;million, received in October 2018, subject to a <ix:nonFraction unitRef="number" contextRef="id08b49a302c4409797ed3baba0f7a8e2_I20181031" decimals="2" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUzNDA_982bae77-5216-4436-9737-1dceef02706a">6</ix:nonFraction>% fixed rate and that will be fully repaid in 2023 at the latest; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a second tranche of &#8364;<ix:nonFraction unitRef="eur" contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU0MzI_ec2688e9-a3df-4f75-97e2-758d0c5a5949">14</ix:nonFraction>&#160;million, received in March 2019, subject to a <ix:nonFraction unitRef="number" contextRef="i7f9f4e02188e458a98c73d7d32919183_I20190331" decimals="2" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU0NzM_61363472-24b5-4166-b6b7-00acb664b76d">5</ix:nonFraction>% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a last tranche of &#8364;<ix:nonFraction unitRef="eur" contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231" decimals="-6" name="ifrs-full:UndrawnBorrowingFacilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU1Nzc_21b970ec-9749-44f3-979e-040a16176c0b">10</ix:nonFraction>&#160;million, subject to a <ix:nonFraction unitRef="number" contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231" decimals="2" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU1OTQ_bc758624-ac03-4d75-8164-8d23af1dc682">4</ix:nonFraction>% fixed interest rate, that will be fully repaid after a period of <ix:nonNumeric contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231" name="nbx:BorrowingMaturityTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU2NjI_df760032-ba29-4f41-8ed2-84507c6e45c3">five years</ix:nonNumeric>, which begins within <ix:nonNumeric contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU2ODY_c67207f5-d181-4a81-80bf-deee2f81f50c">one year</ix:nonNumeric> of obtaining it. The Company has not yet met the criteria to request this tranche. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by <ix:nonNumeric contextRef="i730862d53f524fd48823ccef1c727d85_D20200701-20200731" name="nbx:BorrowingDefermentPeriodToRequestFunds" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwNTU_33e5c031-2c87-49b7-96fd-af87cc351e32">12</ix:nonNumeric> months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the final tranche of the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a <ix:nonNumeric contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731" name="nbx:RoyaltiesAgreementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg2Njg_a2539749-8d58-46ca-891f-1a0f37c9ae38">six-year</ix:nonNumeric> royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn, and indexed on the Company&#8217;s annual sales turnover.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The &#8364;<ix:nonFraction unitRef="eur" contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzYzMTc_1e5a4dad-34ba-4ccf-9656-a49b6a3ef755">14</ix:nonFraction>&#160;million second tranche, which was received in March 2019, was disbursed on the basis of achieving the following criteria:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Determination of the recommended dose at 22% of the tumor volume for head and neck cancers treatment following the end of the Phase I clinical trial with NBTXR3; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Positive evaluation of the clinical benefit/risk ratio of NBTXR3 in the Phase II/III clinical trial in soft tissue sarcomas by the clinical expert mandated by the French notified body covering medical devices, GMED.</span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i7d6c172823774319879c7ba782631f09"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 22 for discussion of royalties that may be due in the case of early repayment or change of control after repayment of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">4.4 Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The collaboration will support multiple new Phase I/II clinical trials involving around <ix:nonFraction unitRef="patient" contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" decimals="INF" name="nbx:NumberOfPatientsInClinicalTrial" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzczNDk_177061e5-ee28-4c4c-830b-a6726cdfc43b">340</ix:nonFraction> patients with Nanobiotix&#8217;s product NBTXR3 for use in treating several cancer types &#8211;, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="ie86596994b614e61888621f5f63b3d95_I20190131" decimals="-6" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc2NDI_960838f3-69dc-4219-8a4f-56c25a39f477">11</ix:nonFraction>&#160;million for those clinical trials during the collaboration, and made an initial $<ix:nonFraction unitRef="usd" contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc3MTc_20732c14-8659-4ebf-b4d8-3f938816e59e">1.0</ix:nonFraction>&#160;million payment at the commencement of the collaboration and a second $<ix:nonFraction unitRef="usd" contextRef="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc3ODI_3151f58e-11ba-44c9-aad0-893e2d81f532">1.0</ix:nonFraction>&#160;million payment on February 3, 2020. Additional payments were made in the <ix:nonNumeric contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" name="nbx:MilestonePaymentDefermentPeriodAfterEnrollment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc4NTQ_88f8e622-b692-408d-b9d0-77b63dab8e7c">six months</ix:nonNumeric> following patients enrollment, with the balance payable upon enrollment of the final patient for all studies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $<ix:nonFraction unitRef="usd" contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzgzMTk_0cb4851f-0b2b-4aaa-878e-81dd682f07f1">2.2</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzgzMjU_0b0122d3-8d85-40b3-9dcd-f0297adc1e74">16.4</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company recognized prepaid expenses for &#8364;<ix:nonFraction unitRef="eur" contextRef="icfe58517db324e8ab08832232c673117_I20211231" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg0MDg_693ace1e-f65e-4f32-a090-64201b656808">1.0</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg0MTU_9035e198-745e-4728-9647-6cf87850f559">1.6</ix:nonFraction>&#160;million respectively. Expenses will be recorded during the course of the collaboration in the statement of consolidated operations based on the patients enrolled during the relevant period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 8.2 for further details on other current assets.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i377d9717844147e799376babda10462f_145"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 5. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDQ_2ebac57b-58ea-4965-a891-4716df95cca4" continuedAt="i4daa909f1bd1404db9fa55599b70b48f" escape="true">Intangible assets</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4daa909f1bd1404db9fa55599b70b48f" continuedAt="i3de8d904aa9f416b906f5c2113f8d52c"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDI_426580b4-e6c9-4629-a079-7974efd8bffb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, intangible assets are carried at their acquisition cost. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research and Development costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, development costs may only be capitalized as intangible assets if the following criteria are met: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company intends to complete the development of the intangible asset and use or sell it; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company has the ability to use or sell the intangible asset; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is probable that the intangible asset will generate future economic benefits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">adequate technical, financial and other resources are available to complete the development of the intangible asset; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Patents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Software </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of intangible assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i3de8d904aa9f416b906f5c2113f8d52c"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of intangible assets</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDM_d78945fb-6b21-4237-896a-62a8ec420b6d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in intangible assets breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtMi0xLTEtMzgxMDI_f2431ed7-875e-4413-8560-49a358195dad">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtNC0xLTEtMzgxMDg_1898a571-acb3-4b9f-86c9-82d72e7f77a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtNi0xLTEtMzgxMTQ_e9eed3f7-9e1e-4ad7-ad7c-3b9e012bf9b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtOC0xLTEtMzgxMjA_9de10c93-02fa-48f8-bf68-6ae1a1672440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtOS0xLTEtNDAyNjM_c0fa4310-40d8-4ab5-a0c5-dd8f6dc3a7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i48e879f68f73480b92b03ede2c9ea8b9_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtMTAtMS0xLTM4MTI5_dddbd471-5b1b-41b2-a602-01690d619311">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia618a699065e48f1b3d3352fbfb17118_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItMi0xLTEtMzgxMDI_18ae7c5a-b0c9-4912-bc5e-64f178a4b03b">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItNC0xLTEtMzgxMDg_345aeff5-2faf-4709-b4b8-57a181c53324">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItNi0xLTEtMzgxMTQ_371d3c29-e041-43fe-b470-f8062ef1d787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItOC0xLTEtMzgxMjA_114a6d0e-f21c-4cf4-be8c-e8c4239c8944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItOS0xLTEtNDAyNjM_acf44d25-cf08-4952-a3c7-c2b0a652552a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6fa32daece2d40c39f286dbb440ed1a2_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItMTAtMS0xLTM4MTI5_56985105-bfc4-414e-be21-21f515df329b">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia68188d7927a49d199519c9b6b2e7235_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtMi0xLTEtMzgxMDI_68370098-74a6-4b82-bd88-0198fd32f9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtNC0xLTEtMzgxMDg_cd5ba5f5-5684-4021-a93e-650e327314f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtNi0xLTEtMzgxMTQ_97b806d3-7a46-42e9-a431-fdaa064a8d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtOC0xLTEtMzgxMjA_955ad290-ec55-4261-b5ac-d241e5c138e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtOS0xLTEtNDAyNjM_855b6d2e-5df7-42c1-bdf3-daeb4af2cbc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id4e7f92a2efb4119907ab206e3174d4a_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtMTAtMS0xLTM4MTI5_6e5a722f-7a38-4061-86bc-fdc7f7ba9898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtMi0xLTEtMzgxMDI_5a379dbc-9bec-4283-a68f-7cbb8feb80f4">717</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtNC0xLTEtMzgxMDg_b9ae792a-6f34-4d27-a7d7-c8f5b72ec72e">5</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtNi0xLTEtMzgxMTQ_d6097d0e-603b-418f-9e81-0ba1e98fe2a1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtOC0xLTEtMzgxMjA_d3299520-73f8-4a4c-981a-bd187b5a1166">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtOS0xLTEtNDAyNjM_6c1a8511-9c9e-4e10-bb65-4ac40f3c320d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i73b9b382940d4e8fa4efbc37ae851522_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtMTAtMS0xLTM4MTI5_eb028d0c-1b04-4379-bf38-4fe88dc07d9d">722</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id7046c37f9b34feca0220aebcdc2b9d6_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtMi0xLTEtMzgxMDI_d243aa3b-5506-4524-ae29-d88fff816e8b">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtNC0xLTEtMzgxMDg_b0a67325-5464-44dc-b885-1789691d2306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtNi0xLTEtMzgxMTQ_637043ab-cf4e-4b33-8b67-32d06c19fd78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtOC0xLTEtMzgxMjA_859ab1d3-c0e3-45d2-9efd-7987a7760ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtOS0xLTEtNDAyNjM_34fcb6b3-a232-42b9-bea8-1c30a83ed5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id1c5ada34f4342ffbb24c0ed227de3b9_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtMTAtMS0xLTM4MTI5_0c111881-8414-4756-8176-1aec6ba5f91e">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i00d268a8bc3d448db012d4136f9d9326_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtMi0xLTEtMzgxMDI_c823a5b3-7b6e-4bb2-990f-2919a2638652">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtNC0xLTEtMzgxMDg_a3605481-8202-45fe-8e2a-493447ea94a8">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtNi0xLTEtMzgxMTQ_a4926ca8-7ae0-44dc-ac05-95b36f9f3b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtOC0xLTEtMzgxMjA_4bdd1972-aa2d-43ca-9325-73ce05b62227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtOS0xLTEtNDAyNjM_0f89f3c5-c1db-4a83-a530-d4829efadf57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifc3d1f32ff2c425093e40400c4b37239_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtMTAtMS0xLTM4MTI5_6ab96ee8-da18-4f03-b8be-6360c431275d">652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctMi0xLTEtMzgxMDI_1e0b9440-475b-4cb1-b90f-2a8280292a3c">695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctNC0xLTEtMzgxMDg_0eee4192-bf32-42da-96ca-61d3505e7def">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctNi0xLTEtMzgxMTQ_8cf32ee6-eaff-4c08-a667-58e1ea53add7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctOC0xLTEtMzgxMjA_18c98519-e6fa-4bf1-a2b7-9f3b2365a1c6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctOS0xLTEtNDAyNjM_6869d565-d1f0-4296-9af6-c3374f9a15d1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctMTAtMS0xLTM4MTI5_e8a6eb87-4d48-4216-8e01-55c35bac55bb">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtMi0xLTEtMzgxMDI_31a022e0-2793-4d19-9e7a-d7ee1663aa4c">21</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtNC0xLTEtMzgxMDg_f816f082-f2c9-4789-b17e-a3caeb777208">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtNi0xLTEtMzgxMTQ_506d1cff-8f1a-4cae-9b62-9f8b50299d9f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtOC0xLTEtMzgxMjA_9e469498-9084-4812-9b75-0ab57bd38811">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtOS0xLTEtNDAyNjM_50452a2b-b57b-4078-a8d2-43f994a644b1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtMTAtMS0xLTM4MTI5_c2e4a4ea-67f0-4c90-af94-94449ec53130">4</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.67pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:28.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i22135b3300e048769f42cc9088154762_I20191231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtMi0xLTEtMTE5OTk_e4bcce90-0682-4134-9f70-a2ee10bd47e1">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtNC0xLTEtMTE5OTk_674083fe-15a8-4c35-aeb6-7de947b615db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtNi0xLTEtMTE5OTk_0194deec-418f-43f9-bb29-09e0f23a173d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtOC0xLTEtMTE5OTk_c9321b3e-8046-4145-945a-68fa0d8a88b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtOS0xLTEtNDAyNjY_9ab3d4fe-d685-4e3b-8311-198548fda414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtMTAtMS0xLTExOTk5_1d96f199-ea69-4f4c-9f40-64da766f6e8e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i661079bae5984baa83e48cf8bf2e0ca0_I20191231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItMi0xLTEtMTE5OTk_0ed4832e-eb49-4fcc-8a16-26287c188d23">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItNC0xLTEtMTE5OTk_47c1ed75-33f7-45a7-8a56-a4897ca219c6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItNi0xLTEtMTE5OTk_dcb40384-1beb-465e-bc5b-9c4137ceb989">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItOC0xLTEtMTE5OTk_eb865029-7403-4a31-81e1-bbaee540139b">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItOS0xLTEtNDAyNjY_a76deca5-0a68-491e-8cfd-5f31ddf39d64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia618a699065e48f1b3d3352fbfb17118_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItMTAtMS0xLTExOTk5_13201d1d-d6ff-4287-a22e-a3a33a0ee08b">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if3447f0049044af6945782db9521890b_I20191231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtMi0xLTEtMTE5OTk_6ed6e41e-72c8-4d96-a9f9-d6f91c04b374">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtNC0xLTEtMTE5OTk_8605d0f1-473c-4d63-a39c-7f01baae7142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtNi0xLTEtMTE5OTk_06c8bfa5-b890-4ef8-892b-5f52df3620fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtOC0xLTEtMTE5OTk_9a5d66f8-cc18-4d4f-9767-8d0bfd64acd7">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtOS0xLTEtNDAyNjY_5d31f4fd-1705-473d-8c88-3ba169aa006a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia68188d7927a49d199519c9b6b2e7235_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtMTAtMS0xLTExOTk5_a31836fa-8da8-4fb7-b2c8-bd27ad4df455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i643b965508bf43d4a88c27237bc3b7fb_I20191231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtMi0xLTEtMTE5OTk_f4a2b2a1-4f86-45a2-9a18-acad5003d52b">710</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtNC0xLTEtMTE5OTk_c5d3b519-078b-4226-9978-192811d3ba21">11</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtNi0xLTEtMTE5OTk_09db3bda-445f-48bf-aab1-23561c815af9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtOC0xLTEtMTE5OTk_fade04c5-58a3-463d-8653-2221a6226ecc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtOS0xLTEtNDAyNjY_a64aedf2-e22a-49b0-b7b1-ead7af25bc2d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtMTAtMS0xLTExOTk5_5f183906-a17f-47f8-947a-c66e1804cc67">717</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i02245261c2374bc991f32f8bc9d1afd3_I20191231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtMi0xLTEtMTE5OTk_2e0f4cf7-cfa7-46d1-a365-92b3f00c5990">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtNC0xLTEtMTE5OTk_4bb13e1c-1a3d-4c7e-b19d-18d39538d5cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtNi0xLTEtMTE5OTk_2a73d4f6-2a1b-4073-a2fb-0a3727763e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtOC0xLTEtMTE5OTk_e427bd9a-cf69-40f8-833e-96a98a52d8fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtOS0xLTEtNDAyNjY_0f79ecb1-c3e9-42e9-8742-2314a77ba68e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id7046c37f9b34feca0220aebcdc2b9d6_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtMTAtMS0xLTExOTk5_89c972c8-dc26-4576-bd2e-c8fc8ceb5563">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifc87ab6886c14a47b7ebba0f7a2fe2cf_I20191231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtMi0xLTEtMTE5OTk_99deba61-0026-483f-9b2b-c9b0d33b1958">483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtNC0xLTEtMTE5OTk_55bf95e0-e1c6-4fce-a6a3-15d393f69d3b">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtNi0xLTEtMTE5OTk_e92b64d0-9233-4a49-81c3-e953dd4c2e23">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtOC0xLTEtMTE5OTk_77bc2378-4f70-4870-930c-b16b8b39c8ce">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtOS0xLTEtNDAyNjY_567d7dbd-0dfd-4d0d-afeb-0a4d5dfc6ef4">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i00d268a8bc3d448db012d4136f9d9326_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtMTAtMS0xLTExOTk5_3c314c6d-b701-4453-b55a-555014fb943c">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i1fd5dc377e504702bf04bf3db9a706ee_I20191231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctMi0xLTEtMTE5OTk_64736178-2bbe-4bdd-b0f4-4ee219b50068">548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctNC0xLTEtMTE5OTk_653469fd-183a-4632-84e0-7150ee5963fc">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctNi0xLTEtMTE5OTk_1dd1f064-9c4d-4284-b2c6-15bb033b0a28">5</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctOC0xLTEtMTE5OTk_99e38fab-6df4-4daf-8044-ccfe2d660634">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctOS0xLTEtNDAyNjY_585bd965-7004-4fc8-b514-fb25ff409edd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctMTAtMS0xLTExOTk5_9ad46815-c808-4b02-bcfb-38b0daf9294c">695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtMi0xLTEtMTE5OTk_7f8a3665-c4d4-42ca-b8b2-190112afc8b6">163</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtNC0xLTEtMTE5OTk_2106968c-0a77-4b6b-b653-f3ef7ae1ef66">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtNi0xLTEtMTE5OTk_557f8b36-93ea-4e2b-9c36-3e3611100b80">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtOC0xLTEtMTE5OTk_bc8f136a-8a9e-4206-872f-b5afa110811f">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtOS0xLTEtNDAyNjY_403dc7c2-2923-47e9-8613-c4e356b6555b">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtMTAtMS0xLTExOTk5_077fde80-1bb1-45d8-9d80-f811e94aa369">21</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="i377d9717844147e799376babda10462f_148"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 6. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzQ_21efa347-4972-4c3c-a538-0aaf95468341" continuedAt="i28b6d06c6533411a99d69beed0674006" escape="true">Property, plant and equipment</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i28b6d06c6533411a99d69beed0674006" continuedAt="i70df71f1ff9c43c08e0972dc7ee9f38e"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzU_5ff974d4-8e29-4348-903e-527f1c7d7288" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company&#8217;s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The depreciation periods used are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">General fixtures and fittings, building work: <ix:nonNumeric contextRef="i857b522132a0476eb6dce6d1596820d4_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYwNQ_4681bf6c-2045-4d06-9ab7-421747aba911"><ix:nonNumeric contextRef="ia9fc3134a84e4b788c49a537b36f4ea2_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYwNQ_5e53b1ce-63ad-4cf1-9752-ae1977ce581c">5</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i383069cd64164d36bf3be6f4fe694362_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYxMQ_b55f42c4-80be-439f-87aa-aa09375a7343"><ix:nonNumeric contextRef="i45392436feb24c1ca988401841003b83_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYxMQ_d2068025-f985-4e18-9127-f5578274cfba">10</ix:nonNumeric></ix:nonNumeric> years;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Technical installations, equipment and industrial tooling: <ix:nonNumeric contextRef="i40f0187d0a71420b849fd1c9efa74737_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzY3NA_ecd1838d-1b14-4d7b-8081-fb84923d34b8">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i740f5b7742a3429183c226bf413db5e0_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzY4MA_1695f46e-afee-4f0a-acdd-f9ffd6754671">10</ix:nonNumeric> years; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Office and IT equipment and furniture: <ix:nonNumeric contextRef="ieec3261b213d45b7859dea5fb22ef918_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_274f2f05-7cd8-4bfe-81b2-578869d17019"><ix:nonNumeric contextRef="i3891cbb9d139409f926550e2d536f939_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_7ea86f4b-2c4f-497f-9838-6d9e51051156"><ix:nonNumeric contextRef="i081e0c1a8c8c4accb7e935ac897dcf77_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_dbbbc9bb-5ef4-4d6b-8093-873e6cc319c8">1</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i83c487a257944224b5d370f39d0697cf_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_24aa1274-e6b4-49e7-bc7f-594c8acc5b56"><ix:nonNumeric contextRef="ia058d7b209a54f6fbe029cc8f59f7699_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_9ec5f072-30e3-4112-92bf-6f60e3732e8d"><ix:nonNumeric contextRef="iada2ffdf9e7841edb4e55be9d4d3d033_D20210101-20211231" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_d9cc08fe-067c-4d75-9f19-2e1c0f917549">10</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of property, plant and equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of property, plant and equipment</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzM_a36a0505-b011-4500-a96d-40dd592e70ce" continuedAt="ib2d14b8f68ea4fe2a613cf2ea0564592" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in property, plant and equipment is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iadbefaf925c74b24a9922616c74a0553_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtMS0xLTEtMzgxOTk_6d93b14f-d811-47a9-9a0c-66f57c14c18c">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtMy0xLTEtMzgyMDY_ee4daf99-d237-4d60-a9e2-abc11f83bca7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtNS0xLTEtMzgyMTI_0a4b2650-3ca4-4657-830c-ed3f012c6328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtNy0xLTEtMzgyNDg_eca7cd6b-bde7-4b09-a5b9-47be1c9c0adc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtOS0xLTEtMzgyNjI_54294fbe-1d3e-43bd-83c9-dcfdc49fd9be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9bd3865bd72e4c6dabd994b9080949fe_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtOS0xLTEtMzgyMTk_5743b95d-0d79-4f3e-9396-8d2fe198cbf6">3,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i992fc55410f2432f87fb2d95d37cf5c7_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItMS0xLTEtMzgxOTk_d1176eac-6dd4-441e-8778-c7a71098a9f0">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItMy0xLTEtMzgyMDY_37baef7a-30c3-493f-bf7e-a11deeb486d4">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItNS0xLTEtMzgyMTI_ce08c4d0-38b6-4664-9351-6607268a0f75">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItNy0xLTEtMzgyNDg_4a57929d-db92-4871-956f-e7cc564303bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItOS0xLTEtMzgyNjI_c2a8d06c-3027-4330-a5d6-8690a11fbb62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icd26e64de5444c1f98cc675c204144c4_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItOS0xLTEtMzgyMTk_d30e8d88-6f8d-4776-acc6-5963b9d359a4">8,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i07d2744884e34de08bb1bf0f018e8367_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtMS0xLTEtMzgxOTk_77d78048-633c-4a25-be41-3ea5424b0b2e">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtMy0xLTEtMzgyMDY_b9a7c6cd-7357-4de1-8155-5976b7133bdf">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtNS0xLTEtMzgyMTI_c9654190-04b6-443a-b199-6edfebf8410d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtNy0xLTEtMzgyNDg_a93104d2-e661-400d-b144-24c25a12dfb0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtOS0xLTEtMzgyNjI_819594df-2b38-4828-83a7-7816ecbb6c53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifed0297807f94baea1c5c2d340771ee8_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtOS0xLTEtMzgyMTk_27e1ee88-7dfb-4840-815d-dfcd25350497">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i88c91a06314d44bbbde5e2e5d56195e0_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtMS0xLTEtMzgxOTk_651912b2-b32f-4509-833c-18d080839f3a">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtMy0xLTEtMzgyMDY_d766756f-364a-4b09-8806-55735dee44bc">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtNS0xLTEtMzgyMTI_6c6720cc-a1dd-45d4-85c6-e76db0c22043">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtNy0xLTEtNDAyNzY_baf947b1-c5e2-4d8c-84a1-5736fb677873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtOS0xLTEtMzgyNjI_4a60622b-a68b-448d-900d-1ab61d038434">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8472a834d7c6410ea1e767fc3c34d64b_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtOS0xLTEtMzgyMTk_52ead060-e16d-4ac8-8926-625542f52666">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i680d6b18b0404cd387ee4220cef45346_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtMS0xLTEtMzgxOTk_58f254cd-7a58-4171-b3de-834aa28e8cf0">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtMy0xLTEtMzgyMDY_855b3452-000e-4ec6-8cc4-ab1246934665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtNS0xLTEtMzgyMTI_23aa7cac-81b3-4f8f-b67e-06cfbde95b8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtNy0xLTEtMzgyNDg_d0fa5d08-b6ca-4ba3-87c6-18c19d89d8d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtOS0xLTEtMzgyNjI_75605737-31ff-4e79-bf79-0994056f450d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idc67e0cf8262400995ad31c3fea9c892_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtOS0xLTEtMzgyMTk_233a76c8-444c-49d4-9ed2-38d712f494be">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie6598955ac8a492fa0a7949b58b5e311_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtMS0xLTEtMzgxOTk_08f63313-d1e9-4b48-84f0-fed7d72b4247">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtMy0xLTEtMzgyMDY_d60f4a70-c609-4577-87a6-86163dd040dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtNS0xLTEtMzgyMTI_04949d60-1e12-4c57-9ce3-13f5bdee28b9">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtNy0xLTEtMzgyNDg_99f4c5f1-1588-4c9d-856d-03ba7bc9b297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtOS0xLTEtMzgyNjI_00335c4f-0fb9-465d-97ca-6c7f8b514788">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2612520a1a2840a7a26c63194c557e76_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtOS0xLTEtMzgyMTk_4005f061-881f-4ff7-8461-07d2f0dfdc0b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i79f8b941671b4fc5b254babe62d0b548_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctMS0xLTEtMzgxOTk_e9e0bf13-538c-4a72-bf19-72bc8aff63d3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctMy0xLTEtMzgyMDY_5c0c0c2a-71bf-4a7b-86de-eab73ede0be2">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctNS0xLTEtMzgyMTI_4ac93a54-70b1-4c0d-82a5-1b7e504b7b60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctNy0xLTEtMzgyNDg_ea38112c-0c9f-4434-8bb9-201e0b736836">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctOS0xLTEtMzgyNjI_5143f888-94ad-4967-a083-06e42dae4a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i24fe0f143f954dc68e1ffd022dae5517_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctOS0xLTEtMzgyMTk_81c0d6e6-63a8-4666-8615-ab37f8d193d4">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbf6a969f3a946aeb176967ed73299f1_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtMS0xLTEtMzgxOTk_2dfae60d-0d76-472a-843f-faf70d632cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtMy0xLTEtMzgyMDY_e35fb151-f16e-4da3-9acb-aa81ceed5f5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtNS0xLTEtMzgyMTI_f15b559e-dacc-4313-800f-588505ee45ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtNy0xLTEtMzgyNDg_46201a58-6ef7-4142-adb5-2dbf23db2100">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtOS0xLTEtMzgyNjI_038c7990-3fef-454c-a207-cbdb625f222c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i065694e284ad457594585f67d682acd4_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtOS0xLTEtMzgyMTk_94d269ea-6d47-4495-9c9a-86bcba6f5e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktMS0xLTEtMzgxOTk_51af0f83-4f0e-40b7-8664-add919269f39">13,630</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktMy0xLTEtMzgyMDY_7e157ef5-7100-4d69-b9ac-798247a83f02">1,590</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktNS0xLTEtMzgyMTI_d1cedf53-33f1-42ec-8e6d-ad82e3fe2ddb">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktNy0xLTEtMzgyNDg_43e40e9a-1cc8-4892-867a-6dd8422f0389">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktOS0xLTEtMzgyNjI_732cecfd-89de-4f94-b8f0-8d1982af392c">8</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i73b9b382940d4e8fa4efbc37ae851522_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktOS0xLTEtMzgyMTk_b9951e1a-64f1-45d3-a1d4-69be4ff7a1d8">15,017</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTEtMS0xLTM4MTk5_f6d99db8-7dd6-456a-8afd-3f230f8a0901">1,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTMtMS0xLTM4MjA2_2a8d88d2-cf40-48ea-9fff-0db71e658197">320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTUtMS0xLTM4MjEy_5c14d490-2373-4a7f-a1cf-8b197100355d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTctMS0xLTM4MjQ4_0bef5d9b-657a-4508-9a19-09f06e10d2e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTktMS0xLTM4MjYy_28e612b3-57e5-4be5-8435-7a6f276c72bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i79cd2925606d4aafab7f52373500d486_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTktMS0xLTM4MjE5_65b1283b-88d6-4a01-889d-ad33a6ecc9df">1,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTEtMS0xLTM4MTk5_25b264ae-7f09-4536-8528-8e2b52d08184">1,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTMtMS0xLTM4MjA2_39964bf3-ef4e-4920-a1c3-9addce883fde">901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTUtMS0xLTM4MjEy_c14cb4a0-cd75-4865-b476-e89e3e5a6029">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTctMS0xLTM4MjQ4_08aabef9-ea86-49fc-8e54-1bb502f77a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTktMS0xLTM4MjYy_5527c6d7-d295-4107-8518-ad6a6a571d2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibb76dbf343af4ef7a2d493513ebc63dc_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTktMS0xLTM4MjE5_fa4828c6-6da3-4591-804a-853664958cb7">2,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i94439a4b662842c2acd86680522e2018_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTEtMS0xLTM4MTk5_16024f5b-5f54-46ac-9916-2644928dec51">1,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTMtMS0xLTM4MjA2_40acbf38-b0c5-430f-ab5e-36ab2d7edd54">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTUtMS0xLTM4MjEy_347f9d4b-84d1-43db-8940-07cc41c23387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTctMS0xLTM4MjQ4_be582a6e-bceb-49ec-8b69-64b36fd5ab75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTktMS0xLTM4MjYy_7d75b554-822c-421e-a687-be44c2655ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="if81a7b8866e64bb5ab7ac45083f0107d_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTktMS0xLTM4MjE5_a0f3437c-61ca-4252-b12c-5bdcc3caf3b5">1,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTEtMS0xLTM4MTk5_30bb2e92-8d7d-4156-ac16-92995a4983a9">783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTMtMS0xLTM4MjA2_b8a49589-9dc3-43b3-a200-8f95df6e4ed4">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTUtMS0xLTM4MjEy_df09b4d2-8c36-49a1-8249-40c5689ba37b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTctMS0xLTM4MjQ4_27a2e4fd-54b8-4e6c-a6c5-933a88edbe0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTktMS0xLTM4MjYy_cb40ff3d-282e-47c1-b0e2-c17a1dce6ed4">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i13580af0c9c0455c808971d25d9c62f9_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTktMS0xLTM4MjE5_0596d4ea-912b-46ed-8ff3-ad8bb8d8e07a">875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i170ffb1f1c9a464dac427c1aae8b927a_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTEtMS0xLTM4MTk5_394f4825-13f1-4cc0-9e31-a383ec7edfff">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTMtMS0xLTM4MjA2_e092cc8f-2777-40c7-8176-5883fb553313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTUtMS0xLTM4MjEy_c84e9963-8445-4359-9dd5-38f74fe29070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTctMS0xLTM4MjQ4_d5966d36-bcca-4c66-837e-7c5dd2c0fe6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTktMS0xLTM4MjYy_ea6847b0-2bc2-4a5c-992b-8fa2a7a9bfac">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i99b3ae8877e44bcea3e5d515c0c8b8d8_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTktMS0xLTM4MjE5_43c101db-2bc6-4656-8b7f-0baef11db24a">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ieb66730c4b2d424b843abc92b234a808_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTEtMS0xLTM4MTk5_d8e7206b-7878-479e-aad3-5128a852cc5c">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTMtMS0xLTM4MjA2_9f5e8ba1-39ab-4799-9f10-cd42b36bfcc1">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTUtMS0xLTM4MjEy_d9b5910a-08ad-4074-a69b-af1fbadb5dab">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTctMS0xLTM4MjQ4_9f218609-2e43-40c1-b28f-641efbcd6686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTktMS0xLTM4MjYy_c0538724-2793-4b0c-abee-9e4a59fdef17">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i26b0bf7b703446948688e7ad02d72cc0_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTktMS0xLTM4MjE5_32a507b8-3f04-423f-ba60-d6bb965126df">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTEtMS0xLTM4MTk5_bfca93bc-0c24-48dd-a085-bfa40d179483">5,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTMtMS0xLTM4MjA2_9bfc5ae7-b5da-4dda-9cce-cc9a282a5a0f">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTUtMS0xLTM4MjEy_4f1373bf-7306-45ff-9a81-421b511333c3">84</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTctMS0xLTM4MjQ4_60a34101-d60b-4d53-b631-d830385492a6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTktMS0xLTM4MjYy_a9549186-edea-4121-9a91-b58a38e21e75">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTktMS0xLTM4MjE5_b543f771-1979-4a45-a688-62911790045b">6,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTEtMS0xLTM4MTk5_b2fe0b5b-e552-4f59-a881-03d55808f00b">8,256</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTMtMS0xLTM4MjA2_f5e08f6a-ea4a-48b3-8bff-889fa896425d">56</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTUtMS0xLTM4MjEy_152a37f2-c77b-4c72-a26d-1ac2e44eaa04">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTctMS0xLTM4MjQ4_e55d9243-cc93-4dca-a518-10e9420eac61">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTktMS0xLTM4MjYy_3f2c0b8b-c92f-4428-a675-3ff3619a9dc8">3</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTktMS0xLTM4MjE5_0ec5e241-127e-41e7-80f1-7e79174a7972">8,186</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2021, the &#8364;<ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2MzM_4f3f036c-4223-42e8-9305-720f02e5dc58">1,362</ix:nonFraction>&#160;thousand increase in Right of use &#8211; Buildings mainly relates to the extension of Villejuif leases for <ix:nonNumeric contextRef="ie783ca6ccd7146eab501b3c72da67598_D20210101-20211231" name="nbx:LeaseContractExtendedPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2OTU_4a3b4dcd-fec0-45b1-ab44-db0188544c4f">4</ix:nonNumeric> years for &#8364;<ix:nonFraction unitRef="eur" contextRef="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2NTA_7cd79a33-627d-49a0-a64c-e7af63ed3efb">1,390</ix:nonFraction>&#160;thousand reduced by approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2Njc_112cca13-be14-4733-b88a-f5fe25cb315d">25</ix:nonFraction>&#160;thousand related to rent indexation impact. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The &#8364;<ix:nonFraction unitRef="eur" contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2ODE_19d81f81-d66a-4adc-8136-c691524d6c1d">139</ix:nonFraction>&#160;thousand decrease in Right of use &#8211; Buildings relates to the termination of a lease contract in Faubourg Saint-Antoine in Paris, France.</span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i70df71f1ff9c43c08e0972dc7ee9f38e" continuedAt="i43b61992c00b4e3f9fa6e8fa7d9a00ac"><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ib2d14b8f68ea4fe2a613cf2ea0564592" continuedAt="i0e84cd837b054868ac8266745a8c699c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaf55c96a01274951b50be727c673d9f8_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMS0xLTEtMTE5OTk_3c638b81-9d1e-4208-8533-d9aa054f537b">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMy0xLTEtMTE5OTk_86950397-b5c3-451e-916b-ae1107e9df7a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtNS0xLTEtMTE5OTk_40e92ebc-905c-4723-b684-7d17370cede8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtNy0xLTEtMTE5OTk_3b39d34c-b102-40a6-a6d5-926e7f5ad8d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtOS0xLTEtMTE5OTk_28b08ba9-ab81-4aca-8df5-44d6f6019308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iadbefaf925c74b24a9922616c74a0553_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMTEtMS0xLTExOTk5_fc79c7c7-a515-4555-9881-985734660521">3,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3fa642340f4542e7a93116c893889a2f_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMS0xLTEtMTE5OTk_56ea52d8-da8a-41d8-b3e9-8323f1bf4b4c">6,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMy0xLTEtMTE5OTk_ea712c0c-72d6-40da-8562-8223e8c8089d">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItNS0xLTEtMTE5OTk_c253a1ed-0d83-42d5-8eff-5b7202b5ec04">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItNy0xLTEtMTE5OTk_ab463ad6-e91a-438d-99d0-4c0cb01daa78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItOS0xLTEtMTE5OTk_d1576929-ff3f-4d0d-abd7-21bbdaf762ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i992fc55410f2432f87fb2d95d37cf5c7_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMTEtMS0xLTExOTk5_74fd0b42-7577-4894-ae8a-dead979daad3">7,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbdff15c03e7404a98464181c8e1cedd_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMS0xLTEtMTE5OTk_d8cf7619-d4e2-4a08-904b-a59ff54bca0d">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMy0xLTEtMTE5OTk_fa274ab7-1aac-4d4e-8aa3-b8201497b4bd">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtNS0xLTEtMTE5OTk_a84c4035-4c3a-49b0-a6b5-24d58586fc66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtNy0xLTEtMTE5OTk_f8858b67-9262-4520-a80f-4d3aa6536508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtOS0xLTEtMTE5OTk_70be5a21-c25d-44e6-8e52-2aa28615162f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i07d2744884e34de08bb1bf0f018e8367_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMTEtMS0xLTExOTk5_b344d3d1-c84b-4d16-acd1-41a2e4565bb1">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3aa22cbb09f04242898c09c6ea3dc0bc_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMS0xLTEtMTE5OTk_aa1f8d97-31db-4952-b8cc-6b8e77aa9b77">957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMy0xLTEtMTE5OTk_6a57c8d0-24cb-4199-9b43-352de4db5e98">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtNS0xLTEtMTE5OTk_db7bb4af-f4d3-41dd-9e31-9bb7a9a85c42">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtNy0xLTEtMTE5OTk_b27496bc-aef3-4e12-8e3d-f3a0aab36774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtOS0xLTEtMTE5OTk_10298080-e231-4e21-a354-2c1b6492c787">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i88c91a06314d44bbbde5e2e5d56195e0_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMTEtMS0xLTExOTk5_1af0d8d9-401f-45d5-999f-94f57af46acd">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3866b055ff984a8f95514cf68bf892bb_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMS0xLTEtMTE5OTk_b2c2071f-b381-4079-a7a6-13798771fd58">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMy0xLTEtMTE5OTk_90789e0f-fc59-4c76-a7d7-b9e930d5faab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtNS0xLTEtMTE5OTk_84dbbaac-33f9-4ebb-bc37-ce4b13a93359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtNy0xLTEtMTE5OTk_fa552e65-ad27-4a7e-b989-28daaafc2c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtOS0xLTEtMTE5OTk_05a31f39-c467-4695-8e84-cc1bc499399b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i680d6b18b0404cd387ee4220cef45346_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMTEtMS0xLTExOTk5_361f535b-0d67-4f5f-915c-77e6fdeaf086">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic272971549af47d782e5f60383a7ecae_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMS0xLTEtMTE5OTk_32b3f063-5b15-4a70-905d-f43449a25865">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMy0xLTEtMTE5OTk_39595662-d123-4e13-808d-c7e4609873d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtNS0xLTEtMTE5OTk_e3d9eba0-37e0-4195-bd1e-4bc166e59b0a">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtNy0xLTEtMTE5OTk_f84f37b3-bd52-49fb-8432-a4f5e00bc7a5">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtOS0xLTEtMTE5OTk_c3eae5e8-bfe7-4fd9-9de6-e264eb6ec255">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie6598955ac8a492fa0a7949b58b5e311_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMTEtMS0xLTExOTk5_fa7ce0c0-c43b-4fc7-ac9b-3ce538119f47">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i105222fe76b34ab481e711fb628a0ce9_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMS0xLTEtMTE5OTk_83be2e47-6243-4263-9e3b-5c6c56da373d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMy0xLTEtMTE5OTk_97711944-01ba-46f2-9598-f68df6d5c97e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctNS0xLTEtMTE5OTk_2071dccd-2a53-4839-b917-84f35f77f0f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctNy0xLTEtMTE5OTk_5cee8fb7-a0fa-4564-b2dc-2148ec8a1fc0">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctOS0xLTEtMTE5OTk_711eb901-3833-45ed-9916-f8a9caabb381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i79f8b941671b4fc5b254babe62d0b548_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMTEtMS0xLTExOTk5_85593b53-36d3-4c01-9baa-e5353f01993b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cf7ac359e404a6e813c1c0ebe727df5_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMS0xLTEtMTE5OTk_6793a472-22fb-48ec-9be5-b7103b6bb6e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMy0xLTEtMTE5OTk_b0c8fe50-2194-4843-815f-e484bc133565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtNS0xLTEtMTE5OTk_4626c25c-1f76-4a7a-8031-5c3c0797e0eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtNy0xLTEtMTE5OTk_ed4d4875-22b9-41ce-a07d-2a67e7592c9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtOS0xLTEtMTE5OTk_bce34813-e561-4c7f-b4d6-c1b635130fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifbf6a969f3a946aeb176967ed73299f1_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMTEtMS0xLTExOTk5_9b8c0f35-26ea-4ab4-b246-ee71f952cf1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i643b965508bf43d4a88c27237bc3b7fb_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMS0xLTEtMTE5OTk_cad4ece1-ed2c-47af-9d55-c6aa67bfe2d3">13,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMy0xLTEtMTE5OTk_7142755f-76aa-4112-ad68-0d71d6137c36">515</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktNS0xLTEtMTE5OTk_c7d08f23-5990-4f0e-bb38-303fd5705b49">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktNy0xLTEtMTE5OTk_aeb77ec2-f450-4caa-8eee-182a5ab9fc88">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktOS0xLTEtMTE5OTk_55181da9-8ab6-4615-8f91-c58952d4bdb0">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMTEtMS0xLTExOTk5_0d400ba5-eb01-48b0-904a-94d6aac5b842">13,630</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="idb9257083bde4c48b34295c66106f1c8_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTEtMS0xLTExOTk5_4dc738bb-e2fd-4e51-b5ed-f951c79bd261">1,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTMtMS0xLTExOTk5_4b2c667b-380d-426c-ad27-512ad7149d46">320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTUtMS0xLTExOTk5_fbfd6ace-277c-4f4c-a95d-0c348d5f19d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTctMS0xLTExOTk5_de77d1d9-2ec5-424d-920d-2dab3c9c5652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTktMS0xLTExOTk5_e232eb22-3880-40a3-93ec-322106dd591f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTExLTEtMS0xMTk5OQ_c0a49c81-f4fc-4fc4-acfa-a6b2a1f47a13">1,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i44e0a92dd7344b67b577f12968b769f8_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTEtMS0xLTExOTk5_2c9c9bf4-22ab-4bb3-82b0-55355858cda1">829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTMtMS0xLTExOTk5_46121a75-3b5d-4ae0-8cf6-d527d1123bc4">911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTUtMS0xLTExOTk5_0131f45e-a5a5-49e8-8442-8d3852bd3e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTctMS0xLTExOTk5_b85a688b-e0eb-4928-adc2-4bb28f5a600c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTktMS0xLTExOTk5_8038c2ec-0060-465f-b7ce-83a7bc1ef580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTExLTEtMS0xMTk5OQ_f03b2549-cd4a-4c54-a7e2-b55abb7fbb44">1,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="icab30071042b444a9fac05b56e56f51c_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTEtMS0xLTExOTk5_e9937a17-ea25-47ad-b8c8-39622fefe0f9">1,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTMtMS0xLTExOTk5_8823a645-b419-4800-8e0b-bf5c48479317">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTUtMS0xLTExOTk5_58d81773-d84a-4017-819e-2e3f263587a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTctMS0xLTExOTk5_4ed0f864-89ab-40bd-b2a7-a6d6f147000d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTktMS0xLTExOTk5_0c9fecb5-049f-4f3b-b372-6e018eee2694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i94439a4b662842c2acd86680522e2018_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTExLTEtMS0xMTk5OQ_f0226be5-db19-4d4a-bf13-6de13428ebd0">1,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i20937f10c0074df48fcf6aae22f3d9fd_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTEtMS0xLTExOTk5_8ef210a2-293b-422f-8495-5811d99e1097">629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTMtMS0xLTExOTk5_e06a4377-7123-4616-98f4-bdd4e7996c98">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTUtMS0xLTExOTk5_af981b6d-2c4c-4960-9698-de061a9c7007">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTctMS0xLTExOTk5_3c9bf396-e82c-46a2-ae1b-69e17f37da58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTktMS0xLTExOTk5_b5e90ea4-24cb-4697-8696-0cda199dba47">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTExLTEtMS0xMTk5OQ_9b84df3b-e2a5-4cd8-945c-e7d65346371a">783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i260064a22ba34ca4a69fe812eb47df77_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTEtMS0xLTExOTk5_7a652edf-297c-4841-ae76-05942b20079d">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTMtMS0xLTExOTk5_2a4c763b-275c-4342-b70c-ed75631cbfa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTUtMS0xLTExOTk5_1f14f61e-3744-4f2b-8bfa-ce63ceb7e559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTctMS0xLTExOTk5_8e4f69f0-c4bf-47a8-bd3a-7ca5099e5c04">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTktMS0xLTExOTk5_f7a347d9-b86e-4e22-937e-64e3604b503d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i170ffb1f1c9a464dac427c1aae8b927a_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTExLTEtMS0xMTk5OQ_4a3e6db6-a170-413d-9a49-ebe73c5e7dc1">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i910c9a241c624e01900913f0b0bdef46_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTEtMS0xLTExOTk5_7d4429ec-28d7-4690-8541-6b3dbec04b5c">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTMtMS0xLTExOTk5_97419d8a-3902-4183-8f00-dff1b364f914">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTUtMS0xLTExOTk5_900986d6-c1d2-4560-a206-8795e7ec5410">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTctMS0xLTExOTk5_7b5828d6-2a69-4712-8ee0-2e9181a4cf6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTktMS0xLTExOTk5_3fb0255b-8adb-461b-a9d6-1f373d4d8efb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ieb66730c4b2d424b843abc92b234a808_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTExLTEtMS0xMTk5OQ_54d4ef8e-af39-4ea8-9856-e898ee81db25">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i1fd5dc377e504702bf04bf3db9a706ee_I20191231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTEtMS0xLTExOTk5_dfba4653-c707-49df-af5e-377c4e4f6e01">3,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTMtMS0xLTExOTk5_512095a7-29be-423f-9336-9ce1fdc12f9b">1,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTUtMS0xLTExOTk5_23a4ef3b-b687-463a-861b-4757c41654ac">43</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTctMS0xLTExOTk5_0aab7eea-90c4-4363-9f55-4f97fc7c98b3">4</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTktMS0xLTExOTk5_0277c61c-74f7-4dfd-b539-8b1e03edb0bd">6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTExLTEtMS0xMTk5OQ_c0ea5f65-f451-4352-8338-7a3075518999">5,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTEtMS0xLTExOTk5_6a64c9ba-eca2-4752-98d3-67497b17212e">9,386</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTMtMS0xLTExOTk5_7ccb26f5-f2bb-4052-b1fb-71613b26f201">1,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTUtMS0xLTExOTk5_e6c79102-3482-434a-83f7-0882293eb2f8">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTctMS0xLTExOTk5_e617e0ec-dded-4e26-88c2-bbe2007d0b4c">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTktMS0xLTExOTk5_78402ebc-8a35-4327-8d17-c07674eec884">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTExLTEtMS0xMTk5OQ_fe2f292b-4336-4c60-a2f7-d91661af1f98">8,256</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i0e84cd837b054868ac8266745a8c699c" continuedAt="id748e4d27c9347019761968f7b8d4250">(1)</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"><ix:continuation id="id748e4d27c9347019761968f7b8d4250">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the &#8364;<ix:nonFraction unitRef="eur" contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE0MjM_ba17326c-5436-4a0f-b593-58f2b26a5cd2">418</ix:nonFraction>&#160;thousand increase in Right of use &#8211; Buildings mainly relates to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"><ix:nonFraction unitRef="lease_contract" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="INF" name="nbx:NumberOfNewLeaseContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE0ODQ_0ed2040e-cc1f-45b3-bb55-a4066afe52f0">Two</ix:nonFraction> new lease contracts: one in Rue Oberkampf in Paris, France for &#8364;<ix:nonFraction unitRef="eur" contextRef="ia7a4c79360f041e5886fda1753c164ae_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE1NTM_f8a04099-4609-40bb-ad10-caa9957c9548">155</ix:nonFraction>&#160;thousand, the other in Rue du Faubourg Saint-Antoine in Paris, France for &#8364;<ix:nonFraction unitRef="eur" contextRef="i34e3193487544206a16d163e6d8f920a_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE2MTQ_78f4fb52-b20b-4425-82d3-8b55c8b52a4f">140</ix:nonFraction>&#160;thousand, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The termination of a lease contract by Curadigm SAS for &#8364;<ix:nonFraction unitRef="eur" contextRef="i01a5d032d32a4c5aa0906fe6968d960c_D20200101-20201231" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE2NzU_45fb363c-2da5-46aa-b6db-ba99477cab5e">43</ix:nonFraction>&#160;thousand; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The addition of a parking for  the Villejuif facility for &#8364;<ix:nonFraction unitRef="eur" contextRef="i9c8540a5ebd94096aee7b210cb09c5da_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE3NTU_b0e4ab60-5b0c-44a8-9121-1c4ae1983c2b">30</ix:nonFraction>&#160;thousand, and </span></div></ix:continuation><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="i43b61992c00b4e3f9fa6e8fa7d9a00ac" continuedAt="i33bbe7a52bf44a1883044070ee11e0b4">&#8226;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"><ix:continuation id="i33bbe7a52bf44a1883044070ee11e0b4">The impact of an annual rent adjustment for the Wattignies and Villejuif leases based on the INSEE (National Institute of Statistics and Economic Studies) index for &#8364;<ix:nonFraction unitRef="eur" contextRef="i353ed3a135f54c7a972415594cd58a8b_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE5Mjk_69c5e032-8085-4dc0-bfcb-de9a81a5d629">35</ix:nonFraction> and &#8364;<ix:nonFraction unitRef="eur" contextRef="i46249c3026ff4190a1f98baf898f61d9_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE5MzY_1bb70e49-1f35-4d84-8533-92bf217b1238">15</ix:nonFraction>&#160;thousand, respectively.</ix:continuation> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i377d9717844147e799376babda10462f_151"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 7. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjY_aea83e79-6465-49b3-a1f5-48319a6bf363" continuedAt="i42925a59910e499d9eeef689f68c0833" escape="true">Non-current financial assets </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i42925a59910e499d9eeef689f68c0833" continuedAt="ib8643b55a3b94818b1565786d44982ff"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjQ_c2db5ad5-a4bf-4fab-ad8f-ab97d275e473" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current financial assets are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No non-current financial assets are estimated at fair value through other comprehensive income (OCI). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, financial assets are classified in three categories according to their nature and the intention of management: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through profit and loss;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through other comprehensive income; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at amortized cost. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All regular way purchases and sales of financial assets are recognized at the settlement date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at fair value through profit or loss </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at amortized cost </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case&#8211;by&#8211;case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="ib8643b55a3b94818b1565786d44982ff"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of non-current financial assets</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjU_cf48b695-71d5-4807-af0f-dd94be2141ea" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in non-current financial assets breaks down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:38.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">contract - </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash account</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other<br/>long-term investments pledged as collateral</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id04209b08bf44c238d4f342e917d80c8_I20191231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMS0xLTEtMTE5OTk_7c602246-0633-4c2d-9d01-e4afc1e47f13">131</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2dbdf51ff17642c88fe93c80600f8cb4_I20191231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMi0xLTEtMTE5OTk_7c002b7e-2662-47d4-8de1-eacbe3e47c22">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i694c290810ce4cc9842fae0c52f55511_I20191231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMy0xLTEtMTE5OTk_7dcf9e3b-be31-44a5-8165-e1492084b11a">399</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtNC0xLTEtMTE5OTk_a622a290-aa28-494f-a032-89df01beac4e">529</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMS0xLTEtMTE5OTk_ae5f21b5-3f2d-44a0-a90d-f93f6b7446e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMi0xLTEtMTE5OTk_c5306e1a-aad1-458a-aa32-429f1eea0dde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMy0xLTEtMTE5OTk_8833289c-757f-4f0d-960b-ef4e5ec3b3be">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItNC0xLTEtMTE5OTk_d6b50e42-8cb4-483c-9b2f-3ac9de1583db">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMS0xLTEtMTE5OTk_a5360710-ce69-4cb0-892d-f98ffca34c5d">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMi0xLTEtMTE5OTk_bbdd5bc2-4d2b-4078-9c48-9c17071f03b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMy0xLTEtMTE5OTk_1507c3f8-eb41-4be4-a602-864502388c99">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtNC0xLTEtMTE5OTk_9748dd70-f0a1-4655-b0c6-8dc2215841b1">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMS0xLTEtNTQyNTE_9aa3b6bc-c7ef-48af-999d-1d7d2a20e3c8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMi0xLTEtNTQyNTQ_97131d70-3112-4729-bf66-f429f7811cb8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMy0xLTEtNTQyNTY_05e373d2-827f-4cac-b08a-bf0245d24360">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtNC0xLTEtNTQyNTg_f73f2778-9f85-43cd-ae31-13bdeb1a89a1">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9e2c65d93df14f99b81bd99646ea83fc_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMS0xLTEtMTE5OTk_95f0ca6e-1451-4a18-b201-079110ea3f36">105</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9df395790ebc462db44260a48f7af4f1_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMi0xLTEtMTE5OTk_95697720-7214-4277-8157-5981eaf51c2c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6e942c5d9cf5421e8899afaab5b13ae1_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMy0xLTEtMTE5OTk_cdfd2a2c-0030-4e89-92d9-a75e624d2925">401</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtNC0xLTEtMTE5OTk_542a9a64-9d84-433c-ab2e-766ea72e8670">505</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMS0xLTEtMTE5OTk_6c627db0-14b1-4a59-bb96-f17f875eeb09">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMi0xLTEtMTE5OTk_a6a0025d-6236-47b1-aa58-619d500def8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMy0xLTEtMTE5OTk_64e91d8a-46d1-4412-a0f6-e66d5ebd6150">9</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtNC0xLTEtMTE5OTk_c94aa526-5abd-442f-86de-81b79645ed00">9</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMS0xLTEtMTE5OTk_5cf5394b-0afa-4428-8bad-c5fd87ed2cd8">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMi0xLTEtMTE5OTk_d43a8e9c-5daa-4e1f-babf-958e7b7b8a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMy0xLTEtMTE5OTk_cc0d44b5-3756-413e-98a1-ecc2464472d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtNC0xLTEtMTE5OTk_ad70ea79-2539-4218-9803-d149e687fdfc">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMS0xLTEtNTQyMTI_9ea6cdb4-f799-44e6-a944-5a0f877088f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMi0xLTEtNTQyMTQ_454812ce-371e-4ab4-b86b-21c2c56d7ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMy0xLTEtNTQyMTY_c99297f7-a9cc-44ed-8a7c-785704ee50ae">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctNC0xLTEtNTQyMTg_97623bb0-52a6-4309-831d-20a880fb6a0c">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMS0xLTEtMTE5OTk_2b7de101-d89a-4cf2-b476-97bf293cc401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMi0xLTEtMTE5OTk_933f2e31-d831-461c-b2ea-926297a7f4b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMy0xLTEtMTE5OTk_c5d656d1-d2aa-4985-bbef-e1322db0fa93">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctNC0xLTEtMTE5OTk_f5faab1e-3925-4e06-8fa9-44bd1de34bbd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i937f4bc37d82433796fe6b3c4ec0ccb2_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMS0xLTEtMTE5OTk_f70e10ca-334c-4b99-bde9-075826f3fd4f">98</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i589f8e8059664ca486811bb10b3d5162_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMi0xLTEtMTE5OTk_c8072727-7266-4c91-a428-9393bb601d45">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2b861ae5f68a416d8f8db4e710c14707_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMy0xLTEtMTE5OTk_6cc6ad68-2463-4e29-addc-52fc910d4410">421</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtNC0xLTEtMTE5OTk_51ffa97f-edc3-4a1e-9aac-81012b7a064a">519</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See note&#160;10.2 Treasury shares</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, non-current financial assets increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzM4Nzc_45783706-6074-45eb-a919-bd5ac1eec0de">14</ix:nonFraction>&#160;thousand compared to 2020. In 2020, non-current financial assets decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzM5NDk_9456723a-be01-4c0d-83b4-9035ce086742">24</ix:nonFraction>&#160;thousand compared to 2019. In 2021, the security deposits paid increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQwMTk_2aeacbb5-2198-49bf-a20f-bad4dec8a0d2">20</ix:nonFraction>&#160;thousand, mainly due to a &#8364;<ix:nonFraction unitRef="eur" contextRef="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQwNDU_097ff86a-8f13-4dbb-8cb9-25481e9c0b01">9</ix:nonFraction>&#160;thousand deposit paid in connection with a new Nanobiotix Corp  headquarters&#8217; lease contract in Cambridge, Massachusetts, United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The decrease of the liquidity contract &#8211; cash account corresponds to treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of change in shareholders&#8217; equity.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i377d9717844147e799376babda10462f_154"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Note 8. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4MzE_8aa2a968-9ff0-4ebb-824b-7293af8af4b7" continuedAt="i9ef5f88333fa4c92aa5ee1589a1f2086" escape="true">Trade receivables and other current assets</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9ef5f88333fa4c92aa5ee1589a1f2086" continuedAt="ic5ac316e9c1d4cd19b1268b66467e4c2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for trade receivables and other current assets are described in Note 7.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">8.1 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjc_87f0672c-624a-4abd-95c4-d0db69d13ef9" continuedAt="i8f1548f4c353486682b7e8ccd51ec35e" escape="true">Trade receivables</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"><ix:continuation id="i8f1548f4c353486682b7e8ccd51ec35e">In 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.</ix:continuation></span><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjg_0a045c48-c8e9-4b3a-adc9-a71137b1db11" continuedAt="i8e62fad0052b4d96a4a48ca8cbb11323" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzItMS0xLTEtMTE5OTk_00489592-3deb-450f-b962-39667d57857b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzItMi0xLTEtMTE5OTk_fa8cb2cc-ce17-47ec-88d6-9b25df050364">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzMtMS0xLTEtMTE5OTk_cd43cc1c-b03c-45d4-b79f-e2297dab83be">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzMtMi0xLTEtMTE5OTk_e9f2edf7-b8b0-4080-8736-56aeb20e6f00">62</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div><ix:continuation id="i8e62fad0052b4d96a4a48ca8cbb11323"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables break down as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in 3 months or less</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i23b8abb72e0b4536a6fe80c714c03c32_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzItMS0xLTEtMTE5OTk_558882e4-c680-431b-99ae-3ecc687bf9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i45a5ffbbe08f4f37926998b489baeab7_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzItMi0xLTEtMTE5OTk_18080005-274f-4f66-be1f-8803d271c260">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 3 and 6 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i92d57836a46444b38c01d05737626c40_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzMtMS0xLTEtMTE5OTk_d6aaf4db-3f7d-450c-ad1f-4309d2d80797">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i75abd63d3d554d209254ec0fe3788db5_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzMtMi0xLTEtMTE5OTk_1d365415-6e66-466b-8053-64fde20fb123">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 6 and 12 months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7fa06ae2654e494ca242be8b5638282c_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzQtMS0xLTEtMTE5OTk_7bb5b433-3736-4afd-b452-cecf86e91c06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6259fe63f29c47ceb1ee63617d3f873e_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzQtMi0xLTEtMTE5OTk_e6d2bec3-f224-411b-99e9-e9a840c7fa3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after more than 12 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i897163af67de42779bade9156e460371_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzUtMS0xLTEtMTE5OTk_c45349f3-1251-436a-90ab-eab6fea71d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iab0221939eca477097e1a9493a0df475_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzUtMi0xLTEtMTE5OTk_2806be42-572b-427f-9b08-fb4586bf00a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzYtMS0xLTEtMTE5OTk_5ffc96cc-8fb4-403a-826f-494bd0b89272">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzYtMi0xLTEtMTE5OTk_bf345180-466a-40df-b663-4cdad69bfdcc">62</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">8.2 Other current assets</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjk_912f4b1e-f499-40ab-b950-6829533fa0de" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other current assets break down as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzItMS0xLTEtMTE5OTk_8b640065-aea2-44f2-94a7-c8d082dfb805">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzItMi0xLTEtMTE5OTk_3cd7fd6b-42e7-4705-a88e-df6e43cf8d34">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzMtMS0xLTEtMTE5OTk_8b83bd4b-e365-4698-93bf-75898fa9ea27">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzMtMi0xLTEtMTE5OTk_8c8559aa-0e85-48e8-852b-7d79d44aedaa">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzQtMS0xLTEtMTE5OTk_dec04910-33c1-4e5b-8b6c-8461bc46451a">2,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzQtMi0xLTEtMTE5OTk_f5c3f551-58fb-421d-9b1e-0434213a679e">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzUtMS0xLTEtMTE5OTk_b8acbe1c-2715-4ae6-ba1e-1a39aad9337f">3,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzUtMi0xLTEtMTE5OTk_639e1ebb-0625-463c-bc8c-3cdacbfa309b">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzYtMS0xLTEtMTE5OTk_ee5ab99e-bb4d-4010-8d92-55f21216f91f">9,139</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzYtMi0xLTEtMTE5OTk_5f08e772-766a-44ed-9ca5-b3d846877e14">6,035</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, prepaid expenses mainly relate to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">research agreements related to the MD Anderson agreement (see Note 4.4 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for &#8364;<ix:nonFraction unitRef="eur" contextRef="icfe58517db324e8ab08832232c673117_I20211231" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzY2OQ_c10abdbf-767e-4262-90fc-7fd3522f1022">1.0</ix:nonFraction>&#160;million, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">insurance related to the Directors &amp; Officers for &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-5" name="nbx:CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NDc_7663f617-0d47-4ee0-a334-9b166c84a974">0.6</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2020, prepaid expenses mainly relate to research agreements related to MD Anderson agreement (see Note 4.4 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for &#8364;<ix:nonFraction unitRef="eur" contextRef="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NjE_6fe292e4-672e-4531-bc7c-799c00a23998">1.6</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Other receivables mainly comprised advances paid to suppliers in the amounts of &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NzU_721fe126-7863-425a-876d-f704e4ddacd6">3,043</ix:nonFraction>&#160;thousand as of December 31, 2021 as compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2OTI_08cf71ca-f52e-4b83-8a9c-8427992ac86c">805</ix:nonFraction>&#160;thousand as of December 31, 2020. This advance payment is mainly related to the new ICON contract signed in 2021 in conjunction with the launch of the 312 study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research tax credit </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives a research tax credit (Cr&#233;dit d&#8217;Imp&#244;t Recherche, or &#8216;&#8216;CIR&#8217;&#8217;) from the French tax authorities. See Note 15 for additional details on the CIR research tax credit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The research tax credit for 2021 was &#8364;<ix:nonFraction unitRef="eur" contextRef="iab6584aaa34740b0aea5f3a15d522bf5_D20210101-20211231" decimals="-5" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0Mzg_415f111d-0225-4ce6-8124-53531af2a847">2.5</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="i89b95576d1404490b4202945e6c02016_D20210101-20211231" decimals="-5" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0NDI_5e9e82dd-1f7c-4e37-88fc-7d59c446faac">2.3</ix:nonFraction>&#160;million for Nanobiotix S.A. and &#8364;<ix:nonFraction unitRef="eur" contextRef="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0Njk_b5aab002-a6d8-4361-8894-dad581ab856b">218</ix:nonFraction>&#160;thousand for Curadigm SAS), while the amount for 2020 was &#8364;<ix:nonFraction unitRef="eur" contextRef="ifdc4df3987ae442da01b94c5efbf38f7_D20200101-20201231" decimals="-5" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1MjE_c3ee4566-0e2b-4725-bf5c-f5dfa4bf7151">1.9</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231" decimals="-5" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1MjU_51da2482-11c0-4163-91ac-b52974750e21">1.9</ix:nonFraction>&#160;million for Nanobiotix S.A. and &#8364;<ix:nonFraction unitRef="eur" contextRef="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1NTI_7e9c130b-2148-4cf1-8927-9efe3c70d5f6">69</ix:nonFraction>&#160;thousand for Curadigm SAS). </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="ic5ac316e9c1d4cd19b1268b66467e4c2"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The 2020 research tax credit was collected by the Company in November 2021, while the 2019 research tax credit was collected in July 2020.  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4MzA_49028e51-19a4-4665-9cee-12da35d7a092" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in research tax credit receivables breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzMtMS0xLTEtMTE5OTk_1686af2e-8dd3-4040-8cc2-6a23c291e2e6">5,688</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2018 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4e0a8e1adc2f4d8daeb375e78b79e118_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzQtMS0xLTEtMTE5OTk_6d71983b-3205-47f3-84a3-fd4e5d353418">3,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="icea5a1f000274c7aa5aec8d463a011bd_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzUtMS0xLTEtMTE5OTk_2b164b49-b950-4952-b952-b58bfac413ba">2,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i3549effa38bf42068215a5f6e7f44599_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzYtMS0xLTEtMTE5OTk_759c70c5-30f5-41cc-ba0c-e1a1e0cd5a38">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Nanobiotix SA </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzctMS0xLTEtMTE5OTk_c28d59cb-9131-4492-a49d-a46ee487a721">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzgtMS0xLTEtMTE5OTk_663e76b9-08e5-4b9b-8c6d-b5fe978c75ba">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMTE5OTk_a2418f1d-2f50-4c8e-8c5b-9ce6ca236597">1,927</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2a3d9c879e064e8595cbe98b04ca6d30_D20210101-20211231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzgtMS0xLTEtMzg1OTg_b9b3d26b-7025-4aba-8756-8b4e99fa973e">1,858</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i9d3f9bb9f0f14b24babfb6bd054d8acf_D20210101-20211231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMzg2Mjc_0219cb54-5799-489a-aa23-426f12406617">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89b95576d1404490b4202945e6c02016_D20210101-20211231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzEwLTEtMS0xLTM4NjI3_77d036f3-5dcb-4bb7-8f41-e66d90723dad">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231" decimals="-3" name="nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMzg1OTg_89100031-39f5-46d8-b9a0-6f7ce7945e15">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2021</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzEyLTEtMS0xLTM4NTk4_aa12207a-9917-4bd8-812d-e4868ed98b82">2,490</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i377d9717844147e799376babda10462f_157"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 9. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDc_8c48a555-9e30-41b5-a1fd-57885d35a575" continuedAt="i0ec10982fd9d47a19dbaf99cdfadc334" escape="true">Cash and cash equivalents</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i0ec10982fd9d47a19dbaf99cdfadc334"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDg_5d34313b-2519-4424-962f-92296a1e5310" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are measured at amortized cost.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDk_17effd42-529f-42ac-b295-c3d3618f09be" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of cash and cash equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzItMS0xLTEtMTE5OTk_ec459d9e-5966-4a1c-b1de-4f174e872f8a">83,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzItMi0xLTEtMTE5OTk_7bd6af5d-b971-4e39-8510-edeb12516c0c">119,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzMtMS0xLTEtMTE5OTk_8e4904e6-41d2-453e-8f66-8b44e95f2525">83,921</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzMtMi0xLTEtMTE5OTk_7d6b2d32-9856-443d-8eec-368ccad16124">119,151</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, cash and bank accounts decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzc5OA_28d18227-8a59-439c-9d1c-aa730b4d52df">35,230</ix:nonFraction>&#160;thousand as compared with December 31, 2020 mainly due to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the non-refundable upfront payment from LianBio in June 2021 of &#8364;<ix:nonFraction unitRef="eur" contextRef="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630" decimals="-5" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM2ODM_20e85345-48e9-4cbc-b892-755b76b2392f">16.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630" decimals="-5" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM2OTg_4ebf8505-5f2d-4f7e-a0dd-3872af96fb6c">20.0</ix:nonFraction>&#160;million);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the payments made to PharmaEngine for a total of &#8364;<ix:nonFraction unitRef="eur" contextRef="ie92e58618b784d11b24590f639ec3c5c_D20210101-20210630" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3MTM_a45a275c-3499-45c4-b3ac-7f412059d9cc">5.4</ix:nonFraction>&#160;million in 2021 pursuant to the PharmaEngine Termination Agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the debt reimbursement related to the EIB loan for &#8364;<ix:nonFraction unitRef="eur" contextRef="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3Mjc_063a0153-14ce-4bcc-b45f-769a09558057">3.0</ix:nonFraction>&#160;million and to the Bpifrance loan for &#8364;<ix:nonFraction unitRef="eur" contextRef="i2bd304d054954aa8889e0379a055b796_D20210101-20211231" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3NDE_4e1037ac-b5c8-4764-ac8e-d58f03a15f61">0.5</ix:nonFraction>&#160;million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">other cash flows used in operating activities.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i377d9717844147e799376babda10462f_160"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Note 10. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQz_a76c5ad1-4914-4ed1-9838-4a8f937c7db5" continuedAt="i6fdd5bf90927446695b2e94632e86bb3" escape="true">Share Capital</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6fdd5bf90927446695b2e94632e86bb3" continuedAt="i5ae5743d741145a4b2e901e36700ab3e"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">10.1 Capital issued</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUw_16f67249-1507-47a8-a195-2ab2f2dd4525" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares are classified in shareholders&#8217; equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders&#8217; equity as a deduction from the proceeds of the issue.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUz_2a388fe4-189e-4b39-9ed3-e7f35d84ba7a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:17.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTItMS0xLTExOTk5_719d1c17-598c-4882-9789-92203b8e974f">672</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icec4369f4c7649dba76e50278de42760_I20191231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTMtMS0xLTExOTk5_68d63a0e-a1c6-44b8-9e56-cf33c260a0bb">153,139</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTQtMS0xLTExOTk5_a955337c-8083-4322-ad1e-3eaebabd08e1">22,415,039</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTItMS0xLTExOTk5_bb721aaf-3039-422d-a697-6be90b068818">9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic6d2b59cd3394eb38b1112a6d40ba562_D20200306-20200306" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTMtMS0xLTExOTk5_0da2946e-a1b4-4ff0-a36b-bf975bf9fb80">0</ix:nonFraction></span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTQtMS0xLTExOTk5_4abf29c8-3464-4b18-ba7f-58d9445982d1">316,083</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 24, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibfcb03f93ca547db9f9c30453f57d130_D20200624-20200624" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTMtMS0xLTExOTk5_06d9c07a-7a1c-44dd-960f-518d638c40f3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 26, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icd06ab95cb464cf7ab36d088f33b9b5c_D20200626-20200626" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTMtMS0xLTExOTk5_f567c194-60d6-4676-894a-998187953f16">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 29, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibccb3f7b5d984a47977843563136cbfd_D20200629-20200629" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE3LTMtMS0xLTExOTk5_fefc06c5-44aa-48f4-b6fe-3f02578c46be">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia1db8fdf89004094a84398a37852bd32_D20200630-20200630" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE4LTMtMS0xLTExOTk5_f9f4b1b8-adf8-41ed-b03f-3eff56587dfe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 27, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5449b75fc7d4fbda4157cb2026ec2f5_D20200727-20200727" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTQtMS0xLTExOTk5_50d0fa06-31ca-4dbd-9495-25d1a19d89f5">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTItMS0xLTExOTk5_abbe75dd-f940-4b85-b3d9-5697b3381293">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTMtMS0xLTExOTk5_cb324179-e252-485e-8acd-4d19a8af2366">20,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTQtMS0xLTExOTk5_83adb8b1-aa64-4d68-ae42-3c0e5236eabe">3,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIxLTMtMS0xLTExOTk5_e54b2864-fcc8-48e6-9824-aa8a0a591ed1">1,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal &#8364; - Nasdaq (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i263948c1f81b493eb8cca425bcebfa1d_D20201216-20201216" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTEtMS0xLTExOTk5L3RleHRyZWdpb246ZGU0ZjJjOGU3ZjQxNGFhZWIxZjMyNmE0ZjUyZThlMWFfMTY0OTI2NzQ0MTczNA_63f41789-fdda-4875-9fd2-4cec62703778">11.14</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTItMS0xLTExOTk5_b9c1aab0-bc90-41d7-a84a-c6ac00bb1092">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i61be2d4b393849cc9560e858d770a26c_D20201216-20201216" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTMtMS0xLTExOTk5_f022c799-e9de-4ff9-ab49-0b1e79dc41f5">20,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTQtMS0xLTExOTk5_29c04428-006b-4862-97fa-b2765a118f51">1,855,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal $ - Nasdaq ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0c448e8551854ba3817ac8e0588ff235_D20201216-20201216" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTEtMS0xLTExOTk5L3RleHRyZWdpb246NDMzNzMyNmRlZWRiNDM4OWI0NTJmMDk4OWViNmY5OWVfMTY0OTI2NzQ0MTczNA_25521d28-410b-4c4d-ba8f-199ce6b1ef09">13.50</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTItMS0xLTExOTk5_d3ec4543-89eb-4334-a896-2c0b69cc82f0">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i76e354131ae34438ad0ee61bab49371d_D20201216-20201216" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTMtMS0xLTExOTk5_38b89bc0-a09a-4e5e-8f19-9dc3ecc9082f">60,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTQtMS0xLTExOTk5_2525f100-8b4d-4077-9096-f8b9c951cecf">5,445,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering green shoe $ - Nasdaq ($<ix:nonFraction unitRef="usdPerShare" contextRef="ie3c6af94c36742b38cd4e03676b70d2e_D20201218-20201218" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTEtMS0xLTExOTk5L3RleHRyZWdpb246ZDkyNGExMGQ2Y2MyNDI3NmEyNjY0MDczNGNiOGQwZmVfMTY0OTI2NzQ0MTczMg_62313a9d-c7ff-4e16-ab49-54b7d6a12cb5">13.50</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTItMS0xLTExOTk5_cd897b44-515e-472a-9e7a-4a406043fde6">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i36d5fe1d4b1c4217af0247979f91d136_D20201218-20201218" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTMtMS0xLTExOTk5_fbdc4d7d-0e2b-4d69-8a54-e6998e9c1bd1">12,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTQtMS0xLTExOTk5_34c97ee4-67de-42a0-b445-374e149d99c6">1,095,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI1LTMtMS0xLTExOTk5_01b41c90-e638-4db6-be3d-1d411b9aa0bd">9,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTItMS0xLTExOTk5_fb868060-7ed2-4fb3-8e59-12711441e3d6">1,033</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTMtMS0xLTExOTk5_361e2ba9-13c7-4975-8f28-99b8687fd00d">255,735</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTQtMS0xLTExOTk5_863ee1ba-0549-46b9-bf07-27cd8e5d87f7">34,432,122</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8de9f777ee344fac809f90733d665d63_D20210331-20210331" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTItMS0xLTM4Njg2_066df9ab-a4d2-4266-8bb9-0d82ba866109">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8de9f777ee344fac809f90733d665d63_D20210331-20210331" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTQtMS0xLTM4Njg2_6a27f53d-2769-4ae2-9f84-5f5360a68f29">24,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2019-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTItMS0xLTM4Njg2_0eaae664-a2e8-4bbb-a33c-63f50023351b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTQtMS0xLTM4Njg2_3ad1162c-cd52-4ac9-8c2a-5ecbe82321a6">369,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants attribution </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i75b881b34146431e87bbf66200b0999b_D20210420-20210420" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE3LTMtMS0xLTM4Njg2_68bbaaa0-fc91-4f94-ac7a-2701a6812fa6">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants subscription (BSA 2021)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icc02833837f240adba65b3984741f75d_D20210531-20210531" decimals="-3" name="nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE4LTMtMS0xLTM4Njg2_1997b70d-7e10-4e9b-8a5e-b8f130b96d48">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTItMS0xLTM4Njk4_ab1ec6e6-e1a6-4512-ae5a-bb679403b857">1,045</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ida63773549fb469180532f7bff7a9b6b_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTMtMS0xLTM4Njk4_1bcdc02c-0b63-4deb-8bdc-ccf7bdea4786">255,767</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTQtMS0xLTM4Njk4_2809f633-f7db-4575-a836-1917aee62e85">34,825,872</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the share capital was &#8364;<ix:nonFraction unitRef="eur" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="2" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQwMg_d11ad454-856e-45af-be6c-87600a85a731">1,044,776.16</ix:nonFraction> divided into <ix:nonFraction unitRef="shares" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQxOA_f2ea49b3-47b7-40fd-a5d3-fba3c95f839f">34,825,872</ix:nonFraction> fully paid in ordinary shares each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQ3Ng_f7877e28-8bfd-40b6-934a-c57005c1244a">0.03</ix:nonFraction>, as compared with the 2020 share capital of &#8364;<ix:nonFraction unitRef="eur" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="2" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzUyMw_46fd238d-cfff-4f7a-b866-7afb17b4dd00">1,032,963.66</ix:nonFraction> divided into <ix:nonFraction unitRef="shares" contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzUzOQ_b3e84fb0-18b3-4aa2-861c-e1fabff8a2a5">34,432,122</ix:nonFraction> fully paid in ordinary shares, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU5OA_daff3182-e6d0-4a7c-9c59-8c9f8908798b">0.03</ix:nonFraction> and the 2019 share capital of &#8364;<ix:nonFraction unitRef="eur" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="2" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzYzMQ_d4b28d0d-9eda-4437-8eee-ce40cba13163">672,451.17</ix:nonFraction> divided into <ix:nonFraction unitRef="shares" contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzY0Nw_d484cc83-0f25-449d-8ccf-e69019f51193">22,415,039</ix:nonFraction> fully paid in ordinary shares each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzcwNQ_981cbdd8-355d-41ed-ada6-79a54855142c">0.03</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, the increase in share capital is inherent to the definitive acquisition of free shares warrants related to the AGA 2018-1 and AGA 2019-1 plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the increase in share capital is mainly related to the U.S. initial public offering, which closed in December 2020. In the global offering, a total of <ix:nonFraction unitRef="shares" contextRef="ibf9ad81b51bf4c808adb6b86c14e2b1b_D20201201-20201231" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEwODQ_d9155bc9-54a3-4108-b5ac-cdd782325bcc">8,395,000</ix:nonFraction> ordinary shares was issued, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"><ix:nonFraction unitRef="shares" contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExMjg_0af665ee-442d-40c6-8d28-4617e4805ba7">5,445,000</ix:nonFraction> ordinary shares in the form of ADSs were issued in the United States at $<ix:nonFraction unitRef="usdPerShare" contextRef="i4304c8534859424ebd1d4888fc19dd31_D20190409-20190409" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMDM_8622107c-2a24-4abe-973c-c318314db700">13.50</ix:nonFraction> per ADS;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"><ix:nonFraction unitRef="shares" contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMTU_477ae558-794b-4fa4-ba13-06520d5e7690">1,855,000</ix:nonFraction> ordinary shares were issued through a concurrent offering in certain jurisdictions outside of the United States to certain investors at &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i75a906e28a874a89ade36d6366ebe2af_D20190409-20190409" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEzNTQ_4cfab22c-311e-4ca1-b799-370c612c42b6">11.14</ix:nonFraction> per ordinary share; and,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the underwriters for the global offering exercised in full their option to purchase <ix:nonFraction unitRef="shares" contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE0NjY_ea82d764-ca5b-485f-9f2b-f28a4d9a4ad2">1,095,000</ix:nonFraction> additional ADSs at the same public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib57fc815199246ce8209d327ed4e9354_D20190409-20190409" decimals="2" name="nbx:IssueOfEquityPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE1MjI_e34af335-d43f-45d4-9246-7649d0ae086b">13.50</ix:nonFraction> per ADS. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE5MTg_b797deee-4ded-45e4-a66d-87e391045ac5">10.7</ix:nonFraction>&#160;million of transaction costs had been recorded, &#8364;<ix:nonFraction unitRef="eur" contextRef="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE5NjE_d3a3ac5c-7895-4a56-8460-6b2f6d6b6dff">9.3</ix:nonFraction>&#160;million of which were related to the initial public offering in the United States, and are recognized as a reduction to premiums related to share capital. Those transaction costs were almost paid in full as of December 31, 2020. The remaining &#8364;<ix:nonFraction unitRef="eur" contextRef="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIxNzA_ccaf9ba0-4aa0-4c78-9797-fca76b4b0d08">349</ix:nonFraction>&#160;thousand were paid in 2021.</span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i5ae5743d741145a4b2e901e36700ab3e" continuedAt="i23cc545d710f40c68f1ca42145a4eb47"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">10.2 Treasury shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On December 31, 2021, the Company held <ix:nonFraction unitRef="shares" contextRef="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIyODc_3caf9d43-c9e5-4070-b8c4-5cf0c0853c70">15,456</ix:nonFraction> treasury shares under a liquidity contract compared to <ix:nonFraction unitRef="shares" contextRef="ia680b82130144ad9af8419938ca05856_I20201231" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIzNDU_74e71fbf-be96-408e-842a-d44f8edbf140">12,970</ix:nonFraction> treasury shares as of December 31, 2020. This liquidity contract complies with the general regulations of, and market practices accepted by, the French Financial Markets Authority (&#8220;AMF&#8221;), entered into following the Company&#8217;s French initial public offering in 2012. These shares were deducted from IFRS equity in the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:TreasuryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzI2NzU_648b697e-3191-4fdd-ba87-bdffde14552e">202</ix:nonFraction>&#160;thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:TreasuryShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzI2ODI_c9249744-415a-4223-8924-0ed8c7b930ab">196</ix:nonFraction>&#160;thousand as of December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">10.3 Founders&#8217; warrants, warrants, stock options and free shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for share-based payments are described in Note 17.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of change in founders&#8217; warrants, warrants, stock options and free shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company had the following type of equity plans in place: founders&#8217; warrant (BSPCE) plans, warrant (BSA) plans, stock option (OSA) plans and free shares (AGA) plans. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUx_f0f5f6ec-26a9-4080-b55f-ccda0d8cea1b" continuedAt="i8d2de18216324c05b99bc2c99b8f9503" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Founders&#8217; warrants (BSPCE)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2 </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtNC0xLTEtNDc4MDk_0466148f-86e4-45e9-80b5-8fd3f1cc87fd">6.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtNi0xLTEtNDc4MDk_0d71f6ca-4256-481d-a7fb-2d61e2ba84f7">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtOC0xLTEtNDc4MDk_16727ad6-c844-42d1-8c1f-fae2190612a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTAtMS0xLTQ3ODA5_bdec3aea-ea5b-477b-825d-b53ef8f4c1d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTItMS0xLTQ3ODA5_e69f0adb-10b8-40b7-ab08-202392beff25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTQtMS0xLTQ3ODA5_9c4578a4-b93a-44b8-834a-161428f8e2c0">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTYtMS0xLTQ3ODA5_62178a1c-e7e5-4ad3-bb7d-59429d49092c">100,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItNC0xLTEtNDc4MDk_6ef0d871-86e6-4ae2-a5ae-51cc1215b581">5.92</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItNi0xLTEtNDc4MDk_7e8c8dd6-2f4a-48de-98e9-c36687691e62">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItOC0xLTEtNDc4MDk_8e368a2d-8a87-495b-a973-d12423ae6115">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTAtMS0xLTQ3ODA5_31d59099-de5b-499e-abdb-b912b8e3e77a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTItMS0xLTQ3ODA5_fabeb0d0-4727-43c7-991d-f6741566fe34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTQtMS0xLTQ3ODA5_d401ecb0-5e66-498f-b65a-7bee55f7b775">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTYtMS0xLTQ3ODA5_7626fbbf-3d0f-40b8-9a50-5927d381ffd6">50,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtNC0xLTEtNDc4MDk_6ac940ef-5a53-4721-b9d2-213fdf640937">18.68</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtNi0xLTEtNDc4MDk_b8a09be5-7951-4e98-9573-c964ce59e7d6">86,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtOC0xLTEtNDc4MDk_ee72f9ad-74d2-44a5-ad8b-95fa03b3cded">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTAtMS0xLTQ3ODA5_b5a7d2e6-7d0e-4949-8de2-066cc13263c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTItMS0xLTQ3ODA5_5e4826ba-ec96-4b90-a46f-579f79f46581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTQtMS0xLTQ3ODA5_491fae2d-8861-4511-ad4a-801500ce222b">86,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTYtMS0xLTQ3ODA5_487add33-da2f-4211-bb87-13bbf7c8899d">86,150</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtNC0xLTEtNDc4MDk_a487ece7-6c6c-433e-8b20-a2ded5ace9ac">18.57</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtNi0xLTEtNDc4MDk_ec18b6ee-3c03-4be5-9b65-81b63f85b355">68,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtOC0xLTEtNDc4MDk_db31855a-8bb4-4742-b39e-a83affc10feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTAtMS0xLTQ3ODA5_f6fac0ac-b34b-41a1-9285-a81e8182d3c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTItMS0xLTQ3ODA5_6d48cdbc-f57c-443d-bec3-21fc14d10804">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTQtMS0xLTQ3ODA5_f9a37154-7433-4a6e-9345-b40734c360de">68,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTYtMS0xLTQ3ODA5_b06687df-9ceb-4927-ae2d-a62364b82f39">68,450</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtNC0xLTEtNDc4MDk_ed3acc92-fce0-4d39-9ce2-53d32adaf0cf">20.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtNi0xLTEtNDc4MDk_d3ee3427-6b26-47a7-8016-fd6933e040a8">30,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtOC0xLTEtNDc4MDk_8998b48b-50c9-4bc5-8213-8b35701691d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTAtMS0xLTQ3ODA5_78dd9539-8197-49eb-b36c-74d1ee936038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTItMS0xLTQ3ODA5_1e70f194-3fb7-4ff1-8d5c-5a1e35a22dbc">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTQtMS0xLTQ3ODA5_138e53db-61a4-469f-bb7a-e47de818b9f6">30,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTYtMS0xLTQ3ODA5_dc55ed0c-9726-4903-bf5f-41c19e832fcc">30,350</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtNC0xLTEtNDc4MDk_83034f26-bb08-4254-a6e0-bcd20d4ea387">14.46</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib015ff2793a347eea190254523e266cd_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtNi0xLTEtNDc4MDk_94069f30-602c-478e-be13-9263d9689d78">202,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtOC0xLTEtNDc4MDk_4ab92a61-35a8-4294-bd1b-43670f532f43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTAtMS0xLTQ3ODA5_f0a16bf6-205b-4d01-b995-045165752299">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTItMS0xLTQ3ODA5_a00ccbe3-8ae9-4d8a-a6ad-849ccdfb046f">1,776</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icbd0d6bab50d405cafa491285cc4f581_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTQtMS0xLTQ3ODA5_7d057666-48b9-49d2-84dd-620c1d15b8a5">200,841</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icbd0d6bab50d405cafa491285cc4f581_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTYtMS0xLTQ3ODA5_6fb178ee-a0ba-4948-b72e-5dfa6c9bbdae">200,841</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctNC0xLTEtNDc4MDk_c8404286-0bcc-429d-a1ac-96581183647b">15.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctNi0xLTEtNDc4MDk_e5dc618c-dfa4-40fa-92f4-e06ab9689542">180,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctOC0xLTEtNDc4MDk_fd9dc0ff-7368-4d9a-a58d-2d2443e89758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTAtMS0xLTQ3ODA5_9180c30b-0753-4170-8f69-94a645bb096b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTItMS0xLTQ3ODA5_e060f67c-eb6f-4ef4-ae9b-b218687c30e7">1,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie58d6cd769d14890874fc2f862b4fd1a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTQtMS0xLTQ3ODA5_453eb595-c19d-4621-9468-5d124cfef3ab">179,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie58d6cd769d14890874fc2f862b4fd1a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTYtMS0xLTQ3ODA5_85fe91fa-6790-4583-b09e-2bd94bce6774">179,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtNi0xLTEtNDc4MDk_1f3fea68-ea88-4264-b1b9-2808ff757f92">718,767</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtOC0xLTEtNDc4MDk_05cf151f-1c36-4573-a038-adb4d6d4a069">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTAtMS0xLTQ3ODA5_687702a5-dc8e-45d1-95d8-563cfe4fa3da">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTItMS0xLTQ3ODA5_2aaad60f-b559-4760-9737-c9e7a112bbf3">3,476</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTQtMS0xLTQ3ODA5_8be40482-4bcb-416d-b5bb-44fbfabe3a1c">715,291</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTYtMS0xLTQ3ODA5_8df03b10-2561-4b24-a76a-aa95587818fe">715,291</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtNC0xLTEtNDc4MDk_f185e78a-ed95-46c5-8a28-7c4b17fae893">6.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic4574c0827bd436bb79456dc0389b57c_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtNi0xLTEtNDc4MDk_28b9eba5-54a8-4f9d-8810-5ad3fd612f64">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtOC0xLTEtNDc4MDk_133ec948-9a74-491d-b439-299ea3906383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTAtMS0xLTQ3ODA5_085804e6-e231-4e9e-88eb-9a943e48c850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTItMS0xLTQ3ODA5_41c08c52-a68d-4490-8029-417cce332515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTQtMS0xLTQ3ODA5_8edbbd89-1fb2-46b3-b652-57754ddbf6b9">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTYtMS0xLTQ3ODA5_10865569-01e3-4e7a-98ca-d5b79cf217e6">100,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItNC0xLTEtNDc4MDk_06461126-c3dd-4056-a945-314f2d5709dd">5.92</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i31d9ddb730e24052933a829799eaa5b5_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItNi0xLTEtNDc4MDk_2b44e5af-2b70-43c4-8973-d7c7c3183d52">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItOC0xLTEtNDc4MDk_9d7384e6-b343-4a71-9ea7-47e4a25d0134">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTAtMS0xLTQ3ODA5_0b4b2750-1df3-4c94-8c05-a52c2adb41b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTItMS0xLTQ3ODA5_c408a49e-68d5-44fe-b12c-53c7d63cceae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTQtMS0xLTQ3ODA5_c912c7ff-3c31-4196-82f3-fc1f3a90a53d">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTYtMS0xLTQ3ODA5_18246923-e370-4c02-a955-90aff1c8983a">50,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtNC0xLTEtNDc4MDk_2b39d715-65ea-4f50-84c0-bca31ac6838d">18.68</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if6119076476e4da0bce1c4d855f1ae02_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtNi0xLTEtNDc4MDk_29850229-3ecf-45b3-a4f6-680f893a21d6">92,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtOC0xLTEtNDc4MDk_3243a391-0d42-4d2e-954e-c5529d1193b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTAtMS0xLTQ3ODA5_a6c11cf3-2d5c-4244-94c7-ee26eca2ec52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTItMS0xLTQ3ODA5_61829074-540e-4c48-9848-66108a4449d8">5,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTQtMS0xLTQ3ODA5_a26a79b7-8908-4934-a2b2-8565d09ef99e">86,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTYtMS0xLTQ3ODA5_81223188-75de-46e2-a400-e76daac4ac49">86,150</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtNC0xLTEtNDc4MDk_5714bcf3-7326-41ad-ba61-f84d8da2db37">18.57</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iddede090f4d14469a738de2cd2066a57_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtNi0xLTEtNDc4MDk_1f2f062e-d563-464d-9518-6ce6fd31a4f1">70,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtOC0xLTEtNDc4MDk_e90ce543-9493-4812-bdf0-af48538eb47e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTAtMS0xLTQ3ODA5_716ee2c4-d463-41e0-ab29-439b41f8d58a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTItMS0xLTQ3ODA5_7eb2ca9d-1bf6-4579-ba74-b30cfec16826">2,500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTQtMS0xLTQ3ODA5_e6929260-4cd8-471f-8c97-71e1489833e9">68,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTYtMS0xLTQ3ODA5_49ec2f26-a9f0-4df4-bef0-9d9403ce696d">68,450</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtNC0xLTEtNDc4MDk_04380e96-ca55-43d8-bf66-8b60020ec921">20.28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i76a7c7c748674e5b922e368dcd8635b5_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtNi0xLTEtNDc4MDk_d8ffd902-259a-416b-b83f-4cb41a284173">38,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtOC0xLTEtNDc4MDk_80b5ad9d-d34b-4ada-91ec-7722bcf3683b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTAtMS0xLTQ3ODA5_44c1b95e-fd4a-46ee-a596-dbb1ae45d381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTItMS0xLTQ3ODA5_f78b8f47-5df0-4e47-a383-98394352137f">7,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTQtMS0xLTQ3ODA5_5b81a6ae-01c2-4a1c-bf9d-d7aad7e1ae45">30,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTYtMS0xLTQ3ODA5_8810d12a-858f-453e-8453-5497f068120f">30,700</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtNC0xLTEtNDc4MDk_032c0da5-683c-44cf-a2ff-bf6f2ea0972a">14.46</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i07dd60f3a2d649f8b0d32174a89ec727_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtNi0xLTEtNDc4MDk_49e4d5a9-080f-4de2-b72c-4fc85e6f2961">212,969</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtOC0xLTEtNDc4MDk_d8cd7994-b0c2-4403-82d5-699e602a108c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTAtMS0xLTQ3ODA5_9a212485-f7e9-42a1-a211-3e8f97596cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTItMS0xLTQ3ODA5_db4f5d33-6714-49da-895c-fe5502ff1f27">10,352</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib015ff2793a347eea190254523e266cd_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTQtMS0xLTQ3ODA5_c71d25a3-da0d-405a-bc2b-1875d464662c">202,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib015ff2793a347eea190254523e266cd_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTYtMS0xLTQ3ODA5_6c4b347a-3d81-4beb-a2c2-b67107f09189">202,617</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctNC0xLTEtNDc4MDk_53f86fc6-6757-4d69-ab36-c18ca8790a4f">15.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3ec3ff678f124faa9cff8cf3e429be81_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctNi0xLTEtNDc4MDk_e55afcc1-e617-4182-b3d9-ca17ca1369b8">187,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctOC0xLTEtNDc4MDk_15f91ae6-7aa8-44dd-8e04-f242a35e189b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTAtMS0xLTQ3ODA5_8897890c-9a3e-489a-8032-9c41bb0b0e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTItMS0xLTQ3ODA5_459a38d3-e456-4ae9-be5f-77bcc3bf9c54">6,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTQtMS0xLTQ3ODA5_501456ae-d1ee-478d-95b1-c6c4c77966af">180,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTYtMS0xLTQ3ODA5_24b192a8-91a6-42b6-a5f6-2d281d5a5e1c">180,850</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtNi0xLTEtNDc4MDk_b6bad0bf-04e8-4fcf-8f35-05501b923c52">751,585</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtOC0xLTEtNDc4MDk_d02463be-ab18-4472-9b40-b0d4e1d39067">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTAtMS0xLTQ3ODA5_98a88556-1728-4fde-832a-bd81958d00a5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTItMS0xLTQ3ODA5_48b0d914-be58-4b12-b3a2-8b011233e42d">32,818</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTQtMS0xLTQ3ODA5_5fdaae55-77ad-4e49-92d2-722db70fdc7a">718,767</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTYtMS0xLTQ3ODA5_66903651-0377-462c-b4d9-24259edb9ab7">718,767</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i23cc545d710f40c68f1ca42145a4eb47" continuedAt="iaadd95bbd0474b8aabefebade3716010"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the Executive Board decided to lift, for <ix:nonFraction unitRef="employee" contextRef="ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NTI_04dc5e32-0acc-458a-abcb-6c4cb6e83baa">three</ix:nonFraction> former employees and for <ix:nonFraction unitRef="employee" contextRef="i0dce03cc95974732b21be1bff36d224d_D20210101-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NTM_772c906d-fd32-4feb-9f26-4deb2d73142d">two</ix:nonFraction> former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact of share-based payments on income is detailed in Note 17.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence, no new instrument became issuable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Warrant Plans (<ix:continuation id="i8d2de18216324c05b99bc2c99b8f9503" continuedAt="ib9fe31eab92f4c0f82de79f9f3a7cef1">BSA)</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="ib9fe31eab92f4c0f82de79f9f3a7cef1" continuedAt="i0fbacce804104ce4b83a7287fc2e72c6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtNC0xLTEtMTE5OTk_9424e676-2f9f-4aaa-be64-839af6bddbf2">6.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtNi0xLTEtMTE5OTk_29e57992-9ddd-47f5-ada1-805380e15689">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtOC0xLTEtMTE5OTk_c31820d7-d3b7-418c-997e-ea5c067fc8e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTAtMS0xLTExOTk5_22f2bbb9-b77f-44ef-8e35-9dd9457d6464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTItMS0xLTExOTk5_de7dbf8f-fde1-407a-b7d1-fdb6318b3c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTQtMS0xLTExOTk5_2203218c-a528-44d7-afbd-5805165e05c3">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTYtMS0xLTExOTk5_d3dba334-ce86-48a9-be8d-4d869f4fdfdd">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItNC0xLTEtMTE5OTk_2008b630-586b-4583-ac7c-a137180937ed">6.37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i510cfe19450a4049be49e84fad36335a_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItNi0xLTEtMTE5OTk_59f0a22f-b7f0-4285-bde0-106273963481">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItOC0xLTEtMTE5OTk_f89d47d2-7248-493a-8bda-f20261f11980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTAtMS0xLTExOTk5_0410f6eb-b533-4a62-a1f5-043374b025dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTItMS0xLTExOTk5_0228bf79-0183-40e5-92d9-f025b2d9755b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTQtMS0xLTExOTk5_3d01684f-a5ab-44ea-91e6-3750bd808d29">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTYtMS0xLTExOTk5_f43dd718-925e-419b-8d80-2c58014d64c0">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtNC0xLTEtMTE5OTk_6eedbb6b-991c-40b5-a55e-0412312194b3">17.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtNi0xLTEtMTE5OTk_089dd796-f0ae-4c2b-af13-8a6ab9714427">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtOC0xLTEtMTE5OTk_ad6c3b14-fcd8-46ac-94b1-1379b655430a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTAtMS0xLTExOTk5_f90183f3-fcac-4ec4-8664-f3f4c5ee9264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTItMS0xLTExOTk5_a36355f7-1471-43a9-bf0d-ec1c7c47e7d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i287ca2164109487e803ea58119f85b0e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTQtMS0xLTExOTk5_d705aebf-4874-4282-b446-f0a5a4ba9c6d">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i287ca2164109487e803ea58119f85b0e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTYtMS0xLTExOTk5_4d20e6b7-f602-44e9-9b31-4de09050888f">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtNC0xLTEtMTE5OTk_d652448c-219c-4c98-8f78-6b4f04791d4b">17.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtNi0xLTEtMTE5OTk_9c908e76-9463-4af5-87ee-0f06e94532fd">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtOC0xLTEtMTE5OTk_7febd003-1929-42c8-ab0e-cb353c1d4397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTAtMS0xLTExOTk5_52b8bded-ad40-4723-b934-6d566a4ff227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTItMS0xLTExOTk5_41a84efe-ca6a-4624-bdbe-0dc7314b8d6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i444894e06ef84e86916f0f43636239a2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTQtMS0xLTExOTk5_dbf67dea-1540-4de0-be7c-bc8cf1e20eed">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i444894e06ef84e86916f0f43636239a2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTYtMS0xLTExOTk5_a9239f32-0159-4f01-8257-dd7ea3f251a8">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtNC0xLTEtMTE5OTk_72b6a965-de72-4761-b9ba-c27dc1000ba0">19.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtNi0xLTEtMTE5OTk_7cd6e8a4-d01a-4cf0-b931-35b4dc70722e">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtOC0xLTEtMTE5OTk_bc069631-6751-472f-a2d2-fb101be3da1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTAtMS0xLTExOTk5_e91b5f67-43bb-4c32-ab27-89d01914cbdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTItMS0xLTExOTk5_69b08b66-3239-49ed-9915-5369eedc49e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTQtMS0xLTExOTk5_f5e37681-3132-4c57-bde0-379ff09abc1f">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTYtMS0xLTExOTk5_abb66f50-37f4-4b29-b31f-8510e568d4a5">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtNC0xLTEtMTE5OTk_8704bde2-45b0-48bd-b429-51755cfd0552">19.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtNi0xLTEtMTE5OTk_746682af-3f0f-4290-be96-8ae6c327ccc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtOC0xLTEtMTE5OTk_9856d3e2-563c-471f-87bc-849c2e0c8623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTAtMS0xLTExOTk5_c1ec80e8-5b5e-4c69-a3cd-021e4e5914e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTItMS0xLTExOTk5_f7d3e031-a696-4ab2-b7ad-13463f67c7f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTQtMS0xLTExOTk5_1cf94580-0526-46cb-b70f-38d965261f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTYtMS0xLTExOTk5_0388b94b-11c6-40c4-a736-9e29a7e46212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic202005056b44f91afe160b576641e45_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctNC0xLTEtMTE5OTk_20de10b8-5b2c-41fe-ae37-eaff8c3fba56">13.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctNi0xLTEtMTE5OTk_256287d0-be8b-4aa6-9c30-91bdc217e250">36,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctOC0xLTEtMTE5OTk_95d2412f-15dc-4dc8-a096-72268b8bc7c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTAtMS0xLTExOTk5_710b3907-8c4f-4a63-b488-7b82be799169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTItMS0xLTExOTk5_d86b8e1c-832e-4767-a25c-cf2e1953c7ac">36,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd6514681b0542d6ad81d4e87b9026b8_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTQtMS0xLTExOTk5_ecdc88df-e821-41d2-a2ed-a8370620a88d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd6514681b0542d6ad81d4e87b9026b8_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTYtMS0xLTExOTk5_1e610ac0-dbfa-454d-a89e-9c349b293394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtNC0xLTEtMTE5OTk_5fa185c4-21eb-4827-a89a-6c2f128a6cd8">15.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtNi0xLTEtMTE5OTk_a1594d0b-5ab3-433b-bbbe-c0c879423d57">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtOC0xLTEtMTE5OTk_104d86d7-222b-45a2-8830-1cb5470bf279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTAtMS0xLTExOTk5_4796a5d1-0be4-4b3c-99b0-f8dcdb081d4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTItMS0xLTExOTk5_0264ca0c-a955-49d2-926e-b8bce77cd89d">8,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTQtMS0xLTExOTk5_4e8703ee-b43e-4695-b26b-71fd0fb3d100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTYtMS0xLTExOTk5_44f38ae5-9c0f-479e-94ae-4ad1a041c37a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktNC0xLTEtMTE5OTk_38b395ce-fc34-4e5d-a222-edb04d361ca0">15.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i82aea750feb9452ea792b03a00878392_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktNi0xLTEtMTE5OTk_f11c7c85-2c10-4094-8fbc-8211c04c6299">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktOC0xLTEtMTE5OTk_7a755190-88e2-4f06-a3e6-0b3b312870fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTAtMS0xLTExOTk5_2405ee12-201a-49bd-a3ab-209cacda6795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTItMS0xLTExOTk5_a3530f6e-e1eb-4af8-bd33-386f4208ffb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c32baad1d584e179d05334758196e37_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTQtMS0xLTExOTk5_f1805c7f-aa75-46b9-93c2-07d31c28ba34">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c32baad1d584e179d05334758196e37_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTYtMS0xLTExOTk5_f13cd59e-f2c2-4ab7-a04a-77b1cee83f62">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTQtMS0xLTExOTk5_64df51fe-de48-44dc-9b29-43d526114282">13.55</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTYtMS0xLTExOTk5_13c44ce2-3acc-409e-9c96-9f977d157500">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTgtMS0xLTExOTk5_d025154e-e865-4e26-843b-f95d6bafcf8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTEwLTEtMS0xMTk5OQ_b2b5d5ce-a685-4d4b-b3f0-6aaabc223981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTEyLTEtMS0xMTk5OQ_74c066a1-d787-4941-b095-e273b404c1a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i185c5465e4f54321893449f2ed13c945_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTE0LTEtMS0xMTk5OQ_99164818-7b64-4aa9-894d-1625025e9e0e">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i185c5465e4f54321893449f2ed13c945_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTE2LTEtMS0xMTk5OQ_c6451e5b-4b01-4769-8a29-d8225d204e0d">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="3" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTQtMS0xLTExOTk5_ab99efae-b77c-489b-905c-2927fbbb428b">16.102</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTYtMS0xLTExOTk5_6f2872c3-c355-465a-ba9e-b9fc991a2dfd">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTgtMS0xLTExOTk5_f4b86281-0c6f-420f-8c07-629998806a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTEwLTEtMS0xMTk5OQ_3719d683-df03-4d76-a608-0bf15a2040ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTEyLTEtMS0xMTk5OQ_7ba69de0-05d6-4ae7-a67a-553505872d13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTE0LTEtMS0xMTk5OQ_b895c6ea-9931-4f7d-81e6-acb8861b3088">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTE2LTEtMS0xMTk5OQ_61014cf8-9210-4a5b-9107-67e10545f66d">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTQtMS0xLTExOTk5_c36fc305-783e-4513-bff1-9c67d9b9e3e4">11.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTYtMS0xLTExOTk5_2ee5a5c4-db29-4624-830c-421e59cb16e4">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTgtMS0xLTExOTk5_3e41bfef-275b-4f79-84ac-7dad6675bf4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTEwLTEtMS0xMTk5OQ_0c8b60ab-f5ae-41b9-8c75-8700ff5ddc8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTEyLTEtMS0xMTk5OQ_de8526a8-6f2e-4a41-9af6-d1cdf17bd93e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a196703767045b4aeaf86e08026e973_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTE0LTEtMS0xMTk5OQ_c1fd2d49-a91c-438c-8d9e-57bb165eeae8">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a196703767045b4aeaf86e08026e973_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTE2LTEtMS0xMTk5OQ_b041ce83-10ac-4336-9678-e6cec8b75f39">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTQtMS0xLTExOTk5_ae48c38f-7698-4f4e-aef9-ced139bee5d8">6.59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTYtMS0xLTExOTk5_d0671599-dcd8-49ca-90d4-2ac7690b1560">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTgtMS0xLTExOTk5_20f036eb-edb8-40a2-aed0-65803c7027d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTEwLTEtMS0xMTk5OQ_387459f2-9d79-4e0b-be02-056fd1563bda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTEyLTEtMS0xMTk5OQ_8519d6fd-4111-4034-9534-49e777909bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTE0LTEtMS0xMTk5OQ_78bf618f-be6f-4be0-9919-edee58f039ff">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTE2LTEtMS0xMTk5OQ_4fcc74a1-08d2-4c32-b8d2-389eb6ee49e1">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4ef0655661e64102ad08b456cde29404_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTQtMS0xLTQ0NTU1_01ce8787-03e8-4b90-b935-649958d5b58b">13.47</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64f2458d1e5f4672ac966ade528e91b9_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTYtMS0xLTQ0NTY0_7d2e8474-92c2-4a11-a146-f5536c107d33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTgtMS0xLTQ0NTcw_da4668f5-f8fa-4a07-a191-9219e02f1549">48,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEwLTEtMS00NDU3Ng_7361d515-3e21-4afd-a5d0-f77b8a379c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEyLTEtMS00NDU4Mg_5eae7100-17e0-46cd-b4c6-e6fa26c46728">33,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE0LTEtMS00NDU4OA_2ffd39ec-cf0f-4a51-9d95-cf3f0f8fa4d6">14,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE2LTEtMS00NDU5OQ_f45d3252-a991-4398-b362-da920342da74">14,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i590691d490654f4a9b933f3df5ec0da8_D20200317-20200317" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTQtMS0xLTQ0NTU1_eeea17c5-37a8-4866-9e5d-a5b910ba88ee">13.64</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0bb4ec8843e44af1897cc09338a3eca3_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTYtMS0xLTQ0NTY0_7972caab-5f1b-416f-a485-cba3e8f5cdac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTgtMS0xLTQ0NTcw_014071ba-2126-4b6b-a4b9-cc406032acba">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTEwLTEtMS00NDU3Ng_2b5bfcc4-3830-40d6-abfa-116787625b9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTEyLTEtMS00NDU4Mg_3233dfc1-46aa-4f01-a0b7-f24a8097c8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTE0LTEtMS00NDU4OA_1a4c3734-092d-4d49-aaed-e85a852002c3">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTE2LTEtMS00NDU5OQ_80f71609-9d1c-4095-a2a6-2e10fa3e79eb">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTYtMS0xLTExOTk5_fd6b2a4e-61cf-4e59-9979-9c362d4fab13">263,028</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTgtMS0xLTExOTk5_75f2a3e8-6bf3-44cb-adcc-a039e011a998">78,103</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEwLTEtMS0xMTk5OQ_224e727d-7cad-434e-8e83-57a32ee74c65">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEyLTEtMS0xMTk5OQ_1d773859-fe72-49ff-bc5e-9f42d879cc41">77,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE0LTEtMS0xMTk5OQ_d85e961d-9828-4556-8f4b-6a6f07f3c5a2">263,251</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE2LTEtMS0xMTk5OQ_08f10af4-aaae-4dc6-8bb6-b889bbef4cb8">263,251</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="iaadd95bbd0474b8aabefebade3716010" continuedAt="i99f9e75fd59840088c3f2a8efd797bae"><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i0fbacce804104ce4b83a7287fc2e72c6" continuedAt="iad8b5fc1e1c946b1ad6e53bdd1ba1b43"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtNC0xLTEtMTE5OTk_3e5f471c-0f10-4779-bb71-88f6dd0c3fec">6.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia368008e38064499b91b8e7a2b6fc5e6_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtNi0xLTEtMTE5OTk_5652ff9a-4ae8-470c-8d52-ad84ca76db16">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtOC0xLTEtMTE5OTk_cb98bcac-c5df-4bdd-9162-8879dfa19413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTAtMS0xLTExOTk5_4b77fa87-806d-438f-8f1e-cd680d57d71e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTItMS0xLTExOTk5_7518c94b-8c3d-44b4-a94b-50c53ebaa5b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTQtMS0xLTExOTk5_2c344954-a621-439b-af5c-780bdc86090d">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTYtMS0xLTExOTk5_72c20e61-c122-410b-8368-1c693beceb8a">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItNC0xLTEtMTE5OTk_f49f465c-f108-472b-a6ef-e97f6f887aaa">6.37</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i968789d68e624749aec48577df75436b_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItNi0xLTEtMTE5OTk_4c11a327-9079-485a-98ab-39fdfc218607">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItOC0xLTEtMTE5OTk_6a7f9861-6b71-44ce-9fb0-cc06b4717baf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTAtMS0xLTExOTk5_2851fc22-4f26-44a3-9948-f1b38a2b2c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTItMS0xLTExOTk5_a5ba0881-d32c-43d7-b330-61f9b1510eae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i510cfe19450a4049be49e84fad36335a_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTQtMS0xLTExOTk5_913e339f-6f4a-4e18-a634-325476d60030">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i510cfe19450a4049be49e84fad36335a_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTYtMS0xLTExOTk5_6ce170f3-cdae-4edd-ba4c-014a65335a42">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtNC0xLTEtMTE5OTk_acc051a5-3e94-474c-bd43-0678b120fbb7">17.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0e1ece5200db4069abd23c1d44f99b24_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtNi0xLTEtMTE5OTk_c4a8fc52-50f8-4f54-8e9e-0bd1ff86853f">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtOC0xLTEtMTE5OTk_56bf6844-60a1-4950-996f-2486fd45efac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTAtMS0xLTExOTk5_eae78cf2-c37a-4a45-9163-be461972d2bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTItMS0xLTExOTk5_b042dcd6-9a2b-4ea1-a618-936c56c558fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTQtMS0xLTExOTk5_9deb6d36-fed1-481d-9db0-17762e76422d">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTYtMS0xLTExOTk5_af1eab60-9c67-470c-8503-187a25d1fadb">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtNC0xLTEtMTE5OTk_25db0a63-dc88-4214-8bec-efe3e3b759e8">17.67</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i243c3f4181bd408d943852138fc86c46_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtNi0xLTEtMTE5OTk_9d50f003-6363-4144-9089-2f68e8f94807">21,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtOC0xLTEtMTE5OTk_1c733462-b928-44e7-bd23-bf3d2dc5fb2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTAtMS0xLTExOTk5_3eef2a50-1330-4b71-835b-8375c9024b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTItMS0xLTExOTk5_65d2fba3-bb43-489a-bc02-923e8016859d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTQtMS0xLTExOTk5_0125e7ad-27e6-4b69-a931-af5f0b3e53d8">21,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTYtMS0xLTExOTk5_4eca452e-219f-4651-8310-1ec3743fcee2">21,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtNC0xLTEtMTE5OTk_814e274f-ccc9-46cb-83c6-521dd909895c">19.54</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i67d44db1d1fd485190ead9f20de4e21d_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtNi0xLTEtMTE5OTk_ad5a422f-0a4b-43d5-8da2-94d8976b90dc">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtOC0xLTEtMTE5OTk_6008afc6-a120-460e-b5b0-e000cd3e0464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTAtMS0xLTExOTk5_578b8252-9a61-4d9e-8f40-a4ad83697c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTItMS0xLTExOTk5_48ffdfc4-960f-455f-a656-6e58ed68c647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTQtMS0xLTExOTk5_5fc45609-5709-4534-8969-cca39bc165e4">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTYtMS0xLTExOTk5_93cb32cc-25b8-4756-b590-9bf81134bcc2">64,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtNC0xLTEtMTE5OTk_3b68c941-f3d6-467e-9eb8-0dafd3ed2c62">19.54</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4d936b0e4f0c4c87887a0435daa8724b_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtNi0xLTEtMTE5OTk_77c1c73f-321b-4842-b861-a5ea245de075">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtOC0xLTEtMTE5OTk_13007f25-8d37-4a3f-9983-a8e742a3ddc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTAtMS0xLTExOTk5_f21c248b-d9f7-4ed4-a6cc-35970874a10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTItMS0xLTExOTk5_5d93dac4-d80e-4a8f-b35c-84ae6f6df7ef">6,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTQtMS0xLTExOTk5_c76e2e30-2931-4fbb-ad45-bd1ecd817906">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTYtMS0xLTExOTk5_7c084159-d5e2-4669-a95c-1ca708ecf797">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic202005056b44f91afe160b576641e45_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctNC0xLTEtMTE5OTk_40328bf6-42ba-4a5c-9ed7-e59c9b225334">13.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i365d674525a9479c8b26b35aa085cdbe_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctNi0xLTEtMTE5OTk_c1f5cde2-338c-4299-b7e5-723025fbec8d">36,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctOC0xLTEtMTE5OTk_cd77df17-ed15-4b9d-af4b-9bd85a87fd55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTAtMS0xLTExOTk5_10332c57-c5dc-48f1-a38f-1bc74d8ddc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTItMS0xLTExOTk5_7ab77017-b7a3-4a65-9b76-5d7d44daccf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTQtMS0xLTExOTk5_3a52de37-1938-4b3d-a107-3d6aa1c73ce7">36,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTYtMS0xLTExOTk5_baad64b6-7351-49c4-bf10-f4f7608f0dee">36,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtNC0xLTEtMTE5OTk_c13960ec-68ef-4998-a00c-7cabf4b0df97">15.01</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b4ed0b8dd1a49078d6c857b4f238367_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtNi0xLTEtMTE5OTk_d57755f7-deb1-4dcb-bb34-06c2405e8b88">8,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtOC0xLTEtMTE5OTk_37345749-f89e-4f33-a694-b9456f4de40b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTAtMS0xLTExOTk5_1ed24f8e-2129-4803-a596-8bdfff95144a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTItMS0xLTExOTk5_56fc97ea-aa8b-4679-b434-800d69f566cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTQtMS0xLTExOTk5_af0d0c98-d0e5-485a-a121-a8bcf4390946">8,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTYtMS0xLTExOTk5_51dbe066-e70f-4fe4-8ae8-f74bc4ccd8b7">8,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktNC0xLTEtMTE5OTk_2364cb49-94a5-4fdc-bfe2-e24af1691786">15.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i637bf676e3a04e68824daeb6b1575335_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktNi0xLTEtMTE5OTk_76e78afe-6cd4-486c-8f0f-bc6a03ac7804">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktOC0xLTEtMTE5OTk_4b5b027e-be33-4cae-b448-191ffb6a1e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTAtMS0xLTExOTk5_00ce25bd-af0d-4644-8b4f-51fc8244545e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTItMS0xLTExOTk5_1f5a65e4-740a-46c1-a041-99de9b16b2e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i82aea750feb9452ea792b03a00878392_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTQtMS0xLTExOTk5_35f1b2d4-2e66-4ec9-b557-0e322cb0acaa">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i82aea750feb9452ea792b03a00878392_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTYtMS0xLTExOTk5_64427ad5-c977-47f0-a417-d59c31b27e18">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTQtMS0xLTExOTk5_ef982d46-40a2-48f9-a326-27b3c2762a25">13.55</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i459ca9e3f16d4cd781dff0c62bdaf84a_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTYtMS0xLTExOTk5_43cd98a9-a85e-42ea-9357-7a74865d775a">28,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTgtMS0xLTExOTk5_63aa4258-1624-4388-8970-50ad303474af">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTEwLTEtMS0xMTk5OQ_e92c4d6d-c2a4-4914-964f-f12a7c9a884f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTEyLTEtMS0xMTk5OQ_8faba873-68e8-4b22-b41e-74feffeeb512">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTE0LTEtMS0xMTk5OQ_8e123d09-2696-4f1e-91c5-b5dd1a3b53a9">28,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTE2LTEtMS0xMTk5OQ_21adc4ac-a51b-4842-a330-d2c969e01a40">28,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="3" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTQtMS0xLTExOTk5_55e8a607-8cbb-49fe-9c3d-2e18e934df43">16.102</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i579df336feef41d99666585cbbcc7e99_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTYtMS0xLTExOTk5_75c07d06-c944-47d4-b3c8-fa8f5425d015">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTgtMS0xLTExOTk5_29872a3f-4a16-4c44-81be-6e41f60f8078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTEwLTEtMS0xMTk5OQ_e6b5f78c-94c8-482c-97bb-26b34d473c83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTEyLTEtMS0xMTk5OQ_0e9e4b15-797f-4e13-8fbc-90099e498ba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTE0LTEtMS0xMTk5OQ_c25a9e98-d869-4333-9dec-ef3bece899e6">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTE2LTEtMS0xMTk5OQ_76ef3817-6d1f-4f15-ab54-cc1c2690a49c">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTQtMS0xLTExOTk5_bb9c2167-1cf2-4bea-8bb5-815176ce95f9">11.660</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i97ac1b9334ed440281d6eb50aa0804a9_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTYtMS0xLTExOTk5_2a492d9e-1004-42c6-90fa-2e893242ed39">18,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTgtMS0xLTExOTk5_258b191a-ca7e-4f17-9cf8-2ef38a3ccad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTEwLTEtMS0xMTk5OQ_757aeefb-1374-4618-88a5-25efb5910853">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTEyLTEtMS0xMTk5OQ_0266939f-15f3-4621-a6e0-f7a0d7638542">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTE0LTEtMS0xMTk5OQ_f9360a85-4af5-47c7-9ed0-48d769f34c4d">18,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTE2LTEtMS0xMTk5OQ_29040478-3d41-4406-99fa-0926b4f8ca6e">18,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTQtMS0xLTExOTk5_dafb05f9-bf3c-44dd-9c7e-1ed4056c4e61">6.59</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i26bedcd322874e948f08ed1dc1e2b254_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTYtMS0xLTExOTk5_ed255a52-d2dc-459b-8a34-563982de9221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTgtMS0xLTExOTk5_1d05ad91-c048-4e4a-9ce2-88d1067d25a9">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTEwLTEtMS0xMTk5OQ_25d2aecb-e738-4521-8769-0bead44a94c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTEyLTEtMS0xMTk5OQ_6eb94c26-df0e-40a5-bf9a-6dc849137b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTE0LTEtMS0xMTk5OQ_5e804166-61a3-49a8-8588-e447b51d63a2">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTE2LTEtMS0xMTk5OQ_9d67c538-312b-487d-9e7f-b56feaad6acf">18,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4483ef3c39a64c83b928490f95c78902_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTYtMS0xLTExOTk5_544ac75f-f541-45a3-b03e-03febd4ae646">251,028</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTgtMS0xLTExOTk5_67e464ff-c6ee-4291-a344-6a7eeadabcbf">18,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTEwLTEtMS0xMTk5OQ_18167c77-1b17-4296-b62d-e96dd23681ce">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTEyLTEtMS0xMTk5OQ_ba28ccb8-a8b2-496f-9a6b-1e6d6c903cc5">6,000</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTE0LTEtMS0xMTk5OQ_cdbda036-b43f-45de-80bc-f75a2403099d">263,028</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTE2LTEtMS0xMTk5OQ_8553f322-ae20-4e12-85fc-f8dfc00c9064">263,028</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company&#8217;s shareholders' meeting held on November 30, 2020 granted <ix:nonFraction unitRef="shares" contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxMzU_e2492c24-fcd6-4405-8d26-7f35b00110ed">48,103</ix:nonFraction> warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe <ix:nonFraction unitRef="shares" contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420" decimals="INF" name="nbx:NumberOfOrdinaryShareSubscribedPerEachBSA" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNDI_d391c27b-2fd6-47f6-a622-a3e4094150a1">one</ix:nonFraction> ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib4b320a95d374a8ba1b1f5bfe078d26f_I20210420" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNDQ_62e7851b-1572-4764-8cf5-439b036b92e6">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNTE_734245b5-56e2-4ae4-9cc9-125aeb067161">13.47</ix:nonFraction> (share premium included). The designated warrants included <ix:nonFraction unitRef="shares" contextRef="ib86beff482d940c8b3f9b44ae18afb4a_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNTk_cdf1649b-30c1-49c9-846c-296dae046615">18,103</ix:nonFraction> warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period was open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNjc_f2959112-ef27-4d69-ab89-b5d07ac3fc3c">14,431</ix:nonFraction> warrants have been subscribed by their beneficiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The warrants can be exercised at any time during a <ix:nonNumeric contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" name="nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxODI_8e31fa6d-b2e8-489e-951e-dad5111ff7bb">10-year</ix:nonNumeric> period, subject to the satisfaction of the following conditions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the subscription by the relevant beneficiary of his/her warrant;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the relevant holder has attended at least <ix:nonFraction unitRef="number" contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMzE_c73e17d9-7753-4841-aee7-a540e3e20a0a">75</ix:nonFraction>% of the Supervisory Board meetings held during the <ix:nonNumeric contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMzU_9a027fa9-0a98-4a62-94bf-46876a062063">twelve months</ix:nonNumeric> preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the recommended dose for <ix:nonFraction unitRef="patient" contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNTM_f1e78f08-7a72-497f-a5d4-910b4017a12d">two</ix:nonFraction> out of the <ix:nonFraction unitRef="patient" contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNjE_c175a9c4-c4c2-4716-a682-ef92718bc00a">three</ix:nonFraction> patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted <ix:nonFraction unitRef="shares" contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxODQ_931d41a5-7b9f-4df2-a774-034b631281e1">30,000</ix:nonFraction> warrants to a consultant of the Company, each warrant giving its holder the right to subscribe <ix:nonFraction unitRef="shares" contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420" decimals="INF" name="nbx:NumberOfOrdinaryShareSubscribedPerEachBSA" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNzE_b501b1ef-7ddd-409a-9994-59ed291bdc5a">one</ix:nonFraction> ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i3f2fe9c5747a478cafb0068a92d9a750_I20210420" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxOTI_8d4cf792-cfbe-436a-b95a-98878de79979">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxOTk_8cea9733-8017-48f5-8be1-31517750729a">13.64</ix:nonFraction> (share premium included) at any time during a <ix:nonNumeric contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420" name="nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMTM_20a7a7d9-cbcb-41f4-a088-b01d5224df91">10-year</ix:nonNumeric> period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i623d044c980a4fe9b59d0cf0c4357c46_D20211231-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMTQ_d8a5acfc-574b-4282-a3e7-3f353ddf4fa3">no</ix:nonFraction> warrants have been subscribed by the beneficiary. In addition, as of December 31, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i99f9e75fd59840088c3f2a8efd797bae" continuedAt="i1a64814c644442bfb7d122aff2d96dec"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 17, 2020, the Executive Board, acting pursuant to the delegation granted by the thirty-fourth resolution of the annual shareholders' meeting dated April 11, 2019 and following the approval granted by the Supervisory Board on March 13, 2020, granted <ix:nonFraction unitRef="shares" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI3OTk_5b77a95f-9e25-48e1-a2b9-fea1f59a1115">18,000</ix:nonFraction> warrants to members of the Supervisory Board, each entitling the holder to subscribe to a defined number of ordinary shares with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i48ba274c2f734a61a9cb2f4453142924_I20200317" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI5NDc_f4ed3157-cc2f-46c7-986d-f5bd3efd8ed7">0.03</ix:nonFraction>, at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI5NjY_39a79d80-0ac4-4f1e-92fa-edac680bd6a6">6.59</ix:nonFraction>. The holders subscribed to the warrants prior to the end of the subscription period on September 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock Option Plans (<ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ0_f001c011-2f02-4f94-9ea1-0c619aa56e37" continuedAt="i0770b5b5a6004dc3a2bdd2faf7184d90" escape="true">OSA)</ix:nonNumeric></span></div><ix:continuation id="i0770b5b5a6004dc3a2bdd2faf7184d90"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtNC0xLTEtMTE5OTk_57a80d26-4eed-44fd-bd72-d98cc23aac05">13.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtNi0xLTEtMTE5OTk_12d9a691-1f3d-4d7d-8e05-43c6994840cd">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtOC0xLTEtMTE5OTk_c77276b0-cde1-40af-b7ec-cc3c2f6d8c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTAtMS0xLTExOTk5_4be12c07-527e-445d-86eb-4cbf7276a6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTItMS0xLTExOTk5_fac4c2e0-f69c-4f39-9387-babba64b42d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdd4d704ab87433eaab118942f97873a_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTQtMS0xLTExOTk5_ae287a89-8363-4fac-9262-1d6a82c2c918">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdd4d704ab87433eaab118942f97873a_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTYtMS0xLTExOTk5_0d2ab806-8b44-4d23-9cc5-128926d3c9a9">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItNC0xLTEtMTE5OTk_1ad17221-37ce-4130-9fe2-48cce0fb80be">14.26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdc086387801445bbd7de462f336e65f_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItNi0xLTEtMTE5OTk_fbcf68a9-4b17-4770-98e4-489503c1eac4">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItOC0xLTEtMTE5OTk_a1aa984b-d708-4bcf-921d-5c0451c613d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTAtMS0xLTExOTk5_7ab87960-b8e8-4b1f-987a-41cddb8e9ee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTItMS0xLTExOTk5_93e5e901-b96d-4264-bff1-1cebca0f749e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTQtMS0xLTExOTk5_5def0feb-4a3b-460b-af4e-1c4fd01825b0">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTYtMS0xLTExOTk5_947c7075-4da7-401f-a99a-ffbc9cff326c">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtNC0xLTEtMTE5OTk_fa705c1e-343b-4bc8-98cf-2df6854fe459">14.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtNi0xLTEtMTE5OTk_9afae065-8c60-4879-a5fd-9e334f6e00cb">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtOC0xLTEtMTE5OTk_7974e90e-6d33-4b0f-bf8c-bbfc2598a5c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTAtMS0xLTExOTk5_ccb523ab-9af6-4f3f-9df7-307d205b607f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTItMS0xLTExOTk5_f52aa876-bb8c-45b5-bb44-62e230ec4bef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf3ccd35f2ba46f3b213016bd228158b_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTQtMS0xLTExOTk5_5655759d-d65a-4b5c-89e9-e54e874bd8b6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf3ccd35f2ba46f3b213016bd228158b_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTYtMS0xLTExOTk5_eaa25012-7686-487d-ae56-c73a012d1cc5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtNC0xLTEtMTE5OTk_c8124155-2988-4046-89de-6dd21f677f0c">12.87</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iff05550398184321955321fa5e96e1e6_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtNi0xLTEtMTE5OTk_a9622fc1-77d1-4296-a4a6-a9c8db957557">52,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtOC0xLTEtMTE5OTk_869bbf37-4809-4ede-9a19-d4fe7a2f8ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTAtMS0xLTExOTk5_739ae50f-beb4-45b9-ba8d-ff9d8c9b20e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTItMS0xLTExOTk5_1f7d6614-7f5e-4610-af5b-39f99f04f5b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTQtMS0xLTExOTk5_77e3f634-1276-4036-ba64-e92be97c2558">52,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTYtMS0xLTExOTk5_97f9b1e3-864b-4121-bfc7-64676233b865">52,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtNC0xLTEtMTE5OTk_e72bdc39-fd8a-4b88-be50-3ca7aae3ebbb">11.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aea800177684b0784cf738a4f290854_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtNi0xLTEtMTE5OTk_766f786c-f34c-40b8-88da-65f9275ae71c">28,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtOC0xLTEtMTE5OTk_9ac981cc-9f37-45e6-9f2f-bac47b7f9c51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTAtMS0xLTExOTk5_f1eca2a1-0adc-4c0b-88a8-37060b7283ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTItMS0xLTExOTk5_d2caeabf-df25-483c-bfcf-28b898c59666">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTQtMS0xLTExOTk5_f928ac3e-8ab0-4ffa-9963-088713a5d3a5">28,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTYtMS0xLTExOTk5_d54301e9-cc79-4cd0-8967-df63b03097f0">28,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtNC0xLTEtMTE5OTk_9253df21-7576-4b36-8022-1541a49b6318">6.41</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtNi0xLTEtMTE5OTk_ac960267-6675-4c0d-8868-c73975fa953d">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtOC0xLTEtMTE5OTk_9c166380-ce44-47d5-9a96-374f29079afd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTAtMS0xLTExOTk5_f7043ed0-0f37-4509-bc23-870b8446ab2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTItMS0xLTExOTk5_f64759b2-5cab-45e9-afa5-f34a0563b599">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41f34aacd8914d92858087d804274e6e_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTQtMS0xLTExOTk5_2b85fdbe-31ee-476d-9a05-837ca48ba2f2">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41f34aacd8914d92858087d804274e6e_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTYtMS0xLTExOTk5_7fe6a225-d543-4376-b858-074e3e7dba43">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctNC0xLTEtMTE5OTk_aca2259f-3a02-4f44-b68e-d777160fb6a0">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctNi0xLTEtMTE5OTk_5020ac81-9c6c-4e93-bbe8-b9043de366a4">400,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctOC0xLTEtMTE5OTk_8f3d96c6-061a-4f21-84e2-f1b99c66e39d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTAtMS0xLTExOTk5_0ef620ae-ac7e-44ba-8182-566c57a89545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTItMS0xLTExOTk5_aa577c49-bfb0-4426-81a2-017cba9de308">13,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTQtMS0xLTExOTk5_ae87e16a-d163-43d0-9326-c868259e8249">387,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTYtMS0xLTExOTk5_b043319b-bd89-436f-828a-c51f0108126c">387,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNC0xLTEtNDQ4NzY_5e1b86ef-423a-478e-9ffe-d798e33bb6c2">13.74</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if5392b89aa5e4f9f80dabd7f2b3a9a2e_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNi0xLTEtNDQ4ODQ_10f25fb2-ee01-4138-a4f8-3578d712e366">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtOC0xLTEtNDQ4OTA_36848e60-ee84-4cae-a872-883e2f20455e">571,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTAtMS0xLTQ0OTAz_893471e2-b840-4179-86a6-7dd0a210f52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTItMS0xLTQ0OTA5_0026e65e-1ab7-4dcd-9dde-e1d3a461422d">80,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTQtMS0xLTQ0OTE1_54f7af41-97b2-42a9-81f7-ad145ad96615">491,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTYtMS0xLTQ0OTIx_be2def3d-1d06-4536-b277-b8da0dcc23a7">491,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktNC0xLTEtNDQ4NzY_a7316aa7-8eed-4a23-b2bd-6a486555fe24">12.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i652de3ad86c34c4db4db1a382b545fa3_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktNi0xLTEtNDQ4ODQ_4681bada-86ee-4e10-a031-703daa050e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktOC0xLTEtNDQ4OTA_f755c819-cb57-46d8-87ff-cbb52d39c208">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTAtMS0xLTQ0OTAz_1918eb6e-294a-4948-ada4-81869a3cd309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTItMS0xLTQ0OTA5_98578723-c360-4835-a44e-6847c0fb2a44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTQtMS0xLTQ0OTE1_48cad5f1-54ba-4cfa-b7a9-4e6cff03f910">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTYtMS0xLTQ0OTIx_7f8ba581-e5c1-4cbd-8590-d39a77c9f22d">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNi0xLTEtMTE5OTk_69ec6660-cd19-49d1-a1bd-23f62fda82f3">986,359</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtOC0xLTEtMTE5OTk_00397d29-199a-4b7d-9760-aadb4eccb7d0">691,200</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTAtMS0xLTExOTk5_e79550c3-1514-47a3-b8fe-ee30e127173f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTItMS0xLTExOTk5_8a6e3c98-3475-4bbc-bdf4-c30f76caf8fd">93,753</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTQtMS0xLTExOTk5_cdb75a6f-0e7a-414f-827f-fb5796e72ec6">1,583,806</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTYtMS0xLTExOTk5_18ac6b7c-2996-4696-9b10-05b31b061554">1,583,806</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1,<br/>&#160;2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtNC0xLTEtMTE5OTk_4fb1d6e9-7179-4cff-afba-f1d2147ce066">13.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9fb46e1a795c49bcb05fc8d3200315fd_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtNi0xLTEtMTE5OTk_1309fc77-cbaf-4b7e-8e60-8e641fd83db2">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtOC0xLTEtMTE5OTk_a10c2102-fb61-443b-9378-1d23fbc563fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTAtMS0xLTExOTk5_c635f248-0dfc-43c3-a10b-f19c39f00eca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTItMS0xLTExOTk5_9ad2b18f-c1b8-49ff-ae4e-895dae7b9d85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTQtMS0xLTExOTk5_0813b444-2fa6-417b-be9f-9282b0d1c15b">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTYtMS0xLTExOTk5_cdfb100a-ddf6-4cf5-b509-50f9920fc375">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItNC0xLTEtMTE5OTk_79431427-037d-4b0f-8fd8-5912b2859a8d">14.26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7fa9412e0984488299213d105f5179a8_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItNi0xLTEtMTE5OTk_e402b8c0-c275-4ea6-9a92-731434d6eac6">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItOC0xLTEtMTE5OTk_63cf265f-5212-4b3d-a087-d81655d18dcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTAtMS0xLTExOTk5_33e70430-4c92-4515-8eb0-2d8d7eaff0bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTItMS0xLTExOTk5_0fbac8ce-dcf2-45eb-8001-6e8b87037029">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdc086387801445bbd7de462f336e65f_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTQtMS0xLTExOTk5_c4cd5c0b-1242-4fba-9524-2f048ee52e18">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdc086387801445bbd7de462f336e65f_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTYtMS0xLTExOTk5_ae43d02d-aa63-472a-8a6c-4b5e9b990c53">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtNC0xLTEtMTE5OTk_7a40307b-eade-420c-ae63-cfe6e2ded858">14.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifa4ccf47be0e4bbd9bb2d8faab31cb87_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtNi0xLTEtMTE5OTk_1f67f258-a4a4-48de-a776-600eeda1e04d">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtOC0xLTEtMTE5OTk_f161c172-b11a-420b-9fca-f80448924f81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTAtMS0xLTExOTk5_60161492-ea95-4744-aab6-d5897c389276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTItMS0xLTExOTk5_a5a27dc4-0806-4f43-9778-e3d9b201baa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTQtMS0xLTExOTk5_e4b06c52-eddf-48bf-9f1f-b716898231a8">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTYtMS0xLTExOTk5_9d9c5770-cd87-49cf-932b-905c01034562">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtNC0xLTEtMTE5OTk_4b2849f8-4ecb-4d62-8b17-f71c4df5802c">12.87</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5abb27847f02467bacf8dcdc5928b771_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtNi0xLTEtMTE5OTk_469c460d-e25e-4959-ae3b-e93d585f4cbe">54,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtOC0xLTEtMTE5OTk_ad020922-d8f0-4072-b3bb-2a3ea4819d02">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTAtMS0xLTExOTk5_c79e4627-22c9-4207-b2d2-d6b588a66ba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTItMS0xLTExOTk5_315145fa-a75d-4016-9dd3-cb437cedb798">2,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iff05550398184321955321fa5e96e1e6_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTQtMS0xLTExOTk5_53663580-f325-4be1-9e33-9464e7a42436">52,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iff05550398184321955321fa5e96e1e6_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTYtMS0xLTExOTk5_2537456b-8228-42cc-8402-cf49c8bedf59">52,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtNC0xLTEtMTE5OTk_4c489d1c-66ee-4e2d-b119-9c12b90a15b8">11.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i354033aa64f342da8206f231dd7c8d2d_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtNi0xLTEtMTE5OTk_f51b5725-123a-4d46-9cd7-44589b7e77d8">30,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtOC0xLTEtMTE5OTk_5749ab1d-6891-46a3-8f67-17a55d8f43aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTAtMS0xLTExOTk5_612bbccd-4043-47d1-9b5c-73cbc1871ade">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTItMS0xLTExOTk5_66c203b6-4afb-4b61-8295-c647768ca10a">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aea800177684b0784cf738a4f290854_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTQtMS0xLTExOTk5_ef05c076-cf2b-498d-86cf-1d49df16954c">28,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8aea800177684b0784cf738a4f290854_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTYtMS0xLTExOTk5_d0ca0a64-c345-4ea2-9e8f-a055b8e6bd52">28,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtNC0xLTEtMTE5OTk_adaef264-ae61-48ef-b1f8-ec69669c029e">6.41</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic71ae7b3a2ec44fe93b98d0ab5cc918a_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtNi0xLTEtMTE5OTk_5390d639-55d2-4c21-8245-bf50aac53c29">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtOC0xLTEtMTE5OTk_c9510ba3-2b4d-4659-acd3-abefb9aacc80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTAtMS0xLTExOTk5_acdc0050-63e3-4fca-805f-331ce1bc0212">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTItMS0xLTExOTk5_8d76f6f6-96fe-42ae-b7e3-a2224bd5a6e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTQtMS0xLTExOTk5_b59761b2-062d-42cb-b13e-b0dfabefe567">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTYtMS0xLTExOTk5_a81a432a-2bd3-40c5-bf6d-d427a76d8977">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNC0xLTEtNDQxNjU_f6438d40-8c58-4b43-993d-2482f80e8921">6.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d97220fa46f480eb51782483039e25d_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNi0xLTEtNDQxNzE_b0e5c33c-be2e-498a-a74b-3d639554ecfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctOC0xLTEtNDQxNzg_84723d1f-47a6-4b6d-b1bd-a46630207f83">407,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTAtMS0xLTQ0MTg0_badcda49-f2b2-43e4-81fe-42d36b06cd19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTItMS0xLTQ0MTkw_1dab2f57-25ba-4cf1-866f-0e0025e3820d">7,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTQtMS0xLTQ0MTk2_ea9fbc4b-3b6a-48af-b68a-e8ee5929be41">400,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTYtMS0xLTQ0MjAy_f48df4b4-a938-48dd-b87a-daff843187ac">400,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNi0xLTEtMTE5OTk_c7f314fc-1991-468c-8bc5-fa3e41573219">589,150</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctOC0xLTEtMTE5OTk_e92dc779-1ddc-4f74-ab70-fb0fa346463c">407,972</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTAtMS0xLTExOTk5_e3d1bcee-19e9-40e1-8162-254514825242">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTItMS0xLTExOTk5_e41e7c59-e011-47fb-a49c-ad928f507a4d">10,763</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTQtMS0xLTExOTk5_ae8ac9da-a24e-4a03-a310-03244cadf5ba">986,359</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTYtMS0xLTExOTk5_56e614d3-ed5f-4f24-beab-ace26ba37460">986,359</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board <ix:nonFraction unitRef="shares" contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNzM_e2ed2417-2fe2-4991-8485-3e8b95dd3721">571,200</ix:nonFraction> stock options (including <ix:nonFraction unitRef="shares" contextRef="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyODI_1a22d87e-6194-4bee-b784-1960ce7b3059">143,200</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyOTE_db4ce786-ca34-4676-9a8c-cd1a4b99f01e">428,000</ix:nonFraction> performance stock options), each giving its holder the right to subscribe <ix:nonFraction unitRef="shares" contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420" decimals="INF" name="nbx:NumberOfOrdinaryShareSubscribedPerEachOSA" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMTQ_a284ea7a-377f-4964-9097-14f8b6ab65cb">one</ix:nonFraction> ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i095127a75d214c5f8b6280cf3229e623_I20210420" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMDA_be609cf4-0291-4815-91d6-7756df77cccf">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMDc_4549d021-b538-4e9b-b0d9-31a714329cf0">13.74</ix:nonFraction> (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company&#8217;s annual shareholders&#8217; meeting held on April 28, 2021 (the &#8220;2020 Stock Option Plan&#8221;). </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i1a64814c644442bfb7d122aff2d96dec" continuedAt="i858c0c7f5fbf4fb9b7c0e035b52a5426"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The ordinary stock options are exercisable as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">up to one-third of the ordinary stock options as from April 20, 2022;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional one-third of the ordinary stock options as from April 20, 2023,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">no later than <ix:nonNumeric contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420" name="nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk0OTE_b1dcd76b-2f89-4242-8f32-f9bd9fa4d170">10</ix:nonNumeric> years after the date of grant, it being specified that stock options which have not been exercised by the end of this <ix:nonNumeric contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420" name="nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk0OTk_d106251c-391b-47f6-b7e4-d56ce152c5fc">10-year</ix:nonNumeric> period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The performance stock options may be exercised under the following conditions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"><ix:nonFraction unitRef="number" contextRef="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MTM_e8d4fc9a-7883-48b3-a755-a400b2eb31fe">10</ix:nonFraction>% of the stock options may be exercised when the market price of the Company&#8217;s shares on the regulated market of Euronext in Paris reaches &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130" decimals="2" name="nbx:SharePriceMilestoneEuronextParis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MTg_27b8f54a-d7e3-4e9d-b4fa-b97262f89639">24.00</ix:nonFraction>,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional <ix:nonFraction unitRef="number" contextRef="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NTA_3eb0ade4-9912-48f9-9e31-a97de5b3ce16">10</ix:nonFraction>% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130" decimals="2" name="nbx:SharePriceMilestoneEuronextParis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MjY_84d5d0ec-c6db-42fa-8d01-1183a7829efb">30.00</ix:nonFraction>,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional <ix:nonFraction unitRef="number" contextRef="i3eba6313515d4559a36c492791143e24_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NTU_6a4f7281-e1a6-4259-bf04-ac2f997fb1de">40</ix:nonFraction>% of the stock options may be exercised when the market price of the Company&#8217;s shares on the regulated market of Euronext in Paris reaches &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i3eba6313515d4559a36c492791143e24_D20201130-20201130" decimals="2" name="nbx:SharePriceMilestoneEuronextParis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MzQ_eea4236c-3c87-49e7-89f6-9af85e2119ba">40.00</ix:nonFraction>,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional <ix:nonFraction unitRef="number" contextRef="i91936820e19b4923b898ad1557219659_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NjA_87727395-a0f2-4318-a1a3-d930695179f7">40</ix:nonFraction>% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i91936820e19b4923b898ad1557219659_D20201130-20201130" decimals="2" name="nbx:SharePriceMilestoneEuronextParis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NDI_f5e719a2-7347-4275-8f69-43ad3eafccb5">60.00</ix:nonFraction>, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">at the latest within <ix:nonNumeric contextRef="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130" name="nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NjQ_3fab69c1-1a46-41bd-8147-b6996ba4c287">10</ix:nonNumeric> years of the date of grant, it being specified that stock options which have not been exercised by the end of this <ix:nonNumeric contextRef="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130" name="nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1ODQ_01ea0677-3ec7-4e63-b50b-4cc7462abb80">10-year</ix:nonNumeric> period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to <ix:nonFraction unitRef="number" contextRef="i5b8343c910974c02b4c1483f76998841_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1ODY_d2ae6ad4-088e-489f-b534-be15a5af766a">10</ix:nonFraction>% of such performance stock options as from April 20, 2022, (y) an additional <ix:nonFraction unitRef="number" contextRef="i1755b173a3d34e8499dc5ce10a9bec9c_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1OTE_f9829a77-712d-4582-998a-db1e455d1731">30</ix:nonFraction>% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., <ix:nonFraction unitRef="number" contextRef="i7fa42a50048a45a9a9d4dbf0fc6f444f_D20201130-20201130" decimals="2" name="nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1OTY_1b3ec9c6-82c6-4f42-9831-1b54755c2c13">60</ix:nonFraction>% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders&#8217; meeting held on November 30, 2020 granted <ix:nonFraction unitRef="shares" contextRef="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MDE_e23bdf0c-b826-4641-b7ce-6b78957e8b23">60,000</ix:nonFraction> ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company&#8217;s annual shareholders&#8217; meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn <ix:nonFraction unitRef="shares" contextRef="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MzM_793fe294-3a2b-48d9-9cda-5473a54ff0bc">60,000</ix:nonFraction> performance stock options governed by such plan. Each of such <ix:nonFraction unitRef="shares" contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MDk_52866721-15e3-47b0-a775-47d3c4cba471">120,000</ix:nonFraction> stock options (whether ordinary and performance) gives it holders the right to subscribe <ix:nonFraction unitRef="shares" contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621" decimals="INF" name="nbx:NumberOfOrdinaryShareSubscribedPerEachOSA" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MjQ_3487b2b4-8ad4-414a-97ad-ff0cb63fa9b0">one</ix:nonFraction> ordinary share, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="idd940520765e4ad5b9784e162babba1b_I20210621" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MTg_8174ec0b-3d08-4bf2-bacb-ae49194823ed">0.03</ix:nonFraction> and at a price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NDE_7713b6b1-bc95-48b0-9d22-9e576c3cfb66">12.99</ix:nonFraction> (share premium included).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The exercise conditions of the <ix:nonFraction unitRef="shares" contextRef="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NDk_2fadcad5-9860-45ec-bc57-36f5432ecd7c">143,200</ix:nonFraction> ordinary stock options and <ix:nonFraction unitRef="shares" contextRef="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NTg_f4353878-54d3-4537-a17e-bc7b2d56dc9f">428,000</ix:nonFraction> performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these <ix:nonFraction unitRef="shares" contextRef="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2Njc_ac6598d9-0c99-4c79-998d-e6ae51990434">60,000</ix:nonFraction> ordinary stock options and <ix:nonFraction unitRef="shares" contextRef="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NzU_e7510cf6-441b-4a16-bb18-32872f8d444c">60,000</ix:nonFraction> performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for <ix:nonFraction unitRef="patient" contextRef="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2ODI_5317b552-f1fc-477b-ba03-aa95ac47b7b3">two</ix:nonFraction> of the <ix:nonFraction unitRef="patient" contextRef="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2OTA_898456ec-da8e-432a-9493-6c4ad9943f03">three</ix:nonFraction> patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 11, 2020, the Executive Board adopted the 2019 Stock Option Plan and, acting pursuant to the authorization granted by the thirty-second resolution of the annual shareholders' meeting dated April 11, 2019, granted <ix:nonFraction unitRef="shares" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM3MTc_f789bdc1-a0a6-4d81-b0ad-94eb4260df63">407,972</ix:nonFraction> stock options (the &#8220;OSA 2020&#8221;), <ix:nonFraction unitRef="shares" contextRef="ia28c239f39194bb4b639651e62839a6e_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM3NTM_cab84ce0-e437-4bcc-8d27-c78ab3d97596">300,000</ix:nonFraction> of which to members of the Executive Board and Mr. Alain Dostie and the remaining <ix:nonFraction unitRef="shares" contextRef="ib4e429614d77462f852336283afd726b_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM4Mzk_5f90b241-3634-4664-9b61-98e2f16cf2a2">107,972</ix:nonFraction> to employees of the Company, under such 2019 Stock Option Plan. Each OSA 2020 entitles its holder to subscribe <ix:nonFraction unitRef="shares" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="INF" name="nbx:NumberOfOrdinaryShareSubscribedPerEachOSA" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM5NTQ_55795eff-ab46-4224-92f3-b2c7abbb32a8">one</ix:nonFraction> ordinary share of the Company with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib6e0b829dfdd4803b7abd6510fa5d82f_I20200311" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjQwMDg_1f02b0db-385d-422e-b7e3-643d79a35c5f">0.03</ix:nonFraction>, at an exercise price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib4e429614d77462f852336283afd726b_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjQwMzc_92a9ad1a-5cb8-470c-9dc0-962a5664108c">6.25</ix:nonFraction> (issue premium included).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The OSA 2020 may be exercised as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">up to one-third of the OSA 2020 as from March 11, 2021;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an additional one-third of the OSA 2020 as from March 11, 2022; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, the Executive Board decided that the exercise of the OSA 2020 granted to members of the Executive Board and Mr. Alain Dostie would also be subject to the achievement of positive results in the 1100 study in 2020. </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i858c0c7f5fbf4fb9b7c0e035b52a5426" continuedAt="i9e307353efa44d2293152c2a2c221776"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the supervisory board, on March 17, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the Executive Board decided to lift the continued service condition of the OSA 2020 for <ix:nonFraction unitRef="employee" contextRef="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NzA_45200db9-acaa-4caf-93ac-17a928309b28">two</ix:nonFraction> former Executive Board members as well as to accelerate, as from June 30, 2021, the vesting of the OSA 2020 <ix:nonFraction unitRef="employee" contextRef="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3Nzg_8865e6f2-c6ce-4891-b1ad-5544cfb4b0df">one</ix:nonFraction></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of these former executive board members holds, enabling him to exercise all of them, in the context of his departure from the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Free share plans (<ix:continuation id="iad8b5fc1e1c946b1ad6e53bdd1ba1b43" continuedAt="ia47047f2b71741f98e81c426b893a1b0">AGA)</ix:continuation></span></div><ix:continuation id="ia47047f2b71741f98e81c426b893a1b0"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtNi0xLTEtMTE5OTk_a841b7ab-8e5d-48e4-9e28-34c94ffac1d0">24,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtOC0xLTEtMTE5OTk_c2b100b1-db7b-47a7-ae31-156a25a8ab62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTAtMS0xLTExOTk5_5106eba3-aaf6-49aa-9b81-28e5518579a4">24,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTItMS0xLTExOTk5_6d042d21-da72-4bf2-b2e2-9c0b757eec46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTQtMS0xLTExOTk5_489ddecc-0918-4255-a1e4-3a3934474f51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTYtMS0xLTExOTk5_9f9114cf-bb06-44ba-b827-21564ab1a23d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItNi0xLTEtMTE5OTk_37f494bd-616c-41ef-b72f-8b66d98a13b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItOC0xLTEtMTE5OTk_92da3f31-52ee-4df9-a962-1b61406525aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTAtMS0xLTExOTk5_b2b16380-a9cc-48d6-841d-69ea79fbd324">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTItMS0xLTExOTk5_b3d6e8e6-bd4a-4557-9745-7a700f62b395">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTQtMS0xLTExOTk5_e6e528e6-882d-4107-839a-d01b8e91fbd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTYtMS0xLTExOTk5_f37f166b-99d8-4105-a37d-33dea4732a7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtNi0xLTEtMTE5OTk_0e988a52-a58f-41f9-a3e2-103f49d2b60a">372,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtOC0xLTEtMTE5OTk_99279326-970b-4c69-b51f-bcd6e69fe2aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTAtMS0xLTExOTk5_d07cb9c6-596e-4596-ad35-afbd89eb0e72">369,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTItMS0xLTExOTk5_fd6a21ce-75ae-45e3-b692-26e8f8b7b734">2,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTQtMS0xLTExOTk5_f8b175bc-af10-4789-bdeb-e5d6e9fc0505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTYtMS0xLTExOTk5_f2caf1e5-cbee-4133-93e6-6f6ddf61cba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtNi0xLTEtMTE5OTk_871e9e57-3788-423f-a181-ce141d612116">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtOC0xLTEtMTE5OTk_c1798094-3a16-438a-9bf5-21bf9a3ef0bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTAtMS0xLTExOTk5_baaffe36-f005-4a19-b610-3b6dd9f7e96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTItMS0xLTExOTk5_f7ac6199-22bd-4b10-9395-c8c2dfbaff8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTQtMS0xLTExOTk5_aa9be4b4-683d-4e9b-9563-e654a76d7c2d">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTYtMS0xLTExOTk5_20d39eb3-bc28-49e2-9b21-0a7876b20301">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib866094a2bed45fbb12978a62862e821_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtNi0xLTEtNDUyMTU_010124c7-6f30-4bf3-9884-41d0cd0942b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtOC0xLTEtNDUyMTk_9786f339-7487-4503-aa47-4d29b2430aae">362,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTAtMS0xLTQ1MjI1_8a7c8952-4a7b-4bec-8e63-4780cdd855f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTItMS0xLTQ1MjMx_eceec68c-1e65-48fb-9108-ad78fbc79291">2,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTQtMS0xLTQ1MjM3_b21e4c3a-f74b-405c-8208-4e45cb5c25f4">360,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTYtMS0xLTQ1MjQz_540f2c34-e3c3-4028-856d-c2bbf471143e">360,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtNi0xLTEtMTE5OTk_4a68f050-95c0-45e6-9dd5-98c4a7ff6589">446,500</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtOC0xLTEtMTE5OTk_24ac1d0c-29dc-4fe3-aec9-87444f10e9f5">362,515</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTAtMS0xLTExOTk5_f1bf6d40-0308-409c-88dc-00f574986220">393,750</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTItMS0xLTExOTk5_c2d6a5aa-db6f-4f8a-ba54-c5f6342bf1e1">4,753</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0979101cec4474688543efa006ec62d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTQtMS0xLTExOTk5_19d15749-4f1c-4ec7-8116-20ce2c080974">410,512</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0979101cec4474688543efa006ec62d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTYtMS0xLTExOTk5_805ce494-fa93-4511-97b3-a8daa1a96675">410,512</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:11.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at January 1, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93d6f1511d6e44e78b354c3721b5d10d_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtNi0xLTEtMTE5OTk_a8944ea4-0d62-40c7-9fd8-8895b811c081">355,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtOC0xLTEtMTE5OTk_556f2048-e119-4e3b-81f9-dba1c464ef15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTAtMS0xLTExOTk5_c0dbc61f-74b5-4d67-9cd6-796aee8dbee6">316,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTItMS0xLTExOTk5_2395d65e-dcde-4d90-acb2-0d8dc1129537">14,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTQtMS0xLTExOTk5_5536dd55-703e-4634-8975-fff6475398f8">24,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTYtMS0xLTExOTk5_559e97d9-d60c-47c8-9657-9984e7f4d752">24,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie8d6ad9db19141c78c82ca8829ef8a66_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItNi0xLTEtMTE5OTk_f1258e44-2f2a-4f00-a7c0-b2257e83fd9d">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItOC0xLTEtMTE5OTk_28d8ff0e-e17c-4fb9-8851-35a745076b06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTAtMS0xLTExOTk5_0bbf5be5-b9c7-4f68-b252-ad73271da0a5">6,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTItMS0xLTExOTk5_f2ee4cba-9e19-4d49-8f2d-666ca0593516">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTQtMS0xLTExOTk5_9a21203e-ca0d-4788-a018-f2b513416944">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTYtMS0xLTExOTk5_42909f9f-0811-41bc-9fb2-32af922d21e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe8ccb113d1241d8bfccb1356614de26_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtNi0xLTEtNDQyOTg_8207a814-b070-459a-9551-3d0abea2467c">385,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtOC0xLTEtNDQzMDQ_4f4bad47-9925-4f5a-9f7f-73bcb54ffde9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTAtMS0xLTQ0MzEw_2647872d-e61a-40b5-b9b3-7d44ed885f22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTItMS0xLTQ0MzE2_bb8d45d4-2f8d-4ae2-8099-9643dcc6d1c9">13,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTQtMS0xLTQ0MzIy_f8481898-1e40-4a21-a2b1-d12fbefc33db">372,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTYtMS0xLTQ0MzI4_22f9833b-0ed2-4696-b04e-3bf42cb6b8e1">372,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1c10d2422b545efaf4328d5268483f0_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtNi0xLTEtMTE5OTk_fb6daaea-835b-4337-9075-751f27fb7371">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtOC0xLTEtMTE5OTk_caaa7f76-640d-4f34-94a1-0d280727ac6d">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTAtMS0xLTExOTk5_c3d3f316-5c14-4731-8eb3-ced7f6a947b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTItMS0xLTExOTk5_533a4911-a0d9-4570-aa43-2ab93a64854e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTQtMS0xLTExOTk5_73b5a9f0-5c18-40b5-b75d-318709e47bb4">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTYtMS0xLTExOTk5_b62b848e-38d1-4260-8b9b-c279f7292c77">50,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia09f2bb3b6114c268acacc4f0ebce171_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtNi0xLTEtMTE5OTk_5d456b9b-78ce-43dc-a030-e4ddf8b7c2a5">746,250</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtOC0xLTEtMTE5OTk_3a500f44-b1fe-4510-8e2e-1a0d7dc2d87c">50,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTAtMS0xLTExOTk5_93500038-eb06-42ac-a3c6-6034d902acf8">322,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTItMS0xLTExOTk5_3f1cc432-5c2f-47f3-a70d-a92b0d8f61c5">27,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTQtMS0xLTExOTk5_2e5d315b-90ac-4384-81c4-172a8460bef8">446,500</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTYtMS0xLTExOTk5_4feaa432-f306-477e-b43d-240dee70ed25">446,500</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company&#8217;s shareholders&#8217; meeting on November 30, 2020, granted <ix:nonFraction unitRef="shares" contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4NjU_5b02ba46-0de9-43c0-8f0d-0e6da7aebed4">362,515</ix:nonFraction> free shares, each with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i140d20eec52d43de90b683cedaafe648_I20210420" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4NzQ_08a024ae-691e-42df-90f9-7ec78883f55b">0.03</ix:nonFraction> to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a <ix:nonNumeric contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420" name="nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4ODk_c05b632c-3320-4643-aa13-915c3c64bb3f">one-year</ix:nonNumeric> holding period starting at the end of the <ix:nonNumeric contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDA_a257d10e-6859-4b6f-8fce-6a3fd884831e">two-year</ix:nonNumeric> acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for <ix:nonFraction unitRef="patient" contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDE_ad3be636-699e-4d54-a6bf-c5a5b87f6b85">two</ix:nonFraction> out of the <ix:nonFraction unitRef="patient" contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDI_3e5edccc-655e-4bfc-9812-8580e50d8ffa">three</ix:nonFraction> patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 11, 2020, the Executive Board, acting pursuant to the authorization granted by the thirty-third resolution of the annual shareholders&#8217; meeting dated April 11, 2019, granted <ix:nonFraction unitRef="shares" contextRef="iaafc498a94374f9f8c4d0dda5b2e6397_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2Xzg3ODc_a852498d-b1f3-4cca-bd41-6efc6d3c87a9">50,000</ix:nonFraction> free shares (the &#8220;AGA 2020&#8221;) with a par value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i3f28affaf7bb40ce8972d14b1c1f055b_I20200311" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2Xzg4Mzk_18dbd020-f56a-4f25-af80-f6fe70c06904">0.03</ix:nonFraction> to Ms. Anne-Juliette Hermant, a member of the Executive Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition to the acquisition and holding conditions detailed below, the acquisition of the AGA 2020 granted to Ms. Hermant is conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board, on March 17, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Free share vesting conditions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The AGA 2020 and AGA 2021 are subject to, for French tax residents, a <ix:nonNumeric contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ2_59b624e8-c6bc-427a-a51e-a06aab9f0e98">two-year</ix:nonNumeric> acquisition period and a <ix:nonNumeric contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311" name="nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ4_6cef750d-4bba-4485-84bf-9e2d44eccf67">one-year</ix:nonNumeric> holding period, and, for foreign tax residents, a <ix:nonNumeric contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUy_3844d867-ae3a-47ab-8888-9d2e792c4428">three-year</ix:nonNumeric> acquisition period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged. </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i9e307353efa44d2293152c2a2c221776"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2020 and the AGA 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2020, until March 11, 2022 and for AGE 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2020 or AGA 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within <ix:nonNumeric contextRef="ia49ffd5f6a8a43efaa547e2eb3e46420_D20191024-20191024" name="nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNDQz_30e5b48e-d926-4403-8637-92cfa320816c">six months</ix:nonNumeric> from the date of death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 17, 2021, the Executive Board acknowledged the definitive acquisition of <ix:nonFraction unitRef="shares" contextRef="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3ODc_70e4ee9f-540e-43d0-97a0-103741ef1e5c">24,500</ix:nonFraction> free shares granted on March 6, 2018 following a <ix:nonNumeric contextRef="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MjM_db504f0e-e45a-43df-910a-4281af98ab1b">three-year</ix:nonNumeric> acquisition period, thus acknowledging the related share capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="if8bf73603bb74c11877603a93c8fee52_D20210317-20210317" decimals="0" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MjU_42200e94-553f-49cf-bff0-60fc43b8ddc9">735</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on April 1, 2021, the Executive Board acknowledged the definitive acquisition of <ix:nonFraction unitRef="shares" contextRef="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MTU_e055c7fc-b888-41e0-aad8-ae64ea063a73">369,250</ix:nonFraction> free shares granted on March 29, 2019 following a <ix:nonNumeric contextRef="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MzA_8d2caeb0-7651-4aab-a285-c410fbb587b8">two-year</ix:nonNumeric> acquisition period, thus acknowledging the related share capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="ibf0906164d3245eca6340ec305f7b4bf_D20210401-20210401" decimals="2" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MzI_95dedff2-8eeb-47d7-bbf8-5c80f517764a">11,077.50</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on September 22, 2020, the Executive Board acknowledged the definitive acquisition of <ix:nonFraction unitRef="shares" contextRef="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNTcw_c4452391-7e7a-4b47-b21f-e32d17956197">6,000</ix:nonFraction> free shares granted on July 27, 2018 following a <ix:nonNumeric contextRef="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727" name="nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ5_1e388e75-92ab-47ab-be6f-c0d9d0248f16">two-year</ix:nonNumeric> acquisition period, thus acknowledging the related share capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="ifa39e4659a8045229764c592849e2e2d_D20200727-20200727" decimals="0" name="ifrs-full:IssueOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNzA3_2dfdccc4-fbe1-416c-a4d2-794fcb83355b">180</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with the terms of the free shares, the Executive Board decided to lift, for <ix:nonFraction unitRef="employee" contextRef="idabb0dddb8454f87a533b1f04427ec7d_D20210101-20211231" decimals="INF" name="nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTExNzI_2cf53af1-7479-45c8-864c-e32b909b30b2">seven</ix:nonFraction> Company&#8217;s employees and a former Executive Board member, the continued service condition to which the definitive acquisition of their free shares is subject, notwithstanding the termination of their employment agreement or corporate office. The impact of share-based payments on income is discussed in Note 17. As of December 31, 2021, the assumptions related to the estimated vesting of the founders&#8217; warrants, the warrants and performance stock-options have been updated (see Note 17).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-32</span></div></div></div><div id="i377d9717844147e799376babda10462f_166"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 11. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfProvisionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTI_f15455fb-fc5f-4d1c-9632-4c50aa41bc1c" continuedAt="iccea423c47cd49018f35c551b7d6b995" escape="true">Provisions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iccea423c47cd49018f35c551b7d6b995" continuedAt="i870b46227e5f404d9dceb9f10b09fa00"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTM_e99c93cb-b089-452a-9ba2-92b834712066" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for contingencies and charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for retirement obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Company employees receive the retirement benefits provided for by law in France: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee&#8217;s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTQ_0c6fc49f-ef98-4415-a764-5223fcc75b7f" continuedAt="i9830891fe4174f0f9be50b72ae2483ad" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3b309086b1c64082bcccc5093b2b7923_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMS0xLTEtMTE5OTk_51dd9f92-cafa-4580-8bc2-adc57e332932">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMi0xLTEtMTE5OTk_dba39b1b-8bb5-41fc-991c-5ede41fff16c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMy0xLTEtMTE5OTk_00ce2560-8561-4298-8037-e0db3e096b98">97</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4c815a380ae74027ad90d5faa79e3d8b_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtNC0xLTEtMTE5OTk_9ba0f86d-c910-4cbf-8480-a9c3d73d4a0b">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i00cc8afb53664ed8b93b3511d260adb5_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMS0xLTEtMTE5OTk_740d06ad-5fb4-4c91-a7cf-3963e8d46de5">414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMi0xLTEtMTE5OTk_a25e4860-1299-4cbb-b6eb-2239200c39b9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMy0xLTEtMTE5OTk_21803fdc-f74e-42ba-9ea4-08b7968cb850">97</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9770c3638b9e47bf84c5dfee8735850b_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItNC0xLTEtMTE5OTk_8944323f-eb39-4c0b-b2a3-91b9055b1574">318</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icf9d433b2a87420884917078664d7f8f_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMS0xLTEtMTE5OTk_e7691cc2-8d22-4c6d-977f-defd08042402">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMi0xLTEtMTE5OTk_c85c002a-947a-4f3d-9e5b-ecbba39b02d4">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMy0xLTEtMTE5OTk_6164c314-9501-4fe5-b016-40812af48ce2">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5c7c68e80ad24f5093d192fa5626429e_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtNC0xLTEtMTE5OTk_b19af4fc-b0da-4d15-b49b-d2755f67d707">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia38ca1b371aa43d5a00e50015286da3e_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMS0xLTEtMTE5OTk_7d0d5d24-d61c-4b91-b417-9b6eb89e52b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i22a92c12751c43379ad3872883245ab6_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMi0xLTEtMTE5OTk_9fe966f2-525a-4507-8d7d-599fb29be7e3">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i22a92c12751c43379ad3872883245ab6_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMy0xLTEtMTE5OTk_1869f656-c97d-46ce-a4c8-4198370e7c9a">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iee51e9d440a047eebd1e8bf2e351748c_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtNC0xLTEtMTE5OTk_4d551be7-9048-49bf-a8e4-e046c2616a03">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib657a40efdff4a8abe6d4859411ae9a1_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMS0xLTEtMTE5OTk_86ebb6b8-729d-4ae9-984c-cfec3314e7e9">40</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMi0xLTEtMTE5OTk_51a3dd2f-9454-4978-9f14-7e355524a7e9">70</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMy0xLTEtMTE5OTk_87b109d7-6eb3-48ad-ac5c-3a07ca33f130">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie7799f346c5b4b37b8b69785c49cf119_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtNC0xLTEtMTE5OTk_610f5768-6521-43f2-9111-3795de119f8f">110</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMS0xLTEtMTE5OTk_27662817-7874-4d0d-8534-6f8b91408a99">454</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMi0xLTEtMTE5OTk_c0e199cc-f1b3-411a-9d13-1e0a9b340f8b">70</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMy0xLTEtMTE5OTk_c0df4ff6-19f0-4535-ae47-54e1e8f76c3a">97</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtNC0xLTEtMTE5OTk_73ed0050-ddb7-4d27-8fc9-5fb3dc3f211d">428</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i870b46227e5f404d9dceb9f10b09fa00" continuedAt="if8423950a06943f39df5caf0a614a7ed"><ix:continuation id="i9830891fe4174f0f9be50b72ae2483ad"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:43.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1ec1a6d0e59f4fa0a6f189b7aa6224ad_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMS0xLTEtMTE5OTk_7dece46f-8c54-4d7e-9292-3c56273f611d">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMi0xLTEtMTE5OTk_7e69c17b-18a8-4941-b34c-7de017278eaa">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMy0xLTEtMTE5OTk_e0e915cc-8176-45ee-8ee5-66798a061460">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3b309086b1c64082bcccc5093b2b7923_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtNC0xLTEtMTE5OTk_f2893a87-e39e-4b7c-9603-6c1426377094">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4b79b0b3f6a5401baa1cee18c3d6fedb_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMS0xLTEtMTE5OTk_66766096-f2b4-4cfa-880f-db19190b7bbc">331</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMi0xLTEtMTE5OTk_63812106-3bdd-4565-979d-911c193d9db2">83</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMy0xLTEtMTE5OTk_b3c4923b-e292-451f-a791-92a7d7ecc7cc">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i00cc8afb53664ed8b93b3511d260adb5_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItNC0xLTEtMTE5OTk_99db3375-09c9-47b8-a04d-00388d7f778e">414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4a2056a247c446a399326de355e4dd00_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMS0xLTEtMTE5OTk_f00a3558-55bf-4b91-9c18-2dae657333b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMi0xLTEtMTE5OTk_ee9578bd-79e0-4db0-b5ac-58fc4e389065">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMy0xLTEtMTE5OTk_77187638-9c06-4711-803a-53a2240ec59e">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icf9d433b2a87420884917078664d7f8f_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtNC0xLTEtMTE5OTk_8faab1ed-bdf3-4be1-bb78-487c5af2b55c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i31eefc648a754106ba154cff1e338702_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMS0xLTEtMTE5OTk_68cde649-6d01-42bc-8174-415839a1d9f8">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMi0xLTEtMTE5OTk_15f57d63-4f15-4d35-a54c-08dc5203b417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMy0xLTEtMTE5OTk_adfad7e9-c210-439f-8d04-9e6e4e1019d3">164</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia38ca1b371aa43d5a00e50015286da3e_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtNC0xLTEtMTE5OTk_e969bf00-c3bf-48b3-9aa5-0027c95d0449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2f8df14f2f9d420ca23cd6a4dbaf06f0_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMS0xLTEtMTE5OTk_306fb1ef-03ca-432b-9bc6-85459510a1ab">164</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMi0xLTEtMTE5OTk_c0bf8060-c344-4998-aae7-1d10f8a94725">40</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMy0xLTEtMTE5OTk_40fd729a-11d3-4483-951a-de9f7a7aadfc">164</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib657a40efdff4a8abe6d4859411ae9a1_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtNC0xLTEtMTE5OTk_18969ad8-0dbb-43ef-a4ad-28a36bf4445e">40</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMS0xLTEtMTE5OTk_0fdb37e5-8aef-4c03-a596-8701b324dc00">495</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMi0xLTEtMTE5OTk_93f47c7c-12b7-4e78-98f1-c108f17a3a29">123</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMy0xLTEtMTE5OTk_933232a8-9652-4168-bd05-5d082db94bdd">164</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtNC0xLTEtMTE5OTk_d94d0824-d9be-4496-b214-d0811d0a81c7">454</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases</span></div></ix:continuation><div style="text-indent:3.83pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">11.1 Current provisions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Provisions for disputes comprise employee disputes in progress. The increase during 2021 and 2020 of &#8364;<ix:nonFraction unitRef="eur" contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI3ODU_1514e101-fedf-43b7-ba9e-ce593e75ddb0">54</ix:nonFraction>&#160;thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI3OTI_6c443398-3ce5-4f4e-9ca1-3b765e6cdb4a">40</ix:nonFraction>&#160;thousand, respectively, were due to a new employee dispute that occurred during the respective years.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the reversal of provisions for charges of &#8364;<ix:nonFraction unitRef="eur" contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231" decimals="-3" name="nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI5Njg_bc7e0c3f-b419-4d00-8391-d13ef8f3d292">164</ix:nonFraction>&#160;thousand were related to termination costs accounted for in 2019 following an employee departure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">11.2 Non-current provisions</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTU_4b903b4a-fb80-4371-8163-41a9f943682e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Commitments for retirement benefits</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzEtMS0xLTEtMTE5OTk_6ad9cf82-c855-47e6-9ca6-58d962c50062">414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzEtMi0xLTEtMTE5OTk_599f0445-886e-4793-926d-f94d366736a3">331</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzItMS0xLTEtMTE5OTk_30553c81-6dd5-4def-982f-c4428eef4626">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzItMi0xLTEtMTE5OTk_f362b09b-519c-4e45-bd98-d6961d4b2abe">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interests / discounting costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzMtMS0xLTEtMTE5OTk_9af69eea-fec4-4c90-ac20-8a24fd30d05d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzMtMi0xLTEtMTE5OTk_7c8c9edc-6adc-47b8-9392-cd2a95243339">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzQtMS0xLTEtMTE5OTk_af849f26-09ec-4a73-9d97-6d9b17b6802e">85</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzQtMi0xLTEtMTE5OTk_51aab08b-a62d-4684-8cdf-3aa3eaa76a27">79</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to experience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzUtMS0xLTEtMTE5OTk_7aefea0d-9a7e-410e-8aec-0649cfbd4ace">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzUtMi0xLTEtMTE5OTk_3f7e3709-43d8-4f2a-ad3d-40416b5e1f51">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzYtMS0xLTEtMTE5OTk_b5c3e745-1c56-4f1f-b4d8-c4e718108a20">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzYtMi0xLTEtMTE5OTk_29f54794-dd98-4947-bb4f-1b1cc7339e86">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in financial assumptions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzctMS0xLTEtMTE5OTk_ed5d7b94-0825-4a73-8494-fe2db605aeed">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzctMi0xLTEtMTE5OTk_c2df9566-f067-49fd-ad97-4891c8f41b0d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial gains or losses recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzgtMS0xLTEtMTE5OTk_4a419b56-5ac1-4fab-b7dd-1c8171e29bc6">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzgtMi0xLTEtMTE5OTk_40bf6ade-e44d-43ba-8eb3-7f17f6143b91">4</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzktMS0xLTEtMTE5OTk_eb925ad7-03bf-4baf-aa20-a08ec178a213">318</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzktMi0xLTEtMTE5OTk_d5f01f1a-00d8-47b8-8cb0-1ec67ee91624">414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTY_8b5dc1b7-a5b2-40d9-9a2a-9b73684a0b38" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The assumptions used to measure lump-sum retirement benefits are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:54.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Measurement date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retirement assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age <ix:nonNumeric contextRef="i2ff4e8698b934f5ca052b72aca594ec8_D20210101-20211231" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZTA1N2NjZGU3NTM0YzhlYTk5YWYxOGUyNWRmNmE5MV8yMQ_cf346467-b900-4984-a575-7c70a694ef06">66</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age <ix:nonNumeric contextRef="i4d9f94f4d137434787ce8c4eaa14426e_D20210101-20211231" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZTA1N2NjZGU3NTM0YzhlYTk5YWYxOGUyNWRmNmE5MV80NA_87f9a485-87e8-4eb0-9b8b-d4bb72b358bb">64</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age <ix:nonNumeric contextRef="if9d81d56997d4d9c87371cf48ed31342_D20200101-20201231" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxOTJmNDc1ODMyMGQ0MzYwYmJjZGZiOTU5YmU1NmNhZF8yMQ_2f691641-709f-45fc-a702-a8f087248aeb">66</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age <ix:nonNumeric contextRef="i00fb905b6ac2460fbb950029daa312f8_D20200101-20201231" name="ifrs-full:ActuarialAssumptionOfRetirementAge2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxOTJmNDc1ODMyMGQ0MzYwYmJjZGZiOTU5YmU1NmNhZF80NA_0126a5ef-4220-4a2a-8919-b1024bae90d2">64</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Social security contribution rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:ActuarialAssumptionOfSocialSecurityContributionRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzItMS0xLTEtMTE5OTk_aeb4858b-34b4-42d6-970b-40031504c0ea">42.01</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="nbx:ActuarialAssumptionOfSocialSecurityContributionRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzItMi0xLTEtMTE5OTk_39636384-894e-4be7-9971-d9cc61f28b81">44</ix:nonFraction> %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzMtMS0xLTEtMTE5OTk_6c7386d6-f52f-4040-9898-0079d62c0019">0.98</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzMtMi0xLTEtMTE5OTk_f2370872-826f-400b-b3f6-18341689bc39">0.33</ix:nonFraction> %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mortality tables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2015 -2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2014 -2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Salary increase rate (including inflation)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: <ix:nonFraction unitRef="number" contextRef="i20fe37bb0cdf444b83b46778e2b4506e_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1Y2I4ODNmMThmOWM0YWQ5YjUzYTM2MGY2ODM1ZDdjY18xNQ_c429f2bf-4f85-45c5-89d5-ebf36ff8c281">3</ix:nonFraction>%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: <ix:nonFraction unitRef="number" contextRef="i52f0c77f0c744ce19a75d7d15fcb5f32_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1Y2I4ODNmMThmOWM0YWQ5YjUzYTM2MGY2ODM1ZDdjY18zMw_712ae07d-6f4b-431c-8044-93729baab5c8">2.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: <ix:nonFraction unitRef="number" contextRef="ie314f470deb843f992c5a952cdab570c_I20201231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxYjhjM2I5ZDM0MzU0ZTc5YTkyNGQ3YTIzNTcwNjJiMF8zMjk4NTM0ODgzMzY3_d167a703-a842-445f-aa42-450c19e7388c">3</ix:nonFraction>%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: <ix:nonFraction unitRef="number" contextRef="i6f003eaa769045d399df6708982c5689_I20201231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxYjhjM2I5ZDM0MzU0ZTc5YTkyNGQ3YTIzNTcwNjJiMF8zMjk4NTM0ODgzMzc0_f8487120-44ee-43e2-8f3d-6f14c80642b6">2.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Staff turnover</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of <ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzYtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo5Yzc1OTllYTJlZjI0ZjhkYTVhMTU2MjcwNmM1NGU4MF8yOQ_d8c939a5-8ae4-4a3a-8943-62b77e5ca33e">5.86</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of <ix:nonFraction unitRef="number" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzYtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxMTRlM2I1NzkxMGY0ZjI5OTdjNzc0MDVhNDA4MTg5YV8yOQ_34b181e2-fc69-4416-aa59-9341257cee8d">5.86</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Duration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzctMS0xLTEtMTE5OTk_3c3d9c7f-7122-4103-9c99-d6b4d8380e39">20</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" name="ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzctMi0xLTEtMTE5OTk_17ca0b08-3aae-4d15-bffd-cbb06cb6d6b1">17</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The rights granted to Company employees are defined in the Collective Agreement for the Pharmaceutical industry (manufacturing and sales of pharmaceutical products). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The staff turnover rate was determined using a historical average over the 2015-2019 period.  </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="if8423950a06943f39df5caf0a614a7ed"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzg_9605f122-6a10-4579-9426-00cc4289a242" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The sensitivity to the discount rate and to the salary growth is as follows:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:53.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMS0xLTEtODI5MDI_141abfc9-d946-4190-97e4-7405430ef660">0.73</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMi0xLTEtODI5MDI_d653edb2-aff8-4728-812d-c00aa1577b22">0.98</ix:nonFraction>%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="nbx:ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMy0xLTEtODI5MDI_61e1d56c-b042-4d69-b223-dabe40876520">1.23</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defined Benefit Obligation as of December 31, 2021<br/>(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231" decimals="-3" name="nbx:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMS0xLTEtODI4OTQ_44ab201d-918e-4b9d-b37d-0fa853b95b75">333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231" decimals="-3" name="ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMi0xLTEtODI4OTQ_2889aaa6-35e2-4f69-be43-a035f5cd4cb0">318</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231" decimals="-3" name="nbx:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMy0xLTEtODI5MDI_0c20c780-feca-4bda-8f75-de78a2647eac">303</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The company does not expect to pay a material amount of benefits for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzk_e3c5a367-0c4d-4262-b3f1-35ea622dad92">five</span> next years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i377d9717844147e799376babda10462f_169"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 12. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfFinancialLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI4_aadf278b-7ba5-4cc0-aa38-6919e4d43dba" continuedAt="i9274b17ca7434a36898940b81b8f0488" escape="true">Financial liabilities </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9274b17ca7434a36898940b81b8f0488" continuedAt="i2e1e8ae09c4f4c20aca2b2ffacfec282"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMz_35da83e6-82e0-4f56-80f3-55bc54bc1e50" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives assistance in the form of grants, conditional advances and interest-free loans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Financial liabilities, including trade and other payables are valued at amortized cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Financial liabilities at amortized cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; Financial Instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i2e1e8ae09c4f4c20aca2b2ffacfec282" continuedAt="i728fa7a0193e4f539733c5b7a1077343"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI5_46f60c89-afad-4eef-93ad-6cb0081e52ff" continuedAt="ie29351a3963241d4889427958ef04cd0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Details of financial liabilities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id9e19e74602b46bfa5b381e3de4fca06_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEtMS0xLTEtMTE5OTk_31f26159-d5e5-43e8-9f7c-8155150a696c">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ice82a034b6964d1d92ad1d346d346b3c_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEtMi0xLTEtMTE5OTk_bde92f1c-45ed-4a5c-9798-aaf773532ccd">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances - Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic3979f010ce54acda1438941b43765cd_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzItMS0xLTEtMTE5OTk_9ab461ad-5214-4473-9a5c-a2427309ef8d">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzItMi0xLTEtMTE5OTk_8d813aff-5d3a-43fd-8595-c417614f1baa">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifb22c0964cc746dd82cf9597bde3d98d_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzMtMS0xLTEtMTE5OTk_f7a032c1-5a40-464f-9b5e-8dc3179fa2f3">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i860acbbc413c411d9552c930dd50330e_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzMtMi0xLTEtMTE5OTk_1431dbf6-a659-4e7f-a8b8-79ee14c440be">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB Loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i70c9105496ee4b008bc01ccddf108a3e_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzQtMS0xLTEtMTE5OTk_726ab57e-c81f-4601-aeff-85550641ff7a">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6063d413a70f4e42ab228ca05274873e_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzQtMi0xLTEtMTE5OTk_6e392b11-ac6b-41eb-ba8a-01609d0503b9">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzUtMS0xLTEtMTE5OTk_5b99c2e0-f708-4015-a8c5-7ba0e1f0edfd">8,204</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzUtMi0xLTEtMTE5OTk_ec2942de-f91f-4861-92f6-a082529ca64e">4,872</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id9e19e74602b46bfa5b381e3de4fca06_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzYtMS0xLTEtMTE5OTk_850f1c90-2817-4d2e-b527-95f8137da173">5,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ice82a034b6964d1d92ad1d346d346b3c_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzYtMi0xLTEtMTE5OTk_ba228755-7dec-4508-97a8-cd747e8e6b13">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic3979f010ce54acda1438941b43765cd_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzctMS0xLTEtMTE5OTk_6a36c693-8e88-4d32-9227-14cccb7d465f">2,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzctMi0xLTEtMTE5OTk_53d5e372-c082-43b3-91d6-5c396d8c915d">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifb22c0964cc746dd82cf9597bde3d98d_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzgtMS0xLTEtMTE5OTk_8de0e258-607e-45c6-b4da-4602f35a0a65">8,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i860acbbc413c411d9552c930dd50330e_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzgtMi0xLTEtMTE5OTk_c9c4f582-d212-48d2-b277-696b4f71c2f3">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i70c9105496ee4b008bc01ccddf108a3e_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzktMS0xLTEtMTE5OTk_382241d3-68f6-42cf-8550-d00b2fafddf8">21,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6063d413a70f4e42ab228ca05274873e_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzktMi0xLTEtMTE5OTk_5e8ae866-226b-490c-ad3d-447effb0876c">26,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEwLTEtMS0xLTExOTk5_474d6d37-3b43-4725-a901-1aff87f589fa">37,816</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEwLTItMS0xLTExOTk5_0930a64e-24a6-4c1f-8ff3-3d741f60bd62">44,107</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzExLTEtMS0xLTExOTk5_fd97b050-3037-435e-a855-80d0ce28804f">46,020</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzExLTItMS0xLTExOTk5_3a7e5cfc-984a-4ea2-8fc3-2b9fb86ecc05">48,979</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Bpifrance conditional advances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives repayable advances from Banque Publique d&#8217;Investissement (formerly known as OSEO Innovation). Some of these advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for <ix:nonNumeric contextRef="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231" name="nbx:AdvancesReceivedDefermentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMwMTc_2fe40ca7-7f96-4e89-8b10-0c478f1df7ef">18</ix:nonNumeric> months. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The other advances are bearing <ix:nonFraction unitRef="number" contextRef="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231" decimals="4" name="nbx:AdvancesReceivedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMDA_abfad00c-73ac-43c3-ad65-ad94bddb37da">1.56</ix:nonFraction>% interest. The amount to be reimbursed corresponds to the amount received to date, &#8364;<ix:nonFraction unitRef="eur" contextRef="id26c49ada5ea49f6925b076f04f65999_I20181231" decimals="-5" name="ifrs-full:Advances" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMwOTM_18ab72b7-f9ab-4c4a-815a-4d3d2150ee03">2.1</ix:nonFraction>&#160;million, increased by the interest amount (see Note 12.1). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In June 2020, Curadigm SAS obtained a &#8364;<ix:nonFraction unitRef="eur" contextRef="i4f9f36c6b44349068238dd8813d5bb59_I20200630" decimals="-3" name="nbx:AdvancesAuthorizedAmountToBeAdvanced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMxODc_f3e8201a-fc48-46ee-af7b-53bfb0c5aab8">500</ix:nonFraction>&#160;thousand conditional advance from Bpifrance, &#8364;<ix:nonFraction unitRef="eur" contextRef="i4f9f36c6b44349068238dd8813d5bb59_I20200630" decimals="-3" name="ifrs-full:Advances" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyMjY_6124fc11-1ba2-49ef-acb0-10cebcab45a3">350</ix:nonFraction>&#160;thousand of which was received at the signature date while the remaining amount had been scheduled to be received by Curadigm at the end of the work, expected as of March 1, 2022 at the latest, but Curadigm SAS requested an extension of the work period to Bpifrance as a result of COVID-19 which - in case of Bpifrance&#8217;s approval - could result in collectibility of the remaining &#8364;<ix:nonFraction unitRef="eur" contextRef="if4f90ba5db684b64a31830ebf03467df_I20211231" decimals="-3" name="nbx:AdvancesOutstandingAmountToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMDc_6254ced9-a7a0-4d0c-87c7-4c40b2a939f9">150</ix:nonFraction>&#160;thousand. As of December 31, 2021, the work had not been completed and the balance, therefore, has not been paid.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i8e7d5a08503c4c58999df6bf6e4c20d4_I20180731" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1MDg_9adee9b3-3e31-4736-898c-9da1d144a12f">40</ix:nonFraction>&#160;million, divided in <ix:nonFraction unitRef="tranche" contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731" decimals="INF" name="nbx:NumberOfTranchesBorrowings" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1MjM_2e940eae-0431-4ca3-ae11-f5aafeb9bde0">three</ix:nonFraction> tranches. The first tranche, with a nominal value of &#8364;<ix:nonFraction unitRef="eur" contextRef="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1Nzk_ef8bfa0c-4a10-4038-b94d-85cb6c59b1e7">16</ix:nonFraction>&#160;million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of &#8364;<ix:nonFraction unitRef="eur" contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM3ODM_c72b8774-9ef1-4b9c-b018-c84cb33ccefb">14</ix:nonFraction>&#160;million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, had been delayed by <ix:nonNumeric contextRef="i730862d53f524fd48823ccef1c727d85_D20200701-20200731" name="nbx:BorrowingDefermentPeriodToRequestFunds" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzQzNDQ_4bf1afab-3c9f-4066-944f-7de40f44a3f7">12</ix:nonNumeric> months to July 31, 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As the conditions were not met by July 31, 2021, the Company will not be able to request the final tranche of the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to the terms of the loan, the Company is also required, during a <ix:nonNumeric contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731" name="nbx:RoyaltiesAgreementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM0_8d782cae-8e72-4810-a63d-e816cf49332f">six-year</ix:nonNumeric> royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.2). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 of our consolidated financial statements for details about the impact of this sales forecast update). A 10% </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i728fa7a0193e4f539733c5b7a1077343" continuedAt="i33cd965ac0774d128e1e3badd95653e6"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">PGE loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#8364;<ix:nonFraction unitRef="eur" contextRef="icdb43c79419c4ae4a549589fcd0ea3d5_I20200630" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzU5MDE_75b40caa-8004-493d-88b2-375387e4901c"><ix:nonFraction unitRef="eur" contextRef="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630" decimals="-6" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzU5MDE_adeff891-3d2f-4624-82b7-418b66d6c40b">5</ix:nonFraction></ix:nonFraction>&#160;million each in the form of state-guaranteed loans (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;, or &#8220;PGE&#8221; in France); the &#8364;<ix:nonFraction unitRef="eur" contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYwMDI_46057d4e-95ec-480c-9dbf-66dcf8897221">5</ix:nonFraction>&#160;million from HSBC (the &#8216;&#8216;HSBC PGE Loan&#8217;&#8217;) was received in June 2020. This loan is booked at amortized cost for a minimum of <ix:nonNumeric contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630" name="nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxMjE_93d1fe47-04f9-43aa-ae2b-834f33e69ad1">12</ix:nonNumeric> months and allows the Company to delay the reimbursement of this <ix:nonNumeric contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630" name="nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxODI_e1823eef-dd57-4eec-8327-5c86bbc91e50">12</ix:nonNumeric> months loan by <ix:nonNumeric contextRef="i677dc547692443839295f53c6d89dbdd_D20200601-20200630" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxOTM_b6f540fb-3fb0-480c-82e4-bdfd50e7a241">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i4e96e3484ed74cb680b4ae9eab1f7e13_D20200601-20200630" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxOTk_9ed4bdfd-9bbc-48cf-b973-d03ef67f9563">5</ix:nonNumeric> years. The Company uses this option and the reimbursement date was delayed by <ix:nonNumeric contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYyNzg_fe2ea2bd-d405-4db8-9a8c-a51c9875ba43">1</ix:nonNumeric> year and will start in September 2022. The effective interest rate amounts to <ix:nonFraction unitRef="number" contextRef="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIwOTg_80da6e90-8d8d-4830-86ed-745448c67ca9">0.31</ix:nonFraction>%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On July 10, 2020, the Company entered into the second &#8364;<ix:nonFraction unitRef="eur" contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" decimals="-6" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY1Mzc_1b55b65f-246a-4e83-8378-03db1bf29a40">5</ix:nonFraction>&#160;million PGE loan with Bpifrance (the &#8216;&#8216;Bpifrance PGE Loan&#8217;&#8217;). The Bpifrance PGE loan has a <ix:nonNumeric contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" name="nbx:BorrowingMaturityTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMw_f3936990-ea96-424f-8edf-c2adc17a3eef">six-year</ix:nonNumeric> term and is <ix:nonFraction unitRef="number" contextRef="i0602bff51649496c9da805f828e74529_I20200710" decimals="2" name="nbx:BorrowingPercentageOfStateGuaranteedLoan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY2NDM_a18ad9a8-ed48-4e18-9f6b-0566013e2d53">90</ix:nonFraction>% guaranteed by the French State. The Bpifrance PGE loan did not bear any interest for the first <ix:nonNumeric contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" name="nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMx_bfc3075a-8ab8-40bb-bc67-8ab30ecf935d">12-month</ix:nonNumeric> period but, following such <ix:nonNumeric contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" name="nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM1_8f01415b-9c14-48be-b0e7-0683219ab998">12-month</ix:nonNumeric> period and for the subsequent <ix:nonNumeric contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" name="nbx:BorrowingMaturityTermSubsequentPeriodBearingInterest" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY4MTI_65460f96-dc18-485d-b563-dc5ed170e98a">5</ix:nonNumeric> years, is bearing an interest rate of <ix:nonFraction unitRef="number" contextRef="i0602bff51649496c9da805f828e74529_I20200710" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY4NDY_8e0c2b98-4c7c-440f-a6b8-6adb82725028">2.25</ix:nonFraction>% per annum, inclusive of an annual State guarantee fee of <ix:nonFraction unitRef="number" contextRef="i0602bff51649496c9da805f828e74529_I20200710" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY5MDY_69dd4941-fe9d-4425-b67c-a0c1b3dec813">1.61</ix:nonFraction>% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in <ix:nonFraction unitRef="quarterly_instalment" contextRef="i44a077384c26495caae329e040555472_D20200710-20200710" decimals="INF" name="nbx:BorrowingNumberOfQuarterlyInstalments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY5OTU_1969c4f3-85a3-4aec-b2d4-f0635e21de58">20</ix:nonFraction> quarterly installments as from October 31, 2021 until July 26, 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.1 Conditional advance, bank loan and loans from government and public authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMy_6dd3e811-f6e3-489b-9d60-490ed5fdea6d" continuedAt="icc480357c83b46eeaabd7cef3cd31d73" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conditional advances and loans from government and public authorities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"></td><td style="width:33.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0110777e52b3473f8b462de884b09e80_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMS0xLTEtMTE5OTk_d6b66057-9647-4cf8-a2de-041fec71b2ad">2,165</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i24a151e2334941ad93f623e660566efd_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMi0xLTEtMTE5OTk_075b50f5-03f0-4fe3-a9a0-549388c636c0">1,210</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ieae65f3974804742b4ab99567efade16_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMy0xLTEtMTE5OTk_1669cfea-d5fb-432b-b8e7-97b35649afd3">34,746</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7917ccaea2634af4a65d44c4873dfc76_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctNC0xLTEtMTE5OTk_2af11f8a-c376-4dec-832c-f57d900a9203">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9ba645486aa240169be18398fc400965_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctNS0xLTEtMTE5OTk_6bcd1703-6a94-4643-ac17-6f945ffdeec7">38,121</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMS0xLTEtMTE5OTk_1e58831b-351d-4988-afc2-ce448612377a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMi0xLTEtMTE5OTk_1e22ffd1-0712-40f9-8575-ed4e04ddc9df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMy0xLTEtMTE5OTk_b39d288e-d52c-4f46-939f-dcf6e0b5d891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNC0xLTEtMTE5OTk_8d655887-a0ff-466e-9684-fc095ce509f3">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNS0xLTEtMTE5OTk_33a3ff05-2abe-4824-ab8b-3b79298bd1ad">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMS0xLTEtMTE5OTk_e3a263ed-0b53-44cd-80d0-224951ac6d42">19</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMi0xLTEtMTE5OTk_51363f8d-541b-4106-8b9e-9dd170b0c0fd">14</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMy0xLTEtMTE5OTk_9455becd-321c-454e-8533-6c7b67785fd7">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktNC0xLTEtMTE5OTk_29a5fc89-ca6d-4538-8f29-04797ad60679">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktNS0xLTEtMTE5OTk_4d9d45a3-f8eb-4c81-a186-9a5b9893ffc8">1,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTEtMS0xLTExOTk5_83f2f73d-656e-4979-860a-619c9c13071a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTItMS0xLTExOTk5_b7db85ee-8706-41f4-9e6b-c5a2baaad5de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTMtMS0xLTExOTk5_1f1c8496-bf5d-4d05-95df-617980188561">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTQtMS0xLTExOTk5_afaa132b-7073-4235-a9ea-c43f7efbe5c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTUtMS0xLTExOTk5_aa3daa5f-7630-4ed1-8a92-f7a43ef7af1b">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTEtMS0xLTExOTk5_5eebd579-77ff-4e92-841e-4f07890934cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTItMS0xLTExOTk5_92e5ebf6-f790-4888-a28d-7244ee556389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTMtMS0xLTExOTk5_b1c3a3af-3a68-42a7-be63-9b8e9ae01382">4,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTQtMS0xLTExOTk5_01048683-908f-4426-8321-90c68504b228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTUtMS0xLTExOTk5_b04539bb-70b8-44ca-8259-0e02cf6a8651">4,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTEtMS0xLTExOTk5_0bc70f06-a89f-4592-80d5-ca3cddcd31ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTItMS0xLTExOTk5_baf67e56-b41f-4a22-905e-8ae6819ff16d">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTMtMS0xLTExOTk5_7a631e2c-f779-4475-9f9b-3f32863b7ded">700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTQtMS0xLTExOTk5_52ac0c85-38c2-4431-bc03-8eb188e08e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTUtMS0xLTExOTk5_76cabfe6-9b71-4d29-b45a-81acf8de3c20">950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2608a211d394427a2eb417f85f7c460_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTEtMS0xLTExOTk5_f84fadc7-1e64-41d9-82b5-a313378d403a">2,216</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4ce52155b2714380bea43bb9d5364790_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTItMS0xLTExOTk5_6bb362a6-fc1f-4f67-9426-0c03ac3c536f">974</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7d080d4ae22f49209fad3088f5cd1717_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTMtMS0xLTExOTk5_5fbce352-4fe6-4f04-9698-b337e92b534c">29,251</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia690845ba75d4a2d9817787693b33552_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTQtMS0xLTExOTk5_5091cde1-6b9b-41fb-a741-23ee7fb1ec1e">285</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3325ccb1e560443f9ddb6eddf043414a_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTUtMS0xLTExOTk5_dbb345aa-d6d0-4dbd-a4c1-1731c245b96f">32,727</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMS0xLTEtMzkwNzI_4b899309-e842-41eb-9a02-27d500f82591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMi0xLTEtMzkwODI_1e706144-84d8-4ec3-a761-905bb5b68ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMy0xLTEtMzkwOTA_42619fa3-d822-4a10-bd4a-591e241a4539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNC0xLTEtMzkwOTY_3ff96a10-c1d8-47d2-90a9-6d8c02596d86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231" decimals="-3" name="nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNS0xLTEtMzkxMDI_bb613b5d-a5b2-43e8-8ead-51d24aaff87f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTEtMS0xLTM5MDcy_4460e9b1-03b2-47e9-9ad6-2e23a0d4326e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTItMS0xLTM5MDgy_cc670076-07d0-4354-bde8-57e14a4ad611">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTMtMS0xLTM5MDkw_463ee946-9a74-45e4-870d-296b6d19170c">5,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTQtMS0xLTM5MDk2_fe38decf-c0a3-46c9-be33-605e530388d8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTUtMS0xLTM5MTAy_fd88c7ab-4728-4b09-b31f-08020343b857">5,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTEtMS0xLTM5MDcy_ebae571f-18f9-4b70-ac54-cb74821a0569">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTItMS0xLTM5MDgy_788042f3-c4cd-4fcc-8d11-0f62afef6005">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTMtMS0xLTM5MDkw_2714abc3-9d97-4a55-be92-e30a55c67124">1,758</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTQtMS0xLTM5MDk2_5d0dfb88-ea45-4281-877d-e3725c3af833">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTUtMS0xLTM5MTAy_f20d6461-b45d-41cd-a776-be3455403cbc">1,790</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTEtMS0xLTM5MDcy_522f9aae-3cf5-4f59-91e9-9b477f8d60c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTItMS0xLTM5MDgy_94ce43ab-48d9-4067-bdcb-99a52057b49e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTMtMS0xLTM5MDkw_1fffb342-4c4b-4a84-b94d-e4ee8e62901c">4,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTQtMS0xLTM5MDk2_c349b474-7ff4-4464-ab86-b823cb1c0085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTUtMS0xLTM5MTAy_1b5d585c-8477-4b96-ac98-d76e51d2552d">4,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTEtMS0xLTM5MDcy_f9c5eef3-56ca-465b-ae7a-b5132fbcc386">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTItMS0xLTM5MDgy_a6e14eac-f6c8-407e-80d8-eac33029752c">500</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTMtMS0xLTM5MDkw_bd15c0d9-3779-4f89-a762-bd4d497a3d28">3,033</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTQtMS0xLTM5MDk2_bdc91560-3408-4eae-8421-e1ee5ac318eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTUtMS0xLTM5MTAy_dea0e59b-7104-468c-800b-78b035912864">3,533</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i501dadac2baa4da2b169943189296894_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTEtMS0xLTM5MDcy_36623d4b-e02d-40dc-b96c-a7a66eeb5e52">2,266</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i166567b173294d53b3207d7758ed8744_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTItMS0xLTM5MDgy_40abb4a5-4252-4191-8d21-efdc8a9dc56d">493</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia6fda04984b54ecd9c6ae4c8f6433521_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTMtMS0xLTM5MDkw_30a59801-7bc5-487f-8d0c-ca10f04cacef">26,374</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5f6c485623c34a36a0a0c935c03af6b5_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTQtMS0xLTM5MDk2_40aa7ae9-6b3d-4372-baeb-36623fdf62d5">300</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9b283275fffa429aa785167b228d13d9_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTUtMS0xLTM5MTAy_a07c541d-5dbf-488c-a8da-a4f78b98d037">29,433</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact of discounting and accretion of &#8364;<ix:nonFraction unitRef="eur" contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231" decimals="-5" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzkwMDQ_07633829-89d3-4d15-bb2d-5a4c5029680b">5.8</ix:nonFraction>&#160;million, in 2021 relates to impact from the &#8220;catch-up method&#8221; related to the variable compensation further to the royalty component in the EIB loan that is linked to future revenue expectations. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. The rest of the catch up impact is presented on the line variable interest future payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The expected royalty payments to be made in the future, initially estimated as &#8364;<ix:nonFraction unitRef="eur" contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231" decimals="-5" name="nbx:RoyaltyPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwMDk0_939a7ccc-3367-4f37-a12e-a22e0ee22bae">17.2</ix:nonFraction>&#160;million as of December 31, 2020 have been updated to &#8364;<ix:nonFraction unitRef="eur" contextRef="ia00db9d1206a4981b2ae432d997b3bfb_I20211231" decimals="-5" name="nbx:RoyaltyPayables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwMTE4_c17e7653-5920-4bf1-913c-fa15cf496e39">3.4</ix:nonFraction>&#160;million as of December 31, 2021. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i33cd965ac0774d128e1e3badd95653e6" continuedAt="ie1ac5f69a9094aeb8f424b552949d771"><ix:continuation id="icc480357c83b46eeaabd7cef3cd31d73" continuedAt="ic1f7c1de408c484a89a61e3588134356"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Bank loan</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i34b69bb03edc48d388d2b08bd8342672_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMS0xLTEtMTE5OTk_4a5a362f-d5f8-4737-b08c-0b7b8ed6b674">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i61f3c9741ef74beea34a7372eea88c9d_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMi0xLTEtMTE5OTk_95ee7181-9941-41a9-bec9-21e5d013114b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i06da0291c1964865b0bee57ea7df6660_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMy0xLTEtMTE5OTk_6a6d6b2d-b942-4ec0-b647-29b9c73824e0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMS0xLTEtMTE5OTk_b1734973-bb18-4ad3-8ac7-fddc2c2e43ba">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMi0xLTEtMTE5OTk_9357e51b-d388-44de-8fd1-bff68d3a7c99">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMy0xLTEtMTE5OTk_f8bdc1cb-1f28-4be2-9dbe-d0ad6fc3b7d7">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMS0xLTEtMTE5OTk_0abc880d-1e2a-4f53-bd93-ca4bfec28c2b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMi0xLTEtMTE5OTk_57120558-1b18-4dfa-b05f-80e47850966a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMy0xLTEtMTE5OTk_efded511-8f5e-41a7-9e0f-7a15d77691bb">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMS0xLTEtMTE5OTk_6044c0c0-96f9-4dd4-b72d-d18e32e7ce79">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMi0xLTEtMTE5OTk_977f3caa-a8ab-4e60-af51-f74f62b6b0f6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231" decimals="-3" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMy0xLTEtMTE5OTk_3f98de85-bbaf-423f-8312-3259f5ccccb9">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i42ac85adcce64257b4ab0b5899397068_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMS0xLTEtMTE5OTk_e9062add-4d1c-4fe8-855c-c9b22a86468d">5,020</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id9db631ab0a946ffa6c39533461876b1_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMi0xLTEtMTE5OTk_a3229c06-b3ae-4ece-bb91-3a4fb3f80f7c">5,044</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id83ab7ac51814807be706998f4cc09e1_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMy0xLTEtMTE5OTk_30a6f582-a6c2-4f2e-a160-d8934fc6fd32">10,064</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMS0xLTEtMTE5OTk_b763f028-2db8-4a84-b195-e57d912726f0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMi0xLTEtMTE5OTk_ae72e5b0-2c05-4dff-9714-b3cbdab48514">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMy0xLTEtMTE5OTk_4bf137ba-becd-49ea-a6b8-a2d75e059f25">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMS0xLTEtMTE5OTk_7a3f0cad-58f1-400a-b6da-fe82275b1223">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMi0xLTEtMTE5OTk_49f585ad-dee9-4070-afe7-de9e68f9f274">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMy0xLTEtMTE5OTk_dcbb0a62-b227-4f2a-9a5c-c340edf513ba">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMS0xLTEtMTE5OTk_80ffc50c-c350-4762-9f34-e89971794975">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMi0xLTEtMTE5OTk_a5598afc-d17d-4d99-8d7e-fe5c74dfc0d7">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMy0xLTEtMTE5OTk_41a4db28-a419-443f-b5bb-98448a80c4ad">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea99a9d2ede149058f2638ecfe804933_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMS0xLTEtMTE5OTk_7b3f1e30-a155-4919-9d2e-1ab6ae2efb0b">5,030</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie2e7563cfe4f4e48bdebe1cd3babc08c_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMi0xLTEtMTE5OTk_fe29eead-fb78-4c91-bbc2-d69ed05685f2">5,038</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3aa2ca3eec9341eea4ebbd1e22088ba8_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMy0xLTEtMTE5OTk_6f6b13e3-6c22-4345-a988-041b07ef113c">10,068</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> In 2020 the fixed interest accrual refers to guarantee fee of <ix:nonFraction unitRef="number" contextRef="i3c4fa6093f8a43df81a2388bcd182126_I20201231" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNDU0_0025f262-a2a0-452b-ae76-3a8cdd18809e">0.25</ix:nonFraction>% of the principal of the HSBC PGE loan and to a guarantee fee of <ix:nonFraction unitRef="number" contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNTIx_af074d85-2914-429a-aa23-b1c4fcba01fe">0.25</ix:nonFraction>% added to a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNTU4_2d3c2125-482c-48cd-9e13-b34ba91664b5">1.36</ix:nonFraction>% for the Bpifrance PGE loan, respectively. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ic1f7c1de408c484a89a61e3588134356" continuedAt="i4c591adee46148dcbf3b8c08e23146e1">(3)</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i4c591adee46148dcbf3b8c08e23146e1"> In 2021 the fixed interest accrual refers to guarantee fee of <ix:nonFraction unitRef="number" contextRef="i127de2da61e64e78845c4c06ce48cee7_I20211231" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNDE_8ac04630-6755-4b83-9d39-5f54ea2d3422">0.25</ix:nonFraction>% of the principal of the HSBC PGE loan and to a guarantee fee of <ix:nonFraction unitRef="number" contextRef="i66337c960fa942618f0543d1c09dfea5_I20211231" decimals="4" name="nbx:BorrowingGuaranteeFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNTQ_b792c8fd-c9a0-4c79-b216-c402f0d7593b">0.25</ix:nonFraction>% added to a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i66337c960fa942618f0543d1c09dfea5_I20211231" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMjg_c5571d54-f921-4e08-9866-84939e36bd29">1.36</ix:nonFraction>% for the Bpifrance PGE loan, respectively.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.2 Lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM2_b1306bfb-3ded-49e8-bf6c-c71b8475017a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1st,  2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i03fc764f222342e8a738cfe4737267f0_I20191231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEtMS0xLTEtMTE5OTk_2c59937e-446e-4963-9bc8-da68a17c2315">6,405</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New lease contracts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzItMS0xLTEtMTE5OTk_6495c425-2239-4618-91d7-8c0bd9a04390">521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting of the new lease contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzMtMS0xLTEtMTE5OTk_b705d05f-9cb7-4b71-bce7-3ed93fe84ddc">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixed interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzQtMS0xLTEtMTE5OTk_0c589a0d-e870-4640-9f14-33c2637e0d0b">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzUtMS0xLTEtMTE5OTk_cf56b725-9c0c-457e-b685-4fc7e9a81c9b">928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231" decimals="-3" name="nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzYtMS0xLTEtMTE5OTk_907f7dd5-a1ab-47ed-bedb-c5277756539b">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i74e0b22ef5ef4129b1e88005177dcf0a_I20201231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzctMS0xLTEtMTE5OTk_54d492cb-e033-4adc-880d-35c120a907af">6,188</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Engagement</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzktMS0xLTEtMTE5OTk_ffe8d330-bfd2-4e19-b3c4-421ef75ee856">1,476</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEwLTEtMS0xLTExOTk5_20a81a5d-f156-45ef-b303-0095131cc907">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzExLTEtMS0xLTExOTk5_79f27960-7533-4464-99d9-3a2991a7452e">288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEzLTEtMS0xLTExOTk5_44684b40-d202-4bd9-aa31-18278bb0ecc6">1,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231" decimals="-3" name="nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzE0LTEtMS0xLTExOTk5_e7c00eb6-e1f9-4ff1-b470-ba0f3e5126f8">128</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i91a2318ff64a450380b9438374b59d05_I20211231" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzE1LTEtMS0xLTExOTk5_abdd3558-f8ad-45d7-97fa-2fdb2dbaa87e">6,519</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:3.83pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="ie1ac5f69a9094aeb8f424b552949d771"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.3 Due dates of the financial liabilities  </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI3_91971737-aade-42bd-acab-57ea56f917a6" continuedAt="i82b67f07738c4c1eb824c838db872ceb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:42.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id119775bd1424312ac886a611fd9da80_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMS0xLTEtMTE5OTk_00105b75-278f-4555-bda1-8a549484ab59">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5226cc30782848c99b13dc241995afe3_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMi0xLTEtMTE5OTk_cdfee4f9-3b75-4c08-b9bf-5df488e27da5">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7a94562c5153457ab46aec435a38bf16_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMy0xLTEtMTE5OTk_99837680-ab95-46e4-9660-8101c7eb0ec9">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if72f0771e7134f64a254bb97d9bc45bd_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItNC0xLTEtMTE5OTk_19aa7218-b101-4ef8-b95b-f1632818f1ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia59396251fd945158fa1538f914cc4b7_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMS0xLTEtMTE5OTk_a296711c-5879-4ae3-92ac-cc8b2dac19c6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2295671454b14d6d91210a5944d6c07b_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMi0xLTEtMTE5OTk_d4d6e360-f22d-4423-901b-21ffa42fe8f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iedbfecf36047400ead3aea1bcc9b8a13_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMy0xLTEtMTE5OTk_0256eca7-6a0e-4a9a-bf47-9ab1c0609542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i124ed568f8a24aa78e3ff34558ad81c5_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtNC0xLTEtMTE5OTk_2447246d-f8c2-42aa-b496-4045534946dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7191a356d1c64bd49a626a0c200e1eaf_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMS0xLTEtMTE5OTk_1aca9dd3-4fd3-4a1f-a804-94a97b2ad3a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i69512fc2f0d34eb4b0cf656265fa6930_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMi0xLTEtMTE5OTk_c68460c1-e621-48b5-9396-98acc16bdf67">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i024c28063f484f59b11cb851e436a1c6_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMy0xLTEtMTE5OTk_eba3ace5-45ed-4aca-b5d9-e55ab900d908">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia1502f4415f84bc0ad1e2d41b2f6944f_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtNC0xLTEtMTE5OTk_0bd5bbad-7725-486f-9362-934454b54cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i836bec40340a45258bbea36837952d12_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMS0xLTEtMTE5OTk_4b9b8875-8f4f-4453-b4be-d1fd0a81af56">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i03054a03855b4b37a9b8768c06f2bd7e_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMi0xLTEtMTE5OTk_0b59a8d5-9975-4554-a601-0c7b9ca6eafb">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4cf7bec92f924353b5d3c40835d5e6fd_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMy0xLTEtMTE5OTk_d6ca33d9-4802-4131-8037-2613f2e416d9">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia8a60e1d925a45289d5b33cdd832c02e_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtNC0xLTEtMTE5OTk_2e863336-063f-4880-ae3f-0e8211d0093e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1f3e0b6ca2a945ed8c4fb13c8274f2cf_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMS0xLTEtMTE5OTk_c4619591-8ccf-489a-bf92-c5b7cdf688cb">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2369a7d63f7d4af9aaccfee568c13c3d_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMi0xLTEtMTE5OTk_a265ab27-1703-4e51-a5b8-25b634f6a59c">2,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i18d3c34726ac4988b595b25c132f4bcc_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMy0xLTEtMTE5OTk_a165e534-3e0e-4dbd-bfa8-872709d4f7fc">2,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if8604d938eea43d1ad397edac29826f0_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtNC0xLTEtMTE5OTk_274b268c-8813-4cb5-803e-3ed02fe56f35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idb9f7ca1927d4697a4fe081256782a2b_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMS0xLTEtMTE5OTk_2819be8b-be52-47df-aedc-f65bb65a14d2">5,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia38f8669a4be407cab008b29e2b85d90_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMi0xLTEtMTE5OTk_d5d083ae-cef3-4580-9c56-923caee58494">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2db0464e08894c07a24540e1493e87e9_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMy0xLTEtMTE5OTk_c25382b3-6bf9-4ad3-b382-7b877e3a7dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5abc10eb5d6945cb92399dbc699bfb72_I20211231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctNC0xLTEtMTE5OTk_f2a5e294-5ce9-43f7-9557-3c6cff02da76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05cfdfc0910e47f6becde04d1178f72d_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMS0xLTEtMTE5OTk_715b16dc-2b81-460b-bfe4-00f97f70cdd5">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0ce13eb6ddc140849ea104ec96d8f749_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMi0xLTEtMTE5OTk_431cc3b8-651c-4fec-90ed-f8dc05611e17">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ied1dea9b89304c059d54ab720191a5d0_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMy0xLTEtMTE5OTk_7d122260-f565-4f89-ba06-f12b2d7d48b9">2,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic1eac451531248ea959e4a652e5278e7_I20211231" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtNC0xLTEtMTE5OTk_e00bd117-a4f6-4733-a286-ea31433b9eac">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05cfdfc0910e47f6becde04d1178f72d_I20211231" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMS0xLTEtMTE5OTk_bd0b36a9-ea80-4990-9c2d-aca1b78dac0e">8,204</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0ce13eb6ddc140849ea104ec96d8f749_I20211231" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMi0xLTEtMTE5OTk_504ad026-43cc-4d66-aacf-d06290be4331">37,747</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ied1dea9b89304c059d54ab720191a5d0_I20211231" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMy0xLTEtMTE5OTk_8d942c47-3cf4-4560-8d63-494112943144">7,346</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic1eac451531248ea959e4a652e5278e7_I20211231" decimals="-3" name="ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktNC0xLTEtMTE5OTk_cf838d5c-e14c-474b-aec4-12c27da223ee">1,714</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i82b67f07738c4c1eb824c838db872ceb" continuedAt="i16790ff9b93d4b9b8da68514bc5f43eb">(1)</ix:continuation></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i16790ff9b93d4b9b8da68514bc5f43eb">&#8221;The Company will reimburse the <ix:nonFraction unitRef="borrowing" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="nbx:BorrowingNumberOfPGE" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNzQ_2eaba664-fcf0-41ef-8348-ba33da962a54">two</ix:nonFraction> &#8220;PGE&#8221;or (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) over <ix:nonNumeric contextRef="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231" name="nbx:BorrowingMaturityTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMTM_23379b87-6a95-4b6c-a247-fdb73da65978">5</ix:nonNumeric> years with a deferral of <ix:nonNumeric contextRef="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231" name="nbx:BorrowingDefermentPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMjY_364fe1f5-5af8-46bc-b5f2-b471d0ed0a8d">1</ix:nonNumeric> year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The outstanding balance of the EIB loan included in the table above was &#8364;<ix:nonFraction unitRef="eur" contextRef="ia00db9d1206a4981b2ae432d997b3bfb_I20211231" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExNjk0_53c9350b-69bc-4187-af64-3d3fd07568ac">33.9</ix:nonFraction>&#160;million as of December 31, 2021, including &#8364;<ix:nonFraction unitRef="eur" contextRef="ic1a681b206df4511b7799f7f5af81474_I20211231" decimals="-5" name="nbx:BorrowingTotalInterestPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExNzMy_6ad83794-2b44-4f3d-a7a0-c6894f82c33e">7.0</ix:nonFraction>&#160;million of total fixed rate interest to be paid over the term of the loan, out of which &#8364;<ix:nonFraction unitRef="eur" contextRef="ic1a681b206df4511b7799f7f5af81474_I20211231" decimals="-5" name="ifrs-full:InterestPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExODE1_21910910-8d79-4aef-bcaa-ba425fe9bc1c">1.8</ix:nonFraction>&#160;million was accrued as of December 31, 2021. The balance in the table above does not include &#8364;<ix:nonFraction unitRef="eur" contextRef="idf95cc261a574c20bb75916fc307fd2a_I20211231" decimals="-5" name="nbx:BorrowingTotalInterestPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMzk_f450b0f9-5dbf-44c8-b03a-bb6169f71d02">3.4</ix:nonFraction>&#160;million of estimated variable rate interest, based on the consolidated forecasted sales expected to be generated by the Company during the <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:ConsolidatedForecastedSalesPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExOTE_c51e1ad8-c380-4515-8db5-1cf5b7605378">six-year</ix:nonNumeric> period beginning January 1, 2021 (see Notes 3.2, 4.3 and 12.1). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On April 07, 2021, the Company received the approval of HSBC on its debt rescheduling request. The HSBC PGE loan will be reimbursed at the same pace as the Bpifrance loan, starting on September 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="i377d9717844147e799376babda10462f_172"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 13. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTI_d5028de0-2f89-439c-89f1-4fbce2473dbe" continuedAt="ie3e1a4c6f5ba4e78988ee1cb69c04382" escape="true">Trade payables and other current liabilities</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie3e1a4c6f5ba4e78988ee1cb69c04382"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">13.1 Trade and other payables</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTM_d8f11f02-bd48-47b8-9b41-8f2e7978fe46" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for Trade and other payables are described in Note 12, &#8216;&#8216;Financial Liabilities.&#8217;&#8217; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accrued expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTQ_77b86ec7-f31c-4ac4-aa58-1753caf6cfc7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Details of trade and other payables</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzItMS0xLTEtMTE5OTk_524c0466-0ac1-44d0-b47e-6d230c44c9cf">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzItMi0xLTEtMTE5OTk_5aaf975a-ec38-4a8d-a5e8-b8f443e9f1ff">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables &amp; other accruals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzMtMS0xLTEtMTE5OTk_86f57a24-e0fe-46ca-83c3-aa66523936d5">4,996</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzMtMi0xLTEtMTE5OTk_8309cbc4-21fb-4c14-a0ae-05276e78658d">5,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzQtMS0xLTEtMTE5OTk_3e369bdb-ae2d-493a-94e5-fb881c591c8f">6,482</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzQtMi0xLTEtMTE5OTk_fd85e507-652a-4e7e-9fcc-9309fd5c6b0b">7,106</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables are not discounted, as none of the amounts were due in more than one year. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other trade payables include &#8364;<ix:nonFraction unitRef="eur" contextRef="i5e92157b10524c51b91a421eb6a8c483_I20211231" decimals="-3" name="ifrs-full:OtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzMyOTg1MzQ4ODk2Mzg_15e2b5a9-431e-4730-81c2-377da6656ceb">447</ix:nonFraction>&#160;thousand of costs relating to the ICON contract not yet paid, as of December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">13.2 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxODg_e1266138-38d8-46bd-96cc-46f8bd067aa9" continuedAt="i29318fefaf18409dbcb33c3b2fa87730" escape="true">Other current liabilities</ix:nonNumeric></span><ix:continuation id="i29318fefaf18409dbcb33c3b2fa87730"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:70.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzItMS0xLTEtMTE5OTk_b657a3b8-fa8f-479c-b750-ce5365cd58e9">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzItMi0xLTEtMTE5OTk_170963cd-3855-4679-8886-152cec5b5a36">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzMtMS0xLTEtMTE5OTk_da5d5069-2324-4b27-a653-16ce00c4f7e0">4,820</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzMtMi0xLTEtMTE5OTk_786190d4-1842-40ca-ac04-b7d307cd752f">6,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="nbx:OtherMiscellaneousCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzQtMS0xLTEtMTE5OTk_b367fbd1-f683-458d-8980-f145a4099395">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="nbx:OtherMiscellaneousCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzQtMi0xLTEtMTE5OTk_fd893a94-3af8-4495-8089-d8c3ac07f316">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzUtMS0xLTEtMTE5OTk_16186325-564d-4d2c-9ad8-c72e8e2925d4">5,531</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzUtMi0xLTEtMTE5OTk_5c342178-d2e8-4640-9ddc-782db978b0ce">7,022</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer costs to be paid on free shares, accrued bonuses, vacation days and related social charges. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Payroll tax and other payroll liabilities decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-5" sign="-" name="nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0MDI_84712a67-62be-49b4-8148-25795135aedb">1.4</ix:nonFraction>&#160;million from &#8364;<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-5" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0MTA_568a8079-b9e2-413c-b1a1-da818658067b">6.2</ix:nonFraction>&#160;million as of December 31, 2020 to &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-5" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0NDA_05c201c3-70a0-4fc8-a476-1449c20a7ec1">4.8</ix:nonFraction>&#160;million as of December 31, 2021 as a result of the decrease in social charges accrual related to free shares and to bonuses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">13.3 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzMyOTg1MzQ4ODk2MzY_f9dcfdff-bf73-492a-b0c0-e8ef15ee1e91" continuedAt="i329ae0e70c004c29abd2589ffbfbb36a" escape="true">Deferred revenues and contract liabilities</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i329ae0e70c004c29abd2589ffbfbb36a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.852%"><tr><td style="width:1.0%"></td><td style="width:63.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzItMS0xLTEtNTYwNDk_d7d1df68-f6aa-44e3-be3f-9a235d7cec49">16,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzItMy0xLTEtNTYwNDk_edfeaec4-9762-4361-b527-2fa34ca54f9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzMtMS0xLTEtNTYwNDk_25a1b0e8-8515-4be9-8968-e321a597613e">16,518</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzMtMy0xLTEtNTYwNDk_e5f4decf-73f1-4acd-b7b3-a8e1c6d1a728">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in deferred revenues and contract liabilities as of December 31, 2021 consists of contract liabilities relating to the LianBio contract in the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="ib6c320981631448bb18db0fd12c61f50_I20211231" decimals="-5" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzI3NDg3NzkwNzM0Njk_8589ada9-db84-4c15-9195-b75273fed570">16.5</ix:nonFraction>&#160;million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i377d9717844147e799376babda10462f_175"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Note 14. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1Mzg_522c0517-8995-40b5-b369-8259031c7b77" continuedAt="i89fd783f52084fd28fb397199fc037a3" escape="true">Financial instruments included in the statement of financial position and impact on income</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i89fd783f52084fd28fb397199fc037a3" continuedAt="i8f3d9a489d9a415aa7a4c33fe2b46067"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for financial instruments included in the statements of financial position and impact on income are described in Note 7, &#8216;&#8216;Non-current financial assets&#8217;&#8217;, Note 8, &#8216;&#8216;Trade receivables and other current assets&#8217;&#8217;, Note 9, &#8216;&#8216;Cash and cash equivalents&#8217;&#8217; and Note 12, &#8216;&#8216;Financial liabilities.&#8217;&#8217;</span></div><div><span><br/></span></div><ix:continuation id="ie29351a3963241d4889427958ef04cd0"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1Mzk_0bf0e8d8-e97f-4c3c-896a-2efee502d45d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on<br/>the statement of<br/>financial position</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets <br/>carried at fair value <br/>through profit or <br/>loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities<br/>carried at amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMS0xLTEtNDI4MTA_c7e54e3a-7111-489e-9a3f-2e43f8ebf30e">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id999c1e7e2574135a234b087144a61d9_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMi0xLTEtNDI4MTA_4789efc3-9d8a-4841-9eda-e179fe15fbf4">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2547d3f63dd142aebf5856fb5e8585d9_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMy0xLTEtNDI4MTA_e6d47af3-2687-4fdd-9190-314d0eac26a6">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtNC0xLTEtNDI4MTA_c08dc33e-ecbc-4ee4-b413-d735a6d2fcd4">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia4e4d5d5fad3437283d2114e123c9052_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtMS0xLTEtNDI4MTA_84969037-ad30-4a4a-8fbb-1c9a83e8548d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i88c4b87a005448a6af125cf0d25e3ca4_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtMy0xLTEtNDI4MTA_59895565-a9b5-4f06-9cea-0592bd76114c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia4e4d5d5fad3437283d2114e123c9052_I20211231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtNC0xLTEtNDI4MTA_1057596d-8fa7-4ecf-a678-6d155b00bfd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id0503316bb634a33b147e9bd8ec248d5_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtMS0xLTEtNDI4MTA_cc27733b-25c0-497e-a295-2f8db1c59409">83,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia3893bd24e354c778100e28facefe020_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtMy0xLTEtNDI4MTA_870d59a2-3071-4986-b9d8-8e8ecbd50d65">83,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id0503316bb634a33b147e9bd8ec248d5_I20211231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtNC0xLTEtNDI4MTA_f6589af6-c76b-4661-be11-3184b0a28bdc">83,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMS0xLTEtNDI4MTA_2e2aba12-019c-4c1e-9ae6-792fd8580dea">84,440</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4d08cfa6357540d1ad2a166b19c12357_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMi0xLTEtNDI4MTA_825c75f7-21ee-4386-8620-81d6d4eaa582">97</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5c39078fac4b4979aea00def2bcbb7e7_I20211231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMy0xLTEtNDI4MTA_93154203-5f34-498f-9d4c-5efd8e578521">84,343</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtNC0xLTEtNDI4MTA_d4455f11-3288-4777-ad02-c5ce03d0e628">84,440</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i50df0717ba78443aa1b28f71669529c1_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtMS0xLTEtNDI4MTA_d19493f9-51da-4cb0-a7ce-ed3255a72f09">38,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idc7f775ffe9b4f938e53f99295d0dd49_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtMy0xLTEtNDI4MTA_6e9cf577-aa18-4fb9-bed2-6630c52fb7ef">38,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i50df0717ba78443aa1b28f71669529c1_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtNC0xLTEtNDI4MTA_2aafe764-a1ef-4d7f-9d60-996ffbe43c7c">38,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktMS0xLTEtNDI4MTA_f5508428-526e-437c-b34e-24f66e1635cc">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id2445eebc99b4373b2eb31de5002f587_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktMy0xLTEtNDI4MTA_3333637a-19d3-4bef-9f77-c344771b1d58">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktNC0xLTEtNDI4MTA_7c45b721-f815-4e25-ba90-844cdab21a3c">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib4882dee440d4a6786f1a85711a2f076_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTEtMS0xLTQyODEw_a277a930-01ae-4067-b265-2076f64115bc">6,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i83d0f6bcf35c4bf6a5b350b635b2cf61_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTMtMS0xLTQyODEw_e52ae7c6-53f0-4a0f-8e88-cdb7d092d061">6,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib4882dee440d4a6786f1a85711a2f076_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTQtMS0xLTQyODEw_8f5940d2-6882-4605-9324-899ccee8bca2">6,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTEtMS0xLTQyODEw_67b889b2-3ba0-44af-ae33-85ab5382355a">52,503</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i13f6b64bccba4b65be62a02815fcc7d7_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTMtMS0xLTQyODEw_22c4eea6-f1bf-440a-b88e-b23714b32626">52,503</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTQtMS0xLTQyODEw_2b8fe886-5bfc-4326-9e20-8caeec1294d8">52,503</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:30.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icc4dd7cc1b414385a787daf2198eed07_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMS0xLTEtMTE5OTk_6d441764-838c-4b11-8bd5-a63794c56d78">505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1a633ef24e1c46b0a69bcaf4403e72ec_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMi0xLTEtMTE5OTk_dcef0a20-a16b-4b22-ae6f-3f8be920f6b7">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i14898c15ca2947e18832b9287191cc4f_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMy0xLTEtMTE5OTk_f9471117-43e8-4fc8-829c-32f628a291dc">401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icc4dd7cc1b414385a787daf2198eed07_I20201231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtNC0xLTEtMTE5OTk_5a87c9dd-6cda-4d58-86fb-951c51492835">505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i844f8507f9df4617831e6d34785b0ce7_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtMS0xLTEtMTE5OTk_4ea46141-7f51-4979-bc72-10d6a04b404d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie4b0a0a486794f239a3054bc37c245ff_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtMy0xLTEtMTE5OTk_c0135660-1e9f-4827-94e2-bf4a7685f1fb">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i844f8507f9df4617831e6d34785b0ce7_I20201231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtNC0xLTEtMTE5OTk_d95108fc-9cdc-4fb8-b767-8a8e9464ce0f">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i62783c3667b540b998e0995fce469eb0_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtMS0xLTEtMTE5OTk_0be9ec73-5782-4139-8554-7f02f8073362">119,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib4e939bfe23c45adaf30417def90ead9_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtMy0xLTEtMTE5OTk_a31c4c4c-3d1c-4af2-ba1f-b0e8a0fae3fd">119,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i62783c3667b540b998e0995fce469eb0_I20201231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtNC0xLTEtMTE5OTk_3eddfc3a-8e30-47be-8262-fb175b9181c1">119,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMS0xLTEtMTE5OTk_08ba381d-c70c-4f9e-899c-e7171890d730">119,717</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7de0719450484ecc8171d036b10ef5e2_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMi0xLTEtMTE5OTk_166a5f47-e87b-4325-8107-7b53c0d90301">104</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaac2ec9156e94f5b90790097f4f6f9e4_I20201231" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMy0xLTEtMTE5OTk_529cc092-a171-4a5e-945b-34caa50e4234">119,613</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtNC0xLTEtMTE5OTk_895304fa-094d-4fd6-8d56-bc60e599f2b4">119,717</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtMS0xLTEtMTE5OTk_a4701234-518e-4325-833f-afb95c477296">44,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4f0f98e9c5bf49a7a5c86be5e8e9f97e_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtMy0xLTEtMTE5OTk_e7c4fb9e-676c-45a7-89f2-d1425d3e86d8">44,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtNC0xLTEtMTE5OTk_6899969c-43f5-444d-8382-4e8f8a439ca6">44,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i963e0d114bd6453f9f66f58da5eff1cf_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktMS0xLTEtMTE5OTk_d31b0335-665c-445c-87c3-8a738fa39d0a">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i005555f4e921493c8254695ac286ae81_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktMy0xLTEtMTE5OTk_c548be67-0aff-4a39-85e9-d7b9b21f362c">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i963e0d114bd6453f9f66f58da5eff1cf_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktNC0xLTEtMTE5OTk_23e1359b-3255-4b74-a877-d4c58f59398c">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9dcca9167f6249298283face31cd7f47_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTEtMS0xLTExOTk5_9d78d74a-7bc6-4644-8dbf-048c8e44083c">7,106</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3f20ea2133e94954bd0a8f66c6e3cc78_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTMtMS0xLTExOTk5_82ef3cff-8221-4c1b-a9d4-2509abaaf7ec">7,106</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9dcca9167f6249298283face31cd7f47_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTQtMS0xLTExOTk5_5f4e93aa-5d2b-4a53-bd39-100ae8d20814">7,106</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTEtMS0xLTExOTk5_39ac34c8-ed07-439b-a0cf-cbb52a134f60">56,085</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea4486c4d182429aa433718272dbe53b_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTMtMS0xLTExOTk5_8036f5dc-cf57-4b3e-88c9-047aa85e3d6e">56,085</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-3" name="nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTQtMS0xLTExOTk5_9c1fcc4a-c49c-4c67-bec4-42909f315151">56,085</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management of financial risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.</span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i8f3d9a489d9a415aa7a4c33fe2b46067"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Liquidity risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Foreign Currency Exchange Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1NDI_eda80d90-8bfa-4b31-8045-8717d0e3629f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company&#8217;s U.S. subsidiaries as of December 31, 2021, and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:40.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtMS0xLTEtNTQxNDY_f249a1d3-9375-46f0-8e6b-41a38e60440b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtMi0xLTEtNTQxNDY_80ba770f-7f0a-4d39-8ddf-79ed3c5bd181">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtNC0xLTEtNTQxNDY_810904e3-f99f-4142-ab8c-a12d0ebff2d3">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtNS0xLTEtNTQxNDY_055ffbda-874f-4793-8508-3390898ebd5f">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtMS0xLTEtNTQxNDY_569579f8-0b86-4656-a389-0b19762078f3">45</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtMi0xLTEtNTQxNDY_5b1c0610-8977-446b-8363-2add773381c5">45</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtNC0xLTEtNTQxNDY_1b8c0e5b-de2f-4936-adca-5fe21a71d364">87</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtNS0xLTEtNTQxNDY_56e421ba-10b7-4a1f-8e54-2f653c9ce402">87</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:40.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtMS0xLTEtMTE5OTk_61b8abc2-5b06-4394-9cfb-57548e9e4909">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtMi0xLTEtMTE5OTk_6c7fa3e5-a68e-4c1b-aa42-22742bf12adf">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtNC0xLTEtMTE5OTk_309ce7b1-5c49-4f78-87c5-ede070735157">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtNS0xLTEtMTE5OTk_4a96e332-171e-41c8-9df4-77e435830d31">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtMS0xLTEtMTE5OTk_173a7573-c9a0-4755-967d-915880d0b146">5</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtMi0xLTEtMTE5OTk_359ea8e8-170a-46b7-8855-745beee97491">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231" decimals="-3" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtNC0xLTEtMTE5OTk_17c840ae-a48c-41d9-a9c3-674120de6853">124</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231" decimals="-3" sign="-" name="nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtNS0xLTEtMTE5OTk_b67b2066-e29e-4edd-b4f8-0401ca05cbf8">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Credit risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers&#8217; high credit rating for other receivables.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Interest rate risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Fair value </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The carrying value of receivables and current liabilities is assumed to approximate their fair value.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-43</span></div></div></div><div id="i377d9717844147e799376babda10462f_178"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Note 15. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfRevenueExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzg0MDI_3e2f2858-f269-4cf0-b1b9-65c5c1c56fb0" continuedAt="iaa2eb872c4ff4f35ac602c58728b717c" escape="true">Revenues and other income </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iaa2eb872c4ff4f35ac602c58728b717c" continuedAt="i926426eb1ce34593913d8eb9b84b9675"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgzOTg_e98afbf3-3f2e-4ef6-b9fe-70e28821cda3" continuedAt="i817ed79812f442a599915676bd1fef9a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue is recognized in accordance with IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A license:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is assessed to be a right to access the Company&#8217;s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is a right to use the Company&#8217;s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Product supply for which the revenue is recognized once the control over the delivered products is transferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application to the license and collaboration agreement with PharmaEngine</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the License and Collaboration Agreement, the Company&#8217;s and PharmaEngine&#8217;s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company&#8217;s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the license of the right to use the Company&#8217;s patent and know-how;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine&#8217;s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the supply of NBTXR3 to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">An upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231" decimals="-5" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTY_cddf0fda-3203-4dd3-a361-5e92932d5b1a">1.0</ix:nonFraction>&#160;million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231" decimals="-6" name="nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzQwMTY_1165eeb7-9853-47b3-937b-cf1cf42fced6">1</ix:nonFraction>&#160;million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company&#8217;s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231" decimals="-6" name="nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzQyMTg_c0739793-beac-47f5-b15d-ef5983fc82c4">1</ix:nonFraction>&#160;million (first patient&#8217;s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be </span></div></ix:nonNumeric></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i926426eb1ce34593913d8eb9b84b9675" continuedAt="i9f37ac63d2a24a5dbe41226e8587cf88"><ix:continuation id="i817ed79812f442a599915676bd1fef9a" continuedAt="ic14fef7ee077445b9acabf8eab8cd12b"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine &#8217;s territory, which had not occurred as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of IFRS 15 to the license and collaboration agreement with LianBio</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">an exclusive license, under the Company's intellectual property, to develop and market the licensed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the right to actively participate in global Phase III registration trials to obtain marketing approval in China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the requirement to purchase products under license to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least <ix:nonFraction unitRef="number" contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531" decimals="2" name="nbx:MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyNzU_3e99d1fd-2e42-40e4-b194-0db3fe81c875">80</ix:nonFraction>% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615" decimals="-6" name="nbx:CollaborationAgreementUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyODA_a9718180-b10b-46bd-b37f-1fd2ef477b3d">20</ix:nonFraction>&#160;million and may receive up to $<ix:nonFraction unitRef="usd" contextRef="i16897dad579b4f4b86092bda744f7b49_I20211231" decimals="-6" name="nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyOTM_e70f12a2-4604-488c-870d-e8045f7e9ae2">220</ix:nonFraction>&#160;million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within <ix:nonNumeric contextRef="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615" name="nbx:CollaborationAgreementMilestonesAchievementPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMzMDY_ecb71335-9427-4a2b-a65e-1cd3b69d39cd">18</ix:nonNumeric> months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i9f37ac63d2a24a5dbe41226e8587cf88"><ix:continuation id="ic14fef7ee077445b9acabf8eab8cd12b"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research tax credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The French tax authorities grant a research tax credit (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, or &#8220;CIR&#8221;), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:ResearchTaxCreditUtilizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzYwMjQ_4801f24c-0dd8-49f9-95ec-d0e45e5ce626">three years</ix:nonNumeric>. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the &#8220;PME&#8221;, it can request immediate refund of the remaining tax credit, without application of the <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:ResearchTaxCreditUtilizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgzOTk_b15ea4da-83a6-4325-aeca-7e65a4b1f1e5">three-year</ix:nonNumeric> period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of revenues and other income</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzg0MDA_91d24728-7bc6-4297-ae82-0defc7180185" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i923e1965fdfa48cb90e163414c18dcc6_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMS0xLTEtMTE5OTk_0a88565d-eedd-4a0b-a3c3-5825430eaa3f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0280ecfc6a714e849f5cba16bb5df0e5_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMi0xLTEtMTE5OTk_6b428797-a2c9-419b-bcad-d282c93ef945">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i66824b4e473b46179fd1ef1f2f501a12_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMy0xLTEtMTE5OTk_5a19129b-29f2-4d7c-83c7-ea1f3fd41943">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib221c9ab85f1428998e5bd37d6eadcba_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMS0xLTEtMTE5OTk_c7c0a40a-2027-4209-8fb2-275c74402315">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2e1b70eaca444c0098a66c5e8a9832bc_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMi0xLTEtMTE5OTk_bed4b90f-ea32-4d95-b236-e357304e9ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9df4ab9cfd314a1baaac83e76837eb48_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMy0xLTEtMTE5OTk_3c28def5-9e25-4664-b2e5-d8cba1ff8492">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMS0xLTEtMTE5OTk_df8e1f0d-91d5-425f-9b79-5dd93dee8899">10</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMi0xLTEtMTE5OTk_9fdb51eb-6cf4-4f75-9eea-b2f4daf74c85">50</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMy0xLTEtMTE5OTk_1c19cfa5-82ed-463b-8955-8d8938763efc">68</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMS0xLTEtMTE5OTk_b94428f0-3293-42a6-844f-fdee270ea388">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMi0xLTEtMTE5OTk_ba44fedf-53ae-4cd0-acc3-7a4e64cbcec8">1,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:ResearchAndDevelopmentTaxCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMy0xLTEtMTE5OTk_50ccecd2-c1d0-4374-b9a7-ffd8b22b5647">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMS0xLTEtMTE5OTk_30316199-fce8-4d59-aa01-fbb6240ad539">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMi0xLTEtMTE5OTk_5c2cc62d-0d0d-49fc-8198-dabd95da327d">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMy0xLTEtMTE5OTk_2dcd0bfb-30e4-452e-b789-79ec5c67b35d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMS0xLTEtMTE5OTk_df35b3fc-5ec8-4319-b9f8-133e4c1661a3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMi0xLTEtMTE5OTk_4725fdf0-4525-4b18-81e0-0a7ae808b170">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMy0xLTEtMTE5OTk_d1f35602-5c7a-4dcd-bd37-538a5a382974">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMS0xLTEtMTE5OTk_7b3cfb8c-741e-43c7-aa09-d40d065428de">2,637</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMi0xLTEtMTE5OTk_bca209c6-c436-4ca5-ae2b-ea7c45e2fcf5">2,462</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMy0xLTEtMTE5OTk_09531758-7f7b-4317-98cb-60dfedfa801b">2,473</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMS0xLTEtMTE5OTk_311ee42b-a130-4a5c-88ae-0d27b2e40ae3">2,647</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMi0xLTEtMTE5OTk_a35da582-3f4e-431b-a6b8-ddf63b937e57">2,512</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMy0xLTEtMTE5OTk_7f681db8-bdd0-4242-94fc-1968ceed0b26">2,541</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s revenue of &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5MjE_fe67c2fe-2911-4e58-89a2-dddd876a3593">10</ix:nonFraction>&#160;thousand in 2021, &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5MzM_03baaf2a-7db0-4afd-9ddd-f52d4474a05f">50</ix:nonFraction>&#160;thousand in 2020 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5NDg_7870bebd-c7ad-44e4-9ac9-d5a87b2e01ca">68</ix:nonFraction>&#160;thousand in 2019 were derived mainly from the charging-back of shared external clinical research organization costs in connection with the development support provided by the Company to PharmaEngine as part of the 2014 amendment to the Company's License and Collaboration Agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="if3840527069c4348acc9ab3731676a5d_D20190101-20191231" decimals="2" name="nbx:ConcentrationRiskPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_3399aa20-3561-4eb0-b2be-2dc3da72fca9"><ix:nonFraction unitRef="number" contextRef="i302b2241ee6d4e209916d02969566345_D20210101-20211231" decimals="2" name="nbx:ConcentrationRiskPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_3a4b4d2e-39a7-4514-9d52-fde145652f75"><ix:nonFraction unitRef="number" contextRef="ie90622151f5e4db4a3a49e27eba46371_D20200101-20201231" decimals="2" name="nbx:ConcentrationRiskPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_ba858256-43f3-46d7-b93f-287c29231b2b">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the revenues recognized in 2021, 2020 and 2019 were derived from the arrangement with PharmaEngine (see Note 4.1).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the Company&#8217;s other income, other than the research tax credit, mainly derives from French State subsidies of &#8364;<ix:nonFraction unitRef="eur" contextRef="i9557dec5d8804e348756bbd9f050ae89_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc5MzU_1def82b4-b001-4919-b8fd-99116b00cca6">312</ix:nonFraction>&#160;thousand provided as part of the &#8216;&#8216;partial unemployment measure,&#8217;&#8217; a National plan allowing companies facing economic challenges during the COVID-19 crisis to receive from the French State approximately <ix:nonFraction unitRef="number" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="2" name="nbx:PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgxMzI_23366376-f1f9-4121-97eb-51cfe9241d83">84</ix:nonFraction>% of specific employees&#8217; net salary, as well as the &#8364;<ix:nonFraction unitRef="eur" contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231" decimals="-3" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgxODU_c3f67207-3e3a-4557-93d2-e00e163848ef">350</ix:nonFraction>&#160;thousand received by Curadigm in connection with the Bpifrance Deep Tech Funding, &#8364;<ix:nonFraction unitRef="eur" contextRef="i62e1ab97b0f340d2806afa0a17c159aa_D20200101-20201231" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgyNjE_cf189d21-aa3b-4f6b-aada-922f48f2c596">187</ix:nonFraction>&#160;thousand of which was recognized as revenue for the years ended December 31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-46</span></div></div></div><div id="i377d9717844147e799376babda10462f_181"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 16. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNzE_2ded4df0-d62d-46bf-a204-6268336ef54c" continuedAt="i70dd261a2d9d4328a5b5f880e584fb01" escape="true">Operating expenses</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:46.2pt"><span><br/></span></div><ix:continuation id="i70dd261a2d9d4328a5b5f880e584fb01" continuedAt="if589a4ee74e54142a7bb64ed5639f92b"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjY_bc08afac-cf73-4a02-9742-8006d5348db6" continuedAt="ic679d18cad644cc588cbd693a1662efc" escape="true">Accounting policies </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="ic679d18cad644cc588cbd693a1662efc">Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for research and development expenses are described in Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.1 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjc_cc928621-6e5f-4674-a920-ccc738310408" continuedAt="i6cbb9f22cbf6434e9bb39c46e11a1559" escape="true">Research and development expenses</ix:nonNumeric></span></div><ix:continuation id="i6cbb9f22cbf6434e9bb39c46e11a1559"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMS0xLTEtMTE5OTk_4a0b8247-2d46-481b-ba9d-7a146c65f29d">19,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMi0xLTEtMTE5OTk_5622e3ab-8605-4fff-b9e0-ef1f70155ecb">12,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMy0xLTEtMTE5OTk_ddb69e00-f431-47bd-9843-9dc2aa2549e6">16,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ResearchAndDevelopmentExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMS0xLTEtMTE5OTk_d72f7338-875b-4ce2-a8a9-ea2a22638c15">9,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ResearchAndDevelopmentExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMi0xLTEtMTE5OTk_7800ba42-7e79-469e-b774-cb75ec4d79da">10,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:ResearchAndDevelopmentExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMy0xLTEtMTE5OTk_17c4d4db-c744-465f-bf1b-5b83910d5bfb">11,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMS0xLTEtMTE5OTk_20d45e93-6762-4ad1-b813-21bcdeece4df">1,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMi0xLTEtMTE5OTk_1daafef3-64b5-4c4a-bb05-5f148f0455f2">1,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMy0xLTEtMTE5OTk_331ed934-3ff9-4255-ae56-9fc3271a23ef">1,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMS0xLTEtMTE5OTk_308a3361-027f-44b8-bd7d-c41ae4cfc451">30,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMi0xLTEtMTE5OTk_6c28770f-56f2-422b-9efd-9b0255f48038">24,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMy0xLTEtMTE5OTk_5a1b417a-0792-4f38-88c9-87aa6a624afd">30,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases, sub-contracting and other expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-5" name="nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzYxMg_8d427b1f-abd3-4636-9c3a-0e0d2729599a">6.9</ix:nonFraction>&#160;million, or <ix:nonFraction unitRef="number" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="2" name="nbx:PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzYxOQ_acb13914-b8fc-4edb-941a-883c1fd2054a">54</ix:nonFraction>% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payroll costs decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="nbx:IncreaseDecreaseInEmployeeBenefitExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzg2MA_7db7fd33-5516-4c5f-b16e-0f476078f441">774</ix:nonFraction>&#160;thousand, or <ix:nonFraction unitRef="number" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="2" sign="-" name="nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzg2Nw_ce2d327a-fbc6-4852-b5af-2d048e3b405e">8</ix:nonFraction>% for the year ended December 31, 2021 as compared with the same period in 2020. This variation is mainly due to a change in the mix and in the location of our research and development staff.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company&#8217;s workforce amounted to <ix:nonFraction unitRef="employee" contextRef="i835b7224a73b4426b167298dea1d3004_I20211231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTkyMjQ_00c2ed2f-7f6d-4c2b-aada-3b77dc690aee">75</ix:nonFraction> research and development staff, including <ix:nonFraction unitRef="employee" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="INF" name="nbx:IncreaseDecreaseInNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTkyMjg_80c2f10c-eae7-4a91-b7ef-642ebe21d7ef">9</ix:nonFraction> additional positions created during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, the Company&#8217;s workforce amounted to <ix:nonFraction unitRef="employee" contextRef="i408716a3b82f46e08e6b6d3596e1b7c5_I20201231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzIxOTkwMjMyNjkwMzY_23cd074d-2a26-4468-ba4d-eef620d617da">66</ix:nonFraction> research and development staff, including a decrease of <ix:nonFraction unitRef="employee" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="INF" sign="-" name="nbx:IncreaseDecreaseInNumberOfEmployees" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzExNzk_d8fbb325-61e4-4367-9b22-5b9a31f78fea">fifteen</ix:nonFraction> positions created during the year ended December 31, 2020 and <ix:nonFraction unitRef="employee" contextRef="ib14b8fcd297d44c2b25d620752b4cc83_I20191231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzEyNTU_7dabbbdf-7107-4d61-b53d-edb5e77b9e31">81</ix:nonFraction> research and development staff, including <ix:nonFraction unitRef="employee" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="INF" name="nbx:IncreaseDecreaseInNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzEzMDA_b3f0741f-9bca-4d1e-8f87-fdeb9f441167">2</ix:nonFraction> additional positions created during the year ended December 31, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The impact of share-based payments (excluding employer&#8217;s contribution) on research and development expenses amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE0OTQ_0cbe6e57-7ee5-4176-a710-2b15f7a52b9d">677</ix:nonFraction>&#160;thousand in 2021 as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE1MjI_70907069-e38c-4ed8-a782-1f4ffac874e9">629</ix:nonFraction>&#160;thousand in 2020 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE1Mzc_48c2e9db-6dad-443a-9480-ea79ba241f94">902</ix:nonFraction>&#160;thousand in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.2 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjg_1855ce6d-a253-4a6c-8a48-585668d13c3e" continuedAt="i1c933818597c4d8192fdb24b59d433f3" escape="true">Selling, General and Administrative (SG&amp;A) expenses</ix:nonNumeric></span></div><ix:continuation id="i1c933818597c4d8192fdb24b59d433f3"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMS0xLTEtMTE5OTk_f8f9d1d4-091a-4f3d-ab66-9d9e23c14ef9">9,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMi0xLTEtMTE5OTk_6dce1372-4381-47dc-b7af-cc52e8021bf9">6,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMy0xLTEtMTE5OTk_fd5987ee-ba76-4069-89a6-b3599a430484">9,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMS0xLTEtMTE5OTk_24b113da-bfd6-4cb7-9912-10b85e5d0196">9,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMi0xLTEtMTE5OTk_90b03a48-56ba-4f7f-b15e-05153c443d45">7,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpensePayrollCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMy0xLTEtMTE5OTk_4b0ab791-c293-423e-9039-ef2d54afe497">9,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMS0xLTEtMTE5OTk_6b287b72-5e88-4c9b-9e36-891e84b788b7">417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMi0xLTEtMTE5OTk_639e2f9b-aee6-45cd-8e81-ecb801a2c9c5">340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMy0xLTEtMTE5OTk_aead04dc-aeda-47d6-874b-19744b5ddc8d">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMS0xLTEtMTE5OTk_27c97fe6-f192-4021-a2b6-146b85f67985">19,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMi0xLTEtMTE5OTk_229cf52c-88c0-4cef-a857-00fa034191e8">14,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMy0xLTEtMTE5OTk_09dc2be2-bd9a-4cff-9fb9-47d9b9141892">18,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2021, purchases, fees and other expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-3" name="nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE3MzI_7c87ff86-a452-40ab-867a-99331158b851">3,156</ix:nonFraction>&#160;thousand, or <ix:nonFraction unitRef="number" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="2" name="nbx:PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE3Mzk_75c46e1f-dd2c-4b26-92a7-1473ae968b63">49</ix:nonFraction>% for the year ended December 31, 2021 as compared with the same period in 2020. This variation reflects <ix:nonFraction unitRef="factor" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="nbx:NumberOfImpactingFactors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE4NDY_2ca8de19-67ed-420f-86ec-87a66d02c92b">two</ix:nonFraction> main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a U.S. public company. The second main impact relates to recruitment expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2020, wages, salaries and payroll costs, together, amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4Mjc_dd83640c-267b-42e3-9c64-72a5557dafcf">15.1</ix:nonFraction>&#160;million as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NDI_e373aaa5-414a-4bb4-9543-883c1a06d4cb">16.8</ix:nonFraction>&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#8217;s contribution following the exercise by beneficiaries of their right to free shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These increases in fees and other expenses were partially offset by the decrease in rental expenses following the application of IFRS 16 for the year ended December 31, 2019. </span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="if589a4ee74e54142a7bb64ed5639f92b" continuedAt="i9df4d76045254bc285aad0198518a2fb"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payroll costs increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-5" name="nbx:IncreaseDecreaseInEmployeeBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMxNDU_bc78e581-1c00-4145-99f2-572788b19c70">1.6</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="2" name="nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMxNTE_a51062de-9644-4d28-8ac2-dc0cfeeeaf21">21</ix:nonFraction>% in 2021, mainly due to a change in the mix and location changes of our staff in SG&amp;A functions (more US based employees) and a one-time severance payment related to the departure of Philippe Mauberna, the prior CFO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company&#8217;s workforce amounted to <ix:nonFraction unitRef="employee" contextRef="iff6c0684a6ed4d3e8d05a4ad259e7b4f_I20211231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMzNTQ_11994a37-140a-4492-9756-beda57f7fcb8">25</ix:nonFraction> staff in SG&amp;A functions in comparison with a Company&#8217;s workforce of <ix:nonFraction unitRef="employee" contextRef="i08cbc41147294b6ea9fed577e2d2ba27_I20201231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM0MTI_7c21f517-6130-442b-8ecc-f3d77858eb9d">24</ix:nonFraction> staff in SG&amp;A functions during the year ended December 31, 2020 and a Company&#8217;s workforce of <ix:nonFraction unitRef="employee" contextRef="ifcca4f14254e4036b189591f841d06e8_I20191231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM1Mzg_bd8b748f-bf30-448d-9032-7292e0ef49c5">29</ix:nonFraction> staff in SG&amp;A functions, including <ix:nonFraction unitRef="employee" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="INF" name="nbx:IncreaseDecreaseInNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM1NjM_e1b281a2-1bab-4140-b5e5-7ac54385a3cf">6</ix:nonFraction> additional positions created during the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The impact of share-based payments (excluding employer&#8217;s contribution) on SG&amp;A expenses amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3Mzg_3bc122bf-6fcb-4c06-b3b2-4c80068d978c">2.5</ix:nonFraction>&#160;million in 2021, as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3NTk_769a580e-9312-414c-871a-243887eece9e">2.3</ix:nonFraction>&#160;million in 2020 and &#8364;<ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3NzQ_829ae0e7-101f-49ac-b368-5639ee584ca5">3.4</ix:nonFraction>&#160;million in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.3 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjk_89c24c5d-f228-4705-b6e5-b319ae13043d" continuedAt="i255899e7edcc4827b5356c23caf79cdf" escape="true">Payroll costs </ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i255899e7edcc4827b5356c23caf79cdf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMS0xLTEtMTE5OTk_e457335c-3df5-452f-9bb0-d0c8feccbad8">11,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMi0xLTEtMTE5OTk_8a39e935-9b77-4f04-abf1-0f73f101ec9d">11,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMy0xLTEtMTE5OTk_f25d9953-6739-4d2f-bafc-79c903eae586">11,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMS0xLTEtMTE5OTk_8d9b64c2-6f2a-4cf6-a899-d208685fbc8b">4,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMi0xLTEtMTE5OTk_69c9f8a1-ef56-4207-a8cd-a99ba18ca7e9">3,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:SocialSecurityContributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMy0xLTEtMTE5OTk_67ac433a-2dda-40a8-94c2-1feaed9b5eed">4,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMS0xLTEtMTE5OTk_7a1a94da-343a-48f6-934d-92be45aaea81">3,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMi0xLTEtMTE5OTk_b52ba501-470f-4f5e-813d-066eeb7ed7dd">2,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMy0xLTEtMTE5OTk_a8640c79-89f4-4fe0-95a6-a8ba7a2ef924">4,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMS0xLTEtMTE5OTk_102d2a55-85e3-4ffd-bc95-2b99ed009eaa">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMi0xLTEtMTE5OTk_0f600a08-ddcf-4a1f-91d9-f35d4c073ebf">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMy0xLTEtMTE5OTk_5aa72266-9bad-4257-87fd-7e5a48b8b91e">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMS0xLTEtMTE5OTk_1e6ad669-617f-4eab-b649-cfd488b7ccdd">18,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMi0xLTEtMTE5OTk_ce4cc5da-3cfb-4775-a7e2-af3c029923aa">18,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMy0xLTEtMTE5OTk_85feecde-bd72-4af3-8b80-98ae0770db8f">21,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMS0xLTEtMTE5OTk_a8087a54-d510-422e-b2de-edf7394e57f7">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="INF" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMi0xLTEtMTE5OTk_ec3a046b-1f01-42cb-8fed-23b911972fa1">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="INF" name="ifrs-full:AverageNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMy0xLTEtMTE5OTk_98d12c56-c695-4fbd-9019-8305b7c17a0c">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMS0xLTEtMTE5OTk_bdcab36b-5653-4385-bdc9-486be68e0cc9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMi0xLTEtMTE5OTk_529324d3-1a3d-4c7d-92d5-576ff87f7718">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="employee" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMy0xLTEtMTE5OTk_acace043-a213-40d2-85dd-86889d88842b">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s workforce totaled <ix:nonFraction unitRef="employee" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM4NzE_6743fa36-f39b-49b3-911c-79aba3b8f4d0">100</ix:nonFraction> employees, compared with <ix:nonFraction unitRef="employee" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM4OTk_0a1bdde4-ab1f-4a33-8bd0-28575b4ebae0">90</ix:nonFraction> December 31, 2020 and <ix:nonFraction unitRef="employee" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM5MjQ_a5edadc4-40d5-45ba-8bdc-942458b99815">110</ix:nonFraction> as of December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, wages, salaries and payroll costs, together, amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NTc_6c4613bf-bae5-4fe5-85bc-812b6ebfa96b">15.7</ix:nonFraction>&#160;million as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NzI_c791b668-c0a3-4899-9384-00f59c08c9b8">15.1</ix:nonFraction>&#160;million in 2020. This is mainly due to the <ix:nonFraction unitRef="employee" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="nbx:IncreaseDecreaseInNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTk4OTQ_7eb24a08-096e-4eee-9b3c-b171490351ca">10</ix:nonFraction> additional positions created during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, wages, salaries and payroll costs, together, amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQwMjA_09118181-0b3b-49ca-b187-6887b9c62b58">15.1</ix:nonFraction>&#160;million as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQwNDA_3e2874b6-bd9c-45bf-99ca-8c35fce68eda">16.8</ix:nonFraction>&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#8217;s contribution following the exercise by beneficiaries of their right to free shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2019, wages and salaries and payroll taxes, together, reached &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-5" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQzNTE_5b5b1e1a-a95b-4a33-aba0-aadf93029206">16.8</ix:nonFraction>&#160;million due to the Company's growth and a related increase in the number of employees during the year ended December 31, 2019, together with the impact of its compensation policy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 2 &#8211; Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQ5MzQ_841a74a6-e622-46c1-a582-a44eeb932fbd">3.2</ix:nonFraction>&#160;million for the year ended December 31, 2021, as compared with &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQ5OTI_a4cd3d44-fab2-4742-b74b-9b3851f3d37c">2.9</ix:nonFraction>&#160;million as of December 31, 2020 and &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUwMjM_5b0a64cb-6f57-47d0-9b34-5fa258af777a">4.3</ix:nonFraction>&#160;million as of December 31, 2019 (see Note 17). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNzA_bd1fc0f6-ecca-48cd-acae-ba014b99cc06" continuedAt="iacb7633698e8410e8f930f9798fdeb0c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMS0xLTEtMzk2Njc_c69a71fd-9de0-440b-8490-cf92ff066e6b">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMi0xLTEtMzk2OTc_40374eee-f71b-45ae-86f7-e51f82289ede">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMy0xLTEtMzk3MDM_24f88c79-7a71-4b20-ac6c-9a31bcdd0a7d">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMS0xLTEtMzk2Njc_38ccfd34-b6e3-4a1b-bc35-bccf7c4f26a6">1,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMi0xLTEtMzk2OTc_77df1ec6-2d36-41e3-80d3-3da9ac4b5d75">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMy0xLTEtMzk3MDM_db8d40ca-f8e0-48b0-a732-b74996fa6651">1,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMS0xLTEtMzk2Njc_92e31367-8126-4cbd-8140-ec1a4c93f68b">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMi0xLTEtMzk2OTc_2b4b5d94-a3b7-4d2f-a135-d22e1b8ead43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMy0xLTEtMzk3MDM_f9029271-02ed-445a-a28f-e5ebd5fa055d">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMS0xLTEtMzk2Njc_459b8511-9f5e-4be9-9648-0a4bd0ce3d7e">1,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMi0xLTEtMzk2OTc_46f8c8a6-252b-4d66-af65-30d86aad9998">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMy0xLTEtMzk3MDM_60494344-8add-40a0-adce-ca2ba05d98dd">1,628</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i9df4d76045254bc285aad0198518a2fb"><ix:continuation id="iacb7633698e8410e8f930f9798fdeb0c"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMS0xLTEtMTE5OTk_d765078d-7d84-42bc-919b-34e5577bd9e2">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMi0xLTEtMTE5OTk_dee64317-9046-4ccc-9859-a1c6645514b6">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMy0xLTEtMTE5OTk_375825cd-e262-4958-bceb-7dd8b8e3350b">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMS0xLTEtMTE5OTk_d75390c9-1a08-4604-8ab0-d3f7b5dc3cf2">1,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMi0xLTEtMTE5OTk_b1d0ab5f-6133-444b-95c6-929849d9976b">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMy0xLTEtMTE5OTk_1ea07342-99ce-4544-a8cc-16d725cfa1d0">1,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMS0xLTEtMTE5OTk_f44e1c34-1001-4482-a4d7-ee1aefaa6e24">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMi0xLTEtMTE5OTk_70c2cfc6-2d44-43f5-8a88-18527987b106">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMy0xLTEtMTE5OTk_4686cbb8-8a6d-41de-83e5-7424ed84a8a2">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMS0xLTEtMTE5OTk_0ea39478-74db-477d-9c99-991f394604fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMi0xLTEtMTE5OTk_75471140-b469-4a18-bc7d-d116cf59fe3f">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMy0xLTEtMTE5OTk_0eb56147-6fd8-4b52-827a-78df387ee17c">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="ifrs-full:UnusedProvisionReversedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMS0xLTEtMTE5OTk_0a1d8a53-e33f-4e2b-a2cb-eb456c886403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMi0xLTEtMTE5OTk_e387e395-a4eb-477a-99de-d5358b34ec9e">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:UnusedProvisionReversedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMy0xLTEtMTE5OTk_0e2c6351-e921-4df0-a400-7487a87d3f83">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMS0xLTEtMTE5OTk_9a3207db-8c94-4e2e-ae83-1baf368152ae">1,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMi0xLTEtMTE5OTk_d42c257d-5249-44bf-ab14-3c04033fe4b9">373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMy0xLTEtMTE5OTk_6dbbe17b-b07d-437b-b457-0cdeccc12ca7">1,630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMS0xLTEtMTE5OTk_fc806f10-6646-4a65-8a5b-16254e69be17">289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMi0xLTEtMTE5OTk_b2984e21-0388-4d17-bc6a-e6a6844bb600">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMy0xLTEtMTE5OTk_46c2d864-4830-4303-8f57-af41f071231f">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMS0xLTEtMTE5OTk_407579d9-f1e3-4890-a17e-bfa45d6027e7">1,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-3" name="ifrs-full:DepreciationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMi0xLTEtMTE5OTk_785b9716-923a-4de2-88ea-435e69b7078d">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:DepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMy0xLTEtMTE5OTk_046ae99f-1e58-47bc-816a-334b1a5bacb1">1,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMS0xLTEtMTE5OTk_82d2dbe4-f58f-436d-be3d-32fce7a19d44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMi0xLTEtMTE5OTk_554a5f55-7088-4bcf-b450-1ffc7a0b53c7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMy0xLTEtMTE5OTk_38235000-b749-4709-a7bf-3c99524f6cbf">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMS0xLTEtMTE5OTk_6c23c631-af07-4a09-9d99-89caf830040e">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMi0xLTEtMTE5OTk_a7b77ae9-4045-4b32-bd0e-b003f6f4006b">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMy0xLTEtMTE5OTk_f9621a00-5c9f-4576-93e1-4dcf308f3c34">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMS0xLTEtMTE5OTk_e92c7d21-5023-4c91-a606-6836bbe65721">1,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMi0xLTEtMTE5OTk_9db9c11d-953b-4b34-8ceb-7ff59093d428">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:DepreciationAmortizationAndProvisionExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMy0xLTEtMTE5OTk_2b32ef98-81d3-434e-839d-790d8497273d">1,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">16.5 <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4MjA_5eeeab1b-b930-4f1b-8bf0-3a303fc507d9" continuedAt="id925431dea1f47f9af65647f3708dbae" escape="true">OTHER OPERATING INCOME AND EXPENSES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="id925431dea1f47f9af65647f3708dbae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:63.197%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract termination indemnity (PharmaEngine)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:ContractTerminationIndemnities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzItMS0xLTEtNTM3MTc_5ebc81c4-d739-40bc-bcca-d8dcc020fa14">5,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:ContractTerminationIndemnities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzItMy0xLTEtNTM3MTc_66142b54-b362-4376-81c9-a4aac7818374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzMtMS0xLTEtNTM3MTc_aeba8157-4b19-4e0c-82a7-45a0e20200f5">5,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzMtMy0xLTEtNTM3MTc_9067a882-88a2-4df1-9216-629997e1e0d8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has made payments for a cumulative amount of $<ix:nonFraction unitRef="usd" contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231" decimals="-5" name="nbx:ContractTerminationIndemnities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE2NDkyNjc0NTE2OTY_3094e0e4-d60e-4fbc-9323-f3645a2d508b">6.5</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231" decimals="-5" name="nbx:ContractTerminationIndemnities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE2NDkyNjc0NTE3MDE_a8bfa6a0-57ea-4146-9c1f-2d5f9553796a">5.4</ix:nonFraction>&#160;million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.2 PharmaEngine.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-49</span></div></div></div><div id="i377d9717844147e799376babda10462f_184"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 17. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODk_ae127d14-7373-4567-bec6-3761e2358ddf" continuedAt="ie37d9a17e4384300a5092de642443e24" escape="true">Share-based payments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie37d9a17e4384300a5092de642443e24" continuedAt="if68ef80531254e129500331431473fba"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODU_c879a435-83fc-4eb3-9aa1-90a780112f03" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had <ix:nonFraction unitRef="plan" contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231" decimals="INF" name="nbx:NumberOfShareBasedPaymentArrangementPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzE3Mw_5c99758e-0bbc-43cc-9c21-765b946e9372">nine</ix:nonFraction> (9) outstanding founders&#8217; warrant plans, <ix:nonFraction unitRef="plan" contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231" decimals="INF" name="nbx:NumberOfShareBasedPaymentArrangementPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIxNw_6935fba1-535a-4a5a-8fc4-514c87763c53">twelve</ix:nonFraction> (12) outstanding warrant plans, <ix:nonFraction unitRef="plan" contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231" decimals="INF" name="nbx:NumberOfShareBasedPaymentArrangementPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzI1Mg_ff94e5a0-c809-4077-8d83-a823e277b40e">nine</ix:nonFraction> (9) stock option plans and <ix:nonFraction unitRef="plan" contextRef="ie0979101cec4474688543efa006ec62d_I20211231" decimals="INF" name="nbx:NumberOfShareBasedPaymentArrangementPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzI4Mg_ad613a52-75de-49d6-a304-45374d69aca6">two</ix:nonFraction> (2) outstanding free shares plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These share-based compensation plans are settled in equity instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has applied IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to all equity instruments granted to employees since 2006. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As required by IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders&#8217; equity for the vesting period during which the rights with respect to the equity instruments are earned. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of share-based payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has granted stock options (option sur actions, &#8216;&#8216;OSA&#8217;&#8217;), warrants (bons de souscription d&#8217;actions, &#8216;&#8216;BSA&#8217;&#8217;), founders&#8217; warrants (bons de souscription de parts de cr&#233;ateur d&#8217;entreprise, &#8216;&#8216;BSPCE&#8217;&#8217;) and free shares (attributions gratuites d&#8217;actions, &#8216;&#8216;AGA&#8217;&#8217;) to corporate officers, employees and members of the Supervisory Board and consultants. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNTY_67941aee-07b7-4859-9651-340abcf32966" continuedAt="i8631b2c47d7845d599fb83249f52773d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Founders&#8217; warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:44.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pre-2021 founders&#8217; warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>08-2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>09-2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-03</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtMi0xLTEtMTE5OTk_1b9e564f-e2a2-4960-9541-51f84f13fd69">100,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtNC0xLTEtMTE5OTk_705acc4b-a995-4db3-8cd9-bb7736b29335">50,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtNi0xLTEtMTE5OTk_7daf627a-5222-4de6-9357-554441432d1d">97,200</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtOC0xLTEtMTE5OTk_22f48355-fa09-4152-a906-f720ae8977f7">71,650</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtMTAtMS0xLTExOTk5_5e7dd204-2087-461b-a0c7-d8246418c750">53,050</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/28/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2015</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctMi0xLTEtMTE5OTk_d7c0daa2-629d-4221-9e15-2e336b29e644">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctNC0xLTEtMTE5OTk_8f407b97-e3ab-4d73-9f25-8964810323a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctNi0xLTEtMTE5OTk_d59f0dbe-458d-47ea-b6f5-83691a3564d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctOC0xLTEtMTE5OTk_b4a6c661-c9c8-471a-add5-a3544d5efa6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctMTAtMS0xLTExOTk5_1957cbd8-81a6-47f0-9ab5-5c36ef35d599">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtMi0xLTEtMTE5OTk_e4f10ddd-ce56-4bed-b1d6-d0055a41e7f9">6.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtNC0xLTEtMTE5OTk_6b216986-7c3a-4f95-9457-de8f769e02de">5.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtNi0xLTEtMTE5OTk_0627c374-fedb-4a42-8358-772ad0c5d73c">18.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtOC0xLTEtMTE5OTk_24295da4-8968-403a-aebb-0f186eb2b248">18.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtMTAtMS0xLTExOTk5_54bd40f0-8ceb-4417-ac7e-10be22b57e22">20.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktMi0xLTEtMTE5OTk_97b25cf7-aa54-42ab-b25f-be3a77ffc5d3">100,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktNC0xLTEtMTE5OTk_f6ced4d4-5886-4548-8120-caa8f1c04b9b">50,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktNi0xLTEtMTE5OTk_b9f49a29-a24d-44b1-ac2c-12fadaf195ec">86,150</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktOC0xLTEtMTE5OTk_391371af-ad18-42ed-8464-b9b0e327f8a9">68,450</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktMTAtMS0xLTExOTk5_2e21d41c-3691-4b53-8ee8-8deec0c8d10c">30,350</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTItMS0xLTExOTk5_900cf9cc-1578-49b5-a5d7-a32ee66baa28">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTQtMS0xLTExOTk5_c1a77d1b-7df9-47ac-87dd-9fde42f6d046">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTYtMS0xLTExOTk5_c73b9307-919e-4c0a-8d4f-c0d049440e91">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTgtMS0xLTExOTk5_0886d553-65a2-41b5-a459-2827cf06b227">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTEwLTEtMS0xMTk5OQ_ac9eea26-966b-414f-b30d-84a1a15f7003">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTItMS0xLTExOTk5_d6c85e16-4046-46c2-9546-17c44c0067d3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTQtMS0xLTExOTk5_943fbda3-f0df-4f08-a002-ef1af2200bb5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTYtMS0xLTExOTk5_6986a6b3-aaf9-4455-ad6e-defaf5f6dea1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTgtMS0xLTExOTk5_796327c8-a66c-4264-a6d3-bedc1cdd5e1e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTEwLTEtMS0xMTk5OQ_f49fd125-d2bb-467d-8abe-ceb019f67327">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTItMS0xLTExOTk5_8234e77a-8c18-470d-a222-3cfa1269627a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTQtMS0xLTExOTk5_28750fbb-5b42-44bf-a9fb-877573f155bf">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTYtMS0xLTExOTk5_6aa3caab-b2c8-49d0-b8cd-fa693ce78eea">11,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTgtMS0xLTExOTk5_1657e782-b3e1-4a0f-876a-7d1cc129a2dd">3,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTEwLTEtMS0xMTk5OQ_72827cf0-e768-4753-b0c9-e4b4c7932b41">22,700</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTItMS0xLTExOTk5_713f45e5-6986-451b-90a8-2742277dee4b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTQtMS0xLTExOTk5_7220ebc6-95fb-491e-92bf-a8d70f91f68a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTYtMS0xLTExOTk5_b8280919-36af-41c1-b9d9-832e26c1db47">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTgtMS0xLTExOTk5_7c80adad-8b70-439f-8037-242704054d47">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTEwLTEtMS0xMTk5OQ_a95e1358-8132-494f-9ab7-b98e66d71e91">350</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="if68ef80531254e129500331431473fba" continuedAt="if9b9630c061542cc8dca4bdc98eba18b"><ix:continuation id="i8631b2c47d7845d599fb83249f52773d" continuedAt="if4aabf4328fa4323b7a029e9e530639f"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:42.680%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 founders&#8217; warrant plans</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE <br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtMi0xLTEtMTE5OTk_52c48aa2-87b7-4fb0-a9ea-d37209725cbe">126,400</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtNC0xLTEtMTE5OTk_02a17482-69a6-430e-b121-70599db4a217">129,250</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtNi0xLTEtMTE5OTk_2713a117-563f-4a97-9384-08b38ffbefa3">117,650</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtOC0xLTEtMTE5OTk_0ea13fe2-5fe5-46f9-93be-9aa17942faa8">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/08/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2027</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctMi0xLTEtMTE5OTk_7825f436-5dd3-4f22-80bd-f10a65197e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctNC0xLTEtMTE5OTk_ca2a2cb1-40fb-4b51-9f20-e8b7653ce083">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctNi0xLTEtMTE5OTk_e8864fef-7adb-42b5-951e-22e9bd4ef6e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctOC0xLTEtMTE5OTk_58836a99-fce4-4895-9077-a419ba2febb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtMi0xLTEtMTE5OTk_7c76aacd-2f60-4d92-8996-9340527380dc">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtNC0xLTEtMTE5OTk_ae6bae17-3916-435b-8d02-fc7cab7872f2">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtNi0xLTEtMTE5OTk_881ffd88-774a-4337-a431-f82f51c01001">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtOC0xLTEtMTE5OTk_c3786e04-2d06-4937-9f2b-fa69eaa61cb6">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktMi0xLTEtMTE5OTk_b2043f08-20fc-46f8-84f3-6ff19e89448e">100,567</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktNC0xLTEtMTE5OTk_09e1a2f4-cc11-4a8b-ab43-9ac2f70f2ee5">100,274</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktNi0xLTEtMTE5OTk_998c8212-8b7f-4284-8cbe-067b8b1ff53d">99,500</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktOC0xLTEtMTE5OTk_8d56d2d9-595f-4392-813d-2df802afc5e4">80,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTItMS0xLTExOTk5_cde51570-2a8f-4a53-a050-09e754e70816">333</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTQtMS0xLTExOTk5_83e42338-a256-451d-8be9-071a68937b26">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTYtMS0xLTExOTk5_03deadba-cc3d-41ab-bf33-72c4a9944447">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTgtMS0xLTExOTk5_02646cb1-74f8-4b72-8ad3-92d83915f4fe">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTItMS0xLTExOTk5_3c929d86-2e49-48d3-921b-8c6945de06c9">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTQtMS0xLTExOTk5_912acbd3-c877-4fe3-b8dc-a918f7683423">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTYtMS0xLTExOTk5_3b42c5ae-27c2-47b5-b45f-a89de79748ee">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTgtMS0xLTExOTk5_cf931fee-56a9-4b1a-8f29-a0915c79cba1">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTItMS0xLTExOTk5_b83346b5-c8f0-447d-a7d8-fd1e87a0f420">25,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTQtMS0xLTExOTk5_87357b3c-940c-4b58-bc7c-61e62573ce8b">28,976</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTYtMS0xLTExOTk5_9782a58c-aa1c-42d6-b627-c98f179040b6">18,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTgtMS0xLTExOTk5_b77269b1-3574-440b-a755-5fed8225ede8">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTItMS0xLTExOTk5_ab58d00e-e485-4631-b760-cfcea65e9a83">350</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTQtMS0xLTExOTk5_83eef242-2b8f-47d0-93a8-51ed67bd3cc2">1,426</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTYtMS0xLTExOTk5_b55bbc91-51bf-430d-bae9-d45710e38f27">1,350</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTgtMS0xLTExOTk5_7117d434-c14d-423d-a4ad-a77456223cbd">&#8212;</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:27.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA 04-2012</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (a)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (b)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 ordinary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMi0xLTEtMTE5OTk_0bee9b14-f573-44ba-9fab-79f34bbb9e7d">52,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtNC0xLTEtMTE5OTk_4ae3a570-af9a-4851-a54a-c6fe1f8fbd0c">10,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtNi0xLTEtMTE5OTk_cac073fc-653f-4dae-bd12-f50358f04f90">14,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtOC0xLTEtMTE5OTk_5ad0384d-5458-4b59-83bf-c601a5c15c5b">26,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTAtMS0xLTExOTk5_15ee401f-95cf-4382-90cb-b13636be68d0">64,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTItMS0xLTExOTk5_aeaa5cbd-fb94-4520-b985-f3c46bf2ff36">6,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTQtMS0xLTExOTk5_c45ca7c1-5e16-45d4-884e-2e4d74c2e8a3">18,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMi0xLTEtMTE5OTk_ebe66902-9a3c-4d4a-8ee1-274c0a8d897c">0.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctNC0xLTEtMTE5OTk_62ace996-3303-49c0-933d-64aef7f7c081">2.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctNi0xLTEtMTE5OTk_2a3a784f-b049-4feb-bf9d-abffe85df109">4.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctOC0xLTEtMTE5OTk_3d57b8d0-5489-47e8-a9a1-3da5546a8897">4.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTAtMS0xLTExOTk5_9edbb6c2-71d1-425b-99af-9b73c4fed872">5.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTItMS0xLTExOTk5_9f4f91db-a26a-4079-ae1d-68b83f47798b">2.80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTQtMS0xLTExOTk5_840a3ba2-2658-471b-887b-2f3bad059c37">1.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMi0xLTEtMTE5OTk_2c70d402-9d0a-474b-a204-9482bf596425">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtNC0xLTEtMTE5OTk_0517db77-10f9-473b-a8f4-12f65349e0b4">6.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtNi0xLTEtMTE5OTk_beb4a4fc-9889-4262-9918-25ffd667c0c3">17.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtOC0xLTEtMTE5OTk_a924f94c-6e95-4bed-9d2a-bbbabba6bf6a">17.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTAtMS0xLTExOTk5_903ea879-d60d-470e-a66d-4d61cd1f4651">19.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTItMS0xLTExOTk5_df9064f0-de5f-44c0-b02d-b1191e084bc8">19.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTQtMS0xLTExOTk5_ca76e44d-9fba-473a-8aa2-09f5106a96cd">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMi0xLTEtMTE5OTk_47f7671f-f26e-4611-9499-ce5050fed200">30,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktNC0xLTEtMTE5OTk_b4571e6f-3c3e-4054-9a7c-6c9665eaa274">6,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i287ca2164109487e803ea58119f85b0e_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktNi0xLTEtMTE5OTk_6522974e-fe4f-4d0b-b7d3-747bacb2fcc6">10,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i444894e06ef84e86916f0f43636239a2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktOC0xLTEtMTE5OTk_72fd466f-d5f9-4d85-9647-6ce0ee8cd9ed">21,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTAtMS0xLTExOTk5_a4551017-f10f-40d1-a2c6-ae12b800a73b">64,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTItMS0xLTExOTk5_f75cecac-9089-400a-8496-8991ced53edd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTQtMS0xLTExOTk5_862d03d1-e28c-4f9a-b6a9-303cd9721791">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTItMS0xLTExOTk5_98961039-46a4-4d47-a67d-16f6a0da107a">22,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTQtMS0xLTExOTk5_ebcb31a5-cc06-4dca-9c2d-8f69d35557a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i287ca2164109487e803ea58119f85b0e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTYtMS0xLTExOTk5_99636bbb-a697-411a-b6b1-60305a4b3059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i444894e06ef84e86916f0f43636239a2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTgtMS0xLTExOTk5_cde35096-5732-45d6-933b-1b8215de9143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTEwLTEtMS0xMTk5OQ_ea0e58c9-43fb-4664-a2ef-71051d75e819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTEyLTEtMS0xMTk5OQ_0b73062b-e673-4168-9198-8e4dfabcd502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTE0LTEtMS0xMTk5OQ_66007f1d-401a-4146-977b-28a1230cdc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTItMS0xLTExOTk5_8c8765d7-568a-44d0-99d7-bcde13c7f9aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTQtMS0xLTExOTk5_953ef057-e38e-4e66-93b2-3162b7ff4c98">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTYtMS0xLTExOTk5_d46843e4-97a4-45f9-994b-0fce00f86ca6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTgtMS0xLTExOTk5_d4b7bbc6-1455-4af1-bd5e-697519707fa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTEwLTEtMS0xMTk5OQ_7253df19-d5fb-4e49-84af-96213bdfb4be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTEyLTEtMS0xMTk5OQ_a66fbb61-845e-4dc0-a41b-48675d2d5c97">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTE0LTEtMS0xMTk5OQ_10e22ab1-37bd-4816-bbc8-f7fded7c7049">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTItMS0xLTExOTk5_79e5f468-5afc-422a-bf57-7c1c64af4347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTQtMS0xLTExOTk5_f461d505-1090-40c2-8ca3-680a511ccdfd">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i287ca2164109487e803ea58119f85b0e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTYtMS0xLTExOTk5_04992af9-aa7c-459a-8fdc-54b6f2748ffe">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i444894e06ef84e86916f0f43636239a2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTgtMS0xLTExOTk5_d428d0f9-8058-43aa-8333-64d25aeb2dff">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTEwLTEtMS0xMTk5OQ_0121b3fc-6c80-426f-aa56-fc53a8cdd9a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTEyLTEtMS0xMTk5OQ_a9cc1c6f-1d13-4c58-9e68-35eac0f015d6">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTE0LTEtMS0xMTk5OQ_7d9a6abd-1fc0-47db-b6c9-9e5bb06bc25d">18,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTItMS0xLTExOTk5_13205109-7b01-4066-b92e-8b493e619923">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTQtMS0xLTExOTk5_073abc58-8cb0-4600-8a63-021d7d202d8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTYtMS0xLTExOTk5_58363023-76d3-47a5-bac0-11640b5e32dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTgtMS0xLTExOTk5_7bcbcd77-237b-4794-b99f-0d4dcf1754e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTEwLTEtMS0xMTk5OQ_b3b46db1-e1b6-4c6d-a3aa-892f503f31cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTEyLTEtMS0xMTk5OQ_b5c3eaa5-febf-49ab-93da-7cdd75496603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTE0LTEtMS0xMTk5OQ_e04b20b3-852e-41b7-a993-6bc7c1aee1ee">18,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMi0xLTEtMTE5OTk_eb35e3b2-8a50-4bba-84c7-daf2a38b9a69">18,105</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtNC0xLTEtMTE5OTk_ca5110bd-5d40-46b9-a1d3-89e8da302dbc">8,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtNi0xLTEtMTE5OTk_e1fb9328-8bf2-4831-b7f4-129f5392c48d">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtOC0xLTEtMTE5OTk_f2520092-9e9f-4e0e-982e-d255d88e5194">28,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTAtMS0xLTExOTk5_ea4347d4-0e01-45aa-b479-6215b45b40c8">5,820</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTItMS0xLTExOTk5_61453cdb-fb49-4693-ae91-b6d99ba0c43c">18,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTQtMS0xLTQ1NjE5_6457f4a5-0213-493f-8533-49aea330d9cf">18,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMi0xLTEtMTE5OTk_9bf9e925-a928-4c28-957f-6b853ec2bd28">1.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctNC0xLTEtMTE5OTk_7e840a19-1a68-402f-8c51-5f3c232d8b20">2.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctNi0xLTEtMTE5OTk_5493f300-a3bc-4ab3-8b7f-48b10d2be8ab">2.26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctOC0xLTEtMTE5OTk_578c39ed-860b-4e5b-b9f5-15d381ef08ee">1.62</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTAtMS0xLTExOTk5_c4348678-8c5d-4a62-96ca-59069069119f">2.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTItMS0xLTExOTk5_dbad452e-95de-47e9-91a7-1f5244a1c03d">1.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTQtMS0xLTQ1NjE5_ea687774-29cb-40a9-9a61-f078d7d438da">0.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMi0xLTEtMTE5OTk_f194a2ba-e62a-4609-80ee-973903f836df">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtNC0xLTEtMTE5OTk_ef8c9bba-ef67-4b1b-84b4-e21d194b6ab7">15.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtNi0xLTEtMTE5OTk_46b25176-1e2f-4f5b-86ba-d9929547d6bf">15.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtOC0xLTEtMTE5OTk_2a226218-8517-4a3e-8b82-2406fc012646">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="3" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTAtMS0xLTExOTk5_e50a28f6-1522-4522-8cad-80356c530c91">16.102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTItMS0xLTExOTk5_c9caafaa-4c77-40c3-828b-bf17728c560b">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTQtMS0xLTQ1NjE5_383baebc-bdfe-4f20-8de8-3816bf2d7e50">6.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMi0xLTEtMTE5OTk_5a4b5d17-c1e8-46fa-ada5-0b1c2ba52942">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktNC0xLTEtMTE5OTk_5a2add9e-1f45-4d29-9d93-159b5d3794a4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c32baad1d584e179d05334758196e37_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktNi0xLTEtMTE5OTk_e68bd732-89c3-481e-a063-497e4864b600">18,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i185c5465e4f54321893449f2ed13c945_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktOC0xLTEtMTE5OTk_84162917-9ffc-4bde-8acc-c6fd75e7f14a">28,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTAtMS0xLTExOTk5_f1daffe8-b15e-43dc-96bf-f2df32ee6427">5,820</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a196703767045b4aeaf86e08026e973_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTItMS0xLTExOTk5_4f3cf2ec-a4f3-4fdc-b336-cef92cc1d203">18,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTQtMS0xLTQ1NjE5_9ff82541-0e7c-4efc-8e9c-810d2bf1547d">18,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTItMS0xLTExOTk5_05883e08-6eda-4b7a-9b98-dc66c0c8c4fd">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTQtMS0xLTExOTk5_f4b145e5-bcb1-4eaf-bcaa-78b42412c38b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c32baad1d584e179d05334758196e37_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTYtMS0xLTExOTk5_19a45753-fb5a-45fd-a218-9fea71b79c4b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i185c5465e4f54321893449f2ed13c945_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTgtMS0xLTExOTk5_fac1fd49-bb43-4e92-834b-6c6818e5721e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTEwLTEtMS0xMTk5OQ_40159b88-f719-4833-b320-0d6cbe4eb4e3">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a196703767045b4aeaf86e08026e973_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTEyLTEtMS0xMTk5OQ_68322c96-5329-4c12-a739-b49a910e9008">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTE0LTEtMS00NTYxOQ_e8811443-cb29-4570-806f-52fe922f9189">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTItMS0xLTExOTk5_b5e42cdc-8e00-41c4-9ccf-ee844d4556d2">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTQtMS0xLTExOTk5_b933fc1d-e0c3-4cc8-a230-631342463f2c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTYtMS0xLTExOTk5_f3e7558f-b15b-494d-9061-5b2492f7b7e4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTgtMS0xLTExOTk5_eb0518fb-edc3-44fd-99fa-da0d04f36a7a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTEwLTEtMS0xMTk5OQ_72436c0e-5684-480a-85e6-3f712a8618e5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTEyLTEtMS0xMTk5OQ_e2bb79d0-366a-45d8-a1be-9b595e5568ec">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTE0LTEtMS00NTYxOQ_40db3d18-dd08-4d3d-881a-b6d7fd36bf36">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTItMS0xLTExOTk5_2054082d-51fd-49c1-a18b-5053fb1f4ab6">18,105</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTQtMS0xLTExOTk5_dbb1f584-4ac8-403a-a371-6bcba781b27b">8,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c32baad1d584e179d05334758196e37_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTYtMS0xLTExOTk5_7a050e0e-30ab-4b4b-a54f-67c154968965">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i185c5465e4f54321893449f2ed13c945_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTgtMS0xLTExOTk5_1d03222d-1d56-4a13-816b-2cd7f9cf5eef">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTEwLTEtMS0xMTk5OQ_a6d29820-033d-4609-80b1-43ee334be14d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4a196703767045b4aeaf86e08026e973_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTEyLTEtMS0xMTk5OQ_325380d3-f130-4467-8026-01a6d171962b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTE0LTEtMS00NTYxOQ_5cdf8f73-e515-45ef-a2a8-12d68c08c268">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTItMS0xLTExOTk5_985539f1-1002-4540-9cfb-87c3f232b351">18,105</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTQtMS0xLTExOTk5_122624df-c189-451d-804b-682236321739">8,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTYtMS0xLTExOTk5_359371e8-3948-4815-a5e0-757e12ecfbc6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTgtMS0xLTExOTk5_ee9e7560-e041-4255-919d-79f64d1dea61">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTEwLTEtMS0xMTk5OQ_999e16ea-c241-42e3-b618-217460e846c0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTEyLTEtMS0xMTk5OQ_97b70f6c-cb17-4749-b968-bdf7e5c4b588">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTE0LTEtMS00NTYxOQ_f79a3a43-8f92-4b7b-a2fe-6473aa8c4107">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="if9b9630c061542cc8dca4bdc98eba18b" continuedAt="if3cfcf3d4e1b49c6ad7629e4e462f794"><div style="margin-top:12pt"><ix:continuation id="if4aabf4328fa4323b7a029e9e530639f" continuedAt="i095e925ca9d54d419b41126769a14ad8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.801%"><tr><td style="width:1.0%"></td><td style="width:58.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzMtMi0xLTEtNDU2ODk_cad231ac-5cb5-46a8-abeb-bd32b9511da2">48,103</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzMtMi0xLTEtMTE5OTk_7bba09b9-a35d-4805-b244-968f801cb1c6">30,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzctMi0xLTEtNDU2ODk_b99dfe3f-b8a9-4e8c-889b-2372a0d57e30">2.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzctMi0xLTEtMTE5OTk_3f406213-13eb-4824-8be3-776f204894c7">0.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants as of Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzgtMi0xLTEtNDU2ODk_ad528871-8e7f-4aa6-aac7-874b1f7a9171">13.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzgtMi0xLTEtMTE5OTk_deb7bcdd-b9bb-4630-afda-0e6c15bf0c6b">13.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzktMi0xLTEtNDU2ODk_45f66b5f-2711-42f1-8de6-5ef25242251b">14,431</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzktMi0xLTEtMTE5OTk_2194c4b1-2c89-44d5-95cc-869d6d69a615">30,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEwLTItMS0xLTQ1Njg5_12b15a4d-a424-4d96-9bb7-01bdb537a6f6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEwLTItMS0xLTExOTk5_66c6fe48-04d0-4295-93b2-27faa2f458fc">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzExLTItMS0xLTQ1Njg5_1313fc5f-0814-4e1f-90ca-b3e58b040cc2">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzExLTItMS0xLTExOTk5_cdec2106-1d64-4d19-8917-66b6f630b708">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEyLTItMS0xLTQ1Njg5_e8377187-8b69-42f7-8fdc-14fe637109db">33,672</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEyLTItMS0xLTExOTk5_98eb9645-d92f-4ebb-be4f-3906949e9550">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEzLTItMS0xLTQ1Njg5_c0bf0f96-87cf-42a8-80eb-280f8bc9164c">33,672</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEzLTItMS0xLTExOTk5_6359a5a7-d9d9-4b0f-aee2-b35dcec6ac2a">&#8212;</ix:nonFraction></span></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODY_6fa377e1-6f7e-4b3e-879f-7fcb1a43ed76" continuedAt="i852afc45447140c99639ce805880b415" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.559%"><tr><td style="width:1.0%"></td><td style="width:27.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2016-1 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>LLY 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMi0xLTEtMTE5OTk_c25a1121-da8d-49db-8e44-bfe77332c1b1">6,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtNC0xLTEtMTE5OTk_bd115176-241b-46bd-a34e-954fc847f31b">4,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtNi0xLTEtMTE5OTk_74328478-7a93-4a83-a6d0-6efc84bc48e3">3,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtOC0xLTEtMTE5OTk_58c9de1d-7527-4fb1-a9c1-b4731f05789b">62,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTAtMS0xLTExOTk5_ad9b9578-77e7-4d18-a1bd-9bb16f752488">37,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTItMS0xLTExOTk5_0a93d0cd-49c7-4d97-8d20-be2880bb7069">500,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTQtMS0xLTQ1NzY0_cad144a1-0a07-4b2b-aa5d-bdfb7815f069">407,972</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMi0xLTEtMTE5OTk_7c5fec0d-b409-4095-a459-a143457b32ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctNC0xLTEtMTE5OTk_0a9e54f7-7fd6-424e-a02d-2b7f44890ea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctNi0xLTEtMTE5OTk_d195f2bb-5f7d-4a32-a8d3-33df0cd1d8c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctOC0xLTEtMTE5OTk_cde113c1-c76d-4fc0-8d78-9b032691fe4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTAtMS0xLTExOTk5_7b98d671-ffca-4180-a775-2bdc5817a8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTItMS0xLTExOTk5_5438b699-d9f5-4fa7-a680-72c5ac546342">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTQtMS0xLTQ1NzY0_9200fe0e-22a0-42cf-882f-72d2fa057c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMi0xLTEtMTE5OTk_b2ee07b1-33f5-42a6-a3d4-50f4dcbb2127">13.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtNC0xLTEtMTE5OTk_87623cb9-5225-438c-9327-75bd49791147">14.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtNi0xLTEtMTE5OTk_9508bfa2-e8ae-46d7-84f7-25c0e93928d7">14.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtOC0xLTEtMTE5OTk_cf6d85eb-13c1-4a1e-b784-e79597cd5582">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTAtMS0xLTExOTk5_af7cc4a3-d146-4094-a434-88f12cd91d4d">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTItMS0xLTExOTk5_a4a9331d-c56a-4af4-94d2-3033386b414e">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTQtMS0xLTQ1NzY0_8469b37f-4466-46a4-9737-0275980abb75">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMi0xLTEtMTE5OTk_a2c4054b-6f91-4a90-a5c0-061191c7c7b0">400</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktNC0xLTEtMTE5OTk_f5baa6a5-92ba-4543-9694-cad6d22841ac">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktNi0xLTEtMTE5OTk_8f481de5-6a62-46ea-8d13-c6a7c813e717">500</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktOC0xLTEtMTE5OTk_5e0263ee-8343-495c-82f0-e4159aace8cc">52,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTAtMS0xLTExOTk5_50d0a33e-2f91-423a-b99b-7b281889612c">28,250</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41f34aacd8914d92858087d804274e6e_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTItMS0xLTExOTk5_a454d085-8b7b-4617-8eba-04ecca2c0266">500,000</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTQtMS0xLTQ1NzY0_78a611b0-6022-4bef-a171-121ee1e5089b">387,456</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTItMS0xLTExOTk5_1d17febf-9455-4c73-9865-bc00cbddca5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTQtMS0xLTExOTk5_e2930953-5d68-46ab-9640-9b776fb7a304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTYtMS0xLTExOTk5_24237b37-5921-4242-becf-30f8ecdb15cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTgtMS0xLTExOTk5_3a556e8a-e2b9-44fb-9bd4-0d2b19c0c987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTEwLTEtMS0xMTk5OQ_1fb4f077-4a8d-41a4-83d5-7ce20f26669a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41f34aacd8914d92858087d804274e6e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTEyLTEtMS0xMTk5OQ_f861f886-66b2-45ed-a965-b9d1409f4b43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTE0LTEtMS00NTc2NA_c8b4ca5f-c0ae-4e3a-aac7-8a98b94ac27d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTItMS0xLTExOTk5_1cdbb5ed-b075-44fb-bb72-fd68e02b78cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTQtMS0xLTExOTk5_93141ef7-1d07-4184-81c1-84995ffea426">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTYtMS0xLTExOTk5_b56f8195-52a5-4c64-a557-70f674987af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTgtMS0xLTExOTk5_ffd07644-8979-4bb0-8731-93e827404ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTEwLTEtMS0xMTk5OQ_d8b9053f-a164-46e1-afad-70460119fea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTEyLTEtMS0xMTk5OQ_977181ed-3a53-42d0-82a1-9f8f5c61ec22">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTE0LTEtMS00NTc2NA_e1e6a2b4-6394-4f52-ba16-452453c198a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTItMS0xLTExOTk5_9272a957-8896-498d-ab87-f9b6abb6d877">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTQtMS0xLTExOTk5_2c38f830-5295-4bef-ae63-261f9a56dc9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTYtMS0xLTExOTk5_8242dab3-f1fd-417c-ac59-4e141ead8c20">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTgtMS0xLTExOTk5_f4004c13-a4a8-434d-b1b4-cd80cc96c8f5">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTEwLTEtMS0xMTk5OQ_d35321e3-6075-4a61-972c-c475b418f246">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i41f34aacd8914d92858087d804274e6e_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTEyLTEtMS0xMTk5OQ_0a9cc41c-6fbe-4080-bd64-5aad07b7f0a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTE0LTEtMS00NTc2NA_cc527bc2-3bc7-4cfd-8c8c-078ea78c6c40">13,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTItMS0xLTExOTk5_0fb28654-0900-4320-ad8b-f8cf75760ed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTQtMS0xLTExOTk5_46f5539b-a00f-47ed-9870-fe86b672e555">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTYtMS0xLTExOTk5_01d04e7e-d857-40e0-85bb-45e13705b40e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTgtMS0xLTExOTk5_3c840c80-a4c8-4ea0-928f-051188bd5846">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTEwLTEtMS0xMTk5OQ_da6e03cb-2247-4c2a-a453-3f9864b096c9">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTEyLTEtMS0xMTk5OQ_d7e88326-7fc1-46ef-a891-b4c81cfa1a5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTE0LTEtMS00NTc2NA_0cebe794-ddd1-4ce7-8679-a938deb2e86b">13,253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.754%"><tr><td style="width:1.0%"></td><td style="width:67.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzMtMi0xLTEtMTE5OTk_bc8a1e5d-826e-4d36-9319-27f3cc59c31a">571,200</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzMtNC0xLTEtNDU3OTQ_42a2f182-b6e9-4d61-aecd-7d261c3555f3">120,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzctMi0xLTEtMTE5OTk_c579d89f-344a-4320-aec3-ba9990532b95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzctNC0xLTEtNDU3OTQ_ecee8262-12ac-4da6-af03-c762b2836d87">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzgtMi0xLTEtMTE5OTk_7406dec7-2c8d-4e5c-a411-48d0797fbed8">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzgtNC0xLTEtNDU3OTQ_9420be90-e394-4753-bf07-c0a37619780c">12.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzktMi0xLTEtMTE5OTk_69975631-c377-494d-be6e-89f67f2d6887">491,200</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzktNC0xLTEtNDU3OTQ_b3a3db44-a483-4944-839e-87381dcbf760">120,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEwLTItMS0xLTExOTk5_ab633ed5-e055-49a1-bec8-066a6541ae74">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEwLTQtMS0xLTQ1Nzk0_c5556fe7-72b0-48b4-afaf-e82b2a88d103">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzExLTItMS0xLTExOTk5_87543b07-b7c5-408f-8209-42fc79fafabf">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzExLTQtMS0xLTQ1Nzk0_29d8b9a4-6d31-467a-b07b-f9136bb2431b">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEyLTItMS0xLTExOTk5_0238144a-5747-4aaf-a1ec-26191c6a0c1a">80,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEyLTQtMS0xLTQ1Nzk0_d01927b0-ed0e-44c7-8755-dc9ef8d59a0a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEzLTItMS0xLTExOTk5_582ce1a9-edd3-4339-b6f3-888164a3a2e8">80,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEzLTQtMS0xLTQ1Nzk0_5b62b005-1eb0-49d8-aa2f-4ad7607743d7">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="if3cfcf3d4e1b49c6ad7629e4e462f794" continuedAt="ib667478e6b0c42aebe7b3a0ed4cf483c"><ix:continuation id="i095e925ca9d54d419b41126769a14ad8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Free shares</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"><tr><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 free shares plan not yet vested</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021 free shares plan</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtMi0xLTEtMTE5OTk_7661967f-1a7b-4eef-92fc-882ae69d2286">396,250</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtNC0xLTEtMTE5OTk_21d22c12-3d08-4073-b545-e58c678c7a9c">6,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtNi0xLTEtMTE5OTk_78a13e9d-effc-4180-9271-d02c4ca5f2b7">438,250</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtOC0xLTEtNDU4ODg_7c7a38e8-4904-44d0-bd8a-c9a31844c85f">50,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtOC0xLTEtMTE5OTk_b98dfdf1-35ee-49c3-92ed-555ecda76bae">362,515</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/11/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtMi0xLTEtMTE5OTk_8beb5378-64d2-4920-8bee-0de01d905c04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtNC0xLTEtMTE5OTk_07475abb-4480-4112-912e-473556da929a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtNi0xLTEtMTE5OTk_e4563a40-6989-4ace-ad15-90addb77534b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtOC0xLTEtNDU4ODg_6ae3664e-8641-4e83-a2df-42cb0b03d9dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtOC0xLTEtMTE5OTk_ee8f4f78-0e4b-43b6-8327-7017c8b5a2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctMi0xLTEtMTE5OTk_1a89bd50-f8e3-4940-8405-9f67eed33066">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctNC0xLTEtMTE5OTk_28ce5308-c56f-48d6-ac5d-7292971706eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctNi0xLTEtMTE5OTk_8d9596da-d312-4e18-8566-aad1b0853af1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctOC0xLTEtNDU4ODg_96ebfc85-9063-4f3f-bb21-59ed1acde6ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctOC0xLTEtMTE5OTk_ced7d6e3-cc6f-44f4-8281-39eaa99eee4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of free shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtMi0xLTEtMTE5OTk_1a29082c-4722-4cda-807e-ae124b2e0791">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtNC0xLTEtMTE5OTk_c611f377-1f83-4caa-8efc-928c781585af">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtNi0xLTEtMTE5OTk_006deb2e-36e8-4b7c-9f1e-b76803cc71fe">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtOC0xLTEtNDU4ODg_0c9df648-adb9-4507-8de6-c1f3a7c4dff1">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtOC0xLTEtMTE5OTk_592bf064-a2e7-4077-a728-d54921d87a11">360,512</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktMi0xLTEtMTE5OTk_299f6d55-fa90-41fc-bc05-64b257f871d3">340,583</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktNC0xLTEtMTE5OTk_9d1ad4d5-ccea-4343-af5b-004951f14840">6,000</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktNi0xLTEtMTE5OTk_2a047384-6850-439b-85e4-2adc6de9ef05">369,250</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktOC0xLTEtNDU4ODg_6b992816-953b-4698-b9db-b1b4e6afbd93">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktOC0xLTEtMTE5OTk_cef101e3-9224-41b9-920f-d999d8295208">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares exercised during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTItMS0xLTExOTk5_b96feb4f-f893-48ab-861c-9d8164854225">24,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTQtMS0xLTExOTk5_7648816d-6bd1-4462-a0ff-d6f53b98e4d1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTYtMS0xLTExOTk5_65a2f0a8-c2e2-4d20-b042-ef0208cbb2a0">369,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTgtMS0xLTQ1ODg4_f5eac470-4e77-4702-8db9-bafc4d5e85bc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTgtMS0xLTExOTk5_8cabdbb3-8dbe-4c58-a184-4fc7534e954e">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares lapsed or cancelled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTItMS0xLTExOTk5_cadce269-bc91-4c52-9cda-d8e465d77077">55,667</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTQtMS0xLTExOTk5_2d268ce2-28c4-4f9c-ac49-04b21f0c6311">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTYtMS0xLTExOTk5_1688718d-3bad-4608-93c0-4f2995761412">69,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTgtMS0xLTQ1ODg4_85474629-e16e-4fac-a74f-5e974dea2ebc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231" decimals="INF" name="nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTgtMS0xLTExOTk5_40412c65-ef0f-4eca-888a-cf85e418cba7">2,003</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares lapsed or cancelled during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTItMS0xLTExOTk5_9cde62ad-857d-466e-8018-25b88d267166">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTQtMS0xLTExOTk5_6e10da41-ce20-4372-83ba-01eef59119a4">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTYtMS0xLTExOTk5_76907b2d-52fb-45a8-81ac-5984c9ea8780">2,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTgtMS0xLTQ1ODg4_8e96f7bb-911f-4d7f-beb7-493cdc680fe2">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTgtMS0xLTExOTk5_73fd334b-1c78-4c80-8436-6ca86aa8b0d7">2,003</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><ix:continuation id="i852afc45447140c99639ce805880b415"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtMi0xLTEtNDU5OTA_42ae6a94-3117-4baa-a152-689f2430e840">715,291</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtNC0xLTEtNDU5OTc_2b33bf81-3b55-486e-aae3-8fcd4ec3d548">263,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtNi0xLTEtNDYwMDM_e07ede2e-20f6-4259-8188-1f07b63185ae">1,583,806</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0979101cec4474688543efa006ec62d_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtOC0xLTEtNDYwMDk_74249a6e-9f12-43a2-add0-d5f2245b4c76">410,512</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtMTAtMS0xLTQ2MDE1_0dca6075-d04e-420e-9e5a-47cbc543a03e">2,972,860</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtMi0xLTEtMTE5OTk_12672d47-ac2f-49bf-b2ce-ae0bd1e53eea">718,767</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtNC0xLTEtMTE5OTk_2470038e-184e-4cdd-b8fc-60e351eec2be">263,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtNi0xLTEtMTE5OTk_0d46e545-67e2-4876-b45e-bfb20ebe2bed">986,359</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtOC0xLTEtMTE5OTk_54ce2b53-734e-4891-87f9-f3369361a960">446,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtMTAtMS0xLTExOTk5_145ea7ae-7dbf-4ef9-85e7-972b5599ef2b">2,414,654</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtMi0xLTEtMTE5OTk_8e99fab8-a959-45a2-8f3e-bb7bc311d3f5">751,585</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4483ef3c39a64c83b928490f95c78902_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtNC0xLTEtMTE5OTk_84de9917-f54c-40bb-bb74-0e75b4581847">251,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtNi0xLTEtMTE5OTk_d4de47d2-4d38-438d-bf6f-9b02c1ccd79a">589,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia09f2bb3b6114c268acacc4f0ebce171_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtOC0xLTEtMTE5OTk_da5c50b0-54c8-421d-a351-f5b52021f498">746,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtMTAtMS0xLTExOTk5_ac0469c9-14b4-4e62-ad0a-8d46cda6d0da">2,338,013</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIyODg_b3b9e3c7-1105-42ef-9794-6859dfd4ec3b">40</ix:nonFraction>, taking into account both the average share price on the <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIzNDg_a9a5ddc0-8828-4914-b960-4f9dbd72e534">20</ix:nonNumeric> days preceding the grant date and the expected development perspectives of the Company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The risk-free rate was determined based on the average life of the instruments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The performance conditions for all of the plans were assessed as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Market-related performance conditions were directly included in the calculation of the fair value of the instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Except for the 2012-1 founders&#8217; warrants, the fair value of the warrants and options was measured using the Black-Scholes model. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of 2012-1 founders&#8217; warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNjI_78a05b15-0673-4e0b-919b-0f0f6a2a82fa" continuedAt="i30e6f7999c454895891224f6b173d62f" escape="true">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence ,  no new instrument became issuable.</ix:nonNumeric></span></div></ix:continuation><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="margin-top:12pt"><ix:continuation id="ib667478e6b0c42aebe7b3a0ed4cf483c" continuedAt="i2ea21135d7804de6b73a634f7669fd8a"><ix:continuation id="i30e6f7999c454895891224f6b173d62f" continuedAt="id937be53a3a54952a09bd6dc46dc6e69"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:18.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMS0xLTEtMTE5OTk_ebda7097-d8ae-4468-938c-bd4dcddb7717">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMi0xLTEtMTE5OTk_f6834a7b-9b70-428c-94ba-0351d24bc552">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMy0xLTEtMTE5OTk_7d6bede7-396d-45a7-a85e-d2d29dc4d09b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowODUwMGUwMThlNDU0ZDM2YTkxY2Q2ZWMzZTkyZDQ4MF80_73e283e2-7cbb-4362-8ea3-c6a856f676e1">3.49</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNS0xLTEtMTE5OTk_4338cc0e-087d-4579-a4ef-a856230d52e3">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNi0xLTEtMTE5OTk_00cb4926-ed82-4fae-b62e-96d1821667df">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNy0xLTEtMTE5OTk_6f074ea5-6807-4ffe-9e21-4d270f5c65cf">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i131da624a9f34a0ea29bf0fb2176cb5f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtOC0xLTEtMTE5OTk_0f373ac2-f42f-49c0-a41c-2a1c977c54f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3e6efed0beb6459b810d1467e0c1183b_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtOS0xLTEtMTE5OTk_692b80e7-c87f-4264-be97-f5f814511013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie9862c8deb0544ba80cef9d729d58100_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMTAtMS0xLTExOTk5_7a2547e2-d9f3-4bb0-ae39-e72ad8447c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMS0xLTEtMTE5OTk_ec566c4b-1071-4c77-bb48-824daff06e1f">6.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMi0xLTEtMTE5OTk_67745d1d-9b4a-49ea-b10a-a349832dc8ee">6.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218" decimals="3" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MjNlYmY1NmMwYzY0MTU5YWQ4NGE3MTUxODczMDA5YV80_e1d3a2ed-3313-44e3-9e4b-ac167a1fd329">44.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie2919f18751144b78569c4161f2e947a_D20121218-20121218" decimals="3" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MjNlYmY1NmMwYzY0MTU5YWQ4NGE3MTUxODczMDA5YV85_70cfca25-3c90-49cc-bfbb-6d8fb7dc3e69">47.6</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i59ef69bbeb80421eb92fd0f71ad1d8e4_D20121218-20121218" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZTk4NmYwMGVhYzU0YjY4YmZjZWI2ODc2YmE5MGM2Nl81_cdba2dcd-d137-475e-8b2f-8f29c514ddc9">5</ix:nonNumeric> - <ix:nonNumeric contextRef="i0f5b8beea7b64bb286271b8eb038177b_D20121218-20121218" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZTk4NmYwMGVhYzU0YjY4YmZjZWI2ODc2YmE5MGM2Nl8xMA_31372c36-17cc-445b-a9fc-4e4bc7c2a88e">7.30</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4ODc3ZDcxNjMzZjQ0NWVlODUwNzIxYjNkZGFlYzM1Yl80_af90ea84-d578-4750-9f89-606456458d1b">0.84</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie2919f18751144b78569c4161f2e947a_D20121218-20121218" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4ODc3ZDcxNjMzZjQ0NWVlODUwNzIxYjNkZGFlYzM1Yl85_517bfe5f-84eb-4a54-bfcb-48df03cec2b7">1.22</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNi0xLTEtMTE5OTk_937d4632-86f1-49c1-b321-0cb64603bb1c">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNy0xLTEtMTE5OTk_b830ef5e-a8bb-4ae3-af2e-52087259a745">288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItOC0xLTEtMTE5OTk_e549b913-333e-47a3-8237-f6aa306dd5b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItOS0xLTEtMTE5OTk_31f43b64-670e-46f0-a7a4-de865d68dad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic47716d92fe342deb87045fda3d7f2c5_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMTAtMS0xLTExOTk5_6bb99f03-0a78-4467-a1d1-9fa57b08d020">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 04-2013</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMS0xLTEtMTE5OTk_3da0c6d5-372d-4502-b869-15688a0442f1">6.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMi0xLTEtMTE5OTk_c3f51e32-7652-4fb0-8438-a81927c5af8a">6.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMy0xLTEtMTE5OTk_995b290e-6343-483f-b025-feb63db1532b">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNC0xLTEtMTE5OTk_65257dc0-c2a8-487b-9fa7-3ea610b1fe4d">5</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNS0xLTEtMTE5OTk_ba57e8c5-8a51-4192-8c73-447bcf0ac6cb">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNi0xLTEtMTE5OTk_ff0fb485-2b4a-4d14-8eb6-db3c3aa7c377">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNy0xLTEtMTE5OTk_97c2c5fd-618e-4c80-8949-f8f4568fe672">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9a43074ca66449b4b97de195d8ec4408_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtOC0xLTEtMTE5OTk_9827f0c3-0bc8-4233-9d51-4a130dc68476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib461318901ed4fe7a3b3fd7d2eb455e6_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtOS0xLTEtMTE5OTk_b0e51164-b7ff-411b-841c-a5c81f0b2991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="idfbec539f6234dc4ac97bed76d788c2c_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMTAtMS0xLTExOTk5_fb57f079-8453-49ff-b1f7-b945f35dcf0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 08-2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMS0xLTEtMTE5OTk_3fd9f755-735e-479c-90d9-eae2779aa005">6.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMi0xLTEtMTE5OTk_e264edeb-68b3-4620-9dcf-7039e9431020">5.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMy0xLTEtMTE5OTk_a8e9c990-52f4-4b38-98e8-84e4b92b21a6">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNC0xLTEtMTE5OTk_0007f1d7-10db-4f82-9931-263cefea70cd">7</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNS0xLTEtMTE5OTk_14d09a75-ce6c-4e99-b989-0025cabd1f14">0.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNi0xLTEtMTE5OTk_3d268a16-89f4-42f4-be07-acbb62697d7f">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNy0xLTEtMTE5OTk_10d19822-cb46-4fc8-bacb-0909f4d5e239">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtOC0xLTEtMTE5OTk_ea978c79-4885-4f57-bf09-b4c4b54e6217">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtOS0xLTEtMTE5OTk_4bbd5f17-08f1-4727-8b23-8b671847c65d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3d6ba050064a421289ccace20cb9938f_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMTAtMS0xLTExOTk5_c7ed3251-1bcf-4e72-92cb-1b4e1ac888ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 09-2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMS0xLTEtMTE5OTk_0bb7717f-6a54-4c4f-baa9-14961d9cf96c">18.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMi0xLTEtMTE5OTk_f1bb174a-a9d1-4b87-8e60-214bc0c516fb">18.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMy0xLTEtMTE5OTk_13953e40-dfb7-4c99-84e9-df356de4e55c">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i529aac24770b44a3a7b925fc089a42f7_D20140916-20140916" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl81_905aefe4-19fa-42ac-83fc-50eec5e92d25">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="iea55eafbda0d41bfa15182895fad5428_D20140916-20140916" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl84_b090995d-a033-44cd-9500-b8ae9a737d3f">6</ix:nonNumeric>/<ix:nonNumeric contextRef="ibb6b9590e1084b969feeba3744fac7fa_D20140916-20140916" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl8xMQ_cfd838ee-bf84-46ff-a176-33f26b8ea8cd">6.5</ix:nonNumeric> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNS0xLTEtMTE5OTk_a940a152-661c-4963-acf2-18baa0248913">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNi0xLTEtMTE5OTk_1e637773-9e2c-42ba-b986-0aab8e2bea6a">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNy0xLTEtMTE5OTk_a191c9a8-5c4f-47b0-b29d-5b35b8761229">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtOC0xLTEtMTE5OTk_bbae3d28-02c5-4adc-89c2-0741091d86cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtOS0xLTEtMTE5OTk_617a7786-7642-4719-b0a4-6f155022eec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4d028643a8ae49cb91443fcb6667aff4_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMTAtMS0xLTExOTk5_3e8444f4-f4a9-4d1a-99e6-dd305eb0be3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMS0xLTEtMTE5OTk_3c6a2009-bc00-46d7-871a-be63fca4d40b">18.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMi0xLTEtMTE5OTk_2f2f61dd-5acf-41b6-9e33-0d9ec434a9a2">18.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0cfb0e0616fc451db5120b69a2855aef_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV80_d980e6e0-c890-4f69-81a3-c38c11d22559">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ieae0ae0f0de24a7a8c7909960e7edc97_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV85_be0d7f5d-9427-473a-8dc7-dae31f1b501f">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i31d2e2aabd79424b9ff15157a58c2098_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV8xNA_38a1d38d-f734-42b3-8491-09e79b781345">61</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1a361874f01d45dfb381dace0aaa6dca_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF80_c2505451-aefa-4fd4-a0a5-bc9802c896c9">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="i3149d9f29e6948679668c8902a58d1d1_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF83_91d950ee-47e5-4cd7-9c02-cf76cac7bc06">6</ix:nonNumeric>/<ix:nonNumeric contextRef="i6508d90ca7934d8a8c8c500934137220_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF8xMA_a4b832df-8bef-473a-a6dc-b88337a2bb85">6.5</ix:nonNumeric></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNS0xLTEtMTE5OTk_322acd54-8ae1-417f-9cb2-64fe0d97a87b">0.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNi0xLTEtMTE5OTk_a9121fbb-18aa-4055-90ef-5bf864239b4e">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNy0xLTEtMTE5OTk_9e7aa809-9f96-4fdf-be05-dcf4f90984a2">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtOC0xLTEtMTE5OTk_b5d2e5ec-f0ce-4677-8a8a-5b744e1f2a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtOS0xLTEtMTE5OTk_9dd7f5c3-ed6f-4fee-bc86-0805cf9330fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i84c141fe66774426ab927cbccd1a4268_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMTAtMS0xLTExOTk5_14e78173-4845-4c76-8783-f1db4c9c0487">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMS0xLTEtMTE5OTk_7270a770-f9e8-4ced-a649-d9142e674467">18.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMi0xLTEtMTE5OTk_59d68d13-3900-4e15-8784-d30c83f19d7a">18.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1cedf3438b9b490a99a1bdf2d42f0411_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl80_66f6fbbf-231c-47b6-b679-6a3aedf6392b">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3b9cdfe23729475a93bb7b74d4885975_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl85_d1e1f187-ad63-4029-902f-89a85c41dcd6">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2c4b9ce0de6e4e6eb552cbf8fa6227a2_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl8xNA_6ddc72b7-8ee4-4d17-a8a0-227b0667c5d8">61</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9f5242dc069c466caf5e1c7529c26b46_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV80_355e8018-94dd-490d-b53a-b859156bb31c">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="i5b7e511fc9c144a38119eb439ec44e9f_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV83_529138a5-040c-47ab-8f79-78237c85f92b">6</ix:nonNumeric>/<ix:nonNumeric contextRef="i207651a4998445daab53f905e5da87aa_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV8xMA_f740b5f9-84e2-44f4-962e-37fb88b8733b">6.5</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNS0xLTEtMTE5OTk_1348224d-e20f-42b6-afa5-2379654022e6">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNi0xLTEtMTE5OTk_285c753b-9775-42e4-b85c-ed5dd9934930">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNy0xLTEtMTE5OTk_a77c3253-a95a-4e8c-ae4b-5f6f9c8af3c8">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0567406eef544202ac9f21ae3e4dedaf_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctOC0xLTEtMTE5OTk_851a4009-d8c7-45aa-bd4e-aa387fc7599d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id2278b3270e54cd99a22052840e92c05_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctOS0xLTEtMTE5OTk_60d14b94-5854-45da-a379-68a775239002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i91baa8cdfc354286a5178aa94929c1b0_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMTAtMS0xLTExOTk5_c6118eb9-7319-4b41-84e6-754caf4061f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMS0xLTEtMTE5OTk_e64821ac-0c20-48ab-be4d-9055a06cb063">20.28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMi0xLTEtMTE5OTk_1dcc59ea-126c-4ae8-bf4b-6513913ed354">20.28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i21f6266a6261424cb3701521e5a643bb_D20150610-20150610" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV80_d7949285-b1d5-46ed-9cbc-d51ba8c7ff4f">61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i39b343cc43b1488fbabbaadbf30a57c5_D20150610-20150610" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV85_02cfd3dd-1cf3-4943-baa5-be0b0a0cb9f2">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia126f4a85d5f4a6c89bd72f4726e6886_D20150610-20150610" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV8xNA_47ea91e8-0578-4994-9f1a-f4a9c8479e5e">61</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4349ffd9c31d4d72afb2c3d5558ef0ff_D20150610-20150610" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF80_59a82fa6-27cd-4941-8d19-bb629000f2c6">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="if88984bd12b3495c88bd5037ff1a7d37_D20150610-20150610" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF83_fc3b4b36-3c6c-4412-9d42-b71e3c58ca15">6</ix:nonNumeric>/<ix:nonNumeric contextRef="i4a26e567a53c4044a0c3a2ccdad0fc3f_D20150610-20150610" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF8xMA_c9412590-a9d6-4f7e-a744-159d7ee95f87">6.5</ix:nonNumeric></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNS0xLTEtMTE5OTk_2ae2a8c1-7f96-4b0d-80b5-a8c1737ec855">0.56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNi0xLTEtMTE5OTk_c7e1366d-5258-4029-b4b8-6c6abec31bd3">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNy0xLTEtMTE5OTk_e7aaf729-7c6d-4109-b147-f3f330d70817">483</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtOC0xLTEtMTE5OTk_d1fa83a3-7d62-4612-b993-a0de239287a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtOS0xLTEtMTE5OTk_e673f54b-b1cc-4a22-93dc-ea23270e5d01">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia1b746c0ab7b412ca2b2dcbaaa72a86a_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMTAtMS0xLTExOTk5_9d7212ac-8278-4e82-9b2f-a990d063c664">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMS0xLTEtMTE5OTk_8f2bfeaa-0f0d-464a-8e56-740dc507dc8c">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMi0xLTEtMTE5OTk_5dbc3027-e930-4ddf-89d6-addafa08d57b">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="idf7662da67c64289867d340b367149ab_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M180_04c498ff-b752-4562-b007-b68af61605af">59</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iee4d7149ad404f968cc08e4aef7c0075_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M185_e54dc30b-9052-45d9-aaf9-c94e0f1a3fcb">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9b964e599c664b8cab5e656560b104ce_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M18xNA_7c9af69c-4f97-40aa-9f3b-c8432cc8811e">60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0a861384c2b240cc81036e74e3cc65b5_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF80_582293b6-a0de-4f65-93d1-42a3cb22db12">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="i774ea0f18ade47cc86a9a59b81faa563_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF83_1d960b84-e75c-43a1-8956-694295255636">6</ix:nonNumeric>/<ix:nonNumeric contextRef="ie2fc173db3ba4df1afee089ed2af09e3_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF8xMA_4b291d83-a54e-4e55-beb4-5f944448a36a">6.5</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNS0xLTEtMTE5OTk_774301f7-de2b-456a-84b5-622343e0ddac">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNi0xLTEtMTE5OTk_4548504b-8cab-4cc6-a3c4-63a4c8fa7938">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNy0xLTEtMTE5OTk_4ffffd0e-2e5d-4c89-8577-027f7592abc2">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktOC0xLTEtMTE5OTk_87f73265-dad6-4580-a87a-d558c7cbcb65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id2b41add39c641428eeb18e53a36b901_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktOS0xLTEtMTE5OTk_8c237094-30de-446e-8d46-55d32d5a5a4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0bf0cda381de45b4a117fd8996ba9e9d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMTAtMS0xLTExOTk5_4b76c4f1-f01f-45f3-b16b-5768f5778b9b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTEtMS0xLTExOTk5_4751f126-6b2e-4796-ab85-b3a3b995c3fd">14.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTItMS0xLTExOTk5_f034d403-8b68-4b60-9642-c0b1dc17656d">14.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTMtMS0xLTExOTk5_2f87fb71-769a-4a00-8017-3432c093a803">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTQtMS0xLTExOTk5_be56310f-db08-4277-9ed6-0d36c0895372">5</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTUtMS0xLTExOTk5_d2a5ea40-ce6c-48bd-b763-7bbe7290b8d5">0.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTYtMS0xLTExOTk5_3aefbad5-3756-46f3-9ae4-07cbd3387a82">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTctMS0xLTExOTk5_f5cc24ce-c080-450d-9466-c43ac3e825cd">1,212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTgtMS0xLTExOTk5_a1ce347e-e891-442b-b22b-293817f8ede2">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i847617a0623e4f41a7bb7506d0ec32e0_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTktMS0xLTExOTk5_1d6cfe8b-4392-48e5-ab88-605988621d8f">99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i329a6fa2c67c4bac97fd56ac1b9a7dfb_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTEwLTEtMS0xMTk5OQ_af395fda-57e9-4a67-8e60-d1b9fa516e36">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTEtMS0xLTExOTk5_d306a970-f844-4725-8e9a-eed34294406c">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTItMS0xLTExOTk5_80f8c97a-5da3-4919-8447-93a99af51b9c">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id634b4f13485463ab1d7a2134ff28cf9_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfNA_90388b00-bb8a-4aeb-ac4c-423c23705041">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie0299ef3d2b54641bfbea01d292269b4_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfOQ_9a813720-8558-4445-bfe3-993df57fc690">61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7e8dd4ad27014b778bbf05ed702bbdc5_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfMTQ_f19e1ce4-cb3f-47fa-b5f6-fff7d567d521">59</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i813aa1603ff64691b4654fe399d47cc0_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfNA_9a994c8b-3ae5-4e8a-8ed0-e284b8294b51">5.5</ix:nonNumeric>/<ix:nonNumeric contextRef="ia0363e72665149cf92fa348abb499297_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfNw_65b3b0c4-12d7-4850-bfd5-89c5602706cb">6</ix:nonNumeric>/<ix:nonNumeric contextRef="ia8f32dfa54044567a9386587ef6bf4fd_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfMTA_45d52024-9952-4de2-a6e6-bba031658897">6.5</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTUtMS0xLTExOTk5_968cc644-e2d5-4ca3-b702-be72cbc0f555">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTYtMS0xLTExOTk5_d16ad01e-e0d1-4801-8ed1-2319cb1223fd">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTctMS0xLTExOTk5_34eff566-8fec-4c5c-8f25-52a518286bdd">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTgtMS0xLTExOTk5_bca8fcc3-36d4-471a-a6c5-eb16fc8dfe9c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8e6fe4ace1c746f6a6dfb0b6c92cabd4_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTktMS0xLTExOTk5_91fbf827-f2e5-4fbc-9f14-2fa455462b44">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i01c0ec932c6f41ba9b4f8939121b36b7_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTEwLTEtMS0xMTk5OQ_6d4c3adb-9609-49ab-8549-cb0239dd5810">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTEtMS0xLTExOTk5_b65d5e9b-d122-4431-b043-8ca1ffeec2a1">15.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTItMS0xLTExOTk5_679179fe-81e7-4e73-9d64-6885b4fbbf68">15.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTMtMS0xLTExOTk5_b47a857e-0c70-46d7-ae4a-4a2e43bf751e">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTQtMS0xLTExOTk5_2d8beff8-5a0b-4be2-ac0a-5d2200309525">5</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTUtMS0xLTExOTk5_ba9a898f-9c21-4688-825a-4e5d1a38cbc3">0.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTYtMS0xLTExOTk5_47d7bc16-6260-4613-801b-d8a3d9ed7576">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTctMS0xLTExOTk5_45941e84-59cb-4910-990c-3212dcbfb81f">622</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTgtMS0xLTExOTk5_4a22f2f4-80ba-4c9c-83eb-4f2a33192987">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3f5763ec171d43428a511bc2c311c914_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTktMS0xLTExOTk5_a3eef298-e64d-4612-8d6b-88c5b228bd0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie0a7ff6bb25f4c1ab55f70225cff85dc_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTEwLTEtMS0xMTk5OQ_b85b2f6b-b3dc-4110-a4ae-e9f7413814b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTEtMS0xLTExOTk5_169c98ab-428e-4ca5-8114-8699bf93345c">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTItMS0xLTExOTk5_daf7c423-8cd9-4437-aa4e-230231f92765">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTMtMS0xLTExOTk5_4ccaa89c-8883-4d68-97a0-e1f6b10fe4af">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTQtMS0xLTExOTk5_32daf879-0c45-4892-a94d-5ad3901a4568">5</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTUtMS0xLTExOTk5_a296696b-0ba8-4d35-81cb-d1999ad9c0b1">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTYtMS0xLTExOTk5_408e8bc3-06cf-4d62-96a9-9397fde43f27">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTctMS0xLTExOTk5_771f6972-86b7-421c-bc50-6a3995085c25">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTgtMS0xLTExOTk5_a694ad16-5aaa-45d5-956e-8561a8bb826e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTktMS0xLTExOTk5_848111b8-7b63-4444-a225-60b1b74298e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if1544d3f2c5e499b98da7226782ca2be_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTEwLTEtMS0xMTk5OQ_59655132-5621-4938-9ea4-81cee1708276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Project</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTEtMS0xLTExOTk5_b50fa101-7774-48f9-b98f-481a1224f815">15.93</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTItMS0xLTExOTk5_c8bee2ec-bfb6-404a-b5bf-a45b63c1cabb">15.93</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTMtMS0xLTExOTk5_68690259-6fb1-4d08-bed5-483001372b15">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTQtMS0xLTExOTk5_42ea369e-3371-4c99-a562-cd3a30b3a787">5</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTUtMS0xLTExOTk5_8cb13781-9283-48bb-b49a-50ad14345c13">0.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTYtMS0xLTExOTk5_4d9d7c3b-c22a-4416-a6eb-2bafc68ab9f0">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTctMS0xLTExOTk5_65bfaae5-154c-4210-b3ac-9b0215515a7d">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i03089c18f63c4ac8a3762b696eec3b39_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTgtMS0xLTExOTk5_e642f66b-ac15-4546-a75d-2be475d3839b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icefaa359b31741c8b95cb9bf016ef953_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTktMS0xLTExOTk5_7801b070-4db6-4b8f-a9ff-bfb081f94fe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7fa4bf2f58fa428f93dd6a7a167a2f65_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTEwLTEtMS0xMTk5OQ_1ffb62a9-50b1-43ef-bc96-e51d070c9955">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSPCE</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTgtMS0xLTExOTk5_56171961-0dd4-4386-b5be-e30b59a9c0cc">32</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTktMS0xLTExOTk5_1055a2b5-9ed9-40a3-a4a6-9861b1b3a01c">107</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTEwLTEtMS0xMTk5OQ_45546b99-87e5-45fa-a258-0072de000ad4">175</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><ix:continuation id="i2ea21135d7804de6b73a634f7669fd8a" continuedAt="i9601951336db4b76803afad8eb285227"><ix:continuation id="id937be53a3a54952a09bd6dc46dc6e69" continuedAt="ibb022088b5a74004991acd413be70e79"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2012</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMS0xLTEtMTE5OTk_88923181-6fc0-48af-a23b-8f962d5c664a">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMi0xLTEtMTE5OTk_8e9d1336-d126-4faf-95aa-a5584d56ca50">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMy0xLTEtMTE5OTk_912b097e-c25e-4fee-9c60-b86da0974bc7">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNC0xLTEtMTE5OTk_50dfb370-c229-40a7-8bb8-46945fe59516">10</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNS0xLTEtMTE5OTk_d71afbf2-0ba8-4630-957f-efe910b866f7">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNi0xLTEtMTE5OTk_f5d5bf1e-09da-44a7-957e-915169312dfa">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNy0xLTEtMTE5OTk_9121add1-1814-487b-a2a9-8eb5d68f0827">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtOC0xLTEtMTE5OTk_c407277a-1f79-4c6e-a932-968125645458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtOS0xLTEtMTE5OTk_ac13fd97-94b3-447d-8712-266a2df8b8df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2ae9590b9fe34d0fb673e82af470816c_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMTAtMS0xLTExOTk5_a5a44002-020b-41a5-83c5-487b13bd3ff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMS0xLTEtMTE5OTk_e4303044-c5c9-4924-91a5-54ed548d72ae">6.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMi0xLTEtMTE5OTk_f4d9f324-48fb-4d00-a03b-e483f2b818a1">6.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMy0xLTEtMTE5OTk_6e91f1dc-e43e-48d7-9eaf-c63ec810f5bf">156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNC0xLTEtMTE5OTk_84e20ba9-9cb6-4bc4-a5cb-2900bb9fb7ad">6</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNS0xLTEtMTE5OTk_1f74f847-d6b3-46dc-b29a-c4e61e58412b">0.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNi0xLTEtMTE5OTk_9d238a0a-1540-4f9d-ad7e-03858c39a8c2">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNy0xLTEtMTE5OTk_cc98003f-1d38-4cbc-8495-bf1f2f0991d9">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItOC0xLTEtMTE5OTk_8fbda852-1780-46d5-888e-f878b41166f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItOS0xLTEtMTE5OTk_71f3bcca-929d-4b47-a687-47d4cd5e183c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i15bc4af9395b4f90b4d7b6e26b0c54be_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMTAtMS0xLTExOTk5_7d6ca16f-b175-4380-89e9-68cc45f3842f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMS0xLTEtMTE5OTk_47f6b1b9-7e2d-42ad-9323-219d75ed2a7f">18.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMi0xLTEtMTE5OTk_f1ff3cde-c07b-47d3-8837-663eed22c974">17.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMy0xLTEtMTE5OTk_e3fb1f26-d8d7-49ee-8de5-5127d2a64212">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNC0xLTEtMTE5OTk_4c2fbe71-1bce-4335-a747-60d714b75bed">5</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNS0xLTEtMTE5OTk_e6378689-1a59-435c-a229-3be4e4ed0e3d">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNi0xLTEtMTE5OTk_4e870f99-11b0-48a0-8d83-ba718bd3ec1e">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNy0xLTEtMTE5OTk_2306ef69-5e08-454a-96ad-d41b1db7a55d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtOC0xLTEtMTE5OTk_5aa1599b-edce-41b7-bf3b-2fde286e09f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtOS0xLTEtMTE5OTk_b3e94b47-883d-41e7-a2dd-05e72c65d450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i702ec3ead1cd4f79b60cc12b87ee7e11_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMTAtMS0xLTExOTk5_f5baf3e9-4d7d-49ea-b5e3-4e35c34939ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMS0xLTEtMTE5OTk_382fba65-d0cf-416c-af48-777a9503be24">17.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMi0xLTEtMTE5OTk_67e9459f-56cf-4a32-8336-eb5d31971a83">17.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMy0xLTEtMTE5OTk_7824a9ab-acc4-4a96-b930-7cd47d0c28c8">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNC0xLTEtMTE5OTk_607f434f-bb7d-496c-9c6e-b3fb202a0b93">5</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ifa0befb495f44c12ba65c30bf98111ac_D20150210-20150210" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZmNmNzIzNTgzZDY0YjFjYWZiZmMxODYyMmNkMTczOV80_7c852b97-1f47-41a6-a3cf-532b7e311b35">0.26</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i52c574e42a78453ca42bf37f9baff97a_D20150210-20150210" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZmNmNzIzNTgzZDY0YjFjYWZiZmMxODYyMmNkMTczOV85_bce46d84-3989-4f04-ae6d-87213a9ad9e7">0.27</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNi0xLTEtMTE5OTk_8454b429-9793-4d91-b7b5-0298207668eb">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNy0xLTEtMTE5OTk_05aa149e-af2b-449c-999a-8e7767e082e6">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtOC0xLTEtMTE5OTk_2a09e29a-2c95-4bca-8d3f-57cd26bff1fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtOS0xLTEtMTE5OTk_d29f6667-cf97-4660-9504-5c048dff77e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1c7eb6413b784b03bfd43acb963cb132_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMTAtMS0xLTExOTk5_eea6bf86-24a9-4df9-bf42-47a1ad6db64a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMS0xLTEtMTE5OTk_30a150fd-cb6d-4d1c-a2bc-8455e942ec52">17.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMi0xLTEtMTE5OTk_8d565f84-2e75-4c3b-a1b2-4e73ad624fe0">19.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i473116fa095c422aba3d6c699591faec_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV80_370b6c4c-c897-4ddb-9f61-9cb4a821de34">58</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="if70f79e4689d4c54bb89ab61ff89be6b_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV83_6f862962-a451-46a2-83aa-c3101e1b4805">58</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i67dd5d3865134117a9b633b2f3f00560_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV8xMA_f022853e-e852-4efb-9fe8-e59dd5be7235">57</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9f1d34c3fdac49f49c878cd386025fdf_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV8xMw_8ebe2c01-a874-4bb0-b7b6-87951b148b55">58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibc916f578f474fecb4f9f2502dbc7c53_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl80_6e0681ae-e73e-4680-a0fb-e03a749eaafc">5</ix:nonNumeric>/<ix:nonNumeric contextRef="i7a8b1058bf864a27b1cf4a2fe6482f13_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl83_2f18a057-afbb-4509-817c-64e4daa98a74">5.1</ix:nonNumeric>/<ix:nonNumeric contextRef="ide4f2071f6814b1e98aebb47c96b9621_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl8xMA_580978e1-910f-4002-9c67-cbdc3d4deaae">5.3</ix:nonNumeric>/<ix:nonNumeric contextRef="ic807dce5e3d345bcbc42d29872af83fb_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl8xMw_5e5bb7d5-21d2-40f8-a8ae-e29e126d8cb8">5.4</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNS0xLTEtMTE5OTk_a863a780-748a-4420-94b6-8f2008aecad1">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNi0xLTEtMTE5OTk_9c27cb03-ac7c-4996-89c1-721157450ea8">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNy0xLTEtMTE5OTk_b081fee9-7e9d-49fb-afe8-07ec053206f2">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtOC0xLTEtMTE5OTk_ba9d4de7-5f6d-418e-98ba-2778cd8696e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtOS0xLTEtMTE5OTk_378908f0-09ee-4e57-820c-5b13bc48b103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i985db50e042a4e9c97fffbb93177626a_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMTAtMS0xLTExOTk5_25e3af93-cb32-43fd-8269-e2aefefb357a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMS0xLTEtMTE5OTk_9b72be5e-1d45-486e-86d6-4df8a25114ff">19.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMi0xLTEtMTE5OTk_00a49564-1695-4678-9107-9de7d25650b1">19.54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2749bb6daaa74679a776487c8f281567_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1ZjEyNzgzYjI4YjY0NmMwODBmZDZjNWRjM2FkODRjN180_d5f0b0fd-9029-439d-af4e-31b33f6ec61d">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1ZjEyNzgzYjI4YjY0NmMwODBmZDZjNWRjM2FkODRjN185_a25ac251-7346-41e1-a7fc-58ff08236594">60</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i207347ba76db4b1193a91409ae7c99f1_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMWMxOGQ4YWNlMGM0Zjg0ODJhYzkzMzVhNzIwZWNhZF80_cb47ae95-605e-4139-b95a-b5344cf95ccf">4.6</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i3d07ad7bcbd0459cbefcedfd8f8f334d_D20150625-20150625" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMWMxOGQ4YWNlMGM0Zjg0ODJhYzkzMzVhNzIwZWNhZF85_67b56437-f01e-4043-b388-6a23729aa552">9.6</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2749bb6daaa74679a776487c8f281567_D20150625-20150625" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMzcwNTNlNTdjMTA0ZWMzYWUyYjMwZjQ2NjE5ZTkwOV80_85da8915-b65a-45e7-b5bb-3cff4ac16d4d">0.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMzcwNTNlNTdjMTA0ZWMzYWUyYjMwZjQ2NjE5ZTkwOV85_e2c56e64-2910-49db-a1a0-483b7c0d3666">0.91</ix:nonFraction>%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNi0xLTEtMTE5OTk_1826cb38-234a-4afc-87b6-598abc245e53">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNy0xLTEtMTE5OTk_b316339c-ee41-4930-868b-59300c7a4f95">284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtOC0xLTEtMTE5OTk_0ffde8bf-fcea-4bda-a26f-d4facf61ff65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtOS0xLTEtMTE5OTk_0d930a41-f1e5-4bff-a6fd-3d857ce8cdc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e0d58d5db0f4384894e4a99e7d095a6_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMTAtMS0xLTExOTk5_07939f81-2510-426f-8a61-f52f123eefd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016o-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMS0xLTEtMTE5OTk_7fb4191c-c195-4fa7-9a9b-b3c8c38931af">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMi0xLTEtMTE5OTk_5a76f959-465b-440c-9ae3-3f262b4c3ea2">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMy0xLTEtMTE5OTk_27ac0b1a-43cb-4105-a755-a4ee32d720f1">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNC0xLTEtMTE5OTk_c66a203e-b273-4998-a069-5c665fbdf900">2.4</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNS0xLTEtMTE5OTk_99c8f3d5-994a-4fa9-8875-8e6cf253d352">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNi0xLTEtMTE5OTk_2070fa0a-f698-4ff1-8804-d150104380b5">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNy0xLTEtMTE5OTk_6d363960-57a3-46d9-9e7e-79d8872200ee">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctOC0xLTEtMTE5OTk_5f532bf7-83c6-4556-b1e6-4ada8476db53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6e6b9424288f466c8a47cebae0ec48a7_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctOS0xLTEtMTE5OTk_91de4f3d-96a6-4cb2-b3bc-9cffae089537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4a9a5316762943d8affcd949d696ec10_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMTAtMS0xLTExOTk5_40ac6514-8d6b-4152-894e-d104d22dc469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016p-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMS0xLTEtMTE5OTk_1f637120-e3f6-477a-a87a-89eadcd47406">13.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMi0xLTEtMTE5OTk_34d1a378-61fc-4b1a-9459-d755761eae61">13.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMy0xLTEtMTE5OTk_2e47876d-3d99-48c1-82c3-3959d92ab6e8">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNC0xLTEtMTE5OTk_6286b8ee-4288-411e-9a93-a9ddd2e6ddf2">2.4</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNS0xLTEtMTE5OTk_f94725b3-3fab-4b43-a696-5fe7dbf2c5f0">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNi0xLTEtMTE5OTk_d116a3e7-d298-4682-85dd-ca17e1496ce6">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNy0xLTEtMTE5OTk_ad802485-36e8-4dc6-8df4-0cfa244b900d">143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtOC0xLTEtMTE5OTk_4574fdd5-e0cb-4ff7-99b8-f9c009bfca54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i433bcdf7285544c9bc5810b1f42b26a2_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtOS0xLTEtMTE5OTk_1a005c0e-70ef-485f-90cc-e98741118815">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i7b3ff9b9323446e5971e03c82d1e528a_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMTAtMS0xLTExOTk5_34aa0ac6-546f-4edc-b39b-c3067208ae34">41</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMS0xLTEtMTE5OTk_14cf8173-9d61-488d-a2ac-a681deb54724">15.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMi0xLTEtMTE5OTk_3cd94234-fad8-41fc-b1e3-0d9ac93454f8">15.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMy0xLTEtMTE5OTk_d0007f02-7bfb-4eb6-ac47-021aacaf84b4">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNC0xLTEtMTE5OTk_1c4b96e6-61ac-4bbc-b826-3f99638f00a9">2.4</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNS0xLTEtMTE5OTk_acd6f7b8-8c17-41c4-81f8-c5575d08dde3">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNi0xLTEtMTE5OTk_9b53f44e-ed9c-4b59-a310-3b53a1d9d9bc">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNy0xLTEtMTE5OTk_b8a33541-285c-478a-bed7-475a230d0297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktOC0xLTEtMTE5OTk_6acb1050-ba46-4d85-a6e5-46ed05671b2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktOS0xLTEtMTE5OTk_948aa8f9-7560-447e-81d4-1cb36cb74c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i34873da26ebb48f083c0f122691b5ad1_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMTAtMS0xLTExOTk5_73b6db7d-a158-4e80-a0a7-3e1a826dad03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2017o-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTEtMS0xLTExOTk5_943de179-5e8c-4340-9ce9-2e12fd121657">15.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTItMS0xLTExOTk5_5190b4e5-1a2b-4a78-a0e6-9faacaf4c70a">15.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTMtMS0xLTExOTk5_dac2ad52-09c1-4a18-a0c3-9b5d501a4080">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTQtMS0xLTExOTk5_820f4a2d-2bac-43bf-b00f-ec251ef01d9d">2.4</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTUtMS0xLTExOTk5_5bdecec7-027c-46dc-8c5d-3638a8736e71">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTYtMS0xLTExOTk5_875ebc86-df42-4d29-ad39-9e498d55e0f6">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTctMS0xLTExOTk5_0a268770-b43e-4455-a00c-2c6bffc0e89c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTgtMS0xLTExOTk5_4892fb8b-d0cd-4989-99ca-f7bfd6c423fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTktMS0xLTExOTk5_1de45634-0546-404d-b02a-e54ace1b1e93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie75d48a141ae4d8fad1403660910f20d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTEwLTEtMS0xMTk5OQ_7bd763a3-0672-48b3-ab18-489a429f76e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTEtMS0xLTExOTk5_60b34b24-21f5-4e3a-93c9-cb0d5a2b014e">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTItMS0xLTExOTk5_90d16038-6218-465e-92cd-fb0937d17e8a">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTMtMS0xLTExOTk5_c486a0c5-b57f-4f7f-acd8-67ec368de0b8">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTQtMS0xLTExOTk5_1ec6f68f-3056-49ca-8e76-d35df3da3295">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6aabc8c23a414a9db5e4f5a8bc2f1f48_D20180306-20180306" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTUtMS0xLTExOTk5L3RleHRyZWdpb246Y2NkNjFiODM3ZTlkNDc3NWE3NzgyMzM5YzQzOTk5NDVfNA_98925c29-6761-4d73-bbe5-637aed21d5aa">0.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic15526fdee1e4d91b1d5060f8b0f7568_D20180306-20180306" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTUtMS0xLTExOTk5L3RleHRyZWdpb246Y2NkNjFiODM3ZTlkNDc3NWE3NzgyMzM5YzQzOTk5NDVfOQ_aec72197-4dd2-44e0-8ad8-36bd5a5e76cb">0.1</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTYtMS0xLTExOTk5_279c8679-3844-4bd7-83ca-3b7a000de076">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTctMS0xLTExOTk5_8afc4987-3469-4914-84e6-c22e63155f04">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTgtMS0xLTExOTk5_69bbf0bf-d7a7-4a01-aa5f-a08e65236aa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTktMS0xLTExOTk5_d4ca5a33-7f5e-40bf-aaeb-88c5035e5aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i48621182e8c349318f629a81af122a57_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTEwLTEtMS0xMTk5OQ_2749f5c1-62e2-4f12-863a-78809819daa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="3" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTEtMS0xLTExOTk5_4552eebf-8840-447e-b801-391581085921">16.102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="3" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTItMS0xLTExOTk5_613dc95d-23ec-49b7-8169-0215be449bb4">16.102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTMtMS0xLTExOTk5_9e264a17-5547-4c00-a488-7ef968df919e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTQtMS0xLTExOTk5_23e70b5f-edb9-4a5b-9cbf-96f2160062a8">4.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1d75b447af424ab48bcfec52ab34781a_D20180727-20180727" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTUtMS0xLTExOTk5L3RleHRyZWdpb246ODg2ODA2MmM2MmJkNGEyNWI5NGMwYjdiYzY3M2RkZDFfNA_53c21cd0-e363-4c93-8ae9-7a802d2061d3">0.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5f33f50e592545199d2ce53e53f832e8_D20180727-20180727" decimals="3" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTUtMS0xLTExOTk5L3RleHRyZWdpb246ODg2ODA2MmM2MmJkNGEyNWI5NGMwYjdiYzY3M2RkZDFfOQ_2807a999-8532-497f-9b51-bf986216aac5">0.1</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTYtMS0xLTExOTk5_8c24bb98-21d4-4852-a10b-796129154feb">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTctMS0xLTExOTk5_0d063233-4546-4d99-be37-c431852374ce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTgtMS0xLTExOTk5_1a542a29-55f9-4d45-83d5-ad79f94ada49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTktMS0xLTExOTk5_112485c0-d859-4ae3-9ee3-c649b30abfe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i62055563f69f41f7a159c6147a4b0329_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTEwLTEtMS0xMTk5OQ_bf1f931d-6d41-4a8d-8f0c-f2e7422c07fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTEtMS0xLTExOTk5_7006f2ff-cc6a-4038-b339-336c8c6c378c">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTItMS0xLTExOTk5_c68135b5-781c-4fc2-a758-0c3c74b82f00">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTMtMS0xLTExOTk5_27b7fa13-b308-4615-8ea7-379b51364f32">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i89b752f6985348a1aa563e64204c8eb8_D20190329-20190329" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTQtMS0xLTExOTk5L3RleHRyZWdpb246YjAwOTE5NmI5ZjJmNDQ1OGIzNDMyNWI2MzA4NDMzOTdfNA_67847376-b382-41c5-863a-56d4ae3fe65d">9.8</ix:nonNumeric>/<ix:nonNumeric contextRef="i4cecda26bbe64fd28d73f2e4da6b44d3_D20190329-20190329" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTQtMS0xLTExOTk5L3RleHRyZWdpb246YjAwOTE5NmI5ZjJmNDQ1OGIzNDMyNWI2MzA4NDMzOTdfNw_25173115-16c0-46ac-8f8d-5f355f8b5dbf">9.9</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9710c7a719da4648bd568199fecfdacd_D20190329-20190329" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTUtMS0xLTExOTk5L3RleHRyZWdpb246YjJhYzdhNmQzNDE4NGVkZWE5ZGY5NGM2MTRiNDRjZWJfNA_a8d4c235-aa77-4d2a-a57c-a7571cada0c0">0.16</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i14e94260ccc24cbe9513a3b50f37537a_D20190329-20190329" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTUtMS0xLTExOTk5L3RleHRyZWdpb246YjJhYzdhNmQzNDE4NGVkZWE5ZGY5NGM2MTRiNDRjZWJfOQ_b64a9d2a-bcfa-49ca-b493-0dc90321f4bd">0.50</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTYtMS0xLTExOTk5_c2f38950-7327-447f-b8f0-b9f83fe66b0b">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTctMS0xLTExOTk5_9315eec7-d2cd-42ae-afb6-84280fee8081">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTgtMS0xLTExOTk5_25abcf63-20c4-426f-a578-16c22860f969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTktMS0xLTExOTk5_69c8937a-0fcb-4e9e-a79e-4b9ea4387058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iaf10e5b531374a0e9d6f2b724723372e_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTEwLTEtMS0xMTk5OQ_3ea8c838-fd5c-4953-a714-efb1203d61ae">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTEtMS0xLTExOTk5_10a80366-e179-43dc-abf2-f92952057583">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTItMS0xLTExOTk5_93d4f913-7079-4fa6-9ee2-bafb2eadb16f">6.59</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="2" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTMtMS0xLTExOTk5_95e26b82-03cd-4283-9834-cd0644ff7f59">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTQtMS0xLTExOTk5_91d146c3-d392-4726-be52-ece764784556">10</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.13%/<br/>-0.07%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTYtMS0xLTExOTk5_de1cc263-6155-4666-8ef6-1b0adac695b2">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTctMS0xLTExOTk5_378b33af-8aba-43da-8f53-96e6b6f8e463">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTgtMS0xLTExOTk5_44b6b2fc-e655-46e3-ad74-91f7ca6fbf51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTktMS0xLTExOTk5_0520c030-4a18-443e-84c8-c11fc5210032">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icaf550bcce0b41ffa51ebe138b5a4a4b_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTEwLTEtMS0xMTk5OQ_8e9f6923-09cb-4b17-904f-1665def8635f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEtMS0xLTQ2NDgw_796884f1-630f-4114-8173-4156775acb3a">13.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTItMS0xLTQ2NDg4_54679b10-860c-42b6-b99d-e0477d5bac63">13.47</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="4" name="nbx:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTMtMS0xLTQ2NDk2_7538da98-078b-46d0-bcb4-28f069d766b5">39.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTQtMS0xLTQ2NTAz_e84a8ef9-ceac-420b-9fef-f69014f55d93">10</ix:nonNumeric></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTUtMS0xLTQ2NTEw_6cf87f03-c44b-4ba4-9feb-7f57df946dbd">0.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTYtMS0xLTQ2NTIx_6b5ec54c-9c1f-467a-8a06-5ba2e9378262">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTctMS0xLTQ2NTI4_c43e96bb-028d-407a-9875-b250410154fb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTgtMS0xLTQ2MTgy_1c268b4d-3c3f-4f53-8989-4d142106ed76">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib6007079e0504a6db30cf3d75e896d43_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTktMS0xLTQ2MTkw_64c68d07-e7f7-48b1-8ef7-f8c7e0471865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i96cf2e24893f48c0896bad782974579f_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEwLTEtMS00NjE5Ng_24d55f48-55c5-40c9-abd4-0e0cb02826c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTItMS0xLTQ2NDg4_8405c747-c225-4816-9e1a-f34c857f0546">13.64</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" name="nbx:OptionLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTQtMS0xLTQ2NTAz_5849c90d-205b-4319-b7b6-8d2818bd4d10">10</ix:nonNumeric></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTUtMS0xLTQ2NTEw_1da014c6-1be1-4c71-8af0-30f938426fb8">0.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTYtMS0xLTQ2NTIx_466fa73a-a5f3-4bf1-8ea6-2bdd14abab9d">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTctMS0xLTQ2NTI4_24252206-93fb-4072-9649-4e865c3f21a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTgtMS0xLTQ2MTgy_b5411b50-d356-4511-95cb-32586f7d026e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia4ca2c02a4834134bc70d6a0b83f4207_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTktMS0xLTQ2MTkw_b42ddae2-f2b3-4d10-9129-7bfe0f0b83d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i74b41d660ccf4571b36b582d24ff5ff6_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTEwLTEtMS00NjE5Ng_22b7de81-5f02-4034-ba07-cc383be3b0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTgtMS0xLTExOTk5_4e19cd3b-116c-409e-8c98-811659b81aa3">44</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTktMS0xLTExOTk5_77b6a6d7-86ab-4d01-9072-8234450696b2">19</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEwLTEtMS0xMTk5OQ_797c2fd2-782a-42df-86ad-333eba15e01a">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><ix:continuation id="i9601951336db4b76803afad8eb285227" continuedAt="i4c1f645a07e24eb383430134c3c4714d"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNTk_5fba9e53-43f9-4df4-9888-3b6e3ce938a7" continuedAt="ib5a3a13d9f0c4df78c7ef1e42c835208" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:15.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMS0xLTEtMTE5OTk_d2aed392-ff3a-4073-8b10-c9aef4221c79">13.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMi0xLTEtMTE5OTk_4cbad3c2-4edf-4f2c-a3c3-ea2524770a74">13.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i3ee4337742624978b8797907bce374b5_D20160202-20160202" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV80_d52e43d9-e059-4f57-92c8-06e7eeae8ee8">59</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib2d89fd172a24e52a024851b281acab3_D20160202-20160202" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV85_18bb54bf-3347-4256-8b8c-42d8e770de1a">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4ca7f4263bac419496f22afb16380f23_D20160202-20160202" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV8xNA_84b8de58-1941-493c-8412-be6c5ffe87c1">60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="idae657f1c9494ab7bdb98d4f741e4ce0_D20160202-20160202" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF81_07ab6f34-311f-4639-bcd4-d97af8d86b89">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="ic968a488e1214d2d8c4c849a19ca99b6_D20160202-20160202" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF8xMA_eae25818-351e-4386-bfb1-eda9e609b44a">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="ifaea4d6cd48f4720982f886453404978_D20160202-20160202" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF8xNA_aa699a25-ac99-4630-ae91-2f649d902833">6.5</ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNS0xLTEtMTE5OTk_5d99dd80-7132-4794-a41e-e0225bf0efe8">0.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNi0xLTEtMTE5OTk_ba018e95-16f4-47e2-83bd-66bcbe2d3e88">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNy0xLTEtMTE5OTk_62bdc66f-abf4-48cf-bc7b-62217f911806">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i3c58f2d20a0a4f05982535c1b79a1d17_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtOC0xLTEtMTE5OTk_f9092e01-97d1-4b05-91fc-a26955e49128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5376aaec1d46476289ea3b5ba880bbca_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtOS0xLTEtMTE5OTk_c35da1e1-beef-4d97-bcef-d38be71bc925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i600323d428624ba1bb39688b7d1835c0_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMTAtMS0xLTExOTk5_0e4e516a-2d84-4299-8d6b-9f4f4422749a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMS0xLTEtMTE5OTk_0854911b-5e0c-47e1-8d5e-e5a99b23e636">13.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMi0xLTEtMTE5OTk_29520ebc-6267-467a-b18c-c6b0c6f4aff2">13.05</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMy0xLTEtMTE5OTk_71a86879-6211-48f5-8738-772b80413f6d">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNC0xLTEtMTE5OTk_91a51344-aa29-4076-b6b8-b0b89ca714e6">5</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNS0xLTEtMTE5OTk_dcaf276a-d3f9-4981-ac48-b49454c3a30b">0.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNi0xLTEtMTE5OTk_75da7162-0ed5-451a-b887-45a5a88f1e3c">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNy0xLTEtMTE5OTk_e7880386-b17e-4737-8402-94c4a889c8e2">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItOC0xLTEtMTE5OTk_4d36ad3e-5f20-457b-90fa-7bd5ddbec8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i52e9a19f5187490e9f895ee7d396fa92_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItOS0xLTEtMTE5OTk_b1fcc1c8-d6a6-4bfa-8d3b-33bf70d99d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if8f126d516ed4651b3e072805f960c62_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMTAtMS0xLTExOTk5_ac7944c0-98c7-444b-b1cf-afb3024586e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMS0xLTEtMTE5OTk_e770d198-5374-4c78-b3e8-1f50f9165f39">14.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMi0xLTEtMTE5OTk_442ca39d-e5e6-431e-ac10-43682aeea0ea">14.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4e278299ecb14d3b90fa008334cbd38d_D20161103-20161103" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV80_fdad301f-316d-4849-b833-b31fbcf987ae">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i95d3653f8d5c496bb69df2a4c27ce1c8_D20161103-20161103" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV85_31ff77f5-9f23-4af9-926f-d4c5c1adb85f">62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i72b78d4a9e1549888d151cde77a2ef7a_D20161103-20161103" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV8xNA_4e8132d3-0a63-44b6-9274-696cd531ff5b">59</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="i8aadf58558ae4edfbdbd94aeefe4c495_D20161103-20161103" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV81_7ece9a4f-dc65-4da5-86e0-5a93b4913376">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="ia55c037dd3314b7f8276f447908d4668_D20161103-20161103" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV8xMA_94fea4d6-2cb2-44ff-825e-ef57f405f20a">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="ib9512072caa04e9ba888206ac0507aad_D20161103-20161103" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV8xNA_71c74405-d5a0-46f3-9bae-fdc2b87b45cd">6.5</ix:nonFraction> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNS0xLTEtMTE5OTk_f7e69af2-24d5-4e0b-9fb4-9b2aa85adc04">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNi0xLTEtMTE5OTk_04339e1a-4366-4cc9-a78f-fcbc5e63cdd9">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNy0xLTEtMTE5OTk_87f457b0-fe73-4924-9951-96b3a4ea4ce2">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtOC0xLTEtMTE5OTk_7dfb15d4-a4a0-4a58-9e24-aa856f4ee945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtOS0xLTEtMTE5OTk_3074c20a-f54f-4827-966e-ce4387147638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib3fb2391fd144d51a52e3aa90706b6f1_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMTAtMS0xLTExOTk5_688def8a-f5b1-48f3-ab1a-aa4ee11b8395">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Ordinary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMS0xLTEtMTE5OTk_a55c3e44-72b0-40ca-9626-0b40e469f014">15.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMi0xLTEtMTE5OTk_4dfe8529-79ec-4055-8be0-9d4fb99af590">14.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4fcc7ccd6a81428d9ed0e09d57d5a084_D20170107-20170107" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV80_d9e930e8-ce63-43b2-8f15-04246ecfcb15">58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9d85d406740e405b90ed84914b379490_D20170107-20170107" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV85_0e57513b-7989-4b0c-b159-0c8915286be3">61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ie3527d165f9d4cd5aa38b20a8500d946_D20170107-20170107" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV8xNA_0ec34592-bd0e-473b-a408-566895efacc5">59</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="ifa4fccf9efb24a25859f2060793c20e4_D20170107-20170107" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV80_cecb80fa-c048-4a3a-9741-de2910180395">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="id1d0968247324343b41e1174b2637006_D20170107-20170107" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV85_e99189b7-9961-4523-af6c-5a1b39cb1c0e">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="i67fd7c980ffd4542aa22782c5e050c9d_D20170107-20170107" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV8xMw_d7ed81a0-88a9-42aa-a1f2-d5548748ba00">6.5</ix:nonFraction> </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNS0xLTEtMTE5OTk_668257dd-7e3f-4b25-81b1-061735e26022">0.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNi0xLTEtMTE5OTk_81c91958-ce31-4ec5-9aaf-c953e03f531e">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNy0xLTEtMTE5OTk_9d5f7940-11bb-48f0-b147-114ce3235649">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtOC0xLTEtMTE5OTk_e1087f9a-e838-4ebf-8c48-f9cb0db9e855">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i368408c4bd784fc5bacc7ae16ca08d7b_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtOS0xLTEtMTE5OTk_765df53e-a227-4173-8cf2-8059216b09e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i40ac6393cd9348b8823b3228b7eee05a_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMTAtMS0xLTExOTk5_197c356b-7458-454e-8935-4f4e6bd2713f">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Performance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMS0xLTEtMTE5OTk_c81c2342-4e8c-4bd5-8ce5-654f20b91cfb">15.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMi0xLTEtMTE5OTk_262ae073-0af0-4c8c-bd55-3e0d32253ac5">14.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMy0xLTEtMTE5OTk_72faf6e0-7848-44e6-9abe-dd7974c670f5">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNC0xLTEtMTE5OTk_ebdcd701-401e-476f-993c-bfa880dc314e">5</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNS0xLTEtMTE5OTk_3204c804-5f58-429e-9ee1-a6765ee11aef">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNi0xLTEtMTE5OTk_af7f92ef-0b90-4ed4-9355-c3eb9e1e6dac">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNy0xLTEtMTE5OTk_8e741b1b-fa25-466a-8799-dab358b5160e">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie5101486495a4ef5bd91b420accb232e_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtOC0xLTEtMTE5OTk_76cd7f8b-0a1f-4c17-a291-7980d5294df9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib3b377dbf1f5453dbe7f2e047889e4ff_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtOS0xLTEtMTE5OTk_282191a9-d24b-46e2-acdf-cb5fbe2dc7b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0b885452a1484ddd888ac4daf4dd2ef6_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMTAtMS0xLTExOTk5_d4512a34-7e03-43fd-80ff-43b99e989593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMS0xLTEtMTE5OTk_c77be93c-61eb-4a32-9385-28451c9e8e96">12.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMi0xLTEtMTE5OTk_3f959d25-ee05-40db-86ac-d9a012725f11">12.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMy0xLTEtMTE5OTk_c1c0b95a-2217-4079-9db9-76bf7d356300">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="i36ceeee7f4fc47d5b756fb41d517c7f5_D20180306-20180306" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl80_773c7f15-d654-4e11-9873-ad14a2b0f2f0">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="i62d4aa90997f4e6c8c19980dc74f6f5c_D20180306-20180306" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl85_754f034b-10a1-4437-af7b-7996b8aeea80">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="i2f5d8be3215b43c697cda5e740dce757_D20180306-20180306" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl8xMw_244d4ea2-d357-4d91-ad2a-d474d9812923">6.5</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNS0xLTEtMTE5OTk_f65303c3-286e-4ac7-ab1e-38ad2cb4fee3">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNi0xLTEtMTE5OTk_d5c87305-fae1-4871-9693-4d87e3dbda20">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNy0xLTEtMTE5OTk_8a8f59b7-a2bb-4469-bbe9-02dd483e1660">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtOC0xLTEtMTE5OTk_6031d4ec-3832-4586-8a55-1b67cf042a52">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtOS0xLTEtMTE5OTk_becf4ae4-a45e-4f56-b251-26e1b5c92cb3">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibb23c53c4def4af9ac2648225e92fe29_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMTAtMS0xLTExOTk5_b4c59dd8-b8c3-4e32-b73f-7fc56e6a0226">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMS0xLTEtMTE5OTk_507e698f-351c-4498-af70-bf1d0e9675cf">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMi0xLTEtMTE5OTk_5e433663-744d-4520-9a8a-7b328aa5dfca">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i09ca631b3e9147edadb169085675ab89_D20190329-20190329" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4Zjk2NmI2Mjc0NmU0OWZkYTQ0MmRlOThlMTc5NmFmYl80_516a7191-4433-4a6d-8c31-6900814ba1aa">38.1</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="i198c812116bc40eba4d502226fd16032_D20190329-20190329" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4Zjk2NmI2Mjc0NmU0OWZkYTQ0MmRlOThlMTc5NmFmYl85_837fa3f1-c730-4345-a0cb-284da9867f47">37.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="i394793f80d274291b22ad542c6d2abd0_D20190329-20190329" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0Nzk5YWRkZjEyZGM0ZTE3YmVjZmFlMWE5NzA4ZjQxOF80_914b41fa-f9aa-4fe6-b837-23fc8a3572ac">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="i1dda9fb982e1491e90a9fcf99f478e19_D20190329-20190329" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0Nzk5YWRkZjEyZGM0ZTE3YmVjZmFlMWE5NzA4ZjQxOF84_4652f57f-aa44-4823-b92f-39bfdf14d7e8">6.5</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i09ca631b3e9147edadb169085675ab89_D20190329-20190329" decimals="5" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMjVhYzMxMGFkMjM0MGZjODM4NDQ1MzU3ZmU5MWFiMV80_4258a805-5041-4704-bd0b-304821f1fdd1">0.103</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="i198c812116bc40eba4d502226fd16032_D20190329-20190329" decimals="5" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMjVhYzMxMGFkMjM0MGZjODM4NDQ1MzU3ZmU5MWFiMV85_eac86faf-a6e4-4aa9-ac35-630ff0917bcf">0.149</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNi0xLTEtMTE5OTk_b7405013-05bc-43c0-bec1-cd3324e4390c">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNy0xLTEtMTE5OTk_51b6280c-f913-4751-8e1d-a4f4977be5cb">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctOC0xLTEtMTE5OTk_6eeed87b-fcf8-4c32-a040-229ba7d7af01">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctOS0xLTEtMTE5OTk_230d5fe3-29e0-46a0-bbe1-1e020b335735">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5200a128866a420b84b1e760ddad6401_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMTAtMS0xLTExOTk5_da311598-ab58-4494-ad3e-5b2864ccbc2d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMS0xLTEtMTE5OTk_fb61754f-b256-4cd8-abc1-4555db4fd326">6.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMi0xLTEtMTE5OTk_2dcaee96-ca86-4a18-8a0a-86db2f4c1d10">6.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMy0xLTEtMTE5OTk_45166de5-beba-405e-a4da-f276db640038">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNC0xLTEtMTE5OTk_ac6f9f1e-961c-47df-a316-1ce8f4d9ef6e">10</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNS0xLTEtMTE5OTk_53d3c021-6a99-4f2a-9591-3f3be57b0373">0.40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNi0xLTEtMTE5OTk_30499bea-f1c2-4d2b-9e7a-c9d9216877af">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNy0xLTEtMTE5OTk_d4d475b9-d731-4551-858c-c42dd0aac11d">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtOC0xLTEtMTE5OTk_fb75e81c-464b-4ad8-b980-529256cefec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtOS0xLTEtMTE5OTk_c75f8184-5bf0-4245-ada5-c7c7b71aec09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i71ced96080c741eb86c560c4806b4bac_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMTAtMS0xLTExOTk5_81e8c852-9058-4731-94c7-6cd919878adb">436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMS0xLTEtMTE5OTk_99f069cc-8523-4a35-aa32-f56cce7135b4">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMi0xLTEtMTE5OTk_851439cc-fa95-4e02-b5cb-51805ac670cd">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMy0xLTEtMTE5OTk_fd588c3c-8534-414d-9acd-4d2d8b44d4e3">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNC0xLTEtMTE5OTk_ed5035eb-bca6-47a1-ac33-939a772e348e">10</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNS0xLTEtMTE5OTk_8a680b84-ff2b-4f58-95ba-a812bfa5bf52">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNi0xLTEtMTE5OTk_d231793f-827d-4dc8-96d1-5971954e1a88">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNy0xLTEtMTE5OTk_a193ddf5-eb47-44fe-9630-2c24d3e599c4">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktOC0xLTEtMTE5OTk_f3312c7b-bb7c-4bcd-a792-bebeb3b201d5">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktOS0xLTEtMTE5OTk_54bfbda4-68e4-4a37-bb8a-88d5858f8dcc">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2b6f2878993e468fa6f8eb36906b91de_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMTAtMS0xLTExOTk5_d55cf6de-55b5-4e85-bbf1-ca692bc5c08e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEtMS0xLTQ2NjYy_91735ff1-325a-4696-9a1c-2d01617ca57a">13.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTItMS0xLTQ2NjYy_bc4a8f99-458e-4e95-b51a-caef36b7c97b">13.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTU4Mw_8ca0ebe6-423f-4f6f-bbf4-7ae8d5fcf8ef">38.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTU5MQ_b02dabd3-7ded-495e-a1b5-2379fbf5eaaf">37.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTYwMA_48d03a8f-4159-4d8a-9c77-0996176f3a22">38.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="i6f36fa16350140b9b69fe1134da42b69_D20210420-20210420" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU3Mw_019af6c7-e234-4734-aab2-cce768094bcf">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="i96c93a64b4574a449d4ad5addda19ec0_D20210420-20210420" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU4NQ_e014b36d-3c98-41e8-a959-81c8e03225cd">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="i73558c5663be437689199c827a5964f1_D20210420-20210420" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU5Mg_380f1b7d-2b73-4c13-af18-ad951063370f">6.5</ix:nonFraction></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.38%/ -0.33%/ -0.28%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTYtMS0xLTQ2NzI4_eee078f0-4fbb-475a-bdf5-88ef492323ef">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTctMS0xLTQ2NzM5_db364d75-54e6-42fe-b356-b4525254dd84">684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i276bc4fd1a094b3088274297dda73e5f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTgtMS0xLTQ2MjM4_2cf14f7d-de2d-428e-9207-6c6a45803ca2">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i9b03d50b925f4ccb87f9715164ee45dc_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTktMS0xLTQ2MjQ4_0557d3ac-8859-4cf6-9709-f361dd5b1d48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie14e3a19e1d44a86a04438f03dbba7fc_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEwLTEtMS00NjI1NA_362ea111-f9d8-4d7e-854e-ff9fff82b81b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEtMS0xLTQ2NjYy_ff314f4d-7219-4d28-87c5-20f3a1090ba9">13.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTItMS0xLTQ2NjYy_666b284a-ccd2-4e2a-bb4c-cbe1c0b65046">13.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTMtMS0xLTQ2Njc2_2bfab553-918f-4a97-9885-d722c74f34a9">39.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTQtMS0xLTQ2Njkz_7acaa167-a531-41aa-ab16-fb1cf551adba">10</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTUtMS0xLTQ2NzA4_6cd3013f-ba0e-452b-9d3a-ac28924c6b4e">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTYtMS0xLTQ2NzI4_76cded92-0b05-427f-b3b4-14e3a555f6fe">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTctMS0xLTQ2NzM5_36536cc0-193c-4d0a-9afd-a2bfe6e30531">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ib3d2e17f384646f2a195144983cd8b67_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTgtMS0xLTQ2NzQ5_f49a2b5b-2ad3-4af8-b40b-7a19e6a3ba49">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i623bf93a1859415a8a96f48101b40599_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTktMS0xLTQ2NzQ5_041b77a5-7cb5-4e97-bf52-8ba4137b700a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="i91bd49a836ca4a4cb9e32546a222901f_D20190101-20191231" xsi:nil="true" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEwLTEtMS02MTI2Nw_7e1e9781-5a66-4fef-9732-e7deec03b3a4"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTEtMS0xLTQ2NjYy_0d5c78b7-8cc8-467e-9721-35456b78c366">12.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTItMS0xLTQ2NjYy_e3e2236e-d5f3-486a-82b9-9748daf013bf">12.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTU4NA_01818bd0-93fd-4a1d-9f94-b23040d2fe1d">39.2</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTU5Mg_9ffcc83b-176f-4861-a1f3-072c87364ae4">37.9</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTYwMA_b088deae-878d-49ac-a5d9-2acfbde029ee">38.1</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="y" contextRef="idf1059b42ec64434bd92678ec7a69180_D20210621-20210621" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU3Mw_8b809071-5707-42c2-8383-3875a47caa1e">5.5</ix:nonFraction> / <ix:nonFraction unitRef="y" contextRef="i3a0277fbafbb433c94c83dbacd512259_D20210621-20210621" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU3Nw_53b4055f-92f0-4f4b-bc44-d12671255dd5">6</ix:nonFraction> /<ix:nonFraction unitRef="y" contextRef="i1da41881e01c4b918d3d6023763371d5_D20210621-20210621" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU4Mw_7827c63b-97a2-45a0-8f26-b69bd7e39d31">6.5</ix:nonFraction> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.35 %/ -0.3 %/ -0.26 %</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTYtMS0xLTQ2NzI4_f4950f5b-3836-4fca-b07c-79f7d8e0f66d">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTctMS0xLTQ2NzM5_10b3cb22-7558-4508-8cd8-42703aa6daae">246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0ae10134a55c4ec0bfa8de540a4fa154_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTgtMS0xLTQ2NzQ5_c9501dbe-8eaa-449f-9390-7d25aaad7339">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8f4fab534e274a858c234a1f5128ae78_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTktMS0xLTQ2NzQ5_38a9d267-8ccf-4729-b524-0aeeac72f630">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i954ef2ab820e48b5b6d82b3be204467e_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTEwLTEtMS00Njc0OQ_4d45adf1-f9b3-4275-920d-076f5281e9dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTEtMS0xLTQ2NjYy_64fb89cf-9441-4d17-91a9-8b12b402da4b">12.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTItMS0xLTQ2NjYy_25d9423b-f306-4df6-a055-45649476f938">12.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTMtMS0xLTQ2Njc2_1cb2e38b-380b-4d0e-9a6b-192bf47c3549">39.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="y" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTQtMS0xLTQ2Njkz_6a1f2c53-08b9-4771-b46f-0a62c3eddc43">10</ix:nonFraction></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTUtMS0xLTQ2NzE4_94cbdb8d-76a0-4e0a-8a1c-71a92d158a18">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTYtMS0xLTQ2NzI4_3e0eeb4d-ed25-4a26-a361-18e46a4f5ded">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTctMS0xLTQ2NzM5_6a10beca-905d-4a04-b929-50400d0b7409">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia03d50617eac462d8a56b671789e4d10_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTgtMS0xLTQ2MjM4_7ef35177-399a-4b8b-a435-13b87c982fd1">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibab950c0a8e24aae8bb9c60287630006_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTktMS0xLTQ2MjQ4_4fe3e3ac-ffc9-476d-94fd-0a187cf5aa4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="eur" contextRef="i4b51e3ab383942a5aa13a3c61bfd07b7_D20190101-20191231" xsi:nil="true" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEwLTEtMS00NjI1NA_7f55b61f-d5ee-4f09-a193-21a6b076325a"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTgtMS0xLTExOTk5_47a60d84-c443-4769-a503-32caee69abff">760</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTktMS0xLTExOTk5_5503fe07-72f2-4281-9d2c-644cdf51f425">509</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEwLTEtMS0xMTk5OQ_62f083db-3397-441d-b835-75cc74816501">543</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><ix:continuation id="i4c1f645a07e24eb383430134c3c4714d"><ix:continuation id="ibb022088b5a74004991acd413be70e79"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:9.077%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.269%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMS0xLTEtMTE5OTk_afd3f960-0ec0-45c4-bd01-b9d76f28d6a3">12.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMi0xLTEtMTE5OTk_42606663-b4e5-448e-935c-fc79ee75d478">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNS0xLTEtMTE5OTk_e3805003-1313-4511-ae66-9a5c855e0de9">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNi0xLTEtMTE5OTk_47cbc952-b47e-4706-a16c-d0727c9f6020">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNy0xLTEtMTE5OTk_17840f0d-e252-4366-afa5-8d73a5035261">4,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtOC0xLTEtMTE5OTk_fa5b322c-39e4-4ea4-a09e-59ce5265ac12">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtOS0xLTEtMTE5OTk_56747d2a-d1c3-433e-a6b3-16a791890514">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="if4d1dc40ee294a4eb862a754e1a7b7a1_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMTAtMS0xLTExOTk5_cfbc03fa-9679-49f2-82de-72df7584758b">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMS0xLTEtMTE5OTk_c8e1802b-94c1-4634-a1b3-db6df3bdad99">12.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMi0xLTEtMTE5OTk_684f641b-9323-4e54-b971-96f1a5075ab0">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNS0xLTEtMTE5OTk_158f85de-6375-4204-8fa3-a299fe8d5eb5">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNi0xLTEtMTE5OTk_7e230195-a40f-4782-bae3-c03b6b31d55e">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNy0xLTEtMTE5OTk_2ddd135c-d708-4343-b510-467a4b499052">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItOC0xLTEtMTE5OTk_dff30274-723b-4078-92dd-3656cb1fcfae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItOS0xLTEtMTE5OTk_6a427b25-95a3-4793-8065-fc6c8fd8c0d0">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6244d605e7d349cd88cc8c11756f1c6c_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMTAtMS0xLTExOTk5_2db6d164-f350-4c6e-99b5-0aa3618f97fa">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMS0xLTEtMTE5OTk_549c4201-654b-47da-9b4f-456795f70369">10.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMi0xLTEtMTE5OTk_2a915dae-df5d-4e97-ab9b-2fd7ddaa6147">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1b3d45ed49f246078f98c1da6b744503_D20190329-20190329" decimals="4" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNjMyZmNmMjNhNjE0N2ViYjdjM2Q1OTcyMWY1YjllNF80_c8b127d3-e8a8-4813-a2c3-cf6dc524ffcf">0.19</ix:nonFraction>% / <ix:nonFraction unitRef="number" contextRef="i43664a271eab453f8088849ba1fb58f7_D20190329-20190329" decimals="5" name="nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNjMyZmNmMjNhNjE0N2ViYjdjM2Q1OTcyMWY1YjllNF85_1c47af10-09fa-46ab-ba58-7f460756fbef">0.141</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNi0xLTEtMTE5OTk_805678e9-97a3-4565-afd5-dd0323ab5478">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNy0xLTEtMTE5OTk_46f0d005-0c8b-42a7-90c8-142079b123ea">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtOC0xLTEtMTE5OTk_4b95b50a-866c-48b6-8a76-04b41947af2f">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtOS0xLTEtMTE5OTk_6496750e-c1f1-4e31-b193-13c73a18c1ba">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ieb041ec28cd441c8a5a4283ac0d8d07d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMTAtMS0xLTExOTk5_6f2beb74-d423-4851-aa2d-8eb7714363b7">1,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMS0xLTEtMTE5OTk_8753bdc9-f1a1-438a-afc1-cf0bf359811a">5.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMi0xLTEtMTE5OTk_a2ec1722-58c2-4f2f-94af-1359fba34350">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.74%/-0.69%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtNi0xLTEtMTE5OTk_aecc4fd1-a91d-44cc-8e06-5fef2bb4ec12">0.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtNy0xLTEtMTE5OTk_0e06f0bf-0b11-4243-a9b0-8cc267b0d55b">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtOC0xLTEtMTE5OTk_4dfc77b1-a2b3-4081-9bd2-8f4e27384d27">144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtOS0xLTEtMTE5OTk_004fdcc3-c30d-4c32-9989-7dddbb9e9e97">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i5f726d12be094192a3269413d8216aaf_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMTAtMS0xLTExOTk5_f6e4d3a4-4201-46b1-aba9-4eac5decdd65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="2" name="nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMS0xLTEtNDY3ODI_fba748b2-2323-42a2-8688-c2495479514e">13.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="2" name="nbx:ExercisePriceOtherEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMi0xLTEtNDYzNDM_be0326a7-1eb7-4700-8705-cd7122303d3f">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.63%/ -0.59%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="4" name="nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtNi0xLTEtNDY3OTg_506845ae-be3f-47cf-8c2d-794f3e43d2d1">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420" decimals="-3" name="nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtNy0xLTEtNDY4MDk_d22d9f02-5626-4c11-84ac-16606a09fa71">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOC0xLTEtNDYzNjY_e5b99cdc-26cb-4dd0-8b1b-64cd1f85315b">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibdea060a980d42ec8049515011a575c0_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOS0xLTEtNDYzNjY_e0242551-f272-484f-a26a-2aa8336e1667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ie6340f94bc5146cd810b425747377b1d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMTAtMS0xLTQ2MzY2_f769c7f8-0989-45e7-8493-5588506ee802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOC0xLTEtMTE5OTk_1dcb9a57-eb1c-4f4f-af3d-321416b0e765">2,366</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOS0xLTEtMTE5OTk_977342b1-1042-40a9-bc6a-23f5517e1afb">2,289</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMTAtMS0xLTExOTk5_09413eeb-d670-476e-bbf8-691894fa34e4">3,618</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><ix:continuation id="ib5a3a13d9f0c4df78c7ef1e42c835208"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtMi0xLTEtNDYyOTA_8835c1c7-5beb-48e2-9fa3-dd6e96f12ab4">32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtNC0xLTEtNDYyOTc_cf4ebd14-07e5-4d13-935b-d8fe266e7a9a">44</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtNi0xLTEtNDYzMDM_845a2fcc-02a7-4139-8063-8eb88b9f4629">760</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtOC0xLTEtNDYzMDk_62c5be62-0e05-4a1d-814c-38c53b112f66">2,366</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtMTAtMS0xLTQ2MzE1_6c09946b-0454-4f4f-a95f-c09f4d2e6b93">3,202</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtMi0xLTEtMTE5OTk_f48104bf-df40-4340-b376-e1717a5615e4">107</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtNC0xLTEtMTE5OTk_b0f94b82-347d-4457-a767-5836fdc064a6">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtNi0xLTEtMTE5OTk_26ba3688-99ac-4de7-be95-b7f63ba1c8f6">509</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtOC0xLTEtMTE5OTk_39b8356b-0769-4fcd-8478-1b8c88f53bf2">2,289</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtMTAtMS0xLTExOTk5_4e1a4f6e-a91a-4682-90ff-7df61cfdc451">2,924</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"></td><td style="width:38.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtMi0xLTEtMTE5OTk_a99b2de3-9e71-4a93-ae2e-29593b8a91be">175</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtNC0xLTEtMTE5OTk_9f24bb40-5500-42ed-808a-653c94be930e">16</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtNi0xLTEtMTE5OTk_31cc0db2-0f0c-4acf-a0bd-65dfa0cb52b1">543</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtOC0xLTEtMTE5OTk_e0ace82a-5710-438f-aa4e-bca3d49d7272">3,618</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtMTAtMS0xLTExOTk5_71bbfdf1-9a6c-40ca-8083-4827df40b9b7">4,320</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-57</span></div></div></div><div id="i377d9717844147e799376babda10462f_190"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 18. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzE1Nzc_48665ab3-f775-45ae-9c54-82d7f353f22f" continuedAt="ib71d0c80856e4aa7ae693ab9fc077502" escape="true">Net financial income (loss) </ix:nonNumeric></span></div><ix:continuation id="ib71d0c80856e4aa7ae693ab9fc077502"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzE1Nzg_1a37419e-185b-4dfb-bae2-c2546e5561dc" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMS0xLTEtMTE5OTk_7127367a-2406-4f2b-b885-cfb980d1f287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMi0xLTEtMTE5OTk_b6d129d5-3d51-4a20-9fc7-c31a7e1876af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMy0xLTEtMTE5OTk_ba3190e9-acc7-4d6f-addd-8a43088818b7">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMS0xLTEtMTE5OTk_49273d6b-215a-49ba-8923-b65e98f861d9">6,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMi0xLTEtMTE5OTk_07821be0-b3c4-496b-87d7-9edb02e4bbbc">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMy0xLTEtMTE5OTk_95e710f0-ecbf-4a65-8e80-098213530e35">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMS0xLTEtMTE5OTk_5160a94d-5237-4d79-9494-4aefe866ecfd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:OtherFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMi0xLTEtMTE5OTk_1cb0d67b-363d-467d-88f7-79b061258427">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:OtherFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMy0xLTEtMTE5OTk_67307554-0087-4d44-b6e5-bc8db93a433b">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMS0xLTEtMTE5OTk_0ab9bb6e-1f0e-4971-83f9-3bbb73b2c292">6,360</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMi0xLTEtMTE5OTk_9dc915c4-d693-40ac-8f05-2fa0a0340fcc">201</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMy0xLTEtMTE5OTk_d43c6bd6-c595-4ae0-8d19-ce137eb0e7c5">837</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMS0xLTEtMTE5OTk_55db790d-d2ce-46d3-baf5-a0188b3a4ade">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMi0xLTEtMTE5OTk_f7b4f15d-7928-4b89-96f7-ae2a28d3d706">4,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMy0xLTEtMTE5OTk_51658653-997f-46df-b83c-a872fc288cf6">4,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IFRS 16 related interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMS0xLTEtMTE5OTk_d5cc462e-a9c7-483b-89e7-b68a217167ef">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMi0xLTEtMTE5OTk_a0a52420-fe09-4138-a2fe-eb758e4dbda2">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMy0xLTEtMTE5OTk_4f516585-8f75-4219-b3f6-d451db3eee21">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMS0xLTEtMTE5OTk_aea1281f-0111-4627-a9d9-ac250d60d363">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMi0xLTEtMTE5OTk_b5facec4-83bc-47fe-8e42-6550e1e3d8ce">1,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMy0xLTEtMTE5OTk_022ebd2c-654b-4dd3-9145-ad2321297596">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMS0xLTEtMTE5OTk_edc46cbd-ee56-46d0-8c0b-09a34eb19e75">780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMi0xLTEtMTE5OTk_7b4684ba-fa58-4e3b-983f-43d4d0a7dc59">2,646</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMy0xLTEtMTE5OTk_e962d1d3-e504-432c-b4e4-359af283e80b">4,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTEtMS0xLTExOTk5_037d5135-68b2-4c3c-a0ea-dca39f747ddb">5,580</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTItMS0xLTExOTk5_a437a7b0-817f-478e-a1b0-1b1d13daf3dc">2,847</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTMtMS0xLTExOTk5_ca86238a-60ac-4fc5-b365-0bfac8527f78">4,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the interest cost was a negative net amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzMyOTg1MzQ4ODUyMjQ_115436a4-2f67-4e8e-9dff-1c7580330a59">383</ix:nonFraction>&#160;thousands, mainly due to the EIB loan interest and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231" decimals="-5" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzM4NDgyOTA2OTk5ODI_75822921-0d2a-4138-bdf6-1761db0519f2">4.2</ix:nonFraction>&#160;million in 2021 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#8364;<ix:nonFraction unitRef="eur" contextRef="icf7abdd665664906840a18afc4669ef7_D20210101-20211231" decimals="-5" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzM4NDgyOTA2OTk5OTc_e89126ea-08ca-47e3-b73c-d19fbc7bc87c">1.8</ix:nonFraction>&#160;million impact of EIB fixed interest cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the interest cost was a positive net amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:InterestRevenueExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzQzMQ_012937b9-afc5-4965-8068-e84c648abe22">4.7</ix:nonFraction>&#160;million, substantially due to the EIB loan interests and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#8364;<ix:nonFraction unitRef="eur" contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231" decimals="-5" name="nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzYyNA_d12bd761-1bbc-4eb8-9e1e-115e9265214c">4.8</ix:nonFraction>&#160;million in 2020 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#8364;<ix:nonFraction unitRef="eur" contextRef="i2a6010c7ae114b0cbe67c4bf3c2b2d79_D20200101-20201231" decimals="-5" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzcxMw_1b8093ef-8e88-4f5f-a5ee-d64402acda54">1.7</ix:nonFraction>&#160;million impact of EIB fixed interest cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, the Company had foreign exchange gains for the total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-5" name="ifrs-full:NetForeignExchangeGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzMyOTg1MzQ4ODkxMzY_311dc3b7-e131-467a-8143-a072ec1e060a">6.3</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This impact was primarily arising from the foreign exchange gains realized by the Company related to the HSBC bank account denominated in U.S. dollars.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the Company had foreign exchange losses for the total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1Xzg1Nw_3faf922c-24e9-4a46-a531-7f338dd6b870">1.7</ix:nonFraction>&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This impact was first arising from retaining $<ix:nonFraction unitRef="usd" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzkwNg_836fc58d-dc3e-458d-99d4-5d329bfb2027">113.3</ix:nonFraction>&#160;million from the gross proceeds of the global offering in a US dollar bank account.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-58</span></div></div></div><div id="i377d9717844147e799376babda10462f_193"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 19. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NjA_c4fa4932-8205-48e2-b866-b44a7d5a944f" continuedAt="ie22b35c1143745d1999d77276229abe0" escape="true">Income tax</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie22b35c1143745d1999d77276229abe0" continuedAt="i2d347f43cc8c4637a4487140a2ff7812"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NTg_fa6f68fb-1cac-4ba8-8250-a57eac45b4e2" continuedAt="i08025ce5bdd04e0f8cd45505d0f03454" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company and its subsidiaries are subject to income tax in their respective jurisdictions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="i08025ce5bdd04e0f8cd45505d0f03454">The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company&#8217;s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of income tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, in accordance with the applicable legislation, the Company has &#8364;<ix:nonFraction unitRef="eur" contextRef="ie8972928b2f3477aa4ff40a52480c1a7_I20211231" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEyODE_79c2dbf2-aaaa-46cb-b499-e805417f4657">284</ix:nonFraction>&#160;million of evergreen tax losses in France, in comparison with &#8364;<ix:nonFraction unitRef="eur" contextRef="i095137ac480d4189b8d3e9c4120fed6e_I20201231" decimals="-6" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEzMzg_fa993895-8293-4d9e-b7ea-1b93a6aa90df">235</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="ibbaf4b30ae8c4e248d5a4b78dcced4ca_I20191231" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEzNDU_f54602b0-8efc-43bb-8758-896b554def46">184.3</ix:nonFraction>&#160;million of evergreen tax losses in France as of December 31, 2020 and 2019, respectively. For fiscal years ended on or after December 31, 2018, the use of tax loss carryforwards in France is capped at &#8364;1.0&#160;million, plus 50% of the portion of profits in excess of that limit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cumulative tax loss carryforwards for the U.S. entities of the Company totaled $<ix:nonFraction unitRef="usd" contextRef="i3bb2c3901cc8428a999595204c3b6eb2_I20211231" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE2ODY_d6e30857-3221-420e-aad0-987ea8c29515">3.4</ix:nonFraction>&#160;million as of December 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i28327906e6194ba78e2313551bf12bd2_I20201231" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE3MTQ_efe3f10e-2d4f-4ad7-8382-a96d4b57ec50">4.4</ix:nonFraction>&#160;million as of December 31, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i6d12dbc4d05a4a798e08dead85d18b91_I20191231" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE3NDU_f2cdc0f6-f0ed-4030-a58c-c1eba1e67330">4.8</ix:nonFraction>&#160;million in the United States as of December 31, 2019. The tax loss carryforwards that were generated before January 1, 2018 will expire <ix:nonNumeric contextRef="i8c9f1e5116224a2e8a73cd903766f102_D20170101-20171231" name="nbx:UnusedTaxLossExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE4NzY_41228865-460a-4507-b412-e895bc8413e5">20</ix:nonNumeric> years after they were generated; those generated after that date have an indefinite carryforward. The tax loss carryforwards in the U.S. comply with the federal and each state&#8217;s Net Operating Loss (&#8220;NOL&#8221;) rules updated by the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) of 2017.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NTk_bcd043e4-16a4-4689-ba94-88aba237fcde" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table reconciles the Company&#8217;s theoretical tax expense to its effective tax expense:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMS0xLTEtMTE5OTk_5a6cb5b4-f947-4b97-9b00-7fdbdbfbb376">47,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMi0xLTEtMTE5OTk_47d122bf-e8c0-4923-99b4-e2195b3bca67">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMy0xLTEtMTE5OTk_63d6ec02-d1c8-4edd-b086-8676f7c0f281">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMS0xLTEtMTE5OTk_46c0c1a7-e011-40bb-996e-f9b2540e042d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMi0xLTEtMTE5OTk_7cc1e9b8-b79b-48d9-b140-173891c80328">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMy0xLTEtMTE5OTk_f743d8e7-5d00-4fe2-9ac4-0fbef6d15af9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recurring loss before tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMS0xLTEtMTE5OTk_aabe4e16-36aa-4022-ac93-4a17ebc4bd8a">47,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMi0xLTEtMTE5OTk_bfb68f44-4ce1-4eae-8a75-a2ad06cb71d3">33,581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMy0xLTEtMTE5OTk_156399d3-f5c9-4e5f-8277-1bc97e21868f">50,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Theoretical tax rate (statutory rate in France)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMS0xLTEtMTE5OTk_7ab17e42-bb18-45cd-8444-fa68c966fb98">26.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMi0xLTEtMTE5OTk_7ca4fb5a-dc75-40de-a608-521d2ece1fa1">28.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="4" name="ifrs-full:ApplicableTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMy0xLTEtMTE5OTk_48d1ce79-7657-48da-9910-8130eabfb1b2">31.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Theoretical tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMS0xLTEtMTE5OTk_b7e43803-bb39-44ad-8af8-a8339584dc07">12,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMi0xLTEtMTE5OTk_8a96a298-c5b0-4950-96ae-1fd3c9e1550a">9,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMy0xLTEtMTE5OTk_f81a46d7-cd2f-46d9-a113-1881332cbb58">15,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:TaxEffectOfShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMS0xLTEtMTE5OTk_e2d8fc95-7967-47d1-a008-745895b1091f">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="nbx:TaxEffectOfShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMi0xLTEtMTE5OTk_f990007b-3dca-4beb-be88-7b7c816fd61f">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="nbx:TaxEffectOfShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMy0xLTEtMTE5OTk_3179bf26-c33a-4765-a786-acccbac628e5">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMS0xLTEtMTE5OTk_c74924c5-f62e-451d-b640-897208e4a6d3">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMi0xLTEtMTE5OTk_d7a0d6ea-f7be-4877-a849-5bebab2baa5d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMy0xLTEtMTE5OTk_09fe56a9-f0c1-46b3-81fe-1fc274768a03">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-taxable items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMS0xLTEtMTE5OTk_4d3c015b-8c72-4b3b-b140-220325b2461d">644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMi0xLTEtMTE5OTk_7c8959f1-fc39-4c06-8c68-409f68272722">540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMy0xLTEtMTE5OTk_78fcb4f0-6cee-4cf6-8f74-2af6a3c1177a">736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:TaxEffectOfTaxLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTEtMS0xLTExOTk5_1be030f3-35c8-4235-ba5a-9578c769a68a">12,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:TaxEffectOfTaxLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTItMS0xLTExOTk5_99d99033-446d-4fb6-918a-c791462d172f">9,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:TaxEffectOfTaxLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTMtMS0xLTExOTk5_0696f9f0-5e2e-43f3-b7e8-28511d7e6b6f">15,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTEtMS0xLTExOTk5_7a2d3822-99f3-4ec7-a026-ad64b515a83a">5</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTItMS0xLTExOTk5_a0e44da5-ad9e-46e8-a628-c27d8f15153c">9</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTMtMS0xLTExOTk5_eb0e8e13-c644-4117-8bee-cc47a9f0fd02">3</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="4" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTEtMS0xLTExOTk5_8a8391a7-a593-4b1e-9d54-b2ff277b98d5">0.00</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="4" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTItMS0xLTExOTk5_3c66a991-e9a9-40b9-89f5-0c11ad80b6c3">0.00</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="4" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTMtMS0xLTExOTk5_335c1720-fe12-4704-bc46-13085c503ada">0.00</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cumulative net unrecognized deferred tax assets amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjE_709b67db-165d-4ecf-804b-71572b9f9c2b">75.4</ix:nonFraction>&#160;million in 2021, including &#8364;<ix:nonFraction unitRef="eur" contextRef="i8c1e08d0df7b47f394f08a0c2faeffba_I20211231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjI_5fe916ab-f8c7-4448-9b26-61c16a883033">14.0</ix:nonFraction>&#160;million of 2021 net operating loss carryforwards in comparison with &#8364;<ix:nonFraction unitRef="eur" contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIyOTY_8a2c07ad-6ccc-4f75-b7ed-037b4df1e4cb">60.2</ix:nonFraction>&#160;million in 2020, including &#8364;<ix:nonFraction unitRef="eur" contextRef="i21e5c44a32c64f1d93ae818113e1b5ce_I20201231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIzMTg_9e85cde1-df7e-4270-afae-c8660ca87c61">59.6</ix:nonFraction>&#160;million of 2020 net operating loss carryforwards and &#8364;<ix:nonFraction unitRef="eur" contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIzODE_088ba5c6-cc90-4f8b-9624-ae64efe73083">51.0</ix:nonFraction>&#160;million in 2019, including &#8364;<ix:nonFraction unitRef="eur" contextRef="i958be4f23f454d25a7eb235f2588e9a7_I20191231" decimals="-5" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI0MDM_5e86cd7f-3af3-4ef3-b441-13e6bffa83cc">49.6</ix:nonFraction>&#160;million of 2019 net operating loss carryforwards.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="i2d347f43cc8c4637a4487140a2ff7812">The deferred tax rate of the Company is <ix:nonFraction unitRef="number" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="3" name="nbx:CompanyDeferredTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjA_5b696cd0-cf60-4f8f-8d9d-3f8479633bc8">25.8</ix:nonFraction>% in 2021, <ix:nonFraction unitRef="number" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="3" name="nbx:CompanyDeferredTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI1NTk_5f07ffc7-eb4e-4b33-842b-27ea9192785a">26.5</ix:nonFraction>% in 2020, and <ix:nonFraction unitRef="number" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="4" name="nbx:CompanyDeferredTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI1NzU_9fef7645-3fb1-4878-93fd-2f9527667254">25.49</ix:nonFraction>% in 2019, based on enacted tax rate reductions in future years.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-59</span></div></div></div><div id="i377d9717844147e799376babda10462f_196"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 20. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTYvZnJhZzo3N2FjMWEyNDU0Njk0YmVkYWJlY2MzZjI5NjJlMjUyMS90ZXh0cmVnaW9uOjc3YWMxYTI0NTQ2OTRiZWRhYmVjYzNmMjk2MmUyNTIxXzEyMjc_e410fe26-0921-4585-bf14-9e3aa07c1a82" continuedAt="i535c10b43d714e37a641e7f18409ba5c" escape="true">Segment reporting</ix:nonNumeric></span></div><div style="text-indent:46.2pt"><span><br/></span></div><ix:continuation id="i535c10b43d714e37a641e7f18409ba5c"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTYvZnJhZzo3N2FjMWEyNDU0Njk0YmVkYWJlY2MzZjI5NjJlMjUyMS90ZXh0cmVnaW9uOjc3YWMxYTI0NTQ2OTRiZWRhYmVjYzNmMjk2MmUyNTIxXzEyMjg_7dfadccb-7ae7-4633-ae53-edaa5d55fbcf" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 8 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Operating Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, reporting by operating segment is derived from the internal organization of the Company&#8217;s activities; it reflects management&#8217;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#8217;s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-60</span></div></div></div><div id="i377d9717844147e799376babda10462f_199"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 21. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzE_d2123fbe-69d9-4b5b-af9e-907077c46a51" continuedAt="if023ea75afa241c182e9a8262b7fa35c" escape="true">Loss per share</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if023ea75afa241c182e9a8262b7fa35c"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzI_c2838898-9942-4d14-b757-4d4abe92e082" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:EarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzM_69837206-d555-4e85-bc98-3217eaa7abb2" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:49.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMS0xLTEtMTE5OTk_8e826b2d-767c-4df3-bc65-b35339438cdc">47,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMi0xLTEtMTE5OTk_36514527-efad-4122-8ab8-b2be1c4df82c">33,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMy0xLTEtMTE5OTk_23d1a2e9-c07f-49d1-9db9-84f4ad681b28">50,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMS0xLTEtMTE5OTk_c7664a7b-2c1d-4b1f-8720-7cb9de287224">34,733,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMi0xLTEtMTE5OTk_3b637d01-a19d-405f-8846-5f93924da35d">24,385,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="INF" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMy0xLTEtMTE5OTk_d28d523d-3548-4100-9796-aa70daf5bb7c">21,631,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMS0xLTEtMTE5OTk_1aa8e8d6-2a0d-454c-b5a1-0a292f6f7fb1">1.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMi0xLTEtMTE5OTk_02f8b3a8-d165-4412-9a48-36afedac07f8">1.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMy0xLTEtMTE5OTk_d1eb936a-ecbd-46b9-aa14-32f9ca834e20">2.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMS0xLTEtMTE5OTk_6f41d3ba-5cec-46da-a8d9-13acf6dd1f0d">1.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMi0xLTEtMTE5OTk_c3535abf-44f2-4fdb-b230-93c34aadae80">1.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMy0xLTEtMTE5OTk_256fa6c7-c616-4026-b998-311b9eeff76d">2.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instruments providing deferred access to the capital are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued but not granted, representing as of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="nbx:AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzExMTg_db9da1c9-17b3-428d-be31-8fe2716bdd0f">3,006,532</ix:nonFraction> potential additional ordinary shares, have been considered antidilutive.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-61</span></div></div></div><div id="i377d9717844147e799376babda10462f_202"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Note 22. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMwMDI_5cb0b563-591d-4f53-bbed-b6a1d6311156" continuedAt="i91cc8db6acac4a27b56abf8cf96f570d" escape="true">Commitments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i91cc8db6acac4a27b56abf8cf96f570d"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.1 Obligations under the loan agreement with the EIB</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than &#8364;<ix:nonFraction unitRef="eur" contextRef="i9f7d1edd94224299addbda5de426a08d_I20211231" decimals="-5" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzM1MA_81ac2c70-b5da-4a44-a482-60a49e54d0df">35.0</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The EIB finance contract contains covenants that impose restrictions on the operation of the Company's business but no financial covenants that the Company is required to comply with.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.2 Obligations under the terms of the rental agreements part of the IFRS 16 exemptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"><ix:nonFraction unitRef="lease_contract" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="INF" name="nbx:NumberOfShortTermLeaseContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzc5OA_74c5b8c5-c27e-46a9-8124-7bb33e243f18">One</ix:nonFraction> short term lease for an office by Nanobiotix Corp., of which the annual rent is &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:AnnualShortTermLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzg4MQ_57cb91e7-7b5e-4140-a1b6-8421d11ddc1d">140</ix:nonFraction>&#160;thousand; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Leases related to low-value assets for Nanobiotix S.A.&#8217;s printers, of which the annual rent is around &#8364;<ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="nbx:AnnualLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzk4OQ_d4b7f75a-5150-4067-9e15-dc8685c52197">10</ix:nonFraction>&#160;thousand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.3 Obligations related to the MD Anderson agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The collaboration will support multiple new Phase I/II clinical trials involving around <ix:nonFraction unitRef="patient" contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" decimals="INF" name="nbx:NumberOfPatientsInClinicalTrial" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzEzNTc_8cd2b4c1-2815-44b9-8402-66fc1c78fd80">340</ix:nonFraction> patients with Nanobiotix&#8217;s first-in-class agent NBTXR3 for use in treating several cancer types &#8211; including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $<ix:nonFraction unitRef="usd" contextRef="ie86596994b614e61888621f5f63b3d95_I20190131" decimals="-6" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE2NDg_2f9cb898-68c1-4d34-a213-bd7117a7b7a1">11</ix:nonFraction>&#160;million for those clinical trials during the collaboration, and made an initial $<ix:nonFraction unitRef="usd" contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE3MjM_6208dbbd-7d6d-4839-ad46-beeec80a8696">1.0</ix:nonFraction>&#160;million payment at the commencement of the collaboration and a second $<ix:nonFraction unitRef="usd" contextRef="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE3ODg_27a2c1c8-6028-4523-a470-c197fa816502">1.0</ix:nonFraction>&#160;million payment on February 3, 2020. Additional payments will be made in the <ix:nonNumeric contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131" name="nbx:MilestonePaymentDefermentPeriodAfterEnrollment" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE4NjA_69c9405e-6dfb-4015-80bf-4c0e6de11f81">6</ix:nonNumeric> months following a patient enrollment, and expense is recorded in the statement of consolidated operations during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $<ix:nonFraction unitRef="usd" contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI0OTM_2605540e-77ff-4eb6-8a48-51483287546e">2.2</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI0OTk_6a12e27d-130a-4d2c-8748-e25f700f4371">16.4</ix:nonFraction>&#160;million. The amount will be determined on the basis of patients enrolled in the clinical trials at the date of FDA registration. This number increases every year and varies between $<ix:nonFraction unitRef="usd" contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI2NzU_6a600799-7b6e-4f5f-9246-37c5e2b9a7d7">2.2</ix:nonFraction>&#160;million (if it had been payable in 2020) and $<ix:nonFraction unitRef="usd" contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI3MTU_7674dacd-0ffa-476d-a516-637e05273dd7">16.4</ix:nonFraction>&#160;million (if payable in 2030). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, &#8364;<ix:nonFraction unitRef="eur" contextRef="i06cb4ce5915c4e4d828fd72b9468368d_D20190101-20211231" decimals="-5" name="nbx:ResearchAndDevelopmentExpenseSinceStartOfCollaboration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI3Njc_675dc90f-9eb4-46e2-9771-de0ba80aca81">1.8</ix:nonFraction>&#160;million have already been invoiced since the beginning of the collaboration and &#8364;<ix:nonFraction unitRef="eur" contextRef="icfe58517db324e8ab08832232c673117_I20211231" decimals="-5" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI4NDI_238d5c5a-0fa8-4da7-917f-1f379fcc3da6">1.0</ix:nonFraction>&#160;million remain in prepaid expenses. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.4  Obligations related to the termination of the PharmaEngine agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjM0_297548e4-1a1e-4085-8858-8f9fc7790ee7">6.5</ix:nonFraction>&#160;million to PharmaEngine (&#8364;<ix:nonFraction unitRef="eur" contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231" decimals="-5" name="nbx:ContractualCommitmentsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjQ4_76bac8c2-2e55-4cfb-90d4-bb9cbbc9d468">5.4</ix:nonFraction>&#160;million converted at the exchange rate on the payment date) in accordance with the termination agreement signed between the parties. PharmaEngine is eligible to receive additional payments of $<ix:nonFraction unitRef="usd" contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331" decimals="-6" name="nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjYy_6a5ed8bf-16bc-4c85-a75f-3d408369cf78">1</ix:nonFraction>&#160;million upon receipt by the Company of clinical study reports and of $<ix:nonFraction unitRef="usd" contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331" decimals="-3" name="nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjc0_d4fa4fb3-8190-469e-ae26-8d7411dd7a65">5</ix:nonFraction>&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction in the world and for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a <ix:nonNumeric contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331" name="nbx:RoyaltiesAgreementPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjg2_7ab94007-5018-402c-91b9-c360a87cbbd7">10</ix:nonNumeric>-year period beginning at the date of the first sales in the region.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-62</span></div></div></div><div id="i377d9717844147e799376babda10462f_205"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 23. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90ZXh0cmVnaW9uOjlmMWEyYWY2MDVjMzQ3M2U4ZWU3ZDYxNGI2NzhiNGI0XzMzOQ_f35e0780-f6b1-4243-b400-c5a402e05c0c" continuedAt="i1c45fb19c85e4b18a3b874b74b57c0e4" escape="true">Related parties </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1c45fb19c85e4b18a3b874b74b57c0e4"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Key management personnel compensation</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90ZXh0cmVnaW9uOjlmMWEyYWY2MDVjMzQ3M2U4ZWU3ZDYxNGI2NzhiNGI0XzM0MA_3bcee91e-d281-4ffc-bfef-ee5bb8bb3b5f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"></td><td style="width:56.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMS0xLTEtMTE5OTk_4aa5f3e7-b5ab-4b05-9ee3-da4a7c0df69a">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMi0xLTEtMTE5OTk_616493ad-af7f-469c-8a53-1a7ccf3481bf">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMy0xLTEtMTE5OTk_dffe15a8-b58b-4f4a-b014-e1f59f4894b0">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMS0xLTEtMTE5OTk_12916898-b5b3-424f-8a58-2e54b8ae17b0">2,018</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMi0xLTEtMTE5OTk_250a5ee1-dd84-42ef-a087-c3b6d193fb15">1,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMy0xLTEtMTE5OTk_f00de9e1-5a95-47ec-a3fa-2c2947ea8933">2,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:DirectorsRemunerationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMS0xLTEtMTE5OTk_5780e2a3-9815-4aea-a5cc-3eff7cad57e4">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:DirectorsRemunerationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMi0xLTEtMTE5OTk_5fed4ca4-4326-4b1b-9b99-073aebd73d8b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:DirectorsRemunerationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMy0xLTEtMTE5OTk_bd4ab1bf-4b57-4f18-a6ba-4b564fd29eb7">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMS0xLTEtMTE5OTk_1858ae9a-ef89-4957-8860-237c518fba05">3,638</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMi0xLTEtMTE5OTk_02624480-99c2-4e34-ba8a-f11660ffad76">2,866</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMy0xLTEtMTE5OTk_3f466916-b7e7-492c-bfce-fde179d5dcdc">3,442</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The methods used to measure share-based payments are presented in Note 17.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-63</span></div></div></div><div id="i377d9717844147e799376babda10462f_208"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Note 24. <ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzI2ODc_506fe6dc-844c-4ade-b90c-a9399d23a882" continuedAt="i4eac36fb5c3744aebf942dae5ee6dcc3" escape="true">Subsequent events</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"><ix:continuation id="i4eac36fb5c3744aebf942dae5ee6dcc3" continuedAt="i662904844f7d4d5786e64e4004d1290e"> </ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i662904844f7d4d5786e64e4004d1290e"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231" name="nbx:DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzI2ODY_638a56d3-da4c-4360-aca8-63358149e45a" continuedAt="i3be3785aa8e2448bb23afb04096b73f8" escape="true">Accounting policy</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="i3be3785aa8e2448bb23afb04096b73f8">The statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of subsequent events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Considerations arising from the Russia-Ukraine war</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Russia launched in February 2022 the invasion of Ukraine, which, in addition to creating humanitarian concerns, may also impact the health care ecosystem in the form of delayed clinical trials. Clinical trial sites originally appointed in Russia and Ukraine for the clinical trial NANORAY-312 were not actively opened at the time of such conflict and, consequently, did not recruit patients. While backup options are being identified and the replacement of such sites by sites located in other countries is actively conducted by the Company, it is currently impossible to exclude any delay in this clinical trial activity, even if no significant delay has been identified as of the date of issuance of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share capital increase</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 11, 2022, the share capital of the Company was increased by a nominal amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311" decimals="0" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzMzI_a8285db7-d0fa-4492-a912-97f794276794">1,500</ix:nonFraction>, through the issuance of <ix:nonFraction unitRef="shares" contextRef="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNDA_5711afba-1e6f-42cd-83c8-17aa35029536">50,000</ix:nonFraction> new ordinary shares with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="i58b267957c564e22a8fe73487217730b_I20220311" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNDg_71450454-d38e-4f32-8eb9-afe0c8c617df">0.03</ix:nonFraction> each, increasing the Company&#8217;s share capital from &#8364;<ix:nonFraction unitRef="eur" contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231" decimals="2" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNTU_d297ae44-7a66-4492-8ce1-cd50a2e989b3">1,044,776.16</ix:nonFraction> to &#8364;<ix:nonFraction unitRef="eur" contextRef="icae5cf18bb21492a86c074c63258fe60_I20220311" decimals="2" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNzA_2b1982fd-555d-4297-9769-c6a2c4f49b57">1,046,276.16</ix:nonFraction>, as a result of the definitive acquisition of <ix:nonFraction unitRef="shares" contextRef="i2d7bf6f87d6c4461a273858821e7fb90_D20220311-20220311" decimals="INF" name="nbx:NumberOfSharesIssuedThroughIssueOfEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzODU_f7b336a6-d37b-4ab6-b31a-e4b5d852d7a8">50,000</ix:nonFraction> AGA 2020. Such acquisition was acknowledged by the Executive Board on March 11, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">F-64</span></div></div></div><div id="i377d9717844147e799376babda10462f_211"></div><hr style="page-break-after:always"/><div style="min-height:70.87pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Table of </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i377d9717844147e799376babda10462f_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">SIGNATURES </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. </span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.665%"><tr><td style="width:1.0%"></td><td style="width:14.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.279%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">NANOBIOTIX S.A.</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">/s/ LAURENT LEVY</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Laurent Levy, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Chairman of the Executive Board</span></td></tr></table></div><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date: April 8, 2022</span></div><div style="height:70.87pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.3
<SEQUENCE>2
<FILENAME>nanobiotix-secx20xf2021xexe.htm
<DESCRIPTION>EX-2.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4b60424a53734b58a47e3c0361394f65_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 2.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit 2.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DESCRIPTION OF SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, Nanobiotix S.A. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title of Each Class</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trading Symbol</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name of each exchange on which registered</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">American depositary shares, each representing one ordinary share, nominal value &#8364;0.03 per share</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NBTX</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NASDAQ Global Select Market</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ordinary shares, nominal value &#8364;0.03 per share*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NASDAQ Global Select Market*</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">* Not for trading, but only in connection with the registration of American Depositary Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, nominal value &#8364;0.03 per share of Nanobiotix S.A. (the &#8220;ordinary shares&#8221;), have been available in the United States through an American Depositary Receipt (&#8220;ADR&#8221;) program. This program was established pursuant to the deposit agreement, dated December 15, 2020 (the &#8220;Deposit Agreement&#8221;), that we entered into with Citibank, N.A. (&#8220;Citibank&#8221;), as depositary, in connection with our initial public offering in the United States. Citibank&#8217;s depositary offices are located at 388 Greenwich Street, New York, New York 10013. Each ADS represents one ordinary share deposited with Citibank Europe plc, located at 1 North Wall Quay, Dublin 1 Ireland, or any successor, as custodian for the depositary (the &#8220;Custodian&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our ADSs have been listed on the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;) since December 2020 and are traded under the symbol NBTX. In connection with this NASDAQ listing (but not for trading), the shares are registered under Section 12(b) of the Exchange Act. The transfer agent and registrar for our ADSs is Citibank. Our ordinary shares have been trading on the regulated market of Euronext in Paris under the symbol &#8220;NANO&#8221; since October 2012. Prior to that date, there was no public trading market for our ordinary shares. The transfer agent and registrar for our ordinary shares is CIC Securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This exhibit contains a description of the rights of (i) the holders of ordinary shares and (ii) ADS holders. Shares underlying the ADSs are held by Citibank, the depositary, and holders of ADSs will not be treated as holders of the shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The following summaries are not intended to be exhaustive and, in the case of our ordinary shares, such summary is subject to, and qualified in its entirety by, Nanobiotix&#8217;s By-laws and by French law and in the case of our ADSs, such summary is subject to, and qualified in its entirety by, the terms of the Deposit Agreement. Such summaries do not address all of the provisions of the By-laws or French law or of the Deposit Agreement, and do not purport to be complete. Our By-laws and the Deposit Agreement are each attached as exhibits to our Annual Report.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Capitalized terms not otherwise defined in this exhibit have the meanings given to them in Nanobiotix&#8217;s annual report on Form 20-F for which this exhibit is provided (the &#8220;Annual Report&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">ORDINARY SHARES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The description below reflects certain terms of our By-laws, and summarizes the material rights of holders of our ordinary shares under French law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, our outstanding share capital consisted of a total of 34,825,872 issued and outstanding ordinary shares, with nominal value &#8364;0.03 per share. We have no preferred shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Rights, Preferences and Restrictions Attaching to Ordinary Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Dividends </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We may only distribute dividends out of our &#8220;distributable profits,&#8221; plus any amounts held in our reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required to be maintained by law. &#8220;Distributable profits&#8221; consist of our statutory net profit in each fiscal year, calculated in accordance with accounting standards applicable in France, as increased or reduced by any profit or loss carried</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">forward from prior years, less any contributions to the reserve accounts pursuant to French law (see below under &#8220;&#8212;Legal Reserve&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Legal Reserve</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to French law, we must allocate at least 5% of our statutory net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Such allocation is compulsory until the amount in the legal reserve is equal to 10% of the aggregate par value of our issued and outstanding share capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Approval of Dividends </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to French law, our executive board may propose a dividend for approval by the shareholders at the annual ordinary general meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Upon recommendation of our executive board, our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when as a result of such distribution our net assets are or would become lower than the amount of the share capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our executive board may distribute interim dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when the interim balance sheet, established during such year and certified by an auditor, reflects that we have earned distributable profits since the close of the last fiscal year, after recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the By-laws, and including any retained earnings. The amount of such interim dividends may not exceed the amount of the profit so defined.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Distribution of Dividends </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Dividends are distributed to shareholders proportionally to their shareholding interests. In the case of interim dividends, distributions are made to shareholders on the date set by our executive board during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders&#8217; meeting or by our executive board in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Dividends may be paid in cash or, if the shareholders&#8217; meeting so decides, in kind, provided that all the shareholders receive a whole number of assets of the same nature paid in lieu of cash. Our By-laws provide that, subject to a decision of the shareholders&#8217; meeting taken by ordinary resolution, each shareholder may be given the choice to receive his dividend in cash or in shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Timing of Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to French law, dividends must be paid within a maximum period of nine months following the end of the relevant fiscal year. An extension of such timeframe may be granted by court order. Dividends that are not claimed within a period of five years after the decision to distribute such dividends will be deemed to expire and revert to the French state.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Voting Rights </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Each of our ordinary shares entitles its holder to vote and be represented in the shareholders&#8217; meetings in accordance with French law and our By-laws. The ownership of a share implies, ipso facto, the acceptance of our By-laws and any decision of our shareholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In general, each shareholder is entitled to one vote per share at any general shareholders&#8217; meeting. The company&#8217;s major shareholders do not have different voting rights than other shareholders of the company. However, pursuant to French law, a double voting right is attached to each registered share, which is held in the name of the same shareholder for at least two years. However, ADSs are not eligible for double voting rights. Holders of ADSs or ordinary shares are unlikely to meet the requirements to have double voting rights attach to any ordinary shares held by them.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, treasury shares or shares held by entities controlled by us are not entitled to voting rights and are not taken into account for purposes of quorum calculation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Rights to Share in Our Profit </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, each ordinary share entitles its holder to a portion of the corporate profits and assets proportional to the amount of share capital represented thereby.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Rights to Share in the Surplus in the Event of Liquidation (Articles 9 and 30 of the By-laws)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If we are liquidated, any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will first be used to repay in full the par value of our outstanding shares. Any surplus will then be distributed among shareholders in proportion to the number of our shares they hold.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Repurchase and Redemption of Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, Market Abuse Regulation (EU) No. 596&#47;2014 of April 16, 2014 and its related delegated regulations (&#8220;MAR&#8221;) provides for safe harbor exemptions when the acquisition is made (i) under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L.22-10-62 of the French Commercial Code and with the General Regulations of the French Financial Markets Authority (Autorit&#233; des march&#233;s financiers or &#8220;AMF&#8221;) and (ii) for one of the following purposes which shall be provided for in the buy-back program&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at an extraordinary general meeting&#59; in this case, the shares repurchased must be cancelled within one month from their repurchase date&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">to meet obligations arising from debt securities that are exchangeable into shares&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">to meet our obligations arising from share option programs, or other allocations of shares, to our employees or to our managers or the employees or managers of our affiliate. In this case the shares repurchased must be distributed within 12 months from their repurchase, after which they must be cancelled.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, we benefit from a simple exemption when the acquisition is made under a liquidity contract complying with the general regulations of, and market practices accepted by, the AMF. All other purposes, and especially share buy-backs made for external growth operations in pursuance of Article L. 22-10-62 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulation and insider dealing rules.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under MAR and in accordance with the General Regulations of the AMF, we shall report to the AMF, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all the transactions relating to the buy-back program in a detailed form and in an aggregated form. In addition, we shall provide to the AMF, on a monthly basis, and to the public, on a biannual basis, a summary report of the transactions made under a liquidity contract.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In any case, no such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than (i) 10% of our issued share capital, or (ii) 5% of our issued share capital in case of repurchase of shares to be used in payment or in exchange in the context of a merger, division or transfer of assets. Shares repurchased by us continue to be deemed &#8220;issued&#8221; under French law but are not entitled to dividends and&#47;or voting rights so long as we hold them directly or indirectly, and we may not exercise the preferential subscription rights attached to them.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Sinking Fund Provisions </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our By-laws do not provide for any sinking fund provisions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Liability to Further Capital Calls </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders are liable for corporate liabilities only up to the par value of the shares they hold&#59; they are not liable for further capital calls.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Requirements for Holdings Exceeding Certain Percentages </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">There are no such requirements, except as described in &#8220;&#8212;Form, Holding and Transfer of Shares&#8212;Ownership of Shares and ADSs by Non-French Persons.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Actions Necessary to Modify Shareholders&#8217; Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders&#8217; rights may be modified as permitted by French law. Only the extraordinary shareholders&#8217; meeting is authorized to amend any and all provisions of our By-laws. It may not, however, increase any of the shareholders&#8217; commitments without the prior approval of each shareholder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Special Voting Rights of Warrant Holders</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights), including founders&#8217; warrants (BSPCE) and warrants (BSA), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%">Rules for Admission to and Calling Annual Shareholders&#8217; Meetings and Extraordinary Shareholders&#8217; Meetings</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Access to, Participation in and Voting Rights at Shareholders&#8217; Meetings (Article 22 of the By-laws) </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The right to participate in a shareholders&#8217; meeting is granted to all shareholders, regardless of the number of shares they hold, whose shares are paid up or for whom a right to attend shareholders&#8217; meetings is established by registration of the shares in an account in the name of the shareholder or the intermediary registered on his or her behalf, on the second business day prior to the shareholders&#8217; meeting, at midnight (Paris time), either in the registered share accounts held by us or in the bearer share accounts held by the authorized intermediary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Each shareholder has the right to attend the meetings, participate in the discussions and vote (1) in person, (2) by granting a proxy to any individual or legal entity of his choosing, (3) by sending a proxy to us without indication of the beneficiary (in which case such proxy shall be cast in favor of the resolutions supported by the executive board), or (4) by correspondence. In addition, shareholders may attend meetings by videoconference or another means of telecommunication if so decided by the executive board in the shareholders&#8217; meeting convening notice.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders may, in accordance with legal and regulatory requirements, send their vote or proxy, either by hard copy or via telecommunications means. The final date for returning such vote or proxy is set by the executive board and disclosed in the notice of meeting published in the French Journal of Mandatory Statutory Notices (Bulletin des Annonces L&#233;gales Obligatoires, or &#8220;BALO&#8221;). This date cannot be earlier than (1) at least three days prior to the meeting, in the case of hard copies, (2) by 3&#58;00 p.m. (Paris time) on the day before the meeting, in the case of, electronic votes by email and (3) by 3&#58;00 p.m. (Paris time) on the day before the meeting, in the case of electronic proxies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders sending their vote within the applicable time limit, using the form provided to them by us for this purpose, are deemed present or represented at the shareholders&#8217; meeting for purposes of quorum and majority calculation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The voting by correspondence form addressed to a shareholder is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two (2) meetings, one ordinary, the other extraordinary, held within a period of fifteen (15) days.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Notice of Annual Shareholders&#8217; Meetings </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders&#8217; meetings are convened by our executive board, or, failing that, by our supervisory board, our statutory auditors, by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a change in control. Meetings are held at our registered offices or at any other location indicated in the convening notice. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A first convening notice (avis de r&#233;union) must be published in the BALO at least 35 days prior to the meeting as well as on our website at least 21 days prior to the meeting. The convening notice must include the meeting&#8217;s agenda and the draft resolutions that will be presented at the meeting. A request to include any issues or draft resolutions in the agenda must be addressed to the company in accordance with French law. Subject to special legal provisions provided by French law, the convening notice (avis de convocation) must be given at least 15 days before the date of the meeting, by means of a notice inserted in the French BALO and a legal announcement bulletin of the registered office department of the Company. Further, holders of registered shares for at least a month at the time of the latest insertion of the notices shall be summoned individually, by regular letter or by registered letter if the shareholders so request and include an advance of expenses, sent to their last known address.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any relevant shareholder requesting it beforehand either by post or by electronic means in accordance with legal and regulatory requirements, specifying his e-mail address. A shareholder may request, at any time, either by post or by electronic means that electronic means of telecommunication is no longer acceptable and should be replaced by a mailing.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The convening notice must also include the conditions under which shareholders may vote by correspondence and how they can obtain voting forms by mail.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">When the shareholders&#8217; meeting cannot deliberate due to quorum not being met, the second meeting must be called at least 10 days in advance and in the same manner as the first notice.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Agenda and Conduct of Annual Shareholders&#8217; Meetings </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The agenda of the shareholders&#8217; meeting shall appear in the convening notice of the meeting and is set by the author of the notice. The shareholders&#8217; meeting may only deliberate on the items on the agenda except for the removal of members of our supervisory board and the appointment of their successors, which may be put to vote by any shareholder during any shareholders&#8217; meeting. One or more shareholders representing the percentage of share capital required by French law (currently 2.5% of our share capital), and acting in accordance with legal requirements and within applicable time limits, may request the inclusion of items or proposed resolutions on the agenda. Such request must be received no later than 25 days before the shareholders&#8217; meeting, and in any event no later than 20 days after the announcement of the shareholders&#8217; meeting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shareholders&#8217; meetings are chaired by the chairman of the supervisory board or, in his or her absence, by the vice president of the supervisory board. Failing that, the meeting itself will elect a chairman. Vote counting is performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of votes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Ordinary Shareholders&#8217; Meeting </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Ordinary shareholders&#8217; meetings are those meetings called to make any and all decisions that do not result in a modification of our By-laws. In addition, pursuant to an AMF recommendation dated June 15, 2015, French listed companies may be required to conduct a consultation of the ordinary shareholders&#8217; meeting prior to the disposal of the majority of their assets, under certain circumstances. An ordinary shareholders&#8217; meeting shall be convened at least once a year within six months of the end of each fiscal year in order to approve the annual and consolidated accounts for the relevant fiscal year or, in case of postponement, within the period established by court order. Upon first notice, the meeting may validly deliberate only if the shareholders present, represented by proxy or voting by mail represent at least one-fifth of the shares entitled to vote. Upon second notice, no quorum is required. This differs from Nasdaq rules that require 33 1&#8725;3% of shareholders be present at a meeting. Decisions are made by a majority of the votes cast by the shareholders present, represented by proxy, or voting by mail. The votes cast do not include those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">attached to shares for which the shareholder did not participate in the vote, abstained, voted blank or the vote is otherwise void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Extraordinary Shareholders&#8217; Meeting </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Only an extraordinary shareholders&#8217; meeting is authorized to amend our By-laws. It may not, however, increase shareholders&#8217; commitments without the approval of each shareholder. Subject to the legal provisions governing share capital increases from reserves, profits or share premiums, the resolutions of the extraordinary meeting will be valid only if the shareholders present, represented by proxy or voting by mail represent at least one-fourth of all shares entitled to vote upon first notice, or one-fifth upon second notice. If the latter quorum is not reached, the second meeting may be postponed to a date no later than two months after the date for which it was initially called. Decisions are made by a two-thirds majority vote cast by the shareholders present, represented by proxy, or voting by mail. The votes cast do not include those attached to shares for which the shareholder did not participate in the vote, abstained, voted blank or the vote is otherwise void.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition to the right to obtain certain information regarding us at any time, any shareholder may, from the date on which a shareholders&#8217; meeting is convened until the fourth business day preceding the date of the shareholders&#8217; meeting, submit written questions relating to the agenda for the meeting to our executive board.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Our executive board is required to respond to these questions during the meeting. The answer to a written question is deemed to have been given when it appears on the company's website in a section devoted to questions and answers. The executive board may delegate one of its members to answer them.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Provisions Having the Effect of Delaying, Deferring or Preventing a Change in Control of the Company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Provisions contained in our By-laws and the corporate laws of France could make it more difficult for a third-party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of French law and our By-laws impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">provisions of French law allowing the owner of 90% of the share capital or voting rights of a public company to force out the minority shareholders following a tender offer made to all shareholders are only applicable to companies listed on a regulated market or a multilateral trading facility in a Member State of the EU or in a state party of the European Economic Area Agreement, including the main French stock exchange, and will therefore be applicable to us only if we continue to dual-list in France&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">a merger (i.e., in a French law context, a stock-for-stock exchange after which our Company would be dissolved without being liquidated into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our Company into a company incorporated in the EU would require the approval of our executive board as well as a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">a merger of our Company into a company incorporated outside of the EU would require the unanimous approval of our shareholders&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our shareholders have granted and may grant in the future to our executive board broad authorizations to increase our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our shareholders have preferential subscription rights proportional to their shareholding in our Company on the issuance by us of any additional shares or securities giving right, immediately or in the future, to new shares for cash or a set-off of cash debts, which rights may only be waived by the extraordinary shareholders&#8217; general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our supervisory board has the right to appoint new members to fill a vacancy created by the resignation or death of a member, subject to the approval by the shareholders of such appointment at the next shareholders&#8217; meeting, which prevents shareholders from having the sole right to fill vacancies on our supervisory board&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the members of our executive board are appointed by our supervisory board and can be removed either by our supervisory board or at the shareholders&#8217; general meeting&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our supervisory board can only be convened by its chairman, or by its vice-president or, on a reasoned request (e.g., when no board meeting has been held for more than two consecutive months), by (1) members representing at least one-third of the total number of members of our supervisory board or (2) a member of the executive board&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our supervisory board&#8217;s meetings can only be regularly held if at least half of its members attend either physically or by way of videoconference or teleconference, enabling the members&#8217; identification and ensuring their effective participation in the supervisory board&#8217;s decisions&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">our shares are nominative or bearer, if the legislation so permits, according to the shareholder&#8217;s choice&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">under French law, (a) any non-French citizen, (b) any French citizen not residing in France, (c) any non-French entity or (d) any French entity controlled by one of the aforementioned persons or entities may have to file a declaration for statistical purposes with the Bank of France (Banque de France) within 20 business days following the date of certain direct foreign investment in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#8364;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold&#59; see &#8220;Form, Holding and Transfer of Shares&#8212;Ownership of Shares and ADSs by Non-French Persons&#8221;&#59;             </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">under French law, certain investments in any entity governed by a French law relating to certain strategic industries (such as research and development in biotechnologies and activities relating to public health) and activities by individuals or entities not French, not resident in France or controlled by entities not French or not resident in France are subject to prior authorization of the Ministry of Economy&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders&#8217; general meeting is required to remove members of the supervisory board with or without cause&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">advance notice is required for nominations to the members of the supervisory board or for proposing matters to be acted upon at a shareholders&#8217; meeting, except that a vote to remove and replace a member of our supervisory board can be proposed at any shareholders&#8217; meeting without notice&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">pursuant to French law, our By-laws, including the sections relating to the number of our supervisory board&#8217;s members and election and removal of a member of the supervisory board from office, may only be modified</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">by a resolution adopted by a two-thirds majority vote of our shareholders present, represented by a proxy or voting by mail at the meeting&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">in the event where certain ownership thresholds would be crossed, a number of disclosures should be made by the relevant shareholder and can impose certain obligations&#59; see &#8220;&#8212;Declaration of Crossing of Ownership Thresholds&#8221;&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">transfers of shares shall comply with applicable insider trading rules and regulations, and in particular with the MAR.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Declaration of Crossing of Ownership Thresholds</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Subject to requirements of French law, our By-laws do not require any specified disclosure by shareholders that cross ownership thresholds with respect to our share capital, except as described in &#8220;&#8212;Form, Holding and Transfer of Shares&#8212;Ownership of Shares and ADSs by Non-French Persons.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The absence of specific requirements in our By-laws is without prejudice to the following disclosures which are applicable to us in accordance with French legal and regulatory provisions, it being understood that the following is a summary which is not intended to be a complete description of applicable rules under French law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Any individual or legal entity referred to in Articles L. 233-7, L. 233-9 and L. 233-10 of the French Commercial Code coming to directly or indirectly own, or cease to own, alone or in concert, a number of shares representing a fraction of our capital or voting rights greater or equal to 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95% shall inform us as well as the AMF of the total number of shares and voting rights and of securities giving access to the capital or voting rights that it owns immediately or over time within a period of four trading days from the crossing of the said holding thresholds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This obligation also applies when crossing each of the above-mentioned thresholds in a downward direction. In case of failure to declare shares or voting rights exceeding the fraction that should have been declared, such shares shall be deprived of voting rights at shareholders&#8217; meetings for any meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with Article L. 233-14 of the French Commercial Code. Additional sanctions may apply pursuant to Article L. 621-15 of the French Monetary and Financial Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In addition, any shareholder crossing, alone or acting in concert, the 10%, 15%, 20% or 25% threshold shall file a declaration with the AMF pursuant to which it shall expose its intention over the following six months, including notably whether it intends to continue acquiring our shares, it intends to acquire control over us and its intended strategy for us.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory public tender offer with the AMF. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than 12 consecutive months, increases his&#47;her&#47;its holding of capital or voting rights by at least 1% of our capital or voting rights, shall file a mandatory public tender offer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Changes in Share Capital</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Increases in Share Capital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to French law, our share capital may be increased only with shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting following the recommendation of our executive board. The shareholders may delegate to our executive board either the authority (d&#233;l&#233;gation de comp&#233;tence) or the power (d&#233;l&#233;gation de pouvoir) to carry out any increase in share capital in accordance with applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Increases in our share capital may be effected by&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuing additional shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">increasing the par value of existing shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">creating a new class of equity securities&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">exercising the rights attached to securities or other financial instruments giving access to the share capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Increases in share capital by issuing additional securities may be effected through one or more of the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuances in consideration for cash&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuances in consideration for assets contributed in kind&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">conversion of existing shares into a new class of equity securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuances through an exchange offer&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuances by conversion of previously issued debt instruments&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">issuances by capitalization of profits, reserves or share premium&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">subject to certain conditions, issuances by way of offset against debt incurred by us.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Decisions to increase the share capital through the capitalization of reserves, profits and&#47;or share premium require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#8217; meetings. Increases in share capital effected by an increase in the par value of shares require unanimous approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting acting under the regular quorum and majority requirements for such meetings.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Reduction in Share Capital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to French law, any reduction in our share capital requires shareholders&#8217; approval at an extraordinary general shareholders&#8217; meeting following the recommendation of our executive board. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Preferential Subscription Right </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">According to French law, if we issue additional shares or securities giving right, immediately or in the future, to new shares for cash, current shareholders will have preferential subscription rights to these securities on a pro rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe proportionally to the number of shares held by them to the issuance of any securities increasing, or that may result in an increase of, our share capital by means of a cash payment or a set-off of cash debts. The preferential subscription rights may be transferred and&#47;or sold during the subscription period relating to a particular offering. Pursuant to French law, the preferential subscription rights will be transferable during a period starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period, it being specified that if the business day starting one of these periods is not a trading day, the relevant period should start the preceding trading day.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a two-thirds vote of our shareholders or individually by each shareholder. Our executive board and our </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">independent auditors are required by French law to present reports to the shareholders&#8217; meeting that specifically address any proposal to waive the preferential subscription rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Further, to the extent permitted under French law, we may seek, during an extraordinary general shareholders&#8217; meeting, the approval of the shareholders to waive their preferential subscription rights in order to authorize the executive board to issue additional shares and&#47;or other securities convertible or exchangeable into shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Form, Holding and Transfer of Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Form of Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Pursuant to our By-laws, our shares may be held in registered or bearer form, at each shareholder&#8217;s discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Further, in accordance with applicable laws, we may request at any time from the central depositary responsible for holding our shares or directly to one or several intermediaries listed in Article L. 211-3 of the French Monetary and Financial Code, information regarding the owners of our shares or securities, if any, giving immediate or future voting rights at our shareholders&#8217; meetings in accordance with Article L. 228-2 of the French Commercial Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Holding of Shares (Article 7 of the By-laws) </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In accordance with French law concerning the &#8220;dematerialization&#8221; of securities, the ownership rights of shareholders are represented by book entries instead of share certificates. Shares are registered in individual accounts maintained by us or by an authorized intermediary (depending on the form of the relevant shares) appointed by us or the relevant shareholder in the name of each shareholder and are kept in accordance with French law. Each shareholder&#8217;s account shows the name of the relevant shareholder and number of shares held.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Ownership of Shares and ADSs by Non-French Persons </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Neither the French Commercial Code nor our By-laws presently impose any restrictions on the right of non-French residents or non-French shareholders to own and vote shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">However, (a) any non-French citizen, (b) any French citizen not residing in France, (c) any non-French entity or (d) any French entity controlled by one of the aforementioned persons or entities may have to file a declaration for statistical purposes with the Bank of France (Banque de France) within twenty business days following the date of</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#8364;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Moreover, under French law, certain investments in any entity governed by a French law relating to certain strategic industries (such as research and development in biotechnologies and activities relating to public health) and activities by individuals or entities not French, not resident in France or controlled by entities not French or not resident in France are subject to prior authorization of the Ministry of Economy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Assignment and Transfer of Shares </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shares are freely negotiable, subject to applicable legal and regulatory provisions (including, in particular, the prohibition on insider trading).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Differences in Corporate Law</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The laws applicable to French </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">soci&#233;t&#233;s anonymes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and French law.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">France</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Delaware</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Number of Directors</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, a soci&#233;t&#233; anonyme with an executive board (directoire) and a supervisory board (conseil de surveillance) (i) must have at least 2 (or 1 when its share capital is below &#8364;150,000) and may have up to 5 (or 7 when the company is listed on a regulated market) executive board members and (ii) must have at least three but no more than 18 supervisory board members. The number of members is fixed by or in the manner provided in the By-laws. The members of the supervisory board are appointed at the shareholders&#8217; general meetings. The number of supervisory board members of each gender may not be less than 40%. As an exception, for a supervisory board having up to 8 members, the difference between each gender may not exceed 2. Any appointment made in violation thereof will be null and void. Moreover, the deliberations of the board in which the member appointed in contravention of the aforementioned rule would have participated will also be deemed null and void.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the certificate of incorporation or by-laws.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Director Qualifications</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, a corporation may prescribe qualifications for executive and supervisory board members under its by-laws. In addition, under French law, members of a supervisory board of a corporation may be legal entities, and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the supervisory board. However, only individuals may be appointed members of the executive board.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or by-laws. Under Delaware law, only individuals may be members of a corporation&#8217;s board of directors.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Removal of Directors</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, the supervisory board members may be removed from office, at any time, with or without cause, at any shareholders&#8217; meeting by a simple majority vote. The members of the executive board may be removed at the shareholders&#8217; meeting or, if provided in the by-laws, by the supervisory board. The executive board member removed without cause may claim damages.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation (1) whose board of directors is classified, stockholders may effect such removal only for cause (unless the certificate of incorporation provides otherwise), or (2) who has cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against such director&#8217;s removal would be sufficient to elect such director if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which such director is a part.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Vacancies on the Board of Directors</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, vacancies on the executive board resulting from death or a resignation or for any other reason will have to be filled by the supervisory board within two months, unless the supervisory board decides to amend the number of executive board members. Vacancies on the supervisory board may be filled temporarily by such board pending ratification by the next shareholders&#8217; meeting. The shareholders&#8217; meeting will immediately be held to appoint new supervisory board members if their number went below the minimum required by law.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, unless the certificate of incorporation or by-laws provide otherwise, vacancies on a corporation&#8217;s board of directors, including those caused by an increase in the number of directors, may be filled by stockholders or by a majority of the remaining directors.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Annual General Meeting</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided each year by the executive board and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the by-laws, provided that the court may order an annual meeting upon the application of a director or stockholder if a corporation has not held a meeting within 30 days of a date designated for the meeting or within 13 months after the latest of the Company&#8217;s organization, the last annual meeting or the last action by written consent to elect directors.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">General Meeting</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, general meetings of the shareholders may be called by the executive board or, failing that, by the statutory auditors, or by a court appointed agent (mandataire ad hoc) or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block, on the date decided by the executive board or the relevant person. General meetings of the shareholders may also be called by the supervisory board.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the by-laws.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Notice of General Meetings</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A first convening notice must be published in the mandatory statutory notices (BALO) at least 35 days prior to the meeting. Additional convening notices must be given at least 15 days before the date of the meeting, by means of a notice inserted in both the BALO and a newspaper for legal notices (journal d&#8217;annonces l&#233;gales) of the registered office department of the Company. Further, the shareholders holding registered shares for at least one month at the time of the latest insertion of the notices shall be summoned individually, by regular letter or by registered letter if the shareholders so request and include an advance of expenses, sent to their last known address. This notice to registered shareholders may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any relevant shareholder requesting it beforehand either by post or by electronic means of receipt in accordance with legal and regulatory requirements, specifying his e-mail address. When the shareholders&#8217; meeting cannot deliberate due to the lack of required quorum, the second meeting must be called at least ten calendar days in advance in the same manner as used for the first notice. The convening notice shall specify the name, acronym, legal form, share capital, registered office address and registration number with the French Trade and Companies Register (Registre du commerce et des soci&#233;t&#233;s) of the company and the place, date, hour, agenda and nature (ordinary or extraordinary) of the meeting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail and, as the case may be, the email address to which they may send written questions. In addition, if the shareholders&#8217; meeting is held by videoconference or another means of telecommunication allowing identification of the relevant shareholder in accordance with applicable laws, the notice also specifies that shareholders may participate in this meeting exclusively by such means.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, unless otherwise provided in the certificate of incorporation or by-laws, written notice of any meeting of the stockholders generally must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and (in the case of a special meeting of stockholders) purpose or purposes of the meeting.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Proxy</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, any shareholder may attend the meetings and vote (1) in person, or (2) by granting a proxy to any person, or (3) by sending a proxy to us without indication of the beneficiary (in which case, such proxy shall be cast in favor of the resolutions supported by the executive board), or (4) by correspondence, or (5) by videoconference or another means of telecommunication allowing identification of the relevant shareholder in accordance with applicable laws. The proxy is only valid for a single meeting or successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, the other extraordinary, held within a period of fifteen days.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Shareholder action by written consent</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, shareholders&#8217; action by written consent is not permitted in a soci&#233;t&#233; anonyme.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, unless otherwise provided in a corporation&#8217;s certificate of incorporation, stockholders may act by written consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting at which all shares entitled to vote thereon were present and voted.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Preemptive Rights</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, in case of issuance of additional shares or other securities giving the right, immediately or in the future, to new shares for cash or set-off against cash debts, the existing shareholders have preferential subscription rights to these shares or securities on a pro rata basis unless such rights are waived by a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the extraordinary meeting deciding or authorizing the capital increase. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or whose votes were blank or null. In case such rights are not waived by the extraordinary general meeting, each shareholder may either exercise, assign or not exercise its preferential rights. Preferential subscription rights may only be exercised during the subscription period. In accordance with French law, the exercise period shall not be less than five trading days. Thus, the preferential subscription rights are transferable during a period equivalent to the subscription period but starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period, it being specified that if the business day starting one of these periods is not a trading day, the relevant period should start the preceding trading day.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, unless otherwise provided in a corporation&#8217;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the corporation&#8217;s stock.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sources of Dividends</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, dividends may only be paid by a French soci&#233;t&#233; anonyme out of &#8220;distributable profits,&#8221; plus any distributable reserves and &#8220;distributable premium&#8221; that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;Distributable profits&#8221; (b&#233;n&#233;fices distribuables) consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;Distributable premium&#8221; refers to the contribution paid by the shareholders in addition to the par value of their shares for their subscription that the shareholders decide to make available for distribution.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Except in the case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become as a result of such distribution, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the by-laws.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, subject to any restrictions under a corporation&#8217;s certificate of incorporation, dividends may be declared by the board of directors and paid by a Delaware corporation either out of (1) surplus or (2) in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and&#47;or the preceding fiscal year, except when the Delaware statutory capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Repurchase of Shares</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, a corporation may acquire its own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, MAR provides for safe harbor exemptions when the acquisition is made for the following purposes&#58; &#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8202;to decrease its share capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction, in which case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer&#59; &#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">with a view to distributing within one year of their repurchase the relevant shares to employees or managers under a profit-sharing, restricted free share or share option plan, not to exceed 10% of the share capital&#59; in which case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be cancelled&#59; or &#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8195;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to meet obligations arising from debt securities that are exchangeable into equity instruments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No such repurchase of shares may result in</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital. A simple exemption is provided when the acquisition is made under a liquidity contract in the context of a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L. 22-10-62 French Commercial Code and in accordance with AMF General Regulations. All other purposes, and especially share buy-backs for external growth operations by virtue of Article L. 22-10-62 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulations and insider dealing rules. Under the MAR and in accordance with the General Regulations of the AMF, a corporation shall report to the AMF, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all transactions relating to the buy-back program in a detailed form and in an aggregated form. By exception, a corporation shall provide to the AMF, on a monthly basis, and to the public, on a biannual basis, a summary report of the transactions made under a liquidity contract.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the Delaware statutory capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Liability of Directors and Officers</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, the by-laws may not include any provisions limiting the liability of the members of the executive and supervisory boards.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a corporation&#8217;s certificate of incorporation may generally include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for&#58; &#8226;&#8195;&#8202;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders&#59; &#8226;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59; &#8226;&#8195;&#8202;intentional or negligent payment of unlawful dividends or stock purchases or redemptions&#59; or &#8226;&#8195;&#8202;&#8202;any transaction from which the director derives an improper personal benefit</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Voting Rights</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">French law provides that, unless otherwise provided in the by-laws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder. As of April 2016, double voting rights are automatically granted to the shares being registered since more than two years, unless the by-laws are modified in order to provide otherwise.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Shareholder Vote on Certain Transactions</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Generally, under French law, completion of a merger or dissolution requires&#58; &#8226; the approval of the executive board&#59; and &#8226; the approval by a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting, or in the case of a merger with a non-EU company, approval of all the shareholders of the corporation.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock or under other certain circumstances, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires&#58; &#8226;&#8195;&#8202;the approval of the board of directors&#59; and &#8226;&#8195;&#8202;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Dissent or Dissenters&#8217; Appraisal Rights</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">French law does not provide for any such right but provides that a merger is subject to shareholders&#8217; approval by a two-thirds majority of the votes cast as stated above.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#8217;s shares equal to the fair value of those shares, as determined by the Delaware Court of Chancery in an action timely brought by the corporation or a dissenting stockholder. Unless otherwise provided in the certificate of incorporation, Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than&#58; &#8226;&#8195;&#8202;shares of stock of another corporation that are either listed on a national securities exchange or held of record by more than 2,000 stockholders&#59; &#8226;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding bullet points&#59; or &#8226;&#8195;&#8202;any combination of the above. In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Standard of Conduct for Directors</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">French law does not contain specific provisions setting forth the standard of conduct of an executive or supervisory board member. However, the members have a duty of loyalty, a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a corporation&#8217;s corporate interest (int&#233;r&#234;t social).</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Shareholder Suits</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the members of the executive board (but not from the supervisory board members) of a corporation in the corporation&#8217;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or group of shareholders. The plaintiff must remain a shareholder throughout the duration of the legal action. There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation. A shareholder may alternatively or cumulatively, as the case may be, bring an individual legal action against the members of the executive or supervisory boards, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff&#8217;s shares thereafter devolved on the plaintiff by operation of law&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">state the reasons for not making the effort.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or settled without the approval of the Delaware Court of Chancery. Stockholders can also under some circumstances bring &#8220;direct&#8221; claims that belong only to the stockholder to challenge directors&#8217; conduct.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Amendment of Certificate of Incorporation</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Unlike companies incorporated under Delaware law, the organizational documents of which comprise both a certificate of incorporation and by-laws, companies incorporated under French law only have by-laws (statuts) as organizational documents. As indicated in the paragraph below, only the extraordinary shareholders&#8217; meeting is authorized to adopt or amend the by-laws under French law.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, generally a corporation may amend its certificate of incorporation if&#58; its board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability, and the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be specified by the corporation) of the voting power of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the voting power of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Amendment of By-laws</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under French law, only the extraordinary shareholders&#8217; meeting is authorized to adopt or amend the by-laws. The extraordinary shareholders' meeting may authorize the supervisory board to amend the by-laws to comply with legal provisions, subject to the ratification of such amendments by the next extraordinary shareholders&#8217; meeting. The supervisory board is authorized to amend the by-laws as a result of a decision to relocate the company's registered office in France, subject to ratification by the next ordinary shareholders' meeting.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal by-laws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Voting Rights</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">French law provides that, unless otherwise provided in the by-laws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder. As of April 2016, double voting rights are automatically granted to the shares being registered since more than two years, unless the by-laws are modified in order to provide otherwise.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The description below reflects certain terms of the Deposit Agreement, and summarizes the material rights of holders of our ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Each ADS represents the right to receive, and to exercise the beneficial interests in, one ordinary share that is on deposit with the depositary and&#47;or Custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the Custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The Custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the Custodian or their nominees.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Beneficial ownership in the deposited property will under the terms of the Deposit Agreement be vested in the beneficial owners of the ADSs. The depositary, the Custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of such ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the Custodian or their respective nominees, in each case upon the terms of the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Holders of ADSs become a party to the deposit agreement and therefore are bound to its terms and to the terms of any ADR that represents such ADSs. The deposit agreement and the ADR specify our rights and obligations as well as the rights and obligations of owners of ADSs and those of the depositary. ADS holders appoint the depositary to act on their behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares are governed by the laws of France, which may be different from the laws in the United States. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">An owner of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. French law governs shareholder rights. The depositary will be the holder of the ordinary shares underlying such owner&#8217;s ADSs. Accordingly, an owner of ADSs will be able to exercise the shareholder&#8217;s rights for the ordinary shares represented by such owner&#8217;s ADSs through the depositary only to the extent contemplated in the Deposit Agreement. To exercise any shareholder rights not contemplated in the Deposit Agreement an ADS owner will need to arrange for the cancellation of such owner&#8217;s ADSs and become a direct shareholder. In the event of a discrepancy between the ADRs and the Deposit Agreement, the Deposit Agreement governs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This summary description assumes ADSs are owned directly by means of an ADS registered in the owner&#8217;s name and, as such, such owner is referred to as the &#8220;holder.&#8221; ADSs may also be held by means of an ADR registered in an owner&#8217;s name, through a brokerage or safekeeping account, or through an account established by the depositary in such owner&#8217;s name reflecting the registration of uncertificated ADSs directly on the books of the depositary, commonly referred to as the direct registration system, or DRS. The manner in which a person owns ADSs may affect such person&#8217;s rights and obligations. Persons who own ADSs should carefully review the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Dividends and Distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder of ADSs generally has the right to receive the distributions we make on the securities deposited with the Custodian. A holder&#8217;s receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the Deposit Agreement in proportion to the number of ordinary shares represented by the ADSs held by such holder as of a specified record date, after deduction of the applicable fees, taxes and expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Distributions of Cash</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we make a cash distribution for the securities on deposit with the Custodian, we will deposit the funds with the Custodian. Upon receipt of confirmation from the Custodian of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to French laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the Custodian in respect of securities on deposit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. The depositary bank will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Distributions of Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we make a free distribution of ordinary shares for the securities on deposit with the Custodian, we will deposit the applicable number of ordinary shares with the Custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs representing the ordinary shares deposited or modify the ADS-to-ordinary share ratio, in which case each ADS a holder holds will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed&#59; fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The distribution of new ADSs or the modification of the ADS-to-ordinary share ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No such distribution of new ADSs will be made if it would violate a law (e.g., the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the Deposit Agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Distributions of Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we intend to distribute rights to purchase additional ordinary shares (including through the allocation of bons de souscription d&#8217;actions (BSAs)), we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the Deposit Agreement (such as opinions to address the lawfulness of the transaction). A holder may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of such holder&#8217;s rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will not distribute the rights to a holder if&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; we do not timely request that the rights be distributed to holders or we request that the rights not be distributed </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to holders&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; we fail to deliver satisfactory documents to the depositary&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; it is not reasonably practicable to distribute the rights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Elective Distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to holders. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will make the election available to holders only if it is reasonably practicable and if we have provided all of the documentation contemplated in the Deposit Agreement. In such case, the depositary will establish procedures to enable holders to elect to receive either cash or additional ADSs, in each case as described in the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If the election is not made available to holders, such holders will receive either cash or additional ADSs, depending on what a shareholder in France would receive upon failing to make an election, as more fully described in the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Other Distributions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to holders. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If it is reasonably practicable to distribute such property to holders and if we provide all of the documentation contemplated in the Deposit Agreement, the depositary will distribute the property to the holders in a manner it deems practicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit Agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will not distribute the property to holders and will sell the property if&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">we do not request that the property be distributed to holders or if we ask that the property not be distributed to holders&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">we do not deliver satisfactory documents to the depositary bank&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the depositary determines that all or a portion of the distribution to holders is not reasonably practicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Redemption</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Whenever we decide to redeem any of the securities on deposit with the Custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the Deposit Agreement, the depositary will provide notice of the redemption to the holders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received into U.S. dollars upon the terms of the Deposit Agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. Holders may have to pay fees, expenses, taxes and other governmental charges upon the redemption of their ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary may determine after consultation with us.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Changes Affecting Ordinary Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The ordinary shares held on deposit for a holder&#8217;s ADSs may change from time to time. For example, there may be a change in nominal or par value, a split-up, cancellation, consolidation or reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If any such change were to occur, such holder&#8217;s ADSs would, to the extent permitted by law and the Deposit Agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to such holder, amend the Deposit Agreement, the ADRs and the applicable registration statement(s) on Form F-6, call for the exchange of such holder&#8217;s existing ADRs for new ADRs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares held in deposit for such holder&#8217;s ADSs. If the depositary bank may not lawfully distribute such property to such holder, the depositary may sell such property and distribute the net proceeds to such holder as in the case of a cash distribution.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Issuance of ADSs upon Deposit of Ordinary Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary may create ADSs on a holder&#8217;s behalf if such holder or such holder&#8217;s broker deposits ordinary shares with the Custodian. The depositary will deliver these ADSs to the person such holder indicates only after such holder pays any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the Custodian. A holder&#8217;s ability to deposit ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The issuance of ADSs may be delayed until the depositary or the Custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the Custodian.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will only issue ADSs in whole numbers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">When a holder makes a deposit of ordinary shares, such holder will be responsible for transferring good and valid title to the depositary. Accordingly, such holder will be deemed to represent and warrant that&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Such holder is duly authorized to deposit the ordinary shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the Deposit Agreement).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">If any of the representations or warranties are incorrect in any way, we and the depositary may, at such holder&#8217;s cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Transfer, Combination and Split Up of ADRs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">An ADR holder will be entitled to transfer, combine or split up such holder&#8217;s ADRs and the ADSs evidenced thereby. For transfers of ADRs, a holder will have to surrender the ADRs to be transferred to the depositary and also must&#58;</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; provide such proof of identity and genuineness of signatures as the depositary deems appropriate&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; provide any transfer stamps required by the State of New York or the United States&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226; pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the Deposit Agreement, upon the transfer of ADRs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">To have ADRs either combined or split up, a holder must surrender the ADRs in question to the depositary with such holder&#8217;s request to have them combined or split up, and such holder must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the Deposit Agreement, upon a combination or split up of ADRs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Withdrawal of Ordinary Shares Upon Cancellation of ADSs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder will be entitled to present such holder&#8217;s ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary shares at the Custodian&#8217;s offices or, at a holder&#8217;s request, risk and expense, at such other place as a holder requests. A holder&#8217;s ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by a holder&#8217;s ADSs, such holder will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares being </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">withdrawn. Holders assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If a holder holds ADSs registered in such holder&#8217;s name, the depositary may ask such holder to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel such holder&#8217;s ADSs. The withdrawal of the ordinary shares represented by a holder&#8217;s ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. The depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder will have the right to withdraw the securities represented by such holder&#8217;s ADSs at any time except for&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">temporary delays that may arise because (1) the transfer books for the ordinary shares or ADSs are closed, or (2) ordinary shares are immobilized on account of a shareholders&#8217; meeting or a payment of dividends&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">obligations to pay fees, taxes and similar charges&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Deposit Agreement may not be modified to impair a holder&#8217;s right to withdraw the securities represented by such holder&#8217;s ADSs except to comply with mandatory provisions of law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Voting Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder generally has the right under the Deposit Agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by such holder&#8217;s ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">At our request, the depositary will distribute to holders any notice of shareholders&#8217; meeting received from us together with information explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#8217;s ADSs in accordance with such voting instructions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure the holders of ADSs, that such holder will receive voting materials in time to enable such holder to return voting instructions to the depositary in a timely manner.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If the depositary receives voting instructions from a holder of ADSs that fail to specify the manner in which the depositary is to vote, the depositary will deem such holder (unless otherwise specified in the notice distributed to holders) to have instructed the depositary to vote in favor of all resolutions endorsed by the members of our supervisory board. With respect to securities represented by ADSs for which no timely voting instructions are received by the depositary from the holder, the depositary will (unless otherwise specified in the notice distributed to holders) deem such holder to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the securities. However, no such discretionary proxy will be given by the depositary with respect to any matter to be voted upon as to which we inform the depositary that we do not wish such proxy to be given, substantial opposition exists, or the rights of holders of securities may be materially adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As long as, pursuant to French law, a double voting right is attached to each ordinary share which is held in registered form in the name of the same shareholder for at least two years, ordinary shares deposited with the depositary will not be entitled to double voting rights. Therefore, holders of ADSs who wish to obtain double voting rights will need to surrender their ADSs, withdraw the deposited shares, and take the necessary steps to hold such ordinary shares in registered form in the holder&#8217;s name for at least two years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Fees and Charges</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Holders will be required to pay certain fees under the terms of the Deposit Agreement. Holders will be notified in advance of all applicable fees by us or the depositary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Holders will also be responsible to pay certain charges such as&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the Custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">certain cable, telex and facsimile transmission and delivery expenses&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the fees, expenses, spreads, taxes and other charges of the depositary and&#47;or conversion service providers in connection with the conversion of foreign currency, such fees, expenses, spreads, taxes, and other charges to be deducted from the foreign currency&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">any reasonable and customary out-of-pocket expenses incurred in such conversion and&#47;or on behalf of holders and beneficial owners of ADSs in complying with currency exchange control or other governmental requirements&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the fees, costs and expenses incurred by the depositary, the Custodian, or any nominee in connection with the servicing or delivery of deposited property.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the Deposit Agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. Note that fees and charges may vary over time and may be changed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary agree from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Amendments and Termination</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We may agree with the depositary to modify the Deposit Agreement at any time without holders&#8217; consent. We undertake to give holders 30 days&#8217; prior notice of any modifications that would materially prejudice any of their substantial rights under the Deposit Agreement. We will not consider to be materially prejudicial to holders&#8217; substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges holders are required to pay. In addition, we may not be able to provide holders with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Holders will be bound by the modifications to the Deposit Agreement if they continue to hold ADSs after the modifications to the Deposit Agreement become effective. The Deposit Agreement cannot be amended to prevent holders from withdrawing the ordinary shares represented by their ADSs (except as permitted by law).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We have the right to direct the depositary to terminate the Deposit Agreement. Similarly, the depositary may in certain circumstances on its own initiative terminate the Deposit Agreement. In either case, the depositary must give notice to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">the holders at least 30 days before termination. Until termination, holders&#8217; rights under the Deposit Agreement will be unaffected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until a holder requests the cancellation of such holder&#8217;s ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Books of Depositary</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will maintain ADS holder records at its depositary office. A holder may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Limitations on Obligations and Liabilities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Deposit Agreement limits our obligations and the depositary&#8217;s obligations to holders. Note the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary are obligated only to take the actions specifically stated in the Deposit Agreement without negligence or bad faith.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the Deposit Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to holders on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for the market value of any ordinary shares or the market</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">value of any distribution on any ordinary shares, for any interest on ordinary shares (other than</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">interest actually received by the depositary), for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the Deposit Agreement, for the timeliness of any of our notices or for our failure to give notice.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the Deposit Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary disclaim any liability if we, the custodian or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the Deposit Agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our By-laws, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement or in our By-laws or in any provisions of or governing the securities on deposit.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the Deposit Agreement, made available to holders.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary also disclaim liability for any action or inaction of any clearing or settlement</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">system (and any participant of such system) for the ordinary shares or the ADSs.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the Deposit Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Nothing in the Deposit Agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary bank and holders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">No disclaimer of any Securities Act liability is intended by any provision of the Deposit Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Taxes</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the Custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. A holder will be liable for any deficiency if the sale proceeds do not cover the taxes that are due.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the Custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on holders&#8217; behalf. However, a holder may be required to provide to the depositary and to the Custodian proof of taxpayer status and residence and such other information as the depositary and the Custodian may require to fulfill legal obligations.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A holder is required to indemnify us, the depositary and the Custodian for any claims with respect to taxes based on any tax benefit obtained for such holder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Foreign Currency Conversion</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the Deposit Agreement. A holder may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">distribute the foreign currency to holders for whom the distribution is lawful and practical&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">hold the foreign currency (without liability for interest) for the applicable holders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Governing Law&#47;Waiver of Jury Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Deposit Agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of France.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>nanobiotix-secx20xf2021xex.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2a1c1713445e4a05924e14a0b6170c84_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">EXECUTION VERSION</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BETWEEN</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NANOBIOTIX S.A.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AND</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIANBIO ONCOLOGY LIMITED</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">EXECUTION VERSION</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.679%"><tr><td style="width:1.0%"></td><td style="width:11.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definitions and Usage</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant of License</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercialization and Marketing</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regulatory</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacture and Supply</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality and Pharmacovigilance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Governance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration, Payments and Records</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intellectual Property</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Confidentiality</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Representations, Warranties and Covenants</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disclaimer, Limitation of Liability and Indemnification</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term and Termination</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Article 15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Miscellaneous</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">This License, Development and Commercialization Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) is entered into and effective as of May 11, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), by and between Nanobiotix S.A., a French soci&#233;t&#233; anonyme having its registered office located at 60 Rue de Wattignies, 75012, Paris, France, registered under number 447 521 600 (RCS Paris) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), and LianBio Oncology Limited, a Hong Kong company limited by shares, having its principal place of business located at Room 1902, 19&#47;F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong ( &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Nanobiotix and Lian are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In presence of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">LianBio,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> an exempted company organized and existing under the laws of Cayman Islands having its registered office located at c&#47;o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, Cayman Islands KY1-9009 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">LianBio Cayman</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), who is entering into this Agreement for the purposes of acknowledging and accepting the obligations imposed on it pursuant to Section 15.13 of this Agreement.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Recitals</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, Nanobiotix owns or controls data, know-how and other intellectual property relating to such products&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, Lian is a biotechnology company focused on bringing paradigm-shifting medicines to patients&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, Lian desires to obtain from Nanobiotix certain rights and licenses to develop and commercialize such nanomedicine product in certain Asian countries, and Nanobiotix is willing to supply such product and to grant Lian such rights and licenses in accordance with the terms and conditions of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Nanobiotix and Lian hereby agree as follows&#58;</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_10"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DEFINITIONS AND USAGE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">1.1 &#160;&#160;&#160;&#160;Definitions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Capitalized terms used in this Agreement shall have the meaning ascribed thereto in Schedule 1.1, or, only to the extent not defined in Schedule 1.1, as otherwise defined herein.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">1.2&#160;&#160;&#160;&#160;Headings, Gender and Number.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> All section and article titles or captions contained in this Agreement and in any exhibit, schedule or certificate referred to herein or annexed to this Agreement are for convenience only, shall not be deemed a part of this Agreement and shall not affect the meaning or interpretation of this Agreement. Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and other gender, masculine, feminine, or neuter, as the context requires.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">1.3&#160;&#160;&#160;&#160;References</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Unless explicitly provided for, references to articles, sections, schedules or exhibits are references to articles, sections, schedules or exhibits of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">1.4 &#160;&#160;&#160;&#160;Usage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Unless otherwise indicated to the contrary herein by context or use hereof, (a) words importing the singular shall also include the plural, and vice versa&#59; (b) all references to days in this Agreement shall mean calendar days, unless otherwise specified&#59; (c) the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;but not limited to&#8221; unless expressly stated otherwise&#59; (d) the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and&#47;or&#8221;, unless otherwise specified&#59;  (f) &#8220;monthly&#8221; means on a calendar month basis, (g) &#8220;quarter&#8221; or &#8220;quarterly&#8221; means on a calendar quarter basis&#59; (h) &#8220;annual&#8221; or &#8220;annually&#8221; means on a Calendar Year basis&#59; (i) &#8220;year&#8221; means a 365-day period unless Calendar Year is specified&#59; (j) references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement&#59; (k) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein will be interpreted in a correlative manner&#59; (l) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein)&#59; (m) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Schedules)&#59; (n) neither Party or its Affiliates will be deemed to be acting &#8220;on behalf of&#8221; the other Party under this Agreement, except to the extent expressly otherwise provided&#59; (o) provisions that require </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that a Party, or the JSC hereunder &#8220;agree&#8221;, &#8220;consent&#8221; or &#8220;approve&#8221; or the like will be deemed to require that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging&#59; and (p) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;&#59; (q) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto&#59; and (r) references to particular Applicable Laws mean such Applicable Laws as in effect as of the relevant time, including all rules and regulations thereunder and any successor Applicable Laws in effect as of the relevant time, and including the then-current amendments thereto.</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_13"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">GRANT OF LICENSE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.1 &#160;&#160;&#160;&#160;License Grant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Licensed IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Subject to Section 3.3(b), Nanobiotix hereby grants to Lian, and Lian accepts, an exclusive (even as to Nanobiotix), sublicensable (subject to Section 2.2), royalty-bearing license under the Nanobiotix IP to Develop and Commercialize the Licensed Products in the Field in the Territory, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that Nanobiotix shall be entitled to continue and conclude, directly or indirectly, the following Development for the Licensed Products in the Territory that is on-going as of the Effective Date of the Agreement&#58; (i) the clinical study known as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Rectal PEP503-RC-1001</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, (ii) the clinical study known as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">NBTXR3 301 Study</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; and (iii) the clinical study known as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">HNSCC PEP503-RC-1002</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;. Manufacturing of Licensed Product for the Territory is reserved to Nanobiotix, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that Lian shall label and package the vials of Licensed Product supplied by Nanobiotix as further set out herein and in the Supply Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Non Development. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Parties shall not Develop or Commercialize the Licensed Product outside the Field in the Territory.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Brand Name</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian may Commercialize the Licensed Products under the Nanobiotix Trademarks. If (i) Regulatory Authorities in the Territory require or (ii) Lian elects to market the Licensed Products within the Territory under a separate brand name than the Nanobiotix Trademarks (including a localized version of any Nanobiotix Trademark), then Lian shall provide such alternative brand name for the Licensed Products within the Territory to the JSC for review and approval and any Trademark composed of such alternative brand name shall be filed and owned by Nanobiotix, unless otherwise agreed in writing or set forth in this Section 2.1(c), and shall accordingly become a part of the Nanobiotix Trademarks. Nanobiotix will use Commercially Reasonable Efforts to diligently file and maintain such Trademarks for the Licensed Products within the Territory, at Nanobiotix&#8217;s sole cost and expense, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that Nanobiotix may elect, upon written notice to Lian, to transfer to Lian the responsibility for filing and maintaining such Trademarks in the Territory.  Upon transfer of Nanobiotix&#8217;s responsibility for filing and maintaining Trademarks in the Territory, Nanobiotix will promptly deliver to Lian copies of all necessary files related to such Trademarks and will take all actions and execute all documents reasonably necessary for Lian to assume control of such filing and maintenance.  In addition, at any time prior to First Commercial Sale in the Territory, Nanobiotix may elect to Commercialize the Licensed Products outside the Territory under a Trademark other than the Nanobiotix Trademarks, in which case, Nanobiotix will notify Lian about the change, the new brand name or Trademark shall become part of the Nanobiotix Trademarks, and Lian may Commercialize the Licensed Product under such new brand name or Trademark. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Combination Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Development or Commercialization of a Combination Product in the Field in the Territory is subject to &#91;***&#93;. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.2&#160;&#160;&#160;&#160;Sublicense to Affiliates or Third Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian will have a right to grant sublicenses to Affiliates of Lian, solely as long as they are Affiliates of Lian, and which shall terminate, if and when a sublicensed entity is no longer an Affiliate of Lian. Lian will have a right to grant sublicenses to Third Party subcontractors involved in the Development of the Licensed Products, &#91;***&#93;. Any sublicense or other contractual delegation to a Person other than (a) an Affiliate of Lian or (b) any such Third Party subcontractors involved in the Development of the Licensed Products (i) shall be pursuant to a written agreement that imposes on such Sublicensee obligations that are at least as protective of Nanobiotix&#8217;s rights as the relevant restrictions and limitations set forth in this Agreement, and (ii) &#91;***&#93;, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that any proposed sublicense or other contractual delegation to a Competitor shall be at Nanobiotix&#8217;s sole discretion. For the avoidance of doubt, any Third Party to which Lian delegates substantially all of the Commercialization of Licensed Products in a given country in the Territory shall be deemed a Sublicensee of Lian. Lian shall remain responsible for its Affiliates&#8217; and each Sublicensee&#8217;s compliance with all obligations under this Agreement applicable to such Affiliates or Sublicensees. Upon the termination of this Agreement, any sublicense shall terminate with this Agreement, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that at the written request of any Sublicensee who is (a) &#91;***&#93; and (b) &#91;***&#93;, Nanobiotix agrees to negotiate in good faith &#91;***&#93; a direct license agreement with such Sublicensee, &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.3&#160;&#160;&#160;&#160;No Implied Licenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. No rights or licenses, other than as expressly set forth in this Agreement, are granted to either Party under this Agreement, and no additional rights will be deemed granted to either Party by implication, estoppel, or otherwise. All rights not expressly granted by either Party, or its Affiliates to the other Party under this Agreement are reserved. Nanobiotix retains the right to directly or indirectly Develop, Manufacture and otherwise Commercialize the Licensed Products anywhere in the world excluding the Territory.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.4 &#160;&#160;&#160;&#160;Transfer of Nanobiotix Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  Promptly as reasonably practicable after the Effective Date, Nanobiotix will disclose and make available to Licensee the Nanobiotix Know-How that exists as of the Effective Date that is necessary or reasonably useful for Lian&#8217;s Development or Commercialization of the Licensed Product in accordance with this Agreement.  Nanobiotix may make such Nanobiotix Know-How available in such reasonable form as Nanobiotix determines, including, if Nanobiotix so elects, in the form such Nanobiotix Know-How is maintained by Nanobiotix.  In addition, Nanobiotix will provide updates throughout the Term to Lian of any Know-How that Nanobiotix or its Affiliates comes to Control that constitutes Nanobiotix Know-How (such updates to be made reasonably promptly after any calendar quarter in which such Know-How comes into Control of Nanobiotix or its Affiliates), and Nanobiotix will (a) promptly after Lian&#8217;s request, make available to Lian all such Know-How in Nanobiotix&#8217;s Control and not previously provided to Lian hereunder, and (b) for a period of &#91;***&#93; months after the initial Nanobiotix Know-How transfer, provide Lian with reasonable access to Nanobiotix personnel involved in the Development of such Licensed Product, either in-person at Nanobiotix&#8217;s facility or by teleconference&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that such support will not exceed &#91;***&#93;, unless the Parties otherwise agree.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.5&#160;&#160;&#160;&#160;Exclusivity.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Generally</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Subject to the terms of this Agreement, neither Nanobiotix or its Affiliates, nor Lian or any of its Affiliates will (by itself or with or through an Affiliate, a Sublicensee or a Third Party) Develop, Manufacture, or otherwise Commercialize any Competing Product in the Field in the Territory. Lian shall not Develop or Commercialize a Licensed Product other than licensed hereunder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) &#91;***&#93;.</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_16"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 3</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DEVELOPMENT</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.1&#160;&#160;&#160;&#160;Development Plans</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Territory-Specific Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian (directly, or through its Affiliates, Sublicensees, and Third Party subcontractors) shall use Commercially Reasonable Efforts to Develop the Licensed Product in the Field in the Territory. Lian will conduct the Development for the Licensed Product in the Field in the Territory in accordance with a development and regulatory plan and regulatory strategy for Development and Regulatory Approval of the Licensed Products solely in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Territory-Specific Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, as set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">). Lian will update the Territory-Specific Development Plan not less than once per Calendar Year, and either Party may propose modifications to the Territory-Specific Development Plan at any time, subject in each case to approval by the JSC.  Once approved by the JSC, each update to the Territory-Specific Development Plan will become effective and supersede the then-current Territory-Specific Development Plan.  In the event of any proposed change to the Territory-Specific Development Plan as a result of any interaction with any Regulatory Authority, the JSC will meet as promptly as practicable to review and discuss any such proposed changes and determine an appropriate revision (if any) to the Territory-Specific Development Plan.  If Lian is delayed in performing (or fails to perform) an obligation assigned to Lian in the Territory-Specific Development Plan as a result of Nanobiotix&#8217;s failure to timely perform any of its obligations under this Agreement, then the timelines for the performance of Lian&#8217;s obligations under the Territory-Specific Development Plan will be extended commensurate with the delay caused by Nanobiotix. Except as expressly provided for otherwise herein, each Party will be responsible for its costs and expenses incurred in performing Development activities pursuant to the Territory-Specific Development Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix&#8217;s global Development of the Licensed Product outside of the Territory will be conducted pursuant to a written plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).  Prior to the first Phase III Trial for any Licensed Product, Nanobiotix will provide the initial Global Development Plan to the JSC for its review, discussion, and &#91;***&#93; regarding activities to be conducted in the Territory, approval. The Global Development Plan will include an outline of all major Development activities for the Licensed Product to be conducted throughout the world by Nanobiotix. From time to time, Nanobiotix may propose updates to the then-current Global Development Plan for the Licensed Products, to the JSC to review and discuss and &#91;***&#93; regarding activities to be conducted in the Territory, approval. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Development Plan Undertaking. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;. If the NMPA provides guidance that the Licensed Product will be classified as a drug, then Lian shall participate in the global registrational Phase III Trials conducted by Nanobiotix pursuant to the Global Development Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Trials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Subject further to NMPA&#8217;s acceptance of Lian&#8217;s or its Affiliate&#8217;s participation in the Global Trial for the following Indications, Lian undertakes to have&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) enrolled at least &#91;***&#93; of the total number of patients (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Enrollment Commitment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) in the following Global Trials, provided that such Global Trial may serve as a registrational study in the Territory&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:77.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:25.05pt">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">HNSCC 312 registration trial starting Q3 2021, n&#61; 500</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:77.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:25.05pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">, n &#126;300 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;&#8221;&#59; </font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:25.62pt">the following three Global Trials (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Additional Global Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;)&#58; (1) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Ph III (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, (2) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; and (3) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> PhIII (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; (each, as listed on page 2 of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> attached hereto)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that one or more of the foregoing three such Additional Global Trials may be substituted with one or more of the following Global Trials by decision of the JSC&#58; (I) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> (Ph III - n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, (II) &#8220;&#91;***&#93; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">III (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, (III) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> - Ph III (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;, (IV) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> Ph III (n &#8776; 500*)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; or (V) &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> - Ph III (n&#61; 500) - </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;&#8221;&#47;&#8221;&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> - Ph III (n&#61; 300) -</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;&#8221; (each, as listed on page 3 of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> attached hereto)&#59;</font></div><div style="text-align:justify;text-indent:131.38pt"><font><br></font></div><div style="text-align:justify;text-indent:131.39pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that, in each case, patient enrollment will be performed on an open and competitive recruitment basis, where (A) patients will be enrolled on a first-presented, first-enrolled basis among all trial centers, (B) to the extent Lian has not met the Enrollment Commitment by the time the full complement of the study population has been reached globally, Lian shall pay to Nanobiotix the difference between Nanobiotix&#8217;s costs for the trial and Nanobiotix&#8217;s costs for such trial had Lian fulfilled the Enrollment Commitment,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) &#91;***&#93;&#58; </font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(A) &#91;***&#93;, and </font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(B) &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development Plan Incentive.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> For each Global Trial (excluding &#91;***&#93;) meeting the Enrollment Commitment, the Royalty Rates shall be reduced by &#91;***&#93;, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> in no event will the applicable Royalty Rate be less than &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development Plan Incentive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.2 &#160;&#160;&#160;&#160;Local Studies.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Non-registrational Studies.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> For any non-registrational Clinical Trial (e.g., a Phase I Trial or Phase II Trial) conducted by Lian that is intended to support the Development or Regulatory Approval of the Licensed Product in the Field in the Territory, Lian will provide Nanobiotix with access, and license and right of reference, to all clinical data and Regulatory Filings relating to such non-registrational Clinical Trial for use outside the Territory.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Local Registrational Studies.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> In the event that Lian intends to conduct a Pivotal Trial for the Licensed Product in the Field in the Territory (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Local Registrational Study</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), Lian will notify Nanobiotix reasonably in advance of the initiation of such Local Registrational Study and provide Nanobiotix with the study design, study protocol, study budget, and anticipated study initiation date (such notice, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Local Registrational Study Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Upon Nanobiotix&#8217;s receipt of a Local Registrational Study Notice, Nanobiotix will have the option to obtain a license and right of reference to the Local Registrational Study efficacy data and Regulatory Filings and Regulatory Approvals containing such Local Registrational Study data (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Territory-Specific Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) for use in Developing, Manufacturing, and Commercializing the Licensed Products outside the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Territory-Specific Data Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;)&#58; </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) by exercising the Territory-Specific Data Option prior to the anticipated study initiation date, subject to Nanobiotix agreeing to be responsible for &#91;***&#93; of the study costs for such Local Registrational Study incurred by or on behalf of Lian for such Local Registrational Study&#59; or</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) by exercising the Territory-Specific Data Option after the anticipated study initiation date, subject to Nanobiotix agreeing to be responsible for &#91;***&#93; of the study costs incurred by or on behalf of Lian for such Local Registrational Study (in which case Lian will provide to Nanobiotix a summary of the results of such Territory-Specific Data reasonably requested by Nanobiotix to help Nanobiotix determine whether or not it wants to exercise the option).</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">            Notwithstanding anything to the contrary set forth in this Agreement, Lian shall provide to Nanobiotix at no cost the safety data resulting from any Local Registrational Study, which Nanobiotix may use as it deems required.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.3&#160;&#160;&#160;&#160;Global Studies.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Non-registrational Studies.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> For any non-registrational Clinical Trial (e.g., a Phase I Trial or Phase II Trial) conducted by Nanobiotix that is intended to support the Development or Regulatory Approval of the Licensed Product in the Field outside of the Territory, Nanobiotix will provide Lian with access, and license and right of reference, to all clinical data and Regulatory Filings relating to such non-registrational clinical Trial for use in the Territory.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Global Registrational Studies. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Without prejudice to Section 3.1(c) Nanobiotix will notify Lian reasonably in advance of the initiation of a Pivotal Trial for the Licensed Product (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Registrational Study</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) and may propose to Lian to participate in any such Global Registrational Study (such notice, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Registrational Study Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Upon Lian&#8217;s receipt of a Global Registrational Study Notice, Lian will have the option to obtain a license and right of reference to the Global Registrational Study efficacy data and Regulatory Filings and Regulatory Approvals containing such Global Registrational Study data (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Registrational Study Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) for use in Developing and Commercializing the Licensed Products in the Field and in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Registrational Study Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), subject to using Lian Commercially Reasonable Efforts to enroll study patients in the Territory equal to a minimum of &#91;***&#93; of the total study patients in such Global Registrational Study, but in any event no more than&#91;***&#93; patients in total per trial (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Registrational Study Commitment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Lian may exercise the Global Registrational Study Option&#58;</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) prior to the anticipated study initiation date, in which case if Lian fails to meet the Global Registrational Study Commitment, then Lian will reimburse Nanobiotix &#91;***&#93;&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) after the anticipated study initiation date, in which case Lian agrees to be responsible for &#91;***&#93; of the total costs incurred by Nanobiotix to conduct such Global Registrational Study in which Lian did not participate. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Parties shall discuss and agree in good faith any Post-Approval Commitment mandated by a Regulatory Authority upon the Regulatory Approval of the Licensed Product in the Territory, including the inclusion of such mandated Post-Approval Commitment in a Global Registrational Study. Notwithstanding anything to the contrary set forth in this Agreement, Nanobiotix shall provide to Lian at no cost the safety data resulting from any Global Registrational Study, which Lian may use as it deems required.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.4 &#160;&#160;&#160;&#160;Study Cost Reimbursement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  In the event that (a) Nanobiotix exercises any Territory-Specific Data Option pursuant to Section 3.2(b) or (b) Lian exercises any Global Registrational Study Option after the anticipated study initiation date pursuant to Section 3.3(b)(ii), then, in each case ((a) and (b)), following the exercise of the applicable option, within &#91;***&#93; days following the conclusion of each calendar quarter during which Lian performs any activities in support of the applicable Local Registrational Study or Nanobiotix performs any activities in support of the applicable Global Registrational Study, the performing Party will provide to the other Party a written report of all costs and expenses incurred by or on behalf of such Party during the applicable calendar quarter, or, to the extent the applicable option is being exercised after the applicable study has already been commenced or terminated, also of all costs incurred before such calendar quarter, together with an invoice for the applicable percentage (pursuant to Section 3.2(b), if Lian is the performing Party, or Section 3.1(c)(i) or 3.3(b)(ii), if Nanobiotix is the performing Party) of such costs and expenses, and the other Party will pay the undisputed invoiced amounts within &#91;***&#93; days after the date of such invoice. Payments due by Lian according to Section 3.1(c)(i) or 3.2(b)(i) shall be invoiced by Nanobiotix after the completion of the respective Global Trial and Lian will pay the undisputed invoiced amounts within &#91;***&#93; days after the date of such invoice.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.5 &#160;&#160;&#160;&#160;Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall conduct, and shall ensure that all of its Affiliates, Sublicensees, and other Third Party subcontractors conduct, Development of the Licensed Product in the Field in the Territory in compliance with Applicable Laws and, with respect to any such Development activities conducted as part of a Global Trial or as part of a Local Registrational Study for which Nanobiotix has exercised the Territory-Specific Data Option pursuant to Section 3.2(b)(i), in compliance with applicable FDA and EU Medical Device requirements to the extent necessary for the submission of data generated from such activities in Regulatory Filings.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 4</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">COMMERCIALIZATION AND MARKETING</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.1 &#160;&#160;&#160;&#160;Commercialization of the Licensed Product in the Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Unless explicitly provided for differently elsewhere in this Agreement, Lian shall have sole control over and decision-making authority with respect to the Commercialization of the Licensed Product in the Field in the Territory, including marketing, strategy, pricing, promotion, physician targeting, reimbursement, branding, distribution, and sales. All costs and expenses of Commercialization, including for distribution, marketing and selling, of the Licensed Product in the Field in the Territory shall be for Lian&#8217;s account.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.2 &#160;&#160;&#160;&#160;Lian&#8217;s Commercialization Diligence</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall use Commercially Reasonable Efforts to Commercialize the Licensed Product in the Field in the Territory.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.3 &#160;&#160;&#160;&#160;Commercialization Coordination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. No later than &#91;***&#93; months before the expected Launch Date Lian shall prepare and submit to the JSC a written plan for the Commercialization of Licensed Products in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), which shall include reasonable detail regarding the activities Lian expects to undertake &#91;***&#93; period immediately following receipt of the first Regulatory Approval in the Territory, including&#58; (i) &#91;***&#93;&#59; (iii) &#91;***&#93;&#59; (iv) &#91;***&#93;&#59; and (v) &#91;***&#93;. The Commercialization Plan shall be updated &#91;***&#93;. The Parties shall discuss, through the JSC, the Commercialization Plan (including the timing of Launch the Licensed Product in the countries in the Territory).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Commercial Updates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall provide to the JSC at each of its regularly-scheduled meetings a written summary of material Commercialization activities conducted during the applicable period in the Field in the Territory (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization Updates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Commercialization Records</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. In connection with its Commercialization of the Licensed Product in the Field in the Territory pursuant to the Commercialization Plan, Lian shall retain, for a period of &#91;***&#93; from the date of creation, any and all training records related to the Licensed Products.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.4 &#160;&#160;&#160;&#160;Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall conduct, and shall ensure that all of its Affiliates, Sublicensees and other Third Party subcontractors conduct, all Commercialization of the Licensed Product in the Field in the Territory in compliance with Applicable Laws and all ethics policies agreed upon by the Parties in good faith. Lian shall make all related disclosures with respect to and record all transfers of value to health care providers in the Territory to the extent required by Applicable Laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.5 &#160;&#160;&#160;&#160;Medical Affairs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall provide medical and scientific support for the Licensed Product in the Field in the Territory in order to ensure physicians are familiar on how to inject the product. Lian shall, subject to Applicable Laws, conduct such activities in compliance with its internal policies on engaging and sponsoring healthcare providers.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.6 &#160;&#160;&#160;&#160;Promotional Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall have the right to develop all written, printed, electronic or graphic material intended for use by sales representatives in promoting the Licensed Product in the Field in the Territory, including visual aids, file cards, premium items, clinical study reports, reprints, drug information updates, and any other promotional support items (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Promotional Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that (a) all Promotional Materials shall comply with Applicable Laws&#59; (b) Lian shall provide the JSC with an annual summary of its planned promotional activities for the Licensed Product, together with digital copies of material newly-generated material (as determined by Lian in good faith) Promotional Materials that Lian intends to use, in the upcoming &#91;***&#93; in the Field in the Territory. In addition, Lian shall provide to Nanobiotix an English translation of those selected Promotional Materials reasonably requested by Nanobiotix for its review and, as applicable, discussion with Lian&#59; (c) all Promotional Materials shall be consistent with the Core Dossier for the Licensed Product&#59; and (d) &#91;***&#93;. Prior to Launch, Nanobiotix shall provide Lian, at Nanobiotix&#8217;s cost and expense, existing marketing and Promotional Materials Controlled by Nanobiotix (including website and digital content) regarding the Licensed Product, whether electronic (including source code thereof, if applicable) or physical copies, provided that Nanobiotix shall have no obligations under this Agreement to assist with the technical aspects of the creation and maintenance of such website or to provide such digital content in any particular format.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">4.7&#160;&#160;&#160;&#160;Territory Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall not, and shall ensure its Affiliates and Sublicensees do not, directly or indirectly&#58; (i) promote, sell or distribute the Licensed Product outside the Field in the Territory, or (ii) actively promote, sell or distribute the Licensed Product for any use outside the Territory, which other territories are exclusively reserved to Nanobiotix, its Affiliates or its licensees. Nanobiotix shall not, and shall ensure its Affiliates and Sublicensees (other than Lian) do not, directly or indirectly, actively promote, sell or distribute the Licensed Product for any use within the Territory (other than to Lian, its Affiliates, Sublicensees or other designees). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 5</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">REGULATORY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">5.1 &#160;&#160;&#160;&#160;Regulatory Interaction. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) Lian, or its relevant Affiliates or Sublicensees, will be solely responsible for all communications, filings with, and approvals sought from the Regulatory Authorities to obtain all Marketing Authorizations in relation to the Licensed Product in the Field throughout the Territory, and will have the sole and exclusive right to file and hold all Regulatory Filings in the Field in the Territory, and all such Regulatory Filings and Regulatory Approvals in the Field in the Territory will be made in the name of Lian, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, that, &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Regulatory Communications</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Subject to Applicable Law and this Section 5.1, Lian will oversee, monitor, and manage all interactions and communications with Regulatory Authorities with respect to the Licensed Products in the Field in the Territory.  Unless explicitly provided for differently elsewhere in this Agreement, Lian will have final decision-making authority regarding all regulatory activities for the Licensed Products in the Field in the Territory, including the labeling strategy and the content of Regulatory Filings for Licensed Products. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">5.2 &#160;&#160;&#160;&#160;Global Dossier</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. As between the Parties and notwithstanding anything to the contrary provided in this Agreement, Nanobiotix shall retain the full unfettered ownership of the Core Dossier. </font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 6</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">MANUFACTURE AND SUPPLY</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">6.1 Supply and Purchase of the Licensed Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Responsibility for Manufacturing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall be responsible for Manufacturing the Licensed Product. &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Effects of Supply Failure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Should Nanobiotix, at any time following a Change of Control of Nanobiotix, fail to supply at least &#91;***&#93; of the binding forecast of Lian&#8217;s requirements of Licensed Products for a given &#91;***&#93;, then Lian may request the appointment of a Third Party contract manufacturer mutually agreeable to both Parties (such agreement not to be unreasonably withheld by Nanobiotix), who shall Manufacture Licensed Products for priority supply to Lian. Nanobiotix will provide (or cause its designee to provide) to such Third Party all Know-How and transition services necessary to enable such Third Party to Manufacture clinical and commercial supplies of the Licensed Product.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Development and Commercial Supply</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall supply to Lian, and Lian shall exclusively purchase from Nanobiotix, all requirements of Licensed Product for Development and Commercialization by Lian in the Territory. Within &#91;***&#93; days following the Effective Date, the Parties will negotiate in good faith and enter into a supply agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) on reasonable and customary terms, which shall at the minimum contain the following terms&#58; </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) Nanobiotix shall supply Licensed Product in unlabeled vials to Lian, or such other form as the Parties may agree as appropriate for use for Development purposes&#59;</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) Lian shall provide non-binding and binding forecasts on a rolling basis&#59;</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(iii) &#91;***&#93;&#59; </font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(iv) &#91;***&#93;&#59; </font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(v) &#91;***&#93;&#59; and</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(vi) &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">6.2 &#160;&#160;&#160;&#160;Interim Supply</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Until such time as Nanobiotix and Lian execute a Supply Agreement, at Lian&#8217;s request, Nanobiotix will, on Lian&#8217;s behalf, place orders with its suppliers for Licensed Products for use by Lian for Development purposes, &#91;***&#93;.  After delivery, Nanobiotix will invoice Lian for the Transfer Price for such Licensed Product and Lian will pay Nanobiotix within &#91;***&#93; days after receipt of such invoice.  Nanobiotix will provide all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Licensed Products provided pursuant to this Section 6.2 with those product warranties and corresponding remedies that Nanobiotix receives from its supplier.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">6.3 &#160;&#160;&#160;&#160;Two-Invoice Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Parties agree that in the event, under the Two-Invoice Policy and tendering policies and Applicable Laws in a given province in the PRC, neither Lian nor any of its Affiliates can, based on their existing qualifications, distribute the Licensed Products for such province directly or indirectly to its distributors for the PRC, then, the Parties will use reasonable efforts to discuss in good faith alternative arrangements for the distribution of the Licensed Product in such province that complies with the Two-Invoice Policy as implemented in such province and that maintains the economic interests of the Parties as agreed under this Agreement.</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_28"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 7</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">QUALITY AND PHARMACOVIGILANCE</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">7.1&#160;&#160;&#160;&#160; Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Parties shall negotiate in good faith and, no later than &#91;***&#93; days after the Effective Date (and in any event prior to the commencement of the supply of Licensed Products to Lian for Development purposes), enter into a quality agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) to comply with the requirements of Regulatory Authorities in the Territory affecting each Party, and, to the extent necessary, each country within the Territory hereunder, as soon as possible. The Quality Agreement shall set forth in detail the quality assurance arrangements and procedures with respect to the Manufacturing and supply of the Licensed Product, reporting customer complaints, conducting timely investigations, Recalls, logistics (including warehousing and shipping requirements) and testing requirements, which Quality Agreement shall be incorporated herein by reference following execution by both Parties. In the event of a conflict between any of the provisions of this Agreement or the Supply Agreement and the Quality Agreement, this Agreement or the Supply Agreement, as applicable, shall govern. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">7.2 &#160;&#160;&#160;&#160;Record Retention.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Lian shall establish and maintain a written records retention policy with respect to the Licensed Products, including maintaining quality system documents in a central, controlled location and using reasonable efforts to prevent any loss, destruction, deterioration or unauthorized access to such documents. Lian shall, for a period of the Term and &#91;***&#93; years thereafter (or such longer period as required by Applicable Laws) retain original documents with original signatures in a central file within Lian&#8217;s quality assurance or document control records.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">7.3&#160;&#160;&#160;&#160;Pharmacovigilance&#59; Safety Data</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Pharmacovigilance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Upon execution of the Agreement, the Parties shall negotiate in good faith and, no later than &#91;***&#93; after the Effective Date, enter into a pharmacovigilance agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) to comply with the requirements of Regulatory Authorities in the Territory affecting each Party, and, to the extent necessary, each country within the Territory hereunder, as soon as possible. The Pharmacovigilance Agreement shall set forth the specific details and processes pursuant to which the Parties shall share adverse event, device incident and other safety data.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Global Safety Database</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall maintain the global reference safety database for the Licensed Product. The Pharmacovigilance Agreement will set forth the terms and conditions under which the Parties will share information pertaining to, and each will receive access to, the global reference safety database for the Licensed Product. Lian shall be responsible for safety review (as further described in the Pharmacovigilance Agreement), collection and timely transfer to Nanobiotix of safety data for the Licensed Product in the Field in the Territory. Lian shall transfer such safety data to Nanobiotix in a timely manner according to the Applicable Laws in an electronic format requested by Nanobiotix as further set out in the Pharmacovigilance Agreement, at Lian&#8217;s sole cost and expense. Lian shall not be responsible for any costs associated with the global reference safety database.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">7.4&#160;&#160;&#160;&#160;Complaints Handling and Reporting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Notifications, communications, handling and reporting of the Licensed Product complaints and adverse events shall be addressed under the Pharmacovigilance Agreement, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that such Pharmacovigilance Agreement shall provide that Lian must (i) investigate any complaints or issues relating to the Licensed Products in the Territory and notify Nanobiotix thereof&#59; (ii) not admit liability or settle any dispute or complaint that imposes any liability on or admits any fault of Nanobiotix without Nanobiotix&#8217;s prior written consent&#59; and (iii) &#91;***&#93;.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">7.5&#160;&#160;&#160;&#160;Returns and Recalls</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Returns</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall handle all returns in the Territory, at its sole cost and expense, as needed. Further processing of returns by Lian shall be governed by the Quality Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Recalls</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party agrees to notify the other Party within &#91;***&#93; hours if it discovers any issue that it reasonably believes could lead to a Recall. If practicable, the Parties shall promptly, following notification, discuss the plans for a Recall, provided that the Parties shall have joint responsibility for determining whether a Recall in the Territory is necessary. If the Parties, through the JSC, decide that a Recall is necessary, then the Parties shall work together to develop and implement a Recall plan, which, unless agreed otherwise, shall be implemented by Lian. All costs and expenses associated with implementing a Recall in the Territory shall be borne by Lian, except to the extent it arises from Nanobiotix&#8217;s (a) &#91;***&#93; (b) &#91;***&#93;. The Parties shall jointly determine the cause of a Recall, or in the event of disagreement between the Parties regarding such cause, an independent laboratory agreed upon by the Parties shall determine such cause. </font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_31"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 8</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">GOVERNANCE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.1&#160;&#160;&#160;&#160;Joint Steering Committee.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> &#91;***&#93; following the Effective Date &#91;***&#93;, a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">JSC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.2&#160;&#160;&#160;&#160;Specific Responsibilities.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> The JSC will provide strategic oversight and serve as forum for communication on the Licensed Product in the Territory, and will&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) monitor the overall state of the alliance&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) discuss the progress of Lian&#8217;s and Nanobiotix&#8217;s Development and Commercialization activities, including, optimal Launch timing and the value of the clinical benefit provided by the Licensed Product in each Indication and to the extent permitted under Applicable Law, to discuss the prices of the Licensed Product in the Territory&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) review and discuss the Territory-Specific Development Plan, the Global Trials, and any Global Registrational Study&#59; </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) review and discuss any additional Indications for any Licensed Product to be Developed and Commercialized&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) review, discuss, and approve any Territory-specific brand name for the Licensed Product, as described in Section 2.1(c)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(f) review, discuss, and approve any update to the Territory-Specific Development Plan, as described in Section 3.1(a)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(g) review, discuss, and, to the extent relating to any activities to be conducted in the Territory, approve the initial Global Development Plan or any update thereto, as described in Section 3.1(b)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(h) determine whether to substitute any Global Trial as an Additional Global Trial, as described in Section 3.1(c)(i)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) review and discuss the initial Commercialization Plan, and any updates thereto, as described in Section 4.3(a)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(j) review and discuss the Commercialization Updates, as described in Section 4.3(b)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(k) review and discuss the annual promotional activities summary for the Territory, as described in Section 4.6&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(l) determine whether to conduct any Recall for the Territory, as described in Section 7.5(b)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(m) perform such other functions as are assigned to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent agreed to in writing by the Parties&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(n) review and discuss any amendment or modification to the Licensed Products as described in Section 10.4&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(o) review and discuss medical affairs, as described in Section 4.5&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(p) perform such other functions expressly allocated to the JSC in this Agreement or by the written agreement of the Parties.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.3&#160;&#160;&#160;&#160;Membership</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The JSC will be composed of a total of &#91;***&#93; representatives of each Party, which will be appointed by each of Nanobiotix and Lian, respectively, including at least one (1) senior leadership member for each Party. Each individual appointed by a Party as a representative to the JSC will be an employee of such Party with sufficient seniority and decision-making authority within the applicable Party to provide meaningful input and make decisions arising within the scope of the JSC&#8217;s responsibilities, and have knowledge and expertise in the Development and Commercialization of products similar to the Licensed Products under this Agreement.  The JSC may change its size from time to time by consent of its members, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that the JSC will consist at all times of an equal number of representatives of each Party, unless otherwise agreed by the Parties in writing.  Each Party may replace any of its JSC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party&#8217;s co-chairperson. The JSC will be co-chaired by one designated representative of each Party. The co-chairperson of the JSC will cast its Party&#8217;s vote on the JSC and such designee will have the authority to make decisions on behalf of such Party. Each co-chairperson will alternate being responsible for each meeting for (a) calling and conducting meetings, (b) preparing and circulating an agenda in advance of each meeting&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, that the applicable co-chairperson will include any agenda items proposed by either Party on such agenda, (c) preparing minutes of each meeting that reflect the material decisions made and action items identified at such meetings promptly thereafter, and (d) sending draft meeting minutes to each member of the JSC for review and approval within &#91;***&#93; days after each JSC meeting.  Meeting minutes issued in accordance with clause (d) of this Section 8.3 will be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within &#91;***&#93; Business Days of receipt. The Alliance Managers will work with the chairpersons to prepare and circulate agendas and to ensure the preparation and approval of minutes.  Each JSC representative will be subject to confidentiality obligations no less stringent than those in Article 11.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.4 &#160;&#160;&#160;&#160;Meetings&#59; Reports</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The JSC will hold meetings at least &#91;***&#93; during the Term for so long as the JSC exists, unless the Parties agree in writing to a different frequency.  No later than &#91;***&#93; Business Days prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the applicable co-chairperson will prepare and circulate an agenda for such meeting. Either Party may also call a special meeting of the JSC by providing at least &#91;***&#93; Business Days prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the applicable co-chairperson of the JSC and the Alliance Managers to provide the members of the JSC no later than &#91;***&#93; Business Days prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered.  The JSC may meet in person or by audio or video conference as its representatives may agree, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that at least &#91;***&#93; JSC meeting per &#91;***&#93; shall be held in person, unless the Parties agree otherwise in writing. Other representatives of the Parties, their Affiliates, or Third Parties involved in the Development, Manufacture, or Commercialization of Licensed Products may be invited by the members of the JSC to attend meetings as non-voting observers if such representatives are subject to confidentiality obligations no less stringent than those set forth in Article 11. No action taken at a meeting will be effective unless at least &#91;***&#93; of each Party&#91;***&#93; is present or participating. Neither Party will unreasonably withhold attendance of at least &#91;***&#93; of such Party at any meeting of the JSC for which reasonable advance notice was provided. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.5&#160;&#160;&#160;&#160;Dispute Resolution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Any disputes among representatives at the JSC will be resolved by escalation to appropriate senior officers of Lian and Nanobiotix (the &#8220;Senior Officers&#8221;). To the extent the Senior Officers cannot reach agreement on the matter at hand within &#91;***&#93; days, then, without prejudice to any contractual obligations or commitment set out herein, which remain unaffected, Lian will have final decision-making authority over&#58; (i) &#91;***&#93;, and (ii) &#91;***&#93;, provided that, with respect to sub-clause (ii) only, for any matter that (A) &#91;***&#93;, (B) &#91;***&#93;, (C) &#91;***&#93; or (D) &#91;***&#93;. For the avoidance of doubt, Nanobiotix at all times has the final decision-making authority over all matters relating to &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">8.6&#160;&#160;&#160;&#160;Alliance Managers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  Each Party will appoint a person to oversee interactions between the Parties for all matters related to the Development and Commercialization of Licensed Products between meetings of the JSC (each, an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Alliance Manager</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).  If the Alliance Manager is not an appointed member of the JSC, then the Alliance Managers will have the right to attend all meetings of the JSC and may bring to the attention of the JSC any matters or issues either Alliance Manager reasonably believes should be discussed and will have such other responsibilities as the Parties may agree in writing.  Each Party may replace its Alliance Manager at any time or may designate different Alliance Managers with respect to Development and Commercialization matters, respectively, by notice in writing to the other Party. The Alliance Managers will have the responsibility of creating and maintaining a constructive work environment within the JSC and between the Parties for all matters related to this Agreement. Without limiting the generality of the foregoing, each Alliance Manager will&#58; (a) provide a single point of communication within the Parties&#8217; respective organizations and between the Parties with respect to this Agreement&#59; (b) coordinate cooperative efforts, internal communications and external communications between the Parties with respect to this Agreement&#59; and (c) take such other steps as may be required to ensure that meetings of the JSC occur as set forth in this Agreement, that procedures are followed with respect to such meetings (including working with the co-chairpersons </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">with respect to the giving of proper notice and the preparation and approval of minutes) and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed.</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_34"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 9</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CONSIDERATION, PAYMENTS AND RECORDS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;In consideration of the rights and licenses granted to Lian by Nanobiotix hereunder, Lian shall pay to Nanobiotix (in USD) the amounts set forth in this Article 9.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.2 &#160;&#160;&#160;&#160;Upfront Payment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Subject to the terms and conditions of this Agreement, Lian will pay Nanobiotix a payment in the amount of twenty million Dollars ($20,000,000), which upfront payment will be due and payable to Nanobiotix within &#91;***&#93; days following the Effective Date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.3&#160;&#160;&#160;&#160;Development Milestone Payments.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> During the Term, upon the achievement by or on behalf of Lian or its Affiliates or Sublicensees of any milestone event set forth in Table 9.3 for the Licensed Product, Lian will notify Nanobiotix promptly after the occurrence thereof, and Lian will pay Nanobiotix the corresponding milestone payment set forth in Table 9.3 no later than &#91;***&#93; days after its achievement of such milestone event.  </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Table 9.3 &#8211; Development Milestones</font></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20.1pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development Milestone Event</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development Milestone Payment (in USD)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.4&#160;&#160;&#160;&#160;Sales Milestones</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. During the Term, upon the achievement of any milestone event set forth in Table 9.4 (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sales Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), Lian will notify Nanobiotix within &#91;***&#93; days after &#91;***&#93; in which such Sales Milestone Event was achieved, and Lian will pay Nanobiotix the corresponding milestone payment set forth in Table 9.4, no later than &#91;***&#93; days after &#91;***&#93; (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).  Each of the Sales Milestone Payments set forth in Table 9.4  is payable only upon the first achievement of such Sales Milestone Event and none of the Sales Milestone Payments will be payable more than once regardless of how many times such Sales Milestone Event is achieved.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#bdd6ee;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Table 9.4 &#8211; Sales Milestones</font></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20.1pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sales Milestone Event</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sales Milestone Payment (in USD)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">6. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Total</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.5&#160;&#160;&#160;&#160;Sales Royalties. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Subject to the terms and conditions of this Agreement and any applicable Development Plan Incentive, during the applicable Royalty Term, Lian will pay Nanobiotix a tiered royalty on the Net Sales of all Licensed Products in the Territory that is the product of the aggregate annual Net Sales of all Licensed Products in the Territory and the applicable royalty rate in the following table (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Royalty Rates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), subject to the provisions of Section 9.6&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:20.1pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Portion of the Annual Net Sales of the Licensed Products in the Territory</font></td><td colspan="3" style="background-color:#bdd6ee;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3. &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4. &#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.6&#160;&#160;&#160;&#160;Reductions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Expiration of Valid Claims and Generic Entry</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. On a Licensed Product-by-Licensed Product and country-by-country basis, if at any time during the Royalty Term in a given country in the Territory, there is no Valid Claim of a Nanobiotix Patent &#91;***&#93;, then the applicable Royalty Rate in effect for such Licensed Product in such country shall be reduced by &#91;***&#93; for the remainder of the Royalty Term for such Licensed Product in such country.  If one or more Competitor(s) launch(es) a Competing Product in a country in the Territory, resulting in a decrease in Lian&#8217;s revenue from the Licensed Product of &#91;***&#93; in such country, then the applicable Royalty Rate in effect for such Licensed Product in such country shall be reduced by &#91;***&#93; for the remainder of the Royalty Term for such Licensed Product in such country, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that the maximum allowable reduction for a given Licensed Product and a given country in the Territory under this Section 9.6(a) will be &#91;***&#93; of the applicable Royalty Rate for such Licensed Product in such country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Third Party Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. If Lian makes a payment under any agreement with a Third Party pursuant to which Lian obtains a license or other rights under Patent(s) (or Patent(s) and Know-How associated with such Patents) owned or controlled by such Third Party in a given country in the Territory (whether by acquisition or license) that is necessary or reasonably useful to Develop or Commercialize one or more Licensed Products in such country, then Lian may offset against the sales milestones (Section 9.4) and sales royalties (Section 9.5) payable to Nanobiotix an amount equal to &#91;***&#93; of the payments made by Lian to such Third Party under such agreement (including any upfront payments, milestone payments, and royalties), subject to &#91;***&#93;, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">that, to the extent the foregoing limitation limits the reduction Lian is permitted to take during &#91;***&#93;, Lian will be entitled to carry forward the amount of the reduction Lian was unable to take during such calendar quarter and apply such amounts to future royalties or milestone payments (reductions set forth in this Section 9.6 are referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Reductions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.7 &#160;&#160;&#160;&#160;Royalty Term.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> On a Licensed Product-by-Licensed Product and country-by- country basis, Lian&#8217;s obligation to pay sales royalties will commence on the date of First Commercial Sale of such Licensed Product in the Field in such country in the Territory and will expire on the latest to occur of (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Royalty Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) the expiration of the last-to-expire Valid Claim of a Nanobiotix Patent Covering such Licensed Product&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) the expiry of Regulatory Exclusivity in such country in the Territory&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) the ten (10)-year anniversary of the First Commercial Sale of such Licensed Product in such country in the Territory&#59; </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.8&#160;&#160;&#160;&#160;Royalty Payments and Reports</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  Within &#91;***&#93; days following the end of each calendar quarter following the First Commercial Sale of a Licensed Product, Lian shall furnish to Nanobiotix a written report for the calendar quarter showing the Net Sales of Licensed Product sold by Lian and its Affiliates and Sublicensees in the Territory during such calendar quarter and the royalties payable under this Agreement for such calendar quarter.  Lian shall pay Nanobiotix the royalty due for such calendar quarter calculated in accordance with this Agreement within &#91;***&#93; days following the end of that calendar quarter.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.9&#160;&#160;&#160;&#160;Mode of Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. All payments under the Agreement shall be made in Dollars by bank wire transfer in immediately available funds to an account in the name of Nanobiotix as Nanobiotix may designate from time to time by written notice to Lian. If any currency conversion shall be required in connection with the amounts hereunder, such conversion shall be made by using the average of the applicable daily foreign exchange rates published in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Wall Street Journal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> (or any other qualified source that is acceptable to and agreed by both Parties) &#91;***&#93;. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.10&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. All amounts set forth herein are exclusive of any applicable taxes, including withholding taxes and value-added taxes. In the event any withholding, value added, or other tax (including any tax based on income to Nanobiotix) is required to be withheld and deducted from payments by Lian pursuant to the Agreement under Applicable Laws, Lian will make such deduction and withholding and will pay the remainder to Nanobiotix, any amounts so withheld and deducted will be remitted by Lian on a timely basis to the appropriate Governmental Authority, and Lian will be deemed to have fulfilled all of its payment obligations to Nanobiotix with respect to such payments.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Lian shall provide all documentation reasonably required and provide all reasonably necessary assistance to Nanobiotix to enable Nanobiotix to obtain a tax credit for such amounts withheld.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.11&#160;&#160;&#160;&#160;Records</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall keep, and require its Affiliates and Sublicensees to keep, complete, true and accurate books of accounts and records for the purpose of determining the amounts payable to Nanobiotix pursuant to this Agreement. Such books and records shall be kept for such period of time as required by law, but no less than &#91;***&#93; years following the end of the calendar quarter to which they pertain. Such records shall be subject to audit by Nanobiotix in accordance with Section 9.12.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.12&#160;&#160;&#160;&#160;Audits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix, at its expense, through an independent, internationally recognized certified public accountant reasonably acceptable to Lian, shall have the right to access Lian&#8217;s, its Affiliates&#8217; or Sublicensees&#8217; relevant books and records in relation to the sales of Licensed Products in the Field in the Territory for the purpose of verifying Lian&#8217;s royalty and sales milestone payments to Nanobiotix hereunder during any portion of the Term&#59; such access shall be conducted after &#91;***&#93; prior written notice by Nanobiotix to Lian, its Affiliates&#8217; or Sublicensees&#8217; during ordinary business hours, shall not be more frequent than &#91;***&#93; and shall not include any books and records that were previously accessed pursuant to this Section 9.12. Such accountant shall execute a confidentiality agreement with Lian, its Affiliate or Sublicensee as applicable in customary form and shall only disclose to Nanobiotix whether Lian paid Nanobiotix the correct amounts during the audit period and if not, any information necessary to explain the source of the discrepancy. If such audit determines that Lian paid Nanobiotix less than the amount properly due, then Lian shall pay Nanobiotix within &#91;***&#93; days after conclusion of the audit an amount equal to such underpayment, along with interest under Section 9.13, &#91;***&#93;, of the amount due over the audited period, Lian shall also reimburse Nanobiotix for the reasonable costs of such audit (including the fees and expenses of the certified public accountant). If such audit determines that Lian paid Nanobiotix more than the amount properly due, then Lian shall be entitled to credit such overpayment against future payments due to Nanobiotix&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, that if no future payments to Nanobiotix hereunder are reasonably anticipated, then Nanobiotix shall promptly issue a refund to Lian of such overpayment.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">9.13&#160;&#160;&#160;&#160;Late Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Any amounts not paid by the date due under the Agreement shall be subject to interest at an annual rate of &#91;***&#93;, except that if the highest rate permitted under Applicable Law is lower, it shall be such highest permitted rate, computed from the due date through and including the date upon which payment is received. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_37"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 10</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">INTELLECTUAL PROPERTY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">10.1 &#160;&#160;&#160;&#160;Ownership of Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall at all times remain the exclusive owner of its pre-existing Intellectual Property and all Inventions relating to the Licensed Products made solely by or on behalf of such Party or its Affiliates in connection with the performance of such Party&#8217;s activities under this Agreement (each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Party-Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), and any and all Patents claiming any such Party-Invention. To the extent an Invention relating to the Licensed Products is made by both Parties (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Co-Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), then such Co-Invention, together with any and all Patents claiming any such Co-Invention (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Co-Invention Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), will be jointly owned by the Parties.  The Parties&#8217; rights to file, prosecute, and enforce Co-Invention Patents shall be agreed in good faith between the Parties through the JSC. Each Party will grant and hereby does grant to the other Party all further permissions, consents, and waivers with respect to, and all fully paid-up licenses under, the Co-Inventions and any Co-Invention Patents, throughout the world, necessary to provide the other Party with full rights of use and exploitation of the Co-Inventions, subject to the licenses granted herein. Lian grants to Nanobiotix a worldwide, non-exclusive, sublicenseable, royalty-free, fully paid-up, perpetual and irrevocable license to any Lian Party-Invention and any Patents claiming such Lian Party-Inventions that is reasonably useful or necessary for the Development, Manufacture or Commercialization of the Licensed Product outside of the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">10.2 &#160;&#160;&#160;&#160;Prosecution and Maintenance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">In the Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. As between the Parties, Nanobiotix shall have the first right, at its expense, to prosecute and maintain the Nanobiotix Patents in the Territory, using counsel of its choice. Nanobiotix shall keep Lian reasonably informed of all steps with regard to and the status of the preparation, filing, prosecution and maintenance of the Nanobiotix Patents in the Territory, including by providing Lian with (i) copies of all correspondence and material communications it sends to or receives from any patent office or agency in the Territory relating to such Patents, (ii) a draft copy of all applications, in each case ((i) and (ii)), sufficiently in advance of filing or response to permit reasonable review and comment by Lian, and (iii) a copy of applications as filed, together with notice of its filing date and serial number.  Before Nanobiotix submits any filing, including a new patent application, or response to such patent authorities with respect to any Nanobiotix Patents, Nanobiotix will provide Lian with a reasonable opportunity to review and comment on such filing or response and will incorporate any reasonable comments or suggestions provided by Lian regarding the prosecution or maintenance of such Nanobiotix Patents under this Section 10.2(a) &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Step-In Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Should Nanobiotix elect not to prosecute or maintain a Nanobiotix Patent in the Territory, it shall give Lian notice thereof within a reasonable period &#91;***&#93; prior to allowing such Patent to lapse or become abandoned or unenforceable, and Lian will have the right, but not the obligation, to assume such prosecution and maintenance at its expense and through patent counsel of its choice. Upon transfer of Nanobiotix&#8217;s responsibility for prosecuting and maintaining any of the Nanobiotix Patents under this Section 10.2(b), (i) Nanobiotix will promptly deliver to Lian copies of all necessary files related to such Patents with respect to which responsibility has been transferred and will take all actions and execute all documents reasonably necessary for Lian to assume such prosecution and maintenance, and (ii) such Patents shall no longer extend the Royalty Term pursuant to Section 9.7.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">10.3&#160;&#160;&#160;&#160;Infringement by Third Parties and Patent Protection.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Monitoring</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. In the event that either Nanobiotix or Lian becomes aware of any infringement or threatened infringement by a Third Party of any Nanobiotix IP, it will notify the other Party in writing to that effect. Any such notice shall include evidence to support an allegation of infringement or threatened infringement by such Third Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Defense and Enforcement of Nanobiotix IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall have the first right to defend the Nanobiotix IP in the Territory at its cost and expense, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that, should Nanobiotix elect not to defend a Nanobiotix Patent in the Territory, it shall give Lian notice thereof and Lian may then assume control over such defense at its expense. &#91;***&#93;. Any proceeds from such enforcement in the Field but also outside the Territory shall be allocated, after reimbursement of each Party&#8217;s reasonable litigation cost therefrom, &#91;***&#93;. Otherwise, Lian shall have the first right to enforce the Nanobiotix IP against an infringement in the Field in the Territory at its expense, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that, should Lian elect not to enforce the Nanobiotix IP against such an infringement in the Territory, it shall give Nanobiotix notice thereof and Nanobiotix will have the second right to so enforce such Nanobiotix IP in the Territory at its expense. At the request of the enforcing Party, the other Party shall lend reasonable assistance in such enforcement. Neither Party will have the right to settle any action enforcing or defending the Nanobiotix IP in the Field in the Territory under this Section 10.3(b) in a manner that imposes any liability on, or diminishes the rights or interests of the other Party under this Agreement, without the consent of such other Party, which consent will not be unreasonably withheld. To the extent Lian is enforcing the Nanobiotix IP, any proceeds from such enforcement shall be, after reimbursement of each Party&#8217;s reasonable litigation cost therefrom, split between the Parties, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> if and to the extent &#91;***&#93;, Lian shall retain &#91;***&#93;. To the extent Nanobiotix is enforcing the Nanobiotix IP where Lian renounces its first right of enforcement, any proceeds from such enforcement shall be &#91;***&#93;, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> (i) &#91;***&#93; and (ii) &#91;***&#93;.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">10.4&#160;&#160;&#160;&#160;Third Party Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall promptly notify the other in writing of any allegation by a Third Party that the activity of either Party pursuant to this Agreement infringes or may infringe the Intellectual Property of such Third Party. In the event that the Parties determine that the Licensed Product(s) or the Nanobiotix IP may infringe a Third Party's Intellectual Property, the Parties, through the JSC, will discuss &#91;***&#93;. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 11</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CONFIDENTIALITY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.1&#160;&#160;&#160;&#160;Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, during the Term and for &#91;***&#93; thereafter, the receiving Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Receiving Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any trade secrets or confidential or proprietary information, and any tangible materials embodying any of the foregoing, whether patentable or otherwise, in any form (written, oral, photographic, electronic, visual or otherwise) that are provided or disclosed to it by the other Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Disclosing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), including (a) all information disclosed by one Party to the other pursuant to the Confidentiality Agreement or the Term Sheet and (b) the terms and conditions of this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.2&#160;&#160;&#160;&#160;Exceptions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Notwithstanding Section 11.1 above, Confidential Information will not include any information that the Receiving Party can demonstrate by competent evidence&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) was already known to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality, at the time of disclosure&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) was generally available to the public or was otherwise part of the public domain at the time of its disclosure to the Receiving Party&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) became generally available to the public or otherwise part of the public domain after its disclosure by the Disclosing Party and other than through any act or omission of the Receiving Party or any of its Affiliates in breach of this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) was subsequently lawfully disclosed to the Receiving Party or any of its Affiliates by a Person other than the Disclosing Party, and who did not receive such information directly or indirectly from the Disclosing Party under an obligation of confidence&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) was independently developed by the Receiving Party or any of its Affiliates without use of or reference to the Confidential Information of the Disclosing Party.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.3&#160;&#160;&#160;&#160;Permitted Disclosures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Notwithstanding the provisions of Section 11.1, each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) filing or prosecuting Patents as permitted by this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) prosecuting or defending litigation as permitted by this Agreement&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) complying with applicable court orders or governmental regulations or as otherwise required by Applicable Laws (including any such disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, pricing and reimbursement approval, import authorization for any Licensed Product in the Territory, or the rules or regulations of the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing entity (including in connection with the public sale of securities))&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) disclosing to its Affiliates, employees, directors, consultants, attorneys, and other professional advisors, and in Lian&#8217;s case (but, subject to Section 6.1(b), excluding any Confidential Information relating to the Manufacturing of the Licensed Products), to its Sublicensees and Third Party subcontractors, in each case who have a legitimate need to know such information, data, or materials and who are bound by written confidentiality obligations at least as restrictive as those set forth herein&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) disclosure to Third Parties in connection with due diligence or similar investigations by or on behalf of a Third Party in connection with a potential license or sublicense to, distribution agreement with or collaboration with such Third Party (including entry into any such agreement), or a potential merger or acquisition by such Third Party, and disclosure to potential or actual Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by similar terms of confidentiality and non-use at least as stringent as those set forth in this Article 11 (provided that the term may be shorter as is customary for the context, but at least &#91;***&#93;).</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 11.3(b) or Section 11.3(c), it shall, to the extent permitted by Applicable Laws, give reasonable advance notice to the other Party of such disclosure and use reasonable efforts to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">secure confidential treatment of such information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable efforts&#59; provided that any Confidential Information so disclosed shall still be subject to the restrictions on use set forth in this Article 11. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.  If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar Governmental Authority in a country other than the United States, then such Party will, a reasonable time prior to any such filing, provide the other Party with a copy of such agreement showing any provisions hereof as to which the Party proposes to request confidential treatment, will provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such Party&#8217;s reasonable comments into consideration before filing such agreement and use reasonable efforts to have terms identified by such other Party afforded confidential treatment by the applicable Governmental Authority. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.4&#160;&#160;&#160;&#160;Public Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. As soon as practicable following the Effective Date, the Parties shall issue a mutually agreed or a joint  press release announcing the existence of this Agreement substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 11.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Except as required by law (including disclosure requirements of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Nasdaq stock market or any other stock exchange on which securities issued by a Party or its Affiliates are traded), neither Party shall make any other public announcement concerning this Agreement or the subject matter hereof without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed&#59; provided that it shall not be unreasonable for a Party to withhold consent with respect to any public announcement containing any of such Party&#8217;s Confidential Information. In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.5&#160;&#160;&#160;&#160;Publication of Licensed Product Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Without limiting the foregoing, Lian shall not, and shall ensure its Affiliates and Sublicensees do not, publish or publicly present any non-public scientific or technical information with respect to the Licensed Product without Nanobiotix&#8217;s prior written consent, which shall not be unreasonably withheld.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.6&#160;&#160;&#160;&#160;Prior Non-Disclosure Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. As of the Effective Date, the terms of this Article 11 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) dealing with the subject of this Agreement, including the Confidentiality Agreement and the Term Sheet&#59; provided that the existing Confidentiality Agreement and Term Sheet between the Parties is hereby terminated and any and all Confidential Information pursuant to the Confidentiality Agreement and the Term Sheet shall be deemed &#8220;Confidential Information&#8221; of a Party pursuant to this Article 11.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">11.7&#160;&#160;&#160;&#160;Residual Knowledge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The Parties acknowledge the practical difficulty of policing the use of information inadvertently retained in the unaided memory of a receiving Party or any of its, its Affiliates&#8217;, Sublicensees&#8217; or Third Party subcontractors&#8217; officers, directors, employees, and agents who have had rightful access to the Confidential Information of the disclosing Party (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Residual Knowledge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), and as such each Party agrees that the receiving Party will not be liable for the inadvertent use (without reference to any Confidential Information of the disclosing Party) by any of its or its Affiliates&#8217;, Sublicensees&#8217; or Third Party subcontractors&#8217; officers, directors, employees, or agents of the Residual Knowledge that is inadvertently retained in the unaided memory of such officer, director, employee, or agent&#59; provided that such officer, director, employee, or agent has not been directed to or otherwise intentionally memorized or retained such Residual Knowledge for use other than as explicitly permitted under this Agreement.  The receiving Party acknowledges and agrees that any use made by the receiving Party of any such Residual Knowledge is on an &#8220;as is, where is&#8221; basis and at its sole risk, with all faults and all representations and warranties disclaimed by the disclosing Party. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i2a1c1713445e4a05924e14a0b6170c84_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 12</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">12.1 &#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party hereby represents and warrants to the other Party, as of the Effective Date, as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Duly Organized</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, and is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent it from performing its obligations under this Agreement, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Due Authorization&#59; Binding Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The execution, delivery and performance of this Agreement by such Party have been duly authorized by all necessary corporate or organizational action. This Agreement is a legal and valid obligation binding on such Party and enforceable in accordance with its terms. It has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such Party&#8217;s charter documents, bylaws or other organizational documents. The execution and delivery of this Agreement by such Party, and the performance of such Party&#8217;s obligations under this Agreement (as contemplated as of the Effective Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement do not (i) violate any law, rule, regulation, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over such Party, or (ii) conflict with, violate, breach, or constitute a default under, or give rise to a right of termination, cancellation or acceleration of, any agreement, instrument or understanding, oral or written, to which such Party or any of its Affiliates is a party or by which it is bound.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Consents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Such Party has obtained all necessary consents, approvals, orders, and authorizations of all Governmental Authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained (except for any Marketing Authorizations, Regulatory Approvals, Regulatory Filings, Manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Products, to be obtained in accordance with the terms of this Agreement).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Debarment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Such Party is not debarred under the United States Federal Food, Drug and Cosmetic Act or similar Applicable Laws outside the U.S. and it does not employ or use the services of any Person who is debarred, in connection with the Development, Manufacturing or Commercialization of the Licensed Products under this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">12.2 &#160;&#160;&#160;&#160;Representations, Warranties and Covenants of Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. As used in this Section 12.2, &#8220;Knowledge&#8221; means, as applied to Nanobiotix, that &#91;***&#93;. Nanobiotix represents and warrants to Lian that as of the Effective Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Right to Grant License</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix exclusively owns &#91;***&#93;, and is entitled to license to Lian, all of the Nanobiotix IP, free and clear of all claims, liens, charges, or encumbrances. Nanobiotix has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in, nor granted any license, option or other rights to, any of the Nanobiotix IP in the Territory in any manner that could adversely affect Lian&#8217;s rights under this Agreement. No Third Party has any license, option or other rights or interest in or to the Nanobiotix IP in the Field in the Territory other than the rights that are expressly reserved or contingent under this Agreement.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Nanobiotix Patents and Nanobiotix Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> sets forth all Nanobiotix Patents existing as of the Effective Date, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> sets forth all Nanobiotix Trademarks existing as of the Effective Date. Nanobiotix does not own or hold rights to any Patents that would be necessary or reasonably useful for the Development or Commercialization of the Licensed Products in the Field and in the Territory other than the Nanobiotix Patents.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent and Trademark Status</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. (i) All Nanobiotix Patents owned or Controlled by Nanobiotix have been filed and prosecuted in good faith in the patent offices in accordance with Applicable Laws, (ii) all issued Nanobiotix Patents and all issued Nanobiotix Trademarks are in full force and effect, valid, subsisting and enforceable&#59; (iii) none of the Nanobiotix Patents and Nanobiotix Trademarks is currently involved in any interference, reissue, reexamination, or opposition proceeding&#59; (iv) neither Nanobiotix nor any of its Affiliates has received any written notice from any Person, or has knowledge, of any such actual or threatened proceeding&#59; and (v) all official fees, maintenance fees and annuities for the Nanobiotix Patents and the Nanobiotix Trademarks that are required to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">be paid to prevent abandonment or other loss of rights have been paid through the Effective Date to the extent due on or before the Effective Date.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Non-Infringement by Third Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. &#91;***&#93; there are no activities by Third Parties that would constitute infringement of the Nanobiotix IP or misappropriation of the Nanobiotix Know-How in the Territory.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Non-Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. &#91;***&#93; the Development, Manufacture, or Commercialization of the Licensed Product, including the use of the Nanobiotix Trademarks, does not infringe or misappropriate any Intellectual Property of a Third Party. Neither Nanobiotix nor any of its Affiliates has received any written notice from any Person, or has knowledge of, any actual or threatened claim or assertion that the Development, Manufacture or Commercialization of the Licensed Product infringes or misappropriates the Intellectual Property of a Third Party. &#91;***&#93; the practice by Lian under the Nanobiotix IP or the Development or Commercialization of the Licensed Product as contemplated under this Agreement, if it was to occur at the Effective Date, does not infringe, misappropriate, or otherwise violate any Intellectual Property of any Third Party. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Absence of Litigation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  There are no judgments or settlements against or owed by Nanobiotix or its Affiliates or Sublicensees, or, &#91;***&#93; pending litigation against Nanobiotix or its Affiliates or Sublicensees, or litigation threatened against Nanobiotix or its Affiliates or Sublicensees, in each case, related to the Licensed Product, including any such litigation any relating to any Regulatory Filings, Regulatory Approvals, or Marketing Authorizations Controlled by Nanobiotix, its Affiliates or its Sublicensees.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Confidentiality of Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  Nanobiotix has taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality, and value of all Nanobiotix Know-How.  &#91;***&#93; the Nanobiotix Know-How existing as of the Effective Date has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality.  </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Assignment of Third Party Rights&#59; Third Party Consents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) Nanobiotix has obtained from each of its employees and agents, and from the employees and agents of its Affiliates, who are performing Development activities for Licensed Products, rights to any and all Know-How created by such employees and agents in the course of such activities that relates to Licensed Products, such that Lian will, by virtue of this Agreement, receive from Nanobiotix, without payments beyond those required by Article 9, all licenses and other rights granted to Lian under this Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) Each Person who has or has had any ownership rights in or to any Nanobiotix Patent purported to be owned solely by Nanobiotix, has assigned and has executed an agreement assigning its entire rights, title, and interests in and to such Nanobiotix Patent to Nanobiotix, and &#91;***&#93; no current officer, employee, agent, or consultant of Nanobiotix or any of its Affiliates is in violation of any term of any assignment or other agreement, in each case, regarding the protection of the Nanobiotix Patents.</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) Prior to the Effective Date, Nanobiotix has obtained all consents from Third Parties necessary to grant Lian the licenses and rights Nanobiotix purports to grant to Lian under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(j) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">No Other Disclosures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  (i) &#91;***&#93; there are no scientific or technical facts or circumstances that have not been disclosed to Lian, and that would adversely affect the scientific, therapeutic, or commercial potential of the Licensed Products&#59; (ii) there is nothing within Nanobiotix&#8217;s Control that has not been disclosed to Lian and that could adversely affect the acceptance, or the subsequent approval, by any Regulatory Authority of any Regulatory Filing&#59; and (iii) &#91;***&#93; there are no safety, efficacy, or regulatory issues that would preclude Lian from exploiting the Licensed Products in the Territory in accordance with this Agreement and applicable Law.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Additional Legal Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) &#91;***&#93; Nanobiotix and its Affiliates have complied &#91;***&#93; with all Applicable Laws in conducting Development and Manufacturing of the Licensed Product prior to the Effective Date, and neither Nanobiotix nor any of its Affiliates has received any written notice from any Governmental Authority in the Territory claiming that any such activities as conducted by them are not in such compliance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) No Governmental Authority in the Territory has commenced or &#91;***&#93; threatened to initiate any action to enjoin production of the Licensed Product at any facility, nor has Nanobiotix or any of its Affiliates or &#91;***&#93; any of its contractor manufacturers, received any notice to such effect, nor has Nanobiotix received any order not to import the Licensed Product into the Territory.</font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify;text-indent:113.38pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">12.3&#160;&#160;&#160;&#160;Mutual Covenants</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Compliance with Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  The Parties will, and will ensure that their respective Affiliates, Sublicensees, and Third Party subcontractors will, comply in all material respects with all applicable Laws in exercising their rights and fulfilling their obligations under this Agreement. The Parties will require any Affiliate, Sublicensee, Third Party subcontractor, or other Person that provides services to such Party in connection with this Agreement to comply with such Party&#8217;s obligations under this Section 12.3(a). Lian will make no representations or warranties with respect to the Licensed Products other than those in the approved label for the Licensed Product or otherwise as specifically authorized in writing by Nanobiotix.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">No Debarment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates&#8217;, Sublicensees&#8217; or Third Party subcontractors&#8217; directors, officers, employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party or individual becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such Party will promptly notify the other Party and take the necessary steps to avoid any such debarment.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">12.4&#160;&#160;&#160;&#160;No Conflict</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  During the Term, Nanobiotix and its Affiliates will not grant any interest in the Nanobiotix IP that is inconsistent with the terms and conditions of this Agreement and the rights and licenses granted to Lian hereunder. </font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_46"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 13</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">DISCLAIMER, LIMITATION OF LIABILITY AND INDEMNIFICATION</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">13.1&#160;&#160;&#160;&#160;Disclaimer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, OR ANY OTHER AGREEMENT CONTEMPLATED HEREUNDER, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE OR USE, NON-INFRINGEMENT, VALIDITY AND ENFORCEABILITY OF PATENTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF THE LICENSED PRODUCT. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">13.2&#160;&#160;&#160;&#160;Limitation of Liability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, OR LOST PROFITS IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER&#59; PROVIDED, HOWEVER, THAT THIS SECTION 13.2 SHALL NOT APPLY TO (A) EITHER PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 13 (B) ANY BREACH OF ARTICLE 11, SECTION 2.5, OR SECTION 12.2(C), OR (C) A CLAIM FOR INTENTIONAL OR WILLFUL MISCONDUCT &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">13.3&#160;&#160;&#160;&#160;Indemnification of Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall indemnify, defend and hold harmless each of Nanobiotix and its Affiliates, and the directors, officers, shareholders, employees and agents of such entities and the successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), from and against any and all losses, liabilities, damages, penalties, fines, costs and expenses (including reasonable attorneys&#8217; fees and other expenses of litigation) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) resulting from any claims, actions, suits or proceedings brought by a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Third Party Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) incurred by any Nanobiotix Indemnitee, to the extent arising from (a) the negligence or willful misconduct of any Lian Indemnitees or any Sublicensees or Third Party subcontractors of Lian&#59; (b) the Development, regulatory and Commercialization activities relating to the Licensed Product conducted by or on behalf of Lian, its Affiliates, Sublicensees or Third Party subcontractors (other than Nanobiotix and its Affiliates and licensees) in connection with this Agreement&#59; or (c) any breach of any obligation, representation, warranty or covenant by Lian under this Agreement or the Supply Agreement&#59; except in each case (a)-(c) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Nanobiotix set forth in Section 13.4(a) or (b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">13.4&#160;&#160;&#160;&#160;Indemnification of Lian</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall indemnify, defend and hold harmless each of Lian and its Affiliates, and the directors, officers, shareholders, employees and agents of such entities and the successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), from and against any and all Losses resulting from any Third Party Claims incurred by any Lian Indemnitee, to the extent arising from (a) the negligence or willful misconduct of any Nanobiotix Indemnitee&#59; (b) the Development, regulatory and Commercialization activities relating to the Licensed Product conducted by or on behalf of Nanobiotix, its Affiliates, Sublicensees (other than Lian and its Affiliates and Sublicensees) or Third Party subcontractors, unless at Lian&#8217;s express direction or (c) any breach of any obligation, representation, warranty or covenants by Nanobiotix under this Agreement or the Supply Agreement&#59; except in each case (a) or (b) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Lian set forth in Section 13.3(a) to (c).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">13.5&#160;&#160;&#160;&#160;Procedure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. A Party that intends to claim indemnification under this Article 13 shall promptly notify the indemnifying Party in writing of any Third Party Claim, in respect of which the indemnitee intends to claim such indemnification. The indemnified Party shall provide the indemnifying Party with reasonable assistance, at the indemnifying Party&#8217;s expense, in connection with the defense of the Third Party Claim for which indemnity is being sought. The indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, that the indemnifying Party shall have the right to assume and conduct the defense of the Third Party Claim with counsel of its choice. The indemnifying Party shall not agree to any settlement of any Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the indemnified Party (other than a monetary obligation on the indemnifying Party), without the prior written consent of the indemnified Party, which consent shall not be unreasonably withheld unless the settlement involves (i) any admission of legal wrongdoing by the indemnified Party, (ii) any payment by the indemnified Party that is not indemnified under this Agreement, or (iii) the imposition of any equitable relief against the indemnified Party (in which case, (i) through (iii), the indemnified Party may withhold its consent to such settlement in its sole discretion). So long as the indemnifying Party is actively defending the Third Party Claim in good faith, the indemnified Party shall not settle any such Third Party Claim without the prior written consent of the indemnifying Party. If the indemnifying Party does not assume and conduct the defense of the Third Party Claim as provided above, (a) the indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim in any manner the indemnified Party may deem reasonably appropriate (and the indemnified Party need not consult with, or obtain any consent from, the indemnifying Party in connection therewith), and (b) the indemnifying Party will remain responsible to indemnify the indemnified Party as provided in this Article 13. The failure to deliver written notice to the indemnifying Party within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the indemnifying Party of its indemnification obligations under this Article 13 if and to the extent the indemnifying Party is actually prejudiced thereby.</font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_49"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 14</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">TERM AND TERMINATION</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.1 &#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The term of the Agreement will start on the Effective Date and will continue in full force until the expiration of the last to expire Royalty Term, unless earlier terminated in accordance with this Article 14 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). Upon the expiration of the Royalty Term for a given country in the Territory, the licenses granted to Lian pursuant to Section 2.1 will become perpetual, irrevocable, fully paid-up, royalty-free, fully sublicenseable, and transferable for such Licensed Product in such country. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.2&#160;&#160;&#160;&#160;Early Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Termination for Cause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall have the right to terminate this Agreement upon written notice if the other Party is in material breach of this Agreement (the Party so allegedly breaching being the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Breaching Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), the other Party (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Non-Breaching Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) and has not cured such breach within &#91;***&#93; after written notice from the Non-Breaching Party requesting cure of the breach, which notice will, in each case (i) expressly reference this Section 14.2(a), (ii) reasonably describe the alleged breach that is the basis of such termination.  &#91;***&#93; If a material breach relates solely to one or more countries of the Territory, then the Non-Breaching Party will have the right to terminate this Agreement solely with respect to such country(ies).  Notwithstanding the foregoing, if such material breach, by its nature, is curable, but is not reasonably curable within the applicable cure period, then such cure period will be extended if the Breaching Party provides a written plan for curing such breach within the objectively earliest possibility to the Non-Breaching Party and uses reasonable efforts to cure such breach in accordance with such written plan.  In addition, if the Breaching Party disputes either (A) whether it has materially breached this Agreement, or, alternatively, (B) whether it has cured such material breach within the applicable cure period, then the dispute will be resolved pursuant to Section 15.16 &#91;***&#93;, and the applicable cure period will be tolled during the pendency of such dispute resolution procedure, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided further that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Termination for Insolvency</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall have the right to terminate this Agreement, to the best extent permissible under Applicable Law, upon written notice upon the bankruptcy, reorganization, liquidation, or insolvency of, or the filing of an action to commence insolvency proceedings against, the other Party, or the making or seeking to make or arrange an assignment for the benefit of creditors of the other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy, or the appointment of a receiver or trustee of such Party&#8217;s property, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, that in the case of any involuntary bankruptcy, reorganization, liquidation or insolvency proceeding such right to terminate will only become effective if the Party subject to such proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Termination by Lian following Change of Control in Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  Following a Change of Control in Nanobiotix, Lian may, &#91;***&#93; prior written notice to Nanobiotix, terminate this Agreement &#91;***&#93;. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Termination by Nanobiotix following Change of Control of Lian</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.  &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nanobiotix shall have the right to terminate this Agreement with immediate effect by giving written notice to Lian if Lian or its Affiliates or Sublicensees bring or join any challenge to the validity or enforceability of any Nanobiotix Patent (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent Challenge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) and does not withdraw such Patent Challenge within &#91;***&#93; days of written notice from Nanobiotix&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that (i) a Patent Challenge does not include Lian&#8217;s or its Affiliates&#8217; or its Sublicensees (A) responding to compulsory discovery, subpoenas or other requests for information in a judicial or arbitration proceeding or (B) complying with any Applicable Law or a court order&#59; and (ii) the foregoing right of termination shall not apply with respect to any Patent Challenge that (I) is first made by Lian or any of its Affiliates or Sublicensees in defense of a claim of patent infringement brought by Nanobiotix under the applicable Patents or any Patent Challenge, (II) was brought by an acquirer of Lian prior to the effective date of such Change of Control, or (III) is brought by any non-Affiliate Sublicensee if Lian (1) causes such Patent Challenge to be terminated or dismissed (or in the case of ex-parte proceedings, multi-party proceedings, or other Patent Challenges in which the challenging party does not have the power to unilaterally cause the Patent Challenge to be withdrawn, causes such Sublicensee to withdraw as a party from such Patent Challenge and to cease actively assisting any other party to such Patent Challenge), or (2) terminates such Sublicensee&#8217;s sublicense to the Patents being challenged by the Sublicensee, in each case, within &#91;***&#93; days after Nanobiotix&#8217;s notice to Lian under this Section 14.2(d).</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.3 &#160;&#160;&#160;&#160;Alternative Remedy In Lieu of Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. If Lian has a right to terminate this Agreement pursuant to Section 14.2(a), Lian may elect, in lieu of so terminating, to have this Agreement continue on all the terms herein save that all milestone and royalty payments owed by Lian to Nanobiotix hereunder will be reduced by &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.4&#160;&#160;&#160;&#160;Accrued Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The termination of this Agreement for any reason shall not release either Party from any liability which, at the time of such termination, has already accrued to such Party or which is attributable to a period prior to such termination, nor will any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.5&#160;&#160;&#160;&#160;Effects of Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Upon the termination of this Agreement as a whole or with respect to one or more countries in the Territory (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Terminated Region</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), except in the case of termination by Lian according to Section 14.2(a) or 14.2(b), the following will apply&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Termination of Licenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. All rights and licenses granted to Lian with respect to Licensed Products and Nanobiotix IP, and all sublicenses granted by Lian and its Affiliates, will terminate in the Terminated Region.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Winding Down of Development Activities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Without prejudice to Section 14.5(c), in the event there are any on-going Clinical Trials of the Licensed Product being conducted by or on behalf of Lian in the Field in the Terminated Region, the Parties shall work together in good faith to adopt a plan to wind down such Development activities in an orderly fashion, with due regard for patient safety and the rights of any subjects that are participants in any clinical trials of the Licensed Product, and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems, in compliance with all Applicable Laws. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Inventory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian will have the right, for a period of &#91;***&#93; days following any termination of this Agreement, to sell or otherwise dispose of any Licensed Products in the Terminated Region, as applicable, on hand at the time of such termination. Thereafter, Nanobiotix shall have the right to purchase from Lian, at the cost incurred by Lian for purchase, all of Lian&#8217;s and its Affiliates&#8217; then-current inventory of Licensed Product in the Terminated Region.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Re-registration of Regulatory Filings or Regulatory Approvals</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. To the extent permitted under Applicable Laws, Lian shall arrange for the re-registration to Nanobiotix or its designee (or to the extent not so re-registrable, Lian shall take all reasonable actions to make available to Nanobiotix or its designee the benefits thereof) of all Regulatory Filings and Regulatory Approvals for the Licensed Product in the Terminated Region, including any such Regulatory Filings and Regulatory Approvals made by or registered to its Affiliates or Sublicensees&#59; all such re-registration or transfer shall be at Lian&#8217;s sole cost and expense. Nanobiotix shall notify Lian before the effective date of termination, whether the foregoing should be re-registered to Nanobiotix or its designee, and if the latter, identify the designee, and provide Lian with all necessary details to enable Lian to effect the re-registration (or availability of the benefit thereof).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> License Grant by Lian to Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian hereby grants Nanobiotix, effective upon the effective date of such termination, a fully-paid, royalty-free, non-exclusive license, with the right to grant sublicenses through multiple tiers, under any and all Party-Inventions and Patents claiming such Party-Inventions Controlled by Lian or its Affiliates and necessary or reasonably useful for Nanobiotix to Develop, Manufacture and Commercialize the Licensed Product in the Terminated Region. If any rights granted by Lian under the foregoing license are Controlled by Lian or its Affiliates or Sublicensees pursuant to an agreement with a Third Party, then Nanobiotix will pay all amounts due under any such agreement to the extent reasonably allocable to Nanobiotix&#8217;s exercise of the rights granted thereunder. If Nanobiotix or its or their Affiliates or Sublicensees exercises the rights or licenses granted pursuant to this Section 14.5(f) and this Agreement has been terminated by Lian pursuant to Section 14.2(a) or Section 14.2(b), then Nanobiotix will pay to Lian, in consideration of the rights granted to Nanobiotix, an amount to be negotiated by the Parties, &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Transition</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall use reasonable efforts to cooperate with the other Party to effect a smooth and orderly transition in the Development and Commercialization of the Licensed Product in the Territory during the notice and wind-down periods. Lian shall provide reasonable transition support to enable Nanobiotix to assume all Development and Commercialization responsibility in the Terminated Region. Lian shall, at Nanobiotix&#8217;s request, assign to Nanobiotix all Third Party contracts, to the extent solely related to the Licensed Product, and if any such contract is not assignable, and if such Third Party agrees to it, Lian shall introduce Nanobiotix to such Third Party to facilitate the discussions regarding the relationship between Nanobiotix and such Third Party after the Term of the Agreement. </font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Ancillary Agreements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Supply Agreement, the Quality Agreement and the Pharmacovigilance Agreement shall terminate effective upon the effective date of termination of this Agreement, except as provided otherwise in the Supply Agreement, the Quality Agreement and the Pharmacovigilance Agreement in conformity with Applicable Laws, and except as to support winding down or exit activities as contemplated in Section 14.5(b) and 14.5(c).</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%"> Return of Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Except to the extent necessary or reasonably useful for a Party to exercise its rights surviving such termination or as required by Applicable Law, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#8217;s possession or Control containing Confidential Information of the other Party&#59; provided that such Party may keep one copy of such materials to ensure compliance obligations of such Party are met.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.6&#160;&#160;&#160;&#160;Survival</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. All rights and obligations of the Parties under this Agreement shall terminate upon the expiration or termination of this Agreement, except those described in the following Articles and Sections&#58; &#91;***&#93;. Furthermore, any other provisions required to interpret the Parties&#8217; rights and obligations under this Agreement, including applicable definitions in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">, will survive to the extent required.  Except as otherwise expressly provided in this Section 14.6, any licenses granted under this Agreement, will terminate upon expiration or termination of this Agreement in its entirety or solely with respect to the Terminated Region, as the case may be, for any reason. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">14.7&#160;&#160;&#160;&#160;Rights Upon Bankruptcy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">and other similar laws in any jurisdiction in the Territory or where a Party is situated (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Bankruptcy Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided in such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall perform all of the obligations provided in this Agreement to be performed by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided in the Bankruptcy Laws and the other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee) shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party&#8217;s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws. In particular, it is the intention and understanding of the Parties that the rights granted to the Parties under this Section 14.7 are essential to the Parties&#8217; respective businesses and the Parties acknowledge that damages are not an adequate remedy.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_52"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ARTICLE 15</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">MISCELLANEOUS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.1&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. If the performance of any part of this Agreement by either Party is prevented, restricted, interfered with or delayed by any reason or cause beyond the reasonable control of such Party (including fire, flood, embargo, power shortage or failure, acts of war, insurrection, riot, terrorism, strike, lockout or other labor disturbance, shortage of raw materials, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, or storm or like catastrophe, acts of God or any acts, omissions or delays in acting of the other Party) (each, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Force Majeure Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), the Party so affected shall, upon giving written notice to the other Party, be excused from such performance to the extent of such Force Majeure Event, provided that the affected Party shall notify the other Party in writing of any Force Majeure Event as soon as reasonably practical, and shall use its substantial efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date (including related government orders) may be invoked as a Force Majeure Event for the purposes of this Agreement even though the pandemic is ongoing and those effects may be reasonably foreseeable as of the Effective Date.  In addition, a Force Majeure Event may include reasonable measures affirmatively taken by a Party or its Affiliates to respond to any epidemic, pandemic, or spread of infectious disease (including the COVID-19 pandemic), or other Force Majeure Event, such as requiring employees to stay home, closures of facilities, delays of Clinical Trials, or cessation of activities in response to an epidemic or other Force Majeure Event. A Party that is subject to a Force Majeure Event shall exert all reasonable efforts to overcome it&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that if such Force Majeure Event continues unabated for a period of &#91;***&#93;, then the Parties shall discuss and agree on alternative solutions &#91;***&#93;, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.2&#160;&#160;&#160;&#160;Waiver of Breach</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. No delay or waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.3&#160;&#160;&#160;&#160;Further Actions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party agrees to execute, acknowledge and deliver such further instruments, and to perform all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.4&#160;&#160;&#160;&#160;Modification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. No amendment or modification of any provision of this Agreement shall be effective unless in a prior writing signed by both Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by both Parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.5&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Lian shall maintain such public liability insurance (including without limitation workers compensation, employer&#8217;s liability, comprehensive general liability, product liability and property damage insurance) adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated at all times during the Term of the Agreement and, upon Nanobiotix&#8217;s reasonable request, Lian will provide Nanobiotix with evidence of such insurance.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.6&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. In the event any provision of this Agreement should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith and enter into a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties. All other provisions of this Agreement shall remain in full force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.7&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. This Agreement (including the schedules and exhibits attached hereto) constitutes the entire agreement between the Parties relating to the subject matter hereof and supersedes and cancels all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect of the subject matter hereof, including the Confidentiality Agreement and the Term Sheet. Each of the Parties acknowledges and agrees that in entering into this Agreement, and the documents referred to in it, it does not rely on, and shall have no remedy in respect of, any statement, representation, warranty or understanding (whether negligently or innocently made) of any Person (whether party to this Agreement or not) other than as expressly set out in this Agreement. Nothing in this clause shall, however, operate to limit or exclude any liability for fraud.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.8&#160;&#160;&#160;&#160;Third Party Right</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each of the Parties and any of their respective Affiliates may enforce any right granted to it under this Agreement. Other than as set out in Section 15.8, no Person who is not a Party may enforce any provision of this Agreement under the Contract (Rights of Third Parties) Act 1999 or otherwise. Nanobiotix and Lian may agree to vary or terminate this Agreement in accordance with its terms without the agreement of any Third Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">15.9&#160;&#160;&#160;&#160;Language</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. The language of this Agreement and all activities to be pursued under this Agreement is English. Any and all documents proffered by one Party to the other in fulfillment of any provision of this Agreement shall only be in compliance if in English. Any translation of this Agreement in another language shall be deemed for convenience only and shall never prevail over the original English version. This Agreement is established in the English language.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.10&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Any notice, request, or other communication required or permitted under this Agreement shall be in writing in the English language, delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized courier, sent by registered or certified mail, postage prepaid to the following addresses of the Parties (or such other address for a Party as may be at any time thereafter specified by like notice), with a courtesy copy sent by email, which will not constitute notice&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:54.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">To Nanobiotix&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix S.A.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">60 Rue de Wattignies</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">75012, Paris</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">France</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Attention&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Email&#58; &#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">To Lian&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">LianBio</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">c&#47;o Ogier Global (Cayman) Limited</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">89 Nexus Way</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Camana Bay</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Grand Cayman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Cayman Islands KY1-9009</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Attention&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Email&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">with a copy to&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Jones Day 2 rue Saint Florentin</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">75001 Paris, France</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Attention&#58; &#91;***&#93; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Fax&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Email&#58; &#91;***&#93;</font></div><div><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">with a copy to&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Ropes &#38; Gray LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">36F Park Place</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1601 Nanjing Road West</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Shanghai, China 200040</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Attention&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Fax&#58; &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Email&#58; &#91;***&#93;</font></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Any such notice shall be deemed to have been given (a) when delivered if personally delivered&#59; (b) on the next Business Day after dispatch if sent by confirmed facsimile or by internationally-recognized overnight courier&#59; (c) on the &#91;***&#93; Business Day following the date of mailing if sent by mail&#59; or (d) upon confirmation of receipt if sent by email. Notices hereunder will not be deemed sufficient if provided only between or among each Party&#8217;s representatives on the Joint Steering Committee.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.11&#160;&#160;&#160;&#160;Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Subject to Section 2.5(b), this Agreement and the rights and obligations of each Party under this Agreement shall not be assignable or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party to any Third Party without the prior written consent of the other Party, provided, however, that either Party may assign or transfer this Agreement together with all of its rights and obligations hereunder, without such consent (but with written notice to the other Party), (a) to an Affiliate or (b) to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which this Agreement relates, or in the event of its merger or consolidation, reorganization, or similar transaction. Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party. Any assignment of this Agreement in contravention of this Section 15.11 shall be null and void.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.12&#160;&#160;&#160;&#160;No Partnership or Joint Venture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Nothing in this Agreement or any action which may be taken pursuant to its terms is intended, or shall be deemed, to establish a joint venture or partnership between Lian and Nanobiotix. Except as set forth in this Agreement, neither Party to this Agreement shall have any express or implied </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.13&#160;&#160;&#160;&#160;Lian Cayman Guarantee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. In consideration of Nanobiotix entering into this Agreement, sufficiency of which is hereby confirmed, Lian Cayman hereby &#91;***&#93; guarantees &#91;***&#93; the due and punctual payment and performance of all obligations of Lian under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian Obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).  Lian Cayman agrees that the Lian Obligations may be extended, modified, or renewed, in whole or in part, without notice or further assent from it, and that it will remain bound upon its guarantee notwithstanding any extension, modification, or renewal of any Lian Obligation. &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.14&#160;&#160;&#160;&#160;Dispute Resolution Process</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Parties recognize that disputes as to certain matters may from time to time arise during the Term that relate to (i) interpretation of a Party&#8217;s rights or obligations hereunder, (ii) any alleged breach of this Agreement, (iii) any issue that is unable to be resolved pursuant to informal channels of resolution. If the Parties cannot resolve any such dispute within &#91;***&#93; days after written notice of a dispute from one Party to another, either Party may, by written notice to the other Party, have such dispute referred to the JSC. If the JSC cannot resolve such dispute within &#91;***&#93; days after such dispute is referred thereto, either Party may, by written notice to the other Party, have such dispute referred to the Chief Executive Officer of Nanobiotix and the Chief Executive Officer of Lian (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Senior Executives</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;). The Senior Executives shall negotiate in good faith to resolve the dispute within &#91;***&#93;. If the Senior Executives are unable to resolve the dispute within such time period, the parties shall submit the dispute for arbitration in accordance with Section 15.16. Notwithstanding anything in this Article 15 to the contrary, Nanobiotix and Lian shall each have the right at all times to apply to any court of competent jurisdiction for appropriate interim or provisional relief as necessary to protect the rights or property of that Party or to preserve the status quo pending the resolution of the dispute resolution process as set forth in Section 15.14 and Section 15.16.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.15&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. The Agreement will be governed by English law, without regard to the conflicts of law principles thereof. Any dispute, controversy, claim or difference of any kind whatsoever arising out or in connection with the Agreement will be resolved exclusively through arbitration in accordance with the then effective ICC Rules.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.16&#160;&#160;&#160;&#160;Arbitration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Any disputes arising in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">ICC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) as amended herein, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) The arbitration shall be conducted by a panel of three (3) arbitrators, or such lesser number as the Parties may agree. Each of the Parties shall nominate an arbitrator and these two arbitrators shall endeavor to agree on the third arbitrator, who shall act as chairman of the arbitral tribunal, within &#91;***&#93; days from the date when both Parties have received from the ICC confirmation of the second arbitrator by the ICC court. All arbitrators shall have a legal qualification. The chairman shall have at least one ICC arbitration before, and the arbitrators nominated by the Parties shall have at the minimum ten (10) years working experience in the pharmaceutical industry. The seat, or legal place, of arbitration shall be &#91;***&#93;, and the Parties consent to the personal jurisdiction of the &#91;***&#93; courts for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement. The language of the arbitration proceedings shall be English. The decision and award of the arbitral tribunal shall be final and binding on the Parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s compensatory damages. Each Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) Any award shall be promptly paid, free of any tax, deduction or offset&#59; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by Applicable Laws, be charged against the Party resisting enforcement. Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Section 15.16, and agrees that judgment may be entered upon the final award in any court of competent jurisdiction. The award shall include interest from the date of any damages incurred for breach of this Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrators.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) The existence and content of the arbitral proceeding, including any rulings or award, shall be kept confidential by the Parties and the arbitrator except to the extent (i) required by Applicable Laws&#59; (ii) required to protect or pursue a legal right&#59; (iii) required to enforce or challenge an award&#59; or (iv) approved by written consent of the Parties. Notwithstanding anything to the contrary herein, either Party may disclose matters relating to the arbitration or the arbitral proceedings where necessary for the preparation or presentation of a claim or defense in such arbitration. The arbitrator shall issue appropriate protective orders to safeguard each Party&#8217;s Confidential Information. Except as required by Applicable Laws, no Party shall make (or instruct the arbitrator to make) any public announcement with respect to the proceedings, rulings or award without prior written consent of the other Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(f) &#91;***&#93; in the event that a dispute arises specifically about the validity, scope, enforceability, inventorship or ownership of any Intellectual Property (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">IP Dispute</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), and such IP Dispute is not resolved in accordance with Section 15.14, either Party may initiate litigation in a court of competent jurisdiction in any country in which such right applies, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that any dispute over the contractual implications and consequences of such IP Dispute shall remain exclusively reserved to arbitration according to Section 15.16, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> that if and to the extent an IP Dispute leads to a final and binding decision, such decision shall also be final and binding with respect to the Intellectual Property in the country in question for the purposes of such arbitration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.17&#160;&#160;&#160;&#160;Fees and Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. Each Party shall bear its own attorneys&#8217; fees and fees and expenses associated with all aspects of the negotiation and diligence of the transaction contemplated hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.18&#160;&#160;&#160;&#160;Hardship</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. If any unforeseen event (e.g., an evolution of the legal or economic framework of the Agreement), while not preventing either Party from performing any of its obligations hereunder, changes the balance of the Agreement to the detriment of such Party and therefore causes inequitable hardship to such Party in the performance of such obligations, and if such Party is able to demonstrate such hardship by competent proof, then both Parties shall attempt in good faith to negotiate an equitable way to adapt this Agreement to the new circumstances, provided neither Party is obligated to make any accommodation or agree to any amendment that is not expressly required by the terms of this Agreement. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">15.19&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. This Agreement may be signed electronically by each of the authorized representatives of the Parties. The Parties acknowledge and agree that electronic signatures via DocuSign may be use used for the execution of this Agreement by such signatories. Each Party acknowledges that it has received all the information required for the electronic signature of this Agreement and that it is signing this Agreement electronically in full knowledge of the technology used and its terms and conditions, and consequently waives any claim and&#47;or legal action challenging the reliability of this electronic signature system and&#47;or its intention to enter into this Agreement. Furthermore, the obligation to deliver an original copy to each of the Parties is not necessary as proof of the commitments and obligations of each Party to this Agreement. The delivery of an electronic copy of this Agreement directly by DocuSign to each Party shall constitute sufficient and irrefutable proof of the commitments and obligations of each Party to this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Schedules</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Schedule 1.1 - Definitions </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Schedule 11.4 - Draft Public Announcement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibits</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Exhibit A &#8211; Territory-Specific Development Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Exhibit B &#8211; Development timelines</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Exhibit C &#8211; Nanobiotix Patents as of the Effective Date</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Exhibit D &#8211; Nanobiotix Trademarks as of the Effective Date</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Exhibit E &#8211; Licensed Product</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">&#91;signature page to follow&#93;</font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_55"></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> the Parties by their respective authorized representatives have executed this Agreement as of the Effective Date.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix S.A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58; &#47;s&#47; Laurent Levy</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Name&#58; Laurent Levy</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58; CEO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">LianBio Oncology Limited</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58; &#47;s&#47; Konstantin Poukalov    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Name&#58; Konstantin Poukalov</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">In the presence of and in agreement to Section 15.13&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">LianBio</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58; &#47;s&#47; Konstantin Poukalov    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Name&#58; Konstantin Poukalov</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_58"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Schedule 1.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Definitions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Accounting Standards</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to a Party or its Affiliates, U.S. generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">GAAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) or International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">IFRS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), as such Party or its Affiliates uses for its financial reporting obligations, in each case.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Acquired Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 2.5(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Active Ingredient</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means those active materials that provide pharmacological activity in a pharmaceutical or biologic product (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants, or controlled release technologies).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Additional Global Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3.1(c)(i).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Adjusted Transfer Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 6.1(c)(iii). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Affiliate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to any Person, any entity directly or indirectly controlling, controlled by, or under common control with, such Person, at the time that the determination of affiliation is made and for as long as such control exists. For purposes of this definition only, the terms &#8220;controlled,&#8221; &#8220;controlled by,&#8221; and &#8220;under common control with,&#8221; as used in this context, means (i) direct or indirect ownership of more than 50% of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such Laws&#59; provided, however, that such ownership interest provides actual control over such Person), (ii) status as a general partner in any partnership, or (iii) the direct or indirect ability or power to direct or cause the direction of management policies of a Person or otherwise direct the affairs of such Person, whether through ownership of equity, voting securities, beneficial interest, by contract or otherwise.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in the first paragraph hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Applicable Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Regulatory Approvals and Marketing Authorizations) of any Governmental Authority having jurisdiction over or related to the subject item.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Bankruptcy Laws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 14.7.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Business Day</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a calendar day, other than a Saturday or Sunday or any public holiday on which the banks in France and Hong Kong are open for business.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Calendar Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a period of twelve consecutive months beginning on and including January 1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CDE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the Center for Drug Evaluation of the China National Medical Products Administration.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to a Party, (a) the acquisition of beneficial ownership, directly or indirectly, by any Third Party of securities or other voting interest of such Party representing more than 50% of the combined voting power of such Party&#8217;s then outstanding securities or other voting interests, (b) any merger, reorganization, consolidation or business combination involving such Party with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately prior to such merger, reorganization, consolidation or business combination ceasing to hold beneficial ownership of more than 50% of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or business combination, or (c) any sale, lease, exchange, contribution or other transfer to a Third Party (in one transaction or a series of related transactions) of all or substantially all of the assets of such Party and its controlled Affiliates. Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of financing the operations of the applicable Party (including the issuance or sale of securities for financing purposes) or to change the form or domicile of a Party shall not constitute a Change of Control.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Clinical Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a trial in which human subjects or patients are dosed with a drug, whether approved or investigational.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CMC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means chemistry, Manufacturing and controls.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Co-Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Co-Invention Patent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Combination Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a Licensed Product that (a) contains or comprises both (i) NBTXR3 &#91;***&#93; and (ii) (aa) at least one additional Active Ingredient or (bb) at least one additional medical device, whether packaged together or in a single finished dosage form, (b) sold for a single invoice price together with any (A) delivery device or component therefor, (B) companion diagnostic related to any Licensed Product, or (C) product, process, service, or therapy other than the Licensed Product (such additional Active Ingredient or medical device and each of (A) &#8211; (C), an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Other Component</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) or (c) that is defined as a &#8220;combination product&#8221; by the FDA pursuant to 21 C.F.R. &#167;3.2(e) or its foreign equivalent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any and all activities relating to the preparation for sale of, offering for sale of, or sale of a product, including activities related to pre-marketing, Launching, marketing, promoting, distributing, having distributed, using, importing, exporting for sale, having imported and exported for sale, pricing and reimbursement, advertising, detailing, packaging, labeling, bidding and listing, storage, handling, having sold, customer service and support, Post-Approval Commitments and Post-Marketing Studies, and interacting with Regulatory Authorities regarding any of the foregoing, but excluding any activities relating to Manufacturing or Development. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialize</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means to engage in Commercialization.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 4.3(a).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercialization Updates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 4.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means &#91;***&#93;. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Competing Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Competitor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the confidentiality agreement by and between the Parties effective as of September 22, 2020.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; (including any variations such as &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Controlled</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), in the context of Intellectual Property and Confidential Information, means possession (whether by ownership or license, other than pursuant to this Agreement) by a Party of the ability to grant access to, or a license or sublicense of, such rights, Know-How and Confidential Information as set forth in this Agreement without violating the terms of an agreement with a Third Party.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Core Dossier</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the compilation of CMC, pre-clinical, clinical data provided by Nanobiotix to Lian necessary to support and maintain Regulatory Approvals in the Field in the Territory.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Cover</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Covering</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">,&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Covered</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, when referring to the Licensed Product&#58; (a) with respect to an issued Patent, that, in the absence of a license granted to a Person under an issued claim included in such Patent, the manufacture, use, sale, offer for sale or import by such Person of a specified activity with respect to such Licensed Product would infringe such claim, or (b) with respect to an application for Patent, that, in the absence of a license granted to a Person under a claim included in such application, the manufacture, use, sale, offer for sale or import by such Person of such Licensed Product would infringe such claim if such patent application were to issue as a patent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">CPI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the consumer price index in France. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Development</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means non-clinical and clinical research, development, and regulatory activities reasonably related to pharmaceutical or biologic products and submission of information to a Regulatory Authority or otherwise related to the research, identification, testing and validation thereof, including toxicology, pharmacology and other discovery and pre-clinical efforts, test method development and stability testing, formulation development, quality assurance and quality control development, generation of data for Regulatory Filings, statistical analysis, clinical trials of a product, whether for purposes of label expansion or otherwise, but does not include Manufacturing or Commercialization. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Develop</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means to engage in Development.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development Plan Incentive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3.1(d).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Disclosing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Dollars</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">USD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the official currency of the United States.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in the first paragraph hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Enrollment Commitment&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.1(c)(i).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">EU Medical Device</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the European Union regulatory framework ensuring the safety and efficacy of medical devices and facilitates patients&#8217; access to devices in the European Union market, including Regulation (EU) 2017&#47;745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001&#47;83&#47;EC, Regulation (EC) No 178&#47;2002 and Regulation (EC) No 1223&#47;2009 and repealing Council Directives 90&#47;385&#47;EEC and 93&#47;42&#47;EEC and Regulation (EU) 2017&#47;746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98&#47;79&#47;EC and Commission Decision 2010&#47;227&#47;EU.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Field</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the use of a product activated by radio therapy in the field of oncology.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">First Commercial Sale</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to the Licensed Product in any country in the Territory, the first arm&#8217;s length sale of the Licensed Product to a Third Party by Lian, or its Affiliates or Sublicensees, for monetary value for use in the Field and in the Territory, after the respective Licensed Product has been granted the first Marketing Authorization that allows the placing on the market of the Licensed Product. First Commercial Sale excludes transfers of Licensed Product to Third Parties as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">bona fide s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">amples, as donations, for the performance of Clinical Trials, or for similar purposes in accordance with Applicable Law pertaining to any expanded access program, any compassionate sales or use program (including named patient program or single patient program), or any indigent program.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Force Majeure Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 15.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Global Registrational Study&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Global Registrational Study Commitment&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Global Registrational Study Data&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Global Registrational Study Notice&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Global Registrational Study Option&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Global Trials&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.1(c).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Glucose</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Unit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means one Unit including glucose thirty percent (30%).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Governmental Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any court, agency, department, authority or other instrumentality, official or officer, exercising executive, judicial, legislative, police, regulatory, administrative, or taxing authority of any national, supranational, federal, state, county, city or other political subdivision.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">ICC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 15.16.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Indication</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a separate and distinct disease, disorder, or medical condition that a Licensed Product is intended to treat, prevent, cure, or ameliorate and for which a separate determination of safety and effectiveness of the Licensed Product is required. By way of example, naive vs. refractory patients, first line vs. second&#47;third line, metastatic, etc., would constitute separate Indications.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; shall mean (i) Patents, (ii) Inventions, (ii) Know-How (iii) Trademarks, (iv) copyrights, all other literary property and author rights whether or not copyrightable and all rights, title and interest in and to all copyrights and copyrighted interests throughout the world and (v) any other proprietary rights of a nature similar or analogous to any of the foregoing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Inventions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any and all inventions, discoveries, processes and techniques, which are, or may be, patentable or otherwise protectable under Applicable Laws of any country or region, and which are conceived, discovered or reduced to practice by or on behalf of a Party (whether solely or jointly with the other Party or its Affiliates).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">IP Dispute</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 15.16(f).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Joint Steering Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">JSC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all tangible and intangible scientific, technical, clinical, regulatory, trade, marketing, commercial, financial or business information and materials, including compounds, solid state forms, compositions of matter, formulations, devices, techniques, processes, methods, trade secrets, formulae, procedures, tests, data, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">results, analyses, documentation, reports, information (including pharmacological, toxicological, non-clinical (including CMC), and clinical test design, methods, protocols, data, results, analyses, and conclusions), quality assurance and quality control information, regulatory documentation, information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, knowledge, know-how, skill, and experience.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Launch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the commencement of the First Commercial Sale of the Licensed Product in a country within the Territory after receiving the required Marketing Authorizations. When used as a verb, to &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Launch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means to engage in the Launch.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Launch Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the date of the Launch.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in the header of the Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian Cayman</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means LianBio, an exempted company organized and existing under the laws of Cayman Islands.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Lian Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 13.4.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Licensed Product</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means Nanobiotix&#8217;s (a) current generation of the proprietary product known as NBTXR3 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NBTXR3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) and (b) second generation of NBTXR3 radio enhancer (i.e., a product activated by radio therapy), as further described in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Local Registrational Study&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.2(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Local Registrational Study Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 3.2(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 13.3.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">MAA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means an application for Marketing Authorization or for Regulatory Approval filed with a Regulatory Authority.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Manufacture</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means manufacture, generate, process, prepare, make, assemble, test, label, package, store, hold, handle, receive, release, serialize, transport, and deliver a product (or any component or intermediate thereof), including any related stability testing, quality assurance and quality control. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Manufacturing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means to engage in Manufacture. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Marketing Authorization</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the grant or issuance of all Regulatory Approvals, including (i) any technical, medical and scientific approvals, licenses, registrations or authorizations (including approvals of MAAs, supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling approvals) and (ii) all licenses, permissions, consents and regulatory authorizations that are (a) necessary to enable the Licensed Product to be imported, marketed, sold, distributed, stored and shipped in any given country&#59; or (b) necessary at each specific institution in any given country, in each case necessary for the Development, Manufacture or Commercialization, as and when applicable, of the Licensed Product in the Field in such country. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">MNC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a multinational pharmaceutical or pharma-biotechnology company with commercial presence in North America, Europe and the People&#8217;s Republic of China and a market capitalization of at least a hundred billion Dollars (USD 100,000,000,000).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in the header of the Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 13.3.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix IP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the Nanobiotix Know-How, the Nanobiotix Patents, the Nanobiotix Trademarks and any and all Intellectual Property Controlled by Nanobiotix or its Affiliates as of the Effective Date or during the Term that is necessary or reasonably useful for the Development or Commercialization of the Licensed Product in the Field in the Territory, including Nanobiotix&#8217;s rights in any Co-Inventions and Co-Invention Patents.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Know-How</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all Know-How owned or Controlled by Nanobiotix or any of its Affiliates as of the Effective Date or during the Term that is necessary or reasonably useful for the Development or Commercialization of the Licensed Product in the Field in the Territory.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Patents</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all Patents owned or Controlled by Nanobiotix or its Affiliates as of the Effective Date or during the Term that are necessary or reasonably useful for the Development or Commercialization of the Licensed Product in the Field in the Territory, including all Patents that claim Product Improvements, including the Patents set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> and Nanobiotix&#8217;s rights in any Co-Invention Patents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Trademarks</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all &#8220;Hensify&#8221; Trademarks Controlled by Nanobiotix or its Affiliates as of the Effective Date or during the Term that are necessary or reasonably useful for the Commercialization of the Licensed Product in the Field in the Territory, including the Trademarks set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">NMPA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the National Medical Product Administrations of the PRC, or its successor.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Net Sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the gross sales recorded by or on behalf of Lian, its Affiliates or Sublicensees (for the purpose of this definition, &#8220;Sublicensees&#8221; will not include any distributors or wholesalers) (each of the foregoing Persons, a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Selling Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) for sales of the Licensed Product to Third Parties (other than Lian&#8217;s Sublicensees), less the following deductions calculated in accordance with the Accounting Standards, applied on a consistent basis by the relevant Selling Party to the extent allocated to such Licensed Product and actually taken, paid, accrued, allowed, included, or allocated, based on good faith estimates, in the gross sales price with respect to such sales, for&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a) &#91;***&#93;&#59; </font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b) &#91;***&#93;&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c) &#91;***&#93;&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d) &#91;***&#93;&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(e) &#91;***&#93;&#59;</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(f) &#91;***&#93;&#59; and</font></div><div style="text-align:justify;text-indent:85.03pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(g) &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:85.03pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Net Sales will be calculated only once for the first </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> arm&#8217;s length sale of the Licensed Product to a Third Party that is not a Selling Party.  Net Sales does not include (a) any sale of such Licensed Product to or between Lian, its Affiliates or its or their Sublicensees for further sale by such entity (but includes the subsequent sale by such entity to a Third Party that is not a Selling Party), (b) samples of Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of a Selling Party, or (c) any use of such Licensed Product as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> samples, as donations, for Clinical Trial or other Development purposes, any expanded access program, any compassionate sales or use program (including named patient program or single patient program), or any indigent program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the event that a Licensed Product is sold as a Combination Product, Net Sales, for the purposes of determining royalty payments on the Combination Product, shall mean the gross amount collected for the Combination Product less the deductions set forth in clauses (a) - (g) above, multiplied by a proration factor that is determined as follows&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(i) If all Other Components of the Combination Product were sold separately during the same or immediately preceding calendar quarter, the proration factor shall be determined by the formula &#91;A &#47; (A+B)&#93;, where A is the average gross sales price of all Licensed Product components containing only NBTXR3 as its Active Ingredient during such period when sold separately from the other component(s), and B is the average gross sales price of the Other Components during such period when sold separately from NBTXR3 (as applicable)&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(ii) If the Licensed Product components containing only NBTXR3 as its Active Ingredient are sold separately from the Other Components, but the Other Components in such Combination Product are not sold separately, then the proration factor shall be determined by the formula &#91;A &#47; C&#93;, where A is the average gross sales price of all Licensed Product components containing only NBTXR3 as its Active Ingredient during such period when sold separately from the Other Components, and C is the average gross sales price of the Combination Product during such period&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(iii) If the Licensed Product components containing only NBTXR3 as its Active Ingredient are not sold separately from the Other Components, but the Other Components in such Combination Product are sold separately, then the proration factor shall be determined by the formula &#91;( C- B) &#47; C&#93;, where B is the average gross sales price of the Other Components included in such Combination Product if sold separately from the other component(s), and C is the average gross sales price of the Combination Product during such period&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(iv) If neither NBTXR3 nor the Other Components included in the Combination Product were sold or provided separately during the relevant period, then the proration factor shall be determined &#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in the first paragraph hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Party-Invention</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means (a) all patents, certificates of invention, applications for certificates of invention, priority patent filings and patent applications, and (b) any renewal, division, continuation (in whole or in part), or request for continued examination of any of such patents, certificates of invention and patent applications, and any and all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, divisions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent Challenge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 14.2(d).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any individual, corporation, partnership, limited liability company, trust, governmental entity, or other legal entity of any nature whatsoever.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 7.3(a). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Phase I Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a Clinical Trial, the principal purpose of which is preliminary determination of safety of an investigational product in healthy individuals or patients or that otherwise meets the requirements described in 21 C.F.R. &#167;312.21(a), or similar Clinical Trial in a country other than the United States.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Phase II Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a Clinical Trial, for which the primary endpoints include a determination of dose ranges or a preliminary determination of efficacy of an investigational product in patients being studied or that otherwise meets the requirements described in 21 C.F.R. &#167;312.21(b), or similar Clinical Trial in a country other than the United States.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Phase III Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Pivotal Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, as to a specific product, a Clinical Trial the results of which are intended (as of the time the first subject is dosed in the Clinical Trial) to be sufficient or otherwise are sufficient, in each case, without any additional Clinical Trial, to support the filing of an MAA with respect to such product.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Post-Approval Commitments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all clinical studies (including pediatric studies and Post-Marketing Studies) conducted after Regulatory Approval for the Licensed Product that are requested by a Regulatory Authority or that are necessary to fulfill commitments made to any Regulatory Authority as a condition for the receipt or maintenance of such Regulatory Approval in any country.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Post-Marketing Studies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means all non-interventional and interventional clinical trials of the Licensed Product with the main objective to collect data to increase product knowledge or for marketing and market access purposes, e.g., pricing studies, post-marketing surveillance studies, patient outcome studies, patient preference studies and investigator-initiated trials.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">PRC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the People&#8217;s Republic of China, which for the purposes of this Agreement, excludes Hong Kong, Macau and Taiwan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Product Improvement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any and all Inventions, and any and all changes, modifications and amendments, by or on behalf of a Party, or by the Parties jointly, during the Term, that relate to the Licensed Product, or a modified form thereof, whether patentable or not, whether in the Field or not.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Promotional Materials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 4.6.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Quality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 7.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Recall</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means Licensed Product recall, withdrawal, Field correction of the Licensed Product or other related action.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Receiving Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Reductions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 9.5.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Regulatory Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to any Licensed Product in any country or regulatory jurisdiction, any and all approvals from the applicable Regulatory Authority (a) sufficient for the import, distribution, marketing, use, offering for sale, and sale of the Licensed Product for use in the Field in such country or jurisdiction in accordance with Applicable Laws or (b) that are necessary for the definition of the public price of the Licensed Product or reimbursement conditions as well as the grant of such public price or reimbursement conditions, and any variation of any such permission where applicable (including approvals, permissions and conditions established by such Regulatory Authorities imposed on a Party for participating in and supplying Licensed Product pursuant to tender processes in such country). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Regulatory Authority</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity&#58; (a) whose review or approval is necessary (i) for the Manufacture, packaging, use, storage, import, export, distribution, promotion, marketing, offer for sale and sale of the Licensed Product, (ii) for reviewing Regulatory Filings for the Licensed Product (or a component thereof) or (iii) for granting Regulatory Approvals for the Licensed Product&#59; or (b) having authority to review and enforce GMP or other Applicable Laws relating to the Licensed Product or the Manufacture, Development, Commercialization, use or sale thereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means, with respect to a Licensed Product in a country in the Territory, the period of time during which&#58; (a) a Party or its Affiliates or its or their Sublicensees has been granted the exclusive legal right by a Regulatory Authority in such country to market and sell such Licensed Product&#59; or (b) the data and information submitted by a Party or its Affiliates or its or their Sublicensees to the relevant Regulatory Authority in such country for purposes of obtaining Regulatory Approval of such Licensed Product in such country may not be disclosed, referenced, or relied upon in any way by a Third Party or such Regulatory Authority (including by relying upon the Regulatory Authority&#8217;s previous findings regarding the safety or effectiveness of the Licensed Product) to support the Regulatory Approval of any product of a Third Party in such country.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Regulatory Filings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any documentation comprising or relating to or supporting any applications, approvals, licenses, registrations, notifications, submissions and authorizations made to or received from a Regulatory Authority in a country necessary for the Manufacture, Development or Commercialization of the Licensed Product in such country, including any MAA or any other applications for Regulatory Approvals.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Residual Knowledge</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 11.7.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Royalty Rate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 9.5.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Royalty Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 9.7.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Senior Executives</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 15.14.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Specification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means (a) the specifications for the Licensed Product established by inclusion in the MAA and as required by a Regulatory Authority in the Territory for approval and (b) such other specifications for the Licensed Product agreed to by the Parties pursuant to the Supply Agreement related to the packaging, storage conditions, shelf life and labeling of the Licensed Product.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Sublicensee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means a Third Party sublicensee to whom a Party or its Affiliates grants rights under this Agreement or any subsequent sublicensee through multiple-tiers.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Supply Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 6.1(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Suspension Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 9.7.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 14.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Term Sheet</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the term sheet entered into between the Parties on April 1, 2021 relating to the subject matter of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Terminated Region</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 14.5.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Territory</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the PRC, Macau, Hong Kong, Thailand, Taiwan, South Korea, and Singapore.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Territory-Specific Data&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.2(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Territory-Specific Data Option&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.2(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">&#8220;Territory-Specific Development Plan&#8221;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> has the meaning set forth in Section 3.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Third Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means any Person other than Nanobiotix, Lian and their respective Affiliates.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Third Party Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 13.3.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Trademark</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means trademarks, trade names, service marks, trade dresses, domain names, logos and brandings, whether registered or arising under Applicable Law (and all registration thereof and interests therein throughout the world and all associated goodwill, and applications for registration thereof).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Transfer Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; has the meaning set forth in Section 6.1(c)(iii). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Two-Invoice Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means the policy described in the &#8220;Opinion on the Implementation of the &#8216;Two-Invoices&#8217; System in the Procurement of Pharmaceutical Products by Public Medical Institutions (trial)&#8221; (Guoyigaibanfa &#91;2016&#93; No. 4), officially issued on December 26, 2016) and in any other Applicable Laws that mandate public hospitals or any other purchaser of drugs in mainland China to purchase drugs from the distributor that purchases the drugs directly from the drug manufacturer, limiting the total number of invoices to two.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Unit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means one unlabeled vial &#91;***&#93; suspension of Licensed Product for intra-tumoral injection.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Valid Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; means either (a) a claim &#91;***&#93; of an issued and unexpired patent included within the Nanobiotix Patents that (i) has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable, unpatentable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction&#59; and (ii) has not been admitted to be invalid or unenforceable through reissue, disclaimer, or otherwise, or (b) &#91;***&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_61"></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Schedule 11.4&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Press Release</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_64"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Territory-Specific Development Plan</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_67"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Development timelines</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_70"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Patents as of the Effective Date</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_73"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Nanobiotix Trademarks as of the Effective Date</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i2a1c1713445e4a05924e14a0b6170c84_76"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit E</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Licensed Product</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>4
<FILENAME>nanobiotix-secx20xf2021xexa.htm
<DESCRIPTION>EX-4.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iebf084e53cb243f5a5491d62184b8984_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.6</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Summary of HSBC France Loan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">On June 22, 2020, the Company entered into a State-guaranteed loan agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">pr&#234;t garanti par l&#8217;Etat</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">) with HSBC France (&#8220;HSBC&#8221;) to be applied to the Company&#8217;s general business needs (the &#8220;HSBC PGE Loan&#8221;). The &#8364;5 million loan is 90% guaranteed by the French State. The loan had an initial maturity of 12 months and an interest rate of 0.00% for this initial 12-month period. No amount was required to be paid during this initial 12-month period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company was required to pay to a &#8220;guarantee fee&#8221; equal to 0.25% of the &#8364;5 million principal amount, which amount was payable on the initial maturity date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company had the option to decide, at the end of the first year, whether to repay the loan amount or to amortize the loan over an additional period of one, two, three, four or five years. Prior to giving effect to an election to extend the amortization period, HSBC notified the Company of the interest rate applicable to the amortization period. The Company elected to amortize the principal amount of the loan over a period of five years, during which the HSBC PGE Loan will bear interest at a fixed rate of 0.310% to which shall be added a guarantee fee of 0.50% per annum for the first two years of amortization and 1% per annum for the third, fourth and fifth year of amortization (payable over 90% of the loan outstanding amount). The loan is prepayable, at the Company&#8217;s option, upon three months&#8217; prior notice.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">HSBC may declare the loan repayable upon eight days&#8217; prior notice as a result of the occurrence of certain events, which remain unremediated by the Company, including (i) the Company&#8217;s failure to pay any amounts due under the HSBC loan, (ii) a merger or demerger with, or the winding-up of, the Company, (iii) the disposition of a Company, (iv) a significant decrease in the value of Company&#8217;s assets or an event likely to alter the Company&#8217;s financial capacity to meet its obligations under the HSBC loan, and (v) the default by the Company in the payment of an amount due under any other loan agreement to which the Company is a party, or (vi) the acceleration of any of any amount due under any other loan pursuant to any other HSBC or third-party loan agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The loan will become immediately repayable upon the occurrence of certain other events of default, including the use of the loaned funds for a purpose not authorized by the HSBC loan, any breach of international sanctions regulations and the occurrence of certain bankruptcy or insolvency events.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>5
<FILENAME>nanobiotix-secx20xf2021xexb.htm
<DESCRIPTION>EX-4.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib14d1f2be3d64a1f9fea2d41563c073a_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.7</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Summary of Bpifrance Loan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">On July 10, 2020, the Company entered into a State-guaranteed loan agreement (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">pr&#234;t garanti par l&#8217;Etat</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">) with Bpifrance Financement to be applied to the Company&#8217;s cash flow needs. The &#8364;5 million loan has a six-year term and is 90% guaranteed by the French State. The loan bore no interest for the first 12 month period but, following such 12 month period and for the subsequent five years, bears an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE Loan will be repaid in 20 quarterly installments from October 31, 2021 until July 26, 2026.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The loan is prepayable, at the Company&#8217;s option, upon one month&#8217;s prior notice. Any early repayment of the loan, be it voluntary or involuntary, shall be subject to a lump-sum indemnity equal to 5% of the prepaid principal amount during the first year and reduced to 3% after this period. Bpifrance Financement&#8217;s acceptance of the early repayment is subject to the payment of the indemnity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Bpifrance Financement may declare the loan repayable upon eight days&#8217; prior notice as a result of the occurrence of certain events, including (i) use of the loaned funds for a purpose not authorized by the Bpifrance Financement loan, (ii) the Company&#8217;s failure to pay any amounts due under the Bpifrance Financement loan, (ii) the transfer or pledging by Company of all or part of the shares or voting rights of the Company or one of its subsidiaries without Bpifrance Financement&#8217;s prior approval, (iv) a merger, demerger or partial asset contribution with, or the winding-up of, the Company, (v) the suspension of or change in the Company&#8217;s business activities, (vi) a breach of the provisions of the Bpifrance Financement loan and (vii) misrepresentation under the Bpifrance Financement loan agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The loan will become immediately repayable upon the occurrence of certain other events, including (i) a share capital reduction of the Company that is not motivated by losses, the distribution of reserves outstanding on the date of execution of the Bpifrance Financement loan or the reimbursement of a shareholders&#8217; loan without the prior approval of Bpifrance Financement, (ii) the seizure of Company assets or the transfer of Company business undertakings and (iii) the occurrence of a material event of a legal or financial nature with significant consequences regarding the Company&#8217;s business or profitability.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4.1
<SEQUENCE>6
<FILENAME>nanobiotix-secx20xf2021xexc.htm
<DESCRIPTION>EX-4.4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i90833f8926584204a4f08ec445d8011d_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.4.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center;text-indent:70.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">AMENDMENT NO. 1</font></div><div style="text-align:center;text-indent:70.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:44pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This Amendment No. 1 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) is entered into as of June 4, 2021 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment No. 1 Effective</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">MD Anderson</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;), a member institution of The University of Texas System (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">UT System</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) and Nanobiotix S.A., with a place of business located at 60 Rue de Wattignies, 75012 Paris, France Nanobiotix (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Nanobiotix</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) (MD Anderson and Nanobiotix each a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221; and collectively the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:44pt"><font><br></font></div><div style="text-align:justify;text-indent:44pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">WHEREAS, MD Anderson and Nanobiotix are parties to that certain Amended and Restated Strategic Collaboration Agreement dated January 23, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) concerning the conduct of multiple research studies to be conducted by MD Anderson and funded and supported by Nanobiotix.</font></div><div style="text-align:justify;text-indent:44pt"><font><br></font></div><div style="text-align:justify;text-indent:44pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">WHEREAS, the Parties mutually desire to amend, modify and restate certain payment terms and conditions of the Agreement.</font></div><div style="text-align:justify;text-indent:44pt"><font><br></font></div><div style="text-align:justify;text-indent:44pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;padding-left:10.5pt">DEFINITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Unless otherwise defined herein, capitalized words in this Amendment shall have the meaning attributed to them in the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;padding-left:10.5pt">AMENDMENTS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Parties agree that, as of the Amendment No. 1 Effective Date, the Agreement is amended as set forth in this Section 2.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Section 1.5 remains unchanged. Section1.4 of the Agreement is hereby amended and restated as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8220;1.4 The Collaboration Budget is $&#91;***&#93;. The Collaboration Funding from Nanobiotix is $&#91;***&#93; which shall be due and payable to MD Anderson within thirty (30) days upon receipt of an invoice according to the payment schedule&#58;</font></div><div style="text-align:justify;text-indent:6pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.275%"><tr><td style="width:1.0%"></td><td style="width:31.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:2.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:108%">Effective Date</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">963,534.00&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:2.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">January 1, 2020</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">963,534.00&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:2.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:108%">&#91;***&#93; &#8211; End of enrollment*</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$ &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:2.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:113%">Upon enrollment of 10 patient safety</font></div><div style="text-indent:2.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">cohort for Study Protocol 2020-0123</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$ &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:2.5pt;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Completion of all Studies**</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$ &#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">* MD Anderson will be paid $&#91;***&#93; per patient enrollment for a total of $&#91;***&#93; for 312 patients. Payment for patient enrollment will occur on either &#91;***&#93; or &#91;***&#93; following enrollment, whichever comes first. For the avoidance of doubt, if &#91;***&#93; patients are enrolled from the period of &#91;***&#93; to &#91;***&#93;, $&#91;***&#93; will be due and payable to MD Anderson on &#91;***&#93;. Additional patients are hereby added to Study 2020-0123 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Phase I Study of Reirradiation with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8221;) will be financially considered at a per patient cost of $&#91;***&#93;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$&#91;***&#93; of the Collaboration Funding will be considered discretionary funds to be used as agreed by the JSC, including but not limited to, for Study modifications or add-ons, screen failures, increased sample size or additional studies agreed to by the JSC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">** Once MD Anderson completes all Studies (enrollment of final patient on all Studies), all remaining payment(s) (including previous milestones not paid) shall be due and payable. In the event the JSC elects to not move additional studies forward, the expenses and payments will be reconciled to ensure MD Anderson costs are covered.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.4.1</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Except for the sections of the Agreement specifically amended hereunder, all terms and conditions of the Agreement remain and shall remain in full force and effect. This Amendment shall hereafter be incorporated into and deemed part of the Agreement and any future reference to the Agreement shall include the terms and conditions of this Amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%;padding-left:10.5pt">COUNTERPARTS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">This Amendment may be executed in counterparts with the same effect as if both Parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument. Signature pages of this Amendment may be exchanged by facsimile or other electronic means without affecting the validity thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:70.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#91;Remainder of Page Intentionally Left Blank &#8211; Signature Page to Follow&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="text-align:justify;text-indent:41.95pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 4.4.1</font></div></div><div style="text-align:justify;text-indent:41.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:126%">IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Amendment No. 1 to the Amended and Restated Strategic Collaboration Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:11.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">THE UNIVERSITY OF TEXAS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NANOBIOTIX S.A.</font></div><div style="text-align:justify;text-indent:11.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">M.D. ANDERSON CANCER CENTER</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.512%"><tr><td style="width:1.0%"></td><td style="width:6.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.574%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; Ben Melson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; Bart Van Rhijn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Ben Melson</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Bart Van Rhijn, MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sr. Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>7
<FILENAME>nanobiotix-secx20xf2021xexf.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i871ae20f87224e6d9efd1069c93733d7_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 12.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Certification by the Principal Executive Officer pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">I, Laurent Levy, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A. (the &#8220;Company&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)  Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="padding-left:81pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Date&#58; April 8, 2022</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.576%"><tr><td style="width:1.0%"></td><td style="width:16.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.333%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; LAURENT LEVY</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Laurent Levy, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chairman of the Executive Board</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>8
<FILENAME>nanobiotix-secx20xf2021xexg.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2d74e4d3b48c4aae893c657ba9d7a2d0_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 12.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Certification by the Principal Financial Officer pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">I, Bart Van Rhijn, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A.(the &#8220;Company&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:45pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font></div><div style="padding-left:85.5pt;text-align:justify;text-indent:-13.5pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Date&#58; April 8, 2022</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.891%"><tr><td style="width:1.0%"></td><td style="width:10.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.633%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; BART VAN RHIJN</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Bart Van Rhijn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>9
<FILENAME>nanobiotix-secx20xf2021xexh.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7358a688f73c4db084e92935a69d6f4e_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 13.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Certification by the Principal Executive Officer pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">18 U.S.C. Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In connection with the Annual Report of Nanobiotix S.A. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Laurent Levy, Chairman of the Executive Board, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Date&#58; April 8, 2022</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.621%"><tr><td style="width:1.0%"></td><td style="width:22.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.475%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; LAURENT LEVY</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Laurent Levy, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chairman of the Executive Board</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed with the Securities and Exchange Commission. Such certification shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>10
<FILENAME>nanobiotix-secx20xf2021xexi.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i87eaec6d94b641c6b7ab00bfd2aa3ddb_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right;text-indent:36pt"><font><br></font></div><div style="text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 13.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Certification by the Principal Executive Officer pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">18 U.S.C. Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In connection with the Annual Report of Nanobiotix S.A. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Bart Van Rhijn, Chief Financial Officer, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Date&#58; April 8, 2022</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.403%"><tr><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.527%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; BART VAN RHIJN</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Bart Van Rhijn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed with the Securities and Exchange Commission. Such certification shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>11
<FILENAME>nanobiotix-secx20xf2021xexd.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib0ad905a23304b0d9975aedba9538edc_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 15.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Registration Statement (Form S-8 No. 333-253062) pertaining to the historical BSA Plans (04-12, 2013, 2014, 2015-1, 2015-2(a), 2016 Ordinary, 2016 Performance, 2016-02, 2017, 2018, 2018-01, 2018-02, 2019-1, 2020), historical BSPCE Plans (2012-1, 08-2013, 09-2014, 2015-01, 2015-03, 2016, 2016 Performance, 2017 Ordinary, 2017), historical Free Share Plans (2017, 2018, 2019), historical Stock Option Plans (2016, 2016-2, 2017, 2018, 2019, LLY 2019),  BSA Plan, Free Share Plan, and 2020 Stock Option Plan of Nanobiotix S.A.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(2) &#160;&#160;&#160;&#160;Registration Statement (Form S-8 No. 333-257239) pertaining to BSA Plan, Free Share Plan and 2021 Stock Option plan of Nanobiotix S.A.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(3) &#160;&#160;&#160;&#160;Registration Statement (Form F-3 No. 333-262545) of Nanobiotix S.A.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">of our report dated March 30, 2022, with respect to the consolidated financial statements of Nanobiotix S.A., included in this annual report (Form 20-F) of Nanobiotix S.A. for the year ended December 31, 2021. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#47;s&#47; ERNST &#38; YOUNG et Autres </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Paris La D&#233;fense, France </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">April 8, 2022 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>nbx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbx="http://nanobiotix.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://nanobiotix.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://nanobiotix.com/role/Coverpage">
        <link:definition>000010001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://nanobiotix.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION">
        <link:definition>100010003 - Statement - STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCONSOLIDATEDOPERATIONS" roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS">
        <link:definition>100020004 - Statement - STATEMENTS OF CONSOLIDATED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS">
        <link:definition>100030005 - Statement - STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>100040006 - Statement - STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCONSOLIDATEDCASHFLOWS" roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS">
        <link:definition>100050007 - Statement - STATEMENTS OF CONSOLIDATED CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Companyinformation" roleURI="http://nanobiotix.com/role/Companyinformation">
        <link:definition>210011001 - Disclosure - Company information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompanyinformationDetails" roleURI="http://nanobiotix.com/role/CompanyinformationDetails">
        <link:definition>240024001 - Disclosure - Company information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralInformationStatementofComplianceandBasisofPresentation" roleURI="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation">
        <link:definition>210031002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneralInformationStatementofComplianceandBasisofPresentationDetails" roleURI="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails">
        <link:definition>240044002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Consolidationprinciplesandmethods" roleURI="http://nanobiotix.com/role/Consolidationprinciplesandmethods">
        <link:definition>210051003 - Disclosure - Consolidation principles and methods</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidationprinciplesandmethodsPolicies" roleURI="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies">
        <link:definition>220062001 - Disclosure - Consolidation principles and methods (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidationprinciplesandmethodsDetails" roleURI="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails">
        <link:definition>240074003 - Disclosure - Consolidation principles and methods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significanttransactions" roleURI="http://nanobiotix.com/role/Significanttransactions">
        <link:definition>210081004 - Disclosure - Significant transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificanttransactionsDetails" roleURI="http://nanobiotix.com/role/SignificanttransactionsDetails">
        <link:definition>240094004 - Disclosure - Significant transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://nanobiotix.com/role/Intangibleassets">
        <link:definition>210101005 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://nanobiotix.com/role/IntangibleassetsTables">
        <link:definition>230113001 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsDetails" roleURI="http://nanobiotix.com/role/IntangibleassetsDetails">
        <link:definition>240124005 - Disclosure - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipment" roleURI="http://nanobiotix.com/role/Propertyplantandequipment">
        <link:definition>210131006 - Disclosure - Property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentTables" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentTables">
        <link:definition>230143002 - Disclosure - Property, plant and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails">
        <link:definition>240154006 - Disclosure - Property, plant and equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>240164007 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Noncurrentfinancialassets" roleURI="http://nanobiotix.com/role/Noncurrentfinancialassets">
        <link:definition>210171007 - Disclosure - Non-current financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentfinancialassetsTables" roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsTables">
        <link:definition>230183003 - Disclosure - Non-current financial assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails">
        <link:definition>240194008 - Disclosure - Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncurrentfinancialassetsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails">
        <link:definition>240204009 - Disclosure - Non-current financial assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradereceivablesandothercurrentassets" roleURI="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets">
        <link:definition>210211008 - Disclosure - Trade receivables and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsTables" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables">
        <link:definition>230223004 - Disclosure - Trade receivables and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails">
        <link:definition>240234010 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails">
        <link:definition>240244011 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails">
        <link:definition>240254012 - Disclosure - Trade receivables and other current assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails">
        <link:definition>240264013 - Disclosure - Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashandcashequivalents" roleURI="http://nanobiotix.com/role/Cashandcashequivalents">
        <link:definition>210271009 - Disclosure - Cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsTables" roleURI="http://nanobiotix.com/role/CashandcashequivalentsTables">
        <link:definition>230283005 - Disclosure - Cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsSummaryofCashandCashEquivalentsDetails" roleURI="http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails">
        <link:definition>240294014 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails">
        <link:definition>240304015 - Disclosure - Cash and cash equivalents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://nanobiotix.com/role/ShareCapital">
        <link:definition>210311010 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://nanobiotix.com/role/ShareCapitalTables">
        <link:definition>230323006 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails" roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails">
        <link:definition>240334016 - Disclosure - Share Capital - Disclosure of Detail of Share Capital Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalCapitalIssuedDetails" roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails">
        <link:definition>240344017 - Disclosure - Share Capital - Capital Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTreasurySharesDetails" roleURI="http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails">
        <link:definition>240354018 - Disclosure - Share Capital - Treasury Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails">
        <link:definition>240364019 - Disclosure - Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalFounderswarrantsDetails" roleURI="http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails">
        <link:definition>240374020 - Disclosure - Share Capital - Founders&#8217; warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalWarrantPlansDetails" roleURI="http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails">
        <link:definition>240384021 - Disclosure - Share Capital - Warrant Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalStockOptionPlansDetails" roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails">
        <link:definition>240394022 - Disclosure - Share Capital - Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalFreeSharePlansDetails" roleURI="http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails">
        <link:definition>240404023 - Disclosure - Share Capital - Free Share Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Provisions" roleURI="http://nanobiotix.com/role/Provisions">
        <link:definition>210411011 - Disclosure - Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsTables" roleURI="http://nanobiotix.com/role/ProvisionsTables">
        <link:definition>230423007 - Disclosure - Provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsDisclosureofChangesinProvisionsDetails" roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails">
        <link:definition>240434024 - Disclosure - Provisions - Disclosure of Changes in Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails">
        <link:definition>240444025 - Disclosure - Provisions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails" roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails">
        <link:definition>240454026 - Disclosure - Provisions - Disclosure of Commitments for Retirement Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails">
        <link:definition>240464027 - Disclosure - Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails">
        <link:definition>240474028 - Disclosure - Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialliabilities" roleURI="http://nanobiotix.com/role/Financialliabilities">
        <link:definition>210481012 - Disclosure - Financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesTables" roleURI="http://nanobiotix.com/role/FinancialliabilitiesTables">
        <link:definition>230493008 - Disclosure - Financial liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails">
        <link:definition>240504029 - Disclosure - Financial liabilities - Summary of Changes in Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails">
        <link:definition>240514030 - Disclosure - Financial liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails">
        <link:definition>240524031 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails">
        <link:definition>240534032 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails">
        <link:definition>240544033 - Disclosure - Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails">
        <link:definition>240554034 - Disclosure - Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradepayablesandothercurrentliabilities" roleURI="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities">
        <link:definition>210561013 - Disclosure - Trade payables and other current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesTables" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables">
        <link:definition>230573009 - Disclosure - Trade payables and other current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails">
        <link:definition>240584035 - Disclosure - Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails">
        <link:definition>240594036 - Disclosure - Trade payables and other current liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails">
        <link:definition>240604037 - Disclosure - Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails" roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails">
        <link:definition>240614038 - Disclosure - Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" roleURI="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome">
        <link:definition>210621014 - Disclosure - Financial instruments included in the statement of financial position and impact on income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables">
        <link:definition>230633010 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails">
        <link:definition>240644039 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails">
        <link:definition>240654040 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails">
        <link:definition>240664041 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuesandotherincome" roleURI="http://nanobiotix.com/role/Revenuesandotherincome">
        <link:definition>210671015 - Disclosure - Revenues and other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandotherincomeTables" roleURI="http://nanobiotix.com/role/RevenuesandotherincomeTables">
        <link:definition>230683011 - Disclosure - Revenues and other income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandotherincomeAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails">
        <link:definition>240694042 - Disclosure - Revenues and other income - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" roleURI="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails">
        <link:definition>240704043 - Disclosure - Revenues and other income - Schedule of Revenues and Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Operatingexpenses" roleURI="http://nanobiotix.com/role/Operatingexpenses">
        <link:definition>210711016 - Disclosure - Operating expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesTables" roleURI="http://nanobiotix.com/role/OperatingexpensesTables">
        <link:definition>230723012 - Disclosure - Operating expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails">
        <link:definition>240734044 - Disclosure - Operating expenses - Summary of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails">
        <link:definition>240744045 - Disclosure - Operating expenses - Research and Development, Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails">
        <link:definition>240754046 - Disclosure - Operating expenses - Summary of Selling, General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails">
        <link:definition>240764047 - Disclosure - Operating expenses - Selling, General and Administrative, Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSummaryofPayrollCostsDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails">
        <link:definition>240774048 - Disclosure - Operating expenses - Summary of Payroll Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesPayrollCostsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails">
        <link:definition>240784049 - Disclosure - Operating expenses - Payroll Costs, Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails">
        <link:definition>240794050 - Disclosure - Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails">
        <link:definition>240804051 - Disclosure - Operating expenses - Summary of Other Operating Income (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails">
        <link:definition>240814052 - Disclosure - Operating expenses - Other Operating Income (Expense), Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedpayments" roleURI="http://nanobiotix.com/role/Sharebasedpayments">
        <link:definition>210821017 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsTables" roleURI="http://nanobiotix.com/role/SharebasedpaymentsTables">
        <link:definition>230833013 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails">
        <link:definition>240844053 - Disclosure - Share-based payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails">
        <link:definition>240854054 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails">
        <link:definition>240864055 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails">
        <link:definition>240874056 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails">
        <link:definition>240884057 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netfinancialincomeloss" roleURI="http://nanobiotix.com/role/Netfinancialincomeloss">
        <link:definition>210891018 - Disclosure - Net financial income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossTables" roleURI="http://nanobiotix.com/role/NetfinancialincomelossTables">
        <link:definition>230903014 - Disclosure - Net financial income (loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails" roleURI="http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails">
        <link:definition>240914058 - Disclosure - Net financial income (loss) - Summary of Net Financial Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails">
        <link:definition>240924059 - Disclosure - Net financial income (loss) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometax" roleURI="http://nanobiotix.com/role/Incometax">
        <link:definition>210931019 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxTables" roleURI="http://nanobiotix.com/role/IncometaxTables">
        <link:definition>230943015 - Disclosure - Income tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/IncometaxAdditionalInformationDetails">
        <link:definition>240954060 - Disclosure - Income tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" roleURI="http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails">
        <link:definition>240964061 - Disclosure - Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentreporting" roleURI="http://nanobiotix.com/role/Segmentreporting">
        <link:definition>210971020 - Disclosure - Segment reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Losspershare" roleURI="http://nanobiotix.com/role/Losspershare">
        <link:definition>210981021 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareTables" roleURI="http://nanobiotix.com/role/LosspershareTables">
        <link:definition>230993016 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareScheduleofBasicandDilutedLossPerShareDetails" roleURI="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails">
        <link:definition>241004062 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareAdditionalInformationDetails" roleURI="http://nanobiotix.com/role/LosspershareAdditionalInformationDetails">
        <link:definition>241014063 - Disclosure - Loss per share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://nanobiotix.com/role/Commitments">
        <link:definition>211021022 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsDetails" roleURI="http://nanobiotix.com/role/CommitmentsDetails">
        <link:definition>241034064 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedparties" roleURI="http://nanobiotix.com/role/Relatedparties">
        <link:definition>211041023 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesTables" roleURI="http://nanobiotix.com/role/RelatedpartiesTables">
        <link:definition>231053017 - Disclosure - Related parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesDetails" roleURI="http://nanobiotix.com/role/RelatedpartiesDetails">
        <link:definition>241064065 - Disclosure - Related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Subsequentevents" roleURI="http://nanobiotix.com/role/Subsequentevents">
        <link:definition>211071024 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequenteventsDetails" roleURI="http://nanobiotix.com/role/SubsequenteventsDetails">
        <link:definition>241084066 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbx_TranchesAxis" abstract="true" name="TranchesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_PrepaymentsOnTangibleAssetsMember" abstract="true" name="PrepaymentsOnTangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA20191Member" abstract="true" name="BSA20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CurrentFinancialLiabilitiesMember" abstract="true" name="CurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementDomain" abstract="true" name="CollaborationAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ConcentrationRiskPercentage" abstract="false" name="ConcentrationRiskPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_BorrowingTotalInterestPayable" abstract="false" name="BorrowingTotalInterestPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSA2013Member" abstract="true" name="BSA2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_AGA2021Member" abstract="true" name="AGA2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_ConsolidatedForecastedSalesPeriod" abstract="false" name="ConsolidatedForecastedSalesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" abstract="false" name="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementBPIFranceMember" abstract="true" name="NonDilutiveFinancingAgreementBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" abstract="true" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ProvisionsForDisputesMember" abstract="true" name="ProvisionsForDisputesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfShareBasedPaymentArrangementPlans" abstract="false" name="NumberOfShareBasedPaymentArrangementPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_ResearchTaxCreditUtilizationPeriod" abstract="false" name="ResearchTaxCreditUtilizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" abstract="false" name="PercentageIncreaseDecreaseInEmployeeBenefitExpense" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" abstract="false" name="ContractualCommitmentsMilestonePaymentAnnualIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_SanofiGeneTherapyPortfolioMember" abstract="true" name="SanofiGeneTherapyPortfolioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" abstract="false" name="AdjustmentsForDecreaseIncreaseInOtherReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" abstract="true" name="GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OSA2018Member" abstract="true" name="OSA2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_InterestFreeLoanBPIFranceMember" abstract="true" name="InterestFreeLoanBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" abstract="false" name="MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_BorrowingNumberOfQuarterlyInstalments" abstract="false" name="BorrowingNumberOfQuarterlyInstalments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_DisclosureOfCashAndCashEquivalentsTable" abstract="true" name="DisclosureOfCashAndCashEquivalentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OSALLY2019Member" abstract="true" name="OSALLY2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfImpactingFactors" abstract="false" name="NumberOfImpactingFactors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" abstract="false" name="IncreaseDecreaseToAnnualRentExpenseIndexationImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DefinedBenefitObligationPayablePeriod" abstract="false" name="DefinedBenefitObligationPayablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BorrowingPercentageOfStateGuaranteedLoan" abstract="false" name="BorrowingPercentageOfStateGuaranteedLoan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" abstract="false" name="DetailedInformationAboutFinanceIncomeCostTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" abstract="false" name="DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" abstract="false" name="AdjustmentsForUSInitialPublicOffering2018CostsOffset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSPCE2017ProjectMember" abstract="true" name="BSPCE2017ProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_SupervisoryBoardMember" abstract="true" name="SupervisoryBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_ContractualCommitmentsPayment" abstract="false" name="ContractualCommitmentsPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AGA20191Member" abstract="true" name="AGA20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_OSA20162Member" abstract="true" name="OSA20162Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA2021AMember" abstract="true" name="BSA2021AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_BSPCE20121Member" abstract="true" name="BSPCE20121Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" abstract="false" name="CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfTranchesBorrowings" abstract="false" name="NumberOfTranchesBorrowings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" abstract="false" name="DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" abstract="false" name="CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" abstract="false" name="ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA20161Member" abstract="true" name="OSA20161Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" abstract="false" name="DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_MilestonePaymentDefermentPeriodAfterEnrollment" abstract="false" name="MilestonePaymentDefermentPeriodAfterEnrollment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_LeaseContractAlfortvilleMember" abstract="true" name="LeaseContractAlfortvilleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_LeaseContractWattigniesMember" abstract="true" name="LeaseContractWattigniesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NonCurrentSecurityDepositMember" abstract="true" name="NonCurrentSecurityDepositMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" abstract="false" name="TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" abstract="false" name="NumberOfOrdinaryShareSubscribedPerEachOSA" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_BSPCE20151Member" abstract="true" name="BSPCE20151Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_BSA2016OrdinaryMember" abstract="true" name="BSA2016OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" abstract="false" name="DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" abstract="false" name="IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ActuarialAssumptionOfSocialSecurityContributionRates" abstract="false" name="ActuarialAssumptionOfSocialSecurityContributionRates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" abstract="true" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SharePriceMilestoneEuronextParis" abstract="false" name="SharePriceMilestoneEuronextParis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" abstract="false" name="AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbx_OSAMember" abstract="true" name="OSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA2016PerformanceMember" abstract="true" name="BSA2016PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CurrentOtherProvisionsMember" abstract="true" name="CurrentOtherProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" abstract="false" name="DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfOperatingExpensesTable" abstract="true" name="DisclosureOfOperatingExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_CashAndCashEquivalentsMember" abstract="true" name="CashAndCashEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" abstract="true" name="ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfSharesIssuedThroughIssueOfEquity" abstract="false" name="NumberOfSharesIssuedThroughIssueOfEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbx_AnnualLeaseExpense" abstract="false" name="AnnualLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyTable" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" abstract="false" name="NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" abstract="false" name="SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AllocationOfPriorPeriodLoss" abstract="false" name="AllocationOfPriorPeriodLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" abstract="false" name="ResearchAndDevelopmentExpenseSinceStartOfCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSA2021AInReplacementOfBSA2016Member" abstract="true" name="BSA2021AInReplacementOfBSA2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_BSA20182Member" abstract="true" name="BSA20182Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" abstract="false" name="IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" abstract="true" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" abstract="false" name="PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_SignificantAccountingPoliciesAbstract" abstract="true" name="SignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" abstract="false" name="SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" abstract="true" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_PharmaEngineNBTWR3Member" abstract="true" name="PharmaEngineNBTWR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" abstract="false" name="DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_TranchesDomain" abstract="true" name="TranchesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_TrancheFourMember" abstract="true" name="TrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NanobiotixSAMember" abstract="true" name="NanobiotixSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TrancheDomain" abstract="true" name="TrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_FormerExecutiveBoardMembersMember" abstract="true" name="FormerExecutiveBoardMembersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AdvancesReceivedDefermentPeriod" abstract="false" name="AdvancesReceivedDefermentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BPIFranceMember" abstract="true" name="BPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSPCE20153Member" abstract="true" name="BSPCE20153Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ConditionalAdvanceBPIFranceMember" abstract="true" name="ConditionalAdvanceBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementMilestonesAchievementPeriod" abstract="false" name="CollaborationAgreementMilestonesAchievementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BSPCE20122Member" abstract="true" name="BSPCE20122Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_RoyaltiesAgreementPeriod" abstract="false" name="RoyaltiesAgreementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BSA2016Member" abstract="true" name="BSA2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NonManagementMember" abstract="true" name="NonManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfShortTermLeaseContracts" abstract="false" name="NumberOfShortTermLeaseContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_VestingDomain" abstract="true" name="VestingDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" abstract="false" name="PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_OSA202106PerformanceMember" abstract="true" name="OSA202106PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_FromFirstYearOfGrantDateMember" abstract="true" name="FromFirstYearOfGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" abstract="false" name="ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_LeaseContractFaubourgSaintAntoineMember" abstract="true" name="LeaseContractFaubourgSaintAntoineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" abstract="false" name="DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BSA2014Member" abstract="true" name="BSA2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageSharePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" abstract="false" name="PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_NetLossForThePeriod" abstract="false" name="NetLossForThePeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA202104PerformanceMember" abstract="true" name="OSA202104PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" abstract="true" name="DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" abstract="true" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_LeaseContractVillejuifMember" abstract="true" name="LeaseContractVillejuifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BSA20162Member" abstract="true" name="BSA20162Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AGAMember" abstract="true" name="AGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CuradigmSASMember" abstract="true" name="CuradigmSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" abstract="false" name="NumberOfOrdinaryShareSubscribedPerEachBSA" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbx_BSPCE2017PerformanceMember" abstract="true" name="BSPCE2017PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementAxis" abstract="true" name="CollaborationAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" abstract="false" name="SellingGeneralAndAdministrativeExpensePayrollCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OpenTaxYearDomain" abstract="true" name="OpenTaxYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSPCE082013Member" abstract="true" name="BSPCE082013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_FormerEmployeesMember" abstract="true" name="FormerEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_CompanyDeferredTaxRate" abstract="false" name="CompanyDeferredTaxRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfGlobalRegistrationalStudiesSupported" abstract="false" name="NumberOfGlobalRegistrationalStudiesSupported" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_MDAndersonCancerCenterNBTXR3Member" abstract="true" name="MDAndersonCancerCenterNBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AdvancesAuthorizedAmountToBeAdvanced" abstract="false" name="AdvancesAuthorizedAmountToBeAdvanced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AGA2020AndAGA2021Member" abstract="true" name="AGA2020AndAGA2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_DisclosureOfOperatingExpensesLineItems" abstract="true" name="DisclosureOfOperatingExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" abstract="true" name="InterestFreeAdvanceToCuradigmBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" abstract="false" name="DisclosureOfNonCurrentFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" abstract="false" name="MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_A2018TaxYearMember" abstract="true" name="A2018TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ConditionalAdvancesMember" abstract="true" name="ConditionalAdvancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInEmployeeBenefitExpense" abstract="false" name="IncreaseDecreaseInEmployeeBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA2017PerformanceMember" abstract="true" name="OSA2017PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" abstract="true" name="DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" abstract="false" name="ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfSubsidiaries" abstract="false" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_NonCurrentOtherProvisionsMember" abstract="true" name="NonCurrentOtherProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" abstract="false" name="CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSA2020Member" abstract="true" name="BSA2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA0412Member" abstract="true" name="BSA0412Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ICONPlcMember" abstract="true" name="ICONPlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BPIFranceAdvanceMember" abstract="true" name="BPIFranceAdvanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" abstract="false" name="TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_NumberOfNewLeaseContracts" abstract="false" name="NumberOfNewLeaseContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_RoyaltyPayables" abstract="false" name="RoyaltyPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BartVanRhijnMember" abstract="true" name="BartVanRhijnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" abstract="true" name="PGELoanAgreementBPIFranceAndHSBCFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_BSA20181Member" abstract="true" name="BSA20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" abstract="false" name="ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_NonCurrentFinancialAssetsMember" abstract="true" name="NonCurrentFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" abstract="false" name="DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_ContractTerminationIndemnities" abstract="false" name="ContractTerminationIndemnities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" abstract="false" name="ProvisionUsedAndUnusedProvisionReversedOtherProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA2017Member" abstract="true" name="OSA2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_FromSecondYearOfGrantDateMember" abstract="true" name="FromSecondYearOfGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" abstract="false" name="ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_NetLossForThePeriodMember" abstract="true" name="NetLossForThePeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_OSA202104Member" abstract="true" name="OSA202104Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementHSBCFranceMember" abstract="true" name="NonDilutiveFinancingAgreementHSBCFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" abstract="true" name="MembersOfTheExecutiveBoardAndAlainDostieMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TradeAndOtherPayablesMember" abstract="true" name="TradeAndOtherPayablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" abstract="false" name="BorrowingMaturityTermInitialPeriodBearingNoInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" abstract="false" name="ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_DisclosureOfSignificantTransactionsTextBlock" abstract="false" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_NonCurrentFinancialLiabilitiesMember" abstract="true" name="NonCurrentFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInNumberOfEmployees" abstract="false" name="IncreaseDecreaseInNumberOfEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_BSA20152AMember" abstract="true" name="BSA20152AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AdvancesOutstandingAmountToBeReceived" abstract="false" name="AdvancesOutstandingAmountToBeReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" abstract="false" name="IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LeaseContractOberkampfStreetMember" abstract="true" name="LeaseContractOberkampfStreetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSPCE092014Member" abstract="true" name="BSPCE092014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OptionLifeOtherEquityInstrumentsGranted" abstract="false" name="OptionLifeOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_LeaseContractExtendedPeriod" abstract="false" name="LeaseContractExtendedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BSPCE2016Member" abstract="true" name="BSPCE2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSPCE2016PerformanceMember" abstract="true" name="BSPCE2016PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BorrowingDefermentPeriodToRequestFunds" abstract="false" name="BorrowingDefermentPeriodToRequestFunds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_BSPCE042013Member" abstract="true" name="BSPCE042013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" abstract="true" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_BanquePubliqueDInvestissementMember" abstract="true" name="BanquePubliqueDInvestissementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_A2020TaxYearMember" abstract="true" name="A2020TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfPatientsInClinicalTrial" abstract="false" name="NumberOfPatientsInClinicalTrial" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" abstract="false" name="CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ExternalConsultantMember" abstract="true" name="ExternalConsultantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" abstract="false" name="ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSPCE20152Member" abstract="true" name="BSPCE20152Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfCommitmentsAbstract" abstract="true" name="DisclosureOfCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_AnnualShortTermLeaseExpense" abstract="false" name="AnnualShortTermLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_LumpSumRetirementBenefitsMember" abstract="true" name="LumpSumRetirementBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NumberOfParentEntities" abstract="false" name="NumberOfParentEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_AnneJulietteHermantMember" abstract="true" name="AnneJulietteHermantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentTaxCredit" abstract="false" name="ResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" abstract="false" name="TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_RevenueByTypeMember" abstract="true" name="RevenueByTypeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BorrowingDefermentPeriod" abstract="false" name="BorrowingDefermentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_RightOfUseTransportEquipmentMember" abstract="true" name="RightOfUseTransportEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" abstract="false" name="ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_ExercisePriceOtherEquityInstrumentsGranted" abstract="false" name="ExercisePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_OSA20161PerformanceMember" abstract="true" name="OSA20161PerformanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" abstract="false" name="IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbx_BorrowingGuaranteeFee" abstract="false" name="BorrowingGuaranteeFee" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_IPOGreenShoeUSDollarMember" abstract="true" name="IPOGreenShoeUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA2021BMember" abstract="true" name="BSA2021BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementTotalPaymentsReceived" abstract="false" name="CollaborationAgreementTotalPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OpenTaxYearAxis" abstract="true" name="OpenTaxYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_InitialPublicOfferingMember" abstract="true" name="InitialPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" abstract="false" name="DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BorrowingNumberOfPGE" abstract="false" name="BorrowingNumberOfPGE" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_LeaseContractParkingVillejuifMember" abstract="true" name="LeaseContractParkingVillejuifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ResearchAndDevelopmentExpensePayrollCosts" abstract="false" name="ResearchAndDevelopmentExpensePayrollCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_FromThirdYearOfGrantDateMember" abstract="true" name="FromThirdYearOfGrantDateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_AGA2020Member" abstract="true" name="AGA2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NonExecutiveMember" abstract="true" name="NonExecutiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AdvancesReceivedInterestRate" abstract="false" name="AdvancesReceivedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_NonCurrentLiquidityContractMember" abstract="true" name="NonCurrentLiquidityContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_OSA202104OrdinaryMember" abstract="true" name="OSA202104OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_DisclosureOfFinancialLiabilitiesTextBlock" abstract="false" name="DisclosureOfFinancialLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BSPCE2017Member" abstract="true" name="BSPCE2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_ProvisionsForChargesMember" abstract="true" name="ProvisionsForChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OtherMiscellaneousCurrentLiabilities" abstract="false" name="OtherMiscellaneousCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AmericanDepositorySharesNASDAQStockMarketMember" abstract="true" name="AmericanDepositorySharesNASDAQStockMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" abstract="true" name="DisclosureOfInformationRelatedToTheCompanyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_A2021TaxYearMember" abstract="true" name="A2021TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_OtherSalesMember" abstract="true" name="OtherSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_ProceedsFromWarrantsSubscription" abstract="false" name="ProceedsFromWarrantsSubscription" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSPCEMember" abstract="true" name="BSPCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DepreciationAmortizationAndProvisionExpenses" abstract="false" name="DepreciationAmortizationAndProvisionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA20161OrdinaryMember" abstract="true" name="OSA20161OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_InterestFreeBPIFranceLoanMember" abstract="true" name="InterestFreeBPIFranceLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" abstract="false" name="DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nbx_ServicesMember" abstract="true" name="ServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BorrowingMaturityTerm" abstract="false" name="BorrowingMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_ExecutiveBoardAndEmployeesMember" abstract="true" name="ExecutiveBoardAndEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSPCE2017OrdinaryMember" abstract="true" name="BSPCE2017OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" abstract="true" name="NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_IPOInitialDealUSDollarMember" abstract="true" name="IPOInitialDealUSDollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OSA202106OrdinaryMember" abstract="true" name="OSA202106OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_RightOfUseBuildingsMember" abstract="true" name="RightOfUseBuildingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" abstract="false" name="TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_LianBioNBTXR3Member" abstract="true" name="LianBioNBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_EuropeanInvestmentBankLoanAgreementMember" abstract="true" name="EuropeanInvestmentBankLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" abstract="false" name="AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" abstract="false" name="IncreaseDecreaseInPurchasesFeesAndOtherExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_AGA20181Member" abstract="true" name="AGA20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" abstract="false" name="CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_OSA2020Member" abstract="true" name="OSA2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" abstract="true" name="AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_NonCurrentInvestmentsPledgedAsCollateralMember" abstract="true" name="NonCurrentInvestmentsPledgedAsCollateralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSA20152BMember" abstract="true" name="BSA20152BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OSA202106Member" abstract="true" name="OSA202106Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nbx_VestingAxis" abstract="true" name="VestingAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nbx_DisclosureOfCashAndCashEquivalentsLineItems" abstract="true" name="DisclosureOfCashAndCashEquivalentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nbx_AGA20182Member" abstract="true" name="AGA20182Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TrancheThreeMember" abstract="true" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OSA2017OrdinaryMember" abstract="true" name="OSA2017OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_UnusedTaxLossExpirationPeriod" abstract="false" name="UnusedTaxLossExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_IPOInitialDealEuroMember" abstract="true" name="IPOInitialDealEuroMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_TaxEffectOfShareBasedPaymentArrangements" abstract="false" name="TaxEffectOfShareBasedPaymentArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" abstract="false" name="DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_BSA2017Member" abstract="true" name="BSA2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_CollaborationAgreementUpfrontPaymentReceived" abstract="false" name="CollaborationAgreementUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbx_A2019TaxYearMember" abstract="true" name="A2019TaxYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_BSA20151Member" abstract="true" name="BSA20151Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_OSA20191Member" abstract="true" name="OSA20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbx_BSPCE2016OrdinaryMember" abstract="true" name="BSPCE2016OrdinaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_NumberOfTranchesReceivedBorrowings" abstract="false" name="NumberOfTranchesReceivedBorrowings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" abstract="false" name="BorrowingMaturityTermSubsequentPeriodBearingInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbx_IssueOfEquityPricePerShare" abstract="false" name="IssueOfEquityPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="nbx_BSAMember" abstract="true" name="BSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" abstract="true" name="TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>nbx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_caccae0f-0c6f-4262-91f2-7f1c6aa5a0b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_9556119d-7c26-4eac-9391-0b29a06d81f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_caccae0f-0c6f-4262-91f2-7f1c6aa5a0b8" xlink:to="loc_ifrs-full_OtherCurrentAssets_9556119d-7c26-4eac-9391-0b29a06d81f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_88fc5276-4c87-4ba2-a067-2e5805d6812a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_caccae0f-0c6f-4262-91f2-7f1c6aa5a0b8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_88fc5276-4c87-4ba2-a067-2e5805d6812a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_efa83487-1492-43e2-902e-d49926b3a200" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_caccae0f-0c6f-4262-91f2-7f1c6aa5a0b8" xlink:to="loc_ifrs-full_CurrentTradeReceivables_efa83487-1492-43e2-902e-d49926b3a200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_de338399-f13f-4fd4-9072-47d41afa0f63" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9abb695f-ab12-4c85-9316-3ba71664ce9a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_de338399-f13f-4fd4-9072-47d41afa0f63" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9abb695f-ab12-4c85-9316-3ba71664ce9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_f65f1951-5c3c-415a-b9ff-d9d349f2903c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_de338399-f13f-4fd4-9072-47d41afa0f63" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_f65f1951-5c3c-415a-b9ff-d9d349f2903c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_356155a5-db6c-40cd-aa62-02c6814096fc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_de338399-f13f-4fd4-9072-47d41afa0f63" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_356155a5-db6c-40cd-aa62-02c6814096fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_496e8175-f4f7-4ebe-8d43-a20bfcedafdb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_48a71c90-7973-4e22-9856-8050972adae4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_496e8175-f4f7-4ebe-8d43-a20bfcedafdb" xlink:to="loc_ifrs-full_CurrentLiabilities_48a71c90-7973-4e22-9856-8050972adae4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_ca0e81f3-9ce3-4448-a21d-bdbc3d1f0ddd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_496e8175-f4f7-4ebe-8d43-a20bfcedafdb" xlink:to="loc_ifrs-full_NoncurrentLiabilities_ca0e81f3-9ce3-4448-a21d-bdbc3d1f0ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_17b806b6-9d3f-4ae2-81b3-4083e7d4d2c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_496e8175-f4f7-4ebe-8d43-a20bfcedafdb" xlink:to="loc_ifrs-full_Equity_17b806b6-9d3f-4ae2-81b3-4083e7d4d2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_104ecb3c-7953-4c03-8e29-d718acdb48e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_2e26a14e-54f5-4f81-8324-cf35b1f38367" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_104ecb3c-7953-4c03-8e29-d718acdb48e3" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_2e26a14e-54f5-4f81-8324-cf35b1f38367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_6fd3f063-5b6b-46f0-b852-a1bf47086bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_104ecb3c-7953-4c03-8e29-d718acdb48e3" xlink:to="loc_ifrs-full_NoncurrentProvisions_6fd3f063-5b6b-46f0-b852-a1bf47086bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_9f672721-0394-4923-a50a-890890da458c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_ifrs-full_OtherReserves_9f672721-0394-4923-a50a-890890da458c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_3db14d38-13fd-40ad-9f76-af3a2dde9ea9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_3db14d38-13fd-40ad-9f76-af3a2dde9ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_3dea9eb5-8888-4840-b5c5-15937d1df8ce" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_ifrs-full_IssuedCapital_3dea9eb5-8888-4840-b5c5-15937d1df8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriod_a5e965b1-54ae-4a53-9ae5-0e2c90752787" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriod"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_nbx_NetLossForThePeriod_a5e965b1-54ae-4a53-9ae5-0e2c90752787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_7c29858c-eaf7-4f67-b2f4-db1b256660d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_ifrs-full_SharePremium_7c29858c-eaf7-4f67-b2f4-db1b256660d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_cf751b84-4d85-4fb8-a736-3feee9c6e3c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8ddaa955-c714-4a92-80c4-89a5f212f727" xlink:to="loc_ifrs-full_TreasuryShares_cf751b84-4d85-4fb8-a736-3feee9c6e3c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_a2640614-4510-41ec-9272-d94005556f29" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_efdd1996-01e5-4e97-9003-6dbb7e9af990" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_a2640614-4510-41ec-9272-d94005556f29" xlink:to="loc_ifrs-full_NoncurrentAssets_efdd1996-01e5-4e97-9003-6dbb7e9af990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_a5cc9a5d-c063-4b7c-a503-c30f62991fbd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_a2640614-4510-41ec-9272-d94005556f29" xlink:to="loc_ifrs-full_CurrentAssets_a5cc9a5d-c063-4b7c-a503-c30f62991fbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_9cc2652b-f4d5-41e5-8d34-71e844e66cf8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_9cc2652b-f4d5-41e5-8d34-71e844e66cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_d5744465-8d6a-43d0-a579-123cfca46ae1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_d5744465-8d6a-43d0-a579-123cfca46ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_18df1b01-f2f2-4355-8ed0-5c70dc171dc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:to="loc_ifrs-full_CurrentProvisions_18df1b01-f2f2-4355-8ed0-5c70dc171dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_734a2526-d01d-4e28-8180-b2dc8ddd23e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_734a2526-d01d-4e28-8180-b2dc8ddd23e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_3547bbf7-b73a-48ef-acf2-c6bd02f43517" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_7279444a-3c11-4751-95b2-4afcc2cb3e9b" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_3547bbf7-b73a-48ef-acf2-c6bd02f43517" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDOPERATIONS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_305e64d5-58be-47e5-89cb-6321159aa2f4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_c8af8941-7f52-469b-b0a3-b57b7a7e291a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_305e64d5-58be-47e5-89cb-6321159aa2f4" xlink:to="loc_ifrs-full_OperatingExpense_c8af8941-7f52-469b-b0a3-b57b7a7e291a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_ba8bcc23-0cee-4ed9-b920-3bb579994d61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_305e64d5-58be-47e5-89cb-6321159aa2f4" xlink:to="loc_ifrs-full_Revenue_ba8bcc23-0cee-4ed9-b920-3bb579994d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_cdd345b2-db86-4ed3-bc3d-c8510adc304c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_cb24179f-c3e1-4dd5-93ee-86d54ad1cdcf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_cdd345b2-db86-4ed3-bc3d-c8510adc304c" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_cb24179f-c3e1-4dd5-93ee-86d54ad1cdcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_21f87ae9-d39c-4543-953b-4f8932cdbbbf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_cdd345b2-db86-4ed3-bc3d-c8510adc304c" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_21f87ae9-d39c-4543-953b-4f8932cdbbbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_7db3b371-8781-4cc1-b140-cb79e4c55f92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_cdd345b2-db86-4ed3-bc3d-c8510adc304c" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_7db3b371-8781-4cc1-b140-cb79e4c55f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_81c61caa-f099-4a1c-b44c-6aa152b8dfd4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_47472bbb-4901-4375-bdf4-6c36240afdce" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_81c61caa-f099-4a1c-b44c-6aa152b8dfd4" xlink:to="loc_ifrs-full_FinanceCosts_47472bbb-4901-4375-bdf4-6c36240afdce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_cb18683a-a986-4bda-90e7-e0d4be7596b0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_81c61caa-f099-4a1c-b44c-6aa152b8dfd4" xlink:to="loc_ifrs-full_FinanceIncome_cb18683a-a986-4bda-90e7-e0d4be7596b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_fd84b7d8-e4ad-4c2e-959c-3d1df57eff92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_efaefea9-057d-4bfe-be92-822f20e63435" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_fd84b7d8-e4ad-4c2e-959c-3d1df57eff92" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_efaefea9-057d-4bfe-be92-822f20e63435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_38d9254a-eabe-4e40-9450-4219c6278332" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_fd84b7d8-e4ad-4c2e-959c-3d1df57eff92" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_38d9254a-eabe-4e40-9450-4219c6278332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_94fba5f6-e301-4ec3-9f71-1219f05e5bc9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_fd84b7d8-e4ad-4c2e-959c-3d1df57eff92" xlink:to="loc_ifrs-full_FinanceIncomeCost_94fba5f6-e301-4ec3-9f71-1219f05e5bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_e538a410-b560-43f1-832d-c357010784a4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_6e8c30bc-a967-4bce-94cb-8b51ed6039b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_e538a410-b560-43f1-832d-c357010784a4" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_6e8c30bc-a967-4bce-94cb-8b51ed6039b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_3ea7e61b-fb48-44b3-a138-6ed95576998f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_e538a410-b560-43f1-832d-c357010784a4" xlink:to="loc_ifrs-full_OtherIncome_3ea7e61b-fb48-44b3-a138-6ed95576998f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_8cc022ca-c93a-414b-a714-0d1b4621c90e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_007b633e-c420-4c1a-abc7-47fa9329ffdd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_8cc022ca-c93a-414b-a714-0d1b4621c90e" xlink:to="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_007b633e-c420-4c1a-abc7-47fa9329ffdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_4252c829-f5de-47dc-831f-1c4d8195488a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_8cc022ca-c93a-414b-a714-0d1b4621c90e" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_4252c829-f5de-47dc-831f-1c4d8195488a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_250af5c9-73e8-41a3-949c-86e3ff95f95f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_197bee89-2949-4ac9-b22b-ebc4f0461d98" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_250af5c9-73e8-41a3-949c-86e3ff95f95f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_197bee89-2949-4ac9-b22b-ebc4f0461d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_97eea203-6727-4b31-915a-2a198d911413" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_250af5c9-73e8-41a3-949c-86e3ff95f95f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_97eea203-6727-4b31-915a-2a198d911413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_5c615de2-449a-48c6-b686-386037d49e36" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_250af5c9-73e8-41a3-949c-86e3ff95f95f" xlink:to="loc_ifrs-full_ProfitLoss_5c615de2-449a-48c6-b686-386037d49e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ac307cad-1048-45aa-ae2e-b01362d40e2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_8e921e16-fec8-495a-91f2-87b25c690ab5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ac307cad-1048-45aa-ae2e-b01362d40e2c" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_8e921e16-fec8-495a-91f2-87b25c690ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_d763c068-8de5-432b-9b0c-059779cff68f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_ac307cad-1048-45aa-ae2e-b01362d40e2c" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_d763c068-8de5-432b-9b0c-059779cff68f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_f9a46359-9324-499c-a8f0-cfb5524f3173" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_fd417c13-7804-44a8-82e3-ac6c8996e98f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_f9a46359-9324-499c-a8f0-cfb5524f3173" xlink:to="loc_ifrs-full_ProfitLoss_fd417c13-7804-44a8-82e3-ac6c8996e98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c55b7cb0-a380-4c7a-9033-a5d832970df5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_f9a46359-9324-499c-a8f0-cfb5524f3173" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c55b7cb0-a380-4c7a-9033-a5d832970df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_8b90cce2-a557-4b9e-8f79-023b523dc573" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_f9a46359-9324-499c-a8f0-cfb5524f3173" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_8b90cce2-a557-4b9e-8f79-023b523dc573" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCASHFLOWS"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_c8eaef9c-3d4c-4178-8590-402f8d4e711b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_c8eaef9c-3d4c-4178-8590-402f8d4e711b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_f44621c5-7ac4-498f-b72e-6b6fc34d696a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_f44621c5-7ac4-498f-b72e-6b6fc34d696a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_22dc2ba1-ea64-4ce1-a905-d5312bf2eb63" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_22dc2ba1-ea64-4ce1-a905-d5312bf2eb63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_dbb67921-c714-452a-8db9-9c1b89ba2300" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_dbb67921-c714-452a-8db9-9c1b89ba2300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_5afa7d41-25ee-4462-96d3-b705e727c7b2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_5afa7d41-25ee-4462-96d3-b705e727c7b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_df117c92-dda2-45ed-9d66-6129d5452735" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_df117c92-dda2-45ed-9d66-6129d5452735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4cffcf07-8930-4113-b643-adce976fa407" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_4cffcf07-8930-4113-b643-adce976fa407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_33f67727-b5b4-49cb-9633-b802d108f53a" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_33f67727-b5b4-49cb-9633-b802d108f53a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_1b8f81c0-f7dc-417d-b494-6a21d58ff61a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_faa66f99-3769-4c54-b20b-ef53f882582b" xlink:to="loc_ifrs-full_ProfitLoss_1b8f81c0-f7dc-417d-b494-6a21d58ff61a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_176d8811-180d-49bc-97f4-3c867b982598" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_176d8811-180d-49bc-97f4-3c867b982598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_34626d14-f43f-4fc0-92e8-c4dd62157416" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_34626d14-f43f-4fc0-92e8-c4dd62157416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_689ca21d-9d33-4e86-9823-186a76a8acc1" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_689ca21d-9d33-4e86-9823-186a76a8acc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_436537a4-d04c-42a1-a59c-2f6506ba068c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_436537a4-d04c-42a1-a59c-2f6506ba068c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_b9bc2891-ef69-4336-9546-f0ead8b96d25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_b9bc2891-ef69-4336-9546-f0ead8b96d25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_21e2f7c2-7a60-46b4-9521-85af9d406d89" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_55be94fc-1a68-47b3-af6e-ec55b39b6b4a" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_21e2f7c2-7a60-46b4-9521-85af9d406d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_cf6bfe93-8254-4b96-aa2b-744fe64c041c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_480b424d-8976-48e4-86ca-96d823c4a3f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_cf6bfe93-8254-4b96-aa2b-744fe64c041c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_480b424d-8976-48e4-86ca-96d823c4a3f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_aa93e828-015e-4d4d-8abe-5ede1cbd8576" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_cf6bfe93-8254-4b96-aa2b-744fe64c041c" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_aa93e828-015e-4d4d-8abe-5ede1cbd8576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c26e8ff-44eb-4c55-9544-dae1bf42f873" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_cf6bfe93-8254-4b96-aa2b-744fe64c041c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c26e8ff-44eb-4c55-9544-dae1bf42f873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_db1e8116-f1a3-4418-958b-ba9cc241fdf9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_cf6bfe93-8254-4b96-aa2b-744fe64c041c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_db1e8116-f1a3-4418-958b-ba9cc241fdf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2b91b312-d557-4918-ab0b-ba435c878ed1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ee9f240f-dea3-4672-8476-61f1a9ddc2d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2b91b312-d557-4918-ab0b-ba435c878ed1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ee9f240f-dea3-4672-8476-61f1a9ddc2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9fd97576-e1b9-49a7-a997-bb71b028a0a4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_2b91b312-d557-4918-ab0b-ba435c878ed1" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_9fd97576-e1b9-49a7-a997-bb71b028a0a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_a4b94eb3-e09f-4641-8a33-8754644fd772" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_a4b94eb3-e09f-4641-8a33-8754644fd772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_92ae801a-5e5a-499a-9917-985b1eb81f4a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_92ae801a-5e5a-499a-9917-985b1eb81f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromWarrantsSubscription_4225b4ae-d9ad-4ac7-8aaf-30fdac2d852e" xlink:href="nbx-20211231.xsd#nbx_ProceedsFromWarrantsSubscription"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_nbx_ProceedsFromWarrantsSubscription_4225b4ae-d9ad-4ac7-8aaf-30fdac2d852e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_44851c08-2662-436b-a0f0-e87caae86885" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_44851c08-2662-436b-a0f0-e87caae86885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_77d9a976-5678-422a-a4cc-784cf73d8558" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_77d9a976-5678-422a-a4cc-784cf73d8558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_85d19288-7231-4781-a4bd-7cc1c77f82c1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_85d19288-7231-4781-a4bd-7cc1c77f82c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_ead0845f-af85-4bf3-a819-5cf8234f2e5a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e488b715-5727-4068-a003-9c4a9b9460b5" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_ead0845f-af85-4bf3-a819-5cf8234f2e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3b60d034-d380-452b-863c-53e81774fe12" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e6e50cf3-abf6-40d1-af67-b8992e7c3f32" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3b60d034-d380-452b-863c-53e81774fe12" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_e6e50cf3-abf6-40d1-af67-b8992e7c3f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_e993960b-31aa-4453-ab56-9fa6ffd80e6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3b60d034-d380-452b-863c-53e81774fe12" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_e993960b-31aa-4453-ab56-9fa6ffd80e6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9f266d51-463f-4a87-a2c8-e550b29b6259" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_3b60d034-d380-452b-863c-53e81774fe12" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9f266d51-463f-4a87-a2c8-e550b29b6259" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_f634f909-50de-4c4c-9eaf-fd02a69c53a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_c3c6ffe8-c881-4476-9bb3-4cc8aba80abd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_f634f909-50de-4c4c-9eaf-fd02a69c53a0" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_c3c6ffe8-c881-4476-9bb3-4cc8aba80abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_14320efe-e8b0-4d63-bd9a-8ba08b9b67b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_f634f909-50de-4c4c-9eaf-fd02a69c53a0" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_14320efe-e8b0-4d63-bd9a-8ba08b9b67b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_2262f08a-0f60-4934-a500-3f61a52bdc04" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_f634f909-50de-4c4c-9eaf-fd02a69c53a0" xlink:to="loc_ifrs-full_OtherCurrentReceivables_2262f08a-0f60-4934-a500-3f61a52bdc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_8d600569-eb60-4cab-8bd5-c2a9865dd835" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentAssets_f634f909-50de-4c4c-9eaf-fd02a69c53a0" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_8d600569-eb60-4cab-8bd5-c2a9865dd835" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_78133c2d-b956-4355-9847-03ff7b9dd776" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_366b11c6-e964-4d25-82ea-2e3b93b10e23" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_78133c2d-b956-4355-9847-03ff7b9dd776" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_366b11c6-e964-4d25-82ea-2e3b93b10e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_cfe07583-51e7-47d3-b276-c101f7afd6bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_78133c2d-b956-4355-9847-03ff7b9dd776" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_cfe07583-51e7-47d3-b276-c101f7afd6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_988de642-28bd-4345-a539-24ebe992b89f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_78133c2d-b956-4355-9847-03ff7b9dd776" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_988de642-28bd-4345-a539-24ebe992b89f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_218bea37-6d88-4a0a-933f-9724ea30e75d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_6b1e1641-57bf-4607-a3d5-594e7c1b7d0d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_218bea37-6d88-4a0a-933f-9724ea30e75d" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_6b1e1641-57bf-4607-a3d5-594e7c1b7d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_a193d758-1805-49cc-a5a1-1663d780de4d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_218bea37-6d88-4a0a-933f-9724ea30e75d" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_a193d758-1805-49cc-a5a1-1663d780de4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_b8480ca3-5644-48ed-8f39-13e00a846cbb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_14233c18-1b2d-4c4a-a9de-1fe286cebfa0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_b8480ca3-5644-48ed-8f39-13e00a846cbb" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_14233c18-1b2d-4c4a-a9de-1fe286cebfa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_ef810b4a-da19-49fd-ae1d-1d0d598573b3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_b8480ca3-5644-48ed-8f39-13e00a846cbb" xlink:to="loc_ifrs-full_OtherCurrentPayables_ef810b4a-da19-49fd-ae1d-1d0d598573b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_8d5fcead-b90e-4029-92d1-dbcd8a9fadf9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities_9e41178f-38a3-468f-8834-04848e147006" xlink:href="nbx-20211231.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_8d5fcead-b90e-4029-92d1-dbcd8a9fadf9" xlink:to="loc_nbx_OtherMiscellaneousCurrentLiabilities_9e41178f-38a3-468f-8834-04848e147006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_04cc0eaf-54fe-41ad-9cc3-51ffb9081c86" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_8d5fcead-b90e-4029-92d1-dbcd8a9fadf9" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_04cc0eaf-54fe-41ad-9cc3-51ffb9081c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_e7dd3ced-638c-4093-8343-3b4fc16e30b3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherCurrentLiabilities_8d5fcead-b90e-4029-92d1-dbcd8a9fadf9" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_e7dd3ced-638c-4093-8343-3b4fc16e30b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_044d66c1-3e5f-4a11-9b4a-1e9b99ee120c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_e62b0d65-d7a1-419a-9332-63d42cbc1cbe" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_044d66c1-3e5f-4a11-9b4a-1e9b99ee120c" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_e62b0d65-d7a1-419a-9332-63d42cbc1cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_e6ef6f37-05d0-4bc0-890b-9f9c7eeb4aa4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_044d66c1-3e5f-4a11-9b4a-1e9b99ee120c" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_e6ef6f37-05d0-4bc0-890b-9f9c7eeb4aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_68a7de8c-5c14-40d0-a0e5-2c263017a393" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_044d66c1-3e5f-4a11-9b4a-1e9b99ee120c" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_68a7de8c-5c14-40d0-a0e5-2c263017a393" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_1ae94272-0bd7-42ec-a7a9-9272c8577a1d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_d94ed28f-7981-4176-866c-4970d89b86f7" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1ae94272-0bd7-42ec-a7a9-9272c8577a1d" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_d94ed28f-7981-4176-866c-4970d89b86f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_c8ee082f-5929-4748-bf1e-95e45d6dfb1b" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1ae94272-0bd7-42ec-a7a9-9272c8577a1d" xlink:to="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_c8ee082f-5929-4748-bf1e-95e45d6dfb1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_ed955343-9b9e-4108-a187-9b2b259c79a2" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_1ae94272-0bd7-42ec-a7a9-9272c8577a1d" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_ed955343-9b9e-4108-a187-9b2b259c79a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_dad7d933-0880-45ce-986f-dde9285cfda9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_7b5bc679-e670-4ffc-963a-bcc7a20fc8b6" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_dad7d933-0880-45ce-986f-dde9285cfda9" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_7b5bc679-e670-4ffc-963a-bcc7a20fc8b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_8c169625-2049-4307-b946-3095c81cd57f" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_dad7d933-0880-45ce-986f-dde9285cfda9" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_8c169625-2049-4307-b946-3095c81cd57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_6d66bef5-2be6-4121-b88d-9d8c5f793b88" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_dad7d933-0880-45ce-986f-dde9285cfda9" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_6d66bef5-2be6-4121-b88d-9d8c5f793b88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_313d22ad-c1fd-4929-8316-58e3c6a1537c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_4744677d-201f-42d0-aed3-7ef3245a74b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_313d22ad-c1fd-4929-8316-58e3c6a1537c" xlink:to="loc_ifrs-full_InterestRevenueExpense_4744677d-201f-42d0-aed3-7ef3245a74b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7a9835e0-b12c-4108-bc1a-6a2e0efe8e97" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_313d22ad-c1fd-4929-8316-58e3c6a1537c" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7a9835e0-b12c-4108-bc1a-6a2e0efe8e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_a3f8cc0c-86ba-4ec2-8964-e70b78090f30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_313d22ad-c1fd-4929-8316-58e3c6a1537c" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_a3f8cc0c-86ba-4ec2-8964-e70b78090f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_1fab1449-feed-40fc-8aac-f3ccba961962" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_03cbc83b-6c98-4d3d-9435-21faf6521837" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_1fab1449-feed-40fc-8aac-f3ccba961962" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_03cbc83b-6c98-4d3d-9435-21faf6521837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_eeee71f2-460d-427c-a894-f12b2feb1dc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_1fab1449-feed-40fc-8aac-f3ccba961962" xlink:to="loc_ifrs-full_NetForeignExchangeGain_eeee71f2-460d-427c-a894-f12b2feb1dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome_01133bf0-bb1c-4080-b7bb-aed7b84e1660" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_1fab1449-feed-40fc-8aac-f3ccba961962" xlink:to="loc_ifrs-full_OtherFinanceIncome_01133bf0-bb1c-4080-b7bb-aed7b84e1660" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_a6b2d885-6ac9-467a-8669-0cfffe95159c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_a6b2d885-6ac9-467a-8669-0cfffe95159c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TaxEffectOfShareBasedPaymentArrangements_4ccea287-da13-4593-99db-91924fa69b24" xlink:href="nbx-20211231.xsd#nbx_TaxEffectOfShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:to="loc_nbx_TaxEffectOfShareBasedPaymentArrangements_4ccea287-da13-4593-99db-91924fa69b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_39731ae5-c186-4601-971b-3d5fb625f540" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_39731ae5-c186-4601-971b-3d5fb625f540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_1304e497-fe33-4cd0-8061-5f6135044ad5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:to="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_1304e497-fe33-4cd0-8061-5f6135044ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_4847da6e-e0b5-4ea5-b247-2f90d6d71586" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_1abe6d05-7518-4239-be33-ad50667bf710" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_4847da6e-e0b5-4ea5-b247-2f90d6d71586" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RelatedpartiesDetails"/>
  <link:calculationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_160562ee-4ece-4530-b5d4-80758cced415" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_48f70f29-2299-4c74-b14c-af1b9252b9bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_160562ee-4ece-4530-b5d4-80758cced415" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_48f70f29-2299-4c74-b14c-af1b9252b9bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7e7cf8fb-aa4f-48e9-9732-e6b1ecef7c1e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_160562ee-4ece-4530-b5d4-80758cced415" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7e7cf8fb-aa4f-48e9-9732-e6b1ecef7c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_ab875d13-7d11-45a1-b1e7-64dad7b88108" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_160562ee-4ece-4530-b5d4-80758cced415" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_ab875d13-7d11-45a1-b1e7-64dad7b88108" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>nbx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://nanobiotix.com/role/Coverpage" xlink:type="simple" xlink:href="nbx-20211231.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/Coverpage" xlink:type="extended" id="if5a4e9a430ef41e4bdb516a89012716e_Coverpage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_16ede2f6-f48b-4adb-81af-642eeb9f5d31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentType_16ede2f6-f48b-4adb-81af-642eeb9f5d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_c201005a-7453-458d-b9ac-134a12c36c11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentRegistrationStatement_c201005a-7453-458d-b9ac-134a12c36c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_63df536b-bc07-4ffd-b87b-7f9e611683ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentAnnualReport_63df536b-bc07-4ffd-b87b-7f9e611683ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_86ad0a0d-e0c0-47df-a5ef-ec72ac0d09ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentPeriodEndDate_86ad0a0d-e0c0-47df-a5ef-ec72ac0d09ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7c6788d0-c8c4-4fc6-996d-b782ebd116d0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_CurrentFiscalYearEndDate_7c6788d0-c8c4-4fc6-996d-b782ebd116d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_38ac8143-d44f-4011-9945-5540430cfea7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentTransitionReport_38ac8143-d44f-4011-9945-5540430cfea7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_f69be603-9676-4fd3-81d0-1f24d997a6b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentShellCompanyReport_f69be603-9676-4fd3-81d0-1f24d997a6b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_89165e8f-b6cf-478a-95f2-2f3c5b6f126e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityFileNumber_89165e8f-b6cf-478a-95f2-2f3c5b6f126e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e7ad8058-7b3c-43bd-a442-968f728b2621" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityRegistrantName_e7ad8058-7b3c-43bd-a442-968f728b2621" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a58bd871-e338-4adf-990f-271189e2e3ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a58bd871-e338-4adf-990f-271189e2e3ea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9a8139d4-a9c4-468e-8afd-088e9e5c0b54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressAddressLine1_9a8139d4-a9c4-468e-8afd-088e9e5c0b54" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_88502430-55ac-49e9-998d-fb6e0d256ed8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressPostalZipCode_88502430-55ac-49e9-998d-fb6e0d256ed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1afe21f0-ad5b-46cc-ae08-a2477934d41d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressCityOrTown_1afe21f0-ad5b-46cc-ae08-a2477934d41d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_66ca2e4f-847d-4710-9164-cb58b5e1671b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressCountry_66ca2e4f-847d-4710-9164-cb58b5e1671b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_878aad00-26b6-40ee-8c14-78812b67253d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_ContactPersonnelName_878aad00-26b6-40ee-8c14-78812b67253d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2de6200e-1808-479e-8610-e97134a09880" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_CityAreaCode_2de6200e-1808-479e-8610-e97134a09880" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_12a36aea-c257-455a-be44-2d329e059a96" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_LocalPhoneNumber_12a36aea-c257-455a-be44-2d329e059a96" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber_65ad74c4-8ae4-4b06-9b49-e9af0d4a3829" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_ContactPersonnelFaxNumber_65ad74c4-8ae4-4b06-9b49-e9af0d4a3829" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7ffde44e-b9b6-4596-a3d7-4f8e003faa60" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_Security12bTitle_7ffde44e-b9b6-4596-a3d7-4f8e003faa60" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_295d5f4c-34d6-44ff-b0da-eb9ee1a840e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_TradingSymbol_295d5f4c-34d6-44ff-b0da-eb9ee1a840e5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ce0ed277-02c0-4d63-8d8e-2101bc343798" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_SecurityExchangeName_ce0ed277-02c0-4d63-8d8e-2101bc343798" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1103b3f8-ce27-4b29-bccd-73ea11e464c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1103b3f8-ce27-4b29-bccd-73ea11e464c9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_31b8a222-8ade-4d33-b5b0-a52da44761db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_31b8a222-8ade-4d33-b5b0-a52da44761db" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d08cf168-9ea4-4c81-bf03-695fa33bfc2c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityVoluntaryFilers_d08cf168-9ea4-4c81-bf03-695fa33bfc2c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_19a8a6c9-f4ee-41ab-aac1-91bb070e87e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCurrentReportingStatus_19a8a6c9-f4ee-41ab-aac1-91bb070e87e7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a555b0ee-5f1c-45d2-86a8-bd47cf7e01d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityInteractiveDataCurrent_a555b0ee-5f1c-45d2-86a8-bd47cf7e01d4" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e5c216e4-c1a1-4319-9501-f7321b6d44a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityFilerCategory_e5c216e4-c1a1-4319-9501-f7321b6d44a9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82aea762-40ea-4540-bfcd-7a78ce8c4b0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityEmergingGrowthCompany_82aea762-40ea-4540-bfcd-7a78ce8c4b0e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c3f90e6c-6cf8-4bef-8bae-21ca603cdb3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityExTransitionPeriod_c3f90e6c-6cf8-4bef-8bae-21ca603cdb3d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_728ed74c-5ea5-42f2-8ae3-e6cdcaecb826" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_728ed74c-5ea5-42f2-8ae3-e6cdcaecb826" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_822f0df3-dfe6-4af1-ab24-d1bf313aa410" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentAccountingStandard_822f0df3-dfe6-4af1-ab24-d1bf313aa410" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b1efcbc1-0326-4e87-8781-a2d481bc8359" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityShellCompany_b1efcbc1-0326-4e87-8781-a2d481bc8359" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4118bf83-a4ff-4260-ae00-d56b52ca130b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCentralIndexKey_4118bf83-a4ff-4260-ae00-d56b52ca130b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f346e63b-0f7d-4971-afee-efac6263742f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentFiscalYearFocus_f346e63b-0f7d-4971-afee-efac6263742f" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f0978ca1-0cac-421c-8bfe-f8ea533ca914" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f0978ca1-0cac-421c-8bfe-f8ea533ca914" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dc4a7687-3777-471c-b713-955738455e67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_AmendmentFlag_dc4a7687-3777-471c-b713-955738455e67" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_752135b7-1101-4c7e-ae60-59b36d050e2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_NoTradingSymbolFlag_752135b7-1101-4c7e-ae60-59b36d050e2a" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:to="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_ce44b578-0a5f-426d-bf23-f7c63f67fae1_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:to="loc_dei_ExchangeDomain_ce44b578-0a5f-426d-bf23-f7c63f67fae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:to="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember_db0faece-0811-4276-b237-9a07542f493e" xlink:href="nbx-20211231.xsd#nbx_AmericanDepositorySharesNASDAQStockMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:to="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember_db0faece-0811-4276-b237-9a07542f493e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_116bd493-b9d7-481d-9115-bd2b295501be_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:to="loc_dei_AddressTypeDomain_116bd493-b9d7-481d-9115-bd2b295501be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:to="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_180988c2-b899-40f1-b786-d77020776df1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:to="loc_dei_BusinessContactMember_180988c2-b899-40f1-b786-d77020776df1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="iedd3533fab6a4346bc80777c9ab07de5_STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_256934cb-251f-4fcc-893a-12b584cc8d1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_256934cb-251f-4fcc-893a-12b584cc8d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5d910134-833a-4a08-a640-715c369cdda8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_Equity_5d910134-833a-4a08-a640-715c369cdda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_16b48172-556b-495e-8079-9bfb9014432f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ProfitLoss_16b48172-556b-495e-8079-9bfb9014432f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d5e76eac-d20e-43b7-8d02-877001fe930f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d5e76eac-d20e-43b7-8d02-877001fe930f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_4b448149-449c-4c37-92ed-0f4cc0ec0e23" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_4b448149-449c-4c37-92ed-0f4cc0ec0e23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_47b577a1-a3d3-4a72-9827-0c88107b290b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ComprehensiveIncome_47b577a1-a3d3-4a72-9827-0c88107b290b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AllocationOfPriorPeriodLoss_e393faa3-833c-47b2-9682-064e6e2a0d51" xlink:href="nbx-20211231.xsd#nbx_AllocationOfPriorPeriodLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_AllocationOfPriorPeriodLoss_e393faa3-833c-47b2-9682-064e6e2a0d51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_5849cceb-948a-4883-9675-5232c366400a" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_5849cceb-948a-4883-9675-5232c366400a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_6e1743f5-3df9-46df-a275-5f9f8c1d8a64" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IssueOfEquity_6e1743f5-3df9-46df-a275-5f9f8c1d8a64" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_7819e3c6-9bb2-4973-827e-c099d162de34" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_7819e3c6-9bb2-4973-827e-c099d162de34" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_47c582ad-7e5f-4aea-ab58-a45691602846" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_47c582ad-7e5f-4aea-ab58-a45691602846" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_f4e23c11-0734-4227-83f3-0754f96c95b9" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_f4e23c11-0734-4227-83f3-0754f96c95b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0d74e72f-1256-4f74-b4d6-0898050b929e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0d74e72f-1256-4f74-b4d6-0898050b929e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_da5e255f-4235-476d-8bb8-f982eb0921c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_da5e255f-4235-476d-8bb8-f982eb0921c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_7bb0e8a1-af08-4b4a-a816-a5a8872b716a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_7bb0e8a1-af08-4b4a-a816-a5a8872b716a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_65a52c95-c71c-457d-85eb-cc651dea4fc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d4dd85f3-c8c5-4750-acea-951972c36272" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_20e0706e-025d-493c-8616-2ad345ec995a_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:to="loc_ifrs-full_EquityMember_20e0706e-025d-493c-8616-2ad345ec995a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:to="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_c18b3649-062f-447a-a8a6-01b5efc25909" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_IssuedCapitalMember_c18b3649-062f-447a-a8a6-01b5efc25909" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_5656b14b-0a90-4ea8-ba6b-08ae4feed1f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_SharePremiumMember_5656b14b-0a90-4ea8-ba6b-08ae4feed1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e3ad835-56b6-4167-b9f4-1b2d71c9b390" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e3ad835-56b6-4167-b9f4-1b2d71c9b390" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_230612a1-ee5b-4113-83d9-628317c7a456" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_TreasurySharesMember_230612a1-ee5b-4113-83d9-628317c7a456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_19401c4c-94db-4043-a45f-73b258dc32d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_OtherReservesMember_19401c4c-94db-4043-a45f-73b258dc32d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember_a7040032-9d32-48fc-95d6-2340c7af6885" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_nbx_NetLossForThePeriodMember_a7040032-9d32-48fc-95d6-2340c7af6885" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CompanyinformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="extended" id="i5936786022ae46eea69fd4a22c301ce4_CompanyinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OnerousContractsProvision_01c6871b-9ca4-426b-9c6d-9609fccb6fa1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OnerousContractsProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_ifrs-full_OnerousContractsProvision_01c6871b-9ca4-426b-9c6d-9609fccb6fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_b521c5de-22e4-4839-ab1d-1db4a9e9441e" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsPayment_b521c5de-22e4-4839-ab1d-1db4a9e9441e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_53d334cf-d07c-41fa-92d5-e8583590a4f9" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_53d334cf-d07c-41fa-92d5-e8583590a4f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_7cce4b2d-de8c-46cc-83e5-49b4e94f0921" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_7cce4b2d-de8c-46cc-83e5-49b4e94f0921" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_f5ee9a17-dc3f-4200-90e2-360d19b37d3d" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_f5ee9a17-dc3f-4200-90e2-360d19b37d3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_7a590cea-70ec-4ef5-9344-a1a0422b436f" xlink:href="nbx-20211231.xsd#nbx_NumberOfGlobalRegistrationalStudiesSupported"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_7a590cea-70ec-4ef5-9344-a1a0422b436f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_9e512673-3ac9-4e6a-a001-a3a2225b342d" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_9e512673-3ac9-4e6a-a001-a3a2225b342d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_d92caa24-f819-4e87-923b-d9c2ff7ced6c" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_d92caa24-f819-4e87-923b-d9c2ff7ced6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:to="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_2ad2c670-17ef-44ed-95ed-6f0e944a9015_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:to="loc_nbx_CollaborationAgreementDomain_2ad2c670-17ef-44ed-95ed-6f0e944a9015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:to="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fadeed19-a18e-4632-8ea9-7065b317f49b" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fadeed19-a18e-4632-8ea9-7065b317f49b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_0862b1f2-386f-4204-ae04-6d5c2acf0944" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:to="loc_nbx_LianBioNBTXR3Member_0862b1f2-386f-4204-ae04-6d5c2acf0944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:to="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e709a9c-f939-4b2a-9222-e92cbfdeccb0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:to="loc_srt_RangeMember_5e709a9c-f939-4b2a-9222-e92cbfdeccb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:to="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_197d3bfc-51e9-44d6-ace6-c25e6b1b9fd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:to="loc_srt_MaximumMember_197d3bfc-51e9-44d6-ace6-c25e6b1b9fd0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SignificanttransactionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SignificanttransactionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SignificanttransactionsDetails" xlink:type="extended" id="ibcc4b43d9a6d492083b876c49ddb30e5_SignificanttransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_d647f5d1-083e-4e64-998f-bf48497b1250" xlink:href="nbx-20211231.xsd#nbx_NumberOfGlobalRegistrationalStudiesSupported"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_d647f5d1-083e-4e64-998f-bf48497b1250" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_4e743f11-47b8-41e1-9c77-dfe8093251b4" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_4e743f11-47b8-41e1-9c77-dfe8093251b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_6539d07c-8dc3-4f0a-9ea7-655b80753c0c" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_6539d07c-8dc3-4f0a-9ea7-655b80753c0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_a3cd3c49-23f1-4128-b9ff-da9183913a40" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_a3cd3c49-23f1-4128-b9ff-da9183913a40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalPaymentsReceived_83d88ccf-67f4-43a6-aec7-50f885110c30" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementTotalPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementTotalPaymentsReceived_83d88ccf-67f4-43a6-aec7-50f885110c30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_d209fb7e-3f3e-404a-8828-14a4be121be6" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsPayment_d209fb7e-3f3e-404a-8828-14a4be121be6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_e9b80cf8-d19d-4e0b-95bc-1b71845c9f8b" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_e9b80cf8-d19d-4e0b-95bc-1b71845c9f8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_d3e3bca2-b713-4dd1-b069-5c647795457a" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_d3e3bca2-b713-4dd1-b069-5c647795457a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_b2cd2162-ba33-435c-87e2-85092e8d537a" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_b2cd2162-ba33-435c-87e2-85092e8d537a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_16499c7b-1f2b-4edd-9ccd-ebbb89a349cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_NotionalAmount_16499c7b-1f2b-4edd-9ccd-ebbb89a349cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_252caca0-668d-44cc-b2aa-0ecd2757936e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_252caca0-668d-44cc-b2aa-0ecd2757936e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_f1470a29-54a2-48cd-baf5-7a7041031f08" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_BorrowingsInterestRate_f1470a29-54a2-48cd-baf5-7a7041031f08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_5f159e6c-7c3f-490e-a892-3c61661601f3" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingMaturityTerm_5f159e6c-7c3f-490e-a892-3c61661601f3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_03bef3d3-b387-4dff-b21c-788759a7bb61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_03bef3d3-b387-4dff-b21c-788759a7bb61" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_3c702154-deb5-49ed-b7e7-fed7d320f726" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingDefermentPeriod_3c702154-deb5-49ed-b7e7-fed7d320f726" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriodToRequestFunds_74540882-41c0-4e67-9e81-4d7eaa33a95f" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriodToRequestFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingDefermentPeriodToRequestFunds_74540882-41c0-4e67-9e81-4d7eaa33a95f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPatientsInClinicalTrial_6cfb7e90-1098-41bc-8da3-f26b389dc7b9" xlink:href="nbx-20211231.xsd#nbx_NumberOfPatientsInClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_NumberOfPatientsInClinicalTrial_6cfb7e90-1098-41bc-8da3-f26b389dc7b9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_6771acd6-00a3-41e3-92cd-3773a6f769b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_6771acd6-00a3-41e3-92cd-3773a6f769b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_b4850795-b9fb-405b-bb93-ba6bdb7b4fdc" xlink:href="nbx-20211231.xsd#nbx_MilestonePaymentDefermentPeriodAfterEnrollment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_b4850795-b9fb-405b-bb93-ba6bdb7b4fdc" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_f261726c-36c0-42e0-a998-7c852b442868" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_f261726c-36c0-42e0-a998-7c852b442868" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_0aa30af9-229f-4edc-98c3-5d2060add265" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_0aa30af9-229f-4edc-98c3-5d2060add265" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a24afdda-8f9a-4973-81bf-86308aece1cd_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:to="loc_ifrs-full_RangesMember_a24afdda-8f9a-4973-81bf-86308aece1cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:to="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_ab514598-cea6-49ce-9999-cb5e55d8a2d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:to="loc_ifrs-full_TopOfRangeMember_ab514598-cea6-49ce-9999-cb5e55d8a2d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_8648e564-3f68-461e-bda9-8ff968ac9cff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:to="loc_ifrs-full_BottomOfRangeMember_8648e564-3f68-461e-bda9-8ff968ac9cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6275f9ac-246d-4083-81f3-0181e19336a6" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6275f9ac-246d-4083-81f3-0181e19336a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_7207b364-194d-49b6-8bf3-876148601dcd_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:to="loc_nbx_CollaborationAgreementDomain_7207b364-194d-49b6-8bf3-876148601dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:to="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_7e4d8b4f-b6a2-41a7-9c5b-5802074f0341" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_LianBioNBTXR3Member_7e4d8b4f-b6a2-41a7-9c5b-5802074f0341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PharmaEngineNBTWR3Member_cdf8dc68-0861-4a87-a79a-7f3dbceb3a37" xlink:href="nbx-20211231.xsd#nbx_PharmaEngineNBTWR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_PharmaEngineNBTWR3Member_cdf8dc68-0861-4a87-a79a-7f3dbceb3a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_9a22d811-3a20-48b6-8ec6-86cfcc6f5054" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_9a22d811-3a20-48b6-8ec6-86cfcc6f5054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_fccb7ccc-8a88-4bf2-8303-c119d5aea7c7" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_fccb7ccc-8a88-4bf2-8303-c119d5aea7c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:to="loc_srt_RangeMember_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:to="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52962100-04ca-4d05-a336-b357c5ced9f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:to="loc_srt_MaximumMember_52962100-04ca-4d05-a336-b357c5ced9f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IntangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/IntangibleassetsDetails" xlink:type="extended" id="i272c4f91df4a426594e8c30654b7abac_IntangibleassetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_5de91712-c83a-400d-9d60-ef0969d66246" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_5de91712-c83a-400d-9d60-ef0969d66246" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9c1458b5-8bef-49c1-a129-deab5750331a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9c1458b5-8bef-49c1-a129-deab5750331a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_4c13ad1b-fcc2-488b-8206-2d4dffefdb3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_4c13ad1b-fcc2-488b-8206-2d4dffefdb3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_5d6cbff4-01ee-496b-96a2-6f2a247aa982" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_5d6cbff4-01ee-496b-96a2-6f2a247aa982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_87b73f42-dfb0-42f2-8589-e6ca93e45e95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_87b73f42-dfb0-42f2-8589-e6ca93e45e95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_528f4ea9-ed93-4f3a-ba81-236a9fa06bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_1108b605-cdb5-4ca3-9739-7992f3a2add5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:to="loc_ifrs-full_CarryingAmountMember_1108b605-cdb5-4ca3-9739-7992f3a2add5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:to="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_dff4cb06-3408-468f-a366-6f23c03ba4aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_dff4cb06-3408-468f-a366-6f23c03ba4aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ef49fd09-71c9-4dbc-80e3-98a0c6300527" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ef49fd09-71c9-4dbc-80e3-98a0c6300527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_e03f0795-55bf-44a2-b7ec-2655d8c49d83_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_e03f0795-55bf-44a2-b7ec-2655d8c49d83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_f648b670-fc1e-4196-9eb7-687404cdb893" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_f648b670-fc1e-4196-9eb7-687404cdb893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_22ebcda8-7da4-47c7-98a0-345f7fa04b1c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_ComputerSoftwareMember_22ebcda8-7da4-47c7-98a0-345f7fa04b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_94a63f30-5193-4c26-af70-6312a23496e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_94a63f30-5193-4c26-af70-6312a23496e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#PropertyplantandequipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended" id="i6577b086429a4ba9aef6da8580a47a40_PropertyplantandequipmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_259d0f4d-ca59-4629-be66-342a57250680" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_259d0f4d-ca59-4629-be66-342a57250680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_7737d42b-3292-4a81-830d-e0c66e95628a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_7737d42b-3292-4a81-830d-e0c66e95628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractExtendedPeriod_94091659-0a35-4751-bc10-a8c81dc3287b" xlink:href="nbx-20211231.xsd#nbx_LeaseContractExtendedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_LeaseContractExtendedPeriod_94091659-0a35-4751-bc10-a8c81dc3287b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_5f466cab-34bf-40bb-ae9a-37e1a11be581" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_5f466cab-34bf-40bb-ae9a-37e1a11be581" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_0cad68b7-a970-4de7-84db-eca7a8e885fa" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_0cad68b7-a970-4de7-84db-eca7a8e885fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_b4e1db6a-3a6f-40bf-a431-25f9569d0eb2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_b4e1db6a-3a6f-40bf-a431-25f9569d0eb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfNewLeaseContracts_8bb98b08-812a-431b-9782-e4557bfcd626" xlink:href="nbx-20211231.xsd#nbx_NumberOfNewLeaseContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_NumberOfNewLeaseContracts_8bb98b08-812a-431b-9782-e4557bfcd626" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_b7d1ed96-c61a-49cc-9d52-f086b0b1db87_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_b7d1ed96-c61a-49cc-9d52-f086b0b1db87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_200a8412-360c-4393-ba6f-bbed71a7e1bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_200a8412-360c-4393-ba6f-bbed71a7e1bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_1061c386-5fe3-4feb-8a9b-82133a5dd110" xlink:href="nbx-20211231.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_nbx_RightOfUseBuildingsMember_1061c386-5fe3-4feb-8a9b-82133a5dd110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_17f00d6f-0679-4ad2-9628-40d3ce78273d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_MachineryMember_17f00d6f-0679-4ad2-9628-40d3ce78273d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_b810dd31-4adf-4643-a1b5-989e421dc820" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_OfficeEquipmentMember_b810dd31-4adf-4643-a1b5-989e421dc820" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_3b90f202-5fdb-4655-8ca9-229d67d833da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_VehiclesMember_3b90f202-5fdb-4655-8ca9-229d67d833da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseTransportEquipmentMember_de7a3132-01c6-49d8-ab5e-2b2fc6a8f831" xlink:href="nbx-20211231.xsd#nbx_RightOfUseTransportEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_nbx_RightOfUseTransportEquipmentMember_de7a3132-01c6-49d8-ab5e-2b2fc6a8f831" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_9dc0f04c-2e6d-4729-adf9-f60facee35fa_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:to="loc_ifrs-full_RangesMember_9dc0f04c-2e6d-4729-adf9-f60facee35fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:to="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c09cbb77-3e42-4c95-b18e-42209ae57d74" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:to="loc_ifrs-full_BottomOfRangeMember_c09cbb77-3e42-4c95-b18e-42209ae57d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_c0ee80a1-21ea-4dd9-a4ca-b588b4798ee2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:to="loc_ifrs-full_TopOfRangeMember_c0ee80a1-21ea-4dd9-a4ca-b588b4798ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_7fa8516d-1e85-4023-ba5e-717b8a9b377d_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:to="loc_ifrs-full_CarryingAmountMember_7fa8516d-1e85-4023-ba5e-717b8a9b377d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:to="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_68c4105e-203b-4547-8124-5a66b18ba971" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_68c4105e-203b-4547-8124-5a66b18ba971" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_e648b33e-7fc2-4317-9ffa-1c2333f2c405_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:to="loc_ifrs-full_TypesOfContractsMember_e648b33e-7fc2-4317-9ffa-1c2333f2c405_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:to="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractVillejuifMember_fc3b6e1f-d5b5-4e78-88dc-785efa0c2397" xlink:href="nbx-20211231.xsd#nbx_LeaseContractVillejuifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractVillejuifMember_fc3b6e1f-d5b5-4e78-88dc-785efa0c2397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractOberkampfStreetMember_19d79a41-43b8-4645-8ea4-493d071196ef" xlink:href="nbx-20211231.xsd#nbx_LeaseContractOberkampfStreetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractOberkampfStreetMember_19d79a41-43b8-4645-8ea4-493d071196ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractFaubourgSaintAntoineMember_ecfbc7a9-22ac-47e9-9493-a19f4fa7385f" xlink:href="nbx-20211231.xsd#nbx_LeaseContractFaubourgSaintAntoineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractFaubourgSaintAntoineMember_ecfbc7a9-22ac-47e9-9493-a19f4fa7385f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractAlfortvilleMember_59f70257-6873-495d-bda4-81f5f5d285df" xlink:href="nbx-20211231.xsd#nbx_LeaseContractAlfortvilleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractAlfortvilleMember_59f70257-6873-495d-bda4-81f5f5d285df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractParkingVillejuifMember_137c6a1f-373d-442b-ad1f-7a8923ef9da6" xlink:href="nbx-20211231.xsd#nbx_LeaseContractParkingVillejuifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractParkingVillejuifMember_137c6a1f-373d-442b-ad1f-7a8923ef9da6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractWattigniesMember_c32a45e2-70e8-48f4-bbd2-97513a158ea3" xlink:href="nbx-20211231.xsd#nbx_LeaseContractWattigniesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractWattigniesMember_c32a45e2-70e8-48f4-bbd2-97513a158ea3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i942711a9ddde4752a5e2c89ecea8a729_PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_0f052ab3-bdfe-4647-a690-a6174170bc32" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_0f052ab3-bdfe-4647-a690-a6174170bc32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_602c9b4d-0adc-4fe2-a9be-9e3e8f917bd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_602c9b4d-0adc-4fe2-a9be-9e3e8f917bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_16503b35-4349-43e3-946b-cc0bea914f43" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_16503b35-4349-43e3-946b-cc0bea914f43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_1f2c01d3-0cb5-469f-b450-2a877d09de3f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_1f2c01d3-0cb5-469f-b450-2a877d09de3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7a95aaea-6ea5-49f0-a128-6a91bb4d983b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7a95aaea-6ea5-49f0-a128-6a91bb4d983b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6f5e0d5f-e99c-433d-b41d-aa3154bc84e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_811ac34b-4e6c-40a4-b283-a0ae03d48b5b_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:to="loc_ifrs-full_CarryingAmountMember_811ac34b-4e6c-40a4-b283-a0ae03d48b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:to="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_6bfe5d6a-4980-4fdc-b963-f0adb0c0898e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_6bfe5d6a-4980-4fdc-b963-f0adb0c0898e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_882a2522-8f35-4bd2-b071-a4169f066fff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_882a2522-8f35-4bd2-b071-a4169f066fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_c82a6b40-b1d1-41fb-8fc5-479df1c492b5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_c82a6b40-b1d1-41fb-8fc5-479df1c492b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_d6cab7ac-7396-4b2a-b4a5-84132d39b88b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_d6cab7ac-7396-4b2a-b4a5-84132d39b88b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_840316f8-8e4a-4926-9fd8-6567e06418c1" xlink:href="nbx-20211231.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_RightOfUseBuildingsMember_840316f8-8e4a-4926-9fd8-6567e06418c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_d120d3b9-aa37-434e-b461-3f74ed6fbf8f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MachineryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_MachineryMember_d120d3b9-aa37-434e-b461-3f74ed6fbf8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_e9305de1-0a28-4fd2-9cb2-64893666baff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_OfficeEquipmentMember_e9305de1-0a28-4fd2-9cb2-64893666baff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_024508da-e0a3-436c-8e2d-5e8696122ccc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_VehiclesMember_024508da-e0a3-436c-8e2d-5e8696122ccc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseTransportEquipmentMember_366632b6-4d06-4be8-a9b7-dcc414eb01be" xlink:href="nbx-20211231.xsd#nbx_RightOfUseTransportEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_RightOfUseTransportEquipmentMember_366632b6-4d06-4be8-a9b7-dcc414eb01be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_e94aefdd-340f-448e-823b-8d591d2a1f19" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_ConstructionInProgressMember_e94aefdd-340f-448e-823b-8d591d2a1f19" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember_4f8f46a5-ce7a-41c3-8eb9-cf9a241f0368" xlink:href="nbx-20211231.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_PrepaymentsOnTangibleAssetsMember_4f8f46a5-ce7a-41c3-8eb9-cf9a241f0368" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" xlink:type="extended" id="iaeb712d3c16c4ee792c798e1e8dff3d9_NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_7d2bbb24-eae1-4299-88c3-b43573ea9f89" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_7d2bbb24-eae1-4299-88c3-b43573ea9f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_f4fe0fcf-434d-42a2-84a8-66e3200fbdff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_f4fe0fcf-434d-42a2-84a8-66e3200fbdff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_4d4aa5ac-7edc-4cfb-8c85-9cda6173562c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_4d4aa5ac-7edc-4cfb-8c85-9cda6173562c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_f9a00d4c-8250-4679-9568-8508ec73e165" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_f9a00d4c-8250-4679-9568-8508ec73e165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_21ee07db-ca77-41ff-9382-46e08e82e300" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_21ee07db-ca77-41ff-9382-46e08e82e300" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_ec797b70-1f5e-4687-996d-79026ea64ab7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3d3be74e-df60-4fa8-b13d-b18ca349c7eb_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_3d3be74e-df60-4fa8-b13d-b18ca349c7eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember_f1a81f56-6f1c-417f-bfa1-5bbdb6329562" xlink:href="nbx-20211231.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentLiquidityContractMember_f1a81f56-6f1c-417f-bfa1-5bbdb6329562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_ac083bb9-12e7-44ff-ad0b-779e0dcf9c31" xlink:href="nbx-20211231.xsd#nbx_NonCurrentInvestmentsPledgedAsCollateralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_ac083bb9-12e7-44ff-ad0b-779e0dcf9c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentSecurityDepositMember_6dd02234-9841-4e5b-98c0-e4eb0fd3caa8" xlink:href="nbx-20211231.xsd#nbx_NonCurrentSecurityDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentSecurityDepositMember_6dd02234-9841-4e5b-98c0-e4eb0fd3caa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_1735b325-51f3-46ac-a874-7f77b7c0793d_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:to="loc_ifrs-full_FinancialAssetsMember_1735b325-51f3-46ac-a874-7f77b7c0793d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:to="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember_dc06acb8-6a50-4b32-8ae1-6d58c43614b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueMember_dc06acb8-6a50-4b32-8ae1-6d58c43614b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_daef8a8f-bc08-4782-ab34-d109f9dc8e80" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_daef8a8f-bc08-4782-ab34-d109f9dc8e80" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NoncurrentfinancialassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails" xlink:type="extended" id="i9c8c07da053649cd829abab8e1484d03_NoncurrentfinancialassetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFinancialAssets_b1518f57-2ff5-4ad1-b456-592c47939c79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:to="loc_ifrs-full_IncreaseDecreaseInFinancialAssets_b1518f57-2ff5-4ad1-b456-592c47939c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_6051c654-4386-4be2-b086-c189da2b0f1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_6051c654-4386-4be2-b086-c189da2b0f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_d7a5f71f-c3da-44e9-b97b-935c4261850c_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_d7a5f71f-c3da-44e9-b97b-935c4261850c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentSecurityDepositMember_cb05b1f6-2c4b-4dea-be00-96314fe05fab" xlink:href="nbx-20211231.xsd#nbx_NonCurrentSecurityDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:to="loc_nbx_NonCurrentSecurityDepositMember_cb05b1f6-2c4b-4dea-be00-96314fe05fab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" xlink:type="extended" id="i7863b40f6e8d45f2b618201e1b0ee092_TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_cd600e99-c225-4514-aa63-84d7936d3d2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:to="loc_ifrs-full_CurrentTradeReceivables_cd600e99-c225-4514-aa63-84d7936d3d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:to="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_54d4190f-8e89-4a6a-a9dc-f2d588097da7_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_54d4190f-8e89-4a6a-a9dc-f2d588097da7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember_f939294a-75cc-4608-b0ea-07c46b0f8447" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_NotLaterThanThreeMonthsMember_f939294a-75cc-4608-b0ea-07c46b0f8447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a97221df-e710-4f9a-b853-e1131e6d775c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a97221df-e710-4f9a-b853-e1131e6d775c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_c6786ae4-0e10-4609-89af-434925a7964d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_c6786ae4-0e10-4609-89af-434925a7964d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_dd8db2c2-fcb0-4fbd-83a1-c6417890467b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanOneYearMember_dd8db2c2-fcb0-4fbd-83a1-c6417890467b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" xlink:type="extended" id="ic61d6e645c584374b9ff38989b927b1b_TradereceivablesandothercurrentassetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_8579075b-3a6b-4ef2-92c6-5e9b08f686ef" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_8579075b-3a6b-4ef2-92c6-5e9b08f686ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_2ffb2a60-8e5d-4618-8e9f-33db98257498" xlink:href="nbx-20211231.xsd#nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_2ffb2a60-8e5d-4618-8e9f-33db98257498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_241b5dc8-548b-4263-9533-907d564f94c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_241b5dc8-548b-4263-9533-907d564f94c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_53e2cfb4-eb52-4c47-b1eb-bfe43d5cdf8e" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_53e2cfb4-eb52-4c47-b1eb-bfe43d5cdf8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_6a73c404-e926-4562-a773-cf026960e35e_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:to="loc_nbx_CollaborationAgreementDomain_6a73c404-e926-4562-a773-cf026960e35e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:to="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a8d8f59b-fd20-4f54-93d6-23e09e236c9f" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a8d8f59b-fd20-4f54-93d6-23e09e236c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd479ab6-abed-436a-a086-2d66fc59194e_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:to="loc_dei_EntityDomain_bd479ab6-abed-436a-a086-2d66fc59194e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:to="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_865ebd84-0913-4202-87c7-74afc89d0f40" xlink:href="nbx-20211231.xsd#nbx_NanobiotixSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:to="loc_nbx_NanobiotixSAMember_865ebd84-0913-4202-87c7-74afc89d0f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CuradigmSASMember_4d56dbf8-eff7-486f-8ae7-98a1b76cf795" xlink:href="nbx-20211231.xsd#nbx_CuradigmSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:to="loc_nbx_CuradigmSASMember_4d56dbf8-eff7-486f-8ae7-98a1b76cf795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_96c5051d-7d72-43c9-b112-76f28a7d91f8_default" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:to="loc_nbx_OpenTaxYearDomain_96c5051d-7d72-43c9-b112-76f28a7d91f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:to="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2021TaxYearMember_042af50a-bf06-4c64-b121-1e4934d5ed27" xlink:href="nbx-20211231.xsd#nbx_A2021TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:to="loc_nbx_A2021TaxYearMember_042af50a-bf06-4c64-b121-1e4934d5ed27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2020TaxYearMember_a5f34ee5-3ade-41c6-8b55-b020566c7516" xlink:href="nbx-20211231.xsd#nbx_A2020TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:to="loc_nbx_A2020TaxYearMember_a5f34ee5-3ade-41c6-8b55-b020566c7516" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" xlink:type="extended" id="i6393572fbac14a8e9e7d269170782af0_TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_eb86705c-f8e6-41a6-a103-5b7e1bb25d72" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_eb86705c-f8e6-41a6-a103-5b7e1bb25d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_781f7fcb-9824-4893-8c2c-82ee8c51695b" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_781f7fcb-9824-4893-8c2c-82ee8c51695b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_9f6f5b15-c292-4ea1-8d16-ae1f102a5d56" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_9f6f5b15-c292-4ea1-8d16-ae1f102a5d56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_acae75b1-a35a-4daf-9fe1-49248a4d3a0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:to="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_b75dda6b-aa55-4272-b35c-57449a5510eb_default" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:to="loc_nbx_OpenTaxYearDomain_b75dda6b-aa55-4272-b35c-57449a5510eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:to="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2018TaxYearMember_af121826-bf4b-4f32-b4f2-af1bd6e7f550" xlink:href="nbx-20211231.xsd#nbx_A2018TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2018TaxYearMember_af121826-bf4b-4f32-b4f2-af1bd6e7f550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2019TaxYearMember_ef563afc-13dd-4b1e-a1a5-1d819029d578" xlink:href="nbx-20211231.xsd#nbx_A2019TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2019TaxYearMember_ef563afc-13dd-4b1e-a1a5-1d819029d578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2020TaxYearMember_2128c518-c14a-47e4-98f6-03a3e5b86dd3" xlink:href="nbx-20211231.xsd#nbx_A2020TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2020TaxYearMember_2128c518-c14a-47e4-98f6-03a3e5b86dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2021TaxYearMember_70312125-f2e6-4638-96a2-87ab144cfbd8" xlink:href="nbx-20211231.xsd#nbx_A2021TaxYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2021TaxYearMember_70312125-f2e6-4638-96a2-87ab144cfbd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:to="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:to="loc_dei_EntityDomain_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:to="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_296bc4f7-1a80-49c5-80bb-724b4f1fb95f" xlink:href="nbx-20211231.xsd#nbx_NanobiotixSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:to="loc_nbx_NanobiotixSAMember_296bc4f7-1a80-49c5-80bb-724b4f1fb95f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CuradigmSASMember_e438ee92-f397-4ce9-8c0b-e49826730a6d" xlink:href="nbx-20211231.xsd#nbx_CuradigmSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:to="loc_nbx_CuradigmSASMember_e438ee92-f397-4ce9-8c0b-e49826730a6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CashandcashequivalentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails" xlink:type="extended" id="i8ad8cf4e83894f5e8483b47ce3285242_CashandcashequivalentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b28cc055-e5c8-4e42-aa55-7a727dee2500" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b28cc055-e5c8-4e42-aa55-7a727dee2500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_f27dcbe4-e965-4d4b-9b5c-2424e19047f2" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_f27dcbe4-e965-4d4b-9b5c-2424e19047f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_254808d8-45e7-4b0f-9bac-ba440e0a65e3" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_nbx_ContractualCommitmentsPayment_254808d8-45e7-4b0f-9bac-ba440e0a65e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0d014250-0827-4162-829d-ea6dbacce73a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0d014250-0827-4162-829d-ea6dbacce73a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:to="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_0eafcfff-6dd7-4f0f-b6df-7c4c82463542_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:to="loc_nbx_CollaborationAgreementDomain_0eafcfff-6dd7-4f0f-b6df-7c4c82463542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:to="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_e731cf1e-2aae-4eb9-bb48-477e50a8e883" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:to="loc_nbx_LianBioNBTXR3Member_e731cf1e-2aae-4eb9-bb48-477e50a8e883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_21bc79d6-c3d8-4db9-89d4-0cf98795d1c6" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_21bc79d6-c3d8-4db9-89d4-0cf98795d1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_e7f348ee-5a84-44b0-b206-21c21c1f6018_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:to="loc_ifrs-full_BorrowingsByNameMember_e7f348ee-5a84-44b0-b206-21c21c1f6018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:to="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e6ba9523-3ae2-48bc-8ce0-76b826321888" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e6ba9523-3ae2-48bc-8ce0-76b826321888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_b6281c3f-402e-489b-a71b-b737404a70c7" xlink:href="nbx-20211231.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_b6281c3f-402e-489b-a71b-b737404a70c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails" xlink:type="extended" id="if19191e6d4ea4bcd83c1c413464f65d1_ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0970f0a0-7ea6-46eb-93fa-062181de27a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_Equity_0970f0a0-7ea6-46eb-93fa-062181de27a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_432d823a-1fc2-41e3-91c5-30ad8abeef1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_IssueOfEquity_432d823a-1fc2-41e3-91c5-30ad8abeef1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_cd0d2d49-3663-4c4b-b983-dafe59488b58" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_cd0d2d49-3663-4c4b-b983-dafe59488b58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_033d028e-357c-4e1e-b69c-ab045f9e8003" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_033d028e-357c-4e1e-b69c-ab045f9e8003" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_57faf3c5-6580-483a-8305-68c81dd1ad99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_aecad866-8137-481c-82b1-19449f03a1cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_aecad866-8137-481c-82b1-19449f03a1cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7e1278ab-a2ad-42a2-802c-b1111efa5347" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7e1278ab-a2ad-42a2-802c-b1111efa5347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_4eb82f27-bf80-46e9-a3d3-30c5b1408358" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IssueOfEquityPricePerShare_16ee0258-0c0c-451e-89b6-5d979d5a0887" xlink:href="nbx-20211231.xsd#nbx_IssueOfEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_IssueOfEquityPricePerShare_16ee0258-0c0c-451e-89b6-5d979d5a0887" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b9590354-5e08-43e8-9942-eb61d6261fa5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:to="loc_ifrs-full_EquityMember_b9590354-5e08-43e8-9942-eb61d6261fa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:to="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f974408d-5ce4-4ad4-b443-1a6d88ee176c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:to="loc_ifrs-full_IssuedCapitalMember_f974408d-5ce4-4ad4-b443-1a6d88ee176c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_1ed293d5-1fc2-4e5e-9228-7bc60f4efae8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:to="loc_ifrs-full_SharePremiumMember_1ed293d5-1fc2-4e5e-9228-7bc60f4efae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_4d640965-ae7f-48b3-b2dc-df503f2ffdbe_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_4d640965-ae7f-48b3-b2dc-df503f2ffdbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealEuroMember_5fd8d999-ba09-4f45-8e12-fe3dd1851777" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOInitialDealEuroMember_5fd8d999-ba09-4f45-8e12-fe3dd1851777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealUSDollarMember_590d86df-bdf3-47ca-96b9-0ee1b78c0879" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOInitialDealUSDollarMember_590d86df-bdf3-47ca-96b9-0ee1b78c0879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOGreenShoeUSDollarMember_3fa39f15-5963-4c79-9fcb-4bd42ecda219" xlink:href="nbx-20211231.xsd#nbx_IPOGreenShoeUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOGreenShoeUSDollarMember_3fa39f15-5963-4c79-9fcb-4bd42ecda219" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_068653bf-a675-405b-83e2-520130588e1b_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_068653bf-a675-405b-83e2-520130588e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_7b429688-d543-484f-80fe-bc5bf49a8ee0" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:to="loc_nbx_AGA20181Member_7b429688-d543-484f-80fe-bc5bf49a8ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_d10b07ea-be5c-487a-98c4-7d0a66edd2e7" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:to="loc_nbx_AGA20182Member_d10b07ea-be5c-487a-98c4-7d0a66edd2e7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalCapitalIssuedDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="extended" id="i209ae6cc85d34c57a18f427f0df7a529_ShareCapitalCapitalIssuedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_681efc67-ae02-4ee0-acfc-eaa3173dc89a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_Equity_681efc67-ae02-4ee0-acfc-eaa3173dc89a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_7b526028-ccba-4d16-8e24-f101fedcda53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_7b526028-ccba-4d16-8e24-f101fedcda53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_bb57411e-62b5-47b1-87c3-411d9195a1da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_ParValuePerShare_bb57411e-62b5-47b1-87c3-411d9195a1da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7a0d1737-0d08-4c06-ba87-cb797b23b3a9" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7a0d1737-0d08-4c06-ba87-cb797b23b3a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IssueOfEquityPricePerShare_ea5ae6e0-4a7f-4c55-931c-87ab6219965a" xlink:href="nbx-20211231.xsd#nbx_IssueOfEquityPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_nbx_IssueOfEquityPricePerShare_ea5ae6e0-4a7f-4c55-931c-87ab6219965a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_6bd27a6d-8f3f-4efc-98c0-586ebfc8b9b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_6bd27a6d-8f3f-4efc-98c0-586ebfc8b9b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_3a5e2447-f48a-4214-99d3-ab1b12a86638" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_3a5e2447-f48a-4214-99d3-ab1b12a86638" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_0f517da7-484c-4baf-96bc-67011329ab61_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:to="loc_ifrs-full_EquityMember_0f517da7-484c-4baf-96bc-67011329ab61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:to="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_8dc0b28a-ae20-4310-898d-0de3d9d7f3ec" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:to="loc_ifrs-full_IssuedCapitalMember_8dc0b28a-ae20-4310-898d-0de3d9d7f3ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_aaa4ef11-ea15-41c9-8eaa-2ba1d0524465" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:to="loc_ifrs-full_SharePremiumMember_aaa4ef11-ea15-41c9-8eaa-2ba1d0524465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_6830df7f-4429-4147-8a68-d30cc1307356_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_6830df7f-4429-4147-8a68-d30cc1307356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InitialPublicOfferingMember_65e904c5-7407-4382-91ae-0d6e519142db" xlink:href="nbx-20211231.xsd#nbx_InitialPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_InitialPublicOfferingMember_65e904c5-7407-4382-91ae-0d6e519142db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealUSDollarMember_af97c63b-55de-458e-9a36-7ab4095b14e9" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOInitialDealUSDollarMember_af97c63b-55de-458e-9a36-7ab4095b14e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealEuroMember_1561a89a-2feb-4e81-ba64-a02167ca79c4" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealEuroMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOInitialDealEuroMember_1561a89a-2feb-4e81-ba64-a02167ca79c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOGreenShoeUSDollarMember_01917fe1-fd28-425f-b6c6-5ad0be11e4a4" xlink:href="nbx-20211231.xsd#nbx_IPOGreenShoeUSDollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOGreenShoeUSDollarMember_01917fe1-fd28-425f-b6c6-5ad0be11e4a4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalTreasurySharesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails" xlink:type="extended" id="i6542f70c11df4c8babb37d5995f91259_ShareCapitalTreasurySharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1433af27-7584-4fae-af19-fe770352741d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1433af27-7584-4fae-af19-fe770352741d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_0052e89c-a30a-45ab-a2d5-466c23363ac7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:to="loc_ifrs-full_TreasuryShares_0052e89c-a30a-45ab-a2d5-466c23363ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a2e14578-37c9-488d-a9fa-f4ac084715c0_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:to="loc_ifrs-full_EquityMember_a2e14578-37c9-488d-a9fa-f4ac084715c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:to="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_aeae42cc-96c5-4ccf-a230-75b9bb898c33" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:to="loc_ifrs-full_TreasurySharesMember_aeae42cc-96c5-4ccf-a230-75b9bb898c33" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="extended" id="ic90a89a3bef84d47b0afecea8e327afa_ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_85f9c956-1cf8-4f0c-b902-f959933de12a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_85f9c956-1cf8-4f0c-b902-f959933de12a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d177ccf7-16d9-42cb-8e89-0191c8f65cbd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d177ccf7-16d9-42cb-8e89-0191c8f65cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e5ad533b-264a-4da7-9406-f09cf496dfff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e5ad533b-264a-4da7-9406-f09cf496dfff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4554e4bf-d153-406a-aed5-ef99bb7667e9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4554e4bf-d153-406a-aed5-ef99bb7667e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_d741ab79-1796-463a-b661-36c7ae3baa3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_d741ab79-1796-463a-b661-36c7ae3baa3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8a135566-3ed5-4337-9269-b1357bf0d0f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_95ac6b73-fd87-4ce6-a165-5d8ca5661e12" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_95ac6b73-fd87-4ce6-a165-5d8ca5661e12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_c3f54b33-f727-470c-86c9-eb3d7bb109f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_c3f54b33-f727-470c-86c9-eb3d7bb109f2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3145bba5-c627-4a5b-8a3d-ff858f2c3909" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3145bba5-c627-4a5b-8a3d-ff858f2c3909" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_80ed06e2-63f0-484b-8b01-5c7ad5027de3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_80ed06e2-63f0-484b-8b01-5c7ad5027de3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6ea7fa03-86dc-49b1-9a83-53c36d04e4d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6ea7fa03-86dc-49b1-9a83-53c36d04e4d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_fa123b33-ef9b-440c-a730-bd639d3ffb5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a6fde404-3501-4b18-863e-3bfebeb756e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a6fde404-3501-4b18-863e-3bfebeb756e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_c6c9acab-fec6-406a-9851-c6f3bdc0f03f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_c6c9acab-fec6-406a-9851-c6f3bdc0f03f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_bab3612a-caab-4b76-b759-4e4f2b151997" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20122Member_bab3612a-caab-4b76-b759-4e4f2b151997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_8aa0e918-80f0-4773-8a86-85dc49470f2b" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE082013Member_8aa0e918-80f0-4773-8a86-85dc49470f2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_0f700ce4-59e9-4edc-b540-03eb81db4760" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE092014Member_0f700ce4-59e9-4edc-b540-03eb81db4760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_899e52e8-b03c-412b-a132-5c3ba8fea5a7" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20151Member_899e52e8-b03c-412b-a132-5c3ba8fea5a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_f379aed8-f8fa-4439-9ee9-4b55a5a2fba5" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20153Member_f379aed8-f8fa-4439-9ee9-4b55a5a2fba5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016Member_4f2eca2a-9a9d-4d37-8570-e0161b61ea35" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE2016Member_4f2eca2a-9a9d-4d37-8570-e0161b61ea35" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_8ec6c4a7-5103-43bc-8f2d-2ca24f0082e9" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE2017Member_8ec6c4a7-5103-43bc-8f2d-2ca24f0082e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_5f3b6eab-cced-420a-8ff2-dae1e7566737" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA0412Member_5f3b6eab-cced-420a-8ff2-dae1e7566737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_af56bd0a-0169-426c-b9cb-1d698f566b86" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2013Member_af56bd0a-0169-426c-b9cb-1d698f566b86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_a0c8b12b-fc93-41ef-8ccd-33bb03872318" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2014Member_a0c8b12b-fc93-41ef-8ccd-33bb03872318" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_c6cee694-c2eb-428a-8b5d-6499fecbd1f4" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20151Member_c6cee694-c2eb-428a-8b5d-6499fecbd1f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_d283ec4f-a223-44bb-b867-1a9bda3c7f13" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20152AMember_d283ec4f-a223-44bb-b867-1a9bda3c7f13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_9cd873f3-fc60-4115-bf82-cc44846441e2" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20152BMember_9cd873f3-fc60-4115-bf82-cc44846441e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016Member_a965c03f-7c42-4be2-9af9-15662f996830" xlink:href="nbx-20211231.xsd#nbx_BSA2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2016Member_a965c03f-7c42-4be2-9af9-15662f996830" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_93166995-6dcb-4dda-a4eb-0ac98597ceeb" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20162Member_93166995-6dcb-4dda-a4eb-0ac98597ceeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_85f553d1-8f33-4b46-b9e2-7f5681817baa" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2017Member_85f553d1-8f33-4b46-b9e2-7f5681817baa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_ed310d80-5186-45fc-b727-8aade337c3b7" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20181Member_ed310d80-5186-45fc-b727-8aade337c3b7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_534de259-7a67-448d-9754-cedf5f6a9b37" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20182Member_534de259-7a67-448d-9754-cedf5f6a9b37" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_9b38b253-3221-4e87-bfb6-7f945a09f40c" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20191Member_9b38b253-3221-4e87-bfb6-7f945a09f40c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_6c5d3538-2c89-41cb-a72f-bebf3ae130dc" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2020Member_6c5d3538-2c89-41cb-a72f-bebf3ae130dc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_7f01acdd-ea31-4897-8f58-a2beef4236fb" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2021AMember_7f01acdd-ea31-4897-8f58-a2beef4236fb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_cddd76b5-0d6a-4d11-8b66-a4a05ac61f2f" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2021BMember_cddd76b5-0d6a-4d11-8b66-a4a05ac61f2f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161Member_5f8ca7a6-189e-4ad5-a964-6ec31da2b7b7" xlink:href="nbx-20211231.xsd#nbx_OSA20161Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20161Member_5f8ca7a6-189e-4ad5-a964-6ec31da2b7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_44d1f700-4a2c-495e-b25a-eab6d67a656c" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20162Member_44d1f700-4a2c-495e-b25a-eab6d67a656c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017Member_51abdeb2-5c9e-4552-aa21-a1fd16903d28" xlink:href="nbx-20211231.xsd#nbx_OSA2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2017Member_51abdeb2-5c9e-4552-aa21-a1fd16903d28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_b20bd8b7-9319-491d-914d-acea3ab75485" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2018Member_b20bd8b7-9319-491d-914d-acea3ab75485" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_d01d5cea-f8d5-4e63-8295-1b401af18fc9" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20191Member_d01d5cea-f8d5-4e63-8295-1b401af18fc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_c81946ee-f661-49f9-b853-c00aac5f0408" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSALLY2019Member_c81946ee-f661-49f9-b853-c00aac5f0408" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_c222c5f8-a5d6-487a-b745-fa6167853ac7" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2020Member_c222c5f8-a5d6-487a-b745-fa6167853ac7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_652d4f8e-886c-4ef2-bdf5-af9743ba302e" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA202104Member_652d4f8e-886c-4ef2-bdf5-af9743ba302e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_7bc9f554-38e4-4326-a94f-d028de9c5ed0" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA202106Member_7bc9f554-38e4-4326-a94f-d028de9c5ed0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_90aafd32-b13a-47b7-aebe-5b1268ba8fde" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20181Member_90aafd32-b13a-47b7-aebe-5b1268ba8fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_e1ba758c-fe3f-40d5-b53f-a1a30f5a96eb" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20182Member_e1ba758c-fe3f-40d5-b53f-a1a30f5a96eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_d39a0979-0413-4d92-b114-b921e8f5a2d7" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20191Member_d39a0979-0413-4d92-b114-b921e8f5a2d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_129ffa79-a9f4-4404-9abe-2d9fb91e4452" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA2020Member_129ffa79-a9f4-4404-9abe-2d9fb91e4452" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_15609e80-f21d-4166-9462-e018410e7690" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA2021Member_15609e80-f21d-4166-9462-e018410e7690" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalFounderswarrantsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails" xlink:type="extended" id="i3fb38bc3e4874c08a50294cbe8181481_ShareCapitalFounderswarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_684e883a-a7e2-4f91-ab15-cb9aef9c591f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_684e883a-a7e2-4f91-ab15-cb9aef9c591f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:to="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2739c2d7-a311-42f0-a855-d17a1eeac99f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2739c2d7-a311-42f0-a855-d17a1eeac99f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerEmployeesMember_7670564c-ca99-4685-9212-60e9c4f2238e" xlink:href="nbx-20211231.xsd#nbx_FormerEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:to="loc_nbx_FormerEmployeesMember_7670564c-ca99-4685-9212-60e9c4f2238e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerExecutiveBoardMembersMember_2ec653d5-3f2a-4f8c-bc64-3fcc6fcddff7" xlink:href="nbx-20211231.xsd#nbx_FormerExecutiveBoardMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:to="loc_nbx_FormerExecutiveBoardMembersMember_2ec653d5-3f2a-4f8c-bc64-3fcc6fcddff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_da962297-3325-4d72-b180-8845f1d7758f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_da962297-3325-4d72-b180-8845f1d7758f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_fcd75d1d-d82e-4e23-b0c4-ac260795e913" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:to="loc_nbx_BSPCEMember_fcd75d1d-d82e-4e23-b0c4-ac260795e913" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalWarrantPlansDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails" xlink:type="extended" id="ib4fdf4c47f8f489d8e5cabfa0a6be7b0_ShareCapitalWarrantPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6f1fba84-ec60-4d3f-9796-e7191b910082" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6f1fba84-ec60-4d3f-9796-e7191b910082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_4dc5f9ab-4588-405e-9d0e-2f5b190d994e" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachBSA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_4dc5f9ab-4588-405e-9d0e-2f5b190d994e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_68f31a53-877d-49cf-99b5-40c1cd7dcd5b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_ParValuePerShare_68f31a53-877d-49cf-99b5-40c1cd7dcd5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1972d2db-5196-4e5a-ae1b-581102f8771a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1972d2db-5196-4e5a-ae1b-581102f8771a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_ed4ec079-321c-4c91-bff5-9d5c43708e21" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_ed4ec079-321c-4c91-bff5-9d5c43708e21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_1f254163-faec-4313-acc8-6bc4e9498e62" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_1f254163-faec-4313-acc8-6bc4e9498e62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_418d24e4-4b32-4ab0-8677-e817a648a55f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_418d24e4-4b32-4ab0-8677-e817a648a55f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_8ad50237-050d-42ba-87b6-b231bff513c8" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_8ad50237-050d-42ba-87b6-b231bff513c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_0f4d0e05-f59e-4b9b-80af-7d82e8f139c1" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_0f4d0e05-f59e-4b9b-80af-7d82e8f139c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_566e898c-7722-4056-adbf-607d141f7c80" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_566e898c-7722-4056-adbf-607d141f7c80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_b3fb29e6-287a-4894-824a-91a9e9d9a8ee_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_b3fb29e6-287a-4894-824a-91a9e9d9a8ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_dff8a040-bed8-42e4-8a11-72c3ae52a008" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2021AMember_dff8a040-bed8-42e4-8a11-72c3ae52a008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AInReplacementOfBSA2016Member_43cda357-e0b7-41ed-b9ce-a4e61d2f5d91" xlink:href="nbx-20211231.xsd#nbx_BSA2021AInReplacementOfBSA2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2021AInReplacementOfBSA2016Member_43cda357-e0b7-41ed-b9ce-a4e61d2f5d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_4f02373e-8071-419e-bff6-745194294a87" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2020Member_4f02373e-8071-419e-bff6-745194294a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:to="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupervisoryBoardMember_bc9fae8e-b73c-43ab-9970-bdad045c9638" xlink:href="nbx-20211231.xsd#nbx_SupervisoryBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_SupervisoryBoardMember_bc9fae8e-b73c-43ab-9970-bdad045c9638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExternalConsultantMember_eb9cec9b-7609-4930-b45f-58c0f9c54046" xlink:href="nbx-20211231.xsd#nbx_ExternalConsultantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_ExternalConsultantMember_eb9cec9b-7609-4930-b45f-58c0f9c54046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_5adaae6a-aa78-4c64-a362-26e234cdc9ba" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_5adaae6a-aa78-4c64-a362-26e234cdc9ba" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalStockOptionPlansDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="extended" id="i3a788d831ac24c2d8aeddfa03d461368_ShareCapitalStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_b36b2315-2823-4403-9d3e-2ec902aa6d7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_b36b2315-2823-4403-9d3e-2ec902aa6d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_8704db80-e9bf-4d6c-8d2e-8c4241d53fe6" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachOSA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_8704db80-e9bf-4d6c-8d2e-8c4241d53fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_34177bfd-0e15-42b2-bdcc-7bcd90efd860" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_ParValuePerShare_34177bfd-0e15-42b2-bdcc-7bcd90efd860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_20738728-b833-4389-a1f5-82af0fb069ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_20738728-b833-4389-a1f5-82af0fb069ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_d9c80cff-4eff-4dc1-b8ad-9e360c8498f8" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_d9c80cff-4eff-4dc1-b8ad-9e360c8498f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_ec5c39ee-9c6c-4687-9f1a-a4d7fe6ed86b" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_ec5c39ee-9c6c-4687-9f1a-a4d7fe6ed86b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SharePriceMilestoneEuronextParis_7153ed74-ee9a-401f-9d53-e95ad5d3b37e" xlink:href="nbx-20211231.xsd#nbx_SharePriceMilestoneEuronextParis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_SharePriceMilestoneEuronextParis_7153ed74-ee9a-401f-9d53-e95ad5d3b37e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_1d44a5aa-ead3-4f09-af4b-3e5396383ca2" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_1d44a5aa-ead3-4f09-af4b-3e5396383ca2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_e7c9ca9c-6814-447b-a0ae-e1113ed1e690" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_e7c9ca9c-6814-447b-a0ae-e1113ed1e690" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_0d188062-9932-4fe8-88e6-28034995e38f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_0d188062-9932-4fe8-88e6-28034995e38f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_6f07a215-37dc-496f-aa68-03b947028eb2" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_6f07a215-37dc-496f-aa68-03b947028eb2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_fa0a3d4b-e142-4804-8b49-51ee7fa6ea56" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_fa0a3d4b-e142-4804-8b49-51ee7fa6ea56" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_9b9b2503-79b7-45cd-9f81-fdb043a87bbf" xlink:href="nbx-20211231.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_9b9b2503-79b7-45cd-9f81-fdb043a87bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_40172d2b-f282-493e-b063-d19e067dac06" xlink:href="nbx-20211231.xsd#nbx_BartVanRhijnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_BartVanRhijnMember_40172d2b-f282-493e-b063-d19e067dac06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_24ece6bb-5aeb-4c30-bc3d-050366db94fc" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_24ece6bb-5aeb-4c30-bc3d-050366db94fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_cea713ce-4232-4eba-8827-eb0d2fb59448" xlink:href="nbx-20211231.xsd#nbx_MembersOfTheExecutiveBoardAndAlainDostieMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_cea713ce-4232-4eba-8827-eb0d2fb59448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmployeesMember_7f3e245d-7698-4193-aef4-839d2aa2df0a" xlink:href="nbx-20211231.xsd#nbx_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_EmployeesMember_7f3e245d-7698-4193-aef4-839d2aa2df0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerExecutiveBoardMembersMember_d47c8237-87d8-4a62-8da6-91a156b7c4d4" xlink:href="nbx-20211231.xsd#nbx_FormerExecutiveBoardMembersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_FormerExecutiveBoardMembersMember_d47c8237-87d8-4a62-8da6-91a156b7c4d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4cd918a9-1bef-4222-958d-2d1f0a3f94d7_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4cd918a9-1bef-4222-958d-2d1f0a3f94d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_ab96db15-1a07-48a0-bc04-d66e59c96c95" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104Member_ab96db15-1a07-48a0-bc04-d66e59c96c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_c9f05ba3-d35d-400a-b32d-ba1c9c0bf8d8" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104OrdinaryMember_c9f05ba3-d35d-400a-b32d-ba1c9c0bf8d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_2518b33d-faf6-4175-8773-716bf4aebf1c" xlink:href="nbx-20211231.xsd#nbx_OSA202104PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104PerformanceMember_2518b33d-faf6-4175-8773-716bf4aebf1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_485df023-f328-4a83-beb2-311022b0672a" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSAMember_485df023-f328-4a83-beb2-311022b0672a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_a26c1bc6-3bde-42e4-be59-f5f938b408b5" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106OrdinaryMember_a26c1bc6-3bde-42e4-be59-f5f938b408b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_09d84a4a-24b3-4976-bc40-2714c8e364d0" xlink:href="nbx-20211231.xsd#nbx_OSA202106PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106PerformanceMember_09d84a4a-24b3-4976-bc40-2714c8e364d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_671cbd24-8cfa-4cc7-9a57-534010dc6cb7" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106Member_671cbd24-8cfa-4cc7-9a57-534010dc6cb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_5208e79e-a0c0-4c31-923f-5a396ba4bde3" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA2020Member_5208e79e-a0c0-4c31-923f-5a396ba4bde3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb_default" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:to="loc_nbx_TrancheDomain_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:to="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_0dcc4d60-96a1-4cac-a243-e604ced004d8" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheOneMember_0dcc4d60-96a1-4cac-a243-e604ced004d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_ff6dc894-5abc-42a1-bd8b-f26209b933f9" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheTwoMember_ff6dc894-5abc-42a1-bd8b-f26209b933f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_7c780d84-7699-4c72-adae-9cbb5434853a" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheThreeMember_7c780d84-7699-4c72-adae-9cbb5434853a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_3500a43c-9f7c-4055-b854-90514f3aac05" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheFourMember_3500a43c-9f7c-4055-b854-90514f3aac05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_10de3310-3a6f-4215-aa5b-8e4b72a902c5" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:to="loc_nbx_TranchesDomain_10de3310-3a6f-4215-aa5b-8e4b72a902c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_50fa33c2-7637-4e63-ad88-d71131a49e86_default" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:to="loc_nbx_VestingDomain_50fa33c2-7637-4e63-ad88-d71131a49e86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:to="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromFirstYearOfGrantDateMember_5cc61a50-3a0d-4d2b-a04f-891fbf95e666" xlink:href="nbx-20211231.xsd#nbx_FromFirstYearOfGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromFirstYearOfGrantDateMember_5cc61a50-3a0d-4d2b-a04f-891fbf95e666" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromSecondYearOfGrantDateMember_d1f387ef-b344-447b-9b59-036a8e52b879" xlink:href="nbx-20211231.xsd#nbx_FromSecondYearOfGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromSecondYearOfGrantDateMember_d1f387ef-b344-447b-9b59-036a8e52b879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromThirdYearOfGrantDateMember_751d88b6-5a54-4ab5-8cf2-b81d6d5da96f" xlink:href="nbx-20211231.xsd#nbx_FromThirdYearOfGrantDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromThirdYearOfGrantDateMember_751d88b6-5a54-4ab5-8cf2-b81d6d5da96f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalFreeSharePlansDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails" xlink:type="extended" id="idbcf832960494532aafb10fdbc14bf5a_ShareCapitalFreeSharePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a40974bb-27b3-425b-b0b2-db34510c7032" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a40974bb-27b3-425b-b0b2-db34510c7032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_032ebfc7-c2c9-46b4-8175-e9d7584c8e73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_ParValuePerShare_032ebfc7-c2c9-46b4-8175-e9d7584c8e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_58cfb02f-9c47-4da1-88aa-d45be1f4af2a" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_58cfb02f-9c47-4da1-88aa-d45be1f4af2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_f582d36a-ace5-4c50-a12e-a46e1fcea53a" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_f582d36a-ace5-4c50-a12e-a46e1fcea53a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_287abb22-f216-4f06-8c64-8d73b1cd41ae" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_287abb22-f216-4f06-8c64-8d73b1cd41ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_86f2accf-5f47-4ffd-9691-8e0f979ae894" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_86f2accf-5f47-4ffd-9691-8e0f979ae894" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_15db1e9f-497d-483b-a7c6-4e56e6cdf9b0" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_15db1e9f-497d-483b-a7c6-4e56e6cdf9b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_3d5be0e3-73d5-415b-a287-580251770f98" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_3d5be0e3-73d5-415b-a287-580251770f98" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_0908cc52-fa9c-4ecd-b1f1-3667e59d121a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_IssueOfEquity_0908cc52-fa9c-4ecd-b1f1-3667e59d121a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_846a5185-63d8-49f6-8058-e2bc4bf0e3b7" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_846a5185-63d8-49f6-8058-e2bc4bf0e3b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:to="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4d104f1c-860f-4153-980d-5ca4acd7c58c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4d104f1c-860f-4153-980d-5ca4acd7c58c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_53beeae1-f0e1-4a02-af56-f15f3b6ed53e" xlink:href="nbx-20211231.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_53beeae1-f0e1-4a02-af56-f15f3b6ed53e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_d4284fb5-7651-4e8f-bf10-c5ac4ff7f9be" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_AnneJulietteHermantMember_d4284fb5-7651-4e8f-bf10-c5ac4ff7f9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmployeesMember_3fb42afa-145b-493c-b987-651bfaf0417c" xlink:href="nbx-20211231.xsd#nbx_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_EmployeesMember_3fb42afa-145b-493c-b987-651bfaf0417c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_034c456c-43b5-40ad-b196-79371b3b5ccf_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_034c456c-43b5-40ad-b196-79371b3b5ccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_9c11db70-424d-4f2b-8885-6650cc0a8c29" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2021Member_9c11db70-424d-4f2b-8885-6650cc0a8c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_c2b47b1c-9988-4592-b28d-5aa25a2dc6e4" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2020Member_c2b47b1c-9988-4592-b28d-5aa25a2dc6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020AndAGA2021Member_4fc19534-af3e-4abb-839e-6f72e5b664f6" xlink:href="nbx-20211231.xsd#nbx_AGA2020AndAGA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2020AndAGA2021Member_4fc19534-af3e-4abb-839e-6f72e5b664f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_a414361e-a491-4d83-a705-5ddda8e67416" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGAMember_a414361e-a491-4d83-a705-5ddda8e67416" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_9c341f80-13d9-469d-b9b0-92a1861148ff" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20181Member_9c341f80-13d9-469d-b9b0-92a1861148ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_768362ac-e64b-4462-84af-fdfc9e80cff1" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20191Member_768362ac-e64b-4462-84af-fdfc9e80cff1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_4bb7f2df-b630-43d8-aed5-e6c92940be61" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20182Member_4bb7f2df-b630-43d8-aed5-e6c92940be61" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofChangesinProvisionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" xlink:type="extended" id="i4030c29ebccc4e848d9513c39e2e1dff_ProvisionsDisclosureofChangesinProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_01a2ffaf-2414-42b4-af07-42f03e07c0d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_OtherProvisions_01a2ffaf-2414-42b4-af07-42f03e07c0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_cf5a1f69-b32b-43e2-9c31-6aa3f235b9e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_cf5a1f69-b32b-43e2-9c31-6aa3f235b9e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_a58e21ad-21f4-438e-a3b0-bc97f4acb41e" xlink:href="nbx-20211231.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_a58e21ad-21f4-438e-a3b0-bc97f4acb41e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_4d69a810-f0ba-46f8-b07e-7b9200292d4e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_56050418-6f3f-4349-bb54-5e4ec9aa84f6_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:to="loc_ifrs-full_OtherProvisionsMember_56050418-6f3f-4349-bb54-5e4ec9aa84f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:to="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:href="nbx-20211231.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:to="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember_2964c304-67d4-4d7a-8212-b5face975931" xlink:href="nbx-20211231.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:to="loc_nbx_LumpSumRetirementBenefitsMember_2964c304-67d4-4d7a-8212-b5face975931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:href="nbx-20211231.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:to="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_2ae84eda-596f-42c8-83bf-652c82a67aa0" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:to="loc_nbx_ProvisionsForDisputesMember_2ae84eda-596f-42c8-83bf-652c82a67aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_ccb67810-4ec2-43b0-83df-b4d1c8df2d5b" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:to="loc_nbx_ProvisionsForChargesMember_ccb67810-4ec2-43b0-83df-b4d1c8df2d5b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="extended" id="i5201acd70f994a5ea32f56555a8d0f20_ProvisionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_9e6366a6-2078-44ec-84cd-ae138e663945" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_9e6366a6-2078-44ec-84cd-ae138e663945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_93447107-dcbe-4afb-8468-35e626c2161c" xlink:href="nbx-20211231.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_93447107-dcbe-4afb-8468-35e626c2161c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationPayablePeriod_6f18f6b2-8b5e-4535-a39e-b2a4f8fcae40" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationPayablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_nbx_DefinedBenefitObligationPayablePeriod_6f18f6b2-8b5e-4535-a39e-b2a4f8fcae40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:to="loc_ifrs-full_OtherProvisionsMember_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:to="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_447efa1a-939c-4c36-80a2-6875b24a3a56" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:to="loc_nbx_ProvisionsForDisputesMember_447efa1a-939c-4c36-80a2-6875b24a3a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_29b1d4de-5e10-4783-a16a-576ec49c0a1a" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:to="loc_nbx_ProvisionsForChargesMember_29b1d4de-5e10-4783-a16a-576ec49c0a1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" xlink:type="extended" id="i5f4719fef5784fd097ac457287954d22_ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_acac551a-4af8-41db-9ec4-c49a4725413e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_acac551a-4af8-41db-9ec4-c49a4725413e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_4dc3a84a-8a63-4a80-88f6-2d012d393133" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfSocialSecurityContributionRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_4dc3a84a-8a63-4a80-88f6-2d012d393133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_7392007b-8dcd-497a-9ab0-c8877cc16671" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_7392007b-8dcd-497a-9ab0-c8877cc16671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_b80df821-afd2-4fcf-b050-5a57d6cf4ea9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_b80df821-afd2-4fcf-b050-5a57d6cf4ea9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_b12101e7-0515-4c3a-a21d-056c20c46e17" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_b12101e7-0515-4c3a-a21d-056c20c46e17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_0fbbcee1-cfe6-4ad0-b32d-b71c182e2345" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_0fbbcee1-cfe6-4ad0-b32d-b71c182e2345" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:to="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_48a810e9-be5a-4e78-a239-007833df8caa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_48a810e9-be5a-4e78-a239-007833df8caa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_547999ac-98db-4b60-96a5-75b87eb0e4dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_srt_ManagementMember_547999ac-98db-4b60-96a5-75b87eb0e4dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonManagementMember_f30e6486-9166-4958-961e-433df57f646a" xlink:href="nbx-20211231.xsd#nbx_NonManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_nbx_NonManagementMember_f30e6486-9166-4958-961e-433df57f646a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_c2fc0d66-3db5-4bd3-a9c8-d44473e8add6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_srt_ExecutiveOfficerMember_c2fc0d66-3db5-4bd3-a9c8-d44473e8add6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonExecutiveMember_781ab4dc-356d-4036-813f-37e9023f8c29" xlink:href="nbx-20211231.xsd#nbx_NonExecutiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_nbx_NonExecutiveMember_781ab4dc-356d-4036-813f-37e9023f8c29" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" xlink:type="extended" id="if6189a21dcbe447eb27ac83c1309403d_ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_884b3cc5-3793-4e4d-83f3-b4a14652c315" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_884b3cc5-3793-4e4d-83f3-b4a14652c315" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_2189b5aa-d51f-47ed-ba78-799bff7d220a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_2189b5aa-d51f-47ed-ba78-799bff7d220a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_d6925091-11dc-4c1e-9c32-16412bab5bdf" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_d6925091-11dc-4c1e-9c32-16412bab5bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_5ab53519-a580-4c30-8280-313bf22e3afb" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_5ab53519-a580-4c30-8280-313bf22e3afb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_b6f27767-daf6-4451-8608-1463369230f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_b6f27767-daf6-4451-8608-1463369230f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_8645308b-4f74-4fad-910c-873c0cfa4f12" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_8645308b-4f74-4fad-910c-873c0cfa4f12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_9bf85d6a-15d2-4303-b443-708fd4b45820_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_9bf85d6a-15d2-4303-b443-708fd4b45820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_fcdc9196-0d35-4f82-a90d-15d35d5f0f76" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_fcdc9196-0d35-4f82-a90d-15d35d5f0f76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="extended" id="i420373e5795f4c828dc5bd6fac3379b1_FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_425a576f-e639-4d94-b1f6-e518fa44daf2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_425a576f-e639-4d94-b1f6-e518fa44daf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_c5fb7a0c-631d-4514-946f-e79edd0bbb0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_c5fb7a0c-631d-4514-946f-e79edd0bbb0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_9594f2c7-7e2b-47f1-8b82-9b4bdc812e7e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_FinancialLiabilities_9594f2c7-7e2b-47f1-8b82-9b4bdc812e7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_baa413c4-62fc-411b-98ee-ebb141846adc_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:to="loc_ifrs-full_BorrowingsByNameMember_baa413c4-62fc-411b-98ee-ebb141846adc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_d777bbd6-237e-422d-a5b6-ad150d6c08a2" xlink:href="nbx-20211231.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:to="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_d777bbd6-237e-422d-a5b6-ad150d6c08a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_a90372f6-d7b4-43ee-abca-a437ef7a29e5" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_a90372f6-d7b4-43ee-abca-a437ef7a29e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_0ee7e640-3cff-4f30-aaf8-681e6e654a8a_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:to="loc_ifrs-full_LiabilitiesMember_0ee7e640-3cff-4f30-aaf8-681e6e654a8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:to="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_f77ff635-8e7e-4897-bd4e-f1d7c23b87b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_f77ff635-8e7e-4897-bd4e-f1d7c23b87b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember_be1ebaa1-e597-4934-86cc-03a9923dba4b" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_nbx_ConditionalAdvancesMember_be1ebaa1-e597-4934-86cc-03a9923dba4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_d4f681ff-c82d-46f1-8c8b-8a0d111de8f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_d4f681ff-c82d-46f1-8c8b-8a0d111de8f8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" xlink:type="extended" id="i328876421ade4c85be4348b4077058ef_FinancialliabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedDefermentPeriod_e8a5fd1f-7485-41fc-9001-998f32d8a4ab" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedDefermentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesReceivedDefermentPeriod_e8a5fd1f-7485-41fc-9001-998f32d8a4ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate_ac5abca4-0696-4c24-a234-04a5577ce5a1" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesReceivedInterestRate_ac5abca4-0696-4c24-a234-04a5577ce5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances_fd076680-24d4-471b-b056-5d4b4037f8cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Advances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_Advances_fd076680-24d4-471b-b056-5d4b4037f8cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_2d2cb979-4149-47f2-a540-8ff6d6d3f61e" xlink:href="nbx-20211231.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_2d2cb979-4149-47f2-a540-8ff6d6d3f61e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesOutstandingAmountToBeReceived_5964c08d-a823-4f34-b656-805236d3387a" xlink:href="nbx-20211231.xsd#nbx_AdvancesOutstandingAmountToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesOutstandingAmountToBeReceived_5964c08d-a823-4f34-b656-805236d3387a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_be35cb48-eabe-4d68-b62a-705932ea5411" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_NotionalAmount_be35cb48-eabe-4d68-b62a-705932ea5411" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesBorrowings_4a8fe989-49e8-413b-9692-333bb1785634" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_NumberOfTranchesBorrowings_4a8fe989-49e8-413b-9692-333bb1785634" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_eefa954e-fd84-429a-bcb9-545c85b48062" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_eefa954e-fd84-429a-bcb9-545c85b48062" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriodToRequestFunds_3b8baf44-9352-4630-822c-ebbd0a9a8907" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriodToRequestFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingDefermentPeriodToRequestFunds_3b8baf44-9352-4630-822c-ebbd0a9a8907" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_4556df5f-bf92-4060-a840-99ebb1b1e512" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_4556df5f-bf92-4060-a840-99ebb1b1e512" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_b86b5bd7-0c66-49f1-96c8-699280b08401" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_b86b5bd7-0c66-49f1-96c8-699280b08401" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_e5355f71-d932-47b5-a61d-dad482988911" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingDefermentPeriod_e5355f71-d932-47b5-a61d-dad482988911" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_c702451e-df2c-41eb-b356-e4e6b0de83e9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_BorrowingsInterestRate_c702451e-df2c-41eb-b356-e4e6b0de83e9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_e80627db-5755-407d-b366-0be3e6c6b109" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTerm_e80627db-5755-407d-b366-0be3e6c6b109" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_eb708193-472e-407f-9188-6908d50fb821" xlink:href="nbx-20211231.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_eb708193-472e-407f-9188-6908d50fb821" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_758b4200-6b94-4723-bdee-a2d6166a740b" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_758b4200-6b94-4723-bdee-a2d6166a740b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_d03cdb26-0088-48f8-84cc-b95c1315aaf4" xlink:href="nbx-20211231.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingGuaranteeFee_d03cdb26-0088-48f8-84cc-b95c1315aaf4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstalments_3a40f726-4101-44b1-b623-ec9357cf394d" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfQuarterlyInstalments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingNumberOfQuarterlyInstalments_3a40f726-4101-44b1-b623-ec9357cf394d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e84a324f-1d08-42fa-a779-69535c11ff0e" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e84a324f-1d08-42fa-a779-69535c11ff0e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltyPayables_dab78c68-4ac8-4e47-82f0-448ac31428ac" xlink:href="nbx-20211231.xsd#nbx_RoyaltyPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_RoyaltyPayables_dab78c68-4ac8-4e47-82f0-448ac31428ac" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_36e3fbfd-1b0b-43a7-989b-710a0077eead" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_36e3fbfd-1b0b-43a7-989b-710a0077eead" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_09798b62-228e-44e7-ace2-e08ea58978a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_Borrowings_09798b62-228e-44e7-ace2-e08ea58978a7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingTotalInterestPayable_a751c901-a076-42bc-ba57-aa5b6adedb5e" xlink:href="nbx-20211231.xsd#nbx_BorrowingTotalInterestPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingTotalInterestPayable_a751c901-a076-42bc-ba57-aa5b6adedb5e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable_916a31cd-2f3f-438d-84c1-4728ed2ac20d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_InterestPayable_916a31cd-2f3f-438d-84c1-4728ed2ac20d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod_11d1463c-9796-4d5c-8416-6aa6da3002ea" xlink:href="nbx-20211231.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_ConsolidatedForecastedSalesPeriod_11d1463c-9796-4d5c-8416-6aa6da3002ea" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_5a9741ee-c625-41a1-9572-2527ddc5e902_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:to="loc_ifrs-full_BorrowingsByNameMember_5a9741ee-c625-41a1-9572-2527ddc5e902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:to="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_aadeee7a-d16d-47b8-ac9f-0955d83e9027" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_aadeee7a-d16d-47b8-ac9f-0955d83e9027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_13565f36-8e24-41b3-b560-343bb319ee77" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_13565f36-8e24-41b3-b560-343bb319ee77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_8a8d39c6-7f8e-4861-9747-1b39b13f69eb" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_8a8d39c6-7f8e-4861-9747-1b39b13f69eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0c38e144-7d43-4667-902f-46cf3b639f73_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:to="loc_ifrs-full_RangesMember_0c38e144-7d43-4667-902f-46cf3b639f73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:to="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0f01b15e-822f-4385-8cc3-f4a6ed2aa901" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:to="loc_ifrs-full_TopOfRangeMember_0f01b15e-822f-4385-8cc3-f4a6ed2aa901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_3c6acbb8-82bd-4784-a3af-3de547e99b25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:to="loc_ifrs-full_BottomOfRangeMember_3c6acbb8-82bd-4784-a3af-3de547e99b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_ca82d514-e607-452e-bddd-bd8187116efd_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:to="loc_ifrs-full_InterestRateTypesMember_ca82d514-e607-452e-bddd-bd8187116efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:to="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_c09c34ab-7cfc-412b-a105-1715a03e6a30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:to="loc_ifrs-full_FixedInterestRateMember_c09c34ab-7cfc-412b-a105-1715a03e6a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_7a18a445-1cfb-49c1-98b0-c32c7759625c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:to="loc_ifrs-full_FloatingInterestRateMember_7a18a445-1cfb-49c1-98b0-c32c7759625c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe9a59b2-6759-4640-bbdf-a2279142fef1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe9a59b2-6759-4640-bbdf-a2279142fef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_850bbc1f-83e8-4f75-a700-47060fe6840f" xlink:href="nbx-20211231.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_850bbc1f-83e8-4f75-a700-47060fe6840f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_6c4a31c2-9b04-46d8-addb-baa1f8596c44" xlink:href="nbx-20211231.xsd#nbx_BPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:to="loc_nbx_BPIFranceMember_6c4a31c2-9b04-46d8-addb-baa1f8596c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_98086974-2e7a-4981-a107-ce809b0faa41_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_98086974-2e7a-4981-a107-ce809b0faa41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_17c6047a-bbe3-4670-ba4b-d635506b11ae" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:to="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_17c6047a-bbe3-4670-ba4b-d635506b11ae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails" xlink:type="extended" id="i5a0314bd78234ded9122bee6dc9f8386_FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_9bf5cdf5-9e16-42e3-a51d-248231248bd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_9bf5cdf5-9e16-42e3-a51d-248231248bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0f9ea817-f7bb-4802-812b-b46f0d43d462" xlink:href="nbx-20211231.xsd#nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0f9ea817-f7bb-4802-812b-b46f0d43d462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_479c9fa6-a635-4187-a2c8-c8e14375c453" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_479c9fa6-a635-4187-a2c8-c8e14375c453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_06900a44-a704-417f-b0fe-ca9e0f6e254e" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_06900a44-a704-417f-b0fe-ca9e0f6e254e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_7a8bfa4e-82d5-438e-9dcf-d842f858b252" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_7a8bfa4e-82d5-438e-9dcf-d842f858b252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_955da57b-856e-4730-9c17-82de5525e300" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_955da57b-856e-4730-9c17-82de5525e300" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_2911baf4-59fe-4bdb-aebb-32af5c40335c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember_e3a775ee-d9a7-4f8d-820d-3bbaeb58e675" xlink:href="nbx-20211231.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_BPIFranceAdvanceMember_e3a775ee-d9a7-4f8d-820d-3bbaeb58e675" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeBPIFranceLoanMember_f63a87e5-4553-4d81-b2a9-320198e2764c" xlink:href="nbx-20211231.xsd#nbx_InterestFreeBPIFranceLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_InterestFreeBPIFranceLoanMember_f63a87e5-4553-4d81-b2a9-320198e2764c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b004102f-0b72-4e31-989f-fa6a08fe4788" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b004102f-0b72-4e31-989f-fa6a08fe4788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember_90a441b9-977f-4349-9e8a-59dadbdaecdd" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_ConditionalAdvanceBPIFranceMember_90a441b9-977f-4349-9e8a-59dadbdaecdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_988fa678-8a62-4d64-85ca-db894f55045e_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_988fa678-8a62-4d64-85ca-db894f55045e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_efddd748-9574-4e18-a812-43703766bc6c" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:to="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_efddd748-9574-4e18-a812-43703766bc6c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails" xlink:type="extended" id="ie05dc306d24b43a7a0e1d2919b8f3354_FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_28355f5b-643d-4631-a3a8-61aee689c390" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_28355f5b-643d-4631-a3a8-61aee689c390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_227969ec-fb0f-47c7-923c-c1b8803c62f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_227969ec-fb0f-47c7-923c-c1b8803c62f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_3e817760-cfa8-4a70-ae07-fed69ddc6057" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_3e817760-cfa8-4a70-ae07-fed69ddc6057" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_902dcd4e-25b3-4a32-aa6d-5cb09fb71acb" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_902dcd4e-25b3-4a32-aa6d-5cb09fb71acb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_42df5fa3-9de1-4947-a7c1-00f2afd2352d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_fe15b6c5-f675-4941-bd47-ed16f76f1085" xlink:href="nbx-20211231.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_nbx_BorrowingGuaranteeFee_fe15b6c5-f675-4941-bd47-ed16f76f1085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_a9a502eb-b491-47a7-998e-5d7c88cb4d14" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_BorrowingsInterestRate_a9a502eb-b491-47a7-998e-5d7c88cb4d14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_de2803f6-29af-4652-a3c8-f871ba938c35_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:to="loc_ifrs-full_BorrowingsByNameMember_de2803f6-29af-4652-a3c8-f871ba938c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:to="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_c7f1501a-f433-4001-8719-dcc815d48b80" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_c7f1501a-f433-4001-8719-dcc815d48b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07b29bcf-61ac-4c35-857d-72fdc605bb42" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07b29bcf-61ac-4c35-857d-72fdc605bb42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_b82e1be8-3f8e-4eea-8406-1efa553c5a7f_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_b82e1be8-3f8e-4eea-8406-1efa553c5a7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_ba97a729-b5d8-4b2d-bd24-8a7556eb5c8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_ba97a729-b5d8-4b2d-bd24-8a7556eb5c8b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails" xlink:type="extended" id="iaab02ea9f216495d89dfac1d22abea4a_FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_b94e4e55-9697-4776-b395-6a0ccae69fc0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_b94e4e55-9697-4776-b395-6a0ccae69fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_e555b093-b55a-4e12-aad3-31516a920aef" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_e555b093-b55a-4e12-aad3-31516a920aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_b24e213b-b45d-4e50-a411-f7b16a260914" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_b24e213b-b45d-4e50-a411-f7b16a260914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_60c0e11e-9b30-4641-92de-55da41cd5029" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_60c0e11e-9b30-4641-92de-55da41cd5029" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_e3800628-833c-4a20-84a4-3645c3c5a29c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_e3800628-833c-4a20-84a4-3645c3c5a29c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_50bb474b-0df5-4ec3-b816-673a78baddef" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_50bb474b-0df5-4ec3-b816-673a78baddef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_17b18ffc-1228-4e06-b3a1-a013e9a553bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_d2f99caf-ae08-41d6-a104-175d44568905_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_d2f99caf-ae08-41d6-a104-175d44568905_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_73eb9fa1-681a-447e-87a6-17f7c0897e6a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_73eb9fa1-681a-447e-87a6-17f7c0897e6a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="extended" id="i86aa51ec26624d13aaf2629da6ec5896_FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_41139d31-3a66-4278-9aef-0a0df26ee99d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_41139d31-3a66-4278-9aef-0a0df26ee99d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_8e08e93e-fbb7-4a8c-8184-54e18841b711" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_8e08e93e-fbb7-4a8c-8184-54e18841b711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9fb5b527-e7df-4565-84cb-6ee6bb0748f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9fb5b527-e7df-4565-84cb-6ee6bb0748f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfPGE_3042a283-3ac0-4ad4-bc9a-8bf0c0f8d7d1" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfPGE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingNumberOfPGE_3042a283-3ac0-4ad4-bc9a-8bf0c0f8d7d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_13349bd5-e248-45fa-aa83-dc73294e0365" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingMaturityTerm_13349bd5-e248-45fa-aa83-dc73294e0365" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_3e29cdda-018d-4e1c-89db-b8a8528084aa" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingDefermentPeriod_3e29cdda-018d-4e1c-89db-b8a8528084aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:to="loc_ifrs-full_BorrowingsByNameMember_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:to="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_5df13cd8-d037-45d4-87fd-f0f7ee36d3f0" xlink:href="nbx-20211231.xsd#nbx_BPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_BPIFranceMember_5df13cd8-d037-45d4-87fd-f0f7ee36d3f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeLoanBPIFranceMember_7c64160e-3a15-411d-b0e5-710298594a93" xlink:href="nbx-20211231.xsd#nbx_InterestFreeLoanBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_InterestFreeLoanBPIFranceMember_7c64160e-3a15-411d-b0e5-710298594a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_5d23d756-f741-4e5b-905a-92dfdc57ce8c" xlink:href="nbx-20211231.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_5d23d756-f741-4e5b-905a-92dfdc57ce8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_bed2884c-1e6b-4e31-b9d0-db67522bf4d6" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_bed2884c-1e6b-4e31-b9d0-db67522bf4d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_c5c603a5-8d47-4e4f-bbca-78e7adcb4421" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_c5c603a5-8d47-4e4f-bbca-78e7adcb4421" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e32f07a0-4fdb-4495-8507-0f09b33b3271" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e32f07a0-4fdb-4495-8507-0f09b33b3271" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_aeea77bc-f02b-4f99-9a3d-205461eb8921" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_aeea77bc-f02b-4f99-9a3d-205461eb8921" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:to="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_2e512ee8-29a3-4b28-829a-52dc459fc213_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_2e512ee8-29a3-4b28-829a-52dc459fc213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_b5f52726-8f71-4cea-aa8e-665abd3f2b8f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_b5f52726-8f71-4cea-aa8e-665abd3f2b8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_ef1c909d-f667-48a6-8f40-0a9275b6d605" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_ef1c909d-f667-48a6-8f40-0a9275b6d605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_39064100-1229-45f4-a631-1cd346a6aed5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_39064100-1229-45f4-a631-1cd346a6aed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_47a30de6-b239-4dc9-bda9-5d220a0a3786" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_47a30de6-b239-4dc9-bda9-5d220a0a3786" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" xlink:type="extended" id="i42dcab7c6ed44ceab419d61976e2be55_TradepayablesandothercurrentliabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_9dbde4a9-c8b3-4140-aa9c-0bea102f2a4f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_OtherCurrentPayables_9dbde4a9-c8b3-4140-aa9c-0bea102f2a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_fafba486-bbec-4ff0-9dbd-fba70fbb38ed" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_fafba486-bbec-4ff0-9dbd-fba70fbb38ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_4028cc28-55b5-4dc2-aa7d-953e938541b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_4028cc28-55b5-4dc2-aa7d-953e938541b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_9d82035d-d1a2-49e6-8449-d0c531cdabf3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_9d82035d-d1a2-49e6-8449-d0c531cdabf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:to="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_79a26471-57c1-41f8-9427-d3ac0e9dea1b_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:to="loc_nbx_CollaborationAgreementDomain_79a26471-57c1-41f8-9427-d3ac0e9dea1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:to="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ICONPlcMember_34c62bcf-b75c-4da3-b97d-c2b4514fa788" xlink:href="nbx-20211231.xsd#nbx_ICONPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:to="loc_nbx_ICONPlcMember_34c62bcf-b75c-4da3-b97d-c2b4514fa788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_4fc2d2cc-0d18-4811-b023-aaf052c0d67e" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:to="loc_nbx_LianBioNBTXR3Member_4fc2d2cc-0d18-4811-b023-aaf052c0d67e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" xlink:type="extended" id="i8743b1795f7a46029306022103a053e5_FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_cfd4b33d-08ad-4bc4-9301-92c724033e95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_ifrs-full_FinancialAssets_cfd4b33d-08ad-4bc4-9301-92c724033e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_a2c2fbd7-bb08-4783-a5a2-2d2b8f0b24fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_a2c2fbd7-bb08-4783-a5a2-2d2b8f0b24fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_a5ac6c2f-1861-45ef-be47-d54a8988122e" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_a5ac6c2f-1861-45ef-be47-d54a8988122e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_92d260dd-b919-493d-b3a4-edeba3e64914" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_92d260dd-b919-493d-b3a4-edeba3e64914" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_6c6634c1-4bf0-4a1c-90fb-fce26186db67_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_6c6634c1-4bf0-4a1c-90fb-fce26186db67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_a62277a7-0463-4d68-ba50-38d45aa90b33" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_a62277a7-0463-4d68-ba50-38d45aa90b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_240958b0-2e54-471d-9d1a-31879fb04962" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_240958b0-2e54-471d-9d1a-31879fb04962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_871a41f7-cd96-4613-8818-41578ca3f532_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:to="loc_ifrs-full_FinancialAssetsMember_871a41f7-cd96-4613-8818-41578ca3f532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:to="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember_a86e840d-10bb-4e75-8e29-65d08a72512a" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_nbx_NonCurrentFinancialAssetsMember_a86e840d-10bb-4e75-8e29-65d08a72512a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_9eecaa1d-02c5-4f32-9568-ffc5691e1f63" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_ifrs-full_TradeReceivablesMember_9eecaa1d-02c5-4f32-9568-ffc5691e1f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalentsMember_41312c3a-3efb-4413-aa89-522309380654" xlink:href="nbx-20211231.xsd#nbx_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_nbx_CashAndCashEquivalentsMember_41312c3a-3efb-4413-aa89-522309380654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember_781cf6b6-34b8-4294-9ef7-9af758dcd91a" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_NonCurrentFinancialLiabilitiesMember_781cf6b6-34b8-4294-9ef7-9af758dcd91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember_a9b6310c-34e9-483a-a91a-e659c21ee54e" xlink:href="nbx-20211231.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_CurrentFinancialLiabilitiesMember_a9b6310c-34e9-483a-a91a-e659c21ee54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember_367aa9ac-0605-45ee-bf57-187340123169" xlink:href="nbx-20211231.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_TradeAndOtherPayablesMember_367aa9ac-0605-45ee-bf57-187340123169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_8bbae07d-35d9-4dfe-90b2-389410e8f951_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_8bbae07d-35d9-4dfe-90b2-389410e8f951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_f35ab31b-9ac5-418e-bba7-698e14191c2b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_f35ab31b-9ac5-418e-bba7-698e14191c2b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" xlink:type="extended" id="i0ef754d09b6a49b5a490503eb7d91177_FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_0fc2fef2-5356-48d2-ad81-274d55bdf135" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_0fc2fef2-5356-48d2-ad81-274d55bdf135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_9ee7a883-382f-4a78-8896-99fddfc41ce4" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_9ee7a883-382f-4a78-8896-99fddfc41ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_61d09d53-6d55-41c6-8d2e-b1c9a5af26c1" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_61d09d53-6d55-41c6-8d2e-b1c9a5af26c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_1b25358a-f4bf-4e71-bb45-0bb1a52a9bae" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_1b25358a-f4bf-4e71-bb45-0bb1a52a9bae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:to="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_cacaf222-4b89-476a-8538-9ba1836436dd_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:to="loc_ifrs-full_TypesOfRisksMember_cacaf222-4b89-476a-8538-9ba1836436dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:to="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_cee595e8-ed7e-476a-8084-bc9cef034ac0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:to="loc_ifrs-full_CurrencyRiskMember_cee595e8-ed7e-476a-8084-bc9cef034ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:to="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_6e50bdee-fd56-4797-b473-e191202859a9_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:to="loc_currency_AllCurrenciesDomain_6e50bdee-fd56-4797-b473-e191202859a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:to="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_761587ec-c5e6-4f41-b0fc-378b5ee1fa0e" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:to="loc_currency_USD_761587ec-c5e6-4f41-b0fc-378b5ee1fa0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" xlink:type="extended" id="i38671d4305574aab913374f4573257fc_FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_e6e68137-8fc6-4d3f-a50d-b29598045fb6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_ifrs-full_NotionalAmount_e6e68137-8fc6-4d3f-a50d-b29598045fb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesBorrowings_9083063e-e89b-48a1-a54b-ea0fafe1111a" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_nbx_NumberOfTranchesBorrowings_9083063e-e89b-48a1-a54b-ea0fafe1111a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesReceivedBorrowings_23627417-9819-45b1-80db-ee2d212a55d8" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesReceivedBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_nbx_NumberOfTranchesReceivedBorrowings_23627417-9819-45b1-80db-ee2d212a55d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_686f5c34-c553-4b0e-a1fe-5af9436eb0f1_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_686f5c34-c553-4b0e-a1fe-5af9436eb0f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9bc827f5-10de-410b-9546-4feffd6ddb6b" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9bc827f5-10de-410b-9546-4feffd6ddb6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:to="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_53b26af6-7ec3-4d1f-9443-1e15e6502019_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:to="loc_ifrs-full_RangesMember_53b26af6-7ec3-4d1f-9443-1e15e6502019_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:to="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bd5be199-3928-43af-a44e-14efcc642b77" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:to="loc_ifrs-full_TopOfRangeMember_bd5be199-3928-43af-a44e-14efcc642b77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" xlink:type="extended" id="i653b5f2061a6416daeaeb6addd594839_RevenuesandotherincomeAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_30b2e3dc-3112-4635-b9ea-0f48f41e5306" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_30b2e3dc-3112-4635-b9ea-0f48f41e5306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_d3e8254e-709b-4fba-a5e4-a3513b7297a8" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_d3e8254e-709b-4fba-a5e4-a3513b7297a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_a4e4df8a-2896-414e-b5fc-be66368ae5e3" xlink:href="nbx-20211231.xsd#nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_a4e4df8a-2896-414e-b5fc-be66368ae5e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_27e197ab-1b4b-4dfd-97f7-8931b01e465f" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_27e197ab-1b4b-4dfd-97f7-8931b01e465f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod_6571be5b-b96f-40be-bb23-3ea8a8ed13b7" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementMilestonesAchievementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod_6571be5b-b96f-40be-bb23-3ea8a8ed13b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchTaxCreditUtilizationPeriod_ae5e46ca-74bf-422d-82da-ac64b907f478" xlink:href="nbx-20211231.xsd#nbx_ResearchTaxCreditUtilizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_ResearchTaxCreditUtilizationPeriod_ae5e46ca-74bf-422d-82da-ac64b907f478" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_7a1f6688-3719-45c0-bd49-fa1d8eb5d943" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_7a1f6688-3719-45c0-bd49-fa1d8eb5d943" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConcentrationRiskPercentage_39cc5722-94d6-405b-a87b-506466dcc0f5" xlink:href="nbx-20211231.xsd#nbx_ConcentrationRiskPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_ConcentrationRiskPercentage_39cc5722-94d6-405b-a87b-506466dcc0f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_ce444e2a-c653-4dbb-9602-afcf2faf237a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_ce444e2a-c653-4dbb-9602-afcf2faf237a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_9c820106-e23c-49d7-aa85-1bdff7a949f1" xlink:href="nbx-20211231.xsd#nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_9c820106-e23c-49d7-aa85-1bdff7a949f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_9606347c-fed4-4000-8585-1c2c3de6c733" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_NotionalAmount_9606347c-fed4-4000-8585-1c2c3de6c733" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:to="loc_nbx_CollaborationAgreementDomain_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:to="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PharmaEngineNBTWR3Member_81f77ad1-e7c0-4016-8162-1353391c214a" xlink:href="nbx-20211231.xsd#nbx_PharmaEngineNBTWR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_PharmaEngineNBTWR3Member_81f77ad1-e7c0-4016-8162-1353391c214a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_e739cbd4-4b98-4ffc-b4b9-64bac453003a" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_LianBioNBTXR3Member_e739cbd4-4b98-4ffc-b4b9-64bac453003a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SanofiGeneTherapyPortfolioMember_a9b68a89-033e-4cc3-a32a-e5d7520acfe7" xlink:href="nbx-20211231.xsd#nbx_SanofiGeneTherapyPortfolioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_SanofiGeneTherapyPortfolioMember_a9b68a89-033e-4cc3-a32a-e5d7520acfe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1185840-7bca-4a2a-80d4-8b34addb072b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:to="loc_srt_RangeMember_c1185840-7bca-4a2a-80d4-8b34addb072b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:to="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20d489ed-b73f-4919-bf2f-27a746c5d902" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:to="loc_srt_MaximumMember_20d489ed-b73f-4919-bf2f-27a746c5d902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_001441dd-a75f-4469-9870-d179f7e26f8d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:to="loc_srt_SegmentGeographicalDomain_001441dd-a75f-4469-9870-d179f7e26f8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:to="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_f899feb5-714e-4d8a-89c4-80e484fa2d8d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:to="loc_country_FR_f899feb5-714e-4d8a-89c4-80e484fa2d8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_7589eca5-caba-4e4c-b6c5-8129ee84e850_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:to="loc_ifrs-full_BorrowingsByNameMember_7589eca5-caba-4e4c-b6c5-8129ee84e850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:to="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_74643604-053f-42f1-bfd8-61e9bfcd683e" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_74643604-053f-42f1-bfd8-61e9bfcd683e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskMember_86bf31b5-92e3-4914-a6f7-cceabf2c999b_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:to="loc_ifrs-full_ConcentrationsOfRiskMember_86bf31b5-92e3-4914-a6f7-cceabf2c999b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:to="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RevenueByTypeMember_214b2605-4e58-491d-a2bb-2f90b6e8ed7e" xlink:href="nbx-20211231.xsd#nbx_RevenueByTypeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:to="loc_nbx_RevenueByTypeMember_214b2605-4e58-491d-a2bb-2f90b6e8ed7e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended" id="i6d4ae932f057471c89f2aaf8f39d4acb_RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_cb55646b-ede2-4e66-9c1a-28073a857958" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_cb55646b-ede2-4e66-9c1a-28073a857958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_37fcba72-a722-45ab-b4ba-4ee0e95e2103" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_37fcba72-a722-45ab-b4ba-4ee0e95e2103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_0873d665-1fb2-48a0-804a-66627d191d6e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_0873d665-1fb2-48a0-804a-66627d191d6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_04523647-d859-4eab-9239-625bac8896e2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_04523647-d859-4eab-9239-625bac8896e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_c201e601-306c-40b9-a735-1d3d6fe33cce" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_OtherIncome_c201e601-306c-40b9-a735-1d3d6fe33cce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_b0ea0b5e-630d-4ccb-8eb0-4306d6d80caf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_Revenue_b0ea0b5e-630d-4ccb-8eb0-4306d6d80caf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_9b71caeb-bb88-40b7-a01b-3b7ea0064409_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:to="loc_ifrs-full_ProductsAndServicesMember_9b71caeb-bb88-40b7-a01b-3b7ea0064409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:to="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_8ac7724e-eb58-44f1-bf79-0f1ca70177cb" xlink:href="nbx-20211231.xsd#nbx_ServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:to="loc_nbx_ServicesMember_8ac7724e-eb58-44f1-bf79-0f1ca70177cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_ae1616ed-5a65-4af6-8e48-fbe0163e27d8" xlink:href="nbx-20211231.xsd#nbx_OtherSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:to="loc_nbx_OtherSalesMember_ae1616ed-5a65-4af6-8e48-fbe0163e27d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesResearchandDevelopmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" xlink:type="extended" id="i64323c8bde4b41ff8f58a3515e3054fd_OperatingexpensesResearchandDevelopmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_c9c84a16-72f3-45de-a34f-80f126ab6a53" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_c9c84a16-72f3-45de-a34f-80f126ab6a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_6b02fd0e-716d-4203-a6bd-c50acbd85bfc" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_6b02fd0e-716d-4203-a6bd-c50acbd85bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_4a52d651-f955-4f8c-b0cd-4e7e34961fe9" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_4a52d651-f955-4f8c-b0cd-4e7e34961fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_90859c95-259e-4fbb-b102-200d0db852fd" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_90859c95-259e-4fbb-b102-200d0db852fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_08f37bb5-ce77-438b-a2bd-6efa71a055d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_ifrs-full_NumberOfEmployees_08f37bb5-ce77-438b-a2bd-6efa71a055d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees_73f80d84-fd26-42e5-85dd-e4c44e5e9005" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfEmployees_73f80d84-fd26-42e5-85dd-e4c44e5e9005" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2b277186-904f-4889-9b75-0ffb9b4263cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2b277186-904f-4889-9b75-0ffb9b4263cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_5f6ef63d-f4e4-4514-a179-b0b35abfe284_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_5f6ef63d-f4e4-4514-a179-b0b35abfe284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseMember_7366f43c-de9b-4dc8-957b-c1b91f3b27e6" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseMember_7366f43c-de9b-4dc8-957b-c1b91f3b27e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" xlink:type="extended" id="iec3e0d093cf3467fbcdcf9e2b58376fb_OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_c782126b-6dca-4319-acad-284390572ad7" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_c782126b-6dca-4319-acad-284390572ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_b08b7087-d7fd-4636-a97a-15e93e26ce0a" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_b08b7087-d7fd-4636-a97a-15e93e26ce0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfImpactingFactors_279e9590-22f3-4738-beb1-69b5504ffa5d" xlink:href="nbx-20211231.xsd#nbx_NumberOfImpactingFactors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_NumberOfImpactingFactors_279e9590-22f3-4738-beb1-69b5504ffa5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_4ab4e07f-59dc-4975-af7a-354fee8cd7c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_4ab4e07f-59dc-4975-af7a-354fee8cd7c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a452cb2d-009f-4261-a2ab-16ded100ff6b" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a452cb2d-009f-4261-a2ab-16ded100ff6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_34ca8007-63cc-469b-87a0-929aac61da91" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_34ca8007-63cc-469b-87a0-929aac61da91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_a479a88f-e709-479e-adc2-877737ca5369" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_NumberOfEmployees_a479a88f-e709-479e-adc2-877737ca5369" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees_a98507eb-084a-4354-ae97-66a4c8ae0b94" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfEmployees_a98507eb-084a-4354-ae97-66a4c8ae0b94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7b789fa3-7185-4315-8230-fc0b17864c42" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7b789fa3-7185-4315-8230-fc0b17864c42" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_42e4be0e-a126-48c0-9c2b-97a240e433b5_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_42e4be0e-a126-48c0-9c2b-97a240e433b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8f239bee-1a17-43da-b504-a119ecfbbb7f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8f239bee-1a17-43da-b504-a119ecfbbb7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="extended" id="i9dfa2a92fa204825b626206e44a59cf5_OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_74863289-2768-44c2-bdec-8938a78d7e7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_AmortisationExpense_74863289-2768-44c2-bdec-8938a78d7e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_380a3a1b-a5e5-4cf7-93a1-441246d8d857" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_DepreciationExpense_380a3a1b-a5e5-4cf7-93a1-441246d8d857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_bc5d165f-8ae0-4139-bf86-06fc07a1f484" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_bc5d165f-8ae0-4139-bf86-06fc07a1f484" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_b17f6fac-8eb3-4367-ba5a-365311531b72" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_b17f6fac-8eb3-4367-ba5a-365311531b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_f821f96a-c07a-4c8e-8c85-2f364c98f8d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_f821f96a-c07a-4c8e-8c85-2f364c98f8d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses_44f6bb5d-2782-44c4-832a-a3b3cfcafca6" xlink:href="nbx-20211231.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpenses_44f6bb5d-2782-44c4-832a-a3b3cfcafca6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseMember_56bf2b7a-30a2-4149-b0a0-a1d45c78844a" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseMember_56bf2b7a-30a2-4149-b0a0-a1d45c78844a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_ea76b2a3-9e0e-42cb-8d2e-7d4c2d1f1fc2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_ea76b2a3-9e0e-42cb-8d2e-7d4c2d1f1fc2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails" xlink:type="extended" id="idda69ae8f2bf4f55aeddfa09cf8fa3e4_OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractTerminationIndemnities_7051eb92-c673-43c3-9254-a4fb7892ebdf" xlink:href="nbx-20211231.xsd#nbx_ContractTerminationIndemnities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:to="loc_nbx_ContractTerminationIndemnities_7051eb92-c673-43c3-9254-a4fb7892ebdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:to="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_576d1ade-9289-4f6e-8e9c-cfe3ed276dec_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:to="loc_nbx_CollaborationAgreementDomain_576d1ade-9289-4f6e-8e9c-cfe3ed276dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:to="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fc89f531-6392-42e7-bb40-63cfce069a06" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fc89f531-6392-42e7-bb40-63cfce069a06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" xlink:type="extended" id="i62c995adc8fb4f79816dfd3ae42c087d_SharebasedpaymentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareBasedPaymentArrangementPlans_82f38e60-6c4f-43a5-bd2c-7df2198ae100" xlink:href="nbx-20211231.xsd#nbx_NumberOfShareBasedPaymentArrangementPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_nbx_NumberOfShareBasedPaymentArrangementPlans_82f38e60-6c4f-43a5-bd2c-7df2198ae100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_87fa854c-5c4c-428c-8586-824871597618" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_87fa854c-5c4c-428c-8586-824871597618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_8f224627-9873-4bc6-92d9-f5babcce2526" xlink:href="nbx-20211231.xsd#nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_8f224627-9873-4bc6-92d9-f5babcce2526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_b0dcdc89-2356-4fc3-84e8-de64a91d8bc9" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSPCEMember_b0dcdc89-2356-4fc3-84e8-de64a91d8bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_0fca05c7-e37c-4a93-bf8b-641d9e1c4423" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSAMember_0fca05c7-e37c-4a93-bf8b-641d9e1c4423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_1839ae77-146b-464a-bb95-e4c37943b5c1" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_OSAMember_1839ae77-146b-464a-bb95-e4c37943b5c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_f7c71e79-26b5-4de3-973d-7c9a56fa9710" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_AGAMember_f7c71e79-26b5-4de3-973d-7c9a56fa9710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_2172edd0-728d-424b-9dd2-f12235e9fb1a" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSA2014Member_2172edd0-728d-424b-9dd2-f12235e9fb1a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails" xlink:type="extended" id="iaf79a46245e5423a9867a3d0c10e16b7_SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6aad2112-aef0-4094-adda-81f0bc55155a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6aad2112-aef0-4094-adda-81f0bc55155a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_906df778-4973-4b50-ae51-ab0841a169f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_906df778-4973-4b50-ae51-ab0841a169f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ea7e4372-ff0f-440b-933a-b0258db0761a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ea7e4372-ff0f-440b-933a-b0258db0761a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1d26bfff-c04f-4168-beb1-00b9cb62581b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1d26bfff-c04f-4168-beb1-00b9cb62581b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_c7937d5d-e16d-4a48-9e42-3a2f212ae9a8" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_c7937d5d-e16d-4a48-9e42-3a2f212ae9a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_21d2a6e1-67ee-4696-b337-5a9180e03976" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_21d2a6e1-67ee-4696-b337-5a9180e03976" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_a7c559c5-4dde-43ff-ad41-a97d6972fdc0" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_a7c559c5-4dde-43ff-ad41-a97d6972fdc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_513a4484-b1db-4d03-a9bd-8042006ba4a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_513a4484-b1db-4d03-a9bd-8042006ba4a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_3f20e8df-08a9-4c93-9554-e1aef0603a68_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_3f20e8df-08a9-4c93-9554-e1aef0603a68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_a98065a2-1f28-4e68-8835-e5ac8b0f1b6f" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20122Member_a98065a2-1f28-4e68-8835-e5ac8b0f1b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_f0d5885b-a19d-42a6-9334-90cf8a08862c" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE082013Member_f0d5885b-a19d-42a6-9334-90cf8a08862c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_7047270b-0bce-48e6-9b8f-fd10855a39de" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE092014Member_7047270b-0bce-48e6-9b8f-fd10855a39de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_c07f36a1-f8c9-4a55-902d-14ee9aa6af6a" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20151Member_c07f36a1-f8c9-4a55-902d-14ee9aa6af6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_6996e3d7-7dc7-4b92-91ec-b4e991777d2b" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20153Member_6996e3d7-7dc7-4b92-91ec-b4e991777d2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_a161c7ea-b01e-4cc9-ae0b-be6f9f45b3e0" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_a161c7ea-b01e-4cc9-ae0b-be6f9f45b3e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_0cf95680-e4a2-4188-ab31-c0390ff39569" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2016PerformanceMember_0cf95680-e4a2-4188-ab31-c0390ff39569" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_52d49ade-f81f-45ea-b3b5-43b8add22d67" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_52d49ade-f81f-45ea-b3b5-43b8add22d67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017PerformanceMember_3b2eff09-4898-4aa2-a52f-6c5d21b4e599" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2017PerformanceMember_3b2eff09-4898-4aa2-a52f-6c5d21b4e599" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_75885b0e-6820-4945-bfd2-22642ca21de7" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA0412Member_75885b0e-6820-4945-bfd2-22642ca21de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_1e3e450f-858f-45ab-84af-88c97b3266a7" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2013Member_1e3e450f-858f-45ab-84af-88c97b3266a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_ca7e68d6-2212-46d1-961e-0e28ee3ac1d6" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2014Member_ca7e68d6-2212-46d1-961e-0e28ee3ac1d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_2d05d06b-b1b5-4438-bd0c-09525f995d9c" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20151Member_2d05d06b-b1b5-4438-bd0c-09525f995d9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_ae86816e-d910-478b-a369-76dc861cfbf1" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20152AMember_ae86816e-d910-478b-a369-76dc861cfbf1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_b14c2128-cca5-41ed-881d-023aa95a4445" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20152BMember_b14c2128-cca5-41ed-881d-023aa95a4445" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016OrdinaryMember_76c6fda8-3bbc-4477-8534-7e8c35449b36" xlink:href="nbx-20211231.xsd#nbx_BSA2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2016OrdinaryMember_76c6fda8-3bbc-4477-8534-7e8c35449b36" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016PerformanceMember_8eae2464-d229-4fbb-9cd9-bf64433dc5dd" xlink:href="nbx-20211231.xsd#nbx_BSA2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2016PerformanceMember_8eae2464-d229-4fbb-9cd9-bf64433dc5dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_50d310fa-275f-4bf7-9e88-757567c8badd" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20162Member_50d310fa-275f-4bf7-9e88-757567c8badd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_9c1db183-9040-4bf1-9d8c-e5a4e377bd66" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2017Member_9c1db183-9040-4bf1-9d8c-e5a4e377bd66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_a18150e0-35b0-4d1b-95c6-58add520415a" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20181Member_a18150e0-35b0-4d1b-95c6-58add520415a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_e55a61b4-f4df-4589-8835-7113c9ee8d8a" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20182Member_e55a61b4-f4df-4589-8835-7113c9ee8d8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_d643dd52-ba44-471d-bfc7-49ba667ba32a" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20191Member_d643dd52-ba44-471d-bfc7-49ba667ba32a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_05922930-0652-4291-8531-c55928eacfc7" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2020Member_05922930-0652-4291-8531-c55928eacfc7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_969da534-18d5-4b95-8eae-c726af7c4702" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2021AMember_969da534-18d5-4b95-8eae-c726af7c4702" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_33fda3c2-d099-4e06-abdc-dbd4a38f81f5" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2021BMember_33fda3c2-d099-4e06-abdc-dbd4a38f81f5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_2025838a-3650-49c5-89e3-161ae46b7564" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20181Member_2025838a-3650-49c5-89e3-161ae46b7564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_775e409a-776b-4cfc-aed5-6ed77f5c7e38" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20182Member_775e409a-776b-4cfc-aed5-6ed77f5c7e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_d64a028d-aa77-41d9-94aa-bba79a2325c5" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20191Member_d64a028d-aa77-41d9-94aa-bba79a2325c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_a1b4d5a0-6b0e-4e8c-95df-0fadf173fb89" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA2020Member_a1b4d5a0-6b0e-4e8c-95df-0fadf173fb89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_4368ab6d-e248-4396-b09d-7e08b9563bc8" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA2021Member_4368ab6d-e248-4396-b09d-7e08b9563bc8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails" xlink:type="extended" id="i7a11d07e596f46fbab3f5a328672f337_SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_62e5300d-d429-4f2c-8913-af9b525fb37d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_62e5300d-d429-4f2c-8913-af9b525fb37d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_5340e4f8-ebf6-4186-bf48-36c45b7f671e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_5340e4f8-ebf6-4186-bf48-36c45b7f671e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_268313cd-1447-42f9-aed5-6ddd152df9eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_268313cd-1447-42f9-aed5-6ddd152df9eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_64ded2bc-dfa5-413d-8a86-6a964520a3b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_64ded2bc-dfa5-413d-8a86-6a964520a3b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_7ef43908-d68b-40a0-b59a-2b9433ef1acd" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_7ef43908-d68b-40a0-b59a-2b9433ef1acd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_5dab8b95-f85c-4e88-915f-c395ead240cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_5dab8b95-f85c-4e88-915f-c395ead240cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_1422ca06-c49b-4ce7-be2f-0179243b3d48" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_1422ca06-c49b-4ce7-be2f-0179243b3d48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_72a31771-2675-4f74-8a4d-d1495e31aae7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_72a31771-2675-4f74-8a4d-d1495e31aae7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:to="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_391ee518-e4bd-4a34-a083-69ce26fbcca9" xlink:href="nbx-20211231.xsd#nbx_OSA20161PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20161PerformanceMember_391ee518-e4bd-4a34-a083-69ce26fbcca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_31ba6f00-0cec-4154-81a7-42a58641a949" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20162Member_31ba6f00-0cec-4154-81a7-42a58641a949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_969588f0-2be9-4f9e-b38c-7cacb8cf894f" xlink:href="nbx-20211231.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2017OrdinaryMember_969588f0-2be9-4f9e-b38c-7cacb8cf894f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_7aa5ad70-3257-4706-98aa-1f1bb34c7ece" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2018Member_7aa5ad70-3257-4706-98aa-1f1bb34c7ece" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_8eb9bdd3-7c3c-4b02-94c6-065e1f453396" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20191Member_8eb9bdd3-7c3c-4b02-94c6-065e1f453396" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_243d698b-289d-424b-970d-a8d729dfe7db" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSALLY2019Member_243d698b-289d-424b-970d-a8d729dfe7db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_38288dd0-2991-458f-ad4d-09f804aa39e4" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2020Member_38288dd0-2991-458f-ad4d-09f804aa39e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_db875686-de95-43a5-9457-037390dc2933" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA202104Member_db875686-de95-43a5-9457-037390dc2933" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_dc6690c1-6a47-45f2-b632-526ab98bff37" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA202106Member_dc6690c1-6a47-45f2-b632-526ab98bff37" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" xlink:type="extended" id="i147b6bbd128e4e84a84b110ae06a8481_SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_24726a36-3035-4cce-be0a-4b85108ebbd6" xlink:href="nbx-20211231.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_24726a36-3035-4cce-be0a-4b85108ebbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_6fb8f54f-fac6-4650-9667-9e0c212cce22" xlink:href="nbx-20211231.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_6fb8f54f-fac6-4650-9667-9e0c212cce22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_5c3c33da-7e95-4594-8c40-b12f9b23b1c7" xlink:href="nbx-20211231.xsd#nbx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_5c3c33da-7e95-4594-8c40-b12f9b23b1c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OptionLifeOtherEquityInstrumentsGranted_4a92724b-a3d9-4afe-968e-24d7c7f6efa2" xlink:href="nbx-20211231.xsd#nbx_OptionLifeOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_OptionLifeOtherEquityInstrumentsGranted_4a92724b-a3d9-4afe-968e-24d7c7f6efa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_05e7dc55-18a4-4a89-8b61-17db464bf10f" xlink:href="nbx-20211231.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_05e7dc55-18a4-4a89-8b61-17db464bf10f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_eb725d95-d5a5-4154-9ac7-202a159c0b4c" xlink:href="nbx-20211231.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_eb725d95-d5a5-4154-9ac7-202a159c0b4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_55b73680-6d8d-46b4-b7d5-5175ed0e3513" xlink:href="nbx-20211231.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_55b73680-6d8d-46b4-b7d5-5175ed0e3513" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_1150ec43-44bc-4f2a-b400-23b96b890ad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_1150ec43-44bc-4f2a-b400-23b96b890ad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ccf5e0e0-f313-46d5-a422-84440f443f52_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ccf5e0e0-f313-46d5-a422-84440f443f52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20121Member_b593876a-6e78-468c-ae80-0b8021dfde89" xlink:href="nbx-20211231.xsd#nbx_BSPCE20121Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20121Member_b593876a-6e78-468c-ae80-0b8021dfde89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_bad03876-e030-49cc-961d-7aea418aa6d9" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20122Member_bad03876-e030-49cc-961d-7aea418aa6d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE042013Member_219c10a6-f5cc-4258-a0da-a8e7f3feb970" xlink:href="nbx-20211231.xsd#nbx_BSPCE042013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE042013Member_219c10a6-f5cc-4258-a0da-a8e7f3feb970" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_ff9424f2-2d8d-4615-8732-9d85921b9b37" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE082013Member_ff9424f2-2d8d-4615-8732-9d85921b9b37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_c6fb7dbd-3533-4d9f-977d-6bf29f02b0b5" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE092014Member_c6fb7dbd-3533-4d9f-977d-6bf29f02b0b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_399fcf9b-fd44-4a57-a8a3-e46e5fc53bb1" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20151Member_399fcf9b-fd44-4a57-a8a3-e46e5fc53bb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20152Member_b5e888d0-a28c-43de-ab4b-b4ee07505a3a" xlink:href="nbx-20211231.xsd#nbx_BSPCE20152Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20152Member_b5e888d0-a28c-43de-ab4b-b4ee07505a3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_e8fc97bc-a9e6-4227-ab73-7760e42c65f7" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20153Member_e8fc97bc-a9e6-4227-ab73-7760e42c65f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_8c39de8c-153e-458f-9c58-8299d396c664" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_8c39de8c-153e-458f-9c58-8299d396c664" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_99bbff33-d2c8-49ac-a7d7-b33e4e087753" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2016PerformanceMember_99bbff33-d2c8-49ac-a7d7-b33e4e087753" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_170666f7-c9a6-4512-acec-6c4f03eb0348" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_170666f7-c9a6-4512-acec-6c4f03eb0348" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017PerformanceMember_ad865ced-3d07-4514-ab8c-d7cb67ccda3b" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017PerformanceMember_ad865ced-3d07-4514-ab8c-d7cb67ccda3b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_11ea6ef4-eab8-4ae6-a43c-d32e324cf723" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017Member_11ea6ef4-eab8-4ae6-a43c-d32e324cf723" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017ProjectMember_cb59604a-d27f-49d3-b658-ea49957e647d" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017ProjectMember_cb59604a-d27f-49d3-b658-ea49957e647d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_9d793026-bce3-411f-8cc5-210dcfa358d8" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA0412Member_9d793026-bce3-411f-8cc5-210dcfa358d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_1d1ed03c-93da-4a42-b9cd-41a3a1047782" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2013Member_1d1ed03c-93da-4a42-b9cd-41a3a1047782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_085cfde6-dbe1-4da4-bc94-df6417b42a4d" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2014Member_085cfde6-dbe1-4da4-bc94-df6417b42a4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_17e5e553-cb76-4bb1-bc98-5f7b56618005" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20151Member_17e5e553-cb76-4bb1-bc98-5f7b56618005" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_76787adf-5e68-4a9a-89d9-70caaffe9673" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20152AMember_76787adf-5e68-4a9a-89d9-70caaffe9673" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_c073c19b-57b5-451b-8ca5-da94288f6f38" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20152BMember_c073c19b-57b5-451b-8ca5-da94288f6f38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016OrdinaryMember_1994c1e9-0209-489f-9914-04a49496aafa" xlink:href="nbx-20211231.xsd#nbx_BSA2016OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2016OrdinaryMember_1994c1e9-0209-489f-9914-04a49496aafa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016PerformanceMember_5f7104f4-2c65-499c-aab2-b746f290da1a" xlink:href="nbx-20211231.xsd#nbx_BSA2016PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2016PerformanceMember_5f7104f4-2c65-499c-aab2-b746f290da1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_aefe86eb-2773-4664-83d2-ce72b3f9b8c9" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20162Member_aefe86eb-2773-4664-83d2-ce72b3f9b8c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_aff52b74-8813-40ff-af90-c8917098b7f7" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2017Member_aff52b74-8813-40ff-af90-c8917098b7f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_e2c12ae1-c72d-4074-a4c5-c6b66eef52fb" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20181Member_e2c12ae1-c72d-4074-a4c5-c6b66eef52fb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_a6f8912f-2def-479c-8ffe-13752a253289" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20182Member_a6f8912f-2def-479c-8ffe-13752a253289" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_c23e530f-8c3b-41f8-9061-cca2dd161f6b" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20191Member_c23e530f-8c3b-41f8-9061-cca2dd161f6b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_9210010d-8c51-49f6-8dc7-1074823ff760" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2020Member_9210010d-8c51-49f6-8dc7-1074823ff760" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_e9733421-0f1d-4577-8a2a-3658febcb333" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2021AMember_e9733421-0f1d-4577-8a2a-3658febcb333" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_3bd74935-f4da-4912-a59b-4658c9add5a4" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2021BMember_3bd74935-f4da-4912-a59b-4658c9add5a4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_9bdc09f1-eb55-451d-88b4-daee63778330" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20181Member_9bdc09f1-eb55-451d-88b4-daee63778330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_7114eead-bc07-4e17-9bcc-77cb9fa527bf" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20182Member_7114eead-bc07-4e17-9bcc-77cb9fa527bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_95a139cb-d779-4413-bfc3-46cb27869951" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20191Member_95a139cb-d779-4413-bfc3-46cb27869951" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_5f771644-4edc-4ab9-80d9-dfb88f0394cb" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA2020Member_5f771644-4edc-4ab9-80d9-dfb88f0394cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_30b73c40-3e82-40a0-a1be-3c4511c179b6" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA2021Member_30b73c40-3e82-40a0-a1be-3c4511c179b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_392e3b0a-baf1-4308-a036-7983286b3962" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_OSA202104OrdinaryMember_392e3b0a-baf1-4308-a036-7983286b3962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_20a81f36-2ead-4466-a43a-4e5141903bd1" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_OSA202106OrdinaryMember_20a81f36-2ead-4466-a43a-4e5141903bd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_55155104-704a-4f09-a1ff-6c012a27800a_default" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:to="loc_nbx_VestingDomain_55155104-704a-4f09-a1ff-6c012a27800a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:to="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_e3be9f0f-82aa-4226-b02c-7f2f2c0e8fa9" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheOneMember_e3be9f0f-82aa-4226-b02c-7f2f2c0e8fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_bbf1f6cc-e8f6-429a-9239-7853d916bf70" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheTwoMember_bbf1f6cc-e8f6-429a-9239-7853d916bf70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_40f21a51-93ff-4de8-9076-9baf21e277eb" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheThreeMember_40f21a51-93ff-4de8-9076-9baf21e277eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_e9b0f90a-ca4f-4520-9765-ac651fed293d" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheFourMember_e9b0f90a-ca4f-4520-9765-ac651fed293d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_5026f239-0e5f-47a9-9455-c2d65d74c4c3_default" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:to="loc_nbx_TrancheDomain_5026f239-0e5f-47a9-9455-c2d65d74c4c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:to="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_4a08b0eb-e78b-49fe-8304-a4b92341efc2" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheOneMember_4a08b0eb-e78b-49fe-8304-a4b92341efc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_212d576f-1157-498a-b134-df4a7162f29a" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheTwoMember_212d576f-1157-498a-b134-df4a7162f29a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_27a673c4-57a2-4518-b55b-3c9f55754a03" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheThreeMember_27a673c4-57a2-4518-b55b-3c9f55754a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_371d69f8-cdb6-440b-b5ff-3089cb541384" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheFourMember_371d69f8-cdb6-440b-b5ff-3089cb541384" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_dd891ee9-f472-4077-9e2f-dea4e2472e9d" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:to="loc_nbx_TranchesDomain_dd891ee9-f472-4077-9e2f-dea4e2472e9d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" xlink:type="extended" id="i79fbcc3d9f8845f596aa8a6c7bef7f0a_SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2c00d13d-0a2c-4983-a7ff-36a3cb646988" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2c00d13d-0a2c-4983-a7ff-36a3cb646988" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b92e6b9e-05dc-4a7a-8cc3-faac993955a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b92e6b9e-05dc-4a7a-8cc3-faac993955a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_36120a31-f299-4873-b324-280a1aa5ea16" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_36120a31-f299-4873-b324-280a1aa5ea16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_056cd957-f319-4806-bd24-4d151139ca73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_056cd957-f319-4806-bd24-4d151139ca73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_62842067-483e-4bf5-9e18-c5534369b5f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_62842067-483e-4bf5-9e18-c5534369b5f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24390f95-63d4-4b33-a3c1-367df0c1a6f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24390f95-63d4-4b33-a3c1-367df0c1a6f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_bf1d81c1-739e-42ef-b283-f5b900ea3cc7" xlink:href="nbx-20211231.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_bf1d81c1-739e-42ef-b283-f5b900ea3cc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_60fdbb8f-9996-48e4-b239-dc08e1ab89d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_60fdbb8f-9996-48e4-b239-dc08e1ab89d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:to="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161OrdinaryMember_b0c9eb02-d92f-4eb7-ae60-e11e7e37d5aa" xlink:href="nbx-20211231.xsd#nbx_OSA20161OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20161OrdinaryMember_b0c9eb02-d92f-4eb7-ae60-e11e7e37d5aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_cc193cf7-46b6-4f42-9df8-1a41f758581b" xlink:href="nbx-20211231.xsd#nbx_OSA20161PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20161PerformanceMember_cc193cf7-46b6-4f42-9df8-1a41f758581b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_c9b4eeb7-aaa0-4ece-bbe2-701872dfcd50" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20162Member_c9b4eeb7-aaa0-4ece-bbe2-701872dfcd50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_cb4bec59-3c47-4ee5-ba40-69ca1b417275" xlink:href="nbx-20211231.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2017OrdinaryMember_cb4bec59-3c47-4ee5-ba40-69ca1b417275" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017PerformanceMember_d95886a6-8c10-4bd6-bd0c-6d3f53dbbaa7" xlink:href="nbx-20211231.xsd#nbx_OSA2017PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2017PerformanceMember_d95886a6-8c10-4bd6-bd0c-6d3f53dbbaa7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_85f2bd29-6425-42c3-ab3c-e408641cafee" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2018Member_85f2bd29-6425-42c3-ab3c-e408641cafee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_47388867-e13c-4361-ab06-71bff93a2ed2" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20191Member_47388867-e13c-4361-ab06-71bff93a2ed2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_204d47d1-7ae2-4e27-9774-61bc18744786" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSALLY2019Member_204d47d1-7ae2-4e27-9774-61bc18744786" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_ae1cf056-ade4-441a-93c0-859856db58c8" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2020Member_ae1cf056-ade4-441a-93c0-859856db58c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_6bd1c868-1d6d-4581-bb52-3c62a01c1fe9" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202104OrdinaryMember_6bd1c868-1d6d-4581-bb52-3c62a01c1fe9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_20c48671-65a9-4797-8f4d-cb78868a0441" xlink:href="nbx-20211231.xsd#nbx_OSA202104PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202104PerformanceMember_20c48671-65a9-4797-8f4d-cb78868a0441" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_cf7b8d12-147e-409d-a2f0-64d78f842b0a" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202106OrdinaryMember_cf7b8d12-147e-409d-a2f0-64d78f842b0a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_a89e8a67-e031-4a8c-87a9-e8bbc50e6f75" xlink:href="nbx-20211231.xsd#nbx_OSA202106PerformanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202106PerformanceMember_a89e8a67-e031-4a8c-87a9-e8bbc50e6f75" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_09018a85-f496-4712-a035-46c3093ffc7d_default" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:to="loc_nbx_VestingDomain_09018a85-f496-4712-a035-46c3093ffc7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:to="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_8364e239-27ce-4fef-9d43-2d2ec8aaeb53" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheOneMember_8364e239-27ce-4fef-9d43-2d2ec8aaeb53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_7db2f0b9-c589-4303-bcd5-f3ebd03006cc" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheTwoMember_7db2f0b9-c589-4303-bcd5-f3ebd03006cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_1f053031-c887-40aa-a47a-186dc81f5e62" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheThreeMember_1f053031-c887-40aa-a47a-186dc81f5e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_00748bfe-835c-402c-b06a-3656fb8c46c9_default" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:to="loc_nbx_TrancheDomain_00748bfe-835c-402c-b06a-3656fb8c46c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:to="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_8baeded7-ab4b-4478-af77-272168fc23ec" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheOneMember_8baeded7-ab4b-4478-af77-272168fc23ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_234d60cb-203b-42bd-ab2c-6188ff1301ea" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheTwoMember_234d60cb-203b-42bd-ab2c-6188ff1301ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_f0bbba03-270a-4eff-b3d7-2f9160b0c4d3" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheThreeMember_f0bbba03-270a-4eff-b3d7-2f9160b0c4d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_8e1d1770-7ef3-41f4-ac23-bfa3df17c686" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:to="loc_nbx_TranchesDomain_8e1d1770-7ef3-41f4-ac23-bfa3df17c686" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NetfinancialincomelossAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" xlink:type="extended" id="i496d608a35ab4bdda498a2eb6226722e_NetfinancialincomelossAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_afe1a234-17cb-4491-9505-fdc14d55ee2e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_InterestRevenueExpense_afe1a234-17cb-4491-9505-fdc14d55ee2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_5b657baa-9118-478a-a2a5-a62687fe4d8c" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_5b657baa-9118-478a-a2a5-a62687fe4d8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_3e184b63-96d0-4163-8711-7e6f3c4e3c2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_3e184b63-96d0-4163-8711-7e6f3c4e3c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_d60f83ac-4fb0-4b9e-8a1f-71d92c1b7b49" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_NetForeignExchangeGain_d60f83ac-4fb0-4b9e-8a1f-71d92c1b7b49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_7f06e47e-7570-49dd-aa1a-42d0c2202c6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_7f06e47e-7570-49dd-aa1a-42d0c2202c6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_2b570dbf-ad45-4a0f-8b38-a5523463ede4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_2b570dbf-ad45-4a0f-8b38-a5523463ede4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_98f6cd5a-859a-48bb-89a9-db182381a7ba_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:to="loc_ifrs-full_InterestRateTypesMember_98f6cd5a-859a-48bb-89a9-db182381a7ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:to="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_ee95755b-8c93-4059-bca8-e6640d8eb644" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:to="loc_ifrs-full_FixedInterestRateMember_ee95755b-8c93-4059-bca8-e6640d8eb644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_23a07eec-0008-4893-941b-559bbfaa16a2_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:to="loc_ifrs-full_BorrowingsByNameMember_23a07eec-0008-4893-941b-559bbfaa16a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9d5a28a5-f4e1-42ac-b7a3-12733bae8242" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9d5a28a5-f4e1-42ac-b7a3-12733bae8242" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IncometaxAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" xlink:type="extended" id="if18244902a4846d48c390f16b1167049_IncometaxAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_d6d29901-d530-4fb7-859e-e6f3b5a99589" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_d6d29901-d530-4fb7-859e-e6f3b5a99589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_UnusedTaxLossExpirationPeriod_e5b8c319-dc51-4ae5-8420-0672a4d71825" xlink:href="nbx-20211231.xsd#nbx_UnusedTaxLossExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_nbx_UnusedTaxLossExpirationPeriod_e5b8c319-dc51-4ae5-8420-0672a4d71825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_5bfbb770-7917-41ae-8e18-4607a92a29ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_5bfbb770-7917-41ae-8e18-4607a92a29ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CompanyDeferredTaxRate_b326fd3c-bb8e-4829-ae24-cec319b26306" xlink:href="nbx-20211231.xsd#nbx_CompanyDeferredTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_nbx_CompanyDeferredTaxRate_b326fd3c-bb8e-4829-ae24-cec319b26306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:to="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1e487e8e-9aa7-4697-8052-3861f7c2bffb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:to="loc_srt_SegmentGeographicalDomain_1e487e8e-9aa7-4697-8052-3861f7c2bffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:to="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_d15ac275-de9a-46f8-98c3-60468008d208" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:to="loc_country_FR_d15ac275-de9a-46f8-98c3-60468008d208" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8cb1128-3e35-4a95-b084-3d2344e99bff" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:to="loc_country_US_f8cb1128-3e35-4a95-b084-3d2344e99bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_dab2a11a-b9af-4c4d-8040-685e2e312066_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_dab2a11a-b9af-4c4d-8040-685e2e312066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_add424b4-5101-41d7-8307-e875646a6c18" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_add424b4-5101-41d7-8307-e875646a6c18" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CommitmentsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="extended" id="i8e926f68d4384496b481c7a91798de31_CommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_22bb8c19-517e-4d75-8e74-ef85806acb2d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_22bb8c19-517e-4d75-8e74-ef85806acb2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShortTermLeaseContracts_805e5105-44f7-4ce6-be15-3cf14c172384" xlink:href="nbx-20211231.xsd#nbx_NumberOfShortTermLeaseContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_NumberOfShortTermLeaseContracts_805e5105-44f7-4ce6-be15-3cf14c172384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualShortTermLeaseExpense_9c668d28-de4c-4ac1-a554-eb15a9c778b4" xlink:href="nbx-20211231.xsd#nbx_AnnualShortTermLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_AnnualShortTermLeaseExpense_9c668d28-de4c-4ac1-a554-eb15a9c778b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualLeaseExpense_0c4f78ec-480d-4e89-bedf-ddb9f35b3e7c" xlink:href="nbx-20211231.xsd#nbx_AnnualLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_AnnualLeaseExpense_0c4f78ec-480d-4e89-bedf-ddb9f35b3e7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPatientsInClinicalTrial_58e728c3-7527-4bb4-9ff8-398e34039f5f" xlink:href="nbx-20211231.xsd#nbx_NumberOfPatientsInClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_NumberOfPatientsInClinicalTrial_58e728c3-7527-4bb4-9ff8-398e34039f5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_2218c3d4-bc78-458c-9327-57543132c940" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_2218c3d4-bc78-458c-9327-57543132c940" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_27b98b20-1c98-48a2-bb00-d92637bc9d7a" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsPayment_27b98b20-1c98-48a2-bb00-d92637bc9d7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_0a2d535d-35cb-4d9b-b090-b98cb012fdcf" xlink:href="nbx-20211231.xsd#nbx_MilestonePaymentDefermentPeriodAfterEnrollment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_0a2d535d-35cb-4d9b-b090-b98cb012fdcf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_e89ba4e8-c862-4ef2-a85b-12ef208b7016" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_e89ba4e8-c862-4ef2-a85b-12ef208b7016" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_d533fec5-f3be-4e61-8ba6-b7510a13912a" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_d533fec5-f3be-4e61-8ba6-b7510a13912a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_858cac22-2318-42c9-8c4b-bd5290a92eac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_858cac22-2318-42c9-8c4b-bd5290a92eac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_bb4d768c-15c1-47df-83d6-c10a3562dd7d" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_bb4d768c-15c1-47df-83d6-c10a3562dd7d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_0e693552-3101-41e4-87ba-49b921eef755" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_0e693552-3101-41e4-87ba-49b921eef755" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_c4de8449-2108-420d-8bdd-4db2b5a1f041" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_c4de8449-2108-420d-8bdd-4db2b5a1f041" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe8725c5-245c-4269-91c6-20c759ff1827_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:to="loc_srt_RangeMember_fe8725c5-245c-4269-91c6-20c759ff1827_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:to="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8558432a-1c66-4286-af40-9b5bc07ce980" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:to="loc_srt_MinimumMember_8558432a-1c66-4286-af40-9b5bc07ce980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_debfc9fc-d099-4248-8488-ce6caef3d9bb_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:to="loc_ifrs-full_BorrowingsByNameMember_debfc9fc-d099-4248-8488-ce6caef3d9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:to="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b864391d-d608-4be9-8c05-284bbae2f16b" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b864391d-d608-4be9-8c05-284bbae2f16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe_default" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:to="loc_nbx_CollaborationAgreementDomain_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:to="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a0449f08-93f1-4585-89a1-318a785742e1" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a0449f08-93f1-4585-89a1-318a785742e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_a14040aa-ce8b-49b7-99f4-4ea0edc0ed17" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_a14040aa-ce8b-49b7-99f4-4ea0edc0ed17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b8d3c19f-e534-4967-bbe7-7ffd2a467c44_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:to="loc_ifrs-full_RangesMember_b8d3c19f-e534-4967-bbe7-7ffd2a467c44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:to="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d99052b8-3e39-4714-8422-20f30d2ba650" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:to="loc_ifrs-full_BottomOfRangeMember_d99052b8-3e39-4714-8422-20f30d2ba650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_7fbb8b82-bc7d-4a99-9110-7ae4b1274e9f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:to="loc_ifrs-full_TopOfRangeMember_7fbb8b82-bc7d-4a99-9110-7ae4b1274e9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SubsequenteventsDetails"/>
  <link:definitionLink xlink:role="http://nanobiotix.com/role/SubsequenteventsDetails" xlink:type="extended" id="i7bc00eab6b3441829b1d9d7ae330bdab_SubsequenteventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_4b98150d-fc60-4611-912a-b9f56c4738d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_IssueOfEquity_4b98150d-fc60-4611-912a-b9f56c4738d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_20520e2f-b646-4a31-8f64-fd884f9ea924" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_20520e2f-b646-4a31-8f64-fd884f9ea924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_0a5e5c9f-6ed7-4058-9d5f-7c29a0f151ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_ParValuePerShare_0a5e5c9f-6ed7-4058-9d5f-7c29a0f151ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3d3b5fd6-80ee-465e-9b99-058b5c79bea7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_Equity_3d3b5fd6-80ee-465e-9b99-058b5c79bea7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_84505669-eaea-4307-bb51-fb88c4329a15_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:to="loc_ifrs-full_EquityMember_84505669-eaea-4307-bb51-fb88c4329a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:to="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_453464b0-bde3-4dcb-ae80-12e436a35811" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:to="loc_ifrs-full_IssuedCapitalMember_453464b0-bde3-4dcb-ae80-12e436a35811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_ca54aa66-38f2-4760-93d9-79e8e84ccd9d_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_ca54aa66-38f2-4760-93d9-79e8e84ccd9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_82c3a266-8ca4-4509-ba08-f380e1070d01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_82c3a266-8ca4-4509-ba08-f380e1070d01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e_default" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_812db0d6-a3d3-488d-92a3-b615475d98cc" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:to="loc_nbx_AGA2020Member_812db0d6-a3d3-488d-92a3-b615475d98cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>nbx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_5895039f-3051-4af8-8df6-df0356dd4d2d_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Performance</link:label>
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_label_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Performance [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2016PerformanceMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2016PerformanceMember" xlink:to="lab_nbx_BSPCE2016PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfEmployees_91547258-61d3-4eed-9198-11b08a00f8ee_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End-of-period headcount</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_90df720e-0c31-4220-90a6-ac9e5e575f6d_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_9ff95111-dc8d-4563-bf14-bfced056a84f_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of break down of other current assets</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Other Current Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Other Current Assets Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_672de524-d439-4fa5-a7b9-39cd23304403_verboseLabel_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGE</link:label>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_label_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGE Loan Agreement, BPI France And HSBC France [Member]</link:label>
    <link:label id="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_documentation_en-US" xlink:label="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGE Loan Agreement, BPI France And HSBC France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:href="nbx-20211231.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:to="lab_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_9e08956d-6ee3-4856-8c22-6dd4849e19c4_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory_c3ebd560-987f-4939-9118-2243ae62ca6c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of changes in provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b46ea0b9-c692-4674-8844-71c7eea22e5f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_eb0ed75d-9828-4552-b3c3-84236fb959cf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnnualLeaseExpense_2c5e82d6-f9c8-4f71-89e5-5c367cc10908_terseLabel_en-US" xlink:label="lab_nbx_AnnualLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual lease expense</link:label>
    <link:label id="lab_nbx_AnnualLeaseExpense_label_en-US" xlink:label="lab_nbx_AnnualLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Lease Expense</link:label>
    <link:label id="lab_nbx_AnnualLeaseExpense_documentation_en-US" xlink:label="lab_nbx_AnnualLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualLeaseExpense" xlink:href="nbx-20211231.xsd#nbx_AnnualLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnnualLeaseExpense" xlink:to="lab_nbx_AnnualLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_5a27a441-8e02-484f-9472-9903075efe82_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_6e55a143-20b3-4303-bfba-61ccf61859e0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_912fa5e0-2aed-452a-9e92-27cf64671eb1_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_1461edca-f188-48f2-b7f6-7e6c038df82c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_aadf7063-1747-4e31-aead-47851503e9e7_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_9c888495-6122-4329-895e-5ba3bca4abaf_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod_9c47d3dd-ef51-4dd8-bb85-4cccb3408b26_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones achievement, period</link:label>
    <link:label id="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod_label_en-US" xlink:label="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Milestones Achievement, Period</link:label>
    <link:label id="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Milestones Achievement, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementMilestonesAchievementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:to="lab_nbx_CollaborationAgreementMilestonesAchievementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_66c0f2da-1aa5-4f7a-9eda-6f57de705680_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease through derecognition, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="lab_ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IPOInitialDealEuroMember_261f660c-4452-49bd-a1de-5fa3dcd39758_terseLabel_en-US" xlink:label="lab_nbx_IPOInitialDealEuroMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO initial deal, Euro</link:label>
    <link:label id="lab_nbx_IPOInitialDealEuroMember_label_en-US" xlink:label="lab_nbx_IPOInitialDealEuroMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Initial Deal, Euro [Member]</link:label>
    <link:label id="lab_nbx_IPOInitialDealEuroMember_documentation_en-US" xlink:label="lab_nbx_IPOInitialDealEuroMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Initial Deal, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealEuroMember" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealEuroMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IPOInitialDealEuroMember" xlink:to="lab_nbx_IPOInitialDealEuroMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_dccb8f06-cc9d-4e25-a9ad-d907c6e3f441_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term investments pledged as collateral</link:label>
    <link:label id="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_label_en-US" xlink:label="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Investments Pledged As Collateral [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Investments Pledged As Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentInvestmentsPledgedAsCollateralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:to="lab_nbx_NonCurrentInvestmentsPledgedAsCollateralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_e01f4d20-8b5a-4c6f-89bc-880eaefb5be0_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average headcount</link:label>
    <link:label id="lab_ifrs-full_AverageNumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_AverageNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageNumberOfEmployees" xlink:to="lab_ifrs-full_AverageNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA0412Member_ea0ec7fe-1adf-44ad-8596-0d8a53ee10ea_terseLabel_en-US" xlink:label="lab_nbx_BSA0412Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 04-12</link:label>
    <link:label id="lab_nbx_BSA0412Member_label_en-US" xlink:label="lab_nbx_BSA0412Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 04-12 [Member]</link:label>
    <link:label id="lab_nbx_BSA0412Member_documentation_en-US" xlink:label="lab_nbx_BSA0412Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 04-12</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA0412Member" xlink:to="lab_nbx_BSA0412Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueMember_d5481bfa-816e-499d-b746-4a6767167d4f_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value, class</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_dc1258aa-c1c9-4331-adb5-2de211ef5cbf_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsAxis" xlink:to="lab_ifrs-full_TypesOfContractsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_edba1b3a-f28f-4bfb-a047-a86ea863a8e4_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ca56f4b8-efdf-4343-a37d-eedb21fb6525_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of tangible assets</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchTaxCreditUtilizationPeriod_3e63316d-b982-44c4-91f4-f3348e33b842_terseLabel_en-US" xlink:label="lab_nbx_ResearchTaxCreditUtilizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit utilization period</link:label>
    <link:label id="lab_nbx_ResearchTaxCreditUtilizationPeriod_label_en-US" xlink:label="lab_nbx_ResearchTaxCreditUtilizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Utilization Period</link:label>
    <link:label id="lab_nbx_ResearchTaxCreditUtilizationPeriod_documentation_en-US" xlink:label="lab_nbx_ResearchTaxCreditUtilizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Utilization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchTaxCreditUtilizationPeriod" xlink:href="nbx-20211231.xsd#nbx_ResearchTaxCreditUtilizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchTaxCreditUtilizationPeriod" xlink:to="lab_nbx_ResearchTaxCreditUtilizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_5d6b5618-1905-4773-b835-be52ca63aa11_terseLabel_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, exercised (in shares)</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_2fc79e40-d63d-4c20-b697-c052d8048b6e_verboseLabel_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercised (in shares)</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number Of Awards Exercised In Share-based Payment Arrangement</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number Of Awards Exercised In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:to="lab_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_465da6c6-858d-45e7-9893-77cbedd9a52a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetLossForThePeriodMember_b22bb705-fbf4-4709-9cec-76f4656e38bd_terseLabel_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_nbx_NetLossForThePeriodMember_label_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss For The Period [Member]</link:label>
    <link:label id="lab_nbx_NetLossForThePeriodMember_documentation_en-US" xlink:label="lab_nbx_NetLossForThePeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss For The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetLossForThePeriodMember" xlink:to="lab_nbx_NetLossForThePeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock_1b3bc053-a5f1-4333-9ca1-61a386ba3f31_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other operating income (expense)</link:label>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income (Expenses) [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Operating Income (Expenses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:to="lab_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_2993ed15-3d0a-4b82-926e-994beb5931ed_terseLabel_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current financial liabilities</link:label>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_nbx_CurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember" xlink:href="nbx-20211231.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentFinancialLiabilitiesMember" xlink:to="lab_nbx_CurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_033f0104-a572-4274-82d5-634a212519c9_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_c9f6fdef-f2e9-41bf-ab19-b929bee02840_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation principles and methods</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_922d6759-5bce-4c1b-b9be-10ec98671d97_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_969c1f9f-1b48-4aba-a530-16803f254030_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated variable interest expense accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare_291f60a3-fc23-44be-8f86-fb50fd5a7a62_terseLabel_en-US" xlink:label="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential additional ordinary shares that are considered antidilutive (in shares)</link:label>
    <link:label id="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare_label_en-US" xlink:label="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-Dilutive Securities Excluded From Calculation Of Earnings Per Share</link:label>
    <link:label id="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare_documentation_en-US" xlink:label="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-Dilutive Securities Excluded From Calculation Of Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:href="nbx-20211231.xsd#nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:to="lab_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_44a70da2-5e44-4b14-8605-66a34dd07ada_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating working capital</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_dc662e1a-325d-46a0-b6c0-06cef4efba39_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_cadb0d04-4267-4c82-8344-5b0afda8e498_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation periods of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_449b864f-50bf-45fd-8977-27bdb2afedb6_terseLabel_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets in progress</link:label>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_label_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConstructionInProgressMember" xlink:to="lab_ifrs-full_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_14eafbd5-db12-4413-8700-b5762b8f137d_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_fc52f9e2-db25-4911-9922-cd94d2d16430_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_48e687cd-00ea-4828-86f5-d0350167f569_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of notes and other explanatory information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a7239127-9d3c-4a99-8f67-1cee954c4332_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates changes on cash</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_5bd280d4-9f74-4440-891d-f0fbff983610_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_9351c826-a694-4f9f-aeb6-ee6d4748fed9_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_976eed33-f9c8-4642-a784-f99fc96a6dd4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about conditional advance, bank loan and loans from government and public authorities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_d1ace658-1b06-4b89-8452-441be6432110_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ebbe242f-e128-4552-bfa7-5654c15c5dee_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_a126d43d-9867-4ff4-a98c-76035c60a406_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other receivables</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_label_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Receivables</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:to="lab_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_621e8bee-2e68-4e75-9156-e153b805729c_terseLabel_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of judgement, estimates and assumptions</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_label_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions [Policy Text Block]</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_documentation_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:to="lab_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_nbx_SignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract" xlink:href="nbx-20211231.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract" xlink:to="lab_nbx_SignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_bc3becb2-fad8-4602-8dce-9933c1c16e39_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_2240e376-c3dd-4c4f-8794-4c8f7709729b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0ee1a592-24f8-4a21-a962-c83cf980ae8e_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementUpfrontPaymentReceived_67c01526-10b1-4271-8858-31699afd2f79_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementUpfrontPaymentReceived_label_en-US" xlink:label="lab_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment Received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:to="lab_nbx_CollaborationAgreementUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSALLY2019Member_0d2bb82e-e968-48be-b5de-3deb63f79539_terseLabel_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA LLY 2019</link:label>
    <link:label id="lab_nbx_OSALLY2019Member_label_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA LLY 2019 [Member]</link:label>
    <link:label id="lab_nbx_OSALLY2019Member_documentation_en-US" xlink:label="lab_nbx_OSALLY2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA LLY 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSALLY2019Member" xlink:to="lab_nbx_OSALLY2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SupervisoryBoardMember_0f2e8ffe-6ded-4e2f-a3af-995a429c602f_terseLabel_en-US" xlink:label="lab_nbx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supervisory Board</link:label>
    <link:label id="lab_nbx_SupervisoryBoardMember_label_en-US" xlink:label="lab_nbx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supervisory Board [Member]</link:label>
    <link:label id="lab_nbx_SupervisoryBoardMember_documentation_en-US" xlink:label="lab_nbx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supervisory Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupervisoryBoardMember" xlink:href="nbx-20211231.xsd#nbx_SupervisoryBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SupervisoryBoardMember" xlink:to="lab_nbx_SupervisoryBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_522cd196-9a2b-47a1-831a-25291b57a916_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements for share-based payment arrangement, acquisition period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_0a49d66f-c2de-45ef-b6b1-c9e4f04a42b9_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7dd5c946-9e63-451b-8f26-32bebfc76817_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_6d693ed5-e5e6-4cc2-8f59-86491711e4f5_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares oustanding</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of outstanding other equity Instruments [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConcentrationRiskPercentage_5930fc54-ac46-403e-8431-f63be3603ce3_terseLabel_en-US" xlink:label="lab_nbx_ConcentrationRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_nbx_ConcentrationRiskPercentage_label_en-US" xlink:label="lab_nbx_ConcentrationRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Percentage</link:label>
    <link:label id="lab_nbx_ConcentrationRiskPercentage_documentation_en-US" xlink:label="lab_nbx_ConcentrationRiskPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConcentrationRiskPercentage" xlink:href="nbx-20211231.xsd#nbx_ConcentrationRiskPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConcentrationRiskPercentage" xlink:to="lab_nbx_ConcentrationRiskPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_FromSecondYearOfGrantDateMember_1bc0cb2b-d3b4-43f2-8032-4b0a80169b87_terseLabel_en-US" xlink:label="lab_nbx_FromSecondYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From second year of grant date</link:label>
    <link:label id="lab_nbx_FromSecondYearOfGrantDateMember_label_en-US" xlink:label="lab_nbx_FromSecondYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From Second Year Of Grant Date [Member]</link:label>
    <link:label id="lab_nbx_FromSecondYearOfGrantDateMember_documentation_en-US" xlink:label="lab_nbx_FromSecondYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From Second Year Of Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromSecondYearOfGrantDateMember" xlink:href="nbx-20211231.xsd#nbx_FromSecondYearOfGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_FromSecondYearOfGrantDateMember" xlink:to="lab_nbx_FromSecondYearOfGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_78cf4feb-f2e4-43ef-8000-41b094d9a492_terseLabel_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curadigm Bpifrance advance</link:label>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_label_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advance, BPI France [Member]</link:label>
    <link:label id="lab_nbx_ConditionalAdvanceBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advance, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConditionalAdvanceBPIFranceMember" xlink:to="lab_nbx_ConditionalAdvanceBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_bdebd4b8-fc8a-4577-8fa4-41c1914fb7f2_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to change in demographic assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_45597320-0930-467f-8e30-a8c119aa484a_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20182Member_5085e5ac-c60c-4f0e-9097-8d2952494cd1_terseLabel_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-2</link:label>
    <link:label id="lab_nbx_BSA20182Member_label_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-2 [Member]</link:label>
    <link:label id="lab_nbx_BSA20182Member_documentation_en-US" xlink:label="lab_nbx_BSA20182Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20182Member" xlink:to="lab_nbx_BSA20182Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NetLossForThePeriod_638e994f-a6a6-4280-b5b1-bae0083923fa_terseLabel_en-US" xlink:label="lab_nbx_NetLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_nbx_NetLossForThePeriod_label_en-US" xlink:label="lab_nbx_NetLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss For The Period</link:label>
    <link:label id="lab_nbx_NetLossForThePeriod_documentation_en-US" xlink:label="lab_nbx_NetLossForThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss For The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriod" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NetLossForThePeriod" xlink:to="lab_nbx_NetLossForThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_67f70736-7534-4440-929b-5cef03635b0e_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_6534e6aa-5fc6-4902-8b00-477d323ae03f_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest expense</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_04677ea7-1277-4f23-a316-2851cfb4b826_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IFRS 16 related interests</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_46bd6017-9451-476c-b623-366cba84891d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractWattigniesMember_58c421b1-aa00-42b1-bb9d-7d745926ed47_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractWattigniesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, Wattignies</link:label>
    <link:label id="lab_nbx_LeaseContractWattigniesMember_label_en-US" xlink:label="lab_nbx_LeaseContractWattigniesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Wattignies [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractWattigniesMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractWattigniesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Wattignies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractWattigniesMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractWattigniesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractWattigniesMember" xlink:to="lab_nbx_LeaseContractWattigniesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA20182Member_8bd17e65-c8c3-4be4-b1b2-791cc61fd5eb_terseLabel_en-US" xlink:label="lab_nbx_AGA20182Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-2</link:label>
    <link:label id="lab_nbx_AGA20182Member_label_en-US" xlink:label="lab_nbx_AGA20182Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-2 [Member]</link:label>
    <link:label id="lab_nbx_AGA20182Member_documentation_en-US" xlink:label="lab_nbx_AGA20182Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA20182Member" xlink:to="lab_nbx_AGA20182Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_d80c79a3-c1dc-4c1e-a941-3822723c01fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSAMember_d339db06-ca71-4f5a-949d-8e5beed56197_terseLabel_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA</link:label>
    <link:label id="lab_nbx_BSAMember_label_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA [Member]</link:label>
    <link:label id="lab_nbx_BSAMember_documentation_en-US" xlink:label="lab_nbx_BSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSAMember" xlink:to="lab_nbx_BSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_a1540be4-dec0-4a22-8f0c-ffebf713c1a7_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_8c85888c-837e-46aa-ab90-09368dbb714f_terseLabel_en-US" xlink:label="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses related to insurance for Directors and Officers</link:label>
    <link:label id="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_label_en-US" xlink:label="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Prepaid Expenses, Insurance Related To Directors And Officers</link:label>
    <link:label id="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_documentation_en-US" xlink:label="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Prepaid Expenses, Insurance Related To Directors And Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:href="nbx-20211231.xsd#nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:to="lab_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_096cfbaf-fd99-4b2e-b11c-daae22953a25_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase / (Decrease) in trade and other payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_ca240811-0ff1-474c-b8e2-a38f30c4cbd1_terseLabel_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items by function [member]</link:label>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_label_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items by function [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c7f919a5-2ff2-40cb-9f1e-2e9a87d104c5_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2016Member_a0381155-3132-4d81-b70f-bdcd0080a2e5_terseLabel_en-US" xlink:label="lab_nbx_BSA2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016</link:label>
    <link:label id="lab_nbx_BSA2016Member_label_en-US" xlink:label="lab_nbx_BSA2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 [Member]</link:label>
    <link:label id="lab_nbx_BSA2016Member_documentation_en-US" xlink:label="lab_nbx_BSA2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016Member" xlink:href="nbx-20211231.xsd#nbx_BSA2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2016Member" xlink:to="lab_nbx_BSA2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheFourMember_0ff4f1c6-29b0-45fa-a37b-b5ebf0550cb3_terseLabel_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche four</link:label>
    <link:label id="lab_nbx_TrancheFourMember_label_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four [Member]</link:label>
    <link:label id="lab_nbx_TrancheFourMember_documentation_en-US" xlink:label="lab_nbx_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheFourMember" xlink:to="lab_nbx_TrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractVillejuifMember_86c4d4ac-1c9a-4f04-a1c1-5bc797aa0d8a_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, Villejuif</link:label>
    <link:label id="lab_nbx_LeaseContractVillejuifMember_label_en-US" xlink:label="lab_nbx_LeaseContractVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Villejuif [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractVillejuifMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Villejuif</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractVillejuifMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractVillejuifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractVillejuifMember" xlink:to="lab_nbx_LeaseContractVillejuifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_43a9b2f1-363f-4bcc-8a56-66a68bd0a230_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_f76b15dc-36e6-4ca9-9a64-547933528df4_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFinancialAssets_9b1d5a1b-1e82-4292-85b1-55b3ce674a84_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in financial assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseInFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentProvisions_6a58e9e5-00d5-431d-9446-844528739a86_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income, expense, gains or losses of financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_34cd8475-2115-432e-b75c-50c3e9d04375_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in loans and conditional advances</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_e2d4787f-5135-4b9b-8bb0-82308c220b35_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_c46ada45-8c6b-4a47-a992-58bfd3083a3a_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercial milestones payments</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_label_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Potential Milestones Payments To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:to="lab_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_ab4c4da6-e7fe-432f-96d6-bc6dc286b739_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation to related parties</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_9dbba11c-399b-4aeb-9b94-6b492f672a4c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wages and salaries</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_573ea801-ffa6-4c23-9f00-976f4fc09d2c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payroll costs</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2020Member_3d17512a-fc63-4bd9-8670-8f76dee84fd0_terseLabel_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2020</link:label>
    <link:label id="lab_nbx_BSA2020Member_label_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2020 [Member]</link:label>
    <link:label id="lab_nbx_BSA2020Member_documentation_en-US" xlink:label="lab_nbx_BSA2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2020Member" xlink:to="lab_nbx_BSA2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_fb8e05a0-8cc1-4db4-9133-e4aab4fc115a_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_label_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Financial Liabilities [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentFinancialLiabilitiesMember" xlink:to="lab_nbx_NonCurrentFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_6dfa04dc-097e-4295-83f5-85849fc90bd4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingDomain_b7cc9959-d6f9-4934-8648-68e19d353685_terseLabel_en-US" xlink:label="lab_nbx_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_nbx_VestingDomain_label_en-US" xlink:label="lab_nbx_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_nbx_VestingDomain_documentation_en-US" xlink:label="lab_nbx_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingDomain" xlink:to="lab_nbx_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_4aa38888-ec37-407b-aa11-d09a484c7e36_terseLabel_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax and other payroll liabilities</link:label>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_9f10e189-5602-4ad5-8ebf-e88e3d40b62e_terseLabel_en-US" xlink:label="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_label_en-US" xlink:label="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant, Laurent Levy And Bart Van Rhijn [Member]</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_documentation_en-US" xlink:label="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant, Laurent Levy And Bart Van Rhijn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:to="lab_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock_8a5bd0e2-a7a8-47ae-958b-c11cb54bdee4_terseLabel_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock_label_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Events After Reporting Period [Policy Text Block]</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock_documentation_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Events After Reporting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:to="lab_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2a620824-2170-4c1a-853a-6868c99bfd3c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20181Member_a6865917-e940-40f4-9d85-02cd96fe88b0_terseLabel_en-US" xlink:label="lab_nbx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-1</link:label>
    <link:label id="lab_nbx_BSA20181Member_label_en-US" xlink:label="lab_nbx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-1 [Member]</link:label>
    <link:label id="lab_nbx_BSA20181Member_documentation_en-US" xlink:label="lab_nbx_BSA20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2018-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20181Member" xlink:to="lab_nbx_BSA20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_46288e9b-205a-4071-9678-aa3622656c3f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_1fe91ee1-d383-4e89-98ef-5a2f0211def0_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total SG&amp;A expenses</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_adb24a32-f3d8-4147-b4da-349ae611f0a8_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increase, net</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_5613d112-dd09-4b28-9f90-04a14de7e1a5_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increase</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_46dbd24d-31df-434a-aefa-2bb40fd5c243_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProceedsFromWarrantsSubscription_fbf37a79-9ad1-4028-a5e7-4fd46c1bc315_terseLabel_en-US" xlink:label="lab_nbx_ProceedsFromWarrantsSubscription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants subscription</link:label>
    <link:label id="lab_nbx_ProceedsFromWarrantsSubscription_label_en-US" xlink:label="lab_nbx_ProceedsFromWarrantsSubscription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrants Subscription</link:label>
    <link:label id="lab_nbx_ProceedsFromWarrantsSubscription_documentation_en-US" xlink:label="lab_nbx_ProceedsFromWarrantsSubscription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Warrants Subscription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromWarrantsSubscription" xlink:href="nbx-20211231.xsd#nbx_ProceedsFromWarrantsSubscription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProceedsFromWarrantsSubscription" xlink:to="lab_nbx_ProceedsFromWarrantsSubscription" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_d09f6ac9-045a-498d-b91e-e1aab9dd1af5_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2020Member_4d83c1ac-dd66-4145-8737-512b7b9cb8e2_terseLabel_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2020</link:label>
    <link:label id="lab_nbx_OSA2020Member_label_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2020 [Member]</link:label>
    <link:label id="lab_nbx_OSA2020Member_documentation_en-US" xlink:label="lab_nbx_OSA2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2020Member" xlink:to="lab_nbx_OSA2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IPOInitialDealUSDollarMember_9595f3d5-73b4-4ada-b637-14867b310c34_terseLabel_en-US" xlink:label="lab_nbx_IPOInitialDealUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO initial deal, US Dollar</link:label>
    <link:label id="lab_nbx_IPOInitialDealUSDollarMember_label_en-US" xlink:label="lab_nbx_IPOInitialDealUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Initial Deal, US Dollar [Member]</link:label>
    <link:label id="lab_nbx_IPOInitialDealUSDollarMember_documentation_en-US" xlink:label="lab_nbx_IPOInitialDealUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Initial Deal, US Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealUSDollarMember" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IPOInitialDealUSDollarMember" xlink:to="lab_nbx_IPOInitialDealUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_f60c1d93-c522-47ed-9a5c-f2a26b32ca62_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_26fadc93-9fca-41b1-bf93-554ba00da24a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_8ec9f1ac-2473-4879-afec-a23555e7aa1d_terseLabel_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated forecasted sales, period</link:label>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_label_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Forecasted Sales, Period</link:label>
    <link:label id="lab_nbx_ConsolidatedForecastedSalesPeriod_documentation_en-US" xlink:label="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Forecasted Sales, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod" xlink:href="nbx-20211231.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConsolidatedForecastedSalesPeriod" xlink:to="lab_nbx_ConsolidatedForecastedSalesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_cb533233-9540-47c1-adf9-22ec81d7d082_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_25e9a19f-57dd-4e80-8278-fd71c9348385_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_6113ae8c-62bc-4a47-af33-8c67152bf6d0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_9a7d0ec4-8292-4586-a5df-cd80b599d3b6_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_648691a1-cbb6-4aee-bad8-100f96b1d8fa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_20af3f3f-5b26-44ee-a990-50881270a6c6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_bdb6fae0-e2f3-470d-8998-c7fdac2cab61_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_0936c25f-91c7-41db-ac21-d93edc784b17_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due between 3 and 6 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:to="lab_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsMember_c50f2390-1d50-4f63-85ab-90f44d53bdf3_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of contracts [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsMember" xlink:to="lab_ifrs-full_TypesOfContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheTwoMember_1826049d-46ad-4f51-a3a5-6699083eee4d_terseLabel_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche two</link:label>
    <link:label id="lab_nbx_TrancheTwoMember_label_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_nbx_TrancheTwoMember_documentation_en-US" xlink:label="lab_nbx_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheTwoMember" xlink:to="lab_nbx_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_de213c86-6cfd-4313-ab3b-59cd43ea61ca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_f4a738ff-4037-47f3-82b6-e45ac32c7e75_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Financial Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_172f37a8-72d9-45d9-8824-541979b967f1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_7f21422a-523a-41fa-aa20-815b25b75bf6_terseLabel_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment upon receipt of clinical study reports</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_label_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_documentation_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:to="lab_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_a62bf65b-13fa-45ed-969e-215b122183d3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_b7f80e33-78d5-44cf-aceb-2b9fd351242d_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisions_756657d7-1b20-4034-96c9-a49f6d48b942_periodStartLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions at beginning of period</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_95777377-03a7-4844-88b3-bcff98ddd906_periodEndLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions at end of period</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="lab_ifrs-full_OtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingAxis_6f321190-97fe-48b9-bd63-cda723c173d3_terseLabel_en-US" xlink:label="lab_nbx_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_nbx_VestingAxis_label_en-US" xlink:label="lab_nbx_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_nbx_VestingAxis_documentation_en-US" xlink:label="lab_nbx_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingAxis" xlink:to="lab_nbx_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_5325cf67-cd38-4f8e-a074-e236fd2e9911_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_5164740e-e282-40c2-a6dd-d6a2032b6079_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPayable_a3b02a9b-6d09-4b72-8956-80761ee2fe4f_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_ifrs-full_InterestPayable_label_en-US" xlink:label="lab_ifrs-full_InterestPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPayable" xlink:to="lab_ifrs-full_InterestPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationExpense_aa695e2b-1930-480e-b3cc-46fdbddac513_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of tangible assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationExpense_label_en-US" xlink:label="lab_ifrs-full_DepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationExpense" xlink:to="lab_ifrs-full_DepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_afc5263a-4646-4047-9e9a-6def238a1372_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConcentrationsOfRiskMember_d922271a-9d4c-426a-8f5d-69ff180f6f30_terseLabel_en-US" xlink:label="lab_ifrs-full_ConcentrationsOfRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of risk [member]</link:label>
    <link:label id="lab_ifrs-full_ConcentrationsOfRiskMember_label_en-US" xlink:label="lab_ifrs-full_ConcentrationsOfRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConcentrationsOfRiskMember" xlink:to="lab_ifrs-full_ConcentrationsOfRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_0f4c8c63-720a-4442-8279-e2913bcc137d_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_43cbc7e3-1d62-4df4-8a28-ab6131b02f10_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_739afafa-b76a-41cc-beb8-15116166d0a4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_65ebfd1e-a795-4692-89c7-9402e2d92470_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of basic and diluted loss per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_a132660f-e086-4a8e-8ed1-49e54c303de0_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_label_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Financial Assets [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentFinancialAssetsMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentFinancialAssetsMember" xlink:to="lab_nbx_NonCurrentFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_ed6182fb-7436-4060-bbd2-ae3c5b069eea_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_406c022f-d928-4903-8fee-1d87f0d4d562_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheThreeMember_32a8d854-cd5d-4449-a2bb-428b7a7afb49_terseLabel_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche three</link:label>
    <link:label id="lab_nbx_TrancheThreeMember_label_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label id="lab_nbx_TrancheThreeMember_documentation_en-US" xlink:label="lab_nbx_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheThreeMember" xlink:to="lab_nbx_TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_a67e0555-6693-42c7-bec0-e6fb57ba6587_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE exercise</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_afd02bd8-eed2-48bd-b63a-3e1d2865f671_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_d2bef5bf-79be-4b4a-b54a-bf5ac2c64bd8_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of deferred income and contract liabilities</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Deferred Income And Contract Liabilities [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Deferred Income And Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_7662de7f-fa06-4673-a19e-39b6365c1415_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and other income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_a3be10cd-4ac3-42f7-b288-8add02cca054_terseLabel_en-US" xlink:label="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</link:label>
    <link:label id="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_label_en-US" xlink:label="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_documentation_en-US" xlink:label="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:to="lab_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_136aade3-bb46-4746-96a7-c59284ba86b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_0916bf22-70b0-4d02-9f8d-265d2e914fda_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_f5965045-1769-4b09-b53b-6b5d34dd9942_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_aa6e7ed3-1b35-496b-9edd-96a86a57753f_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee benefits expense</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2017Member_2bd0e759-a565-42d8-a577-273934364058_terseLabel_en-US" xlink:label="lab_nbx_OSA2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017</link:label>
    <link:label id="lab_nbx_OSA2017Member_label_en-US" xlink:label="lab_nbx_OSA2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 [Member]</link:label>
    <link:label id="lab_nbx_OSA2017Member_documentation_en-US" xlink:label="lab_nbx_OSA2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017Member" xlink:href="nbx-20211231.xsd#nbx_OSA2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2017Member" xlink:to="lab_nbx_OSA2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_47fed71f-da47-4b3d-8de6-5d89c824be47_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_fda65b11-049f-43a4-9bdf-df4d960761ec_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of accretion and discounting</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_09f17a72-2d24-4078-a048-c426a2618482_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of discounting and accretion</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_ff01f120-7179-484a-96bb-e4d8c9ee0d05_verboseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of discounting of the new lease contracts</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_32daf4c1-dbb8-4ccd-80ae-45608692dcc9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_ad7ca0ac-d540-4741-ad1a-49ca8d6e598e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_5022ba96-4898-458c-b346-d449b51a4daa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other operating expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RevenueByTypeMember_2e26766d-d740-4ead-87a7-8d9d1ef81330_terseLabel_en-US" xlink:label="lab_nbx_RevenueByTypeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by type</link:label>
    <link:label id="lab_nbx_RevenueByTypeMember_label_en-US" xlink:label="lab_nbx_RevenueByTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue By Type [Member]</link:label>
    <link:label id="lab_nbx_RevenueByTypeMember_documentation_en-US" xlink:label="lab_nbx_RevenueByTypeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue By Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RevenueByTypeMember" xlink:href="nbx-20211231.xsd#nbx_RevenueByTypeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RevenueByTypeMember" xlink:to="lab_nbx_RevenueByTypeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_40c2f0df-cf11-4098-a8d0-0f95e71bd69d_terseLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense for the period</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-employment benefit expense in profit or loss, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_96a3e73e-5517-455c-b7fd-17ff44bbfb2b_terseLabel_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of State-Guaranteed loan</link:label>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_label_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:label id="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan_documentation_en-US" xlink:label="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:href="nbx-20211231.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:to="lab_nbx_BorrowingPercentageOfStateGuaranteedLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_09c12f33-b104-41ee-98c9-95fc1bc01af1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_020681c2-c526-4daa-94d9-4882839f6147_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f2940c05-4f6f-4e09-826e-7c6a7e04d439_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_d5ce1dbd-74e2-453f-84e1-5daf68966053_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_33b68036-cc4d-4f47-a1b4-975e402e8cea_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [member]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4dd7f64d-83cd-44ba-9668-1845feeecd5b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_4c664b8e-08ec-4020-86a2-aec3c9841feb_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_9ee3b8cc-68db-4723-a081-0195f08a00b7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_6706f478-ec63-455b-bb89-97285c0283fc_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_InitialPublicOfferingMember_b1aec105-6615-417a-81f2-2afd3dcd5458_terseLabel_en-US" xlink:label="lab_nbx_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_nbx_InitialPublicOfferingMember_label_en-US" xlink:label="lab_nbx_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Member]</link:label>
    <link:label id="lab_nbx_InitialPublicOfferingMember_documentation_en-US" xlink:label="lab_nbx_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InitialPublicOfferingMember" xlink:href="nbx-20211231.xsd#nbx_InitialPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_InitialPublicOfferingMember" xlink:to="lab_nbx_InitialPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfTranchesReceivedBorrowings_dee5966f-c424-4021-b6ef-6a2c5810a208_terseLabel_en-US" xlink:label="lab_nbx_NumberOfTranchesReceivedBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches received</link:label>
    <link:label id="lab_nbx_NumberOfTranchesReceivedBorrowings_label_en-US" xlink:label="lab_nbx_NumberOfTranchesReceivedBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches Received, Borrowings</link:label>
    <link:label id="lab_nbx_NumberOfTranchesReceivedBorrowings_documentation_en-US" xlink:label="lab_nbx_NumberOfTranchesReceivedBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches Received, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesReceivedBorrowings" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesReceivedBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfTranchesReceivedBorrowings" xlink:to="lab_nbx_NumberOfTranchesReceivedBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity_0c6348d4-be00-4273-9dfd-8d2fe9d70b33_terseLabel_en-US" xlink:label="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increase, net (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity_label_en-US" xlink:label="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued Through Issue Of Equity</link:label>
    <link:label id="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity_documentation_en-US" xlink:label="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued Through Issue Of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:to="lab_nbx_NumberOfSharesIssuedThroughIssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20122Member_e36e7c72-3df3-43a7-b1b2-f670f1cdd089_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20122Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-2</link:label>
    <link:label id="lab_nbx_BSPCE20122Member_label_en-US" xlink:label="lab_nbx_BSPCE20122Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-2 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20122Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20122Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20122Member" xlink:to="lab_nbx_BSPCE20122Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_e482746c-d9b6-4fcf-b0e6-84d624904702_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonExecutiveMember_6806bfc2-2096-4631-9721-1441434c8e07_terseLabel_en-US" xlink:label="lab_nbx_NonExecutiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive</link:label>
    <link:label id="lab_nbx_NonExecutiveMember_label_en-US" xlink:label="lab_nbx_NonExecutiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive [Member]</link:label>
    <link:label id="lab_nbx_NonExecutiveMember_documentation_en-US" xlink:label="lab_nbx_NonExecutiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-executive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonExecutiveMember" xlink:href="nbx-20211231.xsd#nbx_NonExecutiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonExecutiveMember" xlink:to="lab_nbx_NonExecutiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_c1e5f58c-a01d-4f19-a166-05cddff00cb3_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_8957ff66-93a1-4d67-ae21-57ca22d02b2f_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements for share-based payment arrangement, vesting percentage</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a3ad580b-4058-4e0a-abc2-eeeea3cad853_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_15610582-ff4b-4d38-bca5-75cdb485eddf_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-current Financial Assets [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non-current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:to="lab_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_66604e27-0357-4765-9a75-35288feed46e_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_3a33ca6f-a37e-460b-988b-3f95c1d3ed03_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements for share-based payment arrangement, holding period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Holding Period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Holding Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_221980ec-16ca-45e1-9d49-82da5064f2d5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_43e658c4-0954-4f78-8c8c-3550511e5e59_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through foreign exchange, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_f4a6cff4-a09d-4ae0-8b3d-9ea976083c4d_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_12a2c91b-2677-41ad-aa02-2e3e9e67869e_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost, class</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_97855adb-0b76-4299-9027-7e3ca16f13d7_terseLabel_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3</link:label>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_label_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_MDAndersonCancerCenterNBTXR3Member_documentation_en-US" xlink:label="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MD Anderson Cancer Center, NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:to="lab_nbx_MDAndersonCancerCenterNBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_af1cdf7d-6afc-49e5-8314-5d13d7f8c8f5_terseLabel_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-sum retirement benefits</link:label>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_label_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-Sum Retirement Benefits [Member]</link:label>
    <link:label id="lab_nbx_LumpSumRetirementBenefitsMember_documentation_en-US" xlink:label="lab_nbx_LumpSumRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lump-Sum Retirement Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember" xlink:href="nbx-20211231.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LumpSumRetirementBenefitsMember" xlink:to="lab_nbx_LumpSumRetirementBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems_45c185ed-b457-4a6e-ada5-b699c68ebfaf_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:to="lab_nbx_DisclosureOfCashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PharmaEngineNBTWR3Member_cdfb1159-8c52-46d8-8acf-c4204f3f9afe_terseLabel_en-US" xlink:label="lab_nbx_PharmaEngineNBTWR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PharmaEngine, NBTWR3</link:label>
    <link:label id="lab_nbx_PharmaEngineNBTWR3Member_label_en-US" xlink:label="lab_nbx_PharmaEngineNBTWR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PharmaEngine, NBTWR3 [Member]</link:label>
    <link:label id="lab_nbx_PharmaEngineNBTWR3Member_documentation_en-US" xlink:label="lab_nbx_PharmaEngineNBTWR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PharmaEngine, NBTWR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PharmaEngineNBTWR3Member" xlink:href="nbx-20211231.xsd#nbx_PharmaEngineNBTWR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PharmaEngineNBTWR3Member" xlink:to="lab_nbx_PharmaEngineNBTWR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_f681ba01-c6cc-40d3-9288-3f91bdeeed07_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_2a4b7fe2-6f45-492d-ab2f-8bdc1d6e1f99_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit receivable at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_25a7174e-19af-4fb6-95e7-b87267815a3f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit receivable at end of period</link:label>
    <link:label id="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_e6f0e94f-d768-4f86-988c-9a0f085c00ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ec8ff3fa-e202-4e08-a106-48b44c624b2d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_1af226d5-0db5-40b8-b00d-d3be20e72d1f_terseLabel_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee</link:label>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_label_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee</link:label>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_documentation_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:to="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20191Member_c0d933e6-a6f8-47d7-9e7f-b578e6e67620_terseLabel_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2019-1</link:label>
    <link:label id="lab_nbx_BSA20191Member_label_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2019-1 [Member]</link:label>
    <link:label id="lab_nbx_BSA20191Member_documentation_en-US" xlink:label="lab_nbx_BSA20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2019-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20191Member" xlink:to="lab_nbx_BSA20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_cb0f7b15-ddd1-477e-9494-3e5e210f2f1e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables and other current liabilities</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade Payables And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade Payables And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_39f8aa22-90fb-4328-8db8-989a6f3746a1_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractParkingVillejuifMember_2d57a7a4-d92d-46a5-b77e-10a3d6151d25_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractParkingVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, parking Villejuif</link:label>
    <link:label id="lab_nbx_LeaseContractParkingVillejuifMember_label_en-US" xlink:label="lab_nbx_LeaseContractParkingVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Parking Villejuif [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractParkingVillejuifMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractParkingVillejuifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Parking Villejuif</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractParkingVillejuifMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractParkingVillejuifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractParkingVillejuifMember" xlink:to="lab_nbx_LeaseContractParkingVillejuifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4b22a774-b988-4410-bf8d-06a55b35176d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of other non-cash, non-operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_1acc4450-fd2f-4376-9a8b-54eb1e92d2dd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementAxis_bbe8d47e-cf51-4583-a6ba-fb851c32b9ea_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementAxis_label_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementAxis_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementAxis" xlink:to="lab_nbx_CollaborationAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementPlans_b67f4f3a-16dd-440b-ae60-cea97fe0b147_terseLabel_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share-based payment arrangement plans</link:label>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementPlans_label_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share-Based Payment Arrangement Plans</link:label>
    <link:label id="lab_nbx_NumberOfShareBasedPaymentArrangementPlans_documentation_en-US" xlink:label="lab_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share-Based Payment Arrangement Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:href="nbx-20211231.xsd#nbx_NumberOfShareBasedPaymentArrangementPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:to="lab_nbx_NumberOfShareBasedPaymentArrangementPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_5d4d9cbf-8cb1-4376-a1a2-e5942cd0dcb1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_9753840c-3df6-446b-aa1c-3e8f1e794429_terseLabel_en-US" xlink:label="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum threshold to provide additional know-how to third party under collaboration agreement</link:label>
    <link:label id="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_label_en-US" xlink:label="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement</link:label>
    <link:label id="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:href="nbx-20211231.xsd#nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:to="lab_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCEMember_6ab99d32-ef92-49ca-8344-3d26b01883de_terseLabel_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE</link:label>
    <link:label id="lab_nbx_BSPCEMember_label_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE [Member]</link:label>
    <link:label id="lab_nbx_BSPCEMember_documentation_en-US" xlink:label="lab_nbx_BSPCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCEMember" xlink:to="lab_nbx_BSPCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af992d8b-7d76-4951-bc17-c67ff035b9ed_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_fcadca11-dcf7-4799-a472-3a9e88f4463d_terseLabel_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of options granted for share-based payment arrangement</link:label>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:to="lab_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_0e63adb6-d3c5-41b3-aff8-dc4f8cf4a2c5_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSBC "PGE" and Bpifrance "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France And BPI France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France And BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesOutstandingAmountToBeReceived_00157eb3-fa4b-45c5-8467-b015fe72dce3_terseLabel_en-US" xlink:label="lab_nbx_AdvancesOutstandingAmountToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, outstanding amount</link:label>
    <link:label id="lab_nbx_AdvancesOutstandingAmountToBeReceived_label_en-US" xlink:label="lab_nbx_AdvancesOutstandingAmountToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, Outstanding Amount To Be Received</link:label>
    <link:label id="lab_nbx_AdvancesOutstandingAmountToBeReceived_documentation_en-US" xlink:label="lab_nbx_AdvancesOutstandingAmountToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, Outstanding Amount To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesOutstandingAmountToBeReceived" xlink:href="nbx-20211231.xsd#nbx_AdvancesOutstandingAmountToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesOutstandingAmountToBeReceived" xlink:to="lab_nbx_AdvancesOutstandingAmountToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_7575d94d-9e3b-42ef-9db3-b241a90c9994_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_8b8d643a-d0d1-4c01-98df-f010cdff5e67_terseLabel_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate</link:label>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_8dfad249-83ec-4d5d-89b9-bc95629e62c8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202106PerformanceMember_b4e108ed-1574-4db7-8721-43a6ba0d6ecb_terseLabel_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 P</link:label>
    <link:label id="lab_nbx_OSA202106PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA202106PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA202106PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_OSA202106PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202106PerformanceMember" xlink:to="lab_nbx_OSA202106PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_f1a3cc98-7f21-41bc-ab09-709dda3e189c_terseLabel_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security contribution rate</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_label_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Social Security Contribution Rates</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_documentation_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Social Security Contribution Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfSocialSecurityContributionRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:to="lab_nbx_ActuarialAssumptionOfSocialSecurityContributionRates" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_80b41e51-1d5a-496c-933f-9b11e13b11db_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3a63f162-83d8-4571-a04e-23cfe81b35e3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_60bf803c-71bf-4f09-a980-5a3d55a6cb63_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_3f321c99-9e3c-490e-9960-a4ae737cf52c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_ff1fbb02-96a6-493d-9576-35641487001e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of share options outstanding</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_42e2adf7-e925-4b0c-a8e5-51bc357f7bfe_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20162Member_0bb62932-7955-4c56-9ae4-5320a8ed5910_terseLabel_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-2</link:label>
    <link:label id="lab_nbx_OSA20162Member_label_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-2 [Member]</link:label>
    <link:label id="lab_nbx_OSA20162Member_documentation_en-US" xlink:label="lab_nbx_OSA20162Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20162Member" xlink:to="lab_nbx_OSA20162Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_8b166fe4-c055-47b5-afe7-8b5977abae0d_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_1e1a9743-1778-4217-bcf3-b7479117e730_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_b4c0d8eb-ef5e-434c-9067-80c789a36e43_terseLabel_en-US" xlink:label="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, initial period bearing no interest</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_label_en-US" xlink:label="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term, Initial Period Bearing No Interest</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_documentation_en-US" xlink:label="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term, Initial Period Bearing No Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:to="lab_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_fc0a50b1-8eab-40a5-bd56-2f86cd0c34e1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in deferred income and contract liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_45c33ac0-d904-455c-bff2-3ea2d9f56661_terseLabel_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues and other income</link:label>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosur Of Disaggregation Of Revenues And Other Income [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosur Of Disaggregation Of Revenues And Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:to="lab_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_af4a6274-5bf0-458a-a94c-57bd1ea6b57d_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity contract - Cash account</link:label>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_label_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Liquidity Contract [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentLiquidityContractMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentLiquidityContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Liquidity Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentLiquidityContractMember" xlink:to="lab_nbx_NonCurrentLiquidityContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_f7fba2bc-76b1-4ea4-851f-d473a27e0d3c_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, wages and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_d65ba3ca-6138-460c-8d22-4f1d5163bf66_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums related to share capital</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_eef990db-b613-4934-88f3-d57e674ea991_terseLabel_en-US" xlink:label="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of other equity instruments granted for share-based payment arrangement</link:label>
    <link:label id="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Other Equity Instruments Granted For Share-Based Payment Arrangement</link:label>
    <link:label id="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Other Equity Instruments Granted For Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:to="lab_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_0fc6d812-933b-4e07-9fb6-ee12ae0f67cb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_417bb776-9481-40ab-84e9-99d604a56ec0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options as of including options exercised during the period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CuradigmSASMember_9f18f215-777e-4fb8-8283-e779f0ffb62d_terseLabel_en-US" xlink:label="lab_nbx_CuradigmSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curadigm SAS</link:label>
    <link:label id="lab_nbx_CuradigmSASMember_label_en-US" xlink:label="lab_nbx_CuradigmSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curadigm SAS [Member]</link:label>
    <link:label id="lab_nbx_CuradigmSASMember_documentation_en-US" xlink:label="lab_nbx_CuradigmSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curadigm SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CuradigmSASMember" xlink:href="nbx-20211231.xsd#nbx_CuradigmSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CuradigmSASMember" xlink:to="lab_nbx_CuradigmSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_70a5e030-ba88-4a02-ba19-838df26a5496_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring loss before tax</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b84de72b-054f-452b-b51f-092548175633_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_e636f636-389c-42f3-9a1b-6faa988d46d5_terseLabel_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures, fittings and installations</link:label>
    <link:label id="lab_ifrs-full_FixturesAndFittingsMember_label_en-US" xlink:label="lab_ifrs-full_FixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixtures and fittings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixturesAndFittingsMember" xlink:to="lab_ifrs-full_FixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_5e06a508-cd2a-4708-b8d0-59dccdb84fe1_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_f9f6e41a-2bf6-40d7-92b5-1f7c153454d8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingDefermentPeriodToRequestFunds_cbaacd39-1973-4ee1-933c-cb86870a115d_terseLabel_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, deferment period to request funds</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriodToRequestFunds_label_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Deferment Period To Request Funds</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriodToRequestFunds_documentation_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Deferment Period To Request Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriodToRequestFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:to="lab_nbx_BorrowingDefermentPeriodToRequestFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_8ae50d57-cdca-4e67-a437-21e52d6342d4_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfTranchesBorrowings_2a436811-fb9d-4b0c-b507-01d763eba870_terseLabel_en-US" xlink:label="lab_nbx_NumberOfTranchesBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_nbx_NumberOfTranchesBorrowings_label_en-US" xlink:label="lab_nbx_NumberOfTranchesBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches, Borrowings</link:label>
    <link:label id="lab_nbx_NumberOfTranchesBorrowings_documentation_en-US" xlink:label="lab_nbx_NumberOfTranchesBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Tranches, Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesBorrowings" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfTranchesBorrowings" xlink:to="lab_nbx_NumberOfTranchesBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2021AMember_1e92a2b6-8198-49e0-b2d0-a4892bc6acca_terseLabel_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a)</link:label>
    <link:label id="lab_nbx_BSA2021AMember_label_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a) [Member]</link:label>
    <link:label id="lab_nbx_BSA2021AMember_documentation_en-US" xlink:label="lab_nbx_BSA2021AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2021AMember" xlink:to="lab_nbx_BSA2021AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_5dfd1254-261f-4c77-9aab-e8f6f6dcfcfd_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones payments received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_label_en-US" xlink:label="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Development And Commercial Milestones Payments Received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Development And Commercial Milestones Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:to="lab_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_24c4344d-d388-463d-964c-444dc1803ef6_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_5ae7e4bb-f710-467b-a69b-bbf3bdf20bff_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_970be8ad-1e48-46e9-95ac-f6ad599cfdc7_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_bbc93d7e-72d5-45e7-b59a-ae5c39aadcd4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6d409420-db72-4cbe-894c-b655cbcbac79_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock_3e7ebd40-f5b8-4254-b461-7102e509edbf_terseLabel_en-US" xlink:label="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation between statutory and effective income tax</link:label>
    <link:label id="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock_label_en-US" xlink:label="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax [Table Text Block]</link:label>
    <link:label id="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock_documentation_en-US" xlink:label="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:to="lab_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_4ddf6d83-1ce2-463d-badc-76519590dcda_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_ff328e7b-2eee-4a14-aa59-f71e1d215f00_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE exercise (in shares)</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Number Of Ordinary Shares Issued Through Exercise Of Founders Warrants</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Number Of Ordinary Shares Issued Through Exercise Of Founders Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:to="lab_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_6f451552-7acc-442b-b7df-05ce94b7cb02_terseLabel_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_label_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables [Member]</link:label>
    <link:label id="lab_nbx_TradeAndOtherPayablesMember_documentation_en-US" xlink:label="lab_nbx_TradeAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember" xlink:href="nbx-20211231.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TradeAndOtherPayablesMember" xlink:to="lab_nbx_TradeAndOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_f4a77ffe-775a-42fc-9720-c3705c343676_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_a7f67d1c-5d07-4e1a-8617-bbd5398da5c1_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_c9b89d40-4a58-464e-9c10-17ea25e5502b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_d207a95e-6095-471b-9d4b-7a433aa719cb_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_865397b2-e00d-49e9-abe9-afdd04649a67_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_53eef231-abbf-46c4-b137-9e8316a7e7bb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_a7ddb770-7457-435b-9383-5c37374e2e62_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets in progress</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets under development [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:to="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_976fd750-5f1d-49ad-99c3-683d8b3b105e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_d18694e4-11b3-49d7-89e6-055aa3335dfc_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and IT equipment</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20162Member_6c22e94d-e8b6-4700-94e6-e6192d7016c0_terseLabel_en-US" xlink:label="lab_nbx_BSA20162Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016-2</link:label>
    <link:label id="lab_nbx_BSA20162Member_label_en-US" xlink:label="lab_nbx_BSA20162Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016-2 [Member]</link:label>
    <link:label id="lab_nbx_BSA20162Member_documentation_en-US" xlink:label="lab_nbx_BSA20162Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20162Member" xlink:to="lab_nbx_BSA20162Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_713d23f9-b7a4-47ff-ba79-7028c8966c87_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ebae7872-7d9d-4d04-9984-bb85ca32a810_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_970a0897-2e83-49c8-bb6d-e0dc351697f7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments for retirement benefits</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_8a74c1cd-4dc7-4656-b727-9ac959d8c1bb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-taxable items</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of revenues exempt from taxation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:to="lab_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported_76c215f1-4fb8-454a-bd61-2f9944d25424_terseLabel_en-US" xlink:label="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of global registrational studies supported</link:label>
    <link:label id="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported_label_en-US" xlink:label="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Global Registrational Studies Supported</link:label>
    <link:label id="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported_documentation_en-US" xlink:label="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Global Registrational Studies Supported</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:href="nbx-20211231.xsd#nbx_NumberOfGlobalRegistrationalStudiesSupported"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:to="lab_nbx_NumberOfGlobalRegistrationalStudiesSupported" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_4cb46d25-770d-4523-a9ef-5e307cf06061_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General principles, Statement of Compliance and Basis of Presentation</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_daa55ef0-3815-40af-a32a-acdcfd2ad5de_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_a7d732aa-7fb7-4b14-9fde-a15f3e70ef2b_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains and losses on retirement benefit obligations&#160;(IAS 19)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2021Member_55e5bcc0-af4a-4e4c-b653-4974a3de1dc1_terseLabel_en-US" xlink:label="lab_nbx_AGA2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2021</link:label>
    <link:label id="lab_nbx_AGA2021Member_label_en-US" xlink:label="lab_nbx_AGA2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2021 [Member]</link:label>
    <link:label id="lab_nbx_AGA2021Member_documentation_en-US" xlink:label="lab_nbx_AGA2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2021Member" xlink:to="lab_nbx_AGA2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_5291ce88-1deb-4307-ab62-b051e6ee50ab_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_ab474e91-95fc-45e7-b4e8-024472853601_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other charges with no impact on cash</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_3ba40030-ad8e-4ab5-a311-b292b8de7eac_terseLabel_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curadigm interest-free Bpifrance advance</link:label>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_label_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Advance To Curadigm, BPI France [Member]</link:label>
    <link:label id="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Advance To Curadigm, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:to="lab_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_7f52ac56-6389-4edf-8855-ccf4ac3ed9b4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_94e87d67-7026-4bf1-ae2c-2aeaa16e3d67_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_FromFirstYearOfGrantDateMember_4042ec18-b848-44ae-9dda-4e5b6e5e3b7e_terseLabel_en-US" xlink:label="lab_nbx_FromFirstYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From first year of grant date</link:label>
    <link:label id="lab_nbx_FromFirstYearOfGrantDateMember_label_en-US" xlink:label="lab_nbx_FromFirstYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From First Year Of Grant Date [Member]</link:label>
    <link:label id="lab_nbx_FromFirstYearOfGrantDateMember_documentation_en-US" xlink:label="lab_nbx_FromFirstYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From First Year Of Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromFirstYearOfGrantDateMember" xlink:href="nbx-20211231.xsd#nbx_FromFirstYearOfGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_FromFirstYearOfGrantDateMember" xlink:to="lab_nbx_FromFirstYearOfGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_aa88db65-ec7e-4002-a069-edd756ee3ff9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d7265515-c319-4613-940e-a7eb0fb20f79_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_301591a6-09a4-4bf7-bc03-891f4c3a5b73_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax and other payroll liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_99c45ed2-6dda-477d-bc21-d16847376d0e_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research expense since start of collaboration</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Since Start Of Collaboration</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Since Start Of Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_eba0b479-39bd-47b6-845e-d145aaffe1cc_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information About Non-current Financial Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information About Non-current Financial Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information About Non-current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_95ddb16f-ba9a-4cc5-9465-04a1845388a8_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and bank accounts</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_fca32c9e-e904-43fd-9599-713d056a4088_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_aaf9eb7a-569c-417e-9035-22e5df308826_terseLabel_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates if rates increase by 25%</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_label_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Discount Rates If Rates Increase By 25%</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_documentation_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Discount Rates If Rates Increase By 25%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:to="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_659d2ba5-e785-4718-bc75-f303c22e3f4a_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription of warrants</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:to="lab_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_9782973f-685d-4bdd-befe-2d33676b2c73_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDER&#8217;S EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_cb8ca984-c424-4f9a-a7d8-24e6ba349180_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfSubsidiaries_91529469-d252-4c60-acef-c127e86c9410_terseLabel_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries</link:label>
    <link:label id="lab_nbx_NumberOfSubsidiaries_label_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:label id="lab_nbx_NumberOfSubsidiaries_documentation_en-US" xlink:label="lab_nbx_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSubsidiaries" xlink:href="nbx-20211231.xsd#nbx_NumberOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfSubsidiaries" xlink:to="lab_nbx_NumberOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExternalConsultantMember_80eb6beb-bd78-4bbe-90f6-fa2de0190385_terseLabel_en-US" xlink:label="lab_nbx_ExternalConsultantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Consultant</link:label>
    <link:label id="lab_nbx_ExternalConsultantMember_label_en-US" xlink:label="lab_nbx_ExternalConsultantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Consultant [Member]</link:label>
    <link:label id="lab_nbx_ExternalConsultantMember_documentation_en-US" xlink:label="lab_nbx_ExternalConsultantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Consultant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExternalConsultantMember" xlink:href="nbx-20211231.xsd#nbx_ExternalConsultantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExternalConsultantMember" xlink:to="lab_nbx_ExternalConsultantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_8df7b975-5169-469b-92bd-4a7642a5054b_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_c6e86ec5-feb8-4578-84a9-e868a3a9bdd6_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_c8595298-106a-49ec-a1e3-98fa944b1a5e_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements, attendance period</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Attendance Period Before Date Of Exercise</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Attendance Period Before Date Of Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_5d3438d6-814a-4910-800a-0ba0d0af650a_terseLabel_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_label_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_documentation_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:to="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TranchesAxis_4cfcc902-35d3-49a0-bf8e-c2699bcd2287_terseLabel_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_nbx_TranchesAxis_label_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches [Axis]</link:label>
    <link:label id="lab_nbx_TranchesAxis_documentation_en-US" xlink:label="lab_nbx_TranchesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TranchesAxis" xlink:to="lab_nbx_TranchesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_44b27421-9b8b-48df-9b89-eb19bfcbadc6_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period (in thousands of euros)</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherSalesMember_ad9e2974-092f-41cd-94cd-3b45e0181404_terseLabel_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other sales</link:label>
    <link:label id="lab_nbx_OtherSalesMember_label_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sales [Member]</link:label>
    <link:label id="lab_nbx_OtherSalesMember_documentation_en-US" xlink:label="lab_nbx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember" xlink:href="nbx-20211231.xsd#nbx_OtherSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherSalesMember" xlink:to="lab_nbx_OtherSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_a286034b-6e4a-48d3-82cd-f46e93bf1a5b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_933eb64b-fea6-43ab-998a-90dc24ed44f9_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_595ab582-4e8c-42e6-b48d-d7ded117957e_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of retirement age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:to="lab_ifrs-full_ActuarialAssumptionOfRetirementAge2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_32344880-fc82-41fc-b09d-37a8dea7a9b8_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanThreeMonthsMember_325f2198-fdc0-4a57-ae72-48d04dc9e7f0_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 3 months or less</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanThreeMonthsMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanThreeMonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than three months [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanThreeMonthsMember" xlink:to="lab_ifrs-full_NotLaterThanThreeMonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_15476e39-ea96-4119-9e51-bbaddbe28629_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of depreciation, amortization and provision expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstalments_ba65bb7c-13f6-49f1-b04c-086560332d26_terseLabel_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly instalments</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstalments_label_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of Quarterly Instalments</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfQuarterlyInstalments_documentation_en-US" xlink:label="lab_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of Quarterly Instalments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfQuarterlyInstalments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:to="lab_nbx_BorrowingNumberOfQuarterlyInstalments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_aa538dc5-f6e6-4f35-954f-eb2798a1cf1c_terseLabel_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates if rates decrease by 25%</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_label_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Discount Rates If Rates Decrease By 25%</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_documentation_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Discount Rates If Rates Decrease By 25%</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:to="lab_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_d5e27826-d8ef-478d-983b-715277fe458c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_2a3c6c1e-1453-4a75-9e0a-45b3a2b4abf0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and other income</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_d131effb-4919-4c2d-b5b1-7390b57bfa6f_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other payables</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade And Other Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202104PerformanceMember_b1a1df16-7afb-43cf-b4bf-2d2f8151bb12_terseLabel_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 P</link:label>
    <link:label id="lab_nbx_OSA202104PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA202104PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA202104PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_OSA202104PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202104PerformanceMember" xlink:to="lab_nbx_OSA202104PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_5450d181-efcf-43b9-b2e0-b1e3f1bf4297_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfCommitmentsAbstract_label_en-US" xlink:label="lab_nbx_DisclosureOfCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Commitments [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfCommitmentsAbstract_documentation_en-US" xlink:label="lab_nbx_DisclosureOfCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCommitmentsAbstract" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfCommitmentsAbstract" xlink:to="lab_nbx_DisclosureOfCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_a2b63e4a-e916-4124-8f7a-9a755a0e2aac_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock_37e817d2-03ef-4b35-9ab7-ad04b8b9b321_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of effect of changes in exchange rates</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About The Effect Of Changes In Foreign Exchange Rates [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About The Effect Of Changes In Foreign Exchange Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_17aca900-9fe8-4eb8-884e-f222e7672575_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_d3576f70-c0b4-4801-9634-9a90e3880c95_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to change in financial assumptions</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_139e1245-bbb4-4e1a-b05c-d7ea7bc5ef8d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition in non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_b4a0d22d-c57d-40a0-898d-27aba647a9a0_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReservesMember_74f0627c-204c-4cb3-8050-2f6176496884_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve</link:label>
    <link:label id="lab_ifrs-full_OtherReservesMember_label_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_b827eb1c-9b1e-4871-a0de-c76e5fb482e6_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theoretical tax rate (statutory rate in France)</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_d2c3f4ca-c659-45c0-a3c0-e8ed6b463e4f_terseLabel_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net income due to a 10% increase in exchange rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_label_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_documentation_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:to="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_37cc1f46-211b-4d51-8c31-f860a398367a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_f5fdc7a4-b42b-4d91-856b-c7056150f850_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for charges</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in existing provisions, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:to="lab_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_0143b7b6-f68f-4f22-8a8d-9a9ea17f50ae_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll taxes</link:label>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_label_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social security contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_b89cd9d8-f8b5-4c64-a20f-d38d8d7deb34_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_b75f4c1f-cf46-4376-86aa-c1d2d56b7012_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2020Member_8b32924f-38dc-40c1-8b3a-6d6a132f7700_terseLabel_en-US" xlink:label="lab_nbx_AGA2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020</link:label>
    <link:label id="lab_nbx_AGA2020Member_label_en-US" xlink:label="lab_nbx_AGA2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020 [Member]</link:label>
    <link:label id="lab_nbx_AGA2020Member_documentation_en-US" xlink:label="lab_nbx_AGA2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2020Member" xlink:to="lab_nbx_AGA2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_5427044b-bdb7-4372-9ca8-310deda7e9c1_terseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_label_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnnualShortTermLeaseExpense_84ca0b8d-f405-423a-a17d-e9566b512abd_terseLabel_en-US" xlink:label="lab_nbx_AnnualShortTermLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual short term lease expense</link:label>
    <link:label id="lab_nbx_AnnualShortTermLeaseExpense_label_en-US" xlink:label="lab_nbx_AnnualShortTermLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Short Term Lease Expense</link:label>
    <link:label id="lab_nbx_AnnualShortTermLeaseExpense_documentation_en-US" xlink:label="lab_nbx_AnnualShortTermLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Short Term Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualShortTermLeaseExpense" xlink:href="nbx-20211231.xsd#nbx_AnnualShortTermLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnnualShortTermLeaseExpense" xlink:to="lab_nbx_AnnualShortTermLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_0a277c5c-9d4c-4456-876b-721c3a6a48fb_terseLabel_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, interest rate</link:label>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_label_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances Received, Interest Rate</link:label>
    <link:label id="lab_nbx_AdvancesReceivedInterestRate_documentation_en-US" xlink:label="lab_nbx_AdvancesReceivedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances Received, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesReceivedInterestRate" xlink:to="lab_nbx_AdvancesReceivedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_5229fb2a-6e31-4cae-990c-ef8ab81ef2b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2021BMember_bbc7dc53-1e6c-4854-88dd-beb707036ce8_terseLabel_en-US" xlink:label="lab_nbx_BSA2021BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (b)</link:label>
    <link:label id="lab_nbx_BSA2021BMember_label_en-US" xlink:label="lab_nbx_BSA2021BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (b) [Member]</link:label>
    <link:label id="lab_nbx_BSA2021BMember_documentation_en-US" xlink:label="lab_nbx_BSA2021BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (b)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2021BMember" xlink:to="lab_nbx_BSA2021BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_a0e4cfe3-c4f4-45d0-a079-9ef3832adcb8_terseLabel_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Board and Employees</link:label>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_label_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Board And Employees [Member]</link:label>
    <link:label id="lab_nbx_ExecutiveBoardAndEmployeesMember_documentation_en-US" xlink:label="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Board And Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember" xlink:href="nbx-20211231.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExecutiveBoardAndEmployeesMember" xlink:to="lab_nbx_ExecutiveBoardAndEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasuryShares_8f6fa444-3635-443e-8d8a-812ffb2bf168_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_41748de3-4fd2-434a-84fe-b317af5b3054_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_label_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_9c63fe0a-6fc5-4a80-bf6b-05b67a8fd97c_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after more than 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_c26b6753-8df1-40fe-9b3b-5e9c14311557_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_60c74ebb-94aa-4a27-be3a-c10e9fc304ac_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_d2c5344b-5b47-47c6-9c87-e3867dc8d067_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross book value of intangible assets</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_ab0cba3d-7501-4e03-aab4-7d2106a93c68_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross book value of tangible assets</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_9122cdc8-128d-4061-821f-ffc3b24198e2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock_d12e7bd0-069f-4bcc-a49c-621503b20134_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Liabilities [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfFinancialLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:to="lab_nbx_DisclosureOfFinancialLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_aa1119b2-6e1b-46ea-b0ab-0779ba45df75_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition to annual rent expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) To Annual Rent Expense, Indexation Impact</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) To Annual Rent Expense, Indexation Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:to="lab_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0b98b27f-38b4-4796-944f-fcb095fb7b6a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_debfa59a-e6bf-4490-9e0e-e2c859ad1f8d_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_ca2bd1af-83ec-498e-8563-6bfaa62d3e15_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_be195980-cab9-4190-80ca-795ada50b795_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues and other income</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_9a2524fe-54d9-4431-a0ad-581633bc11c5_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_be960696-3df7-4975-92ba-85ff1ed8ce32_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of details of non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_51436249-a624-4d2e-a4ed-7d25b5be6987_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_f5f89234-8be6-4fbb-bd21-c6e359e20423_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_d56c62ad-a8c8-4eb3-a8f7-8d8df4f2157a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_0f2a9f35-0c2f-41fa-8d5c-bddab68bc7d9_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets at end of period</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSAMember_c53bac4c-434d-45ec-bffa-7b1fe8b492cf_terseLabel_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA</link:label>
    <link:label id="lab_nbx_OSAMember_label_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA [Member]</link:label>
    <link:label id="lab_nbx_OSAMember_documentation_en-US" xlink:label="lab_nbx_OSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSAMember" xlink:to="lab_nbx_OSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MachineryMember_931d649f-6c85-4302-9af4-7a91e107a29a_terseLabel_en-US" xlink:label="lab_ifrs-full_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technical equipment</link:label>
    <link:label id="lab_ifrs-full_MachineryMember_label_en-US" xlink:label="lab_ifrs-full_MachineryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MachineryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MachineryMember" xlink:to="lab_ifrs-full_MachineryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_48a7dae2-0ab6-4951-85b4-0c49af7ddada_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_c7db878d-8e81-4279-9450-ebf23ef5a087_terseLabel_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in euros)</link:label>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:to="lab_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_FormerExecutiveBoardMembersMember_61671d9c-9dc3-4cb4-bf30-243869f9d270_terseLabel_en-US" xlink:label="lab_nbx_FormerExecutiveBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Board members</link:label>
    <link:label id="lab_nbx_FormerExecutiveBoardMembersMember_label_en-US" xlink:label="lab_nbx_FormerExecutiveBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Board Members [Member]</link:label>
    <link:label id="lab_nbx_FormerExecutiveBoardMembersMember_documentation_en-US" xlink:label="lab_nbx_FormerExecutiveBoardMembersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerExecutiveBoardMembersMember" xlink:href="nbx-20211231.xsd#nbx_FormerExecutiveBoardMembersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_FormerExecutiveBoardMembersMember" xlink:to="lab_nbx_FormerExecutiveBoardMembersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_342e60a9-87fa-4235-ad72-5bf5105b579c_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_2265a84a-c6b4-437b-8838-ce7ef164eaed_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_14d33c3e-5f3b-4dd0-be06-802d5f310ebd_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows from (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6c132c82-39a9-41c1-aef6-ed9f351ae7c1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGAMember_b2d47555-868b-4d74-942b-6bcce19148c1_terseLabel_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA</link:label>
    <link:label id="lab_nbx_AGAMember_label_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA [Member]</link:label>
    <link:label id="lab_nbx_AGAMember_documentation_en-US" xlink:label="lab_nbx_AGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGAMember" xlink:to="lab_nbx_AGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_9c7f151b-7ffd-418e-a2fc-33b133f18851_negatedTerseLabel_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in employee benefit expense, percentage</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_c315bf39-04db-4392-b185-0e75a55a049f_terseLabel_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in employee benefit expense, percentage</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_label_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_documentation_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:to="lab_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_51ccd8ef-2d72-48fd-8e02-aa934d45bfdc_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_3dbd75a7-165a-46f4-853b-285e5645a447_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, sub-contracting and other expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Sub-Contracting And Other Expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Sub-Contracting And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_49558055-866e-4beb-83a8-54e0c4d73ca3_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_8fccf99f-68d3-482c-a8ae-ece9aa70b2dc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net financial income (loss)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_8d1e96a8-f423-4d0d-b0b8-3a9ce2366c49_negatedTerseLabel_en-US" xlink:label="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early termination of lease contracts</link:label>
    <link:label id="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Early Termination, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Early Termination, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_a0e02b19-51d8-4685-8864-0a4cd833a735_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_26c20c87-6407-4266-95f4-39d6a8eafae8_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that may be reclassified subsequently to income or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_31a60d25-c2b2-43a4-83e6-e7f0b32ced25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_d77b1581-7dc8-4fb4-bfae-abd3ccf488f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_55d85c51-f256-40cb-9e19-510d33f9b36f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_198fa652-b0cf-42b5-bfb3-6a7fdba6002f_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_91d54233-72aa-4f07-9a35-a9e0aead9423_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average duration of defined benefit obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:to="lab_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_4ba03c17-1f59-424a-a9be-96a3bb294082_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, fees and other expenses</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Purchases, Fees And Other Expense</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Purchases, Fees And Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_4238bccb-cb91-4458-b444-a6dd02a77064_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_52b3dc98-dcf4-4e7f-9fcf-c76d4e40aaed_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_6787c4d1-0132-4b84-a8e5-cd052f2a1178_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital increases</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Advances_f9131eb0-d5ea-4ec4-866b-b2b3f68b1761_terseLabel_en-US" xlink:label="lab_ifrs-full_Advances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances received</link:label>
    <link:label id="lab_ifrs-full_Advances_label_en-US" xlink:label="lab_ifrs-full_Advances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances received, representing contract liabilities for performance obligations satisfied at point in time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Advances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Advances" xlink:to="lab_ifrs-full_Advances" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_54ca977b-754d-4caa-93ae-d85257c5e46a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_5ff94671-61e0-4b3d-b867-b9a90b5cd04c_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortised cost</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_2fba617f-85f8-4351-8029-9f1aa9faa2f4_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests / discounting costs</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_e06db29a-4d4b-4812-a3f9-ddc1d8e5693d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA20191Member_0e2ae1e1-3d76-4977-b45e-11038b8cfbf0_terseLabel_en-US" xlink:label="lab_nbx_AGA20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2019-1</link:label>
    <link:label id="lab_nbx_AGA20191Member_label_en-US" xlink:label="lab_nbx_AGA20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2019-1 [Member]</link:label>
    <link:label id="lab_nbx_AGA20191Member_documentation_en-US" xlink:label="lab_nbx_AGA20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2019-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA20191Member" xlink:to="lab_nbx_AGA20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f0cfa20c-113d-4454-962f-faa7ce525ebd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_c1e9455c-ab85-409f-8b56-ab5bafbb05bf_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_00bc8614-904b-4c92-bb14-fb1d68f263a4_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables and other current assets</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade Receivables And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade Receivables And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c5e57f2b-ce02-4005-9df5-4b7ed62e487c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_e34870b2-5ff9-4e92-b295-2d178a0fc89d_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidies</link:label>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:to="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfShortTermLeaseContracts_0132ea51-c8cc-4e82-83ee-915641e65df7_terseLabel_en-US" xlink:label="lab_nbx_NumberOfShortTermLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of short term leases</link:label>
    <link:label id="lab_nbx_NumberOfShortTermLeaseContracts_label_en-US" xlink:label="lab_nbx_NumberOfShortTermLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Short Term Lease Contracts</link:label>
    <link:label id="lab_nbx_NumberOfShortTermLeaseContracts_documentation_en-US" xlink:label="lab_nbx_NumberOfShortTermLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Short Term Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShortTermLeaseContracts" xlink:href="nbx-20211231.xsd#nbx_NumberOfShortTermLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfShortTermLeaseContracts" xlink:to="lab_nbx_NumberOfShortTermLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017ProjectMember_9063a399-823e-47ad-87c6-218e568892f2_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Project</link:label>
    <link:label id="lab_nbx_BSPCE2017ProjectMember_label_en-US" xlink:label="lab_nbx_BSPCE2017ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Project [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017ProjectMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2017ProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Project</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017ProjectMember" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017ProjectMember" xlink:to="lab_nbx_BSPCE2017ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedProvisionReversedOtherProvisions_7f2cc719-402b-4e22-86c9-18754734c674_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of provision for disputes</link:label>
    <link:label id="lab_ifrs-full_UnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:to="lab_ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20153Member_16faa84e-1634-4535-9c96-32f55b52f129_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-3</link:label>
    <link:label id="lab_nbx_BSPCE20153Member_label_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-3 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20153Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20153Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20153Member" xlink:to="lab_nbx_BSPCE20153Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_793d7750-abbc-4c9f-aad4-5eb104a63fe7_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income (loss)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConditionalAdvancesMember_a58942eb-b039-4993-b51a-bf92558ee810_terseLabel_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayable BPI loan advances</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesMember_label_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advances [Member]</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesMember_documentation_en-US" xlink:label="lab_nbx_ConditionalAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConditionalAdvancesMember" xlink:to="lab_nbx_ConditionalAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_dc4064ab-3477-47a5-b6b1-d317813624cb_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of cash and cash equivalents</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_faf00455-a142-414f-8595-32eb4c3a4b5b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_474ff01f-c1af-44c9-98b8-5c1ed0a782e6_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll costs (including share-based payments)</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Payroll Costs</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Payroll Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:to="lab_nbx_ResearchAndDevelopmentExpensePayrollCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NanobiotixSAMember_3efe095d-45bd-43de-891d-2c7aea159363_terseLabel_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix S.A.</link:label>
    <link:label id="lab_nbx_NanobiotixSAMember_label_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix S.A. [Member]</link:label>
    <link:label id="lab_nbx_NanobiotixSAMember_documentation_en-US" xlink:label="lab_nbx_NanobiotixSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nanobiotix S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember" xlink:href="nbx-20211231.xsd#nbx_NanobiotixSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NanobiotixSAMember" xlink:to="lab_nbx_NanobiotixSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_e9e1aa1e-7b9b-4ff9-888f-94f34fe55f3a_terseLabel_en-US" xlink:label="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of preceding trading days taken into account in the determination of the share price on the grant date</link:label>
    <link:label id="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_label_en-US" xlink:label="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date</link:label>
    <link:label id="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_documentation_en-US" xlink:label="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:href="nbx-20211231.xsd#nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:to="lab_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_8bf9f5d9-e21c-4656-b9cc-37c5bfc0320e_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums related to share capital</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_5ddb7a64-4de3-4833-8bc5-c75c2b700670_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AuditorInformationAbstract_label_en-US" xlink:label="lab_nbx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nbx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nbx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AuditorInformationAbstract" xlink:href="nbx-20211231.xsd#nbx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AuditorInformationAbstract" xlink:to="lab_nbx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_87c04cb9-b118-4bbd-8e65-afd992fceb86_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_c079e62a-944b-4fe6-bb51-7d03310914e5_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options lapsed or cancelled during the period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2021TaxYearMember_86234e7a-ecfc-4281-8e33-d0abe062a0cf_terseLabel_en-US" xlink:label="lab_nbx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Tax Year</link:label>
    <link:label id="lab_nbx_A2021TaxYearMember_label_en-US" xlink:label="lab_nbx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2021TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2021TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2021TaxYearMember" xlink:href="nbx-20211231.xsd#nbx_A2021TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2021TaxYearMember" xlink:to="lab_nbx_A2021TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_2d93ef89-502b-4ab2-bbf7-d449f0da7df5_terseLabel_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability</link:label>
    <link:label id="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_label_en-US" xlink:label="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_131a9978-36c3-4b41-9cca-e15a4ce5f430_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_1e37e4fc-828b-46ca-810a-09d3ed9667f2_terseLabel_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_label_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation [Abstract]</link:label>
    <link:label id="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_documentation_en-US" xlink:label="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:href="nbx-20211231.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:to="lab_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_9cd3a483-8da3-4481-9e69-a4669cf47798_terseLabel_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_label_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Increase</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_documentation_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:to="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_62dfe41b-d79d-460c-8a7c-e770690e769f_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TaxEffectOfShareBasedPaymentArrangements_f5216444-eb54-4431-a6ab-6faa86d29323_terseLabel_en-US" xlink:label="lab_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment</link:label>
    <link:label id="lab_nbx_TaxEffectOfShareBasedPaymentArrangements_label_en-US" xlink:label="lab_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Share-Based Payment Arrangements</link:label>
    <link:label id="lab_nbx_TaxEffectOfShareBasedPaymentArrangements_documentation_en-US" xlink:label="lab_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:href="nbx-20211231.xsd#nbx_TaxEffectOfShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:to="lab_nbx_TaxEffectOfShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20152Member_9dfc462f-475e-44f6-8472-22eccbfc8750_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20152Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-2</link:label>
    <link:label id="lab_nbx_BSPCE20152Member_label_en-US" xlink:label="lab_nbx_BSPCE20152Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-2 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20152Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20152Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20152Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE20152Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20152Member" xlink:to="lab_nbx_BSPCE20152Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_393ef4f6-57d1-455f-8731-da882863586d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current financial liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ServicesMember_e439b65a-0251-4cb3-b102-e502f7d1dce1_terseLabel_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_nbx_ServicesMember_label_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services [Member]</link:label>
    <link:label id="lab_nbx_ServicesMember_documentation_en-US" xlink:label="lab_nbx_ServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember" xlink:href="nbx-20211231.xsd#nbx_ServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ServicesMember" xlink:to="lab_nbx_ServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractFaubourgSaintAntoineMember_233fe744-ddef-4d80-a3a1-973af9eb03f6_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, Faubourg Saint-Antoine</link:label>
    <link:label id="lab_nbx_LeaseContractFaubourgSaintAntoineMember_label_en-US" xlink:label="lab_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Faubourg Saint-Antoine [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractFaubourgSaintAntoineMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Faubourg Saint-Antoine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractFaubourgSaintAntoineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:to="lab_nbx_LeaseContractFaubourgSaintAntoineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d3438e5d-f177-47cf-8a27-e742dd392ea5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_7160fb8a-676e-48d3-94db-c1fa03f53bca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_f2e29513-9789-4716-88f3-66e9dcf90b94_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of changes in financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_66226f90-8e10-4a36-95cd-cb646ccddf0e_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of details of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_8145d3ab-732c-4df5-acd5-4a071051df0d_negatedTerseLabel_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refund of research tax credit</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_label_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Refund</link:label>
    <link:label id="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_documentation_en-US" xlink:label="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Receivables From Taxes Other Than Income Tax, Refund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:to="lab_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_da1e1f07-5fba-45b3-9948-7a5976793720_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development expense</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expense Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Research And Development Expense Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2019TaxYearMember_700d5480-3870-47aa-9c7e-98ef1fa5091c_terseLabel_en-US" xlink:label="lab_nbx_A2019TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Tax Year</link:label>
    <link:label id="lab_nbx_A2019TaxYearMember_label_en-US" xlink:label="lab_nbx_A2019TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2019TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2019TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2019TaxYearMember" xlink:href="nbx-20211231.xsd#nbx_A2019TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2019TaxYearMember" xlink:to="lab_nbx_A2019TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_7b796880-d348-47ea-90ef-05e25a443d6f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_d798597a-c8f8-4ae4-a10f-90d8bb8742c0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0b6bed2b-b291-4cda-87ea-04ffa7119f96_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_f82c9ef8-9404-4e33-ae55-cd274afc9525_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_bf72fdf0-75d7-4bf9-90f2-4f065463bca9_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD / Euro exchange rate</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_a7302532-116b-4a72-9149-85d3a1017705_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_46f08d4a-2231-48c7-a2c4-78d47ecae57f_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_092bf65b-59e0-48ce-b5f9-be37e4ae2b4e_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_ea0ac2a1-3db4-4b61-8207-7a9c8c495788_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_label_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_fe0b6cc7-aa8c-432a-9d7a-b4b1a1b496c3_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_4e5d30b2-8c8c-44d4-9f87-dbe5b102342c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20151Member_2d801537-b0cc-40e5-8bda-3767729c6532_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-1</link:label>
    <link:label id="lab_nbx_BSPCE20151Member_label_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-1 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20151Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20151Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2015-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20151Member" xlink:to="lab_nbx_BSPCE20151Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_2d5dda44-804a-407c-b123-9000f6fade4d_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_91263859-da89-48ea-82f1-af1a9d22d918_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_4f1c82a8-6e3b-4e08-94f2-7a477243799c_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due between 6 and 12 months</link:label>
    <link:label id="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_96915003-9d02-464f-ae30-3fcaeb2c34d5_terseLabel_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions</link:label>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_label_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Other Provisions [Member]</link:label>
    <link:label id="lab_nbx_CurrentOtherProvisionsMember_documentation_en-US" xlink:label="lab_nbx_CurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember" xlink:href="nbx-20211231.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CurrentOtherProvisionsMember" xlink:to="lab_nbx_CurrentOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_e5baed0b-826b-467a-806c-55cfc0c3795e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_901fbe49-4d59-4038-9c4e-289b21db15f3_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_571e2e25-b521-4853-85ff-975717d813ee_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains and losses (IAS 19)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_de1617d5-8e56-45c2-8023-ed3a8d63171c_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on cash and bank balances at central banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_784cdfdd-8404-4e70-ba36-db20e5a61bad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_35bd54d8-93a1-468b-9991-83017eaca0f3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through origination or purchase, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:to="lab_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfEmployees_a462ba98-f6a8-438e-96b5-ffdc56b23be2_verboseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in number of employees</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfEmployees_401e49c9-3295-49b3-bb88-3647f9ed4240_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of employees</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfEmployees_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Number Of Employees</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInNumberOfEmployees_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:to="lab_nbx_IncreaseDecreaseInNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d66eddb9-6fc1-4ace-8cb9-d55bce78054c_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_a7f7ed54-53de-4806-8aec-230c1117952b_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dff401b2-c49f-4d7d-aae8-11ef053f0176_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_d279ec39-a7f3-491b-9cc8-82402f9d2d6a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_65438d21-3661-461f-bd6e-f791f9afbcdc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_bafc8d8c-8e9b-4f3b-a8ac-4efc4b1fa33c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detail of change in founders' warrants, warrants and free shares</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_673f4b98-bea5-4244-bdf3-70a3012982ae_terseLabel_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment increase</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_label_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment, Annual Increase</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_documentation_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment, Annual Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:to="lab_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d774e297-fc74-4312-9f0c-7f62db2b62c2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AnneJulietteHermantMember_f7073a12-a48c-4444-b792-8770ebff8266_terseLabel_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantMember_label_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant [Member]</link:label>
    <link:label id="lab_nbx_AnneJulietteHermantMember_documentation_en-US" xlink:label="lab_nbx_AnneJulietteHermantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anne-Juliette Hermant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AnneJulietteHermantMember" xlink:to="lab_nbx_AnneJulietteHermantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_1ae79146-cc94-4191-8aae-e105a7d4b463_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_label_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:label id="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_documentation_en-US" xlink:label="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Information Related To The Company [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:to="lab_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_a3f83264-dbc8-46a2-abf9-39e44188aac9_terseLabel_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in euro per share)</link:label>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:to="lab_nbx_ExercisePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_53c7f806-de66-4d20-a9a8-0b09c196b758_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CashAndCashEquivalentsMember_78eeb08d-d573-48e1-9bf9-a74fde5a401a_terseLabel_en-US" xlink:label="lab_nbx_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_nbx_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_nbx_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents [Member]</link:label>
    <link:label id="lab_nbx_CashAndCashEquivalentsMember_documentation_en-US" xlink:label="lab_nbx_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalentsMember" xlink:href="nbx-20211231.xsd#nbx_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CashAndCashEquivalentsMember" xlink:to="lab_nbx_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_fe091865-2c42-4e0a-8818-9f75e7fbbfff_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_e6e2986d-bcbe-4bff-af25-a655c26e9062_terseLabel_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use &#8211; Buildings</link:label>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_label_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use, Buildings [Member]</link:label>
    <link:label id="lab_nbx_RightOfUseBuildingsMember_documentation_en-US" xlink:label="lab_nbx_RightOfUseBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use, Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember" xlink:href="nbx-20211231.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RightOfUseBuildingsMember" xlink:to="lab_nbx_RightOfUseBuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementTotalPaymentsReceived_39e0745f-3cce-4664-a926-28054209461a_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payments received under agreement</link:label>
    <link:label id="lab_nbx_CollaborationAgreementTotalPaymentsReceived_label_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Total Payments Received</link:label>
    <link:label id="lab_nbx_CollaborationAgreementTotalPaymentsReceived_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Total Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementTotalPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:to="lab_nbx_CollaborationAgreementTotalPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7c169969-bae3-4f76-85c4-07e227260aad_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_756c18c3-ffd8-4f4e-b9a9-5e0b37b03dcf_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_6a893695-6b9e-4810-a7cd-46b8246ed2d0_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_ec795469-fdc0-4062-bd51-1f4bbd0f3086_terseLabel_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary share subscribed per each BSA (in shares)</link:label>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_label_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Share Subscribed Per Each BSA</link:label>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_documentation_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Share Subscribed Per Each BSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachBSA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:to="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_e31ac176-7407-4f36-b3b1-958de85bb4b7_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_40a369b2-cc49-4013-b01f-e9c5ded2ad80_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_286debca-7bfe-4794-9391-42d0f811fa81_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Information, Statement of Compliance and Basis of Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_53764485-4385-4d1e-965e-7743c72bdf1f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2021AInReplacementOfBSA2016Member_7dc910cb-c9e2-4627-86fc-a716dbad7105_terseLabel_en-US" xlink:label="lab_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a) In Replacement Of BSA 2016</link:label>
    <link:label id="lab_nbx_BSA2021AInReplacementOfBSA2016Member_label_en-US" xlink:label="lab_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a) In Replacement Of BSA 2016 [Member]</link:label>
    <link:label id="lab_nbx_BSA2021AInReplacementOfBSA2016Member_documentation_en-US" xlink:label="lab_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2021 (a) In Replacement Of BSA 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:href="nbx-20211231.xsd#nbx_BSA2021AInReplacementOfBSA2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:to="lab_nbx_BSA2021AInReplacementOfBSA2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_7a2a3dd8-464f-466f-b76a-a32a64206c1e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in euros)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_a3819be5-c65e-41de-8107-f4b0cfa1e819_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_3a9561da-740f-497e-a5d1-ec8a0cf05b5a_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements for share-based payment arrangement, acquisition period for foreign tax residents</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period For Foreign Tax Residents</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period For Foreign Tax Residents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_4788ef33-075d-4763-9492-c8f6693a55c5_terseLabel_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_659fb377-953d-4d68-a965-cfa8fa78501d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_ab27ef3b-cfed-450a-8e0b-4d1d9f452ede_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20161PerformanceMember_fcb57b5d-e1ad-460c-9e4a-f203a29bec91_terseLabel_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 Performance</link:label>
    <link:label id="lab_nbx_OSA20161PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA20161PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA20161PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_OSA20161PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20161PerformanceMember" xlink:to="lab_nbx_OSA20161PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_be384a44-4454-460f-9c90-a87a9e540070_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_d3d92c73-1b03-4669-a44c-04b333eb12f5_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9856654b-8e5b-44f3-b58e-c9e5a2db4bed_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_3af84fa6-16be-4fa6-9b8d-dc22cf75dd30_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_03878cc1-88d5-4cac-8253-3e3032897fae_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_190d19ad-8baa-4e19-95fe-a0824d3efaa1_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other current liabilities</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Other Current Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Other Current Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_64381b6c-b4bd-448c-9e7f-f4e0b6fd3e1c_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_b4e121f7-6714-4f7e-8cbb-515f7788a414_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_cecdfe13-d096-4e08-ba69-985ecf3e2a99_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SharePriceMilestoneEuronextParis_c6f415b8-719f-402b-9d64-9a8ee597e803_terseLabel_en-US" xlink:label="lab_nbx_SharePriceMilestoneEuronextParis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price milestone, Euronext Paris</link:label>
    <link:label id="lab_nbx_SharePriceMilestoneEuronextParis_label_en-US" xlink:label="lab_nbx_SharePriceMilestoneEuronextParis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price Milestone, Euronext Paris</link:label>
    <link:label id="lab_nbx_SharePriceMilestoneEuronextParis_documentation_en-US" xlink:label="lab_nbx_SharePriceMilestoneEuronextParis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price Milestone, Euronext Paris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SharePriceMilestoneEuronextParis" xlink:href="nbx-20211231.xsd#nbx_SharePriceMilestoneEuronextParis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SharePriceMilestoneEuronextParis" xlink:to="lab_nbx_SharePriceMilestoneEuronextParis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_3336d6f8-910d-44b0-826d-0c25a34372c1_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements, minimum attendance</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Minimum Attendance</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Minimum Attendance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_c442a0fc-b148-48c8-a3cc-c9f084a1d4f1_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsAxis_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis" xlink:to="lab_ifrs-full_ActuarialAssumptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_57784191-8659-4d95-b8be-c8b942d8e869_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_7a9bcfe0-21e3-47a1-844e-9e0204354b11_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of assumptions used to measure retirement benefits</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of defined benefit plans [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_31660d71-33da-43a2-8836-da32b384ed71_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_fd46c245-2874-400e-9bd0-3cc7142ee161_terseLabel_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in purchases, sub-contracting and other expenses, percentage</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_label_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:to="lab_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20161Member_f0395d5d-e437-45b6-a1f3-15ff2f29ce87_terseLabel_en-US" xlink:label="lab_nbx_OSA20161Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1</link:label>
    <link:label id="lab_nbx_OSA20161Member_label_en-US" xlink:label="lab_nbx_OSA20161Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 [Member]</link:label>
    <link:label id="lab_nbx_OSA20161Member_documentation_en-US" xlink:label="lab_nbx_OSA20161Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161Member" xlink:href="nbx-20211231.xsd#nbx_OSA20161Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20161Member" xlink:to="lab_nbx_OSA20161Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_5987ace2-0dc7-407e-9b61-301d648636e0_terseLabel_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn borrowing facilities</link:label>
    <link:label id="lab_ifrs-full_UndrawnBorrowingFacilities_label_en-US" xlink:label="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undrawn borrowing facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UndrawnBorrowingFacilities" xlink:to="lab_ifrs-full_UndrawnBorrowingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2014Member_5d2148a3-212a-4ef7-b5f5-a07db15ca823_terseLabel_en-US" xlink:label="lab_nbx_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2014</link:label>
    <link:label id="lab_nbx_BSA2014Member_label_en-US" xlink:label="lab_nbx_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2014 [Member]</link:label>
    <link:label id="lab_nbx_BSA2014Member_documentation_en-US" xlink:label="lab_nbx_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2014Member" xlink:to="lab_nbx_BSA2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_909d05bf-6645-48f6-a5e1-d835b035997d_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable" xlink:to="lab_nbx_DisclosureOfOperatingExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_da714acd-ac32-41eb-8610-d2b8e3ceb375_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_a4b57498-1711-4d48-b108-8c30e83596da_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_f952be5f-c081-403a-8db0-36199773e744_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses related to experience</link:label>
    <link:label id="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionsForChargesMember_2b48811f-bd90-4f66-8e4a-2bd07eb7f3f2_terseLabel_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for charges</link:label>
    <link:label id="lab_nbx_ProvisionsForChargesMember_label_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Charges [Member]</link:label>
    <link:label id="lab_nbx_ProvisionsForChargesMember_documentation_en-US" xlink:label="lab_nbx_ProvisionsForChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionsForChargesMember" xlink:to="lab_nbx_ProvisionsForChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_f5c21834-452f-466c-88d6-7edf2fe4b2fb_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operations, before tax and changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AllocationOfPriorPeriodLoss_5d5d0bb2-1d13-45d9-b6ca-5acc47f028da_terseLabel_en-US" xlink:label="lab_nbx_AllocationOfPriorPeriodLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of prior period loss</link:label>
    <link:label id="lab_nbx_AllocationOfPriorPeriodLoss_label_en-US" xlink:label="lab_nbx_AllocationOfPriorPeriodLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation Of Prior Period Loss</link:label>
    <link:label id="lab_nbx_AllocationOfPriorPeriodLoss_documentation_en-US" xlink:label="lab_nbx_AllocationOfPriorPeriodLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation Of Prior Period Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AllocationOfPriorPeriodLoss" xlink:href="nbx-20211231.xsd#nbx_AllocationOfPriorPeriodLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AllocationOfPriorPeriodLoss" xlink:to="lab_nbx_AllocationOfPriorPeriodLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_a99ef971-3eed-48f3-9147-fe21f5f14ec1_negatedLabel_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_7fd4538f-7bb8-4459-974e-7f4620567940_verboseLabel_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision reversed</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_label_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision Used And Unused Provision Reversed, Other Provisions</link:label>
    <link:label id="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_documentation_en-US" xlink:label="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision Used And Unused Provision Reversed, Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:href="nbx-20211231.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:to="lab_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinanceIncome_c6002e87-b04a-42fa-8bea-2c0a2dcb93df_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financial income</link:label>
    <link:label id="lab_ifrs-full_OtherFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_OtherFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinanceIncome" xlink:to="lab_ifrs-full_OtherFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_b89d2304-8aac-4b06-b8dc-e25062d13a31_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Theoretical tax (benefit) expense</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_16da8317-c366-4b4e-9d92-9edbeaef3888_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_3114ed29-8ade-4288-ba15-533c120f7956_terseLabel_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net financial income (loss)</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_label_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Finance Income (Cost) [Table Text Block]</link:label>
    <link:label id="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Finance Income (Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:to="lab_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_7447e515-acba-411f-ae78-6021a984b76f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_b4362074-6128-47d3-a77e-738fd0b32375_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of payroll costs</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_43bc271a-876b-4ed5-b5a4-162015ccced5_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_07c35abc-4210-4fb8-afb7-9ef86e609458_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_e73e6010-598d-4c06-afaa-7f6b34745d71_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of break down of trade receivables</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade Receivables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Trade Receivables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_8e8d7054-6cdf-499b-af86-90286f1f7455_terseLabel_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, deferment period</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_label_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Deferment Period</link:label>
    <link:label id="lab_nbx_BorrowingDefermentPeriod_documentation_en-US" xlink:label="lab_nbx_BorrowingDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Deferment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingDefermentPeriod" xlink:to="lab_nbx_BorrowingDefermentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_2490b1ae-5e48-4475-ada0-54b6a0d63c2c_terseLabel_en-US" xlink:label="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advances and Loans from Government and Public Authorities</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_label_en-US" xlink:label="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advances And Loans From Government And Public Authorities [Member]</link:label>
    <link:label id="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_documentation_en-US" xlink:label="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional Advances And Loans From Government And Public Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:to="lab_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2f891509-fbde-435a-bc56-85718aecf73d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_86917ee1-81a9-4800-8189-dddc67098d7c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b9861301-2ad0-4200-a6a2-aea433b4dab0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_8aacc39c-fc91-486b-8b4f-6c832a41f0a3_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_a6ee92dd-f74d-44b2-a4a1-cf6a980c5cff_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_90095412-95e6-4092-88dd-cad89e96bc3d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_1142741b-b4ca-4e0d-978d-a0b540de3255_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_16d68c3d-b48f-4807-96b1-c4b4206fea82_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_f51523f7-36ae-4847-a83b-ddba5919317a_terseLabel_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities, at fair value</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_label_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</link:label>
    <link:label id="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_documentation_en-US" xlink:label="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:to="lab_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_2902565c-4c77-4360-9eea-576dc9360dbf_terseLabel_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIB fixed rate loan</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_848d75e0-18d7-47e1-af4a-b05f3b5007a0_verboseLabel_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EIB Loan</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_label_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Investment Bank Loan Agreement [Member]</link:label>
    <link:label id="lab_nbx_EuropeanInvestmentBankLoanAgreementMember_documentation_en-US" xlink:label="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Investment Bank Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:to="lab_nbx_EuropeanInvestmentBankLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TranchesDomain_82e35125-78d0-4ba8-8507-f7ade8098d81_terseLabel_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_nbx_TranchesDomain_label_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:label id="lab_nbx_TranchesDomain_documentation_en-US" xlink:label="lab_nbx_TranchesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranches [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TranchesDomain" xlink:to="lab_nbx_TranchesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_f60999c5-2299-41a0-ab3f-744c01624825_terseLabel_en-US" xlink:label="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of employees' net wages received via subsidies from French government</link:label>
    <link:label id="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_label_en-US" xlink:label="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Employees' Net Wages Received From French Government Via Partial Unemployment Measure</link:label>
    <link:label id="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_documentation_en-US" xlink:label="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Employees' Net Wages Received From French Government Via Partial Unemployment Measure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:href="nbx-20211231.xsd#nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:to="lab_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_43e0fde5-23a0-43e1-b513-4d8c26207acf_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_487b69bc-6c4b-41fc-a28a-9ddedf3afa25_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_2730bc11-0104-4d80-bf21-3a114d3c96c0_terseLabel_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards lapsed or cancelled (in shares)</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_a6b5bbf3-4948-43dc-b3f2-953b3018d71a_verboseLabel_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options lapsed or cancelled (in shares)</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number Of Awards Forfeited In Share-based Payment Arrangement</link:label>
    <link:label id="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number Of Awards Forfeited In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:to="lab_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_b7a0daa8-902c-4616-ae5a-613235a755ee_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share (euro per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_dd8296bd-70d0-46cf-9c29-d690b776f58e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfOperatingExpensesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems" xlink:to="lab_nbx_DisclosureOfOperatingExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_b6f97664-1e45-4785-b2bf-72ddefdfc9fc_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than 1&#160;year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_8d441dd0-13de-4a58-8588-92be4088ea36_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2017PerformanceMember_c95b6d7a-b025-4a04-9e0e-84825366caba_terseLabel_en-US" xlink:label="lab_nbx_OSA2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Performance</link:label>
    <link:label id="lab_nbx_OSA2017PerformanceMember_label_en-US" xlink:label="lab_nbx_OSA2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Performance [Member]</link:label>
    <link:label id="lab_nbx_OSA2017PerformanceMember_documentation_en-US" xlink:label="lab_nbx_OSA2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_OSA2017PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2017PerformanceMember" xlink:to="lab_nbx_OSA2017PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_25687452-74a0-45fe-b0e4-e4b9d758abfb_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SanofiGeneTherapyPortfolioMember_4ead1e67-bd9a-4c8d-906f-30dac6a195ad_terseLabel_en-US" xlink:label="lab_nbx_SanofiGeneTherapyPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi, Gene Therapy Portfolio</link:label>
    <link:label id="lab_nbx_SanofiGeneTherapyPortfolioMember_label_en-US" xlink:label="lab_nbx_SanofiGeneTherapyPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi, Gene Therapy Portfolio [Member]</link:label>
    <link:label id="lab_nbx_SanofiGeneTherapyPortfolioMember_documentation_en-US" xlink:label="lab_nbx_SanofiGeneTherapyPortfolioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi, Gene Therapy Portfolio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SanofiGeneTherapyPortfolioMember" xlink:href="nbx-20211231.xsd#nbx_SanofiGeneTherapyPortfolioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SanofiGeneTherapyPortfolioMember" xlink:to="lab_nbx_SanofiGeneTherapyPortfolioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_e7fe5b52-e7ac-4fe4-8e58-bd6825eed059_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ContractualCommitmentsPayment_d0489ab8-ade3-4920-b23a-d340721346d9_terseLabel_en-US" xlink:label="lab_nbx_ContractualCommitmentsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsPayment_label_en-US" xlink:label="lab_nbx_ContractualCommitmentsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Payment</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsPayment_documentation_en-US" xlink:label="lab_nbx_ContractualCommitmentsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ContractualCommitmentsPayment" xlink:to="lab_nbx_ContractualCommitmentsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_0836538c-5acc-405f-8d4d-47758f6a0c15_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision used</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_0082865d-6d47-48d1-a447-78a7e3901960_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization of provisions</link:label>
    <link:label id="lab_ifrs-full_ProvisionUsedOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision used, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionUsedOtherProvisions" xlink:to="lab_ifrs-full_ProvisionUsedOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_04ebefb9-ab33-46e8-b79d-060ce996f0c9_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_6ac97b00-1d46-40f8-834a-a5b139fff416_terseLabel_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in net income due to a 10% decrease in exchange rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_label_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_documentation_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:to="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_a2c6ad7e-7069-46bf-8795-2f5b7c8b72a9_terseLabel_en-US" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_label_en-US" xlink:label="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lab_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_02882e9e-f757-46fd-9087-27f70fc8210f_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss that will not be reclassified subsequently to income or loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_6cfb6e1b-1bb6-4a76-84ad-d6f532add15e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_ccf35f73-addb-4647-8367-f67f806fdac9_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfTaxLosses_72433b32-0039-43df-acf2-e99dea3e0bda_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax losses</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfTaxLosses_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect of tax losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfTaxLosses" xlink:to="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_697f0009-83ed-461f-94cf-f15f227c6986_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of deferred income related to financial liabilities discounting effect</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_6d029278-26d0-4c7a-80b7-19f3b8250ca2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_1ec30d77-77e6-4c28-8329-fdbd547c4894_terseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Research tax credit receivable</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</link:label>
    <link:label id="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_a82c0ec2-55fa-4ec1-bbdf-9a184e5960b2_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_01f3cd9f-77ae-48f8-920f-090990a669a4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets, at fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_8ad9dccf-e1f3-45d3-8e28-486edc01e774_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based payment</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIncome_9d2f3603-19d7-4eff-9bb2-dfcc1ff74ccc_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_f55f5f9a-7cf5-43e4-bac3-091b56b1e1d6_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_label_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfPatientsInClinicalTrial_3f4691fe-8696-46e9-b606-654b1841d77e_terseLabel_en-US" xlink:label="lab_nbx_NumberOfPatientsInClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_nbx_NumberOfPatientsInClinicalTrial_label_en-US" xlink:label="lab_nbx_NumberOfPatientsInClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients In Clinical Trial</link:label>
    <link:label id="lab_nbx_NumberOfPatientsInClinicalTrial_documentation_en-US" xlink:label="lab_nbx_NumberOfPatientsInClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients In Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPatientsInClinicalTrial" xlink:href="nbx-20211231.xsd#nbx_NumberOfPatientsInClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfPatientsInClinicalTrial" xlink:to="lab_nbx_NumberOfPatientsInClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_552fae2e-5987-4294-ae2a-74a9a17fe44c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_314c9ade-dd51-46c6-82d7-ae870128210a_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentSecurityDepositMember_13bcbd27-85f8-4ea2-9556-ee021019243b_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentSecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposits paid</link:label>
    <link:label id="lab_nbx_NonCurrentSecurityDepositMember_label_en-US" xlink:label="lab_nbx_NonCurrentSecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Security Deposit [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentSecurityDepositMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentSecurityDepositMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current, Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentSecurityDepositMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentSecurityDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentSecurityDepositMember" xlink:to="lab_nbx_NonCurrentSecurityDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_2f34e359-df4b-4877-92c5-62d41b76c821_terseLabel_en-US" xlink:label="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Board and Alain Dostie</link:label>
    <link:label id="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_label_en-US" xlink:label="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members Of The Executive Board And Alain Dostie [Member]</link:label>
    <link:label id="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_documentation_en-US" xlink:label="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members Of The Executive Board And Alain Dostie</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:href="nbx-20211231.xsd#nbx_MembersOfTheExecutiveBoardAndAlainDostieMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:to="lab_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_dcf1c94d-da1b-41c4-936a-46f1fdf55da2_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_f2591f2f-0195-4fa0-b9c5-bb50999a944f_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_78ed0000-274a-4fa3-a25c-3920e5130e9f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_8ead4e5a-2b4c-4c89-b3fd-da3671ccfdf7_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE20121Member_a22f9a6b-29d6-48a8-8be9-5d0803ebf62c_terseLabel_en-US" xlink:label="lab_nbx_BSPCE20121Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-2</link:label>
    <link:label id="lab_nbx_BSPCE20121Member_label_en-US" xlink:label="lab_nbx_BSPCE20121Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-1 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE20121Member_documentation_en-US" xlink:label="lab_nbx_BSPCE20121Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2012-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20121Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE20121Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE20121Member" xlink:to="lab_nbx_BSPCE20121Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ContractTerminationIndemnities_d5b4923c-145c-455a-8504-c6ffeda27563_negatedTerseLabel_en-US" xlink:label="lab_nbx_ContractTerminationIndemnities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination indemnity (PharmaEngine)</link:label>
    <link:label id="lab_nbx_ContractTerminationIndemnities_a82e6cfc-17c7-47bf-93fc-2739f020bdb2_terseLabel_en-US" xlink:label="lab_nbx_ContractTerminationIndemnities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination indemnities</link:label>
    <link:label id="lab_nbx_ContractTerminationIndemnities_label_en-US" xlink:label="lab_nbx_ContractTerminationIndemnities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination Indemnities</link:label>
    <link:label id="lab_nbx_ContractTerminationIndemnities_documentation_en-US" xlink:label="lab_nbx_ContractTerminationIndemnities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Termination Indemnities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractTerminationIndemnities" xlink:href="nbx-20211231.xsd#nbx_ContractTerminationIndemnities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ContractTerminationIndemnities" xlink:to="lab_nbx_ContractTerminationIndemnities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_c62f1ccc-48b3-41f9-a519-336abad05e0f_terseLabel_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payables</link:label>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_label_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Current Liabilities</link:label>
    <link:label id="lab_nbx_OtherMiscellaneousCurrentLiabilities_documentation_en-US" xlink:label="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities" xlink:href="nbx-20211231.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OtherMiscellaneousCurrentLiabilities" xlink:to="lab_nbx_OtherMiscellaneousCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_a8d94b39-fe40-4cf4-b2c3-79aa452362ab_negatedTerseLabel_en-US" xlink:label="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment</link:label>
    <link:label id="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Financing Cash Flows, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease Through Financing Cash Flows, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_30f1c0dd-8a31-4fd3-8b21-b42995138bea_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in payroll tax and other payroll liabilities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:to="lab_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_ffddc6b4-f29f-498a-8098-c06e35bc5f63_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_f6a5c168-190e-4944-9d26-4edaafb6d1dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detail of change in stock options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_522ac5c8-c14a-4494-9250-fb77553358cf_terseLabel_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of initial plan (in thousands of euros)</link:label>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_label_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</link:label>
    <link:label id="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_documentation_en-US" xlink:label="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:href="nbx-20211231.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:to="lab_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_dc91c3cd-7f7d-4582-8e28-dba51b4df1b4_negatedLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Initial public offering costs offset</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_f46774b8-33ad-4eb9-a129-cf5dd21eadc9_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_927e6687-e2f5-4e5a-b02f-b61a367e4903_negatedTerseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_6897e25e-74cf-4720-b268-c6e826a969ca_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in employee benefit expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Employee Benefit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:to="lab_nbx_IncreaseDecreaseInEmployeeBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_24be27e6-86a8-4b1f-acf3-5fc27283b89b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments by type of interest rate [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ICONPlcMember_db6ffcf0-2bb9-4b49-81ef-b22eab672ac2_terseLabel_en-US" xlink:label="lab_nbx_ICONPlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICON Plc</link:label>
    <link:label id="lab_nbx_ICONPlcMember_label_en-US" xlink:label="lab_nbx_ICONPlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICON Plc [Member]</link:label>
    <link:label id="lab_nbx_ICONPlcMember_documentation_en-US" xlink:label="lab_nbx_ICONPlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICON Plc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ICONPlcMember" xlink:href="nbx-20211231.xsd#nbx_ICONPlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ICONPlcMember" xlink:to="lab_nbx_ICONPlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_6ca62754-80ea-446b-adbd-3536ed3ddb03_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant price (in euro per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_75d7457e-fc3d-4758-93ab-77b909fdcc85_terseLabel_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank borrowings, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:to="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_8d74045a-b9d0-49ee-9a78-31e245362b08_terseLabel_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Staff turnover</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_label_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Expected Average Rates Of Staff Turnover</link:label>
    <link:label id="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_documentation_en-US" xlink:label="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial Assumption Of Expected Average Rates Of Staff Turnover</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:to="lab_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_7733e019-fc27-454d-aab3-2e9763fea03f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_11ae2c2c-dde7-438a-a628-f43c2b34a5cc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_7ad8a610-8471-469b-a7d7-c3b461d27217_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0a549871-47dd-40f8-b39c-f50913c036af_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_9b42e107-ac70-4133-8465-ac66bd774afb_negatedTerseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization, and provision expenses</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202104Member_f423bf2c-b8cf-4957-b12c-bf11d3b6d6dc_terseLabel_en-US" xlink:label="lab_nbx_OSA202104Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04</link:label>
    <link:label id="lab_nbx_OSA202104Member_label_en-US" xlink:label="lab_nbx_OSA202104Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 [Member]</link:label>
    <link:label id="lab_nbx_OSA202104Member_documentation_en-US" xlink:label="lab_nbx_OSA202104Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202104Member" xlink:to="lab_nbx_OSA202104Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_ef5fac45-047f-45e1-b995-ad7891395585_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_787e1458-2de1-4d1b-a055-c0ff7b8f46d9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Conditional Advances, Banks Loans And Loans [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2018Member_45be1631-2f41-41be-86c7-82a09fe2aa79_terseLabel_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2018</link:label>
    <link:label id="lab_nbx_OSA2018Member_label_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2018 [Member]</link:label>
    <link:label id="lab_nbx_OSA2018Member_documentation_en-US" xlink:label="lab_nbx_OSA2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2018Member" xlink:to="lab_nbx_OSA2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c595122a-274c-4f8d-9924-ce3790f57a2d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_57f5b846-c5cb-4978-9985-422febc6d5b1_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements, recommended dose determination, total number of patients enrolled</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_26ed30f3-a34b-4a53-929f-06ad25bc56fe_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Receivables and Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:to="lab_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_f1a5f9e2-93eb-43de-9d7e-d0c8c9780eb1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_12783bcd-94f5-434f-8fef-bcc51a0aad4f_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange losses</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CompanyDeferredTaxRate_0c3b1ca2-5f08-4001-afdd-db1b61065df1_terseLabel_en-US" xlink:label="lab_nbx_CompanyDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax rate</link:label>
    <link:label id="lab_nbx_CompanyDeferredTaxRate_label_en-US" xlink:label="lab_nbx_CompanyDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Deferred Tax Rate</link:label>
    <link:label id="lab_nbx_CompanyDeferredTaxRate_documentation_en-US" xlink:label="lab_nbx_CompanyDeferredTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Deferred Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CompanyDeferredTaxRate" xlink:href="nbx-20211231.xsd#nbx_CompanyDeferredTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CompanyDeferredTaxRate" xlink:to="lab_nbx_CompanyDeferredTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_bb4854cc-18ea-4cd2-9d3f-0221e626ae2a_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated fixed interest expense accrual</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_679910ed-3755-48cd-9dfe-9b36b7d7b30b_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_2b348743-f9c7-4dcd-9615-4046832ad840_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in purchases, sub-contracting and other expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:to="lab_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_75d094fe-eee1-49c3-a9d2-49b92dba2f4e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of selling, general and administrative expenses</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_5eb1bc94-3f85-43fc-b2fa-f761ffaf2e43_terseLabel_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary share subscribed per each OSA</link:label>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_label_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Share Subscribed Per Each OSA</link:label>
    <link:label id="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_documentation_en-US" xlink:label="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Ordinary Share Subscribed Per Each OSA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachOSA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:to="lab_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_48f0f31f-d91e-4b80-8d1c-45a58e3a4571_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers and other changes, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a875f152-e8c4-40e9-85da-25c5ebffb858_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8da6b8e4-f9e8-4143-9a7d-361013f7519e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_41ff1f4e-6e87-4571-b713-63115ef289fe_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions of retirement benefits at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_1e27413e-c41b-4c4c-a0d7-09c163e546de_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions of retirement benefits at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_d7d42fd5-0bb0-4b7f-bceb-2c8aea606786_terseLabel_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments on tangible assets</link:label>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_label_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments On Tangible Assets [Member]</link:label>
    <link:label id="lab_nbx_PrepaymentsOnTangibleAssetsMember_documentation_en-US" xlink:label="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments On Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember" xlink:href="nbx-20211231.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PrepaymentsOnTangibleAssetsMember" xlink:to="lab_nbx_PrepaymentsOnTangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_66bc2747-7632-44ef-bfc9-186c3c1be0fb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_f7b8dc51-6660-4454-8edf-b8cf8224389a_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and other income</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RoyaltiesAgreementPeriod_623f94e1-9f18-4dd6-9140-745ab0b73f76_terseLabel_en-US" xlink:label="lab_nbx_RoyaltiesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties agreement, period</link:label>
    <link:label id="lab_nbx_RoyaltiesAgreementPeriod_label_en-US" xlink:label="lab_nbx_RoyaltiesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Agreement, Period</link:label>
    <link:label id="lab_nbx_RoyaltiesAgreementPeriod_documentation_en-US" xlink:label="lab_nbx_RoyaltiesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Agreement, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RoyaltiesAgreementPeriod" xlink:to="lab_nbx_RoyaltiesAgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OpenTaxYearAxis_a2ebbb83-d7dc-4fcd-b2c4-578ddc2c480a_terseLabel_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year [Axis]</link:label>
    <link:label id="lab_nbx_OpenTaxYearAxis_label_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year [Axis]</link:label>
    <link:label id="lab_nbx_OpenTaxYearAxis_documentation_en-US" xlink:label="lab_nbx_OpenTaxYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OpenTaxYearAxis" xlink:to="lab_nbx_OpenTaxYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OptionLifeOtherEquityInstrumentsGranted_f50b3710-8283-4157-a0c2-56a555d02488_terseLabel_en-US" xlink:label="lab_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity (in years)</link:label>
    <link:label id="lab_nbx_OptionLifeOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Life, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_OptionLifeOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Life, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_OptionLifeOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:to="lab_nbx_OptionLifeOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfImpactingFactors_683e676c-dd69-44cd-b7c0-b65aefef8ae9_terseLabel_en-US" xlink:label="lab_nbx_NumberOfImpactingFactors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of impacts</link:label>
    <link:label id="lab_nbx_NumberOfImpactingFactors_label_en-US" xlink:label="lab_nbx_NumberOfImpactingFactors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Impacting Factors</link:label>
    <link:label id="lab_nbx_NumberOfImpactingFactors_documentation_en-US" xlink:label="lab_nbx_NumberOfImpactingFactors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Impacting Factors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfImpactingFactors" xlink:href="nbx-20211231.xsd#nbx_NumberOfImpactingFactors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfImpactingFactors" xlink:to="lab_nbx_NumberOfImpactingFactors" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonManagementMember_2fe08e17-8910-491a-abd6-7e3af66d62f6_terseLabel_en-US" xlink:label="lab_nbx_NonManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-management</link:label>
    <link:label id="lab_nbx_NonManagementMember_label_en-US" xlink:label="lab_nbx_NonManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-management [Member]</link:label>
    <link:label id="lab_nbx_NonManagementMember_documentation_en-US" xlink:label="lab_nbx_NonManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-management</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonManagementMember" xlink:href="nbx-20211231.xsd#nbx_NonManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonManagementMember" xlink:to="lab_nbx_NonManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_222dd688-2fbc-4937-b2ff-b6047442b0cb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IssueOfEquityPricePerShare_f5de3984-2e92-454c-a348-78c7131b3f4b_terseLabel_en-US" xlink:label="lab_nbx_IssueOfEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue of equity, price per share (in euro or dollar per share)</link:label>
    <link:label id="lab_nbx_IssueOfEquityPricePerShare_label_en-US" xlink:label="lab_nbx_IssueOfEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Price Per Share</link:label>
    <link:label id="lab_nbx_IssueOfEquityPricePerShare_documentation_en-US" xlink:label="lab_nbx_IssueOfEquityPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IssueOfEquityPricePerShare" xlink:href="nbx-20211231.xsd#nbx_IssueOfEquityPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IssueOfEquityPricePerShare" xlink:to="lab_nbx_IssueOfEquityPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_32fa2330-4648-4864-bd8a-9004eb40ab4b_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_50721b76-9523-4beb-b547-e0d611a4bd79_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term borrowings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember" xlink:to="lab_ifrs-full_LongtermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_e59d4475-bea0-42e3-baab-340a3f873a07_terseLabel_en-US" xlink:label="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, deferment period</link:label>
    <link:label id="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_label_en-US" xlink:label="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment, Deferment Period After Enrollment</link:label>
    <link:label id="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_documentation_en-US" xlink:label="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment, Deferment Period After Enrollment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:href="nbx-20211231.xsd#nbx_MilestonePaymentDefermentPeriodAfterEnrollment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:to="lab_nbx_MilestonePaymentDefermentPeriodAfterEnrollment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_9b8984d2-0c12-42c3-af52-1d6b1f8b5d11_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_label_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Trade Payables and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:to="lab_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_7412f140-b85c-4a12-96e8-914193827064_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_a0248259-a22c-45b5-b367-141f66ddc036_terseLabel_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for disputes</link:label>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_label_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Disputes [Member]</link:label>
    <link:label id="lab_nbx_ProvisionsForDisputesMember_documentation_en-US" xlink:label="lab_nbx_ProvisionsForDisputesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions For Disputes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ProvisionsForDisputesMember" xlink:to="lab_nbx_ProvisionsForDisputesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_489dd423-b59e-4449-9f15-7ba3f40fe9a0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in lease liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_FromThirdYearOfGrantDateMember_a4f998b9-afe2-4357-b415-c1ca1ea8786e_terseLabel_en-US" xlink:label="lab_nbx_FromThirdYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From third year of grant date</link:label>
    <link:label id="lab_nbx_FromThirdYearOfGrantDateMember_label_en-US" xlink:label="lab_nbx_FromThirdYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From Third Year Of Grant Date [Member]</link:label>
    <link:label id="lab_nbx_FromThirdYearOfGrantDateMember_documentation_en-US" xlink:label="lab_nbx_FromThirdYearOfGrantDateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From Third Year Of Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromThirdYearOfGrantDateMember" xlink:href="nbx-20211231.xsd#nbx_FromThirdYearOfGrantDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_FromThirdYearOfGrantDateMember" xlink:to="lab_nbx_FromThirdYearOfGrantDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_e5306057-acd1-4bce-ac5c-5cc734a9e3e9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans repayments</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_da6a0e6a-7635-42fc-a326-cace9fd268a9_terseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans repayments</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_fec5fea7-02d3-4152-a5fc-1e84e9ecffcd_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of net debt</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_df416a78-e13c-46f2-8cfd-1b7869419c75_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_85969ba1-2589-41a7-8b80-14c8a6910662_terseLabel_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate</link:label>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_92b1c209-f8a1-4553-a06d-91195bdfa96b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax relating to remeasurements of defined benefit plans included in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:to="lab_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_3f4cfb61-fa5a-433a-ba4f-6da5904be66a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_06fc6d2f-db64-48a7-b2ae-c58bfeaadb95_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_e10467c0-5dbd-475e-b5d5-742a78bf9a5a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_803d9b8d-8288-4e18-ab6e-4ac710a53527_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and cash equivalents at end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_3ba6e827-66df-4cd8-b201-1e1960ae28a5_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2b78dee8-4f5e-4e27-b389-49c20213f178_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_2628c5a9-b84d-4cf7-bca4-76e225e8cb04_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_EmployeesMember_eb144032-5dc5-4c96-80a9-807e5bed2e92_terseLabel_en-US" xlink:label="lab_nbx_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_nbx_EmployeesMember_label_en-US" xlink:label="lab_nbx_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_nbx_EmployeesMember_documentation_en-US" xlink:label="lab_nbx_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmployeesMember" xlink:href="nbx-20211231.xsd#nbx_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_EmployeesMember" xlink:to="lab_nbx_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a6589485-3420-4905-94ff-19778c0678a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity (in years)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_98ccd02a-c6a0-42ec-b500-a988a4b83aca_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_99df0ae7-31f9-45e1-b8e9-121ef2ec141d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0afd79ac-ec81-4f9e-ab20-d21a4b8ec073_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractOberkampfStreetMember_89815a98-f789-4ae0-84d0-8782eab0219d_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractOberkampfStreetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, Oberkampf street</link:label>
    <link:label id="lab_nbx_LeaseContractOberkampfStreetMember_label_en-US" xlink:label="lab_nbx_LeaseContractOberkampfStreetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Oberkampf Street [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractOberkampfStreetMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractOberkampfStreetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Oberkampf Street</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractOberkampfStreetMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractOberkampfStreetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractOberkampfStreetMember" xlink:to="lab_nbx_LeaseContractOberkampfStreetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractExtendedPeriod_b205cf96-e8bc-4645-8a17-0ee1453d90b4_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, extended period</link:label>
    <link:label id="lab_nbx_LeaseContractExtendedPeriod_label_en-US" xlink:label="lab_nbx_LeaseContractExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Extended Period</link:label>
    <link:label id="lab_nbx_LeaseContractExtendedPeriod_documentation_en-US" xlink:label="lab_nbx_LeaseContractExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Extended Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractExtendedPeriod" xlink:href="nbx-20211231.xsd#nbx_LeaseContractExtendedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractExtendedPeriod" xlink:to="lab_nbx_LeaseContractExtendedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_b3e1c159-90fb-47db-be7e-d6c14efaec22_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) / Decrease in trade receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_8e7f326c-bebb-4cfa-81e4-c61159765a9d_terseLabel_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RoyaltyPayables_fc2810f1-315e-4977-b9f7-77ed29cf7d39_terseLabel_en-US" xlink:label="lab_nbx_RoyaltyPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future royalty payments</link:label>
    <link:label id="lab_nbx_RoyaltyPayables_label_en-US" xlink:label="lab_nbx_RoyaltyPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payables</link:label>
    <link:label id="lab_nbx_RoyaltyPayables_documentation_en-US" xlink:label="lab_nbx_RoyaltyPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltyPayables" xlink:href="nbx-20211231.xsd#nbx_RoyaltyPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RoyaltyPayables" xlink:to="lab_nbx_RoyaltyPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8486b59d-08d5-49e4-a6a9-77e3ca32c899_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_9973251a-2794-41d2-af27-4465a20e5776_verboseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_4ffc0401-6c02-4a2c-bae2-4b0a40edeb4b_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Ordinary</link:label>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_label_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2016OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2016OrdinaryMember" xlink:to="lab_nbx_BSPCE2016OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_41da3b4e-0897-4689-a113-cdcdfbf82c67_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_43953f54-d4d2-41ec-b50c-479ce9edc9e1_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingMaturityTerm_424c071e-1eac-4ca0-b47a-494ecbddfb6c_terseLabel_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, maturity</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTerm_label_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTerm_documentation_en-US" xlink:label="lab_nbx_BorrowingMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingMaturityTerm" xlink:to="lab_nbx_BorrowingMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_4be300fa-d393-43e6-9f3e-fa087638a137_terseLabel_en-US" xlink:label="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal received</link:label>
    <link:label id="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through Financing Cash Flows, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Through Financing Cash Flows, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="nbx-20211231.xsd#nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LeaseContractAlfortvilleMember_2a67a467-6d59-4640-a2ab-eca9ef02dda1_terseLabel_en-US" xlink:label="lab_nbx_LeaseContractAlfortvilleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease contract, Alfortville</link:label>
    <link:label id="lab_nbx_LeaseContractAlfortvilleMember_label_en-US" xlink:label="lab_nbx_LeaseContractAlfortvilleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Alfortville [Member]</link:label>
    <link:label id="lab_nbx_LeaseContractAlfortvilleMember_documentation_en-US" xlink:label="lab_nbx_LeaseContractAlfortvilleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contract, Alfortville</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractAlfortvilleMember" xlink:href="nbx-20211231.xsd#nbx_LeaseContractAlfortvilleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LeaseContractAlfortvilleMember" xlink:to="lab_nbx_LeaseContractAlfortvilleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_7dc446ae-a337-40c7-ab90-733c228cf55e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingTotalInterestPayable_a6d43ac2-35d5-47e6-b0e0-a802b62094a6_terseLabel_en-US" xlink:label="lab_nbx_BorrowingTotalInterestPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest payable</link:label>
    <link:label id="lab_nbx_BorrowingTotalInterestPayable_label_en-US" xlink:label="lab_nbx_BorrowingTotalInterestPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Total Interest Payable</link:label>
    <link:label id="lab_nbx_BorrowingTotalInterestPayable_documentation_en-US" xlink:label="lab_nbx_BorrowingTotalInterestPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Total Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingTotalInterestPayable" xlink:href="nbx-20211231.xsd#nbx_BorrowingTotalInterestPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingTotalInterestPayable" xlink:to="lab_nbx_BorrowingTotalInterestPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_e6a8fba8-1027-4efd-8d6f-03fe18ce892d_terseLabel_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yield</link:label>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:to="lab_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_b0bb66b4-e4ba-454f-8656-e0818c89e708_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_91b888d3-d749-45ba-b443-10b4709ac95e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_0b86e245-3b38-4a17-8d6b-ae9c8b6edf34_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20161OrdinaryMember_820e2f14-bd16-489b-818a-445895af8c97_terseLabel_en-US" xlink:label="lab_nbx_OSA20161OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016 Ordinary</link:label>
    <link:label id="lab_nbx_OSA20161OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA20161OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA20161OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA20161OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2016-1 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_OSA20161OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20161OrdinaryMember" xlink:to="lab_nbx_OSA20161OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_dd6f929f-5f4f-479d-9cdb-a852d30ac1da_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Ordinary</link:label>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_label_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017OrdinaryMember" xlink:to="lab_nbx_BSPCE2017OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_61b72a9b-dfbe-456a-b227-e2be876230fb_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital Ordinary shares</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_56f0892e-91dd-4ce0-bb73-38beb4bf8f68_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8beef3e3-b63e-4144-8c18-d1e755ace93c_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202106Member_c52c6af1-883c-4d9d-b511-87d4a34132d2_terseLabel_en-US" xlink:label="lab_nbx_OSA202106Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06</link:label>
    <link:label id="lab_nbx_OSA202106Member_label_en-US" xlink:label="lab_nbx_OSA202106Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 [Member]</link:label>
    <link:label id="lab_nbx_OSA202106Member_documentation_en-US" xlink:label="lab_nbx_OSA202106Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202106Member" xlink:to="lab_nbx_OSA202106Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_ed94917a-efd6-4cb9-8f62-a4ec5e8dbe15_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_7aa03076-baa7-4559-a438-1fa2b64320a1_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_b35d28db-7a0e-481e-bf0b-1106f3b2a218_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20151Member_9ecc3be4-f1aa-4fbf-aa7f-228837d2cf64_terseLabel_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-1</link:label>
    <link:label id="lab_nbx_BSA20151Member_label_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-1 [Member]</link:label>
    <link:label id="lab_nbx_BSA20151Member_documentation_en-US" xlink:label="lab_nbx_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20151Member" xlink:to="lab_nbx_BSA20151Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember_668bd136-1acf-4c82-be6f-ba96d1379c1d_terseLabel_en-US" xlink:label="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American depositary shares, each representing one ordinary share, nominal value &#8364;0.03 per share</link:label>
    <link:label id="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember_label_en-US" xlink:label="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, NASDAQ Stock Market [Member]</link:label>
    <link:label id="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember_documentation_en-US" xlink:label="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Shares, NASDAQ Stock Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:href="nbx-20211231.xsd#nbx_AmericanDepositorySharesNASDAQStockMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:to="lab_nbx_AmericanDepositorySharesNASDAQStockMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_748ee06a-41cf-434c-acc6-e011355cfcea_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_db28f745-477e-480b-b690-ed2c9aa7825b_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_11cf990f-2f27-4932-bb27-f78caa9c986f_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in liabilities arising from financing activities [abstract]</link:label>
    <link:label id="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in liabilities arising from financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_ae18aaea-6cd0-4513-9664-ec79507910a1_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements, recommended dose determination, minimum number of patients</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_a31f5e56-bb1d-4031-9962-74e9fb592c4c_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and provision expenses</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_97826148-558a-43c7-9118-da9e1ed5e06b_negatedTerseLabel_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll costs (including share-based payments)</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_label_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Payroll Costs</link:label>
    <link:label id="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_documentation_en-US" xlink:label="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense, Payroll Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:to="lab_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_a4cc6e1f-d71a-48f3-9dbb-d5c35a505094_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7a7cda11-c995-44e9-8145-5cea75d64fb9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_130c171e-8081-4a06-8759-dc5ebb0d2b1a_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for advances loans and lease liabilities</link:label>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_c8212bd6-1775-46a0-a4d1-d20b3dd47be9_verboseLabel_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPI loan</link:label>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_c1d36bba-3a7e-4724-bd72-1aa7a3c992d7_terseLabel_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banque Publique d&#8217;Investissement</link:label>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_label_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banque Publique d&#8217;Investissement [Member]</link:label>
    <link:label id="lab_nbx_BanquePubliqueDInvestissementMember_documentation_en-US" xlink:label="lab_nbx_BanquePubliqueDInvestissementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banque Publique d&#8217;Investissement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember" xlink:href="nbx-20211231.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BanquePubliqueDInvestissementMember" xlink:to="lab_nbx_BanquePubliqueDInvestissementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_53097804-20e0-4b23-a60b-0ae44c002727_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (euro per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BartVanRhijnMember_d5fbfb95-cf72-43e9-b2e4-559e139e2752_terseLabel_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bart Van Rhijn</link:label>
    <link:label id="lab_nbx_BartVanRhijnMember_label_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bart Van Rhijn [Member]</link:label>
    <link:label id="lab_nbx_BartVanRhijnMember_documentation_en-US" xlink:label="lab_nbx_BartVanRhijnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bart Van Rhijn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember" xlink:href="nbx-20211231.xsd#nbx_BartVanRhijnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BartVanRhijnMember" xlink:to="lab_nbx_BartVanRhijnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_82d3e561-6068-467d-9c3a-ff51a141e0ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments included in the statement of financial position and impact on income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1507eaa6-f65c-423d-8b90-201654163c91_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseMember_a844c053-9c1d-4068-b87f-52159812ce80_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseMember" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentExpenseMember" xlink:to="lab_nbx_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_2b438392-24f3-4f7e-bd35-ac2392a8ed92_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_ef125266-f7a5-4ab3-b5ca-37fc422dd161_terseLabel_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in equity due to a 10% increase in exchange rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_label_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_documentation_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:to="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_cdbb3044-3805-414f-a1ac-0cee326e1b7f_terseLabel_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 O</link:label>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202106OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202106OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-06 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202106OrdinaryMember" xlink:to="lab_nbx_OSA202106OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_VehiclesMember_41bd6205-a8bf-497d-96ce-60d8e699c9d4_terseLabel_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transport equipment</link:label>
    <link:label id="lab_ifrs-full_VehiclesMember_label_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_3292c3a8-b824-4358-b082-9e7d8e4f78c6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detail of share capital transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_2886ec88-34d4-406b-aed9-452114ee199c_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_04e3ffd2-7b77-4456-a61d-ffea7c515cfb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_134aba55-452d-4154-866d-87ce49a3ac84_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases</link:label>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional provisions, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_e86cdcbe-7363-4845-ae58-810e3702bd92_terseLabel_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, guarantee fee</link:label>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_label_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Guarantee Fee</link:label>
    <link:label id="lab_nbx_BorrowingGuaranteeFee_documentation_en-US" xlink:label="lab_nbx_BorrowingGuaranteeFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Guarantee Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee" xlink:href="nbx-20211231.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingGuaranteeFee" xlink:to="lab_nbx_BorrowingGuaranteeFee" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_cc629612-bc18-4069-9389-b8027265d06a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_917106e3-faf3-4634-b65e-344d46737c40_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_693884b0-60cc-49e8-947e-6c7fdd1bfe3d_terseLabel_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bpifrance advance</link:label>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_label_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPI France Advance [Member]</link:label>
    <link:label id="lab_nbx_BPIFranceAdvanceMember_documentation_en-US" xlink:label="lab_nbx_BPIFranceAdvanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPI France Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember" xlink:href="nbx-20211231.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BPIFranceAdvanceMember" xlink:to="lab_nbx_BPIFranceAdvanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_a2d3b982-fd4c-4a44-b1ec-8d0a56d582bc_totalLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial gains or losses recognized in other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_91da223c-a886-40ae-a05c-7f5e0dd23408_terseLabel_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability if actuarial assumption of discount rates decrease by 25%</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_label_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_documentation_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d5d550ed-bdfb-4173-915d-845112dcd1bb_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE042013Member_20992c4c-913d-4754-b724-766f3f2ef235_terseLabel_en-US" xlink:label="lab_nbx_BSPCE042013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 09-2014</link:label>
    <link:label id="lab_nbx_BSPCE042013Member_label_en-US" xlink:label="lab_nbx_BSPCE042013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 04-2013 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE042013Member_documentation_en-US" xlink:label="lab_nbx_BSPCE042013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 04-2013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE042013Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE042013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE042013Member" xlink:to="lab_nbx_BSPCE042013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentPayables_7a47c40b-5e46-4d32-959b-71ed970adf15_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables &amp; other accruals</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables" xlink:to="lab_ifrs-full_OtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_97158e12-3cdf-4995-aebe-98e054e9bd0d_negatedTerseLabel_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total depreciation, amortization and provision expenses</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_label_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization And Provision Expenses</link:label>
    <link:label id="lab_nbx_DepreciationAmortizationAndProvisionExpenses_documentation_en-US" xlink:label="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization And Provision Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:href="nbx-20211231.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:to="lab_nbx_DepreciationAmortizationAndProvisionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_8bcc9ebd-9fc9-44cb-af1e-d5f07d75995a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_6b96c7bd-57cd-4a97-924c-524e46c50cb4_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards lapsed or cancelled during the period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_bf46bfd7-36ae-4dbc-9e35-1ecb737d9c42_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_09a5c4c1-56ae-40ea-b658-84ac4204d9f5_negatedLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement benefit obligations</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net defined benefit liability (asset) resulting from current service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_daed8b4e-7b36-405f-ad16-795ab496df28_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2017Member_af5af849-a811-40bb-a6ea-a87db72e3bba_terseLabel_en-US" xlink:label="lab_nbx_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2017</link:label>
    <link:label id="lab_nbx_BSA2017Member_label_en-US" xlink:label="lab_nbx_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2017 [Member]</link:label>
    <link:label id="lab_nbx_BSA2017Member_documentation_en-US" xlink:label="lab_nbx_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2017Member" xlink:to="lab_nbx_BSA2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_4ab686f4-6575-41d2-950d-e53c91a4a1a3_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_1e40d646-a324-4e3a-b705-8668ff2862d5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_b2d9563b-9811-41aa-89fa-7b5db4b76abe_terseLabel_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in equity due to a 10% decrease in exchange rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_label_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate</link:label>
    <link:label id="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_documentation_en-US" xlink:label="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:to="lab_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_dfcbf370-ec8d-4235-963f-aeee0d9b5a4a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_e006fe84-9e50-402e-9e5a-9b50d5e93eb7_negatedTerseLabel_en-US" xlink:label="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Initial public offering 2018 costs reversal</link:label>
    <link:label id="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_label_en-US" xlink:label="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For U.S. Initial Public Offering 2018 Costs Offset</link:label>
    <link:label id="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_documentation_en-US" xlink:label="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For U.S. Initial Public Offering 2018 Costs Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:to="lab_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_8b0c0e87-f8ad-4a33-8ff0-29cf0847d81c_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_label_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRevenueExpense" xlink:to="lab_ifrs-full_InterestRevenueExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_eeacaead-1f59-4a4c-8047-822be833af91_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses - clinical trials</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20152AMember_cc4da83d-8813-4432-b0a3-4060152b1ee4_terseLabel_en-US" xlink:label="lab_nbx_BSA20152AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2(a)</link:label>
    <link:label id="lab_nbx_BSA20152AMember_label_en-US" xlink:label="lab_nbx_BSA20152AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2 (a) [Member]</link:label>
    <link:label id="lab_nbx_BSA20152AMember_documentation_en-US" xlink:label="lab_nbx_BSA20152AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2 (a)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20152AMember" xlink:to="lab_nbx_BSA20152AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_9e2925c3-adc4-4adb-b5c5-ef8c87f16f2d_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BPIFranceMember_e73fed9a-d3b1-49aa-bc44-9d594dee1bf4_terseLabel_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bpifrance</link:label>
    <link:label id="lab_nbx_BPIFranceMember_label_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPI France [Member]</link:label>
    <link:label id="lab_nbx_BPIFranceMember_documentation_en-US" xlink:label="lab_nbx_BPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_BPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BPIFranceMember" xlink:to="lab_nbx_BPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_4bf0abd2-6ce9-44e9-a8cb-974b662dd0ae_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets carried at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_1c3fa45f-3463-48ec-8149-bc1c08b2b0c4_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_2c74adea-a949-47f4-8cab-c49da82f5512_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_a48647de-c66f-4f62-910e-5b3b8e2e7a86_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE exercise (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_cdaefc60-622e-4704-bde0-3ead60ca914a_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards exercised during the period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_1ff83ff9-eb82-4a52-9425-4b99e98ffb0e_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of changes in non-current financial assets</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Non-Current Financial Assets [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_856f1155-8f3f-4c36-aa60-f4288e4c30d1_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelFaxNumber_b5d05831-b6e2-46a7-ac94-ae444217e158_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelFaxNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Fax Number</link:label>
    <link:label id="lab_dei_ContactPersonnelFaxNumber_label_en-US" xlink:label="lab_dei_ContactPersonnelFaxNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Fax Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber" xlink:to="lab_dei_ContactPersonnelFaxNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_a8fcf6ff-828e-441d-890a-6953b5e92153_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_b8af7b2e-765d-4287-8d2b-5f741ea98835_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_a978b8a0-55f8-4922-a123-bc1a9dec4d7c_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_78685be1-a4f0-4a21-9dc3-90c8715485a3_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees with vesting conditions accelerated</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Employees With Vesting Conditions Accelerated</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Employees With Vesting Conditions Accelerated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_30f32736-63cb-4687-b676-2a1ddd813477_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New lease contracts</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA20181Member_f110a1dd-0b84-4a00-b96e-11f06ca9eb22_terseLabel_en-US" xlink:label="lab_nbx_AGA20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-1</link:label>
    <link:label id="lab_nbx_AGA20181Member_label_en-US" xlink:label="lab_nbx_AGA20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-1 [Member]</link:label>
    <link:label id="lab_nbx_AGA20181Member_documentation_en-US" xlink:label="lab_nbx_AGA20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2018-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA20181Member" xlink:to="lab_nbx_AGA20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_e0770a97-b22b-4186-a157-f6876fb1ee45_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_UnusedTaxLossExpirationPeriod_55904349-dddc-4d4e-b445-cff0682598a4_terseLabel_en-US" xlink:label="lab_nbx_UnusedTaxLossExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_nbx_UnusedTaxLossExpirationPeriod_label_en-US" xlink:label="lab_nbx_UnusedTaxLossExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Tax Loss Expiration Period</link:label>
    <link:label id="lab_nbx_UnusedTaxLossExpirationPeriod_documentation_en-US" xlink:label="lab_nbx_UnusedTaxLossExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused Tax Loss Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_UnusedTaxLossExpirationPeriod" xlink:href="nbx-20211231.xsd#nbx_UnusedTaxLossExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_UnusedTaxLossExpirationPeriod" xlink:to="lab_nbx_UnusedTaxLossExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_da6c69e2-49b6-4c99-b4c9-7e188ff99752_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_78a67a7f-8d6d-4540-9748-f16af3e2438d_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGE Loan, BPI France</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_cfa7bdef-c574-498d-b62e-d3dc99caf195_verboseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bpifrance "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, BPI France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DirectorsRemunerationExpense_86939bd6-59c9-4262-85f9-8b3c0e23860b_terseLabel_en-US" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supervisory Board&#8217;s fees</link:label>
    <link:label id="lab_ifrs-full_DirectorsRemunerationExpense_label_en-US" xlink:label="lab_ifrs-full_DirectorsRemunerationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors' remuneration expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DirectorsRemunerationExpense" xlink:to="lab_ifrs-full_DirectorsRemunerationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_0c9af868-5fe1-4ae4-9951-6ff572bc2999_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Financial Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_RightOfUseTransportEquipmentMember_365feebf-86b5-4132-aa69-3fe087fb76fb_terseLabel_en-US" xlink:label="lab_nbx_RightOfUseTransportEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use &#8211; Transport equipment</link:label>
    <link:label id="lab_nbx_RightOfUseTransportEquipmentMember_label_en-US" xlink:label="lab_nbx_RightOfUseTransportEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use, Transport Equipment [Member]</link:label>
    <link:label id="lab_nbx_RightOfUseTransportEquipmentMember_documentation_en-US" xlink:label="lab_nbx_RightOfUseTransportEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use, Transport Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseTransportEquipmentMember" xlink:href="nbx-20211231.xsd#nbx_RightOfUseTransportEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_RightOfUseTransportEquipmentMember" xlink:to="lab_nbx_RightOfUseTransportEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_df7a7aed-f5dc-4326-8103-406650eb6ff6_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2016PerformanceMember_c8b3e02d-6e03-40e6-b8e7-ede9a466ce12_terseLabel_en-US" xlink:label="lab_nbx_BSA2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 performance</link:label>
    <link:label id="lab_nbx_BSA2016PerformanceMember_label_en-US" xlink:label="lab_nbx_BSA2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 Performance [Member]</link:label>
    <link:label id="lab_nbx_BSA2016PerformanceMember_documentation_en-US" xlink:label="lab_nbx_BSA2016PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_BSA2016PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2016PerformanceMember" xlink:to="lab_nbx_BSA2016PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_17e91891-b887-4d9c-b2cd-cec224c3fc42_terseLabel_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Ordinary</link:label>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA2017OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA2017OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2017 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA2017OrdinaryMember" xlink:to="lab_nbx_OSA2017OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_daf55b7d-bfea-4c9b-b89d-2b6ab282d911_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_29e50194-fb0b-443a-ad4a-c1a47f725e68_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial offering costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DefinedBenefitObligationPayablePeriod_3befd96d-dffe-4e5d-8ff9-528285162e8b_terseLabel_en-US" xlink:label="lab_nbx_DefinedBenefitObligationPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable, period</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationPayablePeriod_label_en-US" xlink:label="lab_nbx_DefinedBenefitObligationPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation, Payable, Period</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationPayablePeriod_documentation_en-US" xlink:label="lab_nbx_DefinedBenefitObligationPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation, Payable, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationPayablePeriod" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationPayablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DefinedBenefitObligationPayablePeriod" xlink:to="lab_nbx_DefinedBenefitObligationPayablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_d42a2dfe-516b-43fe-8805-64540ab96294_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary increase rate (including inflation)</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lab_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_f651e985-a44b-4501-a961-f44f0c79cb38_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Non-current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:to="lab_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_3dd02a39-d6bc-423b-a565-4795d0f90878_terseLabel_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:label id="lab_nbx_ResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development, Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ResearchAndDevelopmentTaxCredit" xlink:to="lab_nbx_ResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_57965f53-7b18-4c53-93ab-9ec0f00f9942_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_404e5486-63ec-404a-a21e-0c422bfb55ef_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingNumberOfPGE_e0fb66df-045f-4eb2-84a2-f657bbef3272_terseLabel_en-US" xlink:label="lab_nbx_BorrowingNumberOfPGE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, number of PGE</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfPGE_label_en-US" xlink:label="lab_nbx_BorrowingNumberOfPGE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of PGE</link:label>
    <link:label id="lab_nbx_BorrowingNumberOfPGE_documentation_en-US" xlink:label="lab_nbx_BorrowingNumberOfPGE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of PGE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfPGE" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfPGE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingNumberOfPGE" xlink:to="lab_nbx_BorrowingNumberOfPGE" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_da28b266-6e8c-4a4c-b747-01347bb9c03a_terseLabel_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in rent, fees, and other expenses, percentage</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_label_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Rent, Fees, And Other Expenses</link:label>
    <link:label id="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Increase (Decrease) In Rent, Fees, And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:to="lab_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_17140b64-0bcb-4393-b50d-a55d920f38f2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2020TaxYearMember_63774932-69f7-415f-84b2-ecdef435ce10_terseLabel_en-US" xlink:label="lab_nbx_A2020TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Tax Year</link:label>
    <link:label id="lab_nbx_A2020TaxYearMember_label_en-US" xlink:label="lab_nbx_A2020TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2020TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2020TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2020TaxYearMember" xlink:href="nbx-20211231.xsd#nbx_A2020TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2020TaxYearMember" xlink:to="lab_nbx_A2020TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_842dbc81-0072-4c3f-a5be-8bace1cb9ee4_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e01e9423-617e-4dc2-b77d-f247bd3cd432_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_6d622618-4c9e-42cf-9464-3228a9c824c7_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase / (Decrease) in other current liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a9dda407-5573-4f36-a5be-8a21d0624392_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense for the year</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017Member_12130c3f-aa47-44ee-9d34-d68fb27236b8_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017</link:label>
    <link:label id="lab_nbx_BSPCE2017Member_label_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017Member_documentation_en-US" xlink:label="lab_nbx_BSPCE2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017Member" xlink:to="lab_nbx_BSPCE2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfNewLeaseContracts_1c6cacc0-d065-41df-8c84-b7c266dfac5b_terseLabel_en-US" xlink:label="lab_nbx_NumberOfNewLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of new lease contracts</link:label>
    <link:label id="lab_nbx_NumberOfNewLeaseContracts_label_en-US" xlink:label="lab_nbx_NumberOfNewLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of New Lease Contracts</link:label>
    <link:label id="lab_nbx_NumberOfNewLeaseContracts_documentation_en-US" xlink:label="lab_nbx_NumberOfNewLeaseContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of New Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfNewLeaseContracts" xlink:href="nbx-20211231.xsd#nbx_NumberOfNewLeaseContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfNewLeaseContracts" xlink:to="lab_nbx_NumberOfNewLeaseContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE092014Member_2699f2b8-b346-4405-a180-42b525b20fdf_terseLabel_en-US" xlink:label="lab_nbx_BSPCE092014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 09-2014</link:label>
    <link:label id="lab_nbx_BSPCE092014Member_label_en-US" xlink:label="lab_nbx_BSPCE092014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 09-2014 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE092014Member_documentation_en-US" xlink:label="lab_nbx_BSPCE092014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 09-2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE092014Member" xlink:to="lab_nbx_BSPCE092014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA20152BMember_45f85dec-b8b0-4754-941f-c3e9ae5fee5e_terseLabel_en-US" xlink:label="lab_nbx_BSA20152BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2(b)</link:label>
    <link:label id="lab_nbx_BSA20152BMember_label_en-US" xlink:label="lab_nbx_BSA20152BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2 (b) [Member]</link:label>
    <link:label id="lab_nbx_BSA20152BMember_documentation_en-US" xlink:label="lab_nbx_BSA20152BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2015-2 (b)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA20152BMember" xlink:to="lab_nbx_BSA20152BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA20191Member_8e4461bd-bd1c-46a6-b159-a81b1e73d872_terseLabel_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2019-1</link:label>
    <link:label id="lab_nbx_OSA20191Member_label_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2019-1 [Member]</link:label>
    <link:label id="lab_nbx_OSA20191Member_documentation_en-US" xlink:label="lab_nbx_OSA20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2019-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA20191Member" xlink:to="lab_nbx_OSA20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f925fd48-3c4d-421c-a3f8-28d62e9ae960_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_c0fc9bca-6110-486a-a1d6-15625f304a46_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_LianBioNBTXR3Member_71bc801d-e839-460e-a498-f48fc80f13da_terseLabel_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio, NBTXR3</link:label>
    <link:label id="lab_nbx_LianBioNBTXR3Member_label_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio, NBTXR3 [Member]</link:label>
    <link:label id="lab_nbx_LianBioNBTXR3Member_documentation_en-US" xlink:label="lab_nbx_LianBioNBTXR3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LianBio, NBTXR3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_LianBioNBTXR3Member" xlink:to="lab_nbx_LianBioNBTXR3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheOneMember_cb9e1c68-c190-4944-8552-591d7469e64c_terseLabel_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche one</link:label>
    <link:label id="lab_nbx_TrancheOneMember_label_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_nbx_TrancheOneMember_documentation_en-US" xlink:label="lab_nbx_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheOneMember" xlink:to="lab_nbx_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_be0d07a7-7a37-4e3b-b94a-cd6193d1ae87_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_e068ad1f-7603-4153-ae0f-1ba3a2ccccca_terseLabel_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions</link:label>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_label_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Other Provisions [Member]</link:label>
    <link:label id="lab_nbx_NonCurrentOtherProvisionsMember_documentation_en-US" xlink:label="lab_nbx_NonCurrentOtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Other Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember" xlink:href="nbx-20211231.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonCurrentOtherProvisionsMember" xlink:to="lab_nbx_NonCurrentOtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2016OrdinaryMember_5a29bf49-71cc-462d-b2b6-7ad1ce125360_terseLabel_en-US" xlink:label="lab_nbx_BSA2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 ordinary</link:label>
    <link:label id="lab_nbx_BSA2016OrdinaryMember_label_en-US" xlink:label="lab_nbx_BSA2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_BSA2016OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_BSA2016OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2016 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_BSA2016OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2016OrdinaryMember" xlink:to="lab_nbx_BSA2016OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_f70765b1-0a06-4921-9e24-70474bf620c0_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to share-based payments</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_11cb6538-e013-4942-8f7a-ec36686a1dc2_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_cf1b9970-eb5b-46fc-a2b3-cbd7c3ab5ef5_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1c1a9c6d-a151-4090-9781-29f6da5273d1_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 1 and 3&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE082013Member_fb82e74e-27e0-42d9-a772-6c7904961441_terseLabel_en-US" xlink:label="lab_nbx_BSPCE082013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 08-2013</link:label>
    <link:label id="lab_nbx_BSPCE082013Member_label_en-US" xlink:label="lab_nbx_BSPCE082013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 08-2013 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE082013Member_documentation_en-US" xlink:label="lab_nbx_BSPCE082013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 08-2013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE082013Member" xlink:to="lab_nbx_BSPCE082013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IPOGreenShoeUSDollarMember_b54a8a0c-15f0-4d05-b8c5-7c040d4b6df1_terseLabel_en-US" xlink:label="lab_nbx_IPOGreenShoeUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO green shoe, US Dollar</link:label>
    <link:label id="lab_nbx_IPOGreenShoeUSDollarMember_label_en-US" xlink:label="lab_nbx_IPOGreenShoeUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Green Shoe, US Dollar [Member]</link:label>
    <link:label id="lab_nbx_IPOGreenShoeUSDollarMember_documentation_en-US" xlink:label="lab_nbx_IPOGreenShoeUSDollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Green Shoe, US Dollar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOGreenShoeUSDollarMember" xlink:href="nbx-20211231.xsd#nbx_IPOGreenShoeUSDollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IPOGreenShoeUSDollarMember" xlink:to="lab_nbx_IPOGreenShoeUSDollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSA2013Member_264c417b-1f2f-436b-91f9-cda8482f6f4f_terseLabel_en-US" xlink:label="lab_nbx_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2013</link:label>
    <link:label id="lab_nbx_BSA2013Member_label_en-US" xlink:label="lab_nbx_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2013 [Member]</link:label>
    <link:label id="lab_nbx_BSA2013Member_documentation_en-US" xlink:label="lab_nbx_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSA 2013</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSA2013Member" xlink:to="lab_nbx_BSA2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_CollaborationAgreementDomain_e52dfbf3-1d21-4e4b-880e-b5bddf3d2e33_terseLabel_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDomain_label_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
    <link:label id="lab_nbx_CollaborationAgreementDomain_documentation_en-US" xlink:label="lab_nbx_CollaborationAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_CollaborationAgreementDomain" xlink:to="lab_nbx_CollaborationAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_7b407fdf-3f4e-4ea8-ba65-e80b69c53785_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital issued</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_89fa1e20-a2da-4ed9-9823-2a8e2d083b9c_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_2c5c70f9-6293-4363-861d-7d7d9d5b617d_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionsMember_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial assumptions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember" xlink:to="lab_ifrs-full_ActuarialAssumptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_InterestFreeBPIFranceLoanMember_c4fc0854-2b1e-46d6-a65c-cb7899da8b86_terseLabel_en-US" xlink:label="lab_nbx_InterestFreeBPIFranceLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Bpifrance loan</link:label>
    <link:label id="lab_nbx_InterestFreeBPIFranceLoanMember_label_en-US" xlink:label="lab_nbx_InterestFreeBPIFranceLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-Free BPI France Loan [Member]</link:label>
    <link:label id="lab_nbx_InterestFreeBPIFranceLoanMember_documentation_en-US" xlink:label="lab_nbx_InterestFreeBPIFranceLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-Free BPI France Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeBPIFranceLoanMember" xlink:href="nbx-20211231.xsd#nbx_InterestFreeBPIFranceLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_InterestFreeBPIFranceLoanMember" xlink:to="lab_nbx_InterestFreeBPIFranceLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_ffddccbe-0aa5-433e-9452-fa5b1d04abea_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees with service conditions lifted</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Employees With Service Conditions Lifted</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_e68b8a78-ce2d-475c-b0ef-b647f1e68d74_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_A2018TaxYearMember_e181181f-ae81-42ff-9620-08d23d530fb2_terseLabel_en-US" xlink:label="lab_nbx_A2018TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Tax Year</link:label>
    <link:label id="lab_nbx_A2018TaxYearMember_label_en-US" xlink:label="lab_nbx_A2018TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Tax Year [Member]</link:label>
    <link:label id="lab_nbx_A2018TaxYearMember_documentation_en-US" xlink:label="lab_nbx_A2018TaxYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2018TaxYearMember" xlink:href="nbx-20211231.xsd#nbx_A2018TaxYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_A2018TaxYearMember" xlink:to="lab_nbx_A2018TaxYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_3efc9c3f-9614-4a0f-9d28-5560bd67cdbb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues and contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred income including current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_18925461-0699-4129-94d5-d7bca8e386cf_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OnerousContractsProvision_64476b23-60c8-4f6a-867b-71a853c1c1bd_terseLabel_en-US" xlink:label="lab_ifrs-full_OnerousContractsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Onerous contracts provision</link:label>
    <link:label id="lab_ifrs-full_OnerousContractsProvision_label_en-US" xlink:label="lab_ifrs-full_OnerousContractsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Onerous contracts provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OnerousContractsProvision" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OnerousContractsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OnerousContractsProvision" xlink:to="lab_ifrs-full_OnerousContractsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_6551faec-283b-4851-965f-0d1b8bf2e346_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_a3f13ed0-8c46-4d71-8e48-c53b9103fa7a_terseLabel_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net defined benefit liability if actuarial assumption of discount rates increase by 25%</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_label_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:label id="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_documentation_en-US" xlink:label="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lab_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AGA2020AndAGA2021Member_de6a66b9-5ed9-4778-bc19-b8ca47b0d9bc_terseLabel_en-US" xlink:label="lab_nbx_AGA2020AndAGA2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020 and AGA 2021</link:label>
    <link:label id="lab_nbx_AGA2020AndAGA2021Member_label_en-US" xlink:label="lab_nbx_AGA2020AndAGA2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020 and AGA 2021 [Member]</link:label>
    <link:label id="lab_nbx_AGA2020AndAGA2021Member_documentation_en-US" xlink:label="lab_nbx_AGA2020AndAGA2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AGA 2020 and AGA 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020AndAGA2021Member" xlink:href="nbx-20211231.xsd#nbx_AGA2020AndAGA2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AGA2020AndAGA2021Member" xlink:to="lab_nbx_AGA2020AndAGA2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_InterestFreeLoanBPIFranceMember_4ecd8ce2-ef4f-497f-ac37-0eec2712dc8b_terseLabel_en-US" xlink:label="lab_nbx_InterestFreeLoanBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Bpifrance loan</link:label>
    <link:label id="lab_nbx_InterestFreeLoanBPIFranceMember_label_en-US" xlink:label="lab_nbx_InterestFreeLoanBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Loan, BPI France [Member]</link:label>
    <link:label id="lab_nbx_InterestFreeLoanBPIFranceMember_documentation_en-US" xlink:label="lab_nbx_InterestFreeLoanBPIFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-free Loan, BPI France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeLoanBPIFranceMember" xlink:href="nbx-20211231.xsd#nbx_InterestFreeLoanBPIFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_InterestFreeLoanBPIFranceMember" xlink:to="lab_nbx_InterestFreeLoanBPIFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_d26ccf3a-97b8-4099-a0bf-cba740e08ac9_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transfers, financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_56b50c33-ce72-4c64-b9f0-c87d48b76255_terseLabel_en-US" xlink:label="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, subsequent period bearing interest</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_label_en-US" xlink:label="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term, Subsequent Period Bearing Interest</link:label>
    <link:label id="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_documentation_en-US" xlink:label="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Maturity Term, Subsequent Period Bearing Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:to="lab_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_8999b322-df99-4a9a-aaec-62c02651cc7c_terseLabel_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_documentation_en-US" xlink:label="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:to="lab_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_57641771-81d7-477a-8409-5a3b876af1bc_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_ea7c4018-f01d-4315-a00b-8381670cc7d3_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_label_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCapitalCommitments" xlink:to="lab_ifrs-full_ContractualCapitalCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_0821c5e1-290a-4159-8618-17b99b709e32_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsTable_dac1c99f-6a5c-401b-8f72-1c33f79466c0_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_nbx_DisclosureOfCashAndCashEquivalentsTable_documentation_en-US" xlink:label="lab_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:to="lab_nbx_DisclosureOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NumberOfParentEntities_97192673-a0b2-4f0c-a2e8-4f8fb5982e70_terseLabel_en-US" xlink:label="lab_nbx_NumberOfParentEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parent entities</link:label>
    <link:label id="lab_nbx_NumberOfParentEntities_label_en-US" xlink:label="lab_nbx_NumberOfParentEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Parent Entities</link:label>
    <link:label id="lab_nbx_NumberOfParentEntities_documentation_en-US" xlink:label="lab_nbx_NumberOfParentEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Parent Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfParentEntities" xlink:href="nbx-20211231.xsd#nbx_NumberOfParentEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NumberOfParentEntities" xlink:to="lab_nbx_NumberOfParentEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2017PerformanceMember_9477557b-b956-4f5a-bb8c-d5998e00be9f_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Performance</link:label>
    <link:label id="lab_nbx_BSPCE2017PerformanceMember_label_en-US" xlink:label="lab_nbx_BSPCE2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Performance [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2017PerformanceMember_documentation_en-US" xlink:label="lab_nbx_BSPCE2017PerformanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2017 Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017PerformanceMember" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017PerformanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2017PerformanceMember" xlink:to="lab_nbx_BSPCE2017PerformanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_c87d8771-d4b9-47e3-bff7-d087a0d55088_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposals</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for gain (loss) on disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_BSPCE2016Member_e7ca1ea2-8cdd-42c8-ab3b-88a9fce94ebc_terseLabel_en-US" xlink:label="lab_nbx_BSPCE2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016</link:label>
    <link:label id="lab_nbx_BSPCE2016Member_label_en-US" xlink:label="lab_nbx_BSPCE2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016 [Member]</link:label>
    <link:label id="lab_nbx_BSPCE2016Member_documentation_en-US" xlink:label="lab_nbx_BSPCE2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BSPCE 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016Member" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_BSPCE2016Member" xlink:to="lab_nbx_BSPCE2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a7f48aa6-8fe2-4978-a730-32e6f7fb46c6_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issuable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_47341e15-324b-4271-94fa-3794e80f2401_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 3 and 5&#160;years</link:label>
    <link:label id="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than three years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_0508b5c3-c232-4adf-9d4c-80489b201671_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_d41d489e-72a3-4daf-ae51-bc3109fcb0f9_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_e31cc304-bab3-4330-b39d-ac966fd6b828_terseLabel_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting requirements, maximum percentage exercised</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_label_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Maximum Percentage Exercised</link:label>
    <link:label id="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_documentation_en-US" xlink:label="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Maximum Percentage Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:to="lab_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_63a31c01-005c-4cf3-893e-4826fe05b13c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_7cc982f7-418c-4ad6-883d-567e5a8c67d4_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange losses</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_23074b5e-a938-4f9a-8571-7728afd8f39b_terseLabel_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment upon second regulatory approval</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_label_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment Upon Second Regulatory Approval</link:label>
    <link:label id="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_documentation_en-US" xlink:label="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Commitments, Milestone Payment Upon Second Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:to="lab_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OpenTaxYearDomain_2c547b52-6342-4a0a-a084-f6eeee155bc7_terseLabel_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year [Domain]</link:label>
    <link:label id="lab_nbx_OpenTaxYearDomain_label_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year [Domain]</link:label>
    <link:label id="lab_nbx_OpenTaxYearDomain_documentation_en-US" xlink:label="lab_nbx_OpenTaxYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OpenTaxYearDomain" xlink:to="lab_nbx_OpenTaxYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_377b9b6c-c4ea-41ad-a927-487d8659c0ba_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_1fa78b8d-7c4f-4ebe-82fd-025a6c7c6348_terseLabel_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 O</link:label>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_label_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 Ordinary [Member]</link:label>
    <link:label id="lab_nbx_OSA202104OrdinaryMember_documentation_en-US" xlink:label="lab_nbx_OSA202104OrdinaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OSA 2021-04 Ordinary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_OSA202104OrdinaryMember" xlink:to="lab_nbx_OSA202104OrdinaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f1809ff7-a99a-40b5-84df-86f70ac96742_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_a506211e-9619-48b4-8473-9b12f4e414ba_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_TrancheDomain_22256a64-7438-4683-832f-208735317ea0_terseLabel_en-US" xlink:label="lab_nbx_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_nbx_TrancheDomain_label_en-US" xlink:label="lab_nbx_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche [Domain]</link:label>
    <link:label id="lab_nbx_TrancheDomain_documentation_en-US" xlink:label="lab_nbx_TrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_TrancheDomain" xlink:to="lab_nbx_TrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_734ba9f3-fd42-44a0-ad67-5840f07750c4_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_908308a1-22b3-4ba4-bb3f-0300dd8aa07d_terseLabel_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in rent, fees, and other expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_label_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Purchases, Fees, And Other Expenses</link:label>
    <link:label id="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_documentation_en-US" xlink:label="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Purchases, Fees, And Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:to="lab_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_987b7763-41a4-4a79-9c03-7f8b9f6cc102_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConcentrationsOfRiskAxis_931318d1-5753-4a4f-817f-ccec4a0dbce6_terseLabel_en-US" xlink:label="lab_ifrs-full_ConcentrationsOfRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of risk [axis]</link:label>
    <link:label id="lab_ifrs-full_ConcentrationsOfRiskAxis_label_en-US" xlink:label="lab_ifrs-full_ConcentrationsOfRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of risk [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConcentrationsOfRiskAxis" xlink:to="lab_ifrs-full_ConcentrationsOfRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_0d61121a-7e0d-40ff-8c63-8adb9b0328df_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_6a453295-a5c0-4b84-9037-2a3e483f1e95_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_b6b9e806-1033-4dd0-a988-5556c70b1500_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_b802a18f-40bd-46f9-a107-1c11c0768052_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionsAbstract_87925351-b26c-4c75-9277-b8201e2e60cf_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions [abstract]</link:label>
    <link:label id="lab_ifrs-full_ProvisionsAbstract_label_en-US" xlink:label="lab_ifrs-full_ProvisionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionsAbstract" xlink:to="lab_ifrs-full_ProvisionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_5ed69a03-521b-481e-93c9-80cda40b5dd0_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of changes in research tax credit receivables</link:label>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Research Tax Credit Receivables [Table Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Changes In Research Tax Credit Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:to="lab_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_fd42ee48-5295-4ade-9001-427327dca545_terseLabel_en-US" xlink:label="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:label id="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:href="nbx-20211231.xsd#nbx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:to="lab_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_adc783d4-bf18-4412-85ae-5521702359c6_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_5413bb08-34c6-4ef2-93be-c232214f9e99_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant transactions</link:label>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_label_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Transactions [Text Block]</link:label>
    <link:label id="lab_nbx_DisclosureOfSignificantTransactionsTextBlock_documentation_en-US" xlink:label="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfSignificantTransactionsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lab_nbx_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_9b6ef9f8-214d-4d9e-9f0c-645cc4967819_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal received</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_4d75894d-1d02-42e5-a598-420325af2cd8_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of lease</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_5c1de6e1-a774-4ffa-871f-462ade433712_terseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PGE Loan, HSBC France</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_9fae4503-99ff-4503-a010-897d7ba97c84_verboseLabel_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSBC "PGE"</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_label_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France [Member]</link:label>
    <link:label id="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_documentation_en-US" xlink:label="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Dilutive Financing Agreement, HSBC France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:to="lab_nbx_NonDilutiveFinancingAgreementHSBCFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_b47c8a84-30e2-4986-8995-9c5178ee7f2c_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_28b3e85f-c6f8-4fa5-a44c-ded5097cf354_terseLabel_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount to be advanced</link:label>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_label_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, Authorized Amount To Be Advanced</link:label>
    <link:label id="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced_documentation_en-US" xlink:label="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, Authorized Amount To Be Advanced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:href="nbx-20211231.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:to="lab_nbx_AdvancesAuthorizedAmountToBeAdvanced" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_004c570e-9b80-4952-8940-8305886b8263_terseLabel_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_label_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Line Items]</link:label>
    <link:label id="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_documentation_en-US" xlink:label="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:to="lab_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_8e539158-5648-4d7f-bc76-f7d393a342ff_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_373c559e-8e62-4280-8bac-713c76cae029_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_0ba09950-298e-46ce-92e4-045029340f0c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issuable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_FormerEmployeesMember_1294005a-11df-4f92-92bc-da73c2470428_terseLabel_en-US" xlink:label="lab_nbx_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former employees</link:label>
    <link:label id="lab_nbx_FormerEmployeesMember_label_en-US" xlink:label="lab_nbx_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Employees [Member]</link:label>
    <link:label id="lab_nbx_FormerEmployeesMember_documentation_en-US" xlink:label="lab_nbx_FormerEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerEmployeesMember" xlink:href="nbx-20211231.xsd#nbx_FormerEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_FormerEmployeesMember" xlink:to="lab_nbx_FormerEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbx_AdvancesReceivedDefermentPeriod_534d47e3-2490-43d5-afe7-294de288d459_terseLabel_en-US" xlink:label="lab_nbx_AdvancesReceivedDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances, deferment period</link:label>
    <link:label id="lab_nbx_AdvancesReceivedDefermentPeriod_label_en-US" xlink:label="lab_nbx_AdvancesReceivedDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances Received, Deferment Period</link:label>
    <link:label id="lab_nbx_AdvancesReceivedDefermentPeriod_documentation_en-US" xlink:label="lab_nbx_AdvancesReceivedDefermentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances Received, Deferment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedDefermentPeriod" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedDefermentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbx_AdvancesReceivedDefermentPeriod" xlink:to="lab_nbx_AdvancesReceivedDefermentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_7254da0e-475f-4ef7-946b-7f011d74e649_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>nbx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7e1d99-9431-4421-b952-6074aa1b405d,g:3ab8e14d-d2ce-402b-b0d7-70ce0aac647a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nanobiotix.com/role/Coverpage" xlink:type="simple" xlink:href="nbx-20211231.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_233fba95-07b1-48de-ba1c-cfd98f49ec2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_233fba95-07b1-48de-ba1c-cfd98f49ec2e" xlink:to="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:to="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_ce44b578-0a5f-426d-bf23-f7c63f67fae1" xlink:to="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember_db0faece-0811-4276-b237-9a07542f493e" xlink:href="nbx-20211231.xsd#nbx_AmericanDepositorySharesNASDAQStockMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_b1cbd0b3-ee32-4ccf-abe5-11d27a57a227" xlink:to="loc_nbx_AmericanDepositorySharesNASDAQStockMarketMember_db0faece-0811-4276-b237-9a07542f493e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_116bd493-b9d7-481d-9115-bd2b295501be" xlink:to="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_180988c2-b899-40f1-b786-d77020776df1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_09a0fcc5-da31-4e14-9f6a-d39c97a55d62" xlink:to="loc_dei_BusinessContactMember_180988c2-b899-40f1-b786-d77020776df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_ae6cbd19-737c-49ba-a6a8-c5002e041065" xlink:to="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_16ede2f6-f48b-4adb-81af-642eeb9f5d31" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentType_16ede2f6-f48b-4adb-81af-642eeb9f5d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_c201005a-7453-458d-b9ac-134a12c36c11" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentRegistrationStatement_c201005a-7453-458d-b9ac-134a12c36c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_63df536b-bc07-4ffd-b87b-7f9e611683ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentAnnualReport_63df536b-bc07-4ffd-b87b-7f9e611683ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_86ad0a0d-e0c0-47df-a5ef-ec72ac0d09ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentPeriodEndDate_86ad0a0d-e0c0-47df-a5ef-ec72ac0d09ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7c6788d0-c8c4-4fc6-996d-b782ebd116d0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_CurrentFiscalYearEndDate_7c6788d0-c8c4-4fc6-996d-b782ebd116d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_38ac8143-d44f-4011-9945-5540430cfea7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentTransitionReport_38ac8143-d44f-4011-9945-5540430cfea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_f69be603-9676-4fd3-81d0-1f24d997a6b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentShellCompanyReport_f69be603-9676-4fd3-81d0-1f24d997a6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_89165e8f-b6cf-478a-95f2-2f3c5b6f126e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityFileNumber_89165e8f-b6cf-478a-95f2-2f3c5b6f126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e7ad8058-7b3c-43bd-a442-968f728b2621" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityRegistrantName_e7ad8058-7b3c-43bd-a442-968f728b2621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a58bd871-e338-4adf-990f-271189e2e3ea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a58bd871-e338-4adf-990f-271189e2e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9a8139d4-a9c4-468e-8afd-088e9e5c0b54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressAddressLine1_9a8139d4-a9c4-468e-8afd-088e9e5c0b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_88502430-55ac-49e9-998d-fb6e0d256ed8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressPostalZipCode_88502430-55ac-49e9-998d-fb6e0d256ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1afe21f0-ad5b-46cc-ae08-a2477934d41d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressCityOrTown_1afe21f0-ad5b-46cc-ae08-a2477934d41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_66ca2e4f-847d-4710-9164-cb58b5e1671b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityAddressCountry_66ca2e4f-847d-4710-9164-cb58b5e1671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_878aad00-26b6-40ee-8c14-78812b67253d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_ContactPersonnelName_878aad00-26b6-40ee-8c14-78812b67253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2de6200e-1808-479e-8610-e97134a09880" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_CityAreaCode_2de6200e-1808-479e-8610-e97134a09880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_12a36aea-c257-455a-be44-2d329e059a96" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_LocalPhoneNumber_12a36aea-c257-455a-be44-2d329e059a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber_65ad74c4-8ae4-4b06-9b49-e9af0d4a3829" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_ContactPersonnelFaxNumber_65ad74c4-8ae4-4b06-9b49-e9af0d4a3829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7ffde44e-b9b6-4596-a3d7-4f8e003faa60" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_Security12bTitle_7ffde44e-b9b6-4596-a3d7-4f8e003faa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_295d5f4c-34d6-44ff-b0da-eb9ee1a840e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_TradingSymbol_295d5f4c-34d6-44ff-b0da-eb9ee1a840e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ce0ed277-02c0-4d63-8d8e-2101bc343798" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_SecurityExchangeName_ce0ed277-02c0-4d63-8d8e-2101bc343798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1103b3f8-ce27-4b29-bccd-73ea11e464c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1103b3f8-ce27-4b29-bccd-73ea11e464c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_31b8a222-8ade-4d33-b5b0-a52da44761db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_31b8a222-8ade-4d33-b5b0-a52da44761db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d08cf168-9ea4-4c81-bf03-695fa33bfc2c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityVoluntaryFilers_d08cf168-9ea4-4c81-bf03-695fa33bfc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_19a8a6c9-f4ee-41ab-aac1-91bb070e87e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCurrentReportingStatus_19a8a6c9-f4ee-41ab-aac1-91bb070e87e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a555b0ee-5f1c-45d2-86a8-bd47cf7e01d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityInteractiveDataCurrent_a555b0ee-5f1c-45d2-86a8-bd47cf7e01d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e5c216e4-c1a1-4319-9501-f7321b6d44a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityFilerCategory_e5c216e4-c1a1-4319-9501-f7321b6d44a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82aea762-40ea-4540-bfcd-7a78ce8c4b0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityEmergingGrowthCompany_82aea762-40ea-4540-bfcd-7a78ce8c4b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c3f90e6c-6cf8-4bef-8bae-21ca603cdb3d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityExTransitionPeriod_c3f90e6c-6cf8-4bef-8bae-21ca603cdb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_728ed74c-5ea5-42f2-8ae3-e6cdcaecb826" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_IcfrAuditorAttestationFlag_728ed74c-5ea5-42f2-8ae3-e6cdcaecb826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_822f0df3-dfe6-4af1-ab24-d1bf313aa410" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentAccountingStandard_822f0df3-dfe6-4af1-ab24-d1bf313aa410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b1efcbc1-0326-4e87-8781-a2d481bc8359" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityShellCompany_b1efcbc1-0326-4e87-8781-a2d481bc8359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4118bf83-a4ff-4260-ae00-d56b52ca130b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_EntityCentralIndexKey_4118bf83-a4ff-4260-ae00-d56b52ca130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f346e63b-0f7d-4971-afee-efac6263742f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentFiscalYearFocus_f346e63b-0f7d-4971-afee-efac6263742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f0978ca1-0cac-421c-8bfe-f8ea533ca914" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f0978ca1-0cac-421c-8bfe-f8ea533ca914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dc4a7687-3777-471c-b713-955738455e67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_AmendmentFlag_dc4a7687-3777-471c-b713-955738455e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_752135b7-1101-4c7e-ae60-59b36d050e2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3107bfb3-c7ac-45c8-bd44-04404eb97c4a" xlink:to="loc_dei_NoTradingSymbolFlag_752135b7-1101-4c7e-ae60-59b36d050e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/AuditInformation" xlink:type="simple" xlink:href="nbx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AuditorInformationAbstract_28398c29-6c6c-4a18-b9af-3097a90b41b1" xlink:href="nbx-20211231.xsd#nbx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5f20ff81-a0e0-4724-a1ab-76bbbbc2d0d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AuditorInformationAbstract_28398c29-6c6c-4a18-b9af-3097a90b41b1" xlink:to="loc_dei_AuditorName_5f20ff81-a0e0-4724-a1ab-76bbbbc2d0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_9f2883db-92e7-4959-9c85-7a772338ab38" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AuditorInformationAbstract_28398c29-6c6c-4a18-b9af-3097a90b41b1" xlink:to="loc_dei_AuditorFirmId_9f2883db-92e7-4959-9c85-7a772338ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_58a2dd5d-a1a8-4755-9758-2b29a77b3b52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AuditorInformationAbstract_28398c29-6c6c-4a18-b9af-3097a90b41b1" xlink:to="loc_dei_AuditorLocation_58a2dd5d-a1a8-4755-9758-2b29a77b3b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_bc7439b0-53bd-48ec-909c-fec8bebc822a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_86134955-cc7f-419d-b9a4-6258943dd2d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_bc7439b0-53bd-48ec-909c-fec8bebc822a" xlink:to="loc_ifrs-full_AssetsAbstract_86134955-cc7f-419d-b9a4-6258943dd2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_86134955-cc7f-419d-b9a4-6258943dd2d8" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7532e6e9-d847-4822-99e1-28d79ea27189" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_7532e6e9-d847-4822-99e1-28d79ea27189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_bc1f1c64-2b5e-4932-ac06-795b882f96ca" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_bc1f1c64-2b5e-4932-ac06-795b882f96ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_b747c993-1d3e-474b-bf24-791487e9e073" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_b747c993-1d3e-474b-bf24-791487e9e073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_b7317e40-d28f-4e7c-9d7c-0540e66eb2ed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e702a661-4bf3-41bd-88d0-23c05f73d86d" xlink:to="loc_ifrs-full_NoncurrentAssets_b7317e40-d28f-4e7c-9d7c-0540e66eb2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_86134955-cc7f-419d-b9a4-6258943dd2d8" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_8670103c-2b26-4be0-aedb-04f05ec53a49" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:to="loc_ifrs-full_CurrentTradeReceivables_8670103c-2b26-4be0-aedb-04f05ec53a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_320a4bad-ba32-44fe-9299-ea85746b7d82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:to="loc_ifrs-full_OtherCurrentAssets_320a4bad-ba32-44fe-9299-ea85746b7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_72033868-d3a6-4265-a903-899ca130dca3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:to="loc_ifrs-full_CashAndCashEquivalents_72033868-d3a6-4265-a903-899ca130dca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_1906d2c1-75c8-47f1-bcc5-830cb459ec53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_9a4f12d6-cce8-4477-8819-6e6d344183ad" xlink:to="loc_ifrs-full_CurrentAssets_1906d2c1-75c8-47f1-bcc5-830cb459ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_81a150cd-058f-49ef-996a-135a00862aa1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_86134955-cc7f-419d-b9a4-6258943dd2d8" xlink:to="loc_ifrs-full_Assets_81a150cd-058f-49ef-996a-135a00862aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_bc7439b0-53bd-48ec-909c-fec8bebc822a" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:to="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_599cae98-9112-4334-97e3-8fca47b7a739" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_IssuedCapital_599cae98-9112-4334-97e3-8fca47b7a739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_71a4b3fe-a6ef-4d78-b8ce-caf5364118aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_SharePremium_71a4b3fe-a6ef-4d78-b8ce-caf5364118aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_c1205f3f-da6d-477c-8083-afe7c20af6fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_c1205f3f-da6d-477c-8083-afe7c20af6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_9875e18c-690c-4d7e-9294-c06415236923" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_TreasuryShares_9875e18c-690c-4d7e-9294-c06415236923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_634473f6-1fec-47e1-9c9a-9aa79e35d496" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_OtherReserves_634473f6-1fec-47e1-9c9a-9aa79e35d496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriod_1a939d85-88d4-4c38-952f-31307708e3b3" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_nbx_NetLossForThePeriod_1a939d85-88d4-4c38-952f-31307708e3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4ec646ac-4cf3-430c-b508-e94321f57b63" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_8494ab52-4096-4253-9198-040e0f9414be" xlink:to="loc_ifrs-full_Equity_4ec646ac-4cf3-430c-b508-e94321f57b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_558b2c31-1d67-4204-9f70-f15b3065bf02" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_558b2c31-1d67-4204-9f70-f15b3065bf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_41cdd9fc-5d87-4dcb-ab99-4b9a725d54b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_558b2c31-1d67-4204-9f70-f15b3065bf02" xlink:to="loc_ifrs-full_NoncurrentProvisions_41cdd9fc-5d87-4dcb-ab99-4b9a725d54b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_ce5ae19e-fdb3-4434-9669-80514f1e3234" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_558b2c31-1d67-4204-9f70-f15b3065bf02" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_ce5ae19e-fdb3-4434-9669-80514f1e3234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_3c2362f0-d635-401c-823e-1d1ed2d21a99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_558b2c31-1d67-4204-9f70-f15b3065bf02" xlink:to="loc_ifrs-full_NoncurrentLiabilities_3c2362f0-d635-401c-823e-1d1ed2d21a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_1ad6ede0-0cad-4047-b50c-71e1613af7da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_CurrentProvisions_1ad6ede0-0cad-4047-b50c-71e1613af7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_9aa3f57d-0901-4e78-ba3f-737c0557c25c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_9aa3f57d-0901-4e78-ba3f-737c0557c25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_ae500238-595c-430a-acd7-40b749cca6c3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_ae500238-595c-430a-acd7-40b749cca6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_67973d00-be9c-4b39-8f84-a84ae4415073" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_67973d00-be9c-4b39-8f84-a84ae4415073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_6a8c7136-13e5-4836-b67a-d3e2b0f2aad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_6a8c7136-13e5-4836-b67a-d3e2b0f2aad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_7248c11e-2705-48b0-84d2-417736e4fbf7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_471c6840-6860-4ffd-94f2-41cbad397b28" xlink:to="loc_ifrs-full_CurrentLiabilities_7248c11e-2705-48b0-84d2-417736e4fbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_713bfa47-b7e6-4c50-8bfd-89c95d589c0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_114ca36b-0b83-44e2-b614-4db8b1f300b8" xlink:to="loc_ifrs-full_EquityAndLiabilities_713bfa47-b7e6-4c50-8bfd-89c95d589c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDOPERATIONS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_7f870dae-9c01-4e78-9e90-a9044f91e864" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_RevenueAbstract_7f870dae-9c01-4e78-9e90-a9044f91e864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_040025b9-f46f-4e1c-ba31-71c3ed782f1a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_7f870dae-9c01-4e78-9e90-a9044f91e864" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_040025b9-f46f-4e1c-ba31-71c3ed782f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_72abdcb6-4904-44da-b337-9a833eef0306" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_7f870dae-9c01-4e78-9e90-a9044f91e864" xlink:to="loc_ifrs-full_OtherIncome_72abdcb6-4904-44da-b337-9a833eef0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_27f4c0c5-7ba1-4b44-9672-3686104ae400" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_7f870dae-9c01-4e78-9e90-a9044f91e864" xlink:to="loc_ifrs-full_Revenue_27f4c0c5-7ba1-4b44-9672-3686104ae400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_71032538-0b73-40f4-bce7-24d5968f5773" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_71032538-0b73-40f4-bce7-24d5968f5773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_4da3f434-191c-4dd2-98ff-0487177aef5a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_4da3f434-191c-4dd2-98ff-0487177aef5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_b9924119-1cd2-4753-ad1c-081f0e58afe7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_b9924119-1cd2-4753-ad1c-081f0e58afe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_2f1e7fe0-2daf-430a-8630-c84d630479ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_OperatingExpense_2f1e7fe0-2daf-430a-8630-c84d630479ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_fb6f3e21-4d87-45a7-9e2a-056f5d3afa00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_fb6f3e21-4d87-45a7-9e2a-056f5d3afa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_09b338cf-33c9-4b17-9928-6678680923ac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_FinanceIncome_09b338cf-33c9-4b17-9928-6678680923ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_3ea060a8-4e1d-48c6-a8e5-57e9fc612209" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_FinanceCosts_3ea060a8-4e1d-48c6-a8e5-57e9fc612209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_0eb96e5c-f408-4533-aa28-34ad31e4d9f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_FinanceIncomeCost_0eb96e5c-f408-4533-aa28-34ad31e4d9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_703fc4c9-bb0b-4d56-9692-aa50df5a2ac4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_703fc4c9-bb0b-4d56-9692-aa50df5a2ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7a537d6a-243c-488f-b68e-ab4d89cf5a0b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_ProfitLoss_7a537d6a-243c-488f-b68e-ab4d89cf5a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_6e29d658-0031-4701-9132-d8a96fd4b127" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_6e29d658-0031-4701-9132-d8a96fd4b127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_9596077a-f1f9-4cd3-8ced-33444b40e940" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3ab988ba-d73b-481f-89cb-cdc2cc87b008" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_9596077a-f1f9-4cd3-8ced-33444b40e940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7c088a27-b71b-4977-9ab8-0d5de70d350d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_ProfitLoss_7c088a27-b71b-4977-9ab8-0d5de70d350d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_5dcf8f96-ca45-4e90-8e54-63582a3c84bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_5dcf8f96-ca45-4e90-8e54-63582a3c84bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_38380c27-0144-482d-b8e7-c065e1556107" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome_38380c27-0144-482d-b8e7-c065e1556107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_567f52fa-975e-454e-a972-b17eea1ce37e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_567f52fa-975e-454e-a972-b17eea1ce37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_215f34ce-48f0-4e8a-8dd2-49ef780883bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_215f34ce-48f0-4e8a-8dd2-49ef780883bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_09e4fe02-b1b6-4cbe-9cce-cd23743d3d2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_09e4fe02-b1b6-4cbe-9cce-cd23743d3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_bb31a200-3fc0-45e5-8c7e-b966c078bc95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_bb31a200-3fc0-45e5-8c7e-b966c078bc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_29f4686a-4cf6-428d-a402-04a9dae87c30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_3bfdc982-dc98-47e1-b7de-6bc8d541d3a9" xlink:to="loc_ifrs-full_ComprehensiveIncome_29f4686a-4cf6-428d-a402-04a9dae87c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_bbb60f72-7030-4ef9-ab3b-e7d0d62543a3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_bbb60f72-7030-4ef9-ab3b-e7d0d62543a3" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_20e0706e-025d-493c-8616-2ad345ec995a" xlink:to="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_c18b3649-062f-447a-a8a6-01b5efc25909" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_IssuedCapitalMember_c18b3649-062f-447a-a8a6-01b5efc25909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_5656b14b-0a90-4ea8-ba6b-08ae4feed1f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_SharePremiumMember_5656b14b-0a90-4ea8-ba6b-08ae4feed1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e3ad835-56b6-4167-b9f4-1b2d71c9b390" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e3ad835-56b6-4167-b9f4-1b2d71c9b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_230612a1-ee5b-4113-83d9-628317c7a456" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_TreasurySharesMember_230612a1-ee5b-4113-83d9-628317c7a456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_19401c4c-94db-4043-a45f-73b258dc32d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_ifrs-full_OtherReservesMember_19401c4c-94db-4043-a45f-73b258dc32d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NetLossForThePeriodMember_a7040032-9d32-48fc-95d6-2340c7af6885" xlink:href="nbx-20211231.xsd#nbx_NetLossForThePeriodMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_08fbeb04-f2b7-4b7b-9477-e8e654d87256" xlink:to="loc_nbx_NetLossForThePeriodMember_a7040032-9d32-48fc-95d6-2340c7af6885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_ed12ba95-b28d-4bcf-a3d3-bcf7982fb28f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_256934cb-251f-4fcc-893a-12b584cc8d1f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_256934cb-251f-4fcc-893a-12b584cc8d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5d910134-833a-4a08-a640-715c369cdda8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_Equity_5d910134-833a-4a08-a640-715c369cdda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_16b48172-556b-495e-8079-9bfb9014432f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ProfitLoss_16b48172-556b-495e-8079-9bfb9014432f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d5e76eac-d20e-43b7-8d02-877001fe930f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d5e76eac-d20e-43b7-8d02-877001fe930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_4b448149-449c-4c37-92ed-0f4cc0ec0e23" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_4b448149-449c-4c37-92ed-0f4cc0ec0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_47b577a1-a3d3-4a72-9827-0c88107b290b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ComprehensiveIncome_47b577a1-a3d3-4a72-9827-0c88107b290b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AllocationOfPriorPeriodLoss_e393faa3-833c-47b2-9682-064e6e2a0d51" xlink:href="nbx-20211231.xsd#nbx_AllocationOfPriorPeriodLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_AllocationOfPriorPeriodLoss_e393faa3-833c-47b2-9682-064e6e2a0d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_5849cceb-948a-4883-9675-5232c366400a" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_5849cceb-948a-4883-9675-5232c366400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_6e1743f5-3df9-46df-a275-5f9f8c1d8a64" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IssueOfEquity_6e1743f5-3df9-46df-a275-5f9f8c1d8a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_7819e3c6-9bb2-4973-827e-c099d162de34" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants_7819e3c6-9bb2-4973-827e-c099d162de34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_47c582ad-7e5f-4aea-ab58-a45691602846" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_47c582ad-7e5f-4aea-ab58-a45691602846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_f4e23c11-0734-4227-83f3-0754f96c95b9" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_f4e23c11-0734-4227-83f3-0754f96c95b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0d74e72f-1256-4f74-b4d6-0898050b929e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0d74e72f-1256-4f74-b4d6-0898050b929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_da5e255f-4235-476d-8bb8-f982eb0921c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_da5e255f-4235-476d-8bb8-f982eb0921c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_7bb0e8a1-af08-4b4a-a816-a5a8872b716a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_7bb0e8a1-af08-4b4a-a816-a5a8872b716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_65a52c95-c71c-457d-85eb-cc651dea4fc4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_65a52c95-c71c-457d-85eb-cc651dea4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d4dd85f3-c8c5-4750-acea-951972c36272" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_e8179802-fbdc-4910-b29d-1f0f88587e4b" xlink:to="loc_ifrs-full_Equity_d4dd85f3-c8c5-4750-acea-951972c36272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="simple" xlink:href="nbx-20211231.xsd#STATEMENTSOFCONSOLIDATEDCASHFLOWS"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_2a085d20-5dfa-418e-803c-9eaa9b22421c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_2a085d20-5dfa-418e-803c-9eaa9b22421c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4847d1e5-a145-4f15-bd5d-eaa5883140b1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_2a085d20-5dfa-418e-803c-9eaa9b22421c" xlink:to="loc_ifrs-full_ProfitLoss_4847d1e5-a145-4f15-bd5d-eaa5883140b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_2a085d20-5dfa-418e-803c-9eaa9b22421c" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_a50510c1-d8c6-43a8-81b3-d2c20ecf6a42" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_a50510c1-d8c6-43a8-81b3-d2c20ecf6a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_a8801057-02a5-4df1-8757-3056f4e2fd27" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_a8801057-02a5-4df1-8757-3056f4e2fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_8337ac29-dac2-41a2-b404-b630c3d5ff27" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_8337ac29-dac2-41a2-b404-b630c3d5ff27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_8fd4162a-e566-4596-bd92-ed2959358d71" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_8fd4162a-e566-4596-bd92-ed2959358d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_17658f74-c9d5-4d2a-a695-9a1c6bb2cbf2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_17658f74-c9d5-4d2a-a695-9a1c6bb2cbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_5539196a-7f40-4865-a191-cb1edc38ac37" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset_5539196a-7f40-4865-a191-cb1edc38ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_4ab4b6f8-438a-4466-a15b-82d24cfc9db4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities_4ab4b6f8-438a-4466-a15b-82d24cfc9db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_5f5b95fa-44da-499f-9b22-5ad42c04545f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_5f5b95fa-44da-499f-9b22-5ad42c04545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8c7dce08-0506-4f3b-82f3-4e18383d1148" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8c7dce08-0506-4f3b-82f3-4e18383d1148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_71063f1a-7771-4a84-b6d0-07674467393d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_71063f1a-7771-4a84-b6d0-07674467393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_9ee6eef7-5bd3-47ac-af62-d8ef1a1db6ea" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax_9ee6eef7-5bd3-47ac-af62-d8ef1a1db6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_6f7bbcc5-4e58-4fc4-916b-9a5ce84c615a" xlink:href="nbx-20211231.xsd#nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables_6f7bbcc5-4e58-4fc4-916b-9a5ce84c615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_382a6285-30df-474b-a5a9-bd349fd7f4d1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_382a6285-30df-474b-a5a9-bd349fd7f4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_97093a07-ff60-4dc2-b588-917f5b084d20" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_97093a07-ff60-4dc2-b588-917f5b084d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_4d9ec2d9-75ca-46c7-b829-92daa9e34390" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_4d9ec2d9-75ca-46c7-b829-92daa9e34390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_d53940fb-2fde-4e75-a647-25f01c7f73fb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_50a9f8d8-faf3-451c-8d60-464507f27c02" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_d53940fb-2fde-4e75-a647-25f01c7f73fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3e38374d-7f73-4cba-8576-a7d7e5e39643" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_2a085d20-5dfa-418e-803c-9eaa9b22421c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3e38374d-7f73-4cba-8576-a7d7e5e39643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_073e4418-4998-496f-9b80-37bf9578b508" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_073e4418-4998-496f-9b80-37bf9578b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_a26b87ff-4da9-4c11-a345-4bebf8b5bfb1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_a26b87ff-4da9-4c11-a345-4bebf8b5bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_af5c1393-cd32-4e7a-b560-52cc71386643" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_af5c1393-cd32-4e7a-b560-52cc71386643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c0cfcf44-2321-4051-8549-5aefa7dce529" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_47425ad7-7bb0-4af7-b7f5-1193836da0d4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c0cfcf44-2321-4051-8549-5aefa7dce529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_9e5e7770-8bd9-49f8-bd7e-47c011bbc615" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_9e5e7770-8bd9-49f8-bd7e-47c011bbc615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProceedsFromWarrantsSubscription_e995f396-b80c-40b9-92e6-036d4cb00d9b" xlink:href="nbx-20211231.xsd#nbx_ProceedsFromWarrantsSubscription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_nbx_ProceedsFromWarrantsSubscription_e995f396-b80c-40b9-92e6-036d4cb00d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1d025a50-f130-4db5-9e9a-a238f172e95f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1d025a50-f130-4db5-9e9a-a238f172e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_768c0fec-ef38-491d-a18f-32d67b6c07eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_768c0fec-ef38-491d-a18f-32d67b6c07eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_8f6fa40e-05b0-4db7-a7dc-adfee4b31c30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_8f6fa40e-05b0-4db7-a7dc-adfee4b31c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_53693ee5-d399-4339-a589-4ac68edb655e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_53693ee5-d399-4339-a589-4ac68edb655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_fbd7d6ef-d1d3-4c73-a1c0-f2d2d3ab8276" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsFinancingActivities_fbd7d6ef-d1d3-4c73-a1c0-f2d2d3ab8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_643e66f3-8564-4891-a626-7c3aa48752cc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b091d6f6-e477-4146-b91a-6efc350560f0" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_643e66f3-8564-4891-a626-7c3aa48752cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_2c049fdc-8ffc-4359-8b8a-6775dec5f5c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_2c049fdc-8ffc-4359-8b8a-6775dec5f5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_bddd4b0b-9633-4cb7-990d-75f49a7c9aa9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_bddd4b0b-9633-4cb7-990d-75f49a7c9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_8fb3a1ac-be46-4e28-8084-65f3aa7a2bfe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_CashAndCashEquivalents_8fb3a1ac-be46-4e28-8084-65f3aa7a2bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_63a5dafc-2a0e-4de6-bff2-02b8a6ff9ed7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_dc5fff14-b976-4091-bb91-4d3a8683939a" xlink:to="loc_ifrs-full_CashAndCashEquivalents_63a5dafc-2a0e-4de6-bff2-02b8a6ff9ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Companyinformation" xlink:type="simple" xlink:href="nbx-20211231.xsd#Companyinformation"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Companyinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_92dc7200-a818-4f20-b035-aba316771b4d" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_e2491d27-59f0-4e93-bb49-3a6d70dcbb32" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_92dc7200-a818-4f20-b035-aba316771b4d" xlink:to="loc_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_e2491d27-59f0-4e93-bb49-3a6d70dcbb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CompanyinformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CompanyinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_ec00e933-88b8-408e-bb3d-c8e2b74dc630" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract_ec00e933-88b8-408e-bb3d-c8e2b74dc630" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:to="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_2ad2c670-17ef-44ed-95ed-6f0e944a9015" xlink:to="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fadeed19-a18e-4632-8ea9-7065b317f49b" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fadeed19-a18e-4632-8ea9-7065b317f49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_0862b1f2-386f-4204-ae04-6d5c2acf0944" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_cf9dedbf-8947-41d5-b887-085be44ef5d6" xlink:to="loc_nbx_LianBioNBTXR3Member_0862b1f2-386f-4204-ae04-6d5c2acf0944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:to="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5e709a9c-f939-4b2a-9222-e92cbfdeccb0" xlink:to="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_197d3bfc-51e9-44d6-ace6-c25e6b1b9fd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_37a3ae0b-a225-4885-970c-9fb4ec442216" xlink:to="loc_srt_MaximumMember_197d3bfc-51e9-44d6-ace6-c25e6b1b9fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfInformationRelatedToTheCompanyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyTable_41081405-23c4-40fd-acb2-62ede5a3dbfc" xlink:to="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OnerousContractsProvision_01c6871b-9ca4-426b-9c6d-9609fccb6fa1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OnerousContractsProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_ifrs-full_OnerousContractsProvision_01c6871b-9ca4-426b-9c6d-9609fccb6fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_b521c5de-22e4-4839-ab1d-1db4a9e9441e" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsPayment_b521c5de-22e4-4839-ab1d-1db4a9e9441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_53d334cf-d07c-41fa-92d5-e8583590a4f9" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_53d334cf-d07c-41fa-92d5-e8583590a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_7cce4b2d-de8c-46cc-83e5-49b4e94f0921" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_7cce4b2d-de8c-46cc-83e5-49b4e94f0921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_f5ee9a17-dc3f-4200-90e2-360d19b37d3d" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_f5ee9a17-dc3f-4200-90e2-360d19b37d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_7a590cea-70ec-4ef5-9344-a1a0422b436f" xlink:href="nbx-20211231.xsd#nbx_NumberOfGlobalRegistrationalStudiesSupported"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_7a590cea-70ec-4ef5-9344-a1a0422b436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_9e512673-3ac9-4e6a-a001-a3a2225b342d" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_9e512673-3ac9-4e6a-a001-a3a2225b342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_d92caa24-f819-4e87-923b-d9c2ff7ced6c" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems_12e3b21e-f2a7-4321-b1cd-87051041093f" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_d92caa24-f819-4e87-923b-d9c2ff7ced6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation" xlink:type="simple" xlink:href="nbx-20211231.xsd#GeneralInformationStatementofComplianceandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_0c620176-8784-444c-bc9a-a033a2082f22" xlink:href="nbx-20211231.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_4ab4ff01-0613-43b6-ae23-f83c3186ef40" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_0c620176-8784-444c-bc9a-a033a2082f22" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_4ab4ff01-0613-43b6-ae23-f83c3186ef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#GeneralInformationStatementofComplianceandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2981a087-5d50-40de-b542-2d38c2cb9bac" xlink:href="nbx-20211231.xsd#nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_c70618f8-f0f4-4c86-a993-399b7192a512" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract_2981a087-5d50-40de-b542-2d38c2cb9bac" xlink:to="loc_ifrs-full_CashAndCashEquivalents_c70618f8-f0f4-4c86-a993-399b7192a512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Consolidationprinciplesandmethods" xlink:type="simple" xlink:href="nbx-20211231.xsd#Consolidationprinciplesandmethods"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Consolidationprinciplesandmethods" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_34f35ec7-1e8a-47cb-9f5b-96918c800762" xlink:href="nbx-20211231.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_fd9a2087-36f5-41c9-b943-317a01da1fb6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_34f35ec7-1e8a-47cb-9f5b-96918c800762" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_fd9a2087-36f5-41c9-b943-317a01da1fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" xlink:type="simple" xlink:href="nbx-20211231.xsd#ConsolidationprinciplesandmethodsPolicies"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:href="nbx-20211231.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_ed593ddf-726e-4096-b263-e4948a45e8f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_ed593ddf-726e-4096-b263-e4948a45e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_b350e678-ffc7-4af7-be09-7de60288c5ce" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock_b350e678-ffc7-4af7-be09-7de60288c5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_d56151fc-0e34-440d-b371-d81517d0ba68" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock_d56151fc-0e34-440d-b371-d81517d0ba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_2b6dde79-777c-4ad6-bd5c-4e8892f6c829" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_2b6dde79-777c-4ad6-bd5c-4e8892f6c829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_968968eb-d7a8-4da0-8169-d4563e3340f4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_968968eb-d7a8-4da0-8169-d4563e3340f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_579dcc5b-280a-4a9a-b589-01b2ee8e6692" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_579dcc5b-280a-4a9a-b589-01b2ee8e6692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_0011f8d1-e42e-4c2c-a73d-40c926860801" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_0011f8d1-e42e-4c2c-a73d-40c926860801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_7b235d75-77a8-4680-9649-2dbe03391d97" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_7b235d75-77a8-4680-9649-2dbe03391d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_b9ab3e4a-6a28-45d8-abc2-b24cd549c8c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_b9ab3e4a-6a28-45d8-abc2-b24cd549c8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_4445af60-8ba4-4630-bfbd-ff9f7ba99cb3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_4445af60-8ba4-4630-bfbd-ff9f7ba99cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_52c26a3b-e148-4bb9-abbd-bdcd75683ba4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_52c26a3b-e148-4bb9-abbd-bdcd75683ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_45d2db1d-3426-4df0-8a8a-63ff7dba5ee8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory_45d2db1d-3426-4df0-8a8a-63ff7dba5ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_37fff804-2da5-41f5-8b4e-b239f351dbf9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_37fff804-2da5-41f5-8b4e-b239f351dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_79f27b8d-4c5e-49ea-ba35-9f7d378f44d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_79f27b8d-4c5e-49ea-ba35-9f7d378f44d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_58890c55-2660-4b9a-80ea-c355b76be703" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_58890c55-2660-4b9a-80ea-c355b76be703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_33fb654f-7333-41d3-9fd7-4e33b0fbb942" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_33fb654f-7333-41d3-9fd7-4e33b0fbb942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_c0e0bdb2-7556-484d-a835-e2a2ac02c2d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_c0e0bdb2-7556-484d-a835-e2a2ac02c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_820cf1b3-d988-4a03-8233-ff4ba6801ec3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_820cf1b3-d988-4a03-8233-ff4ba6801ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock_6323fda6-45a0-456b-bc09-d9189592b432" xlink:href="nbx-20211231.xsd#nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_1a8f8cbc-fefc-44c2-b004-4dc688d225cc" xlink:to="loc_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock_6323fda6-45a0-456b-bc09-d9189592b432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ConsolidationprinciplesandmethodsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SignificantAccountingPoliciesAbstract_69368fe3-e6c7-4d75-9eaa-88b44799b8a6" xlink:href="nbx-20211231.xsd#nbx_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_2e342769-beec-4193-98f9-0b2b43a17321" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_69368fe3-e6c7-4d75-9eaa-88b44799b8a6" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_2e342769-beec-4193-98f9-0b2b43a17321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_7708001f-1db1-4f8d-b4a7-3baf35a5b4a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_69368fe3-e6c7-4d75-9eaa-88b44799b8a6" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_7708001f-1db1-4f8d-b4a7-3baf35a5b4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfParentEntities_497a2a42-b0f1-4458-b9e1-3944ed5460a0" xlink:href="nbx-20211231.xsd#nbx_NumberOfParentEntities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_69368fe3-e6c7-4d75-9eaa-88b44799b8a6" xlink:to="loc_nbx_NumberOfParentEntities_497a2a42-b0f1-4458-b9e1-3944ed5460a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSubsidiaries_c4af448a-2953-4184-ad98-467a732a3e1b" xlink:href="nbx-20211231.xsd#nbx_NumberOfSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_SignificantAccountingPoliciesAbstract_69368fe3-e6c7-4d75-9eaa-88b44799b8a6" xlink:to="loc_nbx_NumberOfSubsidiaries_c4af448a-2953-4184-ad98-467a732a3e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Significanttransactions" xlink:type="simple" xlink:href="nbx-20211231.xsd#Significanttransactions"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Significanttransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_09a66de9-db25-4725-b023-eb64facbd4cc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfSignificantTransactionsTextBlock_de89a960-0c8a-4a44-ac03-2dda28a90cf2" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfSignificantTransactionsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_09a66de9-db25-4725-b023-eb64facbd4cc" xlink:to="loc_nbx_DisclosureOfSignificantTransactionsTextBlock_de89a960-0c8a-4a44-ac03-2dda28a90cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SignificanttransactionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SignificanttransactionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SignificanttransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_efeb6f6a-7aa4-488d-9d96-4b630c28c9bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_efeb6f6a-7aa4-488d-9d96-4b630c28c9bd" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_a24afdda-8f9a-4973-81bf-86308aece1cd" xlink:to="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_ab514598-cea6-49ce-9999-cb5e55d8a2d8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:to="loc_ifrs-full_TopOfRangeMember_ab514598-cea6-49ce-9999-cb5e55d8a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_8648e564-3f68-461e-bda9-8ff968ac9cff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_679e9152-ecfa-407b-a56c-69674a15b766" xlink:to="loc_ifrs-full_BottomOfRangeMember_8648e564-3f68-461e-bda9-8ff968ac9cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_33c83e78-6ec7-4cbf-bce0-d1946ec61fb1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6275f9ac-246d-4083-81f3-0181e19336a6" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_e47e4789-25b3-42af-8f9b-6bde44f946aa" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_6275f9ac-246d-4083-81f3-0181e19336a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_7207b364-194d-49b6-8bf3-876148601dcd" xlink:to="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_7e4d8b4f-b6a2-41a7-9c5b-5802074f0341" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_LianBioNBTXR3Member_7e4d8b4f-b6a2-41a7-9c5b-5802074f0341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PharmaEngineNBTWR3Member_cdf8dc68-0861-4a87-a79a-7f3dbceb3a37" xlink:href="nbx-20211231.xsd#nbx_PharmaEngineNBTWR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_PharmaEngineNBTWR3Member_cdf8dc68-0861-4a87-a79a-7f3dbceb3a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_9a22d811-3a20-48b6-8ec6-86cfcc6f5054" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_9a22d811-3a20-48b6-8ec6-86cfcc6f5054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_fccb7ccc-8a88-4bf2-8303-c119d5aea7c7" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_5ff8e334-bf6a-4e7f-afd7-36aca3f14265" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_fccb7ccc-8a88-4bf2-8303-c119d5aea7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45efcb5c-86a9-4bb6-a86f-04c9e4c5b48d" xlink:to="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52962100-04ca-4d05-a336-b357c5ced9f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_565defe6-457c-4535-bf53-1569456b08e8" xlink:to="loc_srt_MaximumMember_52962100-04ca-4d05-a336-b357c5ced9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_ae77e271-bf12-44f0-9b5b-74683c2b49ad" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_d647f5d1-083e-4e64-998f-bf48497b1250" xlink:href="nbx-20211231.xsd#nbx_NumberOfGlobalRegistrationalStudiesSupported"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_NumberOfGlobalRegistrationalStudiesSupported_d647f5d1-083e-4e64-998f-bf48497b1250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_4e743f11-47b8-41e1-9c77-dfe8093251b4" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_4e743f11-47b8-41e1-9c77-dfe8093251b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_6539d07c-8dc3-4f0a-9ea7-655b80753c0c" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_6539d07c-8dc3-4f0a-9ea7-655b80753c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_a3cd3c49-23f1-4128-b9ff-da9183913a40" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_a3cd3c49-23f1-4128-b9ff-da9183913a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementTotalPaymentsReceived_83d88ccf-67f4-43a6-aec7-50f885110c30" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementTotalPaymentsReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_CollaborationAgreementTotalPaymentsReceived_83d88ccf-67f4-43a6-aec7-50f885110c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_d209fb7e-3f3e-404a-8828-14a4be121be6" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsPayment_d209fb7e-3f3e-404a-8828-14a4be121be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_e9b80cf8-d19d-4e0b-95bc-1b71845c9f8b" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_e9b80cf8-d19d-4e0b-95bc-1b71845c9f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_d3e3bca2-b713-4dd1-b069-5c647795457a" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_d3e3bca2-b713-4dd1-b069-5c647795457a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_b2cd2162-ba33-435c-87e2-85092e8d537a" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_b2cd2162-ba33-435c-87e2-85092e8d537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_16499c7b-1f2b-4edd-9ccd-ebbb89a349cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_NotionalAmount_16499c7b-1f2b-4edd-9ccd-ebbb89a349cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_252caca0-668d-44cc-b2aa-0ecd2757936e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_252caca0-668d-44cc-b2aa-0ecd2757936e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_f1470a29-54a2-48cd-baf5-7a7041031f08" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_BorrowingsInterestRate_f1470a29-54a2-48cd-baf5-7a7041031f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_5f159e6c-7c3f-490e-a892-3c61661601f3" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingMaturityTerm_5f159e6c-7c3f-490e-a892-3c61661601f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UndrawnBorrowingFacilities_03bef3d3-b387-4dff-b21c-788759a7bb61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UndrawnBorrowingFacilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_UndrawnBorrowingFacilities_03bef3d3-b387-4dff-b21c-788759a7bb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_3c702154-deb5-49ed-b7e7-fed7d320f726" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingDefermentPeriod_3c702154-deb5-49ed-b7e7-fed7d320f726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriodToRequestFunds_74540882-41c0-4e67-9e81-4d7eaa33a95f" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriodToRequestFunds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_BorrowingDefermentPeriodToRequestFunds_74540882-41c0-4e67-9e81-4d7eaa33a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPatientsInClinicalTrial_6cfb7e90-1098-41bc-8da3-f26b389dc7b9" xlink:href="nbx-20211231.xsd#nbx_NumberOfPatientsInClinicalTrial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_NumberOfPatientsInClinicalTrial_6cfb7e90-1098-41bc-8da3-f26b389dc7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_6771acd6-00a3-41e3-92cd-3773a6f769b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_6771acd6-00a3-41e3-92cd-3773a6f769b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_b4850795-b9fb-405b-bb93-ba6bdb7b4fdc" xlink:href="nbx-20211231.xsd#nbx_MilestonePaymentDefermentPeriodAfterEnrollment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_b4850795-b9fb-405b-bb93-ba6bdb7b4fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_f261726c-36c0-42e0-a998-7c852b442868" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_f261726c-36c0-42e0-a998-7c852b442868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_0aa30af9-229f-4edc-98c3-5d2060add265" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_bc45a475-1b79-4145-b704-faddbe89fbc8" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_0aa30af9-229f-4edc-98c3-5d2060add265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Intangibleassets" xlink:type="simple" xlink:href="nbx-20211231.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_f294c5f4-0eda-4a4a-ae74-55a4ed810029" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_566642a3-8135-4069-a070-52745fe4e2e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_f294c5f4-0eda-4a4a-ae74-55a4ed810029" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_566642a3-8135-4069-a070-52745fe4e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_9b0cdaf0-294d-4db9-8f77-561f4a08eb94" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_76b4bcf1-6728-4121-945f-10db14850576" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_9b0cdaf0-294d-4db9-8f77-561f4a08eb94" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_76b4bcf1-6728-4121-945f-10db14850576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IntangibleassetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IntangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IntangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_2e0e2f5f-79cc-4c7b-b127-44493de467e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_2e0e2f5f-79cc-4c7b-b127-44493de467e3" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1108b605-cdb5-4ca3-9739-7992f3a2add5" xlink:to="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_dff4cb06-3408-468f-a366-6f23c03ba4aa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_dff4cb06-3408-468f-a366-6f23c03ba4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ef49fd09-71c9-4dbc-80e3-98a0c6300527" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_852285ac-73cd-4d5b-9d8d-924136c00489" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ef49fd09-71c9-4dbc-80e3-98a0c6300527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_e03f0795-55bf-44a2-b7ec-2655d8c49d83" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_f648b670-fc1e-4196-9eb7-687404cdb893" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_f648b670-fc1e-4196-9eb7-687404cdb893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_22ebcda8-7da4-47c7-98a0-345f7fa04b1c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_ComputerSoftwareMember_22ebcda8-7da4-47c7-98a0-345f7fa04b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_94a63f30-5193-4c26-af70-6312a23496e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_83cae940-8d28-4e14-bfca-e58106c10017" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_94a63f30-5193-4c26-af70-6312a23496e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c7bca43e-ffba-4b04-b5e7-d6f609113696" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_5de91712-c83a-400d-9d60-ef0969d66246" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_5de91712-c83a-400d-9d60-ef0969d66246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9c1458b5-8bef-49c1-a129-deab5750331a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_9c1458b5-8bef-49c1-a129-deab5750331a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_4c13ad1b-fcc2-488b-8206-2d4dffefdb3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_4c13ad1b-fcc2-488b-8206-2d4dffefdb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_5d6cbff4-01ee-496b-96a2-6f2a247aa982" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_5d6cbff4-01ee-496b-96a2-6f2a247aa982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_87b73f42-dfb0-42f2-8589-e6ca93e45e95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_87b73f42-dfb0-42f2-8589-e6ca93e45e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_528f4ea9-ed93-4f3a-ba81-236a9fa06bac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_47d1eb32-a7fa-4361-be94-1f5caf94fb7c" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_528f4ea9-ed93-4f3a-ba81-236a9fa06bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Propertyplantandequipment" xlink:type="simple" xlink:href="nbx-20211231.xsd#Propertyplantandequipment"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Propertyplantandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_17a6ddf5-a09a-4ce6-b0be-c0fb767b53f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_74324f36-e712-430b-9e41-d83b544b0a25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_17a6ddf5-a09a-4ce6-b0be-c0fb767b53f2" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_74324f36-e712-430b-9e41-d83b544b0a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#PropertyplantandequipmentTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_1a5e11f8-61bc-4c39-b9bb-a6e901390dd3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7bfd1979-5fab-4aa9-adc0-ca9cd4ee2212" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_1a5e11f8-61bc-4c39-b9bb-a6e901390dd3" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7bfd1979-5fab-4aa9-adc0-ca9cd4ee2212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#PropertyplantandequipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_279ad113-e3e8-42b7-9004-a847285db024" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_279ad113-e3e8-42b7-9004-a847285db024" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b7d1ed96-c61a-49cc-9d52-f086b0b1db87" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_200a8412-360c-4393-ba6f-bbed71a7e1bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_200a8412-360c-4393-ba6f-bbed71a7e1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_1061c386-5fe3-4feb-8a9b-82133a5dd110" xlink:href="nbx-20211231.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_nbx_RightOfUseBuildingsMember_1061c386-5fe3-4feb-8a9b-82133a5dd110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_17f00d6f-0679-4ad2-9628-40d3ce78273d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MachineryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_MachineryMember_17f00d6f-0679-4ad2-9628-40d3ce78273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_b810dd31-4adf-4643-a1b5-989e421dc820" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_OfficeEquipmentMember_b810dd31-4adf-4643-a1b5-989e421dc820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_3b90f202-5fdb-4655-8ca9-229d67d833da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_ifrs-full_VehiclesMember_3b90f202-5fdb-4655-8ca9-229d67d833da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseTransportEquipmentMember_de7a3132-01c6-49d8-ab5e-2b2fc6a8f831" xlink:href="nbx-20211231.xsd#nbx_RightOfUseTransportEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_93127e61-6e5e-44e6-909b-2867b43ef562" xlink:to="loc_nbx_RightOfUseTransportEquipmentMember_de7a3132-01c6-49d8-ab5e-2b2fc6a8f831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_9dc0f04c-2e6d-4729-adf9-f60facee35fa" xlink:to="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c09cbb77-3e42-4c95-b18e-42209ae57d74" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:to="loc_ifrs-full_BottomOfRangeMember_c09cbb77-3e42-4c95-b18e-42209ae57d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_c0ee80a1-21ea-4dd9-a4ca-b588b4798ee2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_2edcdc99-8d69-4427-8085-c7487aeffd17" xlink:to="loc_ifrs-full_TopOfRangeMember_c0ee80a1-21ea-4dd9-a4ca-b588b4798ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_7fa8516d-1e85-4023-ba5e-717b8a9b377d" xlink:to="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_68c4105e-203b-4547-8124-5a66b18ba971" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_39d7ad26-9830-4b4a-adff-859426ee8cac" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_68c4105e-203b-4547-8124-5a66b18ba971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_e648b33e-7fc2-4317-9ffa-1c2333f2c405" xlink:to="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractVillejuifMember_fc3b6e1f-d5b5-4e78-88dc-785efa0c2397" xlink:href="nbx-20211231.xsd#nbx_LeaseContractVillejuifMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractVillejuifMember_fc3b6e1f-d5b5-4e78-88dc-785efa0c2397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractOberkampfStreetMember_19d79a41-43b8-4645-8ea4-493d071196ef" xlink:href="nbx-20211231.xsd#nbx_LeaseContractOberkampfStreetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractOberkampfStreetMember_19d79a41-43b8-4645-8ea4-493d071196ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractFaubourgSaintAntoineMember_ecfbc7a9-22ac-47e9-9493-a19f4fa7385f" xlink:href="nbx-20211231.xsd#nbx_LeaseContractFaubourgSaintAntoineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractFaubourgSaintAntoineMember_ecfbc7a9-22ac-47e9-9493-a19f4fa7385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractAlfortvilleMember_59f70257-6873-495d-bda4-81f5f5d285df" xlink:href="nbx-20211231.xsd#nbx_LeaseContractAlfortvilleMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractAlfortvilleMember_59f70257-6873-495d-bda4-81f5f5d285df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractParkingVillejuifMember_137c6a1f-373d-442b-ad1f-7a8923ef9da6" xlink:href="nbx-20211231.xsd#nbx_LeaseContractParkingVillejuifMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractParkingVillejuifMember_137c6a1f-373d-442b-ad1f-7a8923ef9da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractWattigniesMember_c32a45e2-70e8-48f4-bbd2-97513a158ea3" xlink:href="nbx-20211231.xsd#nbx_LeaseContractWattigniesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsMember_74dc0a7a-d440-40a8-82e1-cbddd61fdd59" xlink:to="loc_nbx_LeaseContractWattigniesMember_c32a45e2-70e8-48f4-bbd2-97513a158ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_fc0e0fbe-2364-47af-b00b-456bbac46839" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_259d0f4d-ca59-4629-be66-342a57250680" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_259d0f4d-ca59-4629-be66-342a57250680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_7737d42b-3292-4a81-830d-e0c66e95628a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_7737d42b-3292-4a81-830d-e0c66e95628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LeaseContractExtendedPeriod_94091659-0a35-4751-bc10-a8c81dc3287b" xlink:href="nbx-20211231.xsd#nbx_LeaseContractExtendedPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_LeaseContractExtendedPeriod_94091659-0a35-4751-bc10-a8c81dc3287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_5f466cab-34bf-40bb-ae9a-37e1a11be581" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_5f466cab-34bf-40bb-ae9a-37e1a11be581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_0cad68b7-a970-4de7-84db-eca7a8e885fa" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact_0cad68b7-a970-4de7-84db-eca7a8e885fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_b4e1db6a-3a6f-40bf-a431-25f9569d0eb2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_b4e1db6a-3a6f-40bf-a431-25f9569d0eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfNewLeaseContracts_8bb98b08-812a-431b-9782-e4557bfcd626" xlink:href="nbx-20211231.xsd#nbx_NumberOfNewLeaseContracts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_33bf87b4-40b2-4c76-aeee-a3a34dbb09a5" xlink:to="loc_nbx_NumberOfNewLeaseContracts_8bb98b08-812a-431b-9782-e4557bfcd626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_17e93116-d1ae-4658-acf0-9f9bbd8cf439" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_17e93116-d1ae-4658-acf0-9f9bbd8cf439" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_811ac34b-4e6c-40a4-b283-a0ae03d48b5b" xlink:to="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_6bfe5d6a-4980-4fdc-b963-f0adb0c0898e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_6bfe5d6a-4980-4fdc-b963-f0adb0c0898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_882a2522-8f35-4bd2-b071-a4169f066fff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_a55c0403-d14b-412f-af9f-e74cb3570d74" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_882a2522-8f35-4bd2-b071-a4169f066fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_c82a6b40-b1d1-41fb-8fc5-479df1c492b5" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixturesAndFittingsMember_d6cab7ac-7396-4b2a-b4a5-84132d39b88b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixturesAndFittingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_FixturesAndFittingsMember_d6cab7ac-7396-4b2a-b4a5-84132d39b88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseBuildingsMember_840316f8-8e4a-4926-9fd8-6567e06418c1" xlink:href="nbx-20211231.xsd#nbx_RightOfUseBuildingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_RightOfUseBuildingsMember_840316f8-8e4a-4926-9fd8-6567e06418c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MachineryMember_d120d3b9-aa37-434e-b461-3f74ed6fbf8f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MachineryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_MachineryMember_d120d3b9-aa37-434e-b461-3f74ed6fbf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_e9305de1-0a28-4fd2-9cb2-64893666baff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_OfficeEquipmentMember_e9305de1-0a28-4fd2-9cb2-64893666baff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_024508da-e0a3-436c-8e2d-5e8696122ccc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_VehiclesMember_024508da-e0a3-436c-8e2d-5e8696122ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RightOfUseTransportEquipmentMember_366632b6-4d06-4be8-a9b7-dcc414eb01be" xlink:href="nbx-20211231.xsd#nbx_RightOfUseTransportEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_RightOfUseTransportEquipmentMember_366632b6-4d06-4be8-a9b7-dcc414eb01be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_e94aefdd-340f-448e-823b-8d591d2a1f19" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_ifrs-full_ConstructionInProgressMember_e94aefdd-340f-448e-823b-8d591d2a1f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PrepaymentsOnTangibleAssetsMember_4f8f46a5-ce7a-41c3-8eb9-cf9a241f0368" xlink:href="nbx-20211231.xsd#nbx_PrepaymentsOnTangibleAssetsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8b7ee9e2-1d77-4213-bdcd-5f9eb1a40634" xlink:to="loc_nbx_PrepaymentsOnTangibleAssetsMember_4f8f46a5-ce7a-41c3-8eb9-cf9a241f0368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_69745b86-bb44-4192-829b-076259ca6c92" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_0f052ab3-bdfe-4647-a690-a6174170bc32" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_0f052ab3-bdfe-4647-a690-a6174170bc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_602c9b4d-0adc-4fe2-a9be-9e3e8f917bd2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_602c9b4d-0adc-4fe2-a9be-9e3e8f917bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_16503b35-4349-43e3-946b-cc0bea914f43" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_16503b35-4349-43e3-946b-cc0bea914f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_1f2c01d3-0cb5-469f-b450-2a877d09de3f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment_1f2c01d3-0cb5-469f-b450-2a877d09de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7a95aaea-6ea5-49f0-a128-6a91bb4d983b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_7a95aaea-6ea5-49f0-a128-6a91bb4d983b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6f5e0d5f-e99c-433d-b41d-aa3154bc84e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_fd324a84-8466-41b4-99f1-36301cd8bf3c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_6f5e0d5f-e99c-433d-b41d-aa3154bc84e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Noncurrentfinancialassets" xlink:type="simple" xlink:href="nbx-20211231.xsd#Noncurrentfinancialassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Noncurrentfinancialassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_8d3e2aa9-f089-48ef-ac36-4f3861674a76" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_b6a85d81-232f-4851-a7d6-0ee0b5b575ef" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_8d3e2aa9-f089-48ef-ac36-4f3861674a76" xlink:to="loc_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock_b6a85d81-232f-4851-a7d6-0ee0b5b575ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#NoncurrentfinancialassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_f766972a-e3b2-4f8e-b0a0-8e4c9fec4e1d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_8fdbdc1f-d18f-4e6d-851d-ec51a8637f96" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_f766972a-e3b2-4f8e-b0a0-8e4c9fec4e1d" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock_8fdbdc1f-d18f-4e6d-851d-ec51a8637f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_c2f6cf9e-3580-4297-99bd-686329201db2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_c2f6cf9e-3580-4297-99bd-686329201db2" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_3d3be74e-df60-4fa8-b13d-b18ca349c7eb" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentLiquidityContractMember_f1a81f56-6f1c-417f-bfa1-5bbdb6329562" xlink:href="nbx-20211231.xsd#nbx_NonCurrentLiquidityContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentLiquidityContractMember_f1a81f56-6f1c-417f-bfa1-5bbdb6329562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_ac083bb9-12e7-44ff-ad0b-779e0dcf9c31" xlink:href="nbx-20211231.xsd#nbx_NonCurrentInvestmentsPledgedAsCollateralMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentInvestmentsPledgedAsCollateralMember_ac083bb9-12e7-44ff-ad0b-779e0dcf9c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentSecurityDepositMember_6dd02234-9841-4e5b-98c0-e4eb0fd3caa8" xlink:href="nbx-20211231.xsd#nbx_NonCurrentSecurityDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_67d1edc6-3e5e-4799-9bf3-527d02b1ecf9" xlink:to="loc_nbx_NonCurrentSecurityDepositMember_6dd02234-9841-4e5b-98c0-e4eb0fd3caa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_1735b325-51f3-46ac-a874-7f77b7c0793d" xlink:to="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueMember_dc06acb8-6a50-4b32-8ae1-6d58c43614b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueMember_dc06acb8-6a50-4b32-8ae1-6d58c43614b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_daef8a8f-bc08-4782-ab34-d109f9dc8e80" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_40af9efa-6320-4b23-887b-95df6794f466" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_daef8a8f-bc08-4782-ab34-d109f9dc8e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_cc793826-7a6d-4dee-8f8e-a77b7b819f73" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_7d2bbb24-eae1-4299-88c3-b43573ea9f89" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_7d2bbb24-eae1-4299-88c3-b43573ea9f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_f4fe0fcf-434d-42a2-84a8-66e3200fbdff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_f4fe0fcf-434d-42a2-84a8-66e3200fbdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_4d4aa5ac-7edc-4cfb-8c85-9cda6173562c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_DecreaseThroughDerecognitionFinancialAssets_4d4aa5ac-7edc-4cfb-8c85-9cda6173562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_f9a00d4c-8250-4679-9568-8508ec73e165" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets_f9a00d4c-8250-4679-9568-8508ec73e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_21ee07db-ca77-41ff-9382-46e08e82e300" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_21ee07db-ca77-41ff-9382-46e08e82e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_ec797b70-1f5e-4687-996d-79026ea64ab7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_5c76c64f-464c-4b65-aebd-0e35762f661b" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_ec797b70-1f5e-4687-996d-79026ea64ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NoncurrentfinancialassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_5a5a403d-4ae1-4437-8de9-39c17a704b43" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsAbstract_5a5a403d-4ae1-4437-8de9-39c17a704b43" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_d7a5f71f-c3da-44e9-b97b-935c4261850c" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentSecurityDepositMember_cb05b1f6-2c4b-4dea-be00-96314fe05fab" xlink:href="nbx-20211231.xsd#nbx_NonCurrentSecurityDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_31a7dbb1-a25e-42e8-8813-1769d51cc72c" xlink:to="loc_nbx_NonCurrentSecurityDepositMember_cb05b1f6-2c4b-4dea-be00-96314fe05fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable_b92dadcf-f6af-4880-b42d-be5cdb9a1b17" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInFinancialAssets_b1518f57-2ff5-4ad1-b456-592c47939c79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:to="loc_ifrs-full_IncreaseDecreaseInFinancialAssets_b1518f57-2ff5-4ad1-b456-592c47939c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_6051c654-4386-4be2-b086-c189da2b0f1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems_be1c8204-c69a-43ac-b191-8a0f7461d834" xlink:to="loc_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets_6051c654-4386-4be2-b086-c189da2b0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets" xlink:type="simple" xlink:href="nbx-20211231.xsd#Tradereceivablesandothercurrentassets"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Tradereceivablesandothercurrentassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_04a16667-4db8-4067-8c86-a990101cb52d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_a1df7c96-f987-4722-984b-7f192eed2583" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_04a16667-4db8-4067-8c86-a990101cb52d" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock_a1df7c96-f987-4722-984b-7f192eed2583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8c4b1c7a-1d0c-4fe9-9518-93d5e6542983" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_46c6b341-882d-4718-b1b1-80b2e11a23c1" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8c4b1c7a-1d0c-4fe9-9518-93d5e6542983" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock_46c6b341-882d-4718-b1b1-80b2e11a23c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_8d897979-d07c-4ab5-a9b0-671c0be17070" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8c4b1c7a-1d0c-4fe9-9518-93d5e6542983" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock_8d897979-d07c-4ab5-a9b0-671c0be17070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_17c889f9-b391-473d-920c-e8def6d1029a" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8c4b1c7a-1d0c-4fe9-9518-93d5e6542983" xlink:to="loc_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock_17c889f9-b391-473d-920c-e8def6d1029a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3c57ed47-f0c1-4ea3-925c-b7cfdeb38dfd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3c57ed47-f0c1-4ea3-925c-b7cfdeb38dfd" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:to="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_54d4190f-8e89-4a6a-a9dc-f2d588097da7" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanThreeMonthsMember_f939294a-75cc-4608-b0ea-07c46b0f8447" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanThreeMonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_NotLaterThanThreeMonthsMember_f939294a-75cc-4608-b0ea-07c46b0f8447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a97221df-e710-4f9a-b853-e1131e6d775c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember_a97221df-e710-4f9a-b853-e1131e6d775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_c6786ae4-0e10-4609-89af-434925a7964d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember_c6786ae4-0e10-4609-89af-434925a7964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_dd8db2c2-fcb0-4fbd-83a1-c6417890467b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_c4532841-bc15-4c8b-840e-61fd64074a24" xlink:to="loc_ifrs-full_LaterThanOneYearMember_dd8db2c2-fcb0-4fbd-83a1-c6417890467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_d2ba539a-0eb9-4f1a-becc-cecd1a97bab6" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_cd600e99-c225-4514-aa63-84d7936d3d2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_c5a9cbfd-6077-4f0e-8aaf-3eb68c7f6c18" xlink:to="loc_ifrs-full_CurrentTradeReceivables_cd600e99-c225-4514-aa63-84d7936d3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_977af247-57e7-4b31-8207-a009cd199132" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_977af247-57e7-4b31-8207-a009cd199132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_c0c8a56c-189a-4fa9-be51-35e9851c6ec8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_c0c8a56c-189a-4fa9-be51-35e9851c6ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_9a94a47f-0245-40a8-b153-9434a3524dc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_9a94a47f-0245-40a8-b153-9434a3524dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_3cf883a5-3fb1-4054-a078-6fd0f9f20fa3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:to="loc_ifrs-full_OtherCurrentReceivables_3cf883a5-3fb1-4054-a078-6fd0f9f20fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_c3d85af4-29ba-4d6f-a5a0-1cd963c7e6f9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_56b95ec7-0bee-46dd-9abb-8a75ffa04722" xlink:to="loc_ifrs-full_OtherCurrentAssets_c3d85af4-29ba-4d6f-a5a0-1cd963c7e6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0d396167-4399-4323-a9b7-6ba9525aa6bf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0d396167-4399-4323-a9b7-6ba9525aa6bf" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_6a73c404-e926-4562-a773-cf026960e35e" xlink:to="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a8d8f59b-fd20-4f54-93d6-23e09e236c9f" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_b0fa793a-3e39-4bbc-aa8f-b8b01dd9ad3f" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a8d8f59b-fd20-4f54-93d6-23e09e236c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bd479ab6-abed-436a-a086-2d66fc59194e" xlink:to="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_865ebd84-0913-4202-87c7-74afc89d0f40" xlink:href="nbx-20211231.xsd#nbx_NanobiotixSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:to="loc_nbx_NanobiotixSAMember_865ebd84-0913-4202-87c7-74afc89d0f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CuradigmSASMember_4d56dbf8-eff7-486f-8ae7-98a1b76cf795" xlink:href="nbx-20211231.xsd#nbx_CuradigmSASMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_42850822-8d2f-4019-8810-152fed309b0f" xlink:to="loc_nbx_CuradigmSASMember_4d56dbf8-eff7-486f-8ae7-98a1b76cf795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearAxis_96c5051d-7d72-43c9-b112-76f28a7d91f8" xlink:to="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2021TaxYearMember_042af50a-bf06-4c64-b121-1e4934d5ed27" xlink:href="nbx-20211231.xsd#nbx_A2021TaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:to="loc_nbx_A2021TaxYearMember_042af50a-bf06-4c64-b121-1e4934d5ed27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2020TaxYearMember_a5f34ee5-3ade-41c6-8b55-b020566c7516" xlink:href="nbx-20211231.xsd#nbx_A2020TaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_25290e2b-c3dd-4119-932a-a30972a234b2" xlink:to="loc_nbx_A2020TaxYearMember_a5f34ee5-3ade-41c6-8b55-b020566c7516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_6a60fe4e-bcb0-426b-884a-1ca14ea2ee4e" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_8579075b-3a6b-4ef2-92c6-5e9b08f686ef" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_8579075b-3a6b-4ef2-92c6-5e9b08f686ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_2ffb2a60-8e5d-4618-8e9f-33db98257498" xlink:href="nbx-20211231.xsd#nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers_2ffb2a60-8e5d-4618-8e9f-33db98257498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_241b5dc8-548b-4263-9533-907d564f94c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_241b5dc8-548b-4263-9533-907d564f94c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_53e2cfb4-eb52-4c47-b1eb-bfe43d5cdf8e" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_b8f93c88-5579-400a-a6d8-3e64880ed05c" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_53e2cfb4-eb52-4c47-b1eb-bfe43d5cdf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_01be6e04-4494-4b8c-ae1d-57c41370686c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_01be6e04-4494-4b8c-ae1d-57c41370686c" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:to="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:href="nbx-20211231.xsd#nbx_OpenTaxYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearAxis_b75dda6b-aa55-4272-b35c-57449a5510eb" xlink:to="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2018TaxYearMember_af121826-bf4b-4f32-b4f2-af1bd6e7f550" xlink:href="nbx-20211231.xsd#nbx_A2018TaxYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2018TaxYearMember_af121826-bf4b-4f32-b4f2-af1bd6e7f550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2019TaxYearMember_ef563afc-13dd-4b1e-a1a5-1d819029d578" xlink:href="nbx-20211231.xsd#nbx_A2019TaxYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2019TaxYearMember_ef563afc-13dd-4b1e-a1a5-1d819029d578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2020TaxYearMember_2128c518-c14a-47e4-98f6-03a3e5b86dd3" xlink:href="nbx-20211231.xsd#nbx_A2020TaxYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2020TaxYearMember_2128c518-c14a-47e4-98f6-03a3e5b86dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_A2021TaxYearMember_70312125-f2e6-4638-96a2-87ab144cfbd8" xlink:href="nbx-20211231.xsd#nbx_A2021TaxYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OpenTaxYearDomain_ad0d0e13-b05a-410e-87fe-09322eb42f37" xlink:to="loc_nbx_A2021TaxYearMember_70312125-f2e6-4638-96a2-87ab144cfbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:to="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e0bfe8b2-876e-4bdf-89ac-8d5986736f5f" xlink:to="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NanobiotixSAMember_296bc4f7-1a80-49c5-80bb-724b4f1fb95f" xlink:href="nbx-20211231.xsd#nbx_NanobiotixSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:to="loc_nbx_NanobiotixSAMember_296bc4f7-1a80-49c5-80bb-724b4f1fb95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CuradigmSASMember_e438ee92-f397-4ce9-8c0b-e49826730a6d" xlink:href="nbx-20211231.xsd#nbx_CuradigmSASMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6936a0ae-0bb2-43ec-aa04-36427532a540" xlink:to="loc_nbx_CuradigmSASMember_e438ee92-f397-4ce9-8c0b-e49826730a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable_287f4fc1-a311-4252-8406-c4111a72fce4" xlink:to="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_eb86705c-f8e6-41a6-a103-5b7e1bb25d72" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_eb86705c-f8e6-41a6-a103-5b7e1bb25d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_781f7fcb-9824-4893-8c2c-82ee8c51695b" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund_781f7fcb-9824-4893-8c2c-82ee8c51695b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_9f6f5b15-c292-4ea1-8d16-ae1f102a5d56" xlink:href="nbx-20211231.xsd#nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease_9f6f5b15-c292-4ea1-8d16-ae1f102a5d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_acae75b1-a35a-4daf-9fe1-49248a4d3a0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems_8e9a15fc-4195-4823-a095-d0ca19b5715d" xlink:to="loc_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_acae75b1-a35a-4daf-9fe1-49248a4d3a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Cashandcashequivalents" xlink:type="simple" xlink:href="nbx-20211231.xsd#Cashandcashequivalents"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Cashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6400ab77-633f-4667-aa63-12f3ee14cd52" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_858282dc-77be-46a4-842b-7ac9dddac194" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6400ab77-633f-4667-aa63-12f3ee14cd52" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_858282dc-77be-46a4-842b-7ac9dddac194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#CashandcashequivalentsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1d5cde4d-df86-4170-851f-55adfcd17cb9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_8aecb48d-deb0-4796-b035-3d619f6f968a" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_1d5cde4d-df86-4170-851f-55adfcd17cb9" xlink:to="loc_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_8aecb48d-deb0-4796-b035-3d619f6f968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CashandcashequivalentsSummaryofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_eccc9fd8-ed68-47fc-aaa2-0d8881874f8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_e0f838a9-f5ea-4873-a3de-696417fcaff7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_eccc9fd8-ed68-47fc-aaa2-0d8881874f8b" xlink:to="loc_ifrs-full_Cash_e0f838a9-f5ea-4873-a3de-696417fcaff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_64f92c69-84e6-4730-afdc-fb79b78a9057" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_eccc9fd8-ed68-47fc-aaa2-0d8881874f8b" xlink:to="loc_ifrs-full_CashAndCashEquivalents_64f92c69-84e6-4730-afdc-fb79b78a9057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CashandcashequivalentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_09e83f51-10d4-4325-805e-1552077c3de8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_09e83f51-10d4-4325-805e-1552077c3de8" xlink:to="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:to="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_0eafcfff-6dd7-4f0f-b6df-7c4c82463542" xlink:to="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_e731cf1e-2aae-4eb9-bb48-477e50a8e883" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:to="loc_nbx_LianBioNBTXR3Member_e731cf1e-2aae-4eb9-bb48-477e50a8e883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_21bc79d6-c3d8-4db9-89d4-0cf98795d1c6" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_bc8ffd44-42cb-4e9c-a355-2c0f53195e68" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_21bc79d6-c3d8-4db9-89d4-0cf98795d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_e7f348ee-5a84-44b0-b206-21c21c1f6018" xlink:to="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e6ba9523-3ae2-48bc-8ce0-76b826321888" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e6ba9523-3ae2-48bc-8ce0-76b826321888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_b6281c3f-402e-489b-a71b-b737404a70c7" xlink:href="nbx-20211231.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_35ad1375-fe53-4d82-ae4a-5ce50919de27" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_b6281c3f-402e-489b-a71b-b737404a70c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsTable_9b9b8aea-a32c-449c-9e02-a2b792b1b5a3" xlink:to="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b28cc055-e5c8-4e42-aa55-7a727dee2500" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b28cc055-e5c8-4e42-aa55-7a727dee2500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_f27dcbe4-e965-4d4b-9b5c-2424e19047f2" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_f27dcbe4-e965-4d4b-9b5c-2424e19047f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_254808d8-45e7-4b0f-9bac-ba440e0a65e3" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_nbx_ContractualCommitmentsPayment_254808d8-45e7-4b0f-9bac-ba440e0a65e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0d014250-0827-4162-829d-ea6dbacce73a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCashAndCashEquivalentsLineItems_1d3cfad2-6f26-4e19-903f-17b48af5d7ac" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0d014250-0827-4162-829d-ea6dbacce73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapital" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_838c5358-51ea-4b00-aa1a-7bb842a8ef86" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_a3f427f2-9803-48a1-90f6-054739762ba3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_838c5358-51ea-4b00-aa1a-7bb842a8ef86" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_a3f427f2-9803-48a1-90f6-054739762ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f31920f3-a43f-4ac7-9089-cde4de5d7b31" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_b2a7054a-9730-4130-8ebf-66d1e743201d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f31920f3-a43f-4ac7-9089-cde4de5d7b31" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_b2a7054a-9730-4130-8ebf-66d1e743201d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_0dc2fa6f-7fe4-483a-878e-334e79d82199" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f31920f3-a43f-4ac7-9089-cde4de5d7b31" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_0dc2fa6f-7fe4-483a-878e-334e79d82199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_6b95a823-52f5-492e-8776-9de079e34dfc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_f31920f3-a43f-4ac7-9089-cde4de5d7b31" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_6b95a823-52f5-492e-8776-9de079e34dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_761a290c-d856-42f6-9331-55e779c398f0" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_761a290c-d856-42f6-9331-55e779c398f0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b9590354-5e08-43e8-9942-eb61d6261fa5" xlink:to="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f974408d-5ce4-4ad4-b443-1a6d88ee176c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:to="loc_ifrs-full_IssuedCapitalMember_f974408d-5ce4-4ad4-b443-1a6d88ee176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_1ed293d5-1fc2-4e5e-9228-7bc60f4efae8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c02310eb-112f-490c-9c68-b920de9e8e82" xlink:to="loc_ifrs-full_SharePremiumMember_1ed293d5-1fc2-4e5e-9228-7bc60f4efae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_4d640965-ae7f-48b3-b2dc-df503f2ffdbe" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealEuroMember_5fd8d999-ba09-4f45-8e12-fe3dd1851777" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealEuroMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOInitialDealEuroMember_5fd8d999-ba09-4f45-8e12-fe3dd1851777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealUSDollarMember_590d86df-bdf3-47ca-96b9-0ee1b78c0879" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealUSDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOInitialDealUSDollarMember_590d86df-bdf3-47ca-96b9-0ee1b78c0879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOGreenShoeUSDollarMember_3fa39f15-5963-4c79-9fcb-4bd42ecda219" xlink:href="nbx-20211231.xsd#nbx_IPOGreenShoeUSDollarMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_de0febee-6aed-477f-971e-36c01fb2544c" xlink:to="loc_nbx_IPOGreenShoeUSDollarMember_3fa39f15-5963-4c79-9fcb-4bd42ecda219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_068653bf-a675-405b-83e2-520130588e1b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_7b429688-d543-484f-80fe-bc5bf49a8ee0" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:to="loc_nbx_AGA20181Member_7b429688-d543-484f-80fe-bc5bf49a8ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_d10b07ea-be5c-487a-98c4-7d0a66edd2e7" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e494ee1-49ca-4d3f-9266-092b4c1fd5a8" xlink:to="loc_nbx_AGA20182Member_d10b07ea-be5c-487a-98c4-7d0a66edd2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_58b489f8-5195-4765-958f-d1d22ede11c4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0970f0a0-7ea6-46eb-93fa-062181de27a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_Equity_0970f0a0-7ea6-46eb-93fa-062181de27a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_432d823a-1fc2-41e3-91c5-30ad8abeef1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_IssueOfEquity_432d823a-1fc2-41e3-91c5-30ad8abeef1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_cd0d2d49-3663-4c4b-b983-dafe59488b58" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity_cd0d2d49-3663-4c4b-b983-dafe59488b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_033d028e-357c-4e1e-b69c-ab045f9e8003" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_033d028e-357c-4e1e-b69c-ab045f9e8003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_57faf3c5-6580-483a-8305-68c81dd1ad99" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_Equity_57faf3c5-6580-483a-8305-68c81dd1ad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_aecad866-8137-481c-82b1-19449f03a1cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_aecad866-8137-481c-82b1-19449f03a1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7e1278ab-a2ad-42a2-802c-b1111efa5347" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7e1278ab-a2ad-42a2-802c-b1111efa5347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_4eb82f27-bf80-46e9-a3d3-30c5b1408358" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_4eb82f27-bf80-46e9-a3d3-30c5b1408358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IssueOfEquityPricePerShare_16ee0258-0c0c-451e-89b6-5d979d5a0887" xlink:href="nbx-20211231.xsd#nbx_IssueOfEquityPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_90f609a1-7042-45c2-bc6e-8659f22b6d2c" xlink:to="loc_nbx_IssueOfEquityPricePerShare_16ee0258-0c0c-451e-89b6-5d979d5a0887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalCapitalIssuedDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_b3bdcfc9-c4ff-435d-b1a8-3d2720b525e9" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_b3bdcfc9-c4ff-435d-b1a8-3d2720b525e9" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_0f517da7-484c-4baf-96bc-67011329ab61" xlink:to="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_8dc0b28a-ae20-4310-898d-0de3d9d7f3ec" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:to="loc_ifrs-full_IssuedCapitalMember_8dc0b28a-ae20-4310-898d-0de3d9d7f3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_aaa4ef11-ea15-41c9-8eaa-2ba1d0524465" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a9ea3d9d-0c9b-491b-9e4e-231fb227fec6" xlink:to="loc_ifrs-full_SharePremiumMember_aaa4ef11-ea15-41c9-8eaa-2ba1d0524465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_6830df7f-4429-4147-8a68-d30cc1307356" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InitialPublicOfferingMember_65e904c5-7407-4382-91ae-0d6e519142db" xlink:href="nbx-20211231.xsd#nbx_InitialPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_InitialPublicOfferingMember_65e904c5-7407-4382-91ae-0d6e519142db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealUSDollarMember_af97c63b-55de-458e-9a36-7ab4095b14e9" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealUSDollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOInitialDealUSDollarMember_af97c63b-55de-458e-9a36-7ab4095b14e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOInitialDealEuroMember_1561a89a-2feb-4e81-ba64-a02167ca79c4" xlink:href="nbx-20211231.xsd#nbx_IPOInitialDealEuroMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOInitialDealEuroMember_1561a89a-2feb-4e81-ba64-a02167ca79c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IPOGreenShoeUSDollarMember_01917fe1-fd28-425f-b6c6-5ad0be11e4a4" xlink:href="nbx-20211231.xsd#nbx_IPOGreenShoeUSDollarMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_41769053-cfb2-4cf0-aecb-6cd4d3042b23" xlink:to="loc_nbx_IPOGreenShoeUSDollarMember_01917fe1-fd28-425f-b6c6-5ad0be11e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_3f79ac71-f397-4488-9058-21fd34f11742" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_681efc67-ae02-4ee0-acfc-eaa3173dc89a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_Equity_681efc67-ae02-4ee0-acfc-eaa3173dc89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_7b526028-ccba-4d16-8e24-f101fedcda53" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_7b526028-ccba-4d16-8e24-f101fedcda53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_bb57411e-62b5-47b1-87c3-411d9195a1da" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_ParValuePerShare_bb57411e-62b5-47b1-87c3-411d9195a1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7a0d1737-0d08-4c06-ba87-cb797b23b3a9" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_7a0d1737-0d08-4c06-ba87-cb797b23b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IssueOfEquityPricePerShare_ea5ae6e0-4a7f-4c55-931c-87ab6219965a" xlink:href="nbx-20211231.xsd#nbx_IssueOfEquityPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_nbx_IssueOfEquityPricePerShare_ea5ae6e0-4a7f-4c55-931c-87ab6219965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_6bd27a6d-8f3f-4efc-98c0-586ebfc8b9b6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_6bd27a6d-8f3f-4efc-98c0-586ebfc8b9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_3a5e2447-f48a-4214-99d3-ab1b12a86638" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_a7f88456-8b95-4411-a12a-8049ac312d67" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_3a5e2447-f48a-4214-99d3-ab1b12a86638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalTreasurySharesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_36ac9563-13d3-4c26-84bf-db1703153556" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_36ac9563-13d3-4c26-84bf-db1703153556" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_a2e14578-37c9-488d-a9fa-f4ac084715c0" xlink:to="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_aeae42cc-96c5-4ccf-a230-75b9bb898c33" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_91278901-6bea-4cc0-9a0f-519957e84af2" xlink:to="loc_ifrs-full_TreasurySharesMember_aeae42cc-96c5-4ccf-a230-75b9bb898c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_d1f0259b-32f9-43df-958e-1eb47b2dd895" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1433af27-7584-4fae-af19-fe770352741d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1433af27-7584-4fae-af19-fe770352741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_0052e89c-a30a-45ab-a2d5-466c23363ac7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_10317f89-56f2-4e12-9a56-29d8d7318d48" xlink:to="loc_ifrs-full_TreasuryShares_0052e89c-a30a-45ab-a2d5-466c23363ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_72c76980-accc-445a-a634-b2fbce5c56e3" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_72c76980-accc-445a-a634-b2fbce5c56e3" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c6c9acab-fec6-406a-9851-c6f3bdc0f03f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_bab3612a-caab-4b76-b759-4e4f2b151997" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20122Member_bab3612a-caab-4b76-b759-4e4f2b151997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_8aa0e918-80f0-4773-8a86-85dc49470f2b" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE082013Member_8aa0e918-80f0-4773-8a86-85dc49470f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_0f700ce4-59e9-4edc-b540-03eb81db4760" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE092014Member_0f700ce4-59e9-4edc-b540-03eb81db4760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_899e52e8-b03c-412b-a132-5c3ba8fea5a7" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20151Member_899e52e8-b03c-412b-a132-5c3ba8fea5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_f379aed8-f8fa-4439-9ee9-4b55a5a2fba5" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE20153Member_f379aed8-f8fa-4439-9ee9-4b55a5a2fba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016Member_4f2eca2a-9a9d-4d37-8570-e0161b61ea35" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE2016Member_4f2eca2a-9a9d-4d37-8570-e0161b61ea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_8ec6c4a7-5103-43bc-8f2d-2ca24f0082e9" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_01c13572-52f0-438c-bed1-7021045d4aba" xlink:to="loc_nbx_BSPCE2017Member_8ec6c4a7-5103-43bc-8f2d-2ca24f0082e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_5f3b6eab-cced-420a-8ff2-dae1e7566737" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA0412Member_5f3b6eab-cced-420a-8ff2-dae1e7566737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_af56bd0a-0169-426c-b9cb-1d698f566b86" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2013Member_af56bd0a-0169-426c-b9cb-1d698f566b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_a0c8b12b-fc93-41ef-8ccd-33bb03872318" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2014Member_a0c8b12b-fc93-41ef-8ccd-33bb03872318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_c6cee694-c2eb-428a-8b5d-6499fecbd1f4" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20151Member_c6cee694-c2eb-428a-8b5d-6499fecbd1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_d283ec4f-a223-44bb-b867-1a9bda3c7f13" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20152AMember_d283ec4f-a223-44bb-b867-1a9bda3c7f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_9cd873f3-fc60-4115-bf82-cc44846441e2" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20152BMember_9cd873f3-fc60-4115-bf82-cc44846441e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016Member_a965c03f-7c42-4be2-9af9-15662f996830" xlink:href="nbx-20211231.xsd#nbx_BSA2016Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2016Member_a965c03f-7c42-4be2-9af9-15662f996830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_93166995-6dcb-4dda-a4eb-0ac98597ceeb" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20162Member_93166995-6dcb-4dda-a4eb-0ac98597ceeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_85f553d1-8f33-4b46-b9e2-7f5681817baa" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2017Member_85f553d1-8f33-4b46-b9e2-7f5681817baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_ed310d80-5186-45fc-b727-8aade337c3b7" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20181Member_ed310d80-5186-45fc-b727-8aade337c3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_534de259-7a67-448d-9754-cedf5f6a9b37" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20182Member_534de259-7a67-448d-9754-cedf5f6a9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_9b38b253-3221-4e87-bfb6-7f945a09f40c" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA20191Member_9b38b253-3221-4e87-bfb6-7f945a09f40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_6c5d3538-2c89-41cb-a72f-bebf3ae130dc" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2020Member_6c5d3538-2c89-41cb-a72f-bebf3ae130dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_7f01acdd-ea31-4897-8f58-a2beef4236fb" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2021AMember_7f01acdd-ea31-4897-8f58-a2beef4236fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_cddd76b5-0d6a-4d11-8b66-a4a05ac61f2f" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_86082af7-9589-463d-b9ef-600bb3bd0636" xlink:to="loc_nbx_BSA2021BMember_cddd76b5-0d6a-4d11-8b66-a4a05ac61f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161Member_5f8ca7a6-189e-4ad5-a964-6ec31da2b7b7" xlink:href="nbx-20211231.xsd#nbx_OSA20161Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20161Member_5f8ca7a6-189e-4ad5-a964-6ec31da2b7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_44d1f700-4a2c-495e-b25a-eab6d67a656c" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20162Member_44d1f700-4a2c-495e-b25a-eab6d67a656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017Member_51abdeb2-5c9e-4552-aa21-a1fd16903d28" xlink:href="nbx-20211231.xsd#nbx_OSA2017Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2017Member_51abdeb2-5c9e-4552-aa21-a1fd16903d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_b20bd8b7-9319-491d-914d-acea3ab75485" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2018Member_b20bd8b7-9319-491d-914d-acea3ab75485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_d01d5cea-f8d5-4e63-8295-1b401af18fc9" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA20191Member_d01d5cea-f8d5-4e63-8295-1b401af18fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_c81946ee-f661-49f9-b853-c00aac5f0408" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSALLY2019Member_c81946ee-f661-49f9-b853-c00aac5f0408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_c222c5f8-a5d6-487a-b745-fa6167853ac7" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA2020Member_c222c5f8-a5d6-487a-b745-fa6167853ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_652d4f8e-886c-4ef2-bdf5-af9743ba302e" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA202104Member_652d4f8e-886c-4ef2-bdf5-af9743ba302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_7bc9f554-38e4-4326-a94f-d028de9c5ed0" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_29816d14-4299-48ff-8794-2fc0c1cb6a6a" xlink:to="loc_nbx_OSA202106Member_7bc9f554-38e4-4326-a94f-d028de9c5ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d13846e-8a3d-4ce8-be91-171f4ffc86dc" xlink:to="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_90aafd32-b13a-47b7-aebe-5b1268ba8fde" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20181Member_90aafd32-b13a-47b7-aebe-5b1268ba8fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_e1ba758c-fe3f-40d5-b53f-a1a30f5a96eb" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20182Member_e1ba758c-fe3f-40d5-b53f-a1a30f5a96eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_d39a0979-0413-4d92-b114-b921e8f5a2d7" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA20191Member_d39a0979-0413-4d92-b114-b921e8f5a2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_129ffa79-a9f4-4404-9abe-2d9fb91e4452" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA2020Member_129ffa79-a9f4-4404-9abe-2d9fb91e4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_15609e80-f21d-4166-9462-e018410e7690" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_2fa6e631-9936-4376-afa4-78150a46699d" xlink:to="loc_nbx_AGA2021Member_15609e80-f21d-4166-9462-e018410e7690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6d04371-4f71-4909-bcd1-84311f4d574c" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_85f9c956-1cf8-4f0c-b902-f959933de12a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_85f9c956-1cf8-4f0c-b902-f959933de12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d177ccf7-16d9-42cb-8e89-0191c8f65cbd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d177ccf7-16d9-42cb-8e89-0191c8f65cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e5ad533b-264a-4da7-9406-f09cf496dfff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e5ad533b-264a-4da7-9406-f09cf496dfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4554e4bf-d153-406a-aed5-ef99bb7667e9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4554e4bf-d153-406a-aed5-ef99bb7667e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_d741ab79-1796-463a-b661-36c7ae3baa3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_d741ab79-1796-463a-b661-36c7ae3baa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8a135566-3ed5-4337-9269-b1357bf0d0f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_8a135566-3ed5-4337-9269-b1357bf0d0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_95ac6b73-fd87-4ce6-a165-5d8ca5661e12" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_95ac6b73-fd87-4ce6-a165-5d8ca5661e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_c3f54b33-f727-470c-86c9-eb3d7bb109f2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_c3f54b33-f727-470c-86c9-eb3d7bb109f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3145bba5-c627-4a5b-8a3d-ff858f2c3909" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_3145bba5-c627-4a5b-8a3d-ff858f2c3909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_80ed06e2-63f0-484b-8b01-5c7ad5027de3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_80ed06e2-63f0-484b-8b01-5c7ad5027de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6ea7fa03-86dc-49b1-9a83-53c36d04e4d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_6ea7fa03-86dc-49b1-9a83-53c36d04e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_fa123b33-ef9b-440c-a730-bd639d3ffb5d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_fa123b33-ef9b-440c-a730-bd639d3ffb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a6fde404-3501-4b18-863e-3bfebeb756e6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_308a173e-23da-499f-b448-8aa8082e064d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a6fde404-3501-4b18-863e-3bfebeb756e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalFounderswarrantsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_7529c05c-597b-4a3d-8994-9ad724418b1e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_7529c05c-597b-4a3d-8994-9ad724418b1e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:to="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2739c2d7-a311-42f0-a855-d17a1eeac99f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerEmployeesMember_7670564c-ca99-4685-9212-60e9c4f2238e" xlink:href="nbx-20211231.xsd#nbx_FormerEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:to="loc_nbx_FormerEmployeesMember_7670564c-ca99-4685-9212-60e9c4f2238e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerExecutiveBoardMembersMember_2ec653d5-3f2a-4f8c-bc64-3fcc6fcddff7" xlink:href="nbx-20211231.xsd#nbx_FormerExecutiveBoardMembersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1589187-dbd6-4924-b9d7-021bc596bb7f" xlink:to="loc_nbx_FormerExecutiveBoardMembersMember_2ec653d5-3f2a-4f8c-bc64-3fcc6fcddff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_da962297-3325-4d72-b180-8845f1d7758f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_fcd75d1d-d82e-4e23-b0c4-ac260795e913" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7d7f08e4-5a46-49b8-9e3d-0898fc8a6e79" xlink:to="loc_nbx_BSPCEMember_fcd75d1d-d82e-4e23-b0c4-ac260795e913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_f70be200-33df-4dbe-b278-c292e1797862" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_684e883a-a7e2-4f91-ab15-cb9aef9c591f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_bda3159f-4649-4075-ae32-1432186227f0" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_684e883a-a7e2-4f91-ab15-cb9aef9c591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalWarrantPlansDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_e3b88cd1-5ef5-431c-8dc5-593d445b1617" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_e3b88cd1-5ef5-431c-8dc5-593d445b1617" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b3fb29e6-287a-4894-824a-91a9e9d9a8ee" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_dff8a040-bed8-42e4-8a11-72c3ae52a008" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2021AMember_dff8a040-bed8-42e4-8a11-72c3ae52a008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AInReplacementOfBSA2016Member_43cda357-e0b7-41ed-b9ce-a4e61d2f5d91" xlink:href="nbx-20211231.xsd#nbx_BSA2021AInReplacementOfBSA2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2021AInReplacementOfBSA2016Member_43cda357-e0b7-41ed-b9ce-a4e61d2f5d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_4f02373e-8071-419e-bff6-745194294a87" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_392422bc-fcd5-48e1-bc2a-eb01b9f71fee" xlink:to="loc_nbx_BSA2020Member_4f02373e-8071-419e-bff6-745194294a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:to="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_f58c887b-5cfe-4ae4-bd14-a5adff29ccbe" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SupervisoryBoardMember_bc9fae8e-b73c-43ab-9970-bdad045c9638" xlink:href="nbx-20211231.xsd#nbx_SupervisoryBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_SupervisoryBoardMember_bc9fae8e-b73c-43ab-9970-bdad045c9638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExternalConsultantMember_eb9cec9b-7609-4930-b45f-58c0f9c54046" xlink:href="nbx-20211231.xsd#nbx_ExternalConsultantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_ExternalConsultantMember_eb9cec9b-7609-4930-b45f-58c0f9c54046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_5adaae6a-aa78-4c64-a362-26e234cdc9ba" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_798e71d9-5222-46d9-98a0-8bf62ffd3d91" xlink:to="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_5adaae6a-aa78-4c64-a362-26e234cdc9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_831cae00-8af1-4e26-9b6b-31d1bb466648" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6f1fba84-ec60-4d3f-9796-e7191b910082" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6f1fba84-ec60-4d3f-9796-e7191b910082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_4dc5f9ab-4588-405e-9d0e-2f5b190d994e" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachBSA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA_4dc5f9ab-4588-405e-9d0e-2f5b190d994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_68f31a53-877d-49cf-99b5-40c1cd7dcd5b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_ParValuePerShare_68f31a53-877d-49cf-99b5-40c1cd7dcd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1972d2db-5196-4e5a-ae1b-581102f8771a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_1972d2db-5196-4e5a-ae1b-581102f8771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_ed4ec079-321c-4c91-bff5-9d5c43708e21" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_ed4ec079-321c-4c91-bff5-9d5c43708e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_1f254163-faec-4313-acc8-6bc4e9498e62" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement_1f254163-faec-4313-acc8-6bc4e9498e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_418d24e4-4b32-4ab0-8677-e817a648a55f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance_418d24e4-4b32-4ab0-8677-e817a648a55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_8ad50237-050d-42ba-87b6-b231bff513c8" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise_8ad50237-050d-42ba-87b6-b231bff513c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_0f4d0e05-f59e-4b9b-80af-7d82e8f139c1" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_0f4d0e05-f59e-4b9b-80af-7d82e8f139c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_566e898c-7722-4056-adbf-607d141f7c80" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c58f8d17-7993-44b6-9262-1e2482b3b919" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_566e898c-7722-4056-adbf-607d141f7c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalStockOptionPlansDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_2d547a66-c9d3-4d93-9cad-1dd1c106508e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_2d547a66-c9d3-4d93-9cad-1dd1c106508e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6fc844fd-c478-46ec-a2c8-4fd4c10eb9aa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_9b9b2503-79b7-45cd-9f81-fdb043a87bbf" xlink:href="nbx-20211231.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_9b9b2503-79b7-45cd-9f81-fdb043a87bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BartVanRhijnMember_40172d2b-f282-493e-b063-d19e067dac06" xlink:href="nbx-20211231.xsd#nbx_BartVanRhijnMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_BartVanRhijnMember_40172d2b-f282-493e-b063-d19e067dac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_24ece6bb-5aeb-4c30-bc3d-050366db94fc" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember_24ece6bb-5aeb-4c30-bc3d-050366db94fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_cea713ce-4232-4eba-8827-eb0d2fb59448" xlink:href="nbx-20211231.xsd#nbx_MembersOfTheExecutiveBoardAndAlainDostieMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_MembersOfTheExecutiveBoardAndAlainDostieMember_cea713ce-4232-4eba-8827-eb0d2fb59448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmployeesMember_7f3e245d-7698-4193-aef4-839d2aa2df0a" xlink:href="nbx-20211231.xsd#nbx_EmployeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_EmployeesMember_7f3e245d-7698-4193-aef4-839d2aa2df0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FormerExecutiveBoardMembersMember_d47c8237-87d8-4a62-8da6-91a156b7c4d4" xlink:href="nbx-20211231.xsd#nbx_FormerExecutiveBoardMembersMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53774871-04e4-4015-8116-b0a7abb8db34" xlink:to="loc_nbx_FormerExecutiveBoardMembersMember_d47c8237-87d8-4a62-8da6-91a156b7c4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4cd918a9-1bef-4222-958d-2d1f0a3f94d7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_ab96db15-1a07-48a0-bc04-d66e59c96c95" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104Member_ab96db15-1a07-48a0-bc04-d66e59c96c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_c9f05ba3-d35d-400a-b32d-ba1c9c0bf8d8" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104OrdinaryMember_c9f05ba3-d35d-400a-b32d-ba1c9c0bf8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_2518b33d-faf6-4175-8773-716bf4aebf1c" xlink:href="nbx-20211231.xsd#nbx_OSA202104PerformanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202104PerformanceMember_2518b33d-faf6-4175-8773-716bf4aebf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_485df023-f328-4a83-beb2-311022b0672a" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSAMember_485df023-f328-4a83-beb2-311022b0672a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_a26c1bc6-3bde-42e4-be59-f5f938b408b5" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106OrdinaryMember_a26c1bc6-3bde-42e4-be59-f5f938b408b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_09d84a4a-24b3-4976-bc40-2714c8e364d0" xlink:href="nbx-20211231.xsd#nbx_OSA202106PerformanceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106PerformanceMember_09d84a4a-24b3-4976-bc40-2714c8e364d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_671cbd24-8cfa-4cc7-9a57-534010dc6cb7" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA202106Member_671cbd24-8cfa-4cc7-9a57-534010dc6cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_5208e79e-a0c0-4c31-923f-5a396ba4bde3" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a7724fce-fda1-4687-80c9-05ecfacf80c2" xlink:to="loc_nbx_OSA2020Member_5208e79e-a0c0-4c31-923f-5a396ba4bde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:to="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_0dcc4d60-96a1-4cac-a243-e604ced004d8" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheOneMember_0dcc4d60-96a1-4cac-a243-e604ced004d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_ff6dc894-5abc-42a1-bd8b-f26209b933f9" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheTwoMember_ff6dc894-5abc-42a1-bd8b-f26209b933f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_7c780d84-7699-4c72-adae-9cbb5434853a" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheThreeMember_7c780d84-7699-4c72-adae-9cbb5434853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_3500a43c-9f7c-4055-b854-90514f3aac05" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_09343758-6d23-4579-ac9a-e9b40cc6bc2f" xlink:to="loc_nbx_TrancheFourMember_3500a43c-9f7c-4055-b854-90514f3aac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_10de3310-3a6f-4215-aa5b-8e4b72a902c5" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_cb49a5c0-a937-4c1d-bd13-e97c716ca3cb" xlink:to="loc_nbx_TranchesDomain_10de3310-3a6f-4215-aa5b-8e4b72a902c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingAxis_50fa33c2-7637-4e63-ad88-d71131a49e86" xlink:to="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromFirstYearOfGrantDateMember_5cc61a50-3a0d-4d2b-a04f-891fbf95e666" xlink:href="nbx-20211231.xsd#nbx_FromFirstYearOfGrantDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromFirstYearOfGrantDateMember_5cc61a50-3a0d-4d2b-a04f-891fbf95e666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromSecondYearOfGrantDateMember_d1f387ef-b344-447b-9b59-036a8e52b879" xlink:href="nbx-20211231.xsd#nbx_FromSecondYearOfGrantDateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromSecondYearOfGrantDateMember_d1f387ef-b344-447b-9b59-036a8e52b879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_FromThirdYearOfGrantDateMember_751d88b6-5a54-4ab5-8cf2-b81d6d5da96f" xlink:href="nbx-20211231.xsd#nbx_FromThirdYearOfGrantDateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_a2b59b50-c466-48d8-92dd-b7f5c644d4bd" xlink:to="loc_nbx_FromThirdYearOfGrantDateMember_751d88b6-5a54-4ab5-8cf2-b81d6d5da96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7a48de69-48be-430c-8f45-7194d40c9ab9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_b36b2315-2823-4403-9d3e-2ec902aa6d7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_b36b2315-2823-4403-9d3e-2ec902aa6d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_8704db80-e9bf-4d6c-8d2e-8c4241d53fe6" xlink:href="nbx-20211231.xsd#nbx_NumberOfOrdinaryShareSubscribedPerEachOSA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA_8704db80-e9bf-4d6c-8d2e-8c4241d53fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_34177bfd-0e15-42b2-bdcc-7bcd90efd860" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_ParValuePerShare_34177bfd-0e15-42b2-bdcc-7bcd90efd860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_20738728-b833-4389-a1f5-82af0fb069ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_20738728-b833-4389-a1f5-82af0fb069ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_d9c80cff-4eff-4dc1-b8ad-9e360c8498f8" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_d9c80cff-4eff-4dc1-b8ad-9e360c8498f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_ec5c39ee-9c6c-4687-9f1a-a4d7fe6ed86b" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_ec5c39ee-9c6c-4687-9f1a-a4d7fe6ed86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SharePriceMilestoneEuronextParis_7153ed74-ee9a-401f-9d53-e95ad5d3b37e" xlink:href="nbx-20211231.xsd#nbx_SharePriceMilestoneEuronextParis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_SharePriceMilestoneEuronextParis_7153ed74-ee9a-401f-9d53-e95ad5d3b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_1d44a5aa-ead3-4f09-af4b-3e5396383ca2" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised_1d44a5aa-ead3-4f09-af4b-3e5396383ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_e7c9ca9c-6814-447b-a0ae-e1113ed1e690" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_e7c9ca9c-6814-447b-a0ae-e1113ed1e690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_0d188062-9932-4fe8-88e6-28034995e38f" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_0d188062-9932-4fe8-88e6-28034995e38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_6f07a215-37dc-496f-aa68-03b947028eb2" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_6f07a215-37dc-496f-aa68-03b947028eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_fa0a3d4b-e142-4804-8b49-51ee7fa6ea56" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_0de20188-dff6-4bf1-8938-8fdfe8454ea2" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated_fa0a3d4b-e142-4804-8b49-51ee7fa6ea56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ShareCapitalFreeSharePlansDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_145cefe0-2d47-4c88-84d3-85bd85392ee2" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract_145cefe0-2d47-4c88-84d3-85bd85392ee2" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:to="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4d104f1c-860f-4153-980d-5ca4acd7c58c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExecutiveBoardAndEmployeesMember_53beeae1-f0e1-4a02-af56-f15f3b6ed53e" xlink:href="nbx-20211231.xsd#nbx_ExecutiveBoardAndEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_ExecutiveBoardAndEmployeesMember_53beeae1-f0e1-4a02-af56-f15f3b6ed53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnneJulietteHermantMember_d4284fb5-7651-4e8f-bf10-c5ac4ff7f9be" xlink:href="nbx-20211231.xsd#nbx_AnneJulietteHermantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_AnneJulietteHermantMember_d4284fb5-7651-4e8f-bf10-c5ac4ff7f9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EmployeesMember_3fb42afa-145b-493c-b987-651bfaf0417c" xlink:href="nbx-20211231.xsd#nbx_EmployeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f8ca463-5a56-46bb-be44-509d7e23ba6b" xlink:to="loc_nbx_EmployeesMember_3fb42afa-145b-493c-b987-651bfaf0417c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_034c456c-43b5-40ad-b196-79371b3b5ccf" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_9c11db70-424d-4f2b-8885-6650cc0a8c29" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2021Member_9c11db70-424d-4f2b-8885-6650cc0a8c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_c2b47b1c-9988-4592-b28d-5aa25a2dc6e4" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2020Member_c2b47b1c-9988-4592-b28d-5aa25a2dc6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020AndAGA2021Member_4fc19534-af3e-4abb-839e-6f72e5b664f6" xlink:href="nbx-20211231.xsd#nbx_AGA2020AndAGA2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA2020AndAGA2021Member_4fc19534-af3e-4abb-839e-6f72e5b664f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_a414361e-a491-4d83-a705-5ddda8e67416" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGAMember_a414361e-a491-4d83-a705-5ddda8e67416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_9c341f80-13d9-469d-b9b0-92a1861148ff" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20181Member_9c341f80-13d9-469d-b9b0-92a1861148ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_768362ac-e64b-4462-84af-fdfc9e80cff1" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20191Member_768362ac-e64b-4462-84af-fdfc9e80cff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_4bb7f2df-b630-43d8-aed5-e6c92940be61" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_5e9a9def-9da8-4bc6-a27d-1b16cdcf419b" xlink:to="loc_nbx_AGA20182Member_4bb7f2df-b630-43d8-aed5-e6c92940be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7010ab8a-2df2-4ac4-8896-2cc5fd62231a" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a40974bb-27b3-425b-b0b2-db34510c7032" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a40974bb-27b3-425b-b0b2-db34510c7032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_032ebfc7-c2c9-46b4-8175-e9d7584c8e73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_ParValuePerShare_032ebfc7-c2c9-46b4-8175-e9d7584c8e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_58cfb02f-9c47-4da1-88aa-d45be1f4af2a" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod_58cfb02f-9c47-4da1-88aa-d45be1f4af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_f582d36a-ace5-4c50-a12e-a46e1fcea53a" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod_f582d36a-ace5-4c50-a12e-a46e1fcea53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_287abb22-f216-4f06-8c64-8d73b1cd41ae" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients_287abb22-f216-4f06-8c64-8d73b1cd41ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_86f2accf-5f47-4ffd-9691-8e0f979ae894" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled_86f2accf-5f47-4ffd-9691-8e0f979ae894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_15db1e9f-497d-483b-a7c6-4e56e6cdf9b0" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents_15db1e9f-497d-483b-a7c6-4e56e6cdf9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_3d5be0e3-73d5-415b-a287-580251770f98" xlink:href="nbx-20211231.xsd#nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee_3d5be0e3-73d5-415b-a287-580251770f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_0908cc52-fa9c-4ecd-b1f1-3667e59d121a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_ifrs-full_IssueOfEquity_0908cc52-fa9c-4ecd-b1f1-3667e59d121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_846a5185-63d8-49f6-8058-e2bc4bf0e3b7" xlink:href="nbx-20211231.xsd#nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_a7a72b28-7bd8-405a-a73d-e64e43490ef9" xlink:to="loc_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted_846a5185-63d8-49f6-8058-e2bc4bf0e3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Provisions" xlink:type="simple" xlink:href="nbx-20211231.xsd#Provisions"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Provisions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_2dba8924-73d6-44f7-b856-7252a0b922a1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_ee6d204f-4109-4962-999c-ff0e731ed3b1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_2dba8924-73d6-44f7-b856-7252a0b922a1" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_ee6d204f-4109-4962-999c-ff0e731ed3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_c4d8b408-f27b-423e-b5bc-ef2d48b58660" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_a1f34d59-767f-4010-8192-5879f49760a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_c4d8b408-f27b-423e-b5bc-ef2d48b58660" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsExplanatory_a1f34d59-767f-4010-8192-5879f49760a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_024d8b78-240b-4808-bf67-6a83983d54b3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_c4d8b408-f27b-423e-b5bc-ef2d48b58660" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_024d8b78-240b-4808-bf67-6a83983d54b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_adfddab9-aa27-4e92-b14d-2ba4afef961c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_c4d8b408-f27b-423e-b5bc-ef2d48b58660" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_adfddab9-aa27-4e92-b14d-2ba4afef961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_ad3081a0-55ff-4825-98f2-33e48cfb4898" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_c4d8b408-f27b-423e-b5bc-ef2d48b58660" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_ad3081a0-55ff-4825-98f2-33e48cfb4898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofChangesinProvisionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_7571adbe-33c9-483a-aa6e-0009c187f84a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_7571adbe-33c9-483a-aa6e-0009c187f84a" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_56050418-6f3f-4349-bb54-5e4ec9aa84f6" xlink:to="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:href="nbx-20211231.xsd#nbx_NonCurrentOtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:to="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LumpSumRetirementBenefitsMember_2964c304-67d4-4d7a-8212-b5face975931" xlink:href="nbx-20211231.xsd#nbx_LumpSumRetirementBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_NonCurrentOtherProvisionsMember_b5c73102-303f-4164-b73c-92ae425ed332" xlink:to="loc_nbx_LumpSumRetirementBenefitsMember_2964c304-67d4-4d7a-8212-b5face975931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:href="nbx-20211231.xsd#nbx_CurrentOtherProvisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_4274789e-0b93-4874-949d-aca84b4cc292" xlink:to="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_2ae84eda-596f-42c8-83bf-652c82a67aa0" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:to="loc_nbx_ProvisionsForDisputesMember_2ae84eda-596f-42c8-83bf-652c82a67aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_ccb67810-4ec2-43b0-83df-b4d1c8df2d5b" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CurrentOtherProvisionsMember_35547898-dfeb-406c-8186-dc6be62498b6" xlink:to="loc_nbx_ProvisionsForChargesMember_ccb67810-4ec2-43b0-83df-b4d1c8df2d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_8ef4d06f-5851-4f2c-852d-3eb56fbc287b" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_01a2ffaf-2414-42b4-af07-42f03e07c0d7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_OtherProvisions_01a2ffaf-2414-42b4-af07-42f03e07c0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_cf5a1f69-b32b-43e2-9c31-6aa3f235b9e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_cf5a1f69-b32b-43e2-9c31-6aa3f235b9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_a58e21ad-21f4-438e-a3b0-bc97f4acb41e" xlink:href="nbx-20211231.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_a58e21ad-21f4-438e-a3b0-bc97f4acb41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_4d69a810-f0ba-46f8-b07e-7b9200292d4e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_dc8874eb-52e4-4a23-acc1-e2f9c8cde309" xlink:to="loc_ifrs-full_OtherProvisions_4d69a810-f0ba-46f8-b07e-7b9200292d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_887743ed-d18b-43a2-a5ae-014badad717b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_887743ed-d18b-43a2-a5ae-014badad717b" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_bf7a9df5-8901-4e3e-8f55-e7cc9f42aac2" xlink:to="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForDisputesMember_447efa1a-939c-4c36-80a2-6875b24a3a56" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForDisputesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:to="loc_nbx_ProvisionsForDisputesMember_447efa1a-939c-4c36-80a2-6875b24a3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionsForChargesMember_29b1d4de-5e10-4783-a16a-576ec49c0a1a" xlink:href="nbx-20211231.xsd#nbx_ProvisionsForChargesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1ac060d-84f4-4d33-8def-e75ebf747380" xlink:to="loc_nbx_ProvisionsForChargesMember_29b1d4de-5e10-4783-a16a-576ec49c0a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_0d8d6722-e8d8-466e-923d-f5be6d09f62f" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_9e6366a6-2078-44ec-84cd-ae138e663945" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_9e6366a6-2078-44ec-84cd-ae138e663945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_93447107-dcbe-4afb-8468-35e626c2161c" xlink:href="nbx-20211231.xsd#nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions_93447107-dcbe-4afb-8468-35e626c2161c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationPayablePeriod_6f18f6b2-8b5e-4535-a39e-b2a4f8fcae40" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationPayablePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_4bd51322-36e7-4c4b-b61f-80d2c8261374" xlink:to="loc_nbx_DefinedBenefitObligationPayablePeriod_6f18f6b2-8b5e-4535-a39e-b2a4f8fcae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b2c34c38-bae1-4768-b705-f2b660812524" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_b2c34c38-bae1-4768-b705-f2b660812524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_0df0bbcb-908f-492b-8757-b1b52d7c7e28" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_0df0bbcb-908f-492b-8757-b1b52d7c7e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_15d7dc99-e307-443b-bb33-9563ba4e6403" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_15d7dc99-e307-443b-bb33-9563ba4e6403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_99317796-207e-4ee2-a8cc-1210652e95c6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_99317796-207e-4ee2-a8cc-1210652e95c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_037365dc-3a40-4862-a4b3-e91deccd7e90" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_037365dc-3a40-4862-a4b3-e91deccd7e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_2f9195d2-5fc5-45a8-828c-931839b4d74d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_2f9195d2-5fc5-45a8-828c-931839b4d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a132f192-f2a3-439b-a78f-f900995bfd08" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_a132f192-f2a3-439b-a78f-f900995bfd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6f33b833-e6b5-4458-9c82-f03a94e12ab1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_6f33b833-e6b5-4458-9c82-f03a94e12ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_444e410b-8394-48c8-b36a-0c051bb5067b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_6b12565a-956c-4274-9dfa-18535942df82" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_444e410b-8394-48c8-b36a-0c051bb5067b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_888031ad-ed58-4e65-9946-b76a288e7e6f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_888031ad-ed58-4e65-9946-b76a288e7e6f" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:to="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_48a810e9-be5a-4e78-a239-007833df8caa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_547999ac-98db-4b60-96a5-75b87eb0e4dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_srt_ManagementMember_547999ac-98db-4b60-96a5-75b87eb0e4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonManagementMember_f30e6486-9166-4958-961e-433df57f646a" xlink:href="nbx-20211231.xsd#nbx_NonManagementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_nbx_NonManagementMember_f30e6486-9166-4958-961e-433df57f646a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_c2fc0d66-3db5-4bd3-a9c8-d44473e8add6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_srt_ExecutiveOfficerMember_c2fc0d66-3db5-4bd3-a9c8-d44473e8add6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonExecutiveMember_781ab4dc-356d-4036-813f-37e9023f8c29" xlink:href="nbx-20211231.xsd#nbx_NonExecutiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6c33e07c-32f7-44cf-aa9f-b5570f924f98" xlink:to="loc_nbx_NonExecutiveMember_781ab4dc-356d-4036-813f-37e9023f8c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_72bbd1ef-211d-436b-a585-698b89c90c3d" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_acac551a-4af8-41db-9ec4-c49a4725413e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfRetirementAge2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfRetirementAge2019_acac551a-4af8-41db-9ec4-c49a4725413e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_4dc3a84a-8a63-4a80-88f6-2d012d393133" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfSocialSecurityContributionRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_nbx_ActuarialAssumptionOfSocialSecurityContributionRates_4dc3a84a-8a63-4a80-88f6-2d012d393133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_7392007b-8dcd-497a-9ab0-c8877cc16671" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_7392007b-8dcd-497a-9ab0-c8877cc16671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_b80df821-afd2-4fcf-b050-5a57d6cf4ea9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_b80df821-afd2-4fcf-b050-5a57d6cf4ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_b12101e7-0515-4c3a-a21d-056c20c46e17" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover_b12101e7-0515-4c3a-a21d-056c20c46e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_0fbbcee1-cfe6-4ad0-b32d-b71c182e2345" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_3e6cd0a4-d64f-4afe-bc54-67b645e6b932" xlink:to="loc_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019_0fbbcee1-cfe6-4ad0-b32d-b71c182e2345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsAbstract_aecd3cb8-b6c9-49d2-80b7-8d71cbc9edbf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProvisionsAbstract_aecd3cb8-b6c9-49d2-80b7-8d71cbc9edbf" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:to="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsAxis_9bf85d6a-15d2-4303-b443-708fd4b45820" xlink:to="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_fcdc9196-0d35-4f82-a90d-15d35d5f0f76" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ActuarialAssumptionsMember_97ff44df-bf7c-4e56-8cd8-005c67db400a" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_fcdc9196-0d35-4f82-a90d-15d35d5f0f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable_fdd08c3c-5741-484a-8ac9-ff3b90b08b09" xlink:to="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_884b3cc5-3793-4e4d-83f3-b4a14652c315" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25_884b3cc5-3793-4e4d-83f3-b4a14652c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_2189b5aa-d51f-47ed-ba78-799bff7d220a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_2189b5aa-d51f-47ed-ba78-799bff7d220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_d6925091-11dc-4c1e-9c32-16412bab5bdf" xlink:href="nbx-20211231.xsd#nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25_d6925091-11dc-4c1e-9c32-16412bab5bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_5ab53519-a580-4c30-8280-313bf22e3afb" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption_5ab53519-a580-4c30-8280-313bf22e3afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_b6f27767-daf6-4451-8608-1463369230f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan_b6f27767-daf6-4451-8608-1463369230f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_8645308b-4f74-4fad-910c-873c0cfa4f12" xlink:href="nbx-20211231.xsd#nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems_45d4d886-f564-4e2e-933c-8323addc28bd" xlink:to="loc_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption_8645308b-4f74-4fad-910c-873c0cfa4f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Financialliabilities" xlink:type="simple" xlink:href="nbx-20211231.xsd#Financialliabilities"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Financialliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_fb6a2eae-fa86-4588-983b-b840f5f3aff8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfFinancialLiabilitiesTextBlock_79888d18-f378-4a5c-9466-f883164f4287" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfFinancialLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_fb6a2eae-fa86-4588-983b-b840f5f3aff8" xlink:to="loc_nbx_DisclosureOfFinancialLiabilitiesTextBlock_79888d18-f378-4a5c-9466-f883164f4287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f7d79e5b-4b90-46e5-959c-f07ce9b3c104" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_e5b842cd-8914-47d5-bd53-abc31c5135ec" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f7d79e5b-4b90-46e5-959c-f07ce9b3c104" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_e5b842cd-8914-47d5-bd53-abc31c5135ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_5322d800-475e-4fec-8b6b-245c4d6fc832" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f7d79e5b-4b90-46e5-959c-f07ce9b3c104" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_5322d800-475e-4fec-8b6b-245c4d6fc832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_f0d7271f-b31d-456d-800b-e631c067df60" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f7d79e5b-4b90-46e5-959c-f07ce9b3c104" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_f0d7271f-b31d-456d-800b-e631c067df60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_b6905e2e-f4ae-4bcc-ad70-a0d675ffd445" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_f7d79e5b-4b90-46e5-959c-f07ce9b3c104" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_b6905e2e-f4ae-4bcc-ad70-a0d675ffd445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_1d8ccb2c-2489-474f-a783-170fefd8990d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_1d8ccb2c-2489-474f-a783-170fefd8990d" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_baa413c4-62fc-411b-98ee-ebb141846adc" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_d777bbd6-237e-422d-a5b6-ad150d6c08a2" xlink:href="nbx-20211231.xsd#nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:to="loc_nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember_d777bbd6-237e-422d-a5b6-ad150d6c08a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_a90372f6-d7b4-43ee-abca-a437ef7a29e5" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4028ee56-8d78-48d1-96ed-f0f4fff2ddee" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_a90372f6-d7b4-43ee-abca-a437ef7a29e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0ee7e640-3cff-4f30-aaf8-681e6e654a8a" xlink:to="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_f77ff635-8e7e-4897-bd4e-f1d7c23b87b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_f77ff635-8e7e-4897-bd4e-f1d7c23b87b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesMember_be1ebaa1-e597-4934-86cc-03a9923dba4b" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_nbx_ConditionalAdvancesMember_be1ebaa1-e597-4934-86cc-03a9923dba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_d4f681ff-c82d-46f1-8c8b-8a0d111de8f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_a314a120-a5a8-447c-858d-ba469292504e" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_d4f681ff-c82d-46f1-8c8b-8a0d111de8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_b6819b9f-cfe0-413d-9895-63cf89d3a988" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_425a576f-e639-4d94-b1f6-e518fa44daf2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_425a576f-e639-4d94-b1f6-e518fa44daf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_c5fb7a0c-631d-4514-946f-e79edd0bbb0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_c5fb7a0c-631d-4514-946f-e79edd0bbb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_9594f2c7-7e2b-47f1-8b82-9b4bdc812e7e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_23a9f0ac-f944-4800-bc32-3d4248b91c47" xlink:to="loc_ifrs-full_FinancialLiabilities_9594f2c7-7e2b-47f1-8b82-9b4bdc812e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a06a9c20-5d7f-4e18-add4-7d386fbb6887" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_a06a9c20-5d7f-4e18-add4-7d386fbb6887" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_5a9741ee-c625-41a1-9572-2527ddc5e902" xlink:to="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_aadeee7a-d16d-47b8-ac9f-0955d83e9027" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_aadeee7a-d16d-47b8-ac9f-0955d83e9027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_13565f36-8e24-41b3-b560-343bb319ee77" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_13565f36-8e24-41b3-b560-343bb319ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_8a8d39c6-7f8e-4861-9747-1b39b13f69eb" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_181729f2-1e40-41c5-aef8-9a7987fca82f" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_8a8d39c6-7f8e-4861-9747-1b39b13f69eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_0c38e144-7d43-4667-902f-46cf3b639f73" xlink:to="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_0f01b15e-822f-4385-8cc3-f4a6ed2aa901" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:to="loc_ifrs-full_TopOfRangeMember_0f01b15e-822f-4385-8cc3-f4a6ed2aa901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_3c6acbb8-82bd-4784-a3af-3de547e99b25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b0e87a8a-820b-40fc-bc82-abf1c516680d" xlink:to="loc_ifrs-full_BottomOfRangeMember_3c6acbb8-82bd-4784-a3af-3de547e99b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_ca82d514-e607-452e-bddd-bd8187116efd" xlink:to="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_c09c34ab-7cfc-412b-a105-1715a03e6a30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:to="loc_ifrs-full_FixedInterestRateMember_c09c34ab-7cfc-412b-a105-1715a03e6a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_7a18a445-1cfb-49c1-98b0-c32c7759625c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_71526926-42e4-44d1-935d-836f3d8523ae" xlink:to="loc_ifrs-full_FloatingInterestRateMember_7a18a445-1cfb-49c1-98b0-c32c7759625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fe9a59b2-6759-4640-bbdf-a2279142fef1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BanquePubliqueDInvestissementMember_850bbc1f-83e8-4f75-a700-47060fe6840f" xlink:href="nbx-20211231.xsd#nbx_BanquePubliqueDInvestissementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:to="loc_nbx_BanquePubliqueDInvestissementMember_850bbc1f-83e8-4f75-a700-47060fe6840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_6c4a31c2-9b04-46d8-addb-baa1f8596c44" xlink:href="nbx-20211231.xsd#nbx_BPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f6deb4a-2fff-4462-8478-d0cf5d2a76b6" xlink:to="loc_nbx_BPIFranceMember_6c4a31c2-9b04-46d8-addb-baa1f8596c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_98086974-2e7a-4981-a107-ce809b0faa41" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_17c6047a-bbe3-4670-ba4b-d635506b11ae" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_18dddd75-60ae-49cd-8c67-de7ab8e53aa0" xlink:to="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_17c6047a-bbe3-4670-ba4b-d635506b11ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable_c9d75385-afe6-427c-81f9-d1d3cf7ef7e6" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedDefermentPeriod_e8a5fd1f-7485-41fc-9001-998f32d8a4ab" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedDefermentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesReceivedDefermentPeriod_e8a5fd1f-7485-41fc-9001-998f32d8a4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesReceivedInterestRate_ac5abca4-0696-4c24-a234-04a5577ce5a1" xlink:href="nbx-20211231.xsd#nbx_AdvancesReceivedInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesReceivedInterestRate_ac5abca4-0696-4c24-a234-04a5577ce5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Advances_fd076680-24d4-471b-b056-5d4b4037f8cd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Advances"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_Advances_fd076680-24d4-471b-b056-5d4b4037f8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_2d2cb979-4149-47f2-a540-8ff6d6d3f61e" xlink:href="nbx-20211231.xsd#nbx_AdvancesAuthorizedAmountToBeAdvanced"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesAuthorizedAmountToBeAdvanced_2d2cb979-4149-47f2-a540-8ff6d6d3f61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AdvancesOutstandingAmountToBeReceived_5964c08d-a823-4f34-b656-805236d3387a" xlink:href="nbx-20211231.xsd#nbx_AdvancesOutstandingAmountToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_AdvancesOutstandingAmountToBeReceived_5964c08d-a823-4f34-b656-805236d3387a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_be35cb48-eabe-4d68-b62a-705932ea5411" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_NotionalAmount_be35cb48-eabe-4d68-b62a-705932ea5411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesBorrowings_4a8fe989-49e8-413b-9692-333bb1785634" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesBorrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_NumberOfTranchesBorrowings_4a8fe989-49e8-413b-9692-333bb1785634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_eefa954e-fd84-429a-bcb9-545c85b48062" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_eefa954e-fd84-429a-bcb9-545c85b48062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriodToRequestFunds_3b8baf44-9352-4630-822c-ebbd0a9a8907" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriodToRequestFunds"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingDefermentPeriodToRequestFunds_3b8baf44-9352-4630-822c-ebbd0a9a8907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_4556df5f-bf92-4060-a840-99ebb1b1e512" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_4556df5f-bf92-4060-a840-99ebb1b1e512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_b86b5bd7-0c66-49f1-96c8-699280b08401" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest_b86b5bd7-0c66-49f1-96c8-699280b08401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_e5355f71-d932-47b5-a61d-dad482988911" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingDefermentPeriod_e5355f71-d932-47b5-a61d-dad482988911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_c702451e-df2c-41eb-b356-e4e6b0de83e9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_BorrowingsInterestRate_c702451e-df2c-41eb-b356-e4e6b0de83e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_e80627db-5755-407d-b366-0be3e6c6b109" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTerm_e80627db-5755-407d-b366-0be3e6c6b109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_eb708193-472e-407f-9188-6908d50fb821" xlink:href="nbx-20211231.xsd#nbx_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingPercentageOfStateGuaranteedLoan_eb708193-472e-407f-9188-6908d50fb821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_758b4200-6b94-4723-bdee-a2d6166a740b" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest_758b4200-6b94-4723-bdee-a2d6166a740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_d03cdb26-0088-48f8-84cc-b95c1315aaf4" xlink:href="nbx-20211231.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingGuaranteeFee_d03cdb26-0088-48f8-84cc-b95c1315aaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfQuarterlyInstalments_3a40f726-4101-44b1-b623-ec9357cf394d" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfQuarterlyInstalments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingNumberOfQuarterlyInstalments_3a40f726-4101-44b1-b623-ec9357cf394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e84a324f-1d08-42fa-a779-69535c11ff0e" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_e84a324f-1d08-42fa-a779-69535c11ff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltyPayables_dab78c68-4ac8-4e47-82f0-448ac31428ac" xlink:href="nbx-20211231.xsd#nbx_RoyaltyPayables"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_RoyaltyPayables_dab78c68-4ac8-4e47-82f0-448ac31428ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_36e3fbfd-1b0b-43a7-989b-710a0077eead" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_36e3fbfd-1b0b-43a7-989b-710a0077eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_09798b62-228e-44e7-ace2-e08ea58978a7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_Borrowings_09798b62-228e-44e7-ace2-e08ea58978a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingTotalInterestPayable_a751c901-a076-42bc-ba57-aa5b6adedb5e" xlink:href="nbx-20211231.xsd#nbx_BorrowingTotalInterestPayable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_BorrowingTotalInterestPayable_a751c901-a076-42bc-ba57-aa5b6adedb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPayable_916a31cd-2f3f-438d-84c1-4728ed2ac20d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPayable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_ifrs-full_InterestPayable_916a31cd-2f3f-438d-84c1-4728ed2ac20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConsolidatedForecastedSalesPeriod_11d1463c-9796-4d5c-8416-6aa6da3002ea" xlink:href="nbx-20211231.xsd#nbx_ConsolidatedForecastedSalesPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems_4586dde2-28b0-4b20-900b-e91615265ec9" xlink:to="loc_nbx_ConsolidatedForecastedSalesPeriod_11d1463c-9796-4d5c-8416-6aa6da3002ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_2e2e0b79-3b5b-4706-b141-2d7b25799fdf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_2e2e0b79-3b5b-4706-b141-2d7b25799fdf" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7fb6ccc7-2d37-4fb3-9b1f-b829fee17623" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceAdvanceMember_e3a775ee-d9a7-4f8d-820d-3bbaeb58e675" xlink:href="nbx-20211231.xsd#nbx_BPIFranceAdvanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_BPIFranceAdvanceMember_e3a775ee-d9a7-4f8d-820d-3bbaeb58e675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeBPIFranceLoanMember_f63a87e5-4553-4d81-b2a9-320198e2764c" xlink:href="nbx-20211231.xsd#nbx_InterestFreeBPIFranceLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_InterestFreeBPIFranceLoanMember_f63a87e5-4553-4d81-b2a9-320198e2764c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b004102f-0b72-4e31-989f-fa6a08fe4788" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b004102f-0b72-4e31-989f-fa6a08fe4788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvanceBPIFranceMember_90a441b9-977f-4349-9e8a-59dadbdaecdd" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvanceBPIFranceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_4b41afa5-603d-4bec-b23b-dea184b24f21" xlink:to="loc_nbx_ConditionalAdvanceBPIFranceMember_90a441b9-977f-4349-9e8a-59dadbdaecdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_988fa678-8a62-4d64-85ca-db894f55045e" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_efddd748-9574-4e18-a812-43703766bc6c" xlink:href="nbx-20211231.xsd#nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_812a0c57-8e63-4094-8333-16192c8b2723" xlink:to="loc_nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember_efddd748-9574-4e18-a812-43703766bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_d50c192a-3e22-47b7-aeed-43568c5b2940" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_9bf5cdf5-9e16-42e3-a51d-248231248bd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_9bf5cdf5-9e16-42e3-a51d-248231248bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0f9ea817-f7bb-4802-812b-b46f0d43d462" xlink:href="nbx-20211231.xsd#nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_0f9ea817-f7bb-4802-812b-b46f0d43d462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_479c9fa6-a635-4187-a2c8-c8e14375c453" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_479c9fa6-a635-4187-a2c8-c8e14375c453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_06900a44-a704-417f-b0fe-ca9e0f6e254e" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_06900a44-a704-417f-b0fe-ca9e0f6e254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_7a8bfa4e-82d5-438e-9dcf-d842f858b252" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_7a8bfa4e-82d5-438e-9dcf-d842f858b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_955da57b-856e-4730-9c17-82de5525e300" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_85c854ee-2dce-4f85-9f00-1feb81a95e89" xlink:to="loc_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_955da57b-856e-4730-9c17-82de5525e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_2911baf4-59fe-4bdb-aebb-32af5c40335c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_00e6a6ce-c800-40b4-a5eb-ac5e7d72c3c7" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_2911baf4-59fe-4bdb-aebb-32af5c40335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7222ce38-1aac-4c6f-9863-c1d46f996edd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_7222ce38-1aac-4c6f-9863-c1d46f996edd" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_de2803f6-29af-4652-a3c8-f871ba938c35" xlink:to="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_c7f1501a-f433-4001-8719-dcc815d48b80" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_c7f1501a-f433-4001-8719-dcc815d48b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07b29bcf-61ac-4c35-857d-72fdc605bb42" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_469052f3-2199-45a3-9a18-2c3d4214790a" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_07b29bcf-61ac-4c35-857d-72fdc605bb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_b82e1be8-3f8e-4eea-8406-1efa553c5a7f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_ba97a729-b5d8-4b2d-bd24-8a7556eb5c8b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_a079fe8d-547d-4cc5-9a74-4f309a090f35" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_ba97a729-b5d8-4b2d-bd24-8a7556eb5c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_2722c0de-7b69-4646-af00-ba444c5eed79" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_28355f5b-643d-4631-a3a8-61aee689c390" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_28355f5b-643d-4631-a3a8-61aee689c390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_227969ec-fb0f-47c7-923c-c1b8803c62f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_227969ec-fb0f-47c7-923c-c1b8803c62f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_3e817760-cfa8-4a70-ae07-fed69ddc6057" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_3e817760-cfa8-4a70-ae07-fed69ddc6057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_902dcd4e-25b3-4a32-aa6d-5cb09fb71acb" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_ffc29c05-1650-477a-9e4e-963ea8a42fff" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_902dcd4e-25b3-4a32-aa6d-5cb09fb71acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_42df5fa3-9de1-4947-a7c1-00f2afd2352d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_42df5fa3-9de1-4947-a7c1-00f2afd2352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingGuaranteeFee_fe15b6c5-f675-4941-bd47-ed16f76f1085" xlink:href="nbx-20211231.xsd#nbx_BorrowingGuaranteeFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_nbx_BorrowingGuaranteeFee_fe15b6c5-f675-4941-bd47-ed16f76f1085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_a9a502eb-b491-47a7-998e-5d7c88cb4d14" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6f467b49-ff15-4dfe-a64f-8e7ada2bfcb9" xlink:to="loc_ifrs-full_BorrowingsInterestRate_a9a502eb-b491-47a7-998e-5d7c88cb4d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_50c19462-426f-48db-ae14-f76d04faab8f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_50c19462-426f-48db-ae14-f76d04faab8f" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d2f99caf-ae08-41d6-a104-175d44568905" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_73eb9fa1-681a-447e-87a6-17f7c0897e6a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_baa8cf1a-a95f-45f7-9bb0-32b875495742" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_73eb9fa1-681a-447e-87a6-17f7c0897e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_bfd3e761-d20a-4a35-be27-dd237d5bae2f" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_b94e4e55-9697-4776-b395-6a0ccae69fc0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_b94e4e55-9697-4776-b395-6a0ccae69fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_e555b093-b55a-4e12-aad3-31516a920aef" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_e555b093-b55a-4e12-aad3-31516a920aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_b24e213b-b45d-4e50-a411-f7b16a260914" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities_b24e213b-b45d-4e50-a411-f7b16a260914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_60c0e11e-9b30-4641-92de-55da41cd5029" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_60c0e11e-9b30-4641-92de-55da41cd5029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_e3800628-833c-4a20-84a4-3645c3c5a29c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_e3800628-833c-4a20-84a4-3645c3c5a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_50bb474b-0df5-4ec3-b816-673a78baddef" xlink:href="nbx-20211231.xsd#nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities_50bb474b-0df5-4ec3-b816-673a78baddef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_17b18ffc-1228-4e06-b3a1-a013e9a553bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_6ea96a36-68f0-4501-8191-47905f7e744a" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_17b18ffc-1228-4e06-b3a1-a013e9a553bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f9402d4-c3b6-4e3c-bff4-0a87c7405282" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract_9f9402d4-c3b6-4e3c-bff4-0a87c7405282" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_542c2c5c-9f4e-40b4-8a88-1c43d8cbb898" xlink:to="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BPIFranceMember_5df13cd8-d037-45d4-87fd-f0f7ee36d3f0" xlink:href="nbx-20211231.xsd#nbx_BPIFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_BPIFranceMember_5df13cd8-d037-45d4-87fd-f0f7ee36d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeLoanBPIFranceMember_7c64160e-3a15-411d-b0e5-710298594a93" xlink:href="nbx-20211231.xsd#nbx_InterestFreeLoanBPIFranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_InterestFreeLoanBPIFranceMember_7c64160e-3a15-411d-b0e5-710298594a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_5d23d756-f741-4e5b-905a-92dfdc57ce8c" xlink:href="nbx-20211231.xsd#nbx_InterestFreeAdvanceToCuradigmBPIFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_InterestFreeAdvanceToCuradigmBPIFranceMember_5d23d756-f741-4e5b-905a-92dfdc57ce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_bed2884c-1e6b-4e31-b9d0-db67522bf4d6" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceMember_bed2884c-1e6b-4e31-b9d0-db67522bf4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_c5c603a5-8d47-4e4f-bbca-78e7adcb4421" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_c5c603a5-8d47-4e4f-bbca-78e7adcb4421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e32f07a0-4fdb-4495-8507-0f09b33b3271" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_e32f07a0-4fdb-4495-8507-0f09b33b3271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_aeea77bc-f02b-4f99-9a3d-205461eb8921" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_627821a4-0d5a-4b12-bed8-ed146ae1b59c" xlink:to="loc_nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember_aeea77bc-f02b-4f99-9a3d-205461eb8921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:to="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_2e512ee8-29a3-4b28-829a-52dc459fc213" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_b5f52726-8f71-4cea-aa8e-665abd3f2b8f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_b5f52726-8f71-4cea-aa8e-665abd3f2b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_ef1c909d-f667-48a6-8f40-0a9275b6d605" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_ef1c909d-f667-48a6-8f40-0a9275b6d605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_39064100-1229-45f4-a631-1cd346a6aed5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_39064100-1229-45f4-a631-1cd346a6aed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_47a30de6-b239-4dc9-bda9-5d220a0a3786" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_e898d88a-cd30-4aac-8f84-2bc5f1226fbf" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_47a30de6-b239-4dc9-bda9-5d220a0a3786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_983a7368-161a-4eda-85c2-aa35ef8bcc8d" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_41139d31-3a66-4278-9aef-0a0df26ee99d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_41139d31-3a66-4278-9aef-0a0df26ee99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_8e08e93e-fbb7-4a8c-8184-54e18841b711" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_8e08e93e-fbb7-4a8c-8184-54e18841b711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9fb5b527-e7df-4565-84cb-6ee6bb0748f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows_9fb5b527-e7df-4565-84cb-6ee6bb0748f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingNumberOfPGE_3042a283-3ac0-4ad4-bc9a-8bf0c0f8d7d1" xlink:href="nbx-20211231.xsd#nbx_BorrowingNumberOfPGE"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingNumberOfPGE_3042a283-3ac0-4ad4-bc9a-8bf0c0f8d7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingMaturityTerm_13349bd5-e248-45fa-aa83-dc73294e0365" xlink:href="nbx-20211231.xsd#nbx_BorrowingMaturityTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingMaturityTerm_13349bd5-e248-45fa-aa83-dc73294e0365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BorrowingDefermentPeriod_3e29cdda-018d-4e1c-89db-b8a8528084aa" xlink:href="nbx-20211231.xsd#nbx_BorrowingDefermentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_08caba29-f850-4540-a97d-17500beb8d3b" xlink:to="loc_nbx_BorrowingDefermentPeriod_3e29cdda-018d-4e1c-89db-b8a8528084aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities" xlink:type="simple" xlink:href="nbx-20211231.xsd#Tradepayablesandothercurrentliabilities"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_537b3842-847f-43c3-a0e1-69a9dff150df" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_7a21d2e3-99d4-426a-9733-aa1195db8575" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_537b3842-847f-43c3-a0e1-69a9dff150df" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock_7a21d2e3-99d4-426a-9733-aa1195db8575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_057065bb-fba5-4ea6-8078-2f0a97057a76" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_c796589c-d9b4-4ed2-92fd-7c806a17c33c" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_057065bb-fba5-4ea6-8078-2f0a97057a76" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock_c796589c-d9b4-4ed2-92fd-7c806a17c33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_f4ddc563-5166-4ce0-bce3-b136874c8cac" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_057065bb-fba5-4ea6-8078-2f0a97057a76" xlink:to="loc_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock_f4ddc563-5166-4ce0-bce3-b136874c8cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_849410d9-f3fd-4e7c-9f10-400c1abd920d" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_057065bb-fba5-4ea6-8078-2f0a97057a76" xlink:to="loc_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock_849410d9-f3fd-4e7c-9f10-400c1abd920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c48fec9e-810c-46b4-a056-edef6e2bb5fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_8379c89a-6de5-4bd9-86dd-bf94d56dc4a4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c48fec9e-810c-46b4-a056-edef6e2bb5fd" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_8379c89a-6de5-4bd9-86dd-bf94d56dc4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_f600bbc6-d8d4-450b-a5f5-a4c0b538f774" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c48fec9e-810c-46b4-a056-edef6e2bb5fd" xlink:to="loc_ifrs-full_OtherCurrentPayables_f600bbc6-d8d4-450b-a5f5-a4c0b538f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_153f0ad5-344c-4016-bef5-8f2f75016c1b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c48fec9e-810c-46b4-a056-edef6e2bb5fd" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_153f0ad5-344c-4016-bef5-8f2f75016c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_469fe9e0-889a-4257-bbcf-f58aba1f6d15" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_469fe9e0-889a-4257-bbcf-f58aba1f6d15" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:to="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_79a26471-57c1-41f8-9427-d3ac0e9dea1b" xlink:to="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ICONPlcMember_34c62bcf-b75c-4da3-b97d-c2b4514fa788" xlink:href="nbx-20211231.xsd#nbx_ICONPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:to="loc_nbx_ICONPlcMember_34c62bcf-b75c-4da3-b97d-c2b4514fa788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_4fc2d2cc-0d18-4811-b023-aaf052c0d67e" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_906f6c7c-47e5-45ec-af39-d29525726800" xlink:to="loc_nbx_LianBioNBTXR3Member_4fc2d2cc-0d18-4811-b023-aaf052c0d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable_8f596789-baf6-4a39-a464-01faf4ce2d54" xlink:to="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_9dbde4a9-c8b3-4140-aa9c-0bea102f2a4f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_OtherCurrentPayables_9dbde4a9-c8b3-4140-aa9c-0bea102f2a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_fafba486-bbec-4ff0-9dbd-fba70fbb38ed" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent_fafba486-bbec-4ff0-9dbd-fba70fbb38ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_4028cc28-55b5-4dc2-aa7d-953e938541b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_4028cc28-55b5-4dc2-aa7d-953e938541b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_9d82035d-d1a2-49e6-8449-d0c531cdabf3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems_812095b8-f15b-41e4-bd2d-4d61f2bb1752" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_9d82035d-d1a2-49e6-8449-d0c531cdabf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b377e7bb-5aa0-487e-9903-605318435e03" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_e47eb7ab-0719-4d3e-a627-a1db37d9ded9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b377e7bb-5aa0-487e-9903-605318435e03" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_e47eb7ab-0719-4d3e-a627-a1db37d9ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6ce648dc-b53f-42c0-aa17-a5e2244e3a2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b377e7bb-5aa0-487e-9903-605318435e03" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_6ce648dc-b53f-42c0-aa17-a5e2244e3a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherMiscellaneousCurrentLiabilities_dd1b90d2-bddd-4387-96e8-9bd666832bdc" xlink:href="nbx-20211231.xsd#nbx_OtherMiscellaneousCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b377e7bb-5aa0-487e-9903-605318435e03" xlink:to="loc_nbx_OtherMiscellaneousCurrentLiabilities_dd1b90d2-bddd-4387-96e8-9bd666832bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_e3af4245-b16a-427f-9ee9-f3faeec02f1e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b377e7bb-5aa0-487e-9903-605318435e03" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_e3af4245-b16a-427f-9ee9-f3faeec02f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9f0cb088-aeb7-4814-9f0e-055caac2e41f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_f559d16f-eb6e-4f1c-8a7a-7622e7e7614f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9f0cb088-aeb7-4814-9f0e-055caac2e41f" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_f559d16f-eb6e-4f1c-8a7a-7622e7e7614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" xlink:type="simple" xlink:href="nbx-20211231.xsd#Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_98fae290-c365-4a04-93ee-2371a636680a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_523d2bcf-c282-4cb1-a740-807cd2a5aca0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_98fae290-c365-4a04-93ee-2371a636680a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_523d2bcf-c282-4cb1-a740-807cd2a5aca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e1b13c83-cb05-422e-8054-477710574295" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_39aa4c1c-031c-4a2c-9295-ecfcb844997b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e1b13c83-cb05-422e-8054-477710574295" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_39aa4c1c-031c-4a2c-9295-ecfcb844997b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_71e195f8-531e-4c4c-b5ea-920180daa707" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e1b13c83-cb05-422e-8054-477710574295" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_71e195f8-531e-4c4c-b5ea-920180daa707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock_5149eda7-b01b-4a59-b97c-93912118222a" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e1b13c83-cb05-422e-8054-477710574295" xlink:to="loc_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock_5149eda7-b01b-4a59-b97c-93912118222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_24b5a54b-ee1a-4153-be37-7601f51a71a3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_24b5a54b-ee1a-4153-be37-7601f51a71a3" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_6c6634c1-4bf0-4a1c-90fb-fce26186db67" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_a62277a7-0463-4d68-ba50-38d45aa90b33" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_a62277a7-0463-4d68-ba50-38d45aa90b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_240958b0-2e54-471d-9d1a-31879fb04962" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_24e954ea-69ab-4a73-baa7-38f1fca2ae54" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_240958b0-2e54-471d-9d1a-31879fb04962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_871a41f7-cd96-4613-8818-41578ca3f532" xlink:to="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialAssetsMember_a86e840d-10bb-4e75-8e29-65d08a72512a" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_nbx_NonCurrentFinancialAssetsMember_a86e840d-10bb-4e75-8e29-65d08a72512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_9eecaa1d-02c5-4f32-9568-ffc5691e1f63" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_ifrs-full_TradeReceivablesMember_9eecaa1d-02c5-4f32-9568-ffc5691e1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CashAndCashEquivalentsMember_41312c3a-3efb-4413-aa89-522309380654" xlink:href="nbx-20211231.xsd#nbx_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6e69a616-6a41-402d-a8ec-1051102be985" xlink:to="loc_nbx_CashAndCashEquivalentsMember_41312c3a-3efb-4413-aa89-522309380654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_97d8e7fe-72f1-4d9b-9fb1-2bbc945ad69d" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonCurrentFinancialLiabilitiesMember_781cf6b6-34b8-4294-9ef7-9af758dcd91a" xlink:href="nbx-20211231.xsd#nbx_NonCurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_NonCurrentFinancialLiabilitiesMember_781cf6b6-34b8-4294-9ef7-9af758dcd91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CurrentFinancialLiabilitiesMember_a9b6310c-34e9-483a-a91a-e659c21ee54e" xlink:href="nbx-20211231.xsd#nbx_CurrentFinancialLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_CurrentFinancialLiabilitiesMember_a9b6310c-34e9-483a-a91a-e659c21ee54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TradeAndOtherPayablesMember_367aa9ac-0605-45ee-bf57-187340123169" xlink:href="nbx-20211231.xsd#nbx_TradeAndOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_76c9ffc0-9b57-408a-bc4b-bde202dde9f9" xlink:to="loc_nbx_TradeAndOtherPayablesMember_367aa9ac-0605-45ee-bf57-187340123169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8bbae07d-35d9-4dfe-90b2-389410e8f951" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_f35ab31b-9ac5-418e-bba7-698e14191c2b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_6b2f6319-4fd4-4f80-aa95-67c8daaf43e4" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_f35ab31b-9ac5-418e-bba7-698e14191c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_7ea353a8-5547-45eb-b19e-2de6683b7155" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_cfd4b33d-08ad-4bc4-9301-92c724033e95" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_ifrs-full_FinancialAssets_cfd4b33d-08ad-4bc4-9301-92c724033e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_a2c2fbd7-bb08-4783-a5a2-2d2b8f0b24fe" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_a2c2fbd7-bb08-4783-a5a2-2d2b8f0b24fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_a5ac6c2f-1861-45ef-be47-d54a8988122e" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables_a5ac6c2f-1861-45ef-be47-d54a8988122e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_92d260dd-b919-493d-b3a4-edeba3e64914" xlink:href="nbx-20211231.xsd#nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_25e290d2-603c-4e7c-9e01-2fc04a13ceb3" xlink:to="loc_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue_92d260dd-b919-493d-b3a4-edeba3e64914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_8cb4ab1f-09c0-47d7-b759-04006f56dde4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_8cb4ab1f-09c0-47d7-b759-04006f56dde4" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:to="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_cacaf222-4b89-476a-8538-9ba1836436dd" xlink:to="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_cee595e8-ed7e-476a-8084-bc9cef034ac0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_8902c4b9-85b0-4f3a-a0f9-3f86a0980bba" xlink:to="loc_ifrs-full_CurrencyRiskMember_cee595e8-ed7e-476a-8084-bc9cef034ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:to="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_6e50bdee-fd56-4797-b473-e191202859a9" xlink:to="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_761587ec-c5e6-4f41-b0fc-378b5ee1fa0e" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_e915460b-ad9b-45a7-8d2e-c2cd95060d98" xlink:to="loc_currency_USD_761587ec-c5e6-4f41-b0fc-378b5ee1fa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_39aada35-f468-4171-a726-b7f3519aae0a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_0fc2fef2-5356-48d2-ad81-274d55bdf135" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate_0fc2fef2-5356-48d2-ad81-274d55bdf135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_9ee7a883-382f-4a78-8896-99fddfc41ce4" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate_9ee7a883-382f-4a78-8896-99fddfc41ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_61d09d53-6d55-41c6-8d2e-b1c9a5af26c1" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate_61d09d53-6d55-41c6-8d2e-b1c9a5af26c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_1b25358a-f4bf-4e71-bb45-0bb1a52a9bae" xlink:href="nbx-20211231.xsd#nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_43ad8d38-baa9-4d94-98c0-81a04480ae55" xlink:to="loc_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate_1b25358a-f4bf-4e71-bb45-0bb1a52a9bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_53634155-ba6e-46ce-a59a-4cb4d7520871" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_53634155-ba6e-46ce-a59a-4cb4d7520871" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_686f5c34-c553-4b0e-a1fe-5af9436eb0f1" xlink:to="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9bc827f5-10de-410b-9546-4feffd6ddb6b" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3aae346a-1510-487d-9e26-cf88b95bc418" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9bc827f5-10de-410b-9546-4feffd6ddb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:to="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_53b26af6-7ec3-4d1f-9443-1e15e6502019" xlink:to="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bd5be199-3928-43af-a44e-14efcc642b77" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_5e9b3a58-d5de-4b83-81cd-2e7168d0ff75" xlink:to="loc_ifrs-full_TopOfRangeMember_bd5be199-3928-43af-a44e-14efcc642b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_61dea2c2-0767-47b2-9863-0a5a10f139b5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_e6e68137-8fc6-4d3f-a50d-b29598045fb6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_ifrs-full_NotionalAmount_e6e68137-8fc6-4d3f-a50d-b29598045fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesBorrowings_9083063e-e89b-48a1-a54b-ea0fafe1111a" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_nbx_NumberOfTranchesBorrowings_9083063e-e89b-48a1-a54b-ea0fafe1111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfTranchesReceivedBorrowings_23627417-9819-45b1-80db-ee2d212a55d8" xlink:href="nbx-20211231.xsd#nbx_NumberOfTranchesReceivedBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_cd4d7a2d-db6e-459b-ada5-6038584dccf1" xlink:to="loc_nbx_NumberOfTranchesReceivedBorrowings_23627417-9819-45b1-80db-ee2d212a55d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Revenuesandotherincome" xlink:type="simple" xlink:href="nbx-20211231.xsd#Revenuesandotherincome"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Revenuesandotherincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_f4c4005c-954b-4263-aaef-5433f82f1827" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_bd609c24-5027-41e8-85ac-0cc1e26f5f3d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_f4c4005c-954b-4263-aaef-5433f82f1827" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_bd609c24-5027-41e8-85ac-0cc1e26f5f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_d22e798f-2b7e-4b8d-b56c-da15a9a980a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_b3aa40d7-97bd-425c-9cca-49a60aeeca4d" xlink:href="nbx-20211231.xsd#nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_d22e798f-2b7e-4b8d-b56c-da15a9a980a0" xlink:to="loc_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock_b3aa40d7-97bd-425c-9cca-49a60aeeca4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_e4156c71-0b56-4e75-8cad-ff5da3a4160d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_e4156c71-0b56-4e75-8cad-ff5da3a4160d" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_77ed6a3e-b150-4ff4-95f3-6f4ff584ed32" xlink:to="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PharmaEngineNBTWR3Member_81f77ad1-e7c0-4016-8162-1353391c214a" xlink:href="nbx-20211231.xsd#nbx_PharmaEngineNBTWR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_PharmaEngineNBTWR3Member_81f77ad1-e7c0-4016-8162-1353391c214a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_LianBioNBTXR3Member_e739cbd4-4b98-4ffc-b4b9-64bac453003a" xlink:href="nbx-20211231.xsd#nbx_LianBioNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_LianBioNBTXR3Member_e739cbd4-4b98-4ffc-b4b9-64bac453003a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SanofiGeneTherapyPortfolioMember_a9b68a89-033e-4cc3-a32a-e5d7520acfe7" xlink:href="nbx-20211231.xsd#nbx_SanofiGeneTherapyPortfolioMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_85224d6b-c9f6-4d56-a75e-8b543819785a" xlink:to="loc_nbx_SanofiGeneTherapyPortfolioMember_a9b68a89-033e-4cc3-a32a-e5d7520acfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c1185840-7bca-4a2a-80d4-8b34addb072b" xlink:to="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20d489ed-b73f-4919-bf2f-27a746c5d902" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_87417129-e109-4811-b76f-2dbc78db3e5b" xlink:to="loc_srt_MaximumMember_20d489ed-b73f-4919-bf2f-27a746c5d902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_001441dd-a75f-4469-9870-d179f7e26f8d" xlink:to="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_f899feb5-714e-4d8a-89c4-80e484fa2d8d" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7b0bfcad-6a7f-43ae-be4c-a154d357beec" xlink:to="loc_country_FR_f899feb5-714e-4d8a-89c4-80e484fa2d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7589eca5-caba-4e4c-b6c5-8129ee84e850" xlink:to="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_74643604-053f-42f1-bfd8-61e9bfcd683e" xlink:href="nbx-20211231.xsd#nbx_NonDilutiveFinancingAgreementBPIFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_cdf5131f-5e2c-4b59-8f06-faccfb9f8832" xlink:to="loc_nbx_NonDilutiveFinancingAgreementBPIFranceMember_74643604-053f-42f1-bfd8-61e9bfcd683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ConcentrationsOfRiskAxis_86bf31b5-92e3-4914-a6f7-cceabf2c999b" xlink:to="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RevenueByTypeMember_214b2605-4e58-491d-a2bb-2f90b6e8ed7e" xlink:href="nbx-20211231.xsd#nbx_RevenueByTypeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ConcentrationsOfRiskMember_1ba64f23-1c45-488e-b9cd-f31e710cbe06" xlink:to="loc_nbx_RevenueByTypeMember_214b2605-4e58-491d-a2bb-2f90b6e8ed7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c507883e-15b9-4924-927a-9970d27ff0d9" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_30b2e3dc-3112-4635-b9ea-0f48f41e5306" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementUpfrontPaymentReceived_30b2e3dc-3112-4635-b9ea-0f48f41e5306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_d3e8254e-709b-4fba-a5e4-a3513b7297a8" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived_d3e8254e-709b-4fba-a5e4-a3513b7297a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_a4e4df8a-2896-414e-b5fc-be66368ae5e3" xlink:href="nbx-20211231.xsd#nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement_a4e4df8a-2896-414e-b5fc-be66368ae5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_27e197ab-1b4b-4dfd-97f7-8931b01e465f" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived_27e197ab-1b4b-4dfd-97f7-8931b01e465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod_6571be5b-b96f-40be-bb23-3ea8a8ed13b7" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementMilestonesAchievementPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_CollaborationAgreementMilestonesAchievementPeriod_6571be5b-b96f-40be-bb23-3ea8a8ed13b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchTaxCreditUtilizationPeriod_ae5e46ca-74bf-422d-82da-ac64b907f478" xlink:href="nbx-20211231.xsd#nbx_ResearchTaxCreditUtilizationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_ResearchTaxCreditUtilizationPeriod_ae5e46ca-74bf-422d-82da-ac64b907f478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_7a1f6688-3719-45c0-bd49-fa1d8eb5d943" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_7a1f6688-3719-45c0-bd49-fa1d8eb5d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ConcentrationRiskPercentage_39cc5722-94d6-405b-a87b-506466dcc0f5" xlink:href="nbx-20211231.xsd#nbx_ConcentrationRiskPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_ConcentrationRiskPercentage_39cc5722-94d6-405b-a87b-506466dcc0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_ce444e2a-c653-4dbb-9602-afcf2faf237a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_ce444e2a-c653-4dbb-9602-afcf2faf237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_9c820106-e23c-49d7-aa85-1bdff7a949f1" xlink:href="nbx-20211231.xsd#nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure_9c820106-e23c-49d7-aa85-1bdff7a949f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_9606347c-fed4-4000-8585-1c2c3de6c733" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e2b17682-f043-4d33-9c2c-3a1deb3fbbc8" xlink:to="loc_ifrs-full_NotionalAmount_9606347c-fed4-4000-8585-1c2c3de6c733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_dd2cc2fe-3b52-4985-bfb5-f23ebc3e6f43" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_dd2cc2fe-3b52-4985-bfb5-f23ebc3e6f43" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_9b71caeb-bb88-40b7-a01b-3b7ea0064409" xlink:to="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ServicesMember_8ac7724e-eb58-44f1-bf79-0f1ca70177cb" xlink:href="nbx-20211231.xsd#nbx_ServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:to="loc_nbx_ServicesMember_8ac7724e-eb58-44f1-bf79-0f1ca70177cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OtherSalesMember_ae1616ed-5a65-4af6-8e48-fbe0163e27d8" xlink:href="nbx-20211231.xsd#nbx_OtherSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_bf191202-38df-463c-9690-4816401e1e07" xlink:to="loc_nbx_OtherSalesMember_ae1616ed-5a65-4af6-8e48-fbe0163e27d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_9b4317f4-67f3-4c19-999d-5e078f3368be" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_cb55646b-ede2-4e66-9c1a-28073a857958" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_cb55646b-ede2-4e66-9c1a-28073a857958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentTaxCredit_37fcba72-a722-45ab-b4ba-4ee0e95e2103" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_nbx_ResearchAndDevelopmentTaxCredit_37fcba72-a722-45ab-b4ba-4ee0e95e2103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_0873d665-1fb2-48a0-804a-66627d191d6e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_0873d665-1fb2-48a0-804a-66627d191d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_04523647-d859-4eab-9239-625bac8896e2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_04523647-d859-4eab-9239-625bac8896e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_c201e601-306c-40b9-a735-1d3d6fe33cce" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_OtherIncome_c201e601-306c-40b9-a735-1d3d6fe33cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_b0ea0b5e-630d-4ccb-8eb0-4306d6d80caf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d0d7d942-1724-4a15-90f4-770e04856c47" xlink:to="loc_ifrs-full_Revenue_b0ea0b5e-630d-4ccb-8eb0-4306d6d80caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Operatingexpenses" xlink:type="simple" xlink:href="nbx-20211231.xsd#Operatingexpenses"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Operatingexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1b46122-e200-4850-81c8-5d59cdda44f7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_65f9ed9f-168a-4943-a286-5c33336a0b86" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1b46122-e200-4850-81c8-5d59cdda44f7" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_65f9ed9f-168a-4943-a286-5c33336a0b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_d9e94716-54f9-489b-bfbe-8bbeb2a213c7" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock_d9e94716-54f9-489b-bfbe-8bbeb2a213c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_37fdf66a-c9c8-4ef0-808d-d3963dd5ee8f" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock_37fdf66a-c9c8-4ef0-808d-d3963dd5ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_11c96eeb-90df-4974-aba5-c9f5dcc46ff4" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock_11c96eeb-90df-4974-aba5-c9f5dcc46ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_6ff57f13-05ea-49e8-918a-9e043d225e6f" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock_6ff57f13-05ea-49e8-918a-9e043d225e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock_ce1d0ca8-eb14-41fe-a390-d0a7aa140596" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_4e319635-8420-4b9b-9808-cb8cbb969018" xlink:to="loc_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock_ce1d0ca8-eb14-41fe-a390-d0a7aa140596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c24ea404-a9eb-461d-93f1-acf2a5009596" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_39ca0a23-44c8-46bb-8824-f4804ade6497" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c24ea404-a9eb-461d-93f1-acf2a5009596" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses_39ca0a23-44c8-46bb-8824-f4804ade6497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_fe318d0a-6d0f-4ce7-a810-2e22efdfe1c1" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpensePayrollCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c24ea404-a9eb-461d-93f1-acf2a5009596" xlink:to="loc_nbx_ResearchAndDevelopmentExpensePayrollCosts_fe318d0a-6d0f-4ce7-a810-2e22efdfe1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_a421062f-960a-43d6-a6bc-09ae32a99373" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c24ea404-a9eb-461d-93f1-acf2a5009596" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense_a421062f-960a-43d6-a6bc-09ae32a99373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_65a358ad-b51e-47aa-841f-3deb6523a00e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c24ea404-a9eb-461d-93f1-acf2a5009596" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_65a358ad-b51e-47aa-841f-3deb6523a00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesResearchandDevelopmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_bfc9ad41-7336-4e29-a170-6f9c2c6f6c0d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_bfc9ad41-7336-4e29-a170-6f9c2c6f6c0d" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_5f6ef63d-f4e4-4514-a179-b0b35abfe284" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseMember_7366f43c-de9b-4dc8-957b-c1b91f3b27e6" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_cea7a43e-e254-4d2e-a12b-538fb83830ee" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseMember_7366f43c-de9b-4dc8-957b-c1b91f3b27e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_52f1df10-fb90-4284-93e2-4eff498a96a8" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_c9c84a16-72f3-45de-a34f-80f126ab6a53" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_c9c84a16-72f3-45de-a34f-80f126ab6a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_6b02fd0e-716d-4203-a6bd-c50acbd85bfc" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses_6b02fd0e-716d-4203-a6bd-c50acbd85bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_4a52d651-f955-4f8c-b0cd-4e7e34961fe9" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_4a52d651-f955-4f8c-b0cd-4e7e34961fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_90859c95-259e-4fbb-b102-200d0db852fd" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_90859c95-259e-4fbb-b102-200d0db852fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_08f37bb5-ce77-438b-a2bd-6efa71a055d2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_ifrs-full_NumberOfEmployees_08f37bb5-ce77-438b-a2bd-6efa71a055d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees_73f80d84-fd26-42e5-85dd-e4c44e5e9005" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfEmployees_73f80d84-fd26-42e5-85dd-e4c44e5e9005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2b277186-904f-4889-9b75-0ffb9b4263cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_49f761fe-9377-47aa-923c-4c156b3f1544" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2b277186-904f-4889-9b75-0ffb9b4263cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f72f3063-88db-42c0-ab31-73f95ee379cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_87e02eb7-3e0e-4e63-8cdb-00bfc1ad3a40" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f72f3063-88db-42c0-ab31-73f95ee379cb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense_87e02eb7-3e0e-4e63-8cdb-00bfc1ad3a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_8060db61-da3b-4731-ad7e-787bc1f8f453" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpensePayrollCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f72f3063-88db-42c0-ab31-73f95ee379cb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts_8060db61-da3b-4731-ad7e-787bc1f8f453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_8c6560cb-475e-4d54-a81d-7f0a361b5ec2" xlink:href="nbx-20211231.xsd#nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f72f3063-88db-42c0-ab31-73f95ee379cb" xlink:to="loc_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense_8c6560cb-475e-4d54-a81d-7f0a361b5ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_e45ae180-60e6-4178-8c45-dbcd73dcde93" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f72f3063-88db-42c0-ab31-73f95ee379cb" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpense_e45ae180-60e6-4178-8c45-dbcd73dcde93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fd76a7f3-f04a-485c-8056-4e41b59f6982" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_fd76a7f3-f04a-485c-8056-4e41b59f6982" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_42e4be0e-a126-48c0-9c2b-97a240e433b5" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8f239bee-1a17-43da-b504-a119ecfbbb7f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_07be5c70-b496-4af6-97e4-1506952fd1ba" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8f239bee-1a17-43da-b504-a119ecfbbb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_9cd0b59c-526b-47b1-8225-63862f4ca478" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_c782126b-6dca-4319-acad-284390572ad7" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses_c782126b-6dca-4319-acad-284390572ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_b08b7087-d7fd-4636-a97a-15e93e26ce0a" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses_b08b7087-d7fd-4636-a97a-15e93e26ce0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfImpactingFactors_279e9590-22f3-4738-beb1-69b5504ffa5d" xlink:href="nbx-20211231.xsd#nbx_NumberOfImpactingFactors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_NumberOfImpactingFactors_279e9590-22f3-4738-beb1-69b5504ffa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_4ab4e07f-59dc-4975-af7a-354fee8cd7c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_4ab4e07f-59dc-4975-af7a-354fee8cd7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a452cb2d-009f-4261-a2ab-16ded100ff6b" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInEmployeeBenefitExpense_a452cb2d-009f-4261-a2ab-16ded100ff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_34ca8007-63cc-469b-87a0-929aac61da91" xlink:href="nbx-20211231.xsd#nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense_34ca8007-63cc-469b-87a0-929aac61da91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_a479a88f-e709-479e-adc2-877737ca5369" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_NumberOfEmployees_a479a88f-e709-479e-adc2-877737ca5369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees_a98507eb-084a-4354-ae97-66a4c8ae0b94" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfEmployees_a98507eb-084a-4354-ae97-66a4c8ae0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7b789fa3-7185-4315-8230-fc0b17864c42" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_37748c0d-6031-4dc6-bfff-ac71b1d8fa35" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7b789fa3-7185-4315-8230-fc0b17864c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofPayrollCostsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_ec23344d-1df8-4455-8855-ca98e996735a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_WagesAndSalaries_ec23344d-1df8-4455-8855-ca98e996735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_fa69ed73-e44b-4b96-9abd-ad095341f404" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_SocialSecurityContributions_fa69ed73-e44b-4b96-9abd-ad095341f404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_6251f1ba-753b-4a79-a626-18fff0493b7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_6251f1ba-753b-4a79-a626-18fff0493b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_adc5c6db-f296-4fe8-8e9e-bbfee51547f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_adc5c6db-f296-4fe8-8e9e-bbfee51547f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_7b48f15a-a2a8-42b6-a6f7-9d9286b363ee" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_7b48f15a-a2a8-42b6-a6f7-9d9286b363ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageNumberOfEmployees_3d859c67-3520-4bfa-8ac1-cc55bc4236c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageNumberOfEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_AverageNumberOfEmployees_3d859c67-3520-4bfa-8ac1-cc55bc4236c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_19f6a402-b10e-46bc-8e5d-9de7b8eceff2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9df4ecab-4596-4338-ab65-3aaf56446d22" xlink:to="loc_ifrs-full_NumberOfEmployees_19f6a402-b10e-46bc-8e5d-9de7b8eceff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesPayrollCostsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7ecbb98a-6068-4383-9935-e8c5ec429810" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_a88a1104-b6fb-4a20-99b2-a24996731db9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7ecbb98a-6068-4383-9935-e8c5ec429810" xlink:to="loc_ifrs-full_NumberOfEmployees_a88a1104-b6fb-4a20-99b2-a24996731db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseInNumberOfEmployees_78d4be25-a626-45d0-b948-2af142e9dd5c" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseInNumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7ecbb98a-6068-4383-9935-e8c5ec429810" xlink:to="loc_nbx_IncreaseDecreaseInNumberOfEmployees_78d4be25-a626-45d0-b948-2af142e9dd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_a3024f1b-ed7b-4dc1-b17b-c9d4265a1fba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7ecbb98a-6068-4383-9935-e8c5ec429810" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_a3024f1b-ed7b-4dc1-b17b-c9d4265a1fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_500f823e-4b9a-4169-bed7-d30f23fee58c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_7ecbb98a-6068-4383-9935-e8c5ec429810" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_500f823e-4b9a-4169-bed7-d30f23fee58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_356dbd42-3b6f-41e9-ae30-b6c3ca361b87" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_356dbd42-3b6f-41e9-ae30-b6c3ca361b87" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_0bf8f87a-61c8-4f97-a66b-7ec8eda649e4" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseMember_56bf2b7a-30a2-4149-b0a0-a1d45c78844a" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseMember_56bf2b7a-30a2-4149-b0a0-a1d45c78844a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_ea76b2a3-9e0e-42cb-8d2e-7d4c2d1f1fc2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_661aae9e-aedc-41ab-b57f-3d37b0f9a55c" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_ea76b2a3-9e0e-42cb-8d2e-7d4c2d1f1fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_a0e60a81-29f3-490c-976e-d173b5785620" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_74863289-2768-44c2-bdec-8938a78d7e7a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_AmortisationExpense_74863289-2768-44c2-bdec-8938a78d7e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationExpense_380a3a1b-a5e5-4cf7-93a1-441246d8d857" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_DepreciationExpense_380a3a1b-a5e5-4cf7-93a1-441246d8d857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionUsedOtherProvisions_bc5d165f-8ae0-4139-bf86-06fc07a1f484" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_ProvisionUsedOtherProvisions_bc5d165f-8ae0-4139-bf86-06fc07a1f484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_b17f6fac-8eb3-4367-ba5a-365311531b72" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_b17f6fac-8eb3-4367-ba5a-365311531b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_f821f96a-c07a-4c8e-8c85-2f364c98f8d4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_ifrs-full_UnusedProvisionReversedOtherProvisions_f821f96a-c07a-4c8e-8c85-2f364c98f8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DepreciationAmortizationAndProvisionExpenses_44f6bb5d-2782-44c4-832a-a3b3cfcafca6" xlink:href="nbx-20211231.xsd#nbx_DepreciationAmortizationAndProvisionExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_44c3e4ee-d268-4838-9ae7-dc5f5f4fe6bc" xlink:to="loc_nbx_DepreciationAmortizationAndProvisionExpenses_44f6bb5d-2782-44c4-832a-a3b3cfcafca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_14f0fa8e-ae09-4e6f-8973-7f67bef43449" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractTerminationIndemnities_e18f1973-828f-452a-960f-b60d30f30a1d" xlink:href="nbx-20211231.xsd#nbx_ContractTerminationIndemnities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_14f0fa8e-ae09-4e6f-8973-7f67bef43449" xlink:to="loc_nbx_ContractTerminationIndemnities_e18f1973-828f-452a-960f-b60d30f30a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_298dec74-0099-4a04-9cf8-e82be098adc0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_14f0fa8e-ae09-4e6f-8973-7f67bef43449" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_298dec74-0099-4a04-9cf8-e82be098adc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_201d0bfe-361c-4ac5-9d29-1f3c98172d37" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_201d0bfe-361c-4ac5-9d29-1f3c98172d37" xlink:to="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:to="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_576d1ade-9289-4f6e-8e9c-cfe3ed276dec" xlink:to="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fc89f531-6392-42e7-bb40-63cfce069a06" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_7155654a-ca3f-41be-b7d1-86a3011e28fa" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_fc89f531-6392-42e7-bb40-63cfce069a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesTable_7f9e7e56-0d26-457b-8e34-bbac99959093" xlink:to="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractTerminationIndemnities_7051eb92-c673-43c3-9254-a4fb7892ebdf" xlink:href="nbx-20211231.xsd#nbx_ContractTerminationIndemnities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfOperatingExpensesLineItems_d56c9d81-c177-40b3-84c6-f2fc8548a4b3" xlink:to="loc_nbx_ContractTerminationIndemnities_7051eb92-c673-43c3-9254-a4fb7892ebdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Sharebasedpayments" xlink:type="simple" xlink:href="nbx-20211231.xsd#Sharebasedpayments"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Sharebasedpayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_e6e15277-5d1d-4ebf-b3e1-d8cd8af1dc2a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_233ec12d-1a1a-4e47-b70d-b91f4195dac4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_e6e15277-5d1d-4ebf-b3e1-d8cd8af1dc2a" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_233ec12d-1a1a-4e47-b70d-b91f4195dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_369d2e8c-9968-4228-aab1-5afe458a0402" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_42c54d67-d567-4399-beba-26df27a41638" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_369d2e8c-9968-4228-aab1-5afe458a0402" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock_42c54d67-d567-4399-beba-26df27a41638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_7c1ada07-2fe2-4c23-9710-ba86f4503cd5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_369d2e8c-9968-4228-aab1-5afe458a0402" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_7c1ada07-2fe2-4c23-9710-ba86f4503cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_485dc30e-1687-48b0-b3db-af8bc80facce" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_369d2e8c-9968-4228-aab1-5afe458a0402" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_485dc30e-1687-48b0-b3db-af8bc80facce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_308fa3a1-c1bf-4935-b7dc-dad2664afe73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_369d2e8c-9968-4228-aab1-5afe458a0402" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_308fa3a1-c1bf-4935-b7dc-dad2664afe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_e3f441e8-b8e1-4a93-8089-34f905b0146b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_e3f441e8-b8e1-4a93-8089-34f905b0146b" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fde570fb-01f9-4d77-9b7c-32d71aa6b0f4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_b0dcdc89-2356-4fc3-84e8-de64a91d8bc9" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSPCEMember_b0dcdc89-2356-4fc3-84e8-de64a91d8bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_0fca05c7-e37c-4a93-bf8b-641d9e1c4423" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSAMember_0fca05c7-e37c-4a93-bf8b-641d9e1c4423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_1839ae77-146b-464a-bb95-e4c37943b5c1" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_OSAMember_1839ae77-146b-464a-bb95-e4c37943b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_f7c71e79-26b5-4de3-973d-7c9a56fa9710" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_AGAMember_f7c71e79-26b5-4de3-973d-7c9a56fa9710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_2172edd0-728d-424b-9dd2-f12235e9fb1a" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_c98b6cdc-6a37-45b4-b46b-79f67fa19567" xlink:to="loc_nbx_BSA2014Member_2172edd0-728d-424b-9dd2-f12235e9fb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable_27ee715a-ebf1-45d2-8cdf-66bf5642ff34" xlink:to="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShareBasedPaymentArrangementPlans_82f38e60-6c4f-43a5-bd2c-7df2198ae100" xlink:href="nbx-20211231.xsd#nbx_NumberOfShareBasedPaymentArrangementPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_nbx_NumberOfShareBasedPaymentArrangementPlans_82f38e60-6c4f-43a5-bd2c-7df2198ae100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_87fa854c-5c4c-428c-8586-824871597618" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_87fa854c-5c4c-428c-8586-824871597618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_8f224627-9873-4bc6-92d9-f5babcce2526" xlink:href="nbx-20211231.xsd#nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems_adeeda9e-4cb4-41cf-84b8-6b56ff1db6e4" xlink:to="loc_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate_8f224627-9873-4bc6-92d9-f5babcce2526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2b5d10ac-7e8a-47c6-abe0-6a803ef81edd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2b5d10ac-7e8a-47c6-abe0-6a803ef81edd" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_3f20e8df-08a9-4c93-9554-e1aef0603a68" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_a98065a2-1f28-4e68-8835-e5ac8b0f1b6f" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20122Member_a98065a2-1f28-4e68-8835-e5ac8b0f1b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_f0d5885b-a19d-42a6-9334-90cf8a08862c" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE082013Member_f0d5885b-a19d-42a6-9334-90cf8a08862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_7047270b-0bce-48e6-9b8f-fd10855a39de" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE092014Member_7047270b-0bce-48e6-9b8f-fd10855a39de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_c07f36a1-f8c9-4a55-902d-14ee9aa6af6a" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20151Member_c07f36a1-f8c9-4a55-902d-14ee9aa6af6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_6996e3d7-7dc7-4b92-91ec-b4e991777d2b" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE20153Member_6996e3d7-7dc7-4b92-91ec-b4e991777d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_a161c7ea-b01e-4cc9-ae0b-be6f9f45b3e0" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_a161c7ea-b01e-4cc9-ae0b-be6f9f45b3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_0cf95680-e4a2-4188-ab31-c0390ff39569" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2016PerformanceMember_0cf95680-e4a2-4188-ab31-c0390ff39569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_52d49ade-f81f-45ea-b3b5-43b8add22d67" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_52d49ade-f81f-45ea-b3b5-43b8add22d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017PerformanceMember_3b2eff09-4898-4aa2-a52f-6c5d21b4e599" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017PerformanceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_b41622b5-014a-4de6-aaf2-36d1c7e12dfe" xlink:to="loc_nbx_BSPCE2017PerformanceMember_3b2eff09-4898-4aa2-a52f-6c5d21b4e599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_75885b0e-6820-4945-bfd2-22642ca21de7" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA0412Member_75885b0e-6820-4945-bfd2-22642ca21de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_1e3e450f-858f-45ab-84af-88c97b3266a7" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2013Member_1e3e450f-858f-45ab-84af-88c97b3266a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_ca7e68d6-2212-46d1-961e-0e28ee3ac1d6" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2014Member_ca7e68d6-2212-46d1-961e-0e28ee3ac1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_2d05d06b-b1b5-4438-bd0c-09525f995d9c" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20151Member_2d05d06b-b1b5-4438-bd0c-09525f995d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_ae86816e-d910-478b-a369-76dc861cfbf1" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20152AMember_ae86816e-d910-478b-a369-76dc861cfbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_b14c2128-cca5-41ed-881d-023aa95a4445" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20152BMember_b14c2128-cca5-41ed-881d-023aa95a4445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016OrdinaryMember_76c6fda8-3bbc-4477-8534-7e8c35449b36" xlink:href="nbx-20211231.xsd#nbx_BSA2016OrdinaryMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2016OrdinaryMember_76c6fda8-3bbc-4477-8534-7e8c35449b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016PerformanceMember_8eae2464-d229-4fbb-9cd9-bf64433dc5dd" xlink:href="nbx-20211231.xsd#nbx_BSA2016PerformanceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2016PerformanceMember_8eae2464-d229-4fbb-9cd9-bf64433dc5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_50d310fa-275f-4bf7-9e88-757567c8badd" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20162Member_50d310fa-275f-4bf7-9e88-757567c8badd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_9c1db183-9040-4bf1-9d8c-e5a4e377bd66" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2017Member_9c1db183-9040-4bf1-9d8c-e5a4e377bd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_a18150e0-35b0-4d1b-95c6-58add520415a" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20181Member_a18150e0-35b0-4d1b-95c6-58add520415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_e55a61b4-f4df-4589-8835-7113c9ee8d8a" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20182Member_e55a61b4-f4df-4589-8835-7113c9ee8d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_d643dd52-ba44-471d-bfc7-49ba667ba32a" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA20191Member_d643dd52-ba44-471d-bfc7-49ba667ba32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_05922930-0652-4291-8531-c55928eacfc7" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2020Member_05922930-0652-4291-8531-c55928eacfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_969da534-18d5-4b95-8eae-c726af7c4702" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2021AMember_969da534-18d5-4b95-8eae-c726af7c4702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_33fda3c2-d099-4e06-abdc-dbd4a38f81f5" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_22a10cc6-fe3e-422c-bcfa-95afeae458ee" xlink:to="loc_nbx_BSA2021BMember_33fda3c2-d099-4e06-abdc-dbd4a38f81f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_faf31241-e7fc-4c4f-b347-77fbdd071a98" xlink:to="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_2025838a-3650-49c5-89e3-161ae46b7564" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20181Member_2025838a-3650-49c5-89e3-161ae46b7564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_775e409a-776b-4cfc-aed5-6ed77f5c7e38" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20182Member_775e409a-776b-4cfc-aed5-6ed77f5c7e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_d64a028d-aa77-41d9-94aa-bba79a2325c5" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA20191Member_d64a028d-aa77-41d9-94aa-bba79a2325c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_a1b4d5a0-6b0e-4e8c-95df-0fadf173fb89" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA2020Member_a1b4d5a0-6b0e-4e8c-95df-0fadf173fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_4368ab6d-e248-4396-b09d-7e08b9563bc8" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_e7423498-15b0-488a-a01d-dbaa319a4fcb" xlink:to="loc_nbx_AGA2021Member_4368ab6d-e248-4396-b09d-7e08b9563bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable_a422a77b-d94d-4b84-870b-f483ed0731c5" xlink:to="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6aad2112-aef0-4094-adda-81f0bc55155a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_6aad2112-aef0-4094-adda-81f0bc55155a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_906df778-4973-4b50-ae51-ab0841a169f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_906df778-4973-4b50-ae51-ab0841a169f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ea7e4372-ff0f-440b-933a-b0258db0761a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ea7e4372-ff0f-440b-933a-b0258db0761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1d26bfff-c04f-4168-beb1-00b9cb62581b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1d26bfff-c04f-4168-beb1-00b9cb62581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_c7937d5d-e16d-4a48-9e42-3a2f212ae9a8" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_c7937d5d-e16d-4a48-9e42-3a2f212ae9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_21d2a6e1-67ee-4696-b337-5a9180e03976" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_21d2a6e1-67ee-4696-b337-5a9180e03976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_a7c559c5-4dde-43ff-ad41-a97d6972fdc0" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_a7c559c5-4dde-43ff-ad41-a97d6972fdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_513a4484-b1db-4d03-a9bd-8042006ba4a5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems_2209d769-b553-4442-88bb-62f10c36668e" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_513a4484-b1db-4d03-a9bd-8042006ba4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_54b0f8e4-1561-487f-8dfe-ccbc502b71a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_54b0f8e4-1561-487f-8dfe-ccbc502b71a9" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f82b8c44-a258-42fc-a3f2-3dc5e08b2fbd" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_35136bbf-6374-4c5c-a3f9-235eb229dd69" xlink:to="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_391ee518-e4bd-4a34-a083-69ce26fbcca9" xlink:href="nbx-20211231.xsd#nbx_OSA20161PerformanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20161PerformanceMember_391ee518-e4bd-4a34-a083-69ce26fbcca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_31ba6f00-0cec-4154-81a7-42a58641a949" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20162Member_31ba6f00-0cec-4154-81a7-42a58641a949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_969588f0-2be9-4f9e-b38c-7cacb8cf894f" xlink:href="nbx-20211231.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2017OrdinaryMember_969588f0-2be9-4f9e-b38c-7cacb8cf894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_7aa5ad70-3257-4706-98aa-1f1bb34c7ece" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2018Member_7aa5ad70-3257-4706-98aa-1f1bb34c7ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_8eb9bdd3-7c3c-4b02-94c6-065e1f453396" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA20191Member_8eb9bdd3-7c3c-4b02-94c6-065e1f453396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_243d698b-289d-424b-970d-a8d729dfe7db" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSALLY2019Member_243d698b-289d-424b-970d-a8d729dfe7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_38288dd0-2991-458f-ad4d-09f804aa39e4" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA2020Member_38288dd0-2991-458f-ad4d-09f804aa39e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104Member_db875686-de95-43a5-9457-037390dc2933" xlink:href="nbx-20211231.xsd#nbx_OSA202104Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA202104Member_db875686-de95-43a5-9457-037390dc2933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106Member_dc6690c1-6a47-45f2-b632-526ab98bff37" xlink:href="nbx-20211231.xsd#nbx_OSA202106Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_2165a79e-23b0-44cb-b07c-7ce7acd07759" xlink:to="loc_nbx_OSA202106Member_dc6690c1-6a47-45f2-b632-526ab98bff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_1e17925e-c9fc-4eeb-a43c-ba3f524baac1" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_62e5300d-d429-4f2c-8913-af9b525fb37d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_62e5300d-d429-4f2c-8913-af9b525fb37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_5340e4f8-ebf6-4186-bf48-36c45b7f671e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_5340e4f8-ebf6-4186-bf48-36c45b7f671e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_268313cd-1447-42f9-aed5-6ddd152df9eb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_268313cd-1447-42f9-aed5-6ddd152df9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_64ded2bc-dfa5-413d-8a86-6a964520a3b8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_64ded2bc-dfa5-413d-8a86-6a964520a3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_7ef43908-d68b-40a0-b59a-2b9433ef1acd" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement_7ef43908-d68b-40a0-b59a-2b9433ef1acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_5dab8b95-f85c-4e88-915f-c395ead240cf" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_5dab8b95-f85c-4e88-915f-c395ead240cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_1422ca06-c49b-4ce7-be2f-0179243b3d48" xlink:href="nbx-20211231.xsd#nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement_1422ca06-c49b-4ce7-be2f-0179243b3d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_72a31771-2675-4f74-8a4d-d1495e31aae7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_7c640a27-1477-40fd-8af1-f81fa2e232eb" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_72a31771-2675-4f74-8a4d-d1495e31aae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_30ae0814-4eb3-402b-821d-f52702f6b5af" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_30ae0814-4eb3-402b-821d-f52702f6b5af" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ccf5e0e0-f313-46d5-a422-84440f443f52" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:href="nbx-20211231.xsd#nbx_BSPCEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20121Member_b593876a-6e78-468c-ae80-0b8021dfde89" xlink:href="nbx-20211231.xsd#nbx_BSPCE20121Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20121Member_b593876a-6e78-468c-ae80-0b8021dfde89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20122Member_bad03876-e030-49cc-961d-7aea418aa6d9" xlink:href="nbx-20211231.xsd#nbx_BSPCE20122Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20122Member_bad03876-e030-49cc-961d-7aea418aa6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE042013Member_219c10a6-f5cc-4258-a0da-a8e7f3feb970" xlink:href="nbx-20211231.xsd#nbx_BSPCE042013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE042013Member_219c10a6-f5cc-4258-a0da-a8e7f3feb970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE082013Member_ff9424f2-2d8d-4615-8732-9d85921b9b37" xlink:href="nbx-20211231.xsd#nbx_BSPCE082013Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE082013Member_ff9424f2-2d8d-4615-8732-9d85921b9b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE092014Member_c6fb7dbd-3533-4d9f-977d-6bf29f02b0b5" xlink:href="nbx-20211231.xsd#nbx_BSPCE092014Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE092014Member_c6fb7dbd-3533-4d9f-977d-6bf29f02b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20151Member_399fcf9b-fd44-4a57-a8a3-e46e5fc53bb1" xlink:href="nbx-20211231.xsd#nbx_BSPCE20151Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20151Member_399fcf9b-fd44-4a57-a8a3-e46e5fc53bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20152Member_b5e888d0-a28c-43de-ab4b-b4ee07505a3a" xlink:href="nbx-20211231.xsd#nbx_BSPCE20152Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20152Member_b5e888d0-a28c-43de-ab4b-b4ee07505a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE20153Member_e8fc97bc-a9e6-4227-ab73-7760e42c65f7" xlink:href="nbx-20211231.xsd#nbx_BSPCE20153Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE20153Member_e8fc97bc-a9e6-4227-ab73-7760e42c65f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016OrdinaryMember_8c39de8c-153e-458f-9c58-8299d396c664" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016OrdinaryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2016OrdinaryMember_8c39de8c-153e-458f-9c58-8299d396c664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2016PerformanceMember_99bbff33-d2c8-49ac-a7d7-b33e4e087753" xlink:href="nbx-20211231.xsd#nbx_BSPCE2016PerformanceMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2016PerformanceMember_99bbff33-d2c8-49ac-a7d7-b33e4e087753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017OrdinaryMember_170666f7-c9a6-4512-acec-6c4f03eb0348" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017OrdinaryMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017OrdinaryMember_170666f7-c9a6-4512-acec-6c4f03eb0348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017PerformanceMember_ad865ced-3d07-4514-ab8c-d7cb67ccda3b" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017PerformanceMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017PerformanceMember_ad865ced-3d07-4514-ab8c-d7cb67ccda3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017Member_11ea6ef4-eab8-4ae6-a43c-d32e324cf723" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017Member_11ea6ef4-eab8-4ae6-a43c-d32e324cf723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSPCE2017ProjectMember_cb59604a-d27f-49d3-b658-ea49957e647d" xlink:href="nbx-20211231.xsd#nbx_BSPCE2017ProjectMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSPCEMember_65c7788c-4f38-4d74-b94c-56167e5afffb" xlink:to="loc_nbx_BSPCE2017ProjectMember_cb59604a-d27f-49d3-b658-ea49957e647d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:href="nbx-20211231.xsd#nbx_BSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA0412Member_9d793026-bce3-411f-8cc5-210dcfa358d8" xlink:href="nbx-20211231.xsd#nbx_BSA0412Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA0412Member_9d793026-bce3-411f-8cc5-210dcfa358d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2013Member_1d1ed03c-93da-4a42-b9cd-41a3a1047782" xlink:href="nbx-20211231.xsd#nbx_BSA2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2013Member_1d1ed03c-93da-4a42-b9cd-41a3a1047782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2014Member_085cfde6-dbe1-4da4-bc94-df6417b42a4d" xlink:href="nbx-20211231.xsd#nbx_BSA2014Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2014Member_085cfde6-dbe1-4da4-bc94-df6417b42a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20151Member_17e5e553-cb76-4bb1-bc98-5f7b56618005" xlink:href="nbx-20211231.xsd#nbx_BSA20151Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20151Member_17e5e553-cb76-4bb1-bc98-5f7b56618005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152AMember_76787adf-5e68-4a9a-89d9-70caaffe9673" xlink:href="nbx-20211231.xsd#nbx_BSA20152AMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20152AMember_76787adf-5e68-4a9a-89d9-70caaffe9673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20152BMember_c073c19b-57b5-451b-8ca5-da94288f6f38" xlink:href="nbx-20211231.xsd#nbx_BSA20152BMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20152BMember_c073c19b-57b5-451b-8ca5-da94288f6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016OrdinaryMember_1994c1e9-0209-489f-9914-04a49496aafa" xlink:href="nbx-20211231.xsd#nbx_BSA2016OrdinaryMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2016OrdinaryMember_1994c1e9-0209-489f-9914-04a49496aafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2016PerformanceMember_5f7104f4-2c65-499c-aab2-b746f290da1a" xlink:href="nbx-20211231.xsd#nbx_BSA2016PerformanceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2016PerformanceMember_5f7104f4-2c65-499c-aab2-b746f290da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20162Member_aefe86eb-2773-4664-83d2-ce72b3f9b8c9" xlink:href="nbx-20211231.xsd#nbx_BSA20162Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20162Member_aefe86eb-2773-4664-83d2-ce72b3f9b8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2017Member_aff52b74-8813-40ff-af90-c8917098b7f7" xlink:href="nbx-20211231.xsd#nbx_BSA2017Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2017Member_aff52b74-8813-40ff-af90-c8917098b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20181Member_e2c12ae1-c72d-4074-a4c5-c6b66eef52fb" xlink:href="nbx-20211231.xsd#nbx_BSA20181Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20181Member_e2c12ae1-c72d-4074-a4c5-c6b66eef52fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20182Member_a6f8912f-2def-479c-8ffe-13752a253289" xlink:href="nbx-20211231.xsd#nbx_BSA20182Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20182Member_a6f8912f-2def-479c-8ffe-13752a253289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA20191Member_c23e530f-8c3b-41f8-9061-cca2dd161f6b" xlink:href="nbx-20211231.xsd#nbx_BSA20191Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA20191Member_c23e530f-8c3b-41f8-9061-cca2dd161f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2020Member_9210010d-8c51-49f6-8dc7-1074823ff760" xlink:href="nbx-20211231.xsd#nbx_BSA2020Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2020Member_9210010d-8c51-49f6-8dc7-1074823ff760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021AMember_e9733421-0f1d-4577-8a2a-3658febcb333" xlink:href="nbx-20211231.xsd#nbx_BSA2021AMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2021AMember_e9733421-0f1d-4577-8a2a-3658febcb333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_BSA2021BMember_3bd74935-f4da-4912-a59b-4658c9add5a4" xlink:href="nbx-20211231.xsd#nbx_BSA2021BMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_BSAMember_a27068b4-33d4-4157-80a2-e2da5c1fed2a" xlink:to="loc_nbx_BSA2021BMember_3bd74935-f4da-4912-a59b-4658c9add5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:href="nbx-20211231.xsd#nbx_AGAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20181Member_9bdc09f1-eb55-451d-88b4-daee63778330" xlink:href="nbx-20211231.xsd#nbx_AGA20181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20181Member_9bdc09f1-eb55-451d-88b4-daee63778330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20182Member_7114eead-bc07-4e17-9bcc-77cb9fa527bf" xlink:href="nbx-20211231.xsd#nbx_AGA20182Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20182Member_7114eead-bc07-4e17-9bcc-77cb9fa527bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA20191Member_95a139cb-d779-4413-bfc3-46cb27869951" xlink:href="nbx-20211231.xsd#nbx_AGA20191Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA20191Member_95a139cb-d779-4413-bfc3-46cb27869951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_5f771644-4edc-4ab9-80d9-dfb88f0394cb" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA2020Member_5f771644-4edc-4ab9-80d9-dfb88f0394cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2021Member_30b73c40-3e82-40a0-a1be-3c4511c179b6" xlink:href="nbx-20211231.xsd#nbx_AGA2021Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_AGAMember_16e75add-a1ea-4970-a376-8437f56e7c83" xlink:to="loc_nbx_AGA2021Member_30b73c40-3e82-40a0-a1be-3c4511c179b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_392e3b0a-baf1-4308-a036-7983286b3962" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_OSA202104OrdinaryMember_392e3b0a-baf1-4308-a036-7983286b3962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_20a81f36-2ead-4466-a43a-4e5141903bd1" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0623ff4-eb2f-450c-a4be-a9f49a27be9d" xlink:to="loc_nbx_OSA202106OrdinaryMember_20a81f36-2ead-4466-a43a-4e5141903bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingAxis_55155104-704a-4f09-a1ff-6c012a27800a" xlink:to="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_e3be9f0f-82aa-4226-b02c-7f2f2c0e8fa9" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheOneMember_e3be9f0f-82aa-4226-b02c-7f2f2c0e8fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_bbf1f6cc-e8f6-429a-9239-7853d916bf70" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheTwoMember_bbf1f6cc-e8f6-429a-9239-7853d916bf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_40f21a51-93ff-4de8-9076-9baf21e277eb" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheThreeMember_40f21a51-93ff-4de8-9076-9baf21e277eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_e9b0f90a-ca4f-4520-9765-ac651fed293d" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_10ad054d-b407-4d42-84ce-4b7520030dd7" xlink:to="loc_nbx_TrancheFourMember_e9b0f90a-ca4f-4520-9765-ac651fed293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:to="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_4a08b0eb-e78b-49fe-8304-a4b92341efc2" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheOneMember_4a08b0eb-e78b-49fe-8304-a4b92341efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_212d576f-1157-498a-b134-df4a7162f29a" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheTwoMember_212d576f-1157-498a-b134-df4a7162f29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_27a673c4-57a2-4518-b55b-3c9f55754a03" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheThreeMember_27a673c4-57a2-4518-b55b-3c9f55754a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheFourMember_371d69f8-cdb6-440b-b5ff-3089cb541384" xlink:href="nbx-20211231.xsd#nbx_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_f7a1bcf5-f9ad-4a9f-9957-cf436d0e0a5e" xlink:to="loc_nbx_TrancheFourMember_371d69f8-cdb6-440b-b5ff-3089cb541384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_dd891ee9-f472-4077-9e2f-dea4e2472e9d" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_5026f239-0e5f-47a9-9455-c2d65d74c4c3" xlink:to="loc_nbx_TranchesDomain_dd891ee9-f472-4077-9e2f-dea4e2472e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_7b7d37f9-5738-43b1-a777-402e0add1f39" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_24726a36-3035-4cce-be0a-4b85108ebbd6" xlink:href="nbx-20211231.xsd#nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted_24726a36-3035-4cce-be0a-4b85108ebbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_6fb8f54f-fac6-4650-9667-9e0c212cce22" xlink:href="nbx-20211231.xsd#nbx_ExercisePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExercisePriceOtherEquityInstrumentsGranted_6fb8f54f-fac6-4650-9667-9e0c212cce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_5c3c33da-7e95-4594-8c40-b12f9b23b1c7" xlink:href="nbx-20211231.xsd#nbx_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted_5c3c33da-7e95-4594-8c40-b12f9b23b1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OptionLifeOtherEquityInstrumentsGranted_4a92724b-a3d9-4afe-968e-24d7c7f6efa2" xlink:href="nbx-20211231.xsd#nbx_OptionLifeOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_OptionLifeOtherEquityInstrumentsGranted_4a92724b-a3d9-4afe-968e-24d7c7f6efa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_05e7dc55-18a4-4a89-8b61-17db464bf10f" xlink:href="nbx-20211231.xsd#nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted_05e7dc55-18a4-4a89-8b61-17db464bf10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_eb725d95-d5a5-4154-9ac7-202a159c0b4c" xlink:href="nbx-20211231.xsd#nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_eb725d95-d5a5-4154-9ac7-202a159c0b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_55b73680-6d8d-46b4-b7d5-5175ed0e3513" xlink:href="nbx-20211231.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_55b73680-6d8d-46b4-b7d5-5175ed0e3513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_1150ec43-44bc-4f2a-b400-23b96b890ad4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9a98b0fb-f24d-4d40-b60b-8065fa272c67" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_1150ec43-44bc-4f2a-b400-23b96b890ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_d0ea612d-5fcb-45d8-a908-2b339f92f408" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_d0ea612d-5fcb-45d8-a908-2b339f92f408" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcd1e0a0-e4b4-4775-9475-0a66c60e03e4" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:href="nbx-20211231.xsd#nbx_OSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2d5f3655-2d29-48d0-80d0-a2fc682cf18c" xlink:to="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161OrdinaryMember_b0c9eb02-d92f-4eb7-ae60-e11e7e37d5aa" xlink:href="nbx-20211231.xsd#nbx_OSA20161OrdinaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20161OrdinaryMember_b0c9eb02-d92f-4eb7-ae60-e11e7e37d5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20161PerformanceMember_cc193cf7-46b6-4f42-9df8-1a41f758581b" xlink:href="nbx-20211231.xsd#nbx_OSA20161PerformanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20161PerformanceMember_cc193cf7-46b6-4f42-9df8-1a41f758581b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20162Member_c9b4eeb7-aaa0-4ece-bbe2-701872dfcd50" xlink:href="nbx-20211231.xsd#nbx_OSA20162Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20162Member_c9b4eeb7-aaa0-4ece-bbe2-701872dfcd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017OrdinaryMember_cb4bec59-3c47-4ee5-ba40-69ca1b417275" xlink:href="nbx-20211231.xsd#nbx_OSA2017OrdinaryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2017OrdinaryMember_cb4bec59-3c47-4ee5-ba40-69ca1b417275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2017PerformanceMember_d95886a6-8c10-4bd6-bd0c-6d3f53dbbaa7" xlink:href="nbx-20211231.xsd#nbx_OSA2017PerformanceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2017PerformanceMember_d95886a6-8c10-4bd6-bd0c-6d3f53dbbaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2018Member_85f2bd29-6425-42c3-ab3c-e408641cafee" xlink:href="nbx-20211231.xsd#nbx_OSA2018Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2018Member_85f2bd29-6425-42c3-ab3c-e408641cafee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA20191Member_47388867-e13c-4361-ab06-71bff93a2ed2" xlink:href="nbx-20211231.xsd#nbx_OSA20191Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA20191Member_47388867-e13c-4361-ab06-71bff93a2ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSALLY2019Member_204d47d1-7ae2-4e27-9774-61bc18744786" xlink:href="nbx-20211231.xsd#nbx_OSALLY2019Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSALLY2019Member_204d47d1-7ae2-4e27-9774-61bc18744786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA2020Member_ae1cf056-ade4-441a-93c0-859856db58c8" xlink:href="nbx-20211231.xsd#nbx_OSA2020Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA2020Member_ae1cf056-ade4-441a-93c0-859856db58c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104OrdinaryMember_6bd1c868-1d6d-4581-bb52-3c62a01c1fe9" xlink:href="nbx-20211231.xsd#nbx_OSA202104OrdinaryMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202104OrdinaryMember_6bd1c868-1d6d-4581-bb52-3c62a01c1fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202104PerformanceMember_20c48671-65a9-4797-8f4d-cb78868a0441" xlink:href="nbx-20211231.xsd#nbx_OSA202104PerformanceMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202104PerformanceMember_20c48671-65a9-4797-8f4d-cb78868a0441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106OrdinaryMember_cf7b8d12-147e-409d-a2f0-64d78f842b0a" xlink:href="nbx-20211231.xsd#nbx_OSA202106OrdinaryMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202106OrdinaryMember_cf7b8d12-147e-409d-a2f0-64d78f842b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_OSA202106PerformanceMember_a89e8a67-e031-4a8c-87a9-e8bbc50e6f75" xlink:href="nbx-20211231.xsd#nbx_OSA202106PerformanceMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_OSAMember_9ef8f878-1829-4342-b8ec-da16b27072c2" xlink:to="loc_nbx_OSA202106PerformanceMember_a89e8a67-e031-4a8c-87a9-e8bbc50e6f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:href="nbx-20211231.xsd#nbx_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:href="nbx-20211231.xsd#nbx_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingAxis_09018a85-f496-4712-a035-46c3093ffc7d" xlink:to="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_8364e239-27ce-4fef-9d43-2d2ec8aaeb53" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheOneMember_8364e239-27ce-4fef-9d43-2d2ec8aaeb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_7db2f0b9-c589-4303-bcd5-f3ebd03006cc" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheTwoMember_7db2f0b9-c589-4303-bcd5-f3ebd03006cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_1f053031-c887-40aa-a47a-186dc81f5e62" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_VestingDomain_5c75168b-8e1c-4636-b043-85f928b27d5c" xlink:to="loc_nbx_TrancheThreeMember_1f053031-c887-40aa-a47a-186dc81f5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:href="nbx-20211231.xsd#nbx_TranchesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:href="nbx-20211231.xsd#nbx_TrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:to="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheOneMember_8baeded7-ab4b-4478-af77-272168fc23ec" xlink:href="nbx-20211231.xsd#nbx_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheOneMember_8baeded7-ab4b-4478-af77-272168fc23ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheTwoMember_234d60cb-203b-42bd-ab2c-6188ff1301ea" xlink:href="nbx-20211231.xsd#nbx_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheTwoMember_234d60cb-203b-42bd-ab2c-6188ff1301ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TrancheThreeMember_f0bbba03-270a-4eff-b3d7-2f9160b0c4d3" xlink:href="nbx-20211231.xsd#nbx_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TrancheDomain_5b6c379c-3185-40c8-a0ec-088b8e372a06" xlink:to="loc_nbx_TrancheThreeMember_f0bbba03-270a-4eff-b3d7-2f9160b0c4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TranchesDomain_8e1d1770-7ef3-41f4-ac23-bfa3df17c686" xlink:href="nbx-20211231.xsd#nbx_TranchesDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_TranchesAxis_00748bfe-835c-402c-b06a-3656fb8c46c9" xlink:to="loc_nbx_TranchesDomain_8e1d1770-7ef3-41f4-ac23-bfa3df17c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a9510c3c-2b2e-4824-a329-2741eb2879a9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2c00d13d-0a2c-4983-a7ff-36a3cb646988" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2c00d13d-0a2c-4983-a7ff-36a3cb646988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b92e6b9e-05dc-4a7a-8cc3-faac993955a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b92e6b9e-05dc-4a7a-8cc3-faac993955a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_36120a31-f299-4873-b324-280a1aa5ea16" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_36120a31-f299-4873-b324-280a1aa5ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_056cd957-f319-4806-bd24-4d151139ca73" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_056cd957-f319-4806-bd24-4d151139ca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_62842067-483e-4bf5-9e18-c5534369b5f3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_62842067-483e-4bf5-9e18-c5534369b5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24390f95-63d4-4b33-a3c1-367df0c1a6f0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24390f95-63d4-4b33-a3c1-367df0c1a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_bf1d81c1-739e-42ef-b283-f5b900ea3cc7" xlink:href="nbx-20211231.xsd#nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan_bf1d81c1-739e-42ef-b283-f5b900ea3cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_60fdbb8f-9996-48e4-b239-dc08e1ab89d3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_546df11e-20a0-4f9f-a3b1-0dbb21e54f6a" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_60fdbb8f-9996-48e4-b239-dc08e1ab89d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Netfinancialincomeloss" xlink:type="simple" xlink:href="nbx-20211231.xsd#Netfinancialincomeloss"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Netfinancialincomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_de69b9d5-fe22-4395-8eb4-34b60c14b39a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_0103ccc9-6710-40e9-8fb7-3785b7b4fe19" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_de69b9d5-fe22-4395-8eb4-34b60c14b39a" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_0103ccc9-6710-40e9-8fb7-3785b7b4fe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#NetfinancialincomelossTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_4b101e27-f47b-47b9-80d5-27661344e715" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_79876a16-2dca-46fd-bd29-ba321ee61164" xlink:href="nbx-20211231.xsd#nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_4b101e27-f47b-47b9-80d5-27661344e715" xlink:to="loc_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock_79876a16-2dca-46fd-bd29-ba321ee61164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_848614b3-c48c-4133-b4e0-e71246b6eb36" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks_848614b3-c48c-4133-b4e0-e71246b6eb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_90ed41a5-d4ed-46ce-abbc-23c3f0ff57a6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_NetForeignExchangeGain_90ed41a5-d4ed-46ce-abbc-23c3f0ff57a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinanceIncome_33cf0fb2-f33e-45bd-a08d-d32a91870630" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_OtherFinanceIncome_33cf0fb2-f33e-45bd-a08d-d32a91870630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_d22def4e-f82d-4b99-91d0-ca05fbe7789b" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_FinanceIncome_d22def4e-f82d-4b99-91d0-ca05fbe7789b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_59709ba4-cdd3-45c7-9484-ba21b7ba5ae6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_InterestRevenueExpense_59709ba4-cdd3-45c7-9484-ba21b7ba5ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0cbd5f5b-8ae8-43db-8e97-f23952cc49fc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0cbd5f5b-8ae8-43db-8e97-f23952cc49fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_f87036bf-951e-4efd-8488-31991e367cd5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_f87036bf-951e-4efd-8488-31991e367cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_3e932392-f9d7-4495-90e3-35f40cf5757e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_FinanceCosts_3e932392-f9d7-4495-90e3-35f40cf5757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_3185e683-3144-455e-8b49-283fda1343fd" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_032dda15-310b-48d3-b6b1-1fc553ced8c4" xlink:to="loc_ifrs-full_FinanceIncomeCost_3185e683-3144-455e-8b49-283fda1343fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#NetfinancialincomelossAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_8a2b8b50-7818-4d6b-a20b-f6edda759007" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract_8a2b8b50-7818-4d6b-a20b-f6edda759007" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_98f6cd5a-859a-48bb-89a9-db182381a7ba" xlink:to="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_ee95755b-8c93-4059-bca8-e6640d8eb644" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_440a08a0-ebf7-4731-9558-df2aeb569bf1" xlink:to="loc_ifrs-full_FixedInterestRateMember_ee95755b-8c93-4059-bca8-e6640d8eb644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_23a07eec-0008-4893-941b-559bbfaa16a2" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9d5a28a5-f4e1-42ac-b7a3-12733bae8242" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a5263f2d-c58b-48ee-848d-d8d48a06a2c8" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_9d5a28a5-f4e1-42ac-b7a3-12733bae8242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable_0450fb60-a012-4689-af4b-e1ec23e405f8" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_afe1a234-17cb-4491-9505-fdc14d55ee2e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_InterestRevenueExpense_afe1a234-17cb-4491-9505-fdc14d55ee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_5b657baa-9118-478a-a2a5-a62687fe4d8c" xlink:href="nbx-20211231.xsd#nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities_5b657baa-9118-478a-a2a5-a62687fe4d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_3e184b63-96d0-4163-8711-7e6f3c4e3c2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_3e184b63-96d0-4163-8711-7e6f3c4e3c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_d60f83ac-4fb0-4b9e-8a1f-71d92c1b7b49" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_NetForeignExchangeGain_d60f83ac-4fb0-4b9e-8a1f-71d92c1b7b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_7f06e47e-7570-49dd-aa1a-42d0c2202c6c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_7f06e47e-7570-49dd-aa1a-42d0c2202c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_2b570dbf-ad45-4a0f-8b38-a5523463ede4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems_92542777-9078-4104-ae72-b9d591c4fdd1" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_2b570dbf-ad45-4a0f-8b38-a5523463ede4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Incometax" xlink:type="simple" xlink:href="nbx-20211231.xsd#Incometax"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Incometax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_48b0fa30-2cc9-4dc5-b6a4-3a05c296f950" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_448419a2-aedf-4366-b1af-efb0a645825f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_48b0fa30-2cc9-4dc5-b6a4-3a05c296f950" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_448419a2-aedf-4366-b1af-efb0a645825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IncometaxTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#IncometaxTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IncometaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_32d29fc1-cb08-4a9c-831b-7aec2ce5f6cb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock_70949c01-e400-45d7-8a48-7a8b21cb0b2d" xlink:href="nbx-20211231.xsd#nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_32d29fc1-cb08-4a9c-831b-7aec2ce5f6cb" xlink:to="loc_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock_70949c01-e400-45d7-8a48-7a8b21cb0b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IncometaxAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IncometaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_8d252228-ee51-4c7d-8b7e-11c7190e5072" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_8d252228-ee51-4c7d-8b7e-11c7190e5072" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:to="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1e487e8e-9aa7-4697-8052-3861f7c2bffb" xlink:to="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_d15ac275-de9a-46f8-98c3-60468008d208" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:to="loc_country_FR_d15ac275-de9a-46f8-98c3-60468008d208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f8cb1128-3e35-4a95-b084-3d2344e99bff" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7eaa6c1a-7892-4fa1-8d54-fae590165766" xlink:to="loc_country_US_f8cb1128-3e35-4a95-b084-3d2344e99bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_dab2a11a-b9af-4c4d-8040-685e2e312066" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_add424b4-5101-41d7-8307-e875646a6c18" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_8e386f26-eac2-4ee5-b555-650af8327234" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_add424b4-5101-41d7-8307-e875646a6c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_eb5bd9c6-0b0d-4cfc-9102-4d1049464c12" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_d6d29901-d530-4fb7-859e-e6f3b5a99589" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_d6d29901-d530-4fb7-859e-e6f3b5a99589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_UnusedTaxLossExpirationPeriod_e5b8c319-dc51-4ae5-8420-0672a4d71825" xlink:href="nbx-20211231.xsd#nbx_UnusedTaxLossExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_nbx_UnusedTaxLossExpirationPeriod_e5b8c319-dc51-4ae5-8420-0672a4d71825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_5bfbb770-7917-41ae-8e18-4607a92a29ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_5bfbb770-7917-41ae-8e18-4607a92a29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CompanyDeferredTaxRate_b326fd3c-bb8e-4829-ae24-cec319b26306" xlink:href="nbx-20211231.xsd#nbx_CompanyDeferredTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_49407ebd-12d0-4ac6-a6f8-ab30514b1def" xlink:to="loc_nbx_CompanyDeferredTaxRate_b326fd3c-bb8e-4829-ae24-cec319b26306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_b687b932-3adb-43b8-b777-d2c571d49953" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_b687b932-3adb-43b8-b777-d2c571d49953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b37db47e-9575-44b1-a937-af4218f34e25" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b37db47e-9575-44b1-a937-af4218f34e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_e6d20d33-cb4e-41f4-948b-ce95a47fd1f8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_AccountingProfit_e6d20d33-cb4e-41f4-948b-ce95a47fd1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_7b594ed2-38bb-4d74-97df-de2edd6b9b00" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_ApplicableTaxRate_7b594ed2-38bb-4d74-97df-de2edd6b9b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0a6ebb92-1403-4736-9310-7a52325adac2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_0a6ebb92-1403-4736-9310-7a52325adac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TaxEffectOfShareBasedPaymentArrangements_3813d174-1a91-43c4-a829-715240f6a410" xlink:href="nbx-20211231.xsd#nbx_TaxEffectOfShareBasedPaymentArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_nbx_TaxEffectOfShareBasedPaymentArrangements_3813d174-1a91-43c4-a829-715240f6a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_42307b7e-3391-4470-8c13-a8e0745ebfed" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_42307b7e-3391-4470-8c13-a8e0745ebfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_e941de19-d901-46fc-829a-85a55780f734" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011_e941de19-d901-46fc-829a-85a55780f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_316d2aa7-27fe-4fda-b6a4-06e9ff1511b9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_316d2aa7-27fe-4fda-b6a4-06e9ff1511b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b99688ca-81cd-4077-9ef3-bebf8c246a01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b99688ca-81cd-4077-9ef3-bebf8c246a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_1bc60fc0-7d2c-4f0d-bca4-b375b4aa91e3" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_351733bb-0d21-4f8c-83ce-a93d44fe59a0" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_1bc60fc0-7d2c-4f0d-bca4-b375b4aa91e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Segmentreporting" xlink:type="simple" xlink:href="nbx-20211231.xsd#Segmentreporting"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Segmentreporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_328a2e19-7578-4eae-be76-382765a14e2e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_2ed91d5e-9aec-49cd-b1d5-e46286cc360d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_328a2e19-7578-4eae-be76-382765a14e2e" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_2ed91d5e-9aec-49cd-b1d5-e46286cc360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Losspershare" xlink:type="simple" xlink:href="nbx-20211231.xsd#Losspershare"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Losspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_95bd6992-e9b5-40af-916f-ea7ecbbe20a4" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_9a814533-0e68-4f64-9846-32f12f44207d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_95bd6992-e9b5-40af-916f-ea7ecbbe20a4" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_9a814533-0e68-4f64-9846-32f12f44207d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#LosspershareTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_9b2d63d9-56aa-4b33-96d7-8abfc9f16af6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_88f9ecc3-bcd8-42e1-8335-02436922c8a2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_9b2d63d9-56aa-4b33-96d7-8abfc9f16af6" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_88f9ecc3-bcd8-42e1-8335-02436922c8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#LosspershareScheduleofBasicandDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_c2a18992-5480-4b24-b7f3-7f710d5afda2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_e4bd9238-8a05-4f91-beb5-acb28f9911de" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c2a18992-5480-4b24-b7f3-7f710d5afda2" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_e4bd9238-8a05-4f91-beb5-acb28f9911de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_68a3bf20-8d02-4c02-8353-0cf9eb58a472" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c2a18992-5480-4b24-b7f3-7f710d5afda2" xlink:to="loc_ifrs-full_WeightedAverageShares_68a3bf20-8d02-4c02-8353-0cf9eb58a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_82b16356-aa33-4eaf-8daa-7e47b321ba2f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c2a18992-5480-4b24-b7f3-7f710d5afda2" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_82b16356-aa33-4eaf-8daa-7e47b321ba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_0840bafc-c25f-48ce-b089-2f897ca475c2" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c2a18992-5480-4b24-b7f3-7f710d5afda2" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_0840bafc-c25f-48ce-b089-2f897ca475c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/LosspershareAdditionalInformationDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#LosspershareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/LosspershareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_dade0037-5905-469c-8597-1dd0beb880c5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare_174f5b59-566c-43a7-a63c-e53f5382f8c5" xlink:href="nbx-20211231.xsd#nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_dade0037-5905-469c-8597-1dd0beb880c5" xlink:to="loc_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare_174f5b59-566c-43a7-a63c-e53f5382f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Commitments" xlink:type="simple" xlink:href="nbx-20211231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCommitmentsAbstract_29c92b91-a324-4825-b485-e7d105f26206" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_8b82e406-582f-4377-beb3-51b3ea491017" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCommitmentsAbstract_29c92b91-a324-4825-b485-e7d105f26206" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_8b82e406-582f-4377-beb3-51b3ea491017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#CommitmentsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/CommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nbx_DisclosureOfCommitmentsAbstract_48b405f7-69e7-446d-bae3-35ae12f6be3e" xlink:href="nbx-20211231.xsd#nbx_DisclosureOfCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_DisclosureOfCommitmentsAbstract_48b405f7-69e7-446d-bae3-35ae12f6be3e" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fe8725c5-245c-4269-91c6-20c759ff1827" xlink:to="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8558432a-1c66-4286-af40-9b5bc07ce980" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c34a0c7-9404-4ac4-a64b-435850e47458" xlink:to="loc_srt_MinimumMember_8558432a-1c66-4286-af40-9b5bc07ce980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_debfc9fc-d099-4248-8488-ce6caef3d9bb" xlink:to="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b864391d-d608-4be9-8c05-284bbae2f16b" xlink:href="nbx-20211231.xsd#nbx_EuropeanInvestmentBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_55eb1983-a48c-4564-b9aa-f939bbb6705e" xlink:to="loc_nbx_EuropeanInvestmentBankLoanAgreementMember_b864391d-d608-4be9-8c05-284bbae2f16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:href="nbx-20211231.xsd#nbx_CollaborationAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementAxis_1e04bb0e-8dcb-47f2-99f7-b34bc4cc25fe" xlink:to="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a0449f08-93f1-4585-89a1-318a785742e1" xlink:href="nbx-20211231.xsd#nbx_MDAndersonCancerCenterNBTXR3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:to="loc_nbx_MDAndersonCancerCenterNBTXR3Member_a0449f08-93f1-4585-89a1-318a785742e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_a14040aa-ce8b-49b7-99f4-4ea0edc0ed17" xlink:href="nbx-20211231.xsd#nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nbx_CollaborationAgreementDomain_347a952d-d570-4042-9677-6e8d22e74b85" xlink:to="loc_nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member_a14040aa-ce8b-49b7-99f4-4ea0edc0ed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_b8d3c19f-e534-4967-bbe7-7ffd2a467c44" xlink:to="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d99052b8-3e39-4714-8422-20f30d2ba650" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:to="loc_ifrs-full_BottomOfRangeMember_d99052b8-3e39-4714-8422-20f30d2ba650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_7fbb8b82-bc7d-4a99-9110-7ae4b1274e9f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_b6f39f36-d757-43c5-abfe-b16dc6d13935" xlink:to="loc_ifrs-full_TopOfRangeMember_7fbb8b82-bc7d-4a99-9110-7ae4b1274e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_d54b7533-d327-4459-beff-01b19cec3372" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_22bb8c19-517e-4d75-8e74-ef85806acb2d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities_22bb8c19-517e-4d75-8e74-ef85806acb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfShortTermLeaseContracts_805e5105-44f7-4ce6-be15-3cf14c172384" xlink:href="nbx-20211231.xsd#nbx_NumberOfShortTermLeaseContracts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_NumberOfShortTermLeaseContracts_805e5105-44f7-4ce6-be15-3cf14c172384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualShortTermLeaseExpense_9c668d28-de4c-4ac1-a554-eb15a9c778b4" xlink:href="nbx-20211231.xsd#nbx_AnnualShortTermLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_AnnualShortTermLeaseExpense_9c668d28-de4c-4ac1-a554-eb15a9c778b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AnnualLeaseExpense_0c4f78ec-480d-4e89-bedf-ddb9f35b3e7c" xlink:href="nbx-20211231.xsd#nbx_AnnualLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_AnnualLeaseExpense_0c4f78ec-480d-4e89-bedf-ddb9f35b3e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfPatientsInClinicalTrial_58e728c3-7527-4bb4-9ff8-398e34039f5f" xlink:href="nbx-20211231.xsd#nbx_NumberOfPatientsInClinicalTrial"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_NumberOfPatientsInClinicalTrial_58e728c3-7527-4bb4-9ff8-398e34039f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_2218c3d4-bc78-458c-9327-57543132c940" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_2218c3d4-bc78-458c-9327-57543132c940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsPayment_27b98b20-1c98-48a2-bb00-d92637bc9d7a" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsPayment_27b98b20-1c98-48a2-bb00-d92637bc9d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_0a2d535d-35cb-4d9b-b090-b98cb012fdcf" xlink:href="nbx-20211231.xsd#nbx_MilestonePaymentDefermentPeriodAfterEnrollment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_MilestonePaymentDefermentPeriodAfterEnrollment_0a2d535d-35cb-4d9b-b090-b98cb012fdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_e89ba4e8-c862-4ef2-a85b-12ef208b7016" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease_e89ba4e8-c862-4ef2-a85b-12ef208b7016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_d533fec5-f3be-4e61-8ba6-b7510a13912a" xlink:href="nbx-20211231.xsd#nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration_d533fec5-f3be-4e61-8ba6-b7510a13912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_858cac22-2318-42c9-8c4b-bd5290a92eac" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_858cac22-2318-42c9-8c4b-bd5290a92eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_bb4d768c-15c1-47df-83d6-c10a3562dd7d" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports_bb4d768c-15c1-47df-83d6-c10a3562dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_0e693552-3101-41e4-87ba-49b921eef755" xlink:href="nbx-20211231.xsd#nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval_0e693552-3101-41e4-87ba-49b921eef755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_RoyaltiesAgreementPeriod_c4de8449-2108-420d-8bdd-4db2b5a1f041" xlink:href="nbx-20211231.xsd#nbx_RoyaltiesAgreementPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_f302f854-2b65-4f8c-a5a2-f753433d9378" xlink:to="loc_nbx_RoyaltiesAgreementPeriod_c4de8449-2108-420d-8bdd-4db2b5a1f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Relatedparties" xlink:type="simple" xlink:href="nbx-20211231.xsd#Relatedparties"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Relatedparties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_49e80814-be44-416c-8ef9-c8538e5a25cc" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_bf3dc213-ca3c-4f80-a13f-bcadc27b0733" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_49e80814-be44-416c-8ef9-c8538e5a25cc" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_bf3dc213-ca3c-4f80-a13f-bcadc27b0733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesTables" xlink:type="simple" xlink:href="nbx-20211231.xsd#RelatedpartiesTables"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_161e0f29-a0fd-4b3e-86d9-874e9b21e8e8" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_e11915a6-8fd8-494d-8c1e-68ba9e348b1c" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_161e0f29-a0fd-4b3e-86d9-874e9b21e8e8" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_e11915a6-8fd8-494d-8c1e-68ba9e348b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/RelatedpartiesDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#RelatedpartiesDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/RelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_a1603c13-c220-4589-b96a-072806f24f4e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_6caee08e-1153-4d82-a388-60fa13c85e7d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_a1603c13-c220-4589-b96a-072806f24f4e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_6caee08e-1153-4d82-a388-60fa13c85e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1d337267-da24-4b9c-b5f7-718e610d8a46" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_a1603c13-c220-4589-b96a-072806f24f4e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_1d337267-da24-4b9c-b5f7-718e610d8a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DirectorsRemunerationExpense_af1a4ab0-4cdb-4063-8f21-5e770bc59dd9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_a1603c13-c220-4589-b96a-072806f24f4e" xlink:to="loc_ifrs-full_DirectorsRemunerationExpense_af1a4ab0-4cdb-4063-8f21-5e770bc59dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_cf728186-4c6a-4853-b256-71e38001b3f5" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_a1603c13-c220-4589-b96a-072806f24f4e" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_cf728186-4c6a-4853-b256-71e38001b3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/Subsequentevents" xlink:type="simple" xlink:href="nbx-20211231.xsd#Subsequentevents"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/Subsequentevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_97479929-cf0b-4149-a0bb-a55e5bbde123" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_f2178ded-938e-457b-9e25-a9d2fe85add9" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_97479929-cf0b-4149-a0bb-a55e5bbde123" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_f2178ded-938e-457b-9e25-a9d2fe85add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nanobiotix.com/role/SubsequenteventsDetails" xlink:type="simple" xlink:href="nbx-20211231.xsd#SubsequenteventsDetails"/>
  <link:presentationLink xlink:role="http://nanobiotix.com/role/SubsequenteventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_f2275b26-bb26-496b-8f74-4a6cbd6d7b5f" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_f2275b26-bb26-496b-8f74-4a6cbd6d7b5f" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_84505669-eaea-4307-bb51-fb88c4329a15" xlink:to="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_453464b0-bde3-4dcb-ae80-12e436a35811" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_c83d616b-8b92-4ac5-b07b-8c9c4dd9a101" xlink:to="loc_ifrs-full_IssuedCapitalMember_453464b0-bde3-4dcb-ae80-12e436a35811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ca54aa66-38f2-4760-93d9-79e8e84ccd9d" xlink:to="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_82c3a266-8ca4-4509-ba08-f380e1070d01" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_bdd3b9d8-14c0-4209-b23c-32a4e1b6ee01" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_82c3a266-8ca4-4509-ba08-f380e1070d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6e5b5535-7c19-42d9-81b2-4b28f8e22f6e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_AGA2020Member_812db0d6-a3d3-488d-92a3-b615475d98cc" xlink:href="nbx-20211231.xsd#nbx_AGA2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_ea886e94-7216-4cce-82d4-70274f1dff30" xlink:to="loc_nbx_AGA2020Member_812db0d6-a3d3-488d-92a3-b615475d98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_e4be1ffb-c397-4184-a448-ad469d014368" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_4b98150d-fc60-4611-912a-b9f56c4738d6" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_IssueOfEquity_4b98150d-fc60-4611-912a-b9f56c4738d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_20520e2f-b646-4a31-8f64-fd884f9ea924" xlink:href="nbx-20211231.xsd#nbx_NumberOfSharesIssuedThroughIssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_nbx_NumberOfSharesIssuedThroughIssueOfEquity_20520e2f-b646-4a31-8f64-fd884f9ea924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_0a5e5c9f-6ed7-4058-9d5f-7c29a0f151ea" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_ParValuePerShare_0a5e5c9f-6ed7-4058-9d5f-7c29a0f151ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3d3b5fd6-80ee-465e-9b99-058b5c79bea7" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_46bc2316-4264-4218-a010-b048523a7d0a" xlink:to="loc_ifrs-full_Equity_3d3b5fd6-80ee-465e-9b99-058b5c79bea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nbx-20211231_g1.jpg
<TEXT>
begin 644 nbx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MM6EUSSA<RQG>,(#\J@]MO3\Z];T:];4M(M;AEV-/$KE?0D9H LT444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^P;_ ,$S/VH-)_:&U#P)H/@OXL?L^?!75/#'B#1?$^E^)O'D/B3P^[7EK-!
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MQW)YJQK'_('O/^N$G_H)J2R_X\H?^N:_R% $E?F[_P %;_VU?V@?AE_P4.^
M_P $?@CXX^'W@%?BAH>JW]YJ?BW3$N;.&6T5Y1N<@LNY(R@ '+,*_2*OS/\
M^"K?_!,6;_@H)_P5M_9GN/&'PYO_ !K\$=&T#6[7Q;<I=26MK9RM%*]JLDD,
ML<RDS"(C8>3@'C- 'R_\>_\ @LM^TAX:_8:_:6T#6?&GA6'XJ? 'Q]X;T1/'
M'@VVCCL=8L]0FD$B".560%1"P+!1D.!@%26_1;]F3_@M9\ ?VBS\0=,TOQA?
M+J7PAT,:UXEEO]*GMUFLXT FO+8;=T\0? RJY)=, AE)^??^"L7_  2 \/\
MP[_X)%>(OA'^RY\(XX+O5_%FD:O/I.E2O<75]Y5RIDFEFN9&DDV1C W.<#@
M5QO[2/[(7[26@_\ !1WX[?$KX0>$[S3=1U/]GBT\-^%M<=+?[/+J\<]D9+6,
M.2OGB&.8+O7:&4<]* /K#]CW_@N;^SQ^VWXQ\2:!X5\0Z[I.K>&-&E\1W,'B
M+19M+\_3(O\ 6WD1<$-&@()Z-@YQC.&?LF?\%T/V?/VSOB%K'AWPAJ_BNV;1
M]*N=<.I:QX<N;#3+JQMN9KF.X92GEJO.7V9!XR>*_.G]C3]A+]IK2_VY/A[\
M4/B3\&_B=XLTGQ9\,-8\"^(;7QK\08M7NK.8PRDF681H;*TN9&*16Z!_*$C,
M7YQ67^PS_P $O_VI-2\9^-/AMI_A;XL_ ?X+Z[\/M=\.:OHWC'QS#XDT=[Z[
MM9(;;^SEC2,QHLS*Y;:Q"*V6^;! /TG_ &1O^"[?[./[;/Q\A^&_@GQ-KB^(
MM22:31FU;1)]/M/$*PY,ALY9!B3"@M@[20#@'I7E_P#P<!?M>?M$_L3>%OA7
MXH^"_BSP3H>B^*?$MOX.U*UUG1_MUQ)>WC,;>=6*D+"BQN& .XEA@'FOE3_@
ME)_P34^,7AC]J'X&Z;\7?@W\:--C^ 8N&MO%6K_%6"_\,V,BQE$_LS31;EEB
MFP@:-9?NC)(QBOHO_@Y'^'?QH^/7@7X/^#_A/\%?$GQ,AT3QA:>-M1U+3;^&
M&.S-B75;-D<9W3"4L) <+L/RMG@ Y_\ ;=_:A_;1^ ?_  4._9K^#NA_$CX4
MQVWQHTV.WNI9?#AD6._T^UB?5)2Q3<L<\AD,*KRH(!"XS70_#[]J_P#:LU7_
M (+\:_\  +4/'7PYE^%NAZ;)XX:SCT+;>/H<LWEP68GV;OM2^9$6<D*=K?-S
MBO/O^"@-]^TE\7O^"H?[)_Q8\/\ [*_C34-#^$>F_P!I:JL6MVV/M&KVD0N+
M0N4&UK)RRNVUA(4. @YKH?AQH?Q\@_X.1/$WQ4O/V=_%EG\,=<T%OAPGB5]5
M@-K';03"1-7P%W&.40J!#@$>8"7.,$ _5.J^J:-;:[:_9[J,21L>F<$'U![5
M8I4^^/K0!A^!?#UGHVAV\MO"$DN8E:1R=S'C/4]O:MNJ/AC_ )%RP_ZX)_*K
MU !7Y8?M:_MH?M4>.O\ @KYX^^ GP;^*?PC^&OAWPAX.L/$J3^,])25)C+Y2
M21K+M9BQ:4, > JFOU/K\KOC-_P1KT/]N7_@NY\3O%WQN^%-]XI^#MQ\/].B
MT+5)=1N+*UDU6)K=&16MIXY2PC\X8;Y>">N* .H_8B_X+Z^'X_\ @FE_PMW]
MHR_TW1]>T?QI?> 2?#EE)<_\)5>V^QTDL[9<MEHW&X9V@H3E0P4>RZ/_ ,%W
M_P!FS6OV0-4^-D?B_4H_"VBZQ'X=O=/ETF9=:AU.0;H[/['C>974%A@E2%8[
MOE./%_\ @IK_ ,$T=8^#/@/]F3Q!^S#\*=+US3/V:/&;^(/^%?V-Z+-M6MY@
MID>.6;=OG$D8)9RSGS"WS8(KYI\0?\$U/C)\;?V:_P!I'XG?$+]G/6M0\4?&
M[XF:5XLTGX>Z3XV@TS7?#%O9K.IOH[ORVB:Y/GLHC*9(+,5'RX /H;]N/_@Y
M.\#_  O_ & S\6/A'I6NZKK]YXEC\-6UAXH\,7EI#:SIY<LZW W1X/V=RR%'
M8%L \Y%?8&J?\%&OA_X8_P""?<?[26K1^(K/X?KHT6M3(VF%=1CB>018^SLV
M0V\]"W3G-?E#J7_!/+]L3XS_ /!&#XP>$/%6C_$#6=4F\<Z1KG@/P?XN\0PZ
MMXDMM-M) ;B.2Z^56W$J44A?]4Y"C<,_?G_!1OP/\2_VT/\ @ACXRT2S^&^M
M:/\ $[QCX3M%/@QKF.ZOK.Y$\)>W,GR([!4)S@4 4YO^#C?]E>!O%T9\6>(6
MN/!^DVVLRVZZ#.TVJ0S[ %LU'^O=&D4/C"KACN*JS#MOB)_P6T_9_P#AM^R%
MX%^-EQKVO:GX/^)$KVWAZ#3-$GN]2OIH]WG1&W491HMC;MY &."<C/S;X3_8
M=^)5E_P4S^#_ (PF\ :A'X6\._LO)X+OK\QP^39ZSLD4V1^;(DPVW@8PV,X)
MKYQ\"_LF?MH?L_?\$UOV6O O@[P3\2;"QT?Q#KTGQ \.^%/$5OX<\1J)KEC8
M.M^1)]G@VO*69 V0<,,$8 /T7D_X+D_L\_\ #(OASXW0^(M8N/ ?B/Q/%X.$
MRZ6Z76FZE("3%=1.5,011N9LD $$9S7SQ=?\%>F^*7_!6/X'W'AGQQK6A?L\
M^(/AWXDU_6[35].&GPSOISWR&\D$J>:B#R%93D;E"G'.*^2/ O\ P2Z_:.\'
M?L2:I\)=6^$GB&^U+1OVDM)\:I?G4H=276=+99!/<^8=ID6/:N^1@"YESL'(
MKZ:_X+0?\$F?'?\ P4K_ ."H/P]CM(_%6A_#63X::KH^J^)M+G2&W@O-US-;
M6EQDEC%)-Y&]0I!4XXZ@ ^G?$W_!<[X#^!_V1_#/QHUR?QKH_A3QSJ$FG^%K
M2Y\/RC5O$K1]9;6U4EGAQR)&VJ1CU&?&_P!NK_@XP^'GPN_X)KGXW?!F;_A+
M=6U37!X;T^QU;2+A8]-OT*O/!J$8>-X&$.XJ=Q#,5 SSCYF_:!_8J_:G_:*_
M8X_90\<:E\./'=G\4/V8[R_\.:_X;\/>(8?#NM:U8F*"&#4M,O%#I&YCA0,0
MI))?"XJWXV_X)0_%'X@_\$2_CUH_A_X2^/O"WQ1^*'C.Q\5R>'/%/C>#Q)K.
MLK:W$4C3R3B*%5N) )"RMDL5![@4 ?KG^R=^T9I'[6_[.?A'XCZ#;ZE:Z7XL
ML%O(8K^T:TN$.2K!HF)*_,K8R3D8.:]#KSS]DOQCXD\?_LT^"=6\8>#[_P"'
M_B:ZTJ$:CX>O;I;JXTN5!L,;R*%#$A0V0!]ZO0Z *^I:3;ZW:FWNHUDB8\@]
MO<'L:R_ WANST72DEMX=LDP.]R2S'YCQST'%;J??'UJAX;_Y =O]&_\ 0C0!
M>HHHH **** /SA_X.,_VKOB+^S#X"^ =O\/_ (K2?!J/Q[\1K?P[KOB7R+>:
M'3K"6(AYY1.-GEQ9\PY9.$Y8#FO+_P#@F9_P4-^('@K]O[XL?"OQ!^T!#^U_
M\,?"GPX/CI/%_AS0[>6YL[N.6-'L($L7E65W1VQ'O+%E& OS5]"?\%MO^"?7
MB[_@H#=?LXZ?X?\ #NB^)_#W@GXGV.O>+[+4[F&.!](7Y;@%)3B8,A93& 2P
M.,<UZ9\>/^"?VE?#7]B?XM>#?V7_  SX+^#/CSQEHTL&G:CH&GQ:1NN@/DWR
MPJ"I*[D#_P !?(QUH \]_90_X+G>$/VE?C=JOP[UKX4?&+X2^+H?#%QXPT>P
M\:Z(-.?Q#ID(8M- "V>0IQD8.&P?E-?/?[0'_!R9<^.?^"=GC3XI?!WX,_&.
MSDL]&+V?BF^\/1W&@Z+>M=FV"339,4ACPKN%+!1*@//%>6?L2?\ !&3]I7X!
M_M9?"_XI:OX'\%V,EQX*UCP=XQMT\<7NL7D+RVTJQZE)+>3RAIKB5QF*V/DQ
M@9V@DU] _!G_ ()5?%:S_P"#;[7/V8]:M='TGXHZAI6HQ06[:C'-:><VI&\A
M0SQ[E =55<]%+<XP: -3P#_P<#6/A'X/?L^_\)_\'_C _CKXS>'[V]MM.LM$
M1KZ^N+) "\-HI\QUNVP\&Q2"DBDX'-=5H?\ P</?!_7OV)+'XQ0>&/B'-J6J
M>+9/ 5IX$@TU9O$ESKB!7-DD2MM+>6Z-G/\ $%QN^6O*_A+^P!^T5XN_:5_8
M3\>>.O!?ACP[_P *&T+5=!\60Z?KT-REI&(C;V<B?.6E:6)$=PF0K,1P!7A/
MB'_@WZ^-GCG]D'Q997&F>&8_'6@_'W5OB;X?T.]U]X;/Q-I-S%;QF%[JTD$E
MM*_E':0Z,N#\R$@@ ^PI_P#@X=^&.E_LC>/OB?JW@'XF>'=8^%GB#3_#OBSP
M3K-A'8Z]HL]Z^V"21)'"^6P#'J&^1ACIGZN_9#_:>'[7'PKN/%L/@GQQX%L?
M[3N+&RM?%6F-I]YJ5O'M,=]'$WS?9Y@V48X) )K\I?$W_!$?XO>,/^";GQ<T
M'3?@M\-_AU\4/B-XJ\/WJ:7I'CK4=8DN;#3Y][->7>HW4T9D4M*R>6^2K8/0
M ?M%H-K)8:#8V\W$T%M%&X!SAE0 \_44 6J*** "BBB@#G=?\%:;J/B"SFEM
M_P!Y,[[]K%0^%SR!7011+!&J(JHBC"J!@ 54U'_D*Z=_OR?^@5=H **** "B
MBB@ HHHH **** "BBB@ HHHH *_)C]K7_@J9^T)XY_X*;_$OX&_"?XA_ /X,
MVWPMM;,V</Q&;R[OQW<SQ++LMV?Y=OS!0$P0"&).?E_6>OR7_P""QGP9^*G[
M0OQ9\>^&M4_8/\%_'+3=9TL:;X#^(.EZ[%::IHVZ+:'O9&595,<S;Q&K(H"D
M;G!S0!VW[;__  77\0?\$^/C+^S?\/?B%X=TBX\5>-[6*_\ B.= TV[U"SM8
M9(]J_P!DR>8IE?SP<JX?"8ZY!/L?[1/_  7U_9M_9:_:%D^&WC'Q%XDLM7L9
MK:WU34(O#US-I6BRW"*\:7%P!A6VNI.P,%S@\@@?('Q?_P""?_[17[,WPE_X
M)WZYIO@G4/C-XJ_9ON;Y/%FE:7JL:31?:Q$8T6:3(:.%4,6]58'RU[$&O(O^
M"I7[#/[;G[;/Q#_:0\.ZCX5^(WB#PT^J0ZQX):P\8P6'A6YTRWEC>&S_ ++"
M9O+TKC$DDB%&C8G=A00#[?\ C-_P77TOX5_\%FO"G[-2Z-=77AO4M.2UU+4(
M]&GEO%U>X9#:>1(LHC:S\MQODV'!SSQ7J%C_ ,%N_@;J/[+EO\8([CQ=_P (
M;=>-E\ 1L='_ -*.IE]@'E;_ /5Y_CS^%?._B+X.?'+PY_P6!_9?^/5G\&=<
MU3PSJ/PJM/ WBFVBU.%9/!%Q).[3/<'&9%B64'"J ^UL$$5\<Q_\$\?VL_"7
M['6J?L^M\";N[TGPG\=+7QI!XJM=7AE_MRT>Y;YK:VX/EHB^8TCN,!U79NR:
M /U(\1?\%T_V>_#O[7\GP3_M;Q9J7BRVUQ/#-U>:;X;NKS2;/4W8(+62XC4_
M.'(4D*54YR0 2/L(C::_#KX]?L$_M,>'?^"JVN:_\ _A;\4OA"OBCXAQZUJ7
MBJP^(4%UX*UJQ,JO/=W6G^6KB20!V:(NV"Q0+TQ^XSGYCCIF@!**** "BBB@
M HHHH **** "BBB@ HHHH *N6W^H6J=7+;_4+0!3HHHH **** "BO'?VBO\
M@H)\%?V2]3CL/B)\2O"_AG4I%#BPFN#->A3T8P1!Y I]2H%>1_\ #^S]D?\
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M]\T :%%9_P#;LWI'_P!\T?V[-Z1_]\T :%%9_P#;LWI'_P!\T?V[-Z1_]\T
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M9_\ ;LWI'_WS1_;LWI'_ -\T :%%9_\ ;LWI'_WS1_;LWI'_ -\T :%%9_\
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MP>/]*^(G_"+Z;>ZEJ7@'4+K13%<!8(-3U""UCF,4,FXY0/*L3.P7#K(,87)
M.ZHKY3_X)[?MT:C^TS!/<>(/$7@W5=)U*UT_^Q]3T^U.DI/J\D<\FHZ)'%-/
M(US-8B./>\9_Y:,&4%372?M9^//BM\/?C+\,M-\(^,O".EZ+\1O$@\/-;ZCX
M1DU"?3L6%U<M,)EO8A(2UN!M*  .>3@9 /HBBO#/$/[:^F?#2^^(&DZMHOBO
M7IOA!I$.H^+-;T_3[6VL!YEF;I/)CDNO,9I%4@(H?8V S!?GK3^,W[;7A'X&
M1>+FUBS\0W'_  A?AS3O%%\+*T25I;6^NIK6%(@9 6E$D+EE.  5P23@ 'L%
M%?-7Q@_;6N7\.:O8:/I^O>"/%WA+QIX8TC6;'7+:T:3[!J5_ @F1HY9H3%-
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M '];_&C_ (2&^_Y_+K_OZW^-5-C>A_*C8WH?RH_UDS?_ *"JG_@R7^86+?\
MPD-]_P _EU_W];_&C_A(;[_G\NO^_K?XU4V-Z'\J-C>A_*C_ %DS?_H*J?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "M_0/\ D&K]36!6_H'_ "#5^IH 91110 5^;_\
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ML:S_ .?2U_[]+_A5FBC^Q<N_Y\0_\ C_ ) 5O[&L_P#GTM?^_2_X4?V-9_\
M/I:_]^E_PJS11_8N7?\ /B'_ (!'_("M_8UG_P ^EK_WZ7_"C^QK/_GTM?\
MOTO^%6:*/[%R[_GQ#_P"/^0&;J.D6BR6F+6V&9P#B)>1L;VJS_8UG_SZ6O\
MWZ7_  I-3_UEG_U\#_T!ZM4_[%R]Z.A#_P !C_D!6_L:S_Y]+7_OTO\ A1_8
MUG_SZ6O_ 'Z7_"K-%+^Q<N_Y\0_\ C_D!6_L:S_Y]+7_ +]+_A1_8UG_ ,^E
MK_WZ7_"K-%']BY=_SXA_X!'_ " K?V-9_P#/I:_]^E_PH_L:S_Y]+7_OTO\
MA5FBC^Q<N_Y\0_\  (_Y 5O[&L_^?2U_[]+_ (4?V-9_\^EK_P!^E_PJS11_
M8N7?\^(?^ 1_R K?V-9_\^EK_P!^E_PH_L:S_P"?2U_[]+_A5FBC^Q<N_P"?
M$/\ P"/^0&?J6CV:Z=<$6MJ"(F((B7C@^U26VCV9MH_]$M?N#_EDOI]*EU3_
M )!ES_UR?^1I]K_QZQ?[B_RI_P!BY?:WL(?^ Q_R B_L:S_Y]+7_ +]+_A1_
M8UG_ ,^EK_WZ7_"K-%+^Q<N_Y\0_\ C_ ) 5O[&L_P#GTM?^_2_X4?V-9_\
M/I:_]^E_PJS11_8N7?\ /B'_ (!'_("M_8UG_P ^EK_WZ7_"C^QK/_GTM?\
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M]/SHV_3\Z2B@"M*O_$\M^G_'O+W_ -J.K6WZ?G523_D-P?\ 7"3_ -"CJU0
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M %%%% !1110 4444 %%%% !1110 5ROCO_D=_ __ &%I_P#TW7==57*^._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)?I__/Q_Y#;_  H_X2_3_P#GX_\ (;?X5Q-% ';?\)?I_P#S\?\ D-O\*/\
MA+]/_P"?C_R&W^%<310!VW_"7Z?_ ,_'_D-O\*/^$OT__GX_\AM_A7$T4 =M
M_P )?I__ #\?^0V_PKE_'7BS3V\:^"6\_A=5G)^1N/\ B7W8]/<51KFO&W_(
MW^#_ /L)S?\ I%<UPYA_"7^*'_I<0/6_^$OT_P#Y^/\ QQO\*/\ A+]/_P"?
MC_QQO\*XFBNX#MO^$OT__GX_\<;_  H_X2_3_P#GX_\ '&_PKB:* .V_X2_3
M_P#GX_\ '&_PH_X2_3_^?C_QQO\ "N)HH [;_A+]/_Y^/_'&_P */^$OT_\
MY^/_ !QO\*XFB@#MO^$OT_\ Y^/_ !QO\*/^$OT__GX_\<;_  KB:* .V_X2
M_3_^?C_QQO\ "C_A+]/_ .?C_P <;_"N)HH [;_A+]/_ .?C_P <;_"C_A+]
M/_Y^/_'&_P *XFB@#MO^$OT__GX_\<;_  H_X2_3_P#GX_\ '&_PKB:* .V_
MX2_3_P#GX_\ '&_PH_X2_3_^?C_QQO\ "N)HH [;_A+]/_Y^/_'&_P */^$O
MT_\ Y^/_ !QO\*XFB@#MO^$OT_\ Y^/_ !QO\*/^$OT__GX_\<;_  KB:* .
MV_X2_3_^?C_QQO\ "C_A+]/_ .?C_P <;_"N)HH [;_A+]/_ .?C_P <;_"C
M_A+]/_Y^/_'&_P *XFB@#MO^$OT__GX_\<;_  H_X2_3_P#GX_\ '&_PKB:*
M .V_X2_3_P#GX_\ '&_PH_X2_3_^?C_QQO\ "N)HH [;_A+]/_Y^/_'&_P *
M/^$OT_\ Y^/_ !QO\*XFB@#MO^$OT_\ Y^/_ !QO\*/^$OT__GX_\<;_  KB
M:* .V_X2_3_^?C_QQO\ "C_A+]/_ .?C_P <;_"N)HH [;_A+]/_ .?C_P <
M;_"C_A+]/_Y^/_'&_P *XFB@#MO^$OT__GX_\<;_  H_X2_3_P#GX_\ '&_P
MKAGG532?:EKX''>*7">#KRPV(QT%.+LTFW9]5>*:NNJOH.S.Z_X2_3_^?C_Q
MQO\ "C_A+]/_ .?C_P <;_"N%^U+1]J6N/\ XC!P;_T'P^Z7_P B'*SNO^$O
MT_\ Y^/_ !QO\*/^$OT__GX_\<;_  KA?M2T?:EH_P"(P<&_]!\/NE_\B'*S
MNO\ A+]/_P"?C_QQO\*/^$OT_P#Y^/\ QQO\*X7[4M'VI:/^(P<&_P#0?#[I
M?_(ARL[K_A+]/_Y^/_'&_P */^$OT_\ Y^/_ !QO\*X7[4M'VI:/^(P<&_\
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M?_S\?^.-_A7$T4 =M_PE^G_\_'_CC?X4?\)?I_\ S\?^.-_A7$T4 =L/%^G
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MX5Q=9WB[Q?I/@#1&U/7M4T_1=-62*)KJ^N$MX0\KK'&N]R!EW9549Y9@!R:
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M_P <;_"C_A*M/_Y^/_'&_P *XNB@#M/^$JT__GX_\<;_  H_X2K3_P#GX_\
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MZ'XI\*W/AG2+'7EMK^"WDFU:RO96@M9+8032 O).IA\J0I('*@J 0:\*T/\
MX)2^(M+\,W%C'??#'2KN\^&NK?#V^U'2](FBO-:EN_),>JWDI&^:<M$3(K,V
M-[%78G ]7^,'["=S\6_$^O7TOB"ULH]2\%:)X>M-MLTCVU]I>IR:C%<N,@/"
M9#$"@(8A6Y&10!U6L_M=_P#"+:=:0ZQ\/?'.D^*M6U9='TKP[<'3_M6K2F!K
M@O#.MT;3RTB1V=VG4(5VG#$ Y_A_]O#0?',^B:;X=\-^*]=\3:HVH"\T2W2T
M2ZT%;"<6]XUTTDZPXCF94 BDD,A8% XYK$^-'[*/C/\ :/B\/ZMXX3X3ZYK/
M@_73JND:%=:3/>Z!+$]I);3Q7+3 R.[B4R(XB_=,BC#@DTO@_P#8^\3?"SQA
MX7\5>%9/ACH^N66F7^BZQI=AH;Z7HCVMU=)<HUM';_-YT#(%W./WP+%MAQ@
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M%24 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E1VO^I_$U(>E1VO\
MJ?Q- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<<M'_O_P!#
M5J3_ %C?6JL_WH_]_P#H:M2?ZQOK0 VO._VNO'VJ_"O]E'XF>)M#5FUKP_X6
MU+4;#:,L)XK61T(]PP!_"O1*@U/3+?6M,N;*\ACN;.\B>">&1=R2QNI5E8=P
M02#]: /#/V=_V4_ASH7P;^%OB:'PW8KX@\-:-:ZQ%K=MF'4KR>2S!G>XG0A[
MD2^8Y99F=6)!(R 1Q/PE_; \=>(?"OP6^(VLW?A^;P;\;]<AT>#0+;2WAN]
M2ZCN'M)!=&0^>P\A5E#1H/WA*XV@'TSP!^QE8^ KOPQ;_P#"<?$#5?"W@F02
M:%X;O+^ 6-CM1HXT>2.%+FYCC1BJ)<32* !P<##/ '[$/A[X?>(/#+0Z_P"*
MM0\,^!;Z74O#'A>[FMVTO0;AUD4/&5A6XD$:S2B-9II%CW_* 0I !Y-\'/VN
M_B9XCTOX8^+-:U'PO=>'_'?C[5/ UWH]MHS036@BGU&.VNX[CSFRP^QH'1DV
ML&)!!XKAO!WQ:\=?!_\ 9\^/_B;4]=T;QE-8_&E=%M+34]#'V:W5]2T^VD<*
M96_@E!1!@1NFX9S@?37A7]BOPKX1\#>#?#]M?:])9^!_%MQXSL'DGB,DMY-+
M=2LDA$8!B#7DN H5L*GS'!SF:K^P5X;UGPUX^T.?Q%XK.@_$'Q3;^,;JP62T
M"Z?J$=S!<NT$GD>9LEDMXMR2O(  0FS.: /-/BG^UQ\3/#%[\</$&GZCX73P
M]\&/&6G:2-(FT=Y)]9L9[;3I9@USYP\J93=R%&"$<*&&.:V_CC^V/XN^'?PY
M_:>U;3X]':Y^#]W9PZ")K5F5UET^SN6\\;QYAWW#XQMP,#MD^B>*?V+O"WBW
MP[\5-,N;[7DM_B]J]OK.LM'/$'MYH8;6)%MR8R%0K:1DAPYR6Y&0!B_&G]@'
MP[\:=1\?&;Q5XVT+2OBA;V\?B;2M,N+46NH36\:117 ,L$DL4@CCC5A&ZHX0
M;E;G(!Y#\5_^"BWB72O%_P 4)/#MQ;R-\+=4ATJV\)Q>$=0U.\\7R+;V\]SM
MO(08[=B)RD2@'YD!?AJS/VL_C)XQ_:%_9A^.6K6NH:/I?@OP?XHA\*0Z++IC
M-?7IMKRP\^ZDN2X\MC)(P6)8RH5!N8DG'T?K/[)-E=>,M:U/2/&7CGPKI_BJ
MYM[WQ!I&CWL$%KK$\*)&)6=H6G@9XXXTD-O+%Y@4;LGFL7XE?L$^'_B.?&=F
M/%/C30_#GC_4(M8UO0M-GM5LKF_1H&-TK20/-&S_ &>+>B2"-R"2F230!R?[
M:.C>(-2_;F_97.D^(X='MVUW75>)]+6ZWD:/,SG<9%^]'N0#'REMW)&*R_ W
M[9_C?7/ 7@/XM7%SH/\ P@/CSQO'X5B\-)I;K?:=;3ZA+I]O<_;/,_>3>9&C
MNAC";78 Y4$_07Q ^"&D_$CXH^ ?%U]<:A#J7PYN[R]TV."1%AF>ZM6M9!,"
MI+ 1N2NTKAL$Y'%<3X=_8=\.^&O$.D^3KWBB3PCX?UU_$NE>$));?^Q]/U!I
M'F$J$0BY94FEDD2)YFB1VR%&%P ?./[/SB'Q?\ &;[J?%KXD$X]O[;KT+X8?
MMC^./$7@CX0_$[5+KP_)X)^,?B6'08/#T.EO'>:'%=-<):3?:S(?.D#0IYJM
M&JXD;:?E&?1O#G[#&A>$M8\.WEAXF\60MX3\7ZIXOTR-C9.D$FI"X%Y9G-N2
M]NYNIB-Q,JY&V4  5-X+_8>\.^"=?\.^3KWBFZ\*^#=3EUCP[X4N)K<Z3HEV
M_F8DC*PK<.L?G2F-)9G2,OE5&U< 'BWAW_@H/XXF\9?"'2=1M_#\7G:YJ.C?
M$EQ:LAL3'JC:39M;Y?$0EN2CDMN!7('4&NUNOVN/&<'_  3_ $^*[6^D0ZUJ
MNL0G3H7M6\E--N=;6UM]Z;\F0V;HQ;.-YSC'%=#XG_X)V^"O%)^,#2:IXJMI
MOC(UM)?RV]U"KZ');L9(Y+#,1$3>>3.2XDS(<].*[?QI^S!X9\=?LU+\*[PZ
ME#X;ATVUTZ":WN?+O;;[,8V@F23&!*CQ(^2I!8<@@D4 >-?M0_ME^-/A%XK^
M.VGZ'%H+#X<^%/#^LZ-]KM7?=<W]Y<P2B8JX+)MB3 &"#GDUW_PY^+7B[P]^
MUKJ'PO\ %NI:1XB2^\*CQ=I6HV6FG3Y+5%O/LL]I+'O=7 +Q,D@*D@N&7@&O
M/OVE/V#M0UGX+?%JZT;7?%?COX@?$;0]*T6XEU6ZLK4SQV-TTD;1^3%!%$^V
M63)& =JD ,26]G^&O[.MIX"^)^K>--0\1>(O%WBC5+"+2([[5VM@=/L(Y&E6
MUA2WAB0*9'+,[*TCD+N<[1@ \.^('[9?CC3?!/Q8^)VEW6@6_@GX/>*9O#UU
MX>GTMY;S6H;22".[G^U^8/)D)F<Q(L;+B-=Q.XXT_P!D#2M>A_X* ?M2SWGB
M*&^TO^U/#X2R&F+"P+:/"T3>;YA/R)E"-OSD[N#Q7<^+OV'/#GB[7M>SKWBF
MP\*^+M6CUSQ!X5M9K<:3K5ZAC)ED+0M<()##$9(XID20I\RG<V>W\ _ [2?A
MW\5_'WC"QN-0DU+XBW-C=:E',Z-!"UI:K:QB$!05!C4%MQ;+9Q@<4 ?.?C3]
MKWXD^#O 'Q2^(TE_X7D\,?"OQY-H$N@C2'\_5=-2>UB=_M7FDQW"BX=EQ&R,
M4 8#)(UOBE^V;JWPU_:,T71[?QGX1\16.J>-[7PE<>&[#0+LR:=#.-HEDU/)
MA%W&V&> @#!V\-4WPX_8=O\ Q=?_ !&M_&VK>);'POXB^(]WXE_X1RWNK1M/
MU^W5[:6V>9A&]PB&2$%HDEC#[,.I!.>HU?\ 8#T74+R9;?QMX\T[2%\8#QY9
M:3;SV1M-.U8W)N994WVS2/')(TA,4KNB^8VP(0I !X#;_%?QU\&_A3^V!XJO
MM>T?Q>WAOXB+96&G:IH8:SB/V?2%R5,K IY<H C  #J7SEB!TGQ*_P""BWB3
M3_&'Q*N/#\T-PGPU\2+X?MO!\'A'4-1OO%"Q?9S=2+?0@QP2$32") "!Y0+_
M 'N/9/%7[!OAOQ=I'Q7TJX\0>*H]#^,&IQ:UJVGQO:".RO4%LK36SF RKO6T
MA#+(\B#!VJI.:V-2_9,LW\;ZUJFD^,?''AG2_%&HQ:OKNAZ3>PP66JW:"-3*
M7,+7$/F+%&)%@FC60+\P)+$@'B_B[]K[XE:1_P +0\56NH>&1X9^&/Q(L?"S
M:++HS?:-4TZX_LY78W/G Q3H;UF4A"IV@$=ZJ6OC'XI>!/VFOVNM6\/7P\<7
MWA?1]$E\/^%QIFP3W#V4LD2JPFR2@WAE4*9CC)4@5[;KO[%GA7Q!X3^(6CS7
MVO+:_$KQ/;^+-39)H@\%U"UHR)"?+PL1-G%D,&;YG^89&+.I_LHV-S\5/B!X
MLL?%GC+0[KXDZ;:V.JV^FW,$*0RVJ&.WN[>7R3/%,B$K@2&-L_,A- &;^QW\
M<W^,FFZ]'<^/M'\:7VD26XN+:/PS<>'-4T<RQEO+N[.=V==Q!,;X 8!N6QFO
M9Z\[^#'[.MM\)/%_B3Q->>)/$7C+Q9XJBL[;4-9UK[*L[V]HLBV\"I;0PQ*B
M>;*W";F:0EB>,>B4 %%%% !1110 2_ZM?J?Z5Z7\)_\ D4$_ZZO_ #KS27_5
MK]3_ $KTOX3_ /(H)_UU?^= &K1110 5^;__  =)?\HV-)_['G3O_26^K](*
M_-__ (.DO^4;&D_]CSIW_I+?5T87^-'U.7&_P)>A_//7OG_!,OP;H?CW]LCP
MWI^N6&DZN?LM]/I.FZHP6SU/5([61[*WEW<%7G"#:>#TKP.O6OV'_@3I?[2/
M[2.B^%-:U;6?#^EW$-S>7&JZ9'&\NF+!$TQN&,C*JQH$+,^<J!D9.*UXJY%D
MN+]K4=./LYWDDVXKE=VDK-VWLFF^C3/E:-_:1LKZH_0SP;:_%GXO^)/V>=1^
M)WA>::&ZT_Q7IGQ)_M?08[.STS1OM@WB<>6J0;$BC,3<,2B8)SS^;?[/7AS2
M_$_[4'A729;VXL]%O/$$5O\ :X;@PRPP&7 D60<J0N#N'-?<'AJR^%/[7FL1
M?"M?VP/V@/$T=_F#3]*U+3G^QZL\:DI#'YC!69MN$5\;C@=37SKKW[(WA+X8
M_'/X1ZG9^*+?QI\)_B%JA2&_U"W.E2Q&WN5BNK2\C=OW3H67<VX*5?/'-?D'
M!N+P^!6+P5>]&I4A+DA&A5I12<J]5./M(Q3E:4HQCI[M*UW9\O?B(N7+):J_
M=/LNG]:GEOBOPIX7\-W5_JVD_%+^TM:MI7>!8]*OH+B=]V/]>W ./XB>:\^O
MKZ;4[V:YN)I+BXN',DLLC;GD8G)8D]23SFOK']H70E\*? >WU#3? OP_M_%.
MOZ?/'XGU2SO].<:7!'=R+%%:V<4FR*62(1%Y44N5 QC+D_)-?K'#&/\ KF'E
M6NY6DXW;IM^[H[>S22BVFXWU:L[)-(XJT>5V_P _U"OWZ_X-Z/\ E&#I/_8V
MZM_Z!;5^ M?OU_P;T?\ *,'2?^QMU;_T"VKU\Q_A?,[,I_C_ "?Z'VU7$>,_
MCII_@GXW^"/ MQ97LVH>.H-1GM+F/;Y%L+*..2029.[+"0!=H/(.<5V]?//[
M4O[/FH?&K]K?X*Z@UOXFC\-^'K77_P"U-1T76+K29;)YK>!8%:>VECE =E8;
M0V#MY%>$?3'=:=^U?X16?X@-KE_:^%-.^'.N1Z!J&HZQ=PVUK/-):P7*M&[-
MT*W"KAL$LIXQ@UJ>(OVF_AQX1\,Z+K6J>/?!^GZ/XC .E7MQK$$=OJ(]87+;
M7'NI(KY!U?\ 9#\9^ _BKJFN::OQ0M_#N@_%637X[C2[Q-:U^]LYO#T-FMY
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MO=WF-)_K6QEA@\9Z8[=!U'--71H44#]_PD:?Z]^B$E>_7GD]6[YI7GV7W_\
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MP^< [ASG.<]^I''3BGFQ@,F[=)NW,_\ KFQEA@\9Z>W0=1BC^VL%_P _J?\
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MUZ'^'H,"G-I]NTF[=)NWK)_KFZJ,#C/3U'0]\T?VU@O^?U/_ ,#0$\OWH_\
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M_P#@ 6+/_CUC_P!T5)5.TTV)HHY/WN[<9/\ 6MC)7:>,],=N@/(YYIW]CP[
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MMB<=7I2GC.9:JRE!Q:32:2YK2=KVE?F7,M)-'/644[1"OWZ_X-Z/^48.D_\
M8VZM_P"@6U?@+7[]?\&]'_*,'2?^QMU;_P! MJ]O,?X7S.S*?X_R?Z'VU111
M7A'TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->-O^1O\'_]
MA.;_ -(KFNEKFO&W_(W^#_\ L)S?^D5S7#F'\)?XH?\ I<0.EKG_ (@_%7PS
M\)[73)_$^O:7H$.M:C!I%A)?3B%;N\G;;#;H3P9';A5[FN@KYE_X*;?#32_C
M-H/PA\)ZUO\ [-\1?$2SL)V0XDB#V5\!(A[2(V'4]0R@CI7<!]#6?C;2-1\9
M7WAV#4K2;7=+MH;V[L%?,]M!,SK%(R]0KM%( >Y1O2M3:0>E?FWX?_:&U?P[
M\3?BY:^-_M5UXVT/2?!_P_UR6#66T..XNVU*]BCOYKN,%[6TN(9H;AI(P6"R
MLJX-:_PM^(6N>-?$WA?P/J'BB\_LO3_CEJ/AF6'0_&&H7RRZ=_PCL]VMI_:$
MACNIX1*S%6?!&T;6^0, #]#<$G'>C%?"/PO\97'B/4/ _@OQGXP\06?PZM_&
MWCK1)KZ?Q)<V,]T=-O#'IEE<:BLBSMMA,[#=,&D-NNXO@@S?LY>,M:^*7Q?^
M%UKXB\1>+=4T&U\+>+=1LA%K%S VN6UCK]M%IUW-Y31FX8VP7#-D2!^=P<Y
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M_P )MXZLY&NO%?B'2CJD5ENL+6)K:WWR3?*=UW<QN >6^SDCI7F?P+^+5_\
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M!5*<M@;/[!OQL\4?M _LX6GB'QHN@CQ)'K&K:3>'1K>6"Q<V>H7%JK1I*[N
M5B!.YCR3TZ#A_P!F[7[CQY\1_&W[2%OX;UN\T7QMH>C:1X;T?3Y;6ZU:[L+5
MIY3<R()A#&\DET3Y1EW(D?S88[1?_P"";&G>)O WP8OO"_BKP+XN\(ZA;Z]K
M6K++JJV9M[B&\U2YN(51H+B4EQ'*A8$  DC)Q0 ?M>_&CXN?L[>"/'GQ&MF\
M _\ "%>"5M[FST26TN+G4O$-MF,7!:Y$L:6DI9V6)!%,"54L?FP*/Q,_:A^(
M&H:E\8-5\$GPG::#\$+>-K_3M7L)I[SQ!<BP34)X!,DR+9A89$17,<Q+DD@
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M^U<.8?PE_BA_Z7$"2H;JPM[YH6GMX)VMY!+$9(PYB<9 9<CY6&3R.>375?\
M"K-4_O6?_?QO_B:/^%6:I_>L_P#OXW_Q-=P'%ZAX1TC5UO1>:3I=V-2C6*\$
M]G')]L1?NK+N4^8H[!L@4VP\%Z+I4JR6NC:1:O&RNK0V44;*RIY:L"JC!"$H
M#U"G XXKMO\ A5FJ?WK/_OXW_P 31_PJS5/[UG_W\;_XF@#B=4\%:+KFCS:?
M?:+I%]I]Q*9YK2XLHI8)9"=Q=D92K,6YW$9SSUJU%I%G!<0S1VEK'-:Q>1#(
ML*AH8^/D4XRJ_*ORCCY1QP*ZS_A5FJ?WK/\ [^-_\31_PJS5/[UG_P!_&_\
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MX)T36K=X;S1='O(9+@7CQW%E%*KSC&)B&4@R# PY^88'-=O_ ,*LU3^]9_\
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M-4D66]<6$0:]=#E&E.W]XRGD%LD'D5W7_"K-4_O6?_?QO_B:/^%6:I_>L_\
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M_OXW_P 31_PJS5/[UG_W\;_XF@#FZ*Z3_A5FJ?WK/_OXW_Q-'_"K-4_O6?\
MW\;_ .)H YN@]*Z3_A5FJ?WK/_OXW_Q-'_"JM4;C?9_]_&_^)H Y>S_X]8_]
MT5)6YI7PSU*ZTV"16M=LB!AER#S_ ,!JQ_PJS5/[UG_W\;_XF@#FZ*Z3_A5F
MJ?WK/_OXW_Q-'_"K-4_O6?\ W\;_ .)H YNBND_X59JG]ZS_ ._C?_$T?\*L
MU3^]9_\ ?QO_ (F@#FZ*Z3_A5FJ?WK/_ +^-_P#$T?\ "K-4_O6?_?QO_B:
M.;HKI/\ A5FJ?WK/_OXW_P 31_PJS5/[UG_W\;_XF@#FZ*Z3_A5FJ?WK/_OX
MW_Q-'_"K-4_O6?\ W\;_ .)H YNBND_X59JG]ZS_ ._C?_$T?\*LU3^]9_\
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MX59JG]ZS_P"_C?\ Q- '/XHQ70?\*LU3^]9_]_&_^)H_X59JG]ZS_P"_C?\
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MC2^U/4M2L;6VU'Q*NG06\][-#-%,9_L\>V)"[1<JN%&[BO7?,7^\OYT>8O\
M>7\Z /'?VD_V+?#_ .U)XSL=0\1ZA?+I]OX3USPE<6$"JOVF#5!:"242'E)(
M_LJE< C+9/2O-_VD/V:OB9J?[.VH:;?>.M8^(&L7&K>'(+&'3]%@TY-/M[75
M;>62[\I6?S+C8&>1RPC*Q@+$@R#]5>8O]Y?SH\Q?[R_G0!\Q^(_^"=-]XJ\:
M2^.K_P"(/VCXH+XGT_Q%;ZS_ &!'_9L"6-K<VEM:?8?-RT:Q7ERV\S>9YL@<
M,H54%CX?_P#!/F^^&]_X7OK/XA7-YJ/AGQ[J_C87%[HL<GVQ=4647=HZI*@'
M,\A21<;,J-C!>?I3S%_O+^='F+_>7\Z /GOP9^P)'X6\2>'+*?QA>:A\.?!7
MB"Z\4>'_  PVG1QR6=[.9V"S788M-;Q-=3M%'Y:,"4W.X0 T],_X)ZR_\*?N
M_A?J7Q"U:[^%,&C2Z)HVA6VF6]O<Z?&71X))KH[S/);%%$1"1C _>"4\U](>
M8O\ >7\Z/,7^\OYT >"^,_V1_&GQ3^&][I?BSXKW&KZT=7T35]-NXO#T-K8:
M:^EWT=Y'_H@E)D>:2/$S&8 C;L6,+@T_$_[!UYJT_BJ[T_QU/I>I:IX^MOB+
MHMQ_9"3+H^H1VD5K)%*AE N;>1(C\N8V7><.2 1]#>8O]Y?SH\Q?[R_G0!\[
M:'^P)+HDGAZ\'CB[N-8T?XA:EX_N+J32T"7CZA:7-K<VJHL@\M1'=/Y;AB4*
MKD/@YX?2O^"3TUEX*T#PW/\ $Z]N-#\*^"=<^'VE6Z:!!"T6F:E#%'OE99/W
MEU&88R9<*LF#^[4LS'[!\Q?[R_G1YB_WE_.@#S/XO_LR6?Q:_9]TSP*VM7^E
MS:$VF76F:M!%&\MM=Z?+%-;S&)P4=?,A4LAX921D<$<K\ _V*)?@G^T3XB^)
MTGBQ=0\0>.K%;?Q5:VVC1V.GZG<1,#;W4$0=VMG5-ZN-\GG%]S'*C'NWF+_>
M7\Z/,7^\OYT >$?#G]DKQ;\+_&'C9=.^(>FOX,\>>(-1\07VD3^&-][#)>H%
MDCCO!= !58!@3"3@$'KD96B?\$XM#T?QS\%=:;Q#J,Z_"#0H-$DM6MD$?B+[
M*G^@S3<_NVMY'GD4+D$S$'H*^C/,7^\OYT>8O]Y?SH \!\"?L3:M\/\ PS=>
M#K'XCZE#\-([?5(-+\/Q:3 DUL+Y9@8Y[K<6N(8&GD:) D;9$>]Y-G/JWP>^
M%L/P@^"'A?P3#>37UOX7T*UT..[D0))<+!;I )"HX!8)D@< FNH\Q?[R_G1Y
MB_WE_.@#P>S_ &!] L_V'&^"_P#:3LS>"9O X\2&QC^WK:RQE&8#./O$/LW;
M25%3V'['VL>#?B1J^J>$?B)J7A?0?%E]8ZIXCTV'2H9KB]NK6W@MB]O<LW^C
MK/#;0)*ICDR%8H8V8M7N/F+_ 'E_.CS%_O+^= 'ANF_LF^*/" ^("^&_B-'I
MD/C3Q1)XHBM[KPW!?0P-/$([BTN%>0&XMWVJP"&%U*CYV!(/:?LO?L^V/[+_
M ,%M-\&Z?>R:A%9W%W>RSFW2VC>>ZN9;J;RH4^2&$23.$B7A$"KDX)/?>8O]
MY?SH\Q?[R_G0 ZBF^8O]Y?SH\Q?[R_G0 ZBF^8O]Y?SH\Q?[R_G0 ZBF^8O]
MY?SH\Q?[R_G0 ZBF^8O]Y?SH\Q?[R_G0!G:MX.TW6Y_-N;56D[LK%2WUP>:J
M?\*TT7_GS;_OZ_\ C6YYB_WE_.CS%_O+^=?+XO@GA[%5I8C$X"C.<G=RE2@V
MWW;<;MA<P_\ A6FB_P#/FW_?U_\ &C_A6FB_\^;?]_7_ ,:W/,7^\OYT>8O]
MY?SKG_XA[PM_T+:'_@FG_P#(A<P_^%::+_SYM_W]?_&C_A6FB_\ /FW_ ']?
M_&MSS%_O+^='F+_>7\Z/^(>\+?\ 0MH?^":?_P B%S#_ .%::+_SYM_W]?\
MQH_X5IHO_/FW_?U_\:W/,7^\OYT>8O\ >7\Z/^(>\+?]"VA_X)I__(A<P_\
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M*;YB_P!Y?SH\Q?[R_G6X#J*;YB_WE_.CS%_O+^= #J*;YB_WE_.CS%_O+^=
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MO_M&@"_13?,7^\OYT>:H_B7\Z '44AD51DLH'J32A@>] !11NI!(K=&4_C0
MM%(74'&Y<^F:-Z_WA^= "T4WS5_O+_WT*4.IS\R_+UYZ4 +106Q3?,7^\OYT
M .HIOF+_ 'E_.CS%_O+^= #J*;YB_P!Y?SH\Q?[R_G0!3US_ %5K_P!?4?\
M.KU4=<=3!;_,/^/F+O\ [57/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>
M7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>
M7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>
M7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>
M7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>
M7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .HIOF+_>7\Z/,7^\OYT .JU!_JEJ
MGYB_WE_.K=NVZ%<4 4J*** "OS?_ .#I+_E&QI/_ &/.G?\ I+?5^D%?F_\
M\'27_*-C2?\ L>=._P#26^KHPO\ &CZG+C?X$O0_GGKZ4O/!'A#X._L6>!Y/
M^$+L_%GQ&^.2WS6FJ7LTI7PW:0WGV2,6L*$*UP\J,2SYPN !S7S77T9^SE^W
MY9_!WP)X:T/Q5\,?#'Q(_P"$ U*75_"%WJ5W<6LNAW$CB1E81';/#YBB01R
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MR^S81$@*EF?[1U)P-O0YKPCZ8]B^Q0?\^]O_ -^E_P */L4'_/O;_P#?I?\
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MTO\ A4E% $?V*#_GWM_^_2_X4?8H/^?>W_[]+_A4E% $?V*#_GWM_P#OTO\
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MUQ9/%GBO6?!]F9((PL=YI:WC7#R8D.(F%C-L898[DRJY. #U+[%!_P ^]O\
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MJQJ;5;>WGA@=6;=N$A>9" %(P#R. 0#K/L4'_/O;_P#?I?\ "C[%!_S[V_\
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MCOI+<1SKREA*-*%._NJ492:72[YTF^]DEY%<IU'_  F-C_SYP_\ ?M?\*/\
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M-)?\_.R0<IU'_"8V/_/G#_W[7_"C_A,;'_GSA_[]K_A7+T5R?\3)<6?R4?\
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MH=2_UMG_ -=Q_P"@M5J@"/[%!_S[V_\ WZ7_  H^Q0?\^]O_ -^E_P *DHH
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M /?I?\*DHH C^Q0?\^]O_P!^E_PH^Q0?\^]O_P!^E_PJ2B@"/[%!_P ^]O\
M]^E_PH%E!G_CWM_^_2_X5)0.M %'1;.%M(MLPPD^6O)C'I]*M?8H/^?>W_[]
M+_A4.B?\@>U_ZY+_ "JU0!']B@_Y][?_ +]+_A1]B@_Y][?_ +]+_A4E% $?
MV*#_ )][?_OTO^%'V*#_ )][?_OTO^%244 1_8H/^?>W_P"_2_X4?8H/^?>W
M_P"_2_X5)10!']B@_P"?>W_[]+_A1]B@_P"?>W_[]+_A4E% $?V*#_GWM_\
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M%U"99=0LBN\F:V =I+=V8[8'(.644 ?77V*#_GWM_P#OTO\ A1]B@_Y][?\
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M:WMY=6>I10:7>RQG("$Q-&BRK&X+),L>68*<@'UE]B@_Y][?_OTO^%,EAM8
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M6^+7@B;XH_M2^.KK6/&FB:'K6M>(M!O?AU?1^ [O6_$3Z4+6R9'TB]2\B2&
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M_"C_ (1ZZ_O6OYM_A6Y10!A_\(]=?WK7\V_PH_X1ZZ_O6OYM_A6Y0S!%+-P
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M=%+H-T-<@7=;Y:WE(Y;LT?M[U:_X1ZZ_O6OYM_A7&O\ %?4&U&*;R;/='$Z
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MUU_>M?S;_"C_ (1ZZ_O6OYM_A6]Y?^[^8H\O_=_,4 8/_"/77]ZU_-O\*/\
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MUU_>M?S;_"C_ (1ZZ_O6OYM_A6]Y?^[^8H\O_=_,4 8/_"/77]ZU_-O\*/\
MA'KK^]:_FW^%;WE_[OYBCR_]W\Q0!@_\(]=?WK7\V_PH_P"$>NO[UK^;?X5O
M>7_N_F*/+_W?S% &#_PCUU_>M?S;_"C_ (1ZZ_O6OYM_A6]Y?^[^8H\O_=_,
M4 8/_"/77]ZU_-O\*W-+BN(;0+)Y.1@#:2>  /Z4I3 [?G5F#_5+0!1HHHH
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M  4"^(2:7-I%]HNGZ;J%SXMTWP[8>-=:\&ZSX=\.R07=O-,T[65^\<Y>%X#
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M% !1110 J??'UJAX<_Y EO\ \"_]"-7T^^/K5#PY_P @2W_X%_Z$: +U<?\
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M_P#QX)_U\V__ *.2KQ^ZOT_J:H>(#C3E_P"N\!_\BI5\_=7Z?U- "444 9-
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M )**CQ1B@"2BH\48H DHJ/%&* )**CQ1B@"2BH\48H DHJ/%&* )*Y'XA?\
M(]> O^PQ/_Z;KRNJQ7(_$,?\5OX#_P"PQ/\ ^FZ[KAS#^$O\4/\ TN('945'
MBC%=P$E%1XHQ0!)14>*,4 245'BC% $E%1XHQ0!)14>*,4 245'BC% $E%1X
MHQ0!)14>*,4 245'BC% $E%1XHQ0!)14>*,4 245'BC% $E%1XHQ0!)14>*,
M4 245'BC% $E%1XHQ0!)14>*,4 245'BC% $E%1XHQ0!)14>*,4 245'BC%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNN',/X2_Q0_]+B!UM%%%=P!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4IO^1CM_P#KVE_]#BJ[5*;_ )&.W_Z]I?\
MT.*KM !1110 4444 %%%% !1110 4444 4=9_P!=I_\ U]#_ - >KU4=9_UV
MG_\ 7T/_ $!ZO4 %%%% !1110 4444 %%%% !1110!7UC_D#WG_7"3_T$U)9
M?\>4/_7-?Y"H]8_Y ]Y_UPD_]!-267_'E#_US7^0H DHHHH **** "BBB@ H
MHHH **** "E3[X^M)2I]\?6@"AX8_P"1<L/^N"?RJ]5'PQ_R+EA_UP3^57J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!4^^/K5#PW_ ,@.W^C?^A&K
MZ??'UJAX;_Y =O\ 1O\ T(T 7J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"CXA_Y!;?]=(__1BUJ%&95X/3TK+\1?\ (*;_ *Z1G_Q]:O$Y- $W
MEM_=;\J/+;^ZWY5#10!-Y;?W6_*CRV_NM^50T4 3>6W]UORH\MO[K?E4-% $
MWEM_=;\J/+;^ZWY5#10!-Y;?W6_*CRV_NM^50T4 3>6W]UORH\MO[K?E4-%
M$WEM_=;\J/+;^ZWY5#10!-Y;?W6_*CRV_NM^50T4 3>6W]UORH\MO[K?E4-%
M $WEM_=;\J/+;^ZWY5#10!-Y;?W6_*CRV_NM^50T4 3>6W]UORH\MO[K?E4-
M% $WEM_=;\J/+;^ZWY5#10!-Y;?W6_*CRV_NM^50T4 3>6W]UORH\MO[K?E4
M-% $WEM_=;\J/+;^ZWY5#10!)(C!/NGKZ58MO]0M4ZN6W^H6@#@_^$@O?^?A
M_P A_A1_PD%[_P _#_D/\*IT4 7/^$@O?^?A_P A_A7D/[=?[;MI^PS^S)XA
M^(NL>;J']EJD%A8JP4ZA>2G;##NP=H)R6/958]J]2K\]?^#F)V7_ ()T:;@D
M;O&VG@^_^C7IK6A%2J*+[F.(J.%*4H[I'YM_$C_@O_\ M4?$#Q5=:A;?$J;P
MW:S2%HM/TFPMH[>V7LB[T9S@<99B37/_ /#\;]J[_HM'B3_P&M/_ (U7RC17
MT?L::^RON/DWB:KUYG][/J[_ (?C?M7?]%H\2?\ @-:?_&JU_A__ ,%M_P!J
MC5OB!X?M+CXR>(I;>[U2U@F0V]KAT>9%8?ZKN"17QU6Y\+O^2H^%_P#L,V7_
M *41TG1IV^%?<$<15O\ $_O9_4QX\^//B31/&^L6=O=0I;VMY+#&IA!PJL0*
MR?\ AHWQ5_S^0?\ ?@5A_%/_ )*9X@_[",__ *&:P:_Q\XF\5N,J.<8NC2S2
MO&,:M1)*I)))2:26NR1]K9'=?\-&^*O^?R#_ +\"O2OAE\0M4\3>"X[V\NE^
MT/<21DJH4$+MQQ^-?/=>H> 1GX:6/_7W<?\ LE?LGT;>/>),XXN>$S7'5:U/
MV,WRSG*2NG"SLW:ZNQ2/4O\ A)KK_G[_ %6C_A)KK_G[_5:\]Q1BO[X)/0O^
M$FNO^?O]5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_ )^_U6O/<48H
M ]"_X2:Z_P"?O]5H_P"$FNO^?O\ 5:\]Q1B@#T+_ (2:Z_Y^_P!5H_X2:Z_Y
M^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_G[_5:\]Q1B@#T+_A)KK_G[_5:/^$F
MNO\ G[_5:\]Q1B@#T+_A)KK_ )^_U6C_ (2:Z_Y^_P!5KSW%&* /0O\ A)KK
M_G[_ %6C_A)KK_G[_5:\]Q1B@#T+_A)KK_G[_5:Y?QYXBN6\9>"3]J^[JTQ'
M(X_T"Z']:Q<5S?C,?\5;X1_["4W_ *17-<68?PE_BA_Z7$#V;_A)KK_G[_5:
M/^$FNO\ G[_5:\]Q1BNT#T+_ (2:Z_Y^_P!5H_X2:Z_Y^_U6O/<48H ]"_X2
M:Z_Y^_U6C_A)KK_G[_5:\]Q1B@#T+_A)KK_G[_5:/^$FNO\ G[_5:\]Q1B@#
MT+_A)KK_ )^_U6C_ (2:Z_Y^_P!5KSW%&* /0O\ A)KK_G[_ %6C_A)KK_G[
M_5:\]Q1B@#T+_A)KK_G[_5:/^$FNO^?O]5KSW%&* /0O^$FNO^?O]5H_X2:Z
M_P"?O]5KSW%&* /0O^$FNO\ G[_5:/\ A)KK_G[_ %6O/<48H ]"_P"$FNO^
M?O\ 5:/^$FNO^?O]5KSW%&* /0O^$FNO^?O]5H_X2:Z_Y^_U6O/<48H ]"_X
M2:Z_Y^_U6C_A)KK_ )^_U6O/<48H ]"_X2:Z_P"?O]5H_P"$FNO^?O\ 5:\]
MQ1B@#T+_ (2:Z_Y^_P!5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_G
M[_5:\]Q1B@#T+_A)KK_G[_5:/^$FNO\ G[_5:\]Q1B@#T+_A)KK_ )^_U6C_
M (2:Z_Y^_P!5KSW%&* /0O\ A)KK_G[_ %6C_A)KK_G[_5:\]Q1B@#T+_A)K
MK_G[_5:/^$FNO^?O]5KSW%&* /0O^$FNO^?O]5H_X2:Z_P"?O]5KSW%&* /0
MO^$FNO\ G[_5:/\ A)KK_G[_ %6O/<48H ]"_P"$FNO^?O\ 5:/^$FNO^?O]
M5KSW%&* /0O^$FNO^?O]5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_
M )^_U6O/<48H [J3Q%<'5H6^U?,L,@!R.[)_A5C_ (2:Z_Y^_P!5KSLC]ZOT
M/]*=B@#T+_A)KK_G[_5:/^$FNO\ G[_5:\]Q1B@#T+_A)KK_ )^_U6C_ (2:
MZ_Y^_P!5KSW%&* /0O\ A)KK_G[_ %6C_A)KK_G[_5:\]Q1B@#T+_A)KK_G[
M_5:/^$FNO^?O]5KSW%&* /0O^$FNO^?O]5H_X2:Z_P"?O]5KSW%&* .ZU#Q'
M</):YNL[9P1R./E:K'_"377_ #]_JM>=2#YD^M/Q0!Z%_P )-=?\_?ZK1_PD
MUU_S]_JM>>XHQ0!Z%_PDUU_S]_JM'_"377_/W^JUY[BC% 'H7_"377_/W^JT
M?\)-=?\ /W^JUY[BC% 'H7_"377_ #]_JM'_  DUU_S]_JM>>XHQ0!Z%_P )
M-=?\_?ZK1_PDUU_S]_JM>>XHQ0!WFH>([F33[A3=9#1L,97G@U);^);D6\8^
MU]% ZKZ5Y[*/W;?2B,?NU^E 'HG_  DUU_S]_JM'_"377_/W^JUY[BC% 'H7
M_"377_/W^JT?\)-=?\_?ZK7GN*,4 >A?\)-=?\_?ZK1_PDUU_P _?ZK7GN*,
M4 >A?\)-=?\ /W^JT?\ "377_/W^JUY[BC% 'H7_  DUU_S]_JM'_"377_/W
M^JUY[BC% 'H7_"377_/W^JT+XFNL_P#'W^JUY[BD(XH [K1_$5Q%I-LJW6T+
M&HQD<<59_P"$FNO^?O\ 5:\Y@&85^E28H ]"_P"$FNO^?O\ 5:/^$FNO^?O]
M5KSW%&* /0O^$FNO^?O]5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_
M )^_U6O/<48H ]"_X2:Z_P"?O]5H_P"$FNO^?O\ 5:\]Q1B@#T+_ (2:Z_Y^
M_P!5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_G[_5:\]Q1B@#T+_A)
MKK_G[_5:/^$FNO\ G[_5:\]Q1B@#T)?$UUG_ (_/U6JVD>(KF+38E%UMQGC(
M]37"D<4RWYBH ]&_X2:Z_P"?O]5H_P"$FNO^?O\ 5:\]Q1B@#T+_ (2:Z_Y^
M_P!5H_X2:Z_Y^_U6O/<48H ]"_X2:Z_Y^_U6C_A)KK_G[_5:\]Q1B@#T+_A)
MKK_G[_5:/^$FNO\ G[_5:\]Q1B@#T+_A)KK_ )^_U6C_ (2:Z_Y^_P!5KSW%
M&* /0O\ A)KK_G[_ %6C_A)KK_G[_5:\]Q1B@#T+_A)KK_G[_5:/^$FNO^?O
M]5KSW%&* /0O^$FNO^?O]5H_X2:Z_P"?O]5KSW%&* .ZU;Q)<O8.#=9Y7N/[
MPJQ_PDUU_P _?ZK7G<RYB;\/YT[% 'H7_"377_/W^JT?\)-=?\_?ZK7GN*,4
M >A?\)-=?\_?ZK1_PDUU_P _?ZK7GN*,4 >A?\)-=?\ /W^JT?\ "377_/W^
MJUY[BC% 'H7_  DUU_S]_JM'_"377_/W^JUY[BC% 'H7_"377_/W^JT?\)-=
M?\_?ZK7GN*,4 >A?\)-=?\_?ZK1_PDUU_P _?ZK7GN*,4 >A?\)-=?\ /W^J
MT?\ "377_/W^JUY[BC% 'H7_  DUU_S]_JM'_"377_/W^JUY[BC% 'H7_"37
M7_/W^JT?\)-=?\_?ZK7GN*,4 >A?\)-=?\_?ZK1_PDUU_P _?ZK7GN*,4 >A
M?\)-=?\ /W^JT?\ "377_/W^JUY[BC% 'H7_  DUU_S]_JM'_"377_/W^JUY
M[BC% 'H7_"377_/W^JT?\)-=?\_?ZK7GN*,4 >A?\)-=?\_?ZK1_PDUU_P _
M?ZK7GN*,4 >A?\)-=?\ /W^JT?\ "377_/W^JUY[BC% 'H7_  DUU_S]_JM'
M_"377_/W^JUY[BC% 'H7_"377_/W^JUV?ABZ:\T*WD9_,9@<MZ\FO"L5ZY\(
M/^1)A_ZZ/_.@#FZ*** "OSU_X.9/^4=.E_\ 8[:?_P"DU[7Z%5^>O_!S)_RC
MITO_ +';3_\ TFO:Z,+_ !H^IRXS^!+T/P-HHHKZ0^1"MSX7?\E1\+_]AFR_
M]*(ZPZW/A=_R5'PO_P!AFR_]*(Z4MAQW/Z9OBG_R4SQ!_P!A&?\ ]#-8-;WQ
M3_Y*9X@_[",__H9K!K_#CBS_ )'F,_Z^U/\ TN1]V%>H^ /^2:6/_7W/_)*\
MNKU'P!_R32Q_Z^Y_Y)7[O]%'_DMI?]>*G_I4"9%^O'?V@?CKXM\$_''X;^ _
M!^F^%[C4/'D6J3R7FN2W"P6:6444F%6$;F9_,QR0!BO8J\(_:@_9$L_VF?V@
M_A;JGB+0?#OB3P5X5M-;AU:SU6))_P!Y=V\4<#QQNI!8%7^<8*<$5_I*2)\,
MOVY-,U7X>K=>*=/NH?$T>OZOX=.F>&K&ZUMM1ETV8QW%S:QPQM,UN!M8LRC8
M6VDYQGH]:_;3^'FD:1I=_#JFI:U9ZMI@UM)-&T>[U/[+8%BGVJX$$;&"+<&4
MM(%P48?PG'SYX:_8$\5^!O"_PK6ZT&Q\5?\ "J=/UOPE;:;I?BJX\.2:CI<]
MS!)8WWVBW,>)Q';1K-$YPS.[@E@,]M\-OV;_ !O^R[XC;6O ?@WPC>-KOA.Q
MT.XT:/7YK>QT"\MKBZG$JRSK)-<0,;M]W_+0LA(&&X /:-5_:2\&Z+8Z[<W&
MJ2)#X;UJS\/:@PM)6\F]NS;"WC "_,&-W;_,N5&\Y(VMCG]7_;?^'>AQZW+<
M7VN?9?#VNKX9O;N/0;V2W34VN$MEM$D6(K)(99$&$)X;=TYKR_XH?LV?$K6_
M$/CS2]-TGP]>:+XV\:^'O&*ZJVJ^2UDMG+IINK5H"A9FQ8LT;@[6#@$ CF]J
MO[)GC"\^&.N:3'_97VS4/C1%X\AS=_(-,74X+HY.WB7RXV^3UP,]Z /2=3_;
M)\"Z'X@ATV^N->L9M]I#>S3Z#>QVVB37>W[/!?3&/R[263>F(YF5OG3(&X93
M1_VT/A_KWCFW\/V^H:M]KNM9N_#D-Q)HMW'8R:G:[S-9"Y:,1&?$;E4W9<+\
MN:\@\;_L-76I_'GQY?7'@[3_ !EH7Q%\06&NO>7WC'4-/M=)$4%K#-%/IT$B
MI<D?91)$P!RS@.0$R=/1_P!D?QA8Z-X;MY!I>[2?C;>>/Y_]+R/[+E>\9,?+
MS-B>/*=N>>* /3OV3_VEE_:?\%ZYJPT'6M ;1O$&I:)Y5_I]Q:^>MK=RP+(I
MF1=Q81@NJYV,2IY%>I5Y7^R;\._$7PJ\+>*M'\0:?:VHF\7:UJ^GW-O>K<+?
M6M[?S74;%0 8F590K*V>5)!Q7JE !1110 4444 %%%% !1110 5S?C/_ )&W
MPC_V$IO_ $BN:Z2N;\9_\C;X1_["4W_I%<UQ9A_"7^*'_I<0.DHHHKM ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXL;>\M)1)#, Q4[6'!P01^%:= !7KGP@_P"1)A_ZZ/\ SKR.O7/A!_R),/\
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M+QA9Z9\5M:%Y\2].U75[WQCIUC8RF&UTF[@%XMG;VUN8$5I(XB\L>]V52/E
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MKJ[Y;NS:U6NY+"BBBOW(04444 ,E^_']:?3)?OQ_6GT %%%% !1110 4444
M%%%% !1110 V7_5M]*(_]6OTHE_U;?2B/_5K]* '4444 %%%% !1110 4444
M %%%% !0>E%!Z4 ,M_\ 4K]*?3+?_4K]*?0 4444 %%%% !1110 4444 %%%
M% !1110 4444 !Z5';_ZJI#TJ.W_ -50!)1110 4444 %%%% !1110 4444
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M/\*/^$0M_P#GI-^8_P * .=SQ171?\(A;_\ /2;\Q_A1_P (A;_\])OS'^%
M'.T5T7_"(6__ #TF_,?X4?\ "(6__/2;\Q_A0!SM%=%_PB%O_P ])OS'^%'_
M  B%O_STF_,?X4 <[7-^,_\ D;?"/_82F_\ 2*YKT;_A$+?_ )Z3?F/\*Q]8
M\ VFI_$/P3;R2W"K+J<X)4C/%A='T]JXLP_A+_%#_P!+B!5HKU'_ (4AI?\
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M^)H \NHKU'_A2&E_\_5__P!])_\ $T?\*0TO_GZO_P#OI/\ XF@#RZBO4?\
MA2&E_P#/U?\ _?2?_$T?\*0TO_GZO_\ OI/_ (F@#RZBO4?^%(:7_P _5_\
M]])_\31_PI#2_P#GZO\ _OI/_B: /+J*]1_X4AI?_/U?_P#?2?\ Q-'_  I#
M2_\ GZO_ /OI/_B: /+J*]1_X4AI?_/U?_\ ?2?_ !-'_"D-+_Y^K_\ [Z3_
M .)H \NHKU'_ (4AI?\ S]7_ /WTG_Q-'_"D-+_Y^K__ +Z3_P")H \NHKU'
M_A2&E_\ /U?_ /?2?_$T?\*0TO\ Y^K_ /[Z3_XF@#RZBO4?^%(:7_S]7_\
MWTG_ ,31_P *0TO_ )^K_P#[Z3_XF@#RZBO4?^%(:7_S]7__ 'TG_P 31_PI
M#2_^?J__ .^D_P#B: /+J*]1_P"%(:7_ ,_5_P#]])_\31_PI#2_^?J__P"^
MD_\ B: /+#_K5^A_I3J]'E^#>FIK4,'VB^VR022$[ER"K(!_#_M&K7_"D-+_
M .?J_P#^^D_^)H \NHKU'_A2&E_\_5__ -])_P#$T?\ "D-+_P"?J_\ ^^D_
M^)H \NHKU'_A2&E_\_5__P!])_\ $T?\*0TO_GZO_P#OI/\ XF@#RZBO4?\
MA2&E_P#/U?\ _?2?_$T?\*0TO_GZO_\ OI/_ (F@#RZBO4?^%(:7_P _5_\
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M*0TO_GZO_P#OI/\ XF@#RZBO4?\ A2&E_P#/U?\ _?2?_$T?\*0TO_GZO_\
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M6;.<,N.I']V@#SFBO4?^%(:7_P _5_\ ]])_\31_PI#2_P#GZO\ _OI/_B:
M/+J*]1_X4AI?_/U?_P#?2?\ Q-'_  I#2_\ GZO_ /OI/_B: /+J*]1_X4AI
M?_/U?_\ ?2?_ !-'_"D-+_Y^K_\ [Z3_ .)H \NHKU'_ (4AI?\ S]7_ /WT
MG_Q-'_"D-+_Y^K__ +Z3_P")H \NHKU'_A2&E_\ /U?_ /?2?_$T?\*0TO\
MY^K_ /[Z3_XF@#RZBO4?^%(:7_S]7_\ WTG_ ,31_P *0TO_ )^K_P#[Z3_X
MF@#RZBO4?^%(:7_S]7__ 'TG_P 31_PI#2_^?J__ .^D_P#B: /+J*]1_P"%
M(:7_ ,_5_P#]])_\31_PI#2_^?J__P"^D_\ B: /+)O]2WTIQZUZ/K?P:TVQ
MTBXF6XOBT:%@"RX_]!JV?@AI9/\ Q\W_ /WTG_Q- 'EM%>H_\*0TO_GZO_\
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M_P"?J_\ ^^D_^)H_X4AI?_/U?_\ ?2?_ !- 'EU%>H_\*0TO_GZO_P#OI/\
MXFC_ (4AI?\ S]7_ /WTG_Q- 'EU%>H_\*0TO_GZO_\ OI/_ (FC_A2&E_\
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MF1UE%%%?WP2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FS?\
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MJG_H+U#BNS%?2XS>E3I36 I^_'F^*6GO2C_[:'*?9'_"S_#?_0P:+_X&Q_\
MQ5'_  L_PW_T,&B_^!L?_P 57QOBC%<?_$X6<?\ 0OI?^!S#E/LC_A9_AO\
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MH **** "BBB@ HHHH **** "L_PM_P @&#_@7_H1K0K/\+?\@&#_ (%_Z$:
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M -CMI_\ Z37M?H57YZ_\',G_ "CITO\ [';3_P#TFO:Z,+_&CZG+C/X$O0_
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MN:_RJ/7?^0)>?]<'_P#034EA_P >,/\ US7^5 $U%%% !1110 4444 %%%%
M!1110 4444 9_A7_ )%JQ_ZX)_*M"L_PK_R+5C_UP3^5:% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5G^%O\ D P?\"_]"-:%9_A;_D P?\"_]"-
M&A7C/[<7Q+TOP!\+-)L;WPQH_C#4_&&O6?A[1=+U6%9;&6^N'(228,#^[C4/
M(V!NPF!R17LU>*?MD?L1^'OVNO"ZF>XN-$\6::$?1];@>1FL)(W+KF,.JNI)
M8'HV&.UE/-3.4TKP2;\W;\;/\CHPL*$JG+B9.,>\8J3^YRBOQ)=:^"'B[2=#
MTN2'Q1H>H0VYAMM8TN[T"U@TR[TX-^^@BVJ98E52S(&D<9&"#DD<=X;\9?L_
M^(O$MMI-O\/]'A*Z/<>(=$EE\)QQPZE:0L!/)9#9NW*63*[59@ZD!@0:XC6/
M^"8G_"9:3IMC>:/H^DWC7"G4]8@\5ZI>LL(SN%K!(%"L_  D<A!GES@UQ?@O
M_@D!J^BZAX5N-8L? &M?V+IU_IVJJVIZFCZV\FS[/>%\'R9$V$&)04P['+<
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MF@Z-KWPWUS2K&]<VY\%V"V=C;;@K,L@%Q.6F+$N79]Q##([G[.^!W_)-8?\
MK[F_]EK]@^CW4HU/$O$3P_PNE4MNKZT[NTM5=W?+]F]DVDFYD=90%)&<<#K[
M45\Q_M>?%#7?AQ^V]^S^ND:/XK\36^H6?B476BZ'=6T3WFVVMBDCK<W$$#B,
MDD;GW#=\H/-?Z#$GTX5('3KT]Z*^!=$_;:\7^"_BC\0-+M]'\5:/K?CCXJOH
M]G;:KHLWBBX\,VMOX=M+N7;8:;<2>9N*Y5(I@B^<78@@@]/XU_;[^(>@?!9;
MR[M(_#'CK2;'6=3GT:Z^'>MZA=Z[9V,K)#?"SC=)=-L[A0I\VX+E&<KAPI-
M'VFS!%RQ"@=23TH52Y 4;B>@'>O@O]K/]ICQ9^T]^R=\=SH?]@Z#X/\ #/P\
ML;N_M;RQENM0U.?4],2_*QS+,B6Z0Q2Q*"8Y?,?=]T#->T_M^Z_J&G_LM>']
M-T./5M4\0:]JVDVMAX?TRZ:TN_%JHRSW&F)<!T^S^=;139E9U50O)P<$ ^C&
M4HV&!!'4&E\M@0-K?-R..M?,G_!,?XV6_C[X97OAF*?6M4NO#<SWEY-/(9[?
M0#>W,\T.A&6:0W,ES90A8I/,C 7:OS'(%?*'BOXX>-/@[\&OVE(]2\0:_<:!
M\2-6\81>&-1?493-X?UK3KB138P/G=%'-9QK)&JD /:S8P7Q0!^I%!.!7QU_
MPW7\0M<^+VL:?X4\*ZOKVA^#_%ECX2NM+M/!&JW\VIQLMK]LOO[7C/V.W,(N
M&D$3HQ*P'<REP!UG@;XN?$#]HOX%^(/'BWGA&V^'^L6'B"VCT7^SIUU2SAM_
MM5M#-]K\]HY7=X0SQ^2@59.'8K\P!],@[AQR/445\I_\$K_VCM2_:&^%%G#9
MQ6.G^#_ ?AW0_#T%O<VTL>L7UZ-.MYI;QPQ CLW5U6 ;"TNQY-P7"U]64 %%
M%% !1110 4444 %9LW_)4? O_83N/_3?=5I5DZE=K9?$GP/(^[:NJ7&<?]@^
M[KAS#^$O\4/_ $N('L5<;\>_@K8?'WX;7'A^]NKK39A<07^GZC:[?M&EWMO*
MLUO<Q[@1N21%.#PPRIX8UT'_  E5M_=F_P"^1_C1_P )5;?W9O\ OD?XUW <
M_<_L^^#-6\,>)-)U'POX?OK/QM,+KQ'#)81^5KEQY<<9EG3!#L5AC&6R0(U&
M>!5?4/V9/A[JWQ5M_'%UX,\.W'BZTV&+5GLD:Z1D78C[L<NJ_*K'YE' (%=1
M_P )5;?W9O\ OD?XT?\ "56W]V;_ +Y'^- &7\7O@SX4^/W@2Z\+^-?#^E^*
M/#M\5-SIVHP":VN-IR Z'AA['BJOAW]GWP1X2LVM]-\*Z)9Q2:-'X=<):KE]
M.CWE+1CU,*^;)A#P-[>M;W_"56W]V;_OD?XT?\)5;?W9O^^1_C0!R?BG]ECX
M;^-K/PW;ZMX'\,ZA;^#[;['HD<]A&RZ9;[%C\F(8^6/8BKL^Z0HXX%9>M?L1
M?"'Q'HND:;?_  W\'W>GZ#I;Z)I]O+ID;16M@X(:U5<8\G!/[LY49. *] _X
M2JV_NS?]\C_&C_A*K;^[-_WR/\: .3\8?LM?#GX@6%U;:UX)\-ZE#>75K>S"
M:Q0EY[:+R;>7.,[XXOD5@<A?E''%0Z?^R/\ #'2%TA;/P'X7LU\/ZQ+X@TT6
M]@D0L-0E_P!;<Q;0-DC_ ,1&-W?-=E_PE5M_=F_[Y'^-'_"56W]V;_OD?XT
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MXGMY-'NU"RY:%QT']T^]2V7BBW2SA&V;A%_A'I]: ->BLW_A*K;^[-_WR/\
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M1_C0!I5G^%O^0#!_P+_T(TT>*;8_PS?]\C_&J/AOQ+;PZ+"K++D;N@']X^]
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M_P +$D_Y]4_[^?\ UJ/^%B2?\^J?]_/_ *U '4T5RW_"Q)/^?5/^_G_UJ/\
MA8DG_/JG_?S_ .M0!U-%<M_PL23_ )]4_P"_G_UJ/^%B2?\ /JG_ '\_^M0!
MU-%<M_PL23_GU3_OY_\ 6H_X6))_SZI_W\_^M0!U-%<M_P +$D_Y]4_[^?\
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M?C1X:T?3=4?5;*3P[>PZEI&H:9>-:7^EW,2,B312C.&V,RD,&5E8@@@UVE%
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M#-GX28_:V:.\L;3_ (]?/4\22Q N%D/S 2..AP._HHH **** "BBB@ HHHH
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MVB^<EK>6M]#))$K1S,S++&8G5B&*M\I 7)4>M4 %%%% !1110 4444 %%%%
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M[?YARGU3L;T/Y4;&]#^5?*W]L7G_ #]77_?UO\:/[8O/^?JZ_P"_K?XUR_\
M$XV#_P"A5+_P<O\ Y6'*?5.QO0_E1L;T/Y5\K?VQ>?\ /U=?]_6_QH_MB\_Y
M^KK_ +^M_C1_Q.-@_P#H52_\'+_Y6'*?5.QO0_E1L;T/Y5\K?VQ>?\_5U_W]
M;_&C^V+S_GZNO^_K?XT?\3C8/_H52_\ !R_^5ARGU3L;T/Y4;&]#^5?*W]L7
MG_/U=?\ ?UO\:/[8O/\ GZNO^_K?XT?\3C8/_H52_P#!R_\ E8<I]4[&]#^5
M&QO0_E7RM_;%Y_S]77_?UO\ &C^V+S_GZNO^_K?XT?\ $XV#_P"A5+_P<O\
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M#F/E>S.8;K_KE_[,M0K\QP.2> !WKZDU*",2VGR)_KQ_"/[K5:$$8_Y9Q_\
M?(KLK_1!G4I4J7]JKW$U_ WO)R_Y^Z;V#F/,_P!GWP!=:)]HU:\C>W:XC\J"
M-QABN02Q'O@8KTZBBOZFX#X+P7"F2TLEP#<HPNW)[RE)WE)]%=[+HK+6UR0H
MHHK[  HHHH **** "BBB@"'4O^0;<?\ 7)OY&GVW_'M'_N#^5,U+_D&W'_7)
MOY&GVW_'M'_N#^5 #Z*** "BBB@ HHHH **** "BBB@ H'6B@=: *NB?\@>U
M_P"N2_RJU571/^0/:_\ 7)?Y5:H **** "BBB@ HHHH **** "BBB@ HHHH
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MM_\ GLM']I6__/9: )J*A_M*W_Y[+1_:5O\ \]EH FHJ'^TK?_GLM']I6_\
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M_P#GLM']I6__ #V6@":BH?[2M_\ GLM']I6__/9: )J*A_M*W_Y[+1_:5O\
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MD@U&W\B/]ZOW1_*@!G]E?]-/TH_LK_II^E3?VE;_ //9:/[2M_\ GLM $/\
M97_33]*/[*_Z:?I4W]I6_P#SV6C^TK?_ )[+0!#_ &5_TT_2C^RO^FGZ5-_:
M5O\ \]EH_M*W_P">RT 0_P!E?]-/TH_LK_II^E3?VE;_ //9:/[2M_\ GLM
M$/\ 97_33]*/[*_Z:?I4W]I6_P#SV6C^TK?_ )[+0!#_ &5_TT_2C^RO^FGZ
M5-_:5O\ \]EH_M*W_P">RT 0_P!E?]-/TH_LK_II^E3?VE;_ //9:/[2M_\
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M5&P>@_*EHH 38/0?E1L'H/RI:* $V#T'Y4;!Z#\J6B@!-@]!^5&P>@_*EHH
M38/0?E1L'H/RI:* $V#T'Y4;!Z#\J6B@!-@]!^5&P>@_*EHH 38/0?E1L'H/
MRI:* $V#T'Y4;!Z#\J6B@!-@]!^5&P>@_*EHH 38/0?E2@8HHH \SHHHH *_
M/7_@YD_Y1TZ7_P!CMI__ *37M?H57YZ_\',G_*.G2_\ L=M/_P#2:]KHPO\
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MQQ>:9?>$="^)&L?$FY\::&T>H3R6=G:7EA%IUS!)/]G#^8+9[AAMC*M(D6<
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MH]AXKUZ\TW7]'T._T9_"^K6NIV(U&[BACGDM&M?M"QF-W>-C&$F:/RT8N0*
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MHQ7IVM?MJ_"_P]JWB*QN_%MI'=>%/#$?C+5$6WGD^S:2X8K<@JA#Y"YV(6D
M9#M^=<^9W_\ P4(A\$^/?"^B:A ?%2^-/B%J/A*VN/#OAS5V71((+22X1+H>
M3)NN5**KD%$VN\@PL4A !/\ !?\ 8^\2Q?LN_%#P!XNN8+'2_'37D&AZ*FNW
M>O1^%;2:RB@$*7URJ32CSUEG VJ(_-VKPN:\R^%/_!.+XBZ3\1OA-XF\3:IX
M5GOH;ZXU?XCK;7<\JW]W#=RWFF?9-T0\P12R89I/+(VY .<#U;]F'_@H%HWQ
M5UF;P]XKFBT?Q1=^,O$'AC2$@TJ]CT^^_L^\N8XX1>.K6YNVMX/-,/FAV 9E
M0+T]*^-7[5/@G]GN]AA\5:AJ5GYD(NIIK;1;V_M]/MR^SS[J6WA>.UAW CS9
MV1/E;G"G !XK\&?V/?'GP?\ %OP7OMOAG4H?!D?BZPUS&I30M%#J^HPW<$UN
M/(/G,BPA7C8Q\OD,0.8_V=_V&O%_PGC_ &:UU*]\/R_\*?T[7K36OL]Q*WGO
M?1JL)M]T8W $'=OV8[9KUCQG^W-\,/A_X\U#PWJOB"ZM]2T>^L-.U*1-'OIK
M+2YKY4:S^TW20FW@6;>@5Y)%0LVW=NXKS_6/V_EUKQ9\5O#NEP?\(K??#'Q/
MHVAG5/$GA[5FTW44O/L)?:R0QCS6-TT4061@?W<QS$V2 :'@'X8?%+X/?M7_
M !2U[3?#/@W7O!_Q*US3=2%[-XGFL[[3HH=.M;.4&V^Q2)(P,#.H$P# @$K7
M(?"S]D#XF^$?'7PZTW4%\&-X1^&GC?7_ !%;ZG!J-PU_JUKJ4>IF)&MC $AE
MB>_5&'FNKA-P*_</T#^TE\=M-_9F^!OB3QUJUO<WMGX?M1*+6WQYUY*[K'#"
MA/ :25T0$\ MDUQOA[Q]\>+JXOK'5/A[X#LKJ;3UO=,OX/%$UQI\4PD17L[K
M-LLRR;&++)%')&VQ@2AQD \)M_V-/$GP%^ GP?O_ !#_ &'JUE\$?!/BNW\1
M6EHMQ>MJ/VNS 1+:%8U:<'8P928V.0!DGCG_ /@EOXQTW3?B_H.D7NH:7XZ\
M37?@2'3+76]$\;VWB2V\/:=8M$5T^6*"RM3:JTEQE&G-Q.YC*O*VP$^@>$/^
M"@?Q&_X9%\0_%_Q)X'\$6^E:7J,FDVNGZ9X@NI[B>>+6O[+D9VDM$54X>1<;
MCT4@<D>[_M/?%Z+]F#X!>)O&.G:%!JVIV,4<6GZ9&PMSJM]/*D%K;EPK%?,G
MEC3=M;:&)P<8H ])HKA?V9_C1_PT)\"_#OBY]/\ [(O-4MRNH:<9?-.F7L3M
M#=6Q? W&*>.6/.!G9G Z5YG^VC^W6W[+OC+P7X=T;P]%XJUCQ!JE@FKQO>_9
M8]#TRZOH;!;MR$<L[7$Z+'%@;]DQW*(SD ^AJ*** "BBB@ HHHH **** "@M
MM&3P!U-%8OQ&MKJ\\!:Q%9[OM4EG*L87J3M/ KCS+%2PN$JXF,7-PC*2BMY6
M3=EYNUD!YOXY_:UM-$U:2UT>P_M)86*M/))Y<;$<?*,9(]^]87_#9.H_] .R
M_P"_[?X5XUC;QTQQCTHK_,',OI&<>XK$SKT\;[*+>D(PI\L5V7-%MV[MME\J
M/9?^&R=1_P"@'9?]_P!O\*/^&R=1_P"@'9?]_P!O\*\:HKA_XF \0/\ H92_
M\ I?_(!RGLO_  V3J/\ T [+_O\ M_A1_P -DZC_ - .R_[_ +?X5XU11_Q,
M!X@?]#*7_@%+_P"0#E/9?^&R=1_Z =E_W_;_  H_X;)U'_H!V7_?]O\ "O&J
M*/\ B8#Q _Z&4O\ P"E_\@'*>R_\-DZC_P! .R_[_M_A2Q_MDWX<;]#M-O?;
M<-G^5>,T4+Z07B G?^TI?^ 4O_D Y4?5GPR^+.G_ !6U&&:U22WN+6VE%Q!)
MR8R6CQ@]"#@\^U=Q7S9^R=!<2_$21H=WDQPDSX/&T@@9_P"!8KZ3K_03P7XP
MQ_$_">'S;,TO;-RC)I64N637,ELKVL[:<R=DEHH84445^J %%%% !1110 44
M44 %%%% &?K?_'SIO_7T/_1;UH5GZW_Q\Z;_ -?0_P#1;UH4 %%%% !1110
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MA_X,\-Z1J%C\/?!,MSXGU#4-5:TF$M[8W4L-O:1+$X=UBC#LTK1J/,0 GYB
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M&$E*,Z=2"4N?3FA1HM2]V[3YKQ<6K7:-\1"*M**M\FNWFS^ESXI_\E,\0?\
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MW7E=?7(?$7_D>_ /_89G_P#3=>5PYA_"7^*'_I<0.OKQS]KOX-^(/B#+\/\
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MH/[&/PZD\2:]H'C+Q%;0PRW4L'A[2_M;V]O%M\V>61V2&)$#@YDD4MT4,W%
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M_(SVO_7K-_Z'%5^OTW+<MPF7X6&"P-.-.E!6C&*227DE_3>H!1117< 4444
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MN0^(O_(]^ ?^PS/_ .FZ\KAS#^$O\4/_ $N('7U\^_\ !0?P3XR^,WA7P/\
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M69V7[+=*CQK*-I&2$D<8.1\W3I0!\#:%X2^(&C^,[K4K7POXR\)_#KXB>/\
MQ#K=E>:?X'AU+Q!HD,EC806\?V.YMYOL$-_<1WTLCS0 @>7YAA,K&NC_ .":
M?@'QEX!\5_ U?%GAGQAI<]C\(;WPW=RZAI$T:V-[!JL#BWG=4$<),*9CSM21
M5_=[A@5]Y44 <-X)_9R\)?#]/#*Z;IS!?".C-H&F+-.\RPVAEMY=I#$[F#VL
M+!VRP*<'DUO_  ]\ :7\+O"%KH>C0R6^FV1D,2/(TC+OD:1OF8DGYG8UM44
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ME6A6?X5_Y%JQ_P"N"?RK0H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L_PM_R 8/\ @7_H1K0K/\+?\@&#_@7_ *$: -"BBB@ HHHH **** "BBB@
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M?_L,V7_I1'2EL..Y^S7[6/CS7K']J#XAPPZYK4,,7B*^1(X[Z5411.^  &P
M/05Y]_PL;Q%_T,.O?^#&;_XJNK_:Z_Y.I^(__8R7_P#Z/>O.Z_S+SS&XA9EB
M$JDOCGU?\S/MS9_X6-XB_P"AAU[_ ,&,W_Q5?HW_ ,$NO$FJ7_[+*3S:E=33
MMK-VK2SN9W8#R\#+Y.!D_G7YEU^E/_!*W_DT^/\ [#5Y_P"TZ_3? _$UJG$3
MC.3:]G+=M]8@?2W]M:C_ ,_Q_P"_*?X4?VUJ/_/\?^_*?X5!7G_QF_:=\)_
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M_A431,F,JPW=,CK5.'7+&YURYTN.^LY-4LXTFN+-)T:XMXWSL=XP=RJV#@D
M'!QTH T?[:U'_G^/_?E/\*/[:U'_ )_C_P!^4_PJ)8V8\*QSR,"FD8- $_\
M;6H_\_Q_[\I_A1_;6H_\_P ?^_*?X5!10!/_ &UJ/_/\?^_*?X4?VUJ/_/\
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MY],U%+>4.;&Z159H),?=<*Z$J><,* -O^VM1_P"?X_\ ?E/\*/[:U'_G^/\
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M/^&B_#/_ $4#PG_X,K3_ .*K\9_+7^ZOY4>6O]U?RKG_ .)@L9_T!Q_\#?\
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MUJ/_ #_'_ORG^%044 3_ -M:C_S_ !_[\I_A1_;6H_\ /\?^_*?X5!10!/\
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MU'0Z[+:^.?V__"_BSP[=6J:%X-\,:E:^+];1@ME,)FB-K:M-]V1XV624@$[
M1DC(%>3_ !F\4:S?^';']IBP7P[-H_AGQ$FK6EREZS7TOA\ V4ML%V[/WD;/
M<;0VXLP&,\4<EQ\S/>])_8\G=+=]6\6ZAJUY;V5S:QW"P>0T+2V=O;AX]C?(
M4: RJ!T:0XQSF?Q[^SEJ=WH/@_R/&.L1Q^";3$[_ &=[J[O'66&=[F/#AOM+
MM R%FWY2XE4#FO+]?UO2?C/^US\0M+7X@:TWA,_#JQUZTATSQ*UM;Q3M-<9F
M1HW!7")$Q ..<D<UQO[,_P"TP/B_J?A#0?B?XPFL=%N/ %I?:7='4S8+XCOS
M+)'=.\\;*7GA5(P(PPY=FVDX(/9O<7.>X? +X>>'_BW^S/X)70?$6K:SH^FZ
MPNK07VHV9CNKJ:WN76961MK*&='7#9..N:A\*_L>>*/"VG>'5M_B1J"WGANZ
MO;I)OL>Y=1>X/RFY4OB3RCB1 >DBJ3D J?E/]FGXP-/X(^'O@6Z\9:/X7\&R
M:-K,EM>:AJ-Q:PW^HC5K@,C7,+HPGB@VNJ.XW>8SX) KUKX?Z+=^,OVH=/\
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M/0>U5+G_ (]I/]P_RI+7_CUB_P!Q?Y4 :/\ PD-Y_P ]O_'%_P */^$AO/\
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M_P"%'_"0WG_/;_QQ?\*I44 7?^$AO/\ GM_XXO\ A1_PD-Y_SV_\<7_"J5%
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MD?\ 1/\ QI_X)KC_ .(H_P"&8_B1_P!$_P#&G_@FN/\ XBOV HK'_B7[+O\
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M!;Q=JGCSXIS0^%?$%S!J7[17@_7+5UTV5ENM/@M-*6:[3Y<-!&T<@:0952C
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M=]_X#/\ X4?OO^?.^_\  9_\*[:B@#B?WW_/G??^ S_X4?OO^?.^_P# 9_\
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M_A7;44 <3^^_Y\[[_P !G_PH_??\^=]_X#/_ (5VU% '$_OO^?.^_P# 9_\
M"C]]_P ^=]_X#/\ X5VU% '$_OO^?.^_\!G_ ,*/WW_/G??^ S_X5VU% '$_
MOO\ GSOO_ 9_\*/WW_/G??\ @,_^%=M10!Q/[[_GSOO_  &?_"C]]_SYWW_@
M,_\ A7;44 <3^^_Y\[[_ ,!G_P */WW_ #YWW_@,_P#A7;44 <3^^_Y\[[_P
M&?\ PH_??\^=]_X#/_A7;44 <3^^_P"?.^_\!G_PH_??\^=]_P" S_X5VU%
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M_P */WW_ #YWW_@,_P#A7;44 <3^^_Y\[[_P&?\ PH_??\^=]_X#/_A7;44
M<3^^_P"?.^_\!G_PH_??\^=]_P" S_X5VU% '$_OO^?.^_\  9_\*/WW_/G?
M?^ S_P"%=M10!Q/[[_GSOO\ P&?_  H_??\ /G??^ S_ .%=M10!P>I>=_9U
MQ_HM\/W3<FV< <'VJ2V\[[-'_HE]]P=+9_3Z5UVN_P#($O/^N#_^@FI+#_CQ
MA_ZYK_*@#C_WW_/G??\ @,_^%'[[_GSOO_ 9_P#"NVHH XG]]_SYWW_@,_\
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M]_X#/_A7;44 <3^^_P"?.^_\!G_PH_??\^=]_P" S_X5VU% '$_OO^?.^_\
M 9_\*/WW_/G??^ S_P"%=M10!Q/[[_GSOO\ P&?_  H_??\ /G??^ S_ .%=
MM10!P\WG>2_^B7WW3_R[/Z?2H],\[^SK?_1+X_NUY%L_I]*[BY&;:3_=/\JK
MZ!_R [/_ *XK_*@#E?WW_/G??^ S_P"%'[[_ )\[[_P&?_"NVHH XG]]_P ^
M=]_X#/\ X4?OO^?.^_\  9_\*[:B@#B?WW_/G??^ S_X4?OO^?.^_P# 9_\
M"NVHH XG]]_SYWW_ (#/_A1^^_Y\[[_P&?\ PKMJ* .)_??\^=]_X#/_ (4?
MOO\ GSOO_ 9_\*[:B@#B?WW_ #YWW_@,_P#A1^^_Y\[[_P !G_PKMJ* .)_?
M?\^=]_X#/_A1^^_Y\[[_ ,!G_P *[:B@#B?WW_/G??\ @,_^%'[[_GSOO_ 9
M_P#"NVHH XG]]_SYWW_@,_\ A1^^_P"?.^_\!G_PKMJ* .)_??\ /G??^ S_
M .%'[[_GSOO_  &?_"NVHH XG]]_SYWW_@,_^%'[[_GSOO\ P&?_  KMJ* .
M)_??\^=]_P" S_X4?OO^?.^_\!G_ ,*[:B@#B?WW_/G??^ S_P"%'[[_ )\[
M[_P&?_"NVHH XG]]_P ^=]_X#/\ X4?OO^?.^_\  9_\*[:B@#B?WW_/G??^
M S_X4?OO^?.^_P# 9_\ "NVHH XG]]_SYWW_ (#/_A1^^_Y\[[_P&?\ PKMJ
M* .)_??\^=]_X#/_ (5U&B7&^Q7,<T94*I#Q,IX4=B*O44 >9T444 %?GK_P
M<R?\HZ=+_P"QVT__ -)KVOT*K\]?^#F3_E'3I?\ V.VG_P#I->UT87^-'U.7
M&?P)>A^!M%%%?2'R(5N?"[_DJ/A?_L,V7_I1'6'6Y\+O^2H^%_\ L,V7_I1'
M2EL..Y^PG[77_)U/Q'_[&2__ /1[U\:_M4>)9/"/[2'PYO;7Q%X7\$7G]G:E
M#_;VMLLD+1GRB;/RC)& 7(WB0L,&,CG.#]E?M=?\G4_$?_L9+_\ ]'O7Q7^W
M]\8KKX:V-O;V.G^%OMBZ%J.L1ZAK>FQWJL;;R\6D"N0/,<R;CG.%0_*3T_SH
MRVE.KQ/5HTX\SE*K&SM;523;NFFE>]FFGM8^W/7/@AXMN?&'ARZN+KQIX6\<
M-'<^6+S0HT2" ;5/EL%EE&_G=U'##CO7Z[?\$?O^34)/^PU=?^R5^,_[*7CA
M?&.D>+($T_0[6'0]?ET^*ZTBU6WM=00112!\+P73S/+8C@M&>G0?LQ_P1^_Y
M-0D_[#5U_P"R5][X24'1XPJTVK?NY::+?D:TBDEITLO-7 ^JJ**^._\ @I!\
M5'\%?M-? W1]3UKXF:;X-UFV\1W6LVO@DZB;VZ-M:V[PNZV -P8XRSDX^7GG
MM7]7@?8E%?GS\*_^"C&O?#+X,_#_ $U]2MM1F^)5QK_B#P?K7C:2[,A\+6US
M$+![O[/%),]S+'=0!0X#A 6E^<%6]6^%G[>WCC]IV/3;;X<^!]'M=:L_"]IX
MFURQ\4WES8%3<7%S!':0%82VYFLYF$LBA0K1G;\QP ?6%%?(FA?M'_$;P%\;
M?VF;[Q)JW@6'PEX)NM(CT6/5=2GM+?2VN+"U?$DGEL-A,I8JBEWD(5?O"N5T
M_P#;5OOVF(OAZ$N;.UU+PM\:K+PUJL^A3W4>GZK&VE7%TI43)'+L*RH&CD4@
M/&>6&#0!]RT444 %%%% !1110 4444 %%%% !1110 5R'Q%_Y'OP#_V&9_\
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MP'_!7CX>W-JVM+X?\9BVL76Q=#;VWF,\P+J1^_Q@"!\\YR5X/.&?\/H/AO\
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MO:Z,+_&CZG+C/X$O0_ VBBBOI#Y$*W/A=_R5'PO_ -AFR_\ 2B.L.MSX7?\
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M^)K](**Y_P#B"_"W_/F7_@<O\P/S?_X<K>-_^AQ\*_\ ?FX_^)H_X<K>-_\
MH<?"O_?FX_\ B:_2"BC_ (@OPM_SYE_X'+_,#\W_ /ARMXW_ .AQ\*_]^;C_
M .)H_P"'*WC?_H<?"O\ WYN/_B:_2"BC_B"_"W_/F7_@<O\ ,#\W_P#ARMXW
M_P"AQ\*_]^;C_P")H_X<K>-_^AQ\*_\ ?FX_^)K](**/^(+\+?\ /F7_ ('+
M_,#\[(?^"/\ XRMO#MQHA\6>&3/?7,5\L@BGV*L*2HRGC.29U(_W35+_ (<K
M>-_^AQ\*_P#?FX_^)K]$9_\ D9[7_KUF_P#0XJOUI4\'>&)J,94I>ZK+WY;7
M;[]VP/S?_P"'*WC?_H<?"O\ WYN/_B:/^'*WC?\ Z''PK_WYN/\ XFOT@HK/
M_B"_"W_/F7_@<O\ ,#\W_P#ARMXW_P"AQ\*_]^;C_P")H_X<K>-_^AQ\*_\
M?FX_^)K](**/^(+\+?\ /F7_ ('+_,#\W_\ ARMXW_Z''PK_ -^;C_XFC_AR
MMXW_ .AQ\*_]^;C_ .)K](**/^(+\+?\^9?^!R_S _.&#_@BKXT,R^9XR\+K
M'D;BL$[,!WP,#)_&OLG]D[]DKP_^R7X'FTO2))K_ %#4'674-1G4+)=.HP
M/NHN3A<G&3R22:]5HKWN'O#O(<EQ'UO T;5+63;<FD][7>E^KWMIL 4445]N
M!GZW_P ?.F_]?0_]%O6A6?K?_'SIO_7T/_1;UH4 %%%% !1110 4444 %%%%
M !1110!5UW_D"7G_ %P?_P!!-26'_'C#_P!<U_E4>N_\@2\_ZX/_ .@FI+#_
M (\8?^N:_P J )J*** "BBB@ HHHH **** "BBB@ HHHH S_  K_ ,BU8_\
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M]%_Y^F_[\O\ X5Y?17<!ZA_PL_1?^?IO^_+_ .%'_"S]%_Y^F_[\O_A7E]%
M'J'_  L_1?\ GZ;_ +\O_A1_PL_1?^?IO^_+_P"%>7T4 >H?\+/T7_GZ;_OR
M_P#A1_PL_1?^?IO^_+_X5Y?10!ZA_P +/T7_ )^F_P"_+_X4?\+/T7_GZ;_O
MR_\ A7E]% 'J'_"S]%_Y^F_[\O\ X4?\+/T7_GZ;_OR_^%>7T4 >H?\ "S]%
M_P"?IO\ OR_^%'_"S]%_Y^F_[\O_ (5Y?10!ZA_PL_1?^?IO^_+_ .%'_"S]
M%_Y^F_[\O_A7E]% 'J'_  L_1?\ GZ;_ +\O_A1_PL_1?^?IO^_+_P"%>7T4
M >H?\+/T7_GZ;_OR_P#A1_PL_1?^?IO^_+_X5Y?10!ZA_P +/T7_ )^F_P"_
M+_X4?\+/T7_GZ;_OR_\ A7E]% 'J'_"S]%_Y^F_[\O\ X4?\+/T7_GZ;_OR_
M^%>7T4 >H?\ "S]%_P"?IO\ OR_^%'_"S]%_Y^F_[\O_ (5Y?10!ZA_PL_1?
M^?IO^_+_ .%'_"S]%_Y^F_[\O_A7E]% 'J'_  L_1?\ GZ;_ +\O_A1_PL_1
M?^?IO^_+_P"%>7T4 >H?\+/T7_GZ;_OR_P#A1_PL_1?^?IO^_+_X5Y?10!ZA
M_P +/T7_ )^F_P"_+_X4?\+/T7_GZ;_OR_\ A7E]% 'J'_"S]%_Y^F_[\O\
MX4?\+/T7_GZ;_OR_^%>7T4 >H?\ "S]%_P"?IO\ OR_^%'_"S]%_Y^F_[\O_
M (5Y?10!ZA_PL_1?^?IO^_+_ .%'_"S]%_Y^F_[\O_A7E]% 'J'_  L_1?\
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M^%GZ+_S]-_WY?_"C_A9^B_\ /TW_ 'Y?_"O+Z* /4/\ A9^B_P#/TW_?E_\
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M1J_Q)T>XTFZC6Z8L\+J!Y+\D@^U26?Q,T:.TB5KILJ@!_<OZ?2O,9O\ 4O\
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M_"S]%_Y^F_[\O_A7E=I_QZQ_[HJ2@#U#_A9^B_\ /TW_ 'Y?_"C_ (6?HO\
MS]-_WY?_  KR^B@#U#_A9^B_\_3?]^7_ ,*/^%GZ+_S]-_WY?_"O+Z* /4/^
M%GZ+_P _3?\ ?E_\*/\ A9^B_P#/TW_?E_\ "O+Z* /4/^%GZ+_S]-_WY?\
MPH_X6?HO_/TW_?E_\*\OHH ]0_X6?HO_ #]-_P!^7_PH_P"%GZ+_ ,_3?]^7
M_P *\OHH ]0_X6?HO_/TW_?E_P#"C_A9^B_\_3?]^7_PKR^B@#U#_A9^B_\
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MPL_1?^?IO^_+_P"%'_"S]%_Y^F_[\O\ X5Y?10!ZA_PL_1?^?IO^_+_X4?\
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M#'@2UU#4-1N[N>'5#<:A8+>QI:^5\J&&"2(LSG+,^T!<;J]9_;G^(>J?#_\
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M/%GP7\6>'_!6L6'@72_&VH:5?:Y<W$IU.]TF2U@N%@A6%;>%IUDG+@XD^6(
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M9E_T$5/_  .7^8':?\-&?$#_ *'CQ9_X-9__ (JC_AHSX@?]#QXL_P#!K/\
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M6DU"4MY0275ZM)W2;[6Z %%%%?JP!1110!'/UC_W_P"AJ2HY^L?^_P#T-24
M%%%% !1110 4444 %%%% !1110 V;_4O_NG^5$?^K7Z43?ZE_P#=/\J(_P#5
MK]* '4444 %%%% !1110 4444 %%%% !1110!':?\>L?^Z*DJ.T_X]8_]T5)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %1VO^H6I*CM?]0M $E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5':?\>T?TJ2H[3_CVC^E
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MUX0\7>%X;5?AO\$X]3TK3[^UC"VNN:E/$+2:"U51L-G:QJR,X^5Y6VID1,2
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MZI?>'KWPOKFH&\MI+C7[&ZF>:2.5G@80[9)'*&V$6Q3L'R@ >Z44 ?.NM?\
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M?$5I'XP\=:+:^-/#,7A;Q*MM=6]Q)K]O#"\,,TTMQ#+(+A4D<&2-E+@@.&
MKW:B@#S[XF?L]VOQ 3PG=66O:YX7\0^!]XT?6M-^SO<0))"()HWCGBDAE21
MNY7C(W*K#!4&LGX8_L>^&?A1XM\+:WIU[KEQJ'A?3]4LA)=W"2G4I-2N8KF[
MN;@[ 6F:6(,-I50&("XP!ZO10!YCXM_9,\*^._&WQ"UK5_M]]_PLSPQ;>$]8
MLG=/LPLX/M6TQC;N60_:Y,DL1\J8 P<XL?[&4>ESPS:1\0_B%H5Q>:-8Z%K]
MQ8W-JEQXF@LT,<,D\K0%XKCRRR&:V,3D-UX!'M%% 'EUI^R];Z)\2[W7=%\7
M^+M!TO5M97Q#JF@6$MLECJ-^%16E=VA-PJR>6ADC254<J2RG<V>>\(?L(Z'X
M.\1:+<Q>*O&%UI/AB\U:[T/1IY;4VFE?VDDJW,:LL FD0&9V3S9'*= =ORU[
ME10!Y;X$_9)\/?#Y/A,MG?:S+_PIW3+C2M'\Z2(_:HYK9+9FN,(-S!$!&S8,
MD\$<55\%?LBVO@%WT_3_ !IXVC\&Q&^>P\+"XMTTW3FO!()=I6$3RHIFE:..
M:5TC+ A?E7'KE% 'C_AS]BOPOX:TWP;:Q:AKLL/@?P+=?#^R\R:+,]A<1V\;
MR2XC&9@MLF&7:N6;Y3QCN/@O\-/^%-?"K0?"BZQJ6O0^'[..PM[W4(X$N9(8
MQMC5Q!'''E4"KD("=N3DDD]110 4444 %%%% !1110 4444 %%%% !1110 4
M444 9OB#P7HWBTQG5M(TO5/)_P!7]LM(Y]GTW X_"LS_ (4QX-_Z%'PO_P""
MFW_^(KI:*Y*F PU27/4IQ;[M)O\ (#FO^%,>#?\ H4?"_P#X*;?_ .(H_P"%
M,>#?^A1\+_\ @IM__B*Z6BH_LO!?\^8_^ K_ " YK_A3'@W_ *%'PO\ ^"FW
M_P#B*/\ A3'@W_H4?"__ (*;?_XBNEHH_LO!?\^8_P#@*_R YK_A3'@W_H4?
M"_\ X*;?_P"(H_X4QX-_Z%'PO_X*;?\ ^(KI:*/[+P7_ #YC_P" K_(#FO\
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M3_A![K_GM8_^!"T?\(/=?\]K'_P(6K>*,4 5/^$'NO\ GM8_^!"T?\(/=?\
M/:Q_\"%JWBC% %3_ (0>Z_Y[6/\ X$+1_P (/=?\]K'_ ,"%JWBC% %3_A![
MK_GM8_\ @0M'_"#W7_/:Q_\  A:MXHQ0!4_X0>Z_Y[6/_@0M8GB?X8:CJ'B#
MPW/'-I_EV%])-+FZ4$*;6>,8]?F<?AFNFQ1BLJU%5(\LNZ?W--?B@*G_  @]
MU_SVL?\ P(6C_A![K_GM8_\ @0M6\48K4"I_P@]U_P ]K'_P(6C_ (0>Z_Y[
M6/\ X$+5O%&* *G_  @]U_SVL?\ P(6C_A![K_GM8_\ @0M6\48H J?\(/=?
M\]K'_P "%H_X0>Z_Y[6/_@0M6\48H J?\(/=?\]K'_P(6C_A![K_ )[6/_@0
MM6\48H J?\(/=?\ /:Q_\"%H_P"$'NO^>UC_ .!"U;Q1B@"I_P (/=?\]K'_
M ,"%H_X0>Z_Y[6/_ ($+5O%&* *G_"#W7_/:Q_\  A:/^$'NO^>UC_X$+5O%
M&* *G_"#W7_/:Q_\"%H_X0>Z_P">UC_X$+5O%&* *G_"#W7_ #VL?_ A:/\
MA![K_GM8_P#@0M6\48H J?\ "#W7_/:Q_P# A:/^$'NO^>UC_P"!"U;Q1B@"
MI_P@]U_SVL?_  (6C_A![K_GM8_^!"U;Q1B@"I_P@]U_SVL?_ A:/^$'NO\
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MX0>Z_P">UC_X$+5O%&* *G_"#W7_ #VL?_ A:/\ A![K_GM8_P#@0M6\48H
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M&* *G_"#W7_/:Q_\"%H_X0>Z_P">UC_X$+5O%&* *G_"#W7_ #VL?_ A:/\
MA![K_GM8_P#@0M6\48H J?\ "#W7_/:Q_P# A:/^$'NO^>UC_P"!"U;Q1B@"
MI_P@]U_SVL?_  (6C_A![K_GM8_^!"U;Q1B@"I_P@]U_SVL?_ A:/^$'NO\
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34 %=WX3_ .1>MOH?YFBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nbx-20211231_g10.jpg
<TEXT>
begin 644 nbx-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0 ET# 2(  A$! Q$!_\0
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M"Z3_ /(5>R44 >-_\*,\8_\ 1=/''_@+I/\ \A4?\*,\8_\ 1=/''_@+I/\
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M_L;?\FT^"/\ KA/_ .E,M>T4 >-_\*,\8_\ 1=/''_@+I/\ \A4?\*,\8_\
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M %FQT?\ M%XM!:\6>%UBL;22*/R -]NJO)(_G$[7R4ZC(%O;R;^X>MKGO/\
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MQC\J':[JKE;B0.I9CM4],\>U_M?_ /)K_P 3O^P%<_\ H%/E:5R4[D,?P/\
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MM+O_ %^9-^9>[U/IP:79+'%&+.W$<1)C3REPA)R2!CCFO*?VO_\ DU_XG?\
M8"N?_0*S?%G[66@>#X]9^VZ'J_G6&JC2H[95B\ZY?9))O6/?N5"L3E2P&_Y=
MN<\<O\=_'UQXR_9T^.=K/$%BLM'\^TD\IHG-M<6B31K(I)(D7<RGIT' J5JK
ME;-'TM;_ /'O%_NC^525X/\ M ?&K7_AKINM-H8L81I.BVM_)/>VSSY>XO4M
MTPB,I8(HE8@<DE ,=Z?AG]IS4;73WM/$OA74)M7BB26.>S@%K'>1S7SV=DPA
MG<21&8JK;6X4-DFA:JXGIK_73_,][33;..2X=;2!7N.)F6-09?\ >..?QKX_
MU7]HSQ!X)^,WCR&_CDU/PSX>&H@::UA;10FT@M;5DBMIE'F/+YTXWHP*B-@0
M.*]*O/VQ_#EO$)(= UBY"Z5+JDJKY*M&(HY9)(RIDR2!"XWC*;L#=DUFZK\=
MO $?B;6=,NOAS>7FLV=H^IWB1:9#<-Y\MI&TB,RDC<T#HK.3@@%<G;4[-OR?
M]?@RM-GW7]?BA]Q^U))9Z7IMYJ?@8::@LK^Y47UX$Q<6PFVPPCRL@NL+%=XC
M.TG )5A5.Q_:MLKC4H=.F\$VT;"[A74#'>HZJLD]O%"\7[L><X:ZC+ [=NUL
M$\52\=>/_ %]X-U+2[3P5#I/D^&?.L[^*VM"(8+HB.5+4I)\^!(<M&2H8\^\
M4GQV^%7@.QM+%? ,TUUX;OFT^%$L+>2>"]7SS*%(_P"6ICMO,)'+>9'W/%[/
M7^M?^&(U:T_K0T?#_P"UDNL0VMW<>"K2P2XNK%[J\DU%3%;PSQLT<TC"+=N!
M7;TVC(RRYKO?@E\9H/C5<:ZI\)S:/96,ZS6MS<X9;H&66/?@J,.&A))&X?,,
M,2#CS3XW>++3P!XB\/?\(]X0\*OH<.B+XAN+74=&'G2"*ZM;>)(V!'DNB73D
M$JV",8 )KH?#?Q\\)>#Q?W4OA?\ LH7AU;4+[4K"RAM8YA93SQL"#)NFEVPD
MD*2?F#$ ,<&VOK^'_#,JS>WE^.OY-'T%'9P0S/-'!&DLGWY%0!F^I[U-7ANG
M_M9>'[W1?#NIMH>K6]OJ^IC2CYHB5H9&>-$<*7#2HS31_-&"!DYQC!K7'[87
MANQAT8W.@ZU%=:E>SVJV2QQR7$*Q/&KO)&KEE8&9/W9 ;&XXP,E6>W]?UJ+S
M/>Z^;/V=_P#DZ7]IW_L*:)_Z;A7LGPW\67OBBUUZ'45A^VZ1K%SICR6ZE4E5
M"&C< DX.QT!Y^\&KQO\ 9W_Y.E_:=_["FB?^FX4A]T8/Q"\1ZAX8_;[TVZTW
M3;?5)W^&KQF&YNS;*%_M/.[<(WR> ,8[]:]&U;X^ZQH%NMQJN@>'M+MV;8LU
M]XG\A"W]T,]L 3[5YC\3_P#D_;3/^R;/_P"G(USW[1GA_4/$U[\,[/3;33;N
MX/B3.-9L6O+)!]EG^::-2,K^(Y(H$>]Q_&3Q3+&KIX1TET8!E9?$#D$'H0?L
MO(J/_A=GB3[8UH/"NBF[5!*UO_PD3>8$)P&*_9<[<@C/3BOE&.Z\2_"OQ'X-
M^'.BZMJUWI]@;33;QFTX+;S1W"3L\L;;&(VMM )=0F N&R:P/"OB;QOX=^&\
M0T.6^NM2L_"]BLEUJ&GDW%O(=2>.YRWE;V\N/)VX; &X*W>M+Z;7M^8:_P!>
MI]I?\+@\5_\ 0G:7_P"#]_\ Y%I?^%P>+!_S)VE_^#]__D6ODB/X@?$E&T2<
MZY>3I'!92NT&DF..\$FK>0S.)(@X_<')("Y #X JIX#\3>+/"#>%]-&JZ]=V
MK:YJ%M>Z:^GEYV<W[ 'S'BVM$(F#%0Z$!MRE@-H:C>WG?\!7T;[6_%-_H?8/
M_"X/%?\ T)VE_P#@_?\ ^1:R3XTU5O%+>(SX!T<ZVUE_9IO/^$@EW&WW^9Y>
M/LN,;B3TS7D7Q5UWQII_C*_A\,7-T8[+PG>:G;V$5HDL5Y?+)MB1F9<YP<[5
M()P*\UM?B3X]7P]H\NJ^*-2M]/FNKL'6=*\/O<3-*D,306QCD@7S%:1I1N"(
M#MV[AC-):Z_UNT/5:?ULF>W?\(GX;TO39T;X4^'[6R4,\CR>)[A51/(>%LL8
M/E3RI'4C(7:?85>F71XUN-5D^&WAV.WD$%S)<-XGF6#]R8WCE_X]]@P8HB7'
MWMB[B17BVM>./B++XS^(%C<7!32[73M1-GI;:2\F^);)7@FSY13+2EAAG;=@
MKLXJMJ7BSX@^1XETEFN7T^P\)'7(G;3HVBF,UI$D5H$\O:3',L[;,9P5!&,"
MC9-^5_S_ ,AVO9/T_+_,^A/#MU'X9CNO[(^&NB6D=]8I83^3XCF*S6Z[RBG_
M $;!QYCX;KANN*9JRP:YHN@Z1?\ PPT*YT[0HUBTZ!_$,V((U55"9^S99"JJ
M"K$@[1D'%?/NH_$;XA:/K.M31:I/'80+JL4%O>6"BU@6#3+>>%]P0-_K7D R
M<'D=N.S^%?CS6/$WP?\ %VN_\)#_ &WJ-NET;$*UO+<6H6#=$LP@&SS2Q+8Y
MXVTY+EN^RN)7E;ST.HT7P'96-CJ4.J?#W2=>N;^_GOI;RYU^:.0>9<33+&NV
MW^54,[K\N-P.3UJ?5M+\*/$MIJ'PU\+PB+RCY<OBN:)@#'%;Q@_N <,L$* '
MAB@ZFO)9?B1XVTG5OAY8?VKK&HW=S#I$VJ"ZTM$@N%NY,3<I%UC!P>8PF%SN
M)-<KH_B'Q5J>H:EKFH&^O-=FM]'M;L7>DC;;,-:=9($4Q[6"1D'=R5SNW=Z:
MC:2BN]ON%?F]Y^3^\^F)M#TV=;U&^%6B?Z7N\W;XDN%()G-P2A%OF,^<2X*8
M().*G\,W-AHNIVVK:%\-O#D%U8NT<,]GXCD*PL(4MV7 MMH(CC1",<;?7-?,
MOB[Q=X]\3:/XIM+[4=<2"SF@NKZ.VTTQ'2Y8]714BA81YD0VH\T\OG&<X)%2
MZ7XB\>^#K/Q9'X9DO9XKD:[J-O;S:>&6*9=4C43+A-Q9HI)'P<YQD*<8J8_#
M==G^'],III^=SZVT7QMJWASP_'H>F> ])L]+C5T6"/Q#+P')9CN^S;LDLQSG
M.3FJ.CZQ+X?UI-6T[X;:'::A';+:)-'K\ORQJJJ !]FP#M1%+8R0J@D@"O ?
M"/C;QU<ZA83:GKNH7FFVFAZKJ3M8:0?]/,,ZI N)8D9VVLV-H3S-H.,9KB9/
MC5X[73Q'/XBU6SB>[NEMKT:8KW,ZC2A<1IM\@!L3G&53C)7<<9I[:^5_QL$4
MY.W];7/MC_A<'BO_ *$[2_\ P?O_ /(M,F^,_B>WADFF\):1##&I=Y)/$+*J
MJ!DDDVN  .YKY]\ >+/&^J?&!?#NLW$L=E;:1#K]TOE(J_Z1!%&EJ>,CRYUN
M&]<8R2*Y;XB>/O$VJ>-/&7AZW?4Y]!DTO6;&:QN-/VQJT=AOB:)ECR0S,0&,
MA+Y("#&2I+E_'\/^"*'O-?+\3ZLC^,OBB:-)(_".DR1NH973Q Y5@>001:\@
M^M._X7!XK_Z$[2__  ?O_P#(M?(EIX\\>Z1J%OI=G/J,45KHX6'2QIF8([--
M'\U+L2F/)D^U 1[=W^SLJM??$7XI6/A8JFL7F[[98_:-7NM,R]O'+I@G90L4
M+9!N,+PA.3M)&<AR2BWY?YV!7LGW/L3_ (7!XK_Z$[2__!^__P BTY/B]XLD
M=5'@[2LL<?\ (??_ .1:Y+PK<7UWX7T>?4R&U*6SA>Y(A,.92@+'RSRG.?E/
M(Z5KV_\ KX_]X?SH<;.Q*E=7//OV6/B9XDT?]G_P=:VWA?3KNW6"8I-)K+Q,
MP^T2]5^S-CG/<ULZYI=CXF9CJOPNT._4WLNH!)O$4VT32A?-P!;?<<HI9/NL
M1D@URO[,G_) _!G_ %[3?^E,U>G4O,;9SVH6%CJ@U'S_ (6:%NU#43J]U)%X
MAFC>2Z,0A,NY;8$$QJ$(! (R"#DU#K&BZ9KR%+_X5:'.INYKTC_A([A<S3;/
M-;Y;<<-Y4>5Z?(..*Z>BC;8+LI:'K$WAO69=5TSX<:+::A*DZ/.OB&8DK-,9
MY1S;8^:4EOKTXKGQX9T9;&.S3X4:'%!'!#;)Y7B6X1D2%I&B 86X8%?.E&X'
M.'9<X.*ZVBBW0+LX?QEX4C\73)<+X#TO3+S[59S2W%OX@F+216\B.(5_T?\
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M:NC_ +=\4?\ 0FQ_^#N'_P"(I=!=3J/,?Y?G;Y>G/2D\QSU9OSKF/[=\4?\
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M#VGTKRWXSZ+;:[^W;I4%TURL:_#EW'V6ZEMVS_:)'+1LI(YZ9Q76?\*[T?\
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M]*I#"BBBF(**** "BBB@ HHHH *='_K%^M-IT?\ K%^M 'F/[/O_ ")NO_\
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M$\FV:)2[0!7W,2 P1=^W ]:T-0\5>)M+O;O498'TB;4O[*&KW:E8/LO^@NV
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MH?*CE\Z/RI-H23>-KY^[@]#GMCK7@%OXVUJVOO#>A6LEPMC_ &;;6%UI]Q&
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M(F]XY%"F3<I^7G;MR":]M\,W5W?>'-*N+\QF^EM8WN#"K*AD*@L5# $#.>"
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MG.YLXQUIM% ARNRYVL1]#0)&&,,1CISTIM% #O,;KN.?K1YCX W-@=.:;10
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M*:C#;SSM$&C^P&U8,P4X(8[L8.0.H)H!:FS?>']?U"V>WOO$>B75NPW-#=:
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M_P#(FZ__ -C;KO\ Z7RUZ97F?[/O_(FZ_P#]C;KO_I?+7IE(;"BBBF(****
M"BBB@ KS6'_DYRZ_[$B+_P!.+UZ57FL/_)SEU_V)$7_IQ>@9Z51110(****
M"BBB@ KS?]I7_DWOXB_]@6?^0KTBO-_VE?\ DWOXB_\ 8%G_ )"@:W/1H_\
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M3HL6K[)"3H0!P_VEL*MR&;YY,D@MC)Q1T;\OUM;]0C'F=OZVN?4G_"F?$_\
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M5?\ A3/B?_H>8/\ P1Q__':J_L;?\FT^"/\ KA/_ .E,M>T4@/(?^%,^)_\
MH>8/_!''_P#':/\ A3/B?_H>8/\ P1Q__':]>HI@>0_\*9\3_P#0\P?^"./_
M ..T?\*9\3_]#S!_X(X__CM>O44 >0_\*9\3_P#0\P?^"./_ ..T?\*9\3_]
M#S!_X(X__CM>O44 >0_\*9\3_P#0\P?^"./_ ..T?\*9\3_]#S!_X(X__CM>
MO44 ?)_Q-^%OB&S^,7P:M)/&$,TMSJ6IB*8:.BB(C39F8E?,^;(7&.,9S7J7
M_"F?$_\ T/,'_@CC_P#CM0?%S_DO/P(_["FK?^FJXKV6D!Y#_P *9\3_ /0\
MP?\ @CC_ /CM'_"F?$__ $/,'_@CC_\ CM>O44P/(?\ A3/B?_H>8/\ P1Q_
M_':/^%,^)_\ H>8/_!''_P#':]>HH \A_P"%,^)_^AY@_P#!''_\=H_X4SXG
M_P"AY@_\$<?_ ,=KUZB@#R'_ (4SXG_Z'F#_ ,$<?_QVC_A3/B?_ *'F#_P1
MQ_\ QVO7J* /(?\ A3/B?_H>8/\ P1Q__':!\&?$ZD'_ (3F#_P1Q_\ QVO7
MJ* /D_\ 9W^%?B#5/"/B-K;QA%:QQ^+=>B*MHZ.69=1F5GSYG&XKG';..:]2
M_P"%,^)_^AY@_P#!''_\=J']EG_D2?%?_8Z^(O\ TZ7%>R4@/(?^%,^)_P#H
M>8/_  1Q_P#QVC_A3/B?_H>8/_!''_\ ':]>HI@>0_\ "F?$_P#T/,'_ ((X
M_P#X[1_PIGQ/_P!#S!_X(X__ ([7KU% 'D/_  IGQ/\ ]#S!_P""./\ ^.T?
M\*9\3_\ 0\P?^"./_P".UZ]10!Y#_P *9\3_ /0\P?\ @CC_ /CM>5Q?"_Q#
M_P -47.G?\)?#]I_X0F*4W7]CIC9]OD&S9YG7(SNS[5]95XO#_R>7=?]B##_
M .G&6D!:_P"%,^)_^AY@_P#!''_\=H_X4SXG_P"AY@_\$<?_ ,=KUZBF!Y#_
M ,*9\3_]#S!_X(X__CM'_"F?$_\ T/,'_@CC_P#CM>O44 >0_P#"F?$__0\P
M?^"./_X[1_PIGQ/_ -#S!_X(X_\ X[7KU% 'D/\ PIGQ/_T/,'_@CC_^.UYA
M^T]\*_$.C_L[_$2[N?&$-Y;Q:+<-);KHZ1F0!<[=PD.W..N*^K:\?_:__P"3
M7_B=_P!@*Y_] I A(?@SXF:&,CQS!C:,?\2./T_ZZT__ (4SXG_Z'F#_ ,$<
M?_QVO6K?_CWB_P!T?RJ2F!Y#_P *9\3_ /0\P?\ @CC_ /CM'_"F?$__ $/,
M'_@CC_\ CM>O44 >0_\ "F?$_P#T/,'_ ((X_P#X[1_PIGQ/_P!#S!_X(X__
M ([7KU% 'D/_  IGQ/\ ]#S!_P""./\ ^.T?\*9\3_\ 0\P?^"./_P".UZ]1
M0!Y#_P *9\3_ /0\P?\ @CC_ /CM'_"F?$__ $/,'_@CC_\ CM>O44 >0_\
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MB@ HHHH *\?_ &O_ /DU_P")W_8"N?\ T"O8*\?_ &O_ /DU_P")W_8"N?\
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MU3Z)BZM'BW[&;;_V9? S89=UO,<,,$9N)>".QKVFO%_V-O\ DVGP1_UPG_\
M2F6O:*0!1110 4444 %%%% !1110!XU\7/\ DO/P(_["FK?^FJXKV6O&OBY_
MR7GX$?\ 84U;_P!-5Q7LM !1110 4444 %%%% !1110 4444 >-_LL_\B3XK
M_P"QU\1?^G2XKV2O&_V6?^1)\5_]CKXB_P#3I<5[)0-A1110(**** "BBB@
MKQ>'_D\NZ_[$&'_TXRU[17B\/_)Y=U_V(,/_ *<9: /:**** "BBB@ HHHH
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M7_?$$GC*JPZ8J>B8=S7L_#MQJ+7&H6?Q*N+Q[(/;S7-M9Z=(T.,,\998"5Y
M)7V%8GAGQ%<>)-*N-4_X6%X@TC3(HDN5O=6TRPMH)H'^Y*DAAVE3Z$AAD9 R
M*V/@W\(IOA?8ZA!)/;RS2P06D=W#)<222QPA@CR":1E5OG^Z@"CGKD <U;_
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MA'4 5]121I( '57 (8!AGD<@U#<6%M>1RQSVT,\<H D21 P?'3(/6CI;SO\
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M98=Y')1E)!4]1@GKU/6NAIJJL:A5 55& H& !3J'J[D+1'C?[+/_ ")/BO\
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M_P!?Y_TCYPC^($NCM9>(7>#3IH]!U:-/LML#$K_VM%"C>675<DD99F"@DLQ
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M)7_/7PK_ -^KG_XJ@#N:*X;;\2?^>WA7_OU<_P#Q58NC^-/$_B&]DL]*\2>
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M** "O%X?^3R[K_L08?\ TXRU[17B\/\ R>7=?]B##_Z<9: /:**** "BBB@
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M=R01\B\;5YZ"A;^MW^@MHKY?F>5:?XF\=1^(+#P_KNOZGIGB""VBCM/-G?\
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M_ C_ +"FK?\ IJN*]EH **** "BBB@ HHHH **** "BBB@#QO]EG_D2?%?\
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MM/@C_KA/_P"E,M>T5XO^QM_R;3X(_P"N$_\ Z4RU[12 **** "BBB@ HHHH
M**** /&OBY_R7GX$?]A35O\ TU7%>RUXU\7/^2\_ C_L*:M_Z:KBO9: "BBB
M@ HHHH **** "BBB@ HHHH \;_99_P"1)\5_]CKXB_\ 3I<5[)7C?[+/_(D^
M*_\ L=?$7_ITN*]DH&PHHHH$%%%% !1110 5XO#_ ,GEW7_8@P_^G&6O:*\7
MA_Y/+NO^Q!A_].,M 'M%%%% !1110 4444 %>/\ [7__ ":_\3O^P%<_^@5[
M!7C_ .U__P FO_$[_L!7/_H% UN>N6__ ![Q?[H_E4E1V_\ Q[Q?[H_E4E @
MHHHH **** "BBB@ HHHH *^;/V=_^3I?VG?^PIHG_IN%?2=?-G[._P#R=+^T
M[_V%-$_]-PH&4/%6N+X?_P""@FGW#0F<-\,Y$VJV/^8GG/Z5ZEKGQZTKP[J6
M@6%[87"W.N7O]GV0C(8--Y;288X^4;4;GZ5XM\3_ /D_;3/^R;/_ .G(U'\8
M_AS>_$>^\"Q6US>65GINM_;;Z[TZ]-I=0P^1*FZ)QSNW,HP.<$TQ,["Z_;H\
M"V;6A?3==>WGMY;N2ZAL'DAM(([AK=Y9V4'RT$BD9(Z8-='8_M5>&-2O-/M(
M+2]:YOM7N=$ABV?-]I@1GEW>B!%W!^A#+ZU\M>!?V8;]M0T:U\6F\&A6>BW5
MA<0VFKD&]=]2DG2.XV<RH8V5FSQNX-=MX?\ A)K&E_M&ZSXID%NO@YK5KK3X
MDD'F+J,T<4-P2G9?+@7!_P!HU44M+^?]?<)];?U_3_ ^B?%'BC3_ !=I\-C>
M65PD<5W;WB^1.H;?#*DJ Y4\%D&?8UA6-MHFG^-'\710:@=<FGE>>Z:YC_?1
M.BH+5ODYB38A5>H8$YRS9^=_&WP2\2Z]\3M8\0Z:L%F]U?HUOJ7VK;)%;_V5
M-;,=H.1B=XSM')QGM7EOC#X9ZU\-/ACIEEJ6FZA*]SJ>);>*X74DXL6B>X"(
M(41]YW1Y;.X!FRV12V5_ZUL5O97_ *5S]"[CXL6UG;S3SV1BAAC:61VF&%11
MEF/'0 5F:)\>=,\1,K:?I]S<6<EK#>07X(%M<1R@E?*DQ\Q &2.V1ZU\@S?"
M7Q)XL\5:#JUCH46G>'EM(H$FO;@1W;VCZ=)$T=S$<L'\YUW1KA/XL,>11MO@
M+XXT_P &O_96FZ?I'B+3M%T6#2HUO4,7VVU,Z7!++@!728MGONQU%.UK_P!=
M_P#@"5FOE_E_P3[B'Q0B;&-/8\9&)AT]>E'_  M"+./[/;/IYPS_ "KY"\._
M /6/#/Q@T?5XGEN="TZ&SBMKA=16,6\<-H89(FAV%Y-\F7P&"'<2?F IGBCP
M3K?B7]HB^O=+TU/^);<:-?-JL\YB$4217(DB08^?S-RJVT\=Z&E="[^A]9ZE
M\:]*T62Q2_B6T:^N5L[823@>;,P)$8XZX!_*G:/\8H-9L([M-%O;19&=1#>C
MR9?E8J25(Z'&1Z@@]Z^*/#'P$\86^M:?J>J^&M+,=OK&E:G)IJ7\;1;HA.MR
M\><\CS(V!<EW"\G/ L:?^SSXQ77/"%W>;I8-.9]T=MJRPBS?^TY;GSL[&9]\
M3J-L94DC:QVT15]^_P"@F][=C[,UKXW:3X=T\WVIQK96:R1Q&:6<;0SL$0=.
MI8@#ZU?/Q.C4D?V<^0<']\./TKX7N?V:_$[Z9J@.B:==27,!EDMI;Q-MU.NM
M/=(&SD FW.T,> 25KU3X2_#W6_!/CSQ7?76F6UCHNHL9H7:[%S</*9F?&X ?
MNPK8 D!93\H)4"DE<<M/P/I)OBG"J%O[/8@#/RS*2?IQ7(W?[5'AC3[>W:[M
M+RUNY39[M.F3;=P?:I#% 98\?("X(//&#7ROX;_9Z\8Z7\2+>\N9[=_"\-_,
MH@%SD_8H"\VGX7^]YT\H8=@JU3TW]G/Q'#'HD=YH6FW#_P!DZ#:7US]L3>C6
M=V9+B,]W#1E<$'G9CTH2O9^GW?U]PY:)VZ'W(?B?&/\ F'.?I,/\*/\ A:$?
M_0.D_P"_H_PKPWX,^%=1\$_#?2]$U1$BN[22X'EQRB14C:XD:-0WH$9>.W3M
M7:461-SOO^%H1_\ 0.D_[^C_  K@OBQ>7'Q";P4;.".U_L+Q+9ZW/Y\A_>10
MB0,BX7[QWC&>.#S2446"YWW_  M"/_H'2?\ ?T?X5S-]J&CW'B-M?M+"[TG6
MI#&+B\L;A4-TB<*DRE2LB@<#(R >"*QZ* -GPWK47AOQ%XCU82ZA?-K=PEQ)
M;7!@6.!EC6,",I&&(VJH^8GIGN:Z:/XFQR2*O]G2#<<?ZT?X5P%26_\ KX_]
MX?SH YW]DSQ\FE_LZ^"K<V3R$6\QW"0#_EYE]J]<_P"%H1_] Z3_ +^C_"OG
M/]F3_D@?@S_KVF_]*9J].H&=]_PM"/\ Z!TG_?T?X4?\+0C_ .@=)_W]'^%<
M#1185SOO^%H1_P#0.D_[^C_"C_A:$?\ T#I/^_H_PK@:*+!<[[_A:$?_ $#I
M/^_H_P */^%H1_\ 0.D_[^C_  K@:*+!<[[_ (6A'_T#I/\ OZ/\*/\ A:$?
M_0.D_P"_H_PK@:*+!<Q?BGX^2Y^-7P1N?L3J(-3U4[?,'.=,F'I_M5ZQ_P +
M0C_Z!TG_ ']'^%?._P 2?^2M?!O_ +"6J?\ IMEKTJ@9WW_"T(_^@=)_W]'^
M%'_"T(_^@=)_W]'^%<#1185SOO\ A:$?_0.D_P"_H_PH_P"%H1_] Z3_ +^C
M_"N!HHL%SOO^%H1_] Z3_OZ/\*/^%H1_] Z3_OZ/\*X&BBP7.^_X6A'_ - Z
M3_OZ/\*/^%H1_P#0.D_[^C_"N!HHL%SOO^%H1_\ 0.D_[^C_  I5^)T;,!_9
MTG)_YZC_  K@*='_ *Q?K18+F%^S7\0(]/\ !?B4&Q=_,\8^()/]8!C=J4[8
MZ>]>L_\ "T(_^@=)_P!_1_A7SK^S[_R)NO\ _8VZ[_Z7RUZ90.YWW_"T(_\
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M_A7C/[,.H#5?VE?VE[H1F(2:IHORDYQC3P/Z5U%<5^R3_P G!_M)?]A71_\
MTAI,I%'XG_\ )^VF?]DV?_TY&J?QX^(FJ?#W2=%DTV_T_1Q?7$\<VJ:G!YT,
M CMY)43;N4;I'01@D_Q<9.*N?$__ )/VTS_LFS_^G(UO>,O&FG>%;C0K*_L+
MS4IM;O/L5I;V=J)R9 ADRP)&%"J3N[8I;JP7L[L\8M_CCXRO/#^O:S<7&EZ'
M;07NC:>%NK%F&E_:X+>6>XF8N-RQ^:P"MM XR>*H:#^T9XLU#7?#D,MQI*K>
M#3 ;);0B34!/>W%O))"2^57RXDE& V!GG!KU!OCQX3^TZM:36&J"\MKBVMY+
M%]/ FO#<2F&(HA/S!F4CY]I &<8Q7!?#[XL:4S/XV\118UNYT.W6:UL=..Y@
M-1GMK9(LR$!RS;=@4<G);' TTDTUM?\ 3;^NXK6C*^_^;W_K]6<G\,_B_K7@
MWP*NDS:M806JV%M/IMS-9&1HI;C4KJ$HY,BJV1'D,[*JGKQ72>#/C?\ $#QQ
MI&HWVFW&E03:?X776&M8[(R&ZG%U<1,%;?\ *K);YQ@\MP:O^+OVC(Q9:ROA
MSPVX2TT=+\75_9+B*9;X6TMM+%G.Y6#XQD;NGK6OXI^/7PWO-+31=774M/35
MY)]/GMXX#;7$(BN!!('9&# >8P&$+$AB<8S2NWMN[_JOZ] TOY:?I_7S..M_
MVA/&>HS:5J<$VG0:-J-M:ZK#:SV)\YK2YU7[+$I?>-K>3ALX/S'I4TGQZ\=?
MV#XTU:*+2YH](D6WCB-N$$$S7I@;+^8?,CCB D,A"KEB#@"O0/\ A<OA'PSX
M6N[N'0-6BT30[F32-\6F*8D%MN#[&+8,:;.I.2<  MQ7)^&]>^$WPY\8:U=Z
M)X=U0:G-%-%-?);M-'./LPOFAC+OR6C.\*1R01D=S3IMK^.P_EKI^&YCZM^T
MAXCT?0_#$[W^@RZK._FW5M;1>9#>0?;EME>.4NH!P3D1!_F&?N<G2DF=?V5?
MBL?-<F.\\1!6+G*XNI>_:O6_#_CK0/%VCZIJ>GVLEW8:2QA,BV8??B))2L*C
M)8 .HP!]X8[5R$_[2'@Z#1GN3IVK2*)[NWN+&/3T:6)X(!<3&10^W'EL&SDY
MZ'FE)>ZX^7YV".ZDN_Y7/ /&-CXO\8:YJFG7K6GAWQ--JGA461TN]>XB1EMI
MWA8LR(<L57<N,<GDUFW'B.QUSX:Z-XL\1/'#>IJVNW3^%=3GGMDN9/M"^8MM
M<1D>7>QL"(E.<@D =Z^DH?C):>(?BIX:\/Z':&73KF2[BO[ZXL@JO)%:1SQ+
M#)G.Y1*N[(XS@=ZW=0^)^B+KVLZ!!IU])<:6LCSZA'I?FV-O<K!Y^QG!_P!9
ML(;G .<;LFJ;Y;OU?Y?Y?D)*_+\OU1XMINH>';CXK>([J\FU:+XE/JTJ:+;0
M2O\ :UL3IH:-9HR<?9@=V3C_ %F.<UTO[)<G@^6PA7P]<WEQKLFAV$OB(+,\
MEJ+TEMY?<3MNBV_>.#@+D=*ZK1?CYX;FT^2YN([Z^O;#0(M8O]0@TP1+Y36X
MGP!O+*67D+DJ#\NXD5$/C9:ZAX@\+VVAV4ME;7FL7%EJ]O>6&RYPM@UTC(JD
MY+#80>20<8S37NNW]=OQZ^8:M??_ )_EL>>:]\??'^D^&=$U&*?02=4OM607
M-[!]G@@CM)2D<+,7.YY.3\HW';A5)S6WK/QX\2Z=?^.6BNM&DO=%@N_LGA,V
MDK7DGE6\4JW/F*>8RTC##*H(7Y3G-=$_[0FD:AJ6@:;I'A^^N&O-8;3+R&ZM
M4CDT]Q:M<I*4W8)(&<9R!NSAABI_"?Q^\/ZDWARUN5OKS5-6@L%;5(M+$$#-
M="0P!_G8IN,;_+EL<<]ZA)VM\OFUI_7ZC>EI=-_E=_U_P#B=(^)7BOQ=)X1<
M_P#".WGB"6XUNWL-0M$%PBO%8K)'@JVP,6.UPI8$8Y!S66OQVUW7M$L?&J6>
MGQ&32=?O-)-Q:'S8%M;>$')W<AIA+D8Y4*.V:^HEMX8Q&$AB01YV!4 V9Z[>
M.,^U-^R6Y4*;>': 5"^6N #U&,=#W]:;U^X$U[M^G^9\S:K\??'NGJ;&*72+
MG4?[0EM8IQ8X69A:VTT<+(90(U)G?=+N. B\<U]-6RR+;Q":19IMB[Y$&%9L
M<D#L,UR7C[X0>$?B<MHGB32$OTM=XC4.T8(< .&"D!@0H'//%=;:VT5E:PVT
M$:Q00HL4<:]%51@ >P %/H1V)****0!4EO\ Z^/_ 'A_.HZDM_\ 7Q_[P_G0
M!Y;^S)_R0/P9_P!>TW_I3-7IU>8_LR?\D#\&?]>TW_I3-7IU(;W"BBBF(***
M* "BBB@ HHHH \U^)/\ R5KX-_\ 82U3_P!-LM>E5YK\2?\ DK7P;_["6J?^
MFV6O2J0PHHHIB"BBB@ HHHH **** "G1_P"L7ZTVG1_ZQ?K0!YC^S[_R)NO_
M /8VZ[_Z7RUZ97F?[/O_ ")NO_\ 8VZ[_P"E\M>F4AL****8@HHHH **** "
MO-8?^3G+K_L2(O\ TXO7I5>:P_\ )SEU_P!B1%_Z<7H&>E4444""BBB@ HHH
MH *\W_:5_P"3>_B+_P!@6?\ D*](KS?]I7_DWOXB_P#8%G_D*!K<]&C_ -3'
M_N+_ "%.IL?^IC_W%_D*=0(**** "BBB@ HHHH **** "N*_9)_Y.#_:2_["
MNC_^D-=K7%?LD_\ )P?[27_85T?_ -(:3*11^)__ "?MIG_9-G_].1K7^(5I
MHUI;Z9XHUF2Z2/PS.]]"+7DL[QF':5ZMD2< $<XYK(^)_P#R?MIG_9-G_P#3
MD:UOB=X3N?'&@V6BQ<64^I6LFH,LQB<6L<GF/L8<[B40<<\Y[4D,\_TWX$^"
M]'UN^T./5=>74H+.RU!KR:YC!M%BNY)8&$FP?/YF_.\-E1R<\UM6_P"SUX2M
M=(_L];[40C6<5I%,;Q/-C\N[:[CF1MOWQ*Q.2"" !@\UD:S\+?$-K>:]_9EH
M-2L=3OX21J&I"XG6WAM_W6'N1( #.SY!#$#D#)K/TK]GV[G\/BSUFTM[R[D3
M2],EG:XW-'I\($ET$(QM+R-(N%P2N.@XJE_7S_K43_KY?UH;I^ ?A.19[0WV
MLQQ&P-O=WCW<?EWOF71NB[L5YD$JEB0% #8QZ:$WP-\*PZI%J2ZIJ%A=O=7-
MVTL-^D1N%FG6XDB)QGR_,4$;2#C(+$&J=S\*[JZUZ6:32=-?24U&XOH=/9E,
M)$5FL%C&4Q@#<9&(Z#OUKS_P_P"'7O/&4'AS4M(?4(].%I:0*]JD@CFMH-V\
MN_S16S3$@[5(;Y><$BA:6M_7?_A@:[_T_P"NIW<WP@\$_$+PS'';:WJ!TS^T
MM3D$MM=(HDGN6=+A,,A!P=VP@;AC(//+=#^!T>B^+M9UI-1CO[F&87&BZ7/<
MD6Z$6"6>ZY55W$X5AE>,-TS6;9_!W5CX=TK1Y- T^& Z/#9/+YT6-,NS*7N;
ME54?/(XV['7D;0"0*Z7P3\-;O1?%&FZU>V=I%>E-2NK^ZA<-++<W,R[$+8RR
MK$OTSVHY4M/E]VW_   \_P"M?ZU)? OP?T[PA\&8OAY=WYV7%I/'=W-I,8)&
M:5F:5XR3N 7=@$YP%&:PO#/P+\#Z]X=^V:9JNI:AI]^;R477G1KO\^U%G*0!
M& H"1@@8&#STXI?$7PR\1ZUXPU[4Y(DN\RR7.F3O/;A%46QCAMSF,RJN]FWK
MN"-G)STKHKOPEJ6F_"/2_#N@Z/:6\RPVUK=V):$;8@ )RIQY;2'&<MD')SGI
M1NFWUM_7R#9I&9I?PQ\)>#O'GAS4[2_U2:]NI[AK"U6=9;3S/L:QS2D!>,QP
MIDYQNZ 9J_XD^'_A[0]4UWQ7=ZGK-I;Z@K&\TVTN";>>>2$6PD$*KEY2A557
M)7.#MSS6)X!^'OB3P:UC=S:?!>S6D=]+'9K?1J!-=7:9 8(%"I!&IX4 DD <
MUW_CJ;Q''I]O%X9LH[JXEG"SSM+$CVT6"2\:R$*SYP!DX&<D'&"2U2".CT/$
M_$'@#POJWAZ2PTT>)3XEL])N/#6FZ)>!6DA?[$(S(ZK_  >5)&S8?9E@=NXU
MJ:3\/_!LVE^#EFO/$>H7/B"XFEBU&-MI\]M/:VD61L QA(D<* ,@J,DUUMMX
M6UWP]K5OJ^BZ&LMQ/I<MI(-1U)#-!=/,'-Q,XR)0P5<[.1L   Z6='\&ZEHO
MB3P78I8M<:#X?T^XC;4VN(P9+J554OY6=V,>9^+CMDT]]^N_X_U\PN^G3;YV
M7]?,X[3OA;X/\*>(],TV-_%27/\ ;$+V^K2)&MNUW'9-"(=P0 JT&\'"8SGY
M@:V-.^#?@_P[KV@:1;W&K2WUG%8W<*^8K+%%8>8L+S':,!C*P/\ >(XQ@UMV
M7AG6M9^(&D^(=5TQ=)DTU+B.5DU1KJ"ZWKL3R83Q%C[Q<A6ZKR"35#QMX-\0
MZU>^+/[/B;;?RZ64=98T-Q:Q;O/MU+@J#NR<.-K!\=Z+O1_UV0:;=+'IRW$4
MBATEC="NX,K@@KZY]/>L_P 0>)+'PWH]]J5W(7@LPIF2##R L0JKMSU)88'O
M7DL?P=UR'4-(6VBMHM*GMKK^V()IT'S&=;B&W18D5!&[J VP *NX#.:K>&_A
M+XHDU\ZCJ]I:V<=W-IYO88YX2K"*=[B=@L:#(,@B5=Q9MN<D<BA=+B\SW;<N
M[;N7.2,;AU'4?A65J'BC3=,O=(M9KA3)JLLD5LT;!D)1"[$MG   QGU(%>2-
MX!\;O:QJ=(L?,MH+M"9+V*0W4MW=A[B55(VJ1",*'ZEL$<<Y^F_!WQ#9I!%>
M>'].U:)DU1HX[N[A,5C/=2(L<FP1JK!(8Q]Q0=S' [U([(]N3Q%9/KE_I6\I
M<V-O%=7#R +$B2,P0%B>IV-QZ8K2KQ'6/A/XE:X5HRNIVBW"1/;O- 6N(8;.
M."WDD$Z.C /YS%2"07!&2*];\+Z*OAOPWI6E*\DBV5M';AI'WL=J@<M@9_(?
M051)IU);_P"OC_WA_.HZDM_]?'_O#^=(#RW]F3_D@?@S_KVF_P#2F:O3J\Q_
M9D_Y('X,_P"O:;_TIFKTZD-[A1113$%%%% !1110 4444 >:_$G_ )*U\&_^
MPEJG_IMEKTJO-?B3_P E:^#?_82U3_TVRUZ52&%%%%,04444 %%%% !1110
M4Z/_ %B_6FTZ/_6+]: /,?V??^1-U_\ [&W7?_2^6O3*\S_9]_Y$W7_^QMUW
M_P!+Y:],I#84444Q!1110 4444 %>:P_\G.77_8D1?\ IQ>O2J\UA_Y.<NO^
MQ(B_].+T#/2J***!!1110 4444 %>;_M*_\ )O?Q%_[ L_\ (5Z17F_[2O\
MR;W\1?\ L"S_ ,A0-;GHT?\ J8_]Q?Y"G4V/_4Q_[B_R%.H$%%%% !1110 4
M444 %%%% !7%?LD_\G!_M)?]A71__2&NUKBOV2?^3@_VDO\ L*Z/_P"D-)E(
MH_$__D_;3/\ LFS_ /IR-;OQ \2W?AO3=-73FLUU+4M2M].MVOL^2ID8EV8
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MFB::*%M&MP712 Q'&#@LN>_-6?\ A'_$O_0Z2?\ @GMJ .EHKFO^$?\ $O\
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MJG_IMEKTJD,****8@HHHH **** "BBB@ IT?^L7ZTVG1_P"L7ZT >8_L^_\
M(FZ__P!C;KO_ *7RUZ97F?[/O_(FZ_\ ]C;KO_I?+7IE(;"BBBF(**** "BB
MB@ KS6'_ ).<NO\ L2(O_3B]>E5YK#_R<Y=?]B1%_P"G%Z!GI5%%% @HHHH
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MQW,\;+,B6$6T2([(^W*]-RG'MBMP>$]!'(T'20?^O"'_ .)IOMV!/JSQ+3?
M=]9ZM;:HWB#3+F_:T6;S9M9ACBM[EH9/.B= ID>-I9"V%D4>O*BJ_A[X7D7#
MMK&IZ.;..*\:ULXM=B3R99H($!4Q*JK\T<I!"G;N!^8DFO=?^$3T'_H :3_X
M 0__ !-'_")Z#_T -)_\ (?_ (FEW%?;R/,O!NFR:3<^%K:]OM&M;?2KF]NO
M,M[ZW.V)XA''"Q0JK.S,S'8JKA%XS7J/_"1Z/_T&=-_\#(O_ (JH_P#A$]!_
MZ &D_P#@!#_\31_PB>@_] #2?_ "'_XFFW<1)_PD>C_]!G3?_ R+_P"*H_X2
M/1_^@SIO_@9%_P#%5'_PB>@_] #2?_ "'_XFC_A$]!_Z &D_^ $/_P 32&2?
M\)'H_P#T&=-_\#(O_BJ/^$CT?_H,Z;_X&1?_ !51_P#")Z#_ - #2?\ P A_
M^)H_X1/0?^@!I/\ X 0__$T 2?\ "1Z/_P!!G3?_  ,B_P#BJ\W^-6O:7-+\
M-_+U6PDV>-=-=MEW&=JA9LDX;@>]>B?\(GH/_0 TG_P A_\ B:\W^-/AG189
M?AQY6BZ;%YGC734?991+N4K-E3A>0?0\4 >F?\)'H_\ T&=-_P# R+_XJN \
M4:;!?^,EU72]2TVVN)?LBMJR^(-GDI%(S.C6P.V3<K,HS_>YQBN[_P"$3T'_
M * &D_\ @!#_ /$T?\(GH/\ T -)_P# "'_XFCK<##\/S6-MK_B#6M1UG2C>
M:A.L-ND=_&PALXAB),YZDEW;W?':NDM_$FC^?'_Q.=-^\/\ E]B]?]ZJ_P#P
MB>@_] #2?_ "'_XFGV_A+0//C_XD&D_>'_,/A]?]V@#@OV8R&^ /@L@Y!MIB
M"._^DRUZ=7F/[,:A?@#X+   %M, !T'^DRUZ=2![A1113$%%%% !1110 444
M4 >:_$G_ )*U\&_^PEJG_IMEKTJO-?B3_P E:^#?_82U3_TVRUZ52&%%%%,0
M4444 %%%% !1110 4Z/_ %B_6FTZ/_6+]: /,?V??^1-U_\ [&W7?_2^6O3*
M\S_9]_Y$W7_^QMUW_P!+Y:],I#84444Q!1110 4444 %>:P_\G.77_8D1?\
MIQ>O2J\UA_Y.<NO^Q(B_].+T#/2J***!!1110 4444 %>;_M*_\ )O?Q%_[
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MJG_IMEKTJD,****8@HHHH **** "BBB@ IT?^L7ZTVG1_P"L7ZT >8_L^_\
M(FZ__P!C;KO_ *7RUZ97F?[/O_(FZ_\ ]C;KO_I?+7IE(;"BBBF(**** "BB
MB@ KS6'_ ).<NO\ L2(O_3B]>E5YK#_R<Y=?]B1%_P"G%Z!GI5%%% @HHHH
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M &9J!H])KSGQE\/;^]\8:;XH@\21V,5I>V\\Z7MO"8[>WB20%4D89 +/D@D
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M?\\=0_\ !Q>__'J/^%:Z!_SQU#_P<7O_ ,>KIZ* .8_X5KH'_/'4/_!Q>_\
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MW!6XNUA6+[.@,1!0,3YOF1N(T4#Y"BDGDUZG10#=PHHHH$%.C_UB_6FTZ/\
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M +"6J?\ IMEKTJO-?B3_ ,E:^#?_ &$M4_\ 3;+7I5(84444Q!1110 4444
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M*Z/_ .D-)E(POC1H5CX@_;LTJWU"%YH5^'+R!8YY(3N&HL,YC93W/&<5U?\
MPK+PU_SX7'_@SN__ ([6'\3_ /D_;3/^R;/_ .G(UZ'0@9S*_#'PTS ?8;CD
MX_Y"5W_\=KR73O&/@T27%QJNDK!I<+70FET[6K^[GL_)G\E?M$0(V^8<;0I)
MR<>]?0*MM8'TKFO^$!TW_A$6\.>9<_V>US]J+;QYF_[1]HZXQC?[=./>J6^H
M7T.%O-1^'>D_:3J-IJ,'E33IMBGU&1T2&.-Y7E4/\FQ95)[#U)R*GGO/AM:Z
M;]OG@U.WM5N3:2M--J"&!P%.909/D7#H03U##%:7C/PEX8L9KVXU.XU(W&MO
M>QBVL4:>:5KB*-9O+C1"QVI"ISSMY)ZU6U'X6^$O'=F=475[EK/4"]T7CFBV
M.KI$C$!T.S A7YAAA\PS@D4D,JVM_P##*\:Z$::@!;N\9=Y]0596298'6,F3
M]X1(ZJ=N>M2:Q#X,T#Q==Z+?Z-JD,-M80WKZ@+R]:']Y/Y*ID2==V.??VJU+
MX%TK4/%'AG2[:X62+PS<2:XXDD8RN;AI3&G"A&C+Y?KD&)..];OBCP/I7BB\
MN[VYU.:V\ZT73IO(FC"#9,)HVRRG#K)R!G!S@@T=K_U_3%W_ *_K0Y/5K_X9
MZ+-)'<Q:D3$\J2M#+J$JQ>5*(7+%7. )&5<]\C%2+<?#=O(!AU*-I'9)5DGO
MU-H1+Y1^T?O/W(\SY<MC)K4F^%>A6-C=BZO]3NVO&DCFF:16E=I;M)V.%3 _
M>*O08"Y^M1V/@/PMXJ^V:EIVK7$UI>7<W]H1P3IY=T1<F1HI,KD*LH;&T@D$
MC)!H[ 4[?_A7-UX/?Q0D.H#15D\I9Y+F_1I&+B,!$:0%LN=H(X)[UG:M=^#M
M,O[&"/0=4O1=W5E;;8KN_$T(N!(0\B%_E \H\9SUSCOZ'%X+M+?P9#X9AN+B
M*RAA$"2G8\FT'/S!E*,#T(*D$=JPK'X-Z-IMK;Q6MYJ$3P36LZ2[T8AH&D*_
M*4VA3YS@J!@ @+MP*>EQ7T*7A:S^'7C26\CT@SW+6BK))G4+Q<QL6"R+F7YD
M.UL,/0URYU308X]'O)/"&H#2M1M_M2W$>JWSMY;,XCQAMF<!"RLRG,JA=W->
MF>#/ .G>!H9X-/DE>T=5CCMY$B58HP3A 412WWL;G+-@ 9XJ&W^'=G_PB=AX
M>O+F>ZTZQ$B1(K>7N0AEC#8ZF-6X(QRH/6EZ#,)?#?AR'4O#MK<:1(JZQ%*!
M-!K5U*D5PB!S%D2X8%0_S#NF,<UT/_"LO#7_ #X7'_@SN_\ X[5;0/AG9>';
MK2&@NI9;;3I+BX2*1$7?<3*$,F$"JH5 0%50,L3UKL*8CF/^%9>&O^?"X_\
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M!5@0001D$&M"W_U\?^\/YT >6?LPJ(_V?_!2KPJVLH'.>!<2UZ?7F/[,G_)
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M110 5Q7[)/\ R<'^TE_V%='_ /2&NUKBOV2?^3@_VDO^PKH__I#292*/Q/\
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M!^#/^O:;_P!*9J].KS']F3_D@?@S_KVF_P#2F:O3J0WN%%%%,04444 %%%%
M!1110!YK\2?^2M?!O_L):I_Z;9:]*KS7XD_\E:^#?_82U3_TVRUZ52&%%%%,
M04444 %%%% !1110 4Z/_6+]:;3H_P#6+]: /,?V??\ D3=?_P"QMUW_ -+Y
M:],KS/\ 9]_Y$W7_ /L;==_]+Y:],I#84444Q!1110 4444 %>:P_P#)SEU_
MV)$7_IQ>O2J\UA_Y.<NO^Q(B_P#3B] STJBBB@04444 %%%% !7F_P"TK_R;
MW\1?^P+/_(5Z17F_[2O_ ";W\1?^P+/_ "% UN>C1_ZF/_<7^0IU-C_U,?\
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MJ?:O%7CNQ_M9]26SU*(10RW(E:V5K>-F0 ?=7<6X['-=O;_Z^/\ WA_.N/\
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MX?M/'7Q,U#PA9Z##K<OB63P[J5Y#)'X@^S0Z5=#6YXUGNAOVW2(H$>P*^0N
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M_LQ?$UX[.W1QH5SAEB4$?+]*]JKQ_P#:_P#^37_B=_V KG_T"@$>H6^C:?\
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MGBA-P;];LR(%FR<A2G[TR<_/]XFNZF^!-Q+\%?'?@3^V(A-XEN-6F2]^SG;
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M/_)Y=U_V(,/_ *<9: /:**** "BBB@ HHHH *\?_ &O_ /DU_P")W_8"N?\
MT"O8*\?_ &O_ /DU_P")W_8"N?\ T"@:W/7+?_CWB_W1_*I*CM_^/>+_ '1_
M*I*!!1110 4444 %%%% !1110 5\V?L[_P#)TO[3O_84T3_TW"OI.OFS]G?_
M ).E_:=_["FB?^FX4#)+G_E(C9?]DPD_].@KVGQUX-_X3:UTJTDN1!:6NHPW
MMQ$4W?:%CRPCZC'S[#GG[OO7BUS_ ,I$;+_LF$G_ *=!7H'QX\03Z;I?AO2[
M6;5(9-7UF""8Z(LC7?V:,-/,4$?SX*Q;25YPYI;V7H/_ ".2\/\ [,VH^%?#
M,5EI_BUY-573H;&74)[=U>YQ<"2XW%)%95DC2&$;&!18A@TSP_\  G3_  OI
M_B6W?Q/9MJ.K6UUHT<]M:D?9+B[E>5QM,C,"5: ;2V<1 D\C'-:M'\2)I--T
M:QM_$M@$U&*>RO)GN9REK/>9"S2*X7,,"G=YS2']X!L."U6;+1_&6AZ'J&H>
M%M-URTUF^U#7=:O(;PSD-,NZ&SBVR-A@4D1U5?E?R1UP*J_5^?Z7_-BZV7=?
M\#\D>@Z%\$[R+Q)9:UK6JV-[)!J,5_\ 9;6Q,4*+#9FWMXDW2,0(V>63<>26
M'3&:E^*'PI3Q_P"--+NQJ]M#)'IT]E-IMTTV7MY'0R2((9HR3PJD-N4Y7(]>
M&T;0_&5U'917-[XEGT::[GU"X6%KVUFV06A40[IF\X">:16V?*,QMM %9$GA
M;Q'YMSJ-\WBJQ\36_AK2=-BU:&VN[P%G9Y;O<D;C?R(XG*?O5QO'/S4W>]W_
M %I_2?7J*.VG]:_TSV+PMX:;P?-XCT,:Y:0:AKEQ<:AI@A@*RP1".*)?E9B'
M\H"(<8& N17(>%_V<KW3=1.HZKX@AO[V:?3)+F2.WES.MH\DI#-),Y)DE=')
MZ#8% QBK?PYL]8U_Q%X1FU/3+W3)?#NF7#WGVVYDN2+BY90D*RR?,X6-"YR2
M5WQJ22#7L]&S3Z_Y?U\Q;IK^M?Z^1SUUI_B:;P3/9QZO8P^*'MV1-36R;[.D
MISAQ"9"2!QP7YQ^%<%:_!W6HM"@C.H:5%KEGJD&K1:@+::8W<T:LI^U%Y2SY
M#G&UAMXP,#%>O45/6X_(\H\0?"+6M1\(W^FVVL:?)J>M:G%J.LWE]:2-'.$>
M,B&-%D!1-D*1C+,=N3R377:AX+?6O&^E:YJ-VL]EI,+&RTY8\*ET^5>X8Y^8
MA"448^7>YY)&.IHIW_K\ .+\<>!;GQ5X@T._@O19QV=O?6LQ&?,"W$(0/&<8
MWJRKU[$UYK'^S%=IX'32(-?M]+UB%[".VUBS@GDDBM[:3<5 FG?:S*SXVE54
MMG!Q7OU% [O8\1N/V>+Z;Q9::BNOVZ:?I4KR:1:FUD+6:_9&@@B'[W8%C9B^
M0@9S]X\9J>U^ >H6-YI\%OK]LNB6YTIIH6L2T\HL8\1QA_,VA#*%E^Z3G<.A
MKV>BB_\ 7H(^?+?]FG7EOAJ]QXIL;W7E^QYN+BQFD6X,%R;AC*&G)_>.(B0F
MU4V848K8\0?LZS>([&]6[UY&O+R"Y:>06K*CW4]Q!*[860,(MEM'#M#;MF?F
MSS7M=%"=MOZN'6_]:'*?#KP2/!.DW,4K02W]Y.;FZG@\XB1]JH,M-)([85%7
M);H.@KJZ**0!1110 4444 >+_L;?\FT^"/\ KA/_ .E,M>T5XO\ L;?\FT^"
M/^N$_P#Z4RU[10 4444 %%%% !1110 4444 >-?%S_DO/P(_["FK?^FJXKV6
MO&OBY_R7GX$?]A35O_35<5[+0 4444 %%%% !1110 4444 %%%% 'C?[+/\
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MH= P!_.C^OZ^X#2HHHI %%%% !1110 5XO\ M+_ZSX3?]C]I?_H,U>T5XO\
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MO1114C"BBB@#QO\ 99_Y$GQ7_P!CKXB_].EQ7LE>-_LL_P#(D^*_^QU\1?\
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M&,,3D8R'T;&O,]OL]6LM0N+F"VNHKB:VV><D;!BFY=RYQZJ0?H15NO'?@_\
M\)+X;\077AJ_TE4L(Q+-/>I:2QCS?W81Q.S%)5<%E5% ,:PJ&S7L5#\B4%>/
M_M?_ /)K_P 3O^P%<_\ H%>P5X_^U_\ \FO_ !._[ 5S_P"@4BEN>N6__'O%
M_NC^525';_\ 'O%_NC^524""BBB@##\3>./#_@W[*-<U>TTLW3%81<R!=^,9
M/T&1D]!D9-))XZ\/0ZW/I#ZS9)J<%N;J6V:8!DB R6/H .?ISTK@/B+'<:+X
M\U#59]%O]9L-2\-/I5NMA:/<D7'FNQB<*#L$@=/F;"_N^2.*Y#Q+\*M1TOP[
MH26FG7^JZS;Z5'<:E;^:S6;RQ6\<#JJC[TLH41D \QJ^ "P-"VO_ %U_RO\
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M_P"AET?_ ,#XO_BJ/^%A>%O^AET?_P #XO\ XJI_^$,\/_\ 0"TW_P  X_\
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MA;_H9='_ / ^+_XJC_A87A;_ *&71_\ P/B_^*J?_A#/#_\ T M-_P# ./\
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M_8V_Y-I\$?\ 7"?_ -*9:]HH$%%%% !1110 4444 %%%% 'C7Q<_Y+S\"/\
ML*:M_P"FJXKV6O&OBY_R7GX$?]A35O\ TU7%>RT %%%% !1110 4444 %%%%
M !1110!XW^RS_P B3XK_ .QU\1?^G2XKV2O&_P!EG_D2?%?_ &.OB+_TZ7%>
MR4#84444""BBB@ HHHH *\7A_P"3R[K_ +$&'_TXRU[17B\/_)Y=U_V(,/\
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MX_\ M&_$#PO?2?"S[/XDT>?R?'6FS2>7?Q-L0+-ECAN ,CGWKW3_ (1O2/\
MH%67_@.G^%>-_M):#ID,GPI\O3K1-_CS3$;; @RI6;(/'2@9ZA_PL[P=_P!#
M9H?_ (,H?_BJ\6\<:3H_B3XF'Q!!XM\,G_2+&:UOFU\1?8D@8,R/:KF.Y+$N
M5:0Y7>,8V@U[[_PC>D?] JR_\!T_PH_X1O2/^@59?^ Z?X4+1IBZ-'C/P[_X
M1[P?XON+R'Q%X9T72?+N%D@L_$1NO[0DDF$B2NDI B*#>,*3_K",X %>I?\
M"SO!W_0V:'_X,H?_ (JM3_A&](_Z!5E_X#I_A1_PC>D?] JR_P# =/\ "CHD
M/=MGE'[&C!_V9_ S*0RM;S$,#D$&XEP17M->+_L:@+^S/X' & ()P /^OF6O
M:*!!1110 4444 %%%% !1110!XU\7/\ DO/P(_["FK?^FJXKV6O&OBY_R7GX
M$?\ 84U;_P!-5Q7LM !1110 4444 %%%% !1110 4444 >-_LL_\B3XK_P"Q
MU\1?^G2XKV2O&_V6?^1)\5_]CKXB_P#3I<5[)0-A1110(**** "BBB@ KQ>'
M_D\NZ_[$&'_TXRU[17B\/_)Y=U_V(,/_ *<9: /:**** "BBB@ HHHH *\?_
M &O_ /DU_P")W_8"N?\ T"O8*\?_ &O_ /DU_P")W_8"N?\ T"@:W/7+?_CW
MB_W1_*I*CM_^/>+_ '1_*I*!!1110 4444 %%%% !1110 5\V?L[_P#)TO[3
MO_84T3_TW"OI.OFS]G?_ ).E_:=_["FB?^FX4#)+G_E(C9?]DPD_].@KZ/KY
MPN?^4B-E_P!DPD_].@KZ/H *Q?\ A"]#_L$Z+_9D']E&;[0;3;\GF>;YV['K
MYGS?6MJB@1YIX^T[P]I-]!8P>$8_$&N:_P#; +176(2QO'&+IY)&.%4JD*GN
M3M'O7.MJWP@\:(TNIV=JNI- VHW>G3QR&Y0,RP,)4CSNR\"IMY#-$, D UU/
MQ:6SLY]!U1=8NM(\06\DT.GFRL&OY9U= 9H_LZ@LZ[4#$C&W8#GL>:T?X3:!
M?^$[R?0O%<PM=8M+-S>MM(E6"669VE'REED:9]Z?*!R..11T'ON:&CV7A/QI
MXTT6+2U1M+\-PKX@LEAC0P//=-<Q>8&/SJRXGRO'+C/*XJ;7O$'PN\50WNMZ
ME<6NH1QP_P!E3W 28EHF)D"X4?.F5+K( 0-K,&&":F^&_P )=&^&T+VT.K&^
M2YTU+$1,L<>Z-9;B;<BIC_GX88' "BN:B^&-GXZ^%^FV47CQ[OPU#%&MHTEG
M$L7V3R3&D<R'&]@KJP+X 95.SU'Y?U?_ ( +?^OZW-=K?X6:7H\4%C;:3<07
M,KVRQB4GS-UU"\QW$G)\YXG.?O,5YYJIX=U[X4^.E&L?8[>VNK+4)WV7D,D,
MAE:],.\J0/,#SJ" 00&(X#5+IO[/FCZ??7137KJ1IK;3(8X&$>(3:/$[R* .
MLWD0[^WR#%55^$./'7A5_P"TUN=+T2_O]7:5I41Y%N)3)':N@R7"3LLH<XY1
M1@FKTNM2.C_K^NQZ@W@S16\,IX>&GQIHT:+&EK&60( <KM(.001D$'(-9J_"
M?PC'9I;)H=O'$CP2J4+*^^%F:)]P.[<&=SG.3N;.<FNK5E<94AAG'!].M.J>
MMRC#\.^"-#\)37DND:='8O>-NE\LL1U)PH)PJY9CM7 R3QS4.G_#_0M/TJVT
MT6*W%C:F8V\-P?,6)9=P=%!_AVNR@=E..E=%12 YC1_AOX?T"]TZYL++[.=/
M29;=/,9E5I2OF2'<26<A0NXDD#(Z5T]%% !1110 5XO^TO\ ZSX3?]C]I?\
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M (,X/_BJ/^%K>"?^AQT#_P &<'_Q5;_]DV/_ #Y6_P#WZ7_"C^R;'_GRM_\
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M<WD5]<>22HGDC?S$WCNN_P"?;T+<D<FNJHHH\@\PHHHH *\7_:7_ -9\)O\
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M0\9_8V_Y-I\$?]<)_P#TIEKVBO%_V-O^3:?!'_7"?_TIEKVBD 4444 %%%%
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M?#7_ ,'6H?\ R)1_:'[07_0"^&O_ (.M0_\ D2@#V2BO&_[0_:"_Z 7PU_\
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2[<6]MY)#-+&A); / [F@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>nbx-20211231_g11.jpg
<TEXT>
begin 644 nbx-20211231_g11.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" "; FP# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M'3VJVW[87Q,6!<_$CQ0867"9U1_F[>O\J]/UCXO?#/PE^W?IMY;:;#J7PO\
M Z#P_I,D%G'=&:*WMG@AU%HF"K</]H/V@JY^?@<\5Z?X9_;@^$_A;7K';80Z
ME--J6AKXBU>7PE:Q_P#"1VL%K=1WTXML,(#(TD"[%PS^7N)!R*Z*\J$%%PP"
MES13^%:7Z;;I;F%+V\G)2QK7*VMWK;JM4?,5I^UO\4+%&AM_B+XMW(N9D.JR
M-M[\Y;^=0Z+\6/B=\2O&$.GZ3XQ^(VK:Y>2^7!9:;JUX\UPYR=J1Q/DG )P!
MP![5ZW^U=^TI\,_BC^S!X-\*^"_#>FZ1JVD_9&E3^Q6AN=/,5LT<^;OS2LJS
M2%7VB,'NQ#+SZO\ #+]O;X3?"W6/!^IZ=;W4$FEK;);V<'AFWB?PDB:3/:W:
M"Y!+WGVJZ>)\L!M +'!X,594_JZG2P"YFVK.*TMLWIL_ZZ7JG*?MW"6-?*DG
M>[UOT6O0^7=,\:_&;4=5NM'L_$WQ<N+ZWO4TZ6"+5]2EFAN9&*1VS?.661V5
MP$X8E2 .#CFV^.7CFTN6CD\:^*!-$S1.9]8G9E8'!4[GSN!X.>:^@/V$_P!L
MG1_@KX6UJQ\7:Q?:?]J\:Z#XJ80:.EY]MCMII'NXRPP8W8&-E/3Y"!C<:]"^
M%?[>_P (;+9JGBSPYI=YXI;1%M+N_E\*I<0RF/4[V;[,8(GA&9+2:U7S,X_=
M%7R!DY5I>RK2@\O4HJUFHK6ZO?;;H:T^:I3C)XUQ;O>[??3J?*=C\</B7/IE
MY=6_BKQ@]I9[#=2F]FDM[<.P1/,))5-S?*N<9/ K'F_: \::QY:MXY\4-QA1
M%K,\6,>FUQ7M'['G[3OAWX2>!?'F@^(+NXTG2/$6L:/JD%M%I*:A#/!:WPEN
M+8ACN4/#\JDDCCUKT2Y_;A^%_B7X3_$K3=>\.Z;<:MXAU?4A8D^&(R]WI<Q0
M6,<+1R1);/;!9#^\5^2#\Q+ ]-:-.G5E!8!22:U26SMY=/4PHRJU(*7UQQ>M
M[OM?3?KI;U/GG2_VJ_BYK>D7%G:^//&U]9V,1GG$-_+-]DC3&978$F-5Z%L@
M<\GFL6S_ &G/B!#??:(?B!XH:XSG)U>5N?0 L1VK[-^(G_!0+X1F:\M/"%U=
M:)#J7A;5_#]SJ<?A&%7F\RY@FL1+$,!PL:S1L5VJK$D*%VUF^.OV_?A#XPAU
M[3[CPMIMYHMT=82&R3PO;6TDT)>RDT^+S%4,A'EW8+ Y4R DG/'''$1?O?V:
MK>BO^1TRIR2LL>[^KM^>Q\E7_P"UA\1[ZZ6YN/B-XJ:15V!SK$H SR1@,!G\
M*NM^TA\5K"UL]2;QKXXAAN'D6UN6OY_)G*8#A&)VMMW '&<%AWKZE^*O[?'P
MJN/'^M:MX/T'2;6XDTJ"VTRX7PBD+1K_ &O'<-#(LTDB,T=F)%\Q54'S"J\
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M56+;\8.2?ELYI?5ZOL\)@HS5M^5;WVT7;\3Z#+:TJ]+GQ&+E%WVN[VMOOW_
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MD9_ZD9._^77XL^??A#_P3>TGQI)<QZUXFUJQEME)6.VM8WR <'.X=:M>*/\
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M_+-D$-S@=?6ODOQ$C0WD<B_))&=RD'!%?2'P4^(W]LZ;I]K)\L_DJS%3\KG
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MT->E_L[77G>(M/CW?ZE67Z@=*\QU>Z\ZREBDSN4$$>_M5[X4^.6\*^*M.?\
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M3!CUQ1M'^2:L%.>C#\:#!CLWYUV*)B5]H]*^E_\ @CC&?^'H'P?./^8C=_\
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M[AS^(!K.HO>5Q?9/2[OP^\4$ML%WK;G:A'522,?Y]J9HM@@N8K74V?R[=MK
M#.!D<_E7:6ULEG>R.J"2UD=')ZE@/_UU)K.G0Z[<R.L:QAP%7D+@>]:QI*VA
MS.JWL6=?TZ:8V(TVW>;3UC7RCY;>7N[ENE:>E>';^YU&&UE@3[+,C;FC&W!
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MCVE5;&[CFN5T?5%TOQRMBUQ%OC5XGP^5DQC#8]QS^-%OK"IM1IH69APL9_\
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M_#!S7A-IX5UZ;3Q-;QR+9G'ER%"'(]=G7%6-$\."Q<LUU"]R?O-*C;_R)X_
M5UQ]Y71SRBEN?;'@CXXZUXZTBWD&FZD--= 3]FFC+R=!@G(;OT%=M'^T!<>%
M;9H9+'5C% BN#Y1D:('/!P?;.*\.^ NI_P#"*>!((FU2QO5N_P!_@$K]EZYC
MP<G(Q]*[N?Q%!;6,5U,KR133[YV4#<R^P[@  ?\ ZZSY>Q-CU"W^)/BZX DA
M\/\ B/RFP4<VCJKYY&,\<BJ?B_XC?$)(6_XIWQ-Y*]=EEN"CK1X6^*-JTEJN
MFZK#:V8W.J3*LR1@$<#Y@P&2,#/&#Q6M\0/V@(]%\-7$C76G76%)$B1O&!QW
M(+8/L#6/-(:C$\D\9?%[Q<;RU$.AW]BTF(S+)/!'O./0D\]N/_U<E\2%\4:)
MH-U>ZO>Z?:V[*PW0R&XN!G@ 'A"2Q&#S]#5GX?:Y>>(O$UO?:II6HWNGB[\Z
MWLXCM9'(.V0OUR&(XS@&J_QU^'>N?$J.XL]/NIK:WT\&[>W,1,P"C)B9P H/
MS9! R2.2:TIQON)Z;'@5WJL45XT=LK7=]*?GD/S/_P "/;Z"M/1O#<TF);IO
MF?G&.!4^@:)9Z#;;84^8G+,_WB??UJUJ>K20VQ9?F]!GK7H.RT1GJRP-.5(?
MH*R[R3[.Y XXP#3=)\:6^LVR[9!ELJ5SRI Y!%4_&^K0Z?IT<F[YF;*J/O/_
M /6K.4K(SV9A/K4B>.;>*4[H5C9A'GH>HR.]>;>*1'+XEO&B'[MIW(%=,VM?
M8S<:G)N:9]T-MD_>8_>;Z#I7)X)DW'<><_7/>M,'%M\XY6V*S1X/0?E3_*\S
M"]>W'<T^9E@C+'U 4'U/2O2_#'P4AU&*&9KCSBK#A!E<XSG'^)JL9C(4-'N;
M8;"3JOR1E>$O@7+KU@MS/-Y*,,JJ_>-:3?L^[C\LI51P-_4_I7K6A:-'I^GQ
M1>8?W2XR1RW_ -;T JZIM8_O,"?=L5Y/UBO/5R/5]C0A[J29\M[?\YHV_P"<
MU8,&/X:/(X^[7T1X97VT;>*U;#PM?:F5$-I.V_[IVX4_B>*Z&P^$L\C1_:+B
M.,MR54;B/SQ6,\13CNS2%&<NAQ(3=TKIO!O@Q;BZ2XO=WEJ00G\3_P"%=SI/
MPST^P(:.WWR#!#R9?'X=*Z"V\+0VZ;MJLV.XP*Y:V(<E:)TT\.HN\CAM#6X2
MR6S9&CMX9' 11M+#><9/TK<34)+:'RXU**O0 XQ5O4VAM+@QG]Y(_P R(!N)
M]:K'P;?ZZ<R2#3[9N=L9W2M]3T'X9K&/PV%4^*[,+4/$S)=^7'(LLAXX^;!J
M2"'4KU<CS@&&2-M==I/@C3?#Z?+!N;N[<L:V+:P6<#RUSV Q^F*HF4D=K\ +
MV:S\!1[TD^TP2-%&2,K*F2<$'TSBO9M"T]M-\+6UQ<1%6L7>21%.0P;&X_4*
MYQ]*XGX?>$;RV\)V]N7AM[BVAEN?+<#!0\G=QDM@C&/Z5]%^$Y=.@LH[>2..
M874:LK,%VSL<Y4@^W0>E<<NI48H=:MID<=F\5]9BSF5)%;)99>1@*>^>:O\
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MY ^4CU'4?45[+X&LO!.H_LK7UM]IATN2[TYTCA5\".X*G"[6'S*9./\ @7)
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M_CF2UC\S[':1K#;LX!<A<L=Q]<O@_2LOX^^)8;#Q1H<UO$(0EPRW+E1\[E6
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MFP8QY$2PQ#L0)&91^1-;W[*/Q-O%_:V\"Z*_ANTT7[=?2F7S[^&XN,+:7##
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M!SFG)M*Y"DGL>9^-/A!>>&KW;\UY:L25N(T(W+[CU]<?RJC80&,A(2;ANR1
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M<AED!R,=C7.^ OC9=:5;PZ/XLMUDDAPD-^6'F..@$H'?_;'7OSS7ZXV'[/\
MX&TG3?LEKX3T2WM0P<1):@*".0<?7FJ'B/\ 9+^&'BV-EU3P!X5U!&X*SZ>C
M9K-49+9FGM[Z21^<^G7A8KY+R*OWL2#<"/:M/7=4;PKI#27@LXYIAF%7;:[
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M7A7X;_"GQ=X=M-2T[0?#36-Y:17T/F6@MY/(D&8W:.0*\8;(QO4&M?3?@+X
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M9#&Y'W<=O\*^Z?V\?@CX)^$_P+_MGP_X5T'1]6.J6MNES;6RQ2%#YC,F1U!
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MB_YY1_\ ? H^RQ?\\H_^^!1[9!RG%;QZBC>/45VOV6+_ )Y1_P#? H^RQ?\
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M*3\GXXIFX@=>E1*UM2_:274_)_P+_P $^_ GB7P]#K;:-I:S32-/&(I+JV9
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;<21?O+.X5^A"IP?I7ZLN<4J'BKLTM!<S/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nbx-20211231_g12.jpg
<TEXT>
begin 644 nbx-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEYM_M)*^<OS\2B$L."4)&* /=J*^-1<?\%"/^?7]C7_P*\2?_&Z//_X*$?\
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M_GU_8U_\"O$G_P ;H\__ (*$?\^O[&O_ (%>)/\ XW0!]E45\:^?_P %"/\
MGU_8U_\  KQ)_P#&Z//_ ."A'_/K^QK_ .!7B3_XW0!]E45\:^?_ ,%"/^?7
M]C7_ ,"O$G_QNCS_ /@H1_SZ_L:_^!7B3_XW0!]E45\:^?\ \%"/^?7]C7_P
M*\2?_&Z//_X*$?\ /K^QK_X%>)/_ (W0!]E45\:^?_P4(_Y]?V-?_ KQ)_\
M&Z//_P""A'_/K^QK_P"!7B3_ .-T ?95%?&OG_\ !0C_ )]?V-?_  *\2?\
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M\.M?VT_M;)_PORW\Q4#$_P#">:WTR1_S[^QKO_U;R_\ Z&%/[I?Y%?ZRX_\
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MZQ_;5/\ S7Z#_P +S6__ )&KK_U;R_\ Z&%/[I?Y#_UFQ_\ T 5/OB?JSO\
M9ORIEO=K=1EE#8#LG([JQ4_J*_*C_AUI^VI_T7Z#_P +S6__ )&J.T_X);_M
MJ31$Q_'VW51(ZG_BN];ZAR"?^/?N031_JWE__0PI_=+_ "#_ %FQ[_Y@*GWQ
M/U?+;1W_ "J*:]2!U5MR[@3G'&!UK\J3_P $LOVUO^B_0Y[?\5YK?_R-61XV
M_P""7G[:#6$=K<?%YO$ECJ!:WO;&#QYJ>Z2W96WJPGCC1D;A&&[.USQUQSXK
M(<#2HRJPQL).*;LE*[\EINP_UFQ]K_V?4^^)^MR/',V0.?YU*!@5\3_#K]GW
M]JI_V&];\#GXA>$O!7C2QT.[T'PU,VF-=RQ 6^RRN)+Z.<E'1B%+B!V B#['
M)P?I']E+P-\1_AW\"]!TGXK^/-+^)/CBSB*ZCK]AH2Z+%>DG(S;I(Z;ESM+J
M$#X!\M.E?*PES13:L?68>JZM*-247%M)V>ZNMGZ'H]%%%4;!1110 4444 %%
M%% !1110 4444 %%%8OCSXA:-\+_  S=ZUXAU*ST?1[$(;B]NY1'##N<(NYC
MP,LRCZL* /)?VB?'_P 8O#OQ0^Q^"/#-K?>%UT3[0VH-;1W$S:CNF$=NJFY0
M[69;96)BVJDLCF1=F5CT;XB_%Z[\<+:KX?L;O3X;B_1I)[23389XDN=2$3&1
MF=E*Q1Z.%(!$WVNX8 >6_D=&_P"VQ\,8K-[F3Q1#';1HTAG>RN5B*!69'#F/
M!24*XA8'$Y1UB,C*0.E\4?';PKX+71VU34ULX]>C$UG(\$OEF,M$@DD8(5A3
M?/"NZ4H-TBC.3B@#S'P]\7_B]:Z9,]UX%_M6-9;989W LKBX,EO(\J/ ';R@
MEU$+82$E0MU%.Q,<4C29NE_M!?&2^\-3:]'\+I+FVO-*MKBPTXS^1<&Z:0EX
MW\S$B!D81[F0;702%1&S;?5-;_::^'N@:5=7UQXS\+&"SMY;J01:G#-*8XX?
M.?;&C%W(BP^U025(..16C'\;_!\]S9PIXJ\,23:@T"6J+JUN6N6G_P!2$&[+
M&3^ #[W;- 'G'_"[?BD^IR6:_#>!GLQ8W%W*-0+1B.YC9WBCX&^:W9&63G#!
MHF7[Y5+K>/\ X@>*O!7A_5TT?4/">IK#<CQ#HSP"\^QS?8S*D<<PC8SJDQ6/
MS8(Y%D(8JC<"N]\-_&?PGXSODM='\3>&]6N9)9(%ALM4@N)&DC4,Z!48DLH.
M6'4#DX%<GJG[9WPZT.S\Z_UJZL5\J>=H[C2+Z.:.."\CLI&>)H0Z 7,JH"RC
M=MD9<K'(R 'F<WQ;_:&TWR6OO!=D+<P)>-+9V:S.&-M)_H;QK<LP;[5"NZ1
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M\,1MC)\Y::VC2[GEVQ*C>;;QHS%79O3-.^.OA+5O"T>MP:YITFFLULAEWD-
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M.CM3C>+T>J3TT_ ^%[+_ (.7&OK..:/X)JT<R[USXPSC/;/V+''3CTIFJ?\
M!RFPLVDF^"XBC@*S,P\7DX",&_Y\O:OO"?\ X**? &TMY))/CA\)=L2%V/\
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M? 7Q!X(T>^D^,'PUTU[NRAE>TU#Q-96]Y:,R M%-$TNZ.5#E61N58$'D5Y^
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M\1/^"G?P'^'O@?5M:A^*G@/Q)-IML\\6DZ)XBLKS4=2D ^6"WA67+RNV% )
MYRQ"@D6_#?\ P47^ >I^'[*Y/QK^%<0N(5F5+CQ19Q3+N&</&\@9&&<%6 93
MD$ @BL\/7PL,55]KA')2LXPYI+D6VZU=_-;[6".1YS[>5)8Y\]D^7V<;I;7M
MV??N?GM;_P#!R+K2_$637&\"Z+-X5N+1-/B\,#Q&@O(+H3-_IOVD6V]@X(C,
M/EX"JCA@=X/5'_@Y+E^TQR?\*3&Y4(_Y&\]\?]./M7W:O_!0OX";O^2X?"0G
M_L;[ #_T;7,6_P#P5+^ \_Q?F\,_\+-\%QPVNEK>_P!MOKEHNBSR/)M-HEUY
MFQKE%"R-'UV2 C.UPKP=?"8?F6,PCFY2?+[THV3VBM[VZ-ZL<\ESF@TJF/:Y
MGI>G%:O6RUUV>A\>_P#$2E-_T1%!_P!S@?\ Y!KE_B?_ ,''&O\ BS3(=-\/
M^ ]&\%Z@MQ!>37FH>(EO([FWCE5I+4(UM'M\\ QF0$M&A<J-VTC]$U_X*&?
M,C_DMOPD_#Q;8?\ QVN;^+G_  5&^!/PV^'VI:O;_$[P9XGN+= L6E^'=<M-
M0U*[9F"XB@CDW-M!+MC[JHS'@5KFE?!SPTHT,$Z4OY^>3MWT:2^\>*R/.H49
M3K8YQBEK+V459=[GQEIW_!R\VH6,4\7P37RY5W+GQCG]?L53#_@Y4F'_ #1)
M?_"P/_R%7W5%_P %$/@#<1+(OQN^$K+(H93_ ,);8<@C(_Y:TX_\%"_@&/\
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M8=X;X@_8K^'/B*+QAYFAFWN?'EA)IFL74-Y-YTT+@Y"%G(C8%BRL@!5L,"&
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M*@'Y<@YM]^R]_P %A+[7+YM-^+$4%GYK>0M_JV@K<^3O81EUBM9$!(&>&/\
M0=E#-,32KU)4I2BY6<I?S/S?5HX,!C'0Q]=8>$H2GRRE.S2F]5OU<4E\G8^T
MY/\ @W%^ ,3QM%JGQ(BDCD656&L6[8*D,/E:V*D9'0@TW7O^#>'X$7UVU]>:
MQ\2[NXN&AA+-JMK'D;]N<):J"<-C)R<*!QBOBMOV4_\ @LDBDGXO:6=HR%&L
M:-EO_)*MGQ/^R9_P4ZM/"MC>>%_&GB+3?'&K26W_  D6I:CKN@FSU I'M0A
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MD]"_X\9/^OB?_P!&O7+B,35KRYZTG)]V%:M.K+GJ.[[LM1Q^7NYSN.:KW/\
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M<UTE<W\(-<U/Q+\-=%U#6K&XTW5KNTCDO+>>+R727&&.S)*!B-P5CN4, P#
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M5Q_QZO?V7/%G@V;5?'5Q\(]8TWPS!-?#=+:W,D"[1YGEQ1$R.[!0 B*S,0
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M4=E^C&M,36P4JE.6'P<E%/WDY2;:MLG;1WUN3/#YW>/)CJ=NMX+\-3YAL_\
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M@68 [GP7^RGX4^%VHPW7AA-6T1H;B:X,=O?N\<AGDM))PPD+?+(;* $#&!O
MV[VS@ZA^PWX E\'MH-K!JMGILB3(\,5_)M(EN;2YF/S9_>.]E 6?[S'S'8F2
M65WS].\/?'R>*ZMY/$7AE9-/CM8X9Y($ U*8V\#7+MMB.R(327"QC:K_ +F(
MMN!8MJ:Q\./B'XQ\'Z1<:E>QV?B:RT2\L+Y=.UFZL[.\OG$*I=(D14;,BX=%
M<[U5T!8-DJ ;VG_LM_#K3_%S:]'X:TUM4;4O[7>>1#(9+SS;N19V!X9T>^N"
MA.2F\!<!5Q3L?V/?AWIL/ARWBTNX^S^%S"]A ^H3R1[H9Y)XFD#.?,9))IB-
M^?\ 6L#D8QP^A?"3XV:#K[2ZIXHM_$&FMJ5AJ,8M]4:WNK-8[B^EN[8+Y"QS
MQ3(;*$"0@*LTY 5K>!FZ?QW\)/'VM^,9=8T7Q!)H[7%]8%+1M5N9[&UACB<7
M,S0\!Y"9G"Q*5B9K>!Y P:1: )](_8@^&GABQ@M['19K,6MV]_;NE].7M[A_
MO2JQ8X)(!P?E)49!YS#I'["'PIT.Y,EKX;\MC MJ@^VW#+'&(&@P@+D+E7<D
MCDNQ<_,2:S;GPU\:OB)X'\-WK:EHO@_7O[.<ZS8I-]HB6YEN-/N!'%(BXQ!&
ME];"0ABZE6*@R'R[7@_X/_%;PAKMNB>/-/U#3+=8IF;4K>>Z>622YC-S;JAD
M#+%%:PJD$DDTLA>YF:3)"M0!S_[>?_!//PG^W^_ANQ\5:QXBT>+PMY]S;-I+
MP*TK3[%8/YL;\#REQC'4YKYTNO\ @W)^%,;QRVOB[QG<30W$,I@U..SN;*Y1
M9%:2*6..*)V22,,AVR(1NR#QS[3_ ,%,+C]I:%/!_P#PSBEK)?EKK_A(!*-/
M.(L1?9\?;./O>=]SGU[5\V_#O2_V[O&'BU=+^,2:DO@>:V>:>/0H=)^U7,Z,
MAAC$MJ?-A 8^9N!&?*"\AF%>EF&?8_+<AK5H5FZ<8R_=0;=25]'&,4KWE?2S
M\]#&'!F7YAB(XJLJ?.VM9.STVNO(]4^/G_!$OPA^TA\1[OQCXP\6:E;ZE)81
M6K+X=T^*P2X,6_;)+Y[7&YMA1 5V_+&@.0!CEKW_ (-N_A%>VDD:^-OB1'O&
MW(DL#QW'_'KW''XUYQ?ZC_P4R9[[[(+.\TV*>>*WNIK/P_:R7<*NRI,87PR%
MU ?:PR-V*D-]_P %/RW^HTO_ +Y\.<?K7=PW1Q669/1RW+<7&GAX02C!S=XQ
M:O9\R<E:]K/5;=!X_@;+<7B)8G$JE*<G=N^[^6AZ-=_\&Z'PKU/41=77CKXB
MS,D(@Q&=/08!RN?]&/W<MC_>/H,1VO\ P;G?"&:XN(_^$S^)&(64#]]8<Y4'
M_GVK+U73/VTX/@!INNZ5=:Q_PO.ZNXX-7@ETS3%TV73_ #7"6JE@+97@W^=Y
MPY;=<*"P9 .+AU#_ (*=^?-LM]+W;AORGAWK@8_3%<O"/$F88C"U*."Q#H0H
MU)TU&=XWY7\4+K6$MXM:,XX^&^2I6C"E_P"!,[_Q+_P;>?"Z\T*[@TSQYX^L
M]0FA:.WGN%LKB*%S_$T:PQLP'H'4_P"T*RM*_P"#<?PA'K2W'B+XD:U?6\D,
M=G##I&CP:<4VL2I9I7N P"[EP%7MD\"O.?B)I_\ P4?\<:0_A_Q58ZG-X?U:
M-OM9T+^Q(;H;"C+&)H'62/<V#D$9",O?%:5EKO\ P4ZU:PBG:UM8AY[)$+FV
M\.PROM9E#E"<KN W =@U>E+,,QKYA&4\6O:4E[L^;2TM&D[6;[KL>53X)R.I
MF$L'[&*<(J7->2@^9[)[-JR;]?)GK"_\&X7P@#?\CG\2/^_UC_\ (U<EI'_!
MMQH ETVWU+XIZA<:79W#33+:>'H[>\G5MV]1*T\BJ6)!)\MA\HXX&,3[?_P5
M _YXZ7_WQX<_QH^V_P#!3\#_ %.E_P#?/AW_ !KJQ<\RQ4Z=2OC82=-\T??V
M??8].7AMDLFFX4M/[S/0+'_@W+^$-U;,[>-/B0I621/]=8?PN5'_ "Z^@K/\
M3_\ !N!X%6XL+CPS\1/%&FW5K,9)&U73[;4(I!M(7:L7V<JRL=VXLWTS@UQ-
MI?\ _!3LPMY<&EA/,?/R^'?O;SN[^N:D:]_X*?!?FATO;_N^'?\ &ML5BLVQ
M-&6'KXZ#A)6:Y]T]UL.IX;Y-)6E"E_X$SKO"?_!N'\.[*-;?7/'_ (OU"\N&
MGG,NF6MK8VZ)N3:JQ2),W&\\[^<C  %6O%W_  ;9_#+4_#=Q#H_C[QQ9W\NP
M1S7T-G>6VW>I=7B2.)F#)N7B12"P/.,'K_\ A&/V@U_8L^PR:?<']HQK*34D
MUS^S8/[-%]]J5S:;?M/D?;?LI$8O_)^SA/W>_@QGQD7O_!3X=(=+(/<1^'?\
M:Y\'FF:SHO#PQBC&/NV<K72TTTO;S,:'A_DM1-*G!6TU;5_-?YG6:'_P;C>"
MVU#4[[Q-\2/$FHM/'&8DTG3+?3U5D#!F?S6N-^5V 8V8V=\\;<?_  ;C?"&5
M$;_A-/B1AAG!FL/_ )&KS:>__P""GP@?=#I>W:<_+X=Z?G2K?_\ !3XHH\G2
MMN./D\._XUM@<1FN#H1PV&QT(PBK)<^R^XUCX;9+&*@H4K+^\S>7_@VV\/K?
M1P2?%+4FT2/4C>&)/#\:WS1%B#'YWG&/?Y/[O?Y.. VSC%=+%_P;D_")[V6'
M_A-/B0%C16!$UASN+?\ 3K_LUY]]N_X*?C_EAI9_X#X=_P :BCOO^"G8O9-L
M&E^9L7=\OAWI\V._UJ<%6S/"<ZP^.A'GDY/W]Y.UWJGV%'PUR6.T*>NOQ,Z?
MQ1_P;:>$7U28Z#\3-:LK&ZL39RPZOHL.H2G<6\PJ\4D 5678-I0D%,[N<#Z$
M_:I_X)LZ;^UW\-?!GA7QAKFKZ?HW@Z6,V#:5J4\URG[I+41S-=>8MVQ0*WVF
M9?/5E< [9GKY9-[_ ,%/R?\ 4Z5_WSX=_P :AO;W_@IUY:^;!IFWS$Q\OAW[
MVX;>_P#>Q7)]5Q3QGU]XN'M;I\W/K=*RZ=CLPO N78>G4I4?9J-2RDN9ZVVW
MO^!Z=_Q#A?"%C_R.GQ(_[^V/_P C4?\ $.'\(1_S.GQ(_P"_MA_\C5YN+_\
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M-#_PF?Q(VB,/GSK#N2/^?;VKSW^T/^"H'_/'2_\ OCPY_C48O_\ @IY]L/\
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MY^T+^S-X?USQ%I.K:+XJMHVTW6+74M.FL6>[A #3JLB*?+E!24%<@>85SE&
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MR+]C_P!>\?\ Z"*]0YRUY:^E4U'_ !/'_P"N*_\ H35>JBO_ "''_P"N*_\
MH;4 7/)7=G'([U3UJ)5TZ3 ]#^HJ]5/7/^0=)]!_,4 7**** *>F?\?FH?\
M7P/_ $5'5RJ>F?\ 'YJ'_7P/_14=7* *>J?\?VF_]?)_]%25<JGJG_']IO\
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M/.D^.O#&CW\EKI>OP?#K6575K0@/%,0;I!YAC=1(%4*L@D4?=KEQ_P %??\
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MG1SVMOX6C^%VNMI][$9(]TLF'9VN!Y9\IDE"!&;*MORN!-_P5Y_X*GS-'O\
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MR#5M;T&S-N/%.+UOLU]/NS)Y[VQA#H[,(G#QHS1JC'ZJ(S5+7!BRC_Z^(/\
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M(?I0!<JK/_R%K?\ ZY2?^A1U:JK/_P A:W_ZY2?^A1T 6JKZM_R"KK_KD_\
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M=S[P",(N.2UG_@A7\:K&Q8V_[0MQ)=2#9 LLNI(GF8.,D3,1]<''H>E>!_\
M$15^WE_T99JG_A%^)/\ XFO7_P!@3_@M;^UW^U%^V7\/_ ?Q&_9:OO ?@OQ#
M?RQZGK\OA?7+-=-5+6:5&\VX B7=(B)\_!WXZD5X?#V98K)<OCEF"F_9QYK<
MUIR]YMOWI)RW;MKIT/1S3(,#F&*>,Q$/?=MFXK1)+1-+9:Z:GKUQ_P $GOB%
M!>:L;27P?#:KI5M;VT;ZK=74VJ2Q;58SS-;HPF?&]YSD,8+<;0Y:>/ZOT_\
M9GU*Q^,/A_Q3'KD=G#IEG;VUQ8VL#I%B*(1F*$,QVPMC.UMQ [D\CN/@?\6)
M?C/X*DUF;PSXG\),E]<V7V#7[06MX1#,T8EV*S#RY H=3GD-785Y.686& H+
M#X=OE2:]YN3UU=V[MOS/H98B<IN>EWV22^[H4]".;)_^OB?_ -&O5RJ>@_\
M'BW_ %\3_P#HUZN5U&!3G_Y&&U_Z]YO_ $**KE4Y_P#D8;7_ *]YO_0HJN4
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M3US_ )!TGT'\Q0!<HHHH IZ9_P ?FH?]? _]%1U<JGIG_'YJ'_7P/_14=7*
M*>J?\?VF_P#7R?\ T5)5RJ>J?\?VF_\ 7R?_ $5)5R@ JGH'_((A^E7*IZ!_
MR"(?I0!<JK/_ ,A:W_ZY2?\ H4=6JJS_ /(6M_\ KE)_Z%'0!:JOJW_(*NO^
MN3_R-6*KZM_R"KK_ *Y/_(T 3KT_$TM(O3\32T 4['_D+WW_ &S_ /0:N53L
M?^0O??\ ;/\ ]!JY0!3UC[EO_P!?"?SJY5/6/N6__7PG\ZN4 %4]"_X\9/\
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M5;C"L13M_P!HSP'<:JFG6WB"UN-0>.>2&SMDDFN+A8)9X9/*B52\FV2UF7"
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M[_LL^//!GB+7/#_Q'U#6O#OA>&.37]5M?"^K?9M!CF+)#)/NME<J\@V 1*[
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M%];?;_WUW*ZQ[XX&D1%+1%F;(.QQE=R,IJUI7[07Q5OGTFUF^%2VM_K%M]H
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MHRD%7=2'/EOPS_X*.^ ?'_AB34Y8_$&D-;"-+RRN;'SI["=K!;SR)/(,BB0
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M#)E2F]]S;O\ X)X_#IY9IK>TOK>;^S[C3[1/M!>WL!-'<HSQ1'Y58?:YF&,
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M1BJ$(D3DX4,P]#^*WP:TSXN:G:0ZK/>QKI\;21&W=4)+'!SD'^Z/2O+/'?[
MEOK&NZ;>:#XF_LN.QCF5H=0TXZ@'D? $BE)H=K!-Z\AN)&Z9K\VXBS+C6AC9
MQRC!T:M!)<KE4<9MVUTVWTWV/=P.'RJ=)/%59QGUM&Z_S-[PYXGU#1_B'XCU
M+6/C;H.M^'+Z*X73- 72[2U;2V9P8O\ 25D+S>6H*?,!NW9.,5G>"-0UW0?
M'B33]6_: \-ZUKNHQJFD:LOA^RM5T5@&W-Y"R%9\D@X<@#'N:/!7[".A^$/
M5M9ZEK&H:E>Z?%(HFMT%K"4#,8D$;&1@$CV)DNQ;9DG)K?'[%'A-3Q>:UQZS
MIC_T"O&_M;Q*^S@,-;_K[*_W6M^/S.GZMD7_ #^J?^ K_,Y&#QUJVL_#6;PI
M9_M!Z+#XYT:\2XO?$K>&;40W%O)O*P);LXA;:"H9T=BI3# %L5=\9ZKKVN:7
MH,.A_'SP_P"';[384CUF].A6=X-?D\N(&41O(!;\K(=J$C]Y_LBJ'AS]@F:S
MN="CU3Q997ECHYG\W[)HKVMU>><K&0&5KF15WS>7*W[LY,6!M!XZ>V_8O\)S
M75PC76N 0LH&+A.<J#_<]ZB&=>)4U=9=AUOO5E??1Z)[HFGA\DM[]:?RBO\
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M1B?*/'SG#O'?PW^)FL:SX/\ [#^)NFZ&NF6RKKBR^%([PZZZO#YCHQG7[+O
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MP^N:?<>%OCE+;R(=6\G>I7S$EM=R9[C*$9'49!&>H(XKA/\ @B]_P4$\1?\
M!1']D+PSXPU7P#XB\.V\>G16=UXBO[BT^R>)]4BS%?2V444C2B 7"2G?*D8R
M=JABK;?L-H]RXYKZ6/@SAT[K-,;_ .%#_P#D3@?%$W_S#4?_  !?YGX:?#'X
M?_MGW7_!8ZU\6Z]\1OB-8_"W4M5D^%%S\28O"FCL\EE;.]VEJ+4VYA1'U%C9
MIJ1MC&9I" 3N\NOW)LX_*M(UW,^U0-S8W-[G'&3[53FA_P")[:KN/_'O-S_P
M**KZ+M7'6OUW"T?8THTG)RY4E=VN[*UW9)7>[LEJ?-U)<TG*UK]$1:E_R#KC
M_KFW\C3K3_CUC_W!_*FZE_R#KC_KFW\C3K3_ (]8_P#<'\JZ"22J=O\ \AVZ
M_P"N,7\Y*N53M_\ D.W7_7&+^<E %RJ>N_\ 'G'_ -?$'_HU*N53UW_CSC_Z
M^(/_ $:E %RBBB@"GHO^KN/^OB3^=7*IZ+_J[C_KXD_G5R@"E??\ABQ_[:?^
M@U=JE??\ABQ_[:?^@U=H *I^'O\ D 6/_7O'_P"@BKE4_#W_ " +'_KWC_\
M010!<JBO_(<?_KBO_H;5>JBO_(<?_KBO_H;4 7JIZY_R#I/H/YBKE4]<_P"0
M=)]!_,4 7**** *>F?\ 'YJ'_7P/_14=7*IZ9_Q^:A_U\#_T5'5R@"EJG_']
MIO\ U\G_ -%25=JEJG_']IO_ %\G_P!%25=H *IZ!_R"(?I5RJ>@?\@B'Z4
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MZI90 6V+,]B[AN66*0 ,,(_IT8PG3'M0 R]3S+61<[0ZE23VS3H-JQ*H;=M
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nbx-20211231_g13.jpg
<TEXT>
begin 644 nbx-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M+EE"@$[BPQG- &A131(I_B'YTZ@ HHHH **** "BBB@ HHHH **** "BBB@
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MZQ<:CI>I0RPV:O=GS$B+1&&&2(PY80)&41S.V S84;CCV\=*$ 4444 %%%%
M!1110 5YW^T?\5[[X7?#]VT*WM;SQ5JTC66BVURK-"T^QY&EE"D-Y44:22O@
M@D)M!!85Z)7"_&#]GKPW\;6M)M;M]2^V:;#<065U9:I=6,ENLX42?ZB1-X.Q
M,ALCY?K2E>V@XV3U/)=,_:-^(/Q*\*^'?^$:;PGIFL?\(!:>-=5DU&PFN(;J
M2<-LM(D6=#"K-%*3(S2%1MPK<FO</@]\0H_BQ\*?#?BB*W:UC\1:7;:DL#-N
M,/FQ*^PGOC=C/?%>2Z9^P[_PB'A#P]I?ACQIKV@R:7X;7PIJ%T(4O)-4L@2V
M1YQ;R95=I"C*2J"0J%("@>T>"/"%CX \'Z7H6F0FWTW1;.*PM(BV[RXHD"(,
M]\*HYIQO;4;MT/E_]M[XK>%_$W[57[*_A[3?$F@:AX@TGXNRO>Z9;:A#+>V:
MCPIXB4F2%6+H 70$L!@NH[BOK:OD7]MKX.^$?"?[67[+/B;2_"OAO3?$FL?%
MV9+_ %:UTR&&^O5;PIXB9A+.JB1P61"0Q()13U Q]=4$GRS_ ,%0?@Q=?'ZT
M^#7AJSO=3TB[N/'RW-KJUBC-)HMU#I&IRVMY@<$17"Q-AOE;&T_>K _X)I>)
MO%_Q%T[]HS6?$'A_4/"GB[4/'S07-EM\M8KZW\/:1:S-;23(R/ ;B&1HI2KH
MR%6(;)%?8;1AO_UT",#_ .N:.X^;H>2_LUZ/\1=+NM4/CJ\\172-'$+0:GJ.
MDW85LMNV_8;"U(XQG>7![!>2?CWQ-<6&C>$_VP]%^&.M75[J>HZEI.HRR07E
MUJ%_<V?DV46K3HROY\A2,W"'RF#*5"(5(4#]'2@84TIG^]^=3*-QQ=CY*^ 7
MC[Q%H/[-?QL7X?>&?">H_P#"&M<_\(3J/AG0!I6F^+IQID4P:.U#.)&CN";<
MR([+*8<#!! \\\#?'7XE^"/A7??$V\\<?\)5X0\(:IH^HZQI.G7,VNWYMI(I
M[?5(I6.GVC(R>;:W*VR(SPO;2 D+(%'WSY2GU_.@IGU_.JZW!2/@?Q#^T5\2
M/ OB+X8:/>:IXVF\>37GAV]UJWN&MX]-N+;5]587,,5JD!DNEM;>1X'FWH(#
M#;MG);=Q6@_'KQE^SA^S5XHM8;[7M ^U>#?%EWX4MXM*>:2?7%\2:H084$3,
M\HADMWVD$&,[\%0S#]*Q%@8Q^O%.,>.F?SJ>70.;4_/O]H?]HCQ1XO\ B_XB
M\(Z3-XR>QN=&\2Z%KNF:BT,D,HCT">X@FBM8X?,@B>8((IWD!G!D&UN"O!>&
M=:\2>(?AW\*?#=AJWBCQAX5T&_\ A5=:@-1L-KZ!K2:W"EU:(%AC,>R"*-Y8
MFSY.U&.WS"3^H!3*]_SI3&,=S^-5'1\P<UM#XX_X)]_%+XH_$_XFR77C/Q#I
M^\Z5=_\ "1>&9=1EN+[1]1%V@AQ;FP@6Q1$\Z/89YA,OENI?:TC?9--$8/8_
MGFG4$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 -D^[7S-XJ^/VO:+\3O$T=GXLBOIM.\03Z4?"_D6C26UBNE)<_;$(
M3SD:.4EB\K/&RY3:&92/INJXTFU6X>86\/G2#:\@0;G'H3U(^M!4;=3YHO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4;J3>/44 +12;@>XI=P]: "BC=S1N% !12;AZBEW"@ HHW#UHW4 %%&ZC<*
M"BC<,]:-PH **-P]:-PH **3>/44NX4 %%&X>M&Z@ HHW#UHW4 %%&ZC<* "
MBC=1N'K0 44F\>HI=U !12;AZBEW#UH **3>/44NX"@ HHW4;J "BC<#1NH
M**-PH!S0 4444 %%%% !1110 4444 %%%% !1110 5Y7^U3XN\8:!X*M]/\
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MV[?EA98 B@[>=R-]X]*]"HH \]USX&7FM>!-)T5?'_Q L9M+=G?5;6\MEO\
M4 V[Y9V,!1@-W&U%/RCWSIZU\*[C6/B%I>O+XN\764.G(J/I%O<0+IU[C=\T
MR-$7).[G:Z_='2NOHH XS0_A)<:+XRUK6&\8^,KZ/5XY(X]-N;F!K+3=Y!#6
MZK"&5EQA=S-@$YS5#2_@3>:9\.]0T!OB!\0;R:^F65=8GO+8ZC: ;?DB<0!
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M9G\H$JS1L3&7C.P[1C!!% 'NE%%% !1110 4444 ?-'[?7_)>_V2/^ROR?\
MJ)^)*^EZ^:/V^O\ DO?[)'_97Y/_ %$_$E?2] !1110 4444 %%%% !1110
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MU_X)U[0O%E]J>FPP3R36,,#0L)8Q(H!>52< \\=:\]_X?]_"D'_D5_B!_P"
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M:ZIZW/+C@ZSK/#J+YUI;KH?4E%?F\/\ @YH^#2\?\(3\3/\ P&LO_DFFR?\
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M"QW-J6,OVADW6XMA=A@K@AVB)XY'H'P#U#5M5^$VD7FL>7]MO?-N J2Q3>7
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M?_2B2O[:CTK^)7XF?\E-\3?]AB]_]*)*SJ$R,6OUG_X,_#_QG=\3_P#L0O\
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MUOKR&UNM8MVMK&.1L-=2@^847U(56/T!KN?C+\;?"?Q#\!>+-!T37].U36-
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MY=XA?\C&/^%?FSZ[AO\ W7YG\<]A_P >,/\ US7^52G[PJ*P_P"/&'_KFO\
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MTH?[W^?>O\_NI^Q]#Z:_9)7/PEC'_3W-_P"A5^7'_!T)_P EL^$F/^@%J/\
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MCX[_ /!-#X2?M(_$R\\6>+-#OK[6[Z.**::+4YX%98T")\B, , "N1_X<O\
M[/X_YE?5/_!S=?\ Q=?K.3\<8'"X.GAYQE>*2>BM^9\ACLAKUJ\JD6K-GY<_
M\$Z!_P 9U_"G_L8(O_07K]Y-5;.F77_7)OY&OGWX8?\ !*3X+_!WXAZ/XJ\/
M^']0MM:T.Y%W9ROJUQ*L<@R 2K,0>O0U]%S6:S1,K!6##!SWKXGC3-J.;U.;
M#W7N..O?7_,]K)<%4PE-QJ=[Z'PM&V$6G%Z^KC^S5X-9L_V/'USQ*_\ C0W[
M-?@T#_D#1_\ ?U_\:_S5K_1-XFG4E-8BE9MO>7?_  G[K#Q#P:BDZ<OP_P S
MRG]CW_DH>HG_ *AY_P#1BUZI^TQ_R1?5O^V7_HQ:V/!WPET'P#J$EUI.GI:S
MS)Y;L'9B5SG')]16/^TP"/@UJWUBQ_W\6OZ$RC@G%\*>&6,R?&SC*<:=9WC>
MWO)M;I/\#XO$YI3Q^>4\3232<H;^5CY3CY'X4/U_*B+I0_7\J_S-^T?NTMCZ
M<_9&_P"23Q_]?DW\Z_+7_@Z!_P"2U_"7_L!:A_Z4PU^I7[(W_))X_P#K\F_G
M7Y;?\'0/_):OA+_V M0_]*8:_P!EOH__ /(@RK_KS'_TD_#:?_)03_Q2/S#'
MW_R_K45Q_P >3_0U*/O_ )?UJ*Y_X\G^AK^G)? ??S^'Y']5?[/W_) _ _\
MV+]C_P"DT=?SX_\ !9#_ )2@?%[_ +"=M_Z0VU?T'?L_?\D#\#_]B_8_^DT=
M?SX_\%D/^4H'Q>_["=M_Z0VU?FG!_P#R,)^C_-'YUPM_OT_1GS0W^KKW+_@F
M/_RD4^"__8V6?_H5>&O_ *NO<O\ @F/_ ,I%/@O_ -C99_\ H5?H.8_[I5_P
MO\F?<9A_NU3T?Y,_I=U/_D&W'_7)OY&OYL6_ULG_ %T;^=?TG:G_ ,@VX_ZY
M-_(U_-BW^MD_ZZ-_.OG?#?XZ_I']3^<.*=J?S_09-U/^Z:_1C_@WJ_Y&_P"*
MO_7EIO\ Z'=5^<\W4_[IK]&/^#>K_D;_ (J_]>6F_P#H=U7U7&W_ "**GK'\
MT>1D/^^P^?Y'T%_P6_\ ^3!]1_[#6F_^CQ7XSQ_U/]*_9C_@M_\ \F#ZC_V&
MM-_]'BOQGC_J?Z5Y_A[_ ,BU_P")_DCIXF_WI>@25^SG_!$S_DP/1_\ L+ZA
M_P"E!K\8Y*_9S_@B9_R8'H__ &%]0_\ 2@T>(?\ R+H_XE^3'PS_ +T_1_H?
M.7_!PI_R4CX7_P#8-U#_ -&05^=UO]W\*_1'_@X4_P"2D?"__L&ZA_Z,@K\[
MK?[OX5ZG!O\ R**/S_\ 2F<N>_[Y+Y?D36/_ "$[?_KLO\Z_I)T[_CT@_P!Q
M?_0:_FVL?^0G;_\ 79?YU_23IW_'I!_N+_Z#7R'B5\=#_M[]#V.%?AJ?(_#G
M_@K%_P I%OB9_P!=['_TWVM?/"=!]!7T/_P5B_Y2+?$S_KO8_P#IOM:^>$Z#
MZ"OT#A__ )%M'_#'\D?.YE_O,_5_F?1'_!)\_P#&PGX<_P#7>\_](KBOV&_:
MY_Y-)^*/_8H:K_Z1S5^//_!)\_\ &PGX<_\ 7>\_](KBOV&_:Y_Y-)^*/_8H
M:K_Z1S5^7>(7_(QC_A7YL^OX;_W5^I_%[8?\>,/_ %S7^52G[PJ*P_X\8?\
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MZ7KYH_;Z_P"2]_LD?]E?D_\ 43\25]+T %%%% !1110 4444 %%%% !1110
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M7YIP?_R,)^C_ #1^=<+?[]/T9\T-_JZ]R_X)C_\ *13X+_\ 8V6?_H5>&O\
MZNO<O^"8_P#RD4^"_P#V-EG_ .A5^@YC_NE7_"_R9]QF'^[5/1_DS^EW4_\
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M\Z_I)T[_ (](/]Q?_0:^0\2OCH?]O?H>QPK\-3Y'X<_\%8O^4BWQ,_Z[V/\
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M5+=[QK=9XFN(T$C1!OWBJ20&*]<$JP!Z':?2IA(K'_ZU #J*;YJX]/PIV<T
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M5^SG_!$S_DP/1_\ L+ZA_P"E!K\8Y*_9S_@B9_R8'H__ &%]0_\ 2@T>(?\
MR+H_XE^3'PS_ +T_1_H?.7_!PI_R4CX7_P#8-U#_ -&05^=UO]W\*_1'_@X4
M_P"2D?"__L&ZA_Z,@K\[K?[OX5ZG!O\ R**/S_\ 2F<N>_[Y+Y?D36/_ "$[
M?_KLO\Z_I)T[_CT@_P!Q?_0:_FVL?^0G;_\ 79?YU_23IW_'I!_N+_Z#7R'B
M5\=#_M[]#V.%?AJ?(_#G_@K%_P I%OB9_P!=['_TWVM?/"=!]!7T/_P5B/\
MQL6^)G_7>Q_]-]K7SPG0?05^@</_ /(MH_X8_DCYW,O]YGZO\SZ(_P""3_\
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M_/7_ (/)?^2V_ '_ + FN?\ H^QK]"O^#;[_ )0S?!W_ '-5_P#3M>5^>O\
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M'_L4-5_](YJ_'G_@D_\ \I"?AS_UWO/_ $BN*_8;]KG_ )-)^*/_ &*&J_\
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MLFA_,N.E!ZT#I0>M8F9_5%_P;??\H9O@[_N:K_Z=KROSU_X/)?\ DMOP!_[
MFN?^C[&OT*_X-OO^4,WP=_W-5_\ 3M>5^>O_  >2_P#);?@#_P!@37/_ $?8
MUM+8TD?C/4=S_JV^E25'<_ZMOI64=S,_MY\*_P#(L:;_ ->L7_H J_5#PK_R
M+&F_]>L7_H J_6YH%%%% !1110 4444 %%%% !1110 4444 -D8JO%?+_P"U
M+XGU;XP2^"='L?".LMJEQJ]Y(OA77KQ=+MO$$$-HV^1YX)7VI$TL;("&W/\
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MX]_9D\'^+?#<7Q\TOPWJ&J7%I.VD'4](>^:. .GF[2JMM&XKD'K7U-7Y#_\
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M80^?Y'YA#[_Y?UJ*Y_X\G^AJ4??_ "_K45S_ ,>3_0U^M2^ _59_#\C^JO\
M9^_Y('X'_P"Q?L?_ $FCK^?'_@LA_P I0/B]_P!A.V_](;:OZ#OV?O\ D@?@
M?_L7['_TFCK^?'_@LA_RE ^+W_83MO\ TAMJ_-.#_P#D83]'^:/SKA;_ 'Z?
MHSYH;_5U[E_P3'_Y2*?!?_L;+/\ ]"KPU_\ 5U[E_P $Q_\ E(I\%_\ L;+/
M_P!"K]!S'_=*O^%_DS[C,/\ =JGH_P F?TNZG_R#;C_KDW\C7\V+?ZV3_KHW
M\Z_I.U/_ )!MQ_UR;^1K^;%O];)_UT;^=?.^&_QU_2/ZG\X<4[4_G^@R;J?]
MTU^C'_!O5_R-_P 5?^O+3?\ T.ZK\YYNI_W37Z,?\&]7_(W_ !5_Z\M-_P#0
M[JOJN-O^114]8_FCR,A_WV'S_(^@O^"W_P#R8/J/_8:TW_T>*_&>/^I_I7[,
M?\%O_P#DP?4?^PUIO_H\5^,\??ZG^E>?X>_\BU_XG^2.GB;_ 'I>@25^SG_!
M$S_DP/1_^POJ'_I0:_&.2OV<_P"")G_)@>C_ /87U#_TH-'B'_R+H_XE^3'P
MS_O3]'^A\Y?\'"G_ "4CX7_]@W4/_1D%?G=;_=_"OT1_X.%/^2D?"_\ [!NH
M?^C(*_.ZW^[^%>IP;_R**/S_ /2F<N>_[Y+Y?D36/_(3M_\ KLO\Z_I)T[_C
MT@_W%_\ 0:_FVL?^0G;_ /79?YU_23IW_'I!_N+_ .@U\AXE?'0_[>_0]CA7
MX:GR/PY_X*Q?\I%OB9_UWL?_ $WVM?/"=!]!7T/_ ,%8O^4BWQ,_Z[V/_IOM
M:^>$Z#Z"OO\ A_\ Y%M'_#'\D?.YE_O,_5_F?1'_  2?_P"4A/PY_P"N]Y_Z
M17%?L-^US_R:3\4?^Q0U7_TCFK\>?^"3_P#RD)^'/_7>\_\ 2*XK]AOVN?\
MDTGXH_\ 8H:K_P"D<U?E_B%_R,8_X5^;/K^&_P#=7ZG\7MA_QXP_]<U_E4I^
M\*BL/^/&'_KFO\JE/WA7YV>V?LG_ ,&<'_)?/CM_V -)_P#2BZK[6_X.HO\
ME$IK/_8SZ1_Z/-?%/_!G!_R7SX[?]@#2?_2BZK[6_P"#J+_E$IK/_8SZ1_Z/
M-;?9-#^9<=*#UH'2@]:Q,S^J+_@V^_Y0S?!W_<U7_P!.UY7YZ_\ !Y+_ ,EM
M^ /_ &!-<_\ 1]C7Z%?\&WW_ "AF^#O^YJO_ *=KROSU_P"#R7_DMOP!_P"P
M)KG_ */L:VEL:2/QGJ.Y_P!6WTJ2H[G_ %;?2LH[F9_;SX5_Y%C3?^O6+_T
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M%?!_A&PMK/2?"?AG2[.S\\006FEP01P>?CS]BJH"^9@;\??P,YKIBV#2[N:
M.9T3X*^#?#/A2;0=-\)^&=/T.YMFLIM.MM+@AM)8&+LT+1*H0QEI9"5(P3(Q
MQ\QR:K\%O!^N^ (_"=]X4\-WGA6%(XH]%GTR&33HTC(**MNRF,!2 0 N 1Q7
M2>8,GVI2X% '.:%\'/"/A6\NKC2_"OAS3;B^,#W,MKIL,+W#0 " N54%C&
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M[I5_PO\ )GW&8?[M4]'^3/Z7=3_Y!MQ_UR;^1K^;%O\ 6R?]=&_G7])VI_\
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M8F^.,KYACF$T3(OS>[?LE^(O%_B+X974GC?2[C2]<M]5NX293)_IB;]PE19
M&2/<S(B\KMC4J2I!/I^T>@I0,4"N%%%% @HHHH **** "BBB@ HHHH ****
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M]\">#;+3[72/!/A#2;72;]M5L8K/1[>!+.\:,Q-<Q*J ),8R4,BX8J2,XXH
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M]#^#_A/PQKNN:IIGA?P[INI^)CG5[NUTV&&?53SS<.JAI?O-]\G[Q]356P^
M7@72_#Z:3;>"_"5OI<894LXM'MTMT#6OV,@($VC-KB \<Q#9]WB@#P7XH?\
M!0V]^&GA+P7KUWX%\0Z;_;]QJ-K=Z%J%DUKJ#R6TT%O&8))VA"QR-,LB/)'\
MZ,N1$<XS9?\ @IU)::IK4EU\.]4BTK1;2WM9BNH)<7W]M2^(KS0/L @A1]\/
MVJS9O/1F.QE_=EV6,_1VF_ ;P/I'AW3]'M?!OA.UTG22[6-E#I%NEM9%W#N8
MHPFU"S@,=H&2 3S3==^ 7@7Q.LRZEX+\):@MQ%<P2BYT>WF\V.YF6XN4;<AR
MLTRK+(#P[J&;+ &@#YPU;_@K)H?@F#5;[Q-\.?'7AW1M&_<7DURD"W5M>_V"
M^N&TDM'=94;[/#,N]@$W!"6"L2E3X8_\%*]<U#XW>*O!7B3X?:Y-K5CXQ_LB
M#3_#]NVJ2:)IB:=X?DFN+B6 2),4N=9>1BNP+ A!'F*J2_3VG? WP5I&EQV-
MKX/\+6UE"5,=O%I,"1(5MFM%PH3 Q;,T(XXB8I]TD5EZ5^RM\,=!@TN.Q^'/
M@*SCT2^_M/3D@\/VD:Z?=XB7[1"%C'ERXAA&]<-B*/GY5P ?/?PR_P""F\?B
MK3?B-XVU;PY>:;\/?#/P[\,^/-$MT>"XU74+?5IM7,<CE)3%%YL-I:$1R%?*
M8REW*$,,_P"&_P#P5$OXO%GB_2?&GA"2"Z\-^*Y-,OETZ[@=-#T]KFQL86=B
M_P#I<OVNZ.X0@$1C[N_;&_U)X;^ '@3P=I^N6ND>"?".EVOB=&BUB&ST>W@C
MU9&\S<MPJH!,#YLN0^0?,?\ O'-32OV8_AOH2Z.MC\/O ]FOAVY:]TH0:%:Q
M_P!F3MLW30;8QY4A\N/+)@GRTY^48 /&= _X*1:=XE^(&C^&+7P!XZGUV\U
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M!8*,YP*EN_V>? .H>&=#T2X\#^#YM%\,2++HUA)HULUKI+K]UK>,IMA8<X*
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MC?*S?06J_!OPCKOAC3=#O?"OAN\T712#I^GSZ9#):V.(GA'E1E=L?[N21/E
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M+<$S#TD.\8;FMKPWX<T_P?H-GI>DV-GI>F:?$L%K9VD"P6]M&HPJ(B@*J@#
M   H \#\1?\ !-WPYX@\/6>BKXV^(>GZ!H]S?W&CZ;:W-B(=$6]@N;>X@MW>
MT:7R3#>3QJLDC^4K+Y90HA793_@GG\-+SX<:YX1UG2?^$F\.ZT$,=KK$4%RV
MDR#3HM/::TE\L2PRO#"I+AR5<DIL!Q110!2T+_@G1X-TOQS?>*+S6O%VN>)=
M5N=-N[_4KZ\@\V]DL+K3KFU++%"D8VG2[2,[$7<BOG+NSFS\9_\ @G]X2^-_
MQ$O?$6H:WXPTF35)K*[OK/2-02UM[NZLX9X+>Z+>6TR2I%<,N8Y$4^7$2I9
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nbx-20211231_g14.jpg
<TEXT>
begin 644 nbx-20211231_g14.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX3_Z#VG_ /?='_"\O"?_ $'M/_[[H ZRBN3_ .%Y>$_^@]I__?='_"\O"?\
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M_"\O"?\ T'M/_P"^Z .LHKD_^%Y>$_\ H/:?_P!]T?\ "\O"?_0>T_\ [[H
MZRBN3_X7EX3_ .@]I_\ WW1_PO+PG_T'M/\ ^^Z .LHKD_\ A>7A/_H/:?\
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MT_\ [[H ZRBL/PY\0=%\6W,D.F:E;WLD*[W$3;MHK<H **** "BBB@ HHHH
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MB?J__I%+7C?_  0Y_P"42?P#_P"Q3M__ $)Z /IK_A#]'_Z!>G_^ J?X4?\
M"'Z/_P! O3__  %3_"M2B@#+_P"$/T?_ *!>G_\ @*G^%'_"'Z/_ - O3_\
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M$/T?_H%Z?_X"I_A1_P (?H__ $"]/_\  5/\*U** ,O_ (0_1_\ H%Z?_P"
MJ?X4?\(?H_\ T"]/_P# 5/\ "M2B@#+_ .$/T?\ Z!>G_P#@*G^%'_"'Z/\
M] O3_P#P%3_"M2B@#+_X0_1_^@7I_P#X"I_A1_PA^C_] O3_ /P%3_"M2B@#
M+_X0_1_^@7I__@*G^%'_  A^C_\ 0+T__P !4_PK4HH R_\ A#]'_P"@7I__
M ("I_A1_PA^C_P#0+T__ ,!4_P *U** ,O\ X0_1_P#H%Z?_ . J?X4?\(?H
M_P#T"]/_ / 5/\*U** ,O_A#]'_Z!>G_ /@*G^%'_"'Z/_T"]/\ _ 5/\*U*
M* ,O_A#]'_Z!>G_^ J?X4?\ "'Z/_P! O3__  %3_"M2B@#+_P"$/T?_ *!>
MG_\ @*G^%'_"'Z/_ - O3_\ P%3_  K4HH R_P#A#]'_ .@7I_\ X"I_A1_P
MA^C_ /0+T_\ \!4_PK4HH R_^$/T?_H%Z?\ ^ J?X4?\(?H__0+T_P#\!4_P
MK4HH R_^$/T?_H%Z?_X"I_A1_P (?H__ $"]/_\  5/\*U** ,O_ (0_1_\
MH%Z?_P" J?X4?\(?H_\ T"]/_P# 5/\ "M2B@#+_ .$/T?\ Z!>G_P#@*G^%
M'_"'Z/\ ] O3_P#P%3_"M2B@#+_X0_1_^@7I_P#X"I_A1_PA^C_] O3_ /P%
M3_"M2B@#+_X0_1_^@7I__@*G^%'_  A^C_\ 0+T__P !4_PK4HH R_\ A#]'
M_P"@7I__ ("I_A1_PA^C_P#0+T__ ,!4_P *U** ,O\ X0_1_P#H%Z?_ . J
M?X4?\(?H_P#T"]/_ / 5/\*U** ,O_A#]'_Z!>G_ /@*G^%'_"'Z/_T"]/\
M_ 5/\*U** ,O_A#]'_Z!>G_^ J?X4?\ "'Z/_P! O3__  %3_"M2B@#+_P"$
M/T?_ *!>G_\ @*G^%'_"'Z/_ - O3_\ P%3_  K4HH R_P#A#]'_ .@7I_\
MX"I_A1_PA^C_ /0+T_\ \!4_PK4HH R_^$/T?_H%Z?\ ^ J?X4?\(?H__0+T
M_P#\!4_PK4HH R_^$/T?_H%Z?_X"I_A1_P (?H__ $"]/_\  5/\*U** ,O_
M (0_1_\ H%Z?_P" J?X4?\(?H_\ T"]/_P# 5/\ "M2B@#+_ .$/T?\ Z!>G
M_P#@*G^%'_"'Z/\ ] O3_P#P%3_"M2B@#+_X0_1_^@7I_P#X"I_A1_PA^C_]
M O3_ /P%3_"M2B@#+_X0_1_^@7I__@*G^%'_  A^C_\ 0+T__P !4_PK4HH
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MR[O;K4[6XO@FZ&_MY[B9WMY%7<K*O#_+]W%?E_\  'Q9^SO'^P'X$FUCP?\
MM$7'QV\6:0]KHNLZ9=^(X(]6UMM_V=K65[E;-_WFS[JLGRM\M:@?OE17E_['
M>F^.='_9:^']G\3+G[5\0+?0;1-?EW!FDNUB7>6*_>;=]X_Q-NKU"@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKKNQ3J* &^71Y=.HI<J ;Y='ETZBCE0#=K4ZBBF 4444 %%%% !32C#I3J*
M$V"EQ110 8IOETZB@!J=*=110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'R;\"?^4P_Q_P#^Q(\*_P#H=_7U
ME7R;\"?^4P_Q_P#^Q(\*_P#H=_7UE0 4444 %%%% !1110 5^4_[<_[>GC[P
MW^T7\0_'?P[^!/P;US1?@3KFF^$;WQUXL9EU6.]NO*1OL[1(TB01/<JC-NW?
M,VW=NVU^JS]*_,O_ (*#^ /@Q\ ?'_QRTGXB?M#:'X"\*_M%:,EQ<>#[BP^V
M:AIFNQ"".WUBW6+=/Y7^CJS(R>6TB[MU 'HW_!,[XH?%I/VM/BUX ^*OP_\
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M?M9_%;QS\%O@S>:]\._AS<?%;Q/;W$,47AZ+6(M*:X1WVN_G.CJ-B_-C;\U
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MV>R['+9:R_\ BZ /K3_A:GAC_H8M#_\  ^+_ .*H_P"%J>&/^ABT/_P/B_\
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M%&P4M% !2;!2T4 %)L%+10 FP4;!2T4 %%%% ";!2T44 %)L%+10 4FP4M%
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M_P"42?P#_P"Q3M__ $)Z]D_;*_Y-#^*W_8GZO_Z12UXW_P $.?\ E$G\ _\
ML4[?_P!">@#ZNHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A/\ 8]_Y3H_M@?\
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M2?P#_P"Q3M__ $)Z]D_;*_Y-#^*W_8GZO_Z12UXW_P $.3_QJ2^ ?_8IV_\
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MEN=/U#GA[>56^>/Y?O5^R?[9 _XQ#^*G_8GZO_Z12UXU_P $._\ E$G\ _\
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MV\-\/@Z4:BFW>27WNQF_\1%'@O\ Z(?^T!_X3:?_ !VD_P"(B?P7_P!$._:
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MBE_R.UU_N)_Z+%8&P5V9_P#2QQ>7YA4P2PB:@[7OV^1EA^&85*:GS;GG"_\
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MI8W?^(D;P!_T1GX\?^$^G_QVI+;_ (.// =W<+##\%?CY)+(RHB)X<1F9FZ
M?O:^9P?[S5T'PG_Y*EX9^;_F+6O_ *-2N/#^+6(J553]DM?,PI\25IS4>5'O
MFK_\'%7@OP_J4UGJ'P/_ &@+&\MSB6"?PTD<D?R[OF5I>/E-5_\ B)(\ ?\
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MD.H? []H*QFD02A)_#21LR-]UL-+]UJ^8.#_ !;J]J_;H)'Q3T7YO^9>L?\
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MXF89?_!CZ(V/ O\ R.&G_P#785\-_M$_\ES\8_\ 89NO_1K5]R>!?^1PT_\
MZ["OAO\ :*_Y+GXR_P"PS=_^C6K]\\'?^2>G_C?Y(_)O%'_EV<;7LW[!W_)?
MH_\ L&7G_HDUXS7LW[!W_)?H_P#L&7G_ *)-?K64_P"]P]4?EN5?[S$\=O?^
M/V;_ 'V_]"J.I+S_ (^IO]\_SJ.N.I_$D<57^(SVC]ET_P#%HOB__P!B\O\
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MO\$?R1Z&9?Q%Z+\@KWC]OC_D=O!O_8L6O_H4E>#U[S^WQ_R.W@[_ +%BU_\
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MNS=25%?FGB1P#'BK!PPCJ>SY7?:Y]-PMQ)+)L0\1&'-=6/R^71;K^&UN-O\
MUR:O1?V4-+N+?XZ:(SV\P1?.W%D*_P#+!Z^^!X=L3+_QZ0?]^Q4=UHUI8V4\
MD-M$DBH>BCTK\<P/T=UEM:..^LW]GK:V]M3[3'>)U3%T)8;V7+SJV_<_,CQ1
M_P C!??]?4G_ *%5*KOBC_D8+[_KZD_]"JE7\DYUICJG^)G[IE?^[0_PH]4_
M9E/S^,O^Q<N?YI7EAZM7J?[,I^?QE_V+ES_-*\L/5J^DSS_D1X+_ +>_-'S^
M4_\ (WQ?_;OY"5ZY\+O^38/'O_7S;?\ H2UY'7KGPN_Y-@\>_P#7S;?^A+4\
M!_[Y5_Z]R_)FG%'^[0_QP_\ 2T>2C^*FTX?Q4VOBY?Q?F?2TO@/7]=_Y,[\/
M_P#85F_]&-7D&?W5>OZ[_P F=^'_ /L*S?\ HQJ\@S^ZK[KCK^)AO^O4/R/F
M.&?@K_\ 7R7YA7UM:?\ )&/ ?_8+7_T".ODFOK:T_P"2,> _^P6O_H$=>%#_
M ))O'^D?_2D>)QW_ !</ZO\ (HTZ#_61_P"]3:=!_K(_]ZOQ#*_]\I?XD?'3
M^ ZKXT?\C:O_ %[I_P"S5R==9\:/^1M7_KW3_P!FKDZ^L\1_^1]B/4X\K_W:
M)J^!?^1PT_\ Z[K4WQ"_Y';4?]\?^@U#X%_Y'#3_ /KNM3?$+_D=M1_WQ_Z#
M7J1_Y(E_]?5^1G_S&_+]3$KJ/@__ ,CBG_7%ZY>NH^#_ /R.*?\ 7%Z\;P[_
M .2@P_J;YE_ GZ'.WW_(0N/^NK?^A5#4U]_R$+C_ *ZM_P"A5#7SV=_[_6_Q
M/\S>C\".K^'O_(#\2?\ 7F__ *"U<I75_#W_ ) ?B3_KS?\ ]!:N4K[3B?\
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M[T'_ *315Y/7K'[;W_)U7BS_ 'H/_2:*O)ZWSO\ WVKZLO&?[Q+U/5OV)?\
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MS=S]ZOR7Q@X/7#=#"9="7/9-W]6CZW@'.)9GB<1BY1MS6&UZY\+O^38/'O\
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M /(XI_UQ>N7KJ/@__P CBG_7%Z\;P[_Y*##^IOF7\"?H<[??\A"X_P"NK?\
MH50U-??\A"X_ZZM_Z%4-?/9W_O\ 6_Q/\S>C\".K^'O_ " _$G_7F_\ Z"U<
MI75_#W_D!^)/^O-__06KE*^TXG_Y)W+?27YG'A?]ZJ?+\@KKM$_Y)#K'_7Q'
M_P"A1UR-==HG_)(=8_Z^(_\ T*.EX;_Q\3_UYJ?DQYA\$/5?F<C1117YU]L]
M'[)UVO?\DNTG_KX/\C7(UUVO?\DNTG_KX/\ (UR-?H7B1_OE#_KS3_)'GY7\
M#]6%=1\3?^/71?\ KT_K7+UU'Q-_X]=%_P"O3^M5PO\ \D]F/I'\T+%?[Q2^
M?Y'+U-IW_'_;_P"^O_H50U-IW_'_ &_^^O\ Z%7Q^1_[_1_Q+\SMJ?PY&Q\4
M?^1XO/\ MG_Z+%<^O4UT'Q1_Y'B\_P"V?_HL5SZ]37K<=?\ (^Q/^)F&7_P8
M^B-CP+_R.&G_ /785\-_M%?\ES\9?]AF[_\ 1K5]R>!?^1PT_P#Z["OAO]HK
M_DN?C+_L,W?_ *-:OWSP=_Y)Z?\ C?Y(_)O%/_EV<;7LW[!W_)?H_P#L&7G_
M *)->,U[-^P=_P E^C_[!EY_Z)-?K64_[W#U1^6Y5_O,3QV\_P"/J;_?/\ZC
MJ2\_X^IO]\_SJ.N.I_$D<57^(SVC]ET_\6B^+_\ V+R_SKQ>O:/V73_Q:+XO
M_P#8O+_.O%Z]3'_[M1]'^9WXS^!2]'^85[5X;_Y,3\0?]C1;_P#HI:\5KVKP
MW_R8GX@_[&BW_P#12U&4_'+_  /\A99\<O1GBM%%%>4>=]H]L^,7_)FGPI_Z
M^=1_]&UXJW1:]J^,7_)FGPI_Z^=1_P#1M>*MT6O6SC^+#_ OR1Z.:?&O1#:]
MH_;&^_\ #;_L2]/_ )-7B]>T?MC??^&W_8EZ?_)J>%_W*I\B\'_NE7Y'C,E7
MO"?_ ",^F_\ 7U%_Z&M49*O>$_\ D9]-_P"OJ+_T-:X,+_$B<-#^*CTS]NC_
M ).G\4_[T'_I-%7D=>N?MT?\G3^*?]Z#_P!)HJ\CKLSK_?:GJ;9A_O,_4]*_
M8Z_Y.9\'_P#7X/\ T%JYGXP?\E<\2?\ 83N?_1K5TW['7_)S/@__ *_!_P"@
MM7,_&#_DKGB3_L)W/_HUJ[*O_(KA_B?Y(V?^XKU_R.;KW+]@;_DJ_B#_ +%>
M\_\ 0HZ\-KW+]@;_ )*OX@_[%>\_]"CK'A__ 'Z)CEG^\Q/$)?\ 62?6F4^7
M_62?6F5Y57^-(YZWQ'O'[,7_ ";7\;?^P=8_^A7%>#I_JJ]X_9B_Y-K^-O\
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MXJWQGM_P)_Y-(^,G^[IG_HXUXA7M_P "?^32/C)_NZ9_Z.->(5Z^<?[OA_\
M!^K._'?PJ/I^H5[5>?\ )@5M_P!CF?\ TE:O%:]JO/\ DP*V_P"QS/\ Z2M4
MY3\-3_ PR[[?HSQ6BBBO&CN>?'XCV[]HO_DW/X._]@VY_P#1BUXC7MW[1?\
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MUXWAW_R4&']3?,OX$_0YV^_Y"%Q_UU;_ -"J&IK[_D(7'_75O_0JAKY[._\
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M[#-W_P"C6K[D\"_\CAI__785\-_M%?\ )<_&7_89N_\ T:U?OG@[_P D]/\
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MO_#;_L2]/_DU/"_[E4^1>#_W2K\CQF2KWA/_ )&?3?\ KZB_]#6J,E7O"?\
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M?X%^2/0S#^(O1!7O/[?'_([>#O\ L6+7_P!"DKP:O>?V^/\ D=O!W_8L6O\
MZ%)5Y?\ \BZM\B\/_NT_D>#5T'PH_P"2J^&?^PM;?^CTKGZZ#X4?\E5\,_\
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M8M>(U[=^T7_R;G\'?^P;<_\ HQ:\1KULZ_WG_MU?DCTLT_B?)?D%>T?MT?\
M)4M%_P"Q?L?_ $"O%Z]H_;H_Y*EHO_8OV/\ Z!3P_P#R+Y^J_4>'_P!RJ>J/
M%ZZ;X+_\E@\*_P#87M/_ $>E<S73?!?_ )+!X5_["]I_Z/2O/P7\>'J<6#_C
MP]3<_:U_Y.-\9?\ 82>O/:]"_:U_Y.-\9?\ 82>O/:VS/_>JGJS3'_[U+U9Z
M_P#L(_\ )SWAW_=G_P#1$E>7>*/^1HU#_KZE_P#0C7J/["/_ "<]X=_W9_\
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MQEIWCGQ+::[J'V'Q"SVJQ+-:6Y=Q$\$LD*ON9?D;_=^8 Z'_ ((C6'PE\/\
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M I?_ (FOJ)K*33OA1X(AGCDAFCTU59'&UE;;'\I%?2SV$(Y:./ _V:\B_:1
M34=.4?W9,?\ CM?C?B=X1T>%.$<77I574Y[+:W5';B.,JN=8BG&=/DY;]?(\
MR3I4D'^LC_WJ;]T[:=!_KD_WJ_AO*T_KE*W\R/4J_ =1\9?^1K7_ *]T_P#9
MJY6NJ^,O_(UK_P!>Z?\ LU<K7U'B-?\ M_$>IQY;_NT35\"_\CAI_P#UW6IO
MB%_R.VH_[X_]!J'P+_R-^G_]=UJ7XA?\CMJ7^^/_ $&O6C?_ %)?_7U?D9_\
MQOR_4Q:ZCX/_ /(XI_UQ>N7^]]VNH^#_ /R.*?\ 7%Z\?PY_Y*##^IOF7^[R
M]#G;[_D(7'_75O\ T*H:FOO^0A<?]=6_]"J#<*^?SI/^T*W^)_F;T?X:.L^'
MO_(#\2?]>;_^@M7*5U7P[_Y 7B3_ *\W_P#06KE:^TXG3_U>RWTE^9QX7_>J
MGR_(*ZW1?^20ZO\ ]?$?\XZY'<*Z[1?^21ZQ_%_I$?\ ..H\-_X^*_Z]5/R'
MF'P1]5^9R5%%%?G:3]H>C]DZ[7O^27:3_P!?!_D:Y&NJU_\ Y);I?_7R?Y5R
M>/\ 9K]#\2$WC*'_ %YI_DCS\M^!^K'5U'Q-_P"/71?^O3^M<O74?$S_ (\]
M$_B_T3^HJN%U+^P,Q](_FB<5_O%+Y_D<O4VG?\?]O_OK_P"A5#4NG?\ (1M_
M]]?_ $*OCLB_Y&%'_$OS.ZI_#D;/Q1_Y'B\_[9_^BQ7/KU-=%\3_ /D>KOZ1
M_P#HL5SO=J]7CJ_]O8G_ !,PR_\ @Q]$;'@7_D<-/_Z["OAO]HK_ )+GXR_[
M#-W_ .C6K[D\!_\ (VZ;_P!=A7PW^T1\WQV\9?\ 89NO_1K5^^>#O_)/3_QO
M\D?DWBC_ ,NSC:]F_8._Y+]'_P!@R\_]$FO&:]F_8._Y+]'_ -@R\_\ 1)K]
M:RG_ 'N'JC\MRK_>8GCMY_Q]3?[Y_G4=27G_ !]3?[Y_G4=<=3^)(XJO\1GM
M'[+I_P"+1?%__L7E_G7B]>T?LNG_ (M%\7_^Q>7^=>+UZF/_ -VI>C_,]#&?
MP*7H_P PKVKPW_R8GX@_[&BW_P#12UXK7M7AO_DQ/Q!_V-%O_P"BEJ<I^.7^
M!_D3EGQR]&>*T4#^*C_9KRD>=]H]L^,7_)FGPI_Z^=1_]&UXJW1:]L^,7'[&
MWPK7_IYU'_T;7B->MG'\6/\ @7Y(]'-/C7H@KV?]L7[WPV_[$RP_DU>,5[1^
MV-_S37_L3+#^34\'_N53Y%87_=*GR/&9*O>$_P#D9]-_Z^HO_0UJC)5WPK_R
M-.F_]?47_H:UY^%_C(XJ'\5'IO[='_)T_BG_ 'H/_2:*O(Z]<_;H_P"3I_%/
M^]!_Z315Y'_#FNS.O]]J^IMF'^\S]3TK]CO_ ).7\'_]?@_]!:N9^,'_ "5S
MQ)_V$[G_ -&M73?L=_\ )RW@_P#Z_!_Z"U<W\9/^2N>)/^PI<+_Y%:NJI_R*
MX_XG^2-G_N*]?\CF:]R_8&_Y*OX@_P"Q7O/_ $*.O#:]R_8&_P"2K^(/^Q7O
M/_0HZSX?_P!^B8Y9_O,3Q"7_ %DGUIE/E_UDGUIE>7B/XTCGK?$>\?LQ?\FU
M_&W_ +!UC_Z%<5X.G^JKWC]F'_DV_P"-_P#V#K/^=Q7@Z\1[:]K-/]TP_H_S
M.W$?P:7H_P PKW;3_P#E'E>_]C8/_125X37N^G?\H\KW_L:__:25.2;5?\#%
MEWV_1GA%%%%>'3^(\T]Z_:(_Y-+^$/\ URNO_0EKP6O?/VA_^33/A#_URNO_
M $*O S_#7N<0?QU_@7Y(]#,OXB]%^05[S^WQ_P CMX._[%BU_P#0I*\&KWG]
MOC_D=O!W_8L6O_H4E5E__(NK?(TH?[M/Y'@U=!\*/^2J^&?^PM;?^CTKGZZ#
MX3?\E3\,_P#86M?_ $>M>7@/]XA_B1Q83^*CN?VX?^3I_%O_ %T@_P#2:*O)
MJ]8_;?\ ^3I?%OR_\M(/_2>*O)ZZ,Z_WVIZLO&_[Q+U/5OV)?^3G_"__ %V?
M_P! :N*^+'_)4O$O_86N?_1[UVO[$O\ R<_X7_Z[/_Z U<3\5_\ DJOB;_L+
M7/\ Z/>NVI_R*8_XG^2.B7^Y+U?Z'/U[E^PC_P CAXP_[%B\_E7AM>Y?L+_\
MC=XP_P"Q8O/_ $&L.'_][CZAE?\ 'B>&T4?\LJ*\O$?Q)'GU/XA[?\"?^32/
MC)_NZ9_Z.->(5[=\"O\ DTWXR+_%MTS_ -'&O$:]?./]WP_^']3T,=_"H^GZ
MA7M5X?\ C *U_P"QS/\ Z2M7BO3_ &:]JNO^4?\ :?\ 8Y_^VK5&4_#4_P #
M*R__ )>>C/%:***\=;GFQ^(]N_:+_P"3<_@[_P!@VY_]&+7B->W?M%_\FY_!
MW_L&W/\ Z,6O$:]7.O\ >?\ MU?DCTLR_B_]NK\@KVC]NC_DJ6B_]B_8_P#H
M%>+[?]JO:OVYXV7XIZ-_V+]C_P"@4\/_ ,B^?JOU+P_^Y3]4>*UTWP7_ .2P
M>%?^PO:?^CTKF:Z;X,_+\8/"O_87M/\ T>E<.!_CP]3@P?\ 'CZFY^UK_P G
M&^,O^PD]>>UZ)^UE_P G(>,/^PE)7G=:9I_O<O5FF/\ ]YEZL]?_ &$?^3GO
M#O\ NS_^B)*\N\4?\C1J'_7U+_Z$:]0_83_Y.=\.?2?_ -$/7E_BB/\ XJC4
M/^OJ7_T-JZ*G^X4_5_DCIG_N</5E&O;/V,^GQ&_[%*]_]DKQ.O:OV+_^:C?]
MBC>_^R5GD_\ O).5?QSQ8?=-)2C[II*X:OQ,X*GQGM7PD_Y,T^*G_7UIO_H\
MUXK7M7PD_P"3-/BI_P!?6F_^CS7BM>IF'^[T?\'ZGI9A_"I^GZA7MGBW_DPW
MPG_V,ES_ .BFKQ.O;/%W_)AOA/\ [&:Y_P#14E5E/P5?\'ZH,M^&KZ?Y'B=%
M!_AHKR:7Q(\W[9^LG['W_)M'@O\ [!<'_H->F#I7F?['W_)M'@O_ +!<'_H-
M>F"O[(R'_D74/\"_(_5,-_"AZ$E%%?*GCO\ X+5?LK_#3QIJ_AW7OC1X3TO7
M-!O)=/O[2;SO,M;B)V1XVVI]Y64K7L'0?5=%?(/_  _G_9!_Z+OX-_\ (_\
M\:H_X?S_ +(/_1=_!O\ Y'_^-4 ?7U%?(/\ P_G_ &0?^B[^#?\ R/\ _&J/
M^'\_[(/_ $7?P;_Y'_\ C5 '(_L>_P#*=']L#_L ^#__ $WK7W97YO?\$P?V
MA?!?[47_  5__:Q\:?#[Q!8^*/"^J:+X62UU&TW>5,T5HT3@;E7[KHR_\!K]
M(: "BBB@ HHHH **** &OTK\</&OC?\ 9%\!_P#!4/\ :1M_VHQH/B+Q5=:S
MI\^@ZAK%A<:A:V>G?8(-MDBHK>5)$WWEV_-N5MWS-7[(U^6'_!1/]M;XN_\
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MDLJM\[?>^:OTL_;*_P"30_BM_P!B?J__ *12UXW_ ,$.?^42?P#_ .Q3M_\
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M+2O&&B_#+2[3Q]K&D:YXJA\W[;>Z9:&UM9MTKLFR-B=NU&16_P!I6KR[XZ^
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M_MO^%_BMK'[47C*;P;XH\+Z1HO\ :=POV?4-->XG\WS7W'*D?+]VOTP\!_\
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M*P_#7Q#X?\-ZO_:46^?5[!KR)F9T6+Y5^[M;YFK?KHOA-_R57PS_ -A:U_\
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M?&_2/&FM?\$XM+C\#:QHNB:DOCHM/-J=F;I)(OL4GRJJGY6W;?RK@:]KN_\
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M<Q/R]:^BO^"I.D>+M9\7:)'X+U32=%UK^Q[ M<:G;-<P>5Y39&Q?XMVWYO\
M9KS^O:OVZ?\ DJ6B_P#8O6/_ *!6U/-9U,/4Q')&\6M+*W7H;8>H_JE1^:/D
MGX1^%_BQH_B@S>,O%?A?6=)\EE6WT_37MY?-_A.6/W?O5Z%>:/XWUS7-!MOA
M[K>B^'_$[:O:_9[W5;1KJUC_ 'J_>1?O?-MJU73?!?\ Y+!X5_["]I_Z/2O/
MCF$ZN-A6Y$MMDK?<>?AZC=>+\SSWQ5X+^-GAS]I?Q(WQ-\9>#/$XCN)DNET;
M2'L_,N/EVN-Q^5>O%5OBOI?BO6/"C0^#]4TO1]9\U&%QJ%JUQ!L_B78O\7W:
M]I_:P_Y.,\8?]A*2O.ZUS3,)2QSK<B]U]E;YFF8?[S+U+W_!+SPI\6M'_;.\
M,S>+_%?A?5M'\JZ5[?3]+>WE9_(DVG>Q^[7-_'_2_%&L6>J0>#]3TO1]9:_9
MDN+ZW:X@5-[;UV*?O5[K^PC_ ,G/>'?]V?\ ]$25Y=XH_P"1HU#_ *^I?_0C
M71C,TG5H4L0X1NF]+*VRZ'16J?[)"7FSR'X6^%/BUH_BR.;Q?XJ\+:MHJHZO
M;Z?ICV\[/M^5M[$U]$?"_0_'OB+X>?$>W^'.N:'X=\2?\(Z[_;-6LFNK;[.L
MJ-,FQ?XVCW*K?PM7#U[9^QA][XB?]BG>_P TK+ YA*OCHUG!+E[*R^XG+*G/
M71\@_"SPG\7-+\9V]QXP\6>%-6T.-'66VT_2GMYV.WY-KL?X6VUV7Q/L/$NJ
M>#[B'PIJ6FZ3K3.C17%[;M<1*N[G<B_[-="/NFDKAQ.93JXE8AQ2Y>B2M]QP
MU:C]I<9^S7X(^/>G_!?QQ>>(O'7@C4O ]O-9C5-,M=%>&^NI6?\ <LDK':JJ
MWWO[U8?Q/T_Q)JG@RZA\)ZEI^EZ\S)Y-S>VYG@C7>N_*+][<N5_X%7T3\(S_
M ,8;_%3_ *^M-_\ 1IKQ6O1S3'RE[#$65[;6TW['H9A\%*7E^IY9\,_"?Q@T
MSQ?;3>*_%WA/5M%57\^VLM,>WG;Y?EVNQ_O;:^G_ (\V'B+4_P#@G)X;A\*Z
MAI^E:XWBB;R;F]MVG@C^1L[D7[WRUYG7MOB__DPWPG_V,L__ **DK; YE*K.
MI7<$N6&R2MNNA67S;]H_+_(^//ACX/\ C%H_C>RN/%GB[PEJNAKO^U6MAI3P
M3R?(VS#L?EVOM;_=6NZ^(^G^(-2\&WD/A>^T_3-<DV?9[F\A:>"/YEW;D7[W
MR[O^^JW**\JIFDJN(C6<$N7LE;[CS54;E<^[O^"5O@/]H#PY\/K&Z^*GCSP+
MXG\&W6B0C0]/T;1'LKNREW?>EE8_.OE_+7V$/N"O,_V/C_QC1X+_ .P7!_Z#
M7IT?WJ_K?):G-@:4^\5^1^I8;^%#T!^E>5:_J_P9M]<O!JEU\,$U+SG^U"[E
ML5G\W=\V_=\V[=][=7JK]*^1/B7_ ,$*/V4?B_\ $#6?%'B3X.Z/JGB#Q!>R
MZCJ-V^IW\;7-Q*[.[E4N HW,Q^ZM>L=![!_;WP)_Y_OA+_W]T^C^WO@3_P _
MWPE_[^Z?7A'_ !#O_L:_]$-T/_P:ZE_\DT?\0[_[&O\ T0W0_P#P:ZE_\DT
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M&LV-]^SI\1/@NNGVB3_;O$.E06<&H,SJOE(4^9F7[W_ :^GJ "BBB@ HHHH
M\U_;*_Y-#^*W_8GZO_Z12UXW_P $.?\ E$G\ _\ L4[?_P!">O9/VRO^30_B
MM_V)^K_^D4M>-_\ !#G_ )1)_ /_ +%.W_\ 0GH ^KJ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *38*6B@!NR@]/O4Z@]*4M@/GWX]?\
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M*O\ >8GCMY_Q]3?[Y_G4=27G_'U-_OG^=1UQU/XDCBJ_Q&>T?LNG_BT7Q?\
M^Q>7^=>+U[1^RZ?^+1?%_P#[%Y?YUXO7J9A_NM#T?YG?C/X%+T?YA7M7AO\
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MO73?!?\ Y+!X5_["]I_Z/2N9KIO@O_R6#PK_ -A>T_\ 1Z5Y^#_CP]3BP?\
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M4 %%%% !1110 4444 %%%% !1110 4444 %!Z44'I0]@/G_X[\^/6_Z]E_\
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M_P"O@_R-<C7Z%XD?[Y0_Z\T_R1Y^5_ _5A74?$W_ (]=%_Z]/ZUR]=1\3?\
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M5_B,]H_9=/\ Q:+XO_\ 8O+_ #KQ>O:/V73_ ,6B^+__ &+R_P Z\7KU,?\
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MFG^Z8?T?YG9B?X-+T?YA7NVG_P#*/*]_[&P?^BDKPFO=M/\ ^4>5[_V-@_\
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M#G_E$G\ _P#L4[?_ -">O9/VRO\ DT/XK?\ 8GZO_P"D4M>-_P#!#G_E$G\
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MU-=!\4?^1XO/^V?_ *+%<^O4UZW'7_(^Q/\ B9AE_P#!CZ(V/ O_ ".&G_\
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ME*/NFDKAK?&<-3XCVKX2?\F:?%3_ *^M-_\ 1YKQ6O:OA)_R9I\5/^OK3?\
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M^/PS"MO+-=F.21-[X)7LU 'V]17!?\)!\0O^A?T/_P #6H_X2#XA?]"_H?\
MX&M0!WM%<%_PD'Q"_P"A?T/_ ,#6H_X2#XA?]"_H?_@:U '>T5P7_"0?$+_H
M7]#_ / UJ/\ A(/B%_T+^A_^!K4 =[17!?\ "0?$+_H7]#_\#6H_X2#XA?\
M0OZ'_P"!K4 =[17!?\)!\0O^A?T/_P #6H_X2#XA?]"_H?\ X&M0!WM%<%_P
MD'Q"_P"A?T/_ ,#6H_X2#XA?]"_H?_@:U '>T5P7_"0?$+_H7]#_ / UJ/\
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M_P E2T7_ +%^Q_\ 0*\7KUS]LFXO+CXD:2U]!;VTW]AV:JD3^8K)Y?!HP_\
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ML.GQZ7#]EECEW/)_O+_#7LB]*_LC(/\ D6T/\"/U3#_PH>A)1117LG0%%%%
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M@77^_'_Z&M=L?N_A7$_'P?\ %NKK_?C_ /1BU^?>*4'/A7'17_/N7Y';EO\
MO5/U1X'12=OEI:_QZ_L_$^T_AO?L?J_ME8ZK7_\ DENE_P#7R?Y5RM=5K_\
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MKQ6O:/VQOO\ PV_[$O3_ .34\+_N53Y%X/\ W2K\CQF2KWA/_D9]-_Z^HO\
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M^%_^NS_^@-7%?%C_ )*EXE_["US_ .CWKM?V)?\ DY_PO_UV?_T!JXKXL?\
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M>V>+/^3$/"/_ &,ES_Z*:JRGX*O^#]43EOPU?3_(\3HHHKRJ/QGGQ^(_6/\
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M_P#!#G_E$G\ _P#L4[?_ -">@#ZNHHHH **** "BBB@ HHHH **** "BBB@
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M?^+1?%__ +%Y?YUXO7J8_P#W:CZ/\SOQG\"EZ/\ ,*]J\-_\F)^(/^QHM_\
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M$\-HHHKRL1_$D<5;XSV_X$_\FD?&3_=TS_T<:\0KV_X$_P#)I'QD_P!W3/\
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MT_\ &_R1^3>*?_+LXVO9OV#O^2_1_P#8,O/_ $2:\9KV;]@[_DOT?_8,O/\
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MM\?\CMX._P"Q8M?_ $*2KR__ )%U;Y%X?_=I_(\&KH/A1_R57PS_ -A:V_\
M1Z5S]=!\*/\ DJOAG_L+6W_H]*\S+?\ >(?XD<>#_BH[C]M[_DZKQ9_O0?\
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M?^1XO/\ MG_Z+%<^O4UT7Q/_ .1ZN_I'_P"BQ7.KU->MQU_R/L3_ (F89?\
MP8^B-CP+_P CAI__ %V%?#?[17_)<_&7_89N_P#T:U?<G@7_ )'#3_\ KL*^
M&_VBO^2Y^,O^PS=_^C6K]\\'?^2>G_C?Y(_)O%/_ )=G&U[-^P=_R7Z/_L&7
MG_HDUXS7LW[!W_)?H_\ L&7G_HDU^M93_O</5'Y;E7^\Q/';S_CZF_WS_.HZ
MDO/^/J;_ 'S_ #J.N.I_$D<57^(SVC]ET_\ %HOB_P#]B\O\Z\7KVC]ET_\
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M,_4]*_8Z_P"3F?!__7X/_06KF?C!_P E<\2?]A.Y_P#1K5TW['7_ "<SX/\
M^OP?^@M7,_&#_DKGB3_L)W/_ *-:NRK_ ,BN'^)_DC9_[BO7_(YNO<OV!O\
MDJ_B#_L5[S_T*.O#:]R_8&_Y*OX@_P"Q7O/_ $*.L>'_ /?HF.6?[S$\0E_U
MDGUIE/E_UDGUIE>55_C2.>M\1[Q^S%_R;7\;?^P=8_\ H5Q7@Z?ZJO>/V8O^
M3:_C;_V#K'_T*XKP=/\ 55[>:?[IA_1_F=F(_@TO1_F%>[:?_P H\KW_ +&P
M?^BDKPFO=M/_ .4>5[_V-@_]%)4Y#M5_P,,N^WZ,\)HHHKPX?&>:>]?M$?\
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M[%^Q_P#0*\7KVC]NC_DJ6B_]B_8_^@4\/_R+Y^J_4>'_ -RJ>J/%ZZ;X+_\
M)8/"O_87M/\ T>E<S73?!?\ Y+!X5_["]I_Z/2O/P7\>'J<6#_CP]3<_:U_Y
M.-\9?]A)Z\]KT+]K7_DXWQE_V$GKSVMLS_WJIZLTQ_\ O4O5GK_["/\ R<]X
M=_W9_P#T1)7EWBC_ )&C4/\ KZE_]"->H_L(_P#)SWAW_=G_ /1$E>7>*/\
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M]74444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 48HHH CSS7G/Q7^%EYXVUF
M"XMIHT2./8P;/]ZO1L4$^U?*\6<)8'B/+Y9;F*O3EV.C"XF>'G[2&YXBG[.N
MK?\ /Q;?^/5)9?L]:I!<1NUU;;8V#?Q5[83QTH<@K7Y'A_HT\'8>:JTZ;YH^
M9ZDN(,7)6;/G#XL)Y'CZ_4_,T80?^0EKG*ZCXT_\E&U!?]S_ - 6N7K_ #I\
M2Z$:/$^-HQVC4E^9^@9;KAJ<O)&MX%_Y'#3_ /KL*^&_VBO^2Y^,O^PS=_\
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M-KQ5NBUZV<?Q8?X%^2/1S3XUZ(;7M'[8WW_AM_V)>G_R:O%Z]H_;&^_\-O\
ML2]/_DU/"_[E4^1>#_W2K\CQF2KWA/\ Y&?3?^OJ+_T-:HR5>\)_\C/IO_7U
M%_Z&M<&%_B1.&A_%1Z9^W1_R=/XI_P!Z#_TFBKR.O7/VZ/\ DZ?Q3_O0?^DT
M5>1UV9U_OM3U-LP_WF?J>E?L=?\ )S/@_P#Z_!_Z"U<S\8/^2N>)/^PG<_\
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M*KX9_P"PM;?^CTKS,M_WB'^)''@_XJ.X_;>_Y.J\6?[T'_I-%7D]>L?MO?\
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M^DK5XK7M5Y_R8%;?]CF?_25JG*?AJ?X&&7?;]&>*T445XT=SSX_$>W?M%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDO/^/J;_ 'S_ #J.N.I_$D<57^(SVC]ET_\ %HOB_P#]B\O\Z\7KVC]ET_\
M%HOB_P#]B\O\Z\7KU,?_ +M1]'^9WXS^!2]'^85[5X;_ .3$_$'_ &-%O_Z*
M6O%:]J\-_P#)B?B#_L:+?_T4M1E/QR_P/\A99\<O1GBM%%%>4>=]H]L^,7_)
MFGPI_P"OG4?_ $;7BK=%KVKXQ?\ )FGPI_Z^=1_]&UXJW1:];./XL/\  OR1
MZ.:?&O1#:]H_;&^_\-O^Q+T_^35XO7M'[8WW_AM_V)>G_P FIX7_ '*I\B\'
M_NE7Y'C,E7O"?_(SZ;_U]1?^AK5&2KWA/_D9]-_Z^HO_ $-:X,+_ !(G#0_B
MH],_;H_Y.G\4_P"]!_Z315Y'7KG[='_)T_BG_>@_])HJ\CKLSK_?:GJ;9A_O
M,_4]*_8Z_P"3F?!__7X/_06KF?C!_P E<\2?]A.Y_P#1K5TW['7_ "<SX/\
M^OP?^@M7,_&#_DKGB3_L)W/_ *-:NRK_ ,BN'^)_DC9_[BO7_(YNO<OV!O\
MDJ_B#_L5[S_T*.O#:]R_8&_Y*OX@_P"Q7O/_ $*.L>'_ /?HF.6?[S$\0E_U
MDGUIE/E_UDGUIE>55_C2.>M\1[Q^S%_R;7\;?^P=8_\ H5Q7@Z?ZJO>/V8O^
M3:_C;_V#K'_T*XKP=/\ 55[>:?[IA_1_F=F(_@TO1_F%>[:?_P H\KW_ +&P
M?^BDKPFO=M/_ .4>5[_V-@_]%)4Y#M5_P,,N^WZ,\)HHHKPX?&>:>]?M$?\
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M[%^Q_P#0*\7KVC]NC_DJ6B_]B_8_^@4\/_R+Y^J_4>'_ -RJ>J/%ZZ;X+_\
M)8/"O_87M/\ T>E<S73?!?\ Y+!X5_["]I_Z/2O/P7\>'J<6#_CP]3<_:U_Y
M.-\9?]A)Z\]KT+]K7_DXWQE_V$GKSVMLS_WJIZLTQ_\ O4O5GK_["/\ R<]X
M=_W9_P#T1)7EWBC_ )&C4/\ KZE_]"->H_L(_P#)SWAW_=G_ /1$E>7>*/\
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MZY\%_$#1_P"W/#=Y-%<2VOVB6#<\3;D.Z)E;AO>OG+_B'Q_9,_Z)DW_@\O\
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MB_Y-K^-O_8.L?_0KBO!T_P!57MYI_NF']'^9V8C^#2]'^85[MI__ "CRO?\
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MB=>V?L9]/B-_V*5[_P"R5GE7^\$Y5_'/%!]TTE*/NFDKAK?&<-3XCVKX2?\
M)FGQ4_Z^M-_]'FO%:]J^$G_)FGQ4_P"OK3?_ $>:\5KT\Q_@4?\ #^K/2S#^
M%3]/U"O;/%G_ "8AX1_[&2Y_]%-7B=>V>+/^3$/"/_8R7/\ Z*:JRGX*O^#]
M43E?PU?3_(\3HHHKRJ/QGGQ^(_63]C[_ )-H\%_]@N#_ -!KTP=*\S_8^_Y-
MH\%_]@N#_P!!KTP=*_LG(?\ D74/\"_(_5,-_"AZ$E%%%>P= 4444 %%%% '
MYZ?L$?\ *>']MK_KR\+?^F]*_0NOST_8(_Y3P_MM?]>7A;_TWI7Z%T %%%%
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M_P#!#G_E$G\ _P#L4[?_ -">@#ZNHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH C?_ %+_ $K\@OVB?^2\^,/^PS=?^C6K]?7_
M -2_TK\@OVB?^2\^,/\ L,W7_HUJ_%O&+_=Z'J_T/F>)_P"!#U.,KV;]@[_D
MOT?_ &#+S_T2:\9KV;]@[_DOT?\ V#+S_P!$FOQ3*?\ ?*?J?+Y5_O,3QV\_
MX^IO]\_SJ.I+S_CZF_WS_.HZXZG\21Q5?XC/:/V73_Q:+XO_ /8O+_.O%Z]H
M_9=/_%HOB_\ ]B\O\Z\7KU,?_NU'T?YG?C/X%+T?YA7M7AO_ ),3\0?]C1;_
M /HI:\5KVKPW_P F)^(/^QHM_P#T4M1E/QR_P/\ (66?'+T9XK1117E'G?:/
M;/C%_P F:?"G_KYU'_T;7BK=%KVKXQ?\F:?"G_KYU'_T;7BK=%KULX_BP_P+
M\D>CFGQKT0VO:/VQOO\ PV_[$O3_ .35XO7M'[8WW_AM_P!B7I_\FIX7_<JG
MR+P?^Z5?D>,R5>\)_P#(SZ;_ -?47_H:U1DJ]X3_ .1GTW_KZB_]#6N#"_Q(
MG#0_BH],_;H_Y.G\4_[T'_I-%7D=>N?MT?\ )T_BG_>@_P#2:*O(Z[,Z_P!]
MJ>IMF'^\S]3TK]CK_DYGP?\ ]?@_]!:N9^,'_)7/$G_83N?_ $:U=-^QU_R<
MSX/_ .OP?^@M7,_&#_DKGB3_ +"=S_Z-:NRK_P BN'^)_DC9_P"XKU_R.;KW
M+]@;_DJ_B#_L5[S_ -"CKPVO<OV!O^2K^(/^Q7O/_0HZQX?_ -^B8Y9_O,3Q
M"7_62?6F4^7_ %DGUIE>55_C2.>M\1[Q^S%_R;7\;?\ L'6/_H5Q7@Z?ZJO>
M/V8O^3:_C;_V#K'_ -"N*\'3_55[>:?[IA_1_F=F(_@TO1_F%>[:?_RCRO?^
MQL'_ **2O":]VT__ )1Y7O\ V-@_]%)4Y#M5_P ##+OM^C/":***\.'QGFGO
M7[1'_)I?PA_ZY77_ *$M>"U[U^T1_P FE_"'_KE=?^A+7@M>WQ!_'7^!?DCT
M,P_B+T05[S^WQ_R.W@[_ +%BU_\ 0I*\&KWG]OC_ )';P=_V+%K_ .A25>7_
M /(NK?(O#_[M/Y'@U=!\*/\ DJOAG_L+6W_H]*Y^N@^%'_)5?#/_ &%K;_T>
ME>9EO^\0_P 2./!_Q4=Q^V]_R=5XL_WH/_2:*O)Z]8_;>_Y.J\6?[T'_ *31
M5Y/6^=_[[5]67C/]XEZGJW[$O_)S_A?_ *[/_P"@-7%?%C_DJ7B7_L+7/_H]
MZ[7]B7_DY_PO_P!=G_\ 0&KBOBQ_R5+Q+_V%KG_T>]=E3_D4Q_Q/\D=$O]R7
MJ_T.>KW+]A'_ )'#QA_V+%Y_*O#:]R_81_Y'#QA_V+%Y_*L>'O\ >X^I.4?Q
MXGAM%%%>5B/XDCBK?&>W_ G_ )-(^,G^[IG_ *.->(5[?\"?^32/C)_NZ9_Z
M.->(5Z^<?[OA_P#!^K._'?PJ/I^H5[5>?\F!6W_8YG_TE:O%:]JO/^3 K;_L
M<S_Z2M4Y3\-3_ PR[[?HSQ6BBBO&CN>?'XCV[]HO_DW/X._]@VY_]&+7B->W
M?M%_\FY_!W_L&W/_ *,6O$:];.O]Y_[=7Y(]+-/XGR7Y!7M'[='_ "5+1?\
ML7['_P! KQ>O:/VZ/^2I:+_V+]C_ .@4\/\ \B^?JOU'A_\ <JGJCQ>NF^"_
M_)8/"O\ V%[3_P!'I7,UTWP7_P"2P>%?^PO:?^CTKS\%_'AZG%@_X\/4W/VM
M?^3C?&7_ &$GKSVO0OVM?^3C?&7_ &$GKSVMLS_WJIZLTQ_^]2]6>O\ ["/_
M "<]X=_W9_\ T1)7EWBC_D:-0_Z^I?\ T(UZC^PC_P G/>'?]V?_ -$25Y=X
MH_Y&C4/^OJ7_ -"-;U/]PI^K_)'14_W*'JRC7MG[&?3XC?\ 8I7O_LE>)U[9
M^QGT^(W_ &*5[_[)6>5?[P3E7\<\4'W324H^Z:2N&M\9PU/B/:OA)_R9I\5/
M^OK3?_1YKQ6O:OA)_P F:?%3_KZTW_T>:\5KT\Q_@4?\/ZL]+,/X5/T_4*]L
M\6?\F(>$?^QDN?\ T4U>)U[9XL_Y,0\(_P#8R7/_ **:JRGX*O\ @_5$Y7\-
M7T_R/$Z***\JC\9Y\?B/UD_8^_Y-H\%_]@N#_P!!KTP=*\S_ &/O^3:/!?\
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M2\^,/^PS=?\ HUJ_7U_]2_TK\@OVB?\ DO/C#_L,W7_HUJ_%O&+_ '>AZO\
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MWF?J>E?L=?\ )S/@_P#Z_!_Z"U<S\8/^2N>)/^PG<_\ HUJZ;]CK_DYGP?\
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MO)ZWSO\ WVKZLO&?[Q+U/5OV)?\ DY_PO_UV?_T!JXKXL?\ )4O$O_86N?\
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MK/7_ -A'_DY[P[_NS_\ HB2O+O%'_(T:A_U]2_\ H1KU']A'_DY[P[_NS_\
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M_P!#6O/PO\2)PT/XJ/3/VZ/^3I_%/^]!_P"DT5>1UZY^W1_R=+XJ_P!ZW_\
M2:*O(Z[<Z_WVIZFV8?[S/U/2OV.O^3F?!_\ U^#_ -!:N9^,'_)7/$G_ &$[
MG_T:U=-^QY_R<SX/_P"OW_V5JYOXR_\ )6_$G_82NO\ T:U==3_D5P_Q/\D;
MO_<5Z_Y',U[E^P-_R5?Q!_V*]Y_Z%'7AM>Y?L#?\E7\0?]BO>?\ H4=8\/\
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M?H?4/[1'_)I?PA_ZY77_ *$M>"U[W^T/_P FC_!__KE<_P UKP2N[B+^.O\
M OT.O,OXB]%^05[S^WQ_R.W@[_L6+7_T*2O!J]Z_;Z_Y'KP;_P!BQ:?^C)*K
M+_\ D75OD71_W:7R/!:Z#X4?\E5\,_\ 86MO_1Z5S]=!\*/^2J^&?^PM;?\
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M - KQ>O:/VZ/^2I:+_V+]C_Z!1A_^1?/U7ZCP_\ N4_5'B]=-\%_^2P>%?\
ML+VG_H]*YFNF^"__ "6#PK_V%[3_ -'I7#@K^WAZG)@OXT/4W/VM?^3C?&7_
M &$GKSVO1/VL./VD?&7_ &$I:^.]'_:H\3:I^T_-X/;P[&MFJ"SQ]OMVB6XC
M=GE=9?O,WV9HF\G[RUZ]3*ZF*KU90^Q=LZ,91E4Q,K=&S[?_ &$?^3GO#O\
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M\S;ON)_A3?\ ATAX<_Z&35O^^$_PK[ ^:E^:H_U-RC_GRA?V7A?Y3Y>\%?\
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M'S5A?\.D_#O_ $,FL_\ ?$?^%?7AX'-'1<FM*G!^4U-9T454RW#RUDCY /\
MP22\.@_\C%JW_?$?^%=!X^_X)P:?\1QI/]H^)M0?^P].BTNUV01KMAB^YNX^
M]7T]_#0#LHI\'Y3"+@J2LPCEV'C%Q2W/D'_AT?X?_P"ACU;_ +XC_P#B:FT_
M_@D_X?T^\AN(_$NJ[H9%=?DC^\I^E?78Z4W/O6<>#<H3O[)$_P!EX9?9/E[X
MC_\ !-?3?BOXUO-?U3Q)J+W]^RF4QP1QK\J*B\8_NJ*P?^'2'AS_ *&35O\
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MS3X;/XC> ?"OC2&U&V%M5TY)Y(1G=M1V&Y5_W36+\ _^"??P2_9AU%KWX?\
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M4 ?H)17Y]_\ $1A\+O\ HCW[3G_AO7_^/4?\1&'PN_Z(]^TY_P"&]?\ ^/4
M?H)17Y]_\1&'PN_Z(]^TY_X;U_\ X]1_Q$8?"[_HCW[3G_AO7_\ CU 'Z"45
M^??_ !$8?"[_ *(]^TY_X;U__CU'_$1A\+O^B/?M.?\ AO7_ /CU 'Z"45^?
M?_$1A\+O^B/?M.?^&]?_ ./4?\1&'PN_Z(]^TY_X;U__ (]0!^@E%?GW_P 1
M&'PN_P"B/?M.?^&]?_X]1_Q$8?"[_HCW[3G_ (;U_P#X]0!^@E%?GW_Q$8?"
M[_HCW[3G_AO7_P#CU'_$1A\+O^B/?M.?^&]?_P"/4 ?H)17Y]_\ $1A\+O\
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M4 ?H)17Y]_\ $1A\+O\ HCW[3G_AO7_^/4?\1&'PN_Z(]^TY_P"&]?\ ^/4
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M(C#X7?\ 1'OVG/\ PWK_ /QZC_B(P^%W_1'OVG/_  WK_P#QZ@#]!**_/O\
MXB,/A=_T1[]IS_PWK_\ QZC_ (B,/A=_T1[]IS_PWK__ !Z@#]!**_/O_B(P
M^%W_ $1[]IS_ ,-Z_P#\>H_XB,/A=_T1[]IS_P -Z_\ \>H _02BOS[_ .(C
M#X7?]$>_:<_\-Z__ ,>H_P"(C#X7?]$>_:<_\-Z__P >H _02BOS[_XB,/A=
M_P!$>_:<_P##>O\ _'J/^(C#X7?]$>_:<_\ #>O_ /'J /T$HK\^_P#B(P^%
MW_1'OVG/_#>O_P#'J/\ B(P^%W_1'OVG/_#>O_\ 'J /T$HK\^_^(C#X7?\
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M ,>H _02BOS[_P"(C#X7?]$>_:<_\-Z__P >H_XB,/A=_P!$>_:<_P##>O\
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M'^'M[\;/BOJU_:Z'96FMW3:'8V-G!'+<7MS*T*RMY?F(OE1KN;>N&KS'3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!'+&LL>UQN1A@@]ZJZ78V^F6D=K:0Q6]O"
MN$BBC$<<:^B@=*** +U%%% !1110 4444 %%%% !1110!COX*T>3Q$FJ/I6F
MR:NBX6\-LGGA?3?C=6NJ[:** %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nbx-20211231_g15.jpg
<TEXT>
begin 644 nbx-20211231_g15.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MG?-X0U5;#P?J4MV+*/3M:N#;^5I=XUT1#Y%TR.K/&S!4DC=NB^-'_!33X4?
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MCX<_!GX,^/M)_:EU;QE\,_%VCPS:+9V,:^!8_P"RK^.YAUU-6>RCMVL"L"W
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MXU\-:?K&E74-_IFJVL5[:7,1W1W,,B!TD4]U92"/8T :%%%% !1110 4444
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M'B6[^'?Q&\1V?B+1+>;P_:_:/"<D5[]KG42JP-R;@K K%]BIY.50%WS^D%%
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M+XI:%:^&_'<&A6=O<MKMI;@+$\$TF)+.X$:B/S8R?E'"C<^^E\;_ /@B:WQ
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M^-'C3XB^#?@.=3?X<>%=3TNRM8_#[W^X3//<0J'NF&XL,J@#JA&U5V']"**
M/QH_X).?\$>/''QC^$'@C4OBKXF^(W@7PU\,_C+J'CVU^'.J^'(K)=1O[>4&
MSOEGEC2Y6)@S9#>8K@OL,9)->YW'_!O''/XDU>-?CKXN@\$7GQ@7XRV?A:/0
M;'[/;:J95:02W!S/-F-%B0AT1%R3&[G</TDHH ^#OVI_^"%F@?M1ZC^U%=7W
MQ"UK2Y/VF'\,SSK#IZ.GAZ71%C$)4>8/M"RF,;D?;C/!!"L$\(_\$1[B7XD_
M%CQ3X\^-7B3QYJOQB^%5S\+-7E;P]I^D_8;:95C\ZT2U58HECC7"1&-N22SM
MG%?>5% 'PM\!/^",%]\*M=_9?U'Q'\9-8\:7/[+3:Y;Z!YGA^WL5OM/U"UM[
M6&R?8Y*K;1VZA7)=GW<XP*Y1O^#>S17^-D]PWQ@\9-\%;KXE?\+8E^&9TVT^
MS2:YD-S?8\_[-D!?)Q_JP!NW_O*_12B@#\_?'_\ P02T+QU\(?BIX3D^).LV
ML/Q0^-$OQFGN$TF)FT^X>4R&P12^'C&<>8<-[5[-\"O@]\3=&_X*;?'#QIK7
MBGQE<?"G5M$T.R\-:%J5[YFF0WXB)O9;*$2L(XU6. ,[(K22SSC[L89_IP\T
M@4 ]!^5 'SQ\:/\ @GW8_&3]O_X6_'J;Q/?6%]\,-#U71(-'2T1X;];Z&2)I
M&E+!D*>9D  @[><5X3X#_P"#<KX W?[)'PQ^$_Q4L=0^*UM\*9=9DT74KB\N
M='D0:G>_:YPT=K,JM\RQJ"Q. G&,FOOZB@#Y$_95_P""%'[+G[%7Q1?QE\.O
MAC;Z5X@DL)=-::\U6]U*$P2,C.IAN99(\YC3#;<C!P1DUT=__P $S/"LW_!1
MGP_^T+:W5G8W'A_P6_A&+PW#I$"V3N;M[D7V\8*S*7"C"]%'-?3%% '@OCO]
MA:R\=?\ !0SP'^T%)XBO+?4/ OA>_P##$6BK:JT%VETY<S-+G<K+G&T*0?45
M[U110 4444 %%%% !1110 4444 <Y\2OB=I_PJTBSOM3COY+>^U.RTF/[+:O
M.5FNKB.WB+[1A(P\B[G8A5'?) .3I_[0.@WWQ+U[PO)]JLKKP_$\TUY=*D=E
M,(H[:2?9)N_Y8K>6N\N%&9@%+%7V]5XC\,V/BW3EM-2MH[NV2X@NEC<<"6&5
M)HG^JR1HP]U%8WAKX.^'?!GBZ_\ $&GZ>T>M:G%'!<W<MQ+/)*J)'&.9&;#,
MD,(=AAI!#%O+;%P 3?#'QW#\2/#<FJVYMVM_M][:1/!,)8YD@NI8%D##@[A'
MNXZ9QS6QK>M6OAW2Y[Z^N;>SLK6-I9[BXE$<4"*,EF9L!5 ZDG KF/@><^$]
M2_[&'6/_ $Y7-=@PW4 <EX?^/O@?Q=K=OIFD>,O">JZE=;O)M+/5[>:>;:I=
MMJ*Y9L*K,<#@ GH*ZP2\5SWQ#^&MO\1+;3EEU#5=-N=)NS>VEU83B.:&0PRP
M'[RLI!CFD&"#USU KD/ '[.=YX+\ Z3HK?$#QY>-I-C%9_:7NH%:;RXPF_!B
M.,XSR3]3UJK1M>]B;L]2#9HKR#]BK4XIO@Y=68\52>+I]*\0ZS8O>RW4=Q($
MCU&X6%6,8 '[D1GD9.<\@BO7P<BB<>63B.+NKA1114C"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
MG5_BGI^B_%'3?"<UO?B^U32KO5X[GR?]$CAMI+>.16D)_P!83<H0H!X5B2OR
M[NFK+U?P;IFNZO:ZA=6<,U]8HT=O.1B2%&DBD958<@,\$)(Z'RUSQQ0!YSIW
M[66B^*O@5K/C*SM;W2VTVV>2.RU94CE,ILDO8%;RG=<2030N,,2 ^#M<%1ZQ
M YD@1CU9037F_CKX::#\)_V:/&6D^&]+M-'TV/0[]EM[9-J@_9F ]^%554=%
M5%4850!Z-:?\>L?^X/Y4 9?C/Q[I/P^L8;K6+Z#3[>:3RD>7.&?!.. >P)_"
MN;'[3/@7'_(S:=_X_P#X5WE!&?6FK=0U.#_X:9\"_P#0S:?_ ./_ .%+_P -
M,^!?^AFT_P#\?_PKNMON:-ON:J\>S^__ ( '"_\ #3'@7_H9M._\?_PK9\%?
M%?P_\19[R/0]6L=2DL!&UQ'"^7A63?L+*<$!MCX/0[&]#70[?<UY9\5H[OX<
M?%?0_&%K)X@NM/U:2+1->LK'2GU)5M(;?49H)PD,3W"L+F:-"RDKAP"!UI:/
M1?U^ M3U2BO*K+]KOPW<^,+W1?[)^( FL;.WO&D_X0?6BK+,\Z 8^R[ACR"<
MD '=@$E6QU_@#XL:1\29;^+3?[5CN-,,8N8-0TB[TV9 X)0A+F*-F4[6PR@C
M*D9R"*'%K<=T]CIJ*:'Y]/:G5(!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4V3[M.ILGW: .0^!_P#R*>I?
M]C#K/_IRN:[&N.^!_P#R*>I?]C#K/_IRN:[&@ ILJ;T;W&*=10!X*OP@USX
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT-D)"R[V?<8VD,3 .2'B=6$;J\:?25I_QZQ_[@_E7*_'T?\ %BO&O_8!OO\
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M@UBWDDF<\!54/EB>P KL <BHU6Y04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 -]TU\7?LS>!-7L?^"K_Q6U=KCXH7&B0://:K)=BYF\)F
M6:;3Y$BMY))8XH[J)(F7R;>T90C.S7+2,RG[18X4U\/_ +&'PS\/>#_^"GOQ
MDNM+T'3?"<D%B^FVVDP?#);+?;(=//VN+Q$EI$LL,I,:_P!G^;+M,6\$>654
M ^X*;)]VE+JIP6 /7&:1G5EX(/T- '(? _\ Y%/4O^QAUG_TY7-=C7'? _\
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MG6XA:?VFMS=.+>2PM7PDS*S2*)_M R2<'(!P!COC^TGX+ S_ &XH'_7I/_\
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M=V@DL;103MDLB0P(7(Y4MAKY>=WBOD*_+HSW"BN)_P"&@-!_Y\O&G_A'ZO\
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M?:%XDT?2_$&AZE'Y-YIVI6D=W:7:9SMDBD!1UR <,",@5K44@.6^%'P/\%_
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M@.P/044 >9^,?A;X?^#?[+7BKP_X7TJVT71=/\/WR6UE;9$-NHMF 5%).U0
M %'  & *](M/^/6/_<'\JY;X^_\ )"?&O_8!OO\ TGDKJ;3_ (]8_P#<'\J
M)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ,TV3[M>4_M:?$[QA\+/"&EW
MG@W1UU:^N;YX9D?3Y[T$+9W,L,6V)E*&>XB@M_-;*Q^?D@G%5_!'Q?\ %7B/
MX]^*M(.C^=X9TVT-QITG]FSV<A_<6+Q9N)6\J;SWN+M0$5?*^QD-DDT =?\
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M:A87FA?#?P=K-WJV@^%'A@9;NYBEGM[54ENY7#/%!;11(((^7)) !];4444
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MR_+YX,:J2O'F#(KRCX>?L>>-/#'BO]LB\NH]+\CXX:DMUX9VW>2R#P];:?\
MOQM_=_OXF]?EP?:NN^$?[&8UC_@E-X3_ &??B$JHTGPKL? /B(Z=,)/*<:5'
M97#02,N"58,4<KU"G':@#PC4O@O^U.G[)'_"\(_CWK*_&B/0!XI/@0:-I[>
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MXM_L[ZSX?6Q-G\,OB.OBC6C<7'E.+,:3J-H?*&#O?S+J/Y>.,G/% 'EVI_\
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M/^_]M_\ &: .QHKCO^%67G_0X^,/^_\ ;?\ QFC_ (59>?\ 0X^,/^_]M_\
M&: .KO;A[:V>2.)YV52PC0@-(0/NC<0,GIR0.>HZUA_"GXBP?%GP!IGB*UL[
MZPL]7A^T6\5X(Q*8B2$?]V[H5=0'4JQ!5E/? S+KX9S6T!:X\:>+(XN QDN+
M8+SQS^Y[YQ^-9W@GX.WVD>%K&QD\9>(1-80);2)9/:1V\150-B(MN B@8PH
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MBK%YMHUF)))FA2]6(Q3;QY*G[?-Y@V.9 D0!0*V[TRBB@ HHHH **** ./\
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MLL" AAA@=HX(]:M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>nbx-20211231_g16.jpg
<TEXT>
begin 644 nbx-20211231_g16.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MY\-27/@WPUI9%RUS>:?JS+)!;DS8>&&POYH96D4>0J[RH!^EHHH%% !1110
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M!_\ 9=C_ &9?B_X-^'MG=Z/XHU!X-5'CBV2,7MV4A8;0KI9J<,,[KB,C!4Y
M/V-$BG^(?G4.H:K:Z1I]Q=W=Q!:VMK&TT\TT@2.%%!+,S'A5 !))X %?F-\
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MHH **R_&/B9?"6D1731-,)KVTL@%(!!N+F* -_P$R X[@5IIG;\W6@!:***
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M/&UO>P"$[006#_;I#@C@1$@XW5ZWX*^*_AGXD37,?A_7M(UJ2R"-<+97:3M
M'W;"P4DJ&V/@G@[&QT-.5-I<R3L*,KZ'04445F4%%%% !1110 4444 %%%%
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MUE<G\9_^1/L_^P[H_P#Z<[6NLH ***.] '-?&?\ Y(]XL_[ UY_Z(>MGP_\
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MJPMF>T44U9,GG%.J1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 #=*^)/V-IY/'/_!2[XO>)H=$M;&RMM-_LW_2/#=@=2TZ
M:1K*XD@EU*W\J:'S,^8;&XCN69D\T7*J!#7VVWW:^(?V:-<T^U_X*]_%K3=3
MTW1=4\57FBW4VG^(9;N*]U:TTJ"?2\Z8H&H3/:6JS72R>4+6U65MKD2.C2.
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MMR56Y\ATC?+(K,,KYL88J2 6 R<@FI+JA+S.@HH!S14C"BBB@ HHHH ****
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M68@<L0!ZD@=35B-R3SF@"2BBB@ HHHH **** "BBB@ HHHH **** .3^,_\
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MCCQ#;Z#K%E# ^JZ.MHT3&Y18HWV2RHZ1F)FC*,T9!,9?:22#CVS0/^0#8_\
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M"*[N8[9#$D8,"&-$=7V1A-I/T?0!S/QEB5?@_P"+,*H_XD]X>!_TP>MKP_\
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MN9OA].UY#!;W3:YK/FQPS&:-&_M2ZR%<JI8>Y4?2NTH **** "BBB@ HHHH
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MKM6.3[&886D=@TF] 53S#&#*(Q*_NGA\_P#$AL<=/L\?_H(H N4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5&\\+Z;J-PT
MUQIUC/,W#/);HS-VY)%7J* .?T'X4^&_#-G);V.@Z1;PR3RW+*EJG,DLC2R-
MT_B=V/X\8'%7/^$)T7_H$:7_ . J?X5J44^9]P,O_A"-%/\ S!]+_P# 5/\
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MCWPW_84^A'0_#O@MO#MMK'GK&LMW?M+>W;O-M1E1;=K>-?-D)5MRA/'?#/\
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MTWX8_"?1_#_@NTU>'5/#47@6Q:V\1S7BV@MKB5QM57M#;R,FZ.0YN&VF,Y+
M'N'[;?QLU3]FW]B_XO?$;0H-/N]:\ >"M9\1Z?!?1O):S7%G8S7$22JC(S1E
MXU#!74D$X8'D?-*?M-_M46/Q>^%?A&^'P"-Y\;M U#5["6'2]5\OP,UE]CED
M\XFZSK ,-T%54&GYD&2P4<_4G[6/P+_X:=_9:^)?PS&J'1/^%B>%-4\,G4?L
MWVK^S_MMI+;>?Y6Y/,V>;NV;UW;<;ESFN9U+]DV;4/CC\&?&?_"0(J_"/0M6
MT4V7]GY_M<WT%E$)?,\W]SY?V0G;MDW>9C*[<L > ^$O^"B/Q2\4^!O#_@>W
MT_X>R?&WQ!\5->^&4>IO;7<?AR*+28[J[N-8-EYYN"OV2W0"T%T"9YE'GA,L
M*/QF_P""D'Q>_9[^$GQFT+5M'^'>N?&#X2Z[X,@M+RWMKS3_  YXETOQ'K%O
M8V]P8#//<6<J_P"G1,OFSA7MTE'F*_E#T"__ .":>K:=I-WJ'AOXA0Z+X[L/
MBQJ7Q5\-ZU+X?^U6FFR7Z2V]QIMW:_:4:ZMY+2XN(7:.>!R71UV-& <WQ!_P
M2^U[XH_"[XDKXW^(MCJGQ*^*GB;POKVK>(-.\-M::;96N@ZC9WMGIEI8O=R.
MD ^SSC>]P[&2\FE.>(Z &VGQX^/2_&SQQ\%O%&K?"&;Q=<_#E?&^A:]IGAG4
M4TW3?]->SN+*ZM)-0,MUP 4GCGM\Y),0P ?D3PO8_$C3O^"0/[!DDE[X%U[4
MI?'?@";P?;+IUUI5O90G3Y?(AOYC-<M/(K<O-#'"&'"Q)UK]']2_93;5?VT[
MKXN2:X5@NOA^W@5M&2Q^<;K\W9NA<&3'0[/+\KK\V_\ AKQ'X5_\$Q?'/A_]
ME_X%_#'Q5\3?"^KV?P \6^'];T*^TGP=/82ZEI^DP-#':W2R:C,!<2[LF>,A
M%Q@1-G( "/\ ;7^-GPIT_P#:6\,^(/#GA/XI_$3X)^$=*\7:&O@_2+W28?$2
MZC#J'EV9LI;B[F$D4NG2DM%*[3)(@6-7&&Z[_@G'^UKXC_:DAUZZU#XE? ?X
MHZ-8VUK)'?\ @2WOM'U'2;MRXFLK_2[N>YEAV[04EDFB=OF5H%*ECU6J_L?:
MY'\;OC3X^\/_ !!OO"NO?%;POH7A_3KFST:WN)O#,^EG4F2Z'V@R17(D;4>8
MWB0*L1&XE]R<_P#L_?L3^,_#'[7NH?&OXF>+_ GB3Q@WA-_!MH/"/@F3PW%<
M6DEU!<O/?--?7DMS.&MH5C =(X5,P56,I*@'TU10O2B@ HHHH **** .3^,_
M_(GV?_8=T?\ ].=K765R?QG_ .1/L_\ L.Z/_P"G.UKK&;:,F@ JK-KEE;ZM
M!I\EY:I?74;RPVS2J)ID0J'94SDA2R@D# W#/458,RC^*O)?'/[-LWBS]HW2
M?B#9Z]':3:;:P1&REL/M =X(=5AB=9!*AC!35[K>H!+&. AD"NK@'6_%'7++
M7O@IXLGL;RUO(5TJ_B,D$JR('2*177*DC<K @CJ""#71^'_^0#8_]>\?_H(K
MP_PU^S##\"OV6?%WA^;5[K4_]!DN%GLQ)I?RV^EPV4*E8Y26)BM8VD);;)*S
MML4$(ON'A\YT&Q_Z]X__ $$4 7**;YR^M.H *^*_^"6G_!5>[_;&_86\2?%3
MXGZ-I/@?6/ L+:EX@M-/=WM8M-DTR#5;:[C\QBVQ[.X7.3P\<J\;:^U*_#GX
M+_"GQ-=?LO\ [*/@G0]/O9?#O[87PJ\/?#SQ9-;($_LV/1;M;^YFE)X)GT2Z
MU>VYYS#".BX(!^@__!,/_@H[KW[57[(?B[XE?&33/"?PMF\'Z_<Z=J:&]:"R
MTJUCL[2Z#W,MPV$=1<[7)(4%>/?Z!^$/[5/PS^/OPYO_ !?X)\?^#_%7A?27
MECO]6TO5H+FSL6B7?()I%8K&43#$.1A2#T(-?F%\7?"VLW_[/7QFUBWN+C3_
M  SX-_:_D\0^*Y_[';5X;7288[13=S62D&XM[6Y>TNI%&0J6K.1A#BS\:]'T
M?XR_"3]I;QIX/^)B_M$-J5KX$;QRW@KPK';Z-JNEZ9K?VJ^M8[BWEEBO;TZ6
M]TEQ"K.WD&")E.Y5 !]M_#O_ (*2^"_C[^V+X)\ _#'Q9X#^('A?Q!X2U[7M
M2U/1-6COYM/N;"ZTB*"(^4Y5%E3496^<9;RU*G&<]7\+OVM]#T7]DG3_ (F?
M$[XA?"6TTK?.M[XET75O*\,L1=RP1K#/</DM\JQLI))F#JHZ"OGSP/\ M-?"
M7]I__@L3\*=8^%WB;PMXR6Q^$OBJUU+5=""W$*A]1\/R6UK)<HNPR(HG;[/O
M+PAR61/,&[P;X+_&,?!7_@D-^R^;@_#GPQ_:WC_4[5/'GCW2!J.C_#B5;O7)
M8]3\MGC"7+;#;0R/+$BO=#<^#L< _1_PQ^V+\*/&?P=;X@Z3\2/!.I>!X[Z+
M3)=>M]8@?3X;N2>.W2W>8-M24S311[&(;=(HQDBI_@1^UC\,?VH'UG_A7'Q"
M\%^._P#A'IEM]2&@ZO!?FQ=LE/,\IFVAMK;6/#;6P3@U^3VL7-K\1/V;_P!K
MZ&;Q?J'Q8T/7/C!\*[EM;U70X=.@\2)/?>&$FN$M(X(8'MI FQ)4C99X8XW\
MR<'S7^\=)TZ/3O\ @MM.MK;I;VT?P*MX%$4>R-537Y@B# Q\H)P.V3CK0!U7
M_!0_]J+QI^S7I?PGL? 5EX7NM?\ BA\0;'P4DNOI/)9V*7%K=S&8I"Z.Q!ME
M&-P&&-<;I/[;'Q7^#?QMUCX:_%WPW\/Y-<OO!.L^-_">M^$[V[:QU&+3&@CG
MM+NUN%\VWE!N875UDDC=6=059/FP_P#@M!X&A^):?LPZ#<76N:?;ZI\<-'MY
MKK1]0GT^^MD;3]3R\5Q"RR0MT^=&!&>"*]"OOV&OA[^S7\+_ (G>*=$M_$NM
M>,]9\'7NE7?B/Q3XEU'Q)J\EFD,TBVJ7%]-,\,'F,7,4)1&;#%20" #B_P!B
M[XY_M5_M0?"/X4_$K4+?]GO3O!OC[3-)\17EG;QZP=3MM/NXXIY(XV9O*^T+
M$[!2<IO )RM8O@G]OOX^?&_P5XP^*/PY^'/@#Q1\/O!WB?5M ?P9_:=U'XVU
M*'3;J6TN)5<I]F@O&:)I8[&1"71D4SJSC!_P15_8D\ _#G]B?X"?$?3HO&D?
MB[5/ASI$UW]L\:ZW>:>KW%A"9=NGSW;V<0R3M5(5$?1 HKP/]K'XJ_LWW.K?
M$_QHNJ>)OV8/VO/#,]Y:Q6_A^:6W\2>)[R%W&GN-.13:^(+:] MV&Z*7*3%#
M)$REE /U7TZ\^W644S1R0^:BOY<B[73(!PP[$9P153QC=:M9>$M4FT"STW4M
M<AM)7TZTU"\>RM+FX"$QQS3I%,\4;-@,ZQ2%020CD;3\S_#[QG;>(?C[^SG/
M\4/&'C#P=\=M8^'ES>W?P]TB6X7PQJ%PUO:MJ;W"+')$9+6<E(2]PK ,<>9G
M-?37BOQ/IO@GPOJ6M:Q?6FEZ1I%K+>WU[=2B*"T@C0O)+([<*BJI8L>  30!
MX+_P3G_:A\=_M/> _B))\0M*\)Z3XF\!_$'5O!LL/AR2XEL72S\G#+)/B1R3
M(P+E$#8!V+TKQ_4?^"BWQLUK]F'6OVDO#'@7X?ZE\#=&BO=;M]#EO[I?%>M^
M';2202:I%-M%K%+)#$]U%:E7WQ-&IF1V(4_X(Q_M#> _B9K/[1FD>'?&?AG7
M-4U#XP>)/$=O::?J<5Q-/I<TELL5\BHQ+6\C<+*/D8]":\5^&'[7?A;X'_\
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MG7L>HV$-Q"XDAN$$D;CHRD9!_$&IJ .-_P"&B?A__P!#UX-_\'5M_P#%T?\
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M?_\ 0]>#?_!U;?\ Q='_  T3\/\ _H>O!O\ X.K;_P"+KLJ* .-_X:)^'_\
MT/7@W_P=6W_Q=))^T3X V_+XZ\&Y_P"PU;?_ !==G2.^Q<F@#YP'[76J6_[0
M=CI<NO?#V;P/)J-ZD^HQ:G;HT=H+*&2V;/GL-XN#+&Y8+NXV(PW%/7A^T3\/
MP.?'7@W/?_B=6W_Q=<C'^TWX2_X6[)IZV/B2+5GU ^&[JXFLC%!:/')$(6=7
M8/Y<TMY&D;JC;]^[A 'KU]#E%^E ''?\-$_#_P#Z'KP;_P"#JV_^+H_X:)^'
M_P#T/7@W_P '5M_\77944 <;_P -$_#_ /Z'KP;_ .#JV_\ BZ/^&B?A_P#]
M#UX-_P#!U;?_ !==E10!XC\;/VHK/1CIS>%/&'@6XLY(KI=0;[?;W%Q;L(P8
M9(P)P2 P8,JQRN<KM5BNR3I/AY^TSX6U;P#HEUX@\6^"M-UZZL+>74;--;M2
MMK<M&IEC!69QA7+ 8=AQ]YNI/V@/C5X=^&21V>NV/B&_9=/N/$4,6FV+S>=_
M9\D$HB5\A?.>1XPD9(W8;.%!-=A\.O&UI\2/ NDZ_8;OL>L6L=W"&EBE9%=0
M=I:)WC)&<'8[#(.": ,?_AHGX?\ _0]>#?\ P=6W_P 71_PT3\/_ /H>O!O_
M (.K;_XNNRHH XW_ (:)^'__ $/7@W_P=6W_ ,71_P -$_#_ /Z'KP;_ .#J
MV_\ BZ[*B@#@?$?[2'@NVT"]DTWQGX+NM0C@D:VA;6[4++*$)123(."V!U'7
MJ*Y_X'?M/Z'KGPNTFZ\7>+O!MCX@D1UNXAK%LJN5E=5E"[@R+(@5PC@.@<*P
M#!A7;?&/XHVOP9^'NH>)+VQU+4+/2T,UQ'9"+S$B4%GD)E>.-510S$LZ\# R
MQ"G!_9[^,/ASXCZ=>:7X=M]6M+?P^J)&FH0>4]Q;-)-%'<("2WEM);SH!(%D
M!A;<@!4D U/^&B?A_P#]#UX-_P#!U;?_ !='_#1/P_\ ^AZ\&_\ @ZMO_BZ[
M*B@#C?\ AHGX?_\ 0]>#?_!U;?\ Q='_  T3\/\ _H>O!O\ X.K;_P"+KLJ*
M .-;]HGX?X_Y'KP;_P"#JV_^+K@?#/[5EK=?'77M/U+Q+X'@\&V\&[3[P:O:
MAI/W5H4;=YQW,\LE^C+M!C6TA)&)E9_;V^[7AWA3]K7PGK?QQM](71?%&GZ]
MKES)H,TM]';PV]NUG%'=1JY,WWY%U'Y8T#2[ED5TC:)@ #N/B-XETWQ?\.=.
MU#2=0L=4L)M>T@1W-I.LT,FW5+93AU)!P00<'@@BJ?[4/@WQI\1OA1<>'? ^
ML?\ "-:OK5S#;RZVLI271[4-YDTL87YFD94\I0",-,&SA#G9^,ISX.L_^P[H
M_P#Z<[6NMH ^;]/\)_'_ %7X;Q+>:E9Z;XDN-9GO[Z*.Z@EM4MWLXVCL[>41
MB1;=+EG7<0LQ$9.[##-C]F70/CY8?%*"_P#B1>Z7<^'9O#ILYX8)(5N/[2CO
M[ITN#%&/*CC>UDC3;&S,#'%O:7GROHBB@#G_ (L64VI_"OQ):V\4D]S<Z5=1
M111KN:1VA8!0!U))P!6+HWQMT6WT>UC:U\5AHX44C_A%M3X(4?\ 3O7<.@D'
M/\Z=0!\[:]\7/&4_QEU!HM1OK'PFUSHS:-:1>';\W-U#$\QU19DDL=P9EDC(
M,<A&V"( (3(7]9_X7GH?_/MXJ_\ "6U/_P"1ZP/B-\:[+PE\;O"WAV;2&OIK
M[:6OO/6-K W#211;(R,R[FB</@CRUVM\V<#T^@#CS\<]#(_X]O%?_A+ZG_\
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M"\@_Y9J"6P!FFR_M&Z9#][XN?!Q?^/<\R(/^/B,RV_\ R_?\M8U9T_OJI*Y
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M* "BBB@ HHHH **** .3^,__ ")]G_V'='_].=K765R?QG_Y%"S_ .P[H_\
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MQRS,3ZFHVB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"A-\*_^"FW_P#B*** #_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\
M@IM__B*** #_ (43X'_Z$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B***
M#_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\ @IM__B*** #_ (43X'_Z
M$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B*** #_A1/@?_ *$WPK_X*;?_
M .(H_P"%$^!_^A-\*_\ @IM__B*** #_ (43X'_Z$WPK_P""FW_^(H_X43X'
M_P"A-\*_^"FW_P#B*** #_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\
M@IM__B*** #_ (43X'_Z$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B***
M#_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\ @IM__B*** #_ (43X'_Z
M$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B*** #_A1/@?_ *$WPK_X*;?_
M .(H_P"%$^!_^A-\*_\ @IM__B*** #_ (43X'_Z$WPK_P""FW_^(H_X43X'
M_P"A-\*_^"FW_P#B*** #_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\
M@IM__B*** #_ (43X'_Z$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B***
M#_A1/@?_ *$WPK_X*;?_ .(H_P"%$^!_^A-\*_\ @IM__B*** #_ (43X'_Z
A$WPK_P""FW_^(H_X43X'_P"A-\*_^"FW_P#B*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>nbx-20211231_g17.jpg
<TEXT>
begin 644 nbx-20211231_g17.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" %- FP# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**89<9^7I2I)O)H <1D
M5XS\>OBEXP^'7Q>^%^G:5'H*^%_%6O+I6IS3&1[X$V]Q)MC7&Q5S&F7))[8[
MU[,WW37B_P"T;\'?''Q-\9^#;[PWJGA&PL_"&IIK*QZG;7$LMQ<B*6+:3&Z@
M1[)<CC.5ZXXH H?$CQOXZ^(G[0^K>!?!7B#3_"D?A?P]!K5U>3Z8M^]_<7,D
MR0P8=@%A A8L5&\Y ##!KCO ?[37C#]J4_#?2/"^J6/@J_\ $?A"3Q5KM\=.
M6^:W=)TM5M[=)&V[&G,Q);+;$4 @MFN\^(?P.\;P_%B;QMX'UGPWI^M:YH,.
MA:Q%JEK--;CRG=XKB#8P(=#+(-KDAAMZ8.<32/V0];^#,'P_O/ASJVBIK'@W
MP[+X7NAKEO));ZK;N\<QE;RF5DD$\;/@':1*P.." #BM7_; \6ZC\,?!MU<:
MMI'A&^NFUZSUK5/L0FMI+_2R8DAB61B$6X=7;;DOA=JG(S7:>!_VP(]3U/0[
MOQ1JFA^$])M=!LVUD79\HS:S=01SM:Q%CE%MHR6DST,T8)X;'??!'X&-\&O@
MC:^&5O+;5]40W%]<7EU /*N+^>1YGEV=0GFN2!R0H SGD^<^*_V--83P_HHT
M'6M'DUR/1M8TK6;G5;>22._EU3RGN;I0I!#K)'\JGC8VTG@&@#VOQ?\ %[PG
M\.Q:CQ!XG\.Z%_: +VO]HZE#:_:57&2F]AN R.1GJ/6OF3_@B%\0=4^)W[%N
MI:MJVO:EXDFD\?>*8H+Z]OWOG>W36+E8561V;]VL84* =H4 # P![!\0?V#_
M (3_ !O\)^$=+^(G@+PK\01X+L$T_3)]?TV*\D@0)&CE=X.W?Y2%@.NT5X/_
M ,$"-&M/#G[!FH:=I]K#96&G_$'Q9;6UO"NV.")-9NE1%'954  =@!0!]KLV
MT5&S!F_^M3V&\XKY3_X*U>(+_P .? '19M/OKRQFDUV*-GMYFC9E\F;C*D<<
M _A7DYUF7]GX.IC&N;E6P'U5\H[T87_9K\3!\4O$P'/B/7OPOI/\:7_A:/B3
M_H8M>_\  Z3_ !K\L_XB]#_H'?\ X%_P"?:(_;)2JGJ* REORK\3?^%I>)>W
MB+7O_ ^3_&OU4_80U*XUO]E#P7<WEQ-=7$UHY>65R[N1*XY)Y/2OJ>%>.(YU
MB)8=4G&ROO<<9)['L"#&?K3J!Q17Z ,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^8?VP/VN)OV7/BPT^K:TNEZ(?!5[=:'9RQJR:_K@G58[=3M+M
M(JE"L:D;O,8X."1:_9 \2>-/#'Q?U3P+XN\87WC.\3PMIOB*_DO8(HYM&OKF
M25)+5?+"XB(0,BL"PP?F.:R_&_Q_^*VE_M1SVMG\%O&FO>%=/TF6.WA2_P!.
M6UN[A;H".]5WD 0F,$!"0X#9V]37=? '5_B+XV^+_B+Q)XH\)W7@/PO)IMM9
MV6D7M[:W5U<7:/(TERQ@+!0494P7.=N>* /;(SOC'N*;*-J\<4Z#_5+U]\T3
M?=_&@#R_XB_M=> ?A1XIN-%US6KBWN]/2.34&@TRZNK;24D_U;7<T4;16X;&
M0967CG@<U9^+'[4G@OX,:G!8:]JETEY<6;:B8;'3;K47MK0-M-S,+>-_*AW!
M@)'PIVM@G::^?/VJTN_A#K7Q-TOPKXO\,7>I?%6S\Z;PI?:/-?:O/<RV_P!E
M7[*8YHP(Y J\RJRQE2Q.T$5/X4U?3?V1?BGXJLOB'JD=JFI?#3P]I^E7-PI>
M/4'L(KV&[@C?!W2F26)O+'+>8I /- 'OGCC]J+P1\.SIO]J:X&CU:R74X9;6
MTGNXDLV956YE>)&6& LRCS)"%YZ\5U-KXZTN_P#&MQH%O>+/J=G91W]S#&A8
M6\,K,D3,V-HWE)-HSDB-B!@<_+GAO]EUH?V._".K>(M<U;PN]G\.K?0O$EE#
M9I<336*@3^0@8$QS ED! /WB,9P:PO$'Q'\<? ?4=0O6U"'0]?US1K?Q5'IL
MMBET?$-W)<B"/1][ L%MK98(\1%6WS-)G;D4 ?< /%?&/_!",8_8EUK_ +*/
MXN_]/=U7M/[4'[(T_P"TY?:%-#\4OBW\-1HJS*8O!>N)IJW_ )FP_O\ =%)O
M*;"%(QC<W7->%?\ ! #1_P#A'OV!+S3_ +5>7YL?'_BJW-U=N)+BYV:Q<KYD
MK #<[8RQP,DF@#[8'WZ^1_\ @L'_ ,F]:#_V,$7_ *)FKZX'WZ^1_P#@L'_R
M;UH/_8P1?^B9J^3XV_Y$N(]/U0+]&?G*W.[\:*#W_&BOY1.= W2OUL_X)]\_
MLA>"/^O63_T;)7Y)/]VOUM_X)]?\F?\ @G_KT?\ ]'/7ZMX3Z9C4?]W]32GU
M/:****_H0T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /DG]M7QIH=
MI^T[X1\/>/OB3K7P_P# ]]X>NKRW32]7.FM?:@EPBD3R+EM@B8%!P"P;G( K
MNOV/S\,5U+7/^%?_ !(UKQY,(XOML=]XADU06@R=K*'^YN.<D5R_[<'QA\5>
M'?$=[HOA2+PK8S>'?"=QXNOK_6=+_M"2>))Q"EK;Q[E5<D$NY)V@IQS7>?##
MX@7"?M.:]X06UT./34\+:=KL1L[-89[62626.2*5EX96V!U& 1\W4= #V:+_
M %:_3TI77<._X4B?<%$QPG?KVH K"P@^U"X\F+[1MV^9L&_;UQGKCVI9M.AN
MQ&988Y/+;S$WJ&*''49Z$>U?&O[5OQO\2>$OBE\2XYM>\=65OX=TJTF\.7/A
M=5DTK2[F1&RNK':PC9I-K$S?NQ#SE3U[;4]4\5?'[XP>*=!C\<:MX;A\!^#M
M)U".7PU-&D&IZC?K=R-<,SJ_F0*+9 D9X(=B<Y& #Z8>))$VMN8=\CK3&T^&
MYF1Y(T>2$[D9E!*'U'H?I7QIXG^.?Q&^)'PH\"^)+6Y\56-YKG@2#4M+3P_8
MR2V^I>(6D4-#<;$<+$4P0LA1,,Y+?+D>B>%OVPM'MOB1K6H^)?$%Y8Z*8X['
M2K6VT^XN;9(HI_(N-3N)8HW6&*2Z)@C>5E7;;NP)!) !]'*FT5\9_P#!"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'S?^W3\,8?B7#I,>I?"_6O'&@VUO,D^I>'=
M8%EK>E;R%9(H\J9HI%&64/\ P#Y2<5H?L07/PBAT[7+/X<W5]-K2RQR>(4UM
MK@ZZDFW""Z^T#S> ,*/N]<=ZP_V[_B1IOA#5-%M]8^(GCCPSI4MI-=7>B>#M
M-,NIWT,; /<R7*JS6]NFY58X&2>#GBNW_9V\)?#3X2^.-=\)>#='.F^(([&T
MU74[FY22:[U.&;>(I7N9"SS89&!RQVD'IF@#V1#E?2DE#,ORT1\(/;BB1BJ\
M4 >*>.OV0[S7_%'C"ZT/QOJ_AK3?B$BKXBT^*RM[E;AA%Y#20/(I:%VB 4GY
MAP" ",TSQ-^QDL%_;S^"?%FK>!%;PW;>$KZ*UMH;I;NPM@XM\>:"4FC6655D
M&3A^0<"M/XQ_M47'P8N-8DO/A[X^U+1]%@-U/J]C#9FR\I4WLP,DZ-A1D'*]
M1QFJGBC]LK3]&_LZ/3?"OC#Q!>W'AZ#Q3J%E8VL0GT2PF#%&N!)(H\PE) (D
M+.3$^!TH [*P^#5GX=^!T/@/0+R\T/3[/24T>TN;<AKBUA6,1AE+#&_:#\WJ
M<]:X+X@?L/:3XK2.STO7-2\.:/<>'[;POJEC:P12+J&GP2&2- [@F-_FD4NO
M)$K=\$7_ !M^VMX9\+:9INH65IJWB#2[[0D\47%WIT<9CT_2W952ZD#LK,"2
M?DC#/A&^7BNZT+XL:?XF^(6I>';'SKBXT>SM[R\G5!Y$/G[C%$6SGS&12^ #
MA2"<9 (!TT2=,#;MXP*^-/\ @A",?L2ZW_V4CQ=_Z>KJOLT29-?&?_!"/_DR
M;6_^RC^+O_3U=4 ?9A^^?I7F'[5//@&'/_/=:]//WS]*\P_:J/\ Q0$/_7=:
M_.?%;_DDL;_@?YHZL'_O$3YV(!H(&>E*!P*6O\M^>7?\S[I6[$97CI7U;\%!
M_P 6RTD^D(KY4<\5]6?!,9^&6D_]<17]2?1;DWG6)O\ R?JCPL\_AHZR/H?K
M3J;%T/UIU?W4?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SC^V?
M^S7XS^)-WJ6N> 6\/W6IZUX8G\):EIVL3201S6SR^='-%*BMLDC<OE64JRMU
M! K?_9Q^$'C:U^(VL>/?B%_8=GKNHZ7:Z'8Z1I$\EU;Z99P,TGSSR*IEF>1V
M)(55 "@#.2?6I?&.DQ,R/J6FQNIP0;I 00?K65H_Q>T/7?B-?^%K*[6ZU;3=
M/BU.<1?/&L,DCQK\PXW;HVXZXQ0!U*<+22?=_P \4J'*TD@RM 'B_P"T3X>U
M+XV?$CPO\/AI]\/!KL-<\4WS0LMM=00.&@T\/C:QEF"F10<^4C _?%<GX^UJ
MZ^ ?[37Q%UZ^\/\ BC7-+\?^%M,M]+ETC2IM0S>61OHWM'$*L8F<7,3*TFU.
M6^88./I!P V6Z*.?\_YZTS<./PZ#_/\ G- 'S%HO[)=GH7[)/A+_ (2BS\22
M>(/#O@J'1]5TO1+@E]8C&V5K"155BZ^;E<K@@,WS $FN-\:>&?B/\(;GR[*X
M\91^(=>TB+6;$:'923V5]XBFNQY]O=LJ,BV\, MX4$S(GE)(0=PR/M#V].F#
M0NWGG&?\_P"?K0!Y!^U%^Q%X:_:YOM#N/$/B+XF:"_A])4MQX2\:ZEX=242F
M,MYPM)8_-(,8VE\E03C&37A?_!O]H4/A?]@*ZTNWDNIK?3?'WBJUCDNIVN)Y
M%36+E09)'):1R "68DL<DG)K[91=@KXS_P""$?\ R9+K?_92/%__ *>[J@#[
M,/WS]*\P_:J&/ $/_7=:]//WS]*\O_:J_P"1 A_Z[K7YSXK?\DGC?\#_ #1U
MX'_>(>I\\CI10.E%?Y:GW(U^GY5]6?!+_DF6D_\ 7%:^4WZ?E7U9\$O^29:3
M_P!<5K^I?HL_\CK$_P"#]4>'GGP(ZR+H?K3J;%T/UIU?W6?+A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'S+9_P#!/KX(1_$7QYK&L:+X5UJ;6-1&
ML3VUT0#H@,$:R*?WO"R2+),2P4 S,.1S74_LW_LV?#GX9?$#6/&7PTDT*'1-
M<TR#3);31V6:U,D,LDGG>:KMEB) I7 P%SWKR/X7?\$]M)^(G@/3[[Q!H-OX
M=\;#QCJ%QXNO;FS\RY\:Z?\ ;IW^S3R!P9;:8"V=%<LJ*FT( 6KTGX&_!FS^
M$G[9/CQ?"?A>/PGX)O/#^G-/#960L]-O-3\R;=+#&H$>\0A%<J,GY,DT ?04
M7$8_QS1-]ST_"B+_ %8HE3>OXT ?&OQB\2Z[\2?CW\4+K4_".L>,O"'PO6U@
MBTZS\3G2HXO]&%U/<>2A4SSD,-H=@H"8'S'C8C?1_P!L[XR>+KF\OM>7PKH?
M@/0M7\,QV^H7%B(GU)+V=KTK&ZDS!88%&_(781CYC7KOQ._9"\.?%'Q5J&K3
M:AXHT:;7;5++6X-'U:2QM]>@3(5+E5ZX5F7>A5]K%=V*3XA_L>>%_']_:W4%
MQX@\+2V^DKH$J^'M2;3TN]-3.RTD51@QIN?85"NH=@& )H ^=;W3?B)\>?@3
M\/O%"VGB#7+K5?A[;1V-[8ZHMG'I>M&1&.H7 ,T>4:,*V[#X"L,#=7;>%?VL
M8-#\:^(O%FL6OB+5-/DTRWN8S:$?9=&T1)W@74'1G7<;F=9Y/D5F$,(/ ^]]
M!:A\)=)NOA6W@VW@DTSP_P#V>NE)!8RF!H;8*$$:,.5&P8]<$\]ZY7X@?LB>
M$_B+?V<EPNI:?:Q:;#HUU9:?=?9[;4["&0216LZ@'=&K!L;"IVNZYVL10!C_
M +5'[0?Q+^"6HZ#'\/?@7XF^,T&J+*U[-I/B+2M*72BI0('%[-'YF\,Q!3('
MEG)&17A__!OYJ%UJ_P"P!=7E]I\VDWUWX^\537%C-(LDEE(VL7):)F0E6*DE
M2RDJ<9!(P:^V@F#7QG_P0B&/V)=;_P"RD>+_ /T]W5 'V8?OGZ5YA^U4<^ (
M?^NZUZ>?OGZ5YA^U5QX A_Z[K7YSXK?\DGC?\#_-'7@?]XAZGSP.E% Z45_E
MJ?<C7Z?E7U9\$O\ DF6D_P#7%:^4WZ?E7U9\$O\ DF6D_P#7%:_J7Z+/_(ZQ
M/^#]4>'GGP(ZR+H?K3J;%T/UIU?W6?+A111F@ HI&;;2"0>] #J**0MCUH 6
MBC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%(7"T +135D#4[=1= %%&Z
MC=DT7 **;OYZ-^5.!S0 4444 %%%% !1110 4444 %%%% 'Q5XC_ &D=<\?^
M!?#G@/5O'O\ PA_B^X\=7/AWQ;>P2PV&I:=:)]KFM_)4XV1SQQVZI, 00_7)
M(KT7]D[7+CPQ\>_&/@/3/'6K?$CPGH^F6NH)J&HW:WT^D7DLDB/9-<J,/E$6
M0*>4S[BO4/BI^S+\._C??0W7BSP7X:\17ENH2.YO+!))T4'(428W 9YQG'-;
MWPW^%GAGX/\ AW^R?"^@Z/X=TP,9/LVGVJ6\98\%B% RQP.3D\"@#H4^Z*24
MX6G#@5'<'"?CZ4 >+^-_VE_%5G\=]7\#>%O!>EZ[<:+IUG?37-]XB33MYN#*
M%1(S$Y; B;)]Q3OB+^TQXFT+QK>>'/#/@F+Q)K'AW0;?7_$,;ZNMK%8+,91'
M;1OY;>;,_D3$9"KA%)^\,<7^V#\+#\4+SQ!I]I\$)O$GB;4M.6QTGQA'=65L
M+5RK>7(\YE2XA$+L6PBMGMG<<27O@?Q]\!?B;X@URP\-ZC\2)?&G@[2-'N;N
MRNK>!X=4L%NHR\PF=,0S"Y#[TW%2C#;R,@&OXS_;QM[#PQI>M^'O#LFMZ3/X
M2B\:WLLMZMJ]M82.$"HI4[YL[B5)4#9C.3QZ?X-^,,7CGXA:YHVGV<CV7A^"
MW^T:@S_(UU,ID^S*N.72+8S<\>8HQ7ENE?L@Z;X:_9?\(Z7K'ANW\7>+O!/A
MR/3[>.*[EM8KZ=55C#)AU62W,P!V2[EP"=N>*\]^(G[+'C?PZL%KI5GJVO:I
M>Z'&UEJ]G?K:Q:1XA>\,]W?S*9%.Q@T87"R$1V_EXP>0#[!DOXX64/)&OF'"
M[G"Y^E?&_P#P0@;=^Q'K3 @[OB/XN/'_ &&[JO8_VJO^"??PD_;=OM!N/BAX
M2?Q/-X;66/3W75KZQ\@2E#)Q;31AL[%/S;L8XQDY\/\ ^#?SP[9>#_V ;K2-
M-M_LNGZ7X^\56=K#O9_*BCUBY1%W,2QPH RQ)XY)/- 'VT?OGZ5Y?^U3_P D
M_A_Z[K7J!^^?I7E_[51SX A_Z[K7YSXK?\DGC?\  _S1UX'_ 'B'J?/(Z44#
MI17^6I]R-?I^5?5GP2_Y)EI/_7%:^4WZ?E7U9\$O^29:3_UQ6OZE^BS_ ,CK
M$_X/U1X>>? CK(NA^M.IL70_6G5_=9\N%-?.TXIU-/*U,@.>UGXJ^&O#.H/9
MZEX@T/3[J, M#<WT<4B@\@[6(/-5&^.G@O/_ "-WAG_P9P__ !5?FQ_P4\B5
MOVP=:X7_ (\[7J,_P&OGWR(_[JG_ (#7XQF7BC7PN*J8944^5M7OV)E*SL?M
M2/CKX+/_ #-WAK_P:0?_ !57-!^*/AWQ9J'V72]>T?4KG87\JUO8YI-HZG:I
M)P/6OQ*6VC)_U<?_ 'S7TO\ \$GX43]K2/:JC_B3W6,#WCK7)?$VOC<;3PDJ
M22D[7N3&HF['Z?1GY?PIU-C/R_C3J_8T:!1113 **** "BBB@ HHHH ****
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M>*_'7Q1F^)UIHLWQ,U[P;J'@?57CM=9\'3:5]FU%RH@M;426\4\YV&0<!SD
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M)OQP\!7F@K\'_AEX5^(EO=+,=4?6?%/]B-8E2GE!!Y,GF;@7R>-NT=<UX?\
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M]AS5IH9HIX9OB+XMDCDB<.DBG6KH@@C@@CD$<<T ?9Y^^?I7E_[5)S\/X?\
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M_P 9"W_(!TWIVU6'_P"*K]4=O-*1NKXC.> \OS/%/%XARYG;9V%**>Y^5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Y#_X*!>/O&P\9W^A>%_&&N^$8/#O@BY\7 :*D)N]8EBNEB:(M
M(C_NXXBS%5 )9UR>*UOV-?&&_P#:&\6^']/^*OB3XL>'CX>T[6+*\U&]M;I=
M/>5Y%>%F@AC7S&PC@=0IP1D9KZ$\-^)]!\=V]E>Z;J&FZI#?VIFM9H9$E\ZW
M)P60]3&2,$C@T[P+\*_#?POM+BW\-Z%H^@P7DIGGCL+..W6:0_QL% R>.IH
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MU*Z ?12 YI:8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ%]K7[(?VEU"MY.D^(U4X]C=FLIOV1OVW&;_ )#G[)/_ (*_$7_R57\/<<>
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MXD_^3:8'U9\5_BAHWP;\#7GB/7[IK+2-/"FXF6%YBFY@H^5 6/S,.@KQM?\
M@J+\%0,?\)1>9_[ U[_\:KQ_QS\,OV]OB/X8N=&UC5/V,;S3;P 31-H'B-@V
M&##AKLCJ.X-><_\ # '[71_Y9_L5_P#A-:Y_\D5\/Q%B>):=>*R>E"4+:\SM
MJ:4XP:U=OD?4_P#P]&^"O_0T7O\ X)KW_P"-4V3_ (*B_!7_ *&F^Z=M&O?_
M (U7RT/V /VN5_Y9?L5_^$UKG_R11_PP!^UT1_J_V+=O<#PWK@S_ .3%?/\
MU[CO_H&I?^!/_(TY*?\ -^!^B_@?QG8?$#PEIVN:7,UQINJP)<VLAC9#)&XR
MIVL 1UZ$9K7KXA\.>!_V_/".@V>EZ;K'[&=OI]A$L$$0T'Q& B+P ,7@'3T
MK0.E_P#!0L?=U[]C/'OH/B3_ .3*_3L)[5T8.NK3LKI;7MK^)SO?0^SJ-W-?
M&']F?\%#/^@]^QE_X(/$G_R91_97_!0P_P#,>_8S_P#!#XE_^3:Z@/LUSBL7
MQ+\2/#_@V[C@U;7M'TJ:9=Z1WEY' TB],@,02..M?)9TG_@H4/\ F/?L9_\
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M*>G _P"$9UW _P#)B@?\$_\ ]KG_ )X_L4_AX9US_P"2*_FB7ASQ)=VHQ_\
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M^HA!\DJ1(2EQA8Y50@[7P']]3A!]* $\L?Y-'EC_ ":=10 WRQ_DT&,&G44
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MJ6!*_*: /.OV5?V*?"W@WPGI/B#3=?UB]M_$ENVHZK86\GD^']:%TN_;_9[
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MK#.1D@^A?L[:OXT7QIKVC^-?'_@WQ=J&GVMM<+9Z-HKZ;-8I+N*22;I9-RN
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M&MCINH:]97$<MQ!=0-.[6BDF7R8PR[Y0N,+N&>0.2*^9]9\6_%#Q3;V?Q<\
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M_ 6K>*-1\.W_ (8^,GPOB$.F:QH6FR76G>,87_U< C1<R0S-\KPM\T#-O!
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MI+;2)T/5#MR6!S7J'A/X%Z'X(^*6M^*])2ZTVZ\20JFIV<,FVQO)E(Q<M%C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA$G(9F'I@FONO&4W?WB ??FJNF>%M-T!YFL-/L;%K@[I3;VZ1&0_[6T#/XT
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M ^CZ7JC+/XBU$OJ^O7 '-QJ%RYFG8_1V*CT"@=J]4IL?W!3J "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>nbx-20211231_g18.jpg
<TEXT>
begin 644 nbx-20211231_g18.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M\NFM='BBUS2Q-_9[SJWFJ+N,6UL_S6T4<@D0210B-_T8^.G_  3]^"/[3?\
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MM3NC#_X6?I?]ZX_[]T?\+0TH#[TW_?NMS[&OHO\ WS1]C7T7_OFCFI]G]_\
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M8U]%_P"^:/L:^B_]\T^:GV?W_P# #EJ=T8?_  M'2?[\W_?NC_A:&D_WI_\
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MB@ HHHH R?%YV^&KX_\ 3,U)X/\ ^16T_P#ZX+_*H_%X_P"*8OO^N9J3P?\
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M)T34X=/M;7P5XTU[5=0L9+BVCT\Z9"+^2"TANKM42:^5HA#'/&<SE ^3Y9?
M+?0$GP0\%W$\DDG@_P +M)-<6MY([:5 6DGM0%MI2=G+P@ 1L>4 ^4BK5C\)
MO"NF:M+?VWAGP_;WUQ%'!+<1:="DTD<:/'&A8+DJL<DB*"<!78# )% :&AX6
M\0V_BKPOI^JVK-)::E;1W<#,NUFCD4,I(['!'%<?\6.-7M%_Z8G^==U%:QV-
MDD,,<<,,*A(XT7:J*.  !P !V%<+\6_^0[9_]<3_ #KKP7\9')C=*+9T/PXB
MV^%+?_:+']36^:P_AW_R*EK]&_\ 0C6X16%;^(_4VH_PUZ'S1\*M7;Q!^V;K
M.K6^I2-I>I)/&MLXM5(ECB2/[L;&3&V,G>Y!'W2H)X^E=A/7TKQ_X>*L7[1?
MB:'^R]-T_P"RR-Y#0::D$D\310N9#((2S[G9\MYX#8^X"#7L#'"]_P *S-#@
M];^!=OJMQ'Y=U'!;VY:2"'[(C+%(;@SY/]Y<G:5/!7/0G-?*O_!=#2H_#_[
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MM0T7^RGN6U5K5+U9+_[1$L5KY2W,<JJP+!G*%560R;U$+!OC_P#X*27EU/\
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M@&-M6GTNQMM/E.O&Z\FW@GDD9EBA\O'VA% (.<'GM7S!X$MY/^'<\3>6V/\
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MEMI]-N]%ADMM9BNOM)N;IY96+1X>6.%L*@!&X'N3\D?M1_\ !(O3M:_X*.?
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M=RU8\9#'P?\  OL^I'_R86OH8JZC\C]%C*,J=-KR_)GUA_P0'&/VT]8XV_\
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M2^)I?B>#GV7TZ]+V\V[TTVO.ZMJ>J?\ !'8_NO!G_9"O"/\ Z5:I7UU\6_\
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MJ^&/_AMIO_EG1_PJ#]I?_HM7PQ_\-K-_\LZ/K$_^?<OP_P P_LNC_P!!-/\
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M2:WH=YX#/C3PD/&>F6%SH.7L+<V-Q?,BM$A#2&"QG<&($'RHP2K21*\FO?\
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MF@U$^(K?3]6LK^'0Y+NUT^WU&1;.PN;B81E;9;F4+#&TA4ML;HD;LOANM?\
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MCM;>]#0ZIXDM[V287?AV2*9IM.2\>YM9PZ!C/#_9=XI4[@K6ZKN!DA#@%_\
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M4-4\?:=K#7=G?>);[3I+^U:R?0M1G^P?:$55^R0/ TZQ JJ[@RM\U>N?M._
M+PC\8]6^'VN>-KC2UT7X<Z_+KGV35(8)+#4))M.O--2.;SOE !O]ZGJ71!WK
MYWG_ .",FB6=D]KI?CC4-.L7TF[L%3^S S6TTMOJMM%)"HE6*.*.+59 8A$6
M;R5VR1+),) #I/&/P _97TWPM9ZW?7>F7VC_ !%N)]#@>V\:7]U#XKN-0FO+
M6;Y4NB+R;?JUZ#*0\D(F9@R>4A3LOBG\!/@'<?$N^E\1ZEI>B^+(H+O6;LQ>
M-;K1[Z&&[N=,:>X=8KJ-EA>XTO31DC8&A51CS'#^;^#O^"66G^%=8L;6/XE/
M>:U:ZTOB'6%N[#^T+B6U?6;/5DB@^U7,T]N&NM-\O[1(\SO&T@8M+%%-%H?M
M,?\ !-+1_C[^T9#XLU_XB76EPZQJJ7-EH9A.+J>/31;M $>?R)1Y,$DV1;^?
MCS TKQ(B1@'<W&E?L_?#KPW\"VM[CPK]A\'W4%E\,!::N;IP]Q&-(7[+MD+7
M4?EWH1V;S54,)6PR!U\ZL_A]^RGHE_J'PSM=,:TN_ .OZ#X+N-+M+[5(;C3[
MNXFDU33 &24.87FOKAO.W%&)GC=B(V1>J_X=NZ=I_P 2X?$%AXIFA6Z\0Q:Y
MJ4%SI4=S)*+?Q%>Z_;06KEA]D47%_<1RNJNTT:Q?<*DO)\8?^"8_A7XR_$J3
MQ7=Z]XATW5[CQ8/$DTNGN(3=6WV*SMGTV3^]%OLH;A).)8I0=C!7D60 Z#0O
MAW\ ;SP-!I.GZEX1N-!\4:]I,5NL/B<R)J.J:/\ 9!8PQ.)R7F@_L^U'E(<M
MY'[Q6W/NY6\\%?LY_$CX?W?Q<CB:33E)\4W7]GZMJ%I.7U&/3YS')90S)S>&
MST^0VC1[;B7#F-Y)G9^3^#?_  39T;X4ZSX7N].^)^E7NJ2/)9,TNC6UXFK6
M<*Z0I2VBN)IECNXQHD >=0Z@2R@0H(K06NS\-_\ @GKI?PQ_8LU/P)\-_%4?
MB#3KV_TCQ5HDM](DUM/JEA/9W1)N5$C&VNI["(L")##YLHC_ '2Q0Q '*^)?
M"/[*'CW4O'R:QI?C:'3]*N=8AU'5&N_$EKIEY(=0N;#5;'3YXI0DFZ_U"XMY
M+*VP)9I558Y/+39OZCJ?[.>I^'[RSF\)^-GU;7+J^L9_#UOH^NKXA21=0AUV
MZF6VC_TB)8[K4+>[%Q'@(US L;@M''6O/_P3DTOQMXY\8>(XO'$<4VNW%T\%
M_H&CVMEJ,=_'JL%]:S7\\9:'4)M.N+*.&W,L*NL:R1S-,SLQZE_V6O&NI:_8
M>-X/BTTOQ ADOU@U(^'XY=#BTZ^ALHWL8+'SMXA#Z?;72.UT[B<S$LT4I@ !
MQ-E8?LS>-OAUJLD=E>:OH"ZUX7\&WLT\^JS/>W=[)!JFDAWDD\V7?)XD29YG
M)):[<2L?+(6EX.\;_LO?M":+\%M1TZ2^UK3]:\.6:^%KA[W4Q#<Z?::C:6]O
M;:D6E_TAXM2:UB\N]\QUN)&!&7E)TY?^"?'P[T71-<\6:YXPM]8U(>,O#OC&
M[\;:W!8/J5O)H$&CVCPRWH1%43-HI,[+L"O=7 "J/EKC?!__  3A\#^ /%WP
MVD\#_$&UO+A?#WAO2;FSFU2'R-4M=/NM.O6UFVACRYNKR+08(&\MUB*Q^</G
MBD\T ]K\2Z#\"]-T'P[\(?$$N@:?I7@>WL]*T31=7U1K='26QDT^&")I90UT
M3:W#0E6,A)F7.6*FO-O%/A3]DSX&_&*UT>^U'3?#?BKP=/HMO=1IXBU&TCTQ
M3:0R::E^PG6(P&'P[ P2X+(3;*74F<F7I/C?_P $^O"O[1/QE^)&N3>+9H=8
M\6>"[WPC>6<-O!-)HJ7UK% MTN?F60+ 63< #EL' K=^)7[&OA_Q;^U19_$7
M5_$-M"M[J&B30Z-<V<16]O-,M]72$*[M\VY-2E?:$+*;56!QN  ,30_V OV<
M-6U_3_#.FV,<^K>"](M+:WTRT\<:DUUIEBMI=6=H[1)>;UVVM[<10S.-RHZ;
M&'EQ[?#M&TO]BOQQX?TB^U#2_%/A?3_'EI'J-EJ.NZIK^BQZW:WD>K2?;FN9
M+A \;KJVI!Y'?<OVZ,/@-!CT[]BW]A'P/^R%\>K73=)^)-KXDU[PUX<-M%H-
MS.@U:W2>'3H9KF91.Q\E_P"SXRBK"@7S2&>41P"+I?A%_P $Q?AO\%?AO\,/
M#6FQ6;:A\/YM+O;G4Y;*)KSQ,=-M9K>/[1NSA%>Y,H5?ECD8%0"V: ':W^RW
M^S?I'C6ZNKNZTG1_$5MIO]OF2'QU>Z?>Z=9QP:=;-J$)2[5[:,P:781O<1[
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M;'6-5U2U^'MGHEGK]UJA@O+Q(MMJ+-YY([:26.S665RB/)Y+.[,[$M#\$?V
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MOC3J5U=^)M>\ ZY)XCN=.T&83>)(_+U&?2[TW5K9;%F"/)%=7FYH@,M]H1)
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M'K.MFZO-6\,W1:]C?7?$ 79=QPBWCCM["UTE[?)195NPJF;S%6W +EW^PO\
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>nbx-20211231_g19.jpg
<TEXT>
begin 644 nbx-20211231_g19.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH ***
M* "BBB@ HHHH *_ G]G#_@MU^TEXM_8!\?:=KGCE=0^-WC/6?#Y^&.KOI.GQ
M2+8WNJ7MA=O]G2V$+Q0'1[[=(\;[?.!)X4#]]C7YT_!G_@W5^'_PBUSX,ZL/
M&?B+5=3^#?AWQ#X?M9;C3[=1JBZI<:G<1S2@?=>U?5;DQA3@L$;@CD /V9O^
M"Q/B&;]E_P"!.BKX"\>_'_XX^,?AG;?$3Q+9>'(M/L'LM,+")[V5IG@@\R64
M,L5M "[E& 5?EW=U>?\ !;WPMXV;X3P?"KX:?$+XL:A\:/"6H^*O#EGIALM/
MDC%C,L5U;7;7D\4=N\3"56;<REXMB>8SH&R[+_@BO>?##0/AI=_"CXX>,_AC
MXZ\ _#Z'X8W?B&UT6QU!?$&BQS><BRVTZE([A)"[1S(VY-YX8<5WO[//_!)/
MP3^RW\1/@]JWA'6->ATWX.^"-4\%V-C=A)VU,:A<QW-Q>SR\'SGF1W(10I,K
M8"@   \\\:_\%Y- L_V2_ OQC\)_"/X@>*?"?B[1+S7[ZYN+W3-$MM"AL[B2
MVN+9[B\N(X[B^$L4HCM+<R2R+&6  (SY/^U%_P %6/%D_P 2?B-XB\(^-O$O
MA?X7R?LN:3\6_#\=MH.G7>IZ7>7NIR*MV(K@;7F^S&-##)*8@0>,_,=C3_\
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M7= KGSY$W;&*G.^*?_!"!?B-XB\>6\'QN\<:/X!\??$*W^*EYX6AT;3Y(_\
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M0=<\(>(O WB.[\'^*O#FL&)KS0M6M=OG0,\+O%*F'0K+&Q5@2."K*/F?1/\
M@@M'X1\/^$UT'XY>/-(\0>"/B%K7Q)TC7HM%TW[4E]J5M'%)%)$(A;M")$=F
M18D5HYGB 1=I'T?^P'^PW8?L-_#CQ3I\GBC4O&OBKQ_XIO\ QIXL\1W]M#:2
MZOJEX5\V18(AY<$05$"Q)E5PQ_B- 'SM\!_^#AWX(_'+]MF^^&NGZ],WAK68
M=%LO!VJ#POKD=SK6K7MQ-#-;2QR6@^SQH?LVV:81QGS6.\A&V]Y_P4Q_::^)
M&D?M'_ /]GOX2^)+#P!XL^.EWK$]YXRN=+CU.3P[IVE6@NIA;6TP\F2XGW!%
M,FY4"L2F65E^DO#W[/OA/PK\=O$_Q*LK.:+Q?XPTNPT;5;MKR5X[BVLFG:W0
M1,QC0J;F;YE4$[^2>*\V_;I_8/T_]LBX\!^(-.\7:_\ #?XE?"O4Y=7\(^+M
M%B@N+G2WFB\FY@DAG5HIK:>/:)(V W&-.<!E8 \FN/VC/BK_ ,$M?@%XXU_]
MI#QII/QGTB'7-.TGX=7^@Z5'IOB?Q-/>?NQ8WMJJQ644BS8"2QR;3$LCOM("
MGR7]H;_@NIXH;P!X7B^'?PKUJW^(5O\ %O0?A[XT\.:CJ6E7,VE_;FBGAM[:
MXCNS;2O?PLT4%P&:&-EE,OE[48^C:E_P0U\-_$G]G_XC:'\0_B=XV\>?$CXF
M>)-.\7:IXZO+>UCEMM0TT!; 6^G[&LX[6*/?&8&1O,CFD4L (A'3N?\ @B*U
MY^S-_P (K_PMBZT_QW:^/M+^(FG>+=)\$Z/IEOI=_IK9M(8]-@C6%K>,F1]D
MC,2\C$DJ2A .M^('_!9KPK\,OV>_C%X_U#P-XK6W^"_C^U^'NK:<L]LUQ<WL
M[6*^9$P<Q^6K7Z Y;GRVQP13_B)_P6'T[X=?MA3? &X^$_Q&N?BO>ZW:6>@:
M9#%";/Q!I$\<TC:['=[O+2S@6"03!\2(_P H5RKA/._C9_P0<;XTR_$S36^.
M_CC2?!GQ6\1V'C77?#]MHFG/'<Z[;FV\RZ,S(9?)D^S*WV="H238VXJFQNS^
M*_\ P1R_X6M^U1??':7XP>/-/^,%GX@M+_POK4$4?V/PQH]NDT?]A)9[MDMI
M.L\IG+,&E<AOERX< ^VP<BBD7[HSZ>E+0 4444 %%%% !1110 4444 %%%%
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M+^*(K732UQ?6UM%,\45PLV9DM;D1Y3:76,'96YX%_P""QO\ 9'P@^&>E^'?
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M)-7M@ES+<QM%*59H2DDK,NQA@_,.2: /RG_8C_X+ ?'KXEZ/^SUJ5G^T9/\
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MQ*L>U5VQ#RUVJ<D<Y8UWU !1110 4444 %%%% !1110 4444 %%%% !1110
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MS<?]"WX@_P"^(/\ X[1_PG-Q_P!"WX@_[X@_^.UT%% '/_\ "<W'_0M^(/\
MOB#_ ..T?\)S<?\ 0M^(/^^(/_CM=!10!S__  G-Q_T+?B#_ +X@_P#CM'_"
M<W'_ $+?B#_OB#_X[7044 <__P )S<?]"WX@_P"^(/\ X[1_PG-Q_P!"WX@_
M[X@_^.UT%% '/_\ "<W'_0M^(/\ OB#_ ..T?\)S<?\ 0M^(/^^(/_CM=!10
M!S__  G-Q_T+?B#_ +X@_P#CM'_"<W'_ $+?B#_OB#_X[7044 <__P )S<?]
M"WX@_P"^(/\ X[1_PG-Q_P!"WX@_[X@_^.UT%% '/_\ "<W'_0M^(/\ OB#_
M ..T?\)S<?\ 0M^(/^^(/_CM=!10!S__  G-Q_T+?B#_ +X@_P#CM'_"<W'_
M $+?B#_OB#_X[7044 <__P )S<?]"WX@_P"^(/\ X[1_PG-Q_P!"WX@_[X@_
M^.UT%% '/_\ "<W'_0M^(/\ OB#_ ..T?\)S<?\ 0M^(/^^(/_CM=!10!GZ#
MKDFMQR-)I^H:>8R!MNE12_N-K-6A0!BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **^%_$O\ P6/;P7_P44U[X-ZMX4T>Q\*^'=472KO7Y=4N%N$)
MTG^T3/L^S?9M@'[OR_M(F+$%8V%=G\/O^"S/P?\ B=KOAC2])N=2FU+Q1=2V
MMO:N]JCILC@D4Y,VV1G2YA(CB+R#+;E&QL 'UK17S#\,O^"FVC^,OV/_  3\
M5M2\&^*K.?QYJ%SINE^&]/CCU'4KN6![K=Y:HP#?NK25\<-P% )*@Y'@'_@K
M=X5UZ?Q=#KGA?Q)X?E\/2ZS+8--&JQZU:Z;?6]G,Z&0QF*57N[;>DH4(9,;C
M@D 'UKFBOE#3/^"Q_P (=3U/3X]WB.'3[_2X=2_M-K$&SB::WN;B.V+*Y)E9
M+28#:"I*@;N14%]_P6;^$OAWQ7I.@>((/$_AG7M3U"*P>PU*TBBFL_-,"QRO
MB0AHV:YA4>67;+$[<*V #ZVHKYW_ &@?^"D7@WX >-/$GAR;2_$.M:QX;LP]
MP;2W5;,7TEG/>6VGM,S +--#;R,"1M'RY(+*#S]G_P %,!X;^&GPK\1>+? N
MJZ7!\0/!\_B_4GL;R*[B\/Q1QPN(F)V-*S^>@!51C!S0!]445\H>+O\ @L)\
M,_"WB6?2H]&\<:M=6NK2:+-]ATU)%BN!>_84!S(.)+C"*??)P.:8G_!9/X1R
M>!8/%"1^*)/#DFF_;)M173P8;6Z-C+?+I\GSY%RUO#(P !3.T;LL!0!]99S1
M7A/Q$_;\\(?"+0OAK>>)-/US1IOBA<BWTJTNU@AFAR P,NZ4+N*LI$:,TAW<
M+D$#@U_X*T>%?"HTW_A+/#NN:7#J5AJ^J)J5D8KS3DMM.F>*9W8LDT?S*B9>
M(*9'"JS %J /K*BOE'Q5_P %4=#U?]GOP)X^^'?AR\\:6_C;QO;^"#;R74=G
M_95P9GCN'F?YPWE^6V!'N#Y7! .:J^&_^"S/PK\0^$=/\0-IOC/3]%OM.M-3
MEN[K3HQ'91WJS&Q67;(2'N?L\P0 '&SY]@() /KBBOF?]F+_ (*H?#W]J[X@
MZ9X9T'2_&&EZCJT,LMN=5TY8(F*6T-WY>Y7;YC;W$<@[8.,YXK \&_\ !7/P
MI<_"W5M?\4>&?$'AN\TF&6\6T9H6BU*U2^FLS/;S.Z*562$[A)L;D8#9!(!]
M;T5\NWW_  5V^$-G:^*IUOKYX/"NG:?J$KL(8FN_MT=O);(B/('7>MU#AY D
M9)8!SM..+?\ X+4^"TMM6\0KI;S> ]*^SRG4X;@RW<\,FG&[?; J[3(C@Q[?
M,PP&X,00* /M:BOE&+_@LA\'8/%7A?0M2N=9T76O$VLOH)L;VV1)M,NA=):(
MLZASP\TL8!CWC#;C@ X^KJ "BBB@ HHHH **** "BBB@ HHHH **** "B@M@
MTWS%]: /"_@?\/H?BI^SGXU\.W&H:II5OJ_C+Q5!+<Z=(D=RB'7[[<%9U=?F
M *D%2"K$=Z\-^*5KX9\-:Y\3_#8\"Z]J.CRQKIFN:@?$5QI]O>?8--FU/S8]
MMJ(8;@K/,R1VC>5NB'F"!=BOU4G[=7@_]B'X0FZ\7V?B"[C\1^/_ !?;VHTJ
MUCG96BUN]=M^^1,###&,UP.O?\%GOV<_%,31ZGX%\5ZC&UXNHLEUX<L9E-TJ
M!!/AIS^]" *'^\% &<5Q5\QPU&?)4J1B^S:N?19;PMG./H>WP6%J5(/3FC%M
M76^J1]A?!OX#>'?A#?:]JFB17"W/BRY6]O))]GF-]YE4E5!;#22'<^YR78LS
M<8S?VEI/$G]G>%X?#7_"11W%QKMO'=7&EJCI9V^'9Y;A&!:2+Y=H1<9=T+'8
M&KPSX4_\%K/A/\8/B=X=\):7I/CR'4O$VH0Z9:276FP)"LLK;5+E;@D+D\D
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MHC-9O@^[FO?"VFS7%FNFSS6L3R6BD,MJQ0$Q@@ $*?ER!VK2+8H *XC]G/\
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M% &3J'[=/[4VF^(+IO\ A2-K]G_X2"2UB\M'EEFL@\H57*GAHQY;'&20[$<
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M^"OQ ;2X/"FFZ.YNI=+BD\^"2Z9^!>'Y<2I@YYY]*\*'_!-[]H@?\T3\:?\
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MN;&WA@4Z?;P1^;%+$9/F>6($2-$9216H^A]\BBA>E .12$>5?L>_\DS\0?\
M8\>*?_3]?5ZK7E7['O\ R3/Q!_V/'BG_ -/U]7JM, HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _*:S_ ./O5_\ L-:I_P"E]Q5D]*K6?_'WJW_8:U3_
M -+[BK!/%?T?EO\ NE+_  K\D?QMG'^_UO\ '+\S97_DU77_ /LK&G_^F6VK
M'[UL+Q^RKK__ &5C3_\ TRVU8_>O)X?^/$_]?9?DCW^+O@P/_7B'ZF'\3O\
MDG.N?]>,O_H)KT;]HO\ Y.O^*W_8?@_]-.GUYS\3O^2=:Y_UXR_^@FO1OVB_
M^3K_ (K?]A^#_P!-.GU=?_D<TO\ !/\ .).%_P"2:Q'_ %]A_P"DR.5/2LGQ
MX-W[,7[2OK_P@^C]/^PE=5K'I6/\0<?\,O\ [2N?^A(T8>O_ #$[GMS_ "/T
M/2O-X\_Y$E;Y?F>[X/?\E;A/\1^<!Z?[)]._\_4>O7OG$D-^?]#E)_N-R/H?
M\3]<]\DM([[CN^;!/US_ #SU_4G)R2\%\-MI,><[&[].#G_]?_ZQ_%\=S_9W
M$2_=M+L_R/Z4/V3@1^RQ\-,\'_A%=+R,?].D7L/Y"O0*\_\ V31M_97^&8]/
M"FECIC_ETB[5Z!7[)#X4?Y[XC^++U?YA1115&(4444 %?(O_  5:GNO$?ACP
MUX9M?A[X^\8F]>[N)+[P_H<NHQZ6OV>2+:2CKLED9PBL<E%9W'*\_75?-O\
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M(^G6^FRP$Q0&**,%?D1F7GCVKXN\.-M^ GB09Q_Q,[/CUX>J7C%O^*%\'_\
M7"YQQ_TW-;4\TQ<(IJ;V_4\/'^%7".,J-5L#!>^U>*Y7I"]O=MI?[S]5(_\
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MK*9WNWO2!;YC"[D!W DL!M .:0'0GXJ*/^9?\5?^"UO\:/\ A::_]"_XJ_\
M!:W^-<3XQ\=6>E?MI^"M N-3F^U:OX<U*XM-._?K'^ZDAWS JOE,V&"XD8$
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MQ=X=T[386:XTV_T32X)[[5M-OK;1K34IV!C=Q<1EIWA6..+<286#OYFT>_\
MCKX9^'?BEI,=AXET'1?$6GPS"XCMM3L8KR&.4!E#A) 0& 9AD<@,?4U'H'PI
M\,^%M?\ [6TWP[H.GZI]CCTX7EKI\4-P+5 H2#S%4-Y2A5 3.T!1@<"A%:6/
M/OV&==C\4?!/4M2A@OK6&_\ &/B>X2&]M9+6XC#:Y?$"2*0!XV'=6 (/! KV
M*O*OV/?^29^(/^QX\4_^GZ^KU6@D**** "BBB@ HHHH **** "BBB@ HHHH
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M5$3+R87!DW@8[CZ5R-Q^T5\??A'<^"O#OC3QOXTTCQ)):6[ZG:75[ME+/=2
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M&J5OCEX934%M3J3?:&N[2Q"_99N9KJ/S(%SLQ\R<YZ+T8@\5UFS_ &C1L]Z
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M\GKY'QMKT;CQ)X-_>;F;3-/*G:/D!8\>^/>O.;6%G^.GBU1)AA#K&6VCYO\
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M:;UCPE-\*['0_#_A&RMXM&UY;?;&XMUE1$A;RP-J0WBJJ#:(_-N K2#.,O\
MX*W\_P#!-_XL<\G24'3K_I$/L?Y'Z&OI'8/0?E7SA_P5R&/^"<?Q8_[!"\?]
MO$/^>_T/2N6K&4:$U*5]'_PQ[6!K4ZF8X>5."@E*"LFW=II-ZMZO=].Q^!.T
M ?Y]_P#'WZ]3R7AOFS83%CQL8_H??V/IWY&"1-GG\>_^?KW]>>I$-^=MI-[(
MWX<'Z>GMT[8_=_D4=T?WQ6:]F_0_I,_9/&/V6OAK_P!BKI?_ *21>P_D*] K
MS_\ 9/;=^RS\-3Z^%=+_ /22*O0*_98?"C_//$?Q9>K_ #"BBBJ,0HHHH #R
M*\=_:0_8M\/?M,^)]'U;5M6\1:9=Z+&8X?[-N_(5QO#@L,'D$5[%10!G^%]
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M?$&\-CX8U34=0T^U7QKJEPR?:+_PY<1"1X[>V68)'I^M1A'C*A=05?G\V9@
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MF\5)H9";.SFED^S%HRNR5I& PT8!S?BBQ_:Z\4?&[Q)8Z==>+/#?@J]U2_\
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M^3;WR2VSW'WQIT\MUI\$D\/V>:2-6DAW;O*8C)7(X.#QGOB@":BBB@ HHHH
M**** .3^.G@>7XE_"'Q'H$-YK%C-JVGS6R3:5?/8WH+*>(KA"'A9ON^8C*RA
MB596 8?./@G]GCXN>&OMUUI5U?6>LZY\-_"N@SRZMXB/V72KVVEFCU)+41BX
M$%PMN[2).(9$>>2,NTJ)L7W#]K+XA>+OAG\'5O\ P-96-[XEOO$&@Z+!]MT^
M>_M[.*_UBRL;B[D@ADCDD2W@N)9R!)&,0Y9T7<P^>?AA^UQ\<-:^*7A^UO/
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M@'\"_B5XU6\\ ZE;VLUB/!L-MI5Q(\4,]U' _P!L#WD<=S(1*A3RY+=,@[F
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M K-"2TB_55Y\"_!.HBX%QX.\*SB\TZ/2)Q)I,#>?91D%+5\I\T*D B,_*,#
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M_+NC'EW/V?WOXA?LP> ?B9H6L:?JOA'0Y(?$&G1Z1J$D-HEO<75FC*R6S2H
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MP"X^M8OA_H,%UYT>BZ2DQF^T%UM(PWF>;)+OSC[WF33/GKNED;JS$Y5I\!O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>nbx-20211231_g2.jpg
<TEXT>
begin 644 nbx-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Z ET# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT6TFD8PW*2C(3KC(%?<MQ;QZ3:-;H6B>11B;INH1)VUEXEU3P[(\D]DQM9>
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M''&!@=,4E>ZFI*Z.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCJ?A7X%)QK=U$'50RK"XSVZ\BNR\8%)-)G0(T3G:%Y^7FM5O+M8?)13;H 0
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M/^1S9A1<X^VZ]3Y[ [TA]J&Y]L<4<<8K]*7<^<"BBBF 4444 %%%% !1110
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MI9^(@RR*&1N[,&/RD?2N%^V20W^05LH @)?=R>.*RAKQ738DCS;QO*0;@?\
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MBDB<8*LIP01]0:KYSSC%?7/[>WP5B\/:U8^/-'@VV&J'R[U8^5CGY*M]"/U
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M4 BB"%_O*W/XB@+$UQH-A=/:"[$<TJ\R=#GV/K6;KWAO2+7Q)97]AIEJ)%0
M.L0SUK4MX;<J+J9MLD)PV6Z"KFH31W]G!=0J&BS\S#J,4NHS1M-5O[R14<(X
MC&T*1R/2M?P??7RW%Y/?GSA&<(9OX #VKRBX\;76G^*+6.!B!, AR3ZUUUQ<
MZK<7I^SGS0RX*AS3#R'>,_$5Q_;<(TT^9:DXFV9[]>E<_KFDWGF&[L]TT>[+
MQ[L@#'85J75@^EL;>0_/<8;<H^Z?0U5M;.[TQ6<R^8C/G9N^]03L06,::DJ6
MCK+Y17ECT--T=;2UO7A<%TCZ*^ IJUK&H?9K..2&#RD V^7M.<UC6JPR+YLR
MMN)^;GI]*!G76KPW%]$ABCBR?^68Q7Y2?MJ1^3^UE\4U!R%U<\_]LHZ_5%8U
MMYHFMW^?=G+'FORM_;1+']J_XH[^O]K9_P#(4= >1XO1110 4444 *.=W&:]
MF_9%\+KXF^.^B93?'8"2].1D?*./U(_*O&1W XYKZH_X)YZ<LWQ#\27>!FVT
MS"D]MS?_ %C7@9[6=' U)=4CNP<?:8B$?,^C/BGJ0EN+N+);<W0?Y]:Y[P#X
M&:&?^VKQ \_W4A?L.Q'O761>'7U[Q)<27 'E*Y;YNC5NWL21LL3@Q*OW63I7
MYGDMG)2Z(^DS[$J$?9KL8URHDDVPN;5E_A]:R;Z/YB9HB,\AXZVIF8*P?;<)
MCJOWA66,R;DMY2.WEM_*OUC!WI[GY%6<NG4;;JZ1^9%-YP_NGZ5RGBA0VJV<
M0+6#'+^:OKUQ^-=9>*L<821?)8=2O2N0\07!'B.R9XAJ42Q,?(/<8KU,'#FK
M1N[W9$[X:#BG=I&9;3'&MR"U%R?/13>$8Q\O(^M:D,074M*Y.O2[&8P/@A?<
MXK%A61M%UB>&_80F>,&Q<C+>P'Z5T.G1QR:_I@LD/A^:.T+,'&!)BOU3 8>,
M8IV6O^9^79QC)7:YG=,A:W\S3;R7[9]D99N-.)PIY^[3[BT2^U(!Q_PC#&#+
M%#Q+CM4ES!$UC,D]JTETUQD:GCY>O4GVJQ=2,VI;-07_ (2&-8.&A7=Y9Z8X
MKW8PCLCY"=6=1Z.USG+N!HM*?SK,0PY*G50?F'O^(K"U"T:WBMH[(_VTOWEE
MD.['^S727P;3O"\]W)J'VJP5_FT^0#=CLN/K7'ZAJEQKFL0Q>'0='\B 22+<
M?(&..H]Z\RM&+7W'N8.C5K-**LN_0P=;U*TTV\O;F[F2XGC01BW!R02.H'J*
M\[UK6KW6(UMGE^P0*#@GY5#=00.U:6I-:R6KL8Y)M;DG_P!:5.P\\D'VK#\0
M*[WLL.LR+-+'&(U6$\>HX'6OGZ\'?38^_P )0A1C=N[[_P# ,32XX;FZ,.\B
M?(\BY/3S!DD9]*]T^&?CI]8L7LKQO+O8!B>)SRX(QQZUXA 6\H>=&J6<SE49
M3_J7QC)].M;&CW=Y;ZHES$VW6;/GC@7,?M[XKSERJG>6W8UQ--U(<T'[RV?F
M=1XDMW\*^))X0S"W.)(F8=5;T]Q7T!\#?&3ZI:QV)&/)(W?[2^]>0ZY;P^/?
M"::A;,?/L_W@SUX'S*?I5[X/>(GT*ZD=5WET"H1^?YU^:YM1A@:LY+X7^1]O
ME&*J9AA5"2_>+1_YGU-\9O!Z>/O@9XNT8QB62.QDN[9<9P\?S+C\0*_*-EVM
MMQC'2OUY\)W\FK>&]2,PPL^G21G\5_\ UU^1E[$+>[FB'2-V4?F:^:X8KPJ5
M:\*7PWNOGN?6XRE.G"#J;V5R"BBBOT$\D**** "BBB@ HHHH **** "BBB@
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MD8;VYN71;>9'VY)Y4@]CQTK[N^%_[0FK:UXDUWX4?%_5<V4]O#>R3"#8%>U
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M6+4($4HS;'4G'RD\FOS[ARO[2BD]UH>[F-)U8N)]!:G\UP<KE0,A6/\ 7O\
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M?]G5O^?AY'UN/G^!^TG_  S?^SU_T ]!_P# ?_[.C_AF_P#9Z_Z 6@_^ _\
M]G7XM_:I/^>S_P#?1H^U2?\ /9_^^C2_LVO_ #B^MQ\_P/VD_P"&;_V>O^@%
MH/\ X#__ &='_#-_[/7_ $ M!_\  ?\ ^SK\6_M4G_/9_P#OHT?:I/\ GL__
M 'T:/[-K_P X?6X^?X'[2?\ #-_[/7_0"T'_ ,!__LZ/^&;_ -GK_H!Z#_X#
M_P#V=?BW]JD_Y[/_ -]&C[5)_P ]G_[Z-']FU_YP^MQ\_P #]I/^&;_V>O\
MH!:#_P" _P#]G1_PS?\ L]?] +0?_ ?_ .SK\6_M4G_/9_\ OHT?:I/^>S_]
M]&C^S:_\X?6X^?X'[2?\,W_L]?\ 0"T'_P !_P#[.C_AF_\ 9Z_Z >@_^ __
M -G7XM_:I/\ GL__ 'T:/M4G_/9_^^C1_9M?^</K<?/\#]I/^&;_ -GK_H!Z
M#_X#_P#V='_#-_[/7_0"T'_P'_\ LZ_%O[5)_P ]G_[Z-'VJ3_GL_P#WT:/[
M-K_SA];CY_@?M)_PS?\ L]?] +0?_ ?_ .SH_P"&;_V>O^@%H/\ X#__ &=?
MBW]JD_Y[/_WT:7[5)_SV?_OHT?V;7_G#ZU'S_ _;'P]\!_@7X?U[3]3T;2M)
MM=7LYTGM)[>V_>1RJ<JR_,>0<=JU-<\,?##Q#:W=GKMS;S/-+()/.A9=[;OG
M/WASDFOR/_9-E,W[4?PE1W9T;Q/8@J2<']Z*_27QQ^SGX3\:>*KN>_L@38W\
MUQ"VYLJYE9B<AL]31_9M;K,?UF#[_@>HZ/\ #'X8^'=.&FZ?!%!9*=RQK:L=
MK=<\FNBGT_PBJJ\VI.=O(W6A],>M>+WU]:Z+K]OIMM 2YPID&>..OZ52\4WU
M_?3-"K,ZJ0JA/YGBE_9E7^=?B/ZU#S_ ]JM])\"^<]Q'=DNPPTGV5AQ5BWTW
MP7"'6&^>/=RV+5B*\F\,Z$?[(F34&P'!^7^*I3;01V4D=O(T21)DG;_7O4RR
MRORM*2_$'B86NTSW/P/I?AJW\0QRZ7<M-=F-\ PE!M(^;DFN@\5>'?#FH*[:
M@L9E R"<G] >:^:O 7C9X[]Q:RRQW48D7:%&0H[DGU]*WYK[4M8NI&NY(9)&
M'[L$#>?RKSHT:\I2H*BM'N]O4ZY2A3Y:CJ/;9;DGBNRT?SWM+*^9\?\ +N8O
M*VCU!/6N5<17NGZG%YDTQMK=@H// &,5<_LB:35?.*-"5/$K-N)&>1SVI+K2
M[FU_M"839@F!0+Q@GM7L9=@:^%DW*IS7Z=%Z'-B<1"M&R@EY]3X>^'_@WX5^
M)O&6LV-Q)'X.\17/VNWGL[F03R/YF"I3)PK9W&OGV]NO$?PZ^&?BW0;:WAG\
M*ZEJ/E)?70!DGV,0KQC^Z0.OUKK?'GA+PE\._%7C]/$L6HZ;XFGL9[K1?..4
M$S2'#AE.<X)QGIFO&;/Q!?Z?I<ECK%C<:E#?VNRU29V'E?-E3'V_+M7TQY5S
MUG2?V9]<GATB^T"6Q\3VF([RZM[>80SP%@I"]>G&17H?[.WPU\/_ !8^(&H^
M)=:U/4+[7]*N&-U8W07<JC*HK8]EQ7FW[)NK:SX%^/\ X>M;F^DTZTU ,+N*
M1AMEB$;%0W)XR!C\J^B?AW\4/AFO[0'BX>'89#;ZK!]IN+M]R*LJ$JZX/.,G
M=GWI"/J+X>Z=I^C>&[32;FW4Z6JLJ6P&WR%YQC'N17@'[1'Q*T'P[?W^BRPV
M-_\ 8],DDFT]Y\2R-D  #N2#G\*Z_6_C=X6D\<>&-!L[J745U562:XL8S(BJ
M",$D=*^2?V^/@[#X%^)4&OZ49[VPUA!,3(&*HP.-N3VH Y?X,^--8T3Q98Z#
MX'D/DZW=":9;B$R-:=MI'ITY]#6QXJ_::^)W@7Q=K7AB3[-'?I/+"Y6W![<%
M?;O7&_LY_'*P^#7B34-3U.Q:\$T:HC0J Z$'H/08K[:\"_#'P=^US\.-;\4V
MNF26.I.DB1731A9]X!P=V1D9/)Q0,K_LT_'T_%ZRU&)"NE>)K*V'F%>DBY W
MC/IZ5ZEXLUGQCK7@O4[+PM=PZ-JP0[+VY=<''WF;/ !KX>\'_"7XH?!Z0Q:;
M=Q:;KFIW2J(VD1W6U7<"[@@G!R.!CI5OPC\+_BW\2/C%9>!-<U;5-*T6_FF@
MN-248@\HG<Y4]\\8!HZ!U.:^.?CCQW:6%M\/?'\L!OX;L7R:XK[DF0C*X*C&
M!7#^!/BM<>!OBA8^(+Z^NM6LXT\N?RV8+*NW!QG@@<=*^@/VL/#>B^&_&FA_
M#'2[B3Q'8^&=+)O[B[(@D. 2&,A_# %?-5G"K6NEZ3K&EW-LLNH[[2XD.R-D
M8!2-QY(!P>/>@;T9^F7P;^)WAWXEZ&FM^'H]D# I/&BG<K#L:]1ANHKV'RF0
MND9Y5NXSD5XK^R/\%-1^%'AQ[34+D7#7KFXD6,#:F[L#],5]#W&B&!FC@0#*
M_>/:@DE69M6T\V@D,:J 551T'I7+/H+7WF17*N\:2JR;O;O707&O6OARSC"2
M)]J)"2L^< ^E<=\4/B59^!?"M_KDOF316L7F/'&"6)].E R;Q?\ %31/"OAZ
M^F>\\IM-0B?Y<C(Z#/K7R3I_[5VL?&;4M:TJ'P3)KWA2)E6Z:.4,[1@]2AQ]
M[ X'->/Z+XX\;?%[XJ:\/""![+7\2RI?X,<"C \S![@YKG_'GA+6_P!G/Q9;
MWVD>,H[SQ()#)?65FN-F1P&4'#+]: \SZ_\ V>?CI+XCUS7O"?B#0+3PU#82
M*EE!#)M?8QX3;C@@ 5\O>--)U/X'_M!:GXIO+&XL/#YOW919R"1)$;G![BO'
MX=>\9?$SQ@]Y8M*=6:7[2WV4[ &[MUJKKUOXJU34+N+5;R\N]052\L<TI<X7
MKQF@6Y])?'C1Y=6NM*^+WA+4H[O?&BPP>6-V<X)7^\1Z5]L_ O6M4\2^";$Z
MF&@U?RUF)FQN [_C7Y00ZEXBDL_#FGZ/)<7,EFC7,5I$"WELS==O0UV+_&[X
MH> )(+)M9G%Z9/M+P2*"Z!OX6],_E0.Z/V!FL[_QC;S75G/&$MV"#ID^HK\G
MOVPE=/VHOB4KKME_M3YAG_IE'7UW^Q)^T)XA^*EGJ:.4MY+9U6=1@JV1]X<=
M:^2OVRU<?M6?$_>?G_M7G_OS'0,\:HHHH)"BBB@!>H(KZZ_X)]^((8M0\7:-
M*WS30K<Q)ZD?*:^1.=QV]:]$^ /C[_A6GQ3T;6'<K9^8+>Z7MY3$ _E_2O S
MO"O%8*I!;V_([L'45&O";VN?IM<VXU7P3>VX&6C=L#T&*^/_ (DZ5Y=Y< K\
MO8'UK[(T.9':1$826U['YD;+R&!Z'\17SU\9O"KVNH3;5W#<3T[5^(9+6^K5
MIT7WN?>XBGSJZ9@_!GQ-]MT>719#(9[<$AV.<C\>U=NV%0@D,N<;<'')[9Z5
M\^:)J4OACQ7:W*R/%#O"RA?XESR.:]^6XBOHTNXI/,CD .1D_*3P#7[5E]:$
MDK[GXWGV&=&MSI:/\R.:39;ACR(]Y ;AA^/\5>3_ &IY;"ZDW-B28?*H S\U
M>EZE=!=-G).5C1L;NG/IZ5Y;;ONTRQC90%E<L=S<'#5U8Z$N924?Z9T9)4NI
M)]6C2FC$VI%W!Q#"P4,V,<5ASVX;3(HDV0F=LLRY)SFMC>BF^D7:1N"@$YQD
M4V.%7FLXB0NV%G.U?2IPN,=+79'TM2BI0L<U<:D=/U.075N=0@2(H%F8@1XY
M&*PYY)(=)MYQ?+<V<]R'_LM).@)Y'M71:I&[PSO\Y^T2;5Z#/T-<M?6CVM]N
MLV6WDMQEF]^X.>M?HN#S)R2YGH? X_!QIS]U:O[AW]L2SSZI<Z;<#1$6,HUH
MK LXS[],UDM=13-;+9PMI]XBYD:0_>./6H;RX346GGG#F\D8#?M 7@<''2H;
MJ:1Y&CNQO"Q "5%QQZD?6O2GB.9\R_K_ "/)IT(PM'?^OQ(;BXCFRDWR7#/D
M778^IIDAO)+R.)!'+<I\RRL1A@!]WZTQF,<820&:(],#!7W_  J!8XFF42S/
M%&REHB/X2> 6KBJ5')*QI*BXZ%ZU;_73VL7).RZL'Y/. 2!^9HNKR&TM(X(G
M6>TER\&\_O+=O0T2>8MTSR'R+Z$96XB'RRK[G\*99:7)K&H-)Y03)R%0<<@<
MUX>98Z&'IN*EJ>GE^ EBIIM:(WO!&G2W5[&64EF//^-?9GPDT-K#21.4X*[?
MTKQOX._#66\N8&9#M[YKZG:&Q\(>'VEN9DMK6WC,LTS\*B@9)-?SUGF.]O65
M&G[S;/V/ X=48<\M$?,O[<_BE-'^'^C^&8Y +C4KG[3,BXRL4?.?^^MHKXCR
M<#/7KCTKT3X]_$Z3XL_$J_U@973HSY%E&>T2D\_B<FO.5&W@=*_4<CP;P>#A
M"6^[^9\MCJRK5I26W0=DT9-)17T1YPN31DTE%.[ 7)HR:2BB[ 7)HR:2BB[
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MBG3C37+%:=+(\&4I2;DWN)1116IF%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >L_LC_\ )U'PC_[&>Q_]&BOTV\8:TJ^+=3L!!(JK?S9'
MJS2'GZ5^9/[(_P#R=1\(_P#L:+'_ -&BOU3\6ZS OBC5819)]I2[FW2% ?\
MEH: .)UX:W9ZHTUQ;R2Q$*L9C'0#IGWK6L_%QOM4AM)X7VYV,VT!0^,5<O/$
M9T^Z(DE5UFY5?+X^E5I%DDF\^"!#D_*H[MZG\*!BWEIIL>L0_:$=Y=QV2>I
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M)3A6/!;':IM4U:_\/:/;7$=H+J]R%;(SM'^<TWP[X333!-+%<R37##<@;..
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MJ* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J* &T4ZB@!M%.HH ;13J*
M&T4ZB@!M%.HH ;2;1SQ^%/HH 8% &,4;1Z?I3Z* &;1Z4M.HH&,QW_I1M'^1
M3Z*!#1@=A^5)MYS3Z* &D9HQ[?I3J* &;1Z?I1M'H/RI]% #,?A^%+C_ #BG
M44 , %*..P_*G44 -_STI-H//]*?10 WOG _*DVCT'Y4^B@!H ':C_/2G44
M-I-H]!^5/HH 9M_SBC'^<4^B@!BKMI<#T'Y4ZB@!N!Z#\J,#T'Y4ZB@!O1L@
6 ?A0V64 LW&.^<XIU% #:*=10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>nbx-20211231_g20.jpg
<TEXT>
begin 644 nbx-20211231_g20.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M.N1$@5II-H \R1MSM@ ;G. !Q0!Z!1110 4444 %%%% !1110 4444 %%%%
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MP_X/U[P/8QZ3X6TO2?M5EJUF+::[OWAC\R\U#Y(9&N'<)(\18Q!I'9O;YO\
M@FUX2N_C+\%O&LVJZM)??!K0DT2.V"QBW\1B" Q6,MXN/F:T>2YFA"X"R7+-
MU"X .<\)?\%=? 7B_P"/^F^#X=#UZ#P_KGB:Y\%Z7XMDOM,:POM9@DN(GMQ:
MK='4(XFFM9H8[B6U2*210 VV2)Y/JZOE#X6?\$L=/^$/QPM-<T?QM>6O@W3?
M$M]XML_#T.@:?'>?;+N:>XEMYM3$?VF:Q6XN)94A.'4B-#*T<:I7U?0 4444
M %%%% !1110 4444 %%%% '@_P#PPHO_ $6+X\?^%<?_ (U1_P ,*+_T6+X\
M?^%<?_C5>\45K[:?])?Y >#_ /#"B_\ 18OCQ_X5Q_\ C5'_  PHO_18OCQ_
MX5Q_^-5[Q11[:?\ 27^0'@__  PHO_18OCQ_X5Q_^-4?\,*+_P!%B^/'_A7'
M_P"-5[Q6+K_Q$T7PQXETO1[_ %"WM=3UJ.XFL;=\[KE+=5>9EXQA%92<^M'M
MI_TE_D!Y#_PPHO\ T6+X\?\ A7'_ .-4?\,*+_T6+X\?^%<?_C5;7[+7[>7P
MB_;6T37=2^%OCK1_&%CX9E2#5)[598ULG=690_F(O558Y&1P:]4TG7+/78/-
ML[JUO(L[=\$JR+GN,CC/(_,4>VG_ $E_D!XC_P ,*+_T6+X\?^%<?_C5'_#"
MB_\ 18OCQ_X5Q_\ C5>\44>VG_27^0'@_P#PPHO_ $6+X\?^%<?_ (U1_P ,
M*+_T6+X\?^%<?_C5>\44>VG_ $E_D!X/_P ,*+_T6+X\?^%<?_C5'_#"B_\
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MAU&1W'I3]M/^DO\ (#P__AA1?^BQ?'C_ ,*X_P#QJC_AA1?^BQ?'C_PKC_\
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M)[*,;?(O&G:X*7'S%#&<#GG[_P!GN?SI-N!_]:@1\G_\$\/A1?>!?$-Y=?\
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M/#-J7BR/2=5:Q6:S>ZA$?FA6'F<17 V\D<\?-7MG_!3C]OSXP>#O^"GG[/\
M8_"WQ=J-G\'[RWTJ]\;16]M&UN(I[W>S3%T+C=:,API& ?6OR7&Y37IUY1IT
MY<MY6T>J3_$_JS)>+,OKX&E4Q&(A[3D@YKF2M*44[-=+ZGZP9HKX)^(__!83
M5?!'_!:;PM^RW#X1TFX\/>(-.BO9?$CWKK/ [VD]QM"8V8!B"\G/S?2OISPI
M^VW\)_&O[1>K_"72OB!X;OOB9H<33:AX;AN]U]:HBH[,R8Z!9(S]&%>2TUN?
M61G&7PNYZU15(:M:&#S?M$'E@[2_G#:#Z9Z9IZ:A$)FC\Z+S<;MF\;@/7'6@
MHM455_MFU\E9/M%OY;':K^:NUCZ YZT[^TH?,D3SH=\0W.N\90>I';\: +%%
M5?[8MMD;?:;?;,<1GS!B0^W/-*=5MP9!Y\&8?]8/,'[OZ\\?C0!9HJO_ &K;
MDQXN+?\ ??ZO]X/WGT]?PI/[7ML2'[1;XA.)#Y@^0^A]/QH LT57&I0&2-?.
MAW2#<B[QEQZ@=Z:=7M3"TGVBW\M" S>:-JGT)S0!:HJO_:,/G"/SH?,8;@F\
M;B/7%-_MJU$/F?:K?R]VT/YHVY],YQF@"U15<ZE")6C\V'S%7<R;QN ]2/2F
M_P!L6OE+)]HM]DAVJWFC:Q] ?6@"U15?^TX!)(OG0[X1F1=XS&/4CM^-)_:U
MOMB/VBWQ.<1GS!^\/^SZ_A0!9HJN=5MQYG^D6_[G_6?O!^[^OI^- U2W+QKY
MT.Z89C'F#,GT]?PH L455_M>V$<C_:+?;$<.WF#"'W]/QIPU*'S$C\Z'S)%W
M(H<9<>H'<4 6*,U%;WL5T&,<D<@4[25<-@^G%?-GQ&_X*?\ @/P#K[:7;PW6
MO7VGSWPUF&TN8(O['AM"3([-,R++(5P5AB+2'D!<C% 'TQFBO*?@C^U!'\8_
M%NH:6WAG6M!6.34?[-N[MX9(-9AL;YK&>2,QNS(5E"$I(JMMF0C/./5J "J/
MATXT"S_Z]X__ $ 5>JEX<_Y -G_UPC_] % '@O\ P4E\365E\"H](OO[!NK'
M5=1MAJUE?_V/)+)IXD EDABU62.T9EE: 9DS@.=HWE2.W_8TNM-O/V:?"[:.
MV=,6&6.WQ%ID855FD7 736:S &, 0L1@?-\^X5PW_!27PEKE]\#+C7O"NE^(
MM9\3:-'*EG;:;JNHP*=Z[EW6UE<0/=,TL<,2KORGG%QD*RMWO['UV]_^SSH4
MY@O(+>9[M[(W=Y/=SSVANYOLT[O/))*&E@\N0H[L8R^SC;@ %WXE_"JZ^(7Q
M6\#WUU+9R>&_"CW>K26CY+SZH%CBL9"N-KQ1)+>OAB-LHMW4;D#+YA^R[^R;
MXJ^$O@_6M%N/$%UX,TN=;"#2[#P]KMQK26!MED66XCEU2*4Q+<!HE-LJLD:V
MZD,7D<GWK7/&ND>&M3L++4-5TRQO-4?R[*WN;I(9;Q\@;8U8@N<LHPN?O#UJ
MQHOB*P\1Q32:??6=\EK,UM,UO,LHBE7[T;%2<,.ZGD4 >=_L:6;:?^SCX?@D
MN)KR2%[N-IY@OFSE;R<%WVA5W-U.U0,DX Z5ZA7FO[(Q_P"+ Z/_ -?%]_Z6
MSUZ5G- !1110 4444 %%%% !1110 4444 %%%% !1110 4'I139&VK0!X1J/
M[,?Q O=2N9H?C!KUO%-*[I$L+8B4L2%'S]@<5H^ /V>?&_A7QKIVH:E\4M:U
MJQM9=\UC+$P2Y&"-I.\^H/3M69J?[9M[I^HW%N/ASXMF^SRO%O6$[9-K$9'R
M]\5H^ /VL;SQOXST[29/ GB;35OI?+-U<1$10<$Y8[1QQ^M?#TO$G(*N(6%A
M6?.VHI<DUJW9*_+;?KL=3P591YFM/5'=_'CPKK7C?X2Z]I/AV\AT_7+ZU\JS
MN)25CB?<#EB 3C /05\96W_!.;QQI/Q#O+O_ (0SX9ZOH=UX1O\ PQ!;:CJ2
MR26-U<31NEXLRV"RR1(J':)FDN06;]^P-?8W[0GQ3_X4K\&/$7BKRA.=#M?/
M";=V\[E7&-R^OJ*^.;'_ (*'?&BSUC37OM T9=*O=!\/ZQ]IG\+O8VRR:G=R
M6[)-.VJ,8+9-JXN3$W+DM'@#/W!RGW/X'T:;PWX/TO3;F]EU*XT^SAMI;N7[
M]TZ1JK2-[L02>3UK5IL0P#]:=0 4444 %%%% !1110 4444 %%%% 'S7_P %
M)?@/X9^)?PZT7Q5XL^,'BSX,Z+X$NC<W>L:3J,-I;W,,SPKY%PLR/&^Z5(=F
M5)#\ '<17/\ [1G[/GB[XT?L)^&?A[\,]4\)_$C0]6L(8[W6_%FL7-I<7]JJ
MK+;WMO<Z<B[;@2B-PZ!0, CTK<_X*W:)I_BO]C#4M%O-,\3ZM=:]K&F:9IL/
MAZ^M++41>3W<<<31RW>8!C<=PD!!4L!\Q%?+FL>)-"^//_!+3POKWA2\^)GP
MDU+X0^(M-T6U+>*[>PEGN+F>QQ)J-]"LD M9OML,\LBH?*._:OR[2 ?5_P -
M-&\>?LA_L7>"O"^@_#K3/%7C:PB.G_V5I&N/'I=O(3-*US/?7G[XH>KNRO(\
MLN,<[AZ!^S%\6O%7Q:\(7%QXP\%+X-UBU=4*VNK0:MIM^I'$EM<Q8W*""K*Z
MJRL.A!!KY=U[Q[XF\8?\$^/@[_PC:^-O%'B3Q!K,FCM?P^*(;NZ=@+Z&>=YO
M*$>HVK!'V_(@,;Q290KN'T'^P5\"[/\ 97_9\L?AO#)H?VSPM+*+I=,O))TD
M,LKR+.R2DO"TH.[RB6"G(#,!N(![77Q[_P %.[*"_P#$_A/SX8IEB\&^-)$\
MQ0VUAI]O@CW%?1GQS^/OA[]GSPU:ZIXBDO5M;RX-N@M+9KB0!(I)Y9"J\B..
M&*61VZ*J$U\X_P#!276[.\\<^'K.&[M9KJ#P5XU66!)5:2/_ (E]OP5!R/QK
MJP,K8FG_ (E^:/)SY-Y;B$OY)?\ I+/@_P#9^A _9Z^.+%?G&@Z=@XY -_'G
M^0_*J?@B*.3]C7XA2,BM)%XCT8(Q7E<K<C@^]7OV>2TG[.?QR4JV1H>G;5*G
M)'V].!57P4K#]B_XB;=^X>(]%ZJ<_=N.WM7[K5K0]I4U7\2G^43^%\)A:OU;
M#>X_]VK]/.9%?VT,?[$FDW'E1B9O'%RADV_,5%C'QGKQ5_XNJ#^R%\%]W"^;
MKF?_  *CJKJ49'[#NDK\V?\ A.KHY(.?^/%/QZU<^,2G_AD3X+KM8MY^N9&T
M]/M2=1U%.->G[6&J_BRZ_P!V1-3"5?JU;W7_ +K36S_G@9O[2<$5KX%^$OE1
M+"\W@F*20JN-Q^TW/S'U-:7[7JE/COH:J-JKX<T ?[H^QQ53_:<C8>!/A#^[
M8?\ %#Q;L*3MS=7/'UJY^V$K_P#"^M#98W;/AW01PIQ_QZ15.'JP?LM>E7KY
MHUQ^&K6Q/NOXL-T_NG0?&G0K!_\ @J66-C9LW_"86$18Q*6"%H PW=<')XZ?
M,?>LG]E'P=#X<_X+T>(/B\K1MJWCC5+_ $"ZLW0?9K. (L.^,]0P2T3KQ\[5
MT?QEW'_@J*6VDK_PF>GG.#@?/ 3STK-^!QV?\%&X696POBC4R2R\#_CYQSTQ
M[^XKQ*^7X+$X>+JI-QHW6WQ=SZW+^(LYRW'S6%G)1GB[25KWAV\EKT/N?]EO
M]H=OC1^T%\1/!6K:3X1C\+Z3<^=H7V78WVT!F!D^\1(2@#[@!MSBO6_A/\;O
MAY\:I/$>J>'[JQO)O#,KZ;JER;<QM"%!R,L 3'A3R."%K\M/^"?'B*\\%?&O
M4M4L6:.^TOPKK%U;.8LJDBVQ9>#P>1T[\UTW[)'[3OBCP9X!^,DMC#IL(ET-
M]8EB.GJJW-R]S%$<C .W9+( G0;C7YEBN!<SP554L)7C5@KN4IZ2O-OD22Z)
MVOY']!Y/XT91F.']MF>$G0JS;C"--<T;4TN>4KZWDMDNI^EGP:\>_#WX]_#Y
M-4\*_P!F:EX?M;QXU(MO+2&=/O':P!4X(.<="#7:1Z#H]Y-<7RVEA(]_%LFG
M5%8SIZ%NXXK\LOV6?VFKKP/^QI\7-%N;!X]%"V]K;IIR>1<12WOF1/-O.2VT
M(G'8+CWKH]-_:EM],_X)82>&[5O$5I=1ZK_8$-_')F4NW^E,2 0RQ;<H,9/2
MO'K93G^%7)5PZJ246VX25G/=0775==C[# <<<)YA!5Z.*=*,I72J1?,J>J<Y
M6NM&MMVM3]*AX+T86EK&--L?)L&+VZ^0NV!B<Y4=N>>*<?">DO)>/_9]F6U#
MBY/DC-QS_%Z\^M?!.M_MW:CX<_X)V^$;GPQK\VG^,([M-)\[55#W%ZEOM\]U
MSD8^=!EN2H)ZU[9\8_VZ[GX<?!WX9^)/#^EV_C#_ (32]AL[J6W++&IP!*4&
M,[B^X+G XKR\5F4\(IO&TI04%%MM75Y.W*FMVGHSZ;+J%#,7".6UX57-RY4I
M6=HJ_,T[64EM<^BAX0TE#9O_ &?8@Z=_QZD0C-OSGY?[O//%-?P7HPBNH3IN
MG^7?MON%\A<3L#G+>O))YKQC]H_]K+4?@C\:_AMX7T_PY_;%GXVO#;W-V'(^
MRC<JX7'&X;BQSQM%2_$/]K#4O!O[97A#X:VN@K>:3XBL'NKC5 Y_T=AYF,?P
M[5V#=DY^<5G4S["0E*,F[QE&+T>\MOSWZ';3R'&5(QG%*THRFM5\,;W^>FBW
M?0]G7PQI<5U:W"V-HLUC&(K:01#= @Z*I[#D\#UJ!? VB_V?-:_V7I_V6:3S
MI8?(79(_]XCH35[[=!MW-+#N4==PXI7OHB%/G1KG_;%>U9GB\R[D"^&]-&I1
MW0L;474<7DI+Y0WK'C&T'KC'&*@'@+11IOV'^R]/^QK+YWD>0OEA\8W8Z9QW
MJ\+Z-?\ EO#SQRXI'OH4D7]]'R.N\=J-0YEW(/\ A&M,;49KLV5K]JN(S!++
MY0WR)@ J3W& /RJ+_A"=&^R6]J--L/(M9/.AB\@;8GSG<H[&K@O8'./.BRPS
MC>.*<+Z!68>=%TR?G'% <R*K^%]+>YNIFL;3S=03RKES"-UPOHQ[CZU'_P (
M?H\<5G'_ &=9A=/;=:KY(Q;MG.4'\//I5[^T(2_^NC^4C^,4BWUNAPLT77LX
MHLPYH]RH?!VDN;X'3[/_ (F6#=_N1_I/)/S_ -[J>M.7PGI2S6<BZ?9B33QM
MMF$(S;CT3^[^%6DO82^X31=Q]\>M-_M"$H&\Z/'WOOCFCE?8.9%,^#-&:UNK
M7^S;$PWC"2XC\@;9FSD%AW.?6IO^$>TR*_M[O[':K<VL8A@E$0WQ+TVJ>P]J
MF&H6\2_ZZ%0.>7'K3GOH2/\ 6Q=1_$* YUW(M*T+3_#T+)9VEO:QR/YK+%&%
M#,>,G'>O&/ W[ O@WPCX^_MZX:;7&CUO4O$$=KJ5O#/!%<WBP*SJ&7AD\@;6
M'(W-S7MBW4;.%61&9NP;)JPK;@&H*NGL>4_ []EU?@YXOOM4F\4:MKT.;]-*
ML[F"&*'2(KZ^:^N54HH:1GE\L;G)(6% !G<3ZQ110 52\.?\@&S_ .N$?_H
MJ[5+PY_R ;/_ *X1_P#H H \ _X*@6-OJ/[-#0RZ;X@U2:348X[:'2+F&VF:
M1X9T*^9+'(B/(C211,$+BXEMS&5D".O3_L#7NEZC^RSHMQHMC!I^FSW^K2Q0
M6UU%=6P+:G=EC!)%'%&UNS%FBV(JB-D R!DS_M:^ _B)\2M&T32_!+:!'IXO
M5N=;%]KU]I$UW F,6\<MG$TJJY)9F#H08U!#JSK72?LU^"O$GP[^#6EZ/XMO
M;>^URTDNC(]O>SWT44+W,KV\*SS@32B*!HHM\@WMY>22>2 >4_M2?L\^*/B)
M^T/X+\3^&;$17>FK:VQUQ]5C6'1X$OEGNE>RDA8S&6 %$:-PP<*3LVK(,K]C
MC]EOQM\)_#.J07$>C_#NZ_L70?#Z#23#J*:G/IJ7*W&J.I15#W0GC3YP90MJ
MFXYP!]1O($*CC+=!GK213I,6VLK;3@X.<'WH ^8_A_\ M.:5^S3^SQX'M_$$
M.J:O<:HVI 7%K%&OF-%>.'=EW +N+@X7@<CTKWOX5?$>S^*_@'2_$5C%<06>
MJ1F6-)P!(HR1S@D=NQKX1_:B'_%DOA;_ -=->_\ 2ZNY\2_'+Q+\#_V/?A3<
M>&[Z.SDU)+B.<M"LF]58D?>'')/->7+'.%::G\,5<_0J'"-/&93@Z^%TK5IR
MB[OW=.9_+1'VOYP_'TH63<:^0_'7[4?C;1?V-O!OBRWU2%->U;5)K>ZG-LA$
MB*T^!MQ@<(O(':O3/V5?V@)O$W[/\/B7QMK5C!,]_-:_:IMENAVGY5XP,XS]
M<5T1QE.4U#RO\CP<5PKC</A7BY6:4W3LKM\RNM%;;1GN6:,USNB?$OP_XCT>
M74-/UC2[JQ@?RY+F.Y5HT?CY2V< \CCWK2TGQ!8ZW&S6-Y:WBQD!S#*L@0^^
M*ZHR3V/GYT:D+\\6K;W5K,T**,T9JC,**** "BBB@ HHHH **** "FR?<Z9I
MU(WW: /([O\ ;Q^"-A=S6]Q\7_AE#/;NT<D;^);,-&RG!!'F<$$$8J[X2_;-
M^$/C[Q-9Z+H7Q1^'NL:OJ4@AM+*R\06LUS<O@G:B*Y9C@'@ ]*\4U3_@AK^S
M)K&IW5Y/\/IVN+N9YY2-=OU!9V+,0!-@<D\#@5M_"3_@CU^SW\#?B9HOB[PS
MX'FL?$'A^Y%W87#:S>S"&4 @-L>4JV,G@@BO6E1RA0O"4^:W\L;7^_8Q_>WV
M5OF?17C75]-T#PS?7FL?9_[,MXO,N?."^6$SSNW?+CZUX3KW[?'PMTH1PSZ3
MXHN+&^T.XU6*X7PM.;2]T>V*B2YC=D"R6Z^:I"KEBKA@A5E)]H^+7POTWXT?
M#G6/"^KM-_9>N6YM;GR2 Y0D$@$@CG&.0:\9UC_@FGX)\86]M9^*-8\3>*]*
MT?09_#N@V&IM:21>';>22"19;5E@$@N8C;0A)W9G"Q@$MSGR38^@-%U.WUO2
MK>]M9!-:WD23PR $!T90RGGGD$'FK55='LY-/TV"&:YFO)88U1[B5562=@H!
M=@H"[FQD[0!D\ 5:H **** "BBB@ HHHH **** "BBB@#YI_X*VV%YK?[$6O
M:7;:5=:O:ZMJ.F6>I1VWAA?$MQ!9/?0^?-'8M\LS(HW?-PF"W515/X>Z_P""
M/V>?^"<NE:QK'AG4_$V@WFFV-K?Z5'X.AT_4->FF,%A#%)I8Q&DC8MX?+8A5
M6-02 M3?\%>_"NF^.OV'=>T;5)/$#1ZIJ&G6L%GHFG3:A>ZG.]W$(K=((F1Y
M,N0V-P'[L%LJ"#YG\0?@'XDU[_@B1X?\$Z-X2O/$'B.UTG1)O^$;U/3'LOM;
MP:C;7,MK-;/.CK$1&RE7F#E.2Q;.0#UCXQZC\)_BO^P)_;7Q$^'5]8?#NVLH
MKD>&M1L$M;_2MDOD0K&D4@\B4,0%:.12H;[PYK:_X)R6OPON?V6=%U?X2^$;
MCP;X7UUYKEK*]C/V]IQ(T;M<NSR/)(2GWG=CMV\CH/$]$A36_P#@B/<03^'_
M  #X/CMM NH=0T/5XYK?0;(6]^ZW-M,H>:55/ERH=K.X=OEYP![W_P $_=7@
M\0_LG>%K^WT_P1I<=W]JE^R^$999=(B9KN9F\HRJLFXL6+AE!#EQCB@"[^UW
M^S=<_M*>#--TVRUN/0;JSFN4DN7M?M >UNK*XL;E%7(PYAN7*-R RKD$9%>9
M_%/]GGP)X<_X*%_"?7-/\'^&[36O$]CXD.K7T6GQK<:EBWL\><^,OC_:)KZF
MKPWXW_\ )\GP)_Z\?$O_ *3VE'F&ZL>FCX6>&]IQH.CJIZC[(F&^O%+_ ,*K
M\-8(_L#1\'J/LB<_I72457-+N_O,O84_Y5]R.:/PL\-!<?V!H^W.<?8TQGUZ
M4@^%7AG/_(!T?:O0?9$POK@8KIJ*/:2[B^KT_P"5?<CF_P#A57ALX_XI_16V
M\#-G'Q^E-/PI\,N?FT#2'^4+EK1. /PKIJ*%4DNK'["G_*ON.;_X59X;:7>V
M@Z2TG4-]C3(/KG'M^E"?"[PW&VY=!TE6ZY%HF?Y5TE%'/+NQ^QI_RK[D<RGP
MJ\,I]WP_HT?!'RV:#@]>WIQ0GPH\,J/E\/Z.O&TXLX^1Z'BNFHH]I+>[$J%-
M;17W'-'X5^&1T\/Z+CN/L<>#^E(/A1X9 Q_8&C[>P^QQ]?RKIJ*/:2[B^KT_
MY5]R.9'PH\,[0O\ 8&CE5.0#9IU]>E2?\*Q\.B-?^)'I6%.0/LJ<$=".*Z*B
MIE[RM+4TIPC!\T%9^1SX^&?A]N?[%TM67H?LR<?3CBFM\,?#QE#G1=++*.#]
MF3C/;I714QF\OJ>V*CV<>QISR[L^'/"7[-.H1?\ !234K&;3_%W_  A=C%_;
M5M>27SFQEF;#>65QL,6YW01]MF:I_LY?LM:C<_M=_$C1M7M_&5GX:T6VG@TB
M_N[]Y8;C[0K1A@&&QF"N77'W"@':ONP+@^BGWI73 ]:Y(T\<I*3Q,FE)RM9:
MQ>T=ME?3J*>$RIIVPD4W%*]Y74KJ\UK\4K6?3R/S ^&'POU;PU\*OVA=9O[K
MQK'-X/L+G2=,;5+@O'(#)GS5R!B51$#N7C$M>2_!_P >Z]J/[-/QDO+C5M4F
MO-/CT4VD\ER[26_F7K*^PDY&X8!QU%?K!^T-\,X_B]\#_%?AEKB2R77-/EMY
M)XHQ(Z C)(7^)N. :_,'X?\ POMM&_X)V_%CQ;!=ZDIU#5-.T<VUY;K'L$%V
MCJX;N3YN",<%?R^VX2SK"T:<<KS.K[3$59IQ;BM8J2;5TK*R=O.US\5\3^$,
MRJ8EYUD5)T<%0HS4U&;TG*,DG9N[;:OY'.:/X_UQOV)]?U!M8U1M0C\;65LE
MR;ES*D9LIV*!LY"EL$@'!(J/Q3\0=<B_8Z\%ZA'K&J)?77BG589K@7+B66-8
M;<JA;.2HR<#.!FLS0V67]@[Q%MRW_%>V))_[<)Z9XO.?V(_ O&/^*MU?_P!$
M6]?J-/!X=UO@5O:]EMR;>A_.E3-L?'"/]]-/ZHG\3O?VF^^]M+[FS\<_'VNZ
M=\!_@W=6^M:I#<:CH^H274D=RZM<,+YU4N0<L0O SVI?VJ_'NN:-8?#;['K.
MJ6;7G@;3[B<PW+IYTC&;+M@\L<<GKP*R/C__ ,F]? [_ + FH_\ I>]+^U[_
M ,@_X7?]B!IO_H4]/#X*AS4O<7Q5>BZ-V-,PSG'*GBFJTM(8:WO/2ZC?KUZG
M2_M1>.=:T3]K"&SL]6U*WL]FCDV\5PR1$O;6Y;Y0<<DG/KFM:?QIJY_X*4MI
M*ZE?#2_^$^2V^Q^>WD>4;H*8]F=NW'&,8KE?VM/^3O[?_KGHG_I+;5L3?\I1
M_P#NHB?^E@K"&$H>PB^1?P9/9;Z:G77S?'?7:D56E;ZW37Q/:TM-]BQ^S-XR
MUC6?VVVTV\U34;K3_MFLI]FEN7>+:D%T4&TG'RX&/3 KF/V7/B#KVO:IXR%Y
MK6J70A\#:S<Q"6Z=Q%*EN"DBY/#*>01R*UOV4_\ D_1O^O\ US_T1=UR'[(Q
M_P")MXV_[$#7/_2<5K6P6'_>/D7P0Z+NSBP><8_GPR=:6M>LOB>R4;+?;L?3
MG_!%CQ9JGBOXU^,%U34K[4?L^C1-%]IF:7RB9L$C<3@D<<5^DT:[6;ZYK\R_
M^"&Y_P"+W>-O^P+!_P"CZ_31?]8WX5^9\;4X4\VG&"25H[>B/Z8\$\55K\)T
M*E:3E+FGJW=_$^K'449HKY,_6@JEX<_Y -G_ -<(_P#T 5=JEX<_Y -G_P!<
M(_\ T 4 >%?\%)_#=YXD_9]M/L\%K/9:?KUC>:D+K[*UNEJK,&:2*ZN;:WE4
M,R?)),HSAE!=5%=I^QWI$>A_LU^&+>&VL[2'R99(X[6SM;2'8\TCJR1VMQ<0
MJK!@PV3.#G)P25'F/_!2SXY>#_AGX<\%Z/X@OGLM8U37([[2G2^L[&:+[.#Y
ML\,E^K6,DD:R F&?[RLQ7YU5AZ3^Q:V@R_LW>'YO#,EW-H]W)>7237-Y9W<T
M\TMY/)/(TEF3;?-,TC;8<(N=H50-H . _:=^%]]\0?VG?AU-!\/=4OK/1Y[+
M4+CQC:RP23:8T%\)DLH4DN$:!)"N;F9(W:2W;R@K[OW63^P[\ /&_P $_!_B
M;2=/T]?"-K-)I\EM/XFTW3KW4KV\5)%OY9FTV2)9XF_<^5+*PF+><6&TI7U1
M10!^<O[1DLJ_ ?X4PW,D<UY"-:%P\<+11R.;P9902< D'"[F(Z$GK6A\>[E)
M/V.?@_"N[=$;C=\I ^;)&#T/X=*K_M1'/P/^%GO)KO\ Z7"KGQ_/_&&'P;_[
M>OYFOF\5_%K>B_0_>N%?^19E7_7V?_I-0=\3+Z.7_@GQX!@7=YD>MSALH<=;
MENN,'@CI_0U#?ZI!)_P3OL[3YVE_X2E^/+;;PI/WL8Z,O?U]#BY\4>/^"=OP
M[_[#5Q_Z%=5'J'R_\$W;/_L:6_\ 9ZRDO>?^!?DCLP]O84O^PR7_ *5(;\/K
MB-/^">WCBWRRM)K43K\A(PKVV<G&/XAP<9_"NL_8'^)UA\'_ ((>/]<O(+B:
M'3KF*Y:*!#N9=JJ<$_*#EQU(SSCH<<M\//E_X)V>._\ L.P?^A6])\ OWG[$
M_P 7<_W[<8]!A:NC)QG3DOY'^ICF6%IU\)C*51:2Q,$_1NFG^!]*?#/]N'PO
M\1?#7B355L=8L+/PQ;K<W)D@\UI$8D?+LR,CC@D=<] 2-OX/_M:>$OC;J5Y:
MZ&VIF:R6-Y//LV4$.VU<8SW(^G7I7RE^R4/^,>OC4?[VC(?_ !R:E_80N)++
MP_\ %.2&22.6/PX[I(C;60@/@@CD8/-=E#,*DG34K>\FW\KGS&:<$Y?3ACI4
M>9.C*$8ZW7O*.^EWJ^Y]TIXQLY"N/M&),8)MI1UV8_A_Z:+^9]&PJ>,;*1%8
M-<8;&/\ 1I1UVX_A_P!M?U]#CXN_X)Z?$+7=9\>>)_MVL:I??9O#\L\2W-T\
MJHZNF&PQ(S79_L<_M/>-/BO\7O[+U_5H[S3UTZ:<QBUCCRZE,'*@'N:]+"8A
M5Z?M$K'P7$.1SRG&O!3DI-).Z\U<^GD\8V3D<W'S=/\ 1I?;_9_VA_D50/Q8
MT$:Y'I?]HQ?VE+ UREIL?SWC!P6";<X!XZ>OI7#_  Y_;,\&_%+Q[%X;TN34
MFU*9I542VQ1,Q@EOF_"N4^$.L>'K;]LGQ=I*:?J<GB1X)[Z349[NWDA2'S41
M8(TBZ9)9L-B0!#N'<[0J1FKQ=SS<9@<1A9J&)@XMJ]FK:=SW,^+[-2?FN,CK
M_HTOO_L^QKEM1_:2\*Z;\2+3PDUS>R:]=I)+]GCL9CY,:(7+O\OW2 0",@D$
M5QWAW]H#Q5>_M02^ [SP[?0V4;37:Z@+/-NUFHN-K&4.=I9C:JNY1N/G 9P<
M9\GB<Z7^UY/;PZ#:;K^]@LI]1:"-L@67FJ0YG\Y91]WY+?RBO63.<4<I[4_B
M^S3=EKCY 2<6TI_O_P"S_L-^0]1E'\8V:!LM/\A8-BVE/*[\_P /_3-NG7 Q
MG(SYMXHGU?5_VD=.MO\ A+M/TO1M*2&X&DIJ$8NM0D<$8>( .J?*2 VX-M.-
MN3AOC/6->O\ ]HS2[&/Q-I^C^']+6"[FLC?Q1W.HO(WE",I@OM+,ORL"&) #
M*2, '9^-/CCX8^'=L)M;U2/38V8(OFPR[F)9UX 4D\QN,CC@?WAG9;Q=:(SJ
M?M'[LL#BVE/3?G^'_IF_3T']Y<^/_M*:AH\GQA\+V]YI<FM:G8VDE[961O98
MHY6,BH-JHC!9 >5D=D48QD\E<W]NWQ;<:':>'+%]872=%O#<2ZI)]L:WDG2,
MQ%(H\</([D +\I/.'7D$ ]JU7XA:3H5C-=7MU]DM;96:6::*1(XP"P)+%<=4
M;Z\?WAF9_&=C%#)(TD@CC4LS_9Y-H4;^<[<8^1N?IZC/BO[8FH>&(/#WA1O%
M6H3Z?I*"6ZDADNH+..[5$C/EM-,P/F9*E8P3O(.<XS6Q^T_)IE_\,O#>G7FJ
M:IH=GK5];VB16ML/M-\KH1]DSO186<'&XG:,=.* /5%\86+J&629E;H5MY&#
M=>A"\_=/3KQZC/(_'SXS2?"WX1Z]XBTVUM[ZZT2V-WY-Z)K>!D5OGW2"-BN%
M#'.#C /2O,/VB?&;>'_@/\/=*\-7U]INF^)I;;28+@G[/,T+QJJ1]HQ(P.1G
M:/E8@COW?C_Q+-IO[)TFJ::MK=K'HD$^W5&FCCFAVIO\QD<RC,9/(9F]GZ$
MVO@E\:(_BA\*]%\0W,'V.36(C.(H8IGC52QV;6* L"NT[B!G.<#I733>-;"W
MA:2222.)5WN[P2*J+QR25X'(Z^_H<><_"B^31/V7Y-6T;3O#_AV::TN;N.+3
MU^QZ>DBEE21/-7Y4941MSH"V<LJDD"O\/-3U"R_9X\3ZAKGB)/%E]):W-_<M
MI^H+BW#V_F?9X7'$6W)"G+ <'O@ 'H'@OXL^'_B))=+HFI1ZC]CG-M.8HWVQ
MR  E22H'0C]1U!KI,XKQ/]B?Q7H?B/X;72>']'N-'LK>6-@L[S>;<%XP=\BR
MHA$G&'*KL+ X)(./+_%2?&37OVF/B)J'A^_\06/AOPMKD4<<L^J1_P!FO8KH
MEK-+;PV!@+RRM<2OB42* YZ_(48 ^O,T9KX__8J^,FN:QJVEC2=>\<_%/2;C
MPA8WOB!;\0EM'UF1XP4BGF$"\HT[20[F*>2F I;#6M(_:*U_XC?L'?$)=!\9
M7$'Q8\*:1K=S.ZZ<)]0LG@N+OR5$+*%WLD:(IVMU!VMQ0!];9HS7@7[7?CK4
MO"D/P_CN]?USP?X)U2]EC\2Z]I$.^[M"+5FMHF?RY/(AEFR&F"\&.-,KYF:\
MAL+OXP?%?XV6,/@OQ%XTN-%TO0?#5Y!K&LRQZ/;3(^H:A]KFNK V^;B2>T@C
M&U?+(W(W[HL" #[;S17RI^R=\6?$'B']IW7M$U3Q'XC\2120ZI<7$<L31VNE
M-%?QK;Q36TEK$]C*(G*(J33I.J/)D$*Q^JZ "BBB@#Y9_P""K/PS^'WB?X+>
M'?$GQ'M]7?0?"?B+3_.N[77KW28-'AN;N"&:^G:U(9A"GS*6&%?!RH+,.%^,
MOC"PM/\ @BC8ZS_PKO4O$VD_V#I4O_",ZA=W]_/<VYNX!O\ -1ENY1L/FHQ(
M<@H7 ^85[Y^WK^TQ_P ,D_LW:EXS_LS1-5\J]L=-\K6M373--C^U745OYES<
M,K".)?,R3M;/ QS7"?&O]L#Q!H7_  3AM_BQH=QX5TS6M3M=+87UB)_$FCZ6
MEU>P6\MS&+=%ENXH8Y'D 106V8H \J\7ZIJGA'_@B#:K<?#6UT^2STI;75-$
MT;4_^$<BT>".^*R:A;RW>]HO+""Z7S2S$D%L\Y]T_P""7NG6^E_L.^"5M+>:
MWMY!=RKY^NQ:W<3;KR8F2:[A CDE8Y9@@ 0DI_#7(?$#Q]9_%S_@E1J&O^,/
M$&H^+XM8T/S)M8\,:(=*N;VX^U!;>2VM+T@1LLHB^6X(0[26(0FN[_X)N>%8
M?!?[&G@_3X;+Q-8O$MRUPOB":SEU*:=KF4RRRFS=[<;W)8+&Q 4J#R#0![I7
MAGQP.W]N+X$D\ 6/B7.?^O>TKW.O _VA=%M->_;:^!,-Y;QW$:V?B5PLB[@#
M]FM!GZ\F@#WKSEW;=R[E&2,]!3?M*X'S+AN!\W6L^3PCILFIW%XUG;FZO8O(
MGD*?-+'@#:?;@?E43> M'6QM;?\ L^V\FQD\ZW39Q$_J/>@#5\]06^9?EZ\]
M*43+@?,OS=.>M9S^#-+>XO9C96_F:DFRZ;9S.OHU-'@;25BL5%A:[=-.;4;/
M]0<Y^7TH TOM"G/S+\O7GI2^>N1\R_,,C!ZUE-X"TAH[Y?[/M=NI'==#9_KS
MG/S>O-.C\$Z7%=6<ZV-N)M.3R[9PG,"^B^W)_.@#2\]=N=R8'!^:G"9=VW<N
M3R!GDUCCX>Z+]ANK7^SK7[/>2"6=-GRRL.YJPOA'3DU2WO5L[<75K%Y$4NSY
MHTQC:/;!H O&Y0)NWQXZ9W<4[SESC<N[KC-8P^'6BC2FL?[-M?L;2^<8=GRE
M_P"]CUJRWA'3VU5KXVEO]K:+R3+L^;9C&W/IB@"]]I7;G<NWL=U+YH_O+\O)
MYZ5D?\*[T3^S8;/^S;,VMM)YT47E_*C_ -X>]3/X-TM[ZZNC8V_VB^C\JXDV
M?-,O'!_*@#1\]0!\R8;ISUH,ZY/S+\O7GI62/A_HZVUG"NGVHBT]B]LNSB%B
M<Y7\:?)X'TF5[YFL;8MJ7%T2G^O[_-ZT :1N%&WYD^;ISUH:XCQRT?R]?F'%
M9H\#:2IL=MC:J=,_X],)_P >_?Y?2F?\(%H[P7L1T^V\O46#W*[.)VR3D^O)
MH U5F7(&Y.1E>1S2B=<9W)M'4YK.C\(::MY9W LH%GT^,16S[/FA7I@5"/A[
MHHTRXL_[.M?LMU)YTL?E_+(_]X^] &L[J3PR[L9Q7&_%+X;VOC?X2Z_X?L%T
MW3VU:TFBAD-LC10SNIVRE2,$AL-G&<C-=(?"&F_VFE]]BM_MD<7DI+L^94QC
M:#Z8JF?ASHKZ7]A_LRU^QB7S_)V?+YF/O8]:SJT8U$T^S5^NO9]"HS<7?YV>
MJ=NZV9^>?[9WP"U/]FS_ ()O>%/#>M7ECJ&LP^+5FN)[:,*"&BNF1"V S;0<
M9;^6*^<?%QW?L0>!VYY\6:L3_P!^+:OT0_X*K?!#2?'7[+>L:]>:E8>'[?P;
MN\1:C?30>8TEO;6TV8A@C+-N '/7W-?#W[1OPVM?AC^Q%\';JRU^PU[2_&%]
M=^(=/N[9/+C:"YMK=E7!)^8=#[U^H<"UL/A\OPV C)N4:FE[MV47N^Y_,/C-
MD>95\UQ^>.E:C*@HW227,YQ=DEL<A\?SG]G?X'^VBZC_ .G"2I/VOC_Q+_A=
M_P!D^T[_ -"GJO\ ':TMXOV?O@K-"D:R7&C:B9'7GS"+^0#GV'%2_M<QK%IW
MPM55VJ?A_IW0="6G-?;82SE2_P 57\V?C69*U/%I_P F&_*)I_M=?\GB6_\
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M>:EI=VATRYO? 6CCQS:WCS-<!9V-WL:53<[7:1@"TY"XPU>U?L&^ ?#GC_\
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M3A4BX5$FGT>J^X_+'_@K[X>;PMXC^%ME+INFZ3=0^&W^U6FGH%M(9S(IE$8
M'R[RV#@9'->.?M?G_0/A;[^ --_]"GKZZ_X+2_">RU!_!7BR^O-06-96T5;>
MVM?-SO;S3(6W#!PI 7'S'N*\K_;8_85^(%UXF\$Z?X7T'4/$FFZ/X4L=)2]1
M8X?/F0S,5V,V0=ISCGOSQ7Z3PWQ9EDO8X&=9*I24G.^B7-?EU>COZG\N>)'A
MQGU.MCLVI8=RH8B5-4^75OD:YO=6J2\T>5?M:?\ )W]O_P!<]$_]);:MB;_E
M*/\ ]U$3_P!+!6?^V-IDVE_MHM:W,+PW%H-%AF0_\LV6WM@1^!%7KEO^-HY_
M[*(G_I6*^LHV>'A;_GQ+]#\QQ47#'U4^F,I_E(@_94_Y/T;_ *_]<_\ 1%W7
M'_LC?\A7QM_V(&N?^DXKL?V4^/V]3_U_:Y_Z(NZX_P#9'_Y"_C;_ +$#7/\
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M?_BFX0<'.,<'\B"/J*L?MYHL/Q3T?:JKNT* \#')DE.:A_;!A6.W\ [55?\
MBFX<X&,]_P"I_.OQ/CK_ 'WB3_'2_P#2SU,)\-#T?Y$W[5%[#=?"WX3K%-%(
MT>A@L$<-CY(ASCW4CZ@^E1?'656_9J^$\892\=O.67/(!VXR/?!_*I_VJK>.
M'X5?"7;'&A;1!DJH7/[N$_S)/XFH?CNJC]FCX3-M7<T$^3CKC;_B:.(OX^=/
M_J&P_P"=$JA\-+U?ZGSM_P %E9T;_@E;\)8]Z^8OB\%ESRN8+_&147_!,N[A
M_P"'2%Q#YL?G?\+%N?DW#=_Q[P]NO2K'_!92-5_X)5_"5]J[F\7C)QR?W%_5
M?_@F7 G_  Z-N'VKYG_"Q+GYL<_ZB'O7]C9XO^-"?]PH_P#I*/D\/_R//F=!
M^W=<QC_@C;XXCWKYC>++ !=PR?WUL>GTYKY8_9'D5?\ @C;^U:K,H9]3\/[1
MGDXNX,X^F1^=?5'[=\2_\.;/'4FU=P\6:>0<<C]_;#K7RQ^R/&&_X(V?M7$]
M5U3P^0?3-W!FONO '_DV>7?XJ?\ Z7$X<Z_Y&,_1_D?2/_!K[*J1?&Q2RAGD
MT3:I/+8%]G ]LC\Z_6>OR9_X-?(U:'XV-M7<LFB8..1D7]?K-7N<:?\ (YK^
MJ_\ 24&7_P"[1"BBBOESL"BBB@ HHHH **** /E/_@KWX7@\0?LE:C-K_B/P
M_P"'? ]C-;2:W<ZMX?EUBWM6^VVAM[MTBECD2.%@Y9E)QO#GA#7D_P <O"6H
M/_P2I^&LFC^7-X5T_04N-6OV\3MX%LX-/9%DBNV65+D@,1&RQR$LN_KN.*^@
MO^"G%UXGLOV1]7N/!OA;1?&'B2UO[&XL[#5=,?5+972YC;S3:HZ&9EP-J[@%
M8JYX4BO _P!H'5+31/\ @@S#J'C32;SPS'_8&EW,MOI-@NEMH\CW\#P2QVL_
MF"&.-FC<6\N["@1G#'@ ]X_9;^!VA_%+_@GGX:\$^([?[=H>L:,]O<I!XC_M
M9F1YG=7CU"%8B[AMK+(BJR,HQ@KFO7/@I\%] _9]^&FE^$O#-O<6^CZ2KB(7
M-U+=W$KR2-))++-*S222/([,SNQ)+$DUY/\ \$KG1_V OAL5M[RUG^P3?;$N
M;E+F1[O[5/\ :9/,1$1E>;S'4JJKM9< "OH*@ KPWXW<?MR? G_KQ\2_^D]I
M7N5>&_&__D^3X$_]>/B7_P!)[2@#W*BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH SM;T.SUZ"..\MK>ZCC82*LL8<*XZ,,]Q
MZURWQ0^$%O\ $C7/#]]+=36[:!=_:E5/NS]/E;VQN_/TS7=8S2$5P8[+<-C*
M3HXF/-%V;^3NMM=&;4<14I24J;LU?\59_>C\[?VRO@=X-UW_ (*C?#;0=0MO
M&TMQ\2X+C4=2U&SMBVGZ1+;)&ME&SA"!YS0S Y;(^7ID5X->)Y7_  5)/M\1
M4 ]_]+%?L5LP*_'6^;=_P5.<;2?^+BCG_M\%?K'".85L1&M3J.ZA2:7W_P##
M+Y'\W>,&1X' O U\)24)5<3&4VOM/NRK^RK_ ,GZ-_U_:[_Z(NZY']D?_D+^
M-O\ L0-<_P#285UW[*0Q^WJW_7]K@_\ )>[KD/V1O^0KXV_[$#7/_2<5]SB-
MJO\ U[I_G(_!L'\>%_Z_U_RB?1__  0W_P"2W>-O^P+!_P"CZ_31?]8WX5^9
M?_!#?_DMWC;_ + L'_H^OTT7_6-^%?EG'7_(XGZ1_)']2>!7_)(4/\4__2F.
MHHHKY _8 JEX<_Y -G_UPC_] %7:I>'/^0#9_P#7"/\ ] % 'F7[5'QXOO@]
MI,%GI+:2VMZ[:7%OIB33DW,=XQCBMY!!C]]%YTL:, V\L\:HDK,$KIOV?-?U
M?Q1\(-)O]>O]/U+5+@3&:XLU9(R!,X16#)&1*J!5D&Q/WBOA5' X_P#:Q\5Z
M3\/+_P &Z]J7P\M?&30:IY$>H2WEA:?V"Y DCD#W<B EYHH@H4\,JMP57/8?
ML]?%Z/X]?"'2?%T%K;V5OK1FD@BAOXKX")9Y(T)DBRF]E0,R G8Q9"25)(!X
M%^TK\=?&>A?M!> 6L;K4M#T\W%O;GP?+/';ZEXDDFU"*!IXVCBN(988H_G:/
MSHW6/S&?RP5<2_L3?'KQKXV\,:Q=27&M?$HPZ3H5[<F5+;3Y-,UJY2X.J:8A
M*Q($M?+M6\MMTB?:2A9B,#ZJ=0_^>E"#:/UH \Q_8UN)KO\ 9Q\/RW%NUI/)
M)>/) SJ[0L;R<E"RY!*GC()!QD<5ZA7FW[(W_) ='_Z^+[_TMGKTF@ HHHH
M**** "BBB@ HHHH **** !AE365-X3TVXO#<R:;8O<E@YE:!2^X=#G&<^]:M
M%8UL/2JV56*E;75)_F--K8Y/7/@QX4\2ZS)J6H>'=(O=0D*LUQ-;*\C%< $D
M^F!^5?&?_!0!=O[2=QC_ )\;4?H:^^&Z53N]"LK^8R36EI-)C&YX59N.G)%9
M87 X;#3E4HTXQ<M6TDF_6VXY2;W/BS]O?_DJFC^V@V__ *'+47[8G^H\ ?\
M8M0?TKUC]JO]E3Q%\;OB#;:MI%QI4%M#IZ6A6YE96W!Y&X 4\885YE^W'HTG
MAS5O!>GS,C36.@I;R%/NED;:<>W%?Q=XC</9CA'G^88FBXTJTZ?))[2]_H?3
M8&M"3HPB]4G<;^U?_P DK^$?_8$'_HN"J_QW_P"39/A+_P!<)_\ V6I_VK_^
M25_"7_L"#_T7#4'QW_Y-E^$O_7"X_P#9:\;B'_>,Z_[!L/\ G1-L/\-+_$_U
M/GG_ (+*_P#**?X1_P#8WC_T1?U%_P $R_\ E$3<?]E$N?\ T1#4O_!97_E%
M/\(_^QO'_HB_J+_@F7_RB)N/^RB7/_HB&O['SO\ Y,)_W"C_ .DH^3P__(]^
M9O?MX?\ *&;QU_V-FG_^C[:OEC]D;_E#7^UA_P!A/P__ .E<-?4_[>'_ "AF
M\=?]C9I__H^VKY8_9&_Y0U_M8?\ 83\/_P#I7#7W7@#_ ,FRR[_%3_\ 2XG#
MG7_(QGZ,^D_^#7G_ (]OC=_UTT/^5_7ZR5^3?_!KS_Q[?&[_ *Z:'_*_K]9*
M]SC3_D<U_5?^DH,O_P!WB%%%%?+G8%%%% !1110 4444 ?F[_P '$'P2\4_&
MGP+\*X?!OPS^(7CW7=/U*_DBOO#MQ(UEH*M%#E[ZTC&;M9, (FY,%&^;G!],
M\5>&O%_A/_@BEINDZ?J5G\/?$UCX6T^&\OM7LH=)714$\0N9&ANY)8X76/S"
MJR.WS8QSM%?:JKM%>*_MP?LR>)/VKOAOIGAO0?'5OX)M[75K75+TS^'X-9CU
M+[+,EQ#$\4Q"[1-%&Q'.X J1@T )_P $Z+[Q+JG[%?P_N_%VJ3:UKUYI[7,U
M]+>VMY)<QR3RO"S2VO[AV\DQ@F+*@@@$XS7ME><_LF_ F7]FGX >'_!5QK$>
MOW&CB<S:A'I\>GQW,DUQ+.Q6WC^2)0TI 1>  ,8KM?%OBO3_  +X8U#6M6NH
M;'2M)MI+R\NI6VQV\,:EW=CZ!03^% &C7AOQO_Y/D^!/_7CXE_\ 2>TJ[JG[
M?/POT:6X6XU^X7[/]GRZZ;=-&ZRP"XWHPCPR10G?*RY$(_UA6L[XVW"M^W)\
M"_F4LMEXF# -T_T>TZT >[44TRJ#U'YT><N!\R\].>M #J*;Y@R>G'7GI1YJ
M_P!Y?SH =13#,O/*_G2^8N>O7I[T .HIHE7'WE_.CS.?X<]AF@!U%-,RA<[E
MP/>D\X9ZK^= #Z*:)E_O+^=)YRYZCWYZ4 /HIJS*0/F7GWH\U03\R\=?:@!U
M%-,BCNOYT><O]Y>.O/2@!U%-\P9ZCGD>]!F7';ZYH =13?,7/4>W/6@3+C[R
M_G0 ZBFF51GYAQUH$RD Y'/3F@!U%-,B@]5XZ\]*/-7 ^9?FZ<]: '-TKY#N
M/V+_ (>_\-KKJG]B^(FUI[C_ (27[<=0/V4W E\P#9Z9'W?QZ5]<R2KM/S+Q
MUYJHUI$)&DVQM)M^5R!N'XUC6J8Z+A]2K.E[RYK?:CUB_)G#CLKR_&17]H4(
MU>6[CS?9ETDO-'X[_LI'=^WF3_T_:YG_ ,![JN1_9''_ !./&W_9/]<_])Q7
M7?LIG9^W@58K\VH:YSD=K>[_ ,:Y']D, ZOXW^Z57X?:X1[_ .CBOZ'KM-57
M_P!.Z?YL_@W!T9\^%T_Y?U_RB?1O_!#9L_&[QM_V!(#_ .1Z_31&S(U?F;_P
M0]Q)\<_'#;EW'18<;>W[\U]JZE^VUX"L66&UO[S7=0C+/>:?HUN=1O-)@0*7
MGN8X2QBB571B3R1(NT$G%?EG'.N;S?E'\D?U%X&Q<>$:"?\ -/\ ]*9[!17E
M_P  /VMO#/[1^IZI9Z':Z[97&FP1WBKJ5G]G%[:R2S0QW,)#,&C9[>4#.&&T
M949%>H5\B?KP52\.?\@&S_ZX1_\ H J[5+PY_P @&S_ZX1_^@"@#P;_@I[H\
MVJ_LF:VUOX4N_%T]KOF%K;-=;T3[/.D@*6O[^1)HW>U94Z+=LS$(K$>@?LJ?
MO?@K:W']CW6B+?:EJEZL-R)EFN5FU&YE6[99OWL9N%<7'EN T?G;"!MP,O\
M:M_9^US]HG2-$TNQ\1:#I.CV-\E]J.GZKX>.L6VL[/N0S1_:(E,(RQ*,&RPC
M;(V<]#^SA\(Y_@7\(--\+W&J6^L2Z?-=2_:+>R^Q6ZK-<RSK#%!OD\J*)9!$
MB!R%2-0.!B@#SOXE_$;Q7XM^-/P[TOP?KVM>'(]4O[B?5],U+08D632[!HVO
M+@><GF_O'GM+5"C  W0D^;85;F/V-_VI_%WC#P?XD_X2:-OB!X@THZ?>$^$+
MFPOM/6*\20B*&8?9UWQ-$YDCE+2*CP-N;S!CZ>ELH9;N.X,<?G1*T:2%1O56
M*EE!Z@$JI([[1Z"H='T&Q\/Q2QV-K:6<<\K3R+;PK$LDC?><A0,L>Y/)H \[
M_8WOFO\ ]G#P_<-;W%FUP]W(8+@*)8"UY.=C[25W#.#@D9'!/6O3+6\CO8?,
MADCE0D@,C!E)!P>1Z'BOESQU\+=8^-G_  3*\0>%- MIKS5M=AO+6"&*X^SO
M(#J;E@),KM.P-SD5V_[*_P"SO_PH#QI\8--TG0[+PWX+USQ#;:AX=LK,*MHB
M-I%E#</'"AQ'NN8IBPPNYMS?Q9(![@3@5Y=_PV;\-_\ A=#?#_\ X22+_A*%
MNVT\QFSN!9B[6#[0;3[68_L_V@0YD,/F>8%!.VN _9-_86N_V:?B3>:_/KGA
M;44NK"2R\O3=!O;&4%G1\EYM0N%(^0C 0$DCYAC!P=6LO'WQ._;&C7Q!\,?$
MEAX#\&:S)=>%I;.731I>IWYM73^V-1<7/VDA3))'%"D)V[O,?>VP1 'I7A/]
MO_X1^-?!_B+Q!9>,[./1?"MG'J6HWE[:W%C&MI(SI%=1&>-//@D9&5)8MZ.P
MPI)Q6\/VM_AFWB"+2_\ A._"OVZ;1SX@2/\ M"/YK #)N,YQLVG=G/3)Z FO
M#_@!\#?%'Q*_:"\7>)/'WPWN?"_AWQ-X3M-$\0:+KFL6^N66H7\%P70:>BN_
MDZ?'&TWR,(EE:9&,*LK$_01_9W\#G4([O_A%=!^U1Z-_PCJS?8D\Q=-VE?L8
M;&1#@D;.G/2@#4^%?Q5\/?&[P!I?BKPIJUGKOA_6H%N;*^M7W1SHPS]01T*G
M!!!! ((KH*R_!G@K2?AWX:M=&T/3;'1])L05MK.SA6&WMU+%B$10 HR2<#CF
MM2@ HHHH **** "BBB@"EXBTN76M"O;6WO)].N+JWDACNH #+;,RD"1=P(W*
M3D9!&17CLG[+/B^3PW+9?\+M^(2SOHEKI0N_*L_,2>&;S'O1^ZQYTJ_NV_AV
MG@ U[?10!R'PW^'.I^"=9\376H>+=<\2PZY?"[M;:_2(1Z/&(U0P0[%4["5W
M?-DY)JA\5?V<?#'QEU2WOM<MKJ:XM8C#&8KAHL*3GH/>N^H8;A7GYIE.#S&@
M\+CJ:J4WJXR5UIMIY%TZDH/F@[,^5?VX/A9J#V/@O3O#^CZIJ%GI-K+;*+>!
M[@Q*OE!0Q /8=_2N-_:)TNXT7]G3X5VMY;W%K<P17"R131E)$/R\%3R*^VF7
M%>'_ +9OP/\ $'QIL/#Z:##:S/ITLS3>=-Y6 ZH!CCGH:_!?$3PO<<)F>:9;
MS5*N(A""IJ*LE&4/AMKHH[=CU\%C_>ITZFB3>OW_ .9\#_\ !94_\:I_A'_V
M-X_]$7]1_P#!,L_\:B;C_LHES_Z(AKU+_@JM^QK\3/BQ_P $^OAUX+\)^%KG
MQ-XDT+Q.+R]M+">(F&'R+P;]SLH(S(@X.<M6;^P_^RK\1O@G_P $R9O"?BGP
M?J^D^))/'$^HKIVQ;B?[.T,:K)B)F&"5;OVK]@S^E.'@B\NDOWZI13A]JZBM
M.7<\?#_\CGVOV;[]#G?V[_\ E#-XZ_[&S3__ $?;5\L?LC?\H:_VL/\ L)^'
M_P#TKAKZU_X*&^&=2\)?\$=?'%OJFGWFFW#^*=/=8KF%HG*^?;C.& .,@\^U
M?)/[(O\ RAJ_:O\ ^PGX?_\ 2N&ONO >C4I>&V7TJJ<9*=.Z:LU[\=T<&=-/
M,9V[/\CZ4_X->?\ CV^-W_730_Y7]?K)7Y-_\&O7%M\;O^NFA_ROZ_62O8XT
M_P"1S7]5_P"DH>7_ .[Q"BBBOESL"BBB@ HHHH **** "BC=10 5QOB#X*Z/
MK/C2^\1-]N;5;[2WTIEDO)6L_*(/)M]WE[O]K;DCO7949Q0!\:^*?^";GBK7
M8$M+;Q=X>BL]/M+[3[ RZ=,TODZGIXL]1,F'P7& \..!T8'FMKXB?LA>"/"_
M_!1GX;^-]*\*>3K'B>T\0MKVI++<.LS?9[39ORQ1"=IQ@+G!ZU]8"FNF\CVH
M S&\%::^IW5XUNIN;Z$P3ON/[Q" ,=?0#D5"/AWHZV-G;?8U\C3Y/.MT#M^[
M?.<]?YUM[J-U &._@32Y+F_F:U7S-33R[H[F_>CTZ\?A0G@'2DCT]?LJ[=).
M;3YF_<G.>.>>0.OI6Q1G- &*WP]TADU!?L:[=4(:Z&YOWQ!SSSQR>V*>G@72
MTO+&X%JHFTU/+MFW-^Z7T'/\\UK[J-U &$/AMHPTVZLQ9JMO?2B:=-[?O&!S
MGK_*K*^#=/35K>^6W NK2+R(GW'Y$P1C&<=#BM0G%&: ,$?#/11H[:?]B7[&
MTOGF/>W+XQG.<U:;P;I[ZPU^UN#=21>09-QY3&,8SCI6IFB@#!/PTT4Z5!8_
M8E^RVTOGQIYC?*_KG.?SJP_@?3)-0O;IK56N-0C,-P^X_O%.!CK[5K9HSB@#
M$_X5WH_V6QA^QKY>FN9+9=[?NF)R3U]?6GR> =)E?4&:S5FU88NSN;]\/?GC
M\,5L4;J ,5?A_I*/I[+:JK:5_P >N&;]SSGUYY]::?AUHY@OH_LB^7J3A[E=
M[?O2"3Z\<GM6Y0#F@#)C\$:;%>V-PML!-IL8AMFWM^[0=!UYZGK4)^&^BG2[
MBR^Q+]ENI?/E3>WSN.ASG-;F<T9H RU\&:<NK1WWV=?M4,/V='W'A,8QUQTJ
MJOPST0:/_9_V&/['YWVCRMS8\S&-W7-;V<T9H R6\%::VJ7%Z;9?M5U#Y$LF
MX_.F ,8SCH!4/_"N-'&GVMJ+-1;V4QGA3>WR/G.>OKZUN$XH!S0!DOX'TU[V
M^N/LX\[4X_*N6W-^]7TZ\?A4:_#[25@T^,6JB/2VW6H#M^Z.<^O/XYK:HH Q
MY/ .DR_VANM1_P 37!NOG;][@Y]>.?2A? FEQ3V,RVJ^9I:[;5MS?NAZ=>>O
M?-;%% 'A/A#]G?3[;XU>))+CP;X7MO#]RHDM;B"P"7$LISO.\-D9WD,?XO;F
MG?!O]G73=-\=^);G5O!OA6SM%9K73'MM-2-GM&7RV0\GY65<E2.=V>A 'M[1
MYD##C@TC+ARVWDBO)HY;7A.$WB:CY92E9RT?-?W7_=C?W5T"5'".+BL/!:)?
M"M&K:KS=M7U/FO\ X)L^%/%VF>"O&%]X^^&.D_#?7Y/%>H#3(K-(-UUH[R"2
MTW-$3RBN8R#WC![U7^&?[ 6M?!!+BY\'^.K;2]8U*^O6OKZ;1%G=K.Z@L8W2
M,>8-LT;6$;QR-N4;V!1AC'U!&?\ Z]. P:]S$5Y5JCJ2Z_UU,Z-&G1A[.E%1
M79*R^Y'A_P"RA^QIIO[)^O:S<:->QRV_B*PLH]1B^R>6]Q?0/<;KLON)_>1S
M1JR= T.X8+MGW"@+MHK$T"J7AS_D V?_ %PC_P#0!5VH[6V2SMHXHQA(U"*/
M0 8% $E8?BGQI'H%];:;'&T^L:I%.VGPO',MO/)&F[;).D;K""2!N;GG@,>*
MW** /C73_P!N[QY>:/X;OKFU\(6\UK8:7?:Y816\TKZVU]KTNDF#3V:52C0B
M$OEUD+O- I5 Q-=Q^S!^U_KGCK2[^X\56]GK"R>'M \56K^%M)NKEK2/5A=X
ML9(T:5Y)+?[)EI0%W+/&3&G?VJY^"7@^]OM$NIO"_AV:Z\,R23:1.^FPM)I<
MDAR[P-MS&S'DE<9//6K7@CX7^'?AG!>Q>'-"T;0(M2NGOKM-.LH[5;J=\;I7
M" ;G.!ECSQ0!X_\ L[?&ZW\"?"#3-+U/PK\2+>]AFNWDC_X0_46V![J9UY$1
M'*LIX/>NV_X:>TC_ *%OXD?^$;J7_P 9KTBB@#S?_AI[2/\ H6_B1_X1NI?_
M !FC_AI[2/\ H6_B1_X1NI?_ !FO2** /-_^&GM(_P"A;^)'_A&ZE_\ &:/^
M&GM(_P"A;^)'_A&ZE_\ &:](HH \W_X:>TC_ *%OXD?^$;J7_P 9H_X:>TC_
M *%OXD?^$;J7_P 9KTBB@#S?_AI[2/\ H6_B1_X1NI?_ !FC_AI[2/\ H6_B
M1_X1NI?_ !FO2** /-_^&GM(_P"A;^)'_A&ZE_\ &:/^&GM(_P"A;^)'_A&Z
ME_\ &:](HH \W_X:>TC_ *%OXD?^$;J7_P 9H_X:>TC_ *%OXD?^$;J7_P 9
MKTBB@#S?_AI[2/\ H6_B1_X1NI?_ !FC_AI[2/\ H6_B1_X1NI?_ !FO2**
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MK!TR2[TZUCUVXFO\FWD;][%HDGDQ;=K"2)S(BNQ3M/BA^V9X@TG_ (**:/\
M#>R\1Z'HWA6\\.^&-:BMKB#3/MFI2ZCJ.K031[KK4+>;!CL8 HM8+AU9W.UB
M44]-\:O^"@L7P8^)"^%;WX;^*-2UDZ7I-SY=C-:S*+N_749$L?E<MNCATN^=
MY,>6=L:J6:3 P_%'_!4#PO:76G2:?X#\4:])K$L%IHA5K%+N^NFTZVU26+[,
M9C<PB&UNHF,C1[-_RY'F0-* =K^U5^WGI_[.'_"!R6.CVOBNT\<)->P74.K)
M;02V</V;/V:38\=Q=2BZC,$):-)0LA\Y HSY1=_\%8I/A3^R+\*_B!XR\/\
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M228B2,V[H0#+^('_  5ROK;69_#VG^'?"?\ :]O+!93:CIWB=-:L4N7EE+-
M/)A^TV@BMYHVG#))'<YB,!$<CK]1?LF_$[4/C-\ M!\3:J+,:AJ?VCSOLL92
M+]W<RQ+@$G^%!GGKFO%_V.?VP-:^,/BJQT?Q)X>TC3Y(S<Z4+VVT.[T@SS1Z
M?H^HIY=K=,9H;?;J4D/SG#26B2*2MPBKUWQ$_;PTGX:_$#Q!X?7POK.H3:1J
MECX<MI4OK" :CJ]TVFB.TCBDG694"ZM9NT[)L +CEC$LP!] 4;J^.M"_X+$^
M'_$<^H36_P .?&W]B:095U#47N=."VGV9-+:^/E_:-\BP?VO;*#$'$Q5S'N3
M:[8'P_\ ^"M=]KGPW^&]_JW@.^C\3^*H-(BN]&L9K66.]N=4BTW[%);7/VKR
MX86?4%9DEWRK&N2!NC:0 ^Y,T9S7Q3XX_P""R.D)X=U#_A%O NM:KKD6@-J]
MG!?745M9SW$1TTW5F]PGF(LD,>I1L1DL3$V55)());'AK_@KQI,F@::I\%^(
M]:U+5=:M_"UD]D;2TAO]8EFT]/LXCDNG>&-$U.V8S2'8=D@!):#S@#[.HKD_
M@5\7K'X]?"'P]XPTZVNK.S\0627:6USM\ZV)R&C?:2I96#*2I*G&02,&NLH
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M^(-&\&0^ _L?AC3FM+^[M[.-M%GL9],FUB[^Q36B1HI2UGTJ6=HYI4MV29I
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MNEF3/FF$6_F"23R Y\TTSPC^U]X$TWQ?)I<?C:[OK_Q!>FUO;B\T+4+Q;/\
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MJZFL@]PNS3S]E>(I8K:VY:%S;']^7,DBR.%*W?'MC^TIX@^#GPO.CWUYX?\
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MC@> HS1/&\DK/V7P3^"\GPN36)KC6;C4KK7=0N=0NE$*PV_F2SR.A5?FDW)
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M7&GZU>);Z7;_  ZUN1Q9VE[<VZVKW7G+'-<7D4,-Q%<6\<B1I+N:"2,QRO\
M<M% 'P[XB_:H^/TGP\U*WOO#/V;7[[P%>:Y9VFD^ =<6YFOY+3598+:.X\Z6
M.":V:RM4D24;YGO8E01,\ FKZ]^VY^T9X0TZ%+KX80ZGJ%UX8'BRT-IX*U>.
M&^O&:98?"C?Z0YMKZ;R"W]HRGR+<.GF6WS1F3[JHH ^&?&O[9G[1W@+6O&&H
M3?#>'5_#NAW]_'I]II?@75YM0NK47GB.UM75_M6R9D32-/NGVHHECU>%%\H-
M%-+CWO[5_P >/B1IWAM8]#U3PWXJ34=/1=*@T.YTU/$=JOQ T_3K^Z,,RW$T
M5M'HZ)))(AD1(=5DEWL@C=?OZJMSH]O=:E#>-#"UW;QO%%,8P9(T<J756ZA6
M*(2!P2B^@H _._5_BY^U9HWQ*^(EY_9/C"\\.#7-+T>#3[+1GF;2DF\2WZ?;
M["9[>-KJV2RC@AN (V*P7$%P"BQ/YNWX+^+7QFB?7K+6-4^*TVBR:_;-KVM6
M?AB?[9HUA+<WD<B6=C+IJO#*'6RA<6L^I1):B2Z1XB4EF^_Z* /B;0_BUX[D
M\=Z)]OU[]H"/0/(T\^$RG@2/[5XFF;6[^"Z_M5?LH2W4V:V! N#:,MM*USE9
MA*MMZ[\&M0U?XY^'].W>+O%6EW'@WQ3J1DFM+7;;^(M/M]8O[2VAFFDB,<NZ
M*SQ)Y3"3E9#M6:,O[X>15;2-)M]!TV"SLX8;6SM8UA@@AC$<<**,*JJH 50,
M  #  H ^-OVB?VQOBOX4^-_B:3P#X1\5WGAW2=+CT]AK'@G5+JT;5K9]9D:"
MW2 ))(;U;>R1+M'DMXUE@+ O-%')H7G[7'QL\2>/](\,Z/X!&D7YU[4K77;K
M4?!VKW=CIEE#+>/:%)TDB@FDFM[>(&2.5H]]Q&=HWK&?L*B@#X3\-?MS_M":
M9J?@'3?$'PON+B^UK5=(&L3Z?X"U>.S2QOET5IE5FN7:WFLSJ-XLDDBRHWV"
M0LEN$D".U?XM_M >$](^ >L9US[->> W?Q?]O\&7VH#3]6EN])@%W?PVKQ2N
M8XKBZ*VJ",@B:5SY<3/!]U44 ?',WQV^/?Q'_8]^-GB*X\+7'@WQ-I/@U)/"
M.CZ=X>O&UHZI)H<%X\D9E9EN-MU.84A2WWH\+(Y9PRCFOB5^V!^U!X*;6KK3
M_AOH^N6OVR>#3+*#P5K)FCCDFUZ&V>:5;A@XC_LFREE*1J'75X0OE 1R3_==
M% 'Q=!^V'\=OA]KMU#XP\"IJFE6=[<0R:GH7@36AOBBD\0VJE($FN7D-Q-I>
MESIL)"1:K&IWAH[ALZ3]LK]H;2[?36U;P)::;:^)+G4A'J,7P_UN^C\*1V<U
MU'$+NVBN3-=M>F*W\IHO)$8GWXE7&?N*B@#X?\;V?QRO?&%UXFT;5/B9X=U'
M5-(\$:M!X<O(EU;1-#O]2UN2#6+-_)@C>XBM+18S(J3(43,A:,.'%*']M3]I
M37_$KZ+:_#.PTN_^U66CK/?>#=:DMXR]Y96\^M[EF56M")K@BS+I)&L)D:Y=
M$<'[MHH ^!?$O_!1#XR:7XEU+2Y_",?ARWF\40:1H^J:K\.-<G^U1&TU^:2"
M.TM[EI+R<'2+4B2&0!4OU9H@ I?T[X6?M;_%KQ?\//C%?:K\-88?$OPKTR18
M]$LDDFDU?5I+9]1M[*%UD8R>787&FK*44L]Q-.J8$:JWU'?:/:ZE<6LUQ;PS
M2V,OG6[R1AFMY-C)O0G[K;'=<C!P[#H2*BT'PUI_A>WGBTVQL[&.ZN);N9;>
M%8EEFE<O+*P4#<[N2S,>6))))- 'QO\ #SXL?M#_ !(\:?%C5H8#-:^&OA_-
M#X$@_P"$3O-#TWQ3K3SW;1WHBO)B\9!@@@-O-(>!YRND=PI;)^(/[6_Q"^"_
MPMO=2^'>F_&CXK7,EQ%/CQC\.+M9!(MG+<3V<,<$5E<(TC+$N\PRQPRR&-%D
MVM'#]V44 ?&%O^UY\=M/T21M;\'6^E?VA<6MS;:G#\/M<OH=%M97UL&WGLX9
MVN+JX_XE=DOF1&((=7A8Q$!!/6^&G[;?QL\0>.XYO%O@O3_!/@G2[B\U/Q'J
M%[X0U<OH>GVT=Y)+9;_-$4TX6VB9;R/,<@N %MCA#+]L4CH)$92 0PP01UH
M^._VM?'OQ*M?VDM8_P"$-U7XF6JP>%?#=UX-M='\/2WV@:UJT^J:I%>P7TQM
M9(4A,"V'G,\L300OYJ-&?G&;H7[;OQNU+Q'?6^H> 3H>GIJDBPW+>!M;O&@V
M272KI#I$_P"\FE6"-EU1&%JOFX,'SPF7[5BB\H'ZTZ@#X2T/]M']I;Q9\+5U
MBU^&^FVFK1K>7\]K=>"]:#(D.G0W8TL1F96-QYTC6HNE9HY'#%8 \3PG(\._
MME_M)>&OB-X__M+X?ZAXDCTA]8LK+18/ ^K6,=Z=-MM5\C5+.[9WB^S7DUC9
M(+/=/,S:FCI,551)^@E% 'S1^QW\<?C#\:?'VKP^--%T71_#&BZ'#+;7T?A7
M4],E\07TNHZC!YL7VJ<B&&*WLX2UOB9W^U1RB98WC#^4^#/B?\?--UGPIINM
MZAX[NM7C\:WEG;$>%#'I_B.P7QO>V5X]\RVK+:0P>'UMKBS/G1"82;PUQM!/
MW;0PW+CUH ^7?VI?CKJOB=_@UJWPXUWXAK9^,+FWU*UFT7PK<WVAW%BTUG*T
MVJRI93S0JULTL44 \IG>Z9W,:P&>W\)M?CS\8KSX)V!OM<^.MGKFI:C8K87\
M7P]N'DT^_?3+:XU'^T(8=+=O[,L[AW$<4:!KB=FMO."1NT7Z+0PK!'M7A1P
M!@ 4Z@#YA_8A^+/C[Q1\0-?M?&W_  F,UK>:=IDJKJWAV:SCTCQ 7U$ZOIUO
M*+6)'T^".'3_ ")W,@E,S8FE9\#Z>HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ6TEY>PW,D),TRF, O;B/YRJ@R@E@ :Y?]F'_@K-X<^*-K\8K'XK>&YOV?\
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M.O#DGB72)?$7A2[\1Z%)IMKXRTN)XEDO+%F);:OVBW8Q7"PS[)T?RMF6'OE
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M_EN5XZY!JY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBQG&?L]U37^"/@%!_P BVP'7A+P8_6CFCW%RH]>B.T'T/&*<(UYX->/CX*>
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MDMFZA)ZE2<9Z<5L5BZ),UR]NS* 63<1Z9%;5=,=#GEN%%%%,D**** "BBB@
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ME.,;$2"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU;]!$MPHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK8Z+*S3 9S@C(['J:O:K\;;+1].FNKK0O&%O;VT9EE<Z)*?+4#))QGC%>?\
MQ,^?]M;P*F/FCT^9@??]Y7IWQ<"P?"_Q(0W73)R/;]VU<L9.S?8S17^#_P <
M]&^+DUC=Z+;^();&\#F*[GTJ:W@.T'.6<#'3'UKTZO#_ -AJ-E^ ?AG=_$LS
M#'_71J]PK>GK$SEN%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <U
M\7?^2;:S_P!>K#^5<!XCM/\ A,?CAISV\=C$=(C*-/=A/,?:RE_)QEF(+ ?/
MM R2,UW_ ,7^/AMK';]QC]10_@;0YM:_M1]%TE]44@B\:SC-P#Z^9C=G\:SE
M%R=BXRLKLOWVFV^IVWEW-O#<1YSLE0.OY$$5AV/PQTW3YW:.35-KW;7K1M?R
MM'O;DKM)QLS@[.@P/2MC64OFL_\ 0&LUFW#/VE&9-O?A2#FO/-'\"ZI9>)I[
MB2RFE@FU%KI)'\E7AE++OE!0@M'L!5=P+\\C'-.HTFDT*&O4ZOPYI-KI_B?7
MS:V\,+75Q'-,4&/,<Q*"Q_2MZ-/RSZUR>@WNMOXXUY7TW2TT];J-4F6^<S,G
ME+R4\H 'VW'ZUN7%SJ4.H0I;VEK+9L/WDKW1CD0^R;"&_P"^A3C+W0GN:'EA
M3GJ.]-VXW?W6]35#4KO4H]1MX[6SM9K.3_7RR79B>/\ W4",&]>HI-3N=1M[
MZ!;.QM;BV?B:66\,+Q\]E"-NX]Q5J2)-!%VC_/%"' ]JH:E=:C!>6ZV=E:W,
M$A_?2271A:,>R[&W?F*35;W4;:Z@6RLK6YA8XE>6[,+1#_94(V[CMD4^9 :5
M&:S=3OM1MI[=;.RMKJ)FQ,\EWY)B'J%V-N_,4:S>ZE:30+I]A;WR.W[UI+S[
M.8AQR!L;=QDXX]/>CF0&EFC-9>N:AJEFT L=-M;]7.)3)>_9_*'J/D;=].*-
M:O\ 4K)8?[/T^#43(V)?,O/L_E#U'R-N[\<=/>CF0[&IFBLS6]2U.TCA_L_3
M;?4&9L2B2]%OY8]1E&W?3BEUO4=2L[2)]/TV'4)68"2-[P6XC'<YVMGZ8%',
MA&EFBLS7-0U"QM8WL=-CU"9F >-KL6X0=SN*G./3%+JNHW]K9QO9Z='?3,1N
MB:Y$&P8Y(8J<X/'04<R T1Q2YK-U74+ZTL5DL]/6]N&(W0FY6+8,<_,5(./I
MS1JFIWUKIJ26FGK>73$;H#<B+9Z_,00<?3FA2OL.QI$9I"M4-1U*_MM)6:WT
MW[9='&ZV^T+'CU^<\<?K1=ZI?0:.L\>F_:+MMN;47*(5)Z_.WRG%',(OJN*5
MNE9MSJEY#HR3QZ:\UVP!-J+A%*$]1O/RG%%SJE]#I"W$>GO-=$ FT$Z!@3U&
M\_+Q2]HA\I?";AW'T.*3R0/XF_.J-QJ][!HPN!ILDEUM!-HLR!E/<;R0IQ]:
MCFU:]31OM(TVX:Z(!^R":,.#Z;R=G'UI\Z'ROJ7IHB3P2..AK+NO VCZAXDM
M=8N-+LIM8L4,=O>R1!I[=#G*J_50<GIZU-)J5XFC?:%T^9[K;DVGG1^8#GIN
M)V?K49U"Z&C&?^S;AKIE!^QB6/S"?3?NV?K4\UAJ+6Q)K_ANS\3Z!=Z;J$$=
MY8:A"UM<02<K-&P(93[$'%9OP_\ AIH7PC\(6V@^&=)M-%T:QW>19VJD0Q;F
M+-@$GJQ)JY-J5R=%^T#3[DW&W)LQ+'YA/INW;/UIRZA<-HGVHZ;="XVY^QB6
M+S#[;MVS_P >J>57YNH[NUKZ'D?C=?-_;,\'KN;*Z7,<=SQ)FO2/BU^[^&/B
M#G_F&W!Z]?W9J5M&M;Z>+7YO#Q.MVT1CA#^4;I%Y^4.'V<_[V*K^.8;_ ,5_
M"W6H8=-N(+^]LI88[622/?N92HR58KSG^]6,86BT@WT.6_9!B4?L\^'_ /:$
MI^5C_P ]6KRWXJJLW_!3KX>QMN^7P_,^,^TU>P? 30-4\ ? _2M/U'3;B/4=
M/C</:K)&78[R1@[MG.>["O(_$NA^)M<_X* >%_%'_"'>)(])TS0)H3+)'"R>
M85DPOF+(T0)+# 9P:VHZ-+R_0VH_%H>U?M" 1? ?QHV3\NC7>,M_TR:O/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=5V@C[%_MCQH$S_PCOA?_P **8?^V=']L>-2/^1=\,Y]/^$AF_\ D.OB$?\
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M-XSC(SZ4/4?,>=-\2_$V_P#Y)OXP_"^TO_Y*IW_"RO$O3_A6_B__ ,#=,_\
MDNO1-U-\U2/O+^=3RAS'G3?$CQ'(GS?#7QD<'C-YI7_R75>\\7:QJ*CSOA?X
MND 4KM-UI>W!X(Q]LQR.*].$BD_>'YT;US]X?G5!S,\LF\6ZM)<1R-\)_%3/
M"0T;>=I!VD#:"/\ 2^P) ^IIS^--8F9F/PK\7+(ZE"XGTD/@]MPO,_K7J D5
MFP&7/IFE#JW0C\Z.5=@YF>90>-M9B@C1?A;XN58EVJOVC23@?7[9]/RJ=?B)
MK[C_ ))OXS3V-SI1_P#;RO1MZGN/2C>/44+0D\]7XCZ_&>/ASXR7Z7&E\_\
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M:'K\$/AG7[^6=M.\&W,T<LL=CXA@L[%XUN%&H65R8]'E:Y79'%-<AB8MVVR
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MI_P4\'Z3XK77K7PKX;M]<C:=UU&+2X$NU,[,TQ$H3?F1G9G.?F+$G))KIZ*
M.(\+_LX^"? _B_3=<T7P[8Z/>:-I\^EV$-@#;65E!/)'+-Y=K&1 KR-#%ND"
M;R(U7=MXKMZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>nbx-20211231_g21.jpg
<TEXT>
begin 644 nbx-20211231_g21.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MQL\9>$?#$$NL6^EKI%KIEO;SPPL[1[?(59&);EU56($C$*>F_P"'N$?QB?\
M9Q\8S6OC+X<V&K>-O%&@>+M%M[ZVN;4-I&FW4UPDS>2[W,*F#<GE>4Y;CGO[
MM\/_ /@D7\.?AQ\;?#WCRQUKQS)JWAOQSKWQ M89[VU:U>_UBW2WNHW46P8P
M*D8,:A@RG)9VZ5XKJ?\ P2:UCP=^U;\%_#OA71_[0^"?@CQ#XC\>^(M;\0:U
M!<7M_?:S;W=M/I<=I%!'^Z F1A(<_*[*267+ %G]DO\ X. ?!O[0?B'4(?$7
MA%O!NDR^#]2\>:/<6WB.RURZETZQ&Z>"]M[=BUE>^5F987+*R9&_(YPOC?\
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MQ5XX^+7CG5OC%I%IH&M^+->UFVNM=MM.M7#P6EM)]F$448?YFS$Q=LLQ)"X
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MEU?P/)X@LX9M*UI;>690EY\UO+$^V,+(2BX=B2-ISZ7XI_X) > ?%'PD\/Z
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MW@_7O$/PNUR."+6_$4&B:7!KGB,6D=NTUSIFFASY!OG8"))&5T+ X7GCB_\
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M73__  (3_&C_ (3K2/\ H*Z?_P"!"?XT?VQ@/^?T/_ E_F'LY]G]QL45C_\
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M_P :!XZTD_\ ,4T__P "$_QJ?[8P'_/Z'_@2_P Q^SGV?W&Q16/_ ,)SI/\
MT%-/_P# A/\ &C_A.M)_Z"FG_P#@0G^-']L8#_G]#_P)?YA[.?9_<;%%8_\
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M]!73_P#P(3_&C_A.M(_Z"NG_ /@0G^-']L8#_G]#_P "7^8>SGV?W&Q16/\
M\)UI'_05T_\ \"$_QH_X3K2?^@KI_P#X$)_C1_;& _Y_0_\  E_F'LY]G]QL
M45C_ /"=:3_T%=/_ / A/\:3_A.](S_R%=/_ / A/\:/[8P'_/\ A_X$O\P]
MG/L_N-FBL8^.]('_ #%-/_\  A/\:7_A.=)(_P"0II__ ($)_C1_;& _Y_0_
M\"7^8>SGV?W&Q16.?'6DC_F*:?\ ^!"?XTG_  G>D_\ 04T__P "$_QH_MC
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M\7NOCGXPM/B+=6.L>'[;3?A[:63W%SXWM)0+6.$6WF&ZCW,XV9R5R&X Z]_
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M[!)6T?M8OF>EDK+=W]%U..694XNS?X'V?_PB]Y_TZ>O_ !]Q?XT?\(O> ?\
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MXO\ XJL[RUX^4_\ ?-!C4'[I_P"^:GZQEW_/J7_@7_ #WNZ-#_A%[S_IU_\
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MHUGX^B\$QZ58VEDS0"3REAGO#,PG99S(75K?"J@7()K#U[_@H[>>%_A;X?\
M%6H>!(8X_$$;ZE#80:O)<W0TJ.6*![QO+MS''^^<J%E= 1MY!; _2/\ B%.8
M58TYT*//SI/^(M+JZ6L5=V[7T.'^T:<9.+>WD?7?_")7ICW 6A7KD7<?^--/
MA>[QN/V0?6[C_P :^3OBC^VQJ?A+XV:?ML?LO@WP_>>*;/4X8;J*;4-9?2M-
M:8Y@,>Z%/-"E&#G<#\P P#Z!\'?VC-3^+OP9\3>(-4\-ZE\/;C28&FMYKRTE
MOD>%K<31W,<.Q)I@N<&,)ERI"%@0:Y,P\,L;@\+3QE6A[LN5.U1>ZY2Y4FN6
M[N^VR*IYA3G/D4M?0]R7PM>-T^R<],W<7/\ X]0?#%Y_T[=?^?N+_P"*KYC\
M2_&[XH7_ .RWK7B5=%/AWQ#IBW$]C]E:S3^UK:.!I%N7M[Q]]M&2 7@),X!X
MQG->W?#/Q.OCCX;>']:\R*<ZQIMO>F1(FB1S)$K$JC?,H.> >17C\0\'PR?#
M1Q&+I?;<&E4NTUK_ "[-&E'%*J^6+Z7.N?PG>?=_T0;AU-W%_P#%5I>,/"]T
M?$=RR_9=IV'FYC4_< Z9KFY57RVX'2M3Q<H_X2:[^5>J?^@+7A4<3EW]F55[
M&7Q1^UY2\C:T^=:C?^$8O W6U/\ V^1?_%4-X3O ?F6UZ9_X^XO_ (JN'^-G
MQ,L_@S\'O%'BR[\OR?#^FS7H1N/.=5_=Q^N7D** .[5X#\%_VU->U;P5:Z%-
M)X?\?>.E\7Q>%Y;JWNO[.L)5N+&:\@N00CX3$3Q':IYB;@FOH.'.!JF=X&>.
MP-!N,)*-G-*^EV[M6LE:]VMT8U\5&E)1F]SZV_X1BZ'W?LO_ (%1?_%4Y?"]
MXS8'V7_P+B_QKYM\"?MSQ^-_%'@W1_\ A&39ZEXZ@TZ]TJ%[\,9;65;C[;,3
ML_Y=6MF7 ^_YL1RI; H_'C]I'7/ GB[XA3/J-YH^@_#>'3KB2RTZVLI+[4H;
MF$R27C?:F :!'Q$$A <LK<G&*]#!^&N(J8U8"M0Y).+DKU$[I-1Z1>O,[=M'
MV9$L=!0YU*_R/J#_ (1:\R/^/7_P+B_QIO\ PBUXV>+4[>>+N+_&OF?XB?MN
M:IX$T7Q+>#P;:30Z;XAN_#FC(=1EDN-=FLUDDN&$,-M(T2K%'NRYQG=D@ $X
M>I_MTW_Q$NO!\GAO3(]'T;4-:\,IJ%S=7L37SQZG MX;>.W\L[T\EU5I58,'
M!VC )KNP_A'F5646\/RQN_>]I&VB3MHGW_JQ$LRI+:6OH?6?_"*73_\ /F>A
M&;J+_P"*I?\ A#[MEV[;/:>,&ZBP>WK7A/[*/[5.H?M/KJ-W-X'UCPSI/D0W
MNEW]YN\O4896=0OS(F)%V!CLWIA^&)!KV1HP(S\J^U?%YW@%D^-_L[,*,HSC
M9M*HFM5ILK;'51J*K#VD&K&M<^"+ZS;9,MJ#L4[3=1CAAGIGI[57'@R9?^6>
MGXZD?:(>3^?^<U8\8[6UL<#_ (]X/_12UEA%7'2N3,,5@\+B9X>E&=D_^?G;
MY%4XMQ3=C0'A.Z"<?8^.,"[BX_\ 'J/^$2NO^G4_]OD7_P 57S%\3?VE-;\+
M>-O&EU<:A>:9H'@77=-T<Z?IMK927=U%=I PO9_M3!VA:2?RE6###RV))Y J
M?$K]OO4_AWX)\0:]+X'MIK73M8U?3=+@CU22:YUB+2I;E;R?RXK9_)55@##S
M" -YRP &?NX^%>,KTJ-7#4>?VB3M[1*SDDTKM:NSN[;'-_:$$VI.UCZH_P"$
M4O,8_P!%^7K_ *9%Q^M(/"EVX_Y=3_V]Q?\ Q5?+'B3]M:^UWQAX?&CZ:NF^
M';?Q+:6>I327D3:C>QR:+/J+PK:E/]5@PXE5L[X\<*V6[7]F/]IO4/VB_!>M
M:SJ'A#5/!=C;6D-_I]W=1O/'>6TT<CJZJT:%G01Y95!4[@%9N:QS+POQF"PJ
MQE?#^[I>U17C=V5]->^EQ0S"G.7*I?@>Y_\ ")W6/NVOXW4?_P 51_PB=T.U
MH/K=Q_\ Q5?./A;XP?$CQ]\#O$%\VDOI^I6<J_V)J5G%:V,OB2#:S>8++46S
M:8VY(F)+*"4'/'HO[,GQ#NOBY^SQX,\3:A-97-_KFD07=S+:P-!"\I4!]J,2
MRC<&X)_2O+XBX(638-XO%4]%/D:4[N]E*_PVM;YWO=&M'&*I+EB^E_ZU/21X
M3O"/E^R_A=Q__%5]5?"*UDM/AIHL38+1VJ*VT[AG'8C@U\AR !>E?7'P:0'X
M7:'_ ->B8S]*_>_HHU,+/-,8J%-I\BZW^UZ(\;B+F]G%M]3S_P#:#\/>!K?Q
MAI=UXN\=Z'X2O-:"V>G6VH:C;VK7[JV-L0E93(V7487)R1ZT_P#X8]T\G']L
M7P/_ %S6L;X_?LT:S\8_VN?A_P")+?4;C1M!\+Z#J"W5U'8:=?+<SO>V$B6C
M)=PRF,.D,I,L*JZ[,!US@_/_ ((^&_[21M_B$?$EG\1E\.ZSJFD7SZ3I_BA8
M]6:,7-^-2M]+O)-1D:)#'_9[ J]D&0.J11.6+_U'FW@]PAF6*GCL;@HSJ3=Y
M2;=V_O/GZ.98JG%1A.R1]'VG[*NBWU]=VT'B.2:XL66.YBC:-GMF90RAP#E2
M5((!QD$'I5/_ (9U\,K;:Q,_BV..#PZ[1ZI*[Q+'I[+$LS"5B<1XB='.[&%8
M'I7AW[1WPF^/6H?#?6+'P39>/K5M2N-,ET^9/$JMK&G&'1($ GDBU"V$^;U6
M6=VG="P+F.X1L'TK4O@GXZ\2_LD_M#:/J&E%O%?Q%TNY%C )8E^WW4WAJRM&
MP=P1<W4<J?,0/ESG:03Y_P#Q C@:W^X1^]_YFG]KXS^?\CIO _[/WA+XG^&X
M=:\->-;/Q%H]P66*^TRX@O+:4J2K!9(V*G!!!P>#Q6L/V/\ 3W'_ "&KL@],
M1KS7S+^T1^QQ\9?A1\&H[7X2WFM:AXP\222ZMJFI^'F@\/QV>HV]C#!81?8H
M;NUA-NWEMYCR27 +*N^"92BQ])\>O@-\=M:\,^.=2T77?'Z:AK7CX_Z'8:[(
M\D?AI+,F%+"%;^S2!S>,&<K<0S,B,"S(!&5_Q G@?_H C][_ ,QK-L7;^)^1
M[;K/[*NB>'M*N+[4/$4EC96J&2>XN3''# @ZLS,0% ]2:2?]B'0[S5K>_DO&
MDO[-'BM[A[6,S0(Y7S%1\;E#%%R!@':N<X%>&_$#X0?'RXM+RQM[CQ[XFU2Y
M^%XT>;4;O5+;3;"'5DM3B6*VAO)(GNI9R YDB)BV[DN60A*]O_9N\->.=!_:
M,^+-QXBM_%TGAO4K^*?1[[6]566%OWDH,%G:)<S)%;I'Y6) EN[[L21LZF0[
M4?!#@JE*]/ Q3M;1R6CWZDRS7%M:S_(KZO\ \$^_".OZ3J-C?Q6=]9ZQ,;B^
MM[C3()8;V4A5,DJ,I#L0JC<P)^4>@IH_X)\^#_[/DM?L]C]GN+)=.E@_LJW\
MJ2V4DK R[<&,%F(0_*"QP.37T+17H0\)>%XQY8X?3_%+_,S>98EZN7X+_(^>
M]._X)]>$=&LH[6SAL;.TBM'T](8-,@2-;5SN> *%QY3-R4^Z3R13=1_X)Z^#
M]6O=*N+NWL;JXT$!=,EFTN"233@, >2Q4F/&!C;C&*^AJ*?_ !"7A?FY_J^O
M?FEU^8?VEB-N;\%_D?/>E?\ !/KPCH&N7&J6$-C8ZE=/(\UU;Z7;Q3S&3:9"
MSJH9B^Q"Q)^8HI.<##M6_P""?OA+Q%;:I%J,-G?1ZTB1ZBMQID$JWZIQ&LP9
M3Y@4<*&SMSQBOH*BI_XA'PM[3VWU;WK6OS2O;>U[W'_:F)M;F_!'SW!_P3W\
M(V^F36*6UBEC<VBZ?- NF0".6V4DI"R[<&-2S80\#<<#DU8D_81\.&^^U[H1
M=_:!=^>MA#YHG$(@$F[;G>(0(]V<[/EZ<5[Y11+PCX7DFGA]]_>EKZZA_:F)
M_F_!?Y'B7_#'5B?^8Q?^G^K6D_X8[L?^@QJ'_?"5[=17E_\ $!^!O^@"/WO_
M #+_ +8QG\[_  /$O^&.['_H,:A_WPE)_P ,=V)_YC&H?]^TKVZBC_B _ W_
M $ 1^]_YB_MC&?SO\#Q(?L<V)_YC%_\ ]^UH/[&]B/\ F,7_ /W[2O;:*/\
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M-]49(L-(UL)/WI5,@DQ_=SDXKZ;G_P!4V.N*^0_C;^SOXH\5?M2ZE>6_@O\
MM:/7->\):OIGBXR6FSPW;:3=QS7ENV^07"&14DV+"C+(;J0,5&[/14\*>&)U
ME7EAO>MRWYI7MVNG>P1S+$6:YM/D=IJ__!.;P/XBT2WTW4-/TC4=-M9GN(+2
MYT>VF@AD<LSNJ,A4,Q=RQ R2S9SDU(/^">/@T^)5UIK73O[:4)MU Z5!]J7:
MC1KB7;N&(W9!@\*Q'0D5]#*<BBJCX5<-15HT';7[<^N_VB?[2Q'?\%_D?/\
MX7_8 \*> [6>'0UM=%ANI#--'I^FP6JS2'J["-0&8^IYK3_X8YL0,_VO??\
M?I:]MHKSZW@KP;5K?6*N"C*?=N3?XLTCFV*2Y5+3Y?Y'C>L?LF6>M:K-=2:K
M>1M.Q<J(UP":K?\ #'%C_P!!B^Z_\\EKVVBLJW@=P35FZD\!&[WU?^81S?%I
M64W^!\]WO_!/;P?JWBNVUZZM;"XUVR %MJ<NE027D ' "3%=Z@=L'BJNI_\
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MG5/%%KHMKXRTNZU.]MYKN**%9)%\J(RAV9PA5/\ 438#$%Q&Q7<.:\)\/?\
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M ,>HT X;4/CM]@_:#TOX?R:+K*S:OH][K$&K.(UL7%L]LKPK\V]G_P!*0DA
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MA*H5B1DYUG^WQX^OOBKI_B:QTSP[>^&8_"5E-K^FKKLILTD_X2.\TN6\TYQ
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M0^3<S9#>8Z;=K/N .X@G(SFK6I>'M$UK2+O3[S0=+NM/U!@UU:S6T<D-R1@
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MM7\J\^3XW2M^TI'\/9?#E[;PSZ!/KL&L23P^1<^3/;0O$D2L9./M2Y=PHR"
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MX;:KI4UA;QP$SDRVGB".0Q>2I#QY*LJXP:[;X>?L_?';3O VB0^&?C/\&8-
M@LK;^RDMO@[<B..W6%5@V9US("Q!%&>0H KP_P"+G["O[0'Q*^./C_4+6#3]
M(\'>(? FN>&K+3(_$[R02"ZT)+:Q@FC96+20W0D5Y"_E@;'1<M(:]2_;"_8K
M^(GQK\$?#W2=!O+FS3PO\.?$.D726GB*XTQ3K4UA91Z8Y,+*9%CN(9&W-PF
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M4OB%%^T%:^"+S]I#]GL_$IEC>WTR3X0S-J2 QO*A'_$[++E%9ADC@'%>F_\
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M^BY?"/\ \-%<_P#R\I#\$_VF!_S7/X1_^&BNO_EY7T701F@#Y#\46/Q@\/\
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M?#45^NN?V<?#T[7\%T+R6+R9/MEJRQ%9+8%3(T<0.5)9/L:S61(560[G &6
MQN..3CZT SY[_P"%)?M,?]%R^$?_ (:*Y_\ EY1_PI+]IC_HN7PC_P##17/_
M ,O*^BJ*+@?.J_!3]IE>GQS^$?\ X:*Z_P#EY7MG@?P_K&E^#M,MO$6J6&LZ
MY;VR)?7UEIYL;>[F ^9XX&EE,2D]$,CX'&XUO44 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>nbx-20211231_g22.jpg
<TEXT>
begin 644 nbx-20211231_g22.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M:#_X'Q?_ !5 '045S_\ PMKPM_T,F@_^!\7_ ,51_P +:\+?]#)H/_@?%_\
M%4 =!17/_P#"VO"W_0R:#_X'Q?\ Q5'_  MKPM_T,F@_^!\7_P 50!T%%<__
M ,+:\+?]#)H/_@?%_P#%4?\ "VO"W_0R:#_X'Q?_ !5 '045S_\ PMKPM_T,
MF@_^!\7_ ,51_P +:\+?]#)H/_@?%_\ %4 =!17/_P#"VO"W_0R:#_X'Q?\
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MQ?\ Q5'_  MKPM_T,F@_^!\7_P 50!T%%<__ ,+:\+?]#)H/_@?%_P#%4?\
M"VO"W_0R:#_X'Q?_ !5 '045S_\ PMKPM_T,F@_^!\7_ ,51_P +:\+?]#)H
M/_@?%_\ %4 =!17/_P#"VO"W_0R:#_X'Q?\ Q5'_  MKPM_T,F@_^!\7_P 5
M0!T%%<__ ,+:\+?]#)H/_@?%_P#%4?\ "VO"W_0R:#_X'Q?_ !5 '045S_\
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M^!\7_P 50!T%%<__ ,+:\+?]#)H/_@?%_P#%4?\ "VO"W_0R:#_X'Q?_ !5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_E0!)133.HI//7% #Z*;YRTGGK[_ )4 /HIOFKZTGGKG'/Y4 /HIGGK1YZT
M/HJ/[0N>M+YZGU]>E #Z*;YRFCSUQUH =13!.I[TJS*P[_E0 ZBF&=0*43*?
M;ZC% #J*89U%'GJ?_K4 /HIGVA:0W*@X_I0!)13?.7-!F4-B@!U%,,Z@_P#U
MJ7SEH =13!.I]?RI!<*?_P!5 $E%,,ZCU_*E\Y30 ZBF&=0>_P"5'GKF@!]%
M-,R@=?>D^T+GO^5 #Z*;YRYQ1YZD?CB@!U%,$ZD4GVE??UZ=: )**8)U(I?.
M7- #J*C^T+[_ )4[SE_R* '44QIU4<Y_*D^T*#_]:@"2BF>>N:/M"T /HIAG
M48[[NF.]!G5: 'T4WSU_R*0W"@?AGI0 ^BH_M"9^]U&:4SJ!0 ^BFB92.M!F
M5?7\J '44TS*#1YRXH =13!.I/Z4>>OK0 ^BF>>N:4S*#_\ 6H =14?VE0.O
M'K3EF5CQS]* '449HS0!XW8_\I!-3_[)[9_^G*ZKV2O&[/Y?^"@.J-_#_P *
M]M!_Y4KJO9* "BBB@#Y=_;S^._C;X:_$[X=^&?".J>)M-B\26FK7U\?#/@X>
M)M6(M39K&?*<^7#; W+AY""YD:!5 !<CVO\ 9ZUC5-?^#GAV[UJZUR]U2XM=
M]S/K.D+I%_(VYN9;1>(6QCY1VP>]?,G_  58L-%U/Q;\+8O$'BCP[\+K%1JT
ML7C_ %^\U6UL-&FV6JKIP>QU"P59;M2[*9[@ K9NB([N-ON7[!VO7'B?]DSP
M3>W-C=6;/:RQHT]S?7!OXTGE2*]1KYWN_*N8U6XC6X=Y$CG169BI) .^^*<7
MB*7P'K/_  B"Z&WBHV4@TG^V?-_LX7./W9G\H&3RPV"P7D@8&.M?*FE?L!>-
MHAI+2W'A:&XU22S;Q3<G4I[JX6XM_$G]O3:A:D6D2--=S2SAHMD,<#" H76/
MRZ^S:* /D#QO\&]6^+G_  54\5/IOQ(\??#]=(^&?AF::/PV=.V:J#J^ND1W
M'VNTN#M&T@>68SB1^3QC^43]J5_,_:D^)S;=N[Q?K!P.W^G35_7QX-_Y2H?$
M7_LEGAC_ -.WB"OY!OVH?^3G_B9_V-VK_P#I;-4R)D<-1114DGU9_P $-_!M
MU\0?^"M/P3T6R\1>(/"-WJ&J7J1ZQHAMQJ%B1IEXVZ+[1%-#DA2IWQL-KM@
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MCXS:;I-OI?Q0^(WPW?3?,,T_A8Z8LFI;@H F^V65RORD9'EJG+-G(P*],HH
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M:O\ ^ELU?U\^##G_ (*H?$7_ +)9X8_].WB"OY!?VH3_ ,9/_$S_ +&[5_\
MTMFJ9$R.'HHHJ23[*_X-Z_\ E-+\ ?\ L+W_ /Z:+ZOZZJ_D5_X-Z_\ E-+\
M ?\ L+W_ /Z:+ZOZZ@<BJCL:!1115 %%&:,T %%%% !1110 4444 %%%&<4
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MU1X$_M%E@,\SRE ?(Y"[\9/7%?LYX-_Y2H?$7_LEGAC_ -.WB"OH*@#^<?\
MX@UOCQ_T5;X1_P#?&H__ !BC_B#6^/'_ $5;X1_]\:C_ /&*_HXHI<H6/PC_
M &#?^#8?]H3]A3]K[P-\7=/\>?!GQ%>^![N>ZBTVYFU.WBNC+:S6Q#.MNQ7
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MK\+OA-XFN?&EA<ZA;2:)XCU );I!)'&P?SK5#DF08QGH<]J_6*O-/CI^QO\
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M#A88_P"""?B'_L:=(YQ_U$4K]H\#?%[B/B?/IY?FTHN"IN2M&SNFNOS/.S/
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MV;]+YM<DN97N9[UYT^222>>665F4!=TC851@  ]"HHHH ^??!O\ RE0^(O\
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M]X9\/ZY=6J[()M0TZ&ZDA7.<*SJ2HSS@5MPV45O"D<:"..-0B(GRJ@'   X
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M!BC8[D- 'LU%%% 'S[X-_P"4J'Q%_P"R6>&/_3MX@KZ"KY]\&_\ *5#XB_\
M9+/#'_IV\05]!4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7)_'C_DAOC/_L!7W_I.]=97)_'C_DAOC/\
M[ 5]_P"D[T ?PWZ/_P @BU_ZXI_(5J:'X=O_ !-->1Z?:37DEA93:C<+'C]S
M;0H7EE/^RJC/J>  20#E:.<Z3:_]<4_D*^S_ /@EI^TK\/\ ]FS2/$M_XKU;
M5+6[U#4+&![%+?39K>[M(G.HRM_I$$DOS?V:MHRA@K'48\#< PS(1\C^*?#.
MH>"?%&I:+JUK)8ZMH]W+8WMM(07MIXG*21M@D95E(.">17Z/?\&F?_*7JT_[
M$C6?_0[2OSY^,WQ(N/B[\4]<\27-UJ%]+JUR9C/?Q6\=U+VS*+=$B\PX^8HH
M!.3R237Z#?\ !IF?^-O5I_V)&L_^AVE3+^ON8UN?MQXV/_%9ZM_U^3?^C#67
M6IXV./&>K?\ 7Y-_Z&:R\U_CWQ)_R-<1_CG_ .E,_0Z?\./H%=5\#_\ DKF@
M_P#7P?\ T%JY7=Q75? \_P#%V]!_Z^/_ &5J]+@/_DI,!_U^I_\ I:,\5_!E
MZ,_G!_X+\?\ *9?]H'_L/V__ *;[.OD.OKS_ (+\?\IE_P!H'_L/V_\ Z;[2
MOD.O]=6?G\MPKNOV6?\ DZ;X6_\ 8Y:+_P"G""N%KNOV6?\ DZ;X6_\ 8Y:+
M_P"G""D(_0#_ (.W_P#E+='_ -B'I/\ Z/O:_,6OTZ_X.W_^4MT?_8AZ3_Z/
MO:_,6G+<<MPJOJO_ "#+C_KFW\JL57U7_D&7'_7-OY4A']AGC[_DB'PF_P"Q
M8M?_ $G@KBQT_"NT\>\_!'X3?]BQ:_\ I/!7% \5_F/](#_DN<;_ -N_^DH^
MXRO_ ':(M-;K2[J3J:_&:;7,CT#UWXI_\FX^$?\ ?C_] :O)*]:^*1S^SCX1
M_P!^/_T!J\ES7Z[XU?\ (XP__8/1_P#2$>?EO\)^K"FMP*=FFM]VOR ] ]>M
MO^3/[K_K['_I0E>0KUKUZV_Y,_NO^OL?^E"5Y"#BOU[Q9^'*/^P2E^;.# [S
M_P 3_0=2/]VC=2,<BOR$[S'_ &U3C_@CW^U'_P!B5JO_ *1M7\H\?^K7Z5_5
MQ^VH?^-/?[47_8E:K_Z1M7\H\?\ JU^E?ZF>"/\ R1&7_P"!_P#I3/A\T_WF
M0ZD;^E+2-_2OU0\\_7W_ (-$?^2P_M'_ /8@P_\ HZ6OQ_L_^/2/_=%?L!_P
M:(_\EA_:/_[$&'_T=+7X_P!G_P >D?\ NBCH5+8DHHHH)/T8_P"#5'_E,?X;
M_P"Q6UK_ -$I7]3E?RQ_\&J/_*8_PU_V*VM?^B4K^IRJB:+8****H#Y]TG_E
M*AXD_P"R4:5_Z=]2KZ"KY]TG_E*AXD_[)1I7_IWU*OH*@ HHHH ^&?\ @L)I
MLU]K/PCETZ;1]:UG2=6.L67A?4[?7+B.^-G?Z9=O?H-)L;^19(5@:VWRVY15
MU-\.K863Z$_8-\,S>#_V2O!%A-=7%QY=K+(D<EE>V:Z?&\\LB6445\J72V]L
MK+;Q>>JR&*",LH)Q7S__ ,%;=;LO 7CKX3^)=4U^STC3;./6;!H!\3CX!OKB
M:?[#Y;0W48\ZX0>4P>W4A"TD+MEDC4_1W[%GBRQ\>?LN>"-:TVZFOM/U'3Q+
M;W$OB23Q(TZ%VPW]HR?/=9QD2'J",< 4 =/XT^*]EH>O/X9TR]T&\\=76FR:
MCINAWVHFT:\1<J'9ECE=8MP(+K&Y&#A6/%?/'A/_ (*;7WB6PTNX;P);PI:W
M,<?B=CK,JG2XIM>?1;>6VCDM4EF9I8I9GBN$M9(XT PSL%KZA\6^%+7QMX?O
M-+OC<_8;^$PS"WNI;67![I+$RR(WHR,&'4&O.K+]B/X:Z?/H<R>'6:X\/W;W
M\$TFI7;RW=PUXE\9;MC*3>,+N-+@&Y,FV50Z[3S0!XG\1/VIO _[-7_!5+Q6
MOC/6)M)D\1?#/PU;:<L>F7E[Y[KJVNA@3;Q.$P9$Y?:#GC.#CW3X[_MB?#[]
MFG7M%TSQIK=QI-]XAW?8(X])O;T3;71#EK>*14^9U'SE>N>@)'&>"BR_\%2_
MB(N3_P DL\+YYZG^U?$%?087% 'EOQZ_;(^'O[,>KZ/8^-]<N-'NM?#M8I%I
M-[?><$9%;)MXI G+K]\C.3CH<.^/W[8?@']F#5-%L_&VM3:1<>(/,^PI'I5[
M>^=L9%;)MX9 G,B_?(SGC.#CU#&:* /+?V@_VR/A[^RU)I*>.=<N-';7%E:R
M$6DWM]YPB*!\_9H9-N/,7[V,YXS@X=\?OVP_ '[+MUI$/CK6KC1Y->,GV%8M
M)O;[S?+*!\FWBD"8,B_>QG/&<&O4,9H Q0!Y;^T-^V1\/?V5;?2IO'>MW&CQ
M:XLK6)BTB]OO.$00R9%M%(5P)$^]C.3C.#B7]H3]KWP#^RPFE-XZUJXT<:T9
M5L_*TJ\OO-,>W?G[/%)MQO7[V,Y.,X./30,48YH \M^/_P"V-\/_ -ES3M'N
MO'.MSZ/#X@25K!H=)O;[SQ&$+Y%O#(4P)$^\!G/&<'$OQ^_:^\ _LOZ7I%YX
MXUJ?1[;76=;)HM*O+XS%%5FR+>*0I@,#\P&>W0X]-QFC% 'EOQV_;(^'W[-.
MAZ+J7C36[C2;/Q$K-I\D6DWMYYX549OEMXI&3"NI^<+G/L</^.G[8?P__9K\
M.Z-JWC36[C2=/\0;OL$L6DWMZ9]J*YRL$3LGRL#\X'7U!KT_% &* /,/CA^V
M'\/_ -G+PIHNM>,=:N=*TWQ#Q831Z3>WAG^02<I!$[I\I!^<#KCKQ3?C1^V1
M\/?V>_!6A^(O%VN7&EZ/XC .G3II-[=M< QB092")W3Y"#\X7TZ\5ZB!BC'-
M 'E_QH_;"\ ?L^>!]%\2>+=:N-,T?Q$5%A/'I-[=M/NC\T9C@B=T^3GYU7'3
MKQ1\7OVQ/A]\!_A[H?BKQ5KEQIVA>)-G]G7$>DWMTT^^+S5S'#$\B93GYU7'
M3KQ7J&,T=: /,/BY^V%\/_@3\.-!\6^*M<GT[0/$IC&G7,>DWMTT_F0F9,QP
MQ/(F8P3\ZKCH<'BD^*7[8?P_^"OPQT+QEXFUNXT_PWXE\HZ==)I-[=-<"6'S
MDS%%$TB9C!/SJN.AP>*]0Q0!B@#S#XH_MA> /@Q\+-"\:^)-:N-/\-^)O)&F
MW2:3>W+3^;$9H\Q11-*F8U)^=%QT.#P4^)?[8OP_^$'PFT'QSXBUNXL?"_B8
M0-IMVFD7MP\XFA,\>88HFECS&,_.BXZ'!XKU #!HQS0!YC\1_P!L#P!\)?A%
MH?CSQ!K5Q8^%?$A@&GWB:5>7#SF:)IH\PQ1-,F8T8_.BX(P<$@$^('[8'@#X
M6?!K0?B!KVN36GA/Q(MN^GWB:3>SO.+B+SHLPQQ-,F8P3\Z+CH<'BO3L4=:
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MGDV,_EQI>PLS;5!8X4$X )/8$U_11_Q!X_LM_P#0T_&S_P 'UA_\@UK> /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX10[?M5W-JNN^;,WJ[;$R>^T5]&?\*H\._\ 0$T__OB@#HLT9KG?^%4>'?\
MH":?_P!\4?\ "J/#O_0$T_\ [XH Z+-&:YW_ (51X=_Z FG_ /?%'_"J/#O_
M $!-/_[XH Z+-&:YW_A5'AW_ * FG_\ ?%'_  JCP[_T!-/_ .^* .BS1FN=
M_P"%4>'?^@)I_P#WQ1_PJCP[_P! 33_^^* .BS1FN=_X51X=_P"@)I__ 'Q1
M_P *H\._] 33_P#OB@#HLT9KG?\ A5'AW_H":?\ ]\4?\*H\._\ 0$T__OB@
M#HLT9KG?^%4>'?\ H":?_P!\4?\ "J/#O_0$T_\ [XH Z+-&:YW_ (51X=_Z
M FG_ /?%'_"J/#O_ $!-/_[XH Z+-&:YW_A5'AW_ * FG_\ ?%'_  JCP[_T
M!-/_ .^* .BS1FN=_P"%4>'?^@)I_P#WQ1_PJCP[_P! 33_^^* .BS1FN=_X
M51X=_P"@)I__ 'Q1_P *H\._] 33_P#OB@#HLT9KG?\ A5'AW_H":?\ ]\4?
M\*H\._\ 0$T__OB@#HLT9KG?^%4>'?\ H":?_P!\4?\ "J/#O_0$T_\ [XH
MZ+-&:YW_ (51X=_Z FG_ /?%'_"J/#O_ $!-/_[XH Z+-&:YW_A5'AW_ * F
MG_\ ?%'_  JCP[_T!-/_ .^* .BS1FN=_P"%4>'?^@)I_P#WQ1_PJCP[_P!
M33_^^* .BS1FN=_X51X=_P"@)I__ 'Q1_P *H\._] 33_P#OB@#HLT9KG?\
MA5'AW_H":?\ ]\4?\*H\._\ 0$T__OB@#HLT9KG?^%4>'?\ H":?_P!\4?\
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MLC'@_7FOY5$.47Z5_J9X(_\ )$9?_@?_ *4SX?-/]YD+0:*">*_5#SS]?/\
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MTM?C_9_\>D?^Z*.A4MB2BBB@D_1C_@U1_P"4Q_AK_L5M:_\ 1*5_4Y7\L?\
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M2H?$7_LEGAC_ -.WB"OH*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:QJ-YJT=O/8VEY9VMG=:5+KF@QW"SM<0RR.IO'TS=%;JKS0_:(W=4<FO:_\
M@GE)I\W[)'A=]..I,S7&I-J37S6SRMJ9U&Z_M!E:V MS$;W[28S !$8RGE@)
MM%<%^V5^QOH_[6'C*+0?&/Q8M8M+N#_:.E^$M4\,>'-4BM&@$:27$'VZSEG^
M](A+%CCS0. 0*]L_9ITO2M ^"'AO2]#\26'BS2=%MFTNWU2RM[2VMYEMY&@*
M)%:(EO&L9C,6R)%5?+Q@8- '?4444 ?/O@W_ )2H?$7_ +)9X8_].WB"OH*O
MGWP;_P I4/B+_P!DL\,?^G;Q!7T%0 445F>)_%=CX0TUKW4;C[-:QL%:0@D
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MM]D29G6(DSQ1AMQC<?+G&WG'% 'O-%%% !1110 4444 %%%% !1110 4444
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M_P#L08?_ $=+7X_V?_'I'_NBOV _X-$?^2P_M'_]B##_ .CI:_'^S_X](_\
M=%'0J6Q)11102?HQ_P &J/\ RF/\-_\ 8K:U_P"B4K^IROY8_P#@U1_Y3'^&
M_P#L5M:_]$I7]3E5$T6P44450'S;H'_*7SQ9_P!D>T3_ -/6K5])5\VZ!_RE
M\\6?]D>T3_T]:M7TE0 4444 ?$W_  5&\;ZAJ'C?P?X=\/\ Q0C\+7EC97VJ
MZAH>E^/;3POJFH-%/82QH\DLB-Y4UNMY;(0RJDU[!(P*1L\?M/\ P3L\17'B
MO]CKP7?76L7FOM(+Q(K^]UM-:O9X$O;A(1=7D;O'/<K&J+,T3M%YJR",[ M>
M,?MA?MA_!WX;?M#ZAI/C+X2>#?%WB+0[6.V75=2\3>";6X$,J)+Y8BU/4X+N
M-0=O#Q*#C*Y4@GZ5^!/Q1TGX@? '0O%6CZ.ND:-<:;Y]IIMC<6>HBWB3<JQQ
M-I\L]O)PF%$$C@Y '/% 'H5%> _&?]HWQ5X-NKK4M,BL[?0Y/!&I:W9V^H:;
M/!?0W4%Q91^=<I)M9(HTN&8QA0Q"L2PR .63]ISQ?I_C:^TEM:T^[A\+ZQ:6
M"2M9QA_%J7.K163JNW 1X%<H3$ #,5+ +E" =+X-_P"4J'Q%_P"R6>&/_3MX
M@KZ"KY6^&/CK5M5_X*E?%9I_!OB+3FLOAYX=LX1<3V!_M")-5UW;=1>7<-B&
M3<=HDVR#8VY%XS]&_P#"5ZA_T+.L?]_K7_X]0!N48K#_ .$KU#_H6=8_[_6O
M_P >H_X2O4/^A9UC_O\ 6O\ \>H W ,48K#_ .$KU#_H6=8_[_6O_P >H_X2
MO4/^A9UC_O\ 6O\ \>H W,45A_\ "5ZA_P!"SK'_ '^M?_CU'_"5ZA_T+.L?
M]_K7_P"/4 ;E%8?_  E>H?\ 0LZQ_P!_K7_X]1_PE>H?]"SK'_?ZU_\ CU &
MY16'_P )7J'_ $+.L?\ ?ZU_^/4?\)7J'_0LZQ_W^M?_ (]0!N45A_\ "5ZA
M_P!"SK'_ '^M?_CU'_"5ZA_T+.L?]_K7_P"/4 ;E&*P_^$KU#_H6=8_[_6O_
M ,>H_P"$KU#_ *%G6/\ O]:__'J -S;[48K#_P"$KU#_ *%G6/\ O]:__'J/
M^$KU#_H6=8_[_6O_ ,>H W**P_\ A*]0_P"A9UC_ +_6O_QZC_A*]0_Z%G6/
M^_UK_P#'J -RBL/_ (2O4/\ H6=8_P"_UK_\>H_X2O4/^A9UC_O]:_\ QZ@#
M<HK#_P"$KU#_ *%G6/\ O]:__'J/^$KU#_H6=8_[_6O_ ,>H W**P_\ A*]0
M_P"A9UC_ +_6O_QZC_A*]0_Z%G6/^_UK_P#'J -RBL/_ (2O4/\ H6=8_P"_
MUK_\>H_X2O4/^A9UC_O]:_\ QZ@#<HK#_P"$KU#_ *%G6/\ O]:__'J/^$KU
M#_H6=8_[_6O_ ,>H W**P_\ A*]0_P"A9UC_ +_6O_QZC_A*]0_Z%G6/^_UK
M_P#'J -RBL/_ (2O4/\ H6=8_P"_UK_\>H_X2O4/^A9UC_O]:_\ QZ@#<HK#
M_P"$KU#_ *%G6/\ O]:__'J/^$KU#_H6=8_[_6O_ ,>H W**P_\ A*]0_P"A
M9UC_ +_6O_QZC_A*]0_Z%G6/^_UK_P#'J -RBL/_ (2O4/\ H6=8_P"_UK_\
M>H_X2O4/^A9UC_O]:_\ QZ@#<HK#_P"$KU#_ *%G6/\ O]:__'J/^$KU#_H6
M=8_[_6O_ ,>H W**P_\ A*]0_P"A9UC_ +_6O_QZC_A*]0_Z%G6/^_UK_P#'
MJ -RBL/_ (2O4/\ H6=8_P"_UK_\>H_X2O4/^A9UC_O]:_\ QZ@#<HK#_P"$
MKU#_ *%G6/\ O]:__'J/^$KU#_H6=8_[_6O_ ,>H W**P_\ A*]0_P"A9UC_
M +_6O_QZC_A*]0_Z%G6/^_UK_P#'J -RBL/_ (2O4/\ H6=8_P"_UK_\>H_X
M2O4/^A9UC_O]:_\ QZ@#<HK#_P"$KU#_ *%G6/\ O]:__'J/^$KU#_H6=8_[
M_6O_ ,>H Y?]IH?\69U+_?@_]')7R\.OYU]/_&&RUKX@^ KO2;/P_J$,\[QE
M3-/;!/E=6.2)2>WI7C3?LV>,O^@2O_@5%_\ %5_$/TCN!<_SCB.EB<KPDZL%
M22O&+:OS/2_<^DR?%4H4>6<DG?\ R.&I'^[7<_\ #-?C+_H$K_X%0_\ Q5 _
M9K\9?] E?_ J'_XJOY]_XA+QC_T+JO\ X"SUOKV'_G7WGEO[:HS_ ,$>_P!J
M/_L2M5_](VK^4>/_ %:_2OZ\_P!IC]F+QW\2?^"?GQL^&FD:#Y_B;Q_X;OM+
MTOS+VWCM_/FMS&GF.7^5=QY.#@5^$J_\&JG[9&T?\4GX'Z?]#7;_ .%?Z*^$
M>6XK <(X+!XV#A4A'6+5FGS/='Q^8S4\1*4=4?G12-_2OT9_XA5/VR/^A3\#
M_P#A5V_^%'_$*I^V1_T*?@C_ ,*NW_PK]'.)'LG_  :(_P#)8?VC_P#L08?_
M $=+7X_V?_'I'_NBOZ'O^" /_!';X_?\$XO'_P 8-3^)7AC1X[?QMX4CTC3?
M[+UNVNV:X61V.\;EVKAASS7Y\V__  :I?MDQ0(O_  BO@GY0!SXKM_\ "GRZ
M%,^*?V;/V>KS]IOXCR>&K#7?#?A^Z33KG4$N-<O19VTS0Q[E@5R"/,E?8BJ>
M6+  ,VU&X%OE=E#*X4D!ESAO<9YQ7Z+-_P &J7[8[C!\)^!R/3_A*[?_  IW
M_$*K^V1_T*?@C_PJ[?\ PI$A_P &J/\ RF/\-_\ 8K:U_P"B4K^IROPB_P""
M%O\ P0K_ &D/^"?7_!0W1_B9\1/"V@IX9L=#U*PD.F>(+:ZN/-GC58\(2O&1
MR<\9K]Q+R]UC4O"]XUA;QZ;J[0RK:+J"B6&.;:?+:01/EH]V"0K!L9Y!YJT6
MMC9HKYQ71/VN=HSXH_9RSWQX7UK_ .3Z/[$_:X_Z&?\ 9S_\)?6O_D^F!'H)
MQ_P5\\6?]D>T7_T]:M7<?M ?MT?"G]EWQ%I^C>./&%II.N:K;/>VNDP6T^H:
MC+;(VUKC[-;)),(0WR^:4"9XW9KD?V>OV=?BEHO[4_B3XI?$[Q#X!U*^U3PI
M8^%;.S\+Z5=V44,=O>7=T99#<3REF8W17Y2  M>._#OX^^!?V-?^"D?[24GQ
MC\1:+X!U#XD7&AZSX3U_Q%<QZ?8:[HMKI4-LUG;W,A$1DM;Q;MG@W!Q]K63:
M1)F@#VSQ3_P5+_9^\'^'/"NKWGQ0\/RZ7XVL;C4]%NK)9KZ.^MK>40SR@PH^
MU8IB(WW[=C_*V""*]D^''Q(\/_&#P+I?B?PKK6F>(O#NN6ZW>GZGIURES:WL
M3<AXY$)5E/J#V-? ?Q7^*_BKX]?M[_#OQA^S#K7P[N[S5/@OXON=,NO$VDWK
M:3JH77](1M@BD@D0R7*@B<[T9"SA7#*U>S?\$D/''@7PO^Q)H7AFQU2[TO7_
M  IJ%_8>,-+\0/!:ZGI/B%[F2ZU*"6)"(T7[1<N\?E9B,,D3(60J2 <'_P %
M(-9_:%T_Q-K!\*^']2L?AZOV!;?6O ?A^UU[Q/.K2Q+>?:5N',L"I$9O+%G9
MW4AVHWF(?DKZJ_9@C\,K\!_"Z^#]4U[6?#?V3_0KW6[B[GU*X&]M[7#7?^D>
M=YF_>)0&5LJ0N !Z$5S1B@"K<Z1;WDWF20PR-Y;19:,,2C8W+D_PG R.AP/2
MJ%K\/=#LH]-2'1]*A712QT\1V<:_8-PPWDX'[O(Z[<9K9HH ^>_!8V_\%3OB
M(/3X5^&/_3KX@KZ$KQ/XV_L26?Q@^,3>.M/^('Q+^'_B&?2(-"O)O"VJ6]O'
MJ%K!-/- LJ3V\R[HWN9R&3:2)"#G QS_ /P[^UC_ *.._:,_\'>F?_*^@#Z,
MHKY*^,/[#GB[2_!%Y9^&OVG/C=I_C+6(9K/PX=9UO3C9RZ@()98UD5-/WNH6
M)W95YV1MCI6WH7[$5UXGLC<Z?^TO^T->6ZS36YEBU[2W4212-%*F1I_WDD1T
M([%2.U 'TU17SG_P[^UC_HX[]HS_ ,'>F?\ ROH_X=_:Q_T<=^T9_P"#O3/_
M )7T ?1E%?,^N?L.WGANS2XOOVE_VA+6*2>*VC>;7M+17FED6*),_P!G]7D=
M5 [E@*Q?A3^P]XHU7P98VNO_ +3GQROO%NE006?B+^R-<T[[)%J/D123+&KZ
M?O1#YBNJM\P21,]: /K*BOG/_AW]K'_1QW[1G_@[TS_Y7T?\._M8_P"CCOVC
M/_!WIG_ROH ^C**^:]4_83O]$T^>[O/VE/VAK6TM8FFGGFU[2HXX8U&69F-@
M J@ DDD  5Q/[/O[*FL?$[PE>2W'[5GQDU[4;/4[Q7?0M>TXPPVCW4KV"NKZ
M?N$GV(V^\X"N^]DRI!H ^RJ*^<Q_P3_U@C_DX[]HS_P=Z9_\KZ/^'?VL?]''
M?M&?^#O3/_E?0!]&45\Y_P##O[6/^CCOVC/_  =Z9_\ *^N9\"_L-^*]6\4>
M,+>__::^.%U;:;JR6^GQ6&N:=Y]E ;*UD,5UNT_'G&6260;>/*EA[YH ^LJ*
M^<_^'?VL?]''?M&?^#O3/_E?1_P[^UC_ *.._:,_\'>F?_*^@#Z,HKYR;]@#
M6%'_ "<;^T9_X.]+_P#E?7 >'OV8KS5O&1O?^&M/BY<^#==,&C^'3;^)-,:\
MNM8BDOA?0EOL&Q\)%"%1/F5H+C=_#0!]F45\Y_\ #O[6/^CCOVC/_!WIG_RO
MH_X=_:Q_T<=^T9_X.],_^5] 'T917SFW_!/_ %@#_DXW]HS_ ,'>E_\ ROKE
M9_V'?%E[\7;>PL?VG?C>^BZ?IDLNLV3:YIQU*.XEDC^Q.N-/VK"4CO V[DD)
MC[K4 ?6U%?.?_#O[6/\ HX[]HS_P=Z9_\KZ/^'?VL?\ 1QW[1G_@[TS_ .5]
M 'T917SF?^"?^L ?\G'?M&?^#O2__E?7G/Q=_9QN?A[XZ\*Z7)^UE\9-)-Q=
MFXU>SU'7=.^UW&GM!<1H;8)IYP_VO[/\S_*424=<4 ?:5%?.?_#O[6/^CC?V
MC/\ P=Z9_P#*^C_AW]K'_1QW[1G_ (.],_\ E?0!]&45\Y_\._M8_P"CCOVC
M/_!WIG_ROKSO]H+]F>\^%&CZ?'_PUG\8O#NJ7UY!*AU[Q!IJ0RV45S!]N*[=
M/SN$#LJL?E622,MQ0!]H45\WV7[!.J7]I'-!^TA^T5)#,H>-TUW2V5U/((/V
M Y!'0]ZD_P"'?VL?]''?M&?^#O3/_E?0!]&45\Y_\._M8_Z.._:,_P#!WIG_
M ,KZQ_B+_P $^O'$WP_UU?"?[27QW@\4-IUPNCR:GK&G/8QWIC;R&G":?O,0
MDVE@OS;<XYH ^I**^9?#/[$5WXOT"SU33?VE_P!H2^T_4($N;:Y@U[2Y(KB-
MQN5T;^S^5(.0>XJ]_P ._M8_Z.._:,_\'>F?_*^@#Z,HKYS_ .'?VL?]''?M
M&?\ @[TS_P"5]97C/]C.3X>^'+K5]:_:<_:"TO3;)0TUU<Z_I:119(5<G^S^
M[,!]2* /J&BOC_X!?LAZU\2?A;I%Y=?M3?&G7M:BMT@UBYT+7M-:Q^W(B^>L
M8;3]ZKN.0K@,%92>HKM/^'?VL?\ 1QW[1G_@[TS_ .5] 'T917SG_P ._M8_
MZ.._:,_\'>F?_*^H[O\ 8(U2SMWDE_:0_:*CCC4L[MKFEJJ*!DDG^S^ !WH
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MI+]HBXM[A%EBEBUW2GCE1@"&5A88(((((ZB@#Z2HKYS/_!/[6,?\G&_M&?\
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MSM*@ +D8R<UZPQPIJG#K=O/+<1K/;M+9D"X42 F E0PW#JN5(/..#GI0!<'
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M=>(K76/%WBDZ3J"^'],L-1U&=$T74KPQPQWA6 9FM8BS%EP@?##.: /&-?\
MV4OB[\ OBMX3TGX;PZI)X=;Q%8^)=3O_  ZZ:1HJO<:U"=6L_P"S?[0CAM[5
M-.BW(#;WLDTES.P:.0;VP_"?[+WQP^&7P6TG0O!>E^*]%U3P]IVKZ7J$]]K4
M5[-J"R:_I$[G3G-ZKQK/IL-\(1YUKM?.XP2,)!J>/_\ @IU\4/A_\._$&DZA
MX5\%Q^.-#\%ZM-<ZI;ZA.VGV'B32]%AU&]M7B:+]Y&AD<9ADE0$1J9"781]M
MX[_;[\;_  Y^).M>#;7P79^*O&1U-+.TT^WU0C38O*T&UU&=(IEMA,^]IP$$
MB$X\V0E5CV$ Y_PY\!OCQ<0Z7J3>(/B:TFAV>D3Z9;7NN)8M)/\ \)1=37T5
MW;K?7*SA-(:&(?:)YB\07),X^79\/?LN^*]*_P""8/QT^%</ASQ.WBK6-*\7
MZ3ID&K:U'?0ZY)>+>BT>T=[AUB@E6:+Y9?)VNSEU4[FJA\</^"EGCCPEX+^(
M%[I?@7P[I=OI-CJ]AHUU?ZXUS>0ZM:>%E\0#[5:QP>3Y 7S(28KB0LT:$?)(
M2GL?[2GC?XF:9^S_ .';CPS)H=CXPUC5;.VOX=&U"SENI[9_,>9-(?4A%;37
MA1 R+<JJ%5E."5&0#SCX9_ 76-%\:>./%'AWX8^(_A7X9UK3]!T]/#6@WVF:
M7JFKW]O?F2XU)UM9WM856!TB?,GG30Q2(1\L0.I_P44F\8ZIXW^'V@^$X?B5
M??VQ8>(-]IX.UM-&G>Z2V@%I+-</-"JQ1RN6P7.21E)%W*>W_9%^/&H?%OP)
MX3DDU)=8CO8-=BU"ZUQ[73O$"7FG:I]A>$V5H'MI4C8312W$$HCWQPLBLL_R
M^/?%;]K'XG_#O]J+XH75K<2S?#;X972-K0U&PMH=#T[3AX=2^9VNH@VH->->
M21*J10SCRY,>7GD %CX4? 'Q%X2\>>(U^(GP>MOB-XX\2ZQ:ZO#\0[>'29+:
MV*Z?:Q*Q:XF6ZMC:RQS+''#$P*[73!D<+8_X)6?LE^+OV0+:YT_Q7X=T2SGU
MCP=X;@^W^'[2VT[3X);&U:&:RN;6.1VDOTEEE9KT,Z7$9B3]W]G57Q])_P""
MB'Q(\9>-FTO_ (1/PUX9;P[8>*T\2VEQJ;M=+-IMKHMY!+9MY#+O\G5#NAF4
M892&(V8,L'_!4+Q1;>$?%.M6WPSFUCP[X'T*YFU#5)M72V>34+;PW%KF) (0
MBQRB181Y89P6$OE>63M ."\!? KX[_"SX<ZQI.@^&OB+:VFV:WU6SNO%*.EU
M-+KXN([O1H[;486A6&Q:X$D8GM/-\Z(-O='!V/"GPT_:FL$\%M]H\677B:+P
MK?:;-+K.J11Z1H]XO]L"SO9VM]1D6[G(DTT20S6MT#LC9;E2LI/JGAK]KGXF
M^)/VI?#O@&Z\.^ ]+DM=5U?3/$L<6LW-U',L%AHNH6\ME*UK&S2"#4W5HI(T
M#/"<,%YIG[67_!3>Q_9&^+&J>&]<\+R7EOH^FP>(KJ]@OU#0:/,D]O'=M&4Y
M;^UEM;/RP2=MT)<X0I0!XIK_ ,#_ -H#6_@3<Z/JUG\9/$6FZM;ZG;W>B1:[
M:Z9J46H2:7%!:2?:WUB=Y=/\\7+2H;A%\V2-E@\D%1[U\=/AO\0+#X)_"72]
M)T_QK?:;H=HEKXITKP=KD.DZQ(ZZ8T-L8[AIX5,4=UM+JLHW$(2'1'1O+OB3
M^W;\4]/\3^,--TZ'P_IBZ'X6\<:G?"]NEGN=+N])LM"DA^R;;<),L4FI2?),
M/W@R6<!50^\_LX?M+>)OB#HGCJS\7^'M'T[Q+X#ALYI4TC5'O[748[C3X[R,
MAW@A9),LZ,OE[?E4@G<54 \X^!?P8^.VC_$CPKXF\;>(/$FH:O'XALK/7[>#
M7 ="FTK_ (1"!+N:.R#",;M=21E(02@DD 1L<Y'Q0^!'Q0/[9/C#6_"VD^,K
M6T\2:M8W0U./7+:/PY=:;%HGV6Z@N+,S[Y;F28(D;- 2C+$X=41P=JS_ ."D
M&K^/]0\%Z1X-\)^&M2USQMI_AF[MQ?\ B-X+.S?5]*U?4MLKPVTKXBCTL!<)
MF07"GY  30TG_@J/J/B'X0>(O'UKX+T*'PWX-\-6.KZW:7OB0PZG)=W>DKJ2
M16J"V:.2V7S%C:XD>//EW3!/W&UP#S+QWX4_:$^%?PD\2ZA*WC[3]0\-^#KZ
M?^T;/6[=]%@TZ'P:8XK6&SCF+#4DUQ/-$J0YVACYS1E(JT-=^&W[0/\ PBO]
MH>&;/XO3:;_;GVO1O#>N>*8FO+I#IUHDC7VH0ZFDUK"]VMQ)$%>\B0/*7M2&
M@2/MOB-_P4K\;?#M_%&DK\/_  =J'B+X?VOB._\ $)3Q7.E@UOH]AH^H2"TD
M^QEWEDAUB./;*L8CEAD!9E )YG6OV_\ Q]\*O%_Q.\7:])#KGAO1;KQ2="\/
M6MU;6\'V;1M.AG"2R&S,Z2RLX9G\^50SMA0J@$ ]D_9%C^(&L_M!?$^#Q%KU
M]J7@_P"'>J7'AWP_+).S'6GNI(]3EFG##YVLXI[6PC8$\V]R2<L0OCOB'P!^
MT%%=>.[*#2?B)K6DZQXJBFCU67Q ]GJ=K9/=:C*R6=K!K<<+Q1*;&(21S6(>
M*7<]N[P,I[SQ3^W+\5/#/Q5D\(CX;_#MM0M-;TSPU=2CQK>&&.]U"VFN8&0_
MV:"\*1QIO)56)D8*N%RV7X'_ ."H^M^/M2TMK#X6WEYI5CI.EZAXKEM-3$LN
MF->FZ1FM@\:K/#$UJP#.T;S9943?'L8 Y_X?_LV_'_QC9^"[SQUXD^(UCJ<"
M^%K+6XM/\8"SA>W&E.FM,R6\VPR-=%29%)D!4-"R_,QR?AKH'QTN?CKX7\.:
MA<_$V;7/"&G>#I;V\/B.)=%M+4:IJ@U,WZ>=_IMQ<Z;!$FY8YF$WEL6B;<Y]
MH_8V_:D\8?'WXA^,+KQ+#X=L]+A\'>&?$NEZ3H6I?VJ+./45U*9O,G,$+-.\
M<-OE "@"JR']XU<I!_P4:\97_P *?!_B2W\&_#^-OB#X8N?'.C17/C"6**#2
M(+%+QX[R469$=XR2Q!5021D1W3[]L $@!QW[(GP ^/GPL\>_"72O$4GB;2?"
MOA7P_H6GK9Z8]O<:3:P0:(L%[97H_M*-/,-]YKB5+*X?'V?RYE4.J]A^T%\%
MOB5;_'CQCX@T71O&M_X0\0:C8/>6W@_7X-)UK4$BT:>"%XYFGA*QQ7C1EU,B
M[OD8B2-75FW_ /P4:\>>)?%C0>$/AOX5GTG4+]],TR77?$US87QFC\/6VNN;
MF".RE6(>3.\.U9'(D4$_*3CGOBO_ ,%2/%$_PL\2ZYX?\+Z'I.DSZ;<VFBZB
M^L&XU>UU%O!2^)X;A[)K;R6MXD<1.?.8D@-LVDB@!;CP1^T)IGA3Q@=>TKX@
M>*_B#<:7IT.GZAHWBB.Q\,BW.GZ;#?K':QWUK)]N6Z&I3H0(S(P11<PQN%CX
M_1OV<_VB+2#_ (2'[-XW/Q!F\&^*/#F@:G<Z_#MTECJ=Q<:6;^+[?*LC/:2(
MD3M)<LDJ1^:X*B0=I\:_^"E'Q"T;P#\4[KPCX&L/LO@&UU"QB\0ZI>;88]1L
MK6"XD:XMP@ BD$DOEK&S.0(9&5(Y6,7J?@/]LGQ=XS_:8NO K_#R%=)T+5E\
M-Z[K5MJC.FGZ@=)BU(R(LD4?FVY\Z.%>5E8L9/+"@T ?-7QU_9W^/?Q)_9SU
M[PM-I?Q=\4:5XDT'Q+86&D'7;72[JPU*>&RCL?MKR:O<27.GX74#MENIOFG9
M3#L^SA/I3]O'X9_$[QYK&EW'PW-_;W%MX6U^Q:[L;V"TN+:\N)=+-L8WD(96
M*176&7@8^;JH.7\8_P!O3Q3\-_B%XUTO3O .DZII/AKQ1I/@FSO&UV5;N]U3
M4;33KJ(O;+:E4MT2]92PF:1Y(XT5/WA9>?\ $G_!2OQ;\/X[>;Q1\,8?#,'_
M  CU_?R"]U::;[;JEI::E<OIT$L%M)#&YCT]9 +MX)'CN"50O$8V .@\=_LW
M^._%7[$'[1'PSDN=>U>Z\10Z]IO@IM5UUKF[N;2YT]/L\;W;N9-GVJ2=!YSY
M5/E/R 5P^B?LV_%+3OBEJ?CGP7%X\\*WFJZYIPM;'Q#XE%U&U@N@26LLFI0B
MXF2YD2[\G+,TD@$2%#@'.K>?\%)O%]CJNI>&YO!'@>/QAI<,^JS.WBZ5=!-C
M%I,.ILGVLV8D%YY<Z Q&$*(LS%MN$,Z_\%+O$FKZ]<7.E_#6SOO#]U/<Z7HL
M<GB#[-K5_J*>%H_$4<4T#P""W1XV:W+>>Y60*V"I. #:_88^%GQ4@^$WC#2_
MB;J'C0:EK&GVUF(M;EC(@O/LLD=Y/;7$>HWLI220QMD&"-2H,4* L!XW\+O@
MY\>O ]G\!]#T/PS\2/#.F>"=-\-V6L&^\3I?Q3M%J/E:S%<K_:QA^SBS7=!M
MMKEW6557[.8@!WFC?\%0/$GB77]+T30_AS;^(M=M8)K[Q):VM[=63Z;'%?QV
MDD*I>VL#K<QAFDD$RQQ+^Y E83!U^SEB&3D4 ?FK^TG9_%+]GC]G;P1%K?B[
MXF7WC;Q+X&U!4LK3QTD.I+XS,=A';[8_/C:\MXR9%6VMA*"S%GBE:3S4Z3XN
M?LX?'CXI7WQ,L_$4WCW6;:;4)+^TLM,OH;/3=5M8/$5C>V"6<S:IF"[BT^V:
M(!+2T#2-+YLKG9+)^A C5>@H$*C^$4 ?,/[8_P )?B-X_P#!?@6^^&-G?6'B
MCP[HVM&RGU6\C>[TJ[GT2>WM?.D>5@\WG.B%][J'^9F*Y)\KT?X9_'S2F\#W
M<#?%;5K>U\1SRSZ)JM]'I]O#:M)IO-Q>1Z]<76V/RKZ1/.:^C<3S1F!!]G(^
M\C"I/W:#$I[4 ?#7@/X1_'WPKXK\&V\EMXLADLSHOV6ZL]<M8M TRV34;I]9
MBU"S68>?//9NJPNL4@5G@VF(Q2L?5_V%?A'\2/A3*P\=:MXLU:/5/ _AJ>].
MN:\=5,/B("^&K+%EV\I>;/*H!$2 4YWU]'"!!_"*/+7TH <OW:*** "BBB@
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M@W>>+-'U9?">GR7>EZ#=+9:BWA1EU/2[)9X+:2UCM6A%]'$_VM"=D/E;6RQ
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MYX_U'PSHVL0ZGJVDJ6NA;V\S6R,%B=HUN=OD/(JSPLT:N742H2H!%><_M/\
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A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>nbx-20211231_g23.jpg
<TEXT>
begin 644 nbx-20211231_g23.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" "1 FP# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MJ?R)J/\ X2.Q_P"?RS_[_K_C3K)?^)I>_5/_ $&K>WW- %+_ (2.Q_Y_+/\
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M"8X]K,#N< E5ZL!QFK%]XTT;3/$EIHMSK&FV^L:@ADM;&6Z1+FY49RR1D[F
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M\1_#MCK::9-X@T:'4I+@6B6CWT2SM,4#B((6W%RA#!<9((/2@"[_ ,)'8_\
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MUW'')?'&<1*3F0X(/RYZT 6/^$CL?^?RS_[_ *_XT?\ "1V/_/Y9_P#?]?\
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MXY5D1ED6X*D,#0!]@?\ "1V/_/Y9_P#?]?\ &C_A(['_ )_+/_O^O^-?-?Q
M_P""H&F?![X8>&M4\9?"OXK^&_&GCG79/#WA;X?O:Z?>>)?$5Q'$)6D@2VNY
M;9850DM++.BH$);:"I,UE_P5#\,Z7\0OA[X5\8>!?B5\.]=^(%AXCU%;;Q%I
M]O"=&AT2&">Z>X,4\BNCQSJT;VYE1]K#<",4 ?1W_"1V/_/Y9_\ ?]?\:/\
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MMO\ ;!IQD-[%L6Z+;/LY8,1YN_Y=F<[N,9KF/C%^TAX=^%?PI^(7B2WOM/\
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M%I]_HT,'B3PU'JU[=1NH659U6Q@E51!,BL/-(B5AN _7+;??\_5G_P" [?\
MQR@I>D_\?5G_ . Y_P#CE'M8=T!_/[^P-K?A'XE_\%$;?5;S1?#FN^,-?\4_
M$,> )(=,TB[ENM3NI+S:^NW*7C:R+6.*,B)[BPMC&93M8J03ZO\ LL?\$=_C
MMJS?&*#QU\)O#?A>V\?? J]\(PVCVWAFSTK_ (259XIK7R[?2RVZ))%$D-W<
MA[A?+#.ZL%!_8G0_@[X?\+^,;_Q%IF@^$=.\0:ID7NIVNBQ0WEYD@GS)E8.^
M2 ?F)Z5T6V^_Y^K/_P !V_\ CE'M8=T!^2MG_P $\_B-I>D?!'7-;_9)T;QU
MX7\*_"R\\#:C\++C6?#T*:)XB:6%G\1 -/\ 89#=K$5:5)&N4!#;=Q(KN?V%
MO^"0?B[X8?M._L_:E\8/"?AWQQI7PG^")\/?VQ>7$&HP:5XA&MFZ@AACF/G,
MT%LY6.?R]J^6-K*VT5^F.V^_Y^K/_P !V_\ CE&V^_Y^K/\ \!V_^.4>UAW0
M'QC^WE^R)\:_VL_V]/A=>>$]0\,^#?AW\+O#>K:FNNZ_I">(+/5=:U%#I[6A
MTZ.]MILQ633.)F8(#-@!CG'Q?XW_ ."5_P"T,/V*?AG\.;OX5GQMXT^ >N>)
M-"\#ZO-J7AZZ\/:KI-Q+!]CN=1TS4)9/]%DAW)^[D^VVQMQL0[PZ_L]MOO\
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M,,,K*7P002"#U!J+1="/AO2;73]._LFPL+&%+>VMK>R\J&WC0!51$5P%50
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MG\_9 MZ&2W;S6<2;RRJ#*0QX)K[&VWW_ #]6?_@.W_QRC;??\_5G_P" [?\
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M?%)!:WKZ>&N+:.3;YB)(7W*K;5W $ [1G.!1[6'= ;P.115$+>@?\?5G_P"
MY_\ CE&V^_Y^K/\ \!V_^.4>UAW0%ZBJ.V^_Y^K/_P !V_\ CE&+[_GZL_\
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M/^-09-&37S7]I8S_ )^R_P# I?YG1[./;\"8ZC<Y_P"/BX_[^G_&E&HW./\
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M&DJV=*\F[N+;48\K:O[R=W)*/E>Y+K3>JI:>A]MC4KC_ )^+G_OX:4ZE<?\
M/Q<?]_&_QKY,M_V?OCUI?EZA-\0-8U74(?$#ZC=6\_B.3^S[RU)E&(HHHHY8
MQY;AEMS+Y(ECC#(Z;ZYWX>_ /]I/6/AWHUQJ'C34=+O+VQAD:QO/%-T]YI%\
M;.P4WD\@C_?(L\5ZS:>Q,1,X&3CC'_5.'*Y_VS3LFE\<O/SOTWV^>@_K&MO8
MO[D?:G]I7 _Y>+C_ +^-_C1_:=P?^7BX_P"_I_QKY-TC]G/X^:/!8,?B!+J%
MRM_8WMTEWXEO6MI62[U+ST8*%D\@VD]B!#$\:M+:J6#@.)/4_P!D?X:>//AE
MX.U.#XA>*-4\4:U>72S?:+G4EO(%(7#M;CRD:"-R-WDDL$Z+@<'Q\VR=8/"S
MQ%'-857&UHQE/F=WK:[Z&E.ISRLZ37FTCV :E<8_X^+C_OZW^-!U&Y_Y^+C_
M +^G_&JXXI<FOC/[2QG_ #]E_P"!/_,Z_9Q[?@3C4;G'_'Q<?]_6_P :0ZC<
MY_X^+C_OZ?\ &H<FC)H_M+&?\_9?^!2_S#V<>WX$XU&X_P"?BX_[^M_C2?VC
M=?\ /Q<_]_3_ (U#DT9-']I8S_G[+_P*7^8>SCV_ G.HW'_/Q<?]_6_QI/[1
MN?\ GXN?^_I_QJ')HR:/[2QG_/V7_@4O\P]G'M^!.=1N,?\ 'Q<?]_&_QIJZ
MM.WW;J=LC(Q,3D>O6L_7[.34M U"VCVK+<VTL,9;H&9"HS^)KX5\&?\ !/;X
MY_ _P%<Z#X+\7Z/;V\?A[2M+TRX77+NTO]+:-;R>ZA29$PT*WTZ,F\-N@9T*
MAE4U]?PSE]/,J-1XK,OJ\XM<JFY6DGN[WTMII9W^1RUY.FTHT^9>1]Z6/B4:
MK$\EKJ7VJ..5X7:&Y\Q4D1BKH2"<,K @@\@@@U.-2N,_\?%Q_P!_3_C7R'K7
M[,'[08?4H=%^)-GHMMJHU2_D:*^F$EO?;[TV*Q*(PBQ2_;$:?()#6,/#Y./H
M#]GGP7KWP_\ A58Z7XDUC6=<U>*:>62XU345U"X57E9UC,XC0R*@.U2P+!0
M2<9IY[EL<#A_K&&S)5O>248RES6UU?31JWS3%1FYOEE3Y?6QWIU&Y_Y^+C_O
MZ?\ &D&I7'_/Q<?]_3_C4.32QMLE4^AS7Q_]I8OK5E_X$_\ ,Z_9Q[?@.;6)
MD0L;R95&>3.0!CKW[4]-4N'0,MU.RL,@B4X(_.O@KQ1_P3%^(%_K.JP6>O:"
M_AOQ)J&L:S>V-Q=2,]E?7FKV\QD@W1.A26RMX=Z,I59HCPRNU?5W[+GPIO\
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MWP7X,718Y]<U"VFLELKR:>\EC;5 CETFG2"2.%IU8Y298U>,JNPKM7&U<_\
M!+'X:W.N0ZI_Q-(-3M[B*ZCO+;4+NVN$ECMQ:AQ)'.K;F@"QR'.90B>9OV@C
MN_V*_P!G;4OV9?A)>^%+R#25CAUFYN[-M)M4L[-X)5C9=EI&BQ6N&#*T<>59
ME:3K*0/7?L\G]QO^^37DS\.,@G4=:=*7,[Z^TJ==_M^FFQ?URJM+K[E_D?,N
MF?\ !*GX6Z-I?B>QM=/$=GXRMQ9ZS"?-=+N 232K$ TI\I%DN)G58M@5I&(
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M\+_C7K'V>3^XW_?)H-M(1]Q_^^:?_$"^!?\ H7Q_\"G_ /)$_P!JXK^?\O\
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M<QL45C_VI<?\]/\ QT4?VI<?\]/_ !T4<H<QL45C_P!J7'_/3_QT4?VI<?\
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M70;6UU[Q'JFGZ#J&EQ_:(;Z*"-98+8N+A_WXADBEFD*+M,JIY*C,J_5]>/\
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M_P"8#J'_ 'R/\:!\%_%G_0!U#_OD?XUZ#9?LKMK/A?QA:2?$37]8TGQEHO\
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M0#<T:OMC_4ZBGA?!/"X>$J<,94M)M_#3W;4G:T5:[7R6BL*68.6\5][/S/\
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MSW&Q=L?"_+G)/KE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>nbx-20211231_g24.jpg
<TEXT>
begin 644 nbx-20211231_g24.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M6WO)AI-F)R[2+%#%;2R-)E)54QJS  ^K/@]_P5A^!OQ_\7^"]&\+^*-2O?\
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M\_:F=&P] 'W5JGQS\-Z-\;=%^'=Q>R1^+/$.C7VOV-IY#E9;.SFM8;B0R8V
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M!PLDT?VZXV'Y@ELC$ .I/UU&<I0 ZBBB@ HHHH **** "BBB@ HHHH ****
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M-(6VBN2_X7YX&_Z'3PG_ .#BW_\ BZP_%/QZ\%GQ)X;\OQKX7$?VR42A=9@
M*_9I<9^?D9 _'% 'I( QQ2XYKD4^/G@8*/\ BM/"9_[B]O\ _%T?\+\\#?\
M0Z>$_P#P<6__ ,70!UP&*X7]I']GKP]^U-\([SP5XJ2\DT2^O+"^E%I/Y,WF
M6=[!>PX;!X\ZWCR,<KD=ZN?\+\\#?]#IX3_\'%O_ /%T?\+\\#?]#IX3_P#!
MQ;__ != '5QJ2#N'?(!YQ4.KZ5;ZYI5Q97EM!>6=Y&T$]O-&)(IXV&UD=3PR
MD$@@\$'%<U_POSP-_P!#IX3_ /!Q;_\ Q='_  OSP-_T.GA/_P '%O\ _%T
M=-I>EV^CZ?#:6MO#:VMJBQ000H$CA10%554<*H   '  JQCFN1_X7YX&_P"A
MT\)_^#BW_P#BZ/\ A?G@;_H=/"?_ (.+?_XN@#KL9IKKN4_2N3_X7YX&_P"A
MT\)_^#BW_P#BZ/\ A?G@;_H=/"?_ (.+?_XN@#=TKPKINC:OJ&H6NFV-K?ZL
M4>^N8;=$FO&1=J&5P,N57@%B<#@<5H@8KD?^%^>!O^AT\)_^#BW_ /BZ/^%^
M>!O^AT\)_P#@XM__ (N@#KBV* <BN/F^/7@=HSCQIX3Z?]!BW_\ BZQ_AM\>
M_!:_#_1?M'C7PLTWV.(N7UJ!F)VC.27SF@#TBBN1;X^^!@O_ ".?A+_P<6__
M ,775P3">(.I5E;E2#D$>M #Z*** "BBB@ HHHH **** "BBB@!&;;UI0<US
MTD\G_"T?+\Q_+_LHOMS\N?.'..F?>NA48% !1110 4444 %%(QVK2"3CZ4 .
MHIOF>W/<4H.: %K^7K_@[1C5_P#@KE< C@>#-)Q_WU<5_4+7\O?_  =G_P#*
M72Y_[$S2?_0KBD]A/8_,S[.G]T4?9T_NBGT$X%00,\B/^Z*3R(_[HJ1/G/';
MVJ2[LY+"7RYHWBDP#M==IP0"./<'(]1S1?H!!]G3^Z*/LZ?W13P<B@G% #/(
MC_NBC[/'_=%3V-J]ZS^7'))Y:%VV#.U1U)]AZU&_R-CKQFBX#/LZ?W11]G3^
MZ*4M@U+;6KW:3,L<CQP+OD902(UR%R3V&X@9/<@=Q0]-PN0>1'G[HI?LZ?W1
M3V^1L>E(6Q0/4;Y"?W11]GC_ +HJ>RM9+^X\N-))'P2%12S$ $GCV )/H 3T
M%1R#RVQ1S:V$,^SI_=%'V=/[HIY.!3K:%KN=8XU9GD.%51DL>P [DT.5M6!%
M]G3^Z*/LZ?W14L\36\IC=65U)#*1@J1D$$?@?RIM%[ZH!GV=/[HI/(C/\(J:
M&)KF98U5F9C@ #))]!1<P-:3-'(CQNA*NK @JPZ@CL1Z'FES*]@(OLZ?W12&
M",?PBI-W%(IWL*=P&_9T_NBC[.G]T5/>6DEC(%D1XV95<!U(.U@"I^A!!![@
M@]*BW4)WU0;[#?LZ?W12>1&#]T5(/F8+Z_Y_S]*DN[22R=5DCDC9E#X=2N58
M J>>Q!!'J#Z4<R6X7Z$'V=/[HH^SI_=%.W4 Y;% #?LZ?W11]G3^Z*GO+22Q
MG,<L<D,BD95P0PR 1P>G!!_&HP<BB_5 ,^SI_=%'V=/[HI]!.!0 PP1C^$4@
M@C/\(J>VM7O9EC16DDD8*J*,EB>@'^%,D0P2LC*RLA*D$<@CJ/PZ4<R"_09]
MG3^Z*3R(\_=%/W4JKN^]A1ZG_/\ G-&P>8SR(_[HH^SI_=%37MK)IUW);S1R
M0S0L8Y(Y%*NC D$$'D'CH:CS1S=03OL,\A/[M+]GC/\ "*>J"0_-T%/N[633
M[J2":.2&:)MKQNI5D/<$'!!H;L[,"'R$/\-'V=/[HIX.: NXT; ,^SI_=%'V
M=/[HJ>[M)+*2-9(Y(_,19%W*1N4YP1Z@]CT-1@YH] (S!&/X12_9T_NBGJHD
M;!J6;3Y+:.-FCDC692\;,I < D9'KR&'U!%%^@%?[.G]T4?9T_NBGDXH4;VQ
M1<!GV=/[HH^SI_=%67L)([:.9HY%BE9E1\':Y7&[![XR,^F1ZU">#^-%[[ ,
M,"?W12>1'C[HJ0?,<5,-/D6U\[RY/)W^69,'8&QG&>F<=NM%QE;R(S_"*/LZ
M?W13V&UR**!$4T"B,_+7]S7PI&/A=X;Q_P! JU_]$K7\-!3S1CJ.!BO[D/A)
M?+<?"GPR\.V:-M)M2K*P*D>2G<<'\*I25[%1.FHI VX^U+5%!1110 4444 %
M%%% !1110!S<G_)6/^X.?_1PKI*YN3_DK'_<'/\ Z.%=)0 4444 %%%% 'DW
M[6WC;6M"\ 6>A^&7UA/$OC&_CTFRETM(GN[.+F:ZN8Q*50-';1S%2QQYC1@]
M<4O[.WQFU'XL?#ZTN-6DL+'Q)9:;Y.M:.0$OK'4(99K>X9U#D"%I(6\L@8.#
MAF'3U)[?><_+U)_S^%0IHT"ZBUX(85O)(A"TP0>8R E@I.,X#,QQTRQH ^,?
M!'[6/C[X;^&?!<7BZ_N+RZ;P;-XAAU.XLS]EUJ*=M/2'S]FU1<6TMQ)'(NZ,
M%6BD9E5V9.C\)?MV:\;&]\2ZKI,-UI.B1>3K"Z?F3,8U/4;&.:"..65-S/%:
M,VV60".1V#$**^L6LUD&UEC92"I!&00>HQ[TU;%4& J@8 &!CCTQ0!\^_"3]
MJSQCXL_:!C\$Z]H>DZ?/"[6E_!%,@N+=TL(KEKI%,YF:W:9S$NZ!4PR-YS-\
MA_GI_P"#HS5_$&M_\%4[R?Q-H=CX?U(>%=.C2UM-2_M"-H0]P(Y#)Y<>&8<E
M-OR_WFZU_4RMF%N/,^7S,!2^T;B.N,^GM7\P7_!V?_RETN?^Q,TG_P!"N*4M
MA2V/S/H-%(3BH(/9?V'O@'8_M ?'O3K#7+RQT_PUI>+_ %::YN$@62%3Q"I8
M@%I'VK[+N/:OHC_@KU\"?#VH/IOQ)\*ZAH=Q)MCTK6;2RO8I&554B"X"*2=H
M4"-CV_=^]?"<CJZD,,_44)A!]W'T%>#BLIKU,RIXZ%:R@K<O1WWN<=3"SE7C
M7Y[)= QM8TJ#+K29W,Q]31G!KWCL/T3_ ."77[.?@_PW\&=:\3>,K[P_]N\=
MVDNG)975_"DD&F-\K JS95Y6!//153U-?%'[2'P4/P#^,NN>&UO;?5+&SFW6
M%[;S+-'=VS#=&^Y3C=MX8=F##M7!,JOU4$]R1UIZ2;4VA0%]A_G_ "37A9?D
M]?#XVKBJE9R53[+5DNUCEH8>=.M*JYWYN@V,?O!]:_23_@GG^RYX'T+]E[6&
M\::CX?;4OB=9^5=P2ZA LUE8$9A3YFRDF[][ZAO+_NU^;2_*?UZ4KE2?NKN]
M0*O.\KK8^@J%.JZ>J=UN[;!C,*Z\.2,N76YTWQI^&-S\&?BIK7AFZNK6^DTF
M?RDNK:020W<9 :.5&!((92#UX)QVKF$&2/K28'\/RCH!_G_/ I0<&O6HQE&F
MHR=VDDWW.F":23=S[Q_X)%? OP[I3:A\2/%5_H,,[J^FZ+:WMW$C;&5DN)F1
MSG#*WE+[&3VS\W_MN?L_6/[/WQWU'3=%O+/4O#>HC[=I$UM<I<!(78_N6921
MNC;*D?W=I[UX^Y5^J[CW)%.C=8XRNT*I]!7BX7**]/,:F.=9RC-6Y>BMM;S1
MR0PLXXB59STET&+T'UKZE_X)<? 31_B)\;!XK\37FEV.A>"VCN88[VZCA^W7
MAR8E <C<L>-[=LA ?O5\MCC'US02&'S*IYSDBN_-,'/%86>'ISY')6NM6N]C
M;$475IN$7:_4^K/^"JGP&TCP+\:%\9>&;W2;S1?&3M-=1V=U'-]DO\EI<A"<
M+("'&?XM_H*^4A][\>E*DBQ_P@<Y.._^?ZTG\7XYI97@ZF%PT,/4GSN*M=JS
M9.%I.G24&[V/I_\ X)?? 71_B7\<4\3>)KS2[+P_X-9+M8[RZCA%[=YS"@#$
M;@I7>W;A0<YXU/\ @JU\!]'\'_&-?&WAF_TJ\TCQB[2WT=G=QS&TO\EI20A.
M%ESO!_O;_:ODUF5UP5'MGM0A6-3M5?F]JX/[(K_VFLP]L^6W+R6TM_G?J9_5
M9_6/;\^EK6!Q@MVKU?\ 8W^ UM^T-\=M)T?5+VTTW0+5A?ZM<W%PD"K;1LNZ
M-78@;Y"RH,<C<3T!KRAFR2:-RLFTKNQZ]J]?%49U:,J=.7*VFK]K]3IJ1<H.
M*=F??7_!6SX">&=:T'2_B%X3OO#\D^DQ1:5JEE97D4C-;C"6\JHIS^[X0X_A
M*<84X^!9@#(VWBD0JAX7!]10_P Q)Z5PY)EM3 X58:=1U&NKWL98/#RHTE3D
M[GJ/[(OP%M?VA?CEI.AZC>VNF:'&WVO5KJ>X2%8[:,@NH9B!N?(0=2-V<8!-
M?6'_  5I^ 7AC7?"^D^/O"-YX?-QH,,6E:G8V5Y#(SVH*I;R*BL3^[X0]?E9
M>@4U^?[NKYW+NH0(I)"*#["N?&916K9A3QT*W*H:<O1WWN9U,+.=>-;GLH]
MD&U_I7M'["?[/^G_ +0/QXT^SUZ[LK'PQI*_VAJLMU<K;K+&I^6!2Q&6D; P
M/X=Y["O%W.\T>8K)@C=V /\ GTKU,91G6H2I4Y<K:M?JCHK0=2G*$79L^YO^
M"O7P-T&_U2P^)7A?4-#N6N]FGZW:V=W%(RLJA8)U12>-H\MO38G;-?#3_?\
M\*1,1GY55?<"@G)_2N7)<OJX+"QPU2HZG+U:UL9X6C*C25.4N:P4-THH/2O4
M.@^K/^"47P)T?QM\87\:>)[[2;/1_!SJ]G#>W44)N[XC,9 <C*Q@;R1_%L'K
M5+_@J+\ ='^&OQO;Q1X9O-+O- \:%[IH[*ZCF^PW@QYRD*3M5R?,&>,EP/NU
M\O;0S?=4_P!*<KJG15!Z9%>#'**ZS/Z_[9VMR\EM+?YG&L+/ZQ[=3TML-%?0
MG_!-SX Z7\:OCW#?>)+K3;/POX5V7]XMY<QPB]ER?)@&\@,"Z[F']U".]?/?
M:CC/S*K=^1FO2S##SKX>5"G/D<E:_:YM6@YTW"+M<^R_^"N'P-T72_B);?$7
MPUJ&CWEGXG?R-7@L[R*5K>\5>)MJDD+*H.3TW)SRPKXT'%/C9$'RCG&*8*QR
MG SP>$AAZM3GY=+^72X86BZ5)4I2NSW[_@G+\ =+^-WQ]@N/$=WIMGX7\,;-
M0OQ>7,<*WCY/DP+O(W;G7+ =%1NF17JG_!73X&:+8^.;7XD^&M0T:\MO$#BU
MUBVLKN*5HKL*2LVU#D+(B[2>FY1GEJ^+3M;&Y0V.F>W^>?SIR%8QD*H[9 KB
MJY/7EF<<>JSM%<O+T:>YC+"U'B%7YM.P#O\ 6N^_9D^#'_"_OC7HOAF6]MM,
MT^ZE\S4;V>985M;5"#*P9CC<5^51W9A]:X$'-"L%/S=QCI7LXB$ITY0IOE;3
M2>]O,Z:D6XN*=O,_0_\ X*F_LZ>$O$7P>T7Q3X/OO#XOO MG#I4UE;7T+/-I
MB_*FU5.2T3'/KM9^NT"OSP'2E!C7[J@#U Y':DSG^=>;D>5U<OPWU:K5=2S=
MFUKKT,,'AY4*?LY2YCI/@[\-KKXO_%#1?#-G<6UG+K%TD#7-Q((X;6,D;Y78
M\!47)/<XP.2*_03]OC]EGP3X@_9.T6W\%ZIH+:M\,;(+8QIJ,#37]H.9U.&^
M:0G,O^]O'\5?FN.">,Y[4;@#G:OMQ6&:9/7Q6*HXBG6<%3=[):/IK\B<1A9U
M*D9QG;EZ?F-)!8_E6GX,\,7?C3Q7I^CV/E_;-4N$M83*XCC5G8*"S'A5&<EC
MP ">U9QY8^_--7OZ8P?>O=ES<K4=SLE=ZWU/T^_:!_8X\#ZI^P_I_@CP[KGA
MN;Q-X+A:_P!.N?[0@\S4+LX-T&^;/[[D =BL8[5^83CYO3V/6G!ESG8HQ37/
MS=]OUZ5XN1936P$)PJUG4YFY:]+[_(X\%A94$XRGS7=R;3;&;4]1M[6W3S+B
MXD$429'S,QPHY]R*_3T?L4^!S^PA_P *T/B/PK_PE17^U_[0_M.#C5L9^]N_
MU>W]S_N\]<U^7J/Y;?\ UZ,J?^6:_3%+.LIK8YT_95G3Y)*6BW:_0,9A9UN7
MEERV)-1LIM-U&:WN$\NXMY&BD7^ZRG!'X&HSTI,\TIZ5[<4TK/<[$>Y?\$]_
M@!IOQU^/UI_PD5WI]EX7\.[-1U+[9<I;K=8;]U "Q&=[CY@/X U?N;XZ^-_Q
MPA_8T\2>!O!MCY%GI=@+ZPN;;^V[;Q*L_P!HA-I%I8L;>59&^T-'\DP6(JY#
MYB$A7^;R49C^90W<?7_/\S7]R7PN@)^&?APAMO\ Q*K7&.O^I3_/^>?!Q&3X
MBIF<,PC7:C%6Y;:6>_WG,L/)UU6Y]%T.4_8UN/BI=?LR^!Y/C9#X=M_BF^F(
M?$<>A%FL4N<G&TGC?LV>8$)C$GF!"4VFO4:1>E+7TB.T**** "BBB@ HHHH
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M;L_L:V6OZ!;Q?!/25CO;N2.8#5M0^=1;RL!_K_50?PHY0Y3^4,4$9K^M9?\
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MC_P;:C_\D468<I_)0%P:7-?UJ2_\&XO[%X3/_"D-)^7G_D+:CQ_Y'K)^'O\
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M110!S?PX_P!5K?\ V&+G_P!"%=)7-_#C_5:W_P!ABY_]"%=)0 4444 %%%%
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M+_OL4?;8?^>T7_?8K^AS_A_O_P $V_\ HB"_^&KTS_XJC_A_O_P3;_Z(@O\
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M$CI__P :HY0Y3^)W[;#_ ,]HO^^Q1]MA_P">T7_?8K^V+_A@KX%_]$7^$_\
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M'_KQB_\ 010!T%%%% !1110 4444 %%%% !1110 4444 <W)_P E8_[@Y_\
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M#3A0J3BYQ5U'5AY=S'I,\TI&UL4W&6K(:OT/Z6?^#7 8_P"",\'_ &4*Z_\
M2NSK]7:_'/\ X-8_C?H-_P#\$Z-3^&0EN(?%NB^*5U][>:-56YM+F]@19(?F
MRX1H\/P ID3KGC]9?A7\9/"OQJT34-0\)^(-+\0V>EZG=:/>R64ZR"SO+:0Q
MSV\@'*2(PY5L'!!Z$$[2ISIOEFFGYE1=UH=/10#FBI&%%%% !1110 4444 %
M%%% !1110!S?PX_U6M_]ABY_]"%=)7-_#C_5:W_V&+G_ -"%=)0 4444 %%%
M% !1110 4444 %%%% !7.^+_ /D:_"O_ %_2_P#I+-715SOB_P#Y&OPK_P!?
MTO\ Z2S4 ="GW!]*6D3[@^E+0 4444 %%%% !1110 4444 %%%% #9O]4WT-
M8/PI_P"2::#_ ->,7_H(K>F_U3?0U@_"G_DFF@_]>,7_ *"* .@HHHH ****
M "BBB@ HHHH **** "BBB@#FY/\ DK'_ '!S_P"CA725S<G_ "5C_N#G_P!'
M"NDH **** "BBB@#RCXU^#M8'Q5\&^,--\/IXKM_#=MJ5I/I8N88)U:Z^S;+
MJ(S,L1=!!)&0S*=EPQ!X*M4_9R^'NI?#;PY<:-J6EW%G=30W6HJ(+TR:98+=
M7]Y.EA$N0H:!)%5G5 "N "550/8#&I[4>4H XZ=* /C'PY^R3\2OA!X:\,Z?
MX;M[.ZTW3_"$L9LUU1K>?1M7G-@+V*W='C+0R^5/,H66+$ID4R(LJLFYX2^#
MOQN\,>&KB]M;RZDUS20?[(M-0UPR0W:-J6H?N;C,DIPEE=1%0TC[7@B7<=@-
M?67DK@^_O1Y"^GY&@#YS^$_P5^)/@G]HF.;5/$&N:MX8L6:-;NXU$RPWUD+"
M*&*&2-IV/G"Y5I680(<[CYS!V0_SV_\ !T7X2OO!/_!5*[L=0\2:UXJN&\*Z
M=<"]U1;99T5WN"(0+>*)-B=%RI;!Y9CS7]3QA5C]VOY??^#L_P#Y2Z7/_8F:
M3_Z%<4I; ]C\SZ",D44$9J#,Z[X-ZOH7ACQK#J6N?:&@L1YD,<<7F;Y.@)]-
MO7ZUV'Q\^)WA?XJZ/;2V#WRZK9-A"]OM$L9ZJ3GL<$?C7D.*3;@U[6'SRM1P
M<L#&*Y);W6OK<RE1@ZGM-;BN-KM76_!W6-!\,>,8=2UPW#6]DN^&.*+S-\O8
MD>@SG\JY+;28KS<'B'AZL:J2;B^NQI)<T7%GL/QZ^*OA7XIZ#"UD;Q-4LVQ&
MTEOM61#U4G]17C[G<WY"@#!HQ71FF95,=7^L54N;K96N12IJG'DCL:W@Y-,7
MQ-9R:PTRZ?'())Q$FYG4<E1]>F?2O8/BO\:_!OQ&\"3Z;']NBGC DLV-K@1.
MO0>P(R#]:\)Q01FNC 9U6PE">'IQBU/>ZNW_ ,,34HQG)2ET%E_UI[?6K.@K
M:R:U:K?22167FCSVC7<X3()P/4\BJN.:,8->33ERR4ET-MS]@/\ @EY^PY\4
M/VD?AEH'Q>^%NHMHW@NSUM=!N7L/%-QX=U>2..>%9H8Y84+1AMRX8-UY(X!K
M]</^"<W_  30U+]COXW_ !:^(WB#QMXHU[6OB5?+;Q:9=^)+S6+6UT^VQ':S
M7$UU^\N+]XU4O*P C5O*0;5W-\S_ /!KG\W_  1H@S_T4*Z'_DU9U^K2QJHP
M!7K9IFU;'RC.NE>*LK*VA-&C&FK1'#I1117EFP4444 %%%% !1110 4444 %
M%%% '-_#C_5:W_V&+G_T(5TE<W\./]5K?_88N?\ T(5TE !1110 4444 %%%
M% !1110 4444 %<[XO\ ^1K\*_\ 7]+_ .DLU=%7.^+_ /D:_"O_ %_2_P#I
M+-0!T*?<'TI:1/N#Z4M !1110 4444 %%%% !1110 4444 -F_U3?0U@_"G_
M ))IH/\ UXQ?^@BMZ;_5-]#6#\*?^2::#_UXQ?\ H(H Z"BBB@ HHHH ****
M "BBB@ HHHH **** .;D_P"2L?\ <'/_ *.%=)7-R?\ )6/^X.?_ $<*Z2@
MHHHH **** "BBB@ HHHH "<"OYD/^#JOP)KWC3_@K=?2:+H.N:TEOX-T<3-I
M^GS70A+&Y*AC&IVYP<9ZX/H:_IMD^XWTK\>?^"BO_!;RU_X(_P#_  55^*%G
M<?#6[^(#>/\ PIX8G5H=;73!8_91J"D',$N\MYX_NXV=Z /Y^O\ A1_CG_H1
M_&O_ ((;O_XW1_PI#QS_ -"/XU_\$-W_ /&Z_;__ (C6--_Z-OU/_P +B/\
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M]4WT-8/PI_Y)IH/_ %XQ?^@BMZ;_ %3?0U@_"G_DFF@_]>,7_H(H Z"BBB@
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M4V[TG0TU!+.3PMI]ZXO=4NM1E\V62X9_WMS))(%ST0,$4#"JO?\ JDK^7O\
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M4 %%%% !1110 V;_ %3?0U@_"G_DFF@_]>,7_H(K>F_U3?0U@_"G_DFF@_\
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M  18^)G_  3Y^$^F^-M=UCPUXD\/W%U'87L^E/*KZ;<R E%9)%4LK%6 9>A
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M>"=6\2>(K^WT?0=#M9+[4+ZY;9#:01C<\CGLJJ"2?04 ?/G_  \AU7_HVO\
M:<_\)G3_ /Y/H_X>0ZK_ -&U_M.?^$SI_P#\GU]-";=T5N>]8_Q ^(FC_"SP
M'K?B?Q!>1Z7H/ARQGU/4KR0%DM+:%&DED8*"2%16. ">.E 'S[_P\AU7_HVO
M]IS_ ,)G3_\ Y/H_X>0ZK_T;7^TY_P"$SI__ ,GUZ+^S]^W'\+/VI-<U#2_
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M*JHIQ<KQCR[<JZ-]>YTU*DW2C%QT76VY^5/ASXL^$_V<?&>FZ?X#\:?L^?M
M^&=?^+@N5\'ZEHX7XC:7J5]K9DFGCD$CF::PFDDF$EQ;1NL5L,S+L5JI> _B
M9X9_9J^ G[05JWQ(\:?\)=J'QGU?0+K2G\?KH:^&8;SQ+FWU6ZF,<DFGVTJ/
M'YEV(V\Q9@JD-(&'VW\%/^"A7P1^-GQ9T^RT*XU*T\0>*)KO2](U/5/"-_I=
MOX@EM&D$]M:WT]ND-PZ?9I3Y:2%BL+, 0A(]XU70-%9+^XOK'32MY!Y5[+/
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M0/\ T[ZO7TU,<0M]*^8_"IV_\%@O'7_9'] _]/&KU],2/M')H$SX0_X+"_\
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M?]E_Z515T-<]\4/^147_ *_[+_TJBKH: "BBB@ HHHH **** "BBB@ HHHH
M**** .;^''^JUO\ [#%S_P"A"NDKF_AQ_JM;_P"PQ<_^A"NDH **** "BBB@
M HHHH **** "BBB@ KG?%_\ R-?A7_K^E_\ 26:NBKG?%_\ R-?A7_K^E_\
M26:@#H4^X/I2TB?<'TI: "BBB@ HHHH *",BBB@#Y*U;PE)X]_X*E_$[1H]5
MU30WU+X+Z' NH:;*(KRS+:OJ_P"\B<@A7'4'!K5_X=OZQ&G'[1'[09QZ^)(^
M?_(-2>$1G_@L%XZ_[(_H'_IXU>OIIU5D:L:F'A4=YK\ST,'FF(PJ<:+23WND
M_P TSX!_:3_X)+^,/'^K:#/I?Q?^)FO+I\Z!Y=:UA+N6)7GB#[4\M!Y2HID8
M;R7,:@*#\U?:'P+\%7OP_P#A9HNDZA<-<7MC;*DQ,J2HC==D;)%$OEK]U/W:
MX4#//)ZA=I'RX].*DCP(..1S6='!TJ,W.&[.O,>(L=CL/3PN):<:;;5HI;^B
M5S\O/"^G^,/BG_P3"N/V9K#X2_$Z+QYXDU#5-+GU'6?#=QIFA>'(YM<N+I=4
M>]N D<@@C9)XU@,DCNJ!5ZD1^._V=?%.L?MQ^*KSQM'XSL_%%Q\2-.U7P?XG
MT?X9W>O78T2*2S:"&VUN*?R+"W$:3PW4$L:#;)<,4D\U6/W_ .+/VO?A/X$^
M*]KX%UKXF> -)\:7CQ10:%>Z_:PZE*\N/*00,X?=)D;%QE\\ T_Q_P#M7?#7
MX5?$VS\%^(?&WAW1?$][82ZLNGW5VL4D=G$DDCW,I^[#$%AE.^0J#Y3X)VG'
M4>(?G;\+OA/XH\7_ /!1?P-XLN/A=JG@S7)OB/XAMO&UII7PVFL=/71I=/U>
M**6^UYV8:FETRV$V$_<AY5&V,QIFM^S_ /L/^']6_9I^!GPVN/@GKFDZIX8^
M+<0^)<$_AJZL;:_@BLO$$<5P]R%6.\M<2P+YB.\96XC1OO[:_3'X)_'+PE^T
M9X!M_%'@G7+/Q%X?NY)(8KRV#+&[(VU@-P!X/?&#D$9'-8'A_P#;1^#_ (L^
M*\G@32_BI\.]0\;1SR6C:#;>(K2341-'GS(A )"YD3#;D )7!R!0!Y[_ ,$U
M_@]>? 7PS\5O"BZ#>>&/"NE?$G5SX2TUX6AM;?2I4MYD%HIX%L9WN"H7Y02X
M7 &*^E*S?#'BC2O&&BPZEH^I:?JNGSEA'=6=PD\,A1BCX=25.UE93@\$$=0:
MT/,#G"LOO@T .HKGO OQ,T/XF6^HW&@:M9ZM;Z5J=UHUX]N^Y;:\M96AN(&]
M'CD5E8=B#6^T@SP<GTH =17E_A+]M/X0>/\ XHR>"="^*OP[UGQC#+) VB6/
MB*TGO_,BSYJ>2LA<LFUMR@97!R!@UZ?YB_WA^= "T4WS%_O+^=8^I>/]%T3Q
M7I6@WNL:7:ZWKJSOINGS721W6H+ %:8PQD[I!&&4L5!VAAG% &U135E7'WEZ
MXZUA_$+XDZ'\,-'L[W7M4L])MM0U.ST>VDN'VK->7=Q';6T"_P"W+-+'&H[L
MXZ=: -ZO#?\ @IW_ ,HUOVAO^R9^)/\ TUW->W0;BOS?K7B/_!3O_E&M^T-_
MV3/Q)_Z:[F@#T_X/?\DD\+?]@BT_]$I71USGP>_Y))X6_P"P1:?^B4KHZ "B
MBB@ HKR?]J;XZ:Y\#-)\*WNA:!>^*[G5M;DT^32+*(-=WZC3;ZX5(BS*J-YE
MO&2YR @DX)Q6Q\%OB!J7C;X<Z7JUSJ&C:Y#J.FKJ*:KI:M#:3/(SMY*1/F15
MC4*NYR&8@Y5&!4 'H%%?)/PS_;\\1'0_#,/BZQT>W\02^&9=?OK: FWBU6&7
M[%]@N+9G9MJ.UQ)$Z8D831,BACL#]1X;_;[L[N1M0UK2;W1-&LU\C57E4JND
M2K?:A9>8YE2.0H\UI&@#Q(P-Q'D [@ #Z.K^7O\ X.S_ /E+I<_]B9I/_H5Q
M7]"WPN_;';XE?%"U\.'P;XDTM)I&LIKN:VF:*RODLTNY()9!%Y 559HPPF+F
M1"#&%(8_SF?\'1?C:3Q__P %4KN_ET+7O#K)X5TZV^RZO;I#<.$>X'FA4=P8
MWZJ<YZY I2V%+8_.ROZD?^#4;_E#IX5_[&/6_P#TM>OY;,U_0-_P;X_\% =2
M_9M_X)A>%_#=K\$/C3X\B36-6N?[7\,^'S>Z>Y>[<^6LFX9=.C#'!XK"K6A2
MCSSV.S+LNKXVI[+#I-[ZM+;S;2/VN:3::=7YSZG_ ,%B?''B#X[Z5X?LOA+\
M0/!]G<LJL/$FC+9M'YL;(K3[W "B10R$/'O.4) ^:OT&\.ZK/K&EVUQ-:W5F
MUQ"DK07"JLT)(R48*64,,X."1D'DU.'QE.O?V?339H]#..'L;E:I_7$E[1<R
MM)2T^39I44@ZGZTM=1X@4444 %%%% !1110!SWQ0_P"147_K_LO_ $JBKH:Y
M[XH?\BHO_7_9?^E45=#0 4444 %%%% !1110 4444 %%%% !1110!S?PX_U6
MM_\ 88N?_0A725S?PX_U6M_]ABY_]"%=)0 4444 %%%% !1110 4444 %%%%
M !7.^+_^1K\*_P#7]+_Z2S5T5<[XO_Y&OPK_ -?TO_I+-0!T*?<'TI:1/N#Z
M4M !1110 4444 %%%% 'QSX_M?&=_P#\%*_BM#\.[SP[I_C:3X+:"-'N=>@E
MN--AG_MC5L&=(F61DQGA2#TK-_X0;_@H,5P/'_[*>.@_XIK6?_C]=YX1_P"4
MP/CK_LC^@?\ IXU>OIF10L+?3K0!\'7W@O\ : MO&D<G[25Q=>-O"/\ 9TB:
M(GP0AUC2Y+34_,0JUZD5P+EV*#$,FX6\3"0R[2R,/K[]FZS\6:;\ /!MOX\F
M$_C*'1[9-:?S$D)NQ&!+N:/Y&8-D,4^4MDCC%=!H/B32_$5]J%O8ZAI]]=:3
M/]FOH;>Y65[*;:K^7*JDE'VLK;6 .&!Z&M3&V/ ]* /RSB^+GPG^%_[!'Q^^
M#OQ/73I/C=XEUSQ@FH^%;BS+Z]XUU.^O;M]*N;*+89+@30RV7V>:/<L(15W)
MY#!.'_:-_9PUC_A3'[96H>,->\=/XTT7X*^%8M4CM/$=[%8W]_\ V-=I<AX(
MY/*E0R1$[2&4>;+@?O&S^LVC?$OPSXB\3W&CV/B#0[[6;'>MQ96]_%)=0;3A
M@T:L67!P#D#!K;EEAM(&>1XXXX5+,S-M5 .I)[# H \4T3X<_$CX1>*-+T/2
M]3T'6/A#IMK*=0N_$&IZMJOC"0L)Y'VW#,XDP[H$W$L$&T?=45\0_LC?&+1?
M@[XQ^#?PH^%OQ.^&G[0W@"XUTZ3:>'E\+MIWC?P#8&&X<ZG<7,<AP]MA4E>>
MUMY69\;A(V#^GCZ_IZZO:6,M]9K>WT;SVUN9U$MPB8W.BYRRKN7) (&X>HJ_
MY2%F.%RW4^OUH _([]C3XK^&_P!DG]E3X77$/Q/\2Z:WA'XLG3?BM9ZKXIN[
MF#PG9R7/B&"W6]@FD*V44\[0,Y*JLKK%(Q.%:NDNOVR7^).H:I?>(_BQXF\.
M_ /7/CUK&DZAXOLM7N-,6UTV'P]:SZ?8)?#:]I8SWAD/F1L@9@J*X$QW?J3=
M36]K \DTD4<7 =G8!>>!G/'/3FI&1#E3CYA@@GK0!^4GP7^.][^Q]^R9_P +
MX\,ZGXQ\7?#3P3\7?&UCK^E+=3W5SXGTG4M5EAL;UA)F2>YCO18E965G,=Q<
M$G#$U]\?LZ> _$GPZ_8ZTG2_BAKVIZ]XLDTBYO?%5\)7N)DN;DRW-U# 4W/Y
M<+3/#"J9*QQ1*H. *TOB%I?PS_:@URW\'ZEX@T7Q!?>#];LM?GT2SUI#/!=6
M<PFMS<P1ON*),J/LD&TM&I(.*]2**1U_6@#\O_V*?CAIOPL^(/P/^%'PS^)G
MPK_:.\!QW#:1I]A:^%/[.\8_#S3H;&<QZE=SQR-'F/9#;S--;VTLDEP.=Y93
M:_9;_;JOOB,/V0_!4?Q&U;6/B'90Z]9?$S3&NY9+V&[M="O_ -WJ?!"R+=1*
MR+*0S%-Z@A21^F%_=6VD65Q=W$T-M;P1M+--*X1(U49+,QX  ')/0"N?\#_%
M[PC\2]+N+_P[XI\-Z_86[B.>YTS4X;J*-R=H5GC8@$D8 )SD4 ?GY\+[CQQ^
MSS_P3I^#'[3&H?$SXN>-+S2;#0O$_P 0[#6=9FOK>\T.6T:#43'9*JH&MH[D
M7@(4R.UD-S,S,QZ+P*OQ+^(7C#X"VGB?Q=XV\/WWQRTKQWXAU&WM[^6.;PQ#
M>VUM)IMI$>/*>QMY8E3 7$R2-U8Y_0<QJS_[7UK/\4^(]-\%^&;[5M6U"STK
M2=,@>YO+V\N%@M[2) 6>221R%15 )+,0  2: /S/T_\ ;*^(OB_]G3XC>./&
MD?C:UM_@-X1@^'7B73])UBXT$:OXLFOXK?5=3-W&CO%!:6\5I.ERL<GEQ7UT
MZC<F*X7P#\5M<\?>'?%7A]O'EK\0O"N@_&;X0:AHMU8>(=0\1V-F;GQ'9_:8
M[?4+[,\\8:W1B=QC5B^T)\RC]=-/ECNK6.6.19(Y%#(R-E64C@@]Q[U,(5"[
M>BXQ@'H* !#DM]:\/_X*=_\ *-;]H;_LF?B3_P!-=S7N*H$Z5X=_P4[_ .4:
MW[0W_9,_$G_IKN: /3_@]_R23PM_V"+3_P!$I71USGP>_P"22>%O^P1:?^B4
MKHZ "BBB@"AJ7AZUU>\LY[FUM;B;39S<VDDD89K:4QO&9$)'RMLD=,C!VNPS
M@D5EZ!\*]"\*:U=WVEZ58Z;/?1F*?[-$L22AII)W)50!N:6:5V/5F=B3DDUT
M=% ')ZK\#_".O:=:VE]X5\-W=M8V1TVVCFTV%UM;4M&QMXP5^2(M#"=BX&8D
M/51B*S^ /@K3M&NM.M_!WA6'3[U/+N+5=+@\F=1*TX#+MPW[YFDY'WV+?>)-
M=C10!S<'PF\-VOCR3Q1'X?T2/Q),NR35$LXUO'&U5.9,;N555)SDJB@Y  '\
MS_\ P=G_ /*72Y_[$S2?_0KBOZA*_E[_ .#L_P#Y2Z7/_8F:3_Z%<4I;"EL?
MF;7]1_\ P:FQ-+_P1R\* ?\ 0QZW_P"EKU_+E7]2/_!J-_RAS\*_]C'K?_I:
M]3'<2;/OS6_A'X?\1ZQ#J%]HVFW5W#O'F20AO,#QF)]XQA\QDKA@>#VKI8T\
MM=H554< "G44U%)W1I*I*5N9WL%%%%42%%%% !1110 4444 <]\4/^147_K_
M ++_ -*HJZ&N>^*'_(J+_P!?]E_Z515T- !1110 4444 %%%% !1110 4444
M %%%% '-_#C_ %6M_P#88N?_ $(5TE<W\./]5K?_ &&+G_T(5TE !1110 44
M44 %%%% !1110 4444 %<[XO_P"1K\*_]?TO_I+-715SOB__ )&OPK_U_2_^
MDLU '0I]P?2EI$^X/I2T %%%% !1110 444V1BJ''7M0!\R>$UW?\%@O'7;_
M (M!H'_IXU>O/M7?_@H\NJ7GV"U_8C_L\3R?9?/NO% F\G<=F_:F-^W&<<9S
MCBCXN?M6?#O]DW_@K)XEU3XC>+--\(Z?K?PFT2VL+B_#K'=R1ZMJK.J%5.2J
MNI(X(#"O0S_P62_9?9<?\+H\'\^DDO\ \10!^2USJ/[66E_\%GC'\#X?V>V^
M,<S&7XI6GPXN-9?P6R&0!G\1"Z A6ZSO^:V_TK);/[P\_OYHXF72K?[5Y/VG
MRU\[R<^7OQ\VW/.W.<9YQ7RMX>_X*K?LB^$M0U2[TKXH?#W3;K7+G[;J4UK"
MT,FH3[53S9BL8,C[55=S9.% S6K'_P %C_V7XX]H^-'A#:/^FLO_ ,10!\D_
MLZ?LKZU\5/%&K>/(/"?PX\-:%\,OCQXN\777C?3YII_'&K0V>L:@TNF) EH@
M$4V?)<O=R!XEV^5EE*<3H?[5/C;X[>!O&/A[3_B=JGB3PO\ %KX#^+?$]MI,
M_C#3/$GB+2Y88;0VAFBM--MX]/FDCNYHF@62Y#%2 4>(LWW%8?\ !7?]E/2D
MD6T^,'@BU621YV6(R1JSNQ=W(" ;F8EB>I))-9/A3_@IY^QOX'N)+C0_B-\,
M=(FN)))I);"S%NTCR%3(Q9(@2SE%W'J=HST% '@/AOXXZM\&_A+\(-4^'/C3
M_A<6J6?P6\:>(+#[<-/U6Z_M.STO1);;38I;6%'2-7< PJ=[^:-Y?"8Y-?VM
M/C)X5_9?^)GC#2OC9X7UZ%_A9+XAM7A\:Z?XCUBTU875HL=_;VD6G6PM;4I/
M.DD4GF*LBP* #O)^KO"G_!4+]COP)#''HOQ(^&FCQPO+)&+&T^S"-I=OF,-D
M0P7V)N/\6U<YP*K:7_P4H_8MT2;5I+'QY\*;1]>8MJ;0:>L9U$DY)F*PCS,G
MGY\\\T ?.7_!0JV\9?#_ ,&?M#?#/6OB[X^\4>&](\,^"_',>J:NVG+?Z.TO
MB&>&\ DAM(XUM?+M(Y=K1G88F(8*66OLWXRPZ]%_P3B^(J?"[QEK7Q"\8+X'
MUQ?"_B,7EM=7VHZE]DN?LS++:I'"TBS[$7RT4 H!U'/+7?\ P5J_9.U":ZDN
M/BSX#G>^@^RW+2(S&XA^;]TY,?S)\[?*<CYCQR:;X9_X*S?LE^"M#M]+T?XL
M> M(TVS4I;VEDC6]O I.<)&D851GT% 'S=JDG[/LW[/7[,J_ /\ X0=?BQ_P
ME?A9?#HT!8!XD2$7$)UW[?Y?^D[#IXO_ +9]IZR?ZS,FVNC^&?Q;^*$$7PM^
M*5[\6O&6L0^+?CKK_P .[OPK=0Z>NAC2(]=US3X0JI;+<>?$MG ZRM,3E=I!
M6O8-"_X*>_L;^%_%5]KVF_$3X8Z?KFJ9^V:C;6GE7=YDY/F2K$'?) /S$\U>
MC_X*R?LEPV\,*_%;P"L-O<M>11B-@L4[,SM*H\O D+.[%AR2['.2: .?_;6T
M'QA\8?V5O&6@_&[4O@_\&?#DFLZ3+H>MIXCN->TK49HM1CFAM=7MKJSLHQ:7
M#110RPB5ED2:1"P&"?D7]H?QI::Y^SQ\>/";:+\$]!UOP_I_@_7]8^(7P2,4
M6GW-D/$$:_9=0\R)_LT\$<4MRJ-+,!$Q;<JY#?;VM_\ !7#]E'Q+I5Q8ZE\7
M/ NH6-TGES6]R'FAF7T9&C*D?45F^&O^"GW['/@SPS/HNC_$7X9:3HMUO\ZP
MLK,6]K-O&UMT2Q!6R.#D<B@#S[XC?MIVG[-_B_XG:)>?'*UU7P_IOP5B\0^$
M=;U[5-.\W6-4%YK,<T\,L4<45Q*ACLXRD2D+MB&W<V6^>?VP?VG-6^-G[)_Q
M@T_XB_&K4/A\/#_P*T;5=%T*WO=-TX>/KG4]&GEN[F<7$+R7*M< 6PCMR@0J
MW\3J5^O?^'D/[%9LM'MCXX^$YMO#V[^RHCIR^7IF[[WD+Y.(LYYV8S4^M?\
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M ,:H_P"';L?_ $7;]I+_ ,+I_P#XU0!])9HS7S;_ ,.W8_\ HNW[27_A=/\
M_&J/^';L?_1=OVDO_"Z?_P"-4 >X?$]P?"B_]?\ 9=?^OJ*NA#[O_P!5?&'[
M0_["<?@CX=QW<?[2WQJ\,S'5+#%YXA^(#1V9A2[BDN$!\L?O#;)-L/\ "V&/
MRJ:[N'_@G'#<1*Z_';]I%E;E2/';D$=L'RJ /I7-&:^;?^';L?\ T7;]I+_P
MNG_^-4?\.W8_^B[?M)?^%T__ ,:H ^DLT9KYM_X=NQ_]%V_:2_\ "Z?_ .-4
M?\.W8_\ HNW[27_A=/\ _&J /I+-&:^;?^';L?\ T7;]I+_PNG_^-4?\.W8_
M^B[?M)?^%T__ ,:H ^DLT9KYM_X=NQ_]%V_:2_\ "Z?_ .-4?\.W8_\ HNW[
M27_A=/\ _&J /I+-&:^;?^';L?\ T7;]I+_PNG_^-4?\.W8_^B[?M)?^%T__
M ,:H ^DLTA;:*^;O^';L?_1=OVDO_"Z?_P"-54UO_@GK8^'](NKZ^^/W[1EG
M96,37%Q<3>/VCB@C0;F=F,> JJ"23Q@4 >\_#CB+6_\ L,7/_H0KI,U\3?#[
M]BFUT;Q7?^'?$7[3GQBGU_6-1N=1T33[#X@M%</IKY:WWQM'EI-JN2R@AMK$
M9 )'HJ?\$WXW0-_PO;]I+YAG_D>W_P#C5 'TIFC-?-O_  [=C_Z+M^TE_P"%
MT_\ \:H_X=NQ_P#1=OVDO_"Z?_XU0!])9HS7S;_P[=C_ .B[?M)?^%T__P :
MH_X=NQ_]%V_:2_\ "Z?_ .-4 ?26:,U\V_\ #MV/_HNW[27_ (73_P#QJC_A
MV['_ -%V_:2_\+I__C5 'TEFC-?-O_#MV/\ Z+M^TE_X73__ !JC_AV['_T7
M;]I+_P +I_\ XU0!])9HS7S;_P .W8_^B[?M)?\ A=/_ /&J/^';L?\ T7;]
MI+_PNG_^-4 ?21.*YOQA(!XI\*MV^W2]O^G6:O#W_P"";T:J?^+[?M)?^%V_
M_P :K@OB5^PQ;Z)XETJZ7]ICXTZ7H_A>Z-UXJ74?B"PG@M9K6>.V\L^7B-VN
M#'@MC<@<+DD4 ?9\;!D%.S7S!X>_X)_:;XMT.UU33?V@?VB=0T^_B6>WN;;Q
M^TD,\;#*LK+'@@CD$5=_X=NQ_P#1=OVDO_"Z?_XU0!])9HS7S;_P[=C_ .B[
M?M)?^%T__P :H_X=NQ_]%V_:2_\ "Z?_ .-4 ?26:,U\V_\ #MV/_HNW[27_
M (73_P#QJC_AV['_ -%V_:2_\+I__C5 'TEFC-?-O_#MV/\ Z+M^TE_X73__
M !JC_AV['_T7;]I+_P +I_\ XU0!])9HS7S;_P .W8_^B[?M)?\ A=/_ /&J
M/^';L?\ T7;]I+_PNG_^-4 ?26:,U\V_\.W8_P#HNW[27_A=/_\ &J#_ ,$W
M8Q_S7;]I+_PNG_\ C5 'T?/((XF8G;P>36#\*Y<_#70<Y)^PQ?\ H(KYL\>?
ML7^&OAI9VLGB']I+X]Z"M_+]GMGO_B-]G6:3&=JEHQG'4XZ#GBL_X4_\$\;S
M1?"&A^'_ !1^T1\=+KQM8Z-!/JL.F>.WAA+?<:6*%H]Z0F17"Y&.,=C@ ^Q,
MT9KYM_X=NQ_]%V_:2_\ "Z?_ .-4?\.W8_\ HNW[27_A=/\ _&J /I+-&:^;
M?^';L?\ T7;]I+_PNG_^-4?\.W8_^B[?M)?^%T__ ,:H ^DLT9KYM_X=NQ_]
M%V_:2_\ "Z?_ .-4?\.W8_\ HNW[27_A=/\ _&J /I+-&:^;?^';L?\ T7;]
MI+_PNG_^-4?\.W8_^B[?M)?^%T__ ,:H ^DLT9KYM_X=NQ_]%V_:2_\ "Z?_
M .-4?\.W8_\ HNW[27_A=/\ _&J /I+-&:^;?^';L?\ T7;]I+_PNG_^-4R?
M_@G'#;Q,[?';]I(*HR2?';@ ?]^J /<I)"OQ6'I_9!_/SA71!LBOA=?V5O#\
MOC)?%2_M8?%1OAV+'^S/.'Q)!F.J&428$VS9Y?D?-MZXP_W1FO5E_P"";L>/
M^2[?M)?^%V__ ,:H ^D6<*1U^8^E.!R*\1^$/[$R?"+X@V/B ?%CXV^)C8B0
M?V;X@\5M?:?<;XV3]Y"4&[;NW+SPRJ>U>VHNQ OH,4 +1110 4444 %%%%
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MH/$G@?X$_!/6(]4O? ]_\1)8(]8N=3\(3:AJ.GLVB7=Z8VTZ!V:.X^T01HZ
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/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>nbx-20211231_g25.jpg
<TEXT>
begin 644 nbx-20211231_g25.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M8_\ !.;X^:3I.GWVKZMJGPY\06EE8V-N]Q=7L\FFW"1PQ1("\DCL0JJH+,2
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M(GPON+.34OA^?#UA:>'_  Y/I]C/:R,]])IEM!+ILL0G@B*7C-<Q7&U2Y+8
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M%E(^O7CK7Y-_\1C/[,[#_D1_CAS_ -0;3?\ Y/K-D_X/"/V<?^$FAN/^$/\
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MB-"K*K#Y@W2E8<4BC:.!Q]:7/M7WBV//Y6='\+?!$WQ!\86>EQ;E25MT[_\
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M:RN$MT#QNNWA@<@BO=/^'\'['G_1PWPW_P#!@?\ XFN=_P""3?['OPE\;?\
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M ,).P_\ C5'_  PK\$O^B-_"G_PD[#_XU0!X[_P_@_8\_P"CAOAO_P"# _\
MQ-'_  _@_8\_Z.&^&_\ X,#_ /$U[%_PPK\$O^B-_"G_ ,).P_\ C5'_  PK
M\$O^B-_"G_PD[#_XU0!X[_P_@_8\_P"CAOAO_P"# _\ Q-'_  _@_8\_Z.&^
M&_\ X,#_ /$U[%_PPK\$O^B-_"G_ ,).P_\ C5'_  PK\$O^B-_"G_PD[#_X
MU0!X[_P_@_8\_P"CAOAO_P"# _\ Q-'_  _@_8\_Z.&^&_\ X,#_ /$U[%_P
MPK\$O^B-_"G_ ,).P_\ C5'_  PK\$O^B-_"G_PD[#_XU0!X[_P_@_8\_P"C
MAOAO_P"# _\ Q-'_  _@_8\_Z.&^&_\ X,#_ /$U[%_PPK\$O^B-_"G_ ,).
MP_\ C5'_  PK\$O^B-_"G_PD[#_XU0!X[_P_@_8\_P"CAOAO_P"# _\ Q-'_
M  _@_8\_Z.'^&_\ X,#_ /$U[%_PPK\$O^B-_"G_ ,).P_\ C5'_  PK\$O^
MB-_"G_PD[#_XU0!X'J__  7,_9"N/&FBW*?M!_#EK>UBN5E;[<V%+"/'\/?!
MK:'_  7A_8\(_P"3A_AO_P"# _\ Q->AZW^Q!\%5\>:#&OP>^%BQR0W19?\
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M_@MH7@W6+O2M5N]&\4:D+.YG\E[>;1[?[--</=S02*LFR-8<R+@.J[FQ\I%
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M@8_"I:S)YC]!O^&AO^":/_1NO[1G_A60?_)5)_PT/_P31'_-NO[1G_A6P?\
MR57Y]5]@?\$H_P#@DSJW_!32_P#%=TWBR'P9X8\'_9XKR]^P?;KBXN)Q*8XH
MHO,C& L1+,6 &Y0 Q)QY&?9_@,EP,\RS.HJ=*%KR?2[LOO;2-L/1J5IJG35V
MST;_ (:&_P"":/\ T;K^T9_X5D'_ ,E4?\-#?\$T?^C=?VC/_"L@_P#DJOFO
M_@H5^P]KG_!/K]I+4/A[K6IV>M*EE#JFGZE;H8DO[27>J2>623&P:.164DX*
M'!(()\-!S73EN98;,,)3QV#DITZB4HM;--73)J1E3DX26J/T&_X:&_X)H_\
M1NO[1G_A60?_ "51_P -#_\ !-'_ *-U_:,_\*R#_P"2J_/FMSX6_#O4_BY\
M3?#OA31(XYM:\3ZI;:381R.$5YYY5BC!)X W,.3VS754JQIP=2;LDKM^A$;M
MV1]U?\-#?\$T?^C=?VC/_"L@_P#DJC_AH?\ X)H_]&Z_M&?^%9!_\E5<_;]_
MX-_]>_8G_98OOB99_$2Q\8+X;,!U^Q&E&Q^S++-'!YD#F5_-59)%!#*C;3N
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M7QKU+Q]X\O+>\U[4D2W"VT(@M[.",8C@BC'W47)ZDL222222?-P<#K7Z$_\
M#77_  3G/_-I/Q8_\+V3_P"/4?\ #7/_  3G_P"C2?BQ_P"%[)_\>K?!X.AA
M*$,-AHJ,()))*R26R2[$RDY/FD[L_/?=5SPOXFO_  5XGTW6M*NIK'5-'NHK
MZSN83B2WFC</&ZGU5E4_@*^_!^US_P $YS_S:3\6/3_D?9/_ (]1_P -=_\
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MC\A7O9I6RZ="E'"1:E%>]?J^YC255.7/L4VY%;OP[\%7'Q \4V>EVP;=</\
MO& _U<8Y9OP'YG%81.16[X+^).J_#VYFFTF9+:6X0([F%)"0.PW X_"O,P+H
MK$1>)OR7UMY&LK\KY=SIOVAOA3'\,O$L;6*L-*U!0T&?X' PRY_7Z&O/!74^
M,_C-XA^(&D"QU:\CNK<2"4 6\:$,.ARH![URRC)_S_GM6^<5,+4Q4IX--0?1
MD4>?D7/N*>E>H? #X)K\2[/5+R^+1V20M;VY]9R =W7^'C\3[5Y?GBNQ\/\
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MA\NO_!+??_&:/^'Y?[-/_0^77_@EOO\ XS1_:6$_Y^1^\?\ J?G?_0)4_P#
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M'_\ KA=_^@QUTM<UKG_)0?#_ /UPN_\ T&.NEH **** "BBB@ HHHH ****
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M.5CHL,EG8W'@_P 2WXM_,9HX))K*XDD$8)^1"[,P1<*"QP .*]X\Q?6O(?\
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M (/MK/1!J%IXBUN+2[R\>Z6--/5PVU@O+2.Q    4 $E@<*V'X^^,7B[X>?
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MX4#([\5+4$/<_1S_ (>W?L=_](Y/ /\ X7<G_P @4G_#W#]CO/\ RCE\ _\
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MY?68N2MIZGS1/"T5P\17]XK%"NX'YLXQG..O?.*_K._X(K?!3QQ_P3V_9S\
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MH **** "BBB@ HHHH **** "BBB@ HHHH *1NGXBEI&Z?B* .=^%'_(CV_\
MUWN?_2B2NCKG/A1_R(]O_P!=[G_THDKHZ "BBB@ HHHH ;YBYH\Y<_>]Z\A_
M:<^,.M_#76O!6GZ+<0V9\2:C<VUS.?#UWKTL216DDX"6MJZR$ED +9PH/XUI
M>!/B/XLO/@A<:YXD\/+H^N6VD27YC8>5#+(!,5'DL[20Y5(G9'8E3-MW$HU
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MQ&\3:WI>I:E)XD\,^(--LWT/1IY \#6MXD%Y<0*TCV:%(P9!*Q\EFVOM/R@
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M@I6WMVED:60J"3]Z1W8^['UKLT^X/I2T %%%% !1110 4444 %%%% !1110
M4444 1W7_'M)_NG^58OPL_Y)GX?_ .P;;_\ HI:VKK_CVD_W3_*L7X6?\DS\
M/_\ 8-M__12T ;U%%% !1110 4444 %%%% !1110 4444 %%%% '-:Y_R4'P
M_P#]<+O_ -!CKI:YK7/^2@^'_P#KA=_^@QUTM !1110 4444 %%%% !1110
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M\E6M?^P5/_Z/BKHZYR;_ )*M:_\ 8*G_ /1\5 '1)]P?2EI$^X/I2T %%%%
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MSQIH:Z)*%7SHK4"ZCE,AR8PQ.T1JF]<RE%WX:OZ6].NOMUI',8YH?,4,8Y0
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M /!W:_\ Q=<F?V /@+N_Y(A\(?Q\&Z=_\:IW_#OKX#?]$1^#_P#X1NG?_&:
M.J_X:2^'O_0_>"__  =VO_Q='_#27P]_Z'[P7_X.[7_XNN5_X=]? ;_HB/P?
M_P#"-T[_ .,T?\.^O@-_T1'X/_\ A&Z=_P#&: .J_P"&DOA[_P!#]X+_ /!W
M:_\ Q='_  TC\/#_ ,S]X+Z_]!NU_P#BZY7_ (=]? ;_ *(C\'__  C=._\
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M1-4^"6N^+[3Q/#X:CT=?#E_'91W$5M831:E-+<1S6\EP([@A)(G@23G=L7]
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M%FG^%_''@NS^'_[/C>,M1\#>)O%DVJ2>/+[;!<1:U9*+BZ@CMXA!<02R)*)
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MR^\,Z'-J&O6C6&H7OV&(7=Y RA6C>;;O92JJ,$]%7T&.K\Q=VWO3J .4\9?
MKP5\1==LM4\0^$?#&O:EIJ".TN]1TJWNI[50V_;&\B%D&X!L*0,C-;^N:!8^
M)]+FL=2M+;4+&X 66WN8EEAE'7#*P((S@\CM5HR*#UI!.A.-U &0?AUH!\1R
M:Q_8ND_VQ+)'*]_]CC-T[QI)'&QDV[B4CFE13GY5E<# 8@^7_MQ^%M-\-_L(
M_'7^SK&ST_[=X*\07=S]GA6+[1.^GSEY7V@;I&P,L<DXY->T><N>O7I7D/\
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M_P#[!MO_ .BEK:NO^/:3_=/\JQ?A9_R3/P__ -@VW_\ 12T ;U%%% !1110
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M\$+/)+>3;50/+)(S/(P554%F.%4 8 Q7?"@ KR'_ (*#?\F$?&__ +$#7O\
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MQ-X+^-MQX+\8VN@:G+>:5K5N/!^H:O$\;O''(\#)+:N8Y$#++ >H"D^I2?\
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MU.^EOKVX$:A0\T\I:260XRTCL68DD]: -NBF^:O]Z@SJ/XJ '5Y#_P %!O\
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MF_Y*M:_]@J?_ -'Q5T=<Y-_R5:U_[!4__H^*@#HD^X/I2TB?<'TI: "BBB@
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M7HT&E?L*?' PPPPFX\#:]-*8XPGF2'3I\NV!RQP,DY/ KV;.*\A_X*!1K/\
ML&_&V-N5;P#KH('H=.GH _B<L]2MX[6,&:+.T?QCTJ7^U;?_ )[0_P#?8K[Z
M\'_\',O[7WA'PCI6DV/C3PI'8Z79PV=NC>$K%F2*.-40$E,G"J!FM+_B*&_;
M(_Z'CPC_ .$A8?\ Q%9DZ'YY_P!JV_\ SVA_[[%"ZO  ?](BP>HWBOT,_P"(
MH;]LC_H>/"/_ (2%A_\ $4?\10W[9'_0\>$?_"0L/_B*!:=SX9UCX^^*_$G@
M:S\+ZAXT\0:AX;TTAK32;C5YI;&U8<*4A9BBX[8'%?L1_P &78M]0^.7QXF
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MB1IUSXJ\;Z9MMIV\)Z@]E"S3JT*++:IYR):FWNF=V9PRE=D@/\TA\'ZS_P!
M?6/_  "E_P#B:_I/_P"#0[2+C3/^"7_B%+JUN+.9_B%J+;9H&B9E^RV.#@@9
M'!QVJHE1/U6HHHJB@HHHH **** "BBB@ KG)O^2K6O\ V"I__1\5='7.3?\
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M ,%_OVJ/VK_^"D'PI^'?CCQYI.J^$_%&J26NI6L/ANPMGF1;::0 21Q!U^9
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M29&$QSTH _&'QG_P<5:A^R]^W(MWJDGQ ^(GP+^)MVJ6>E:I\/KSP[XB\$W
MV1>79>;%&FI6[?*Q3<9MS-C!QYG[*Z%J<>M:'9WD2W*17D*3HMQ;O;3*K ,
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M *2QUW-<-^S#_P FU?#S_L6=-_\ 26.NYH **** (KNTCO(MLD4<@!# .H8
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M_P -='_\GT?\,_?M+?\ 1QGA'_PUT?\ \GT ?2%%?-__  S]^TM_T<9X1_\
M#71__)]'_#/W[2W_ $<9X1_\-='_ /)] 'T9=G%K)_NG^58OPK.?AGX?_P"P
M;;_^BEKPF[^ G[2T=M(R_M%>$78*=JGX7QC<<<#_ (_^YXKF?@Y\#_VIKGX2
M>%WUKXY^#?#NN-I%HVH:2OPYANAI<YA7?!YJWP$FQLKN  ;;D4 ?75%?-_\
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M?/\ P\/B?_Y.I/\ AG[]I;_HXSPC_P"&NC_^3Z/^&?OVEO\ HXSPC_X:Z/\
M^3Z %_X=>> ?^AP^/G_AX?$__P G4?\ #KSP#_T.'Q\_\/#XG_\ DZD_X9^_
M:6_Z.,\(_P#AKH__ )/H_P"&?OVEO^CC/"/_ (:Z/_Y/H 7_ (=>> ?^AP^/
MG_AX?$__ ,G4?\.O/ /_ $.'Q\_\/#XG_P#DZD_X9^_:6_Z.,\(_^&NC_P#D
M^C_AG[]I;_HXSPC_ .&NC_\ D^@!?^'7G@'_ *'#X^?^'A\3_P#R=1_PZ\\
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M!='M!X0U#Q7/>:@T,31:?/J%KHF^WE1KZ>VB_P!?Y:L1''CF1TPT>#(OMM%
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ML%YXTTM9-92VU&?^P]*%EHEJ_B>RCMY-)E>!OM(;1&O)9C/Y_E,BG]W)^[H
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MBXZ"M2W\":19"W$&DZ7 +41+;B.TC7R!$K+%LP/EV*S!<?=#$# - 'R'??\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>nbx-20211231_g26.jpg
<TEXT>
begin 644 nbx-20211231_g26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M\*/]?N&O^AA1_P#!L/\ ,#H**Y__ (6?HO\ S^?^.-_A1_PL_1?^?S_QQO\
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M\_G_ (XW^%'^OW#7_0PH_P#@V'^8'045S_\ PL_1?^?S_P <;_"C_A9^B_\
M/Y_XXW^%'^OW#7_0PH_^#8?Y@=!17/\ _"S]%_Y_/_'&_P */^%GZ+_S^?\
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M:7%XQN%@02EE8DMM&<G'K1_K]PU_T,*/_@V'^8'545S_ /PL_1?^?S_QQO\
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M &4;[Q;XVT;PS\1M)\!KI5IIMMH_C'5I+Z2[UB>\6*.6)3+/*D:K(-^&^;@
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M_;U_P2E.?^"87[._?_BVWA[D_P#8-@K^(&O[?O\ @E+_ ,HPOV=_^R;>'O\
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M6U_[Z/\ A1_Q"?C#_H7U/N7^87.0HKK_ /A3&J?\];7_ +Z/^%'_  IC5/\
MGK:_]]'_  H_XA/QA_T+ZGW+_,+G(45U_P#PIC5/^>MK_P!]'_"C_A3&J?\
M/6U_[Z/^%'_$)^,/^A?4^Y?YA<Y"BNO_ .%,:I_SUM?^^C_A1_PIC5/^>MK_
M -]'_"C_ (A/QA_T+ZGW+_,+G(45U_\ PIC5/^>MK_WT?\*/^%,:I_SUM?\
MOH_X4?\ $)^,/^A?4^Y?YA<Y"BNO_P"%,:I_SUM?^^C_ (4?\*8U3_GK:_\
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MA"4VV_:5-]>J)EN?H-_Q%$_MJ?\ 15(?_!%9?_&Z/^(HG]M3_HJD/_@BLO\
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MB?VU/^BJ0_\ @BLO_C=?GS10!^@W_$43^VI_T52'_P $5E_\;H_XBB?VU/\
MHJD/_@BLO_C=?GS10!^@W_$43^VI_P!%4A_\$5E_\;H_XBB?VU/^BJ0_^"*R
M_P#C=?GS10!^@W_$43^VI_T52'_P167_ ,;H_P"(HG]M3_HJD/\ X(K+_P"-
MU^?-% 'Z#?\ $43^VI_T52'_ ,$5E_\ &Z/^(HG]M3_HJD/_ ((K+_XW7Y\T
M4 ?H-_Q%$_MJ?]%4A_\ !%9?_&Z/^(HG]M3_ **I#_X(K+_XW7Y\T4 ?H-_Q
M%$_MJ?\ 15(?_!%9?_&Z/^(HG]M3_HJD/_@BLO\ XW7Y\T4 ?H-_Q%$_MJ?]
M%4A_\$5E_P#&Z/\ B*)_;4_Z*I#_ ."*R_\ C=?GS10!^@W_ !%$_MJ?]%4A
M_P#!%9?_ !NC_B*)_;4_Z*I#_P""*R_^-U^?-% 'WYK7_!SC^V9XATFXL;KX
MI0R6UU&8I%&AV0W*>HR(ZFM/^#G_ /;0L;2*&/XJ0K'"@1!_8=EP ,#_ )9U
M^?M% 'Z#?\11/[:G_15(?_!%9?\ QNC_ (BB?VU/^BJ0_P#@BLO_ (W7Y\T4
M ?H-_P 11/[:G_15(?\ P167_P ;H_XBB?VU/^BJ0_\ @BLO_C=?GS10!^@W
M_$43^VI_T52'_P $5E_\;H_XBB?VU/\ HJD/_@BLO_C=?GS10!^@W_$43^VI
M_P!%4A_\$5E_\;H_XBB?VU/^BJ0_^"*R_P#C=?GS10!^@W_$43^VI_T52'_P
M167_ ,;KZZ_X(4?\%Z/VH/VR_P#@J/\ #/X=?$+X@1ZUX1\0-?B^LAI-K!YW
MEV,\J?.B!AAT4\'M7X?U]^?\&PO_ "FU^#?^]J?_ *;+J@#^P"BBB@ HHHH
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MN7_@+_R KT58_LFZ_P"?6X_[]G_"C^R;K_GUN/\ OV?\*/[/Q7_/N7_@+_R
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M !ZC_B&J_;4_Z(GJG_@SLO\ X]0!\*T5]U?\0U7[:G_1$]4_\&=E_P#'J/\
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M -[4_P#TV759O_$-5^VI_P!$3U3_ ,&=E_\ 'J^PO^""_P#P0_\ VH/V1?\
M@JE\,?'_ ,0OA;J'A[PCH37YOM0DO[618/,L9XDRJ2,QR[J.!WH _I0HHHH
M**** "BBB@ KA_AK_P E+\<?]?D'_HD5W%</\-?^2E^./^OR#_T2* .XHHHH
M **** "BBB@ HHKE_B[\9?#WP-\*?VQXCO&M;5YEMX(XH7GN+N9ONQ11("\C
MGLJ@G@GI0!U%%<#\'?VD_#/QMU#4K'2_[6L-5TE4DNM/U;3Y;"ZCC?.R0)(
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M\7?]#"I]Z_R#E1UG_"Y=5_YYV?\ WP?\:/\ A<NJ_P#/.S_[X/\ C7)T4?\
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M^^#_ (UR5%/_ (BMQ?\ ]#"I]_\ P Y4=;_PN;5O^>=I_P!\'_&C_A<VK?\
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M<VK?\\[3_O@_XUR5%<G_ !%;B_\ Z&%3[_\ @!9'6_\ "YM6_P">=I_WP?\
M&C_A<VK?\\[3_O@_XUR5%'_$5N+_ /H85/O_ . '*CYB_P""G7_!PYX9_P""
M57COPOX?\7> =<\67'BNPEU&WFTN[BMTMTCD\LJP<$DD\\5\Q?\ $;E\*O\
MHBOCK_P;6W_Q-?(G_!X7_P G)?!W_L6;O_TJ%?CQ7]U^%N98K,.%<'C,;-SJ
M3BW*3W;YI+7Y$L_I"_XC<OA5_P!$5\=?^#:V_P#B:/\ B-R^%7_1%?'7_@VM
MO_B:_F]HK] $?TA?\1N7PJ_Z(KXZ_P#!M;?_ !-'_$;E\*O^B*^.O_!M;?\
MQ-?S>T4 ?TA?\1N7PJ_Z(KXZ_P#!M;?_ !-'_$;E\*O^B*^.O_!M;?\ Q-?S
M>T4 ?TA?\1N7PJ_Z(KXZ_P#!M;?_ !-'_$;E\*O^B*^.O_!M;?\ Q-?S>T4
M?TA?\1N7PJ_Z(KXZ_P#!M;?_ !-'_$;E\*O^B*^.O_!M;?\ Q-?S>T4 ?TA?
M\1N7PJ_Z(KXZ_P#!M;?_ !-'_$;E\*O^B*^.O_!M;?\ Q-?S>T4 ?T17O_!Z
M!\+[KXEV.N#X-^-Q#:V4EJ8_[5M]S%F!S]WVKH/^(W+X5?\ 1%?'7_@VMO\
MXFOYO:* /Z0O^(W+X5?]$5\=?^#:V_\ B:/^(W+X5?\ 1%?'7_@VMO\ XFOY
MO:* /Z0O^(W+X5?]$5\=?^#:V_\ B:/^(W+X5?\ 1%?'7_@VMO\ XFOYO:*
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MYQJ* /Z0O^(W+X5?]$5\=?\ @VMO_B:/^(W+X5?]$5\=?^#:V_\ B:_F]HH
M_I"_XC<OA5_T17QU_P"#:V_^)H_XC<OA5_T17QU_X-K;_P")K^;VB@#^D+_B
M-R^%7_1%?'7_ (-K;_XFC_B-R^%7_1%?'7_@VMO_ (FOYO:* /Z0O^(W+X5?
M]$5\=?\ @VMO_B:/^(W+X5?]$5\=?^#:V_\ B:_F]HH _L*_X(^_\%XO"/\
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MRQY5>[:VWLE=Z@%%%%?G8!1110!^!7_!X7_R<E\'?^Q9N_\ TJ%?CQ7[#_\
M!X6?^,D_@[_V+-W_ .E0K\>*_P!'_!O_ )(S ?X'_P"ER(EN%%%%?IH@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"[!_^$\?\PL=I]M\&_\ /O>?D?\ &C[;X-_Y][S\C_C7%T4?\1,K?]"["?\
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M%-3_ .1#4[#_ (4Y/_T$K/\ S^-'_"G)_P#H)6?^?QKC_.?^^_\ WT:/.?\
MOO\ ]]&C_6/@[_H32_\ "FI_\B&IV'_"G)_^@E9_Y_&C_A3D_P#T$K/_ #^-
M<?YS_P!]_P#OHT><_P#??_OHT?ZQ\'?]":7_ (4U/_D0U.P_X4Y/_P!!*S_S
M^-'_  IR?_H)6?\ G\:X_P Y_P"^_P#WT:/.?^^__?1H_P!8^#O^A-+_ ,*:
MG_R(:G8?\*<G_P"@E9_Y_&C_ (4Y/_T$K/\ S^-<?YS_ -]_^^C0)7/\;_\
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M^879_7Q_PI&\_P"?RW_[X-'_  I&\_Y_+?\ [X-?R#_\/ZOVP_\ HX+XB?\
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M_@3;?_&J_$3_ (?U?MA_]'!?$3_P/_\ K4?\/ZOVP_\ HX+XB?\ @?\ _6H
M_;O_ (@N?V<_^AY^)_\ X$VW_P :H_X@N?V<_P#H>?B?_P"!-M_\:K\1/^']
M7[8?_1P7Q$_\#_\ ZU'_  _J_;#_ .C@OB)_X'__ %J /V[_ .(+G]G/_H>?
MB?\ ^!-M_P#&J/\ B"Y_9S_Z'GXG_P#@3;?_ !JOQ$_X?U?MA_\ 1P7Q$_\
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M1_Q!<_LY_P#0\_$__P ";;_XU7XB?\/ZOVP_^C@OB)_X'_\ UJ/^']7[8?\
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MX+XB?^!__P!:@#]N_P#B"Y_9S_Z'GXG_ /@3;?\ QJC_ (@N?V<_^AY^)_\
MX$VW_P :K]"O^"6/Q*U[XQ?\$Z?@WXI\4:I=:UXAU[PO:7FH7]RVZ:[F9,L[
M'N37OM 'X\?\07/[.?\ T//Q/_\  FV_^-4?\07/[.?_ $//Q/\ _ FV_P#C
M5?L/10!^,/C[_@S8_9W\*^"M4U*'QQ\36EL;9YD#7%L5) R,_NJ_2K_@G#^Q
M1X;_ ."?7[(OAGX8^$]0U74]%TD2745QJ+*UP[3N96SM & S'''2O3?C1_R2
M?Q#_ ->,G\JU_"?_ "*NF?\ 7I%_Z * -"BBB@ HHHH **** "BBB@ HHHH
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M_P#I0]<#7??M4?\ )S/Q!_[&*_\ _2AZX&O]9,'_  (>B_(S"BBBN@ HHHH
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M[]"C_B9+A3^2M_X!'_Y,.5G\SO\ Q"'?MC?] GX?_P#A2K_\;H_XA#OVQO\
MH$_#_P#\*5?_ (W7],7_  MK6O\ GM#_ -^A1_PMK6O^>T/_ 'Z%'_$R7"G\
ME;_P"/\ \F'*S^9W_B$._;&_Z!/P_P#_  I5_P#C='_$(=^V-_T"?A__ .%*
MO_QNOZ8O^%M:U_SVA_[]"C_A;6M?\]H?^_0H_P")DN%/Y*W_ (!'_P"3#E9_
M,[_Q"'?MC?\ 0)^'_P#X4J__ !NC_B$._;&_Z!/P_P#_  I5_P#C=?TQ?\+:
MUK_GM#_WZ%'_  MK6O\ GM#_ -^A1_Q,EPI_)6_\ C_\F'*S^9W_ (A#OVQO
M^@3\/_\ PI5_^-T?\0AW[8W_ $"?A_\ ^%*O_P ;K^F+_A;6M?\ /:'_ +]"
MC_A;6M?\]H?^_0H_XF2X4_DK?^ 1_P#DPY6?S._\0AW[8W_0)^'_ /X4J_\
MQN@?\&AW[8W_ $"?A_\ ^%*O_P ;K^F+_A;6M?\ /:'_ +]"C_A;>M?\]H?^
M_0H_XF2X4_DK?^ 1_P#DPY6?S&>%_P#@TU_:\\7:2+RSTGP'Y)D>+Y_$2J<H
MQ4\;/4&M'_B$._;&_P"@3\/_ /PI5_\ C=?TH^&/&=_X0TK['8R(L'F/+AD#
M'<S%CS]36C_PMK6O^>T/_?H4?\3)<*?R5O\ P"/_ ,F'*S^9W_B$._;&_P"@
M3\/_ /PI5_\ C='_ !"'?MC?] GX?_\ A2K_ /&Z_IB_X6UK7_/:'_OT*/\
MA;6M?\]H?^_0H_XF2X4_DK?^ 1_^3#E9_,[_ ,0AW[8W_0)^'_\ X4J__&Z/
M^(0[]L;_ *!/P_\ _"E7_P"-U_3%_P +:UK_ )[0_P#?H4?\+:UK_GM#_P!^
MA1_Q,EPI_)6_\ C_ /)ARL_F=_XA#OVQO^@3\/\ _P *5?\ XW1_Q"'?MC?]
M GX?_P#A2K_\;K^F+_A;6M?\]H?^_0H_X6UK7_/:'_OT*/\ B9+A3^2M_P"
M1_\ DPY6?S._\0AW[8W_ $"?A_\ ^%*O_P ;H_XA#OVQO^@3\/\ _P *5?\
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M+A3^2M_X!'_Y,.5G\SO_ !"'?MC?] GX?_\ A2K_ /&Z/^(0[]L;_H$_#_\
M\*5?_C=?TO77QAUJVM99/-A;RD9\>4.<#-?C;X[_ .#U>[\#^-]9T5O@7!<-
MH]]/9&7^WBOF^5(R;L>7QG;G%??<#>)F4\5RK1RR,U[+E<N>*7Q7M:TGV=Q6
M/B&?_@TW_:\M_%-OH[:3X#^V7,#7*8\1+MV*0#D[.N36E_Q"'?MC?] GX?\
M_A2K_P#&Z^F[O_@].N+KX@V>N_\ "B[<&UM)+7R_[>;YMS YSY?M6Y_Q&_W/
M_1!8/_"@/_QNOT(#Y(_XA#OVQO\ H$_#_P#\*5?_ (W1_P 0AW[8W_0)^'__
M (4J_P#QNOK?_B-_N?\ H@L'_A0'_P"-T?\ $;_<_P#1!8/_  H#_P#&Z /D
MC_B$._;&_P"@3\/_ /PI5_\ C='_ !"'?MC?] GX?_\ A2K_ /&Z^M_^(W^Y
M_P"B"P?^% ?_ (W1_P 1O]S_ -$%@_\ "@/_ ,;H ^2/^(0[]L;_ *!/P_\
M_"E7_P"-T?\ $(=^V-_T"?A__P"%*O\ \;KZW_XC?[G_ *(+!_X4!_\ C=?7
M_P#P1?\ ^#C2;_@K3^TUJGP]D^&4?@]=-T635OMJZI]JW['1=FW8O7=G/M0!
M^1/_ !"'?MC?] GX?_\ A2K_ /&Z/^(0[]L;_H$_#_\ \*5?_C=?U>44 ?RA
M_P#$(=^V-_T"?A__ .%*O_QNC_B$._;&_P"@3\/_ /PI5_\ C=?U>44 ?RA_
M\0AW[8W_ $"?A_\ ^%*O_P ;I#_P:'_MC ?\@CX?_P#A2K_\17]7M% 'BO\
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M=D56[5Y_\#_V0_&7CZZ^':ZEJ'Q ^&<VF_#1+*>ZT:]^R26]Z;N1C;RD9W[
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MD?\ *2SQ5_V)MQ_Z.BK\A:_7K_@S(_Y26>*O^Q-N/_1T5 ']05%%% !1110
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MO1_PDOA/_H$O_P!\_P#UZ/\ 4'+O^ASA?OJ?_*PN<717:?\ "2^$_P#H$O\
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MO1_J#EW_ $.<+]]3_P"5A<XNBNT_X27PG_T"7_[Y_P#KT?\ "2^$_P#H$O\
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MC_A)?"?_ $"7_P"^?_KT?Z@Y=_T.<+]]3_Y6%SBZ*[3_ (27PG_T"7_[Y_\
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M7_H K(^-'_))_$/_ %XR?RK7\)_\BKIG_7I%_P"@"@#0HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQA_V'+W_ -'O7*UU7QS_ .2V>,?^PY>_^CWKE:_UDH_PX^B,PHHHK0 HHHH
M**** "OZ6/\ @R?_ .3)?BK_ -C;%_Z3"OYIZ_I8_P"#*#_DR7XJ_P#8VQ?^
MDPH _:2BBB@ HHHH **** "BBB@ HHHH YCXT?\ ))_$/_7C)_*M?PG_ ,BK
MIG_7I%_Z *R/C1_R2?Q#_P!>,G\JU_"?_(JZ9_UZ1?\ H H T**** "BBB@
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M[2G:_>W/N',<#17??\*.;_H(?^0Z/^%'-_T$/_(=9_\ $#^-?^@+_P GI_\
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M_#SO]HC_ *+5\2O_  ?7'_Q5?TD_\%[O^40WQM_[!5M_Z76]?R@U_9WT9?\
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MOBCXU\1>"]2T*UT6_P!.>'39Y7N"\Z!5(#*!@$<\T ?MK1110 4444 %%%%
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M^"T/CC_@E+\(/"/BC0_#&@^-)?$VJR:;+!JL\L"6ZI%O#J8^22>,'C%?G/\
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M/<?^DXK^?BOZ(/\ @[%^'/B+XD_LL_#*V\.:#K7B"XM_$D[RQ:;8RW3Q*;<
M%A&I(&>,FOP=_P"&4OBE_P!$U\??^$]=_P#QNO\ 07Z/_P#R1>'_ ,53_P!+
MD3+<X&BN^_X92^*7_1-?'W_A/7?_ ,;J.?\ 9<^)MKM\WX=>.H_,8*N[0+M=
MQ/8?N^M?M!)PM%=]_P ,I?%+_HFOC[_PGKO_ .-T?\,I?%+_ *)KX^_\)Z[_
M /C= ' T5WW_  RE\4O^B:^/O_">N_\ XW1_PRE\4O\ HFOC[_PGKO\ ^-T
M<#17??\ #*7Q2_Z)KX^_\)Z[_P#C='_#*7Q2_P"B:^/O_">N_P#XW0!P-%=]
M_P ,I?%+_HFOC[_PGKO_ .-T?\,I?%+_ *)KX^_\)Z[_ /C= ' T5WW_  RE
M\4O^B:^/O_">N_\ XW1_PRE\4O\ HFOC[_PGKO\ ^-T <#17??\ #*7Q2_Z)
MKX^_\)Z[_P#C='_#*7Q2_P"B:^/O_">N_P#XW0!P-%=]_P ,I?%+_HFOC[_P
MGKO_ .-T?\,I?%+_ *)KX^_\)Z[_ /C= ' T5WW_  RE\4O^B:^/O_">N_\
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MJAL/$NGZIJ-Q9VU]:W%U9G$\,<H9XO\ > Y% %ZBJMMKEE>7=U;PWEK+<6)
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M1#E.W_X6%H/_ $ Q^2T?\+"T'_H!C\EKB**/^(O9_P!J/_@BE_\ (ARG;_\
M"PM!_P"@&/R6C_A86@_] ,?DM<%J.I6VCV,EU>7%O:6L(W2332"..,>I8X _
M&FZ5J]GKUA'=V-W:WUK+]R:WE66-_HRD@T?\1<X@M?EHV_Z\4O\ Y .4[_\
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MA_V?/^2=+_U^W/\ Z.:NXH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?+DPTQ RTP;!#C PH&*\T^"WQE\4?!;]FWX=R>&O&DGB+^WM!UO[7IACC9-
M6V@FEBG4 ;EV2*D9W\,9*_0/_A$]+V,O]FV.UKDWA'D+S,?^6O3[_P#M=:SM
M(^$OA7P_/=26'AO0K.2^B,%PT%C%&9XSU1L+RI[@\&@#Y9T7QIXV?QCX>\*:
M_P#$[5-%L;[P1_PESZ])#!"U[>R,%:W0L-@AA4!]@^8B09.!FO;/V4/'NJ_%
M7X=^&?$FMZTK:KJ_AZWFN-)5%C56+O\ Z6$^^OF>AXXXKT'Q'\./#_C"PM;7
M5M#TG4K:Q_X]XKJTCE2#@#Y0P(7@ <>E)8?#S2=,\:S>((+2./4Y["+3#(H
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MP=^S7X<L=>_X*V?M@&\OULS&WA0+DCYLZ2F>M?>-?GC\&^?^"M_[77U\+?\
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M (Y1_P -9?%3_HI?Q _\*&[_ /CE ']7W_$,C^Q7_P!$GA_\&]W_ /'*<O\
MP;'_ +%K=/A-&?IJ]W_\<K^3_P#X:R^*G_12_B!_X4-W_P#'*_;C_@RY^+OB
MSXF_&+XX+XD\4>)/$*6NC:<84U/4Y[M829Y<E1(Q"D]R.M 'Z$?\0QG[%W_1
M)8__  ;7?_QRC_B&,_8N_P"B2Q_^#:[_ /CE??E% 'P'_P 0QG[%W_1)8_\
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M +/G_).E_P"OVY_]'-7<5P_[/G_).E_Z_;G_ -'-7<4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!PNL?\G#Z-_P!@>?\ ]#6NZKA=8_Y.'T;_
M + \_P#Z&M=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',?&
MC_DD_B'_ *\9/Y5K^$_^15TS_KTB_P#0!61\:/\ DD_B'_KQD_E6OX3_ .15
MTS_KTB_] % &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %</\
M#7_DI?CC_K\@_P#1(KN*X?X:_P#)2_''_7Y!_P"B10!W%%%% !1110 4444
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M1ZI<:O?+"DLDTQDD7RX 7"JJY+ %LC@5[I7D?Q._8^TWQ_X[U+Q%I/C#X@>
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MG9M.P'PG_P )E_P4L_Z$S]FG_P &UY_A1_PF7_!2S_H3/V:?_!M>?X5]V?\
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M>W- 'G__  F7_!2S_H3/V:?_  ;7G^%'_"9?\%+/^A,_9I_\&UY_A7L6I?\
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M==\33^)/$-CX9T_3M(C62YN+N[<I$ &(&W(Y.>!7DDW_  5BT/1O"6H2:O\
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M!U%>U?L_?M :-^T3\!M"^(.DPWEGI.N6;7?D7D?EW%H49DDCD7LR.CJ<=UH
M^,?^$R_X*6?]"9^S3_X-KS_"C_A,O^"EG_0F?LT_^#:\_P *],\"?\% ]0\*
M_LGW7QQ\76FI:]X>\;>*HM-\(:#HUBOVR"RGO!8V8.6'F22L/-/3 D"CI6M)
M_P %2M&\/^'?%'_"2?#[QYH?BWPCK&EZ3>>%UMH[S4IAJ3[+.:$1,5D20[A\
MIR"C ]* /'?^$R_X*6?]"9^S3_X-KS_"C_A,O^"EG_0F?LT_^#:\_P *]+^)
MG_!7?0?A0\ECK/@/Q-I_B+2='_M_Q!HUY>V5K=Z'9&21(V(>4":218FD6*(L
MVW&>3BO8_#7[=/PE\7OI5OI_CG0;C5M;T9-?L=)6Y7^T;BS:V^U+(MOG?_J<
MMC&<"@#Y1_X3+_@I9_T)G[-/_@VO/\*/^$R_X*6?]"9^S3_X-KS_  KIO'7_
M  5TU/Q;^Q%X\^+7P[^'.LW.GZ/X>EUO0]0NKRSFM[H*X4">))3);O@E_+E"
MMA3W&*]X^#?[7[>/O%VA^%]>\(ZYX4\4:MX8F\3M:W;PR+';Q310GYHV899I
M00/0'.#0!\P_\)E_P4L_Z$S]FG_P;7G^%9>B3?\ !2;0]<U:_C\(?LV-)JTB
M2R*=4NP$*J%&,#T'>O?-<_X*76&NZ1X=M_ G@?Q9XV\1>)?#TWB8Z=9>1"VD
MV".8EFG>1P@+2#"H"6;!QTKGOV*O^"EEGXT_9E\"ZC\2IVM?%FI?#"/XB7UX
MD"PVFH0H2MT(5S]^(^7N7TE2@#P+XG_MX_MN_LE?%'X0Q_%SP;\#H_"/Q(\>
M:5X-FET*_NIKR W<P4NJM@<*&.?7%?I]7YP_\%B?'K?%/X;?L8>)6TG4-#.O
M?&OPG?C3[]0MU9B5RX24 D!P",C/!XK]'J "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O@']G_PO?>(O^"MW[7WV.'S?+/A4-\P&,Z2E
M??U?G_\  7Q#>Z'_ ,%;OVO/LMP\/F'PKNV]\:2E?F?B\\M7"V(>;J;HWAS>
MSY>?XXVMS:;VO?H-'T__ ,*QUK_GS_\ 'Q1_PK'6O^?/_P ?%0_\+!UG_G_F
M_3_"C_A8.L_\_P#-^G^%?Q?[3P[_ ),9]]'_ "'J3?\ "L=:_P"?/_Q\4?\
M"L=:_P"?/_Q\5#_PL'6?^?\ F_3_  H_X6#K/_/_ #?I_A1[3P[_ ),9]]'_
M "#4F_X5CK7_ #Y_^/BC_A6.M?\ /G_X^*A_X6#K/_/_ #?I_A1_PL'6?^?^
M;]/\*/:>'?\ )C/OH_Y!J3?\*QUK_GS_ /'Q1_PK'6O^?/\ \?%0_P#"P=9_
MY_YOT_PH_P"%@ZS_ ,_\WZ?X4>T\._Y,9]]'_(-2;_A6.M?\^?\ X^*/^%8Z
MU_SY_P#CXJ'_ (6#K/\ S_S?I_A7XL_\%3O^#GG]HG]A[]N/QI\,_">F_#N^
MT'PW)"EK-J>ES373AXE<[V690>6[**^YX!X'X'XKQT\!@GBH2A'G;E*E:R:5
MM(O74-3T/_@J#_P:Q_%+_@H/^V?XG^*FC_$?P+X:T_Q!';1QZ?J,%U)<0^5"
MD1W&-"O)7(P>AKY]_P"(([XS?]%E^&/_ ("7W_QNO.?^(RW]JO\ Z ?PE_\
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MP9T70[N/5/AE\2M%;0=8DA6YM[W1XM6CNXKW9N7=Y$)*R1DJ283V85[7H?\
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MG_T<U??M? 7_  7C_P!=^R?_ -E[\,_^CFK[]H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_/'X-?\ *6_]KKZ^%O\ TTI7Z'5\&_LU
M^+8?#7_!6S]L 2V,5YYK>%"-^/EQI*>WO7YGXOX/"8KA7$4,=75"FW"\W%SM
M:<6O=CJ[O3RO<:W/<J*[;_A:UG_T!;7\E_PH_P"%K6?_ $!;7\E_PK^+/]4>
M%?\ H>1_\)ZI1Q-%=M_PM:S_ .@+:_DO^%'_  M:S_Z MK^2_P"%'^J/"O\
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M&JE%M^\[Z6ML)L_FW_X=@_M&?]$/^*7_ (3=U_\ $4?\.P?VC/\ HA_Q2_\
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MK?E0!] ?\/7_ -IC_HO'Q4_\*.Y_^+H_X>O_ +3'_1>/BI_X4=S_ /%U\_\
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MYD\T2>86.[ PG?\ 5K[!;K'M\F$+O\S&P8W>OU]ZQ8]>\,^*O&][HXFTJ_\
M$'AV.&>YMF59+BP6;<8F((RH?8V#WVF@#\Q_%_Q-^(WB+]JWQG'JGQ8\)^ /
M&&D?$&VAT:UUG6]4@N1I*&+9!;Z='";:XAN5:0;R6;)Y9<5V/A[1_%5GJ$'Q
M,;QE\1IO$7_"_1X=6TFU:9M.BT>2Z$+VHM?]68=ISN8%@1D,!Q7Z.W&B65WJ
M$5W-9VLMU!Q',\2M)']&QD?A62GC709/B WA-9H/[<CL_P"UVM/*/$/F>7YN
M<8SO..N: /F?_@L9\-=,^,7P5^%_A?7--_M;0]>^*GARRU&V\LN'MWG=7SCI
M@'.>Q -?&/BNY\5>'?$O[0WPQ\4:7JT>I_"+X)W'A_3]6GB::/7=+.H))872
MOCYW$(*.O7,)SUK]9O'?Q!T'P*^C)K=U%;G6]2ATS3P\9?SKJ0GRT& <$X/)
MP!ZU-X5\2Z#\1]';5-(NM/U>RF>6T:XAVR(YC=DDC)[[75@1Z@T ?G?^R/\
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M"L?Q$U9O'4-MK,/CN*3S)+JPFATV[ -\I'WDF56"MR2H(S6]_P $[?VH=/\
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MH1& 3SS7,>'O''CR_LF\-VWC:^CTJZ\5:/9)>:;K!U:YMHKA)3<1_:VA52&
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M$7C#4K'XLZ=>:G?&.WT,FX6;S8';R;>-(Q;^0\2JV3\I))K]5$18T"JH55&
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MA/-8RIXRFUO7-:CM;77DLH0MM=30L;B%5<2!8\K&' &.U?KK'"D(.Q%7)+'
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M@"-+6*,R%8XU,QS(0H^<XQSZ\>M,MM,MK-E,-O!$8T\M2D87:O7:,=O:IZ*
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M?M _L;? _P#:O\(6_A_XE:+I_C/0[6Y6\ALK^5Q'', 0'&PJ<@$CKCFO'/\
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MKQ/I_A?X2^+;S0XK[3TMYOM<4;6R1Q"/SM[3EI]QP NTKSG(KW7]CK]E&/\
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M2^,G[7?A7PKX5\$ZQKWP^\8>!++Q?::U"(8I+47%PL>^59)581HK8954L&Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+T;]D;0[3[/-J6M>*/$&H6^JVVK+>ZC>J\IDMU98DPJ*@0!CD!023DFO5J*
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M+[+Y*LN"#(^[.[VZ5ZP'WY1110 5P?QV_P!5X7_[#MM_[-7>5P?QU&8O"_\
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M>&;Y/-D/5VQ#RQQR3S7VO_PK+PW_ -"]H?\ X 1?_$T?\*R\-_\ 0O:'_P"
M$7_Q- 'QA_Q$C?LA_P#11K__ ,)V_P#_ (U1_P 1(W[(?_11K_\ \)V__P#C
M5?9__"LO#?\ T+VA_P#@!%_\31_PK+PW_P!"]H?_ ( 1?_$T ?&'_$2-^R'_
M -%&O_\ PG;_ /\ C5'_ !$C?LA_]%&O_P#PG;__ .-5]G_\*R\-_P#0O:'_
M . $7_Q-'_"LO#?_ $+VA_\ @!%_\30!\8?\1(W[(?\ T4:__P#"=O\ _P"-
M4?\ $2-^R'_T4:__ /"=O_\ XU7V?_PK+PW_ -"]H?\ X 1?_$T?\*R\-_\
M0O:'_P" $7_Q- 'QA_Q$C?LA_P#11K__ ,)V_P#_ (U1_P 1(W[(?_11K_\
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M_P#H7M#_ / "+_XF@#XP_P"(D;]D/_HHU_\ ^$[?_P#QJC_B)&_9#_Z*-?\
M_A.W_P#\:K[/_P"%9>&_^A>T/_P B_\ B:/^%9>&_P#H7M#_ / "+_XF@#XP
M_P"(D;]D/_HHU_\ ^$[?_P#QJC_B)&_9#_Z*-?\ _A.W_P#\:K[/_P"%9>&_
M^A>T/_P B_\ B:/^%9>&_P#H7M#_ / "+_XF@#XP_P"(D;]D/_HHU_\ ^$[?
M_P#QJC_B)&_9#_Z*-?\ _A.W_P#\:K[/_P"%9>&_^A>T/_P B_\ B:/^%9>&
M_P#H7M#_ / "+_XF@#XP_P"(D;]D/_HHU_\ ^$[?_P#QJC_B)&_9#_Z*-?\
M_A.W_P#\:K[/_P"%9>&_^A>T/_P B_\ B:/^%9>&_P#H7M#_ / "+_XF@#XP
M_P"(D;]D/_HHU_\ ^$[?_P#QJC_B)&_9#_Z*-?\ _A.W_P#\:K[/_P"%9>&_
M^A>T/_P B_\ B:/^%9>&_P#H7M#_ / "+_XF@#XP_P"(D;]D/_HHU_\ ^$[?
M_P#QJC_B)&_9#_Z*-?\ _A.W_P#\:K[/_P"%9>&_^A>T/_P B_\ B:/^%9>&
M_P#H7M#_ / "+_XF@#XP_P"(D;]D/_HHU_\ ^$[?_P#QJC_B)&_9#_Z*-?\
M_A.W_P#\:K[/_P"%9>&_^A>T/_P B_\ B:/^%9>&_P#H7M#_ / "+_XF@#XO
M;_@Y(_9#1<M\2+Y0.I/AZ_X_\A4H_P"#D?\ 9#(_Y*/??^$]?_\ QJOJGXR?
M#7P[%\*O$#+X?T166QD((L8N./\ =K7\*_#/PVWA?32?#^AY-K%G_0(O[@_V
M: /C_P#XB1OV0_\ HHU__P"$[?\ _P :H_XB1OV0_P#HHU__ .$[?_\ QJOL
M_P#X5EX;_P"A>T/_ , (O_B:/^%9>&_^A>T/_P  (O\ XF@#XP_XB1OV0_\
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M,C;V;)P<B@#F?^'=G[0'_1Z'Q(_\)72?_C='_#NS]H#_ */0^)'_ (2ND_\
MQNOLRB@#XS_X=V?M ?\ 1Z'Q(_\ "5TG_P"-T?\ #NS]H#_H]#XD?^$KI/\
M\;K[,HH ^,_^'=G[0'_1Z'Q(_P#"5TG_ .-T?\.[/V@/^CT/B1_X2ND__&Z^
MS** /C/_ (=V?M ?]'H?$C_PE=)_^-T?\.[/V@/^CT/B1_X2ND__ !NOLRB@
M#XS_ .'=G[0'_1Z'Q(_\)72?_C='_#NS]H#_ */0^)'_ (2ND_\ QNOLRB@#
MXS_X=V?M ?\ 1Z'Q(_\ "5TG_P"-T?\ #NS]H#_H]#XD?^$KI/\ \;K[,HH
M^,_^'=G[0'_1Z'Q(_P#"5TG_ .-T?\.[/V@/^CT/B1_X2ND__&Z^S** /C/_
M (=V?M ?]'H?$C_PE=)_^-T?\.[/V@/^CT/B1_X2ND__ !NOLRB@#XS_ .'=
MG[0'_1Z'Q(_\)72?_C=>5_M3_L2?M/>";?P.=!_:>^)GC(ZEXJL[*]5/"VF#
M^R+9P^^].R/I'@<'CYJ_2"OD_P#:[_:(\26_Q\U#P5H.H^+M%MO"_A0^)KNZ
M\/Z=#=S,YD=09A,"I@14W%$_>.20.E &(?\ @G9^T!G_ )/0^)'_ (2FD?\
MQND_X=V?M ?]'H?$C_PE=)_^-U]5_";Q6OCGX8^']834+?55U*PAN/MD$9CC
MN=R [U4\J#UP>G2NAH ^,_\ AW9^T!_T>A\2/_"5TG_XW1_P[L_: _Z/0^)'
M_A*Z3_\ &Z^S** /C/\ X=V?M ?]'H?$C_PE=)_^-T?\.[/V@/\ H]#XD?\
MA*Z3_P#&Z^S** /C/_AW9^T!_P!'H?$C_P )72?_ (W1_P .[/V@/^CT/B1_
MX2ND_P#QNOLRB@#XS_X=V?M ?]'H?$C_ ,)72?\ XW1_P[L_: _Z/0^)'_A*
MZ3_\;K[,HH ^,_\ AW9^T!_T>A\2/_"5TG_XW1_P[L_: _Z/0^)'_A*Z3_\
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M&_\ AW9^T!_T>A\2/_"5TG_XW1_P[L_: _Z/0^)'_A*Z3_\ &Z^S** /C/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIIE4'[R_G10 0_ZL
M?C3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
)"F.E%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>nbx-20211231_g27.jpg
<TEXT>
begin 644 nbx-20211231_g27.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M4G6W\V"WB+MY-N3:PE8RSD%<EF9F9O2J "BBB@ HHHH **** "BBB@ HHHH
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MX3?LO3>(_ 6BMKE]K=K>:')=6VEWUXV[6+[1[O9)<Z=K"2!XYG:3<CNK/O\
M)BF1T=C7O6AZ%9^'-)MM/L;2UL;"QB2WMK:WB$4-M&@VJB(H 50H     &*
M,SX:_#+0_A%X.L] \/:;:Z7I5BN(X8EY=CR\CMU>1V)9Y&)9V)9B22:H?%CX
MPV'PIT@S36.KZUJ#P27-KI&DV_VC4=02-XEE\B+(WE!,C%0<[02 <&J_QR^/
M7AWX ^#UU?Q!=30K<3"UL[>&WEN)[VX*LRQ)'$KN20C'(4@ &O$_ ]MX^_:A
M\2:??>+-/;PWH=WID6N>&]5T:X,6H>#-:MII(9X)8YXL-(\5VT)8&:WN([2<
ME$24*X!A^*_"_BG]LJXNO#-K\0M2O/".H)8^([;7-(TD6^DS6DTS>;IAFCE2
M8R"&-0N'8XN)#/&ZM&H^E/A-\&_#_P &/#<>GZ#IUK:[HXQ=W2P1QW.IRJ@4
MSW#(JB29L%F<CEF8]S6AX&\"Z;\/O#D.EZ78V-C9Q%Y3':VZP))-(QDEE*J/
MOR2,[LQR69V)))).T.*  #%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% #9T,D+*IPS# /I7SB/V*;4^*+R7QMKTWB;PS8
MM/-#<ZS=[[FZCNW2>:*X(")&\-U;V\MO<P^6Z)^Y"A4!/N'Q-^*?AWX.>$IM
M<\4:Q8Z#H\,T-O)>WD@BACDFE6*(,QX&Z1U4$\9-?&(^-WB;]N7XU6NFZ=IE
MBWA_39GO_#LV);K3XIHA()%U6-)'MKN,[#;R+F.2WDFBD@^T)(DZ@'4>._VH
M=2\5^*?^%>?#:W\1>$[71["#4="UJPTN34(-5"ND<<,T30,%MI9/M$6YIHW:
M:U9)'A62-I/H'X/?"*ST35;[QM>:##HOCCQQ8V3>)TBO9+F)YX8@H0;B5Q&"
M4!0 %0,YP#47[/G[+'A+]FW1I+3PWI<5IYEQ=S@YRMJEQ<O<-#"@ 2*,%E7$
M:KO$,9;<5!'I0&T<4 -)6,].6]*\O_:!_:K\*_ 233[35-5TZ'5-2EA6.WN+
MM8$MX'E"/=S,?N01*'=W[+&YX"LR^@^*O#L/BWP_?Z7<FX6UU*UEM)FM[A[>
M8)(I1BDB$,C8)PRD$'!!!YKP+]E[_@GSIGP&U:'5-6U:]\1:QI<EQ%ITRO'9
M6\5NUS).F8+>.)2Q+*61_,B65&DC6,R,H .?^!?[->N?M#:E:^.OBQ-=:HLD
M0-IHMXEM-I]U%-;V4AF2+#M L=U 6A*-$[1K&TL0E,CR?4UAIEOI=E#:VUO#
M;VUM&L4,42!(XD48554<     < 5,B;1[GK3J "BBB@ HHHH **** "BBB@
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M*R1;?.+3'G>> * /9**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .+
MD^/GABU\4:II,U]/"VAJQU&]DM)4TZR98TD:.2Z*^2KA)$)4OD;@.O%1:_\
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MC+PWXATD6NN:CXE\02?8H].^UWMW']H^SQ)=)$FZ.- =J7DJ[B-[?*69FR6
M.C\+_M*>$?%_BW2-!L=7AFUK6([N:&PR/M$<=NY21Y(\[D4L,*Q&&[4OP[_:
M9\%_$^VNIM,UE8OLC1ATU&"33Y&60(8I%6=4+QOYL>UU!5BZ@')Q6#X8_8P\
M%^%O&G]M1P:A>*9)K@Z?>2I<637$NS?<%&3<TA6.)1EBJ^4I50Q9FSM=_8/\
M#WO@_2]%TR&\\/6^E1NN=.,<9U$M)!-NNODS*1+;6[DY5F,>TL5+*0#;U+XQ
M?"_XZW.I>!IM?\,^(;?6--9IK5;Z*6"_@8SI(J.K?,T?D2E@AW1[0Q(X-/\
MAIXL^%?PK\/?8=&\3^"[99F66ZN%U2U%QJ4P1(S<7#JP,T[*BAI&RS;1DUQO
MP._X)_\ AOX7>!+'1]8N)-?^QQ&V!"/;P&W,=W'Y)5I))'RM]=%FDE9B9.H5
M44>8I_P;S_L8JNU?@+X7PO'_ !^7W&/^V] 'U'_POSP+_P!#IX3_ /!O;_\
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M+]:_\+WQ%_\ )U&H'W+_ &M:_P#/U;_]_!1_:UK_ ,_5O_W\%?#(_P"#:_\
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M2[6O_"]\1?\ R=35_P"#:_\ 8U?I\+]:_P#"]\1?_)U&H'W-_:UK_P _5O\
M]_!1_:UK_P _5O\ ]_!7PW_Q#6?L;?\ 1+M:_P#"]\1?_)U'_$-9^QM_T2[6
MO_"]\1?_ "=1J!]R?VM:_P#/U;_]_!1_:UK_ ,_5O_W\%?#?_$-9^QM_T2[6
MO_"]\1?_ "=1_P 0UG[&W_1+M:_\+WQ%_P#)U&H'W)_:UK_S]6__ '\%-.IV
M9/\ Q\6__?P?XU\._P#$-9^QM_T2[6O_  O?$7_R=1_Q#6?L;?\ 1+M:_P#"
M]\1?_)U&H'W'_:=GG_CXM_\ OX/\:3^T;/\ Y^+?_OX/\:^'?^(:S]C;_HEV
MM?\ A>^(O_DZC_B&L_8V_P"B7:U_X7OB+_Y.HU ^XO[2L_\ GXM_^_@_QI?[
M3L\_\?%O_P!_!_C7PU_Q#7_L:@_\DOUK_P +WQ%_\G4[_B&M_8U/_-+]:_\
M"]\1?_)U&H'W%_:=G_S\6_\ W\'^-+_:EI_S\V__ '\'^-?#G_$-9^QM_P!$
MNUK_ ,+WQ%_\G4?\0UG[&W_1+M:_\+WQ%_\ )U&H'W)_:UK_ ,_5O_W\%']K
M6O\ S]6__?P5\-_\0UG[&W_1+M:_\+WQ%_\ )U'_ !#6?L;?]$NUK_PO?$7_
M ,G4:@?<G]K6O_/U;_\ ?P4?VM:_\_5O_P!_!7PW_P 0UG[&W_1+M:_\+WQ%
M_P#)U'_$-9^QM_T2[6O_  O?$7_R=1J!]R?VM:_\_5O_ -_!1_:UK_S]6_\
MW\%?#9_X-K?V-0/^27:U_P"%[XB_^3J:?^#;']C7_HE^M=<?\C[XB_\ DZC4
M#[F.L6@_Y>K?_OX/\:/[7M?^?JW_ ._@K\C_  !_P2W_ &)/B7IEEJVC_!75
M+CPVWB-M#U'5D^)OB&:'38I/L[6-RRQW3-_I4=U"0I 6-BRNXQFOHP?\&UO[
M&Q_YI=K?_A>^(?\ Y.HU ^Y/[6M?^?JW_P"_@H_M:U_Y^K?_ +^"OAO_ (AK
M/V-O^B7:U_X7OB+_ .3J/^(:S]C;_HEVM?\ A>^(O_DZC4#[D_M:U_Y^K?\
M[^"C^UK7_GZM_P#OX*^&_P#B&L_8V_Z)=K7_ (7OB+_Y.H_XAK/V-O\ HEVM
M?^%[XB_^3J-0/N3^UK7_ )^K?_OX*/[6M?\ GZM_^_@KX;_XAK/V-O\ HEVM
M?^%[XB_^3J/^(:S]C;_HEVM?^%[XB_\ DZC4#[D_M:U_Y^K?_OX*/[6M?^?J
MW_[^"OAH_P#!M=^QJ#_R2_6O_"]\1?\ R=2_\0UG[&W_ $2[6O\ PO?$7_R=
M1J!]R?VM:_\ /U;_ /?P4?VM:_\ /U;_ /?P5\-_\0UG[&W_ $2[6O\ PO?$
M7_R=1_Q#6?L;?]$NUK_PO?$7_P G4:@?<G]K6O\ S]6__?P4?VM:_P#/U;_]
M_!7PW_Q#6?L;?]$NUK_PO?$7_P G4?\ $-9^QM_T2[6O_"]\1?\ R=1J!]R?
MVM:_\_5O_P!_!1_:UK_S]6__ '\%?#?_ !#6?L;?]$NUK_PO?$7_ ,G4?\0U
MG[&W_1+M:_\ "]\1?_)U&H'W)_:]I_S]6_\ W\'^-</\:?VJ_AS^SF?#Y\=>
M,_#_ (3A\5:B-)TR?4KH06]S=&-Y!$93\B,51B-Y4$C )) /RG_Q#6_L;8_Y
M)?K7_A>^(O\ Y.KSG]H?_@U>_9M^*5KX=M?!MMXC^&\%CJ8NM9GM=<U#6+G5
M;01NOV6/[?<30P,796\T1L0$(QAJ /TMM;V*]MXYH9%EBF4.CH=RNIY!!'!!
M'.17+?&+XX^%O@%X:76O&&M6N@Z2\RVRW%P&*M*P8JGR@G)"L?PK#_9/_9.\
M$_L5_!+2?A_\/]/O=-\-Z/EH8KO49[Z5G;&]VDF=FRQ&=HPHS\JJ.*X;_@I#
M^RUKO[7?P)M?"_AV^TRPU"#5H;\R7SNL1C2.52,JK')+CMZ\UG4E)0;@KL[<
MMHT*N*IT\3+E@VDWV75GHOP;_:9\#_M"VFH7'@OQ'9^(+?2BHNW@#*MN6!*[
MMP'4*?RKK] \26'B?3%O=-OK74;.0D)/:S+-$V#@X921P?>OD[_@GG^P+XJ_
M97^'_P 0-$\2:IHMR_C")(H)-/:25(1Y4D9+!E7H7!P#S[5L^$OV"O%'A];!
MX_&EOIC*UL;J'28[FSAMVMX+2W$MN$F'[V:*U*2-(",3G: 5RTT92E!.:LS?
M.<-A:&,G2P53VE-/27=6/J&YOH;*"26:1888@6=W.U4 Y))/  '.34@D4KN[
M>M?,/AW]ACQA;^'_ !-8ZY\2;W6HM>\&7?A6U@D@"VM@TZ&,2M&,&8@ ,6++
MEFDVHH;C6U#]D?QUXC\::YX@NOB1J6G7>K"U2VM-.DD2QTV)8U@N(DCRK-NC
M\YD=V)228,!\OS;'EGT!)J]O#J$-H\T*W5PCR10EP))50J'95ZD+O7)' W#U
M%,'B*Q.FB\^V6OV-C@3^<OE$[MOWLX^]QUZ\=:\9^!G[*&M?"WX@W&O:UXRO
M_%DCR:JL:7XWXBNWM6C48 "[%M@K<,7R#N[#,;]D#7&_9M_X0EM2\-[H2?L>
MFC3(_P"P[)AJ!NXYXX]GGK-&"$7$H0;0P0'F@#W/_A,])-^]K_:FG?:HYUM6
MA%RGF+,REEC*YR'*@D+U(!/2K]K=QWL*21,LD<BAD=6#*P/0@CJ#ZU\N^)O^
M"<A\9ZSKEY?:];VMQ=7]Q=Z;>6,$L-W:>??WU^S2,)0)75[P0KN! CC+ !V7
MR_H#X0>#[[P#\-]%T74M075+S2[-+:6Z6/RUE*C P/0 !1GDA03SF@#IJ***
M "BBB@ HHHH Y7XJ^.Y_ &F:;=1MIRQW.IV]G*+J4H721MI$?8R=, \8!ZUP
MW@W]H;5-?&@M</X;ABU>\-JSM*\7S'3?M8C3+')CDS%(V3T'RJ20OK=]=6MJ
M8OM$T,7FR"*/S'"[W/11GJQ]!S5&/Q1HMQ"LJZIIKQLTB!Q<H5+("T@!SC*@
M$MZ 9- '%Q_&74-7^!%OKVD_V'J7B.:UM7^R13%K;S9I5B['<$+;P">?E/H1
M4/@W]H*3Q;9>)-0CL5-G8V0U'2+7:R7U_$L;^:"C?Q"5"HVC@,F>HKO(M3T>
M'37U..ZT]+.4!GNUD18W&=H)?H>>!SUJ;[3I[WL[^=:M<V";9FWKYENK /AC
MU4$ 'G&0 >PH \S^'O[0LOBK7=/M[F[T6.-K::?45)6(VH&/+=)/.='1B=H
MY.QR2I7;3?'W[0E_H/C/5]+L;>S6&Q1$AN[R)XX99D,;7$8D=HXG812KM02
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M*223N].[6A\33?\ !T9XLMYFCD^$OA>*1"59'\0S!E(ZC_4TP?\ !TCXJ/\
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M?A+^SHRUEX8W9;K%!_>/M6+X]\9?#[X<RZ3'J5KH"MK5ZMC;^3:12[&;^.3
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M?_"AF_\ C-!_X.D/%('_ "2?PK_X4,W_ ,9K];!H?@W_ )\_#7_?J"@Z)X-
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M>!?#FE6]C9Z?X:AMK5!&B%87; [LS99F/)+,2222222:N+HO@TG_ (\_#/\
MWZ@_PKCEEN:7TK_^2GNTN+.$HP2GE-W;5^UEK^!^2O\ Q%'^*?\ HD_A7_PH
M9O\ XS0?^#I'Q2/^:3^%?_"AF_\ C-?K9_8?@W_GT\-?]^H/\*1M%\&@_P#'
MIX:_[]04O[,S3_G_ /\ DI7^MO"'_0I7_@V1^2?_ !%)>*?^B3^%?_"AF_\
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M%-_X/3_\CUYV897Q!C'3=:_N.ZLXK7Y;GEYAEN38R4)5)27([JS:U\]"1?\
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M']<@<V5?U<=_Q#]3#_FL-]_X)C_\?J.3_@@%*E]%'_PMZ\/F([!CHAR,;?\
MIX]Z<?\ @X)F7K\(9A]=</\ \CU#)_P<!22WT4W_  J2;]VCKC^W3SG;_P!.
M_M^M+_C)_P"N07/E/]7+0_X-^IF/_)8+SU_Y G_V^C_B'VF_Z+!>_P#@E_\
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M</H?^G>I?^(@N;_HD<W_ (/#_P#(]+_C)_ZY!<V5?U<D_P"(?>;_ *+!>_\
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MUBO^?/XK_(_2TZ78@?\ 'M9_]^T_PKY"_:I_X)N?L\:MX^OO'WQ$U#7--O\
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M[_H,_P#))?YG3]:Q/_/C\4?I;_9=B?\ EULO^_:4?V78_P#/K9_]^TK\T?\
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MJLPAF,3(/!? GPROOC;^UGX3\0:3?>+-*L?@_>70U?0=#9(XC,MS<6ZR0/\
M*)8YIX+B"8@,-D,@R@W%_3_V[/V%_%'[<^O>$X1K&I>!KKPWY[3HLAO-$>.4
M';)$JF-OM88["<8"&3L5W>70ITYU(1G4Y8O=V>GRZ_([:EXQ;C&[Z+N>_? C
MX0'P+=^,+S4(W_XGVO3W5G93ZC+?QV5H@6&+897;9YOEM.43 4S[<#;7;SZ5
M8_VS;_Z+9X\J3K&G'*5^;G_#@3Q3NS_PN"W_ /!7/_\ 'Z9+_P $$/%2WD<?
M_"WK;=(K,&_LR?@#;_TW]Z]C^S<N_P"@S_R27^9YOUG%?\^/Q7^1^F TRQ_Y
M][/_ +]I2G3+#_GUL_\ OA*_--O^" WBMA_R6"#_ ,%D_P#\?IO_  X"\5'_
M )K#!_X+)_\ X_1_9V7?]!G_ ))+_,KZUB?^?'XH_2TZ98C_ )=;/_OVE']G
M6/\ SZV?_?M*_-,?\$ O%7_18(/_  63_P#Q^FG_ ((!^*L_\EAM_P#P63__
M !^C^SLN_P"@S_R27^8OK6*_Y\_BO\C]+O[,L?\ GULO^_:4?V98_P#/K9?]
M\)7YH_\ #@+Q5_T6&W_\%D__ ,?I?^' 7BHC_DL,'_@LG_\ C]']G9=_T&?^
M22_S*^M8G_GS^*_R/TM_LNQ_Y];/_OA*/[+L?^?:R_[]I7YI?\. ?%6/^2PP
M?^"R?_X_2?\ #@+Q5_T6&W_\%<__ ,?H_L[+O^@S_P DE_F+ZUB?^?/XK_(_
M2:\TNQW0?Z+9_P"M'_+)/0U8&EV/_/M9_P#?M*_-%_\ @@5XHAV9^+UN=SA>
M=,G_ /C]+_PX%\5.?^2P0?\ @KG_ /C]']FY=_T&?^22_P P6)Q+_P"7'XH_
M2T:98_\ /K9?]^TH&F6/_/K9?]^TK\T1_P $!/%0_P":P0?^"N;_ ./T?\.!
M/%0_YK!!_P""N;_X_3_LO+O^@W_R67^8_K&)_P"?/XK_ "/TN&FV!_Y=K+_O
MA*IWM[HND:CI\$DFEVMWJ5P;:Q1S&DES,L4DQ2,=6<1Q2/@<[8V/137YN_\
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M+KH+^)/ >@>)[;Q?&]Z)SJKVJ:+<\&73 4B;S%B!!25L,X+<?+7D?_$4=XF
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MTOQ-9ZK=74.M7%C%+% FK:J+Z%!)MW_NY"5R=B\XXP*ZC_A7WPP7C^P_ /\
MX!VG^%>3PSE_$-/+J=/-\5%UTK2<5=/71ZV_(C"YYPW3IJ%;*W4EUESRC?Y+
M8_*M/^#HOQ,LA;_A4GA?Y@!_R,DW_P 8I_\ Q%&>)A_S2/PO_P"%+-_\8K]2
MW\"_#&!KB5M%\ K#;P&>1C9V>V-%#,[DXX 4$DG@ 9K87X(>"7'_ ")OA?\
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M3PK_ .%+-_\ &*!_P=&^)O\ HDGA?_PI9O\ XQ7ZS#X'>"1_S)OA?_P46_\
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MBFW8S)+^Y;+(  V#Q7IUC\)/"WAW4K:ZT_PSX?T^Z64!9;?388Y%ZGAE4'J
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M>U'%2;Y;*3VW^%,^QX2S+.\'*H\F:3=N:ZB_3XDSX+;_ (-==8S_ ,EKTO\
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M81Z>-3>:+>9I&#SAX ;F8H8R9]T.&5E6$(1CZ!3[@^E&T>E+0 4444 %%%%
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M_P##%NND_P#(T1C_ (!)_P#%4#]BW72/^1HC_P"^)/\ XJOSS_6_BK_HFO\
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MG[9;6'GR1!@9KB58HUPH)^\V2>BJK,<!21U7V#2PVWR;'/\ N+S7YI_M_?\
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M-'CD\Q"</@#.03U[>M6[N[TVSFFDN)+.*2*(/,\C*K)&2<%B>BY!P3QD'TH
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M+(1M^Z64C/J*\R6#S!;XA?<CTEQ+P?\ ]"F7_@V7^1^9P_X.B[L#_DCVF_\
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M7JHW7_(9M?\ KE-_-* +J?<'TI:1/N#Z4M !1110 4444 %%%% %;4?O6_\
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MTOX@_M):3JFGV:^#;/S-52XN]1GN76ZM]/E>'*)#B<?)%*BCRRV6$WRD[68
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M,1DVJ&B1L,5SV!PIQ[#TKA9O@M_:/PGF\%W"V?\ 9<D<!FF1"&O)3/YUTQ0
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M "BBB@ HHHH **** *VH_>M_^NH_D:LU7U#[UO\ ]=1_(U8H **** "BBB@
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M)-6N-(O)5@36!IEQ]D9I+?3[B%U(0DQ.FI0 R-M6-@0^W(- 'N%%-1MRTZ@
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M[66C2"X>2YM;N%%95@N(+B2&6,;B<[9$8;@2#C()!!KN:_0C@"BBB@ HHHH
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MG^S[\W5S<O'=NL-A'%*(Y)6C1E:WNG)50S&[;))SGVK-  HP**,T9H ****
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M4 9_A7X*:[X2NM(NDU#3;N31Q(MO'(LI1%D7RS'EB6VJ#N#$D]4& <U)XQ^
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M,OP9I%KH'AVSL[&UMK&SMU:.&WMXEAAA4,<*J* JCV  K6JCH?\ R#H?J_\
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M\--;O/$7@NRO+]=MU,K%CY1B\U0[*LFP\KO4*V#TW4 ;U%%% !1110 4444
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M$VRMN*[BX;YANX;VH EU;7?%%@=0-G:W,K2ZAY-E'<PPS8C\MR7'ER)B,LH
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M5"MRV1A8-7\</J<L;V6F+;0>45F*?\?7 \P!1-\G.<$[L=P:[CRU]*/*7TH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH  ,48S110 8Q01FBB@
MQ1CFBB@ VYHHHH *,<T44 %!7)HHH ,<T=*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>nbx-20211231_g28.jpg
<TEXT>
begin 644 nbx-20211231_g28.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '. 9,# 2(  A$! Q$!_\0
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MV=;WX?>'IHI+T6%O8VTM_(55A$4Y=@"<D)Z=:L?\,]Z=_P!#KX__ /"KO/\
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M:6_KS^^R^[0N?"GX?ZIX+\4_$C4-0:W-OX@U[^TK/R9"S"+[/%'\X(&&W(W
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M^$IT7_H+V'_@2G^-'*^P7-2BLO\ X2G1?^@O8?\ @2G^-'_"4Z+_ -!>P_\
M E/\:.5]@N:E%9?_  E.B_\ 07L/_ E/\:/^$IT7_H+V'_@2G^-'*^P7-2BL
MO_A*=%_Z"]A_X$I_C1_PE.B_]!>P_P# E/\ &CE?8+FI167_ ,)3HO\ T%[#
M_P "4_QH_P"$IT7_ *"]A_X$I_C1ROL%S4HK+_X2G1?^@O8?^!*?XT?\)3HO
M_07L/_ E/\:.5]@N:E%9?_"4Z+_T%[#_ ,"4_P :/^$IT7_H+V'_ ($I_C1R
MOL%S4HK+_P"$IT7_ *"]A_X$I_C1_P )3HO_ $%[#_P)3_&CE?8+FI167_PE
M.B_]!>P_\"4_QH_X2G1?^@O8?^!*?XT<K[!<U**R_P#A*=%_Z"]A_P"!*?XT
M?\)3HO\ T%[#_P "4_QHY7V"Z-2BLO\ X2G1?^@O8?\ @2G^-'_"4Z+_ -!>
MP_\  E/\:.5]@NC4HK+_ .$IT7_H+V'_ ($I_C1_PE.B_P#07L/_  )3_&CE
M?8+HU**R_P#A*=%_Z"]A_P"!*?XT?\)3HO\ T%[#_P "4_QHY7V"Z-2BLO\
MX2G1?^@O8?\ @2G^-'_"4Z+_ -!>P_\  E/\:.5]@NC4HK+_ .$IT7_H+V'_
M ($I_C1_PE.B_P#07L/_  )3_&CE?8+HU**R_P#A*=%_Z"]A_P"!*?XT?\)3
MHO\ T%[#_P "4_QHY7V"Z-2BLO\ X2G1?^@O8?\ @2G^-'_"4Z+_ -!>P_\
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M%O\ R+_A4K?&_P#8O5<GQ!X5 QGK+_A7X@V;%538BER?O'M5UG:W42O\T8X
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MH'(_&CV]7^=_>P]E3_E7W'[B?\+V_8L_Z&'PM_Y%_P */^%[?L6?]##X6_\
M(O\ A7X=;A7MOA']F_3=<\$^%_$.M_$K0?"4GB0S#3K'48IBS^7)Y9+.HVJ-
MV.3ZTO;U?YW]['[&G_*ON1^K'_"]OV+/^AA\+?\ D7_"C_A>W[%G_0P^%O\
MR+_A7XU>+/A+XJ\'^.-6\)W6DW%YJ^F/B9;"-IE92 5D4J.58$$'OFN>70=3
M:2",:;>%YV9(E\ALR,OW@HQR1W':G[>K_._O8O94_P"5?<?MM_PO;]BS_H8?
M"W_D7_"C_A>O[%G_ $,/A7_R+_A7XU?"KX8W_P 5O%+:/:7=MI<%O;R7M[J5
M\2(+.WC&7D?'/'H.M=Q>?LW_ -B^-8]+U3QSH-AX:FTU-8MO%3LYM;FW8[5\
MM -Y?=D%<9&.:7MZO\[^]A[&'\J^Y'ZN_P#"]OV+./\ BHO"O_D7_"O?]/\
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MY@,<=CWH=5AD^YNR"">_YTC*VYBI,?0[@.E2-OF90\ID[DXQ0 ;0RK(Q "C
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M_HFO<Z\,^+7_ "<9\'/][4/_ $377AOC?I+\F<];X5ZK\T>YT445RFX4444
M%%%% 'S3X%_Y/0\:_P#8,_I!7SW_ ,%(EQ\6?#QZYTLC'_;0U]">!?\ D]#Q
MK_V#/Z05\\?\%)FV?%CP]AN3I9&#_P!=#7=B=X_X4<]'9^K/DIFY/#8XX%4)
MH<MGI\V0:T8\[=V""/7I5>9?1AZUPG08\Q-O)(RY&3T7K6]H?BZXT]6B:63;
M(-I=3SCTK+OK=MG7W%9^V6%5#+D YSTH ]*LKR.=!+%^\.,G\*GCD\Q2T;,F
M[EL?RKSS3=6EM;A2I&#_  GTKJ-/\2(RL'&"3R!Q0!O#9N)0!OE_*JRNJ8 Y
M5NC8Y_"JYU*$\KR,?0"G_:$D5<.-@'&V@!\UP=OEB1L'AEV]*(6*L=HW;1CK
M3-N&.#G/;/:GPD^68RN&;H >M $\+>3(<D)L/U)S44F?.."Q;G<:211&^X?>
M/KR?2E>&1<;FX;^*@!C/]GSQ^-(S!OGZ\8!HNH4:/8).>K#-4@S!L,"%'3GB
M@!?.+3,"WS= H'7VID3'S=JG!S\WM4$^H0%5D!V#IGI63<:DS2L02^WOZT =
M/(D5OLW.$5?F(]?:HYO$@BMPMN/FZ,?:N6:^:8*6)+=<9Z#WI0Q*''4]<T 6
M9+J2X\PS,Q/8@U'""^!TCZ[J8S2*#@\G@<<BGH6B7 [4 +Y89L;MF3GY>U.%
MOR0P!'?WJ3_EFYV\MZ4D9"J1U+=30!76(JV<]P0.U?N)X+_Y$_0O^O&#_P!%
MK7XCK;X9#]\YS]*_;GP;_P BCH?_ %XP?^BUI=0-BBBBF 4444 %%%% !111
M0 5X9^UY_P D[TG_ +#5K_,U[G7AG[7G_).])_[#5K_,UZ66_P"^4_4X,=_N
MT_0]ML_^/6'_ '%_D*FJ&S_X]8?]Q?Y"IJ\Y[G>%%%%( HHHH **** "O#/B
MU_R<9\'/][4/_1->YUX9\6O^3C/@Y_O:A_Z)KJPWQOTE^3,*WPKU7YH]SHHH
MKE-PHHHH **** /FGP+_ ,GH>-?^P9_2"OG3_@I-;S7'Q>\/>3#)(%TOEE0L
M!\Y]!7T7X%_Y/0\:_P#8,_I!6'^VS^V5HW[)NH^&DU3P5_PEK:U',ZR*T:F$
M(5&,L#US7=B?BC_A1ST=I>K/SA-A>+G_ $>XV\#'E-_A43:;=[<"UGR/6)NO
MY5]$?\/DO!YZ_!QS_P!MX/\ XFC_ (?(>#_^B-O_ -_X/_B:X3I/G.33[Z.'
M'V*<L?\ IBW^%1?8[N3=OLK@^QA;_"OI'_A\CX0_Z(VW_?\ @_\ B:0?\%D/
M!_\ T1MO^_\ !_\ $T ?.D.CR^8#]CG!QD?N6Y_2E.BW(;*VMP,9ZQ-_A7T7
M_P /DO"'_1'&_P"_\'_Q-'_#Y+PA_P!$<?\ [_P?_$T@/F]M)U'!S#=-D<$1
M-_A3)+/4K<82UNB.O^J?_"OI+_A\CX0_Z(VW_?\ @_\ B:/^'R'@[O\ !MO^
M_P#!_P#$TP/G,?VI'AUM;O=C&/*;_"I4&M95EMKG=Q\WDMQ^E?1'_#Y#P?\
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MNEAL+&I/S94&K<^G_P!GL[ '&,X'K0!R\&DKY?SJP/8CJ:IW/AB*?+E,D_\
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MT&>U68$#@$\>E?MG\*_^2:>%O^P9;_\ HM:T^Q\Q=3J:***S&%%%% !1110
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MII&:X-E)SM5B0,^E;\/@?Q+XHM)CI%M-?QPHLC_9UW87U)H \F:WOXV(DB?
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MH#0_$'>.&RW^Z!36D3=G)!^E?N!_PVE^QU_S]>%__">7_P"-4?\ #:'['/\
MS\^%_P#PGE_^-4 ?A_YP;@[CGVIK3$9Y(/TK]PO^&T/V.O\ GZ\+C_N7E_\
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M9KJIOA%K<_A-O$$-A-+I@.&G520*]0^$/P.TLR+JWCC45T?34'F>0QQ-+CG
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M;TK]R/AC_P DY\+_ /8,M_\ T6M?SC-X^U2\N$+73%F8+C:  ,\U_1S\,?\
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M_P#!U;__ !- 'Y.1ZK*OSF9]_P#>W'FK*^+-0MY 4O954?PDU^K?_#K#]G/
M'_"?ZKP<_P#(:M__ (FD;_@E?^SF[9/C_5#_ -QJW_\ B: /RP?QWJD@P^HR
M;2,87BJ$GB"YDW8N9\>N\U^KH_X)6?LY_P#0_P"J_P#@ZM__ (FE;_@E;^SI
M_P!#_JO_ (.K?_XF@#\E)-6F?87ED?'3<U!OI)6;J!CDY[5^M0_X)5_LY_\
M0_:H1_V&K?\ ^)IW_#JW]G5?^9^U4?\ <:M__B: /R.-[(&W #![XI!>.,[F
MSFOUQ_X=7_LZ;=O_  L#5=O_ &&K?_XFD_X=5_LYGIX_U8'_ +#5M_\ $T ?
MD7+<,R 9QZDU'YG)Y+#'>OUZ7_@E;^SG&"#X^U4_76K?_P")I/\ AU9^SHQ_
MY'[5?_!U;_\ Q- 'Y#,S<'!([U&2 #ANG/UK]?5_X)6_LY]/^$_U7_P=6_\
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MJJ63%NZSD?,/PR?2M*=6=*:G3=FC.=.-2+A-73/2K.VBL;6&WA18X8D"(JC
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MQB\4>%?B3KFDZ9=PW4":%<7&GV-K"))(KJ.(OF=2-VT\;2O&>#S6;*1Z$WP
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MQ+'/)<03O#-O1/+4AT8$?(2O!Y!-5;SX!^ [X0&;P]:E;?3GTF)5!4+;/]Y
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MY QG'?-<;\6O^3C/@Y_O:A_Z)KLPWQOTE^3.:O\ "O5?FCW.BBBN8V"BBB@
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MN=2N##'96D<D[R1J#\J@LY '4XSG'6OD.Z^#/Q-\3>/O$$UWX?;1M&OH!;W
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MN9?L;1-="X8/;;-K-D  YK]V/[#T[_H'VO\ WY7_  H_L/3O^@?:_P#?E?\
M"@/F?BMK'QAO/$6K*^H>%_$%WH_^N^QMJ!CF6X\Y)@T<D<*XCRB@J<D@YSFO
M#/B!X#U?QQXXU[Q UE-:#5+Z6\\@02.8][%MN<<XS7]#G]AZ;_T#[7_ORO\
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M?IO_ $43XC?^%&__ ,17N5%'UJM_,'U>E_*>&_\ #)^F_P#11/B-_P"%&_\
M\11_PR?IO_11/B-_X4;_ /Q%>Y44?6JW\P?5Z7\IX;_PR?IO_11/B-_X4;__
M !%'_#)^F_\ 11/B-_X4;_\ Q%>Y44?6JW\P?5Z7\IX;_P ,GZ;_ -%$^(W_
M (4;_P#Q%'_#)^F_]%$^(W_A1O\ _$5[E11]:K?S!]7I?RGAO_#)^F_]%$^(
MW_A1O_\ $4?\,GZ;_P!%$^(W_A1O_P#$5[E11]:K?S!]7I?RGAO_  R?IO\
MT43XC?\ A1O_ /$4?\,GZ;_T43XC?^%&_P#\17N5%'UJM_,'U>E_*>&_\,GZ
M;_T43XC?^%&__P 11_PR?IO_ $43XC?^%&__ ,17N5%'UJM_,'U>E_*>&_\
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)N8W"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>nbx-20211231_g3.jpg
<TEXT>
begin 644 nbx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )2!+T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<5[#\;?CA\)O'5Y\!?$GB7P%K.MSZ]JP&@23G[)+ILPE1?,EC9@2-VTXP>E
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M#.3%/NXC)B4(H8@9.*^T]+_;L\*ZG^R_JOQJ&A:C%ING7?V&71VDC-R9O,1
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MBDSGB(OC&0./:OJ5?C%\/XU"KXW\-*JC  U:W  _[[H$SX"_:S^'W@_XH_\
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M ?BY?$_A[Q1I5YKD4;16]UJWB.&Y-LI&#Y8+84X)&?0T <-\&2?^'I7QD_[
MT/\ Z*MJ^W]?_P"0#J7_ %[2?^@FO$_#_AWX(>&?C1K_ ,4K'QCHR^+=<MUM
MKR5_$$+0L@" !8]^%.(UKT:Z^+GP]O+::"3QQX<,<J%&QJ]N#@C!_CH$?C3X
M'_9Y;XG?LZ_&+QSIUQ>_V[X6UP?Z'%*?(FM<;Y<QC[SC=D'L%K[H^'GQ\^'G
MP[_X)W:5XQM?"&G7^GVD*V4OA[RE>&74MVUO,W \%@7+'G'3M7K?P?\  OP$
M^!_A[Q/HGAGQ7HHTWQ).T^HPWWB"&?S&9-C ;GX!4XQ7,:!^S_\ LV>'/A?X
MF^'UKXITQ_"WB"=;JYM)_$T4ABE7 5X6+_NR,#IZ4#/D;]I&X\?ZUIGP'\0^
M.O$FB@ZMJ\%QIG@_0;>..WTJV)B*$L"69MI"_P!T8QZU[O=7EOIO_!6&W:_F
MC@%QX:"VK3,%!/V8\ GOPU;FD?L?_LKZ2FE,/%-I=WFFW*7,%[=>+$>8;""L
M>=^/+!&=H&.37;_'+X/_ +/7[0GB/2->\4>+M+BUC3(_(BO-+\216LCQ DA'
M97R0"3COR>: /'OV3[F.\_:X_:@FAF2>-A+B2-PRM\YZ$=:Y#]BGXG:%\'OV
M%/B+XJ\1Z1'KVFV>M3YTN:-72ZD81JD;!@1@L1R1Q7T_\*?AO^SY\%=<\0ZK
MX1\2Z'IDVN6RVMW%_P )!$\6Q0!\JE_E)QDGN235#PO\'?V=?"/P?U_X96?B
M?1YO"FMS/<7<%UXBBED\QL?,KE\J1M!&.A% 'Q;^U)JGCWQA\(?A/XN\7ZSH
M>EZ5J^MV\NC>!_#]NB0:?;DY5V<'<S@<<  ;O6O<OVF+R&Q_X* ?LS3W,\=O
M!'I[%Y97"JHS(.2>!72Z?^QO^RI9:/!8R>*;6]DM[A+B"\NO%J//#M.0B'?A
M4SR5 Y-=S\?O@]^SY^T@-&D\6^,-+6]TB$V]K>V'B*&&41G!*L0WS#(S]: N
M</XN=9/^"HW@IU(96\)S$,#D$?-S7.?LBZQ8>'_VQ/VIAJU_;:<TFIO)']LF
M6/=&)YB6&XC@ K^8KWC3_"/P.T[XE>'?'B>--)?Q)H6DKHMI-)XAA*?9PNWY
MDWX9L?Q5Q7QJ_9Q_9H^._C*3Q3K_ (HTNRUN=%CNKG2?$<-M]I4#'[P!L$X
M&?:@#Y5^ R/_ ,.W/CS+@^1)JTWEM_">(,X_,5J_M$<?\$[/V?P.G]JVG\IJ
M^R8?!/P!L_@C<?">S\1^'['P;<1&*:WMM=A263+!F=I-^2Q(&365XK^%/[/G
MC+X4^%_AWJ?B[2W\,^&YDN-/CC\21)*K)NV[G#Y8?.>M 7/HGP[_ ,B_IG_7
MK%_Z *T*I:+<6-UI-G)IES%>:>8E$$\$@D1T P"&!P1QUJ[02%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !4-Y9P:C9SVMU"EQ;3HT<L4BY5U(P5([@BIJ* /-/^&9_A/_T3KPU_
MX+8O_B:/^&9_A/\ ]$Z\-?\ @MB_^)KTNB@9YI_PS/\ "?\ Z)UX:_\ !;%_
M\31_PS/\)_\ HG7AK_P6Q?\ Q->ET4 >:?\ #,_PG_Z)UX:_\%L7_P 31_PS
M/\)_^B=>&O\ P6Q?_$UZ710!YI_PS/\ "?\ Z)UX:_\ !;%_\31_PS/\)_\
MHG7AK_P6Q?\ Q->ET4 >:?\ #,_PG_Z)UX:_\%L7_P 31_PS/\)_^B=>&O\
MP6Q?_$UZ710!YI_PS/\ "?\ Z)UX:_\ !;%_\31_PS/\)_\ HG7AK_P6Q?\
MQ->ET4 >:?\ #,_PG_Z)UX:_\%L7_P 31_PS/\)_^B=>&O\ P6Q?_$UZ710!
MYI_PS/\ "?\ Z)UX:_\ !;%_\31_PS/\)_\ HG7AK_P6Q?\ Q->ET4 >:?\
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M_AF?X3_]$Z\-?^"V+_XFO2Z* /-/^&9_A/\ ]$Z\-?\ @MB_^)H_X9G^$_\
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MMINEV<-AI]L@C@M;= D<:CH%4< 5=HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[V(...U?7U !1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO=_:?%FGP>=8:C)P^H6Z_>5_61!SGN.>H.?NF@@****!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5@^/O$T7@OP/K^OS8,>F6$
M]V03C.Q"V,^^*WJX;XU> KKXG?#C4_#%I<1VK:A) DLDN=ODB9&E''JBL/QH
M ^+?@'X9G^%OQ,\/Z_<X%R=5T^PU(*,9.J6;/EC[3-'U]*_0NOF34/AW+\1O
M%'QX\.:=/'I]ZT^BRV4S#Y(9HH \9XZ#*#I7TTN=HSU[XH&Q:***!!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'PQ_P %-->U358_ '@O0Y9%O)+Y=5G$:YV@31P0GZ[Y
M6Q7V#\,_%B^.OA[X;\0KM!U+3X;EU7HKL@++]0V1^%?(/QG<>-/BUXO\2,9)
M;30_$_A?PO9NW"HXNXY[E1_P*5.?:OH;]F\_V+HGBOP>V5/ACQ#>6<*O]\V\
MK"YA8^VV; _W:!]#UZBBB@04444 8WC"?[/X9U%^G[K;^9 _K3/!4OF^%]/.
M<[8]OY$BJOQ%D\OPK<#^^RK^N?Z4WX?S?\4A"2?]69!_X\37Q#Q/_&3^QZ*A
M^//_ )&]OW5_,SOA_=>?K>OG.?,FW_\ CS?XU=^)EQY/AEU!P7E0?D<_TKGO
MA;,6UJ_!ZM#N_P#'A_C6I\6)/^)39IG[TQ)_!37RF%QCEP97JWU]]?\ @4W_
M /)&SC^_2.JM[C&AQ39Y^S!\_P# <US?PPNO.T2ZR?NSLWY\U?ANMO@,39_Y
M<^OX8KG?AK/Y6BZP,_=&_P#\</\ A7M5L=;-\NUT=*;^^*?_ +:0H^Y+U-+X
M;71N$U?<<DW1?\__ -5-\ 7ANM7U\DYW3"3\RW^%9OPMNMK:L<\!%D_]"IGP
MNF_XG&H+G[Z;OR;_ .O7SN3X]SCDR;WE6O\ BE^9I./Q_(T?B7=^1/HZYZ3&
M3\L?XUTGBJ;[/X<U%P<'R6 _$8KB?BI-_P 36P3^['N_-O\ ZU=)XVN/^*+F
M?_GHL8_,BO9^NN.*SMW^&,;?*#7YD<NE,X^343'I'A-,_P"KE9OR;']:]8KP
MAKHO;::N?]2[?^A U[?)-_H#R_\ 3(M^F:YN!\=]8>);>D8TOPIV?Y#KQM;Y
MG(?#N\-S?:YD_>N-_P#,?TIWB*\,?C[0T!X53GZMD5E?"N;=JFI#/WT#?^/'
M_&F>*KC;\1+/G_5O"/S(_P :\VEF#7#.%JMZNLOPJ.7Z%./[UKR_0[7Q=/\
M9_#6HOTS$5_/C^M0>!9C-X5L">H4K^3$5#\0Y/+\*W0_OE%_\>!_I4?PWDW^
M%XQ_=D9?US_6OM98E_ZTQH=/8/[^>_Y(PM^ZOYG3R-LC9O09KE/AO<_:-*O.
M<_Z5(WYG-=)J4GDZ?<O_ '8V/Z5Q?PED)T^_0_PR*?S6ML?B'#/L#1[QJ_E%
M_H$5^[D_0[VBBBOL3 **** "BBB@ HHHH **** /Q._;B\%KX7_:J\3V#ZE=
M:F^H7$%W+<W)&\-,%)48Z*H.%] !7[)> ?"Y\%>"M%T#^T+C55TVUCM4O+O'
MFR*HPI;'?  _"OR2_P""B''[86J?[FG_ /H"5^Q%OS!&?]D?RKW,?)NA0OV_
MR.:DO>D24445X9TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'CG[7GQ>;X(?L]^+O%$#A-12V^R6!/_/Q*=D?Y%L_
MA7X(R2232/++(TLTC%WD<Y9V)R6)]2237ZQ?\%>M9FL?@?X2L(V(BO\ 7@LJ
MYZA()''Z@5^3=!<=CU#]FOX%ZA^T7\7=(\%V-Q]BAG#7%[>8SY%LF-[ =VY
M ]2*_:SX7_LL_"WX0Z-%8>'_  =I895 DO+RW6XN)F Y9G<$Y/?&![5\#?\
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M$<98G/$9:,?H@H"1[111100%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X]\*O^2[?&;_KXTO\ ])37L->/?"O_ )+M\9O^
MN^E_^DIKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH _'C_@HV,?M>7O\ U[V'\EK]?M-_Y!MI_P!<D_\ 017Y!?\
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M=;W2Q@&5D;""V>42#)PI)R#7W-XL^'OACQY'"GB/P_INN+ <Q?;[5)BGKM+
MXJY<>%]&O-#_ +%GTFQFT?8(QI[VZ& *.B^7C;CVQ0!\0W_BSQOJEU\6_",_
M_"(^+/'$W@>:YB\8^"4,<DL09E%K<("P60@N4Y)ZX[5P5W9R>(OV>/ UA/\
M%[P7;:'/-I\6DZ7H'AD/J]O>JZ;$C1)/,6564AVP.-Q)YY_1'PGX#\.>!;>:
M#P[H6GZ)#,V^5;"V2+>?5MHY_&JMC\+?!VE^('URS\*Z/:ZPQW&^AL8UFW>N
MX+D'WZT!<Z6$%8D!.2% )-/HHH$%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,?M7?\DYT7_L
M:M#_ /3A#7L]>,_M6_\ ).=&_P"QIT/_ -.$->S4#"BBB@0444G3F@#P75&\
MS5+MO[TK?SK*T^\-[',Q0)Y<SQ<=]K8S5ZX8M<2D]W;^=4M/NDNHY62/RPDK
MQD>I!P3^-?Q94?M/:SY;Z[]KW_,]KJE<LT445Q%A112T 51= ZDUKL^981+O
M]BQ&/TI'O"NJ0VNP$/$TF[N,$#'ZTX30_P!I-%L_T@0AR^/X=Q 'Y@TCW2+J
M45N8\R/$SB3T (!'ZUW**YK<GV?TW_4SOIOU+5)2TE<)H+Z4E+SQ24#"BBB@
M0M7/ 5U++XH@\T8$=YY:<8^7 _Q-4ZL>"[YKCQ);%E"B&^6,8[@8.?UKV<IO
M'%4YVO:4->WO(SJ'3_%!MWB*-?2!?YM7'^';Y;G4(V5/+\J\\H^Y!'/ZUU?Q
M*;=XG8?W84'\ZY'1KB*:Z#1)L$=UL;C&6!&37M9Y*^=8J=KVJ;]K,B'P11]$
MT4@YYI:_JT\D**** "BBB@ HHHH **** /Q__P""E''[6<O_ %Y6-?KAX?\
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MDTF+Q;#>/)<W\"QE(XA 5Q&77:C.2<#)QFMOXI?LO>./%W[%?@7X8Z?'I_\
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MDSX/G_C,S_ND^E_^E5?6=!(4444 %%%% !1110 4444 %%%% !1110 4444
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M]_Y^K_P&/^0?5Z?8],_X6M9_\^,__?2T?\+6L_\ GQG_ .^EKS.BC_7K/?\
MGZO_  &/^0?5Z?8],_X6M9_\^,__ 'TM'_"UK/\ Y\9_^^EKS.BC_7K/?^?J
M_P# 8_Y!]7I]CTS_ (6M9_\ /C/_ -]+1_PM:S_Y\9_^^EKS.BC_ %ZSW_GZ
MO_ 8_P"0?5Z?8],_X6M9_P#/C/\ ]]+1_P +6L_^?&?_ +Z6O,Z*/]>L]_Y^
MK_P&/^0?5Z?8],_X6M9_\^,__?2T?\+6L_\ GQG_ .^EKS.BC_7K/?\ GZO_
M  &/^0?5Z?8],_X6M9_\^,__ 'TM'_"UK/\ Y\9_^^EKS.BC_7K/?^?J_P#
M8_Y!]7I]CTS_ (6M9_\ /C/_ -]+1_PM:S_Y\9_^^EKS.BC_ %ZSW_GZO_ 8
M_P"0?5Z?8],_X6M9_P#/C/\ ]]+1_P +6L_^?&?_ +Z6O,Z*/]>L]_Y^K_P&
M/^0?5Z?8]1M/B?:7=U# +.93(X0$L.,G%=%XF\2:?X/\.ZEKFJW"6FFZ=;R7
M5Q/(<*D:*68G\!7C&C?\ABQ_Z[I_Z$*];\?:38Z[X)UVQU*S@O[*:RF66VN8
MQ)&XV$X*D8-?J_!6=8W.J->>-DFXM):);I]CDKTXP:Y3\W?V-_VW+[Q5^UUX
MIC\27;0Z%X]N/+T^&9_ELY8\K;(/3<GRD#JQS7Z@U^&'_!/K2;'7/VK_  /:
MZE9P7]M^_D\FYC$B;EB)5L'C((!![5^Y]?I)SL****"0HHHH **** "BBB@
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M#-;0QDI,AR" 6/R#W-?N#7Z\<DMPHHHH)"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#QG]J__DF.F_\ 8R:-_P"E\-8,G^L;ZFM_
M]J[_ ))EIW_8R:-_Z70U@2?ZQOJ:_#/$OX\)_P!O_P#MIZ&%V8VBBBOQ([0H
MHHH 6J>FK.L<WG[MQGD*[C_#N.W]*N53TV6>:.<SYW+/(JY&/E#''Z5TPO[&
M>UKKUZ[?J0_B1;HHHKF+"EI*6@"HKS_VLZ$-]F^SJPXXW[CGGZ8I)%G_ +6A
M89^S>2X;GC=D8_K2BZ<ZHUMM_="!9=V/XBQ&/R%)))/_ &M#& ?LYA=FXXW
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M65UCC0;F=S@*!U)->5Z]\>M.@^(/P]T#0)-/\0V/B>[O;2>^M+Q7^R-;PB3
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M-\(_$-O!;:!JL,MFVBZEI+B*ZU.[EB_U4KJ"TZR$DLK9'TKYZ\!^%_%GQ/\
MACX^U[5_ W@+6[B\U+45U?Q-XCU:2#4=/DCD<*,^63 (0%VA6'"@]Z /KCXA
M?'O4O!O[0WASX>0:9;7%AJGAG4=<>\D=A(DEL1M0 <8.>36S^S'\7K[XZ?!O
M1O&6I6$&FW=\\RO;6SED79*R#!//(6OE#1Y]4N/CM\"I-:UJU\1ZH?A1K GU
M:SD,D-V0% D5B 6!&#GO7N7_  3Q_P"34?"?_76[_P#2AZ /I*BBB@04444
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M<G[!/@M!C_A(/%;?[VMSG_V:OINBG_86!_EE_P"!S_\ D@]I(^9O^&"_!?\
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M?_GA'_WP*/L=O_SPC_[X%'_$/:/\\?NE_P#)A]9\CXT_X7%J_P#T2OQM_P"
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MWPG\*ZEXLD\23Z5&=8?17\/F=25'V%GWM"%' &[GI77T4 <1/\%O!MU\*_\
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M3PWX9L%TS1K4NT-LK%@I9BS<DYY)-=)10 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]C\5>.?[-;_A)M+UR^TBTO/M$F([7(&S9NVDX ^8@GWK]!Z 84444""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I&^Z:6D;[IH \<N&VW%SP#^\;K]369-J5M#J,=FY(F897G@UHW4FVZN.
M,_O&_F:S;BSMYKJ*X>+=.A^5O0>E $]]8KK$ AD7YD.5]ZK:]?*_E6%H?WG
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MVM:1HNI7NI0ZIJ<VJ2/?;=R/(<E1M X%>K5D>+O%>F>!O#.I>(-:N/LFE:=
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MY>ZC=8681\_6NFT7Q-;7UH@?;$_0J3Z5D>:\DKMO 7[K**R3IH:9V48.>Q-
M'<7<\4T+QP,K2L. #5/2]'&F,SRN79_FY[5EZ3XFL]%7[/);EW8YW\'%6I/%
M"ZI<+"BF.-CR6(Q0!I0WPNE8A=I!Q]:F4$8/XU9>PAAM@8F5QC.5-4C(8BP/
M;B@"0H78%>?K7+'PO->:W+<7DFZ -F-<?I731R[NIXIZL&;B@ "@*%QL Z"E
M  SBB3YN!UIJ_+UH [CX<C$=[_O+_*NSKC/AR<Q7G^\O\J[.@ HHHH ****
M"BBB@ HHHH **** "BBB@ I&8(I9B%4#))Z"EJ*ZM8KVVEMYXUE@F0QR1L,A
ME(P0?PH 6&>.XCWQ2+(G]Y&!'YU%_:5IY7F_:H?+SMW^8,9],YZU^8'Q.UWX
MD?LB^-O%OP+\'7+7^E?$2:.7PI>7-V3+I?GR>7*@)/!QE02>-JMW-=9^VO\
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MG+O<NZC=G'*D&N3\5_L?_$/5OV:?@G>:!;P6'Q3^'1:XCTVZE79*#*7:/?\
M=W<(>3@\B@-#<UW]H'XZ_LP>._ L?QDG\,>)O"'BN\73FNM!@>&>QN&Q@'=]
MX#/I@C/-6OB'\?\ XUZC^V)X@^$'P\;0EMQI,-W!=:Q;L8[#*!I)G*G<_) "
M^IKE?%WP\^.O[9_CKP#:>/\ P%9_#7P?X5U%-2O)S>>=+=2KCB-< X(& .@R
M<FL#X@:M\0O#O_!27QAK?PYT2U\3:K8>'+=[K1;JX\C[7;% &5'[.#M(]>E
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M8_;U\-WT]^NA>#/&GBJ:XF/V?[+IS0C9M '+C YS7K?AGX1^$O#N8]+\):+
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M6,P:%X.\/QI"=NX6$4KJV23\[*3WQU[58\6^+([.:6*\U.ST73[?_6W-Y<I
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MIM]HOIV/5C(W(R<]/6@9X>O@O]H7]K;,OBW4I/@C\.I^FAZ6V[5[R,]I9/\
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M,EAWH Z^2Q18_F;Y@>.:H3#8P&<C-9VBW$EW,T\]P3M!"!CQBM $22?WAVH
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M;=G('>NN4DYS04+24M9?B;Q3H_@O1;C5]>U2TT?3+==TMW>RB.-?Q/4^PYH
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MW1OUU7W'P)7U?_P3]^'QU;QQJ_BZXBS;:3!]FMW(X\Z0<D?1-P/^\*\*\-_
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M87CY/VK3?]'?)[D+\K'Z@UTGPA^%.E?!OP='X=TB6:XMEFDG,US@R.SG/S$
M#CI^%=K16$</2C/VD8I/N>C4S'&5J'U:I5E*%[V;NCF_B-X*M/B+X'UKPW>@
M>1J%NT6XC.Q^J-^# '\*_)'Q/X;U#P=X@U#1-5@:VU"QF:&6-Q@Y!Z^X/4'W
MK]DJ\I^,W[-GA#XV-%<ZM#-8ZO"FR/4K%@LI7LK@@A@/?GT->7F6 >+2G3^)
M?B?6\*\10R6<Z.)3=*>NG1][>?7Y'Y;Z?I]SJU_;6-E ]S>7,BQ0PQ@EG=C@
M #ZU^KWP)^&,7PC^&.C^'P%^UHGGWLB_QW#\N??'"_117*?![]DWP7\']676
M+;[3K&LH"(KR_(/DYX.Q0  ?<Y->UU&69?+"WJ5?B?X&_%?$M/..3#82_LXZ
MMO2[].R/C?\ X*"?#-KK3=&\<6<.Y[4_8;YE'_+-CF-C]&R/^!5\0U^R?B7P
MYIWB[0;[1M6MEN].O8C#/"_1E-?%GBS_ ()XZPNN$^&O$MDVD.Y(74E=9H5]
M/E!#X]>*X,SRZK4J^VHJ]]_4^BX3XGPF'P:P6.GRN'PM[-;V]5^1XG^S-\-7
M^*'Q@T73W7-A9N+^\;MY<9!"_P# FVCZ$U^@G[1GPM;XL_"75M#M8U.I1A;J
MPSP/.3D+^(++_P "J+X!_L_Z-\"?#\MM:2?VAJ]W@WNI2)M:3'15'.U!V&?>
MO4Z]/ X!4<.Z=7>6Y\GQ!Q$\=F<,5A'[M*W+YN]V[>?Y'XO75K-8W4UM<Q-!
M<0N8Y(I!AD8'!!'8@U:T'0=0\4:S9Z3I5K)>ZC>2"*"",9+,?Z>]?I5\6?V1
M_ WQ7U275IHKC1=8F.Z6[TY@HF/JZ$$$^XP3W-;'P?\ V:_!GP7D:[TBVEO-
M7==C:E?,'E"GJ%P %'T&?>O$CDM;VO*VN7O_ ,#N??3X\P/U7VD(/VMOAMI?
MU[?CY%SX _!^U^"_P\L]%39+J4O[_4+E1_K9B.1G^ZO0?3WKTFBBOL:=.-*"
MA!:(_#\3B*N+K2KUG>4G=F3XB\*Z3XLM[>#5["&^CMYTN8?,7F.5&#*ZGJ""
M.U:U%%797N8N<G%1;T05QUZV+ZX.,_O&_G78UQUZ3]NN &&?,;^=:1(.;UBW
M2\\0:;;,6,>TNR'H><\U:\3,--T.18H=L+?)^[Z)FH])Q?:Q>7A'RQD1)QD<
M=34NLL-6T74(XSO*$QDX[U1/74\TC,IO$D$F5W$84\G\*Z&PU)=0M66-62=0
M3M8?,OJ<=JY5?W,>&&7C?OQFNGM;NWLX3*Z;#@!F SR>V>] NHS4+BTNI+6V
MGN;:WN;E&*K,X#-MQN*_0$5YE\>O"]Q<?#'5%M=1^S,I2=;@/P0K@\,,@=!^
M=5OC?X3U*]U32-7TN.2582J*$ 8)DL&8@]5P_-=SX5L8+#P?I6DWZ+]I^R>5
M+&WSHP[$Y[$]J"3Y[_9UT*[UWXF+KESJ;7\UK:O$)K.4B$Q\KA0!RPP.O0^M
M>M?&+XAR_#7PQI5_IL4=[JE_?16R071)0 G,A;'/"@GTKJ_ ?P]\+?#>SU/^
MQ(Q%'?R&XD8R$_,QR ,] .>*Q?B?\.V^*G@:/2X]333989S(TCP^8&!!7;VZ
M@]<T/8KH?)7Q(\5:CX5^-%]XT\+:JJ03S_*;=C)L#Q@OL"_+M)QGFOK7X?Z'
M_P (OX?O+AYI[J]U8QWDLBY"C<@)*^V3UJWX%^&9^'G@_3M,@,&IW%LS2><R
M*NXGD #)X'I6Y;03W4MP3(;4,H,C.,9(ZX_PK##TG0HPI.3ERI*[W=EN_43U
M=R?06MXVBCD,CRSJ6<Y_U9[$U'?:M=7-Q);:>T2!#\TV" ?;/K5.)DU*X:R@
MN&B1?FEFVY:0YQ@5O6^FPJH'F*LD)P-_RC . *W$<A>)J:ZDMI%=7#QOR6)R
M"<?TK3T31O/MW-];DHO#2LQ&0>AQ_GK6Q);_ &=RDN453@2,0.3T&/KWJU:1
MO=,Z"15D0>6VYNH(XYZ=.U %:W\/KN$L2-"""J20G:2?ZBJ5OIU_ILT@5$NK
M4 EDF'W\]<8J\S2M-$A7R3"[9;=RJCN/6I)+?/DAV\L,22I'MD4 9>S3Y;,6
M]I;II@5O-:-D"L23Z=ZAN;&6SB8K(KIQB3E>3P #ZYK8GTN;488#)&I 4KN1
M@"#C@FLN026EPZ78^V1JH4NHP8@#W Z_6@">VU)/+:QO+9(8E3(F)^88&#U^
MOZ5S5]X[\-^![R]T^XN))8KDK_J\$"1O4G    /7TK?C@C\Y[R:5;R! %4+@
M=>.3["O O&&J'2KSQ4NOE;>,(LFDW6!AFW*2N.1S\N<_=V>]1+XD(^@[>1[G
M3H3.DQN8\*A*?PL.-WN.]9^EVJ:>UT9I!N,[REL8 .!T_*N0NOCQI'PU\)Z0
MEQ:W&K3W$<<YM_,RPCR=\@=00P 'L.1]*[[0?$MAX\T>/4K6 S:?='"3KD&,
M^A7':JLKIE6[D=E?O>*"6)<,1N)ZCL#6Q;S3Z7<_;8FPF,.N>/I658::]O\
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M%'8*V" >_P"'-:$RE[RTG\SYC*!M[KT^7_/K5G5-#MY&)B+Q2;NCKD#KG\Z
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M:G#;R"2&0DK)&0<D*XY /0CH<UTFCZ/8>'M+MM-TNSAT_3[9!'#;6Z!$11V
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MNRCU'I5K3;E=0MRZL$/_ #S]:[+4+>+4HY 57<1UKSK4+6YTG4LHC!=O&T4
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MLH[T -AVM]T*.,'-3(W16B81XP&]:SY98;96EED$<<8X9SP:LV^;K&9@4(R
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M!OR0,<X_&N,T3598;G['=*$9<,))3N!'IBND6Y6)IDN(S,DKA"8_EVDG^7-
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1ONFEHH \*U*.22_G&TX\QOYFHC&4P"I_*O=?LL).?)CS_NBD^R0?\ /&/_
M +X%+49X849@,#-32_ZM/I7MOV.#_GA'_P!\"C['!_SPC_[X%,1X=)D[0!UX
MIZVY\MN#7MWV.#_GA'_WP*7[+#_SQC_[Y% 'A!L_-0[E_,52^RWFGMOMW8^D
M;5]"?98/^>,?_?(I/LD'_/&/_O@4#/G&/7&U286U[:ALG;TK1N?A[:7MJ98D
M9&89"BO>_P"S[7.?LT.?78*D%O$.D:#_ ("*!'RG=:3=:+=+'*&7)XSZ5H>9
M)(OEAV>/NM?3+V-O)R]O$Q_VD!I!I]JO2VA'_ !0!\V*K+$4V$9JM=692'?M
M.ZOIW[#;?\^\7_? H-C;-P;>(_\  !0,^6[=G^7/!]*TKV:98<A>V,^E?2']
MFVG_ #[0_P#?L4[[#;'K;Q?]\"@1\UVSW!D4[#]?6GK&LW)/[SJ#7TC]AMO^
M?>+_ +X%(-/M1TMHA_P 4 ?-\EK*MPN\[1C(XJ[<0JZAD)8D8%?0GV&W_P"?
M>+_O@4?8;;_GWB_[X% 'SC'F.+S&XQ_#BF2EF^A/W<5](_8;8];>+_O@4GV"
MV_Y]XO\ O@4 ?-3PS>6K(#R<5.VZ&%%9#ANI]Z^C_L-O_P ^\7_? H-C;-UM
MXC_P 4 ?/,C#R01S^%101&3#8)3.?I7T7]AMO^?>+_O@4"QMUX%O$!_N"@#Y
M^;/F*EO\\K<!<41V\D.\R C'7ZU] BQMU;(@C!]=@I39P'K!&?\ @ H X#X0
MN6@U$'LR_P J]%J.*".'/EQK'GKM %24 %%%% !1110 4444 %%%% !1110
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M)*LDFV)2%7<<AAC^9-<_JUQ+INE%)&^96V;-W '/2M>;3_L.U@OVB&2,%L\
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MM* DLDK^6BKSRHC;=Z<4-X7\01^)-T&FW2_99)MN ! \,<!C@02;LE7.,J
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M*O474^<V&JH</X>U13_UQS3DAUF;_5>&]4D/_7(#^=?15%</^H.1WORR_P#
MF5]8J'S_ &_A_P 5WAQ#X9N(3ZW4J(/YUIVOPO\ &%]_KY=-TI>_+3'^E>VT
M5Z>'X/R/#N\<.F_[S<OP;M^!+K5'U/,+'X&VCD-K&KWNI'KY2,(8_IQR17<:
M%X1T;PS&$TS3K>T_VD3YC_P(\UKT5]50P]'"P]G0@HQ[))+\#%MO5A11170(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $91(I5@&5A@@C((ID%O
M%:PI%#&D,2#"QQJ%51Z #I4E% !1110 4444 %%%% !1110 4444 %%%% !1
M110 R2))=N]%?:=R[AG!]1[T^BB@ HHHH **** "HKBUAO(C'/#'/'D'9(H8
M9!R#@^]2T4 )@9SCGUI:** "BBB@ IIC5G5RJEU& V.1GK3J* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>nbx-20211231_g4.jpg
<TEXT>
begin 644 nbx-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &= ET# 2(  A$! Q$!_\0
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M5V$P@4K%\I.U<!B. ,]Z3PY\,_#OA7QAXH\5:;8M#KOB8P'5+IYGD\_R4*1
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M[>R3)<QC".DIEWKC/0$#OBNS^&/PA\-_!_3[S3_#<>H);7<HFE_M#4[B^8N
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M0!U__"U+RQU2[6\C*VJR;4&T';V[=?6MVS\97&H7$Z6UQ!=6V T<\> 1G'#
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MF:&TN@X22548J3<'!PQQP:_3.\A6WO;F)?NQR,HS[,1_2OP'^#3?\7B\"?\
M8>L/_2B.OW\U08U6^_Z[R?\ H1KX+BS"T,-&BZ,%'5[(5/=GJ7@7/_",V7T;
M_P!"-=#7/^ _^19LOHW_ *$:Z&OO\L_W.D_)')+XF%%%%>H2%%%% !1110!C
M:PI:Z4XS\G^->:>+]4;4KS[' 2(83N+_ ,+$=1CT%=G\2+J2UT:X>)I$DV##
M1YR.?7TKRVU\W4DAG*;6,OS GC_>^E '/:U,?,&GV[^9=2C#'H *FL/"-K:P
MQ":+?(>/,D.5/U_I5W1;>*:\O9G4CSI2JACCA3V(Z=#6]+$GG1Y+3'.] #R^
M1^F,=_2@#!FTA6VBZCAVQ@A=BD9''S CE>?2J<FDW]C<M))<23P,0 T/+8Z@
ME3UKJU!;4(R-ER&&XJQ  XZ$_2EB@74$9 45%+,&[C X./:@#CIE>XUB"\,2
MW"2*5"1CKCC&/2KKRQ&WE9(Y("5&%9N/3 ]LXJWJ&CB23%O"97QOEASMW$#&
M5QT;O[XQ7 ?'+QM>?#?P#/XETRUBOXX62'S)E9EMT(.\O&/XN,=>,\T =W'K
MABMH?M3J-T6UHY!COQCCGVK;T7Q7>:3% A5[BUR6"%OFQW"^HKQ;X(_&*V^.
M?AN_<Z<;6_TF.+S4"[HI,G 9&&0 >A4DG&#7HD<CI&/,+%4!)AC'*8(_2@#T
MWQ?K#2:+#%:F2&XO@,&(AF08!(Z<Y&5J?P:VK1PR0:@JQQ1*%B4KAOTX/%<#
MI>H30W375E\[0C 61<DCT4'I_GK7H>F>)K.[M_-DN%MI" &AD(&"!SC.,T =
M$&]J,BJ\<Z21>:CAX]NX,O(Q3=.O[?5+5;FV9GB8\,5*Y_/M0!)(-U;.F_\
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MIG.DLJ,7,A!^[CIR5ZU375-2^&-Q;WNJ>9;SZ[X5:$ELAV?!1,^X7;R>E/\
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M?A3U^[799+8\^[ZBTSUI],]:&!QGQ0_Y!MI_UV_]E-?$_P#P4@_Y,O\ $_\
MV&M-_P#0VK[8^*'_ "#;3_KO_P"RFOB?_@I!_P F7^)_^PUIO_H;5^?O_DHE
MZ?H=/_+L_&<D^M.7+4WN:GMK>2X;;&I8]:_0M+79SIVU9)9P^=<HK@F,$;L5
MU&N%;>WCB@R(,#MWK,L;.6S;:T>"W)XK1U.ZDGC&]/**CCCK7GU).4TEL>=6
MJ.I47+L.\*WC:??Q7##"HXY].:^S]8_:,\/7_P &7L([ADU?[.(3$>AQ7PU#
M?"68JX**?3UJU8QW%U-*FYOW?\/K7BYAE5+'2C.KIRZGS^:9-1S&<*M73E+=
MPK:KJTLL<6]=Q+<?K6C=V,MK#'=JP6,\!>],MHVT]EC"[7DXYIYAEOLPDD$9
M&/2NN4MET1UN?NJ*^%%QM62ZACA9%\WH6]:O:39B"Z"RG:#R3^M8.FV_D2$.
M,G.0QKHI[R&ZV.QP/ND+WXKDJ))VCL<-:*^&.Q]#?LN_$?1M)OM0TW4'AMGN
M@/+NGQA<=OQKRS]KKQ5#XN^(##3)A);QA81*IR&([UYY)*=,5)H&;+'(4=:S
M;S6?[04JR;F+@ACU%>;A<LA2QOUV)Y.#RB%#,/K\=783POJEWX5U=6#?/&<M
M@\5Z5\1OV@-4\;:)%ICR,;>*/:(_IW->9:AI<L<(<C:6YR#4']ES6*AY?D5E
MR,GK7KU,+A\14C6J1]Y;'NUL'A<35C7JQ]Y;%*PTR36+I5'!8X7/%:-K8RZ7
M=26[X(W;2IZ4D<BO-^X)1E'R[?6I;JUU"X@0&/:JMNW'K79*;;Y6[([G4=[-
MV1:\17%BT:F"$13 ;9!]!BN FPI(P?\ "MZ;?<2,,$D=?>L_4(?.)=5"%1@C
MUKIP_N+E._"OV?NMF]\&/^2Q^!/^P]8?^E$=?O\ ZI_R%+S_ *[R?^A&OY__
M (,?\EB\"?\ 8>L/_2B.OZ =4_Y"E[_UWD_]"-?"\9_!1]7^A[%'=GJ7@/\
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MK[?$-J%CS,5)JG8VM-L6UC4&BA&X1Y);V%8_BJ1X[Z)"!L7@ 5O65T^EL3!
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M5\PK&X9"@QP:]%UK]J[PUH^I:]9#0M<U!M#2YFU&2UBC*PP02B.67EQD!B,
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ME ?. 3R#45JRS*S#&5'>I+FS*J&W$# KJ48PCR+1'2H1A'V:5D:>J:Q\Z$,
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M$LK9V\-N7@]A5W7_ -G7PKK^L/J\C7UMJ^^S>&[B="T+6T+0IM5T*D&-B&#
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M@^&_"MSKSA\>1:YP96[^RCO7J&CZ+:Z/;>3;1!%[GJ6]R:N0QI#&$1555&
M,8J45^RY5DM#+8Z:SZLXY3<@&*6DI:^C,PIE/IGK0P.,^*'_ "#+3_KM_P"R
MFOB?_@I!_P F7^)_^PUIO_H;5]K_ !0_Y!=K_P!=O_937Q1_P4@_Y,O\3_\
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M)%G6U>3EHUR-F>1WY(KTWP[:I8Z+:V\?W(UP/S- &C1110 4QCUIS=*8RDC
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M?%#_ )!EI_UV_P#937Q/_P %(/\ DS'Q,/\ J-:9_P"C&K\_?_)1+T_0Z/\
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M/)+X8U"TTO[=82MH%K)9^29(8G22Y-D6,4X)8*5=U+\/PPKZP_9W\.Z_X/\
M@[X;T7Q'IUII&K6<4D<EG93/-%&OF,4 9V8@[2,KN(7. < 5Z5Y:^E C5>@H
M 6EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .19LOHW_H1KH:Y[P'_R+-E]&_\ 0C70U_165_[G2]$>=+XF%%%%>H2%%%%
M!1110 4444 %5M3T^#5M-N[&ZC\VVNHGAECSC<C AA^1-6:* /)K7]F7X<V'
MAVZT.#PZ%TNYN+*ZEM_.?YI+0*+=LYS\H1>.^.:N>-?V??!7Q \3'7M9TF27
M4I%ABNC#=2PQWJ1-NA6X1& E5&.0&''TKTVB@#P3P;^RMHEI+\4+KQ:EEKUW
M\0+U)M3CL;9K2!(8_P#51H-[,"&R[-NY8Y]JWQ^S'\//^$AMM7ET::6YAG@O
M&AEO)7M[BYA4+%<31EMLDJA1AV&> 3DUZY10!\W_  U_8A\#^%/ NG:)XDAD
M\5WUM;75LUS--,D*_:)&:5X82[+$S A25YX/3-=*W[(OPN?4%N#X?F58KF:]
MAMDOIU@@FF5EG>- V%,@8[B.N>U>UT4 >2^'?V9_ 'AGQ-8>([?2;BZU^R>-
MX-4OKR6>=0D;Q1IN8\JB2. I_O&MWPO\$_!_A&_T.[TO2!:W&B)=I8/YK-Y0
MNG\RX')YW,,\_A7>T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3:=3/6DP.,^*'_(
M,M/^NW_LIKY@_:@F\*P_!W5QXLLKO48'PMC;::K&\:\_Y9& J,JX;G=T SFO
MI_XH?\@VT_Z[?^RFO+[S4K/3%C>]O+:S21PB-<S+&&8]%4L>3[#FOQS/ZGLL
MVY[7M;8[*?P'S=XLTCQC_P ,P^!XO'L+:SKUKK>DW.HQ06YGD%LDX8B50#O=
M8_OD#DCIS7"?%3X<)\5/'LTGASP_J6C_  _U35M'M;EX+)[-9[I6G,EU%"5!
M3RU9 9-H!.!VK[1O+V'389+FZN(K.",;GFGD$:*/4L2 !]:@TO7+#7+5;K3=
M1M=2MI/E6>TN%E1CZ;E)&?:O/HYG5H7J1I=7Z:_\,7RH^,+VW^)NH:Y\0/"V
MH:%<7?B'6DTGPT^I+NCMKVU@$IFN?-P0H>+"GKAG-=GIN@^(=!_9U^,'PZOO
M#\]G)I-G<MH]K!(UVCV=PIDCACEVKYA0[UP!GI7U1N;& 3CTH^;CKZBIEG,I
MI)TTM4_FA<GF?(/C*^N5U'0_$GPR\,ZUIS:1X>EM=<OM-TPV+2LZ1I$@5X\2
M/&X>3=M;: 2,DXJMX4\1?$CQ5XP'AZ77O%5KH$=S=R+>0&0220BR#Q#SY(PS
M*9@<' /;H:^Q]S$Y))(]Z#(S=6)_&J6=*,;.DOGN')?J?&[>+/BCX>T/2IKO
M4O%FHC5]"L[K4IMH5K&Y-UMD96$3&%?*X8*K,!R.>:RM(^)WCUO[>MO%'B'Q
M7H^F:7:ZI/H]SI\#FXN9$8&W,S-'O>,(<J74 @_,<BOMSS''(8@]<YKG?%GP
M[\,>/);>3Q%H=GK$ENK1Q272$LB-]Y,@@E3W4\&M*6=4;_O*6GD)P?1GRMX(
M\>?%O7-8T"XN-4U7[1<'2I+!621K>^LG@1KB21$B*,2Q?+LZE2%P,=?LMOO&
MFPQ):V\=O"JQ01J$2*,855 P% [ #C%+7B9AC8XR=XP44C2*MH%%%%>44%%%
M% !1110 4444 %*.])2CO3CN@/7/ ?\ R+-E]&_]"-=#7/> _P#D6;+Z-_Z$
M:Z&OZ+RO_<Z7HCSI?$PHHHKU"0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IGK3Z9ZU+ XSXH?\@VT_Z[?^RF
MOF;]I:31#\(=9MM;\-7GBX7:B"STJPMWEFDN3_JV5D!,6T\^9QC]*^F?BA_R
M#;3_ *[?^RFO+[S6+31UC>[OH+%96\M&N)EC#L?X02>3["OQSB"I[+-E4M>U
MG8[*>L#YZU[P7KNG_LK^'-%^($VK:YJ]O<6<EU<Z1;K=36>V3<C2QG_CXCB&
M%<8)8 \5YS':WM]XWTW5;6UN(M(MO$\<DOB7PWIMS8VVHEK.11(;4AMA5@J%
MU&P[L'FOM"XO(=/59)YX[<,ZH&ED"@LW 7)[D\ =ZF$KJ1\[ XP.<8]J\ZCF
MTJ*DI4KW;?EK\BW"Y\7S>(OBMI/@[P3<ZAXA\2 :QH<][=W4\#K)#J@?;%;;
M(X&8#9AA&P 8DY8=*M?\)]\2X=8U&*ZUO7GU:6"=66QTB7;8?Z,"KM:-%M9
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M6L_ WQ]J?@GQ+-+=>'8YU6WO9F+?9U<_NWS_ '#T]C0!]:45%#-YL:NK*ZL
M593D$'H0:9-?06N//GCBST\QPO\ .@"Q14:R"1=R,K*>A!R*?0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ-_Z$:Z&N>\!_P#(LV7T;_T(UT-?T3E?^YTO1'G2^)A1117J$A1110 4444
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M% #=OO1MIU% #=OO1L]Z=10 SRZ7:*=10 W;1MIU% #=M&VG44 )M%)MIU%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\$^$](T&S>1[#2;.*RA>X??(8XT"*6;N<*,FO&/A0I^)7QK\7>-G/F:?IO\
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MZ&G>2FXMM&X]3@9J2B@")K6)@H**0IR 5& ?7ZTOV>/(.Q<CI\HJ2F<[CZ4
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MPKV#^$5X/!G[1%QT=?YU[O']U:_4N$:\Y4)TY/1-6.:LM1]%%%?H9SA1110
M4444 %%%% !4<G:I*9(NXBD!\G?M'1RQ?$ E\^6]NIC_ *_K7N7P5M;6U^'>
MD_9@@+Q;W9>I8]365\<OAE)XWTF*[L0HU.TSLSQYB]UKQOX>_%;5OA9))I>H
MV$LMFK']P_R/$>^W/:O*_@5W*2T9^C_\C?)J6'P\OWE/==SZPN(TFMW20!D(
M.0W2OFSX26BVWQNU:.P_X](C*#MZ8S_CFM#Q%^T-?>*+4Z;X:TF9;J<;1(WS
M,,\<**[?X(_#6;P783WNH_-JM[S(<Y*#KM^O>MI/VU2/+LNIY5*G4RG!UEB-
M)5%91_4]23YB#4M1JH!XJ2O0/C0HHHH **** .$^*FFR7NAI+&I8P2;VQ_=Z
M&N+\!^*D\/W<D=P3]EF.2P&2I]37M%Q;I/"R. 48;2#W%>8^(/A5+]H>73)%
M",<B&3M]#7X?Q9D694<SAG>5+FDEK$JYV%QXXT>"U\[[;$PQD*IRQ_"O-UNI
M?&GC:"5$94$BX']U%.?Y_P Z6S^&.L3RXD6.%<\L6Y_2O1?"?@VU\-VYVGS+
MA_ORD8_ >@KEHPS[BK$489A1]E1@TWYM#.@6(-C*@X'>G^4.X'Y4HXSSFG5^
M[1BDK$W8SR5]!^5'DKZ#\JDHJ[(+LB:$8^Z*Y[Q%\/=#\775I/K6G1:D;4EX
M8Y_FC1C_ !;>A/N>G-=-14RA&2M)%1J2@[Q=F4K?3H;%%CMX8X(E&%2-0JC\
M!6+X\A,GAN< <*58_G_]>NFJM?6:WEO+#( 8Y%*MGWKCQE%UL/.E'JA)OFNS
MPL=*XGXR>.I/AU\/-3UN">WM[N-XH+=[J!YH_,DD5%!1""3\W'(&<9(KTK7M
M N-!NVCD4F'_ )9RX^5AZ9]:Q+VQMM4LY+:[MHKNUD&'AG0.CCT(/!K\ E1E
M@L3RUX?"_O.^_,M#Y@\._M#>.O%WB*'PQ8W6@VU\NIZI93ZA<6)D/E6MK%.C
M>4DY578NRG#D<>H-<KXH_:6\5_$'X.^,;R._T3PBUCX5@OFCD5_M&H33APWV
M5]X\L+MPN YW<&OKRQ\)Z'I<B266C:?9R("JO!;(C %=I&0/3CZ5%<>"O#UX
MEJL^@Z;,MJAC@$EI&1$I.2%R.!R>!7NK-,&I75!:6_X)#@SRCQ=\4M<T/4O#
MWA^QUC0O#47_  BJZW+K'B)&DBN)$5%\D8=<==S,,D \"N!;]IOQ=K.H:A#'
M8Z>;%=1DT5K.",AI$,&[[5%.\@8G)WJGE8V=\U].ZIX:TC78[>+4M*LM0BMV
M#0QW4"2",CH5!''X42>&='DU3^TGTJQ;4MGE?;#;H9=N,8W8SC'&*RIYCA8:
MNCJ'*^Y\>?#KQ5K=S^SY\8KN76+V:\M=%TJ2"=YV+Q,UD&9E)/RDMSD=34_C
M+XZ>(_$/@54O$30]1C;5+ Z2K317VG+'I4DL4DKK(%E:3"L#M*C/'(S7U]#X
M=TJWM)[6+3+.*VG14EA6!0D@484,,8( X /2DN/#.CWEP9Y])L9YRGEF22W1
MF*[=NTG&<;21]#BM8YQ04G)T>M_R%R/N?#NA_'+Q/X#&IWMG-'JE[&L\D+:I
M--+&IVV2!2@<*5_>L>02#T([^N'X\>-+/XJ2_#?4M2\/Z?=1ZFUL_BB>S=+9
M(Q:K.(S$9<;V8LH)<?*IXS7T$WA/1&SG1]/.[.?]&3G./;OM7\AZ5B>-_A9H
MWCM83<R76FSQ7 NOM&FM'&\KA=H\T.C+( .FY3CMBM99IA*\U[2E;SWL/E:1
MC?L\_$;4_BM\+X/$.K_83?-J%[:,^FHRP.L,[1HZY)."%SU[UZ17/^ _ ND?
M#7PK9^'M$C>+3K4NX,KAG=W8L[L<#+,Q)/\ *NJT_3+G5;A8+6,R2$_@ON3V
MKYRO'ZUBI?5XZ-Z(O9:G>?"^-O[/O'Q\ID !]P.?YUW%9GA[24T73(K53NV\
MLW]YCU-:=?O65X=X7"4Z4MTC@D[L****]4D**** "BBB@ HHHH **** "BBB
M@!CUY1\0(S'XDE)Z-&K#^5>L-7)^.O#+ZQ;K<6PS=0CA?[Z^GU]*^5XBP=3&
M8-QIK5:FM.5I'R;\==2\GQM\++.ZF,.CMJMW?W9R=I>UM'EB# <D;N<<YQTK
MQV[_ &O?%MAIMW*+C0)Y)]-L=1M+BYLV@BB$]\ENP*><7*"-]P+;&XR1BOJ?
MQEX%T[QE)I7]IBY@N=(OX]0M9K=Q'+',F1@Y!RC LK*>H.*QO%GP:\'>+]#D
MTJYT2TLK:2XBNF:P@CAD+1RK*!N"_=+*NX=QQ7YOA<9AJ-*-+$4[M;^6ITM.
M^AY#-\?O%</Q E\"+JOAV8_VK;V2^-%MF^P*DELTYB,?FX,P*[<>8!R*P-&_
M:@\7^([[6K8ZKX3T*+1=#N=3%U=V[O'JTD%U-%^Y)E7;&XC'3<02<9%?3G_"
M'Z!_9+Z6-#TU=,>0RM9"TC\DL><[,8SGOBL67X0^$[GQ:/$,^D6]Q=KI\6F1
M6TT4;6T,,<C2*4C*_*^YSR#T[5<,RP&K]C9^@6D?.?@?X_\ C:^N+R6[U:PL
MI/$&NV-C#%JULWE:#'/:),68>8"5R?+4' +G.><5=F_:A\8)<Z@K3>'X].T2
MXN8+K5+:U-PETL4RH)O*\Y62$AB"T?F$,N.17T]>^&-&U W1N](L;@W:"*X,
MENC>:B_=5LCD#MFH)O!GAZ>.Q1]!TR1+'_CT5K1,0<Y^08^7\*EYG@Y2YO8!
MRON?+6F?M(>)]-L]0N;:72;31K;4+^:>>2.:]E"K>&,&1'E$D<17^*,-@\;5
M'%>X?%+XE:AI?AWPI<^#;W2;R?7=?M-%6ZN ;FWB\XL'.$93N4CH3D=#S7;W
M'@WP_>30S3Z%ILTL$C2Q-):1L4=CEF&1U)YSW-0^'_ ^B>%]+33M/T^-+1+R
M2_5)/G*SNQ=I 3T;<3R.F>*Y:V.PE64:D:=FGL'*^Y\PS?M6>-_[2U#0DM]+
MAOM)746FU5K,F"]-M/Y:($:91$"N"Y#,1N&!77Z/^T%XFU^YO[^>[\->%DT^
M\MK%O#NL;WN[MI(%E,D<BMGDGY $((5LD=O=;KPAH5^BI<Z'IUPBS&X"RVJ,
M/,/5^1U/'/?%33^&=&N=4BU*;2;*74(4\N.[DMT:5%QT#8R!6TLQPDE_ #E?
M<^<-!^.WQ U>U\/'4-7\)^'_ .U]"N?$$=Y=64@AQ"=HMEW3#+D89FS\HX -
M8G_#57BK5M&_M+4HM)T?2[VU6&*VC@DFW226C2!6E2020N6'RYCV[2#O&<U]
M3WGA71-3L;:RN](L+JSMCF"WFMD:.+_<4C"_A22>$-"FU'^T)=%TZ2_\OROM
M36J&39C&W)&<8X^E4LRP=_X ^67<^</A_P#M%Z]'?>%H=<O-&TSPY<+8V@D:
M-YQ\]HLK>;<&4O%+G/\ K$*[1DOWKV_QYJWACQ1X,U_1KC7=,D2\L9HML=[&
M7R83(I4!MQ;;AQ@9Q@CCFMQ_!/AZ2Z-PV@Z:\YA^SF1K2,MY6W;LSC[NWC'I
MQ5+Q%\-_#_B30[[3)=.ALDO(6A>YLHDBG12GEDH^T[3L^3/4+P,5SU,5AL16
MA44'&W8=G8H?L^:Q?^*/@_X U&_+2ZA>:;;-*S<L[8 R?<@ _C7U>O"BO+OA
MAX%BTFUL!';BTTW3X$ALX",?*BA5X]  /K7J6,*,U^C\.X65*-2O)64W=>AS
M5'=CZ***^T, HHHH **** "BBB@ I&&>^*6B@!AC!Z\UE:GX2TG6?^/ZPM[K
M_KI&"?SK8HI-)Z,N,Y4W>#L8ND^$=)T-MUA86]JW]Z., _G6OY8]:=2TE%)6
M03G*H[S=V,6/:V<YI]%%40%%%% !1110 FT$8/2D\L?6G44K -\L4;13J*+(
M!-M%+13 **** "BBB@ I,<YI:* *]Q9Q7<;),BRHW564$&LJ3P1HLC%C9("?
M0D?UK=HKDJX3#UW>K!/U0TVMCG_^$$T3_GR7_OH_XTO_  @NB?\ /DO_ 'T?
M\:WZ*P_LW!_\^H_</FEW,#_A!=$_Y\E_[Z/^-)_P@FB?\^2_]]'_ !KH**/[
M-P7_ #ZC]P<TNYS_ /P@FB?\^2_]]'_&C_A!-$_Y\E_[Z/\ C7044?V;@O\
MGU'[@YI=SG_^$$T3_GR7_OH_XT?\()HG_/DO_?1_QKH**/[-P7_/J/W!S/N<
M_P#\(+HG_/DO_?3?XUK6>F6VGQ>7;0I"GHBXS5JBMJ>#P]%\U.FD_05V(!CW
MI:**[!!1110 4444 %%%% !1110 4444 %%%% "$9IC0ANIJ2BEN!F7WAS3]
M3Q]IMDE8?Q$8;\QS5/\ X071?^?)/S/^-;]%<-3 86J^:=--^A7,S _X071?
M^?)?S/\ C1_P@NB?\^2_F?\ &M^BH_LW!_\ /I?<',^Y@?\ ""Z)_P ^2_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>nbx-20211231_g5.jpg
<TEXT>
begin 644 nbx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X3 ^17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C S.C(Y(#$W.C4V.C(S   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HP,SHR-2 Q-3HS,SHP,  R,#(Q.C S.C(U(#$U.C,S.C P      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  'I$         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ X0$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M!)SG'YX/Y46'B+3-26W\BY7?.NY(VX;'/;\#0!-+K6F0S2PRWT"21*7<,X&
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M  4NHZB]W/J4[<NT:,"=FYD<8R<8#1KP ..#5FZ\+&^FGGN[YGEFBBB8K$%
M$<ID&!GWQ1;2P=2M:>!;.UG5_M#R1DJTD;@X8J[,I'.!][T/0=*CA\ 6D$:B
M.[E,BN^68'!1@ $P".   * +VG^%8].U"UGBNC]GM3*8H/+'&\ 'G/08]*='
MX5MX-,GM;>8PSS2F4W4:!9.7W%<C!QVZ]* ,]? D8M9(#J$A$B2(Y,>2=\WF
M]SV.1]*GN?!<$\^H2"\D3[>)4N!L!S&^W('/!^7K[]* &'P1"([F);Q_*N=Z
MRJ4^\C2%\ YX.2>:R[/P3<W#^3?HL<(=G,BG+?>8A5^8_+AO04 :]]X2GO\
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M0<C]V.^,_P A^5/_ +/L]P;[+%N#%@=@ZGJ: 'R6=M++YLD$;R8QN9034?\
M9MCL"?9(=HSQL'?K0 R32+"1E9K6,%9%DX7&64Y&?7!Y^HJ[0 44 %% !10
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MPZJ)HL*HS, 6SN;)!SR* -&:>.W3?(<+G&:='(LB;UZ<CGVZT +D>HHR/44
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M 44 %% !10 4R4,T+JA 8J0"?6@#/T339=-MY!/+YLTK;W;)ZUIT %% !10
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MW"@!U%)D49H 6BDR*,B@!:*3=1F@!:*3-+0 44F:3<#T.: '44W>,9HW#UH
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M4=0 X +!AGD9/AGQ.^(?QC\0?\%/=7^&O@KXF:QX:LM0:.V@BN+R:XL+"/\
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M/C%\4/\ @H-^T#XK\,^!O'6I?#3X/>%65+G5/#Y\O4=0R[+&5G&&0R;)&7!
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M24XQ_?4UT=_R*N_9U;K6*_&Z/U&0;5 ' IU(OW12T$K8****!A1110 4444
M%%%% !1110 4444 ?GC_ ,%K.?V??!0[_P#"3I_Z2SU[YI_P5TC]H+]A[PIX
M&UE%6WU/PEIRPW!7+6UP+6,Q3*/5'"GW&1T)K(_X*%_LK^+?VL/A?X>\-^#]
M0T;3K[3]874)9-;FEBB,8@ECP#'%(2V9!U &,\U[Q\(_!]YX#^%/@[PSJ$D,
ME]H^D6FGW$ELQ:)I(H41BA(!*DJ<9 ..U))2ISA+JU^0I-JI3E'HG^9\M?\
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M#) KZQ^+?[+W[3O[5%I9>%OBAX]\ >%? :S)->VO@:WO))[THP9=XN .A&0
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M_P#@H3\(_C9X._9GU?4?''[0 ^(&A+>V:2:%_P (;8Z9YKF90K>?$Y<;3@X
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M]G'X>?M%?M&?&73OB%X>_P"$AL]-GDGM8_MMQ;>7(UW(I;,,B$Y Z$FOJ/\
M:0_X)T_"7X>?!7Q9XQ^&&F:E\/\ QEX=T^?5[/5=+UN]9R8(S(8V\V9L!@I&
M5VD'!R<$&>9*"G+JKE*-ZCIK=.Q][AE]:7-?'_\ P3&_:&\1?'_]GV67Q9=O
MJ6O>'M0;2I-1F/[V[C$:/%)(>[X<J3U.S)R237TYXR^)7A'X<V<-WXL\4Z+X
M7MIFV1S:SJ$5HCMZ R,H)]A6LH\DK&<6Y*YTHZ4M<[X-^(WA/XB64EYX4\3:
M/XFLXSM>XT>_BNXU/7!:-B!6S>ZC:Z;:2W5W<1VMM"I>2:9PB(HZEB> /K4[
M;E;[%FBO.=*_:2^$FNZI'INF?%'P9J.HR/Y:6=IX@M)9F;.-H19"2<\8Q7<Z
MOK6G^']+O-3U2^M].TZSA:XN;R[E6*&"-02SN[$!5 !)).  :.EPZV+M%<"O
MQ_\ AA)X8/B1?B-X3;PZ+@VIU<:W;&T\X $Q^=OV;L$';G/(K8\%_$WP?\2+
M6:Z\)>*]$\4VT+;)9M%U&&\1&]&:-F /UH\A7ZG344QI57J:\_U/]HKX4Z+K
M<NC:C\3?!]AK$3^7)I]UKUK'<(V<;3&T@8'VQ1UL,]#HJ*&ZBN(4EBD66-UW
M*Z'(8>H(ZBN5'Q@\"'Q;<^%1XT\/?\)/;(TD^B?VK!]MB54$C%H-^]0$(8DC
MA3GI1Y!N=?17">&_CU\,_&6M#1_#_P 1/"NNZN25_L_3=:MKBXR.H\M'+9X/
M;M7<^8N,YXHZ7 =17 ^*/V@/A?X(U:32O$?Q'\)>']4CQOL=4URUMIUSTRCR
M!A^5=;H7B+2O%&EPZEHVI6FK:=,-T5Y8SK-#(/574D$?0T;ZH-M&:-%9'B;Q
M=H?@O29=4\0:SI^A:9#_ *R]U*Z2WA3ZNY"C\ZQO!?QC\ _$FXF@\(^-_#GB
MF>$;I8]%U:WO&0>K"-VP/K23OL!U])N'.32;@W(IDT@CC9B<*!S2D^5.3V#R
M//\ XS?M!?#[]GS1+35OB!XF@\/6=Y-]GM]T,L\LSXR0D42.[8XR0N!D9QD5
MVVAZQ;>(M&LM4LA/]DO(5GB^TV\EO+M89&Z.15=#@\JR@CN!7YJ? BU;]O#]
MNSQ7\2-=_P!/^'?PYD%KH%C)\T$DH=EADQC!W%))V[Y\H'( K]-EQM YJDK0
M4I;O7Y";]]QCLOS)!1N%-,B(A9F"J.23VKS'P'^TE\._BE\1-=\&^$/$5OXB
MUC0[=9]1DL,R6T.7"A/.'RNV<Y"%@,$$@\4>0_,]/8]:0L!@9YI.>/2OS6_X
M+-,-4L?@SX>.2=0U:[) ('06Z=>Q_>TM7*,8[MI?>-*]V^B_)7/TK_&F[AD\
M\U\JQ_\ !+O]F3RUW_#7YL<DZ]J?/_DS7K?P4_9K^''[-]AJMI\.O#G_  CU
MMJDB2WD?VZYNO-9 P4YGD<K@,?NXS3TL[D7;M8]/W ]\T*XR<&OS'\'Z)9_M
MZ?MR_%?0_B;)?:Q\/_ RS66F>&4OY[:U65)O($Q$3H=Q*2N3G)W*"=J@5J_L
MP^(-0_9Q_P""@GB_]G[3=;U+4_AW=VOGZ5INI7#7']G2?94N@L;,254*TB'^
M]A"<D9*I^_RWZJZ*FG%RM]EI/\/\S])"PZD\4A85\3?\%%OVCM9\.Z7I'P2^
M' DO?B;X[(M EJV)+.T<[&;/\+2?,H/\*K(V1@$^Y?LF_LWZ1^R]\'=*\'Z<
M4N+\_P"E:KJ(7#7EVP&]_P#=& JCLJKU.22/O1<NFWK_ ,,$O=:CU?Y'M*_=
MIU,5L*,UR^N?%CP3X9\4V'AG6/&&@Z3XDU#9]CT>^U.&&\N=[%4\N%F#ON8%
M1M!R00*8=+G5=Z9+(D2EG8(JC))X %+N7;N!R.N:X?\ X6%\/_B%>>(/"%KX
MNT'6-2M[>>'5=*L=5ADNK6,9CE\V-6+QX)VDD#!/K4R;6PU;KL:G@SXF>$/B
M-!=3>$O%6B^*(;6017$FBZA#=K"YZ*YC9MI]C73>^:^6?V)O@'\#O@M#XNE^
M#OCI/'#:B]O_ &G<+KEKJ1M@OF&)/]'550?-(1N!)P>3BO?O&GQ1\&_#6&"7
MQ?XMT/PK%.<12:UJ4-FLA]%,C+G\*IV5B5>[.H^M8'C+Q]X9^'>EKJGBOQ#I
M/AG3#((1>ZQ>Q6D&\@D)OD8+N.#@9SQ3/!_Q&\*?$.Q>[\*^)M'\2VB':UQH
M]_%=QJ?0M&Q KXZ_X+"DG]D^W_N_\)#9_P#H$M9SDXI>;7XLN"4_Q/MK0]<T
M[Q-H]IJND7]KJFF7D:S6U[93+-#/&1D.CJ2K*1T(.*O5\Z_L^_%?P%\)?V9?
M@]8>,/&WA[PG=3>%--DC@UW58+*1P;9"<+*ZG&3VKW;P[XHT;QAI,&J:%JUC
MK6F3Y,5[I]PD\+XZ[70D'\#6\X\LG%=#.+YHIF1XD^*W@KP=X@T_0=?\7Z#H
MFN:B5%EINHZG#;W-UN;8OE1.P9\M\HV@\\5U0;-?EM_P4;Y_;Z_9W/\ TWTW
M'K_R$Z_453M49XK./O4E4\VON9<M)\ODB6BO/]<_:$^%OA?6I-&UKXD^$='U
M>-MCZ??Z[:P7"MZ&-Y P/X5W%KJ%M?6L5S;3QW%O*H>.6)@RNIZ$$<$&FM=A
M;:,L44W</6JFK:U8:#I]Q?ZG>V^G6%NADFNKN58HHU'5F=B ![DTKK<"[17G
MWAW]H;X6>+M6BTO0OB5X0UO4Y6VQV6G:[:W$SGT")(23]!7?^8OK3 =17!>)
MOC[\,?!6L-I'B'XC>$]!U52 UCJ>N6MM.,],H[AOTKL].U2SUBRAO+&ZAO+2
M9!)%<6\@>.13T96'!!]10M5= <]>_%;P5IWC.'PA=>+]!MO%EP 8=!FU.%+Z
M4%2P*P%MY^4$\#H":D\;?$SPA\-;.WO/%WBG1?"UI<2>5#<:UJ$-FDC@9*JT
MC*"V.<#FOSA^,3!O^"R/@+OFWM__ $BF]JZG_@M=_P D6\ 9_P"@^_?_ *=W
MK/F_=J?=V_&Q?+^]<.ED_P +GZ*V5Y!J%G#=6LT=Q;3()(IHF#(ZD9#*1P01
MR"*GKDOA,P7X7^$<GG^R;7_T2E9.N?M%?"GPSK$NDZQ\3?!VDZK$VR2QOM?M
M(9T;I@QM(&!]L5K*T9.)C3DYP4NYT'Q \?:+\,?"6I>)O$4]Q:Z)IL1FN[BV
MLI[MHHQU<QPH[E1U)"X4 DX )JA\*_BUX0^-G@VU\5>"=<@U_0KAF1+J%70A
ME.&5D<*Z,/[K 'D'H1706M[I_B/2UN;2XMM2TZZCRDT+K+%,A&.""0P//UK\
MVOAV\O["?_!0JX^'EM(8/A=\3=EQI]ISY-I<R%EB"#H"LH:' _@DC)Z"E%7G
MR/KMZ]BI?!SKI^1^FPI::OW:=0,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _)K]LBZDU?_@JY\)K.ZC,EO:7
M&AQ1*V<%?M+29_[Z8_E7ZPQ_=7Z5^87_  4^\)ZC\*/VDOA'\?;>RFNM#TZZ
MM+?46A3<(Y+:X,R!O^NB,ZC_ *Y_2OTF\&^+]'\>>%=*\1:!?PZGHVI6Z7-K
M=P-N22-AD'V/8CJ""#S3I_P$NS8JG\:_>*-=_I7YD?M->)+W]KS]OCPW^SU<
MZC=VGPXT-EN-8L[20Q_;IDMC<ON(ZX79$,_=)<CDU]7>//VX/ /@G]HOP[\'
M5@U+7O$NK,L,SZ/$L\>GS.1L2<;@1\NYV(R44 D8.1\?Z[:_\*!_X*^66N^(
MV6P\/^,%9K'4+C"Q%IK/R N[H")UV^VY2>#FHII3J0<OA=[>JV')N,)VW5ON
M9]4_&G_@G_\ !CQU\)]1T+2? 6A^%=4@LV_LW6-'LDMKJ"=4/EN\BX:89QD2
M%LY/.<$>6_\ !+7]I'7?C-\$_$_A;Q5J$VJ:[X/9(8[ZX<M--9RH_E!W)RS*
M8Y%W'G:%ZG)K[+^)GC+2?A]\/?$'B37+J*QTG3;&6YN)I7VJ%53QGU/  ZDD
M <FOSP_X(W_#K4M+^'?Q/\=WD3PZ?KDL5A8^8"OFBW65I7![KNF5<^J..U2_
M>C5OMR_B59<L'UN>2?\ !)OX!^#/C-XJ^(%]XUTF+Q+9>'39O9:/J \RQ,T_
MGAII(#\DC!8MHW @!VXSC%W_ (*9?!O1OV;OC1\//%7PIB'P^O?$,%U:RIH'
M^BQPNGEQF2-4P(]Z7!4A<#Y<X!))[G_@B7\NH?&<GIG2C^MY4_\ P6<;_BK/
M@?G@>??_ /H=I75-+VU&+V=OQ0:WK?,^H/$/_!/?X)W'P.OO!]MX%TF"[-@Z
MQ>(?LZMJBW&TD3FY/[QFWX8J6VG[N-O%>+?\$:_B=K7BKX0^,/"&JW<UW:^&
M+Z'[ 9FW&&&=9"85/]T-$S =MYQ7W_?M_P 2.?H/W#=_]FOS1_X(G*1IOQ@S
MP?M6G=?I<UG%WG6O_*G^)D_X4&N_Z'D_[)7P/\,_'C]O?XQ:3XQ@FU30-,U/
M5-5?2&E9;>\G34"D?G@'YU7S68*>">O&0?I;_@H5^QI\/-'^!&J?$3P%X<T_
MP!XN\(>5J%O=>'(%L%EC$BJZLL05=P#;U<#<&0?-@FO&_P#@GIKEAI?_  48
M^-]G=W<5M=:A+K$5I%(V#.ZZBKLJ>K!59L=<*3V-?87_  4F\=Z/X+_9!\=0
MZI=QPW.M01Z986Y8![B9Y%.U1WVJ'<^RFLJEU0IN.]E]]S:.N(FI=_P/./#/
MQQU#]H+_ ():^,?$^MR^=K\7A;5-/U&8=99H8W3S#P &=0CG'&6.*K_\$E=6
M@T+]C74-2NGV6MGK-_/*P[*D<;$_D#7)? 'X?ZAX#_X)'^-GU*![:XUS0-7U
M=8I!@B*2-A$WT:-$<>SBNA_X)6Z&?%'[#^N:+YGE?VCJ6I6@?^[OBC7/X;JT
MJW7MG!:V7WG,M8TG+;F?W6/)OV+O ]O_ ,% /CEX^^,'Q;M_^$BT71;B.UT3
MP]>2,]G;[RS*ACZ,D:*ORGAF<LP)KHO^"CW[/^A?LXZ1X6^./P?L8?AWXFTC
M58;2Z30(Q:VTT<BMM;R4 3(9=I4 !UD(8-BO(?\ @G3^S#\(_B9XL^(WP\^,
M7A3[;\0- NQY%G<:G=6CB%"T<ZJL,J;]KA<GGAQCBOJGXQ?L:_L4_ '0;36?
M'OA>W\/V%U<+:P-)K>K2/)(2/NQI.S$#J2%PHY-*7N\G([6M;^O,W3<I3Y]=
M]/Z[&Y^T/)X1_:&_8&U/XJ:KX1T6[U^?P:U]9WMY8137&GRL@9U@E=2Z8<-C
M:1TS7%?\$I?A%X%U[]FO0_%.I^"O#NH^)K76+IX-;NM*@EO8620;"D[(74KV
MP>.U>T_M+>$_#?@/]@?QWH/A"W6U\,V7A:9=.B29YE6$KN7#NS,P.<Y))YK@
M_P#@D?\ +^QYII/3^U[X?^1!5)_O*G*K:?J8RO[*FWWU^X\0_:%U;4_VTOV_
M]+^!5YJ-S:_#3PPWGZG8VDQC%X\<(FE=L=6+.L*G^$;B.2<^]?M5?L%_"36_
MV?M>7PKX*TCPEXCT#3I+[2=4T:V6VG,L,9=4FD49F#;=I,A8Y.[.>:^2OB9\
M%?!-O_P5+O\ 0OC#I?VWP5XU8W6G23W4UK%)+-"!'^\B=&'[]'BQGJ1FOK[Q
M5_P3K_9-\#>'-0\0:]X%M])TC3X&N+J]N?$6II'%&!R2?M/X =^E86;PT=;-
MJ[?G_P #L=$FO;.^J6R\B/\ X)?_ +0FN?'?]GMX?$]Y-J7B#PS>'3);^X8M
M)=1;%>%W8\L^"4)/)V9.22:^PCT)KP?]CWPC\#]#^&T^M? >U2'PKKEQYTSK
M<7<I>:,;"&6Z8NA'3' [U[P?E4Y/%=-9W;=K&,%96\S\:/V$OC7_ ,*6_:*^
M,EZ/ ?C;QW]LFEB^S>"='_M*:#;=R'=*N]=JG. ?6O?OVA_^"A7_  M;P[KO
MP3\"?"OQU8_$WQ5;/I":9XLL8-,>".>([W*&9FW>620&"KR&)(&#Q7_!*,C_
M (:>^._?EO\ TLDKJ_\ @K5\'=2\.S>#/C_X1+6FN^&[J"UO[F$#<JB3?:SG
M_<DRASG/F(.@KF7+[.E&?PM*YOK[:JX?%?3U/9/V4/@S<?L&?LA^)-1\4M#=
M:]#!=^)=6@MG#+&R0#;;J_?"Q*"1QN9L$C!KY_\ ^">WP6T_]L+6_&/QX^,U
MO#XYU-]4;3M-TW4U\VRMPJ*[_N6RK(HF541@57#'!)R/K:W\90_ME_L3ZO?^
M'2B7WBSPS=6GV<-_J+TQ/&\)SV64%<GJ,'O7PI_P34_9@^!GQ\\$>*]'^(_A
M/^TOB)H.JNL]K<:E>VD\=HRHJYBBF0?+(LJDXR#@'J*WU=6IS;I*W_ .=6]C
M%KJ]?^#\SJ_V_OA?8?L3?$#P#\;_ (.6T7@VXN;\Z=J>CZ:/)LKK"B15\E?E
M5'5'5T4!>$8 ,"3)_P %5_B)?^+_  I\"KAI[^Q^%?B4+J&I-;Y 8L('19,#
M[RQ-(RJ>I#'!*\>L?%C]D3]B+X%W&@P>-_#EKH$^N70M;"*;7-6=I'[L52=B
MJ X!=@%!8 D9KZ(\?ZI\$?!_A_PO\*O&UUX:CTO4(8--TCPWKTBS^;&BA(0%
MEW'C8%61S][ W;B,PK<L>MI:?JOU\C5WY[K33^G\CSV\_8T_9C^/'PK@T[PU
MX8\+MI3VZK9^(/"?DI>QD#:LGVB/+2..XEW@D?,#70_%_P"&>F?![]AWQYX-
MT:XU"ZTO2/!^H6\$VJ7;W,[*+:3[SMT]E4!0,!550 / _P!KK_@G[\%_A[\%
MO%WQ!\%6=U\.?%/AZTDU6SU+3=4N0C2H,K%L>1@NXX4>7M(8K]#+\#?BIXL^
M+G_!+?QWK/C&[GU+4[?0=:L(]2N3F6[ABA<*[-_$PR4+=3LR23DU%1WIU&F7
M17+5I7ZL\J_X)-_LR^ /BK\,M>\:^-="M_%UY8ZQ+I>GZ?K2"YL;2,0PR.RP
M/E"[F7DE3]P8P<Y3]O[X5Z?^Q+\3?A]\;/@]#'X1N+F^:SU#1;#,5G.5 < 1
M#A8Y$#HZ#"\*0 <D^E?\$6=<T^?]G[QAI,=Y"^IVWB5[F:T#CS$BDMH%1RO7
M:QCD /JC>E<U_P %E?$UCK^D_#'X>:4W]H^+;[5&O8M.MSNE$97R8\J/^>CN
M0OKL;TKHK7C4AR;Z?BD94DI<W/MK^MC=_P""EW[3VM#X8_#?P7X#O9].O?B5
M"MS+=0.5E%DXC"Q!A\P\QI0&(ZA&'1J^@O!/_!/OX&>$_A?;^#[SX>:'KS?9
M?)NM9U&S1]0G<CYY1<X\R,DY(\ME"]!C%?&7_!2GX5ZM\)]#_9T\7B![W2_"
M%G;:'J$L8RL<D(A>//IO\N49]5 [BOU(\-^)M+\7>'=/UW2+V&^TF_MDNK>[
MB8-')$R[E8'TP:CW5"37\S3_ $_ E2DW!2[)_/J?G%^Q+XXU+]G7]L[QS^S5
M<:S=:KX,\Z:;0(;R3>UFXB%RJ*>P:%FW 8!=-P R:\O\3?"_1_C)_P %=/$_
MA'Q$;F;P_J$RM?VEM.\/VN./3(IA"[*<["\:;@",@<8XQV/[/>DQ_'+_ (*Q
M^._B!X=E-YX9\-O/)+J$7S12/]D%BJJPX.YO,9?54)'%,\'Y7_@M7K?^]*?_
M "CK5T4I3I.6LN1W"M[JJV[K_@GIO_!23]D?X9>&/V:=4\;>#_!^C^#/$?A>
M:TGM[O0;1+(R(]Q'$R2", .?W@8,?F!48(!(/7>%/C3X^\??\$NY_'&EW-W<
M>.AX=NH#?0?\?),$\EO)<*1SYGEQM)D<[N1S7=_\%,/^3)?B1_USL?\ TOMZ
MYC_@GCXPT/P#^P#X)USQ)J]EHFBVHU SWVH3K##&#J-R!EFXR2< =23@>E8K
MWJ5:,GU7XIF_PNE-*^K1XM_P3&^&/P#^)GP'9/$6C>%/%?Q$NKVY?5H=>BAN
MK^/YV$9C64%T0Q[3N3 +$Y.1Q]<_L]_L=^ ?V8]<\4:GX&;5[6#775VTVZU&
M26TM54<)$AZ\Y^>0NX!P& R#Q&H?L9?LO_M+:'#XTTSPAH^H6FK1-+#J_ARY
MFLE<L3ERD+HGF!LY#H2""&&>*^=/^"?_ (B\1?#/]L;XF? O3O%=]XM^'.C0
M7;68O9C,+1HI8E7:>B$>8T;A0%9AG J]92<4K2L_P,6DHWO=7.=^".F0?\%&
MOVS?&_B+Q_-)K'PY\%$KHWAXRL+8J\C)!N4'G>(FD?\ O-M4G: M>C_\%&OV
M5?!WPS^$8^+WPQT:S^'?B_PC=VLR77AF);!98I)EAP4BVJ'#2*0X&2 0<YKY
MV_8Y_9A^%VL_M3?%'X1_&C0?[3UVP<_V'#=7]S9F98W<NR>3)'O,D3Q2 '/R
MJQ'&:^P/BU^Q#^QI\"_!\_BCQOX0AT'189%A-Q)KFK.S.YPJI&EP6=NIPH)P
M">@)K/\ Y=4VG;;4V=O;36Z_0]X_9!^-%S^T!^SKX,\;7ZJNIWUJT5]M7:K7
M$4C0RL!T 9HRP Z!@.U=!^T5XCN/"'P%^(NMVC-'=Z?X>O[F%UZK(EN[*?P(
M%/\ @'X,\!>!_A/H&G?#&WC@\#RPF\TT0W$LZM',QEWAY69SDN3\QXSCC&*U
M/BYX/_X3_P"%OC#PP" =8TB[T\$] TL+(#^;48IWC.R[Z$8>T91YG='QS_P1
MNT6WT_\ 9@U>_C \^_\ $5P\K8Y^2*%%7/<#!/\ P(U[S^U1^V-X)_9.T*PN
M/$D=]J>N:J)!I6BZ="6ENF3:&)<_(B@NF23GGY5;!%?.O_!&OQ0L_P #?&'A
M*Y/DZMH/B!WFM7XDCCFC0+N';YX9A^%?1G[5'['/@K]K+0["#Q')?:7K>E"0
MZ5K6FS%9;1GVE@4/R.I*(2",_+\K*3FM:U[JW9?D9T=.92[O\SYEM_A9^T=^
MWI(+OXGZC<_!/X0W!ROA32SMU+4(3_#-N&X9!.3* ,@$0]Z^R?@=^SKX!_9U
M\,C1/ GA^WTB)POVF[_UEU=L,_--*WS/R3@9VKDA0HXKXUM_BG^TE^P9(+;X
MFZ=<_&SX10<#Q5I8+:C81#^*;)W8 !SYQ*DL )ATK[+^!G[1'@#]HGPN-<\"
M^(+?5H5 ^TVAREU:,?X9H6^9#G."1M;&5)'-"M;]WM^/S&[W_>;_ (?(](5=
MJX]*_.7_ (*F^#_''B/XJ_!'5/"W@/Q!XUL=!N9[V[CT?3YIXP?.MF$;R(C"
M,L(R,MQWYQ7Z-9]*\R^(W[2'PU^$_C#0/"WBKQ?I^D>(M=E2*RT^5R9#O)57
MDP"(D9@5#OM!((!)K/:<9=F7]EI'@7C+XD_MG^&_"]SXOM_AY\,9M-BC^UR>
M%8+N]N=9AB R4,@=())%7KLSG'RAB0*] _8U_;,\/?M@>#;^^LM.D\/>(M)=
M(M3T:683>7OSLDCDPN]&VMU4$%2".A/O>L:Q8Z#H]YJ>HW4-EIMG"T\]U,P2
M.*-5+,[,>@ !.:_+3_@D=I%QX@_:"^,7C72+:2U\'RH]O"-A5"\UUYL2#ME(
MT.0.F\>M73]Z<H/M]W_#D3]VFI+O_7W'HMEX'\;?L6?ME?$+Q_:_#OQ3\1/A
MQXZ22='\%V(O[RTNGE$Q5X RD*KF4 G VNN&)!%<?H]UKW@/XZ_$G]L7XK>$
MKSP%H5O9&S\,^&]6VQZE?W30+;0H8_O(QC1MVX#&\D95":_3^XFCMX7EED5(
ME4LSN0%"XR2?:OS,O+BY_P""FG[6PL8S*_P$^'4^Z5U)$.K7&<#Z^85('I$I
M.5,G.=.]U"+V5O1=_P#(TDTN:H^MF_-_UN<A\$_'2_!&8?M+?%O2+WQC\7?B
MA=-;^"_"UD )OL[;5$B[L^4C Q1(0&8(5P&WG'U7I?[>NK>#_BEX;\#_ !L^
M$FI_".\\2,(M(U(ZQ!JUE,Y8*%DEB50GS,H.-Q7>I;:IS7B'[>%G_9'[>W[,
M<\Z+!H2W=G;V^X8A1UOE! '08#1=O[OX3_\ !99OMWA_X0Z78?O-?N-9N#9P
MP_Z]CLC4;<<C+L@^N/2M*;4U3LM'+EMY)V^_JR7%\\HMZVO?S_K0_20'Y1FO
MSJ_X+"?#>]M_"O@/XO:'N@UCPGJ:V\MQ&!E(I&5X9#_N31@#WFK]$+/?]EC\
MPY?'.17G_P"T3\*H/C;\$_&7@F=4)UC3I((&?I'.!NA?_@,BHW_ :QJMP7.O
MLZ_<.BU*U]F<O>?M*:3#^R4WQH^3[$WAP:LL&X?Z\Q\09S][S3Y>/6OE+_@E
M3\-KQ/@K\1_BOK6Z;6O&=W.B7,WWI(8@Y=\X_CF>7/KY8KXPF^.VK:E^Q)H?
M[/MMYI\62>-9;)]-S^]-J"LJ1D?PYNI<#WC-?L]\-_AK:_!OX Z+X+LMGDZ)
MHJVK2  "201GS'/NSEF/NQJZRY85:BZJR]+7?^1,+WA3?1W?RT7^9\$?\$1<
M?V)\6,#'[_3?K]VYKZ?\/_\ !/\ \#S?'#Q7\2O'UY/\5;_5V'V&R\66\5Q!
MIT9SNC$>/+D SA,H B@  G+'Y6_X(NW4FF^#?C-<PPM<RPFPE6%>LC*ET0H^
MO]:YW]B'P#9_\%"O&WQ#\4_'37-5\8-I,L"VGADZG/;6EN)C(2RQQNI1%\L*
MJH5'WBVXX-=-9<U;3I%?DC*+Y82;[EO]N?P7I'[%O[3_ ,)_B+\*[&/P<=8>
M1-0TO2@(;2989(0Z>4"%"R)+M90 N5#8W9->^?\ !8)MW[)-N><'7[,X_P"
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M23DMSQ']F#]D_P -?LH>&M7T#PIKWB+5M(U&Z%X;77KB"9;>7;L9H_+ACQN
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M0S07-UXTNAJ-W>I)(SE9Y"J[P-VU>.%51VKT#\*,'-2M(\BVW&[MIL^0[?\
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M !1110 444E "T4F:-PH 6BDS1N% "T4FX4FX4 .HI-PHW=J %HI-PI-PZ4
M.HINX<<T;AZT .HI-P]:-PH 6BF[AG&:"P% #J*3<*3>#WH =12;A0&!Q0 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#=P7.3BC(K%\8:]-X:T&[U&VTN\UNXB"B*PL$W2S.6"@#L!DY)/  )[5R^A_
M$?4_^$T@\,^)]#MM#O[NQ?4+.:QU$WEO,D;*)49C%&5==Z'&TJ0>&-+=V![7
M/0]W&:*\DM_C=?/HMMXJD\-I#X&N+M;:/53?YNA&TOE)<M;^7@1%R.DA;:<[
M:]:'2F ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,UY9\1/VH/A
MA\)]>O=%\6>*X-'U:TMK>[>SDMIY)9$G=XX1$J(?.=FC?]W'N?"DE<<UZD:^
M3K'1=$U#_@IAK-_?1P2ZUI_P[M'T[S@"T8>\F261 >A *J2.TA'<TEK)+^MA
M2=HM^GYI'O7PK^-7@GXW:'-J_@GQ#;Z[96\I@N!&KQ36\@ZI+#(JR1-QT=0>
M]:/Q%^(WA_X3>"]3\6>*;YM-T#3462[NTMI;@Q*6"!MD2LY&6&2 <#DX )KY
M<U:^U?P7^WM\0+OP)X<7Q'J%S\-H-1O]#@NX[)+_ %%+TQVRR3.-J2-%N 9@
M?E%>A^#]>^)OQZTOQ3X+^*OP-_X5MX9U+2)[4W__  EEGJWGM(!&8O+A4,OR
MNS;CP-N.]*_NJ45T?]?@-6C)J7E^*3/7_&GQ(\-?#_P'J'C37]5CL/#-C;B[
MGU#8\JK$<88*@+-G(P%!)R,5R7Q$_:?^&/PJ_L=?$_BA;&\U: 7-EIT-G<7-
M]+$1D2?988WF5>#RR  @CJ,5\=>'?$5_\9/A;\$OV?=7D^T:Y8^)Y])\71#+
M*;'0V#L')YQ,/L>&[[_>O:-2\?SS?M0>.[#X0_"ZQ\3>.K&PL;/Q1XMU[7GL
M+.T5D,EM;1ILF9@5RS>4B#(&[)P:;\OEYI+<6R]_?KZWM8])N/VB/"WQ*^!/
MC7QI\,_%%MK']E:9>2)<0QD2VES' [J)895#(P(!VR*,CL153X)_'JQN_@[\
M%+GQQKF_Q=X[TNW^SO\ 9&'VV\^S":7_ %2;(^-S<[5[#TKYD^%\GB0^.?VV
MT\6+H<>O'0=/>]A\--,U@DC:;='Y3* S/M";F*C<P)P!@"]X?8#PC^P620 =
MHR3CDZ2P _\ K4[<M[=>3\;W*E=:=5S?@DT?:WB+XG^&O"GC3PMX2U74OLOB
M#Q0URND6?D2O]I-O&)9AO52J;4(/SE<]!DUQ_P 4OVK?A7\&?$":'XM\6PV&
MLM";E]/M;2XOIX81SYDJ6\<AB3'.YPHQSFO+_P!H:\A_X;9_9:MQ*/M"MXDD
M\L'D*=.7G'ID'\C7DG[*EU\:;S7?C7K/@[2?A[?WUWX\U*#5+CQ1J5]!J"/$
MP2*$B&WD'E)&5"#=T)XYHM>*>VC?W.PY)12ZWM\KW_R/NOPIXQT/Q]X;L=?\
M.ZK:ZWHM\GFVU]8RB2*5<XR&'H001U!!!YKQ_P#:8^+'BCPWKW@#X=^ I[2P
M\:^.KZ:WM]5OK?[1%IEI;Q^;<W/E9 D=5P$1B 2W)XQ6!^Q3\/\ 7OA[!\3[
M/6=9\'W8O?%,^H+I/@O49+RVT>:15,ULWF1H8FW#=Y>.-W;-4_CDW]D_MO?L
MXZC<QJ+*YM?$&G1S-T6=K6)U7..K!6 SUYH:C*44]G_E>WZ&:DTI/>U_\K_J
M6/"_CCXC_!?X^>%/AQ\0_&4'Q#T3QM:7<FBZ])I4.G7EI>6J+)+;2I!B-T:,
MEE8!6!!!SU/OOCKQ?9_#WP7KWB?4]QT[1K"?4+G8,L8XHV=L#N<*:^>OVF)/
M[2_:H_9DTFVC$M['JNK:BX7DQP1V6'8^@RZC/KBO1_VMM+NM<_9?^*MC9QF>
MZF\,Z@L4:C)9OL[G ]S64Y/V3D]-U_7Y?(TBE[11[VO_ %^)X)'XL_:(F^!9
M^/2^-M*CA.GMXC3X9OHD+61TW9YH@-[Q<>?Y/S>9G;O^79CFOIRR^,WAF;X,
MVOQ.O+P:?X5FT>/6VN9^L4#1"3D#JV"!@<D\5Y=IOBS3!^P#;>("\(TM/AX)
MR,X3:-/Y3IZC&/PKYTT4>,'^''[._A/6_A?XR\5?#71?#.GZ]J=OX;LX9SJ.
MH!0UK;3K--$!%%@2LI)W-L!7"FM9Z2G!:)6M^-_R,J;YHQF]WO\ A;\SVG]C
M7X^?$#XU_$CXP1>-;5]%L--GTR;1= FAC2;3[6YMWE19&5=S2.GELP<G:Q(&
M,8K2_;C_ &D=<^"GPZO]*\ QB[^(EUIEUJ4)$:R+I=A;INN+Z56!7"\(@8$,
M[C@@,*\O_9E^,UYJG[7'Q]?_ (5QXUL7UF72YGCO;.W0Z:8-.<A+O;.VPR[<
M1[-^=PSMKS?QEXV\56/P*^.OB+Q[\'?B)#X_\::3>PWFKR:?:G3-'LEC=;:V
MCD-SO$$2G>["/<SL[$'BE5M9*.GNI_A^I<+\S;[GU'\6/V@O$?PM_9!T+Q]:
M16FJ^+=2L-)ABFU#$5JMU=^3&9IM@ "*TA8A<#@#BN7\0>,/B_\ LU^/?AB/
M&/Q%M?BCX?\ &NNP^';NQDT*#3KBPN9E<QS6K0<O$",,LNX@ ?-DDCA_B%\6
M-1\1?L9?"WPO%X:N/#'_  F>I:/X'FN?&&FP2)%#+ I:]BAWR)(IV?N]^#NP
M2!@5'\9?@3!^R1>?#3XGZ'XL\2>-[K1=6L]!.C^.+[^UPUM=.(7-EO7-M< 8
MP8B!A2",9#7M4=^LK?EI^._GY&,=**O_ "W_ *^[^KG5_M!?MC>-/A7\>-&\
M*V7@2^FTZUF9I%AU33A!JT%Q$(;5IY9&W:>OVM@JF3;YFPXSRM?8&C7=U?:3
M8W%[9-IUY-"DDUFTJR&!RH+1EE)5BIR,@X..*JW7A?2-1EN)KK2;&ZENDCCG
MDFMD=I5C8O&KDCY@K$LH/0DD<FM55P!4K16-=6[CA2T@I:!A1110 4444 %%
M%)F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,TM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^/O&VE?#KPKJ
M7B+6I&ATZQC#RLB[G.6554#U+,HYXY&2!7EOP\US0/B-XDN=>O\ Q9H%SXLU
M*PDL[#0M,U6"Z;3;4C>R@(V9)25#.XX&T <+D^Y,I)SC-)L..GO2MOY@?+S:
MU9ZE^SC8?#&.X7_A._+M]$DT,G-U'(DRAY63J(@JE_,(VE>]?1.D^,-'U3Q%
MJ_AZTO?.U?1UA:^M_+=?)$JEHSN(VMD _=)QWQ6P(\<8X],UGV/ARQTS4]2U
M"UM_+O-19'N9V=F:0JNU1R3@ #@# Y)QDDFKMZL5NQJ*01Q4<ZRLG[EUC?U=
M2P_($5(*6D,H^3J/_/U:_P#@,W_QRE\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _
M5K_X#-_\<H\K4?\ GZM?_ 9O_CE7:* *7E:C_P _5K_X#-_\<H\K4?\ GZM?
M_ 9O_CE7:* (HA(L:B5E>3NR*5'Y9/\ .OB;Q[\(=,^+G_!0K7(+K6-<\.ZA
MIOP_L;NPUGP[?FTO+23[;,K%6PR,I4E2LB,I!Z=#7VZ:85.X<4*ZDI+^M+">
MJM_6Z9YG\&OV?_#?P376;C2Y]4UO7M;F6XU;Q'K]X;O4M0=1M3S9=H&U%X5%
M"J!T [^F =AQ3MO %&VD'F>2^$_V9?!W@WX[>+/BUIR7G_"4>)+:.UN8Y9$-
MM$JA [1($!5I/*CWDL<[!TYSB>._V1_#_C#XE:AXYTGQ9XR^'_B#5(([;59O
M"&JK:)J:QC;&9U>-_F5?E#IM('?/->[$4F#1:R270?5WZGA'@S]C;P)\/[CQ
M^^@SZU:Q>-]+73-8BFOOM'FD+*INO,E5I&G;SY"SN[ D_=J[X@_9-\&>)O@O
MX1^&]W<ZS#9>$X[;^Q-<L[T6^J6,T";([B.9%"B0*3_!M.?N],>TX-+@^E'F
M_+\-OS \ \,_L:^%M!^)GA?X@7WB;Q=XI\9>'WN##J_B#5$N9)XY8'A\EP(U
M58T61V58EC^9B6W59\<?LB>&_%7CC4_%^A>*O&'PWU_5T5-7N?!>K"S74MJ[
M4:>-XY$+J,@.JJW/7->[<TFW]:>]K] .'^#_ ,&?"_P-\(KX=\*6<D%HT\EW
M<W-U,T]S>7,AS)//*QW22,>I/H ,  5#\9/@QX;^.'A:/1/$D5U&+:YCOK#4
M=.N6MKW3KJ,YCN+>9>4D7)P>>I!!!KT"FLH/6D]=6):'C_PG_9DT#X6^*K[Q
M7-KOB7QQXONK86/_  D'B[41>7<%J"&\B':B)&FX;B%0$GDDUV/A?X=KX:\2
M>*]6?Q#KVN)X@GCG;3M7OOM%GI^Q-GEVD>T>4C=67)R?RKL"M'X4]P/FG_A@
M;P LC:>-=\8KX#:\^W'X>+K97P_O+[]GD!-_E;_G\KS-F?X:^D(+:.WC2*-%
MCB0;550  ,8  ':IN:1<]Z.E@ZW."\%_!O1_ OQ'\>>-K"ZOYM5\926<NH0W
M,J-!$UM"88_*4(& *DD[F;)Z8Z5I_$[X?6'Q6^'OB/P?JLUS;:;KMC-IUS+9
MLJS)'(A1BA96 ;![@CCI75\XH_G2?O*S&M'='GGB3X#^$/&7PCM/AOX@T]M9
M\-6UI;VD:W$A6<>0JB.42)M*R#8IW+MY_*N#\*_L:^&M%\5:%KOB+Q?XW^)$
M_A^43Z/:^,]:%Y;6$P!"S)&D:!Y%!.'DWL.#G(!KW_FEQ3UO<5DERB+D+S3J
M2EH&%%%% !1110 4444 %(:6B@"DT-_N.RXME3/ -NQ('UWBCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6
MO_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6
MO_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6
MO_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6
MO_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6
MO_@,W_QRCRM1_P"?JU_\!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\
M!F_^.5=HH I>5J/_ #]6O_@,W_QRCRM1_P"?JU_\!F_^.5=HH @MX[A<^?+'
M(>WEQE/YL:F'%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129Q0 M
M%13W4-K"\TTJ0Q(,M)(P55'J2>E<[<?%#P;:RM'/XMT.&13ADDU*%2/J"U '
M3T5RO_"V/!'_ $./A_\ \&D'_P 71_PMCP1_T./A_P#\&D'_ ,70!U5%<K_P
MMCP1_P!#CX?_ /!I!_\ %T?\+8\$?]#CX?\ _!I!_P#%T =517*_\+8\$?\
M0X^'_P#P:0?_ !='_"V/!'_0X^'_ /P:0?\ Q= '545RO_"V/!'_ $./A_\
M\&D'_P 71_PMCP1_T./A_P#\&D'_ ,70!U5%<K_PMCP1_P!#CX?_ /!I!_\
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M /@T@_\ BZ .JHKE?^%L>"/^AQ\/_P#@T@_^+H_X6QX(_P"AQ\/_ /@T@_\
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M_P#WZ?\ ^*KZ HH ^?\ _A@3]GK_ *)-X?\ ^_3_ /Q5'_# G[/7_1)O#_\
MWZ?_ .*KZ HH ^?_ /A@3]GK_HDWA_\ []/_ /%4?\,"?L]?]$F\/_\ ?I__
M (JOH"B@#Y__ .&!/V>O^B3>'_\ OT__ ,51_P ,"?L]?]$F\/\ _?I__BJ^
M@** /G__ (8$_9Z_Z)-X?_[]/_\ %4?\,"?L]?\ 1)O#_P#WZ?\ ^*KZ HH
M^?\ _A@3]GK_ *)-X?\ ^_3_ /Q5'_# G[/7_1)O#_\ WZ?_ .*KZ HH ^?_
M /A@3]GK_HDWA_\ []/_ /%5;T_]A?X :9*)(?A+X79@<C[18K.OY/D5[K10
M!C>&_!^A^#-.&G^']%T_0[$=+;3;5+>+_OE !6PO"TM% #2O.:Y#QU\'O WQ
M.B\OQ?X.T+Q. ,!M6TZ&Y9?3:SJ2,>U=C10!X%/^P5^SY<2&1_A-X=#$Y(CM
MR@_($"F?\,"?L]?]$F\/_P#?I_\ XJOH"B@#Y_\ ^&!/V>O^B3>'_P#OT_\
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MVU^O_ _S/ID4M-3&T8Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI* %HHHH **** "BBB@!K5\3?L
M_K_QLJ_:.]/[,TC_ -$15]LM6#I_@7P]I/B;4O$=CX?TNS\0ZFJ1WVK6]G&E
MW=*@ 1990NYPH  #$XP,5*TFI>3_ !"6L''T_!W/CS]N#3YOA'^T1\%OV@;C
M3KC4/"OAN6?2?$$EM$TKV4$Z,D=QM R54S29]PHZL*S?VWOVI/A]\8/@++\,
M_AKKMC\0O&WCQ[6QTS2M#<7#1CSHY&DFQ_J=JH>'PV><85B/NVXM4NH)(9HU
MEBD4J\<B@JP/4$=Q[5R?A'X-^!/A]J5SJ'A;P1X<\-7]T,3W6D:3;VDLH)R0
MSQH"W//-2HKE]F]KW_&]BN:TN>.^WW;,XZ_^)7@S]D_X3> =+\?^(O[.B6&S
M\/6UW]EGN/M-TL 4#$2,1D1L<L /4U[%MXKR?]HSX(K\=_"FC^'9H-*-K'K%
MK>W-YJ%L)I[:&)][FUX.R9]HBWY&U)9#R0%/K"J<8/6M7+FO)[W_ ,O^"91C
MRI16R1\4^$^/^"M'C8?]4\B/_D>UK[6[5AQ^!?#MOXNG\51:!I<?B>XMQ9RZ
MTEG&MY) ""(FF"[RF54[2<<#BMS!Q41T@EVO^;?ZFCUE?T_)(<.E+2"EJA!1
M110 4444 %%)10 M%%% !1110 4F:6H+NZALK>2>>5888U+O(YPJ@#DDT;Z"
M;LKLCU#4K?2[.:ZN95A@A7>\C'  KA/"/QAL/%&O7&GR1_8]SXM'D/\ KACH
M?1L\CZ@=>*\Q^*'Q(E\87K6=HS1Z1"YVJ<@S,.-S#^0-<(K,CJRMAAR&!P0>
MQSV(->U1P/-3;GN]CP*^8N-6U/9;GV:K J.<TM>8?"GXG#Q% FE:E)C5(U^2
M1N!<*._^\,<^N,^M>G*>.N37E5*<J4N61[5&K&M'FB.HHHK(V"BBB@ HHHH
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M1_:-W_S]3?\ ?QO\:/\ B)N#_P"?$OO061Z9N'K^M&X>OZUYG_:-W_S]3?\
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MI6"HB@9+$G@ #O6)X)^(6@?$;39]0\/7S7UI#,;=Y&MY82'"JV,2*I(VNI!
MP<\&@#HZ*XFQ^,/AS4[S[/9IKEW_ *0]K]H@\.Z@]OYB.48><(/+P&!!;=@8
M/-=KN!&10'D+1124 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNX=QD#@\'H01Q7!_!5 NJ?$=5 4#Q/,,*  /]'MQ7H>LZ3%KFGSV5P]S'!,
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M[ZB_^+H^W3_] ZZ_[ZB_^+J[10!2^W3_ /0.NO\ OJ+_ .+H^W3_ /0.NO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 2N'^+'Q&O/AIH5MJ-EX+\1>.)9KD0&Q\,
MV\4UQ&"K-YC"61%VC:!G.<L.*[BFM]ZD]AH^=?\ AK;7O^C>/BWUQQIMC_\
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MHH **** "BBB@ HHHH **** #TKU./[B_05Y9Z5ZG']T?05^\^%^V+_[=_\
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M7;OKIZ"CI2T@I:P.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCG_D?XC_ +=_])184445\" 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ[5KS.2OUT_6WX$2MSKY_?I?]#J%.5IU-7I3JDH**** "BBB@ HHHH ****
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M"BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110!R7CG[]G_P "_I7+5U/CG[]G_P "_I7+5_)7'/\
MR/\ $?\ ;O\ Z2BPHHHKX$ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M35RB@"G_ &M!_P \[K_P$E_^)H_M:#_GG=?^ DO_ ,35RB@"G_:T'_/.Z_\
M 27_ .)H_M:#_GG=?^ DO_Q-7** *?\ :T'_ #SNO_ 27_XFC^UH/^>=U_X"
M2_\ Q-7** *?]K0?\\[K_P !)?\ XFC^UH/^>=U_X"2__$U<HH I_P!K0?\
M/.Z_\!)?_B:/[6@_YYW7_@)+_P#$U<HH I_VM!_SSNO_  $E_P#B:/[6@_YY
MW7_@)+_\35RB@"G_ &M!_P \[K_P$E_^)H_M:#_GG=?^ DO_ ,35RB@"G_:T
M'_/.Z_\  27_ .)H_M:#_GG=?^ DO_Q-7** *?\ :T'_ #SNO_ 27_XFC^UH
M/^>=U_X"2_\ Q-7** *?]K0?\\[K_P !)?\ XFC^UH/^>=U_X"2__$U<HH B
MM[N.Y4E!(H'7S(V3_P!" J:DYHH 6BBB@ HHHH **** "BBB@ HHHH ****
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M10 >E>IQ_<7Z"O+/2O4X_NCZ"OWGPOVQ?_;O_MPF.I:2EK]Z)"BBB@ HHHH
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MXE_ KQ;X=LYO%:0C7?#/C."=["6:)2JSQR0Y=6P3\H Y9CDY $]I=T_^&?\
M78MZ)Q]/Z_KS/!/B!HOQ-\5?MV?L[:U\14TS1]9OI[Z6S\(Z/,;M-(L8(0Y>
M:? $DLC%\E1M B7!/(K]*U^Z/2OF[X"_LP^*/#OQ0U/XM_%KQ5:^-/B7?6?]
MG6JZ; 8=-T:TSDP6RM\S9/5V ."<@DL6^D@"*T7NP4?5_>_Z^9FU>?-Y)?<+
M2T@I:104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\Q0 ^TY7<!@XR*U^SYZ&;^.W36WIT-,4M(*6I*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#DO'/W[/_ (%_2N6KJ?'/W[/_ (%_2N6K^2N.?^1_B/\ MW_TE%A1117P
M(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !Z5ZG']Q?H*
M\L]*]3C^Z/H*_>?"_;%_]N_^W"8ZEI*6OWHD**** $W"EIC+GMFOB+X@_P#!
M73X/?#/Q[XE\(:GX;\<7&I>']3N=)NIK2QLVA>6"5HG9"UV&*ED)!(!QC(%
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MWQ _\%UC_P#)E 'W_17P!_P^K^"'_0K?$#_P76/_ ,F4?\/J_@A_T*WQ _\
M!=8__)E 'W_17P!_P^K^"'_0K?$#_P %UC_\F4?\/J_@A_T*WQ _\%UC_P#)
ME 'W_17P!_P^K^"'_0K?$#_P76/_ ,F4?\/J_@A_T*WQ _\ !=8__)E 'W_2
M%@.M? /_  ^K^"'_ $*WQ _\%UC_ /)E=]\!?^"GWPL_:*^+.A_#[PWH'C"R
MUK6//\B?5+.UCMU\J"2=M[)<NPRL3 84\D=!D@ ^P:*0<<4M !1110 4444
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MEJZGQS]^S_X%_2N6K^2N.?\ D?XC_MW_ -)184445\" 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 >E>IQ_<7Z"O+/2O4X_NCZ"OWGPOV
MQ?\ V[_[<)CJ6DI:_>B0HHHH 2OYK?VL?^3IOC)_V.>L_P#I=-7]*5?S6_M8
M_P#)TWQD_P"QSUG_ -+IJ /*J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OJK_@ES_R?7\,_^XG_ .FR[KY5KZJ_X)<_\GU_#/\
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MUC_R=-\9/^QSUG_TNFK^E*OYK?VL?^3IOC)_V.>L_P#I=-0!Y51110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]5?\$N?^3Z_AG_W$
M_P#TV7=?*M?57_!+G_D^OX9_]Q/_ --EW0!^_P!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ4 J,<XR2#0@ZG844BYVC/6HY[>*Z39-&LJ?W74$?K0!)1FJ7]B:?_SX6O\
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M_P"?"U_[\K_A1_8NG_\ /A:_]^5_PH N$C'/2OYK?VLN/VI_C)G_ *'/6?\
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M0!<S1FJ?]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A0!<S1FJ?]BZ?_SX6O\
MWY7_  H_L73_ /GPM?\ ORO^% %REJO!906N1!#'"#U\M O\A4X]Z %HHHH
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M4 %%%% !1110 4444 %%%% !1110 4444 <EXY^_9_\  OZ5RU=3XY^_9_\
M OZ5RU?R5QS_ ,C_ !'_ &[_ .DHL****^! **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH /2O4X_N+]!7EGI7J<?W1]!7[SX7[8O\ [=_]
MN$QU+24M?O1(4444 )7\UO[6/_)TWQD_['/6?_2Z:OZ4J_FM_:Q_Y.F^,G_8
MYZS_ .ETU 'E5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7U5_P2Y_Y/K^&?_<3_ /39=U\JU]5?\$N?^3Z_AG_W$_\ TV7= '[_
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@7]*Y:NI\<_?L_^!?TKEJ_DKCG_ )'^(_[=_P#246%%%%? @%%%% !1110
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M-EW0!^_U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 2FLO)IU+0!'M].O:G@;1BEHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .2\<_?L_\ @7]*Y:NI\<_?
ML_\ @7]*Y:OY*XY_Y'^(_P"W?_246%%%%? @%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 'I7J<?W%^@KRSTKU./[H^@K]Y\+]L7_V[_[<
M)CJ6DI:_>B0HHHH 2OYK?VL?^3IOC)_V.>L_^ETU?TI5_-;^UC_R=-\9/^QS
MUG_TNFH \JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *^JO^"7/_ "?7\,_^XG_Z;+NOE6OJK_@ES_R?7\,_^XG_ .FR[H _?ZBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI*1G"]32 =13=P]:7-,!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .2\<_?L_P#@7]*Y:NI\
M<_?L_P#@7]*Y:OY*XY_Y'^(_[=_])184445\$ 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 >E>IQ_<7Z"O+/2O4T^X/H*_>/"_P#YB_\
MMS_VX3'4M)2U^]$A1110 E?S6_M8_P#)TWQD_P"QSUG_ -+IJ_I2K^:W]K'_
M ).F^,G_ &.>L_\ I=-0!Y51110 4444 %%%% !1110 4444 %%%% !1110
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MKR[T2SEFGE=BSR.[1$LS,22Q))))- '\WE%?T<_\,4_!#_HF'A+_ ,)^Q_\
MC-'_  Q3\$/^B8>$O_"?L?\ XS0!_.-17]'/_#%/P0_Z)AX2_P#"?L?_ (S1
M_P ,4_!#_HF'A+_PG['_ .,T ?SC45_1S_PQ3\$/^B8>$O\ PG['_P",T?\
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M_P#C- '\XU%?T<_\,4_!#_HF'A+_ ,)^Q_\ C-'_  Q3\$/^B8>$O_"?L?\
MXS0!_.-7U5_P2Y_Y/J^&9_["?_ILNZ_8_P#X8I^"'_1,/"7_ (3]C_\ &:U?
M"_[*OPL\#Z[;:WX<\$Z%X?UFUW>1J.EZ3:VUQ%N4HVV1(@RY5F4X/(8CO0!Z
MS2UB_P#",_\ 45U/_P "/_K4?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/
M_P "/_K4?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!1
M74__  (_^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!174__  (_^M0!M45B
M_P#"-?\ 45U/_P "/_K4?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/_P "
M/_K4?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!174__
M  (_^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!174__  (_^M0!M45B_P#"
M-?\ 45U/_P "/_K4?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/_P "/_K4
M?\(U_P!174__  (_^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!174__  (_
M^M0!M45B_P#"-?\ 45U/_P "/_K4?\(U_P!174__  (_^M0!LYHJCI^E_P!G
MM)_I5S=;\?\ 'S)OVXST].OZ5>H 6BBB@ HHHH **** "BBB@ HHHH ****
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M->X07,L2$!Y$C)W,JEE!8# +#/6CR U**:6 ZFC>,9SQ0 ZBDW#KFDW <9H
M=13=P]:-ZYQF@!U%)N'K2>8/7- #J*;N'K1O% #J*;O'K2[A0 M%-W#UQ2[@
M1D'B@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO/&6AQR6=_'Y5S:3IJ<220S("=KHZLI'/3()&#7MWQW^/$/P9M=#L+#P_?\
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MPB_:9^#^H:_IGPTU[X8:]X6U+6+S6(IO&MOJ,>I1-<RF5HW:V)67:6P'/S$
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M HHHH **** "BBDH 6BDS10 M%)N'K2>8/6@!U%-W#UI=PH 6BDW#UI-P]:
M'44FX4@D4C(/% #J*3<*-PH 6BF[A2YH 6BDR*3>* '44F:3<!0 ZBDW"C-
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M'M$\5:%:ZUI'P/\ C9J>A7*>9'JUGX02>U>,$AG$B7!4J,')&>AKWSPS\=O
MOBWX11_$ZPU^W'@IK-[V34YLQK#&F1('!&59"K*5QG(Q7PU^R_\ MUZ3\#/V
M3_ NG:S\*/BA=VEA;?95U^TT",:/<2R7#^6([IYE4@LX3..O&#7U)^R!\)M9
M\"_ 4Z3XXT>UM-3U[4-0U:^T%BEQ#:I=3O(+9N"K81@&[9)%;3CRN7EU_P"
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M>C%]7;\+GW/X1\6:7XZ\*:/XDT2Y^VZ-J]G%?V5QY;1^;#*@>-MK ,N58'!
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M=?M3</OD2,(5AD*DD*\A.,C(.,&EX4_8U\9V?P!L/A]J'BG2=+UGP7XC;6?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **0L%ZFDW#UH =12;A1N% "T4FX4FX4 .
MHI-PHW#I0 M%-W@=Z-P]:/,!U%)N!HW"@!:*3-&X4 +129%&X4 +124;A0 M
M%)D4%@* %HINX<<]:4,#0 M%)FC- "T4FX4;A0 M%-W#UH\Q?6@!U%-+@=Z-
MP/0T .HI"P'4TGF#UH =13=PHW#&: '44WS!US2[@: %HHHH **** "BBB@
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M)XKF_P!F/]G/X9_%#X*^-+_Q;X,T?Q%J5WXB\06YO]3MEGN+>,7]P L$C@M
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M%RW?Z?\ #FD*6DI:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC) XP!U'PL^#^D_"'PE>^'M'N;ZYLKN_O-1DDOI$:027,SS2 %44;0SD*,9
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MG\@VNFOJTL;P:/ WWXK2)$14W_Q.VZ0XQOQD5Z9@T<U6M[]2;:6/&?C1\/\
MQ!\7O%GA3PHUD;/X?6=Y#K>NZA)-&?[1:WD#VU@D88O@RJDDC,H7;&%!)8[?
M9%^[[TN#00?K0NP#EI:2EH&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M)10 M%)FDW#F@!U%)D49H 6BF[@.,T;A0 ZBDW#UHW"@!:*3-% "T4F:-PH
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MF/#%]\3O$/P^M/BEX6^$GA_PH(K.[U&XO["+4+FZ*;C;VD-UF*.*)2@>1HI
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MND>)_CIX9^%JBP22=HI["VU&ZN<_,Z"_\V-(..%\IV.[[ZXY-EJ"MTV/<))
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M6\MHYX^4E0.I((.",C@_7I5B@%L+124M PHHHH **** "BBB@ HHHH ****
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M!:^!-6ODGUB\M+E]8U.T8GS[ZZ:22YF0LH)'F2OM+ ' 7CM6'\+? 7Q=\$^
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MLLMW;Q) D%K"]LT"JHB56;*S-N9CP,YKW;FDQ[427-==] VU/D2/]G'XJ_\
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MMQ93E<5U/PY^&7B+PO\ &SXI>,-=_LJZLO$C62Z9>07<AN8+6W@V+;/"T(5
M)&GDW+*V[S.5&*]AP>.*Q_%7@_1/'6CS:/XBT73]?TF8JTMAJEK'<V\A5@RE
MHW!4D, 1QU --MMM_P!:_P!?H+HEV/EO]EGX57GBGQWXQ^(>L31W?A"3Q;J>
MK^$+5 VR=YB(7U)@3ALI&4A./N/(XR)%(^F?']KXIN_"6H)X,O-+T_Q,4'V.
M?6;9Y[7<&!*NJ.K88 C<"<9!PV,'>M;2*RMH;>WA2"")!''%&H544# 4 <
M<8%2[2!2V48K9)(+>\Y/J[GAUY\+?&GQ8\6>"-7^(EAX;T&S\(ZA_:]K8^']
M0GU&2\O!$\:,TTMO;F&-?,=O+"N6.S+ +AO.=8\.^(/A['K/@^;7XM*^*?QG
M\2:C<6NNZ;*S1:9:PQ#R\,X1V:*UBB0(FUB\AVLH!D'UQMK!\8> ?#?Q"TLZ
M9XJ\/:5XETS>)/L>KV4=U#N'1MDBD9&3SCO1Y?U_6@^MW_6_^9\T:'X>OO@+
M\;?!&C:?I'PMU;5_%%Q-#J2^%/!S:-JUO9I"\CWLLYO+@R1B01J=ZC<TJC=D
MUZO\(_A7KW@*X^)/B'5I=.O_ !9XLUN?44,,KF".WCC6&QMV<H&PL4:EL*<,
M[XW<9[KP;\-O"OPYLY;3PEX7T7PQ:R'<]OHUA%9QNW8E8U )_"NC"GIC %#6
M]OZ_JPOZ_K[SY@T/]EGQ';_#/X5^$-4U/3;J+3_$?_"5>-+E)9-VIW@>6Z"Q
M QC>ANWB)+[,)$./X:]*T?X5:LW[1'B#XB:Q/9RV2:);:'H%O!([201F1IKN
M24% JM))Y0&TGY8ES@\5ZKS1M/.*?_!_%6_+0'[U[_UK?\SYEO/V5-:\3?!'
MXF>'=;U73XO&'C;7Y=?N+V'S+BU5DN8WL[=MP1FB6&V@C88'5\9ZGTS0;?XL
MZ[K5K)XA'A;PEI%O%*);70[N?5IKR1D*HWFS6]N(%1CNVA7+$ ;@,Y]/QE:,
M&E96Y?Z[%=?Q/D32?V<_BUI?[,?B+X46K^#M-U.^M;F&?Q1#J5W+<:U).[&:
M:X5K8&WED5VS)ON,9P%P!CU&3X*ZEJ7Q6^&&L7$>FV'A'P/HMPEIH]K.\K+J
M4L<<"L,QJK110"55<X8F0_*M>U;:0K3O9W_K^M2+:6/)=#^%6N+^T!XO^(NK
M3Z?+%+HUKH7AV"%W=[>!6>:Y:8%0%:29DX4M\L2Y.>!6_98^&?BKX2_"Y/#W
MB^#26UH7MU>7.I:7J,MV-0FN)6FEGD\R"$QL7D8;!O "K\_:O9,$4FT]:FW*
MK(IZW_KI8\*\>?"CQM<?M$Z+\1M%M?#OB73++0WTF'2]?U">S;3)GG#RW=NR
M6\ZL[H%1@0AP@&_!-2?#3X2^-_"GB+XPZ]J]]HMWXA\5W44VEZK:/*%CABM1
M%!!) Z?NEC<,WRR2;_,8G:>#[E^%(0:+>ZXKS_%W"^O-Z?AH>4?LQ?#?7/A/
M\%?#W@_Q%::7;:II,1BEGTG49;R.\=COEN6>2"%E>25Y&*[6QD?,W->>0_ 3
MXI^'O'GQ*M_#/B70-+\&^.M435;C676=]:TXFWCAFB@B*^2Q*Q+LE9_DR?W;
MX KZ;P:,<4WK)OOI_7W"2TL>-?LH?"GQ-\$?@UI7@;Q&-$E;0R]K8W.C2RL+
MJVW%DEF#QILE8LQ95W#/(8YX;\>OAEXM\>>+OAAJ>@Q:/J&D^&-9?5[_ $O5
MM0ELA<2K"T=O(CQP39,;2.X0J 2%^88S7M%!JI-R?,]P2LFEU/)W^%.K:I^T
MC'\0=4GLY-$TGP^=*T2S1V::.XGF\R[FD4H%7*Q6Z+M9B0'R!QGBM>^!/CS4
M%^.VM6>JZ1;^,/&\,6CZ#<O/-Y6FZ;%!Y49=A'N63=-=2[5##<R#=U(^C&!H
M].*SY=$NFOXZCZW]/P/(?B#^S[9>)OV;;KX2Z+=+I%G'I,&F6,\D?F)'Y 0Q
M;U&-RDQJ& (R"U:/AFW^*^JZII3>(U\+>%=,LF+7=OH-W/J<FI?(RA \UO +
M9 Q#$!9&.T*'7DGTT@T<U?5M]0V22Z'B^K:7\;M2_P"$DT.6/P%=Z-J$LT=A
MKSS7<<]G:R+A5ETXPNEPZ9.?]*C5_1>E9&A?LS2>&O%'P9L+.[AF\!_#?2KA
M;:"XD8W=WJ3Q+!',ZA-FU8FN&SNR'E&%Q7O^.*,4E=:_U_6HM]#QP_!?5-<^
M.WBWQKKUW:MI<WAV+PYH,-J[-/;1.S27DL@9 JN[^4!M+96(9QG Y/P-\&_B
MAHOP>TSX2W=_X=T/PWIVGKHW_"5:)=W$NI75FHV'9:O"L=M,\?'F>=,%8DA3
MQCZ.YYXI=M)+2W3^O\V-ZN_]=/\ (\)D^!.I:/\ &KX8:MH=GHX^'W@O0;K2
M;/39;J2*XL)I5C03Q((G67]U$(\,\9 D<Y;I5/P+\+/B7\)]:^(=GX='A74=
M'\3ZW>^(;35]3O;B*[M+BX5289+5(&69%90 XF0[<?+Q@_06VDVGTHMY]_Q=
MQ?\  _R/,OV<_A9??!WX1Z-X?UB[BU+Q%F:_UG4("2EU?SRM-<2 E5)4R2,!
MD [0.!7.'X9^.O _QF\;>,/!]IX;URP\9)8->QZWJ,]C<:?+;0F &,Q6\PG0
MKAMA,1#;OFPW'N.WVI,&F]7V&M/Z^9\]>+/V<-?N/@_\0]'TG7K6X^('Q D0
M:]XDNE>V3RF"0R) B!V1(K8.D,9)YP6<EF:O=M!T2S\,Z'I^D:?"MO86%O':
MV\*# 2-%"JH]@ !5_::3;UXIAOJSPN+X9_$+P#\7O'WB?P?!X8UG3/&DEG<S
M_P!N7]Q:7&G3P6ZV^56.WE%Q&556"EHB#N&[G(KZM\$O'WA'X8:W:?#CQ;I]
MI\3O$FK1ZCK/B_6+0,&)91*88"LB@)"HBAB?(55 +9R]>_$4FTU*5K!<\?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>nbx-20211231_g6.jpg
<TEXT>
begin 644 nbx-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $S :8# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_O@U-10!#]J7^[)_WP:/M2_W9/\ O@U-10!#]J7^[)_WP:/M2_W9/^^#4U%
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MSC=M)QG!K&^*>DVVJ>"=2:==-26WB:6&ZU6%)(K=NA?YE(!QG!P><5QG[/\
MX7OO"%WXIT^]OH[PBXB>,^;$9#&RDHY2-$"*5(QD$Y#<]* /8:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HK,F\1V%O*T;RL&4D'Y">GX4S_A*-._Y[-_W[;_"O EG^40DXRQ=--?W
MX_YCLS4==ZLN2,C&1U%?'?P=\+?#F\^(GQP\&'3KN\\*:DVGW8BN[6ZQJ!A@
M#7,AE=096\T'=SECZBOK#_A*-._Y[-_W[;_"C_A*-._Y[-_W[;_"I_UBR?\
MZ"Z?_@<?\PLSYY^!"Z#X'\'M<Z]83>%-7^*^K7MW;:?8VCV[VL(A;R(L(/W3
M+;1ALG!W,>]3?L7W/AG21\3/#GARWGL=/C\4W%[86\MG/"KV;6]LBRJTBC?N
M='R<DD@DU[U)KVCS3PS2;7FASY<C0DLF>N#CC-3?\)1IW_/9O^_;?X4?ZQ9/
M_P!!=/\ \#C_ )A9FM163_PE&G?\]F_[]M_A1_PE&G?\]F_[]M_A1_K%D_\
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M=<DTA)"U['%YSJ%. N0.O3/(X]ZX>678]/GCW-&BBBH+"BBB@ HHHH ****
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >;:Q_R$KG_KHW\S5*KNL?\A*Y_P"NC?S-4J_AS,/]\K?XI?FR
MPHHHKSP"BBB@ HHHH [#P3_J;G_@/]:Z:N9\$_ZFY_X#_6NFK^N>!_\ DGL-
M_P!O?^ER%+<\:_: _P!=H_T?_P!"6O1_ G_(FZ-_UZQ_RKSC]H#_ %VC_1__
M $):]'\"?\B;HW_7K'_*OTNK_NM/YGCT?]]J^B_0WJ***\X]8**** "BBB@
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MCR 1@@]1VK.^'_Q?\'_%)K]/"^NP:K+8E?M$2*Z21JP)1]K@$HP!PP&#C@T
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M#_71_P"\/YT ?U10S)<1)+$ZR1NH970Y# \@@]Q3ZYKX9\?#?PH!T_LFT_\
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M_J?\*/\ A-8O^>/ZG_"C_7CA_P#Z"?\ R67_ ,B'*SIJ^+_^"N7_ "9GK/\
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M[G\\G_#N_P#:&_Z)GJW_ (Y_C1_P[O\ VAO^B9ZM_P".?XU_0W17KB/YY/\
MAW?^T-_T3/5O_'/\:/\ AW?^T-_T3/5O_'/\:_H:R#T.:K_VE:%H5^TQ;IF*
MQC>/G(Z@>N* /Y[?^'=_[0W_ $3/5O\ QS_&C_AW?^T-_P!$SU;_ ,<_QK^A
MNB@#^>3_ (=W_M#?]$SU;_QS_&OJ;_@FW^R7\6?@G^TU9^)O&O@O4-"T--+N
MX&O)E!42.%VKP>^#7ZZT4 4_[5M_5_\ O@_X5)#?PSN$0MD^JD58HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J6K:3;:W8M:72EH697(4X.58,/U
M J[10!DIX9L85?RD>&5D9/.1SO /7';OZ4RS\+6EG<64WF3S/9Q>5#YKYP,8
MR>.3CBMFB@ HHK"\=7NK:;X*UZ[T&W^UZW!8S264&W=YDP0E%QWRV..] &[1
M7S+X+^)_B+[9_9_A^YU#78IKZU2YUG75FN%"M!+),J0*D9AE5H]IBRRC<O?B
ML#Q%^T=XV\0>"=;6QB712TUS;V>KG3)Q),1!%)'!'&CMLF)D<!B2!Y1R,\4
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MU (+>>&#\],5?DTOXD6FH:9:KJ%_)8PSS)%=?NI)& N<HUSP-R^3P,8.>O-
M'M=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !35159B% +<D@=:** '4444 %%%% ",H8
M$$9'H:38NX/M&[&-V.<444 .HHHH **** "BBB@ HHHH **** &>6GR_(ORG
B*\=/I3Z** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>nbx-20211231_g7.jpg
<TEXT>
begin 644 nbx-20211231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $- 8 # 2(  A$! Q$!_\0
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MZXWB"ZFN(DUI;LKL_>$^7((<?*,?+R>>: /M>BBB@ HHHH **** /F']J/\
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M=#UV'3]3\)>*M-BMQI_]NW5W9QHN@-?2F.S2['F9#.0&(0-M# GTK-M_V.O
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M?TZ\U73#HVI3P))<:>TRS&WD(RR;UX;!XR.M &G1110 4444 %%%% !1110
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MQL &1<CA2  0/0>E5O\ A$?#6ZW;^P]-W6ZLD)^QI^[5E"L%^7@$  ^U8_\
MPB/C#_H?IO\ P4V_^%'_  B/C#_H?IO_  4V_P#A0!=\11^#O"_AU=3UJVTN
MPT;0XFE2XNH%$5DF-K%21\HP<'%7[?PWX?MUN?)TFPC6[V&?9:H!-M ";N/F
MP ,9Z5S4OPI?Q!<0GQ=XAO/%5E"V]=+G@B@LG;L98T4>;CJ Y*YYQFBS^&>L
M>'XQ::!XVU.PTI.(;&\@AO1 O9$DD7?M'0!F.!Q0!TMCX9\/Z9&T=II-C;1M
M<?:BD5LJCSLY\S 'WL\[NM:WVB/^]^AKC?\ A$?&'_0_3?\ @IM_\*/^$1\8
M?]#]-_X*;?\ PH [+[1'_>_0T?:(_P"]^AKC?^$1\8?]#]-_X*;?_"FR>#_&
M3*0OQ E5NQ.D6YQ^E ':?:(_[WZ&C[3'_>_0UR'A?6/$NG^)9/#WB6*WO]UL
M;JRUNPA:**=595>.6,EO+E!92,,0P)(QM(KM* (OM,?][]#3TD$@RIR*=10
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MHJ'S9/\ GB?^^A1YLG_/$_\ ?0H FHJ'S9/^>)_[Z%2(S,/F7;^.: '4444
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M!3J;'_JU^@IU?W?#X40%%%%6 4444 %%%% !1110 4444 %%%% !7AL-T_\
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M2,P12S'"@9)K'TWQ78ZM<0Q6QD?S%)#[?E!Y.T\\$@$X]* -FLGQ1_R!Y/\
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D*&VBA_@@AB4A(T'IEF;GDEC6Y110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>nbx-20211231_g8.jpg
<TEXT>
begin 644 nbx-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_$+]@WQI^T%\1-'^*WQ*M?#?B5?#8\'_  \\E=0T^/R8I7U"Z9PS>4!+@!0
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M)%P-JM(!S'YS45)>+ E[,+5I9+7S&\AI5"R-'D[2P!(#%<$@$C-1T%!1110
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MB!I-U\*WDL=#N+".RC_X275E\D26B2/R+K+9<D_,3CH,#BOT9KS/X3?\E_\
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M$:*,DDG&3SFOT'KX+_X-\_\ DW#XT?\ 9;O%W_I3'7WI0 4444 ?QC_M*_\
M)RGQ(_[&S5__ $NFKBZ]&_:!\%ZUKG[17Q(N+'1M8OK<^+M742VUC+-&2+Z;
M(W*I&17(_P#"M?$__0M^(/\ P63_ /Q%9FACT5L?\*U\3_\ 0M^(/_!9/_\
M$4?\*U\3_P#0M^(/_!9/_P#$4 8YZ5]R?\$D/B'X9_9^O=-\>6?[73_ 7Q'9
MZV!XF\+7OAB]U.Q\0:5$T;*R^5F&=W5I8Q&Z[T)+HR]_C/\ X5KXG_Z%OQ!_
MX+)__B*/^%:^)O\ H6O$'_@LG_\ B* /T\E_:B_9%_:&^,'[1'Q MH?AAX$\
M<:YXNL[OPK>_$CPA>Z]I#Z.EO!%=7-KI]O\ NUOY9XYY]LJEF\Z-2O,A74_:
MA_X*._!'XB_M ?MJZYI7CBSOM-^*WP@TOPSX7G&EW<0UC4(K9DDMU1HLQ[6(
M&7VKSP<#-?E?_P *U\3_ /0M^(?_  63_P#Q%'_"M/$^?^1;\0?^"R?_ .(J
MN8GE/U-^!G_!0_X<^+_V+OV<;33/B;\%_A3\1_@18S:7?1_$#X<7/B.X@VRP
M^3?Z5<PQDQR.L8=XT(=G(R5$89_'/"O[0'PR_::_8)_:0\"?$+XO:+X3\<>(
M/BQ)\2]/U&X\-W MO%T:Q%#Y%O%G[/)*VXK$S93>@.1N9?A7_A6GB;_H6_$/
M_@LG_P#B*/\ A6GB;_H6O$'_ (+)_P#XBE<.4_7;X"_MF:3X>_X("/\ &;4K
M2XA^,7PUT#4_@)X:U61>9X+^6T>!HV(PS6MJL9!#?+]GFR/GP/CO_@A+^U!\
M/?V1/VTM8\1?$KQ(OA/PWJ7@?5-"CU%[&XO5CN9WMC&ICMT>3!$;G.W'')&1
M7SKJ?B#XK:U\)=*\ W;>/+CP1H=[)J6GZ"]O='3[.ZDW[YTBV[1(WF29;&?G
M;U-<O_PK7Q,/^9;\0_\ @LG_ /B*0'W-I/QY^ O_  3O_P""?_Q@^'/PS^)M
MY\=/B1\?K*RT75M3L?#%UH6E>&M,A\T2QI]KQ)-,ZW%P%9<*Q:,LJ",A_IB7
M]KK]D/X$?"SXX:=\+?&7PFT#PIX^^$M[H7AC1M-\%ZHOBZ[U&6UPZZOJDJOO
MD:;A$RJG=N;[@=_R!/PV\3G_ )EOQ#_X+)__ (BC_A6GB;_H6O$'_@LG_P#B
M*=PY3[\L_B=^S7\<?V+OV.8_B-\1+>U;X&W]UH_C'P-'IM[_ &EJEE>ZI"[R
MPW$( 6*.!#,Y1BQ3<B$2E17H?[<'[6?[/^C_ /!-WX]?"GX=^,_@Y-<^+/%>
MCZGX3T'P!X(OM%B738+^WD'VNYF4BYO!#$6E+, I^5/O!$_,#_A6OB?'_(M^
M(?\ P63_ /Q%'_"M?$W_ $+7B#_P63__ !%%PY3V/]E#_@II\8/V)_ ^H>'/
MAWK&@Z;I.J7YU*X2^\-V&I2-.8TC)$EQ$[@;8T&T'&<G&2:ROVN_V_\ XI?M
MS+X?'Q)U;1]47PO]I.G"PT*RTOROM'E>;N^SQ)YF?(CQNSC!QC)KS'_A6GB8
M?\RUX@_\%D__ ,11_P *U\3_ /0M^(/_  63_P#Q%(9]I?\ !(O]O?P[^PW^
MR[^U6TWB#2M)^('BS0-)C\&66H:4VHPZK=V[7V]#&8WBPOG1\2D*=W?!QT'[
M"'_!5[4?%G[1_P 9O'W[0GQ)F;4M<^#>L^$/#LKV!CACN))+=K>RMH+2+9 "
M5=L[5!(RS9P:^#?^%:^)_P#H6_$/_@LG_P#B*/\ A6OB;_H6O$'_ (+)_P#X
MB@5C[,^'O[1WP/\ $'[#G[%_PX^(^K76IZ;X ^(&M7OC[1K..ZCN-.TJYO&>
M-S(B@M&5*LRV[F39N"X?%?3WQA_;*_9_\$?LE?$#X;_#_P",/PE\%76M?$GP
MYKGA6X^'?P[U&RC\-Z9;:I:RK>W/F*3?7L$,)FE4OC*A$^]L7\E?^%:>)_\
MH6_$/_@LG_\ B*!\-?$X_P"9;\0_^"R?_P"(IW'TL?J=\7?^"A'P#^'WQZ_9
MS^+VKZA\-_B1\;O#/C26^\;>*/AMX;O-'M=2T*2VFA%Q>0W"*)M1W3I-A<L&
M@=<Q@HIX'_@H]^V)X=U7X&_%[1?AW\;O@/KWA7XK:_#J;>'?"?PMN=&\0:S$
M-0-PLNHWKHB)/"1N9VW23$L0J"0U^=__  K/Q-_T+7B#_P %D_\ \11_PK3Q
M-_T+?B'_ ,%D_P#\13YA6/J3]GC]I7P/X*_X(N?M/?"W5-?AL_'WCW7-%O-
MTEK:9GU&*":W:5A(J&-=JQN<.ZD[>,DC/W>_QL^%_P"TG_P5EUS]J?0]6C\7
M?"W]F'X.P:Y>7*6TMO'=:VD=W%:V $\:-YI,CNA QYD2<GD5^-G_  K7Q/\
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M==D\()&=DB\,O0BG/\)_#$EYIERVA:2TVC6$FEV$AMEW6=I(JJ\$9Q\L;*B
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M=K-:NJQ&[1VVJP7>JX;+@\  ^T],T^WTC3X+6UCCAMK:-8HHD&%C10 J@>@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB=O#=I;PZ--:_P!KIH]UES9FZ**&E!5Y(P[J1M4_HU_P35_:JF^(O[.OP_\
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MRCD>(JP52-K,^E/,Q_=I/-^E?-@_:6\4?\]+'_P'_P#KT?\ #2WBC_GI8_\
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M#_5_$KL?21F8?Q=L<&A964?*VW\:^;?^&E_%'_/2Q_\  ?\ ^O2?\-,^)_\
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M//-*\DC,\CO)([,S,22W6NP\WZ5\V?\ #2WBC_GI8_\ @/\ _7H_X:6\4?\
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MQM]CZU0\3^)M.\%>'+[6-8OK?3=*TR![J[N[B39%;1(-S.Q/10!DDU\J^/\
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M 9P5!. 6& <\5J3_ ! T*S\=P>%Y-8TU?$EQ:O?1:6;A?MC0(P5I?+SNV!F
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M>FKQ]^TI.2M>]U32=E]JZV.&CCZDY*$HVUU\CZJQ_G-&*!Q17X4>D&*,444
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MGSPC_P! =?\ O[)_\52?\,^>$?\ H#Q_]_I/_BZ/^)3>)O\ H(H_?+_Y$/\
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MXH>^)I??+_Y$/]8,/V?X?YGS&6(%(K[5P&('H*^G1^S[X1'_ #!X_P#OZ_\
M\72_\,^^$?\ H#Q_]_7_ /BZI?11XI7_ #$TOOE_\B'^L&'[/\/\SYAW#'MV
M'I3C*2/O-QTYZ5].?\,^^$?^@/'_ -_7_P#BZ/\ AGWPC_T!X_\ OZ__ ,72
M_P")4>*%MB:7WR_^1#_6"AV?X?YGR;XT\(:9\0_"M_H>M6JW^DZI$8+NV=F5
M9XV^\C%2#M.,$9Y&0<@D'27";=JA=O3'&*^H/^&?O".?^0/'_P!_9/\ XN@_
ML^^$3_S!X_\ OZ__ ,76S^BSQ:Z2H/%TN5-M*\[)NR;MR]DON#_6##7ORO\
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M .+KS?\ B4WB;_H)H_?+_P"1'_K!0[/^OF?,@9E'#''UZT!BJXR<>G:OIO\
MX9]\(_\ 0'C_ ._S_P#Q='_#/OA$?\P>/_O\_P#\75?\2H\4_P#032^^7_R(
M?ZP4.S_ ^4M2\)Z9K&NZ7JMU90S:GH9F^PW++^\MO-39(%/HR\$'@X!Z@$:+
M2%^I8_6OIT_L_>$3_P P=/\ OZ__ ,71_P ,^>$1_P P=/\ O[)_\76U3Z+'
M%DXQA/%TFHJR5Y:*][+W=%=M_-A_K!A_Y7^!\PA\G\,=:<S$CD_0$]*^G/\
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M#Q_]_7_^+JO^)4.*-OK-+[Y?_(A_K!0[/\/\SYD'%&:^F_\ AGSPC_T!X_\
MO\__ ,71_P ,^^$?^@/'_P!_G_\ BZG_ (E-XF?_ #$T?OE_\B'^L&'[/^OF
M?,F:,U].?\,^^$/^@/'_ -_G_P#BZ/\ AGWPA_T!X_\ O\__ ,71_P 2F\3?
M]!-'[Y?_ "(?ZP4.S_KYGS'FG6QQ=1_[P_G7TS_PS[X1_P"@/'_W^?\ ^+I]
MM^S]X1%Q'_Q*(^&'_+:3_P"*K2E]$_B:,T_K%'?O+_Y$7^L%#LSY#_X-S?\
MDT?XH?\ 98/$W_HR&OT"KX'_ .#>FW6U_9D^,$48VQP_&KQ7&B_W5%Q& /P
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MIR20P6AMXH+D1RYN8L,)))(W*GT;XF?%#QY^S=\6?V@?B=X2^*@UW2_!>H^
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M$>B>6OI1Y:^E.HK.[&-\M?2CRU]*=2%L4[L!/+7TH\M?2CS1@>AZ&AW*FB[
M/+7TH\M?2C>0#2&1@.E%V OEKZ4>6OI1YAY^7D4))N/2B[ /+7TH\M?2G447
M8#?+7TI\* 3+]124Z'_6K]10F[@?#'_!OB<?LW?&3W^-OBW_ -*8Z^]:^"O^
M#?+_ )-N^,G_ &6WQ;_Z4QU]ZUZ,=B9;A1115$GP=_P0(_Y,\\;?]E8\7?\
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M_N.EHKFO^%P>&?\ H-:;_P!_Q1_PN#PS_P!!K3?^_P"*/];,D_Z#*7_@<?\
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MO[C \'_LK>"? ^J^%]0M+'5[O4O!LU_<:3?:IKU_JEU;R7RA+HM+<S2/)O4
M 2%@@ VA:Y+3O^"?OPX^'NG>%IO ^BR>%=?^'NEZAIOA2^@U34#'IZ7DWVF2
M.XC%PHO8/M2I,8;@NNY?EVUZ9_PN#PS_ -!K3?\ O^*/^%P>&?\ H-:;_P!_
MQ3_UNR7_ *#*?_@<?\P^KUOY7]QA?LL? &Q_9:_9R\%?#S3[IKZW\(Z3#I[7
MCQB-[^91F:X903AI92\A&3RYY/4^A#I7-?\ "X/#/_0:TW_O^*0_%_PSC_D-
MZ;_W_%+_ %LR3_H,I?\ @<?\P^KU?Y7]QSUE_P G?ZI_V)=E_P"E]W7HL?\
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M+17-?\+@\,_]!K3?^_XH_P"%P>&?^@UIO_?\4?ZV9)_T&4O_  ./^8?5ZO\
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M_AR[SS0M(MA<74UTTH(C'[X/,P!^[@#Y<\U];#X$^+2/^0.W_?Z/_P"*I?\
MA17BW_H$/_W_ (__ (JJP53Q,PF%6"P]&O&FFW;V?5N[UY;[ML)?4I/FDXW]
M3XY\6?L,+KG[:?P;\806JMX;^&'A9K">YFN5,VIW,&([!'B &3%OEE\PX ;
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MGAGP'_9ET/\ 9\_9Z@^&^CW6HW&D0Q7<;7$YC69VNI)9)6 15C0;I6VJJA5
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M*J 9'*@ NV,D@ 9)X%7#TKJC\"O%N/\ D#M_W_C_ /BJ7_A1?BX_\P=O^_\
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M\5VW@&ZOKOPWI2:/;Z>+.2Z783--&2TWEQX1>%SM!.3G/TQ_PHOQ;C_D#O\
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MYB9E)4LL2(3@D L1GBO:!76-\"/%V?\ D$2?]_H__BJ;_P **\7+_P P=O\
MO]'_ /%5\AG_  CQ?FN.J9AB,OJJ4W>RIRLK*R2WT25CII8C#PBH1FOO.5I]
MK_Q]1_[P_G74?\*+\7?] =O^_P#'_P#%5)9_ GQ<;N/_ (E#?>'_ "WC]?\
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M;_8>E^*Y=7$^HP72VFJ>')8QJ&FHR#;*S02?:(I 0'C1_E4HP#Y6&A]8[/\
M:_04A&/X_P!!7SW\>_VZF_9__9Y^''C+7/"(TO5?B-<V5@--UK7(-*L= NKB
MSENO*OM0D0Q0X,1@4[3OFDC0 ;LCA?C#_P %@?!OP7_: _X0/4]&M_M&CW>B
MZ9XCW^)]-AU'3;S5$MWABM=/:3S]02%+JW>:6$!520E/-*2*BY6%D?7W_ _T
M%*%S_%^E?)FO_M[^(O%EOXFDT_P1XB\*^'/"_P 3=-^'T?B./4M/G;6KMO$=
MII<R1VTD;LMNR3DO(P5QB14(8+)6Y\%?^"CUO\7_ !]X%5O 6NZ/\/\ XMWU
M]IW@3Q;)J%O-'KEQ:P7-R5FM%(EM%GM[.ZE@9RVY8@'$3LJ$Y7L%D?2^S_:/
MY4;/]H_E7RC/_P %5='M/@=X+\<2>"/$4UOXQ^$M[\6%L;2=)[BUM[;^S]UF
M1M 9C]O4F7A56)V(QTU_CI^USXB'_!+SXD?&+PVV@:-KVE>$]5U;1;S2=8M?
M$VF,\"/Y-S#<1KY5Q&=H;#(.<J5XY L?2P/^TWY48SCYCS[5\'_!'_@H#\1_
M&?QF^%7@/Q%<6.G>,-+T+QKIWQ&T^.RC\NXU;2H='FT^^A)7,<%S;7ZW:!"%
M9+P*03'A>5_X)X?M@?%?]J[4?"_A/5OBIXHM;SX@?"K3_&/]M:IX"M]#NM,U
M<RVIN(=(%Q9QV^J6GERN9)%CF6(/$1*2_P M<H<I^C6.?O?H*"N!]X_E7Y]^
M ?VAOC5X$_8A\0?'C7/BU<^+X/ /B_4X]7\/W^@Z186^J:+IFM76GW44,L,$
M<@O9+6,2Q /\]S%'$!B4BN;^(?\ P4$^(EG\+?@?XVUKXE:MX)\,_&E/%/BR
M23PMX-A\577AS28;.*?2[,Q0VMRTWDQD/=2;01(\RF2-$4J<K"Q^E 7(^\?R
MI=G^T?RK\_/VA?VN/C5X/_X)Z?#OXK7/BK5/"_CK5/"!U9M(\+^!1X@T'4KX
M^3)%-J>H!)X--L#"ZM(S3PJ@DF99W\H"OJ']IC]JZ3]G/X&^'/%EIX=?X@7W
MB?6M%T&PT_0]1AACOKG4IXX(GAGF(C,6^0$,S %2#D=:FS#0]B*X'WC^5(!G
M^+]*^/\ 3O\ @L!X<B_:0TKX<ZKX;L;'46\0:?X.UA(O%^G7%_IVN74<3&&&
MPW+<W5G#+-'#)=JB@/O*QLB,XY2U_P""FFL?LQ_L8:7XZ\9:3%XPC.L^+GO[
M_4/%FEZ+</;:=KE_$EK9PW#J][=K:Q*(X45581 &4,R@OE#E1]V;/]K]*3_@
M?Z"OBJ__ ."IFN?#CXC_ !XU/Q=X1TT?"?X96^ASZ/JMIJT4-]=OJD%O]CAE
M2?8@-S+<)\[O&EN,ARP!8:_@#_@K/I?Q-\#,OA[P;'XB\?R^,(?!-CH6C>*M
M/U+2]2O);!M1$T>JQ$PFW2TCE:1MGF(\+1^63M+%F%D?7Q&!]X_E2[/]K]!7
MS1^Q-X]\??M0?LP>.9M6\0ZYX)\6GQ_XFTBUNC#87]YX<AM=8FBBM0"DEK-Y
M4<?D[B'!'S DX-?-NI_M+_&_P3^R5KWCB]^,GBK6+\?&:;X91)9>"](NKFTL
M;;Q5)I37-M;0VFZ>[DMH?]60ZEW.U <8.4+(_2C./XC^5##'\3?E7Q_\;_C_
M ..O ?[&GA'3/"_Q!U:+XJ_%;Q#_ &!X<\1?$#PS;:%<Z2!YUS<W%SI[0P1A
M8+.TN"@>,;V>'[Q=0WEOC#_@HKXU^-$'[--YX=\2>//!NG_$KP-XBU?Q-;^"
M_!$7BC4XM9TVYTFTEM_(>VN&CAAN+B]1F50,B,$\BGRARGZ)[/\ :/Y4;#_>
M/Y54\-036OA^QBN+RXU"XBMHTFNIX5AENG"@-(Z*JJC,<DJJ@ D@ #BKU9\P
M'FMBN?VO=4_[$NRY_P"XA=UZ,BDK]X\<=*\[LN/VO]4_[$NS_P#2^[KT:/\
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M$/0_#GAW2(FN-$U#XQ2?%#Q3/J=\1-$LRSR7=M;B-!NBN'9+<Q,<"*:4LS$
M'VO_ (:E\-^FH?\ @./\:/\ AJ7PW_U$/_ 8?_%4?\1<X0_Z&-+_ ,"0?V;B
MOY&6OVC/@*G[1W@>3P_<>+/%GA6RNDGAO3H,MHIU&WFA>&2WF6YMYXVC*N2,
M(&5E!##D'AO"/_!/SPO\+?%]GJ7@;Q1X\\"V<=MH]I?:1H]_;-8ZPFEP1VMJ
MUQ]HMY9M_P!EABMW>*2,O'$@)R,UU_\ PU)X;]-0_P# 8?XT?\-2^&_34/\
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MOASTU#_P''^-'_#4OAO_ *B'_@,/_BJ/^(N<(?\ 0QI?^!(/[-Q7\C/.Y?\
M@FSX?M?@S:_#K2/B+\6_#_@6'2KO0IM$T_6+5;:ZL+BXFF-N3):N\81)W@1X
M6CD$(1"[%%8>G?$7]FWPO\2/ O@_PW/#=Z;H_@76M'US2;>PE$8AETN:.:UB
M.X-F(&)%9>"5XW \U5_X:E\-C_H(?^ X_P :/^&I?#?_ %$/_ <?XT_^(N<(
M?]#&E_X$@_LW%?R,R]/_ &0--\-_&_5?&V@^,?'7AN/Q!K$6OZQX?TZZM%T?
M5;U($@:61'MGF3S4BB\Q8IHU=H]Q&68MYSXV_P""2WP[\7Z']AM_$GQ%\/K-
MHVO>'+^72]3MDEU/3-9U&34;VTE,EO(%4SR.%>(1R!#M+GK7K0_:E\-@=-0_
M\!Q_C1_PU-X;]-0_\!Q_C2_XBYPA_P!#&E_X$@_LW%_R,X+Q7_P35\!^+=5\
M632ZMXSM=/\ &F@:7H>K:;;:A#':SR:8!_9^I+F$R1WUOMC*ND@0F*,M&VT"
MM7Q1^PY8^.?!FFZ?KGQ'^*&K:UH/B./Q1HOB66\L(M6T2[2W:VVP>59I;^4T
M4DRNDD+AO.<G)VXZC_AJ7PYGIJ'_ (#C_&C_ (:F\.?]1#_P''^-'_$7.$/^
MAC2_\"0?V;B_Y&6OV9_V=-$_96^'4WAK0=0\0:K;7FKWVN75YK=[]LO;J[O+
MA[BXD>7:NXM(['D<9Q7"^*O^">G@WQ)\#;[P'!KGC+1;*\\=W'Q&CU/3[Z!-
M2LM7FU:35B\3O"\8C2YD.U&C;"*H))!8]A_PU+X;_P"HA_X#C_&C_AJ7PYZ:
MA_X#C_&E_P 1:X/_ .AC2_\  D']FXK^1G-Z9^P?X5U7Q%X6U7QUKGBCXL7G
M@^SU&UT[_A-#8ZA"#?20/),\4=K%&TR+;K'&^WY(WD')8FN.O?\ @E1X)TKQ
MM;:_X-\9?$KX:WUC?ZY>V*^%]0LK>WT]=8:PDOK:&.:TE6.W>;3H9@@'RR23
M$'#!5]5_X:E\.?\ 40_\!Q_C0/VI?#?_ %$/_ <?XU7_ !%SA#_H8TO_  )!
M_9N*_D9Z!X=TUM"T"QLI+R\U![.WC@:[NV5KBZ*J%,LI554R-C<Q55&2< #B
MKGF+ZUYG_P -2^&_^HA_X##_ .*H_P"&I/#?_40_\!Q_\54?\19X/_Z&-+_P
M)!_9N*_D9-9-_P 9?:I_V)=G_P"E]W7HJ,%SGUS7SS9_M&Z"O[46I7Q6^\F3
MPE:6X_<<AA?73'C/H17=M^U)X;W':NHCO_Q[_P#UZUJ>*G",+.>84U=)KWNG
M<2R[$O:#/3/,7UH\Q?6O,S^U+X;]-0_\!Q_C1_PU)X;_ .HA_P" X_\ BJR_
MXBSP?_T,:7_@2'_9N*_D9UWQ*\(7'C_P?=:5:>(M>\*W%PT;)JFBO"E[:E)%
M?Y#-%+'\VW:P:-@59AP3FL']G[X Z/\ L[>']1M;'4-<U[4M>U)M8UO7-;N5
MNM4UN[9(XA+.Z(B?)#%#"BHBHD<**J@#G/\ ^&I?#?\ U$/_  &'_P 51_PU
M+X;]-0_\!Q_C37BUP>O^9C2_\"0?V;BOY&>0^&O^"=%SK_[&U[\$?%7C+Q%H
MWA.UUC6(+)_"MY!%/J>A7-U--;6MVUQ;2X:..;RV\O!)B5MW)%;WQ,_X)O>&
M?BW?6M]J_CKXH#5IO#3>#O$.HVNJVMO=>,=(:9IOLNH%+8*0#),JO;K!(JSR
M .-V1Z!_PU+X<_ZB'_@./\:/^&I?#?\ U$/_  ''^-5_Q%SA#_H8TO\ P)!_
M9N*_D9G>.OV2;/QCX7\7:+9^./B'X9T?Q9;65C]ATG4;=;71+6VMS;FVL8IK
M>5+>*9#^] 4EF (*XJEX2_8FT'P[\(O 7@74/$WC3Q3X:^'NHVVHV5MK%U;/
M]O\ LBXLK>Z,,$8E@MG6.5$P"9(8F<OMP=[_ (:E\-_]1#_P&'_Q5'_#4OAL
M_P#00_\  <?XT?\ $7.$/^AC2_\  D']FXK^1GC?Q5_X)IVD7P4^+>B_#_6K
MZ'Q%\5-$N?"L4^O7*-9^&-+O]1N[J]CM$AA5_E.HWDD8E:1BR01EPB#'U'X?
MT2S\+Z)8Z981"WL--MH[2VBSGRHHU"(OX* *\_/[4GAL]M0_\!Q_C2_\-2^'
M/^HA_P" X_QJ?^(M<'O_ )F-+_P)!_9N*_D9Z9YB^M'F+ZUYG_PU-X<_ZB'_
M (#C_&C_ (:F\-C_ *"'_@,/\:7_ !%G@_\ Z&-+_P "0?V;BOY&>F;U]:\Y
M^%SA?CQ\5?\ K[TO_P!-\=0_\-3^&_\ J(?^ P_QKA?AS^T=X?LOC+\2+J1+
MYH[RYTTQ@09/RV$8.1FM:7BKPE.,G#,*;45=^]LKI?FU]Y,LNQ*^PSZ&\U?[
MPH$JFO,Q^U+X;S_S$/\ P&_^RH/[4OAL]M0_\!A_C6/_ !%K@[IF-+_P(K^S
M<5_(STSS%]:/,7UKS,?M2^&_^HA_X#C_ .*H_P"&I?#?_40_\!A_\53_ .(L
M\'_]#&E_X$@_LS%?R,],\Q?6N0^/WP;T?]HWX)^+O .O27T.A^--(N=%U![*
M417*03QM&YC9E8*^UC@E2 >QK"_X:E\-_P#40_\  <?XT?\ #4OAS_J(?^ X
M_P :?_$6N#_^AC2_\"0?V;BOY&<5\3O^";WP[^*'QQD^)#S>)="\8R>!KSX?
MMJ.D7Z6TC6-RH0SD&-A]JB4%8Y?X0W*MM3;K:#^P#\*_!/B7X;ZQX9\,6'A'
M4_A?(?[*N=$MH+.6[@-E)9-;7;+'F>%HW5B#@[XHV##!SO?\-2^&_34/_ <?
MXTH_:E\-_P#40_\  <?_ !5/_B+?"'_0QI?^!(/[-Q7\C/2DD '-.\Q?6O,_
M^&IO#?\ U$/_  &'^-'_  U-X;_ZB'_@,/\ &H_XBUP=_P!#&E_X$@_LW%?R
M,],\Q?6CS%]:\S_X:F\.?]1#_P !Q_C1_P -3>'/^HA_X#C_ !I_\19X/_Z&
M-+_P)!_9N*_D9Z9YB^M.AD'G+S_$*\Q_X:E\-_\ 40_\!Q_C3[;]J/PV]Q&,
M:@<L/^7?W^M./BQP>VE_:-+_ ,"0?V;BM^1GS)_P;XG/[-WQD_[+;XM_]*8Z
M^]J^!_\ @WFNEOOV8OB]<1_ZNX^-'BJ5,CG:T\1&??!K[XK]2HU(SIJ<=FDT
M>?+>S"BBBM"3\AO^"60_XL/XU_[*;XH_].#U]*CI7S3_ ,$LSGX$^-O;XF^*
M?_3@PKZ6'W:_R)\8/^2TS+_K[+\S](R__=*?HA,XI2<5\V_MK>+-5L/CC\-]
M"L]0^)5O8ZQH'B6ZDMO!+2?;[B[MSI?V:1@OR[$\Z49D_=CS/FX-5]:_:L\;
M? _2?!6G>*HO"NM:Q;V>AVOBVWM&O)=2@N;Z5+=I2T$!L[<!WW 2R+YNU]F/
MESMA/"O,L9@,-C,)4A*5:+DH7M)13:OKOJK=$KK4F6.A&<HR3T/IG=2@Y%?)
MOA3XY_%&;5=';Q-<>&+[2;CXS7'@Q6TRYN[2[B5;B>.-" HCEMT$?W7^9_EW
M$FM#X:_M^:Y\0_#=_P")(/!Y/AFZ\-:KXCTNX6RU*)K$6:&2&&]FEMTMF-RH
MRIMY'"E64Y.&KJK^#>>QBYT.2:6[4DDG>UM;:]?\]!+,*-[.Z/J*BOD3XN?M
M@?%+2OAMXBM(]*\'>&_%UOH6A>*[">WO)KZ&*QOM2CM)()-\0!G5F4$J"A21
M\895)];N_CIXI\-?'[0O!GB*Q\-:-;:A:6Q&HR+>BVUV[D%QYUM83%/*66(Q
M1_N;AEED60E1QD\&,\*<ZP]'VLG!NTW923?+!)MKHUK;1WNGH5''4Y.ROT_$
M]@)Q2;J^?OVC_P!M>\_9XUCQ383>'H=2N]*_LJ^TN))BK:EI\XN6OIL'^.UC
ML;IR%SQY1/WC69XH_:<U[Q?XGDF\-16<-NT7B^W\/WDE[+]DOETN"V7[3+$N
M5D#7!N A[+&#SO-/+?"K.\51IXIJ,:4U=2<E9^ZI+1.^WY/LPGCJ,6X]4?2@
MZTN:^3O#/Q*^+GB:3]G_ %"+_A$=2\5>*/!VJ:A<B>]N;32Y8FM]*E2XG1$+
M-/\ .PV1KL5I25(4'/INF?M1R>,/V3_"/Q&TV/0M%NO%\%HUO;:U/<211S3$
MJ842VB>>XDW!@D<:;GQGC!HS3POS/"RH1I2C4]K+D]U[2YIQ2?6SY&T[=UT%
M3QT))WNK:_E_F>R9HS7SIX8_:X\:?$WPY\/+?PWX9\.+XG\9:SK6AW:ZK<W5
MK8Z?+IHDWS@&+[1L?R\B)XUD&\*<$$UDZ7_P4)OM0^&5KK;^&;.#4O$GAR.]
M\,6/VIV&J:LFJ-I5U9%L#Y4N'M75@ 3'.20"I-"\)>(FG:G&Z;37/&ZM)QO:
M^UXR=^R;V*^OT>_X'U#G%&<5Y3^TG\==:^!USX9\JQT>#2=4>9=5U[5%NFTK
M2&01^7'*\",81,S,%FEVQ+L.X\BN3T_]LG6M<^/=_H&F>%9+[PYIGBFY\(W4
MT5AJ+WMO-;JPEOGF%O\ 8EMEF7RRAF\P ASUVUQY7X9YYF&&6+PL(N#4G?F2
M7NNS6KWO>R^?8J>+I0ERR>I] EL4N>*^9_ W[4_B?7/ GPK\<>,=(TW2+'Q=
M9:AKL5EH>ISS>59PZ'<7_P"_1U599#Y7RIT4LO.Y:A\5?MM^,OAK\/CKWB'P
MKX;":]X+NO&GAV/3]0GF,<=N;3S+6\W(N'V7L+"2/Y"5=?[I/H?\0DSV3C&D
MHR;NM)+=2E%I.^MN5M]EW,UCZ6[=OZ7^9]/$\4A/O7CGQ;_:+\1>"/$WQ,TK
M1?#)UJX\"#0WB,4<]Q(\5^S^=<20PJTKI B&3;$I=@#Q6AXGNO\ A=?[,2ZY
M#XGN+6;^S)]4BU+PAJLUK#/)'%+@)(0)#'N',;@$,N#RM>3+@',*'L:F.M3I
MU)QAS?%9RBI*Z6NS7G]QI]:IN_)JTKGJ0-.S7Q/:S>+!X!_9KAL]>^+/BBZ^
M(VD7FLZY!8>*A;7UY,ND6TXV33.BQPI([OY>[G)QDXKHOVVOCGJWPJM_"OAO
MP]XPNO#&L>%=!?QG>Q:A>+-=ZXMJT<<.ES2\B1KD_:=Q!^9H!S@DU]-+PAQ,
M\70PF'Q$9.KSZV:453;BV^NLE9:6U6NYC_:$5%RDMK?B?6W>BOEOQGXSU;XT
M?M;Z-:Z!-\1=2\'ZEX!TGQ#;Q^&?$,6E169NK^Z!NIP[J908EC&U-Q^0\=*]
M:^.GQ3\5>$_'G@3PWX/TGP]J6I>-+R]A>;5[J6WM[&.WMS.TF(U9G. 5"@#)
M(YQDUX>8>'..PV(P^"4XNK5@YN+T44ES/F;>EDGNEMI<VABX23ET3MZGI!//
M'Y4X&OEKPE^VKKWQKT[4FL_"]Q!X7US2-=-AJ%M9ZDD^E?9(IA'+<SR6Z6I\
M\QML$$K%&*J2Q!P6?[76K?";P-\+XF30M=T^32?"MOKD0>_N-9B.I?9K=9W=
M(&MH,-*) MQ*K3!6VD$KGU)>#N>I>SM'VM_ANMK-WO>R=U:S^^QBLPHO;8^I
M<T$U\K^'?VKO'WP^^%OC36O%T?AO6[M?B+=^"_#Z:?#>,(YOMCP@3K%$TC01
M(I9?+1YG (/S,#6QX<_:Q\=?$/4+/PKI?A'2;'QA)'JUY<2ZL-1T[3KNPLC;
M(+BU66W6YS.]TBKYD8"&)R2W K-^$.>\S<>1PB[.7,DM$I-ZV=E>S\REF%'S
MOZ'T?]VES7RK=?%CQMX2_P""6'@?Q9X=U2U_X2IM%T*2>_U9FN&?SYK>*1B2
M&W.WF8+-GY2Q'S;:ZCX@_M4>-/ 4WC:]E\.^%KK1_A3-8VOBXQ7MS'<W,UQ!
M#/*VGHR$%(H[B/ F(:0A@-N,URP\+\TK^T>$E":A4G3U?*[P<8K1_P SDE'7
M=_,IXVFK<U]4F?06:,UYC\<_BCXL\(?$GP/X5\(:3X?U"]\7'4&FN-8N9H(-
M/BM(XI"^(U9W+;]H48Y()( :O/O%'[=<W@'XFZM9:I9:#JWAJWL=>N[>YT1K
MZ26!])A,TL,L\L"6LLCJKJRP.QBD&UL]:X\J\-<[S&C&MA8*7-%R2YES64G'
M;I=QE9.U[,JIC*4':3\OPN?1Q-*#Q7Q[X^^-WQ \.ZW\0=<\50V.GBQ^$$7B
M&PL= UJZ6$%[V9@Q=D4QW"@;#(@((48(' ]-7]J?5E_:5T[P7#;^%]2TO7-3
MU#1+.ZL6OY'T^]MK5YU6ZG:!;5B?*97AAD,L1(SNPQKVL1X0YO&'/1E&?+'F
ME9JRM%2>O6R?3>VAG''TWO=?\.>Z[J"<5\:_"S]JSX@:+X)^%GBKXA2:+J6D
MZQ'XDNYY=&GN+>[D&GVUY,PEAP(95VVY5 ,8.UCSFNP\4_MH^-OAKX-FO_$'
MA+PU)>:QX0;QCX>M].U*9T,:3V<4EI=,Z#;(!>Q$2QY1B'&!CDQ'@[GD:L:5
M!PJ7;2:DDFU)Q:5[-VM=Z*R%',*5KRNOEY(^F2W^<T=OYUYE\#?B[XD\<>.O
M'W@_Q-I>@:?XH\"3V D;2[J6XL+A+VV:>'YI$5]R%'1^,' 88S@>!^!_BW\8
M_'.D?!N^N9O".I>(-8\:Z[IUJ!<W%G:2PP6VIQM]K"1_,L1B4HJ*2P12Q#Y8
M<.7^&./Q%>MAZM2$'2M>\KI\T)3BTUI9J.KOI>_1HJ>,A%*23:?Z'V5GB@&O
MD^?_ (**:YK?AW15T#PC:W'B.30;[7-3L3!J5]%(;34;G3OLEJUI;RL'FGLY
MRDLX1%78#DMQZ!9?M)^*M8^(OC"&/1/"VA^$O!.AV&K7]YKVI36=U%+=V#72
MQ2 1LL*Q,NV1VY SA2PHQ7A/Q!ADGB(1C>^\X])*/?JY)*U[CCCJ,MF>X9HS
M7S+HO[;7BW5K:_TJW\.^']0\36_B71-#MI1_:.G:==PZI'(\<VVZ@6X7R]C9
M.QE< %3SQ>;]N'4O %UJ,?CK1-)TVWT&ZUW1=1O=.N9);>34]/L;?4[>.(N
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MT^;>P-N9HO*EX!P=R9'S X[8/->O?\,KZ_\ \_VF?F_^%*/V5M?_ .?[2_\
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M;EI5U;^_Y*/\W;3TT#ZY@.LD>#W7P)\)7_P67X>2Z/"W@U=/32UTTR2!5MT
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M$1G@)IRA9;:OG@^_9/[B)YGA6X^^M_T?^9B+W^M+7I9_95UX=+[2_P#OI_\
MXFD_X97\0?\ /]I?_?3_ /Q->/\ \01XW_Z%\_P_S+_M3"?SH\UW4@.QMW'M
MQFO2O^&5]?\ ^?[3/S?_  I1^RQKW_/]IOYO_A51\$^-XOF6 G^'^8?VIA?Y
MT?/O@+]G7PC\-/$XUG2['4&U2.T>P@N;_5KO46L[=G5WBA^T2N(49D0D1A<[
M%!X  IZ[^SY9^(?BKX@UZXO+C^S?%F@VNCZII\$DEM))+:W#RV]PD\3K)&RK
M)(AVD$_(<C!!^CA^ROK_ /S_ &E_F_\ A1_PROKW_/\ :7_WT_\ \37T%/P[
M\2XUGB'AJLIRCRW;3?+=-)7>EFDUV>J,WCL#:W,M[GSSH_[-O@W0='N+*'2[
MIEN]6MM<NI[C4[JXO+N\MV0PR27$DAED">6@",Y4 8Q@D4WPU^S%X'\'_$F3
MQ;INC/#K;3W5U&[7]S);VDUT<W,L-NSF&&24DEVC12VYN?F;/T0/V5]?_P"?
M[2_Q9_\ XF@_LKZ__P _VF?F_P#A1_Q#SQ.:FG0K^^K2]_=-)._O=E;TT#Z]
M@?YHGSGJW[+7@/7O#NCZ5>:*UQ8Z&TSP(+VX1I?/D66<3,K@W ED57<2EP[
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MNIW#Q2O90/;W6J7T:LQ1+JVLT4L\D8]8MOA'XI_:7UW]N?X*_"OQ8WAVWO\
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M.K%6(#*0I%<@'Z,D#.-O-*H5OX:_%G]G[XY_$#QWH/@GX"^*OB9\6O"LFO\
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MA#!"05P?W29)Q6IKW[&/PM\4,QU#P)X?NED\(-X!*/$=G]@D@G3]H.!#E5(
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MXP!1N%>(_P##8#?]"^O_ (&__:Z3_AL)_P#H7_\ R<_^UU/_ !,'P)_T&_\
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M,6)8DY8DX8_; D[^'U_\#?\ ["C_ (;"?_H7_P#R<_\ M='_ !,+P+_T&_\
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MS"BBBMB3\A?^"6@V_ ?QK_V4SQ3_ .G!J^E=HKYL_P""6G_)"?&G_93/%/\
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MB*H5U^9N&!'S'UJX?".CN]XS:5IA;4;9;.[8VD>;J!0RK#(<9>,!F 5LJ Q
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M'^L.%\_N_P""=]NIULW^EQ_[PQ^=>?\ _#NC]L[_ *+K\$O_  A;C_X_0O\
MP3H_;05U8?';X) J0?\ D1;@X_\ (]:4_HG\81DI>TH_^!R_^1#_ %APW2_W
M?\$Z#_@W/Y_9(^*&/^BP>)?_ $9#7Z!5\L_\$DOV&?%O[ /[/'B+PGXT\1:#
MXHUKQ!XPU'Q/)>:1;26]N!=B$E-DG(;?&YXX 8#)QFOJ:O\ 1#+Z$J.%IT9[
MQBD_DDCXJ4KR;"BBBNPD**** "BC-% !1110 449HH **,\T4 %%%% !1110
M 4444 %%%% !1110 444 YH **** "BBB@ HHSS0#D4 %%%% !1110 4444
M%%%% !1110 4449H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI7AC1?AGJVO0&33]1:\-W9Z9+,K.RM&NV0K%MV@G>W("Y"U\[^!_^"DWQ/\
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M,D:>5]T(KLS!% 7+'CDU:^(_[,7P]^,5W?7'BGP;X?UZXU,6:W4MY9K))/\
M8WG>U);KF%KFX*'JOG/CJ: /-_CK^V'JO[//ACPO:R>%=2\7>)+SPGJ7C#58
MFN;;1S:Z?I<=G]N?:[R+]IWWL"I K&,DONF15#-Y%\-?^"G7BBRMO%-QK/@7
MQ!XOT^Z\2^)++PE)HPC>_ODT_$T=J]E&AF55MV/[T"24M#(#$28C+]/^/?V4
M_AO\3O"FAZ'XA\$^'=:TGPS ;;2[6\M%ECLH2BQM$F?^6;(BJR?=8*H8' K/
M'[%OPH_X2W7->C^'_AB'6O$GG'4K^*S6.XNVF='E<NN"'=HHRSC#'RTR?E&
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MK@[<"QJ'['WPC\:>+=6\0W/@'P?J.K:Q%=6-_>M8QR/.LL(M+F-B. 7B012
M8+! K9VC !ZFIS2TV&)8(EC10JH J@=@*<6VT %%(7P.] <-0 M%(6P:1)-_
MK0 ZBC/%-,@![_E0 ZBF[^*AU'5+?1[">ZNYHK6UM8VEFFE<)'$BC+,S'@*
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MHOBGQ9XHTVYGD\'76JH+4:_<S(YAA6R8 VL5O(T,<C*[P2*C2QD#>H]+M/\
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M9SE_WFV(N!]U"!?[M+Y2X^Z* /A#_@GE%\7/!/Q:\"?"+Q!<7FG>&?A[\.M
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M#_:7^ /Q \12_"'6_!D.J)XG\!^#];^PP>=$NGV^L?V7&EBMPDF0<W V9SC
M()P3GYM_:/\ @#\;/C_X)NK=?#_Q.\4:)96>IP:4OBN&U768I[GP\\=V#LV?
MN'NV1(\C[XFV'RO+Q^IWE+_='Y4&%2?NB@#X+NM6_:8T[6O$VL:?%\0]0U;P
M^-6UC5-(O(K)-(UMK37+>32]/TEP P%UI*743MDC,D9D(F&:[3]D&P_:>-WJ
M5OX\U+3X[KPTMKIWVG6;0/9>(/M%Q<7US=0);N'#06\]E9(7.W?;7!VX()^P
M/*7'2CR5'\(]* /S7^-GQH_:"\ Z!9VNK7'Q2T6UTW4;7P]J6KV%I9"36;F\
M\=V%M!_9QD#++(^CR2B-F0)MF4']X&">K?&?XG?%+X4?\$M?$FO7VJ>--)\7
M6_B%+?1KJ:.U_P"$C72IO$<4%FLBNI@-V]C(B?O%Y+KYGS;J^T)+.*9 KQI(
MJL& 89P0<@_4$9SZT36D<\?EO'&\>0VUE!&0<CCV(!_"@#\_],_X:6NO&_AF
MW36OB1I7@O\ M2\;1+S4-(AOM29$U2W$2:O%%M;8]KYPC\QHQY3,TC+,(R*O
M_" ?M'^'_AO\+]:DN/B%K'BB[\,ZK)XRN7CT^;5M)\[6?#XDM;(F,+'-_9L-
M^8D7(=XM[;I-K5^AAB7^[0(E]![4 ?FG^U9X-_:$^*O[)>O>$YK?XM:KHOB'
MP[XTT_2+2TM;$ZUJ$LEQ%#HMOK&Y<+!)9/=[C\C%2A<_: E=QXXU'XA-^T39
M:/X@?Q%J4EQ\8-(N_!>L:C$;.%H%N-6DO[&WL\9Q;Z+%.INHW,=Q'+"SJLHG
M#?>GE+_=7\:3[-'NSL7(Y!QTH RO GB=_&/A/3]4DTO5M%DU"!9FL-3B2.\M
M"?X)51F4..X#$>];%-5 G2G4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\A_$7_@DSI_BWQEI/B;1_'NM>&?$VEZUXGU;^T+2QB<W"ZS%J"I
M$ZDC)LY-0ED@<G(8N",2,*^NV.*^:/C?_P % _\ A0OC#16USP?XBAT/4/"D
MFN3:>EO$^O1W;:QI>F6]L(_/\CYFU$,W[PD;1@YX(!+\,?V';K]E[XQZ7J'P
MNUZXTSPCJ\&E:=XHTO6;N?4Y&M--M;V*W-H\S.4ED,UG$_*HL-H-HW8%4/C3
M_P $PM#^.0\50ZIXHU6WL_%GB_4?%EW';6T8=&O/"S>'6MU9LC"1MYX8@Y8;
M2NWFM[PM_P %#-%\>:IX?TG0_ 7Q#U7Q1K5[K-G>Z%##IRW?A_\ LB]MK+4)
M;N5[Q;8I%->6P MYIGD67<BN$?;R?[)W_!3&P^+GP:\%WGBC3+Y?%6N:CH^@
MW[:99I'IRWVI61O(GC$D[2"!8QAB26#'A6'- '0>%/V$]:T/XIZ;X\OOB NH
M^,(O$L.MZC<)H$=O9W]K'I7]EFS6 2DQ,8=S^=O8B1S\I0*@P?VF?^">6N?&
M?XMZ[XXC\>:E?&.QU-]$\-WJ.;2SN+GP_/HXACE,I2* F9[AML'F&660EV7:
MJ\M#_P %@](M?B!=:AJ'AC7M-^'^J>'- U+PHUXEA::AXDFU.YU(1W"32WRV
MT-HUK9"4"Z>WD39(' 9D0^O_  2_X*!^$/V@_B+H/AG0=*\117/B#PM:^+(9
M[_[':(EK<"3:@B>X$\S(T91WMXI849E!E^8&@#P?0/\ @F?\3?#/B+X3^(+/
MX@Z2/&&@+;6NLZJVAQ&WTVTM?#UYIL$,5H' N',UW(6E+I]X$*JKL/0:3_P1
MF\,:'HFJ:9;^,==%A?>&[_P["K6D+26PN=.\,V23EC\KM&?#4,NPKM<W4BD!
M5&?3+/XY?$X_M!^.O!5KIO@'Q)_8VA'6]/>WN;NPAT>62Y,=I8ZA/MGWRSVZ
MO<;HHD*",KY;*Z2M7U7]M#7_  O^P]\,?BF? ]YXLUOQN/"\5YI&B75O;+;/
MJ]Q:P.\;7<T8*J]QMC4N2SM$'*(9)8P##^+?_!/3Q5\>_'F@ZWXO^+FH:A'I
M4UI=2:9;:.UM8":VEO'5[>'[24BWI=HDC2":1OLL1#H-RGC;O_@C79^,O 6F
MZ+XN^(VJZRVE^'8/"5O<V6CPZ>RZ7!HFK:3"A4.X,P_M>>8R'@F-%"*N[/5?
M$3_@KOX%^%UQK$>J>#_'\4>DZ[J7A^*>4Z1;0ZG/IREKXV[3W\898AL&&VO(
MTJI$LC!U32^*W_!4'POX$UKQ+H6F^&]>USQ!I?A6^\4Z7#'>::D>L16MC;WK
M(4^U&YM"8KF,_P"EP0DA7VAR%# 'J7[,G[/S_L_^&]7M[F^T[5M5U[41J6H7
M]K93VK7DBVT%LK2>=<7$CN([=!N:0@*%5555 KTROE&T_P""K&G/XAAT-O@_
M\7I==?4;#0WM;:/1Y$74[S2EU6"S$K:@J,S6I9B_$:%,.R%DW-U[_@L9\*M
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M^.$TWQ)?66DV?B"ZLK:+33?W>C_VQ!:,OV@W(D-J'!/D%$DC*LPRA:;XW_\
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MEM>2&VU>_P#L5G80SSC>1^XM+142(*%W2F0Y?!KU44 %'6BB@!H7!ZTZBB@
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1SL.$"?12C HHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>nbx-20211231_g9.jpg
<TEXT>
begin 644 nbx-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !] EP# 2(  A$! Q$!_\0
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MS,_:_P#X)8ZA>:O^Q_H%Y?7DU]<MJ.H*9;B1I'/[X@98DDU]@^9A?4U\;_\
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M/#(P& ,*6&<GUKW&2XB\16 GM+TSQ2$8>&5@1GCFL#X7^"+'0=!M(8(U58T
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M6/ =QX2DLUN&5EO Y;RT$08@_>PN!0R(GTA;_$2[\4:DUO\ )L)V@1MF,?\
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MR;=N]R.IP ,FMC<*-P]:8'G]]\$_"VI>(/%&LW>G&ZO?$VG1Z5J?FR%HYK=
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MN:%<Z'XHN;C2KZ>PEEM[6$HTD3E&*DR D9!P<5F?\/2OAK_T+?B__P !(/\
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MBW5].7PZ]AJFL7E_;F;4V1_+EF=UW+Y9P<,,\FL'_AV[\:_^>7AC_P &S_\
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M"3?_ "9EX<_[">H_^E!K[-K;J3T"BBBJ$%%%% !24M% $;1!FR>:<J[:=10
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M_@BDV[QM\4!_U#;/_P!&R5JQ+<_6:WZ-4U1PKA34E"V&%?%?[:"EOB9IO/\
MS#5X_P"!M7VI7G7Q"^ _A?XG:S%J>MI=/<Q0^0GDSE %R3V^M=F%JQHU%.6Q
MW8.M&A5YY['YZ=^H/^Z.*,>]?</_  Q_\/O^>&H?^!;4?\,?_#[_ )X7_P#X
M%M7M?VA1\_N/HO[5P_F?#I!KWO\ 8U./B)JNWC_B7?0??':O9_\ AC_X?_\
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M_P")TO\ X!__ &RG_9&'[L/KE5=#CFO(.SYJM<7"2;\-GG*X]/2NZ_X4J_\
MT&U_\!/_ +92GX+O_P!!I?\ P$_^V4O[(H=V/Z]4/)=4AGG1O)B+G'8BO-->
M\(Z[?7&4L'*CDG<O^-?4H^"\@_YC:_\ @(?_ (Y3O^%*R%<_VVO_ (!__;*N
M.4T.DF0\949\A_\ " Z[_P ^#_\ ?2_XT?\ " :[_P! ]_\ OI?\:^NF^"[K
M_P QI3_VY_\ VRD_X4R__097_P  _P#[95?V71_F?X!]9F?(W_" :[_T#W_[
MZ7_&C_A -=[:>^?]Y?\ &OKG_A3+_P#097_P#_\ ME'_  IA_P#H-+_X!_\
MVRC^S*/\S#ZS,^??!ND:M8VH2[M'A(X^9A^?6N\M&\I/G)!QWKTC_A2L@'_(
M;7_P#_\ ME-_X4Q(>/[;7'_7I_\ ;*S_ +(H?S,%C*BV1Q<=Y#P"XS4Z:A O
M60?E77?\*5?_ *#2_P#@'_\ ;*/^%+2?]!M?_ /_ .V4O['P_P#,RECJO8YF
MSU:V@OK.5I=JQSH[''0!N37VAX/_ &D/ASI>@PV]QXFACE51E3#(><?[M?*H
M^"LF3_Q.U_\  /\ ^V4'X*R?]!M3];/_ .V4_P"R,/\ S,/KM1]#9_:6\;:%
MXW\56=[H%^NH0+ T;LJLNT[L@<@5X;=6\TV (\CZBO6?^%+R?]!M?_ /_P"V
M4?\ "EY./^)VO_@'_P#;*/[(P_=A]=J6V/&+K3;AH\+"Q)[9%<=KO@C7;V-1
M!ILT@WG.,<5]+_\ "F9%8?\ $Z4]_P#CS_\ ME78_AG?0J$77(\9)YLLGG_M
MI6-3*Z<-8,<<4Y?&C[H_X)8Z==:1^R#H%K=Q>3.FI:AE#U&9R:^PE.5&:^;?
MV#]);P_\ ;"P,XN3%J-X/,V;,YD!Z9/KZU])*<J#7B5(J$W%'="7-!,6BBBH
M*"BBB@ HHHH **** "BBB@!&Z5^,'_!6KPMJFM_M50S65JT\:^'K-2P(X.^7
MC]:_9\U^;'[>WP_?Q%^T%%J":BMKC2[5?+-OOZ%^<[Q_*NK#4HUI\LMC&K)P
MC='Y;_\ "O-?*#&GOGO\R_XT+\.]>#$M8/\ ]]+_ (U]CW'PUN(X21JL66&,
MFS.?_1E5)OA+=7"Q^9KJL ,C_0^G_D2O4I8"G4WV,9U7'8^5-+\%ZY;DJ^GR
M;>H.Y?\ &NRT'2]1M<>;;,@]R/\ &O=?^%+R=3K:_P#@'_\ ;*/^%+2?]!M?
M_ /_ .V5T/*J#W;,/K51/8\_L941 'RIK3M=2CM;F"99,&*17Z'L<UUO_"EY
M?^@XO_@'_P#;*/\ A3,F?^0TH_[<_P#[94?V10[LU^N5>R/J[PW^TM\.H-#A
MBN_$L,4_E -&T$AP<=/NU\Z_'3QKX8\5:M97FBZFEX8RP<*C#Y6^H]0*YO\
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M^:]0\,ZO(962SD8G./F'^-<Q_P *^U]1_P @]\GK\R_XU]=_\*7D_P"@VO\
MX"?_ &RD;X+R<#^VU_\  /\ ^V52RJ@MI,S^M3['R0OPU\23*-NERMWRN"/Y
MU^BG_!&OPWJ/A_QS\31?VS6WF:=9JH;&3B9\UY3#\)[NU/R:ZO39C[&>G_?R
MOK+_ ()T^#9/"?C#QK*U_P#;&GL;<?ZG81B1N^XYKAQ&!C1@YIG3"OSM(^^X
@3E34E1P]#]:DKQEL=@4444P"BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487272056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NANOBIOTIX S.A.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">I0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 rue de Wattignies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#8364;0.03 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">34,825,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001760854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 rue de Wattignies<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Paris<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">FR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Mr. Bart van Rhijn<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(0)1 40 26 04 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">33 (0)1 40 26 04 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=nbx_AmericanDepositorySharesNASDAQStockMarketMember', window );">American depositary shares, each representing one ordinary share, nominal value &#8364;0.03 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American depositary shares, each representing one ordinary share, nominal value &#8364;0.03 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=nbx_AmericanDepositorySharesNASDAQStockMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=nbx_AmericanDepositorySharesNASDAQStockMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487137624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">ERNST & YOUNG et Autres<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Paris-La D&#233;fense, France<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487785928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CONSOLIDATED FINANCIAL POSITION - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="nump">&#8364; 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">8,186<span></span>
</td>
<td class="nump">8,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">8,709<span></span>
</td>
<td class="nump">8,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">9,139<span></span>
</td>
<td class="nump">6,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">83,921<span></span>
</td>
<td class="nump">119,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">93,060<span></span>
</td>
<td class="nump">125,248<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">101,769<span></span>
</td>
<td class="nump">134,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Premiums related to share capital</a></td>
<td class="nump">255,767<span></span>
</td>
<td class="nump">255,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserve</a></td>
<td class="num">(183,459)<span></span>
</td>
<td class="num">(153,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NetLossForThePeriod', window );">Net loss for the period</a></td>
<td class="num">(47,003)<span></span>
</td>
<td class="num">(33,590)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">26,790<span></span>
</td>
<td class="nump">70,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current provisions</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">37,816<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">38,134<span></span>
</td>
<td class="nump">44,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current provisions</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">8,204<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other payables</a></td>
<td class="nump">6,482<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">5,531<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred revenues and contract liabilities</a></td>
<td class="nump">16,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">36,845<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">&#8364; 101,769<span></span>
</td>
<td class="nump">&#8364; 134,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NetLossForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Loss For The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NetLossForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487659432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CONSOLIDATED OPERATIONS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues and other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues and other income</a></td>
<td class="nump">2,647<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(30,378)<span></span>
</td>
<td class="num">(24,330)<span></span>
</td>
<td class="num">(30,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="num">(19,434)<span></span>
</td>
<td class="num">(14,611)<span></span>
</td>
<td class="num">(18,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income and expenses</a></td>
<td class="num">(5,414)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="num">(55,226)<span></span>
</td>
<td class="num">(38,941)<span></span>
</td>
<td class="num">(49,320)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income (loss)</a></td>
<td class="num">(52,579)<span></span>
</td>
<td class="num">(36,428)<span></span>
</td>
<td class="num">(46,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">6,360<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(780)<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="num">(4,970)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial income (loss)</a></td>
<td class="nump">5,580<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
<td class="num">(4,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (47,003)<span></span>
</td>
<td class="num">&#8364; (33,590)<span></span>
</td>
<td class="num">&#8364; (50,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (1.35)<span></span>
</td>
<td class="num">&#8364; (1.38)<span></span>
</td>
<td class="num">&#8364; (2.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (1.35)<span></span>
</td>
<td class="num">&#8364; (1.38)<span></span>
</td>
<td class="num">&#8364; (2.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487063224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (47,003)<span></span>
</td>
<td class="num">&#8364; (33,590)<span></span>
</td>
<td class="num">&#8364; (50,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses on retirement benefit obligations&#160;(IAS 19)</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome', window );">Tax impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive loss that will not be reclassified subsequently to income or loss</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Currency translation adjustment</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome', window );">Tax impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income that may be reclassified subsequently to income or loss</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">&#8364; (46,915)<span></span>
</td>
<td class="num">&#8364; (33,469)<span></span>
</td>
<td class="num">&#8364; (50,863)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 90<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 90<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480013880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS&#8217; EQUITY - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital Ordinary shares</div></th>
<th class="th"><div>Premiums related to share capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Reserve</div></th>
<th class="th"><div>Net loss for the period</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,633,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">&#8364; 14,243,000<span></span>
</td>
<td class="nump">&#8364; 589,000<span></span>
</td>
<td class="nump">&#8364; 122,799,000<span></span>
</td>
<td class="nump">&#8364; 381,000<span></span>
</td>
<td class="num">&#8364; (124,000)<span></span>
</td>
<td class="num">&#8364; (79,057,000)<span></span>
</td>
<td class="num">&#8364; (30,345,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(50,915,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,915,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation adjustments</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses (IAS 19)</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(50,863,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,915,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AllocationOfPriorPeriodLoss', window );">Allocation of prior period loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,345,000)<span></span>
</td>
<td class="nump">30,345,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,566,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="nump">28,079,000<span></span>
</td>
<td class="nump">&#8364; 77,000<span></span>
</td>
<td class="nump">28,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants', window );">BSPCE exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">BSPCE exercise</a></td>
<td class="nump">1,306,000<span></span>
</td>
<td class="nump">&#8364; 6,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">4,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury shares</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">U.S. Initial public offering costs offset</a></td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,415,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2019</a></td>
<td class="num">(1,908,000)<span></span>
</td>
<td class="nump">&#8364; 672,451.17<span></span>
</td>
<td class="nump">153,139,000<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
<td class="num">(105,070,000)<span></span>
</td>
<td class="num">(50,915,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(33,590,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,590,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation adjustments</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses (IAS 19)</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(33,469,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,590,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AllocationOfPriorPeriodLoss', window );">Allocation of prior period loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,915,000)<span></span>
</td>
<td class="nump">50,915,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,017,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="nump">102,942,000<span></span>
</td>
<td class="nump">&#8364; 361,000<span></span>
</td>
<td class="nump">102,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">2,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury shares</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">U.S. Initial public offering costs offset</a></td>
<td class="num">(10,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,432,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="nump">70,468,000<span></span>
</td>
<td class="nump">&#8364; 1,032,963.66<span></span>
</td>
<td class="nump">255,735,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="num">&#8364; (196,000)<span></span>
</td>
<td class="num">(153,070,000)<span></span>
</td>
<td class="num">(33,590,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(47,003,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,003,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation adjustments</a></td>
<td class="num">(94,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and losses (IAS 19)</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">(46,915,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,003,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AllocationOfPriorPeriodLoss', window );">Allocation of prior period loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,590,000)<span></span>
</td>
<td class="nump">33,590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share based payment</a></td>
<td class="nump">3,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury shares</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,825,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="nump">&#8364; 26,790,000<span></span>
</td>
<td class="nump">&#8364; 1,044,776.16<span></span>
</td>
<td class="nump">&#8364; 255,767,000<span></span>
</td>
<td class="nump">&#8364; 643,000<span></span>
</td>
<td class="num">&#8364; (202,000)<span></span>
</td>
<td class="num">&#8364; (183,460,000)<span></span>
</td>
<td class="num">&#8364; (47,003,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AllocationOfPriorPeriodLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation Of Prior Period Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AllocationOfPriorPeriodLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Ordinary Shares Issued Through Exercise Of Founders Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Issue Of Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesIssuedThroughIssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857483168040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CONSOLIDATED CASH FLOWS - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (47,003)<span></span>
</td>
<td class="num">&#8364; (33,590)<span></span>
</td>
<td class="num">&#8364; (50,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Elimination of other non-cash, non-operating income and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Provisions</a></td>
<td class="nump">152<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Expenses related to share-based payments</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Cost of net debt</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Loss on disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset', window );">U.S. Initial public offering 2018 costs reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities', window );">Impact of deferred income related to financial liabilities discounting effect</a></td>
<td class="num">(1,554)<span></span>
</td>
<td class="num">(6,463)<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other charges with no impact on cash</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows used in operations, before tax and changes in working capital</a></td>
<td class="num">(41,412)<span></span>
</td>
<td class="num">(33,300)<span></span>
</td>
<td class="num">(39,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase) / Decrease in trade receivables</a></td>
<td class="nump">62<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax', window );">Decrease in Research tax credit receivable</a></td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">5,688<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables', window );">Increase in other receivables</a></td>
<td class="num">(5,034)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
<td class="num">(4,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase / (Decrease) in trade and other payables</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(995)<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities', window );">Increase / (Decrease) in other current liabilities</a></td>
<td class="num">(1,652)<span></span>
</td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Increase in deferred income and contract liabilities</a></td>
<td class="nump">16,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in operating working capital</a></td>
<td class="nump">11,540<span></span>
</td>
<td class="nump">5,762<span></span>
</td>
<td class="num">(1,522)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(29,872)<span></span>
</td>
<td class="num">(27,538)<span></span>
</td>
<td class="num">(41,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Acquisitions of intangible assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisitions of property, plant and equipment</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="num">(1,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Addition in non-current financial assets</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows from (used in) investing activities</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="num">(1,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Capital increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">113,650<span></span>
</td>
<td class="nump">29,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProceedsFromWarrantsSubscription', window );">Warrants subscription</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Transaction costs</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(10,359)<span></span>
</td>
<td class="num">(1,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Loans repayments</a></td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of lease liabilities</a></td>
<td class="num">(909)<span></span>
</td>
<td class="num">(928)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="num">(5,180)<span></span>
</td>
<td class="nump">111,769<span></span>
</td>
<td class="nump">41,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rates changes on cash</a></td>
<td class="nump">64<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(35,230)<span></span>
</td>
<td class="nump">84,056<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents at beginning of period</a></td>
<td class="nump">119,151<span></span>
</td>
<td class="nump">35,094<span></span>
</td>
<td class="nump">36,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents at end of period</a></td>
<td class="nump">&#8364; 83,921<span></span>
</td>
<td class="nump">&#8364; 119,151<span></span>
</td>
<td class="nump">&#8364; 35,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Other Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments For U.S. Initial Public Offering 2018 Costs Offset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProceedsFromWarrantsSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrants Subscription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProceedsFromWarrantsSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485480856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract', window );"><strong>Disclosure Of Information Related To The Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">Company information</a></td>
<td class="text">Company information<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Presentation of the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix S.A. was incorporated in 2003 as a spin-off from the State University of New York (SUNY) in Buffalo. Nanobiotix S.A. (together with its subsidiaries, the &#8220;Company&#8221;), is headquartered in Paris, France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, as well as the utility and efficacy of radiotherapy. Its lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline metallic nanoparticles approximately 50 nanometers (50 billionths of a meter) in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Alongside the Company&#8217;s core NBTXR3 development program, the Company is also pursuing a development program to explore the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across several solid tumor indications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company is listed on the Euronext regulated market in Paris (under the ticker symbol &#8220;NANO&#8221;; Code ISIN: FR0011341205, Bloomberg code: NANO:FP) and on the Nasdaq Global Select Market (under the ticker symbol &#8220;NBTX&#8221;).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">Significant events of the period</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix and PharmaEngine mutually agree to terminate their collaboration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Termination Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8221;). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5&#160;million in the aggregate as described below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">PharmaEngine was eligible for and received in March 2021 a $2.5&#160;million payment following the announcement of Nanobiotix&#8217;s collaboration with LianBio for the Asia-Pacific region. In May 2021, PharmaEngine received an additional $4.0&#160;million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PharmaEngine will be eligible to receive an additional $1.0&#160;million in administrative fees and a final payment of an additional $5.0&#160;million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of December 31, 2021, these future payments were not accrued because the triggering events have not occurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix&#8217;s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the terms of the agreement, the Company received a $20&#160;million upfront payment and is entitled to receive up to an aggregate of $220&#160;million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (&#8220;the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supervisory Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Executive Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221;). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfInformationRelatedToTheCompanyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Information Related To The Company [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfInformationRelatedToTheCompanyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485441304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information, Statement of Compliance and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract', window );"><strong>General Information, Statement of Compliance and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General Information, Statement of Compliance and Basis of Presentation</a></td>
<td class="text">General Information, Statement of Compliance and Basis of Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">General principles</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders&#8217; equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management&#8217;s supervision and were approved by the Executive Board of the Company (the &#8220;Executive Board&#8221;) and reviewed by the Supervisory Board of the Company (the &#8220;Supervisory Board&#8221;) on March 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (&#8216;&#8216;IFRS&#8217;&#8217;) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company&#8217;s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of &#8364;83,921&#160;thousand as of December 31, 2021, as compared to &#8364;119,151&#160;thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements&#8217; publication. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Statement of Compliance and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#8220;IAS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;) as well as interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS-IC&#8221;) and the Standard Interpretations Committee (the &#8220;SIC&#8221;), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Those are available on the European Commission website: </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.15pt">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IFRS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Covid-19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Related rent concession.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of these standards had no impact on the consolidated financial statements of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations early adopted by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations not yet applied by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 :</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">IFRS 17 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and related amendments. No impact expected on the financial statements. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 1 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality&#8221;.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 37 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Onerous Contracts - Cost of Fulfilling a Contract. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IFRS 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conceptual framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 8 -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> Definition of an accounting estimate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IAS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Property, Plant and Equipment: Proceeds before Intended Use</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General Information, Statement of Compliance and Basis of Presentation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487269016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidation principles and methods<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Consolidation principles and methods</a></td>
<td class="text">Consolidation principles and methods<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">3.1 Basis of consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 10 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company&#8217;s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting methods of the Company&#8217;s subsidiaries are aligned with those of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company involves one parent entity, &#8220;Nanobiotix S.A.,&#8221; and five wholly owned subsidiaries: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Germany GmbH, incorporated in Germany in October 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Spain S.L.U., incorporated in Spain in December 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">3.2 Use of judgement, estimates and assumptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Measurement of share-based payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, vesting terms) and market data (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, expected share volatility) (see Note 17).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred tax assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Clinical trial accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly.  See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 15 for additional detail regarding the Company&#8217;s accounting policies for its additional sources of revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Fair value of financial assets and liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value measurement of the loan granted by European Investment Bank (&#8220;EIB&#8221;) requires the Company to assess the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company&#8217;s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487269272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text">Significant transactions<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.1 LianBio</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In May 2021, Nanobiotix announced a partnership with LianBio Oncology Limited a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, a non-refundable upfront payment of $20&#160;million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220&#160;million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 15 Revenues and other income for further details on this new partnership.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.2 PharmaEngine</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In August 2012, the Company entered into an Exclusive License and Collaboration Agreement (as amended in 2014, the &#8216;&#8216;License and Collaboration Agreement&#8217;&#8217;) with PharmaEngine, a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer in Asia. Under the terms of the License and Collaboration Agreement, PharmaEngine will receive the exclusive right to further develop NBTXR3 to obtain regulatory approval, leverage the data generated by the Company&#8217;s development activities and commercialize NBTXR3 in multiple countries throughout the Asia-Pacific region. Under the same Agreement, PharmaEngine is responsible for developing (non-clinical and clinical research) and commercializing NBTXR3 throughout the contractual territory and making certain development and minimum commercial milestone payments to the Company. Key provisions of the License and Collaboration Agreement include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">An exclusive perpetual license granted to PharmaEngine, with the right to sublicense the Company&#8217;s technology in order to exploit or have NBTXR3 exploited and use the Company&#8217;s trademark in connection with the exploitation of NBTXR3 in the contractual territory (with exploitation including among others developing, obtaining and maintaining regulatory approval, commercializing, distributing, promoting and marketing);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The Company&#8217;s commitment to furnish PharmaEngine with know-how necessary and useful to develop and commercialize NBTXR3 in the contractual territory, know-how meaning any results of experimentation and pre-clinical, clinical and non-clinical trial data by providing PharmaEngine with access to an electronic data platform; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The Company&#8217;s commitment to supplying or having supplied PharmaEngine with all quantities of NBTXR3 required and used by PharmaEngine for clinical testing and subsequent commercialization if and when regulatory approvals are obtained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In return, PharmaEngine commits to use commercially reasonable efforts to develop NBTXR3 in the contractual territory at PharmaEngine&#8217;s cost. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the License and Collaboration Agreement, the Company has received and/or is entitled to receive:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A $1.0&#160;million up-front payment on signature of the contract, fully received in 2012; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments upon the achievement of development milestones, including key stages of product development, first filing for regulatory approval, and first regulatory approval in the contractual territory; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments upon the achievement of commercial milestones based on specified sales thresholds; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Up to double-digit royalties based on net product sales in the Asia-Pacific region; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Payments for the supply of NBTXR3. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Potential development and commercial milestone payments, including those paid to date, amount to an aggregate of up to $56&#160;million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company and PharmaEngine amended the agreement in October 2014, as part of which PharmaEngine agreed: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To join the global pivotal clinical trial of NBTXR3 for the treatment of Soft Tissue Sarcoma initiated by the Company in the Asia-Pacific area, with each party committing itself to share clinical trial results in order to increase the tested population and to accelerate growth and value creation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To pay the first development milestone ($1&#160;million, received by the Company in 2014) and share external clinical research organization costs charged to the Company in proportion to its contribution in recruiting the patient population included in the clinical trial; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">To pay the development milestone ($1&#160;million, received by the Company in 2016) related to the launch of the first Phase II of the pivotal study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, $3.0&#160;million has been received since the signature of the License and Collaboration Agreement. The next potential milestone payment under the agreement will become payable only if PharmaEngine files a commercialization authorization of NBTXR3 in their region.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. While both Nanobiotix and PharmaEngine believe in the potential of NBTXR3 to improve treatment outcomes for patients with cancer, the parties have had disagreements regarding the optimal strategy for development in the Asia-Pacific region. As such, after discussion between the two parties, Nanobiotix and PharmaEngine have mutually agreed to discontinue the collaboration. This agreement to terminate the License and Collaboration agreement represents a full resolution of outstanding disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region. See Note 15 for additional detail regarding the accounting policy applied to the License and Collaboration Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, the Company paid a cumulative amount of $6.5&#160;million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1&#160;million upon receipt by the Company of certain clinical study reports and of $5&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. These future payments were not accrued because the triggering events have not occurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">4.3 Financing Agreement with the European Investment Bank (&#8220;EIB&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to &#8364;40&#160;million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a first tranche of &#8364;16&#160;million, received in October 2018, subject to a 6% fixed rate and that will be fully repaid in 2023 at the latest; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a second tranche of &#8364;14&#160;million, received in March 2019, subject to a 5% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">a last tranche of &#8364;10&#160;million, subject to a 4% fixed interest rate, that will be fully repaid after a period of five years, which begins within one year of obtaining it. The Company has not yet met the criteria to request this tranche. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the final tranche of the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn, and indexed on the Company&#8217;s annual sales turnover.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The &#8364;14&#160;million second tranche, which was received in March 2019, was disbursed on the basis of achieving the following criteria:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Determination of the recommended dose at 22% of the tumor volume for head and neck cancers treatment following the end of the Phase I clinical trial with NBTXR3; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Positive evaluation of the clinical benefit/risk ratio of NBTXR3 in the Phase II/III clinical trial in soft tissue sarcomas by the clinical expert mandated by the French notified body covering medical devices, GMED.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 22 for discussion of royalties that may be due in the case of early repayment or change of control after repayment of the loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">4.4 Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix&#8217;s product NBTXR3 for use in treating several cancer types &#8211;, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11&#160;million for those clinical trials during the collaboration, and made an initial $1.0&#160;million payment at the commencement of the collaboration and a second $1.0&#160;million payment on February 3, 2020. Additional payments were made in the six months following patients enrollment, with the balance payable upon enrollment of the final patient for all studies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2&#160;million to $16.4&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company recognized prepaid expenses for &#8364;1.0&#160;million and &#8364;1.6&#160;million respectively. Expenses will be recorded during the course of the collaboration in the statement of consolidated operations based on the patients enrolled during the relevant period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 8.2 for further details on other current assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Significant Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485447928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, intangible assets are carried at their acquisition cost. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research and Development costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, development costs may only be capitalized as intangible assets if the following criteria are met: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company intends to complete the development of the intangible asset and use or sell it; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company has the ability to use or sell the intangible asset; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is probable that the intangible asset will generate future economic benefits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">adequate technical, financial and other resources are available to complete the development of the intangible asset; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Patents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Software </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of intangible assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of intangible assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in intangible assets breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(17)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.67pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">710</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(548)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(141)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485448056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">Property, plant and equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company&#8217;s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The depreciation periods used are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">General fixtures and fittings, building work: 5 to 10 years;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Technical installations, equipment and industrial tooling: 3 to 10 years; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Office and IT equipment and furniture: 1 to 10 years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of property, plant and equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of property, plant and equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in property, plant and equipment is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,630</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,590</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,017</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,641)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,534)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,256</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,186</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2021, the &#8364;1,362&#160;thousand increase in Right of use &#8211; Buildings mainly relates to the extension of Villejuif leases for 4 years for &#8364;1,390&#160;thousand reduced by approximately &#8364;25&#160;thousand related to rent indexation impact. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The &#8364;139&#160;thousand decrease in Right of use &#8211; Buildings relates to the termination of a lease contract in Faubourg Saint-Antoine in Paris, France.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">515</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,630</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,001)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3,811)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,386</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,101)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,256</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the &#8364;418&#160;thousand increase in Right of use &#8211; Buildings mainly relates to: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Two new lease contracts: one in Rue Oberkampf in Paris, France for &#8364;155&#160;thousand, the other in Rue du Faubourg Saint-Antoine in Paris, France for &#8364;140&#160;thousand, </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The termination of a lease contract by Curadigm SAS for &#8364;43&#160;thousand; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The addition of a parking for  the Villejuif facility for &#8364;30&#160;thousand, and </span></div>&#8226;The impact of an annual rent adjustment for the Wattignies and Villejuif leases based on the INSEE (National Institute of Statistics and Economic Studies) index for &#8364;35 and &#8364;15&#160;thousand, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487013720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock', window );">Non-current financial assets</a></td>
<td class="text">Non-current financial assets <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current financial assets are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No non-current financial assets are estimated at fair value through other comprehensive income (OCI). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, financial assets are classified in three categories according to their nature and the intention of management: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through profit and loss;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through other comprehensive income; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at amortized cost. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All regular way purchases and sales of financial assets are recognized at the settlement date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at fair value through profit or loss </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at amortized cost </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case&#8211;by&#8211;case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of non-current financial assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in non-current financial assets breaks down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:38.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">contract - </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash account</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other<br/>long-term investments pledged as collateral</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">131</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">529</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">401</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">421</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See note&#160;10.2 Treasury shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, non-current financial assets increased by &#8364;14&#160;thousand compared to 2020. In 2020, non-current financial assets decreased by &#8364;24&#160;thousand compared to 2019. In 2021, the security deposits paid increased by &#8364;20&#160;thousand, mainly due to a &#8364;9&#160;thousand deposit paid in connection with a new Nanobiotix Corp  headquarters&#8217; lease contract in Cambridge, Massachusetts, United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The decrease of the liquidity contract &#8211; cash account corresponds to treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of change in shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857483603016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock', window );">Trade receivables and other current assets</a></td>
<td class="text">Trade receivables and other current assets<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for trade receivables and other current assets are described in Note 7.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">8.1 Trade receivables</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables break down as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in 3 months or less</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 3 and 6 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 6 and 12 months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after more than 12 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">8.2 Other current assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other current assets break down as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,035</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2021, prepaid expenses mainly relate to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">research agreements related to the MD Anderson agreement (see Note 4.4 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for &#8364;1.0&#160;million, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">insurance related to the Directors &amp; Officers for &#8364;0.6&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As of December 31, 2020, prepaid expenses mainly relate to research agreements related to MD Anderson agreement (see Note 4.4 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Collaboration Agreement with the University of Texas MD Anderson Cancer Center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">for &#8364;1.6&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Other receivables mainly comprised advances paid to suppliers in the amounts of &#8364;3,043&#160;thousand as of December 31, 2021 as compared to &#8364;805&#160;thousand as of December 31, 2020. This advance payment is mainly related to the new ICON contract signed in 2021 in conjunction with the launch of the 312 study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research tax credit </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives a research tax credit (Cr&#233;dit d&#8217;Imp&#244;t Recherche, or &#8216;&#8216;CIR&#8217;&#8217;) from the French tax authorities. See Note 15 for additional details on the CIR research tax credit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The research tax credit for 2021 was &#8364;2.5&#160;million (&#8364;2.3&#160;million for Nanobiotix S.A. and &#8364;218&#160;thousand for Curadigm SAS), while the amount for 2020 was &#8364;1.9&#160;million (&#8364;1.9&#160;million for Nanobiotix S.A. and &#8364;69&#160;thousand for Curadigm SAS). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The 2020 research tax credit was collected by the Company in November 2021, while the 2019 research tax credit was collected in July 2020.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in research tax credit receivables breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:84.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,688</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2018 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Nanobiotix SA </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,927</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,858)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2021</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,490</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade Receivables And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857483603016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are measured at amortized cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of cash and cash equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">83,921</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,151</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, cash and bank accounts decreased by &#8364;35,230&#160;thousand as compared with December 31, 2020 mainly due to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the non-refundable upfront payment from LianBio in June 2021 of &#8364;16.5&#160;million ($20.0&#160;million);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the payments made to PharmaEngine for a total of &#8364;5.4&#160;million in 2021 pursuant to the PharmaEngine Termination Agreement; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the debt reimbursement related to the EIB loan for &#8364;3.0&#160;million and to the Bpifrance loan for &#8364;0.5&#160;million; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">other cash flows used in operating activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484865496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">10.1 Capital issued</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares are classified in shareholders&#8217; equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders&#8217; equity as a deduction from the proceeds of the issue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:17.639%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">672</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">153,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22,415,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">316,083&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 24, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 26, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 29, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 27, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal &#8364; - Nasdaq (&#8364;11.14)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,855,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal $ - Nasdaq ($13.50)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,445,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering green shoe $ - Nasdaq ($13.50)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,095,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,033</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">255,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,432,122</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2019-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">369,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants attribution </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants subscription (BSA 2021)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,045</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">255,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,825,872</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the share capital was &#8364;1,044,776.16 divided into 34,825,872 fully paid in ordinary shares each with a par value of &#8364;0.03, as compared with the 2020 share capital of &#8364;1,032,963.66 divided into 34,432,122 fully paid in ordinary shares, each with a par value of &#8364;0.03 and the 2019 share capital of &#8364;672,451.17 divided into 22,415,039 fully paid in ordinary shares each with a par value of &#8364;0.03.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, the increase in share capital is inherent to the definitive acquisition of free shares warrants related to the AGA 2018-1 and AGA 2019-1 plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the increase in share capital is mainly related to the U.S. initial public offering, which closed in December 2020. In the global offering, a total of 8,395,000 ordinary shares was issued, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">5,445,000 ordinary shares in the form of ADSs were issued in the United States at $13.50 per ADS;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">1,855,000 ordinary shares were issued through a concurrent offering in certain jurisdictions outside of the United States to certain investors at &#8364;11.14 per ordinary share; and,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the underwriters for the global offering exercised in full their option to purchase 1,095,000 additional ADSs at the same public offering price of $13.50 per ADS. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, &#8364;10.7&#160;million of transaction costs had been recorded, &#8364;9.3&#160;million of which were related to the initial public offering in the United States, and are recognized as a reduction to premiums related to share capital. Those transaction costs were almost paid in full as of December 31, 2020. The remaining &#8364;349&#160;thousand were paid in 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">10.2 Treasury shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On December 31, 2021, the Company held 15,456 treasury shares under a liquidity contract compared to 12,970 treasury shares as of December 31, 2020. This liquidity contract complies with the general regulations of, and market practices accepted by, the French Financial Markets Authority (&#8220;AMF&#8221;), entered into following the Company&#8217;s French initial public offering in 2012. These shares were deducted from IFRS equity in the amount of &#8364;202&#160;thousand and &#8364;196&#160;thousand as of December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">10.3 Founders&#8217; warrants, warrants, stock options and free shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for share-based payments are described in Note 17.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of change in founders&#8217; warrants, warrants, stock options and free shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company had the following type of equity plans in place: founders&#8217; warrant (BSPCE) plans, warrant (BSA) plans, stock option (OSA) plans and free shares (AGA) plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Founders&#8217; warrants (BSPCE)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2 </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,350</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,776)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,841</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179,500</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,476)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">92,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212,969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10,352)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">751,585</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(32,818)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the Executive Board decided to lift, for three former employees and for two former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact of share-based payments on income is detailed in Note 17.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence, no new instrument became issuable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Warrant Plans (BSA)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(36,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">78,103</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(77,880)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.660</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,000)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company&#8217;s shareholders' meeting held on November 30, 2020 granted 48,103 warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;13.47 (share premium included). The designated warrants included 18,103 warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period was open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of December 31, 2021, 14,431 warrants have been subscribed by their beneficiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The warrants can be exercised at any time during a 10-year period, subject to the satisfaction of the following conditions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the subscription by the relevant beneficiary of his/her warrant;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the relevant holder has attended at least 75% of the Supervisory Board meetings held during the twelve months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the recommended dose for two out of the three patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted 30,000 warrants to a consultant of the Company, each warrant giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;13.64 (share premium included) at any time during a 10-year period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of December 31, 2021, no warrants have been subscribed by the beneficiary. In addition, as of December 31, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 17, 2020, the Executive Board, acting pursuant to the delegation granted by the thirty-fourth resolution of the annual shareholders' meeting dated April 11, 2019 and following the approval granted by the Supervisory Board on March 13, 2020, granted 18,000 warrants to members of the Supervisory Board, each entitling the holder to subscribe to a defined number of ordinary shares with a par value of &#8364;0.03, at a price of &#8364;6.59. The holders subscribed to the warrants prior to the end of the subscription period on September 30, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stock Option Plans (OSA)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">387,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">387,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">571,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(80,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">491,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">491,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">691,200</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(93,753)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1,<br/>&#160;2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">407,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">589,150</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">407,972</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(10,763)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company&#8217;s shareholders&#8217; meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board 571,200 stock options (including 143,200 stock options and 428,000 performance stock options), each giving its holder the right to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;13.74 (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company&#8217;s annual shareholders&#8217; meeting held on April 28, 2021 (the &#8220;2020 Stock Option Plan&#8221;). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The ordinary stock options are exercisable as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">up to one-third of the ordinary stock options as from April 20, 2022;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional one-third of the ordinary stock options as from April 20, 2023,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The performance stock options may be exercised under the following conditions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">10% of the stock options may be exercised when the market price of the Company&#8217;s shares on the regulated market of Euronext in Paris reaches &#8364;24.00,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional 10% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#8364;30.00,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional 40% of the stock options may be exercised when the market price of the Company&#8217;s shares on the regulated market of Euronext in Paris reaches &#8364;40.00,</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an additional 40% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#8364;60.00, and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">at the latest within 10 years of the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such performance stock options as from April 20, 2022, (y) an additional 30% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., 60% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders&#8217; meeting held on November 30, 2020 granted 60,000 ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company&#8217;s annual shareholders&#8217; meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn 60,000 performance stock options governed by such plan. Each of such 120,000 stock options (whether ordinary and performance) gives it holders the right to subscribe one ordinary share, each with a par value of &#8364;0.03 and at a price of &#8364;12.99 (share premium included).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The exercise conditions of the 143,200 ordinary stock options and 428,000 performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these 60,000 ordinary stock options and 60,000 performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for two of the three patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 11, 2020, the Executive Board adopted the 2019 Stock Option Plan and, acting pursuant to the authorization granted by the thirty-second resolution of the annual shareholders' meeting dated April 11, 2019, granted 407,972 stock options (the &#8220;OSA 2020&#8221;), 300,000 of which to members of the Executive Board and Mr. Alain Dostie and the remaining 107,972 to employees of the Company, under such 2019 Stock Option Plan. Each OSA 2020 entitles its holder to subscribe one ordinary share of the Company with a par value of &#8364;0.03, at an exercise price of &#8364;6.25 (issue premium included).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The OSA 2020 may be exercised as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">up to one-third of the OSA 2020 as from March 11, 2021;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">an additional one-third of the OSA 2020 as from March 11, 2022; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition, the Executive Board decided that the exercise of the OSA 2020 granted to members of the Executive Board and Mr. Alain Dostie would also be subject to the achievement of positive results in the 1100 study in 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the supervisory board, on March 17, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">By way of exception, the Executive Board decided to lift the continued service condition of the OSA 2020 for two former Executive Board members as well as to accelerate, as from June 30, 2021, the vesting of the OSA 2020 one</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of these former executive board members holds, enabling him to exercise all of them, in the context of his departure from the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Free share plans (AGA)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(369,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">362,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">360,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">360,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">362,515</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(393,750)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,753)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at January 1, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">355,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316,083)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">746,250</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(322,083)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(27,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company&#8217;s shareholders&#8217; meeting on November 30, 2020, granted 362,515 free shares, each with a par value of &#8364;0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 11, 2020, the Executive Board, acting pursuant to the authorization granted by the thirty-third resolution of the annual shareholders&#8217; meeting dated April 11, 2019, granted 50,000 free shares (the &#8220;AGA 2020&#8221;) with a par value of &#8364;0.03 to Ms. Anne-Juliette Hermant, a member of the Executive Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In addition to the acquisition and holding conditions detailed below, the acquisition of the AGA 2020 granted to Ms. Hermant is conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board, on March 17, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Free share vesting conditions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The AGA 2020 and AGA 2021 are subject to, for French tax residents, a two-year acquisition period and a one-year holding period, and, for foreign tax residents, a three-year acquisition period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2020 and the AGA 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2020, until March 11, 2022 and for AGE 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2020 or AGA 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on March 17, 2021, the Executive Board acknowledged the definitive acquisition of 24,500 free shares granted on March 6, 2018 following a three-year acquisition period, thus acknowledging the related share capital increase of &#8364;735.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At a meeting on April 1, 2021, the Executive Board acknowledged the definitive acquisition of 369,250 free shares granted on March 29, 2019 following a two-year acquisition period, thus acknowledging the related share capital increase of &#8364;11,077.50.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">At a meeting on September 22, 2020, the Executive Board acknowledged the definitive acquisition of 6,000 free shares granted on July 27, 2018 following a two-year acquisition period, thus acknowledging the related share capital increase of &#8364;180.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with the terms of the free shares, the Executive Board decided to lift, for seven Company&#8217;s employees and a former Executive Board member, the continued service condition to which the definitive acquisition of their free shares is subject, notwithstanding the termination of their employment agreement or corporate office. The impact of share-based payments on income is discussed in Note 17. As of December 31, 2021, the assumptions related to the estimated vesting of the founders&#8217; warrants, the warrants and performance stock-options have been updated (see Note 17).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484888696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">Provisions<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for contingencies and charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for retirement obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Company employees receive the retirement benefits provided for by law in France: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee&#8217;s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:43.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">318</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">110</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">454</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">428</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:43.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">83</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">495</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">123</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">454</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases</span></div><div style="text-indent:3.83pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">11.1 Current provisions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Provisions for disputes comprise employee disputes in progress. The increase during 2021 and 2020 of &#8364;54&#160;thousand and &#8364;40&#160;thousand, respectively, were due to a new employee dispute that occurred during the respective years.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the reversal of provisions for charges of &#8364;164&#160;thousand were related to termination costs accounted for in 2019 following an employee departure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">11.2 Non-current provisions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Commitments for retirement benefits</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interests / discounting costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to experience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in financial assumptions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial gains or losses recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">318</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The assumptions used to measure lump-sum retirement benefits are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:54.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Measurement date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retirement assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age 66</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age 64</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age 66</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age 64</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Social security contribution rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42.01 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.98 %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.33 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mortality tables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2015 -2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2014 -2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Salary increase rate (including inflation)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: 3%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: 2.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: 3%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: 2.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Staff turnover</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of 5.86%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of 5.86%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Duration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17 years</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The rights granted to Company employees are defined in the Collective Agreement for the Pharmaceutical industry (manufacturing and sales of pharmaceutical products). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The staff turnover rate was determined using a historical average over the 2015-2019 period.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The sensitivity to the discount rate and to the salary growth is as follows:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:53.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.73%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defined Benefit Obligation as of December 31, 2021<br/>(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">333</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The company does not expect to pay a material amount of benefits for the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzk_e3c5a367-0c4d-4262-b3f1-35ea622dad92">five</span> next years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487124184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfFinancialLiabilitiesTextBlock', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives assistance in the form of grants, conditional advances and interest-free loans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Financial liabilities, including trade and other payables are valued at amortized cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Financial liabilities at amortized cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; Financial Instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Details of financial liabilities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances - Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB Loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,204</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,872</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">37,816</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">44,107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,979</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Bpifrance conditional advances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives repayable advances from Banque Publique d&#8217;Investissement (formerly known as OSEO Innovation). Some of these advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for 18 months. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The other advances are bearing 1.56% interest. The amount to be reimbursed corresponds to the amount received to date, &#8364;2.1&#160;million, increased by the interest amount (see Note 12.1). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In June 2020, Curadigm SAS obtained a &#8364;500&#160;thousand conditional advance from Bpifrance, &#8364;350&#160;thousand of which was received at the signature date while the remaining amount had been scheduled to be received by Curadigm at the end of the work, expected as of March 1, 2022 at the latest, but Curadigm SAS requested an extension of the work period to Bpifrance as a result of COVID-19 which - in case of Bpifrance&#8217;s approval - could result in collectibility of the remaining &#8364;150&#160;thousand. As of December 31, 2021, the work had not been completed and the balance, therefore, has not been paid.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">EIB loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of &#8364;40&#160;million, divided in three tranches. The first tranche, with a nominal value of &#8364;16&#160;million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of &#8364;14&#160;million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, had been delayed by 12 months to July 31, 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As the conditions were not met by July 31, 2021, the Company will not be able to request the final tranche of the EIB loan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to the terms of the loan, the Company is also required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.2). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 of our consolidated financial statements for details about the impact of this sales forecast update). A 10% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">PGE loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#8364;5&#160;million each in the form of state-guaranteed loans (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;, or &#8220;PGE&#8221; in France); the &#8364;5&#160;million from HSBC (the &#8216;&#8216;HSBC PGE Loan&#8217;&#8217;) was received in June 2020. This loan is booked at amortized cost for a minimum of 12 months and allows the Company to delay the reimbursement of this 12 months loan by 1 to 5 years. The Company uses this option and the reimbursement date was delayed by 1 year and will start in September 2022. The effective interest rate amounts to 0.31%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On July 10, 2020, the Company entered into the second &#8364;5&#160;million PGE loan with Bpifrance (the &#8216;&#8216;Bpifrance PGE Loan&#8217;&#8217;). The Bpifrance PGE loan has a six-year term and is 90% guaranteed by the French State. The Bpifrance PGE loan did not bear any interest for the first 12-month period but, following such 12-month period and for the subsequent 5 years, is bearing an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in 20 quarterly installments as from October 31, 2021 until July 26, 2026. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.1 Conditional advance, bank loan and loans from government and public authorities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conditional advances and loans from government and public authorities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"/><td style="width:33.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,165</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,746</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38,121</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">974</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">29,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32,727</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,033)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,533)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">493</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,374</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">300</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">29,433</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact of discounting and accretion of &#8364;5.8&#160;million, in 2021 relates to impact from the &#8220;catch-up method&#8221; related to the variable compensation further to the royalty component in the EIB loan that is linked to future revenue expectations. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. The rest of the catch up impact is presented on the line variable interest future payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The expected royalty payments to be made in the future, initially estimated as &#8364;17.2&#160;million as of December 31, 2020 have been updated to &#8364;3.4&#160;million as of December 31, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Bank loan</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,044</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,038</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,068</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.2 Lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:84.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1st,  2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,405</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New lease contracts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting of the new lease contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixed interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,188</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Engagement</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,476&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,519</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">12.3 Due dates of the financial liabilities  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:42.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,204</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">37,747</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,346</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,714</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8221;The Company will reimburse the two &#8220;PGE&#8221;or (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The outstanding balance of the EIB loan included in the table above was &#8364;33.9&#160;million as of December 31, 2021, including &#8364;7.0&#160;million of total fixed rate interest to be paid over the term of the loan, out of which &#8364;1.8&#160;million was accrued as of December 31, 2021. The balance in the table above does not include &#8364;3.4&#160;million of estimated variable rate interest, based on the consolidated forecasted sales expected to be generated by the Company during the six-year period beginning January 1, 2021 (see Notes 3.2, 4.3 and 12.1). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">On April 07, 2021, the Company received the approval of HSBC on its debt rescheduling request. The HSBC PGE loan will be reimbursed at the same pace as the Bpifrance loan, starting on September 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfFinancialLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfFinancialLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485264968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock', window );">Trade payables and other current liabilities</a></td>
<td class="text">Trade payables and other current liabilities<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">13.1 Trade and other payables</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for Trade and other payables are described in Note 12, &#8216;&#8216;Financial Liabilities.&#8217;&#8217; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accrued expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Details of trade and other payables</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables &amp; other accruals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,996&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,482</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables are not discounted, as none of the amounts were due in more than one year. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other trade payables include &#8364;447&#160;thousand of costs relating to the ICON contract not yet paid, as of December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">13.2 Other current liabilities</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,531</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer costs to be paid on free shares, accrued bonuses, vacation days and related social charges. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Payroll tax and other payroll liabilities decreased by &#8364;1.4&#160;million from &#8364;6.2&#160;million as of December 31, 2020 to &#8364;4.8&#160;million as of December 31, 2021 as a result of the decrease in social charges accrual related to free shares and to bonuses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">13.3 Deferred revenues and contract liabilities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.852%"><tr><td style="width:1.0%"/><td style="width:63.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,518</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in deferred revenues and contract liabilities as of December 31, 2021 consists of contract liabilities relating to the LianBio contract in the amount of &#8364;16.5&#160;million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Trade Payables And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857486988440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments included in the statement of financial position and impact on income</a></td>
<td class="text">Financial instruments included in the statement of financial position and impact on income<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for financial instruments included in the statements of financial position and impact on income are described in Note 7, &#8216;&#8216;Non-current financial assets&#8217;&#8217;, Note 8, &#8216;&#8216;Trade receivables and other current assets&#8217;&#8217;, Note 9, &#8216;&#8216;Cash and cash equivalents&#8217;&#8217; and Note 12, &#8216;&#8216;Financial liabilities.&#8217;&#8217;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on<br/>the statement of<br/>financial position</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets <br/>carried at fair value <br/>through profit or <br/>loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities<br/>carried at amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,343</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management of financial risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Liquidity risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Foreign Currency Exchange Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company&#8217;s U.S. subsidiaries as of December 31, 2021, and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:40.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(45)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(87)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:40.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Credit risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers&#8217; high credit rating for other receivables.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Interest rate risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Fair value </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The carrying value of receivables and current liabilities is assumed to approximate their fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487788616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenues and other income</a></td>
<td class="text">Revenues and other income <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue is recognized in accordance with IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A license:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is assessed to be a right to access the Company&#8217;s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is a right to use the Company&#8217;s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Product supply for which the revenue is recognized once the control over the delivered products is transferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application to the license and collaboration agreement with PharmaEngine</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the License and Collaboration Agreement, the Company&#8217;s and PharmaEngine&#8217;s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company&#8217;s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the license of the right to use the Company&#8217;s patent and know-how;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine&#8217;s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the supply of NBTXR3 to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">An upfront payment of $1.0&#160;million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1&#160;million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company&#8217;s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1&#160;million (first patient&#8217;s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine &#8217;s territory, which had not occurred as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of IFRS 15 to the license and collaboration agreement with LianBio</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">an exclusive license, under the Company's intellectual property, to develop and market the licensed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the right to actively participate in global Phase III registration trials to obtain marketing approval in China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the requirement to purchase products under license to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20&#160;million and may receive up to $220&#160;million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research tax credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The French tax authorities grant a research tax credit (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, or &#8220;CIR&#8221;), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the &#8220;PME&#8221;, it can request immediate refund of the remaining tax credit, without application of the three-year period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of revenues and other income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,637</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,462</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,473</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,647</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s revenue of &#8364;10&#160;thousand in 2021, &#8364;50&#160;thousand in 2020 and &#8364;68&#160;thousand in 2019 were derived mainly from the charging-back of shared external clinical research organization costs in connection with the development support provided by the Company to PharmaEngine as part of the 2014 amendment to the Company's License and Collaboration Agreement. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100% of the revenues recognized in 2021, 2020 and 2019 were derived from the arrangement with PharmaEngine (see Note 4.1).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the Company&#8217;s other income, other than the research tax credit, mainly derives from French State subsidies of &#8364;312&#160;thousand provided as part of the &#8216;&#8216;partial unemployment measure,&#8217;&#8217; a National plan allowing companies facing economic challenges during the COVID-19 crisis to receive from the French State approximately 84% of specific employees&#8217; net salary, as well as the &#8364;350&#160;thousand received by Curadigm in connection with the Bpifrance Deep Tech Funding, &#8364;187&#160;thousand of which was recognized as revenue for the years ended December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487557208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">Operating expenses</a></td>
<td class="text">Operating expenses<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for research and development expenses are described in Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.1 Research and development expenses</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,734)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,980)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(24,330)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,411)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases, sub-contracting and other expenses increased by &#8364;6.9&#160;million, or 54% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payroll costs decreased by &#8364;774&#160;thousand, or 8% for the year ended December 31, 2021 as compared with the same period in 2020. This variation is mainly due to a change in the mix and in the location of our research and development staff.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company&#8217;s workforce amounted to 75 research and development staff, including 9 additional positions created during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2020, the Company&#8217;s workforce amounted to 66 research and development staff, including a decrease of fifteen positions created during the year ended December 31, 2020 and 81 research and development staff, including 2 additional positions created during the year ended December 31, 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The impact of share-based payments (excluding employer&#8217;s contribution) on research and development expenses amounted to &#8364;677&#160;thousand in 2021 as compared with &#8364;629&#160;thousand in 2020 and &#8364;902&#160;thousand in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.2 Selling, General and Administrative (SG&amp;A) expenses</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,482)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(19,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14,611)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,909)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2021, purchases, fees and other expenses increased by &#8364;3,156&#160;thousand, or 49% for the year ended December 31, 2021 as compared with the same period in 2020. This variation reflects two main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a U.S. public company. The second main impact relates to recruitment expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In 2020, wages, salaries and payroll costs, together, amounted to &#8364;15.1&#160;million as compared with &#8364;16.8&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#8217;s contribution following the exercise by beneficiaries of their right to free shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These increases in fees and other expenses were partially offset by the decrease in rental expenses following the application of IFRS 16 for the year ended December 31, 2019. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payroll costs increased by &#8364;1.6&#160;million or 21% in 2021, mainly due to a change in the mix and location changes of our staff in SG&amp;A functions (more US based employees) and a one-time severance payment related to the departure of Philippe Mauberna, the prior CFO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company&#8217;s workforce amounted to 25 staff in SG&amp;A functions in comparison with a Company&#8217;s workforce of 24 staff in SG&amp;A functions during the year ended December 31, 2020 and a Company&#8217;s workforce of 29 staff in SG&amp;A functions, including 6 additional positions created during the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The impact of share-based payments (excluding employer&#8217;s contribution) on SG&amp;A expenses amounted to &#8364;2.5&#160;million in 2021, as compared with &#8364;2.3&#160;million in 2020 and &#8364;3.4&#160;million in 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.3 Payroll costs </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,984)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,094)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(21,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s workforce totaled 100 employees, compared with 90 December 31, 2020 and 110 as of December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, wages, salaries and payroll costs, together, amounted to &#8364;15.7&#160;million as compared with &#8364;15.1&#160;million in 2020. This is mainly due to the 10 additional positions created during the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, wages, salaries and payroll costs, together, amounted to &#8364;15.1&#160;million as compared with &#8364;16.8&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#8217;s contribution following the exercise by beneficiaries of their right to free shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2019, wages and salaries and payroll taxes, together, reached &#8364;16.8&#160;million due to the Company's growth and a related increase in the number of employees during the year ended December 31, 2019, together with the impact of its compensation policy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 2 &#8211; Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to &#8364;3.2&#160;million for the year ended December 31, 2021, as compared with &#8364;2.9&#160;million as of December 31, 2020 and &#8364;4.3&#160;million as of December 31, 2019 (see Note 17). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">16.4 Depreciation, amortization and provision expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(416)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,628)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(373)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%">16.5 OTHER OPERATING INCOME AND EXPENSES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract termination indemnity (PharmaEngine)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,414)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has made payments for a cumulative amount of $6.5&#160;million (&#8364;5.4&#160;million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.2 PharmaEngine.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487562424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text">Share-based payments<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders&#8217; warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These share-based compensation plans are settled in equity instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has applied IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to all equity instruments granted to employees since 2006. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As required by IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders&#8217; equity for the vesting period during which the rights with respect to the equity instruments are earned. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of share-based payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has granted stock options (option sur actions, &#8216;&#8216;OSA&#8217;&#8217;), warrants (bons de souscription d&#8217;actions, &#8216;&#8216;BSA&#8217;&#8217;), founders&#8217; warrants (bons de souscription de parts de cr&#233;ateur d&#8217;entreprise, &#8216;&#8216;BSPCE&#8217;&#8217;) and free shares (attributions gratuites d&#8217;actions, &#8216;&#8216;AGA&#8217;&#8217;) to corporate officers, employees and members of the Supervisory Board and consultants. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Founders&#8217; warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:44.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pre-2021 founders&#8217; warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>08-2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>09-2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-03</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97,200</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/28/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2015</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;6.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;5.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;20.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">86,150</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">68,450</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30,350</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22,700</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">350</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:42.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 founders&#8217; warrant plans</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE <br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">126,400</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">129,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/08/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2027</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,567</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,274</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">99,500</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,976</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">350</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1,426</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1,350</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:27.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA 04-2012</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (a)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (b)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 ordinary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;0.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;4.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;4.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;5.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">64,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">22,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,820</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;0.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;15.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;16.102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,820</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.801%"><tr><td style="width:1.0%"/><td style="width:58.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48,103</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;2.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;0.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants as of Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,431</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33,672</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">33,672</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.559%"><tr><td style="width:1.0%"/><td style="width:27.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2016-1 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>LLY 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">62,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">407,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;12.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">400</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28,250</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">500,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">387,456</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">13,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.754%"><tr><td style="width:1.0%"/><td style="width:67.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">571,200</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">491,200</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">80,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Free shares</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"><tr><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 free shares plan not yet vested</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021 free shares plan</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">396,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">438,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">362,515</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/11/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of free shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">360,512</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">340,583</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">369,250</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares exercised during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">24,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">369,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares lapsed or cancelled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,667</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,003</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares lapsed or cancelled during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,003</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,972,860</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,414,654</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">751,585</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">589,150</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">746,250</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,338,013</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at &#8364;40, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The risk-free rate was determined based on the average life of the instruments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The performance conditions for all of the plans were assessed as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Market-related performance conditions were directly included in the calculation of the fair value of the instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Except for the 2012-1 founders&#8217; warrants, the fair value of the warrants and options was measured using the Black-Scholes model. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of 2012-1 founders&#8217; warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence ,  no new instrument became issuable.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:18.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.49</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44.3% - 47.6%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5 - 7.30 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.84% - 1.22%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 04-2013</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 08-2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 09-2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5/6/6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 61%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 61%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61% - 62% - 61%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59% - 62% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 61% - 59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Project</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSPCE</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">175</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:10.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2012</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.26% - 0.27%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58%-58%-57%-58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/5.1/5.3/5.4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 60%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.6 &#8211; 9.6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.25% - 0.91%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016o-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016p-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2017o-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.7% - 0.1%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.7% - 0.1%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.8/9.9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.16% - 0.50%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.13%/<br/>-0.07%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:15.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59% - 62% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Ordinary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 61% - 59%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 / 6 /6.5 </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Performance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 / 6 /6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.1% / 37.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 /6.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.103% / 0.149%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.9% - 37.8% - 38.3%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.38%/ -0.33%/ -0.28%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.2% / 37.9% / 38.1%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.35 %/ -0.3 %/ -0.26 %</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">760</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">543</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19% / 0.141%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.74%/-0.69%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.63%/ -0.59%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,366</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,289</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,618</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">760</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,366</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,202</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">509</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,289</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,924</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,618</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,320</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487677496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract', window );"><strong>Income, expense, gains or losses of financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Net financial income (loss)</a></td>
<td class="text">Net financial income (loss) <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,360</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">837</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IFRS 16 related interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,646</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,580</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the interest cost was a negative net amount of &#8364;383&#160;thousands, mainly due to the EIB loan interest and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#8364;4.2&#160;million in 2021 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#8364;1.8&#160;million impact of EIB fixed interest cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the interest cost was a positive net amount of &#8364;4.7&#160;million, substantially due to the EIB loan interests and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#8364;4.8&#160;million in 2020 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#8364;1.7&#160;million impact of EIB fixed interest cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2021, the Company had foreign exchange gains for the total amount of &#8364;6.3&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This impact was primarily arising from the foreign exchange gains realized by the Company related to the HSBC bank account denominated in U.S. dollars.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In 2020, the Company had foreign exchange losses for the total amount of &#8364;1.7&#160;million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This impact was first arising from retaining $113.3&#160;million from the gross proceeds of the global offering in a US dollar bank account.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485399880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text">Income tax<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company and its subsidiaries are subject to income tax in their respective jurisdictions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company&#8217;s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of income tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, in accordance with the applicable legislation, the Company has &#8364;284&#160;million of evergreen tax losses in France, in comparison with &#8364;235&#160;million and &#8364;184.3&#160;million of evergreen tax losses in France as of December 31, 2020 and 2019, respectively. For fiscal years ended on or after December 31, 2018, the use of tax loss carryforwards in France is capped at &#8364;1.0&#160;million, plus 50% of the portion of profits in excess of that limit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cumulative tax loss carryforwards for the U.S. entities of the Company totaled $3.4&#160;million as of December 31, 2021, $4.4&#160;million as of December 31, 2020 and $4.8&#160;million in the United States as of December 31, 2019. The tax loss carryforwards that were generated before January 1, 2018 will expire 20 years after they were generated; those generated after that date have an indefinite carryforward. The tax loss carryforwards in the U.S. comply with the federal and each state&#8217;s Net Operating Loss (&#8220;NOL&#8221;) rules updated by the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;) of 2017.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table reconciles the Company&#8217;s theoretical tax expense to its effective tax expense:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recurring loss before tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(47,058)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(33,581)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(50,912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Theoretical tax rate (statutory rate in France)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Theoretical tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-taxable items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cumulative net unrecognized deferred tax assets amounted to &#8364;75.4&#160;million in 2021, including &#8364;14.0&#160;million of 2021 net operating loss carryforwards in comparison with &#8364;60.2&#160;million in 2020, including &#8364;59.6&#160;million of 2020 net operating loss carryforwards and &#8364;51.0&#160;million in 2019, including &#8364;49.6&#160;million of 2019 net operating loss carryforwards.</span></div>The deferred tax rate of the Company is 25.8% in 2021, 26.5% in 2020, and 25.49% in 2019, based on enacted tax rate reductions in future years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485399752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segment reporting</a></td>
<td class="text">Segment reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 8 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Operating Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, reporting by operating segment is derived from the internal organization of the Company&#8217;s activities; it reflects management&#8217;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#8217;s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485177704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Loss per share<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:49.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,733,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,385,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,631,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instruments providing deferred access to the capital are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued but not granted, representing as of December 31, 2021, 3,006,532 potential additional ordinary shares, have been considered antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485346760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCommitmentsAbstract', window );"><strong>Disclosure Of Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Commitments</a></td>
<td class="text">Commitments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.1 Obligations under the loan agreement with the EIB</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than &#8364;35.0&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The EIB finance contract contains covenants that impose restrictions on the operation of the Company's business but no financial covenants that the Company is required to comply with.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.2 Obligations under the terms of the rental agreements part of the IFRS 16 exemptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">One short term lease for an office by Nanobiotix Corp., of which the annual rent is &#8364;140&#160;thousand; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Leases related to low-value assets for Nanobiotix S.A.&#8217;s printers, of which the annual rent is around &#8364;10&#160;thousand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.3 Obligations related to the MD Anderson agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix&#8217;s first-in-class agent NBTXR3 for use in treating several cancer types &#8211; including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11&#160;million for those clinical trials during the collaboration, and made an initial $1.0&#160;million payment at the commencement of the collaboration and a second $1.0&#160;million payment on February 3, 2020. Additional payments will be made in the 6 months following a patient enrollment, and expense is recorded in the statement of consolidated operations during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2&#160;million to $16.4&#160;million. The amount will be determined on the basis of patients enrolled in the clinical trials at the date of FDA registration. This number increases every year and varies between $2.2&#160;million (if it had been payable in 2020) and $16.4&#160;million (if payable in 2030). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, &#8364;1.8&#160;million have already been invoiced since the beginning of the collaboration and &#8364;1.0&#160;million remain in prepaid expenses. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">22.4  Obligations related to the termination of the PharmaEngine agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company paid $6.5&#160;million to PharmaEngine (&#8364;5.4&#160;million converted at the exchange rate on the payment date) in accordance with the termination agreement signed between the parties. PharmaEngine is eligible to receive additional payments of $1&#160;million upon receipt by the Company of clinical study reports and of $5&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction in the world and for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487180520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text">Related parties <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Key management personnel compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,638</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,866</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,442</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The methods used to measure share-based payments are presented in Note 17.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485380040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text">Subsequent events <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of subsequent events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Considerations arising from the Russia-Ukraine war</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Russia launched in February 2022 the invasion of Ukraine, which, in addition to creating humanitarian concerns, may also impact the health care ecosystem in the form of delayed clinical trials. Clinical trial sites originally appointed in Russia and Ukraine for the clinical trial NANORAY-312 were not actively opened at the time of such conflict and, consequently, did not recruit patients. While backup options are being identified and the replacement of such sites by sites located in other countries is actively conducted by the Company, it is currently impossible to exclude any delay in this clinical trial activity, even if no significant delay has been identified as of the date of issuance of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share capital increase</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 11, 2022, the share capital of the Company was increased by a nominal amount of &#8364;1,500, through the issuance of 50,000 new ordinary shares with a nominal value of &#8364;0.03 each, increasing the Company&#8217;s share capital from &#8364;1,044,776.16 to &#8364;1,046,276.16, as a result of the definitive acquisition of 50,000 AGA 2020. Such acquisition was acknowledged by the Executive Board on March 11, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487503608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidation principles and methods (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">General principles, Statement of Compliance and Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">General principles</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders&#8217; equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management&#8217;s supervision and were approved by the Executive Board of the Company (the &#8220;Executive Board&#8221;) and reviewed by the Supervisory Board of the Company (the &#8220;Supervisory Board&#8221;) on March 30, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (&#8216;&#8216;IFRS&#8217;&#8217;) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company&#8217;s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of &#8364;83,921&#160;thousand as of December 31, 2021, as compared to &#8364;119,151&#160;thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements&#8217; publication. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Statement of Compliance and Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#8220;IAS&#8221;) as issued by the International Accounting Standards Board (&#8220;IASB&#8221;) as well as interpretations issued by the IFRS Interpretations Committee (&#8220;IFRS-IC&#8221;) and the Standard Interpretations Committee (the &#8220;SIC&#8221;), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Those are available on the European Commission website: </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.15pt">Amendments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IFRS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Covid-19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Related rent concession.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of these standards had no impact on the consolidated financial statements of the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations early adopted by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of New or Amended Standards and Interpretations not yet applied by the Company</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 :</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">IFRS 17 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">and related amendments. No impact expected on the financial statements. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 1 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality&#8221;.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 37 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Onerous Contracts - Cost of Fulfilling a Contract. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IFRS 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conceptual framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendment to IAS 8 -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> Definition of an accounting estimate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Amendments to IAS 16 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Property, Plant and Equipment: Proceeds before Intended Use</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. No significant impact expected on the financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%">3.1 Basis of consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 10 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company&#8217;s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The accounting methods of the Company&#8217;s subsidiaries are aligned with those of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Consolidated entities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021, the Company involves one parent entity, &#8220;Nanobiotix S.A.,&#8221; and five wholly owned subsidiaries: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Germany GmbH, incorporated in Germany in October 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Nanobiotix Spain S.L.U., incorporated in Spain in December 2017;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div>The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock', window );">Use of judgement, estimates and assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">3.2 Use of judgement, estimates and assumptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Measurement of share-based payments </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company measures the fair value of stock options (OSA), founders&#8217; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, vesting terms) and market data (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, expected share volatility) (see Note 17).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Deferred tax assets </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#8217;s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Clinical trial accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly.  See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See Note 15 for additional detail regarding the Company&#8217;s accounting policies for its additional sources of revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Fair value of financial assets and liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value measurement of the loan granted by European Investment Bank (&#8220;EIB&#8221;) requires the Company to assess the amount of additional interest (&#8220;royalties&#8221;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company&#8217;s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, intangible assets are carried at their acquisition cost. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research and Development costs </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Intangible Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, development costs may only be capitalized as intangible assets if the following criteria are met: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company intends to complete the development of the intangible asset and use or sell it; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company has the ability to use or sell the intangible asset; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">it is probable that the intangible asset will generate future economic benefits; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">adequate technical, financial and other resources are available to complete the development of the intangible asset; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Patents </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Software </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of intangible assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company&#8217;s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The depreciation periods used are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">General fixtures and fittings, building work: 5 to 10 years;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Technical installations, equipment and industrial tooling: 3 to 10 years; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Office and IT equipment and furniture: 1 to 10 years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Recoverable amount of property, plant and equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Non-current financial assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-current financial assets are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">No non-current financial assets are estimated at fair value through other comprehensive income (OCI). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Pursuant to IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, financial assets are classified in three categories according to their nature and the intention of management: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through profit and loss;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at fair value through other comprehensive income; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Financial assets at amortized cost. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">All regular way purchases and sales of financial assets are recognized at the settlement date. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at fair value through profit or loss </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial assets at amortized cost </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case&#8211;by&#8211;case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade receivables</a></td>
<td class="text">Trade receivablesIn 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash equivalents are measured at amortized cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Capital issued</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares are classified in shareholders&#8217; equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders&#8217; equity as a deduction from the proceeds of the issue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for contingencies and charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Provisions for retirement obligations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Company employees receive the retirement benefits provided for by law in France: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee&#8217;s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company receives assistance in the form of grants, conditional advances and interest-free loans.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Financial liabilities, including trade and other payables are valued at amortized cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Financial liabilities at amortized cost</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 &#8211; Financial Instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accounting policies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounting policies for Trade and other payables are described in Note 12, &#8216;&#8216;Financial Liabilities.&#8217;&#8217; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accrued expenses </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue and other income</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Accounting policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue is recognized in accordance with IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">A license:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is assessed to be a right to access the Company&#8217;s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt">If the license is a right to use the Company&#8217;s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">Product supply for which the revenue is recognized once the control over the delivered products is transferred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application to the license and collaboration agreement with PharmaEngine</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Under the License and Collaboration Agreement, the Company&#8217;s and PharmaEngine&#8217;s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company&#8217;s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the license of the right to use the Company&#8217;s patent and know-how;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine&#8217;s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt">the supply of NBTXR3 to PharmaEngine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">An upfront payment of $1.0&#160;million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1&#160;million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company&#8217;s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1&#160;million (first patient&#8217;s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine &#8217;s territory, which had not occurred as of December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Application of IFRS 15 to the license and collaboration agreement with LianBio</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">an exclusive license, under the Company's intellectual property, to develop and market the licensed products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the right to actively participate in global Phase III registration trials to obtain marketing approval in China;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt">the requirement to purchase products under license to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20&#160;million and may receive up to $220&#160;million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Grants</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Research tax credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The French tax authorities grant a research tax credit (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Cr&#233;dit d&#8217;Imp&#244;t Recherche</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, or &#8220;CIR&#8221;), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the &#8220;PME&#8221;, it can request immediate refund of the remaining tax credit, without application of the three-year period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Operating expenses</a></td>
<td class="text">Accounting policies Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders&#8217; warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">These share-based compensation plans are settled in equity instruments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has applied IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> to all equity instruments granted to employees since 2006. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As required by IFRS 2 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Share-based Payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders&#8217; equity for the vesting period during which the rights with respect to the equity instruments are earned. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company and its subsidiaries are subject to income tax in their respective jurisdictions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.</span></div>The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company&#8217;s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">In accordance with IFRS 8 &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Operating Segments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">, reporting by operating segment is derived from the internal organization of the Company&#8217;s activities; it reflects management&#8217;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#8217;s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Accounting policy </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock', window );">Subsequent events</a></td>
<td class="text">Accounting policyThe statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 46<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Basis Of Consolidation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Events After Reporting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485379912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in intangible assets breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(22)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(717)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(17)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.67pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:28.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">710</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of intangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(548)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(141)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857513822536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in property, plant and equipment is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Transfer  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,630</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,590</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15,017</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,641)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,534)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(6,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,256</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(129)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,186</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">movements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&amp; transfer.  </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Currency <br/>translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tangible assets in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments on tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">515</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,630</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixtures, fittings and installations</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,001)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,320)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Buildings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Office and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transport equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right of use &#8211; Transport equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated depreciation of tangible assets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3,811)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">43</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value of tangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,386</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,101)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(12)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,256</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857488068568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock', window );">Disclosure of changes in non-current financial assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in non-current financial assets breaks down as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:38.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liquidity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">contract - </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash account</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other<br/>long-term investments pledged as collateral</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Security <br/>deposits paid</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">131</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">529</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">105</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">401</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">505</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net book value as of December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">421</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">519</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See note&#160;10.2 Treasury shares</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Non-Current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485472552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock', window );">Disclosure of break down of trade receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables break down as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in 3 months or less</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 3 and 6 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due between 6 and 12 months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after more than 12 months</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">62</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock', window );">Disclosure of break down of other current assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other current assets break down as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,035</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock', window );">Disclosure of changes in research tax credit receivables</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The change in research tax credit receivables breaks down as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:84.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,688</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2018 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2019 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Nanobiotix SA </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,927</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,858)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Refund of 2020 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Nanobiotix SA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021 research tax credit &#8211; Curadigm SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Receivable as of December 31, 2021</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,490</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Changes In Research Tax Credit Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Current Assets Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade Receivables Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485605336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock', window );">Summary of cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of cash and cash equivalents</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalent break down as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank accounts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">83,921</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,151</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480600456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Disclosure of detail of share capital transactions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Detail of share capital transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:17.639%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.731%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands or number of shares)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nature of transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share Capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Premiums related to share capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">672</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">153,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">22,415,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 6, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase </span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">316,083&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 24, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 26, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 29, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subscription of 2020 warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 27, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,300,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 28, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Private placement Capital increase transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal &#8364; - Nasdaq (&#8364;11.14)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,855,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 16, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering initial deal $ - Nasdaq ($13.50)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,445,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering green shoe $ - Nasdaq ($13.50)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,095,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 18, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Initial public offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,033</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">255,735</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,432,122</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital increase AGA 2019-1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">369,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants attribution </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants subscription (BSA 2021)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,045</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">255,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,825,872</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Disclosure of detail of change in founders' warrants, warrants and free shares</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Founders&#8217; warrants (BSPCE)</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2 </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,350</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,776)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,841</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">179,500</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,476)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant<br/>date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise<br/>price<br/>(in&#160;euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at January 1,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>at December<br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares<br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 18, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 08-2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 28, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 09-2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">92,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86,150</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,450</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2015-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,700</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212,969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10,352)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">202,617</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSPCE 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">187,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">180,850</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">751,585</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(32,818)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span></td></tr></table></div>BSA)<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(36,208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(33,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">78,103</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(77,880)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 04-12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">May 4, 2012</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 10, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 16, 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 10, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 25, 2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2018-2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2019-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.660</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 17, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(6,000)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table>AGA)<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(369,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">362,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">360,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">360,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">362,515</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(393,750)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,753)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at January 1, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definitively acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">355,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(316,083)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,667)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2018-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 27, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">385,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">372,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">746,250</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(322,083)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(27,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Disclosure of detail of change in stock options</a></td>
<td class="text">OSA)<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">387,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">387,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 20, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">571,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(80,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">491,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">491,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2021-06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 21, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">691,200</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(93,753)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise <br/>price<br/>(in euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding at <br/>January 1,<br/>&#160;2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding <br/>at December <br/>31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of <br/>shares <br/>issuable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 2, 2016</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2016-2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 3, 2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 7, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2019-1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA LLY 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 24, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OSA 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">March 11, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">407,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">400,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">589,150</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">407,972</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(10,763)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857479980024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Disclosure of changes in provisions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:43.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">318</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">110</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">454</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">70</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(97)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">428</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:43.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increases</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decreases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lump-sum retirement benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current provisions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">83</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provisions for disputes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Current provisions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">164</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">40</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total provisions</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">495</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">123</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(164)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">454</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Disclosure of commitments for retirement benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Commitments for retirement benefits</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">331</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interests / discounting costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">85</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">79</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to experience</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in demographic assumptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gains or losses related to change in financial assumptions </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial gains or losses recognized in other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(182)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Provision as of end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">318</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Disclosure of assumptions used to measure retirement benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The assumptions used to measure lump-sum retirement benefits are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:54.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Measurement date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retirement assumptions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age 66</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age 64</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Management: Age 66</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Non-management: Age 64</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Social security contribution rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42.01 %</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44 %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.98 %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.33 %</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mortality tables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2015 -2017</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Regulatory table<br/>INSEE 2014 -2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Salary increase rate (including inflation)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: 3%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: 2.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Executive: 3%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-Executive: 2.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Staff turnover</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of 5.86%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Constant average rate of 5.86%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Duration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Disclosure of sensitivity analysis for actuarial assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The sensitivity to the discount rate and to the salary growth is as follows:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:53.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Discount rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.73%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.98%</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Defined Benefit Obligation as of December 31, 2021<br/>(in thousands of euros)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">333</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">303</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 138<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_138&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 145<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487500648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Summary of changes in financial liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Details of financial liabilities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances - Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB Loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,204</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,872</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">37,816</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">44,107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,979</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on<br/>the statement of<br/>financial position</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets <br/>carried at fair value <br/>through profit or <br/>loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities<br/>carried at amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,343</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Disclosure of detailed information about conditional advance, bank loan and loans from government and public authorities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Conditional advances and loans from government and public authorities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"><tr><td style="width:1.0%"/><td style="width:33.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EIB Loan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Curadigm Bpifrance advance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,165</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,210</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">34,746</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">38,121</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">974</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">29,251</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">285</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32,727</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,817)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated variable interest expense accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,033)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,533)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">493</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">26,374</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">300</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">29,433</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Bank loan</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HSBC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bpifrance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,044</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,064</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal received</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,038</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,068</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. </span></div>(3) In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Disclosure of reconciliation of changes in lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:84.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of January 1st,  2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,405</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">New lease contracts</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">521&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting of the new lease contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fixed interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,188</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Engagement</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,476&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impact of discounting and accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated fixed interest expense accrual</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Early termination of lease contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,519</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Disclosure of maturity analysis for advances loans and lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:42.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%">As of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Less than 1&#160;year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 1 and <br/>3&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Between 3 and <br/>5&#160;years</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">More than </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest-free Bpifrance loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Curadigm interest-free Bpifrance advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">HSBC &#8220;PGE&#8221; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bpifrance &#8220;PGE&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB fixed rate loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,204</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">37,747</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,346</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,714</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div>(1)&#8221;The Company will reimburse the two &#8220;PGE&#8221;or (&#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485155272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Disclosure of trade and other payables</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Details of trade and other payables</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses - clinical trials</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables &amp; other accruals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,996&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total trade and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,482</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock', window );">Disclosure of other current liabilities</a></td>
<td class="text">Other current liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll tax and other payroll liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,820&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other current liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,531</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock', window );">Disclosure of deferred income and contract liabilities</a></td>
<td class="text">Deferred revenues and contract liabilities<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.852%"><tr><td style="width:1.0%"/><td style="width:63.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Deferred revenues and contract liabilities</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">16,518</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Deferred Income And Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Other Current Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Trade And Other Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857486988408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Disclosure of details of non-current financial assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on<br/>the statement of<br/>financial position</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets <br/>carried at fair value <br/>through profit or <br/>loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities<br/>carried at amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,343</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of details of financial liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Details of financial liabilities</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:70.790%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Short term</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances - Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB Loan &#8211; Short term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,204</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,872</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Long term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayable BPI loan advances &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">PGE*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EIB loan &#8211; Long term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total non-current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">37,816</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">44,107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">46,020</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">48,979</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(*)&#8221;PGE&#8221;or in French &#8220;Pr&#234;ts garantis par l&#8217;Etat&#8221; are state-guaranteed loans</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Detail of financial instruments included in the statements of financial position and impact on income</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on<br/>the statement of<br/>financial position</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets <br/>carried at fair value <br/>through profit or <br/>loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities<br/>carried at amortized<br/>cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,343</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">84,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">52,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:30.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial assets carried at fair value through profit or loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and liabilities carried at amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair value </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">505&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,613</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">119,717</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current financial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current financial liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7,106</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56,085</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#8220;level 3&#8221; inputs, in the IFRS 13 classification for fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock', window );">Disclosure of effect of changes in exchange rates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company&#8217;s U.S. subsidiaries as of December 31, 2021, and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:40.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">45</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(45)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">87</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(87)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:40.257%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Impact</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Increase</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Decrease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">USD / Euro exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(124)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About The Effect Of Changes In Foreign Exchange Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485159208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock', window );">Schedule of revenues and other income</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">50</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subsidies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,637</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,462</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,473</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total revenues and other income</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,647</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosur Of Disaggregation Of Revenues And Other Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487569624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock', window );">Summary of research and development expense</a></td>
<td class="text">Research and development expenses<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, sub-contracting and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,562)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,734)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,804)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,980)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,290)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(24,330)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(30,411)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock', window );">Summary of selling, general and administrative expenses</a></td>
<td class="text">Selling, General and Administrative (SG&amp;A) expenses<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases, fees and other expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,482)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll costs (including share-based payments) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation, amortization and provision expenses </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total SG&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(19,434)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(14,611)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,909)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt">see note 16.4 Depreciation, amortization and provision expenses</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock', window );">Summary of payroll costs</a></td>
<td class="text">Payroll costs <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Wages and salaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11,876)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,913)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Retirement benefit obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total payroll costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,984)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(18,094)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(21,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Average headcount</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End-of-period headcount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock', window );">Summary of depreciation, amortization and provision expenses</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation, amortization and provision expenses by function are detailed as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(416)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,628)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of tangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reversal of provision for disputes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,257)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(373)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,630)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SG&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization expense of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(289)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation expense of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,478)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Utilization of provision for charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total depreciation, amortization and provision expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,609)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock', window );">Summary of other operating income (expense)</a></td>
<td class="text">OTHER OPERATING INCOME AND EXPENSES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:63.197%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract termination indemnity (PharmaEngine)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,414)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Employee Benefits Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Research And Development Expense Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Operating Income (Expenses)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484838808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock', window );">Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares oustanding</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">Founders&#8217; warrants</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:44.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Pre-2021 founders&#8217; warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>08-2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>09-2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2015-03</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97,200</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53,050</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/28/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/18/2014</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2015</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/18/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/10/2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;6.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;5.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;20.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">86,150</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">68,450</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30,350</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22,700</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">350</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:42.680%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.824%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 founders&#8217; warrant plans</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2016 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE <br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE<br/>2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founder&#8217;s warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">126,400</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">129,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117,650</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/23/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/08/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/07/2027</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of founders&#8217; warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,567</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">100,274</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">99,500</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">80,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of founders&#8217; warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">28,976</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including founders&#8217; warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">350</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1,426</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1,350</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:27.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA 04-2012</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2013</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2014</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (a)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2015-2 (b)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 ordinary</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">52,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">14,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">26,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">64,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/18/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/04/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/10/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">09/16/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;0.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;4.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;4.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;5.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">30,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">6,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">10,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">21,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">64,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">22,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">18,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 warrant plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2016 performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">BSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">28,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,820</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">07/27/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/17/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;2.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;1.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;0.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;15.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;16.102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">5,820</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">18,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">18,105</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">8,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.801%"><tr><td style="width:1.0%"/><td style="width:58.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48,103</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;2.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;0.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants as of Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,431</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">30,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of warrants lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33,672</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including warrants lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">33,672</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Free shares</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"><tr><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Pre-2021 free shares plan not yet vested</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021 free shares plan</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2018-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">396,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">438,250</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">362,515</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07/27/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/11/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of free shares as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">360,512</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">340,583</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,000</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">369,250</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares exercised during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">24,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">369,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of free shares lapsed or cancelled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,667</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,003</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including free shares lapsed or cancelled during the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,003</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,972,860</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,414,654</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">751,585</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">589,150</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">746,250</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,338,013</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of share options outstanding</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.559%"><tr><td style="width:1.0%"/><td style="width:27.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.343%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Pre-2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2016-1 Performance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2016-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2017 Ordinary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>2019-1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA<br/>LLY 2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OSA <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">62,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">37,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">500,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">407,972&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/25/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/23/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">06/14/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">05/23/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">04/11/2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">02/02/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">11/03/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">01/07/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/06/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/29/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10/24/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">03/11/2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;13.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;12.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8364;6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">400</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">4,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">500</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">52,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">28,250</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">500,000</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%">387,456</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">9,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">13,253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.754%"><tr><td style="width:1.0%"/><td style="width:67.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 stock option plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Type of underlying asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">571,200</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of shareholders' resolution approving the plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/30/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/28/2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contractual expiration date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/20/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/21/2031</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8364;12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">491,200</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">120,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options as of Including options exercised during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Number of options lapsed or cancelled</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Including options lapsed or cancelled during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">80,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">715,291</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,583,806</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">410,512</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,972,860</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">718,767</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">263,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">986,359</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">446,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,414,654</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.732%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total number of shares underlying grants outstanding as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">751,585</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">251,028</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">589,150</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">746,250</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,338,013</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period</a></td>
<td class="text">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence ,  no new instrument became issuable.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:18.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.49</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2012-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44.3% - 47.6%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5 - 7.30 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.84% - 1.22%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 04-2013</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 08-2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 09-2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5/6/6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 61%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 61%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61% - 62% - 61%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59% - 62% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 61% - 59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5/6/6.5</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">622&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSPCE 2017 Project</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSPCE</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">107</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">175</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:10.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.685%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2012</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2013</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2014</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.26% - 0.27%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58%-58%-57%-58%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/5.1/5.3/5.4</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2015-3</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 60%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.6 &#8211; 9.6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.25% - 0.91%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016o-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016p-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2017o-1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.4</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.7% - 0.1%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2018-2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16.102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.7% - 0.1%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.8/9.9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.16% - 0.50%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.59</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.13%/<br/>-0.07%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.47</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BSA 2021 (b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.64</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total BSA</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">44</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:9.077%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.269%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2018-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19% / 0.141%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2020</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.90&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.74%/-0.69%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AGA 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n.a.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.63%/ -0.59%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total AGA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,366</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,289</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,618</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">760</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,366</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,202</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">509</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,289</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,924</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,618</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,320</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:15.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in years) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk-free rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">initial plan </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros) </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Expense for the year ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">thousands</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of euros)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Ordinary</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59% - 62% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016 Performance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.05&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2016-2</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 62% - 59%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Ordinary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58% - 61% - 59%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 / 6 /6.5 </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2017 Performance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.5 / 6 /6.5</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.1% / 37.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6 /6.5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.103% / 0.149%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2019-2</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38.9% - 37.8% - 38.3%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.38%/ -0.33%/ -0.28%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-04 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 O</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.2% / 37.9% / 38.1%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;5.5 / 6 /6.5 </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-0.35 %/ -0.3 %/ -0.26 %</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OSA 2021-06 P</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">39.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total OSA</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">n.a.</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">760</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">509</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">543</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">760</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,366</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,202</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">509</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,289</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,924</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"><tr><td style="width:1.0%"/><td style="width:38.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.781%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSPCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OSA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AGA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expense for the year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,618</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,320</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487088168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract', window );"><strong>Income, expense, gains or losses of financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock', window );">Summary of net financial income (loss)</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other financial income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6,360</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">837</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest cost</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IFRS 16 related interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,646</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,580</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(4,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Finance Income (Cost)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485428648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock', window );">Schedule of reconciliation between statutory and effective income tax</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The following table reconciles the Company&#8217;s theoretical tax expense to its effective tax expense:</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recurring loss before tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(47,058)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(33,581)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(50,912)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Theoretical tax rate (statutory rate in France)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.00&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Theoretical tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(12,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(9,403)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-taxable items </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrecognized tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.00</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485421832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of basic and diluted loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:49.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss for the period (in thousands of euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(50,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average number of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,733,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,385,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,631,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Basic loss per share (in euros)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Diluted loss per share (in euros)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(2.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485428648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Disclosure of significant transactions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"><tr><td style="width:1.0%"/><td style="width:56.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(in thousands of euros)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Salaries, wages and benefits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supervisory Board&#8217;s fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total compensation to related parties</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,638</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,866</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,442</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478827800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information (Details)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>study</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">&#8364; 5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports', window );">Milestone payment upon receipt of clinical study reports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval', window );">Milestone payment upon second regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OnerousContractsProvision', window );">Onerous contracts provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfGlobalRegistrationalStudiesSupported', window );">Number of global registrational studies supported | study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">&#8364; 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems', window );"><strong>Disclosure Of Information Related To The Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Potential development and commercial milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OnerousContractsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for onerous contracts. An onerous contract is a contract in which the unavoidable costs of meeting the obligation under the contract exceed the economic benefits expected to be received under it. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OnerousContractsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Second Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfInformationRelatedToTheCompanyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Information Related To The Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfInformationRelatedToTheCompanyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfGlobalRegistrationalStudiesSupported">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Global Registrational Studies Supported</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfGlobalRegistrationalStudiesSupported</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RoyaltiesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Agreement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RoyaltiesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485265224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>General Information, Statement of Compliance and Basis of Presentation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract', window );"><strong>General Information, Statement of Compliance and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 83,921<span></span>
</td>
<td class="nump">&#8364; 119,151<span></span>
</td>
<td class="nump">&#8364; 35,094<span></span>
</td>
<td class="nump">&#8364; 36,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General Information, Statement of Compliance and Basis of Presentation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487420984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidation principles and methods (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>subsidiary </div>
<div>parent_entity</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="nump">1.1326<span></span>
</td>
<td class="nump">1.2271<span></span>
</td>
<td class="nump">1.1234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average foreign exchange rate</a></td>
<td class="nump">1.1835<span></span>
</td>
<td class="nump">1.1413<span></span>
</td>
<td class="nump">1.1196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfParentEntities', window );">Number of parent entities | parent_entity</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSubsidiaries', window );">Number of subsidiaries | subsidiary</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfParentEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Parent Entities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfParentEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474779544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="7">12 Months Ended</th>
<th class="th" colspan="1">101 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>study</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>patient</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,350<span></span>
</td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfGlobalRegistrationalStudiesSupported', window );">Number of global registrational studies supported | study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,500<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Potential development and commercial milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member', window );">PharmaEngine, NBTWR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived', window );">Development milestones payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementTotalPaymentsReceived', window );">Total payments received under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports', window );">Milestone payment upon receipt of clinical study reports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval', window );">Milestone payment upon second regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfPatientsInClinicalTrial', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual capital commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MilestonePaymentDefermentPeriodAfterEnrollment', window );">Milestone payment, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Increase in loans and conditional advances | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowing facilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriodToRequestFunds', window );">Borrowing, deferment period to request funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | PharmaEngine, NBTWR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Potential development and commercial milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease', window );">Milestone payment increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range | EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range | MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease', window );">Milestone payment increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriodToRequestFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period To Request Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriodToRequestFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Development And Commercial Milestones Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementTotalPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Total Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementTotalPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment, Annual Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Second Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MilestonePaymentDefermentPeriodAfterEnrollment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Deferment Period After Enrollment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MilestonePaymentDefermentPeriodAfterEnrollment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfGlobalRegistrationalStudiesSupported">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Global Registrational Studies Supported</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfGlobalRegistrationalStudiesSupported</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfPatientsInClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients In Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfPatientsInClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RoyaltiesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Agreement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RoyaltiesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480318824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">&#8364; 21<span></span>
</td>
<td class="nump">&#8364; 163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of intangible assets | Intangible assets in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">(717)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of intangible assets | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at beginning of period</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Increases</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets at end of period</a></td>
<td class="num">&#8364; (652)<span></span>
</td>
<td class="num">&#8364; (630)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857479551208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>lease_contract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 56<span></span>
</td>
<td class="num">&#8364; (1,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 129<span></span>
</td>
<td class="nump">&#8364; 14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfNewLeaseContracts', window );">Number of new lease contracts | lease_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractVillejuifMember', window );">Lease contract, Villejuif</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_LeaseContractExtendedPeriod', window );">Lease contract, extended period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact', window );">Addition to annual rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractWattigniesMember', window );">Lease contract, Wattignies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact', window );">Addition to annual rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 1,590<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings and installations | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings and installations | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember', window );">Fixtures, fittings and installations | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 1,362<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets | Lease contract, Villejuif</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact', window );">Addition to annual rent expense</a></td>
<td class="num">&#8364; (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets | Lease contract, Oberkampf street</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets | Lease contract, Faubourg Saint-Antoine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets | Lease contract, Alfortville</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Gross book value of tangible assets | Lease contract, parking Villejuif</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember', window );">Right of use &#8211; Buildings | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Technical equipment | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 73<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Technical equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Technical equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office and IT equipment | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 53<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office and IT equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office and IT equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember', window );">Transport equipment | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember', window );">Transport equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember', window );">Transport equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember', window );">Right of use &#8211; Transport equipment | Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increase in right-of-use assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, property, plant and equipment</a></td>
<td class="nump">&#8364; 38<span></span>
</td>
<td class="nump">&#8364; 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember', window );">Right of use &#8211; Transport equipment | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember', window );">Right of use &#8211; Transport equipment | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Depreciation periods of property, plant and equipment</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) To Annual Rent Expense, Indexation Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_LeaseContractExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Contract, Extended Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_LeaseContractExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfNewLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of New Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfNewLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractVillejuifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractVillejuifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractWattigniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractWattigniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractOberkampfStreetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractOberkampfStreetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractFaubourgSaintAntoineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractFaubourgSaintAntoineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractAlfortvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractAlfortvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=nbx_LeaseContractParkingVillejuifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=nbx_LeaseContractParkingVillejuifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857477966024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">&#8364; 8,256<span></span>
</td>
<td class="nump">&#8364; 9,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">56<span></span>
</td>
<td class="num">(1,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">8,186<span></span>
</td>
<td class="nump">8,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">13,630<span></span>
</td>
<td class="nump">13,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">15,017<span></span>
</td>
<td class="nump">13,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Fixtures, fittings and installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,318<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Right of use &#8211; Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">7,171<span></span>
</td>
<td class="nump">6,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">8,393<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Technical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">2,061<span></span>
</td>
<td class="nump">2,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">2,135<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Office and IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Transport equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Right of use &#8211; Transport equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Tangible assets in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross book value of tangible assets | Prepayments on tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(5,374)<span></span>
</td>
<td class="num">(3,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(6,831)<span></span>
</td>
<td class="num">(5,374)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Fixtures, fittings and installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,320)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(1,641)<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Right of use &#8211; Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,739)<span></span>
</td>
<td class="num">(829)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(901)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(2,610)<span></span>
</td>
<td class="num">(1,739)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Technical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(1,466)<span></span>
</td>
<td class="num">(1,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(1,466)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Office and IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(783)<span></span>
</td>
<td class="num">(629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(875)<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Transport equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation of tangible assets | Right of use &#8211; Transport equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Decreases</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">&#8364; (28)<span></span>
</td>
<td class="num">&#8364; (36)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_FixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_RightOfUseTransportEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_PrepaymentsOnTangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=nbx_PrepaymentsOnTangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478498920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">&#8364; 505<span></span>
</td>
<td class="nump">&#8364; 529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Decreases</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets', window );">Transfer</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Currency translation adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember', window );">Liquidity contract - Cash account | Financial assets at fair value, class</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Decreases</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentInvestmentsPledgedAsCollateralMember', window );">Other long-term investments pledged as collateral | Financial assets at amortised cost, class</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets', window );">Transfer</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentSecurityDepositMember', window );">Security deposits paid | Financial assets at amortised cost, class</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at beginning of period</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets', window );">Transfer</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Currency translation adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets at end of period</a></td>
<td class="nump">&#8364; 421<span></span>
</td>
<td class="nump">&#8364; 401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in financial assets resulting from derecognition. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughDerecognitionFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from transfers. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentLiquidityContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentInvestmentsPledgedAsCollateralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentInvestmentsPledgedAsCollateralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentSecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=nbx_NonCurrentSecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484705304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFinancialAssets', window );">Increase (decrease) in financial assets</a></td>
<td class="nump">&#8364; 14<span></span>
</td>
<td class="num">&#8364; (24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">&#8364; 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=nbx_NonCurrentSecurityDepositMember', window );">Security deposits paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems', window );"><strong>Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFinancialAssets', window );">Increase (decrease) in financial assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets', window );">Additions</a></td>
<td class="nump">&#8364; 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Non-current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=nbx_NonCurrentSecurityDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=nbx_NonCurrentSecurityDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480571928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember', window );">Due in 3 months or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember', window );">Due between 3 and 6 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember', window );">Due between 6 and 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember', window );">Due after more than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484705448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable</a></td>
<td class="nump">&#8364; 2,490<span></span>
</td>
<td class="nump">&#8364; 1,927<span></span>
</td>
<td class="nump">&#8364; 5,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivable</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">&#8364; 9,139<span></span>
</td>
<td class="nump">&#8364; 6,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857488110728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 2,213<span></span>
</td>
<td class="nump">&#8364; 2,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers', window );">Prepaid expenses related to insurance for Directors and Officers</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Current advances to suppliers</a></td>
<td class="nump">3,043<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember', window );">2021 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember', window );">2020 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember', window );">Nanobiotix S.A. | 2021 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember', window );">Nanobiotix S.A. | 2020 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_CuradigmSASMember', window );">Curadigm SAS | 2021 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nbx_CuradigmSASMember', window );">Curadigm SAS | 2020 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Prepaid Expenses, Insurance Related To Directors And Officers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Receivables From Taxes Other Than Income Tax, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_NanobiotixSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_CuradigmSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_CuradigmSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487755048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable at beginning of period</a></td>
<td class="nump">&#8364; 1,927<span></span>
</td>
<td class="nump">&#8364; 5,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax', window );">Research tax credit receivable at end of period</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2018TaxYearMember', window );">2018 Tax Year | Nanobiotix S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund', window );">Refund of research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,251)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2019TaxYearMember', window );">2019 Tax Year | Nanobiotix S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund', window );">Refund of research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,374)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2019TaxYearMember', window );">2019 Tax Year | Curadigm SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund', window );">Refund of research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember', window );">2020 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember', window );">2020 Tax Year | Nanobiotix S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund', window );">Refund of research tax credit</a></td>
<td class="num">(1,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember', window );">2020 Tax Year | Curadigm SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund', window );">Refund of research tax credit</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember', window );">2021 Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember', window );">2021 Tax Year | Nanobiotix S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember', window );">2021 Tax Year | Curadigm SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems', window );"><strong>Disclosure of Trade Receivables and Other Current Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease', window );">Research tax credit</a></td>
<td class="nump">&#8364; 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Receivables From Taxes Other Than Income Tax, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Receivables From Taxes Other Than Income Tax, Refund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Receivables and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2018TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2018TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_NanobiotixSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_NanobiotixSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2019TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2019TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nbx_CuradigmSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nbx_CuradigmSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2020TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OpenTaxYearAxis=nbx_A2021TaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487006440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash and bank accounts</a></td>
<td class="nump">&#8364; 83,921<span></span>
</td>
<td class="nump">&#8364; 119,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents</a></td>
<td class="nump">&#8364; 83,921<span></span>
</td>
<td class="nump">&#8364; 119,151<span></span>
</td>
<td class="nump">&#8364; 35,094<span></span>
</td>
<td class="nump">&#8364; 36,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478774248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents - Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (84,056)<span></span>
</td>
<td class="nump">&#8364; 1,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Loans repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Loans repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BanquePubliqueDInvestissementMember', window );">BPI loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Loans repayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">&#8364; 16,500<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems', window );"><strong>Disclosure of Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfCashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Cash and Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfCashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_BanquePubliqueDInvestissementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_BanquePubliqueDInvestissementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857475012120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Disclosure of Detail of Share Capital Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 18, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 26, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 24, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 06, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70,468,000<span></span>
</td>
<td class="num">&#8364; (1,908,000)<span></span>
</td>
<td class="nump">&#8364; 14,243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,077.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">102,942,000<span></span>
</td>
<td class="nump">28,079,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">U.S. Initial public offering costs offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,700,000)<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,790,000<span></span>
</td>
<td class="nump">70,468,000<span></span>
</td>
<td class="num">(1,908,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember', window );">IPO initial deal, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember', window );">IPO initial deal, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember', window );">IPO green shoe, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,963.66<span></span>
</td>
<td class="nump">672,451.17<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,044,776.16<span></span>
</td>
<td class="nump">&#8364; 1,032,963.66<span></span>
</td>
<td class="nump">&#8364; 672,451.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,432,122<span></span>
</td>
<td class="nump">22,415,039<span></span>
</td>
<td class="nump">19,633,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,750<span></span>
</td>
<td class="nump">12,017,083<span></span>
</td>
<td class="nump">2,566,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,825,872<span></span>
</td>
<td class="nump">34,432,122<span></span>
</td>
<td class="nump">22,415,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | AGA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | AGA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO initial deal, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO initial deal, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO green shoe, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 255,735,000<span></span>
</td>
<td class="nump">&#8364; 153,139,000<span></span>
</td>
<td class="nump">&#8364; 122,799,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,591,000<span></span>
</td>
<td class="nump">28,002,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity', window );">Subscription of warrants</a></td>
<td class="nump">&#8364; 43,000<span></span>
</td>
<td class="num">&#8364; (11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">U.S. Initial public offering costs offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (9,322,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,387,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,030,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 255,767,000<span></span>
</td>
<td class="nump">&#8364; 255,735,000<span></span>
</td>
<td class="nump">&#8364; 153,139,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital | IPO initial deal, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital | IPO initial deal, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital | IPO green shoe, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IssueOfEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IssueOfEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Issue Of Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesIssuedThroughIssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857477646056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Capital Issued (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 18, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 06, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 09, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70,468,000<span></span>
</td>
<td class="nump">&#8364; 26,790,000<span></span>
</td>
<td class="nump">&#8364; 70,468,000<span></span>
</td>
<td class="num">&#8364; (1,908,000)<span></span>
</td>
<td class="nump">&#8364; 14,243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,700,000<span></span>
</td>
<td class="num">&#8364; (1,030,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Initial offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 349,000<span></span>
</td>
<td class="nump">10,359,000<span></span>
</td>
<td class="nump">1,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember', window );">IPO initial deal, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember', window );">IPO initial deal, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember', window );">IPO green shoe, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,032,963.66<span></span>
</td>
<td class="nump">&#8364; 1,044,776.16<span></span>
</td>
<td class="nump">&#8364; 1,032,963.66<span></span>
</td>
<td class="nump">&#8364; 672,451.17<span></span>
</td>
<td class="nump">&#8364; 589,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,432,122<span></span>
</td>
<td class="nump">34,825,872<span></span>
</td>
<td class="nump">34,432,122<span></span>
</td>
<td class="nump">22,415,039<span></span>
</td>
<td class="nump">19,633,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">316,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,750<span></span>
</td>
<td class="nump">12,017,083<span></span>
</td>
<td class="nump">2,566,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO initial deal, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,445,000<span></span>
</td>
<td class="nump">5,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO initial deal, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,855,000<span></span>
</td>
<td class="nump">1,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | IPO green shoe, US Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares) | shares</a></td>
<td class="nump">1,095,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IssueOfEquityPricePerShare', window );">Issue of equity, price per share (in euro or dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 255,735,000<span></span>
</td>
<td class="nump">&#8364; 255,767,000<span></span>
</td>
<td class="nump">&#8364; 255,735,000<span></span>
</td>
<td class="nump">&#8364; 153,139,000<span></span>
</td>
<td class="nump">&#8364; 122,799,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="nump">&#8364; 9,322,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,030,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Initial offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IssueOfEquityPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IssueOfEquityPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Issue Of Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesIssuedThroughIssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOInitialDealEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_IPOGreenShoeUSDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nbx_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nbx_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487658280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Treasury Shares (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="nump">&#8364; 202<span></span>
</td>
<td class="nump">&#8364; 196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="nump">15,456<span></span>
</td>
<td class="nump">12,970<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857443322552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 25, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 10, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 10, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 16, 2014 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 28, 2013 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 10, 2013 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 18, 2012 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 04, 2012 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,414,654<span></span>
</td>
<td class="nump">2,338,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,972,860<span></span>
</td>
<td class="nump">2,414,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,767<span></span>
</td>
<td class="nump">751,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,476)<span></span>
</td>
<td class="num">(32,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,291<span></span>
</td>
<td class="nump">718,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,291<span></span>
</td>
<td class="nump">718,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member', window );">BSPCE 08-2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">92,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">70,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
<td class="nump">38,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="num">(7,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,350<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,350<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016Member', window );">BSPCE 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,617<span></span>
</td>
<td class="nump">212,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,776)<span></span>
</td>
<td class="num">(10,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,841<span></span>
</td>
<td class="nump">202,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,841<span></span>
</td>
<td class="nump">202,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSPCE 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,850<span></span>
</td>
<td class="nump">187,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,500<span></span>
</td>
<td class="nump">180,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,500<span></span>
</td>
<td class="nump">180,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,028<span></span>
</td>
<td class="nump">251,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,103<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,880)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,251<span></span>
</td>
<td class="nump">263,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,251<span></span>
</td>
<td class="nump">263,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member', window );">BSA 04-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member', window );">BSA 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member', window );">BSA 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016Member', window );">BSA 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,208<span></span>
</td>
<td class="nump">36,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,208)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member', window );">BSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member', window );">BSA 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member', window );">BSA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember', window );">BSA 2021 (b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,359<span></span>
</td>
<td class="nump">589,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,200<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,753)<span></span>
</td>
<td class="num">(10,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,806<span></span>
</td>
<td class="nump">986,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,806<span></span>
</td>
<td class="nump">986,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161Member', window );">OSA 2016-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017Member', window );">OSA 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750<span></span>
</td>
<td class="nump">30,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
<td class="nump">28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
<td class="nump">28,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA LLY 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,253)<span></span>
</td>
<td class="num">(7,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,456<span></span>
</td>
<td class="nump">400,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,456<span></span>
</td>
<td class="nump">400,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member', window );">OSA 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member', window );">OSA 2021-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
<td class="nump">746,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393,750)<span></span>
</td>
<td class="num">(322,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,753)<span></span>
</td>
<td class="num">(27,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,512<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,512<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member', window );">AGA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="nump">355,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,500)<span></span>
</td>
<td class="num">(316,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member', window );">AGA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,750)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of shares issuable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485489336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Founders&#8217; warrants (Details) - BSPCE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>employee</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_FormerEmployeesMember', window );">Former employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted', window );">Number of employees with service conditions lifted</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember', window );">Former Executive Board members</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted', window );">Number of employees with service conditions lifted</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_FormerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_FormerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478004760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Warrant Plans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>patient </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">BSPCE exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a) | Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA', window );">Number of ordinary share subscribed per each BSA (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">BSPCE exercise (in shares)</a></td>
<td class="nump">14,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement', window );">Maximum term of other equity instruments granted for share-based payment arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance', window );">Vesting requirements, minimum attendance</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise', window );">Vesting requirements, attendance period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients', window );">Vesting requirements, recommended dose determination, minimum number of patients | patient</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled', window );">Vesting requirements, recommended dose determination, total number of patients enrolled | patient</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a) | External Consultant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA', window );">Number of ordinary share subscribed per each BSA (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">BSPCE exercise (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement', window );">Maximum term of other equity instruments granted for share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AInReplacementOfBSA2016Member', window );">BSA 2021 (a) In Replacement Of BSA 2016 | Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">BSPCE exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Other Equity Instruments Granted For Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfOrdinaryShareSubscribedPerEachBSA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Share Subscribed Per Each BSA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfOrdinaryShareSubscribedPerEachBSA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Attendance Period Before Date Of Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Minimum Attendance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_SupervisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_SupervisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_ExternalConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_ExternalConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AInReplacementOfBSA2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AInReplacementOfBSA2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857476994440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Option Plans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>shares </div>
<div>patient </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>employee </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member', window );">OSA 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,200<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Maximum term of options granted for share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | From first year of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised', window );">Vesting requirements, maximum percentage exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | From second year of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised', window );">Vesting requirements, maximum percentage exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | From third year of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised', window );">Vesting requirements, maximum percentage exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SharePriceMilestoneEuronextParis', window );">Share price milestone, Euronext Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SharePriceMilestoneEuronextParis', window );">Share price milestone, Euronext Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SharePriceMilestoneEuronextParis', window );">Share price milestone, Euronext Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA | Tranche four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SharePriceMilestoneEuronextParis', window );">Share price milestone, Euronext Paris</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member', window );">OSA 2021-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA', window );">Number of ordinary share subscribed per each OSA | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA', window );">Number of ordinary share subscribed per each OSA | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Maximum term of options granted for share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting requirements for share-based payment arrangement, vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | OSA 2021-04 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_BartVanRhijnMember', window );">Bart Van Rhijn | OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_BartVanRhijnMember', window );">Bart Van Rhijn | OSA 2021-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_BartVanRhijnMember', window );">Bart Van Rhijn | OSA 2021-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA', window );">Number of ordinary share subscribed per each OSA | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember', window );">Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn | OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients', window );">Vesting requirements, recommended dose determination, minimum number of patients | patient</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled', window );">Vesting requirements, recommended dose determination, total number of patients enrolled | patient</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_MembersOfTheExecutiveBoardAndAlainDostieMember', window );">Executive Board and Alain Dostie | OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_EmployeesMember', window );">Employees | OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember', window );">Former Executive Board members | OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted', window );">Number of employees with service conditions lifted | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated', window );">Number of employees with vesting conditions accelerated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfOrdinaryShareSubscribedPerEachOSA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Share Subscribed Per Each OSA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfOrdinaryShareSubscribedPerEachOSA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SharePriceMilestoneEuronextParis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price Milestone, Euronext Paris</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SharePriceMilestoneEuronextParis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Employees With Vesting Conditions Accelerated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Maximum Percentage Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_FromFirstYearOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_FromFirstYearOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_FromSecondYearOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_FromSecondYearOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_FromThirdYearOfGrantDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_FromThirdYearOfGrantDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_BartVanRhijnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_BartVanRhijnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_MembersOfTheExecutiveBoardAndAlainDostieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_MembersOfTheExecutiveBoardAndAlainDostieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_FormerExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474526952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Free Share Plans (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>patient </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Oct. 24, 2019</div></th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>employee </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,077.5<span></span>
</td>
<td class="nump">&#8364; 735<span></span>
</td>
<td class="nump">&#8364; 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 102,942,000<span></span>
</td>
<td class="nump">&#8364; 28,079,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee', window );">Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member', window );">AGA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod', window );">Vesting requirements for share-based payment arrangement, acquisition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod', window );">Vesting requirements for share-based payment arrangement, acquisition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member', window );">AGA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod', window );">Vesting requirements for share-based payment arrangement, acquisition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod', window );">Vesting requirements for share-based payment arrangement, holding period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod', window );">Vesting requirements for share-based payment arrangement, acquisition period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients', window );">Vesting requirements, recommended dose determination, minimum number of patients | patient</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled', window );">Vesting requirements, recommended dose determination, total number of patients enrolled | patient</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember', window );">Executive Board and Employees | AGA 2020 and AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod', window );">Vesting requirements for share-based payment arrangement, holding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod', window );">Vesting requirements for share-based payment arrangement, acquisition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents', window );">Vesting requirements for share-based payment arrangement, acquisition period for foreign tax residents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantMember', window );">Anne-Juliette Hermant | AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_EmployeesMember', window );">Employees | AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted', window );">Number of employees with service conditions lifted | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period For Foreign Tax Residents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Holding Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_ExecutiveBoardAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020AndAGA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020AndAGA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_AnneJulietteHermantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478802584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Disclosure of Changes in Provisions (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">&#8364; 454<span></span>
</td>
<td class="nump">&#8364; 495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember', window );">Non-current provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember', window );">Lump-sum retirement benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember', window );">Current provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember', window );">Provisions for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember', window );">Provision for charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Decreases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other provisions at end of period</a></td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision Used And Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_NonCurrentOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_LumpSumRetirementBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_CurrentOtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484612664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provision used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 145<span></span>
</td>
<td class="nump">&#8364; 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Provision reversed</a></td>
<td class="nump">&#8364; 97<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DefinedBenefitObligationPayablePeriod', window );">Payable, period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember', window );">Provisions for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Provision used</a></td>
<td class="nump">&#8364; 54<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Provision reversed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember', window );">Provision for charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions', window );">Provision reversed</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DefinedBenefitObligationPayablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Obligation, Payable, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DefinedBenefitObligationPayablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision Used And Unused Provision Reversed, Other Provisions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForDisputesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=nbx_ProvisionsForChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478832120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Disclosure of Commitments for Retirement Benefits (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Provisions of retirement benefits at beginning of period</a></td>
<td class="nump">&#8364; 414<span></span>
</td>
<td class="nump">&#8364; 331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Cost of services</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">&#8364; 76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Interests / discounting costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Expense for the period</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Gains or losses related to experience</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains or losses related to change in demographic assumptions</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Gains or losses related to change in financial assumptions</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains or losses recognized in other comprehensive income</a></td>
<td class="num">(182)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Provisions of retirement benefits at end of period</a></td>
<td class="nump">&#8364; 318<span></span>
</td>
<td class="nump">&#8364; 414<span></span>
</td>
<td class="nump">&#8364; 331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 5<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474682360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ActuarialAssumptionOfSocialSecurityContributionRates', window );">Social security contribution rate</a></td>
<td class="nump">42.01%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover', window );">Staff turnover</a></td>
<td class="nump">0.0586%<span></span>
</td>
<td class="nump">0.0586%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019', window );">Duration</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement assumptions</a></td>
<td class="text">66 years<span></span>
</td>
<td class="text">66 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_NonManagementMember', window );">Non-management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019', window );">Retirement assumptions</a></td>
<td class="text">64 years<span></span>
</td>
<td class="text">64 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Salary increase rate (including inflation)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nbx_NonExecutiveMember', window );">Non-executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Salary increase rate (including inflation)</a></td>
<td class="nump">0.025%<span></span>
</td>
<td class="nump">0.025%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfRetirementAge2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfRetirementAge2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 147<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_147_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Expected Average Rates Of Staff Turnover</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ActuarialAssumptionOfSocialSecurityContributionRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Social Security Contribution Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ActuarialAssumptionOfSocialSecurityContributionRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_NonManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_NonManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nbx_NonExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nbx_NonExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480578040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25', window );">Actuarial assumption of discount rates if rates decrease by 25%</a></td>
<td class="nump">0.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25', window );">Actuarial assumption of discount rates if rates increase by 25%</a></td>
<td class="nump">1.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Actuarial assumption of discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Net defined benefit liability if actuarial assumption of discount rates decrease by 25%</a></td>
<td class="nump">&#8364; 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan', window );">Net defined benefit liability</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Net defined benefit liability if actuarial assumption of discount rates increase by 25%</a></td>
<td class="nump">&#8364; 303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 144<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Discount Rates If Rates Decrease By 25%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actuarial Assumption Of Discount Rates If Rates Increase By 25%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474474952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Summary of Changes in Financial Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">&#8364; 8,204<span></span>
</td>
<td class="nump">&#8364; 4,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">37,816<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">46,020<span></span>
</td>
<td class="nump">48,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">5,393<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember', window );">Repayable BPI loan advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">2,259<span></span>
</td>
<td class="nump">2,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember', window );">PGE | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">8,982<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Changes In Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current financial liabilities</a></td>
<td class="nump">5,192<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current financial liabilities</a></td>
<td class="nump">&#8364; 21,182<span></span>
</td>
<td class="nump">&#8364; 26,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nbx_ConditionalAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857477401432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 10, 2020 </div>
<div>EUR (&#8364;) </div>
<div>quarterly_instalment</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 10,350<span></span>
</td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ConsolidatedForecastedSalesPeriod', window );">Consolidated forecasted sales, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember', window );">Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of accretion and discounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,765<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
<td class="num">&#8364; (4,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember', window );">Banque Publique d&#8217;Investissement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdvancesReceivedDefermentPeriod', window );">Advances, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdvancesReceivedInterestRate', window );">Advances, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Advances', window );">Advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nbx_BPIFranceMember', window );">Bpifrance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Advances', window );">Advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdvancesAuthorizedAmountToBeAdvanced', window );">Authorized amount to be advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AdvancesOutstandingAmountToBeReceived', window );">Advances, outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfTranchesBorrowings', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,000<span></span>
</td>
<td class="nump">&#8364; 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriodToRequestFunds', window );">Borrowing, deferment period to request funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltyPayables', window );">Expected future royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">&#8364; 17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of accretion and discounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,214<span></span>
</td>
<td class="num">&#8364; (4,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingTotalInterestPayable', window );">Total interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPayable', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingTotalInterestPayable', window );">Total interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">PGE Loan, HSBC France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest', window );">Borrowing, initial period bearing no interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingGuaranteeFee', window );">Borrowing, guarantee fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">PGE Loan, HSBC France | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">PGE Loan, HSBC France | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">PGE Loan, BPI France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest', window );">Borrowing, initial period bearing no interest</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingPercentageOfStateGuaranteedLoan', window );">Percentage of State-Guaranteed loan</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest', window );">Borrowing, subsequent period bearing interest</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingGuaranteeFee', window );">Borrowing, guarantee fee</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingNumberOfQuarterlyInstalments', window );">Number of quarterly instalments | quarterly_instalment</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Advances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Advances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesAuthorizedAmountToBeAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances, Authorized Amount To Be Advanced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesAuthorizedAmountToBeAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesOutstandingAmountToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances, Outstanding Amount To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesOutstandingAmountToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesReceivedDefermentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances Received, Deferment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesReceivedDefermentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AdvancesReceivedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances Received, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AdvancesReceivedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriodToRequestFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period To Request Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriodToRequestFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingGuaranteeFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Guarantee Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingGuaranteeFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term, Initial Period Bearing No Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term, Subsequent Period Bearing Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingNumberOfQuarterlyInstalments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Number Of Quarterly Instalments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingNumberOfQuarterlyInstalments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingPercentageOfStateGuaranteedLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Percentage Of State-Guaranteed Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingPercentageOfStateGuaranteedLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingTotalInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Total Interest Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingTotalInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ConsolidatedForecastedSalesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Forecasted Sales, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ConsolidatedForecastedSalesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfTranchesBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches, Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfTranchesBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RoyaltiesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Agreement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RoyaltiesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RoyaltyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RoyaltyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_BanquePubliqueDInvestissementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nbx_BPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nbx_BPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474492856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember', window );">Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">&#8364; 32,727<span></span>
</td>
<td class="nump">&#8364; 38,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="num">(5,765)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">4,214<span></span>
</td>
<td class="num">(4,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment</a></td>
<td class="num">(3,533)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">29,433<span></span>
</td>
<td class="nump">32,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember', window );">Bpifrance advance | Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeBPIFranceLoanMember', window );">Interest-free Bpifrance loan | Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB Loan | Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">29,251<span></span>
</td>
<td class="nump">34,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="num">(5,817)<span></span>
</td>
<td class="num">(1,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">4,214<span></span>
</td>
<td class="num">(4,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment</a></td>
<td class="num">(3,033)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">26,374<span></span>
</td>
<td class="nump">29,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember', window );">Curadigm Bpifrance advance | Conditional Advances and Loans from Government and Public Authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="nump">&#8364; 285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Financing Cash Flows, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Through Financing Cash Flows, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeBPIFranceLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeBPIFranceLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_ConditionalAdvanceBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487520152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">&#8364; 10,064<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="num">(145)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 10,068<span></span>
</td>
<td class="nump">&#8364; 10,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">PGE Loan, HSBC France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingGuaranteeFee', window );">Borrowing, guarantee fee</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">PGE Loan, HSBC France | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">&#8364; 5,020<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 5,030<span></span>
</td>
<td class="nump">&#8364; 5,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">PGE Loan, BPI France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingGuaranteeFee', window );">Borrowing, guarantee fee</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">PGE Loan, BPI France | Long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">&#8364; 5,044<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Changes in liabilities arising from financing activities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Principal received</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting and accretion</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated fixed interest expense accrual</a></td>
<td class="num">(112)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 5,038<span></span>
</td>
<td class="nump">&#8364; 5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingGuaranteeFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Guarantee Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingGuaranteeFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478456456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Fixed interest expense</a></td>
<td class="nump">&#8364; 288<span></span>
</td>
<td class="nump">&#8364; 333<span></span>
</td>
<td class="nump">&#8364; 359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Summary Of Conditional Advances, Banks Loans And Loans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at beginning of period</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">6,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New lease contracts</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities', window );">Impact of discounting of the new lease contracts</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Fixed interest expense</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Repayment of lease</a></td>
<td class="num">(1,195)<span></span>
</td>
<td class="num">(928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities', window );">Early termination of lease contracts</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Liabilities arising from financing activities at end of period</a></td>
<td class="nump">&#8364; 6,519<span></span>
</td>
<td class="nump">&#8364; 6,188<span></span>
</td>
<td class="nump">&#8364; 6,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease Through Early Termination, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474913288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>borrowing</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingNumberOfPGE', window );">Borrowing, number of PGE | borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember', window );">Bpifrance | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember', window );">Interest-free Bpifrance loan | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember', window );">Interest-free Bpifrance loan | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember', window );">Interest-free Bpifrance loan | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember', window );">Interest-free Bpifrance loan | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember', window );">Curadigm interest-free Bpifrance advance | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember', window );">HSBC "PGE" | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">Bpifrance "PGE" | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Less than 1&#160;year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Between 1 and 3&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | Between 3 and 5&#160;years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember', window );">HSBC "PGE" and Bpifrance "PGE"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingMaturityTerm', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_BorrowingDefermentPeriod', window );">Borrowing, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankBorrowingsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG31A<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankBorrowingsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingDefermentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Deferment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingDefermentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_BorrowingNumberOfPGE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Number Of PGE</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_BorrowingNumberOfPGE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_BPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeLoanBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_InterestFreeAdvanceToCuradigmBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484835400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Accrued expenses - clinical trials</a></td>
<td class="nump">&#8364; 1,486<span></span>
</td>
<td class="nump">&#8364; 1,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Trade payables &amp; other accruals</a></td>
<td class="nump">4,996<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">&#8364; 6,482<span></span>
</td>
<td class="nump">&#8364; 7,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474780664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Trade payables &amp; other accruals</a></td>
<td class="nump">&#8364; 4,996<span></span>
</td>
<td class="nump">&#8364; 5,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent', window );">Decrease in payroll tax and other payroll liabilities</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Payroll tax and other payroll liabilities</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred revenues and contract liabilities</a></td>
<td class="nump">16,518<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_ICONPlcMember', window );">ICON Plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Trade payables &amp; other accruals</a></td>
<td class="nump">447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems', window );"><strong>Disclosure of Trade Payables and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred revenues and contract liabilities</a></td>
<td class="nump">&#8364; 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Trade Payables and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_ICONPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_ICONPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487304024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Tax liabilities</a></td>
<td class="nump">&#8364; 258<span></span>
</td>
<td class="nump">&#8364; 283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Payroll tax and other payroll liabilities</a></td>
<td class="nump">4,820<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OtherMiscellaneousCurrentLiabilities', window );">Other payables</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">&#8364; 5,531<span></span>
</td>
<td class="nump">&#8364; 7,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OtherMiscellaneousCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OtherMiscellaneousCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857481954424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred revenues and contract liabilities</a></td>
<td class="nump">&#8364; 16,518<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857479892872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#8364; 84,440<span></span>
</td>
<td class="nump">&#8364; 119,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">84,440<span></span>
</td>
<td class="nump">119,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">52,503<span></span>
</td>
<td class="nump">56,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">52,503<span></span>
</td>
<td class="nump">56,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">52,503<span></span>
</td>
<td class="nump">56,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember', window );">Non-current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">38,733<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">38,733<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember', window );">Non-current financial liabilities | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">38,733<span></span>
</td>
<td class="nump">44,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember', window );">Current financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember', window );">Current financial liabilities | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember', window );">Trade payables and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">6,482<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue', window );">Total financial liabilities, at fair value</a></td>
<td class="nump">6,482<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables', window );">Total financial liabilities</a></td>
<td class="nump">6,482<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember', window );">Non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">83,921<span></span>
</td>
<td class="nump">119,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total financial assets, at fair value</a></td>
<td class="nump">83,921<span></span>
</td>
<td class="nump">119,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets carried at fair value through profit or loss | Non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">84,343<span></span>
</td>
<td class="nump">119,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost | Non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost | Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">&#8364; 83,921<span></span>
</td>
<td class="nump">&#8364; 119,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Financial Liabilities Including Trade Payables And Other Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_NonCurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_CurrentFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=nbx_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nbx_NonCurrentFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nbx_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857488103864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details) - Currency risk - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate', window );">Change in net income due to a 10% increase in exchange rate</a></td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate', window );">Change in net income due to a 10% decrease in exchange rate</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate', window );">Change in equity due to a 10% increase in exchange rate</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate', window );">Change in equity due to a 10% decrease in exchange rate</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">USD / Euro exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate', window );">Change in net income due to a 10% increase in exchange rate</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate', window );">Change in net income due to a 10% decrease in exchange rate</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate', window );">Change in equity due to a 10% increase in exchange rate</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate', window );">Change in equity due to a 10% decrease in exchange rate</a></td>
<td class="num">&#8364; (87)<span></span>
</td>
<td class="num">&#8364; (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487681208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments included in the statement of financial position and impact on income - Additional Information (Details) - EIB fixed rate loan<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfTranchesBorrowings', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure Of Detailed Information About Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="nump">&#8364; 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfTranchesBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Tranches, Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfTranchesBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478430696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and other income - Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchTaxCreditUtilizationPeriod', window );">Research tax credit utilization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 126<span></span>
</td>
<td class="nump">&#8364; 526<span></span>
</td>
<td class="nump">&#8364; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure', window );">Percentage of employees' net wages received via subsidies from French government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember', window );">PGE Loan, BPI France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">FRANCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member', window );">PharmaEngine, NBTWR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived', window );">Development milestones payments received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member', window );">PharmaEngine, NBTWR3 | Revenue by type</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ConcentrationRiskPercentage', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="nump">&#8364; 16,500<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement', window );">Minimum threshold to provide additional know-how to third party under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementMilestonesAchievementPeriod', window );">Milestones achievement, period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member', window );">LianBio, NBTXR3 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived', window );">Potential development and commercial milestones payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Development And Commercial Milestones Payments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementMilestonesAchievementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Milestones Achievement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementMilestonesAchievementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Potential Milestones Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ConcentrationRiskPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ConcentrationRiskPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Employees' Net Wages Received From French Government Via Partial Unemployment Measure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchTaxCreditUtilizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Tax Credit Utilization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchTaxCreditUtilizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_NonDilutiveFinancingAgreementBPIFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_PharmaEngineNBTWR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConcentrationsOfRiskAxis=nbx_RevenueByTypeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConcentrationsOfRiskAxis=nbx_RevenueByTypeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484377160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues and other income - Schedule of Revenues and Other Income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="nump">&#8364; 68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentTaxCredit', window );">Research tax credit</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Subsidies</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenues and other income</a></td>
<td class="nump">2,647<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember', window );">Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2021-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development, Tax Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_ServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nbx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487006696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Summary of Research and Development Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses', window );">Purchases, sub-contracting and other expenses</a></td>
<td class="num">&#8364; (19,562)<span></span>
</td>
<td class="num">&#8364; (12,734)<span></span>
</td>
<td class="num">&#8364; (16,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpensePayrollCosts', window );">Payroll costs (including share-based payments)</a></td>
<td class="num">(9,605)<span></span>
</td>
<td class="num">(10,306)<span></span>
</td>
<td class="num">(11,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense', window );">Depreciation, amortization, and provision expenses</a></td>
<td class="num">(1,211)<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(1,627)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">&#8364; (30,378)<span></span>
</td>
<td class="num">&#8364; (24,330)<span></span>
</td>
<td class="num">&#8364; (30,411)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Depreciation, Amortization And Provision Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpensePayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Payroll Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpensePayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Sub-Contracting And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484381288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Research and Development, Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense', window );">Decrease in employee benefit expense | &#8364;</a></td>
<td class="nump">&#8364; 774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense', window );">Decrease in employee benefit expense, percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfEmployees', window );">Increase (decrease) in number of employees | employee</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments | &#8364;</a></td>
<td class="nump">&#8364; 3,201<span></span>
</td>
<td class="nump">&#8364; 2,924<span></span>
</td>
<td class="nump">&#8364; 4,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses', window );">Increase in purchases, sub-contracting and other expenses | &#8364;</a></td>
<td class="nump">&#8364; 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses', window );">Increase in purchases, sub-contracting and other expenses, percentage</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfEmployees', window );">Increase (decrease) in number of employees | employee</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments | &#8364;</a></td>
<td class="nump">&#8364; 677<span></span>
</td>
<td class="nump">&#8364; 629<span></span>
</td>
<td class="nump">&#8364; 902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Employee Benefit Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInEmployeeBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase (Decrease) In Employee Benefit Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857488099448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Summary of Selling, General and Administrative Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense', window );">Purchases, fees and other expenses</a></td>
<td class="num">&#8364; (9,638)<span></span>
</td>
<td class="num">&#8364; (6,482)<span></span>
</td>
<td class="num">&#8364; (9,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts', window );">Payroll costs (including share-based payments)</a></td>
<td class="num">(9,379)<span></span>
</td>
<td class="num">(7,789)<span></span>
</td>
<td class="num">(9,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense', window );">Depreciation, amortization and provision expenses</a></td>
<td class="num">(417)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A expenses</a></td>
<td class="num">&#8364; (19,434)<span></span>
</td>
<td class="num">&#8364; (14,611)<span></span>
</td>
<td class="num">&#8364; (18,909)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpensePayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Payroll Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpensePayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling General And Administrative Expense, Purchases, Fees And Other Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474532552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Selling, General and Administrative, Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>employee </div>
<div>factor</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfImpactingFactors', window );">Number of impacts | factor</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Short-term employee benefits expense</a></td>
<td class="nump">&#8364; 15,700<span></span>
</td>
<td class="nump">&#8364; 15,100<span></span>
</td>
<td class="nump">&#8364; 16,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense', window );">Increase in employee benefit expense</a></td>
<td class="num">&#8364; (774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense', window );">Increase in employee benefit expense, percentage</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfEmployees', window );">Increase in number of employees | employee</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="nump">&#8364; 3,201<span></span>
</td>
<td class="nump">&#8364; 2,924<span></span>
</td>
<td class="nump">&#8364; 4,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses', window );">Increase in rent, fees, and other expenses</a></td>
<td class="nump">&#8364; 3,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses', window );">Increase in rent, fees, and other expenses, percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense', window );">Increase in employee benefit expense</a></td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense', window );">Increase in employee benefit expense, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfEmployees', window );">Increase in number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="nump">&#8364; 2,500<span></span>
</td>
<td class="nump">&#8364; 2,300<span></span>
</td>
<td class="nump">&#8364; 3,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInEmployeeBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Employee Benefit Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInEmployeeBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Purchases, Fees, And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfImpactingFactors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Impacting Factors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfImpactingFactors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase (Decrease) In Employee Benefit Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase (Decrease) In Rent, Fees, And Other Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485353544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Summary of Payroll Costs (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="num">&#8364; (11,391)<span></span>
</td>
<td class="num">&#8364; (11,141)<span></span>
</td>
<td class="num">&#8364; (11,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Payroll taxes</a></td>
<td class="num">(4,308)<span></span>
</td>
<td class="num">(3,953)<span></span>
</td>
<td class="num">(4,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(3,201)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
<td class="num">(4,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Retirement benefit obligations</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total payroll costs</a></td>
<td class="num">&#8364; (18,984)<span></span>
</td>
<td class="num">&#8364; (18,094)<span></span>
</td>
<td class="num">&#8364; (21,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageNumberOfEmployees', window );">Average headcount | employee</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of personnel employed by the entity during a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 141<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484770760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Payroll Costs, Additional Information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">End-of-period headcount | employee</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseInNumberOfEmployees', window );">Increase in number of employees | employee</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Short-term employee benefits expense | &#8364;</a></td>
<td class="nump">&#8364; 15,700<span></span>
</td>
<td class="nump">&#8364; 15,100<span></span>
</td>
<td class="nump">&#8364; 16,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments | &#8364;</a></td>
<td class="nump">&#8364; 3,201<span></span>
</td>
<td class="nump">&#8364; 2,924<span></span>
</td>
<td class="nump">&#8364; 4,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseInNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseInNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478727128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">&#8364; (45)<span></span>
</td>
<td class="num">&#8364; (176)<span></span>
</td>
<td class="num">&#8364; (292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(1,515)<span></span>
</td>
<td class="num">(1,579)<span></span>
</td>
<td class="num">(1,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Provision for charges</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversal of provision for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="num">(1,628)<span></span>
</td>
<td class="num">(1,630)<span></span>
</td>
<td class="num">(1,879)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Provision for charges</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversal of provision for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="num">(1,211)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
<td class="num">(1,609)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">SG&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Amortization expense of intangible assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Amortization expense of tangible assets</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Provision for charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversal of provision for disputes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DepreciationAmortizationAndProvisionExpenses', window );">Total depreciation, amortization and provision expenses</a></td>
<td class="num">&#8364; (416)<span></span>
</td>
<td class="num">&#8364; (373)<span></span>
</td>
<td class="num">&#8364; (270)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in existing other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 84<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DepreciationAmortizationAndProvisionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Amortization And Provision Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DepreciationAmortizationAndProvisionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=nbx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480602360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Summary of Other Operating Income (Expense) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractTerminationIndemnities', window );">Contract termination indemnity (PharmaEngine)</a></td>
<td class="num">&#8364; (5,414)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Total Other operating income and expenses</a></td>
<td class="num">&#8364; (5,414)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractTerminationIndemnities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Termination Indemnities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractTerminationIndemnities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484421560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Other Operating Income (Expense), Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractTerminationIndemnities', window );">Contract termination indemnities</a></td>
<td class="nump">&#8364; 5,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure Of Operating Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractTerminationIndemnities', window );">Contract termination indemnities</a></td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractTerminationIndemnities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Termination Indemnities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractTerminationIndemnities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474681272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 16, 2014 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>plan </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate', window );">Number of preceding trading days taken into account in the determination of the share price on the grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfShareBasedPaymentArrangementPlans', window );">Number of share-based payment arrangement plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfShareBasedPaymentArrangementPlans', window );">Number of share-based payment arrangement plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfShareBasedPaymentArrangementPlans', window );">Number of share-based payment arrangement plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfShareBasedPaymentArrangementPlans', window );">Number of share-based payment arrangement plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member', window );">BSA 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems', window );"><strong>Disclosure Of Detailed Information About Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="nump">&#8364; 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfShareBasedPaymentArrangementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Share-Based Payment Arrangement Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfShareBasedPaymentArrangementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857453289144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 25, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 10, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 10, 2015 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 16, 2014 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Aug. 28, 2013 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 10, 2013 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 18, 2012 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 04, 2012 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,972,860<span></span>
</td>
<td class="nump">2,414,654<span></span>
</td>
<td class="nump">2,338,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,291<span></span>
</td>
<td class="nump">718,767<span></span>
</td>
<td class="nump">751,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
<td class="nump">32,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member', window );">BSPCE 08-2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">86,150<span></span>
</td>
<td class="nump">92,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">70,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,350<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
<td class="nump">38,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember', window );">BSPCE 2017 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,103<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,251<span></span>
</td>
<td class="nump">263,028<span></span>
</td>
<td class="nump">251,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,880<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member', window );">BSA 04-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member', window );">BSA 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member', window );">BSA 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember', window );">BSA 2016 ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember', window );">BSA 2016 performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member', window );">BSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member', window );">BSA 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member', window );">BSA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember', window );">BSA 2021 (b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,512<span></span>
</td>
<td class="nump">446,500<span></span>
</td>
<td class="nump">746,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,750<span></span>
</td>
<td class="nump">322,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
<td class="nump">27,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member', window );">AGA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="nump">355,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="nump">316,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member', window );">AGA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards issued (in shares)</a></td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Grant price (in euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of awards, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of awards lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Number Of Awards Exercised In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Number Of Awards Forfeited In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857476626600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,200<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583,806<span></span>
</td>
<td class="nump">986,359<span></span>
</td>
<td class="nump">589,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,753<span></span>
</td>
<td class="nump">10,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember', window );">OSA 2016-1 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,250<span></span>
</td>
<td class="nump">28,750<span></span>
</td>
<td class="nump">30,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA LLY 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">407,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,456<span></span>
</td>
<td class="nump">400,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,253<span></span>
</td>
<td class="nump">7,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member', window );">OSA 2021-04</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member', window );">OSA 2021-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price (euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement', window );">Number of options, exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options as of including options exercised during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement', window );">Number of options lapsed or cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options lapsed or cancelled during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Number Of Awards Exercised In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Number Of Awards Forfeited In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857428337400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Mar. 17, 2020</div></th>
<th class="th"><div>Mar. 11, 2020</div></th>
<th class="th"><div>Mar. 29, 2019</div></th>
<th class="th"><div>Jul. 27, 2018</div></th>
<th class="th"><div>Mar. 06, 2018</div></th>
<th class="th"><div>Jan. 07, 2017</div></th>
<th class="th"><div>Nov. 03, 2016</div></th>
<th class="th"><div>Feb. 02, 2016</div></th>
<th class="th"><div>Jun. 25, 2015</div></th>
<th class="th"><div>Jun. 10, 2015</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Sep. 16, 2014</div></th>
<th class="th"><div>Aug. 28, 2013</div></th>
<th class="th"><div>Apr. 10, 2013</div></th>
<th class="th"><div>Dec. 18, 2012</div></th>
<th class="th"><div>May 04, 2012</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,202<span></span>
</td>
<td class="nump">&#8364; 2,924<span></span>
</td>
<td class="nump">&#8364; 4,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember', window );">BSPCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20121Member', window );">BSPCE 2012-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member', window );">BSPCE 2012-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE042013Member', window );">BSPCE 09-2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member', window );">BSPCE 08-2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member', window );">BSPCE 09-2014 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member', window );">BSPCE 2015-1 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member', window );">BSPCE 2015-2 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member', window );">BSPCE 2015-3 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember', window );">BSPCE 2016 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember', window );">BSPCE 2016 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember', window );">BSPCE 2017 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember', window );">BSPCE 2017 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member', window );">BSPCE 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017ProjectMember', window );">BSPCE 2017 Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember', window );">BSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member', window );">BSA 04-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member', window );">BSA 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member', window );">BSA 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member', window );">BSA 2015-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember', window );">BSA 2015-2(a) | Tranche four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b) | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b) | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b) | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember', window );">BSA 2015-2(b) | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember', window );">BSA 2016 ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember', window );">BSA 2016 performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member', window );">BSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member', window );">BSA 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member', window );">BSA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member', window );">BSA 2018-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member', window );">BSA 2018-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member', window );">BSA 2018-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member', window );">BSA 2019-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.13%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member', window );">BSA 2020 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.07%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember', window );">BSA 2021 (a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember', window );">BSA 2021 (b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_OptionLifeOtherEquityInstrumentsGranted', window );">Maturity (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember', window );">AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member', window );">AGA 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member', window );">AGA 2018-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member', window );">AGA 2019-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.141%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.74%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member', window );">AGA 2020 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.69%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Share price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExercisePriceOtherEquityInstrumentsGranted', window );">Exercise price (in euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.63%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member', window );">AGA 2021 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.59%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.38%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.33%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.28%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="nump">&#8364; 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 79<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="num">(0.35%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free rate</a></td>
<td class="num">(0.26%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ExercisePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ExercisePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_OptionLifeOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Life, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_OptionLifeOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20121Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20121Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20122Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE042013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE042013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE082013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20152Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017ProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017ProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA0412Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2016PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20182Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857440273144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 21, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 24, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 06, 2018 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 07, 2017 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 03, 2016 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 02, 2016 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,202<span></span>
</td>
<td class="nump">&#8364; 2,924<span></span>
</td>
<td class="nump">&#8364; 4,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember', window );">OSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember', window );">OSA 2016 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember', window );">OSA 2016-1 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member', window );">OSA 2016-2 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember', window );">OSA 2017 Ordinary | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017PerformanceMember', window );">OSA 2017 Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member', window );">OSA 2018 | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.103%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.149%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1 | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member', window );">OSA 2019-1 | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member', window );">OSA LLY 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member', window );">OSA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember', window );">OSA 2021-04 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember', window );">OSA 2021-04 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="nump">&#8364; 246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">39.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">37.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">38.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember', window );">OSA 2021-06 O | Tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember', window );">OSA 2021-06 P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in euros) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility</a></td>
<td class="nump">39.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Maturity (in years) | yr</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan', window );">Value of initial plan (in thousands of euros)</a></td>
<td class="nump">&#8364; 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TranchesAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TranchesAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_VestingAxis=nbx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_VestingAxis=nbx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20161PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2017PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSALLY2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202104PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106OrdinaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_OSA202106PerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485333912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) - Summary of Net Financial Income (Loss) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract', window );"><strong>Income, expense, gains or losses of financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks', window );">Income from cash and cash equivalents</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">6,347<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other financial income</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total financial income</a></td>
<td class="nump">6,360<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest cost</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">4,676<span></span>
</td>
<td class="num">(4,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">IFRS 16 related interests</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total financial expenses</a></td>
<td class="num">(780)<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
<td class="num">(4,970)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial income (loss)</a></td>
<td class="nump">&#8364; 5,580<span></span>
</td>
<td class="nump">&#8364; 2,847<span></span>
</td>
<td class="num">&#8364; (4,133)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and bank balances at central banks. [Refer: Interest income; Cash and bank balances at central banks]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857443037768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income (loss) - Additional Information (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest cost</a></td>
<td class="num">&#8364; (383)<span></span>
</td>
<td class="nump">&#8364; 4,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (4,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">6,347<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities', window );">Accumulated variable interest expense accrual</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Fixed interest rate | EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems', window );"><strong>Disclosure of financial instruments by type of interest rate [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">&#8364; 1,800<span></span>
</td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857478735736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">&#8364; 75.4<span></span>
</td>
<td class="nump">&#8364; 60.2<span></span>
</td>
<td class="nump">&#8364; 51.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CompanyDeferredTaxRate', window );">Deferred tax rate</a></td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">25.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Unused tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">&#8364; 14.0<span></span>
</td>
<td class="nump">&#8364; 59.6<span></span>
</td>
<td class="nump">&#8364; 49.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">FRANCE | Unused tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">&#8364; 284.0<span></span>
</td>
<td class="nump">&#8364; 235.0<span></span>
</td>
<td class="nump">&#8364; 184.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Unused tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_UnusedTaxLossExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CompanyDeferredTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company Deferred Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CompanyDeferredTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_UnusedTaxLossExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unused Tax Loss Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_UnusedTaxLossExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857476552824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net loss</a></td>
<td class="num">&#8364; (47,003)<span></span>
</td>
<td class="num">&#8364; (33,590)<span></span>
</td>
<td class="num">&#8364; (50,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Effective tax expense</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Recurring loss before tax</a></td>
<td class="num">&#8364; (47,058)<span></span>
</td>
<td class="num">&#8364; (33,581)<span></span>
</td>
<td class="num">&#8364; (50,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Theoretical tax rate (statutory rate in France)</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Theoretical tax (benefit) expense</a></td>
<td class="num">&#8364; (12,470)<span></span>
</td>
<td class="num">&#8364; (9,403)<span></span>
</td>
<td class="num">&#8364; (15,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_TaxEffectOfShareBasedPaymentArrangements', window );">Share-based payment</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other temporary differences</a></td>
<td class="nump">117<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011', window );">Other non-taxable items</a></td>
<td class="num">(644)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="num">(736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Unrecognized tax losses</a></td>
<td class="nump">12,154<span></span>
</td>
<td class="nump">9,138<span></span>
</td>
<td class="nump">15,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Effective tax expense</a></td>
<td class="num">&#8364; (5)<span></span>
</td>
<td class="num">&#8364; (9)<span></span>
</td>
<td class="num">&#8364; (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenues that are exempt from taxation. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_TaxEffectOfShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Share-Based Payment Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_TaxEffectOfShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857484665336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Schedule of Basic and Diluted Loss Per Share (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss for the period (in thousands of euros)</a></td>
<td class="num">&#8364; (47,063)<span></span>
</td>
<td class="num">&#8364; (33,590)<span></span>
</td>
<td class="num">&#8364; (50,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (in shares)</a></td>
<td class="nump">34,733,418,000<span></span>
</td>
<td class="nump">24,385,827,000<span></span>
</td>
<td class="nump">21,631,514,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share (in euro per share)</a></td>
<td class="num">&#8364; (1.35)<span></span>
</td>
<td class="num">&#8364; (1.38)<span></span>
</td>
<td class="num">&#8364; (2.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share (in euro per share)</a></td>
<td class="num">&#8364; (1.35)<span></span>
</td>
<td class="num">&#8364; (1.38)<span></span>
</td>
<td class="num">&#8364; (2.35)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857485311288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare', window );">Potential additional ordinary shares that are considered antidilutive (in shares)</a></td>
<td class="nump">3,006,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Anti-Dilutive Securities Excluded From Calculation Of Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857474944984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>patient</div>
</th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease_contract</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>lease_contract</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfShortTermLeaseContracts', window );">Number of short term leases | lease_contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AnnualShortTermLeaseExpense', window );">Annual short term lease expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_AnnualLeaseExpense', window );">Annual lease expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">&#8364; 2,213<span></span>
</td>
<td class="nump">&#8364; 2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfPatientsInClinicalTrial', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual capital commitments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_MilestonePaymentDefermentPeriodAfterEnrollment', window );">Milestone payment, deferment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration', window );">Research expense since start of collaboration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3 | Bottom of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease', window );">Milestone payment increase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member', window );">MD Anderson Cancer Center, NBTXR3 | Top of range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease', window );">Milestone payment increase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member', window );">Termination of PharmaEngine License and Collaboration Agreement, NBTXR3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,400<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports', window );">Milestone payment upon receipt of clinical study reports | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval', window );">Milestone payment upon second regulatory approval | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember', window );">EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_RoyaltiesAgreementPeriod', window );">Royalties agreement, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | EIB fixed rate loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,000<span></span>
</td>
<td class="nump">&#8364; 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2021-01-01<br> -Paragraph 86<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AnnualLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AnnualLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_AnnualShortTermLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Short Term Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_AnnualShortTermLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment, Annual Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Milestone Payment Upon Second Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ContractualCommitmentsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Commitments, Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ContractualCommitmentsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_MilestonePaymentDefermentPeriodAfterEnrollment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Deferment Period After Enrollment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_MilestonePaymentDefermentPeriodAfterEnrollment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfPatientsInClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients In Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfPatientsInClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfShortTermLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Short Term Lease Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfShortTermLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense Since Start Of Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_RoyaltiesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Agreement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_RoyaltiesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857487617144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries, wages and benefits</a></td>
<td class="nump">&#8364; 1,245<span></span>
</td>
<td class="nump">&#8364; 1,073<span></span>
</td>
<td class="nump">&#8364; 1,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Supervisory Board&#8217;s fees</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation to related parties</a></td>
<td class="nump">&#8364; 3,638<span></span>
</td>
<td class="nump">&#8364; 2,866<span></span>
</td>
<td class="nump">&#8364; 3,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139857480131656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2022</div></th>
<th class="th"><div>Apr. 01, 2021</div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Jul. 28, 2020</div></th>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Mar. 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,077.5<span></span>
</td>
<td class="nump">&#8364; 735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 102,942,000<span></span>
</td>
<td class="nump">&#8364; 28,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 26,790,000<span></span>
</td>
<td class="nump">&#8364; 70,468,000<span></span>
</td>
<td class="num">&#8364; (1,908,000)<span></span>
</td>
<td class="nump">&#8364; 14,243,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (euro per share)</a></td>
<td class="nump">&#8364; 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,000<span></span>
</td>
<td class="nump">&#8364; 12,000<span></span>
</td>
<td class="nump">&#8364; 361,000<span></span>
</td>
<td class="nump">&#8364; 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">316,083<span></span>
</td>
<td class="nump">393,750<span></span>
</td>
<td class="nump">12,017,083<span></span>
</td>
<td class="nump">2,566,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,044,776.16<span></span>
</td>
<td class="nump">&#8364; 1,032,963.66<span></span>
</td>
<td class="nump">&#8364; 672,451.17<span></span>
</td>
<td class="nump">&#8364; 589,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital Ordinary shares | Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Capital increase, net</a></td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">&#8364; 1,046,276.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital Ordinary shares | Major ordinary share transactions | AGA 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity', window );">Capital increase, net (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbx_NumberOfSharesIssuedThroughIssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Issue Of Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbx_NumberOfSharesIssuedThroughIssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>nbx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbx="http://nanobiotix.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nbx-20211231.xsd" xlink:type="simple"/>
    <context id="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">nbx:AmericanDepositorySharesNASDAQStockMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05ef069d6d904f1cbf20114a97bea67a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ff9c4acb5c74c6790f0853cd162580f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief56ec2bd42a44a6a729bc2731655345_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i120ec80e331e46b4a8d8c2e900c322ce_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib9dafc6f49b842eab8640526d732bb38_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i086600f2d4fd4f29b9e0175fa9980649_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i215f01165ded46dda75650b910df1253_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id5767bd39bba43819d6569d194f2f1d6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifb077c12bc264a7ab30586528053d5b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9373d1667a940b68a4392136b2737e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9bd38845088a4ebdb68c1b1393b7169b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icec4369f4c7649dba76e50278de42760_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a2f48357d7645e5a28e6091cc904770_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib450eccc21d24368a1877065c5e022e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b268f53590247bcb64f8ce92ed3144d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib91c813e0c574310a2f8c983ce2042ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib58665d50b9245cbb263201dd383577d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05eefb483e484cf597b3e3872a255374_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2aad128401e440c58786e8375faef035_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b4b95efdee94328b574c4dd5a972a78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia680b82130144ad9af8419938ca05856_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e365c4a4f144b5e87711257c20e4830_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e4260d8f2204ff1897746ec6304ec1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7da366d77c294b75876c03db3346763e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iead84a7b542a49db9faee4780fc37284_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0283091d6704f18a2ff733acf943ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida63773549fb469180532f7bff7a9b6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56d7277ffa0b489fa8a0f3ad5aa861e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i919a1afd086a4da19822485db27af8c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if46cc205e82045279e50f91253f8ea1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nbx:NetLossForThePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fbf747738f94b4484ec6e4bf65b8025_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib4221b386b8a41008368fa79a2422241_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ia4324070196a42ce81514023ff835c69_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf991456c15f4bd0beed8a02658e4984_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="i4b5f453227ff4a7692568ee182571454_I20120831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-08-31</instant>
        </period>
    </context>
    <context id="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i0383e3a745c6410a8ad6434d35604d24_D20120801-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-08-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib667123634854784a7a53e8925b6cdd7_D20210301-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie66ef1f72fe74f22bed3a4ecb3ee2669_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="id08b49a302c4409797ed3baba0f7a8e2_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7f9f4e02188e458a98c73d7d32919183_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="icd3f097755a84ae28952d3b990109fcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i730862d53f524fd48823ccef1c727d85_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i019a762512c74bd995f218b15c627c60_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="ic0738eac499e4251a6854800b581173f_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="ie86596994b614e61888621f5f63b3d95_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-03</startDate>
            <endDate>2020-02-03</endDate>
        </period>
    </context>
    <context id="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i924453673b444fda9c3c28b015994d6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfe58517db324e8ab08832232c673117_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48e879f68f73480b92b03ede2c9ea8b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia618a699065e48f1b3d3352fbfb17118_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6fa32daece2d40c39f286dbb440ed1a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia68188d7927a49d199519c9b6b2e7235_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4e7f92a2efb4119907ab206e3174d4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad4e681a419c4d16b32f5518228877ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73b9b382940d4e8fa4efbc37ae851522_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7046c37f9b34feca0220aebcdc2b9d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1c5ada34f4342ffbb24c0ed227de3b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00d268a8bc3d448db012d4136f9d9326_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc3d1f32ff2c425093e40400c4b37239_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i946464e2c020499fa8273a1147673bf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22135b3300e048769f42cc9088154762_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i661079bae5984baa83e48cf8bf2e0ca0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3447f0049044af6945782db9521890b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i643b965508bf43d4a88c27237bc3b7fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02245261c2374bc991f32f8bc9d1afd3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2713ac30115344d4be481a055affe757_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc87ab6886c14a47b7ebba0f7a2fe2cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fd5dc377e504702bf04bf3db9a706ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i857b522132a0476eb6dce6d1596820d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9fc3134a84e4b788c49a537b36f4ea2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i383069cd64164d36bf3be6f4fe694362_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45392436feb24c1ca988401841003b83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40f0187d0a71420b849fd1c9efa74737_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i740f5b7742a3429183c226bf413db5e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieec3261b213d45b7859dea5fb22ef918_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3891cbb9d139409f926550e2d536f939_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i081e0c1a8c8c4accb7e935ac897dcf77_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83c487a257944224b5d370f39d0697cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia058d7b209a54f6fbe029cc8f59f7699_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iada2ffdf9e7841edb4e55be9d4d3d033_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadbefaf925c74b24a9922616c74a0553_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bd3865bd72e4c6dabd994b9080949fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i992fc55410f2432f87fb2d95d37cf5c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd26e64de5444c1f98cc675c204144c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07d2744884e34de08bb1bf0f018e8367_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifed0297807f94baea1c5c2d340771ee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88c91a06314d44bbbde5e2e5d56195e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8472a834d7c6410ea1e767fc3c34d64b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i680d6b18b0404cd387ee4220cef45346_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc67e0cf8262400995ad31c3fea9c892_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6598955ac8a492fa0a7949b58b5e311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2612520a1a2840a7a26c63194c557e76_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79f8b941671b4fc5b254babe62d0b548_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i24fe0f143f954dc68e1ffd022dae5517_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifbf6a969f3a946aeb176967ed73299f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa5e055bdd934a89b887335915deb655_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i065694e284ad457594585f67d682acd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79cd2925606d4aafab7f52373500d486_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb76dbf343af4ef7a2d493513ebc63dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94439a4b662842c2acd86680522e2018_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if81a7b8866e64bb5ab7ac45083f0107d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13580af0c9c0455c808971d25d9c62f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i170ffb1f1c9a464dac427c1aae8b927a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i99b3ae8877e44bcea3e5d515c0c8b8d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb66730c4b2d424b843abc92b234a808_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26b0bf7b703446948688e7ad02d72cc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie783ca6ccd7146eab501b3c72da67598_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf55c96a01274951b50be727c673d9f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fa642340f4542e7a93116c893889a2f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbdff15c03e7404a98464181c8e1cedd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3aa22cbb09f04242898c09c6ea3dc0bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3866b055ff984a8f95514cf68bf892bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic272971549af47d782e5f60383a7ecae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i105222fe76b34ab481e711fb628a0ce9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cf7ac359e404a6e813c1c0ebe727df5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:PrepaymentsOnTangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb9257083bde4c48b34295c66106f1c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44e0a92dd7344b67b577f12968b769f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5c8eab481334a328766007df5fec6db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icab30071042b444a9fac05b56e56f51c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20937f10c0074df48fcf6aae22f3d9fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i260064a22ba34ca4a69fe812eb47df77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i910c9a241c624e01900913f0b0bdef46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i811a11b85e114a59b32992557918554f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseTransportEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7a4c79360f041e5886fda1753c164ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractOberkampfStreetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34e3193487544206a16d163e6d8f920a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractFaubourgSaintAntoineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01a5d032d32a4c5aa0906fe6968d960c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractAlfortvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c8540a5ebd94096aee7b210cb09c5da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">nbx:RightOfUseBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractParkingVillejuifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i353ed3a135f54c7a972415594cd58a8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractWattigniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i46249c3026ff4190a1f98baf898f61d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">nbx:LeaseContractVillejuifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id04209b08bf44c238d4f342e917d80c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2dbdf51ff17642c88fe93c80600f8cb4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i694c290810ce4cc9842fae0c52f55511_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i752591c410134e60bdd79d9b16eff052_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e2c65d93df14f99b81bd99646ea83fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9df395790ebc462db44260a48f7af4f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e942c5d9cf5421e8899afaab5b13ae1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i937f4bc37d82433796fe6b3c4ec0ccb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentLiquidityContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i589f8e8059664ca486811bb10b3d5162_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentInvestmentsPledgedAsCollateralMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b861ae5f68a416d8f8db4e710c14707_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">nbx:NonCurrentSecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23b8abb72e0b4536a6fe80c714c03c32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45a5ffbbe08f4f37926998b489baeab7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92d57836a46444b38c01d05737626c40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75abd63d3d554d209254ec0fe3788db5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fa06ae2654e494ca242be8b5638282c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6259fe63f29c47ceb1ee63617d3f873e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i897163af67de42779bade9156e460371_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab0221939eca477097e1a9493a0df475_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab6584aaa34740b0aea5f3a15d522bf5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89b95576d1404490b4202945e6c02016_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2021TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdc4df3987ae442da01b94c5efbf38f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e0a8e1adc2f4d8daeb375e78b79e118_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2018TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icea5a1f000274c7aa5aec8d463a011bd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2019TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3549effa38bf42068215a5f6e7f44599_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2019TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a3d9c879e064e8595cbe98b04ca6d30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:NanobiotixSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d3f9bb9f0f14b24babfb6bd054d8acf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:OpenTaxYearAxis">nbx:A2020TaxYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nbx:CuradigmSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie92e58618b784d11b24590f639ec3c5c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2bd304d054954aa8889e0379a055b796_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-06</startDate>
            <endDate>2020-03-06</endDate>
        </period>
    </context>
    <context id="ic6d2b59cd3394eb38b1112a6d40ba562_D20200306-20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-06</startDate>
            <endDate>2020-03-06</endDate>
        </period>
    </context>
    <context id="ibfcb03f93ca547db9f9c30453f57d130_D20200624-20200624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-24</startDate>
            <endDate>2020-06-24</endDate>
        </period>
    </context>
    <context id="icd06ab95cb464cf7ab36d088f33b9b5c_D20200626-20200626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-26</startDate>
            <endDate>2020-06-26</endDate>
        </period>
    </context>
    <context id="ibccb3f7b5d984a47977843563136cbfd_D20200629-20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="ia1db8fdf89004094a84398a37852bd32_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie5449b75fc7d4fbda4157cb2026ec2f5_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-28</startDate>
            <endDate>2020-07-28</endDate>
        </period>
    </context>
    <context id="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-28</startDate>
            <endDate>2020-07-28</endDate>
        </period>
    </context>
    <context id="i263948c1f81b493eb8cca425bcebfa1d_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i61be2d4b393849cc9560e858d770a26c_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i0c448e8551854ba3817ac8e0588ff235_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="i76e354131ae34438ad0ee61bab49371d_D20201216-20201216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-16</endDate>
        </period>
    </context>
    <context id="ie3c6af94c36742b38cd4e03676b70d2e_D20201218-20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="i36d5fe1d4b1c4217af0247979f91d136_D20201218-20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="i8de9f777ee344fac809f90733d665d63_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75b881b34146431e87bbf66200b0999b_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="icc02833837f240adba65b3984741f75d_D20210531-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ibf9ad81b51bf4c808adb6b86c14e2b1b_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:InitialPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4304c8534859424ebd1d4888fc19dd31_D20190409-20190409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-09</startDate>
            <endDate>2019-04-09</endDate>
        </period>
    </context>
    <context id="i75a906e28a874a89ade36d6366ebe2af_D20190409-20190409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOInitialDealEuroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-09</startDate>
            <endDate>2019-04-09</endDate>
        </period>
    </context>
    <context id="ib57fc815199246ce8209d327ed4e9354_D20190409-20190409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nbx:IPOGreenShoeUSDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-09</startDate>
            <endDate>2019-04-09</endDate>
        </period>
    </context>
    <context id="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-18</startDate>
            <endDate>2012-12-18</endDate>
        </period>
    </context>
    <context id="i294a61301bf542ec867f89a9f95e7c74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0205324a5c7d4615881636c0201fd64e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-08-28</startDate>
            <endDate>2013-08-28</endDate>
        </period>
    </context>
    <context id="i5575b3f42d764a5dbad1316d83a15f52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8877fe5b26124a419df3fe7bdbc217a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-16</startDate>
            <endDate>2014-09-16</endDate>
        </period>
    </context>
    <context id="i6164f9d60bc2408f8040f375730909e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i650e54c23e864e5a9837d51c41b31a11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="ice4bbee7b8464e3bbabeace3aa802581_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie08726f70e014e668fe8d3b22f627e3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="i1f7c12d22fc24156bb81feb9babf660b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic05285b50bea41d4bb12c71770ac7c9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ib015ff2793a347eea190254523e266cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbd0d6bab50d405cafa491285cc4f581_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c71468be56c45e99adce81f572af018_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ic30eabe785c742e8b11a208b390d5b0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie58d6cd769d14890874fc2f862b4fd1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7fa7d04b56046148c18d80e87276dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae6315b11bee49a48773726a45aedbb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4574c0827bd436bb79456dc0389b57c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31d9ddb730e24052933a829799eaa5b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i218535f19cea498592b94ff4a7972768_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6119076476e4da0bce1c4d855f1ae02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iddede090f4d14469a738de2cd2066a57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76a7c7c748674e5b922e368dcd8635b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07dd60f3a2d649f8b0d32174a89ec727_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ec3ff678f124faa9cff8cf3e429be81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dce03cc95974732b21be1bff36d224d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-04</startDate>
            <endDate>2012-05-04</endDate>
        </period>
    </context>
    <context id="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b30f82903f44b5d81bcdfca5c57db77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7f654804005436cb50f2932eeb50225_D20130410-20130410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-04-10</startDate>
            <endDate>2013-04-10</endDate>
        </period>
    </context>
    <context id="i510cfe19450a4049be49e84fad36335a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78e26a224e474ffb99418761b34ca069_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id80ebbb46eb64299bfbf12da7eb08344_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-16</startDate>
            <endDate>2014-09-16</endDate>
        </period>
    </context>
    <context id="i7fd5c20435184561a25fd67367fe177e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i287ca2164109487e803ea58119f85b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="icd30db4dc68e4dcd81aa001f304ccf02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i444894e06ef84e86916f0f43636239a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i873a0cd9fb8c4033a253afbd56030396_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id7ea1268150748fba93569448532c0ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic15cc4f8cfe94884af5dec143cec0074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="ie729c807456a4342ae1d1ec7e0b01004_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac18bcb7a8e547b58905c1c5db99010c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic202005056b44f91afe160b576641e45_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ibe646b429ac44edb9d5b3c79beecffdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd6514681b0542d6ad81d4e87b9026b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="i3ec3b243e08547a7a32d94cc27e3f446_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1112922487994275ba7f128834f46d02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93dc071a53df4b658e48104f724a4d81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i82aea750feb9452ea792b03a00878392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c32baad1d584e179d05334758196e37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="ie220c08e5abd4acc97a8dc56ed476133_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i185c5465e4f54321893449f2ed13c945_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="i035962ed0e9a4ed88c5d0e27de65b632_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ec46661f19e44898198a21b96fcd9e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="ia215c2b217c345f5a90b27a71eb9f095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i934217d99b564cd898bba1870f16acd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a196703767045b4aeaf86e08026e973_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iffce4cb7839e46bf9d2e020d8104e671_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ef0655661e64102ad08b456cde29404_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i64f2458d1e5f4672ac966ade528e91b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35f615a359f04a498a53989136de928e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib7d97c2e219d4ae29053a4b79902220a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i590691d490654f4a9b933f3df5ec0da8_D20200317-20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="i0bb4ec8843e44af1897cc09338a3eca3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i084aeefdb60241db94c5f459f1acd1e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i525d2a7385a042e2ab94b0f0b95ba373_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic84c12e1bb5740c281fb000429621cde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia368008e38064499b91b8e7a2b6fc5e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i968789d68e624749aec48577df75436b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e1ece5200db4069abd23c1d44f99b24_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i243c3f4181bd408d943852138fc86c46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67d44db1d1fd485190ead9f20de4e21d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d936b0e4f0c4c87887a0435daa8724b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i365d674525a9479c8b26b35aa085cdbe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b4ed0b8dd1a49078d6c857b4f238367_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i637bf676e3a04e68824daeb6b1575335_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i459ca9e3f16d4cd781dff0c62bdaf84a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic842508dfcc549caa3953140c12e7710_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i579df336feef41d99666585cbbcc7e99_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09df6772a877464aaef8a472647e85c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97ac1b9334ed440281d6eb50aa0804a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26bedcd322874e948f08ed1dc1e2b254_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4483ef3c39a64c83b928490f95c78902_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="ib4b320a95d374a8ba1b1f5bfe078d26f_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="ib86beff482d940c8b3f9b44ae18afb4a_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AInReplacementOfBSA2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:SupervisoryBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i3f2fe9c5747a478cafb0068a92d9a750_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="i623d044c980a4fe9b59d0cf0c4357c46_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExternalConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48ba274c2f734a61a9cb2f4453142924_I20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-17</instant>
        </period>
    </context>
    <context id="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="idca2359b6d7e4ffaabb4dff17cf89642_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdd4d704ab87433eaab118942f97873a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="ifdc086387801445bbd7de462f336e65f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb14a6fe101644f2853849ed9da8bc5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ie5f5a42a1d914ed8aded2558448aef2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf3ccd35f2ba46f3b213016bd228158b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="iff05550398184321955321fa5e96e1e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6efe15242bc44621ad8fa904a5ae89df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i8aea800177684b0784cf738a4f290854_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieff82164675b4db0ae05af2af10c6d6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="ifc595b28b04c43efa8c9724856fa5a57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i41f34aacd8914d92858087d804274e6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i534aabb6b4774e578e1faec31a145c88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="if5392b89aa5e4f9f80dabd7f2b3a9a2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60258ef3e9154ad4963d258d41dfd8e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i652de3ad86c34c4db4db1a382b545fa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18f5317d31b44749b1f183f90bf871b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d069488ce3f445a8572023fb43124a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14e72259f766468696e8950f2f900687_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3beab101ac5944d8996b39264b8500e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fb46e1a795c49bcb05fc8d3200315fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fa9412e0984488299213d105f5179a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i956533d5e0a2448295b775623b2026d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa4ccf47be0e4bbd9bb2d8faab31cb87_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5abb27847f02467bacf8dcdc5928b771_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i354033aa64f342da8206f231dd7c8d2d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic71ae7b3a2ec44fe93b98d0ab5cc918a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d97220fa46f480eb51782483039e25d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88d7422749c74ea7ab142d893e856969_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i095127a75d214c5f8b6280cf3229e623_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i3eba6313515d4559a36c492791143e24_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i91936820e19b4923b898ad1557219659_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i5b8343c910974c02b4c1483f76998841_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromFirstYearOfGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1755b173a3d34e8499dc5ce10a9bec9c_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromSecondYearOfGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i7fa42a50048a45a9a9d4dbf0fc6f444f_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:FromThirdYearOfGrantDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i475209eaa2224a61a801471a000eda08_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="idd940520765e4ad5b9784e162babba1b_I20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:BartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-21</instant>
        </period>
    </context>
    <context id="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantLaurentLevyAndBartVanRhijnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="ia28c239f39194bb4b639651e62839a6e_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:MembersOfTheExecutiveBoardAndAlainDostieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="ib4e429614d77462f852336283afd726b_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="ib6e0b829dfdd4803b7abd6510fa5d82f_I20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-11</instant>
        </period>
    </context>
    <context id="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:FormerExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i954049ede5c54ffaa561a7d9cfab1443_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fd83d8297074b52a62595e69d21c63a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i618e2a4f0714405d93ca3cb13691d6ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0dd068ca5156440caa5babda88800ff1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34704d55c6ee4757afcef3b7be3465b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i438c89d9de71485fa265416e30bb0e74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fd9280336d448658f2102d170064e8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia48a5f2ef4da4715821c24e44aa102ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib866094a2bed45fbb12978a62862e821_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ca07aabfb0141ccb67f650409efd173_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15a8434290bb4198a83ded0ca18c27a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0979101cec4474688543efa006ec62d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93d6f1511d6e44e78b354c3721b5d10d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8d6ad9db19141c78c82ca8829ef8a66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe8ccb113d1241d8bfccb1356614de26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1c10d2422b545efaf4328d5268483f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia09f2bb3b6114c268acacc4f0ebce171_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75412d7d9d294b44b69018586184ee05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i140d20eec52d43de90b683cedaafe648_I20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="iaafc498a94374f9f8c4d0dda5b2e6397_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i3f28affaf7bb40ce8972d14b1c1f055b_I20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:AnneJulietteHermantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-11</instant>
        </period>
    </context>
    <context id="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020AndAGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="ia49ffd5f6a8a43efaa547e2eb3e46420_D20191024-20191024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-24</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="if8bf73603bb74c11877603a93c8fee52_D20210317-20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="ibf0906164d3245eca6340ec305f7b4bf_D20210401-20210401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ifa39e4659a8045229764c592849e2e2d_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="idabb0dddb8454f87a533b1f04427ec7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if17a2f2e90aa4abfa844349f8bbeffdd_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="id8d3dbb65e224379b7a93e55ca7be0c4_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="if2dd11d82dad4017b9e787f657b62484_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:ExecutiveBoardAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i9ca1834853e14961be45fc7a1f5a71d2_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i3980c93822e74e5291bc063308f06aee_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i3b902764e68a4c7ca60c0b4162e645fd_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i3b309086b1c64082bcccc5093b2b7923_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c815a380ae74027ad90d5faa79e3d8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00cc8afb53664ed8b93b3511d260adb5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9770c3638b9e47bf84c5dfee8735850b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf9d433b2a87420884917078664d7f8f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c7c68e80ad24f5093d192fa5626429e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia38ca1b371aa43d5a00e50015286da3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22a92c12751c43379ad3872883245ab6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee51e9d440a047eebd1e8bf2e351748c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib657a40efdff4a8abe6d4859411ae9a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7799f346c5b4b37b8b69785c49cf119_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ec1a6d0e59f4fa0a6f189b7aa6224ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:LumpSumRetirementBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b79b0b3f6a5401baa1cee18c3d6fedb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:NonCurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a2056a247c446a399326de355e4dd00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForDisputesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31eefc648a754106ba154cff1e338702_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id481c669f10348a6bb361ea9989abe14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:ProvisionsForChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f8df14f2f9d420ca23cd6a4dbaf06f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">nbx:CurrentOtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ff4e8698b934f5ca052b72aca594ec8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d9f94f4d137434787ce8c4eaa14426e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9d81d56997d4d9c87371cf48ed31342_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i00fb905b6ac2460fbb950029daa312f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20fe37bb0cdf444b83b46778e2b4506e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52f0c77f0c744ce19a75d7d15fcb5f32_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie314f470deb843f992c5a952cdab570c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f003eaa769045d399df6708982c5689_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nbx:NonExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2dc5ff1dff994b4eb048694b27359b44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9e19e74602b46bfa5b381e3de4fca06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice82a034b6964d1d92ad1d346d346b3c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3979f010ce54acda1438941b43765cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nbx:ConditionalAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb22c0964cc746dd82cf9597bde3d98d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i860acbbc413c411d9552c930dd50330e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:PGELoanAgreementBPIFranceAndHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70c9105496ee4b008bc01ccddf108a3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6063d413a70f4e42ab228ca05274873e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id26c49ada5ea49f6925b076f04f65999_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BanquePubliqueDInvestissementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4f9f36c6b44349068238dd8813d5bb59_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if4f90ba5db684b64a31830ebf03467df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e7d5a08503c4c58999df6bf6e4c20d4_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="icdb43c79419c4ae4a549589fcd0ea3d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i677dc547692443839295f53c6d89dbdd_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4e96e3484ed74cb680b4ae9eab1f7e13_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44a077384c26495caae329e040555472_D20200710-20200710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="i0602bff51649496c9da805f828e74529_I20200710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="i0110777e52b3473f8b462de884b09e80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24a151e2334941ad93f623e660566efd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieae65f3974804742b4ab99567efade16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7917ccaea2634af4a65d44c4873dfc76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ba645486aa240169be18398fc400965_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2608a211d394427a2eb417f85f7c460_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ce52155b2714380bea43bb9d5364790_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d080d4ae22f49209fad3088f5cd1717_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia690845ba75d4a2d9817787693b33552_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3325ccb1e560443f9ddb6eddf043414a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfb5e49da6c84216827391eff4e26057_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaca493780d654d98a11eee83335034c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i501dadac2baa4da2b169943189296894_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceAdvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i166567b173294d53b3207d7758ed8744_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeBPIFranceLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6fda04984b54ecd9c6ae4c8f6433521_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f6c485623c34a36a0a0c935c03af6b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:ConditionalAdvanceBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b283275fffa429aa785167b228d13d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">nbx:ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia00db9d1206a4981b2ae432d997b3bfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34b69bb03edc48d388d2b08bd8342672_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61f3c9741ef74beea34a7372eea88c9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06da0291c1964865b0bee57ea7df6660_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42ac85adcce64257b4ab0b5899397068_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9db631ab0a946ffa6c39533461876b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id83ab7ac51814807be706998f4cc09e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea99a9d2ede149058f2638ecfe804933_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2e7563cfe4f4e48bdebe1cd3babc08c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3aa2ca3eec9341eea4ebbd1e22088ba8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c4fa6093f8a43df81a2388bcd182126_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9daf524aa9d74916971b8de78a30e4c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i127de2da61e64e78845c4c06ce48cee7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66337c960fa942618f0543d1c09dfea5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03fc764f222342e8a738cfe4737267f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74e0b22ef5ef4129b1e88005177dcf0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19e15c2a272c4daca720310496d521ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91a2318ff64a450380b9438374b59d05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id119775bd1424312ac886a611fd9da80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5226cc30782848c99b13dc241995afe3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a94562c5153457ab46aec435a38bf16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if72f0771e7134f64a254bb97d9bc45bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:BPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia59396251fd945158fa1538f914cc4b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2295671454b14d6d91210a5944d6c07b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedbfecf36047400ead3aea1bcc9b8a13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i124ed568f8a24aa78e3ff34558ad81c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeLoanBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7191a356d1c64bd49a626a0c200e1eaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69512fc2f0d34eb4b0cf656265fa6930_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i024c28063f484f59b11cb851e436a1c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1502f4415f84bc0ad1e2d41b2f6944f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:InterestFreeAdvanceToCuradigmBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i836bec40340a45258bbea36837952d12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03054a03855b4b37a9b8768c06f2bd7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cf7bec92f924353b5d3c40835d5e6fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8a60e1d925a45289d5b33cdd832c02e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f3e0b6ca2a945ed8c4fb13c8274f2cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2369a7d63f7d4af9aaccfee568c13c3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18d3c34726ac4988b595b25c132f4bcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8604d938eea43d1ad397edac29826f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb9f7ca1927d4697a4fe081256782a2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia38f8669a4be407cab008b29e2b85d90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2db0464e08894c07a24540e1493e87e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5abc10eb5d6945cb92399dbc699bfb72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05cfdfc0910e47f6becde04d1178f72d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ce13eb6ddc140849ea104ec96d8f749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied1dea9b89304c059d54ab720191a5d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1eac451531248ea959e4a652e5278e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1a681b206df4511b7799f7f5af81474_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf95cc261a574c20bb75916fc307fd2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e92157b10524c51b91a421eb6a8c483_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:ICONPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6c320981631448bb18db0fd12c61f50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id999c1e7e2574135a234b087144a61d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2547d3f63dd142aebf5856fb5e8585d9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e4d5d5fad3437283d2114e123c9052_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88c4b87a005448a6af125cf0d25e3ca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0503316bb634a33b147e9bd8ec248d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3893bd24e354c778100e28facefe020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d08cfa6357540d1ad2a166b19c12357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c39078fac4b4979aea00def2bcbb7e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50df0717ba78443aa1b28f71669529c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc7f775ffe9b4f938e53f99295d0dd49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2445eebc99b4373b2eb31de5002f587_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4882dee440d4a6786f1a85711a2f076_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83d0f6bcf35c4bf6a5b350b635b2cf61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13f6b64bccba4b65be62a02815fcc7d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc4dd7cc1b414385a787daf2198eed07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a633ef24e1c46b0a69bcaf4403e72ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14898c15ca2947e18832b9287191cc4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i844f8507f9df4617831e6d34785b0ce7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4b0a0a486794f239a3054bc37c245ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62783c3667b540b998e0995fce469eb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4e939bfe23c45adaf30417def90ead9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nbx:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7de0719450484ecc8171d036b10ef5e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaac2ec9156e94f5b90790097f4f6f9e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f0f98e9c5bf49a7a5c86be5e8e9f97e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:NonCurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i963e0d114bd6453f9f66f58da5eff1cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i005555f4e921493c8254695ac286ae81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:CurrentFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dcca9167f6249298283face31cd7f47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f20ea2133e94954bd0a8f66c6e3cc78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">nbx:TradeAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea4486c4d182429aa433718272dbe53b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbf161735ab842849b194cad877786e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70e283091672405988eeb41d8577edbe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-15</startDate>
            <endDate>2021-06-15</endDate>
        </period>
    </context>
    <context id="i16897dad579b4f4b86092bda744f7b49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:LianBioNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i923e1965fdfa48cb90e163414c18dcc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0280ecfc6a714e849f5cba16bb5df0e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66824b4e473b46179fd1ef1f2f501a12_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:ServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib221c9ab85f1428998e5bd37d6eadcba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e1b70eaca444c0098a66c5e8a9832bc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9df4ab9cfd314a1baaac83e76837eb48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nbx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3840527069c4348acc9ab3731676a5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i302b2241ee6d4e209916d02969566345_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie90622151f5e4db4a3a49e27eba46371_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:PharmaEngineNBTWR3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ConcentrationsOfRiskAxis">nbx:RevenueByTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9557dec5d8804e348756bbd9f050ae89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62e1ab97b0f340d2806afa0a17c159aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:NonDilutiveFinancingAgreementBPIFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2be74eb72584233979cc9db5230eafb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i835b7224a73b4426b167298dea1d3004_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i408716a3b82f46e08e6b6d3596e1b7c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib14b8fcd297d44c2b25d620752b4cc83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">nbx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff6c0684a6ed4d3e8d05a4ad259e7b4f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08cbc41147294b6ea9fed577e2d2ba27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcca4f14254e4036b189591f841d06e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fb9374b2e884918a3005c23955386db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0017336596444f75835cadbb51aedd4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i80e4592fbfd14066969841772071af84_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="id607143fbf804fcb95f3a7824923bd6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15b60bdf71454ad2b8b8f960988c0487_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i189db34738f54105b56656b53ef3d1c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30d417b93bee43c780915df01c38d487_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ibabf9bb1fb1a49fbb1705b814228871c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="id0da65f2ab874878b39ebf2ec076918d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i712e048fe4d145e490466b4059621db8_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i792610cd47d74497aa1f7ab82c8af31f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="i57fee7234b3649239c7682326fc183b4_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-04</startDate>
            <endDate>2012-05-04</endDate>
        </period>
    </context>
    <context id="i131da624a9f34a0ea29bf0fb2176cb5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e6efed0beb6459b810d1467e0c1183b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9862c8deb0544ba80cef9d729d58100_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20121Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-18</startDate>
            <endDate>2012-12-18</endDate>
        </period>
    </context>
    <context id="ie2919f18751144b78569c4161f2e947a_D20121218-20121218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-18</startDate>
            <endDate>2012-12-18</endDate>
        </period>
    </context>
    <context id="i59ef69bbeb80421eb92fd0f71ad1d8e4_D20121218-20121218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-18</startDate>
            <endDate>2012-12-18</endDate>
        </period>
    </context>
    <context id="i0f5b8beea7b64bb286271b8eb038177b_D20121218-20121218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-18</startDate>
            <endDate>2012-12-18</endDate>
        </period>
    </context>
    <context id="ic47716d92fe342deb87045fda3d7f2c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20122Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-04-10</startDate>
            <endDate>2013-04-10</endDate>
        </period>
    </context>
    <context id="i9a43074ca66449b4b97de195d8ec4408_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib461318901ed4fe7a3b3fd7d2eb455e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfbec539f6234dc4ac97bed76d788c2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE042013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d6ba050064a421289ccace20cb9938f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE082013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i529aac24770b44a3a7b925fc089a42f7_D20140916-20140916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-16</startDate>
            <endDate>2014-09-16</endDate>
        </period>
    </context>
    <context id="iea55eafbda0d41bfa15182895fad5428_D20140916-20140916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-16</startDate>
            <endDate>2014-09-16</endDate>
        </period>
    </context>
    <context id="ibb6b9590e1084b969feeba3744fac7fa_D20140916-20140916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-16</startDate>
            <endDate>2014-09-16</endDate>
        </period>
    </context>
    <context id="i4d028643a8ae49cb91443fcb6667aff4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE092014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0cfb0e0616fc451db5120b69a2855aef_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="ieae0ae0f0de24a7a8c7909960e7edc97_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i31d2e2aabd79424b9ff15157a58c2098_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i1a361874f01d45dfb381dace0aaa6dca_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i3149d9f29e6948679668c8902a58d1d1_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i6508d90ca7934d8a8c8c500934137220_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i84c141fe66774426ab927cbccd1a4268_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i1cedf3438b9b490a99a1bdf2d42f0411_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i3b9cdfe23729475a93bb7b74d4885975_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i2c4b9ce0de6e4e6eb552cbf8fa6227a2_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i9f5242dc069c466caf5e1c7529c26b46_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i5b7e511fc9c144a38119eb439ec44e9f_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i207651a4998445daab53f905e5da87aa_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i0567406eef544202ac9f21ae3e4dedaf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2278b3270e54cd99a22052840e92c05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91baa8cdfc354286a5178aa94929c1b0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21f6266a6261424cb3701521e5a643bb_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="i39b343cc43b1488fbabbaadbf30a57c5_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="ia126f4a85d5f4a6c89bd72f4726e6886_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="i4349ffd9c31d4d72afb2c3d5558ef0ff_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="if88984bd12b3495c88bd5037ff1a7d37_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="i4a26e567a53c4044a0c3a2ccdad0fc3f_D20150610-20150610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-10</startDate>
            <endDate>2015-06-10</endDate>
        </period>
    </context>
    <context id="ia1b746c0ab7b412ca2b2dcbaaa72a86a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE20153Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf7662da67c64289867d340b367149ab_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="iee4d7149ad404f968cc08e4aef7c0075_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i9b964e599c664b8cab5e656560b104ce_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i0a861384c2b240cc81036e74e3cc65b5_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i774ea0f18ade47cc86a9a59b81faa563_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ie2fc173db3ba4df1afee089ed2af09e3_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="id2b41add39c641428eeb18e53a36b901_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0bf0cda381de45b4a117fd8996ba9e9d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i847617a0623e4f41a7bb7506d0ec32e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i329a6fa2c67c4bac97fd56ac1b9a7dfb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id634b4f13485463ab1d7a2134ff28cf9_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ie0299ef3d2b54641bfbea01d292269b4_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i7e8dd4ad27014b778bbf05ed702bbdc5_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i813aa1603ff64691b4654fe399d47cc0_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ia0363e72665149cf92fa348abb499297_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ia8f32dfa54044567a9386587ef6bf4fd_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i8e6fe4ace1c746f6a6dfb0b6c92cabd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01c0ec932c6f41ba9b4f8939121b36b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f5763ec171d43428a511bc2c311c914_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0a7ff6bb25f4c1ab55f70225cff85dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if1544d3f2c5e499b98da7226782ca2be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i03089c18f63c4ac8a3762b696eec3b39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icefaa359b31741c8b95cb9bf016ef953_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fa4bf2f58fa428f93dd6a7a167a2f65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCE2017ProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSPCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ae9590b9fe34d0fb673e82af470816c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA0412Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15bc4af9395b4f90b4d7b6e26b0c54be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i702ec3ead1cd4f79b60cc12b87ee7e11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifa0befb495f44c12ba65c30bf98111ac_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i52c574e42a78453ca42bf37f9baff97a_D20150210-20150210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-10</startDate>
            <endDate>2015-02-10</endDate>
        </period>
    </context>
    <context id="i1c7eb6413b784b03bfd43acb963cb132_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i473116fa095c422aba3d6c699591faec_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="if70f79e4689d4c54bb89ab61ff89be6b_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i67dd5d3865134117a9b633b2f3f00560_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i9f1d34c3fdac49f49c878cd386025fdf_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="ibc916f578f474fecb4f9f2502dbc7c53_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i7a8b1058bf864a27b1cf4a2fe6482f13_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="ide4f2071f6814b1e98aebb47c96b9621_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="ic807dce5e3d345bcbc42d29872af83fb_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i985db50e042a4e9c97fffbb93177626a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2749bb6daaa74679a776487c8f281567_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i207347ba76db4b1193a91409ae7c99f1_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i3d07ad7bcbd0459cbefcedfd8f8f334d_D20150625-20150625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-25</startDate>
            <endDate>2015-06-25</endDate>
        </period>
    </context>
    <context id="i4e0d58d5db0f4384894e4a99e7d095a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20152BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6e6b9424288f466c8a47cebae0ec48a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a9a5316762943d8affcd949d696ec10_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i433bcdf7285544c9bc5810b1f42b26a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b3ff9b9323446e5971e03c82d1e528a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2016PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34873da26ebb48f083c0f122691b5ad1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie75d48a141ae4d8fad1403660910f20d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6aabc8c23a414a9db5e4f5a8bc2f1f48_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="ic15526fdee1e4d91b1d5060f8b0f7568_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="i48621182e8c349318f629a81af122a57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d75b447af424ab48bcfec52ab34781a_D20180727-20180727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="i5f33f50e592545199d2ce53e53f832e8_D20180727-20180727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-27</startDate>
            <endDate>2018-07-27</endDate>
        </period>
    </context>
    <context id="i62055563f69f41f7a159c6147a4b0329_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89b752f6985348a1aa563e64204c8eb8_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i4cecda26bbe64fd28d73f2e4da6b44d3_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i9710c7a719da4648bd568199fecfdacd_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i14e94260ccc24cbe9513a3b50f37537a_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="iaf10e5b531374a0e9d6f2b724723372e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icaf550bcce0b41ffa51ebe138b5a4a4b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6007079e0504a6db30cf3d75e896d43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96cf2e24893f48c0896bad782974579f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021AMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia4ca2c02a4834134bc70d6a0b83f4207_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74b41d660ccf4571b36b582d24ff5ff6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2021BMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i3ee4337742624978b8797907bce374b5_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ib2d89fd172a24e52a024851b281acab3_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i4ca7f4263bac419496f22afb16380f23_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="idae657f1c9494ab7bdb98d4f741e4ce0_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ic968a488e1214d2d8c4c849a19ca99b6_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="ifaea4d6cd48f4720982f886453404978_D20160202-20160202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-02</startDate>
            <endDate>2016-02-02</endDate>
        </period>
    </context>
    <context id="i3c58f2d20a0a4f05982535c1b79a1d17_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5376aaec1d46476289ea3b5ba880bbca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i600323d428624ba1bb39688b7d1835c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52e9a19f5187490e9f895ee7d396fa92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8f126d516ed4651b3e072805f960c62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20161PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e278299ecb14d3b90fa008334cbd38d_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="i95d3653f8d5c496bb69df2a4c27ce1c8_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="i72b78d4a9e1549888d151cde77a2ef7a_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="i8aadf58558ae4edfbdbd94aeefe4c495_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="ia55c037dd3314b7f8276f447908d4668_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="ib9512072caa04e9ba888206ac0507aad_D20161103-20161103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-03</startDate>
            <endDate>2016-11-03</endDate>
        </period>
    </context>
    <context id="ib3fb2391fd144d51a52e3aa90706b6f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fcc7ccd6a81428d9ed0e09d57d5a084_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i9d85d406740e405b90ed84914b379490_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ie3527d165f9d4cd5aa38b20a8500d946_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ifa4fccf9efb24a25859f2060793c20e4_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="id1d0968247324343b41e1174b2637006_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i67fd7c980ffd4542aa22782c5e050c9d_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="i368408c4bd784fc5bacc7ae16ca08d7b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40ac6393cd9348b8823b3228b7eee05a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-07</startDate>
            <endDate>2017-01-07</endDate>
        </period>
    </context>
    <context id="ie5101486495a4ef5bd91b420accb232e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3b377dbf1f5453dbe7f2e047889e4ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b885452a1484ddd888ac4daf4dd2ef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2017PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36ceeee7f4fc47d5b756fb41d517c7f5_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="i62d4aa90997f4e6c8c19980dc74f6f5c_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="i2f5d8be3215b43c697cda5e740dce757_D20180306-20180306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-06</startDate>
            <endDate>2018-03-06</endDate>
        </period>
    </context>
    <context id="ibb23c53c4def4af9ac2648225e92fe29_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i09ca631b3e9147edadb169085675ab89_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i198c812116bc40eba4d502226fd16032_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i394793f80d274291b22ad542c6d2abd0_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i1dda9fb982e1491e90a9fcf99f478e19_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i5200a128866a420b84b1e760ddad6401_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i71ced96080c741eb86c560c4806b4bac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSALLY2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b6f2878993e468fa6f8eb36906b91de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i6f36fa16350140b9b69fe1134da42b69_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i96c93a64b4574a449d4ad5addda19ec0_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i73558c5663be437689199c827a5964f1_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i276bc4fd1a094b3088274297dda73e5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b03d50b925f4ccb87f9715164ee45dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie14e3a19e1d44a86a04438f03dbba7fc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2405c669e044cb79852038f6f907b3f_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="ib3d2e17f384646f2a195144983cd8b67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i623bf93a1859415a8a96f48101b40599_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91bd49a836ca4a4cb9e32546a222901f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202104PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="idf1059b42ec64434bd92678ec7a69180_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i3a0277fbafbb433c94c83dbacd512259_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i1da41881e01c4b918d3d6023763371d5_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:VestingAxis">nbx:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="i0ae10134a55c4ec0bfa8de540a4fa154_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f4fab534e274a858c234a1f5128ae78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i954ef2ab820e48b5b6d82b3be204467e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106OrdinaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="ia03d50617eac462d8a56b671789e4d10_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibab950c0a8e24aae8bb9c60287630006_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b51e3ab383942a5aa13a3c61bfd07b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSA202106PerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:OSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if4d1dc40ee294a4eb862a754e1a7b7a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6244d605e7d349cd88cc8c11756f1c6c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20182Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b3d45ed49f246078f98c1da6b744503_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="i43664a271eab453f8088849ba1fb58f7_D20190329-20190329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-29</startDate>
            <endDate>2019-03-29</endDate>
        </period>
    </context>
    <context id="ieb041ec28cd441c8a5a4283ac0d8d07d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f726d12be094192a3269413d8216aaf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdea060a980d42ec8049515011a575c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6340f94bc5146cd810b425747377b1d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e5a3763fc65486f85e8d7953a8d5b82_D20200317-20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="ie13f58ebae684d3a9931caa0b61af23e_D20200317-20200317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:BSA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-17</startDate>
            <endDate>2020-03-17</endDate>
        </period>
    </context>
    <context id="if631599c27df453a8c0ab011671a4c75_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="ib1ee66f5e8304133a7dea90f9c6c7899_D20200311-20200311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-11</endDate>
        </period>
    </context>
    <context id="ic9fa057bcb1a4c2e9c49ddc99225a69e_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="i61ac332477d243c19cdd74fe9fc3ff31_D20210420-20210420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:TranchesAxis">nbx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-20</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="icf7abdd665664906840a18afc4669ef7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a6010c7ae114b0cbe67c4bf3c2b2d79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8972928b2f3477aa4ff40a52480c1a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i095137ac480d4189b8d3e9c4120fed6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbaf4b30ae8c4e248d5a4b78dcced4ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3bb2c3901cc8428a999595204c3b6eb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28327906e6194ba78e2313551bf12bd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d12dbc4d05a4a798e08dead85d18b91_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c9f1e5116224a2e8a73cd903766f102_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8c1e08d0df7b47f394f08a0c2faeffba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21e5c44a32c64f1d93ae818113e1b5ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i958be4f23f454d25a7eb235f2588e9a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f7d1edd94224299addbda5de426a08d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nbx:EuropeanInvestmentBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06cb4ce5915c4e4d828fd72b9468368d_D20190101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:MDAndersonCancerCenterNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nbx:CollaborationAgreementAxis">nbx:TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="i58b267957c564e22a8fe73487217730b_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="icae5cf18bb21492a86c074c63258fe60_I20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="i2d7bf6f87d6c4461a273858821e7fb90_D20220311-20220311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001760854</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nbx:AGA2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="study">
        <measure>nbx:study</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="parent_entity">
        <measure>nbx:parent_entity</measure>
    </unit>
    <unit id="subsidiary">
        <measure>nbx:subsidiary</measure>
    </unit>
    <unit id="patient">
        <measure>nbx:patient</measure>
    </unit>
    <unit id="lease_contract">
        <measure>nbx:lease_contract</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>nbx:employee</measure>
    </unit>
    <unit id="tranche">
        <measure>nbx:tranche</measure>
    </unit>
    <unit id="quarterly_instalment">
        <measure>nbx:quarterly_instalment</measure>
    </unit>
    <unit id="borrowing">
        <measure>nbx:borrowing</measure>
    </unit>
    <unit id="factor">
        <measure>nbx:factor</measure>
    </unit>
    <unit id="plan">
        <measure>nbx:plan</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV8zLTEtMS0xLTExOTk5_1dda997e-375e-4d4e-9d67-b5330f3c7f78">0001760854</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV80LTEtMS0xLTExOTk5_bbe421ef-295e-4355-9fbc-d40c1018f705">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV81LTEtMS0xLTExOTk5_b4f6ecbb-c5e3-4bb1-86ae-1b2843116d39">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV82LTEtMS0xLTExOTk5_a6f32501-1ca2-4bd9-8f54-2bfe222b12d9">false</dei:AmendmentFlag>
    <dei:NoTradingSymbolFlag
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl80L2ZyYWc6MGJjODM2OTRiZjU0NGZhZWIzZWU1YjUxMTNiMGZmMTkvdGFibGU6ZjI5ZjE1ZDE5M2NmNGZmYmI0ZTI1M2FhNzllNGFmZjUvdGFibGVyYW5nZTpmMjlmMTVkMTkzY2Y0ZmZiYjRlMjUzYWE3OWU0YWZmNV83LTEtMS0xLTgwMTUy_64867d8a-0129-4f1f-aa8f-bfb5118d230f">true</dei:NoTradingSymbolFlag>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="if17a2f2e90aa4abfa844349f8bbeffdd_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NDI_b6d1ab61-248d-489f-b8db-8ba6f3e01cd0"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="id8d3dbb65e224379b7a93e55ca7be0c4_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NTc_d8adfe99-3e02-48e9-9c69-e1e3dbc80b5b"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="if2dd11d82dad4017b9e787f657b62484_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzMyOTg1MzQ4ODU1NzI_d1597e81-3e58-49ac-b721-28d4a5009159"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i9ca1834853e14961be45fc7a1f5a71d2_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzY0_d9b20358-8953-4463-9179-9d7adb90635b"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i3980c93822e74e5291bc063308f06aee_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzEzMw_2ef548ad-5852-4638-8e16-835d4d6b527d"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i3b902764e68a4c7ca60c0b4162e645fd_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjMvZnJhZzoxMGY2NTIzNzc3MjY0OTY1OWE2OWY4NDlkYzk3OWJkMy90ZXh0cmVnaW9uOjEwZjY1MjM3NzcyNjQ5NjU5YTY5Zjg0OWRjOTc5YmQzXzIxMQ_06992599-c9eb-46ca-a946-bf14f87f19af"
      unitRef="number">0.3333</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:DefinedBenefitObligationPayablePeriod
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzk_e3c5a367-0c4d-4262-b3f1-35ea622dad92">P5Y</nbx:DefinedBenefitObligationPayablePeriod>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i0e5a3763fc65486f85e8d7953a8d5b82_D20200317-20200317"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzEz_3bc3b12d-83c6-4365-8b9c-0ddaa7d9e357"
      unitRef="number">-0.0013</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ie13f58ebae684d3a9931caa0b61af23e_D20200317-20200317"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzE5_5a737926-08c9-4448-b678-9588fb8ad5dd"
      unitRef="number">-0.0007</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0NjM_3528a10d-8dc7-41af-9286-357ec34972e5"
      unitRef="number">-0.0038</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0NTU_f4629138-ffe6-4e7f-a972-88b7a840dd85"
      unitRef="number">-0.0033</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1NDY_77cd5865-102b-4753-89dd-1a6200edff3a"
      unitRef="number">-0.0028</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0OTc_17f17278-681c-4b4a-9d47-5f87085e2fea"
      unitRef="number">-0.0035</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1MTI_7d366768-49b0-4a41-b3e1-48475e35e611"
      unitRef="number">-0.003</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM1NjE_b5a1c3ca-69f3-4049-bbd8-47de4850cb2b"
      unitRef="number">-0.0026</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="if631599c27df453a8c0ab011671a4c75_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMy_cfc2bd88-f5f7-4ec5-bd34-decad6d14f85"
      unitRef="number">-0.0074</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ib1ee66f5e8304133a7dea90f9c6c7899_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzM4_532341f7-df2a-4a08-93aa-46f7d933d173"
      unitRef="number">-0.0069</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ic9fa057bcb1a4c2e9c49ddc99225a69e_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODMzOTY_1dbd6775-0578-4491-8c93-d78c2d2d8037"
      unitRef="number">-0.0063</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i61ac332477d243c19cdd74fe9fc3ff31_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODcvZnJhZzozNmVjYjJiNWZhM2Y0YmQ5ODdiNTg0YWU4MWEyZDk5OS90ZXh0cmVnaW9uOjM2ZWNiMmI1ZmEzZjRiZDk4N2I1ODRhZTgxYTJkOTk5XzMyOTg1MzQ4ODM0MTE_5f8c6b5a-dd56-4360-86b2-e989dff768d4"
      unitRef="number">-0.0059</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <dei:DocumentType
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk4_7219d0c2-b2ee-4b1e-9edf-ad25bb356950">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8xLTAtMS0xLTExOTk5_76ada55c-22a7-4211-a212-c03d36f6cd87">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTAtMS0xLTExOTk5_4dec6b62-03b8-4a5f-89be-01f081cfeb22">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTEtMS0xLTExOTk5L3RleHRyZWdpb246YTQ3NTY2NTAzMjUxNDQ5YjgyNjczOTM4NGZiNmJjMThfMjE5OTAyMzI1NTc5Mg_603e3f6c-c540-4b11-8f74-786029e60493">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8yLTEtMS0xLTExOTk5L3RleHRyZWdpb246YTQ3NTY2NTAzMjUxNDQ5YjgyNjczOTM4NGZiNmJjMThfMjE5OTAyMzI1NTc5Mg_ed1d81a5-6578-4090-825e-add257b7d640">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV8zLTAtMS0xLTExOTk5_3b4cece5-ffaa-434f-9ad1-738a86e068dc">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6ZGViZTI1YThmNjM2NGZjZmI1NWQzYTE5N2E1NzI1OWUvdGFibGVyYW5nZTpkZWJlMjVhOGY2MzY0ZmNmYjU1ZDNhMTk3YTU3MjU5ZV80LTAtMS0xLTExOTk5_73ea32d0-61b3-4957-b278-7f8cfd5850f3">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA5_281546a2-3afc-48a2-90db-bd85403239b1">001-39777</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzEx_af4d249d-af2d-401e-ae77-d69093e34186">NANOBIOTIX S.A.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njkz_1dbb6e45-f2b6-4e50-a521-cccf8b75153a">I0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAw_4d838404-1a51-4ae6-83f5-90dd158c24eb">60 rue de Wattignies</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV81ODY_9b09a36f-6d38-4229-9cc3-656aa506c286">75012</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njkx_bd9dc867-07d8-46b6-9b4c-0e4407829965">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAx_46208eab-51b9-4df2-9210-947fb74f8987">FR</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA2_b22a3992-d951-428e-a30b-096ee26b1eb6">Mr. Bart van Rhijn</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA3_b22ff745-31c9-4938-9d2f-4d31c80f2302">60 rue de Wattignies</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV83Mjg_62b6f154-b6ef-4d9a-bc29-ece446f3bed7">75012</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk0_0b34cb4a-f76e-479f-a126-79e1ac402637">Paris</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzEz_40f1f669-55fc-4da7-b81c-14dd2b2af960">FR</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV83NTE_8a909b34-954c-4e20-b270-cd4a65006420">33</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzA4_8a771207-c837-497f-ab8c-a26f85fb7474">(0)1 40 26 04 70</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="i38576a2316924bcc8e920e926fb75d11_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk1_43ca0425-535e-4e4c-9123-6f282ec224d0">33 (0)1 40 26 04 44</dei:ContactPersonnelFaxNumber>
    <dei:Security12bTitle
      contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTAtMS0xLTExOTk5_f7e1c218-64d8-4d3d-a124-6cd05a03e0bb">American depositary shares, each representing one ordinary share, nominal value &#x20ac;0.03 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTItMS0xLTExOTk5_ff5c2248-3016-4b2a-9904-4b96234fc2cb">NBTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1e1a07f6d9bc4302b4f94f9c1a4bd97e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18xLTQtMS0xLTExOTk5_f6a8bbc3-6c14-4b91-8a3d-4f94b3f78f05">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18yLTAtMS0xLTExOTk5L3RleHRyZWdpb246YjhjZmU2NzUzZmMyNGZkMWI0MDNlNzAzZDJkMGZjOTVfMjE5OTAyMzI1NTY0OQ_73dd2852-eac9-4c86-a897-323aef20240a">Ordinary shares, nominal value &#x20ac;0.03 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6M2EzNjQ1ZjZiYWFiNGNhYmExODIyYWIyY2RlZWIyMmMvdGFibGVyYW5nZTozYTM2NDVmNmJhYWI0Y2FiYTE4MjJhYjJjZGVlYjIyY18yLTQtMS0xLTExOTk5L3RleHRyZWdpb246NGQwMjRmM2I2YjQwNGFmN2JlMjRlNWM3NmIzYTBjMWNfMjE5OTAyMzI1NTYxMQ_90d967e0-5e92-47d0-b18c-7152f1e5b4da">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV8xNDkx_56ef539f-5e62-4dce-91fd-a7878d5748c5"
      unitRef="shares">34825872</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAy_3162ef92-89b2-4128-b10a-02b80cbabfa3">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE1_a58679d5-0be3-4096-8b11-0d075371e748">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80Njk2_7032f30d-4e97-4f40-9c1c-9f63b9a6f47b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzAz_54a6c375-afb0-4267-bd48-803a3f881a69">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV84Nzk2MDkzMDI3MDQw_b27bcf83-956e-41e5-8405-e52b17c51118">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV84Nzk2MDkzMDI5Mzg2_49b96337-fda6-4d55-9cb8-17c9a938f820">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE2_5be76fd8-d61c-4a39-a47b-ac3971bc9282">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV80NzE3_7ac9a61e-b496-44a2-ba73-cf4cbf5385cc">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGFibGU6OGQ3YzE1YjhiMzcyNDYzYTk3NWRmMDZkYTRkZTkyOGMvdGFibGVyYW5nZTo4ZDdjMTViOGIzNzI0NjNhOTc1ZGYwNmRhNGRlOTI4Y18wLTEtMS0xLTExOTk5L3RleHRyZWdpb246YmYyYjJhMzE4MWMyNDlhMTkzYzVhNWQ1ZDY2YTBlZjJfMjE5OTAyMzI1NTcwOA_e5b48859-1c39-411b-b897-e937e5550a03">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xL2ZyYWc6MmRmNTM1NDRmOTY4NDYwMTlkODBkZjk0YWNjNmEwZTEvdGV4dHJlZ2lvbjoyZGY1MzU0NGY5Njg0NjAxOWQ4MGRmOTRhY2M2YTBlMV8zMTg4NTgzNzIxMjY4NA_09a4baab-4e1e-43c9-861a-d0c20d2a44ed">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMDkvZnJhZzpjZGE4NWNhZThiZWE0ZjEzODhjZGI1ZDNmMDMwMmJjOC90YWJsZTpkMjYyN2MyZjI4MTc0OWRkOGI3YjIzZmU0YzFmYWY5ZC90YWJsZXJhbmdlOmQyNjI3YzJmMjgxNzQ5ZGQ4YjdiMjNmZTRjMWZhZjlkXzEtMC0xLTEtMTAxNzk1L3RleHRyZWdpb246YWFmMTdmYmFjOTNjNDM0OWJmMGMxNDcyOTQ4ZTVhMmJfMTY0OTI2NzQ0MjY1OA_45fc76d1-305b-49d0-843f-09a3fe24a496">1704</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTIvZnJhZzowMTE4MGYwOWQxZGM0MzIwOGUzZDk4NDIyOWUwOTUyOS90ZXh0cmVnaW9uOjAxMTgwZjA5ZDFkYzQzMjA4ZTNkOTg0MjI5ZTA5NTI5XzMxODg1ODM3MjI3Njc5_24fc71aa-297f-4375-9725-e3ea4939fa4f">ERNST &amp; YOUNG et Autres</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTIvZnJhZzowMTE4MGYwOWQxZGM0MzIwOGUzZDk4NDIyOWUwOTUyOS90ZXh0cmVnaW9uOjAxMTgwZjA5ZDFkYzQzMjA4ZTNkOTg0MjI5ZTA5NTI5XzMxODg1ODM3MjI3Njgw_bf33533f-daff-4e5d-8292-70603561751e">Paris-La D&#xe9;fense, France</dei:AuditorLocation>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzQtMy0xLTEtMTE5OTk_5c4b6a21-1ee1-4a51-93ee-70810c3b8c16"
      unitRef="eur">4000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzQtNS0xLTEtMTE5OTk_60257f91-fcb8-45cd-aab8-b880a4c44a7a"
      unitRef="eur">21000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzUtMy0xLTEtMTE5OTk_1c14da3b-06f5-437f-a883-9f3696014ddc"
      unitRef="eur">8186000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzUtNS0xLTEtMTE5OTk_4980886d-9fc9-45c6-a587-db74ed11dfb7"
      unitRef="eur">8256000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzYtMy0xLTEtMTE5OTk_313f9457-f18e-4a42-b666-9782d19ac236"
      unitRef="eur">519000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzYtNS0xLTEtMTE5OTk_29926383-702f-41e2-9d01-d87990e324fb"
      unitRef="eur">505000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzctMy0xLTEtMTE5OTk_163b0901-fac3-48e1-bfcc-10bdcd3a55ef"
      unitRef="eur">8709000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzctNS0xLTEtMTE5OTk_7315f3f5-35ba-404a-8f31-81a3318f7a57"
      unitRef="eur">8782000</ifrs-full:NoncurrentAssets>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzktMy0xLTEtMTE5OTk_5b7a20c1-34da-4b1f-9d60-8102292a4816"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzktNS0xLTEtMTE5OTk_a4916f65-6cf2-489b-9f68-27c110ad3f01"
      unitRef="eur">62000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEwLTMtMS0xLTExOTk5_cc6c2d57-ba9e-4b79-9e86-6b45de571a58"
      unitRef="eur">9139000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEwLTUtMS0xLTExOTk5_f757c235-de2c-45c3-9b8d-ada41c40981f"
      unitRef="eur">6035000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzExLTMtMS0xLTExOTk5_8c458f5a-c329-47ba-a631-3cf98a09f2b5"
      unitRef="eur">83921000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzExLTUtMS0xLTExOTk5_5d470d8f-de94-48d9-b113-ede5f17f2361"
      unitRef="eur">119151000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEyLTMtMS0xLTExOTk5_639e73cd-fb0c-45db-bedf-aa4aec937879"
      unitRef="eur">93060000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEyLTUtMS0xLTExOTk5_e117f349-64fc-4eb3-aaa9-1e9018fc9a58"
      unitRef="eur">125248000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEzLTMtMS0xLTExOTk5_d1123014-6300-49c3-af81-c63e70cc18f1"
      unitRef="eur">101769000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTphYjVlZTRiZjhkZGM0NmMyYjlhZDI4ODY2YjY0YTVkYS90YWJsZXJhbmdlOmFiNWVlNGJmOGRkYzQ2YzJiOWFkMjg4NjZiNjRhNWRhXzEzLTUtMS0xLTExOTk5_10f39f2b-d8b8-4779-8f96-5116aa40986c"
      unitRef="eur">134030000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzQtMy0xLTEtMTE5OTk_73de1033-6d0b-406f-9563-2e59a50aafd9"
      unitRef="eur">1045000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzQtNS0xLTEtMTE5OTk_17e2c251-85d5-41f3-a0bd-6000e9afd4cb"
      unitRef="eur">1033000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzUtMy0xLTEtMTE5OTk_9ab460ad-e546-4a42-9336-75d87b9faf38"
      unitRef="eur">255767000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzUtNS0xLTEtMTE5OTk_bd954601-f734-466f-a3bf-43a57349bf41"
      unitRef="eur">255735000</ifrs-full:SharePremium>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzYtMy0xLTEtMTE5OTk_b1f72463-8f6e-4b11-bf8c-e6910e0324af"
      unitRef="eur">643000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzYtNS0xLTEtMTE5OTk_75f6be93-587a-42c8-94e9-54ac0c1eff22"
      unitRef="eur">555000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:TreasuryShares
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzctMy0xLTEtMTE5OTk_3152f480-c302-497f-9110-8b51b06f63f7"
      unitRef="eur">202000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzctNS0xLTEtMTE5OTk_a067c87f-218a-4a32-95f5-36ef0b0d8e9d"
      unitRef="eur">196000</ifrs-full:TreasuryShares>
    <ifrs-full:OtherReserves
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzgtMy0xLTEtMTE5OTk_6c12337f-56fe-49bb-ac4f-6d428cf08fbe"
      unitRef="eur">-183459000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzgtNS0xLTEtMTE5OTk_9d6907ed-f46c-44e6-b5f7-86126b441761"
      unitRef="eur">-153069000</ifrs-full:OtherReserves>
    <nbx:NetLossForThePeriod
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzktMy0xLTEtMTE5OTk_dafb1352-5dde-4bcc-a112-1ad0ac045a41"
      unitRef="eur">-47003000</nbx:NetLossForThePeriod>
    <nbx:NetLossForThePeriod
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzktNS0xLTEtMTE5OTk_063d88d3-eeb4-411b-825d-5427365becde"
      unitRef="eur">-33590000</nbx:NetLossForThePeriod>
    <ifrs-full:Equity
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEwLTMtMS0xLTExOTk5_592e6a3f-8997-46c7-a383-d1ff42266061"
      unitRef="eur">26790000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEwLTUtMS0xLTExOTk5_c5472aa4-6ba6-45cb-9870-807af1f3f968"
      unitRef="eur">70468000</ifrs-full:Equity>
    <ifrs-full:NoncurrentProvisions
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEyLTMtMS0xLTExOTk5_f67a4521-629e-454d-85bc-f4ffa12220f6"
      unitRef="eur">318000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEyLTUtMS0xLTExOTk5_50e5ac64-b020-4c98-98b6-d1e90ff6f97c"
      unitRef="eur">414000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEzLTMtMS0xLTExOTk5_4945c2f4-c2b8-4aae-a1a0-82c4a110d458"
      unitRef="eur">37816000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzEzLTUtMS0xLTExOTk5_911cab24-ad63-4ff8-b92a-7c8cdc2710ee"
      unitRef="eur">44107000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE0LTMtMS0xLTExOTk5_8e635fad-7433-4bd6-a887-9cc03ea310f2"
      unitRef="eur">38134000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE0LTUtMS0xLTExOTk5_706f5f67-3481-4a2a-be94-e353769aadc7"
      unitRef="eur">44522000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE2LTMtMS0xLTExOTk5_96326dcb-492f-47d3-8937-fcbca45f1023"
      unitRef="eur">110000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE2LTUtMS0xLTExOTk5_22656e51-8296-496a-804b-914f82815c3c"
      unitRef="eur">40000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE3LTMtMS0xLTExOTk5_19412bb0-77f9-4a62-b738-bcc656dac58d"
      unitRef="eur">8204000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE3LTUtMS0xLTExOTk5_9d742a47-7cea-4f51-9e7d-55f71b040f78"
      unitRef="eur">4872000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE4LTMtMS0xLTExOTk5_2499ddc5-6b61-4aa2-93f2-aaa3e5bab61c"
      unitRef="eur">6482000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE4LTUtMS0xLTExOTk5_0fb993d6-90ae-4225-aa65-82965fe343a7"
      unitRef="eur">7106000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE5LTMtMS0xLTExOTk5_b1d3e4ec-84c9-4173-a39d-80badc997ebe"
      unitRef="eur">5531000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzE5LTUtMS0xLTExOTk5_5cc569bc-186b-4792-9a25-259fa0291d5e"
      unitRef="eur">7022000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTMtMS0xLTU2MDcz_7e38b8d7-f67a-4675-9061-fe5fc077cb66"
      unitRef="eur">16518000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTUtMS0xLTU2MDc1_63b77ef2-8a01-467a-970b-d90e0e667436"
      unitRef="eur">0</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTMtMS0xLTExOTk5_2fb68df5-5696-4841-b7c4-06d6e454526e"
      unitRef="eur">36845000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIwLTUtMS0xLTExOTk5_67b6465f-1372-4990-8447-5609bb257d18"
      unitRef="eur">19041000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIxLTMtMS0xLTExOTk5_268f6557-f845-4ca0-81aa-b3fd14a02bb2"
      unitRef="eur">101769000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTUvZnJhZzoxM2UzOGRhYWM5OTQ0Y2Q2OTQ4M2JiMzFiMDQ0Y2E0Yy90YWJsZTpmMmJiZjhlZjc5NmE0MWUyYjEyNDYxYTRkOWE2MDUxYi90YWJsZXJhbmdlOmYyYmJmOGVmNzk2YTQxZTJiMTI0NjFhNGQ5YTYwNTFiXzIxLTUtMS0xLTExOTk5_20b2e5c6-cc1a-4f11-a5b3-e02d633ff2b3"
      unitRef="eur">134030000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtMy0xLTEtMTE5OTk_dc1ab5c6-99b4-416f-940f-6847f6908b38"
      unitRef="eur">10000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtNS0xLTEtMTE5OTk_964ff7e5-745d-4186-af97-b8dd09aadf6f"
      unitRef="eur">50000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzMtNy0xLTEtMTE5OTk_d317ce1c-8805-4868-8e6c-36f3400335fd"
      unitRef="eur">68000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:OtherIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtMy0xLTEtMTE5OTk_09d32c2a-a81c-4e4e-bb6b-8dcdec3e68d6"
      unitRef="eur">2637000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtNS0xLTEtMTE5OTk_17f28db1-1196-423b-b98a-fc5e1232d8f0"
      unitRef="eur">2462000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzQtNy0xLTEtMTE5OTk_aa334842-6756-491c-92e3-4cf9c6f7b5ff"
      unitRef="eur">2473000</ifrs-full:OtherIncome>
    <ifrs-full:Revenue
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtMy0xLTEtMTE5OTk_4372f900-ea7b-4cb8-8c36-9c79d1f86b94"
      unitRef="eur">2647000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtNS0xLTEtMTE5OTk_7d6024f5-1309-4779-9108-7676943c98fd"
      unitRef="eur">2512000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzUtNy0xLTEtMTE5OTk_c25dd5d5-9670-4eb9-91e4-f8d4d3578acf"
      unitRef="eur">2541000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtMy0xLTEtMTE5OTk_a0da21ae-91a7-4c0f-90f2-e04156552701"
      unitRef="eur">30378000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtNS0xLTEtMTE5OTk_af8febf4-30b4-4f6f-bb69-cc06db04d192"
      unitRef="eur">24330000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzYtNy0xLTEtMTE5OTk_5aafb4c9-ca62-464a-9d2f-dbf872883a48"
      unitRef="eur">30411000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctMy0xLTEtMTE5OTk_50d124af-f867-4e35-b212-676af53603c9"
      unitRef="eur">19434000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctNS0xLTEtMTE5OTk_8a0d3aba-8a63-4c38-b083-77a33662c0fd"
      unitRef="eur">14611000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzctNy0xLTEtMTE5OTk_3a5f583c-d1ba-4601-9277-22cbb9884c5e"
      unitRef="eur">18909000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtMy0xLTEtNDE5NzE_80f5acb8-197b-4a69-a2d2-bff5737fa99c"
      unitRef="eur">-5414000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNS0xLTEtNDE5NzQ_41e40d66-1d4d-4a08-b9e6-e8d5a6d17dee"
      unitRef="eur">0</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNy0xLTEtNDE5NzY_44dbbd63-36ec-471f-9b78-0e93299a95fd"
      unitRef="eur">0</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OperatingExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtMy0xLTEtMTE5OTk_30c72dc9-2170-4e48-8065-0b45560745e3"
      unitRef="eur">55226000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNS0xLTEtMTE5OTk_6e92b38e-34e7-46cf-a6cf-496e41e6b2a7"
      unitRef="eur">38941000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzgtNy0xLTEtMTE5OTk_828ae11e-13a9-4f9f-b022-651c281155b8"
      unitRef="eur">49320000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktMy0xLTEtMTE5OTk_95492a31-5988-4335-ad9e-51bf3655106d"
      unitRef="eur">-52579000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktNS0xLTEtMTE5OTk_2808e368-3597-466b-bd2e-bdd8f51cd2c2"
      unitRef="eur">-36428000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzktNy0xLTEtMTE5OTk_73a75a3d-dc9d-4aa1-a673-715629b8c6d0"
      unitRef="eur">-46779000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTMtMS0xLTExOTk5_d565f462-7718-42cf-9c0a-75dcfb81347e"
      unitRef="eur">6360000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTUtMS0xLTExOTk5_a21c1cb1-b587-41ea-a6e9-2c270bce4a67"
      unitRef="eur">201000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEwLTctMS0xLTExOTk5_1dca2eb0-2b93-4e2a-a043-d60ed05df710"
      unitRef="eur">837000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTMtMS0xLTExOTk5_ad2f511e-ae95-43e1-8528-7aa2043cfb81"
      unitRef="eur">780000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTUtMS0xLTExOTk5_009f0be3-2d90-4086-9fe4-52401785b5b7"
      unitRef="eur">-2646000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzExLTctMS0xLTExOTk5_52fd07df-95c5-4ab0-8196-ffc0643bf122"
      unitRef="eur">4970000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTMtMS0xLTExOTk5_f0b166d5-2d70-44c9-afa6-12e930827361"
      unitRef="eur">5580000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTUtMS0xLTExOTk5_dfb2da7e-23a5-445f-81ca-6332c726ebfe"
      unitRef="eur">2847000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEyLTctMS0xLTExOTk5_962c21b9-0118-41c3-a5dc-07511ed69f65"
      unitRef="eur">-4133000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTMtMS0xLTExOTk5_f3fb85f7-4203-480d-98e3-ed5152c64d60"
      unitRef="eur">5000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTUtMS0xLTExOTk5_4c67dec4-513a-4b95-b325-c11d129a168b"
      unitRef="eur">9000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzEzLTctMS0xLTExOTk5_70ca0841-87a0-4de6-856e-70a6e15fa084"
      unitRef="eur">3000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTMtMS0xLTExOTk5_eb83a53d-af7e-4996-b7ba-57f6994dd227"
      unitRef="eur">-47003000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTUtMS0xLTExOTk5_e136f06c-665e-4f87-a97e-6e757e78898d"
      unitRef="eur">-33590000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE0LTctMS0xLTExOTk5_e51bfa38-f665-4396-8438-8ec219bcd467"
      unitRef="eur">-50915000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTMtMS0xLTExOTk5_559d3ba4-8d2f-4656-b14a-d6c153825f9e"
      unitRef="eurPerShare">-1.35</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTUtMS0xLTExOTk5_bbae062b-e39e-4dca-8e83-bc290d478f5f"
      unitRef="eurPerShare">-1.38</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE1LTctMS0xLTExOTk5_1129da95-20bc-4bac-ae22-d9ec7cc8d7cc"
      unitRef="eurPerShare">-2.35</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTMtMS0xLTExOTk5_8fb61338-4b1a-4561-8478-f775caf7a8d5"
      unitRef="eurPerShare">-1.35</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTUtMS0xLTExOTk5_06466f9c-455f-42c0-af89-78eba7f3eb1a"
      unitRef="eurPerShare">-1.38</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMTgvZnJhZzo5MGJhYTk5MjkxNmY0OGFhYmE4YzQ2ZTY3MmM5ODZiYS90YWJsZTphMzZkNzc4YmM4ZDI0OGYxOGZhZTU3OWIxOTUwM2NhOS90YWJsZXJhbmdlOmEzNmQ3NzhiYzhkMjQ4ZjE4ZmFlNTc5YjE5NTAzY2E5XzE2LTctMS0xLTExOTk5_030e7e3b-6cc7-47df-89b9-7da068e9e4c4"
      unitRef="eurPerShare">-2.35</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItMy0xLTEtMTE5OTk_2f853355-adf6-42c9-bcb3-714b187ac4e4"
      unitRef="eur">-47003000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItNS0xLTEtMTE5OTk_2076c25c-c84a-469e-b95d-5e62008923c3"
      unitRef="eur">-33590000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzItNy0xLTEtMTE5OTk_8655ea2f-6f4c-4c6b-9c8e-879e58f9fa82"
      unitRef="eur">-50915000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtMy0xLTEtMTE5OTk_e408ab9b-6d29-4534-bbd2-213bf82194bb"
      unitRef="eur">182000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtNS0xLTEtMTE5OTk_9e1150fb-f0f0-45f0-9bfe-5125ef71ea85"
      unitRef="eur">-4000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzMtNy0xLTEtMTE5OTk_8ca670f0-09cc-47c6-8524-57f28b4546bd"
      unitRef="eur">88000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtMy0xLTEtMTE5OTk_3b1bbc83-ce8e-44b5-b9f1-fd832e165aa6"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtNS0xLTEtMTE5OTk_ea2b10a8-7a53-40dd-9416-3a745271e97d"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzQtNy0xLTEtMTE5OTk_27883b34-6fc5-42d6-9935-5f55daeb32fd"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtMy0xLTEtMTE5OTk_e1583cde-3cab-4943-846b-858f4663ab61"
      unitRef="eur">182000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtNS0xLTEtMTE5OTk_82828682-0b53-4a9b-bb08-d8aab8c68458"
      unitRef="eur">-4000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzUtNy0xLTEtMTE5OTk_f415ad59-8d3c-41d0-a8a7-df7e669af8d5"
      unitRef="eur">88000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtMy0xLTEtMTE5OTk_500331c9-91bf-411e-a954-2a38b3265a3d"
      unitRef="eur">-94000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtNS0xLTEtMTE5OTk_f4e9362e-5056-472f-b07b-eae86c206974"
      unitRef="eur">125000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzYtNy0xLTEtMTE5OTk_db119ef5-e5fe-4185-a00c-10db4ddec6be"
      unitRef="eur">-36000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctMy0xLTEtMTE5OTk_a878edcd-4555-43fb-a3da-a7b15a3cb561"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctNS0xLTEtMTE5OTk_f7aa85c3-f558-4843-bed3-8114790ac8d5"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzctNy0xLTEtMTE5OTk_fb320636-84e5-42ef-828a-8a8457734a92"
      unitRef="eur">0</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtMy0xLTEtMTE5OTk_f8269794-d6a3-4704-89b1-6a4d9f423ac9"
      unitRef="eur">-94000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtNS0xLTEtMTE5OTk_27a63369-1e26-4f65-92e0-bb224a098fc7"
      unitRef="eur">125000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzgtNy0xLTEtMTE5OTk_c633309d-7f6c-48cc-a3ad-fa93f6a12dcc"
      unitRef="eur">-36000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktMy0xLTEtMTE5OTk_f0e88a81-e6e4-486b-8b33-e42767e5d881"
      unitRef="eur">-46915000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktNS0xLTEtMTE5OTk_90683383-9e79-483d-805a-face9e2d7ed3"
      unitRef="eur">-33469000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjEvZnJhZzpjMWRmOWZkNjNjMDc0ZWVlYTVmYjYxZjcwNDNmYjAyOC90YWJsZTozYTNkMGY4MmUxYzY0ZmE5ODM3YWFiYzE4MGEyM2FjYi90YWJsZXJhbmdlOjNhM2QwZjgyZTFjNjRmYTk4MzdhYWJjMTgwYTIzYWNiXzktNy0xLTEtMTE5OTk_9be3be9d-1697-45a1-896a-d13f48c8fbcb"
      unitRef="eur">-50863000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ief56ec2bd42a44a6a729bc2731655345_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTItMS0xLTExOTk5_41854b91-e8dd-498f-9acc-fd77e0fbd636"
      unitRef="shares">19633373</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="ief56ec2bd42a44a6a729bc2731655345_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTMtMS0xLTExOTk5_7d71070e-ab59-46ba-a3a8-001ab6ef67d6"
      unitRef="eur">589000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i120ec80e331e46b4a8d8c2e900c322ce_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTQtMS0xLTExOTk5_f856a28d-8487-448f-ae8f-3d0e588ebc00"
      unitRef="eur">122799000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ib9dafc6f49b842eab8640526d732bb38_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTUtMS0xLTExOTk5_dbb8a8d3-8aa2-4982-b22f-5fe25c3984a0"
      unitRef="eur">381000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i086600f2d4fd4f29b9e0175fa9980649_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTYtMS0xLTExOTk5_465fec94-7a1b-4111-afac-6326eb45fe45"
      unitRef="eur">-124000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i215f01165ded46dda75650b910df1253_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTctMS0xLTExOTk5_2fa01c80-04f4-47f6-9c41-6cc1c6e42a2f"
      unitRef="eur">-79057000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="id5767bd39bba43819d6569d194f2f1d6_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTgtMS0xLTExOTk5_0f7f013d-51f7-4710-b4aa-3a47fea3202a"
      unitRef="eur">-30345000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifb077c12bc264a7ab30586528053d5b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEyLTktMS0xLTExOTk5_0b9233f7-ae6a-4762-95f6-279f526e182d"
      unitRef="eur">14243000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEzLTgtMS0xLTExOTk5_642d429f-c1fb-45c3-8e7e-9641fc92ec40"
      unitRef="eur">-50915000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzEzLTktMS0xLTExOTk5_fc924b51-08a6-4d90-8c42-23e64c8f30d4"
      unitRef="eur">-50915000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE0LTUtMS0xLTExOTk5_14b4a48a-512a-4479-b066-62e76a2d7f55"
      unitRef="eur">-36000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE0LTktMS0xLTExOTk5_cd66a73c-d115-4cef-ab63-5103b8b1d6fe"
      unitRef="eur">-36000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE1LTUtMS0xLTExOTk5_5ca1a511-98fd-41a6-82c3-10dc9d9bcca4"
      unitRef="eur">88000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE1LTktMS0xLTExOTk5_cd3af095-bfd3-4e86-a4e9-698060cf5aaf"
      unitRef="eur">88000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="i0deb2170f5194f58a2cb110d33b08a8a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTUtMS0xLTExOTk5_0b081a5f-5ab6-4cec-bab5-680b14f4af3d"
      unitRef="eur">52000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTgtMS0xLTExOTk5_4f37ffe1-e595-45a3-aebf-481ef5f6771e"
      unitRef="eur">-50915000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE2LTktMS0xLTExOTk5_5862ea2b-8a9a-4974-bec4-3cc70a67b5cf"
      unitRef="eur">-50863000</ifrs-full:ComprehensiveIncome>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTctMS0xLTExOTk5_b916ba93-3cf8-4d63-b497-2071a8093744"
      unitRef="eur">-30345000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i0f8e9d96a5fc48e198d5d485e3674dde_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTgtMS0xLTExOTk5_cdf783a3-8cad-40d5-b106-8fa420f9e35a"
      unitRef="eur">30345000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE3LTktMS0xLTExOTk5_85adcc32-9042-48d7-9257-ef4d2123c688"
      unitRef="eur">0</nbx:AllocationOfPriorPeriodLoss>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTItMS0xLTExOTk5_fdc3882f-677e-441b-a09a-2e8e58a0c59e"
      unitRef="shares">2566666</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTMtMS0xLTExOTk5_24391c5f-6b9f-45d3-8ecf-bdb2bf3a68f2"
      unitRef="eur">77000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTQtMS0xLTExOTk5_97f44ee5-d3be-4b82-a842-b10b6c28ab8d"
      unitRef="eur">28002000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE4LTktMS0xLTExOTk5_02addf01-4764-45e4-9099-a892d2592d44"
      unitRef="eur">28079000</ifrs-full:IssueOfEquity>
    <nbx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants
      contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTItMS0xLTExOTk5_dc77ea11-8178-4bad-8baa-314dda41796a"
      unitRef="shares">215000</nbx:IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="ib85f7c0e70224e72b0eee4c081b47d5c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTMtMS0xLTExOTk5_445627f9-b697-4ced-aa17-e26150086cf8"
      unitRef="eur">6000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTQtMS0xLTExOTk5_9da9b3be-9333-4388-9d1d-3be8e66600ce"
      unitRef="eur">1300000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzE5LTktMS0xLTExOTk5_da86f1fa-3998-415b-afa4-557ffe619646"
      unitRef="eur">1306000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTQtMS0xLTExOTk5_ecef7aa4-1f52-4f97-9b64-391f8d79e022"
      unitRef="eur">8000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTctMS0xLTExOTk5_81e0b97d-cf09-4cb7-bf19-d821a143d227"
      unitRef="eur">13000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIwLTktMS0xLTExOTk5_c3e60585-7da3-49d7-a0f5-e87c4934855e"
      unitRef="eur">21000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i611f16c7ec5f4d8184c90b3715408030_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIxLTctMS0xLTExOTk5_ec9035a9-986b-415d-a71e-5f76df01d1fd"
      unitRef="eur">4320000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIxLTktMS0xLTExOTk5_b6c22837-88fa-4fb5-80da-53f1f8fcdb71"
      unitRef="eur">4320000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="ib9373d1667a940b68a4392136b2737e8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIyLTYtMS0xLTExOTk5_c0fd4ef5-8adf-40b8-80a9-a81427b1f887"
      unitRef="eur">-45000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIyLTktMS0xLTExOTk5_80c6fe40-232f-4c0a-82eb-27254d13a8cc"
      unitRef="eur">-45000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i4ec5d607440a4fb68f1a546cca3d255f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIzLTQtMS0xLTExOTk5_2410c027-be2f-485b-ba9e-85e8118bbb5f"
      unitRef="eur">-1030000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzIzLTktMS0xLTExOTk5_04fa9603-7e88-49f8-bc98-39102fcaf888"
      unitRef="eur">-1030000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTItMS0xLTExOTk5_2c164b02-a344-4731-be32-f49059a9555e"
      unitRef="shares">22415039</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTMtMS0xLTExOTk5_87956b08-5592-4537-a9a3-a8a29f95d9b1"
      unitRef="eur">672000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="icec4369f4c7649dba76e50278de42760_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTQtMS0xLTExOTk5_8f5164ee-f68e-4f0e-bac0-ecc46e945e9a"
      unitRef="eur">153139000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i5a2f48357d7645e5a28e6091cc904770_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTUtMS0xLTExOTk5_04e922d5-7f5b-4b59-8265-658293300537"
      unitRef="eur">433000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ib450eccc21d24368a1877065c5e022e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTYtMS0xLTExOTk5_2e86d89c-284b-4005-949f-e586beaba162"
      unitRef="eur">-169000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i5b268f53590247bcb64f8ce92ed3144d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTctMS0xLTExOTk5_9fe9823d-ee66-4675-9517-466781191663"
      unitRef="eur">-105070000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ib91c813e0c574310a2f8c983ce2042ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTgtMS0xLTExOTk5_b0259920-707a-42cd-b5a6-5b75ec9db3ac"
      unitRef="eur">-50915000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI0LTktMS0xLTExOTk5_c6414a47-ed46-468b-ac95-1204704dc081"
      unitRef="eur">-1908000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTgtMS0xLTExOTk5_79fc77e3-3d75-45b7-aef6-435a2991d03c"
      unitRef="eur">-33590000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTktMS0xLTExOTk5_4a5c6f0b-8162-4d14-baf6-ef83e4efa5a0"
      unitRef="eur">-33590000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTUtMS0xLTExOTk5_5a17908d-0d28-488d-96b5-f3922bc92969"
      unitRef="eur">125000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTktMS0xLTExOTk5_cca12336-cf32-446d-986b-c51e1ee6a889"
      unitRef="eur">125000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTUtMS0xLTExOTk5_8c1a6587-8703-4d21-a5b0-5e13cb15b42a"
      unitRef="eur">-4000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTktMS0xLTExOTk5_5087d1ad-5f7e-4fb5-b71d-e12fe926617a"
      unitRef="eur">-4000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="i033bd022a8074a3aa14e45ed356c525c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTUtMS0xLTExOTk5_993ea9ab-25a4-41c8-9f67-fead856faecd"
      unitRef="eur">121000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTgtMS0xLTExOTk5_70f5e62d-ea56-4b9d-a913-5ea1e9ea087e"
      unitRef="eur">-33590000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTktMS0xLTExOTk5_dbb5fab7-6347-4750-bdc0-00ee0b5368a6"
      unitRef="eur">-33469000</ifrs-full:ComprehensiveIncome>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTctMS0xLTExOTk5_6ae55812-abdd-45c9-8ff5-4c2e5a06ed44"
      unitRef="eur">-50915000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="id71c1221ff7c40349a8be9c9b26022d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTgtMS0xLTExOTk5_cc3613bc-b299-4ed5-bb13-ddd0820e281c"
      unitRef="eur">50915000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTktMS0xLTExOTk5_1d4bd82f-465e-4dae-a700-83f4fd4ce44a"
      unitRef="eur">0</nbx:AllocationOfPriorPeriodLoss>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTItMS0xLTExOTk5_fea60bff-c3eb-4a57-8d4f-a650e27e4857"
      unitRef="shares">12017083</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i57327ebc08ae4b6f91837459ba87ba7a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTMtMS0xLTExOTk5_db826e18-c54a-4126-aada-0e5ae4102e09"
      unitRef="eur">361000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i05eefb483e484cf597b3e3872a255374_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTQtMS0xLTExOTk5_330faaa7-53db-4cf5-bd0a-90bef1f7f9af"
      unitRef="eur">102591000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTctMS0xLTExOTk5_f597b912-52ce-4014-8017-d08726895b39"
      unitRef="eur">-10000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTktMS0xLTExOTk5_b912220c-291d-4926-a5b9-acb2998d88bf"
      unitRef="eur">102942000</ifrs-full:IssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i05eefb483e484cf597b3e3872a255374_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTQtMS0xLTExOTk5_e4a934ab-2996-4984-87e2-1a01a7cddb8c"
      unitRef="eur">5000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTktMS0xLTExOTk5_b9eb6ead-b454-495a-97fa-bc9537c63574"
      unitRef="eur">5000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="ib58665d50b9245cbb263201dd383577d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTctMS0xLTExOTk5_0f3564a5-67ac-47ae-820e-088ddca4bdf7"
      unitRef="eur">2924000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTktMS0xLTExOTk5_b1fa7951-9ecd-4d46-aacf-cde98495dc94"
      unitRef="eur">2924000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i2aad128401e440c58786e8375faef035_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTYtMS0xLTExOTk5_722882f5-1a7b-4484-b15c-2c8324d4190b"
      unitRef="eur">-27000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTktMS0xLTExOTk5_a2f58de3-0519-4f7d-90c2-16df98c6db7c"
      unitRef="eur">-27000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTItMS0xLTExOTk5_9586508f-4503-4b38-9644-03718735d88c"
      unitRef="shares">34432122</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTMtMS0xLTExOTk5_271e2117-54cf-423f-b839-55dcaadd0a50"
      unitRef="eur">1033000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTQtMS0xLTExOTk5_4cebb5ae-8d50-4690-85aa-5dd40adac373"
      unitRef="eur">255735000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6b4b95efdee94328b574c4dd5a972a78_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTUtMS0xLTExOTk5_affe4d73-0114-4ce5-895d-b1d1d5cec3a6"
      unitRef="eur">555000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia680b82130144ad9af8419938ca05856_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTYtMS0xLTExOTk5_0f5c0316-1081-4214-ab2b-e227c59a4acf"
      unitRef="eur">-196000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i5e365c4a4f144b5e87711257c20e4830_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTctMS0xLTExOTk5_fdfcf86e-4faa-4bc0-b0ea-f525abe1b5b1"
      unitRef="eur">-153070000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4e4260d8f2204ff1897746ec6304ec1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTgtMS0xLTExOTk5_967ad1be-a0d2-45fe-b854-ab1a6cdab319"
      unitRef="eur">-33590000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM0LTktMS0xLTExOTk5_435883da-cb13-483a-b768-cb6f0f4ca559"
      unitRef="eur">70468000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTgtMS0xLTI4ODAw_13ddda2b-8851-49d0-97d1-423238557499"
      unitRef="eur">-47003000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI1LTktMS0xLTI4ODAw_ac1521b4-a1f0-485c-8009-22d13f6414f1"
      unitRef="eur">-47003000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTUtMS0xLTI4ODAw_abcd063b-05a3-4d1b-a531-eea2e38f7bbd"
      unitRef="eur">-94000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI2LTktMS0xLTI4ODAw_df08f222-fb38-47ef-acd9-a41f79d2ebe3"
      unitRef="eur">-94000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTUtMS0xLTI4ODAw_93b0f70a-246b-4fc3-aee7-46d65f98093b"
      unitRef="eur">182000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI3LTktMS0xLTI4ODAw_c661866d-2098-4776-9387-27d2f0559909"
      unitRef="eur">182000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="i53ae4fc9312d4b178fe8a7f7654fb255_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTUtMS0xLTI4ODAw_19066845-fa0f-4699-b578-25b27b1ef211"
      unitRef="eur">88000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTgtMS0xLTI4ODAw_09b3e6e5-7d4d-4cb4-a420-c9bcf77a772f"
      unitRef="eur">-47003000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI4LTktMS0xLTI4ODAw_2fed3391-5509-4d55-88f5-02d03881bd42"
      unitRef="eur">-46915000</ifrs-full:ComprehensiveIncome>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTctMS0xLTI4ODAw_ee815b16-3680-4b4e-a094-922307943a04"
      unitRef="eur">-33590000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i698417cecfc34dc3b8f5af964f5ddaba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTgtMS0xLTI4ODAw_5683b03e-fae4-4b66-9d75-91413c067765"
      unitRef="eur">33590000</nbx:AllocationOfPriorPeriodLoss>
    <nbx:AllocationOfPriorPeriodLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzI5LTktMS0xLTI4ODAw_684694fe-e3c7-44bd-9fc9-dc46e9f2d3b0"
      unitRef="eur">0</nbx:AllocationOfPriorPeriodLoss>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTItMS0xLTI4ODAw_021f8e6d-c8ea-445e-836e-4c3cc1be9835"
      unitRef="shares">393750</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="iea36202a09dc43e0951837f3efaa42c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTMtMS0xLTI4ODAw_4f8244c3-8483-4df9-8388-dfb53c07bdd4"
      unitRef="eur">12000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTctMS0xLTI4ODAw_ff0f5291-ce1f-4199-98d2-edff1822e4f3"
      unitRef="eur">-12000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMwLTktMS0xLTI4ODAw_79a73fb5-6b27-42a5-a485-455768479593"
      unitRef="eur">0</ifrs-full:IssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTQtMS0xLTI4ODAw_52a30009-1b71-442d-8442-bd6e2e00503f"
      unitRef="eur">32000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTctMS0xLTI4ODAw_c623c740-b9e3-40ab-b3b7-f8fdb5150f4e"
      unitRef="eur">11000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMxLTktMS0xLTI4ODAw_78cc3a38-2717-4ad4-aa6a-bb07d1a17adc"
      unitRef="eur">43000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i7da366d77c294b75876c03db3346763e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTctMS0xLTI4ODAw_545ddf8c-42a7-46bd-a860-9225e7da94fc"
      unitRef="eur">3201000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMyLTktMS0xLTI4ODAw_447d353b-b6a3-458b-bc5e-9e36b24c8487"
      unitRef="eur">3201000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="iead84a7b542a49db9faee4780fc37284_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTYtMS0xLTI4ODAw_b42aceb6-e90a-4a6e-af76-bc3faca2db51"
      unitRef="eur">-6000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzMzLTktMS0xLTI4ODAw_51ef1105-f11c-469b-9271-c0a833d7b9cd"
      unitRef="eur">-6000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTItMS0xLTI4ODAw_1fd5596b-c2d0-455b-876e-30656562a00c"
      unitRef="shares">34825872</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTMtMS0xLTI4ODAw_1092fc97-9eb6-4a2e-aded-140c2d42e98c"
      unitRef="eur">1045000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ida63773549fb469180532f7bff7a9b6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTQtMS0xLTI4ODAw_d807f5cd-9829-4a35-aab1-7b7b154467b8"
      unitRef="eur">255767000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i56d7277ffa0b489fa8a0f3ad5aa861e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTUtMS0xLTI4ODAw_d274a360-4d04-46c9-96d6-8765966d727b"
      unitRef="eur">643000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTYtMS0xLTI4ODAw_95d23112-b80b-4f3b-baf5-636f30470f31"
      unitRef="eur">-202000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i919a1afd086a4da19822485db27af8c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTctMS0xLTI4ODAw_c584f937-2604-4ead-908e-846084c386fb"
      unitRef="eur">-183460000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="if46cc205e82045279e50f91253f8ea1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTgtMS0xLTI4ODAw_9c04800d-b539-49e0-abcc-0269bd2c38c2"
      unitRef="eur">-47003000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjQvZnJhZzpmMzZkZjdmNzkxZWM0OTVjODg3NzI0NWZhYzM4Y2FkMS90YWJsZTphNjZmNjZmOWY4YzM0MjdkYTVhZjg1NDkzNGFjNTgxMS90YWJsZXJhbmdlOmE2NmY2NmY5ZjhjMzQyN2RhNWFmODU0OTM0YWM1ODExXzM1LTktMS0xLTI4ODAw_ad4fb02c-7752-4319-9bc6-53d7a2cd8a14"
      unitRef="eur">26790000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtMy0xLTEtMTE5OTk_de03d710-737b-407b-a8d4-e703d8c97ed8"
      unitRef="eur">-47003000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtNS0xLTEtMTE5OTk_04eb5671-6765-429d-baa4-46fc5cd470a2"
      unitRef="eur">-33590000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzQtNy0xLTEtMTE5OTk_c71d7c8c-66e2-4761-b114-c9c618f6f2ee"
      unitRef="eur">-50915000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtMy0xLTEtMTE5OTk_a5f1ea5b-6f3d-4fcb-86c7-f2e804c5bcdc"
      unitRef="eur">1560000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtNS0xLTEtMTE5OTk_afd2cd00-9721-40aa-a96a-0c911425b473"
      unitRef="eur">1754000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzYtNy0xLTEtMTE5OTk_be2dc5c7-67d2-446d-ab42-d743bd36eaac"
      unitRef="eur">1767000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctMy0xLTEtMTE5OTk_3f384908-10b7-4564-9906-81e38f377f22"
      unitRef="eur">152000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctNS0xLTEtMTE5OTk_f2a3011c-903c-40cb-9514-6b1537d6a340"
      unitRef="eur">-48000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzctNy0xLTEtMTE5OTk_f22bb1f8-6b75-4153-9f1b-285dbaf253fb"
      unitRef="eur">164000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtMy0xLTEtMTE5OTk_c1c999a8-9980-4947-b142-6d804822bbf9"
      unitRef="eur">3201000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtNS0xLTEtMTE5OTk_200e6db2-4b60-4596-9038-292bf71b94c7"
      unitRef="eur">2924000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzgtNy0xLTEtMTE5OTk_1cf213e0-533e-444b-bb2c-a5596a849d68"
      unitRef="eur">4320000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktMy0xLTEtMTE5OTk_dbca0659-758f-4930-a777-99ee05bded5a"
      unitRef="eur">2224000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktNS0xLTEtMTE5OTk_5fd1f072-f553-463d-801f-226c13fcd5e2"
      unitRef="eur">2115000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzktNy0xLTEtMTE5OTk_fcbc2d81-6a16-4987-af10-83ae4eeb9b25"
      unitRef="eur">1940000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTMtMS0xLTExOTk5_8eed1bcf-b5b9-49a2-8ed2-93bed8965340"
      unitRef="eur">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTUtMS0xLTExOTk5_fc494b07-fd28-42ab-8424-e5c9fcacc595"
      unitRef="eur">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEwLTctMS0xLTExOTk5_168d5874-9f2d-45c3-a302-608f390ddffd"
      unitRef="eur">-45000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTMtMS0xLTExOTk5_2e1bbc4e-fb02-4efc-874a-42049a3da75a"
      unitRef="eur">0</nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset>
    <nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTUtMS0xLTExOTk5_95f9c546-c5c6-40fb-af3e-69f90e409b29"
      unitRef="eur">0</nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset>
    <nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzExLTctMS0xLTExOTk5_d627a62f-5502-4422-a88d-02884898ee20"
      unitRef="eur">-201000</nbx:AdjustmentsForUSInitialPublicOffering2018CostsOffset>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTMtMS0xLTExOTk5_b3b7799b-1453-4c06-a01a-0be91a0b7315"
      unitRef="eur">-1554000</ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTUtMS0xLTExOTk5_ace728bf-eb6d-45ee-ba04-8fb1bfef4104"
      unitRef="eur">-6463000</ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEyLTctMS0xLTExOTk5_27263edd-70ff-49da-abf8-d2dfc0db0715"
      unitRef="eur">2833000</ifrs-full:AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities>
    <ifrs-full:OtherAdjustmentsForNoncashItems
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTMtMS0xLTExOTk5_049d6af8-467a-492b-a870-de19ad949399"
      unitRef="eur">8000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTUtMS0xLTExOTk5_4436da1e-d186-44b8-9eff-86b12a6eaca5"
      unitRef="eur">7000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzEzLTctMS0xLTExOTk5_04adc81b-3662-4c33-a1f9-93adefd7e755"
      unitRef="eur">-5000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTMtMS0xLTExOTk5_de52d175-c57d-4618-a0b8-77984c2f5332"
      unitRef="eur">-41412000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTUtMS0xLTExOTk5_0a229baf-2340-49a5-988d-19d7b3184ada"
      unitRef="eur">-33300000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE0LTctMS0xLTExOTk5_39ca4592-0ab4-4141-a11a-72fd58f29218"
      unitRef="eur">-39647000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTMtMS0xLTExOTk5_35058ba5-725f-4ffa-9152-d285df89bc64"
      unitRef="eur">62000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTUtMS0xLTExOTk5_d820579e-057a-49af-b6f3-7d9d2acf5081"
      unitRef="eur">-51000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE1LTctMS0xLTExOTk5_007ac72e-a0cd-449d-b364-d288371ed9f4"
      unitRef="eur">-85000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTMtMS0xLTExOTk5_227f7d7d-e457-46d2-8731-cf6329a6de56"
      unitRef="eur">1927000</nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTUtMS0xLTExOTk5_878681d9-c45b-47ee-8c95-f5cf6a8139b9"
      unitRef="eur">5688000</nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE2LTctMS0xLTExOTk5_3454a244-9d9d-4e99-b571-79d30c058bf6"
      unitRef="eur">0</nbx:AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTMtMS0xLTExOTk5_3a7625f3-af05-4b14-8d52-28d806feb771"
      unitRef="eur">-5034000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTUtMS0xLTExOTk5_e65f2d9d-6138-44cd-b4a8-f3132b69ee4b"
      unitRef="eur">-721000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE3LTctMS0xLTExOTk5_064ad78a-8d67-434b-8463-d6a2a407a68a"
      unitRef="eur">-4640000</nbx:AdjustmentsForDecreaseIncreaseInOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTMtMS0xLTExOTk5_5b6ce493-9d63-4424-812e-516330416d81"
      unitRef="eur">-281000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTUtMS0xLTExOTk5_13402dfe-e548-4bb2-a1fc-4ae650f1e423"
      unitRef="eur">-995000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE4LTctMS0xLTExOTk5_efc622db-89cf-4b2d-9b07-f3d9f01660d1"
      unitRef="eur">2057000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTMtMS0xLTExOTk5_17e063e4-c184-49eb-9f1d-db532475f75f"
      unitRef="eur">-1652000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTUtMS0xLTExOTk5_e73aac66-9554-43b7-b108-e1273ee4a20e"
      unitRef="eur">1840000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzE5LTctMS0xLTExOTk5_ede46322-3886-45b9-b75d-7bd4d90c7484"
      unitRef="eur">1146000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTMtMS0xLTU2NzUz_8131685b-1598-4b9c-a251-1699850ef4c6"
      unitRef="eur">16518000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTUtMS0xLTU2NzU1_49bcd819-b8d8-433b-b070-4b80313a9b53"
      unitRef="eur">0</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTctMS0xLTU2NzU3_0e90f9aa-7473-473e-a077-44089a8672b5"
      unitRef="eur">0</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTMtMS0xLTExOTk5_0cfbf5c9-43bb-43bd-a1ea-e6ac8e14d404"
      unitRef="eur">-11540000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTUtMS0xLTExOTk5_3429d743-75b2-4578-ba85-4109c792d21e"
      unitRef="eur">-5762000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIwLTctMS0xLTExOTk5_5db3b9ef-9c38-4f2a-adc0-ccbee8756622"
      unitRef="eur">1522000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTMtMS0xLTExOTk5_2ee104fc-1a86-4b35-a822-b990f98e8677"
      unitRef="eur">-29872000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTUtMS0xLTExOTk5_50000d89-4938-48a0-9704-73d47df0afb9"
      unitRef="eur">-27538000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIxLTctMS0xLTExOTk5_1c41f6ef-73bb-4070-a80d-9df379a5b962"
      unitRef="eur">-41169000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTMtMS0xLTExOTk5_ee1cd264-3989-48fc-9051-6e02ed933ec6"
      unitRef="eur">5000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTUtMS0xLTExOTk5_7d2398e6-d444-4741-9ae0-84412e0ae3fe"
      unitRef="eur">11000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzIzLTctMS0xLTExOTk5_fe345245-f08e-4a39-abfb-f8c2a2d9cdf6"
      unitRef="eur">353000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTMtMS0xLTExOTk5_d89f7916-1651-4f04-b39a-5131078b3a7a"
      unitRef="eur">228000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTUtMS0xLTExOTk5_d501dddb-19b9-431f-b7ca-be36e286321b"
      unitRef="eur">96000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI0LTctMS0xLTExOTk5_9bf3dafe-031e-4db8-ae95-99d43f532ee8"
      unitRef="eur">1091000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTMtMS0xLTExOTk5_4f869215-f5d4-4eb2-a527-445d37af9610"
      unitRef="eur">9000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTUtMS0xLTExOTk5_ea6580ea-e49a-4ac4-965c-dd026144816e"
      unitRef="eur">4000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI1LTctMS0xLTExOTk5_7d88c156-ea1d-4c62-a6a3-94f54b820d47"
      unitRef="eur">16000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTMtMS0xLTExOTk5_3c1ac336-c8b8-4ea0-bcef-26e92fc03a93"
      unitRef="eur">-242000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTUtMS0xLTExOTk5_f217207e-0ee0-44ee-94c8-834b621680c2"
      unitRef="eur">-112000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI2LTctMS0xLTExOTk5_8a353e94-444d-4393-a5e6-1444b2dde020"
      unitRef="eur">-1459000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTMtMS0xLTExOTk5_9318a9ad-0c0d-46df-beb5-1e8c6b79cfec"
      unitRef="eur">0</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTUtMS0xLTExOTk5_fca821bf-0987-4e7b-b094-8f87d1f97e01"
      unitRef="eur">113650000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI4LTctMS0xLTExOTk5_451b12c9-1800-46b4-b2db-65b46ba6fa7d"
      unitRef="eur">29517000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <nbx:ProceedsFromWarrantsSubscription
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTMtMS0xLTExOTk5_03cc79db-000e-4d44-99ba-9ae5cd024305"
      unitRef="eur">43000</nbx:ProceedsFromWarrantsSubscription>
    <nbx:ProceedsFromWarrantsSubscription
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTUtMS0xLTExOTk5_4b3824c5-f1c9-43ab-a74d-040dbd4025b3"
      unitRef="eur">5000</nbx:ProceedsFromWarrantsSubscription>
    <nbx:ProceedsFromWarrantsSubscription
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzI5LTctMS0xLTExOTk5_02a7038a-e5e6-4ad1-b22a-48322fd3c570"
      unitRef="eur">1327000</nbx:ProceedsFromWarrantsSubscription>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTMtMS0xLTExOTk5_a6442294-1bbc-4659-8c10-ae7322b9d731"
      unitRef="eur">349000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTUtMS0xLTExOTk5_a3de3ac9-a2d3-45a7-b14d-bd6fe5c22d94"
      unitRef="eur">10359000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMwLTctMS0xLTExOTk5_234f42c4-f839-47f1-881e-7383c1a6f35c"
      unitRef="eur">1438000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTMtMS0xLTExOTk5_a79a366d-db2a-4939-8848-59b37ce0f4b6"
      unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTUtMS0xLTExOTk5_1b379ce2-ee3b-441c-8b94-9e7737911997"
      unitRef="eur">10350000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMxLTctMS0xLTExOTk5_a3d966e8-1932-43b6-80a6-ef27e5a3f3e4"
      unitRef="eur">14000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTMtMS0xLTExOTk5_c7b0aa29-38dc-4f36-9f38-200e24112d0f"
      unitRef="eur">2833000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTUtMS0xLTExOTk5_a66fe3e3-6fef-4b9b-aa2a-1f2c82c408c8"
      unitRef="eur">250000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMyLTctMS0xLTExOTk5_65c5cd36-a33d-4b51-acbf-bd485ce08fcf"
      unitRef="eur">500000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTMtMS0xLTExOTk5_5eaf42a9-1a25-4dea-a83e-a6d04fe6c0b1"
      unitRef="eur">909000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTUtMS0xLTExOTk5_ad84d45f-da76-4238-845e-f3b3ab9e8751"
      unitRef="eur">928000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzMzLTctMS0xLTExOTk5_fd2aed02-028d-4512-b658-2439cc85d950"
      unitRef="eur">1067000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTMtMS0xLTExOTk5_b7e3edcb-e4b1-4307-afc3-d8a5ffc37f43"
      unitRef="eur">1132000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTUtMS0xLTExOTk5_9ce9ab12-fa91-4f0e-9efb-643f93445021"
      unitRef="eur">700000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM0LTctMS0xLTExOTk5_ec3a49c1-0b58-4848-b2f1-38666ea33311"
      unitRef="eur">350000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTMtMS0xLTExOTk5_86655f30-8ced-40e2-972c-f5d61f57aea6"
      unitRef="eur">-5180000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTUtMS0xLTExOTk5_ce7375da-5171-4068-ad66-1ccb50baac8f"
      unitRef="eur">111769000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM1LTctMS0xLTExOTk5_08caa502-eee2-4a6f-8a0f-bd2f9c0bf57b"
      unitRef="eur">41489000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTMtMS0xLTExOTk5_485b1696-d5fd-4e9e-9956-cb353654632d"
      unitRef="eur">64000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTUtMS0xLTExOTk5_37fa1356-f494-4c37-9bf7-ca3a349d3cfc"
      unitRef="eur">-63000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM2LTctMS0xLTExOTk5_5f97fd04-1885-41ed-9b3b-c15ed8d171f0"
      unitRef="eur">29000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTMtMS0xLTExOTk5_ae5ae4ca-0d7d-4e9e-9d96-1254b8e9ce32"
      unitRef="eur">-35230000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTUtMS0xLTExOTk5_30c2b3db-4ff8-42e1-b3c0-b9c9e93287da"
      unitRef="eur">84056000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM3LTctMS0xLTExOTk5_fcececa5-367c-4211-9c33-dafd1a9386bf"
      unitRef="eur">-1109000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTMtMS0xLTExOTk5_8bd4a27e-f00a-4ef9-aab1-518d0521594c"
      unitRef="eur">119151000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTUtMS0xLTExOTk5_a36abcfb-5d9f-4557-a15c-95c50a38d3f5"
      unitRef="eur">35094000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="ifb077c12bc264a7ab30586528053d5b8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM4LTctMS0xLTExOTk5_11bd8a17-8242-4d6b-a47b-a9735cef1604"
      unitRef="eur">36203000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTMtMS0xLTExOTk5_9ffe195a-2d05-4b86-aa16-587bc516a2fe"
      unitRef="eur">83921000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTUtMS0xLTExOTk5_37f8ac3b-4575-495c-a4c7-fc5db3e9e587"
      unitRef="eur">119151000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMjcvZnJhZzpmNWVlMGQ0MWQwNGY0M2I4ODAzOWYxOGEyMzIxYjU3Mi90YWJsZTo0MjFlNzcwY2YzODY0NzY5YjE2NmNkYWE0YmUyMmJjZC90YWJsZXJhbmdlOjQyMWU3NzBjZjM4NjQ3NjliMTY2Y2RhYTRiZTIyYmNkXzM5LTctMS0xLTExOTk5_96bfdd47-e4b0-4211-9f18-02eb1768943f"
      unitRef="eur">35094000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzc4MjA_942ac4db-97a4-4ca0-8c09-eef1d5d6f3a7">Company information&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Presentation of the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Nanobiotix S.A. was incorporated in 2003 as a spin-off from the State University of New York (SUNY) in Buffalo. Nanobiotix S.A. (together with its subsidiaries, the &#x201c;Company&#x201d;), is headquartered in Paris, France. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, as well as the utility and efficacy of radiotherapy. Its lead product candidate, NBTXR3, is an aqueous suspension of functionalized crystalline metallic nanoparticles approximately 50 nanometers (50 billionths of a meter) in diameter, designed for injection directly into a malignant tumor. When exposed to ionizing radiation, NBTXR3 amplifies the localized, intratumor killing effect of that radiation. NBTXR3 is designed to enhance the overall efficacy of radiotherapy without resulting in additional side effects on the surrounding healthy tissues.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Alongside the Company&#x2019;s core NBTXR3 development program, the Company is also pursuing a development program to explore the use of radiotherapy-activated NBTXR3 in combination with immune checkpoint inhibitors across several solid tumor indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company is listed on the Euronext regulated market in Paris (under the ticker symbol &#x201c;NANO&#x201d;; Code ISIN: FR0011341205, Bloomberg code: NANO:FP) and on the Nasdaq Global Select Market (under the ticker symbol &#x201c;NBTX&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;Significant events of the period&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Nanobiotix and PharmaEngine mutually agree to terminate their collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In March 2021, in light of disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region, Nanobiotix and PharmaEngine mutually agreed to terminate the licensing and collaboration agreement entered into in August 2012. Accordingly, on March 4, 2021, Nanobiotix and PharmaEngine entered into a termination and release agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Termination Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x201d;). Under the Termination Agreement, Nanobiotix retained all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region. Nanobiotix agreed to make total termination payments to PharmaEngine of up to $12.5&#160;million in the aggregate as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;PharmaEngine was eligible for and received in March 2021 a $2.5&#160;million payment following the announcement of Nanobiotix&#x2019;s collaboration with LianBio for the Asia-Pacific region. In May 2021, PharmaEngine received an additional $4.0&#160;million in conjunction with the completion of various administrative steps in connection with the winding-up of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PharmaEngine will be eligible to receive an additional $1.0&#160;million in administrative fees and a final payment of an additional $5.0&#160;million upon a second regulatory approval of an NBTXR3-containing product in any jurisdiction of the world for any indication. PharmaEngine is entitled to receive a low-single digit tiered royalty based on net sales of NBTXR3 in the Asia-Pacific region for a 10-year period commencing on the corresponding first date of sales in the region. As of December 31, 2021, these future payments were not accrued because the triggering events have not occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As part of the Termination Agreement, PharmaEngine re-assigned to Nanobiotix rights for the development, manufacture, commercialization and exploitation of NBTXR3 in the Asia-Pacific region, as well as all development data, regulatory materials, and all regulatory approvals that are in the name of PharmaEngine or its affiliates. Consequently, NBTXR3 clinical trials conducted by PharmaEngine in Asia are in the process of being concluded or terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Nanobiotix and PharmaEngine also agreed to a mutual release of all claims against the other party and its respective affiliates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Nanobiotix partners with LianBio for the development and commercialization of NBTXR3 in several oncology indications and in combination with several anti-cancer therapies, in China and other Asian markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May 2021, Nanobiotix entered into a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix&#x2019;s lead product candidate, NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy. LianBio will also support the expansion of global phase III registrational study in head and neck cancer into Greater China with longer term strategic alignment across multiple tumor indications and therapeutic combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under the terms of the agreement, the Company received a $20&#160;million upfront payment and is entitled to receive up to an aggregate of $220&#160;million in potential contingent, development and commercialization milestone payments. The Company will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will fund all development and commercialization expenses in the collaboration territory, and the Company will continue to fund all development and commercialization expenses in all other geographies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Nanobiotix announces the appointment of Dr. Gary Phillips as Chairman of the Supervisory Board &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May 2021, Dr. Gary Phillips was appointed Chairman of the Company's supervisory board of the Company (&#x201c;the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Supervisory Board&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;). Dr Phillips succeeded Laurent Condomine, who retired from the Supervisory Board after 11 years of leadership.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Nanobiotix announces the appointment of Bart Van Rhijn as Chief Financial Officer and member of the executive board of the Company to support its international expansion&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On June 1, 2021, the Company announced the appointment of Bart Van Rhijn, MBA, as Chief Financial Officer and member of the executive board of the Company (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Executive Board&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x201d;). Mr. Van Rhijn brings proven capabilities in global financial management, business development and pharmaceutical commercialization as the Company prepares for the planned launch of its second clinical registration study for NBTXR3 in head and neck cancer (NANORAY-312), continued development in immunotherapy, and planned expansion across solid tumor types and therapeutic combinations. He succeeded Philippe Mauberna, who stepped down from his roles as Chief Financial Officer and Executive Board member after 8 years of service to the Company.&lt;/span&gt;</ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:OnerousContractsProvision
      contextRef="i5fbf747738f94b4484ec6e4bf65b8025_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkwMzM_b4823bda-b465-4adb-a5c2-2b2fe0abbb81"
      unitRef="usd">12500000</ifrs-full:OnerousContractsProvision>
    <nbx:ContractualCommitmentsPayment
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkxMjA_d3073d99-f4ad-4606-be01-9d8b0159ad05"
      unitRef="usd">2500000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsPayment
      contextRef="ib4221b386b8a41008368fa79a2422241_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NjkzMDE_88199cd8-4afc-4069-95e0-3ed391d904db"
      unitRef="usd">4000000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0Njk0ODU_95d3b827-9cc2-49db-a753-d73d92777df4"
      unitRef="usd">1000000</nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports>
    <nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0Njk1NDk_fbe14aab-b58b-4942-87d7-bae601819099"
      unitRef="usd">5000000</nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval>
    <nbx:RoyaltiesAgreementPeriod
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzM4NDgyOTA3Mzk0OTc_9bef500f-9d04-42cf-bffc-bba183de507b">P10Y</nbx:RoyaltiesAgreementPeriod>
    <nbx:NumberOfGlobalRegistrationalStudiesSupported
      contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzEyNjM_8f78d38a-9591-4baf-8528-a1a8c18c93f5"
      unitRef="study">5</nbx:NumberOfGlobalRegistrationalStudiesSupported>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzE2Njg_57278a18-51bf-4769-a9ed-a9cd845e11ed"
      unitRef="usd">20000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
      contextRef="ibf991456c15f4bd0beed8a02658e4984_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzMvZnJhZzoyMjk5MTkyZTI4M2U0YTJiYTlkNDkxZTliMWM1ZWI5Zi90ZXh0cmVnaW9uOjIyOTkxOTJlMjgzZTRhMmJhOWQ0OTFlOWIxYzVlYjlmXzE2NDkyNjc0NzE3Mzc_28317907-ef10-431f-9f06-fd6502d5e98b"
      unitRef="usd">220000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzgzNzU_7ab62dcc-b141-4b73-ba5c-0073672ddf0c">General Information, Statement of Compliance and Basis of Presentation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;General principles&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders&#x2019; equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management&#x2019;s supervision and were approved by the Executive Board of the Company (the &#x201c;Executive Board&#x201d;) and reviewed by the Supervisory Board of the Company (the &#x201c;Supervisory Board&#x201d;) on March 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (&#x2018;&#x2018;IFRS&#x2019;&#x2019;) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company&#x2019;s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of &#x20ac;83,921&#160;thousand as of December 31, 2021, as compared to &#x20ac;119,151&#160;thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements&#x2019; publication. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Statement of Compliance and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#x201c;IAS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;) as well as interpretations issued by the IFRS Interpretations Committee (&#x201c;IFRS-IC&#x201d;) and the Standard Interpretations Committee (the &#x201c;SIC&#x201d;), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Those are available on the European Commission website: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendments to IFRS 16 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Covid-19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Related rent concession.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The application of these standards had no impact on the consolidated financial statements of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations early adopted by the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations not yet applied by the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 :&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;IFRS 17 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;and related amendments. No impact expected on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 1 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 37 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Onerous Contracts - Cost of Fulfilling a Contract. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IFRS 3 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Conceptual framework&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 8 -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt; Definition of an accounting estimate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendments to IAS 16 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Property, Plant and Equipment: Proceeds before Intended Use&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzgzNzY_9da1be2c-af39-481f-b1f9-09779fd58385">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;General principles&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The statement of consolidated financial position as of December 31, 2021 and 2020 and the statements of consolidated operations, the statements of consolidated comprehensive loss, the consolidated changes in shareholders&#x2019; equity and statements of consolidated cash flows for the years ended December 31, 2021, 2020 and 2019 were prepared under management&#x2019;s supervision and were approved by the Executive Board of the Company (the &#x201c;Executive Board&#x201d;) and reviewed by the Supervisory Board of the Company (the &#x201c;Supervisory Board&#x201d;) on March 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All amounts presented in the consolidated financial statements are presented in thousands of euros, unless stated otherwise. Some figures have been rounded. Accordingly, the totals in some tables may not be the exact sums of component items.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The preparation of the consolidated financial statements in accordance with International Financial Reporting Standards (&#x2018;&#x2018;IFRS&#x2019;&#x2019;) requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements (see Note 3.2 for additional information).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared using the historical cost measurement basis, with the exception of financial assets and liabilities, which are measured at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements were prepared on a going concern basis. The Executive Board determined it is appropriate to apply a going concern assumption because the Company&#x2019;s historical losses are due to the innovative nature of the products it is developing, which necessitates a research and development phase spanning several years. With cash and cash equivalents of &#x20ac;83,921&#160;thousand as of December 31, 2021, as compared to &#x20ac;119,151&#160;thousand as of December 31, 2020, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements&#x2019; publication. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Statement of Compliance and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements have been prepared in accordance with IFRS, International Accounting Standards (&#x201c;IAS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;) as well as interpretations issued by the IFRS Interpretations Committee (&#x201c;IFRS-IC&#x201d;) and the Standard Interpretations Committee (the &#x201c;SIC&#x201d;), which application is mandatory as of December 31, 2021. The consolidated financial statements are also compliant with IFRS as adopted by the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Those are available on the European Commission website: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;https://ec.europa.eu/info/law/international-accounting-standards-regulation-ec-no-1606-2002&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The accounting principles used to prepare the consolidated financial statements for the fiscal year ended December 31, 2021 are identical to those used for the previous year except for the standards listed below that required adoption in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company adopted the following standards, amendments and interpretations, whose application was mandatory for periods beginning on or after January 1, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Amendments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;to IAS 39, IFRS 9, IFRS 7 and IFRS 16 related to the interest rate benchmark reform - Phase 2; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendments to IFRS 16 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Covid-19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Related rent concession.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The application of these standards had no impact on the consolidated financial statements of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations early adopted by the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company elected to early adopt no new standards, amendments and interpretations which application was not yet mandatory for the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of New or Amended Standards and Interpretations not yet applied by the Company&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The application of the following new standards, amendments and interpretations was not yet mandatory for the year ended December 31, 2021 :&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;IFRS 17 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Insurance contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;and related amendments. No impact expected on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 1 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Classification of Liabilities as Current or Non-Current, Disclosure of significant accounting policies, and Update of Practice Statement 2 "Making materiality&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 37 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Onerous Contracts - Cost of Fulfilling a Contract. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IFRS 3 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Conceptual framework&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendment to IAS 8 -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt; Definition of an accounting estimate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Amendments to IAS 16 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Property, Plant and Equipment: Proceeds before Intended Use&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;. No significant impact expected on the financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzE3Njk_aaa07eeb-ed39-415e-8546-4f1d040bd7ed"
      unitRef="eur">83921000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzYvZnJhZzpiYzc4NmE1OGM1MTI0OWJjYTY2ZGEyOGUxMmU0MmVhZC90ZXh0cmVnaW9uOmJjNzg2YTU4YzUxMjQ5YmNhNjZkYTI4ZTEyZTQyZWFkXzMyOTg1MzQ5MDQ1NDg_a6aa7da0-7015-406a-9733-bc5406a0b3e8"
      unitRef="eur">119151000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzM_1f3a3ee7-e1dd-4932-a194-e3acf9bf33b5">Consolidation principles and methods&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;3.1 Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company&#x2019;s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The accounting methods of the Company&#x2019;s subsidiaries are aligned with those of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, the Company involves one parent entity, &#x201c;Nanobiotix S.A.,&#x201d; and five wholly owned subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Germany GmbH, incorporated in Germany in October 2017;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Spain S.L.U., incorporated in Spain in December 2017;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;3.2 Use of judgement, estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Measurement of share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company measures the fair value of stock options (OSA), founders&#x2019; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, vesting terms) and market data (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, expected share volatility) (see Note 17).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#x2019;s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Clinical trial accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly.  See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;See Note 15 for additional detail regarding the Company&#x2019;s accounting policies for its additional sources of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair value of financial assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value measurement of the loan granted by European Investment Bank (&#x201c;EIB&#x201d;) requires the Company to assess the amount of additional interest (&#x201c;royalties&#x201d;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company&#x2019;s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzQ_6ab41ecd-630f-46ff-a515-d5d0048a93ef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;3.1 Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 10 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, an entity is consolidated when it is controlled by the Company. The Company has decision-making authority over the financial and operating policies of all its subsidiaries and holds greater than 50% of the voting rights of each subsidiary. Accordingly, each of the Company&#x2019;s subsidiaries has been fully consolidated from the date on which the Company obtained control over it. A subsidiary would be deconsolidated as of the date on which the Company no longer exercises control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All intra-Company balances, transactions, unrealized gains and losses resulting from intra-Company transactions and all intra-Company dividends are eliminated in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The accounting methods of the Company&#x2019;s subsidiaries are aligned with those of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements are presented in euros, which is the reporting currency and the functional currency of the parent company, Nanobiotix S.A. The financial statements of consolidated foreign subsidiaries whose functional currency is not the euro are translated into euros for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of operations, statement of comprehensive loss and statement of cash flow items at the average rate for the period presented, except where this method cannot be applied due to significant exchange rate fluctuations during the applicable period. The dollar to euro exchange rate used in the consolidated financial statements to convert the financial statements of the U.S. subsidiary were $1.1326 as of December 31, 2021 and an average of $1.1835 for the year ended December 31, 2021 (source: Banque de France) compared with $1.2271 and $1.1413, for 2020 and $1.1234 and $1.1196 for 2019, respectively. The resulting currency translation adjustments are recorded in other comprehensive income (loss) as a cumulative currency translation adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Consolidated entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, the Company involves one parent entity, &#x201c;Nanobiotix S.A.,&#x201d; and five wholly owned subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Corp., incorporated in the State of Delaware in the United States in September 2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Germany GmbH, incorporated in Germany in October 2017;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Nanobiotix Spain S.L.U., incorporated in Spain in December 2017;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Curadigm S.A.S., incorporated on July 3, 2019 and located in France; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Curadigm Corp., a wholly-owned subsidiary of Curadigm S.A.S., incorporated in the State of Delaware on January 7, 2020 and headquartered in Boston, Massachusetts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The consolidated financial statements as of and for the year ended December 31, 2021 include the operations of each of these subsidiaries from the date of their incorporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accordingly, the consolidated financial statements as of and for the year ended December 31, 2020 include the operations of each of these subsidiaries from the date of their incorporation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;The consolidated financial statements as of and for the year ended December 31, 2019 include the operations of each of these subsidiaries from the date of their incorporation, excluding Curadigm Corp which was created in 2020.</nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE3Mjc_2d786c22-7499-4e4d-a064-5742070d00ba"
      unitRef="number">1.1326</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE3NzI_8bf0a7aa-eb2e-4fbc-8414-3717529ac0ae"
      unitRef="number">1.1835</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4NTM_78c2701b-cdac-4a90-be94-ae9865b62ee2"
      unitRef="number">1.2271</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4NjA_48d20211-7b11-4c29-9d4b-27268901f7a4"
      unitRef="number">1.1413</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4Nzc_f48b1e09-c2d1-486f-b79d-f3cfc7d336d6"
      unitRef="number">1.1234</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzE4ODQ_d65bfaf9-bc4a-4700-b787-3800747cd4cb"
      unitRef="number">1.1196</ifrs-full:AverageForeignExchangeRate>
    <nbx:NumberOfParentEntities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzIxMjc_2773b557-f644-4a35-826a-f2f7f302e4c3"
      unitRef="parent_entity">1</nbx:NumberOfParentEntities>
    <nbx:NumberOfSubsidiaries
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzIxNjg_2c10af6d-cde1-4658-af6e-b6a1944297b6"
      unitRef="subsidiary">5</nbx:NumberOfSubsidiaries>
    <nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xMzkvZnJhZzpjMmE5ZWMyYTgwYTI0YTM4ODAxNmJmMmUzY2NiYTU1MS90ZXh0cmVnaW9uOmMyYTllYzJhODBhMjRhMzg4MDE2YmYyZTNjY2JhNTUxXzcyNzU_8d8fb3b8-21d2-4506-80d9-dc862561230a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;3.2 Use of judgement, estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The preparation of consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the amounts and information disclosed in the financial statements. The estimates and judgments used by management are based on historical information and on other factors, including expectations about future events considered to be reasonable given the circumstances. These estimates may be revised where the circumstances on which they are based change. Consequently, actual results may vary significantly from these estimates under different assumptions or conditions. The main items affected by the use of estimates are share-based payments, deferred tax assets, clinical trials accruals, revenue recognition and the fair value of financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Measurement of share-based payments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company measures the fair value of stock options (OSA), founders&#x2019; warrants (BSPCE), warrants (BSA) and free shares (AGA) granted to employees, members of the Supervisory Board and consultants based on actuarial models. These actuarial models require that the Company use certain calculation assumptions with respect to characteristics of the grants (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, vesting terms) and market data (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, expected share volatility) (see Note 17).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred tax assets &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred taxes are recognized for temporary differences arising from the difference between the tax basis and the accounting basis of the Company&#x2019;s assets and liabilities that appear in its financial statements. The primary temporary differences are related to the tax losses that can be carried forward or backward, depending on the jurisdiction. Enacted tax rates are used to measure deferred taxes (see Note 19).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The deferred tax assets are recorded in the accounts only to the extent that it is probable that the future profits will be sufficient to absorb the losses that can be carried forward or backward. Considering its stage of development, which does not allow income projections judged to be sufficiently reliable to be made, the Company has not recognized deferred tax assets in relation to tax losses carryforwards in the Statements of Consolidated Financial Position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Clinical trial accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Clinical trial expenses, although not yet billed in full, are estimated for each study and a provision accrual is recognized accordingly.  See Note 13.1 for information regarding the clinical trial accruals as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In order to determine the amount and timing of revenue under the contract with LianBio, the Company is required to use significant judgments, mainly with respect to identifying performance obligations of the Company and determining the timing of satisfaction of support services provided to LianBio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;See Note 15 for additional detail regarding the Company&#x2019;s accounting policies for its additional sources of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair value of financial assets and liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value measurement of the loan granted by European Investment Bank (&#x201c;EIB&#x201d;) requires the Company to assess the amount of additional interest (&#x201c;royalties&#x201d;, as defined by the royalty agreement with EIB) that will be due according to the loan agreement during a royalty calculation period commencing on January 1, 2021. The royalties due during this period will be determined and calculated based on the number of tranches that have been withdrawn and will be indexed to the Company&#x2019;s annual sales turnover. For the purpose of measuring the fair value of the EIB loan, the Company forecasts the sales that it expects to generate during the royalty period, taking into consideration the operational assumptions such as market release dates of the products, growth and penetration rate in each market. (see notes 4.2 and 12 for details about this loan and the accounting treatment applied).&lt;/span&gt;&lt;/div&gt;</nbx:DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock>
    <nbx:DisclosureOfSignificantTransactionsTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg2Njk_8f380790-4531-4932-b6d4-28f20fb9133e">Significant transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;4.1 LianBio&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In May 2021, Nanobiotix announced a partnership with LianBio Oncology Limited a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize NBTXR3 into Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;LianBio will collaborate in the development of NBTXR3 in Asia Pacific, and contribute to patient enrollment in five future global registrational studies across several tumor types and therapeutic combinations. LianBio will also support the expansion of the global phase III registrational study in head and neck cancer into Greater China, while supporting longer term strategic alignment across multiple tumor indications and therapeutic combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, a non-refundable upfront payment of $20&#160;million has been collected by the Company at the signature of the LianBio Agreement. The Company is entitled to receive up to an aggregate of $220&#160;million in potential contingent, development and commercialization milestone payments. Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;See Note 15 Revenues and other income for further details on this new partnership.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;4.2 PharmaEngine&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In August 2012, the Company entered into an Exclusive License and Collaboration Agreement (as amended in 2014, the &#x2018;&#x2018;License and Collaboration Agreement&#x2019;&#x2019;) with PharmaEngine, a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer in Asia. Under the terms of the License and Collaboration Agreement, PharmaEngine will receive the exclusive right to further develop NBTXR3 to obtain regulatory approval, leverage the data generated by the Company&#x2019;s development activities and commercialize NBTXR3 in multiple countries throughout the Asia-Pacific region. Under the same Agreement, PharmaEngine is responsible for developing (non-clinical and clinical research) and commercializing NBTXR3 throughout the contractual territory and making certain development and minimum commercial milestone payments to the Company. Key provisions of the License and Collaboration Agreement include: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;An exclusive perpetual license granted to PharmaEngine, with the right to sublicense the Company&#x2019;s technology in order to exploit or have NBTXR3 exploited and use the Company&#x2019;s trademark in connection with the exploitation of NBTXR3 in the contractual territory (with exploitation including among others developing, obtaining and maintaining regulatory approval, commercializing, distributing, promoting and marketing);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The Company&#x2019;s commitment to furnish PharmaEngine with know-how necessary and useful to develop and commercialize NBTXR3 in the contractual territory, know-how meaning any results of experimentation and pre-clinical, clinical and non-clinical trial data by providing PharmaEngine with access to an electronic data platform; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The Company&#x2019;s commitment to supplying or having supplied PharmaEngine with all quantities of NBTXR3 required and used by PharmaEngine for clinical testing and subsequent commercialization if and when regulatory approvals are obtained. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In return, PharmaEngine commits to use commercially reasonable efforts to develop NBTXR3 in the contractual territory at PharmaEngine&#x2019;s cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under the License and Collaboration Agreement, the Company has received and/or is entitled to receive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;A $1.0&#160;million up-front payment on signature of the contract, fully received in 2012; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Payments upon the achievement of development milestones, including key stages of product development, first filing for regulatory approval, and first regulatory approval in the contractual territory; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Payments upon the achievement of commercial milestones based on specified sales thresholds; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Up to double-digit royalties based on net product sales in the Asia-Pacific region; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Payments for the supply of NBTXR3. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Potential development and commercial milestone payments, including those paid to date, amount to an aggregate of up to $56&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company and PharmaEngine amended the agreement in October 2014, as part of which PharmaEngine agreed: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;To join the global pivotal clinical trial of NBTXR3 for the treatment of Soft Tissue Sarcoma initiated by the Company in the Asia-Pacific area, with each party committing itself to share clinical trial results in order to increase the tested population and to accelerate growth and value creation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;To pay the first development milestone ($1&#160;million, received by the Company in 2014) and share external clinical research organization costs charged to the Company in proportion to its contribution in recruiting the patient population included in the clinical trial; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;To pay the development milestone ($1&#160;million, received by the Company in 2016) related to the launch of the first Phase II of the pivotal study.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2020, $3.0&#160;million has been received since the signature of the License and Collaboration Agreement. The next potential milestone payment under the agreement will become payable only if PharmaEngine files a commercialization authorization of NBTXR3 in their region.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. While both Nanobiotix and PharmaEngine believe in the potential of NBTXR3 to improve treatment outcomes for patients with cancer, the parties have had disagreements regarding the optimal strategy for development in the Asia-Pacific region. As such, after discussion between the two parties, Nanobiotix and PharmaEngine have mutually agreed to discontinue the collaboration. This agreement to terminate the License and Collaboration agreement represents a full resolution of outstanding disagreements over a number of issues with respect to the development of NBTXR3 in the Asia-Pacific region. See Note 15 for additional detail regarding the accounting policy applied to the License and Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In March 2021, the Company and PharmaEngine mutually agreed to terminate the License and Collaboration agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of December 31, 2021, the Company paid a cumulative amount of $6.5&#160;million to PharmaEngine in accordance with the termination agreement signed between the parties. PharmaEngine will receive additional payments of $1&#160;million upon receipt by the Company of certain clinical study reports and of $5&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction of the world for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region. These future payments were not accrued because the triggering events have not occurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;4.3 Financing Agreement with the European Investment Bank (&#x201c;EIB&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In July 2018, the Company signed a non-dilutive financing agreement with the EIB to borrow up to &#x20ac;40&#160;million in order to fund its research, development and innovation activities related to NBTXR3 in various therapeutic indications, subject to achieving a set of agreed-upon performance criteria. This financing is divided in three tranches:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;a first tranche of &#x20ac;16&#160;million, received in October 2018, subject to a 6% fixed rate and that will be fully repaid in 2023 at the latest; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;a second tranche of &#x20ac;14&#160;million, received in March 2019, subject to a 5% fixed rate, with repayments beginning in 2021 and continuing into 2024; and, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;a last tranche of &#x20ac;10&#160;million, subject to a 4% fixed interest rate, that will be fully repaid after a period of five years, which begins within one year of obtaining it. The Company has not yet met the criteria to request this tranche. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, was delayed by 12 months to July 31, 2021. As the conditions have not been met by July 31, 2021, the Company will not request the final tranche of the EIB loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In connection with this financing agreement, the Company also entered into a royalty agreement with EIB pursuant to which the Company is required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) royalties to EIB. The amount of royalties payable is calculable based on low single-digit royalty rates, which vary according to the number of tranches that have been drawn, and indexed on the Company&#x2019;s annual sales turnover.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The &#x20ac;14&#160;million second tranche, which was received in March 2019, was disbursed on the basis of achieving the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Determination of the recommended dose at 22% of the tumor volume for head and neck cancers treatment following the end of the Phase I clinical trial with NBTXR3; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Positive evaluation of the clinical benefit/risk ratio of NBTXR3 in the Phase II/III clinical trial in soft tissue sarcomas by the clinical expert mandated by the French notified body covering medical devices, GMED.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;See Note 22 for discussion of royalties that may be due in the case of early repayment or change of control after repayment of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;4.4 Collaboration Agreement with the University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix&#x2019;s product NBTXR3 for use in treating several cancer types &#x2013;, including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11&#160;million for those clinical trials during the collaboration, and made an initial $1.0&#160;million payment at the commencement of the collaboration and a second $1.0&#160;million payment on February 3, 2020. Additional payments were made in the six months following patients enrollment, with the balance payable upon enrollment of the final patient for all studies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2&#160;million to $16.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021 and 2020, the Company recognized prepaid expenses for &#x20ac;1.0&#160;million and &#x20ac;1.6&#160;million respectively. Expenses will be recorded during the course of the collaboration in the statement of consolidated operations based on the patients enrolled during the relevant period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;See Note 8.2 for further details on other current assets.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfSignificantTransactionsTextBlock>
    <nbx:NumberOfGlobalRegistrationalStudiesSupported
      contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjE5Mjg_1a53a34a-55f7-4f09-a00b-fbc69fa23b9a"
      unitRef="study">5</nbx:NumberOfGlobalRegistrationalStudiesSupported>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="iecce05c62c4b41a1a61e42d71dd76595_D20210501-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjIzMjY_5e749e6d-3877-4d5c-8551-d09eae0d63b5"
      unitRef="usd">20000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
      contextRef="ibf991456c15f4bd0beed8a02658e4984_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzE2NDkyNjc0NjI0NjQ_9c3b5627-a74b-4d6f-94b0-accd0b3a8241"
      unitRef="usd">220000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzIyMTk_1dd02968-e2bd-4769-8696-a397b335e8fc"
      unitRef="usd">1000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
      contextRef="i4b5f453227ff4a7692568ee182571454_I20120831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzI4MzM_1a378e71-1928-438b-8501-d5a53fc74796"
      unitRef="usd">56000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived
      contextRef="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTM_7d0e162b-5a5c-40e6-a2c7-e83ae6ba3ac5"
      unitRef="usd">1000000</nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived>
    <nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived
      contextRef="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzM1NTE_c04441e4-38a8-46f1-947c-181c8fcef2ef"
      unitRef="usd">1000000</nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived>
    <nbx:CollaborationAgreementTotalPaymentsReceived
      contextRef="i0383e3a745c6410a8ad6434d35604d24_D20120801-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzM2ODA_9bd9f11c-1fbc-43d8-adff-205b66fcb469"
      unitRef="usd">3000000</nbx:CollaborationAgreementTotalPaymentsReceived>
    <nbx:ContractualCommitmentsPayment
      contextRef="ib667123634854784a7a53e8925b6cdd7_D20210301-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMDc_57873ea6-ded1-4c3c-997e-36c326f55877"
      unitRef="usd">6500000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMjE_30d28939-8481-4448-88b6-33e5c757d7fc"
      unitRef="usd">1000000</nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports>
    <nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwMzM_af4eda95-da1d-4f9f-8704-a757240eff62"
      unitRef="usd">5000000</nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval>
    <nbx:RoyaltiesAgreementPeriod
      contextRef="id232537486714bc2980db8ae01fdd5e3_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwNTI_21d0be1a-946c-42d6-9442-7d1b8c88bc5c">P10Y</nbx:RoyaltiesAgreementPeriod>
    <ifrs-full:NotionalAmount
      contextRef="ie66ef1f72fe74f22bed3a4ecb3ee2669_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUwNDI_b136838a-5be1-49a5-b82a-d3eaaf8011ea"
      unitRef="eur">40000000</ifrs-full:NotionalAmount>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUyOTc_bda4f23c-1935-4872-b68b-6ba906137668"
      unitRef="eur">16000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="id08b49a302c4409797ed3baba0f7a8e2_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzUzNDA_982bae77-5216-4436-9737-1dceef02706a"
      unitRef="number">0.06</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU0MzI_ec2688e9-a3df-4f75-97e2-758d0c5a5949"
      unitRef="eur">14000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i7f9f4e02188e458a98c73d7d32919183_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU0NzM_61363472-24b5-4166-b6b7-00acb664b76d"
      unitRef="number">0.05</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU1Nzc_21b970ec-9749-44f3-979e-040a16176c0b"
      unitRef="eur">10000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU1OTQ_bc758624-ac03-4d75-8164-8d23af1dc682"
      unitRef="number">0.04</ifrs-full:BorrowingsInterestRate>
    <nbx:BorrowingMaturityTerm
      contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU2NjI_df760032-ba29-4f41-8ed2-84507c6e45c3">P5Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingDefermentPeriod
      contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzU2ODY_c67207f5-d181-4a81-80bf-deee2f81f50c">P1Y</nbx:BorrowingDefermentPeriod>
    <nbx:BorrowingDefermentPeriodToRequestFunds
      contextRef="i730862d53f524fd48823ccef1c727d85_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzMyOTg1MzQ5MDYwNTU_33e5c031-2c87-49b7-96fd-af87cc351e32">P12M</nbx:BorrowingDefermentPeriodToRequestFunds>
    <nbx:RoyaltiesAgreementPeriod
      contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg2Njg_a2539749-8d58-46ca-891f-1a0f37c9ae38">P6Y</nbx:RoyaltiesAgreementPeriod>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzYzMTc_1e5a4dad-34ba-4ccf-9656-a49b6a3ef755"
      unitRef="eur">14000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <nbx:NumberOfPatientsInClinicalTrial
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzczNDk_177061e5-ee28-4c4c-830b-a6726cdfc43b"
      unitRef="patient">340</nbx:NumberOfPatientsInClinicalTrial>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="ie86596994b614e61888621f5f63b3d95_I20190131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc2NDI_960838f3-69dc-4219-8a4f-56c25a39f477"
      unitRef="usd">11000000</ifrs-full:ContractualCapitalCommitments>
    <nbx:ContractualCommitmentsPayment
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc3MTc_20732c14-8659-4ebf-b4d8-3f938816e59e"
      unitRef="usd">1000000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsPayment
      contextRef="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc3ODI_3151f58e-11ba-44c9-aad0-893e2d81f532"
      unitRef="usd">1000000</nbx:ContractualCommitmentsPayment>
    <nbx:MilestonePaymentDefermentPeriodAfterEnrollment
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzc4NTQ_88f8e622-b692-408d-b9d0-77b63dab8e7c">P6M</nbx:MilestonePaymentDefermentPeriodAfterEnrollment>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzgzMTk_0cb4851f-0b2b-4aaa-878e-81dd682f07f1"
      unitRef="usd">2200000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzgzMjU_0b0122d3-8d85-40b3-9dcd-f0297adc1e74"
      unitRef="usd">16400000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="icfe58517db324e8ab08832232c673117_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg0MDg_693ace1e-f65e-4f32-a090-64201b656808"
      unitRef="eur">1000000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDIvZnJhZzpiMjFjYzY3ZjE5NmY0YzNmOTZjYmE0MDMwMjUwMzhjMy90ZXh0cmVnaW9uOmIyMWNjNjdmMTk2ZjRjM2Y5NmNiYTQwMzAyNTAzOGMzXzg0MTU_9035e198-745e-4728-9647-6cf87850f559"
      unitRef="eur">1600000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDQ_2ebac57b-58ea-4965-a891-4716df95cca4">Intangible assets&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IAS 38 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, intangible assets are carried at their acquisition cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and Development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, development costs may only be capitalized as intangible assets if the following criteria are met: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company intends to complete the development of the intangible asset and use or sell it; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company has the ability to use or sell the intangible asset; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;it is probable that the intangible asset will generate future economic benefits; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;adequate technical, financial and other resources are available to complete the development of the intangible asset; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Patents &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Software &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recoverable amount of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in intangible assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.67pt"&gt;Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDI_426580b4-e6c9-4629-a079-7974efd8bffb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IAS 38 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, intangible assets are carried at their acquisition cost. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and Development costs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Research costs are recorded in expenses in the period during which they are incurred. Under IAS 38 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, development costs may only be capitalized as intangible assets if the following criteria are met: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;it is technically feasible to complete the development of the intangible asset so that it will be available for use or sale; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company intends to complete the development of the intangible asset and use or sell it; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company has the ability to use or sell the intangible asset; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;it is probable that the intangible asset will generate future economic benefits; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;adequate technical, financial and other resources are available to complete the development of the intangible asset; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the Company is able to reliably measure the expenditures attributable to the development of the intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company believes that because of the risks and uncertainties related to the grant of regulatory approval for the commercialization of its product candidates, the technical feasibility of completing its development projects will only be demonstrated when requisite approvals are obtained for the commercialization of products. Accordingly, pursuant to IAS 38, the Company has recognized all of its research and development costs incurred as an expense in 2021 and prior periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Patents &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Costs incurred by the Company in connection with the filing of patent applications are recognized as an expense until such time as the relevant patents are obtained, in line with the treatment of research and development costs. Once the patents are obtained from relevant authorities, their related patent costs are amortized on a straight-line basis over the patent protection period. The useful life of the patents is reassessed each year, according to IAS 36. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Software &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The costs of acquiring software licenses are recognized as assets on the basis of the costs incurred to acquire and implement the software to which the license relates. These costs are amortized on a straight-line basis over the life of the license. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recoverable amount of intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Intangible assets with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. Impairment tests involve comparing the carrying amount of an intangible asset with its recoverable amount. The recoverable amount of an asset is the higher of (i) its fair value less costs to sell and (ii) its value in use. If the recoverable amount of any asset is below its carrying amount, an impairment loss is recognized to reduce the carrying amount to the recoverable amount.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90ZXh0cmVnaW9uOmRmY2MxYjZlMDI4NjQ3NmNhMGQ1NzIxOTllYmMzZjU1XzM0MDM_d78945fb-6b21-4237-896a-62a8ec420b6d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in intangible assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;722&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.67pt"&gt;Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Intangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;710&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtMi0xLTEtMzgxMDI_f2431ed7-875e-4413-8560-49a358195dad"
      unitRef="eur">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtNC0xLTEtMzgxMDg_1898a571-acb3-4b9f-86c9-82d72e7f77a8"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtNi0xLTEtMzgxMTQ_e9eed3f7-9e1e-4ad7-ad7c-3b9e012bf9b6"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtOC0xLTEtMzgxMjA_9de10c93-02fa-48f8-bf68-6ae1a1672440"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="if2daccb9fbcb47af8384c0037e9495da_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtOS0xLTEtNDAyNjM_c0fa4310-40d8-4ab5-a0c5-dd8f6dc3a7a1"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i48e879f68f73480b92b03ede2c9ea8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzEtMTAtMS0xLTM4MTI5_dddbd471-5b1b-41b2-a602-01690d619311"
      unitRef="eur">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ia618a699065e48f1b3d3352fbfb17118_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItMi0xLTEtMzgxMDI_18ae7c5a-b0c9-4912-bc5e-64f178a4b03b"
      unitRef="eur">651000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItNC0xLTEtMzgxMDg_345aeff5-2faf-4709-b4b8-57a181c53324"
      unitRef="eur">5000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItNi0xLTEtMzgxMTQ_371d3c29-e041-43fe-b470-f8062ef1d787"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItOC0xLTEtMzgxMjA_114a6d0e-f21c-4cf4-be8c-e8c4239c8944"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="ic4199e65acac4ff9835cd0cd2463ddb8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItOS0xLTEtNDAyNjM_acf44d25-cf08-4952-a3c7-c2b0a652552a"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6fa32daece2d40c39f286dbb440ed1a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzItMTAtMS0xLTM4MTI5_56985105-bfc4-414e-be21-21f515df329b"
      unitRef="eur">657000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ia68188d7927a49d199519c9b6b2e7235_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtMi0xLTEtMzgxMDI_68370098-74a6-4b82-bd88-0198fd32f9da"
      unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtNC0xLTEtMzgxMDg_cd5ba5f5-5684-4021-a93e-650e327314f8"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtNi0xLTEtMzgxMTQ_97b806d3-7a46-42e9-a431-fdaa064a8d1c"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtOC0xLTEtMzgxMjA_955ad290-ec55-4261-b5ac-d241e5c138e2"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="ib83d70b3be4946f986afbd6d00e76a3d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtOS0xLTEtNDAyNjM_855b6d2e-5df7-42c1-bdf3-daeb4af2cbc4"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id4e7f92a2efb4119907ab206e3174d4a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzMtMTAtMS0xLTM4MTI5_6e5a722f-7a38-4061-86bc-fdc7f7ba9898"
      unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtMi0xLTEtMzgxMDI_5a379dbc-9bec-4283-a68f-7cbb8feb80f4"
      unitRef="eur">717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtNC0xLTEtMzgxMDg_b9ae792a-6f34-4d27-a7d7-c8f5b72ec72e"
      unitRef="eur">5000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtNi0xLTEtMzgxMTQ_d6097d0e-603b-418f-9e81-0ba1e98fe2a1"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtOC0xLTEtMzgxMjA_d3299520-73f8-4a4c-981a-bd187b5a1166"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtOS0xLTEtNDAyNjM_6c1a8511-9c9e-4e10-bb65-4ac40f3c320d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i73b9b382940d4e8fa4efbc37ae851522_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzQtMTAtMS0xLTM4MTI5_eb028d0c-1b04-4379-bf38-4fe88dc07d9d"
      unitRef="eur">722000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id7046c37f9b34feca0220aebcdc2b9d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtMi0xLTEtMzgxMDI_d243aa3b-5506-4524-ae29-d88fff816e8b"
      unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtNC0xLTEtMzgxMDg_b0a67325-5464-44dc-b885-1789691d2306"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtNi0xLTEtMzgxMTQ_637043ab-cf4e-4b33-8b67-32d06c19fd78"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtOC0xLTEtMzgxMjA_859ab1d3-c0e3-45d2-9efd-7987a7760ce8"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i3ecafc5e06ee4ce29f573122fcf4c0d3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtOS0xLTEtNDAyNjM_34fcb6b3-a232-42b9-bea8-1c30a83ed5b9"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id1c5ada34f4342ffbb24c0ed227de3b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzUtMTAtMS0xLTM4MTI5_0c111881-8414-4756-8176-1aec6ba5f91e"
      unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i00d268a8bc3d448db012d4136f9d9326_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtMi0xLTEtMzgxMDI_c823a5b3-7b6e-4bb2-990f-2919a2638652"
      unitRef="eur">-630000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtNC0xLTEtMzgxMDg_a3605481-8202-45fe-8e2a-493447ea94a8"
      unitRef="eur">-22000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtNi0xLTEtMzgxMTQ_a4926ca8-7ae0-44dc-ac05-95b36f9f3b99"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtOC0xLTEtMzgxMjA_4bdd1972-aa2d-43ca-9325-73ce05b62227"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="id4d6f74a3d9d4aafb2d2f5e0b20382c3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtOS0xLTEtNDAyNjM_0f89f3c5-c1db-4a83-a530-d4829efadf57"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ifc3d1f32ff2c425093e40400c4b37239_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzYtMTAtMS0xLTM4MTI5_6ab96ee8-da18-4f03-b8be-6360c431275d"
      unitRef="eur">-652000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctMi0xLTEtMzgxMDI_1e0b9440-475b-4cb1-b90f-2a8280292a3c"
      unitRef="eur">-695000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctNC0xLTEtMzgxMDg_0eee4192-bf32-42da-96ca-61d3505e7def"
      unitRef="eur">-22000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctNi0xLTEtMzgxMTQ_8cf32ee6-eaff-4c08-a667-58e1ea53add7"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctOC0xLTEtMzgxMjA_18c98519-e6fa-4bf1-a2b7-9f3b2365a1c6"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctOS0xLTEtNDAyNjM_6869d565-d1f0-4296-9af6-c3374f9a15d1"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzctMTAtMS0xLTM4MTI5_e8a6eb87-4d48-4216-8e01-55c35bac55bb"
      unitRef="eur">-717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtMi0xLTEtMzgxMDI_31a022e0-2793-4d19-9e7a-d7ee1663aa4c"
      unitRef="eur">21000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtNC0xLTEtMzgxMDg_f816f082-f2c9-4789-b17e-a3caeb777208"
      unitRef="eur">-17000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtNi0xLTEtMzgxMTQ_506d1cff-8f1a-4cae-9b62-9f8b50299d9f"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtOC0xLTEtMzgxMjA_9e469498-9084-4812-9b75-0ab57bd38811"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtOS0xLTEtNDAyNjM_50452a2b-b57b-4078-a8d2-43f994a644b1"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZToxNWY4YWIyMDA4YTg0NjkyYTRjZjJiMWI5NzA3YWQyZC90YWJsZXJhbmdlOjE1ZjhhYjIwMDhhODQ2OTJhNGNmMmIxYjk3MDdhZDJkXzgtMTAtMS0xLTM4MTI5_c2e4a4ea-67f0-4c90-af94-94449ec53130"
      unitRef="eur">4000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i22135b3300e048769f42cc9088154762_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtMi0xLTEtMTE5OTk_e4bcce90-0682-4134-9f70-a2ee10bd47e1"
      unitRef="eur">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtNC0xLTEtMTE5OTk_674083fe-15a8-4c35-aeb6-7de947b615db"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtNi0xLTEtMTE5OTk_0194deec-418f-43f9-bb29-09e0f23a173d"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtOC0xLTEtMTE5OTk_c9321b3e-8046-4145-945a-68fa0d8a88b7"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i4e8d2485e43541c89b5d60d66c62f86d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtOS0xLTEtNDAyNjY_9ab3d4fe-d685-4e3b-8311-198548fda414"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i9c047da0d7e0441db4b61d1d3f91b51d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzEtMTAtMS0xLTExOTk5_1d96f199-ea69-4f4c-9f40-64da766f6e8e"
      unitRef="eur">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i661079bae5984baa83e48cf8bf2e0ca0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItMi0xLTEtMTE5OTk_0ed4832e-eb49-4fcc-8a16-26287c188d23"
      unitRef="eur">584000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItNC0xLTEtMTE5OTk_47c1ed75-33f7-45a7-8a56-a4897ca219c6"
      unitRef="eur">11000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItNi0xLTEtMTE5OTk_dcb40384-1beb-465e-bc5b-9c4137ceb989"
      unitRef="eur">5000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItOC0xLTEtMTE5OTk_eb865029-7403-4a31-81e1-bbaee540139b"
      unitRef="eur">61000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="iec3bd5da8c714577a632f5747af8d69f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItOS0xLTEtNDAyNjY_a76deca5-0a68-491e-8cfd-5f31ddf39d64"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ia618a699065e48f1b3d3352fbfb17118_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzItMTAtMS0xLTExOTk5_13201d1d-d6ff-4287-a22e-a3a33a0ee08b"
      unitRef="eur">651000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="if3447f0049044af6945782db9521890b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtMi0xLTEtMTE5OTk_6ed6e41e-72c8-4d96-a9f9-d6f91c04b374"
      unitRef="eur">61000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtNC0xLTEtMTE5OTk_8605d0f1-473c-4d63-a39c-7f01baae7142"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtNi0xLTEtMTE5OTk_06c8bfa5-b890-4ef8-892b-5f52df3620fa"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtOC0xLTEtMTE5OTk_9a5d66f8-cc18-4d4f-9767-8d0bfd64acd7"
      unitRef="eur">-61000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i59cb7a1a64c34d7eb87e6f1b4fd29bc1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtOS0xLTEtNDAyNjY_5d31f4fd-1705-473d-8c88-3ba169aa006a"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ia68188d7927a49d199519c9b6b2e7235_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzMtMTAtMS0xLTExOTk5_a31836fa-8da8-4fb7-b2c8-bd27ad4df455"
      unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i643b965508bf43d4a88c27237bc3b7fb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtMi0xLTEtMTE5OTk_f4a2b2a1-4f86-45a2-9a18-acad5003d52b"
      unitRef="eur">710000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtNC0xLTEtMTE5OTk_c5d3b519-078b-4226-9978-192811d3ba21"
      unitRef="eur">11000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtNi0xLTEtMTE5OTk_09db3bda-445f-48bf-aab1-23561c815af9"
      unitRef="eur">5000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtOC0xLTEtMTE5OTk_fade04c5-58a3-463d-8653-2221a6226ecc"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtOS0xLTEtNDAyNjY_a64aedf2-e22a-49b0-b7b1-ead7af25bc2d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzQtMTAtMS0xLTExOTk5_5f183906-a17f-47f8-947a-c66e1804cc67"
      unitRef="eur">717000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i02245261c2374bc991f32f8bc9d1afd3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtMi0xLTEtMTE5OTk_2e0f4cf7-cfa7-46d1-a365-92b3f00c5990"
      unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtNC0xLTEtMTE5OTk_4bb13e1c-1a3d-4c7e-b19d-18d39538d5cb"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtNi0xLTEtMTE5OTk_2a73d4f6-2a1b-4073-a2fb-0a3727763e9d"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtOC0xLTEtMTE5OTk_e427bd9a-cf69-40f8-833e-96a98a52d8fa"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i2713ac30115344d4be481a055affe757_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtOS0xLTEtNDAyNjY_0f79ecb1-c3e9-42e9-8742-2314a77ba68e"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id7046c37f9b34feca0220aebcdc2b9d6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzUtMTAtMS0xLTExOTk5_89c972c8-dc26-4576-bd2e-c8fc8ceb5563"
      unitRef="eur">-65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ifc87ab6886c14a47b7ebba0f7a2fe2cf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtMi0xLTEtMTE5OTk_99deba61-0026-483f-9b2b-c9b0d33b1958"
      unitRef="eur">-483000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtNC0xLTEtMTE5OTk_55bf95e0-e1c6-4fce-a6a3-15d393f69d3b"
      unitRef="eur">-152000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtNi0xLTEtMTE5OTk_e92b64d0-9233-4a49-81c3-e953dd4c2e23"
      unitRef="eur">-5000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtOC0xLTEtMTE5OTk_77bc2378-4f70-4870-930c-b16b8b39c8ce"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i2ea99006a0484d8e9ff810c2a07f5803_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtOS0xLTEtNDAyNjY_567d7dbd-0dfd-4d0d-afeb-0a4d5dfc6ef4"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i00d268a8bc3d448db012d4136f9d9326_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzYtMTAtMS0xLTExOTk5_3c314c6d-b701-4453-b55a-555014fb943c"
      unitRef="eur">-630000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i1fd5dc377e504702bf04bf3db9a706ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctMi0xLTEtMTE5OTk_64736178-2bbe-4bdd-b0f4-4ee219b50068"
      unitRef="eur">-548000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctNC0xLTEtMTE5OTk_653469fd-183a-4632-84e0-7150ee5963fc"
      unitRef="eur">-152000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctNi0xLTEtMTE5OTk_1dd1f064-9c4d-4284-b2c6-15bb033b0a28"
      unitRef="eur">-5000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctOC0xLTEtMTE5OTk_99e38fab-6df4-4daf-8044-ccfe2d660634"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctOS0xLTEtNDAyNjY_585bd965-7004-4fc8-b514-fb25ff409edd"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzctMTAtMS0xLTExOTk5_9ad46815-c808-4b02-bcfb-38b0daf9294c"
      unitRef="eur">-695000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtMi0xLTEtMTE5OTk_7f8a3665-c4d4-42ca-b8b2-190112afc8b6"
      unitRef="eur">163000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtNC0xLTEtMTE5OTk_2106968c-0a77-4b6b-b653-f3ef7ae1ef66"
      unitRef="eur">-141000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtNi0xLTEtMTE5OTk_557f8b36-93ea-4e2b-9c36-3e3611100b80"
      unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtOC0xLTEtMTE5OTk_bc8f136a-8a9e-4206-872f-b5afa110811f"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtOS0xLTEtNDAyNjY_403dc7c2-2923-47e9-8613-c4e356b6555b"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDUvZnJhZzpkZmNjMWI2ZTAyODY0NzZjYTBkNTcyMTk5ZWJjM2Y1NS90YWJsZTplZDhlMjMxM2Y2M2U0ZWVmODczYWIyNDFjNjcwMmE5OC90YWJsZXJhbmdlOmVkOGUyMzEzZjYzZTRlZWY4NzNhYjI0MWM2NzAyYTk4XzgtMTAtMS0xLTExOTk5_077fde80-1bb1-45d8-9d80-f811e94aa369"
      unitRef="eur">21000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzQ_21efa347-4972-4c3c-a538-0aaf95468341">Property, plant and equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company&#x2019;s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The depreciation periods used are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;General fixtures and fittings, building work: 5 to 10 years;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Technical installations, equipment and industrial tooling: 3 to 10 years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Office and IT equipment and furniture: 1 to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recoverable amount of property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in property, plant and equipment is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,630&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In 2021, the &#x20ac;1,362&#160;thousand increase in Right of use &#x2013; Buildings mainly relates to the extension of Villejuif leases for 4 years for &#x20ac;1,390&#160;thousand reduced by approximately &#x20ac;25&#160;thousand related to rent indexation impact. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The &#x20ac;139&#160;thousand decrease in Right of use &#x2013; Buildings relates to the termination of a lease contract in Faubourg Saint-Antoine in Paris, France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;movements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&amp;amp; transfer.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,630&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(3,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, the &#x20ac;418&#160;thousand increase in Right of use &#x2013; Buildings mainly relates to: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Two new lease contracts: one in Rue Oberkampf in Paris, France for &#x20ac;155&#160;thousand, the other in Rue du Faubourg Saint-Antoine in Paris, France for &#x20ac;140&#160;thousand, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The termination of a lease contract by Curadigm SAS for &#x20ac;43&#160;thousand; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The addition of a parking for  the Villejuif facility for &#x20ac;30&#160;thousand, and &lt;/span&gt;&lt;/div&gt;&#x2022;The impact of an annual rent adjustment for the Wattignies and Villejuif leases based on the INSEE (National Institute of Statistics and Economic Studies) index for &#x20ac;35 and &#x20ac;15&#160;thousand, respectively.</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzU_5ff974d4-8e29-4348-903e-527f1c7d7288">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment are recorded at their acquisition cost. Major renovations and improvements necessary to bring an asset to the working condition for its use as intended by the Company&#x2019;s management are capitalized. The cost of repairs, maintenance and other renovation work is expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment are depreciated on a straight-line basis according to the estimated useful life of the relevant assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The depreciation periods used are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;General fixtures and fittings, building work: 5 to 10 years;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Technical installations, equipment and industrial tooling: 3 to 10 years; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Office and IT equipment and furniture: 1 to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Recoverable amount of property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment with a definite useful life are tested for impairment when there are events or changes in circumstances that indicate that the asset might be impaired. An impairment loss is recognized for the excess of the carrying amount of the asset over its recoverable amount. The recoverable amount of an asset is equal to the higher of (i) its fair value less costs to sell and (ii) its value in use.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i857b522132a0476eb6dce6d1596820d4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYwNQ_4681bf6c-2045-4d06-9ab7-421747aba911">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="ia9fc3134a84e4b788c49a537b36f4ea2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYwNQ_5e53b1ce-63ad-4cf1-9752-ae1977ce581c">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i383069cd64164d36bf3be6f4fe694362_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYxMQ_b55f42c4-80be-439f-87aa-aa09375a7343">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i45392436feb24c1ca988401841003b83_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzYxMQ_d2068025-f985-4e18-9127-f5578274cfba">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i40f0187d0a71420b849fd1c9efa74737_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzY3NA_ecd1838d-1b14-4d7b-8081-fb84923d34b8">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i740f5b7742a3429183c226bf413db5e0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzY4MA_1695f46e-afee-4f0a-acdd-f9ffd6754671">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="ieec3261b213d45b7859dea5fb22ef918_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_274f2f05-7cd8-4bfe-81b2-578869d17019">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i3891cbb9d139409f926550e2d536f939_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_7ea86f4b-2c4f-497f-9838-6d9e51051156">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i081e0c1a8c8c4accb7e935ac897dcf77_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzcyNw_dbbbc9bb-5ef4-4d6b-8093-873e6cc319c8">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="i83c487a257944224b5d370f39d0697cf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_24aa1274-e6b4-49e7-bc7f-594c8acc5b56">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="ia058d7b209a54f6fbe029cc8f59f7699_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_9ec5f072-30e3-4112-92bf-6f60e3732e8d">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment
      contextRef="iada2ffdf9e7841edb4e55be9d4d3d033_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzczMw_d9cc08fe-067c-4d75-9f19-2e1c0f917549">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzI4MzM_a36a0505-b011-4500-a96d-40dd592e70ce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in property, plant and equipment is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Transfer  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,630&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;15,017&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(6,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,186&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;movements &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&amp;amp; transfer.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Currency &lt;br/&gt;translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tangible assets in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepayments on tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,630&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixtures, fittings and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(829)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Technical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Office and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right of use &#x2013; Transport equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accumulated depreciation of tangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(3,811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,256&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;(1)Expenses for the period are detailed in Note 16.4 Depreciation, amortization and provisions expenses</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iadbefaf925c74b24a9922616c74a0553_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtMS0xLTEtMzgxOTk_6d93b14f-d811-47a9-9a0c-66f57c14c18c"
      unitRef="eur">3313000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtMy0xLTEtMzgyMDY_ee4daf99-d237-4d60-a9e2-abc11f83bca7"
      unitRef="eur">5000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtNS0xLTEtMzgyMTI_0a4b2650-3ca4-4657-830c-ed3f012c6328"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtNy0xLTEtMzgyNDg_eca7cd6b-bde7-4b09-a5b9-47be1c9c0adc"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ia7eac69b826a43558458161cd04f85c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtOS0xLTEtMzgyNjI_54294fbe-1d3e-43bd-83c9-dcfdc49fd9be"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i9bd3865bd72e4c6dabd994b9080949fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEtOS0xLTEtMzgyMTk_5743b95d-0d79-4f3e-9396-8d2fe198cbf6"
      unitRef="eur">3318000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i992fc55410f2432f87fb2d95d37cf5c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItMS0xLTEtMzgxOTk_d1176eac-6dd4-441e-8778-c7a71098a9f0"
      unitRef="eur">7171000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItMy0xLTEtMzgyMDY_37baef7a-30c3-493f-bf7e-a11deeb486d4"
      unitRef="eur">1362000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItNS0xLTEtMzgyMTI_ce08c4d0-38b6-4664-9351-6607268a0f75"
      unitRef="eur">139000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItNy0xLTEtMzgyNDg_4a57929d-db92-4871-956f-e7cc564303bc"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItOS0xLTEtMzgyNjI_c2a8d06c-3027-4330-a5d6-8690a11fbb62"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icd26e64de5444c1f98cc675c204144c4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzItOS0xLTEtMzgyMTk_d30e8d88-6f8d-4776-acc6-5963b9d359a4"
      unitRef="eur">8393000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i07d2744884e34de08bb1bf0f018e8367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtMS0xLTEtMzgxOTk_77d78048-633c-4a25-be41-3ea5424b0b2e"
      unitRef="eur">2061000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtMy0xLTEtMzgyMDY_b9a7c6cd-7357-4de1-8155-5976b7133bdf"
      unitRef="eur">73000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtNS0xLTEtMzgyMTI_c9654190-04b6-443a-b199-6edfebf8410d"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtNy0xLTEtMzgyNDg_a93104d2-e661-400d-b144-24c25a12dfb0"
      unitRef="eur">1000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i096e097fb2cb4ea8b12cdee49ccaa6f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtOS0xLTEtMzgyNjI_819594df-2b38-4828-83a7-7816ecbb6c53"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifed0297807f94baea1c5c2d340771ee8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzMtOS0xLTEtMzgyMTk_27e1ee88-7dfb-4840-815d-dfcd25350497"
      unitRef="eur">2135000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i88c91a06314d44bbbde5e2e5d56195e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtMS0xLTEtMzgxOTk_651912b2-b32f-4509-833c-18d080839f3a"
      unitRef="eur">988000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtMy0xLTEtMzgyMDY_d766756f-364a-4b09-8806-55735dee44bc"
      unitRef="eur">53000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtNS0xLTEtMzgyMTI_6c6720cc-a1dd-45d4-85c6-e76db0c22043"
      unitRef="eur">35000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtNy0xLTEtNDAyNzY_baf947b1-c5e2-4d8c-84a1-5736fb677873"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="if9159792612a40a0a5d5cb6d6e3adfdc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtOS0xLTEtMzgyNjI_4a60622b-a68b-448d-900d-1ab61d038434"
      unitRef="eur">4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i8472a834d7c6410ea1e767fc3c34d64b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzQtOS0xLTEtMzgyMTk_52ead060-e16d-4ac8-8926-625542f52666"
      unitRef="eur">1010000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i680d6b18b0404cd387ee4220cef45346_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtMS0xLTEtMzgxOTk_58f254cd-7a58-4171-b3de-834aa28e8cf0"
      unitRef="eur">31000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtMy0xLTEtMzgyMDY_855b3452-000e-4ec6-8cc4-ab1246934665"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtNS0xLTEtMzgyMTI_23aa7cac-81b3-4f8f-b67e-06cfbde95b8f"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtNy0xLTEtMzgyNDg_d0fa5d08-b6ca-4ba3-87c6-18c19d89d8d9"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i452b8b95c0614675934aec9150bac2d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtOS0xLTEtMzgyNjI_75605737-31ff-4e79-bf79-0994056f450d"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="idc67e0cf8262400995ad31c3fea9c892_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzUtOS0xLTEtMzgyMTk_233a76c8-444c-49d4-9ed2-38d712f494be"
      unitRef="eur">33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie6598955ac8a492fa0a7949b58b5e311_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtMS0xLTEtMzgxOTk_08f63313-d1e9-4b48-84f0-fed7d72b4247"
      unitRef="eur">65000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtMy0xLTEtMzgyMDY_d60f4a70-c609-4577-87a6-86163dd040dc"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtNS0xLTEtMzgyMTI_04949d60-1e12-4c57-9ce3-13f5bdee28b9"
      unitRef="eur">38000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtNy0xLTEtMzgyNDg_99f4c5f1-1588-4c9d-856d-03ba7bc9b297"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i89d26ee08bcc4aa092daa1afd8919fc5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtOS0xLTEtMzgyNjI_00335c4f-0fb9-465d-97ca-6c7f8b514788"
      unitRef="eur">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2612520a1a2840a7a26c63194c557e76_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzYtOS0xLTEtMzgyMTk_4005f061-881f-4ff7-8461-07d2f0dfdc0b"
      unitRef="eur">28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i79f8b941671b4fc5b254babe62d0b548_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctMS0xLTEtMzgxOTk_e9e0bf13-538c-4a72-bf19-72bc8aff63d3"
      unitRef="eur">1000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctMy0xLTEtMzgyMDY_5c0c0c2a-71bf-4a7b-86de-eab73ede0be2"
      unitRef="eur">97000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctNS0xLTEtMzgyMTI_4ac93a54-70b1-4c0d-82a5-1b7e504b7b60"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctNy0xLTEtMzgyNDg_ea38112c-0c9f-4434-8bb9-201e0b736836"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ifbd9a892fe534389aeca7564bb0315e8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctOS0xLTEtMzgyNjI_5143f888-94ad-4967-a083-06e42dae4a6f"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i24fe0f143f954dc68e1ffd022dae5517_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzctOS0xLTEtMzgyMTk_81c0d6e6-63a8-4666-8615-ab37f8d193d4"
      unitRef="eur">98000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifbf6a969f3a946aeb176967ed73299f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtMS0xLTEtMzgxOTk_2dfae60d-0d76-472a-843f-faf70d632cee"
      unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtMy0xLTEtMzgyMDY_e35fb151-f16e-4da3-9acb-aa81ceed5f5c"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtNS0xLTEtMzgyMTI_f15b559e-dacc-4313-800f-588505ee45ac"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtNy0xLTEtMzgyNDg_46201a58-6ef7-4142-adb5-2dbf23db2100"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ifa5e055bdd934a89b887335915deb655_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtOS0xLTEtMzgyNjI_038c7990-3fef-454c-a207-cbdb625f222c"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i065694e284ad457594585f67d682acd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzgtOS0xLTEtMzgyMTk_94d269ea-6d47-4495-9c9a-86bcba6f5e2b"
      unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktMS0xLTEtMzgxOTk_51af0f83-4f0e-40b7-8664-add919269f39"
      unitRef="eur">13630000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktMy0xLTEtMzgyMDY_7e157ef5-7100-4d69-b9ac-798247a83f02"
      unitRef="eur">1590000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktNS0xLTEtMzgyMTI_d1cedf53-33f1-42ec-8e6d-ad82e3fe2ddb"
      unitRef="eur">212000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktNy0xLTEtMzgyNDg_43e40e9a-1cc8-4892-867a-6dd8422f0389"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="if0134cdab3d8497fa92c760081a0c9b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktOS0xLTEtMzgyNjI_732cecfd-89de-4f94-b8f0-8d1982af392c"
      unitRef="eur">8000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i73b9b382940d4e8fa4efbc37ae851522_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzktOS0xLTEtMzgyMTk_b9951e1a-64f1-45d3-a1d4-69be4ff7a1d8"
      unitRef="eur">15017000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTEtMS0xLTM4MTk5_f6d99db8-7dd6-456a-8afd-3f230f8a0901"
      unitRef="eur">-1320000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTMtMS0xLTM4MjA2_2a8d88d2-cf40-48ea-9fff-0db71e658197"
      unitRef="eur">-320000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTUtMS0xLTM4MjEy_5c14d490-2373-4a7f-a1cf-8b197100355d"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTctMS0xLTM4MjQ4_0bef5d9b-657a-4508-9a19-09f06e10d2e5"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i9b02a23ba5a14f249ebb663b14ded622_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTktMS0xLTM4MjYy_28e612b3-57e5-4be5-8435-7a6f276c72bd"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i79cd2925606d4aafab7f52373500d486_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEwLTktMS0xLTM4MjE5_65b1283b-88d6-4a01-889d-ad33a6ecc9df"
      unitRef="eur">-1641000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTEtMS0xLTM4MTk5_25b264ae-7f09-4536-8528-8e2b52d08184"
      unitRef="eur">-1739000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTMtMS0xLTM4MjA2_39964bf3-ef4e-4920-a1c3-9addce883fde"
      unitRef="eur">-901000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTUtMS0xLTM4MjEy_c14cb4a0-cd75-4865-b476-e89e3e5a6029"
      unitRef="eur">-30000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTctMS0xLTM4MjQ4_08aabef9-ea86-49fc-8e54-1bb502f77a2d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i0bdb16f3683241539be898f5e0f6294f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTktMS0xLTM4MjYy_5527c6d7-d295-4107-8518-ad6a6a571d2d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ibb76dbf343af4ef7a2d493513ebc63dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzExLTktMS0xLTM4MjE5_fa4828c6-6da3-4591-804a-853664958cb7"
      unitRef="eur">-2610000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i94439a4b662842c2acd86680522e2018_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTEtMS0xLTM4MTk5_16024f5b-5f54-46ac-9916-2644928dec51"
      unitRef="eur">-1466000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTMtMS0xLTM4MjA2_40acbf38-b0c5-430f-ab5e-36ab2d7edd54"
      unitRef="eur">-178000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTUtMS0xLTM4MjEy_347f9d4b-84d1-43db-8940-07cc41c23387"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTctMS0xLTM4MjQ4_be582a6e-bceb-49ec-8b69-64b36fd5ab75"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="id1b60074ed5b43c8a2c7b0804805bcd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTktMS0xLTM4MjYy_7d75b554-822c-421e-a687-be44c2655ef9"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="if81a7b8866e64bb5ab7ac45083f0107d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEyLTktMS0xLTM4MjE5_a0f3437c-61ca-4252-b12c-5bdcc3caf3b5"
      unitRef="eur">-1644000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTEtMS0xLTM4MTk5_30bb2e92-8d7d-4156-ac16-92995a4983a9"
      unitRef="eur">-783000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTMtMS0xLTM4MjA2_b8a49589-9dc3-43b3-a200-8f95df6e4ed4"
      unitRef="eur">-124000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTUtMS0xLTM4MjEy_df09b4d2-8c36-49a1-8249-40c5689ba37b"
      unitRef="eur">-34000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTctMS0xLTM4MjQ4_27a2e4fd-54b8-4e6c-a6c5-933a88edbe0d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i848f3c0da6864f5a8e3643d6d6a4f7ae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTktMS0xLTM4MjYy_cb40ff3d-282e-47c1-b0e2-c17a1dce6ed4"
      unitRef="eur">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i13580af0c9c0455c808971d25d9c62f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzEzLTktMS0xLTM4MjE5_0596d4ea-912b-46ed-8ff3-ad8bb8d8e07a"
      unitRef="eur">-875000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i170ffb1f1c9a464dac427c1aae8b927a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTEtMS0xLTM4MTk5_394f4825-13f1-4cc0-9e31-a383ec7edfff"
      unitRef="eur">-31000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTMtMS0xLTM4MjA2_e092cc8f-2777-40c7-8176-5883fb553313"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTUtMS0xLTM4MjEy_c84e9963-8445-4359-9dd5-38f74fe29070"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTctMS0xLTM4MjQ4_d5966d36-bcca-4c66-837e-7c5dd2c0fe6a"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i1d8f6d2542c34bfbb660ac6173e15435_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTktMS0xLTM4MjYy_ea6847b0-2bc2-4a5c-992b-8fa2a7a9bfac"
      unitRef="eur">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i99b3ae8877e44bcea3e5d515c0c8b8d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE0LTktMS0xLTM4MjE5_43c101db-2bc6-4656-8b7f-0baef11db24a"
      unitRef="eur">-33000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ieb66730c4b2d424b843abc92b234a808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTEtMS0xLTM4MTk5_d8e7206b-7878-479e-aad3-5128a852cc5c"
      unitRef="eur">-36000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTMtMS0xLTM4MjA2_9f5e8ba1-39ab-4799-9f10-cd42b36bfcc1"
      unitRef="eur">-12000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTUtMS0xLTM4MjEy_d9b5910a-08ad-4074-a69b-af1fbadb5dab"
      unitRef="eur">-20000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTctMS0xLTM4MjQ4_9f218609-2e43-40c1-b28f-641efbcd6686"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="id3911824096d4aefb6c54ec8307b0971_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTktMS0xLTM4MjYy_c0538724-2793-4b0c-abee-9e4a59fdef17"
      unitRef="eur">-1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i26b0bf7b703446948688e7ad02d72cc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE1LTktMS0xLTM4MjE5_32a507b8-3f04-423f-ba60-d6bb965126df"
      unitRef="eur">-28000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTEtMS0xLTM4MTk5_bfca93bc-0c24-48dd-a085-bfa40d179483"
      unitRef="eur">-5374000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTMtMS0xLTM4MjA2_9bfc5ae7-b5da-4dda-9cce-cc9a282a5a0f"
      unitRef="eur">-1534000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTUtMS0xLTM4MjEy_4f1373bf-7306-45ff-9a81-421b511333c3"
      unitRef="eur">-84000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTctMS0xLTM4MjQ4_60a34101-d60b-4d53-b631-d830385492a6"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i946464e2c020499fa8273a1147673bf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTktMS0xLTM4MjYy_a9549186-edea-4121-9a91-b58a38e21e75"
      unitRef="eur">-6000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i0fe13d91957b4f5d9b92fe0c5c865255_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE2LTktMS0xLTM4MjE5_b543f771-1979-4a45-a688-62911790045b"
      unitRef="eur">-6831000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTEtMS0xLTM4MTk5_b2fe0b5b-e552-4f59-a881-03d55808f00b"
      unitRef="eur">8256000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTMtMS0xLTM4MjA2_f5e08f6a-ea4a-48b3-8bff-889fa896425d"
      unitRef="eur">56000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTUtMS0xLTM4MjEy_152a37f2-c77b-4c72-a26d-1ac2e44eaa04"
      unitRef="eur">129000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTctMS0xLTM4MjQ4_e55d9243-cc93-4dca-a518-10e9420eac61"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTktMS0xLTM4MjYy_3f2c0b8b-c92f-4428-a675-3ff3619a9dc8"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTo3NmVjZDIyZjkxMTk0ZjdjODg4ZjA0ZDA5OGI4MmVmYi90YWJsZXJhbmdlOjc2ZWNkMjJmOTExOTRmN2M4ODhmMDRkMDk4YjgyZWZiXzE3LTktMS0xLTM4MjE5_0ec5e241-127e-41e7-80f1-7e79174a7972"
      unitRef="eur">8186000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2MzM_4f3f036c-4223-42e8-9305-720f02e5dc58"
      unitRef="eur">1362000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <nbx:LeaseContractExtendedPeriod
      contextRef="ie783ca6ccd7146eab501b3c72da67598_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2OTU_4a3b4dcd-fec0-45b1-ab44-db0188544c4f">P4Y</nbx:LeaseContractExtendedPeriod>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2NTA_7cd79a33-627d-49a0-a64c-e7af63ed3efb"
      unitRef="eur">1390000</ifrs-full:AdditionsToRightofuseAssets>
    <nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact
      contextRef="i0b81d8a5a73a407bb988138960f2851e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2Njc_112cca13-be14-4733-b88a-f5fe25cb315d"
      unitRef="eur">-25000</nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ibb1347c41497424f9aa4ac3cedd80f7f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzMyOTg1MzQ4OTQ2ODE_19d81f81-d66a-4adc-8136-c691524d6c1d"
      unitRef="eur">139000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iaf55c96a01274951b50be727c673d9f8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMS0xLTEtMTE5OTk_3c638b81-9d1e-4208-8533-d9aa054f537b"
      unitRef="eur">3297000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMy0xLTEtMTE5OTk_86950397-b5c3-451e-916b-ae1107e9df7a"
      unitRef="eur">16000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtNS0xLTEtMTE5OTk_40e92ebc-905c-4723-b684-7d17370cede8"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtNy0xLTEtMTE5OTk_3b39d34c-b102-40a6-a6d5-926e7f5ad8d7"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i554bfad111f84dc29b2fb78b94a90bad_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtOS0xLTEtMTE5OTk_28b08ba9-ab81-4aca-8df5-44d6f6019308"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iadbefaf925c74b24a9922616c74a0553_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEtMTEtMS0xLTExOTk5_fc79c7c7-a515-4555-9881-985734660521"
      unitRef="eur">3313000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3fa642340f4542e7a93116c893889a2f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMS0xLTEtMTE5OTk_56ea52d8-da8a-41d8-b3e9-8323f1bf4b4c"
      unitRef="eur">6766000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMy0xLTEtMTE5OTk_ea712c0c-72d6-40da-8562-8223e8c8089d"
      unitRef="eur">418000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItNS0xLTEtMTE5OTk_c253a1ed-0d83-42d5-8eff-5b7202b5ec04"
      unitRef="eur">14000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItNy0xLTEtMTE5OTk_ab463ad6-e91a-438d-99d0-4c0cb01daa78"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItOS0xLTEtMTE5OTk_d1576929-ff3f-4d0d-abd7-21bbdaf762ee"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i992fc55410f2432f87fb2d95d37cf5c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzItMTEtMS0xLTExOTk5_74fd0b42-7577-4894-ae8a-dead979daad3"
      unitRef="eur">7171000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifbdff15c03e7404a98464181c8e1cedd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMS0xLTEtMTE5OTk_d8cf7619-d4e2-4a08-904b-a59ff54bca0d"
      unitRef="eur">2019000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMy0xLTEtMTE5OTk_fa274ab7-1aac-4d4e-8aa3-b8201497b4bd"
      unitRef="eur">42000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtNS0xLTEtMTE5OTk_a84c4035-4c3a-49b0-a6b5-24d58586fc66"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtNy0xLTEtMTE5OTk_f8858b67-9262-4520-a80f-4d3aa6536508"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i20c9c9c231d54dfda11bb978b834e09a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtOS0xLTEtMTE5OTk_70be5a21-c25d-44e6-8e52-2aa28615162f"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i07d2744884e34de08bb1bf0f018e8367_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzMtMTEtMS0xLTExOTk5_b344d3d1-c84b-4d16-acd1-41a2e4565bb1"
      unitRef="eur">2061000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3aa22cbb09f04242898c09c6ea3dc0bc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMS0xLTEtMTE5OTk_aa1f8d97-31db-4952-b8cc-6b8e77aa9b77"
      unitRef="eur">957000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMy0xLTEtMTE5OTk_6a57c8d0-24cb-4199-9b43-352de4db5e98"
      unitRef="eur">37000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtNS0xLTEtMTE5OTk_db7bb4af-f4d3-41dd-9e31-9bb7a9a85c42"
      unitRef="eur">1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtNy0xLTEtMTE5OTk_b27496bc-aef3-4e12-8e3d-f3a0aab36774"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ia5dda1151b434d7f837612e613cb2bb3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtOS0xLTEtMTE5OTk_10298080-e231-4e21-a354-2c1b6492c787"
      unitRef="eur">-4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i88c91a06314d44bbbde5e2e5d56195e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzQtMTEtMS0xLTExOTk5_1af0d8d9-401f-45d5-999f-94f57af46acd"
      unitRef="eur">988000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i3866b055ff984a8f95514cf68bf892bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMS0xLTEtMTE5OTk_b2c2071f-b381-4079-a7a6-13798771fd58"
      unitRef="eur">34000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMy0xLTEtMTE5OTk_90789e0f-fc59-4c76-a7d7-b9e930d5faab"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtNS0xLTEtMTE5OTk_84dbbaac-33f9-4ebb-bc37-ce4b13a93359"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtNy0xLTEtMTE5OTk_fa552e65-ad27-4a7e-b989-28daaafc2c92"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ib02b54496e4a4425898a6c02fa9ffb10_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtOS0xLTEtMTE5OTk_05a31f39-c467-4695-8e84-cc1bc499399b"
      unitRef="eur">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i680d6b18b0404cd387ee4220cef45346_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzUtMTEtMS0xLTExOTk5_361f535b-0d67-4f5f-915c-77e6fdeaf086"
      unitRef="eur">31000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ic272971549af47d782e5f60383a7ecae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMS0xLTEtMTE5OTk_32b3f063-5b15-4a70-905d-f43449a25865"
      unitRef="eur">115000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMy0xLTEtMTE5OTk_39595662-d123-4e13-808d-c7e4609873d3"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtNS0xLTEtMTE5OTk_e3d9eba0-37e0-4195-bd1e-4bc166e59b0a"
      unitRef="eur">41000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtNy0xLTEtMTE5OTk_f84f37b3-bd52-49fb-8432-a4f5e00bc7a5"
      unitRef="eur">-5000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i46c73ac71585489db372fdcaebf27a35_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtOS0xLTEtMTE5OTk_c3eae5e8-bfe7-4fd9-9de6-e264eb6ec255"
      unitRef="eur">-4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ie6598955ac8a492fa0a7949b58b5e311_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzYtMTEtMS0xLTExOTk5_fa7ce0c0-c43b-4fc7-ac9b-3ce538119f47"
      unitRef="eur">65000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i105222fe76b34ab481e711fb628a0ce9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMS0xLTEtMTE5OTk_83be2e47-6243-4263-9e3b-5c6c56da373d"
      unitRef="eur">11000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMy0xLTEtMTE5OTk_97711944-01ba-46f2-9598-f68df6d5c97e"
      unitRef="eur">1000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctNS0xLTEtMTE5OTk_2071dccd-2a53-4839-b917-84f35f77f0f7"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctNy0xLTEtMTE5OTk_5cee8fb7-a0fa-4564-b2dc-2148ec8a1fc0"
      unitRef="eur">-11000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="iea85c7de3a4c40df90c9e4154ba61655_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctOS0xLTEtMTE5OTk_711eb901-3833-45ed-9916-f8a9caabb381"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i79f8b941671b4fc5b254babe62d0b548_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzctMTEtMS0xLTExOTk5_85593b53-36d3-4c01-9baa-e5353f01993b"
      unitRef="eur">1000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i2cf7ac359e404a6e813c1c0ebe727df5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMS0xLTEtMTE5OTk_6793a472-22fb-48ec-9be5-b7103b6bb6e1"
      unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMy0xLTEtMTE5OTk_b0c8fe50-2194-4843-815f-e484bc133565"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtNS0xLTEtMTE5OTk_4626c25c-1f76-4a7a-8031-5c3c0797e0eb"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtNy0xLTEtMTE5OTk_ed4d4875-22b9-41ce-a07d-2a67e7592c9a"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="idad3c7104e304e4da1bf9b29f0858396_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtOS0xLTEtMTE5OTk_bce34813-e561-4c7f-b4d6-c1b635130fdb"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ifbf6a969f3a946aeb176967ed73299f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzgtMTEtMS0xLTExOTk5_9b8c0f35-26ea-4ab4-b246-ee71f952cf1f"
      unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i643b965508bf43d4a88c27237bc3b7fb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMS0xLTEtMTE5OTk_cad4ece1-ed2c-47af-9d55-c6aa67bfe2d3"
      unitRef="eur">13197000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMy0xLTEtMTE5OTk_7142755f-76aa-4112-ad68-0d71d6137c36"
      unitRef="eur">515000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktNS0xLTEtMTE5OTk_c7d08f23-5990-4f0e-bb38-303fd5705b49"
      unitRef="eur">57000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktNy0xLTEtMTE5OTk_aeb77ec2-f450-4caa-8eee-182a5ab9fc88"
      unitRef="eur">-15000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i817d699bc73b41f394b7a0794977c5d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktOS0xLTEtMTE5OTk_55181da9-8ab6-4615-8f91-c58952d4bdb0"
      unitRef="eur">-11000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="iad4e681a419c4d16b32f5518228877ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzktMTEtMS0xLTExOTk5_0d400ba5-eb01-48b0-904a-94d6aac5b842"
      unitRef="eur">13630000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="idb9257083bde4c48b34295c66106f1c8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTEtMS0xLTExOTk5_4dc738bb-e2fd-4e51-b5ed-f951c79bd261"
      unitRef="eur">-1001000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTMtMS0xLTExOTk5_4b2c667b-380d-426c-ad27-512ad7149d46"
      unitRef="eur">-320000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTUtMS0xLTExOTk5_fbfd6ace-277c-4f4c-a95d-0c348d5f19d7"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTctMS0xLTExOTk5_de77d1d9-2ec5-424d-920d-2dab3c9c5652"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i120ef72c0c394fa78a04da36cbe83462_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTktMS0xLTExOTk5_e232eb22-3880-40a3-93ec-322106dd591f"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i314d8ba3f1444ae684a7df4dfaa4261b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEwLTExLTEtMS0xMTk5OQ_c0a49c81-f4fc-4fc4-acfa-a6b2a1f47a13"
      unitRef="eur">-1320000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i44e0a92dd7344b67b577f12968b769f8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTEtMS0xLTExOTk5_2c9c9bf4-22ab-4bb3-82b0-55355858cda1"
      unitRef="eur">-829000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTMtMS0xLTExOTk5_46121a75-3b5d-4ae0-8cf6-d527d1123bc4"
      unitRef="eur">-911000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTUtMS0xLTExOTk5_0131f45e-a5a5-49e8-8442-8d3852bd3e3c"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTctMS0xLTExOTk5_b85a688b-e0eb-4928-adc2-4bb28f5a600c"
      unitRef="eur">2000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="id5c8eab481334a328766007df5fec6db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTktMS0xLTExOTk5_8038c2ec-0060-465f-b7ce-83a7bc1ef580"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ia001cea76fd148669eb3dd9bb6d15f4a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzExLTExLTEtMS0xMTk5OQ_f03b2549-cd4a-4c54-a7e2-b55abb7fbb44"
      unitRef="eur">-1739000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="icab30071042b444a9fac05b56e56f51c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTEtMS0xLTExOTk5_e9937a17-ea25-47ad-b8c8-39622fefe0f9"
      unitRef="eur">-1272000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTMtMS0xLTExOTk5_8823a645-b419-4800-8e0b-bf5c48479317"
      unitRef="eur">-194000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTUtMS0xLTExOTk5_58d81773-d84a-4017-819e-2e3f263587a7"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTctMS0xLTExOTk5_4ed0f864-89ab-40bd-b2a7-a6d6f147000d"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i87c4d1dec39a4049ace6541aa71161fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTktMS0xLTExOTk5_0c9fecb5-049f-4f3b-b372-6e018eee2694"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i94439a4b662842c2acd86680522e2018_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEyLTExLTEtMS0xMTk5OQ_f0226be5-db19-4d4a-bf13-6de13428ebd0"
      unitRef="eur">-1466000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i20937f10c0074df48fcf6aae22f3d9fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTEtMS0xLTExOTk5_8ef210a2-293b-422f-8495-5811d99e1097"
      unitRef="eur">-629000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTMtMS0xLTExOTk5_e06a4377-7123-4616-98f4-bdd4e7996c98"
      unitRef="eur">-157000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTUtMS0xLTExOTk5_af981b6d-2c4c-4960-9698-de061a9c7007"
      unitRef="eur">-1000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTctMS0xLTExOTk5_3c9bf396-e82c-46a2-ae1b-69e17f37da58"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i18d4f0e4ee2d4c5d992adb8b5ed1d15a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTktMS0xLTExOTk5_b5e90ea4-24cb-4697-8696-0cda199dba47"
      unitRef="eur">2000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i399b1e119c0f4ecea8fb1e6cc1ba7ebc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzEzLTExLTEtMS0xMTk5OQ_9b84df3b-e2a5-4cd8-945c-e7d65346371a"
      unitRef="eur">-783000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i260064a22ba34ca4a69fe812eb47df77_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTEtMS0xLTExOTk5_7a652edf-297c-4841-ae76-05942b20079d"
      unitRef="eur">-34000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTMtMS0xLTExOTk5_2a4c763b-275c-4342-b70c-ed75631cbfa1"
      unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTUtMS0xLTExOTk5_1f14f61e-3744-4f2b-8bfa-ce63ceb7e559"
      unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTctMS0xLTExOTk5_8e4f69f0-c4bf-47a8-bd3a-7ca5099e5c04"
      unitRef="eur">1000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i2cb04ef034ec4205a1c1159d0214af2e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTktMS0xLTExOTk5_f7a347d9-b86e-4e22-937e-64e3604b503d"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i170ffb1f1c9a464dac427c1aae8b927a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE0LTExLTEtMS0xMTk5OQ_4a3e6db6-a170-413d-9a49-ebe73c5e7dc1"
      unitRef="eur">-31000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i910c9a241c624e01900913f0b0bdef46_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTEtMS0xLTExOTk5_7d4429ec-28d7-4690-8541-6b3dbec04b5c"
      unitRef="eur">-45000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTMtMS0xLTExOTk5_97419d8a-3902-4183-8f00-dff1b364f914"
      unitRef="eur">-35000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTUtMS0xLTExOTk5_900986d6-c1d2-4560-a206-8795e7ec5410"
      unitRef="eur">-42000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTctMS0xLTExOTk5_7b5828d6-2a69-4712-8ee0-2e9181a4cf6f"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="i811a11b85e114a59b32992557918554f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTktMS0xLTExOTk5_3fb0255b-8adb-461b-a9d6-1f373d4d8efb"
      unitRef="eur">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="ieb66730c4b2d424b843abc92b234a808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE1LTExLTEtMS0xMTk5OQ_54d4ef8e-af39-4ea8-9856-e898ee81db25"
      unitRef="eur">-36000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i1fd5dc377e504702bf04bf3db9a706ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTEtMS0xLTExOTk5_dfba4653-c707-49df-af5e-377c4e4f6e01"
      unitRef="eur">-3811000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTMtMS0xLTExOTk5_512095a7-29be-423f-9336-9ce1fdc12f9b"
      unitRef="eur">-1616000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTUtMS0xLTExOTk5_23a4ef3b-b687-463a-861b-4757c41654ac"
      unitRef="eur">-43000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTctMS0xLTExOTk5_0aab7eea-90c4-4363-9f55-4f97fc7c98b3"
      unitRef="eur">4000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="ie682b39dff074a35b1bbc60c3300908d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTktMS0xLTExOTk5_0277c61c-74f7-4dfd-b539-8b1e03edb0bd"
      unitRef="eur">6000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i4f8a44047f7a4394b908bddc6ac9cf9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE2LTExLTEtMS0xMTk5OQ_c0ea5f65-f451-4352-8338-7a3075518999"
      unitRef="eur">-5374000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTEtMS0xLTExOTk5_6a64c9ba-eca2-4752-98d3-67497b17212e"
      unitRef="eur">9386000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTMtMS0xLTExOTk5_7ccb26f5-f2bb-4052-b1fb-71613b26f201"
      unitRef="eur">-1101000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTUtMS0xLTExOTk5_e6c79102-3482-434a-83f7-0882293eb2f8"
      unitRef="eur">14000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTctMS0xLTExOTk5_e617e0ec-dded-4e26-88c2-bbe2007d0b4c"
      unitRef="eur">-12000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTktMS0xLTExOTk5_78402ebc-8a35-4327-8d17-c07674eec884"
      unitRef="eur">-4000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90YWJsZTpmN2FkNmJiYmY1NTM0ODE2OTAyZTgwYmFjZmRkZWRlNS90YWJsZXJhbmdlOmY3YWQ2YmJiZjU1MzQ4MTY5MDJlODBiYWNmZGRlZGU1XzE3LTExLTEtMS0xMTk5OQ_fe2f292b-4336-4c60-a2f7-d91661af1f98"
      unitRef="eur">8256000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="i339290eaa25e44c49131f9b65da8e0ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE0MjM_ba17326c-5436-4a0f-b593-58f2b26a5cd2"
      unitRef="eur">418000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <nbx:NumberOfNewLeaseContracts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE0ODQ_0ed2040e-cc1f-45b3-bb55-a4066afe52f0"
      unitRef="lease_contract">2</nbx:NumberOfNewLeaseContracts>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="ia7a4c79360f041e5886fda1753c164ae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE1NTM_f8a04099-4609-40bb-ad10-caa9957c9548"
      unitRef="eur">155000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i34e3193487544206a16d163e6d8f920a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE2MTQ_78f4fb52-b20b-4425-82d3-8b55c8b52a4f"
      unitRef="eur">140000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="i01a5d032d32a4c5aa0906fe6968d960c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE2NzU_45fb363c-2da5-46aa-b6db-ba99477cab5e"
      unitRef="eur">43000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i9c8540a5ebd94096aee7b210cb09c5da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE3NTU_b0e4ab60-5b0c-44a8-9121-1c4ae1983c2b"
      unitRef="eur">30000</ifrs-full:AdditionsToRightofuseAssets>
    <nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact
      contextRef="i353ed3a135f54c7a972415594cd58a8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE5Mjk_69c5e032-8085-4dc0-bfcb-de9a81a5d629"
      unitRef="eur">35000</nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact>
    <nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact
      contextRef="i46249c3026ff4190a1f98baf898f61d9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNDgvZnJhZzpmMDUzNjZkMzk4OWM0Yjc1OTJkZjRiZjY2Y2U3NTIxYi90ZXh0cmVnaW9uOmYwNTM2NmQzOTg5YzRiNzU5MmRmNGJmNjZjZTc1MjFiXzE5MzY_1bb70e49-1f35-4d84-8533-92bf217b1238"
      unitRef="eur">15000</nbx:IncreaseDecreaseToAnnualRentExpenseIndexationImpact>
    <nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjY_aea83e79-6465-49b3-a1f5-48319a6bf363">Non-current financial assets &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-current financial assets are recognized and measured in accordance with IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;No non-current financial assets are estimated at fair value through other comprehensive income (OCI). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Pursuant to IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, financial assets are classified in three categories according to their nature and the intention of management: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at fair value through profit and loss;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at fair value through other comprehensive income; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All regular way purchases and sales of financial assets are recognized at the settlement date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial assets at fair value through profit or loss &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial assets at amortized cost &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case&#x2013;by&#x2013;case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Detail of non-current financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in non-current financial assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;contract - &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash account&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;long-term investments pledged as collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Security &lt;br/&gt;deposits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transfer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;See note&#160;10.2 Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2021, non-current financial assets increased by &#x20ac;14&#160;thousand compared to 2020. In 2020, non-current financial assets decreased by &#x20ac;24&#160;thousand compared to 2019. In 2021, the security deposits paid increased by &#x20ac;20&#160;thousand, mainly due to a &#x20ac;9&#160;thousand deposit paid in connection with a new Nanobiotix Corp  headquarters&#x2019; lease contract in Cambridge, Massachusetts, United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The decrease of the liquidity contract &#x2013; cash account corresponds to treasury shares transactions whose counterpart is recorded as capital on the "treasury shares" line in the statement of change in shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjQ_c2db5ad5-a4bf-4fab-ad8f-ab97d275e473">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-current financial assets are recognized and measured in accordance with IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;No non-current financial assets are estimated at fair value through other comprehensive income (OCI). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Pursuant to IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, financial assets are classified in three categories according to their nature and the intention of management: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at fair value through profit and loss;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at fair value through other comprehensive income; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Financial assets at amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;All regular way purchases and sales of financial assets are recognized at the settlement date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial assets at fair value through profit or loss &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This category includes marketable securities, cash and cash equivalents. They represent financial assets held for trading purposes, i.e., assets acquired by the Company to be sold in the short-term. They are measured at fair value and changes in fair value are recognized in the consolidated statements of operations as financial income or expense, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial assets at amortized cost &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This category includes other financial assets (non-current), trade receivables (current) and other receivables and related accounts (current). Other financial assets (non-current) include advances and security deposits and guarantees granted to third parties as well as term deposits and restricted cash, which are not considered as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;They are non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset, except trade receivables that are initially recognized at the transaction price as defined in IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;After initial recognition, these financial assets are measured at amortized cost using the effective interest rate method when both of the following conditions are met:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Gains and losses are recorded in the consolidated statements of operations when they are derecognized, subject to modification of contractual cash flows and/or impaired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;requires an entity to recognize a loss allowance for expected credit losses on a financial asset at amortized cost at each Statement of Financial Position date. The amount of the loss allowance for expected credit losses equals: (i) the 12 - month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased significantly since initial recognition of the financial instrument. An impairment is recognized, where applicable, on a case&#x2013;by&#x2013;case basis to take into account collection difficulties which are likely to occur based on information available at the time of preparation of the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Disputed receivables are written-off when certain and precise evidence shows that recovery is impossible, and existing credit loss allowance are released. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Financial assets and liabilities are monitored for any indication of impairment. Under IFRS 9, the impairment model is based on the accounting on expected credit losses during the life of the financial assets. A financial asset is impaired if its credit risk, determined with both historic and prospective data, increased significantly since its initial booking. The loss will impact the net income (loss) recorded to the statement of operations.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQ1MjU_cf48b695-71d5-4807-af0f-dd94be2141ea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in non-current financial assets breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;contract - &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash account&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;long-term investments pledged as collateral&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Security &lt;br/&gt;deposits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;105&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;401&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;505&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transfer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net book value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;421&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;See note&#160;10.2 Treasury shares&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="id04209b08bf44c238d4f342e917d80c8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMS0xLTEtMTE5OTk_7c602246-0633-4c2d-9d01-e4afc1e47f13"
      unitRef="eur">131000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i2dbdf51ff17642c88fe93c80600f8cb4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMi0xLTEtMTE5OTk_7c002b7e-2662-47d4-8de1-eacbe3e47c22"
      unitRef="eur">0</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i694c290810ce4cc9842fae0c52f55511_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtMy0xLTEtMTE5OTk_7dcf9e3b-be31-44a5-8165-e1492084b11a"
      unitRef="eur">399000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzEtNC0xLTEtMTE5OTk_a622a290-aa28-494f-a032-89df01beac4e"
      unitRef="eur">529000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMS0xLTEtMTE5OTk_ae5f21b5-3f2d-44a0-a90d-f93f6b7446e0"
      unitRef="eur">0</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMi0xLTEtMTE5OTk_c5306e1a-aad1-458a-aa32-429f1eea0dde"
      unitRef="eur">0</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItMy0xLTEtMTE5OTk_8833289c-757f-4f0d-960b-ef4e5ec3b3be"
      unitRef="eur">9000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzItNC0xLTEtMTE5OTk_d6b50e42-8cb4-483c-9b2f-3ac9de1583db"
      unitRef="eur">9000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMS0xLTEtMTE5OTk_a5360710-ce69-4cb0-892d-f98ffca34c5d"
      unitRef="eur">27000</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMi0xLTEtMTE5OTk_bbdd5bc2-4d2b-4078-9c48-9c17071f03b2"
      unitRef="eur">0</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtMy0xLTEtMTE5OTk_1507c3f8-eb41-4be4-a602-864502388c99"
      unitRef="eur">5000</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzMtNC0xLTEtMTE5OTk_9748dd70-f0a1-4655-b0c6-8dc2215841b1"
      unitRef="eur">31000</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="ie57c26a1d23545f3805ce56697aec8e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMS0xLTEtNTQyNTE_9aa3b6bc-c7ef-48af-999d-1d7d2a20e3c8"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="i2cc66a3f5ebe44d1bdd3ed962e82176a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMi0xLTEtNTQyNTQ_97131d70-3112-4729-bf66-f429f7811cb8"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="i752591c410134e60bdd79d9b16eff052_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMy0xLTEtNTQyNTY_05e373d2-827f-4cac-b08a-bf0245d24360"
      unitRef="eur">-2000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtNC0xLTEtNTQyNTg_f73f2778-9f85-43cd-ae31-13bdeb1a89a1"
      unitRef="eur">-2000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i9e2c65d93df14f99b81bd99646ea83fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMS0xLTEtMTE5OTk_95f0ca6e-1451-4a18-b201-079110ea3f36"
      unitRef="eur">105000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i9df395790ebc462db44260a48f7af4f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMi0xLTEtMTE5OTk_95697720-7214-4277-8157-5981eaf51c2c"
      unitRef="eur">0</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i6e942c5d9cf5421e8899afaab5b13ae1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtMy0xLTEtMTE5OTk_cdfd2a2c-0030-4e89-92d9-a75e624d2925"
      unitRef="eur">401000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzQtNC0xLTEtMTE5OTk_542a9a64-9d84-433c-ab2e-766ea72e8670"
      unitRef="eur">505000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMS0xLTEtMTE5OTk_6c627db0-14b1-4a59-bb96-f17f875eeb09"
      unitRef="eur">0</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMi0xLTEtMTE5OTk_a6a0025d-6236-47b1-aa58-619d500def8d"
      unitRef="eur">0</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtMy0xLTEtMTE5OTk_64e91d8a-46d1-4412-a0f6-e66d5ebd6150"
      unitRef="eur">9000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzUtNC0xLTEtMTE5OTk_c94aa526-5abd-442f-86de-81b79645ed00"
      unitRef="eur">9000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMS0xLTEtMTE5OTk_5cf5394b-0afa-4428-8bad-c5fd87ed2cd8"
      unitRef="eur">6000</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMi0xLTEtMTE5OTk_d43a8e9c-5daa-4e1f-babf-958e7b7b8a13"
      unitRef="eur">0</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtMy0xLTEtMTE5OTk_cc0d44b5-3756-413e-98a1-ecc2464472d7"
      unitRef="eur">0</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzYtNC0xLTEtMTE5OTk_ad70ea79-2539-4218-9803-d149e687fdfc"
      unitRef="eur">6000</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets
      contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMS0xLTEtNTQyMTI_9ea6cdb4-f799-44e6-a944-5a0f877088f4"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets
      contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMi0xLTEtNTQyMTQ_454812ce-371e-4ab4-b86b-21c2c56d7ff8"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets
      contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMy0xLTEtNTQyMTY_c99297f7-a9cc-44ed-8a7c-785704ee50ae"
      unitRef="eur">8000</ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctNC0xLTEtNTQyMTg_97623bb0-52a6-4309-831d-20a880fb6a0c"
      unitRef="eur">8000</ifrs-full:IncreaseDecreaseThroughTransfersFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="if603194df5564dc9b8fc218cfbbe55a7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMS0xLTEtMTE5OTk_2b7de101-d89a-4cf2-b476-97bf293cc401"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="i7686208d4618428d8aed474cee2bf37a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMi0xLTEtMTE5OTk_933f2e31-d831-461c-b2ea-926297a7f4b5"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="i0b49cd285c2b4213b5a2fa799078f63c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctMy0xLTEtMTE5OTk_c5d656d1-d2aa-4985-bbef-e1322db0fa93"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzctNC0xLTEtMTE5OTk_f5faab1e-3925-4e06-8fa9-44bd1de34bbd"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i937f4bc37d82433796fe6b3c4ec0ccb2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMS0xLTEtMTE5OTk_f70e10ca-334c-4b99-bde9-075826f3fd4f"
      unitRef="eur">98000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i589f8e8059664ca486811bb10b3d5162_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMi0xLTEtMTE5OTk_c8072727-7266-4c91-a428-9393bb601d45"
      unitRef="eur">0</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i2b861ae5f68a416d8f8db4e710c14707_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtMy0xLTEtMTE5OTk_6cc6ad68-2463-4e29-addc-52fc910d4410"
      unitRef="eur">421000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90YWJsZTpiNWViNzMyOGZkNmY0MTE3OGUzNzY1MjhkNTdkYzQyNy90YWJsZXJhbmdlOmI1ZWI3MzI4ZmQ2ZjQxMTc4ZTM3NjUyOGQ1N2RjNDI3XzgtNC0xLTEtMTE5OTk_51ffa97f-edc3-4a1e-9aac-81012b7a064a"
      unitRef="eur">519000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:IncreaseDecreaseInFinancialAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzM4Nzc_45783706-6074-45eb-a919-bd5ac1eec0de"
      unitRef="eur">14000</ifrs-full:IncreaseDecreaseInFinancialAssets>
    <ifrs-full:IncreaseDecreaseInFinancialAssets
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzM5NDk_9456723a-be01-4c0d-83b4-9035ce086742"
      unitRef="eur">-24000</ifrs-full:IncreaseDecreaseInFinancialAssets>
    <ifrs-full:IncreaseDecreaseInFinancialAssets
      contextRef="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQwMTk_2aeacbb5-2198-49bf-a20f-bad4dec8a0d2"
      unitRef="eur">20000</ifrs-full:IncreaseDecreaseInFinancialAssets>
    <ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets
      contextRef="iacd19705657b4e5bb067db21856a14b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTEvZnJhZzplODNjY2JjMmU0ZWY0NzQ2ODQ0NjRkYWVmZjRjOWY5MS90ZXh0cmVnaW9uOmU4M2NjYmMyZTRlZjQ3NDY4NDQ2NGRhZWZmNGM5ZjkxXzQwNDU_097ff86a-8f13-4dbb-8cb9-25481e9c0b01"
      unitRef="eur">9000</ifrs-full:IncreaseThroughOriginationOrPurchaseFinancialAssets>
    <nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4MzE_8aa2a968-9ff0-4ebb-824b-7293af8af4b7">Trade receivables and other current assets&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for trade receivables and other current assets are described in Note 7.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;8.1 Trade receivables&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables break down as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in 3 months or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due between 3 and 6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due between 6 and 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after more than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;8.2 Other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other current assets break down as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of December 31, 2021, prepaid expenses mainly relate to:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;research agreements related to the MD Anderson agreement (see Note 4.4 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Collaboration Agreement with the University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;for &#x20ac;1.0&#160;million, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;insurance related to the Directors &amp;amp; Officers for &#x20ac;0.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As of December 31, 2020, prepaid expenses mainly relate to research agreements related to MD Anderson agreement (see Note 4.4 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%"&gt;Collaboration Agreement with the University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;for &#x20ac;1.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Other receivables mainly comprised advances paid to suppliers in the amounts of &#x20ac;3,043&#160;thousand as of December 31, 2021 as compared to &#x20ac;805&#160;thousand as of December 31, 2020. This advance payment is mainly related to the new ICON contract signed in 2021 in conjunction with the launch of the 312 study.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research tax credit &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company receives a research tax credit (Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche, or &#x2018;&#x2018;CIR&#x2019;&#x2019;) from the French tax authorities. See Note 15 for additional details on the CIR research tax credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The research tax credit for 2021 was &#x20ac;2.5&#160;million (&#x20ac;2.3&#160;million for Nanobiotix S.A. and &#x20ac;218&#160;thousand for Curadigm SAS), while the amount for 2020 was &#x20ac;1.9&#160;million (&#x20ac;1.9&#160;million for Nanobiotix S.A. and &#x20ac;69&#160;thousand for Curadigm SAS). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The 2020 research tax credit was collected by the Company in November 2021, while the 2019 research tax credit was collected in July 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in research tax credit receivables breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,688&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2018 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2019 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2019 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2020 research tax credit &#x2013; Nanobiotix SA &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2020 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2020 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2020 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2021 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2021 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjc_87f0672c-624a-4abd-95c4-d0db69d13ef9">Trade receivablesIn 2020, trade receivables related mainly to invoices issued to PharmaEngine, in connection with the charging-back of shared external clinical research organization costs under the License and Collaboration Agreement as amended (see Note 4 for more detail on the License and Collaboration Agreement). This agreement terminated in March 31, 2021 and the related receivables have been settled.</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjg_0a045c48-c8e9-4b3a-adc9-a71137b1db11">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables break down as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in 3 months or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due between 3 and 6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due between 6 and 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after more than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzItMS0xLTEtMTE5OTk_00489592-3deb-450f-b962-39667d57857b"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzItMi0xLTEtMTE5OTk_fa8cb2cc-ce17-47ec-88d6-9b25df050364"
      unitRef="eur">62000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzMtMS0xLTEtMTE5OTk_cd43cc1c-b03c-45d4-b79f-e2297dab83be"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTozNzYyYTI2MTU1YmM0Y2Y3OWQ1YjJiYmY4ZjE0M2Y2MC90YWJsZXJhbmdlOjM3NjJhMjYxNTViYzRjZjc5ZDViMmJiZjhmMTQzZjYwXzMtMi0xLTEtMTE5OTk_e9f2edf7-b8b0-4080-8736-56aeb20e6f00"
      unitRef="eur">62000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i23b8abb72e0b4536a6fe80c714c03c32_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzItMS0xLTEtMTE5OTk_558882e4-c680-431b-99ae-3ecc687bf9a3"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i45a5ffbbe08f4f37926998b489baeab7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzItMi0xLTEtMTE5OTk_18080005-274f-4f66-be1f-8803d271c260"
      unitRef="eur">62000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i92d57836a46444b38c01d05737626c40_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzMtMS0xLTEtMTE5OTk_d6aaf4db-3f7d-450c-ad1f-4309d2d80797"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i75abd63d3d554d209254ec0fe3788db5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzMtMi0xLTEtMTE5OTk_1d365415-6e66-466b-8053-64fde20fb123"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i7fa06ae2654e494ca242be8b5638282c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzQtMS0xLTEtMTE5OTk_7bb5b433-3736-4afd-b452-cecf86e91c06"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i6259fe63f29c47ceb1ee63617d3f873e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzQtMi0xLTEtMTE5OTk_e6d2bec3-f224-411b-99e9-e9a840c7fa3c"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i897163af67de42779bade9156e460371_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzUtMS0xLTEtMTE5OTk_c45349f3-1251-436a-90ab-eab6fea71d0d"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="iab0221939eca477097e1a9493a0df475_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzUtMi0xLTEtMTE5OTk_2806be42-572b-427f-9b08-fb4586bf00a5"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzYtMS0xLTEtMTE5OTk_5ffc96cc-8fb4-403a-826f-494bd0b89272"
      unitRef="eur">0</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjMGM1MjQ4NzkzNmY0Y2Y2YTg3NTYxMmYyNmUyMDk2ZC90YWJsZXJhbmdlOmMwYzUyNDg3OTM2ZjRjZjZhODc1NjEyZjI2ZTIwOTZkXzYtMi0xLTEtMTE5OTk_bf345180-466a-40df-b663-4cdad69bfdcc"
      unitRef="eur">62000</ifrs-full:CurrentTradeReceivables>
    <nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4Mjk_912f4b1e-f499-40ab-b950-6829533fa0de">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other current assets break down as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;9,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzItMS0xLTEtMTE5OTk_8b640065-aea2-44f2-94a7-c8d082dfb805"
      unitRef="eur">2490000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzItMi0xLTEtMTE5OTk_3cd7fd6b-42e7-4705-a88e-df6e43cf8d34"
      unitRef="eur">1927000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzMtMS0xLTEtMTE5OTk_8b83bd4b-e365-4698-93bf-75898fa9ea27"
      unitRef="eur">1058000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzMtMi0xLTEtMTE5OTk_8c8559aa-0e85-48e8-852b-7d79d44aedaa"
      unitRef="eur">971000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzQtMS0xLTEtMTE5OTk_dec04910-33c1-4e5b-8b6c-8461bc46451a"
      unitRef="eur">2213000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzQtMi0xLTEtMTE5OTk_f5c3f551-58fb-421d-9b1e-0434213a679e"
      unitRef="eur">2217000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzUtMS0xLTEtMTE5OTk_b8acbe1c-2715-4ae6-ba1e-1a39aad9337f"
      unitRef="eur">3378000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzUtMi0xLTEtMTE5OTk_639e1ebb-0625-463c-bc8c-3cdacbfa309b"
      unitRef="eur">920000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzYtMS0xLTEtMTE5OTk_ee5ab99e-bb4d-4010-8d92-55f21216f91f"
      unitRef="eur">9139000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTpjYTE0OWY4YWQ0ZGE0YjgwYTRkYzQ0YzdkOTMzOTQxNi90YWJsZXJhbmdlOmNhMTQ5ZjhhZDRkYTRiODBhNGRjNDRjN2Q5MzM5NDE2XzYtMi0xLTEtMTE5OTk_5f08e772-766a-44ed-9ca5-b3d846877e14"
      unitRef="eur">6035000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="icfe58517db324e8ab08832232c673117_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzY2OQ_c10abdbf-767e-4262-90fc-7fd3522f1022"
      unitRef="eur">1000000</ifrs-full:CurrentPrepaidExpenses>
    <nbx:CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NDc_7663f617-0d47-4ee0-a334-9b166c84a974"
      unitRef="eur">600000</nbx:CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="i314cd9d76fc14624b016b4bc4d2bdef2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NjE_6fe292e4-672e-4531-bc7c-799c00a23998"
      unitRef="eur">1600000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2NzU_721fe126-7863-425a-876d-f704e4ddacd6"
      unitRef="eur">3043000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzMyOTg1MzQ4OTA2OTI_08cf71ca-f52e-4b83-8a9c-8427992ac86c"
      unitRef="eur">805000</ifrs-full:CurrentAdvancesToSuppliers>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="iab6584aaa34740b0aea5f3a15d522bf5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0Mzg_415f111d-0225-4ce6-8124-53531af2a847"
      unitRef="eur">2500000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i89b95576d1404490b4202945e6c02016_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0NDI_5e9e82dd-1f7c-4e37-88fc-7d59c446faac"
      unitRef="eur">2300000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE0Njk_b5aab002-a6d8-4361-8894-dad581ab856b"
      unitRef="eur">218000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="ifdc4df3987ae442da01b94c5efbf38f7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1MjE_c3ee4566-0e2b-4725-bf5c-f5dfa4bf7151"
      unitRef="eur">1900000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1MjU_51da2482-11c0-4163-91ac-b52974750e21"
      unitRef="eur">1900000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE1NTI_7e9c130b-2148-4cf1-8927-9efe3c70d5f6"
      unitRef="eur">69000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90ZXh0cmVnaW9uOmI1NDQ2NmRiNWIzZjRlYTliZGJiMWNlYTBlYmEyMmMyXzE4MzA_49028e51-19a4-4665-9cee-12da35d7a092">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The change in research tax credit receivables breaks down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,688&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2018 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2019 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2019 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2020 research tax credit &#x2013; Nanobiotix SA &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2020 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2020 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Refund of 2020 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2021 research tax credit &#x2013; Nanobiotix SA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2021 research tax credit &#x2013; Curadigm SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Receivable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzMtMS0xLTEtMTE5OTk_1686af2e-8dd3-4040-8cc2-6a23c291e2e6"
      unitRef="eur">5688000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund
      contextRef="i4e0a8e1adc2f4d8daeb375e78b79e118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzQtMS0xLTEtMTE5OTk_6d71983b-3205-47f3-84a3-fd4e5d353418"
      unitRef="eur">3251000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund
      contextRef="icea5a1f000274c7aa5aec8d463a011bd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzUtMS0xLTEtMTE5OTk_2b164b49-b950-4952-b952-b58bfac413ba"
      unitRef="eur">2374000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund
      contextRef="i3549effa38bf42068215a5f6e7f44599_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzYtMS0xLTEtMTE5OTk_759c70c5-30f5-41cc-ba0c-e1a1e0cd5a38"
      unitRef="eur">64000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="if78734d4ecae4539a86ca4df95e5f303_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzctMS0xLTEtMTE5OTk_c28d59cb-9131-4492-a49d-a46ee487a721"
      unitRef="eur">1858000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i9e8e4426755c4d5f962be7d70e588f5f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzgtMS0xLTEtMTE5OTk_663e76b9-08e5-4b9b-8c6d-b5fe978c75ba"
      unitRef="eur">69000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMTE5OTk_a2418f1d-2f50-4c8e-8c5b-9ce6ca236597"
      unitRef="eur">1927000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund
      contextRef="i2a3d9c879e064e8595cbe98b04ca6d30_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzgtMS0xLTEtMzg1OTg_b9b3d26b-7025-4aba-8756-8b4e99fa973e"
      unitRef="eur">1858000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund
      contextRef="i9d3f9bb9f0f14b24babfb6bd054d8acf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMzg2Mjc_0219cb54-5799-489a-aa23-426f12406617"
      unitRef="eur">69000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i89b95576d1404490b4202945e6c02016_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzEwLTEtMS0xLTM4NjI3_77d036f3-5dcb-4bb7-8f41-e66d90723dad"
      unitRef="eur">2272000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease
      contextRef="i7a1a08ae94e844b39ea70b66903a21e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzktMS0xLTEtMzg1OTg_89100031-39f5-46d8-b9a0-6f7ce7945e15"
      unitRef="eur">218000</nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTQvZnJhZzpiNTQ0NjZkYjViM2Y0ZWE5YmRiYjFjZWEwZWJhMjJjMi90YWJsZTo2ZjAxZmI0YTI2OGE0YWU4YWQ1OTcyMjllMTJlZDU4MS90YWJsZXJhbmdlOjZmMDFmYjRhMjY4YTRhZThhZDU5NzIyOWUxMmVkNTgxXzEyLTEtMS0xLTM4NTk4_aa12207a-9917-4bd8-812d-e4868ed98b82"
      unitRef="eur">2490000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDc_8c48a555-9e30-41b5-a1fd-57885d35a575">Cash and cash equivalents&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash equivalents are measured at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalent break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and bank accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;83,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, cash and bank accounts decreased by &#x20ac;35,230&#160;thousand as compared with December 31, 2020 mainly due to:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the non-refundable upfront payment from LianBio in June 2021 of &#x20ac;16.5&#160;million ($20.0&#160;million);&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the payments made to PharmaEngine for a total of &#x20ac;5.4&#160;million in 2021 pursuant to the PharmaEngine Termination Agreement; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the debt reimbursement related to the EIB loan for &#x20ac;3.0&#160;million and to the Bpifrance loan for &#x20ac;0.5&#160;million; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;other cash flows used in operating activities.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDg_5d34313b-2519-4424-962f-92296a1e5310">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other reasons. They are easily converted into known amounts of cash and are subject to an insignificant risk of changes in value. Cash and cash equivalents consist of liquid assets that are available immediately and term deposits. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash equivalents are measured at amortized cost.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzE1NDk_17effd42-529f-42ac-b295-c3d3618f09be">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalent break down as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and bank accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;83,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,151&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock>
    <ifrs-full:Cash
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzItMS0xLTEtMTE5OTk_ec459d9e-5966-4a1c-b1de-4f174e872f8a"
      unitRef="eur">83921000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzItMi0xLTEtMTE5OTk_7bd6af5d-b971-4e39-8510-edeb12516c0c"
      unitRef="eur">119151000</ifrs-full:Cash>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzMtMS0xLTEtMTE5OTk_8e4904e6-41d2-453e-8f66-8b44e95f2525"
      unitRef="eur">83921000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90YWJsZTowNDVjMmQ4NjY4OWQ0NDNlOGJlNTFmYmJkODRlNTg1Yy90YWJsZXJhbmdlOjA0NWMyZDg2Njg5ZDQ0M2U4YmU1MWZiYmQ4NGU1ODVjXzMtMi0xLTEtMTE5OTk_7d6b2d32-9856-443d-8eec-368ccad16124"
      unitRef="eur">119151000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzc5OA_28d18227-8a59-439c-9d1c-aa730b4d52df"
      unitRef="eur">-35230000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM2ODM_20e85345-48e9-4cbc-b892-755b76b2392f"
      unitRef="eur">16500000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="ic1626ac569db48a794e6c432c5ce473b_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM2OTg_4ebf8505-5f2d-4f7e-a0dd-3872af96fb6c"
      unitRef="usd">20000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:ContractualCommitmentsPayment
      contextRef="ie92e58618b784d11b24590f639ec3c5c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3MTM_a45a275c-3499-45c4-b3ac-7f412059d9cc"
      unitRef="eur">5400000</nbx:ContractualCommitmentsPayment>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3Mjc_063a0153-14ce-4bcc-b45f-769a09558057"
      unitRef="eur">3000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="i2bd304d054954aa8889e0379a055b796_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNTcvZnJhZzpkMmE0YTJkMDJiNGY0NzdmYjJjZjQ4NGVkZDMxYjIzYi90ZXh0cmVnaW9uOmQyYTRhMmQwMmI0ZjQ3N2ZiMmNmNDg0ZWRkMzFiMjNiXzMyOTg1MzQ4OTM3NDE_4e1037ac-b5c8-4764-ac8e-d58f03a15f61"
      unitRef="eur">500000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQz_a76c5ad1-4914-4ed1-9838-4a8f937c7db5">Share Capital&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;10.1 Capital issued&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in shareholders&#x2019; equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders&#x2019; equity as a deduction from the proceeds of the issue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of share capital transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands or number of shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Premiums related to share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;153,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;22,415,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 6, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;316,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 24, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 26, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 28, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Private placement Capital increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 28, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Private placement Capital increase transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering initial deal &#x20ac; - Nasdaq (&#x20ac;11.14)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,855,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering initial deal $ - Nasdaq ($13.50)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 18, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering green shoe $ - Nasdaq ($13.50)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 18, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;255,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,432,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;369,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants attribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants subscription (BSA 2021)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;255,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,825,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, the share capital was &#x20ac;1,044,776.16 divided into 34,825,872 fully paid in ordinary shares each with a par value of &#x20ac;0.03, as compared with the 2020 share capital of &#x20ac;1,032,963.66 divided into 34,432,122 fully paid in ordinary shares, each with a par value of &#x20ac;0.03 and the 2019 share capital of &#x20ac;672,451.17 divided into 22,415,039 fully paid in ordinary shares each with a par value of &#x20ac;0.03.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2021, the increase in share capital is inherent to the definitive acquisition of free shares warrants related to the AGA 2018-1 and AGA 2019-1 plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, the increase in share capital is mainly related to the U.S. initial public offering, which closed in December 2020. In the global offering, a total of 8,395,000 ordinary shares was issued, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;5,445,000 ordinary shares in the form of ADSs were issued in the United States at $13.50 per ADS;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;1,855,000 ordinary shares were issued through a concurrent offering in certain jurisdictions outside of the United States to certain investors at &#x20ac;11.14 per ordinary share; and,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the underwriters for the global offering exercised in full their option to purchase 1,095,000 additional ADSs at the same public offering price of $13.50 per ADS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2020, &#x20ac;10.7&#160;million of transaction costs had been recorded, &#x20ac;9.3&#160;million of which were related to the initial public offering in the United States, and are recognized as a reduction to premiums related to share capital. Those transaction costs were almost paid in full as of December 31, 2020. The remaining &#x20ac;349&#160;thousand were paid in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;10.2 Treasury shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;On December 31, 2021, the Company held 15,456 treasury shares under a liquidity contract compared to 12,970 treasury shares as of December 31, 2020. This liquidity contract complies with the general regulations of, and market practices accepted by, the French Financial Markets Authority (&#x201c;AMF&#x201d;), entered into following the Company&#x2019;s French initial public offering in 2012. These shares were deducted from IFRS equity in the amount of &#x20ac;202&#160;thousand and &#x20ac;196&#160;thousand as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;10.3 Founders&#x2019; warrants, warrants, stock options and free shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for share-based payments are described in Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of change in founders&#x2019; warrants, warrants, stock options and free shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021 and 2020, the Company had the following type of equity plans in place: founders&#x2019; warrant (BSPCE) plans, warrant (BSA) plans, stock option (OSA) plans and free shares (AGA) plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Founders&#x2019; warrants (BSPCE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;br/&gt;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;br/&gt;price&lt;br/&gt;(in&#160;euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at January 1,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at December&lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2012-2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 18, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 08-2013 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 28, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2016 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2017 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;179,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;br/&gt;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;br/&gt;price&lt;br/&gt;(in&#160;euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at January 1,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at December&lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 18, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 28, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;92,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;187,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;751,585&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(32,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;By way of exception, the Executive Board decided to lift, for three former employees and for two former members of the Executive Board, the continued service condition, and, where applicable for a former Executive Board member, the performance conditions to which the exercise of certain BSPCEs was subject, notwithstanding the termination of their employment agreement and/or corporate office.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The impact of share-based payments on income is detailed in Note 17.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence, no new instrument became issuable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Warrant Plans (BSA)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 04-12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;May 4, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 10, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(36,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 17, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(33,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;78,103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(77,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 04-12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;May 4, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 10, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 17, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;251,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At a meeting on April 20, 2021, the Executive Board, acting pursuant to the delegation granted by the Company&#x2019;s shareholders' meeting held on November 30, 2020 granted 48,103 warrants to members and observers of the Supervisory Board, each entitling its holder to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;13.47 (share premium included). The designated warrants included 18,103 warrants that were issued in replacement of certain 2016 ordinary warrants that became null on February 2, 2021. The subscription period was open from the date of the meeting of the Executive Board until September 30, 2021, inclusive. As of December 31, 2021, 14,431 warrants have been subscribed by their beneficiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The warrants can be exercised at any time during a 10-year period, subject to the satisfaction of the following conditions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the subscription by the relevant beneficiary of his/her warrant;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the relevant holder has attended at least 75% of the Supervisory Board meetings held during the twelve months preceding the exercise of the warrants or, as the case may be, the date the holder ceases to be part of the Group; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the recommended dose for two out of the three patient cohorts enrolled in the study 1100 has been determined in order to define the next steps of the immuno-oncology development plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;It is being specified that (i) the Executive Board, with the prior approval of the Supervisory Board, shall acknowledge the satisfaction of such condition and (ii) such condition shall automatically be waived in the event of a change of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At the same meeting, the Executive Board, acting pursuant to the above mentioned delegation, also granted 30,000 warrants to a consultant of the Company, each warrant giving its holder the right to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;13.64 (share premium included) at any time during a 10-year period subject to (i) the subscription by such consultant of the warrants and (ii) the drafting by such consultant of a Chemistry, Manufacturing, Control (CMC) risk assessment report. The corresponding subscription period has been fixed from the date of the meeting of the Executive Board until July 20, 2021 inclusive. As of December 31, 2021, no warrants have been subscribed by the beneficiary. In addition, as of December 31, 2021 the report is not prepared yet. Therefore, the warrants are not vested yet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on March 17, 2020, the Executive Board, acting pursuant to the delegation granted by the thirty-fourth resolution of the annual shareholders' meeting dated April 11, 2019 and following the approval granted by the Supervisory Board on March 13, 2020, granted 18,000 warrants to members of the Supervisory Board, each entitling the holder to subscribe to a defined number of ordinary shares with a par value of &#x20ac;0.03, at a price of &#x20ac;6.59. The holders subscribed to the warrants prior to the end of the subscription period on September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stock Option Plans (OSA)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 24, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;387,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;387,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2021-04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;571,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;491,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;491,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2021-06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;691,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(93,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1,&lt;br/&gt;&#160;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares &lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;54,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 24, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;407,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;589,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;407,972&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(10,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on April 20, 2021, the Executive Board, acting pursuant to delegations granted by the Company&#x2019;s shareholders&#x2019; meeting held on November 30, 2020, granted to certain employees of the Group and members of the Executive Board 571,200 stock options (including 143,200 stock options and 428,000 performance stock options), each giving its holder the right to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;13.74 (share premium included). Such stock options are governed by the 2020 stock option plan adopted by the Executive Board on February 9, 2021 and approved by the Company&#x2019;s annual shareholders&#x2019; meeting held on April 28, 2021 (the &#x201c;2020 Stock Option Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The ordinary stock options are exercisable as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;up to one-third of the ordinary stock options as from April 20, 2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;an additional one-third of the ordinary stock options as from April 20, 2023,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;the balance, i.e., one-third of the ordinary stock options as from April 20, 2024, subject to, for each increment, a continued service condition, and in any case,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;no later than 10 years after the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The performance stock options may be exercised under the following conditions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;10% of the stock options may be exercised when the market price of the Company&#x2019;s shares on the regulated market of Euronext in Paris reaches &#x20ac;24.00,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;an additional 10% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#x20ac;30.00,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;an additional 40% of the stock options may be exercised when the market price of the Company&#x2019;s shares on the regulated market of Euronext in Paris reaches &#x20ac;40.00,&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;an additional 40% of the stock options may be exercised when the market price of the Company's shares on the regulated market of Euronext in Paris reaches &#x20ac;60.00, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;at the latest within 10 years of the date of grant, it being specified that stock options which have not been exercised by the end of this 10-year period will be forfeited by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;It being specified that (i) among such performance stock options that may be exercised, and subject to, for each increment, a continued service condition, their holders may only exercise (x) up to 10% of such performance stock options as from April 20, 2022, (y) an additional 30% of such performance stock options as from April 20, 2023, and (z) the balance, i.e., 60% of such performance stock options as from April 20, 2024, and (ii) such additional vesting condition shall be automatically waived in the event of a change of control. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The number of ordinary and performance stock options that may be exercised under the above exercise schedules would always be rounded down to the nearest whole number.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At a meeting on June 21, 2021, the Executive Board, acting pursuant to the delegation granted by the shareholders&#x2019; meeting held on November 30, 2020 granted 60,000 ordinary stock options to Mr. Bart Van Rhijn following his entry into the Company and his appointment as a Member of the Executive Board. Such stock options are governed by the 2020 Stock Option Plan. Acting pursuant to a delegation granted by the Company&#x2019;s annual shareholders&#x2019; meeting held on April 28, 2021, it also decided to adopt the 2021 stock option plan and to grant to Mr. Bart Van Rhijn 60,000 performance stock options governed by such plan. Each of such 120,000 stock options (whether ordinary and performance) gives it holders the right to subscribe one ordinary share, each with a par value of &#x20ac;0.03 and at a price of &#x20ac;12.99 (share premium included).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The exercise conditions of the 143,200 ordinary stock options and 428,000 performance stock options granted on April 20, 2021 described above shall apply mutatis mutandis to these 60,000 ordinary stock options and 60,000 performance stock options respectively, save for the anniversary date which shall be June 30 rather than April 20. In addition, in accordance with French regulation, the exercise of the above stock options (whether ordinary and performance) are subject to an additional performance condition as soon as they are granted to a member of the Executive Board: determination of the recommended dose for two of the three patient cohorts enrolled in the NBTXR3-1100 clinical study, in order to be able to define the next stage of the development plan in immuno-oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on March 11, 2020, the Executive Board adopted the 2019 Stock Option Plan and, acting pursuant to the authorization granted by the thirty-second resolution of the annual shareholders' meeting dated April 11, 2019, granted 407,972 stock options (the &#x201c;OSA 2020&#x201d;), 300,000 of which to members of the Executive Board and Mr. Alain Dostie and the remaining 107,972 to employees of the Company, under such 2019 Stock Option Plan. Each OSA 2020 entitles its holder to subscribe one ordinary share of the Company with a par value of &#x20ac;0.03, at an exercise price of &#x20ac;6.25 (issue premium included).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The OSA 2020 may be exercised as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;up to one-third of the OSA 2020 as from March 11, 2021;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;an additional one-third of the OSA 2020 as from March 11, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the balance, i.e., one-third of the OSA 2020 as from March 11, 2023, subject to, for each increment, a continued service condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In addition, the Executive Board decided that the exercise of the OSA 2020 granted to members of the Executive Board and Mr. Alain Dostie would also be subject to the achievement of positive results in the 1100 study in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the supervisory board, on March 17, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;By way of exception, the Executive Board decided to lift the continued service condition of the OSA 2020 for two former Executive Board members as well as to accelerate, as from June 30, 2021, the vesting of the OSA 2020 one&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;of these former executive board members holds, enabling him to exercise all of them, in the context of his departure from the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Free share plans (AGA)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definitively acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(369,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;362,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;360,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;360,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;362,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(393,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at January 1, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definitively acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares &lt;br/&gt;exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;355,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(316,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;746,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(322,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(27,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on April 20, 2021, the Executive Board, acting pursuant to the authorization granted by Company&#x2019;s shareholders&#x2019; meeting on November 30, 2020, granted 362,515 free shares, each with a par value of &#x20ac;0.03 to certain employees of the Group and members of the Executive Board. Such free shares will be subject to a one-year holding period starting at the end of the two-year acquisition period, i.e. starting on April 20, 2023. Such free shares are governed by the 2020 free share plan adopted by the Executive Board on February 9, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Furthermore, the final vesting of the free shares granted to members of the Executive Board is conditioned upon the determination of the recommended dose for two out of the three patient cohorts enrolled in the NBTXR3-1100 clinical study in order to define the next steps of the development plan in immuno-oncology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on March 11, 2020, the Executive Board, acting pursuant to the authorization granted by the thirty-third resolution of the annual shareholders&#x2019; meeting dated April 11, 2019, granted 50,000 free shares (the &#x201c;AGA 2020&#x201d;) with a par value of &#x20ac;0.03 to Ms. Anne-Juliette Hermant, a member of the Executive Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In addition to the acquisition and holding conditions detailed below, the acquisition of the AGA 2020 granted to Ms. Hermant is conditioned upon the achievement of positive results in Study 1100 in 2020. The satisfaction of this performance condition was acknowledged by the Executive Board, with the approval of the Supervisory Board, on March 17, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Free share vesting conditions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The AGA 2020 and AGA 2021 are subject to, for French tax residents, a two-year acquisition period and a one-year holding period, and, for foreign tax residents, a three-year acquisition period. The free shares granted by the Company are definitively acquired at the end of the acquisition period as set by the Executive Board. At the end of such period, the beneficiary is the owner of the shares. However, during the holding period (as set by the Executive Board), if any, the shares may not be sold, transferred or pledged. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unless otherwise decided by the supervisory and executive boards of the Company, the AGA 2020 and the AGA 2021 are subject to continued service during the acquisition period (i.e., for the AGA 2020, until March 11, 2022 and for AGE 2021, until April 20, 2023), it being specified that, failing such continued service, the beneficiary definitively and irrevocably loses his or her right to acquire the relevant AGA 2020 or AGA 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unless otherwise decided by the supervisory and executive boards of the Company, in the event of disability or death of a beneficiary before the end of the acquisition period, the relevant free shares shall be definitely acquired at, respectively, the date of disability or the date of the request of allocation made by his or her beneficiary in the framework of the inheritance, provided that such request is made within six months from the date of death.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on March 17, 2021, the Executive Board acknowledged the definitive acquisition of 24,500 free shares granted on March 6, 2018 following a three-year acquisition period, thus acknowledging the related share capital increase of &#x20ac;735.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At a meeting on April 1, 2021, the Executive Board acknowledged the definitive acquisition of 369,250 free shares granted on March 29, 2019 following a two-year acquisition period, thus acknowledging the related share capital increase of &#x20ac;11,077.50.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;At a meeting on September 22, 2020, the Executive Board acknowledged the definitive acquisition of 6,000 free shares granted on July 27, 2018 following a two-year acquisition period, thus acknowledging the related share capital increase of &#x20ac;180.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with the terms of the free shares, the Executive Board decided to lift, for seven Company&#x2019;s employees and a former Executive Board member, the continued service condition to which the definitive acquisition of their free shares is subject, notwithstanding the termination of their employment agreement or corporate office. The impact of share-based payments on income is discussed in Note 17. As of December 31, 2021, the assumptions related to the estimated vesting of the founders&#x2019; warrants, the warrants and performance stock-options have been updated (see Note 17).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUw_16f67249-1507-47a8-a195-2ab2f2dd4525">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Ordinary shares are classified in shareholders&#x2019; equity. The cost of equity transactions that are directly attributable to the issue of new shares or options is recognized in shareholders&#x2019; equity as a deduction from the proceeds of the issue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUz_2a388fe4-189e-4b39-9ed3-e7f35d84ba7a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of share capital transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands or number of shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Share Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Premiums related to share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;153,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;22,415,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 6, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;316,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 24, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 26, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 29, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subscription of 2020 warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 27, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 28, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Private placement Capital increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 28, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Private placement Capital increase transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering initial deal &#x20ac; - Nasdaq (&#x20ac;11.14)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,855,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 16, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering initial deal $ - Nasdaq ($13.50)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,445,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 18, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering green shoe $ - Nasdaq ($13.50)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,095,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December 18, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Initial public offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;255,735&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,432,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital increase AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;369,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants attribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants subscription (BSA 2021)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;255,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,825,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:Equity
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTItMS0xLTExOTk5_719d1c17-598c-4882-9789-92203b8e974f"
      unitRef="eur">672000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="icec4369f4c7649dba76e50278de42760_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTMtMS0xLTExOTk5_68d63a0e-a1c6-44b8-9e56-cf33c260a0bb"
      unitRef="eur">153139000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzEzLTQtMS0xLTExOTk5_a955337c-8083-4322-ad1e-3eaebabd08e1"
      unitRef="shares">22415039</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IssueOfEquity
      contextRef="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTItMS0xLTExOTk5_bb721aaf-3039-422d-a697-6be90b068818"
      unitRef="eur">9000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ic6d2b59cd3394eb38b1112a6d40ba562_D20200306-20200306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTMtMS0xLTExOTk5_0da2946e-a1b4-4ff0-a36b-bf975bf9fb80"
      unitRef="eur">0</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i1cfea6435b0f4c408b7f7924589c0170_D20200306-20200306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE0LTQtMS0xLTExOTk5_4abf29c8-3464-4b18-ba7f-58d9445982d1"
      unitRef="shares">316083</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="ibfcb03f93ca547db9f9c30453f57d130_D20200624-20200624"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTMtMS0xLTExOTk5_06d9c07a-7a1c-44dd-960f-518d638c40f3"
      unitRef="eur">1000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="icd06ab95cb464cf7ab36d088f33b9b5c_D20200626-20200626"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTMtMS0xLTExOTk5_f567c194-60d6-4676-894a-998187953f16"
      unitRef="eur">1000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="ibccb3f7b5d984a47977843563136cbfd_D20200629-20200629"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE3LTMtMS0xLTExOTk5_fefc06c5-44aa-48f4-b6fe-3f02578c46be"
      unitRef="eur">2000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="ia1db8fdf89004094a84398a37852bd32_D20200630-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE4LTMtMS0xLTExOTk5_f9f4b1b8-adf8-41ed-b03f-3eff56587dfe"
      unitRef="eur">1000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="ie5449b75fc7d4fbda4157cb2026ec2f5_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTQtMS0xLTExOTk5_50d0fa06-31ca-4dbd-9495-25d1a19d89f5"
      unitRef="shares">6000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTItMS0xLTExOTk5_abbe75dd-f940-4b85-b3d9-5697b3381293"
      unitRef="eur">99000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTMtMS0xLTExOTk5_cb324179-e252-485e-8acd-4d19a8af2366"
      unitRef="eur">20030000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="ic4150d5a7b134d3ab7d6771a1e91d970_D20200728-20200728"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIwLTQtMS0xLTExOTk5_83adb8b1-aa64-4d68-ae42-3c0e5236eabe"
      unitRef="shares">3300000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i520da1379d5d429f9609aa68943b9d29_D20200728-20200728"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIxLTMtMS0xLTExOTk5_e54b2864-fcc8-48e6-9824-aa8a0a591ed1"
      unitRef="eur">1387000</ifrs-full:ShareIssueRelatedCost>
    <nbx:IssueOfEquityPricePerShare
      contextRef="i263948c1f81b493eb8cca425bcebfa1d_D20201216-20201216"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTEtMS0xLTExOTk5L3RleHRyZWdpb246ZGU0ZjJjOGU3ZjQxNGFhZWIxZjMyNmE0ZjUyZThlMWFfMTY0OTI2NzQ0MTczNA_63f41789-fdda-4875-9fd2-4cec62703778"
      unitRef="eurPerShare">11.14</nbx:IssueOfEquityPricePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTItMS0xLTExOTk5_b9c1aab0-bc90-41d7-a84a-c6ac00bb1092"
      unitRef="eur">56000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i61be2d4b393849cc9560e858d770a26c_D20201216-20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTMtMS0xLTExOTk5_f022c799-e9de-4ff9-ab49-0b1e79dc41f5"
      unitRef="eur">20609000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIyLTQtMS0xLTExOTk5_29c04428-006b-4862-97fa-b2765a118f51"
      unitRef="shares">1855000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IssueOfEquityPricePerShare
      contextRef="i0c448e8551854ba3817ac8e0588ff235_D20201216-20201216"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTEtMS0xLTExOTk5L3RleHRyZWdpb246NDMzNzMyNmRlZWRiNDM4OWI0NTJmMDk4OWViNmY5OWVfMTY0OTI2NzQ0MTczNA_25521d28-410b-4c4d-ba8f-199ce6b1ef09"
      unitRef="usdPerShare">13.50</nbx:IssueOfEquityPricePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTItMS0xLTExOTk5_d3ec4543-89eb-4334-a896-2c0b69cc82f0"
      unitRef="eur">163000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i76e354131ae34438ad0ee61bab49371d_D20201216-20201216"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTMtMS0xLTExOTk5_38b89bc0-a09a-4e5e-8f19-9dc3ecc9082f"
      unitRef="eur">60494000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzIzLTQtMS0xLTExOTk5_2525f100-8b4d-4077-9096-f8b9c951cecf"
      unitRef="shares">5445000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IssueOfEquityPricePerShare
      contextRef="ie3c6af94c36742b38cd4e03676b70d2e_D20201218-20201218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTEtMS0xLTExOTk5L3RleHRyZWdpb246ZDkyNGExMGQ2Y2MyNDI3NmEyNjY0MDczNGNiOGQwZmVfMTY0OTI2NzQ0MTczMg_62313a9d-c7ff-4e16-ab49-54b7d6a12cb5"
      unitRef="usdPerShare">13.50</nbx:IssueOfEquityPricePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTItMS0xLTExOTk5_cd897b44-515e-472a-9e7a-4a406043fde6"
      unitRef="eur">33000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i36d5fe1d4b1c4217af0247979f91d136_D20201218-20201218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTMtMS0xLTExOTk5_fbdc4d7d-0e2b-4d69-8a54-e6998e9c1bd1"
      unitRef="eur">12165000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI0LTQtMS0xLTExOTk5_34c97ee4-67de-42a0-b445-374e149d99c6"
      unitRef="shares">1095000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI1LTMtMS0xLTExOTk5_01b41c90-e638-4db6-be3d-1d411b9aa0bd"
      unitRef="eur">9322000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:Equity
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTItMS0xLTExOTk5_fb868060-7ed2-4fb3-8e59-12711441e3d6"
      unitRef="eur">1033000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ifb7d6dc08eb8459583e4919daa51ec7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTMtMS0xLTExOTk5_361e2ba9-13c7-4975-8f28-99b8687fd00d"
      unitRef="eur">255735000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzI2LTQtMS0xLTExOTk5_863ee1ba-0549-46b9-bf07-27cd8e5d87f7"
      unitRef="shares">34432122</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IssueOfEquity
      contextRef="i8de9f777ee344fac809f90733d665d63_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTItMS0xLTM4Njg2_066df9ab-a4d2-4266-8bb9-0d82ba866109"
      unitRef="eur">1000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i8de9f777ee344fac809f90733d665d63_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE1LTQtMS0xLTM4Njg2_6a27f53d-2769-4ae2-9f84-5f5360a68f29"
      unitRef="shares">24500</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTItMS0xLTM4Njg2_0eaae664-a2e8-4bbb-a33c-63f50023351b"
      unitRef="eur">11000</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i78cbf3b349bc443892e3a76629fb91d9_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE2LTQtMS0xLTM4Njg2_3ad1162c-cd52-4ac9-8c2a-5ecbe82321a6"
      unitRef="shares">369250</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="i75b881b34146431e87bbf66200b0999b_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE3LTMtMS0xLTM4Njg2_68bbaaa0-fc91-4f94-ac7a-2701a6812fa6"
      unitRef="eur">-11000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity
      contextRef="icc02833837f240adba65b3984741f75d_D20210531-20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE4LTMtMS0xLTM4Njg2_1997b70d-7e10-4e9b-8a5e-b8f130b96d48"
      unitRef="eur">43000</nbx:IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity>
    <ifrs-full:Equity
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTItMS0xLTM4Njk4_ab1ec6e6-e1a6-4512-ae5a-bb679403b857"
      unitRef="eur">1045000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ida63773549fb469180532f7bff7a9b6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTMtMS0xLTM4Njk4_1bcdc02c-0b63-4deb-8bdc-ccf7bdea4786"
      unitRef="eur">255767000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmNzMwZTA1MzBmNzU0ZDA0ODM5M2NkMWEwZjVlMjA5OC90YWJsZXJhbmdlOmY3MzBlMDUzMGY3NTRkMDQ4MzkzY2QxYTBmNWUyMDk4XzE5LTQtMS0xLTM4Njk4_2809f633-f7db-4575-a836-1917aee62e85"
      unitRef="shares">34825872</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQwMg_d11ad454-856e-45af-be6c-87600a85a731"
      unitRef="eur">1044776.16</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQxOA_f2ea49b3-47b7-40fd-a5d3-fba3c95f839f"
      unitRef="shares">34825872</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzQ3Ng_f7877e28-8bfd-40b6-934a-c57005c1244a"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:Equity
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzUyMw_46fd238d-cfff-4f7a-b866-7afb17b4dd00"
      unitRef="eur">1032963.66</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i0ad15a6858b8477e914d12d1e3e78e6b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzUzOQ_b3e84fb0-18b3-4aa2-861c-e1fabff8a2a5"
      unitRef="shares">34432122</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU5OA_daff3182-e6d0-4a7c-9c59-8c9f8908798b"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:Equity
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzYzMQ_d4b28d0d-9eda-4437-8eee-ce40cba13163"
      unitRef="eur">672451.17</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i9bd38845088a4ebdb68c1b1393b7169b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzY0Nw_d484cc83-0f25-449d-8ccf-e69019f51193"
      unitRef="shares">22415039</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzcwNQ_981cbdd8-355d-41ed-ada6-79a54855142c"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="ibf9ad81b51bf4c808adb6b86c14e2b1b_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEwODQ_d9155bc9-54a3-4108-b5ac-cdd782325bcc"
      unitRef="shares">8395000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i19cfc82a23c14e51bbec51f1b5b41025_D20201216-20201216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExMjg_0af665ee-442d-40c6-8d28-4617e4805ba7"
      unitRef="shares">5445000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IssueOfEquityPricePerShare
      contextRef="i4304c8534859424ebd1d4888fc19dd31_D20190409-20190409"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMDM_8622107c-2a24-4abe-973c-c318314db700"
      unitRef="usdPerShare">13.50</nbx:IssueOfEquityPricePerShare>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i065febd6a2fd486ea1495281566fd9bb_D20201216-20201216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMTU_477ae558-794b-4fa4-ba13-06520d5e7690"
      unitRef="shares">1855000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IssueOfEquityPricePerShare
      contextRef="i75a906e28a874a89ade36d6366ebe2af_D20190409-20190409"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEzNTQ_4cfab22c-311e-4ca1-b799-370c612c42b6"
      unitRef="eurPerShare">11.14</nbx:IssueOfEquityPricePerShare>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i1a6b4baa09364a22b04d9e906d351f49_D20201218-20201218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE0NjY_ea82d764-ca5b-485f-9f2b-f28a4d9a4ad2"
      unitRef="shares">1095000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <nbx:IssueOfEquityPricePerShare
      contextRef="ib57fc815199246ce8209d327ed4e9354_D20190409-20190409"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE1MjI_e34af335-d43f-45d4-9246-7649d0ae086b"
      unitRef="usdPerShare">13.50</nbx:IssueOfEquityPricePerShare>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE5MTg_b797deee-4ded-45e4-a66d-87e391045ac5"
      unitRef="eur">10700000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="i33af316e330a4027bde94cbab22c7d5b_D20201218-20201218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzE5NjE_d3a3ac5c-7895-4a56-8460-6b2f6d6b6dff"
      unitRef="eur">9300000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="i496ccb84d3414b0ebe4458b724809514_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIxNzA_ccaf9ba0-4aa0-4c78-9797-fca76b4b0d08"
      unitRef="eur">349000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="i90dcabddc9d44876a0d15dec2ba9b83f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIyODc_3caf9d43-c9e5-4070-b8c4-5cf0c0853c70"
      unitRef="shares">15456</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="ia680b82130144ad9af8419938ca05856_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzIzNDU_74e71fbf-be96-408e-842a-d44f8edbf140"
      unitRef="shares">12970</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:TreasuryShares
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzI2NzU_648b697e-3191-4fdd-ba87-bdffde14552e"
      unitRef="eur">202000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzI2ODI_c9249744-415a-4223-8924-0ed8c7b930ab"
      unitRef="eur">196000</ifrs-full:TreasuryShares>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUx_f0f5f6ec-26a9-4080-b55f-ccda0d8cea1b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following tables summarize activity in these plans during the years ended December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Founders&#x2019; warrants (BSPCE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;br/&gt;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;br/&gt;price&lt;br/&gt;(in&#160;euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at January 1,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at December&lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2012-2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 18, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 08-2013 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 28, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2016 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,841&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2017 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;179,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant&lt;br/&gt;date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;br/&gt;price&lt;br/&gt;(in&#160;euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at January 1,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;br/&gt;at December&lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares&lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 18, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 28, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;92,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(5,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;202,617&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSPCE 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;187,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;180,850&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;751,585&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(32,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;BSA)&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 04-12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;May 4, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 10, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(36,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 17, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(33,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;78,103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(77,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 04-12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;May 4, 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 10, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 10, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 25, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;36,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.660&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 17, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;251,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;AGA)&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definitively acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(369,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;362,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;360,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;360,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;362,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(393,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(4,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at January 1, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definitively acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares &lt;br/&gt;exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;355,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(316,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 27, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(6,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;385,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;372,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;746,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(322,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(27,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtNC0xLTEtNDc4MDk_0466148f-86e4-45e9-80b5-8fd3f1cc87fd"
      unitRef="eurPerShare">6.63</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtNi0xLTEtNDc4MDk_0d71f6ca-4256-481d-a7fb-2d61e2ba84f7"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtOC0xLTEtNDc4MDk_16727ad6-c844-42d1-8c1f-fae2190612a4"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTAtMS0xLTQ3ODA5_bdec3aea-ea5b-477b-825d-b53ef8f4c1d1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTItMS0xLTQ3ODA5_e69f0adb-10b8-40b7-ab08-202392beff25"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTQtMS0xLTQ3ODA5_9c4578a4-b93a-44b8-834a-161428f8e2c0"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzEtMTYtMS0xLTQ3ODA5_62178a1c-e7e5-4ad3-bb7d-59429d49092c"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItNC0xLTEtNDc4MDk_6ef0d871-86e6-4ae2-a5ae-51cc1215b581"
      unitRef="eurPerShare">5.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItNi0xLTEtNDc4MDk_7e8c8dd6-2f4a-48de-98e9-c36687691e62"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItOC0xLTEtNDc4MDk_8e368a2d-8a87-495b-a973-d12423ae6115"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTAtMS0xLTQ3ODA5_31d59099-de5b-499e-abdb-b912b8e3e77a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTItMS0xLTQ3ODA5_fabeb0d0-4727-43c7-991d-f6741566fe34"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTQtMS0xLTQ3ODA5_d401ecb0-5e66-498f-b65a-7bee55f7b775"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzItMTYtMS0xLTQ3ODA5_7626fbbf-3d0f-40b8-9a50-5927d381ffd6"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtNC0xLTEtNDc4MDk_6ac940ef-5a53-4721-b9d2-213fdf640937"
      unitRef="eurPerShare">18.68</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtNi0xLTEtNDc4MDk_b8a09be5-7951-4e98-9573-c964ce59e7d6"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtOC0xLTEtNDc4MDk_ee72f9ad-74d2-44a5-ad8b-95fa03b3cded"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTAtMS0xLTQ3ODA5_b5a7d2e6-7d0e-4949-8de2-066cc13263c9"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTItMS0xLTQ3ODA5_5e4826ba-ec96-4b90-a46f-579f79f46581"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTQtMS0xLTQ3ODA5_491fae2d-8861-4511-ad4a-801500ce222b"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzMtMTYtMS0xLTQ3ODA5_487add33-da2f-4211-bb87-13bbf7c8899d"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtNC0xLTEtNDc4MDk_a487ece7-6c6c-433e-8b20-a2ded5ace9ac"
      unitRef="eurPerShare">18.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtNi0xLTEtNDc4MDk_ec18b6ee-3c03-4be5-9b65-81b63f85b355"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtOC0xLTEtNDc4MDk_db31855a-8bb4-4742-b39e-a83affc10feb"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTAtMS0xLTQ3ODA5_f6fac0ac-b34b-41a1-9285-a81e8182d3c6"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTItMS0xLTQ3ODA5_6d48cdbc-f57c-443d-bec3-21fc14d10804"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTQtMS0xLTQ3ODA5_f9a37154-7433-4a6e-9345-b40734c360de"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzQtMTYtMS0xLTQ3ODA5_b06687df-9ceb-4927-ae2d-a62364b82f39"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtNC0xLTEtNDc4MDk_ed3acc92-fce0-4d39-9ce2-53d32adaf0cf"
      unitRef="eurPerShare">20.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtNi0xLTEtNDc4MDk_d3ee3427-6b26-47a7-8016-fd6933e040a8"
      unitRef="shares">30700</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtOC0xLTEtNDc4MDk_8998b48b-50c9-4bc5-8213-8b35701691d1"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTAtMS0xLTQ3ODA5_78dd9539-8197-49eb-b36c-74d1ee936038"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTItMS0xLTQ3ODA5_1e70f194-3fb7-4ff1-8d5c-5a1e35a22dbc"
      unitRef="shares">350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTQtMS0xLTQ3ODA5_138e53db-61a4-469f-bb7a-e47de818b9f6"
      unitRef="shares">30350</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzUtMTYtMS0xLTQ3ODA5_dc55ed0c-9726-4903-bf5f-41c19e832fcc"
      unitRef="shares">30350</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtNC0xLTEtNDc4MDk_83034f26-bb08-4254-a6e0-bcd20d4ea387"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ib015ff2793a347eea190254523e266cd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtNi0xLTEtNDc4MDk_94069f30-602c-478e-be13-9263d9689d78"
      unitRef="shares">202617</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtOC0xLTEtNDc4MDk_4ab92a61-35a8-4294-bd1b-43670f532f43"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTAtMS0xLTQ3ODA5_f0a16bf6-205b-4d01-b995-045165752299"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i419a2af657384b48a599157e9e3ccca1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTItMS0xLTQ3ODA5_a00ccbe3-8ae9-4d8a-a6ad-849ccdfb046f"
      unitRef="shares">1776</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="icbd0d6bab50d405cafa491285cc4f581_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTQtMS0xLTQ3ODA5_7d057666-48b9-49d2-84dd-620c1d15b8a5"
      unitRef="shares">200841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="icbd0d6bab50d405cafa491285cc4f581_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzYtMTYtMS0xLTQ3ODA5_6fb178ee-a0ba-4948-b72e-5dfa6c9bbdae"
      unitRef="shares">200841</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctNC0xLTEtNDc4MDk_c8404286-0bcc-429d-a1ac-96581183647b"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctNi0xLTEtNDc4MDk_e5dc618c-dfa4-40fa-92f4-e06ab9689542"
      unitRef="shares">180850</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctOC0xLTEtNDc4MDk_fd9dc0ff-7368-4d9a-a58d-2d2443e89758"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTAtMS0xLTQ3ODA5_9180c30b-0753-4170-8f69-94a645bb096b"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTItMS0xLTQ3ODA5_e060f67c-eb6f-4ef4-ae9b-b218687c30e7"
      unitRef="shares">1350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie58d6cd769d14890874fc2f862b4fd1a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTQtMS0xLTQ3ODA5_453eb595-c19d-4621-9468-5d124cfef3ab"
      unitRef="shares">179500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ie58d6cd769d14890874fc2f862b4fd1a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzctMTYtMS0xLTQ3ODA5_85fe91fa-6790-4583-b09e-2bd94bce6774"
      unitRef="shares">179500</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtNi0xLTEtNDc4MDk_1f3fea68-ea88-4264-b1b9-2808ff757f92"
      unitRef="shares">718767</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtOC0xLTEtNDc4MDk_05cf151f-1c36-4573-a038-adb4d6d4a069"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTAtMS0xLTQ3ODA5_687702a5-dc8e-45d1-95d8-563cfe4fa3da"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTItMS0xLTQ3ODA5_2aaad60f-b559-4760-9737-c9e7a112bbf3"
      unitRef="shares">3476</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTQtMS0xLTQ3ODA5_8be40482-4bcb-416d-b5bb-44fbfabe3a1c"
      unitRef="shares">715291</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpkZTljYzYwOGMwZDc0NGY2YmFmYzkwNWViNGVhOWIzZi90YWJsZXJhbmdlOmRlOWNjNjA4YzBkNzQ0ZjZiYWZjOTA1ZWI0ZWE5YjNmXzgtMTYtMS0xLTQ3ODA5_8df03b10-2561-4b24-a76a-aa95587818fe"
      unitRef="shares">715291</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtNC0xLTEtNDc4MDk_f185e78a-ed95-46c5-8a28-7c4b17fae893"
      unitRef="eurPerShare">6.63</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic4574c0827bd436bb79456dc0389b57c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtNi0xLTEtNDc4MDk_28b9eba5-54a8-4f9d-8810-5ad3fd612f64"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtOC0xLTEtNDc4MDk_133ec948-9a74-491d-b439-299ea3906383"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTAtMS0xLTQ3ODA5_085804e6-e231-4e9e-88eb-9a943e48c850"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTItMS0xLTQ3ODA5_41c08c52-a68d-4490-8029-417cce332515"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTQtMS0xLTQ3ODA5_8edbbd89-1fb2-46b3-b652-57754ddbf6b9"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i294a61301bf542ec867f89a9f95e7c74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzEtMTYtMS0xLTQ3ODA5_10865569-01e3-4e7a-98ca-d5b79cf217e6"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItNC0xLTEtNDc4MDk_06461126-c3dd-4056-a945-314f2d5709dd"
      unitRef="eurPerShare">5.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i31d9ddb730e24052933a829799eaa5b5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItNi0xLTEtNDc4MDk_2b44e5af-2b70-43c4-8973-d7c7c3183d52"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItOC0xLTEtNDc4MDk_9d7384e6-b343-4a71-9ea7-47e4a25d0134"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTAtMS0xLTQ3ODA5_0b4b2750-1df3-4c94-8c05-a52c2adb41b1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTItMS0xLTQ3ODA5_c408a49e-68d5-44fe-b12c-53c7d63cceae"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTQtMS0xLTQ3ODA5_c912c7ff-3c31-4196-82f3-fc1f3a90a53d"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i5575b3f42d764a5dbad1316d83a15f52_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzItMTYtMS0xLTQ3ODA5_18246923-e370-4c02-a955-90aff1c8983a"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtNC0xLTEtNDc4MDk_2b39d715-65ea-4f50-84c0-bca31ac6838d"
      unitRef="eurPerShare">18.68</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="if6119076476e4da0bce1c4d855f1ae02_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtNi0xLTEtNDc4MDk_29850229-3ecf-45b3-a4f6-680f893a21d6"
      unitRef="shares">92100</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtOC0xLTEtNDc4MDk_3243a391-0d42-4d2e-954e-c5529d1193b6"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTAtMS0xLTQ3ODA5_a6c11cf3-2d5c-4244-94c7-ee26eca2ec52"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTItMS0xLTQ3ODA5_61829074-540e-4c48-9848-66108a4449d8"
      unitRef="shares">5950</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTQtMS0xLTQ3ODA5_a26a79b7-8908-4934-a2b2-8565d09ef99e"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i6164f9d60bc2408f8040f375730909e3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzMtMTYtMS0xLTQ3ODA5_81223188-75de-46e2-a400-e76daac4ac49"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtNC0xLTEtNDc4MDk_5714bcf3-7326-41ad-ba61-f84d8da2db37"
      unitRef="eurPerShare">18.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iddede090f4d14469a738de2cd2066a57_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtNi0xLTEtNDc4MDk_1f2f062e-d563-464d-9518-6ce6fd31a4f1"
      unitRef="shares">70950</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtOC0xLTEtNDc4MDk_e90ce543-9493-4812-bdf0-af48538eb47e"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTAtMS0xLTQ3ODA5_716ee2c4-d463-41e0-ab29-439b41f8d58a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTItMS0xLTQ3ODA5_7eb2ca9d-1bf6-4579-ba74-b30cfec16826"
      unitRef="shares">2500</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTQtMS0xLTQ3ODA5_e6929260-4cd8-471f-8c97-71e1489833e9"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ice4bbee7b8464e3bbabeace3aa802581_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzQtMTYtMS0xLTQ3ODA5_49ec2f26-a9f0-4df4-bef0-9d9403ce696d"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtNC0xLTEtNDc4MDk_04380e96-ca55-43d8-bf66-8b60020ec921"
      unitRef="eurPerShare">20.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i76a7c7c748674e5b922e368dcd8635b5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtNi0xLTEtNDc4MDk_d8ffd902-259a-416b-b83f-4cb41a284173"
      unitRef="shares">38400</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtOC0xLTEtNDc4MDk_80b5ad9d-d34b-4ada-91ec-7722bcf3683b"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTAtMS0xLTQ3ODA5_44c1b95e-fd4a-46ee-a596-dbb1ae45d381"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTItMS0xLTQ3ODA5_f78b8f47-5df0-4e47-a383-98394352137f"
      unitRef="shares">7700</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTQtMS0xLTQ3ODA5_5b81a6ae-01c2-4a1c-bf9d-d7aad7e1ae45"
      unitRef="shares">30700</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i1f7c12d22fc24156bb81feb9babf660b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzUtMTYtMS0xLTQ3ODA5_8810d12a-858f-453e-8453-5497f068120f"
      unitRef="shares">30700</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i7d09ab1f7d794af2ba35923bab69e98b_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtNC0xLTEtNDc4MDk_032c0da5-683c-44cf-a2ff-bf6f2ea0972a"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i07dd60f3a2d649f8b0d32174a89ec727_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtNi0xLTEtNDc4MDk_49e4d5a9-080f-4de2-b72c-4fc85e6f2961"
      unitRef="shares">212969</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtOC0xLTEtNDc4MDk_d8cd7994-b0c2-4403-82d5-699e602a108c"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTAtMS0xLTQ3ODA5_9a212485-f7e9-42a1-a211-3e8f97596cef"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0add56845b6445a7b3b6c21f91bdcab0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTItMS0xLTQ3ODA5_db4f5d33-6714-49da-895c-fe5502ff1f27"
      unitRef="shares">10352</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ib015ff2793a347eea190254523e266cd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTQtMS0xLTQ3ODA5_c71d25a3-da0d-405a-bc2b-1875d464662c"
      unitRef="shares">202617</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ib015ff2793a347eea190254523e266cd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzYtMTYtMS0xLTQ3ODA5_6c4b347a-3d81-4beb-a2c2-b67107f09189"
      unitRef="shares">202617</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctNC0xLTEtNDc4MDk_53f86fc6-6757-4d69-ab36-c18ca8790a4f"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i3ec3ff678f124faa9cff8cf3e429be81_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctNi0xLTEtNDc4MDk_e55afcc1-e617-4182-b3d9-ca17ca1369b8"
      unitRef="shares">187166</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctOC0xLTEtNDc4MDk_15f91ae6-7aa8-44dd-8e04-f242a35e189b"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTAtMS0xLTQ3ODA5_8897890c-9a3e-489a-8032-9c41bb0b0e9a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTItMS0xLTQ3ODA5_459a38d3-e456-4ae9-be5f-77bcc3bf9c54"
      unitRef="shares">6316</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTQtMS0xLTQ3ODA5_501456ae-d1ee-478d-95b1-c6c4c77966af"
      unitRef="shares">180850</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic30eabe785c742e8b11a208b390d5b0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzctMTYtMS0xLTQ3ODA5_24b192a8-91a6-42b6-a5f6-2d281d5a5e1c"
      unitRef="shares">180850</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtNi0xLTEtNDc4MDk_b6bad0bf-04e8-4fcf-8f35-05501b923c52"
      unitRef="shares">751585</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtOC0xLTEtNDc4MDk_d02463be-ab18-4472-9b40-b0d4e1d39067"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTAtMS0xLTQ3ODA5_98a88556-1728-4fde-832a-bd81958d00a5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTItMS0xLTQ3ODA5_48b0d914-be58-4b12-b3a2-8b011233e42d"
      unitRef="shares">32818</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTQtMS0xLTQ3ODA5_5fdaae55-77ad-4e49-92d2-722db70fdc7a"
      unitRef="shares">718767</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToxMDQxZjFhOTNmZDU0NzRkODIxN2IzMjk1YTgxZTYyNy90YWJsZXJhbmdlOjEwNDFmMWE5M2ZkNTQ3NGQ4MjE3YjMyOTVhODFlNjI3XzgtMTYtMS0xLTQ3ODA5_66903651-0377-462c-b4d9-24259edb9ab7"
      unitRef="shares">718767</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted
      contextRef="ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NTI_04dc5e32-0acc-458a-abcb-6c4cb6e83baa"
      unitRef="employee">3</nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted
      contextRef="i0dce03cc95974732b21be1bff36d224d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NTM_772c906d-fd32-4feb-9f26-4deb2d73142d"
      unitRef="employee">2</nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtNC0xLTEtMTE5OTk_9424e676-2f9f-4aaa-be64-839af6bddbf2"
      unitRef="eurPerShare">6.00</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtNi0xLTEtMTE5OTk_29e57992-9ddd-47f5-ada1-805380e15689"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtOC0xLTEtMTE5OTk_c31820d7-d3b7-418c-997e-ea5c067fc8e7"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTAtMS0xLTExOTk5_22f2bbb9-b77f-44ef-8e35-9dd9457d6464"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTItMS0xLTExOTk5_de7dbf8f-fde1-407a-b7d1-fdb6318b3c4d"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTQtMS0xLTExOTk5_2203218c-a528-44d7-afbd-5805165e05c3"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEtMTYtMS0xLTExOTk5_d3dba334-ce86-48a9-be8d-4d869f4fdfdd"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItNC0xLTEtMTE5OTk_2008b630-586b-4583-ac7c-a137180937ed"
      unitRef="eurPerShare">6.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i510cfe19450a4049be49e84fad36335a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItNi0xLTEtMTE5OTk_59f0a22f-b7f0-4285-bde0-106273963481"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItOC0xLTEtMTE5OTk_f89d47d2-7248-493a-8bda-f20261f11980"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTAtMS0xLTExOTk5_0410f6eb-b533-4a62-a1f5-043374b025dc"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTItMS0xLTExOTk5_0228bf79-0183-40e5-92d9-f025b2d9755b"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTQtMS0xLTExOTk5_3d01684f-a5ab-44ea-91e6-3750bd808d29"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzItMTYtMS0xLTExOTk5_f43dd718-925e-419b-8d80-2c58014d64c0"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtNC0xLTEtMTE5OTk_6eedbb6b-991c-40b5-a55e-0412312194b3"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtNi0xLTEtMTE5OTk_089dd796-f0ae-4c2b-af13-8a6ab9714427"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtOC0xLTEtMTE5OTk_ad6c3b14-fcd8-46ac-94b1-1379b655430a"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTAtMS0xLTExOTk5_f90183f3-fcac-4ec4-8664-f3f4c5ee9264"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTItMS0xLTExOTk5_a36355f7-1471-43a9-bf0d-ec1c7c47e7d4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i287ca2164109487e803ea58119f85b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTQtMS0xLTExOTk5_d705aebf-4874-4282-b446-f0a5a4ba9c6d"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i287ca2164109487e803ea58119f85b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzMtMTYtMS0xLTExOTk5_4d20e6b7-f602-44e9-9b31-4de09050888f"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtNC0xLTEtMTE5OTk_d652448c-219c-4c98-8f78-6b4f04791d4b"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtNi0xLTEtMTE5OTk_9c908e76-9463-4af5-87ee-0f06e94532fd"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtOC0xLTEtMTE5OTk_7febd003-1929-42c8-ab0e-cb353c1d4397"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTAtMS0xLTExOTk5_52b8bded-ad40-4723-b934-6d566a4ff227"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTItMS0xLTExOTk5_41a84efe-ca6a-4624-bdbe-0dc7314b8d6f"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i444894e06ef84e86916f0f43636239a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTQtMS0xLTExOTk5_dbf67dea-1540-4de0-be7c-bc8cf1e20eed"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i444894e06ef84e86916f0f43636239a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzQtMTYtMS0xLTExOTk5_a9239f32-0159-4f01-8257-dd7ea3f251a8"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtNC0xLTEtMTE5OTk_72b6a965-de72-4761-b9ba-c27dc1000ba0"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtNi0xLTEtMTE5OTk_7cd6e8a4-d01a-4cf0-b931-35b4dc70722e"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtOC0xLTEtMTE5OTk_bc069631-6751-472f-a2d2-fb101be3da1c"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTAtMS0xLTExOTk5_e91b5f67-43bb-4c32-ab27-89d01914cbdf"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTItMS0xLTExOTk5_69b08b66-3239-49ed-9915-5369eedc49e9"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTQtMS0xLTExOTk5_f5e37681-3132-4c57-bde0-379ff09abc1f"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzUtMTYtMS0xLTExOTk5_abb66f50-37f4-4b29-b31f-8510e568d4a5"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtNC0xLTEtMTE5OTk_8704bde2-45b0-48bd-b429-51755cfd0552"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtNi0xLTEtMTE5OTk_746682af-3f0f-4290-be96-8ae6c327ccc1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtOC0xLTEtMTE5OTk_9856d3e2-563c-471f-87bc-849c2e0c8623"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTAtMS0xLTExOTk5_c1ec80e8-5b5e-4c69-a3cd-021e4e5914e8"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTItMS0xLTExOTk5_f7d3e031-a696-4ab2-b7ad-13463f67c7f7"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTQtMS0xLTExOTk5_1cf94580-0526-46cb-b70f-38d965261f0b"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzYtMTYtMS0xLTExOTk5_0388b94b-11c6-40c4-a736-9e29a7e46212"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic202005056b44f91afe160b576641e45_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctNC0xLTEtMTE5OTk_20de10b8-5b2c-41fe-ae37-eaff8c3fba56"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctNi0xLTEtMTE5OTk_256287d0-be8b-4aa6-9c30-91bdc217e250"
      unitRef="shares">36208</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctOC0xLTEtMTE5OTk_95d2412f-15dc-4dc8-a096-72268b8bc7c5"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTAtMS0xLTExOTk5_710b3907-8c4f-4a63-b488-7b82be799169"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i7105db7f602043d090b9479ccc41f0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTItMS0xLTExOTk5_d86b8e1c-832e-4767-a25c-cf2e1953c7ac"
      unitRef="shares">36208</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="icd6514681b0542d6ad81d4e87b9026b8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTQtMS0xLTExOTk5_ecdc88df-e821-41d2-a2ed-a8370620a88d"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="icd6514681b0542d6ad81d4e87b9026b8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzctMTYtMS0xLTExOTk5_1e610ac0-dbfa-454d-a89e-9c349b293394"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtNC0xLTEtMTE5OTk_5fa185c4-21eb-4827-a89a-6c2f128a6cd8"
      unitRef="eurPerShare">15.01</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtNi0xLTEtMTE5OTk_a1594d0b-5ab3-433b-bbbe-c0c879423d57"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtOC0xLTEtMTE5OTk_104d86d7-222b-45a2-8830-1cb5470bf279"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTAtMS0xLTExOTk5_4796a5d1-0be4-4b3c-99b0-f8dcdb081d4c"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTItMS0xLTExOTk5_0264ca0c-a955-49d2-926e-b8bce77cd89d"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTQtMS0xLTExOTk5_4e8703ee-b43e-4695-b26b-71fd0fb3d100"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzgtMTYtMS0xLTExOTk5_44f38ae5-9c0f-479e-94ae-4ad1a041c37a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktNC0xLTEtMTE5OTk_38b395ce-fc34-4e5d-a222-edb04d361ca0"
      unitRef="eurPerShare">15.76</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i82aea750feb9452ea792b03a00878392_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktNi0xLTEtMTE5OTk_f11c7c85-2c10-4094-8fbc-8211c04c6299"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktOC0xLTEtMTE5OTk_7a755190-88e2-4f06-a3e6-0b3b312870fc"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTAtMS0xLTExOTk5_2405ee12-201a-49bd-a3ab-209cacda6795"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTItMS0xLTExOTk5_a3530f6e-e1eb-4af8-bd33-386f4208ffb5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5c32baad1d584e179d05334758196e37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTQtMS0xLTExOTk5_f1805c7f-aa75-46b9-93c2-07d31c28ba34"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i5c32baad1d584e179d05334758196e37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzktMTYtMS0xLTExOTk5_f13cd59e-f2c2-4ab7-a04a-77b1cee83f62"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTQtMS0xLTExOTk5_64df51fe-de48-44dc-9b29-43d526114282"
      unitRef="eurPerShare">13.55</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTYtMS0xLTExOTk5_13c44ce2-3acc-409e-9c96-9f977d157500"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTgtMS0xLTExOTk5_d025154e-e865-4e26-843b-f95d6bafcf8d"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTEwLTEtMS0xMTk5OQ_b2b5d5ce-a685-4d4b-b3f0-6aaabc223981"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTEyLTEtMS0xMTk5OQ_74c066a1-d787-4941-b095-e273b404c1a5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i185c5465e4f54321893449f2ed13c945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTE0LTEtMS0xMTk5OQ_99164818-7b64-4aa9-894d-1625025e9e0e"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i185c5465e4f54321893449f2ed13c945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEwLTE2LTEtMS0xMTk5OQ_c6451e5b-4b01-4769-8a29-d8225d204e0d"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTQtMS0xLTExOTk5_ab99efae-b77c-489b-905c-2927fbbb428b"
      unitRef="eurPerShare">16.102</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTYtMS0xLTExOTk5_6f2872c3-c355-465a-ba9e-b9fc991a2dfd"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTgtMS0xLTExOTk5_f4b86281-0c6f-420f-8c07-629998806a65"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTEwLTEtMS0xMTk5OQ_3719d683-df03-4d76-a608-0bf15a2040ee"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTEyLTEtMS0xMTk5OQ_7ba69de0-05d6-4ae7-a67a-553505872d13"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTE0LTEtMS0xMTk5OQ_b895c6ea-9931-4f7d-81e6-acb8861b3088"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzExLTE2LTEtMS0xMTk5OQ_61014cf8-9210-4a5b-9107-67e10545f66d"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTQtMS0xLTExOTk5_c36fc305-783e-4513-bff1-9c67d9b9e3e4"
      unitRef="eurPerShare">11.66</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTYtMS0xLTExOTk5_2ee5a5c4-db29-4624-830c-421e59cb16e4"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTgtMS0xLTExOTk5_3e41bfef-275b-4f79-84ac-7dad6675bf4e"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTEwLTEtMS0xMTk5OQ_0c8b60ab-f5ae-41b9-8c75-8700ff5ddc8e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTEyLTEtMS0xMTk5OQ_de8526a8-6f2e-4a41-9af6-d1cdf17bd93e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4a196703767045b4aeaf86e08026e973_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTE0LTEtMS0xMTk5OQ_c1fd2d49-a91c-438c-8d9e-57bb165eeae8"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i4a196703767045b4aeaf86e08026e973_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEyLTE2LTEtMS0xMTk5OQ_b041ce83-10ac-4336-9678-e6cec8b75f39"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTQtMS0xLTExOTk5_ae48c38f-7698-4f4e-aef9-ced139bee5d8"
      unitRef="eurPerShare">6.59</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTYtMS0xLTExOTk5_d0671599-dcd8-49ca-90d4-2ac7690b1560"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTgtMS0xLTExOTk5_20f036eb-edb8-40a2-aed0-65803c7027d7"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTEwLTEtMS0xMTk5OQ_387459f2-9d79-4e0b-be02-056fd1563bda"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTEyLTEtMS0xMTk5OQ_8519d6fd-4111-4034-9534-49e777909bc8"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTE0LTEtMS0xMTk5OQ_78bf618f-be6f-4be0-9919-edee58f039ff"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzEzLTE2LTEtMS0xMTk5OQ_4fcc74a1-08d2-4c32-b8d2-389eb6ee49e1"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i4ef0655661e64102ad08b456cde29404_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTQtMS0xLTQ0NTU1_01ce8787-03e8-4b90-b935-649958d5b58b"
      unitRef="eurPerShare">13.47</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i64f2458d1e5f4672ac966ade528e91b9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTYtMS0xLTQ0NTY0_7d2e8474-92c2-4a11-a146-f5536c107d33"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTgtMS0xLTQ0NTcw_da4668f5-f8fa-4a07-a191-9219e02f1549"
      unitRef="shares">48103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEwLTEtMS00NDU3Ng_7361d515-3e21-4afd-a5d0-f77b8a379c92"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEyLTEtMS00NDU4Mg_5eae7100-17e0-46cd-b4c6-e6fa26c46728"
      unitRef="shares">33672</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE0LTEtMS00NDU4OA_2ffd39ec-cf0f-4a51-9d95-cf3f0f8fa4d6"
      unitRef="shares">14431</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE2LTEtMS00NDU5OQ_f45d3252-a991-4398-b362-da920342da74"
      unitRef="shares">14431</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i590691d490654f4a9b933f3df5ec0da8_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTQtMS0xLTQ0NTU1_eeea17c5-37a8-4866-9e5d-a5b910ba88ee"
      unitRef="eurPerShare">13.64</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0bb4ec8843e44af1897cc09338a3eca3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTYtMS0xLTQ0NTY0_7972caab-5f1b-416f-a485-cba3e8f5cdac"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTgtMS0xLTQ0NTcw_014071ba-2126-4b6b-a4b9-cc406032acba"
      unitRef="shares">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTEwLTEtMS00NDU3Ng_2b5bfcc4-3830-40d6-abfa-116787625b9a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTEyLTEtMS00NDU4Mg_3233dfc1-46aa-4f01-a0b7-f24a8097c8b4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTE0LTEtMS00NDU4OA_1a4c3734-092d-4d49-aaed-e85a852002c3"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE1LTE2LTEtMS00NDU5OQ_80f71609-9d1c-4095-a2a6-2e10fa3e79eb"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTYtMS0xLTExOTk5_fd6b2a4e-61cf-4e59-9979-9c362d4fab13"
      unitRef="shares">263028</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTgtMS0xLTExOTk5_75f2a3e8-6bf3-44cb-adcc-a039e011a998"
      unitRef="shares">78103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEwLTEtMS0xMTk5OQ_224e727d-7cad-434e-8e83-57a32ee74c65"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTEyLTEtMS0xMTk5OQ_1d773859-fe72-49ff-bc5e-9f42d879cc41"
      unitRef="shares">77880</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE0LTEtMS0xMTk5OQ_d85e961d-9828-4556-8f4b-6a6f07f3c5a2"
      unitRef="shares">263251</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpjNTcwZmYxZTM2ZTQ0ZTE0ODIwYzE0M2E4ODFmMGFmNS90YWJsZXJhbmdlOmM1NzBmZjFlMzZlNDRlMTQ4MjBjMTQzYTg4MWYwYWY1XzE0LTE2LTEtMS0xMTk5OQ_08f10af4-aaae-4dc6-8bb6-b889bbef4cb8"
      unitRef="shares">263251</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtNC0xLTEtMTE5OTk_3e5f471c-0f10-4779-bb71-88f6dd0c3fec"
      unitRef="eurPerShare">6.00</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia368008e38064499b91b8e7a2b6fc5e6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtNi0xLTEtMTE5OTk_5652ff9a-4ae8-470c-8d52-ad84ca76db16"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtOC0xLTEtMTE5OTk_cb98bcac-c5df-4bdd-9162-8879dfa19413"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTAtMS0xLTExOTk5_4b77fa87-806d-438f-8f1e-cd680d57d71e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTItMS0xLTExOTk5_7518c94b-8c3d-44b4-a94b-50c53ebaa5b9"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTQtMS0xLTExOTk5_2c344954-a621-439b-af5c-780bdc86090d"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i9de2c0bfa1fd43238bbb2ccf3e4ba7da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEtMTYtMS0xLTExOTk5_72c20e61-c122-410b-8368-1c693beceb8a"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItNC0xLTEtMTE5OTk_f49f465c-f108-472b-a6ef-e97f6f887aaa"
      unitRef="eurPerShare">6.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i968789d68e624749aec48577df75436b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItNi0xLTEtMTE5OTk_4c11a327-9079-485a-98ab-39fdfc218607"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItOC0xLTEtMTE5OTk_6a7f9861-6b71-44ce-9fb0-cc06b4717baf"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTAtMS0xLTExOTk5_2851fc22-4f26-44a3-9948-f1b38a2b2c4e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTItMS0xLTExOTk5_a5ba0881-d32c-43d7-b330-61f9b1510eae"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i510cfe19450a4049be49e84fad36335a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTQtMS0xLTExOTk5_913e339f-6f4a-4e18-a634-325476d60030"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i510cfe19450a4049be49e84fad36335a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzItMTYtMS0xLTExOTk5_6ce170f3-cdae-4edd-ba4c-014a65335a42"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtNC0xLTEtMTE5OTk_acc051a5-3e94-474c-bd43-0678b120fbb7"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0e1ece5200db4069abd23c1d44f99b24_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtNi0xLTEtMTE5OTk_c4a8fc52-50f8-4f54-8e9e-0bd1ff86853f"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtOC0xLTEtMTE5OTk_56bf6844-60a1-4950-996f-2486fd45efac"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTAtMS0xLTExOTk5_eae78cf2-c37a-4a45-9163-be461972d2bc"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTItMS0xLTExOTk5_b042dcd6-9a2b-4ea1-a618-936c56c558fe"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTQtMS0xLTExOTk5_9deb6d36-fed1-481d-9db0-17762e76422d"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i7fd5c20435184561a25fd67367fe177e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzMtMTYtMS0xLTExOTk5_af1eab60-9c67-470c-8503-187a25d1fadb"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtNC0xLTEtMTE5OTk_25db0a63-dc88-4214-8bec-efe3e3b759e8"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i243c3f4181bd408d943852138fc86c46_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtNi0xLTEtMTE5OTk_9d50f003-6363-4144-9089-2f68e8f94807"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtOC0xLTEtMTE5OTk_1c733462-b928-44e7-bd23-bf3d2dc5fb2f"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTAtMS0xLTExOTk5_3eef2a50-1330-4b71-835b-8375c9024b74"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTItMS0xLTExOTk5_65d2fba3-bb43-489a-bc02-923e8016859d"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTQtMS0xLTExOTk5_0125e7ad-27e6-4b69-a931-af5f0b3e53d8"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="icd30db4dc68e4dcd81aa001f304ccf02_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzQtMTYtMS0xLTExOTk5_4eca452e-219f-4651-8310-1ec3743fcee2"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtNC0xLTEtMTE5OTk_814e274f-ccc9-46cb-83c6-521dd909895c"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i67d44db1d1fd485190ead9f20de4e21d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtNi0xLTEtMTE5OTk_ad5a422f-0a4b-43d5-8da2-94d8976b90dc"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtOC0xLTEtMTE5OTk_6008afc6-a120-460e-b5b0-e000cd3e0464"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTAtMS0xLTExOTk5_578b8252-9a61-4d9e-8f40-a4ad83697c4e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTItMS0xLTExOTk5_48ffdfc4-960f-455f-a656-6e58ed68c647"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTQtMS0xLTExOTk5_5fc45609-5709-4534-8969-cca39bc165e4"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i873a0cd9fb8c4033a253afbd56030396_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzUtMTYtMS0xLTExOTk5_93cb32cc-25b8-4756-b590-9bf81134bcc2"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtNC0xLTEtMTE5OTk_3b68c941-f3d6-467e-9eb8-0dafd3ed2c62"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4d936b0e4f0c4c87887a0435daa8724b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtNi0xLTEtMTE5OTk_77c1c73f-321b-4842-b861-a5ea245de075"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtOC0xLTEtMTE5OTk_13007f25-8d37-4a3f-9983-a8e742a3ddc0"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTAtMS0xLTExOTk5_f21c248b-d9f7-4ed4-a6cc-35970874a10d"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTItMS0xLTExOTk5_5d93dac4-d80e-4a8f-b35c-84ae6f6df7ef"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTQtMS0xLTExOTk5_c76e2e30-2931-4fbb-ad45-bd1ecd817906"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ie729c807456a4342ae1d1ec7e0b01004_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzYtMTYtMS0xLTExOTk5_7c084159-d5e2-4669-a95c-1ca708ecf797"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic202005056b44f91afe160b576641e45_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctNC0xLTEtMTE5OTk_40328bf6-42ba-4a5c-9ed7-e59c9b225334"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i365d674525a9479c8b26b35aa085cdbe_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctNi0xLTEtMTE5OTk_c1f5cde2-338c-4299-b7e5-723025fbec8d"
      unitRef="shares">36208</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctOC0xLTEtMTE5OTk_cd77df17-ed15-4b9d-af4b-9bd85a87fd55"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTAtMS0xLTExOTk5_10332c57-c5dc-48f1-a38f-1bc74d8ddc9f"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ie08565e7a4fd4687be1cb2136d6e01f6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTItMS0xLTExOTk5_7ab77017-b7a3-4a65-9b76-5d7d44daccf7"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTQtMS0xLTExOTk5_3a52de37-1938-4b3d-a107-3d6aa1c73ce7"
      unitRef="shares">36208</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ibe646b429ac44edb9d5b3c79beecffdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzctMTYtMS0xLTExOTk5_baad64b6-7351-49c4-bf10-f4f7608f0dee"
      unitRef="shares">36208</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtNC0xLTEtMTE5OTk_c13960ec-68ef-4998-a00c-7cabf4b0df97"
      unitRef="eurPerShare">15.01</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i2b4ed0b8dd1a49078d6c857b4f238367_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtNi0xLTEtMTE5OTk_d57755f7-deb1-4dcb-bb34-06c2405e8b88"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtOC0xLTEtMTE5OTk_37345749-f89e-4f33-a694-b9456f4de40b"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTAtMS0xLTExOTk5_1ed24f8e-2129-4803-a596-8bdfff95144a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTItMS0xLTExOTk5_56fc97ea-aa8b-4679-b434-800d69f566cf"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTQtMS0xLTExOTk5_af0d0c98-d0e5-485a-a121-a8bcf4390946"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i3ec3b243e08547a7a32d94cc27e3f446_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzgtMTYtMS0xLTExOTk5_51dbe066-e70f-4fe4-8ae8-f74bc4ccd8b7"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktNC0xLTEtMTE5OTk_2364cb49-94a5-4fdc-bfe2-e24af1691786"
      unitRef="eurPerShare">15.76</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i637bf676e3a04e68824daeb6b1575335_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktNi0xLTEtMTE5OTk_76e78afe-6cd4-486c-8f0f-bc6a03ac7804"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktOC0xLTEtMTE5OTk_4b5b027e-be33-4cae-b448-191ffb6a1e3c"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTAtMS0xLTExOTk5_00ce25bd-af0d-4644-8b4f-51fc8244545e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTItMS0xLTExOTk5_1f5a65e4-740a-46c1-a041-99de9b16b2e7"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i82aea750feb9452ea792b03a00878392_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTQtMS0xLTExOTk5_35f1b2d4-2e66-4ec9-b557-0e322cb0acaa"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i82aea750feb9452ea792b03a00878392_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzktMTYtMS0xLTExOTk5_64427ad5-c977-47f0-a417-d59c31b27e18"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTQtMS0xLTExOTk5_ef982d46-40a2-48f9-a326-27b3c2762a25"
      unitRef="eurPerShare">13.55</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i459ca9e3f16d4cd781dff0c62bdaf84a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTYtMS0xLTExOTk5_43cd98a9-a85e-42ea-9357-7a74865d775a"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTgtMS0xLTExOTk5_63aa4258-1624-4388-8970-50ad303474af"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTEwLTEtMS0xMTk5OQ_e92c4d6d-c2a4-4914-964f-f12a7c9a884f"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTEyLTEtMS0xMTk5OQ_8faba873-68e8-4b22-b41e-74feffeeb512"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTE0LTEtMS0xMTk5OQ_8e123d09-2696-4f1e-91c5-b5dd1a3b53a9"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ie220c08e5abd4acc97a8dc56ed476133_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEwLTE2LTEtMS0xMTk5OQ_21adc4ac-a51b-4842-a330-d2c969e01a40"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTQtMS0xLTExOTk5_55e8a607-8cbb-49fe-9c3d-2e18e934df43"
      unitRef="eurPerShare">16.102</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i579df336feef41d99666585cbbcc7e99_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTYtMS0xLTExOTk5_75c07d06-c944-47d4-b3c8-fa8f5425d015"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTgtMS0xLTExOTk5_29872a3f-4a16-4c44-81be-6e41f60f8078"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTEwLTEtMS0xMTk5OQ_e6b5f78c-94c8-482c-97bb-26b34d473c83"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTEyLTEtMS0xMTk5OQ_0e9e4b15-797f-4e13-8fbc-90099e498ba9"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTE0LTEtMS0xMTk5OQ_c25a9e98-d869-4333-9dec-ef3bece899e6"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i035962ed0e9a4ed88c5d0e27de65b632_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzExLTE2LTEtMS0xMTk5OQ_76ef3817-6d1f-4f15-ab54-cc1c2690a49c"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTQtMS0xLTExOTk5_bb9c2167-1cf2-4bea-8bb5-815176ce95f9"
      unitRef="eurPerShare">11.660</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i97ac1b9334ed440281d6eb50aa0804a9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTYtMS0xLTExOTk5_2a492d9e-1004-42c6-90fa-2e893242ed39"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTgtMS0xLTExOTk5_258b191a-ca7e-4f17-9cf8-2ef38a3ccad6"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTEwLTEtMS0xMTk5OQ_757aeefb-1374-4618-88a5-25efb5910853"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTEyLTEtMS0xMTk5OQ_0266939f-15f3-4621-a6e0-f7a0d7638542"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTE0LTEtMS0xMTk5OQ_f9360a85-4af5-47c7-9ed0-48d769f34c4d"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ia215c2b217c345f5a90b27a71eb9f095_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEyLTE2LTEtMS0xMTk5OQ_29040478-3d41-4406-99fa-0926b4f8ca6e"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTQtMS0xLTExOTk5_dafb05f9-bf3c-44dd-9c7e-1ed4056c4e61"
      unitRef="eurPerShare">6.59</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i26bedcd322874e948f08ed1dc1e2b254_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTYtMS0xLTExOTk5_ed255a52-d2dc-459b-8a34-563982de9221"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTgtMS0xLTExOTk5_1d05ad91-c048-4e4a-9ce2-88d1067d25a9"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTEwLTEtMS0xMTk5OQ_25d2aecb-e738-4521-8769-0bead44a94c1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTEyLTEtMS0xMTk5OQ_6eb94c26-df0e-40a5-bf9a-6dc849137b14"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTE0LTEtMS0xMTk5OQ_5e804166-61a3-49a8-8588-e447b51d63a2"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i200b12d44d8f401ebd9ec5e5c792ed43_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzEzLTE2LTEtMS0xMTk5OQ_9d67c538-312b-487d-9e7f-b56feaad6acf"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4483ef3c39a64c83b928490f95c78902_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTYtMS0xLTExOTk5_544ac75f-f541-45a3-b03e-03febd4ae646"
      unitRef="shares">251028</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTgtMS0xLTExOTk5_67e464ff-c6ee-4291-a344-6a7eeadabcbf"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTEwLTEtMS0xMTk5OQ_18167c77-1b17-4296-b62d-e96dd23681ce"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTEyLTEtMS0xMTk5OQ_ba28ccb8-a8b2-496f-9a6b-1e6d6c903cc5"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTE0LTEtMS0xMTk5OQ_cdbda036-b43f-45de-80bc-f75a2403099d"
      unitRef="shares">263028</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2NhMzcyYTc3YmY0YzQ3ODFjYzJmM2MyNWQ5ZmM3Ni90YWJsZXJhbmdlOmZjY2EzNzJhNzdiZjRjNDc4MWNjMmYzYzI1ZDlmYzc2XzE0LTE2LTEtMS0xMTk5OQ_8553f322-ae20-4e12-85fc-f8dfc00c9064"
      unitRef="shares">263028</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxMzU_e2492c24-fcd6-4405-8d26-7f35b00110ed"
      unitRef="shares">48103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:NumberOfOrdinaryShareSubscribedPerEachBSA
      contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNDI_d391c27b-2fd6-47f6-a622-a3e4094150a1"
      unitRef="shares">1</nbx:NumberOfOrdinaryShareSubscribedPerEachBSA>
    <ifrs-full:ParValuePerShare
      contextRef="ib4b320a95d374a8ba1b1f5bfe078d26f_I20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNDQ_62e7851b-1572-4764-8cf5-439b036b92e6"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNTE_734245b5-56e2-4ae4-9cc9-125aeb067161"
      unitRef="eurPerShare">13.47</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib86beff482d940c8b3f9b44ae18afb4a_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNTk_cdf1649b-30c1-49c9-846c-296dae046615"
      unitRef="shares">18103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxNjc_f2959112-ef27-4d69-ab89-b5d07ac3fc3c"
      unitRef="shares">14431</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxODI_8e31fa6d-b2e8-489e-951e-dad5111ff7bb">P10Y</nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMzE_c73e17d9-7753-4841-aee7-a540e3e20a0a"
      unitRef="number">0.75</nbx:VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMzU_9a027fa9-0a98-4a62-94bf-46876a062063">P12M</nbx:VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNTM_f1e78f08-7a72-497f-a5d4-910b4017a12d"
      unitRef="patient">2</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled
      contextRef="ied96e134ea364e66aa1870ebc331d541_D20211231-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNjE_c175a9c4-c4c2-4716-a682-ef92718bc00a"
      unitRef="patient">3</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxODQ_931d41a5-7b9f-4df2-a774-034b631281e1"
      unitRef="shares">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:NumberOfOrdinaryShareSubscribedPerEachBSA
      contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNzE_b501b1ef-7ddd-409a-9994-59ed291bdc5a"
      unitRef="shares">1</nbx:NumberOfOrdinaryShareSubscribedPerEachBSA>
    <ifrs-full:ParValuePerShare
      contextRef="i3f2fe9c5747a478cafb0068a92d9a750_I20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxOTI_8d4cf792-cfbe-436a-b95a-98878de79979"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkxOTk_8cea9733-8017-48f5-8be1-31517750729a"
      unitRef="eurPerShare">13.64</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement
      contextRef="ic25934c89fbb44c08a3adf38aa8a523f_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMTM_20a7a7d9-cbcb-41f4-a088-b01d5224df91">P10Y</nbx:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i623d044c980a4fe9b59d0cf0c4357c46_D20211231-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyMTQ_d8a5acfc-574b-4282-a3e7-3f353ddf4fa3"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI3OTk_5b77a95f-9e25-48e1-a2b9-fea1f59a1115"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ParValuePerShare
      contextRef="i48ba274c2f734a61a9cb2f4453142924_I20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI5NDc_f4ed3157-cc2f-46c7-986d-f5bd3efd8ed7"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMTI5NjY_39a79d80-0ac4-4f1e-92fa-edac680bd6a6"
      unitRef="eurPerShare">6.59</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ0_f001c011-2f02-4f94-9ea1-0c619aa56e37">OSA)&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 24, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;387,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;387,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2021-04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 20, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;571,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(80,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;491,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;491,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2021-06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 21, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;691,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(93,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise &lt;br/&gt;price&lt;br/&gt;(in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding at &lt;br/&gt;January 1,&lt;br/&gt;&#160;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding &lt;br/&gt;at December &lt;br/&gt;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of &lt;br/&gt;shares &lt;br/&gt;issuable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 2, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 3, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 6, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;54,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 24, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;March 11, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;407,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;400,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;589,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;407,972&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(10,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtNC0xLTEtMTE5OTk_57a80d26-4eed-44fd-bd72-d98cc23aac05"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtNi0xLTEtMTE5OTk_12d9a691-1f3d-4d7d-8e05-43c6994840cd"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtOC0xLTEtMTE5OTk_c77276b0-cde1-40af-b7ec-cc3c2f6d8c11"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTAtMS0xLTExOTk5_4be12c07-527e-445d-86eb-4cbf7276a6ba"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ic194b37f48d44b48b60f462971e7abd5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTItMS0xLTExOTk5_fac4c2e0-f69c-4f39-9387-babba64b42d0"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifdd4d704ab87433eaab118942f97873a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTQtMS0xLTExOTk5_ae287a89-8363-4fac-9262-1d6a82c2c918"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ifdd4d704ab87433eaab118942f97873a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzEtMTYtMS0xLTExOTk5_0d2ab806-8b44-4d23-9cc5-128926d3c9a9"
      unitRef="shares">400</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItNC0xLTEtMTE5OTk_1ad17221-37ce-4130-9fe2-48cce0fb80be"
      unitRef="eurPerShare">14.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifdc086387801445bbd7de462f336e65f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItNi0xLTEtMTE5OTk_fbcf68a9-4b17-4770-98e4-489503c1eac4"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItOC0xLTEtMTE5OTk_a1aa984b-d708-4bcf-921d-5c0451c613d2"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTAtMS0xLTExOTk5_7ab87960-b8e8-4b1f-987a-41cddb8e9ee4"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTItMS0xLTExOTk5_93e5e901-b96d-4264-bff1-1cebca0f749e"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTQtMS0xLTExOTk5_5def0feb-4a3b-460b-af4e-1c4fd01825b0"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzItMTYtMS0xLTExOTk5_947c7075-4da7-401f-a99a-ffbc9cff326c"
      unitRef="shares">4000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtNC0xLTEtMTE5OTk_fa705c1e-343b-4bc8-98cf-2df6854fe459"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtNi0xLTEtMTE5OTk_9afae065-8c60-4879-a5fd-9e334f6e00cb"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtOC0xLTEtMTE5OTk_7974e90e-6d33-4b0f-bf8c-bbfc2598a5c3"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTAtMS0xLTExOTk5_ccb523ab-9af6-4f3f-9df7-307d205b607f"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i31f4fe8c8a904fb1bad553d56878676c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTItMS0xLTExOTk5_f52aa876-bb8c-45b5-bb44-62e230ec4bef"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ibf3ccd35f2ba46f3b213016bd228158b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTQtMS0xLTExOTk5_5655759d-d65a-4b5c-89e9-e54e874bd8b6"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ibf3ccd35f2ba46f3b213016bd228158b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzMtMTYtMS0xLTExOTk5_eaa25012-7686-487d-ae56-c73a012d1cc5"
      unitRef="shares">500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtNC0xLTEtMTE5OTk_c8124155-2988-4046-89de-6dd21f677f0c"
      unitRef="eurPerShare">12.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="iff05550398184321955321fa5e96e1e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtNi0xLTEtMTE5OTk_a9622fc1-77d1-4296-a4a6-a9c8db957557"
      unitRef="shares">52000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtOC0xLTEtMTE5OTk_869bbf37-4809-4ede-9a19-d4fe7a2f8ebf"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTAtMS0xLTExOTk5_739ae50f-beb4-45b9-ba8d-ff9d8c9b20e4"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTItMS0xLTExOTk5_1f7d6614-7f5e-4610-af5b-39f99f04f5b2"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTQtMS0xLTExOTk5_77e3f634-1276-4036-ba64-e92be97c2558"
      unitRef="shares">52000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzQtMTYtMS0xLTExOTk5_97f9b1e3-864b-4121-bfc7-64676233b865"
      unitRef="shares">52000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtNC0xLTEtMTE5OTk_e72bdc39-fd8a-4b88-be50-3ca7aae3ebbb"
      unitRef="eurPerShare">11.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i8aea800177684b0784cf738a4f290854_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtNi0xLTEtMTE5OTk_766f786c-f34c-40b8-88da-65f9275ae71c"
      unitRef="shares">28750</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtOC0xLTEtMTE5OTk_9ac981cc-9f37-45e6-9f2f-bac47b7f9c51"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTAtMS0xLTExOTk5_f1eca2a1-0adc-4c0b-88a8-37060b7283ea"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTItMS0xLTExOTk5_d2caeabf-df25-483c-bfcf-28b898c59666"
      unitRef="shares">500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTQtMS0xLTExOTk5_f928ac3e-8ab0-4ffa-9963-088713a5d3a5"
      unitRef="shares">28250</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzUtMTYtMS0xLTExOTk5_d54301e9-cc79-4cd0-8967-df63b03097f0"
      unitRef="shares">28250</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtNC0xLTEtMTE5OTk_9253df21-7576-4b36-8022-1541a49b6318"
      unitRef="eurPerShare">6.41</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtNi0xLTEtMTE5OTk_ac960267-6675-4c0d-8868-c73975fa953d"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtOC0xLTEtMTE5OTk_9c166380-ce44-47d5-9a96-374f29079afd"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTAtMS0xLTExOTk5_f7043ed0-0f37-4509-bc23-870b8446ab2d"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTItMS0xLTExOTk5_f64759b2-5cab-45e9-afa5-f34a0563b599"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i41f34aacd8914d92858087d804274e6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTQtMS0xLTExOTk5_2b85fdbe-31ee-476d-9a05-837ca48ba2f2"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i41f34aacd8914d92858087d804274e6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzYtMTYtMS0xLTExOTk5_7fe6a225-d543-4376-b858-074e3e7dba43"
      unitRef="shares">500000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctNC0xLTEtMTE5OTk_aca2259f-3a02-4f44-b68e-d777160fb6a0"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctNi0xLTEtMTE5OTk_5020ac81-9c6c-4e93-bbe8-b9043de366a4"
      unitRef="shares">400709</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctOC0xLTEtMTE5OTk_8f3d96c6-061a-4f21-84e2-f1b99c66e39d"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTAtMS0xLTExOTk5_0ef620ae-ac7e-44ba-8182-566c57a89545"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTItMS0xLTExOTk5_aa577c49-bfb0-4426-81a2-017cba9de308"
      unitRef="shares">13253</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTQtMS0xLTExOTk5_ae87e16a-d163-43d0-9326-c868259e8249"
      unitRef="shares">387456</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzctMTYtMS0xLTExOTk5_b043319b-bd89-436f-828a-c51f0108126c"
      unitRef="shares">387456</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNC0xLTEtNDQ4NzY_5e1b86ef-423a-478e-9ffe-d798e33bb6c2"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="if5392b89aa5e4f9f80dabd7f2b3a9a2e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNi0xLTEtNDQ4ODQ_10f25fb2-ee01-4138-a4f8-3578d712e366"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtOC0xLTEtNDQ4OTA_36848e60-ee84-4cae-a872-883e2f20455e"
      unitRef="shares">571200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTAtMS0xLTQ0OTAz_893471e2-b840-4179-86a6-7dd0a210f52d"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTItMS0xLTQ0OTA5_0026e65e-1ab7-4dcd-9dde-e1d3a461422d"
      unitRef="shares">80000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTQtMS0xLTQ0OTE1_54f7af41-97b2-42a9-81f7-ad145ad96615"
      unitRef="shares">491200</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTYtMS0xLTQ0OTIx_be2def3d-1d06-4536-b277-b8da0dcc23a7"
      unitRef="shares">491200</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktNC0xLTEtNDQ4NzY_a7316aa7-8eed-4a23-b2bd-6a486555fe24"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i652de3ad86c34c4db4db1a382b545fa3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktNi0xLTEtNDQ4ODQ_4681bada-86ee-4e10-a031-703daa050e59"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktOC0xLTEtNDQ4OTA_f755c819-cb57-46d8-87ff-cbb52d39c208"
      unitRef="shares">120000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTAtMS0xLTQ0OTAz_1918eb6e-294a-4948-ada4-81869a3cd309"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTItMS0xLTQ0OTA5_98578723-c360-4835-a44e-6847c0fb2a44"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTQtMS0xLTQ0OTE1_48cad5f1-54ba-4cfa-b7a9-4e6cff03f910"
      unitRef="shares">120000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzktMTYtMS0xLTQ0OTIx_7f8ba581-e5c1-4cbd-8590-d39a77c9f22d"
      unitRef="shares">120000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtNi0xLTEtMTE5OTk_69ec6660-cd19-49d1-a1bd-23f62fda82f3"
      unitRef="shares">986359</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtOC0xLTEtMTE5OTk_00397d29-199a-4b7d-9760-aadb4eccb7d0"
      unitRef="shares">691200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTAtMS0xLTExOTk5_e79550c3-1514-47a3-b8fe-ee30e127173f"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTItMS0xLTExOTk5_8a6e3c98-3475-4bbc-bdf4-c30f76caf8fd"
      unitRef="shares">93753</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTQtMS0xLTExOTk5_cdb75a6f-0e7a-414f-827f-fb5796e72ec6"
      unitRef="shares">1583806</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZToyMTcwYzFjZDhmNzM0NGM4OWMwODZjMDFlNGY1MGE2NS90YWJsZXJhbmdlOjIxNzBjMWNkOGY3MzQ0Yzg5YzA4NmMwMWU0ZjUwYTY1XzgtMTYtMS0xLTExOTk5_18ac6b7c-2996-4696-9b10-05b31b061554"
      unitRef="shares">1583806</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i5322b0724ec1456ea693e8796acf0e98_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtNC0xLTEtMTE5OTk_4fb1d6e9-7179-4cff-afba-f1d2147ce066"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i9fb46e1a795c49bcb05fc8d3200315fd_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtNi0xLTEtMTE5OTk_1309fc77-cbaf-4b7e-8e60-8e641fd83db2"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtOC0xLTEtMTE5OTk_a10c2102-fb61-443b-9378-1d23fbc563fd"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTAtMS0xLTExOTk5_c635f248-0dfc-43c3-a10b-f19c39f00eca"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ida5e70e977144fe8bd1cbc0803c5f641_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTItMS0xLTExOTk5_9ad2b18f-c1b8-49ff-ae4e-895dae7b9d85"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTQtMS0xLTExOTk5_0813b444-2fa6-417b-be9f-9282b0d1c15b"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="idca2359b6d7e4ffaabb4dff17cf89642_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzEtMTYtMS0xLTExOTk5_cdfb100a-ddf6-4cf5-b509-50f9920fc375"
      unitRef="shares">400</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItNC0xLTEtMTE5OTk_79431427-037d-4b0f-8fd8-5912b2859a8d"
      unitRef="eurPerShare">14.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i7fa9412e0984488299213d105f5179a8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItNi0xLTEtMTE5OTk_e402b8c0-c275-4ea6-9a92-731434d6eac6"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItOC0xLTEtMTE5OTk_63cf265f-5212-4b3d-a087-d81655d18dcb"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTAtMS0xLTExOTk5_33e70430-4c92-4515-8eb0-2d8d7eaff0bc"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTItMS0xLTExOTk5_0fbac8ce-dcf2-45eb-8001-6e8b87037029"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifdc086387801445bbd7de462f336e65f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTQtMS0xLTExOTk5_c4cd5c0b-1242-4fba-9524-2f048ee52e18"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ifdc086387801445bbd7de462f336e65f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzItMTYtMS0xLTExOTk5_ae43d02d-aa63-472a-8a6c-4b5e9b990c53"
      unitRef="shares">4000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iac4418fa45ed4b03a9dc352fe13d721b_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtNC0xLTEtMTE5OTk_7a40307b-eade-420c-ae63-cfe6e2ded858"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifa4ccf47be0e4bbd9bb2d8faab31cb87_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtNi0xLTEtMTE5OTk_1f67f258-a4a4-48de-a776-600eeda1e04d"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtOC0xLTEtMTE5OTk_f161c172-b11a-420b-9fca-f80448924f81"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTAtMS0xLTExOTk5_60161492-ea95-4744-aab6-d5897c389276"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="id1126eed801a4c2cb18a12256f598cf1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTItMS0xLTExOTk5_a5a27dc4-0806-4f43-9778-e3d9b201baa5"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTQtMS0xLTExOTk5_e4b06c52-eddf-48bf-9f1f-b716898231a8"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ie5f5a42a1d914ed8aded2558448aef2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzMtMTYtMS0xLTExOTk5_9d9c5770-cd87-49cf-932b-905c01034562"
      unitRef="shares">500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtNC0xLTEtMTE5OTk_4b2849f8-4ecb-4d62-8b17-f71c4df5802c"
      unitRef="eurPerShare">12.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i5abb27847f02467bacf8dcdc5928b771_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtNi0xLTEtMTE5OTk_469c460d-e25e-4959-ae3b-e93d585f4cbe"
      unitRef="shares">54000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtOC0xLTEtMTE5OTk_ad020922-d8f0-4072-b3bb-2a3ea4819d02"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTAtMS0xLTExOTk5_c79e4627-22c9-4207-b2d2-d6b588a66ba0"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTItMS0xLTExOTk5_315145fa-a75d-4016-9dd3-cb437cedb798"
      unitRef="shares">2000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="iff05550398184321955321fa5e96e1e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTQtMS0xLTExOTk5_53663580-f325-4be1-9e33-9464e7a42436"
      unitRef="shares">52000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="iff05550398184321955321fa5e96e1e6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzQtMTYtMS0xLTExOTk5_2537456b-8228-42cc-8402-cf49c8bedf59"
      unitRef="shares">52000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtNC0xLTEtMTE5OTk_4c489d1c-66ee-4e2d-b119-9c12b90a15b8"
      unitRef="eurPerShare">11.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i354033aa64f342da8206f231dd7c8d2d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtNi0xLTEtMTE5OTk_f51b5725-123a-4d46-9cd7-44589b7e77d8"
      unitRef="shares">30250</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtOC0xLTEtMTE5OTk_5749ab1d-6891-46a3-8f67-17a55d8f43aa"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTAtMS0xLTExOTk5_612bbccd-4043-47d1-9b5c-73cbc1871ade"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTItMS0xLTExOTk5_66c203b6-4afb-4b61-8295-c647768ca10a"
      unitRef="shares">1500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i8aea800177684b0784cf738a4f290854_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTQtMS0xLTExOTk5_ef05c076-cf2b-498d-86cf-1d49df16954c"
      unitRef="shares">28750</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i8aea800177684b0784cf738a4f290854_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzUtMTYtMS0xLTExOTk5_d0ca0a64-c345-4ea2-9e8f-a055b8e6bd52"
      unitRef="shares">28750</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtNC0xLTEtMTE5OTk_adaef264-ae61-48ef-b1f8-ec69669c029e"
      unitRef="eurPerShare">6.41</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ic71ae7b3a2ec44fe93b98d0ab5cc918a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtNi0xLTEtMTE5OTk_5390d639-55d2-4c21-8245-bf50aac53c29"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtOC0xLTEtMTE5OTk_c9510ba3-2b4d-4659-acd3-abefb9aacc80"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTAtMS0xLTExOTk5_acdc0050-63e3-4fca-805f-331ce1bc0212"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTItMS0xLTExOTk5_8d76f6f6-96fe-42ae-b7e3-a2224bd5a6e6"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTQtMS0xLTExOTk5_b59761b2-062d-42cb-b13e-b0dfabefe567"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="ifc595b28b04c43efa8c9724856fa5a57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzYtMTYtMS0xLTExOTk5_a81a432a-2bd3-40c5-bf6d-d427a76d8977"
      unitRef="shares">500000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNC0xLTEtNDQxNjU_f6438d40-8c58-4b43-993d-2482f80e8921"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i5d97220fa46f480eb51782483039e25d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNi0xLTEtNDQxNzE_b0e5c33c-be2e-498a-a74b-3d639554ecfa"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctOC0xLTEtNDQxNzg_84723d1f-47a6-4b6d-b1bd-a46630207f83"
      unitRef="shares">407972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTAtMS0xLTQ0MTg0_badcda49-f2b2-43e4-81fe-42d36b06cd19"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTItMS0xLTQ0MTkw_1dab2f57-25ba-4cf1-866f-0e0025e3820d"
      unitRef="shares">7263</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTQtMS0xLTQ0MTk2_ea9fbc4b-3b6a-48af-b68a-e8ee5929be41"
      unitRef="shares">400709</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i86a51c85347e4e2aa0356c91bc13bfa9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTYtMS0xLTQ0MjAy_f48df4b4-a938-48dd-b87a-daff843187ac"
      unitRef="shares">400709</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctNi0xLTEtMTE5OTk_c7f314fc-1991-468c-8bc5-fa3e41573219"
      unitRef="shares">589150</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctOC0xLTEtMTE5OTk_e92dc779-1ddc-4f74-ab70-fb0fa346463c"
      unitRef="shares">407972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTAtMS0xLTExOTk5_e3d1bcee-19e9-40e1-8162-254514825242"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTItMS0xLTExOTk5_e41e7c59-e011-47fb-a49c-ad928f507a4d"
      unitRef="shares">10763</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTQtMS0xLTExOTk5_ae8ac9da-a24e-4a03-a310-03244cadf5ba"
      unitRef="shares">986359</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpiYjlhYzFiOGQ4ZDA0MjUxOGY0YTQwODFmMjQ2NjkwYS90YWJsZXJhbmdlOmJiOWFjMWI4ZDhkMDQyNTE4ZjRhNDA4MWYyNDY2OTBhXzctMTYtMS0xLTExOTk5_56e614d3-ed5f-4f24-beab-ace26ba37460"
      unitRef="shares">986359</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyNzM_e2ed2417-2fe2-4991-8485-3e8b95dd3721"
      unitRef="shares">571200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyODI_1a22d87e-6194-4bee-b784-1960ce7b3059"
      unitRef="shares">143200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkyOTE_db4ce786-ca34-4676-9a8c-cd1a4b99f01e"
      unitRef="shares">428000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:NumberOfOrdinaryShareSubscribedPerEachOSA
      contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMTQ_a284ea7a-377f-4964-9097-14f8b6ab65cb"
      unitRef="shares">1</nbx:NumberOfOrdinaryShareSubscribedPerEachOSA>
    <ifrs-full:ParValuePerShare
      contextRef="i095127a75d214c5f8b6280cf3229e623_I20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMDA_be609cf4-0291-4815-91d6-7756df77cccf"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODkzMDc_4549d021-b538-4e9b-b0d9-31a714329cf0"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk0OTE_b1dcd76b-2f89-4242-8f32-f9bd9fa4d170">P10Y</nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="i58dc3e97273c4fe39b66b4639203ebc0_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk0OTk_d106251c-391b-47f6-b7e4-d56ce152c5fc">P10Y</nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MTM_e8d4fc9a-7883-48b3-a755-a400b2eb31fe"
      unitRef="number">0.10</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:SharePriceMilestoneEuronextParis
      contextRef="ife0e763b31ee461c89aeedfcb8296cd4_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MTg_27b8f54a-d7e3-4e9d-b4fa-b97262f89639"
      unitRef="eurPerShare">24.00</nbx:SharePriceMilestoneEuronextParis>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NTA_3eb0ade4-9912-48f9-9e31-a97de5b3ce16"
      unitRef="number">0.10</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:SharePriceMilestoneEuronextParis
      contextRef="i0dfe8cbcfd864e65920fae7b9d562506_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MjY_84d5d0ec-c6db-42fa-8d01-1183a7829efb"
      unitRef="eurPerShare">30.00</nbx:SharePriceMilestoneEuronextParis>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i3eba6313515d4559a36c492791143e24_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NTU_6a4f7281-e1a6-4259-bf04-ac2f997fb1de"
      unitRef="number">0.40</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:SharePriceMilestoneEuronextParis
      contextRef="i3eba6313515d4559a36c492791143e24_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1MzQ_eea4236c-3c87-49e7-89f6-9af85e2119ba"
      unitRef="eurPerShare">40.00</nbx:SharePriceMilestoneEuronextParis>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i91936820e19b4923b898ad1557219659_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NjA_87727395-a0f2-4318-a1a3-d930695179f7"
      unitRef="number">0.40</nbx:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <nbx:SharePriceMilestoneEuronextParis
      contextRef="i91936820e19b4923b898ad1557219659_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NDI_f5e719a2-7347-4275-8f69-43ad3eafccb5"
      unitRef="eurPerShare">60.00</nbx:SharePriceMilestoneEuronextParis>
    <nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1NjQ_3fab69c1-1a46-41bd-8147-b6996ba4c287">P10Y</nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1ODQ_01ea0677-3ec7-4e63-b50b-4cc7462abb80">P10Y</nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised
      contextRef="i5b8343c910974c02b4c1483f76998841_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1ODY_d2ae6ad4-088e-489f-b534-be15a5af766a"
      unitRef="number">0.10</nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised
      contextRef="i1755b173a3d34e8499dc5ce10a9bec9c_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1OTE_f9829a77-712d-4582-998a-db1e455d1731"
      unitRef="number">0.30</nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised
      contextRef="i7fa42a50048a45a9a9d4dbf0fc6f444f_D20201130-20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk1OTY_1b3ec9c6-82c6-4f42-9831-1b54755c2c13"
      unitRef="number">0.60</nbx:VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MDE_e23bdf0c-b826-4641-b7ce-6b78957e8b23"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MzM_793fe294-3a2b-48d9-9cda-5473a54ff0bc"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MDk_52866721-15e3-47b0-a775-47d3c4cba471"
      unitRef="shares">120000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:NumberOfOrdinaryShareSubscribedPerEachOSA
      contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MjQ_3487b2b4-8ad4-414a-97ad-ff0cb63fa9b0"
      unitRef="shares">1</nbx:NumberOfOrdinaryShareSubscribedPerEachOSA>
    <ifrs-full:ParValuePerShare
      contextRef="idd940520765e4ad5b9784e162babba1b_I20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2MTg_8174ec0b-3d08-4bf2-bacb-ae49194823ed"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i475209eaa2224a61a801471a000eda08_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NDE_7713b6b1-bc95-48b0-9d22-9e576c3cfb66"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i9140bf6cd8a547318cdcdb9bdcde6edf_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NDk_2fadcad5-9860-45ec-bc57-36f5432ecd7c"
      unitRef="shares">143200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i0dd7c666e9474e3ead869f75fb119652_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NTg_f4353878-54d3-4537-a17e-bc7b2d56dc9f"
      unitRef="shares">428000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ied10bcb637b148bdb4fd855c039c1fee_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2Njc_ac6598d9-0c99-4c79-998d-e6ae51990434"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="icdd4c34c1953482892a35ce9a5217f8d_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2NzU_e7510cf6-441b-4a16-bb18-32872f8d444c"
      unitRef="shares">60000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients
      contextRef="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2ODI_5317b552-f1fc-477b-ba03-aa95ac47b7b3"
      unitRef="patient">2</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled
      contextRef="ia528c899031a4df1aa3b0a724bd228bd_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk2OTA_898456ec-da8e-432a-9493-6c4ad9943f03"
      unitRef="patient">3</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM3MTc_f789bdc1-a0a6-4d81-b0ad-94eb4260df63"
      unitRef="shares">407972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ia28c239f39194bb4b639651e62839a6e_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM3NTM_cab84ce0-e437-4bcc-8d27-c78ab3d97596"
      unitRef="shares">300000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="ib4e429614d77462f852336283afd726b_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM4Mzk_5f90b241-3634-4664-9b61-98e2f16cf2a2"
      unitRef="shares">107972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <nbx:NumberOfOrdinaryShareSubscribedPerEachOSA
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjM5NTQ_55795eff-ab46-4224-92f3-b2c7abbb32a8"
      unitRef="shares">1</nbx:NumberOfOrdinaryShareSubscribedPerEachOSA>
    <ifrs-full:ParValuePerShare
      contextRef="ib6e0b829dfdd4803b7abd6510fa5d82f_I20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjQwMDg_1f02b0db-385d-422e-b7e3-643d79a35c5f"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib4e429614d77462f852336283afd726b_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzU0OTc1NTgyMjQwMzc_92a9ad1a-5cb8-470c-9dc0-962a5664108c"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted
      contextRef="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3NzA_45200db9-acaa-4caf-93ac-17a928309b28"
      unitRef="employee">2</nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated
      contextRef="i71d86a7c8d7449e7bf488afb514a983b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3Nzg_8865e6f2-c6ce-4891-b1ad-5544cfb4b0df"
      unitRef="employee">1</nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtNi0xLTEtMTE5OTk_a841b7ab-8e5d-48e4-9e28-34c94ffac1d0"
      unitRef="shares">24500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtOC0xLTEtMTE5OTk_c2b100b1-db7b-47a7-ae31-156a25a8ab62"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTAtMS0xLTExOTk5_5106eba3-aaf6-49aa-9b81-28e5518579a4"
      unitRef="shares">24500</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTItMS0xLTExOTk5_6d042d21-da72-4bf2-b2e2-9c0b757eec46"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTQtMS0xLTExOTk5_489ddecc-0918-4255-a1e4-3a3934474f51"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzEtMTYtMS0xLTExOTk5_9f9114cf-bb06-44ba-b827-21564ab1a23d"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItNi0xLTEtMTE5OTk_37f494bd-616c-41ef-b72f-8b66d98a13b4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItOC0xLTEtMTE5OTk_92da3f31-52ee-4df9-a962-1b61406525aa"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTAtMS0xLTExOTk5_b2b16380-a9cc-48d6-841d-69ea79fbd324"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTItMS0xLTExOTk5_b3d6e8e6-bd4a-4557-9745-7a700f62b395"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTQtMS0xLTExOTk5_e6e528e6-882d-4107-839a-d01b8e91fbd3"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzItMTYtMS0xLTExOTk5_f37f166b-99d8-4105-a37d-33dea4732a7a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtNi0xLTEtMTE5OTk_0e988a52-a58f-41f9-a3e2-103f49d2b60a"
      unitRef="shares">372000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtOC0xLTEtMTE5OTk_99279326-970b-4c69-b51f-bcd6e69fe2aa"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTAtMS0xLTExOTk5_d07cb9c6-596e-4596-ad35-afbd89eb0e72"
      unitRef="shares">369250</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTItMS0xLTExOTk5_fd6a21ce-75ae-45e3-b692-26e8f8b7b734"
      unitRef="shares">2750</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTQtMS0xLTExOTk5_f8b175bc-af10-4789-bdeb-e5d6e9fc0505"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzMtMTYtMS0xLTExOTk5_f2caf1e5-cbee-4133-93e6-6f6ddf61cba0"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtNi0xLTEtMTE5OTk_871e9e57-3788-423f-a181-ce141d612116"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtOC0xLTEtMTE5OTk_c1798094-3a16-438a-9bf5-21bf9a3ef0bc"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTAtMS0xLTExOTk5_baaffe36-f005-4a19-b610-3b6dd9f7e96a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTItMS0xLTExOTk5_f7ac6199-22bd-4b10-9395-c8c2dfbaff8a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTQtMS0xLTExOTk5_aa9be4b4-683d-4e9b-9563-e654a76d7c2d"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzQtMTYtMS0xLTExOTk5_20d39eb3-bc28-49e2-9b21-0a7876b20301"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ib866094a2bed45fbb12978a62862e821_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtNi0xLTEtNDUyMTU_010124c7-6f30-4bf3-9884-41d0cd0942b5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtOC0xLTEtNDUyMTk_9786f339-7487-4503-aa47-4d29b2430aae"
      unitRef="shares">362515</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTAtMS0xLTQ1MjI1_8a7c8952-4a7b-4bec-8e63-4780cdd855f2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTItMS0xLTQ1MjMx_eceec68c-1e65-48fb-9108-ad78fbc79291"
      unitRef="shares">2003</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTQtMS0xLTQ1MjM3_b21e4c3a-f74b-405c-8208-4e45cb5c25f4"
      unitRef="shares">360512</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTYtMS0xLTQ1MjQz_540f2c34-e3c3-4028-856d-c2bbf471143e"
      unitRef="shares">360512</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtNi0xLTEtMTE5OTk_4a68f050-95c0-45e6-9dd5-98c4a7ff6589"
      unitRef="shares">446500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtOC0xLTEtMTE5OTk_24ac1d0c-29dc-4fe3-aec9-87444f10e9f5"
      unitRef="shares">362515</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTAtMS0xLTExOTk5_f1bf6d40-0308-409c-88dc-00f574986220"
      unitRef="shares">393750</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTItMS0xLTExOTk5_c2d6a5aa-db6f-4f8a-ba54-c5f6342bf1e1"
      unitRef="shares">4753</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie0979101cec4474688543efa006ec62d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTQtMS0xLTExOTk5_19d15749-4f1c-4ec7-8116-20ce2c080974"
      unitRef="shares">410512</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ie0979101cec4474688543efa006ec62d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTo3MDkwYTk5YWE1MTE0MTY1YjRkMThjMWZlMWJlN2FlZS90YWJsZXJhbmdlOjcwOTBhOTlhYTUxMTQxNjViNGQxOGMxZmUxYmU3YWVlXzUtMTYtMS0xLTExOTk5_805ce494-fa93-4511-97b3-a8daa1a96675"
      unitRef="shares">410512</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i93d6f1511d6e44e78b354c3721b5d10d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtNi0xLTEtMTE5OTk_a8944ea4-0d62-40c7-9fd8-8895b811c081"
      unitRef="shares">355250</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtOC0xLTEtMTE5OTk_556f2048-e119-4e3b-81f9-dba1c464ef15"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTAtMS0xLTExOTk5_c0dbc61f-74b5-4d67-9cd6-796aee8dbee6"
      unitRef="shares">316083</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTItMS0xLTExOTk5_2395d65e-dcde-4d90-acb2-0d8dc1129537"
      unitRef="shares">14667</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTQtMS0xLTExOTk5_5536dd55-703e-4634-8975-fff6475398f8"
      unitRef="shares">24500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i954049ede5c54ffaa561a7d9cfab1443_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzEtMTYtMS0xLTExOTk5_559e97d9-d60c-47c8-9657-9984e7f4d752"
      unitRef="shares">24500</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie8d6ad9db19141c78c82ca8829ef8a66_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItNi0xLTEtMTE5OTk_f1258e44-2f2a-4f00-a7c0-b2257e83fd9d"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItOC0xLTEtMTE5OTk_28d8ff0e-e17c-4fb9-8851-35a745076b06"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTAtMS0xLTExOTk5_0bbf5be5-b9c7-4f68-b252-ad73271da0a5"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTItMS0xLTExOTk5_f2ee4cba-9e19-4d49-8f2d-666ca0593516"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTQtMS0xLTExOTk5_9a21203e-ca0d-4788-a018-f2b513416944"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i618e2a4f0714405d93ca3cb13691d6ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzItMTYtMS0xLTExOTk5_42909f9f-0811-41bc-9fb2-32af922d21e6"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibe8ccb113d1241d8bfccb1356614de26_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtNi0xLTEtNDQyOTg_8207a814-b070-459a-9551-3d0abea2467c"
      unitRef="shares">385000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtOC0xLTEtNDQzMDQ_4f4bad47-9925-4f5a-9f7f-73bcb54ffde9"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTAtMS0xLTQ0MzEw_2647872d-e61a-40b5-b9b3-7d44ed885f22"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTItMS0xLTQ0MzE2_bb8d45d4-2f8d-4ae2-8099-9643dcc6d1c9"
      unitRef="shares">13000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTQtMS0xLTQ0MzIy_f8481898-1e40-4a21-a2b1-d12fbefc33db"
      unitRef="shares">372000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="ifdfc6b9fa68a414fa5e2b419895c7c75_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTYtMS0xLTQ0MzI4_22f9833b-0ed2-4696-b04e-3bf42cb6b8e1"
      unitRef="shares">372000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="id1c10d2422b545efaf4328d5268483f0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtNi0xLTEtMTE5OTk_fb6daaea-835b-4337-9075-751f27fb7371"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtOC0xLTEtMTE5OTk_caaa7f76-640d-4f34-94a1-0d280727ac6d"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTAtMS0xLTExOTk5_c3d3f316-5c14-4731-8eb3-ced7f6a947b1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTItMS0xLTExOTk5_533a4911-a0d9-4570-aa43-2ab93a64854e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTQtMS0xLTExOTk5_73b5a9f0-5c18-40b5-b75d-318709e47bb4"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i438c89d9de71485fa265416e30bb0e74_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzMtMTYtMS0xLTExOTk5_b62b848e-38d1-4260-8b9b-c279f7292c77"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia09f2bb3b6114c268acacc4f0ebce171_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtNi0xLTEtMTE5OTk_5d456b9b-78ce-43dc-a030-e4ddf8b7c2a5"
      unitRef="shares">746250</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtOC0xLTEtMTE5OTk_3a500f44-b1fe-4510-8e2e-1a0d7dc2d87c"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTAtMS0xLTExOTk5_93500038-eb06-42ac-a3c6-6034d902acf8"
      unitRef="shares">322083</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTItMS0xLTExOTk5_3f1cc432-5c2f-47f3-a70d-a92b0d8f61c5"
      unitRef="shares">27667</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTQtMS0xLTExOTk5_2e5d315b-90ac-4384-81c4-172a8460bef8"
      unitRef="shares">446500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90YWJsZTpmY2FjZTAxNjI5NGE0MDYzOWU3ODg3YTFlMzBlMmU5YS90YWJsZXJhbmdlOmZjYWNlMDE2Mjk0YTQwNjM5ZTc4ODdhMWUzMGUyZTlhXzQtMTYtMS0xLTExOTk5_4feaa432-f306-477e-b43d-240dee70ed25"
      unitRef="shares">446500</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4NjU_5b02ba46-0de9-43c0-8f0d-0e6da7aebed4"
      unitRef="shares">362515</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ParValuePerShare
      contextRef="i140d20eec52d43de90b683cedaafe648_I20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4NzQ_08a024ae-691e-42df-90f9-7ec78883f55b"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod
      contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk4ODk_c05b632c-3320-4643-aa13-915c3c64bb3f">P1Y</nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod
      contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDA_a257d10e-6859-4b6f-8fce-6a3fd884831e">P2Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients
      contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDE_ad3be636-699e-4d54-a6bf-c5a5b87f6b85"
      unitRef="patient">2</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled
      contextRef="ib476cd009b5f41deb741c87d1ded1608_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5ODk5MDI_3e5edccc-655e-4bfc-9812-8580e50d8ffa"
      unitRef="patient">3</nbx:VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="iaafc498a94374f9f8c4d0dda5b2e6397_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2Xzg3ODc_a852498d-b1f3-4cca-bd41-6efc6d3c87a9"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:ParValuePerShare
      contextRef="i3f28affaf7bb40ce8972d14b1c1f055b_I20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2Xzg4Mzk_18dbd020-f56a-4f25-af80-f6fe70c06904"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod
      contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ2_59b624e8-c6bc-427a-a51e-a06aab9f0e98">P2Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod
      contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ4_6cef750d-4bba-4485-84bf-9e2d44eccf67">P1Y</nbx:VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents
      contextRef="i1d27ede222ff4bb28bef6740294c83ae_D20200311-20200311"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzUy_3844d867-ae3a-47ab-8888-9d2e792c4428">P3Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents>
    <nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee
      contextRef="ia49ffd5f6a8a43efaa547e2eb3e46420_D20191024-20191024"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNDQz_30e5b48e-d926-4403-8637-92cfa320816c">P6M</nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg3ODc_70e4ee9f-540e-43d0-97a0-103741ef1e5c"
      unitRef="shares">24500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod
      contextRef="i6e9b9ccdcaa249d39806dad574f9790d_D20210317-20210317"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MjM_db504f0e-e45a-43df-910a-4281af98ab1b">P3Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod>
    <ifrs-full:IssueOfEquity
      contextRef="if8bf73603bb74c11877603a93c8fee52_D20210317-20210317"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MjU_42200e94-553f-49cf-bff0-60fc43b8ddc9"
      unitRef="eur">735</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MTU_e055c7fc-b888-41e0-aad8-ae64ea063a73"
      unitRef="shares">369250</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod
      contextRef="i9cd4c4d0c1dd456aaf2e5e51fbef315c_D20210401-20210401"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MzA_8d2caeb0-7651-4aab-a285-c410fbb587b8">P2Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod>
    <ifrs-full:IssueOfEquity
      contextRef="ibf0906164d3245eca6340ec305f7b4bf_D20210401-20210401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTg4MzI_95dedff2-8eeb-47d7-bbf8-5c80f517764a"
      unitRef="eur">11077.5</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNTcw_c4452391-7e7a-4b47-b21f-e32d17956197"
      unitRef="shares">6000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod
      contextRef="ib9ff229322e449d193e82d67cac77abf_D20200727-20200727"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzEyMzQ5_1e388e75-92ab-47ab-be6f-c0d9d0248f16">P2Y</nbx:VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod>
    <ifrs-full:IssueOfEquity
      contextRef="ifa39e4659a8045229764c592849e2e2d_D20200727-20200727"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzExNzA3_2dfdccc4-fbe1-416c-a4d2-794fcb83355b"
      unitRef="eur">180</ifrs-full:IssueOfEquity>
    <nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted
      contextRef="idabb0dddb8454f87a533b1f04427ec7d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjAvZnJhZzpkMjJiZTJlYWIyYjI0YTlmYWNmYmYyMmM1ZWYzNDRhNi90ZXh0cmVnaW9uOmQyMmJlMmVhYjJiMjRhOWZhY2ZiZjIyYzVlZjM0NGE2XzMyOTg1MzQ5OTExNzI_2cf53af1-7479-45c8-864c-e32b909b30b2"
      unitRef="employee">7</nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted>
    <ifrs-full:DisclosureOfProvisionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTI_f15455fb-fc5f-4d1c-9632-4c50aa41bc1c">Provisions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provisions for contingencies and charges &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provisions for retirement obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Company employees receive the retirement benefits provided for by law in France: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee&#x2019;s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current provisions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:3.83pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;11.1 Current provisions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Provisions for disputes comprise employee disputes in progress. The increase during 2021 and 2020 of &#x20ac;54&#160;thousand and &#x20ac;40&#160;thousand, respectively, were due to a new employee dispute that occurred during the respective years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, the reversal of provisions for charges of &#x20ac;164&#160;thousand were related to termination costs accounted for in 2019 following an employee departure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;11.2 Non-current provisions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Commitments for retirement benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interests / discounting costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to experience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to change in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to change in financial assumptions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Actuarial gains or losses recognized in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The assumptions used to measure lump-sum retirement benefits are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Retirement assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management: Age 66&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-management: Age 64&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management: Age 66&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-management: Age 64&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Social security contribution rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42.01 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.98 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.33 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Mortality tables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Regulatory table&lt;br/&gt;INSEE 2015 -2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Regulatory table&lt;br/&gt;INSEE 2014 -2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Salary increase rate (including inflation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Executive: 3%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-Executive: 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Executive: 3%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-Executive: 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Staff turnover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Constant average rate of 5.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Constant average rate of 5.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The rights granted to Company employees are defined in the Collective Agreement for the Pharmaceutical industry (manufacturing and sales of pharmaceutical products). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The staff turnover rate was determined using a historical average over the 2015-2019 period.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The sensitivity to the discount rate and to the salary growth is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Defined Benefit Obligation as of December 31, 2021&lt;br/&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The company does not expect to pay a material amount of benefits for the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzk_e3c5a367-0c4d-4262-b3f1-35ea622dad92"&gt;five&lt;/span&gt; next years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTM_e99c93cb-b089-452a-9ba2-92b834712066">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provisions for contingencies and charges &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Provisions for contingencies and charges reflect obligations resulting from various disputes and risks which due dates and amounts are uncertain, that the Company may face as part of its normal business activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;A provision is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The amount recorded in provisions is a best estimate of the outflow of resources that will be required to settle the obligation, discounted, if required, at year-end. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Provisions for retirement obligations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Company employees receive the retirement benefits provided for by law in France: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Lump-sum retirement benefit paid by the Company to employees upon retirement (defined benefit plan); and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Pension benefits paid by social security agencies, which are financed through employer and employee contributions (State defined contribution plan). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The cost of retirement benefits payable under defined benefit plans is estimated using the projected credit unit cost method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Based on this method, the cost of retirement is recorded in income such that the amount is distributed uniformly over the term of the employee&#x2019;s career. Past service cost related to non-vested benefits is recognized as an expense (increase in the benefits granted) or as income (reduction in the benefits granted) when the plan amendment or curtailment occurs. Actuarial gains and losses are recognized directly and in full in other comprehensive income (loss) under equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Retirement benefit obligations are measured at the present value of future estimated payments by reference to market yields on high quality corporate bonds with a maturity equivalent to that estimated for the plan. The Company uses experts to carry out an annual valuation of the plans. The Company's payments to defined contribution plans are recognized as expenses in each period to which they relate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021 and 2020, the Company updated the parameters for calculating the lump-sum retirement benefit plan to take recent changes into account. The salary increase rate, staff turnover and discount rate were all updated (see Note 11.2 for further details on assumptions used).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTQ_0c6fc49f-ef98-4415-a764-5223fcc75b7f">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(97)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decreases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lump-sum retirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provisions for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Current provisions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;495&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;454&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;See Statement of consolidated cash flows and Note 16.4 for the nature of these decreases&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:OtherProvisions
      contextRef="i3b309086b1c64082bcccc5093b2b7923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMS0xLTEtMTE5OTk_51dd9f92-cafa-4580-8bc2-adc57e332932"
      unitRef="eur">414000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMi0xLTEtMTE5OTk_dba39b1b-8bb5-41fc-991c-5ede41fff16c"
      unitRef="eur">0</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="ia8bf98f4a9b34ccfb91705de89cbe955_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtMy0xLTEtMTE5OTk_00ce2560-8561-4298-8037-e0db3e096b98"
      unitRef="eur">97000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i4c815a380ae74027ad90d5faa79e3d8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzEtNC0xLTEtMTE5OTk_9ba0f86d-c910-4cbf-8480-a9c3d73d4a0b"
      unitRef="eur">318000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i00cc8afb53664ed8b93b3511d260adb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMS0xLTEtMTE5OTk_740d06ad-5fb4-4c91-a7cf-3963e8d46de5"
      unitRef="eur">414000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMi0xLTEtMTE5OTk_a25e4860-1299-4cbb-b6eb-2239200c39b9"
      unitRef="eur">0</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="ic4682a95b745438eaff3173e7c9b6abb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItMy0xLTEtMTE5OTk_21803fdc-f74e-42ba-9ea4-08b7968cb850"
      unitRef="eur">97000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i9770c3638b9e47bf84c5dfee8735850b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzItNC0xLTEtMTE5OTk_8944323f-eb39-4c0b-b2a3-91b9055b1574"
      unitRef="eur">318000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="icf9d433b2a87420884917078664d7f8f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMS0xLTEtMTE5OTk_e7691cc2-8d22-4c6d-977f-defd08042402"
      unitRef="eur">40000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMi0xLTEtMTE5OTk_c85c002a-947a-4f3d-9e5b-ecbba39b02d4"
      unitRef="eur">54000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtMy0xLTEtMTE5OTk_6164c314-9501-4fe5-b016-40812af48ce2"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i5c7c68e80ad24f5093d192fa5626429e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzMtNC0xLTEtMTE5OTk_b19af4fc-b0da-4d15-b49b-d2755f67d707"
      unitRef="eur">94000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="ia38ca1b371aa43d5a00e50015286da3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMS0xLTEtMTE5OTk_7d0d5d24-d61c-4b91-b417-9b6eb89e52b5"
      unitRef="eur">0</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i22a92c12751c43379ad3872883245ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMi0xLTEtMTE5OTk_9fe966f2-525a-4507-8d7d-599fb29be7e3"
      unitRef="eur">16000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i22a92c12751c43379ad3872883245ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtMy0xLTEtMTE5OTk_1869f656-c97d-46ce-a4c8-4198370e7c9a"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="iee51e9d440a047eebd1e8bf2e351748c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzQtNC0xLTEtMTE5OTk_4d551be7-9048-49bf-a8e4-e046c2616a03"
      unitRef="eur">16000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="ib657a40efdff4a8abe6d4859411ae9a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMS0xLTEtMTE5OTk_86ebb6b8-729d-4ae9-984c-cfec3314e7e9"
      unitRef="eur">40000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMi0xLTEtMTE5OTk_51a3dd2f-9454-4978-9f14-7e355524a7e9"
      unitRef="eur">70000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i923c7bdf4ecb459c9fc321f843ed3ebc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtMy0xLTEtMTE5OTk_87b109d7-6eb3-48ad-ac5c-3a07ca33f130"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="ie7799f346c5b4b37b8b69785c49cf119_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzUtNC0xLTEtMTE5OTk_610f5768-6521-43f2-9111-3795de119f8f"
      unitRef="eur">110000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMS0xLTEtMTE5OTk_27662817-7874-4d0d-8534-6f8b91408a99"
      unitRef="eur">454000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMi0xLTEtMTE5OTk_c0e199cc-f1b3-411a-9d13-1e0a9b340f8b"
      unitRef="eur">70000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtMy0xLTEtMTE5OTk_c0df4ff6-19f0-4535-ae47-54e1e8f76c3a"
      unitRef="eur">97000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3MjVmODhjOTNmZTQ0YzIxYThkZTI1YTk4M2ZjYzg4OC90YWJsZXJhbmdlOjcyNWY4OGM5M2ZlNDRjMjFhOGRlMjVhOTgzZmNjODg4XzYtNC0xLTEtMTE5OTk_73ed0050-ddb7-4d27-8fc9-5fb3dc3f211d"
      unitRef="eur">428000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i1ec1a6d0e59f4fa0a6f189b7aa6224ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMS0xLTEtMTE5OTk_7dece46f-8c54-4d7e-9292-3c56273f611d"
      unitRef="eur">331000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMi0xLTEtMTE5OTk_7e69c17b-18a8-4941-b34c-7de017278eaa"
      unitRef="eur">83000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i37e7e226c7d54a2191d6629432e72fb0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtMy0xLTEtMTE5OTk_e0e915cc-8176-45ee-8ee5-66798a061460"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i3b309086b1c64082bcccc5093b2b7923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzEtNC0xLTEtMTE5OTk_f2893a87-e39e-4b7c-9603-6c1426377094"
      unitRef="eur">414000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i4b79b0b3f6a5401baa1cee18c3d6fedb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMS0xLTEtMTE5OTk_66766096-f2b4-4cfa-880f-db19190b7bbc"
      unitRef="eur">331000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMi0xLTEtMTE5OTk_63812106-3bdd-4565-979d-911c193d9db2"
      unitRef="eur">83000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i97e0d765eda44dc5b18b926d68d359a4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItMy0xLTEtMTE5OTk_b3c4923b-e292-451f-a791-92a7d7ecc7cc"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i00cc8afb53664ed8b93b3511d260adb5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzItNC0xLTEtMTE5OTk_99db3375-09c9-47b8-a04d-00388d7f778e"
      unitRef="eur">414000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i4a2056a247c446a399326de355e4dd00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMS0xLTEtMTE5OTk_f00a3558-55bf-4b91-9c18-2dae657333b3"
      unitRef="eur">0</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMi0xLTEtMTE5OTk_ee9578bd-79e0-4db0-b5ac-58fc4e389065"
      unitRef="eur">40000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtMy0xLTEtMTE5OTk_77187638-9c06-4711-803a-53a2240ec59e"
      unitRef="eur">0</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="icf9d433b2a87420884917078664d7f8f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzMtNC0xLTEtMTE5OTk_8faab1ed-bdf3-4be1-bb78-487c5af2b55c"
      unitRef="eur">40000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i31eefc648a754106ba154cff1e338702_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMS0xLTEtMTE5OTk_68cde649-6d01-42bc-8174-415839a1d9f8"
      unitRef="eur">164000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMi0xLTEtMTE5OTk_15f57d63-4f15-4d35-a54c-08dc5203b417"
      unitRef="eur">0</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtMy0xLTEtMTE5OTk_adfad7e9-c210-439f-8d04-9e6e4e1019d3"
      unitRef="eur">164000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="ia38ca1b371aa43d5a00e50015286da3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzQtNC0xLTEtMTE5OTk_e969bf00-c3bf-48b3-9aa5-0027c95d0449"
      unitRef="eur">0</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i2f8df14f2f9d420ca23cd6a4dbaf06f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMS0xLTEtMTE5OTk_306fb1ef-03ca-432b-9bc6-85459510a1ab"
      unitRef="eur">164000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMi0xLTEtMTE5OTk_c0bf8060-c344-4998-aae7-1d10f8a94725"
      unitRef="eur">40000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="ieb817ae55abe461184e3f7ea8e5b9f59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtMy0xLTEtMTE5OTk_40fd729a-11d3-4483-951a-de9f7a7aadfc"
      unitRef="eur">164000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="ib657a40efdff4a8abe6d4859411ae9a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzUtNC0xLTEtMTE5OTk_18969ad8-0dbb-43ef-a4ad-28a36bf4445e"
      unitRef="eur">40000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMS0xLTEtMTE5OTk_0fdb37e5-8aef-4c03-a596-8701b324dc00"
      unitRef="eur">495000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMi0xLTEtMTE5OTk_93f47c7c-12b7-4e78-98f1-c108f17a3a29"
      unitRef="eur">123000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtMy0xLTEtMTE5OTk_933232a8-9652-4168-bd05-5d082db94bdd"
      unitRef="eur">164000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkNWY4MWZkMjkxZWE0MTgwOWVkMTdjOTYxYjZjOWVjZC90YWJsZXJhbmdlOmQ1ZjgxZmQyOTFlYTQxODA5ZWQxN2M5NjFiNmM5ZWNkXzYtNC0xLTEtMTE5OTk_d94d0824-d9be-4496-b214-d0811d0a81c7"
      unitRef="eur">454000</ifrs-full:OtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI3ODU_1514e101-fedf-43b7-ba9e-ce593e75ddb0"
      unitRef="eur">54000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="i4d88f328ecfa4f8d96dd42703c3b3268_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI3OTI_6c443398-3ce5-4f4e-9ca1-3b765e6cdb4a"
      unitRef="eur">40000</ifrs-full:ProvisionUsedOtherProvisions>
    <nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions
      contextRef="id481c669f10348a6bb361ea9989abe14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzI5Njg_bc7e0c3f-b419-4d00-8391-d13ef8f3d292"
      unitRef="eur">164000</nbx:ProvisionUsedAndUnusedProvisionReversedOtherProvisions>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTU_4b903b4a-fb80-4371-8163-41a9f943682e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Commitments for retirement benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interests / discounting costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to experience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to change in demographic assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gains or losses related to change in financial assumptions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Actuarial gains or losses recognized in other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Provision as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzEtMS0xLTEtMTE5OTk_6ad9cf82-c855-47e6-9ca6-58d962c50062"
      unitRef="eur">414000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzEtMi0xLTEtMTE5OTk_599f0445-886e-4793-926d-f94d366736a3"
      unitRef="eur">331000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzItMS0xLTEtMTE5OTk_30553c81-6dd5-4def-982f-c4428eef4626"
      unitRef="eur">84000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzItMi0xLTEtMTE5OTk_f362b09b-519c-4e45-bd98-d6961d4b2abe"
      unitRef="eur">76000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzMtMS0xLTEtMTE5OTk_9af69eea-fec4-4c90-ac20-8a24fd30d05d"
      unitRef="eur">1000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzMtMi0xLTEtMTE5OTk_7c8c9edc-6adc-47b8-9392-cd2a95243339"
      unitRef="eur">3000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzQtMS0xLTEtMTE5OTk_af849f26-09ec-4a73-9d97-6d9b17b6802e"
      unitRef="eur">85000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzQtMi0xLTEtMTE5OTk_51aab08b-a62d-4684-8cdf-3aa3eaa76a27"
      unitRef="eur">79000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzUtMS0xLTEtMTE5OTk_7aefea0d-9a7e-410e-8aec-0649cfbd4ace"
      unitRef="eur">-133000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzUtMi0xLTEtMTE5OTk_3f7e3709-43d8-4f2a-ad3d-40416b5e1f51"
      unitRef="eur">-61000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzYtMS0xLTEtMTE5OTk_b5c3e745-1c56-4f1f-b4d8-c4e718108a20"
      unitRef="eur">-5000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzYtMi0xLTEtMTE5OTk_29f54794-dd98-4947-bb4f-1b1cc7339e86"
      unitRef="eur">3000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzctMS0xLTEtMTE5OTk_ed5d7b94-0825-4a73-8494-fe2db605aeed"
      unitRef="eur">-43000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzctMi0xLTEtMTE5OTk_c2df9566-f067-49fd-ad97-4891c8f41b0d"
      unitRef="eur">62000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzgtMS0xLTEtMTE5OTk_4a419b56-5ac1-4fab-b7dd-1c8171e29bc6"
      unitRef="eur">-182000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzgtMi0xLTEtMTE5OTk_40bf6ade-e44d-43ba-8eb3-7f17f6143b91"
      unitRef="eur">4000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzktMS0xLTEtMTE5OTk_eb925ad7-03bf-4baf-aa20-a08ec178a213"
      unitRef="eur">318000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo3M2M5NWRmNTkyN2M0YmFjYTZhNTJhZDY3NmYwNWQyZi90YWJsZXJhbmdlOjczYzk1ZGY1OTI3YzRiYWNhNmE1MmFkNjc2ZjA1ZDJmXzktMi0xLTEtMTE5OTk_d5f01f1a-00d8-47b8-8cb0-1ec67ee91624"
      unitRef="eur">414000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzM0OTY_8b5dc1b7-a5b2-40d9-9a2a-9b73684a0b38">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The assumptions used to measure lump-sum retirement benefits are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Measurement date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Retirement assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management: Age 66&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-management: Age 64&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management: Age 66&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-management: Age 64&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Social security contribution rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42.01 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.98 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.33 %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Mortality tables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Regulatory table&lt;br/&gt;INSEE 2015 -2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Regulatory table&lt;br/&gt;INSEE 2014 -2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Salary increase rate (including inflation)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Executive: 3%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-Executive: 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Executive: 3%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-Executive: 2.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Staff turnover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Constant average rate of 5.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Constant average rate of 5.86%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Duration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019
      contextRef="i2ff4e8698b934f5ca052b72aca594ec8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZTA1N2NjZGU3NTM0YzhlYTk5YWYxOGUyNWRmNmE5MV8yMQ_cf346467-b900-4984-a575-7c70a694ef06">P66Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019
      contextRef="i4d9f94f4d137434787ce8c4eaa14426e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZTA1N2NjZGU3NTM0YzhlYTk5YWYxOGUyNWRmNmE5MV80NA_87f9a485-87e8-4eb0-9b8b-d4bb72b358bb">P64Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019
      contextRef="if9d81d56997d4d9c87371cf48ed31342_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxOTJmNDc1ODMyMGQ0MzYwYmJjZGZiOTU5YmU1NmNhZF8yMQ_2f691641-709f-45fc-a702-a8f087248aeb">P66Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <ifrs-full:ActuarialAssumptionOfRetirementAge2019
      contextRef="i00fb905b6ac2460fbb950029daa312f8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzEtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxOTJmNDc1ODMyMGQ0MzYwYmJjZGZiOTU5YmU1NmNhZF80NA_0126a5ef-4220-4a2a-8919-b1024bae90d2">P64Y</ifrs-full:ActuarialAssumptionOfRetirementAge2019>
    <nbx:ActuarialAssumptionOfSocialSecurityContributionRates
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzItMS0xLTEtMTE5OTk_aeb4858b-34b4-42d6-970b-40031504c0ea"
      unitRef="number">0.4201</nbx:ActuarialAssumptionOfSocialSecurityContributionRates>
    <nbx:ActuarialAssumptionOfSocialSecurityContributionRates
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzItMi0xLTEtMTE5OTk_39636384-894e-4be7-9971-d9cc61f28b81"
      unitRef="number">0.44</nbx:ActuarialAssumptionOfSocialSecurityContributionRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzMtMS0xLTEtMTE5OTk_6c7386d6-f52f-4040-9898-0079d62c0019"
      unitRef="number">0.0098</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzMtMi0xLTEtMTE5OTk_f2370872-826f-400b-b3f6-18341689bc39"
      unitRef="number">0.0033</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="i20fe37bb0cdf444b83b46778e2b4506e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1Y2I4ODNmMThmOWM0YWQ5YjUzYTM2MGY2ODM1ZDdjY18xNQ_c429f2bf-4f85-45c5-89d5-ebf36ff8c281"
      unitRef="number">0.03</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="i52f0c77f0c744ce19a75d7d15fcb5f32_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1Y2I4ODNmMThmOWM0YWQ5YjUzYTM2MGY2ODM1ZDdjY18zMw_712ae07d-6f4b-431c-8044-93729baab5c8"
      unitRef="number">0.00025</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="ie314f470deb843f992c5a952cdab570c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxYjhjM2I5ZDM0MzU0ZTc5YTkyNGQ3YTIzNTcwNjJiMF8zMjk4NTM0ODgzMzY3_d167a703-a842-445f-aa42-450c19e7388c"
      unitRef="number">0.03</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="i6f003eaa769045d399df6708982c5689_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzUtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxYjhjM2I5ZDM0MzU0ZTc5YTkyNGQ3YTIzNTcwNjJiMF8zMjk4NTM0ODgzMzc0_f8487120-44ee-43e2-8f3d-6f14c80642b6"
      unitRef="number">0.00025</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzYtMS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo5Yzc1OTllYTJlZjI0ZjhkYTVhMTU2MjcwNmM1NGU4MF8yOQ_d8c939a5-8ae4-4a3a-8943-62b77e5ca33e"
      unitRef="number">0.000586</nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover>
    <nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzYtMi0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxMTRlM2I1NzkxMGY0ZjI5OTdjNzc0MDVhNDA4MTg5YV8yOQ_34b181e2-fc69-4416-aa59-9341257cee8d"
      unitRef="number">0.000586</nbx:ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzctMS0xLTEtMTE5OTk_3c3d9c7f-7122-4103-9c99-d6b4d8380e39">P20Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTpkZDNhMTczZDkzNTA0MWIzOTdlOWIzZDI3Y2E3YmVkOS90YWJsZXJhbmdlOmRkM2ExNzNkOTM1MDQxYjM5N2U5YjNkMjdjYTdiZWQ5XzctMi0xLTEtMTE5OTk_17ca0b08-3aae-4d15-bffd-cbb06cb6d6b1">P17Y</ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation2019>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90ZXh0cmVnaW9uOmMzM2E5NzJlMmY1ODQwODg4MzVmZjMyYjc5ZmM2OTIyXzMyOTg1MzQ4OTQyNzg_9605f122-6a10-4579-9426-00cc4289a242">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The sensitivity to the discount rate and to the salary growth is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.73%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.98%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Defined Benefit Obligation as of December 31, 2021&lt;br/&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMS0xLTEtODI5MDI_141abfc9-d946-4190-97e4-7405430ef660"
      unitRef="number">0.0073</nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMi0xLTEtODI5MDI_d653edb2-aff8-4728-812d-c00aa1577b22"
      unitRef="number">0.0098</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <nbx:ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzAtMy0xLTEtODI5MDI_61e1d56c-b042-4d69-b223-dabe40876520"
      unitRef="number">0.0123</nbx:ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25>
    <nbx:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMS0xLTEtODI4OTQ_44ab201d-918e-4b9d-b37d-0fa853b95b75"
      unitRef="eur">333000</nbx:DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan
      contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMi0xLTEtODI4OTQ_2889aaa6-35e2-4f69-be43-a035f5cd4cb0"
      unitRef="eur">318000</ifrs-full:RecognisedLiabilitiesDefinedBenefitPlan>
    <nbx:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="i2dc5ff1dff994b4eb048694b27359b44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjYvZnJhZzpjMzNhOTcyZTJmNTg0MDg4ODM1ZmYzMmI3OWZjNjkyMi90YWJsZTo1YjEwZmY1M2U3NzM0Mzk1OTRhNDAxN2Y3Yzg4YTBkOS90YWJsZXJhbmdlOjViMTBmZjUzZTc3MzQzOTU5NGE0MDE3ZjdjODhhMGQ5XzEtMy0xLTEtODI5MDI_0c20c780-feca-4bda-8f75-de78a2647eac"
      unitRef="eur">303000</nbx:DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <nbx:DisclosureOfFinancialLiabilitiesTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI4_aadf278b-7ba5-4cc0-aa38-6919e4d43dba">Financial liabilities &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company receives assistance in the form of grants, conditional advances and interest-free loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Financial liabilities are recognized and measured in accordance with IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; Financial liabilities, including trade and other payables are valued at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial liabilities at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 &#x2013; Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Details of financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances - Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB Loan &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;37,816&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;44,107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;48,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*)&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Bpifrance conditional advances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company receives repayable advances from Banque Publique d&#x2019;Investissement (formerly known as OSEO Innovation). Some of these advances are interest-free and are fully repayable in the event of technical and/or commercial success. In 2018, the Company was informed that the initial date of reimbursement of the Bpifrance repayable advance was deferred for 18 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The other advances are bearing 1.56% interest. The amount to be reimbursed corresponds to the amount received to date, &#x20ac;2.1&#160;million, increased by the interest amount (see Note 12.1). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In June 2020, Curadigm SAS obtained a &#x20ac;500&#160;thousand conditional advance from Bpifrance, &#x20ac;350&#160;thousand of which was received at the signature date while the remaining amount had been scheduled to be received by Curadigm at the end of the work, expected as of March 1, 2022 at the latest, but Curadigm SAS requested an extension of the work period to Bpifrance as a result of COVID-19 which - in case of Bpifrance&#x2019;s approval - could result in collectibility of the remaining &#x20ac;150&#160;thousand. As of December 31, 2021, the work had not been completed and the balance, therefore, has not been paid.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;EIB loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In July 2018, the Company obtained a fixed rate loan from the EIB. The loan could reach a maximum amount of &#x20ac;40&#160;million, divided in three tranches. The first tranche, with a nominal value of &#x20ac;16&#160;million, was received in October 2018 and will be repaid in full in 2023. The accumulated fixed-rate interest related to this tranche will be paid at the same time. The second tranche, with a nominal value of &#x20ac;14&#160;million, was received in March 2019 and will be repaid between 2021 and 2024. The accumulated fixed-rate interest related to this second tranche will be paid twice a year together with the principal due. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The third tranche, which abides by specific conditions (NBTXR3 should obtain the European Commission trademark and reach the main performance criteria for the Phase III pivot, for head and neck cancer treatment), has not been requested by the Company. The deadline for requesting this third tranche, initially scheduled as of July 26, 2020, had been delayed by 12 months to July 31, 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As the conditions were not met by July 31, 2021, the Company will not be able to request the final tranche of the EIB loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Pursuant to the terms of the loan, the Company is also required, during a six-year royalty calculation period commencing on January 1, 2021, to pay (on each June 30 with respect to the preceding year within the calculation period) additional interest in the form of royalties, calculated according to the number of tranches that have been withdrawn and indexed on the annual sales turnover (see Note 4.2). Initially, the Company calculated estimated future royalties based on its forecast of future annual sales turnover, and this estimated amount was included in the amortized cost of the loan. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. Due to the delay caused by COVID-19 in clinical trials and the revision of the related sales development plan, the sales forecasts were updated resulting in a change in estimate of the accrued royalties (see Note 12 of our consolidated financial statements for details about the impact of this sales forecast update). A 10% &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;increase of the estimated future net sales would result in an immaterial change of the EIB loan valuation recorded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;PGE loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company announced in June 2020 that it has received approval for financing from both HSBC and Bpifrance for &#x20ac;5&#160;million each in the form of state-guaranteed loans (&#x201c;Pr&#xea;ts Garantis par l&#x2019;Etat&#x201d;, or &#x201c;PGE&#x201d; in France); the &#x20ac;5&#160;million from HSBC (the &#x2018;&#x2018;HSBC PGE Loan&#x2019;&#x2019;) was received in June 2020. This loan is booked at amortized cost for a minimum of 12 months and allows the Company to delay the reimbursement of this 12 months loan by 1 to 5 years. The Company uses this option and the reimbursement date was delayed by 1 year and will start in September 2022. The effective interest rate amounts to 0.31%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;On July 10, 2020, the Company entered into the second &#x20ac;5&#160;million PGE loan with Bpifrance (the &#x2018;&#x2018;Bpifrance PGE Loan&#x2019;&#x2019;). The Bpifrance PGE loan has a six-year term and is 90% guaranteed by the French State. The Bpifrance PGE loan did not bear any interest for the first 12-month period but, following such 12-month period and for the subsequent 5 years, is bearing an interest rate of 2.25% per annum, inclusive of an annual State guarantee fee of 1.61% per annum. The principal and interest of the Bpifrance PGE loan will be reimbursed in 20 quarterly installments as from October 31, 2021 until July 26, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;12.1 Conditional advance, bank loan and loans from government and public authorities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The table below shows the detail of liabilities recognized on the statements of financial position by type of conditional advances and loans from government and public authorities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Conditional advances and loans from government and public authorities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Interest-free Bpifrance loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;EIB Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Curadigm Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;38,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;29,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;32,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;26,374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;29,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The impact of discounting and accretion of &#x20ac;5.8&#160;million, in 2021 relates to impact from the &#x201c;catch-up method&#x201d; related to the variable compensation further to the royalty component in the EIB loan that is linked to future revenue expectations. When the Company revises its forecasts of estimated royalties, the carrying value of the liability is subsequently adjusted based on the revised estimate of future royalties, which is discounted at the original effective interest rate. The related impact on the carrying value of the liability is recorded as financial income or expense, as applicable. The rest of the catch up impact is presented on the line variable interest future payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The expected royalty payments to be made in the future, initially estimated as &#x20ac;17.2&#160;million as of December 31, 2020 have been updated to &#x20ac;3.4&#160;million as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Bank loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;HSBC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;12.2 Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1st,  2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;New lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting of the new lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixed interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment of lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Early termination of lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Engagement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment of lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Early termination of lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;12.3 Due dates of the financial liabilities  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest-free Bpifrance loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;37,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;The Company will reimburse the two &#x201c;PGE&#x201d;or (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The long-term debt obligations relate to the fixed rate interest and principal payable on repayable advances, the interest-free Bpifrance loan, EIB loan, PGE loans and the lease liabilities. These amounts do not include the discounting impact, but only reflect the committed amounts under those contracts as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The outstanding balance of the EIB loan included in the table above was &#x20ac;33.9&#160;million as of December 31, 2021, including &#x20ac;7.0&#160;million of total fixed rate interest to be paid over the term of the loan, out of which &#x20ac;1.8&#160;million was accrued as of December 31, 2021. The balance in the table above does not include &#x20ac;3.4&#160;million of estimated variable rate interest, based on the consolidated forecasted sales expected to be generated by the Company during the six-year period beginning January 1, 2021 (see Notes 3.2, 4.3 and 12.1). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;On April 07, 2021, the Company received the approval of HSBC on its debt rescheduling request. The HSBC PGE loan will be reimbursed at the same pace as the Bpifrance loan, starting on September 2022.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfFinancialLiabilitiesTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMz_35da83e6-82e0-4f56-80f3-55bc54bc1e50">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company receives assistance in the form of grants, conditional advances and interest-free loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under IFRS, a repayable advance that does not require the payment of annual interest is considered to be an interest-free loan. The difference between the amount of the advance at historical cost and the advance discounted at the Company's average borrowing rate is considered to be a government grant. These grants are deferred over the estimated duration of the projects they finance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The long-term (more than one year) portion of conditional advances is recognized in non-current financial liabilities and the short-term portion in current financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-repayable conditional loans are treated as government grants when there is reasonable assurance that the Company will comply with the conditions for non-repayment. Otherwise, they are classified in liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Government grants made available to offset expenses or losses already incurred, or as immediate financial assistance to the Company with no future related costs, are recognized in income in the period in which the grant is allocated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Financial liabilities are recognized and measured in accordance with IFRS 9 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; Financial liabilities, including trade and other payables are valued at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Financial liabilities at amortized cost&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Loans and other financial liabilities are recognized and measured in accordance with IFRS 9 &#x2013; Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;They are recognized at amortized cost, which is defined under IFRS 9 as the initial value of a financial asset or liability, after deduction of reimbursement of principal, increased or decreased by the accumulated amortization, calculated using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Transaction costs directly attributable to the acquisition or issuance of financial liabilities are deducted from the financial liabilities. The costs are then amortized on an actuarial basis over the life of the liability using the effective interest rate, namely the rate that exactly discounts estimated future cash flows to the net carrying amount of the financial liability in order to determine its amortized cost.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI5_46f60c89-afad-4eef-93ad-6cb0081e52ff">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Details of financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances - Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB Loan &#x2013; Short term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayable BPI loan advances &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;PGE*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB loan &#x2013; Long term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;37,816&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;44,107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;46,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;48,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(*)&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on&lt;br/&gt;the statement of&lt;br/&gt;financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets &lt;br/&gt;carried at fair value &lt;br/&gt;through profit or &lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities&lt;br/&gt;carried at amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="id9e19e74602b46bfa5b381e3de4fca06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEtMS0xLTEtMTE5OTk_31f26159-d5e5-43e8-9f7c-8155150a696c"
      unitRef="eur">1126000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="ice82a034b6964d1d92ad1d346d346b3c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEtMi0xLTEtMTE5OTk_bde92f1c-45ed-4a5c-9798-aaf773532ccd"
      unitRef="eur">1197000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="ic3979f010ce54acda1438941b43765cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzItMS0xLTEtMTE5OTk_9ab461ad-5214-4473-9a5c-a2427309ef8d"
      unitRef="eur">800000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzItMi0xLTEtMTE5OTk_8d813aff-5d3a-43fd-8595-c417614f1baa"
      unitRef="eur">500000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="ifb22c0964cc746dd82cf9597bde3d98d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzMtMS0xLTEtMTE5OTk_f7a032c1-5a40-464f-9b5e-8dc3179fa2f3"
      unitRef="eur">1086000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i860acbbc413c411d9552c930dd50330e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzMtMi0xLTEtMTE5OTk_1431dbf6-a659-4e7f-a8b8-79ee14c440be"
      unitRef="eur">141000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i70c9105496ee4b008bc01ccddf108a3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzQtMS0xLTEtMTE5OTk_726ab57e-c81f-4601-aeff-85550641ff7a"
      unitRef="eur">5192000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i6063d413a70f4e42ab228ca05274873e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzQtMi0xLTEtMTE5OTk_6e392b11-ac6b-41eb-ba8a-01609d0503b9"
      unitRef="eur">3033000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzUtMS0xLTEtMTE5OTk_5b99c2e0-f708-4015-a8c5-7ba0e1f0edfd"
      unitRef="eur">8204000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzUtMi0xLTEtMTE5OTk_ec2942de-f91f-4861-92f6-a082529ca64e"
      unitRef="eur">4872000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="id9e19e74602b46bfa5b381e3de4fca06_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzYtMS0xLTEtMTE5OTk_850f1c90-2817-4d2e-b527-95f8137da173"
      unitRef="eur">5393000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="ice82a034b6964d1d92ad1d346d346b3c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzYtMi0xLTEtMTE5OTk_ba228755-7dec-4508-97a8-cd747e8e6b13"
      unitRef="eur">4991000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="ic3979f010ce54acda1438941b43765cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzctMS0xLTEtMTE5OTk_6a36c693-8e88-4d32-9227-14cccb7d465f"
      unitRef="eur">2259000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i463e0971fc9c41bdbbf5a0f2cca7226c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzctMi0xLTEtMTE5OTk_53d5e372-c082-43b3-91d6-5c396d8c915d"
      unitRef="eur">2975000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="ifb22c0964cc746dd82cf9597bde3d98d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzgtMS0xLTEtMTE5OTk_8de0e258-607e-45c6-b4da-4602f35a0a65"
      unitRef="eur">8982000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i860acbbc413c411d9552c930dd50330e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzgtMi0xLTEtMTE5OTk_c9c4f582-d212-48d2-b277-696b4f71c2f3"
      unitRef="eur">9922000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i70c9105496ee4b008bc01ccddf108a3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzktMS0xLTEtMTE5OTk_382241d3-68f6-42cf-8550-d00b2fafddf8"
      unitRef="eur">21182000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i6063d413a70f4e42ab228ca05274873e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzktMi0xLTEtMTE5OTk_5e8ae866-226b-490c-ad3d-447effb0876c"
      unitRef="eur">26218000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEwLTEtMS0xLTExOTk5_474d6d37-3b43-4725-a901-1aff87f589fa"
      unitRef="eur">37816000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzEwLTItMS0xLTExOTk5_0930a64e-24a6-4c1f-8ff3-3d741f60bd62"
      unitRef="eur">44107000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzExLTEtMS0xLTExOTk5_fd97b050-3037-435e-a855-80d0ce28804f"
      unitRef="eur">46020000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowOWU2YThkMzI3OTQ0MjI0YTU1YWU5YjE2ZjNmMzIyMy90YWJsZXJhbmdlOjA5ZTZhOGQzMjc5NDQyMjRhNTVhZTliMTZmM2YzMjIzXzExLTItMS0xLTExOTk5_3a7e5cfc-984a-4ea2-8fc3-2b9fb86ecc05"
      unitRef="eur">48979000</ifrs-full:FinancialLiabilities>
    <nbx:AdvancesReceivedDefermentPeriod
      contextRef="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMwMTc_2fe40ca7-7f96-4e89-8b10-0c478f1df7ef">P18M</nbx:AdvancesReceivedDefermentPeriod>
    <nbx:AdvancesReceivedInterestRate
      contextRef="ib3732170796b4f54ba0ef45e82d153ab_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMDA_abfad00c-73ac-43c3-ad65-ad94bddb37da"
      unitRef="number">0.0156</nbx:AdvancesReceivedInterestRate>
    <ifrs-full:Advances
      contextRef="id26c49ada5ea49f6925b076f04f65999_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMwOTM_18ab72b7-f9ab-4c4a-815a-4d3d2150ee03"
      unitRef="eur">2100000</ifrs-full:Advances>
    <nbx:AdvancesAuthorizedAmountToBeAdvanced
      contextRef="i4f9f36c6b44349068238dd8813d5bb59_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMxODc_f3e8201a-fc48-46ee-af7b-53bfb0c5aab8"
      unitRef="eur">500000</nbx:AdvancesAuthorizedAmountToBeAdvanced>
    <ifrs-full:Advances
      contextRef="i4f9f36c6b44349068238dd8813d5bb59_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyMjY_6124fc11-1ba2-49ef-acb0-10cebcab45a3"
      unitRef="eur">350000</ifrs-full:Advances>
    <nbx:AdvancesOutstandingAmountToBeReceived
      contextRef="if4f90ba5db684b64a31830ebf03467df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMDc_6254ced9-a7a0-4d0c-87c7-4c40b2a939f9"
      unitRef="eur">150000</nbx:AdvancesOutstandingAmountToBeReceived>
    <ifrs-full:NotionalAmount
      contextRef="i8e7d5a08503c4c58999df6bf6e4c20d4_I20180731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1MDg_9adee9b3-3e31-4736-898c-9da1d144a12f"
      unitRef="eur">40000000</ifrs-full:NotionalAmount>
    <nbx:NumberOfTranchesBorrowings
      contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1MjM_2e940eae-0431-4ca3-ae11-f5aafeb9bde0"
      unitRef="tranche">3</nbx:NumberOfTranchesBorrowings>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i5d8497a0eadd41ffad7a1799d920109b_D20181001-20181031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM1Nzk_ef8bfa0c-4a10-4038-b94d-85cb6c59b1e7"
      unitRef="eur">16000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i61d2d9900b1a431685d2e41bcb4b0951_D20190301-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzM3ODM_c72b8774-9ef1-4b9c-b018-c84cb33ccefb"
      unitRef="eur">14000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <nbx:BorrowingDefermentPeriodToRequestFunds
      contextRef="i730862d53f524fd48823ccef1c727d85_D20200701-20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzQzNDQ_4bf1afab-3c9f-4066-944f-7de40f44a3f7">P12M</nbx:BorrowingDefermentPeriodToRequestFunds>
    <nbx:RoyaltiesAgreementPeriod
      contextRef="i019a762512c74bd995f218b15c627c60_D20180701-20180731"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM0_8d782cae-8e72-4810-a63d-e816cf49332f">P6Y</nbx:RoyaltiesAgreementPeriod>
    <ifrs-full:NotionalAmount
      contextRef="icdb43c79419c4ae4a549589fcd0ea3d5_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzU5MDE_75b40caa-8004-493d-88b2-375387e4901c"
      unitRef="eur">5000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzU5MDE_adeff891-3d2f-4624-82b7-418b66d6c40b"
      unitRef="eur">5000000</ifrs-full:NotionalAmount>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYwMDI_46057d4e-95ec-480c-9dbf-66dcf8897221"
      unitRef="eur">5000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest
      contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxMjE_93d1fe47-04f9-43aa-ae2b-834f33e69ad1">P12M</nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest>
    <nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest
      contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxODI_e1823eef-dd57-4eec-8327-5c86bbc91e50">P12M</nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest>
    <nbx:BorrowingDefermentPeriod
      contextRef="i677dc547692443839295f53c6d89dbdd_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxOTM_b6f540fb-3fb0-480c-82e4-bdfd50e7a241">P1Y</nbx:BorrowingDefermentPeriod>
    <nbx:BorrowingDefermentPeriod
      contextRef="i4e96e3484ed74cb680b4ae9eab1f7e13_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYxOTk_9ed4bdfd-9bbc-48cf-b973-d03ef67f9563">P5Y</nbx:BorrowingDefermentPeriod>
    <nbx:BorrowingDefermentPeriod
      contextRef="i4eee114cf6374d4b8c1c643e2b22f03d_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzYyNzg_fe2ea2bd-d405-4db8-9a8c-a51c9875ba43">P1Y</nbx:BorrowingDefermentPeriod>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i819aeccc566b4f4a9fe1fa62c3d4f26f_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIwOTg_80da6e90-8d8d-4830-86ed-745448c67ca9"
      unitRef="number">0.0031</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY1Mzc_1b55b65f-246a-4e83-8378-03db1bf29a40"
      unitRef="eur">5000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <nbx:BorrowingMaturityTerm
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMw_f3936990-ea96-424f-8edf-c2adc17a3eef">P6Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingPercentageOfStateGuaranteedLoan
      contextRef="i0602bff51649496c9da805f828e74529_I20200710"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY2NDM_a18ad9a8-ed48-4e18-9f6b-0566013e2d53"
      unitRef="number">0.90</nbx:BorrowingPercentageOfStateGuaranteedLoan>
    <nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMx_bfc3075a-8ab8-40bb-bc67-8ab30ecf935d">P12M</nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest>
    <nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM1_8f01415b-9c14-48be-b0e7-0683219ab998">P12M</nbx:BorrowingMaturityTermInitialPeriodBearingNoInterest>
    <nbx:BorrowingMaturityTermSubsequentPeriodBearingInterest
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY4MTI_65460f96-dc18-485d-b563-dc5ed170e98a">P5Y</nbx:BorrowingMaturityTermSubsequentPeriodBearingInterest>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i0602bff51649496c9da805f828e74529_I20200710"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY4NDY_8e0c2b98-4c7c-440f-a6b8-6adb82725028"
      unitRef="number">0.0225</ifrs-full:BorrowingsInterestRate>
    <nbx:BorrowingGuaranteeFee
      contextRef="i0602bff51649496c9da805f828e74529_I20200710"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY5MDY_69dd4941-fe9d-4425-b67c-a0c1b3dec813"
      unitRef="number">0.0161</nbx:BorrowingGuaranteeFee>
    <nbx:BorrowingNumberOfQuarterlyInstalments
      contextRef="i44a077384c26495caae329e040555472_D20200710-20200710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzY5OTU_1969c4f3-85a3-4aec-b2d4-f0635e21de58"
      unitRef="quarterly_instalment">20</nbx:BorrowingNumberOfQuarterlyInstalments>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTMy_6dd3e811-f6e3-489b-9d60-490ed5fdea6d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Conditional advances and loans from government and public authorities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.336%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Interest-free Bpifrance loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;EIB Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Curadigm Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;34,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;38,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;974&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;29,251&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;32,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated variable interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;26,374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;29,433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Bank loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;HSBC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,044&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;PGE&#x201d;or in French &#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; are state-guaranteed loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; In 2020 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively. &lt;/span&gt;&lt;/div&gt;(3) In 2021 the fixed interest accrual refers to guarantee fee of 0.25% of the principal of the HSBC PGE loan and to a guarantee fee of 0.25% added to a fixed interest rate of 1.36% for the Bpifrance PGE loan, respectively.</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i0110777e52b3473f8b462de884b09e80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMS0xLTEtMTE5OTk_d6b66057-9647-4cf8-a2de-041fec71b2ad"
      unitRef="eur">2165000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i24a151e2334941ad93f623e660566efd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMi0xLTEtMTE5OTk_075b50f5-03f0-4fe3-a9a0-549388c636c0"
      unitRef="eur">1210000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="ieae65f3974804742b4ab99567efade16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctMy0xLTEtMTE5OTk_1669cfea-d5fb-432b-b8e7-97b35649afd3"
      unitRef="eur">34746000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i7917ccaea2634af4a65d44c4873dfc76_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctNC0xLTEtMTE5OTk_2af11f8a-c376-4dec-832c-f57d900a9203"
      unitRef="eur">0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i9ba645486aa240169be18398fc400965_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzctNS0xLTEtMTE5OTk_6bcd1703-6a94-4643-ac17-6f945ffdeec7"
      unitRef="eur">38121000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMS0xLTEtMTE5OTk_1e58831b-351d-4988-afc2-ce448612377a"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMi0xLTEtMTE5OTk_1e22ffd1-0712-40f9-8575-ed4e04ddc9df"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMy0xLTEtMTE5OTk_b39d288e-d52c-4f46-939f-dcf6e0b5d891"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNC0xLTEtMTE5OTk_8d655887-a0ff-466e-9684-fc095ce509f3"
      unitRef="eur">350000</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNS0xLTEtMTE5OTk_33a3ff05-2abe-4824-ab8b-3b79298bd1ad"
      unitRef="eur">350000</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMS0xLTEtMTE5OTk_e3a263ed-0b53-44cd-80d0-224951ac6d42"
      unitRef="eur">19000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMi0xLTEtMTE5OTk_51363f8d-541b-4106-8b9e-9dd170b0c0fd"
      unitRef="eur">14000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktMy0xLTEtMTE5OTk_9455becd-321c-454e-8533-6c7b67785fd7"
      unitRef="eur">-1736000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktNC0xLTEtMTE5OTk_29a5fc89-ca6d-4538-8f29-04797ad60679"
      unitRef="eur">-65000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzktNS0xLTEtMTE5OTk_4d9d45a3-f8eb-4c81-a186-9a5b9893ffc8"
      unitRef="eur">-1769000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTEtMS0xLTExOTk5_83f2f73d-656e-4979-860a-619c9c13071a"
      unitRef="eur">32000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTItMS0xLTExOTk5_b7db85ee-8706-41f4-9e6b-c5a2baaad5de"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTMtMS0xLTExOTk5_1f1c8496-bf5d-4d05-95df-617980188561"
      unitRef="eur">1731000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTQtMS0xLTExOTk5_afaa132b-7073-4235-a9ea-c43f7efbe5c6"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTUtMS0xLTExOTk5_aa3daa5f-7630-4ed1-8a92-f7a43ef7af1b"
      unitRef="eur">1763000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTEtMS0xLTExOTk5_5eebd579-77ff-4e92-841e-4f07890934cb"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTItMS0xLTExOTk5_92e5ebf6-f790-4888-a28d-7244ee556389"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTMtMS0xLTExOTk5_b1c3a3af-3a68-42a7-be63-9b8e9ae01382"
      unitRef="eur">-4789000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTQtMS0xLTExOTk5_01048683-908f-4426-8321-90c68504b228"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTUtMS0xLTExOTk5_b04539bb-70b8-44ca-8259-0e02cf6a8651"
      unitRef="eur">-4789000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ic84d7eaa7fe543d18ef636217fa1fd8f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTEtMS0xLTExOTk5_0bc70f06-a89f-4592-80d5-ca3cddcd31ec"
      unitRef="eur">0</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i2f9530e882084cc9aa2d3573c8ba1526_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTItMS0xLTExOTk5_baf67e56-b41f-4a22-905e-8ae6819ff16d"
      unitRef="eur">250000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i0fc5d850f7a34e638b96c4904d810cdc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTMtMS0xLTExOTk5_7a631e2c-f779-4475-9f9b-3f32863b7ded"
      unitRef="eur">700000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ifca17e3355b44538ab617c0d4f238d98_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTQtMS0xLTExOTk5_52ac0c85-38c2-4431-bc03-8eb188e08e9c"
      unitRef="eur">0</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ibd7bbdafe0324317afdd377a454094a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTUtMS0xLTExOTk5_76cabfe6-9b71-4d29-b45a-81acf8de3c20"
      unitRef="eur">950000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="if2608a211d394427a2eb417f85f7c460_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTEtMS0xLTExOTk5_f84fadc7-1e64-41d9-82b5-a313378d403a"
      unitRef="eur">2216000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i4ce52155b2714380bea43bb9d5364790_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTItMS0xLTExOTk5_6bb362a6-fc1f-4f67-9426-0c03ac3c536f"
      unitRef="eur">974000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i7d080d4ae22f49209fad3088f5cd1717_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTMtMS0xLTExOTk5_5fbce352-4fe6-4f04-9698-b337e92b534c"
      unitRef="eur">29251000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="ia690845ba75d4a2d9817787693b33552_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTQtMS0xLTExOTk5_5091cde1-6b9b-41fb-a741-23ee7fb1ec1e"
      unitRef="eur">285000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i3325ccb1e560443f9ddb6eddf043414a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTUtMS0xLTExOTk5_dbb345aa-d6d0-4dbd-a4c1-1731c245b96f"
      unitRef="eur">32727000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMS0xLTEtMzkwNzI_4b899309-e842-41eb-9a02-27d500f82591"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMi0xLTEtMzkwODI_1e706144-84d8-4ec3-a761-905bb5b68ef1"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtMy0xLTEtMzkwOTA_42619fa3-d822-4a10-bd4a-591e241a4539"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNC0xLTEtMzkwOTY_3ff96a10-c1d8-47d2-90a9-6d8c02596d86"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzgtNS0xLTEtMzkxMDI_bb613b5d-a5b2-43e8-8ead-51d24aaff87f"
      unitRef="eur">0</nbx:IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTEtMS0xLTM5MDcy_4460e9b1-03b2-47e9-9ad6-2e23a0d4326e"
      unitRef="eur">17000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTItMS0xLTM5MDgy_cc670076-07d0-4354-bde8-57e14a4ad611"
      unitRef="eur">19000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTMtMS0xLTM5MDkw_463ee946-9a74-45e4-870d-296b6d19170c"
      unitRef="eur">-5817000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTQtMS0xLTM5MDk2_fe38decf-c0a3-46c9-be33-605e530388d8"
      unitRef="eur">16000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEwLTUtMS0xLTM5MTAy_fd88c7ab-4728-4b09-b31f-08020343b857"
      unitRef="eur">-5765000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTEtMS0xLTM5MDcy_ebae571f-18f9-4b70-ac54-cb74821a0569"
      unitRef="eur">32000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTItMS0xLTM5MDgy_788042f3-c4cd-4fcc-8d11-0f62afef6005"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTMtMS0xLTM5MDkw_2714abc3-9d97-4a55-be92-e30a55c67124"
      unitRef="eur">1758000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTQtMS0xLTM5MDk2_5d0dfb88-ea45-4281-877d-e3725c3af833"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzExLTUtMS0xLTM5MTAy_f20d6461-b45d-41cd-a776-be3455403cbc"
      unitRef="eur">1790000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTEtMS0xLTM5MDcy_522f9aae-3cf5-4f59-91e9-9b477f8d60c0"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTItMS0xLTM5MDgy_94ce43ab-48d9-4067-bdcb-99a52057b49e"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTMtMS0xLTM5MDkw_1fffb342-4c4b-4a84-b94d-e4ee8e62901c"
      unitRef="eur">4214000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTQtMS0xLTM5MDk2_c349b474-7ff4-4464-ab86-b823cb1c0085"
      unitRef="eur">0</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEyLTUtMS0xLTM5MTAy_1b5d585c-8477-4b96-ac98-d76e51d2552d"
      unitRef="eur">4214000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="if6c1018ba0524ead82b4904338b482f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTEtMS0xLTM5MDcy_f9c5eef3-56ca-465b-ae7a-b5132fbcc386"
      unitRef="eur">0</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i7829cab64d9446a1b79adc8445e2b824_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTItMS0xLTM5MDgy_a6e14eac-f6c8-407e-80d8-eac33029752c"
      unitRef="eur">500000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTMtMS0xLTM5MDkw_bd15c0d9-3779-4f89-a762-bd4d497a3d28"
      unitRef="eur">3033000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="iaca493780d654d98a11eee83335034c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTQtMS0xLTM5MDk2_bdc91560-3408-4eae-8421-e1ee5ac318eb"
      unitRef="eur">0</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ifd3e633a94c842cda348f8e98ada1b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzEzLTUtMS0xLTM5MTAy_dea0e59b-7104-468c-800b-78b035912864"
      unitRef="eur">3533000</nbx:DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i501dadac2baa4da2b169943189296894_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTEtMS0xLTM5MDcy_36623d4b-e02d-40dc-b96c-a7a66eeb5e52"
      unitRef="eur">2266000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i166567b173294d53b3207d7758ed8744_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTItMS0xLTM5MDgy_40abb4a5-4252-4191-8d21-efdc8a9dc56d"
      unitRef="eur">493000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="ia6fda04984b54ecd9c6ae4c8f6433521_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTMtMS0xLTM5MDkw_30a59801-7bc5-487f-8d0c-ca10f04cacef"
      unitRef="eur">26374000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i5f6c485623c34a36a0a0c935c03af6b5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTQtMS0xLTM5MDk2_40aa7ae9-6b3d-4372-baeb-36623fdf62d5"
      unitRef="eur">300000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i9b283275fffa429aa785167b228d13d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTo0YzE3YWJlMTU1YTE0ODIyODllMjc2ZTA1OThiNjgyZS90YWJsZXJhbmdlOjRjMTdhYmUxNTVhMTQ4MjI4OWUyNzZlMDU5OGI2ODJlXzE0LTUtMS0xLTM5MTAy_a07c541d-5dbf-488c-a8da-a4f78b98d037"
      unitRef="eur">29433000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="icfb5e49da6c84216827391eff4e26057_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzkwMDQ_07633829-89d3-4d15-bb2d-5a4c5029680b"
      unitRef="eur">-5800000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:RoyaltyPayables
      contextRef="icd3f097755a84ae28952d3b990109fcb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwMDk0_939a7ccc-3367-4f37-a12e-a22e0ee22bae"
      unitRef="eur">17200000</nbx:RoyaltyPayables>
    <nbx:RoyaltyPayables
      contextRef="ia00db9d1206a4981b2ae432d997b3bfb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwMTE4_c17e7653-5920-4bf1-913c-fa15cf496e39"
      unitRef="eur">3400000</nbx:RoyaltyPayables>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i34b69bb03edc48d388d2b08bd8342672_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMS0xLTEtMTE5OTk_4a5a362f-d5f8-4737-b08c-0b7b8ed6b674"
      unitRef="eur">0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i61f3c9741ef74beea34a7372eea88c9d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMi0xLTEtMTE5OTk_95ee7181-9941-41a9-bec9-21e5d013114b"
      unitRef="eur">0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i06da0291c1964865b0bee57ea7df6660_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzEtMy0xLTEtMTE5OTk_6a6d6b2d-b942-4ec0-b647-29b9c73824e0"
      unitRef="eur">0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMS0xLTEtMTE5OTk_b1734973-bb18-4ad3-8ac7-fddc2c2e43ba"
      unitRef="eur">5000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMi0xLTEtMTE5OTk_9357e51b-d388-44de-8fd1-bff68d3a7c99"
      unitRef="eur">5000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzItMy0xLTEtMTE5OTk_f8bdc1cb-1f28-4be2-9dbe-d0ad6fc3b7d7"
      unitRef="eur">10000000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMS0xLTEtMTE5OTk_0abc880d-1e2a-4f53-bd93-ca4bfec28c2b"
      unitRef="eur">14000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMi0xLTEtMTE5OTk_57120558-1b18-4dfa-b05f-80e47850966a"
      unitRef="eur">34000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzMtMy0xLTEtMTE5OTk_efded511-8f5e-41a7-9e0f-7a15d77691bb"
      unitRef="eur">47000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i8b95c5f4c72e4170afccfea28c221eaa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMS0xLTEtMTE5OTk_6044c0c0-96f9-4dd4-b72d-d18e32e7ce79"
      unitRef="eur">7000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ib1854f1e3e354d17a9cccc5377ffe269_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMi0xLTEtMTE5OTk_977f3caa-a8ab-4e60-af51-f74f62b6b0f6"
      unitRef="eur">10000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i564658b6430c45ebbef310ef73a5d0c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzQtMy0xLTEtMTE5OTk_3f98de85-bbaf-423f-8312-3259f5ccccb9"
      unitRef="eur">17000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i42ac85adcce64257b4ab0b5899397068_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMS0xLTEtMTE5OTk_e9062add-4d1c-4fe8-855c-c9b22a86468d"
      unitRef="eur">5020000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="id9db631ab0a946ffa6c39533461876b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMi0xLTEtMTE5OTk_a3229c06-b3ae-4ece-bb91-3a4fb3f80f7c"
      unitRef="eur">5044000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="id83ab7ac51814807be706998f4cc09e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzUtMy0xLTEtMTE5OTk_30a6f582-a6c2-4f2e-a160-d8934fc6fd32"
      unitRef="eur">10064000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMS0xLTEtMTE5OTk_b763f028-2db8-4a84-b195-e57d912726f0"
      unitRef="eur">17000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMi0xLTEtMTE5OTk_ae72e5b0-2c05-4dff-9714-b3cbdab48514"
      unitRef="eur">-14000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzYtMy0xLTEtMTE5OTk_4bf137ba-becd-49ea-a6b8-a2d75e059f25"
      unitRef="eur">3000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMS0xLTEtMTE5OTk_7a3f0cad-58f1-400a-b6da-fe82275b1223"
      unitRef="eur">26000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMi0xLTEtMTE5OTk_49f585ad-dee9-4070-afe7-de9e68f9f274"
      unitRef="eur">120000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzctMy0xLTEtMTE5OTk_dcbb0a62-b227-4f2a-9a5c-c340edf513ba"
      unitRef="eur">146000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i1f4fc5024d414ca0b7195456d710b4de_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMS0xLTEtMTE5OTk_80ffc50c-c350-4762-9f34-e89971794975"
      unitRef="eur">-33000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ib18a330b76204ec2a6152967f171a3b8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMi0xLTEtMTE5OTk_a5598afc-d17d-4d99-8d7e-fe5c74dfc0d7"
      unitRef="eur">-112000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="i89e857a3c6174fa9be33c1855cbca0fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzgtMy0xLTEtMTE5OTk_41a4db28-a419-443f-b5bb-98448a80c4ad"
      unitRef="eur">-145000</nbx:IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="iea99a9d2ede149058f2638ecfe804933_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMS0xLTEtMTE5OTk_7b3f1e30-a155-4919-9d2e-1ab6ae2efb0b"
      unitRef="eur">5030000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="ie2e7563cfe4f4e48bdebe1cd3babc08c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMi0xLTEtMTE5OTk_fe29eead-fb78-4c91-bbc2-d69ed05685f2"
      unitRef="eur">5038000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i3aa2ca3eec9341eea4ebbd1e22088ba8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTowYmJkYTBiMzhhZjM0NWUwYmRhNWQzYzM4M2I2OGU5My90YWJsZXJhbmdlOjBiYmRhMGIzOGFmMzQ1ZTBiZGE1ZDNjMzgzYjY4ZTkzXzktMy0xLTEtMTE5OTk_6f6b13e3-6c22-4345-a988-041b07ef113c"
      unitRef="eur">10068000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <nbx:BorrowingGuaranteeFee
      contextRef="i3c4fa6093f8a43df81a2388bcd182126_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNDU0_0025f262-a2a0-452b-ae76-3a8cdd18809e"
      unitRef="number">0.0025</nbx:BorrowingGuaranteeFee>
    <nbx:BorrowingGuaranteeFee
      contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNTIx_af074d85-2914-429a-aa23-b1c4fcba01fe"
      unitRef="number">0.0025</nbx:BorrowingGuaranteeFee>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEwNTU4_2d3c2125-482c-48cd-9e13-b34ba91664b5"
      unitRef="number">0.0136</ifrs-full:BorrowingsInterestRate>
    <nbx:BorrowingGuaranteeFee
      contextRef="i127de2da61e64e78845c4c06ce48cee7_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNDE_8ac04630-6755-4b83-9d39-5f54ea2d3422"
      unitRef="number">0.0025</nbx:BorrowingGuaranteeFee>
    <nbx:BorrowingGuaranteeFee
      contextRef="i66337c960fa942618f0543d1c09dfea5_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNTQ_b792c8fd-c9a0-4c79-b216-c402f0d7593b"
      unitRef="number">0.0025</nbx:BorrowingGuaranteeFee>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i66337c960fa942618f0543d1c09dfea5_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExMjg_c5571d54-f921-4e08-9866-84939e36bd29"
      unitRef="number">0.0136</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTM2_b1306bfb-3ded-49e8-bf6c-c71b8475017a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The table below shows the detail of changes in lease liabilities recognized on the statements of financial position over the periods disclosed:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of January 1st,  2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;New lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting of the new lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fixed interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment of lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Early termination of lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,188&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Engagement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impact of discounting and accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated fixed interest expense accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repayment of lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Early termination of lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,519&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i03fc764f222342e8a738cfe4737267f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEtMS0xLTEtMTE5OTk_2c59937e-446e-4963-9bc8-da68a17c2315"
      unitRef="eur">6405000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzItMS0xLTEtMTE5OTk_6495c425-2239-4618-91d7-8c0bd9a04390"
      unitRef="eur">521000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzMtMS0xLTEtMTE5OTk_b705d05f-9cb7-4b71-bce7-3ed93fe84ddc"
      unitRef="eur">-94000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzQtMS0xLTEtMTE5OTk_0c589a0d-e870-4640-9f14-33c2637e0d0b"
      unitRef="eur">333000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzUtMS0xLTEtMTE5OTk_cf56b725-9c0c-457e-b685-4fc7e9a81c9b"
      unitRef="eur">-928000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities
      contextRef="i156c816f0a104457ab18e7ef69315b18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzYtMS0xLTEtMTE5OTk_907f7dd5-a1ab-47ed-bedb-c5277756539b"
      unitRef="eur">49000</nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i74e0b22ef5ef4129b1e88005177dcf0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzctMS0xLTEtMTE5OTk_54d492cb-e033-4adc-880d-35c120a907af"
      unitRef="eur">6188000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzktMS0xLTEtMTE5OTk_ffe8d330-bfd2-4e19-b3c4-421ef75ee856"
      unitRef="eur">1476000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities
      contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEwLTEtMS0xLTExOTk5_20a81a5d-f156-45ef-b303-0095131cc907"
      unitRef="eur">-110000</nbx:IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzExLTEtMS0xLTExOTk5_79f27960-7533-4464-99d9-3a2991a7452e"
      unitRef="eur">288000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities
      contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzEzLTEtMS0xLTExOTk5_44684b40-d202-4bd9-aa31-18278bb0ecc6"
      unitRef="eur">-1195000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities
      contextRef="i19e15c2a272c4daca720310496d521ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzE0LTEtMS0xLTExOTk5_e7c00eb6-e1f9-4ff1-b470-ba0f3e5126f8"
      unitRef="eur">128000</nbx:DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="i91a2318ff64a450380b9438374b59d05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTplY2VhZjU1YmVjZGY0MzFiOTllZTY0YzU1NjMyZDBjMC90YWJsZXJhbmdlOmVjZWFmNTViZWNkZjQzMWI5OWVlNjRjNTU2MzJkMGMwXzE1LTEtMS0xLTExOTk5_abdd3558-f8ad-45d7-97fa-2fdb2dbaa87e"
      unitRef="eur">6519000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzEyNTI3_91971737-aade-42bd-acab-57ea56f917a6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The due dates for repayment of the advances loans and lease liabilities at their nominal value and including fixed-rate interest are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Less than 1&#160;year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 1 and &lt;br/&gt;3&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Between 3 and &lt;br/&gt;5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;More than &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest-free Bpifrance loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Curadigm interest-free Bpifrance advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;HSBC &#x201c;PGE&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Bpifrance &#x201c;PGE&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;EIB fixed rate loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;37,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#x201d;The Company will reimburse the two &#x201c;PGE&#x201d;or (&#x201c;Pr&#xea;ts garantis par l&#x2019;Etat&#x201d; or state-guaranteed loans) over 5 years with a deferral of 1 year (last reimbursement being in 2026), for the reasons mentioned in the paragraph below.</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="id119775bd1424312ac886a611fd9da80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMS0xLTEtMTE5OTk_00105b75-278f-4555-bda1-8a549484ab59"
      unitRef="eur">300000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i5226cc30782848c99b13dc241995afe3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMi0xLTEtMTE5OTk_cdfee4f9-3b75-4c08-b9bf-5df488e27da5"
      unitRef="eur">1300000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i7a94562c5153457ab46aec435a38bf16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItMy0xLTEtMTE5OTk_99837680-ab95-46e4-9660-8101c7eb0ec9"
      unitRef="eur">808000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="if72f0771e7134f64a254bb97d9bc45bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzItNC0xLTEtMTE5OTk_19aa7218-b101-4ef8-b95b-f1632818f1ce"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="ia59396251fd945158fa1538f914cc4b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMS0xLTEtMTE5OTk_a296711c-5879-4ae3-92ac-cc8b2dac19c6"
      unitRef="eur">500000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i2295671454b14d6d91210a5944d6c07b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMi0xLTEtMTE5OTk_d4d6e360-f22d-4423-901b-21ffa42fe8f7"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="iedbfecf36047400ead3aea1bcc9b8a13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtMy0xLTEtMTE5OTk_0256eca7-6a0e-4a9a-bf47-9ab1c0609542"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i124ed568f8a24aa78e3ff34558ad81c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzMtNC0xLTEtMTE5OTk_2447246d-f8c2-42aa-b496-4045534946dd"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i7191a356d1c64bd49a626a0c200e1eaf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMS0xLTEtMTE5OTk_1aca9dd3-4fd3-4a1f-a804-94a97b2ad3a0"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i69512fc2f0d34eb4b0cf656265fa6930_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMi0xLTEtMTE5OTk_c68460c1-e621-48b5-9396-98acc16bdf67"
      unitRef="eur">200000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i024c28063f484f59b11cb851e436a1c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtMy0xLTEtMTE5OTk_eba3ace5-45ed-4aca-b5d9-e55ab900d908"
      unitRef="eur">150000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="ia1502f4415f84bc0ad1e2d41b2f6944f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzQtNC0xLTEtMTE5OTk_0bd5bbad-7725-486f-9362-934454b54cec"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i836bec40340a45258bbea36837952d12_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMS0xLTEtMTE5OTk_4b9b8875-8f4f-4453-b4be-d1fd0a81af56"
      unitRef="eur">661000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i03054a03855b4b37a9b8768c06f2bd7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMi0xLTEtMTE5OTk_0b59a8d5-9975-4554-a601-0c7b9ca6eafb"
      unitRef="eur">2572000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i4cf7bec92f924353b5d3c40835d5e6fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtMy0xLTEtMTE5OTk_d6ca33d9-4802-4131-8037-2613f2e416d9"
      unitRef="eur">1904000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="ia8a60e1d925a45289d5b33cdd832c02e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzUtNC0xLTEtMTE5OTk_2e863336-063f-4880-ae3f-0e8211d0093e"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i1f3e0b6ca2a945ed8c4fb13c8274f2cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMS0xLTEtMTE5OTk_c4619591-8ccf-489a-bf92-c5b7cdf688cb"
      unitRef="eur">425000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i2369a7d63f7d4af9aaccfee568c13c3d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMi0xLTEtMTE5OTk_a265ab27-1703-4e51-a5b8-25b634f6a59c"
      unitRef="eur">2662000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i18d3c34726ac4988b595b25c132f4bcc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtMy0xLTEtMTE5OTk_a165e534-3e0e-4dbd-bfa8-872709d4f7fc"
      unitRef="eur">2237000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="if8604d938eea43d1ad397edac29826f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzYtNC0xLTEtMTE5OTk_274b268c-8813-4cb5-803e-3ed02fe56f35"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="idb9f7ca1927d4697a4fe081256782a2b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMS0xLTEtMTE5OTk_2819be8b-be52-47df-aedc-f65bb65a14d2"
      unitRef="eur">5192000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="ia38f8669a4be407cab008b29e2b85d90_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMi0xLTEtMTE5OTk_d5d083ae-cef3-4580-9c56-923caee58494"
      unitRef="eur">28762000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i2db0464e08894c07a24540e1493e87e9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctMy0xLTEtMTE5OTk_c25382b3-6bf9-4ad3-b382-7b877e3a7dfc"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows
      contextRef="i5abc10eb5d6945cb92399dbc699bfb72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzctNC0xLTEtMTE5OTk_f2a5e294-5ce9-43f7-9557-3c6cff02da76"
      unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i05cfdfc0910e47f6becde04d1178f72d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMS0xLTEtMTE5OTk_715b16dc-2b81-460b-bfe4-00f97f70cdd5"
      unitRef="eur">1126000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="i0ce13eb6ddc140849ea104ec96d8f749_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMi0xLTEtMTE5OTk_431cc3b8-651c-4fec-90ed-f8dc05611e17"
      unitRef="eur">2252000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ied1dea9b89304c059d54ab720191a5d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtMy0xLTEtMTE5OTk_7d122260-f565-4f89-ba06-f12b2d7d48b9"
      unitRef="eur">2247000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="ic1eac451531248ea959e4a652e5278e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzgtNC0xLTEtMTE5OTk_e00bd117-a4f6-4733-a286-ea31433b9eac"
      unitRef="eur">1714000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="i05cfdfc0910e47f6becde04d1178f72d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMS0xLTEtMTE5OTk_bd0b36a9-ea80-4990-9c2d-aca1b78dac0e"
      unitRef="eur">8204000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="i0ce13eb6ddc140849ea104ec96d8f749_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMi0xLTEtMTE5OTk_504ad026-43cc-4d66-aacf-d06290be4331"
      unitRef="eur">37747000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="ied1dea9b89304c059d54ab720191a5d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktMy0xLTEtMTE5OTk_8d942c47-3cf4-4560-8d63-494112943144"
      unitRef="eur">7346000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows
      contextRef="ic1eac451531248ea959e4a652e5278e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90YWJsZTpmZGM4MGQzZTU3M2I0NWIwYTFhY2ZiNjdjZWQ2ZWYyYy90YWJsZXJhbmdlOmZkYzgwZDNlNTczYjQ1YjBhMWFjZmI2N2NlZDZlZjJjXzktNC0xLTEtMTE5OTk_cf838d5c-e14c-474b-aec4-12c27da223ee"
      unitRef="eur">1714000</ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows>
    <nbx:BorrowingNumberOfPGE
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExNzQ_2eaba664-fcf0-41ef-8348-ba33da962a54"
      unitRef="borrowing">2</nbx:BorrowingNumberOfPGE>
    <nbx:BorrowingMaturityTerm
      contextRef="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMTM_23379b87-6a95-4b6c-a247-fdb73da65978">P5Y</nbx:BorrowingMaturityTerm>
    <nbx:BorrowingDefermentPeriod
      contextRef="id1c136d714de4dc09076b8c6ea0eb401_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMjY_364fe1f5-5af8-46bc-b5f2-b471d0ed0a8d">P1Y</nbx:BorrowingDefermentPeriod>
    <ifrs-full:Borrowings
      contextRef="ia00db9d1206a4981b2ae432d997b3bfb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExNjk0_53c9350b-69bc-4187-af64-3d3fd07568ac"
      unitRef="eur">33900000</ifrs-full:Borrowings>
    <nbx:BorrowingTotalInterestPayable
      contextRef="ic1a681b206df4511b7799f7f5af81474_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExNzMy_6ad83794-2b44-4f3d-a7a0-c6894f82c33e"
      unitRef="eur">7000000</nbx:BorrowingTotalInterestPayable>
    <ifrs-full:InterestPayable
      contextRef="ic1a681b206df4511b7799f7f5af81474_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzExODE1_21910910-8d79-4aef-bcaa-ba425fe9bc1c"
      unitRef="eur">1800000</ifrs-full:InterestPayable>
    <nbx:BorrowingTotalInterestPayable
      contextRef="idf95cc261a574c20bb75916fc307fd2a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MDIxMzk_f450b0f9-5dbf-44c8-b03a-bb6169f71d02"
      unitRef="eur">3400000</nbx:BorrowingTotalInterestPayable>
    <nbx:ConsolidatedForecastedSalesPeriod
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNjkvZnJhZzpiMTVjN2ZkNjk1YTc0MmRhYjRmMGZkMTIwMDczNWQ0OS90ZXh0cmVnaW9uOmIxNWM3ZmQ2OTVhNzQyZGFiNGYwZmQxMjAwNzM1ZDQ5XzMyOTg1MzQ5MTExOTE_c51e1ad8-c380-4515-8db5-1cf5b7605378">P6Y</nbx:ConsolidatedForecastedSalesPeriod>
    <nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTI_d5028de0-2f89-439c-89f1-4fbce2473dbe">Trade payables and other current liabilities&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;13.1 Trade and other payables&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for Trade and other payables are described in Note 12, &#x2018;&#x2018;Financial Liabilities.&#x2019;&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accrued expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Details of trade and other payables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses - clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables &amp;amp; other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables are not discounted, as none of the amounts were due in more than one year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Other trade payables include &#x20ac;447&#160;thousand of costs relating to the ICON contract not yet paid, as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;13.2 Other current liabilities&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities consist primarily of payroll taxes, namely the employer costs to be paid on free shares, accrued bonuses, vacation days and related social charges. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Payroll tax and other payroll liabilities decreased by &#x20ac;1.4&#160;million from &#x20ac;6.2&#160;million as of December 31, 2020 to &#x20ac;4.8&#160;million as of December 31, 2021 as a result of the decrease in social charges accrual related to free shares and to bonuses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;13.3 Deferred revenues and contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.852%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred revenues and contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred revenues and contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Change in deferred revenues and contract liabilities as of December 31, 2021 consists of contract liabilities relating to the LianBio contract in the amount of &#x20ac;16.5&#160;million, accounted for in accordance with IFRS 15. See Note 15 Revenues and other income for more details.&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTM_d8f11f02-bd48-47b8-9b41-8f2e7978fe46">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for Trade and other payables are described in Note 12, &#x2018;&#x2018;Financial Liabilities.&#x2019;&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accrued expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taking into account the time lag between the time at which treatment costs are incurred in studies or clinical trials and the time at which such costs are invoiced, the Company estimates an amount of accrued expenses to record in the financial statements at each reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The treatment costs for patients were estimated for each study based on contracts signed with clinical research centers conducting the trials, taking into account the length of the treatment and the date of injection of each patient. The total amount estimated for each study has been reduced by the amount of invoices received at the closing date.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory>
    <nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxOTQ_77b86ec7-f31c-4ac4-aa58-1753caf6cfc7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Details of trade and other payables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses - clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables &amp;amp; other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,482&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzItMS0xLTEtMTE5OTk_524c0466-0ac1-44d0-b47e-6d230c44c9cf"
      unitRef="eur">1486000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzItMi0xLTEtMTE5OTk_5aaf975a-ec38-4a8d-a5e8-b8f443e9f1ff"
      unitRef="eur">1532000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentPayables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzMtMS0xLTEtMTE5OTk_86f57a24-e0fe-46ca-83c3-aa66523936d5"
      unitRef="eur">4996000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzMtMi0xLTEtMTE5OTk_8309cbc4-21fb-4c14-a0ae-05276e78658d"
      unitRef="eur">5574000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzQtMS0xLTEtMTE5OTk_3e369bdb-ae2d-493a-94e5-fb881c591c8f"
      unitRef="eur">6482000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTpmY2QzNDQwMWRmODI0Mjg0YTJjZDk4MTIzNTBhYmU4Yy90YWJsZXJhbmdlOmZjZDM0NDAxZGY4MjQyODRhMmNkOTgxMjM1MGFiZThjXzQtMi0xLTEtMTE5OTk_fd85e507-652a-4e7e-9fcc-9309fd5c6b0b"
      unitRef="eur">7106000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="i5e92157b10524c51b91a421eb6a8c483_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzMyOTg1MzQ4ODk2Mzg_15e2b5a9-431e-4730-81c2-377da6656ceb"
      unitRef="eur">447000</ifrs-full:OtherCurrentPayables>
    <nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzIxODg_e1266138-38d8-46bd-96cc-46f8bd067aa9">Other current liabilities&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll tax and other payroll liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</nbx:DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzItMS0xLTEtMTE5OTk_b657a3b8-fa8f-479c-b750-ce5365cd58e9"
      unitRef="eur">258000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzItMi0xLTEtMTE5OTk_170963cd-3855-4679-8886-152cec5b5a36"
      unitRef="eur">283000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzMtMS0xLTEtMTE5OTk_da5d5069-2324-4b27-a653-16ce00c4f7e0"
      unitRef="eur">4820000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzMtMi0xLTEtMTE5OTk_786190d4-1842-40ca-ac04-b7d307cd752f"
      unitRef="eur">6248000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <nbx:OtherMiscellaneousCurrentLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzQtMS0xLTEtMTE5OTk_b367fbd1-f683-458d-8980-f145a4099395"
      unitRef="eur">453000</nbx:OtherMiscellaneousCurrentLiabilities>
    <nbx:OtherMiscellaneousCurrentLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzQtMi0xLTEtMTE5OTk_fd893a94-3af8-4495-8089-d8c3ac07f316"
      unitRef="eur">491000</nbx:OtherMiscellaneousCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzUtMS0xLTEtMTE5OTk_16186325-564d-4d2c-9ad8-c72e8e2925d4"
      unitRef="eur">5531000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZToxZjQyM2UxMDQ4NTE0MDQ1OWZlOGVmZTI1MGY1MjVhMy90YWJsZXJhbmdlOjFmNDIzZTEwNDg1MTQwNDU5ZmU4ZWZlMjUwZjUyNWEzXzUtMi0xLTEtMTE5OTk_5c342178-d2e8-4640-9ddc-782db978b0ce"
      unitRef="eur">7022000</ifrs-full:OtherCurrentLiabilities>
    <nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0MDI_84712a67-62be-49b4-8148-25795135aedb"
      unitRef="eur">-1400000</nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0MTA_568a8079-b9e2-413c-b1a1-da818658067b"
      unitRef="eur">6200000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzE0NDA_05c201c3-70a0-4fc8-a476-1449c20a7ec1"
      unitRef="eur">4800000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzMyOTg1MzQ4ODk2MzY_f9dcfdff-bf73-492a-b0c0-e8ef15ee1e91">Deferred revenues and contract liabilities&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.852%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred revenues and contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Deferred revenues and contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;16,518&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</nbx:DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzItMS0xLTEtNTYwNDk_d7d1df68-f6aa-44e3-be3f-9a235d7cec49"
      unitRef="eur">16518000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzItMy0xLTEtNTYwNDk_edfeaec4-9762-4361-b527-2fa34ca54f9c"
      unitRef="eur">0</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzMtMS0xLTEtNTYwNDk_25a1b0e8-8515-4be9-8968-e321a597613e"
      unitRef="eur">16518000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90YWJsZTo5MzQ1NWVkNjlhMTE0NzVmYTQ4OTc4NTQ2NGU5ZjRiOC90YWJsZXJhbmdlOjkzNDU1ZWQ2OWExMTQ3NWZhNDg5Nzg1NDY0ZTlmNGI4XzMtMy0xLTEtNTYwNDk_e5f4decf-73f1-4acd-b7b3-a8e1c6d1a728"
      unitRef="eur">0</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities
      contextRef="ib6c320981631448bb18db0fd12c61f50_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzIvZnJhZzpjMTU3M2U4Y2EzYjg0YzliODYwZTVkMWVlNjgyMDlkYi90ZXh0cmVnaW9uOmMxNTczZThjYTNiODRjOWI4NjBlNWQxZWU2ODIwOWRiXzI3NDg3NzkwNzM0Njk_8589ada9-db84-4c15-9195-b75273fed570"
      unitRef="eur">16500000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1Mzg_522c0517-8995-40b5-b369-8259031c7b77">Financial instruments included in the statement of financial position and impact on income&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for financial instruments included in the statements of financial position and impact on income are described in Note 7, &#x2018;&#x2018;Non-current financial assets&#x2019;&#x2019;, Note 8, &#x2018;&#x2018;Trade receivables and other current assets&#x2019;&#x2019;, Note 9, &#x2018;&#x2018;Cash and cash equivalents&#x2019;&#x2019; and Note 12, &#x2018;&#x2018;Financial liabilities.&#x2019;&#x2019;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on&lt;br/&gt;the statement of&lt;br/&gt;financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets &lt;br/&gt;carried at fair value &lt;br/&gt;through profit or &lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities&lt;br/&gt;carried at amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Management of financial risks&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The principal financial instruments held by the Company are instruments classified as cash and cash equivalents. These instruments are managed with the objective of enabling the Company to finance its business activities. The Company's policy is to not use financial instruments for speculative purposes. It does not use derivative financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The principal financial risks faced by the Company are liquidity, foreign currency exchange, interest rate and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Given the amount of cash and cash equivalents held by the Company as of December 31, 2021 (see Note 9), the Company does not believe that it is exposed to short-term liquidity risk.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Foreign Currency Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The functional currency of Nanobiotix S.A. is the euro. Exposure to foreign currency exchange risk is derived almost entirely from intragroup transactions between Nanobiotix S.A. and its U.S. subsidiaries, for which the functional currency is the U.S. dollar, as well as trade relations with customers and suppliers outside the euro zone.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;At this stage of its development, the Company does not use hedging to protect its business against exchange rate fluctuations. However, a significant increase in its business activity outside the euro zone could lead to a greater exposure to foreign currency exchange risk. If this occurs, the Company may implement a suitable hedging policy for these risks. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company&#x2019;s U.S. subsidiaries as of December 31, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;USD / Euro exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;USD / Euro exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Credit risk arises from cash and cash equivalents, derivative instruments and deposits with banks and other financial institutions as well as from exposure to customer credit, in particular unpaid receivables and transaction commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The credit risk related to cash and cash equivalents and to current financial instruments is not material given the quality of the relevant financial institutions. Customer credit risk is limited, due in part to low trade receivables as of December 31, 2021 and in part to its customers&#x2019; high credit rating for other receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Interest rate risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company's exposure to interest rate risk is primarily related to cash equivalents and investment securities, which consist of money market mutual funds (SICAVs). Changes in interest rates have a direct impact on the interest earned from these investments and the cash flows generated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair value &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value of financial instruments traded on an active market is based on the market price on the reporting date. The market prices used for the financial assets held by the Company are the bid prices in the market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The carrying value of receivables and current liabilities is assumed to approximate their fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1Mzk_0bf0e8d8-e97f-4c3c-896a-2efee502d45d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Detail of financial instruments included in the statements of financial position and impact on income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on&lt;br/&gt;the statement of&lt;br/&gt;financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets &lt;br/&gt;carried at fair value &lt;br/&gt;through profit or &lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities&lt;br/&gt;carried at amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;84,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;52,503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance and the EIB loan, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Financial assets carried at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and liabilities carried at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,613&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;119,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;7,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;56,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value of current and non-current liabilities include loans, repayable advances from Bpifrance, the EIB loan and the HSBC and Bpifrance state-guaranteed loans, recorded at amortized cost was assessed using unobservable &#x201c;level 3&#x201d; inputs, in the IFRS 13 classification for fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMS0xLTEtNDI4MTA_c7e54e3a-7111-489e-9a3f-2e43f8ebf30e"
      unitRef="eur">519000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="id999c1e7e2574135a234b087144a61d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMi0xLTEtNDI4MTA_4789efc3-9d8a-4841-9eda-e179fe15fbf4"
      unitRef="eur">97000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i2547d3f63dd142aebf5856fb5e8585d9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtMy0xLTEtNDI4MTA_e6d47af3-2687-4fdd-9190-314d0eac26a6"
      unitRef="eur">421000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="ie0283ae4a8ee4f2a9f56a03279a1443c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzMtNC0xLTEtNDI4MTA_c08dc33e-ecbc-4ee4-b413-d735a6d2fcd4"
      unitRef="eur">519000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="ia4e4d5d5fad3437283d2114e123c9052_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtMS0xLTEtNDI4MTA_84969037-ad30-4a4a-8fbb-1c9a83e8548d"
      unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i88c4b87a005448a6af125cf0d25e3ca4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtMy0xLTEtNDI4MTA_59895565-a9b5-4f06-9cea-0592bd76114c"
      unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="ia4e4d5d5fad3437283d2114e123c9052_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzQtNC0xLTEtNDI4MTA_1057596d-8fa7-4ecf-a678-6d155b00bfd1"
      unitRef="eur">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="id0503316bb634a33b147e9bd8ec248d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtMS0xLTEtNDI4MTA_cc27733b-25c0-497e-a295-2f8db1c59409"
      unitRef="eur">83921000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="ia3893bd24e354c778100e28facefe020_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtMy0xLTEtNDI4MTA_870d59a2-3071-4986-b9d8-8e8ecbd50d65"
      unitRef="eur">83921000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="id0503316bb634a33b147e9bd8ec248d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzUtNC0xLTEtNDI4MTA_f6589af6-c76b-4661-be11-3184b0a28bdc"
      unitRef="eur">83921000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMS0xLTEtNDI4MTA_2e2aba12-019c-4c1e-9ae6-792fd8580dea"
      unitRef="eur">84440000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i4d08cfa6357540d1ad2a166b19c12357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMi0xLTEtNDI4MTA_825c75f7-21ee-4386-8620-81d6d4eaa582"
      unitRef="eur">97000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i5c39078fac4b4979aea00def2bcbb7e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtMy0xLTEtNDI4MTA_93154203-5f34-498f-9d4c-5efd8e578521"
      unitRef="eur">84343000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzYtNC0xLTEtNDI4MTA_d4455f11-3288-4777-ad02-c5ce03d0e628"
      unitRef="eur">84440000</ifrs-full:FinancialAssetsAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i50df0717ba78443aa1b28f71669529c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtMS0xLTEtNDI4MTA_d19493f9-51da-4cb0-a7ce-ed3255a72f09"
      unitRef="eur">38733000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="idc7f775ffe9b4f938e53f99295d0dd49_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtMy0xLTEtNDI4MTA_6e9cf577-aa18-4fb9-bed2-6630c52fb7ef"
      unitRef="eur">38733000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i50df0717ba78443aa1b28f71669529c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzgtNC0xLTEtNDI4MTA_2aafe764-a1ef-4d7f-9d60-996ffbe43c7c"
      unitRef="eur">38733000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktMS0xLTEtNDI4MTA_f5508428-526e-437c-b34e-24f66e1635cc"
      unitRef="eur">7288000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="id2445eebc99b4373b2eb31de5002f587_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktMy0xLTEtNDI4MTA_3333637a-19d3-4bef-9f77-c344771b1d58"
      unitRef="eur">7288000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i11046d1327a94b8c80f7853bbc1ddcb0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzktNC0xLTEtNDI4MTA_7c45b721-f815-4e25-ba90-844cdab21a3c"
      unitRef="eur">7288000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="ib4882dee440d4a6786f1a85711a2f076_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTEtMS0xLTQyODEw_a277a930-01ae-4067-b265-2076f64115bc"
      unitRef="eur">6482000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i83d0f6bcf35c4bf6a5b350b635b2cf61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTMtMS0xLTQyODEw_e52ae7c6-53f0-4a0f-8e88-cdb7d092d061"
      unitRef="eur">6482000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="ib4882dee440d4a6786f1a85711a2f076_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzEwLTQtMS0xLTQyODEw_8f5940d2-6882-4605-9324-899ccee8bca2"
      unitRef="eur">6482000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTEtMS0xLTQyODEw_67b889b2-3ba0-44af-ae33-85ab5382355a"
      unitRef="eur">52503000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i13f6b64bccba4b65be62a02815fcc7d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTMtMS0xLTQyODEw_22c4eea6-f1bf-440a-b88e-b23714b32626"
      unitRef="eur">52503000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTozYjY2NDM2ZmU3NDQ0M2I0YjEwYmYzYjRmNTNmNGI3OS90YWJsZXJhbmdlOjNiNjY0MzZmZTc0NDQzYjRiMTBiZjNiNGY1M2Y0Yjc5XzExLTQtMS0xLTQyODEw_2b8fe886-5bfc-4326-9e20-8caeec1294d8"
      unitRef="eur">52503000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="icc4dd7cc1b414385a787daf2198eed07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMS0xLTEtMTE5OTk_6d441764-838c-4b11-8bd5-a63794c56d78"
      unitRef="eur">505000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i1a633ef24e1c46b0a69bcaf4403e72ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMi0xLTEtMTE5OTk_dcef0a20-a16b-4b22-ae6f-3f8be920f6b7"
      unitRef="eur">104000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i14898c15ca2947e18832b9287191cc4f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtMy0xLTEtMTE5OTk_f9471117-43e8-4fc8-829c-32f628a291dc"
      unitRef="eur">401000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="icc4dd7cc1b414385a787daf2198eed07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzMtNC0xLTEtMTE5OTk_5a87c9dd-6cda-4d58-86fb-951c51492835"
      unitRef="eur">505000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="i844f8507f9df4617831e6d34785b0ce7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtMS0xLTEtMTE5OTk_4ea46141-7f51-4979-bc72-10d6a04b404d"
      unitRef="eur">62000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="ie4b0a0a486794f239a3054bc37c245ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtMy0xLTEtMTE5OTk_c0135660-1e9f-4827-94e2-bf4a7685f1fb"
      unitRef="eur">62000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="i844f8507f9df4617831e6d34785b0ce7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzQtNC0xLTEtMTE5OTk_d95108fc-9cdc-4fb8-b767-8a8e9464ce0f"
      unitRef="eur">62000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="i62783c3667b540b998e0995fce469eb0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtMS0xLTEtMTE5OTk_0be9ec73-5782-4139-8554-7f02f8073362"
      unitRef="eur">119151000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="ib4e939bfe23c45adaf30417def90ead9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtMy0xLTEtMTE5OTk_a31c4c4c-3d1c-4af2-ba1f-b0e8a0fae3fd"
      unitRef="eur">119151000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="i62783c3667b540b998e0995fce469eb0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzUtNC0xLTEtMTE5OTk_3eddfc3a-8e30-47be-8262-fb175b9181c1"
      unitRef="eur">119151000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMS0xLTEtMTE5OTk_08ba381d-c70c-4f9e-899c-e7171890d730"
      unitRef="eur">119717000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="i7de0719450484ecc8171d036b10ef5e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMi0xLTEtMTE5OTk_166a5f47-e87b-4325-8107-7b53c0d90301"
      unitRef="eur">104000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="iaac2ec9156e94f5b90790097f4f6f9e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtMy0xLTEtMTE5OTk_529cc092-a171-4a5e-945b-34caa50e4234"
      unitRef="eur">119613000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzYtNC0xLTEtMTE5OTk_895304fa-094d-4fd6-8d56-bc60e599f2b4"
      unitRef="eur">119717000</ifrs-full:FinancialAssetsAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtMS0xLTEtMTE5OTk_a4701234-518e-4325-833f-afb95c477296"
      unitRef="eur">44107000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i4f0f98e9c5bf49a7a5c86be5e8e9f97e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtMy0xLTEtMTE5OTk_e7c4fb9e-676c-45a7-89f2-d1425d3e86d8"
      unitRef="eur">44107000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i7ca7a36461924d479d77dfafdaa0f0a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzgtNC0xLTEtMTE5OTk_6899969c-43f5-444d-8382-4e8f8a439ca6"
      unitRef="eur">44107000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i963e0d114bd6453f9f66f58da5eff1cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktMS0xLTEtMTE5OTk_d31b0335-665c-445c-87c3-8a738fa39d0a"
      unitRef="eur">4872000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i005555f4e921493c8254695ac286ae81_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktMy0xLTEtMTE5OTk_c548be67-0aff-4a39-85e9-d7b9b21f362c"
      unitRef="eur">4872000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i963e0d114bd6453f9f66f58da5eff1cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzktNC0xLTEtMTE5OTk_23e1359b-3255-4b74-a877-d4c58f59398c"
      unitRef="eur">4872000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i9dcca9167f6249298283face31cd7f47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTEtMS0xLTExOTk5_9d78d74a-7bc6-4644-8dbf-048c8e44083c"
      unitRef="eur">7106000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i3f20ea2133e94954bd0a8f66c6e3cc78_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTMtMS0xLTExOTk5_82ef3cff-8221-4c1b-a9d4-2509abaaf7ec"
      unitRef="eur">7106000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i9dcca9167f6249298283face31cd7f47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzEwLTQtMS0xLTExOTk5_5f4e93aa-5d2b-4a53-bd39-100ae8d20814"
      unitRef="eur">7106000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTEtMS0xLTExOTk5_39ac34c8-ed07-439b-a0cf-cbb52a134f60"
      unitRef="eur">56085000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables
      contextRef="iea4486c4d182429aa433718272dbe53b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTMtMS0xLTExOTk5_8036f5dc-cf57-4b3e-88c9-047aa85e3d6e"
      unitRef="eur">56085000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables>
    <nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTo5MGU4ZTVlM2I4NTY0MDcxYjM0MzdjYTU4NGU2MGU4Yy90YWJsZXJhbmdlOjkwZThlNWUzYjg1NjQwNzFiMzQzN2NhNTg0ZTYwZThjXzExLTQtMS0xLTExOTk5_9c1fcc4a-c49c-4c67-bec4-42909f315151"
      unitRef="eur">56085000</nbx:TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue>
    <nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90ZXh0cmVnaW9uOjU4ZjA0OWE5MmMyNTRjNDM4ZWMwN2NhOWQ0NmQ1ZTQzXzU1NDI_eda80d90-8bfa-4b31-8045-8717d0e3629f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table shows the impact of a 10% increase or decrease in the exchange rate between the euro and the U.S. dollar, calculated on the amounts of capital contributions and loans to the Company&#x2019;s U.S. subsidiaries as of December 31, 2021, and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;USD / Euro exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Decrease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;USD / Euro exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate
      contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtMS0xLTEtNTQxNDY_f249a1d3-9375-46f0-8e6b-41a38e60440b"
      unitRef="eur">45000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate
      contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtMi0xLTEtNTQxNDY_80ba770f-7f0a-4d39-8ddf-79ed3c5bd181"
      unitRef="eur">-45000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate
      contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtNC0xLTEtNTQxNDY_810904e3-f99f-4142-ab8c-a12d0ebff2d3"
      unitRef="eur">87000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate
      contextRef="i47c9f773de2643d0b6590e36425e046a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzMtNS0xLTEtNTQxNDY_055ffbda-874f-4793-8508-3390898ebd5f"
      unitRef="eur">-87000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate
      contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtMS0xLTEtNTQxNDY_569579f8-0b86-4656-a389-0b19762078f3"
      unitRef="eur">45000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate
      contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtMi0xLTEtNTQxNDY_5b1c0610-8977-446b-8363-2add773381c5"
      unitRef="eur">-45000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate
      contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtNC0xLTEtNTQxNDY_1b8c0e5b-de2f-4936-adca-5fe21a71d364"
      unitRef="eur">87000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate
      contextRef="ibbf161735ab842849b194cad877786e7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpiMWExYTc3MWM5NDE0ZTUyYTgzODA2NDIzYzk2Y2ZjOS90YWJsZXJhbmdlOmIxYTFhNzcxYzk0MTRlNTJhODM4MDY0MjNjOTZjZmM5XzQtNS0xLTEtNTQxNDY_56e421ba-10b7-4a1f-8e54-2f653c9ce402"
      unitRef="eur">-87000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate
      contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtMS0xLTEtMTE5OTk_61b8abc2-5b06-4394-9cfb-57548e9e4909"
      unitRef="eur">5000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate
      contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtMi0xLTEtMTE5OTk_6c7fa3e5-a68e-4c1b-aa42-22742bf12adf"
      unitRef="eur">-5000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate
      contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtNC0xLTEtMTE5OTk_309ce7b1-5c49-4f78-87c5-ede070735157"
      unitRef="eur">124000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate
      contextRef="i70e283091672405988eeb41d8577edbe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzMtNS0xLTEtMTE5OTk_4a96e332-171e-41c8-9df4-77e435830d31"
      unitRef="eur">-124000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate
      contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtMS0xLTEtMTE5OTk_173a7573-c9a0-4755-967d-915880d0b146"
      unitRef="eur">5000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate
      contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtMi0xLTEtMTE5OTk_359ea8e8-170a-46b7-8855-745beee97491"
      unitRef="eur">-5000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate
      contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtNC0xLTEtMTE5OTk_17c840ae-a48c-41d9-a9c3-674120de6853"
      unitRef="eur">124000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate>
    <nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate
      contextRef="i7201f97233954a5394e14b9c67b97bdf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzUvZnJhZzo1OGYwNDlhOTJjMjU0YzQzOGVjMDdjYTlkNDZkNWU0My90YWJsZTpmMzM4MjQ1M2Y4YzA0ZGU1OWExZWY4M2YyMjIxMjY2OC90YWJsZXJhbmdlOmYzMzgyNDUzZjhjMDRkZTU5YTFlZjgzZjIyMjEyNjY4XzQtNS0xLTEtMTE5OTk_b67b2066-e29e-4edd-b4f8-0401ca05cbf8"
      unitRef="eur">-124000</nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzg0MDI_3e2f2858-f269-4cf0-b1b9-65c5c1c56fb0">Revenues and other income &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Revenue is recognized in accordance with IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;A license:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt"&gt;If the license is assessed to be a right to access the Company&#x2019;s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt"&gt;If the license is a right to use the Company&#x2019;s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Product supply for which the revenue is recognized once the control over the delivered products is transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application to the license and collaboration agreement with PharmaEngine&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under the License and Collaboration Agreement, the Company&#x2019;s and PharmaEngine&#x2019;s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company&#x2019;s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the license of the right to use the Company&#x2019;s patent and know-how;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine&#x2019;s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the supply of NBTXR3 to PharmaEngine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;An upfront payment of $1.0&#160;million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1&#160;million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company&#x2019;s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1&#160;million (first patient&#x2019;s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine &#x2019;s territory, which had not occurred as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of IFRS 15 to the license and collaboration agreement with LianBio&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;an exclusive license, under the Company's intellectual property, to develop and market the licensed products;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;the right to actively participate in global Phase III registration trials to obtain marketing approval in China;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;the requirement to purchase products under license to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20&#160;million and may receive up to $220&#160;million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research tax credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The French tax authorities grant a research tax credit (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, or &#x201c;CIR&#x201d;), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the &#x201c;PME&#x201d;, it can request immediate refund of the remaining tax credit, without application of the three-year period). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Detail of revenues and other income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company&#x2019;s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsidies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenues and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue of &#x20ac;10&#160;thousand in 2021, &#x20ac;50&#160;thousand in 2020 and &#x20ac;68&#160;thousand in 2019 were derived mainly from the charging-back of shared external clinical research organization costs in connection with the development support provided by the Company to PharmaEngine as part of the 2014 amendment to the Company's License and Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100% of the revenues recognized in 2021, 2020 and 2019 were derived from the arrangement with PharmaEngine (see Note 4.1).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, the Company&#x2019;s other income, other than the research tax credit, mainly derives from French State subsidies of &#x20ac;312&#160;thousand provided as part of the &#x2018;&#x2018;partial unemployment measure,&#x2019;&#x2019; a National plan allowing companies facing economic challenges during the COVID-19 crisis to receive from the French State approximately 84% of specific employees&#x2019; net salary, as well as the &#x20ac;350&#160;thousand received by Curadigm in connection with the Bpifrance Deep Tech Funding, &#x20ac;187&#160;thousand of which was recognized as revenue for the years ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgzOTg_e98afbf3-3f2e-4ef6-b9fe-70e28821cda3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Revenue is recognized in accordance with IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under IFRS 15, revenue is recognized when the Company satisfies a performance obligation by transferring a distinct good or service (or a distinct bundle of goods and/or services) to a customer, i.e. when the customer obtains control of these goods or services. An asset is transferred when the customer obtains control of the asset (or service). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Given the wide spectrum of therapeutic research and development opportunities, aside from the fields that the Company intends to research and develop with its own scientific and financial resources, the Company has entered and expects to enter into license and collaboration agreements with third parties in certain specific fields that have generated or will generate revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Therefore, each agreement has been and will be analyzed, on a case-by-case basis to determine whether the arrangement contains performance obligations to the other party and, if so, to identify the nature of these performance obligations in order to determine the appropriate accounting under IFRS 15 principles of the amounts that the Company has received or is entitled to receive from the other party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;e.g.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Development services performed by the Company to create or enhance an intellectual property controlled by the client, for which revenue is recognized over time, when services are rendered;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;A transfer of control of an existing intellectual property of the Company for which revenue is recognized at the time such control is transferred; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;A license:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt"&gt;If the license is assessed to be a right to access the Company&#x2019;s intellectual property as it exists throughout the license period, revenue is recognized over the license period; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.81pt"&gt;If the license is a right to use the Company&#x2019;s intellectual property as it exists (in term of forms and functionality), revenue is recognized when the other party is able to use and benefit from the license; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Product supply for which the revenue is recognized once the control over the delivered products is transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Contingent revenue arising from successful milestones or sales-based royalties are not recognized before the related milestone has been reached or sale has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application to the license and collaboration agreement with PharmaEngine&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Under the License and Collaboration Agreement, the Company&#x2019;s and PharmaEngine&#x2019;s rights are clearly identified and, financial terms are defined in the contract. The contract has commercial substance (the Company&#x2019;s cash flows have been affected by the terms of the contract) and the Company has collected and is entitled to collect in the future consideration in exchange for the goods and services transferred to PharmaEngine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company identified three performance obligations in the License and Collaboration Agreement described under Note 4 above: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the license of the right to use the Company&#x2019;s patent and know-how;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the support provided by the Company to PharmaEngine until the first regulatory approval is granted in PharmaEngine&#x2019;s territory that the Company views as a series of distinct periods of access to information and experience that is satisfied over time; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;the supply of NBTXR3 to PharmaEngine.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;An upfront payment of $1.0&#160;million was fully recognized as revenue when the license was transferred to PharmaEngine in 2012. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Development milestones constitute variable payments that are recognized over-time. As milestone payment timing was defined to reflect the efforts of both parties over time and were amended to reflect all changes in the contractual development plan, the Company concluded that the terms of variable payments reflect its efforts to satisfy the performance obligation related to each development phase and that no portion if any of such consideration that would relate to the license would impact the timing of recognition because of the highly probable collectability requirement. On this basis, the first milestone payment of $1&#160;million (upon signature of the first amendment that allowed PharmaEngine to benefit from the results of the Company&#x2019;s clinical studies for soft-tissue sarcoma indication) and the second milestone payment of $1&#160;million (first patient&#x2019;s injection with NBTXR3 in soft tissue sarcoma study in Asia) were received and recognized in 2014 and 2016, respectively. The next milestone will be &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;received following the first filing for regulatory approval for marketing NBTXR3 in PharmaEngine &#x2019;s territory, which had not occurred as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Royalties are considered at market conditions and will be fully recognized once the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement. See note 4 Significant Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Application of IFRS 15 to the license and collaboration agreement with LianBio&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Under the clause 8.5 of the license and collaboration agreement between the Company and LianBio, LianBio has the final decision on development and marketing activities in its territory. Consequently, the agreement does not qualify as a partnership under IFRS 11, which requires joint control and unanimous approval of strategic decisions by both parties. The agreement falls within the scope of IFRS 15.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;We identified the separate performance obligations of the contract under IFRS 15. The agreement includes the following obligations to LianBio:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;an exclusive license, under the Company's intellectual property, to develop and market the licensed products;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;the right to actively participate in global Phase III registration trials to obtain marketing approval in China;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;if a pivotal trial is initiated by the Company in another country, the right to obtain a license and the right to reference efficacy data from the study and regulatory filings and approvals;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;if a Phase I and Phase II trial is initiated by the Company, the right to obtain access to and a license to all clinical data and regulatory filings relating to such clinical trial; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:14.85pt"&gt;the requirement to purchase products under license to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The Company's know-how as disclosed and made available to LianBio could not technically be used by LianBio, or by a third party, to manufacture the licensed products. The provision of additional know-how data and information by the Company is necessary to enable a third party to manufacture the licensed products. This information will only be provided if the Company, at any time following a change of control of the Company, fails to provide at least 80% of LianBio's forecasted need for licensed products in a given calendar year. The license cannot be separated because LianBio cannot benefit from the license alone (i.e. without the ongoing manufacturing service provided by the Company). On this basis, we concluded that the license and the manufacturing service are not distinct.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;As the license is not separate, any services performed in connection with the clinical trials cannot be analyzed as a separate service provided by the Company to LianBio, because LianBio cannot benefit from the clinical trials alone.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;LianBio has the exclusive right to purchase and sell the licensed products in its territory but has no enforceable obligation to make the purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Accordingly, the agreement contains only one performance obligation: the manufacturing and the supply by Nanobiotix to LianBio of the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In consideration for this exclusive right to purchase and sell the licensed products granted to LianBio, the Company received on June 15, 2021, a non-refundable upfront payment of $20&#160;million and may receive up to $220&#160;million in potential additional payments upon the achievement of certain development and commercialization milestones. The development milestones events refer to the effort provided by LianBio to register the licensed product as a drug and to enroll patients in the global phase III registrational study in head and neck within 18 months and the receipt of marketing authorization for the Licensed Product in the territory for any indication in the field. The Company is entitled to receive sales milestones payments, once the aggregate net sales of the Licensed product in the territory achieve graduated amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;No revenue is to be recognized when such a right is granted. The upfront payment and milestone payments are considered as advance payments for future deliverables. Therefore, no revenue will be recognized until the first sales of the licensed products occur. In accordance with paragraph 106 of IFRS 15, upon receipt of an upfront payment from LianBio, the Company shall recognize a contractual liability to the extent of the upfront payment. The Company shall derecognize this contractual liability (and recognize revenue) when it transfers the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The upfront payment and milestone payments must be allocated to the sales of licensed products. Significant judgment will be required to determine how to allocate the upfront payments to the sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Nanobiotix will also be eligible to receive tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories. The method of recognizing these revenues is also yet to be determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Due to its innovative approach to nanomedicine, the Company has received various grants and other assistance from the government of France and French public authorities since its creation. The funds are intended to finance its operations or specific recruitments. Grants are recognized in income as the corresponding expenses are incurred and independently of cash flows received.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research tax credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The French tax authorities grant a research tax credit (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Cr&#xe9;dit d&#x2019;Imp&#xf4;t Recherche&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, or &#x201c;CIR&#x201d;), to companies in order to encourage them to conduct technical and scientific research. Companies demonstrating that they have incurred research expenditures that meet the required criteria (research expenses in France or, since January 1, 2005, other countries in the European Community or the European Economic Area that have signed a tax treaty with France containing an administrative assistance clause) receive a tax credit that can theoretically be compensated with the income tax due on the profits of the financial year during which the expenses have been incurred and the following three years. Any unused portion of the credit is then refunded by the French Treasury. If the Company can be qualified as small and medium-sized enterprises, in France the &#x201c;PME&#x201d;, it can request immediate refund of the remaining tax credit, without application of the three-year period). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has received research tax credits since its creation. These amounts are recognized as "Other income" in the fiscal year in which the corresponding charges or expenses were incurred. The portion related to capitalized expenses is deducted from the amount of capitalized expenses on the statements of financial position and from the amortization charges for these expenses on the statements of operations.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="i53b56ef6f56a4b4ea0c95e305f4aa85b_D20120101-20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTY_cddf0fda-3203-4dd3-a361-5e92932d5b1a"
      unitRef="usd">1000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived
      contextRef="ia2582b36bc7243aeb8e6181c608549bc_D20140101-20141231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzQwMTY_1165eeb7-9853-47b3-937b-cf1cf42fced6"
      unitRef="usd">1000000</nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived>
    <nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived
      contextRef="i7838fc32ffd9409cab54c74bfbe9029e_D20160101-20161231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzQyMTg_c0739793-beac-47f5-b15d-ef5983fc82c4"
      unitRef="usd">1000000</nbx:CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived>
    <nbx:MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement
      contextRef="ia4324070196a42ce81514023ff835c69_D20210501-20210531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyNzU_3e99d1fd-2e42-40e4-b194-0db3fe81c875"
      unitRef="number">0.80</nbx:MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement>
    <nbx:CollaborationAgreementUpfrontPaymentReceived
      contextRef="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyODA_a9718180-b10b-46bd-b37f-1fd2ef477b3d"
      unitRef="usd">20000000</nbx:CollaborationAgreementUpfrontPaymentReceived>
    <nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
      contextRef="i16897dad579b4f4b86092bda744f7b49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMyOTM_e70f12a2-4604-488c-870d-e8045f7e9ae2"
      unitRef="usd">220000000</nbx:CollaborationAgreementPotentialMilestonesPaymentsToBeReceived>
    <nbx:CollaborationAgreementMilestonesAchievementPeriod
      contextRef="i9bb2cbcf9b954bf9ac10800e23941332_D20210615-20210615"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzMyOTg1MzQ5MTMzMDY_ecb71335-9427-4a2b-a65e-1cd3b69d39cd">P18M</nbx:CollaborationAgreementMilestonesAchievementPeriod>
    <nbx:ResearchTaxCreditUtilizationPeriod
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzYwMjQ_4801f24c-0dd8-49f9-95ec-d0e45e5ce626">P3Y</nbx:ResearchTaxCreditUtilizationPeriod>
    <nbx:ResearchTaxCreditUtilizationPeriod
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgzOTk_b15ea4da-83a6-4325-aeca-7e65a4b1f1e5">P3Y</nbx:ResearchTaxCreditUtilizationPeriod>
    <nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzg0MDA_91d24728-7bc6-4297-ae82-0defc7180185">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company&#x2019;s revenues and other income per category for the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Subsidies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,637&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total revenues and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i923e1965fdfa48cb90e163414c18dcc6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMS0xLTEtMTE5OTk_0a88565d-eedd-4a0b-a3c3-5825430eaa3f"
      unitRef="eur">5000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i0280ecfc6a714e849f5cba16bb5df0e5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMi0xLTEtMTE5OTk_6b428797-a2c9-419b-bcad-d282c93ef945"
      unitRef="eur">50000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i66824b4e473b46179fd1ef1f2f501a12_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzItMy0xLTEtMTE5OTk_5a19129b-29f2-4d7c-83c7-ea1f3fd41943"
      unitRef="eur">40000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ib221c9ab85f1428998e5bd37d6eadcba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMS0xLTEtMTE5OTk_c7c0a40a-2027-4209-8fb2-275c74402315"
      unitRef="eur">5000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i2e1b70eaca444c0098a66c5e8a9832bc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMi0xLTEtMTE5OTk_bed4b90f-ea32-4d95-b236-e357304e9ad7"
      unitRef="eur">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i9df4ab9cfd314a1baaac83e76837eb48_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzMtMy0xLTEtMTE5OTk_3c28def5-9e25-4664-b2e5-d8cba1ff8492"
      unitRef="eur">28000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMS0xLTEtMTE5OTk_df8e1f0d-91d5-425f-9b79-5dd93dee8899"
      unitRef="eur">10000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMi0xLTEtMTE5OTk_9fdb51eb-6cf4-4f75-9eea-b2f4daf74c85"
      unitRef="eur">50000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzQtMy0xLTEtMTE5OTk_1c19cfa5-82ed-463b-8955-8d8938763efc"
      unitRef="eur">68000</ifrs-full:RevenueFromContractsWithCustomers>
    <nbx:ResearchAndDevelopmentTaxCredit
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMS0xLTEtMTE5OTk_b94428f0-3293-42a6-844f-fdee270ea388"
      unitRef="eur">2490000</nbx:ResearchAndDevelopmentTaxCredit>
    <nbx:ResearchAndDevelopmentTaxCredit
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMi0xLTEtMTE5OTk_ba44fedf-53ae-4cd0-acc3-7a4e64cbcec8"
      unitRef="eur">1927000</nbx:ResearchAndDevelopmentTaxCredit>
    <nbx:ResearchAndDevelopmentTaxCredit
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzUtMy0xLTEtMTE5OTk_50ccecd2-c1d0-4374-b9a7-ffd8b22b5647"
      unitRef="eur">2437000</nbx:ResearchAndDevelopmentTaxCredit>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMS0xLTEtMTE5OTk_30316199-fce8-4d59-aa01-fbb6240ad539"
      unitRef="eur">126000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMi0xLTEtMTE5OTk_5c2cc62d-0d0d-49fc-8198-dabd95da327d"
      unitRef="eur">526000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzYtMy0xLTEtMTE5OTk_2dcd0bfb-30e4-452e-b789-79ec5c67b35d"
      unitRef="eur">20000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMS0xLTEtMTE5OTk_df35b3fc-5ec8-4319-b9f8-133e4c1661a3"
      unitRef="eur">21000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMi0xLTEtMTE5OTk_4725fdf0-4525-4b18-81e0-0a7ae808b170"
      unitRef="eur">10000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzctMy0xLTEtMTE5OTk_d1f35602-5c7a-4dcd-bd37-538a5a382974"
      unitRef="eur">17000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:OtherIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMS0xLTEtMTE5OTk_7b3cfb8c-741e-43c7-aa09-d40d065428de"
      unitRef="eur">2637000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMi0xLTEtMTE5OTk_bca209c6-c436-4ca5-ae2b-ea7c45e2fcf5"
      unitRef="eur">2462000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzgtMy0xLTEtMTE5OTk_09531758-7f7b-4317-98cb-60dfedfa801b"
      unitRef="eur">2473000</ifrs-full:OtherIncome>
    <ifrs-full:Revenue
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMS0xLTEtMTE5OTk_311ee42b-a130-4a5c-88ae-0d27b2e40ae3"
      unitRef="eur">2647000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMi0xLTEtMTE5OTk_a35da582-3f4e-431b-a6b8-ddf63b937e57"
      unitRef="eur">2512000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90YWJsZTpiZjljNWI5ODg5MWQ0ZjY0ODk2ODc5NzU4ODE1NDQyNC90YWJsZXJhbmdlOmJmOWM1Yjk4ODkxZDRmNjQ4OTY4Nzk3NTg4MTU0NDI0XzktMy0xLTEtMTE5OTk_7f681db8-bdd0-4242-94fc-1968ceed0b26"
      unitRef="eur">2541000</ifrs-full:Revenue>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5MjE_fe67c2fe-2911-4e58-89a2-dddd876a3593"
      unitRef="eur">10000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5MzM_03baaf2a-7db0-4afd-9ddd-f52d4474a05f"
      unitRef="eur">50000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzY5NDg_7870bebd-c7ad-44e4-9ac9-d5a87b2e01ca"
      unitRef="eur">68000</ifrs-full:RevenueFromContractsWithCustomers>
    <nbx:ConcentrationRiskPercentage
      contextRef="if3840527069c4348acc9ab3731676a5d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_3399aa20-3561-4eb0-b2be-2dc3da72fca9"
      unitRef="number">1</nbx:ConcentrationRiskPercentage>
    <nbx:ConcentrationRiskPercentage
      contextRef="i302b2241ee6d4e209916d02969566345_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_3a4b4d2e-39a7-4514-9d52-fde145652f75"
      unitRef="number">1</nbx:ConcentrationRiskPercentage>
    <nbx:ConcentrationRiskPercentage
      contextRef="ie90622151f5e4db4a3a49e27eba46371_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc2NTE_ba858256-43f3-46d7-b93f-287c29231b2b"
      unitRef="number">1</nbx:ConcentrationRiskPercentage>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="i9557dec5d8804e348756bbd9f050ae89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzc5MzU_1def82b4-b001-4919-b8fd-99116b00cca6"
      unitRef="eur">312000</ifrs-full:RevenueFromGovernmentGrants>
    <nbx:PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgxMzI_23366376-f1f9-4121-97eb-51cfe9241d83"
      unitRef="number">0.84</nbx:PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure>
    <ifrs-full:NotionalAmount
      contextRef="i9daf524aa9d74916971b8de78a30e4c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgxODU_c3f67207-3e3a-4557-93d2-e00e163848ef"
      unitRef="eur">350000</ifrs-full:NotionalAmount>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="i62e1ab97b0f340d2806afa0a17c159aa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xNzgvZnJhZzo3ZmFlYmFhNmMzMzg0MzhhOWRhMzExMTY0MTQ4MzhiMS90ZXh0cmVnaW9uOjdmYWViYWE2YzMzODQzOGE5ZGEzMTExNjQxNDgzOGIxXzgyNjE_cf189d21-aa3b-4f6b-aada-922f48f2c596"
      unitRef="eur">187000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNzE_2ded4df0-d62d-46bf-a204-6268336ef54c">Operating expenses&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Accounting policies for research and development expenses are described in Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;16.1 Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, sub-contracting and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(30,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(24,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(30,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;see note 16.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Purchases, sub-contracting and other expenses increased by &#x20ac;6.9&#160;million, or 54% for the year ended December 31, 2021 as compared with the same period in 2020. This reflects the increase of the clinical development activities, especially driven by the launch of our global Phase III clinical trial for elderly head and neck cancer patients ineligible for platinum-based (cisplatin) chemotherapy (NANORAY-312).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Payroll costs decreased by &#x20ac;774&#160;thousand, or 8% for the year ended December 31, 2021 as compared with the same period in 2020. This variation is mainly due to a change in the mix and in the location of our research and development staff.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, the Company&#x2019;s workforce amounted to 75 research and development staff, including 9 additional positions created during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2020, the Company&#x2019;s workforce amounted to 66 research and development staff, including a decrease of fifteen positions created during the year ended December 31, 2020 and 81 research and development staff, including 2 additional positions created during the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The impact of share-based payments (excluding employer&#x2019;s contribution) on research and development expenses amounted to &#x20ac;677&#160;thousand in 2021 as compared with &#x20ac;629&#160;thousand in 2020 and &#x20ac;902&#160;thousand in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;16.2 Selling, General and Administrative (SG&amp;amp;A) expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, fees and other expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(19,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;see note 16.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In 2021, purchases, fees and other expenses increased by &#x20ac;3,156&#160;thousand, or 49% for the year ended December 31, 2021 as compared with the same period in 2020. This variation reflects two main impacts, first the legal expenses relating to partnership agreements as well as consulting fees, legal and compliance expenses as a result of being a U.S. public company. The second main impact relates to recruitment expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In 2020, wages, salaries and payroll costs, together, amounted to &#x20ac;15.1&#160;million as compared with &#x20ac;16.8&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#x2019;s contribution following the exercise by beneficiaries of their right to free shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;These increases in fees and other expenses were partially offset by the decrease in rental expenses following the application of IFRS 16 for the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;Payroll costs increased by &#x20ac;1.6&#160;million or 21% in 2021, mainly due to a change in the mix and location changes of our staff in SG&amp;amp;A functions (more US based employees) and a one-time severance payment related to the departure of Philippe Mauberna, the prior CFO.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, the Company&#x2019;s workforce amounted to 25 staff in SG&amp;amp;A functions in comparison with a Company&#x2019;s workforce of 24 staff in SG&amp;amp;A functions during the year ended December 31, 2020 and a Company&#x2019;s workforce of 29 staff in SG&amp;amp;A functions, including 6 additional positions created during the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The impact of share-based payments (excluding employer&#x2019;s contribution) on SG&amp;amp;A expenses amounted to &#x20ac;2.5&#160;million in 2021, as compared with &#x20ac;2.3&#160;million in 2020 and &#x20ac;3.4&#160;million in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;16.3 Payroll costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total payroll costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(21,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End-of-period headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company&#x2019;s workforce totaled 100 employees, compared with 90 December 31, 2020 and 110 as of December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2021, wages, salaries and payroll costs, together, amounted to &#x20ac;15.7&#160;million as compared with &#x20ac;15.1&#160;million in 2020. This is mainly due to the 10 additional positions created during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, wages, salaries and payroll costs, together, amounted to &#x20ac;15.1&#160;million as compared with &#x20ac;16.8&#160;million in 2019. This is mainly due to a decrease in staff over the period because of the COVID 19 pandemic and to the reversal of a provision related to employer&#x2019;s contribution following the exercise by beneficiaries of their right to free shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2019, wages and salaries and payroll taxes, together, reached &#x20ac;16.8&#160;million due to the Company's growth and a related increase in the number of employees during the year ended December 31, 2019, together with the impact of its compensation policy. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 2 &#x2013; Share-based Payment, the share-based payment amount recognized in the statements of operations reflects the expense associated with rights vesting during the fiscal year under the Company's share-based compensation plans. The share-based payment expenses amounted to &#x20ac;3.2&#160;million for the year ended December 31, 2021, as compared with &#x20ac;2.9&#160;million as of December 31, 2020 and &#x20ac;4.3&#160;million as of December 31, 2019 (see Note 17). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;16.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and provision expenses by function are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization of provision for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation expense of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization of provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:35.43pt;text-align:justify;text-indent:35.43pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:107%"&gt;16.5 OTHER OPERATING INCOME AND EXPENSES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract termination indemnity (PharmaEngine)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Other operating income and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has made payments for a cumulative amount of $6.5&#160;million (&#x20ac;5.4&#160;million converted at the exchange rate on the payment date) to PharmaEngine in accordance with the termination and release agreement signed between the parties. See Note 4.2 PharmaEngine.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjY_bc08afac-cf73-4a02-9742-8006d5348db6">Accounting policies Leases included in the practical expedients under the IFRS 16 standard and used by the Company (low value asset and short-term leases) are recognized in operating expenses. Payments made for these leases are expensed, net of any incentives, on a straight-line basis over the contract term (see Note 22).</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjc_cc928621-6e5f-4674-a920-ccc738310408">Research and development expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, sub-contracting and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,627)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(30,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(24,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(30,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;see note 16.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock>
    <nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMS0xLTEtMTE5OTk_4a0b8247-2d46-481b-ba9d-7a146c65f29d"
      unitRef="eur">19562000</nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses>
    <nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMi0xLTEtMTE5OTk_5622e3ab-8605-4fff-b9e0-ef1f70155ecb"
      unitRef="eur">12734000</nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses>
    <nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzItMy0xLTEtMTE5OTk_ddb69e00-f431-47bd-9843-9dc2aa2549e6"
      unitRef="eur">16804000</nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses>
    <nbx:ResearchAndDevelopmentExpensePayrollCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMS0xLTEtMTE5OTk_d72f7338-875b-4ce2-a8a9-ea2a22638c15"
      unitRef="eur">9605000</nbx:ResearchAndDevelopmentExpensePayrollCosts>
    <nbx:ResearchAndDevelopmentExpensePayrollCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMi0xLTEtMTE5OTk_7800ba42-7e79-469e-b774-cb75ec4d79da"
      unitRef="eur">10306000</nbx:ResearchAndDevelopmentExpensePayrollCosts>
    <nbx:ResearchAndDevelopmentExpensePayrollCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzMtMy0xLTEtMTE5OTk_17c4d4db-c744-465f-bf1b-5b83910d5bfb"
      unitRef="eur">11980000</nbx:ResearchAndDevelopmentExpensePayrollCosts>
    <nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMS0xLTEtMTE5OTk_20d45e93-6762-4ad1-b813-21bcdeece4df"
      unitRef="eur">1211000</nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMi0xLTEtMTE5OTk_1daafef3-64b5-4c4a-bb05-5f148f0455f2"
      unitRef="eur">1290000</nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzQtMy0xLTEtMTE5OTk_331ed934-3ff9-4255-ae56-9fc3271a23ef"
      unitRef="eur">1627000</nbx:ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMS0xLTEtMTE5OTk_308a3361-027f-44b8-bd7d-c41ae4cfc451"
      unitRef="eur">30378000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMi0xLTEtMTE5OTk_6c28770f-56f2-422b-9efd-9b0255f48038"
      unitRef="eur">24330000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2N2NmZWMyZjdmYzY0OTg1YjVjMGVmMTY2NzIyM2YxMi90YWJsZXJhbmdlOjY3Y2ZlYzJmN2ZjNjQ5ODViNWMwZWYxNjY3MjIzZjEyXzUtMy0xLTEtMTE5OTk_5a1b417a-0792-4f38-88c9-87aa6a624afd"
      unitRef="eur">30411000</ifrs-full:ResearchAndDevelopmentExpense>
    <nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzYxMg_8d427b1f-abd3-4636-9c3a-0e0d2729599a"
      unitRef="eur">6900000</nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses>
    <nbx:PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzYxOQ_acb13914-b8fc-4edb-941a-883c1fd2054a"
      unitRef="number">0.54</nbx:PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses>
    <nbx:IncreaseDecreaseInEmployeeBenefitExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzg2MA_7db7fd33-5516-4c5f-b16e-0f476078f441"
      unitRef="eur">-774000</nbx:IncreaseDecreaseInEmployeeBenefitExpense>
    <nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzg2Nw_ce2d327a-fbc6-4852-b5af-2d048e3b405e"
      unitRef="number">-0.08</nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="i835b7224a73b4426b167298dea1d3004_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTkyMjQ_00c2ed2f-7f6d-4c2b-aada-3b77dc690aee"
      unitRef="employee">75</ifrs-full:NumberOfEmployees>
    <nbx:IncreaseDecreaseInNumberOfEmployees
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTkyMjg_80c2f10c-eae7-4a91-b7ef-642ebe21d7ef"
      unitRef="employee">9</nbx:IncreaseDecreaseInNumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i408716a3b82f46e08e6b6d3596e1b7c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzIxOTkwMjMyNjkwMzY_23cd074d-2a26-4468-ba4d-eef620d617da"
      unitRef="employee">66</ifrs-full:NumberOfEmployees>
    <nbx:IncreaseDecreaseInNumberOfEmployees
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzExNzk_d8fbb325-61e4-4367-9b22-5b9a31f78fea"
      unitRef="employee">-15</nbx:IncreaseDecreaseInNumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="ib14b8fcd297d44c2b25d620752b4cc83_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzEyNTU_7dabbbdf-7107-4d61-b53d-edb5e77b9e31"
      unitRef="employee">81</ifrs-full:NumberOfEmployees>
    <nbx:IncreaseDecreaseInNumberOfEmployees
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzEzMDA_b3f0741f-9bca-4d1e-8f87-fdeb9f441167"
      unitRef="employee">2</nbx:IncreaseDecreaseInNumberOfEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE0OTQ_0cbe6e57-7ee5-4176-a710-2b15f7a52b9d"
      unitRef="eur">677000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE1MjI_70907069-e38c-4ed8-a782-1f4ffac874e9"
      unitRef="eur">629000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE1Mzc_48c2e9db-6dad-443a-9480-ea79ba241f94"
      unitRef="eur">902000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjg_1855ce6d-a253-4a6c-8a48-585668d13c3e">Selling, General and Administrative (SG&amp;amp;A) expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchases, fees and other expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll costs (including share-based payments) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation, amortization and provision expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(19,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(14,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.4pt"&gt;see note 16.4 Depreciation, amortization and provision expenses&lt;/span&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock>
    <nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMS0xLTEtMTE5OTk_f8f9d1d4-091a-4f3d-ab66-9d9e23c14ef9"
      unitRef="eur">9638000</nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense>
    <nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMi0xLTEtMTE5OTk_6dce1372-4381-47dc-b7af-cc52e8021bf9"
      unitRef="eur">6482000</nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense>
    <nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzItMy0xLTEtMTE5OTk_fd5987ee-ba76-4069-89a6-b3599a430484"
      unitRef="eur">9435000</nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense>
    <nbx:SellingGeneralAndAdministrativeExpensePayrollCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMS0xLTEtMTE5OTk_24b113da-bfd6-4cb7-9912-10b85e5d0196"
      unitRef="eur">9379000</nbx:SellingGeneralAndAdministrativeExpensePayrollCosts>
    <nbx:SellingGeneralAndAdministrativeExpensePayrollCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMi0xLTEtMTE5OTk_90b03a48-56ba-4f7f-b15e-05153c443d45"
      unitRef="eur">7789000</nbx:SellingGeneralAndAdministrativeExpensePayrollCosts>
    <nbx:SellingGeneralAndAdministrativeExpensePayrollCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzMtMy0xLTEtMTE5OTk_4b0ab791-c293-423e-9039-ef2d54afe497"
      unitRef="eur">9205000</nbx:SellingGeneralAndAdministrativeExpensePayrollCosts>
    <nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMS0xLTEtMTE5OTk_6b287b72-5e88-4c9b-9e36-891e84b788b7"
      unitRef="eur">417000</nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMi0xLTEtMTE5OTk_639e2f9b-aee6-45cd-8e81-ecb801a2c9c5"
      unitRef="eur">340000</nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense>
    <nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzQtMy0xLTEtMTE5OTk_aead04dc-aeda-47d6-874b-19744b5ddc8d"
      unitRef="eur">270000</nbx:SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMS0xLTEtMTE5OTk_27c97fe6-f192-4021-a2b6-146b85f67985"
      unitRef="eur">19434000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMi0xLTEtMTE5OTk_229cf52c-88c0-4cef-a857-00fa034191e8"
      unitRef="eur">14611000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4ODI3ODhkODI1N2Q0OTE1YjAzNmNjYjBiZThjNzEzMi90YWJsZXJhbmdlOjg4Mjc4OGQ4MjU3ZDQ5MTViMDM2Y2NiMGJlOGM3MTMyXzUtMy0xLTEtMTE5OTk_09dc2be2-bd9a-4cff-9fb9-47d9b9141892"
      unitRef="eur">18909000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE3MzI_7c87ff86-a452-40ab-867a-99331158b851"
      unitRef="eur">3156000</nbx:IncreaseDecreaseInPurchasesFeesAndOtherExpenses>
    <nbx:PercentageIncreaseDecreaseInRentFeesAndOtherExpenses
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE3Mzk_75c46e1f-dd2c-4b26-92a7-1473ae968b63"
      unitRef="number">0.49</nbx:PercentageIncreaseDecreaseInRentFeesAndOtherExpenses>
    <nbx:NumberOfImpactingFactors
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE4NDY_2ca8de19-67ed-420f-86ec-87a66d02c92b"
      unitRef="factor">2</nbx:NumberOfImpactingFactors>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4Mjc_dd83640c-267b-42e3-9c64-72a5557dafcf"
      unitRef="eur">15100000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NDI_e373aaa5-414a-4bb4-9543-883c1a06d4cb"
      unitRef="eur">16800000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <nbx:IncreaseDecreaseInEmployeeBenefitExpense
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMxNDU_bc78e581-1c00-4145-99f2-572788b19c70"
      unitRef="eur">1600000</nbx:IncreaseDecreaseInEmployeeBenefitExpense>
    <nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMxNTE_a51062de-9644-4d28-8ac2-dc0cfeeeaf21"
      unitRef="number">0.21</nbx:PercentageIncreaseDecreaseInEmployeeBenefitExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="iff6c0684a6ed4d3e8d05a4ad259e7b4f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMzNTQ_11994a37-140a-4492-9756-beda57f7fcb8"
      unitRef="employee">25</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i08cbc41147294b6ea9fed577e2d2ba27_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM0MTI_7c21f517-6130-442b-8ecc-f3d77858eb9d"
      unitRef="employee">24</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="ifcca4f14254e4036b189591f841d06e8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM1Mzg_bd8b748f-bf30-448d-9032-7292e0ef49c5"
      unitRef="employee">29</ifrs-full:NumberOfEmployees>
    <nbx:IncreaseDecreaseInNumberOfEmployees
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM1NjM_e1b281a2-1bab-4140-b5e5-7ac54385a3cf"
      unitRef="employee">6</nbx:IncreaseDecreaseInNumberOfEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3Mzg_3bc122bf-6fcb-4c06-b3b2-4c80068d978c"
      unitRef="eur">2500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3NTk_769a580e-9312-414c-871a-243887eece9e"
      unitRef="eur">2300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM3NzQ_829ae0e7-101f-49ac-b368-5639ee584ca5"
      unitRef="eur">3400000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNjk_89c24c5d-f228-4705-b6e5-b319ae13043d">Payroll costs &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Payroll taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Retirement benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total payroll costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(18,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(21,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Average headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;End-of-period headcount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</nbx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock>
    <ifrs-full:WagesAndSalaries
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMS0xLTEtMTE5OTk_e457335c-3df5-452f-9bb0-d0c8feccbad8"
      unitRef="eur">11391000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMi0xLTEtMTE5OTk_8a39e935-9b77-4f04-abf1-0f73f101ec9d"
      unitRef="eur">11141000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzItMy0xLTEtMTE5OTk_f25d9953-6739-4d2f-bafc-79c903eae586"
      unitRef="eur">11876000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMS0xLTEtMTE5OTk_8d9b64c2-6f2a-4cf6-a899-d208685fbc8b"
      unitRef="eur">4308000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMi0xLTEtMTE5OTk_69c9f8a1-ef56-4207-a8cd-a99ba18ca7e9"
      unitRef="eur">3953000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzMtMy0xLTEtMTE5OTk_67ac433a-2dda-40a8-94c2-1feaed9b5eed"
      unitRef="eur">4913000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMS0xLTEtMTE5OTk_7a1a94da-343a-48f6-934d-92be45aaea81"
      unitRef="eur">3201000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMi0xLTEtMTE5OTk_b52ba501-470f-4f5e-813d-066eeb7ed7dd"
      unitRef="eur">2924000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzQtMy0xLTEtMTE5OTk_a8640c79-89f4-4fe0-95a6-a8ba7a2ef924"
      unitRef="eur">4320000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMS0xLTEtMTE5OTk_102d2a55-85e3-4ffd-bc95-2b99ed009eaa"
      unitRef="eur">84000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMi0xLTEtMTE5OTk_0f600a08-ddcf-4a1f-91d9-f35d4c073ebf"
      unitRef="eur">76000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzUtMy0xLTEtMTE5OTk_5aa72266-9bad-4257-87fd-7e5a48b8b91e"
      unitRef="eur">76000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMS0xLTEtMTE5OTk_1e6ad669-617f-4eab-b649-cfd488b7ccdd"
      unitRef="eur">18984000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMi0xLTEtMTE5OTk_ce4cc5da-3cfb-4775-a7e2-af3c029923aa"
      unitRef="eur">18094000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzYtMy0xLTEtMTE5OTk_85feecde-bd72-4af3-8b80-98ae0770db8f"
      unitRef="eur">21185000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMS0xLTEtMTE5OTk_a8087a54-d510-422e-b2de-edf7394e57f7"
      unitRef="employee">96</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMi0xLTEtMTE5OTk_ec3a046b-1f01-42cb-8fed-23b911972fa1"
      unitRef="employee">97</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:AverageNumberOfEmployees
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzctMy0xLTEtMTE5OTk_98d12c56-c695-4fbd-9019-8305b7c17a0c"
      unitRef="employee">112</ifrs-full:AverageNumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMS0xLTEtMTE5OTk_bdcab36b-5653-4385-bdc9-486be68e0cc9"
      unitRef="employee">100</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMi0xLTEtMTE5OTk_529324d3-1a3d-4c7d-92d5-576ff87f7718"
      unitRef="employee">90</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiZDIzNDEwM2UyMGQ0NDcxOWY5N2Q4NjEyYTcyZWJlNC90YWJsZXJhbmdlOmJkMjM0MTAzZTIwZDQ0NzE5Zjk3ZDg2MTJhNzJlYmU0XzgtMy0xLTEtMTE5OTk_acace043-a213-40d2-85dd-86889d88842b"
      unitRef="employee">110</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM4NzE_6743fa36-f39b-49b3-911c-79aba3b8f4d0"
      unitRef="employee">100</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM4OTk_0a1bdde4-ab1f-4a33-8bd0-28575b4ebae0"
      unitRef="employee">90</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzM5MjQ_a5edadc4-40d5-45ba-8bdc-942458b99815"
      unitRef="employee">110</ifrs-full:NumberOfEmployees>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NTc_6c4613bf-bae5-4fe5-85bc-812b6ebfa96b"
      unitRef="eur">15700000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4NzI_c791b668-c0a3-4899-9384-00f59c08c9b8"
      unitRef="eur">15100000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <nbx:IncreaseDecreaseInNumberOfEmployees
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTk4OTQ_7eb24a08-096e-4eee-9b3c-b171490351ca"
      unitRef="employee">10</nbx:IncreaseDecreaseInNumberOfEmployees>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQwMjA_09118181-0b3b-49ca-b187-6887b9c62b58"
      unitRef="eur">15100000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQwNDA_3e2874b6-bd9c-45bf-99ca-8c35fce68eda"
      unitRef="eur">16800000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQzNTE_5b5b1e1a-a95b-4a33-aba0-aadf93029206"
      unitRef="eur">16800000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQ5MzQ_841a74a6-e622-46c1-a582-a44eeb932fbd"
      unitRef="eur">3200000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzQ5OTI_a4cd3d44-fab2-4742-b74b-9b3851f3d37c"
      unitRef="eur">2900000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUwMjM_5b0a64cb-6f57-47d0-9b34-5fa258af777a"
      unitRef="eur">4300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzUyNzA_bd1fc0f6-ecca-48cd-acae-ba014b99cc06">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Depreciation, amortization and provision expenses by function are detailed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of tangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization of provision for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reversal of provision for disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SG&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization expense of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation expense of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Utilization of provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Provision for charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total depreciation, amortization and provision expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock>
    <ifrs-full:AmortisationExpense
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMS0xLTEtMzk2Njc_c69a71fd-9de0-440b-8490-cf92ff066e6b"
      unitRef="eur">34000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMi0xLTEtMzk2OTc_40374eee-f71b-45ae-86f7-e51f82289ede"
      unitRef="eur">10000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzItMy0xLTEtMzk3MDM_24f88c79-7a71-4b20-ac6c-9a31bcdd0a7d"
      unitRef="eur">45000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMS0xLTEtMzk2Njc_38ccfd34-b6e3-4a1b-bc35-bccf7c4f26a6"
      unitRef="eur">1109000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMi0xLTEtMzk2OTc_77df1ec6-2d36-41e3-80d3-3da9ac4b5d75"
      unitRef="eur">406000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzMtMy0xLTEtMzk3MDM_db8d40ca-f8e0-48b0-a732-b74996fa6651"
      unitRef="eur">1515000</ifrs-full:DepreciationExpense>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMS0xLTEtMzk2Njc_92e31367-8126-4cbd-8140-ec1a4c93f68b"
      unitRef="eur">68000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMi0xLTEtMzk2OTc_2b4b5d94-a3b7-4d2f-a135-d22e1b8ead43"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzQtMy0xLTEtMzk3MDM_f9029271-02ed-445a-a28f-e5ebd5fa055d"
      unitRef="eur">68000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="id2be74eb72584233979cc9db5230eafb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMS0xLTEtMzk2Njc_459b8511-9f5e-4be9-9648-0a4bd0ce3d7e"
      unitRef="eur">1211000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i9d3ae9550b1b4feb9b30bd460735160a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMi0xLTEtMzk2OTc_46f8c8a6-252b-4d66-af65-30d86aad9998"
      unitRef="eur">416000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZToxZDFlNTNjYmIxOGY0Zjk3YjYxOGNmZTdhZTEyZDcxMC90YWJsZXJhbmdlOjFkMWU1M2NiYjE4ZjRmOTdiNjE4Y2ZlN2FlMTJkNzEwXzYtMy0xLTEtMzk3MDM_60494344-8add-40a0-adce-ca2ba05d98dd"
      unitRef="eur">1628000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <ifrs-full:AmortisationExpense
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMS0xLTEtMTE5OTk_d765078d-7d84-42bc-919b-34e5577bd9e2"
      unitRef="eur">152000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMi0xLTEtMTE5OTk_dee64317-9046-4ccc-9859-a1c6645514b6"
      unitRef="eur">23000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzItMy0xLTEtMTE5OTk_375825cd-e262-4958-bceb-7dd8b8e3350b"
      unitRef="eur">176000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMS0xLTEtMTE5OTk_d75390c9-1a08-4604-8ab0-d3f7b5dc3cf2"
      unitRef="eur">1250000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMi0xLTEtMTE5OTk_b1d0ab5f-6133-444b-95c6-929849d9976b"
      unitRef="eur">329000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzMtMy0xLTEtMTE5OTk_1ea07342-99ce-4544-a8cc-16d725cfa1d0"
      unitRef="eur">1579000</ifrs-full:DepreciationExpense>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMS0xLTEtMTE5OTk_f44e1c34-1001-4482-a4d7-ee1aefaa6e24"
      unitRef="eur">145000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMi0xLTEtMTE5OTk_70c2cfc6-2d44-43f5-8a88-18527987b106"
      unitRef="eur">0</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzQtMy0xLTEtMTE5OTk_4686cbb8-8a6d-41de-83e5-7424ed84a8a2"
      unitRef="eur">145000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMS0xLTEtMTE5OTk_0ea39478-74db-477d-9c99-991f394604fc"
      unitRef="eur">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMi0xLTEtMTE5OTk_75471140-b469-4a18-bc7d-d116cf59fe3f"
      unitRef="eur">40000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzUtMy0xLTEtMTE5OTk_0eb56147-6fd8-4b52-827a-78df387ee17c"
      unitRef="eur">40000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMS0xLTEtMTE5OTk_0a1d8a53-e33f-4e2b-a2cb-eb456c886403"
      unitRef="eur">0</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMi0xLTEtMTE5OTk_e387e395-a4eb-477a-99de-d5358b34ec9e"
      unitRef="eur">19000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzYtMy0xLTEtMTE5OTk_0e2c6351-e921-4df0-a400-7487a87d3f83"
      unitRef="eur">19000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i8a8af3db131046179bc38bde8260edc9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMS0xLTEtMTE5OTk_9a3207db-8c94-4e2e-ae83-1baf368152ae"
      unitRef="eur">1257000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i4fb9374b2e884918a3005c23955386db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMi0xLTEtMTE5OTk_d42c257d-5249-44bf-ab14-3c04033fe4b9"
      unitRef="eur">373000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo4NWJjNTA2NjAyMDI0MjM0YjM0NzJmNWM4NmU3N2MzZS90YWJsZXJhbmdlOjg1YmM1MDY2MDIwMjQyMzRiMzQ3MmY1Yzg2ZTc3YzNlXzctMy0xLTEtMTE5OTk_6dbbe17b-b07d-437b-b457-0cdeccc12ca7"
      unitRef="eur">1630000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <ifrs-full:AmortisationExpense
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMS0xLTEtMTE5OTk_fc806f10-6646-4a65-8a5b-16254e69be17"
      unitRef="eur">289000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMi0xLTEtMTE5OTk_b2984e21-0388-4d17-bc6a-e6a6844bb600"
      unitRef="eur">3000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzItMy0xLTEtMTE5OTk_46c2d864-4830-4303-8f57-af41f071231f"
      unitRef="eur">292000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMS0xLTEtMTE5OTk_407579d9-f1e3-4890-a17e-bfa45d6027e7"
      unitRef="eur">1208000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMi0xLTEtMTE5OTk_785b9716-923a-4de2-88ea-435e69b7078d"
      unitRef="eur">270000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzMtMy0xLTEtMTE5OTk_046ae99f-1e58-47bc-816a-334b1a5bacb1"
      unitRef="eur">1478000</ifrs-full:DepreciationExpense>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMS0xLTEtMTE5OTk_82d2dbe4-f58f-436d-be3d-32fce7a19d44"
      unitRef="eur">0</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMi0xLTEtMTE5OTk_554a5f55-7088-4bcf-b450-1ffc7a0b53c7"
      unitRef="eur">55000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzQtMy0xLTEtMTE5OTk_38235000-b749-4709-a7bf-3c99524f6cbf"
      unitRef="eur">55000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMS0xLTEtMTE5OTk_6c23c631-af07-4a09-9d99-89caf830040e"
      unitRef="eur">112000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMi0xLTEtMTE5OTk_a7b77ae9-4045-4b32-bd0e-b003f6f4006b"
      unitRef="eur">52000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzUtMy0xLTEtMTE5OTk_f9621a00-5c9f-4576-93e1-4dcf308f3c34"
      unitRef="eur">164000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i44b3aa644a314b799bb5c95e6dba3768_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMS0xLTEtMTE5OTk_e92c7d21-5023-4c91-a606-6836bbe65721"
      unitRef="eur">1609000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="iae50d890d5334a8a97fcd3083bbb3631_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMi0xLTEtMTE5OTk_9db9c11d-953b-4b34-8ceb-7ff59093d428"
      unitRef="eur">270000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DepreciationAmortizationAndProvisionExpenses
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTpiYmJjNGUyYjI5OWY0YzU2YWM1NDU2OGFmMTVkYzkyNy90YWJsZXJhbmdlOmJiYmM0ZTJiMjk5ZjRjNTZhYzU0NTY4YWYxNWRjOTI3XzYtMy0xLTEtMTE5OTk_2b32ef98-81d3-434e-839d-790d8497273d"
      unitRef="eur">1879000</nbx:DepreciationAmortizationAndProvisionExpenses>
    <nbx:DisclosureOfOtherOperatingIncomeExpensesTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzMyOTg1MzQ4OTU4MjA_5eeeab1b-b930-4f1b-8bf0-3a303fc507d9">OTHER OPERATING INCOME AND EXPENSES&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.188%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract termination indemnity (PharmaEngine)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total Other operating income and expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</nbx:DisclosureOfOtherOperatingIncomeExpensesTableTextBlock>
    <nbx:ContractTerminationIndemnities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzItMS0xLTEtNTM3MTc_5ebc81c4-d739-40bc-bcca-d8dcc020fa14"
      unitRef="eur">5414000</nbx:ContractTerminationIndemnities>
    <nbx:ContractTerminationIndemnities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzItMy0xLTEtNTM3MTc_66142b54-b362-4376-81c9-a4aac7818374"
      unitRef="eur">0</nbx:ContractTerminationIndemnities>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzMtMS0xLTEtNTM3MTc_aeba8157-4b19-4e0c-82a7-45a0e20200f5"
      unitRef="eur">-5414000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90YWJsZTo2MDgxMzY1OGJkOGQ0Y2NiYjIxODVkMjViZTQ0YzYyOS90YWJsZXJhbmdlOjYwODEzNjU4YmQ4ZDRjY2JiMjE4NWQyNWJlNDRjNjI5XzMtMy0xLTEtNTM3MTc_9067a882-88a2-4df1-9216-629997e1e0d8"
      unitRef="eur">0</ifrs-full:OtherOperatingIncomeExpense>
    <nbx:ContractTerminationIndemnities
      contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE2NDkyNjc0NTE2OTY_3094e0e4-d60e-4fbc-9323-f3645a2d508b"
      unitRef="usd">6500000</nbx:ContractTerminationIndemnities>
    <nbx:ContractTerminationIndemnities
      contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODEvZnJhZzoyMWFjYjgyZjM5MmY0NzMwYWFjYjYwOTZiM2NkNGM0Zi90ZXh0cmVnaW9uOjIxYWNiODJmMzkyZjQ3MzBhYWNiNjA5NmIzY2Q0YzRmXzE2NDkyNjc0NTE3MDE_a8bfa6a0-57ea-4146-9c1f-2d5f9553796a"
      unitRef="eur">5400000</nbx:ContractTerminationIndemnities>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODk_ae127d14-7373-4567-bec6-3761e2358ddf">Share-based payments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders&#x2019; warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;These share-based compensation plans are settled in equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has applied IFRS 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; to all equity instruments granted to employees since 2006. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As required by IFRS 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders&#x2019; equity for the vesting period during which the rights with respect to the equity instruments are earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of share-based payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has granted stock options (option sur actions, &#x2018;&#x2018;OSA&#x2019;&#x2019;), warrants (bons de souscription d&#x2019;actions, &#x2018;&#x2018;BSA&#x2019;&#x2019;), founders&#x2019; warrants (bons de souscription de parts de cr&#xe9;ateur d&#x2019;entreprise, &#x2018;&#x2018;BSPCE&#x2019;&#x2019;) and free shares (attributions gratuites d&#x2019;actions, &#x2018;&#x2018;AGA&#x2019;&#x2019;) to corporate officers, employees and members of the Supervisory Board and consultants. In certain cases, exercise of the options and warrants is subject to performance conditions. The Company has no legal or contractual obligation to pay the options in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Founders&#x2019; warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Pre-2021 founders&#x2019; warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2015-03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founder&#x2019;s warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/28/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12/18/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;08/28/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;09/16/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/10/2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12/18/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;08/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;09/16/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/10/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of founders&#x2019; warrants as of Number of founders&#x2019; warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;30,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;22,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Pre-2021 founders&#x2019; warrant plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE &lt;br/&gt;2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founder&#x2019;s warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/08/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of founders&#x2019; warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;99,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,976&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;1,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;1,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA 04-2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-2 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-2 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2016 ordinary&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;52,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/10/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;09/16/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/10/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;09/16/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;64,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;22,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2016 performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;28,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;07/27/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/17/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;07/27/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/17/2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;28,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.801%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants as of Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.559%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 stock option plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA &lt;br/&gt;2016-1 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;62,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;407,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10/24/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/11/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10/24/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/11/2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of options as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;28,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;387,456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options as of Including options exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;13,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including options lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;13,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.754%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 stock option plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;571,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/28/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/21/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/21/2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;491,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options as of Including options exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including options lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Free shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Pre-2021 free shares plan not yet vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021 free shares plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;396,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;438,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;362,515&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;07/27/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/11/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of free shares as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;360,512&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;340,583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;369,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including free shares exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;24,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;369,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including free shares lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,972,860&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,414,654&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;751,585&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;251,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;589,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;746,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,338,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The measurement methods used to estimate the fair value of stock options, warrants and free shares are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The share price on the grant date is equal to the exercise price, except for the BSA 2014 which exercise price was set at &#x20ac;40, taking into account both the average share price on the 20 days preceding the grant date and the expected development perspectives of the Company;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;The risk-free rate was determined based on the average life of the instruments; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Volatility was determined based on a sample of listed companies in the biotechnology sector on the grant date and for a period equal to the life of the warrant or option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The performance conditions for all of the plans were assessed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Performance conditions unrelated to the market were analyzed to determine the likely exercise date of the warrants and options and expense was recorded accordingly based on the probability these conditions would be met; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Market-related performance conditions were directly included in the calculation of the fair value of the instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Except for the 2012-1 founders&#x2019; warrants, the fair value of the warrants and options was measured using the Black-Scholes model. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value of 2012-1 founders&#x2019; warrants was determined using the Monte Carlo valuation model to take into account the exercise conditions, which depend on the realized gain compared to the expected stock market listing price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence ,  no new instrument became issuable.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44.3% - 47.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5 - 7.30 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.84% - 1.22%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 04-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5/6/6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;61% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59% - 62% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 61% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Project&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.26% - 0.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58%-58%-57%-58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5/5.1/5.3/5.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.6 &#x2013; 9.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.25% - 0.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016o-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016p-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2017o-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.7% - 0.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.7% - 0.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9.8/9.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.16% - 0.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.13%/&lt;br/&gt;-0.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59% - 62% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 61% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2017 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5 / 6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.1% / 37.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.103% / 0.149%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2019-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.9% - 37.8% - 38.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.38%/ -0.33%/ -0.28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.2% / 37.9% / 38.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.35 %/ -0.3 %/ -0.26 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;760&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19% / 0.141%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.74%/-0.69%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.63%/ -0.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,202&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,320&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODU_c879a435-83fc-4eb3-9aa1-90a780112f03">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has adopted a number of compensation plans since its inception. As of December 31, 2021, the Company had nine (9) outstanding founders&#x2019; warrant plans, twelve (12) outstanding warrant plans, nine (9) stock option plans and two (2) outstanding free shares plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;These share-based compensation plans are settled in equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company has applied IFRS 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt; to all equity instruments granted to employees since 2006. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As required by IFRS 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, the cost of remuneration paid in the form of equity instruments is recognized as an expense, with a corresponding increase in shareholders&#x2019; equity for the vesting period during which the rights with respect to the equity instruments are earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The fair value of the equity instruments granted to employees is measured using the Black-Scholes or Monte Carlo model, as described below.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <nbx:NumberOfShareBasedPaymentArrangementPlans
      contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzE3Mw_5c99758e-0bbc-43cc-9c21-765b946e9372"
      unitRef="plan">9</nbx:NumberOfShareBasedPaymentArrangementPlans>
    <nbx:NumberOfShareBasedPaymentArrangementPlans
      contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIxNw_6935fba1-535a-4a5a-8fc4-514c87763c53"
      unitRef="plan">12</nbx:NumberOfShareBasedPaymentArrangementPlans>
    <nbx:NumberOfShareBasedPaymentArrangementPlans
      contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzI1Mg_ff94e5a0-c809-4077-8d83-a823e277b40e"
      unitRef="plan">9</nbx:NumberOfShareBasedPaymentArrangementPlans>
    <nbx:NumberOfShareBasedPaymentArrangementPlans
      contextRef="ie0979101cec4474688543efa006ec62d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzI4Mg_ad613a52-75de-49d6-a304-45374d69aca6"
      unitRef="plan">2</nbx:NumberOfShareBasedPaymentArrangementPlans>
    <nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNTY_67941aee-07b7-4859-9651-340abcf32966">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The number of options and warrants outstanding on December 31, 2021 and their main characteristics, are detailed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Founders&#x2019; warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Pre-2021 founders&#x2019; warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2015-03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founder&#x2019;s warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;53,050&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/28/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12/18/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;08/28/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;09/16/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/10/2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12/18/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;08/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;09/16/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/10/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of founders&#x2019; warrants as of Number of founders&#x2019; warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;86,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;68,450&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;30,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;22,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Pre-2021 founders&#x2019; warrant plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE &lt;br/&gt;2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;br/&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founder&#x2019;s warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;126,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;129,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;117,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/08/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of founders&#x2019; warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,567&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;100,274&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;99,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of founders&#x2019; warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;28,976&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including founders&#x2019; warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;1,426&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;1,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA 04-2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-2 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2015-2 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2016 ordinary&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;52,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;26,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;64,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/18/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/10/2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;09/16/2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/10/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/04/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/10/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;09/16/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/10/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;30,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;10,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;64,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;22,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 warrant plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2016 performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;BSA &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;28,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;07/27/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/17/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;07/27/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/17/2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;28,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;5,820&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;18,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,105&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.801%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48,103&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants as of Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,431&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of warrants lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including warrants lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;33,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Free shares&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.044%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Pre-2021 free shares plan not yet vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021 free shares plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;396,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;438,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;362,515&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;07/27/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;03/11/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of free shares as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;360,512&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;340,583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;369,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including free shares exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;24,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;369,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of free shares lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including free shares lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,003&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,972,860&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,414,654&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;751,585&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;251,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;589,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;746,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,338,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtMi0xLTEtMTE5OTk_1b9e564f-e2a2-4960-9541-51f84f13fd69"
      unitRef="shares">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtNC0xLTEtMTE5OTk_705acc4b-a995-4db3-8cd9-bb7736b29335"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtNi0xLTEtMTE5OTk_7daf627a-5222-4de6-9357-554441432d1d"
      unitRef="shares">97200</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtOC0xLTEtMTE5OTk_22f48355-fa09-4152-a906-f720ae8977f7"
      unitRef="shares">71650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzMtMTAtMS0xLTExOTk5_5e7dd204-2087-461b-a0c7-d8246418c750"
      unitRef="shares">53050</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctMi0xLTEtMTE5OTk_d7c0daa2-629d-4221-9e15-2e336b29e644"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctNC0xLTEtMTE5OTk_8f407b97-e3ab-4d73-9f25-8964810323a3"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctNi0xLTEtMTE5OTk_d59f0dbe-458d-47ea-b6f5-83691a3564d7"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctOC0xLTEtMTE5OTk_b4a6c661-c9c8-471a-add5-a3544d5efa6d"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzctMTAtMS0xLTExOTk5_1957cbd8-81a6-47f0-9ab5-5c36ef35d599"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtMi0xLTEtMTE5OTk_e4f10ddd-ce56-4bed-b1d6-d0055a41e7f9"
      unitRef="eurPerShare">6.63</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtNC0xLTEtMTE5OTk_6b216986-7c3a-4f95-9457-de8f769e02de"
      unitRef="eurPerShare">5.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtNi0xLTEtMTE5OTk_0627c374-fedb-4a42-8358-772ad0c5d73c"
      unitRef="eurPerShare">18.68</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtOC0xLTEtMTE5OTk_24295da4-8968-403a-aebb-0f186eb2b248"
      unitRef="eurPerShare">18.57</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzgtMTAtMS0xLTExOTk5_54bd40f0-8ceb-4417-ac7e-10be22b57e22"
      unitRef="eurPerShare">20.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktMi0xLTEtMTE5OTk_97b25cf7-aa54-42ab-b25f-be3a77ffc5d3"
      unitRef="shares">100000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktNC0xLTEtMTE5OTk_f6ced4d4-5886-4548-8120-caa8f1c04b9b"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktNi0xLTEtMTE5OTk_b9f49a29-a24d-44b1-ac2c-12fadaf195ec"
      unitRef="shares">86150</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktOC0xLTEtMTE5OTk_391371af-ad18-42ed-8464-b9b0e327f8a9"
      unitRef="shares">68450</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzktMTAtMS0xLTExOTk5_2e21d41c-3691-4b53-8ee8-8deec0c8d10c"
      unitRef="shares">30350</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTItMS0xLTExOTk5_900cf9cc-1578-49b5-a5d7-a32ee66baa28"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTQtMS0xLTExOTk5_c1a77d1b-7df9-47ac-87dd-9fde42f6d046"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTYtMS0xLTExOTk5_c73b9307-919e-4c0a-8d4f-c0d049440e91"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTgtMS0xLTExOTk5_0886d553-65a2-41b5-a459-2827cf06b227"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEwLTEwLTEtMS0xMTk5OQ_ac9eea26-966b-414f-b30d-84a1a15f7003"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTItMS0xLTExOTk5_d6c85e16-4046-46c2-9546-17c44c0067d3"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTQtMS0xLTExOTk5_943fbda3-f0df-4f08-a002-ef1af2200bb5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTYtMS0xLTExOTk5_6986a6b3-aaf9-4455-ad6e-defaf5f6dea1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTgtMS0xLTExOTk5_796327c8-a66c-4264-a6d3-bedc1cdd5e1e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzExLTEwLTEtMS0xMTk5OQ_f49fd125-d2bb-467d-8abe-ceb019f67327"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i0205324a5c7d4615881636c0201fd64e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTItMS0xLTExOTk5_8234e77a-8c18-470d-a222-3cfa1269627a"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i8877fe5b26124a419df3fe7bdbc217a9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTQtMS0xLTExOTk5_28750fbb-5b42-44bf-a9fb-877573f155bf"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i650e54c23e864e5a9837d51c41b31a11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTYtMS0xLTExOTk5_6aa3caab-b2c8-49d0-b8cd-fa693ce78eea"
      unitRef="shares">11050</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ie08726f70e014e668fe8d3b22f627e3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTgtMS0xLTExOTk5_1657e782-b3e1-4a0f-876a-7d1cc129a2dd"
      unitRef="shares">3200</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ic05285b50bea41d4bb12c71770ac7c9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEyLTEwLTEtMS0xMTk5OQ_72827cf0-e768-4753-b0c9-e4b4c7932b41"
      unitRef="shares">22700</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTItMS0xLTExOTk5_713f45e5-6986-451b-90a8-2742277dee4b"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTQtMS0xLTExOTk5_7220ebc6-95fb-491e-92bf-a8d70f91f68a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTYtMS0xLTExOTk5_b8280919-36af-41c1-b9d9-832e26c1db47"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTgtMS0xLTExOTk5_7c80adad-8b70-439f-8037-242704054d47"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmNWNmNmZkMDBiYzk0YjQ5YTliZjdiMDA2YTVmNGZiYi90YWJsZXJhbmdlOmY1Y2Y2ZmQwMGJjOTRiNDlhOWJmN2IwMDZhNWY0ZmJiXzEzLTEwLTEtMS0xMTk5OQ_a95e1358-8132-494f-9ab7-b98e66d71e91"
      unitRef="shares">350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtMi0xLTEtMTE5OTk_52c48aa2-87b7-4fb0-a9ea-d37209725cbe"
      unitRef="shares">126400</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtNC0xLTEtMTE5OTk_02a17482-69a6-430e-b121-70599db4a217"
      unitRef="shares">129250</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtNi0xLTEtMTE5OTk_2713a117-563f-4a97-9384-08b38ffbefa3"
      unitRef="shares">117650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzMtOC0xLTEtMTE5OTk_0ea13fe2-5fe5-46f9-93be-9aa17942faa8"
      unitRef="shares">80000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctMi0xLTEtMTE5OTk_7825f436-5dd3-4f22-80bd-f10a65197e8e"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctNC0xLTEtMTE5OTk_ca2a2cb1-40fb-4b51-9f20-e8b7653ce083"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctNi0xLTEtMTE5OTk_e8864fef-7adb-42b5-951e-22e9bd4ef6e5"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzctOC0xLTEtMTE5OTk_58836a99-fce4-4895-9077-a419ba2febb9"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtMi0xLTEtMTE5OTk_7c76aacd-2f60-4d92-8996-9340527380dc"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtNC0xLTEtMTE5OTk_ae6bae17-3916-435b-8d02-fc7cab7872f2"
      unitRef="eurPerShare">14.46</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtNi0xLTEtMTE5OTk_881ffd88-774a-4337-a431-f82f51c01001"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzgtOC0xLTEtMTE5OTk_c3786e04-2d06-4937-9f2b-fa69eaa61cb6"
      unitRef="eurPerShare">15.93</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktMi0xLTEtMTE5OTk_b2043f08-20fc-46f8-84f3-6ff19e89448e"
      unitRef="shares">100567</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktNC0xLTEtMTE5OTk_09e1a2f4-cc11-4a8b-ab43-9ac2f70f2ee5"
      unitRef="shares">100274</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktNi0xLTEtMTE5OTk_998c8212-8b7f-4284-8cbe-067b8b1ff53d"
      unitRef="shares">99500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzktOC0xLTEtMTE5OTk_8d56d2d9-595f-4392-813d-2df802afc5e4"
      unitRef="shares">80000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTItMS0xLTExOTk5_cde51570-2a8f-4a53-a050-09e754e70816"
      unitRef="shares">333</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTQtMS0xLTExOTk5_83e42338-a256-451d-8be9-071a68937b26"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTYtMS0xLTExOTk5_03deadba-cc3d-41ab-bf33-72c4a9944447"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEwLTgtMS0xLTExOTk5_02646cb1-74f8-4b72-8ad3-92d83915f4fe"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTItMS0xLTExOTk5_3c929d86-2e49-48d3-921b-8c6945de06c9"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTQtMS0xLTExOTk5_912acbd3-c877-4fe3-b8dc-a918f7683423"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTYtMS0xLTExOTk5_3b42c5ae-27c2-47b5-b45f-a89de79748ee"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzExLTgtMS0xLTExOTk5_cf931fee-56a9-4b1a-8f29-a0915c79cba1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="id607143fbf804fcb95f3a7824923bd6d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTItMS0xLTExOTk5_b83346b5-c8f0-447d-a7d8-fd1e87a0f420"
      unitRef="shares">25500</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i6e7ec5c57a2e4b92b84497e7b79da2db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTQtMS0xLTExOTk5_87357b3c-940c-4b58-bc7c-61e62573ce8b"
      unitRef="shares">28976</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i15b60bdf71454ad2b8b8f960988c0487_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTYtMS0xLTExOTk5_9782a58c-aa1c-42d6-b627-c98f179040b6"
      unitRef="shares">18150</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i189db34738f54105b56656b53ef3d1c4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEyLTgtMS0xLTExOTk5_b77269b1-3574-440b-a755-5fed8225ede8"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTItMS0xLTExOTk5_ab58d00e-e485-4631-b760-cfcea65e9a83"
      unitRef="shares">350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTQtMS0xLTExOTk5_83eef242-2b8f-47d0-93a8-51ed67bd3cc2"
      unitRef="shares">1426</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTYtMS0xLTExOTk5_b55bbc91-51bf-430d-bae9-d45710e38f27"
      unitRef="shares">1350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNmUzOGE1NmYzYWU0YTgxYWU3YmQ3MTU2ZWI3ZWNhNS90YWJsZXJhbmdlOjE2ZTM4YTU2ZjNhZTRhODFhZTdiZDcxNTZlYjdlY2E1XzEzLTgtMS0xLTExOTk5_7117d434-c14d-423d-a4ad-a77456223cbd"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMi0xLTEtMTE5OTk_0bee9b14-f573-44ba-9fab-79f34bbb9e7d"
      unitRef="shares">52500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtNC0xLTEtMTE5OTk_4ae3a570-af9a-4851-a54a-c6fe1f8fbd0c"
      unitRef="shares">10000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtNi0xLTEtMTE5OTk_cac073fc-653f-4dae-bd12-f50358f04f90"
      unitRef="shares">14000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtOC0xLTEtMTE5OTk_5ad0384d-5458-4b59-83bf-c601a5c15c5b"
      unitRef="shares">26000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTAtMS0xLTExOTk5_15ee401f-95cf-4382-90cb-b13636be68d0"
      unitRef="shares">64000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTItMS0xLTExOTk5_aeaa5cbd-fb94-4520-b985-f3c46bf2ff36"
      unitRef="shares">6000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzMtMTQtMS0xLTExOTk5_c45ca7c1-5e16-45d4-884e-2e4d74c2e8a3"
      unitRef="shares">18103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMi0xLTEtMTE5OTk_ebe66902-9a3c-4d4a-8ee1-274c0a8d897c"
      unitRef="eurPerShare">0.60</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctNC0xLTEtMTE5OTk_62ace996-3303-49c0-933d-64aef7f7c081"
      unitRef="eurPerShare">2.50</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctNi0xLTEtMTE5OTk_2a3a784f-b049-4feb-bf9d-abffe85df109"
      unitRef="eurPerShare">4.87</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctOC0xLTEtMTE5OTk_3d57b8d0-5489-47e8-a9a1-3da5546a8897"
      unitRef="eurPerShare">4.87</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTAtMS0xLTExOTk5_9edbb6c2-71d1-425b-99af-9b73c4fed872"
      unitRef="eurPerShare">5.00</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTItMS0xLTExOTk5_9f4f91db-a26a-4079-ae1d-68b83f47798b"
      unitRef="eurPerShare">2.80</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzctMTQtMS0xLTExOTk5_840a3ba2-2658-471b-887b-2f3bad059c37"
      unitRef="eurPerShare">1.67</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMi0xLTEtMTE5OTk_2c70d402-9d0a-474b-a204-9482bf596425"
      unitRef="eurPerShare">6.00</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtNC0xLTEtMTE5OTk_0517db77-10f9-473b-a8f4-12f65349e0b4"
      unitRef="eurPerShare">6.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtNi0xLTEtMTE5OTk_beb4a4fc-9889-4262-9918-25ffd667c0c3"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtOC0xLTEtMTE5OTk_a924f94c-6e95-4bed-9d2a-bbbabba6bf6a"
      unitRef="eurPerShare">17.67</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTAtMS0xLTExOTk5_903ea879-d60d-470e-a66d-4d61cd1f4651"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTItMS0xLTExOTk5_df9064f0-de5f-44c0-b02d-b1191e084bc8"
      unitRef="eurPerShare">19.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzgtMTQtMS0xLTExOTk5_ca76e44d-9fba-473a-8aa2-09f5106a96cd"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMi0xLTEtMTE5OTk_47f7671f-f26e-4611-9499-ce5050fed200"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktNC0xLTEtMTE5OTk_b4571e6f-3c3e-4054-9a7c-6c9665eaa274"
      unitRef="shares">6000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i287ca2164109487e803ea58119f85b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktNi0xLTEtMTE5OTk_6522974e-fe4f-4d0b-b7d3-747bacb2fcc6"
      unitRef="shares">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i444894e06ef84e86916f0f43636239a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktOC0xLTEtMTE5OTk_72fd466f-d5f9-4d85-9647-6ce0ee8cd9ed"
      unitRef="shares">21000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTAtMS0xLTExOTk5_a4551017-f10f-40d1-a2c6-ae12b800a73b"
      unitRef="shares">64000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTItMS0xLTExOTk5_f75cecac-9089-400a-8496-8991ced53edd"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzktMTQtMS0xLTExOTk5_862d03d1-e28c-4f9a-b6a9-303cd9721791"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTItMS0xLTExOTk5_98961039-46a4-4d47-a67d-16f6a0da107a"
      unitRef="shares">22500</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTQtMS0xLTExOTk5_ebcb31a5-cc06-4dca-9c2d-8f69d35557a8"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i287ca2164109487e803ea58119f85b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTYtMS0xLTExOTk5_99636bbb-a697-411a-b6b1-60305a4b3059"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i444894e06ef84e86916f0f43636239a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTgtMS0xLTExOTk5_cde35096-5732-45d6-933b-1b8215de9143"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTEwLTEtMS0xMTk5OQ_ea0e58c9-43fb-4664-a2ef-71051d75e819"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTEyLTEtMS0xMTk5OQ_0b73062b-e673-4168-9198-8e4dfabcd502"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEwLTE0LTEtMS0xMTk5OQ_66007f1d-401a-4146-977b-28a1230cdc9f"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTItMS0xLTExOTk5_8c8765d7-568a-44d0-99d7-bcde13c7f9aa"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTQtMS0xLTExOTk5_953ef057-e38e-4e66-93b2-3162b7ff4c98"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTYtMS0xLTExOTk5_d46843e4-97a4-45f9-994b-0fce00f86ca6"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTgtMS0xLTExOTk5_d4b7bbc6-1455-4af1-bd5e-697519707fa3"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTEwLTEtMS0xMTk5OQ_7253df19-d5fb-4e49-84af-96213bdfb4be"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTEyLTEtMS0xMTk5OQ_a66fbb61-845e-4dc0-a41b-48675d2d5c97"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzExLTE0LTEtMS0xMTk5OQ_10e22ab1-37bd-4816-bbc8-f7fded7c7049"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i6b30f82903f44b5d81bcdfca5c57db77_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTItMS0xLTExOTk5_79e5f468-5afc-422a-bf57-7c1c64af4347"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="id80ebbb46eb64299bfbf12da7eb08344_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTQtMS0xLTExOTk5_f461d505-1090-40c2-8ca3-680a511ccdfd"
      unitRef="shares">4000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i287ca2164109487e803ea58119f85b0e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTYtMS0xLTExOTk5_04992af9-aa7c-459a-8fdc-54b6f2748ffe"
      unitRef="shares">4000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i444894e06ef84e86916f0f43636239a2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTgtMS0xLTExOTk5_d428d0f9-8058-43aa-8333-64d25aeb2dff"
      unitRef="shares">5000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ic15cc4f8cfe94884af5dec143cec0074_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTEwLTEtMS0xMTk5OQ_0121b3fc-6c80-426f-aa56-fc53a8cdd9a7"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="iac18bcb7a8e547b58905c1c5db99010c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTEyLTEtMS0xMTk5OQ_a9cc1c6f-1d13-4c58-9e68-35eac0f015d6"
      unitRef="shares">6000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ibabf9bb1fb1a49fbb1705b814228871c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEyLTE0LTEtMS0xMTk5OQ_7d9a6abd-1fc0-47db-b6c9-9e5bb06bc25d"
      unitRef="shares">18103</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTItMS0xLTExOTk5_13205109-7b01-4066-b92e-8b493e619923"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTQtMS0xLTExOTk5_073abc58-8cb0-4600-8a63-021d7d202d8e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTYtMS0xLTExOTk5_58363023-76d3-47a5-bac0-11640b5e32dc"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTgtMS0xLTExOTk5_7bcbcd77-237b-4794-b99f-0d4dcf1754e2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTEwLTEtMS0xMTk5OQ_b3b46db1-e1b6-4c6d-a3aa-892f503f31cc"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTEyLTEtMS0xMTk5OQ_b5c3eaa5-febf-49ab-93da-7cdd75496603"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjYjAxNmJlZjRmYWI0YTg1YTgzOGZjYjUyZGRhNDFkYS90YWJsZXJhbmdlOmNiMDE2YmVmNGZhYjRhODVhODM4ZmNiNTJkZGE0MWRhXzEzLTE0LTEtMS0xMTk5OQ_e04b20b3-852e-41b7-a993-6bc7c1aee1ee"
      unitRef="shares">18103</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMi0xLTEtMTE5OTk_eb35e3b2-8a50-4bba-84c7-daf2a38b9a69"
      unitRef="shares">18105</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtNC0xLTEtMTE5OTk_ca5110bd-5d40-46b9-a1d3-89e8da302dbc"
      unitRef="shares">8000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtNi0xLTEtMTE5OTk_e1fb9328-8bf2-4831-b7f4-129f5392c48d"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtOC0xLTEtMTE5OTk_f2520092-9e9f-4e0e-982e-d255d88e5194"
      unitRef="shares">28000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTAtMS0xLTExOTk5_ea4347d4-0e01-45aa-b479-6215b45b40c8"
      unitRef="shares">5820</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTItMS0xLTExOTk5_61453cdb-fb49-4693-ae91-b6d99ba0c43c"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzMtMTQtMS0xLTQ1NjE5_6457f4a5-0213-493f-8533-49aea330d9cf"
      unitRef="shares">18000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMi0xLTEtMTE5OTk_9bf9e925-a928-4c28-957f-6b853ec2bd28"
      unitRef="eurPerShare">1.67</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctNC0xLTEtMTE5OTk_7e840a19-1a68-402f-8c51-5f3c232d8b20"
      unitRef="eurPerShare">2.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctNi0xLTEtMTE5OTk_5493f300-a3bc-4ab3-8b7f-48b10d2be8ab"
      unitRef="eurPerShare">2.26</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctOC0xLTEtMTE5OTk_578c39ed-860b-4e5b-b9f5-15d381ef08ee"
      unitRef="eurPerShare">1.62</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTAtMS0xLTExOTk5_c4348678-8c5d-4a62-96ca-59069069119f"
      unitRef="eurPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTItMS0xLTExOTk5_dbad452e-95de-47e9-91a7-1f5244a1c03d"
      unitRef="eurPerShare">1.15</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzctMTQtMS0xLTQ1NjE5_ea687774-29cb-40a9-9a61-f078d7d438da"
      unitRef="eurPerShare">0.29</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMi0xLTEtMTE5OTk_f194a2ba-e62a-4609-80ee-973903f836df"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtNC0xLTEtMTE5OTk_ef8c9bba-ef67-4b1b-84b4-e21d194b6ab7"
      unitRef="eurPerShare">15.01</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtNi0xLTEtMTE5OTk_46b25176-1e2f-4f5b-86ba-d9929547d6bf"
      unitRef="eurPerShare">15.76</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtOC0xLTEtMTE5OTk_2a226218-8517-4a3e-8b82-2406fc012646"
      unitRef="eurPerShare">13.55</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTAtMS0xLTExOTk5_e50a28f6-1522-4522-8cad-80356c530c91"
      unitRef="eurPerShare">16.102</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTItMS0xLTExOTk5_c9caafaa-4c77-40c3-828b-bf17728c560b"
      unitRef="eurPerShare">11.66</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzgtMTQtMS0xLTQ1NjE5_383baebc-bdfe-4f20-8de8-3816bf2d7e50"
      unitRef="eurPerShare">6.59</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMi0xLTEtMTE5OTk_5a4b5d17-c1e8-46fa-ada5-0b1c2ba52942"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktNC0xLTEtMTE5OTk_5a2add9e-1f45-4d29-9d93-159b5d3794a4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5c32baad1d584e179d05334758196e37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktNi0xLTEtMTE5OTk_e68bd732-89c3-481e-a063-497e4864b600"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i185c5465e4f54321893449f2ed13c945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktOC0xLTEtMTE5OTk_84162917-9ffc-4bde-8acc-c6fd75e7f14a"
      unitRef="shares">28000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTAtMS0xLTExOTk5_f1daffe8-b15e-43dc-96bf-f2df32ee6427"
      unitRef="shares">5820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4a196703767045b4aeaf86e08026e973_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTItMS0xLTExOTk5_4f3cf2ec-a4f3-4fdc-b336-cef92cc1d203"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzktMTQtMS0xLTQ1NjE5_9ff82541-0e7c-4efc-8e9c-810d2bf1547d"
      unitRef="shares">18000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTItMS0xLTExOTk5_05883e08-6eda-4b7a-9b98-dc66c0c8c4fd"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTQtMS0xLTExOTk5_f4b145e5-bcb1-4eaf-bcaa-78b42412c38b"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i5c32baad1d584e179d05334758196e37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTYtMS0xLTExOTk5_19a45753-fb5a-45fd-a218-9fea71b79c4b"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i185c5465e4f54321893449f2ed13c945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTgtMS0xLTExOTk5_fac1fd49-bb43-4e92-834b-6c6818e5721e"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTEwLTEtMS0xMTk5OQ_40159b88-f719-4833-b320-0d6cbe4eb4e3"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i4a196703767045b4aeaf86e08026e973_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTEyLTEtMS0xMTk5OQ_68322c96-5329-4c12-a739-b49a910e9008"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEwLTE0LTEtMS00NTYxOQ_e8811443-cb29-4570-806f-52fe922f9189"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTItMS0xLTExOTk5_b5e42cdc-8e00-41c4-9ccf-ee844d4556d2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTQtMS0xLTExOTk5_b933fc1d-e0c3-4cc8-a230-631342463f2c"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTYtMS0xLTExOTk5_f3e7558f-b15b-494d-9061-5b2492f7b7e4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTgtMS0xLTExOTk5_eb0518fb-edc3-44fd-99fa-da0d04f36a7a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTEwLTEtMS0xMTk5OQ_72436c0e-5684-480a-85e6-3f712a8618e5"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTEyLTEtMS0xMTk5OQ_e2bb79d0-366a-45d8-a1be-9b595e5568ec"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzExLTE0LTEtMS00NTYxOQ_40db3d18-dd08-4d3d-881a-b6d7fd36bf36"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="id0da65f2ab874878b39ebf2ec076918d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTItMS0xLTExOTk5_2054082d-51fd-49c1-a18b-5053fb1f4ab6"
      unitRef="shares">18105</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i93dc071a53df4b658e48104f724a4d81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTQtMS0xLTExOTk5_dbb1f584-4ac8-403a-a371-6bcba781b27b"
      unitRef="shares">8000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i5c32baad1d584e179d05334758196e37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTYtMS0xLTExOTk5_7a050e0e-30ab-4b4b-a54f-67c154968965"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i185c5465e4f54321893449f2ed13c945_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTgtMS0xLTExOTk5_1d03222d-1d56-4a13-816b-2cd7f9cf5eef"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i1ec46661f19e44898198a21b96fcd9e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTEwLTEtMS0xMTk5OQ_a6d29820-033d-4609-80b1-43ee334be14d"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i4a196703767045b4aeaf86e08026e973_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTEyLTEtMS0xMTk5OQ_325380d3-f130-4467-8026-01a6d171962b"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="iffce4cb7839e46bf9d2e020d8104e671_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEyLTE0LTEtMS00NTYxOQ_5cdf8f73-e515-45ef-a2a8-12d68c08c268"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTItMS0xLTExOTk5_985539f1-1002-4540-9cfb-87c3f232b351"
      unitRef="shares">18105</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTQtMS0xLTExOTk5_122624df-c189-451d-804b-682236321739"
      unitRef="shares">8000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTYtMS0xLTExOTk5_359371e8-3948-4815-a5e0-757e12ecfbc6"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTgtMS0xLTExOTk5_ee9e7560-e041-4255-919d-79f64d1dea61"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTEwLTEtMS0xMTk5OQ_999e16ea-c241-42e3-b618-217460e846c0"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTEyLTEtMS0xMTk5OQ_97b70f6c-cb17-4749-b968-bdf7e5c4b588"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyZTU0YmE5NWZhMDc0NWRkYmJlODA2NzY0NjMwMmM3Yy90YWJsZXJhbmdlOjJlNTRiYTk1ZmEwNzQ1ZGRiYmU4MDY3NjQ2MzAyYzdjXzEzLTE0LTEtMS00NTYxOQ_f79a3a43-8f92-4b7b-a2fe-6473aa8c4107"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzMtMi0xLTEtNDU2ODk_cad231ac-5cb5-46a8-abeb-bd32b9511da2"
      unitRef="shares">48103</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzMtMi0xLTEtMTE5OTk_7bba09b9-a35d-4805-b244-968f801cb1c6"
      unitRef="shares">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzctMi0xLTEtNDU2ODk_b99dfe3f-b8a9-4e8c-889b-2372a0d57e30"
      unitRef="eurPerShare">2.95</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzctMi0xLTEtMTE5OTk_3f406213-13eb-4824-8be3-776f204894c7"
      unitRef="eurPerShare">0.68</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzgtMi0xLTEtNDU2ODk_ad528871-8e7f-4aa6-aac7-874b1f7a9171"
      unitRef="eurPerShare">13.47</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzgtMi0xLTEtMTE5OTk_deb7bcdd-b9bb-4630-afda-0e6c15bf0c6b"
      unitRef="eurPerShare">13.64</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzktMi0xLTEtNDU2ODk_45f66b5f-2711-42f1-8de6-5ef25242251b"
      unitRef="shares">14431</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzktMi0xLTEtMTE5OTk_2194c4b1-2c89-44d5-95cc-869d6d69a615"
      unitRef="shares">30000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEwLTItMS0xLTQ1Njg5_12b15a4d-a424-4d96-9bb7-01bdb537a6f6"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEwLTItMS0xLTExOTk5_66c6fe48-04d0-4295-93b2-27faa2f458fc"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzExLTItMS0xLTQ1Njg5_1313fc5f-0814-4e1f-90ca-b3e58b040cc2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzExLTItMS0xLTExOTk5_cdec2106-1d64-4d19-8917-66b6f630b708"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ib7d97c2e219d4ae29053a4b79902220a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEyLTItMS0xLTQ1Njg5_e8377187-8b69-42f7-8fdc-14fe637109db"
      unitRef="shares">33672</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i084aeefdb60241db94c5f459f1acd1e9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEyLTItMS0xLTExOTk5_98eb9645-d92f-4ebb-be4f-3906949e9550"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEzLTItMS0xLTQ1Njg5_c0bf0f96-87cf-42a8-80eb-280f8bc9164c"
      unitRef="shares">33672</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowZjRlZjAzM2JkZGE0ODczYTBmODhkOTUyNDA3NWNjMC90YWJsZXJhbmdlOjBmNGVmMDMzYmRkYTQ4NzNhMGY4OGQ5NTI0MDc1Y2MwXzEzLTItMS0xLTExOTk5_6359a5a7-d9d9-4b0f-aee2-b35dcec6ac2a"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzM2ODY_6fa377e1-6f7e-4b3e-879f-7fcb1a43ed76">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.559%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Pre-2021 stock option plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA &lt;br/&gt;2016-1 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA&lt;br/&gt;LLY 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;OSA &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;62,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;407,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/25/2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/23/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;06/14/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;05/23/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;04/11/2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10/24/2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/11/2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;02/02/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;11/03/2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;01/07/2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/06/2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/29/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10/24/2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;03/11/2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x20ac;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Number of options as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;4,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;52,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;28,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;500,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;387,456&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options as of Including options exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Number of options lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;9,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;13,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including options lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;13,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.754%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 stock option plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Type of underlying asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;New shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;571,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Date of shareholders' resolution approving the plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11/30/2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/28/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/21/2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contractual expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;04/20/2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;06/21/2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x20ac;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;491,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;120,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options as of Including options exercised during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Number of options lapsed or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Including options lapsed or cancelled during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;715,291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,583,806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;410,512&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,972,860&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;718,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;263,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;986,359&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;446,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,414,654&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total number of shares underlying grants outstanding as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;751,585&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;251,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;589,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;746,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,338,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMi0xLTEtMTE5OTk_c25a1121-da8d-49db-8e44-bfe77332c1b1"
      unitRef="shares">6400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtNC0xLTEtMTE5OTk_bd115176-241b-46bd-a34e-954fc847f31b"
      unitRef="shares">4000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtNi0xLTEtMTE5OTk_74328478-7a93-4a83-a6d0-6efc84bc48e3"
      unitRef="shares">3500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtOC0xLTEtMTE5OTk_58c9de1d-7527-4fb1-a9c1-b4731f05789b"
      unitRef="shares">62000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTAtMS0xLTExOTk5_ad9b9578-77e7-4d18-a1bd-9bb16f752488"
      unitRef="shares">37500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTItMS0xLTExOTk5_0a93d0cd-49c7-4d97-8d20-be2880bb7069"
      unitRef="shares">500000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzMtMTQtMS0xLTQ1NzY0_cad144a1-0a07-4b2b-aa5d-bdfb7815f069"
      unitRef="shares">407972</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMi0xLTEtMTE5OTk_7c5fec0d-b409-4095-a459-a143457b32ef"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctNC0xLTEtMTE5OTk_0a9e54f7-7fd6-424e-a02d-2b7f44890ea5"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctNi0xLTEtMTE5OTk_d195f2bb-5f7d-4a32-a8d3-33df0cd1d8c4"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctOC0xLTEtMTE5OTk_cde113c1-c76d-4fc0-8d78-9b032691fe4b"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTAtMS0xLTExOTk5_7b98d671-ffca-4180-a775-2bdc5817a8b4"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTItMS0xLTExOTk5_5438b699-d9f5-4fa7-a680-72c5ac546342"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzctMTQtMS0xLTQ1NzY0_9200fe0e-22a0-42cf-882f-72d2fa057c4a"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMi0xLTEtMTE5OTk_b2ee07b1-33f5-42a6-a3d4-50f4dcbb2127"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtNC0xLTEtMTE5OTk_87623cb9-5225-438c-9327-75bd49791147"
      unitRef="eurPerShare">14.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtNi0xLTEtMTE5OTk_9508bfa2-e8ae-46d7-84f7-25c0e93928d7"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtOC0xLTEtMTE5OTk_cf6d85eb-13c1-4a1e-b784-e79597cd5582"
      unitRef="eurPerShare">12.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTAtMS0xLTExOTk5_af7cc4a3-d146-4094-a434-88f12cd91d4d"
      unitRef="eurPerShare">11.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTItMS0xLTExOTk5_a4a9331d-c56a-4af4-94d2-3033386b414e"
      unitRef="eurPerShare">6.41</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzgtMTQtMS0xLTQ1NzY0_8469b37f-4466-46a4-9737-0275980abb75"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMi0xLTEtMTE5OTk_a2c4054b-6f91-4a90-a5c0-061191c7c7b0"
      unitRef="shares">400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktNC0xLTEtMTE5OTk_f5baa6a5-92ba-4543-9694-cad6d22841ac"
      unitRef="shares">4000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktNi0xLTEtMTE5OTk_8f481de5-6a62-46ea-8d13-c6a7c813e717"
      unitRef="shares">500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktOC0xLTEtMTE5OTk_5e0263ee-8343-495c-82f0-e4159aace8cc"
      unitRef="shares">52000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTAtMS0xLTExOTk5_50d0a33e-2f91-423a-b99b-7b281889612c"
      unitRef="shares">28250</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i41f34aacd8914d92858087d804274e6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTItMS0xLTExOTk5_a454d085-8b7b-4617-8eba-04ecca2c0266"
      unitRef="shares">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzktMTQtMS0xLTQ1NzY0_78a611b0-6022-4bef-a171-121ee1e5089b"
      unitRef="shares">387456</ifrs-full:NumberOfOutstandingShareOptions>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTItMS0xLTExOTk5_1d17febf-9455-4c73-9865-bc00cbddca5b"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTQtMS0xLTExOTk5_e2930953-5d68-46ab-9640-9b776fb7a304"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTYtMS0xLTExOTk5_24237b37-5921-4242-becf-30f8ecdb15cc"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTgtMS0xLTExOTk5_3a556e8a-e2b9-44fb-9bd4-0d2b19c0c987"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTEwLTEtMS0xMTk5OQ_1fb4f077-4a8d-41a4-83d5-7ce20f26669a"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i41f34aacd8914d92858087d804274e6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTEyLTEtMS0xMTk5OQ_f861f886-66b2-45ed-a965-b9d1409f4b43"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEwLTE0LTEtMS00NTc2NA_c8b4ca5f-c0ae-4e3a-aac7-8a98b94ac27d"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTItMS0xLTExOTk5_1cdbb5ed-b075-44fb-bb72-fd68e02b78cb"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTQtMS0xLTExOTk5_93141ef7-1d07-4184-81c1-84995ffea426"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTYtMS0xLTExOTk5_b56f8195-52a5-4c64-a557-70f674987af3"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTgtMS0xLTExOTk5_ffd07644-8979-4bb0-8731-93e827404ceb"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTEwLTEtMS0xMTk5OQ_d8b9053f-a164-46e1-afad-70460119fea3"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTEyLTEtMS0xMTk5OQ_977181ed-3a53-42d0-82a1-9f8f5c61ec22"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzExLTE0LTEtMS00NTc2NA_e1e6a2b4-6394-4f52-ba16-452453c198a6"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i792610cd47d74497aa1f7ab82c8af31f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTItMS0xLTExOTk5_9272a957-8896-498d-ab87-f9b6abb6d877"
      unitRef="shares">6000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ibb14a6fe101644f2853849ed9da8bc5d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTQtMS0xLTExOTk5_2c38f830-5295-4bef-ae63-261f9a56dc9f"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="if61ce7df74c8400ea1884c4ef3f4fe9b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTYtMS0xLTExOTk5_8242dab3-f1fd-417c-ac59-4e141ead8c20"
      unitRef="shares">3000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i6efe15242bc44621ad8fa904a5ae89df_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTgtMS0xLTExOTk5_f4004c13-a4a8-434d-b1b4-cd80cc96c8f5"
      unitRef="shares">10000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ieff82164675b4db0ae05af2af10c6d6c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTEwLTEtMS0xMTk5OQ_d35321e3-6075-4a61-972c-c475b418f246"
      unitRef="shares">9250</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i41f34aacd8914d92858087d804274e6e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTEyLTEtMS0xMTk5OQ_0a9cc41c-6fbe-4080-bd64-5aad07b7f0a7"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i534aabb6b4774e578e1faec31a145c88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEyLTE0LTEtMS00NTc2NA_cc527bc2-3bc7-4cfd-8c8c-078ea78c6c40"
      unitRef="shares">13253</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTItMS0xLTExOTk5_0fb28654-0900-4320-ad8b-f8cf75760ed8"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTQtMS0xLTExOTk5_46f5539b-a00f-47ed-9870-fe86b672e555"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTYtMS0xLTExOTk5_01d04e7e-d857-40e0-85bb-45e13705b40e"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTgtMS0xLTExOTk5_3c840c80-a4c8-4ea0-928f-051188bd5846"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTEwLTEtMS0xMTk5OQ_da6e03cb-2247-4c2a-a453-3f9864b096c9"
      unitRef="shares">500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTEyLTEtMS0xMTk5OQ_d7e88326-7fc1-46ef-a891-b4c81cfa1a5f"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpiMGMxNjdiZTlmYzk0MWZkODQ1ZDFkMTlhYzY2OWMyOS90YWJsZXJhbmdlOmIwYzE2N2JlOWZjOTQxZmQ4NDVkMWQxOWFjNjY5YzI5XzEzLTE0LTEtMS00NTc2NA_0cebe794-ddd1-4ce7-8679-a938deb2e86b"
      unitRef="shares">13253</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzMtMi0xLTEtMTE5OTk_bc8a1e5d-826e-4d36-9319-27f3cc59c31a"
      unitRef="shares">571200</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzMtNC0xLTEtNDU3OTQ_42a2f182-b6e9-4d61-aecd-7d261c3555f3"
      unitRef="shares">120000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzctMi0xLTEtMTE5OTk_c579d89f-344a-4320-aec3-ba9990532b95"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzctNC0xLTEtNDU3OTQ_ecee8262-12ac-4da6-af03-c762b2836d87"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i06d540fd0c3e4ab5876b141ba7dbd310_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzgtMi0xLTEtMTE5OTk_7406dec7-2c8d-4e5c-a411-48d0797fbed8"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i8519f82b32be4a26badf1a015f86a100_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzgtNC0xLTEtNDU3OTQ_9420be90-e394-4753-bf07-c0a37619780c"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzktMi0xLTEtMTE5OTk_69975631-c377-494d-be6e-89f67f2d6887"
      unitRef="shares">491200</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzktNC0xLTEtNDU3OTQ_b3a3db44-a483-4944-839e-87381dcbf760"
      unitRef="shares">120000</ifrs-full:NumberOfOutstandingShareOptions>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEwLTItMS0xLTExOTk5_ab633ed5-e055-49a1-bec8-066a6541ae74"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEwLTQtMS0xLTQ1Nzk0_c5556fe7-72b0-48b4-afaf-e82b2a88d103"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzExLTItMS0xLTExOTk5_87543b07-b7c5-408f-8209-42fc79fafabf"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzExLTQtMS0xLTQ1Nzk0_29d8b9a4-6d31-467a-b07b-f9136bb2431b"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i60258ef3e9154ad4963d258d41dfd8e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEyLTItMS0xLTExOTk5_0238144a-5747-4aaf-a1ec-26191c6a0c1a"
      unitRef="shares">80000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i18f5317d31b44749b1f183f90bf871b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEyLTQtMS0xLTQ1Nzk0_d01927b0-ed0e-44c7-8755-dc9ef8d59a0a"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="ib3414475b6e048eba55c7bd137b5db59_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEzLTItMS0xLTExOTk5_582ce1a9-edd3-4339-b6f3-888164a3a2e8"
      unitRef="shares">80000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i083165b820af42bf8fe67cd2a26bf604_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTozNTYzNTIwZWVjOWY0ZjNhYWRhYmQ3ZGQ1NGY4Y2JmMS90YWJsZXJhbmdlOjM1NjM1MjBlZWM5ZjRmM2FhZGFiZDdkZDU0ZjhjYmYxXzEzLTQtMS0xLTQ1Nzk0_5b62b005-1eb0-49d8-aa2f-4ad7607743d7"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtMi0xLTEtMTE5OTk_7661967f-1a7b-4eef-92fc-882ae69d2286"
      unitRef="shares">396250</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtNC0xLTEtMTE5OTk_21d22c12-3d08-4073-b545-e58c678c7a9c"
      unitRef="shares">6000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtNi0xLTEtMTE5OTk_78a13e9d-effc-4180-9271-d02c4ca5f2b7"
      unitRef="shares">438250</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtOC0xLTEtNDU4ODg_7c7a38e8-4904-44d0-bd8a-c9a31844c85f"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzMtOC0xLTEtMTE5OTk_b98dfdf1-35ee-49c3-92ed-555ecda76bae"
      unitRef="shares">362515</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtMi0xLTEtMTE5OTk_8beb5378-64d2-4920-8bee-0de01d905c04"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtNC0xLTEtMTE5OTk_07475abb-4480-4112-912e-473556da929a"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtNi0xLTEtMTE5OTk_e4563a40-6989-4ace-ad15-90addb77534b"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtOC0xLTEtNDU4ODg_6ae3664e-8641-4e83-a2df-42cb0b03d9dc"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzYtOC0xLTEtMTE5OTk_ee8f4f78-0e4b-43b6-8327-7017c8b5a2ad"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctMi0xLTEtMTE5OTk_1a89bd50-f8e3-4940-8405-9f67eed33066"
      unitRef="eurPerShare">0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctNC0xLTEtMTE5OTk_28ce5308-c56f-48d6-ac5d-7292971706eb"
      unitRef="eurPerShare">0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctNi0xLTEtMTE5OTk_8d9596da-d312-4e18-8566-aad1b0853af1"
      unitRef="eurPerShare">0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctOC0xLTEtNDU4ODg_96ebfc85-9063-4f3f-bb21-59ed1acde6ce"
      unitRef="eurPerShare">0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzctOC0xLTEtMTE5OTk_ced7d6e3-cc6f-44f4-8281-39eaa99eee4c"
      unitRef="eurPerShare">0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtMi0xLTEtMTE5OTk_1a29082c-4722-4cda-807e-ae124b2e0791"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtNC0xLTEtMTE5OTk_c611f377-1f83-4caa-8efc-928c781585af"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtNi0xLTEtMTE5OTk_006deb2e-36e8-4b7c-9f1e-b76803cc71fe"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtOC0xLTEtNDU4ODg_0c9df648-adb9-4507-8de6-c1f3a7c4dff1"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzgtOC0xLTEtMTE5OTk_592bf064-a2e7-4077-a728-d54921d87a11"
      unitRef="shares">360512</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktMi0xLTEtMTE5OTk_299f6d55-fa90-41fc-bc05-64b257f871d3"
      unitRef="shares">340583</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktNC0xLTEtMTE5OTk_9d1ad4d5-ccea-4343-af5b-004951f14840"
      unitRef="shares">6000</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktNi0xLTEtMTE5OTk_2a047384-6850-439b-85e4-2adc6de9ef05"
      unitRef="shares">369250</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktOC0xLTEtNDU4ODg_6b992816-953b-4698-b9db-b1b4e6afbd93"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement
      contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzktOC0xLTEtMTE5OTk_cef101e3-9224-41b9-920f-d999d8295208"
      unitRef="shares">0</nbx:TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTItMS0xLTExOTk5_b96feb4f-f893-48ab-861c-9d8164854225"
      unitRef="shares">24500</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTQtMS0xLTExOTk5_7648816d-6bd1-4462-a0ff-d6f53b98e4d1"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTYtMS0xLTExOTk5_65a2f0a8-c2e2-4d20-b042-ef0208cbb2a0"
      unitRef="shares">369250</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTgtMS0xLTQ1ODg4_f5eac470-4e77-4702-8db9-bafc4d5e85bc"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEwLTgtMS0xLTExOTk5_8cabdbb3-8dbe-4c58-a184-4fc7534e954e"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i1fd83d8297074b52a62595e69d21c63a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTItMS0xLTExOTk5_cadce269-bc91-4c52-9cda-d8e465d77077"
      unitRef="shares">55667</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i0dd068ca5156440caa5babda88800ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTQtMS0xLTExOTk5_2d268ce2-28c4-4f9c-ac49-04b21f0c6311"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i34704d55c6ee4757afcef3b7be3465b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTYtMS0xLTExOTk5_1688718d-3bad-4608-93c0-4f2995761412"
      unitRef="shares">69000</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="ia48a5f2ef4da4715821c24e44aa102ea_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTgtMS0xLTQ1ODg4_85474629-e16e-4fac-a74f-5e974dea2ebc"
      unitRef="shares">0</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement
      contextRef="i5ca07aabfb0141ccb67f650409efd173_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzExLTgtMS0xLTExOTk5_40412c65-ef0f-4eca-888a-cf85e418cba7"
      unitRef="shares">2003</nbx:TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTItMS0xLTExOTk5_9cde62ad-857d-466e-8018-25b88d267166"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTQtMS0xLTExOTk5_6e10da41-ce20-4372-83ba-01eef59119a4"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTYtMS0xLTExOTk5_76907b2d-52fb-45a8-81ac-5984c9ea8780"
      unitRef="shares">2750</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTgtMS0xLTQ1ODg4_8e96f7bb-911f-4d7f-beb7-493cdc680fe2"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTowMDA0MzBkY2Y0OGY0ZGJkOTg2NTY1N2U2ZDRjM2Y1Yy90YWJsZXJhbmdlOjAwMDQzMGRjZjQ4ZjRkYmQ5ODY1NjU3ZTZkNGMzZjVjXzEyLTgtMS0xLTExOTk5_73fd334b-1c78-4c80-8436-6ca86aa8b0d7"
      unitRef="shares">2003</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="iae6315b11bee49a48773726a45aedbb0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtMi0xLTEtNDU5OTA_42ae6a94-3117-4baa-a152-689f2430e840"
      unitRef="shares">715291</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic84c12e1bb5740c281fb000429621cde_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtNC0xLTEtNDU5OTc_2b33bf81-3b55-486e-aae3-8fcd4ec3d548"
      unitRef="shares">263251</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i3beab101ac5944d8996b39264b8500e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtNi0xLTEtNDYwMDM_e07ede2e-20f6-4259-8188-1f07b63185ae"
      unitRef="shares">1583806</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ie0979101cec4474688543efa006ec62d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtOC0xLTEtNDYwMDk_74249a6e-9f12-43a2-add0-d5f2245b4c76"
      unitRef="shares">410512</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToxNzNlZTUyYWUwMjQ0NGVmOWU5OTlhZThkZTExNzIwMS90YWJsZXJhbmdlOjE3M2VlNTJhZTAyNDQ0ZWY5ZTk5OWFlOGRlMTE3MjAxXzEtMTAtMS0xLTQ2MDE1_0dca6075-d04e-420e-9e5a-47cbc543a03e"
      unitRef="shares">2972860</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ic7fa7d04b56046148c18d80e87276dc9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtMi0xLTEtMTE5OTk_12672d47-ac2f-49bf-b2ce-ae0bd1e53eea"
      unitRef="shares">718767</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i525d2a7385a042e2ab94b0f0b95ba373_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtNC0xLTEtMTE5OTk_2470038e-184e-4cdd-b8fc-60e351eec2be"
      unitRef="shares">263028</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i5d069488ce3f445a8572023fb43124a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtNi0xLTEtMTE5OTk_0d46e545-67e2-4876-b45e-bfb20ebe2bed"
      unitRef="shares">986359</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i15a8434290bb4198a83ded0ca18c27a8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtOC0xLTEtMTE5OTk_54ce2b53-734e-4891-87f9-f3369361a960"
      unitRef="shares">446500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo5ZDRhNDRiZjM5NDI0NzAzYjUyNmU5Zjg1NDkwYzgwNi90YWJsZXJhbmdlOjlkNGE0NGJmMzk0MjQ3MDNiNTI2ZTlmODU0OTBjODA2XzEtMTAtMS0xLTExOTk5_145ea7ae-7dbf-4ef9-85e7-972b5599ef2b"
      unitRef="shares">2414654</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i8ef3caf9891b4a16a8cbd88faa3b6b39_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtMi0xLTEtMTE5OTk_8e99fab8-a959-45a2-8f3e-bb7bc311d3f5"
      unitRef="shares">751585</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i4483ef3c39a64c83b928490f95c78902_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtNC0xLTEtMTE5OTk_84de9917-f54c-40bb-bb74-0e75b4581847"
      unitRef="shares">251028</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i1ccfbb0da249487aaffb44ac5cf9b866_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtNi0xLTEtMTE5OTk_d4de47d2-4d38-438d-bf6f-9b02c1ccd79a"
      unitRef="shares">589150</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="ia09f2bb3b6114c268acacc4f0ebce171_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtOC0xLTEtMTE5OTk_da5c50b0-54c8-421d-a351-f5b52021f498"
      unitRef="shares">746250</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo3ZThmODJhMjQyMDc0ZTliOGVhYjYzNjYyZDZlYmRkNS90YWJsZXJhbmdlOjdlOGY4MmEyNDIwNzRlOWI4ZWFiNjM2NjJkNmViZGQ1XzEtMTAtMS0xLTExOTk5_ac0469c9-14b4-4e62-ad0a-8d46cda6d0da"
      unitRef="shares">2338013</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIyODg_b3b9e3c7-1105-42ef-9794-6859dfd4ec3b"
      unitRef="eurPerShare">40</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <nbx:NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzIzNDg_a9a5ddc0-8828-4914-b960-4f9dbd72e534">P20D</nbx:NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNjI_78a05b15-0673-4e0b-919b-0f0f6a2a82fa">The probability of meeting the performance conditions for the 2016 BSPCE, BSA and OSA performance plans was reassessed as of December 31, 2021. As a consequence ,  no new instrument became issuable.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.49&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2012-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44.3% - 47.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5 - 7.30 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.84% - 1.22%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 04-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 08-2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 09-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5/6/6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;61% - 62% - 61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59% - 62% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 61% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5/6/6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSPCE 2017 Project&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.008%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2012&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.26% - 0.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58%-58%-57%-58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5/5.1/5.3/5.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2015-3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.6 &#x2013; 9.6&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.25% - 0.91%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016o-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016p-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2017o-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.7% - 0.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16.102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.7% - 0.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9.8/9.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.16% - 0.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.13%/&lt;br/&gt;-0.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;BSA 2021 (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;44&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.077%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2018-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19% / 0.141%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.74%/-0.69%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;AGA 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.63%/ -0.59%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,366&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,202&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,320&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMS0xLTEtMTE5OTk_ebda7097-d8ae-4468-938c-bd4dcddb7717"
      unitRef="eurPerShare">5.26</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMi0xLTEtMTE5OTk_f6834a7b-9b70-428c-94ba-0351d24bc552"
      unitRef="eurPerShare">5.26</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMy0xLTEtMTE5OTk_7d6bede7-396d-45a7-a85e-d2d29dc4d09b"
      unitRef="number">0.41</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowODUwMGUwMThlNDU0ZDM2YTkxY2Q2ZWMzZTkyZDQ4MF80_73e283e2-7cbb-4362-8ea3-c6a856f676e1">P3Y5M26D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNS0xLTEtMTE5OTk_4338cc0e-087d-4579-a4ef-a856230d52e3"
      unitRef="number">0.0020</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNi0xLTEtMTE5OTk_00cb4926-ed82-4fae-b62e-96d1821667df"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i21b55d08407543a8b83088ef05a9752c_D20120504-20120504"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtNy0xLTEtMTE5OTk_6f074ea5-6807-4ffe-9e21-4d270f5c65cf"
      unitRef="eur">307000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i131da624a9f34a0ea29bf0fb2176cb5f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtOC0xLTEtMTE5OTk_0f373ac2-f42f-49c0-a41c-2a1c977c54f3"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3e6efed0beb6459b810d1467e0c1183b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtOS0xLTEtMTE5OTk_692b80e7-c87f-4264-be97-f5f814511013"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie9862c8deb0544ba80cef9d729d58100_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEtMTAtMS0xLTExOTk5_7a2547e2-d9f3-4bb0-ae39-e72ad8447c5b"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMS0xLTEtMTE5OTk_ec566c4b-1071-4c77-bb48-824daff06e1f"
      unitRef="eurPerShare">6.65</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMi0xLTEtMTE5OTk_67745d1d-9b4a-49ea-b10a-a349832dc8ee"
      unitRef="eurPerShare">6.63</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MjNlYmY1NmMwYzY0MTU5YWQ4NGE3MTUxODczMDA5YV80_e1d3a2ed-3313-44e3-9e4b-ac167a1fd329"
      unitRef="number">0.443</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ie2919f18751144b78569c4161f2e947a_D20121218-20121218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MjNlYmY1NmMwYzY0MTU5YWQ4NGE3MTUxODczMDA5YV85_70cfca25-3c90-49cc-bfbb-6d8fb7dc3e69"
      unitRef="number">0.476</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i59ef69bbeb80421eb92fd0f71ad1d8e4_D20121218-20121218"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZTk4NmYwMGVhYzU0YjY4YmZjZWI2ODc2YmE5MGM2Nl81_cdba2dcd-d137-475e-8b2f-8f29c514ddc9">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i0f5b8beea7b64bb286271b8eb038177b_D20121218-20121218"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZTk4NmYwMGVhYzU0YjY4YmZjZWI2ODc2YmE5MGM2Nl8xMA_31372c36-17cc-445b-a9fc-4e4bc7c2a88e">P7Y3M18D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i9db6a7676d934d6fa99b3d38c667a496_D20121218-20121218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4ODc3ZDcxNjMzZjQ0NWVlODUwNzIxYjNkZGFlYzM1Yl80_af90ea84-d578-4750-9f89-606456458d1b"
      unitRef="number">0.0084</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ie2919f18751144b78569c4161f2e947a_D20121218-20121218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4ODc3ZDcxNjMzZjQ0NWVlODUwNzIxYjNkZGFlYzM1Yl85_517bfe5f-84eb-4a54-bfcb-48df03cec2b7"
      unitRef="number">0.0122</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNi0xLTEtMTE5OTk_937d4632-86f1-49c1-b321-0cb64603bb1c"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItNy0xLTEtMTE5OTk_b830ef5e-a8bb-4ae3-af2e-52087259a745"
      unitRef="eur">288000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i454d0bee95bb49c4b8b19a46a8d765ed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItOC0xLTEtMTE5OTk_e549b913-333e-47a3-8237-f6aa306dd5b8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i9ece9101dc1b41da87e28fee0a3e1d19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItOS0xLTEtMTE5OTk_31f43b64-670e-46f0-a7a4-de865d68dad0"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ic47716d92fe342deb87045fda3d7f2c5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzItMTAtMS0xLTExOTk5_6bb99f03-0a78-4467-a1d1-9fa57b08d020"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMS0xLTEtMTE5OTk_3da0c6d5-372d-4502-b869-15688a0442f1"
      unitRef="eurPerShare">6.30</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMi0xLTEtMTE5OTk_c3f51e32-7652-4fb0-8438-a81927c5af8a"
      unitRef="eurPerShare">6.30</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMy0xLTEtMTE5OTk_995b290e-6343-483f-b025-feb63db1532b"
      unitRef="number">0.56</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNC0xLTEtMTE5OTk_65257dc0-c2a8-487b-9fa7-3ea610b1fe4d">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNS0xLTEtMTE5OTk_ba57e8c5-8a51-4192-8c73-447bcf0ac6cb"
      unitRef="number">0.0090</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNi0xLTEtMTE5OTk_ff0fb485-2b4a-4d14-8eb6-db3c3aa7c377"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ie9f04bf3732f4644b2a575d5eddff21a_D20130410-20130410"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtNy0xLTEtMTE5OTk_97c2c5fd-618e-4c80-8949-f8f4568fe672"
      unitRef="eur">167000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i9a43074ca66449b4b97de195d8ec4408_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtOC0xLTEtMTE5OTk_9827f0c3-0bc8-4233-9d51-4a130dc68476"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib461318901ed4fe7a3b3fd7d2eb455e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtOS0xLTEtMTE5OTk_b0e51164-b7ff-411b-841c-a5c81f0b2991"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="idfbec539f6234dc4ac97bed76d788c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzMtMTAtMS0xLTExOTk5_fb57f079-8453-49ff-b1f7-b945f35dcf0b"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMS0xLTEtMTE5OTk_3fd9f755-735e-479c-90d9-eae2779aa005"
      unitRef="eurPerShare">6.30</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMi0xLTEtMTE5OTk_e264edeb-68b3-4620-9dcf-7039e9431020"
      unitRef="eurPerShare">5.92</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMy0xLTEtMTE5OTk_a8e9c990-52f4-4b38-98e8-84e4b92b21a6"
      unitRef="number">2.56</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNC0xLTEtMTE5OTk_0007f1d7-10db-4f82-9931-263cefea70cd">P7Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNS0xLTEtMTE5OTk_14d09a75-ce6c-4e99-b989-0025cabd1f14"
      unitRef="number">0.0090</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNi0xLTEtMTE5OTk_3d268a16-89f4-42f4-be07-acbb62697d7f"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i042226127b5340ababdd5ec7f0476f19_D20130828-20130828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtNy0xLTEtMTE5OTk_10d19822-cb46-4fc8-bacb-0909f4d5e239"
      unitRef="eur">152000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="if1d97a8e48b645658e82e45ef862dee1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtOC0xLTEtMTE5OTk_ea978c79-4885-4f57-bf09-b4c4b54e6217"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i218535f19cea498592b94ff4a7972768_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtOS0xLTEtMTE5OTk_4bbd5f17-08f1-4727-8b23-8b671847c65d"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3d6ba050064a421289ccace20cb9938f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzQtMTAtMS0xLTExOTk5_c7ed3251-1bcf-4e72-92cb-1b4e1ac888ff"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMS0xLTEtMTE5OTk_0bb7717f-6a54-4c4f-baa9-14961d9cf96c"
      unitRef="eurPerShare">18.68</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMi0xLTEtMTE5OTk_f1bb174a-a9d1-4b87-8e60-214bc0c516fb"
      unitRef="eurPerShare">18.68</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMy0xLTEtMTE5OTk_13953e40-dfb7-4c99-84e9-df356de4e55c"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i529aac24770b44a3a7b925fc089a42f7_D20140916-20140916"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl81_905aefe4-19fa-42ac-83fc-50eec5e92d25">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="iea55eafbda0d41bfa15182895fad5428_D20140916-20140916"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl84_b090995d-a033-44cd-9500-b8ae9a737d3f">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ibb6b9590e1084b969feeba3744fac7fa_D20140916-20140916"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphYzYwNmUwYzRlM2E0YWJiYWNjZTk4NGNkODhhYzViNl8xMQ_cfd838ee-bf84-46ff-a176-33f26b8ea8cd">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNS0xLTEtMTE5OTk_a940a152-661c-4963-acf2-18baa0248913"
      unitRef="number">0.0064</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNi0xLTEtMTE5OTk_1e637773-9e2c-42ba-b986-0aab8e2bea6a"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i2944026f2b0344aa938cc31b562e7278_D20140916-20140916"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtNy0xLTEtMTE5OTk_a191c9a8-5c4f-47b0-b29d-5b35b8761229"
      unitRef="eur">932000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0d66f9d9e6b64e7ba9e037bc1a2ab0f8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtOC0xLTEtMTE5OTk_bbae3d28-02c5-4adc-89c2-0741091d86cf"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2ccfa604cbe44d4d98d5e9f728269760_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtOS0xLTEtMTE5OTk_617a7786-7642-4719-b0a4-6f155022eec0"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4d028643a8ae49cb91443fcb6667aff4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzUtMTAtMS0xLTExOTk5_3e8444f4-f4a9-4d1a-99e6-dd305eb0be3c"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMS0xLTEtMTE5OTk_3c6a2009-bc00-46d7-871a-be63fca4d40b"
      unitRef="eurPerShare">18.57</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMi0xLTEtMTE5OTk_2f2f61dd-5acf-41b6-9e33-0d9ec434a9a2"
      unitRef="eurPerShare">18.57</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i0cfb0e0616fc451db5120b69a2855aef_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV80_d980e6e0-c890-4f69-81a3-c38c11d22559"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ieae0ae0f0de24a7a8c7909960e7edc97_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV85_be0d7f5d-9427-473a-8dc7-dae31f1b501f"
      unitRef="number">0.62</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i31d2e2aabd79424b9ff15157a58c2098_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4YjE5NTM2MDQ1YTU0ZjE4OTcyNTg4MmNhMDE5MTk2YV8xNA_38a1d38d-f734-42b3-8491-09e79b781345"
      unitRef="number">0.61</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i1a361874f01d45dfb381dace0aaa6dca_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF80_c2505451-aefa-4fd4-a0a5-bc9802c896c9">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i3149d9f29e6948679668c8902a58d1d1_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF83_91d950ee-47e5-4cd7-9c02-cf76cac7bc06">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i6508d90ca7934d8a8c8c500934137220_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpkMDM0YTE0ZWY5NWM0M2E1YWQ2OWUyNzQwNDVjOGE5NF8xMA_a4b832df-8bef-473a-a6dc-b88337a2bb85">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNS0xLTEtMTE5OTk_322acd54-8ae1-417f-9cb2-64fe0d97a87b"
      unitRef="number">0.0039</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNi0xLTEtMTE5OTk_a9121fbb-18aa-4055-90ef-5bf864239b4e"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i7766a627e16e48f5a62212db0b794f46_D20150210-20150210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtNy0xLTEtMTE5OTk_9e7aa809-9f96-4fdf-be05-dcf4f90984a2"
      unitRef="eur">50000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i150cd4858a9f4806a5868c5ce046d7de_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtOC0xLTEtMTE5OTk_b5d2e5ec-f0ce-4677-8a8a-5b744e1f2a8f"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6e87da98f07b44ad87b1cd8ca78dd53b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtOS0xLTEtMTE5OTk_9dd7f5c3-ed6f-4fee-bc86-0805cf9330fa"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i84c141fe66774426ab927cbccd1a4268_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzYtMTAtMS0xLTExOTk5_14e78173-4845-4c76-8783-f1db4c9c0487"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMS0xLTEtMTE5OTk_7270a770-f9e8-4ced-a649-d9142e674467"
      unitRef="eurPerShare">18.57</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMi0xLTEtMTE5OTk_59d68d13-3900-4e15-8784-d30c83f19d7a"
      unitRef="eurPerShare">18.57</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i1cedf3438b9b490a99a1bdf2d42f0411_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl80_66f6fbbf-231c-47b6-b679-6a3aedf6392b"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i3b9cdfe23729475a93bb7b74d4885975_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl85_d1e1f187-ad63-4029-902f-89a85c41dcd6"
      unitRef="number">0.62</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i2c4b9ce0de6e4e6eb552cbf8fa6227a2_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphZDVkOGQwOGRlZTQ0ZTdlYjdkMjM5NTJmNDZmYjg1Yl8xNA_6ddc72b7-8ee4-4d17-a8a0-227b0667c5d8"
      unitRef="number">0.61</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i9f5242dc069c466caf5e1c7529c26b46_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV80_355e8018-94dd-490d-b53a-b859156bb31c">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i5b7e511fc9c144a38119eb439ec44e9f_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV83_529138a5-040c-47ab-8f79-78237c85f92b">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i207651a4998445daab53f905e5da87aa_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjozNTIxZjkzYTk4MGM0NzIzOTkxNTgxZDRkZjg1YTk1ZV8xMA_f740b5f9-84e2-44f4-962e-37fb88b8733b">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNS0xLTEtMTE5OTk_1348224d-e20f-42b6-afa5-2379654022e6"
      unitRef="number">0.0039</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNi0xLTEtMTE5OTk_285c753b-9775-42e4-b85c-ed5dd9934930"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="if9b4078b070542dea9fb4efd6ebc7f3e_D20150210-20150210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctNy0xLTEtMTE5OTk_a77c3253-a95a-4e8c-ae4b-5f6f9c8af3c8"
      unitRef="eur">650000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0567406eef544202ac9f21ae3e4dedaf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctOC0xLTEtMTE5OTk_851a4009-d8c7-45aa-bd4e-aa387fc7599d"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="id2278b3270e54cd99a22052840e92c05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctOS0xLTEtMTE5OTk_60d14b94-5854-45da-a379-68a775239002"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i91baa8cdfc354286a5178aa94929c1b0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzctMTAtMS0xLTExOTk5_c6118eb9-7319-4b41-84e6-754caf4061f6"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMS0xLTEtMTE5OTk_e64821ac-0c20-48ab-be4d-9055a06cb063"
      unitRef="eurPerShare">20.28</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMi0xLTEtMTE5OTk_1dcc59ea-126c-4ae8-bf4b-6513913ed354"
      unitRef="eurPerShare">20.28</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i21f6266a6261424cb3701521e5a643bb_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV80_d7949285-b1d5-46ed-9cbc-d51ba8c7ff4f"
      unitRef="number">0.61</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i39b343cc43b1488fbabbaadbf30a57c5_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV85_02cfd3dd-1cf3-4943-baa5-be0b0a0cb9f2"
      unitRef="number">0.62</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ia126f4a85d5f4a6c89bd72f4726e6886_D20150610-20150610"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDIyYzAyYTg5ZmM0OTYwODk1NjEwZTUyZWIzOGVkNV8xNA_47ea91e8-0578-4994-9f1a-f4a9c8479e5e"
      unitRef="number">0.61</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i4349ffd9c31d4d72afb2c3d5558ef0ff_D20150610-20150610"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF80_59a82fa6-27cd-4941-8d19-bb629000f2c6">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="if88984bd12b3495c88bd5037ff1a7d37_D20150610-20150610"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF83_fc3b4b36-3c6c-4412-9d42-b71e3c58ca15">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i4a26e567a53c4044a0c3a2ccdad0fc3f_D20150610-20150610"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMWRhZjAxNTdjZjQ0MDFhYjBmMzRlMWY3YjJmZGY0NF8xMA_c9412590-a9d6-4f7e-a744-159d7ee95f87">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNS0xLTEtMTE5OTk_2ae2a8c1-7f96-4b0d-80b5-a8c1737ec855"
      unitRef="number">0.0056</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNi0xLTEtMTE5OTk_c7e1366d-5258-4029-b4b8-6c6abec31bd3"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="iddd0952b0f2346d48d1240e7b7b9b428_D20150610-20150610"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtNy0xLTEtMTE5OTk_e7aaf729-7c6d-4109-b147-f3f330d70817"
      unitRef="eur">483000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ifc77df5bebf442b39b8c727aca9b4ab9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtOC0xLTEtMTE5OTk_d1fa83a3-7d62-4612-b993-a0de239287a9"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2bcd03966a8a4479a8cbd6a167893270_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtOS0xLTEtMTE5OTk_e673f54b-b1cc-4a22-93dc-ea23270e5d01"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia1b746c0ab7b412ca2b2dcbaaa72a86a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzgtMTAtMS0xLTExOTk5_9d7212ac-8278-4e82-9b2f-a990d063c664"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMS0xLTEtMTE5OTk_8f2bfeaa-0f0d-464a-8e56-740dc507dc8c"
      unitRef="eurPerShare">14.46</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMi0xLTEtMTE5OTk_5dbc3027-e930-4ddf-89d6-addafa08d57b"
      unitRef="eurPerShare">14.46</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="idf7662da67c64289867d340b367149ab_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M180_04c498ff-b752-4562-b007-b68af61605af"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="iee4d7149ad404f968cc08e4aef7c0075_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M185_e54dc30b-9052-45d9-aaf9-c94e0f1a3fcb"
      unitRef="number">0.62</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i9b964e599c664b8cab5e656560b104ce_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphODE2YzdhMmEwYTk0ZWFmOTVhYzdkMjY1Yzc2YzU5M18xNA_7c9af69c-4f97-40aa-9f3b-c8432cc8811e"
      unitRef="number">0.60</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i0a861384c2b240cc81036e74e3cc65b5_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF80_582293b6-a0de-4f65-93d1-42a3cb22db12">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i774ea0f18ade47cc86a9a59b81faa563_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF83_1d960b84-e75c-43a1-8956-694295255636">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ie2fc173db3ba4df1afee089ed2af09e3_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowM2U1NWFhNTE1NjU0MTM4ODgyYzY4ZjMxMzdlZDA2NF8xMA_4b291d83-a54e-4e55-beb4-5f944448a36a">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNS0xLTEtMTE5OTk_774301f7-de2b-456a-84b5-622343e0ddac"
      unitRef="number">0.0032</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNi0xLTEtMTE5OTk_4548504b-8cab-4cc6-a3c4-63a4c8fa7938"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i67f6fff75fbb41b2a803b9710513cd0c_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktNy0xLTEtMTE5OTk_4ffffd0e-2e5d-4c89-8577-027f7592abc2"
      unitRef="eur">1080000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i30d417b93bee43c780915df01c38d487_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktOC0xLTEtMTE5OTk_87f73265-dad6-4580-a87a-d558c7cbcb65"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="id2b41add39c641428eeb18e53a36b901_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktOS0xLTEtMTE5OTk_8c237094-30de-446e-8d46-55d32d5a5a4d"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0bf0cda381de45b4a117fd8996ba9e9d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzktMTAtMS0xLTExOTk5_4b76c4f1-f01f-45f3-b16b-5768f5778b9b"
      unitRef="eur">10000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTEtMS0xLTExOTk5_4751f126-6b2e-4796-ab85-b3a3b995c3fd"
      unitRef="eurPerShare">14.46</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTItMS0xLTExOTk5_f034d403-8b68-4b60-9642-c0b1dc17656d"
      unitRef="eurPerShare">14.46</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTMtMS0xLTExOTk5_2f87fb71-769a-4a00-8017-3432c093a803"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTQtMS0xLTExOTk5_be56310f-db08-4277-9ed6-0d36c0895372">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTUtMS0xLTExOTk5_d2a5ea40-ce6c-48bd-b763-7bbe7290b8d5"
      unitRef="number">0.0019</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTYtMS0xLTExOTk5_3aefbad5-3756-46f3-9ae4-07cbd3387a82"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ifd97519c1c214f078632873aa1cb6752_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTctMS0xLTExOTk5_f5cc24ce-c080-450d-9466-c43ac3e825cd"
      unitRef="eur">1212000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3a6930365513487f8ea12d07a61a2d1d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTgtMS0xLTExOTk5_a1ce347e-e891-442b-b22b-293817f8ede2"
      unitRef="eur">32000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i847617a0623e4f41a7bb7506d0ec32e0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTktMS0xLTExOTk5_1d6cfe8b-4392-48e5-ab88-605988621d8f"
      unitRef="eur">99000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i329a6fa2c67c4bac97fd56ac1b9a7dfb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEwLTEwLTEtMS0xMTk5OQ_af395fda-57e9-4a67-8e60-d1b9fa516e36"
      unitRef="eur">79000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTEtMS0xLTExOTk5_d306a970-f844-4725-8e9a-eed34294406c"
      unitRef="eurPerShare">15.93</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTItMS0xLTExOTk5_80f8c97a-5da3-4919-8447-93a99af51b9c"
      unitRef="eurPerShare">15.93</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="id634b4f13485463ab1d7a2134ff28cf9_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfNA_90388b00-bb8a-4aeb-ac4c-423c23705041"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ie0299ef3d2b54641bfbea01d292269b4_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfOQ_9a813720-8558-4445-bfe3-993df57fc690"
      unitRef="number">0.61</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i7e8dd4ad27014b778bbf05ed702bbdc5_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTMtMS0xLTExOTk5L3RleHRyZWdpb246ZmI4M2EzYTM3NWQ0NGEyZTk0MTQ2MTI0Y2QzMjZjZDJfMTQ_f19e1ce4-cb3f-47fa-b5f6-fff7d567d521"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i813aa1603ff64691b4654fe399d47cc0_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfNA_9a994c8b-3ae5-4e8a-8ed0-e284b8294b51">P5Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ia0363e72665149cf92fa348abb499297_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfNw_65b3b0c4-12d7-4850-bfd5-89c5602706cb">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ia8f32dfa54044567a9386587ef6bf4fd_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTQtMS0xLTExOTk5L3RleHRyZWdpb246Nzc5OGMwZDYwODkzNDA1YjgyNDJlZjYwZWUwZTdkZWVfMTA_45d52024-9952-4de2-a6e6-bba031658897">P6Y6M</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTUtMS0xLTExOTk5_968cc644-e2d5-4ca3-b702-be72cbc0f555"
      unitRef="number">0.0023</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTYtMS0xLTExOTk5_d16ad01e-e0d1-4801-8ed1-2319cb1223fd"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ie8ea0dca207444b6a14ca81f3742e3be_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTctMS0xLTExOTk5_34eff566-8fec-4c5c-8f25-52a518286bdd"
      unitRef="eur">1000000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia0a88cf9ad7446dcaac27107c76c58f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTgtMS0xLTExOTk5_bca8fcc3-36d4-471a-a6c5-eb16fc8dfe9c"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8e6fe4ace1c746f6a6dfb0b6c92cabd4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTktMS0xLTExOTk5_91fbf827-f2e5-4fbc-9f14-2fa455462b44"
      unitRef="eur">8000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i01c0ec932c6f41ba9b4f8939121b36b7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzExLTEwLTEtMS0xMTk5OQ_6d4c3adb-9609-49ab-8549-cb0239dd5810"
      unitRef="eur">86000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTEtMS0xLTExOTk5_b65d5e9b-d122-4431-b043-8ca1ffeec2a1"
      unitRef="eurPerShare">15.93</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTItMS0xLTExOTk5_679179fe-81e7-4e73-9d64-6885b4fbbf68"
      unitRef="eurPerShare">15.93</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTMtMS0xLTExOTk5_b47a857e-0c70-46d7-ae4a-4a2e43bf751e"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTQtMS0xLTExOTk5_2d8beff8-5a0b-4be2-ac0a-5d2200309525">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTUtMS0xLTExOTk5_ba9a898f-9c21-4688-825a-4e5d1a38cbc3"
      unitRef="number">0.0011</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTYtMS0xLTExOTk5_47d7bc16-6260-4613-801b-d8a3d9ed7576"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i80e4592fbfd14066969841772071af84_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTctMS0xLTExOTk5_45941e84-59cb-4910-990c-3212dcbfb81f"
      unitRef="eur">622000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i1692f600b5eb407b9403006411ba40d6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTgtMS0xLTExOTk5_4a22f2f4-80ba-4c9c-83eb-4f2a33192987"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3f5763ec171d43428a511bc2c311c914_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTktMS0xLTExOTk5_a3eef298-e64d-4612-8d6b-88c5b228bd0a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie0a7ff6bb25f4c1ab55f70225cff85dc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEyLTEwLTEtMS0xMTk5OQ_b85b2f6b-b3dc-4110-a4ae-e9f7413814b7"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTEtMS0xLTExOTk5_169c98ab-428e-4ca5-8114-8699bf93345c"
      unitRef="eurPerShare">15.93</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTItMS0xLTExOTk5_daf7c423-8cd9-4437-aa4e-230231f92765"
      unitRef="eurPerShare">15.93</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTMtMS0xLTExOTk5_4ccaa89c-8883-4d68-97a0-e1f6b10fe4af"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTQtMS0xLTExOTk5_32daf879-0c45-4892-a94d-5ad3901a4568">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTUtMS0xLTExOTk5_a296696b-0ba8-4d35-81cb-d1999ad9c0b1"
      unitRef="number">0.0011</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTYtMS0xLTExOTk5_408e8bc3-06cf-4d62-96a9-9397fde43f27"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i2c71468be56c45e99adce81f572af018_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTctMS0xLTExOTk5_771f6972-86b7-421c-bc50-6a3995085c25"
      unitRef="eur">627000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="id25b3aadb19a47b8a27e9c20333b98fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTgtMS0xLTExOTk5_a694ad16-5aaa-45d5-956e-8561a8bb826e"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i40c149f4b43742fa97ae7461ae0cbcaa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTktMS0xLTExOTk5_848111b8-7b63-4444-a225-60b1b74298e3"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="if1544d3f2c5e499b98da7226782ca2be_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzEzLTEwLTEtMS0xMTk5OQ_59655132-5621-4938-9ea4-81cee1708276"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTEtMS0xLTExOTk5_b50fa101-7774-48f9-b98f-481a1224f815"
      unitRef="eurPerShare">15.93</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTItMS0xLTExOTk5_c8bee2ec-bfb6-404a-b5bf-a45b63c1cabb"
      unitRef="eurPerShare">15.93</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTMtMS0xLTExOTk5_68690259-6fb1-4d08-bed5-483001372b15"
      unitRef="number">0.59</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTQtMS0xLTExOTk5_42ea369e-3371-4c99-a562-cd3a30b3a787">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTUtMS0xLTExOTk5_8cb13781-9283-48bb-b49a-50ad14345c13"
      unitRef="number">0.0011</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTYtMS0xLTExOTk5_4d9d7c3b-c22a-4416-a6eb-2bafc68ab9f0"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i1052c68eb87344759bbe00721613fcc1_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTctMS0xLTExOTk5_65bfaae5-154c-4210-b3ac-9b0215515a7d"
      unitRef="eur">94000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i03089c18f63c4ac8a3762b696eec3b39_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTgtMS0xLTExOTk5_e642f66b-ac15-4546-a75d-2be475d3839b"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="icefaa359b31741c8b95cb9bf016ef953_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTktMS0xLTExOTk5_7801b070-4db6-4b8f-a9ff-bfb081f94fe8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i7fa4bf2f58fa428f93dd6a7a167a2f65_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE0LTEwLTEtMS0xMTk5OQ_1ffb62a9-50b1-43ef-bc96-e51d070c9955"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTgtMS0xLTExOTk5_56171961-0dd4-4386-b5be-e30b59a9c0cc"
      unitRef="eur">32000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTktMS0xLTExOTk5_1055a2b5-9ed9-40a3-a4a6-9861b1b3a01c"
      unitRef="eur">107000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTo1OTkyYmIwNDJmMzE0N2U5OTY3OGJmM2Q1Y2UzNDM0Zi90YWJsZXJhbmdlOjU5OTJiYjA0MmYzMTQ3ZTk5Njc4YmYzZDVjZTM0MzRmXzE1LTEwLTEtMS0xMTk5OQ_45546b99-87e5-45fa-a258-0072de000ad4"
      unitRef="eur">175000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMS0xLTEtMTE5OTk_88923181-6fc0-48af-a23b-8f962d5c664a"
      unitRef="eurPerShare">6.00</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMi0xLTEtMTE5OTk_8e9d1336-d126-4faf-95aa-a5584d56ca50"
      unitRef="eurPerShare">6.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMy0xLTEtMTE5OTk_912b097e-c25e-4fee-9c60-b86da0974bc7"
      unitRef="number">0.49</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNC0xLTEtMTE5OTk_50dfb370-c229-40a7-8bb8-46945fe59516">P10Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNS0xLTEtMTE5OTk_d71afbf2-0ba8-4630-957f-efe910b866f7"
      unitRef="number">0.0096</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNi0xLTEtMTE5OTk_f5d5bf1e-09da-44a7-957e-915169312dfa"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ib8509869803a4544b04f73038ac3daf9_D20120504-20120504"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtNy0xLTEtMTE5OTk_9121add1-1814-487b-a2a9-8eb5d68f0827"
      unitRef="eur">183000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib85cad7b845b4d56aab31cb343f33021_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtOC0xLTEtMTE5OTk_c407277a-1f79-4c6e-a932-968125645458"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i1ec42d3a605745c684dbb7167d63c05c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtOS0xLTEtMTE5OTk_ac13fd97-94b3-447d-8712-266a2df8b8df"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2ae9590b9fe34d0fb673e82af470816c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEtMTAtMS0xLTExOTk5_a5a44002-020b-41a5-83c5-487b13bd3ff8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMS0xLTEtMTE5OTk_e4303044-c5c9-4924-91a5-54ed548d72ae"
      unitRef="eurPerShare">6.30</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMi0xLTEtMTE5OTk_f4d9f324-48fb-4d00-a03b-e483f2b818a1"
      unitRef="eurPerShare">6.37</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMy0xLTEtMTE5OTk_6e91f1dc-e43e-48d7-9eaf-c63ec810f5bf"
      unitRef="number">1.56</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNC0xLTEtMTE5OTk_84e20ba9-9cb6-4bc4-a5cb-2900bb9fb7ad">P6Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNS0xLTEtMTE5OTk_1f74f847-d6b3-46dc-b29a-c4e61e58412b"
      unitRef="number">0.0090</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNi0xLTEtMTE5OTk_9d238a0a-1540-4f9d-ad7e-03858c39a8c2"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ic7f654804005436cb50f2932eeb50225_D20130410-20130410"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItNy0xLTEtMTE5OTk_cc98003f-1d38-4cbc-8495-bf1f2f0991d9"
      unitRef="eur">1000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i78e26a224e474ffb99418761b34ca069_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItOC0xLTEtMTE5OTk_8fbda852-1780-46d5-888e-f878b41166f8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i64d7535fdcaa43ce9a69ee9d90456576_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItOS0xLTEtMTE5OTk_71f3bcca-929d-4b47-a687-47d4cd5e183c"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i15bc4af9395b4f90b4d7b6e26b0c54be_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzItMTAtMS0xLTExOTk5_7d6ca16f-b175-4380-89e9-68cc45f3842f"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMS0xLTEtMTE5OTk_47f6b1b9-7e2d-42ad-9323-219d75ed2a7f"
      unitRef="eurPerShare">18.68</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMi0xLTEtMTE5OTk_f1ff3cde-c07b-47d3-8837-663eed22c974"
      unitRef="eurPerShare">17.67</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMy0xLTEtMTE5OTk_e3fb1f26-d8d7-49ee-8de5-5127d2a64212"
      unitRef="number">0.57</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNC0xLTEtMTE5OTk_4c2fbe71-1bce-4335-a747-60d714b75bed">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNS0xLTEtMTE5OTk_e6378689-1a59-435c-a229-3be4e4ed0e3d"
      unitRef="number">0.0041</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNi0xLTEtMTE5OTk_4e870f99-11b0-48a0-8d83-ba718bd3ec1e"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="if7f9fdfbb9e24d228a6a7bbc453e7e6f_D20140916-20140916"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtNy0xLTEtMTE5OTk_2306ef69-5e08-454a-96ad-d41b1db7a55d"
      unitRef="eur">0</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8ab5d6d7d9804892a6908fc081095f62_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtOC0xLTEtMTE5OTk_5aa1599b-edce-41b7-bf3b-2fde286e09f7"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5433efadd0ae413f9f2c5ab481f5160e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtOS0xLTEtMTE5OTk_b3e94b47-883d-41e7-a2dd-05e72c65d450"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i702ec3ead1cd4f79b60cc12b87ee7e11_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzMtMTAtMS0xLTExOTk5_f5baf3e9-4d7d-49ea-b5e3-4e35c34939ea"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMS0xLTEtMTE5OTk_382fba65-d0cf-416c-af48-777a9503be24"
      unitRef="eurPerShare">17.67</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMi0xLTEtMTE5OTk_67e9459f-56cf-4a32-8336-eb5d31971a83"
      unitRef="eurPerShare">17.67</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMy0xLTEtMTE5OTk_7824a9ab-acc4-4a96-b930-7cd47d0c28c8"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNC0xLTEtMTE5OTk_607f434f-bb7d-496c-9c6e-b3fb202a0b93">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ifa0befb495f44c12ba65c30bf98111ac_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZmNmNzIzNTgzZDY0YjFjYWZiZmMxODYyMmNkMTczOV80_7c852b97-1f47-41a6-a3cf-532b7e311b35"
      unitRef="number">0.0026</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i52c574e42a78453ca42bf37f9baff97a_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoyZmNmNzIzNTgzZDY0YjFjYWZiZmMxODYyMmNkMTczOV85_bce46d84-3989-4f04-ae6d-87213a9ad9e7"
      unitRef="number">0.0027</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNi0xLTEtMTE5OTk_8454b429-9793-4d91-b7b5-0298207668eb"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i50859b6af2ef4e108f9817ce50e70789_D20150210-20150210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtNy0xLTEtMTE5OTk_05aa149e-af2b-449c-999a-8e7767e082e6"
      unitRef="eur">63000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4445e7cbebc44a48b32005f6620cb5fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtOC0xLTEtMTE5OTk_2a09e29a-2c95-4bca-8d3f-57cd26bff1fd"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4e1c90fbe3974c148fa944c5b2f85baa_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtOS0xLTEtMTE5OTk_d29f6667-cf97-4660-9504-5c048dff77e3"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i1c7eb6413b784b03bfd43acb963cb132_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzQtMTAtMS0xLTExOTk5_eea6bf86-24a9-4df9-bf42-47a1ad6db64a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMS0xLTEtMTE5OTk_30a150fd-cb6d-4d1c-a2bc-8455e942ec52"
      unitRef="eurPerShare">17.67</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMi0xLTEtMTE5OTk_8d565f84-2e75-4c3b-a1b2-4e73ad624fe0"
      unitRef="eurPerShare">19.54</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i473116fa095c422aba3d6c699591faec_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV80_370b6c4c-c897-4ddb-9f61-9cb4a821de34"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="if70f79e4689d4c54bb89ab61ff89be6b_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV83_6f862962-a451-46a2-83aa-c3101e1b4805"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i67dd5d3865134117a9b633b2f3f00560_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV8xMA_f022853e-e852-4efb-9fe8-e59dd5be7235"
      unitRef="number">0.57</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i9f1d34c3fdac49f49c878cd386025fdf_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjoxZDNlNzI3MjM1NmI0OGJhYjUxZTY3ZTUwMTdlYjU2OV8xMw_8ebe2c01-a874-4bb0-b7b6-87951b148b55"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ibc916f578f474fecb4f9f2502dbc7c53_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl80_6e0681ae-e73e-4680-a0fb-e03a749eaafc">P5Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i7a8b1058bf864a27b1cf4a2fe6482f13_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl83_2f18a057-afbb-4509-817c-64e4daa98a74">P5Y1M6D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ide4f2071f6814b1e98aebb47c96b9621_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl8xMA_580978e1-910f-4002-9c67-cbdc3d4deaae">P5Y3M18D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ic807dce5e3d345bcbc42d29872af83fb_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNDdkYmIyODkxNzk0ZjNlYTkyZTgzOWYzYjA1ZGNkYl8xMw_5e5bb7d5-21d2-40f8-a8ae-e29e126d8cb8">P5Y4M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNS0xLTEtMTE5OTk_a863a780-748a-4420-94b6-8f2008aecad1"
      unitRef="number">0.0039</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNi0xLTEtMTE5OTk_9c27cb03-ac7c-4996-89c1-721157450ea8"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i15cbbdf0fbf54bc79f4d3daa083b2cd7_D20150625-20150625"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtNy0xLTEtMTE5OTk_b081fee9-7e9d-49fb-afe8-07ec053206f2"
      unitRef="eur">16000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="id7ea1268150748fba93569448532c0ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtOC0xLTEtMTE5OTk_ba9d4de7-5f6d-418e-98ba-2778cd8696e4"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i46f02e3e649341a69b26677a6a0e2e2d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtOS0xLTEtMTE5OTk_378908f0-09ee-4e57-820c-5b13bc48b103"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i985db50e042a4e9c97fffbb93177626a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzUtMTAtMS0xLTExOTk5_25e3af93-cb32-43fd-8269-e2aefefb357a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMS0xLTEtMTE5OTk_9b72be5e-1d45-486e-86d6-4df8a25114ff"
      unitRef="eurPerShare">19.54</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMi0xLTEtMTE5OTk_00a49564-1695-4678-9107-9de7d25650b1"
      unitRef="eurPerShare">19.54</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i2749bb6daaa74679a776487c8f281567_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1ZjEyNzgzYjI4YjY0NmMwODBmZDZjNWRjM2FkODRjN180_d5f0b0fd-9029-439d-af4e-31b33f6ec61d"
      unitRef="number">0.58</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1ZjEyNzgzYjI4YjY0NmMwODBmZDZjNWRjM2FkODRjN185_a25ac251-7346-41e1-a7fc-58ff08236594"
      unitRef="number">0.60</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i207347ba76db4b1193a91409ae7c99f1_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMWMxOGQ4YWNlMGM0Zjg0ODJhYzkzMzVhNzIwZWNhZF80_cb47ae95-605e-4139-b95a-b5344cf95ccf">P4Y7M6D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i3d07ad7bcbd0459cbefcedfd8f8f334d_D20150625-20150625"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMWMxOGQ4YWNlMGM0Zjg0ODJhYzkzMzVhNzIwZWNhZF85_67b56437-f01e-4043-b388-6a23729aa552">P9Y7M6D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i2749bb6daaa74679a776487c8f281567_D20150625-20150625"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMzcwNTNlNTdjMTA0ZWMzYWUyYjMwZjQ2NjE5ZTkwOV80_85da8915-b65a-45e7-b5bb-3cff4ac16d4d"
      unitRef="number">0.0025</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i2c3172c3fe9642ae8f23f80f73e8e02b_D20150625-20150625"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMzcwNTNlNTdjMTA0ZWMzYWUyYjMwZjQ2NjE5ZTkwOV85_e2c56e64-2910-49db-a1a0-483b7c0d3666"
      unitRef="number">0.0091</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNi0xLTEtMTE5OTk_1826cb38-234a-4afc-87b6-598abc245e53"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ib903dfdf892b4397ae52dc4c5c2b4a3a_D20150625-20150625"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtNy0xLTEtMTE5OTk_b316339c-ee41-4930-868b-59300c7a4f95"
      unitRef="eur">284000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i9ad3ad6506054110b14315fd4c99143f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtOC0xLTEtMTE5OTk_0ffde8bf-fcea-4bda-a26f-d4facf61ff65"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="if4472b998b8a4b09ba041270bec8b07b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtOS0xLTEtMTE5OTk_0d930a41-f1e5-4bff-a6fd-3d857ce8cdc2"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4e0d58d5db0f4384894e4a99e7d095a6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzYtMTAtMS0xLTExOTk5_07939f81-2510-426f-8a61-f52f123eefd8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMS0xLTEtMTE5OTk_7fb4191c-c195-4fa7-9a9b-b3c8c38931af"
      unitRef="eurPerShare">13.74</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMi0xLTEtMTE5OTk_5a76f959-465b-440c-9ae3-3f262b4c3ea2"
      unitRef="eurPerShare">13.74</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMy0xLTEtMTE5OTk_27ac0b1a-43cb-4105-a755-a4ee32d720f1"
      unitRef="number">0.57</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNC0xLTEtMTE5OTk_c66a203e-b273-4998-a069-5c665fbdf900">P2Y4M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNS0xLTEtMTE5OTk_99c8f3d5-994a-4fa9-8875-8e6cf253d352"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNi0xLTEtMTE5OTk_2070fa0a-f698-4ff1-8804-d150104380b5"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i9913fadb11d74b1e993b792fb5c2ca9e_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctNy0xLTEtMTE5OTk_6d363960-57a3-46d9-9e7e-79d8872200ee"
      unitRef="eur">37000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0f6596196957458f8ce683ec4b289c52_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctOC0xLTEtMTE5OTk_5f532bf7-83c6-4556-b1e6-4ada8476db53"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6e6b9424288f466c8a47cebae0ec48a7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctOS0xLTEtMTE5OTk_91de4f3d-96a6-4cb2-b3bc-9cffae089537"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4a9a5316762943d8affcd949d696ec10_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzctMTAtMS0xLTExOTk5_40ac6514-8d6b-4152-894e-d104d22dc469"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMS0xLTEtMTE5OTk_1f637120-e3f6-477a-a87a-89eadcd47406"
      unitRef="eurPerShare">13.74</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMi0xLTEtMTE5OTk_34d1a378-61fc-4b1a-9459-d755761eae61"
      unitRef="eurPerShare">13.74</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMy0xLTEtMTE5OTk_2e47876d-3d99-48c1-82c3-3959d92ab6e8"
      unitRef="number">0.57</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNC0xLTEtMTE5OTk_6286b8ee-4288-411e-9a93-a9ddd2e6ddf2">P2Y4M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNS0xLTEtMTE5OTk_f94725b3-3fab-4b43-a696-5fe7dbf2c5f0"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNi0xLTEtMTE5OTk_d116a3e7-d298-4682-85dd-ca17e1496ce6"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i8b5515c8bf3e4256a08e7e795df3e20f_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtNy0xLTEtMTE5OTk_ad802485-36e8-4dc6-8df4-0cfa244b900d"
      unitRef="eur">143000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4c61f0c2ae7a4fa2800b1634710c8cf7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtOC0xLTEtMTE5OTk_4574fdd5-e0cb-4ff7-99b8-f9c009bfca54"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i433bcdf7285544c9bc5810b1f42b26a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtOS0xLTEtMTE5OTk_1a005c0e-70ef-485f-90cc-e98741118815"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i7b3ff9b9323446e5971e03c82d1e528a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzgtMTAtMS0xLTExOTk5_34aa0ac6-546f-4edc-b39b-c3067208ae34"
      unitRef="eur">-41000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMS0xLTEtMTE5OTk_14cf8173-9d61-488d-a2ac-a681deb54724"
      unitRef="eurPerShare">15.01</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMi0xLTEtMTE5OTk_3cd94234-fad8-41fc-b1e3-0d9ac93454f8"
      unitRef="eurPerShare">15.01</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMy0xLTEtMTE5OTk_d0007f02-7bfb-4eb6-ac47-021aacaf84b4"
      unitRef="number">0.57</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNC0xLTEtMTE5OTk_1c4b96e6-61ac-4bbc-b826-3f99638f00a9">P2Y4M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNS0xLTEtMTE5OTk_acd6f7b8-8c17-41c4-81f8-c5575d08dde3"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNi0xLTEtMTE5OTk_9b53f44e-ed9c-4b59-a310-3b53a1d9d9bc"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="icacb1b92a41446d5ab9ac3d1b302f5f2_D20161103-20161103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktNy0xLTEtMTE5OTk_b8a33541-285c-478a-bed7-475a230d0297"
      unitRef="eur">0</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i1112922487994275ba7f128834f46d02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktOC0xLTEtMTE5OTk_6acb1050-ba46-4d85-a6e5-46ed05671b2a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3eca82cb5047415f90b7efe4a10e7317_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktOS0xLTEtMTE5OTk_948aa8f9-7560-447e-81d4-1cb36cb74c63"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i34873da26ebb48f083c0f122691b5ad1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzktMTAtMS0xLTExOTk5_73b6db7d-a158-4e80-a0a7-3e1a826dad03"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTEtMS0xLTExOTk5_943de179-5e8c-4340-9ce9-2e12fd121657"
      unitRef="eurPerShare">15.76</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTItMS0xLTExOTk5_5190b4e5-1a2b-4a78-a0e6-9faacaf4c70a"
      unitRef="eurPerShare">15.76</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTMtMS0xLTExOTk5_dac2ad52-09c1-4a18-a0c3-9b5d501a4080"
      unitRef="number">0.33</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTQtMS0xLTExOTk5_820f4a2d-2bac-43bf-b00f-ec251ef01d9d">P2Y4M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTUtMS0xLTExOTk5_5bdecec7-027c-46dc-8c5d-3638a8736e71"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTYtMS0xLTExOTk5_875ebc86-df42-4d29-ad39-9e498d55e0f6"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ibecdc76da5fa40a994907db8522646b2_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTctMS0xLTExOTk5_0a268770-b43e-4455-a00c-2c6bffc0e89c"
      unitRef="eur">0</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i852871309f8a4f10a651705ef8f508d2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTgtMS0xLTExOTk5_4892fb8b-d0cd-4989-99ca-f7bfd6c423fd"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="iabec141a2b994b80b7d8f9c182ea01af_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTktMS0xLTExOTk5_1de45634-0546-404d-b02a-e54ace1b1e93"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie75d48a141ae4d8fad1403660910f20d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEwLTEwLTEtMS0xMTk5OQ_7bd763a3-0672-48b3-ab18-489a429f76e7"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTEtMS0xLTExOTk5_60b34b24-21f5-4e3a-93c9-cb0d5a2b014e"
      unitRef="eurPerShare">13.55</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTItMS0xLTExOTk5_90d16038-6218-465e-92cd-fb0937d17e8a"
      unitRef="eurPerShare">13.55</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTMtMS0xLTExOTk5_c486a0c5-b57f-4f7f-acd8-67ec368de0b8"
      unitRef="number">0.38</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTQtMS0xLTExOTk5_1ec6f68f-3056-49ca-8e76-d35df3da3295">P4Y9M18D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i6aabc8c23a414a9db5e4f5a8bc2f1f48_D20180306-20180306"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTUtMS0xLTExOTk5L3RleHRyZWdpb246Y2NkNjFiODM3ZTlkNDc3NWE3NzgyMzM5YzQzOTk5NDVfNA_98925c29-6761-4d73-bbe5-637aed21d5aa"
      unitRef="number">0.007</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="ic15526fdee1e4d91b1d5060f8b0f7568_D20180306-20180306"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTUtMS0xLTExOTk5L3RleHRyZWdpb246Y2NkNjFiODM3ZTlkNDc3NWE3NzgyMzM5YzQzOTk5NDVfOQ_aec72197-4dd2-44e0-8ad8-36bd5a5e76cb"
      unitRef="number">0.001</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTYtMS0xLTExOTk5_279c8679-3844-4bd7-83ca-3b7a000de076"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="id242bd3f2bad41c3905c5f2665c48955_D20180306-20180306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTctMS0xLTExOTk5_8afc4987-3469-4914-84e6-c22e63155f04"
      unitRef="eur">2000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6e837a1a6d1345e4bbc909cb933b4694_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTgtMS0xLTExOTk5_69bbf0bf-d7a7-4a01-aa5f-a08e65236aa8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ic842508dfcc549caa3953140c12e7710_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTktMS0xLTExOTk5_d4ca5a33-7f5e-40bf-aaeb-88c5035e5aa5"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i48621182e8c349318f629a81af122a57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzExLTEwLTEtMS0xMTk5OQ_2749f5c1-62e2-4f12-863a-78809819daa1"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTEtMS0xLTExOTk5_4552eebf-8840-447e-b801-391581085921"
      unitRef="eurPerShare">16.102</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTItMS0xLTExOTk5_613dc95d-23ec-49b7-8169-0215be449bb4"
      unitRef="eurPerShare">16.102</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTMtMS0xLTExOTk5_9e264a17-5547-4c00-a488-7ef968df919e"
      unitRef="number">0.38</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTQtMS0xLTExOTk5_23e70b5f-edb9-4a5b-9cbf-96f2160062a8">P4Y9M18D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i1d75b447af424ab48bcfec52ab34781a_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTUtMS0xLTExOTk5L3RleHRyZWdpb246ODg2ODA2MmM2MmJkNGEyNWI5NGMwYjdiYzY3M2RkZDFfNA_53c21cd0-e363-4c93-8ae9-7a802d2061d3"
      unitRef="number">0.007</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i5f33f50e592545199d2ce53e53f832e8_D20180727-20180727"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTUtMS0xLTExOTk5L3RleHRyZWdpb246ODg2ODA2MmM2MmJkNGEyNWI5NGMwYjdiYzY3M2RkZDFfOQ_2807a999-8532-497f-9b51-bf986216aac5"
      unitRef="number">0.001</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTYtMS0xLTExOTk5_8c24bb98-21d4-4852-a10b-796129154feb"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i6353fadf817f4d359aa46682fa7459dd_D20180727-20180727"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTctMS0xLTExOTk5_0d063233-4546-4d99-be37-c431852374ce"
      unitRef="eur">1000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia2b5709907b0401a9dd46a4c352faf26_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTgtMS0xLTExOTk5_1a542a29-55f9-4d45-83d5-ad79f94ada49"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i09df6772a877464aaef8a472647e85c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTktMS0xLTExOTk5_112485c0-d859-4ae3-9ee3-c649b30abfe8"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i62055563f69f41f7a159c6147a4b0329_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEyLTEwLTEtMS0xMTk5OQ_bf1f931d-6d41-4a8d-8f0c-f2e7422c07fc"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTEtMS0xLTExOTk5_7006f2ff-cc6a-4038-b339-336c8c6c378c"
      unitRef="eurPerShare">11.66</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTItMS0xLTExOTk5_c68135b5-781c-4fc2-a758-0c3c74b82f00"
      unitRef="eurPerShare">11.66</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTMtMS0xLTExOTk5_27b7fa13-b308-4615-8ea7-379b51364f32"
      unitRef="number">0.37</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i89b752f6985348a1aa563e64204c8eb8_D20190329-20190329"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTQtMS0xLTExOTk5L3RleHRyZWdpb246YjAwOTE5NmI5ZjJmNDQ1OGIzNDMyNWI2MzA4NDMzOTdfNA_67847376-b382-41c5-863a-56d4ae3fe65d">P9Y9M18D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i4cecda26bbe64fd28d73f2e4da6b44d3_D20190329-20190329"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTQtMS0xLTExOTk5L3RleHRyZWdpb246YjAwOTE5NmI5ZjJmNDQ1OGIzNDMyNWI2MzA4NDMzOTdfNw_25173115-16c0-46ac-8f8d-5f355f8b5dbf">P9Y10M24D</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i9710c7a719da4648bd568199fecfdacd_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTUtMS0xLTExOTk5L3RleHRyZWdpb246YjJhYzdhNmQzNDE4NGVkZWE5ZGY5NGM2MTRiNDRjZWJfNA_a8d4c235-aa77-4d2a-a57c-a7571cada0c0"
      unitRef="number">0.0016</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i14e94260ccc24cbe9513a3b50f37537a_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTUtMS0xLTExOTk5L3RleHRyZWdpb246YjJhYzdhNmQzNDE4NGVkZWE5ZGY5NGM2MTRiNDRjZWJfOQ_b64a9d2a-bcfa-49ca-b493-0dc90321f4bd"
      unitRef="number">0.0050</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTYtMS0xLTExOTk5_c2f38950-7327-447f-b8f0-b9f83fe66b0b"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i63094f49f9314743aa30aa5674f4671c_D20190329-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTctMS0xLTExOTk5_9315eec7-d2cd-42ae-afb6-84280fee8081"
      unitRef="eur">24000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i934217d99b564cd898bba1870f16acd3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTgtMS0xLTExOTk5_25abcf63-20c4-426f-a578-16c22860f969"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i29cf2477c5574499aa4da392a0d0be7c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTktMS0xLTExOTk5_69c8937a-0fcb-4e9e-a79e-4b9ea4387058"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="iaf10e5b531374a0e9d6f2b724723372e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzEzLTEwLTEtMS0xMTk5OQ_3ea8c838-fd5c-4953-a714-efb1203d61ae"
      unitRef="eur">24000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTEtMS0xLTExOTk5_10a80366-e179-43dc-abf2-f92952057583"
      unitRef="eurPerShare">0</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTItMS0xLTExOTk5_93d4f913-7079-4fa6-9ee2-bafb2eadb16f"
      unitRef="eurPerShare">6.59</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTMtMS0xLTExOTk5_95e26b82-03cd-4283-9834-cd0644ff7f59"
      unitRef="number">0.38</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTQtMS0xLTExOTk5_91d146c3-d392-4726-be52-ece764784556">P10Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTYtMS0xLTExOTk5_de1cc263-6155-4666-8ef6-1b0adac695b2"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="iea27b8bf74854847b5c27e9ec66876e7_D20200317-20200317"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTctMS0xLTExOTk5_378b33af-8aba-43da-8f53-96e6b6f8e463"
      unitRef="eur">19000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i90cae536d7304635a280e0661eeb9d94_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTgtMS0xLTExOTk5_44b6b2fc-e655-46e3-ad74-91f7ca6fbf51"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i7043f75a85d244aeaede0edc201c5482_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTktMS0xLTExOTk5_0520c030-4a18-443e-84c8-c11fc5210032"
      unitRef="eur">19000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="icaf550bcce0b41ffa51ebe138b5a4a4b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE0LTEwLTEtMS0xMTk5OQ_8e9f6923-09cb-4b17-904f-1665def8635f"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEtMS0xLTQ2NDgw_796884f1-630f-4114-8173-4156775acb3a"
      unitRef="eurPerShare">13.47</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTItMS0xLTQ2NDg4_54679b10-860c-42b6-b99d-e0477d5bac63"
      unitRef="eurPerShare">13.47</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedVolatilityOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTMtMS0xLTQ2NDk2_7538da98-078b-46d0-bcb4-28f069d766b5"
      unitRef="number">0.3910</nbx:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTQtMS0xLTQ2NTAz_e84a8ef9-ceac-420b-9fef-f69014f55d93">P10Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTUtMS0xLTQ2NTEw_6cf87f03-c44b-4ba4-9feb-7f57df946dbd"
      unitRef="number">0.0027</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTYtMS0xLTQ2NTIx_6b5ec54c-9c1f-467a-8a06-5ba2e9378262"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i97e958a626c14173b7a27c1b4c7ea283_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTctMS0xLTQ2NTI4_c43e96bb-028d-407a-9875-b250410154fb"
      unitRef="eur">44000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i35f615a359f04a498a53989136de928e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTgtMS0xLTQ2MTgy_1c268b4d-3c3f-4f53-8989-4d142106ed76"
      unitRef="eur">44000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib6007079e0504a6db30cf3d75e896d43_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTktMS0xLTQ2MTkw_64c68d07-e7f7-48b1-8ef7-f8c7e0471865"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i96cf2e24893f48c0896bad782974579f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEwLTEtMS00NjE5Ng_24d55f48-55c5-40c9-abd4-0e0cb02826c0"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTItMS0xLTQ2NDg4_8405c747-c225-4816-9e1a-f34c857f0546"
      unitRef="eurPerShare">13.64</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:OptionLifeOtherEquityInstrumentsGranted
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTQtMS0xLTQ2NTAz_5849c90d-205b-4319-b7b6-8d2818bd4d10">P10Y</nbx:OptionLifeOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTUtMS0xLTQ2NTEw_1da014c6-1be1-4c71-8af0-30f938426fb8"
      unitRef="number">0.0027</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTYtMS0xLTQ2NTIx_466fa73a-a5f3-4bf1-8ea6-2bdd14abab9d"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i12320deb40a549b7b50f0636bd45ace7_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTctMS0xLTQ2NTI4_24252206-93fb-4072-9649-4e865c3f21a2"
      unitRef="eur">0</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0127f9cff5b148deb46758ce7d552b99_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTgtMS0xLTQ2MTgy_b5411b50-d356-4511-95cb-32586f7d026e"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia4ca2c02a4834134bc70d6a0b83f4207_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTktMS0xLTQ2MTkw_b42ddae2-f2b3-4d10-9129-7bfe0f0b83d2"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i74b41d660ccf4571b36b582d24ff5ff6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE2LTEwLTEtMS00NjE5Ng_22b7de81-5f02-4034-ba07-cc383be3b0fa"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTgtMS0xLTExOTk5_4e19cd3b-116c-409e-8c98-811659b81aa3"
      unitRef="eur">44000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTktMS0xLTExOTk5_77b6a6d7-86ab-4d01-9072-8234450696b2"
      unitRef="eur">19000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjOGUyZDU3NTE2ZjM0MzllOWQ4OTE3YjBlMWViY2UyMy90YWJsZXJhbmdlOmM4ZTJkNTc1MTZmMzQzOWU5ZDg5MTdiMGUxZWJjZTIzXzE1LTEwLTEtMS0xMTk5OQ_797c2fd2-782a-42df-86ad-333eba15e01a"
      unitRef="eur">-16000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90ZXh0cmVnaW9uOjRlYWY1NDBlOWZhOTRkYmU4MDNkOTc0NTgyMTcyYTM1XzMyOTg1MzQ4ODgwNTk_5fba9e53-43f9-4df4-9888-3b6e3ce938a7">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in years) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;initial plan &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expense for the year ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;thousands&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of euros)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59% - 62% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 62% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2017 Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;58% - 61% - 59%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2017 Performance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.5 / 6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.1% / 37.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.103% / 0.149%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2019-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38.9% - 37.8% - 38.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.38%/ -0.33%/ -0.28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-04 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 O&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.2% / 37.9% / 38.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;5.5 / 6 /6.5 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-0.35 %/ -0.3 %/ -0.26 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;OSA 2021-06 P&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;39.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;n.a.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;760&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;509&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;760&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,366&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,202&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,289&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.498%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSPCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;BSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;OSA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AGA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expense for the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,618&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,320&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMS0xLTEtMTE5OTk_d2aed392-ff3a-4073-8b10-c9aef4221c79"
      unitRef="eurPerShare">13.05</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMi0xLTEtMTE5OTk_4cbad3c2-4edf-4f2c-a3c3-ea2524770a74"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i3ee4337742624978b8797907bce374b5_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV80_d52e43d9-e059-4f57-92c8-06e7eeae8ee8"
      unitRef="number">0.59</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ib2d89fd172a24e52a024851b281acab3_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV85_18bb54bf-3347-4256-8b8c-42d8e770de1a"
      unitRef="number">0.62</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4ca7f4263bac419496f22afb16380f23_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjNTVkNzFmN2UwMjI0MTc1OTc4NGQxMWEyNzAxYWQyZV8xNA_84b8de58-1941-493c-8412-be6c5ffe87c1"
      unitRef="number">0.60</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="idae657f1c9494ab7bdb98d4f741e4ce0_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF81_07ab6f34-311f-4639-bcd4-d97af8d86b89"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ic968a488e1214d2d8c4c849a19ca99b6_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF8xMA_eae25818-351e-4386-bfb1-eda9e609b44a"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ifaea4d6cd48f4720982f886453404978_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1YzE1MzYyNGQ5MjQ0OThiYWJhYjMyNzgyZWJhZjljZF8xNA_aa699a25-ac99-4630-ae91-2f649d902833"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNS0xLTEtMTE5OTk_5d99dd80-7132-4794-a41e-e0225bf0efe8"
      unitRef="number">0.0032</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNi0xLTEtMTE5OTk_ba018e95-16f4-47e2-83bd-66bcbe2d3e88"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="icd9430cc35a3492d8d7a150cde47be86_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtNy0xLTEtMTE5OTk_62bdc66f-abf4-48cf-bc7b-62217f911806"
      unitRef="eur">117000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i3c58f2d20a0a4f05982535c1b79a1d17_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtOC0xLTEtMTE5OTk_f9092e01-97d1-4b05-91fc-a26955e49128"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5376aaec1d46476289ea3b5ba880bbca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtOS0xLTEtMTE5OTk_c35da1e1-beef-4d97-bcef-d38be71bc925"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i600323d428624ba1bb39688b7d1835c0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEtMTAtMS0xLTExOTk5_0e4e516a-2d84-4299-8d6b-9f4f4422749a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMS0xLTEtMTE5OTk_0854911b-5e0c-47e1-8d5e-e5a99b23e636"
      unitRef="eurPerShare">13.05</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMi0xLTEtMTE5OTk_29520ebc-6267-467a-b18c-c6b0c6f4aff2"
      unitRef="eurPerShare">13.05</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMy0xLTEtMTE5OTk_71a86879-6211-48f5-8738-772b80413f6d"
      unitRef="number">0.59</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNC0xLTEtMTE5OTk_91a51344-aa29-4076-b6b8-b0b89ca714e6"
      unitRef="y">5000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNS0xLTEtMTE5OTk_dcaf276a-d3f9-4981-ac48-b49454c3a30b"
      unitRef="number">0.0019</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNi0xLTEtMTE5OTk_75da7162-0ed5-451a-b887-45a5a88f1e3c"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i712e048fe4d145e490466b4059621db8_D20160202-20160202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItNy0xLTEtMTE5OTk_e7880386-b17e-4737-8402-94c4a889c8e2"
      unitRef="eur">69000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i1b3a108f904141f98c3f321bbb06dc5f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItOC0xLTEtMTE5OTk_4d36ad3e-5f20-457b-90fa-7bd5ddbec8ae"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i52e9a19f5187490e9f895ee7d396fa92_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItOS0xLTEtMTE5OTk_b1fcc1c8-d6a6-4bfa-8d3b-33bf70d99d0d"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="if8f126d516ed4651b3e072805f960c62_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzItMTAtMS0xLTExOTk5_ac7944c0-98c7-444b-b1cf-afb3024586e7"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMS0xLTEtMTE5OTk_e770d198-5374-4c78-b3e8-1f50f9165f39"
      unitRef="eurPerShare">14.26</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMi0xLTEtMTE5OTk_442ca39d-e5e6-431e-ac10-43682aeea0ea"
      unitRef="eurPerShare">14.26</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4e278299ecb14d3b90fa008334cbd38d_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV80_fdad301f-316d-4849-b833-b31fbcf987ae"
      unitRef="number">0.58</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i95d3653f8d5c496bb69df2a4c27ce1c8_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV85_31ff77f5-9f23-4af9-926f-d4c5c1adb85f"
      unitRef="number">0.62</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i72b78d4a9e1549888d151cde77a2ef7a_D20161103-20161103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0YTQxYTUyYThmNTI0ZjZmODlkOGQ1OGQyOGIzYTAyMV8xNA_4e8132d3-0a63-44b6-9274-696cd531ff5b"
      unitRef="number">0.59</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i8aadf58558ae4edfbdbd94aeefe4c495_D20161103-20161103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV81_7ece9a4f-dc65-4da5-86e0-5a93b4913376"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ia55c037dd3314b7f8276f447908d4668_D20161103-20161103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV8xMA_94fea4d6-2cb2-44ff-825e-ef57f405f20a"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ib9512072caa04e9ba888206ac0507aad_D20161103-20161103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo1OWQ0MzIwN2ZkYTY0MTE4OGM2N2I3NTU3Zjc0OTRlMV8xNA_71c74405-d5a0-46f3-9bae-fdc2b87b45cd"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNS0xLTEtMTE5OTk_f7e69af2-24d5-4e0b-9fb4-9b2aa85adc04"
      unitRef="number">0.0004</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNi0xLTEtMTE5OTk_04339e1a-4366-4cc9-a78f-fcbc5e63cdd9"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i85816f2b832740a69b2eb6713e187daa_D20161103-20161103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtNy0xLTEtMTE5OTk_87f457b0-fe73-4924-9951-96b3a4ea4ce2"
      unitRef="eur">27000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i84ec8250c85d43728ca59d8cc08b390f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtOC0xLTEtMTE5OTk_7dfb15d4-a4a0-4a58-9e24-aa856f4ee945"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i956533d5e0a2448295b775623b2026d6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtOS0xLTEtMTE5OTk_3074c20a-f54f-4827-966e-ce4387147638"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib3fb2391fd144d51a52e3aa90706b6f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzMtMTAtMS0xLTExOTk5_688def8a-f5b1-48f3-ab1a-aa4ee11b8395"
      unitRef="eur">3000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMS0xLTEtMTE5OTk_a55c3e44-72b0-40ca-9626-0b40e469f014"
      unitRef="eurPerShare">15.93</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMi0xLTEtMTE5OTk_4dfe8529-79ec-4055-8be0-9d4fb99af590"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4fcc7ccd6a81428d9ed0e09d57d5a084_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV80_d9e930e8-ce63-43b2-8f15-04246ecfcb15"
      unitRef="number">0.58</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i9d85d406740e405b90ed84914b379490_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV85_0e57513b-7989-4b0c-b159-0c8915286be3"
      unitRef="number">0.61</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ie3527d165f9d4cd5aa38b20a8500d946_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowZThkNDE1NzRhYmY0MmNiYTY5Zjc3NzJhM2I4ZmMzMV8xNA_0ec34592-bd0e-473b-a408-566895efacc5"
      unitRef="number">0.59</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ifa4fccf9efb24a25859f2060793c20e4_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV80_cecb80fa-c048-4a3a-9741-de2910180395"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="id1d0968247324343b41e1174b2637006_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV85_e99189b7-9961-4523-af6c-5a1b39cb1c0e"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i67fd7c980ffd4542aa22782c5e050c9d_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjowMjA5OTUzYTQxNzU0YzBjYjgyMTE1YzA5ZGY0NDYxYV8xMw_d7ed81a0-88a9-42aa-a1f2-d5548748ba00"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNS0xLTEtMTE5OTk_668257dd-7e3f-4b25-81b1-061735e26022"
      unitRef="number">0.0023</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNi0xLTEtMTE5OTk_81c91958-ce31-4ec5-9aaf-c953e03f531e"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i27e0c7a43bbf4be8b509cbc37a130176_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtNy0xLTEtMTE5OTk_9d5f7940-11bb-48f0-b147-114ce3235649"
      unitRef="eur">31000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2e48ca892e704ddd9c8f9f1c9f8bd0d6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtOC0xLTEtMTE5OTk_e1087f9a-e838-4ebf-8c48-f9cb0db9e855"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i368408c4bd784fc5bacc7ae16ca08d7b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtOS0xLTEtMTE5OTk_765df53e-a227-4173-8cf2-8059216b09e6"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i40ac6393cd9348b8823b3228b7eee05a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzQtMTAtMS0xLTExOTk5_197c356b-7458-454e-8935-4f4e6bd2713f"
      unitRef="eur">1000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMS0xLTEtMTE5OTk_c81c2342-4e8c-4bd5-8ce5-654f20b91cfb"
      unitRef="eurPerShare">15.93</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMi0xLTEtMTE5OTk_262ae073-0af0-4c8c-bd55-3e0d32253ac5"
      unitRef="eurPerShare">14.97</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMy0xLTEtMTE5OTk_72faf6e0-7848-44e6-9abe-dd7974c670f5"
      unitRef="number">0.59</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNC0xLTEtMTE5OTk_ebdcd701-401e-476f-993c-bfa880dc314e"
      unitRef="y">5000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNS0xLTEtMTE5OTk_3204c804-5f58-429e-9ee1-a6765ee11aef"
      unitRef="number">0.0011</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNi0xLTEtMTE5OTk_af7f92ef-0b90-4ed4-9355-c3eb9e1e6dac"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ia9c05fe79c4343e2a069c5ebbb95b879_D20170107-20170107"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtNy0xLTEtMTE5OTk_8e741b1b-fa25-466a-8799-dab358b5160e"
      unitRef="eur">35000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie5101486495a4ef5bd91b420accb232e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtOC0xLTEtMTE5OTk_76cd7f8b-0a1f-4c17-a291-7980d5294df9"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib3b377dbf1f5453dbe7f2e047889e4ff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtOS0xLTEtMTE5OTk_282191a9-d24b-46e2-acdf-cb5fbe2dc7b6"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0b885452a1484ddd888ac4daf4dd2ef6_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzUtMTAtMS0xLTExOTk5_d4512a34-7e03-43fd-80ff-43b99e989593"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMS0xLTEtMTE5OTk_c77be93c-61eb-4a32-9385-28451c9e8e96"
      unitRef="eurPerShare">12.87</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMi0xLTEtMTE5OTk_3f959d25-ee05-40db-86ac-d9a012725f11"
      unitRef="eurPerShare">12.87</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMy0xLTEtMTE5OTk_c1c0b95a-2217-4079-9db9-76bf7d356300"
      unitRef="number">0.35</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i36ceeee7f4fc47d5b756fb41d517c7f5_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl80_773c7f15-d654-4e11-9873-ad14a2b0f2f0"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i62d4aa90997f4e6c8c19980dc74f6f5c_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl85_754f034b-10a1-4437-af7b-7996b8aeea80"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i2f5d8be3215b43c697cda5e740dce757_D20180306-20180306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo3MGRkMWIxNWNhYTE0NjFhYjA1OWY0YjkzNjI5MjBhZl8xMw_244d4ea2-d357-4d91-ad2a-d474d9812923"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNS0xLTEtMTE5OTk_f65303c3-286e-4ac7-ab1e-38ad2cb4fee3"
      unitRef="number">0.0000</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNi0xLTEtMTE5OTk_d5c87305-fae1-4871-9693-4d87e3dbda20"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i75bd11bda7e340aabe26ba159b3bb76a_D20180306-20180306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtNy0xLTEtMTE5OTk_8a8f59b7-a2bb-4469-bbe9-02dd483e1660"
      unitRef="eur">252000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6d8876e68922425c9cda69e61c8cc0fe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtOC0xLTEtMTE5OTk_6031d4ec-3832-4586-8a55-1b67cf042a52"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia5bfe742a2d04b96a2dafd66dd6c1352_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtOS0xLTEtMTE5OTk_becf4ae4-a45e-4f56-b251-26e1b5c92cb3"
      unitRef="eur">7000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibb23c53c4def4af9ac2648225e92fe29_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzYtMTAtMS0xLTExOTk5_b4c59dd8-b8c3-4e32-b73f-7fc56e6a0226"
      unitRef="eur">66000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMS0xLTEtMTE5OTk_507e698f-351c-4498-af70-bf1d0e9675cf"
      unitRef="eurPerShare">11.08</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMi0xLTEtMTE5OTk_5e433663-744d-4520-9a8a-7b328aa5dfca"
      unitRef="eurPerShare">11.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i09ca631b3e9147edadb169085675ab89_D20190329-20190329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4Zjk2NmI2Mjc0NmU0OWZkYTQ0MmRlOThlMTc5NmFmYl80_516a7191-4433-4a6d-8c31-6900814ba1aa"
      unitRef="number">0.381</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i198c812116bc40eba4d502226fd16032_D20190329-20190329"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMy0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo4Zjk2NmI2Mjc0NmU0OWZkYTQ0MmRlOThlMTc5NmFmYl85_837fa3f1-c730-4345-a0cb-284da9867f47"
      unitRef="number">0.374</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i394793f80d274291b22ad542c6d2abd0_D20190329-20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0Nzk5YWRkZjEyZGM0ZTE3YmVjZmFlMWE5NzA4ZjQxOF80_914b41fa-f9aa-4fe6-b837-23fc8a3572ac"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i1dda9fb982e1491e90a9fcf99f478e19_D20190329-20190329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNC0xLTEtMTE5OTkvdGV4dHJlZ2lvbjo0Nzk5YWRkZjEyZGM0ZTE3YmVjZmFlMWE5NzA4ZjQxOF84_4652f57f-aa44-4823-b92f-39bfdf14d7e8"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i09ca631b3e9147edadb169085675ab89_D20190329-20190329"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMjVhYzMxMGFkMjM0MGZjODM4NDQ1MzU3ZmU5MWFiMV80_4258a805-5041-4704-bd0b-304821f1fdd1"
      unitRef="number">0.00103</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i198c812116bc40eba4d502226fd16032_D20190329-20190329"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjpjMjVhYzMxMGFkMjM0MGZjODM4NDQ1MzU3ZmU5MWFiMV85_eac86faf-a6e4-4aa9-ac35-630ff0917bcf"
      unitRef="number">0.00149</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNi0xLTEtMTE5OTk_b7405013-05bc-43c0-bec1-cd3324e4390c"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i2bd983e6f20d45ffac8e644ea168ccad_D20190329-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctNy0xLTEtMTE5OTk_51b6280c-f913-4751-8e1d-a4f4977be5cb"
      unitRef="eur">140000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i09f2f5e3ec7e455f9b2e37d50499c404_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctOC0xLTEtMTE5OTk_6eeed87b-fcf8-4c32-a040-229ba7d7af01"
      unitRef="eur">17000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie4c54f39727140ea8641a018ebc83dc3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctOS0xLTEtMTE5OTk_230d5fe3-29e0-46a0-bbe1-1e020b335735"
      unitRef="eur">49000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5200a128866a420b84b1e760ddad6401_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzctMTAtMS0xLTExOTk5_da311598-ab58-4494-ad3e-5b2864ccbc2d"
      unitRef="eur">38000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMS0xLTEtMTE5OTk_fb61754f-b256-4cd8-abc1-4555db4fd326"
      unitRef="eurPerShare">6.41</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMi0xLTEtMTE5OTk_2dcaee96-ca86-4a18-8a0a-86db2f4c1d10"
      unitRef="eurPerShare">6.41</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMy0xLTEtMTE5OTk_45166de5-beba-405e-a4da-f276db640038"
      unitRef="number">0.37</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNC0xLTEtMTE5OTk_ac6f9f1e-961c-47df-a316-1ce8f4d9ef6e"
      unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNS0xLTEtMTE5OTk_53d3c021-6a99-4f2a-9591-3f3be57b0373"
      unitRef="number">0.0040</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNi0xLTEtMTE5OTk_30499bea-f1c2-4d2b-9e7a-c9d9216877af"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="icd8b194f13b44df4bc1c59d5c0fe2d1a_D20191024-20191024"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtNy0xLTEtMTE5OTk_d4d475b9-d731-4551-858c-c42dd0aac11d"
      unitRef="eur">252000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5da24119b5de4abf9bb7cc22d07b5a2d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtOC0xLTEtMTE5OTk_fb75e81c-464b-4ad8-b980-529256cefec5"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="id5190f8fe06b4d19a5108cdb770d7ee1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtOS0xLTEtMTE5OTk_c75f8184-5bf0-4245-ada5-c7c7b71aec09"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i71ced96080c741eb86c560c4806b4bac_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzgtMTAtMS0xLTExOTk5_81e8c852-9058-4731-94c7-6cd919878adb"
      unitRef="eur">436000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMS0xLTEtMTE5OTk_99f069cc-8523-4a35-aa32-f56cce7135b4"
      unitRef="eurPerShare">6.25</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMi0xLTEtMTE5OTk_851439cc-fa95-4e02-b5cb-51805ac670cd"
      unitRef="eurPerShare">6.25</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMy0xLTEtMTE5OTk_fd588c3c-8534-414d-9acd-4d2d8b44d4e3"
      unitRef="number">0.38</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNC0xLTEtMTE5OTk_ed5035eb-bca6-47a1-ac33-939a772e348e"
      unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNS0xLTEtMTE5OTk_8a680b84-ff2b-4f58-95ba-a812bfa5bf52"
      unitRef="number">0.0031</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNi0xLTEtMTE5OTk_d231793f-827d-4dc8-96d1-5971954e1a88"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i4e605e67bf9041dc8b105605958772bd_D20200311-20200311"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktNy0xLTEtMTE5OTk_a193ddf5-eb47-44fe-9630-2c24d3e599c4"
      unitRef="eur">939000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ic7dc41430c87420aac326dcb45472bc3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktOC0xLTEtMTE5OTk_f3312c7b-bb7c-4bcd-a792-bebeb3b201d5"
      unitRef="eur">329000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="iba1b7fce95b64db19872ba2bf376c123_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktOS0xLTEtMTE5OTk_54bfbda4-68e4-4a37-bb8a-88d5858f8dcc"
      unitRef="eur">453000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2b6f2878993e468fa6f8eb36906b91de_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzktMTAtMS0xLTExOTk5_d55cf6de-55b5-4e85-bbf1-ca692bc5c08e"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEtMS0xLTQ2NjYy_91735ff1-325a-4696-9a1c-2d01617ca57a"
      unitRef="eurPerShare">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTItMS0xLTQ2NjYy_bc4a8f99-458e-4e95-b51a-caef36b7c97b"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i4b06a3f5d2f7472db4caa5fc92672fa6_D20210420-20210420"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTU4Mw_8ca0ebe6-423f-4f6f-bbf4-7ae8d5fcf8ef"
      unitRef="number">0.389</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i7611d0d295d749ec9624b6c580daf2c0_D20210420-20210420"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTU5MQ_b02dabd3-7ded-495e-a1b5-2379fbf5eaaf"
      unitRef="number">0.378</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i6b89967813ab4889b7d9c0458d61d244_D20210420-20210420"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246ZjM1NTE5Yjk3ODA0NDA5OTlkMWUzNTk4YzE3Y2FkOGVfMjE5OTAyMzI1NTYwMA_48d03a8f-4159-4d8a-9c77-0996176f3a22"
      unitRef="number">0.383</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i6f36fa16350140b9b69fe1134da42b69_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU3Mw_019af6c7-e234-4734-aab2-cce768094bcf"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i96c93a64b4574a449d4ad5addda19ec0_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU4NQ_e014b36d-3c98-41e8-a959-81c8e03225cd"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i73558c5663be437689199c827a5964f1_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246MGQ1YWZmNzgyN2ZhNGQxZGJkMDNmZGNjNDEzMDRlMTVfMjE5OTAyMzI1NTU5Mg_380f1b7d-2b73-4c13-af18-ad951063370f"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTYtMS0xLTQ2NzI4_eee078f0-4fbb-475a-bdf5-88ef492323ef"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i01debe0cf5634d9abe5b0af321b794da_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTctMS0xLTQ2NzM5_db364d75-54e6-42fe-b356-b4525254dd84"
      unitRef="eur">684000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i276bc4fd1a094b3088274297dda73e5f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTgtMS0xLTQ2MjM4_2cf14f7d-de2d-428e-9207-6c6a45803ca2"
      unitRef="eur">188000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i9b03d50b925f4ccb87f9715164ee45dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTktMS0xLTQ2MjQ4_0557d3ac-8859-4cf6-9709-f361dd5b1d48"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie14e3a19e1d44a86a04438f03dbba7fc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEwLTEtMS00NjI1NA_362ea111-f9d8-4d7e-854e-ff9fff82b81b"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEtMS0xLTQ2NjYy_ff314f4d-7219-4d28-87c5-20f3a1090ba9"
      unitRef="eurPerShare">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTItMS0xLTQ2NjYy_666b284a-ccd2-4e2a-bb4c-cbe1c0b65046"
      unitRef="eurPerShare">13.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTMtMS0xLTQ2Njc2_2bfab553-918f-4a97-9885-d722c74f34a9"
      unitRef="number">0.3910</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTQtMS0xLTQ2Njkz_7acaa167-a531-41aa-ab16-fb1cf551adba"
      unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTUtMS0xLTQ2NzA4_6cd3013f-ba0e-452b-9d3a-ac28924c6b4e"
      unitRef="number">0.0003</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTYtMS0xLTQ2NzI4_76cded92-0b05-427f-b3b4-14e3a555f6fe"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="if2405c669e044cb79852038f6f907b3f_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTctMS0xLTQ2NzM5_36536cc0-193c-4d0a-9afd-a2bfe6e30531"
      unitRef="eur">1816000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ib3d2e17f384646f2a195144983cd8b67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTgtMS0xLTQ2NzQ5_f49a2b5b-2ad3-4af8-b40b-7a19e6a3ba49"
      unitRef="eur">131000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i623bf93a1859415a8a96f48101b40599_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTktMS0xLTQ2NzQ5_041b77a5-7cb5-4e97-bf52-8ba4137b700a"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i91bd49a836ca4a4cb9e32546a222901f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEwLTEtMS02MTI2Nw_7e1e9781-5a66-4fef-9732-e7deec03b3a4"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTEtMS0xLTQ2NjYy_0d5c78b7-8cc8-467e-9721-35456b78c366"
      unitRef="eurPerShare">12.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTItMS0xLTQ2NjYy_e3e2236e-d5f3-486a-82b9-9748daf013bf"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i74a3603a73494c8bb79eb97049d0e18d_D20210621-20210621"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTU4NA_01818bd0-93fd-4a1d-9f94-b23040d2fe1d"
      unitRef="number">0.392</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i008d6758b72e4f2a8ae6f54a8dff50ef_D20210621-20210621"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTU5Mg_9ffcc83b-176f-4861-a1f3-072c87364ae4"
      unitRef="number">0.379</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i909a2b98b71e4edbbc5035450cf6b405_D20210621-20210621"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTMtMS0xLTQ2Njc2L3RleHRyZWdpb246MDRhMGExZTUxNDUwNDkyM2E4OTNiMzI4YzY2OWMxNmFfMjE5OTAyMzI1NTYwMA_b088deae-878d-49ac-a5d9-2acfbde029ee"
      unitRef="number">0.381</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="idf1059b42ec64434bd92678ec7a69180_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU3Mw_8b809071-5707-42c2-8383-3875a47caa1e"
      unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i3a0277fbafbb433c94c83dbacd512259_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU3Nw_53b4055f-92f0-4f4b-bc44-d12671255dd5"
      unitRef="y">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i1da41881e01c4b918d3d6023763371d5_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTQtMS0xLTQ2NjkzL3RleHRyZWdpb246YmMyYjI4YWUxMDVmNDUzYjg1OWJkMjA3ZTg1YTA2YThfMjE5OTAyMzI1NTU4Mw_7827c63b-97a2-45a0-8f26-b69bd7e39d31"
      unitRef="y">6.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTYtMS0xLTQ2NzI4_f4950f5b-3836-4fca-b07c-79f7d8e0f66d"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i13a8f73ead0b4a989fc00aab757d88d1_D20210621-20210621"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTctMS0xLTQ2NzM5_10b3cb22-7558-4508-8cd8-42703aa6daae"
      unitRef="eur">246000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i0ae10134a55c4ec0bfa8de540a4fa154_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTgtMS0xLTQ2NzQ5_c9501dbe-8eaa-449f-9390-7d25aaad7339"
      unitRef="eur">79000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8f4fab534e274a858c234a1f5128ae78_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTktMS0xLTQ2NzQ5_38a9d267-8ccf-4729-b524-0aeeac72f630"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i954ef2ab820e48b5b6d82b3be204467e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEyLTEwLTEtMS00Njc0OQ_4d45adf1-f9b3-4275-920d-076f5281e9dc"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTEtMS0xLTQ2NjYy_64fb89cf-9441-4d17-91a9-8b12b402da4b"
      unitRef="eurPerShare">12.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTItMS0xLTQ2NjYy_25d9423b-f306-4df6-a055-45649476f938"
      unitRef="eurPerShare">12.99</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTMtMS0xLTQ2Njc2_1cb2e38b-380b-4d0e-9a6b-192bf47c3549"
      unitRef="number">0.3910</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTQtMS0xLTQ2Njkz_6a1f2c53-08b9-4771-b46f-0a62c3eddc43"
      unitRef="y">10000</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTUtMS0xLTQ2NzE4_94cbdb8d-76a0-4e0a-8a1c-71a92d158a18"
      unitRef="number">0.0013</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTYtMS0xLTQ2NzI4_3e0eeb4d-ed25-4a26-a361-18e46a4f5ded"
      unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="ie85ccfe66be64e9493c497fdb88855ba_D20210621-20210621"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEzLTctMS0xLTQ2NzM5_6a10beca-905d-4a04-b929-50400d0b7409"
      unitRef="eur">212000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia03d50617eac462d8a56b671789e4d10_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTgtMS0xLTQ2MjM4_7ef35177-399a-4b8b-a435-13b87c982fd1"
      unitRef="eur">16000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibab950c0a8e24aae8bb9c60287630006_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTktMS0xLTQ2MjQ4_4fe3e3ac-ffc9-476d-94fd-0a187cf5aa4e"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i4b51e3ab383942a5aa13a3c61bfd07b7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzExLTEwLTEtMS00NjI1NA_7f55b61f-d5ee-4f09-a193-21a6b076325a"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTgtMS0xLTExOTk5_47a60d84-c443-4769-a503-32caee69abff"
      unitRef="eur">760000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTktMS0xLTExOTk5_5503fe07-72f2-4281-9d2c-644cdf51f425"
      unitRef="eur">509000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpkMTZmMDkxZTI0OTA0YjAwOGQ0NzE0NmUxZjk4YmUyMS90YWJsZXJhbmdlOmQxNmYwOTFlMjQ5MDRiMDA4ZDQ3MTQ2ZTFmOThiZTIxXzEwLTEwLTEtMS0xMTk5OQ_62f083db-3397-441d-b835-75cc74816501"
      unitRef="eur">543000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMS0xLTEtMTE5OTk_afd3f960-0ec0-45c4-bd01-b9d76f28d6a3"
      unitRef="eurPerShare">12.87</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMi0xLTEtMTE5OTk_42606663-b4e5-448e-935c-fc79ee75d478"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNS0xLTEtMTE5OTk_e3805003-1313-4511-ae66-9a5c855e0de9"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNi0xLTEtMTE5OTk_47cbc952-b47e-4706-a16c-d0727c9f6020"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i0c6e83c1208043fda3b8e9368d7a7f03_D20180306-20180306"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtNy0xLTEtMTE5OTk_17840f0d-e252-4366-afa5-8d73a5035261"
      unitRef="eur">4951000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ifa96dfe87911430586ee8380cfd0c1d1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtOC0xLTEtMTE5OTk_fa5b322c-39e4-4ea4-a09e-59ce5265ac12"
      unitRef="eur">16000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8bba77021c3946eba8707d6734dc214f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtOS0xLTEtMTE5OTk_56747d2a-d1c3-433e-a6b3-16a791890514"
      unitRef="eur">268000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="if4d1dc40ee294a4eb862a754e1a7b7a1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzEtMTAtMS0xLTExOTk5_cfbc03fa-9679-49f2-82de-72df7584758b"
      unitRef="eur">2052000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMS0xLTEtMTE5OTk_c8e1802b-94c1-4634-a1b3-db6df3bdad99"
      unitRef="eurPerShare">12.87</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMi0xLTEtMTE5OTk_684f641b-9323-4e54-b971-96f1a5075ab0"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNS0xLTEtMTE5OTk_158f85de-6375-4204-8fa3-a299fe8d5eb5"
      unitRef="number">0.0000</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNi0xLTEtMTE5OTk_7e230195-a40f-4782-bae3-c03b6b31d55e"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i18587370b0324c7484eecfea6bdc3909_D20180727-20180727"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItNy0xLTEtMTE5OTk_2ddd135c-d708-4343-b510-467a4b499052"
      unitRef="eur">75000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5dbdfbbdcc634d8aa2b18492eaec91ac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItOC0xLTEtMTE5OTk_dff30274-723b-4078-92dd-3656cb1fcfae"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5b0059025b2a459e98dbfc7e44d80ff9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItOS0xLTEtMTE5OTk_6a427b25-95a3-4793-8065-fc6c8fd8c0d0"
      unitRef="eur">21000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6244d605e7d349cd88cc8c11756f1c6c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzItMTAtMS0xLTExOTk5_2db6d164-f350-4c6e-99b5-0aa3618f97fa"
      unitRef="eur">37000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMS0xLTEtMTE5OTk_549c4201-654b-47da-9b4f-456795f70369"
      unitRef="eurPerShare">10.90</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMi0xLTEtMTE5OTk_2a915dae-df5d-4e97-ab9b-2fd7ddaa6147"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i1b3d45ed49f246078f98c1da6b744503_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNjMyZmNmMjNhNjE0N2ViYjdjM2Q1OTcyMWY1YjllNF80_c8b127d3-e8a8-4813-a2c3-cf6dc524ffcf"
      unitRef="number">0.0019</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted
      contextRef="i43664a271eab453f8088849ba1fb58f7_D20190329-20190329"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNS0xLTEtMTE5OTkvdGV4dHJlZ2lvbjphNjMyZmNmMjNhNjE0N2ViYjdjM2Q1OTcyMWY1YjllNF85_1c47af10-09fa-46ab-ba58-7f460756fbef"
      unitRef="number">0.00141</nbx:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNi0xLTEtMTE5OTk_805678e9-97a3-4565-afd5-dd0323ab5478"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i5f126c52f7914e389b3f5d9270e564e1_D20190329-20190329"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtNy0xLTEtMTE5OTk_46f0d005-0c8b-42a7-90c8-142079b123ea"
      unitRef="eur">4776000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8dae6bafe85b47fdbe2f3a351195964f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtOC0xLTEtMTE5OTk_4b95b50a-866c-48b6-8a76-04b41947af2f"
      unitRef="eur">422000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i830ea4df74924951ad3f4b9f539b4ea3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtOS0xLTEtMTE5OTk_6496750e-c1f1-4e31-b193-13c73a18c1ba"
      unitRef="eur">1884000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ieb041ec28cd441c8a5a4283ac0d8d07d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzMtMTAtMS0xLTExOTk5_6f2beb74-d423-4851-aa2d-8eb7714363b7"
      unitRef="eur">1529000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMS0xLTEtMTE5OTk_8753bdc9-f1a1-438a-afc1-cf0bf359811a"
      unitRef="eurPerShare">5.90</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMi0xLTEtMTE5OTk_a2ec1722-58c2-4f2f-94af-1359fba34350"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtNi0xLTEtMTE5OTk_aecc4fd1-a91d-44cc-8e06-5fef2bb4ec12"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i930277d5c0a44b63957306f0338fa85e_D20200311-20200311"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtNy0xLTEtMTE5OTk_0e06f0bf-0b11-4243-a9b0-8cc267b0d55b"
      unitRef="eur">287000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6fd9280336d448658f2102d170064e8b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtOC0xLTEtMTE5OTk_4dfc77b1-a2b3-4081-9bd2-8f4e27384d27"
      unitRef="eur">144000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ia825e6230971416399dd4d660a4bf3c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtOS0xLTEtMTE5OTk_004fdcc3-c30d-4c32-9989-7dddbb9e9e97"
      unitRef="eur">116000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i5f726d12be094192a3269413d8216aaf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzQtMTAtMS0xLTExOTk5_f6e4d3a4-4201-46b1-aba9-4eac5decdd65"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMS0xLTEtNDY3ODI_fba748b2-2323-42a2-8688-c2495479514e"
      unitRef="eurPerShare">13.60</nbx:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <nbx:ExercisePriceOtherEquityInstrumentsGranted
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMi0xLTEtNDYzNDM_be0326a7-1eb7-4700-8705-cd7122303d3f"
      unitRef="eurPerShare">0.00</nbx:ExercisePriceOtherEquityInstrumentsGranted>
    <nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtNi0xLTEtNDY3OTg_506845ae-be3f-47cf-8c2d-794f3e43d2d1"
      unitRef="number">0.0000</nbx:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan
      contextRef="i57fee7234b3649239c7682326fc183b4_D20210420-20210420"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtNy0xLTEtNDY4MDk_d22d9f02-5626-4c11-84ac-16606a09fa71"
      unitRef="eur">4869000</nbx:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibbaa914baa3442b9a00dd2758e278902_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOC0xLTEtNDYzNjY_e5b99cdc-26cb-4dd0-8b1b-64cd1f85315b"
      unitRef="eur">1784000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibdea060a980d42ec8049515011a575c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOS0xLTEtNDYzNjY_e0242551-f272-484f-a26a-2aa8336e1667"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ie6340f94bc5146cd810b425747377b1d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMTAtMS0xLTQ2MzY2_f769c7f8-0989-45e7-8493-5588506ee802"
      unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOC0xLTEtMTE5OTk_1dcb9a57-eb1c-4f4f-af3d-321416b0e765"
      unitRef="eur">2366000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtOS0xLTEtMTE5OTk_977342b1-1042-40a9-bc6a-23f5517e1afb"
      unitRef="eur">2289000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpjMWU0OWFjZTY4NDA0OGU0YWM2NjgwMmZkZTNjMTZlOS90YWJsZXJhbmdlOmMxZTQ5YWNlNjg0MDQ4ZTRhYzY2ODAyZmRlM2MxNmU5XzUtMTAtMS0xLTExOTk5_09413eeb-d670-476e-bbf8-691894fa34e4"
      unitRef="eur">3618000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtMi0xLTEtNDYyOTA_8835c1c7-5beb-48e2-9fa3-dd6e96f12ab4"
      unitRef="eur">32000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i51e1e6c05b0740aca1bf0e44a9bd8f11_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtNC0xLTEtNDYyOTc_cf4ebd14-07e5-4d13-935b-d8fe266e7a9a"
      unitRef="eur">44000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i14e72259f766468696e8950f2f900687_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtNi0xLTEtNDYzMDM_845a2fcc-02a7-4139-8063-8eb88b9f4629"
      unitRef="eur">760000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i6654f1c0cd8e4abd9fc70921fa80fdc0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtOC0xLTEtNDYzMDk_62c5be62-0e05-4a1d-814c-38c53b112f66"
      unitRef="eur">2366000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyMDdhZTA1N2EzNTU0Yzg0OGVlNmQ0OTk3MTg5ZWVmNy90YWJsZXJhbmdlOjIwN2FlMDU3YTM1NTRjODQ4ZWU2ZDQ5OTcxODllZWY3XzEtMTAtMS0xLTQ2MzE1_6c09946b-0454-4f4f-a95f-c09f4d2e6b93"
      unitRef="eur">3202000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i8fbdcddab03249a2a2c1af7be59fea80_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtMi0xLTEtMTE5OTk_f48104bf-df40-4340-b376-e1717a5615e4"
      unitRef="eur">107000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i2df547425462403b9be10a7f1cf90c93_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtNC0xLTEtMTE5OTk_b0f94b82-347d-4457-a767-5836fdc064a6"
      unitRef="eur">19000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i88d7422749c74ea7ab142d893e856969_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtNi0xLTEtMTE5OTk_26ba3688-99ac-4de7-be95-b7f63ba1c8f6"
      unitRef="eur">509000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i75412d7d9d294b44b69018586184ee05_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtOC0xLTEtMTE5OTk_39b8356b-0769-4fcd-8478-1b8c88f53bf2"
      unitRef="eur">2289000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZToyNTI4NDczNGEyMGI0ZjcxYTlkM2QzZjIyZTVlNmVhZS90YWJsZXJhbmdlOjI1Mjg0NzM0YTIwYjRmNzFhOWQzZDNmMjJlNWU2ZWFlXzEtMTAtMS0xLTExOTk5_4e1a4f6e-a91a-4682-90ff-7df61cfdc451"
      unitRef="eur">2924000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i024a0a55d48b44e2a0dcd85a171d927d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtMi0xLTEtMTE5OTk_a99b2de3-9e71-4a93-ae2e-29593b8a91be"
      unitRef="eur">175000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="idd687f1e0304417ebf07505422bc35f1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtNC0xLTEtMTE5OTk_9f24bb40-5500-42ed-808a-653c94be930e"
      unitRef="eur">-16000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i99ad695f92cf40e787d2016f537d80e4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtNi0xLTEtMTE5OTk_31cc0db2-0f0c-4acf-a0bd-65dfa0cb52b1"
      unitRef="eur">543000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="ibc5fc42496604303abf0a59b8fa87688_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtOC0xLTEtMTE5OTk_e0ace82a-5710-438f-aa4e-bca3d49d7272"
      unitRef="eur">3618000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xODQvZnJhZzo0ZWFmNTQwZTlmYTk0ZGJlODAzZDk3NDU4MjE3MmEzNS90YWJsZTpmMzE5MzhiODczMDQ0MzU0YjAyMGRkMTdkZmM0NGU4ZC90YWJsZXJhbmdlOmYzMTkzOGI4NzMwNDQzNTRiMDIwZGQxN2RmYzQ0ZThkXzEtMTAtMS0xLTExOTk5_71bbfdf1-9a6c-40ca-8083-4827df40b9b7"
      unitRef="eur">4320000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzE1Nzc_48665ab3-f775-45ae-9c54-82d7f353f22f">Net financial income (loss) &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IFRS 16 related interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2021, the interest cost was a negative net amount of &#x20ac;383&#160;thousands, mainly due to the EIB loan interest and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#x20ac;4.2&#160;million in 2021 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#x20ac;1.8&#160;million impact of EIB fixed interest cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2020, the interest cost was a positive net amount of &#x20ac;4.7&#160;million, substantially due to the EIB loan interests and discounting impact (see Note 12.1 Conditional advance, bank loan and loans from government and public authorities) which was a net income of &#x20ac;4.8&#160;million in 2020 as a result of the EIB royalties sales reforecast catch up effect and the accretion of the debt cost, offset by &#x20ac;1.7&#160;million impact of EIB fixed interest cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2021, the Company had foreign exchange gains for the total amount of &#x20ac;6.3&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This impact was primarily arising from the foreign exchange gains realized by the Company related to the HSBC bank account denominated in U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In 2020, the Company had foreign exchange losses for the total amount of &#x20ac;1.7&#160;million.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;This impact was first arising from retaining $113.3&#160;million from the gross proceeds of the global offering in a US dollar bank account.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzE1Nzg_1a37419e-185b-4dfb-bae2-c2546e5561dc">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income from cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;6,360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;IFRS 16 related interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,646&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(4,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock>
    <ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMS0xLTEtMTE5OTk_7127367a-2406-4f2b-b885-cfb980d1f287"
      unitRef="eur">0</ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks>
    <ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMi0xLTEtMTE5OTk_b6d129d5-3d51-4a20-9fc7-c31a7e1876af"
      unitRef="eur">0</ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks>
    <ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzItMy0xLTEtMTE5OTk_ba3190e9-acc7-4d6f-addd-8a43088818b7"
      unitRef="eur">105000</ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks>
    <ifrs-full:NetForeignExchangeGain
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMS0xLTEtMTE5OTk_49273d6b-215a-49ba-8923-b65e98f861d9"
      unitRef="eur">6347000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMi0xLTEtMTE5OTk_07821be0-b3c4-496b-87d7-9edb02e4bbbc"
      unitRef="eur">104000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzMtMy0xLTEtMTE5OTk_95e710f0-ecbf-4a65-8e80-098213530e35"
      unitRef="eur">599000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:OtherFinanceIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMS0xLTEtMTE5OTk_5160a94d-5237-4d79-9494-4aefe866ecfd"
      unitRef="eur">13000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMi0xLTEtMTE5OTk_1cb0d67b-363d-467d-88f7-79b061258427"
      unitRef="eur">97000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzQtMy0xLTEtMTE5OTk_67307554-0087-4d44-b6e5-bc8db93a433b"
      unitRef="eur">133000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMS0xLTEtMTE5OTk_0ab9bb6e-1f0e-4971-83f9-3bbb73b2c292"
      unitRef="eur">6360000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMi0xLTEtMTE5OTk_9dc915c4-d693-40ac-8f05-2fa0a0340fcc"
      unitRef="eur">201000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzUtMy0xLTEtMTE5OTk_d43c6bd6-c595-4ae0-8d19-ce137eb0e7c5"
      unitRef="eur">837000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestRevenueExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMS0xLTEtMTE5OTk_55db790d-d2ce-46d3-baf5-a0188b3a4ade"
      unitRef="eur">-383000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMi0xLTEtMTE5OTk_f7b4f15d-7928-4b89-96f7-ae2a28d3d706"
      unitRef="eur">4676000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzYtMy0xLTEtMTE5OTk_51658653-997f-46df-b83c-a872fc288cf6"
      unitRef="eur">-4434000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMS0xLTEtMTE5OTk_d5cc462e-a9c7-483b-89e7-b68a217167ef"
      unitRef="eur">288000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMi0xLTEtMTE5OTk_a0a52420-fe09-4138-a2fe-eb758e4dbda2"
      unitRef="eur">333000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzctMy0xLTEtMTE5OTk_4f516585-8f75-4219-b3f6-d451db3eee21"
      unitRef="eur">359000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMS0xLTEtMTE5OTk_aea1281f-0111-4627-a9d9-ac250d60d363"
      unitRef="eur">-109000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMi0xLTEtMTE5OTk_b5facec4-83bc-47fe-8e42-6550e1e3d8ce"
      unitRef="eur">-1697000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzgtMy0xLTEtMTE5OTk_022ebd2c-654b-4dd3-9145-ad2321297596"
      unitRef="eur">-176000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:FinanceCosts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMS0xLTEtMTE5OTk_edc46cbd-ee56-46d0-8c0b-09a34eb19e75"
      unitRef="eur">780000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMi0xLTEtMTE5OTk_7b4684ba-fa58-4e3b-983f-43d4d0a7dc59"
      unitRef="eur">-2646000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzktMy0xLTEtMTE5OTk_e962d1d3-e504-432c-b4e4-359af283e80b"
      unitRef="eur">4970000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTEtMS0xLTExOTk5_037d5135-68b2-4c3c-a0ea-dca39f747ddb"
      unitRef="eur">5580000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTItMS0xLTExOTk5_a437a7b0-817f-478e-a1b0-1b1d13daf3dc"
      unitRef="eur">2847000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90YWJsZTpiNzc0YTdhMGI3OTU0MmZjYTA4MjZkNmJhMDI1Mjk4MC90YWJsZXJhbmdlOmI3NzRhN2EwYjc5NTQyZmNhMDgyNmQ2YmEwMjUyOTgwXzEwLTMtMS0xLTExOTk5_ca86238a-60ac-4fc5-b365-0bfac8527f78"
      unitRef="eur">-4133000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:InterestRevenueExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzMyOTg1MzQ4ODUyMjQ_115436a4-2f67-4e8e-9dff-1c7580330a59"
      unitRef="eur">-383000</ifrs-full:InterestRevenueExpense>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzM4NDgyOTA2OTk5ODI_75822921-0d2a-4138-bdf6-1761db0519f2"
      unitRef="eur">4200000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="icf7abdd665664906840a18afc4669ef7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzM4NDgyOTA2OTk5OTc_e89126ea-08ca-47e3-b73c-d19fbc7bc87c"
      unitRef="eur">1800000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestRevenueExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzQzMQ_012937b9-afc5-4965-8068-e84c648abe22"
      unitRef="eur">4700000</ifrs-full:InterestRevenueExpense>
    <nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities
      contextRef="iace126c94a324f9b8f89bfece6675bf1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzYyNA_d12bd761-1bbc-4eb8-9e1e-115e9265214c"
      unitRef="eur">4800000</nbx:IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i2a6010c7ae114b0cbe67c4bf3c2b2d79_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzcxMw_1b8093ef-8e88-4f5f-a5ee-d64402acda54"
      unitRef="eur">1700000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:NetForeignExchangeGain
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzMyOTg1MzQ4ODkxMzY_311dc3b7-e131-467a-8143-a072ec1e060a"
      unitRef="eur">6300000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeLoss
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1Xzg1Nw_3faf922c-24e9-4a46-a531-7f338dd6b870"
      unitRef="eur">1700000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTAvZnJhZzphOWU3ZWRjOWVjOWY0ZGQ2YThlNGE1OWJhZDU4M2MzNS90ZXh0cmVnaW9uOmE5ZTdlZGM5ZWM5ZjRkZDZhOGU0YTU5YmFkNTgzYzM1XzkwNg_836fc58d-dc3e-458d-99d4-5d329bfb2027"
      unitRef="usd">113300000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NjA_c4fa4932-8205-48e2-b866-b44a7d5a944f">Income tax&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company and its subsidiaries are subject to income tax in their respective jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company&#x2019;s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of income tax&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, in accordance with the applicable legislation, the Company has &#x20ac;284&#160;million of evergreen tax losses in France, in comparison with &#x20ac;235&#160;million and &#x20ac;184.3&#160;million of evergreen tax losses in France as of December 31, 2020 and 2019, respectively. For fiscal years ended on or after December 31, 2018, the use of tax loss carryforwards in France is capped at &#x20ac;1.0&#160;million, plus 50% of the portion of profits in excess of that limit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The cumulative tax loss carryforwards for the U.S. entities of the Company totaled $3.4&#160;million as of December 31, 2021, $4.4&#160;million as of December 31, 2020 and $4.8&#160;million in the United States as of December 31, 2019. The tax loss carryforwards that were generated before January 1, 2018 will expire 20 years after they were generated; those generated after that date have an indefinite carryforward. The tax loss carryforwards in the U.S. comply with the federal and each state&#x2019;s Net Operating Loss (&#x201c;NOL&#x201d;) rules updated by the Tax Cuts and Jobs Act (&#x201c;TCJA&#x201d;) of 2017.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table reconciles the Company&#x2019;s theoretical tax expense to its effective tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recurring loss before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(47,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(33,581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(50,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Theoretical tax rate (statutory rate in France)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Theoretical tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(15,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non-taxable items &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unrecognized tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effective tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The cumulative net unrecognized deferred tax assets amounted to &#x20ac;75.4&#160;million in 2021, including &#x20ac;14.0&#160;million of 2021 net operating loss carryforwards in comparison with &#x20ac;60.2&#160;million in 2020, including &#x20ac;59.6&#160;million of 2020 net operating loss carryforwards and &#x20ac;51.0&#160;million in 2019, including &#x20ac;49.6&#160;million of 2019 net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;The deferred tax rate of the Company is 25.8% in 2021, 26.5% in 2020, and 25.49% in 2019, based on enacted tax rate reductions in future years.</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NTg_fa6f68fb-1cac-4ba8-8250-a57eac45b4e2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company and its subsidiaries are subject to income tax in their respective jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Deferred taxes are recognized on a full provision basis using the liability method for all temporary differences between the tax basis and accounting basis of assets and liabilities in the financial statements.&lt;/span&gt;&lt;/div&gt;The main temporary differences relate to tax loss carryforwards. The prevailing income tax rates on the reporting date are used to determine deferred taxes. Deferred tax assets, which mainly arise as a result of tax loss carryforwards, are only recognized to the extent that it is probable that sufficient taxable income will be available in the future against which to offset the tax loss carryforwards or the temporary differences. Management uses its best judgment to determine such probability. Given the Company&#x2019;s current stage of development and its short-term earnings outlook, the Company is unable to make sufficiently reliable forecasts of future earnings and accordingly, deferred tax assets have not been recognized and offset only to the extent of deferred tax liabilities in the same taxable entities.</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="ie8972928b2f3477aa4ff40a52480c1a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEyODE_79c2dbf2-aaaa-46cb-b499-e805417f4657"
      unitRef="eur">284000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="i095137ac480d4189b8d3e9c4120fed6e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEzMzg_fa993895-8293-4d9e-b7ea-1b93a6aa90df"
      unitRef="eur">235000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="ibbaf4b30ae8c4e248d5a4b78dcced4ca_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzEzNDU_f54602b0-8efc-43bb-8758-896b554def46"
      unitRef="eur">184300000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="i3bb2c3901cc8428a999595204c3b6eb2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE2ODY_d6e30857-3221-420e-aad0-987ea8c29515"
      unitRef="usd">3400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="i28327906e6194ba78e2313551bf12bd2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE3MTQ_efe3f10e-2d4f-4ad7-8382-a96d4b57ec50"
      unitRef="usd">4400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="i6d12dbc4d05a4a798e08dead85d18b91_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE3NDU_f2cdc0f6-f0ed-4030-a58c-c1eba1e67330"
      unitRef="usd">4800000</ifrs-full:DeferredTaxLiabilityAsset>
    <nbx:UnusedTaxLossExpirationPeriod
      contextRef="i8c9f1e5116224a2e8a73cd903766f102_D20170101-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzE4NzY_41228865-460a-4507-b412-e895bc8413e5">P20Y</nbx:UnusedTaxLossExpirationPeriod>
    <nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI2NTk_bcd043e4-16a4-4689-ba94-88aba237fcde">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The following table reconciles the Company&#x2019;s theoretical tax expense to its effective tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Recurring loss before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(47,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(33,581)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(50,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Theoretical tax rate (statutory rate in France)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Theoretical tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(12,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(9,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(15,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other non-taxable items &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unrecognized tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effective tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMS0xLTEtMTE5OTk_5a6cb5b4-f947-4b97-9b00-7fdbdbfbb376"
      unitRef="eur">-47003000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMi0xLTEtMTE5OTk_47d122bf-e8c0-4923-99b4-e2195b3bca67"
      unitRef="eur">-33590000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzItMy0xLTEtMTE5OTk_63d6ec02-d1c8-4edd-b086-8676f7c0f281"
      unitRef="eur">-50915000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMS0xLTEtMTE5OTk_46c0c1a7-e011-40bb-996e-f9b2540e042d"
      unitRef="eur">5000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMi0xLTEtMTE5OTk_7cc1e9b8-b79b-48d9-b140-173891c80328"
      unitRef="eur">9000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzMtMy0xLTEtMTE5OTk_f743d8e7-5d00-4fe2-9ac4-0fbef6d15af9"
      unitRef="eur">3000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AccountingProfit
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMS0xLTEtMTE5OTk_aabe4e16-36aa-4022-ac93-4a17ebc4bd8a"
      unitRef="eur">-47058000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMi0xLTEtMTE5OTk_bfb68f44-4ce1-4eae-8a75-a2ad06cb71d3"
      unitRef="eur">-33581000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzQtMy0xLTEtMTE5OTk_156399d3-f5c9-4e5f-8277-1bc97e21868f"
      unitRef="eur">-50912000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMS0xLTEtMTE5OTk_7ab17e42-bb18-45cd-8444-fa68c966fb98"
      unitRef="number">0.2650</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMi0xLTEtMTE5OTk_7ca4fb5a-dc75-40de-a608-521d2ece1fa1"
      unitRef="number">0.2800</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzUtMy0xLTEtMTE5OTk_48d1ce79-7657-48da-9910-8130eabfb1b2"
      unitRef="number">0.3100</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMS0xLTEtMTE5OTk_b7e43803-bb39-44ad-8af8-a8339584dc07"
      unitRef="eur">-12470000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMi0xLTEtMTE5OTk_8a96a298-c5b0-4950-96ae-1fd3c9e1550a"
      unitRef="eur">-9403000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzYtMy0xLTEtMTE5OTk_f81a46d7-cd2f-46d9-a113-1881332cbb58"
      unitRef="eur">-15782000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <nbx:TaxEffectOfShareBasedPaymentArrangements
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMS0xLTEtMTE5OTk_e2d8fc95-7967-47d1-a008-745895b1091f"
      unitRef="eur">848000</nbx:TaxEffectOfShareBasedPaymentArrangements>
    <nbx:TaxEffectOfShareBasedPaymentArrangements
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMi0xLTEtMTE5OTk_f990007b-3dca-4beb-be88-7b7c816fd61f"
      unitRef="eur">819000</nbx:TaxEffectOfShareBasedPaymentArrangements>
    <nbx:TaxEffectOfShareBasedPaymentArrangements
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzctMy0xLTEtMTE5OTk_3179bf26-c33a-4765-a786-acccbac628e5"
      unitRef="eur">1339000</nbx:TaxEffectOfShareBasedPaymentArrangements>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMS0xLTEtMTE5OTk_c74924c5-f62e-451d-b640-897208e4a6d3"
      unitRef="eur">117000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMi0xLTEtMTE5OTk_d7a0d6ea-f7be-4877-a849-5bebab2baa5d"
      unitRef="eur">-6000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzgtMy0xLTEtMTE5OTk_09fe56a9-f0c1-46b3-81fe-1fc274768a03"
      unitRef="eur">-1000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMS0xLTEtMTE5OTk_4d3c015b-8c72-4b3b-b140-220325b2461d"
      unitRef="eur">644000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMi0xLTEtMTE5OTk_7c8959f1-fc39-4c06-8c68-409f68272722"
      unitRef="eur">540000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzktMy0xLTEtMTE5OTk_78fcb4f0-6cee-4cf6-8f74-2af6a3c1177a"
      unitRef="eur">736000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTEtMS0xLTExOTk5_1be030f3-35c8-4235-ba5a-9578c769a68a"
      unitRef="eur">12154000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTItMS0xLTExOTk5_99d99033-446d-4fb6-918a-c791462d172f"
      unitRef="eur">9138000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEwLTMtMS0xLTExOTk5_0696f9f0-5e2e-43f3-b7e8-28511d7e6b6f"
      unitRef="eur">15177000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTEtMS0xLTExOTk5_7a2d3822-99f3-4ec7-a026-ad64b515a83a"
      unitRef="eur">5000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTItMS0xLTExOTk5_a0e44da5-ad9e-46e8-a628-c27d8f15153c"
      unitRef="eur">9000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzExLTMtMS0xLTExOTk5_eb0e8e13-c644-4117-8bee-cc47a9f0fd02"
      unitRef="eur">3000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTEtMS0xLTExOTk5_8a8391a7-a593-4b1e-9d54-b2ff277b98d5"
      unitRef="number">0.0000</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTItMS0xLTExOTk5_3c66a991-e9a9-40b9-89f5-0c11ad80b6c3"
      unitRef="number">0.0000</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90YWJsZTowY2U3NTMwNmVmYjk0ZjdjOTQyOWQyMzEyMTVlMDA1ZS90YWJsZXJhbmdlOjBjZTc1MzA2ZWZiOTRmN2M5NDI5ZDIzMTIxNWUwMDVlXzEyLTMtMS0xLTExOTk5_335c1720-fe12-4704-bc46-13085c503ada"
      unitRef="number">0.0000</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i05ef069d6d904f1cbf20114a97bea67a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjE_709b67db-165d-4ecf-804b-71572b9f9c2b"
      unitRef="eur">75400000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i8c1e08d0df7b47f394f08a0c2faeffba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjI_5fe916ab-f8c7-4448-9b26-61c16a883033"
      unitRef="eur">14000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i6ff9c4acb5c74c6790f0853cd162580f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIyOTY_8a2c07ad-6ccc-4f75-b7ed-037b4df1e4cb"
      unitRef="eur">60200000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i21e5c44a32c64f1d93ae818113e1b5ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIzMTg_9e85cde1-df7e-4270-afae-c8660ca87c61"
      unitRef="eur">59600000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i64a32d6adbc0421e9abe2f62cfb9d425_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzIzODE_088ba5c6-cc90-4f8b-9624-ae64efe73083"
      unitRef="eur">51000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="i958be4f23f454d25a7eb235f2588e9a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI0MDM_5e86cd7f-3af3-4ef3-b441-13e6bffa83cc"
      unitRef="eur">49600000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <nbx:CompanyDeferredTaxRate
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzMyOTg1MzQ4ODY1NjA_5b696cd0-cf60-4f8f-8d9d-3f8479633bc8"
      unitRef="number">0.258</nbx:CompanyDeferredTaxRate>
    <nbx:CompanyDeferredTaxRate
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI1NTk_5f07ffc7-eb4e-4b33-842b-27ea9192785a"
      unitRef="number">0.265</nbx:CompanyDeferredTaxRate>
    <nbx:CompanyDeferredTaxRate
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTMvZnJhZzo0MDE2YzUwODkwYTY0MWVjYjQ5ZDEzNjRjYWM0MjJmOC90ZXh0cmVnaW9uOjQwMTZjNTA4OTBhNjQxZWNiNDlkMTM2NGNhYzQyMmY4XzI1NzU_9fef7645-3fb1-4878-93fd-2f9527667254"
      unitRef="number">0.2549</nbx:CompanyDeferredTaxRate>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTYvZnJhZzo3N2FjMWEyNDU0Njk0YmVkYWJlY2MzZjI5NjJlMjUyMS90ZXh0cmVnaW9uOjc3YWMxYTI0NTQ2OTRiZWRhYmVjYzNmMjk2MmUyNTIxXzEyMjc_e410fe26-0921-4585-bf14-9e3aa07c1a82">Segment reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Operating Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, reporting by operating segment is derived from the internal organization of the Company&#x2019;s activities; it reflects management&#x2019;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#x2019;s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTYvZnJhZzo3N2FjMWEyNDU0Njk0YmVkYWJlY2MzZjI5NjJlMjUyMS90ZXh0cmVnaW9uOjc3YWMxYTI0NTQ2OTRiZWRhYmVjYzNmMjk2MmUyNTIxXzEyMjg_7dfadccb-7ae7-4633-ae53-edaa5d55fbcf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In accordance with IFRS 8 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Operating Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;, reporting by operating segment is derived from the internal organization of the Company&#x2019;s activities; it reflects management&#x2019;s viewpoint and is established based on internal reporting used by the chief operating decision maker (the Company&#x2019;s Chief Executive Officer and Chairmen of the Executive Board and of the Supervisory Board) to allocate resources and to assess performance. The Company operates in a single operating segment: research and development in product candidates that harness principles of physics to transform cancer treatment. The assets, liabilities and operating loss realized are primarily located in France. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Revenue in 2021, 2020 and 2019 was derived mainly from the charging-back of shared external clinical research organization costs, in connection with the development support provided by the Company to PharmaEngine as part of the Company's License and Collaboration Agreement in Asia by Nanobiotix S.A. (see Note 15). For territorial analysis purposes, management allocates revenue based on the place of delivery of licenses or on the place in which services are provided.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzE_d2123fbe-69d9-4b5b-af9e-907077c46a51">Loss per share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss for the period (in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(47,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(50,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,733,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,385,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,631,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basic loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Diluted loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instruments providing deferred access to the capital are considered to be anti-dilutive because they result in a decrease in the loss per share. Therefore, diluted loss per share is identical to basic loss per share as all equity instruments issued but not granted, representing as of December 31, 2021, 3,006,532 potential additional ordinary shares, have been considered antidilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzI_c2838898-9942-4d14-b757-4d4abe92e082">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Loss per share is calculated by dividing the net loss due to shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The diluted loss per share is calculated by dividing the results by the weighted average number of common shares in circulation, increased by all dilutive potential common shares. The dilutive potential common shares include, in particular, the share subscription warrants, stock options and founder subscription warrants as detailed in Note 17. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dilution is defined as a reduction of earnings per share or an increase of loss per share. When the exercise of outstanding share options and warrants decreases loss per share, they are considered to be anti-dilutive and excluded from the calculation of loss per share.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzEyMzM_69837206-d555-4e85-bc98-3217eaa7abb2">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss for the period (in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(47,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(33,590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(50,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,733,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,385,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,631,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Basic loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Diluted loss per share (in euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(2.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMS0xLTEtMTE5OTk_8e826b2d-767c-4df3-bc65-b35339438cdc"
      unitRef="eur">-47063000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMi0xLTEtMTE5OTk_36514527-efad-4122-8ab8-b2be1c4df82c"
      unitRef="eur">-33590000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzItMy0xLTEtMTE5OTk_23d1a2e9-c07f-49d1-9db9-84f4ad681b28"
      unitRef="eur">-50915000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMS0xLTEtMTE5OTk_c7664a7b-2c1d-4b1f-8720-7cb9de287224"
      unitRef="shares">34733418000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMi0xLTEtMTE5OTk_3b637d01-a19d-405f-8846-5f93924da35d"
      unitRef="shares">24385827000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzMtMy0xLTEtMTE5OTk_d28d523d-3548-4100-9796-aa70daf5bb7c"
      unitRef="shares">21631514000</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMS0xLTEtMTE5OTk_1aa8e8d6-2a0d-454c-b5a1-0a292f6f7fb1"
      unitRef="eurPerShare">-1.35</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMi0xLTEtMTE5OTk_02f8b3a8-d165-4412-9a48-36afedac07f8"
      unitRef="eurPerShare">-1.38</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzQtMy0xLTEtMTE5OTk_d1eb936a-ecbd-46b9-aa14-32f9ca834e20"
      unitRef="eurPerShare">-2.35</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMS0xLTEtMTE5OTk_6f41d3ba-5cec-46da-a8d9-13acf6dd1f0d"
      unitRef="eurPerShare">-1.35</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMi0xLTEtMTE5OTk_c3535abf-44f2-4fdb-b230-93c34aadae80"
      unitRef="eurPerShare">-1.38</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90YWJsZTpkZmVmMWU1Y2I4ZDA0NmFiYjhiNzgzNzAxMDY3ZmQ0MS90YWJsZXJhbmdlOmRmZWYxZTVjYjhkMDQ2YWJiOGI3ODM3MDEwNjdmZDQxXzUtMy0xLTEtMTE5OTk_256fa6c7-c616-4026-b998-311b9eeff76d"
      unitRef="eurPerShare">-2.35</ifrs-full:DilutedEarningsLossPerShare>
    <nbx:AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8xOTkvZnJhZzoyM2ZlZWVjNjJhMzA0Nzk2OWMyZjAwYmQ2MmExYTQ5MC90ZXh0cmVnaW9uOjIzZmVlZWM2MmEzMDQ3OTY5YzJmMDBiZDYyYTFhNDkwXzExMTg_db9da1c9-17b3-428d-be31-8fe2716bdd0f"
      unitRef="shares">3006532</nbx:AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare>
    <ifrs-full:DisclosureOfCommitmentsExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMwMDI_5cb0b563-591d-4f53-bbed-b6a1d6311156">Commitments&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;22.1 Obligations under the loan agreement with the EIB&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In the event the EIB loan is repaid early, or in the event of a change of control after repayment of the loan, the amount of royalties due will be equal to the net present value of the royalties as determined by an independent expert, such amount not to be less than &#x20ac;35.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The EIB finance contract contains covenants that impose restrictions on the operation of the Company's business but no financial covenants that the Company is required to comply with.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In certain circumstances, including any material adverse change, a change of control of the Company or if Dr. Laurent Levy, Chairman of the Executive Board, ceases to hold office, the Company may be required to pay a cancellation fee. If Dr. Laurent Levy ceases to hold a certain number of shares or ceases to be an officer, the EIB may require early repayment of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;22.2 Obligations under the terms of the rental agreements part of the IFRS 16 exemptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The obligations of the Company related to the leases falling under the practical expedients (leases related to low-value assets and short-term leases) are as follow:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;One short term lease for an office by Nanobiotix Corp., of which the annual rent is &#x20ac;140&#160;thousand; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;padding-left:14.85pt"&gt;Leases related to low-value assets for Nanobiotix S.A.&#x2019;s printers, of which the annual rent is around &#x20ac;10&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;22.3 Obligations related to the MD Anderson agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;In January 2019, the Company and the University of Texas MD Anderson Cancer Center, world prominent center of research, education, prevention and care for cancer patients announced a large-scale research collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The collaboration will support multiple new Phase I/II clinical trials involving around 340 patients with Nanobiotix&#x2019;s first-in-class agent NBTXR3 for use in treating several cancer types &#x2013; including head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As part of the funding for this collaboration, Nanobiotix is committed to pay approximately $11&#160;million for those clinical trials during the collaboration, and made an initial $1.0&#160;million payment at the commencement of the collaboration and a second $1.0&#160;million payment on February 3, 2020. Additional payments will be made in the 6 months following a patient enrollment, and expense is recorded in the statement of consolidated operations during the course of the collaboration on the basis of patients enrolled during the relevant period, with the balance payable upon enrollment of the final patient for all studies. Nanobiotix may also be required to pay an additional one-time milestone payment upon (i) grant of the first regulatory approval by the Food and Drug Administration in the United States and (ii) the date on which a specified number of patients have been enrolled in the clinical trials. The milestone payment increases on an annual basis ranging from $2.2&#160;million to $16.4&#160;million. The amount will be determined on the basis of patients enrolled in the clinical trials at the date of FDA registration. This number increases every year and varies between $2.2&#160;million (if it had been payable in 2020) and $16.4&#160;million (if payable in 2030). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;As of December 31, 2021, &#x20ac;1.8&#160;million have already been invoiced since the beginning of the collaboration and &#x20ac;1.0&#160;million remain in prepaid expenses. An additional payment will also occur in the event of a successful first registration of NBTXR3 with the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:107%"&gt;22.4  Obligations related to the termination of the PharmaEngine agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company and PharmaEngine mutually agreed to terminate the license and collaboration agreement entered into in August 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company paid $6.5&#160;million to PharmaEngine (&#x20ac;5.4&#160;million converted at the exchange rate on the payment date) in accordance with the termination agreement signed between the parties. PharmaEngine is eligible to receive additional payments of $1&#160;million upon receipt by the Company of clinical study reports and of $5&#160;million upon the second regulatory approval of NBTXR3 in any jurisdiction in the world and for any indication. The Company has also agreed to pay royalties to PharmaEngine at low single-digit royalty rates with respect to sales of NBTXR3 in the Asia-Pacific region for a 10-year period beginning at the date of the first sales in the region.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="i9f7d1edd94224299addbda5de426a08d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzM1MA_81ac2c70-b5da-4a44-a482-60a49e54d0df"
      unitRef="eur">35000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <nbx:NumberOfShortTermLeaseContracts
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzc5OA_74c5b8c5-c27e-46a9-8124-7bb33e243f18"
      unitRef="lease_contract">1</nbx:NumberOfShortTermLeaseContracts>
    <nbx:AnnualShortTermLeaseExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzg4MQ_57cb91e7-7b5e-4140-a1b6-8421d11ddc1d"
      unitRef="eur">140000</nbx:AnnualShortTermLeaseExpense>
    <nbx:AnnualLeaseExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzk4OQ_d4b7f75a-5150-4067-9e15-dc8685c52197"
      unitRef="eur">10000</nbx:AnnualLeaseExpense>
    <nbx:NumberOfPatientsInClinicalTrial
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzEzNTc_8cd2b4c1-2815-44b9-8402-66fc1c78fd80"
      unitRef="patient">340</nbx:NumberOfPatientsInClinicalTrial>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="ie86596994b614e61888621f5f63b3d95_I20190131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE2NDg_2f9cb898-68c1-4d34-a213-bd7117a7b7a1"
      unitRef="usd">11000000</ifrs-full:ContractualCapitalCommitments>
    <nbx:ContractualCommitmentsPayment
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE3MjM_6208dbbd-7d6d-4839-ad46-beeec80a8696"
      unitRef="usd">1000000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsPayment
      contextRef="iaad70d6df1ab4fb0825b1a28a76096bd_D20200203-20200203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE3ODg_27a2c1c8-6028-4523-a470-c197fa816502"
      unitRef="usd">1000000</nbx:ContractualCommitmentsPayment>
    <nbx:MilestonePaymentDefermentPeriodAfterEnrollment
      contextRef="ic0738eac499e4251a6854800b581173f_D20190101-20190131"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzE4NjA_69c9405e-6dfb-4015-80bf-4c0e6de11f81">P6M</nbx:MilestonePaymentDefermentPeriodAfterEnrollment>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI0OTM_2605540e-77ff-4eb6-8a48-51483287546e"
      unitRef="usd">2200000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI0OTk_6a12e27d-130a-4d2c-8748-e25f700f4371"
      unitRef="usd">16400000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i60c6db77bf1848c292256b99f67f9809_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI2NzU_6a600799-7b6e-4f5f-9246-37c5e2b9a7d7"
      unitRef="usd">2200000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease
      contextRef="i924453673b444fda9c3c28b015994d6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI3MTU_7674dacd-0ffa-476d-a516-637e05273dd7"
      unitRef="usd">16400000</nbx:ContractualCommitmentsMilestonePaymentAnnualIncrease>
    <nbx:ResearchAndDevelopmentExpenseSinceStartOfCollaboration
      contextRef="i06cb4ce5915c4e4d828fd72b9468368d_D20190101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI3Njc_675dc90f-9eb4-46e2-9771-de0ba80aca81"
      unitRef="eur">1800000</nbx:ResearchAndDevelopmentExpenseSinceStartOfCollaboration>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="icfe58517db324e8ab08832232c673117_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzI4NDI_238d5c5a-0fa8-4da7-917f-1f379fcc3da6"
      unitRef="eur">1000000</ifrs-full:CurrentPrepaidExpenses>
    <nbx:ContractualCommitmentsPayment
      contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjM0_297548e4-1a1e-4085-8858-8f9fc7790ee7"
      unitRef="usd">6500000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsPayment
      contextRef="i0017336596444f75835cadbb51aedd4f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjQ4_76bac8c2-2e55-4cfb-90d4-bb9cbbc9d468"
      unitRef="eur">5400000</nbx:ContractualCommitmentsPayment>
    <nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports
      contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjYy_6a5ed8bf-16bc-4c85-a75f-3d408369cf78"
      unitRef="usd">1000000</nbx:ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports>
    <nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval
      contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjc0_d4fa4fb3-8190-469e-ae26-8d7411dd7a65"
      unitRef="usd">5000000</nbx:ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval>
    <nbx:RoyaltiesAgreementPeriod
      contextRef="if1ea1ee72a164bc8980c8af519b34ee9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDIvZnJhZzo4YWNkN2ExM2NlNTk0NDkxOTEwMjViOWVlOGFjYjYwYS90ZXh0cmVnaW9uOjhhY2Q3YTEzY2U1OTQ0OTE5MTAyNWI5ZWU4YWNiNjBhXzMxODg1ODM3MjEzNjg2_7ab94007-5018-402c-91b9-c360a87cbbd7">P10Y</nbx:RoyaltiesAgreementPeriod>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90ZXh0cmVnaW9uOjlmMWEyYWY2MDVjMzQ3M2U4ZWU3ZDYxNGI2NzhiNGI0XzMzOQ_f35e0780-f6b1-4243-b400-c5a402e05c0c">Related parties &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Key management personnel compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Salaries, wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supervisory Board&#x2019;s fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total compensation to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The methods used to measure share-based payments are presented in Note 17.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90ZXh0cmVnaW9uOjlmMWEyYWY2MDVjMzQ3M2U4ZWU3ZDYxNGI2NzhiNGI0XzM0MA_3bcee91e-d281-4ffc-bfef-ee5bb8bb3b5f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The compensation presented below, granted to the members of the Executive Board and Supervisory Board was recognized in expenses over the period shown:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.982%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands of euros)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Salaries, wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share-based payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supervisory Board&#x2019;s fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total compensation to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2,866&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,442&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMS0xLTEtMTE5OTk_4aa5f3e7-b5ab-4b05-9ee3-da4a7c0df69a"
      unitRef="eur">1245000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMi0xLTEtMTE5OTk_616493ad-af7f-469c-8a53-1a7ccf3481bf"
      unitRef="eur">1073000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzItMy0xLTEtMTE5OTk_dffe15a8-b58b-4f4a-b014-e1f59f4894b0"
      unitRef="eur">1306000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMS0xLTEtMTE5OTk_12916898-b5b3-424f-8a58-2e54b8ae17b0"
      unitRef="eur">2018000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMi0xLTEtMTE5OTk_250a5ee1-dd84-42ef-a087-c3b6d193fb15"
      unitRef="eur">1723000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzMtMy0xLTEtMTE5OTk_f00de9e1-5a95-47ec-a3fa-2c2947ea8933"
      unitRef="eur">2066000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMS0xLTEtMTE5OTk_5780e2a3-9815-4aea-a5cc-3eff7cad57e4"
      unitRef="eur">375000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMi0xLTEtMTE5OTk_5fed4ca4-4326-4b1b-9b99-073aebd73d8b"
      unitRef="eur">70000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzQtMy0xLTEtMTE5OTk_bd4ab1bf-4b57-4f18-a6ba-4b564fd29eb7"
      unitRef="eur">70000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMS0xLTEtMTE5OTk_1858ae9a-ef89-4957-8860-237c518fba05"
      unitRef="eur">3638000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMi0xLTEtMTE5OTk_02624480-99c2-4e34-ba8a-f11660ffad76"
      unitRef="eur">2866000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i21e9f3b008f44783a89a44cbc80ff554_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDUvZnJhZzo5ZjFhMmFmNjA1YzM0NzNlOGVlN2Q2MTRiNjc4YjRiNC90YWJsZTpiYWFiZGVhNWUxYzY0OWIyOTFjZjIxNjAyZWU1ZjQ3NC90YWJsZXJhbmdlOmJhYWJkZWE1ZTFjNjQ5YjI5MWNmMjE2MDJlZTVmNDc0XzUtMy0xLTEtMTE5OTk_3f466916-b7e7-492c-bfce-fde179d5dcdc"
      unitRef="eur">3442000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzI2ODc_506fe6dc-844c-4ade-b90c-a9399d23a882">Subsequent events &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting policy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Detail of subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"&gt;Considerations arising from the Russia-Ukraine war&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Russia launched in February 2022 the invasion of Ukraine, which, in addition to creating humanitarian concerns, may also impact the health care ecosystem in the form of delayed clinical trials. Clinical trial sites originally appointed in Russia and Ukraine for the clinical trial NANORAY-312 were not actively opened at the time of such conflict and, consequently, did not recruit patients. While backup options are being identified and the replacement of such sites by sites located in other countries is actively conducted by the Company, it is currently impossible to exclude any delay in this clinical trial activity, even if no significant delay has been identified as of the date of issuance of this Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share capital increase&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March 11, 2022, the share capital of the Company was increased by a nominal amount of &#x20ac;1,500, through the issuance of 50,000 new ordinary shares with a nominal value of &#x20ac;0.03 each, increasing the Company&#x2019;s share capital from &#x20ac;1,044,776.16 to &#x20ac;1,046,276.16, as a result of the definitive acquisition of 50,000 AGA 2020. Such acquisition was acknowledged by the Executive Board on March 11, 2022.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
    <nbx:DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock
      contextRef="i289cde5104064d92bd0d42d43cec761b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzI2ODY_638a56d3-da4c-4360-aca8-63358149e45a">Accounting policyThe statements of consolidated financial position and statements of consolidated operations are adjusted for post-closing events prior to the approval of the financial statements for issuance as long as they have a significant impact of the amounts presented at the closing date of the statement of financial position. If they do not, they are disclosed.</nbx:DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock>
    <ifrs-full:IssueOfEquity
      contextRef="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzMzI_a8285db7-d0fa-4492-a912-97f794276794"
      unitRef="eur">1500</ifrs-full:IssueOfEquity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i23cf69ba85e8443a80134ddac6e6373c_D20220311-20220311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNDA_5711afba-1e6f-42cd-83c8-17aa35029536"
      unitRef="shares">50000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
    <ifrs-full:ParValuePerShare
      contextRef="i58b267957c564e22a8fe73487217730b_I20220311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNDg_71450454-d38e-4f32-8eb9-afe0c8c617df"
      unitRef="eurPerShare">0.03</ifrs-full:ParValuePerShare>
    <ifrs-full:Equity
      contextRef="ia0283091d6704f18a2ff733acf943ed1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNTU_d297ae44-7a66-4492-8ce1-cd50a2e989b3"
      unitRef="eur">1044776.16</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="icae5cf18bb21492a86c074c63258fe60_I20220311"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzNzA_2b1982fd-555d-4297-9769-c6a2c4f49b57"
      unitRef="eur">1046276.16</ifrs-full:Equity>
    <nbx:NumberOfSharesIssuedThroughIssueOfEquity
      contextRef="i2d7bf6f87d6c4461a273858821e7fb90_D20220311-20220311"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3N2Q5NzE3ODQ0MTQ3ZTc5OTM3NmJhYmRhMTA0NjJmL3NlYzozNzdkOTcxNzg0NDE0N2U3OTkzNzZiYWJkYTEwNDYyZl8yMDgvZnJhZzpiNTA0ZmQ0YzJlNmE0NmJlYmJjNzQ3MWQ0OTExNDE3ZS90ZXh0cmVnaW9uOmI1MDRmZDRjMmU2YTQ2YmViYmM3NDcxZDQ5MTE0MTdlXzMyOTg1MzQ5MDMzODU_f7b336a6-d37b-4ab6-b31a-e4b5d852d7a8"
      unitRef="shares">50000</nbx:NumberOfSharesIssuedThroughIssueOfEquity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>161
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ5?G&(J"7E8XA>A2,T1G0DRN,S0<0S\88 Q5:I_W= Z#+QSZ8TNL.PC Z9.
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M8;S]Z_\L.V(O@/*& %8&L(, WO0+O S@AP&B(4"4 >(@0%@- 6898!ZVH2G
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M!)/J%?/^>'9,+N,P+T1SM7Z(PD#-DD=5K)5/#)(LSXK+K*&R0$FD!H=]/.X
MK/.OY)/J];/-FDOE #J9<A<M,% B&1.JQ'"W@7@ED52OD94OKU/L0&M($2VD
MK@$7X:A$VOO5QV;"I,?4/APCF)2:G'+$ER-0P:$-F: \+9CP @4:IF'#N33%
ML'K;0BN!IWJ%?X<]IU#8^YR;+L:X"[2^,:U< &MQ 1^PZ SJ-V6PZ'CMN#KI
M2N697N4_:-,9E/L^W.9YK; ZZ[U# +TI>(]59U#/U9 +9.Y[")0BJCO%4VIG
M4642F-XD?,"P,RCOAZL:@31M81&H?DVSRB\PO5_XD&MGT!1058UMPVDXCF&5
M*V MF^JNOIU!S:<&<P7<R8U*:.VDQ$*<&Y[2="'T H'VJ6:N58Z#Z1W'>PPI
M@[X!3IYQ&ZI.M+(63&\M.AI-AG@$%SM^Z@"L,ZV\!--[B0Y&DR&JR>#>;E+B
MK&9<G6,EK4POK;]D-!FBH'3K#AJ(\4I!N5Y!_R\'R0RLD'"HH5RH_05E[/ 4
M$U-;UVYJ7R6V7"^VW8PFRG[(H93:AK 0HUDB[5IEX<RU^/'>44=Y (QLVTW3
MYH@%0:"FB>R/2ES]#-B%&^T+)&%?V5S4:6)8O>+RRDSPED<*W9TF1X1?*+[0
M<$\[0>N,]YXCZ#W"1YPF1QR BUBV=ER=="7^7"_^'W2:')%_!^JNUXZK\ZY,
M F\Y.GB'U^38V8"%V2P/@2(GW5,THWX:5?+/6X[HWV\U.=1WL*PAI&DWAD!;
M%G7E&+C>,7S(:G)H"[C+;;.)3>4*N-X5=#::O/7P?<2A+:!P/5P@F?I4LQXJ
M]\#U[N$]II%#LX \K1PC,(XU"<(H;6R1J&R'T-N.CNY2(/Y!;40@SP[ .M/*
M0 B]@>C@+@6BE%!\)P)1Z>:'?J(24_%KS^<[6SB*+5 !194+AYF.?6CA$"0U
MA=GPJ$=4TBNZ/L/76CB,_5# 9]G,LI'"."J1=0LGA&U;Q_30PF%9E86SX(["
M0Z 6LAXG"*[/#&1%8D#J<&$AQ1[#-BC98.]MI>+]N&]^^E18AD@^JECCV%;#
MFFY?.=M>Y,EJ\P+30Y+GR7+S<2']N4P+@/K^,4GRMXOBG:C=BW]G_P%02P,$
M%     @ R(B(5(A<K\5'"   <2,  !@   !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6R=6F%OHSH6_2M65EIUI$F#;2!AMJW423IZE6:FU;2S\YF TZ!'( ^<
MM/-^_5X;$HA]<?KV2TO(L?&Q?>\YON'JM:S^K-="2/*VR8OZ>K26<OMI,JF3
MM=C$]66Y%05\LRJK32SA8_4RJ;>5B%/=:)-/F.>%DTV<%:.;*WWOL;JY*G<R
MSPKQ6)%ZM]G$U>_/(B]?KT=T=+CQ(WM92W5C<G.UC5_$DY _MX\5?)H<>TFS
MC2CJK"Q()5;7HUOZ:>%[JH%&_#<3KW7OFB@JR[+\4WVX3Z]'GAJ1R$4B51<Q
M_-N+N<ASU1.,XZ^VT]'QF:IA__K0^Q=-'L@LXUK,R_Q7ELKU]6@V(JE8Q;M<
M_BA?_Q MH4#UEY1YK?^2UP8[!7"RJV6Y:1O#"#99T?R/W]J)Z#6@X4 #UC9@
M9@-_H %O&_#W-O#;!KZ>F8:*GH=%+..;JZI\)95"0V_J0D^F;@WTLT*M^Y.L
MX-L,VLF;I^?;Y[MO=]^?G\C#%S)_^/[T\/5^ ?<69'[[] ?Y\O7AUQ,9D[N?
M/\C%O_\UXZ'_GP^DO2!909[7Y:Z.B[2^FD@8C^IUDK3/_MP\FPT\FS+RK2SD
MNB9W12K2TPXF0.3(AAW8?&;.'A<BN22<?B3,8Q09T/S]S3VD^>+=S6GD8,./
M:\-U?WR@OWE<K\D*(K,FNUJD:K8AWJM89L5+$S"9S$3M>))_?)*OG^0//.D[
M))B\K&L"B83(M2#PF*Q,L25M.@IU1RJI[&_&_M3S^-5DWY]H!,9Y$'FGL 4"
M"[R(!D?8"9W@2"=P3MQ=GD&HQ#JQE"M2 J.*%&4Q3F!&/^JK;B*S(BDW@L 6
M)N(-TFGMG-'P.(30.:,+ 6DXR9HQJ+[C35G)[&]] YO7IKN@-Q,T"(WIFB.@
M:> ;<XJ!PBD^H],CG:F3SF-5[C.5Z]$PGR)C9\;0;<S8GQDC1_H)?7S@L^/
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ME9UM5FOD%=Z$!'::4@"'36OZ\O.PD*/2@0$[Y6O$+W8[4DVBD33YDN)6 8C
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M(SJB*[Z.8>&!D=%&OS9.^U(7V:YI_M:ZJHS6Q<DJ-].'R(UR"O> .SU3:NP
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M648[N==P\+H<?'?^C$-W; >'R?P5"I4:UF.?)%N;V9EY_<(<B^XK8>O,L.?
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M-$9X=W="L WOR\(&VK[\6-/G#KJH0.]7UH:]$!T</J 6_P)02P,$%     @
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MP!K=(\?J 1D:#41YEQW6=<_.R9R&XQVWI=R7B3D-T/_&W$M/YPYQH/8EMC*
MZZM;C:&A^1[#U<K'K4@I]3JE8%$I:"#5G[8O*G%L!LATD]7ZV =2=Z(_1WSD
M+K^,/VZT ILXK-.Q.\WHA1G+8QJ--OT6F\JH&"_$N_U"NVL_^FLK>N?$EAYM
M2^_KJ^$OHRBL.G!QP@":KN42'%;\)LG2G&<>1R5#!Q5:]><DQ;"6+H?Z)DQ/
MO.A,C(H%CWW)P0X)AWY'>DRQ&;H. M;.4ON,ZT<3)3K<@$38 (8'DNF&#ZF
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M1/#N^5D@WUA+E7*NPG _M8V'!/FJ!65#JX&JB5U:L\%!@Z]<6D7T&G47XY.
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M4D9?J5P1_Z3?/IP>'V9..Q>;E_.TK+]=U/H!0?H0T23Q:AJHQLWI',<=.H#
MC E$"%'07N>H="=U@3H^!7<= 6B\0/A53/2>!+4\2%BP/UMMMSL=W;<D4*/X
M80B?/,7QN0F8A$I>H,-XTA1QM)/>._B<>J<^:'T9@;NO^/N/$_SZ.'PD:6:;
M3TS7X<O*;GGX/O5!6I1VQ*1:@G38GYWWX-#\S2<,O"GX.\O">,06WZ[1@2A+
M"_!\:= <50/:H/GP=O5O4$L#!!0    ( ,B(B%3]=H13\Q(  &XV   9
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MA:8V,DB08ZYA_#$*C& U!@F$;,8G"E'1$F-YVWM'(*>D Z/0@<:)B =,S4'
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MO8#GJQK!X#_0!O%/S)[]'U!+ P04    " #(B(A4I.N(^ D+  !4)   &0
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M!N#YO(#:S1=:H/LAT9O_ %!+ P04    " #(B(A4K/=-FG 1  "820  &0
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M%,U!7:SIMW=NB[HNEM1\4.E"E7@#7+\KBKHYP ':'V/Z\']02P,$%     @
MR(B(5 -DPLV9!   _ L  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
MS59M;]LV$/XK!V\8'$"0]>:WUC%0IRV:#^V"N-D^#/M 2R>+*$6Z)!7'^_4[
M4O)+YB3MA@';%XFD[H[//<^)O-E6Z2^F0K3P4 MI+GN5M9M7@X')*ZR9"=4&
M)7TIE:Z9I:E>#\Q&(RN\4RT&212-!C7CLC>?^;4;/9^IQ@HN\4:#:>J:Z=T"
MA=I>]N+>?N&6KROK%@;SV8:M<8GV;G.C:38X1"EXC=)P)4%C>=E[$[]:9,[>
M&_S"<6M.QN R62GUQ4VNB\M>Y "AP-RZ"(Q>]WB%0KA !.-K%[-WV-(YGH[W
MT=_[W"F7%3-XI<2OO+#596_2@P)+U@A[J[8?L,MGZ.+E2AC_A&UK.YKV(&^,
M577G3 AJ+MLW>^AX.'&81,\X))U#XG&W&WF4;YEE\YE66]#.FJ*Y@4_5>Q,X
M+ITH2ZOI*R<_._]$NI=<,IES)H#+7-4(?:&,N9@-+&W@S 9Y%VS1!DN>"18G
M\%%)6QEX)PLL'@<8$+(#O&0/;Y&\&/$MYB&D<0!)E,0OQ$L/Z:8^7OI,O&N?
M8 #X0%5M:+"FNC6@-+B4D4;E(SJ,U0V5H#7P&UO1A(KH]Q=@9 <8F8>1_3NL
M_^-@0)4+MD+8(=,&T*D"Q"G6*]2>USZ79* :PV3AL\=&*W)T?+M'1(]X"BUO
M4&I50\Y,!63>#O!KP^^9\!S]],,DB9/7AW<<#1T"^C,D,9Y73*ZQ8WP4I-F8
M##(83J?P,V'4YTG$*4S)*$WAL[*T?&9 448>(4S2,8&TJ-%8R!4]^NDDO8 L
M&(U'T,^"+,TNX/K][1+B$9TF@EFB@G<>!OK)9')!/FGJGL/IQ3GPKD+Z<41?
M^W$PFH[=>SRZ.(/7E1<9CR<1D1F,,@]B.J;92WH-@^&$$@HF1 [9QP[.J89/
M2>BD"KP%?T3 EAE@(''-W,%' PNL5HVT3F:2*!UEKXFCH_P!N%-<[*!H$*SR
M(=]=+RAQ)H^QG?(%-[F+Q.4:>+VAOP+Z!A$^*4NJ)6$,5TH6W)V[E"(K[BE9
M^ME63'YIH[D@;F#:DEJK>]32_6C^RZ99"9X#:PB:IBA(S&PKGE>'G.R>MV,J
M69C0 2F$.^NIJ'T!>VM"34>TL]PGI-6."1<6#%6N<9<+B4WE3,PQ2]LT&\"R
MI(O#PW%N+,\U^GNDBU/@JN4YH)72$*+5;@\E#B='*"T]Y.5V+OG#2=EY__![
M!(Z>%WBC#']>X"P<[Z$$=//2&<9(-B:^H;+Y'\L\^8O,T7\G\_COR'PM3W[5
M*T4.<@<5*Z!\^H@LN[*P_G Y4W84IOO=0_A<<;/'X,C;:$X]%B>5Z6F<?EX
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M-^&+]_%X^+_!>VZVN)'BSE% -)HN%R-FPK=X>'&Z\=^_&^WP->T?2\'1,ND
M]@NMW>&%%/3_$+G^'U!+ P04    " #(B(A4\0:61B4$  #W"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6RE5FUOXS8,_BN$!VQW0!<G;KKKVC1
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MWS"7RQ?/WKZZG+T&":0\XY"(FN$/>(YI)V"2\OIB\7JV>/[@^^>SB%4N75G
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M7-6/U89CI?Q?VWV@P7(_/.9*#I8TR$/"JVG>P>%7T-^C262"GR&%H%Z]=]V
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M^YE:=\ ,R=Q$RYVH$IJMQ)6LVJ<XUJQTBI=D5?89"'H^(WG?J!-(=%0TO7D
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M&KH_N&%)%S94UH#>YY*2ZR<VP' %7/T/4$L#!!0    ( ,B(B%2(Y-@DW 0
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M>#:A:U1U<V&W,'+M9K%4&IKLW&=)HS0J*T#GA91FN[  N^%\^1]02P,$%
M  @ R(B(5!;GD8QM @  C04  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL?51-;]LP#/TKA$\M$-0?2;LT2 (T[8;MT*%H]W$8=I!M.A8B6ZXHU]V_
M'R4G;C;4N=@B13X^2GI<=MKLJ$2T\%JIFE9!:6VS"$/*2JP$7>@&:]XIM*F$
M9=-L0VH,BMPG52I,HN@JK(2L@_72^Q[,>JE;JV2-#P:HK2IA_FQ0Z6X5Q,'!
M\2BWI76.<+ULQ!:?T'YO'@Q;X8"2RPIKDKH&@\4JN(D7FYF+]P$_)'9TM ;7
M2:KUSAE?\E40.4*H,+,.0?#O!6]1*0?$-)[WF,%0TB4>KP_HGWSOW$LJ"&^U
M^BES6ZZ">0 Y%J)5]E%WGW'?SZ7#R[0B_X6NC[VZ"B!KR>IJG\P,*EGW?_&Z
M/X>CA'DTDI#L$Q+/NR_D6=X)*]9+HSLP+IK1W,*WZK.9G*S=I3Q9P[N2\^SZ
M5E )HLXA<PM\;N6+4%A;@K-O(E5(Y\O0<AT7'69[S$V/F8Q@Q@G<Z]J6!!_K
M'/-_ 4(F.+!,#BPWR4G$.\PN8!I/((F2^ 3>=.AZZO&F(WA/;9HI020+F0GW
M.@AT >Q 2Q-04J1222N1_-&X4_'&+Y&2-?R0?I_@,!LXS#R'V2@'+P-7.!N[
MA/?._B2JT_""&I'A*F"1$IH7#/CXK)#J9"48>PB0LM9WD.N.)410:,4ZI@6<
MR1ILJ5OB'']ZV!I-YW#C#;XPK%(TPZ6-^*.WNJFH=RS23+>.SGPZN>:L.+Z>
MQ)<Q?.7Q-,[]O^#W+B<\DDB%9NL' 8&OUJME\ ZSYJ:7V%MX/ZCNA=E*?C$*
M"TZ-+CY<!F!Z\?>&U8T77*HMR]<O2YZ7:%P [Q=:VX/A"@P3>/T74$L#!!0
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MKC; ^XPQV1!*0?OIZ/P_4$L#!!0    ( ,B(B%3LW&E+T@(  "L&   9
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M .]G GJ_Z@85U-]O>O\"4$L#!!0    ( ,B(B%2P4BR"^PT  )M#   9
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M5H!V5JRO45RJ?YLOV;*XHC>ORBUT>E7_A=V2K$T=>"4$O*J,L6V#5H)RP3T
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M7)N"5+@B5_\L'3D@VQ'6*EIL[-A8"$U#R(H%37V4QH"^KX30.\5<T/]'9O\
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M-Y]HGIYFH'AI>VO'E>Y4&^;ZM09A 'H]XUP=!Z9=N_<__@-02P,$%     @
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M]GE,(_G-G(N0I/*M6 R36% RRX/"8(@<9S0,"8L&)T?Y9_?BY(AG:< B>B]
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MUFU+CB5^P)-,4,#GZZX\I>D+I>HD%Y"4SD!,A%2^!/Q;80"6TC#YCR4#M\S
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M@<<=3SX-PWY3HC$E0%/%!.DW)9P'CCJ6((7E9]SX&8-^/N=1JA8R]]D9!^U
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M&ZC_:\;D^T2W\?::G_T#4$L#!!0    ( ,B(B%1,R5X5^P,  )\0   9
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;,58:X_B-A3]*U>I5.U*6Q([/+>
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M"Y:8)#@5A*6 XVG7NH"?QS#4@$SB&\$K45H#[<H38S_T9A1W+4=;A"F.I*9
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MRPO]OP!)P<.<+87B$>?@@]Z/":5*6'1LJ:S4NNS(6-3/+7*/6'2S3!L !N?
M=5SX>#\$9Q\^'F 9U&#QG)SE\O$.G!EC#W$-7\%UW*++:I8Q>@$>/$5R=8J$
M-VJP?'G#X%Q7<PUQ5,>BT9NPW+R"Y91?7]_$HMOZ+,XIB\:UN6"[@LM6+:#H
M V[1!]R,W#M&3D1$F5AR#-@4%%TA6UR6NL*_MPH(1A(GXK\*M5ZAULO4^L=]
M4N.&P+IE1,=:T:%"R&G#C%8/)\\]+W ]IV,_EY.S+_6IY3M!N"TVWA>#T&D7
M0EN>^85G?J5GMPRE0HTV"_22'',B9PA*>MV6Y^WXX.\9YP8[?H[W90+'.6Q_
M4-@?5-I_.>H#[4-%DL."*GS/VFH6:IN_G8'F7@8\YUCD6H7>5J7>_F0$:'7D
MV@55^STC!YW-5.#\=NP,15"GZF!I'H'5F@E*^X2=@[_[#__<>57>;'H;?-?F
M!C?=#5:WM\?%E+-4 A-&%= (JWM*?' JRJE:Y8.^<\X'\$"G"LM!-^/,::KK
M:IEM?S<]#U8WO0?,U92:CXDJTI,Y4D/C93K38;TED;KOX3SRC%+TQ'@N>3'C
M&.OXU$GZIG_!X%V3ONEV,'Q-T@].BN%>\/WM_%P9$0C+"6H$VU)?C-16Y_=W
MZV%TB"O<Y;JIQ?7U%%<>-+MT(]$? -3<JHI  (JG"N4TFBIW/+]3YQO)%MDE
MY8E)=>G)EG.,8LRU@'H_94RN-_K>4WS9Z/T/4$L#!!0    ( ,B(B%1(H-AI
M=P@  &4T   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;+U;67/;-A?]
M*QBUTTEG8@L[R=;V3&([CN(LKA=]#]_T@99@FU.*5$DJ;F;ZXPM2E$ 2( Q6
MC?(0:[GW !?GXEPLU-%SFOV1/PE1@+\6<9(?CYZ*8OG+>)S/GL0BS _3I4CD
M-P]IM@@+^39['.?+3(3SRFD1CS&$?+P(HV1T<E1]=I6='*6K(HX2<96!?+58
MA-FWMR).GX]':+3YX#IZ?"K*#\8G1\OP4=R(XFYYE<EWXRW*/%J()(_2!&3B
MX7CT!OTRY:1TJ"RFD7C.&Z]!&<I]FOY1OIG,CT>P[)&(Q:PH(4+YYZLX%7%<
M(LE^_%F#CK9MEH[-UQOT=U7P,IC[,!>G:?R_:%X\'8_\$9B+AW 5%]?I\WM1
M!\1*O%D:Y]7_X'EMZWDC,%OE1;JHG64/%E&R_AO^50]$PP'#'@=<.^"N ^IQ
M(+4#<76@M0/M.O3%P&H'YMH"KQVX:PM>[>!U'6B/@U\[^!T'TM="4#L$KBT@
MN&$.ND:!MF1K;/>Z;.A&SGRC#>'(F7&TH1QIG/>Z;$A'SJRC#>W(F7>T(1XY
M,X\VU*,N]_TN&_*1QGY?Q_"&?>S,/MZPCYW9Q]O)7K$_7LM*I4EG81&>'&7I
M,\A*>XE7OJB$K?*74A0EI0;?%)G\-I)^Q<G-4Y@)<!HNHR*,P0$XB_)9G.8K
M^6'Z ,Y$$49Q^:IM=YN%21Y6*IJ#5VNK_.>C<2%[5.*.9W7K;]>MXY[6/X7?
M $&O 888G=]=@U<__> 33G\U09W:H=XLLT.)XX9UYH %'?MU_E*($LL88UX.
M:6Y ?.> B#RWWEW8L<[$3&+Y%19TZ]W[ 8@_@C'H!9JX '%#U^J_6^S>%CX,
M:,':U4L[T(=5+'-OT"A^=$'TAB!^>@DQD7D(#8@&K,\.6#APP_KB@F6BV8!U
MY8)%W;!^<YAET-2O7@:N752E&C44='/8 '<S ,Z:O;<.TV"80MVY(SJ.W=09
M$04O(HYE$=Q60KRMA+AJ@O0UT:I\LSC,<Y&7+ZL6P*PN??\O_4!4B$7^NZ55
MLFV55*W2GE;/_UQ%Q3<0%N!>/$9)$B6/99M+D47IW,3E&HY7<.4&Z^N)!RGW
M(81'XZ]-BG3# Q1 W7"J&R***6D:MD*CV]"H-;3-8B%*9G)WF M3'5XC!,VV
M$?2\0];NXSNJ1TTZ-A]U&^1W8KU=V["&37?8= L$<4"Q/FZZ)?:A%_2.&]N.
M&[..V\WJ/I]ET;+:H\I<> XSN=PJC#.;:7UH$[>.2;=B>CBZ$4:]L?!M+-P:
MR]WAS2&8)%$1R418KN[C:"9#>I#9+?-\EN9%.<,><E&81(9K/3J0R0&AWG?=
M$D$">WOO;7OO.4Y.D<SMT]+31X]7N=#E0C<TS]^I;JC-WU90_C8HWQK4Y.J+
MG))K1N8BC%^#\U666J0LV ('>Q10!-4.!MH#RO-5U:2HZ'H-EEDT$R57=<NO
MH@0(&2-(,S!/XSC,U)<_@[^!0RV>U'WP6DIUB*B9"]38?J&!;-S=@+.JD[;!
M444-[;.J(576D+VN[4R*=47SH6X=X28?I%$VVMU6)0O9:U9)QV,F1"+;3H4C
M&4K8$=LG&4J$D5V%OR\9[^O67<E0ZHOL\MLZ<[ -A)(^Y.^3 *6,*/AO5WDU
M'B+MDH8#3@XY[Y04DS'W,&52H+Q.5:EM6VL!OW_-@I4*8[L*.ZSV+FN(YA(M
M"+3*]YO)3+.ZK:U:15]?I=T9S A'>KDUV'E>_[@H@<=V@1^PAJB16C4&4NIY
M_!!U.3?:FO-C:K#5TZ,=7F/3A*WA?5XM[J52;*:0G$RK(B_"9%ZFN#G?*[59
M6Y?:TK]MK9MN44<IP0CC[FCHEAA3Q" )NF.A6R(Y:(1XI&<H5,G#]I+7G0&O
M02(*UV O:_!6L,2PUOUH,.2&.62 0QSZI#N+#'8!\9@VC70[.=N0IR%.#9:8
M\?)?SP"KXHSMQ?FE7&M-,/<LT_=QA/J8^9Z6929+4SY.#99:/K8'0:TA\ N[
MP]9!_-_@S<6;\E#$/T"V,Q"U5,!\CQ42JUJ/[;7>H7R<UQ"M'7Z_0JM% ;9O
MB'::M^<U>(MJRGI[I98,V+YDZ.49VTZ=5+DF<)^G7:H<$GLY=.&YAFCQW$\T
M4;6*V&O5;D030S7B 69]W6J< -KK1I?IP1MTHA24T'VRKD2+V$7+@?5)#=%D
MG?%^UI6B$?OF9R?6)\1PM.0SUM\OI7C$KGC[.+:XKOO@>&Q!E&82NV:^G+,N
M.V>BU)#L\VR)*IFD.^]J)E3?KB!N.3Y76DF':>6PS*W!6SL]2OLSERH=I78=
M_;['"3=UZX['"53I+!VNLT//>FCC\F.?4DN5U-*=I?:"ZE)++ FKI)9^1ZF]
MH*93_,"2L$IJZ7>6VA<2UAN4L$IDJ5UDKS*QB%:+'&0B#@LQ!T7:SAY;PBAI
MI?N45J:DE=FE=?"9&--U%C/F$?TNZ\Y@BAA!1#]&FII,,?8"RSV>$G"V\V+W
MDNF+70P[EU?K+;W!4HM;UWP$,0L,YUT&4^Q#B/O#5O6!V>O#@ O,MS54,RC#
M#>:IP>P Z5%],MCI5I\-5OK)X1<GK"LGJUMFV#P8#BL-9J:;6MVJ_UJ0J?K(
M[/5QE[O:"V9XW" @6(_QTF2)B.\9XC2<.=FN=9DJSLQ^DC3@4);ICQ64JL/U
M_M[UF!H$:FHPU06J'5SC\0'["N#%LO%O]IA,+0+8/D^0F"KR;.<3I G33Y P
MY- RZJI8LQV+];_>)3%5RMD^2SE7I9SOODOB>IWED :T_Q$356:YO<RZ#OW0
MQ3Y7%8_O\Y:=*\GFPZX<3,K,#<]W8<0-Z^IQXS'R\@<XG\),+LQR$(L'Z0H/
M/:D[V?HW+>LW1;JLGBR_3XLB750OGT0X%UEI(+]_2--B\Z9\6'W[RZ*3?P!0
M2P,$%     @ R(B(5*SCHV5%!@  T2(  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C8N>&ULQ5I9;]LX$/XKA+=8-$!K\=#9=0PT<=(F;1RC07<?%ON@R'0L
MK Y7HI(6Z(]?2J)%60<MIXBW#XUL?_,-Y^ ,A_;D*4[^3=>4,O ]#*+T=+1F
M;/-.TU)O34,W'<<;&O%/5G$2NHR_3!ZT=)-0=UD(A8&&(32UT/6CT712O+=(
MII,X8X$?T44"TBP,W>3'&0WBI],1&FW?^.(_K%G^AC:=;-P'>D?9U\TBX:^T
MBF7IAS1*_3@""5V=CMZC=[<ZS 4*Q)\^?4IKSR WY3Z._\U?7"U/1S!?$0VH
MQW(*E_]YI.<T"'(FOHYO@G14Z<P%Z\];]LO">&[,O9O2\SCXRU^R]>G('H$E
M7;E9P+[$3Q^I,,C(^;PX2(O_P5.)M<P1\+*4Q:$0YBL(_:C\ZWX7CJ@)8*M'
M  L!W!30>P2($" - 0)[!'0AH \5,(2 ,=0&4PB838$^#980L(8*V$+ 'NHE
M1P@X0P40W$8.-OW49S:J@MV,=K_(-MRH&>]^D6W 42OBO2+;D*-FS'M#B+9!
M+Q->*S.^V"XSE[G321(_@23'<[[\H=ASA3S?)7Z4EX<[EO!/?2['IG=K-Z'@
MW-WXS W V^KI*DTSN@2O9Y2Y?I">3#3&M>4RFB>8STIFW,,\H]X8(/L-P!##
MBZ]?P.O??[.)J?]QDN8ZTP[&\P,87P$-]!+-AA"9)9%854772WIQ .FK_727
M:KKK+!@#?)#[/@QAM$K&7I*/:I(;-QD#:.XAN5*3O-_D)$Y.@IRF_SOHK@^@
M4^;%IP$A)*C#YX.3Y/-P#>AY&FY>W(;Y8 W(>9Z&V^$:[+VYK_&25]4]7-4]
M7*@@?2K\U OB-./%+UX!+W#3E*;Y8Z$!>*(,_IW+ 9_1,/U'H9546DFA5>_1
M>O$M\]F/KL0LY<Q"+C_2/4XMJ)LVA'"B/=;SJPW$IN7 %O!F*..\#7R+'-@&
MWK:!2,<ZJ0-WO*)77M&57EFX"7AT@XR"#4U$ %[3+(GEZQ/P$PPH%)]*159M
MB7 ,2<.%0T W0T#S/: =;QB5-PRE-\J.[.?]EY^_ Y?Q-NS%*>LJ!48[(M""
M[628MX%O$22P-W1FM5A3N=BKR&<^WR?Q:D43/WHH5MI9%\W6"HCNM+.VA!D[
M%A&C#9QW '5B]QID5099:H,6M\ 71BVI&[P!7^_ + X"-U'L?[MBMX]8=9Q*
MJZ.VJ<@EKH46Y><-V"2^M[/9_ @4^RU.P+*P=7?G*7OJ1:D<X7HHR-CHC@."
M\F *#XS$!5^BPAVH=N9%1PP#DCT'X9<-Q( 2.!-KJ!<EA,9([XF';%U(W;OR
M>#PDE$9<=TR'[0LD6P#2CQD266R1NMJ^[-XX%]J';@Y9=I&Z[NZ,;2I'R+J'
MK&,&0%9$9#_S2"0$K=U>@!V3C$VST=([L;IN6>88-; W!_#..["FA76#;RBK
M<3H2T'J',VRGMR$A6;V1NGS/L_">9]PV%#PH&4N9&RWS?OM3->PXK1Y)=)U@
MA''3?5U(&QNVA9O.&\HY[T!BK",#$J?IN382\6@08O4<I;!L(EC=1+;7&7[D
M)=1->=F**"OV=.FV$Y4#+P7YCK&DXWCUH0-HME ?N^B0">WF^;0+YQ#+:)Z5
M.G"(3TQ6BW'>@<2&F?_K<;!LI1@-+T3<F=L#X2*[#WP/W(ISH6IBJXULQYS9
ML.Q\6-WY?BF)/@GRNN]MXAB]A0'+GHG5<U/+]\\ZNV+9*[%Q3/_+9H?5S>Z7
M_#_#[4G!T'6CM3TO!@!W#9"]%>\9*E[TD'$MM \\9&#9FK&Z->_/KSTG<BQ[
M'':.>1TC^P-YP?XP(QT%V#8Z4FL <-< 67^)NOX>8Z2X$FL8.%(06=")>A[J
M2K!#1PQ2NWLCQ\PQ6::)NDS_4HZ="?+=&Q%%^R"RG)/_<_2Y)@>-/D1V Z+N
M!HN$AGX6IM7E&(MW(Z@*FBS9Y)CC$)$UESQW'"+M^0(;AD7:Y>9S#]2T.FZ)
M![/..Z#(((BT+^=NNZ 86T[_.$1DJR#J<>B ^]$S055?AT,P;BWXL@.(B-WV
MU[P#J+Y)U64OTO=<> V^2Q5$BLO4<@E:[7OA_,<>-V[RX$<I".B*"\*QQ;=H
M4OY^HGS!XDWQ5?%]S%@<%H]KZBYID@/XYZLX9ML7^;?/U:]8IO\!4$L#!!0
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M<,7@=G:W_>_TK]TG@0ZPH0-@=P!H#["[ ZQS (0.B'<'Q-H#DMT!B?: ='=
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M+"<4S!^*>A^T0=T$C-!.0"_L1$< GZ/>?%#+ "/T#- +NZ(A (5A-L$8U!;
M"'T!!HB[HE, CW%((T<2F@7T%W5%]P >XW!&1B0T#]B).1>A,2C1;^P)A6@,
MBNP;(;-_N!A-?29CL9#;\RPDY*@/@(F/&Z6IZ[>6VE.(W,V*,LX9 O(BH6F
M;KMB786=\2S&(8CL1N@9H)=I(O;O<]1;28R;:AXH5&.(2/^8ON)Z/T'A?R.D
M_P?HM*(? (5AIRDR&*$M0'^M5O0)H# L;^0Q0JN 6J^%]JW( .(3BM08%-$W
M0D;_8(K]0WTF)U43F<#E0+%_DQPW5U/7QS,E)[[-23!G ,AQA X!*KG^H:["
MTYQ0,'\HZ@".06T$C-!'0*_J1"L GZ/>>5"O ",T"]"K.A'S'Y/30N\^J!^
M$1H"#!!U18L "L/-9=SSF3>C_II.] 3P:?L8CC:R(J%QP$[2N82D06E^DYQ0
M#L>@N+X1\OJ'2TG69W($/0OL0C>H"8!).FP(Z"7H4L*FGDZ=DC@&-0PP0L<
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M;S-B\ST)S!-&7)!C"<%_E>:_J*NT'^44WOW\:PH86W^GZ80"^N-6;Q"SJ(V
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M\N-,\*F0^@+U]\<L*U9?]+LZUF^DN?@;4$L#!!0    ( ,B(B%3,5UEQ@@8
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M3WZC^")[,^*>*\63[').242%$=#?/W"N5C?F98OR=:JC?P!02P,$%     @
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M<6P;'V\4WS6=US57BE?-94'2G(@:H-]O.%>/-_4 7?-^^2]02P,$%     @
MR(B(5+JHBE?T @  & H  !D   !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL
MM59=;]HP%/TK5B9-K;0UWWQT :E I_6A$FK7[6':@TDNQ&H29[8#[;^?[800
M"&1(:U_ =NXY]]Q[G-C!AK)G'@,(])(F&1\9L1#YM6GR,(84\RN:0R:?+"E+
ML9!3MC)YS@!'&I0FIF-9/3/%)#/&@5Z;LW% "Y&0#.8,\2)-,7N=0$(W(\,V
MM@L/9!4+M6".@QROX!'$4SYG<F;6+!%)(>.$9HC!<F3<V-<SVU4 '?&#P(8W
MQDB5LJ#T64WNHI%A*4600"@4!99_:YA"DB@FJ>-/16K4.16P.=ZR?]7%RV(6
MF,.4)C])).*1,3!0!$M<).*!;KY!59"O^$*:</V+-F5L7V8,"RYH6H'E/"59
M^8]?JD8T ';O!,"I ,XAP#L!<"N >R[ JP">[DQ9BN[## L\#AC=(*:B)9L:
MZ&9JM"R?9,KW1\'D4R)Q8CQG=$V4B1Q]1C=11)0;.$%W6;FGE#<7,Q"8)/Q2
MAMP^/:"+CQ\&;L_[<HFJ 2(9^A[3@N,LXH$II"[%;H:5ADFIP3FAP7;0/<U$
MS-%M%D&T3V#*@NJJG&U5$Z>3<0;A%7+M3\BQ'/N(H.GY<.L(?'8VW!YV5./6
M'KF:SSW%1WB84%XP0'2)J(B!H7SGVR^!%PG\[DCDU8D\G<C[UV9 !3_TH>Q;
MB>]IO/JDK,>VYP?FNMF<=HR_"]G3Y=>Z_#-U,5@#.ZYMXK?R#OO[TJ9EB-^4
MW_..:^O5VGK=VO"K:O\GE ,C]*BP;@(?O0)FO,.^?BVE?UZ;.)(O+XH(SPL!
M7<R#FGGPOCMP6"<:_M\.G S;N\L[<'G8<MFSCIML6[O/I/4&6[ B:::V#L1U
MANR+:WS#[3/%*=_#&+-5I^VVLV-VWM=X>_>1L]VWZ+#;\K_5X79(^RTW&T=F
M"K)?ZNK!44B+3)3G3+U:7V]N]*%^L#Y1UQY]%.]HRCO3O;2!R"8EL)24UE5?
M>L[*:T@Y$337!_.""GG,ZV$LKV[ 5(!\OJ14;"<J07T9'/\%4$L#!!0    (
M ,B(B%3-+-' H0,  +T+   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM
M;*56VX[;-A#]%4(%@@1H5E?+=F(;6-N;- \!%IND?2CR0$MCB8A$.B1M;_OU
M'5*RUI9D[:)YD4AJ+N?,C(8S.PKY0^4 FCR6!5=S)]=Z]\YU59)#2=6-V ''
M+ULA2ZIQ*S-7[230U"J5A1MX7NR6E'%G,;-G]W(Q$WM=, [WDJA]65+YSQ(*
M<9P[OG,Z>&!9KLV!NYCM: 9?0'_;W4O<N8V5E)7 %1.<2-C.G5O_W=H/C(*5
M^)/!49VMB:&R$>*'V7Q*YXYG$$$!B38F*+X.L(*B,)80Q\_:J-/X-(KGZY/U
M#Y8\DME0!2M1_,52G<^=B4-2V-)]H1_$\0^H"8V,O404RC[)L9;U')+LE19E
MK8P(2L:K-WVL W&FX,=7%():(6@K1%<4PEHA?*E"5"M$-C(5%1N'-=5T,9/B
M2*211FMF88-IM9$^XR;O7[3$KPSU].)>B@,S253D+5DSE11"[240L24K499,
M8XZU(EA@Y $TDV#V9 D<M@S/7Z]!4U:H-ZA]]^V!O'[UVR2,H_=O2+T@C).O
MN=@KRE,U<S5"-H[=I(:WK. %5^#Y ?DLN,X5N>,II)<&7.3:$ Y.A)?!H,4U
M)#<D]'\G@1?X/8!6+U?W>M37+U;WIP-LPB9]H;47/I^^O^E&:8G_T?<!NU%C
M-[)VH^?M8B7(I\QO3IFG9ITQSAG/C,P.)!-I7X8K3['U9-K081'YT<P]G >]
M*Q.&?B-S06'44!@-4E@)I0TP!?+ $N@MOLK"Z,SMI(VL*S*.+T76HP[X,Y$+
M['&#/1[$_HEKD* PS"Y)\:<4>ZY-G!/DU$LD[J#T6SRZ$F$_QG&#<3R(\>X1
M[QX%MC7H' 8*8-R-\JB%KBLRGO;#FS3P)H/P/N*=A\4K"38T!0IKN* :4J(%
M@4>#%7@"?6@G'2AO_3!LX>T1BJ_4Z[0!//V_@).<\@Q,*TVA%)FDNYPEA"J\
MK'?F]NPMB6D78COJ79$K->%[3]>)]^LLMHQ3GC!:/,>A=G9!(FKGHD<H#J[P
M.+L6_4$>MXG>4VD@9AU&B<@X^Q=)(16!I2_QORQQZLK-.'0P#''?6UNUT\OB
MF@1M0EVIZ J?X(E/\.L-'7@ZW,IK)Q=]VI^TX7>%.@U_W6>IT_'=L[FF!)G9
M^5 1VPZK&[\Y;6;06SMYM<Z79C:U\]*3F6JP_4QE9O);P!9->C=CC+JL9L5J
MH\7.3D\;H7$6L\L<YVN01@"_;X70IXUQT$SLB_\ 4$L#!!0    ( ,B(B%2Q
MN&PJ; ,   D.   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;+U7T6[3
M,!3]%2L2$DC0Q$G;M:BMM&X@>!B:-@$/B <WN6DMG+C8SKK]/==.EK20>F."
MO;1QG'-\SKW)]?5L)]4/O0$PY+80I9X'&V.V;\-0IQLHF![(+90XDTM5,(-#
MM0[U5@'+'*@081Q%X[!@O P6,W?O4BUFLC*"EW"IB*Z*@JF[)0BYFP<TN+]Q
MQ=<;8V^$B]F6K>$:S.?MI<)1V+)DO(!2<UD2!?D\.*5OS^C4 MP37SCL]-XU
ML5964OZP@X_9/(BL(A"0&DO!\.\&SD (RX0Z?C:D0;NF!>Y?W[._=^;1S(II
M.)/B*\_,9AY, I)!SBIAKN3N S2&1I8OE4*[7[)KGHT"DE;:R*(!HX*"E_4_
MNVT"L0>@XR. N '$OP.&1P!) TB<T5J9LW7.#%O,E-P199]&-GOA8N/0Z(:7
M-HW71N$L1YQ97"IYPVU.-'E#SKE.A=25 B)S<JHQMUOCYCYKR(B1Y *8F[X"
MPQ5@.@U90@DY-YJ\/ ?#N-"O9J%!998_3!L5RUI%?$0%C<F%+,U&DW=E!MDA
M08B66E_QO:]E[&4\AW1 $OJ:Q%%,>P2=/1X>>>0D;9@3QY<<XSN(++YF.)^1
M51TZLA4,8_S-L)6 [Y[5ANUJ0[?:\,AJUS+E3! -::6XN2,IQE;Q5>4^',4,
M]&7(3SF,!Q%]T1?(!W##012]\'@:M9Y&7B(;05GA^W9,OQ\>#::37OD/P9+$
MIW[<JA_[,V)8GA-3J5+>@.J3[\='@V@T&?<:> +PP,)):^'$GX *(X\O4)]X
M/S*.R!TPI?O4^Y'TI ]Y('_2RI]XJ2Y8B=N2K5@>LFE+-GV&SYE&79&.O.+W
MRBWKJG)OG?43C<?'4_$DZ*&AO5V'>LD^R?)-\9B,T+BCC)\C)UU%I\F_RHF?
M:#STY.0IT$-#W:9!_:7ZW2WN%[:I\K%UY9J.GB,=78&E#U18)K -);Q,L9O5
MX+8)\A*'HLIXN<:)7+CZU=^>^,F3/S>Q)C]_C3NTUQ5?ZJ^$]H.!QR2HJX=T
M\AP)ZDHFG?[/!/G)<9N+1_T9^GM@;3#<:ZH+4&MWUM#$-2%U']K>;<\SIZZ+
M_^W^TIYS7+/>T=2'I NFUAS#+"!'RFAP@I^4JL\=]<#(K6O=5]+@0<!=;O"L
M!LH^@/.YE.9^8!=H3W^+7U!+ P04    " #(B(A4S65U:,@"  !:"0  &0
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MQF;/\G3X.DVTV!?GEY70YC14#'?FP$JD!9C[&R'TX\0>B:HC\.P[4$L#!!0
M   ( ,B(B%1[TIV--P@  ,PN   9    >&PO=V]R:W-H965T<R]S:&5E=#<Y
M+GAM;,U:VV[C-A#]%<+%%BVP:XN41#N[28 XSL5[#?;2/A1%04NT+502O125
M;(I^?$E9%F5+(I5N"_@ED6W.T7 X/&>&TND#XW]F:TH%^);$:78V6 NQ>3D:
M9<&:)B0;L@U-Y2]+QA,BY$>^&F4;3DE8&"7Q"#D.'B4D2@?GI\5W=_S\E.4B
MCE)ZQT&6)PGACU,:LX>S 1SLOO@8K=9"?3$Z/]V0%?U$Q9?-'9>?1A5*&"4T
MS2*6 DZ79X,+^/(-/E$&Q8A?(OJ0U:Z!FLJ"L3_5AWEX-G"41S2F@5 01/Z[
MIY<TCA62].-K"3JH[JD,Z]<[].MB\G(R"Y+12Q;_&H5B?3:8#$!(ER2/Q4?V
M<$O+"?D*+V!Q5OP%#^589P""/!,L*8VE!TF4;O^3;V4@:@8>[#! I0$Z,(!>
MAX%;&K@'!JCK#EYIX/4U\$L#OZ\!+@WPH<&DPV!<&HS[WF%2&DSZ&IR4!B=]
M#:"S6SFGMTFUV-NDVV9)D6(S(LCY*6</@*OQ$D]=%'E:V,O,BE*UI3X)+G^-
MI)TXOXY2D@81B4$<D4441R*B&7@!+L(P4CDO?YBGVYVK=L!/,RI(%&<_@Q]_
MF+C8>P6B%'Q>LSPC:9B=CH1T20&/@O+VT^WM4<?M7^?Q$$#G.4 .<JZ^? 0_
ME;@_?\T)%Y3'CW]$:29(++>Q:,&_[('OPBU^B_G,9IY*\S;W6K"NS%CO"-^Y
M D]L6-=FK ^!J+ F-JR;WB$ZP!)<IL::MD#>FB%G-*BB#FWNS?MC69?@=6\L
M^Q*\Z8]E6H*1W)#5KD35KD0%N-L%'F5!S+*<4_!A";9[CH9[._%B(042Z.W[
MMK9]?WLK\<!<T"3[W>"-6WGC%MYX'=[<<190&F9@R5D"%HQ+^RA=M6WWVRT2
M+I"4G-^?RVUW7U_NY@CHN/[!J-<MHSS'T:/V)N)5$_&,$[ED:<;B*"1"!E.&
MD@8D4Y<9B6GV'&PHCUC8-BLS+ :/E/#,$&F_<M"W.5C1[D5X+Y=6KJ9D5O"6
MD;2,_PV[ISQ5=%C\<I<OXB@ %[E8,UXLO\$/7/F!CR#_QI4W8V-4YLE&5EZ
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M\^VKT]L/@FV*-UX71<U27*XI"2E7 ^3O2\;$[H-ZB;9Z@?W\'U!+ P04
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MT)\OA5"/-WD#NP-UD_\!4$L#!!0    ( ,B(B%0<J%=M0@4  +89   9
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;,5945/C-A#^*YITVKF;@=B2G1!H
MR Q)H$>'FS+0:Q]N^J#82J(Y6THEF="9_OC*LK$2QU8"!^4%;&>_U;?KU7YK
M>[CFXIM<$J+ 8YHP>=Y9*K4Z\SP9+4F*99>O"-._S+E(L=*G8N')E2 X-J T
M\9#O][T44]89#<VU6S$:\DPEE)%; 626IEC\,R8)7Y]W8.?IPAU=+%5^P1L-
M5WA![HGZLKH5^LRKO,0T)4Q2SH @\_/.!3R[#,(<8"S^H&0M-XY!'LJ,\V_Y
MR75\WO%S1B0AD<I=8/WO@4Q(DN2>-(^_2Z>=:LT<N'G\Y/W*!*^#F6%))CSY
MD\9J>=X9=$!,YCA+U!U??R)E0+W<7\03:?Z"=6GK=T"42<73$JP9I)05__%C
MF8@- .RW % )0'5 V ((2D!P*" L >&A@%X),*%[1>PF<5.L\&@H^!J(W%I[
MRP],]@U:YXNRO%#NE="_4HU3HRO*,(LH3D!"\8PF5%$BP3&84ADE7&:" #X'
M4Z(P34@,KEE1F^8>SW3A@3%FW\ -QPQ\**SD1PV__'('/OSTPR#HAS]_!.4!
MH S\ON29Q"R60T]I^CD)+RJIC@NJJ(4J1. S9VHIP26+2;SMP--Q5\&CI^#'
MR.EQ2J(N". 10#Z"#80FA\/]!OC4#?\U2[H ^JWPRWUPIE=OA&\E(Z@J(3#^
MPA9_-YPMCA41*9AQH;&4+:3#;5BY#8W;H,7M?=&!P&]S,.$LIGGIZ&J[B!]T
MW1%Y9 I(F@J2X(+%Y='7&^T'7"N2RK\<+'H5BYX[N(WBQH)*'1R8"YZ">5'_
M^M2TK-)"@1E94,;RZ[K\5T10'C=5;+%JWZR:]^2'$=0=.AQZ#YMEM&OE5Q9;
MX?2K</K.I$Z6F"TT4;VADF=%]A7/I!+Z@BNI)Q6+$V=2;P75"ZSTW10D(KK?
M-Z:H\-';"#ZHI6?70B?1;TG1H"(W<)*[3E<ZS/SNQ;J5\8PIDPI=8#B*!,G+
ML(GM8)=+V*_QW;4)3YK)GE9D3YUD+Z(H2[,$*]UBY_11_Z5,;T4B%2"/>B:0
MQ+#.<-+$^72'SS$,>S72NT:PA33TK7;XK[NKB$Z_<S^5"]8WU* 63(M9V!+0
MAAA"=T7_<FGZSQ'X=#^>@"N1]RC'3H'(>D;ON&.A;?+0W>7'3[W]""PRK.-3
MA( Y(8TWP^W*[Z+>CTVJ^7S<=C!66F!X6#!:1JH-(_0N:E+3/;[\;@"=K*S4
M0+?6-!81^!<\4V"A%0/H5H.WE5AHY0"Z]>"M1+9<=G.W]\S,L]T3=JU:) 1:
M#8&#]]RU5AZ@6Q\.4UKH[/%EEG9M>JU:BZP2(+<2O%!M2Z^;;%!=;1ML8$NC
M1[;1(W>C_S[!+9UO*6Y0GVH:C%H$%UD50>A_%MQRP>V]%=3W5J,5:JL:*T;(
MK02V4XYOK_>K+;+"@-P/'6^[;Y&5 N26@N>H[1Y7K6K[0MQT#PYV^TX]1%:>
M4/_55'J\QQ?L!OWF++P,-]V#0WMF%63%$>UY6&JH]></!<A*%W)+U]L.!<A*
M%W)+UUL-!>6RVRTIK#]Y-UBU=*W :EW@OV-S":R&!7L>5@X:"H(&K8+U-#48
MM4\%@96KP"U7+YP*2J];BK\S[C48!2UC0;#Q"LPM2-\W%I3.MU,-49WXKA5L
MR[05O,#]]/+Z@T&Y8&TPJ#^(-UJ%]?O@;;R?3HE8F \#$IB**-[65E>KCP\7
MYI5[[?H8GDV*3PC63?%%XS,6NFU(D)"Y=NEW3W1^1?&1H#A1?&7>@L^X4CPU
MATN"8R)R _W[G'/U=)(O4'VJ&?T'4$L#!!0    ( ,B(B%30[LG;J0,   D,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;,5636_;.!#]*X0*+%J@
MC;X5J[4-Q'&*#9#N!LYV][#H@9;&%A&)=$DZ3O[]#BE%D6U9\*' 7B22>O/X
M9D8<SG@GY*,J #1YKDJN)DZA]>:SZZJL@(JJ"[$!CE]60E94XU2N7;610'-K
M5)5NX'F)6U'&G>G8KMW+Z5AL=<DXW$NBME5%Y<L,2K&;.+[SNK!@ZT*;!7<Z
MWM U/(#^OKF7.'-;EIQ5P!43G$A839PK__/<#XV!1?S-8*<Z8V)<60KQ:":W
M^<3QC"(H(=.&@N+K":ZA+ T3ZOC9D#KMGL:P.WYE_VJ=1V>65,&U*/]AN2XF
MSL@A.:SHMM0+L?L=&H=BPY>)4MDGV358SR'95FE1-<:HH&*\?M/G)A = S\Y
M81 T!L&A073"(&P,PG,-HL8@LI&I7;%QF%--IV,I=D0:-+*9@0VFM4;W&3=Y
M?] 2OS*TT].OC%.>,5J2DM$E*YEFH,@G,F<J*X7:2B!B11:0"40AQ"8+5ZX+
MRM>(9)S< <:=W'7,W\]!4U:J#TAT\WU!WO_V;A0FT9</I!D8L[\*L564YVKL
M:G3$R'&S1O2L%AV<$.T'Y)O@NE#DAN>0[Q.X&($V#,%K&&;!(.,<L@L2^A])
MX 5^CZ#K\\V]'O/YV>9^.N!-V"8UM'SA";Z'^A"3/S%/@N?,) TS?)4_8:Y!
M?20SRA\5N1.4*W+%\V;T[QWRD%L-E?HQH")J5416173RUWJ&'#.M08+2!)ZQ
M5BGHRW;-DU@>4ZB>IL%H-':?N@DXQH1AN(^9]V#BM,7L.1&W3L2#3M0_=^=L
M# 0F:3F3_S$]EZV*RV'/.@>62J887Y.5%!59U24!I[8H-PA-EK!FG)MU//\;
MD$SD?<FL=XT[24C\HVSV@"(O[D_5J'5H-.C0'WC)E#9=6*RT1/&]I65TM+4?
M728'^HY!L:D+??+25EXZ*.^VVJ D$[L<:ZO8<MV$4A= ^'G:TR-9GWS?.]#>
M TJC?NV^]W9->+_H,#=$\>!I[@%UC_.^R,Y=Y@^*7,"&OF!38J-LP]DKT.^+
M8AH?2NR!I<'HA,;@36,PJ/&&RO*%8!CQ,F]OTS-2W]#NJPZ.XMJ#BDZ40/_M
M.O'#7ULJ (O68)%H-NR6ZB3VTT-O>E!'M63>ASHN)FZG1ZI KFVOJ8@]B'6?
MT*ZV_>R5[>(.UF>FS[6]UQM-W21_HQ(KI,)LKI#2N[C$-,BZ[ZPG6FQL)[84
M&OLZ.RRP5P=I /A])81^G9@-VNY_^A]02P,$%     @ R(B(5+'$SH8J!P
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M7 O4?,&8W';T53;\N9*_4$L#!!0    ( ,B(B%37=TM+2@(  /H$   9
M>&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;(U4[VO;,!#]5X0'HX4N\H\F*YUC
M6).-%38H3;M]&/L@V^=85)9<24[:_WXGV3$N:T:_Q'?2O:=[3Q>E>Z4?3 U@
MR5,CI%D&M;7M):6FJ*%A9J9:D+A3*=TPBZG>4M-J8*4'-8+&8;B@#>,RR%*_
M=J.S5'56< DWFIBN:9A^O@*A]LL@"@X+MWQ;6[= L[1E6]B O6]O-&9T9"EY
M ])P)8F&:AE\CBY7B:OW!3\Y[,TD)DY)KM2#2Z[+91"ZAD! 81T#P\\.5B"$
M(\(V'@?.8#S2 :?Q@?VKUXY:<F9@I<0O7MIZ&5P$I(2*=<+>JOTW&/3,'5^A
MA/&_9#_4A@$I.F-5,X"Q@X;+_LN>!A\F@.C\"" > /%; <D \,[1OC,O:\TL
MRU*M]D2[:F1S@??&HU$-E^X6-U;C+D><S>XT*X&T[)GE @QALB3*UJ#Q;*U!
M6B(XR[G@EN/N![+FIA#*=!J(JL@:*L"JDES+0C7@T2LEK<;+(=\GP),U6,:%
M.46*+_>WY.3]NXMD<?[IE P!X9+<U:HS2&%2:E&9ZX\6@XJK7D5\1,4:BAE)
MHC,2AW'T"GSU=GCX$D[1S]'4>#0U]GS)$;Y-EQ>"&<,K7C WK<:YA0M@S=D+
M1YUC\-CUR6^6&^_=G__TD(P])+Z'\Z.:AKO1L /9#6<5A]N9-/&:W3WWPG.[
MAV"718MY=)'2W=35?ZO"L:)OFDXFT[T*/YC><K1#0(68</9Q'A#=_]/ZQ*K6
M#VNN+(Z^#VM\G$"[ MROE+*'Q,W_^-QE?P%02P,$%     @ R(B(5-(C:._+
M!0  BB8  !D   !X;"]W;W)K<VAE971S+W-H965T.#@N>&ULS9IK;]LV%(;_
M"N$!0PNTM7B3[2XQT#H+-F ;BEZV#\,^,#(="Y5,EZ23%MB/'RFKHFQ2]"4>
MH"^)9!\>O>1+/:2.=?4HY&>UY%R#KV6Q4M>#I=;KU\.ARI:\9.J56/.5^68A
M9,FT.97W0[66G,VK1F4Q1$F2#DN6KP;3J^JS=W)Z)3:ZR%?\G01J4Y9,?GO+
M"_%X/8"#[Q^\S^^7VGXPG%ZMV3W_P/6G]3MISH9-EGE>\I7*Q0I(OK@>O(&O
M9VEB&U01?^;\4;6.@>W*G1"?[<FO\^M!8A7Q@F?:IF#FWP.?\:*PF8R.+W72
M07--V[!]_#W[;=5YTYD[IOA,%'_E<[V\'HP'8,X7;%/H]^+Q%UYWB-I\F2A4
M]1<\UK') &0;I459-S8*RGRU_<^^U@/1:@!)1P-4-T#'-L!U UQU=*NLZM8-
MTVQZ)<4CD#;:9+,'U=A4K4UO\I6U\8.6YMO<M-/3VWS%5EG."I"OE)8;XY!6
MYC@K-G,^-P= +SE0FFENOP)B 19-D[50^=:,E0DMU\838,Y,:U%R\!+<Y"HK
MA-I(;MO](58O9QLI;1IWV3=*<7-%F\%]^%O.[O+"Y.8*/+OAFN6%>FX2_OSI
M/7CVXP]CG)*?GH/ZP(K\N!0;97*HJZ$VHV+[-LSJ$7B['0'4,0(W/'L%,'P!
M4()@H/GL^.;);O.A\:(Q!#6&H"H?[LJW,V;SJN^5$=M;MAKM.W,_MFQH._>W
MS0=RXY;Z)Z(&-VIPI89TJ/DHM+F NQ2KW H-\C9/6N6Q['B8C@DA9D0>VF/I
M1T$X&<%1$[:CDC0JR1DJ7P!F1HGE$CRP8L-#HK=IZ0'1?E1,-&U$TY-$%V[.
MAZ123P1%-,%[4@-1:3*F8:5IHS0]5^D18YP>)3P0U2U\U @?187?AB1;Q:P4
M4N?*W%>94#IRGXR;*XU[<-=.&C632TZMR5$.!:*Z'8*)6W^2J%:[*F3UJG"$
MXMVKM%8YV -_H(,\1)=TJ,[6'GP\'N%]BP)AA,"D U30+0+PM%7@- #4R0^*
M]\-BXMW: ..+P\$)!OX%3P<%=-B'M ]3T<$=GDWWH)L^J8-N^F$Q-QW181SI
MLW-1X4@.^X!RZ%@.+PISZ'-ZA,;C?7O\*#(>H; [R,$<Q6'^-%#4R0](#T1%
MI+L5 L'S)]9%$(%:CP!]> 9 CO_H;/X'??1)'O(QP/MN'QWNT8%G <GF'*S9
M-W97\.USI3"/L++Y*#8B#N*H#Q!'#N+HHA!'/IU3,D;[#OE1(YBD'0XYA*,X
MPI\(B=%1TOVHB'2W-J#QTR;794#AU@8TZ<$TQ([_^&S^!VL&/LH#7@:BNKW$
M#O@X#OSPOC!4X-B]@*,X[@/%<:N4<[%:CH]F"B?[M@2"DH['0>SPC?^G4@[V
MJS0!S8&@3LUN,< '*CD5%23/>/YP:(G!#NDX[</T<=C&IV$[,GU\^'IUP #%
M.Y9^[.B,#]#Y[+DS/BS8#^D4[/"-XUO[&5/+:A')[ '_LC'SI[#N10PC#L8D
MZ<$$(@ZX) [<XR=0G6BG+HLGMCJ_6Y?UPR"<0 K#OA!';G):=>;X>K)?@ D*
M]\.BPAWB21SQMWN2S<22,C>F[R@'>BG%YGX)UE(L<@V$!&:>1"==JQ)/^C#I
M')O):57VR*3S:^>3T;YQ?@Q,2(=KCO0DOGE_DFMFQWGF3H8X])-1'TQUH"?G
M@#YHJH]MWU0_IMM4QW829[MGZBE/ -1!GO8!\M1!GEX*\C0 >8*)]XM6$/(I
MQ&&#J(,\C4/^L$'GWUK4$9OB/OCG^$W/V7\'_?/WTL1;Z4)!2<<R1UN_G,:A
M?I1UI^S*J6,U[<.NG#HTTTOMRNGA77D@I&N32QVL:1S61YEUSDZ8.A;3/I1)
M4@?M]+0R2;=I=:+TP(8R$!;<4 Y;+PK9M[1^9_+>]!04?&$:)J]&QGJY??%I
M>Z+%NGIWZ$YH+<KJ<,G-?25M@/E^(83^?F)?1VI>/YO^!U!+ P04    " #(
MB(A4-C,5#E4#   _#   &0   'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6S-
M5]MNXS80_96!BA:[0#>Z^+I;V\#&]J)]6"!(FO:AZ ,CC2PB$NDEJ3CY^PXI
M659B2=A%@* O,4G-.3-G1D--%@>I[G6&:."QR(5>>IDQ^T^^K^,,"Z8OY!X%
M/4FE*IBAK=KY>J^0)0Y4Y'X4!%._8%QXJX4[NU*KA2Q-S@5>*=!E43#U=(FY
M/"R]T#L>7/-=9NR!OUKLV0YOT-SNKQ3M_(8EX04*S:4 A>G2^QQ^6H<C"W 6
M?W$\Z-8:K)0[*>_MYH]DZ04V(LPQ-I:"T<\#KC'/+1/%\:TF]1J?%MA>']F_
M./$DYHYI7,O\;YZ8;.G-/4@P965NKN7A=ZP%32Q?+'/M_L*AM@T\B$MM9%&#
M*8*"B^J7/=:): '":0\@J@'12\"X!S"J 2YS?A69D[5AAJT62AY 66MBLPN7
M&X<F-5S8,MX814\YX<SJ"Q=,Q)SEP(4VJJ0*&4WK."\33&@!)D/0AAFTCT"F
MD#:0O=2\*H8@TV)/-0':$5H6"!]@PW6<2UTJM+AMFF+L&-89$SNT;F#[&+L-
M7),'#>\V:!C/]7M"KTNE4,1/H+B^I_WV]AK>_?+3?#0=__8>ZH7E^#.3I:80
M],(WE!(KS(]K^9>5_*A'?AC!5RE,IF$K2.]S I]RV20T.B;T,AIDW&!\ :/P
M5XB"*.P(:/W]\& @G%%3WY'C&_7Q/2M!XK+KZEK= *YX=]3>K:JV7X1_+!]P
M*K[^=R":<1/-V$4S[HFF*KRMF: ;JGY/DA+!2& 0!C_;,[J-M+/!X[NAZ-WH
MJFWE;.J<V?OJ836>+/R'=K;/34X6SR1,&@F35TI(\ <D5,XFK?@^G&GHL.D1
M,6U$3+]3!'XKN7EZ10VF9\'-9R_B/S<)HW&W@%DC8/8* 3]4@=EY=L\4=-CT
M2I@W$N:#$FYO-N##ME1R*,9GU!\;ZH__@Z8/@],W)GC+MJ^]38;ZOL.FIV?"
MUJ<R?,O6K[T-]WZ749^0Z"0D>JOVKST-]G^'36_WA*</6SAZJRN@]C0=O .Z
MC,YE^*U1K$"U<Q.JAEB6PE1#1'/:3,&?W>SWXOS23L=NQ#O15*/U5Z9VU*Z0
M8TJ4P<6,$JNJ:;7:&+EW ]^=-#0^NF5&$SXJ:T#/4RG-<6,=-/\SK/X#4$L#
M!!0    ( ,B(B%0?NX<[J@(  &\&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#DP+GAM;,U5VV[30!#]E9&14"M!G3A7E212THL(:J%J*3P@'C;V.%YU+V9W
MW12I'\_LVG$#:O+,B[V7.6?.G/6.)QMM'FR!Z.!)"F6G4>%<>1K'-BU0,GNB
M2U2TDVLCF:.I6<>V-,BR )(B3CJ=82P95]%L$M9NS&RB*R>XPAL#MI*2F=\+
M%'HSC;K1=N&6KPOG%^+9I&1KO$-W7]X8FL4M2\8E*LNU H/Y-)IW3Q<C'Q\"
MOG'<V)TQ^$I66C_XR3*;1ATO" 6FSC,P>CWB&0KAB4C&KX8S:E-ZX.YXRWX9
M:J=:5LSBF1;?>>:*:32.(,.<5<+=ZLU';.H9>+Y4"QN>L&EB.Q&DE75:-F!2
M(+FJW^RI\6$'D(SW )(&D 3==:*@\IPY-IL8O0'CHXG-#T*I 4WBN/*'<N<,
M[7+"N=DE5TREG G@RCI3D=_.TC@55889#< 5"-8QAWX+= YY"RFUY;6WBD)E
M218#S0BM)<)[F&=9V*?0I:H_(!]]=(Z.<6&/*>1BN2#")TIE* 4(S12\?3/N
M#?L??/)K+@1!["1V5*R7'*=-88NZL&1/85VXULH5%BX4%?(W/B:36J>2K5.+
MY"#AITJ<0*_[#I).=WQQ?PM'C<YC9\B/ @_DZ+6GT0LY>GMRG'.;"FTK@_ E
MA]HFLF;7O/F*KA:\'-L59RLNR&:T\..*^&!)1V5_'E#3;]7T@YK^'C6?*[E"
MXX^\J=#",[Q:;.U?S38(;+X9/,YZD_CQ%0&#5L#@H("ONO39*>/ZD+O#EF[X
M'[@[:M6,#KNKFZO!I*[H9CUOO_O7K*VIACO6]CO_>!OO- &)9AU:G874D]?]
MH%UMN^F\;B(OX74KOF9F3>T !.8$[9R,Z)A,W=[JB=-E:"DK[:A!A6%!?P0T
M/H#V<ZW==N(3M/^8V1]02P,$%     @ R(B(5 B?!4)M!0  =A@  !D   !X
M;"]W;W)K<VAE971S+W-H965T.3$N>&ULS5EM;]LV$/XKA-=M+9#&HOP2N7,,
M-+'3NJN+(&G6 <,^,!)M$9%(CZ3M>-B/WU%B),>6:+6?\B76R]W#A^3=<R=F
MN!'R0<64:O28)ER=MV*ME^_:;17&-"7J5"PIAS=S(5.BX58NVFHI*8DRIS1I
M^Y[7;Z>$\=9HF#V[EJ.A6.F$<7HMD5JE*9';"YJ(S7D+MYX>W+!%K,V#]FBX
M) MZ2_7=\EK"7;M B5A*N6*"(TGGYZWW^-W,#XQ#9O$'HQNU<XW,5.Z%># W
MT^B\Y1E&-*&A-A $?M;TDB:)00(>_UC05C&F<=R]?D*_RB8/D[DGBEZ*Y!N+
M='S>"EHHHG.R2O2-V'RD=D(]@Q>*1&5_T<;:>BT4KI06J74&!BGC^2]YM NQ
MX^#C&@??.OA-'3K6H=/4H6L=NOL.=7/H68=>TQ'ZUJ'?U.',.IPU=0BL0]#4
M86 =!DT=L/>T<UYCEV*S&^\V?MINW'B_\=.&XVS'VWDL9H$\)IJ,AE)LD#3V
M@&<NLFS(_"%^&3>)>ZLEO&7@IT<W=$WYBBI$>(2$CJE$C(<BI>@M>A]%S&07
M2="4YQIA<NWUF&K"$O4&_?)3T.EW?P,/]#46*P48Z@2],O<SEB1@K(9M#2S-
M6.W0,KK(&?DUC#ZM^"G"O1/D>SZ^NQVCUZ_>5*!<-D#I>#G*Y.X&O;9DJ[#&
MWX%5SVCB1IF1+>K@8R!7;I Q#4\;H'SX#I1CB_.Q.99W#&O:& L/CF%]:H[5
MKU^IWYNC=.M1/C='\>M19LW#T+72;9" 0@?\0@?\#+Q31Y&I,!%J)2D2<Q0Q
M118+21=YQL,3F>L$FDN1HE!P+:'D*I K'5NAHE*AOPPL8IJFZF\'J4Y!JI.1
MZM:*DZ)$AC'2Y!&%DH(<H95F"?LWY[6DDHFH*O[=N!VT!5SE8-@M&':/,,SE
MLXI#[MG//$W_M!YA;]A>[Z;6H4EOSV1Z:-(/"I-GG'L%YYZ3\^WJ7K&(59/N
M'9+V^WNL#VUZ^S;30QO?JZ;=+VCWG;2OJ0PIU]!-FGBDZ3(16TK5KXA#>[N!
MQPJ"-*30!D9HS0BTHG::><Q>2<HADA9B326'SE-729V;0= ]];R?'5%S5DSE
MS#V5#Q/T61!^@BZNI\",\) Z8(,"-G@Y.3PH2 U^.-H^#@ZC+3BK#A/LE1V-
MYQSQB[!-"TG%JGJ?+4)O9^#.?N;-K-'S[/1JHACO-%S82>_JYOV7RXEC97&I
MV?@%B38N51N[Y=6YY=9W=U4[V*]9U%*&L5N'KV,"[>F$+^#Y"?IR\?7;3<<U
MEU(K<>\%+7&IA=@M17=+&)!KM"1;HV6E\OV'7E7V)SE<L)MI-6M>BAAVJ]@8
MIIZ(939^RA(*D^6@MI:2.L;IDX6OYF2;,Y?)<]JE2.+@NT,%*-I*CNZW2&^7
M+CG&I?3AP<L)'K\42-\MD)>"FTHJ<QZ2J0?32=GB6M44','#GG=8&/-L_V'/
MZ8]X/E^/4I%]MR)_9H1?,)$%PY].W?!WVND7),U^*<V^6YKK=*/J,]U"!=4]
M7/X1[A^J.>[WO#VS<0.H*[?-\_F6=<%WUX49XRQ=I4C'DJI8)!'2 BVE6+.(
M(E*>;SQPL7D; SJ\UC&3$:R0U%NTXA&5L#])0NZ%31@"&TEK.LC)$3[!T:@M
M*Y/O;N-GI>22,&803X;32?U'T<410!R@%&(C=GT7^66%\MT5:B^I0&%GY-'L
MA0N]K#W^V0M*K[*V^$=JB]"P!PP"*MHICN9H+10I#!F:5U6ULKI$3NQPSW+B
M,''<1OE4VCM'A.9$?D8D%$"%$CH'+^_T#&)#YH?<^8T6R^S4\%YH6*WL,J8$
MLL$8P/NY@+G:&W,06?RK8?0_4$L#!!0    ( ,B(B%3K60TT?0,  /(,   9
M    >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;,U776_;-A3]*X0&%"VP1B(E
MRW9G&VCB#NM#L2!IMX=A#XQT;1&51(^D[.S?CZ1DV:9H)=A37VR1.N?RG'OY
MI<6!B^^R %#HN2IKN0P*I78?PE!F!514WO =U/K-AHN**MT4VU#N!-#<DJHR
M)%&4AA5E=;!:V+Y[L5KP1I6LAGN!9%-55/Q["R4_+ ,<'#L>V+90IB-<+79T
M"X^@ONWNA6Z%?92<55!+QFLD8+,,/N(/:SPQ!(OX@\%!GCTC8^6)\^^F\3E?
M!I%1!"5DRH2@^F\/=U"6)I+6\4\7-.C'-,3SYV/T7ZUY;>:)2KCCY9\L5\4R
MF 4HAPUM2O7 #[]!9\@*S'@I[2\Z=-@H0%DC%:\ZLE90L;K]I\]=(LX(.+U"
M(!V!N(3D"B'N"/%K"4E'2&QF6BLV#VNJZ&HA^ $)@];1S(--IF5K^ZPV=7]4
M0K]EFJ=6#["'N@&):)TCK@H0B-49KP"]1X]ZDN5-"8AOT 7N=XO[W.+>KD%1
M5LIWFO'IVP-Z^^:G69PFO[Q#W8,.B+X6O)&:*A>ATJK-V&'6*;QM%9(K"C%!
M7WBM"HD^U3GDEP%";;?W3(Z>;\EHQ#5D-RC&/R,2$>P1=/=Z>N2AKU]-Q_,1
M-W%?P=C&BZ_%8S(KN6R$K5/.)-UN!6RI75:Z1[250QO!*Y3I3 J]UJ2>9JKH
M)A@(B?XR81%34,F_1T0EO:C$BDI>F%:^<K?,U#+-MK1?89W&_7D!AI") UD/
M(>FLAUQHGO2:)R]HED!%5B!%GU$F(&?*)[\-,CD;F"1SU\ 0A.=DZECP18JG
M?A-I;R(=-?'8/$F6,W_FTZ$JDCK*AYB)BUD/,23RRY[VLJ>CLNV.XI,\'0Z%
M'<5#B#N?UA[(E3S/>L&SEP5W6Z5/]VRH.XV="7#G 24I<;3[0-/8KW[>JY^/
MJO_*%2V/.\-P[_<9FGL,):XA#VB"74,^4(+]AG!T.L>B\8D/8L\R=]Y?!CL[
M%/&/LZ=B<I)%_O>NVE$O%JY3'1_$72D>3')E;>/3"87C5RP62<OQ\IP.%YS\
M0.4YG1_XI0-DI#R3X9'FEF<(&51G""'NJ1>>70:USZV]5$N=AJ96[1VI[^TO
M[A_M==7IOS47>GO)/(5IOP:^4+%EM40E;'3(Z&:J98GV@MTV%-_9*^<35SK9
M]K'0'R4@#$"_WW"NC@TS0/^9L_H/4$L#!!0    ( ,B(B%29>O@!(P,  *@(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;(U6WV_:,!#^5ZQ,FEJI
M-#\)T %26SIM#]407;>':0\F.8C5Q,YL V5__<Y.2($%U!>PG?N^N\]WN<MP
M(^2+R@ T>2URKD9.IG5YX[HJR:"@ZEJ4P/')0LB":MS*I:M*"32UH")W \^+
MW8(R[HR']FPJQT.QTCGC,)5$K8J"RNT=Y&(S<GQG=S!CRTR; W<\+.D2GD _
MEU.).[=A25D!7#'!B83%R+GU;R8]8V\-?C#8J+TU,4KF0KR8S==TY'@F(,@A
MT8:!XM\:[B'/#1&&\:?F=!J7!KB_WK%_MMI1RYPJN!?Y3Y;J;.3T'9+"@JYR
M/1.;+U#KZ1J^1.3*_I)-;>LY)%DI+8H:C!$4C%?_]+6^ASV 'Y\ !#4@. 9$
M)P!A#0C?"XAJ0&1OII)B[V%"-1T/I=@0::R1S2SL95HTRF?<I/U)2WS*$*?'
MWTJ05#.^)/"*I:1 D0YYJFJ B 69@0(JDXQ0GI()K+%.2LRZ)@\[\XL):,IR
M=8G A^<9N?CXH1_&T:=+4B\(X^1[)E8**=30U1BU\>TF=81W583!B0C]@#P*
MKC-%'G@*Z2&!BW(;S<%.\UUPEG$"R34)_2L2>('?$M#]^^%>"WSR;K@_.*,F
M;#(86K[P!-\MI_E6,66RQ7@B"K"YJM-)?M&YTA)?K]]G?$6-K\CZBD[XFJZP
M%/ M4U?8)^:=!/-BJ$WY&)]"9R";0FI+=44?6WK3D=;CCC_HQL'07>\GH,TL
MZ(71H=FDS2SN>V]F!R*[C<CN>9%T*T6>DT0HC>6-=YJO4B-1951"QW29E)1T
M:UX#==FFLN+O[L<UB+WND<@6*]\+O?A(9)N9/^A[[2+C1F1\5N0$<$HDC)KF
M>T5H(:1F?W<[3&4IQ9K9WGXNG7%+;('O'PEMM1IX1SK;K.*@URZSU\CLG95Y
MT+[2O?9U3E7O_[(*O;#7/Y+58A9$87BLJY4MVKND2IB[U\,+D$L["Q46X8KK
MJK4UI\VXO;53YNC\#L=P-37?:*H9_DCEDG%%<E@@I7?=P\N6U5RL-EJ4=E+,
MA<:Y8Y<9?DJ - ;X?"&$WFV,@^;C9/P/4$L#!!0    ( ,B(B%0],8C(S0,
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M"@=I#/#]2@B]NS$!JF^OZ=]02P,$%     @ R(B(5$%OJZHI P  E0@  !D
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M=2OVO[.:4%G@4B2R_(OV-=8=H>5.*I'6P;J"E&?5)WVJ&W$4@,.! %('$#/
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M40;G7TF5JD9CM3%RZ8;%3!H:/6Z9T]\$E36@[W,IS79C'33_I\%_4$L#!!0
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M43L#NE\H9;<;]T ]DP>_ 5!+ P04    " #(B(A4_R3B#3,#  !.#   &@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&ULS5=M;],P$/XKIR AD%@3I^_0
M5NHZ7B8!JS8!'Q ?W.3:6DOB8+OK)O'C.3MI&FUMV)=I?&ELQ_?<<\_9E^MH
M*]6U7B,:N$V33(^]M3'Y6]_7T1I3KELRQXS>+*5*N:&I6ODZ5\AC9Y0F?A@$
M/3_E(O,F([<V5Y.1W)A$9#A7H#=IRM7=*29R._:8MUNX%*NUL0O^9)3S%5ZA
M^9;/%<W\"B46*69:R P4+L?>E+V=L8$U<#N^"]SJVAAL* LIK^WD/!Y[@66$
M"4;&0G!ZW. ,D\0B$8_?):A7^;2&]?$._8,+GH)9<(TSF?P0L5F/O8$',2[Y
M)C&7<OL)RX"Z%B^2B7:_L"WW!AY$&VUD6AH3@U1DQ9/?ED+4#,+.$8.P- CO
M&PR.&+1+@[8+M&#FPCKCAD]&2FY!V=V$9@=.&V=-T8C,IO'**'HKR,Y,KM9<
MX8D5(H:<WU&"C(83F,:QL#+S!,ZSXK!8T5^=H>$BT:]'OB'G%L*/2D>GA:/P
MF"/,6\!Z;R ,6.?EBT&[UWD'/FCK7Q^ FS7#G6'4@C:S<"'+$YXU0_HD2Z5-
M6&D3.A_M8SZ$CA*I-PKA8@E%Z"1379#I@JX&U$6<[T3\^9G@X-Q@JG\UD&E7
M9-J.3.<(F:^;=($*Y!+HND88BVP%1G'WC/F=!L.O,0.1&4EW(Y*;S- $S!KI
M5!M4='8*RH1@%YU*A"4B!%GL6RE.1C$W>"@?S?3"P+%H"+13!=II1#J]FL_>
M-^!T*YSN\V>O5Y'I/3)[^N&% ZY(^16ZL3W+!^]#X:#K'-CB?#,9COR; YSZ
M%:?^/X2>-D0VJ% &SR_SL"(S?&J9AP]D9N%AG5FPK[%!(ZV+1J59K5:SY]>:
M[<LC"Y]:[=+#(TXUVQ=*UER*IA\;U=[7(=;Y#]3>ES/6?7*UNP_4/G:V]X6-
M-5<VJB+ND]X4X[XBL?Y_(/F^M+%!8VSO;U%%0N\^DZ_H>XH;)37DE B7A=?P
M!Q[1S)R6COKULM)O]?J5^F6"BFV]VK9.<"]#?JW9LYWV%ZY6(M.0X)*,@E:?
MTJN*YK68&)F[_F\A#763;KBFAA^5W4#OEU*:W<2VE-5?B,E?4$L#!!0    (
M ,B(B%2Y@,W(518  #+A   :    >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX
M;6S5G?MOVTB2@/\5P0?<S0 3F57-YUX2((]QWH])-K9^56PF$4:VO)2<3(#]
MXX^217617=U=W&'+IP5V-YDI-JO55'TDQ?IX_\>B^G/YK2Q7H[\NYU?+!T??
M5JOK?QP?+\^_E9?3Y7AQ75[5_^;+HKJ<KNJ_5E^/E]=5.;W8;'0Y/\8H2H\O
MI[.KHX?W-__L??7P_N)F-9]=E>^KT?+F\G):_7Q<SA<_'AS!4?,//LR^?ENM
M_\'QP_O7TZ_EQW+UZ?I]5?_M>#?*Q>RRO%K.%E>CJOSRX.@1_&.B<+/%)N1T
M5OY8DC^/UG/YO%C\N?[+BXL'1]$ZI7)>GJ_68TSK__M>/BGG\_50=2+_VHYZ
MM-OI>D/ZYV;TD\WLZ]E\GB[+)XOYV>QB]>W!47XTNBB_3&_FJP^+'\_+[8R2
M]7CGB_ER\[^C']O8Z&AT?K-<+2ZW&]<97,ZN;O]_^M?VDR ;*-L&N-T .QN@
M;0.UW4!)-XBW&\32#9+M!HET#NEV@U2Z0;;=()-ND&\WR*4;%-L-"ND&$#4K
M%XDWV2VV>+6A66[HKK=]DV;!H;OB]DV:)8?NFMLW:18=Q*L.S;*#>-VA67@0
MKSPT2P_BM8=F\4&\^MBL/G97'PO;)LWJH_R[OONRB[_MV*P^BK_OV*P^;E;_
M^+9X;2K?T^EJ^O!^M?@QJM;Q]7CK/VS*YV;[NN#-KM:E_N.JJO_MK-YN]?#C
MMVE5WEO7RHO1]?1G7<17R]&]T=/9\GR^6-Y4Y6CQ9?3VYO)S68VF5Q>CLTWI
MK(,??2^KF@6C#^4:*+.KKZ,GBZM555?NF^E\]'KV9;/ER>+FZJ*LEO\S.IM6
MU;0>_#?RI_6 )U59CC99+$?OZAG7_VP]V"]/R]5T-E_^>O]X54]SG>SQ^79*
MCV^GA)8I/;JNQB.,?JO_B[#<C/S?_Y6K-/[?T?'H]N_,H$\$@T9 !V4&>>H>
MY,VT'@0RSR"_NP=Y>3.OIW<[2&0=Y$2>223^C)Y)!H6>@SX7#(K%>E HQ(.^
M$'^&D(L'?2G(-$I[#OK*D^GTJA[T-M-,/.AK]Z!O%]_K0=5FT%0\Z!OWH"?E
MYWI0[#GH6]]"U=/'9#-H(A[TG6!0B'H.^EXP_=Z#_N$>]&-Y70]Z>TC%XD$_
M>$K9S=?Z,\TW@RKQH!\%]7$[??F@_W0/^K0\KP>]S13%@W[R?4U_CJ*XYYBG
M@D05]$3.F7Q0>Z&?B =IRF=[D./ZA&%WUH"[LP;<C*ILH[9.#Z[TZ<&/YO1@
MNCT]J':G!^?D]&"^/3U8K+[5&Y;_NIFM?HYF5\M5=7-[!E)?E#:G HYTU2Y=
MM4DWMM6[VP3K'4Y_3*N+UO"C7V97VR7BSC5.;T=.-B.OKYN_/\0BPSR-[A]_
MIVO)Q,40ITG<CILP<4KE]9=F%]>:8KR;8NR<XN./[Y_\[OBHDMTXR2&L;+I+
M-^VWLK/E\J9.TK.HJ;$(W>5T1;0RS7:99L&.P<Q()H,$"^CDS(7E69IUCD F
M+($D3_CYY;OYY<[Y/;J=5?E769W/UE<3%S?5>FKU<3"Z+JO9PKLHN7=17!&M
MI(M=TD6_19E/K]>Y+ZK1^?3JO)S/_Y.)%$::*L[2SER8(,PAY^<#D;Z<B_QU
M8,.V>^CX?@&Y/H1#* B@T008H"3\<SLJ71"(UO]IK]LI$]<]3)TA[5EI@H$;
M8<_6E\RCZVIV7FYF4MY4B_7A>#NE7T?_'HE.MVYWD@HRT^ !-WE^WW[C.\DM
M_X/L;G>4D>S2<6H!(VBB01*L\FZ']AT59\*XB3^N/4G-0>@'PM]()?;-4<PZ
MT+ #-^W^/@W Q)3QH;M"VHEKBH$;8R(B^%(7<PHTJ. N2 4FA8P/V172OGC0
MD$()I*+\'F[.>^V7(YI2>!"40G(!%8)2']!$2\) B@GKKJLSI#TI#2G< Z0^
MH!A2J"&%>X+4!S0AE8P+M"2H(87A((4F5)B#XDP6-O&&M6>H"87!"(5B0J$F
M%(8F%/H)Y0QI)ZX)A>$)A6)"H284W@6AT$\H9TC[?I$FE!(1JE@3*G;=@=*$
M4@=!**4)I4(0Z@]E<J7(T" 4$V;<41,32I$;@7L@U!]*3"BE":7V1*@_E$DH
MR,>IY=:"THA2X1"E3*CD*23&DHO")DQ8@6!#E-*(4L$0I<2(4AI1*C2BE!]1
MSI!VXAI1*CRBE(DH@"BQY:8QI>X"4\J/*28D*6SSB36I8N$-O^0>..I^K$$5
M'P2H8@VJ. 2HWL<F7C)(N[7FE GKKJPSI#TI#:IX#Z!Z'XM!%9,?FO8$JO<Q
M"ZHDLV2H016' U5LHB7-8P-4LK )$Y9%]B^]!E4<#%2Q&%2Q!E4<&E2Q'U3.
MD';B&E1Q>%#%)J@4VLY%8LVI^"XX%?LYQ81@8IM/HCF5B#GENN67:$XE!\&I
M1',J"<&I=PESRT]%!J>8L.[*.D/:D]*<2O; J7>)F%.)YE2R)TZ]2TQ.831&
MRP550AZU",>IQ"2+BI3!*38L,^[Y<6%Y;/W2:TXEP3B5B#F5:$XEH3F5^#GE
M#&DGKCF5A.=48G(*,;.NL095<A>@2ICG(\RCVPS*K#-*-:I2(:K2T;NJ_C).
MJY^N1Y4TL=*#(%:JB96&(-:;E'F4 E-K.4DU;-(]P.9-*H9-JF&3[@DV;U+F
MHB@>QZDE0PV;-!QL4O:IA22U7*FEY.F]8'Q(33XH97E6)-6$2$,3(A67_U27
M_S1\^4^9\I]8S^M37?[3NRC_J;O\MY_ U(4]$Q?V]V6UZ9.M,W24RDS7]NP@
M:GNF:WL6I+9G7&TOT+HVNK9G^ZCMF;BV9[JV9_NJ[5FOVI[IVIZ%J^T96]LQ
MBRU)Z=J>!:OMF?SI:_+X=>C*GHDK>Z8K>Q:^LF=,9<^+S'94Z<J>W45ES\S*
M#C%:DLUU:<^%I3V3G+/GNJ[G!U'7<UW7\Q!U_57.U'7(4EM=SW5=S_=0UU_E
MXKJ>Z[J>[ZFNO\J9NIZ,"\O9:*[K>AZNKN?,;^2%]7POUV4]#U;6<W%9SW59
MST.7]5Q<UG/2"Q.^K.?,#^ Y6+^0NJSG=U'6<Z:L6\_8"UW6"W%9EYVQ%[JR
M%P=1V0M=V8L@E;TP*WMN?YZST(6]V$=A+\2%O="%O=A782]Z%?9"%_8B7&$O
MF&>D'.NI"WL1K+ 7XL)>Z,)>A"[LA;BP%[JP%^$+>R%O8R1]C'?2R"A^LK:^
M9-RENOZSNZ8_<C7Z1:0U,3J($@X1:4Z,0A3QTV;8UD\=.42Z$MW^(L+%06[O
M+XM( V(4KHF^&;MUC9HJ3+HMS); B/S8>ON+)1N80&3[518BTM 8N?DQ0//:
M=@_.QBIG3"=YTNP8]43+,(UB$?,D4Y;GYJ28!Z,<AQ_I;XS<>*JKQBB*[X&S
MJSDB#8I1=ABU@[0F1CWA(ZH=GYIA6T^0M![I:=;8WX'OCNG,C#0W1FY\#7(N
M^:G9"SU=B\:66TM >^H]3?6#G5!^:O9$SW>M"=(>?0A7F[=CMY\185J<97$3
M?UQGF@2>/5O[^S0Y,TWY:'^N#6AGOJ<U?P!<@ DS\^-WQ722)ZSS=.\/TN\,
M<I+1MOV^??O#D(QIP3<_:U=,9T($89X>_37"/!W/0%OLX3 (1IOK^W;7BPCV
M$9B.>N#<',[.^V9MY02C[?F>_OQ!"/:QV4OK4<.QQ<P#I.$>/!WW@Q'L8[.G
MMJ5#61X% =+"#Q@08FA")V48)@J;>,,Z<Z1NFG $DW?L VG9!T_/_@#T0@&]
MG#&=Y F]/&W]@] +37K%CL4F .O;TS\,P)@&??/CE@.,=/"#IX5_"S!70S20
M#GS PP 8Z;V'OLWWLJ9H8!KN(68 YFS,;]96#C#2O0^>]OUA.J.;O5 ZQ./<
M1@?2D ^>COSA^J.;/;7NZF?CKB?OM(E+6X7!-A/".160<\HD$W,F=":,F_CC
M.M,DJ.OI#^B#.GGK/RBJ4 N..B5 G3.FDSQ!G<</, CJ5"_4$34 ]'4##(,Z
MIM'?_+CEJ",F /"H +:H<S=5 ^GE!W48L"-=_-"WC5_66 U,ZSZ:9]FG7)RY
MNG+8$0< >"0 PW17-WL1PH[T](.GJ7^X'NMF3W;8=9(D'(L#<BPVN;,V>!CK
M+XN;^.,ZTR0<ZZD7Z,,QN1D B!H /&Z  3@6"SCFC.DD3VVA>^!8;'(L<2PV
MX5A?=< P'&,\ .;'+><8$06 QQ2PXQC^,OW5Q072[0_Q8:",]/E#WT9_$<K>
M M/<GW+7;4R<N<!RE!%- '@\ 8.@[&VS%WJM8[OM2'K^P=/T/QC'WC9[:G&L
M&">6-@4@'@%( G(L8>X4F@?(F3!NXH_K3)-PK*=^H _'Y.8 (.H \+@#!N!8
M(N"8,Z:3/.&81R\P",<2^0]G"?5=WPG$&$F ^5G+(48L N#1"!"(?79"C*@
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M>D0<@X"N,$%G38U KJ]^8QC("<0<[IC.A C@/+J-+> \CQ@36P86AP$XXLC
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MGS_&<;9[4GR-R?Z+BL[_#U!+ P04    " #(B(A4H&Q:OVD?  #J-P$ &@
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M+.69IEB.RE;MRHCRSK)5R3*<=TH#$O;"9V$E0 %AC>LI3"K%??]I/+%0*3
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MRL:4NP)@I0AA18) K/D\#O@J11@I7Q!89@3HE+(QI:H6STLA,DO"0#)4^BP
M0:4("M5/D "04C:F]!00*448*5EZ^HZYV64>!_B3$O%/.VL4B&!,.)0"'DH1
M($H:%^)&,(\#2$H12JJO6@'ZI%Q$Q_PI0*'405BH=\S-+O,XP*(4P9KN(Y,E
M'Z:7XYO1]$?0,YXI%='.)07PDR+TDW@Z]Z;QM/86S ZL[Z V0)T499UZ3.?>
M-%[%'0+%).@2G<Z]81[2@0F>J:& >E(NG&/ZIG-OF"&=S@'CI CDM.]T[DUS
M@35.+BU\$R& GQ2EGZ1'HRD^G^-MAEUME/<^0+4S81K;RH\\C0(L2F4QY;(
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M-CO6RG.^@@(\2A'$23P[+K9WFVX5;^AJ5):;\^..1GGIN1, K)24L,I%RW-
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MFU$1I:<&&#9#&#;9BLA;YH:OB!A@WXQBN'"O00(@-J,B H4-@&V&@&WB>,A
M875'/"99<CGZ$0P/L&Z&T&J]1P^ V(R."!4V +(9@J%) T3<- $R*R0U404/
M$8@KX=3Z#BR KYD5719)A$!K";TFCI"L_+AM(J0MCQ (+X73[B/T>V@1Q "?
M9F+BTPSP:>90?-I;T\6G^=<<#/!IYB'XM+>FBT\+= CX-$,(,^^R S.DRPY
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M.[8=U=64]^L#NGN@ZFI64%VMJ\U6R:ZPHXW[ )GFY=66^B=/'0!^LS%57+-
MSUE2<8TF<,?,PT]U'FW^$CHBPP(T9P5ETS:B0%($@.%L3#74+$!QEF!M@B@0
M#W44TCP<!2#C+$':5E%02?@ 6 L8FW4QO>P"HLT2,$V<#SQO/&UL/K$><,P"
MT68)T=8K)WC>>!5W"-20D&S!I. YLS8E6U(%&LT2&DV6%#QG;B1) 8!LEI1&
MHX_L<^:!'=EL@5ZSA%[SI2C/F2%-48!>LX1>VS=%>=Y< %,4ZULC XK-$@Y-
MG*)DVR?;;I45[6JTM=@7;+-Q'R#+F526@T=26>#5;!:3+ .Z9@F!UE,1LTZ)
MSKQ?(I!H@K%)98BXD<@0(&R6(&P"&:*5TX@, 8=F"8?FER%BR&4(E)F423N
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MZ3%/D=GC)EG-"%2[H0C$-[GM:**9H?<4V3VSB8%C85R,>@K0WHCF SQ%76_
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M2;Q(\JJ!_/M=EI7-+U/I_SG+/V^.<?I_4$L#!!0    ( ,B(B%3*V4J+GP,
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M)UP!X/V6,?DT40N,_TEL_@=02P,$%     @ R(B(5.*TL\:3 P  J0L  !H
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M==HO'I?J%@H\#U#OYXS)]T8^0'VO'?T/4$L#!!0    ( ,B(B%1]J&O/& 0
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MG5X,MTI4_;*:*+XV'63!%?0C,\S@$X,(#8#G2\[5;J(W:#Y:1O\ 4$L#!!0
M   ( ,B(B%2>0>J%*P(  )T$   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M,BYX;6Q]5-UOFS 0_U<LGCII*PDDVU01I*3IM$JK%+7:]C#MP<$7L&IL9A^A
M^^][-H0R:<D+^.-^'S[?.>N,?785 +*76FFWBBK$YB:.75%!S=VU:4#3SL'8
MFB--;1F[Q@(7 52K.)G-/L8UESK*L["VLWEF6E12P\XRU]8UMW\WH$RWBN;1
M:>%1EA7ZA3C/&E["$^#W9F=I%H\L0M:@G32:63BLHO7\9K/P\2'@AX3.3<;,
MGV1OS+.?W(M5-/.&0$&!GH'3[PBWH)0G(AM_!LYHE/3 Z?C$_B6<G<ZRYPYN
MC?HI!5:KZ'/$!!QXJ_#1=%]A.,_2\Q5&N?!EW1 [BUC1.C3U "8'M=3]G[\,
M>9@ DG. 9  DP7<O%%QN.?(\LZ9CUD<3FQ^$HP8TF9/:7\H36MJ5A,/\FW&.
M-4#75'$+[ -;"R%]OKAB][J_=)^]JRT@E\J]RV(D60^.BT%BTTLD9R3F"7LP
M&BO'[K0 \2]!3'Y'T\G)]":YR+B%XIJE\_<LF27S8-Q=8$W'5*2!-3W#>L>M
MEKJ<IN,7WSNT5#F_+_ O1OY%X%^<X=\9!(V2$LO?<FRLD)JZH1=T#"N.S$L7
MA@I?@ 7!.*&$5*VO7W8E]1#[WZOH+2R#!=^0QSRE]ERF218?I][C2<G48,O0
M&(Y46XU]]8RK8^^M^Y)["^\;]X';4FK'%!P(.KO^1.JV;X9^@J8)!;@W2.4<
MAA6]'V!] .T?#&5FF'B!\47*7P%02P,$%     @ R(B(5+$G6^K"!0  HAH
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MO<@;"+$?%>[%F@9)E="\0"O'F$D-&G;0&D:/LC=/'W](=->KO$$1>X.ZO+Y
M"_[*8!^H9B@0-++AYOV&O-U!@>0-A]B/"L?MT54-FE<;9S=O2FY=4XIXN HA
MLX^+N)LW&Q>_W5N0O*VX]G'\4FD>@A]S\"F"N8)#];+%@OG:8H5UADT5%CG<
M/:SRV]IE&X?:A=?)YM^;*970?A4*V +DG-,>D(7<_"&RN=$B3MXPSY(9-/FZ
M9!0F)[, GB^$T-L;\](Z^UMJ]"]02P,$%     @ R(B(5#!FS=?? @  '@@
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M2F5D09N:MV+6P#0?% 0R!9 I=_1*6Q4Z;\^(I=%EII>%LD*6N5AX37: VNR
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M[55O#]#;J]X>H+=7O3U ;Z]Z>X#>7O7V +V]ZNT!>@?5.P#T#JIW .@=5.\
MT#MTFR4 O8/J'0!Z!]4[ /0.JG< Z!U4[P#0.ZC> :!W4+T#0.^H>D> WE'U
MC@"]H^H= 7I'U3L"]([=9C= [ZAZ1X#>4?6. +VCZAT!>D?5.P+TCJIW!.B=
M5.\$T#NIW@F@=U*]$T#OI'HG@-Y)]4X O5/W9R5 [Z1Z)X#>2?5. +V3ZIT
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M;JZK[#B X>:ZTHX#*&ZNJ^TX@./FNN*. TANKJON.(#EYKKRC@-H;JZK[SB
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M/UG^T>#F)U!+ 0(4 Q0    ( ,B(B%0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R(B(5*>S?5#N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ R(B(5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #(B(A4+G/D?XH&  "R'P
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ R(B(5*""V3 S @  @@4  !@              ("!S0X  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,B(B%2F\'N,@P4
M 'L6   8              " @381  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #(B(A4(B=2RVL$   5$0  &               @('O
M%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ R(B(5$_T
MD 6[ P  VPL  !@              ("!D!L  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( ,B(B%1>KZ-PT@<   0H   8
M  " @8$?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #(
MB(A4B%ROQ4<(  !Q(P  &               @(&))P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ R(B(5#<[UJ? "P  EQX  !@
M         ("!!C   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( ,B(B%170G>,,P@  $,8   8              " @?P[  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #(B(A4_!8+ P8,  ##(
M&0              @(%E1   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( ,B(B%1;"(BL/A$  *4P   9              " @:)0  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ R(B(5#1%)1!M
M!P  /14  !D              ("!%V(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #(B(A4,?#'4!<(   M%P  &0
M@(&[:0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,B(
MB%09S10D- D  *08   9              " @0ER  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ R(B(5!=$ZG)$!@  9!(  !D
M         ("!='L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #(B(A4KJ"T'QP$  !,"0  &0              @('O@0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,B(B%1H8?(0[1D  +MG
M   9              " @4*&  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ R(B(5$39/*Z."0  T!@  !D              ("!9J
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #(B(A4G6B^
M-TP3  ",.@  &0              @($KJ@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( ,B(B%2,+[]P:P4  $H.   9
M  " @:Z]  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MR(B(5 HW-;?W"   A!L  !D              ("!4,,  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #(B(A4_7:$4_,2  !N-@  &0
M            @(%^S   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( ,B(B%2DZXCX"0L  %0D   9              " @:C?  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ R(B(5*SW39IP$0
MF$D  !D              ("!Z.H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #(B(A4 V3"S9D$  #\"P  &0              @(&/
M_   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,B(B%2^
M%\0$! <  !P1   9              " @5\! 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ R(B(5/$&ED8E!   ]P@  !D
M     ("!F@@! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M" #(B(A4/S,)QC,$   9"@  &0              @('V# $ >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,B(B%1.\Q"6X @  )X5   9
M              " @6 1 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!
M A0#%     @ R(B(5&#U1*/U @  6P8  !D              ("!=QH! 'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #(B(A448O 1.@$
M  #2"@  &0              @(&C'0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+ 0(4 Q0    ( ,B(B%2G>$_D+S,  %JP   9              "
M@<(B 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ R(B(
M5(N]_.!\ P  #@H  !D              ("!*%8! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #(B(A4B.38)-P$  "&#@  &0
M        @(';60$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( ,B(B%03$QLN\P(  /4&   9              " @>Y> 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ R(B(5 W#+*>[ P  J L
M !D              ("!&&(! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #(B(A4%N>1C&T"  "-!0  &0              @($*9@$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,B(B%2U()GI
M( D  #LE   9              " @:YH 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ R(B(5"7+[P<Z!0  90X  !D
M ("!!7(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #(
MB(A4P#CDS!,)  !"'0  &0              @(%V=P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,B(B%3$.186)P,  +4(   9
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M970T-2YX;6Q02P$"% ,4    " #(B(A4P2E-'>\"  !3!@  &0
M    @(&LH0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M ,B(B%0>J6GH60,   L'   9              " @=*D 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ R(B(5 7G5O^( @  B@4  !D
M             ("!8J@! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " #(B(A4;PZ0V>T"   0!@  &0              @($AJP$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,B(B%1QO%3J> 0
M (,2   9              " @46N 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ R(B(5"$N<GI0 @  "P8  !D              ("!
M]+(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #(B(A4
M99P;]\,"  "Z!P  &0              @(%[M0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,B(B%3![=TX$ @  /\L   9
M      " @76X 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ R(B(5+!*#>9&!@  P"D  !D              ("!O, ! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #(B(A4&_PJ*Y<'   Z.@
M&0              @($YQP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( ,B(B%3HR.%[< L  $)9   9              " @0?/ 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ R(B(5$(O$@;%
M!   N!8  !D              ("!KMH! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " #(B(A4E2D3$< "  #U!P  &0
M@(&JWP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,B(
MB%1$FY['U0(  -X*   9              " @:'B 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ R(B(5'J AX77 @  \@<  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( ,B(B%1(H-AI=P@  &4T   9
M  " @1+X 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MR(B(5*SCHV5%!@  T2(  !D              ("!P  " 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " #(B(A4BT_]:D\"  #^!0  &0
M            @($\!P( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( ,B(B%0#FI9BUAH  /;S   9              " @<() @!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ R(B(5(DHU2&% @
MF 8  !D              ("!SR0" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " #(B(A4496^_V %  #\&P  &0              @(&+
M)P( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,B(B%1P
MY8! 2@D  )U&   9              " @2(M @!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ R(B(5,Q767&"!@  6B4  !D
M     ("!HS8" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,B(B%3-975HR (  %H)   9              "
M@<%, @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ R(B(
M5.C#\L&/ P  #@\  !D              ("!P$\" 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " #(B(A4>]*=C3<(  #,+@  &0
M        @(&&4P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( ,B(B%0O-ZW!808  %PG   9              " @?1; @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ R(B(5!RH5VU"!0  MAD
M !D              ("!C&(" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    " #(B(A4T.[)VZD#   )#   &0              @($%: (
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( ,B(B%2QQ,Z&
M*@<  #4X   9              " @>5K @!X;"]W;W)K<VAE971S+W-H965T
M.#,N>&UL4$L! A0#%     @ R(B(5(:JN.&. @  /P8  !D
M ("!1G," 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " #(
MB(A4B/&#KBH#  !)"@  &0              @($+=@( >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( ,B(B%0^DP^!DP(  ,4&   9
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M970Y,"YX;6Q02P$"% ,4    " #(B(A4")\%0FT%  !V&   &0
M    @($FBP( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (
M ,B(B%3K60TT?0,  /(,   9              " @<J0 @!X;"]W;W)K<VAE
M971S+W-H965T.3(N>&UL4$L! A0#%     @ R(B(5)EZ^ $C P  J @  !D
M             ("!?I0" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"
M% ,4    " #(B(A4/3&(R,T#  "'#0  &0              @('8EP( >&PO
M=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( ,B(B%1!;ZNJ*0,
M )4(   9              " @=R; @!X;"]W;W)K<VAE971S+W-H965T.34N
M>&UL4$L! A0#%     @ R(B(5 "8^1$=!   N@\  !D              ("!
M/)\" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #(B(A4
M'#PRJ6@#  #%"@  &0              @(&0HP( >&PO=V]R:W-H965T<R]S
M:&5E=#DW+GAM;%!+ 0(4 Q0    ( ,B(B%087^ I_0(  %D(   9
M      " @2^G @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%
M  @ R(B(5!?W^OU^!   BA0  !D              ("!8ZH" 'AL+W=O<FMS
M:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " #(B(A4$SV;9IL"  "K!@
M&@              @($8KP( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q0
M2P$"% ,4    " #(B(A4X9$4]=L"  "?!P  &@              @('KL0(
M>&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " #(B(A4_R3B
M#3,#  !.#   &@              @('^M ( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,BYX;6Q02P$"% ,4    " #(B(A4N8#-R%46   RX0  &@
M    @(%IN ( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M" #(B(A4 QDBFW$(  "T2   &@              @('VS@( >&PO=V]R:W-H
M965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " #(B(A4H&Q:OVD?  #J-P$
M&@              @(&?UP( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q0
M2P$"% ,4    " #(B(A47K<=ITL/  !?A@  &@              @(% ]P(
M>&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " #(B(A4RME*
MBY\#  !5#   &@              @('#!@, >&PO=V]R:W-H965T<R]S:&5E
M=#$P-RYX;6Q02P$"% ,4    " #(B(A4XK2SQI,#  "I"P  &@
M    @(&:"@, >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4
M" #(B(A4(0K"C\ #  #C#@  &@              @(%E#@, >&PO=V]R:W-H
M965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " #(B(A4?:AKSQ@$  !@#@
M&@              @(%=$@, >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q0
M2P$"% ,4    " #(B(A4BPG\EA8#  # "   &@              @(&M%@,
M>&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " #(B(A4GD'J
MA2L"  "=!   &@              @('[&0, >&PO=V]R:W-H965T<R]S:&5E
M=#$Q,BYX;6Q02P$"% ,4    " #(B(A4L2=;ZL(%  "B&@  &@
M    @(%>' , >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4
M" #(B(A4,&;-U]\"   >"   &@              @(%8(@, >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " #(B(A4=$O^#74$  !S%
M&@              @(%O)0, >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q0
M2P$"% ,4    " #(B(A4LV,]=VD#  #X%@  #0              @ $<*@,
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,B(B%27BKL<P    !,"   +
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4!08     >P![ .0A  "I/ ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>987</ContextCount>
  <ElementCount>449</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>193</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION</Role>
      <ShortName>STATEMENTS OF CONSOLIDATED FINANCIAL POSITION</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - STATEMENTS OF CONSOLIDATED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS</Role>
      <ShortName>STATEMENTS OF CONSOLIDATED OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - STATEMENTS OF CONSOLIDATED CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CONSOLIDATED CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Company information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Companyinformation</Role>
      <ShortName>Company information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation</Role>
      <ShortName>General Information, Statement of Compliance and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210051003 - Disclosure - Consolidation principles and methods</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Consolidationprinciplesandmethods</Role>
      <ShortName>Consolidation principles and methods</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210081004 - Disclosure - Significant transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Significanttransactions</Role>
      <ShortName>Significant transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210101005 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210131006 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Propertyplantandequipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210171007 - Disclosure - Non-current financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Noncurrentfinancialassets</Role>
      <ShortName>Non-current financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210211008 - Disclosure - Trade receivables and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Tradereceivablesandothercurrentassets</Role>
      <ShortName>Trade receivables and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210271009 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Cashandcashequivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210311010 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210411011 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Provisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210481012 - Disclosure - Financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Financialliabilities</Role>
      <ShortName>Financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210561013 - Disclosure - Trade payables and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities</Role>
      <ShortName>Trade payables and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210621014 - Disclosure - Financial instruments included in the statement of financial position and impact on income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210671015 - Disclosure - Revenues and other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Revenuesandotherincome</Role>
      <ShortName>Revenues and other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210711016 - Disclosure - Operating expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Operatingexpenses</Role>
      <ShortName>Operating expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210821017 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Sharebasedpayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210891018 - Disclosure - Net financial income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Netfinancialincomeloss</Role>
      <ShortName>Net financial income (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210931019 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Incometax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>210971020 - Disclosure - Segment reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Segmentreporting</Role>
      <ShortName>Segment reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>210981021 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Losspershare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211021022 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211041023 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Relatedparties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>211071024 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/Subsequentevents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>220062001 - Disclosure - Consolidation principles and methods (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies</Role>
      <ShortName>Consolidation principles and methods (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230113001 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Intangibleassets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230143002 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Propertyplantandequipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230183003 - Disclosure - Non-current financial assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NoncurrentfinancialassetsTables</Role>
      <ShortName>Non-current financial assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Noncurrentfinancialassets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230223004 - Disclosure - Trade receivables and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables</Role>
      <ShortName>Trade receivables and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Tradereceivablesandothercurrentassets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230283005 - Disclosure - Cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsTables</Role>
      <ShortName>Cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Cashandcashequivalents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230323006 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/ShareCapital</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230423007 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Provisions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230493008 - Disclosure - Financial liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesTables</Role>
      <ShortName>Financial liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Financialliabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230573009 - Disclosure - Trade payables and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables</Role>
      <ShortName>Trade payables and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230633010 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230683011 - Disclosure - Revenues and other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenuesandotherincomeTables</Role>
      <ShortName>Revenues and other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Revenuesandotherincome</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230723012 - Disclosure - Operating expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesTables</Role>
      <ShortName>Operating expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Operatingexpenses</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230833013 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Sharebasedpayments</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230903014 - Disclosure - Net financial income (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossTables</Role>
      <ShortName>Net financial income (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Netfinancialincomeloss</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>230943015 - Disclosure - Income tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IncometaxTables</Role>
      <ShortName>Income tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Incometax</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>230993016 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Losspershare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231053017 - Disclosure - Related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesTables</Role>
      <ShortName>Related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Relatedparties</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - Company information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CompanyinformationDetails</Role>
      <ShortName>Company information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Companyinformation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240044002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails</Role>
      <ShortName>General Information, Statement of Compliance and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Consolidation principles and methods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails</Role>
      <ShortName>Consolidation principles and methods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240094004 - Disclosure - Significant transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SignificanttransactionsDetails</Role>
      <ShortName>Significant transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Significanttransactions</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240124005 - Disclosure - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IntangibleassetsDetails</Role>
      <ShortName>Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/IntangibleassetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240154006 - Disclosure - Property, plant and equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails</Role>
      <ShortName>Property, plant and equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240164007 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240194008 - Disclosure - Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails</Role>
      <ShortName>Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240204009 - Disclosure - Non-current financial assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails</Role>
      <ShortName>Non-current financial assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240234010 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails</Role>
      <ShortName>Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240244011 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails</Role>
      <ShortName>Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240254012 - Disclosure - Trade receivables and other current assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails</Role>
      <ShortName>Trade receivables and other current assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240264013 - Disclosure - Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails</Role>
      <ShortName>Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240294014 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails</Role>
      <ShortName>Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240304015 - Disclosure - Cash and cash equivalents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails</Role>
      <ShortName>Cash and cash equivalents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240334016 - Disclosure - Share Capital - Disclosure of Detail of Share Capital Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails</Role>
      <ShortName>Share Capital - Disclosure of Detail of Share Capital Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240344017 - Disclosure - Share Capital - Capital Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails</Role>
      <ShortName>Share Capital - Capital Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240354018 - Disclosure - Share Capital - Treasury Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails</Role>
      <ShortName>Share Capital - Treasury Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240364019 - Disclosure - Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails</Role>
      <ShortName>Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240374020 - Disclosure - Share Capital - Founders??? warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails</Role>
      <ShortName>Share Capital - Founders??? warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240384021 - Disclosure - Share Capital - Warrant Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails</Role>
      <ShortName>Share Capital - Warrant Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240394022 - Disclosure - Share Capital - Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails</Role>
      <ShortName>Share Capital - Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240404023 - Disclosure - Share Capital - Free Share Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails</Role>
      <ShortName>Share Capital - Free Share Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240434024 - Disclosure - Provisions - Disclosure of Changes in Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails</Role>
      <ShortName>Provisions - Disclosure of Changes in Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240444025 - Disclosure - Provisions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails</Role>
      <ShortName>Provisions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240454026 - Disclosure - Provisions - Disclosure of Commitments for Retirement Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails</Role>
      <ShortName>Provisions - Disclosure of Commitments for Retirement Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240464027 - Disclosure - Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails</Role>
      <ShortName>Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240474028 - Disclosure - Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails</Role>
      <ShortName>Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240504029 - Disclosure - Financial liabilities - Summary of Changes in Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails</Role>
      <ShortName>Financial liabilities - Summary of Changes in Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240514030 - Disclosure - Financial liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Financial liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240524031 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240534032 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails</Role>
      <ShortName>Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240544033 - Disclosure - Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240554034 - Disclosure - Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240584035 - Disclosure - Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240594036 - Disclosure - Trade payables and other current liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Trade payables and other current liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240604037 - Disclosure - Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240614038 - Disclosure - Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails</Role>
      <ShortName>Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240644039 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240654040 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240664041 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails</Role>
      <ShortName>Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240694042 - Disclosure - Revenues and other income - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails</Role>
      <ShortName>Revenues and other income - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240704043 - Disclosure - Revenues and other income - Schedule of Revenues and Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails</Role>
      <ShortName>Revenues and other income - Schedule of Revenues and Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240734044 - Disclosure - Operating expenses - Summary of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails</Role>
      <ShortName>Operating expenses - Summary of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240744045 - Disclosure - Operating expenses - Research and Development, Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails</Role>
      <ShortName>Operating expenses - Research and Development, Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240754046 - Disclosure - Operating expenses - Summary of Selling, General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Operating expenses - Summary of Selling, General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240764047 - Disclosure - Operating expenses - Selling, General and Administrative, Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails</Role>
      <ShortName>Operating expenses - Selling, General and Administrative, Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240774048 - Disclosure - Operating expenses - Summary of Payroll Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails</Role>
      <ShortName>Operating expenses - Summary of Payroll Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240784049 - Disclosure - Operating expenses - Payroll Costs, Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails</Role>
      <ShortName>Operating expenses - Payroll Costs, Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240794050 - Disclosure - Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails</Role>
      <ShortName>Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240804051 - Disclosure - Operating expenses - Summary of Other Operating Income (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails</Role>
      <ShortName>Operating expenses - Summary of Other Operating Income (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240814052 - Disclosure - Operating expenses - Other Operating Income (Expense), Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails</Role>
      <ShortName>Operating expenses - Other Operating Income (Expense), Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240844053 - Disclosure - Share-based payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-based payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240854054 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails</Role>
      <ShortName>Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240864055 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails</Role>
      <ShortName>Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240874056 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails</Role>
      <ShortName>Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240884057 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails</Role>
      <ShortName>Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240914058 - Disclosure - Net financial income (loss) - Summary of Net Financial Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails</Role>
      <ShortName>Net financial income (loss) - Summary of Net Financial Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/NetfinancialincomelossTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240924059 - Disclosure - Net financial income (loss) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails</Role>
      <ShortName>Net financial income (loss) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/NetfinancialincomelossTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240954060 - Disclosure - Income tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IncometaxAdditionalInformationDetails</Role>
      <ShortName>Income tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240964061 - Disclosure - Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails</Role>
      <ShortName>Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>241004062 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails</Role>
      <ShortName>Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>241014063 - Disclosure - Loss per share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/LosspershareAdditionalInformationDetails</Role>
      <ShortName>Loss per share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>241034064 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Commitments</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>241064065 - Disclosure - Related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/RelatedpartiesDetails</Role>
      <ShortName>Related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/RelatedpartiesTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="nbx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>241084066 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanobiotix.com/role/SubsequenteventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanobiotix.com/role/Subsequentevents</ParentRole>
      <Position>115</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="nbx-20211231.htm">nbx-20211231.htm</File>
    <File>nanobiotix-secx20xf2021xex.htm</File>
    <File>nbx-20211231.xsd</File>
    <File>nbx-20211231_cal.xml</File>
    <File>nbx-20211231_def.xml</File>
    <File>nbx-20211231_lab.xml</File>
    <File>nbx-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbx-20211231_g1.jpg</File>
    <File>nbx-20211231_g10.jpg</File>
    <File>nbx-20211231_g11.jpg</File>
    <File>nbx-20211231_g12.jpg</File>
    <File>nbx-20211231_g13.jpg</File>
    <File>nbx-20211231_g14.jpg</File>
    <File>nbx-20211231_g15.jpg</File>
    <File>nbx-20211231_g16.jpg</File>
    <File>nbx-20211231_g17.jpg</File>
    <File>nbx-20211231_g18.jpg</File>
    <File>nbx-20211231_g19.jpg</File>
    <File>nbx-20211231_g2.jpg</File>
    <File>nbx-20211231_g20.jpg</File>
    <File>nbx-20211231_g21.jpg</File>
    <File>nbx-20211231_g22.jpg</File>
    <File>nbx-20211231_g23.jpg</File>
    <File>nbx-20211231_g24.jpg</File>
    <File>nbx-20211231_g25.jpg</File>
    <File>nbx-20211231_g26.jpg</File>
    <File>nbx-20211231_g27.jpg</File>
    <File>nbx-20211231_g28.jpg</File>
    <File>nbx-20211231_g3.jpg</File>
    <File>nbx-20211231_g4.jpg</File>
    <File>nbx-20211231_g5.jpg</File>
    <File>nbx-20211231_g6.jpg</File>
    <File>nbx-20211231_g7.jpg</File>
    <File>nbx-20211231_g8.jpg</File>
    <File>nbx-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2331">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>167
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbx-20211231.htm": {
   "axisCustom": 4,
   "axisStandard": 34,
   "contextCount": 987,
   "dts": {
    "calculationLink": {
     "local": [
      "nbx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nbx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nbx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 815,
   "entityCount": 1,
   "hidden": {
    "http://nanobiotix.com/20211231": 19,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 24
   },
   "keyCustom": 153,
   "keyStandard": 296,
   "memberCustom": 136,
   "memberStandard": 48,
   "nsprefix": "nbx",
   "nsuri": "http://nanobiotix.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover page",
     "role": "http://nanobiotix.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210051003 - Disclosure - Consolidation principles and methods",
     "role": "http://nanobiotix.com/role/Consolidationprinciplesandmethods",
     "shortName": "Consolidation principles and methods",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ContractTerminationIndemnities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804051 - Disclosure - Operating expenses - Summary of Other Operating Income (Expense) (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails",
     "shortName": "Operating expenses - Summary of Other Operating Income (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ContractTerminationIndemnities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814052 - Disclosure - Operating expenses - Other Operating Income (Expense), Additional Information (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
     "shortName": "Operating expenses - Other Operating Income (Expense), Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i0017336596444f75835cadbb51aedd4f_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbx:ContractTerminationIndemnities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844053 - Disclosure - Share-based payments - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
     "shortName": "Share-based payments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854054 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
     "shortName": "Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Oustanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "id7048d78dba6499cafa5c9c0c63bb7c3_D20121218-20121218",
      "decimals": "2",
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i14e72259f766468696e8950f2f900687_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864055 - Disclosure - Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails",
     "shortName": "Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Share Options Oustanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i712e048fe4d145e490466b4059621db8_D20160202-20160202",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874056 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
     "shortName": "Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Founders' Warrants, Warrants, and Free Shares Granted During Period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i93e3b83680474099afdc1f6ff9bd7940_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884057 - Disclosure - Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
     "shortName": "Share-based payments - Disclosure of Indirect Measurement of Fair Value of Goods or Services Received, Share Options Granted During Period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i14e72259f766468696e8950f2f900687_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914058 - Disclosure - Net financial income (loss) - Summary of Net Financial Income (Loss) (Details)",
     "role": "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails",
     "shortName": "Net financial income (loss) - Summary of Net Financial Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestIncomeOnCashAndBankBalancesAtCentralBanks",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestRevenueExpense",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924059 - Disclosure - Net financial income (loss) - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
     "shortName": "Net financial income (loss) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ifrs-full:NetForeignExchangeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954060 - Disclosure - Income tax - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails",
     "shortName": "Income tax - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210081004 - Disclosure - Significant transactions",
     "role": "http://nanobiotix.com/role/Significanttransactions",
     "shortName": "Significant transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964061 - Disclosure - Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)",
     "role": "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails",
     "shortName": "Income tax - Schedule of Reconciliation Between Statutory and Effective Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004062 - Disclosure - Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)",
     "role": "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails",
     "shortName": "Loss per share - Schedule of Basic and Diluted Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014063 - Disclosure - Loss per share - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/LosspershareAdditionalInformationDetails",
     "shortName": "Loss per share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfShortTermLeaseContracts",
      "reportCount": 1,
      "unitRef": "lease_contract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034064 - Disclosure - Commitments (Details)",
     "role": "http://nanobiotix.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nbx:AnnualShortTermLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064065 - Disclosure - Related parties (Details)",
     "role": "http://nanobiotix.com/role/RelatedpartiesDetails",
     "shortName": "Related parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ibf0906164d3245eca6340ec305f7b4bf_D20210401-20210401",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IssueOfEquity",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084066 - Disclosure - Subsequent events (Details)",
     "role": "http://nanobiotix.com/role/SubsequenteventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i58b267957c564e22a8fe73487217730b_I20220311",
      "decimals": "2",
      "lang": "en-US",
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210101005 - Disclosure - Intangible assets",
     "role": "http://nanobiotix.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210131006 - Disclosure - Property, plant and equipment",
     "role": "http://nanobiotix.com/role/Propertyplantandequipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210171007 - Disclosure - Non-current financial assets",
     "role": "http://nanobiotix.com/role/Noncurrentfinancialassets",
     "shortName": "Non-current financial assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfNonCurrentFinancialAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210211008 - Disclosure - Trade receivables and other current assets",
     "role": "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets",
     "shortName": "Trade receivables and other current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210271009 - Disclosure - Cash and cash equivalents",
     "role": "http://nanobiotix.com/role/Cashandcashequivalents",
     "shortName": "Cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210311010 - Disclosure - Share Capital",
     "role": "http://nanobiotix.com/role/ShareCapital",
     "shortName": "Share Capital",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210411011 - Disclosure - Provisions",
     "role": "http://nanobiotix.com/role/Provisions",
     "shortName": "Provisions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfFinancialLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210481012 - Disclosure - Financial liabilities",
     "role": "http://nanobiotix.com/role/Financialliabilities",
     "shortName": "Financial liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfFinancialLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://nanobiotix.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210561013 - Disclosure - Trade payables and other current liabilities",
     "role": "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities",
     "shortName": "Trade payables and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210621014 - Disclosure - Financial instruments included in the statement of financial position and impact on income",
     "role": "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome",
     "shortName": "Financial instruments included in the statement of financial position and impact on income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210671015 - Disclosure - Revenues and other income",
     "role": "http://nanobiotix.com/role/Revenuesandotherincome",
     "shortName": "Revenues and other income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210711016 - Disclosure - Operating expenses",
     "role": "http://nanobiotix.com/role/Operatingexpenses",
     "shortName": "Operating expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210821017 - Disclosure - Share-based payments",
     "role": "http://nanobiotix.com/role/Sharebasedpayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210891018 - Disclosure - Net financial income (loss)",
     "role": "http://nanobiotix.com/role/Netfinancialincomeloss",
     "shortName": "Net financial income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210931019 - Disclosure - Income tax",
     "role": "http://nanobiotix.com/role/Incometax",
     "shortName": "Income tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210971020 - Disclosure - Segment reporting",
     "role": "http://nanobiotix.com/role/Segmentreporting",
     "shortName": "Segment reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210981021 - Disclosure - Loss per share",
     "role": "http://nanobiotix.com/role/Losspershare",
     "shortName": "Loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211021022 - Disclosure - Commitments",
     "role": "http://nanobiotix.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - STATEMENTS OF CONSOLIDATED FINANCIAL POSITION",
     "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
     "shortName": "STATEMENTS OF CONSOLIDATED FINANCIAL POSITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211041023 - Disclosure - Related parties",
     "role": "http://nanobiotix.com/role/Relatedparties",
     "shortName": "Related parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211071024 - Disclosure - Subsequent events",
     "role": "http://nanobiotix.com/role/Subsequentevents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220062001 - Disclosure - Consolidation principles and methods (Policies)",
     "role": "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies",
     "shortName": "Consolidation principles and methods (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230113001 - Disclosure - Intangible assets (Tables)",
     "role": "http://nanobiotix.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230143002 - Disclosure - Property, plant and equipment (Tables)",
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230183003 - Disclosure - Non-current financial assets (Tables)",
     "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsTables",
     "shortName": "Non-current financial assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230223004 - Disclosure - Trade receivables and other current assets (Tables)",
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables",
     "shortName": "Trade receivables and other current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230283005 - Disclosure - Cash and cash equivalents (Tables)",
     "role": "http://nanobiotix.com/role/CashandcashequivalentsTables",
     "shortName": "Cash and cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230323006 - Disclosure - Share Capital (Tables)",
     "role": "http://nanobiotix.com/role/ShareCapitalTables",
     "shortName": "Share Capital (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230423007 - Disclosure - Provisions (Tables)",
     "role": "http://nanobiotix.com/role/ProvisionsTables",
     "shortName": "Provisions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - STATEMENTS OF CONSOLIDATED OPERATIONS",
     "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS",
     "shortName": "STATEMENTS OF CONSOLIDATED OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:OperatingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230493008 - Disclosure - Financial liabilities (Tables)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesTables",
     "shortName": "Financial liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230573009 - Disclosure - Trade payables and other current liabilities (Tables)",
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables",
     "shortName": "Trade payables and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230633010 - Disclosure - Financial instruments included in the statement of financial position and impact on income (Tables)",
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables",
     "shortName": "Financial instruments included in the statement of financial position and impact on income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230683011 - Disclosure - Revenues and other income (Tables)",
     "role": "http://nanobiotix.com/role/RevenuesandotherincomeTables",
     "shortName": "Revenues and other income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230723012 - Disclosure - Operating expenses (Tables)",
     "role": "http://nanobiotix.com/role/OperatingexpensesTables",
     "shortName": "Operating expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230833013 - Disclosure - Share-based payments (Tables)",
     "role": "http://nanobiotix.com/role/SharebasedpaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230903014 - Disclosure - Net financial income (loss) (Tables)",
     "role": "http://nanobiotix.com/role/NetfinancialincomelossTables",
     "shortName": "Net financial income (loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230943015 - Disclosure - Income tax (Tables)",
     "role": "http://nanobiotix.com/role/IncometaxTables",
     "shortName": "Income tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230993016 - Disclosure - Loss per share (Tables)",
     "role": "http://nanobiotix.com/role/LosspershareTables",
     "shortName": "Loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231053017 - Disclosure - Related parties (Tables)",
     "role": "http://nanobiotix.com/role/RelatedpartiesTables",
     "shortName": "Related parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS",
     "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS",
     "shortName": "STATEMENTS OF CONSOLIDATED COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ib4221b386b8a41008368fa79a2422241_D20210501-20210531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ContractualCommitmentsPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - Company information (Details)",
     "role": "http://nanobiotix.com/role/CompanyinformationDetails",
     "shortName": "Company information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:StatementOfIFRSCompliance",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240044002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation (Details)",
     "role": "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails",
     "shortName": "General Information, Statement of Compliance and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Consolidation principles and methods (Details)",
     "role": "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails",
     "shortName": "Consolidation principles and methods (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbx:DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094004 - Disclosure - Significant transactions (Details)",
     "role": "http://nanobiotix.com/role/SignificanttransactionsDetails",
     "shortName": "Significant transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i0383e3a745c6410a8ad6434d35604d24_D20120801-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbx:CollaborationAgreementTotalPaymentsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124005 - Disclosure - Intangible assets (Details)",
     "role": "http://nanobiotix.com/role/IntangibleassetsDetails",
     "shortName": "Intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i64a32d6adbc0421e9abe2f62cfb9d425_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154006 - Disclosure - Property, plant and equipment - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
     "shortName": "Property, plant and equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nbx:NumberOfNewLeaseContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease_contract",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164007 - Disclosure - Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "role": "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, plant and equipment - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i64a32d6adbc0421e9abe2f62cfb9d425_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194008 - Disclosure - Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)",
     "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails",
     "shortName": "Non-current financial assets - Disclosure of Changes in Non-current Financial Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i64a32d6adbc0421e9abe2f62cfb9d425_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IncreaseDecreaseInFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204009 - Disclosure - Non-current financial assets - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails",
     "shortName": "Non-current financial assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IncreaseDecreaseInFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nbx:DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234010 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)",
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails",
     "shortName": "Trade receivables and other current assets - Disclosure of Break Down of Trade Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i23b8abb72e0b4536a6fe80c714c03c32_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ief56ec2bd42a44a6a729bc2731655345_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "STATEMENTS OF CONSOLIDATED CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ib9dafc6f49b842eab8640526d732bb38_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244011 - Disclosure - Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)",
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails",
     "shortName": "Trade receivables and other current assets - Disclosure of Break Down of Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254012 - Disclosure - Trade receivables and other current assets - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
     "shortName": "Trade receivables and other current assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbx:CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264013 - Disclosure - Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)",
     "role": "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails",
     "shortName": "Trade receivables and other current assets - Disclosure of Changes in Research Tax Credit Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i4e0a8e1adc2f4d8daeb375e78b79e118_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nbx:CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294014 - Disclosure - Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)",
     "role": "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails",
     "shortName": "Cash and cash equivalents - Summary of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304015 - Disclosure - Cash and cash equivalents - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
     "shortName": "Cash and cash equivalents - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ibde68ac988834ab2910c0b14649ffa2a_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334016 - Disclosure - Share Capital - Disclosure of Detail of Share Capital Transactions (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
     "shortName": "Share Capital - Disclosure of Detail of Share Capital Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i8de9f777ee344fac809f90733d665d63_D20210331-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:IssueOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344017 - Disclosure - Share Capital - Capital Issued (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
     "shortName": "Share Capital - Capital Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ibf9ad81b51bf4c808adb6b86c14e2b1b_D20201201-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "nbx:NumberOfSharesIssuedThroughIssueOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TreasuryShares",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354018 - Disclosure - Share Capital - Treasury Shares (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails",
     "shortName": "Share Capital - Treasury Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364019 - Disclosure - Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
     "shortName": "Share Capital - Disclosure of Detail of Change in Founders' Warrants, Warrants, Stock Options and Free Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "iae6315b11bee49a48773726a45aedbb0_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374020 - Disclosure - Share Capital - Founders\u2019 warrants (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
     "shortName": "Share Capital - Founders\u2019 warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ia2769b605fb84b87a90e1def012f90a6_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - STATEMENTS OF CONSOLIDATED CASH FLOWS",
     "role": "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS",
     "shortName": "STATEMENTS OF CONSOLIDATED CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384021 - Disclosure - Share Capital - Warrant Plans (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
     "shortName": "Share Capital - Warrant Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i72085c84778e4ed2b24b1a8a1dd6548b_D20210420-20210420",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394022 - Disclosure - Share Capital - Stock Option Plans (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
     "shortName": "Share Capital - Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "id6f118b85eb74114b47a6ec28db6f4b4_D20201130-20201130",
      "decimals": null,
      "lang": "en-US",
      "name": "nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unitRef": "eurPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404023 - Disclosure - Share Capital - Free Share Plans (Details)",
     "role": "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
     "shortName": "Share Capital - Free Share Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ia49ffd5f6a8a43efaa547e2eb3e46420_D20191024-20191024",
      "decimals": null,
      "lang": "en-US",
      "name": "nbx:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434024 - Disclosure - Provisions - Disclosure of Changes in Provisions (Details)",
     "role": "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails",
     "shortName": "Provisions - Disclosure of Changes in Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i64a32d6adbc0421e9abe2f62cfb9d425_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "iac7deafff4bd4c28baa3ff4492ed5d5e_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444025 - Disclosure - Provisions - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
     "shortName": "Provisions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ieea5574aa32340a388b2a156f8e176a2_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i6ff9c4acb5c74c6790f0853cd162580f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454026 - Disclosure - Provisions - Disclosure of Commitments for Retirement Benefits (Details)",
     "role": "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails",
     "shortName": "Provisions - Disclosure of Commitments for Retirement Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ActuarialAssumptionOfSocialSecurityContributionRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464027 - Disclosure - Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)",
     "role": "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails",
     "shortName": "Provisions - Disclosure of Assumptions Used to Measure Retirement Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ActuarialAssumptionOfSocialSecurityContributionRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474028 - Disclosure - Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)",
     "role": "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails",
     "shortName": "Provisions - Disclosure of Sensitivity Analysis for Actuarial Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentFinancialLiabilities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504029 - Disclosure - Financial liabilities - Summary of Changes in Financial Liabilities (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
     "shortName": "Financial liabilities - Summary of Changes in Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514030 - Disclosure - Financial liabilities - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
     "shortName": "Financial liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "nbx:ConsolidatedForecastedSalesPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Company information",
     "role": "http://nanobiotix.com/role/Companyinformation",
     "shortName": "Company information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i3325ccb1e560443f9ddb6eddf043414a_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524031 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
     "shortName": "Financial liabilities - Disclosure of Detailed Information about Conditional Advances and Loans From Government and Public Authorities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i9ba645486aa240169be18398fc400965_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "id83ab7ac51814807be706998f4cc09e1_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534032 - Disclosure - Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
     "shortName": "Financial liabilities - Disclosure of Detailed Information about Bank Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i06da0291c1964865b0bee57ea7df6660_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nbx:DetailedInformationAboutFinanceIncomeCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544033 - Disclosure - Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails",
     "shortName": "Financial liabilities - Disclosure of Reconciliation of Changes in Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i19e15c2a272c4daca720310496d521ca_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:BorrowingNumberOfPGE",
      "reportCount": 1,
      "unique": true,
      "unitRef": "borrowing",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554034 - Disclosure - Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)",
     "role": "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
     "shortName": "Financial liabilities - Disclosure of Maturity Analysis for Advances Loans and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:BorrowingNumberOfPGE",
      "reportCount": 1,
      "unique": true,
      "unitRef": "borrowing",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584035 - Disclosure - Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)",
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails",
     "shortName": "Trade payables and other current liabilities - Disclosure of Trade and Other Payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:OtherCurrentPayables",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594036 - Disclosure - Trade payables and other current liabilities - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails",
     "shortName": "Trade payables and other current liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbx:IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTaxLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604037 - Disclosure - Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)",
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails",
     "shortName": "Trade payables and other current liabilities - Disclosure of Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentTaxLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614038 - Disclosure - Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details)",
     "role": "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails",
     "shortName": "Trade payables and other current liabilities - Disclosure of Deferred Income and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644039 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)",
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails",
     "shortName": "Financial instruments included in the statement of financial position and impact on income - Disclosure of Non-Current Financial Assets and Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ibbf161735ab842849b194cad877786e7_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654040 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)",
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails",
     "shortName": "Financial instruments included in the statement of financial position and impact on income - Disclosure of Effect of Changes in Exchange Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "ibbf161735ab842849b194cad877786e7_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - General Information, Statement of Compliance and Basis of Presentation",
     "role": "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation",
     "shortName": "General Information, Statement of Compliance and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i019a762512c74bd995f218b15c627c60_D20180701-20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfTranchesBorrowings",
      "reportCount": 1,
      "unitRef": "tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664041 - Disclosure - Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
     "shortName": "Financial instruments included in the statement of financial position and impact on income - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:ResearchTaxCreditUtilizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694042 - Disclosure - Revenues and other income - Additional Information (Details)",
     "role": "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
     "shortName": "Revenues and other income - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbx:ResearchTaxCreditUtilizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704043 - Disclosure - Revenues and other income - Schedule of Revenues and Other Income (Details)",
     "role": "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails",
     "shortName": "Revenues and other income - Schedule of Revenues and Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "nbx:ResearchAndDevelopmentTaxCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734044 - Disclosure - Operating expenses - Summary of Research and Development Expenses (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails",
     "shortName": "Operating expenses - Summary of Research and Development Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:IncreaseDecreaseInEmployeeBenefitExpense",
      "reportCount": 1,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744045 - Disclosure - Operating expenses - Research and Development, Additional Information (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
     "shortName": "Operating expenses - Research and Development, Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "id2be74eb72584233979cc9db5230eafb_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbx:IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754046 - Disclosure - Operating expenses - Summary of Selling, General and Administrative Expenses (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails",
     "shortName": "Operating expenses - Summary of Selling, General and Administrative Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nbx:SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfImpactingFactors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "factor",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764047 - Disclosure - Operating expenses - Selling, General and Administrative, Additional Information (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
     "shortName": "Operating expenses - Selling, General and Administrative, Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbx:NumberOfImpactingFactors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "factor",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774048 - Disclosure - Operating expenses - Summary of Payroll Costs (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails",
     "shortName": "Operating expenses - Summary of Payroll Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WagesAndSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i05ef069d6d904f1cbf20114a97bea67a_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfEmployees",
      "reportCount": 1,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784049 - Disclosure - Operating expenses - Payroll Costs, Additional Information (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails",
     "shortName": "Operating expenses - Payroll Costs, Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794050 - Disclosure - Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details)",
     "role": "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails",
     "shortName": "Operating expenses - Summary of Depreciation, Amortization and Provision Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbx:DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbx-20211231.htm",
      "contextRef": "i289cde5104064d92bd0d42d43cec761b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AmortisationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 193,
   "tag": {
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "FRANCE"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD / Euro exchange rate"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number",
        "terseLabel": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]",
        "terseLabel": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag",
        "terseLabel": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Recurring loss before tax"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r68",
      "r74",
      "r114",
      "r126",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Accumulated depreciation of tangible assets",
        "verboseLabel": "Accumulated depreciation of intangible assets"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income [member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates [member]",
        "terseLabel": "Actuarial assumption of discount rates"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases",
        "terseLabel": "Salary increase rate (including inflation)"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfRetirementAge2019": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of retirement age",
        "terseLabel": "Retirement assumptions"
       }
      }
     },
     "localname": "ActuarialAssumptionOfRetirementAge2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [axis]",
        "terseLabel": "Actuarial assumptions [axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [member]",
        "terseLabel": "Actuarial assumptions [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions",
        "terseLabel": "Gains or losses related to change in demographic assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions",
        "terseLabel": "Gains or losses related to change in financial assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments",
        "terseLabel": "Gains or losses related to experience"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "verboseLabel": "Increases"
       }
      }
     },
     "localname": "AdditionalProvisionsOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Increases"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Increases",
        "verboseLabel": "Increase in right-of-use assets"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "(Increase) / Decrease in trade receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Cost of net debt"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "negatedTerseLabel": "Loss on disposals"
       }
      }
     },
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities",
        "terseLabel": "Increase in deferred income and contract liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in derivative financial liabilities",
        "terseLabel": "Impact of deferred income related to financial liabilities discounting effect"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other current liabilities",
        "terseLabel": "Increase / (Decrease) in other current liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Increase / (Decrease) in trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "AdjustmentsForProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Elimination of other non-cash, non-operating income and expenses"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Expenses related to share-based payments"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Advances": {
     "auth_ref": [
      "r22",
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time",
        "terseLabel": "Advances received"
       }
      }
     },
     "localname": "Advances",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r25",
      "r86",
      "r177",
      "r184",
      "r185",
      "r203",
      "r229",
      "r238",
      "r254",
      "r255",
      "r257",
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]",
        "terseLabel": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationExpense": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation expense",
        "negatedTerseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Theoretical tax rate (statutory rate in France)"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r22",
      "r168",
      "r169",
      "r170",
      "r245",
      "r248"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "auth_ref": [
      "r3",
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]",
        "terseLabel": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Average effective tax rate",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "AverageEffectiveTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      },
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average foreign exchange rate"
       }
      }
     },
     "localname": "AverageForeignExchangeRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_AverageNumberOfEmployees": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The average number of personnel employed by the entity during a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Average number of employees",
        "terseLabel": "Average headcount"
       }
      }
     },
     "localname": "AverageNumberOfEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "auth_ref": [
      "r231",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Bank borrowings, undiscounted cash flows",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per share (in euro per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]",
        "terseLabel": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]",
        "terseLabel": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Borrowings, interest rate"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r194",
      "r224",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r68",
      "r72",
      "r114",
      "r118",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r200",
      "r209",
      "r213",
      "r270",
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r72",
      "r118",
      "r125",
      "r127",
      "r128",
      "r200",
      "r209",
      "r213",
      "r270",
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash and bank accounts"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r18",
      "r149",
      "r166"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Net cash and cash equivalents at end of period",
        "periodStartLabel": "Net cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Net cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsSummaryofCashandCashEquivalentsDetails",
      "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentationDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r130",
      "r152"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flows from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r130",
      "r152"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash flows from (used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flows from (used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r130",
      "r152"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "auth_ref": [
      "r141",
      "r153"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations before changes in working capital",
        "totalLabel": "Cash flows used in operations, before tax and changes in working capital"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]",
        "terseLabel": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]",
        "terseLabel": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in liabilities arising from financing activities [abstract]",
        "terseLabel": "Changes in liabilities arising from financing activities [abstract]"
       }
      }
     },
     "localname": "ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r253",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]",
        "terseLabel": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r209",
      "r214",
      "r216",
      "r218"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r209",
      "r214",
      "r216",
      "r218"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r253",
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]",
        "terseLabel": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]",
        "terseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]",
        "terseLabel": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]",
        "terseLabel": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]",
        "terseLabel": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      },
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Closing foreign exchange rate"
       }
      }
     },
     "localname": "ClosingForeignExchangeRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r41",
      "r156",
      "r158",
      "r159",
      "r164"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerSoftwareMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software [member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ConcentrationsOfRiskAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Concentrations of risk [axis]",
        "terseLabel": "Concentrations of risk [axis]"
       }
      }
     },
     "localname": "ConcentrationsOfRiskAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ConcentrationsOfRiskMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the concentrations of risk. It also represents the standard value for the 'Concentrations of risk' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Concentrations of risk [member]",
        "terseLabel": "Concentrations of risk [member]"
       }
      }
     },
     "localname": "ConcentrationsOfRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Construction in progress [member]",
        "terseLabel": "Tangible assets in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contractual capital commitments",
        "terseLabel": "Contractual capital commitments"
       }
      }
     },
     "localname": "ContractualCapitalCommitments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r241",
      "r258",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      },
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Current advances to suppliers"
       }
      }
     },
     "localname": "CurrentAdvancesToSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r26",
      "r159",
      "r160"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "terseLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": {
     "auth_ref": [
      "r22",
      "r34"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current deferred income including current contract liabilities",
        "terseLabel": "Deferred revenues and contract liabilities"
       }
      }
     },
     "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofDeferredIncomeandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current financial liabilities",
        "terseLabel": "Current financial liabilities"
       }
      }
     },
     "localname": "CurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r28",
      "r159",
      "r162"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current payables on social security and taxes other than income tax",
        "terseLabel": "Payroll tax and other payroll liabilities"
       }
      }
     },
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentProvisions": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions",
        "terseLabel": "Current provisions"
       }
      }
     },
     "localname": "CurrentProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current receivables from taxes other than income tax",
        "periodEndLabel": "Research tax credit receivable at end of period",
        "periodStartLabel": "Research tax credit receivable at beginning of period",
        "terseLabel": "Research tax credit receivable"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase in net defined benefit liability (asset) resulting from current service cost",
        "negatedLabel": "Retirement benefit obligations",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Tax liabilities"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r27",
      "r31"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": {
     "auth_ref": [
      "r209",
      "r211",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through derecognition, financial assets",
        "negatedTerseLabel": "Decreases"
       }
      }
     },
     "localname": "DecreaseThroughDerecognitionFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "terseLabel": "Deferred tax liability (asset)"
       }
      }
     },
     "localname": "DeferredTaxLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationExpense": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "negatedTerseLabel": "Amortization expense of tangible assets"
       }
      }
     },
     "localname": "DepreciationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]",
        "terseLabel": "Non-current financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial liabilities [text block]",
        "verboseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for issued capital [text block]",
        "terseLabel": "Capital issued"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases [text block]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue and other income"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other receivables [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Maturity (in years)"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per share (in euro per share)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      },
      "en-us": {
       "role": {
        "label": "Directors' remuneration expense",
        "terseLabel": "Supervisory Board\u2019s fees"
       }
      }
     },
     "localname": "DirectorsRemunerationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Cashandcashequivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Disclosure of detail of share capital transactions"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of commitments [text block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [line items]",
        "terseLabel": "Disclosure of contingent liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [table]",
        "terseLabel": "Disclosure of contingent liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [text block]",
        "terseLabel": "Disclosure of assumptions used to measure retirement benefits"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [line items]",
        "terseLabel": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]",
        "terseLabel": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Disclosure of detailed information about conditional advance, bank loan and loans from government and public authorities"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]",
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]",
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Losspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Net financial income (loss)"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Netfinancialincomeloss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [text block]",
        "terseLabel": "Disclosure of details of non-current financial assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]",
        "terseLabel": "Disclosure of financial assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]",
        "terseLabel": "Disclosure of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [line items]",
        "terseLabel": "Disclosure of financial instruments by type of interest rate [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial instruments, by type of interest rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments by type of interest rate [table]",
        "terseLabel": "Disclosure of financial instruments by type of interest rate [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsByTypeOfInterestRateTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial instruments included in the statement of financial position and impact on income"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Financialinstrumentsincludedinthestatementoffinancialpositionandimpactonincome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r205",
      "r214",
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Summary of changes in financial liabilities",
        "verboseLabel": "Disclosure of details of financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables",
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]",
        "terseLabel": "Disclosure Of Changes In Financial Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]",
        "terseLabel": "Disclosure Of Changes In Financial Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "General Information, Statement of Compliance and Basis of Presentation"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/GeneralInformationStatementofComplianceandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Incometax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]",
        "terseLabel": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]",
        "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]",
        "terseLabel": "Summary of Maturity Analysis for Advances Loans and Lease Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [text block]",
        "terseLabel": "Disclosure of commitments for retirement benefits"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Subsequentevents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]",
        "terseLabel": "Company information"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Companyinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Disclosure of detail of change in founders' warrants, warrants and free shares"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Disclosure of detail of change in stock options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of share options outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Segmentreporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Operatingexpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [text block]",
        "terseLabel": "Disclosure of changes in provisions"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]",
        "terseLabel": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]",
        "terseLabel": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Propertyplantandequipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provisions [text block]",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DisclosureOfProvisionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Provisions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]",
        "terseLabel": "Disclosure of reconciliation of changes in lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]",
        "terseLabel": "Summary Of Conditional Advances, Banks Loans And Loans [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]",
        "terseLabel": "Summary Of Conditional Advances, Banks Loans And Loans [Table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Relatedparties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "terseLabel": "Revenues and other income"
       }
      }
     },
     "localname": "DisclosureOfRevenueExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Revenuesandotherincome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]",
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]",
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [line items]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]",
        "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [table]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Share Capital"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapital"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Sharebasedpayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Consolidation principles and methods"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/Consolidationprinciplesandmethods"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Disclosure of significant transactions"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]",
        "terseLabel": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedTerseLabel": "Decreases"
       }
      }
     },
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Decreases",
        "terseLabel": "Disposals, property, plant and equipment"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Schedule of basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effect of exchange rates changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "negatedTerseLabel": "Total payroll costs"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r22",
      "r33",
      "r155",
      "r157",
      "r168",
      "r169",
      "r170"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity at end of period",
        "periodStartLabel": "Equity at beginning of period",
        "terseLabel": "Equity",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDER\u2019S EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities",
        "terseLabel": "Estimated financial effect of contingent liabilities"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Exercise price (in euros per share)"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend as percentage, share options granted",
        "terseLabel": "Yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from equity-settled share-based payment transactions",
        "terseLabel": "Expense for the year"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedTerseLabel": "Share-based payments",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedTerseLabel": "Financial expenses",
        "negatedTotalLabel": "Total financial expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Financial income",
        "totalLabel": "Total financial income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "totalLabel": "Financial income (loss)"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r204",
      "r209",
      "r213",
      "r216",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Total financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]",
        "terseLabel": "Financial assets at amortised cost"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]",
        "terseLabel": "Financial assets at amortised cost, class"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value",
        "terseLabel": "Total financial assets, at fair value"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value, class [member]",
        "terseLabel": "Financial assets at fair value, class"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]",
        "terseLabel": "Financial assets carried at fair value through profit or loss"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]",
        "terseLabel": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r253",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]",
        "terseLabel": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r227",
      "r271"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]",
        "terseLabel": "Financial liabilities at amortised cost"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]",
        "terseLabel": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r253",
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]",
        "terseLabel": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FixedInterestRateMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fixed interest rate [member]",
        "terseLabel": "Fixed interest rate"
       }
      }
     },
     "localname": "FixedInterestRateMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FixturesAndFittingsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fixtures and fittings [member]",
        "terseLabel": "Fixtures, fittings and installations"
       }
      }
     },
     "localname": "FixturesAndFittingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FloatingInterestRateMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Floating interest rate [member]",
        "terseLabel": "Floating interest rate"
       }
      }
     },
     "localname": "FloatingInterestRateMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income",
        "totalLabel": "Actuarial gains or losses recognized in other comprehensive income"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax",
        "terseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r14",
      "r90"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Foreign exchange losses"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r68",
      "r114",
      "r126",
      "r129",
      "r200",
      "r213",
      "r216",
      "r217",
      "r270",
      "r277"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Gross book value of tangible assets",
        "verboseLabel": "Gross book value of intangible assets"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r183",
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income, expense, gains or losses of financial instruments [abstract]"
       }
      }
     },
     "localname": "IncomeExpenseGainsOrLossesOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r45",
      "r55",
      "r57",
      "r58",
      "r98",
      "r167",
      "r244"
     ],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income tax",
        "negatedTotalLabel": "Effective tax expense",
        "terseLabel": "Effective tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r48",
      "r56"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to exchange differences on translation of foreign operations included in other comprehensive income",
        "negatedTerseLabel": "Tax impact"
       }
      }
     },
     "localname": "IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r48",
      "r56"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to remeasurements of defined benefit plans. [Refer: Other comprehensive income; Reserve of remeasurements of defined benefit plans; Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to remeasurements of defined benefit plans included in other comprehensive income",
        "negatedTerseLabel": "Tax impact"
       }
      }
     },
     "localname": "IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "negatedTerseLabel": "Decrease in cash and cash equivalents",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in existing other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase in existing provisions, other provisions",
        "negatedLabel": "Provision for charges"
       }
      }
     },
     "localname": "IncreaseDecreaseInExistingProvisionsOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInFinancialAssets": {
     "auth_ref": [
      "r209",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in financial assets",
        "terseLabel": "Increase (decrease) in financial assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTotalLabel": "Changes in operating working capital"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "verboseLabel": "BSPCE exercise"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities",
        "terseLabel": "Principal received",
        "verboseLabel": "Repayment of lease"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": {
     "auth_ref": [
      "r209",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through foreign exchange, financial assets",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share based payment"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers and other changes, property, plant and equipment",
        "terseLabel": "Transfer"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFinancialAssets": {
     "auth_ref": [
      "r209",
      "r212",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from transfers. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, financial assets",
        "terseLabel": "Transfer"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "terseLabel": "Transfer"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r146",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "New lease contracts"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets": {
     "auth_ref": [
      "r209",
      "r210",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through origination or purchase, financial assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseThroughOriginationOrPurchaseFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r17",
      "r118"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Intangible assets at end of period",
        "periodStartLabel": "Intangible assets at beginning of period",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r105",
      "r119",
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible assets other than goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsUnderDevelopmentMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets under development [member]",
        "terseLabel": "Intangible assets in progress"
       }
      }
     },
     "localname": "IntangibleAssetsUnderDevelopmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IntangibleassetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)",
        "terseLabel": "Interests / discounting costs"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on borrowings",
        "terseLabel": "Interest expense on borrowings"
       }
      }
     },
     "localname": "InterestExpenseOnBorrowings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedTerseLabel": "IFRS 16 related interests",
        "terseLabel": "Fixed interest expense"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnCashAndBankBalancesAtCentralBanks": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and bank balances at central banks. [Refer: Interest income; Cash and bank balances at central banks]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on cash and bank balances at central banks",
        "terseLabel": "Income from cash and cash equivalents"
       }
      }
     },
     "localname": "InterestIncomeOnCashAndBankBalancesAtCentralBanks",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as financing activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPayable": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest payable",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestRateTypesMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate types [member]",
        "terseLabel": "Interest rate types [member]"
       }
      }
     },
     "localname": "InterestRateTypesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRevenueExpense": {
     "auth_ref": [
      "r47",
      "r245",
      "r249"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income (expense)",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "InterestRevenueExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Capital increase, net",
        "verboseLabel": "Capital increase"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital Ordinary shares",
        "verboseLabel": "Share Capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total compensation to related parties"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RelatedpartiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Salaries, wages and benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RelatedpartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r184",
      "r185",
      "r229",
      "r237",
      "r240",
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "More than 5 years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r229",
      "r235",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than three years [member]",
        "terseLabel": "Between 1 and 3\u00a0years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r24",
      "r269",
      "r275"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]",
        "terseLabel": "Due after more than 12 months"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "auth_ref": [
      "r229",
      "r234",
      "r240",
      "r269",
      "r274"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than six months and not later than one year [member]",
        "terseLabel": "Due between 6 and 12 months"
       }
      }
     },
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "auth_ref": [
      "r229",
      "r233",
      "r240",
      "r269",
      "r273"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three months and not later than six months [member]",
        "terseLabel": "Due between 3 and 6 months"
       }
      }
     },
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r229",
      "r236",
      "r240"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than five years [member]",
        "terseLabel": "Between 3 and 5\u00a0years"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r147",
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities",
        "periodEndLabel": "Liabilities arising from financing activities at end of period",
        "periodStartLabel": "Liabilities arising from financing activities at beginning of period"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [axis]",
        "terseLabel": "Liabilities arising from financing activities [axis]"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities arising from financing activities [member]",
        "terseLabel": "Liabilities arising from financing activities [member]"
       }
      }
     },
     "localname": "LiabilitiesArisingFromFinancingActivitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]",
        "terseLabel": "Liabilities [member]"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "periodEndLabel": "Provisions of retirement benefits at end of period",
        "periodStartLabel": "Provisions of retirement benefits at beginning of period"
       }
      }
     },
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "auth_ref": [
      "r3",
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Line items by function [member]",
        "terseLabel": "Line items by function [member]"
       }
      }
     },
     "localname": "LineItemsByFunctionMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "auth_ref": [
      "r147",
      "r154"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Long-term borrowings [member]",
        "terseLabel": "Long-term borrowings"
       }
      }
     },
     "localname": "LongtermBorrowingsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MachineryMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Machinery [member]",
        "terseLabel": "Technical equipment"
       }
      }
     },
     "localname": "MachineryMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Major ordinary share transactions [member]",
        "terseLabel": "Major ordinary share transactions"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Disclosure of maturity analysis for advances loans and lease liabilities"
       }
      }
     },
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r25",
      "r86",
      "r177",
      "r184",
      "r185",
      "r203",
      "r221",
      "r229",
      "r254",
      "r255",
      "r257",
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]",
        "terseLabel": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r14",
      "r90"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Foreign exchange gains"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "auth_ref": [
      "r14",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "terseLabel": "Foreign exchange losses"
       }
      }
     },
     "localname": "NetForeignExchangeLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r26",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial assets",
        "periodEndLabel": "Non-current financial assets at end of period",
        "periodStartLabel": "Non-current financial assets at beginning of period",
        "terseLabel": "Non-current financial assets"
       }
      }
     },
     "localname": "NoncurrentFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial liabilities",
        "terseLabel": "Non-current financial liabilities"
       }
      }
     },
     "localname": "NoncurrentFinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r28",
      "r159",
      "r163"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentProvisions": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions",
        "terseLabel": "Non-current provisions"
       }
      }
     },
     "localname": "NoncurrentProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-derivative financial liabilities, undiscounted cash flows",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r23",
      "r184",
      "r185",
      "r229",
      "r240",
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than 1\u00a0year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r10",
      "r269",
      "r272"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than three months [member]",
        "terseLabel": "Due in 3 months or less"
       }
      }
     },
     "localname": "NotLaterThanThreeMonthsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotionalAmount": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      },
      "en-us": {
       "role": {
        "label": "Notional amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "NotionalAmount",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfEmployees": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of employees",
        "terseLabel": "End-of-period headcount"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r195",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Issued (in shares)",
        "verboseLabel": "Number of awards issued (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Number of shares issuable (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "BSPCE exercise (in shares)",
        "verboseLabel": "Awards exercised during the period (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Number of awards lapsed or cancelled during the period (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r187",
      "r191",
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Number of share options outstanding in share-based payment arrangement (in shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Number of shares issuable (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Number of options as of including options exercised during the period (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Forfeited (in shares)",
        "terseLabel": "Options lapsed or cancelled during the period (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Issued (in shares)",
        "verboseLabel": "Number of options granted (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares outstanding at end of period (in shares)",
        "periodStartLabel": "Number of shares outstanding at beginning of period (in shares)",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OfficeEquipmentMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Office equipment [member]",
        "terseLabel": "Office and IT equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OnerousContractsProvision": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provision for onerous contracts. An onerous contract is a contract in which the unavoidable costs of meeting the obligation under the contract exceed the economic benefits expected to be received under it. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Onerous contracts provision",
        "terseLabel": "Onerous contracts provision"
       }
      }
     },
     "localname": "OnerousContractsProvision",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments for non-cash items",
        "terseLabel": "Other charges with no impact on cash"
       }
      }
     },
     "localname": "OtherAdjustmentsForNoncashItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r29",
      "r50",
      "r76"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Actuarial gains and losses on retirement benefit obligations\u00a0(IAS 19)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r29",
      "r49"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r29",
      "r49",
      "r76"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Actuarial gains and losses (IAS 19)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r52"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Other comprehensive income that may be reclassified subsequently to income or loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r52"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "totalLabel": "Other comprehensive loss that will not be reclassified subsequently to income or loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Trade payables &amp; other accruals"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncome": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income",
        "terseLabel": "Other financial income"
       }
      }
     },
     "localname": "OtherFinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossSummaryofNetFinancialIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r1",
      "r2",
      "r97"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 2.0,
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "terseLabel": "Other income",
        "totalLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 3.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other operating income (expense)",
        "terseLabel": "Other operating income and expenses",
        "verboseLabel": "Total Other operating income and expenses"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisions": {
     "auth_ref": [
      "r32",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions",
        "periodEndLabel": "Other provisions at end of period",
        "periodStartLabel": "Other provisions at beginning of period"
       }
      }
     },
     "localname": "OtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]",
        "terseLabel": "Other provisions [member]"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserve"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r8",
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Reserve"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Other temporary differences"
       }
      }
     },
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Par value per share (euro per share)"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Payables on social security and taxes other than income tax",
        "terseLabel": "Payroll tax and other payroll liabilities"
       }
      }
     },
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedTerseLabel": "Transaction costs",
        "terseLabel": "Initial offering costs"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payment of lease liabilities"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "auth_ref": [
      "r76",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense in profit or loss, defined benefit plans",
        "terseLabel": "Expense for the period"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofCommitmentsforRetirementBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Increase in loans and conditional advances",
        "verboseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Capital increases"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issuing shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r178",
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]",
        "terseLabel": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r178",
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]",
        "terseLabel": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r40",
      "r137",
      "r156",
      "r158",
      "r159",
      "r245",
      "r247",
      "r256",
      "r268"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the period",
        "totalLabel": "Net loss for the period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCOMPREHENSIVELOSS",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Net loss for the period (in thousands of euros)"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r201",
      "r245",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r47",
      "r100"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r16",
      "r72"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r73",
      "r105",
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "terseLabel": "Provision used",
        "verboseLabel": "Utilization of provisions"
       }
      }
     },
     "localname": "ProvisionUsedOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails",
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProvisionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions [abstract]",
        "terseLabel": "Provisions [abstract]"
       }
      }
     },
     "localname": "ProvisionsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of other long-term assets, classified as investing activities",
        "negatedTerseLabel": "Addition in non-current financial assets"
       }
      }
     },
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Acquisitions of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r194",
      "r224",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r194",
      "r224",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RecognisedLiabilitiesDefinedBenefitPlan": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit in a defined benefit plan. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability",
        "terseLabel": "Net defined benefit liability"
       }
      }
     },
     "localname": "RecognisedLiabilitiesDefinedBenefitPlan",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedTerseLabel": "Loans repayments",
        "terseLabel": "Loans repayments"
       }
      }
     },
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedTerseLabel": "Research and development expenses",
        "negatedTotalLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r43",
      "r159",
      "r165",
      "r201",
      "r243",
      "r246",
      "r250",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue",
        "totalLabel": "Total revenues and other income"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]",
        "terseLabel": "Revenues and other income"
       }
      }
     },
     "localname": "RevenueAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 1.0,
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "terseLabel": "Subsidies"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedTerseLabel": "Selling, general and administrative expenses",
        "negatedTotalLabel": "Total SG&amp;A expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails",
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r3",
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense [member]",
        "terseLabel": "Selling, general and administrative expense",
        "verboseLabel": "SG&amp;A"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "U.S. Initial public offering costs offset",
        "terseLabel": "Share issue related cost"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Premiums related to share capital"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Premiums related to share capital"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Short-term employee benefits expense"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SocialSecurityContributions": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Social security contributions",
        "negatedTerseLabel": "Payroll taxes"
       }
      }
     },
     "localname": "SocialSecurityContributions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of IFRS compliance [text block]",
        "terseLabel": "General principles, Statement of Compliance and Basis of Presentation"
       }
      }
     },
     "localname": "StatementOfIFRSCompliance",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenues that are exempt from taxation. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of revenues exempt from taxation",
        "negatedTerseLabel": "Other non-taxable items"
       }
      }
     },
     "localname": "TaxEffectOfRevenuesExemptFromTaxation2011",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of tax losses",
        "terseLabel": "Unrecognized tax losses"
       }
      }
     },
     "localname": "TaxEffectOfTaxLosses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Theoretical tax (benefit) expense"
       }
      }
     },
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      }
     },
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r194",
      "r224",
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade payables and other payables",
        "totalLabel": "Total trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r30",
      "r34"
     ],
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Accrued expenses - clinical trials"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofTradeandOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r10",
      "r208",
      "r215",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r33",
      "r99"
     ],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 6.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedTerseLabel": "Treasury shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalTreasurySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r179",
      "r264"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]",
        "terseLabel": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r179",
      "r264"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [member]",
        "terseLabel": "Types of contracts [member]"
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]",
        "terseLabel": "Types of interest rates [axis]"
       }
      }
     },
     "localname": "TypesOfInterestRatesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r202",
      "r206",
      "r207",
      "r258",
      "r259",
      "r260",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r202",
      "r206",
      "r207",
      "r258",
      "r259",
      "r260",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UndrawnBorrowingFacilities": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Undrawn borrowing facilities",
        "terseLabel": "Undrawn borrowing facilities"
       }
      }
     },
     "localname": "UndrawnBorrowingFacilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused provision reversed, other provisions",
        "terseLabel": "Reversal of provision for disputes"
       }
      }
     },
     "localname": "UnusedProvisionReversedOtherProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses for which no deferred tax asset recognised",
        "terseLabel": "Unused tax losses"
       }
      }
     },
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      },
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Unused tax losses"
       }
      }
     },
     "localname": "UnusedTaxLossesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, property, plant and equipment",
        "terseLabel": "Depreciation periods of property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]",
        "terseLabel": "Transport equipment"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "negatedTerseLabel": "Wages and salaries"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofPayrollCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average duration of defined benefit obligation",
        "terseLabel": "Duration"
       }
      }
     },
     "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement",
        "verboseLabel": "Grant price (in euro per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Exercise price (euro per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Share price (in euros)"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareScheduleofBasicandDilutedLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbx_A2018TaxYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Tax Year",
        "label": "2018 Tax Year [Member]",
        "terseLabel": "2018 Tax Year"
       }
      }
     },
     "localname": "A2018TaxYearMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_A2019TaxYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Tax Year",
        "label": "2019 Tax Year [Member]",
        "terseLabel": "2019 Tax Year"
       }
      }
     },
     "localname": "A2019TaxYearMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_A2020TaxYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Tax Year",
        "label": "2020 Tax Year [Member]",
        "terseLabel": "2020 Tax Year"
       }
      }
     },
     "localname": "A2020TaxYearMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_A2021TaxYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Tax Year",
        "label": "2021 Tax Year [Member]",
        "terseLabel": "2021 Tax Year"
       }
      }
     },
     "localname": "A2021TaxYearMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA20181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2018-1",
        "label": "AGA 2018-1 [Member]",
        "terseLabel": "AGA 2018-1"
       }
      }
     },
     "localname": "AGA20181Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA20182Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2018-2",
        "label": "AGA 2018-2 [Member]",
        "terseLabel": "AGA 2018-2"
       }
      }
     },
     "localname": "AGA20182Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA20191Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2019-1",
        "label": "AGA 2019-1 [Member]",
        "terseLabel": "AGA 2019-1"
       }
      }
     },
     "localname": "AGA20191Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA2020AndAGA2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2020 and AGA 2021",
        "label": "AGA 2020 and AGA 2021 [Member]",
        "terseLabel": "AGA 2020 and AGA 2021"
       }
      }
     },
     "localname": "AGA2020AndAGA2021Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2020",
        "label": "AGA 2020 [Member]",
        "terseLabel": "AGA 2020"
       }
      }
     },
     "localname": "AGA2020Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGA2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA 2021",
        "label": "AGA 2021 [Member]",
        "terseLabel": "AGA 2021"
       }
      }
     },
     "localname": "AGA2021Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGA",
        "label": "AGA [Member]",
        "terseLabel": "AGA"
       }
      }
     },
     "localname": "AGAMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumption Of Discount Rates If Rates Decrease By 25%",
        "label": "Actuarial Assumption Of Discount Rates If Rates Decrease By 25%",
        "terseLabel": "Actuarial assumption of discount rates if rates decrease by 25%"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesIfRatesDecreaseBy25",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumption Of Discount Rates If Rates Increase By 25%",
        "label": "Actuarial Assumption Of Discount Rates If Rates Increase By 25%",
        "terseLabel": "Actuarial assumption of discount rates if rates increase by 25%"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesIfRatesIncreaseBy25",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumption Of Expected Average Rates Of Staff Turnover",
        "label": "Actuarial Assumption Of Expected Average Rates Of Staff Turnover",
        "terseLabel": "Staff turnover"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedAverageRatesOfStaffTurnover",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ActuarialAssumptionOfSocialSecurityContributionRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actuarial Assumption Of Social Security Contribution Rates",
        "label": "Actuarial Assumption Of Social Security Contribution Rates",
        "terseLabel": "Social security contribution rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfSocialSecurityContributionRates",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_AdjustmentsForDecreaseIncreaseInOtherReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Decrease (Increase) In Other Receivables",
        "label": "Adjustments For Decrease (Increase) In Other Receivables",
        "terseLabel": "Increase in other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherReceivables",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax",
        "label": "Adjustments For Decrease (Increase) In Receivables From Taxes Other Than Income Tax",
        "terseLabel": "Decrease in Research tax credit receivable"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AdjustmentsForUSInitialPublicOffering2018CostsOffset": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For U.S. Initial Public Offering 2018 Costs Offset",
        "label": "Adjustments For U.S. Initial Public Offering 2018 Costs Offset",
        "negatedTerseLabel": "U.S. Initial public offering 2018 costs reversal"
       }
      }
     },
     "localname": "AdjustmentsForUSInitialPublicOffering2018CostsOffset",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AdvancesAuthorizedAmountToBeAdvanced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances, Authorized Amount To Be Advanced",
        "label": "Advances, Authorized Amount To Be Advanced",
        "terseLabel": "Authorized amount to be advanced"
       }
      }
     },
     "localname": "AdvancesAuthorizedAmountToBeAdvanced",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AdvancesOutstandingAmountToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances, Outstanding Amount To Be Received",
        "label": "Advances, Outstanding Amount To Be Received",
        "terseLabel": "Advances, outstanding amount"
       }
      }
     },
     "localname": "AdvancesOutstandingAmountToBeReceived",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AdvancesReceivedDefermentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances Received, Deferment Period",
        "label": "Advances Received, Deferment Period",
        "terseLabel": "Advances, deferment period"
       }
      }
     },
     "localname": "AdvancesReceivedDefermentPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_AdvancesReceivedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances Received, Interest Rate",
        "label": "Advances Received, Interest Rate",
        "terseLabel": "Advances, interest rate"
       }
      }
     },
     "localname": "AdvancesReceivedInterestRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_AllocationOfPriorPeriodLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation Of Prior Period Loss",
        "label": "Allocation Of Prior Period Loss",
        "terseLabel": "Allocation of prior period loss"
       }
      }
     },
     "localname": "AllocationOfPriorPeriodLoss",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AmericanDepositorySharesNASDAQStockMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Shares, NASDAQ Stock Market",
        "label": "American Depository Shares, NASDAQ Stock Market [Member]",
        "terseLabel": "American depositary shares, each representing one ordinary share, nominal value \u20ac0.03 per share"
       }
      }
     },
     "localname": "AmericanDepositorySharesNASDAQStockMarketMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Coverpage"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AnneJulietteHermantLaurentLevyAndBartVanRhijnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anne-Juliette Hermant, Laurent Levy And Bart Van Rhijn",
        "label": "Anne-Juliette Hermant, Laurent Levy And Bart Van Rhijn [Member]",
        "terseLabel": "Anne-Juliette Hermant, Laurent Levy and Bart Van Rhijn"
       }
      }
     },
     "localname": "AnneJulietteHermantLaurentLevyAndBartVanRhijnMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AnneJulietteHermantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anne-Juliette Hermant",
        "label": "Anne-Juliette Hermant [Member]",
        "terseLabel": "Anne-Juliette Hermant"
       }
      }
     },
     "localname": "AnneJulietteHermantMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_AnnualLeaseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Lease Expense",
        "label": "Annual Lease Expense",
        "terseLabel": "Annual lease expense"
       }
      }
     },
     "localname": "AnnualLeaseExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AnnualShortTermLeaseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Short Term Lease Expense",
        "label": "Annual Short Term Lease Expense",
        "terseLabel": "Annual short term lease expense"
       }
      }
     },
     "localname": "AnnualShortTermLeaseExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anti-Dilutive Securities Excluded From Calculation Of Earnings Per Share",
        "label": "Anti-Dilutive Securities Excluded From Calculation Of Earnings Per Share",
        "terseLabel": "Potential additional ordinary shares that are considered antidilutive (in shares)"
       }
      }
     },
     "localname": "AntiDilutiveSecuritiesExcludedFromCalculationOfEarningsPerShare",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/LosspershareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbx_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_BPIFranceAdvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BPI France Advance",
        "label": "BPI France Advance [Member]",
        "terseLabel": "Bpifrance advance"
       }
      }
     },
     "localname": "BPIFranceAdvanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BPI France",
        "label": "BPI France [Member]",
        "terseLabel": "Bpifrance"
       }
      }
     },
     "localname": "BPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA0412Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 04-12",
        "label": "BSA 04-12 [Member]",
        "terseLabel": "BSA 04-12"
       }
      }
     },
     "localname": "BSA0412Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2013",
        "label": "BSA 2013 [Member]",
        "terseLabel": "BSA 2013"
       }
      }
     },
     "localname": "BSA2013Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2014",
        "label": "BSA 2014 [Member]",
        "terseLabel": "BSA 2014"
       }
      }
     },
     "localname": "BSA2014Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20151Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2015-1",
        "label": "BSA 2015-1 [Member]",
        "terseLabel": "BSA 2015-1"
       }
      }
     },
     "localname": "BSA20151Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20152AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2015-2 (a)",
        "label": "BSA 2015-2 (a) [Member]",
        "terseLabel": "BSA 2015-2(a)"
       }
      }
     },
     "localname": "BSA20152AMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20152BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2015-2 (b)",
        "label": "BSA 2015-2 (b) [Member]",
        "terseLabel": "BSA 2015-2(b)"
       }
      }
     },
     "localname": "BSA20152BMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20162Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2016-2",
        "label": "BSA 2016-2 [Member]",
        "terseLabel": "BSA 2016-2"
       }
      }
     },
     "localname": "BSA20162Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2016",
        "label": "BSA 2016 [Member]",
        "terseLabel": "BSA 2016"
       }
      }
     },
     "localname": "BSA2016Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2016OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2016 Ordinary",
        "label": "BSA 2016 Ordinary [Member]",
        "terseLabel": "BSA 2016 ordinary"
       }
      }
     },
     "localname": "BSA2016OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2016PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2016 Performance",
        "label": "BSA 2016 Performance [Member]",
        "terseLabel": "BSA 2016 performance"
       }
      }
     },
     "localname": "BSA2016PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2017",
        "label": "BSA 2017 [Member]",
        "terseLabel": "BSA 2017"
       }
      }
     },
     "localname": "BSA2017Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20181Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2018-1",
        "label": "BSA 2018-1 [Member]",
        "terseLabel": "BSA 2018-1"
       }
      }
     },
     "localname": "BSA20181Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20182Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2018-2",
        "label": "BSA 2018-2 [Member]",
        "terseLabel": "BSA 2018-2"
       }
      }
     },
     "localname": "BSA20182Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA20191Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2019-1",
        "label": "BSA 2019-1 [Member]",
        "terseLabel": "BSA 2019-1"
       }
      }
     },
     "localname": "BSA20191Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2020",
        "label": "BSA 2020 [Member]",
        "terseLabel": "BSA 2020"
       }
      }
     },
     "localname": "BSA2020Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2021AInReplacementOfBSA2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2021 (a) In Replacement Of BSA 2016",
        "label": "BSA 2021 (a) In Replacement Of BSA 2016 [Member]",
        "terseLabel": "BSA 2021 (a) In Replacement Of BSA 2016"
       }
      }
     },
     "localname": "BSA2021AInReplacementOfBSA2016Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2021AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2021 (a)",
        "label": "BSA 2021 (a) [Member]",
        "terseLabel": "BSA 2021 (a)"
       }
      }
     },
     "localname": "BSA2021AMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSA2021BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA 2021 (b)",
        "label": "BSA 2021 (b) [Member]",
        "terseLabel": "BSA 2021 (b)"
       }
      }
     },
     "localname": "BSA2021BMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSA",
        "label": "BSA [Member]",
        "terseLabel": "BSA"
       }
      }
     },
     "localname": "BSAMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE042013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 04-2013",
        "label": "BSPCE 04-2013 [Member]",
        "terseLabel": "BSPCE 09-2014"
       }
      }
     },
     "localname": "BSPCE042013Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE082013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 08-2013",
        "label": "BSPCE 08-2013 [Member]",
        "terseLabel": "BSPCE 08-2013"
       }
      }
     },
     "localname": "BSPCE082013Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE092014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 09-2014",
        "label": "BSPCE 09-2014 [Member]",
        "terseLabel": "BSPCE 09-2014"
       }
      }
     },
     "localname": "BSPCE092014Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE20121Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2012-1",
        "label": "BSPCE 2012-1 [Member]",
        "terseLabel": "BSPCE 2012-2"
       }
      }
     },
     "localname": "BSPCE20121Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE20122Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2012-2",
        "label": "BSPCE 2012-2 [Member]",
        "terseLabel": "BSPCE 2012-2"
       }
      }
     },
     "localname": "BSPCE20122Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE20151Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2015-1",
        "label": "BSPCE 2015-1 [Member]",
        "terseLabel": "BSPCE 2015-1"
       }
      }
     },
     "localname": "BSPCE20151Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE20152Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2015-2",
        "label": "BSPCE 2015-2 [Member]",
        "terseLabel": "BSPCE 2015-2"
       }
      }
     },
     "localname": "BSPCE20152Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE20153Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2015-3",
        "label": "BSPCE 2015-3 [Member]",
        "terseLabel": "BSPCE 2015-3"
       }
      }
     },
     "localname": "BSPCE20153Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2016",
        "label": "BSPCE 2016 [Member]",
        "terseLabel": "BSPCE 2016"
       }
      }
     },
     "localname": "BSPCE2016Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2016OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2016 Ordinary",
        "label": "BSPCE 2016 Ordinary [Member]",
        "terseLabel": "BSPCE 2016 Ordinary"
       }
      }
     },
     "localname": "BSPCE2016OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2016PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2016 Performance",
        "label": "BSPCE 2016 Performance [Member]",
        "terseLabel": "BSPCE 2016 Performance"
       }
      }
     },
     "localname": "BSPCE2016PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2017",
        "label": "BSPCE 2017 [Member]",
        "terseLabel": "BSPCE 2017"
       }
      }
     },
     "localname": "BSPCE2017Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2017OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2017 Ordinary",
        "label": "BSPCE 2017 Ordinary [Member]",
        "terseLabel": "BSPCE 2017 Ordinary"
       }
      }
     },
     "localname": "BSPCE2017OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2017PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2017 Performance",
        "label": "BSPCE 2017 Performance [Member]",
        "terseLabel": "BSPCE 2017 Performance"
       }
      }
     },
     "localname": "BSPCE2017PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCE2017ProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE 2017 Project",
        "label": "BSPCE 2017 Project [Member]",
        "terseLabel": "BSPCE 2017 Project"
       }
      }
     },
     "localname": "BSPCE2017ProjectMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BSPCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BSPCE",
        "label": "BSPCE [Member]",
        "terseLabel": "BSPCE"
       }
      }
     },
     "localname": "BSPCEMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BanquePubliqueDInvestissementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Banque Publique d\u2019Investissement",
        "label": "Banque Publique d\u2019Investissement [Member]",
        "terseLabel": "Banque Publique d\u2019Investissement",
        "verboseLabel": "BPI loan"
       }
      }
     },
     "localname": "BanquePubliqueDInvestissementMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BartVanRhijnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bart Van Rhijn",
        "label": "Bart Van Rhijn [Member]",
        "terseLabel": "Bart Van Rhijn"
       }
      }
     },
     "localname": "BartVanRhijnMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_BorrowingDefermentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Deferment Period",
        "label": "Borrowing, Deferment Period",
        "terseLabel": "Borrowing, deferment period"
       }
      }
     },
     "localname": "BorrowingDefermentPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_BorrowingDefermentPeriodToRequestFunds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Deferment Period To Request Funds",
        "label": "Borrowing, Deferment Period To Request Funds",
        "terseLabel": "Borrowing, deferment period to request funds"
       }
      }
     },
     "localname": "BorrowingDefermentPeriodToRequestFunds",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_BorrowingGuaranteeFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Guarantee Fee",
        "label": "Borrowing, Guarantee Fee",
        "terseLabel": "Borrowing, guarantee fee"
       }
      }
     },
     "localname": "BorrowingGuaranteeFee",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_BorrowingMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Maturity Term",
        "label": "Borrowing, Maturity Term",
        "terseLabel": "Borrowing, maturity"
       }
      }
     },
     "localname": "BorrowingMaturityTerm",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_BorrowingMaturityTermInitialPeriodBearingNoInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Maturity Term, Initial Period Bearing No Interest",
        "label": "Borrowing, Maturity Term, Initial Period Bearing No Interest",
        "terseLabel": "Borrowing, initial period bearing no interest"
       }
      }
     },
     "localname": "BorrowingMaturityTermInitialPeriodBearingNoInterest",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_BorrowingMaturityTermSubsequentPeriodBearingInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Maturity Term, Subsequent Period Bearing Interest",
        "label": "Borrowing, Maturity Term, Subsequent Period Bearing Interest",
        "terseLabel": "Borrowing, subsequent period bearing interest"
       }
      }
     },
     "localname": "BorrowingMaturityTermSubsequentPeriodBearingInterest",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_BorrowingNumberOfPGE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Number Of PGE",
        "label": "Borrowing, Number Of PGE",
        "terseLabel": "Borrowing, number of PGE"
       }
      }
     },
     "localname": "BorrowingNumberOfPGE",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_BorrowingNumberOfQuarterlyInstalments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Number Of Quarterly Instalments",
        "label": "Borrowing, Number Of Quarterly Instalments",
        "terseLabel": "Number of quarterly instalments"
       }
      }
     },
     "localname": "BorrowingNumberOfQuarterlyInstalments",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_BorrowingPercentageOfStateGuaranteedLoan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Percentage Of State-Guaranteed Loan",
        "label": "Borrowing, Percentage Of State-Guaranteed Loan",
        "terseLabel": "Percentage of State-Guaranteed loan"
       }
      }
     },
     "localname": "BorrowingPercentageOfStateGuaranteedLoan",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nbx_BorrowingTotalInterestPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Total Interest Payable",
        "label": "Borrowing, Total Interest Payable",
        "terseLabel": "Total interest payable"
       }
      }
     },
     "localname": "BorrowingTotalInterestPayable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_CollaborationAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Axis]",
        "terseLabel": "Collaboration Agreement [Axis]"
       }
      }
     },
     "localname": "CollaborationAgreementAxis",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Development And Commercial Milestones Payments Received",
        "label": "Collaboration Agreement, Development And Commercial Milestones Payments Received",
        "terseLabel": "Development milestones payments received"
       }
      }
     },
     "localname": "CollaborationAgreementDevelopmentAndCommercialMilestonesPaymentsReceived",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CollaborationAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Domain]",
        "terseLabel": "Collaboration Agreement [Domain]"
       }
      }
     },
     "localname": "CollaborationAgreementDomain",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_CollaborationAgreementMilestonesAchievementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Milestones Achievement, Period",
        "label": "Collaboration Agreement, Milestones Achievement, Period",
        "terseLabel": "Milestones achievement, period"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonesAchievementPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Potential Milestones Payments To Be Received",
        "label": "Collaboration Agreement, Potential Milestones Payments To Be Received",
        "terseLabel": "Potential development and commercial milestones payments"
       }
      }
     },
     "localname": "CollaborationAgreementPotentialMilestonesPaymentsToBeReceived",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CollaborationAgreementTotalPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Total Payments Received",
        "label": "Collaboration Agreement, Total Payments Received",
        "terseLabel": "Total payments received under agreement"
       }
      }
     },
     "localname": "CollaborationAgreementTotalPaymentsReceived",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CollaborationAgreementUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment Received",
        "label": "Collaboration Agreement, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentReceived",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CompanyDeferredTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company Deferred Tax Rate",
        "label": "Company Deferred Tax Rate",
        "terseLabel": "Deferred tax rate"
       }
      }
     },
     "localname": "CompanyDeferredTaxRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ConcentrationRiskPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Percentage",
        "label": "Concentration Risk Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ConditionalAdvanceBPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Advance, BPI France",
        "label": "Conditional Advance, BPI France [Member]",
        "terseLabel": "Curadigm Bpifrance advance"
       }
      }
     },
     "localname": "ConditionalAdvanceBPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Advances And Loans From Government And Public Authorities",
        "label": "Conditional Advances And Loans From Government And Public Authorities [Member]",
        "terseLabel": "Conditional Advances and Loans from Government and Public Authorities"
       }
      }
     },
     "localname": "ConditionalAdvancesAndLoansFromGovernmentAndPublicAuthoritiesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ConditionalAdvancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conditional Advances",
        "label": "Conditional Advances [Member]",
        "terseLabel": "Repayable BPI loan advances"
       }
      }
     },
     "localname": "ConditionalAdvancesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ConsolidatedForecastedSalesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Forecasted Sales, Period",
        "label": "Consolidated Forecasted Sales, Period",
        "terseLabel": "Consolidated forecasted sales, period"
       }
      }
     },
     "localname": "ConsolidatedForecastedSalesPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_ContractTerminationIndemnities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Termination Indemnities",
        "label": "Contract Termination Indemnities",
        "negatedTerseLabel": "Contract termination indemnity (PharmaEngine)",
        "terseLabel": "Contract termination indemnities"
       }
      }
     },
     "localname": "ContractTerminationIndemnities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofOtherOperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Commitments, Milestone Payment, Annual Increase",
        "label": "Contractual Commitments, Milestone Payment, Annual Increase",
        "terseLabel": "Milestone payment increase"
       }
      }
     },
     "localname": "ContractualCommitmentsMilestonePaymentAnnualIncrease",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports",
        "label": "Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports",
        "terseLabel": "Milestone payment upon receipt of clinical study reports"
       }
      }
     },
     "localname": "ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Commitments, Milestone Payment Upon Second Regulatory Approval",
        "label": "Contractual Commitments, Milestone Payment Upon Second Regulatory Approval",
        "terseLabel": "Milestone payment upon second regulatory approval"
       }
      }
     },
     "localname": "ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ContractualCommitmentsPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Commitments, Payment",
        "label": "Contractual Commitments, Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "ContractualCommitmentsPayment",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CuradigmSASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Curadigm SAS",
        "label": "Curadigm SAS [Member]",
        "terseLabel": "Curadigm SAS"
       }
      }
     },
     "localname": "CuradigmSASMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_CurrentFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Financial Liabilities",
        "label": "Current Financial Liabilities [Member]",
        "terseLabel": "Current financial liabilities"
       }
      }
     },
     "localname": "CurrentFinancialLiabilitiesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_CurrentOtherProvisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Other Provisions",
        "label": "Current Other Provisions [Member]",
        "terseLabel": "Current provisions"
       }
      }
     },
     "localname": "CurrentOtherProvisionsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Prepaid Expenses, Insurance Related To Directors And Officers",
        "label": "Current Prepaid Expenses, Insurance Related To Directors And Officers",
        "terseLabel": "Prepaid expenses related to insurance for Directors and Officers"
       }
      }
     },
     "localname": "CurrentPrepaidExpensesInsuranceRelatedToDirectorsAndOfficers",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Receivables From Taxes Other Than Income Tax, Increase",
        "label": "Current Receivables From Taxes Other Than Income Tax, Increase",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTaxIncrease",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Receivables From Taxes Other Than Income Tax, Refund",
        "label": "Current Receivables From Taxes Other Than Income Tax, Refund",
        "negatedTerseLabel": "Refund of research tax credit"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTaxRefund",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease Through Early Termination, Liabilities Arising From Financing Activities",
        "label": "Decrease Through Early Termination, Liabilities Arising From Financing Activities",
        "negatedTerseLabel": "Early termination of lease contracts"
       }
      }
     },
     "localname": "DecreaseThroughEarlyTerminationLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease Through Financing Cash Flows, Liabilities Arising From Financing Activities",
        "label": "Decrease Through Financing Cash Flows, Liabilities Arising From Financing Activities",
        "negatedTerseLabel": "Repayment"
       }
      }
     },
     "localname": "DecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption",
        "label": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption",
        "terseLabel": "Net defined benefit liability if actuarial assumption of discount rates decrease by 25%"
       }
      }
     },
     "localname": "DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption",
        "label": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption",
        "terseLabel": "Net defined benefit liability if actuarial assumption of discount rates increase by 25%"
       }
      }
     },
     "localname": "DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofSensitivityAnalysisforActuarialAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DefinedBenefitObligationPayablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Obligation, Payable, Period",
        "label": "Defined Benefit Obligation, Payable, Period",
        "terseLabel": "Payable, period"
       }
      }
     },
     "localname": "DefinedBenefitObligationPayablePeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_DepreciationAmortizationAndProvisionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Amortization And Provision Expenses",
        "label": "Depreciation, Amortization And Provision Expenses",
        "negatedTerseLabel": "Total depreciation, amortization and provision expenses"
       }
      }
     },
     "localname": "DepreciationAmortizationAndProvisionExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Basis Of Consolidation",
        "label": "Description Of Accounting Policy For Basis Of Consolidation [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Events After Reporting Period",
        "label": "Description Of Accounting Policy For Events After Reporting Period [Policy Text Block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEventsAfterReportingPeriodPolicyTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions",
        "label": "Description Of Accounting Policy For Use Of Judgements, Estimates, And Assumptions [Policy Text Block]",
        "terseLabel": "Use of judgement, estimates and assumptions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForUseOfJudgementsEstimatesAndAssumptionsPolicyTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information About Deferred Income And Contract Liabilities",
        "label": "Detailed Information About Deferred Income And Contract Liabilities [Table Text Block]",
        "terseLabel": "Disclosure of deferred income and contract liabilities"
       }
      }
     },
     "localname": "DetailedInformationAboutDeferredIncomeAndContractLiabilitiesTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DetailedInformationAboutFinanceIncomeCostTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information About Finance Income (Cost)",
        "label": "Detailed Information About Finance Income (Cost) [Table Text Block]",
        "terseLabel": "Summary of net financial income (loss)"
       }
      }
     },
     "localname": "DetailedInformationAboutFinanceIncomeCostTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NetfinancialincomelossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information About Other Current Liabilities Explanatory",
        "label": "Detailed Information About Other Current Liabilities Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of other current liabilities"
       }
      }
     },
     "localname": "DetailedInformationAboutOtherCurrentLiabilitiesExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information About The Effect Of Changes In Foreign Exchange Rates",
        "label": "Detailed Information About The Effect Of Changes In Foreign Exchange Rates [Table Text Block]",
        "terseLabel": "Disclosure of effect of changes in exchange rates"
       }
      }
     },
     "localname": "DetailedInformationAboutTheEffectOfChangesInForeignExchangeRatesTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosur Of Disaggregation Of Revenues And Other Income",
        "label": "Disclosur Of Disaggregation Of Revenues And Other Income [Table Text Block]",
        "terseLabel": "Schedule of revenues and other income"
       }
      }
     },
     "localname": "DisclosurOfDisaggregationOfRevenuesAndOtherIncomeTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Cash And Cash Equivalents Explanatory",
        "label": "Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]",
        "terseLabel": "Summary of cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfCashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Cash and Cash Equivalents",
        "label": "Disclosure of Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Disclosure of Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Cash and Cash Equivalents",
        "label": "Disclosure of Cash and Cash Equivalents [Table]",
        "terseLabel": "Disclosure of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Changes In Research Tax Credit Receivables",
        "label": "Disclosure Of Changes In Research Tax Credit Receivables [Table Text Block]",
        "terseLabel": "Disclosure of changes in research tax credit receivables"
       }
      }
     },
     "localname": "DisclosureOfChangesInResearchTaxCreditReceivablesTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Commitments [Abstract]",
        "label": "Disclosure Of Commitments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses",
        "label": "Disclosure Of Detailed Information About Depreciation, Amortization And Provision Expenses [Table Text Block]",
        "terseLabel": "Summary of depreciation, amortization and provision expenses"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutDepreciationAmortizationAndProvisionExpensesTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Employee Benefits Explanatory",
        "label": "Disclosure Of Detailed Information About Employee Benefits Explanatory [Table Text Block]",
        "terseLabel": "Summary of payroll costs"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Financial Liabilities",
        "label": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Financial Liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Financial Liabilities [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Financial Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialLiabilitiesTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Non-current Financial Assets",
        "label": "Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Non-current Financial Assets [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Detailed Information About Non-current Financial Assets",
        "label": "Disclosure of Detailed Information About Non-current Financial Assets [Table]",
        "terseLabel": "Disclosure of Detailed Information About Non-current Financial Assets [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Non-Current Financial Assets",
        "label": "Disclosure Of Detailed Information About Non-Current Financial Assets [Table Text Block]",
        "terseLabel": "Disclosure of changes in non-current financial assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutNonCurrentFinancialAssetsTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Other Current Assets Explanatory",
        "label": "Disclosure Of Detailed Information About Other Current Assets Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of break down of other current assets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherCurrentAssetsExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Research And Development Expense Explanatory",
        "label": "Disclosure Of Detailed Information About Research And Development Expense Explanatory [Table Text Block]",
        "terseLabel": "Summary of research and development expense"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory",
        "label": "Disclosure Of Detailed Information About Selling, General And Administrative Expenses Explanatory [Table Text Block]",
        "terseLabel": "Summary of selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutSellingGeneralAndAdministrativeExpensesExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Share-based Payments",
        "label": "Disclosure Of Detailed Information About Share-based Payments [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutShareBasedPaymentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Share-based Payments",
        "label": "Disclosure Of Detailed Information About Share-based Payments [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Share-based Payments [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentsTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory",
        "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Trade Receivables Explanatory",
        "label": "Disclosure Of Detailed Information About Trade Receivables Explanatory [Table Text Block]",
        "terseLabel": "Disclosure of break down of trade receivables"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutTradeReceivablesExplanatoryTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfFinancialLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Financial Liabilities",
        "label": "Disclosure Of Financial Liabilities [Text Block]",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Financialliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Information Related To The Company [Abstract]",
        "label": "Disclosure Of Information Related To The Company [Abstract]",
        "terseLabel": "Disclosure Of Information Related To The Company [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfInformationRelatedToTheCompanyAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Information Related To The Company",
        "label": "Disclosure Of Information Related To The Company [Line Items]",
        "terseLabel": "Disclosure Of Information Related To The Company [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfInformationRelatedToTheCompanyLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfInformationRelatedToTheCompanyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Information Related To The Company [Table]",
        "label": "Disclosure Of Information Related To The Company [Table]",
        "terseLabel": "Disclosure Of Information Related To The Company [Table]"
       }
      }
     },
     "localname": "DisclosureOfInformationRelatedToTheCompanyTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfNonCurrentFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Non-current Financial Assets",
        "label": "Disclosure Of Non-current Financial Assets [Text Block]",
        "terseLabel": "Non-current financial assets"
       }
      }
     },
     "localname": "DisclosureOfNonCurrentFinancialAssetsTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Noncurrentfinancialassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Line Items]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding [Table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments",
        "label": "Disclosure Of Number And Weighted Average Remaining Contractual Life Of outstanding other equity Instruments [Table Text Block]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of founders' warrants, warrants, and free shares oustanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstrumentsTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfOperatingExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Operating Expenses",
        "label": "Disclosure Of Operating Expenses [Line Items]",
        "terseLabel": "Disclosure Of Operating Expenses [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfOperatingExpensesLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfOperatingExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Operating Expenses [Table]",
        "label": "Disclosure Of Operating Expenses [Table]",
        "terseLabel": "Disclosure Of Operating Expenses [Table]"
       }
      }
     },
     "localname": "DisclosureOfOperatingExpensesTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfOtherOperatingIncomeExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Other Operating Income (Expenses)",
        "label": "Disclosure Of Other Operating Income (Expenses) [Table Text Block]",
        "terseLabel": "Summary of other operating income (expense)"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExpensesTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure Of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "terseLabel": "Share Capital [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfSignificantTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Significant Transactions",
        "label": "Disclosure Of Significant Transactions [Text Block]",
        "terseLabel": "Significant transactions"
       }
      }
     },
     "localname": "DisclosureOfSignificantTransactionsTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Significanttransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Trade Payables and Other Current Liabilities",
        "label": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]",
        "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Trade Payables and Other Current Liabilities",
        "label": "Disclosure of Trade Payables and Other Current Liabilities [Table]",
        "terseLabel": "Disclosure of Trade Payables and Other Current Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade Payables And Other Current Liabilities",
        "label": "Disclosure Of Trade Payables And Other Current Liabilities [Text Block]",
        "terseLabel": "Trade payables and other current liabilities"
       }
      }
     },
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Tradepayablesandothercurrentliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Trade Receivables and Other Current Assets",
        "label": "Disclosure of Trade Receivables and Other Current Assets [Line Items]",
        "terseLabel": "Disclosure of Trade Receivables and Other Current Assets [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsLineItems",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Trade Receivables and Other Current Assets",
        "label": "Disclosure of Trade Receivables and Other Current Assets [Table]",
        "terseLabel": "Disclosure of Trade Receivables and Other Current Assets [Table]"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTable",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofBreakDownofTradeReceivablesDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Trade Receivables And Other Current Assets",
        "label": "Disclosure Of Trade Receivables And Other Current Assets [Text Block]",
        "terseLabel": "Trade receivables and other current assets"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/Tradereceivablesandothercurrentassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_EuropeanInvestmentBankLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Investment Bank Loan Agreement",
        "label": "European Investment Bank Loan Agreement [Member]",
        "terseLabel": "EIB fixed rate loan",
        "verboseLabel": "EIB Loan"
       }
      }
     },
     "localname": "EuropeanInvestmentBankLoanAgreementMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ExecutiveBoardAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Board And Employees",
        "label": "Executive Board And Employees [Member]",
        "terseLabel": "Executive Board and Employees"
       }
      }
     },
     "localname": "ExecutiveBoardAndEmployeesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ExercisePriceOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price, Other Equity Instruments Granted",
        "label": "Exercise Price, Other Equity Instruments Granted",
        "terseLabel": "Exercise price (in euro per share)"
       }
      }
     },
     "localname": "ExercisePriceOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nbx_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "label": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "terseLabel": "Yield"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ExpectedVolatilityOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Volatility, Other Equity Instruments Granted",
        "label": "Expected Volatility, Other Equity Instruments Granted",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_ExternalConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "External Consultant",
        "label": "External Consultant [Member]",
        "terseLabel": "External Consultant"
       }
      }
     },
     "localname": "ExternalConsultantMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_FormerEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Employees",
        "label": "Former Employees [Member]",
        "terseLabel": "Former employees"
       }
      }
     },
     "localname": "FormerEmployeesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_FormerExecutiveBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Executive Board Members",
        "label": "Former Executive Board Members [Member]",
        "terseLabel": "Former Executive Board members"
       }
      }
     },
     "localname": "FormerExecutiveBoardMembersMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_FromFirstYearOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From First Year Of Grant Date",
        "label": "From First Year Of Grant Date [Member]",
        "terseLabel": "From first year of grant date"
       }
      }
     },
     "localname": "FromFirstYearOfGrantDateMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_FromSecondYearOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From Second Year Of Grant Date",
        "label": "From Second Year Of Grant Date [Member]",
        "terseLabel": "From second year of grant date"
       }
      }
     },
     "localname": "FromSecondYearOfGrantDateMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_FromThirdYearOfGrantDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From Third Year Of Grant Date",
        "label": "From Third Year Of Grant Date [Member]",
        "terseLabel": "From third year of grant date"
       }
      }
     },
     "localname": "FromThirdYearOfGrantDateMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General Information, Statement of Compliance and Basis of Presentation",
        "label": "General Information, Statement of Compliance and Basis of Presentation [Abstract]",
        "terseLabel": "General Information, Statement of Compliance and Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "GeneralInformationStatementOfComplianceAndBasisOfPresentationAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_ICONPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ICON Plc",
        "label": "ICON Plc [Member]",
        "terseLabel": "ICON Plc"
       }
      }
     },
     "localname": "ICONPlcMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_IPOGreenShoeUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Green Shoe, US Dollar",
        "label": "IPO Green Shoe, US Dollar [Member]",
        "terseLabel": "IPO green shoe, US Dollar"
       }
      }
     },
     "localname": "IPOGreenShoeUSDollarMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_IPOInitialDealEuroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Initial Deal, Euro",
        "label": "IPO Initial Deal, Euro [Member]",
        "terseLabel": "IPO initial deal, Euro"
       }
      }
     },
     "localname": "IPOInitialDealEuroMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_IPOInitialDealUSDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Initial Deal, US Dollar",
        "label": "IPO Initial Deal, US Dollar [Member]",
        "terseLabel": "IPO initial deal, US Dollar"
       }
      }
     },
     "localname": "IPOInitialDealUSDollarMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_IncreaseDecreaseInEmployeeBenefitExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Employee Benefit Expense",
        "label": "Increase (Decrease) In Employee Benefit Expense",
        "negatedTerseLabel": "Decrease in employee benefit expense",
        "terseLabel": "Increase in employee benefit expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeBenefitExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseInNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Number Of Employees",
        "label": "Increase (Decrease) In Number Of Employees",
        "terseLabel": "Increase in number of employees",
        "verboseLabel": "Increase (decrease) in number of employees"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfEmployees",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesPayrollCostsAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nbx_IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Exercise Of Founders Warrants",
        "label": "Increase (Decrease) In Number Of Ordinary Shares Issued Through Exercise Of Founders Warrants",
        "terseLabel": "BSPCE exercise (in shares)"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedThroughExerciseOfFoundersWarrants",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbx_IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current",
        "label": "Increase (Decrease) In Payables On Social Security And Taxes Other Than Income Tax, Current",
        "negatedTerseLabel": "Decrease in payroll tax and other payroll liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPayablesOnSocialSecurityAndTaxesOtherThanIncomeTaxCurrent",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseInPurchasesFeesAndOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Purchases, Fees, And Other Expenses",
        "label": "Increase (Decrease) In Purchases, Fees, And Other Expenses",
        "terseLabel": "Increase in rent, fees, and other expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPurchasesFeesAndOtherExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses",
        "label": "Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses",
        "terseLabel": "Increase in purchases, sub-contracting and other expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPurchasesSubContractingAndOtherExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "label": "Increase (Decrease) Through Accumulated Fixed Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "terseLabel": "Accumulated fixed interest expense accrual"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAccumulatedFixedInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "label": "Increase (Decrease) Through Accumulated Variable Interest Expense Accrual, Liabilities Arising From Financing Activities",
        "terseLabel": "Accumulated variable interest expense accrual"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAccumulatedVariableInterestExpenseAccrualLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/NetfinancialincomelossAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities",
        "label": "Increase (Decrease) Through Impact Of Discounting And Accretion, Liabilities Arising From Financing Activities",
        "negatedTerseLabel": "Impact of accretion and discounting",
        "terseLabel": "Impact of discounting and accretion",
        "verboseLabel": "Impact of discounting of the new lease contracts"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughImpactOfDiscountingAndAccretionLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofReconciliationofChangesinLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity",
        "label": "Increase (Decrease) Through Subscription Of Warrants And Attribution Of Free Shares, Equity",
        "terseLabel": "Subscription of warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSubscriptionOfWarrantsAndAttributionOfFreeSharesEquity",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseDecreaseToAnnualRentExpenseIndexationImpact": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) To Annual Rent Expense, Indexation Impact",
        "label": "Increase (Decrease) To Annual Rent Expense, Indexation Impact",
        "terseLabel": "Addition to annual rent expense"
       }
      }
     },
     "localname": "IncreaseDecreaseToAnnualRentExpenseIndexationImpact",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Through Financing Cash Flows, Liabilities Arising From Financing Activities",
        "label": "Increase Through Financing Cash Flows, Liabilities Arising From Financing Activities",
        "terseLabel": "Principal received"
       }
      }
     },
     "localname": "IncreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_InitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering",
        "label": "Initial Public Offering [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_InterestFreeAdvanceToCuradigmBPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest-free Advance To Curadigm, BPI France",
        "label": "Interest-free Advance To Curadigm, BPI France [Member]",
        "terseLabel": "Curadigm interest-free Bpifrance advance"
       }
      }
     },
     "localname": "InterestFreeAdvanceToCuradigmBPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_InterestFreeBPIFranceLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest-Free BPI France Loan",
        "label": "Interest-Free BPI France Loan [Member]",
        "terseLabel": "Interest-free Bpifrance loan"
       }
      }
     },
     "localname": "InterestFreeBPIFranceLoanMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutConditionalAdvancesandLoansFromGovernmentandPublicAuthoritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_InterestFreeLoanBPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest-free Loan, BPI France",
        "label": "Interest-free Loan, BPI France [Member]",
        "terseLabel": "Interest-free Bpifrance loan"
       }
      }
     },
     "localname": "InterestFreeLoanBPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_IssueOfEquityPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity, Price Per Share",
        "label": "Issue Of Equity, Price Per Share",
        "terseLabel": "Issue of equity, price per share (in euro or dollar per share)"
       }
      }
     },
     "localname": "IssueOfEquityPricePerShare",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nbx_LeaseContractAlfortvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Alfortville",
        "label": "Lease Contract, Alfortville [Member]",
        "terseLabel": "Lease contract, Alfortville"
       }
      }
     },
     "localname": "LeaseContractAlfortvilleMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LeaseContractExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Extended Period",
        "label": "Lease Contract, Extended Period",
        "terseLabel": "Lease contract, extended period"
       }
      }
     },
     "localname": "LeaseContractExtendedPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_LeaseContractFaubourgSaintAntoineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Faubourg Saint-Antoine",
        "label": "Lease Contract, Faubourg Saint-Antoine [Member]",
        "terseLabel": "Lease contract, Faubourg Saint-Antoine"
       }
      }
     },
     "localname": "LeaseContractFaubourgSaintAntoineMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LeaseContractOberkampfStreetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Oberkampf Street",
        "label": "Lease Contract, Oberkampf Street [Member]",
        "terseLabel": "Lease contract, Oberkampf street"
       }
      }
     },
     "localname": "LeaseContractOberkampfStreetMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LeaseContractParkingVillejuifMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Parking Villejuif",
        "label": "Lease Contract, Parking Villejuif [Member]",
        "terseLabel": "Lease contract, parking Villejuif"
       }
      }
     },
     "localname": "LeaseContractParkingVillejuifMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LeaseContractVillejuifMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Villejuif",
        "label": "Lease Contract, Villejuif [Member]",
        "terseLabel": "Lease contract, Villejuif"
       }
      }
     },
     "localname": "LeaseContractVillejuifMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LeaseContractWattigniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Contract, Wattignies",
        "label": "Lease Contract, Wattignies [Member]",
        "terseLabel": "Lease contract, Wattignies"
       }
      }
     },
     "localname": "LeaseContractWattigniesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LianBioNBTXR3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LianBio, NBTXR3",
        "label": "LianBio, NBTXR3 [Member]",
        "terseLabel": "LianBio, NBTXR3"
       }
      }
     },
     "localname": "LianBioNBTXR3Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails",
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_LumpSumRetirementBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lump-Sum Retirement Benefits",
        "label": "Lump-Sum Retirement Benefits [Member]",
        "terseLabel": "Lump-sum retirement benefits"
       }
      }
     },
     "localname": "LumpSumRetirementBenefitsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_MDAndersonCancerCenterNBTXR3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Cancer Center, NBTXR3",
        "label": "MD Anderson Cancer Center, NBTXR3 [Member]",
        "terseLabel": "MD Anderson Cancer Center, NBTXR3"
       }
      }
     },
     "localname": "MDAndersonCancerCenterNBTXR3Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-Based Payment Arrangement",
        "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement",
        "terseLabel": "Maximum term of options granted for share-based payment arrangement"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee",
        "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement In The Event Of Death Or Disability Of Optionee",
        "terseLabel": "Maximum term of options granted for share-based payment arrangement in the event of death or disability of optionee"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangementInTheEventOfDeathOrDisabilityOfOptionee",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Other Equity Instruments Granted For Share-Based Payment Arrangement",
        "label": "Maximum Term Of Other Equity Instruments Granted For Share-Based Payment Arrangement",
        "terseLabel": "Maximum term of other equity instruments granted for share-based payment arrangement"
       }
      }
     },
     "localname": "MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_MembersOfTheExecutiveBoardAndAlainDostieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members Of The Executive Board And Alain Dostie",
        "label": "Members Of The Executive Board And Alain Dostie [Member]",
        "terseLabel": "Executive Board and Alain Dostie"
       }
      }
     },
     "localname": "MembersOfTheExecutiveBoardAndAlainDostieMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_MilestonePaymentDefermentPeriodAfterEnrollment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment, Deferment Period After Enrollment",
        "label": "Milestone Payment, Deferment Period After Enrollment",
        "terseLabel": "Milestone payment, deferment period"
       }
      }
     },
     "localname": "MilestonePaymentDefermentPeriodAfterEnrollment",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement",
        "label": "Minimum Threshold To Provide Additional Know-How To Third Party Under Collaboration Agreement",
        "terseLabel": "Minimum threshold to provide additional know-how to third party under collaboration agreement"
       }
      }
     },
     "localname": "MinimumThresholdToProvideAdditionalKnowHowToThirdPartyUnderCollaborationAgreement",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_NanobiotixSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanobiotix S.A.",
        "label": "Nanobiotix S.A. [Member]",
        "terseLabel": "Nanobiotix S.A."
       }
      }
     },
     "localname": "NanobiotixSAMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NetLossForThePeriod": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Loss For The Period",
        "label": "Net Loss For The Period",
        "terseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetLossForThePeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDFINANCIALPOSITION"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_NetLossForThePeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Loss For The Period",
        "label": "Net Loss For The Period [Member]",
        "terseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetLossForThePeriodMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentFinancialAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Current Financial Assets",
        "label": "Non-Current Financial Assets [Member]",
        "terseLabel": "Non-current financial assets"
       }
      }
     },
     "localname": "NonCurrentFinancialAssetsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Current Financial Liabilities",
        "label": "Non Current Financial Liabilities [Member]",
        "terseLabel": "Non-current financial liabilities"
       }
      }
     },
     "localname": "NonCurrentFinancialLiabilitiesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentInvestmentsPledgedAsCollateralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current, Investments Pledged As Collateral",
        "label": "Non-current, Investments Pledged As Collateral [Member]",
        "terseLabel": "Other long-term investments pledged as collateral"
       }
      }
     },
     "localname": "NonCurrentInvestmentsPledgedAsCollateralMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentLiquidityContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current, Liquidity Contract",
        "label": "Non-current, Liquidity Contract [Member]",
        "terseLabel": "Liquidity contract - Cash account"
       }
      }
     },
     "localname": "NonCurrentLiquidityContractMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentOtherProvisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Current Other Provisions",
        "label": "Non-Current Other Provisions [Member]",
        "terseLabel": "Non-current provisions"
       }
      }
     },
     "localname": "NonCurrentOtherProvisionsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonCurrentSecurityDepositMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current, Security Deposit",
        "label": "Non-current, Security Deposit [Member]",
        "terseLabel": "Security deposits paid"
       }
      }
     },
     "localname": "NonCurrentSecurityDepositMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/NoncurrentfinancialassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/NoncurrentfinancialassetsDisclosureofChangesinNoncurrentFinancialAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonDilutiveFinancingAgreementBPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Dilutive Financing Agreement, BPI France",
        "label": "Non-Dilutive Financing Agreement, BPI France [Member]",
        "terseLabel": "PGE Loan, BPI France",
        "verboseLabel": "Bpifrance \"PGE\""
       }
      }
     },
     "localname": "NonDilutiveFinancingAgreementBPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Dilutive Financing Agreement, HSBC France And BPI France",
        "label": "Non-Dilutive Financing Agreement, HSBC France And BPI France [Member]",
        "terseLabel": "HSBC \"PGE\" and Bpifrance \"PGE\""
       }
      }
     },
     "localname": "NonDilutiveFinancingAgreementHSBCFranceAndBPIFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonDilutiveFinancingAgreementHSBCFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Dilutive Financing Agreement, HSBC France",
        "label": "Non-Dilutive Financing Agreement, HSBC France [Member]",
        "terseLabel": "PGE Loan, HSBC France",
        "verboseLabel": "HSBC \"PGE\""
       }
      }
     },
     "localname": "NonDilutiveFinancingAgreementHSBCFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofDetailedInformationaboutBankLoanDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesDisclosureofMaturityAnalysisforAdvancesLoansandLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonExecutiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive",
        "label": "Non-executive [Member]",
        "terseLabel": "Non-executive"
       }
      }
     },
     "localname": "NonExecutiveMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NonManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-management",
        "label": "Non-management [Member]",
        "terseLabel": "Non-management"
       }
      }
     },
     "localname": "NonManagementMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_NumberOfGlobalRegistrationalStudiesSupported": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Global Registrational Studies Supported",
        "label": "Number Of Global Registrational Studies Supported",
        "terseLabel": "Number of global registrational studies supported"
       }
      }
     },
     "localname": "NumberOfGlobalRegistrationalStudiesSupported",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfImpactingFactors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Impacting Factors",
        "label": "Number Of Impacting Factors",
        "terseLabel": "Number of impacts"
       }
      }
     },
     "localname": "NumberOfImpactingFactors",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfNewLeaseContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of New Lease Contracts",
        "label": "Number Of New Lease Contracts",
        "terseLabel": "Number of new lease contracts"
       }
      }
     },
     "localname": "NumberOfNewLeaseContracts",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfOrdinaryShareSubscribedPerEachBSA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ordinary Share Subscribed Per Each BSA",
        "label": "Number Of Ordinary Share Subscribed Per Each BSA",
        "terseLabel": "Number of ordinary share subscribed per each BSA (in shares)"
       }
      }
     },
     "localname": "NumberOfOrdinaryShareSubscribedPerEachBSA",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbx_NumberOfOrdinaryShareSubscribedPerEachOSA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Ordinary Share Subscribed Per Each OSA",
        "label": "Number Of Ordinary Share Subscribed Per Each OSA",
        "terseLabel": "Number of ordinary share subscribed per each OSA"
       }
      }
     },
     "localname": "NumberOfOrdinaryShareSubscribedPerEachOSA",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfParentEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Parent Entities",
        "label": "Number Of Parent Entities",
        "terseLabel": "Number of parent entities"
       }
      }
     },
     "localname": "NumberOfParentEntities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfPatientsInClinicalTrial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patients In Clinical Trial",
        "label": "Number Of Patients In Clinical Trial",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatientsInClinicalTrial",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date",
        "label": "Number Of Preceding Trading Days Taken Into Account In The Determination Of The Share Price On The Grant Date",
        "terseLabel": "Number of preceding trading days taken into account in the determination of the share price on the grant date"
       }
      }
     },
     "localname": "NumberOfPrecedingTradingDaysTakenIntoAccountInTheDeterminationOfTheSharePriceOnTheGrantDate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_NumberOfShareBasedPaymentArrangementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Share-Based Payment Arrangement Plans",
        "label": "Number Of Share-Based Payment Arrangement Plans",
        "terseLabel": "Number of share-based payment arrangement plans"
       }
      }
     },
     "localname": "NumberOfShareBasedPaymentArrangementPlans",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nbx_NumberOfSharesIssuedThroughIssueOfEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Shares Issued Through Issue Of Equity",
        "label": "Number Of Shares Issued Through Issue Of Equity",
        "terseLabel": "Capital increase, net (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesIssuedThroughIssueOfEquity",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCHANGESINSHAREHOLDERSEQUITY",
      "http://nanobiotix.com/role/ShareCapitalCapitalIssuedDetails",
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofShareCapitalTransactionsDetails",
      "http://nanobiotix.com/role/SubsequenteventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbx_NumberOfShortTermLeaseContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Short Term Lease Contracts",
        "label": "Number Of Short Term Lease Contracts",
        "terseLabel": "Number of short term leases"
       }
      }
     },
     "localname": "NumberOfShortTermLeaseContracts",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Subsidiaries",
        "label": "Number Of Subsidiaries",
        "terseLabel": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ConsolidationprinciplesandmethodsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfTranchesBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Tranches, Borrowings",
        "label": "Number Of Tranches, Borrowings",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "NumberOfTranchesBorrowings",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_NumberOfTranchesReceivedBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Tranches Received, Borrowings",
        "label": "Number Of Tranches Received, Borrowings",
        "terseLabel": "Number of tranches received"
       }
      }
     },
     "localname": "NumberOfTranchesReceivedBorrowings",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_OSA20161Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2016-1",
        "label": "OSA 2016-1 [Member]",
        "terseLabel": "OSA 2016-1"
       }
      }
     },
     "localname": "OSA20161Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA20161OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2016-1 Ordinary",
        "label": "OSA 2016-1 Ordinary [Member]",
        "terseLabel": "OSA 2016 Ordinary"
       }
      }
     },
     "localname": "OSA20161OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA20161PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2016-1 Performance",
        "label": "OSA 2016-1 Performance [Member]",
        "terseLabel": "OSA 2016-1 Performance"
       }
      }
     },
     "localname": "OSA20161PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA20162Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2016-2",
        "label": "OSA 2016-2 [Member]",
        "terseLabel": "OSA 2016-2"
       }
      }
     },
     "localname": "OSA20162Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2017",
        "label": "OSA 2017 [Member]",
        "terseLabel": "OSA 2017"
       }
      }
     },
     "localname": "OSA2017Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA2017OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2017 Ordinary",
        "label": "OSA 2017 Ordinary [Member]",
        "terseLabel": "OSA 2017 Ordinary"
       }
      }
     },
     "localname": "OSA2017OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA2017PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2017 Performance",
        "label": "OSA 2017 Performance [Member]",
        "terseLabel": "OSA 2017 Performance"
       }
      }
     },
     "localname": "OSA2017PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2018",
        "label": "OSA 2018 [Member]",
        "terseLabel": "OSA 2018"
       }
      }
     },
     "localname": "OSA2018Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA20191Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2019-1",
        "label": "OSA 2019-1 [Member]",
        "terseLabel": "OSA 2019-1"
       }
      }
     },
     "localname": "OSA20191Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2020",
        "label": "OSA 2020 [Member]",
        "terseLabel": "OSA 2020"
       }
      }
     },
     "localname": "OSA2020Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202104Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-04",
        "label": "OSA 2021-04 [Member]",
        "terseLabel": "OSA 2021-04"
       }
      }
     },
     "localname": "OSA202104Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202104OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-04 Ordinary",
        "label": "OSA 2021-04 Ordinary [Member]",
        "terseLabel": "OSA 2021-04 O"
       }
      }
     },
     "localname": "OSA202104OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202104PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-04 Performance",
        "label": "OSA 2021-04 Performance [Member]",
        "terseLabel": "OSA 2021-04 P"
       }
      }
     },
     "localname": "OSA202104PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202106Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-06",
        "label": "OSA 2021-06 [Member]",
        "terseLabel": "OSA 2021-06"
       }
      }
     },
     "localname": "OSA202106Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202106OrdinaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-06 Ordinary",
        "label": "OSA 2021-06 Ordinary [Member]",
        "terseLabel": "OSA 2021-06 O"
       }
      }
     },
     "localname": "OSA202106OrdinaryMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSA202106PerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA 2021-06 Performance",
        "label": "OSA 2021-06 Performance [Member]",
        "terseLabel": "OSA 2021-06 P"
       }
      }
     },
     "localname": "OSA202106PerformanceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSALLY2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA LLY 2019",
        "label": "OSA LLY 2019 [Member]",
        "terseLabel": "OSA LLY 2019"
       }
      }
     },
     "localname": "OSALLY2019Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OSA",
        "label": "OSA [Member]",
        "terseLabel": "OSA"
       }
      }
     },
     "localname": "OSAMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalDisclosureofDetailofChangeinFoundersWarrantsWarrantsStockOptionsandFreeSharesDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OpenTaxYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Tax Year",
        "label": "Open Tax Year [Axis]",
        "terseLabel": "Open Tax Year [Axis]"
       }
      }
     },
     "localname": "OpenTaxYearAxis",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_OpenTaxYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Tax Year",
        "label": "Open Tax Year [Domain]",
        "terseLabel": "Open Tax Year [Domain]"
       }
      }
     },
     "localname": "OpenTaxYearDomain",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsAdditionalInformationDetails",
      "http://nanobiotix.com/role/TradereceivablesandothercurrentassetsDisclosureofChangesinResearchTaxCreditReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_OptionLifeOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Life, Other Equity Instruments Granted",
        "label": "Option Life, Other Equity Instruments Granted",
        "terseLabel": "Maturity (in years)"
       }
      }
     },
     "localname": "OptionLifeOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_OtherMiscellaneousCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Miscellaneous Current Liabilities",
        "label": "Other Miscellaneous Current Liabilities",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherMiscellaneousCurrentLiabilities",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/TradepayablesandothercurrentliabilitiesDisclosureofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_OtherSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Sales",
        "label": "Other Sales [Member]",
        "terseLabel": "Other sales"
       }
      }
     },
     "localname": "OtherSalesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_PGELoanAgreementBPIFranceAndHSBCFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PGE Loan Agreement, BPI France And HSBC France",
        "label": "PGE Loan Agreement, BPI France And HSBC France [Member]",
        "verboseLabel": "PGE"
       }
      }
     },
     "localname": "PGELoanAgreementBPIFranceAndHSBCFranceMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesSummaryofChangesinFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_PercentageIncreaseDecreaseInEmployeeBenefitExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase (Decrease) In Employee Benefit Expense",
        "label": "Percentage Increase (Decrease) In Employee Benefit Expense",
        "negatedTerseLabel": "Decrease in employee benefit expense, percentage",
        "terseLabel": "Increase in employee benefit expense, percentage"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInEmployeeBenefitExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses",
        "label": "Percentage Increase (Decrease) In Purchases, Sub-Contracting And Other Expenses",
        "terseLabel": "Increase in purchases, sub-contracting and other expenses, percentage"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInPurchasesSubContractingAndOtherExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_PercentageIncreaseDecreaseInRentFeesAndOtherExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Increase (Decrease) In Rent, Fees, And Other Expenses",
        "label": "Percentage Increase (Decrease) In Rent, Fees, And Other Expenses",
        "terseLabel": "Increase in rent, fees, and other expenses, percentage"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInRentFeesAndOtherExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSellingGeneralandAdministrativeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Employees' Net Wages Received From French Government Via Partial Unemployment Measure",
        "label": "Percentage Of Employees' Net Wages Received From French Government Via Partial Unemployment Measure",
        "terseLabel": "Percentage of employees' net wages received via subsidies from French government"
       }
      }
     },
     "localname": "PercentageOfEmployeesNetWagesReceivedFromFrenchGovernmentViaPartialUnemploymentMeasure",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_PharmaEngineNBTWR3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PharmaEngine, NBTWR3",
        "label": "PharmaEngine, NBTWR3 [Member]",
        "terseLabel": "PharmaEngine, NBTWR3"
       }
      }
     },
     "localname": "PharmaEngineNBTWR3Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_PrepaymentsOnTangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments On Tangible Assets",
        "label": "Prepayments On Tangible Assets [Member]",
        "terseLabel": "Prepayments on tangible assets"
       }
      }
     },
     "localname": "PrepaymentsOnTangibleAssetsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ProceedsFromWarrantsSubscription": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Warrants Subscription",
        "label": "Proceeds From Warrants Subscription",
        "terseLabel": "Warrants subscription"
       }
      }
     },
     "localname": "ProceedsFromWarrantsSubscription",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/STATEMENTSOFCONSOLIDATEDCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ProvisionUsedAndUnusedProvisionReversedOtherProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision Used And Unused Provision Reversed, Other Provisions",
        "label": "Provision Used And Unused Provision Reversed, Other Provisions",
        "negatedLabel": "Decreases",
        "verboseLabel": "Provision reversed"
       }
      }
     },
     "localname": "ProvisionUsedAndUnusedProvisionReversedOtherProvisions",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ProvisionsForChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisions For Charges",
        "label": "Provisions For Charges [Member]",
        "terseLabel": "Provision for charges"
       }
      }
     },
     "localname": "ProvisionsForChargesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ProvisionsForDisputesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provisions For Disputes",
        "label": "Provisions For Disputes [Member]",
        "terseLabel": "Provisions for disputes"
       }
      }
     },
     "localname": "ProvisionsForDisputesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsAdditionalInformationDetails",
      "http://nanobiotix.com/role/ProvisionsDisclosureofChangesinProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Depreciation, Amortization And Provision Expense",
        "label": "Research And Development Expense, Depreciation, Amortization And Provision Expense",
        "negatedTerseLabel": "Depreciation, amortization, and provision expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseDepreciationAmortizationAndProvisionExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "R&amp;D"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesResearchandDevelopmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesSummaryofDepreciationAmortizationandProvisionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ResearchAndDevelopmentExpensePayrollCosts": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Payroll Costs",
        "label": "Research And Development Expense, Payroll Costs",
        "negatedTerseLabel": "Payroll costs (including share-based payments)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePayrollCosts",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ResearchAndDevelopmentExpenseSinceStartOfCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense Since Start Of Collaboration",
        "label": "Research And Development Expense Since Start Of Collaboration",
        "terseLabel": "Research expense since start of collaboration"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseSinceStartOfCollaboration",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Sub-Contracting And Other Expenses",
        "label": "Research And Development Expense, Sub-Contracting And Other Expenses",
        "negatedTerseLabel": "Purchases, sub-contracting and other expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseSubContractingAndOtherExpenses",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofResearchandDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ResearchAndDevelopmentTaxCredit": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development, Tax Credit",
        "label": "Research And Development, Tax Credit",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCredit",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ResearchTaxCreditUtilizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Tax Credit Utilization Period",
        "label": "Research Tax Credit Utilization Period",
        "terseLabel": "Research tax credit utilization period"
       }
      }
     },
     "localname": "ResearchTaxCreditUtilizationPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_RevenueByTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue By Type",
        "label": "Revenue By Type [Member]",
        "terseLabel": "Revenue by type"
       }
      }
     },
     "localname": "RevenueByTypeMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_RightOfUseBuildingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right Of Use, Buildings",
        "label": "Right Of Use, Buildings [Member]",
        "terseLabel": "Right of use \u2013 Buildings"
       }
      }
     },
     "localname": "RightOfUseBuildingsMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_RightOfUseTransportEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right Of Use, Transport Equipment",
        "label": "Right Of Use, Transport Equipment [Member]",
        "terseLabel": "Right of use \u2013 Transport equipment"
       }
      }
     },
     "localname": "RightOfUseTransportEquipmentMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/PropertyplantandequipmentAdditionalInformationDetails",
      "http://nanobiotix.com/role/PropertyplantandequipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_RoyaltiesAgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Agreement, Period",
        "label": "Royalties Agreement, Period",
        "terseLabel": "Royalties agreement, period"
       }
      }
     },
     "localname": "RoyaltiesAgreementPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_RoyaltyPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payables",
        "label": "Royalty Payables",
        "terseLabel": "Expected future royalty payments"
       }
      }
     },
     "localname": "RoyaltyPayables",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SanofiGeneTherapyPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi, Gene Therapy Portfolio",
        "label": "Sanofi, Gene Therapy Portfolio [Member]",
        "terseLabel": "Sanofi, Gene Therapy Portfolio"
       }
      }
     },
     "localname": "SanofiGeneTherapyPortfolioMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax",
        "label": "Schedule Of Detailed Information About The Reconciliation Between Statutory And Effective Income Tax [Table Text Block]",
        "terseLabel": "Schedule of reconciliation between statutory and effective income tax"
       }
      }
     },
     "localname": "ScheduleOfDetailedInformationAboutTheReconciliationBetweenStatutoryAndEffectiveIncomeTaxTableTextBlock",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbx_SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense",
        "label": "Selling General And Administrative Expense, Depreciation, Amortization And Provision Expense",
        "negatedTerseLabel": "Depreciation, amortization and provision expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseDepreciationAmortizationAndProvisionExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SellingGeneralAndAdministrativeExpensePayrollCosts": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling General And Administrative Expense, Payroll Costs",
        "label": "Selling General And Administrative Expense, Payroll Costs",
        "negatedTerseLabel": "Payroll costs (including share-based payments)"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePayrollCosts",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling General And Administrative Expense, Purchases, Fees And Other Expense",
        "label": "Selling General And Administrative Expense, Purchases, Fees And Other Expense",
        "negatedTerseLabel": "Purchases, fees and other expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePurchasesFeesAndOtherExpense",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/OperatingexpensesSummaryofSellingGeneralandAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate",
        "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Decrease In Exchange Rate",
        "terseLabel": "Change in equity due to a 10% decrease in exchange rate"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentDecreaseInExchangeRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate",
        "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Equity Due To Ten Percent Increase In Exchange Rate",
        "terseLabel": "Change in equity due to a 10% increase in exchange rate"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInEquityDueToTenPercentIncreaseInExchangeRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate",
        "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Decrease In Exchange Rate",
        "terseLabel": "Change in net income due to a 10% decrease in exchange rate"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentDecreaseInExchangeRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate",
        "label": "Sensitivity Analysis For Types Of Market Risk, Increase (Decrease) In Net Income Due To Ten Percent Increase In Exchange Rate",
        "terseLabel": "Change in net income due to a 10% increase in exchange rate"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfMarketRiskIncreaseDecreaseInNetIncomeDueToTenPercentIncreaseInExchangeRate",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_ServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services",
        "label": "Services [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServicesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/RevenuesandotherincomeScheduleofRevenuesandOtherIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Value Of Initial Plan",
        "terseLabel": "Value of initial plan (in thousands of euros)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfInitialPlan",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_SharePriceMilestoneEuronextParis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price Milestone, Euronext Paris",
        "label": "Share Price Milestone, Euronext Paris",
        "terseLabel": "Share price milestone, Euronext Paris"
       }
      }
     },
     "localname": "SharePriceMilestoneEuronextParis",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nbx_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Abstract]",
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://nanobiotix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nbx_SupervisoryBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supervisory Board",
        "label": "Supervisory Board [Member]",
        "terseLabel": "Supervisory Board"
       }
      }
     },
     "localname": "SupervisoryBoardMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TaxEffectOfShareBasedPaymentArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Share-Based Payment Arrangements",
        "label": "Tax Effect Of Share-Based Payment Arrangements",
        "terseLabel": "Share-based payment"
       }
      }
     },
     "localname": "TaxEffectOfShareBasedPaymentArrangements",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxScheduleofReconciliationBetweenStatutoryandEffectiveIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3",
        "label": "Termination Of PharmaEngine License And Collaboration Agreement, NBTXR3 [Member]",
        "terseLabel": "Termination of PharmaEngine License and Collaboration Agreement, NBTXR3"
       }
      }
     },
     "localname": "TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/CashandcashequivalentsAdditionalInformationDetails",
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/OperatingexpensesOtherOperatingIncomeExpenseAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables",
        "label": "Total Financial Liabilities Including Trade Payables And Other Payables",
        "terseLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayables",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value",
        "label": "Total Financial Liabilities Including Trade Payables And Other Payables, At Fair Value",
        "terseLabel": "Total financial liabilities, at fair value"
       }
      }
     },
     "localname": "TotalFinancialLiabilitiesIncludingTradePayablesAndOtherPayablesAtFairValue",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbx_TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Number Of Awards Exercised In Share-based Payment Arrangement",
        "label": "Total Number Of Awards Exercised In Share-based Payment Arrangement",
        "terseLabel": "Number of awards, exercised (in shares)",
        "verboseLabel": "Number of options, exercised (in shares)"
       }
      }
     },
     "localname": "TotalNumberOfAwardsExercisedInShareBasedPaymentArrangement",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nbx_TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Number Of Awards Forfeited In Share-based Payment Arrangement",
        "label": "Total Number Of Awards Forfeited In Share-based Payment Arrangement",
        "terseLabel": "Number of awards lapsed or cancelled (in shares)",
        "verboseLabel": "Number of options lapsed or cancelled (in shares)"
       }
      }
     },
     "localname": "TotalNumberOfAwardsForfeitedInShareBasedPaymentArrangement",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofFoundersWarrantsWarrantsandFreeSharesOustandingDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofNumberandWeightedAverageRemainingContractualLifeofShareOptionsOustandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nbx_TradeAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade And Other Payables",
        "label": "Trade And Other Payables [Member]",
        "terseLabel": "Trade payables and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofNonCurrentFinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche",
        "label": "Tranche [Domain]",
        "terseLabel": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Four",
        "label": "Tranche Four [Member]",
        "terseLabel": "Tranche four"
       }
      }
     },
     "localname": "TrancheFourMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche one"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Three",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche three"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Two",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche two"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_TranchesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranches",
        "label": "Tranches [Axis]",
        "terseLabel": "Tranches [Axis]"
       }
      }
     },
     "localname": "TranchesAxis",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_TranchesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranches [Domain]",
        "label": "Tranches [Domain]",
        "terseLabel": "Tranches [Domain]"
       }
      }
     },
     "localname": "TranchesDomain",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_UnusedTaxLossExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused Tax Loss Expiration Period",
        "label": "Unused Tax Loss Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "UnusedTaxLossExpirationPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_VestingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nbx_VestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails",
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedShareOptionsGrantedDuringPeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period",
        "terseLabel": "Vesting requirements for share-based payment arrangement, acquisition period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period For Foreign Tax Residents",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Acquisition Period For Foreign Tax Residents",
        "terseLabel": "Vesting requirements for share-based payment arrangement, acquisition period for foreign tax residents"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementAcquisitionPeriodForForeignTaxResidents",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Attendance Period Before Date Of Exercise",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Attendance Period Before Date Of Exercise",
        "terseLabel": "Vesting requirements, attendance period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementAttendancePeriodBeforeDateOfExercise",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Continued Service Condition Lifted, Number Of Employees",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Employees With Service Conditions Lifted",
        "terseLabel": "Number of employees with service conditions lifted"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementEmployeesWithServiceConditionsLifted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Employees With Vesting Conditions Accelerated",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Employees With Vesting Conditions Accelerated",
        "terseLabel": "Number of employees with vesting conditions accelerated"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementEmployeesWithVestingConditionsAccelerated",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Holding Period",
        "terseLabel": "Vesting requirements for share-based payment arrangement, holding period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementHoldingPeriod",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Maximum Percentage Exercised",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Maximum Percentage Exercised",
        "terseLabel": "Vesting requirements, maximum percentage exercised"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementMaximumPercentageExercised",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Minimum Attendance",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Minimum Attendance",
        "terseLabel": "Vesting requirements, minimum attendance"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementMinimumAttendance",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Minimum Number Of Patients",
        "terseLabel": "Vesting requirements, recommended dose determination, minimum number of patients"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationMinimumNumberOfPatients",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Recommended Dose Determination, Total Number Of Patients Enrolled",
        "terseLabel": "Vesting requirements, recommended dose determination, total number of patients enrolled"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementRecommendedDoseDeterminationTotalNumberOfPatientsEnrolled",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nbx_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage",
        "terseLabel": "Vesting requirements for share-based payment arrangement, vesting percentage"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nbx_WeightedAverageSharePriceOtherEquityInstrumentsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Share Price, Other Equity Instruments Granted",
        "label": "Weighted Average Share Price, Other Equity Instruments Granted",
        "terseLabel": "Share price (in euros)"
       }
      }
     },
     "localname": "WeightedAverageSharePriceOtherEquityInstrumentsGranted",
     "nsuri": "http://nanobiotix.com/20211231",
     "presentation": [
      "http://nanobiotix.com/role/SharebasedpaymentsDisclosureofIndirectMeasurementofFairValueofGoodsorServicesReceivedFoundersWarrantsWarrantsandFreeSharesGrantedDuringPeriodDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/FinancialinstrumentsincludedinthestatementoffinancialpositionandimpactonincomeDisclosureofEffectofChangesinExchangeRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/CommitmentsDetails",
      "http://nanobiotix.com/role/CompanyinformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails",
      "http://nanobiotix.com/role/SignificanttransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/FinancialliabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/IncometaxAdditionalInformationDetails",
      "http://nanobiotix.com/role/RevenuesandotherincomeAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://nanobiotix.com/role/ProvisionsDisclosureofAssumptionsUsedtoMeasureRetirementBenefitsDetails",
      "http://nanobiotix.com/role/ShareCapitalFounderswarrantsDetails",
      "http://nanobiotix.com/role/ShareCapitalFreeSharePlansDetails",
      "http://nanobiotix.com/role/ShareCapitalStockOptionPlansDetails",
      "http://nanobiotix.com/role/ShareCapitalWarrantPlansDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 18
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44D",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "46",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r183": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r184": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r185": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r186": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r187": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r188": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r189": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r191": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r192": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r193": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r194": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r195": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r196": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r197": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r198": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r199": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r200": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r201": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r202": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r203": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r204": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r205": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r206": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r207": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r208": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r209": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r210": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r211": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r212": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r213": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r214": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r215": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r216": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r217": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r218": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r219": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r220": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r221": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r222": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r223": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r224": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r225": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r226": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r227": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r228": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r229": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r230": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r231": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r232": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r233": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r234": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r235": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r236": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r237": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r238": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r239": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r240": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r241": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2021-03-24"
  },
  "r242": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24"
  },
  "r243": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r244": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r245": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r246": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r247": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r248": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r249": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r250": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r251": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r252": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r253": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r254": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r255": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r256": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r257": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r258": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r259": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r260": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r261": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r262": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r263": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r264": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r265": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r266": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r267": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r268": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r269": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r270": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r271": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r272": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r273": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r274": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r275": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r276": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r277": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r278": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r279": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r280": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r281": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r282": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r283": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r284": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r285": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r286": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r287": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r288": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "90",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_g&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "144",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "5",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>168
<FILENAME>0001628280-22-008842-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-008842-xbrl.zip
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MN&*ADP?'B?[P($BSL8+Y*B][KI?2G(_)<X[Y)):$8; S%95Y1E8Q&#(P&TX
M28#=L(L9ETH3F44))17R#CDD<;<3"@//Q+,!\YRRU<M*ZG;G#'JS1JK3_8NP
MICF,#(CN/9#8/,],U 8$6\(!=?:2X"4 JBTE_$ WCIW7Y1SK 01D$@\. [,2
M*]$'C/]NGG%+[ 7!1YR!>0V08<>AKO[")>\*6U0,)S*;(W'&*H4K:A<YR>>)
M5 &CO%?HV,?<*B3BDHON6#MOK@^G0T-7T2<5\(VSW1,E!D.?ZS -#B=79^&^
M"9;(^YUCT@?\5-<(&N;2W %%/0=@1X] =XVY8H=N"=6+8I!E7B0Y+?)=4L %
ML1<X.(]2M7S##,W@\ZM(+U?G:8L,RS0Y:K5<7%#5"^>43"*\SLV31,J=+L2E
M-T8EGLQ5&/12L>L&RV$=%@S[8*>@^3'QPUNYH>,]7$V2RZ*Y\JM_&MO]20+W
ME(8[A H8#Z "PI&-!994G]$ NB :%JX;L6%*F'STJ&N^R]V_E(IF?=-__M.;
MG;=_^<M?X+][;X<GL_N/3/569IQK?SY)/2>_""_F55+$P3<$PEG%5B#N1GD)
M$1=OVJI.$XO@B+@[^:D(<%2&&$LHS=G9#&2RH'3PKI^3]"(NRQRQ$OA>11D#
M_"W&19Q7Q^Q2)XK+<GH-Q<3M^'KX.R_([C\&U\><X#RI,!4RR:[S]%H9PO>N
MT;1;((7-:[!/07MS_B:!0K\(2R9!,5 ,\L')FY*QZ<@LC+QU+9>LK/&F3@VX
M^MK+(<O/&!(NY$A'%H[$'68";B*ZMR5^'\V$4Y.P9UL5I*"<4-X"Z$J5Q"=Z
M=#0I+2[]_ 8OCY'KCC54>=EANCA9>.)ZWO3/;:U4^8&\H$A3" %!MN9=21B$
MR5Q5*"8L^2PQI>*DG!0*']\.WHF%%EWG"5>+ RG$>3VFTUIX) [O8E8B!?4T
M"45BB9*VV&S$]PN%=\J^SI!:%%PF&)_E^OA%6_JUZJQ\4O?X$?^V4#.JYM=V
M1LH. S_I5#:&5?G(OT!FT] ' #\WI?2T0N=R=66<HD]!9PQIH\*71<Z;P!IG
MDTEJ]+5BT*K3"87W&/)H,'5=*^ _\W2[)#]-,U'TF@$/TRXIEY($6@I%@,>C
MF'6-6YS+#3O@CI.8R]0E?(+G 01(A??3" ^F,:+$I4TF@>7M=(Q-AMZ4=H\\
M__BYO_XUS3\>6$ONK8D\SH.C&0?/A"$/H0_#+$3' (:H%<70U<6\%.+EN@5H
M-Z1TLAO'*S;HK@D@DSTWCA40K#*91E9UWZCC!>I?J51HA &PE'P^5VGHU8-L
M4W6VC(QQ)KL>/3 ,Y X<=A1'B//ZMD('*0OE6+/GX\5RZ"0334XKZ=V),5I9
M#8-FMU_KME[%702\]08#KUJ:W^1%&CMIWTVWX8//INPO0KWH=)8&?T?0L%_S
MFP&N)AXC>U(CSY\Y1R54%!MBJ1V93FUG'JJ<:5[J< $Z4J^C)-7JT7LM?AL>
M.KU^EN*$V%GVYU?I3"SK<J4PCYEZ7:IIG1H_K-'O5O'8=#H!.V&6?*2!IK^5
MUDZ2O6N9=E-T,*6P01B8]PP7[SP8*U;]5.GDN)-E[V;*Y1(1#/5%I)%Z)P$+
MT.[W9ORJZ8GN\+Y3U*Z>Q\RUKHJ\OKS2SEMJ(J0=\J)\^4?LXNBU>"#Z<DOV
M5;/;G!ZA<H^DPNJ3SN5LT$+-C*BJ;!;%RB=J3>M$T3BO5KVJ<5?3>&9XGA0A
MD.II^7>XM8[-%O87[1VJG(UY>%0J2FO8>7U04B(&B#>U).LR ?4L6?IAE:FZ
M3O+:*]'18YJ2B-#HOWA[(ETS"ROU=5HJ&2X=QD 5GB!9.R^U,+W0T(VXDRJ/
M[B,JPO 3IW "\'VFTML\+;0ES9L;:GD+FA^/U&,O@_#C^!2L&FMP\2+EF52M
M<#'+DW5%6XRY6*":F=@-U8"IN&DO2?R[<C)P&K'PAXY%L;O]HD\+&$FV.A#<
M "!"CZ*DXOXC4[^H3!7H&1NVH$+[ECK07T)3FKU,;,&O=  [9Q$) W65<&^@
M7525*J6B?N+FY&0D5<!SK(=--QZ%D:W'<;/3$O'-JX8E@O,2=RA8&"M%UCRO
MX=)$P*@C#=":JB9\8J3F'\L ?##QX*;7[#$4;TUN7?/7*.Y\N;;%G7MW6^_0
M4V? RW^,WI^<?A@=7SP$\,*][9U^+$NK(I^F\(H!1-,CX %#:!M&JFV=:U"'
MYFD/E?>P80OO''V@J62X83&V.ONC[#I:OF+JJI;K?;Z<6U4$4F\0.KL6T,E5
M2@9O2^MI^Y BC35N$"\+FPX^3Z.L^5E98:KV):<8-GM!NJGD.L^Y-P-!LDN6
M3WG0]H3K2."F)#%JY#_<\TR8X\4*R(D<ES^1%HJ_^N%O(P9_#/;O?7<VW=O#
M?CB?H/I/DM'XV&& =@=>D3GHVQY(&W,)+S*#GE;)IFB@:(DEM,J[G33;T*3>
M(?!')#FKE'QA8'06NKI@.\!.A\IBX]BO0GY8;\+J<Y&(%&6S.JU#":8='5A*
MLG(]B)$5!F:'+CZ)Y?$F(FXR43C=]DZ[AM!ZA2KKU(Q&R'"<-"T,+EMT5;A(
M1386:-!Z9TKI/"43B7###X1V9(HX,,10EZ7-SFHLHA1L,_&8HR%*)S0O$L8S
M9I"O8(/RXL#V7'W1N(N2(D;X>&FT8'\D' WZVM$4W< $]RA)&>J&/Z<T,YM)
M(E" CO^UR7I7W_=.7V:28B!/P'[2A9Z&:\S?EM<BE3I$:S@(M38QO;9X/)U&
MY+FONP:^$^TS:%NLI/M&5M:%D_&B>-OA7A*J<R-J,5J&1S7UW D&G0HO*G,3
M/8&N5"(L2]&5 '/=?(,N8), /+F,]Y=+NMPTOY7)[1$HST-4IDK+OL'UB>VN
MZWO9GEQ?7%+7:<CW5G-S(-+PA_!(=Y8I*9F#JGGK<A2V%R[LKI3:4 B5RFU.
MKU -.#HZ"B[P31P<RQ8=\::^2*D;(^M9<[-PD?M0HMP+M=#CLJ"L$6T13'NJ
M*+(,AR.@E@(ZJO!$I^%ZAKY9T3(LNCT2'6Z?KK":1?]L&B-V#KVV4G-RC0 R
M9Y TF/N[-HQ=(^BN54$G"-Q2EOJ6V5O"&+KGTJ>*?/43>>1)?R^^OZ2_QU*$
MW[HY'U'+JZ)/0.T#8#PT*D..I/KOP^F^YKT@4FO)>:<P=B=#,A(S1>6<8)U)
MTXZ+^K*C:IT@+).YI/[BB"*VN7$PF^6(H>0+CM*Y_3Z625,][&-3ZR"L>2D#
MBF@=[M3H+Y@R @=N5"A&ANLV3QKA3O.%/=(D-P:9NV C(2R2V!%W<N 6'$0>
MM=P%YO98*\7@7_>LR._L[&WOO;YG9I1L!BHK8'.X2S:7'_EB4135*D=\,>F[
M Y_I?IG#4O>()D]7#9W,285_#D;E-H=/4YMW^T(GB<ODYGCDB@H1Y0=KEX''
MF!@%K*F!W$*L=XYFOWJU_>;%_9(A7>B=;TD]G1Y9;VMV016@9:\;N-K>SJY'
M"$%%I%)6$?>2^>^]8/?9[DX8 ,-\N?,V>/'LV5 78'GOW"=*_#)*]-CQ&I E
M4!KFRN^^?+OW[-G RJ.'!/\]2=XU(;27N[AL7V:!7:]\-0J$/+I<";5W*$F_
M;RN!W*D-)NL%(';'M#%:MVMZ>D4VS 8=V:M7+TDR_.5;&I^W8<+NKNU>K<TN
M<2K_WOINU.G5.A&5X4MED(*"A%!P68 NIF 7;90U#/'_?/^YXU%51=CR*>!6
M%IM/I1%L?N69XDY>A8G&V*;N+ 09&J!;\I1DK6&''H18H"(GZ0?8.7"G18@.
M):"7I'0JV?[K_$!DR]'ZLH$-D2Y;P9IP A O1SW[M0ZDODY,D[9JC6EK*U@_
MU>7H'^N[7VNV6X3$M,;;Y9"7<9ALPJ=K8L@^?V7_7O>=VZ.=6XN-Z]<$]YXT
MP:6:X!=[3?9V7*_)'XM]X%AOOKH'Y@OUT6$0@T,O?S74 1:)SPCTD,#/<>8:
M$SFF=\Q5)FUU&&P,$U +-2EJ#HCH/M&,^+&QOVFC-R:!3T>!J&TS9=!L838>
M=10,Y0/S(QHOB&:Y=.UCES2G'& _ZI]-AJ9T<^6*]8A!5F8">]X9O-$9N9PT
M@JIS38G],^EOJ-5D#H;,\[DT":31QXH0I)C(.;J+)0U>%'C1J%:G_$1IN#Q1
M,$1U@Z-T9'EQ/J$.*?*:?;2 CI^2"<&_O8H$QQ:6-$UH(WNW(7P$T4?8NT>P
MRC:FXIW#R\O6\/WMQWX+J TOT:/=CI\?805N/$ "<2LMYRA#@06B<@ \!X3V
M)%GOA?\W+/Z61Q*;5&ZA8;FZY05]=<9]$(,SQO[4N)R%BNL)IR^M+[@K.>7N
M_R02+&22"AMN)7"E7(!0=TMQ+VW%D^]D&C0-II^VA\OX>N!0,7O;N_W]=['!
M#G423%1YEXUX,+ 20_3'/<ZSK4;&5/,([I?!8[5!UI[4@>[JJ)G^]N4VHJU(
MWJE\#,_K1%3^9-//0Y7N,(RJ1^U(8MTCA<&>6GA;Q5W*C6_K=VNK1G6UA%=%
M@86$! T6"@BYH.AB;31ND]> GK+U4529?I=Q5$7- NEWU']%VL&0+!3HYMNW
M&.TPK$/O[)'R&/2M\0 YY\P$S];E0GJEM+:Y)=^<4AH4$^7#34RN*=O5SR&^
M(WB =D@.IA3T'L!@[6TW7;XA/80\&%P#^HC("_&US@:WA5@:\I.1 WL7R'U*
M>QB3]1[%"FMZ0^U+*O(JAVW0_Q[7\:42*&)$T.?:@=BDX9KY4,'XAO B;.FU
MGJ<>'-/D!JP!("#]SGYC$Y7,N29]V:D>R^XV"_:HOPE!,,]UXX5\3$WOHEM$
MCW93+GFIFB)"P62Q5"CU@'E0[8C7G&W)BVC\M</O@$D-ET^O!7=BNM(2AJ[7
MYYDOJ L&IPWE59NDK>.>!R=$R@.G-WX='>?[\\DEFX3[_ADIJFS!H7>>E.WV
M1PZ$V^2%12WQHQ$$LRK:;0>L06=I#K^@$7)8PF@,",*8L'-A1F-U%2$DI !E
MK# ()Y'EQ:-UVR9?0B,6>WDP OD:AX_MA)W^D!W&8&/.,.!L1J#O/"'&0BF-
M)M>W;8Y&*!#;K2),+-E3Z;P3>1T#GE1L"$O"P&-2!3=1QH!C<G"NWG GG]77
MI.;[)-S ^3_0IU CQ@917/>>+;#S[Z7F8@SG5MS2W*.C,W3C^"MTL5*38*+&
M:*HJ47>8$/"54T0*('R&7K(+A>8:" *H($0E'B[V!"EUW^WXJQOVCZ.,_^7W
M5\9__[[?WMX]$L]Y\OT^^7Z_G>_7RUZY'P]P'VQ1/WJ.[1<QI"=XTNT);H&(
M/CF!OXD36-AACQ?X_A/M?@-Z1,"B>:'^"7-@!]"Y8OS#O>T=Q 9?UNS\#B[*
ME=W(@SN*^P]I.$^Q-*.R^% :=A$1&GTD%P,JN60=:^.>73;']?#/-AH;.9[9
MV^?N^O?_N%-VV?N^KE=VV9N&=\LNF]T:^F?OX(_U5 Q\;+WPK)=M_,#^6<\]
M5)/_B:[>"E#KG,6M@UXZ$;RU\V!%PV()>A(,N616S]HMQ3QLH/: M]VM,!C7
ME6;A')G-<JZ;Q PK_UW>3.F%B#;-F=5K2R5K $HD"-\H2SV?U^W$33& 1QP"
MN*M'WW>*)MJ?JH&E"3+[MIUO9'1FCD M5#(;UT7I1;2;B>5W=<I_O^<#!W0G
M=WJ'R]IV!5_5D\Z,I^U)]QW2.I/D5MW"S(FF$R?2]='JM_<.)_UJ]W[/\<)I
M-L@^9!>@E0ZHT:@=9<4I',"6<6 XQ4,S>"H2+TG4B6,?U*CD4K+TW7TACMO#
MM'05TX^Z SK)*68FO7,E37@)=6Q_)?^\VVZVZ:7G:W G__Q2>>Y0\]=RS?>1
MYW>6+=S?7UHS?MC^,\WB!]$8F@TGR+>([ER'@K0*P;T<;@N).P"IULFRB_CQ
M6"0._R%*\<>\72^Y"]_OF<,>O!Q%" M9O_0RV, U2T]=^(6+C*6L#B6LPBD5
M8$,W)*=GTJP/B*-%V1@*KJ_#->3]C<[&,>6XN/=*BC]YLQRD:M*WV?';GMJ2
M6&Y>-'KWWGWTI2S!:3Y!;1]MVP:'#Y&?H+)-8BS<?:'T2\DOO*2E0T= FS@Q
MCR@;V9AY<[^Q_94!#Y?:U<Y31I_[F.+PFB!BERSMSYDJL3@U2@L585XAEI=R
MGPPLRD$5D\+5$57:1FF9^ZNU"U2(3\.+:D^\RB\YV"UM7*CY,GHXM>/1F12<
M!P86L3Q^H_^2AD:'3<K.8Z1F8;[W%/5F^-"]87['\YZA-LUQM8^8(P=-$F$2
MBKA:N 8!6<YK1FBG9<=8GEQSB7/?=;0'1JQ"ST!&V(87+69D<L:U,CGWW!%,
MI'#/XG=I\9NV LM,RM<5[02XP-GM:(_ZJ/02\HK$<"^<A(MON0%#1R_O7TJ_
MZ)72V+@V3=#=/X!<=E(LQ+;@.\$?4;\= 4K'?[=Z_W9U[N.KU-^_S[YHE:XF
MM_;1FYCM8_ZT[\BFZ(;N>ZB[RQ/=D^=)>_9[6E78H&C$8.">G]K$4KTOETA"
M9)2M#),K:DRD6?PJ>8"]_'2#N&%[+QS&_.YPGTYG]#'XH&(*7,+:D8N+ZLS\
MR!=0F<+X*MH!FM7#4<Z24FL6I,E?4JMKW"O2Y&E;??G>=J#?K3'N]_+=XTKG
M>=6?SA.OWLSXC6EFO XY0,.U3G[^190V:.OD@Y,/'T9G!T?[[X_^[_[%T<EQ
ML']\&'S8/_O[Z.+H^)<_NJ!UD-O/MW>6R6T3B(I<_>I6'\\ <OYC1N7EH/B"
M0$BJ9B<\#5.#7ZBT5(SGLSPED\*PV#J6O44Y2,1K54B_14:>W)I1(Y@@,CZR
MIB#&?;GS1O:5CEK/V2PJ/A&N 99<<9M<[)$ 2\>/L+5DSA;U_&I1PJ<8_H^*
M2WFD<)TE83 NV$M&C;>J(AG7E6F]58*U5&X'^]T6)*RCM3AWFKSU[IAFXCRZ
M2E-Z\9=I1\9(P/=XT7<T-4"#?^BE],^7E=*[^]$FP4-05"[5X$KYBDVNW?FK
M+R"5N^EC:WO:>W=@U@<Y&=O1(,'V.T5?OI8%_.!S==N'/%0CSSP 99\<("TX
MEQD\?U5JEQL;6R@-X:J^C^H,;5+TF'BU#PJL3-WX&>PO(SFQ"6&C?Z<VU#J%
MZBUY,NN5([,FIVGS8MB"YS/1+3 +RXYC545)ZC1[)->H-80E(H%G33S;= =K
M$,@<IIG#8<#J8W2RI O'N^^DS1&$(34D[8HW+M&.! 2\ SSN#7[<A2I'7UQW
M?D[AC.97W$2T^P2M6L*=.>.N1SLCM^CRI\Z@FOC#'E+GYGA^(+5*R">,MX"O
MV3(I2=I1(>X+;Q_O W[HP2=OVQ,+/G)WUF&UK$:\B-AJQ7$S<7D6=,6*=+%5
M(@1HC1"; IU6.BS8J4:<H0!()##ODV>GH[$[C*29P7(VO3XL>JCCO$=PL ??
MT[5]JF>(-QT/<4F/T*F=9>+M)N\!7L>OY#)H-5KM%B6>VZ- ,9^%W/5;W\]6
M_BJYPMWPUP0T!>TV8!09AC>69/&"=Y@KC[C8JC.QN9^^O09<Y!%]*#9\?X++
MPPF=W3%RAB-^K3NP6@R-7JDJ4('+8)ZC$Q$GC8[!F!/?!%U;*VY>:IVW63-4
M>?DF,:VC=I?FN%UE1Z NEKNA[TM63E5!KC50<VO%9?I16F'F FRXB/*B(^_<
MCVWIC#&<>&.]#]\MUA^-UL%!(-0(C(OUT,MF,BFZ7A-,UJ?@J,X;^D(<-?@
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MA#83@JB\M7$DI3.L,0<]ATBN9-]](SF"S)42S]8>;*4F5RSVHI(=_V*C:7>
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MM++;2">PBB^<JI/7R'U+&";50</#B39?[#9LH7PK+2PPMW!B[JF3%*G9C_P
MWX4YS 30APP(KF&28BMVJ[$[3YM+,LFW@/:2 FY B>V0VWR2O^=5(V/BYB,D
M^!K,Q-L]'LH?WKFE<E3([7!/_$E=YQCSS<QO&?('435TXQ._8Z]E-;#2!L?
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M%TO,3P/9[WK%HZJ3<>3HVR=@9=<,]-\NT2&GDPK:G@PFH)%0/+W+#;FXK4V
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MW6E$2,D-;%X#J-GA!CP3!QE#E=M6%*W%)M*I2$_20-87>&49%=I/OM=X& R
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M1#A?@GGE3!OBG*(.,./4V;L*%5\IZBEK4L IA29-U:5Q0-YA+4V$OL=P.88
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M,)$&Q(E@<OH'9;! ,->A9.1BLI T] SI? 3!$#FI15-R*C1)@& ("RKJPK:
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MH["\6J=+T<NT]&>TO< &_4.;QNM>DUZ$%V0@<_T;K,NC1Q-B+51F] A$WV0
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MHQ3C3,T_"R7\>[',>J.+'989BL"P0+.?;YF9LM;))NLZVQL:>:S6&-L@7:9
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M=5E!;A"CAZ $4QIW5A4H'(H9JVJ.:&N-=QTLN\X=Q\7#.N&&]\$:D.Q&BL9
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M,&?"[_^W#$W8RU)QN=8959W!O_J"M0\N<]B+Q7)*.'(#U3Q>VHYJ765S2!0
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MK%GIQIQG%3:58;0!;0 C.'A+O+OI:N*SM<1N<+1^710&.] @T176C=?<GZ"
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M6*,:84R78(WHZICKK8,FYA$"1L1\*=Z D(%VJ"V+VERP6K%*-&3&>I.E5-W
M32J('$,=]*"XD @$5-Z_%&)TP>_C34Q78@<[-OFE6)X:1']45P']R<P^98Y8
MN9B60W HIQ@Q5L4DY%L3\HCK.T$<A"/^ ]YSW(KP:'^V$^[NQ).8;$],\.UA
MMW[0W&#O\C@<K+?X?F+R1,0D!D'YCAL=1B8IVOP=G4^8WGCO"'O/9QX+</;*
M&UM"36 FYE_Z@"+8'N>TFC.?#V,\4(=.JK^F)THOJ7D0PPLP&8)F_XA4 ]TA
MD#FC'G5$L(RXNX%@'@HO02I.[6OHAQ'X4+'OO62,'M-#2G4LD8D_$;&G[_0
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M54M.'N=\WO^+M00"(W458YY76Y.;(/P8+"E?*IB]S#</CB5HFX3X"N)B!1>
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M:C\=);'9/B'=$[E"1UWW-.KH<E]G1+'O_8[(AU6A&0?!LY^C-AC,I!['FKD
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M6^].\5R*XH+=4@8?58HU8W'DXX#S"NL,B#00_Q"9C!@=5M_;QX'Q<)=9AL3
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M(@-'_3+PEWD6W<!_5N4Z^>O_!U!+ P04    " #)B(A4U!,1G[^/"  A/UP
M$    &YB>"TR,#(Q,3(S,2YH=&WLO6N7&\>M+OQ]_PJ__GP8UP55!7@E/DNV
M9"_E6))CR_&6OG@!52B)\ERT9T:VI%__HC@SNL6)QWO((;O%)(Y[R&:3W0^
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M<K: IT+S66+H*7D, ;$4WF?I)\^1W?D(M;'$U1:JSA2JH> ,=&<.V\1BV;E
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MJ\ L!>?NT:]Z>K9Z^[L#;4^TW3K]ZOA@^"DG?+ #4G3A(&G[ZOAT*FG\;/Y
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M#6),&25QZ%R(7,&>8YVW_'UTE+E]@1M;C$%J+ T#Q%AHE(9)K*#5U2IA$C/
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M0]] L5A@$;+@7-EN*CW4*U?Q0H%AM+%IB87&#@0OT86>>CCG.G,_X^+R8&9
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MB%P(P?%<Z6[#>K?&7F+D,OD&]J\$'9C&:GF/K2>MKC'./K;SF][LNI7@SHF
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M#>4O7LO5]>]NPL*=TI\=YS3N\7M[*QH6;AEG[VL"/=4"L)@E/GMINGUR/?5
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M2=8/7S#NN%N:O56;@CBC=F52+FTVFE!9<#]Q=ZIU^]/$G914FQ3L [$),$.
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M <+/F6W8^QP5>]B'T*H$7+AZA=$F\=1Y0?@ER_27-V_?WOQXL$I]>C:A<3-
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M0)AJZ:GQ0$"2L;(L=,BM-ZES S@^Q9Y\]X/<_BB_O_[SU;6%1_E_GN]1WEN
MN+D>\</N?_;#*L5O/_F/]K-=O[,O?UEK&'MD$*02Q1FS69MH)3'G-E/AQK6%
MYZD;J,P7!IU4$QBG%O*N9J^&4U% D*U$'1%LT/,&-,&%0:=5([7V::-.HH06
M9:S7<.F3/=4D1KP!!JU%KC^]C=]_/?\'N_GSK?STP]60UP\;%3?O MY?_N7K
M/^X+N1:&0-:.1'+ - NE)BY)<A^YLL@&D#OGJ<ZG!W@6M8ZFO53"M1O5.23F
MU%H@;*#K!N3!;P!_\?;M[96^6TGV6__]?_\43]@=UF_?W=KW-]__8%>W7[^[
M'G<5X+WT^\;D=JQ;0[^+3/SZYJ?U@Q_^^!X+.D$-O O*6G+#TG3M4C--DSPA
MI4VT2=X$U(?I8KJ&(#0!I>+8+)$U;1,JM[5V,S9Q V1KZ+W@17@A<9B:837
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MW<9:V/(2QF;JZ.-^[V@#Q#G+[A@[IDT7TIPJJ5-#*5WS\/BW6T,JGK=.FXO
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MN%'!#@4!03%;SAVU-.@I79+/1@Y^G80\K?OL@RFY3ZQ81,K::!IUW4H>/#=
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M+T9D6RFH75,(:OSAL9'8O3]?R1V:-Y32G8_^U AG9KFZ!8ZO'=B1'X*UQ</
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MWQ H3\ZS7S*@L6M^#$V364%@#N, 31K3YT-FZ>%0#US.33<T> BJZ*C<T5Z
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M-.LZF;&^I?H'YU<L'Z,TQ]$N&.MSZ-C>P3FRUPY'^)]1,=,(1D1X,0,MG,_
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M@?3WW]EVK1QAIU&@T\(W$RI!S#P0JO"EMG<\.CL8G9W>UQRUV_W:9@4N@YW
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M$[8?&"_-I7$'^X^<&P(E(I3 '+]%IV#0N6F!?=<+8;36+T8DI==;JO!"7LR
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MF\W*NEVFG,APP9+B1Z60P2>PK'0N@@$)5G@.I"')O\A9KI0+%7G,KF'),.1
M9[\_YIO%)U+W)T!)I* RVAKOLB?89A%,GECI)A+Q/O,%:G1V+HJRFQ#/?^:P
MJ90_G9(_E_.L)^<&D/-<=-XNA7# T1/8_D!E^0EA2O5G<!.(UCJ#8!?/N#R#
MM8^$G\'"E@S;J;'TH.[B$*TCRXF=SWEQ.1P7ERIP/RU3T=0'EQ[G\(CG*LRS
M++);CE@=#E0]-FF>X-7Q!F2TBW#3U:NZ_NZ= $$?*MXX1JQ-.ZJ%F&;%0O4/
M19S'E2C@P>_(7O]CK/!!WGC*L-@JH<(X[&A*\]]ZVCXP;>LRPPN>S\$OQ\!?
M7J&Y';$I=NR+5^(4/]9Z=3F[B,J>6MO;&;UY""XZ< DU>X&N$:/$FZ+-GOH;
M<+*Q<&Y>"82D1([UF<K"V;29\0ZD+DG"GY?%)=::"'"J)M7+XWG$*9JCQ@5U
M>:1"[".F6C-K%29K=;'?G!8"7('7[#GC@3F#;/DKJSF7<SZRZ?;;%9,[LF2R
M;\A9TY!C7MV0T_?6;'J'RJ_66_, Y:N[J*-$FKJI9J_+NR\1L2F7#?>H?Q;%
MO.[0OZY>?'U?/+7O8RT4EZEL%H'= E_:T5[.2Q2/DP(S&:DP=JZY?OLB"!0D
M+C.0;I+X/5I(I*FZ%'Y'.\Q!KL+3J_H,;%.@! :A!G1+R=5F7+F* 6U'"]E
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M//J"1PSG(=&@5$GS(C\O&L3/'$RJJ= 2R^ U=5Y9R9I+,9!YS-E%*IJM9#6
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M0D](<HP):%13*EQ-^'@.XJG3KY734&HJEHWHNQC)E%X+E3?0Z6U26Q)3=/U
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MFQ1BXY&MH_DW+@O;GBFS"GP,\,2OFA16KOKF;5?T>MA$W(2:Z5J3NTGVKB8
M0A9]!C,-6&(HSTY"?Y[?Z4D"&ENN_=SV=G0-KIFI#E84))BXT7#X<ZSM\X@
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M::UE6C4HXRCC4%2Q2_P)P^\*+7(+R?>=963[PAGL8GNW:^V;%(ATYD6!)AA
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M(:MBBIZ,A'5NH6')I&@*LHPXGL( W:<4PYKE] 20>^AN<*IXI"/"ER ]6MN
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MZ D4]8,'CY%9T]1(_L4U+,7=I"<DVQ:!)3, S2H,^3Z;=-3X7*2=H#?0HH]
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MIDWRF8/D>B( 9FA7O"YW[ JKF<JZPQ:6^]2J_%33QQE.!!+EDC@5$F7SHGT
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MP13C$B>A9Q1-BVU6U-0M1O-A!-M.%S]Z#234KOQ%)O*KO&TEIWH[Y ^N.J.
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M>M&Q)C)!]7?JC$9,><D=]X<5M%NPX'ZB0(*&R+#7EI_S,U(NQ^EE<N5^FGM
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MO(Y1VU.A;]6S;^?).V+=KK&1[(+*D1/X9L5 RC>W&,5)<!"NZY[25Y1[Q$T
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MJ2B.#A""[6,P+V92#;A?<S>XYL;:0% .J FTE=Y8][O6*\Y6D&W31MS.)+,
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MU@A]DJ[IT?(\?,C;2:_Y*_P%52,SZ'U8?ZI_&4.>Z2],?#L9#Q/M"!":$GY
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MW>@C"-5-8D!9)MZT9)9/G]:NM,WV!I"'NLTQC)Q/(W)O;NO:P_!F8P77])%
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M1[1J$0#7'B+$7BZR!MDC^BJ280:DW]!SE28MX;L[U*PW\L)0$^-0AP$;&.B
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M;1VNE.N82MMO.TRF!.?KIBH00F4\]HOU!KM].@F)I'A5\'2'EW6Q4I_LD@0
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MA$L!<K'EL\IPZ8; &^ZPBGLUPHWP[?YEL#5*OS7B6X1G\%7% #E@F[Q(C,A
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MW*?;<[C7R2\$QH7[S._7GC_]0V1^OSS;QTO+2_PD;N!= [Q'$0,*U1/+XH3
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MZ:'J:M2RN=2I*["MN'7CRLV$EOY0RC]7\>P2]^2RSU\^/4]6#0T9E\+#B6%
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M1NSUL4@;N'SMY^JF+#=*I)L7';.TBI/N,$U?"6I"]R]8S1EB:_V;WB(7<D2
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M#]2"(K&: 3LA@!6ALK!#ZHK*X<O!3I)=2<MN( - Q0!(6.(7X!RV(*-[06X
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MNNYM%\8'S09LUP:.$2I+6H.:1EWV>&@ TLB?7J=D7KG1U?S9L?XI'3+IP2\
M"_<@#^APM0=TV-FK]_+1/:"F3_]M3\9;;G+@UKF@?M8JJUC(O[ #P-2NYV'-
MNC$*O+)'8IZ0ELQ$(N,9HS:Z0@VI[AV_U]9- (1S,E*M')7)_]0*9BLUQ@X]
MAQ:"P<O^KAD\>$1%=T^DV_U774BW7UP(^#+WPJL=')!8" :M8'\\!(#VB1L#
M>K;;_,J?'+DXMV ZGO?UV0)QF,;T^#XG[>]Y,9M$OR2D&*^B]\4TSM(_]?C/
M/%& 0^7CK,/,H3V 3E,)Y)7Y'##>AE9>?R-31VI);_A&"OV!!,G<C.\P30?_
M5MM6CO9V>X.C7?D]]P"0MMX5,!'+J:<D>N?Y. 4(@'=%>$;RFT$G@D@OVA_V
MAGN[T2+)0;!]8W!C2"--L[PT';_!\V/AM"S^F56!_,-)FC0:M9BO]TU-CAMW
M5'AKVW_9HY<:S$.S'?7O! J6:)G$A0&;OTYV\,^0.RYT&PWX)\D58&V;;RZ<
MO=H;O/B1_#TE\]5OH7FH)+T;\RL1V/X<XL H.S) 5_;$8H0+F=!S<C]*XRXO
MULV7O #@_W(A($RA<!2 .Z6WD0/-@>QGX<.E&GS2DQ,+2\H[[Q\=7+=YV5[#
MEH:?M6#G4XMKR- HZ%E,+.^S8D'*>_5!$QFP1%Y\:70"7[<?G=?DKRA\@;J%
M /&YI "(>UYHV_.%X@HW9=%@E F%4G.A_>BWO$AR1L<S_3_V]V4-YFH+9]5Y
M"0 0+Q?:6\/Z0Y3Y$C^3KTZ6Y66=.6^6=I'V.A5&2@7%(M51]KJFG[PP;2&M
M7WC%E\D-]PAR1Y,")?B-/0Q28Q#QSZN$'K%":#B676X'AD8TSG\ZNS"RH2CQ
M,7=P[H"3,.4IF=:O,:W CRK]1OQUL"E/%8"&&1>P%KTB\RACM"*><<@PHP5F
ML4QEF4 U&,- \V'F!Z]!R"KAL3?66PI%PPZD:]DBX>"79-L/8])\!4*RKHDT
M99X4Y!T24_?DMW!ITH[_DM\D+%+83OP<O9;TU(:80CN]7 1OL828;K=@^\^F
M4;2=#8*R1 P5=S#1^E7"C'CUH_<@4@FAQ,EA'A?IB.,L=#\9T)J)U_37A=^J
MGA?+&6[+/6+ARS*RV9,3#O>:],,$*L?1393F"([]'C6QL85%RT@^D3/=CWYJ
M91V0*BT6/IRS<;U9WLP.)Z9WV&-:K,ID=BFG@P2&#3OWD;KH=Q+/\6H:NW[%
M/LC2V9I-2K@K)7RP20EO4L*;E/#* \*V7G4.XRA(3S1K3E90I)FKHAZW\KV&
M-P@LL6KP,#V1Y6Y:V(T*>GF2]7)S[\'*XNB6)M^.D>6.I6KF9W?O"Z[IH=NW
MOH0L9H+$(OJQV^+3<S6\HR:O:(.DRB^GL*O!HP6>>R2AL;F97!,9O@!,%/-,
M 8[HFW_V(YOV[$;(-&2FP7)931120J%+#_<\MY=>0VKJ!3=P:$;"5/[#BDQI
M$#=N_<(\&MFD\>7NF"_::@9!7P#.[-L/#1BX1O,N+,-/"^H?;_Q61-LFK*24
MRF2P6M'\H< $IM&1BALD1\[CB-9W%3A[^UX'KAY9=+([,V$5B'=DBB7 W?8F
MQSE-9;UNA^XCHS2<!N+IG=9Q>$08T2>A&!43<LUD^6TJL4X5=\V-M<3:6BP6
M:P<F&4(_6JS(6  BYPH0J8)ILZ,F+0J_Y<S&S^\S//%T&6TQRN2V!M31?\9T
ML6(I*=-;;_ S:9X"IY.G ^GS$XU7SY=S!%7U'-<^>;_S\^G:*:<S'\7S]E>H
M<YL"WR:@$_2Y5UZMY'SKKEZR=TI;:G26Z(%H:[#[HA<-#NA_AD/ZG[T]P03:
M'[[8MC":,XKR[@ZG!;<+>&!TSQ&F&V$H:=^2#)!H+'23))E+IF.4=$"\*9Q9
M)QYSFC2PX\1"KP;[W3K[,'R][26;$D:;IB=CK3OP4$M#_%&']"L*W$SBR9QL
MB/FT"M&)MN#5;O_5"]:S]NJ_^)2F0HUZ[\N]'/3W&Y>[C9TG_9HS9U^MG.QO
M8*\YYR==-/*>.,^(Y!"F0B'K7?O6BY!H-I7IB4-T54 5!?3GLZ/G2*_E1G'W
M#_H'+T#*'@M6<W/2^3E:TN_^PX>WXH:6@:+?!Q+< 5Q%FND^N%6/#UO5E3);
MU:GQ<G6GQLNN3HWAJ]VGTJOZS3$LN*SDR&F43[IGSAI/98='Q.6E0^5Z&< Z
M.W<D;N,9M;"8W;=##(BU@[___:YN0253N*QG0=D!R7"@<B"U7V?TPK@=!O$F
MY_R![)IY_,K*H6 +7O3,!5EJP'ODJ+Q)E@IE-=L/*2%NNQ.20@LWV*^#_F4#
MF( BEZR\!*NX]5QL8,YLT$ROBLKY ^B@G_5[YCI\2,1M6HQXH]VS^UU,EMV"
MG*Q%Z2E9JXU[CEC".X:6MX[[[^I,_,1WQ^_>GQW_GYV]P?!K[N^F.W]U*>9P
M=2GF 7UA!P>V+VQ3P'GJ99!- ><;]"1^B#E-!H_&9$)_>QT=<\<V@NFQ !6A
M@8FL3UZ(JY.6PAN_.M_^9!IR-]V)2B?4>M'<M%+$@-J:)/$$\;[Q);ESD=1=
MPMU4!C!]_]5![^7+/3*\-YP]]=H'?TZON=T]YH[V:5(H_=S9KM?AI##3<W9U
MQKEQN6SD:.A/YCDZ3R0'DTRE,V.>VA_Q'=BC$R$KM^VD!:-*9>A;RA>2T@"L
MU@[#:IF6EEYW_TQJ1TO)4;B."X"DTNWS>/)'?8T.).Z,3J9I8II^&!FM#;"L
MM%6F3[.HA4S/==K(M(&DE+!3>CE&G9+^&PDFY-,=R_+GRJ)*Q$1KSYO-)<&&
M8\'DN#;[4E?T>0HX'\8Q2D"I"61X2VH$30LL72:[)AV4QBMI=#"2D UVUZY=
MD<)!@^2EH9]HEE@3:;[<V)8R.FQ)14)L\+IC^OH2^<$)27PFXH4@,,-V3O)Z
M-#/T1.?2T61?!=*+:*N;)%G>;H;\\/K8=D.&*(NL]VZ8$$B$R[(U8YZDHN,P
MJIF S>:#4J&![AG1<1UBX>S4B"GBF$-(Q$_332WCHFO\Z>S#BC6B9Y$G:3QN
M2Z-28M98' ?BIOXN,T+8-:(L-(V=SK&V& W51H,A.<,'IDQFW!UG*#^Y11$)
MK\DUUCBY9=6_'G>MVG(MEJ0P"XWVRW:#IQV2$SPT!S"8&QEQ>C1IA)]8*-YK
M3[^:U!4#R4]3"I9H5[!33042OB'LN*!8TD-X.8JN?9:^-M.I80^T[5%,;>G.
M:21H:XFW$6>O/O#/Q3$P!0CV<Z+7W(VQ9EHL(!#ECN,DVYG%(U!+2JUU)R[F
MR#8[I66VI>0XFX6^M$4L3E0!FY_'[;B8X74!M,K)*%.X(;K$$L^3]L%':YGJ
M:/<X29Y")\%("W&2:PM5)U(U1[L'/T:#(YY9*+4NQ2>93BL?9$<=#**Y*:F&
M*W6K,'OFY2OAF9%R2#).6I++@Y=FB^MV8!%]^'D#KG9\10;*]#%;[T4DQQL*
MLT3P[$^A!=8#F[=W:G=J>XI'FMT;ZE?*70[KDI.DXY2^YV?B3;;'BM@D4+CD
M*WY*Y_7<7*=(_J=."ZG!)9Q*3<LK*Y7]Z)_"EKN/KA-4ICR>4KVCGXZ*[>7Y
M&"0S5IOVA_32^&69H@*?C,M4BHEX''I$^9'7R1O^7CN.^3)T%9:!YHKL]?E@
MV?-D9ET*KN^(^'%)DL=QC"Y719!YI(=N,LA6YRPUHIS_6*&!S:;'?B<';8\#
MX^QFFNT%K\;Q;W$9D\FL\(@SG9PQ.V;?$FSQ[N#'1]03]\PK'>X^BWE#\$]M
MHOHO$]4_U<%"[YVWY@J_Q$#AH/^2@O/9C/%^&T.%]X\\[4QAU;CCE;3,%(G5
M=@VRL[V#'AU'+R<!E][;!#=XV#6O2*%"UQV[OGKK,@9[@]Z1&ZOD-I;@561*
M+ON.K+) 9# YL?\=$V6\.S_YU849:;EZH,W]F$*V,=/Y\6P7'>BC?:9FC1OW
M,+M1-@<@5X3O#,2!]<!_\%(#L!_#@Q>WN&C/155T^?G?I.OZCG5*80OG:F=W
M,/RJO==WK&QE[_53T9^WQ3GD\.X(_>)GQSEQAT^K].GP7';23*9-[P=H$_B&
MG2%3[Y:82<O99OB.&2+SHA-\YBF]G<^+BC0>2C-ZH06G0'X].U-U50H;Q#&V
M\/3T]#,#)=YI-GE=H8SANKI.VN_QFP0MRA(ZD.L&4P JD-PI624D,]5R9YY/
M:FE$7#T^>_J;&Y^%.-DXD"S:P)NVUT'$3.PB^B]+<O8QK<UL87O_V-.)%K*X
ME]'^0?2S7.+ S=)&J6V3Q&I[ANIU*(]366)?37N%6#S^J<*BN6'##'8R \S=
MMS7^3?)IK+PN+E"A9]@UO][U?NT6(Z^R5E>CQ3KA$U+(<]TGRO2_OS+B' S=
M!3XWQEP12NJJFQ'ED]4F;UP^ H^0UX55Y8TY&==ZPZ_'CX\Z\!\\'\KQ:!:)
M);%)E5I:>G+'IDEW,8LSG&HO34*Z*LW9L:X7XA>#XH03//(;OTM9^H5IXVG+
M4!P@_34<2J,R&I:1>:>'X[S[E/N'I(9VG<_J^2W,,7_KUI*7C]):<KAI+7D^
M#1J;UI)OD'YZ4^:+*SH0I&O7,PEUQPGYV[26/"0_E;2$HI6E*M-/CP]^=;"_
MW]M]>?A9N%?E?7"O;LT.O>H--4?5?G[)6MDTE41WC=\?] [V;'))L59:5R*/
M-TR-[;X(8$TELY-T+,&6^[DSG5V1B.V7ER]Z]L?QR21Z[C5>;Q(]PZ^9Z/E[
M#ME?>.6O+U,'3\J[Z^ K1O0Y6V%B;@Y% +8E^C(HS#Y25NBYO\H'YI*F5:N\
MKIFCTYW3T]-FBY69A1,-6I<NJ^10S1HTB@])-WV#I-%M<M=(:/V%DO@73%#<
MF9EXWA+MY3."]$+/(JC=FF*@MZ68O ]K O"GUF]O 5C= _"9)?^@LO_ 1--]
M@_>7+Y]#_?X#V1MXE^JF/7L/[&\3$#5>G*GA"O0,%X6X8]1$-1+.<,W80\1U
MO]CQ8R& VWNA4&>EFOY(>N 1@YM&S7W_B.,1@_%K[%$(\;MH;$([K-G;[PT"
MS%]<"+"]%@7BCH&$1I34W[>="!TC"A^,7V![:NG_F^;Y1.<$#% I$OJP/8SV
MVWB(7C2J);'<?#H+[]D$^F5'T$>$;3;.M_KE6XC"Z^:E'3.!/,/)\JZ3C%=D
MN_#L'Q-I O1 8B_;>\UPH6CVYK:%A1H.#ZU>7H*'K6(%J7DT'?.$'0$V8QS@
MGU=O'H?.XJ4:CUOG-MX 1(N6/"KB\=72N.IF3$+.PAM&%KKHPG#E06(6'(&$
MY0*7=Q=%*J:X@Z%P9YHD\<8^[ 2"I=V&*;4 MCT?1Y=^K6W=96/S_7WF(D*I
MIP%$Z#S;PD&'LA#<!VSCR9BE^W6  $KMF^<&[M4$0E[,<VC_>-Y*ZG><,7)=
M=2AG-=Z>"Z":R'M:<\=Y,> /WK=- !.H.CUY,N-B<;H;"K!OI]SW73P4UBMY
M'(9Y0"HYL QA7:3EQY8VQ= -6U,["D+/T:$#@TR$ 4:6_G">K:GXRP %7-%I
M]UZ*E/6B$["9]- ?!E/<ZLP0AOM>G0OB]:BK==OM&N7Y4'UCR]X\+AS<TQ!K
MUPL5@$X["0[!26BG5/+1N@B,*\6B*A(X[Y(KJ *X\K7<,@,Q:0 4K4=G\H!-
MR$M%4<16M?)]GEZH.E 5Q? J M<J0+ 5:1OKC"P; KV8U:5\^G"D1G>@PBTP
M3Q<H/=X(FVJ4FR'&USD  ] 8_*:%'66QOSJ_[GSU*4#YZ;\_O#U7NB/=T_?G
M?(F>>4QVN4/$.+F*V<20_(BIXO /[(2/,2G>6+":49HC#\L6X3).9W4!Y)I+
MP"/KJW%7O(?Z6K/#0V:4RW#D.S"6*X:+R"/TTTTQ)(G,X;@N]9S1O9E,D"<R
MS<2'#PYSAQ5MC71>(21CC+UD_-$!W5I6@YN$_> TJT.!;ME*A\B/[P. AFZ'
M)B/TPJ,_VE\E(LTBGOMLA@;.WU^MA_1SBS?]MV[9.7J4EIVCPTW+SK-I?-FT
M['SA.),#WV(>O\FF<$PX]%TWG.#3+#JNIW3?:+@[&+*>9^7%)0\F342O+[E&
M*3//D&;37!*M:A:/<L.%."W0((R2"4*%8-]L.<M3_'(%\NF*<8I$HBV)A%;@
MN$SCG0\Q)W8T[<@ K;_%Q?B*T[$]06>G!^(\<5K:E90R?15[U4)EUND"1.ZV
MG:N7P3N%IP@>=5Y7M=A5K()MN2GYB"MD5P>?$5VMAO>A ;BRY<J$9%6KF!82
M+$*0Y<W.'H^K?IKUSVE7Y +;'A8]^57!&O52XINB5"Z4L[B46:K6SAAWGN\-
MNUU@D\NN_?K\E]F+%G51UG%FWP/6('YV=.$5R[CLE<P8N>'8RAJG IL2VQ;
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M[;BZH75I#4W7R>NC?T07 C:?9I?IS(RXL+38.13<1K^%W..BRAT>_<7)F44
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MZJQ*E7M#ATR$/ Q^3L];X;Q(F7QIVAZD0.5&$B,/E[6'V']I5XUL7^">!X\
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M+-)J]J^2\<=%3@X(_?@J':45B>OC1X[?C&Y<!MO))D\FJ0GE6RY5+[I))$=
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M*;\0JS]$P]!EO0M1")=<0_U+Q*V:3'X_@[+"TL336D#+\R7\G< [FIE[2!1
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MLLC0W9Q8",E"(&87N?V,?E'0+9OGV<2CEBSVYG,G'M?-X^!@%$L>N<.URI7
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MW-A=;PGGE.+F\!%M(IVMXE]8,#PZ[&EE\."U((XU+K:8A0[_B6\&NV$6K,#
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M7#'+?IM)ZM#)4X^Q60-&TD)PH$"D.S_22/2 54(E6D^(<JEXSV8*<['Z,B0
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M\V+2X5ZZ1RD9^\ <Y/+"XUC0\ND!JG&BLJ82T'NOC3)BQ_Q,G#!R(J9%:\X
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MA"PQ73DO/N92H=(UKD-Q6!S'8'NV*QT-E-0']+^K",)P?1S-L!R_<*8H$P@
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M]LG8FW9/ZP07"KQE&$8H\4F&CSV293W2',]R,"S+Y:#&"85V\Z ?9#RFK$2
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M/O$5.P6AX-A//I3SXB-$?^8LX.!2%R)X[%K['9OQ[1G1@"9TP&AH<WHKCLR
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MN0/*P2U@&DZ( )->]7061"?Q:%28Y\1+D+$ %TJEB?E9W%K_BI,?MO4V'XU
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M_ +> Y<DI8U7$*Y!5L:]^G>>9L%HON6+1<N\"3)XAW<W )PNT/%'X:8BM<+
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ML8EO.#L*MWEZAF118W^+&C>ZR\!4M2T_5]"&BQ?H 0GXI8LO?UR].W$&@"6
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M;7-ZS5]>D "6I"0GN#2L;ZI2F,MD=$VKK4LQJ ,55RANG/WR;*2,]7C)BJ,
M#W"GJ95G@2YC]X68$4&#8$R%+(E4C5@DC8*DOLTFJK"K*).\HOSB%SHL*1EX
M7]/5[65T)QK5*H3+5+$#B1R]JWMTM9N-3M&D2UW<3J.M>UN9O++T95E4$0"8
MYS87=%>#OV$AGW&I@#I/4Z-8;B7"S%8%J>#F:ZWFV54FIE;GK75BO57INU]
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MC*'%2-UN-5<Y+)"<%NQQ,F$+J]#T4Z#["*FV,-E5;SMRU>@Y]"H.9!=4#$N
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M2E\T2%]D%E&G[6)G4EI(&DD3<<N.4H.MDL$3<BPW65(JS=-GJ#.. 7LJ73#
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MARX-]:#_M-;X+;3G"JVA#/4O*Z.D?UD9)8/+RB@97%9&R>!B,DK>:^\+0._
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M+3$/$Q(L_MPN8TN/&HFA822J7R1>F5"[?\0*W3KPAI3PX1\\T_04/DBOKA_
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M6DE989;#@PB5'?D*Z4^5:>\!*LE\=@4F7NIC2[@^6EJ9:Z5X"'+:V%/_J !
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M;:-/$;9O].Z3=/F2.M&L>#FM#G$&!)!SZAWDK:\%P#FG7O,!UDZ]F\/C$+6
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M3;5&74]1N/-M7OHSV)K%UHSZ>1JC8Z70P_MH7,^<?0>W(#3FC9C4*)0$H!>
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M"?<9*)^9)U\<(L]7R;[S ^,+0^65E,GDWV\;(9]>UF2HV6DN;-G&!AWKASC
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MIH"EY(KT)$V:R+3TATVLP5RG.Z620)->0FH.'QRU"1U!9MPO17E<2CVX'91
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MO1/YQ"YC=15E"M/&DOGER E+#EA)NGF=2?N'/%_G'-G9ZT=)/PM?.$D'-N7
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M_[WUZ]UOG__7^OS;W2^?[MY]_NGC+Y].(\_@TQ.Z3;8>4"D[/EN1AIX".;V
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M54I=D BTEN]L2<#F,O%'M_8H>Z0.)+O=7QY[:=OK6=]W@C,\,3##SQ'R!%^
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MC?4R&3$B OZ7 L<"J#$P0;CV;R(P1ZH"TY/)B%7+D!9G["R.EX*4+^9)0:"
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MU;> ]!!N*A$>!%\3K"PU@2<NOD4\>7VW08,CWAAVY!;^!.J]TBI6\0+5MXO
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M]0 OLAY@J89_Q+$57;R"4 OFL LNXV%VNXI<4 5U$N@)"DM"_!-M3F<RHDR
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MS..;["M9<&0K*.8'L82V;@56C\8%XJL&@7_RS.L9#>V^B)51*_2 ,F8FIR6
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M3;7G#H]2CEF(7O&06H.DKK>6:5>F'BV_-UIN@D[QP?RKG$'GI_)!/)\MPB!
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M%U\EQBCQN4\O8S41^'BC1T ]65%X8/7_S4S,-A;9;F]KSRX,*?61\IC+&^%
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MYGIW(X0K2R@[SJHT,IT!CS'/<A)\^+S*.;79TF*RZ-SR4](THQC]S:08&=2
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MFYX?':"9RM_FS^0V T][;"DL\+K!%.^5"2H2S)\NY1I9"36ZB*8,,@QN8S'
M"?MMS&\VSBS*T9L^!T<-RG90Y>!H76L-72\SM0IPJ7Z;6 )R,9/1Y"@J4"9T
M>4X<>&]"_CZ&0T?D<VOY ,6+P+#Q(CBMPS9[*,1G.0@)!45@*)C'!/,?#8>)
M&[?RRI754N_NM.U\S6F2Q>-\AC0#GK)F*">XY3#M).N# Z7[BP.U]5IVK3RA
M8,^ C H)6D>468?)#RG[X;=[K'=R<0N[R*HV^.[VT7:"4^0E@C]CFI_F28/W
MAP0F#+5:P8Z1,!5=1XZXMTS(-NFF&$[\#0YW*O!N7@TB,M=:.924<9)RKP_D
MMRMB9:?#^DAL$8]BYDQ&^E9*[1J/(Q])NVTZ^R,0@7]5$;PI)_<:#>81&6Q$
MK4M](\W0X;\CE7&<L#B69'B*;,"?C:6&2/U@9^V_%HV@^T_T+))4X*@V8G<;
M7X)?3 KH!9"QW][>=E)#C=^!$_#DADHG^%,*M4@U@C]3LGOEG9*,?2Y=/7.(
M;>%2@O%OEEZO&($NAQ/GQK**2S(^ O%/*7[>Z_&1$3A,Z+W6\:.D0C06K#&+
M-G@^WK!I;G1V$PW%N8\#E8@'E.-4]=\B;W7,:HK.KGAU*-450;8',3JLSTF[
M^S@"<2&*0X\/WL.Z8BO793E^^]MO*+>@GCM7V<VJ[%\F7Y8;(I1KE!$X=O<=
MS4JZLN0V**Y!HP%.I:NG*UCX09U&$B&_F%0\M6W/,Z+54%]<A>^%+O,2E-0.
M2MI=@I*6H*2% "4]DF'#<4;3E=Q<1 53"+5?9E*=0<F7J%=:7@I#[> UZ1%]
MZSQ;/88TQ@LZRA.GUI$T^22K%%M./[/9U>ODDH X91GUVN!2U"Y>7F38,?WA
M,VWMV*7HZM$U[$[H$;@9Y@YVO'FF8,=))SBOX&[N)QA2=\VLGSO^M+WQ7!MR
M<?0QZ'8[P7]_V3^].+G8OSCY^U&P?WJ(?_B@_WUX<G[PX=/YE[.C\V#__:<O
M%\''_;/_.KH(SD[._^NE1JKNZ=L<2^SF@%IN]B;65S]+BJ^+9C6#HU$57$L9
M5WE&*:4*ZQK2GH!P>KH. A]"SQZS(U0G.8K^B>"@B2*Y#,^^9,-CA&NDBB[%
M-R""OF1="4^YBC4MUH]OXF$V'C'[C\;).)<.RA7A!:-H:")K!D&0XZ;T*]+
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MIN^-_7#F!C6_MMPEOYD&&01H932CQJ$:I+1EO&&:]<-;3RA<!:R7"5GI'3<
M+J4;1KU%;)%X"<,DOI'*O(AZELD%C@:5Q'QJ?H]3]UF+QWJ[>6=XX@DW]Y%^
M]W-#5_:6T)4E=.7GAJ[<,UCY(?E7E?0Q.94O7J#R=U!X:8U%8'I44-N8NU;*
ME)"@$_S>6_7M&H.0]>XQ[BSD9(&=P-[0VX).\!U6^C,)SP%<]4FYB)+CS(PR
M>+'DK*9*3P@.+)7(<"$HLNG;>*J&;MF@Q2BOB[UM[;I#(8+;&$O*Y=5^DK>
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MYF(G>F#700133[YB<1MB'\//8976:M^G@&U&X$WM#Z]Q6RQZ60V%YY?8'<%
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M:1>,YJ"&#OTJC[7C,K++]*QKTC*"J' "%]*$&B,:G:#UF/HUM_X^NO6@ZN?
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MM#<F[H,GPX %JF0PZ^N=+3L:#(%XWS21\9KH..T(J6DSX1;SF$;34W[W#%5
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M)7!#/]A5[OB,=J_M&7T+EP!9( 9W,+<KCIX DG25%!KB-%SSN4Z[:XDK"7:
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M]^?)YT?KK?.31MKH>U/4V/.93>V9#_A<]QRPQ70*#VY1RD+W\M#L=(2YK</
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M=U9#\F">P=7JM(^3VE4[^>1@;6,MO_*AT6^DNOUC-:GYC_(4LO(QGAE6KP[
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M5[?[RR<B8C"ZPC/":&UI=F?98]$(/W6OHIB8@9CX76N!#V%]G5_A7.U/+W*
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M$($*4"$44 A*(+C@RHL&)8/G&:\RM(@=N2.X+ 6XS"^F%<%EIN RIKEDF)F
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M=EBT6 Y[AN &)\IAXPQQFD(,-*$44$&0-^P(!HXJR)16K#B2AU=IJ(A-)ML
M#+GN6;6<Q\1^JM'1^#5@Q:1*]#B@F):>&H_B/I+OQ\IP2Z$83Z$$C"D,*","
M:*4)T%)CY10S*D4KZUQ,=C:+#!\9_K<,G]F,$JX<S02GRJ1:<,L@%M)8B@6'
M#V?X:.+,$@W&G+K2,:\&6 L<EQ90!RWPE R!S3+*K:+,*NU-'$96450!(B(\
M!A&8QHY*PH3QB,"L_U-:#A7*,@6I$(] A,CT#V3ZK^-^#:LP-@P(QU) 4Z:
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M-CY$03#'D@=#7<"!T\ 90%A)X@I>UQ&O'Z_BU7HB*'$<69(PXEIXI#$VB-)
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MP"ZGP/(%7Q,Q6$K-!? )3KD)GT%.*(VH<%0Y$A/LS9-=76J6BQ0HQT!A@,(
MA0'6I_SP6HV@U#6M4EV8JT/$QK$HHT J\("XSQ5.G&+DC?-)*:L432NH:RK
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M>5VBX1STBC*Q)+H.KJ*+)TTY0 EIKG,+L&0 75JCD)P [5^Y$,!<)S]<(E.
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MZ_^ZN_#FA BG$]FUHQ4\V'EOT,[\^;0?.W;8_A1_^]P.P].G!->R;.:+8X;
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M*D:DO1$H"4"\U8099\!^:TG]PYG'!>_;6S-U7W@O76%^ .KSL38NN*6<(Q/
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M6YJMWH_T%@MF%E$12Q8Y\D1SQ$UTR"024'""4:Y$@O_EM$ I?J3=QT:XM[<
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M_;BC???D#EWKEVA.OZ:MA>ZKC?2:A)T6Y5[I _L0ULPD\=HGEX0WV?'L\H^
M+(D616F]CH0'GJ=V$M(2U[B?)_A[0$W]VR+U$3J5%:GQ&)F"16H\CC5T6=%.
M35"<(24<15PHC9S5 G&"C5>&!E"7<]&DNJ8':1$::RLTMJ0;?1$6ZV%#32H%
M@F/.Q(2,S_69B5ID@\?(>Q>C5D)*2G-(3- E4EBVJHWA YI5AW%8#PJ^?F@8
MF%:9\)]6%AXK,\%^AIE@W9.]2ZXIPG2%PO3+8IO &&%SDT?$YOP"QP2RFE+D
M3'94Z:BE4D]VJ6EI5>9_%7GP./._BCRX/WDP9XF)K"8$;1 W6;G2%B.C,$>*
M!:Y"PC;E-H)4M01;C$87>5"LJX>8]57DP?W)@SECBWA.D@1C2]7^W!RBMAH'
M9$)BRECAC&SF@Q)IUET>;$00J[[0T^Q&:/O;A+6FME<"F%2_C"VP7!GV*0Z6
M-\%6&>!B2WB=?JK[;85#X/K$V3W_GU%[T*X',E:]!&PXM-V3MNO$R@X&<;C]
M6;*BI,BN::WBO(;Q:M3WIW80C]+^)9?NU4SZK /,VD[M&/8&^Q-!.JMT%+UB
M&;WBZX+?(4;B Y4<,9.-#9T\,E@0)",&4](P%G/6:^D0L5T8OH=DUX+AA\/P
MG*] !0KHC1(%SCGBBA-D;,1(<TYHQ#:RE"L-2\>F=;+YUZ*!9@'QXX%XSL!/
MD7%!N4 )ZXBX9099EQQ*VE-+ ^A<>9@ $VP]4+P1-OQ2!M)Y/P=+AQ>MZKQC
MN\.ZNC#"1\YS)O>VM'"1J_ \W&=-]SIH1_=JX;P:L]FKS&1[W?!BPF)%PJY4
MPN(%4R=HDY0A$A$)!@Y/F"/'C$6",(*5=LPJ^V27TMO'4]8BD6P[,7BO%DK!
MX(-A<'ZZM< DA. 0,2[GII.$G/(6N<ADI%HR2MR37;/80Z% <+OLB[M#L(09
M5XG/.2O$N,2"31%A1L *"4XC&XU QH#ZDP2C,>J<TXG-[;T))7/SVW8(K+"&
M8KM; 3G1I(%D:G=MU[=MYV>)UZ@2K]DX:Z9N1O5GKWL"/'16/$7W(*/)@AW#
MDY:&DCQ2-G#$8V[K+6BN71:!*9N,)!ATJ/7P$Q48;X)!5&#\ #">[P]II= X
ME^1R8Q&WGB,CA4<A8"H)YYI(8,<?&4Y88/R3!6T*C!\ QGX^^*JU)T*B:$E
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M=CJ@K)/?S4P0VH.:)&<-5X"0 F'9'674Y+>;HZ81<W!NG6=P9.(!Z\Q*U*S
M7LK'_.;>H&W1*^LSUV68-P?RK3<H+.P0K-AG924+\VZXNEO5Y1-4M6NI5FJS
M4M"M]D8G0.[LD* [U9Z'4R0?I9V+5H9_0Q,^<5]\:WE7KFLOEU;?'#[;C\U4
MV>E"?IG1P1_<-W,\L[R]R9+N<177<]U4,KZ]%*/7KNP*Z?N@;+:S>I5UJ3K$
M,KB.XQHF. /;.T<1VE\OS<[O\N$5>VK*;6?V8Y8+(&RN[.YD1G;^R!6.@%N-
MSO-?_Y\; Z:C09@+F(KDDN)*,9T,=YQK'KV,W"4IG,9-P)02S.8"IF+13734
MC: 8#K('-M]W\*K?^]3.NOSM8J;RIW,6O:!PO8O##Q[6_/$SW/^]XYHR%RQR
M7 K$;7#("D\1=31%;)USFN3Q8#OBAG8]9XV!,^$U>P+,=)+EE:VM!-]O.^ M
M!SS[>9OT.YJ=/;-0R/Z/""MIYSA&-N0:D>AC^U/C7Y@>/B [E\%+H(P*IKB6
MBG#GJ=$X.&TC)BD$$=G8H\K&'M6;@=-U7YY.L +G#*BF9^W:VAZ,YSL6V-P"
M-E^ROS4PK%@P!B6 #.(22^1@0Y )VF$BC U8/-G]/FK&DA7HW@& Y(.]!E&W
M"_:NCY=JQ:6LGC$%9\_^6C7YLVV[O[=[-?/=*/9K+>AB?-A?8>!+7K57#/)E
M.-5Q..M<+OK6EA.,-9,Z664LA3<H)V-.%1-.%853[Y-3OQX\?_%>:V*,#QID
M>_*YC[U!1D2,6 S,D)SV'7(CZ9W%AD$+\AWV^L/80=9P7.:R["KLQ(GB\0D,
MU^Q6LP&4![!W^W5J DCC>#X87Z(;YZ[PN5V[=A!H$F.#[ IS;Y,KMLYON'IL
M 'GA=)P>':!,C9'X T!\@"/CH-V)@V&O&\>(?'O>Z[[."S\?'J5G8^?RF^$H
M7+R.Y[W^;?/8?G+(XJ/G;]\;$9C35"'C01/C)NMD2C 4\I%#E5(A<=#);@/9
M.1RFF%W6H)C8.OFH<WG^9-_TIG';FPBK"*\;]UFO?[&77?&?,B\51OLNHQ'X
M_7URD7!K'7)".V T3I%602%GH\R%I08;\V17?)?11N?9!5 -Z@V9.#1A1YKH
M"&S)F+\:LQ1EY@'S-FL[DSA-9M7N1?5AU&\/0MO/AD\_]_J=,-:H+V;<Q3M7
MU9?V(/LGVL-.8\E>RM *]"J4728@6P/(V&$U;-=>C'[OPG:&%Y6SXPA7-PZK
M@<U!G=M8T,V*OID*<2=<3)'PNEY@.PXN?02O:D?E%?Z&,\@_#:,^4"D,8O>G
M8^H#?OC\!#Z_QPZ^@O0\]N^-BTE@G$ 7QQQQZA-R"50?YRS1+$2!\^0,@M%%
MM/WY!(:Q+[CQJC3#^L8N<M_K9]]?KPE#U2'0*@<6,[,T7#/FE8FFO5?ST7/@
MP]J/.,T0:C)"TV@XZL>I:^4S,&7.)<W)I?U1;3)[FZ,QM>.]WSXY@97EZ%SC
MNCZUGYJ/][P?P<K"MAG70+Z9%-J;?&9S%@S*<T0G<<E9?UKC0IM81C,^M%9U
M9KNCE ^<?FQ=XTVK \XY0-8>WMZ]=B5\G7UXLUX[X!K;FI62.7B<Z35H-6=S
M]ODMRM!Q5-T"FXQOG$5%7LY5EUR_SH6P*;4[[1R,WZG@2!W$_XS@WMGG.U[\
M)/Z?>2M?/(MND,29\2[F)&NW?L39.\.*?!S4#.YBYDKXMN^,0A:D_:G/>NN8
M\EO>\3K8.G6EVK$W_](MGH] V%G?L>TSV)\3. %!A-1!\SJ-)7-[D]^0]V\<
M9ZB/L.E6SN67SN50W2^!R_<>]'MSZ>?;G.ZO;D[W+XG[ZY[^OKV)^]=FJ'XW
MXW0^0Y6%X*D,S%+/=20Z10E?=<HE1B6V-P)QW;()\O'4S5EMU_J:EXQ*3A*!
M0&MHD@%GLH":(_":#*/)ERS0%TT2!NL4I3K?$[[R[!2^T.2UU$=J5ENZX[2:
MP?:H(K78O.+(G]FGN2#]9-M.V^=7=@Y4S1MR/D&)RUO1:#$NVQRUH6YS2MC)
M&8(KI3IO[RQ_#I951X7/89]JN^3*+IS9#[VY76CE3X^Y98%3XG61CF_G<S;/
M^4?.&X4-;V[]RQGH5IU\\?IUJ_J?'JSW_\*/5G5LVY]MMU&T#RQ86/]H56]Z
M(R#,_^W!1> %/)L]S^EP^2/'I[:=K[1-BFP&]@2_M?MYZFZ_5/!OS&NI+8&Q
ML=,:;V 73 @W&L891@ V[,-5Z^_#MVYT)@ZR@WB^;SUGE&.%B9$6S/>HB2 <
M4Y:29L)+\YTHTO[ARUDORF&=QG.4FMRVUV">-=[0[.7,[FF0'6]&Y]E#':_Q
MK'1'9Y>>E;'C$/]T/I89Q^'7%_#OP7N=E Y,6V2$(8@[FY 65"-+K/9$>U/W
M/$R@IBYX#B>.CY,FU[!_94.J0;,C\PFC3:KH\.)\[+YNQ'X<#6N7V^4Y45<@
M@!E:IQ7G?-1I9O@5AJ]-M4&SZS6[@X%O+Y/ QRL[/\U6V_[^_G5KS"=674)0
M+Z<;_<=)"OLU\JB6NSFQ-S:V<55?#"[JJUH -*=F\\1G.2OZ/,>!YK-CO_G@
MVR:?ILE2F6"7F9IVZOF9376>AJZ7BEM$[R,&B0*:F>,$>%>2R&E0) 0EA1%S
M@F:AA8.\&K>8B5E>>JC>GJ<^W'(<M7@]7F>)4-Q"T-###R?OA:)*6Z*1 ,4;
M<24-LB8&^.&#YB(2 M3<I=\/4-3;<!GNJE7,ZP,&33Y;#H9=9C(!\RV5!9&,
M(5Q(3T0>O8)=C$%;3*70D1O-Q_EM\\D/M^"F5[ULL "V+L-ADWR(P7'O]UC8
M:PGV8@=?_7NJ&5$&*Q03P8@SDI!)6*(4I, TB&BT _;Z+G_!87 ^V9NQ 7A2
M2ZGOVT5GDZV\# 7L5+.% ],#ZX8L@2:<U<IQKG%3#]3$N?J3^-&M0EQ-:G'&
M0NSW<]5&.[N.KQR;:33V3G__J>! S5>[#(I<35>:W.*B-3G4KC[NQ(3.CWG'
MF^9O-$;@2<R%+N>G[8VL%OJ1]/\FB:PI^;+G=5'.1*%_WM^I_LA%>:].,PN?
M#W*@XAD8.R W+B.OH!?'_J?V($<A?N_9?MBV3)PK-O0B27)*YYAN,2Q09\RQ
M_U^N(9S2R=5TNOJ1ZI=Q#OPCI</7S[JPF0^9"D_QE53XY_TID0>CW*(H1X[^
MM& 7 'L^ZW5#[PR^WJH^GV8Y-VQGA\:T<GB!+6N'<$5(E4.ZM6S+3H/&ZU$P
M/\'\[SF<^K^PS->G[0_=!O#MF*J7EVV(CG+59FQ2E\_BI/RE,9"B']71J&L9
M?#@UI]JU$PCVHSNQERZ-J\>*7EWOR/V^8_;!D''4K?Z9BR=G4P0N:3O9T_#]
M/6U5![_OM5:ZLX]5PE/3Y<7EVAY;8AW X3"%3NT5K0O?/\4\1??<NER=WFY4
MC['_8-K="PX->S(V6]UHD'VF@P5UYKR.)?O:M*^5R(5$A,&5C3GOQW/;C].D
MAMP")6<^="QPRVE=MY9[(C0Y69?1_EE?QMB3D2\PU06O=6K\DHM&7^^]0XS0
M?[2F(8XK3P%?ON)T:92[R;*F+I:);V>F"/C[GIV=ZG_BS%F1CX_V^7F$\WOD
MLJQISHJ<9WR>E]7[W&T.C%,P\_J]NE+_VZB8X[4)2IJC14]/ED$^>WR<E&.-
MMV-ZRBQ(M6NY5<-_/]#_Z'IV?4#U;,._5]XL;S[>FS]ABH=>34='63HZ;DQZ
MQ?8FAGR+'>ZIZ1Y]X*9[?\1N#KS-]-C;<[W1\%)U>G/9L':=>N^]F[2@;K_[
MZOGAV0MR],<!.3C>QT=__?/#N^-W].\_7EP<_?'VR\'96WQP]K^GN9WT%8?R
MV3\_P+WHN^.W_-U7^-R'?XEW9X>GAQ_^AGOM\[^/7US\??ROB[__>OGQWU]/
M8!UOWROK) W>(T=X#H8JAIP5'F&LF%0TA(3]?%I0,D)JQXVV6'.%N15,:L5=
MBEH!B^+YWGOC_:AF-J1576Y"1EE61#OMNA%35F=_MX-VK:_.=J1;=;N^[S_%
MU:?.A4T)3 @GDN/"6H>=\M)%@5E4/,\LOW<FOZ394=I_^?K-E&H_)?.^>V]
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MYIHFAHTCK.*H&52+516C;\6F^SOF/JE_31(T]^K\S':_W6F_?3XXMHG'8(U
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M<NBB<N;/MECR@VYQ,=;.JNG^AC] 2KN3"&QN]=TT$&GK(1\X8&OK4ZQ>D+S
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M.:T%(DH;:4B@#'_+7@<ME+10TL;0'B%,+,30) /MD%F'8!4CXHXQI)U4B-&
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MA/]'ZD' N3$)-H]BEA"NI&(NJ3;^L;6 L1C_P#%&3@S-E;0YNRI89*2W2)+
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M*HFG3''GC0'=C28-OP5B$^AMUX;;;DCA:U%PDRCX9BGN1B-.W">%?+(*K,5
MD&52($,=2QA[80Q>R8:W=HK>(VE:???1;(@ <WN%?YTN/XHPZQDF1##. W>1
M@QJ$A;!@5BFA'D$$K+79-@(@2^18SA$6B4?$LH"X5Q$Y8@(B.C CF ["?\N&
M'RV4M%#25OH\0IA8U#.LRH3;$E%+'.)8,61I<@A;IJA2DD7S+7M^M##1PD0;
MT]H:]%AB_^)4N6 L6"F9LQOG.D'&(C+2&FT%#7KS=8(M>K3HT<:8MA]*%F),
M."D3O2/(@\J!.(4?6G&*8(6Y5<I9F>G_6RCYOJ%D';]G4)A+SU0RCO$4O<64
M8AN=#YXZ$^3U09_6[WE_?L_%Z(\VWA0"(5BE7'"@9*YPBLCKY+6/3@C)ML+Q
MN4UU3VT+D/6@!;:BLDYJ+3V<3EPY%9VS<(2![1RI3VU(Y<&AY>U22,68$$&-
M( CCC"R:)60<=<@;AP-CCABAG[V UUO:\2<EK#1:8W*).^::!QU-2II@3RU6
M26A\E[RU:Z6V+0=Z4!%?#'H(X9(1$:-(O,S]?B*RTC)$1&"&)6D"<\]>$$%;
M$7_T(OY()+RMJ/EVTKMP0$=#G>0!(T-9[B7 #=+$,Q2-8"%P3V/IUO6(>(HW
M+<!K7.,QB^X]G\XMP=A#2_)B7$ IE[/-,DV)PJ!JPP_#L$>.2*<=,]F2?_9B
MF3-@Z11NI6M;I.N+_>FMJ*TG:HO<7E(%%5Q .*2 X/0,R*:8 _@\B)"\C(G?
MOZ@]*4UTK61;'*C45CO/ N<Z.)"IP F3R03#:.MT?@PRM.1T9IX1[F5 3@$2
M<BX8<D)8)(3 A"=G.///7DAV!S%ZBNTQ0O?#O5;V['D_OAB?VU$,("27 Y"3
MXD&YD7AK(^,3NUHT0RS7>MX=P1?\K2CQ,QB)Q1/T?!!AX-T/\><<6$!LE^0+
M+LRL@W,S7^'9B\X/9+J%RCQ_96QO:\NYUD%9DN!L\TRI*#!7F+J$N4LL.&,5
MEC&V_O<'1UF_W!^$*R8)& 74N8BX"P"W.''$8Z3$. %JJ@;SGNN-AO8>L)+S
MSH/94%C_NQ#]*#4%"S*DA!6W3#CBG)?8,X:QP3JTWORM!8Q%;[X4C$N3:8LU
MLYDQ@R+-(T:*"!RC,)(E_[7>_!8PMA$P'@E>M+&!;X<%"\H#"8$D+'EN$1YR
M%T.>V8\E(L(YS)C#ENI5L8''7Q+>(E"+0&U%Q+;BU%)K%1.93M8A&;)I$VQ"
M&G..O$^1!BFQ9#>T1F[1JD6K[P:MV@J,!X:NQ4B2%BX8*1#L(9Z3IS1R@G"4
M'!4I<6QBV&J6KQ:ZMA&ZUO$-\:0MYYBKI"S/_(0 6"X$+ZTW/AG?!M\> >PL
M!=^,#5QJ(I#76"/N,$7.)X>8=ACT)T,-S\$WL]F2C_OGW7I4%1^KA0V.Y'OH
M<^/ZHU'_8JGHYBF@U5I=<"P#B\ &YS&G)!KK(DV2PM8W@5/1=L%Y*(PZ60I=
M*3A8F 35R/, JA'U%CGM*"(&$T(MJ$I./GM!Y'+IR.-7BS8HF_=+C?K%0]T
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MUO[,/I!JN65")Z#[7OOR V/N:%IF#T9U/)_S8F<C.LBC\<%L3GM[)_[7ZU3
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MT,8Y0!M2]#N[^H%3U\E2[&-'KC1LNZ2W!VT-HW)V^K^-62,K)4X#&"2(SND
M.K5NC,&Y(*W614OUF2G;G7ONE'N.E_SWK =HJ#8*6]E@ $=)("HGM - '?@Y
MVT4Y!3AW_0AC[ZZZ02#.*CHI/91L(Y@42"<?)0L>QG%,677__1:B>^"_!TF)
M=<0@HDQL)1A9!45;A'$4=?8E9]NB<WZYRKUC>].P?;O0[L4*=XCB@3O?@*^8
M(8H 63&*,W^'((7T*8%*VIC@-[&9<H?SQL*Y^_0W#O0#GWXL-FAR1<14H@!L
M+?>B0^$@&E>SI>C77EO00?\M@K[[].\*\@.?OL^^#1(#$;1. K0J@ESP(A:
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M31609184LQ=:Q9BI>J=+Z8B_OXA'U#59"TI6#4;7X&O4&6TV/E6;?/?A;QB
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M%W.=/(9OC(""\MDAQN1-A-:L$:)GBQ@!O4\V]P&TV\-,Q\/<)=#>VBH\4Y$
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M=(A$AG\ U"7;;#=B,G7GL'5RV"!NYE.*VE56O'1LLR^9PZ*J47CEE&FOZ!:
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M_Y'\^!:*L\D>*P&7ON4<"!(S;IG>$E07*1$_"(4#!?G<U[;*$\W*LRKIE0\
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M!70*^ H* #(Z.\HQL;F@"E(LNCJ=:L0V%*E3P.U3P/-_?$H!Y+0FYFE!I(,
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M*:)YM60/VU2M08A"4J5&-$&$2'QT;<W!EZQ3#CN[;C/*F.XMX.[6 .[%\W>
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M5Y)A >;@ +_Y+G+]10*)L9HIX;+2,0'7VGK$ <ND2J"HT*P6W_,!)%\FL_E
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M#'',2L*=YYG'""6];X$*3<<;"J!A_,(*2[=ZL=5QO;-&O^#>L%8\_'!Y%>]
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M*0V%8JT%WD?&L4DM4$744+0CNG3[!HB16$51QK'B/3>HRF2QM/K@CL(U1RX
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M().U+H9D6)8:S23*AG5R&@TB32Y>U*&QIX;<,!$:"P8H<*,(]2$4GV$DCKE
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MB*Z8W__R89WL,K ?9F(OWL+[.DK5W[.$Z,WS?J.;5[_[LG>*YBYP:/KJ-@[
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MG(MN9J:W%M,IA%T3IBLA+-7NLQL1:EN:X_76H"A6<!XUT3+E&*X-TXO6CVY
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M:V5-_5*XUIHK[X0#)877FOXLJ+,W6633>M:6%"D+O!UZ(V6)@EF;! /I#4-
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MTS07 E?<!I8Q90:21X:95'DLV629<G+:=327MS?:C-A.)?R"[X008P$;,L]
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MT$5O)3AM"FK4MK%:RPK !58K:&^-"))Q(U/MOPDL"$4HY*E4-S9K8UN ^2
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MV13)?50DEZTZYL:#<S&K J#1:4OZ0I4 2DC -@AT:57$0LLD9H?1)V0H(3-
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MJ[R>6BQ 741XJD:ZG-3P>HRC,29[L)!5QN2,+U:7>NZFT;))S?))S=;S[12
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M;<?[.?9+O_*>.SA9P/K'G3Z!> <IR-X;UD_DO;G/<QQ0Y[V9RNB/5TB^CK+
M#US$WF\GP8W4(C+E1:CEJJ:>GP$L:1.ST#+J$JN(L2I2I^1LG_X:IM['_F!
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MC^_C3B:E-CK7Q_R^#LLB'Y%4XCS[=2.SLFY.^-JLK!N7LDJ,@+-!!F"NYKU
M #)O,3'27]6A+.@#O[M962EYX"1 UN@,F'3PUD$61@8, 468S<I:$)HV*^L2
M,K#U=ML)"SGRP%3BCD$HD@6,@6$&+SSY)"JGVYB5=4U=T69E74\4Z/JVK14J
MF$"!2/2Z-AYQYI.4S&=M352Q!%.KT^6Z/ST.^_Q96?<L?U"S-D?IE>,&R'E\
MU ;>WGN@O-^6!5,DB\2\,YR!SA3%1VV9,D6#DCDF&[\P\/:\<11M\NT#$!\R
MN0645LXZ"A<3.?=:68;"9I(A\L:2-BGZ<I7)MT?)DE/#Z6G39U[R+$$\S<;C
M_O[@L+=[,,%)?]S]3>IL/$MOCB^KS%HB<O6D\5W<QFBTKQD,'KUG$*VOY&1B
MV6#6PGL."BZ=B+R\+FN9L-63GD]_;&>K!8_%,( Z<@.%82$(QY1T5M*V <"5
M,F$D(/LYUD3SX'"M-ZX%=+6BIZ.X]O;HZ=&X2EU7E#<MLCLB&#M&1_'>"+ND
M1S<M:*X.UWLOCJLMUKHQ33&2#'=7T(6O/X_R'GW;K,9Z7A=T[/+-_+R9&KUL
MGJ6ZR,=52@NE'Y^OQC%QBN/>>#C]F[[\<)I=/S[@ V?G=YR3H'],&)GDT2Y=
M3_=MLW>-<ASNDJ1/&<#Q=''/!>P^?;9#Q0G$$C)==*0@E$!(12"JP-%*"!0T
MD/Z_7';G\I4!_SF^AV=T"\\^O\_-_EZM&I@K@-^F-S!NF:$+P+H>Z:"5L$%K
MR8HHD8&U@87N:#?T&B/88(-ZM#'Y.#S#(GPE$%H]8=H:3G"P*$K/]T;#P:!6
MH321^KI(;3W==MZ!-A0J):SU=4HB\^ 5,Q$P>0^J\"I2.Z-\1KIQ)C0D,SO#
MT:22F-/5GQ>.O/QQZ[__44P(SGN1@O9:74+:^2 ==DJ^._VJ:LM:?U)'G';'
M,!4*[F=U#__4PFU\>Z3>4R;#,]SO6-".^:,OZ>_N'NP-V7"OYA?>'MZCQ,:9
MQUMMXHCLH!#S0Z7.FE0^'V0^I4R%/\WP5A-X;@$%'DQH._N?SJ1ZZP3'R6%%
M%)G"Z@_4.=>?F; SJ-__/;K^U+5'3:W^]!:$7[MB@05DPW4V-A3RA46*+@BN
MZ2FO:WO83#5Q4ES3(X_K@^:9WK:^^8/3M0F*K@\WZ=XVM^)VL:XFT@1#7MNR
MDQ.L#M\@I9,#2,-3,:KV[MDU;^57*;3/!N2_^OUI!XGY2/POU%.>*4](EDXJ
M7U3-KX< %#%[HT4VTBF/)C=Y6CIY>KFUN1TQ.(B9LPS*,@@Q,I>D9=$Z#"IY
MJ[VI1;SG!<IE%J>0[OO*B7LU:JB5)4\']>0^<D?(]DU+3SK/?9>>O?S9:@$R
M2%\/O+2U*:4X+96J(H<E66E"D[IEDSK8_/1^6Y/1"1($4Z8[):L>9Q2,8-YE
M682)1:*L70GG:#$2ME,G/\YJJ-9F5:-=4<G9QGM6>3)7>+5TK#\9=(4"QX=J
M7:,\X,8,:RL/N&'9TR^W7F]K;;W.I3 ,M6]22I(]610+,EH,(9 +[RY4'K @
M>3=<)Q!,YG4N8"HI@>,JT,4E,JB\H$Y.ENEQS8O2T^H$+BH,KS]N/GN[+0J7
M@:? E-.I"D,]Y#%3^ 8J65]SM?J\,[76NB*!X\;7FR@7N*8Y:^4"UY2(3W';
M2_28!#(=@V-@>60^1<Z\D:C)4 GN:NIW7>HSJ@7ZX_'!_:X6.#IUY<A\GFK;
M>+ 'K71K<P>3'NAW+W?0RM'>S3N@3F1%Q(H>K;)\R_^5HU6^O WRR>K./%F^
MK;C(@2I?W@]US2-4[IL1.$$YGA7P'[6@[,P&SBRRC4?K_1GQ=Y4DPKP)<-QE
MPC\C(KN$:MSIYP_=!M4OG1XQ^*%F',8' PKX9JGV+L?>I=;K,_6J+G4FY ,Z
M^[ V=+>S#]O9ARMQ]N%7SS)<./O09\6MTBH7!$A2>E4/6)%(_TEA[=*=?3BN
M-6YE%F#.IRV=77'QL?8]QO=[PX^#G-Z>>T[OVC2/T:G.[F3>ZKG,IOX=[%>C
M-AZ.R..?OO>84;-3W_&^6;D?:S/_85V!_$_,^Q>P=L/>H%^F!N\+WL I&_C%
M4I5YMG-QAH5(SJ"-+EFH0U))QIW#$K0 ]$Z%67D!_;\K+Q!2W6QYP?-Y$O8O
M$IG?I[?XTU'Q^+]I&5HEP=<K";;>JI>?GFZ#EIRGX!E&1 81"_,*(Q,6O72*
M^R#=.<4I=87SZ)1(SGTI O['7 MCNR)8C#$/,NEB<H3GCNZLN.SS<0'S61>+
M<KK2,CK[^+&,/CU:C":H%Q/4M]O.&9U-D2R:V(V4$BP(3$QK@%@"!)[*V0GT
MY=/QG4\[%?%IN6#%43["43B!H\H-C==Z>8]\J.G<@=V.BIJ'-;52<_I=NVOS
MN&*&A?I\-<TI[^-H<C#*4]Q]1A^LKN&T9QK.GT=Y-C&D*S4:][X[VT/#Y((N
M4601/9@J2"9K%5(2M1L2U**'AF YV"(#N8L@BG?9B4B>7'"D+47M['SZR]/O
MSXC63BS3V9?RU:\^$;O@Z"V%+Y/A/HG1F>D7>O^D<[>/8KU:L,5HV0>X/\Z/
MYP^>I/Z8UNCP<7^O6\?N0T]FWS\+$#7]PH<\Z@8,S7ZE^\'IR[.HR?MU[V0-
MG"8C^B_-?W@64ZUW,=4/DW3&:X(^J<]]F:^+*[X&8*[TR2]=K%O77JW(M=IU
MNS+KNE)"8-:-AA6YUM426'_%;[T#@>7KRI[_\I)=++TH+W9!/W3J>ZK"R4A4
MP_7_'I$E/)GZ?RSW_^F)DY9GFA!<M!2[_90&^>+6_R?Z6!CUS['_[FOV?]I1
M?+B?CVSN[(:_<"^\WLFC"[UUJ6^[H]6[0MT'>//S8H->YYAV]1#=H^_(&<X'
MH^'X^P>X**\.)N.N!94B!IQ,E^97),=S=-BC6+O[=XU\'^#2O*CE$ND!WOBS
MVJ71G_8!]C!VR8R'N X_S\?"/\![_UPO=$J E,.S'*=MC]T3:E:/\0 7Y^71
M!-EN)68G!<TR+34\/K$F7_&7 L;W;[O)L&QVV3'F7,J364#>A?#[D]YX..BG
M7KVG)U]8I%I7<+M+=,[(UU]J1E8X=A'YN,827$"D[N<"3XDMT[59N7NVQG>!
M]+-7>6\=U^]H<>5-+2[OG;'$W9S!95CA2PYOTL#!YY1UK",_$;41:)./!8,
M4-.Z\R_0-*<;:5[5\0'/R<F9'+[8&T]&!QUO\YG]>\AM-?0]X[^WAFKSV?N/
M;[;>ZS=_/1>;6\_I^MZ(-^_^\WYS:^?=YE]_#S;_^G7P4OX\^/OWV6?^^^M.
MV$V#5^_BQU=;/^Z\VAKLO-GZXQ^Z+[J6/_LO?WG]SZM?-O_Y>_>/?][L_J'>
M_/7GX+^?GD]>]OD__]YZ/J'?H'M_OXT.1.TM8"[7"GA7C_'.TC$%T=?]CR+Q
M1QL2UO09_5__]W^$X4\6X7MC&JN#%;\XJ)K^N'O]4=";>B+Z])!<KIW)V2G'
M8TF<9$E<G.\]K4@^UQYGZI194\-)C5'Z_^3$/N71L"F+2RJ+5S^=5!91!L%Y
M$"P%&QA8M QS/8Y#&Y0:'08CIX6_0CYIVN(A:HOOED==G*TCCD[:>36JY2 /
MNZGWMA4*W>-D\_=.J?Q#]Z*WM>"&EK[.X*GCMCPB\\'19I,[HH73UB.<ZWZ<
M2B<W77*O=,FRJY*C].5E5$AS1ZZA/5Z<U!XF<9!)DC^"5L[&?,LLF8\\6&US
MCF":/])TR(5UB"C)J>2DM]Q";1(P4GN=C2<ABT;A=#K_W64_FO*XAO)X?5)Y
M@/.)]C R[H5C(+5F*'(]_49Y!6"A:-&41U,>RZ<\GA_S8$UYW)+R>'-2>?A2
MO<Q86 B\C@D.6(^\LTP*;0"#0*G2:BF/JQ>=+0MA=\2(REMCS)?EUG\]&!SV
MI+TP5[FZ]0+78A$O8=?NJY$RPF6)4+@5 %PGKR*J&(0R7B23RUWS>\U(7=%(
MO3A%[2E;P$-(S @3&8A,ULK*PEPP)GF'0@6XHHWZ=MYJ@VA?IY!*""F2TPC)
M(<H@''B9,4<O,#8*;85 N4BA>9E0%268ECDS2,4S]$8R$8P ;K34B V4#PN4
MWX"H:HB],F)/<52!MMHHQPFH,=9SD0US(,BL^HS6EY"4;':T0;810G< U05"
M*"B*85PV+"1 !EI;YBUH9M%R7HP,RNL&U>6#*D^)&Q=1U_09\(BHN_%/SKDZ
MD4HTWF6%,;K NV23M:P8=4XF"DNY9?6("):X""Y[40UJP^@#QFBC-VX?HPOT
M1E&V"&,"\SZYBE'-4-G$E$H9P2J)]BZCU*LV?*U )G]&8OCKM77=1&/1"BS6
MM$5+^NE16$N\8"O'E%Q]H2Y0&G!?+61))9K@"QJ'(*"@SC* \,[K:*/5=\VM
MM.KEZYC)S5,$"\_>.=22H7:%U9%A9"6S9(*K C[)8#A9267EF8=G7:T(X [J
MA!KDSX>\2YA-P)*=#F!+"ED6A4H+X;4W4!I7LT+X/L75>&F]DH9YRP.#:#P+
M6A068C+9^)+EE;F:AN\5:5#ZE@!O#4I+IP).D3^)VQA\-(QV.S.@/QDF1>%P
M"<GY''BVDFR\\6M2WT"'4H/_0X?_E3BD!OOKPGZ!2"K)H!0Q,ZNQPCXK%HR7
M3)KLB@LV6%7[$M=L _T*@/YRF%=U#G32.IJ<P6J+)>:B:,^S J.#;&34"N-\
M@8PB+ NK0R1[+C@#Z\C%3SFPK,G%]R5RS:]*&#>X-[@W7NN.X;[(:\E(0,^:
MQ5"K+X52S*MLF"DFI6)$#,B7$>[WI3E'\@?7FG/B$,G;N_V58YQ:A44?E(O.
M)Y^R%>!T06DT"),5#S7/ (T_6F5S]/H4?^2LR#YKRY1UM0-=%8;""1:S )&,
M(*_#/-K0_/+T42N$^I8M="5YZ;A2)@$XHUV1@LLD+.<&LKO$D6:-\[ES3)X:
M<2>L=]S7,1#",-+(=2!5T4R*4#RJ7'B(K3KQ88&R]><L$V)/]^<@EI*5885S
MS0"%9\$(SE2@H,X7F[UI+74-LJT_YPZ@NDBK6(Q&>,^D#(E!()1ZY36++LI4
M N'8-:@N(501'.HB<X&$8(6F_8D2,OS_['UY4QO)LN]747#BWC?S@F)J7^P;
M1'@&VX^)(QA[\/C /T2M(*R%J\48/OW+ZI9 2 *S")!$GXCC :3NKJ[*_.6>
MR:T%EHTOWA>MLDP?RZ@3<1%KC8O<<20U T:-QB$C)$-1"FZ5# KXM3)-7R^?
M/C"64?'I8_ET(J!!<6 F.H:<IQIQDYN?.DH0MDHKZ2AFF+P<GZY\G<Z=AG.]
M]BJ==Z?=1A,VZ\[3S%YJPQ8&]*LBG:<3D4Y+B0VWU,7 17*.4*.TE51+&D%>
MOG20I3(W'R@=OUS&5W:VOIS7][X<9M<!Y5XAF1C.[<$9,EISQ$G /@ 14%<E
M]ZPXMSNP9 B'?QF'XS86XQ"H$CI2I0VFSQ^KJ53@QS'Y*&!3,OFW0P!O8&]F
MD.):(2YPGB7"X:= 01/F#%L;<X(^71=$5$Q>,7D5^UE>YK^*_7PB]9-M<JBM
M\MH(BKC-$\E<]$A'R7(F+XCXH(5(<Y](5G'_8M7H/#_[5S4Z+\+[VV.\7_]Q
M&(&NO=0>D2@%XCHY9 C6R 8%/WMEJ"&Y1@=C5M7H+#S3W[.WH[=86>N2PX03
M[YU420K,L8DI$,6J@-2R,_NG<69GAXZ2R#VS*"D.@AX+$/04F)U'+KP3GHK$
MLYJ/0<VGE:"O>+X*;BT?S^^/\?RGBT/!<:*><129!Y4>4XVTD$#NU+G$51[S
M&!>1YW\6]BKG^+A.O]]IO6'PD- 9 *V5LWSN/.7G94,]:B9#[W7ZMEF[2^CB
MD7MPEPA0]8@7?@2=*\DOBBB;3?GW'!4GK.:,4X-=T2#.:A9BP-X2[:FR^J6#
M4)4HFT\D:E15P*W4"0N,C/ XMY.0R(0@D-&>6Y5 C=%F;9-S.7/.]0A/GU$S
MNUUXSD> S5.?KB#LN2%,2L$3\=@'';EUP22OL*$D68U3\+B*K"T;:$V60E%N
M?8Z4(VJ"1SQ%AO+D#*05YW#T.)HD;HZL5:!5@=8S@-8]8P5/B5I5.[^%@[2I
M6K%$7)*!8X19=AYBXY'6@&X8)Z&XT9)2#)AFV/TZ>U784F'+"V!+%8=\T3CD
M$%,\#=(*:U%P,H&>I"UR5G#D19)@X[M$(@'C#A#E'G'("E%6$5'N!R@1&V4
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M7F!K.7&>^+4KM\"[[,+Q/EI.F>?*!YYGLB0FO!#$J2"=,6(-C&)O3S,T=P?
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MF754Q3G>^4S6BQA(?GP,1:7]Z(KUW$4@1_91;$_5T=_5]E]P>="-_6%D\QH
MKAB%C3#D*@8(A!9SN*Y,OKC<@TN.OJQES)ODSFM->Y9I\D,WAZ7>S']_AB-2
M4#.F_ALFKX]!&MZI_%.CG5N1O$%$%_.:GFT/BSZ"\NT3JFBSGOOVVL80OJ%%
M?NU_#UJGJ#=HS3@[@/G&5*,0X/VKLR]ZL8U=^$O9*35<W0$LC5_?%EA='=A\
M#NROV"Z$_!6##4^IU_&-W TU^D$W5RS;H8ZV/E2MLA*5FX<#V^7\S&YG<'0\
M.LMN6<(]/-A"Q^LVW*"$L%_^[F<Y,3K;\0_+ UY).>H[96GW3$RSYX7243C+
M:K.(OI"T5S'\K("620D ASEC(>\C"$;X=L[#*1_6BOWCSBSQN-R;6>3WU(JF
MC;EXO7C)45;(U!8/5=>1YC+,KB@JX"^U_J&&4Z9<E*28M[C=R,D.S?-:GBQP
MF0 R4F]&M'V9Q>*!'V)WH_97UF6OLE)Z_?%,C':GC;X7D\6O#O^Z=IUUXW8M
M_C@%MHRU7RX3#8=U_I=7#1-;?\W:M>V-7NP7H(%!F8]UXP67^GLY$B%W&[],
M6AEDBZA9_NKAM]RQU/<'-A]:[0B,I=*.:G9ZO>'<A;&E!]ATWQ]UPVC7LA^I
MZ'N=$Z%A*UI@(AQGM/D>+]>;[_3KD.YCD;VX<O3Z>5H0CBMT>1-;<,2#L>98
M(UOJLAMP&O3A\S$ N$P9 J &.SGFGH^Q&-%@N]\B*,>-V Q%0M$Q+*7VOP-;
M=)VXRDIRG7;HC3H/PSU+C,]'  ^-HW[:MC_VS%$KEDPW93K32(@/,C5DFLU-
MT7.O%]OMGA=M^#.%E5VU\[M<&P!1P-JU^_R?WM5[7;9)GR$@IBC/]D8<4[1I
M+89:#=O(C&>#G0]9<>5([(:DL((1KPHL+D]KF*)5'(+-C4/Z>:A'X8RQ33_(
MH<^A=&G>ILUE^,A48K\5AU$TQC_.Z9;Y$(I6-X7M-FJ1VRS;E0SQ+!/A.FR.
M34 -@VZ[ -F\WI')5WRC=I:= ;G?RHR\,K)!RT:&Y4B387_@@NC'$^& .,.L
M#+1Q__YXE-)VCQKM<E@BG:D\/H?W?2P,5-215.[VD;O]TR'V,C?.3R@FHQ'G
M1""K)$>"4I:\5\*I-!E1,9IA;4B*G"B><#(N"NP4M9%RS6R8<L\7\RROHOW%
M $W@X:8][<4WHQ_>9K]CTYZ_:;0+IBPN>CNDH&&* "C9D_,S"Y(J/QY&P(W9
M,)KF('@>IGDU\',8']\HXN,3PT#+SSC;8%3>^#'>(#=^=MMM"=U0AE6W54;<
MZ;;%$-3AV<T8#CTQ9W4<5+(U]K2#E!_@D"IR1GXI5,C. &Y:MM^*@VZG]^OD
M;-K[O6Z9^O),+WSKY.A2:/YIV\6\KZ'(7)67VQ[*V=[C7NA6XIQ/;M,\WA8T
MGXFW+:7\DA_B#6K=M2/]"?#<.#%Z,1#I5ORYQ95X,UG3G[_Z8H^]O]O>W*/:
MD#F&#=;2$2\YUM1Y^)_ ACGJE*%L]LQ[Q*:UT@E-]+(BBBVI(EI.I^^P^LD_
MK=VMXY/=O9W6P=XGO'^Q_6-_[_C;P=XVV=_[QNOTX&3_ N[SQ\1T^A-_OO-U
MG^]^K OX3G-GZ_-)_>3#\>['STVX)ZSCZ.*@M7.2%=K_7+P?3:;OU_?>P[M_
M.Q0D!),,1=XFB[C0&&GG*;+!"Q49RV7':YN<\*D:JD=-B7^B.? 5%][&A58[
ML%82M\8Q[GURAB@L0@1KT44CQ$_*'V>QX[OA"!W;O.+)*18=;S.0&C]B0!>Q
MVZE8][ZLV[C.NL%99AQQP+!.($[R&$%#/!(Q@(F94BKZ:A;.8?IVZ=CW#OK#
MW1:CAHM95 ;^Y24X.-<O7[+HEUX,[]KA2SN[J2[_^CG/)8 _5!+WD6Q[?IUM
M,?:1"@ER5DB".#4::<P4BC@X%K&1+D_4,6J*8V^V>BM1-\DHW&LB+-/8QCP9
M1ME@<!#)6F4B"[H<0'@G"5>1_^/(?^>/Z^1OG,5)2Z!/0S#BWB6D.6B=UG@6
M% O<8K>VR8A>"HEU;],W%?];+--WMN6_TVDC/^AVBR' 8V4)#\"@&2^]*$@S
M^]WO@30 YU[;Y 23DD> %C!JF2 D4(EM<*(R;9\':;:G3%L _H"E#4@DQP%I
M#$%6^828D2SJP&6(8K9I>\^LJ'G(MGN"VVP8>5*;>969V'.IJ37"*2XXT]&F
MQ(AB47GCI'6S Z:59;PPG#]A&5LJ(M>@8A-J3-8Q''(R.D0I,Q0 &\QF<[-E
M_&JY_YYZR^(8UK/Y_SZ&]=P H#*LGX_K)PQK2L".3L&CI'@$P]I99*+E"&NG
MC-3>:8'G:%BOLCPT2@%*2@;:;.3*)<V]""E&K9B 7:S,YV<C\DGS61O.&64)
M1<>R:,,@VJAER!!GL!".",5GF\^O2JRM<$AZHD9K5';Z&.?@(F+8HUV /IG
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ME]-9 <5S L7V=:# AN&<NXDHMV!4> )&14H,L: X21*[(.G:)N?K!$\WDJJ
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MKW>G]WO]0N]&W3C')'RR.[\?3K;>?-B5/C/(X(D(+J/RUIHX*7.I&"AI1F]
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MX'CP[)>+Z>KM+IF:NNFW_JYU<^F+Y[S8%Z\SZ6,!8[7XS]'/2/WR+1PE/.P
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M*Q70!72:?"H-WR@KAS%-4MP+:42V:"GSF*PM==&2I56%4'>5AF_G^KRA 3S
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MX$C)S'>Q&]7R/:[9/-[>V6/H&ROT>[_A^'8M!"JUH$2;$M/W5A 7A2,J*YD
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MZP).!0PT(< LDQHII0I$! 4#65AA6 $LJ=A:L.1:J,27<MC?YKP+EF2C#[K
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MM($S)]T*LND3-J??WKOU])13B$CJV>\)H])H;I53.$HEF+6.> ^J=JU'K!5
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M![4TDJ%!X6'"C]!JL/P;>05K.AWT83%Y6'IH;+__^*E!6,.UX%;-"(>0<1W
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M@:6=-TPW3'UF2$*)6'MEB^U%O;8W&_"%O>E+TZU.\I;[QEFS?Y2_IV./@TO
MDJ>ZMX&F$XE/KJ#?J98+=X.[V,0$P Z-)(9^9([-7S;\_'_V&J> X>Z\T>RE
M:]N=/O!-6/+(B05ZI\$-2G1KG ZZ 'GIEMM)3 "O#Z\'(0$/ES^T\%:;C6="
M,9D[&BDVM9!86DV@ M_LGV^DS84;MBO0A1,)/]V1:1^&!$S]T V ;UU Q)*"
MN@&N*N^^ (J60L_1D,,WE83GFA=89TW?/WI)<%:$)RZL] $\OL18D/Z#_O)+
M[C"K_$[G4?:@ +5L9E\F_CSJCK,0#P.RW6"^(Q-AC2]-Z\R<]U[\,:UZ@-XQ
MLW6S3WTIC2Y]\!CO]\%+K<@G"9D/_R4H>*%;ZAG_97[M AI'W60T_4>32>FU
M)%)Q3K@,4FLF"VNL-P3S@L9O$O@IRVM N?_ZPZS7RM\F S$/4#"O%U'@#'N6
MQIB*S&O#E4Y_$F&,--PQ%@.UO,"%7,I9#P-UU]<<,_C]SQ#%,B MH?Z5AN^_
M /M*[0\TRD&IXBP5UXM%?R]=LQ5<.+&AVV!DHP&V/VG\U@NAL=L!W-:_;TQ=
M,1*8%@P!T$CA3=!H =5!%(>?2;#Z)))[1Z#B(H"FD[&TR/N\V9@7HJNQU3<D
MG_>5Y'L[E'SO*LG7^+BFY)1-J4$[F_Z@!(Q$.E#(K@&#I-GI-W\V/FV^V<QZ
M%WPZ#+J=37AP./8!Z 5)C5NF#^3#3]=E)2NIEJV39/P :39!CI^7!A?H#%V3
M+/S3!OS0[I5^"- (0_\L *W/KB,1>M(8/V]^VFST!K8'A&:ZH"]FS:1Q=M1T
MI0ZZZ+FJA\C7^DZK9;H;B2'.0BLUF4X+R,,I6Z9<0]9G'1Q+!\RE,K>]-S@]
M!2Z WSI@BS5]&.U*XZ+3GC6WUEI=I$ @;_KP?+!K8.,>9C&7MMXGL[1SFA3D
M)4B15.NCX ^SUM\!A1-PQ?5G-/U#DQ3M"7))2F-L#5R_E#B@?/]WYPR^*QU2
MHP<[D(U< #U07T$3RH;(0NOA?/'A@.T] $!L!9,!RS0.X2X 6"6*78N<P8*(
MY8YT''RB-_W\)P9([.2T55J?L.9!,SN)1GM1V3")4/O9DBH5XWLR,J9L^VD'
M,%7:^2! ^N.">TVMQYY3SYD+3A;$?MM*0@##ORC]4'J"Q[[?K= WS5;PV^W2
M<PNG\\;"'@-^O(L1CG8OOLV;U-MN5R@YQ,:/L,.]K"7MPVK^;'7<]S5U['[]
M]Q%V)_^TS1<]V#O^S+\>O\%[7]Z)G9.=\]W]C\>[6SO\ZY>=L^2DW?OR >^>
M?"!?]S]<_/OB,]G=VOX6O%&I*S!2-IH4(B)(82Z0 D7-X\ *JN.+1N@Y<YI.
MOCL(CZQ-72TJ #([9YFI,UF#R#\K$16H'G@O 81I$/Q_QAP*E ZJZHA;,S].
M,?P0YT><.O2T38&T,ZULS8,4Z4SJ/[U2 3I-,CQ3?+=I!R5XI_MD3USBZ@DN
MS3%_^6J!!%FF&VWD>Z4(R7)XGW#Z$KK,ZUOMVM!2S2YJEY[PM!=>#G]XY9N]
MTY8Y?]ELYU/(%[VJ[E^9MV+>3YN_L'R[LOFTWM0J@?@PUZ[ZXLHBW,P6X8R[
MO7R/XTTJY-*W\299^MYEMR5T4PN^2K>][#VZ22E;I<5>>5MUK=M>L\O)TC:4
M1+R8(>&**"\/M+R:<[.L0@SU?2F)&^?!@!K03M[Z.?:?BDRM4X^8Q8^\G:%Z
M:5YJ,7NZ5\?05O-H=T-6%$%UOT9+UZN?=2D_/)D->P=&>__\)M2^XIG:-XPK
M_I;UD\X ;NJS(I#4D=[O]T(]*WWPVY6R]O2?="O<XY->HU'SFF_7,R>,)]&U
M83'6??ZTU?BC\2[96U/FV%V:-:Q73MW=F\U*IZ.4S =:<.:Q+81.5CRG(F!>
MF(4NE67)=9]".X4KD^_J3=NTSGO-'JBF^^>GH;<7=TSW>^@G'_.0(8?DNMT&
M+6<[*SE;@[#?V0_MOT,WL=7PD]M3CI@GDEQWVMSY\N[GP;YC.U]V1/JNK_N?
MSP_V#R_VMM[0W:WMBX.+[_2 ?CW>^S237'>R#=>]/]J]<#_A,_!<'UN[^_\Z
MVMO:X3M;!WCG>/=X;__K\=>3'?'OBU&.;W]W_\-/6/NW2+DVQ#.DF12(%Q$C
M%0J+.#$,?L"<8_OB-9_/J[M=M=UJ9-0^(?[^[7$9/#FMX:<'Y?3Q)VI.OPNG
M-Z<Y76%KI,0Q368WB*="7N4]_*J#9TY83Q19R.ES!L/J,/DU=)<[J+W/!$+6
M3D4H[?I:/W@(U!AVH1NA!L$:\\!0U#J"5L I,E8Y9 CU.-@8J6<O7JO[ZGI=
MZP>U?G IF]?*P?VP^8P9@(6(T7J#E.3 YE(SI 16B#&-E5;!>A$7LOF**0?K
M'\W(56G7\5K4Y8!CY+(VDH)()D V<:JXMD1S9[R24JHBR-IUL?:8]6'.=2$*
M+:2."F&K4E-*42##E(9?B98%Q5)%MM"@6;F2P-4K0G[RX'(3O>@>T*7VFZP/
MS,SX380E#A<$(Z6E1)P7%BE6,$2!UD%99HHX<3._R8JP^URLZ]8KNHX'Y<DC
MRMJI*[4;Y>% 9-:-0JQR. B+P+8&^THST%6\,TC$0(F1Q(.5O="^JG656E=9
M8UVE]N$\(,;,V4.!4V(-(MB"HF)(1"H(CF@L!'/:!8[IS7PX*]>1Y&X%1K>Y
MKLYPKS/<ZPSW5<ILNT:&.WY".;_WE/I^1=>I=4USO%E._.TWX3K)\D]TB^LL
M^EMGT3]1BKA)%O43W8*;Y-T_ .H\_0VN::Q.X;^'%/Y5=/+<.0M/XD 5PVD,
M#^58:*5"L)QX):0,WH;LX\%#'\\577#K:/>-O#LG.Q<[?.?X ]FA!_S@X@W^
M^M=GLO?EW<^O7PXXO':^<[S]<^?X@.Z]G?7N'%SL7!R>[VY]OOAZ? 3?\?'[
MU_W/XF#_?>OK\2&\M@W7OCO?/3[@DXGZPW&P!;'*6$>1L+A(PR0XTBY:)*3@
M*NC -=8O7M]7GGX]+^N><NKN@5?KV/'Z,&USAFF=C(8%@4RA0C5;SW"**)6<
MVDBH\7$1T]XXJ^X7)-;?1_K\^O#\VHGG9QC=?30VGQW5#H?M@K0$"<<UXE$J
MI*03*/B )99,$"%?O":4U]*YELYUM/37\.R,/LV-+@)C%!%)0#03IY#VD2,X
M>,X$$(6'LU[(L[]$.*^WR_5^,M[KR3C7@32 J:@E94R+-+)5\T"XU:Z05DOK
M8^T<6'LP^S#G'""2&2DD0TX;C+@4 NE">J2)4 I[; DO%MD9*Y==MHK#<6HT
MNHN&=7<XJOT?ZX-+,_X/)G0P*BA0LE+/@<)*I!2 D^3"AA"TY)K<S?^Q8OAP
M_:C4@R;;/U]L6CM-J?;3/!P<S?IIB'2*8Q.0X<J!S><U,MHQ5$@.U.-#H01;
M;//5BE*M*#TK1:EV13T@+,U8;Q;.F.*B0('J@'CP'EF>ZIHY)LY@X6Q4=W5%
MK0 \+$CIGYW>N [C1:Z?/IC'#+P=#XQ[0J-49IZL8>#/X<31I>.;-B:G$TZ-
M7(0/^Y 'W%4S:JQI?R]?[Z29RS.S#)O]X4B$\:B;_-63<T^&8VZJD7UYRNBI
M2?0Y:)DN0/&I >KN!A>:>49I^743(WL GT].FOVG.S9Q8I9A.2.HG'NU?/Q6
MWJ#.:#KMXEF5S7)BSDD:1)/>.QQ-^/K? 3QN/P]C2K_"5X8?9NX^P\/=;+R=
M/L'1^*56$XXE>""G01B>:EI7JW,VFG@T<:I+YH/EN4OCBQ/IC28C52,U&D>P
M8Z-O![IM'^91-R5-3GS)&DY)NB&,;4]-PES7:7/3 U@GT:(Y]WR)TDZ[H%YU
MX<OG^&.6+9KM'W!U'I/4"\ @>>+K1C6]"Q0]4+SR-)F33CNDN4I)\VJ<#/J#
M-+1TD#++?_NT_?;-/[W?@>[+R4-Y&-3DLGJ-(P/(:1J^V<W3IZH9-25WC3X:
M3+<-*\V V*_&VPX7UQM-H\E/$5MIWLUA:(=T?__TR?C]>,SVNM+O]*3PQ1B<
M43!/%DJ3OLO!Q17- 56G">BCL4/5RT#I+@Q?ZX(L[F:T\T 6Y=SBR<_UTCPT
M/YSZ-;&&- +\D@G-Z7<+0K>Z27-J!</U@($!/)DY*7_[^M'DU8+7=+OG:7M'
MQSBKABP<^)Y'K,,)E\/>3D^[G9_-)&;3OC6OF)$^-YCX&F-S5^C-X=$\IS'*
M;/D8Y;3*;&I?.1<7WGHQO*H>OKSJ(XR?[O#ER\CA+MPSYWC+()O'_A(!5MO#
MC)!LQFX/Q4&K]7*KV7.MK$7NQ8\!+)U!>/?SM&7:IM_IGO]RA]CAT"'&OIZ\
M;QV<O#_:36XNN';GXNAH[PO<_^+=SYW]@_3='%YK[GR:'0SI3PZ^_ /W?D>3
MFPO6>;'WUSOQ]:]W%SO[[W[N'J?N$X?PVO;/?Z?[;FU_8X%&JH1"D18:<1<Q
MLL1J5 @G''&BB!:7[D\02<&_Z<,>&4.#59(Z'B./3!A78.H$O*(LT)Z;'219
M;?:DDZ L!&[,>97N:Q;I_/3PJQ<]_9":%IP6P1(7&!>::<*\"E9;Q:TNI'CQ
M4#-/)P@6MK';/$W/L!??.)>&3H(J\G<>Y/J^T_T(4'#8;I;O5YO\_,CX8F__
M\%O0RD0;&6*1)K]L+)#5,:"<-:HH<=ZPV1-61 8OM2(T<DZ-T%H340!<>A)#
MU.:7SD-=:BPM1M$Q=91S?D$)73]E_(8&8D7QZ_><UWFJ9$)T2_Z^"-G[9>"(
MNQZLMU#Z7;???_R4!.<Z&L>?D^8R?((->-!%SWQV5#DCAW9I#^"\%_.PW,9I
MZ.9QT&D[.A:>HX3Z9,DFMW ,W6YBAN2 @:=KNW[CL-/Q:20PK/A',J!_@Y\G
MWK:@394*7?I@EE5_C#_=^[V<VCUT.VXTFIM@;8^6./)@=VP_C18OYP%W6I4#
MM1>JNT[<<;/QIEU:X7DT_'#5DP]^Q5VKJW\;W_3W)^?\_FODDCY+,]5[I\$E
MUTFU UV YT$?A&\7MMATW5$5GQC-B&]T3I-_) 5SLY//Y,GL0W]; XBIY=,4
M:=.?HK3DH$N./CCS17<N&3"YH3MGL V M@"]$9:1/C-VL<"EG4'7A9E)[4>F
MU\A&*AQUNB#\3 ^5ORR_G+Z]TP ,#&V@F^QB2,VK;*7V-\QA-X32>937T3]J
M=GT9+RD]-2YT$[GDS<K+FGS,[)<<N1$309XU6ZW1*T->?'*$M _4$@ RPD8C
MF'2<PUW,YV'3&/"TU7DS;-IVTSJ_2)&+M./)!0M6^#E*?R>G7#,?EP]P7&!Z
MA\2R6:_-7-GM)J=POG=BV,RYB_%J-!^\U(K3&9ZG90"\Q$:OLY'=W3Y35^FB
M ULE><%'J++LMG#Z.4 \O<J\NN2,.H7MA+,V8ZUA,(G(R>L')'R:7%Q#J*E&
MGL^Q2MJ]TB564E,S$W>SWRI]7]5;8Y:;?-(;INH\A!(1-@\W'V(9EW[IR]O)
M["JRCU(UR$M6+)ST7K[4;">B>8F(ROF'C_9@*1A'BU>/O*&OIC:&\$TETF-O
M38B!H= =,DR8<WJG:%$W)*[HI%YE1YFE3!G6:;4 H%/X)[%.2)1;">+6^#ZN
ME:3 1O:TEZ&DQ5I-YT?BRN9)V"CE_&AER>O>34W20"Z\JFG@?FC@S4BQ2D V
MH3[!HL+/K/L=+CGB"OB&]''5N5:PF$ZVT1N4D<3\9=/*W:OE<K4^VAL>;:4B
MS:/IPAV5="5W5$M,?_V.YCSU[9+BAYIG&<0*O5XIR9-2U,BY8]D4<H!9O4D.
MJ1(Q>DO8"=2$9K_DN719MS,X/.H,^E/?")]L=OPR>[!$SKF/OP+ KBG@P2A@
M?.2#7KCM>>?&?*"$YC XB-_2%1P'[9R]E5.-?K_2#3"I.::5I?A+M:QT-PL6
M3(2O'&F:U5-<GSYJS+T*<__N=OS @3HU.#UM3<K$,A5A(=<F/2HK2$/A.V1C
M'UI@&20K^+2\;6]&5CZU?(*WV?U\F/31X5ZE9,R<JI:(%M2&!*IQT&K 5X9>
MO],.I<O(P&^HS 7I=LY-*UOZ26%,Z7L3FVVSA3M,V<L&_NA.8SNWFPS@TEI+
M=\YO=%S.8UBPYZNQL3<TZ]X ?39=Z2^I3.QK.%1*?\K?1P8LZG?M0[CKBN[&
M-9RKZ9'_9^*1WTX]\IOA(V\LA/1TP>0VC-[(PJ D/=<*I@L@4/DGFJ4W:V/"
M_Y40O_RL!V1NEV[L$108UR_3E8:_93I,B;RAFR_O#6ROG\VPWQ:M<2(K+ONT
M2A=.C""(QE99N81*E1]^T>^CS+I))T:BB?+:G"0X[<:HWAP^0!QD-TQ.%O2A
MVM-F>]P,<9AO-?(EC^V\24\OW'ERFY\:X$WD<$Z2"6A_X5+7U35I%\@J!4@M
MW+)T7^5< @Z: <B8E_?OP*R5A1LI"Y.@.\PCOTJ7/#4I-24?^O=VYPP==<YJ
M7\@]GD=2W#K=E!O:^='T"[U@DX#42-[A5A4JZ:;<YG X:.5\F=*1_,-D!\<A
M8%J_Q/>%8J.?PG'YJCG_\8]F.,N9_R9!9+/T.(^B<J6)EU\;6IPI 3P#1RF[
MJP *7%DJFB:'TX:AP@E_VZOTV9J6[I>66ME/MOOG_K\_LJ<NS=ZT&X-34-0!
MGT[->1E=C(W_9VGAZ*#G9PI'!;.B"+&(HC#<\F"PTR(P+"(W1HF<%41HE15$
MZ%SAJ)BL%YT2BB.9^+E<X=_E C]6@9D7C9)C8 T_^R_;@Q/D.SF5,-UY5!1:
M/+ODH9WSO?V#;\[[B*,WB%',$/>>(<,*@D305#/JA27FQ6NRB9?T! 0":Z63
M/TNU;8-6+D$9^X5[(V-OY,D82L5TP27J8(+31 =/+A8[&9F9L'23.IUKRD+C
M!QC&V<%3<5H5>"QC)%,>092P?;/QIC=AZ0[9$]Y*QG7:YJ$%DD.2,>ORZ21"
M!,;H9_EB.V#[#:/H(ZE1!H5#-T5 RPDV$W<PK5;#C2N )FV,Y N;S$-(>:;3
M:0#P2=<:Y#L.9>+(6IE__.%7IJ2#X:)A):6<*V7XDI28B7*H'/B>6M61J53L
MO(9VIY&K29(QDT(D&=R'P8P)2R=_^*PS:/GJ[K,V=OE>5?14A472293E$\.D
M13#9G!F,M<-4P@?, VJ%S0]?&5UE645BJO\=-,MRD\W&7EI%62#3K/(K2@UE
MG@IN"-*&"D4M*ZR3E#,3K H%4<056 FNK<L@S8<@S>= NK@:I"?H_TW;OQV9
MO#LC7JCPNU<#^.4 _N$,[O6-D$*$8"722@" 2\N09M(B%XF+G$87? $ ?@5\
M_S8XA3]39X;))(N*K#+WEZ"2@:C5ZIR%:2=)&229<4)W0V_0ZO=FHHEC)P:
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ME-&*T7**S?WKX),ET;'Y,WAT$;J=F@5ORH(SNKD-GEN-(PA[EF2_%LA25J#
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M&AQ6PG*IP>&AP&'&@,%:,"*%0C)*FQQS$FGE+"JP3REP1F%B,SA(5H/#$XY
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M";P:(UDOG62YE)6!;6R8Y>;(%,>"2EQHQQE7QJ6&ZTPR4H"8$?X*;J:3U=3
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MZ4?/*0MAT.WT?E]:SGT-$KEV<<5J4D22L,_[\?&S?GRB;\+TZ]$C;S'O_ST
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M.U>Y<+1SG>6#OUSMG+P_Q-C3&&A"*LD 1IH.6-F94RIX:;"%N=E4HVTG/\'
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M?%(E,KI:@-/1@W),U_]S[DHUNK(9W25%=Z8:I(;N"J$[5)N4JI]5C]UP*F5
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MA!@X.0F^T"/O@10P"N0B2AL:G4M.Y\PYGD;GDM"Y=Y5.[CPJHR24H,AVJI+
MUWH'5[(W/!@7L=&Y['3.G/]I="X)G>^&;*>/O"1T$ )*LIU.@)480$=MN<W*
M")X;G<M.YZRYH4;GDM#9_>D(W28Z=U^^15;W'5D+Q7 ':*6$( 4#EG0,&7/
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M;!=D>E]43";)=55]\W=:KNBZ[BMWC^K57"X]-[TUL=YZ-^)Q^*2$M8:#S:8
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MA,)+W9MO(OBH'&"N*6V?;!3LP5/93/>ZXGU;%7H-[SO!>SBO1E,$(Y?@T5M
MB0D"#P@Q61:CT]$6]> IO[ZE6^-[#?B^K;JZQO>=\#V:EI-*"IXEZ&YSJ-<<
MG!$1(M8!Y[8(U ^>NFN[OC; UP#PVRJ&:['WPMD>SN<Q[V)$'D&7D &991"2
M1E#>U^RM*<S/O<B^T;U4=-]6^5HSWW>#^$@-6U3"A"A AF@ (P7A-MH(C$;:
M&QMU1(J_N23[+9>(\)4H5.L^Z'&/YGXOC@'F:(G:-0G">U6L-J$ E[-\;5C3
MM4T/MZKDOHQD!UD)PFJ%P!QC@%(P\,D&*#86HXQF.=FV*VD5D%U405M#=M'(
M#J7]4!>EI O@&2N A@3KK&%0LM5!&Y&54@W954!V425N#=E%(SN4R&,\,<PF
M0[** @F6&5@50FVAPZ5A*M"O&K*K@.RBBMX:LHM&=KB'9MU0$2VYPQ@M8/8,
MG+ %F.+<DGI6%EO9^$H@NZ@RN+&1;6A.B.9H7LWKS&0,0$JX+LP)3Y@J";(X
MJS$PIZ.[_C#G!N;R@+FHXK=F2Q<.['"R+)ELK10:3(F\UJ<6H+B'0R#CRF/Q
MW*MIMZHV:!<*[:+*X::"MN7 9B9W. ?&8@[9.(24$I$;LP&KC0/OI$V97"FK
MPW0YL+FENAZ=^-#/]'?J_?7TG_3C\AL^^L&[WL%Y/TC1(=R]<N@,00*NRR4]
MOGSP)/6.C_K^[''OH*.E>].3BP\+AR<GAQ\?JZ.1*^NN_/SI)Y]ZZ63_L5&;
M1F%%["(;=_'%Y\_RS8Z^(:F</Z?-)I<W/\TV^53/\4WAQ)3OO/EJN-A4J%?E
M8G&3X7B2'3./>J-YF."E;ISL;"1]EP>W:T3L6$?(5LU.7W48/URD8S>(EX/C
M*Z O4'J3'/*[U'+=_>/91I4M,!RGV'7Z;M1K*#$]R>Q;SEKIX5N^WE][=7:4
M:Z4T77P>],_JA@=_?)Q/;K4\>B[-T9=D)MU0@IX_;9Q[O+,(<CY,WB\1+_-^
MI3%O;*1]P3N*4$[&:EDPA2%<ZD&><'%6)X6L)!9E70-2UNC D0=O4DB2LXMP
MDB)-N'PP53CY_'P\6C!)W_5JC_Z\^/3F]9_O=U_OL3?O=_;W7O].UT77^?PE
MWWF^AWOB7Q^WAX/)]]M\A_YLO_^I_^;UMGKS_O>/V^+7_3?/?^V]V4H?WFS]
MASYK__W>Q[W/__VR?;+=Z](I)]NO?J%[__ V1.MY5@FLT!DP20U.<@?"%!FC
M<G7?[(.GRO"'XIJ%VT;2W^W_4=P5*X(4@4@2.OA4N&=<%:L]9Y<D:7&^,%,?
M-))6@Z2=G\])HNN@>WGY%H47A5L!06=')&D./L<$)@G-HU1*U8ZY-(FNK1R\
M+W[REC_I_.2.EOW#/GE.Q_]G@\ Y[)]V//FCH\'A7U\W#%,$>]<N]$JH)<X?
M2?:(= AKXAI#7 P?"5O%Q6<#KW3_6P7P.@NQD0B_J2;(T(U.-4'^7EC+-4'8
MZ 1IXKI!7/J1X'/@:74,V<_TBFJ\3WU_(W\^Z@U\9[ZF!NP^:N *F)P.L'LG
MK@O Y$2 K0!'YW;I:-"+XW"S8MG_&4/*?#KX+0^ZD&Z^*S1B-*I\W5U13L](
M(/Y=OFQ\^UL=F"EB3<&X6_.].XL*->/(HDU4QB7K"DA$?U$?EJ.$X)VK'>=%
M<*W89%G1G7%)J*&[4N@.KQ)E\CFLT *X\!$P>0V^, G1:!&$E;7S:^MF?1NH
M7F(QMJ^Q]MTWQI,;S46I\<E2."E75-LUBNU<=345-8&*>C?B71BD@<O1@(@V
M 685P2/G@#8QXTP)7?4YEYL&%]5?XX<ZI"%\>PC/WUEI"-\"PL->AB-5&K)C
MD+LS,XRBV* P4X]]ET9S9RR+-1>UZ=SR(+Q*:QG7[WN[Z2CW+?+ZNF<D?[@Q
MYIKR_=DM.&&M+Q/*YB*SXPI]0J=EHM\DY*DDF\7?MO<:3:3OGIX<G_B#*JGO
M%5)+E\]/17T8\3*T<T9IR2%*8P!=[;.;=0;KBC9%)&UK((1NZHTG;2/NQ/VE
M;%&2&W+- Z)!%WCA5A;'0K&&?M?06DZTAJU_D%XF&D)RVZVL:"%8Z7(]'];R
M%$,QFK6=**/&.E\>]G;7&:F5T3IS:=XQJT&_H5_G\-%]][,;[Z*T4.T&,-3%
MS@<M94X*,E.*U)#G9.&C!::UUPJYSP9O7NIL^_V7@LZ9?8)&YY+0>=FPCC[S
MRP?V-BJE=,D&C @,T :LAU,7R%8$X:U-G/W@<.HUVX1P4^ ^VN#VJX]P.VUM
MUWHS?)#(L1ZRH#-#FX-7*IJ0N#1!I:!<.[1W)77+YQ'+;XU"&9B!8**J7?@+
M6,$<H"C1.-(R/OR@L4CCZ._*LZSD6@42J2\HR!"7K$U,HJ[/%SV_WEF-HT5S
M-&2CA4LV.(^@R?\"U,8#416@."YU" +)*YN/C5ZO0'[1QU2ORR;3Y0C<VT$;
MB]<]HR=4,R$MK]L+E:G=_#R%!I[G6,^Q=3QJSV(M#+5CK"$VVI8Y$&^'5BT:
MM"$CGQAWPE ,GA/+@!@-D/^L($67BTW*>>;7*1"?L!'>'9XQLWQ!Q*TV$5Q4
M>-Z:""Y>[8R>,:.LB)E[1VHG24 I'01=)%AKN48OO<AV%OO>Z+J;H+WUU5TT
M6$/VG/2G"(PIX+DNK%,(#]Z+0BYT,IH9@S+]8(?_J#V_VDCSXO4T\C2+X_F_
MZSSK'9SZ\P_XKM7F_N7>D$U;^] >'1[WZFL>#W*?7OQ7ONB(R5DWG;][XT4_
M3?;M+3YT'1IN?LL(M./C^6S0\_T;X'1CN=*_@A)?)7<NI^]^[@^^:9IW&<(@
M^P_@"UWC8]__Y,^.'SRZVJ&T=P!#HAN^Z_-[>_K/,'CT].H7?WWRFALO9;XW
M?JXI24D<GE<?/S[O/D>OHJOT=WL!&_N#JO?^T9/&)&>XL4CNA<G&.6ET\"%Y
MSE"+\I9H>-5U@#TL&_]\Y%?KRFL9.$WWX^["KYF!0WB>Z]0B8XE%)LP4N#D*
MIDDS")<QUT\U#L]-![TGIV=50P>M*0BW60<64?C:^S=(SW+"6-#*^."&[V%.
M92=4]"XI3,A=0#(LVFCG.:DC^^!'C7F_-\/O3X]/>N5LSDA/:&]_'>0\W*GN
M&W*+;2+L[";#J9H((]]4VLZ]+R_;=$K.O2^OW=3<M6M=F6M%-=W,6A>Y<K')
M['A-KQ?8";G6Q,RX!#,?1VO&+<5<D?1^&^0N0-DHW]1QUZ9KX^#P9.,LGVS\
ME8^_;[)Y;@QO.U!<$>E=*[EK1-7Z=$^^V?W9\V>=/RX8MS!65YE6(7!5:*()
M;5*AN3;3)A;:6#T*[Z5@[DWWM)O:Y<_4YKUM[F[]\IN(FXB;B!<EXB;(^W!\
MQO?Q:CM"8\QT;]39RDAOM0QE25X&FYW4-AEO"NM.9.262:;A\L'8Z=X7!\<G
M@].:Q3W>/=G/@U_^WVGOY.R[WUZT4KD7.R@^;6\]8]M??OJP)_;8[O.]^A[Z
M[G=BY]4>I^\5;[9^?[\M]OC>V7"B]QF]]^67[>>_OW_S_B6^>?_[A[V/+]7N
M%KWO_7_H'M]\V'F^_>7-^S_?7W=RAM&:.VT*<&\"(.DR<*)$L%;XK%T2PNH'
M3Z73#X6Z+SLHYKK?45DC#0M,"HP&+4DXENQU2%$ZYBX ,L+ Y8,&T%(#=-FF
MX!(@P8D1TI @$[. S$@("A5D9:,V-AKOXH.G^AYM0)KG,=Z%"QU532=SS-*Z
M((M*3AB6E<;,.WP<L>7@\D'#9[GQ&;8_UG.970)RHB,@J4"R/X9#8B)B]*J(
M4!OH2-OLSS0 .<F$,4E%YA&#EDX9\M'(<Y.V>*MRMU^/,<F[_7K=@P;04@.T
M^ZU-#NYNO7MKR,)(F\GT.(: F!B$9#U$YR6WB-&J\N"IND\[8.=I@$S)V0B)
M06IT0KIHM!52Z!*YE0%G.4.P\7.7_'P].M#95%+A(%7.!%&49(!R J54CLG7
MK7(T0Z46#Q57][8ZM1UX=CMR9?H1KT?(<-/$-8ZXU",AJ[AL$U<3U]S%A8]X
M/9V(NR:N,<1UPV&-JY\SF.B0P77SCYE\5$_I&D]GK-W-FT?"W-N;)U/AQE5_
M:WCSG>Z?]ZZNU;CYZX\)7>-X9K+S^MH!'%.?\#=; GGB8\*N7TCYV@)L=_!G
MMZV_'1VVH/66O9&$LPTY*&DL:$P"T D&]*L,+&7&DV,JLA_TT[VE8SVF/@ZP
M:89I-<.,F?&F&59>,PQGTIE!HWP(@&@9U!I?<%QD0".5TLD[X7[00JAIAG71
M##,F_9MF6'W-,.0S9%1:>F2@G76 /F;PB2MPC#@(QBB)/^@@VC3#NFB&&7<S
M-,VP\IIA>/>#]EEJ,@I@-7) BC7!BU0 10S5M4PNQ:89UE\SS+A/HVF&M=$,
M7WV&; L68X%EI)!"!@U64C!I&#?1!N6%3\NH&58_?3;Q$>43:+>U5F+S7RP=
M[YCBIH'FH('BR$HG]Q2Z)L6@V-P=8,C (J.HI6B3<Y(T?'I*#71[+DAC\;:6
M)QN+"V1QI$K'QJPDLQ"5INC )@T^J@1&.%&;(S*=IUU!:"RNWH)@8W&1+ YG
M )-33B</27)!,3NW8)4F('WB@5DE?>&-Q25E<?Y+<(W%!;(XO'[FR.Z5:.M2
MNB8?M<@"(0@.RN7$?4Q9Q]Q87%(6Y[_HU5B\ Q8O[6+,R21-H6*,U4?%@F"%
MY2!=]MZYG#-.NY:]@(6IU=@->'WONNN;Q)P?GKN58^Z>E?SAQL@6R=9I:%)9
M3]@_HR0KDZ48C1D,2G@ME%-=8Q(>M?1_>U[8:-GE]4OWNZ<GQR?^H,KO?A\Y
MLB#U]^Z:Y3+AF!41T @*"R(%"):9##YS@4%D1M'?3,?MMA9KM\\K2XEI&[WB
M%)DCB]ZK[J@):VT]_8(W7E>6U^$EM:@Y+](8X,52Z$!##3:7"$[8:"Q75OG9
MCL=NO-X^KQ(-PZ14U.1=&F5\B;G(8$*6J%7X^]-O&Z]+R^N0?65,ITQV%*2N
MW4*"(50+SQ H:&0R1L/+#T+]QNM2\.K1UIY(N6#R:$C)DALL,"-ZSYG(=^X/
MM^XDLT$[O#['HDM%HP6?@@-4S(!-64,DT^M-Q%3J6OGTW7U:I#HO,E7TS'@?
M2F <>8Q!FZ(50^9R2=S(1N9ZD'EI3I43H3"-X$4VM>^C 6^$A:30"9ZL\9S7
MOD'LH>)B#0Z\GJ++<K[<#GE/#\J82P/961? #L+GQZ\.3WS_4JL\^^0'Z=M6
MU0L=\E/3(;>M0SZ,+'D)YXJFZ(OFEZL5;Q0]A\@4: Q"F6(-3Y)T")(.L7(J
M\WZO3NR92\?S61>P&F_+P]OPDI5+W"=,"LA!]8 2)?BB C"&3O'"T2*;H5=S
MHVWART^-MB6B;=BZ>89&6@1M%5DWZ0)8E1&$3U&G3'$14]5#=M.V=FZ\+7SY
M:)Z\M;7=J5$;*8,,S@G+-3@E Z!V%H)+ 0(/F+4O(3DYT]IN ^J65GT:4$L%
MU+>]6(4SGFLO:($4F05'CUB!Y)RKT;@2S(X)U&KOF^H^Z'&/)F@OCD'/BX/8
M/ZV7??U"T$8Z'7SM$4U?>3C.TM"]Z+0ZH9PGTU+%.YU*ML9QCI(I2^ZVE9;%
MDECDB5]L%*7_8$Z+U!-60C='?'[*[)=/_W[UXF3[CTZA?:9[46^#TR4'+%"L
MDT ^('GBFD<@5<8U6H5"D"<N\*%:PBS2O2!4I9!*""E&+3%9[T7@%AVYY#DZ
M[N.2$=H\C1G@?'D53D,$$H8)=$@<$+4 SPJY&KJ0,^]LQG1+^QX;G6/2:9//
M.GBRH"J@*2ED4:27BO-:R89ER>AL]G-61/>N(JJ5%X5Y"U%D 9@$@\!00"Z,
MXH 8@O!LMI6LANB,B.J2G+!,2IT0K5:V$)""0G#&-&8;E@S19D!GH//=!9TO
M^>[6.WQ;5/81#0/,Q@ ]$&#K;BE2V!&3JDK[!W53C<X%T!F"]XXC_92((CC/
M6$K"*)N%L8Z)1N?ZT7EA.VWT(84@*Y,9,"H+GD(;P!)KW\[L%(Z[[7A=]TGU
M_5%=&SL<;$1_$'._WTZFO[-]4;\>#DKNG;3,\0*5QN>1!:OH4\Q"DPV/CE>E
M(<#5@L!$T;!6R="@FP=/E7JHM6F'FB[+'J>IV&FV=@9LAI:21!(TKA2B"ANK
MA741R#-VP# (7ACI13[;4M+]YN:V=BLUFW,G\ PM\G!MK>$V@0P^ 6IFP<E(
M4641SBFC.7+QX*EV[2#M9=IYU&S.HK$96GVQ"@UJX2!S3?%=\61S#!90V1E,
MV8L\X^K+_>;FMC88-9MSI_!<V!QD9%2B5C634 !S]$!.N(=8ZDY9;F/P%.<(
M,CE_4_[1-AE=MXK2MAO=D^U&P]JLK?+>JB([&UFP<;55I""_V2I3G6=R!2SC
M%H0*UE)4:OB/>ITW*M=RBU&C<M%4#JT'Z<P9A5L<8A:U L<(L!3= N,T[15I
M9^=_<-9JHW(MMQ9-167S_&=%<V]XUY]C)H@$2I0 J+P%2TH8E+,87?;66%8]
M?],V%-V7#47-7"Z:R>&EK.QT,2$ 64:*QI,I$'(P@$[&%+5E)8MF+N_91J)F
M+N\4S4MS*4N2$@/P:"Q@M/4L+:E!1V^U]S:P-,%"V:,3'_J9_DZ]OY[^L_MQ
M_I(P>/3MY=WOZ;/J!.P=G/IN>G;#9Y6H>PL5HN'(HG-:NI@M4]:R@%P]N/C0
M[FN&ZF()L&ZEZO'E@R>I=WS4]V>/>P<='=V;GGST@W>] PB')R>''Q^KHY&E
MN [O\Z>??.JED_W'SFTZ*RI2%PN!%U]\_BS?[&@;:@Q__IQTFUSH&Y]FFWS*
MYYR\^4M_],X?7:S;-$*V:VW7NCK7*L58GSKF_L8)$F'+GS-S8[5B_.F/WW[^
M9:URA>/>][-[>->[]_*NGSV_CW?=I:97/Y4YP<UN''S=!'Z1N:1[R8/^6<U4
MOJOG+!UO''[K\=J.H9EQ%\9<VFYG+;D*G(><T7FTQD@CM$?E<PJ!M>:^MQ)O
MTG?L]-^\^L_9WNO_?-I^_Y+M//_SX^[K_]#U]???O-K_\(;BPYTO+SYM_S$<
M;])GB3_[.Z_HNU\].]NA>WOS>D^]H5AR]_6O_=WGO_>W7]%KWC_[3/'FU\:<
M=!WTV<_>HJ 1]PY!<FZ@+C> YTJ MJX(E"QWC0(-5P^%XZU7_G)"&RU&+C(/
M01F*TH7E)=!EH7!:\)AR@W:UH=WY^7MHXUL1I RE'I@7E *T.H/W68(M,6&.
M,BFT#YX*+1\*U:!=4FAER#YPQGU4#C%9YW203F@,5C&6]330?L/S^R,M&XQS
MA?&K!=W[M+VU_38SDU,6&00K&E H!Y9;"[PP$\B9LN0Y/7C*:V/KAY;IAN-R
MXIB9,XYPC#EBW>=MK4*9BV=,YZA%:C9TM;']UDBT8OOAK4%!\0U93E?JV>S2
M"Z!)S2"I(@2J@-'H!T^1CW&J18/VS@YA5+DP[9).CF'A,13!.$?O#!E7;=HA
M42L.+=WCY<8%L;WU"W_+4O2:&06)829CRXC?K#R@B2&2PO9,YIH==48\M/IO
M-A1-FB&E'Y<47"0M*V7Z.I0>M)1H2X>U:VW7VE*B+27:4J(M)=I2HBTE.K>4
M*&LIT45F5TSQAN*-H#1#S=%&;I-EV1IA=(JN"S)9"S+G'&2J-UN_[^]L_=Y[
M\WY;[6R]8#M?GGW9>_^?LYV/_U%OWK_C.UL?/NU]>?=IIS<<9/8_[#RG:WO^
MKX_;7SXP"E#E]M9.;^?5"U&_?W?K/VSWU4_OZ?O%]RG1RQ,Q*!HR(J$!'T4!
M=*% $#&#SRPDGI7,V=>4J'UHINO)U5:&%G!(L5!)>".M\@Q%%CXX#*RPX%3P
M\J*;1(-V9:$=/O!0(,T::3-P6Q>&8DH0;(F@69:*YQQ%R.<I429L@W9)H4U,
M.[0V9EFP5@HJ0Y3*$E!R@1ZG@?8>IT07!^.0!64)=5:H0)O:1=X:#0%5AE""
M8#ED8C$]>.JL?BB5:S N)XR<^$.)PK$0D#OKK4PYL>BYC<)XVRSH:D,[?!"<
MPDA@*@E&5@MJ'0=KBH,BI792<^\T>_ 44<_][*0&[=R@U:6XB#X&%0U&;1RY
MO%;)F+@6RK+2H%UM:+\E1"][>9)=]<9G,"G4OFH$K%79@#/$LG(N%Q%J0A0Y
M/M0*ITF(3I#S;)G39<Y$K5+6K%UKN]:6.6V9TY8Y;9G3ECEMF=/Y9$ZY:YG3
M!4:C-A<9?7'6\8">:V]C2-86[V6HQ2XU&N6N1:-SCD;I6O8I<OS7/D639]M;
MD=%[>[O/_]S?>[_W9><]?<?6FSY=XX>=D>VY].?Y'M+GG5$4^VGGR^_]W=<O
MD*ZAM_-^6]#]?-CY^&?OS?.7_+K,J<W.%1\L>*=<;?4GP!:9(003HN0\R:(>
M/#6J%L.HMH2TG- B6EFYE<YKC%8&)RPZ5IR*YXW'&K0K#>UPYM1B(FRY@:(P
M K(0*J\(+!L54%ENL38<(VA;YG1IH>4QEA!8\@(=6N-]*0'11Q6+"U;K::"]
MQYG3Q<$X9$$3P8@FU:.WI064-D$HNH +3$0:Y&2<?_!46?>0S[E=;H-Q?CU4
MF"LB!/)Q.<<HM/71QXB%Y1 S-[Q9T-6&=CASFKR*B@4&9$ )6L$3U+[F9%"#
MJO6'!9TEMQ?U0]&@759H-7HIDO8I1$9#F)VO#>JU(+OJ$@K5H%UM:$<RIY[&
M6;OH@&- P*QK 3CS8!/JF+Q.Y$W5S*F4]B'CDS?;?3344/>ZWRPPN_K^]/BD
M5\[&1_#9H.?[8Z[;7=_P^M5^WOB8_?'IH)O/]/AD_S =;YS6TZM.#C<R71'-
M[]R=6E5\;[#QE^^?YFZ)[^0P?M@X/'<Y'VY\\H/S%3[BYLI16/2#:#R.@UZ@
MSPRY?_CI\8W"N5$:?R/4"VT'=3WTL;Q>KN>_ZATDNM''P&VG=!<A::[^O_-.
M[4(_N;R#!7WODRN"X;AI5;WM.NS=\&P<#7J1AO.@&^!NC78CU?'N'6_D_W?J
M^W42U*?RYSR(O>.+-SRD?\=,!H?47_?T3W\\JVNWN/%IOQ?WAUY-<^-XXSB?
M;/B3#1*#U/CD1L6?3P>_Y4&G<X=7*GU022>3G&5HG?#:,5LBLYPY15;@;[JM
MBU$C\,O%5?Y6+_+[ .IYE4-.U9JLO!)_\]]]%C_^>>!?N]/=][_W]U[O\9VM
MGT@1O]G??54[G]/KMW;J=;"=5^_.ME_%L[U7VZ207YSM;KU[2SZRRS(:X)PI
M\IPR13K&(6BK7"I=+ZOPX"F..DT/-T[\A[K,WSN@.43>-;DO)QOA\&2_FS&>
MW __[MII>#$YR$;3C(]79X&P]70OQ1DRC<F)0#8 14(9<S2:7W\2QK?#)R_M
M_F^#'',%X]7 U[^V_-GQ*_\A'[R@BWUV?JTO#@B3K4R*_6/OH+,&NX5^TTV4
M;LKLUA=T<V6+D+GB"Q"L\7$Z'21_=O_FS9<=FC?>>9529&"M((_;<83@=#W!
MV*60C,A*(MGNK_/F8K2?DOHY.Z;Y<#$^PWJI6I=S?724XTD]53'_12;EJ+->
M1WEP7'_=^RMWJ:7ZPI\//Y*J/7O23,?\3,>@=_P!.AL_J&-2U7NZX*2:>-\=
M?7EP!?-^K^3+(>E]\[2?U %M0S.?H?GSL$]JJD^QS(U#XC>._<>C?C<4_=YQ
M!2AV@/2(F-[YD(7>X4F.^P=T_>_.R&['$S+RHQY"Y^?1,_[B--.K_L+WXWWA
M&M;34,_=Q<VY^W]WYD5WL^#5^9&NG?X_(#M&%BOU.D_B7$+]_J4HCOKT+1N?
M,ID\?WR<C^NP^/JJ/KG%Q\TOOF."?KM^$$\/!IG0.@^)ZC!2#/>!_-GS<3SP
M_;,OY\]]1>Z"@0^Y?_;-&>ZPN<K$>;AT$41UCZMA.S@^5ZID!.OZ3NJ\IT&]
M7OJX*^KU:' 8?#AGGOY]?.6R/QV>]FO$5:.ZIFCG.$VVN^&'RTEQ _K=[$@]
M&L03&K9>=TXTO?I"RU)4$4_[Y^?X7,R)J_'UD*5<-YWYR]4 LE8\ *=_=EN&
MCKMSS<R3KY@\O$% UV)4T;E8U$@;I\>77N1/?1\_P!]Q_[!/QN[C8<K]S8TU
MD^JK$2G]C6"'/85OXMJN8=?&SW[0/^P^[7RJ=F+KU"!%2U=#NRO+!-\X>'BQ
M)I R*;:OBFN02495:[[S!$3G@PR^Z=>OWOWY(M.%NJT.2[VZ+EA<NZ&[I:CW
MVW+'5N\X]@\K%;OEQ<&Y8MK^MO:W6WZEB?-GG3>[Y?GA83K>'?R1!W^1K(]_
MIVB,@JIT_7+YQ7+)5G>^_6^=,_C+Y^KI>/(<[U_\NWVV^^H=W_[R$G>WWGW:
M>?_BK;&>J< 5,&TD8&;U5$<7@!56M!?>BN+/5[MZ!Z<Y/:MK"))E78QSKA[M
M9IVRC@N!10=N9-*B/-C(Q]$?U6D[.,T7/NAWW@"A_S'GDTN:?^">7JA?O='M
M17_8K>55=;I+?W__M@O?M?-+OG=>KSL09'/C&>GD^DW'%!;D^O:'&QL'AQL'
M^=-W5HV<DTBS=*-W?'Q:%^8WAU<#KK+ZP]7Y_<M$TZ8U!-S1X7%WCX\[*TV3
M]Z*6B+,N\?3=&R\JD=BWM_AP?-@_/;GY+3<M_2]DS?Y74')(+M_]W!]\<^K>
M90@T5A_ %[K&Q[[_R9\=/WAT-1W1.X AT0W?]0^5YXTW7LI\;_S<_TS5)>X&
M__'YYF)Z%5VEO]L+V-@?5#W]CYXT)CG#C47D:#+Q*XTF)I,GW4W4OC5$:E<[
M1]3\\Y%?K2O_N=HD4OC=A5\S Z_/<G'1A0K7'EX9M#9H;-:!Q7K.2<@F2,]R
MPEC0RCBL%47V9-ZD2L8R3/0V([V66(S6KB3K;_J>O]>F5[\GT=V'K*277J%3
MPC,7DDX1Z8_.VJU0"22WFXAF[L5?:E--6:CVHT_5FUR[N7^JV>1R_I]J-SFS
MMR !=.,5U4TV6E+/_U/-IKZ%.6 V)9M_L:+9=#A=(?"//]6X\4HRQRR!O),:
MG_$VZTQ:JCCIK<S'OYK'G?[Q74YRG&CQEJZQ^Z#Q#R__O[V#U;G8?#HX//[?
M(>FN]:3ZY>J>B-49*II7&W,<KN79??@M7W8OM-JV/SD=U*6!"1?1;V]6G64_
M6+M9]?N5Y/AL,VMY[FJOE_OI7F#RY\7*^1TJZ!]>7^^@=]+S_6XY[O]G[VV;
MHSR2/>^O0K Q=^Q&;#+UD%65.;-!A&>Q.4RLQ.(#YI;>$)GU8"/ .# S&#[]
M5@DX-MT"TY*ZU>HNV^!&0*NOZ\I?/E3]*_.:19'7/[W\5W_3\NOU^=@OVV7&
MOFN"P+<?]J _K@X//WVC_ESJYW>0K_@3?S*$>NN-ZKJS,%'8;A3,];&IB<)$
M88TH_*&;S-;;U ZB<"T['JVP&OI!7?/9NLA=U@E.<^.,6_%J?)S-WHNS3> <
MIWF<U1"*(31IS(0D)6^(:C-!. 67AZ*EOWDP"!]?G'F:9QSJ>'SZ66KYYKW6
M_ \'-+XD5[GV)WL^',^T_7W?'KVXU]]O-*@]_5[]LQWY^Z-AK7M@C]RC=X=W
M#LSQ4F/;\>?^^?3HY!MS\.+HW?OK>A8.3S(>]5\?W_GAY/CA@3EX]_V+T^.9
M__GIF>JJ19+A!(6D F(D8$\9M&#)I6A*-MV\'6ZYY8':_]]_L]'\?1&;RT%E
M_-8I,E^/RN3V2KC]Y/S=9/5265UH6M(B>92DP)H,H.N8,JJ \<$6AYI#<)/5
M:\GJ^Z:+:\7TO1CW]^V2KV,5W(3UZV!]^RFLJ42MI2;P',OHT9= *%0HKC@N
M&8OA<>367CVJFT_&SX;C+^OMT'(Y-?NI*[D2IW&VIOP\+N)WK_#^J/S_>=K^
M+'*?<2IZK!Q,W_!5OF&A%>"_R]T?L/S'/Y\?N^?_UI.7;^[?>?3FX&[_\?"G
MY_VSFN,[!ZY?PV]'[H$[?GSPKK_WV^,[#_#@.S)/DJ^.^@](61701P=4Q4..
MW;_$%E.L]N9M?POY3W38,P:O/P9_0MO85/[N5:WWQHI/_?7U]_+Z*S/F&86_
MEK2%\A9]+V:SJ6 HC2B<& 1K&Z$X.F]*<-7?O&UNN>76%S,.3P^Q:0_Q,4N_
M\_3?3TO]N7SS:Z_@QPJQ_#@]Q25[BL59BB8KLHM0"SG )A4TN@H]>[?D;(RI
MM.$ISIC)MF7%]7056^ JZK\NV4^ _Z.C.%W5^\=H(C!:X]2??ST])O.'IH;_
M>/O['_G8\O"-O"H?CH;>>Z\_^K_/Y>?_<AU^>HZO\QP+E7YL)F&5 )%,ZIZC
M=:=1G04L+ID6<@RY>PYOEF>8;YGCF!#_*<36VR+1H7#S**:*8VVFJ;,I9@WM
M3_K7_0[Q'QO8G>[(?_?JY8OWT?W7^OKU\UJ66I8^['#_^OXC_GKOY\?C//YG
M3GC?>5H.7[Y^\*]^;]K;[UZ^ZE]_^>//I\=BO_GUFU_[-UAH+]Z>_E8+O*NO
M7DYOL*(W6&Q2;)I/7K*#AJX!<C:]XK 9G-C,*>6 S;_OA&+=WZ='N/8>P==8
M6RU&JT8,K&1-L1A3-=E:\N^[.IB/'F%I).ST"+OG$1;6("([)5,39$K=([B(
MH)7'')!&%H/MIC$]P@YYA,H47:92U01$%3*Y-B[)<0G=.YC31)\_>(3E5N?3
M(^R<1UCJB9[$!4S50>EY)*!J3Q*J9ZC)22'$GB;H]7().W(R^KT6T'W%LL9N
MN*[/"(1*,D@E45&)R)RE2<@]E<W1JZ;LWZ]5]'\)/KZ8PKZK]#'WEH5].<28
M4<&:9 %S2J"*!.2P2&LF5MMNWHZWXO* P"_ZE_7E#Y.HKR1J2N[61]'"KD!,
M"4.Q!5A1>C5?!=0: ?'(Y%W)5.LI1<MS2S9*T;J.J%R=W.4K=]^X:)044RSL
ML<0FS.J+IQQC$N3X)USYJ9';)%UOOZB#\0<G_=I?'-G#%P=OCMX=]?OT*!P]
M?H"'=_MG?OBH7V=^=W#GFW#T YDGU18OKI<DWMN>0V/UP+7'.\FV/WK;BG=\
M\S;BK64T_W(#;JQF9M6QY68I]7*]UW2)0N2,-MKF*F.2:6:[:6:]5#.YY5ZN
M@<]LQGIN!FVJ$ LU327[TT9RF&XMBZ[_<D7G"J_ :7\(=E]0*@:N+;)J53J=
M^Z;L6C$M6>GAE2J>2=!4*FX8G3]1*O[6_RX>OCAZ<S FQ[U[9(Y.COK[')\<
M/[[G.C;NZ,6WX>#N@3M\3O9)[LEN3Y$*%.L38 H52%T#:HYSL%A*[NB$I>$Q
M\,7A0:8%):U5DD94=11=LDI5C2>;DDY#VC%#^NW@FR<]Q">7?02;N@-&##W.
M<^NO>L3/*3LAZOYP-!U<LJ;]<<(;S9RGLG7#0/WG%X'"#HT_OM.O^>3@W?')
M W/X^(?G0U=^^.[>;T<GA\^.[W[7[\V!/7K><V=I;*H00@F)AF<VP(T8HHD8
M^G]4K ZQ&^'5Y\[3T*ZMH84GP29M-?28CU4!)6#/GG-_1:69,?C :;IYV]YR
M;N7L>:<6#L\$YX)KAE-9?$4 +:PALD\%HW= L=E105I0[RR8W!/8:/JSM/D\
MRN+=D@GO ,3+4H +$CPUOUO#](+F=XBW:^L%K= XA"?5@_1T!H(SE%Q@21AN
MWG9$<W-MC7AAP"&\JQQ4NU]%);4L&*4S%T,M4XV[;YPNJG%K0%:V'KSWM1<Z
MXH&<3]"BB#>QE*!T3J'-9'4E5KG3P)W$DJVB+4*I.FJU&O'5%LM3)[MWK"XH
M5KQMZ'M*##&9SFIL!B0)0JD40XE4I)C)ZB98S9B2C85=JQY=J4H]CPVMB"^I
MN1RF@G7?6%U2L$95YF8\&!DKB!@32'?CP+W"26JH=!]^A;#N?,_*]Z=$_47.
MW^Z&Z_J,WJYVXT0=9[%<PXBHKMME*+TH**TY^W[1V1NT!CZ^F K6J_0Q!TL*
M5E_$Y%@"^.1&[P[C0"DRV!")Q""Z9H?VSE_6B?PK.!HS&?Q*!J?F=7W<+:Q7
M9]^"K=Y!BF%TPE #A)Y R+)+.4@;(SHG=]NX972YR$V=XGK!6UA49@[JN->^
MT:,')-] C0O0JD9?U ;O].;M<%G=77>@(=7%,OIM8_Q,N=NYB)YRMPVCO"!W
M>](C9T@E&QC2M([R:-K<)(&O$JU1VRJ6,Z2/>U[.K2.D3?G0ADE8J.*T/ZU*
M.0!)L( ]A03*:1S82)J;D1SSJ=2,-Y9-;G]8F[1?"NU3\[0YZA='%8RF6$@!
MW.FYR6(1J&>Q4-1G+Y*R3^E2NRGNEAAJE[$_JV'*A9B?*JFM\0*+!6W*+H=6
M(%JJ@)D,$"-#HX8A4JLQN9NW;;RLSHAS(>F2M!J"WB3,$CN-K*B<2K4<"M6,
M:&CJJO:-[$5=%9-+S60/1G.O;YWWP&7D]]+]<\F1,,7+;F TZ;X<NA6C]9;8
MV%JPU21>?2NIN*H80HU3B;5W="_6[*8&:T>?PM1:K]FM HT>IA(RV6;4,=M)
M]W;279K6'#RWZ#R6C)(Y:2TIED24/[09G]JM/:)[2;O5-/3@G;A#'3P@=\;5
MM@3*&)H/)7?$MQ'O7>DQ:.AKM5N[X:$^(P\QZ)R+UB4-'HVH:.DU?^ZFV9/'
M]EX1WK-)<N]OUW@Q)5I7Z4H>+$NT6N&60H#DPSA>P1G8%(8JU:7$(L:$\TA%
MIE[[RHF:@JOU4;2P6%Y=Q%JJ0B3M\3@ZTXOIW" 9SY71VU,M=;C%RX?D)T67
MNOMTN0!-^=1Z,5I8;1:JG)D-!-<04#T!4Z71>@*5G3HK\>9MMZI^:@?VD[\D
MDVJG_UQ[F=2YR)TRJ0TCNRB3ZF:2FBT)K"D*V,@!L[?@HL^U54DFEYNWTSED
M4C-"G1FAIAIJPP:_4##9,?==4H!<X^A>QPS*Q&","[D_2]LLGD<-M0-!:K*[
M"KM3V[0YAI\NGDMSD<1&(!YYYD@VM9H$DE6CBYQ*.M>DV-V2,.T Q,N;*Q<D
M>"J5MH;IA=IQ#.UC<@ZR8NR):";HI9*"8=,A[\_8>;YYVX:Y K-.O'HIP*F7
M\4ACEF(,O7IW%4-M%%VIU4[=T;YQNM3/23A13@Q(%#JG(8$VTY-HS*@!:W0V
MS1XQFQEG3L&''O-R%60*[)2Q-93$R:5(4T6T=ZPNU+JH6KJ!)# T^IYVJQCM
M_WW_*29+F'(,9;*ZD1G%):J88$Q$P7ZWB7.67)W)RNRI34W0OK&ZI G*J1;O
M@@6KN0'6Y(!=3X"M8K62B:BUV<]IC9H@'NCA/!OT&6F#8T3C8G-J/*)(=ULY
M>ZLANFZKZ33=L&C81OCX8HJ%KM+'/%H2"QG5E&QJ$,<8@)ZPMUYC"X-%CKWP
MRXUC[C4VW8HK=DV>FN)K".'4%ZT/O,7#N%;5)A00+CT15^J)>(T&G$7-)@<;
MFT[PKAZ\,S>-+I>Y*4E:+WF+R\J>@Z]HH#1-/>3QT-Q7[K_T(9:*-80>\L+&
ML-O^7> UYO1;,Z?M*X9E.A;)#E,RVJ'WDI1=:-D0]P*^I3.AGVJF#=/^Y1F'
MO_QT].[HS>&+1V^.WGW__,!].[Y7O];#D]/9AW</G]V_\U/_,S\\/1V6R29(
M;17!<A- )QG(MPS!U)I#95=<&"+@I9Y1?_UB]S )H4K3(J:@U28V6'+$H4D)
MZ,Z.'M.0KJ\AX1,=>Y8<"HCQH\U2+L#!&%"2RI)\*K[=O!U7,B/5J!S85&L(
ME2.W6E5\0FR24Y-I1CMF1K\=/'B26R%/M8(VPC&/H8'8%,'[YJ)2%1KBS+CL
MD?YLY.K,YL^;S4_YYH:)6EC"$D;30ZB#&&T&Y.A!<G-@246,0V+KA_0K+L]-
MW=N,?M)^*;1/P>?FJ%]8/[,U^I22!ZZN4^]4AF@[@A'I8=!IE2BSF=U>8G^&
M+N9BS$^)Z-9X@<7CA99M9B$(8^<*D_:2RG&!H#XHI6B=XYNWV:\H$9UKZ.O6
M;)<8&Q>N42/6I,+5^*39BA,U;3:SVSNR%T6EJE)]<03&Y0 H)0-Q=F 2VNZ?
M"\5\7NW+I'O=X3;G)M%@UHI8L#"54+DE1^,D3C13AKIW="_4[-$F2:FGZRFB
MZW';,J@1A-AL",:Y6O-Y)Q5.NM<]X+L81Q&]D%3DK&P1?<L:8TS2&D[AZK[1
MO21<]940L2$T%!Z=Y@6XYWI0BC>AJM'J\S;BO2O-[#IW >S>' C]C#(NI1@E
MNE1MK$@M]-?=WDHWO\3=.$][ZMHPZ@SX^&+*4Z_2DQPM][++47JFV+.#; Q@
M+ DH=6^B-?:0(SVY-.]5<F'%=O7SL,J5(S7%INO#:&&QW#77HBT%@HR#)%8C
M</4>3.&:T?<@+6XK,+IXK-T:0=F*;4AR4U--M+%E#+9HZ.^BL3\7"D.#M!I8
M4U&Z7KS>?DG3\1*/3KX-AP\/W,&=_CT?/C+')]]BOP=O#Q_^B <O#G\ZN/-M
M.'CXS!W]0.9)83(U5@.9N(>X%AG(BH?L*5M;G N!SY2C_N4&W%AQCI=4T_]K
MIE2'DF0<VC;,T=142^8TC6PWC2P\T6I*:J$ HTN R0M0R0F*5&^;U6#LT)\M
M;Y.L;F2^VVQU(EIZ2N!0N34;;$@2*#O#-(UL-XWLM\-OGG@26SP5:,F/+DSJ
M@9 M&*Z)-9'U.%I/VV4S^Q-UVN[E!6=*.KO?CY82-F,+AM+4DRV2N]<6B27+
MF>Q,2>>&H?D32>>S@_X]^G7U:S@*AX_[WW/?VJ/'#]S]QX_>'KY[T#_?#R?W
M[W:PONOA/[M@0L_XH"=YTL-_01 CH1>\/2]P/2>(F5>7F'N+7+@YKI&18N(8
M:>07KGOA8HN=AK1CAN2?L"T\SB7TZ%X#8"X).!L'N:68)2?-)JXJ,8_!4&&3
M);''0CUAI!R,Z;^P/CEGIAGMF!G]=O#-$T$E[TH#TMK>YXHC^( 2>9_$J5(X
M4V+^U0KS'5@B.S/UO>#JV!22;YB;Q<5FYR27@$!2QU3TU+H'50<16R^?1A.\
M=#H5W?/L SS9G3/.MX+AIXN'0:RS314L24^G30C IH>QH(TB.L^*=?8!W@&(
MEW4I%R1XBKRWANG%B>4UB9!AX,:C#W!/3;6: "4W;&R8<.Q>A3G.;)UT=6!R
M00HDW)!,E$"Q%X.YFK$K7^I4;.\;IDN*[5!<#35#,[D"QI1Z(DW20V]"K+8Y
MH:OL5KA'K,9*J0A3,VET*BF];K&Y4)9$I02O4W^]=ZPNE+I<QG9@]E!+;#VD
MCH8">9R>)!-R8^]-D\GJ)E@ES!9MJ['[2T071=FEK#D7*_V7--74^\;JDIK:
M8DUDDP<D'"O[*0(E\M!L4<R<#=)5]M??^3; IVIJ-P]5?T83VEC1)%*33$!7
M:B\0%&LKL6I.S=<IL]XR%Y.79-;))2,I&6A<J7N8[KHE(D-ABZ[&'IAB.I<^
M=![&NH803F'V^L!;6*X.7"(5Z\'S.-]0>Z#IH1VA>)/)-\LER7:#MP^]05?;
M2;+=?3:/GK0SR4:8Q6IIKJ!K!NW9VILI@+PB(+\H@/SEI_[GG]V_^^#-_;O?
M/S]^^, </RS/CT[*LX.3@W#X\)\O#N\<OS@Z^=$>/2?S),86FVJ#7J3ET8TD
M@L;$$,5+MXGHV>DE2;F]<BZM.I\<8PK"7C5IPC)F<'$*T\AVT\C"DV*K;982
M2(F])#2.@8UK0"P4,MJ22[PD*;?+V,VLFE)CQ?Y#0W!9&[6QM9;$32/;32,;
M4NY82DY.QU2"BN,(=S<XDOZ@75(38\JAT 6EW#N?,)RIJ>067,_0LXF<,<8L
M+52;4W"<7=3/;%-/3>6&:?JRIK)?\\-[OQV?/'O7/S<>W#TPA^_NO>M_[K?#
MAS_^=GSG^V?'@Z2'S^SQ..+E0ZAD+ %C*=!SP@(:O(#V4&U#5.WIPNH:[Z"I
M!FM;YFQ'/WJREJNB'T<ZL?+91P:G(5U?0_)/NI.PGB2 03,23%&@UA/,1#T1
MS!3::8*YFL;;F12#%60FQ%!$NFDV-J'VUY1DGCG9-3,:&N^6T&@WES'YQ,%I
MJQ:.KH)/38F4DO=Z,8WW+B_#G9DL7W %;HJ_-PS4PA*X]4C.88'J3!M'%R-(
MZYZV.U:. 4=/LG@>\??L(CYIGW+QK:%^L3$*A5YZ>05.*73J>ZG;D_(,M812
MF#VR-[.+^%YBORS5N2#S4V"^-5Y@L8MX2MF[X$$X"&"E#%)1(;38.),TG\=:
MUZH*\[GYO>XNXB'V.B;V"PR(SCC)W)R5ZBN66J1-3?J^D;VH2:>QLC'Z!Q;*
M"3"(@!:L(.(IM1[ZF<LV-B*=='=;=ZX'6^^2J0%SS\;$.1,<H:GLL@E3Q;YW
M="]V$3?%HC)"H#&\/A0!\6._G7I$#VYH:MRD>SOI9JLRAA6V[,?,TRC!)A)A
M9,?9JIFZ]WVC>TGWGJ.U5)4A><N BG8L5T=(/1Q(ZXF?;7$;\=ZI+N)^;XZ3
M?T996THQ')R:YCS&@E2LZRE(TC3T?>YC/\/XL>J/4]Y^M9[DQR5Y>XW8?81D
M,-D90!(%[24BL E!3,QJHK]YVYE;;EF:-\^Z;3=24ZR^/HP61VZ6G -7 >MB
M!I1*H T58K">K:^E9W);@='N=0O]6L%FSXC<:1>4:-%A5I\Z/\[6(!&]ZFI@
M3<'F>O'Z$\'FX9U[;X_>??/VZ.&/X?C%@>F?X<W].\_LX<FW_7H>O3U^?._=
M_;L_/#L\[2*>1N5$ =26 !A[$<)9,Y30ZRS*J35L9\LU5Y>>LWKT.7>#LDC4
M5+27<D6;-Q)2#M/(=M/(PA/C<BN^%+"Y>4!&#_W)A]&-1XV8K-S<)4G/I<>8
MAD*AA/Z_F(FU)-<PN5@C49Q&MIM&-J3GF*JP[=F%"8FZF3$"-RNGP\0R8>(:
MZNPB_GE%)WKDU@IG;PMV:J2IR[Z$$*@VT]J9[$Q%YX:A^1-%YYN#Q]__='SR
MS6^'#\O)\4F_3W>^^^GHY!_],WW__.#QD3_J]^?X[I$Y[2(>6,@UB>!2'@KS
ML516QE!-C8Z[ 3:7X^H*\T;$A-JKLQ[Q.60B+<'XGDQ82<6G:4@[9DC^2<M>
M47T$GT>-A]8!%W2@R5:? V6Q856%.4H/VB$F"3ZC0>R9@A>7<Y%B^O>;_FC7
MS&@HS'/W02ZP >$RFC:F"I(0P08NJ58.;32MF5W$EU/?"ZZ.32'YAKE96&QV
M4EVON"VDTVZE:@J0T0#C:\FGFBF$(2D-<781G^Q.6?A6,+RPTIU3M3[& L$%
M>G_&OF=%!#%'T=KK*BU^=A'? 8C/4)U=C. I\MX:IA=$WJ.)>$N=Y)0[V&C'
M4&F+"9IOWIN2#-F>D"+YN06\SC,4.:72@E9M..8#LE).+DF63I<H3\GVOG&Z
M*-DNM@EY\9!*=(#1.E!F#S*FUGIVE(1G:^)-L.HT%^,Y1B%!3-PK&"U1;$S$
M0Y8]!=A[Q^J2L"KY%E![),U#$>(<L"\9JKCWNOUB[&1U$ZR*U80Q&^EY*EJ7
MQ:DK644D.:$H4TZ];ZPNR:FYI(ZA9" WME4K=5C5-1!F4TST.4:<;<37*J>.
M-^Z_ZA]67KV=AZL_HPV-J<766@I-NR/3[KR,5T[6!.M[.I)/'5GLZ8:#CR^F
MW/HJ/<VS);DU-:>MBH!IIE?:$06HA@@)3<G!I)(IW[QM\1:NN 0^#V5=0PBG
M0'M]X"UV$R^:O7$)*GL#6,8,Y['[VDU5FA@J80RPW6;P]J@YZ-?N*+44HRL2
M4X[HB"FFXM&HC\DBBZZ&XA1"KA?(/Q%"WK_SK3MZ5W[JG^_-Z6?OUW+_X0\_
M]:\].S@YLD?O<O_]1^' DGEB,"-3:Z I., 0':@Q"322M-@?=9!V\W98[D>V
MNMJV5BRGYE308.-(.1NJ*+6EW+]EF$:VFT86GM2 I<<,'6?AAI$5!I'&D!FK
M:59\RWI)DFY6CE@#\R@TE;)HJ#'T?XW:;NMU&MEN&MF0=*?,W6=QANY=$J#I
MQ0$WKY )O<N9R-HAZ5[>3I_=Q+^L]39"T7K"[-2AZ7?2&A]KPNISCD'/]MQ3
M6[EAFOY46^D>V</'W_UT^/!;>WCRJ-^G [Q_Y\>W1^^.\/CDX+>#=^7Y\9UO
MW'NM-SG'?O0G-:5VH&(8B^X6T(G/ZEQ1ZU;7>J=N,](]/DFIF+HA16$)K&2;
M2(A^&M*.&9)_8@OWV$L(-87NF;W87BZ&")'1<7"A/_6XJM:[NC9DCD6]"I:>
M0+1:#7$M3IKA.LUHU\QH:+U1'=M"'B1@]T@UC".!BA :8_^'Q$>9W<172I8O
MN (W1> ;!FIQH&9";VQ+4*K34;L+$&J Z)Q'7TTIDD^[B2\75K.;^*3](K1/
MV?CFJ%]8?\> % PJC,4-P%Z!04_)$:(7S-0DL:?937POL5]6[%R0^34*S?\H
MP.GN"LK+U_#A&T\5SJHN8D&%COV1MV(JN!I*=Q'$0"$E,"YU4V GFGOQ;O^G
MH2WQ$9/7CVUO3$&;E+W6BCXG,FQ#:<9F3P4I3>7ZOK&]U&R\(^Q=#%!D''D.
M9&!,4(,2 N64-6L,V]BO=-(]FHWW(-POS'..:-%1K6JI!B\^*AL[M>Y[1_>B
MJBT[GPPC^--E=XP5NM^/$$+QK@0)@G.4P);2;;297,:(U%(Q*(JUJ15BCBI<
MN5PC=?RD>+5][$45/&J*&9N%GKFU'J2;![51(:1(K6?BI#PT<MN4?>]0/_%X
MX__65Z<!ZN=<]^:(^6=4MJUP"I:SS<YB,XFB=Y2\B.V98@IN2MVWS)U\^^8T
M(?C$G?0GV*R+$-7UK"!Q!-'1AK4GCLH<LF_E7)+;>?[MRIF:RO4U<G3O4XZ:
M\5C0>""-!*C1 $=TD(W:DFV*(4Z.-C3:]E(1FCK--8-T\"E(KE%JFBRDR (H
MQ@ 9F\ /H:5A/[89SE2-[WKSL:]*F+<-V;/;LIX'T*FQVCB9#SXE4VN(WIH&
M14T/<2XEX%HBF.)C-L3!IZ';_*Q&:D:B%2/1%$%MVN(??6KQQ4FH@@9R'<V$
M20MHBAZ2:DV.C5(Y;85I]R\:37BGIFE+(3[Z%&(OM:F4 #Z%"!B;!Y:*8%+6
MXCTE(3=[8>X Q6<TZ[L8PE.B=$V(SPMK,2%GA[E"STH-8# %&&.$C%ZRK^1"
M'FLQ_]/9%=7+<RUF-<611/;&QQ"LQU[54Q7KBDD2K;ABRS52'$TD5T3RQT^1
M[!ZW>DP5*K&%T3D5U/6?''NRPS)*[4%XU=,$D\>5>"1,T28QT?F*#:WT.B8%
M$XNIV;MZG?IA3AY7Y/'9ISS:$G.KI(">7:]L:QC;?@31!":*SA9J-V_S9=>U
MD\=/XJ-CB4U<CBFC2N;42HB2K;*DTG2J>G:7Q]^WX@_ZG[O_X(DTSZ$5@9 J
M TI,0#4:*-T:F@0;ZSC,G*Z R'UH;)EF8\L_4R;4GKZ;DL69A(@:Q6(6LLTG
M=-7K^_8WJ7NK!!]?3+7/E;J9WY;4/L6;*)P,-$($3"YT)\,"M1:/CA%-')TM
MPRU><8K$5 !?0PJG/FB-Y"WH@\@TZ@E>#^]%QNAIR] 13,!>F*6%'N6WG+P]
MZE3UM:TMHT?%-A:W D8O:DL2UW_9FJ/<>#46I]!HS41^*C3Z/_[[Y_4_OG][
M_+C\H@[C\8M[>."^?7<T[LOC!^;P[K=O^_N-^^4.'MXS1^[!NX.3XY/C._]L
MA]\\8>.)U!A0I2%3J@J2,0,Z?WK.)ABT-V\'NHSFEL8QU^:+TVYF:+5ICP&V
M.'8NLN(TLQTULUX5<H_M/CD#%,8@/\0 VJH'9E]:2"U'-F>/DE_9S%*E4E"*
MZQ:$.@Z2:#.AEF2<:LEAFMF.FEG_VI-FN=I<$;+ZU@N#)J"A11@-'DJ(_8>S
M9_?JG?TMOZAU[/B*]/3-MQ8QLE6, 3O!S&5T*31G4C6UCAO'Z<$7<3I\U^_)
MW8,WQW>.WMR_TZ_USC?VZ.3'M_US/3\^.7IS_/A1OZ[R[/CQ#Z?)0<_I,9."
MEQK&I)HQ0*(8J(Y0J=?9&NSJ'2[%^.AK<C$&B]SS2]>DIYZBBLR.TS2EG3.E
M-T]B4*\F(UA7$HSV3#T!* &(<XBFQ^IXVM]Z-4.BYEUI$M#TA"(F84\Q4*HM
M:L-6IB'MFB'U^_4$0P_BQF'/'4>G]%(=2*RQ%S#=L=C^_(G3;'*Y6F5VL<6X
MJ>_>-%$+^N[301$1L0?F[E+[L_.@O=R!H>[.FDT+X53?[3:V)G>=A-\3]PO@
M/A7A&\1^01%>;)1B;(5J1MMY,G:DYQ:<MYS5.G=ZYGVVN=Q#[I=%.A>$?FK(
MKXF/6-"0>^P6'6($:C7WU"#D_LH%"$Z")4=1RZF&W&R+DYC _M<RB=#8?9/2
M@8V=7,DN=2ISBCE0NTY]+B?$*T*\H#K7[JE;SAY\+$/N8J67O#E 51M;IM+J
MV'2? &\7P%1CJRBYVIPPMBBQ-#4:,[LL6G#*U'<7X 69.MNFC5R"YL9">M,,
MW"R":X(A8'2*>//V\B;[!/A*NU7:;&IF[W)L:%58L1%[MLZJCYJFKGUW 5[2
MM??(F[T4!8Z&84S\!0K(D-4XSZ4$LJ8CO$T#G7>H7V6:_2K_D%B8BH%=#RG%
MHHF1(Q/:E'II;Z712D*JJ6#?A$-YNZ1@UQA*J*Q0K'. Z"VH03\FUMC6:LU.
M[+ETM//LVI4S-?7H:^1H08\>$]O$K0+9F@!K\L E(D2BT-,UU19I<K21;:7+
M16@*+]<,TD*_2L4D%%(%DY,!C"6!5!R2<%?1:TMA3 :?_2JO<;_*<P$Z]5(;
M)W.A7Z4KI+TD) AB%%"'X"F;<0++.6.\&2.B9[_*2XQ$4\^T:8M?T#.IL!!3
M \[.]EA$!.2"C(G6Q8JGK-F?]JM</B^RZ]%HPCO525L*\='B1(Z2--L(T<61
M4%H_&J K%!)?N)844IS]*G> XC-V/B^&\!JU1G,?9$6H%^1$_;&BK800..LX
M_F^ V63PSKJ2M2G9=O-V=+,!WCKYLK'#%8W14!5-4L9>!IB(UJJ@*?$:28/F
MD,Q+ G5!,H3B7',->\S5GCAGSD"^=F2;$^\M.Z9TSBF9$];5NN.UGNCXFFVR
M!3TZDM YS2Y[:S/;ZR0#FK!>$JP+\B#QM;9.)-2(9:3*#JA$!:(<U#G28F3"
MNA&5O)'46E1UH6&VHB&T9)P+N34*)5\CR<^$];)V[A>E0$J=RFXDH+YDZ%F7
M 4&I4+DEM)Y&VY$KQ'4O^ES.\SV?$3*XG"Q&&D.N,H;*+"777I6%Y*092U,<
MM&TNYMV2.*C7=YE)>K;NJ([SO '(VI[+1V9M[#V&+6^R-RF\/ JGG&B-Y"W(
MB8JTE-$-'5[A(<M+(((5G#<]U6OL4@R3O*LG[\R=H\N%;@J0UHS>@@ )<Q:A
ML4Y%Y %+). D!JKMJ;8UXRA56UV M,LM+"Z6TV\;Y&=*ELZ%])0L;9SE!<F2
M=SV04F(P_:D!$CL0Q@)!BF=C!<-0Y9Y'LC2#VFI!;6J9-HW"@I9)'(\-< 6C
M0CVL^5'+Y7'N@\>SY&S4GD?+M,N!;>)^*;A/]=,&L5]4/QFJI-F#B;F-;-8!
M1V%@/Z9C5?3-I=F;:2^Y7]YUNB#T4R^U/6Y@02^54J]>.3F@J G0V0R:@X$H
MGCD8"GEH]Z-+V^$%)I$?1Z*XH%ZDJ&7!I"0N5<[.>.^5J5VGD;]S'_B2T%X<
M!1P9I=C8BUH1&%V)@4.L0"%:(55RL9YS%WCBO6:\T62+W%!QM#]LPDEJPO[<
MJLF:1:8F:__P7M!D$9*U5@F21C\FUB"(<P%BK]>U&PU3]1/O[<2[V8!8>HF5
M0T7F'K&+).=B(I?%?>AU.E5<>X7WDHHK< S!>@<ACD.&[ FX"H[5N5I[D45N
MG$_:/L!WJZO3JY<G-;_>K</WJPA%K DN1ZI*R2.FP*K5F.1LM+[E;#<AU_IB
M ^;I7O[<O9CE]D[!-!GQ):6$@-081MW87UFQSF$C^UD=R83A,F!8134U ;@X
M  M"JDQ:JZL9M&D$-#@&\6D#P=#SZ6RSJ*X,P$X=/CAS^^=R"9@2IC4;_8*$
M*5)DXP)#;-I3RF((M(Z)/.2-&?-/=7C]V4/I>D2N,P5)YP)T"I(V3N:"( E=
M%1^Y@O?)CN.P#-+K/LC%BS?J)8WCL+.'TJ5%HJD[VK3%+^B.*&N/.&2!W9#3
MDBHHLD P4BR.$R1V/3V4ML;>]Z3]RMKIG3*B#5*\*",J7%+V"MDY 40;Q[!3
M!:?2^O,5Y69F$Z4=H/B,)B\70WB*@K8'Z@514 S:9$Q4MP'S$ 49Z!EH!E;C
M; @V2"HW;S/.3@_K'.[B#7&VU*+/*)G$I^@T<JRU^UO/4^&S?YPN*'QJ1-=B
M5)!L V# 'GQ3*#WXUNZ/BR?/.MNR; +67+O#]#T$>IO09E(.65F;L;$V#G[J
M=?8/U@6]3AK-1<UH75_&AH-2 ^'6QOZ#(=L86Z4)ZR9@34U0FVN!^@M'C7TI
M49+8F*3[TS#5-_L'ZY+ZQK:FT0E#,&.KQ-=.:N8(-=C2*<[,(<P>2NM0WSQ\
M^5J>WSC5X%SD9+F^?%7J*]"7KU^_?/$WW^]S>?DO?5YOC _^\7=?O_SE;^,1
M_/KR^=/R_G>V:P/H[%OT\RVY->_-O#?SWLQ[,^_-O#?7\MY\A?C_,N[-MI0M
M9]^A%<H6]M4K^4@&$QIF:27;%EMC+8G17*,%P5F>K%*>V*6%OQ!MLAPMF%*P
M%R<4AWBQ0O5& PMGD_/-VWYYR,%'&#=8F)_O(,(E><5-G%":3NJ/DU6:EER*
MJ/$.69RX;*4EK8%;%3+7:"%T.JD5G=3"@J<U(8C3 %Q'JTHC?G2ACL 4K5KU
M8NQH$FN66PM,+S6]U%J]E'$H1D(H2(I8G9CNM"C(&('!+I5KM (\O=2*7FII
MI1=#P*C,0*F.7=0F("X0#"U+J=U4I6#W4RE,/W7NE>J_OI;^[6Z?WL%!XM.?
M_R4?;N'R5\K3?]_^7_VGCY?U0E[]^/3G]Y_/?>I\3O[UZ^L.QP='<_M_Z:N_
M_JZ)7GR?GSYZCUN4^MO\\O+74Y;^]JJ.\R?_KG]_\[2\_NEOUIQZDS_\Q0_W
MS?S^5T3[7?K7Z\__E3]\QJ%$K*^^WA=^\^JI//^,D?!7&<EW$/#3N_#'GW]Z
M]?M&Q(\5]%659R"M?\:_R?,W\O;7FW_]]/;W>[]PZQ:O^HNW_[,7WMKE7OA[
MP^AN^N6K4U/Z6P>AOAI_JG]*N=H/<..G5R/R_+>G/J7"R29"M)AJ8O8IJF@1
M:S"Z]B3=O/UPP'+C9;OQO_XJU^N3_^\197]^_>OI!S_# D]_6B#^?>!R59RU
M/I1$!DN-FKQ$CRW%R*V0O(_@_>_4\LW8\.38 W.PWL>BJ"F2\=*D4%5'P8W>
M=6=_G](_=:]&O'@)R*&'?M822\;^(];(B]]'U3AGB#1(ZG<.F:WD@M9K3:;?
MA/Y]3GW;[[[BU)GV9_5<?OFU_NWCB[^7I[_^\ES>_NWISZ<W__0O_?V#:_O@
M8,(O2[[T]+F\_^T/U#'?8G(#O _;?Q^^\0<F;YTRN1 8/O)ZBP)^]K?-+?OY
MO_J%MPVW(H5+?]=XRQA:P[O&-=R!=*O;_S5YUW#+K^%=^9;SO(9W3<Y?HW?]
M.GO=A?X8WUSL).47+^1RLJC+N,[3VNW&+^. _HW/9I7K_XRG;_2WIZ_[G\Y?
MD?W]]Z<_7Y\/VVOSE[_^CX6[N]-&];'OP[2K]=O599C5^^O9!K?[>Y^$O?"^
M!_+Z7Z_ZQ=Y8SS++ZM9_8QQPWS6C&D>?H;VJ]4:O_.K%#&M[KNKH:7U>]H*2
MT_-O-UZV*W3-7_Q\3]\?S+O1:]^?9[!;SX=]_=/+?_4W++]>GX_\LMVXO!!]
M35#]L$4T1/LW7O]43\/)C?ISJ65;X1TZHNMC4Y/9R>QD=LAJKH]-368GLY/9
M(3*Y/C8UF;TZ9G?XW-\__O.;T7/;7<*!@6NB8[NTOL1*P3!%'IO@&!#58$O>
M>)+LB[337B']S8-!^/CBTIMT[\1D]U].[M]]]/;XSB-_^/!;=WPRA&//G]]_
M_ #O/_S6'YW\X_G!XQ^>'KE';P_>+@C17AS@\<-_/CM\F.W!P^,7!^\>O+O_
M^%$XOO-C.'A8GA[<??3;\>-_GAP_O/?N_W_W7]VX7Q\\_+9?^[,G1.R\)0NQ
M90-(TD"<5Z#&T9608T2Y>3M>WCR^;52G3F[/S^TJ_<0GJZNQ^G2!U<IE*(^@
M6!<!6V>5@PA("(0EQ"S!3%:O):MG-JN\7$SWLNGY!F%]^RFL;)T:3A6R"[7#
M6BMPC@:48I'^&Z@YW;R-*_8\WSRJ&Z3C:_JD7_P&;.6E?ZFU^KG<P&RMOF'^
M#__WI_P'4YKZ9$:'VM-C: G&\$O R!A:#1QL',?0SM%:?8;(RPJ1LQO[AB%9
MJ#Y+LM*T.3 J PUO>D:;&M16V9H>*F,[G0;/<8;)E3H_3Q>Q%A>Q]RW?-^@J
M%HK?%DK09BL8+J/C>X^GW57TI-KV0,K>NM+D/!W?IZO82U>Q?#C[@GYB]I7?
M&L^Q7(G;;K 6+-DQ<S(IR.BP255#B=3&1-N>B=/RP+TM<QP3XJ^!.$M)2AAT
M+(F*J+=9/?KFO7'V&C6KVND>NYOS!O<7ZO*,)KF4!&Q+O2[/L8*P=\"1K NQ
M>_YPWG[8TR-LH4>P-:,K7J()"4..A$4UV9A*]-F$?(TZ0TV/<#D>86$10K+U
MK7"O)U!]KRQ2 4K6@8M1>E5!2J5-C[ ['L%)Y<!&N56/Q32-R5=RTC 9LC%?
MHRY,TR-<SM[=PV\^[2$G0;#;F8,>$1302@#R.9P6#]9K\:U=LR1A)T[_#YV>
MWYNY=Y\1[^348D R_0T#^I@UF.9Z!EM[.6N<>S]&Q!NT!CZ^F**[J_0O]Y9$
M=Q6]Z0\&(8?<:Q!V"#Q\3,!:^J,MJ8>H(>3QFYU>.8FZ.%%3#K<^BA9W!+!P
M\VXLZ;4>I(LQ(,8K5"3?G)(EL:<4+7=ZG11=ZA;;Y0(TA6KKQ6AA>3Q6MLV6
MW+GQ%4;T :[2($=?,UG3@O;RUX85M^!W89/LJ_+CK;F.+VG(SD7HU)!M&,U%
M#1EA[?6G,' ^G=V8$21D!<?&J'+3)*5'N'-(R&8D.C,233W8A@U^H3"R+6$C
M3%#B6(J-/2JI8X&,-=H:"*W34SW89@NCK0A&$]Y5X)U*K<U!O%"7<7&>Q C8
M@ :P<0$IJ8+Q%"A[%LKN/$JM"?&607S&//*+$3PU5%O#]$*1F#.3,;Z!+9X
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M-<$8# \8R0&%4B"+3=4BQUSCA'@'(%[>1KD@P5.2M#5,+U2)4L@XI "^EX.
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MZ@"Q&>#AC^M#UB C3>LECTA;]<3]LW+1%#M[E7/L5:8"[JK06E+ N9@*AYC
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M6Z%I W@9K%:RR73NS82,U28A:[C4'*.IL36[0:*@R>KYL+IRJB)UMHQ N1M
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M?[;[Z,=W>P_U,^C]VW??/[M_]Z>NUZ%?N_UV]]T]_1Z]KC\.N(C1?!L G>^
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MJ.RS36E.4>]59(K]/S/%NWMXT%HSD8=%2\]YG*LHD(>^C[EU3,X[WZ:=X18
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M_[;SS<[) FWL6$1QT3;)2+ZS869,66S/Q#U^)=!H!MJF!AH=V()1NC5@4A?
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MXI/!WK :Q\\5QZVY[&%7BDEIBAA7N2^I4,@JJ9#03&9/B.16 HZO3M2K8?R
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M=5OP^X/35A?>VWU[TCSZ=+J]<W#RG[.MJ>OBW$NI"%5,*HLH["[BB8+XK+5
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MRY\**G* Z17;4EGHBX$>-B5;GAO>#@:GL)DG=A" \/,#C@?QJX5-*$:3<]2
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M=N)XA:=UVMWVLXL\S(K1)$ [VPNN6-]I%$\);9H*F-/%F\H7)<0'%OXV\0M
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ME@ ]J1&'@U]JJN"_],5KP>\2-U8#[M&)WC7@?AK@Y@1JI9-W/&$D0>X%P"4
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M.GSQ^Z4%Z+9[:&[!Y]?J!CNZ9+E26NUR56X68&W]*K#SY;@7XB#_"D9I'W8
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MY%_W!_#@W!"S/ 8>,!X-1]G&E4U^X\'TI3"X=C\\.^-2B75K9S$X5&MZTTV
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M"K!)EA@ (A8 1,TE$LDP0WFP3(07KRE?8UJL:7KGSI$U$%=^(MY-FJ^!^$!
MG!/: ]5!@.2.F. :]&^,D5%&(FL5#C8)YQ3HWY2L24;60%5_1$!\%KZ!Y7Z0
M/^RP[>>CB+)CX%?S!2Q?GN]:':;A&JN5X.EWC ]EMZ;1(MD&<3&$"7?"-7>Z
M 7=ZOR"O$VMUU$$B:C&("8)[Y(0E"%MJ:))))4=>O";K[-$;%&J4W@BE=Q3O
M:Y3^%)3."?.8)NU  $2!2($X)Q2!+*@1DS;%8+,Y4!>4+NK3-4J?(DKO*/O7
M*/TI*)V7]$ET!B")HG=PEDIG0,@G'#&:C+>:\4@Q2/I/X"Q]%L;YY6C<7)Y
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MX_'QV]O;SV]G/WO^[/CTY*1S_(\OCR/:]$/2UK'=[X76[R^^P]J?'>/7+V9
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MYMI3>V*Z8>B;;F!.$+$DR:J !2+RNA/[UPH4RN$R\L@.M%#:10(<@KUS<ZY
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M7B2@YA<SC/PU1T BS*D<Q\-HE]RT1?\"OKK ",)Z?,4&M>:<8(=<?,#1H^[
M8RQA<6FNRE(%E=T7LLCX'HV+RTYE$B%#7I)!N)^.#LDE5ZY^(8V2[PZYN#HK
MR1=4H>4^>DDD*9"7Q10$FM+T_&$"JIXWW&"G A%_C4''6S'&NN2/@1$FKE'
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MQ?+B+V<AXFSSZF1:EBLH9[/9Y-G9<DG3Y&BUPO5JDD)* 5D!EDP!)8P SXL
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M2^X6W'PG73.%ZX>M)LHJ*V@V@O*,!EU:#3$7!29)(Q0+)??+];LJV,B"F,-
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M?CWW'B3YN,XIA_)" UAQ0";_M77Y53KZ;'%Z.MV6.I;%\BVNI]N[',YO<#B
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MMMS\.2V*?^^5KUF8^+_QRS_#/&R9T1M<KA;S.<Z>+4XK,#:23[AAV@C$>B!
M_VC)(.JL:+);[8A)9<6[.>[[Q3W<P3R?+@FWB^7J+9Z>S<_GP^6)L"N6%>%!
M"$]Q1;(*(E<)0N'1"RVB[W=7UUV"CBLH;(RR[]U-,YLU7*CN5WH3I<0K4<K$
MHDW%E0@AJ%)[;'EB<5( UK:F"8M-',<SU[Z3?US!YN"H&]K"G<&X6*[KK;4O
M:.E;?$&\N(1F$J*S.E.D;#/G-$B!T_Q!"T;5%,+H'&=N3*"\18]Q19>C &<+
MB^](U,Y?K__4^?#W/_TW4$L#!!0    ( ,F(B%2D.K?=-]P  !/4"0 4
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MWR?3]XMG9V&QF)0)YI/%R\DT3!/]]H3$\]ND"N-4:)%""@R,J:4754H010C
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MDN&U?4M*X+,64)@SD45:1MUHU^S=(#^.&**6.G-_,%$[[@:Y7[H7WN4M11>
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MT:X=LN]VXN<Q%Z S3"0?5086R)57A;:1X"."1XFN>&YI)QE+S[Z9 G3]E/(
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MH+R/9#=PO5= ]081[UN9MR_\1,N!J1?TRR6R^W[!;E3+LCZAY$60K;6X5]1
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MQIF.DR'?]VB_:Y5_H#SGA? R&JK[PZV_N7?\=E,B*@0Y=)D@A^9WBV0 +27
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M;,^4D&V8/HHK^"& OZ>$=+B+WTHS]KZ+WX76H]#'A!ARE0@8;>5SJ7IVW9,
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MLE64S2\^-S]VL:#9Q9VZM#>E+%^$9[_.ZGSQ9=GP8/=RP1YOW;LNL/O2UPH
M#5O2F'QV5$RS<)*1L3@9O2.5R-J3'@#V:(!U)P2Q1/+^&@EO<N\:DK=72#8F
MY@6I1+0I0)4V@9%D6F?TP@KM)!MO27H[9+K0/ACVWRWOOF'UXI-84B'#7V0.
M;1BV;"F'&#.(1"B%J@K-9$[")H#3[9*3*LG#+71O=KKG1-QO?_?K;(7JW>R/
M>8O/_4'Y.I!7/N+?_/.V@G8(\'\Z_T+\L^OEG%2L"4W@4R!1!E.K@+8RX)]Z
M45/2@<J SZ<CI!>N5H<D<!2_8GOH)T:HD+,*8&UJHX&7@6)?(%I-40=K9)HL
M^W=[^"]<02=C=A2_XUH:RU*0!94K9/S/L\O2&H->_>G;^>QB@?FNS'@_#TIH
M6Z!(5& B&\;!F A%9*O9;<)4)[L9VG41KT8S)V&Y<S++#N*ZNEL+U4;G [MG
M6%UKSA8!C3,@)._];,ZK8H<TA=_U_6-7ZQSL%)Z$D$/7X;2%OIV?\4_FBZ6[
M=G-KO[Q[\1&5,UZ"]5FR[&J :%KCOU8M2[&P+9L&Z-;C;YCZ8GLZ8N?=!=PY
MK78SJA^7&_L@7)NOLK=0@*MW37L1W9./)RG>0YA3DAV%JRY[=@\\L55FV5'
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M:_$D+!^P!X".B 6U99BN908S3&QSW9*OVDK^0Q)X+&[$T?8 V$41QR3J>'H
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M#$5$[_T6=^! $Z%V$/F*]9,FN U2#;2-LI6[K@-M8^LIN\D]EJ[2!MI.$G,
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MNN^E9]H*3%TF#^SYV9-T(^R#<<?PZL$L'S&H^CO]8"N]@;E@F;.0;$DUT<8
M>HO =:ZVC(F9=9H9T^/;+TI.!F=^ZZ9H=U[7=U^^+H.X;^F7Z6Q^*:S/7I,]
M*Q99 58Z"#EP,#YHS50IJ+L$P7:M_Z) ;\+$06I'/_XQG=W<Y-F7C8C;_'MD
M-JC,; 'M4YW=:C5@(=&36I6<74PVCN8.>H[8%R,S ^'3,"2Z5W0?E18QB 2,
M^=K(SW! @0&X(561,U:*Z9(_?-91\G9Z10,F-PZ#]HCD2Q71,6;!R$AB2_<=
M.(L,O/"(T?"$?K_)WZ]2. 9F_" QT\=A7%36HW,%LJV#2NA)!$Q1$%W62AM1
M2S-:]=MY!-4/>U,.0Z!Q'+-+G!^]T\SF ,RI:BMI!9@]B;!!%1UF%GR75.=S
M3:%H]W0<QMK'R-MCI5#88)VG?8/E3E?K68,3DD&)+'#KC(IJM*RKEY-"<=BU
M,CR2CP70#9Q"X6-B0?L(NKIJE"73S FAZ?%T1A1Z2I5]<2D4?:^;QNP\XQ0*
M);(*F2W"*08J,\%'$<!;%(IE)6708]U.+R2%8B_).3R%8A\$1XYX=R'M1PK%
MH(#O$?KN@];( L5LR#I:!D%YLZQ\]38KX)H97S/J>< 7*DCM4RB&DJ-]0!I$
M?AX&9B\V [,/H_^N".E#SL"1UY3\A! TJ]DDW.=80@AVM*Y?^Q!^6OD9>V'^
MV',\%&#'2=>X_?(%9]^FY>?\=9;CU7*<_)?I[.;J_RW^'2?IM]GTSZMZL%<'
MM66^QB'?'R!AHQD[-C(V?"HHT OZ)U-.Z&"$$<QDI9"TKZ*W9&P<0LKP5?(J
MRJQ(L),PCNYCZ<!CMI"B+KJHDDWH4OP[;,K&VGNSX-M\P;>5QY:L,2.%\R!L
MW8** D+*$9R7#JU+-MO1WN<M])VD)V,?V+>8"P>B,,@PJO7C=>_,=PPE\@"H
MLP85BP5/OR?RN% FN>3T>%W^']/W D7C4!2&ZN>UO%[_-L_+S)'[/YE?AJ@3
M-[I ]>:"XK(.<'<&F"F16>1%C5?/\12A+U!8FN$R2.K'EI A63"5#]^I?$0T
MM\44C+5AK"0]T5@(J!&DT9)S^G^PH_G=>]#_ F5L:!0'*:/_V^2VQ@96%-4N
MGK,M1Z0XP8LW"/5 T,7J,KCH-(@BC8K>%9=&N[JZD?P"!6P K!JGG^PR/"ZV
M&![$C&)"T(GT.">J'J? 28& ,LA8(M+_NA1[[//-%R,4@S*[8;))QY@"LFP8
M.@["U^1+SR)X:X@CW,J@K=-D^;ZTX%YOV-NR\XR#>XRTM.+HCC,\$@>+MX#&
M!+"9[KR$1OG\HSYZO^#>7I)S>'!O'P3'CL5T(.U'<&]0P/<)RO1 :V2!,H8C
MYIK/EVMZ.*]3S[0M().T@16/6L<7*DCM@WM#R=$^(!VA/EJ;4$2H-04,28OC
MJE:$(P/D2>EHG5.J2^G7V=5'[P7+GO71^_!T$'?R7N'!C-8$@1)\#6TK42<&
MU7)QFU04B1=>XFANG_.-Y_:1IQ$ .THW\VWC[>ZV,'3I?=]/MX_B-F'"1@ W
MT3M$%IVCVX7,.:U)UE)!YF.IB9NDCS2C8O#8;=(F^D1F0>2UEQ<+$IR*!HHH
MT6GE4(4N[;^'+[=?M3C^E&=T)!=,>D>0?*DB4E.<F>8Y> '1V.INC70L:\<-
M5*4F/XL<4NFPCZ>_<I).IGT07']!&S*T<>U\!VO6%I]MU@;8HBME[7KBLE00
M D;O:[6O/UAL3\VMU!?HQNP\MEMI*;O7]"?3V=(K^GF6%TLO^RM9DSBF3-+J
M/-D/)M-6?(18LLQ)T$]SEV24W5\X4?_.7A!.F[.RL<FTG:J?%Y=F)[JV.W#V
M@'KYK7'=+RWQ>!;B Y@Y)MB6:VVT0H@H"RGT=%B"31R<0<DXSX)4KI,$>8=K
MY!@8[\/#QMBN:1<?RF]_(.FWOTP^TYOV_BHNM-])VD[ZKV\^_=OO\L[4H@?.
M%RTY&$D:B1+9TKVF6*VO+C$S4L99EX!B$V+&50+;X3H])BACY#-_+XC\NBR(
MG#>V<O?\P,&V["$;VAS')4@)T)BB*T$5ZQTWJ22)68G(G$V7>WZKC7*_7"VG
MM0]<A.GMS8*8-VNEK6M:,-V-.6&=3!&#(IF/A;3@X, $;4KA*9C-T."SFG\/
M,EIT>WJT_,5LAI//BX/VVS5.YI=.%.FRH2,5:^MSB1I"$A%L*H)[AYFS+L'S
MSA\\GGT[M"1L:Q35EO^#.)!_^0?9!U?S_-N,+N8%O1^^+NJ[_T*4WI ^P+B_
M=+8@V7\1=*1_*.$B..T,.*$<O1#>&KY1/SUDG?[S!+]\*1L0P($ZS_TVRS$G
M,BH_S;#^\C-^([OR/_/DW>1F>A'C]'9R\V[RZ8],+%Q7'NA/%KM:[.]#_0N+
MC?V,-[G6.PEEA 7OJ@<I1$-*;?)0=, 08Q9:=%':!B3QY4OB*6'<>*98/W8N
MG27"YDPG"R&'PNNT10$NI@+&A**-$J7(X92(H_@5QQ2XL9 YMB?R^S7_B?[F
M_$ZC"-LUBN4<\Y*RMJP$8+R0>9^LK<-L(DB1+$<T@971$MNZ$GULA^>@(O3H
MQ1X$RF&JQ9\B<66C=R!R[%RW#G0?*^MM&/"W-!P=!KFCB5GT+IB8(AB4EHX<
M/1=!U:0M7PPIM]QK,UJ-Y-'$Z]E<N!.2KGT :VQRO/GXVT^_W)$16"(B:L&O
MU 94B36DF1T=5:/0\^1"[#+W=VW)8V0C-6?X]'!N-0[)O_EXL<K'+1&9CA:R
M)(FD[\I:4AG *)Y\YE$IT27R?K_@RP.L#Z<:G[$/]T1P)VOMB05>B5<D*!""
MUW5\I[1>R:!CEQ[ 'UXJ7/TXU=B4O?C+BHABH^79TA$G(XMN_BS!6YG 1H]D
M=*&WO(O']W[!EP97/TXU[LE.1UPPKNX($=R*G!(#*UP")50 G\CF*%S0/9U]
M";Q+@/K!HB\-MOX<VUG&.FC@\+OY.2U+]QE.TK_FJ\]_W.1T\2?]]C.M7AE[
M-?F\2J2[Q>OW5X7^B[?3VPF1.O]7K!R\N?^5UG@[RTMGVOS#[?R&_J#ZX1H&
M)(]"^ "!SN,#L!% Q6(]*B.4SIK>;?3.6)2)1<XR-\%N": >90]M_*E+<B\Z
MD_NA+&?I_-?MU<VW=Y/YS>QVP8(/MS<K K^[%85@/EGC(6@M09$:!,X%THM$
MX2Q*8XQ[3O#'I+==-_[U#VW]_%U0Z-(@IKI;P%P8*.858$H(CA<6HM9<Z]&Z
M4>U+_/%B*B<CM+NG 0PB 8-$GC=X^"".N8MQJ[^4/LS^GN<WU6/[E%*QB'UZ
M9E*QUM6I.C6 I!EM67/ P)SBR(TOH[5Q'FG//T[(EA-RBO(VB#NU4T9 1IN5
MM*02%U:(EXPT9"G)(&5"NQ28-9LVQ6M-Z3AAD6Z.]" =RE9/T[-L>?IP7?)$
MAG@=81!9S97BYF[*'F/!QV!H-SR,K;,<N*<?4OV$*C.FO#3VWWR:WN#U:A\7
M_XVS]/TIN:-Z1UK@9;1>VJ03D-&70*%RX#,Q4*(H@@O,'KO,*NE/P0^9?)C)
M/@Z4#9NI=3U)>RHWEX(.%)K,P=B<Z\PY T%*"QH]=RPSZ:TYC?MWSYW]D/B]
M;^$A9:=Q"[DM!_CM=%;RU<VS!Q@M&<(^5N=_(JIE'9^4%*]3FY/Q5I04N\1*
M^E/P0S*?NXN'@++A;,2NYVES&[O.D>82E7(* D^!]D)W(_J0P#$E&#,!%8[F
MS&BRHQ\2OO?=.X2L-!P*.0*?[_H-*B'0V@#)*U*O NW46;)NBW(R)V8EC[K#
M[3P&K6/G8I^<;)^D4)QA=K<L@F67"C"''E3T$KS6BBR,ZL8W3*(9K1+K7+*[
M3T/6^J>![X/YT?)SNQ#Y(PU\8/![)>KV0>YXU098)!>DMV=;(A&K"MF1RH*U
M)20Z<AS]:/??"T@#'UZZ]@%LR#1PQ8T000/C=4!ZR@80BP!I$H\V<Y%*EXR0
M,T@#WXOAN]+ ]^!6\S1P(D,P+L0=+40N,QH%\"(<J&P<:9M20]8876"%!].E
M[=[FNN/:G;V9NPE07\X,<;28(VKN6[6PI)W3 9#[FG&)ID89%7@6BT/FG!%=
MFJ(]6OA,<>K-F\9YWTMB_%IJK&7*BJJELA S*$?;\L$5*(DSIS5*GSK?A.L+
MGRM0?7G3/.-[>;HU7R5",UND00[%17J:46N2%Y& JYP]HL%BNB5]/USW3&'J
MRYG&,XKN:5D=;>.]R3+1\YJB)1/0"_ \1P@J>\^MM4F$?5 Z[UNO+V<:1WQ6
MM)@/,S+6<?9M]6!R4_=04U]X;3E TH.93GO(IOBB=)"Y2SAGQ_+GB]DA?&H8
M*WE TF]YMJC%G\15,W1Z++TVCD%6BU[[S@$&R2$RZ5DIDG[8N9)SZQ?.&,##
MN-78^;^BRFZ(E19)^=IXLCA>0.DJ8+)65LG@,"4ATF8)]Y, VI=R_ [ATV/H
M7!/H'@N4#"*7PNC!=9ZL#22I0BT*F*B3X'2K:[_/\7O\A3,&\#!N/<;0'X;A
MJH!1".0LUO[=6=;Q$8)>WU@0O,:2,2OM<C=5_\1+/?N[//IPJKDI?<$47]GT
M=F$HL@R&#$A07FD()0D0PB@14?"4N]V1:XN.?;!Z,77:@B/MH5FSXCGM0FE6
M:N>\>BUC *>0?DM6B U2&(,=H3F>=Z,!-#TYTMROL5[N&]%FXY(AH>"D[-"U
M#=Z0ZLJRH(U(C#QUZ0-XI +IEM#TX<@@M>OWUKI(3"=FR'K@58=1TD%(+ +S
M6NCBO4Z^FV/PXHA>C#;@].))<P_&@A*QVA%F9QRO4SH]I^O5N@ HC0=K4G1D
M!I90NG3OV%CV3/'IQ97FSHLE*6]6RBE7D<ZP@QB19(7G1/<K3\"$1*1]*:6Z
M9#EM+'NN /7A2G,7Q<46GXDUT92$#F0(I(,J:^E5E IL=E%JI7R0W9^@(WN6
MVH!U"(>:>R0NMGM)'&U#**. K.HZ"R,$\#%YTC -W<HRD;66NJ-V=).V$7"'
M\:FY2V)!T\H<T"Q)SF@OPFK2.4.QX+-S8+75QD87<!_$SM="ZLN3]LZ&Z@"Y
M(\236AFXD^"98I40TCJ3BS4BK;*T-B33_1*TYXQ-'XYLL5X/[:A'E+B5THGT
MKYIE!I+,:5")TQG6M#]=G8I:D,F]V?+C"7#<62OBO7BR!9X&W@6W.L19:S0\
M*"@J56/:^64VA^5<1I^S2VX/>,[Z8NO%DRWP-/ P^)6D)*-D%0D(I%N214"Z
M9B@UL.D#&F,#2M$='G_6IZ<73[; <[B70;!5M$M[4DPD V9T'13E>=4M.=2:
M+T'*2R2RNJ*S6O0LP>G%D2W8'.YC$'RU(6]\PJKI<Y=TS0304/5)B%88+#8J
MRT1G</@Y>QCZ\60+/(=[& 1?F=)2DE4FHX#$/.GVF1G D"*DD!1*5X.0G1T,
M]ZN>*3Q]>+(%GH/\"]\;D&:KA%3> 5]H)\XA(*-+-@5$R3VJ$KLD%YU\J]:^
M\;M^G&K?67==HQ2UJXZD[TNC:[@JTL'V60(WG,3/!++(NLQ]>;CJN*>I)UNG
M37C2.(1W1\E],-'JK)A'$JW:@9D>0<!,%[#)B81-1YMEE^8J#U<]4W3Z\&20
ML[.N3R*K#7L1Z_AQGCQXA;5)-EJ/0@K=J:#WX:KGB4XOGC0.Y"THN5<HD>RP
MI)&!J<%XE5VD1[56#A5,A5M9@NN2__-@T;/$IA='&D?QEH2L9$1)XS"8!%DH
M!TK6YBK,)["9.=(LC0RQ\ZTFSOG8].+(SOC="??_7N_U=XIMOI^F[^2Z>>_!
MSHVFW18Y)PTU:V^*,B5@D$6C%,Y84:1LW[3[:5(/+<$]L&S^>X'\.IGO[SM'
MV&@40U$'8-3'C)4$#@M?)+JBR/2:Y=$Z. Z[U7;]@K:T]7RF[XL164O&Z,Y4
MBV =V<#.<PE8?*CY)4':-!:7>^_B&+;J"4G_[IY P\K#$3I][[VA15=;+17+
MJK@Z@M'4^@9ZX0N]]=)$I8,MQO(\EI /L+\?XG]B,G2\3MW".,EEK/6-BO@F
MBK^SSU-*7(M4_'B/YFEUZCX3T6V.\K!=NK<SX](HTGI%B)#*(N-.5A[0B3'H
MC=*"H0RC=5YYAM8?$C@@MJ?3*=OF0I8]<Y","\039!"T1Q#!*RESX1B[I(*=
M0Z?LDY:S$6$<M$OV.D<VB=_98S-AJ!XE8I".U0?HP'-=($JO,R:A6"S'M+4Z
M[N.')!]))DZGUS6OP7)D!J+R-0R4+80L"C!NO5 RR*1ZSATXN5[7)RV#(\(X
M:)_K=8YT[5AL!4IN+0=A+.DAQ2KBETJ0N**C(SGB9O7KN+?IR?6T/FE)'E\F
M&I:-#,S990-9GNNIU!FBKXDO.0= )2,$E$4+%1 W1V>?F3]\E.;79W((3D2.
MSK#I=7$BN*@4H-"N^D8BT,8$U+JC&M 5)8P6T#C5IM>G)V?]&U[O@_?Q.A%W
M(/)'P^N!P>_7DK@'<L?KJZZY-"$4,)(T'Q7U@E@/=8Q]$,*GM-GU[ 6*5[N&
MU\-+USZ -4YV_? ]#9X;C=9G^FK-HE(Q0& V@B5[$&-BUNHNR7H?3KWSTU[,
MGA[*J<:MKC\LJWCYENYAGN>LN8.L0AT<*$E>F9-@?,S"E! C=H1O^P?&3>[K
MR>QI:TZU/VWK1=B2!S2%,6 QDV[$-=FI'&LH#[4SBJ-7>V!VE-3R9D#UX4GC
MU/(E)9NM%;WQVKG"0(1<4V%HAT&ZNB^,]"X4YU679O);%S]/K [A4.-0X)(@
MMRI+0-28+ ,I-$F,90:\0P1>> A219MCE^:%#Q8]3XCZ<*1QOOF'AX6_+@<?
M4I*T ;+^5& "O(JFUIIF7I26TG?I\_!PU?,$IQ=/&D=]B)+W[_^]$K/:DI*D
M^+@ PBT&#J@ WK($Z)(EI:ADF[H4#FZN>X8(]>=+XZY1'QY49TLGG$N);EGO
M>6ULL)A&FH#YXIA"E#YWJ1)\L.@9HM.3(XV[0RT)X6S5.S$%9[5Q!E+VM>LR
M:CK)=.,R::5G*0HO96=P[I<]3WCZ<:5Q"Z@5*69%2C3&L\C!8,V5TV2_!R,%
M:&$PT/$N17;I]K"Q[+D"U(<K.[M C5;S]&Z2KF8YWOPU8_V#^O-I>8M7L[_C
M]2W]_"_3:9I/9Q_S[,^KF.>_DVYS]6=.;Z>W$Z)W_J]8G0$W][_B)+V=Y65V
MY2JO\N?;V=7D,]F,5],T5&G4D;8Q< 75*8"S46C%E0TFA,2%RRH[A4X%SAEF
M9NA?'7^FT.I(.VH9>_Z49U_F%Y/TTY3VLJS_>M+A^?X^;NG1UWE@ 8JH<TJ3
M8G0SL !U?%A!847<'+PP3IBY]XX.>4PV(F&+[RVK"+8.?;T#EU3'VIE%&I!,
MZCH3A>SBS+!.?=6<D?(?.K68[O?U8R>4C"-ZZX_;""@U]N8^K$AYDDI3@BM:
M%2A(!J*J33&\,;5I(ZM-;8EJT:4A4O<OOC[Y&0B-QB[D7_[QE=ZDG/X^O<:;
MJVNB[VE2=911RH1@%SJX]@I<K"SAHOA ^B/OU.9LS\^^1ND9#I?6?NZO2]6O
M/"/E"CWM5]4^YJD.S2N9I-R1T:&2C;:83/SH8C-U^]SK$YDA<&CL7__]:OZ?
M56M]1X20VGKS.]X\0RS3V::H-7"'BHBM_3>#X<!M"LK4;K:L2[AD[P^_/O$9
M%IO&T8#5]?CSU9]7B8RTBSE9/9&((TWM::)SL$(GNB.37A2::04>HZTB@US[
MR(+J,@RD-P&O3[#&P:IQ0.-[A<-/TR]?\V2.2Y#N^?+FV^,BB%HFL;#F/Y"U
M3\S%Z]^N<7*I=;"R#D(TR1'C3% 0;-*@N=4YL5Q32#J(7$.27I\0'@O/00I<
MZHF:S/-;XO+R[,SSS<UU3H]8^(FV-\>XX/"[R;_^<17_6+B9/CQR,_U\E7Z=
MWOS?6[R^*M_>3F?TY]//=T(QOYC3!^:7O#8JCTJ"4G5\1A$(03%6O<;>!.<9
MIHV0T9!M ([!@M=U;H[-[;T$;O#"FWUYO\Q7MW0S2%L\:"MK&[C  >VB=$-D
M(C_Q(D=+GCUX-\<IHSF6T(\+_AD6Q<18=*ZC*XKDLD[XTX!*"'!**5:4JA49
M/XIBCB1._6M?]H'U:$4)78C\4?LR,/B]JA/Z('<T,4-FA"Q%00ZBCG]AD8BE
M$X^^*$\O2,A^M+J_%U#[,KQT[0-8\UG-W^>Y&QVM=:XJK?6J3I9,1*\B:,.-
MS1I+*5W2']>6/-7ZE[T8OCFYO@>W&L=,%V0(QN_[-@?MI;,&P61+M!A7>]&3
MK<^"(W122;E3D_'-=<>>1M*3N9L ]>7,$$>KTK(JZPB86"4&,I.+>0ZQ#I=.
M8#&CX@[1I+U0.M*PLH8H]>%,XT#@@A:FUL:S"^XC9VB@:*)#U8)'9 D!7;9%
MEAR\95UA6E_X3''JS9O&8;@E,6Z-F%*\$JH($$N7)M?@K!1U4J3V@@<?.N6S
M/EKX7('JRYO&8:XE,9Z(6>5 1U/("@P)I):D025?P%N;P(0B?&$BL-!M5-;&
MPN<*5%_>- X7K:YAO7HLI?<E%A^@I#J8$+6E@XT2LC)9EZAE"-V&VC]<]TQA
MZLN9QA4P][3</Y8Z.^<2 Q1U9S*1WAI4@*!R9E8SC;+;2,V'ZYXQ2GTXT[@8
MYIZ6U06<78G>!E(W?39UHAY)3+"R3HMB68EH=.G\.*VM>\8H]>%,XXJ8%2UF
MHWK71>E3'41$5.9E%96/I-LXX7V2WD33:?K<CN7/%[-#^+2S5N9 Z!XW,_ ^
MU"H="4E$VJ5'$BV;+ 0IL\K,6:N[I"KL_L(9 W@8M[98Q$T<%YO5\]PR8TRQ
M$#W9%DIS 5A;'YBH"I,Y,-FIB>J.Y<\7OD/XM 6[)NX,^UBD,#G::28=-K%:
M0L<5W>BTZV1C,#;&A+*SXW#K%\X8P<.XM07$P[T=E:R50/&,)E='*)% >BT]
MR(O.=$F*+(6*Q8I]KDY[]G#UX,L6C YW="Q$9S;]CT7MW=)0#-H;II#N;5OH
MWDX2@J&W-Z/R7MMLU.9XJF<.V?KJ9XQ8?RYM >[0^>VK(R[HHG9!@91)U1Q0
M"XZA@"P2ZLA+3J*;B7;B?<3ZQU'Z<*JY?_Z"*;ZR'7VR7C)A(,0LB1!>P,6H
M07"68D&I7>JF@JPM>JQI[GLQ==J"(^VA6?-E\L1S8G3[^EHKI% )NB)B(I+(
MGN=,T?W1I0;GP:)G"$U/CC2/EURL>2^9T[$D>AU3R)QN;Z3;.WH%J1C%;5 "
M5;=':6W1\X2F#T>:1T@NUGV6G)[/K+6$&"P9"R'P2HD#76S0QG#'6#>O^_JJ
MYPE.+YXT#XLL*!&K'5ECG<540&=354R/X'SR8%E$TGJR-[:;ZOU@V3/%IQ=7
MFH=#EJ2\6:F2S,K(?0!-LE'MM$#O'VI(Z)5PKAA26/< Z,UY ]2'*\TC(1=;
M?)+<D[G LP<FF ?E:@#-DTU-1H#RRAL2FXZZ]O$]MVW .H1#S<,B%]N]D'3A
MDIY"ED/U]Y.=YLERP$!JC%6F",\2\CU0.[K#J!%PA_&I>;#D05-:S"4[DP,(
M:VL:I%'@9!(0LQ5!%A]<[):]=+Q&O<UPZL.3YO&0BS5_%3V-6H0ZX\?5'%56
M2AU3S2 ZSRWS+MB.T<:+XWGQVF#3AR/MPQR+_K,KI3.+R 62-1"M(!N-$5&H
MR)".)AB3,]'9,:]V?=7S1*<73]I',A:DW!]B4T@F1 %!7 1EZ8IUI&D"EU8+
M%%J*CLFSZZN>*3Q]>-(^1O&@07 4,FO)JO-)!MI1<>"9(<&)*%+BAA?3_?0<
MIVER*WAZ\:1]>&*]_ZP7G#'.$E&B.>DGQ8!+T0*G$^VJ;]B:;LFR1^O(VPB<
M7AP9( )16;O:4/962E4K<PJG2U9;VA *!&FT*SG$(#MUY'VXZGFBTXLG6^ Y
MW,,@^,J4EB%9Y:6&HJH7U]=HOJ[31XF4Z#$EC=VRCM97/5-X^O!D"SP'^1<N
M_K+:##?9:OH8(,^5"LL I:6#K*0MFGX879>#<[_@2XO?]>-4XT@$$;&N4?J0
M(O.%TU[TPC%%-W"5QX0Y&VFMD[++2_1PU7%/4T^V3IOPI'$([XZ2E4)I.5<Y
M8X(0:])+YA9\B!&LC<$7U"1K75JB/5SU3-'IPY-!SLZ]/NDU<NEC@&2M!Z7(
M8@XE5H]&#,(ZX[WNDOC_<-7S1*<73QH'\A:4W"N4NEC+32T[R"F"PN#I94T>
M4@EUXI#T*G8Q@!XL>I;8].)(XRC>DI#[LA 6K*P=2V5V A1#V@ZG]Y/^3',>
MN?6A2W?K!XN>)S1].-)^G,]R\L9&^$-ZD65@"*$.G5:2U9I%:<!Z)X4S07K3
MJ87K]N5?FFK7@HM###BK$SLV2!(,'2]$@ZB/J%)FD:1)LILU5]PSLB6ZO%H[
MEG^IP!["Q<:7Z=_S_.9J\GG194-K3O]C"FS-WE2%>;HX2@$3&1>T+<=8EX#@
MVI*OK6O2(1QMK%[>D?'S0NX[$;*][=%3$"\7'[<WT4$L?@S3 ?QI;*T])(B3
MB#&M4FU<:&L+NMKL)F90P6K!F&0I=8DFC@#4CBX_P^"T#UL:XU-;5,8_\H?)
M*B^ WN+L2XT ",1:1&D@,$&V8Q%%1)9=Z33J>'/=<97/ ]@[;<2;QIUY[FCY
M]-_3.UI"*+P8,NKIJ[78U2-X(3U8IV7RW(32J9G(YKIGC%,_W@QSGCX1RU=2
MHU@1'#4'3]H5;2O7F!K9/YX47L&SL#9W,;,?KWS.6/7D3V-UXHZ:M]/;V7T4
M)[#BR1J)J*H2+!AX:S1@-'H1:_"R2][YHX7/&*N>W&ELJ]T1L^R<IYDPI9YH
MEG7-(D!?9U]JB"(9G:R**G8)HZRO^1J5^MX\'0;;E=;:@9 ]M/H'BX^OU??G
M\6.@#F#0,,_<'4'%(@^Q:"B^6OJXR /6%F)1TB1&,JB[C(8? :DGU/H!@-J'
M+T/K]0J9"RP'R-:%FCV2P4E6D^,"Z4:*YQ*[."N/J]<?P-ZG]/I]>#.T7B^X
M2-J: KQF.BCO$ *7M<Q+H>6&# W?Q5UU7+V^*4[]>#.\7B\LFAJ2H%<718V!
M.PA:!Y#1%ZVM)JG:0PDYFE[?%JN>_!E<KY>6)^.+@Y@"F82*!2*&S W)G(]!
M*RY=EY2H(^OU3;'JR9V!]/J[/:7D/,_90U&VAOELG?LI"NE8J'*=)ONHQ?B3
MFOT+T"7Z<&;G<3KU<?*+19>C&\]@:GQ':O_Y.X-/:#A\'U9OS("WOH089:*;
MPRE==*WX<VBB#;G8PG"8&? ="3_FM*/W]T-WM#*I<)Y)&I&!*G1'8[7/60I!
M\*Q5,1OJW&E./'I_Z*CW[V3L'"6^!=B:-W4I(F.)RP0,1:QJGP2T]74R*&,P
MRGCGQN+AOL2?[XRT?23W\72*04%N:(.M3W5;FU"^BTJR![,)/@/3BP0QB[5U
MC82"&+V77FMD8XEB%X)?J_@U!W.0F3L_YWF<72T(^U >SSC?0O>E-)P8(CF0
MK5M+[JV$((4"X1AR)(4?N1GM/=F;_-<JC@,#W=!ZWD'S]VGJVVAEVL14+<\B
M>:65&0B):%6):UYSG7&SX\Q(0ODDV3^$L2FP#?T".VC=-I-]&]5&."68L41P
M;28=BB9+F3N(6DLEC0^Z'$<<.V[@AV .!';#+-.'TX!W#73?1K!0TK/B-9A%
M/6.0I.C*R$G1M:FPR-&4$57(O6A_K8(Y),2-:Q5:3G8/A2?'B6XK24E6(A<(
M@NRRHH-G+-.68I=LS88DO2X!/":>#3NL'7UPNF&%N%Q'2GAOZ)W(BO8M/:3(
M7.88G$^CZ0/'8<'K.C?'YO9> M>P+U[+E#+TFK,H(X@@Z*YPI/2C%!Z$53S3
MK6']9AKX:?JM%[MI*/YX?7WJ0C\N^-L<8_^SLB_=_.]*1D[_\D\WL]O\_0^G
MI"/]X^:7Z\4'_^6?YOES_9?#A?[3MXYSETM,/%?.9A5(/;.63 9%_V!H3#0L
M,YG56++=E>AS3D_=2YP>B?,@L [BSNU29-F%R.W)K2]PE/JNO-FAP>\U2[T/
M<D<3,Y%TD49K$$E4QUUBM9%!G5]8HG$B%N[BBQ>O'0DZ)RE=^P#6.+7QPWVK
M+9^+*\XZX*X2(>OT!Y<C).0F",NLZ)0C_.'4I\OLQ>SIH9QJG#'\8=DIF&]4
MVP<6?0Y,0/*U>C\'"Y@-22SID39+FS1VR1O>OOJX68X]V;S9DN P'K4_9 N*
M'C?BCI%[&8L%96KN95%UEG:A+:/BQ6JG'>]2'KCS ^>*W6&<:IQ0?$?4JL%6
M]'7R;Q4?K 9:CAE"R (LX\Z*1,^%[E)\^W#5,P6J#T^&Z./R:*9E#"KDJ'UM
M$52[H&4- 14#XR/RH+@5MLN8FJV+GR=6AW"H<8>6.X(>'_+DM7,&#;C(28Q"
MJB%G%L$D6;1,(2!V"3KL6O],@3N,3T/TP^+NCA"GBPA5CS)*:% B2L! QGY6
MS!G%(Y;<I?COP:+GB5(?CC2>9+,DY+[5H++2D918TG!DG5MO.%'"#%@>2O$2
M14Z=.Y0=J?UB*W!Z\:3QT!JBY/W[?Z_$W+?(4DG9Q,$BO90J"PO>6@6&ATBO
MIE+6=6GSM[GN&2+4GR^-A],LNYFM&D)BYK$P;0!35K57)P*IH&0N:N^T24&[
MV&54UX-%SQ"=GAQI/)EF5P=!$Q*/SM#&DJF=UQTGS5,+TFJ,0,9KC_ N+8N.
MWH>Q)5R'<:GUW)I[FA[K,8)%1;<Q!Z/1UX$@%EQ1J<Y1I%O:(2,1VP>\EZ'Q
M'<ZKUK-M=G5Y)'L\N,0%<&4S*.93=:.1#:&2I?TK$3JU5SQZK\RVX!W"I=9C
M;^YI>BQ0Z'QV6'4A)CDH=!%<K4_-+H2H63:ENXF\]0MGB]]AO&H]&F>]Y2#S
M9&F@JX,L:G*)K8,LF-2U?;ADM856M%TJI%](/],^L>5#.#IH/],NA)QG/].]
M6+RS3V8?_@S:SU1'J[EQ 1QIQ42&K TAE21EN'CAZ*)).IX&4!W[F;;!:1^V
M#-WWR$E#]J.L-T)M>5=R 9^(%I%$C@XQ![U'EY:3Z&>Z%WN?ZGNT#V^&[GMD
M4R"%*'B(VM47FTD(,9$@RAP2DXR9V.4HG5(_TP-QZL>;X?L><3+_9=6!HG.U
MQR BH+)(JI9)T?&B<Z>Q!\?N>]06JY[\&:;OT3)IA=6Y@&'1RTS'V@LRTI;,
M8B"=*<%%NM/WZ.3\*K,0#^+IH$TRNQ!RIDTR]^+QSMZ+?1@T:)-,'4B'JO-N
M)2?]2K%8YYR02<J<(]-46H&LBZ__A)IDM@%J'[X,KBP&S"DG"QA4@!IF "S6
MTATAZ'$H=3KN'DK(233)W(N]3RJ+>_!F\":94B7#8B#6US'%(B2BBL3/<.=*
MX9+Q?&Y-,@_$J1]OAE<626T- 6M:L&5U]$\I$"0)D2B>&Q985)NU=R>I++;%
MJB=_!E(6[S9%BF_BUC*PN<@Z^IOT(SK4$ K*5+B-IE,L^I0Z+Q[X0/7AS!B=
M%W_--[0(D7B%]-_2'V?2C.<7::D,X_6[R<)U77_3OV%BCX\<W.?PT(UMM"=4
MWM!-Z%#J^F2EA+5CL,C!"&&L$/FRQ_=:5F:^77W[W61^,[M=9*B_^5:+$FK=
M]O>V%^_O"P.]T$K4SOZ>T?.KZN AS%9 \$E['E5)FX/IQJG*W'LGAU?!W"^;
M_\R3VWQ7Z7N))7.D)Q#H6%8MQ7/PFFDH*7*5M,Y9Y+$XM)W$8]=B#RMUCZM?
M&@#56)U\-XFSC//\<U[^2N_Q]/;S'Q<QWGZYO<;:F@MG5]5IL*+]CFCZ&[-;
MO'Y//ZM]NZ[HF9E=S:\FGVN!^1U?)Y\OXLW5GXN?5D5!VX (GG/BG'4(*% #
M&F&<+5FES3*LK6_J: 2_#MD\71D8I%YP8P,?)F^FL]GTOXG*^:7,W*E@)-!3
MR8A]]&_.<DZ:CBDRJBRC*&-?EUOH?!URV1ZR01H#DM;T=CK+5Y\GO_PC_E&=
MK']9]"<WK#B)I&>74!/2/:G=R M8GKR(/-B@1NL8L9W$UR9%#8 :I*G?8[K>
MD]I]:0LSN:9'64VVEO)U8CCR.F<QL2@(ZVA&JUG>3N(/ =H;J$%:[OTVF\:<
MT[P^N>_F\UNZ%Q?QG_FE"$12"@4P*0T*ZZS.(!V@UJ1K&IG3>*T]=E+YVL2H
M#5P-BY@.8\LRG,B49B48!LBX &6<!RPJ0.:YNL(5TV6TIO2]=W&<QDACR]\X
M()]<(Z3U[2S]H=X5$Y/&6JQ!U[4+ 9Q'#REP)Z3C2';*6#*[B\C32#$84$QV
M-3@Z#*Y!+<?%3BN5J^SJ#H2-W<1H!ZU';EQT(*B[G6D-$!E59)1BR%SMH!-J
M P<KJ[M/.TA%U#1#XT,9S7,]JJAT;4(TEJ3L \0@$O+VZA\YK5-W1UC.7MLZ
M']!%+X'N3 \AHH-LC&+)Y6#4:*K[#AJ/H;@WP?&1=+0 H:%7_CMAWQU=;[[]
MBE_RXB0(B<SF&F!GC-0_1Z1YQ0-H[4,H9'L:%&.)QC8"7Y_.<C!,@W@F-ZFZ
MSXAYGJZQU97MI!Y+6SD<SF<EY  L!GF&=M"'6AA91*JI]J&V;L[@E$N07%)T
MVQ)UFP7_+T-&GE53QA.1?2!HG,#VR^UL^C7CY-WD3[HL%^WU<?*?[Z<XN?@\
MRPL[?:5PDV(F'-9"J<Q!"8P0+$K@PDH9,#NANA1!=/[@,52/%OA,AV;N3BVD
M8<+5NT5N$)WIQCE6W=8].*VJ!_D;F52%+ ZE/!.HG#($<ZP#3K@)G!O+E+_L
M]HFV;>V_?)W.</;MYZM22+>9Q/RWR>T\IT_XCQJER+5"Y/Y/?IIEHFO^W:.H
MO**;*R22J1I%Q6@ 37&U41/37 5.K#Z&^_:P;;48N$5?G2T_=Y?B\&TQU> R
MF22\9QR2EK4I?;#5,,U0P\Y!H_?:C3<18!>5QPZMC"B5V^9GM<"N<;+5@^W_
M\H^O5[/%E;"<U7R9=:"[A-?1&+HV5<@:ZC@O8,;279,LW3M=&E \^9%7*!-M
M&3^(_KW!@K?3V6+JRJ_3-2E>"._=@!7ZRY<ZE! 6B=B>6U <<RW7),73,(M>
MH/";91_#74$]Z'^%@C@>WHV+(^JT+9Q\6R.NNDXN@Q2F)$GZ:'"+(E(/F(6"
MF.MA"J08=RKBV[[Z*Y2/1JP>)$WI8-8L'6TYZ) \,8,%ED#%$L%S)NH,5=*<
ME5&1C^:\;+.E8XU3.J9J-;XL'#N?8#Z[N?QX0R>Q+O*7//T\PZ]T8^/UPO/#
MLW(VT\'TB+4A>VU%QVHW06=XL5&$4L)CJ9ZO9*'@/"P$@KZRD.A_SM<W\_H[
M6 HOA[OK\DDR3L/Q/I9 3%L#TU"Q6Q"U%+AUDNXJZ+H0M=L#WU=J=I$SKI>]
M(5S3H7@]FB#8C&@B1[#.DY07Y."25E#( "'[U&AKS+D*P X7^MCX[\/BAKC'
MZ>WD9O;M\NWOEXEKC,)J.A,U<:&^LIZ,33!,&<>82X)MB:'<@SS/\7]]GO[Y
MSW<K+G&^^\T"Y@7 W[\WGMK<D/'3@[C6T$>SHN!O'R^+BX'L% <RUY9OZ#4$
MYA3()*12V7L2QF:X_>WC2\!M3ZX-XDGII7XL+I^$02"GG0>/A;0/E>CRJ?,_
MG,XB2R[8MMMXH'S0OKMXE3K@V.@/DJ[1B_35^),.Q(^=TW' ?HZ6ICJ.]+21
MV@.@/YV+=]5-*9.&5X2!3(_^W>@EK348S; X*2P]'J]6;I_/F3U#L=T'\3$B
M+JMLCI24J%---2?K2?%$!HAD%K*SVBA3-:/1$IZV4G@,K_AH.#\7)ND!TA@)
M,3]-OWRY6J3PS/MGOVQ9Y.!4E^<(V\AK<=D+4XQ+2CJEO G*\6C1<^M=HMO@
M<LMZ+<,*/TTGM0<M+;_63^*[S[I()HHC4T0$0Z8%61J &@44JZ62,GEICU)C
M^#39A]]4O\QOKK[4'ASW*<V_T#&,-SN^?"E$""YR3\>C3M=(9$2[;!5D8IYC
M!F,0:2P^[4G[L6-^#27P\64V)(Z-TU1^O:U<JWV$I[.;VF#X?>T*4\F<8;R9
M7SJF,UV^Q -5RRUB-A RUR!CX62@T:7NU#/W78?/O$!I:,W<QAF_%Y/)+5X_
M)&S5HHIL<GH:A"-#2L4:,N2U,)W$,7"-/EKK0A?,G_C$"\6[%5,;YW0LR7I
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M4(?\@@JY.N$9Z4I.A8!9U/Z4'9Q#Y]B"=2]\>K5@W8>YC5.Q'P3F[NFZZY;
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MS'_FO<\<6"'LG7U6W6M]U\E)6*.L&6#G22L;*X"#@P.XP/X!6$3 W1(9Z <
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M*\55?-7LX]#CJN^E=L#UZ3^RB.EOQ2-Z0.D.=T0;GCN J?+U)WJJ*)AZ9M%
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M:[3B07,S7=2I)G)H2LGB$X-ATP-%@DMPOHG)0IFY]Q=:A1QB'X7U<&@D@RR
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M'BY'/YKBTE#]H'7O;K<[ 9?+=2Y=S/1XBMESX@O\D3-\^1#;-'C&2WU=67"
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MU1Q&A#7#Q5"G$HY3XDK2:A5M[?#Q,LO=21$>!M:R4_OOO;ZKH-.Z5H<$%EA
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M1/8UNF8'.V$0$_4_UZF!UE,L(,BX_O^X1";L,<\2%C#"[FB_*E4Z[WY9?FK
M%3M%K]^5D<M(*/OKKOG*$_=_"]G_]#'N-!^F^2_L9HL]@VOP/IPR!V&$P[]I
M'G(>G@_9]_VBF7?8+\R8'LWNJG<@1)31SH0& 8.%;!!:[[>1P=PJHEU'G& !
MJWG U_^*P6?V36:UC_\B\KZE:O\_[*<;#_MVOHH%5/#32S>]08Q[WA&!;NO<
MN#CSS[1SO2MC[U59 "Z \UAR+W,JOQ]&F\_X;Q^S- .WAR#"[*HB0OA.V!8M
MB!BK%U%=8HP7$1E! 1L!$GS@%!VV(@=,_A^S[=\W>+V(!2A[PAA;L U.ES(I
M%N#Q8-% 0Y1>P0(^P!J"1OZ2HO4X"BS]V5UZ]P\H8]WZ?P?_$P;_P$+>?YUP
M'[?K\G33K#.\M"'!(?S[1FC4$!M)AS'>K&*\8:.V[=-&?768%EN-G.* RTOO
M+C:]#2G;RQL[]S3KE!*_N<E(?^U6,PO@/5$%)=O=TB1T&E\Q8\.2^J$ZI7WG
M5+#A6$E#N8-9TYWKJZ15Z<4G9I0CU-J*(.F\NLK2TR.&D;GA>@.3'SNU?B[;
M7+0/=QMT@)]"(1TL?]]G+P&X;,!8 ,\ YO/^<LSRY4$V))*_P41J;D/9'6P@
M?D[&&4\U",)L"[^_X@=KV7IRWXF.R69 \ &%R>2,YW_SML@_TQSJ)@M0K;S-
M I:U8<S\GTNE%2Z=^#5C$,IL&6 !/W _WX9#B+H4"Q9@FZAX3L(E#3V.4=SL
MC9X6)==V9!AD%XT',W>EV PUV92.V=[T)@8[Q[L)3W[M^.YFVY&YHR>Q?(_6
M!X&?G&,!E;ET.YHK\A?Q<6XS2$IHQ4BO,%61PW9"2TPAJ==C=B6WTG\BQYS9
MZ"VL 9)_*:OSS5XCD7.0$C?FB)D,KK;_>?J(^\0KY#PFX2MGZ$.Y5"_T @*;
M".LC"!V<K/Q\\ K'XEF7SVA-QOO*ID"*-5$0J6M-.6[&3[%.T;?3"7&^J7DH
MF-05?,2 :>5A^GE@%\WNS4J4&&2_SMDW8L$C:!GF\+0DV%@*BO1:9IQ[FTWB
MC5>GA&3NWSVAN6>:[^,[Y9Y/I[+O"#3>#OBV,/<)V-C6G&<!8NBO3TS)D)40
M(I1W$IE"7$@.H;M5V/M'$4.4/EL.HW2?";J5I#B]?3!Y8)]0F&9"C-[N"+ZV
M6=/.EHP)CTZE/0-,<>2Z8WZ+$Q(RZY)8H2>L:173$8#8N.*\\NKYS6I5K6Z-
M,?-,TWL"?ENVE[>BS>H+<1A&/MJ$;D.1[H2DFDF"<?Y$&S7RD8KL%S_JGDC'
M7+^6OB:8)#?U[&'GN!K/3LX[B6+@1'IP^&SGBCQ)EQO=*0T7;8+-,"X.G \V
ML<WIBUB2DLXSMC-UZ%*?:A):MJL)76L*JQ93V:44;J[TR1+% F8P<G1S,(.,
M;<NKCV<>H*M1+DFIV9<$C^LFR"WN%],(7 D-N4\O-;LNZ;W_ K]0],Q('HBA
MO@:KBM#M!"$S53"VS4LPRSYIX <<,93=DMWZ'!0;GI^V\6UXHMZ8^7.G<:=8
MM>G)Y^?\E:^:\XZ==<FA'P8_,J49V BL/#C1J<1+@2=L7'LW*-Z&D[I]__.2
M?5(DXL"KZHS#.Q>=]RJ(22MD\>:CKC)PNGKV8Q.DQ]2TF5XYI#^)-PX%"2.M
MJ)X<7KG,-7(]3M$'EQ'2]>&30K2L<I;EP\/"4F[GHLT>%^+LP3F:([)KQG[Y
M-AE^/K]-"JTP3 ^K_)ZWN[8"N=C?@5@>K12SOD^Z]"9/T+PU:&5,Y2F7_WQW
M9(/_BC^1!=S!<9"9Y;.P1*8TI2*!I.WGN1?E2Z0=UKZFN,]!%$ELB&A\9/VV
M:%=VF/R89(R4XP>E!4O41#%ZJ@&?@H.A]/NOX1-P6BG-9B;DZV6DA_J"WU^5
M_RPOJLL;\\XI"JY2Z?#)CX+O+39#R0!).X*0+DP!P6+D>K.7R% -+($%B-;:
M]B8Z(TJ1"*MT1>,C%N=>I^_YEK=^.3=%87^'7_*AA4_RASX62+;N,#^RG;S5
MZ\YNK_*12B,M^ EWZP1Z!"G-@-#2V>%^)\\+R[.B:6<S5_\V*BMP%G&07_FN
MZ8&$NRLFDN0P>Y+N"J%HB=ULH3RYR\ E8D]YX8\&ZT1MW0J]8/FN-(N3.-P)
MY:;:N.?(<2-9=T,;^KM"R-L.^5!SLP>%N% R?&7V%H*B2O+#SL*X@\=%XHCP
M1&<EOOY-?8.#QSK6!.'J"V/7UP"_M[S7VSEVW_%!1L!=ON(.-\\R-$D:=)7M
MD)_/7B)YSS3TG7+AN!#K-+BK-MU'XF"HD?G:JU/+TB)OA+ROFIN4:L[!0(WZ
ME;X7S(']]F$DB"C2\%Q_A*8GC 9U&E@YG96]N&9MFI>>I.!DKWJ^^Z)JQLT.
MS%P1SYFS(S8T-W"=5-]*2,4+U1#XP*X68Z\4BGQ;;&LWX@5H97?LEHF4M(OV
M_H>(BV)BPS,A>P"1J,.RP+9*,KEW)W-\V[_5=C51[G1Y(5CIE4_DR10I(G4C
M[ =60E[Q/O0+S?Z4;EMY(,_2<<>>6VG17Z07RF&IA+J1.V@>2]+\L!;=(HP%
M\,$3]%8EX(*:QW.>U>(:\H8E$F4Y H_??>=[&)!L5IL!;G)+KKMT0";<Y^A&
M9:,!V^CW,QG22-N.)S+]^OF*5\?[BFD\SS [^#.+[@><<C+WY:A/VEEV257@
M*_B.%M0=1I-&CI 66KL-@M-,6L+?M]?V5/I95KPOF3AO51]YO4!-Y*N>2KA$
M>7U8!M+YV+-HL[A"W"%*/5VBT95LOZ))*;/*&[#*_X#C)Z?]+""6/:N_>WY1
MKCSN<4[WH+WRE2PK3,VN<V<%CEIOI2.IVJK4\B;R*1QO/RJ2"!,?FP1OUTPI
M_6I[[=K,$]/0/2C0,B7Y4WBXX]Z#X:/B;3)Q!_WU.%;8B1LCP (">^61N6UX
M@?+5VH#YA#:".#V0^-[&\I'FPFA@JRM-S3QNZ^2M+*$&8K[WY.GYWJ%[P%]K
MI)..AH>KDO7A$X-59BW8,XO.6,3 ?(():E 3>W*N\W3-_B'U^/-#$A[)-XW<
MQF N%PX_=NEPR1W1\LF9R2@L57RK].T<##R!P"^L+3&9]>"@X7W'T<F:JZJ:
M+[]=+!R=3EBK7(<:D'I4RE->FE[?5UH6^>71G+S)XKO0>R&U638A/L<(=#5#
MPOI6! O >- #V'DAGL;$Z.!7ES!I9W^O+_*Y ?W<Q (VLPU9P--2+'@0/B^E
MS0):+&ZQ %@N_-<FOB/C3Q(,V:5]Q^PS,"R@OV !;H<PVP(OV>5>G>E]\3_$
M*>/OY],://)\SF/%13[F+B1OK%F5,.K$ HC*.!: [:JD;1-FSR9CC9!'(!LE
MEQ$66RX%J233,<>GP_M*FNEKS*BMVPBFF/SJ%KV!!>#+F7J8/PM0^GN%0]5[
MR)P79OM3/KM[.V=/E]5=%Y3ZYQRL_ZQJT/..#5B.O/Q7YEG,JX=X!O=9%M"<
MQ0+V5_V'.%G_-S':/5+I6=0]U#R^)9OS]K#9!@OXL_5ES\:?ADPSX[%_&"->
M,W'=]UB*:RE6D':5&1CUOS;\!T;^(ZM>TDZ15RWV<LEZ8(<?/=F%.^M ;:S@
M@0VS;6AT-G$BMC_.T:6@\MAYZ_Q;EK9+YW1[F).-NOMU,/]^W)?U_C=ML/\6
M/D'S.;,F78)Q@>J!14SU\$98TOR;WXM*/6QE$152>_KRK \# JN?P>K$ -++
MP0^D4IIMQ=D2C<B^JU/K\&"]@?%FGZ]-IDR_.#_"=)S]#Y=]&?&S:S6"^AMQ
MX9OM7I4;S)3\$FDGTAM\I=/^PF1-\W^M\9#\W<D?$60>W<_N=/$;JB[BJQGE
M3E_QW\0A=,$_WD0-_7<^X"M0SP(H+,"'!7C*LX"C^D&E!!;0R<A@7$,PN(9*
M_ZZ/E_TF38PY"[@;Q+"[X,QDMT>[AK;S -_?G2$:P0[F?OA:6IH&L_.Q"0NP
M091MQ.#9?IKYH;MEU9'-%JKG,0LHKA_JBV/JW3I]'D%6_XXQW7"PO*6\IOS'
MAZC9!/_* NCR=BQ@3TLM"ZBJ9J?7KR%+6S.5WS%,X><LX)XW&ZZ-CK'=^-U@
ML_D!"Q"<O^%F3V':;Y@Q"I,IT/%(:L:(F33*@PR)N6:+Y0&OSW;N)/286I!Z
M]6NZ(FM%):M/S-X7U_XR'>CK=-#[8GA"AV:+V0/JHF;G)G8<RY242B!.'>J4
MLQLNF5UQLL.>;>PWA02:52M<?WW8#>%RM4@;WZMDR :KHSAOQ\Y>E!LM=%&.
ML!)%7FV=%DGP'&9"P80/D3B#K/437WUP<E]MO$^HVGA9!N1>OE,G'?F@[^4'
M#0#JX."UEW:0CJ)@5B)I"J!UYPVEA]XS6 ED8<OT^D>*5,Z1]GL>K\\7.TQ:
MJW8<-8%^.;^I6AO5^X$PCB6YM&''RG[?G4UW(^DF,&7K*9%)EZ_=#+X%;1FI
M/^A;Z__F9F0@PA5-WRUUINQ;[J1%7#.PW9%,\811M\C"[.C77Q6O4=I?2WZ2
M@-#_'#P HHG7IMQ4WDI]T9H#MGK\]B7?T30R.M.590R#, ?E1*K"B8T>4QH=
M2O*#32ZO[ I<1X/SM.Z[P *3^WY.7#&":[7*[\]TNY=9;_(&X"WJ\[)XP9Q
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M9Y+ZG%:MJLW<Z;DJTLT1KP%'\^2\'>-2NY3O+U,WT&.U*1+7;.X;6;T\WJ4
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M>M6>7UMH\YZ:H-RPX#T3ALP/106S]&UZ?+!>..Z.'C?)H.\VP<X@OMN5G6#
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M?K/*B=AJ<_'?N+Z81(YF_HJJ_WH?O+W>QZP)_[Z['O\[*QIBMRK+M?#>7T^
MT^8Y=^"TDG='4QV>O4*MU!N\AM&X0' .O&?D#T)T$*[LH>DI*'3[,DT/P=>5
MEI!I/Q4?)9$3.!,?D]?FSAW0DV=6&1$TV^Q-=DO^/;)*J=^G- =TCA/)]6;A
MM%CA<'TE<0F#?#K0G<"=\IV\-G/Q'[PFZ1^\)F+S=_$4JQM16@,ZQFC$@@.T
MO9YXL7U)V4_/L'<QT>-+^!I-VHIPA$OA%5^*=5+Q'VV,K438C8#U>S?I:/&1
M.>DW_652VH(?@C$/@H$TKOH?F>FC@DAI 0DJ8&I- DEC)Q]X-;F7HW[CI"FC
M;[@J?@N/?7 D%"M*HW2[/Q48?H_\U5)&_YC"XKI\]X'L)TOM_N&8<TH#S*$N
M#S>H 'AEI^EORF?6O-[MMY^<]'M,[KD=-4+6FW6\FJ,AM GRK?'5IHW]KD:/
M-O8DW?SS>VB'4XB2HB>-^>=H/(R&,2.#V\J;=_\9EZW3"^"/&^FH *ON34K5
MO^CI>X=GP33#7F#97Z+0O?PMW/S!$>__Z'T_3B0]/;!%E,9UY?U]_HR*BVVZ
M(5TT8O#LC0YM^"\2_R)FOS, TQ;V>S0KAJ(PV(WF T.D,33:/':634&LI(>N
MN$VMJ&7QI4%9G944,;UBG5=!:].M$ZQW6675[9Z<=[QTU>;<DPRLT.J[ Z-E
M,-"V2M)EG]]!,9;WL%I8:N=# LSK:HAL>O;Q+GER29D7]RI:(QG#0^6FSYRO
MNLQUUBO'$<7B&7U,;P<!M!XJVRJO-+-TXBG[?]A[[Z@FNR]?/"B""$A1NA 5
M$)0FTD1*1 1$1!2D!H@(2!,B2@D0"!9 NH* !"$@O4O'4")=Z1WI)""]))00
M("0WOM^9[_A^9^:=63/WKON;NWY_9*T\><ZSS][G[/9Y<L[98RG)/BK)D72<
MW-5W""&F,U7']5U6IT9,R2 )"H-U/WASZ1 !3BG4>@YB4]6!SD:>-^<?6S$8
M+-^+[[E7$H]%ZEW$ =;$KMI?:F]HXY2XJ-S-@.W#VE !4I25XOW=Q04QS)R?
M5XN]C&,RDN9'CII]5_"P2.>"T-*YRTH;I2+FO]Q5NN.LFNR@AUAL[!U73H;7
M;0>'67)_()>_V:E'[M^FN</C 6B4L$?+'Y5\4J#[K:UK?\^@YC_I<]._L 4Z
MCI5DV,K5/\T6IGF'[-P-Y-_5ZU)U/Y;SEU<I_V?<XGOR54Z+@CSL'D!UG5M^
MWD'U7/ON[MR.V]X_3Y>^^Z_HB-CG+U\34%9)*MY%[.\D*B9RZC&SJ4@(<R2:
M':X;\/U2E0J[MWN1C3N4Q;S(_<#.MD-:0E2/V-]^#-I0.MRB:4CFEL$!:/=;
M>A=HE0J8/I]#WXF8@AXLT/RHMBUE"S$-.O2%R%,!M.@.#U,=H/0<;HK3R0%W
MDR@TQ['2]X$*J)W>I27FU@G_1"#ZGQL#[OR'G06>DJ4"?# ;*$H=7_1!%^TI
M*F!G"?ZW7O[6-/7_Y^?_/C\YT//@8ADOA!>V=:#JW4I4^@^"=AT@QC#S]$7;
ME[[1F;Z01L3>Z5,4-&:K^,(U^0MJ7U!NK=&TE$G,?4'M^73.F9,20^J<YAD!
MIR94.[^KE#W65L5?78A*9N2ZV)%'1LS056B=-@:8TGHG"XI2 >(_^A&K/@.8
M[?A]S"V)+03E9 P5\/Z)$XBHNC2]K^=OQ0N9U1G\V4H%'+$.V>JQ6ECM.[CN
M#"QC:]67:>7WCPS.)\HCA[?NUC.NCL5E$.2-QK]'W:AUZW@WH+R0^=1SEW%5
M=G;Z!9JQ@55Q^G8U"8&-CLZ7S+)RP-V-4T_[!)R2#5DM*GI8]33IRH#V];,?
MHR2$9#O37G?8KSWM;[Z1_46\13$FQONY\V8$=__[!TBTU]HF";9EH./B<NB3
M/+**FM%G;KF631:;/HIXC.!Q##C_V23)@" 3"7\@C,\.MO-L&WN7\4".MVG]
MNEX*7</Y>LW#3(SC#_6+)+:O 8S]V[P>@CS8R<).0PXOMXRA"HD0D[HZA[,V
M]C&7C1E/I/I+K+"1+H%>U:O"QHF&) W_6:8*&7X:GNI$4]*QN>K3GZ0/*A3M
M*G(V;^S1TT_0,;];@:"N:277K>=#H=Y>\@?F(@^0<\W]_LFZ#:[A';9%C!?J
M)9HZ65F>Q?M8N.>*=]]_&7F[XJ-:4N[=]>=)SVOMQ8ZM8NT55R>2KLD:NA^.
MF>R)UJ5\=]HM&Z^('A70134@ PKVJ\@2=9KWV,-=A5L&;I9"RE\\Q?.676GU
M/L)O9@Q0E@9\)^C[W:S&#W_QR9H\/KQBD+PVS]%>FNKQJ##$T#A8YY@N8X["
M-J9E.@S#Y(DZ"4/WZ UO'QKI)FD&CS<AS?$O*NO+,%JO^5+(E)U "=F.&H:3
M=,:ST([4AZ9C^$HQ0>OWV1'S%OD7-5HR^IVD773'B'%["5?Z]<_LO#<JOX$)
MP,Q,1>]IG_Q5'<BMD I(!9O.2/WK P.*H;\.]UO]/[E;@A; WX"XX'+XE)$[
MJ.9]8D*J9J'S92=N3LC=<^":[^-/%!<-&'3<N/R0BQ+S$-+%JB9]F5G%5_B0
M1M]A*F!UF@-^L^QS\EO<K5>C$+KS0OW"-H,[+*E1<1.,O<,!BOT*0#X(S(OU
M=K^KMUYE,'&] 2(WKB%WK458YEY1WRVZ]?MU$D9.C)D!KB0$,7B(K$)0POTL
MCJ0,><ZZLNGB$4V'S\P4XGMGJVM<;Q/%-^9K(G@JRJN#'=WX;S4\+"TM8G4A
M2Y&"BF CS5,\>/4T7'C/:AUH-CX=FVC32[;)@4BBO<G"99.%V<37P2JY6,XR
M+H<& >WAO:, MMX)3O>I"--&$#/9WAVGIOF5PDQ 1:AJ.."7IUNGKO5=J$<U
M)RC*30HJXMNRS"V=)<YWC]O(?9Z\[,2*7I=YR3)=EA!141P&X:'P6)#"FZVE
MAN0%(,RPJONE'"X\EQ6_N-H6CVME6W7]E'^,C?QL*6=W"YC<T'U=?;'M]*D7
ML5^7==<@'W\MYA.%A<_V1*]N(YA)P59'0!$(%H5"YT9>REG(BF]F?=KIRC4'
MJ<9;N5R1_7SFUA(FXY'+VJ<4MDU7-0C(+>*[I!;4:1D%@1PR2#HQTW%XS">Y
M*S.#2$0X#HIR'/:=JT8[)@9V2PT93'X%[$!#@.5M31OA^Y/K25@$[^*UGT34
M*0-WUL)OCTHDGCAIS*C:5$N_SKG*-U\ .T5\A9=I816S'E15FF4[Z8)$!!59
M]YC5E&*BP/Z*=AK"&:5'2[S2)4Y]!#Q'[DW?(2!"**(!D_5TU=<V7M9Z8VE
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M^W[_.E#+$5&Q$5A1D_R,>W"'51K*YH0:]Y9U1FI-H43& FX?EAY#*BBQNPG
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MVJ,TKV_ZTF1JON=F?#]NP9# 6FG+<ZSH9DEF1F9RO C''29CR8 G)T"G0,[
M-_S!F817QGA=?'+6*_R-*47,0(4?4W8MX=BWS_HW8/3?KTA],+.[:2K;J1=S
M"_!PB(0I)LWBQ-:4W;-)^5A0=(7,:PHC<FSW9K@6F#F';)4K+0*N>2<Z<2>>
MV%75\2)A(0[>BF4W@39'!PM=P_M/KS&E+ZH?':[5!;;E#&_I#IY#5X2-WT8G
MW8Z^BY2@ JX8P^+E.+^C11.>2@*^S1W-(!T2MG )(>I,I"3<PNMUU:/V,VQL
M)&T@MU/EM>3DEODT'->!+!IYT5[WD]ZY,F?A8Q_C1=\</>&AK@PW(WW)A,N.
MJ)^#.=4R8:>9'(78#$YIVA>.6D*<^0N_OE@7JTB,,3/LXN!BOT7?:?XACNXI
M#"0(<VDU29'!%S=.@K&HR)V-EP@V#\$K2E]ZXUL1I+LR,U&7W]V)L;K99_ZU
M+]AQ]+EJDL;AV-L#2'E(J*HGP1LWGXBU,L7J-#,7O[J\-+Q?5.!18B,U$KK!
M&Z)_Q<.ENE.Q]RU+.[-/YY&C/X.GZ+;%&J//4 &-O21S+.J4?["K$H53ZM*(
MD6(LHJ!B*TU7M7+7BA:0?6_G8]?T*Y(9NM<*9.0KO[P04?1V#%7+NJX.SI,[
M:[]XHPR@0Q]6(0I0K -A0>0P6MBW@NR-?##-_GW/$&#HUVKLXBXJ@'1-CW*_
MY-?)7%O9B"6IG8"W_];_FNC+F-;HW(Y("GT=VT+*RZ?BQ320]-)V<4RH[N Q
MZ?&X18@6.JYP ZQ5-?3M@+6[2"I#D:.KYN>E$2&SIJ=W)?J[Y4039B1L,WE$
M[W+&Q6_$*4&; D*^#T3+O_?["&F CC'BLE=S_4_FSQ1SP,H:F9]F/3PK'>_M
M>)R^]BZ+81:.;B+#+F*$T0''G 1DS\K!/$9NJD17(#+ ;?+2!U7POL_B[0;&
M9W.7(DQ7E%Z1U0B8%O3TZF$QV6S ,[BJ[#/!*J&%&<,^)N+EA9:S^HFK%J'7
MDFT-/EO[D[WXSL@<F5]2_3SAE9G3+K?7\*ZI 5=Y56P!^R=N%>9O$^*MRFZ,
MOJ1N-MP=:2CXU/V^3+X6B^?9H@HB>299L2A)<&G6@L &7U9,?1UOV)67M]<G
M9;)O4@&0K_OYL\#(;14J(#A%?"2I\9I:RBL<ZF234%"V!G[)XZ!0>N%R6HT2
M[EA$V[QD(FS.E>(<F/M1YIOQ+ML:,X%SX2[)#S?)9CA4SU^9:YL^8:%>8H\K
MQ_!C4J2\FZ#9:1>4;.AM].1$_"P#K]0$"!6E $88E3K:O\15&.H_*S)!ZF46
M3==/[L78X0+._MO'K_5"R0+16'#Q*43#Y7(JH*Q<8@Y692PU+RMH,OYCWW1X
M'M2XEVQN0* 8;*NW?4(;D(R1V;L%5,#&+((@CV@L& +5.5 !"%H>&EI\?-\V
MZ:^;I)YT"UL"84V<45-E5  FDI;R]_TJN?R LH,Z)$,I%P*5T1(9O^K>YB%\
M>R@4)2K@E [Y4I?1P3!BEX A(0'SBT6Q%*['N8<KH /2-%D?B,]7,-@PI^%D
M6O:%<SSZ?Y^!?]C;X&OP^^,_R9[X#L/P5FMF$S_]?N>R2]@>,LD*N'Y@>M*&
M+$H11RRY'[D=O-PXM9?FM#:37#C'V6P7H1S:>MW^VYZ9W:;RW(CQG]B-_EU6
MA0E&GAR8SJVAX6UKIVM6/P;3S8KIB>[?B<T0=.FZT;SXJL!9HR>J/)^6# OB
MT8KOG FEZ'+%^]KM[2D6GR^ETY\39[N7?31*HO*OY,=Y&AQS1,]'*Z+\/RWQ
MC/DW9_D42DM^BF>R$W/WTC8L:/DRH?V\QZ*"^YW#L68Y'2>7,\,E/NS?/N<X
MVL[.&47DD?,WH]3OMQU!]_SE--&I"RWN/^I2C,U8]-7.:#6WJ7VE%]+YTH>'
M5>F$DNRLET$W U-!="#PV"K"83K(%Q&TZL9_L-H_835IK8 &5^P,-6]:6M[M
MRVX/^ADW[HQ/#;QZI [\5_,6W*_*F$KRU9L?V);B,7"]%^L[7,EQ \K4#>_/
M4^V<.US=4=#4(\G-3)XP%RG!(UZOVB$OO-2NZBM,<Q*&U@EP:<2Y+</46GS_
M-%I_UK1>1A0)@HT.AK/YB+:&8%$G%Q-.B26(H ,2CQ7$7'A>7N[,Q >8(;P#
MQ_7_>3C2?V<<\,SKFE9*XID.%R<7YRI.^?XW-F;-1=,^XP WVXD4?7L2 NL=
M1!9%*$S%8J-9EY1,C]O&^TE),_N(&GTWL;MN)C2#=^G]2Q.XF@QL0,J$>)C+
M3X)T^CT.%5WG]53 XFE5L0A6M,*];&]XE-\@$WZVR7W1"VU!\FY:R?S1+BU5
MT)ITO*KJ_9E03K4:XQ<BZX S*153M$CV[TOR%$\2T*R,YXF^V9?N=U\\**95
M]/(>9L7K+4::-B>M2MY=SWQ'5G>R5B#<M5PX3:F*RJ29XVZ8DFVP_S7>U$IT
MBARSI6384>D?YKW:J3+=X!@&M;^TS3A^?_1T16]5H)7\(V%0O&I_X-R%50<W
MGU;W%.?XS)GD4Q95,*B\E= FG_2QV39W^]-Y6Q&/'O'=NL+"HKP7S*@P_I?2
MN.=CDQ7.ET5Z3"K;#LQM%;);9(V;-@C,\C8J\@6;,LZK9^5WS4@Q+!@C*?J,
M-V,HV-D8</;GH.RX="K I/.G-R>J4;>=V.(-^3/7?S;&ZV?@0L"!M:"JA.P?
M;41%AZI1MW"B%WS]XHO-^._?>;OO^@Y:>+\J]S^_=:^ZK&\[2272;+T>R7QU
M-H:TU5F0QQ(2NULV..+R[SL1>;K&,3@(?Q@2;-\GM<UZ<EJK>G)^J<\)G_FQ
MYHMK;]"/YR\^1CFWH(+EZU3NQ+=.WQEP776@UW/E*G!B"0S,N$)7_O/ZF:C
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MKZ^V'YRVL.93G1^F=]T\N17_H^EFG73(8_V)^P9T0TB.HUC^BEN_.P@<U=
M$\R\74V*RO-_<BMZ5D7Y;K.RHFPYT5WXYF) ]*VY]>G8A=*J]?H#Q553;LT>
M9FY_OP.(Y;BR#ZZ-K9,S0R_E446 D^V)?)F9F>D%!%*DL37].:T6_)('$-:U
MO<Y^C) 6N@V,5:6-,"14O1,--ASKE&:4QXOK=",9O8^03656(";9S3_*9<<2
MJ'AVK+M\B][/Y\5MEO</.5=0W&1 1"^P;C.$(@1WU89(/O5NL]1!Z)_%I1+
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MS:Z-G?M!,!34UCBV&.INX5SO;Q)$%S]E#J&YR?=Q7(E@9OE^$;DC\"+4-V,
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M\X)"X*[!^CM9I B"\'?#B+7FXG"8A/^SSOUG'44VWP@KC.ZX&=U16Z< 2@+
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M5B<$$9>E&'Q0_&0C*/1=W5A>:\Y&!I/.(VS'$&O#<<W?"XD;XC=XOVG9CDT
M:V(P5(6;]4WU1/#SN:QO\VL9/]6G(J<'W^Y_: XN7<QI8\Z*[]]U)4.+BC[5
MSS(1?9O(4;0K$.$4OZB;_7ZG;HHLLC9*+P@,!);(AFIZ]H/YX>!Y7YD;1 DM
M(%^+Q4<'BBW9LQSL4[])S=6H:ZP;]5V7R9AT<^FT^[(\E_&#UW7 '2Y*SB:\
M44=&H[G4E87K<SQ#B1.#G1><9U=2O]]UNMM;*I+)@C*/DJS^X,JC>OU)E?M=
MVRD2A96H8_OX^@J>ESNN]J@%ZHW\;J!C[>_D  EYZ/K8PD];P(3OX&H)L7L/
M$ZRM@^.A")Q^6?1MTB;#]_WT:R5W:,OO[ ME8:D32.U/C?9S-+9F<@Y)8!<9
MTX9MZ&K^<*^&'%Y CM]=Q&3LHCU;6@_AQ-XAM>Y.PW-M6LFFBM-FR0K+T&/D
M8$MN^Q]&IPO#2[(3WIQGGOGL$7NI-^DA^Y=65O<E.H =+E< ZX3%CV*TN2M:
M/B7X?\"XGG Z^@0KLP68^<1S9)%YI.GZ'3/;$S9_KJ$E9TH)P'VVE(,-7EJ2
M&2IBF0HJ*1OD2R%GA,LQV-F"4?FUP])M6BT >^>B_T[!^R<@W0@^N!-QLBV%
M+ =*1O&3\^VK&L@Y^$-E0;(?F+-W_M#U#JJI&:69 /6E5?L'-O"U^,5;/VL<
MY$[F=*1FUZ;F1PQG*2>KZZK9D=@Q@]_I@([[LX1E%<4FFWSOPN77C0TORV[+
M5K'9W^;23(9LKT-YE_:T6QR>96A:^?!53*UGL7KG2Q"!XD\6MG67/3\UI!9Y
M1 I#GG.<58ETO_66;4<BE[?D'6\_</H(SH+\9GX@S)(4G3?7>F6K&\=!N9CE
M@28<QKF >/UR_+Y.[HJ?? E/-KO^2^LIQI!/\4YDJVW/"IIEQ194Q[K7:6&.
M.6A(5*I5X-#C]]&J4?"Y/2W)?[KV\[ =/\TM*S-KNMPTX"13W+Y1>/@\8NK7
MBBTYB4 '\,$\"5H).H)HOE,-"9W"PC896L%[USC]?5)$L">#GR:>O+-Z4>[.
M_*7!=Y0+9'E\Y3,$CXX\WDG&XME2!,?HNY'MJ,#WH6MYT1I)*C)<Z]A\6=?3
M3T!:"(CE6@*:,V*<DQ". ;]L W*SE35BC8:;,P</6_7"9Q0:J.5ZDDM(#AW+
M0QNR9]LO8,S!M7SB*"9"^G/]L.] :TO#P <?%8N3\1*^D-<NR1QN!HTO7WZN
M!+T7\*Z?/'U;KK4EVN7]E>'2T*>/_>;?!@^:S2.\0$^RP&L"1.P&INGYK[P"
M]4E-VR$?!XAL2$:(<,BM&4>3PO3T2 M^R>1CGWX<;5=GVLJD"$B-=OB20@C=
M5?A0/0FR,Y#?J, $Q4I,6LR!YG/""N,V[$(OG%^)=BGH.7I7O_G-Z[?A"<ZW
MB96[X)?M"-%U/6G8RVZ'O62XT^F$/[S!6F=VR@O?VMB<]G](*K 9/I7A;<T1
MW-<!N*"&M/FG'WO_6P?@+[CS(^@'Q6>@X>#YNV.!?T#'?^U54SER;%^<QFEY
MR GKIQT3.92>(O.V-3AP%]5!"8X63DC;QK PQ.DSYUU=Q&0"FM7.L_UPU9F8
M"I6S4=J[1/)_E'^F)PSXE57H@,&@^*IH(Z!M<;(E'1#57$DSRJ>==*46('YK
M$1DXB3T$3$EPWIOX0 >HZGDN,S1".C);W79)BW*EY]"$@8F@>!"-9QV]+YQ"
M?IZRF\H L+@.!$5R!K&IQ$ @E%Z]8O"^_7Z-4<1+1*<BHC:%RD83H /FUE?H
M@%0O.B#6C@[P!AYP4^3I@/:9/_8-&-[Y"/H:]1=)&E1A!FA&,T SXB^@>6OQ
M7U4/7(8C7AN<RF: B$^\JYY !I06_^$5XD!8R<Q*#3_]<UV)4G+5X-KBU<LH
MP]2&T:SY'IMB[> $5'&$8TSIL1^C"69?#ZKCSU1*['7\1\^H43D6L:D#XZ5A
M&(U8:EIOPBZ@3M(!O:2_>8DTX;^"GJ&[>*GGI8-J;QF%_+N&K/^7!Y,9=%_T
M;U"X^4X1HT^3<;16!HT8(I36_M,L?QCZG/XP]#$PSY!4I;6D)S7X[WCX7VXE
M\9=#:"=EGWD6,<D!VA:PLD?TO +M#"!>?/BG9QE@]Y\8#O^T]LG]Z4A\3$J4
M4<M'&-IG^<W2<6,,</.\'6*2Y0_/X7]OAP*A/[UPN1E=S8/[C?M;"&$H33^8
M#KCVYS['SO].".(_=V1(B44L".-V1D!4T;H/M][81HV.5/]A[9=F]%M%*I(2
M[D.ZI,ZDE8&;@7Y)44(WX=(-C0 6/QOV'#?S^Z'K#3]O#NL+A/I2)R@?-J</
MR_?OJ-]DF75$!*'/Z=335B*LN07_NV:6C6W76UI9LE%"CRG=+LW +0L_N0@B
MFR@C%O%TP,D_O*4-PAC@DG>?E_@Q\";KX-\O"2V &L!KS=Z'7+2ON2?)"66A
M33&[#@7"PN?:;^2%GIWFNOPI./*1W:ZU*[;5#*V+F/LES^!0D8'>GV7]2/6Y
MO.@#C:5R+R.S]PGKKK$?\&96R4O ; 0_:(ZQXM49=_(*.?D(X_B+B#-E(\()
MEB,/E/(;ZIU[FX??SOEGW+<(H .(%"BVF99@' <BGABE Y)LOZC;#A^>@*Q6
M?M[7BONX\PL1IE=!!\3,1XSCMAUT3.F )Q-(BD\=[8\0FKYT@$^2(X$]9NV\
MGBHLWC&LU6J"X\4T%C_\R^@>K?2SK&V/=2.QF6:6PJ#1JVJ,FA<>'PGTGL:#
M'QH?MZ$#! Z_4Z_#MN8'X]0MQ5>$@_=N%K:6+WSJ+N)[^+'S6!\=$)U$LJ70
M#.B "-9[% 8R3WM#X#T\.LB@:%GME:2MN!:;^7.7NL\G*8ZTN)ZHXS<K2#,U
M+<AHE@TO3YU!8*Z12VD(:3H ?:15 9_9J72[<Y8S>7=S*6)HC_^:V8>;5]9Z
M@$GP/>>\N>/(Z S0SIX_'5!MNXJ\-JM+N#Z?D"N@T6-=;CDUL/GM45K3PYJ:
MX*9FP10K.N!9U@HM@@ZPSJ?Q0RKW#ZDV+7N"]]$H#EW.OYY((9M6H!<W=ARV
M?C XZ[;R7Y,@_.DF.@")'H<,^E\[PSR$_FO:Z^^E5NHR."_OE7]#S)/_9"&-
M""E8_,\6][F7NY7-I=>-95*V.?.H$!&A ?)71)<C'GC(P="!!;8:7:\1'(AX
MX,%=_5WH/ZV)0NW_;QKU?X7\MQ72]++3EMWF.6I\2U$5\.AR->*YW3\(NRRS
M5[H-&LGY+Z_EF([QPTV'7RN7/5D>7=QW*$-T6# 0&0CQ<3+'1,_M8)2D+\58
M$CDT)BE46JDQ1782O+5W4!ZZ?J8+\%CDKTD@\:438A"W7+?X.5^0Z3?X+\G:
MOQ>62TB\R9[WM_3PWXIT#HM7^;=%A&3%Q*Z[C:X+SKBI/U!)7XRR<B1G+#AV
MZTT.ZR^CTA>K4V8:1F)[UB>7]*7B_NNJ^7<1G 1(&1W0\Z>, IEXP'HMXOA=
MHX+I<S.^G"<2W?R[[/_A65YZXB%T<.?U?[NA/939.<EH1\K@N$]]*D'A=>W4
M*R??;ECOCD9':I<J[O4'YN'_<Z;Q>(OIHUT>[HE0Y_G#CG^<'E\;X]"\BS?^
MDP?8_Q7Q_U!$<(1H$V3@V.PUA,IKB8;*TRT*0BO(HZ %TQA:$VCK'8_?G]LN
M_ %4+?>-;V32 :[U#'I4,%EW( 3.11,#Y"GYQ>9T0-4T@^V-0+!_C8ZI]D=T
M3&:O_[E[0X.>"*+O%A%-C7Z WGZOC2D??([;O -7I@/N92M3SR2_JI<( 15!
MXQ&;MW48V/">&!VPK6:GT4JRI)EYQH)694"T: @;&I.LR*!*O]1HJ#&&K(7P
M*=L/9&:::6$*-7R0DM;2U&K<!MRT4$2LK",6T@_1P\8T<V_$9#SRX Y':D1+
MR.Y3\@H!QT+Q)T/G0.Q+*)'/8SJAPB4ZF5D+#9RL6?9&@J^MG_EY(-0D7K I
M3)5V@'QXO_,/[KZAOJ,)+^>>&H)?)EBRPFQ&'6-L:L;O,X!S: A4\*&.?],+
M.R'$6Y=B%ML#,Q,D%]K/0LV:_+C!^>SH>AY)_3&M$C]:!//I7G'TO>:DZ2K9
M-5#VL'M4X[.X7<V9*4?O2]V/=2&[H^30 N\33A3MHL)R^V6LR\2(A;AQ\QBM
MW\6N&%O!<KPJ4JG]5>W3A[=BB&_A^_C**8&N"#8BNJ.N:>@!W)H..%9L.4&1
M\RU:BCCWF;B0E9RI^Y7?#A?^_D=/7&?P<-GP)8Q:<Z0=URZ.&^U!!XC3^E$R
MOI"V"&YBTCP$)5 UM*[NM;-?OAK(V0])*.DL55R1G>13:0[';0Y5\[.)/^'U
M&D=X*[/]KM=>&^@N.66(;_49Q&"C.$T=^UJ;-3MF+QRAM"?-H+\VWFI92"I/
M1MA2&VB2O_U7'OT 0Y#NQ-TFE%AK<XI!:]J,AN9G<_=:4^%3U2;NJ6Q\N>(A
M-R#]M#,1 TC^.C0?><M\-!#)Z^R%TB15QK3<;RKU09G;*[UM\FZJ\SHF[-&5
MH.[',\'#!$B&^J"K/1.5]417LJXCOH,?C.FI&\WW!H1L<JL$73R??&-6;G,>
M^G*26?<W\T@0:%J^K0D8>W(46J&Q(M: -0Q3/^!>#<;*3H9%#+)N=X/.C]AK
M%<F\24<%]HI'WS:FUNH!5V8O-1"IJ+S2\(H5^V;B@A:_5X/_5%\)=D/-GC,C
M\:IGIY^UEGL'I;%2FH1>U0@JH822?N[T1-72 6)>X.-P@WL5K3_W$H.X]29-
MCQM N(8MBPU.%?8!W?FOMDG4/%E@Z1ME3%8WA*C=[UGQAA?>8;7(I(9<$)*J
M+'-XWK;%K:?_ZU2N3K%?*.&)[N5=2VIAYBZ2Z-Q8RLWN,"1^C<16^#[4]B"\
MJS*WON%16_79-R+^]T3/E^8DFN4:/4X/!:]F$S<ZP<=:E CEP,X3X>4?LKNP
M$Y7%/Z9GRSMP#K.X@2!Q(8#H&YN;9>6Y=U[X.Y?\:TM'0(0:8[HU=(!V^;/I
M ),*2$$%M!NQJ4DVIG7<1BP)#?A[ #O A!A:)I^VV9GWS?K_S-+QOW64*8$)
MW,GIC^Z!5?&O\(DP;/&HABU-.+V8<CBX'T_!J)+R(R^(OL&KV*=K7+RLWECH
MT6";Z-"T4O$D<-M6A0[@-!NEA2]2NH#$VG+0XBSBJRTOQ;@"P&"9;QFL&$EY
M(JDK]!71,<)X5LA0.D#%F**D8+F_A]P21'0^GN,]$,/0 4PE=$ OT^CPW9Z_
M7_S''/][Y8T@=_[$LW=[R9D^P[5HS^RC5XZGXN3I /<".N!YH3<=H+=%NU]7
M,E_,U'[M]M=WK](GFV];!U<20RS@3Y9^5[C^K1M >&\'Q& +'?"Z#$W0?<A.
MY<(SN#QC95P _)/[6GM^G:4#.D/_L39LQ99&GK^=Y>I(+ ]</'A:JB]@E,DT
MH3QPH?NE;G;U#D/)3.LDA]OC9DKJ-,C'[^6CP\M,1H*V!7]XK3'+'9*HWMM]
M$12$0_@_=1[0!._X;K\'[4"VW__MWSOV?V:YN_GXEL&2/E<#'6"%-@M7Q5'-
MJ&>W_UU;GU2Z)/K@XXOM/]Y[C]]D>?4?^#%H6GY&,"!(T1=_\0C@MYP_A[>4
M/ &$S>P*H 23*I]23A)G@4*F<Y>Y]6@T E3@=+;<X#2_K4DY 1)B\_#4O:V^
M$VGZO6(R'XG*:Z9S"'&X.'$CN8C$EHF?X>WL92V%9+Y86J_YF;Z6_?6ASD)0
MH!O+V[QN8PV"MG+/!CMM$$&\F9*<&:$ZJ10H-U8+YNJ_)['\R\G\2^2J]O3[
M$N^W_*5U3 \^B?8)+:!Y7,91W'!E<@ >>/RWWG%B=SXA"=CY>.$Q.E%'Q;_<
M5,!'N_1;D^ %(\7+?KEGYST,3\_7>"5]ZM+7ZR:AUV[-(6*0$BU XH;-I/HA
M6  VRYF0I"G2TJ!O(_V:ZX3^_BO45&0IU-U%V]:V@&),7$<3LM=X,)W:W+N-
MA8FS2_789ZJS]KP'D&-5L(.4%G8'LN.NVWA961UR"F$S\:5G@2QB.R3?W/K\
M55=)J*9*C]?J_EE-\HRUZ#JK*$]T*>4"N6!6E5J@QPQ1\IS#'>V!$LK]!F\1
M?Z7BLTN5C#'\/["SYZ9]M 8U^V1SK6VF7%*^/I(T!W  J(#P1]U*%F4.NP-0
MUZ@U"S^/6ZJ8'-2]ZPNG#<2K$DE971,T-;(61ML(E5<"PW0T!2.#CLP8! 65
M3F-8B%7'JF5JGKLIZG-QL+Q02U-HHVG#1BW)%H>!@Z6PYT6C@3A^BC+RVL@Z
M=@8KOO)[(]?0(_%=BDY!?+\8YL*WH8?^>'1U2!Q<AIAO1WT+U3LEEYQ9_)W"
M=,'\=+G7=9N*R0R#_(=?@FNX/EBI]OP4T[G)CG.6(<?A<6QVWYT@SM)#VV$6
M9G<B1\+6KHA[513XOS+Y/L7N(?&DX"6V96_.<NW>>XHA-;=%8QXI[",E3K2D
MR-Z^Z]@EM%LJV:(D&\+?\2'MNFW8A93@X4'Y^'W+79-1WG9+,8KT>(2"?5\!
M^084L'("'$T'U)?-Y(VLRT\ZP)2.?8*>"E7'^,0F,@L]Z[YD59=.#.A"$A-I
M@PRX1SFK%S5'!W!S&W<XS-5.P!WQ"N4.IE^SWL91$R!^:6U6H8(%S\7V5#\^
M%7=YP;2+3J0#?! L,/9Y]#.:A$_6+Z0O(>6$PP^GI2'=GTWN]S;;;+BEPT?>
MJ(A:^_Z4X&UV\D"21#!-#0F5.B!O O>QE<X3CSG.;W\..NJ&JKN=J/XB6E5Z
MX=$7]E,H46K6#L01>IS6];B^_)2A,D4AW%$?,OT[6V4YUSDW%=O\6<Z#5^*)
MC.3W:\QY9;BI%3RM%(9CTU&KA&$,1EO"Y\#'9Y:;OJ44PWC6=/0;6)PX!]<X
M=UM5$L)2U!NP7"<]9H3;'EU@VD,FT,[!'/%+/;$ZEO@!%KSXB8QB5B1/UTT:
M*7/C@O3C%_H+=[",M<^2%V9%$ UR0AB._&HZ>B]YZV8T6W88BT7>E/"/A3/=
MCSJ9TOS!JA1W$OH)#8AH-PI*,NQ9*\04H#L^^$[X7AD=?-ZP'+#^#%ZFU<MV
MQ%4Y$G"QRQ_WJ:&C-<"0C"0& X5^[UU8>0QJA\3*:*=7>:N/8&M]6<Z#+\N:
MZ+R[D_-%@#WO'6_U]D9LKM2$CE,H_A#$YQ42(3WZ2G<VDR>/*W,BWC]*]F1B
M["6)ZN3W^<2>+EXNV"P=<+-N&&Z.7_-8,0F0I B?>*6E:O=)5BC]5EQBY%$,
M *:Q3P<<GJ-HCVDX,>.!SRFF\]P*EJ2>ISOF5$/GX6TH8%8^+LTC?DTY8@8.
M%8.7IJA_0O9VKMY3B4I-1MB/UB49[P:3+#LVG@=X@?G5?2_C]Y.!? XP3=_+
MG5F2+=I)'\*!-ZW/^17E3J]QW;\%57@-/)O)K0_,?RS?A3M*SL8T/.[.)J"Y
M?!QTG^5:CU,K2J$:Y:5$S;YSC5<?I&+X0H62YD%8QS84!_DV8UA9$)"\."\I
MWFAOC4NK09>],SA.674?F74Q>DTL%5=-^YK?"E<ZO$)V ,8A6%'JL&P#DF<,
MW FJ_%2=RD; =$BQ-0[7O@E>OM5W-"1M?<X\B%],L/.=Z#Q<4Y7U<<,:8]GK
M(V<>FMK]/CCJ&!XP%U2UJ;BJ(DDE2#JH=WS$_^*H,K9A]EJ*!QR &2JP-N1I
MT!_AN-B34A)TM(K)D,Y/74I).^NEOES\Z@F?#7^)Z=2<N61C=-]0@:>[GN)$
MDL'06.IK7MI-UNK*+OO^M.-<(9>C<.=591+">%521*W[+BV!CPV4%U:F1/"1
M^W1,YW3%\2L4V82KG\8HAOC0G8%S2A;N*6OU7TXV-O#=[?U0NB7L?=5*6LR*
M)V5U#\\MOQM(SL%_B#BY+.+0$PU%"3G^SN4;"YHY8JZLBE@3;_13=*T/3B__
MY25;;?W\=>\2?[(9'T"OGIH9H69Y:$#[YLQ%&O_Y'/72GY!S6O*&HTFAJK&/
MTZ,[:@ 3J8)C->41PQ&LP[03Y*BN/@*.>UD*2&Q1[?\P\]UG8K3K@:M5MZ;_
MZ:X7\TSV3V6?SK9<WH6.^Z$DZ8!V*1T5!J(YFC085U&+C+EBB"]YYW\ZO_Y[
MC0]I37F+]]4'JTXW@*70O![_.!I_B9Q-LKEL8=B..EE'TFI;4MI>(&9&GP\L
MUUR'2?T6=[/W?'UW\,B7A'1LK]B=][EGF->A44"10& *CE.=5Y3L<2!I>)4D
M^<JV?L18_9$@3UY+@TK-F50.[++HFKM+Z!\!+6/6QO$XK%8WF+\VVTE[PS0!
M/]._VIQ[2_;Q>)JICE+XT9M'$RTA 5*7+L5*4-ILE8@;\TEH!B4ERZ['$#8X
M%1\7TI[.<=HI^J[B5=6SWCL8'VF[=2TDH4R!RXWO^X:S,=%RKKA3>0I)V%BE
M [1B:\&< ^\L\)#*F!/;6-:9V;R \(>_L:]$1#CD:N^9.QD'YG/-M>+%%F69
M?U=&H>N4XU$:7B@1DG VL?X Q$+&CLUZ:]= )M;\!97$3:%*/RO:7))OBK!I
MY;Q\O'[KVUG*96I)2_A\"I;7F1SF3T0;CD)U%'R+P3Z3"?/@6F.AUJ7,?J_,
MU7/N07RH.Z_6M@)ZTN!:I)[H6E "F$N=@?8<%A.D1W=\@TTHMG,*O14./9BF
M>Y$>N::^?B(1;V0#8CO.N-MX8C_<67A<V9ZD3> EGUGL7BEN>*-4H:.!#XSW
M2(Q=4-BEMCOFR<A<7$K5EZ"ET@&L F- ?'IEIZ0C_L=C*"8[10#)A2H1B>,G
MT&88L^;;ZY>MR.]#H1[SWB<]%#]^Q[C$K^X,8C$.Z$GX?1T1XOIA=Q80<]BG
M/@.Y:7%?7,RC^;G0NM*J2R"TMH__$W<KWFKQ?@V?/XD.P&P\/Q$3B?8<?!YQ
M?J)2Q[>,+,R;X!!/KNG(U.(W+3;D8JCK*9Q<TSN7^KWH"0^6ZNHTDXNB>^!(
MM(@Z:&H90]B(HOCK[J3$0G5\*\@I1C6'$J.#!(C3M=O^T%V^>)S7RX#7]@**
M%<@+@$A]72U':IE&. )S<*..N(A?+YP?Y%G.%0<+GJ\Z7Y!E]%*_[55]7$'2
MU\P'[Y!G/IY+]$LU/=((B@<1K6;8V^D 9AW@_ 8/3*MK5G4$[N1>Y%,X%Z<X
M-Z((K9!I,/7S?+$?X9*FKQ/;WSMM-W<&YPS*H]R#?H_:?4 V/KRXDO5#CY7D
M43*WG=TY>W),PM 7'R;R0\Y$%IH&6?3PRC>2-8Y._VS-/1*!PQVGB9*9:1S3
M163CCJ;=.)[44UX0?*DX)$5]Q@Z[G'$O5UK5Z=:I^P.T?H'9)WHCJ3J-8H@F
M?XNRP:.P+2-R]CO#<G+8G>J)VC!"]^SFR"U9-4#7C0D)"3YCO$,@P+8"+LU@
M=*>!![_I@&\MR:T!>'9*W 4Z8-*8%L@T\*=K[V(E1:*/#CBS-$('K :/T@';
M6;OH*Z5;DS0>-SK@5> 28O<R@Z0<6(3]U;D7<<0Y9LY7\!;8!!YKL]BQL7].
M3X0.^#2027ME;!?TK]X69F"2%[<'_J5EIP'%X"9]UTGLU&>>=,#0@,LDV;\+
MN:G3C9C$(@_NIC0?VP$"$'WJ571 92,=D&:;^2\L/^B0@S.,_+[*!Z3;=(#9
M4U7E2>;YE&0P,9HVA.:%'VFZGID&VYV^\]EQ' F=0G4)6O&Y8D,VME1R^ALD
MMYQV8,"URX?*0"S[+I(,^KB<):$]&$51@%8@(*&9'KRG'&-/FC\2<G)[4 V:
MZ15=K$,4%.0((=<0^#4M>_)3*,$(RCM-!G:28,[R1QRGD^Z'*KYK!I^>%?U:
MMG#=."-^+?9[DZ>(QN"T CXE!BY9!(M<[,I8RU\>-O=G[6K-&1C,%+2H]O8P
MR?=L2-9B=0M-%]9D4;$Z6ID=9#DE[DRT[;0P=QB"@RJ-\#,BA.NH4Z/;*=SD
MMTN/<VA(_SS#^YN./^HZW65-]Y#GO?-G\QH!'Y1(,:LE)#$=H5 \E1TCI3E"
M42:4,SNG;R>!".)* Q6M8?XR2M]*87N<&IV/KF "'[8,ER5)3\W%G6&>04#
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M4D8Q@>IY\Q.1HG<2E?QM74Q'?[23T.4NO)K")MM^_<+E%'6F;5PR'>#++<!
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MC:/@"H0<H.&XCB,^1\N!!+ 963U?9W*J:<SP(9=*#=L+J6F#@8 FSS4U_(P
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M[[PC.$]$OR2H<0F/6NZN#/M]31OXU53Y4E&![VB78ZH^\#IY8K"-#F"CR<S
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MWOZN.88S^@E?$DXJNY9IU'L_N-G#UT^),MUS9DT#VUVK)_K#^;&S9M%#@!D
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M=>9O0GY>&%-G(CUORSQ<;J<9=($8HOK3\AUN<7TA1>&,!5>E%YK)64I@S]9
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M:5&A$R<\8:%365\=>VOFEGJ$#?#CZ1N.$2\/3]&D\H>M(@];V4+B%(T_1!T
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M/$ 7J]49W/;SZ]J"W\/IU20,&Q]->/-0=<\$=HXVDGE4:2H<4KF]3*N]%D_
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M6E-L<8K/D^+E.]W#-8ZH'7"(-@^4\,BY9Q>Q5]KU@?*A8]:DZ;B%R=^MM?<
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MP3GF8N1^T@H^A; =;CTAI/9XQ)/C>G=-@F9_FK;&9\&Y!F0FTQP,=VOI=FQ
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M8^SLO<J<<ZTYYV]EK3FYR=<TN:DQ-^B:8( &R(K[;Y6BPS_>E&@:X,TM%#Z
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MR/?WHV20E\:8@BI6F3=/@#_AM/M%Z:,8]^AFGLH=!U%Y!,QSJ=BKWG=XQ*V
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MQ$(S<RS#QZ/MN5%H'6N7D_Z]0DGOC-@S'F>F_IBH3[>2+DQ4N,(V\($&2$L
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M=%;#';>;!6:;6"HX%;"<.'\)8Q'J]Q$T4V<^%-M^C)#6;2GH=<$B:Z$+/"0
MSC[Q\P:S&^?L"9&&#SQB;RY'G7T@=3^]A$EKH"$RW..W+%/H)%MO3WZ$HP?L
MB3,D!V)7)[AX+1_X+1#.["4\5Y+]H;@MNXAO?'R^B+<ALOGL"QSFE/$QG2<2
MWSE0=!=1B*Z&<O:J"9-14(,JJ+(/"V:\*1,&NQ@7NX5I&7-I3UW>,W:B3,BF
M;1!G;?1GVG_V ,+5_M+NLET(#K[H:*N/CRWC7"GPT?7'K-.GAM?5!Z^$E!YD
M",EY"!X(*G=#;G[ZU&?HP [KN!4A\EK//GX''I_I\TV2\."L"28I-F/[<M"G
ML4+!+OV7# =<K(*&Z<^XB_\Z6.VQ0-P^?A\S-[*99S^QX;,3YG?".S<VI=0\
MW*-@-8<A62 G0((RZULAE7S4)[V>CTW-@A"'H^#I8]R.!DBNJD%A)-Y'?SP[
MH]E8;K<:8'&/<<Z08R)=.HG:9-9-4 (+/J@'^$]$7D3\GL<B]&E9^<47!>;F
M_@ECTG &@M&V24C58D];=K]R^[5#]:;]IN)/PBR_WH7TD<;\SK*KS/6!%!GR
MWE+G0-R!:3S$+1,P[I*/.6:BK-A+&'GB=O\7WR"S#)'+<6GSFUF=/!_8K.OW
M+0!A1_\R7CZC.&@ 7]R-+2RJ$\;<F%^RE >+YX^0;OE ,$J+F[G6V.P#NIXZ
MK_XKUV.J-D%(.N :-OT]P"RFF<0<L8"G?M-C((:50MHYS2T)?<D-8=57T,L-
M+Y75V^[.7+T1V/@L0VCI1LSS]&?F*HNL *#EQI\55FA(!S!-.*X'F H2U%4,
M<O/P\<+_L*L=55J)K\U8E1M51@@5?^HU_/I9<]'%Y'%>%[P1$:UK[;5X4+6)
MR 6)@2_$1A=OU@=MJU1%3.[%0"D]0%<X!^2!BAZ^@-O\MUXS_DTA?N@I"F\%
MC ,):EP4%SFO:T 'NIDFK9/JX2:V(\6U=>,^U<<$G&ZE=7@&"&6]"R9W!7P?
M3XL$-H/B:+_C>"=F$#T,\?M)@3O.W#/$W(7K$TK9G<K&O5B;5-;JI9!M]Y2]
MLW/OF#_'HF\?8<"%_5FEFAL!9/_,WQO#^JQ_'J^W&JX?^:O&/@G(^W<4. I=
M V'D&A=A?55SJ)E$Q&^.OU6C&Y4A.AAPJH?]]+<^!%C\65&5%$;R_GG<57@6
M,/V%<W;R#)I_G@+9B7]70&VW$>@U"J$!<M[0 (7S?VI!>($,747M[H!V["=B
M_F?4G-P=9[R,7(25_TZ/-<&FU\7-2+';V_NO0P2K_,]Y5_0GWL%B;L$ZM=P^
MT@#77[>]I?Y^[<W?IM7Z;_'G_S9#>3WI!:[C6Z+?V!,H6_\8EEC@+ZHH^P.*
M[D7P;D1P0V27G,:J&]DK=>Y()HQ\!EYX\$FRMUC%V'CE>KB:OICX7V9WJ@D)
M M5IF5P:H;^]7FW6&/AM?E[1>(YY5./S!G21(SP#^FK':E*R24^:.BG.2K0(
MJ[!?MYU\:%8\J]PXF>,EW7[SA/?T@8&,/C(RX\*1A3EUAM6_C',G0P'<('X3
MLC%_\<::]=BI.S@A9<<8=(.517P_J=M0H5^?"L -7SMWD\HFA\>@ZB>_3NK.
MW334.]6<$+B2/C^Y_T+[1H2KU*/4CP%&#!6;?Y&0TV68#^QH_[=&Y(7='1Y[
MB\!M]-3!L/ZS&<-'IUS+7AGY\T);Z_/5$H?'86 _EI^'?K%;,IFW--OEFP0F
M,MCEQ!TK+3E8_>6U3XM\\@>(>NP7+ ), 3N#?S'.Y[[1 &!N3B(<TQN-K;XP
MY-0V C5ZVU=LIQ[L]H4'F6^G5N&7Q>Z?.:K[Y Y5A/(>RHB%D,]+:^5\Z\,.
MY+4Z*O]H/%LR8)>RSV&O;63:96J^]-WF8JV^>.M?#1.<#?0 =80,GMAA!W(M
MS#F!$M0/@D1."\_VB10'F(F\44Z;5[Q\8)!1Q+1X[L?X?STT%-:MHHOF'H+&
M4+\T9!(K:N.>4*O#PFX&I1TPS<$F!:C&K\M@_7K<ARNHSY$R_Y[!^?]^@2M'
MZ:ZP[M?_T;\OZWY3O'VH>AK@HX6Y,2$N">E/.+K0/3(]O]KR->X>9JI&Z7[3
M!S,)2 ;LC+8R.^-[CDIQ(B(#_-./*//(^/?9AJ<8:H_CH^NMB;\6KIC4DA[8
MA.!\L>@UTW<A)B=;'5.U ?GC WVW;T_T$U2*?PCV\CQ_+NKZ_;DC=K9(/7,S
M:SS3$?[%I<0[<2%A UC?6TV2I'YU%MN !I5"MI8X=[]&*^78*9<,Q4JRWM.;
M.*&;7,<HG_PLF/PF?J7= ._S8R^NE\*_:#K*GG;"_HKT/?2(;\O-]ZG=/[1Q
MS@7H(;*NY-#-UABD6>FGY?XU)\Z0KG61NZ^R."5.A3, EAHCPHA '!#?$JC:
M^'K2&?_,[N"'Q(IEH^RFB=BCT<2#(>XUXS:HL<+M<E?9I6M:J9(:Z,0?7GIV
MZJ%!F8^W'^G@?(*ZO>Z!P>@YY#1%Y;^!BB[[_Z^C(F39$@JG&(1'84$Q9%[,
M ML<I*O72:D!.>;S(&;'+KR!/SOVA'K=D(0$=/*$PMM*?N6I(V"*C/2NM^(7
M/[J'30.PDR\2?3"4,*S%.*)S8!!RCE.QVW9OU9^CW#1=RW@CM3)R9CP>_?G:
M[.(CD  *O)[&2"3U"/.GN6&2&H:AS (I2KL6]H[4H5%?CIP;'VL'M!,-3NJX
M<?_@7 C;W"_@#BQ$RNV549!019*V)\Z#JPA# ?<.+_R<&($$>B>)??'W%HYI
M+,O5MW%I]#@GKZ#U=(,+HX5[1+*!P/=<6[[)OB,&S*N,0 TJO0XYM/S7OTWK
MADPV'SF67I3..B7TO#[ZXT4N><99^1I%0^*XBP>&%$L(1&L]W<5)F5Y8:2SY
M]+;/GY)^GR-Z*$/_9*ASRZ.5XP++?H:W=.U)CE!E/'\SN'3=^;BN5/&"4Y(;
MAY9=L94:^S.+5NA@YZ>&#3F&VEY/QF'Y&O8N&J!1M0O&1P0Z$31?+Z6QST-@
MG;\:A-O(CY_>Y]0T F2]K'^J?4]"U.-A;X!""W72F7T!,X=(@F'H[A1^#K<Z
M*C%VK4@PROY=U8('$WRWU2HM9__=A>LLA<,.P%BZ&$!Q>JK$Y/SC(V0?3.76
M2;-C[QU51(CHU6>],J277Z%-W,WE-U^YMG[^^Q 9_XAL$36&6%5R6@0##?#N
M"PUPZ(NL$>TBFI.OTR<XEL79297D%C'XN QW79<1,S$F/0H5*R5FBX5U^WE4
M.-SVUF+U$AGPXD,^<QFCU/<'NT@>K_5_A6TK1([N91$I_GA#"_Q@=F91'Y:;
M'[)DEZ;_K>' MZ>8Y]JPN=J >NOM8BM#CKJSUO=/G7EKQC?+,J3EC+^V( 15
M)FR65$"XK]>.-X2+].7"NF'<4Y#,;H%F+8$<7-FLUV%U8\]8[:"TEU* ]/
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M!U133=LV&D0$1'H'(8H4I4I76FPT$1!4.D0%I0D(2)- Z*&'HJ @!*5WZ8A
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M'_WGG7A>:EH;[L,)$YW@^!_$.XA6B]JH[+5Y;C75\K*W\'W?+1?)ZA,AW'#
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MTCES[#\K;:EY'[&UZ7A5^[&G)80+XE(> :;3. NT=T\TR^$W<[%DT*E-I&F
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M)':S1@+* /12(G^SD"\9U*$R^_87:L'72X;%(>&;[1.:1KCME[KT=9;Y&>T
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M5,0ZS-QW2-CBX<%-:9_O\N=?,#-<BG_$$^':\BM(G9O$QC]XN$$&Q<O\R6]
MS[A,W*?$!FZBQ#<IM(,U=VM#75P> 1[?2.N6\[M9J';(Y32;8B/F8=7T#<+4
M7-57"6N=;>X;P3?C=;KHOZE8@#=NXY<[T.=J9/C,@.GV5 V.H65_YQ,CU[''
ME>_/1D3?6\@)JHP+.R.2"EJRHQZ&_XLY;UQ;0&V %^8Q<HQ.BZVOJ]-^QH?Z
MG:"\_ 7>$"RJCZFKW7N%Q+\_E-N<M'2\=DW-U/T&][]JJM#H_V-U<M:O#[M[
M/7]20(_B]1/Q4HY_AUS_OM+T=@YO3I5)RO/$=]09'U\7*/9./,J!=\?"-\M)
M(=54R]5&FB#.PS4RB%8._EWE%?I8@ +U3T2;RG\4_9/G?%K<P-#>=7=42^I'
M@%^3PW08+,3YW_E C_[8&OYME*A-!E4DD4%DD':3W^QKL0TO,DCL 0%,ZM*C
M="NXM^Q%>F(_ORW7 8^''SW0F)'8S2?16Y)!HBCP240Y9#\CT-ETQ9#(5D?2
MUX <,]K -U1.;K>@#R_/G_BG+K-H(,OCT0L?YRZ%MJ)K[=<WBFU@-T*Q 7%-
M=5'9J1VF+!:ZI\_MUTX_<:N1N'7NW04[UT,#U8G)ZM_YOH&+<LME([$3^RQ@
M%!E4:Q\)DU.$TQ-O:<CAH5UZQ6"&L.%J*=<NA\'HYWK=[NY9LY,X'B]3+Y:W
M$==YPF(T+);2T*R!O>X$[BZDIYL[>..B3*<JKYJ0@ AI GE#F>NYK*LVL5TS
M%7/GF#FQ4?\7;.^(>S]*;KX1GKX%FPVLCE$M<IF9]LSX@@N"7-_5A4%\%C=D
M2*R>YU'\W(M[OX-'^EQT7U$50_:#)*_SO:S>N7T*5BX/WI[@A"Z 0[(!\T]$
M>D)>#/;K3X)6[N*6H-GJ]E2WL"FF*3+9.E/U.K0P*C>:*U;Y>WE-ZNFEDSU\
M.=8F%>^C.:9P(E"N,5CBK-RPT5*?W@=Q;'C3*SU#%3YC,#1 ZVDMFQ@?^'PY
M=- "1$S'IW;HBE03WAX@%%%TOAK,@C#F,2]G '8I%XJIS2AN]W+MI]GKJV-K
MFLL]YWDOJ8_MREOS]V^>W%AOI/'!,I\#+#OF5/"%>' $[!*X WS:Z0B)4+M4
M.NVTADW7TS7F[]=:*=E.[+XBWA\;])D[4,]V5WE1K&U#>;&N7=^T[?5N6M#P
MGMW-2QBK:FZ6:@_)BF_\R(85(8ES(7*-(7),M&WS4Y@)++I#=8M[WC>[2U"!
M\(B4(1CO91V(F\JKJ]*U>'+:T?DTJ_A[G@H1!G9D.C4'%0'>@0*T2)*3P+'-
M*.P)5AW2?I5HU8 >&>EZ_:S_()2HQ_IC@Y5M)?O5PQA)NQ#CSG/1N<:W;I17
M0>QDN)3CX<^93ZWV8[\BZ0*J=,)3M3(=GSO3\#ZZOT,E<?$^+P5?CEL%^9;K
M<K-);.Z ?<K\\MB3;_S7!"PT'LT:9%#B8 L9M,^53@;I'WB-F4HL;AV>)S*3
M04\<T;OS/E;F"'PJ\)%B61U,1<VOR:"0-*!9#SR%(K$<JT/,QA4AT6E-^:&?
M/@\;"1[]PF /H(=W-Z/O3G:_"GQNM 6]-6Y3L5 *[A"\,*SHO"'=M?,03TSJ
MS;/6I_-[(6C69ZQPS\]X*"DGODAGRSH+)H%'+FJAL3((04% (J<;YQ:.GB*#
MN$9:+<LNUB$>#1%5?5R\BAS;I)]%*R5R2K$V/_[*<TX)U(H?C%?S7T#%D(0
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MQ_>NO2]'E,U-K]1[YC^MEM>6M7^5:#&SWBDTA@OPNVRE?&6J-72RXV''Q\:
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ML26Z!/2_^6WHA<Q9],";'3HKA&)!W=C=;&("!>;D?6RMX"V7[,[LYB*3-'2
MSH>BTI$;6*(0$\(W>,BQ1NWOT'9GT7/G?ZU*,VDR-3=HA]'$,EPTX#^1F_U
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M2]/:3QOEH"-?>FK4<\W_((^!.!)\:/CSSXEX]BL/_7[%/1MN[*H>A:RJ^C,
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M3=6QFJ0^']F:+AIP88LSL!E]?!O+@7@W9?PQQ4&'TH:'4R>^_1;N&I63<O2
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MN6E,VNE"L]!TZQM';H^B0"V%=A-3[9\4UP7V+LR_Z#F6(GWY*A0.EEI4G;&
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M&ZTHD8H0=5WB]+>:E=NY=N<<RK_+)=DEG+:\?E[SD\45-JDT\K&_SDSX;N"
M@R[I4XS4@]/0*T)6;(^/K'-J1 ,HT/E\&D^YEL&\?)Q^<].IRL$M:K>PU?#V
M"8>QD21C'@W?R@S^"-UU>!0#$"F/F*5'@HXQ +/I"709K)$<YG.Y(_?]CP^'
M2GY<J-/$*2?!I(/!!OFW(.H, +YGAODWJZL5N_-]G@&(RJ&?+)U'[YU$RC,
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M4<D/?KWWS1W>3T'OH:VP:!V)<553WQ;R3NJO';V1QX[3ESB_$G=1IL,&)V-
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M5R;!\*U,+HJKV<CV4W\\QC@X2.O+THZP3M:AUTO>"Z%W;;0Z[X*K,+T?Q P
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M<KF-\F9NEF*=R>7?Q_:9F]EA-B8>4MK<%<^.DOOE,P7/E&==-(>FF27KE.'
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MZ3D1RYOK*CZZ3,%#?R-&TOB\"0D)JAAN2KIQ]2"*<^GAPK?"(@=3UUOOX R
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M[4R94?M2NEY%H9EZ>KXS]/=UOO_IIYT)VZ1.3X_PA4EK/=&KW]2,^Q^@VM)
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M3$Q#^<BF5LE5G]IK^%S^F')\,%$$C)XH7U1_&9 7CQ2]^"=02P,$%     @
MR8B(5.V-D<Q=#P$ 8$<! !0   !N8G@M,C R,3$R,S%?9S$P+FIP9^R[9SB<
M7=LO/KH$T7M+E"!:$%U,1+0(@NAEB-Z)7B=$[R6('CUZA-$97?3HO?<^^F#,
M[+F?_9;]WL]['._S_W_:'_9RK2]KSEG7.M<ZUZ\X0,VB5@$D;^65Y $8&!@
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MR@P%D)OH8X83%*  9Y3,_S3BRTZ!\?\"_V\-/#MI=\+S>P6O@*5V+7-/MHG
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MC\()#7YT9IIZ]3H03 Y)(&?9;B)C+8N>^X1X)OE_0D4BYH/3)7D-)-ML%[
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MS6>WB.M OSG$&;@C?'<7;+9Y1H4R4!Y%TW@0'=\+%:]K>3[OZO^C)R+ 6O8
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MP0K&9P586QB/0_$&I(I@&1QJ/"Q4X!!]*<*NN;+':UOM:2//U#'_/_Q(I7U
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M5.&$>NI(MT5X'7A)^>4&T,E?!W!UU6)@BFG +<#-0HB:MJ4]2&/1DVNX,ZF
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M41E7;S1?LH4@@]95AC%-GXE2++#OTS4Z\'#ML]G<CW'B4;!_1:TFH?.8 11
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MQV,1C.2J8)H3O-#Y:Q!@K<.<AV(-+W! & WT&N,0D<CA[88T WT?_ $P=@"
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M1)T8R,9&M I^J(L-W3^<%S@_DL',M]^IE6TB',&J\8KVN#VV+HQ25'2V=0,
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MC_%X"W+?'?4RH?P]VB/6K*J/.MOD!F-YQ2H<>_O3O@GX*FB. -0$15J ,&.
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MQ.2$?</#U%#0_RQ<D^YY1NE6XTA]!][:))S"+&=[6F]'#B1DXC6M&KS1LA"
MD<5^B]9XQI3RE#\Q#\Z4TNV8NPUF:)RFUI88]V+4+/;MN=<:^25J':7=IG3#
M$?-Q/V!6U$C*59!/E1+H8!U)5!_K=YW$GBB#5O7NT<#1O0K,H*;[<9TZ(:0E
M.WTNK<I'K_N[N;PI5)M;8N:.; VU%PG(C5B>#A7$LM\OQII-K:_D]^E&W&V"
M[A]SM#<Y78=BUXRCO:/3 $TE](@U#>?6<&M\[A1+#% -[>)%3OR[8@2K7L1I
MO0/-\N% 'RP>UF>M1V,C03/V$H%%EX@.@AUG1;B3E4-.8?U< ^I3G]YZDML
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MC=[S:;[VKYA@5@-(_V?C=Y#6_/5LE$&C]>@BQ(W"DL-(^5/(/K,7YU.E5 W
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M)"<66H.I)FH["+_'@^2+^ 1VG0]\&UCOWVIQPDH0LN4R9!MK%;T!8-X NFX
M-0YA_.\1U%;S((L@QO8WVJN]MZO!_P][[QW5Y->MBP91D-Y[5:I2I4HO2A<I
M2A<0Z2!$>B<" M*+ @K2NS2IH02B5&G203JA=Q) B!"2&[]][[=5?N?L?>X]
MX_YU_F PQB+ORF*^:\[Y/'/.M69O<5H]52]/2L*=44'C4O8[S-&<QV],79#
MLZN&U3J_[M4-+F8J0%F.HQZMV&;H58_9#E>)0PDS)1]$F+"G?[8T]1NE]>W[
M698->VJ0H!=_>RKBEW92^!9U,\#@M&'%<5J&8[O'4Y!&?=FRC":7WB3R]R)M
M%DOGCRDU5_C26Q&X)Q%P_ ZSG4%ERTAIEU5&@:E( 3;=6O+:#IJ^/H1Z8^P'
MTX]W",F4W1J*(4@8+(;%Z"$8*]+V"A[]"?$*D.[AR=S,C,!J<^!VGL.:)Y'
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M9-)**^B+!2UX\GE=IO2AVOU[Q?,6O<RC\^H&S\"1-CI-[[_-?; N7;F;O7/
ML#CA'"?Q;7]_<CO F+NYGG_R2(/>_M6GF2[ZV$HU?!85#_1-1/A4Y/$%*?=8
M\H;E1''\)(N\%%HEL=3/N!>\KQJ]:P:44>Q6+YH.? Q/S0\^,9S9*P?SN;%4
M?M89X@P/O<9I%<*[)+)JJ_Y-18:H<'#6A4B[-OE0*TA^$K\U[5NSPY*!Z%<
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MD_CN8X6;NO\]5*1_R]5_[=]02 V( ; B0,T**1K_(F?$"E2^*QUHDG/>*?$
M;?[Y.\8J R$^*PP*2DEOAFUL1C56JLCN50P5R-?:I'^@7=\VLWN'I_ZRUWH3
ML+$UI+DD?[/'+0]YI#MA/P+\D4&BU:%3:%81GC^7Y+;>0O^!5^9JR-CZ<Z']
MGQS1J[):\#*]491,+E=1)NCCCL398Q_&%&CZH-UA%Y"9]&/^@1:O'@/@B+$-
MP$]"A%V_.:@/ Q"IJ(!69F]8;YIIE0 KK)K 2;:A-B8<27[$!384NRK:3Z =
MF<Z&4Q!1ELEJQQ.S;&GU%6!-K_/&_7)EK55UK:[&I[O62>8JDDV_*C+N_?=A
M'^-ZM54>!O!%^;FK.-..BSPNO&M8PTNDLQ!:CP^H9I#S/:GRQP#"PV' ,P9/
M$(KL5[>JJNN38K-RC]"$-+8D>P5T2601@NTRKU-5\,]UW7%8G!>A,&(LY[T
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MJ7#?,?!,?&(^#;*?N_W5@/OU'=LY?*\Y)$<B2QF;/E(-YJ*U5WPN9J;AYRK
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M=U&+-'BV)7PQ!$6'EQ*$??5D=3NR1^$)1O'/8CC+88R&-PJ?,N&I JI[Q:.
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MWZG<Y]>[/U^0:QF4J51@_WPU6UL0P[%0XSD3M*\F3TSIC?5[FCC!O3 NTOQ
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MR<WOO]Y[[Y?[X;[OF9FL6>O,3)[]//N4G34A_26M &YIJFJH JY<N0+H(F\
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M]O\ ^W]Q(0'7*:Z0%X^"$0 $X$^);!.0SNTP+)S(< C$;_!A.D+#2( 7A\E
M##B(!("+?#WBNN@]*AST/*0[;=8=]_,AA&//Q0F0/(6S9!K>.ZT#<F"$YN%=
M?!7J[U_I<$ELJN3G=R2 YV*.[9X@:'$ZY"X!7 I3?]]VY&M5A@=_Z#4L,)@M
MX7!IU,C_@H].[M.MTM#-3IJ:^[LO#4'>1E'%@AI9.Q2QJ:_;^2XL43J7M(,5
MR$RT+E;*0*\1>$O)ZOZ!BKO>N]/]F>Z/'Y\JJD\L#(X_R;JDOV 0)P'R)4B
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M)8.K)^(C^\-NFF6LBOPV$'E?2&NQ,UQ7VV@'^KH_Q:(*JRVQU#,T7<0=N1T
M5TL[!*5[_BNU=M#F;L[$BD2B?*E'I]-R7.#401I\2=)A8!+<<)\[C,*(2WVA
M*I $L%EYHDNNOIV#J*!Q16+XR*%#?KR*#&@:'X E 5;EL- 3U<^/$1X?%ZXH
ML*?]J^2C DV@')/J6K,KQ..6'B9V/?_2@K68?K0>$?[6;JM$Y=M/Q%W7JILH
MF2%1>@ M3F9+[^G-9?^]+$)FG_D-88.RWALL5%-S8EM['=QKY;.]T_[K&^6+
M9[QEE2Y6K-+&/YP[!$ )OG6:>N*L"^K;%K^H6/5S>)O&5=(/R<5#$\@)VM,F
MI^2*4+X__C >$,2TOJFS16J^H]77W_T!<:+MCF0MVH.<TX ]:B[XTF<9%_#C
ML;!G), UXP2B;!'&[=S%"'SNW@H;,^"L3O!-!8OP%0Y[>2X:*NK,5X7SAY+%
M;$0AP05S&$.\9X7W?^1?5ARO>,@R433WT_IY$?]9CP?7J1N%@(BM4.26;"=5
M^.-=*>U?!)?Z@,8F,S42(/X(K?&YS24@0G6#UUH0/A+MFY]2;4:DF_&H 7=K
MJ4A[,1#>I>:!]W+\CQ%_?T-:ZJ>T\YO9-OX.Z$V?TN?2HP9B,4=\S):A;Z?7
M)X=[^4WA:_1E'CD: A+1--!G"E]YN7XH#+$+F77S/L:GK]TP1+S D !QX7=<
MD$G=(I[.CN66"SH2W;;U+S+< #H\ !@EYN0'Y!8RM()8'1*"J Y]E/^B#I^^
M>M;V&@'&)+\HFY<M%37R&W/B>=W-S)CQL,EVJ=-@)?$&77.8\[L2#@UE<>9S
MMW!]^-?R:>^Z=\*:$JYFLBW92PK8V'[QZ' !=[D^T],^\9N[&;MI,GDE94MF
M.IR_AIO5O)[_6K?SS8(!T7+8J[@A6W <KW#J$B]X7>+Q'#YV8LLR>H4$0((U
MLW'#6+D^"!,<E\VU%^;DC'ECW>@]7Y?!)GL>:JFU$?!R8/&IT@/]'<M%%-]\
M]LIAO$RV6445[RQ"KS'#MF3W+>@Y@B@PI?/C&?WBUZ>Z*HO/'-)L ZQ[?_&>
M./4D) I^T LM:_A1%3CE$%K/.2-<)I/D/?,S)Q=YV'SD/X%6P%)M(A\XX*-1
M[:V1 U55KP$4!1<G'<L\*E(@Q]<6IE:W0Y].[;N_IO$4R'-"H^08.:PI(<-*
MV]U^U(<?C!VKPAC%T;68#-J#1V@_=G"M?Y@F"7#A881I_^5N<_^W;;U6]&N^
MVD\RE%+L*3&C!PH"\8@&,K52\*J7H4"QLC(+5]J0P!4L[.\BWH8UF5Z+GC[;
M79ME@6[0TB2P L#E5F3D9+I69@"U<LRH4#[D"0[B84RL$G=.#MR!$?ATVL[$
M@,A.E/U(#:P/S*8411B6T0!=NNA0$USQ5:A#3I.=%K9$I; *U\S)(%9<0TON
M6-]Q];JP:F7_UP\Z%/(L>YUU) ":!0-#!>Y#5CKI\%8:K+QBO\50QTD=GWBB
MM)C4[@&_W14;']7D+OQP)IBN?K7=%Q=PV=9QG<"&=\9T+,E[9EIA<G"G<IED
M'CWW</]4W1%Q(/CML< -@3^/!>R@6E*W +M5>EF]PG4U)^/SAANF9@[_YE)>
MO0/%:H/@PZF!F\&G6A9_CLC*7YI@BC$L%O4_9 %=O&H#'O40B9O(%[%VUT0>
M"WBHF:]QZ"D:VH;_65+)VR7WO5''_:D:,PU[^A&=YD 6'+!W O^@L=?"J#><
MKPT[ZHV/[&?-NS'EEY QK?0@\ZW90M=1=M,[-8%GLUNA=H_O&@WW7FEI Z+X
MT(ID"MX.U<;+5F\;-N8SM+$X_E2I_?&LJ-<-8>2M<&&3<3%U-?N=IT]5(V]Q
M(I^@AKSAR*2S8JN(HM"/EKW?$GKI\F6Z XT!+;O0\[E_2F% )PCW*Z9:$ G0
MKV@6[8F>.R,!X+M:#'R$YPBT/_T(F!E_M(O03+K?F77#!HNJ-O**F_R51L,1
M]]8,D/9Q+.P3+'QYF=:/',RGP1EI/W: .Z;YL;89!^+4]T0WHMO1\\N%:E+#
M+[*=;2!>R(D(JJN1YH']0"1B-;GVXB&^L)O((L>I/%!?^'=G]OPJR$,$5-@2
M:2 GN:B\FSM:^Z*6QK>N6+ZK<DU/TEM+3!/M@JHSM3SW>Y$IS0Q+]AAJYT+4
MUZLX3(8_ JWI3[^OKL5"D@X\Q7[>@GNR-@=*IRK>8C%X&;7Q"0!0$&*IAX)@
M*'ATJ%;ISI.8>JPDW'1RU?EP7TR&:]7;GE/H*_J>E$?2\UM]OP!7I68[HO"4
M%[8$<;P.9K[K?@A7W D?0Y*RF'0?9OTF[CSQ26E3OBG;G*2"Z^N^._P*72L
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M@EI1,'7O65J_-[CH1DU0^=<X]#4[BNX)6W.&]+0_%3_P(>4:)9:O*W+0"R5
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M&"1[0$5F%.F746B7!AAKKL*5EQ<'P:D%*+K= J3!4(Z9R?.^CJ-,6GMZH^=
M;[@EGD%]4DF_&+DH<VRRI+6A^4>]]<MG[R$KRR>!92KB(/Z7&/\<]Q_]55:O
M2TY1)K<J@W8&7QTB8*MFB,]FNY;\B\)G*0-5'U,5Y+O7V/D!D7N&]7))?A61
M<H=LSD9+<V**ZUM"]UJ+^K_US-@(./+>'EJ"1NF(07I3+0>J5;:A)N9?9R)7
M'NSDV,+XDH+>OF6@B$:U2UEB7PU$BD[_*3FT7.CCNXAYD;_M.FZH7'6J#N>
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M=UH%U/=V2F1E$C=0!@J/3%>=_!3QQ!/X>5VDM]SR$XW]!Q[UWG_"1K/<LRM
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M,QP@UJ/ 7J&SBJ>MIX[NHHX8=/\ #]FTRJ9);C5_ECSUR%4DX/H*\W\;7WQ
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M$? RW\(^)H[S1=-TV&3>TR*+<1M%NZ@,HP,D]<9K6\6Z!XBOK&;SI+>$MD;
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MMK4:CA][ +,FJY*PJJ2J9;3/PCN:O1ESVS77JO6(<1L3A]I*'>Q-8K1!=P%
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MVN7^G@83?!"L,1+=E\3BET,QC?C*#D.!>QE@0%MR.5$C%_,H3SV&(5S.\9G
M;OP<OY;T=<X(!U.H':?B3Z@CV/;?P,TJ.(5;TM='2(BDR/FWEE[=X#B2.PZ3
M-+GN8Z%F?Y)> G\^IU?'?#0Q^NMQ&6O48VF.4FY.<R1N46'&+>&0*3J2YKGR
MI0ALP^QE4D<<?UUKC7M\T4^A,1:7">W-Q:9TF<Z?8;6.#E/5C=9V+T7GVOO_
M(>01:_@_>61*^6DK1]\1ZBV\ )[/MPSJ1#*[>K2+-X]3E8KG7(ZKVK./+56E
M;5QSGTU9>35"Y:)@0TT[K]W"IO5L7MS\'.;ZWW\TP36)B&Z%,P#KFN7/Q9#A
M*H+L!'+%RI>+,#6C]CQ3->VQ([,837&Z#_VH@H= 4CCJWUUA4H-B;4H?+W1"
MQ%2#YS..3;=B_<-EO#@D$;H4Q]9)YM_7-(/"/7TG*D?[);+-UW3NXLU.T/)W
MQSOM;;HX<[.H+ RJXP$M# ?;&0-XJSF<&]2W(9ZA/]2'#;_QJZYPUE,*<GMO
M/L=,G5X%IV74$?:_M]\1EDG]'P*IC_WH$^V.FY4!HQWSB%R)&$7)Y\WZR> Z
MJK&K_'VN8W(@>Z8P$-)4RRQFZX(+&RP3/[P(&/[<<\G@XO#[,\#Y\A'-&+W4
M4G+N[, $UABB"6E,[PH\!$Z49^Y^>]/O[7!%S(?3W@6Z:!Y=KXLZ=0+[_8L!
M1> ?/E@TC70Q;=N4L+^^D.=%OLT4ZTE5Y:DBM&EX\G$/:O<6X/S5J]_'$/7?
M53UWPN?,"T&BF>G+NQ$W:.+[#K'3Q/DEY/H^2;=+^7)=:[H!FH1_4P_TNO;Z
M5\-RT)LB <$5)P75;RNT+T1Q[?],4GBFV!F@ H$\5%=_8K(F ?<IR<3\YV0]
MW4BU_C^$[_\]^YH>58%S_UJ&U:JC3TPB#_N*<45+RO)_[5A"UO,"G@ZT> 9P
M^ ]6R<)JQF^E&>CHV$M%_(X:YI&TE5MN-R5'SL=M^.^/HZPL$N_AV1H?]40T
M\H;_V?_:7:-L:JHG'Z4?>&-\<%:8^HHTVSS+LLW6F]( <6O8?:<)<;[2]/YN
M8TGHAD>*'"#AH/!%Q_7Z#L3IU32(C*M@&DX3U<1RTRCMG.]53;GYEP_Y=Y C
M&O?Q&)]C$W6+E$.P:*2;_K3.;"C3ABCWP]&C""B>@Z(T=4H4(2IU$O_ V,B#
M"[V?%A(I?VR4?VZL;_(HE[YWHQ]R5ZA621/L7?3PYKC'C\CC@>X9Q,I]I'ME
M@C^\+0IZ ;I #78OAIMAGTRPAXL?<&?R01:M*A?CX[J"NQ2X:\Y[/J033;=%
M+2"C"YB^I\["S4;=$Z>I.26%3X+YT:GVYU_\#EQJ^M.)L<Z';HB A8@)3@0Z
MVPP6%$H"IQT %J(R_'4XA204'Z9TM0$GDUD'X=?G2-"M<%+1,]5*444O;:2(
M%#)W/(,!+.%<QW\H%S&0YF3>A;>M:&U?$Q Q\+;?S*T.\V)?JS- E4ZUNJ:
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M'^O@5?-MRR'0U^N5H2:H>O.5Q\JU"O=F4:OZ!*6^HXEN"2P1O0JPJ [_DD.
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M9V'^NHI\@7PF^KHV8I@!%^#T$W(J@: F@3 E/TB@Y2H&W VSGZIHKA:F_>"
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MH4_ D4 5D '1'A+H]3O'_Y#NEN4,(BT#AMWURBW<#":C;]_A I!!JZ?QNTF
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M/7W3(U/X;D^#=R7U.7% RF1[XHP7X.JU76B,%[%YB<=8BU,J[!!*1P(]0VO
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M]&H4.T5<I1Q8'.;7.RW]"=Q-TQ'QQAT875B]F?=ZI^)9:(<Q T[1"+BQK!;
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MUJZXXML<ZY#F(C &4Q8&/[1J8014B,UYYIZW5 ,8-50-\$] HB37GB(1\"&
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M=@2'ZN#BB=2"KI&[C.'0>E/X6/=7ITA%"3N-9#OQ^Y7?!7QW;!/PCL0^.,8
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M)Y;F=?]L%5M!!!B'=]Y[I02]N'OXO1B^,.<9UC +]6@8#Q74]8*Q+JDK-5?
M?L=]O%#S>">U4TO@N.RMBB$>&&*MQE42VG<@BU&)U5*T..V).5@<CQ-TV"G
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MOZ.G!$LV*$E!K(O:'D3PPF4UL2,G]E5YYDS0<\;V-GA1RK5:K[U,'QDG[A@
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M<2Y0R8J.7I^8']EW<]T]EN,7$&&*IL[?.Y\8$S[::!=9LN<<_=W;+2Y=A;8
M%]><KI'DFN!XQW;+4A5(_SWBU2>85*<Z&N.B&[QAE=Z]I!OJ>$^<[D+=8^H6
M[?4/]_6^B- ]I?DMY/&KK%=9_Z+P)ZYP$1A4"?)5UIUJ8D;-O/T)9X\AM@2^
MGDT0/BR5Q-H$P2PO 1'-+'*S9BZSBT-ER\:[#MD3J[40*\9.?EEG^OO1W(&"
M#ZR>O+T2]>G*"-)0NIIA),+V/;>]N8*CB]W.:DSYYZRQ79]T#_Y@5]C<RE)3
M8J '?J%:%5KQKTP62F_)I'8)H$)WJ#5T0V$0$Y) 8"56;B-PBLKM2L4-">?
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MO8#LE-(J[*PLUB=;CZ[BA+)T/C69QKSED9C/,MVXGG.#8X.BT4ZR ^'?C(J
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M))%X?:B^#89QY&NOOSN%-B7QEO!CZO[@=%>)9 C$TC&L5KZ@D__%G)/*_H8
MX(IA@QG)OAF"] 1!P9DN:F6?^RVZ_[>&W)&\9\*L9[Z[5\R#Y( [:\MJMWZK
MK%"47@("+4\"P'\J=J3M3BE.(B B<H+3P(IWQ$$VM+V1?*K?^*HO<B=+79*
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M_6%LLN@H(*T;FGG3T*0*CL@OE)6R-\Q96+&UN,;<>V8,:/%WH=S_#E JHXJ
M9JYM[KXD0?ON__H3*9=8O?7)UU=DXA7%-WN^WXA )S\Y"$GI-%K3>G8DLHYO
MV?.R^?\%/6SXWF7PZQ[#ATKD1_+>/_II16JVN#<GJB-0N0R=W,%"KW ]9&J[
M1Q.K5<*:>&N%/PKDWO-5P-"B0A-]7Y0'*9IOT%W\^A&O. Q_\Z]27+F93@DN
MK$H[O$;2II'6B6M04-5O0/!302>Q.98R\I#QOI7#P PG'X%IO+U._FO.K&18
MPUN>X^2@/<EB:V15#*9;]DU!O.;OZ*(R1[47'R5PPJY,"MTD7<JBPH.-K(11
M$QXZO&D7L>7"6VAFU^ -5C0$LLNS/JI4>AHORS3W,B3Z6+T.<B+(XF)7G!AQ
MWP;L.25DW;^=*$]Q/NQ*NQ_O+E]-DD3NTNLR$.Y8S51JR_X/]P0-?M+P*)]<
MP:QEL1D>0)H$( ;?IM OX8K1L I+_P7V< F#N'XQ#;&>)2,8*OLZ=\SGMY<
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M[&HA1(470]8M&"UJ[%B*P^9F\*I=LW,NXI;E,3IIGO^DVVH,8@:]%S%A]BC
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MT)4]' -;ER(KS)DK;)G<XQ) A#.IGE+@@'?X*-1Z(RC[/=)JDP8%:S_T;U:
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M7B4?C<C[DANND L&>HM8PR*7:"QI>W('D.:,\CH./,V!<(TU('^(<.:;N,
MC]CA6#^1)SZ1Z2XL:R+M5LNATIGL04!\1T.L1@CS"F.<4WU<GX":J^0/YUMT
ML?>%ZNFK?H_(3<8$7:TX9X#*3]785L8JQX\LZM\6!/N)A]]F^F91(\22\APL
MV>+WGF6N40F0"MC":6#:.P-N8*Z/)!<[Z1B9&Y<EJ$_ 7WRCJ3.C=-;FFUNO
M!DKW%Y>^T&_HK+R)(CAXE&C!J:C %!(XLZH-^17/)FL3[QP9'&B,2!@,UVM)
MLZE->?LN7ILH8RBA^Q)07?\!Z@ZZ&7!KPM"R(5AHS-RR?]^,K,813J[?0<IS
M=6-5) UHG/%"#U7NJ6C%%4+;X934QI+PPOF62DV=3,9ZWDQV:4$E6'@UT=C;
M=&$XG=/F];T?A?%WR8RS<6_1L>$M8K#R+=\/\,P$:Q##5'V=@2$3+?!F7/C-
MWO[0X<[[=K2_[S5O4&@"5V*C VBPD=YR,@JM]MZNH&H/E=1[U^QM2/6_"[79
MN*DEDI#?3GH0&CWMCH+9MU\W=CQ+2F.7^>0K4FDO'+R1),G2\VGKELK'L'J0
MVJO/PIP+I_'T\;LOP#AQ^Z!9I$ILI+!PK2"'6^<^\L@^\$RI\5<\T%;K<[KJ
MJ'P7\ZS3!E(Y*N[==4WWXT0T4P@NJ0W#F]_B?4-^-MU B^_NIV!QX"WSRJ\G
M3ZG6KGKKL]@!=K4P]IU>XYJ\?>$2IOHUQOG)**8B\O#;Z?,#MZF5KE43L\":
MFXGE(C8.L^9D$6W1I?Y--%<W2WS6%DWW'*)23#^2=MWH#MR_2S%A[:-C^)"'
M[OS8$"U2E+LU \I;\#&1#_Z:YBC@E.SH2B65#Z=9)G\:/-6_UF_4O ?Z,?>%
M.G 5N1=TB&*<N03@Z82Y=IE,*HZOMU2:"\4-!(AHEIB43[@+C,2RW5IGE;X>
M71;)R'43>J_(QVZV._5ZW^=;-ONUS%F0E+HGJFQ98FWZ>,R*S>R#XH A"[+9
M%G[[;#,'VYIHJ0WD!J5>:T.X]J@BG%<KL4-,HMETD.?+SW=W*0 E7+M@-,K%
MXS0/#5\T<TPM/5MXL+ X*I<%RAJB?]&SL.=# FSV4C-[%>] G'Q1W;Z2RW55
M<25S5H&K#=NSZM#"YHSL25T&VD^"P0$_T2#'QXQC_88.20J6@-^K#Q]B:+#A
M6L>\EX <!&'V_=!&F-+[/5&PN@H<??)*.^ZFS$[7L2*+'+.<M3-"3+(W/M2@
M[=LY3S(;HW6:<8YP@PISUV]B,// :' 65BKM^#:!0GKB+9,K</I-)URGLL"%
MZRA1/.7>N1#VH"/SSJR<(H9+>Z9%%@&Q3K"<!D%%2_S3E&*L!J@2?M<9"NQ?
M?_>T_'O&#P9BF9__]2SULXM$!2GL3%=G&PDVT6=5D<F9:J# H0D<4JO?U.ZI
M^K&8I2PW/$#/RD1-!4!GI)=)09 SO% *K#!ZJ">3%BV55@'1ZF@3IE<HR#6U
MZ/.[/IKR1GCMJL;/@O00%45!]2=)5MGN$?T7J>TK48I5H]\5(WV_MJ*]E1O0
MR5$MW.U=OL,S6>5:15H.!_,FYI]M-0[>QJG/')@.?)YFSN\E%_A9D5YF*GL,
M:;=_EB6.O[Z&$O6$T6MY+S5/X%%)OVQR0VH5C!7W'.M:9;>6BW8Y[Q&,BX,*
MH]5V3RX!E&"CV9@L=/ONEB]42X#8:F;_402?9MX SZC 9_Q@F(OU6P/UCXG7
M]W_UC6(?[1SK8SW1]KTFO]ZW<9MB=WJE#.@TLS<IL[=G@O2:KS$^3#4&O>36
MP0KUA-SDQ%84_$D2Z9!6X(#:8*\M4^)L"]2068"%X5^+CM(&:-,^5_[4R;1$
M/X]H1(M/7I):4UA>%4L^SUJ)Z+ "P<8@BW8;+@9(O4J:%M;''[$H_:1=6B8X
M,3E<$DC=%,+.6U,U[(%BO_VYV><VCYW>%17M;0*D H<[9"(FZEHKIE;]-OU=
MSR4"EA6O70*<]T).,L6P_JMW)2LHC!;R/S6US!C*^(<W@$^M$LSZ6-57/K)H
M5^H,LI&^4R@J@0[;#W"C*&2.5F:CH207@7)LZ,ACF3&%JSMQL6$*5]$-C&=0
MA=MU$792E>8LN\C/ A_BROH^!6I^J8\O544"C_TM]XS_1& ) M*$R)&;]@+N
M>5.;5)X,+V?Z?R8</A&]@)TR@V [2^ +"H%&O5^7@+B067SKQB5@+(=PECJ?
M0.([L6<;R_V398JK,XHG9/M?MRWWJ1L(= O"1<M,XN6M+P%O80* ^+^G!Y4D
MOEC&*]=;'O6*_N(EP+/O'LZ' />6-V";4P16)\C7V(>7@!TDS07K)R(W CA0
M_"U]YQ]Y/5\H#)?WF2LO 7599]?-B_]^\.5*$=8/_YA1\6B/"Q](T"+H$]P[
M(4);%"](M$D'<]KWV6%GR/8S-OWMO_:U2;<+R@E:2.L+WJI<7]X=KS3A3W9P
M\]]&_%TE%/TS%@_(_Z=(</IG+)Y@S'^LMDIHV#\"[B;_E!"/&8O_'G*?COA+
M04@0R1SB-(7O_-D = G-_=AZ<D'XYS&G]7\> ?X2"HE_B\5K$^D=BF(Q"7]]
MZ\&$;UT<-DN8?L\D-Z^LZS<2/B6CXKSB0F#ZK_V[5Z8EWVT[3EOJ5^$G)NWK
M#_@B1Z-SE^D_Q8F+);X^,?(DJ_QR[?#BR:C!MY#]$8A+&9C;.#N5;)E]<Y"B
MJ0K]O?P:]R/F<F^M62@-AG/D0+EZ2NY!N;([R;+CM[J&D!4@_2-C#=4/N/P!
M*O7SODRGBLZL(%J<))8T&\((>G(), H%CN=.\+9DVIVK3)1:F$KA?IL=Q+CE
M$LL9IN\L?U-(0 Z%V4VU:%;TCSNH/=Y'35!"3'B#$2%6$9\/<A9X5)DI[X10
MY ( ODNQ9,%0EI4N/RL/<]FN8ZE>@Z;HW)@99FNJ86[@R9-R\TCZ7J.$J>EH
MRN\R-"%'FLK:DQYI;++#QA^2O1G1)'Z!K&HLMV !QED<TL."_K^LH!J],+06
M2+IWB6-*HB26"9LJ:_YLO9P_46>N?&W111A7_4@3;Z2YPN<5G&E[.TAD$7P#
MWR,5((9M+H.4Z&&N5EP"Z"D1GL[.=IU$+NUSQTG%'#'(X9MUO4A&(F@17]P[
MH>Z/-+;FK+VR$*2I.N-=+Q^'VVS6<]%IJ@_GWT=Y?.][YM^3F%V;8A>A>$<%
M+"&#BRK8<]E5&ACQUX3N("JP_*4RHCUI_DX[W0F6#G5UKCW@5\+<'^;5D]'+
MH$CP$/M5=4.Q=VJ+ K0M?<EJ75EH+11_9QU<SB" #T,'L[Z(2U)+'O$+%_YM
MX9G8,K$B=F#+IG?MY-EO[:;.L7=^ 4'Y#IOQ3JQFC+<][30&1$ O77V]!/*"
M9_=P[Q];:0V2.4U5D*(5=YERL**&DV 8@ALCDJV0+"=]0_Y'9?6#/A^&V=1?
M+B9VUT!1Z?1O#$3"R$^*_ZN:@^9.FR<V_YP!6T(8&!B@QD@VQ7!X6X(S4J7.
M5/!A]+@EC=P]NA14*/P)N=G3\?AP3IW?T*01FG$];;)WF^U5!)ROQ5!EH;^)
M<FLZ=<)GKHO?-3+:VKH^O(8<%E\/SC:M9OJ-:ZR[4Y%*RQU]7>WX#38A%ZN
MG.]:IDT=0?,>S#VVC@.]H?IVJZX^S 6\T,6?FNM622X0=Z#"*7\6 3@]6STV
MPR;:VHMO*3+N2<Q'/W$H%_DJQ><6+USRN(>X7Y69@>?^>IP-/T2V;#NK>J]'
MV&1>[URT)W*1PJ"MC56#-W7)/W#DL<[/AQ_?R\7=B+<SGP\3Z D2 WNDH\(;
M^QHJTBH4Q' >=1C[",:]#E?X9AUK4N[5F#<>1RT-4Z76$=:DO0$S^C;VC!WZ
MB=!1*;.<:T, ZA)DP6Y/*=1T8D_D13L8 :-U8GUJ8I/<]$;\V<#ZR,3[C62@
MB92"P0J+A@_$2C\BTVGU6 HSL:U1Q-]]*E*1TYRYMUOOI5N7YE%/-IH)-V)<
ML^.&%-U)_QW#+22XW\C=C/8."[B#S7J&,<CR:%)(*WV2:1!;W);HSO%!7"'#
M:8A;B:=3(\^TKY&*N'.>6^\A>(G390AIV4M#LWTR9@FQ&+6(F?T1 UP)+K6.
MZCN.CN^4&S#Q3*%;>A)TE?L!WZ_7-0!M[.OS.Y!<!#X..2RRVA._G6H?7M.L
M\10H8CI:E02G9?WFSJ)&MQ9.V?N]5+WYN8T*Q]ZU@%'%&WB694?:+04)\R<C
M2WZ\4_,O4^T3]$*NB[#9N;%!0M0::P*?W.EDWF@B\8DG)Y7G/P["UI9O#\O@
MA#.7NC2>,LTL@R^.%LHK]V*NQM%J/#5.N[7KFK@0];7,T;*&J<?TUP3(#JM7
M5W_64P\')!B\9HC(,[!P?PXMI\F #,;%IL1/V/&P"P.D#H[OM6%$(UW*:T?#
M @1:)NS]4EY7UR:";*O%MYFDU2N?$]GH1\!N)79'10QL7/O98[A\[(L-YP]!
M24QC,R2;-:U"]9KJOHD-N19*3B4ST2N?=[Z.4+H7;;WPW)']M6E$=2[N!39\
M]1)PS9(;HG/P'7^G=N;-G8A'$=LW%K:J%IXFF E]N$/.^,#MN8]0YC,Q4AM]
M%[X=Y!Z*EBQ,V !,O'5_\\0WTG012-HTZIHW#VZ#U8C,US$1O8H9?ZQGZ%-Y
M7FM\_)UHTI&@P.R[.?@$.YBZ=\*YTUXVMIBZVH%6(2(B=@WQ<U$N%*X\KD+C
M*,B$\-!!<[567L!H%CWH"&(WI2#FQ!I=UKIFZ$BW)68J\9F:)^9)=$ATQ'S5
M%\"]@XZE*H$^TV[+FP'WAU:N,^X]0<>DN98"LR526PPCA:M-G0K'!=6H5,+B
MQ7O?V&DWZXD/W.I%T9!CAU9)0\/6*V>@TMG;2<<5#IK#^7USU@TA2/67*39V
M;X:=*BV $@$FI8%^+]EHT@$T#_XL?!DPR,4"<_I,0'LT#&G;U^57=OWWUVF;
M2(LIB=Q"M;M13_/F FU^ZBB'KH#[1S2AM2O+6#Y[E-+*A;M)+6:O1S'<0JZV
M:8+*5W(F='6G7O/.Z5PH_'MK4[VK*T#/8;!(=^.;<%S$\24 *[2,8PCM7D8_
M:Q8-;4H.P=,MXHS [$!_9[FWVP_F+@%VD:^)!>D9:LY;1N6;@ON2E^6@ LMH
M;UCWAAR^SS?[$M 8?WX)2/3,=&3]O-!D#)8M8 +[,NH:.)D\&RZ!CPYN'G[S
MR7\N_\F:,1E2< D@.0HA-.]9P#SKZ/O5IJEVQPHZAS+)SYG;S/C;V.#R4E.[
MC<=6U*6;;@I/MKM=&V@S+?'7"(1&LGU1$D >,'L)0"="?3'@GD@P!>[Q)%N/
MN I9A,G6$8?)'+*^OFYV8%%<_4U@?U@5R6L*%>YUJJM<@8IHCTM MU9T.S-4
M=&5G;\YNM8LQX.[4RB3?M$N+FN_8UH[@!W'Q#$FB7@CI)_IWQFK<AT.=EK7K
MTWM=E+ ;EA#^[K-/LZP7=<%KV(#NI2J?W\4B9F(ZW_J:3Z)'EF@"Y)^_N-/&
MEUKT4E!-D\XR7O5AQ)%@'QPH+,L3ZQ%[87(A4!:*^P!NWR$0WR:E0>XEP*#]
MQ;1!%_Z)]/+1..R0M$)N541?WGIO[M]<2T"9RI-= CDB8'%?*#^]5 'HCL%6
M>]K_NUQ6$8-<_E=LM/'QS7_2;.(_4/?QC?\18UW^!^#]0BZ0T8X+=6G?B;(<
M>=:HA[H$K,G^61_?"N]&X,R"\DM 7SKL"$.&CR:</5K&[O^5IW[W_R)/G<"'
MD5SGA$[Y91K^SR. 0%9H^QK1?]=)E^LKTL#ZK_3A6PE#Q)@* :K_42+]GQ73
M%L6^OW!!>6<T&W^"]/]_J?1?I=+"AEP$AR(YL]%9*UD14&"^HYNS[]?(K\.>
M]J\:KVS;ZJ[GTIYHUTF+?==?Z'Y'SA&L@^$,LD=F4.QI3@FOME2VA7_)9+EJ
MH.=R33$8X)Y%@1<RQFEA;V=C!V=4XT<-)E:G#)2NA:GG2S.J+.W4K"0*<N?>
M(S6?"E4P_;,J@.P*%Q?62O.%$4XI3_);M*A0^1OHUBZ_,VG+/L\^500/0),9
M\'$4S#?1;VU_0D.#===$QX:\.?27UJJ9/,R06A1"O4$AC%;J@V\*J(8]U*<
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MZ941'7D8/];@(! (Z1:])YAA-)BOQ='\)PGO2FD*2HWS5L,>1H#.F5DU$*!
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MX+QA>S7O]V8TPK70KSM\$A:$V?AZ[AYET)X$K,E"F9JCPD@2QR:-26#0CUD
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MN<_-H)>Y'?HTG"OR/$ FI&IIH.0!_UB S*<VB6/BQS&6P7U;TR*1CJ!(^&K
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M9H7HG<6DEA%&9QW^6N2Q_P$X$*7#2JWF>2PPD&6=R]W4UN3V>J;8T7UZD('
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M!VR@C<?DO__%049ZD6E9;['6X\PS?=,&\"=)BCP9@CIZ5EOB2D=P+=6(5>)
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M;O\S/H@*)>-]V=A]??'"#7]^!?SYSU_^7 [\N3NKC[FCHI#FX4%:!E%O<\?
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M9[ZK+C?.MU['CJ WSPAZ=\O46=O6VCK27;N# S[Y-@NTO%WT$+V:8\CS(>3
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M_Z!A]CROPT;QXV!K1KV'GF#Z]LL1WHZYY?C+L]M^65+P(Y@1!^9+(DB]-]=
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M7NN9TCP7#:(>0A"P:@TTZ,23;-9AU$/^!F"-M2N(X::TP9<1'7@;_'#A.DR
M+CE"Z%.J'=K52=?)^.P58]AS4'CQ9*0I82 P29='N"Y^D9LJ@NU5F:#XKL-$
M>D%)JFAF"'XH_ID1LA!+^@U//60"!ZO7@L%'_'3[ZU9LC UCH1+=E80-Q%_&
ML5%,3_46T1"[IOGSGO58NT>CUX8%@NO;Y_/QH@8/D']@7N0WS!OQN^AH!OZ;
MZ#AO2I&7K\UE:D#R:NZV3_W:XQ,X$>Q2S*YU?"_2[9S)N.["X1GT:2H_16X[
ML\]3*"R(A"(1C -/7T_0QD!DE,I?A4A0=M]&!7<#[BZZ.-2G;VB7>\!B!I<)
MN:':V@#C/K]U<'K-6?O VU(CEZ6&&-[=!\QUF(1# 5&DZ(A!PS=+BGU@)1\=
M4X^@R C8@VRR9"7PS0:-JNRI]+%C(=I!'(SY>(\S70=Z9:$\<;._*=2-'W!)
M610]@E34D/$:0[XL+\#>0+WK(E/8:" <FK ><%+#@L&'<>2\TC+P9,F O@L
MS7>3)L W0\ 4=QVZ!MV+6'!"[ %F3G4#2Y'7Z-!<O6=/P9F03&?[2*NGN^?W
M=2Y1KN?M,AIW>1&^4BC"!"Z6OX!BG0T"-1^1O#M@>*)V?DO)VTQ<F!CI2J[T
M%-IQ3<=TAIKV.=S]$^O:C[#ZS0:L1CN2VRZNPX0/02Q!!3Q[@%;]'%K!F+W
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MVQBIU>/NYSQL%<D+?+'9C-V>(0+7L5OE,#KX/NEW.\&L LD5RNKR=ZDO-6+
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M,G)7)'F9Q"B-6(>AN/@)!BB)L#R*T;*6DF[HRM5.@_)@HS=J"?"!B2(N7MB
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M/P>S2.WY<5SC%_-4'OM!>UA#9'I@9L?/M1WD0<>1@$;86I 2M:94W5&J3R;
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MV.]F+.A><V+B';0+H?Z[<^_5- K?JE#=>E;LH:*@A<#HZT+$_?#*>DCJ#:7
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M-[_/^$)29#*=W<_>W(AB^)PF>[&S;0X+B@7QH$%4\Z0K/3F\NT^:K[59\IN
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MM=[<.+F<Z!7\JF"CKEY>D)\58==8WQ VOS!6M/=8(:6W3#AQ15PJS3"?<]:
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M]DK]U8LA7/47#ZY[L[78VO*[GU-II-%)=YL:G;7\LD>_D6^3G K)/"1X'LE
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ME;W05'P13NO7I9ID3%<50B@':@@;.UTV8VGMIR<FPMS+TE9<#AM)9(,$;W]
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MBF0O4B8^[USP7E=:N3><4?&1[:O(=Z]->D>YC=HKTJ\G14)(II4[=Y_5*E[
MZ6[O+BO4_#B>=;X<UZ_=[GB9/VOPL'06T81FMXE3P3 1L7XC\BX#CA6-D$Z'
M0'?3?@RI21R,S3O,"/:**NA+[Y?U>+]$E,PKNW*)/G)@$YC,\ZEI5?001=^]
M+$3$?+/%63@()9S,EZSSE>3YHS<<G1>"RX8=)=VS&+Z"Y :A$[D:V@U&'A*&
M3!%S0^?K+ .8B5G@'332]=R;',UNG,6'\&!?R-N+]9$3? O5"OLMS$-\,+JA
M>3QB38$21D2+O R&\ I.:(7#EON0G?F:Y1:SZ7"8*#>?_-10FHL2H^_1K\$,
M",X9'7"@AO9@68A(HJ?,M@G2Z9RVRD.LLQZ:W*_1E: RNV 2^)%R%,=]B2CV
MLU >9/C@D+"8Y!H[)0]8C#<L)N"$/BP&\2%;[R4+F_\@-WZ/0=[TJ8*9;$DO
M]3G1MXV=+$X"W454#SBRWY$#E^UL>?I1<WT.NZRLD:1=<]^Z5=-L?,YY]#\S
M?_^18DI<.P%(]L3.<OHJ>8@XNB%>K=T,-F'HEB%N6ZS9LF"Z<"KEB;]1UKJI
M7*NQ;L=Y@SP9A]> GY<<(WS!E%!JB?$;>VX/4OJ0I\!X+GG5.I?0>\A-++_)
M;,,MQ<CM_+X$['J&*7$-$!%__)WS"P*<]U2E[B*?P7MQ/(1NJ";NWH!!E]50
M./=#T-XNLAW;-(WX>LL6.MB-',8D?V2SZ$19AAP(H++LN2:-!3YUD)+L21 R
MQD.KD[79D[>C*LPO\\W+C=M]4+;L8KV>2W_59V/L+*8OCH=Y0#?&:W5\@^G]
M6MP]PHXJ$S$%89NK]_I*<*4!M*#J2-NQ9I[@WCTH!TJ5^ 42&SP2[,OW12G*
M$F 9 QJ%,X0Z6,9U;&:!>"P]1 [8A(=<[MNZ)T) ]H:E*"])<?M#BE2] V\]
M)%"P$]8UA,R<5^&L:<G5RV3=?-WVO0]_Y7TJW>PX2M#"P F9]V#25$;E:PF)
M0R<S7H(J8H<NU(Y0[T\_I3#K=X>.,&W=:M_G3WZMKBSB7Z$.+)1]5F*&1^E$
MA9&FLD0VC9P-T%H7+&<=?5.KD%8_K_8^ 22XNYB9TZRO;%UX?[^@G!!027 5
M(5CIX@Y9&F&-%-MMA8;]8$G*SE"GULWF]*UQ3>85EP9,ZQ].BD-HP>Y/3/4_
M<LS[^\<4)R<,X>GQ0L02?@+;A)?JZI'K(-WS>".1==?L-FA3LI.=78'#ID3D
MIY^M R84/7$M*2(BBRK^)$M#J4A]Z9\A7:BY(KK!?K5;C4H-;P,>A\THJ"L*
MO#&CJ^75RS$96,A6G(PU;(9=DA2'L@29PFL<#S!>.##$1<>\KDC1%TI9]:YY
M1]:;K\=8[K7>SWP>L(!M(F(Q;%/Q/7"G*&WT"!@DV36!U*@R75.UIX&WL@J+
MS<C_-)D<]R'4/=D37TG#=RE\*]7X*@>*]!L82#P61%6,UI/N7<?KB_8F7S]X
M8U70;Z5.YYP#/^"__HRA4))Q+655)'&IK% .^.+N4#9,WT!'$XL^I8L\ZQS8
M=;L\?HAK[*DX_7&J,M5D.S=81^?!])(.)PP_,#P%<1 :Y @C@MIBD*L#4>M#
M$_A/:F2WS8LU\P=.\/O0+]9OD4I(+;1AMH>CQ!WJ990@:A!QT4?  (G)!%++
MRD*\(PL:B&M,JCBQT%J)1]G6\F<NAO7/!BY]GTW]0?80^A%_&!P5%@5@>3ZU
ME:2[J*WNA]TN?\[LX76SCFELO?QNEO<SYMDS9B GV:<Z+)D?)KD@)8(Z(O<;
MQ'N<(NB5*!R&A9ZQ.'XOW@_[VB2%3;/^VJ)":Y'Q.0T'D4X.'FC)]]++8(RH
MA7N9Q:QOBPI!KC0#!5]I=FL# HW<7]]VU ZTZGVL'NA]E883$DL]L))+$!.#
M1"E*W:*/@EC)[@GD!OQ^O1<:G9./0IN9Q\Y-:_=[<#XD:>$2'76"!>2/<L#[
M%BHWK2I$; IVBI!#E#J= D]>2&TX*7+QJX4@0#/>N%SS3>?A[ ?%885;=GSY
M6!?(X5(/R J)6 H)HP#ILWWA8 GW$B=XX+JZ1_6+;7[-D$K$#T=,]^<=&K95
M26+EPG)X+Q$Y.ZC:LCB4&?X8*! V.?2@=N#UWH'[J&X3)+\5,:A*S;=,S1;U
MDS34E6.QE:_#SGAS%KPJP;S;,(K%FI"0"G0]EW'T:J(W6? @95/#W9 ]D^O
M6O8QS5G3BA+4V;>5YMV. 6S&< 80<=PZE#&%$3%XF"92-&V1TH"X&X)6"B*'
M#^%P&?94Z[S2KOT:50+S;=:8W]XV#G370GW$TI F^UN8]7MEAESB%"<;[_UY
MNN1;17DW3Q1!?UB6O&9KGMO"Z=HIMJ/#_#1T@%%W$.G@X*$OT9#BP$31)'<@
M)P]_&CQR58AS*>EJ+7CS&%4-ZQ,,G0T0D\QW/':^\7"\&"<M[I<Z-D%]C%)B
M$^Z6AU7G#<X]=''\?&.\[DP+7\ORM:XQK3VI.6"*;I.XR]AM6($6"!D B]=B
MA8)>VA"CP80$(;I+D;%(I4!H]42PQ265 RC<NB/YI5(W"^V0AHU7%NCNI<T$
MN'],DTF?'&AR=:((Z\17&6#[ZX%S$;F39Z,;RA8M>]NJF5,0;#&+YFP)C:C+
M@=-8%@RT18A>ZA"G 4D:0/28(6*1*][082DA>0%>66V\E69)79M[\WTXZG[%
M(]N#BV D?(U31N+;BQB#2@_FR(@H.5"<,=H8;[SXL2TL^Q"/';'A7&MU\H?+
M25H^"[^R&3":S_2EJLAB4&CI63C+<@L")7#&#*?>8;(B.@YY>5G<O]CC=CHF
MX6HRWD&OM6"&[S\*YQ08A WY3,D!7O7&-BYN:C9<E&77970Y95',:0A>M!!?
M>26^'VNK(OC",)\ %D_'"G&]R>)(D"HY[&OYC=-@<L<9LWRZ1'(_[6T9I?Y7
M[)K<K8:F]+$T>Q//'><M!OK/,<H8_".BXD&MV!M8=!2CN!M6P>)4:9@ ]X/(
MG1XOH^R(2#-Z4BN9-VFMN(5*2*O2$NO+7D&[")]3=*N#1&<&XYDU;@7FH>EO
M:7#_DTC6_>:/@HH="2V]S5IKYFE.&'ZYY!<8Y%&"2 BVU!!4@/$&\^P]GRYC
M(ZDC+@V.Y!5[#+:NNA0AZ7Y65!D\]1*1GDT%9/>)OL0X8HD>A:>-,L CJD!#
M\^1M6T_&$M?7Y,L!K!*BNEC]>+%WEX1-P\%K+Q=BHTN8C;B^>8?/Z:";!#V
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M>S!HI38M%^>/EGQ])?,XY2OXX&A>\J5#1]:V7(^QM?[9;NL;\'9I_I?W'\2
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M]BSP_^YD. \ NB"9HIS-P(,8T5RL!$,<IF1S@L$%K$C"C_BW]]Y"(3##$;!
MCZ]?B"CG+29N*N/$QET^64+I^ <:4EJJM@9H8:' 3BZ">GEPE^/80+D?H2'M
MQJA#EHF8N2]C'-(V0F2F&H)4HVES+YNFH@$:TK?01%AP"3CKPCTW@I(F:4AE
MJ\^K[(96B(6#CM:,WVB[ <$KFP5H?*\(ZIQYU+&N"Y%N](55*$=9ZM""2"20
MK">IS:JP.30%>[$I8A[_!?&Z"S^;!BS7=KX;DHFAV*,6 B^AU.X^5X5"3P2&
MC&NLLX1B+9%;C45WML-?RO:ZV!0)45DEW%NM$IC][:#R,;A\JIMU-/;R+F-P
M<CX<75Y3[X?!P*GR$97N6@</(4BA3$(%AN\H45+4.$5B]JP_&5NI3YD,M[%R
M03S J@5.8YF!VS2D:-$0\1I\\NX>E<RB]X@0X]R%1&[38+%K5R3G3Y/L98PE
M*B'I'LQ50]K[MD*E,'YOQSO\4T 6\)6+V$"PWWDN)"(]\:$"H=(XB;!4&DJ9
MD^'VUR6"=( [4@9PK#L'.HEPBU:+=\4H#:EO&E!2U^S9&8"-YA764LZW,P:7
M6!U7$)";AA2$#)M$70=#YB0C0NA%8MHJ;E%T,0T](^=H*UW%UU!$0]HGU9!6
M2?P_\Y)L&5GA;, 96BWA/KH!SK68[RD>Q"YPPJ"^@T @5=K13>FU+8AR"30>
M?E7)!.,XGS@?;2=TE%_3<O%IHOO;UI^PN23G'$8!<9KK)>83^6]+,8;TUY+3
MQ.;J%BH>V .IEN<Z9B_T5Y9*]A(CE(:5SZTMNDX)[K-?(7XM27CX>4H9K[@7
M3/(A1IZX@2@J)[?5_*@AO>G!(H ILW<H#<QQ3\5)X!KNU0 <S/"QGF=B Q[#
MTF7=B$RF1YS** @AYFPQH13;W&0W4J3'",!9_<GXW(C<J#P?.;BLLTD2JOHE
MW&WNV.;[^C*<7R-;_@QJ<N_Q=^\#SFR\#-!5%48!_FTF.4ML&@R'^HQ\@>)S
MSF:^ZB6VN(-D*T.AX2EI[JTZ6&S%1/C5%J#R-V0<!QH@>@\$2/F<0V"\-+YR
M1F- 7!^ %"-&$45NV@1W;1.<$CQD/Q)*';'OP:SG=1(A,UT!I1BL7%(.->UC
MG41ZYZBJYP-KW#[;NYEO-@'SF"'+-VR"W,R4RY%(1#Y.RYS33 NJ<<> TKYB
M,,L"21914 >I=(M9J^ 4OI>YAN13J(*>]1;!7\2AC [=@7H82WRJ($K N*_%
MY,[-:P H>^X$'<#7*VAX^XZVU2 W?&G@(L>GM9AO6\\Z@G+,%4B]/F%OUD+&
MCV:#$Y[/G9C7*P\#,P<4O(:T)PT9-N*/X/N$05%( :7,X-0!;'T7\BV?A>=#
M;<?%3/ST%$0U.;99-@AEE6)13>- ?MLGT"XZ\<S '/DRHUFPP@/C?)T6W&*#
MQ3+&@+$X@X"TN>$C>QDX#_!"7@M7/7HWW#7,7[900V*%HM&EP83):DY# +&%
M5\P=!+-WO9)V5G";W2"4^M(7O+=P0M8+1.BINB?A#DZ4K=DM-SI$5#<!!$^K
MT)"N6!QA3(':DEEQQ&,!I%K3FX&'PVV=&!B2"U=#^LY3E+\ +MLN,<-#TN#A
M ,$!JG)R(4:5VJQ#WL3Q\''^>>5R73!\I(0B7T"'3<3U"K-7-H0->2K\ZNX)
MC,<%TDWHVK-E&\9*T%\_F78QC)@392*<-D !P-!6;;T$SKD)=Z^EA0JRM#<[
M.KL1+2,&+@+'BF2%@&A0YU,P"F^U1/CX1K<J),"Q$[N@FX5'N6M(MLZY3GDI
M0\3F40U$Z3)PY:D.YS +Z%'A(@TI+N&,Q'G>M=R# R<D*.<P#I"V[0T!)OS5
M\LZW6BXRP*\?D/BYG6(_HB +4BWQ*O*J>X$TP?VU2L.J9\AI#>DP_XEI/728
MHS1Q-L-/RR'5"%9>@$U_)7!<.Y M[[)+P>PD@F0Y6ZGBUP#3F23<DOAWYX\&
MJ/ZCF(^']$/#_K1E+I8%L'*!]I9P=_*2",ZFY@+8P"!IK@XJEEDB7I!R)05,
MU";GH>QAJ+Z!V *5,.23_(>>-H K\D_N>0I.DF=7FY"G!G-3]@+UZ8: &@*1
M .10Y2TS? V@]U<M_$/[0#0;0RU"($I4LS>]?Q\6U""J":D]\ ,'&1RSR@1^
M4%A[SJL!<F4J;W'E\T#*-.=/XA_"SZ@"-X KVJ0M4-X"(-5D"]1=%(NO2+Z?
M.!"_J3E5\KN%M6%]_B2X+#X0T#)^JB5PRWB)LYQ_DBMUX^I"O;WV  D[@$6L
M2M')<*$JO>H9%$*MEHV25^C!96$L*E&RFXM/KA7Y]B< OSP[7LS!S\1!JODI
M][B_\E%HQQ::N!8H'L.BKFL1TEN8.Y<2AN_'.4A;O14PU(\/H.'IPP5T=S4%
M+KO/,B,*?H*[++J#;\#[VR#IHJL ,BDI>Y$0\@^;YEW+"[[ROL'H,TUPY>BE
M5"%*:RE!4CR6WU3OJ!YN.,U;'3A%O:YLTM*Y.HH+_T(%)=R[@UB2C?P1L!H9
M,(7AI@QY19AO S2Z2^!\_NJ1L0G<I,<*2\M)3PPCFN;H7V[DK-_Z\#F)/0\N
MF $=(/^,B!TY7[&R1*']TV[;2):ULI-%HQ]8+*3L%B2\'E[MRVR<LSRL.Q.Z
MF)G9R,OR[*^O583V@13YU6;404TF:NJ02?F3Z"CO\?&C._?L\J1/)6K.]VZJ
M":S5-VHP7,9+A.^7=_'V#&J;&;Z:C9^##N<=R)_UJBO&8U5I& <@1HNAV"FS
MKCRP*K#I:(C9E\O<!U-,EP_F,2S9+Q+&H+^ ;UW6D'XM#S1#=5J0TW03]*(8
M$66>]KO5>'#ZL-#SX4NKZ[^'.]YKL#ZX]K!+3IS_/7'J=],8DZ"]U%.P>"N$
MKO1J-0/ <W 9ZW2ABE$X$]J9D15%>"V/:H?29].$HWF6 QWGO-6Y@JML[2-2
M?FA@O(IKN9DAH<G72N(B\_70UH+E_-N1$^W= OKUZ1N_W"2VFY%SR<<D5GDQ
M-K][V^7:E^P*AC3#O92C-LQDJ"QM^&E(<R*2D702<N6_II0TF4B.9[G>Y,O7
MU^9?\EZ0DMX3QYPT9^L/W!.O+\<-X+5O2MN=28 F?)6!9WEK[_X#WS7[E3 .
MBCUD8>_4F.I[:4545[_O-[O+'X#DM/<"DZYV\?-9S^K$]!/55FBP'#" 7_>@
MUM DYS<[>Q(6Y^9(H-=S./LS[S2N.+B#[UV9@F!CMGU'.8YLPK@XD!E>%?6N
M.R3&I17367JB*(Y8V)(%/$>WFSZ1* \MW.H9'R)]49?LZS]HFM88>>QVLF(7
M;="LB5^GT\VX"&7I%2&O+5O\^FD2SO>2#:D2JI/$KZAB=/$UUM!C8F+5H(7+
M&K]BO=?,]HAYSBOX,7/L.3D#>/L5\B;\9PLHD@O2!!,*HXS)MPC<?U:T7R@.
MW\6*>RS<7YDZK-9/M=Z=].ONT)V*I5MBBM/=.IQHC=GY _SG7'1V6IPX:QLJ
M:%WC6D@LQJ]8SV*)UGPAM'/9+=H2;)V0?9@S&?"*>YGNX8;,WWF6DN6-#;0.
M?I7G_VJS^#<[V8.^[.-$M;-W#7<&IMTU\,!7O:M@G1L!!-UFR8X!\]6K+XZ)
M<6[(L=R^@]:1,.>G,2R>SAC#Y#ZEB_SA\)N%13%E=\D3IOJX[,3R7:;THMZ'
MEP/J.9>_'C]GGG,:CHHW7)-;H/?BS:Y1&E*Y#C]?)_309D32K8.K=6?617JX
M'K#ZK6%=C(E!Q!I3R3-R9>.!C,0HU7,\(3-37J/>[!=>N^28T2GYGMR>!@6T
MU IP7\,1"CS(%J"PHTF.B*.<:H;T]E#Q4<DTZ1;?FZN2T(OJFS2BGRQ.K(7<
M'(;0\H]%7]Q?HN_ZWT0?X?"GZ*,_%.<0]L&EB&P(.//5A2=F^G<^'E0N?]ME
M\SR+.)EAI4,H@5(JE[K]O@V<2P*XDYU-#$=TLSI4XN E:L<8%X?OYW\ID'TB
M[_R)') %_5HT)/6HYR#I3L\-AK+YV:U\T5ZDMP8R[%CAWLS7D!A&RI @;P_
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M]A)-[8!%Y8NO_6Q:Z#UCPIPC_/-WTR;/[A^U9AYO\E:=BT0-/-U"0_J9^\U
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MM0PPM(I<+:5>"0_/Y<^N&."]LK*1$D^FD_&3[=W$D(#3J7!L.Z)JYYUB#/=
MT5;SM8$QX_,D.Y184/H+U#<%47WEV[Q-V_*R>)A#G./H<Z#3H3(X>L-E'=43
M(*!O5E_1D'91U+4HFT8H[;"-Z&M,Q_'#@G):^H<=,(Q=(@CCW#5(,J 1_9-H
M[XN6C9[,,(9TM2<TR,&_OOI9XLW?#DG7(2H58@@I(Y7LFT:^VOL MAVAJD2R
M<L$V,4S83-:0TLSHEJ&P=.M>W'[(K)GZLI.)M,TZ G+1;NW]%SR]_LZVE7V#
M.)&%<CN8-LTV-+&"^(X-. ??\BW'V-1#_'$O$ZZL WC<:-I\AD>1AB3=TIX?
M@[T Q*B6&M>F*SC(E6[TY:BT#\?[X8.>%ZSU_TF!N?'_+S#_?[K 7-J)>H.T
M3^=B\0EZ^-.D)[D4]0U&=.O'E+IVFLD'.QZ\@D=C&W\WAR(XF_%LJ*T;<R"&
M*2I[76W#W"=M+^F )P8E]WA?@',K:H;Y_[B'X9CP'REX'XC@V0_@<&+C:PWI
M 9\A79FM,'NE3VQ"P)S1<K4"DS^6?Q3_!6GCH<%$<4 %/FI5J;8O_IKK>3BW
M2#(2KK.5W71H_Z/.3'=DM&[L3)48?+:CY?.['DXDJ6]2*@EW-T/4/(_RWVYO
M&)/3KUKV&&@D<8LDP>,S]61!/Z +<^/$H<1#%[C+CCZ:+AP/SP09?^/P,K+(
M;)WN)VTMN=/S.N5 N$8W% CE"P"IZMKN"*Y+NBA5:D8F^J'HYMJ/^EK2V-GD
M$(K4,1 PT;U>3-P@MN, ,C@>8/L*,5QL<T3-A,MJ6>GOU)*_[./.ESJE4-W/
M<*(OPT7T)!Z[")'Z$'K_YWL;2C_:VP F(+KPW^QM,  @&,!)7FDC$;&\ 7MR
M,@3*EA?H_NE.A@#X$5=ISCG#'>CFJE8(PFC\W^$<P& +5.G(3,S$FGN+]G<J
MS2OVJN=#;8]2D3X?2+6I=B6UT.'=>H"VL:PDJI-+"9,/UIL1]A7-@WCP87AX
MGR!,\)F>ET.]>"?1R(A9LZ :Y1HI1WS2S_*VM0Q$2_)!1&[V"MA+>ZL<J1DW
M!;<!'GHTN8>C]TE#BX]%=:!V7WE!"U F]=K>)&@$QO+_?2?46ECS!D^%VUH#
M#P!K&O/7\'_XX# U'5*D)-RNIA R,R=_@'% O1BO:1$JW % 3*3%L4!^C%Q+
MY-\ KAWIS_G'MYD.^&,N#XNN=,"?&MQ.I+]63QM&(P%PQ X2973C#X]WM3,&
MOVIGE%IM!<QZDW7W];3IPFF%#J(UGQ23/5&@G>=Z2!R(_/M"W,"KV*OZ&?R+
M#0;QUBPH1'?@0 <=DKAC%T)/PGW[M55]>^VY/J+;O/FHB58ZK6M'QC*H4JLM
M@!J;<$JTNU'JJ*_4A'UB 2P?K6V9XV^>:0K4U"<UY[[?0XGU-= CQ%"VV5)\
MM<L6**H[Q_Y\7/A(HA217J8T?$D\TBY\5?L+&F/%7.U.K?F5^!VH[TN0+W'+
MU*#7']R4U>"(>A/Q+%\/3[6>:GDR<*_!C;GA1NUY0T:1?9E'E7<VSJ%>GKJ\
ML? &F\5N@+Z!]_/#X/N,_I&B"OTN1)=O00GQMYK>><;WTEBZ5&"S._/4B%#[
MK ,_<3UCEH>V,>( %?!''"DWV'O8;QAW3CU@KT&S"E<)2B@GV2-1'<G9$F>_
MJ$ [C[0>RE[)Z#4I1>G.N^..3"I8\!MOX(!2'Q=>^/*JAO2KX<Y (^""18-Z
M.UG,EKABLY/YT ,Q?O[V,>:TWI@>1KVS1>' *:G0YY[WT'C3H#JG XQ!;WP>
M/P)8&AF954P!^5WD5YQ*%5$><R=:Y$<DD,7LD.;+=-..ZD!(M[5BAB)GY[T*
MPZ6!/.FB#L: H/X<Z=USY?_5@632L'C*VQL!P_CL\[E,XAM@SWEG4<"F]EU&
MB).R/CB3@8&H+N:\_XS/QY\9_I?,=_*ED(6 <=L^V/I%Y?JY+=^-7@]>(2T$
M_^AK_S0.]Y"8!VXC$U&GTF+5CO.K8F];GD\/0F^X/*V].2K:KAKE):3.<PH^
M62MZ>N;&-)]US4C+!0SXQP^90!'_7$Y,YHJ?T;\$,,W0WCS8-VV(Z[R9X@SF
MK=;J$O$+F,>?$[/4M&D:$G1 D=[!:7!ON<$/)29WKX)#CSGM=$4J7O==<7-\
MDWHV8WT@GP)D_OA#&M)O<T%*^?GHVU:3 //1B^N?ZO>83$A:=YI(@]2=$5A<
MI-78Q^X W=,V\-.=[&(7ZG+N Q ;;]I^@<D+L YB'J]XQD%I_@K\7[X<[(LX
M;0'^5OQ3^]4M-K_.2E@Y*WZ-A6-T29U3 ^7I^J %\O%1SBO$T&O^;/SZ=_8V
M6[;AKY=H;_W0RC9FV=B$K+#1H\?2'!+*O7QM#AN>2>G<&7'DLO66W3*I5=FJ
M';^][=Y@-J[V> FG414\E&E*[3V7BCV1F6 ZVR1QQ(:,]S0[-HW7:H9%>KVG
MV::,;2(+#2E+ GCV[G_DV9$J+<^.>\NSX_[@V<Z  &__=SN)"47C!^WE\#CX
M77?Y@/3?%[.#?^)S7YPE7OY1S2:FKZKXL'CM*!XDOJ/_1;Z=U5N,J3C]@^;R
MU$JX[;<>< UON\MG/L[NU]/>!Q!C=(/\M:+'RI*P-B7R=F"A%P(G +)=M@V0
M[7IJO<$GY>R4/W87PS(I''N4I2&Y(6LELRS/ (>B>Q ;AZ3"7U1W:VL"[0'I
M=-$C\J!4;?5^,SA:,PE%*J%;*2V^9GUC2JN@>&-=0F+7J9R19Y\$E^*(NO=M
M#\NBRQK2+'U8H24+_*@G2-M>&\QN:'4*/&Y#13%%:6 &]7.)T[H5? <7/: H
ME 9I1/3;G<6#Q_FT*#Z>%ZXA35I<#K"5LNX0ZUVKS2B4*0?A']/9:J8>TP@^
M7L=_J%T),3Q\"63ZD$!+];I X<S< ^_W':L[@Q$IE8HQI39M38",E*='\MWP
M8*0- <'T8WD%/M&KY)..<]P+&#4@- 5:^!1IVL?J[\2"[ DEX3O3]J]>\SV^
M4+AA!%\RK9]R#_C:Z?42F"AN)WQ%LD]>Z''5D!J3_:%GPTO^ZP[SI#\ZS">]
M(][?$28@>N;_&_)=<68/NT0X2D DO-MMG'D$VZDA:;F;#S72_UN^.WZ7K2@$
M4+< .DL[0]-V=@S9PWV;[Q#V5!VBW:'-20^O2GHBN6CR\;YBO\>(U/S]ON+.
M%OA,U-M]Q<1_VE<,%\;WO=V)>LF-,KA,ML94OAJ\'R>&<389'\&[B *V:N13
MQ)5/TN;55!?+/J"2C!?^N?/84KOSN#,<ZIO_$Z+4Y:4D81&M?VOL\/IO&CNL
M_WUC!XOSS[R;HEP.E)J&)!^73OCI-O<6!7C5O^\O/T+Y=_WE*K\_F#B"7X]=
M.;<6?E3\ME-Y/>"+,Z&PS[67"Z&#L-*\XGVEF_\E5$CO_)-WFXG,U@,>]W$9
MF__UQTWGNV#L-"\P<AZ<0VUC67Q4Q.:F!;=88K'0VX9S$(PVJ2=89$48'#YC
M)U64^!!_  /]! 2@R[=_M';PZB P'\I5C"D8(OWC;EP)V<OXBOJ$V[G,__N5
M[2*,IM4 (N;[RG;]1Y5M_'.5;02+;/JCL@V@^/8*&!^POAJK(1D8GZJTP>Y=
MR\VUD<PY(8/"/F';68& O)ZU1Y\@Q5E_M)EO>-=F3JD97B)\G/AV;S%(96>^
MR/BKNCT,X"\OI9< XA6D!U<N49^QP4%< X23J=E?>XQ]'W:4BM9\IK?\,Y5O
M&A"= "VR:&T<NZ6$&9Z-?/L1^]85J>%ZOB?^L/4 FI0(?]3N 214.[2#E?JY
MGO.*<LE?I>X]*RB BC=K6\ZM/VXY-^X'0&@\JY6L'FE+]W-VXPX>_:/C_.)_
M[#B']D+*E<)Q0<;@'&0Z0Q2F?8Y6#=3;P\#'\JZ]JW7?A =^^DS+.?\50GA:
MXA&6VF8/D&]RSVJ[/?:^[_;PQ#8W)TL2/BEM9P2"S'?6'$T&&<J927 L1!D]
M;I2!8;A E7!^+V;"!M(IDY5%;+9\#,N7:IWIIG9/L\0/N\ $L-7GIH62[8X'
MH!$,,?O64N$I?I+2P'B]#GJ0/S>NB&/9S_UOBMW\OC,?TW%=:5*4AM2<P;B'
M%%*G>Q(S!?GF+*J=P%R_[)A:;9L[N+1.9+R?U> 9U'[ E%[P,HBV/A!0!7(G
M_AO<E8."7 [\6Y("M6 :TCTRKJ=M[6Z#"8OO*(QM#!!UA4H-:3]%M8@8"XP/
M.(4G!X6A/NUZF;  40(4B]RJ8_BY+I,.!39)1QXB9O0#D3<"QF\'>HC515.L
MYXGSDZ^ANQ;ZZMLW[7BNF[BN^;"C.NT,(IZ.S_KD430_2?@ Z?8S_@4TZE;@
M__IP_9F#UK,ECG7I2157>J87AY1<]7)/"OIU;.;&6ZGMMI."M \4=&H<LF _
M$;2'8I.I\CHT1T,:Z5[,G!BXN"I_>A?[7RA%--.T,%Z>E'JP+-FS:5[-HAL9
M43NO.KG<7?_%&Y/TK&<-;(;\.VMPC;]Z ^XA7RT)+:),6*NV:$"MR>/7)EV/
M1^36L4?<S5[GUI:TFBQJ%W)BO?J>*@WE=!0HL#%L(7<2,9K54$B0,UC#+:W4
MKWL(ROTI&I+GRP,Y ?NS<O; _(CUCF\04V\W8F PM>OOS2H<;2L*]_W#/$#
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M5U>G XKVY%:981OR=BL\<=HI+&HI))[4&[+[4MI 5P*I_,[Q.PT%J_I]317
M:'XUAM_"4LL0FY@5USHZ.I0*>3AOX@W:\$GQUCX-R-X1X%3L$&]SWWB[[6BY
M= Q?)C%IQR[OOA%6KJV/1Y?<.ESOS<R)J>L*\B0-S]T?<Z&)VYB##AO%SG?S
M(9LV9 0%EBV=#-"C/73/3":X>AOVB.Z%Y^BU,G5) P)B!XNW^1'IVP8]DI)
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M4,_D\#+Z&1YV5R#M>0K_I/:>A&[+7+)]1#ZM&! >CI4O.,5RX,I,UR7RF.+
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MVD"BG0QQZKG.RJ0D3J"X(5B Q@K6)K97/B1I)KI/.N>]B+6LXF7'?L$*&*Y
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M(=)P(1^^/W#T#SDG7\/H]X.>MIE:JP'^%/XZN3>9:_POP#QJ0K_R-.<,6LD
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M-EU3R!F.P*OZ.:OX\!BK$ZDK.,TIHHBT"Y;+[<.S(,J>WH'IDD+.QQP@@:)
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M=9DIRH_8CBQ.MBY3W]#@.8I6>'/2GS5YOK]J99+7_.S,LVS?#?0K)+@ZG:-
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MBP3GX>@/F& 7']0Q.Z%WHEB=0O3$I-QPBVT-GC(T70>'%@$<[H[#0.A@2E!
MS)N9A\:>#$"8UU3!Y@5,<./HKO(_Z<D57_MCIR*RJ'U8<@W^HIKDBL@H%! .
M=LY001?$3*.*,>TK@+:.?DKE*3J<G;?_KH6^W_E7[T_62BP<ZFF278&8P1R
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MFX\MDB$6^K';]^5WV/!1O.4=:A/19:_:7HZT^:5>SZP<B[$]%NG#;+5MSIU
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MS"+25N*I2K"B_+FMQGXGJU/A&Z:_KT@8S9O<F13'.])<W.;W*H>*"*@44J*
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M)WP^K/['P^J.8I14A#CS4\Q@+;\'TH17YH(M5VQ!QJ<-XC]M(H_9!P4,-?+
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MJ5#O21M--T%0#^1!PZ(K8< ;I4$MZ5JJ[R2=?QKH5CDC*:I<YBY5:IW%ZF[
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M;N=M$.N#^_DHH9^$/*L(;\ 4:55C62OK./MI:H-8&6SE@5[AJ#]0-LFR+G'
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M2_F=:9QN',U5L:*B[:!N6\V0OSO3)NU<B;B)^GZ>>H9H*@E'[B.,"U/ K8.
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M\ZP<CL/S)_-K!N>XXX/DE:37Y%4TX&$?<2T_*#'&=#\NS]/(^8!@D]!0&,O
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MCPQN)FKJT!7<4FC!:,ZO6XT(;\8%&;XXSGUVK,+TK:;L%^MR_],>*3)<)(/
M(3,EPT.,3M,8A!<I3JO27$(_?L1#4%CS\'8%LB#8,T 4#LPS]@9IV/EEIYFU
M\.:<S QXO&EZWU1^_[YJSD_?MC,"KOS;U8=&:6VA@R"]9*67Q_Y/%G-/J5Z*
ML<(QJ"D;B@)JH$2H6]Y"Y=X* M(W?QA?LA[U5?VR2DO#'MO!CKC\=VFW+M!#
M* ?&'PJB/@RR1_+@,]@0HTU6<2VO-%5]5^TI+)4/Y0I''^XM$.XJWZ)6?IX+
MRR# B-77B9^R:]V05X&H^Z]ABR/$G7RT2&+-RKS]S.@M%:^G5BW668X)6668
MCRA/;I0:NO?]XFH"Q&=U*68)VYV MST)5 SC(;U=BH,%"63?VA.EM$(<I]6+
MT8I/LG[GO@T>'QPS"':,=ORF8:X+CFY0I^I1R*8'%M3BM$KX(3S2&/P9FHXZ
MY0_AI,I$X7@$8*ZV":%2:A"]?8=9-7QC8]/5QQU6=\XFMI_R2123?8?B1WTI
M.=D-Z8U0C*9&K6$D+"IS1&Q>PAXN%BP%?UI>%PEJ[QVZ_T+\ $_G7'C)H ZP
MD2'/81Z:C!.G'C!F\BIJ9$49**<XHT8A0D;25.89HQ, !#O9G[A&6DT+1HW>
M*A%2:/\BEZR8/"?B?:_1AIZY,?+AN>6=IS4-?:+,^YQ:0]0(X BT5O(U UN[
MD4J7011>(2;$-<TGZQ===R@<;7U<GNF=>D&ZL"C'HKU^!'.,X8,3QA_.@UHI
MX>GDJT(B 5.2'A[GE-0,8=LRDB*BGU2T$UNC@Q=Y[W*W-$WU+3Z9ZDR<-K[C
M:Y8V]>Y373</11WIQO!8E3%0&T8"&52Q26?O>-<"Q 4%E7YU!WQ7CD#;>38U
M9L*OY4G+[+?R%7[+G#^3*MIR?E2>EXG&/23T^N":8_N(4=.K<SPHPRU2)9T#
MRL _&J 05\E[P!1Q%UN?#,&*Q*[5%;VV*?WI&MX/RQ#"9,#5MH/J?>(/<5K>
M7KPN'^74\]KJ5RB#CZ"+#+EG2K%&6M)>U87"F0",-6!=J;/]6F1H;%GN.K%)
MK_Q3]AOV\#$6\UOIC7>&F7[O#R6ME\B/OJMBW4H:>/%(W #SD+I%'"-; A.D
M%#*&L2SC](]H 76DV=J2+2^B<<TFM[JJ\6=&4FA35X'AE6_'GQYO+PYMR[UX
M@R7)Y\;"TH.5W2,02SOCN#CZYQ(P.GAKEY5Z$\A?J^=!Q.AWN1B8$;T'4/QY
MQG.:G+KT**-=TTX.=-/4Y^#L3P]N:OG9;8Z> M' 0#_%BJI#*S8O1IU"&A.=
M'J.;4V.&Z?Q2#Y>L*?"\UO&]SGT;2GC%PPV)>4,SG;4-@B%QDAQ?XI"!98@8
M6V9@TT;J=N1?(KD+]E;K:1XB\>.I\+W^@P=!RVE+$F*]]2<8_DVBQHY )^EZ
MZ%Z(D2HB>TB:^Y]*3VLW </3:?T6$7A(G_(MO-Q!G\BUU3L!N;_?+W G/,TV
MD(H#Q-X@^LD6M!+,K2 >,CRO9Y43Z4.Y_G/:!;'DV4Z<$3D"+6DL+AJ3]W5
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M_+8G:\BO-&U</W)&/<U_E;5BG5B[D^R-L-(8RP&!FXUT <:DQ&,$D."U"?3
MHF<VKCZ1.PR<H/DAG_JA**#6_DX;;SU)=&JJ4(J98_NR,0^.ND6:)&L PR1]
MK.HDE7^RMZ.[=FWY^F4@!3OQZ,:>@59P<,V?PB@>F]R^Y>#33@5G\$Y>*BV[
MHL_Q]TXQ.;]']]Y"![@%63@ Y!4U8BQ29AH%:>U=!P(--&,LION5*/XSK8S*
M(7!OX3Z]?ERB99LV"T)-,U9SNIHD@&NE"J')%43'O"%;L OU"G$) <'Z$2Z&
M$3\M]3<BKLSNA*FJ>&JH-N5Y2\A:.@IJ5!:/[TSH<#13'KQ'+MFZ?V:NJI]<
M!902"":D?A,&+"J0/( <L1YW(F/-!HRS>!*V1;N$MR/.B'_I-ZSA'\E^=<&<
M?OO)@=,$WTYO:*:).19]&PZ<J20$D:;I[-5$6QPXMIN5P==-(BD&U\*6H,*!
MK(./PI]D#6XW*[8TH<\ZLA$TK_SH+.>H9=>UVWS)_&>OW0? KU4";U=8H"*
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M;8H+.W,2S[7X!%$<>6IU;WOMC7N\RO@G5/(_5R1]L 5-M)M<6!T"L_[EX?4
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M$R/OD#6Q;/WFY,6N)#+=15UN7'&S.6%@Q![?HI#B^I?GL*:!_I=$QW]1&!%
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MO(#:6=0>.6=V*>GALZ&D%F>!H@CQQB\_28E@^V1YCFT^BNF_?^>B;9Y<?(1
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M]ROQ))Q-4Y$W94W@DZOY;F"Q!'[KP]Q"=Q38X\W 0R):E[@]_0&#Q$@G6OI
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M,DW\,%;;EPY=; $WC6KGY9&(<;MA;:RG:59TS8]TO8R8F)5WV0M>4;5MJ,F
M6,I;+$_@V& E!2_*L*\/->M#S,:/$'@24;YG/0^0VGS3 5$3JC@[ZR9,]??Z
M%(LXF<(TM0\7E@S*,FYF#=WX>5;IV:7+FGH.P.;A(^\[:[NJ+_UU3LUC'6RT
M"YAS"X4L=DVO86P7.EV]<3(/I1RQ/JFB3A)*,Y+#V%/X#2=DT[;#$B1ZU ;:
MU16H,AT8QC4%L2$%YBSO\TPWL4/#-+[*<G"WI"VR6M5KGBD65^QGD.^H^.X,
M.OS-K/B[U-+I56V D$FGNFMOG5>F.JJG2 $[+[9KXCG'V<^KN2+%P="_;OOF
MOS=?R*:.H4$_@$/O_#D:R-.S)2RW=./T\[(>[<PG)9/G>1\>?WZE[C-ZEUOM
M]"6-1,.J:CY_N#'] -) Y*> <-@Q*(?/!=/K;,9X_+)[IEV(B/.35NGE1EU!
M!IS[SE)BTU"0X?C54[R7#YC^+;AB.R<Z!MH=?U@P!"P4BC43Q.;%E)4Y&?::
M.FB@6=N]94BW&1N0[<OEN:^>F?YD=*.V>&W<,Z$6EG4Q3ASNE<:[9(:,MD[3
M>3-_C;TPR5AU3.D_4=$K<B<$/) 9#^HAL21N4[3\!.]:;\Q<T%]@*T%(#R3[
MO3(W9)F=8B=9#%)?:DO^K9$:H8- :S22L]X[C&E*24#+N\>1?_*WG9I8XY22
M [?W'VF;C#<<EB?O!ZM1>3H&ZHE37\+&=-LEH%)=ENJA[:VU-3$5$C]*B[UM
M+U0[>^)C]8N[A4V'&LDR9Z],Z/F#7K[N]TI ,9R)N;;QHADH=V.AO/H'<6""
MH(J^)-W^"A^2[,8!XI_HZ:G4=P0K8$*0R:E8/%T;IRWBH((-"?9?DVY3K6BI
MZ/GQ2/*<=;],1Q*K3[NG[5WPVR&AE04<,S2$\ S^<'X3QZZ\VS"_8 ?W&/$L
M\$I1[OG@V"\^O:3RMJ DDSE%U=AY_F/WZWSGBZ"#0BIW<9[.RCD\G,)A3P.1
MN)H*-N4V,; @N3X_SF<N3'G<T?H8X]=?.]B_[DBMF+W*XP=:"P$:J.,@)H7B
M4PW-N4W\/>& ,V".JNAV>;V^WSC^2'G"^=R5B86>JS9\^N@T<]57K6%(8O*'
M[)KX+/:^ ,[G_5=BF[C'[0884NM:U+@<H*NL##_"E08B9L/N-??\Y^]>_8OH
M\M%CFTJ*\6H 6,CT(?R*/!#DV&*=XY%]HD"^?Z?H*[CIO']-?!N:8$O/>CT]
MO8OG-QVO$A=[<RKL'/O]BCR>+4@/=/D)]HIN^XK6?[1WO:WMG-O!)>U;)J0+
M1*@>G6J7H('0<G 21F?YX0+X3\9?S84]H($(J!4(,B62I=>,"^I^!S4Q?Q<Y
MYE/KXW1KAJ):H?5><4&K4K_BAFB"7QN*>_R*W2W3QI\^#3W?=J^.M[-1;!.N
M?W;0PZ\FUZ!N'AK/CYQ)+>^,''PLXGDJP:+,]MK$9<Y4G^SK8@,5XXP;#TD<
M!&J4TSDX[JT.L,U&XO;GHX$BK;IQD7]7]<?1*=*)5UGKY'(.OC;>__#[1)[R
MI_HQ5*E!*W4P#8O1$TP5*O<-[%<$=2\N(?.Y3KP8"6]G)@6%ARG8 #D]V LD
ML[CJ+7^3(Q5>IUM3)5"FH1;_U$ZNZC35LZ'QOK\RA?UQ7@P=/U\^ )=6U5A0
M!_@R#(U>JT?SGF=/S<[ALKK.FBV175]?WQ$>S?L@,/G$[\I[_\<M_/Y_(@RT
MN?\&4$L#!!0    ( ,F(B%0(':K0^7L  -6'   4    ;F)X+3(P,C$Q,C,Q
M7V<Q-BYJ<&><NP=44]'6+KH1D$ZD2PW2%0&5IE("(DW$"$HO47H1$ $)&HB"
M]":@H"!$!$1 1(2 % D0.M)[D))$07IB"1%"\N*Y][WWG_/7>U<RQ\@8*SMK
MS36_.>?W;3:,6<8R<.22F:49P,+" K0S7P ##\B9POU] ,#:&C@!   G<TX0
M8&5^8F&^_C$8\X )<(B%Y>_[?P]6=M:_XS ;&RL[QV$.CK_&R<7#Q<G)S<G!
MP<W'S<W#RQP<7/P@/E[^OY___LC?R_]>Q7SS<G)P\OX?#T8[(,#)_)5;K"QR
MP"$!%E8!%D87 &;NE9WE'P/XWX/E$"L;^V'FEKAYF%] 'V%NGY7U$'.S[&QL
MS-EHYCS )L N>.RT\6$AFYL<<J'"9QYF%7/*7ZCM$+$=(REH>MR)Y>(6%3LJ
M+J&HI*QR_(26MH[NV7/G32Z:FIE;6%ZZ=MW.WL'1R=G3R]O'U\\_("P\XFXD
M/.I>W*/XA,2DY)3LG"=/<_.>/<]_55):]KK\347EA[IZ=$/CQZ;F3FQ7=T]O
M7__ ^,3DU/3,[!P.3R!^_;:R^GUMG?SCYZ_?E%WJG[V_?K$ K"S_[_@/_1)@
M^G6(&0,VCK]^L1R*_/L% 3;V8Z</"QK;<-P,%9([\Y!3^$)6<6T'E[RF+4G$
MX\X8MZB"%EZ1_->U?WCV/W,L]O_*L__/L?_?+QS R\K"#!ZK   !#FBO4E2
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MZ6_D:=3R1J''4ON>L,3=@O,NO:_-RK:W2_/QV'-?2C[+WK*54<,\@I#LEC+
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MN0@?7H I(SMN(P.6Q&.Z8*3+T"0&(&P(ACFOM:F3/C=?F/WBBC./D/(@.GQ
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MR1]@?Y65(IMCGK#T(X090-;YGW0L;H1>J%[U[IWY<CDM>09%D9E&_EJ+<(L
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M#W&)?[4W:J0^!M,OR'!<A=*H;N"#:KOFB[_U*E6?4$^3!=H4:+*DFJ0:P][
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M1_F*'-%4F<(U$ ?H"2BF@PO.KQA5[A$8ZR0_?<@T?9S89=#,G>K"+:U+KUM
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M];PX':W!@WN@+'"C&9G9K#CT)Z)==W9DG6SUXK)Z)IR)]II?ZC.?[)]G@,?
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M?'M\\ 74B8;'C'(I<CB'+SYT=_4(LF0P]>8HJG+RKDWG-R>/(U@!\S@B_ R
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MI_L8%7G]Q*7O%>E&\0;*RF?.-AZG;/5Z0+C"/2JJ*]HUX%P45_^(EF<^,8V
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MDNPQ_].]_S/4_QGJ_U=#@<YF_P=02P,$%     @ R8B(5.A_4R-TE   :9T
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M QOG"J^6%0HV=%Z^+&I#?J5N.&_&@H0-JS-CM_A@B)]X=9E\8A3%>.Q<G*?
MX9*AA;'5=BOVW$EYJ6-M#$M7BC&")!2Q)(\RY#,Q3N+!YS?.V4,-4]00%E3
MU-:V/JSNF-JP_RNZ\Y>TKNJ$C$\.C?KA&*R)T?/P:,HYO'B4NKC?+)2Y.W_R
MSK@[;_67:FMK7K=MQ53IN])<7,[7>:],9DG03HJHS0MCWTI,-'B;AI(M]O9_
M< ;-=(:H8["R&WZSD#!AR9I^OQ\/L--;9@8+0P*L\JNKDX:&T.&J7_UZ_;;A
MG=K)J7&(T\/9T9 J\><4E@>/;GM,Y TXV-WYDGNO;-"KBO=+)6OEK^\R\Z@+
M0BTA";@"C[N9^4U(\J>!K3FV*KR*,0X=39+S+T1:5>SDX_((\4H$M,;W+U3
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ML:R/UZR(3SV%8C?B/G[Q7@GL3^!;Y05^")N_9YK\3&1JH_5[,LU-+K[;1_+
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M.ZJNJ5?>&4,$N28R&\S&N\\H;&3-#24S!)8:3FI![I^9D)J'$L]"2&D7JZB
M,Z1CYC"P#GV?_(ERGO0(Q[WT',- X4=88\4:![[[Z8\@+<F1(V)& =H,2>)I
M-;S=\U[]HTIS8(: +X[D!!T!]F9%=]H*5I,01QT6#C9M*IE"E5VW:^7UT,\:
MK<II[SJQ_),?1&Q848%S=-"]?RQW;5.!B8+X"#"R1OW0/Y&W0#IO)DAA.'B/
MIJ7@V2V7$P:B&(RD2%6:"QZ[I*+5WN>P[>N5V8?8JNVW_WI.-MZ]0P421L1)
MD$_JZCNS^G?^,'_+^W]4/65-TTXRMG5PI5SX@O-G2#(&9]E&!?A#2]B-C<W(
MO#!- KH4.IL#J]A_V1!P9+8Z\>4M'"Z6,?+E=_$@_96;+?/;Z).0\HA8QC_T
M $IBLJ'(8(MW9-]GW'>W*N$:6GP?N.F^=V%@_SU/0&OU=ZD5&%&,@93YVF%"
M:68GKN%K\#=A1<OL<K![LQ:C?1"<27Q(DR@QX,CP?,$GV\D.ESK[=MO$1\L^
M7%V0,+]'I@&I([V7AE9N12<EEE_/_C@2T8!=#PZ3<MPIN*D="=RL(K\V>_-_
M8Q'.0G63M.)>DC'PE.9T"M:LL0K#]GJX,A:SF(':_XKF)'^A AYJO>-JK77*
M>:ZY+27*)4\('6(UEXH1]N-?+3-&?T)P![%PR@L-!2IP'$X%.M?F?;RDNS]?
MCHCHP*!*0Y>J+;?:W$'%F>(.TIX!P<MEE!+45CJ1"]7BLM="!>2%0< /5:$"
M\[Z_0=-4J"XD7JA^ICA5W PAIF&N@QZANN/8E:$^E40%NO6_UV<C-[J,$!;-
MUNFD1\0=;US2G$MRT>T5XZ*U:;'&BO[=H,L]BWD=&_TTM!A<9^C3"L!T;))6
MR:RY&L93.2.X@D,DW23Z%;G[VZ8<LFH*1JOUB)2]X=NO?ZFGQ7"6C2VH:)=)
M/B:W@#6K/:MD@533*_PZ0!^ZG(Z?80B>_+.2-E<?:]N6#HFOVM"<GNF]L]Z@
MY"=J+?Z#@R\WJ-[IE5RWE;J$*([5KIQ<WG!Z^AB>K1%YV)1 !1A+U@.?Y.7#
M5K9U"W5\)'3HI. ]:D9B,?D_6JJ]^^9O:-R>0W7&BV<WPJ!$"&$@VHKX#"\
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M)>.5:NGISG62^>B,Z+$N)H61D,N@:@K^>9(H3O#$S80]7/>5\6G/8NUW+!M
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MQK<?9N[B==C"',4M)K_N7+0_+J*=6<ORB$%Q<;1!818^$8'M(HE.Q*4>3PK
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MPRQF(K6#[Y[3EZ=J5(!--]?^]\#V3$-H3YR5] ?'P&==_$4P(77^>3A#<)^
M67LO \*EIXN5+50\ EWY$C[0N4JG<+"F49G(FB:^Z'?YU[&=[=EN'$,S11&O
MWP7E(!GA"R)  DS_H]"=ITXH+AZ.3*T^I<N5>-VU-AG0.;_"]*GT29AZ1A]#
MK=[CYYDF,9ZZAY8?:6+#[E&$BGJ:1()'FDX0K;%K&Q#KAF'U#;$SJ3=K*P>\
MO-9W;V9@S]=G*;K-3HTNBS#OG)956KV>]H"(P8Y&KU-XQH('IT^.BM3".9!Z
MM4\QK'>BW44]'TN5G)OX)C%WE_%^]<EOQ0K;KN*TZ<"A5 <5J%P.)7'.1S:H
M!04AJF,\+0+N#2YG_?PZ)6=[3Z/U;)RLTC/FQG#$7FEVV[3&0(,E-M;'L*S&
M([J7M9M+9?8:]K)H@GJ'UH*GRYCVW0\;OVH[5P^.L,OK.[S/F_C%(^%*]@&;
M2Y_[-O9DV2>E3^FB'RBK\?Q@?O,](52Y;Y'O6-$D?ZFM+AX>HWF<9!/:"ITL
MG:A,WXS:=O>X)U@0I??^XH;#049.TLG-I'OZ5B_/W&AYQ@\<B=V^^Y=2,(7>
MM__'CN%]/X?>HQM$^/R7VJ<YT)9L3I(\;J-!ZM)P:D>ZV,B'?1:C  ?#YX@O
M -W;4-<K#F_0KU'.6V-;A%ERK.9I!P2TI>DB.=G/A&?>=LAOIG+-AJ?!:R']
M<-6X\/'9NFM,PGI,P)Q6MW@Z0.9PH0'9U YD(@-D2;3LY"?<L^(&H,H).TT%
MVH\("KWD$.0?15 5/R\;#JG&Q"N&50Q5H<<6L;?8CTIXVR/!H&EN.QSMPH\8
M1_YX?-K4/JQ:PV <IOMT7_72L A36<8776R,X,[60*IC(/O/&ITCD>!)D)%]
M]2<8@>H?%ED#-OX).I> \<0<L@5W0XE2>%X0H*SQ["1C.&\U;A!LGPK,0LS(
M%>'5L)K--(@0[P[Z4Q/3:9+< &HMDALW3@8KH_]4%EG)1T3_626KZ4/R@YX*
MX'[&T\=F51\)EC26TVD=0E[R8S@)W\CU+>Q,/C]YOGO<KU#BYM?K2;$>6>L6
M=G&-SW-@4MP,JF%7M.Z$C,-P-_*@%QN/P)9F0]NS26_U":XD+@5*Z$Q9*H51
M_8]5DLE:"-?QW:X$(_(JL?=(@<($/JR]-0;J(SIA45!:?3-;SR9*@#9ZL[\.
M$LWGD%.H;<_K(>L8MSD04*^NOVIG3*IF6.1N"7-QR,[T<9 C9T&]XH4\6#_"
M/&#ED G[J]5)'XBQ-^?'IM*_P<<%";]<J,"KY74P$3S'<*"VK5#LWETA2+-T
MUYJ,8 Z=1!]/AUM/CN(+6I>&SAK))6\VQ&TYJN#P0[.C.92>+B@(@1LCIBAN
M- ULG)?PBP$ZF5UNV 7=9O[+YK<PH5#7WLF"9ION(44RG*!]I!W[GDQ(PBK?
M.,$_:Q]OU$2+XXV2CSO3NG0[C]W5U+W>S#; C:]A(,Q(_@7<?R&($*,\6(3=
M&P -EF,$7= XXD?];3EC<AHX'2Q4X-W^NC/8=7;0#,XH^/LE]HK?CL]@?"@7
M5(L.]/>_54@S\,40)>Y!MH7),50 IX,UHYCD,PQG<U,DW&:.DU@#L!K!*\65
ML>J2-6GW J*\[KY?U+I-^J[*A*\"6\\E<=-"<*\=7"G-HQC2@P94%Y0% X='
M4OAJ^ZMB+0ER#8-P@//:!$/DF#+?I;G2KZMJH0Y@>F*A.;*''+@><5.!.:52
MU+8N$LIQ'Y&2B2C.>BW&[/%]HS#O<DN)?9/^$-BG7?ASS*XB*,-FT_>I0*RE
MT]]?3 5R\H\*/ 7^7+/NT2$ Y%)KRIW@#A31Q".;E*!/NL2PX:M_B!FKAC]2
M5RD%3;+0@029?,T6Y5DA:M:,%'M%D@JHS 9'$R&=3R GU<4*/-+M?GCGKWX6
M^U$<KJPCZB5?X 'H.[QPJ5K#0M@0$ ()%Q?J"BK;KG57>,'8M<_:)_N0>L?.
MX8".62$-H(06E 8M5[NF1C&.ZD]_:_[EE62U$QOV?*JK@^5UM@X3%'&U&9WU
M516?_V(B] G6)"Y0*'Q_2E  VV%_B3I0K@LY4OHIQ=N..:4.G9VLF1VNVH 8
MI3M/)TP[Z-,:-,K3GC28+T&F^(*>?^/?>3X5V/;TAG!AG+<F8?,7\SP"L)*8
M^_5K]9=CY(PH0GC:\IPK7;V^B)^F#"4!5SH>>EY@0S ]^+!;:5=KN562&15C
M&;RC"1+#L)W9[,/3ZB"K";T-)8+0@22*4R+8F<&9&&&G7,! H7,ST*K/4/S6
M$2<XD0I_)E*6I+9/J.XE/:5T,% 62_Q!C)!:0%755%-""L%ZO<3CE)_Q.\$,
MOV\EX:-;@\\,Y524X?4CMBYN"G)HPS_JB"9FU5BQ)O7M[I:^.3VZ+!N*N3\S
MR=DL+%XQH@@"V/VW07HMU2T2N.D& >46?GHO;8:DOGVEE>QQ%.Y&V:##7TZL
M#3KQ=?2G;CG^V >F=Y+%3*W[Q8,TKKOD-O'ZK*]*S;.O]Q(E7,D,&$=9TDD$
M&.!)$I3OH.'"47U/"?*@[1E>0@_D&W/9*]9ZJ<"#MOCQ;"P'92O<3QH<@73R
M3L1_1B=C&,Z?Q$7;/J$[DOW1 U(6^R-S5X8.K_P,>[6\LSG<@G7IDG;7F5$>
M9SVKSU62.@&Z>3LZ<<O-;5ZST.A&EA[R$OH3:BX$Y1';1H80)%= ''[A:@_^
M[8YB((&V)=12@2QHF=G<7*;/'XL>Y#J<QHM-?>RB K14( 1:9$E!-1_8VRX>
MM7D]'5V%DS@9EPG0/N_1#97;5 !3 I-6^:N9&O$WJ/LY5.#Q"-A@-_?O:3JB
MY5$ 4A&W(* 7\3&X@\##<Q1U+9TA<EA;7'3.JWEA]!<QJ/5*I^T;HR;-#$=A
MV_-YP5.TXZT"';^.WIWN![T8Q)@6'092%\812CI)3 5MZ?9?V!+C(7JD^3X!
M-_.M2?'OVZX4G9FR; HCTACL2&6$\9]$R+GC,5.6-7,$$/_,B1O-3#5\8VT^
M?KQB_J&#$(Z,B1 M2S*-6J_:*ZXP;,Q\MNBL'9\ZT.!*$5[$6U."D""P/E^A
M D3R;>+,$7WPV$RE2HSC:(-Q87"WQ:KY9%[IF@>$4RN,*U'3'!%P$+]BAR*I
M6A/R(=OD(RDJ,),-&FC;/E@MPXED:REHD7^JI'!'[:*'>]ZS'5_5>.+3U ZS
M@ST<C,)< ++;O9)9,^*%KO:M4XAYW<%2&=+I+X=A))Z!-[L';0\#N$U/O)F=
MS<JM@1!]T1LF5  Z4XXA'^#U0>@?+J&EG' \LD:XVI<-E: QSM J]WV.7QU-
M,QTL]?VA+/%?6&+BTDK5-8T[C8KMC9HVALF;J5?WZRKV5,47"X_"D'?3820N
MT<U)=' GBG@6#VJ,\X.8\C^) +8K_._\?U(DEY_@1X=MNO1?3$CJD2R%B2=P
M[:\Y^-N%M8+>V-+B/^AW+T01OZ^ *?G]*!A.^%^HNW]-A\?;I+E4$M<#?6D,
M)\;9]Y?A1)/@\".%2?(]=53&B-(#4R@+?$=2*CM@,S]-:G:&> N&,V\9Q4:L
MHT%?'BD".4]?,#^J12_RH$F<TL.BP1Z^!Z-<+#OL@"V0;CPN79XV.MB$,CVZ
MPHWGB9B#$R6>)+@YONV$E!\O.(^=]AN-V-OS.XU\I_LX^MFF0J]-G2(8PB[_
M2'P1?Q*?_:4D#ZO[9I42Z!AH!70V)_N/,3!_V^+]?\47/FO^E*87["I!WO7M
M_6<&Q/R= (NGGK9@<.:L=QR/H+$8)T](S\^M<L13.[B*9I-GV[SPV-IT1:$*
M-Z+HV3[/K-L4C!X2CL*9MPV"HRW[QVB[)%%S8.BUZ#.0AMG'':G B49K*A!G
M#1VY0 5ZJ_=S$\T*]Y\A#8<L0Q?\T"_6*8*H%MV<^BC#)A'*-W_OSKGO\D0?
MZ_&+T!<;KR\QD!/9<[@;ZLQ(7)+'CX,\:;Z:9/!7Y%1574A,W']_3V&#Z;^+
M:U\X=I.WNJ:.M\V?(UXPCK0@5Z8.?]_P%FB-JF"\;I+TZBCR<I<1*D)3S6U:
MDMC[B7BN4]O_H]OA38'*_4M?$Z^>NB,:ZRAF]@U4<)<OSX;"5"C],[2:IUN.
M#&Q7ZAB:92!8E?BJ'^<]'<T5IML*;D_:*G4.JO\X?RU)O3YD+*PL2TMI#5+.
M&X)NH#F.=E5I03.1Q"N2>A($]8;/-'CJ'M 9.,:R?U/E$4=ST6Q*[KN[?\YH
MK]TMN$%CWEC^=;7]V#=#RSAKS60Q+AK(>,B*R9$$2:M9,UF)"^AGBE(O,\T-
M$5R,WW;S8X(>[LX/-"QCMS;,<6!LF$7MVG-V3)^OZ/-C#13/^F[7(?O:4<_*
M-?%&_N6;"A)34A*BLYQ: KWX>!U4- SWHD5Q5)7TA,&B+HK/N.L>FY:.>NAB
M3"WT7%G/O4@^2WLGH]+:#J3&/.A,=DAFO.!M8G0'1S>.'<M3?;ZLB-C9'Y/^
M>KL[7M9TZ.)[>$KWUXF+7(^BSMU_5CTZB*H 0R%(9UXX]6F)[6_8&(4YP +"
M:O;H>W5@8WFIP$K.&;Y[CZ&^?%M.@E]O?&-D^, X].1]C_#NJL1GUNVN \4
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M_[F^IVA"7@F+^CG[LC]L+TXS)D-&>*:/_@$/XLV Q09I&/\ZI+8_3&V.#Y>
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M<[>'9AG7];6'&'-:'NI1Y7%1WYU+73,@7.T#)WOYC[MB9B<_/E6SF,;" L>
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M,ZN%_*Z'T X7I8:QX*Y0M<"XP![!19@=H4EO[H#90KW$NAK0\J^S6]&3V!L
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M ):GK4>+^RG8TH.1KS^DHFMM!Y!V2A;,#G<5&FD-3@N<^Q><[N^9"(Z/O+.
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MX=,-5.X[4P"FJKXIQ4MB"M9OP^[QHOZ,EYGAT/?]5@9_HF>K&=_[ ++ZO*]
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M],=<<?C*"VW%?4^09H;I!9SN(JB8UKJT>P-).B@=7WAOT<<1&Q<A 15RYN1
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M!@9&)G*AI6=A969B^=O^.\C?[G][D;],=+1T3/_I0NH"L-%1B%YX2DDA"KC
M1D')1D'J P#)NE)3_%, _RX4%RBIJ&G(*C$PD@4:+I+5IZ2\0%:6FHJ*_#2<
M_!Q Q4;-+G+M%@V'Z1-:45_.ZQ$I^71BMVNZN<PF,.**3GZOZ!FX>7CY^"4D
MI:0ORR@IJZC>N*FF<T=73]_ \.Y#<PM+JT?6-LXNKF[N'F!/_X# H&!(R(O7
MD5'1,6]BXU+3WKU/S_B0F5506%3\J:2T['-M77U#8U-S2VM/;U__P.#7H6^3
M4],SLW/S"XLH]-K/]8W-7UO;V,.CWW^.3W"G9W_MH@!04OR7\K^TBXULUP7R
M&E#1_K6+XD+P7P$V*FJ1:S3LMTQIG_ARB%Z/H..\G9)?TTTOIFB&X7+RFV#@
M%E="26#_FO:/9?]WAKWZ_V39?S7LO]FU"&"BI" O'B4;  0X)Q3$20/^S[47
MR-ZN@;PHT.-5Y;&'_K"K5[IXM2,>?TN.*?=!R]5G1U22)FDC2TW!?&.<%"VZ
MOL>P>N#+/T)ZL]^1 [D<N=MX<[A.8[2FTW)1\_0EJC&W.*"<+R]5NX[\AY\,
M.S--K-@\ZH)7SV6!7<B+]<#8Q0O;*P*S]<D7P=Y7WC*.JARJM_F+/S.[<R0F
M$2Q6+LOT\_K;Y[J IZ:ZG !3@]'Z@+')FG9&K( V#IXO7XZJ]-''LF2(UVHW
MM;KN!J?O_>W)KC?2EC+S/MJ/[M*A-*5GG'3>A?]T+2F%1 \:>/2OKU>69*;F
M!@P+$YQO#&WR 7- QK/>RA\6*N4K]U/N3XY_K05 5M^^. 2I >IT.1]0Z')1
M;Y3XE'P@G!;$C/KRAR3QA K'*4[G=CV@^FW.K?:./_7KXZS+[1G7#&MZG_K.
MW%>[NL\JFAINMK((<4KU2+5->)/RD>9=1"IGX%/6NX :7:NI/T;AEFQR]>,_
M;B]<,/BHELK"*I;$RN7TDN&R4*.\9\'.L0]88G"QDCA&+VK8/G.X)G;@6A>1
M1'Q'X1=7Z5.^M/S#D--?1[R&6CX.E4D9/JG]DW+^I%P)\(]#_V_J@VV;]YV)
M)6/!(;[,E945WDI3]U!B49RNF1\PGP'B:5T7FDD 6N@4D$5+%")EA56-(5Z"
M2-ECD#&$J<^>BT$MWH'.GT*T,\-.4[[I?I'E7M$;+[G1G<>R&/=M)BRPP.,J
MN!;IQ6__T6:F+R@K="P@I9(P>6&BGU[J)&F[PL)*XN4-6IIFDXO$)00U0:S2
M$=S:U'\0=>90^,E$HG*]$AGW]''NI,=\1<K71&F70%>1]R\OO6*YIBV<K^L'
MXB !/( 4!/;)ISX$\)H/'4YOT/RMCJM_Y0[W69AJTO,+ T=J,<XMSSG3CEA-
M;0W7<KB-_0:-[)V-O$W,ZD/QZK<"X!YMC;<C-A,56]8>7GG<^BKO:R;HZE>:
M8JZO*V$PC'!.>2/<=\V1WG:;;7O\%[.79/6S.OGBZS[17_/#D1XI6J[Q O-^
M%%PU53B\#J:SJ6BK-;VN&'R6WB&[M)6>H0IF.GOW)FKYDIY(L:OVHTBJE_0:
M#V@:H*JP;K,P5:R8/@GP:M,QS!RGO^F VUGUZ9:3'3#*+Y%%5UY3[KC-;&3\
M9"X@O<Y@Z^7@2*Q*F5\4S*$(2WS-FF#56UT)-D+3U'@_ $?O4:/JK=@:QM)R
MB 9^G$.)^6_XAJJ%F\Z+20 W75RY5&(!+@9S!;*X<]^>_L\TEB;CO$3N;<:H
MK0XH<X/W3@DD.6AY\,8H 'J/V.LHM(8KAV'T'3 C04%9"OW5B]F#3<<95F?*
MB1N%GY96'@WY4[TUU##+]HIDB6P79S<ON](.+(0]45C:69O;$\ _#%/'T:)9
MV>STUWPB@J&2+3A4V:W";G9<*J-Z5.-$Z@7G!?[E^#<;/M*RUWOZN*@B_DP;
MXX4)='-/ZRVRCWTQSXI7.SS7K.J_'-6':X4SFK^G\O]19&WY:OT==3"%W4L*
MY3TH PZ\FB/5O[B9I*&>A_-$.F!_6OIMGQWGN#,L0U[=$%WPF/IQ:?EY3=^2
M\Y41KOL\%UZ")$%N8S@9V&"RD(=C'7)@YR ^EW-NEZA.,->Z, UEU$?MJ(>T
M7W.5V)MI3E6/D%K2FO 1I%>L1XKPT-$MU7<HX"2L]G30L%=JJKO.JSF@OMDS
MJ5=$<=P.NEY+K#Y3KN\%?/Y *GTB;(BSE>O]T 45^_XO_EW54V,QH!IDER9H
M+;T<^[ 'QDSD&<32'\@_GM8P*OYU#%LT#&F9W0G#5JTW7]FO_1@K('Y34R:'
M!-BUPJL1?'".7BB^3EZ".%;_=;MBY;(Q36J64.(LO'C;R0UO*6I^67###&WZ
MLC^>EE;\ >U&=0\,)SVW1X^_A1-8C<J(Z;S:6^P8=A]W@!ZC-D13C?_>NPW:
MM?40#W64402F[[Y1U3OG:^0YXI"9"A,Z;P.!]^@[^7!P!]R$.]J;9? X#0A0
MUN1VI%VP;7JS:XSO.<L9P:(*VQ@N%'2Q7V5CI)48)N:%W3S/A#)T)J*6'_9H
M4>+<%H/2RL;0<@P'!A.[Q#%P^(W+RGMU?=F68!J+XMM\K>Q>=Q46I% NW"JS
M-015C(RM-2Z;R&$@RB_TQ2!P>8D$:.!\VM6^?!2R=I*Y&0B 6N_ ,!8*\;/
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MVI@+/-G!!>O,/X*^[_'?=_J.%5!3BQ$#NSSY^-H.F0 #F\0XLOQN.6B_M79
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MY78;^_!]!#^?GL<:$Q9. E#'X+!X]3 )W,3J^3,8(VX-[?@*>A4,9*Q7X%B
M^-E"7)+-F[RB6M/N);DI&K,/_'I;5!C:KIW>K3 4%GI>TGD%.HY@(')#8.B-
MV/#SXE7@8GS7<9;^FWV"HD*T&U;N74\(NV']@K".M\9](5Z:Q5N)+X5L?U</
MP# FB @0!T$6*S-H@^&)^5,IBU[_K58=/QOBFJKIL+W$R+F+)P$"L+N\'G%<
MLKG,+F%7R-'#A?A]Y0+.J@ 'ZP6Q!HAC]G/0V3"A!8W@#)[K)I6WX%(/4M>+
MP5(I?MK7U>5O#-S(8QV3=5P26[/J1D:3 -RTW<ET2XORE7@3R(D!5FCS-4$F
M5Q0K;CD[)B"W7)4B-PU[UIQ2ZYYB2/>&I?NM?B &?KR<?=R,(P'P%R"O+=LQ
MK$GM^J60F(%%O<H*&XC?B6'SQ/Z>4DWGC;TJQY&&YGE3MX<= C?OR5ZN;B"*
MDC>C/,+]X$VN8/O4G^J8%[;]X>B=,<'L4I^J/86\.05KZ%0(\[19!69(D>I;
MWW;1Y\1VIF<$E7^") ].']A;C-GL/0>2<5"4L2\L&*7WRK )_!"9;S04S"-I
M+6FFHU$\OUGE07GH3J1OP]L3G,\3$$_@KW.O3A!T,"2 )<ZB(NQI&RZP%'+%
MX["Q1>$XO>[Y6%#3JV?R*3E9ZH%O1&*<%:\Y\>RSXA00>R!L^;'+>6R8:2E!
M%E,\G>62)?>C=3.I4L.8)C-X54=PMH>^H/&Y2]OUF/>^;-1!?M G#I48))%N
MDYP)1'%E>9"Y7@0M0;$$DM9SXN?)[ST?LO%(?GEA="+.D%^UV=*_UMTR]>I%
M,>D[C+]5.K/N-%Z8LB2.>7G?FIT;:E]T;@G:$IY#Q0XN__SX@#:3V _CTI(.
M<\3=.B_#^J-R$#UPCL$7LUCP14@6LH\QT+/FSL3R*4:FX"#H[5,QL6&J<Y3C
MRQ?( 59>XE=$C?Z>=FO=BB><&@8&LD$.>KF)YE=V4"8\ULLCL_TM74G$A;OL
M-,&+KY8LK]N>F73.!IP+I>U9639&1<Q+O-5OX_U^7?]>\B=="/(-;#471*F,
M6,#W 1D"010>_CC* 9OIUHWB0A.E%?OC0B7T^B:+RQ&WWGM50H+:19KKTI1'
MKQ^=%Q#%P@"X-+P);AAU/P8%QQEJ<> H41FQ#1>5JM6.^LXT7H15EMH8BQE&
MU,YKI+12NQXV'K6V^0#)&\:K4PR2T9.KB8O'?/=A6 F[B<WH!S(3!'%&I5[I
M9OHE@Z'^/AN>+T:Q9K5#3Y/"FF?LM3WF50QD0#H$$?SEL.LXG[4Q=J]%QVBE
M-B'_01N+]*B*;Y.&(C-/*_(\O/-<@F0L;^1D1*32+V=M#.[R8:3TS]/$<3Q2
M+PD*P)Y'3A($U>?6E4[L=DIHX^\#NCX:&58_>*^>&G1UT:; NK5 GLGQ-LB]
M4&S;*FO_GE5/I\I<)[OUK\6.IOCVFY]4,IA_\G_T^]HX%_3)D)LQ\O"P[5%,
MPOXE9[GCQUL.JG@AZ "(%N2$I/',,NDF >A^07FGE+UJ DN'7=67C</5/HV[
M-:>LZ"^6K#/]E%][J2J(O[2E3<UI^O]:@2*P;KN]*X$=JJO"B>B!UT0NO3:L
MLU$MML]*ZISF<'YQ13FQ8Q74YF48J/Q%WQJJY\S_-OCQ:3*!2Q^5T06/ M+
M/.C"0$5;#H*XH4KHF-85N2?Y2T;>7"M1/M[UQB&<#'*#&8I7GAO>8/%7NV/
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M >0,BVZ-Z:<C@'U1H2'MAL!8_03NO7UW5^(<O].64<@ZS^%(O%,\P_KSO&>
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MF3W.BXTG<.=<D4!>)FWKUR^U'#X^H.V!\VKPD '7  *(<+57[ &Q[,.>CET
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MPBI]2RYLQXZ\L-5"+1[<9:PGC&$[5Q!;.9U^5K E%^[L[:/9XNOC['LE(NQ
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MG&B(-+Y2!KX1E<=\,>@)+YOZ)?.>*"? YQ-$;5-OY4.K:84J#;'"T<#/#B0
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M01ZS4JB\'!/1K@GV50*ZNB?-RXOBU9<X32=T=,0*O0<P?@N7V(I(@#J?".#
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MR4=R519TE)^\OHY=9[)X:E[^P.A]9;5[@15(YUN=)^<7;+%%&PF0'41(7@)
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MN<OV'U1OZ")'/RPRH+E#K9U-@\5ZYG0_[?3L]->'^_/9&><=HD_?OZ!2:-^
M!;4OZ?@#E^?1<FE_B$[G#2XW/P(@^M;TAER,E2TNP2OE'1%[#&M&@-N<1=/*
M'N9B,MH&4*_99T"C+0S7NE&&4<? ]^*:E( +W@M_#(383;<P FBE%<H89;)\
M[,-Q.Z*.#7?L&/HRZ#K442PN.Q==$^FKXJQ1+*;ST.S1D-FUY$+S1\5*?X;6
M-N^H:/>LJ%H,E^](2[Y>VO/FX[BN05D"_4D_<]%?"5DJ!\*H:U6)[>FZ??XR
M"[X.AFVKPDZ^I:/)NB'TQYMVOUK4D-F<7H&_TV:G1E\U1G:;P&(K+O=2NV[L
M;[:/U=/1,QW)+W+'*VC,Z'K5'QEM)@;BG%YM!RK^QA^@/2KH)P>$T;IX:A;B
M*TCC\H"V\$AF.<N;F(PRTT7+Q1GAT>""K?HXIJ7?.OGG:44/[,)Y)X "Y*0S
M%^"?B/KT[G@N,Q7PBRGX\NWZ#.6T\7T1T8H]DSF;MY?+[[6I[!8?.'&I W@Y
M8!ZT3WF*O0X"WUZ8#0[M%7<;W]./UQCZE VS; MYBJ,-W$1Z&]H:?DQ]8$RZ
M2JK)U0#([2AT=.?:QE;@BN%+T&DX/0'PECY<,02&2NR\6&\._J[,?"M_QT@6
M,?/,W4N$SR9Q\,U=ZT]?)+;E>TWW@&]',<)/+ &X+R?@@P\Y-]'D 715*MGQ
MS1AAH^3!5_7^<>-D&YK]$:0(\E*V>?7[SQ76DE=X4MPP=9-@3';5Z ])6'';
MK.KTWA\<M^%\8Q$TO.4*L7EV,?9(^GA%4"<,9=_E( /.O3;G]V[$!I;)%VG!
M+&IB+3;-OJA[U^!1U^O^E&9NF4#GW#VXXTKJKP/I6"B]WZ-Q\9NR295F?G/Z
M]1.5JW4Z\L6^-0R#/-I+"V;TK>U\UQ6G19WH>%*S-64\FW*4Z%\&)67"P:>J
M'_(;=#^ V/)0&^$M#X.7FQ64O2LW#<=U<6'Y"#/9/(\^GT^D6HSW*-^EY'RE
M<+I7JWH;3(DTC,\C3EUNI. Q3E<[2Z]A*L?LL7WQT_CKS!X1&85'GS5[!<MS
M[\P.R3&N!3AX"WA[^4CKT\)WZ]<LW2N";-%<V878)PU1R_#8_4*4Y<%N@W7F
MA&]LE5,*) ]_*7Q4E7@6YF\I.:,&./XNE) .D2TJF)W7L?<N'G6GUCR=%HD7
MK;E^-7[(::M1JUUPJ)&2/ %,MJR1 -/EVJR?-BV.D#F@&B12D'$W^+L6>;)%
M-V-YM$?.TP1R#P";[W6WP#@)P(Y#"78<& $7HJGB[CY_0?[)2!RUTZN8&V<[
MS:*'JFQ=3BIZ^]+$3#;_] !7?.-[DB=+"B]2MA^@RI[P8)4N?80 (#JM0H!@
MII\AXXCK,/'W!$!-;T*+?F&Y:*F?[\/6WWM7NIQ0&59A"[XEMU/[5DGIE&*.
MKBDM$P![*B6.=6?<J+JVF[T;7=7.0'J7PT:V7NS[9B,5;6SUFIYK91K.5(56
M#+3G&.CX.XYI[\#S[6[6K'B3:D)^&Q$R(NPO=:WQVAL=KEBY= BVN@#/E+NG
M#%FO#+K[]P@K,<>@4&ZY+CYXD*CV!( 49+<)>'Q3EP @LNXJ?;X@- >X;!HR
M@3@V4KT)66XA0M]:JCA66'PV$!^ST0'Z1Z$U!3LW"8!<#Z*Z0X: U5N07\^
MV%P"X*-J9'Z;_S_J\)P &#/'$(N-/#P@ -)>Y:+*"0#'74B_.>;9?WX9; 4Y
MV@>=BQ, ?.*[3:#_KQIYFW^K88*?F"$ DAM11&:_MH8@ $1*Z3MU9XE".?RO
M10?;_6<IP'\OI>@RLH$[%G+(64, 5 J<3^?@1W*OMPF8AHQ;WL<$HEE J-QH
M>+6RTK>=*=\FL6BQU!_S\Y:/QIJTW&5W@S,T;R<4QQR+_\OO\U*G#(3N\3N;
M7K;2"RBU#UYC>?Y,Y\F$4<VSN_5:NQ<%_T9YD3_PG$3@*04?N^*HIM:>N<9G
MZ&%8\I 7]&&N+5*7!MN*W0L)[ZZEM;#.6#PQ7M!^2:N8E)L:Q9?;'"G/9FWY
MJU5X Q')=4?'=7:ERY([;;33T=_*KM'$":O 63'Q6%(D9MA]7>K^:FEP0:!U
M43!YJ[#4XPA,^HKN=8RO97W]^+%_\<1J;' WIDY.V"6HFWS7B+;[58TSV1=:
M+N%5 @ CYCPY?+!+5C#L#X"U9%E.+"*O>]SYV'W/&\O.BX(V9K[2'Y%?O0R<
M[H(39^"YQ!SPDHW8@\=7RVI(\&AZ_:D^^.H;#:PF-AV7 UQ=PE(2 -;,Q"%0
M)#'-M^)U"&E#7#!4UI\2^RKE/8H;%V<*P7_J-?^4NT,<<\'$Y@$YX7G/=/#$
M;@K.7J+'"%-V)<[0+XUV$K$.8_\,%3R5!%[^(S;U3'W$WUY4I$:*MG! XF<O
MTS%\EX0HA2#TV=Z],K]298-\C/'C_#FS?I<F)RFS*D?.]GE++<G[!:&4EK#S
M=/1G;-M5HO.A31SKCW/:/A']+#4.,/!ZL&HO<7X6\$.E;H9_W6ILV ZJ=$Q>
M*HI(=;5KS$),YI;D,.)*7%ITD<' Y\Y<BS*MV59B8JQ[E'''4+OWZ,1#\ H!
M$'4F;K]B(6FS5O!%<>.W3>)OH]? MXF,5[:^7>*7" "TP;)A^P+4+G$4G?%L
M/?6*K<O&^">CN.Y+([7"V;E.R+=Y<PO6&UHV$>%Y(GD-E#DG?X*$,8.NZ*>6
MP3E3@< JIWG;U[[["Q/<^YDK:5R%!K/*W__<.EX9E=^:WRLI&5\V#V7SW'I)
MEMFU2BV8_W>%.50RR'9I#LBQ*7?+^[#&;/YU<A1MH=?MBY@-/#N6?AQ_"S'L
M#>;O[OX]6#/T.3'5,QD H'.?:G:I)8F!O=3R*,XK?#LBX::K;GC+AL@AB3SS
MYIKA<BF#[ L::@*E9"KWT@+X*W-=?G0Z.],*D;[7#*\DZ6,EX[BA6_=V0UN(
M=L#^88U]?.;X9)S)87^TUM/*B03Y@5#55":B&$CC7L[NL\<J.?+"25R,!LGV
M %ZT&@*<"A6W!$EC_5QZ=%SY=W=G.4A^=!1IDCQ@[9&G*L"3JEQ1.38S83"H
MV)NQ3AE^,%9*10 LDG%PZ:J\76 D>2Y*,7(U4W//V3HI]$H:$^V#S:N]3KDC
MWV?]>+5^M,I==VP*DI*V$MTB+:7I_[E"5KHU!2OY2GV?^+!9A]6$@1$%'I&^
M'=*R>ZXM#WO)SWI-6__C\DN2%"3BG,45OI-1JLQ.G,G?B /:<@O[_>^R?%]S
M, %@/JRUM*\L7$P 3)/C#8K_G&>((X/@^D2]=S'3@M'/4"*?,$_5L]1+8GS0
M;\)I]+SY$M>^6$DF-E,FRZ:$)?55/L9?345>)C+@!S,M<]V7&5&^6%Y]K:+.
M*ZU9LW\0W1$98GL&DR;Y27:4@:0F9\E#6C)3^ 7#=R]P"6W\<Y]B7(&=]4D?
M"ND&W9[:4,442K$L/A_.>=I^YBRA>56=Z*V2XR><O$ S[.T^ <[QZ^E@9U=W
MMJJF]P]E/N5OZXF(WI@U*5<USYKHUS&^(=K,+&- 6K/M^NL +Q(D4H5I7[XJ
M[:P.GC/SYY!(&YOD)Z.M;+1]$Q6_&H?^6'VCR%A8? A$; =;8"0!P E<^FY8
MT&-)_4OYR3"J8@WH6G?S38I!/./1_+VYW.?"LR%"(=.W@)W7?, R$S+/ I2,
M[3.1*SJ9XYI[IF09RQ^E!]!]290I=%]E.[Z;])DB1;!JCD1D:#?-'& SU:E0
M6E9BCY!0?'_C[5CU]2YGI]"0+?E>>>3[V<F;@@LFNX._(.T"0+LL"VV=/VV4
M6+F$PS=U.A%C^2:%'!Q2*WQ!9;\) *IC)D?(4CJHIJ._(8@;)>@4.2^]-O*P
M3^&$,FD3O%CR?2/=$VA/L3^NZ@["\''O-J4EFT%_ B/*7*7*DY](4\EJ;K,*
M,]1?";4#Y#RPZ]5_F8OAB]KM<<GT1 DL)V7G,:\_SNMLZ>)EH!JT5E+^<=/U
MV5<QB>[@FVI&L%P?([Y ;M4M.$I;?*9&'>8@@K^*5:H)B[9F:DOBT$OV$W@;
M*O5S8S9=CZA'^OCAB^[BF0-5:JQ*2[W\D/Z6Q"!;KVYJ&(?/,?2K0^EI<NN^
M;G7D*<C]Z(+80$(0>_(?ESQ89DQ0798R]+:CQ(<Z:Y>%;(GZ.&O6E:(7KAC>
ML]VZT_R%-@!6&.SM>?L#)F3^JQ5 M-Y%\E&)0"D@@/I"-:;H)=ANX-1]-^B<
M$GOCW2D8-BGF6H#A1VTK[?2(NWMD*H-E.IGI=!K8/Z>11%MY=*KXEU'BK[I>
M*J7.$0#4OC^;/9.!-4;3P*&-'<LS-7%'@6:;IA>!16?<*MMPE-;H3+%EM#4<
M<P>%Q,O<_CZ_.?;TN_J#GZ\#*-X0"5'U6WDBAA^^NU_"@F<\"".%/I">_ D-
MS$^O37<[?;';MK+1?(#A.]N=+%U\Z.Z-TE@>GNPNHPAWK'4H3":EVRVXKIT]
MO\HP*KVG@[^J=2F[8PBQ;\4(H/8/$7=:RN)Y%*S)[2G!I/+]O=^>!5]1 SJJ
M[JI\4A)O.$>*8_CJ=X<IOM8G8:]AP)Q(]3LF$T^B;5]1\5)QT$90D9)\<09X
M(>-!^*O"EU)^82O.CY=<.\&G$4-)6=G,]^*<?,('&SAN5BEPSX,>@AZ/Z<SJ
M-."^N ;R;F2-8OBF=R=*"BIZ?Q+M @O-'9$=L?B;47S[?.$*YXT;<!7'65_L
MC<!3\!A,1VD'& ZD*S^HW0U.7K_&([]>VZ-YN/# IITOOM#Z;MO[_ 3[^2+&
M.F6X!BX.?POC7,G^#-45X-CR(IUBZG2=7D7=C=OIG1N;/*5\_TG^Y:DXQO:[
M8YJLD25SY/;@LQ=I/D>6YEK7,B/^D&O:S(:*#Y"&A?5JGU#?\[R_II&8^X=E
M:8=7''O;5':&W9.V/U*U>'T5I7#*E=H KRX.8S'!C]]2Z?L=E%N#@UZ^/!B5
M<%E8.SCR=5H8F5]17I'9_/2RF>Z5?SQ\UQVU.-[1,R5^K=RGR3P_4/[&Q9IU
MS4>7SIXV.X;(]?-/9$?<^KI9IP\Q_FXR) )1LVI3 (L'L@5>(8NDNZ2NBWC4
ME?.0('2O]G'3O8785!_EFB>X&%46C/T+LV&Y#I]99V2/E5FL3MD'_E?R U$F
M)+,^E>IN/HD/7R3^L5Z6;R.Z;9&.1!Z[&5SX5"!WZ,8^8MT%D7W9YKS@.6IZ
MDBFX;KVF,02J(P!VTU'[$Z>6F"PH$4:D7%5AULLZY[=;&QMSD Y#/H?502.K
M'PN3299LT/U0+C0">^-HN;)Y"?1!QQE5CU0K<+P(;CU-]/^*.=Q6@E_7MM;)
MN%VK5<DF"O%KTQJ(*Y"$4CI>9)UN$ST<<0S10;1*()J%PFJC?,Q+?@BM8R/W
MX18+/E0X,UM+Y+$C+O6\IJV0!\6@>[Y&S-6%=<,5 I<^Y0AC/"_-_$*..O"W
MZR?P;)LAU_'3K:A]^$JT'?H*TFSN^=E+'7+;-%\3"Y: QI<O7B][@J2),F <
ME/C>\@HJ?C3"FV:/U&P/I!>.U+GVTB]N,RV-+J;;9I4B]0]==_\!:(S_(%PZ
M6,<B\57#^/%EO#:[B4CRNB93D3&?D,T'";8_W:]2-]TM?=&04RW4=%?K38V)
M72\<32=J*Z#<-"Y'(ZIV)[4QSOGHJ["R6 G_*S7[!^Q4!?*LT,+V#8;W*T+'
MOS\%);=='OA6;O2O2#I.EGS7^[[2.M7JO#'>NZY:A@)W2H#,G<9/2R9=\EZ(
M%?\TF%S^0')TS) &RN-I<\,<Y'<3B0<CB-@]7\YB@PD#Z3")9A.W)Z4WO=DC
MZG[SIG1YSC7UA:':\PSB-C#JPJ?V)KAWQ_1L0>KHPHNTJ.5L\4=3:;/!L@=J
MD3K.=L+0VJRLXC1#42XNXV4G(8#Z4F#*H<:>!M$JQD[ H!C!C9^NUQUR;[8
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ME_V>XXRE9@4*89ZECJZ(GSJ_>RG<,D?S1?7/GR6\,50--'NQ*8X-<\;I7NA
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M+.<MGC\$5/H^X(W/\'AJI1_:0F8YW$P#4L+>Q<2RQ!  ;Q<<*[ /.:;.<IS
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M7U&1,VW&E1T<QS^8&2Z8BS0S_,P>&\UL=WL.^2B6&7&OY9#,QI-AA$(3</;
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M61GGX%O$RU1"3$"8D"U[K'Y8,%1[' >U'C(4."_OJU:6P?>S2^K<U]JWW=*
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M/.M7=T'T77R:/(/KV[J.(43XT?FNR^#+#BKL+)K2@B_:CY9E1S6/"A?Q#M?
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MM<9+()J.*I^['1(H_EXO2N^C_ 5H7B.WRJFWKY_&TXEF/1>3XFX&&_#VVKX
M,ZX2VG3ES#%"(^OHL!= ('KAZW"E(OJW_-^E:BQ$]":^R#&N,.LAQO;A$><1
M/H[4YY* /<GX93T!Q*-AMAKCF"E-(T)MU/ME[3-:R% MOV'OYL74'E% ]ZID
MM4IJ2J]!0,"19;!PA0ZO4(=2)(U1(/R4)CTKA0.?Q/V=>C)&J,+P*\,4(EN^
M"K7]R:NP>PS[813G SY!\) @C3J/Z5A]V8]X.*X35@+A#O8,HSAN:IDR;:K#
MN"QR-R2\#*R9TCS''E0=_=(8(8\87\^MW?ZF=(KE-MXL <G1J!^9,&#X5_95
MA*4_BN944.>4':U4&TN":2\"1/?77J+NBJTOAQP YM]FRF2GDU;#;XRIK0N-
M^&Z<!]4<4Z\=F5JK&S8Y'6=SA9($M+GUA%<0)A/4P]=S/>78)UKR-YY)L!D5
MDX,-"RX&>QV"25^YH?E0F AX1I_2F'@'TF??_ @GN0/=PZRHI.S<D?4XDV,I
ML-%\E76<P>%'4]P#\ZXYN"10NO,:B;[]+NJXX>W\Z*WE^]Y;8D]PB1E"]2._
MAM,T3D8]<NM_SH;-;S-D,G+)SD\ZB: X\Q"TP[HI1<S5=P-4JRB#"?,8M#'.
M8UKWCTY%XT81A%KC7>W.D9- !0LSP9C-?_5G(\-L/?9P"J,&S(@++&HK]_GL
M[Y[_X8%B2;*9X"; *+?[7<AU$PT#0F[R=;5*/DG#(]/3WN":/VV5W"PN2&CR
MZ?V8EC\/[1'7!3,;<,__\"9>#N^KNS-A\3<X7RQKP/J,S#,5#K!6#2.,>74%
MM1?3INVLC%9D':M<T>.J']E4PAC[JC$;XSZ-JWT3ECGK&E)9(?I]VB(N1_.)
MU%.7,K988XGW 8"/3#L1$^\1Y8O7%VSX?-N_R,A?NF"NW1:W7RM881>6:M"Q
MW_X"5U8[7 Y^_EE)KE."(0N*"E=AW4OO"'[Y)S9@QF6A(Z(]W;2D/G+&,2S^
M^^2O25"3(/.*+]\#F?B'0==M4Y\"5M248I  F [WR?22-1?>^B&$1:6WLF.Y
MGIR*;.&70QD^%;S>3GGAX@6JV31Z%P/\&4YS]-]:A.F<9]YD&3.0P;07-S+-
M;IK0S";HX>A2AP=@BV3S_[IDWJG*:48/FJ>0U$)]9=H^S)IDYZ8S- _Y/CG<
M++"N)]0XVBRW:HO[E"R3KH93QU!\B,\K4HJ !?69[DE;R@6WQ //YIE>.9<7
M/^2PP=+\5VZZBCR#?#)@_BV7FV4M$:NV/K4OU>$@C1V1)HZN9?!/SO#Y/C+N
M)*V%GDHX*GW];W7L 2"@2O\<ASP%?(K=*ZX[AD=D=J(6O +VKRW;Q5B,BVRW
M9^#<?\8\;/@Z_BS@+^6==%;E;ZZ$$ 7T5YE,:^LD<Z &;$TK=V/Y,R-\YSN,
MDS'Y&_IB;:\3R>.XLK?&B))VOB,6M.9>E[PO*9.T_A#;*,0[+^7TK:H>>#&P
M$L3B3S>E89,0KI0;>+^+5A"LD/D)]NM"TJ2/\ES7EY8PB#J+EA'S,.M!?762
MJ+_"M761GHL#JMK*:V"Z ZVBJ/('?)8GP4RI_=13@IVZ%)FQ.$09K<RO3MQX
M7+6+C=5?I4\8;P9LR:GR#0@4 XZT3]J%]\]J, *_](B]7ZK,4\20D2=G!W3V
MR@=#@T.E18K3Q'ZF#Z 0.=(F.9[2&8U^\A(*447SVZ+LOKE:V02JH\7HIV9B
M[3ZD+0-"AL0TC;5K:H45%WK#8-#/@JC]RY2Q3**2XI_^P/K4U\(A)J,H-B>-
MNFTPK#XH",FYCB6J7UY0.LOHW.XD30OR?';LR;M=2-)1F8TTL%#U^O2][ZO\
MC!/@BY[# D+B4 '(5- K'6<JR?P8ZS8&7P_F@<-,&FJR'L5TCP,#F&BMWY@L
M+[>^K++NV@N78$"B9-7?MN5X<[5C))9I'HMK-$#B+.LR[3CN9&X17'QV\-ZP
MFC/X$20@(*/33.^"I+<[=X 9NNV.]=O(CZB;3XKQ4QUZ OOI>B=93S##VQ@Q
MS;;P:]2 /6#3F#<%:#BBJVSV2<7[<WAK8.PW5^K&&;[Y:OYG16,?>U"?&'.'
MM.Y1*S?Y:2B*88-F@D>,'<WSS39"*L23&\]O4E#TN_PA<&1YR?[H-WM-P%E'
MCJ/8<)GPSF8)&FS3PI,F9$OCKI4/+?5*UR]TFFRWH>_>QXZ/G*O8W/4UNV=+
M.E>=9?W8KQYPQHR'?G3_/W4HTISZ/<OM,.]\\RO!%!*F,MHEDN[LG2'O'>CI
MM<GG G.NPV)Y]543>Y.R+H3X;5(W14WWXUE^Y'U)YL,1EA4Y#-25D;JFX9#4
M^ 6RI_!R!OWS96VN+^2CXCD=7US=)W&CL#[Z2MN\VH5?VS^P=%XJ:".*MC9A
M-A(N36*DNU G8KAK';C[5]0A 3EB6L(5'A;:$C('@)J%*V6G3^P:>[XS B04
M,0P.>=+!@%%MR80V'F[O*ONZ?"H;JDA?MLKHE<73E$>A'MCD3=&:2-L&E2AP
MQLT+YP%U7D=(<QM8IN:JN#H.UX@;"4#R.GH3II:,$8&A);.K1+^6$D>-?$Y3
M3*A7OXAS),Q/_-LJK^T3F7=ZV+=L $N"0:/PG%CA0GMITKSUN)I&H+_DS1Z;
MR9:1$[:K8J:J+333?-7V=8F+%W*G57SUW$1V=,'L4X-NGW//M"FUZUI"-5M?
M.F=')=;2S_9)9^"NK5K4QJ(X3VJ4?C"Y:#%3F,:W>D=_,6BN9IG%+SDX;]XI
M)M$Q"N^SI'$3L^![_0G!QSN]U4]6Y9K_E0Z-Z?A"&L18&F2L5'.D;=W9B0-H
MEB/$J"#*<M=<K(-3IF*11/QO+JZH"=*J.E"CS^Z5>G;3>+OH1^#24XC\%??Z
M2"'QN\9.KTZ$^*92!B<SAKS#+P]7J/,<]T)E_HYNE"T,*UH3%$'&/<:-;04Z
M.L96*'Z+G<PV(RY\?TOFN^'V%_@S4N+YZ ' /4M,:*$D04^2D=5N@\LNKLIW
M\4*=:\Z"E<35KA8[1H@7^0E;P.OBD\^7X:0<V_Q?"!>%Y-S;P3" 9-!IA![U
M#/O&?GZMKB-Y.U*=&XBXO%^DF WQ#MQ':>-$$S)2T(O;6R,:F2"%*]CN**?&
M%!Y#FM*WRM=(@7!9QF'>:(D?40^#6%:S9XD!-92IZ*J<65.>C0/ IG#ML!_]
MF7J.I!#P[+VHRSM?C#XR-.>#-R8H3>!V$S_**H89JFN&,:Y4PON51GH="DTQ
MI$!H:3NHR+>OB#1MLM2C(OOM['G A0/ Z4/\D:+'.\JZ&D "M<MONK7M_8DF
M3ICBXH_73TKCS*)SL%?8$,<!G\=?HPU>=6#P1)LTX[L61E7_6BE+J>7RK8'.
M!4(=.U%6D . 0$"BT6W:Q8Q,,4Q%EGHB!06_7'W\DZL<;WU*1J:!)9;/234D
M_@C,>!]U&.RT)4ZOD_ BN1$>0XM#*,.Q2AG&:W_=[!Q4("S$4^ (B5J$5^(>
M_^FW\4,OZ$KP%:D74^2)C2Z:9E<F$2-81&[ 9($OFN2M$6A63J2V4GB<;!U.
M"T']2)1OX//*2X5F/S4(8SX42M'4I:FR.36+&&TVF+& 7)$U+>Z?MNS+C;F]
M55[$7::;3</8T[/TW=O/100;E#M[5*)/'4^0ADJ;Q[D>&J#KT(:>N#=;%';1
M1\A&T,]Y=02_YSLI5]U4-8)6'/OK+YD5#;VFF61KFWA\1ZI%L_?;L4+PI"K=
MG1%*TV]#<OPK;I"AG:!GZMQV+^RCA/E0E-V*$TX]89J$9H!K.H'EQ!L>LJH_
M-<9NI&3-ZM!R-Q:8^NN$LSKN96 G'Q28'^-*'N3A,IVY]UV)OSDK1*T4%932
M<S$XZ*N3OJJ\<R?MB 8'__OPT84__WH"(S'FG5EB'$XT]]K,NAAR-OC!& OH
M6B8M$KD77OHLP\2=M[X^7L=1\BF@0M;])L=),6TZ<(AUC,IL>XF85:(=SQ#G
MHLTLMQLUC6]S]R?M#(1JMTC7*$^>WD?'/3L ]*ET9;C=$G==@!T+[VL^Q:CZ
M G=S& H\ *BV!GM7^KR,Z$-/K^CQUPO^P59UR0REHLN%>IIP'VY_(+?3$O-J
MY5U0%*73B!/[:/2ON=A@K>_)%?8S7M39IL62.%\%J+J9RCBE^:V/(,W\8K -
M5?1=2E=04BI7W9GSGH&(N;>Y7RNR:(T+#HRUA0X;#;I6Y//23#'!*:;#C<2:
MJ01MJ(7]A=7=C_H]4)7[8K.WDA(N67Q;15)-LT'DDC>59PDT%0$J/:Y T#;+
M,+IW9&1):4,X9V=UUL,>F&%^=DK[5L>Y+K^ -.TR0S? +,.,&DRW2AF@B>KC
MJ'U3/]8T@WC"2N'52Q#1$"NFRZPQ43XAX[5KP)BZ9;R (6U:Z-8CP[Y&H6_F
MKY U@UT\1QA!9MJ/(CIG5>KM\7H3I$[T%]/G>[HU>-?E3.^CL:[O6Z7?'O/T
MXGY[UI1LR^+O7;C-6"]FD$;;1<[FNW+$5&X]'I.J3C+5M;)K'OLM7Z\D575?
MP<+>86VO".^YR?>7MD;0$)EQ>="X0-@HFT<F@/A89K1C=HRHP$^," /<T#,%
MWWRB3H(2Y[3W'_DPR)DA3INK.2';Y[-]3RXG402<"]W.\6ACJ+ --!5&<4'G
M548'#FBLDYL_"RC'28__''GV&\)]K<V9E[3UKH4^M\'4-IE).?GQR7OG_VI[
M9TJ20![)DTCK40RDZ<GNH=:XB,4/WAO;BDFL"/BK]IK/9^ $?D>&I ;$.HZ'
MVU[[CC7+;KU!=V<]/824#EX$@7!%Q!U:V')<^:\HVLSB5DF@_\F(TVM$@A>U
M/5P\U"I\!$$\>L7FYS<WX>Q'*%*^#RARCFJ6S'D \%I]^4GO1D*'%B@ZT-1;
MK71S SJC4^;LL&RU4RECZQ?\0K'B8LC&^13%H+_59@IY8K6';HW@&>:[T(+B
M>$3-JHQQ?$"-3KRHIQCP9LU46+*A:K0XT3<(;'(\^N:3^/E[*R."#\^\=;R,
MYV>JL\*J1IH%N\+RUS/$N1.^CP*?Z9B\2(GXW/9E2A?GU/:<NSU-'_89]JJQ
MNF#[&L!&W+D2V2*B PK=3R0WR5.2BCYE:[9IN:3ZN9[_TJ4V9#?U8TKFA[%<
M[))^29ZKRL 18/L3XX54;2_DH<_E>;/7N:3$!\E(=V2!)+@K1$8NY LY/$WX
MG% WU2O3/EAJ="7[D7&RIT3_<(_:"T!0.#?#@*G+B*!LQ5$(/&NSHLTT4!S,
M<USMSRC>52UU?5??/U G;3]3.U=VNSL'@@44EBN O<SP8?Q@+78?B&J>K4F'
M,=!^"R&8V-^5O&LB 9EA?5TE6:&!TPJCB#OV)1]5S[\]W>OQ_(%?E>"-T94O
M@/^_&WSU(ID;J&&!T^#02>H2.++[FL'-U"+!@V8N$ZBSN=Z%,]XY_'7X6MI;
M.E8D<"M;9L%^LB-0K+>/>PQ:ZG+U4>![XN)"V,J=":7YW*C<:E\"M; #4H*-
MK"6<<4S4;]6['+W>SN]-:;\'#&C,"AE?MGE=["PX?CZ)B*SY&VN29OC2-I=Z
M[PH,P>5:H)E4J+R:(X:G&C3F<I$. -TGUXC:WJ91CT=\LB0ML=\[SGT\.G4\
M\VDJ[=]H+C78*8C#V:9\>%/Y;Z73=?DR-1"1NR\3$[_A<41?V=!Z1#=KV8"X
M]<;X^ZG LU.1:9WS8MMOS3>8')M^)78^>\LQR9T\_.!VZ*]4"F?FCF.9\[6_
MO .9IM6R(F&+/Z:[&XEW>SSLZG;WQ% ;<TQ^>.Z#NF'%\F>!B;:/,(Q0SP+[
M]3\.^6]V:))3/@JS(5)U:78;1'NG IT<4^T:;;XA%N_^*X00%=D5?F1<1WY!
M/T0VM;2#HGL3AL^:0OMT\IS^ 8?MOZC&$QK>$-V>'^/>?5PAYD7U9/$;F5"5
M.IHX.C5SKM?7Q[1HC2]5%MW>S[UX7-\OL-3E'JH&Y19X;:#4V(;\1J7@8G2:
M?5'*T=QV\(\N>M"0CG8EW !A "-SAVL'C\&4Y&CC4SYU/3HOPS[DK S"G^;,
M1"5E2:!>N AY7>[- *E7"K';"#6":.H*1*OK!W]K\]5$*#!0&!%6VN;I?Z(]
M.%6FJ)SR2W*J1VR?5'[N>FQ<^*._5KZP#B6&K&\ZTSA\Q!;)Y\%(" PLKFLX
MOS("?:PIV*-;\@.Z5)>NBFF$IIN>;K]5<]*;SRC%2*1K%/%OO'C0)&.9C,EY
M[4;YJ$;'C"-L$1Z-(ZYCP %L;$ESV@ZO;W^I=)R2_:4/RX_OB$DGF;@]YW*Y
MP@ R-6=O4Z":]CBJHV("+%@I%EJ!?SBW<FYZ9M+L^<2]"0F<4?WHLQZ5QQYB
M36)M+]C ?13!G<!X]+(.]9R.JTO_M*("C_=ZI@,MG?$A3 J2 HG9S 8IO*9L
M!U!)<=[.FO7*%WQ:+*Y<XNT_4Y)J&?'&86,0%B4#E,'3:Q-Z"M6U-&[6\PZ_
MBZ@]G1K3H VQ+3Z!T7,>MXXG2Z8K\)U:3N A2[!X.XE=]+ JZO?&!>/Q0&[9
MM:5=IF2G[/6U";9HV-'YML!8HK,ZL#@X?FJ#QJ/NAO@B>>N5>),W=8X.&_FU
M'9OY<0(O 4Q.V$R.0EC[ARR8*%XR]G6AF&]01YRJ)^/$UX+L\G>^@Q<EKFW^
M9.LRY.B!#!DT(QS$[S6K1O3%0(]930P0<TO7,T==5C5L-4:=G>?P5HTN!L=)
M__%(9"]5AQ : (H</+0I-F>87W ^,+?-V;\--_A6;>8HDL=I<GW$@!N-P6QH
M,9CWAQ3X8U+G; -/#)VWR^[ZKQCBF!Q$V]XPF%<28\R1G2<2LQY,H%E"9*A1
MR\N@A"]M%S-P4\X:J!<C:L^0+U<RK^K9"-\SN>H:F7=6R)$VM]&0Q^Z?U2$2
ML,!G" GJ < :"G-*OS\!(X_79DW)L+\GP3,YHWY"I8,,+["*+9Z_?C5;W;P6
MKL4P9RJP+M+8'RO72,Z+T55N%+%C1J-!:R]K,Q9LF[-,F<<MILH[I30"]A7M
MG^=>,TR[YR>5L:YC?@CMQ@[?$A< $K'OJ@3;$1+QH(7$HW2X0K[]44;.GGR/
MAQQC]D>[5'*PM=M_MM8T#KK]T!9;<!T7A*:8J/T(A FOL%6;QV7LR-;I]PFC
MGG6OMK2M[SNXHQN>O#!T?',KCT>;FML*F@RF@*-8@0ORFE7-(RPM]5 DWT>\
M2:DF2ZH*/3XV,8RIJ@<]B>U'J40F2EGJ/14-6GBOA=Q(IMDZF.!-2EP85I:,
M;/^7H&J\K485>9BBR3OCH^*,J=TQ$NA-0/HI!$OS<AE_2;Z8*BD70FVC:P^!
M/'0=.ZP@$GS 7Y.(T!/+,0$WTTBC1O4UFJ2<PL_G+1<7\/C=WT*G!H6/N()G
M:DRT^UHA(*I)F*CEL%7;"&-=?P@CWQ+F#ROQ$A>.,!U]$O6K;K0H9^H!?W6'
M!C-6)M-N,&.CZFK<$0? +PG2,3)X8X:\ZXV&4Z!GOT,];3):1^;A24NS(4KN
M8P'OZG?PC5'N7A6U3==[5P\ XH?9U),.@;Y&CP, W9C!K]GB".;NXRYW.4>]
M YY6HS&J=ZXJN(Y%HH3>4*A.<3FB[^M5M,RE#,FIL9<?5JISL/C]DFH^K4WD
MJ"0\'#_[-;.N27I6(JZP>0=OYD>YD5=CF]K<^H:R9B=6H]H#B%45EK+W ;T&
M41]L_ZM(<&V$1>,R"G!!C1HU[A0YG"%[))[HK+=#=+[6^\2&-^0$.B>W^,=-
M>=[Z^*&JG9D_ .Y!3G,J%R7@Y9^6F:..7)MRK9:3B/MC5O?&/9,&37.85NF.
MF$;'[N(39U#W_OC$LNUB*X_*/KJ)9JJP^Y7RX8I;VI5<4ZM[15'8&):Z/V0!
MD@#_G24/=\4D=5Z5:@37Z2^V'=6YVUTMX$R>RNRKVG^#X*)NS\.ZP#SK$N>:
M^R T46.<'G LTTZAD/H+9;5FNSM]K?%Z]+3)Y_MNT4&!QI*)PHM'/M8?  0/
M YTJZ^Z?69X#0"38ACI;YEWJ4Y=9$A^8E>&NY^1RN8X8X4W?E9E,C.^ZQBD2
M['VA\ZE"T. Y#BSB7M5^;K/:FJUMN.P$_EB%"44[6_OV!S.*,:O),$SQUXS#
MY#/[-SJISBZ^7J_ZPO+Y;O5:0_KU%!&\^^_9_([M>[NS8##<AGU%-FFN4Z2Y
MI'1R\+CR6HI!:-UFT;7/!0;2WB_N\=2XWCK;TG 8]JE&L+,K.&22VA0A;F)6
M:@P#XYR#7UM-&S,F24RI36E;:'T:_4[M_^K8=BW/_6U(?:)40E]B</CEP^U=
MQ(-HHA:T1R@7E7$T9:(B<'+SOH9[,<;9C7E[*\TVS<9$HR_\OL<-<NN=_/:*
M@:N 57QH2?@ \EBS.'QE3<@F#0[N8K(X*$\Q$]OJHJ8WAF&?M,+'LU%F29>#
MX8CZXY)*JJ_R;7WK$IDWP@<)IW7.L!5&T8^;AUBP"B]4C+7YN3F?OO(Y;A?1
M;"WKCUO2LP7[A>F7_H;>GF/FM=:#SAU2*/'K , ']]DV3>]"I3IPOP3ZFV%$
MM,P\/9[4C3WFK>4WE3SO5ZJ<=@&1Y>28%T_BEQY0"EN0F(P'11$ M8(P/J\J
M9X9F%X%:%2AF;N57[&VP/+;4.&8+$1:<O<R]^"/*?LJM7.8G$'?GR'?V((':
MUZS+X/WL!'>T';%JR5$;O3PFFV!#LQY1PSW(#H"B2^*UL])ET)$O2HU;0_P2
M>QL--S$-9*5HB1J]&IH_T]^(R!)"4J"6+#R1GJ,:DC^N6/%SK.2V^H>&Z]/:
MNEO%PV6=4\$]7X^(;-! ,02J&2B2(*0CX3I_ .!F/1UBV>>M!@OBVEJ*,.]_
M_YJ@9ZHYR/^M-E*]^A5RDS=SK&-G^GY:2+YC+^PI\0 P_\%%:%R]<\R-J%B^
M->>"<DFS4V.X?9QD6;M35(4#VZ!\=EVP_Y;[;JX5O%)U9_@S%=C?1:PG$A^@
M\]%=$5O/U3D1[L%E/D$HA_L2M%4NDT#I3J\\V%5TRA9\25E+Y9X%5L>3BIQG
ME\]J,=Z'44S+!J[]Y:>(=73%X&\'NH4]'5K5?Y"SPY6M!]\2X2PO!RY<CU;^
M".3B'OQS0X+[$+DC5 N\@H."Q14(#:[DT#D..R>DYU8&L1<BGW!#UE^AVF-+
M'9>=:<PJ_0_;=^96,WMJ'K7!(Q&I)XX(&/XM&OMKCN$X@2M*3,%D;9KEK?R1
M\/;:'.XU%-5$D8H8=TIZH29Y<Y+M%;=T*,L4T&'"QE5'>YHI$5^K*_0-TBSZ
M85/] T(WQ)^\KUZ2K#%,F%3<ACZ#UO /B-ZSZ;S^MG/V>O;OY6^5KPX -96;
MG-3MNUAJ;KR2CJ=:]&XK=7*@;(TX>Z'N=<[T7^-1':VP>*27RM\K?-Q?<F6G
MX'C\H<>=SR2<7J *M<-B#G$O!+Y+"4]$2_J,=AQ;SX2^9W%Z^LG4*ICLO%.1
M5WDE^J),/"2K*_>K41LAF:W<$&%(JT7UY:]# BL[_+[T471#C7".?:'?,K2*
M.MKFO"H&GO'WOKG-)]5H(*"2>P/@#^*/V4@[ ' U2WMI$1- L3JJE!F8)74B
M :JP@8'>GW:Z'1I2.3<0BS41L/GC@)[I<^K / EY(Y684K#GS$ZF8IT9($K9
M]GF?"9'.Y K6+=-]4TOF75P W>&_8")M=4?AJY8.;\OYYARIC_9W4XPN?GK_
M'OOB7P.R-T8,\T<,,S0<9$33C%6;D;,?(RZ!ZDQD\_:L<^G2#O(DAT9C]#FF
MFJ=W3V*SW5(\_%'KC% RZ+%=N!KB+./U_+[G0W'1F,Y9()9($;G%O!\D6,<[
M:?^CL]E+0I6T6K=]Z1NG],@5!0%M@-6_SJ4A+"[&+G6- CLYP+-G.>6MPD@V
MH,F,[X]E$/U_U-BK#]5[/ ;5%#@)S0@4VZ=\&C&1^FWYST/KG1E =Y1B([?%
M=S0RC()HXJ7A$PI5+OH*N\FUE-"8Y(=-W#KY/V$Z:>U14O6,(TS0#\0)5(?G
M WP&14+ 1P,7<>NQG5N-QIYU=";O>7@;\$UWV$^IO/,K[XZ0FV\>TN7'NL1(
M])/.[(KR5<P(0?O*O0[<-!0-;0"Z52=-%L?)\78_<=;J+_ZM[<#7=F9'L ;V
M[\2=80JAA$*?@$YCIQ1\-S%<=\-<_FZ65T"7J^M-8Q^K7BAX7S2*%C&ZRZV<
MB&^EV.LSS02.#++4&=Z%+&GJ)Q&)F(W.W$^D/IUAQ[A/*+<!^8'+TXL?MM*,
M?,U%OUX'G!^R, # P9L]3-7U7,QRE)K$,30]SG4^M._S%L(2.V02*%LHXHAS
M('TZ/?SF1'N<_]+'1YUT"T E?I-62GBZ3;JQXM#9X+^0J/&'(I@/#793U'$N
MOUTPW7$ .)5I=V>89%2MK9'N% 6S1X][Q,F$U=2X.TX> * #<H^(:O\.SZ48
MJPB._;H# !6E%.$Y=HDH\F-RF@M:6<*+N"04/=T--$Z/G/N@0T5PM!X !$#>
M@T<9BJ8#0FU[1(Q[(;J6=#*JTOO%0"DD*)@M,PZ$YC<WI_8/FT$*$S5"[F<5
MW]%T4G:[=.FB J&*8Y-WWBQ<UP(/+=.O9"38U%&+<_7>H]=>EM-))P8Z:^B=
M^!R#H[+5F#&#W[7I]Z<4RR_5F5PP+M/TI"G11?;S\58+<^>0[O 1RD2;"B-C
MV[XJ%1_V6;&,'@+$Q$K5Q;&_4QW;/P<_.0X!!.Y,"Q<I&RA/-NP7L_7T-6.L
MC(99^A3YT#A!.U\86]AE9;#R^X3(2Q/7Y\FJ8BH7R/5X]\;LAZIW3^T*3@XL
M<U$=Z07[G\(O(DX/;[),"M:(6!'-:/2SWY#D<PP?:D_A%S%9Z3'VI'0N38V0
M*9_PUZ7G5&I)_ UDT'"C$^#E<N<!8+)K82(9Z;K-P0 9$VM#>6)M;#6E;)IJ
M:2Z8DJB(C<PW#A>V+6T:0@2]%<[D^-^/>%I1)F5T3N=W\H8]C=+7]K G<&&=
M.6!EIQ7)5HA7$O.A*9:>)93,D!PG35[O_P>JL;*J4W$H/^$ GU@"F(AS;)"9
M2,3]\68%>*@I+1KM6@HW<AA3YR)L=N,UZ/Y%V<5-8>2?M1F3SHMUF90=Z&D[
MTJ-+G>KW/[!>U]3N5]8FBQT VEXPE!R&MIJOS'G7G?/*H'KA'A(5?MF+F-WS
M"PGPW?@9>C+P5:<B\#?$1O_T':A'M)7\PY.$J$.XRA,+/L,68W&/U39IMN$J
MX]F",VL[<UX3+E(-D-!8S"E?*\[2/M]=,VDSZ9MI=A'W=(ARX<?@GFW@'T8+
M?Z)(ZZUZPC0;#+D1?.*'MX/#6E<'J:CY??E4XA&^/P^JJCE_ME;/&5_PL2AM
M>%7XWGDU!CJQ.<PT7PT6 2:5%!X /.$1SM5-334C"]23A?[ [V4PKU&-)%Y\
ML:/Z!\>[L.&B!&@?^P!P(TTQ?=ZHBX<4T8;DW4"HHE=%Z)_=Q&O0664#CFV:
M!I5N8<'M1X*<NTYAD[1#N9QE-G<LW!V_?O'8/0_]INC,/M1]L7*6]KRNT.WQ
M#99VP:K>)<*X^H5TRME&X#P&3]/M^$4=]$NE3X0IN@JNIDX_&#FB4C%IKDI5
M97/V,?59\@P_<BZ/TMNET7\#[!F0V\.RU:,(Y!>9XGPWMQ(O^A\'IZN+KSU&
M![T_&Z/H;.=V4_]SW#%P2N5";L(<IK.(BKS+)IJ%SZY;T$[&P)#^^?"SFTIJ
M"4'5P^J0LN$SJFKI!N?'<%&O(PJ[N#H7_Z>SZXIG@VW[Z4.'!U6C9E%;:Q5!
M:2I5M=_4J+UB$ZE5*XBDRZ[]X,536L0HJ:H]TQJA%+6"V F>VDEK!!%?WI/O
MX#MX#[Z#^^SZW=?ONG_W?UP']W6O7AV>G$%-B3=:MD])H2\/;,!+-G=*XRFQ
M]&?P8 /?JF\5FU;((I?&U0DG>P5[X\VMPURH@II4]X4- OJS0$I#[6SARF(&
M<(ECT_'H.3TDDLS6<:]J*\_N)**"XRCZ35* \GL@!#3Q5?3D<?8P;UYKPYLN
M+2&[H0YO)J$<T/K(7$E$E21@?L=ERN(B>3NI!E;$1;U4BE$,YH0[=[8DR;R4
MCI*.B;6Z_ZLJT23X2+&:)^?R'-AO[Q(=TDF3H)23^GL9RJU4VQQRT)_.B#@D
MV">7>\LVO<:!_: UR68MC: 0D;\@E:-G/Y!3!MD<9_07E'=2R%!J^FM0>"UB
MVI%P4"NR%2EVHX/*\:\)Z,:G/I^OF:7)=Z7B_E4F:5CW_D)3E40J(,KD+(EQ
MUP];:XB$:':6F9/8UB84!4B:C64NYP"?_K,/;?[#E7TBSH'/S2O8+/)!8R+M
M0.R?TN/T&V>I#!T#ZGI/KZL.]5)<)=.O)S?L7<.\HXIAT#=X^H(^?HV4:=!Z
M:%Z?Q,_XH@B7_"B!SKV?+)))O;B7J(%+=U7,)Y]5;*-$ADE1BG1+']X^R7.
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M.O?[V<?E?.MXZ=VF-Z.'!GP7* /G@)=/$:=Z#;28J)5.3R/*?UY@8Q#)@KO
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M7V<Q.2YJ<&?LNW=4D]^_+A@$I!/I4J/2I4F7(E&1)B*"2!6B4D. B( $"41
M>A-04!""=$1 I(1F(KWW)B E05!Z@A@BA'#S_:US9]:Y<\^<<V;-_#<[^2RR
MUKOWF\_S[D]YGIW%R;>39<"9F\9FQ@ &!@; 5_H+<(('7#!"0#T   L+P$4
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M;6R2ZM9$@4=/QM@%I33PTJ1_H/T+V7\-6.3_(V3_![#_$]<<@).1@;YYC#P
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M=5I&S6%>!"4_$]=>WHW4M&3^]FWA16Z]:MG]G@#_4/U6D,Z:R1.>ZQD*#^0
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M@2EX"KP2Z4&Z@HFQZRQU2#3)Z)A[Y+%[#YNR9FS%'^_*-'8#'R$D9/OMQ_-
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M@CWIG.*2A"@%2JSN=%$B*E<4MY$8VWY3<-:AHKU5!"+5JH<C[DUNL@(X[[F
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MDS"%WX33>#2ALRA8EF<D6!\7- =WJ6FA FH1]2MK0NJ05K7326CP>R">P8A
M;AEO0(2'>K0F4 '/4JF (;-CT*GQ(NO;N8]*,Y+S<\=>G@@S/OGTO-!.;4S
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MEOM&0$+"7WG1HI( OU.%K8V%%*[C<=-33SJ^M7(ZO71N LCUVV2S,P&Q!E1
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M 9B@2/WO*0"VVX*>G<&,G@E-US*MX(S1%F53QVOG7Q%;N\S6X6P],K[-OZF
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MT&U+*H!-C:X<>KK57,40WQFV9,4DJS3Y$ 91BUD.F_<\JHS)^D@W;62)LI^
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M0E\ .(R6SIFBVI)IN ?Y 6E\S]74<G^L!U]D[V:LT8-U00Z5CZPIS9LO*F'
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M2//)F?GXBL4,[>;='YS;$,[A)GZ-VN6\/Z=8["0;/@ZO'TC2DH.%I!.CLVI
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M"GJ#+^N:B,9];+.J55">8LOD5C&(JXCCMN_5.@:]E/WMU4($<A,><8;'@E.
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MGM9!3)_GK?ES5N9X9$N/T9JK6OV;TKH+TN;-^GZEO6*&&T'!2S/OCWC<FPZ
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MB_K7>[*) $+\!54C^=C&!3'K(X*!G:#[:E4N5@I/O\/3-%U0Z%IF_V2F!KO
M5_OQO0Z^#PI\!45%EB"]X"3 51C1&U.V70]POL+;2$V[T"<[JG4,PA0'E4=8
MM3DQ*GZ:YD346K:2"@C(>9C+/\9B=0,NJD(\>16<VOC!^086NZ;E1WT&6V D
MX;+6]OA&[U.S3](BJ&&.$9N-L\DZZ*A5\QJ>.60O*VSV+H(RR^2;ZC<H4B.?
MT_N5(N-O5&L:9Z+#H@)R7CZE:_.M_=[TYS/FHYQ[+=^'D^=/,EZ1F-E)(MR
MV97K1)2YPU.P 7^"F,O;H-._7\D[+2*@('K%3&7DR"*=^,6WV+##W1^8+#/'
MF$Y!6%M1'9<5O P7,I1M$]X?6@S.%"HN9P4;:M4C/[XJD+M3FKOO*V.]L\<3
ME5D&S4QQTG:<0PJX4119KK$M&'VB/$#WAWEVZ?<CQ@W6$?B9F+53HI,/]^=$
MM]U^,M]@MSKP Y1&$8^%]4;;H6JYSM1X>S(IM,D].)]9I=\,]>-W-""HA%X6
M/7]*_=[1YDF=5YS >%#4R<!V>E0CN,'M%1Z< H\%,\VK=V^ROWUT<#8U@T98
M@@RXZSS1^YC?J[G)C*]]T3\#,Z&Z<FS.5'FCAVW]=*=6GRENUEWMV%^")<Y$
MESQ#F31I*J^3*CO]QR^^7I<6D"R72N6!@,9'L]_8KCO\'KK,%EO\V%:@Y!P>
MSYL;'"H4R[SG=L>OU, L4/^UV^>?+Q8688^V(+D@>'8O10X+!W:*20W^#-2D
MJM[[2KV><N-^[XC[TX);-#,ZW*2W6Y@>\Y<G2(P;ZX6DAYS97'%(L8ODO"0@
M&<9S1*NWN8JAI4/G/26/EE1EAC?P1Y<UXA#[BG(> P,VJ$B<]B@4IC*[T=F[
MTM[>E'98.*_@4A@2_.I^Z(>[]RI)LW;_\6+K0='B\(&L:%).MPS4<,G.FY^D
MA"--N2H4UF> MPF0_5,O(QN^K+O?$R>^!;[*QV7JMW3VJ=9^PY?,\E0PBO]^
MK@&EQWNG?M^"?6!$ELA<T_4+>8=_LYNS%7&Q4#Y.1RE\#/+*CI3ST6'9W@NH
M[!L6CQ6=G)<0HI+5,B4:*SY;^_C(-5/7#4@=OYT3ZRJV\U7.2HYX9'G4,)8G
M^FGEI,"&(6*CS"35=5]LV3LC-*J[&3%'/P=$I57_%<R9TAO46OD#MT9?]OH\
MN-8'9$RMBGTZ @'@=O968)]\0S57YS*LO] [M OK,6XQ'!@21/R2$9C]0?)]
M^';95KY;G_4NNA?3HV/1DKW$>RPP5:&675<WB"8I(&RH<;C00O9'B[UGD&%<
M![Z 3)0I#@:4>R:5'$KJ>Q>'1:_Z5']2_F0\ RF/2H>_,=,*<M2:_FR>YVYY
M]FP9WS])/3#@SIL#.$"TGL"FCCF.&RF#3T]*E*48.R/C![8K\$@)\4OA7?3U
MPGPDAUWJLF8I[5D-UW8OZ3VJWNG0=;EMLV3E9):23F4UJQ6\#!,.OJN&^L.K
M9G2SY="$:@(+'<>T-^E.,[UP[OSA5EBYYL9G(/KE1-C?&'Y IYE(6#\B\L@V
M%SU6D0@I.P[*M'&_>R%Z*$+:H$$;5'PSF4_=A9#^$**J:TT>(T1Z:3/A%*<V
MXR:/&_F>QY4&KU8I(_1?5+\UNW.\ZK>'%O#VHRN.C7V\9#V0B^YY<&[D.U89
MB5,>UT4X3F%,:;9$>XL)*'1,KP47DKY_VW[YG&R?EO:R8.(.,>-.Y +W?&,Z
M1@%8AW<Q,,<E<)5Q^'GND+F8:H3##:Q5WCEV %G_Q@SB'X&/JT1_06L9$.2%
M.?9O4E+*O!S P0;6LWB*P&%>97WOF18"@5(A[LB\KIGY7_1[YW_I5UW*FR>;
ME/P!V0VD<[V1&[_XF$M)S54]X]WK>]N_^&BT0Z-]WO=CWY)2DA8)$OY+" 16
M,M8>?3;QVA<9+S=O6K#DA']62(>?WJU-8";QJ=$NVB^QX-V:!-XW&FX)"!W(
M.M &<-I =SK[0#<*'T(!CS>2.F2]G)0;;#7'HB1NOG?)]U2G%0=!5O.) G-1
M8J9 H<V=Q.S!2F)C,B8&O^&RAU,96RQQ8?B/K'>]AK_VSE9T(SUE11VSK<U]
M]BRK]E$AW"FD&+#>! -C/1P7XU8>*"0;;&+3.0K>NL_6>M-FE\!<[>ZR0!C3
M]Q3.JQ0:&V!*QU%WF)9JJ'T;WLS\1>[9_5M7GS=P76#IEV <2/SGK_=FG]?+
M_DS9TZ.)URA/KS<'N_L@ O8EQ@UMN]3<#.[J1%@?S;2316Y,1OT8YEZ)"B)<
M[^(0HILW;,5HSSVF6;/9\-^&,O8,6Y[C1=RD;JS?$-/H'_WXB\\=F21Q8$Z(
MI5#[3<I.Y,8ULFQ&9Y 1[M9G5LM:KUYT*IY_N!V:JF&.)83'=#=[4Q.P,ERT
MJ_=Q+M*\6W@X(J:NSD6*AO8/^Q. MHE)/P+A/.:ESS"[;@+4L^H@C8,K1U41
M@F*\^:-B'YS%7&C; 5,JE^AV_6H:8^!T)FD5X;U57FZCL"45YV1(J[[E_ME/
M__WK%^0ZNN#SEGT,4GY>'8"G1GH_QLF,1:&$!@R#9N4J.(00CEB8_YFU@AB.
M6;'SID.[5#\/H9 67/MM/)_ $1CNZ>:?]VX9GS\!D$INE821Z'A+/_^.P 0\
MN,VTHJZ@3E539X#X9@TM?: ,I.="6"]_8$6Y:!=2NTY VMZMM&4SN^[2U>+Q
MQ^T\7QSAW;_-(C!\(&]RE9M:0_\K-J3GKA:EE=S:?,FTJWP3G! 5%E?GH1SG
M/D*3=)U\.6V#U3O7K"^L=!Q&Q/AR_]X1HO[B4\((+27*0>5J63P#1HM;W;C1
MF?;Q5Q>-;%!*0?IH96;#[*"K <CLKF-T8Q%6[Z=?D@CF@GQ[U O=-(P%N?C;
M%57Z]!&_SUT4\!"(8;:GA&8X2EL]<=)_Y%'" S5-X(S)Q!9R$#7%\(;F.=6;
M;Q19[;9"JE=ZEQ]"8SAJW*856'8W,3I]N5$%>5>*,M'I*DN>SX-X:2?**T8&
MGS)*83#I,3&:X;;'LMR%2J\%).DJ6M%W6X\(6> $EP*Q"YG1XKHN2UPZ%:6*
M7'!FD+*_@ ]0OOY:C^]SR$ZVF _B;?&$?CWOFQYF!PTQ>3.U%7ZP^\/ UROD
MB2UV'>.B)IDX]ISA$YT"TO[HDHEO.UZ5FZ/O'_9XM1'O']1-9#_L-))X&8].
MAFK4TWPQ1N;^K:-;2_)3/M"F/\L=44_.#JGX/%PQK3I9 (W9QQQX H>_^'**
M;DT\./DIB&R_5M6JIE%D<^2@I-W<D6U396Y:_WAL!]602-84[%"JWWZX<,56
M7:[%&!! P7@MA9BS4)^;WI#;\NRRS=P@DP8&%R &OK75H5(;%TZ\YX1Q$YXS
M/:^B%V&""&I<F,0<2RTSM $R0H08O!9)BYTI;5"[W:2>4[:Q"2GW.E]OW#K)
M6=MPA@Z>ZXMC2!Z+ILW?X^/'.0CPW1P1U&"'C95!BVF8^/BQ+U6"_UQ51>S6
M2?+%MZW#:QZ>\A'BEN]66583=\/8\/\C^/7_D6"_9OX34$L#!!0    ( ,F(
MB%0'.)DTN'0  #-Y   3    ;F)X+3(P,C$Q,C,Q7V<R+FIP9^2[=51<P1<F
MV 0+'A)<$]R#NX00/$ @N"<$;5P;=PC:P8-#\" ="(V[:P@-= >';B0XC3:^
M^<W.[LSNV3-G9L_^M_>]^_YXMZK._:K>J?KNNU4/?Q[6 $\T5-15 %A86 #K
M?Q?@81&@!,!^].@_]S_!^7?C/L;%Q<'!)<3'QWM,3$A,3$1(1$1"^O0)"2DY
M*1'1$ZHGY,\H*"DIB<FH::@H:)Y24%+\IQ$L[']U<' )<'$)*$B(2"C^E^6A
M!T#^&'#]R (;BP7PB!P+FQSK80# # !@X6+]%P'\5\%Z],]'//S'!(1$_PI
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M5!%P]V%6GOSV^8W^DX4@A>/9NJGFS1_:>-(ST)=A#P#B P%!6>SUC*2(_0=
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M!=\(25\J9,@I'Q:"%R,]<N2/:)'=EF(Z\U/K1?7)P1+K#X 8UV\V27V#U \
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M+XJ4D:\&SU$O.O<V&6V0,57HO5YIA9BB63>\;F>A8/LG5ZX 2>&8!X"MJDY
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MD,SZLNI@VV9Y2KF9V-SY?I>YX)"P-FAT6-%$/\^Q/\>6;6L_807_6+X>331
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M,FSV_,;'15ZSU!7GO3-6:\^>=OLS)<]FW6VGTP)W)[.-=OC+@LT7"S^%.(G
M0TGR.XTW_BZ'<PF4P[\D%31P% R[6N98FUNCW><?3Y2 33O70ZF<,OTBI/([
MBC/ZGR4:"J2)%EA,O.-8\V?X%&EJ*/YSEWR4=>!C/&NFLW4.8+G%1%:U)HW@
M4S(?K=K?<TYPIO)TR*0SG:W'J7(JGH?Y5C%RKY-T"W?F^5*BRMJ8MK*/-/R[
MZS\7RJ-9,PW&7Q:SPL)DC93KT62Q1R^W9VMM A]]3?)U#^_D?8;RBY+EK OB
MG1/3LMK?\[ [GJ!MW08!T*.N[KQ+8B3R1_HP%Q<UY1E%>1O4UB_)T3/(,W1!
MGLMYK4V_WI\D>]4.\D&A=]H4B;<5]?C,&?RO_Z(:F>-6G_H<T3D:7H,C1%-L
MRA4*'6N=Q,O^S-?3$.7=GY9[6(J@OZ\:WY5T._7:?-\)J,LN7M7F/[!\7/H.
MS2'O$ON<>*M;59X<PZG3=FS12'U\!8>CQIKC4<2]TD$#YV*+H,C>-M(X__(]
MWR;WJV/EUD<#%0PG(O'60=GK+S$<W=%!+]&L&G!+WT*-&U[)AHY1)C?[7PO7
M(@;A'8 O.]+>*IHTS_"QN<\IVRN#%&/-.E+]OYF9&:?S,(8'WSEE??X42MZ3
M185EF_CB*H;LI(BX#"%Z,]YKXT<H-I#B:K0X@C][C;9BNO6_2]^"=WB$(@\D
MC-MBWW_-^IF4_M6&9@BF('V-T;$M4R&!#[?:XM.KK,=#JGA .50K"83?-Z4)
M\;U.\?7O,H.,UD+Q=T/8&N8R;K5<1*0B1@13BO\.>JPNPKH2C[?[.H&#A8"S
MA,#SQFF?>=KL?[.L H\O6$JOGW9)%5_L*%.!]-#Y]@WB]]=#%W0KDI,7 S>$
MDMPN1$_EE=,\[E/Y_NKZG?HOD)^&"[U2O6,V(TJ'"U7"E%W7W=_&OSPP;:)Y
MTD6G$M+[:E*D_YXV<Q?HX4<D^OPJ5T=YT&\: WY]''R;4_!MT>6M"]5O/-)S
M0"@/'BAK@,2H?^4Y[*BVM#7=8E'>6E5A<%=DH0/5&Y!1$1;TH<*I+6+*U2!2
MU*E#\P$ KY(7#WH%VT*[#$CKD_L[=_,^QV;L04)EF9&,$D.6U*V%YM&&]Y.$
M?9*T/:C(5TSMQ]47J.,'0-P]NQ7HT8V*= !O7'&.O5ZJ@+M@Z3E$$SV5Q,?O
MYL/<,(S3)/S*( L0MEW\KZO8,>1K<B^1U,.\29:G6D^6YJO<I$5^/,?_;333
MQ34MFAN8V79CHQ)A+NU?&)HLR*7HU=M%&43+1(X>@M3Q0W)#JW3X3I;.KH@^
M<9E;DP(7<*0;4[%=$^N?Q9A;ZU-=1[4YD["^T2B@<K@IKHY!:FG .6*NBI1^
M/_(O(AWNE7[;=OK6ER*#VBT['%YGMN-'%W2$\\NBV1E;#OB^_YWZ^@U-H@9,
M2\)$^KT>['KKQ&0Q5JF[>)":,8<>B9?5/Z@K2-N#DPR]TKVQ&=VZGUU]QDS+
MJ<]\S2%])SL'$;C5]*!?NS^*L?2 =PMV.[,[=#N]C'/J+Z_$OU=,3HKT\QJN
M_!:/0Z&K#*#P0<9S=4*QZ'G*8HFE/:P\0T:8\9#'+Z-7A]LFL&\TWVGE!+R5
M=_BXUUZ0& S<"IU'K"=V4W;Q. 8X1_IFN_XCYEW.'IO<^,Q@YMI@%)IS0-=1
M'*4#'?#-G/Z,5%X#2%[;=<L@W_;Y)1.FP4V[M8?G-EK8==O.Q<T8[ =>TC?"
M-&3[U#DYY8"#1U#L8/?)I'FW/<,.]3IU?]$HIO/:X]7>!DS\K?KS!X!J7&2K
M:^QBF3^(CYE/+V+VK+ZEI5>J^5-RQ;I5N/I0L\\3GW=C/UJF7#OB]SNL];0X
MO!]/2RU0%V;ES+D)P)G9*1:+<  ECQID55E#;<8L;M>WN!83"Z#G>GTW=-I.
M9LR/JZ=HX]H#? 5KS[ZX.G<<<Q X8Q8D*8E7]'8N/FJ=X&5KCW1U[NXW"._F
MONFV-6@*4LU[-ERF6K[ ^V='ZX=9HJLC&T.S'*[[/1K*TU:H2/ ^;3.>3YD^
M^-N6_VO1)_7DPWC86,EG1PVQ\8^BN$?<^-'=!>?VX\8VG:G+OIF>Q%DT!I5,
MNPI-16_'%>9C=BB2(I?H]A+K>5R&#19ODWBDW<TR7/D6A<'I^3WG#'0.#3JK
M9SCK[:%)G!=%\30 +Q_1&0H9_^'6*CB25H#8\;F][FG2%>OQ8(!NM<E-DN@O
M[D#:+OV13>AK>F;_=,F=1715<31;2K%;#G?:EOFQ:LC9C3^+76*!VIBG#L9@
M',2RE)28[KIZ_SW.,$/BR-F>3T)XND"N9D<88V-9L$JR236A.A=H>!];*]<.
M:9)&^*/I^S3K'#R<!(G5G01!&_&G],:TM#0G(CM6_%_?QS8Z.@=@>& 9[),=
M.A\P2<>'9,F%^"]%3RBAFL:W-]QDNCR)X85*,VC(Y$VN"9^K77,VG=0++_HA
M%*XQD^JV55DA@5B]G2DM_>:'O&<["UWZ=XU=%/]B+R(T_8WK$(MWOJN(=RU-
M7\WJ4.S2<:BTI!_]/OIIG]9-K:7"AI<=A3GJH.U</A"[\\5%<>O%,(7'$.]9
MV=)5S[=X[K#_8=I)H4'U-E^A3^&&CN\_J:0J>9S[B15F=,606WR!2$L^= L\
MT%9;:E@95L3A3QR>GARP9C1NU:!SFR_Q7^HH_*M3V2&"_A#$ZH^:PEIL*EM;
M?0HLX(%OTBWG5Q$UFO_D=94EAB@=:%S0R4N@RQM6R4(=EC7?3Y]%VKI]V_WP
M;>:VA.X WU7\ C_GG#]P72=:UKX<$SMX^=?[Z"FTXB)1GE:=ZAF#+<C9YY?V
M45\-R&A-OA:-/3 \U$6 3JKX'%T[-%HZ=RE[.D+VRT1MW$>RNK!IJ'6=GM%T
M1KNQ.2/(![?1T4.N7/<=Y4T=?AV(L0JLU'M/A\$?9.(P0DM$N4RDFJQ\RWWC
M24.\S99<(HGLUNM@=O&J<I0&[HJG]/JZS(Y]ER1KYK]&C##_Z(ZXU2G>;>MH
MOGB)E\2G*>KH'D7+D*P5O+Y^WN1"7F=*LP[*Q4)L]LA5LE6O[[#]=/R0^F?Y
MC;ES>D'V+L]F4D=.4]O?8Y47Y@=CUTSI=QKKSM[EK5$DN5F$):UB4^HH!V<?
M]4S$%M'HZ#WKSB3 IY:K.1DI ^3*F$O>?BP"UA@Y7JXK]J\UUY$Y:'#75QS!
M7J6HQV27_7:MJUVW:@S3O$;!L]=<-$Z-H05[$\9]&T_F&0+>T3-J-659NY8^
MK7D[5F1MPXH?::S5%.QQ*93OMZ:R5,ETGOT10OVYM#7'4\D#:GSZE_=#F(7U
M8Z3!"'VX_/PDP%69H#'5AK>RR1H0RQ"(M@RLV/F]!"I;JLAV;MB,$!!)#D-;
MB UD>6GY;(^-E*E,'/-R:#YS93 ;C;4Y%?9XY2.'%>18IN1!E4'$_[U.7KD/
M<EK7_2Z5YNS#5L,X'62\)0)P1GEZ-QRKMZW7F#OQB3 4=-6+;)\,M#+Q-OY
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M^1_GW^8TQYRS"O9-5:C3WAH] !!6*5GU1(&MWQA9?76O<J[J:""$&<"^K/Y
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MK$&/I<WG"29(+00/*UDT'\3=O-F]WH(P1WF;U>;X?*L,K#81V<ZC_"3)B,6
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MRSOO!%GAUW9Z6AF#F-NJ_T6W06G-@H[O*#+ Z)Q>G8Q0ULB74N:!/J^FG]F
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M(J:;ESC]M+O -/C7Z!.,H%E\UJK#KEWS6! ZA5XRBH9%US/,/><S@J4&0T:
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ML:5; ;^Q1^=L&0Y2M:@[+9A=<JFQ:4B:M\E::I3; ><O'_-R-^5$_4 ?NI>
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M[(26)F0<2!\D_"T3&B?%$4,$"/Z!2D+1,XCDLBX_F##6L=F_8"'>FR7(#34
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M:M=HC9SA1P7_OF]C>T""?3EC ZAQC[_X^63R):G]=5= XLS_ U!+ P04
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M3P<,/"83Z8 H?SI@P1J..:UZ+*R* ))M@30M1W#5V-82(8$T.J U;8Z')-?
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M9NA+-=? AWZVJ'4XX2XZNLGXB[^/%NF;7&TZ_EE38"++!5S(WS<.+LS'C89
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M+88N:*Z/-M5Z_Q22W14BK=:L+O3N_ 6I4M^L4WV7#[P!%Q$Q=S0Y0'\/$73
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M&[UO+GNTQ03'EVJ1 #=#XWE-/,F]9AX^N>A;="G CLS<HD:=[IG":^Y*$IM
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M</"C+.0< !F(V!NSN'60])]F24Y4!^X>N-K3[F%^B:M%+TJ,WGWOG8QW/ D
M:B<?IY6X1CN]L6*&'>#P*S77?KNQNEXF;9.3<Z^K>HWC6T/?]=C%4SB*NOC-
M+11.@C8F:4@ ?@(1K&./OV.ATA',-(EL:7W^>:EL5-@E*>E@X">]<9K7C<U-
MVT#>B:^S7$L96J_21^,[N9U6S)?H'K"'J$NQ51]>YEC_8+N)#?X5*[T^AE.>
M/:PW"ISHV\)7@2[B6P'.*H6JTD>]GF_<>R0C,&T*6-UR;&B'S[):K;/VKXBG
M+K&L,DU95<D"E!%=]ES](SZ1G=SNF'1P2-0J,J%G\W>SNBVY1]1_%-DC1J.N
MP'/0:O'07J%3?!9,,BV>W/JCI9Q3>NHCX+)6V)-<!0YH5G;A8M,\+!M:Y]\N
MKH]Q(1NH>\"KKJ#IK;B<DJ[UZ?3U8(?.,&ZQO&?B'T=J>&WA*6([0 Z^U4KJ
M3XO9$/-B%A(@5+SX["F1MA3U5!M-KDR)\VQZ<F0D$L_3W&T1>_9/8*Q0:VW-
M_)>W,=5N ._9I=FNU1KW+F=P!*B2HV.Q6#RTRWH"_R[$?YU/_6A>M6&!+L/9
MS[A#>)N/L34TI[VV @N!TW^,R?CNY!A<;\O1? 1]A!U)V#8^?1,:L&<14_!@
M63!5)M,JT9(WLN\4-K^Z!JV+)@^2O4Z=)$P;""V)M2(!/N!>DD5O?A$)P%<J
MODZ M=&.T&I6O7%8^)HP"WL4?0G8F?,T(LY*E5CX=TX;+^0CB%G_^ CERV'F
M=)6,2  V\ @LUDYG"NU( MSG.?F:C[."#JR39=0L'R,)H%U:_!YZJ0,B3#TC
M 28JS>"UM34VF.9P=CDZP2 17S[.#&<(,;#4O;K/F02@ IF]C[6) WTQ+"K8
MI5[H!756YA./&:_0DO\<=%O9%(&N8O(O7WS&&%]"W?U)@'*D.PGPS&I6!">
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M$;[%LGN,O0O'IQSS0.?8&0E <%XTL1).BQ\B&S,/"3#@AJXG?'I+ HR?7SG
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M!2"V%J?1K&#RF;@HB9WMA+/GQ8)<5 8LGIG-@NO?'WKD^&MZP_2#<"U[)B3
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M& ^U*I RP;Y\ (:5.Y%S")67GUZJ<OBAN/D!/'L@%YQ)ME2!="(9J+0U4DF
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MK5@Q9T]"O.\O<<R?(NL2A7NVZ5MV4VZVEG7F\&"N!E,.?LN/XY>+-WD\I$D
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M:.3SP1=6L\@0;J0NJ>V;@&,<^GJ%S5:'*/8+)$MNRVI.:+U;W]SX3@GCE=N
M<+DOE9CS"#D0Q9]082]H,/'2)TBZAQM57Q_YK*G)HC?FKOG9=RFO;JXV_H\]
MY,]FQ#2T^%9=)&/G]X.TEC;G39Q:0QF ]<KO)>V_)?QX8'2;GWNY+GA03S&U
M^_5T2-<.Y6U]1RRTB 4C.SH$(F0-!8Y1*P/&:W9G*'XY +6= W.FJ\0%PDC)
M8K9K#\XV.MYWE*.[VI&E#0(]B#$NZ)-X?,.@]O&VE#]R6E.Z%/GD^#-2B93Q
MN*D#!ZPN;FZ,Z>:/(^1WI>9$S+=M\GERKZU^>L"F](78O.E1I%'Q+@V;Y?[;
M7BLE8C6B7N_)<;,>CP>;TV*[=O>17EFIS89ZW<RUIK#=2_<ZS,U[&'[Y'U1K
MD&/'=U4=IR<(]E4K[;U50^QV\LE@?M 5&II;)X[JGL%]2DHH^*F7OH)T_TH\
M<KN!'SKRJ5>=]YFW9"@_DZBY#B4ZLNLH>G6Y!!1#ABVJQ:^$%^=7?G!FB\*O
M%S0YX3J=CC=]-MU2WQR? %:1;/^]>=$GE8>\#2%K)!VS_Y^#EJ,T#^EE^@^I
M47I,5+LI_6(558!VG_+?OM5'%-]%##/%=JUG7O(G^H&B(DQ>)N;CLWW%\\<C
M/RX,Q=S4'+2$;^M396E&E/^.&Q_(Z@J^3@RN*:2DF F9E59GUWK*4+4-!"H_
MQGY\FN9Y7$&^1/] 6(P?+,0$EQG>#*HHK=+TUT'JTQ*#:J8[CB_[D_=.$50%
ML47O&]8_ 1C/6 V*GAJ%O!KR*;Y^S8T^E8MJ@2,<_:(@(=NTRY%H["@$V<P,
M6LUZ1;\^,?>\)3+_=4=0\P@?P[N(T49D*E7\E'$%,*<P066FA)P [A%J6HDB
M"?<<!)T/RDOXKT^T>@P'DN:$^"?,E++;]+\?/?I_ITL<SX(@9JLXFE:S]3>E
M/?%4M9*'0YZ<  KS3H5KEW3Q6GZ'W?;_W#1ASA# W4>)6*Q.JJ2,4WO Y-4I
M>$/3^*<7Z+1*6CZ;]()_1MMQ58M$N]]C5ZXSI)JXD,6L'%G<4U-3."_BC9RN
MWCC5[*ORQH1JQX.2DGC=NP/1G5ZAQ.6PL;!55(=X\'>'"T0,C<N5@$DXJ+D8
MH-4?NZ-S!T\NK)O5&EIP;9C&R#]DQGN%MG1N.5I?A!;OZY8R**&YBSM*?!'8
M34]XWHT'U*2]*Z%*N)^7#>_H":]O.;G"R&K[JO]TMGPN+[0AUW1#LF&[!;X
M)TR8:HL"?!7ZY(^:ZOYNXNKQ^L%6/^$.@NF>R<%?JNS.^ .8GLOQP AB+>?6
MU@:$RU7U3-P"FT\4^'9P7YOO'8%U3_C"%>]1G=>!SW-RSHV/[_<MVI9F@<T4
MIILT=C-^>M/^V%)+YV[Q&1!0[U1G*I1<*N!!US)]YA?03[US,#\J:R)\#J:J
M]M)G62I,T#&Y7O\X&9WX^PWB)F6X7$)O&'?K<KGME!S'!O>-_UO5W1E<YA_Q
MMLSJ; W<8@W&+LZ!>-^_F VX[\0WHF59[/;E$B=QPE#K,8_^<\>Z&=.UOAPG
M9,W6Y[4_%6R+0<K@.^2-JB?5:A>&--B:Z:0'Y[6HEBBWD6L,G'3N^20RA"^X
MK\,A<]74>7ZA]?EK,T='6V3.F7'GH-N9PS:-S^+K6S!(W7_+Q-Z7#UM#E:P(
M])2DDCI\.2KM!"#2['(\JOEW+=?6G>);\%&Q@"K^[TUJ=(O]#G6<60_].M!R
M!; :JNQ$-,KBWDGHFCFCGL47-=W4M/O31SA@\\VD#*$CSJ<M7K%6<=JSZ,\*
M>.=/\[KW9^RJMY$; Q#)7Z)0)7PXC=LQ[R;[!/6_[5/""<N6TU3&SB<=YY+Y
MZ/UK004_9G_]44J8\X9,#_-_N91.M,S$%_5NH!P;[0U^FTHO_RD&]*DDAC[6
M)U:K>I7@\?%J/.1'_ 3PSKZ>=TY'1V/S@VM,JF=2Z$P3#N2CY>WED<GE_6J(
M=_#?("T2Y3&42 59JU)ZRV,.4',>#$V[B=Y;H\N9^/Q0I=_$RZF*Y*BMTSS#
M:2=8DXT)C,AUT#S(0S(7]>J^&_3H<$EO@YW^T?H;W[4:)+:7ZPQ![\IQ]@$5
MGN @F;+<V<&+(A[_B 5ZBGUE]I(OT1XA3O//&X@ND5>SB7"R[X3/@C E?<V2
M"(]\N<.=B;L?"%.3<&UPWI]FDUEQMDN3R)Y>OR4R/[9ZJSN154)!"#5O4B.=
M"''@?#LO7;#RH<@5**IVC#O^M3!G?_;QJT0%.;9S^8X7QRH\T'.-06:G/+.8
MI<=%\ONT6,/GB* 2$E.)"XZIO6]")\3K333LW?;$4B:\[YI=JW82.WPG\M>1
MD+M]K@IYQ30^EXFR.6.*59/;PG9T9-VUF:O<_5*;,*ZTREIOA&5'OU9?$?S%
M]>Q=T&W^$\#61&AGC3>[PY-RK92M8U^5 J-LOD"MAP_M4^JHR:?9ORYZV[V8
M/G!$KO<J<.@'8F(JY0LFGU-ET@]Y?^KV;=518X]_>QM59C,8-#]M<YV]QH**
MZ_DI^S_7#=N7[L!21O W"_A,)L63;IT_!P!9!U\G%;XY]Q>5)033JRTWU'8G
MHKV!Z'VC+-2 EM'6!<FPEI:UT/ZXV?Q0/;6)$X#GGHB#&UVPHZ61&(G&H@3L
MR2W/N-'C'2@<_J 5%&'FDG9/59SCG^_[MN&S:;=Z<%[4&\&XH[7$AC9J$C=D
M>HM%)KJ!C=L6$]F059'>D&3)BZA-475W  'I ^D?SLW6]]UW7\!7!S,C],C4
MNZU9773AS*UN99!ZLO;&UX9,NQ2AMF\SWH)*O]/ZS'0]<.%ZO*<<\9FW%N%]
M9ZSA0J-<24<;6.N']I/6;%*KU87S:S?YG4:YSBR?PF)3WU;(6:38A&J[61>&
M [CW+'/G=Q+]RK$ABJGU$RZ97:CB^N)A]0Q=(/ 4H?+@2\9T]M93@\M?8Y(?
MJK/P__BZX/\O^/])P4(XWAOT[ 0@OM"31)/P5:2K.*0: A!F/;FQF2$]0$BW
MOWEN@NU92J YU>?]1@[WY/.DQ_;O<@R_J:_YA*B_NO'ZS#"8&+)4G4LL^,:3
M*=Q%<R$]QE;)H8HJ$68/,_>#=D<8ZF9*NZ(NWF"Z*#=[K>A'*,6*SL)2M;G0
M@-E67&)C1DA\PW T8JXX> @@?^)EWM;DNYKL/IS=35%SX.+$=H@??]9W&8W+
M.76IX2^"?\XS3.EQ(A\TDEP3U%@%8 +?*)XKF22QYMB5J^$?[,L+:3V<,VK4
MQ( "(:N?*S1#1^:WUB:&-\O*YN8/P=IP5,Q:6>2[M1T1<NT_IQ/ >3I2F=2_
M71M$DAU<8NO&Q.3PIO;Z"]RUA<Y1_-9^9/R@6K^O+T]+>/SCDZO8I;7:_LU7
MFESG.O/1M(D;.=K<.O9W4],:(&XIQZS7QA\OYHF$&7)9Y;C]C[UB?:FF] 6M
MM>UEZL--L@9. +P6KJ-;V.^MD%!L8U@*/1P/2MS=^19936BU>@\I_T;&-IFK
M#X;)]5@8-67<.WWD1G=]XD=W!]') ^&+K ;F4XGO%.5U'@KOIH9H=A#;&US-
M6FY<18-SKD4'7IAP[DWK =SLF9I#/CUN:F![>PJKC?&:-*GRS12$_\,)FFKF
M6W^>&^U]M:7QEJ@)0J)[BHL59- OH.O?-?Y!=?$/)8+E(9T6.F<(N=&HUL(<
M%E)V"5FDK=2M=4B%$@R%B+*9/CUZ:_MVJU3G^0^W9T%:&[9N+DI?9/^@V7F3
M 9KV3'068;T\8LUMTKG#,*1*T::>6-W/G 7CC+Z65M.$%S:#+ML8ITOX-YTA
MGG7S1DFH#9<P\:RG:<<J/2%-]_$UVU\ZM,8/CJ4GK$FZ44F\D0?K<$%(FU94
M>6T5)A?J63YZ"2:6>Z/M$^QY^L.O9YE2W4X 1$N>K+[Y:Q.^"Y$XVRRW,>AU
M8'4R,'5 )+<8D64[YOIIM25'[</-B?QGGJ5M+US_S8DJ^>J)G=9JF;M&"(.>
M&+1#E#A$UI,E.B_$^%QU*A_@[&DMCB]QM+.+VB]<D&H%.\L+_@R?>4_+ZP5X
MDT^O9VV:=,G-TL(CYUP<J:&=AWTI(/4QE"5!VVZFNI"</V+-G(C71.O[.00X
MWWD_S)4#J=Y7!9Z*5[5M>H5OX<8;Q^X@43N22!'P^(-ENH@R"*BF7>IK.JPP
MITI-;WS2FK +9!G9%H<BI(RGY7)EZVBG#'S.D=@4CWY207FP1: W!1!N'@"M
M'I%8"6C3P%B?E7IE&U.7SF1IZL,_3UQ!Z=>^V=Q=84Y60&C3+VH3]Q:?5%?E
M-W7G<B&\N_59/27-N* :&J\\6/(]_/%1%<QF-X8E#U_;+TRW?JHS'0P!O)94
M+GS*'WPJ5.&]WYM^;HGP$^T[V@E!3B;-6!_OH$IA9=-V+:RNWQ*4EA4@>%CK
MEA*@!,-WF7S^'K?]J(&21W5!1(!.?QQW&AG6;;1QWOH\-YJX%Z566E4M-J$W
M769:NJG5P&G<NF7>E'5>F^]LO+6"L,WLSO.'9F!2!?TB"V]G4BP+ ;(01;\V
MV9A:M*&A9_\.6W^M#6-O=+?VGQUJG3"^E_V[/]VOK]RF\%LWR9C&S=!%SK#U
MR0P)I3VL 56:GBN.>5)IL7NTT; %L[#N&'+1N!$#\\QWDC"N#QE,7KTU'NJ'
M:;3:62NACX@2PP:<"O"4ZHE^9K5M7O/- 1@CZM5QEKY+JE._E^^UUG>=S&[C
MYG6BFF??_3-<H'''F47JUREV86)$E(DG@*A"+-J7=1A;XE0(51&$\@&KEYNR
MJWY#_?Y(&^A(_/C8I=,U]LG@3&MN'&:Q7(2;$E2T_D8QLH-_DSEOH[4_V@<&
M7(-: V% !<@MC@:_,95AEAE;1/CH8$*!^0B_,E.Z\X'C-)5,_8EQJTG(U _S
MV8O&[^8&J6?KQWB6M.6:I>! C5"HX$>IN4OCS)+9:J:O+(&]?#^L/^S/FU_.
M)6CT+O AO8]S?;-&63=%6!Q%-^AB4ZI?FV(E?LT80ZOL9F2RN<Q6ST.ME34%
M/^\NOM+1@)P&+IL2_PU+UG\9W9F)JBC>[)#]2A+Y<!2W 2LVABZUV?."TI=<
MYV'B",]QJ^1E\5LLY9$Z'HA3GRJQA!&AE(#'?885.X_T:=*H8$'TF"_XCJ;M
M@@G8Y;"G@L$A_W['Z>T8UT<^!XDO^/L]&GKBS,(4AW%O=UWBR:X$UT!H5TF\
MD4B9I04V!-2A=H)G=7.KMVE_$S5F$.BD^#F?,9SP'HA.GLUHJ6]#_0F-'WYU
MGHTB%[=EVY#A^$M$=.S D6UZBV,SUK>&'^ZK^5*>M1OL)'"[U5[6V.VM5ES$
M:GC(&$XN1_&_0?#?#N!J:*KI8L@E8>F1"SQX]J7H*"<=%4J<[BWT.$3628 S
MWL=M6=XTH.K*PLH;Q\Z]&<=>!_'F]M1>6\7P99M&5G%M;;#6P&^5=7QZN<_W
MS/G]Z[O FGS+=/Z[WY_[G369'SGO_.PG[51EPV,I9M\P#5+]W7PTEFJH[?X]
M^0-_5-ST2U^Y4H?^H4A/2><HT>N-%]A&"&E3'_+;OM4#M!>;:%S<'>*G*1S;
M"-8 C2%5B#/=ZG0Q4]$=Q08/['<%M=(U@7?/F'ZM]7U4@5.[1005AN[)9%/,
MZ"P/H=6_H*U%:V$',_IL%. RBJ1&"Y8,8$WHP6FD$^79=3-U!K*>**N&\R8-
M/95X7RSXI?$_@:%84KOHHEA53'2. CJB+Z/5,NF%1)99PFYC@E'7H'G<P!^]
M&ZB,6IX6I]^[%F$#+Q1YDD[3TH.?.T!X-.UJ9O1T/K;HYU*8>#A^ 93.8J_I
M(%<1)M<;$1C\M;+'@)W!#7@UTA.@F:!!9Q$%SI<4;W$BC'B)0PQ/QAL'87K[
MIFU9NO=8V@(ABE)XOOG'S<VM#8W[\WS9TF@[6FVM.MK@]%I!S>&S&K2K1_>U
M1E*7^!MTC0T=V24'_LAO,#2NO9?@3Y^WL)RU4YI>*0U(^J![JB;"E<A3H&$\
MI(20K"R)'4GP@%(;BE//%7<.#\7+&06;O'7303FFT4F>5"C(LZ!9&P> 5(0*
MLV<,(YVH;Q"XSF!YK(Z^I#Z;KS6-K=0#N#QX0.P]3H:X+7]%% 9I02+\X8S)
M<U\#J;Z32T\2>=VZ1E$WV.Y1LD_O%#B.9B<N$S"QJNV7<7:-E$A"B\X3CA"/
MQKST<?5:HZ;:A?-;@VM0"BWK>:UJN,:@!.S1;PQ'R&(^AB>8-[@W]QS-UZN(
MIHTF:?10&N6RCO%O:VUME7\Y.$[/X!GX_K#(7WOW0BRTZC!VMEVF.VD&UWL"
M$)"G.3N[YE-4NH\.(^#P'54(J\MT0G_LBPA(^T1^RT0^]&-!FJ6V>JB1:\)*
M:Q8CONMJ8&8(D;@@@%B[.[Y"'(E<9/5PY$?<Z>X1X4J4:UZ)P],AV=+C2UB0
M@D)5BON25AUF^M=TR_EI#I##REN <$EG+N5Z+:6,"MI88/5$\U[.*&W\NQM?
M-BS2JL#:?ER9F:D-,?IIY/DRB?QX>8<_\=9V^=.N[P.],R> 3ELX6J98$I\1
M#E03/-\L\&SR.38=;Q!T8THJ%,3T?H [W[#XWL0<?XA/2<B'S9JFK.;3!II/
MV3*;:JBIIXC@>GAMMU$.(A-%C<19LG=W@&8M:'<EN4:R8;]CVH^\- #7.!_'
M#!X+W]7,\.[5)UKD\BN^E?<%LW7K\4^Q]J)MP<-OT^N+9M]\SG3)0QYV6'_8
MK8^FZB'NLW\2\>>(J;Y@J )P)#+1N,=_C-Z:RN@5@$=[-E:I']IZ7XY8NK";
MOC_R0_&*W3]47H%ECIH][_<_7^/VKK^6P#M5OPFAR%FV% 6/6[8R9CIV#QL8
M1/WPF]PYR.7I?S-Q/^,-[*N],N$IDWGS'&(3>-^\_KL?/"$5>GC*WT1SP;US
MP2-T45):?T1>D U<Q\K9&TYF]IGP=R=0U$"2@0AG/=_Z.?5<GL$ ?[2X_R6A
M'O\7E IR)VDM:K65&)7!VQW"COB!W3-LG5@ $U<F;\RX'V(/]V/E=Q1JQ, V
M[]WWWP9JK\_?I1K$<,T$/ I]&=P?0GRXM8=G6&JBB6E%13A=KA#R'S,MQ\^=
M@^O-/?^H_^NCZW8'>.B"#*>2>UVQJJ65$D6%W$-R[=0_1[N'"Y;R$(A.JM*Y
M7N'1ZON1V!^^BHH:\_FN\\^Y+5LZ\^;=\LV\HFMQYI]SO+K^"[G5WSXTR?EW
M,"=QRQH!OQODL6![9<[0J:;0@;,6]R 9*AGF0G72G1OZE7YMR"]]9/Y^"C-C
MD$8T9C$_^&9N3T*Q*2'[_-9CXLZVEF5[ =K5;%)1L7IMRBGTSH)[#IXQTF<J
MQ973_BI(6MQDN"T/,$@).^V&KSM06%<B.9>P<.H:H#.#YS[@$[.7?+"5%BLK
M'^IOZ7P,GG 3;\I4_ZP,$AYY?H-=*!'S,'@ P]G(]FX!T"#*Z9$_Y"&0B]?9
MJ^NS4)R;'>18Y B)/!^PE4D*^;5&_H;MN$$I[S<FG3KI!#V3X9$/BK &[7:Q
M4=4WP4FE)1E0GSXW&'G3PN#/9]7T6/&4I@L5..3=8[1J;A3FBLYMPE]B1WTI
MN- C74\(E:98*2:06..#=TL<OUF8[?*8I<*F[<' U[/+Z4KRWT1O/6SMT/J)
M6:S5$R4)';W%G@ N(V''L87\5N:3#FL/6-S)+\;QE'\A;@OBG<<U+[_T"-U_
M,A28"D4Q_7<4IYP]N86X0&BG5RUJK]/,EDI58ZH/H/Q5SHGDM<?Q8"I7.D[?
M8Y\0F6MN^2(#62'P.ZQ5_3W#[OVQS[A>O9NG7>_[!C-ASH#.#C^[95O=PA.*
M;__,BWL(L1GU8I\ 3V7-RGR,EU3:?%C++W\?G/8XA5FJEE!#D>M+E0XK+B,Z
MQORM,GV"K:(!7Y"-QL<%CY_;-!Q0;R::EB"<[D[N?!R^^LO/Y(S4ES^A>B/Y
M+?IACKR5P;K(J\3#=ZI;T IM_2LV4GB(W<Z?JMCO;@ONLC;6RBF%97VW)<ZW
M_OB_)J8P?ZM6[%QH, [7NXJ\-866R:-4=!\UQ3;P^$[Z#)I.IJSB!GT3[;YH
MZMF]JVWA__5;XEES]7 BU['<<B[/?ZNNU89=^_2N-L.%$9[";#T"Z*,8XLPZ
M#ERX!59H@E>@-2P3$+"I3.W F.) DSP-^*M#7CGU"<[0H"1#I 1AE"()'&_^
MB;Q-XC0F646.;]V?A/M4G #8=,8=8ER(%0,P!2K*L4X+\=RZ(&&*)+QNI!SO
MI\%+,SO5ILJIQIJ+ZWX:#CK$G2QW_WTP\$#@$NI0H&AVD,N]VDP&OX^\)<P
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MGO@OA+$Y"1<-1)J5VQ^'3X"AE:/>7JM\[TP _SZ;5+Z]_+B,B4\-:GM<I2>
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M[&5C"OC-M:7F%Y')YNEQ-T97CC+BD*Y4W:W<QI"88M*+8/X)NB12-ZYK/\C
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M>F1_I=;->?AN['W:#:XQ6A3Z6 KO^A;XA5G].5?0M.Z-5_3_WXOR<WKCJ"M
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M,*(9B385%3*-="X[CO9\]DY(?">+<W@QE>-4Z3:]WO^+LF!-WO>YUL]O1B_
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M(BK6XM(*I:MA,:K&4R@GDN?%A1/MCB RYH%:_6-ALG[2\_BEKE4,E1$@S&@
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M_>/DX@DY&[&,$.BNF1(63N4'QE5:6&[K.MMW._M"8I)'73#+ M4W@F3V@GZ
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M(%&G1P9X1!%R!8@L_;>K0*:,XJ0<*-U<$"Q];/%8=!';7YSI/Y)0J>])&3M
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MR]F, !?/_H1E7LCO36T$<PL@0 *[R.E9-'KG#)9V;S/FN(*I&>-R^+?YK_C
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MY^QNT"6?/,)A?9Z@7C^BJGZ8YKH(1G<6XK/YM0 EGT8TMM)QKLY)JLM->>>
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M1D\SD4\1ED1@O.$:O$M/G:-_@+%%'F6ONI\>Z^4-(QK5C1]4LY$AME<"O:D
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M7NE%?VH:^@3@2=*LX-O592-2 8E&(P7%A2W9FTFFBC9J2937ZDQ40%?N.!6
M"5:?P/4-D)^$ A&G5Q?@NVI!=I1IT/5&%E)]<+^>JD<.%1!=SJ.(UR(R&,U(
M5):0#"LL>^1^\J5>E_S]Z2,#,!5IVYU1;_U;^ZN:\$(@(;55CP#;.;TZ3P7L
MJJEYDCV']UP%6*'%E=Z@P\5<'(A_#)O[3#[!?>UY+*PWL*7MGJZ T3R /K[1
MA+B1Z.K2R=&)O1EG;NZ!;<C14Q&6T5M['*_+?4]AU4P846*KF2V&7OLF$W)K
MHH/8 ?K#@#4D\\VSS&Y/\>L,7$_T!5X] R$]Z2CH:3 TOK&\3 %QJZ_42O.J
MK-4<8EY?B/_;#6GAB[^[YL/&'OF%<N+2B2IR;)9GZ6O2:S(5>7;'CIEB8V5H
M;^7XE]IZ&U[>0[,U!@VVO(KD80H[657CP7FNE$$-;9YM5$ W" LEWW&F OXH
M;T4S7E8+GNWJ9(,O5R(XVBX1V6PFW*D )Q#/%D?PLP*UHG:R>-#JX@!OFH69
M1QG7*]DNH>Q?12[&)(QDHH"?]9>D&GBCJ@L;B)!(LJ4"KHI%4>8FSFIP+T!_
MK F_PD#8F^<GX./6RG4JX-(G4A.0%3;4H<(;$M%^WKDE"YG#;*68"EB$#:NK
M 35"J(#!M*19ER.XU]3NR5G&8N?(*?0TH'^=XHA@M*?TBW4>,R?AEWB9\[@)
ML^.!B;84S>HK9S&=T"5NV#2<K9H,6F%Y3[E#"G!V+FG8=%-.0OP9P4X\MFU[
M+]WT3_2](5WLX2!%.NC^TUE+R2+/P<YF5CFCL])=O4>V%_S?8S(3+U066+*:
M/5TOTWZ3(9S2_&8K3XX!0=)N4]D_=TFQMI3'^7YCW#14P*V!J'.XN?;SOQ7!
M>50 __:C?V#>SAPOJWD-,F '!WO&#.@/2#03?*%![*:'YM=X )\K%R;?2[$L
MG)!][#.4OH",.&[999;.KG85^!.B!!<K.D/B^)PIUW/IU!&$CZ#S'B;YX?T/
MS^-7?P6>9IYG,-F-%QZO$*#X/.G[4F7[/!&#GG=20UXZN6^-27LHN/IV.7:K
M+B\*]&12(7TDRT:E( -ZC31N+\ ^ 9X5N.4)VK4,)]+%7SEN$RVH/NVX*4H%
M>)1_/"N#NTIH'GJC?./B6"YMP:0I,^FZ"W)GO6C\<V^,49/2F?@ "_G&3J\P
M"ZE676' )G2)(FVI'5]8%<7CG=*B,ZFW8LC)MA=HK \\ E(!^!OP;JV5T00J
MX$9>SC[/7]#IHXYS6HG*A^2YE9'$<(8Y92.=9#L$)_G&J653KC'E1G4"S/Y]
M  AX?#GF]2;\*6S(.NEK)Y)LR84@/=Z&(3#G<C3^A6*TJGFS!%8-E$H%:!Q0
M ;@;YQV$/LQXV(!L.E45 =;%E4<7?JSX;7=#6)/+F7:7F6ZR#DI1M#1_/"R9
M^DWG;H'Z3 C\$[.,EV20NR2=ZCK76K-5BK^[DO )9U2LJF4SD!#]NTH9WGM\
M;N@'Y8"L@>4(4B'^?*-T!4[,_HK@E3N64A_RQ5MX%L3K*P-O1M3&9RDFBZ@_
M=5A.37P[?2:[4I17 H=Z>OA=45\ S>$+,T7F**8>.$@*YY6E0!J\CIS-2)6%
M_XW I#ZZ\W'AO9<.>#6I@/HRG1C59S(ZX?;'K52 >Q\5T+]5I,T+B2!%$)O;
M:%98OE=%A85VF$.517ZL(Q?DGCWA^1DKO>:O.R5PE_A &$B_MU-Y'J87%14;
M:H!<(X0H(@]'N$!%7JRP:::E[I9&'>-.*N![4>IAQ=VE7?'-GG@$XGR[@E)C
M>!QWR+;M_Z$/)BR*N#Q(=Q;IL2F[0@6PUI([F%/Y!V<D2%4!W4OU+D2=Z$I?
M*H"DXR<.;]!E&PT8TIGZ0_[:DL1&-D"1;T+NS6[=^FK-\/Q6E[_=A5_T?#X8
M4?0W^8+;?H*'WHD)[*O$@&AR Q40*^FOWHGA6,*9'"38FA,O9\@G'+U%[_[:
M\#=@;&DH%X[[JZ$ZA2 T[R]T*B#*Q;6+JB[$@,9_7(C*VCNXJP%P?J]LIO?5
M;7SKQ* =W[&&;(MQBJ[%WS9W\,(D3A?M?'\BJ5(@A:T\S'<L_;TQC 5NJRG0
MNDRD4!9UEY^77+W.[/6#SW<T^/9KEV4F;=5SA!$"-[B:KZ=CM6X8"Y^S,.!_
MT58I$AMF)P/O//-1[I2%T&I&(N:X_'J.0^FJIN)0X=L@53/U4#CNLI,H-J]"
MY7R:.?4@R#$VR=D,=G&0-ZKS@:=].(IKWGFN/N2>%W_B!!5 3P7$?4SH9))?
M@I-R-I;(P>W P(%SX5;]GW!C40%=:S/_<NZ'ZF<Q=$(\5;EC%)US&.T>(-I1
M :/21$[L-]=.,JP=^.;@!E3@ZUM5M&$,3'*,G')^EA&GL:X(<O(3=1'2=Y;C
MVQ21$[CKQN=S-.X+UGC#8J1-3"S(R]MGW-,A1:V4Q[S\0S);D1C^R+5I:2&D
M]@8V86 +).5K7B!4]\:MA9'=E&W'$+;[>1 4;>P"MR'NV2@/\WI&22+9@)>_
M\RI9#WA!IB7RDPS=LXP;6W#^P)3%@&1U3E*N@#L4BN>_O\X/6ETGK[7+CE@Y
M>^-FY8+BDMK:0L:%1L=ZX6R2\)7?I,J,$I[(+"K@I_S=T*?$!X;'(AV2IE1
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M5&P<D.$O3UZ-_RA6:1V(EHZ[%/?4)-W\:<W [;XN/3MG\#MZDTS<:"4T#MY
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M#"&PFT,Q=HOA?5?5>^.6J[N7T$ *SR2JST:]+L>4D)CDI?2] 7(JY.5Z&V-
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MO#VG1, Q3[0$(Q\VRN1$NR^0"S<:H*2[#8AH&+=K<$8$67F"],&2*)F W?(
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MNEK]$S M@C8Z!LP'[U0@B]1.2.VUBJW]A(B,6M\HY<Q-EA12@)U52J6/'Z0
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M2CQ1<#AU_IE&;]+$K2_1-*I1GFM@G,'V]QWL_MOC&&_028*6*A3$X6>UH;A
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M@*SH%]K'!3\/=Z( $<HY8EP4X-DXC!/S2R%;K>9JZ24,N*J92Z)1-+M1G$?
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MRZI8D9^S.IXE)=8_IB"SC@4KG/<[W\I\:2;3?X> YX^6XQ R\(I\6"UF8?;
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M05TZR\2'"IGALK?BWUN,PG]>MZ4 -H;P7U"]20KP4X9:%FS8X;\<LC]2@/Z
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M= ,I*&R_\S9\(]*MZ%HQ80GE#0=-V4Y?-9%\\T?E]/T%0CEEF7OIA%N)X%.
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MWXS9]<_;+/HZ#S&=?HB6YJTMMXI:N8V4]+6VHL[\+JVM\XZLZR%%#JGY#_;
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M"KR/U6"48/>5&F>]U:XZT0:>BW_Z[BG,2_I^62X)^#J3&^&'M(LNF]OH:,:
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M\3#>B.)B9'.T;_'#HON1CB;&\A6- CLN-J< M4>J#[+(+9.W-#/O@J!$QN4
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MQ!\'N?]B+O+!?PP6WR -3" =,+V JF 8<17'J$2,!U9 "<R^=F06LTAC?@H
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MB;I.#+!R*L7 \#"*FT?S3)K7PZ^$L6EW$@/3T]2XG/C(&?)?I\P5*:5R#,0
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M0'-4]+/RHF7O"HLC5@KV\U(YS(5]$+N>NH(1F(ADT>\3@DJ\$87=S%XSDXS
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M8/W"9:5W4]8#41?LBINUHLY^%;L]$/ ]0)VKK\-1&>%-"8B; QAF44!8I)3
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M#Y,%;>JHW^[*=&0Y7Q!<>TQ&T8G3Y699U>:GLC,#ITP/_E*X!UMR'1+ITHG
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M%#: IPJITB7L("-*BA.FNT:>=19ZI)$;(O"6>BKS6&_BXXTIMO9OIBM7PSB
MRO[";723$8TB.EB_WO@L@W&1:MT@7W+AG019>+]JOGJ5@O*<?K.SU^O8/6L1
MK.S?1P7_! ]==^1,"?V^44^>+QI)E_I_M;P77<BO,KO;1#@_\$$P9D57P7<M
M<A.N,<C\WO9@ K<^MP>:5]W!KL]R Z%4Q:0W!CO:(R3.NQ4/O?^\AG(J+,,F
M^V%>$EOS58X*9G:<D'2B*R/<3[\S:&.*V:BRPKZ]7W,\GRKGJ9I\_N<^E-2,
MGU7]^#!_X",.T).I^GT"MQ4)4-;>TIZT'OT-C9\/Q#:/H2/,7G[+NBD8Q_MS
M)B_T6_GN1>Z%R"B?/YF[;409R8XCE=.H 8)(C13KK#@Q;@RLLQQP EUN+JJ-
M/HAH'62[,"J_+J)[9(9(&J.0,%W"!M(\DC^0A:06U"ZQBS8-'M2X3*',667"
MACSD^[>&QKV9&QN8_=G " G_D>KQ IF<#=0W/.G1(QY6%DE1C3O_\[KL%^;^
M^(*UU8?#5\%EMVB2ZG5H+QUE!VGG3/6)$Y#4B!9*ZZ[;^H9AT+7=SJOWVGFT
M4V&I=_(MWJ_*=4=46_13D C!UPH^'&BO'7*UJ>C1/XP[!X5+OM]YRH/JDZDN
M[M)[#8<OZ+<O^U;./:Y&CXS:%Q=-$PS1*0M% N";:[V_T#1VOW)^?M"/TE2E
M[EGU->]+^4(-IK<]/?;=>/[H!;O#Z>.FAM=]11TG4#LX0+W&-';)E83TI'0:
MD0,<[.  VP<_<(".5!8:>?N,Q(K$WC$_@9*'F^ZX#?.RT_4NC;3A@W4$ZX@B
MRD]O^F95=?F.]?*DN1X:^BHOK!6A81IK*.44LSB1[S'5NK9JS %>9 ?$P2UG
MXCE UH-S-<%_.Z8/1]_<H4PK"P<]]N^>KG?DAR*],R"[OHL.8HV.W S>T*L>
ME;K9Q=4K9;WKW7>:Q_G#7*\6\+:(G/_0T"HVA>V?0PLIU[8+<( Z:PZP39 E
MC77F !AX*!$39[ZHJ;D^WM6AQ.^$FK(\HMKDXRB,]'LR4 %#@;*_N3YY?@LR
MS0WUE .47HEK4**8\ASWL$@1-N]:/4'?,Q;O:==2(N,??!2^=J+RN6;[-+E@
M/DS/E@KV]]5KUFAI[J :OTMNCYW:ZCDO\QASH#1V2LXX0J&L;&<5XXR?D=K9
MW(=O+O!FF1MJ?L/.*T^<0*$A3=CB+4,,;G%]BEZ:I?+!!B1WU)HV!P@GK&BZ
M<X!U^V,@5G\[\B X&V?( 0IM*7BV;D PZ3EVX#$':,*PD!J@H!+1L[/__?7S
MSR0CY'*DF0KPCFG$M)TL+@[PL9H#P$G*N>M3Q%'K__B<]^![7?$M(N:67!NG
M#("YH<B_W'L; 9$+$NHN#_GDOLL-G4"&_2]NX4=GI@"Y-%^);.!==%T$(/<N
MZ@>7(3"^\0FYT]2]$-]JFE<@"WV3R"[?(N*5Y@N(F%=$?T:&261O+/VH=D[>
MY[\MZ[*QBL@%WO8*#"OC5 -AY9PZD:T[=6E)%,=,YP"MEGH(B*ZGG4-Z[)H,
MK,&%/X,;0;IE-;=)C[X42Z$&(6QT/5JXRC1S8-HD*P#M2/><",OS.O#"5JGI
MC?XW$8)KP-:G*IU2"I&E!B5AOE/HD03$SN)P&UEP?EZ1%G*V$V?NFK5'70Z'
M/O)8T>61Z^)X;*^1WS-;R=M\P28/4K__T#U+^<5 TZW).S&4H?N4O)[X#QIV
M3Z+$\WXRML.*O56ZDJ_<#W7%,KC=[C1*-WJF)RSW&M759OS2LAJP/3X-;UNF
M:;,>,/\*4+"LJ J]6!XK$>E?4];CM>SAP0%DIFX$=7@'^DH7#=D;C\U'^-]Q
M#J?=+E:YP#7+FQ$@.,O_'DKJH\E$"B3+ADM%92;<M5E:3I[QU^2]=*G[25_B
MB\.E]N@^UOMH-:/%3=;D;&X1+CK\-IMU+Q+F"V'LKY)-QTF6OPS@-;!TL+?I
M?LN+$<__M.*J[U $LPB:7\T7E.=6BIP+UD(8RO .7F@5H7!,&,M(MF$^9"4V
M(/)218_D9KC#^6&[6NL%E-3S2D9<GRA3^]^./GX?!N#;'("ZPQN/6KI4(\0!
MR.)X#K G#3[0"S$X@*$]!<5F9', 1@3\3"ZC=3=Z*P>X0H8T4"N/V4_0'O/<
M.(<N5B#=M<&ZAK<R=4I)8]S3;%@A3>E#;X-:7J7HYY=EP,(;?^(Y=C9I) I=
MEC4KR#P)%36M6\\:94*\9@PE1E49?26:.K]3Z6ELI2@N.[CIH7(KAD_;J3&H
M12A)_A'DQ %VPF"M ?KW4CZ)_I&!4)ZP$>O4&D(.2-6=UEF!T$)] YIE&C1A
M;OB090(AOMDLRR;I\3)0]0/+?;.XBK'\T/=V4VINB4'*C&UEW19[8\\$7[ ,
MV??(3\. @A==-QOHFW4KI]43BE)U71OLVCG @;Z.=)<(8*V9Z;I2R@'>^J_X
M(-M$VG* 47%T*>CAO2X&NJ)9<B4$V("8AF3XU^!_?QK! 4;>@W0'#O ,2S<&
M]P5H&C"(=?./AV4^,3*>?'_K*1-./7[B4(6!].V/H$Z/@/%SI[V_?09(-KG?
M]'6"FA!^Y !N0UA,#82GMWW6/U[5>2U T97!$^*9W>8J\?Q[3/&71M&(X!--
M9T6X(*0H%TH/6(3#T"%(1D@OYP T$;#!35*/ [P31 H<EOP1--08U C69Y*<
MR>N:V& 0,IPDL]SQT-V^F4H.<&::CN$ 6ZMU.4"T1;<=X1F)(8[&(VP4*_2W
MZ2 R/1JWDUW% 6Z0GY$*^Y!^(%(C2  2R[I!$E(O/V;"KQL-6GGDWHW7?!SG
MF?GKV>,<J>,*@X/PMF/,([,<(,X7.H1$O%4*0H[OL0,H"AQ*SZ(H/]'3IE2C
M3.@<('3)E7F$D#G9V^+IYLSWEG_?[3=\$;H ($JO.33QLRKQZ>W S"U$#S/-
MZ)Z>N83<G+Y':>(E-+/[:E\PLXE,A()_%-%E.0!O4C.2#\TYP(Y_>WC)0HO9
MMM;IA&H@I8 [E-,3)3*\ L"1X@?**_H21<PV KT?6XQE\Z,WH>F!N1Q@X= M
ML(R7)<J]$LQ^ CI5SD>+3SS2YYL>1GWL5KH[7MA59?!>B5:URK\I9MQN\V>7
MEK4*0;N9$XC?0!T$G[# ;B3,@K=!H7!3BM1KL-M0807/C7.DZLNV9R6.=T8&
M9X[F2>AF5K#:==4^FZ>9)*6NSN$*T2-+6)03?%;SCRL_;;@2<88RGO0[) #)
M[7PF!%@5&]'J8PC:+:+0?D'='*#AQK ^:M& A>( 3PXA\-U#S 1=E"$M89KK
MK"E3 (>%&&DL!<@Z,\!_I$MGZI[O?!@1'GQ0.HRDKSL6/[,4#J!4]X4,D))_
MN9 <T"-X%EA;@2US9=]%@-3E4*+R:1!$MD WLYZ#6T&*$1(+3?)HJCH6!7;P
MT$%8)!'-ND82M9[K[*P4[6=>1,#X#F+"8?_40'2)S!+V@/G9C"*8S].'L4MY
M&R+/)4HOY)TF4X+S!87<-SN<;L(DH _WU%P=0U4_^D(<GR,YDD:ZE->V!_6@
M5@X8L.8F,]6_%_;!@J:,Y:'B._B'PX*#!Y\"4.R$%(+S=CZ0=2:2-K]^8!BA
MB+K8"0X094UUB42"^3YVG4KX<NF]=O#$+.;?!R'YME83'!E5CL+2+V(&7-!/
M:H0A(WIS?45#DF'OQR/+>"&RA/>17PU[T;XWOY6OO7FF6DN<\"*9H$>ZT&LF
M0UGL</%V.-3#8NR-X530@#NAI&QV?[J[OT9A@,>(KHFGPFFF;[73YIS:YO5#
M2#WPM)7]CO3;!D+*FY!O6 X0<W@B^A,C-8\#8./ WRZ%*WUK8Z\?2$%M@L_R
M0K,L]A6\B%W=W?*3N=5YC[_( !CH!$LHKR#L\M9I! ,++(/PJ3Q!?AA!03$^
MTI?IH-%7C^:RHC)6SESO\WWXJ58OQN7!<064E\=[:)\JP]N  Q#Q[/C<LB=!
M,?NN/OM^JUSQ] C%(EU*^?;-T3C6]NDQK8"N%^]29G^QF.PB],@DTDD1"C1G
M36B8)^*KM830BJ:BD?O=A97572RC "6OO6\BKEPP]I+@<N9^KLU3U09+&3)6
MV3N]>3D Q7@#* H494B9Q,K$KB"=P4<V"4Z>51C5X0 G_'ZL:?QGL!31)V!!
M(2B<H4#5#,4=\Z!KUFJ4.4KW>*J_E$EN2'2\?/2RV?/<4J66@;VU6IM']EE3
M9OVQA>VL%,TZ,G,?$L%:!J8JGY@4)$7((T:.UE=%/*P"NAV#G*CSCTG;<4:Y
M+6GV'EB/#I8A3JE7>]C2DCU;6$H9C0UHVKI*))#^&[2K3L$"(RA&Z6\.,'.J
M$UQZ,!MT[<=/S9S_)+Q(&QXZKMR<L+)PELR%^RNLNX"[(7$?#?YI3?UFW0..
M[D72[>7!-0LD4-B!6+@;6UR33$$)3(M)[H%X2N%#!?@+I89])4]OT.X:<9%^
M,%YK[7/-<$%*>N>@#B?8F? (#>GUHM=V5;2C4% A:AMIQJ8$J3$#%"(&8[ -
MPXH!8XU[>86I=ZIJ;EGF+ PP3*=%5O4)W D_<@W-_$DYKAO@06+BK2L"'L%C
M>/AT&BPANQ+AO980M!D<F4?P.7HN[Z.%4 @VQ6A2J2EO<. 4!P",7/\PY'>B
M \1FF@;XUZZ(CS6'HEU7BKHCPDYZ5+0$&>CA"V@%\Y=761J861'T^-_P7;V!
M;P6DY<5#S<I(Z4!"P0][1C-\L&^@.%J9R.BGZ'T:?+?,X\4O^D?<:Y4G-=!J
MQXH/&WS"^I4I@O7.< >XI,A"$F'M> $'^/("K+\.=WAR@*/MG_&L_=,H5OBE
M4KXS%(]%,O3JV3$.0'B.]/)"_>SHIS/PXGLL4LD4TW#'O865$5$1W_T>76A-
M\;==5*N2Q130<O9/$Y!H;-N(1MM_1J-"CQ)B@Q]'P.D9</*D]?-GID&/FH=U
M;Y^Q+%P->2U66E^73MS,GM0$#=_]&*U#I-7VP9[I'2-"-TD#RO"3?SCH$1/Q
MF.N_>"SWIDA4N2B2%UCGF\41OOH"CFR=@IOK[5U78W".[$_H&_,(BHID&P0C
M_"4%(='L&R2!I<@\1[AS!VAEG_PX6$K^[*J=YZ]6E:,GVNU8PRCZ/4T\8A9I
MB5H. %E<WBC2V-O9)1B6&VWE'=)\*%Q"@*%!')-!+WLL$><PVZ&0O2FWO@NK
M-ZM/=4>/=A96#PQF-G]URGE_*45K!C] @J+%FLE+!E7_2"-IL-09!I*:DP3_
M600H6&@N$2LKM2^BT[&0C#=+C$GS9HD*-TIJ=U9)T8LHF*?C]-W/DGIHTY)2
MW7R_3G]O*45(_=F(Y?)GXDL:8N7.JON'%<"Z4#KX58T#2/W9*!\#[Q"BT01G
MD:VO;4>OZ]BQ@HI0OQ'M*N0^&<WZ_QMIF_\'VH#R#,6N.Q!^3+"$TV"!"Q!B
MEBV'V=F*02*0-46P'BTX+?XTQ3_GT'@>58'FGN/U_FM66ZG++__;35K$7D*P
MF*16!5W:FR'05^<7=$CMK#2^/M%?S.J@(CP3FJHUJE26K1"U)$-ZA8&.G7"%
M^:4H!*9H"9&]*YYMRA61;L<G]^XE2G\2O1 ON OLE^LD+<WG6)LR)E:6(#6F
M$O2TS0B*9ISZ7+.MIV1K4)>W\P>/G8.7];2;DPN2;T6]CA[=(BT9<.SK?YO?
MCI;T;5/NGU^I@"@T_%-T,7YFC0**>B2L7Z[1IVLV_)22YQYPFQ2M>C>E6W[$
M\TIL3QI:SUIHMZMS[9%T[BE\.)E^ 16,1EKGCR!%$2JA3]3G4J./^SKL7Q;<
M:7\B*2-YY^[QW4KA![7W^!XR,SHVF;J-48-G2-65ZDR$+GMJ7N[PU6I8N?>4
M<"=1H^QV*GY?V+E"9K!AD#=K%_LC#HF9'8-T?RJJX1 =_YFMT(0JTJIP$,-V
M>RY5FJIF]GI*,P_N964<%MF56V+6D9+V7$U_&R1&[6L@A6'%JDR9"E,5F%"8
MUV-8,V'ZY(T? Y-)Q32SC\_@50SOUI58\J&.70UZGZX+ZR3L*']X'V2)<#?!
M6CWH&^"6 $<T?\" -T^+V_OX,OI\0R3(3P[(]"TK?6VZ)^+&W+#NV<[)Z]&O
M=K[J>$:5NKB$GG&C*JDUDHMX'RV;BKASG^U6[T[ZBIV></PDM*O1?_B5M-H^
M_R/GZ%6>!WQ0I6)/J@[Z8@2A-#NH\C[=J4%R_\?NQM0RM^S)W@5,UDMJ*JQ]
MD/3TAO.3W0-[7U55=^R)#Y%3E"AE)[*T*>CM+'[ZJ"-O'YHB1__6;>&N,=!/
M,AGOD_X4/^=:'=@U&FL\D6!K^V++D-15RRN X,F-/ZN:(/-L],OZ!SE OR*]
M&4ZI,L :6+?7[-@XA/G7LX6_G\+\+^^B9:0\G!R6C]!:EM"]_X6J&^-RHA9S
M/JKWB>@S*<%SU9KGBBW?K9HZH"V7]EWOJM!NARP=]Z(7-W4B(;3?#4VY #G!
M#W6P,'?>W1?6>#AWE ,L\2-M 8!?$YM]#ZHQOWO#HH)/T;^Y,Y#F1J>O!6EO
ML#^MF]"E)):PO2.$I1.,.N?T#!]\F$PL78D;:G;F>L:?GG"QFOYFEG<:>_/"
M&8\BWK@K*G$K+^UVALSO28>7GAR.38@FM"+T$H*DGIM?P2^)&U2CH(1N2H3_
MPB(5R&\3) V+)A!HV)Z=(^:.H?*)\JQ\I.15X "EKNQM01N44-C%\ICG #]E
MX:V+C,45A,:#E>$>\C:<*<5!PQN%,Q,VI@RI87H]\[>LW+SZ6/Y%8?/>(]&K
M_4;501V=GK7S:STVN:@6%42(6Z#G&_3HXRD4=/$WR$I&&LTG3$^P@Z\;3<_Z
MP0'6-$AY[P\'&H^A8[%0*/_* -)?B6:#%,Q;I%OP#(H&:VL(]//*>/1'4=*L
MQ'O<%>B^ST@UNB%UJ[V#AJVO/3^YQ&3/)]<+2EDO\D4?M0':T]ART59<@!:T
MGX9F<F'!2=VNCS/@CB1E5K 2.!T!_F7U/C]*-1W9IT\$/IEG*:Q4]U]U9\_?
MZTXW;)+O.M*9\KQ"4.1X$\ES9WO!)=US%H/K,\W[VP?Q$N"7B5RP[Q=Y7:77
MP3U@$#92LH=KQCE Q]/":=8]*F9-G(IN1K/E"6\MX'T/-E40D4IMP5H=M0ZA
MU_FM%1RL/R.:*R0)LG$H]I;<SA'TFKP*:GF= ">$-8(\CE'P+7"$A%IX!0[P
MPO4K'&#=NXCX?'JZ'5)N_O>ZS\%VC57&-T=R)JSI>#\AK6C?(*W?"BZW^^]/
MGL>L(^TGKS>BE'T:DLT$C1&!5TO6(K%96+H?@I&,"C1SYQ*!C;J/?5D\5CY6
M?NF!-6R0B%K^1HJW>;].9(4<04\G@X=/HC^VH\"6G9 IDEL:B7!<[64;O2#1
M@0 F?#:TSINY6PE<2N6C,H-$82?V ?3H)Z3W'B2LG].G(1#S"[MHGZ>3-.3!
M> _N.L[=%X04E"WED!$;0F*#ARA-M(>R.( ,C8):17+;#_&J6)(#(Q<VV@,R
M>1&ITZ7:V\#';)N+&.AB3E89!8M/86,<2Y%N&%V!%.)(?LO8YGBRVJ,OCX24
M'*3_*CE*UE<C40)(CKOR@J1Q:\2? !%^Z\3 LTI2[ '6XWE5DB?R3OP>.YLT
M<ZX'7(K.73/"L^W8"NOE[!)P3! L0;'#[8AP3 DHQ^  N=@,,"<5J;Y:A!(Y
M .*-R?,0KHL]?BI'8MVB$\GF/8)Z[(U?ZYT&1S_"'1Q@Y0#2W*=E$)N9:&@)
MS^[ ?D31;^!9":@!--RP!URZ6X)HCQ14DC$;^?FW9:DT0F/2[+W($I:"+*]3
M]=@5!0_L^B&%]63B&![>@0C[HCG &V[T].  IS/ B_'FZO8;YYK_=G@X+:D*
MB8T0PI+8J7E401[(VJ%'O5.\<]&\\TI%>8G4VV=&)UN-"D1'U__[F2/@ Q^!
M3"C8,+&55;O5ISATOH-=_A>9;O7?7NE/?%XKZ,2FZ8U8_=(PMZ^+:0K6HET(
M"U]XS_49$ !$E42X&%DLD?GZE4+<1>C4!P_'O8R),#T%C^,]F8@+MQ97>"<C
M_:5G)U'QPQ&I&CFB]VT?Y[W.3PU?#6R.W"%2F'>_?>8V95IY1]!W2;%G32B1
MTV4M^CFZ4)3]D3Q?'__;2CV-C9]+T:ZV,DENSH,"4IM."%TZ8;XPSQ*U,O'>
MS[H)^62ZK03)844#T+!L:9\U>NNQ^3V_^0JF["[]'-0G2%ZK4G*)F0_[9.-<
M'EVWU\E]77>%BXYG'4#R@G7(TOP,V][D9^)%=N*%#O#C:,BWRE2'@DGFKWY[
M%@<H+W%1WLPC]W/NU G);W\.:_]34B$2<!(<0/X"A/0%UXOJ4>M^C"T/MOQO
M3I3_-_<=4!(]^A1JAS];D]?-EGNM91DT^*QW%,)*6Q"(I<^?0-4'(77Y@<@_
M/;E59BAED ,(FP9*$MR.C2;LONBNR2^)]O'D$TNX"+=FM^>, ,; V(T)'5,B
M^S9F5&$&*74/9<TJ($7IRLU./1.06FUO65+9?8Q_CV2CTE)_WMSL09_L5O+D
M3F/E;^RDTJBWP07=3I]_<6__8O0%EJ=_?SM"$'&W.Y+G<>A97MI0F]-]S[^V
MS&:%MQI+7(F)=SXPDFH8A =K,\&%Q%P,<]<Q EN@DZ0?I(8[6PY5,C"7&8>^
M];Y]<"3OCHL:N=%[?W=UD5S9Z<BO6FL1<IM'%XR/K>_8(&("-/@/=KZH/#WG
M9$\HD]1 ,VRGR,MKFG#4L42[5 VM?^GY%[$T\B[P2Y\0K+T1GFP! IWV6[0'
MAR2WV$]O$/)':MD?=I\<?EE?HB-8;!S\ 4XC?./LOE0N")\[S\L.0E@H(TW/
MFN[\NWV"%^9'PEX^D?T&G$$C!)K)U%D3J*E"LB(+;'7F #=03$'$ZI,UG36G
MB,L]!$+;K?SI%22%Q&5"]AS *0$!0M96A2?_X:'\5C: A'D9!QA30ICB9V@Z
M!_C-'& U$KN(D"X(6PRAV&'W,#"^FOC5[LZO.[\.U^0BWF[#KX^36S_\"T/_
MA?KIBB>-AN%D$&Z_UL<!C$?R%>^R%(H9\^C-0<+@SP*$*]+IUB*"_TK+I'_0
M<G'OM$E%7 ZQR:WD*_[$,CD"7/#2%^( 06@V5VZ+0F^-_#[X^S\?^&#SH1ZD
MVXA"LT,0N3N%)L9(=4$?Y/,^9[DDD?U(!Q!N1SBX?>Z_.)AHMSSMO:;&)*XS
M4>L7XD</4$F.#%=**WIF5^+X]^T"BPAJV;P6Z*$T7ZE]$1NDC%#$13PD19XU
M0O*,%:)UNB>V50^<ZIO$]C3/9H,T#%@B]G^"E_=L\#(XI@HC45Y@;X>D47EL
M]QBH"-+=\:Q,]#_9^O7[\'<;_S?AC?Z#3G#LL*0TPA+F&> DV8+X)G=B2!:V
M>$O%, ^)6\,IRX?7^?[V]ZP(ZP?7N15A/=!;Q[HR.Y;S7(U[GA4X4QZ8D2^7
M/X/ZR9.)WD$AQ@6DF.M/KGAX+@R^N-1-%LA[$O<;\U.S7BT O7*.;OBXSUI,
MTN%#H?0=6\?^?()$NV*XLXAU:Z*)]\T/I8S J<(];Z(*@V]CT1R@UMZW4IDK
M8)J"#O<U#6H_VW63UGM3G(NA!?&L4]W@^K%B37.\#H7W1>UL]V,EZ2/]UZ,Q
M'>0"UTA%7"#S2("479=79DW7\GX]$^_;RN'2#"FS)X,[V&FR[;ZOKY^]%ZSZ
M682K"^JB5B>$$M%/[[8-\2PV6]O=3'J6_);L+M-!%+KSMC]!V^':KZU'"C[M
MT;+2LVZ71/J@X&1L0$*]2;GW)ONZA#+59JJ?SM?W=\LS^PB&90D#VDH6MJ\R
M(FQ3%1Z7Q&K]V*[VT6X]M+%&I(11%CJO7DGS69& SJOQW\_Q=*Z=BVUH.ZB9
M)L6SWX"H4\@.@\4G%W_[R(;:YNNA_5;IIC(9?@M#OXY1L7N]?K::TOC+.T<D
MXF3Z+75F]7[PAK-.LW.J!)G'P%K+*JL:M5Z9SNL,L7KT#GNW-LE7@?<G*J8&
M?E\QK3(3YCD]MA*2JA:"OPO-,Z_A]-E)OK-BYQF99;?3R0&A_C^E\,;5U<*>
M=T\EE$488EYUX\;N3;R1OIW*ITBB6Y+"(N,X@'11W=I$#MR#9 L>,1&N,9(D
MZ28^E%0D24S["2'.[Y@KH<]>BW'3+!N^=<;P9G) ^K8V(EE*6^OWK7D\N13U
M$'39<=&PB%%:HA%SFRJH-B,O&7___L3-ZU8M94]/O/Y"PD5-1(W0NE63Y+C;
MP!OH02G*_$R)3&RJ=M\1=;^^W5:%0G_6#GN#8R?MU:!]Q59O3*"04:2;:""H
MK<SNM+Y.;[YZX#&:[$\K)9D5YK>%5MZ6LH@3+X\J#S?Y--WR0-8&&H% []D=
MS.NXX^QXSZ6<*O^\7S<8'I$*-B^+(P?GM4[O;(GQ%'ER2QI3'35*T])*7'G,
M)N*XF8HR+X8W5K^=M]>JO;63J%S5)3FTQM2S\&Q:9O[\;H:8UI1;Q"D)6" C
M^:Y4$PG=?A^SCKDJG[SVM'KJYO@/XOL1D=J%'BO'>&]_HB*-J>)!1+JMW#P_
MP/R,+H03TQT#:'8$H](^V]Z6=\@&48VBMH5*U.>9W-R+7*E# L<U]Z9MF'W_
MAMG)16:A[Z8<U7OGU)/10@H:!&D[T]F)5%'SY+&RB#/G%7+6ZB;TFP6A2>95
M%IJ=Q-)-<Q_>&)R";I"HJ55$!D\2W!5>?Q#2E6W]S!KQ7>:I1HMP10"+@L]0
MI:@-X=OJDHZ4T/:[3YSKPIUJ?-PQJ5GV%'QNW&H@7(%+1[T6*)]NU*09S<;0
M5U?NTZU"J<IB'HGBCGBJBD"*#N(GSUO;KQF\"):]N[85K84UJ[+.?A2A^@T(
M!)OP@_R?4443CY:PNP+*[,J[U$$AT=W"S>G#0\7,M,4S3AMSM-=Z;G<117".
M[ )]%(X7NO\6RFVT&VM*>1L0Y[KBVW#/=+8+4Z-\S&>?JE[XBXF)2\T;.SBI
M^[X15($^,:_BT) PG6; \(XH:5F:Y6[(5,VZO+&#.GQ=YOK76PT+,DZ;65/E
MOV\%I$,9&R:"%.C-)QF)X265T>CZH$,+SU+N)B%[7-YV=3%.U5#X[*LHX<7W
MM+>UU.I3?S-3!+I4[*'^=ISBCRH/JJD[#4,GAU?%9 [)Q-V_T[56L#?MJ_GI
MSDPGBZ"[E^]JZ8E B<QKR"X&]&0#1GM8264DBA]Z>6+ <\!-K$Q0*TE8+_"I
M7)+-XI[V[Y'/0GDCE@&5&\WJ7.-H)*/=% 1PAR##M]!B@WA/(_X)[NP5\0=4
M-^M$0>TDF22]>A'3HR[J3HOO1J+V[>+2/Q#T4Q* ;.D>!M CHD><70"F(=)K
M'1FO651%I2KK*-;O0\:K8/ZVS]*,>>]#/1*5=S9\!/6$S%.,"1,?+SM&>%QU
M]HJ#SO+=Y/YA'W5/Q<"G6DG76Z50*6+[!02.SDL@>W!!/G03(R@ZS\-Z=ZI
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M75 -TCF^0R_8;) Z<^=5I GN[*.Q":Q[1O!OXD]!2-T(-OG77S^""+/ASW*
M(9&[A^UWF1N*[ J* FO?2Z'I-AQ@!_@S+P_\_8(XZ50'%F=&,M"4W5DT9>[^
M:7VMXJZ!\3T?U)G8 BSVUPF_*B&E1?M,ZB^>F$ZUOB!MXCCA[^>AD,<_SD,O
MH(7T>)T9Z%J=LM!E^6-;EV9=>DUT$SZ2DNI^2T4)[Z,7F@C?TSGZ<<;0TG1W
M,QZLOP[1X&B0-@'S!)AP@,07__8D/I$#".1NG-L88*,(D)\>A@.T+ E"AUSK
M.CB ZC^?+9\X1=]?Y<;07!EB:#8H>5-"HVKV_58:\437E](:$NW.QPW_:LYV
MO(Q.2! K.R%G')=X^,XM+F)&[BBZOY*R/W&&L?%+5D9B,$OW ]0[4>^#4^T\
M%N><#Q$M^LR549>Z_R_VWCNJJ6[=%XXB(@I$D2(@1 4$I2G26U2D!$2*!:D1
M*=(1Z1"(@O02 0$! >D=I 00 I$N(KU)J F"TA-*""0D-[[OOO>>??:[S]UG
MW/O=[QO?.'^LD3$RUIIKSC5_S^]Y?G,^ZUE8OS>S U=BTQ1R[W]\>9N->:GE
M;Q4_!K)(5]#K_/,*5$G,+Y_9:WA$.,P%*]OP,4R>%)WS:V](76D9$]O<.S7;
ML<8K-J7L,*3)3.8>:+R2"AQ!X_61-8G$VWC5L;@J8,3%,9<-68BLJ*R8A2;?
M<H5K04/RXX+:A_77>81?1)Z,6+A=E'M"[#UI:19$:B*DZZEQD/H*24"<<?ON
MJ$SJQ2WGS92>ANA[#8UA3F8Q_%\3'(;%XQN3MA^P?UU#KF35U+>5R\\/M!Z"
MV@\LR_TJIDSW]X#%YB@]R5R5[1YWE?7%JQU-2\F:D^QE]N>N7BTZ"5".^KTN
M\A?5.&#DOTK _",+]W_CT N.#4[^_9.2S_%'ENT1.FR?'UYQ &V \@'P:W-X
M[SU*?@GH?VR6( ^\?F^L9)&F'H")%Y?!!VI$]'6?![HOA/]N"V7FX:XZ#<#^
MY]+=&\3:C>ZYK3MJ_W-ECGO4V&%A<__2O\U!F>F$OZ.S%",-P-,E3YVF_VFX
MQV-,KM5@X'@]/Z@'L)E8>#"6A[BY._#WZW77+>L)^E2][C;P9C<-\$'63SBH
M:<&8$G>-!B "M>@M:F71HQ;F@X^=U\.XLO1<M1:AB,Q7J^-S6_;<T%TB>"?;
MZ8MQN?]N%0T0\_<[*[N;7&KG"ZFM5X*<YS\?H@G@02_!0(RI%AFYSSQK'80)
MH<KLD>D&^3VIA 98YC/>0H .D ?&N^YD1QK@JP -X @FLR.AAX*.5,,%&N 1
M6H<&N*]"[WB"H!0-P$ ?82I^OY#\+=Q(?B<_SVT96B+@=T"F 8Y'T*W+ZC"7
M!EB[10]NM'2A""*<L PBYZ"?@.>'0/OBX%KX801]@+^6G0C4 :JJ( W@:3A8
M[ RA3R'DX#J]B2)Z#ZPI\G1.JJ,_WQPC=/%7*IU]YL= ^W?A8?26'XVC=W2,
M=Q4?GM7X:*C!>1,V]0'^%:IB0@/8!-RA VR\' HQ[FMDHN1O=V81M6KU#U4=
MQW:2_JC,\GL/@%'V, ,&P@U$JS$3N)KG?R!'7-=E3[EX=)ERMY&E>)VJ=+)L
MN1Z]T%)-VNCU \-@(VX7'[T2!)Y^LWG 1.0:D=7C(QK@]3*KL&3HJ1G,),IP
M&?]KR#[?9=R!$57]N)/<!"D(^9IFYH6[8NL)<.GTVUL?(S_TK9D'=NB'-P+#
M=@.!M\([ZP[*.V<6)UYZ(?AF7&NY,DVU"I=]3O?'UV/.-_<FQY[L>'T\Z<8Z
MF,['T9N40'Q(^T%7(9RKL,B1:]9YSY#DNM<>K3C=_GQDTV+#I1&88&RWH-C*
M<63(M[VS3HT!7U%8[IB0'BBO59M\L&$02BEZ>GMCZJ80]L%[ *3[:,/889&*
M!.=LHIO787WA0)F2N/O,,O<UU8\)7O6A/UFR/D'LGL37S"OV2W-&#).:\,%S
MN)94(>E9J-E=\0V)IU#%Q9&Y_IAL>2X-5'0^#SGQ"L-[3@7!7HHBF:T^W.WN
MF]7&P#)>Y&[STB=KZ]S#M'Y#-UC]H(8MZ'W0E\PG[I<7KL"5-/G.!0. Q^E(
M NJ1(KXK@$^I7)^BYORN_%(#%:5<)UW$2K'1G9>1FIB6-7;FZ@39&OLS'.F$
MY5 .&O.1*ZW8KY$OK>OHV:PU'LK"EZ@HTP W]<!4T@>V:!F[3W.DAP+\=(NZ
MG$4#P.@P/YG;CMXY-D(#;$8!?M5H.M$C\%!#[-S!40<:8*\3]%_7_]?U_XGK
M]>"I3EG_O 5@/-@-3;J@]1E-N@+J[B0A"+RKW?&D2)D&&2\+D+&N+OP25WSB
M#WOSC6^5B9F^\\91\(Z+<]7A%/J]S&F MC@IJE;EL-M_T 4*7<5&J*-M@?O4
MW^4A0L]#*0B]="HK\V'BS\CXRA9)ER>W:( H>D.:E<.(?]Z0.%,$=3B3LQZO
M&3V_SC70+^=_+XLHRE(H:1UIK3']7'KJ9D_WHJ41H4;S:_6YR;<OOW)4GW]^
M\\DMP<H+" ,M3N(Q] F*_'6^'7XZ;<^^/A_D.8+W:&>BVJ[32?U(,CJ)<O-
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MSC[QT*TB#S\6T_C-/]%T2BZ7M<DT?RC";_FL=(TFJ.CVE[S*VP_U#<28;I.
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M0;5]EOF&5=5;,V3J@_O-U\6N 8HK-4!X_4.K,#@V]]_,?4Z,GR.+Y5*+US^
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MOJ8;S>Q9>0:"<Q%I:^'$4T,+RS/?$?=X]<I.VT<SKB?]H@['JK0'+C4DB5>
M0,^VEAZRE7X/&H0RM@B;47P)B @9"[ZN>NIIPO'<)WO)L\")^6&O\EN7A@J#
MN>/L,MFK.GV'4NY?VM@_%REH_,B%!J!WN#M3F&!]"PL,HW)F04:EYNZ."$_
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MCS%RV*K@G7,"#W]_;;!56460;&KB.R2[?M]B9 -E995O(K&4)>0^[2!1V$R
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M]36^_AI\1B>N @?M#K>_0;#VGV<IQ#S1:UA[<A)*.Z.)V P,XF:FHBW&]0@
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MU@SAEAGS$A6YF"A4!"H\;W2WXQ3^&0+%OSS'T^R./E([%J5FF!92T?H%YR.
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MB?$BT2>K;M!ADKSX@A1GF+M*(;H-555#C9IDP/BA[0>L6<+V<^LLBW2BPT4
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ML:<_-E179WH\[G^F=J2W%_OJ!$M]K"J'.7B\BT1//;N%DIK+>+0[C==3FF;
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M"3LWU92OV&M)7/=DJC9%C=Z4),M^5W50[ !AC.6X\1EHVI9$+D/$J:K]5C*
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MQVK[R<M+B!$J&>_<E@E7PP6#:J?WO^3^&:!;)FU"@H6<?'YY*>/GJLP0$]/
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MNWSC"H @B(0M6>)^94E@ ":YN-9A5P2MJNW!ZD=%AH]%-=9/X[*FX8.#MZ\
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M4GK)J^Y=PP&'G/@98R-@E.5G[>@-')'5%VR*QG!H&(+?H>U-5T,@7ZGH-%3
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MZ=$+I].$[>338KFY]8P*;L"9'I>A[S/=<+67PD4WC"!S#A\4;+G,B,5& WG
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M<M^+ZBP/]L<C:UEG'.<\@I0NKQ(>)!!OME06[ :OQ'Y(YT+8^.9N&]$.]SE
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M @1= ;[#.F.#%_!W7UMHL4 [&1&Q$:]1]KX%X\$K($7J"9Q'H<_+N^53IWC
M^1MLL?/E+E&:?CC"<(Q()XBX"D0T:[R9;BY/][UVE'^_ZMSZ$/N>"Y$,@'[H
M3KUHY[(S-J[EY\WM_86'RQO6DB=<7#$T6(I,3\P;\*1W1%9'3" OI<]X]?J9
M1I.\YK()KWD83K8!NY.+;1_$B#4%QZ2(!2$YGDZ7LJKXF-VKDG<"S<5KIY(M
MIOZ8+?AYH70=PG2,5TW.<ZO&"0BB&*5ULKZ.GFGE>(54%=/#+]$Y>TQ-7ECG
MY=^K*&EB1)%TJ?:U]KO\S46T*];%TW@SI5W;@!:I/3MI(C-_6M'<GF6[7OH
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MD5\B)24C)2$AHR C([^,OT@N45)17*;\]?NO17Z)_Y+"?U\F)2&]_#^^<*T
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M8N>MJ.$..""&92T:);RL;2QWU5>E']'3T>1P>[4F<;"C+G72L'W"B.2<4\U
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MV3$IO%F@I?L)EZ]4BE967LFE^<)5@+FK\S7D_)]VV3]6!GOQE^U^#N?(Q^"
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MI\0!IKMP.^U0?&/<(K[>PIQR-'-_="=O7YSU^YJQX<0XJ6BYG=2LT:K.W-M
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MCBUT C74?TU\SY,\IJRD=F9)FNH^11%HNU)&!?_,H7@:I!(L]QRMC31":(=
M'=ZNC<LHE#G-,U78Q;KNB-,*2DXHMM]X\E)MVEON68-A\EOY".GX]VW?J?;Q
MU8I$&:UQU@9&&@@TL2MUIDU&E;&V-WJU?AYG^&ZO[%//22V$>"7!J]R7TK;Z
M=M]J#!5N?#Z-M8(N;N'=K9DW>/XJ31L;[JYA1CB%&<R*25 FLLOZNME"\?.4
M\:6,,V5>6>#'K H.FUL]C.]:'@1G:GT.JIF"0- ?EJ!1C;+5M520QM*DQ^0S
MVU>Z_0OO;#U37;94BM*J%]]^O-\W]LRCM5L@T6S.>?,YGTYHX;9X?9E$DY$9
MTL=X"')KF<E+Z-FL^.?$W9=2V?N2_5,)ZV*9?0U"U6]ADB21OOX518FN(F7=
MB>;#[O;E&']T\9)5E/]E(1LW6OVJIRHC9MLFU(>Z4!U+N1_/@Q2#;SIT>=J]
M2[[O!2TQT$PO32Y3YG=Z[\=54;JX,LK8.>'A3"&Z@?K"_?Y>^KLQ#_U ?_N1
MSZ$(>#><&*."Y#Y]"G6-\FU-'(@M(WKPF:2<Z^JY<[N[ G-9#+&7V25%7W_W
M:+WYGWANU$&K&V//P^?)8'687S=1LB[@?+W&J6Y$G3XU3>8HUD?J?L@S66W.
MHN6T6Z&66G<\>M4])6;/@_&YPS*H(Y,.[ AZ:4K2M1O>&.TP3UXU,:G0$$!%
M-^OK8Y0H]2/<[N6=QXK#+V?K'\WY<04['W9@+PW@^<C0&-P:'HL#&%JX?$.[
MYV],UL!>&?6[,;SS06@./)F8U*[M]*XRU_(ZZX\^CM5O+@%BS?H4:GPDO^)9
M@7/FKQ4<0L$'#\LBL%HFDS]'NHMN7O3__LG%#'3C6Z-15&5E;=AP#HO3,-M=
M'67ZU?3?'?/_(Q+,OP;O!?@[*O1=6&O:<2QXL71RQ*&1LJ&4!Q[JZ2[F> J9
M5+S2O5)@S?*AH:W;?_&4!9MN<Q9[ .O)1-^ 81CV)K&D.  '7#1 ?[1W1T[L
M(@A]<4![!M,'4W87SS;K(YT"/I*;FLUU&>"FV _KA">G." <M)QY2H-QQD<)
M*QPKJ8KAH\*7EJ'X92L,]1R>9#6>PW% Y,3MA5.)<SQC(H_$6Y$L'AUKK84'
MY#:&=W-]/ YX72PKG62-(L321<1!UU51,"RI*YX2SH&0N3)XY(K@6"A2R0?/
MM3:/< "6RW@4NCYS",8(<^& %7XP0CQ6$AL+QS.<=@08JYCS8.G_+O4WE_J4
M2,[QR^7$7WSM]9"9&)IY5BTSK3'/8CC:F)%JQ7+Z<W.3UG@&JW/PLT!WJ\+#
M/3QE%3GS4,('"<?Y"PP/*H3J\L 2*4:G\$1)/05C)5Y1.][R%0JY(CL38]:R
MV+WU?*(EJ_C&_S*\_T2#!=+1[MAB,QQ0WC6(#1/(_6T+>J%A <_ZOTPN69UB
M4W& NEU9U)_O9%&&RRV>ZH[P_CJAO]WYZ<+/]'5GDB5M3)(6";;Y"3YFE=VT
ML(4M+\N#Z'! [^TAZ&:WR#G10Q*%?Q'<_SY()'DQR?%GH9GG; *Y9?_9%O\[
M"] /H#L0M:&+[-".1KN*PNF-R0R!%A=I#?7*[*-5:S](GELC4_8MULA9%6+U
M"Z6^UCUWH3&>J<VC93D-=7&.VW/MR=-(#62?Q'M0BMJL_<>9GE+ 1<?<Z 74
M 4R*N3]RP+I-;EXU5H+1<G'WR]=DJ3=9KK,UZ>6F"&<>$ZTEO<.T:4$!CW*!
MB8,K._C[K[T0-DAF[?>TLV6U.8OQB$TF>GU3K8T9&/N#*0_^P91QP+^HLJQJ
M88]0ZRO;\%Q^[JD2<B(9XFY_V@Q_HWUR?-5VN QMLQ &_^-5;MTI;>M],-V3
M*.DQ:J8<^O6%*JJM!!3)41\ZI84&_3RK'T'Q3'Y2[VKRU9<3-,$V*2:D:I/<
MERM67A,[PJOQWO^((CR20+^=IT''+ITT@\M8O9I?72Z4D7QXBY\GRKA7G=&C
MO"\IA/2GP"!VHBW0YTQRNF=F)CWIW7.SS[  O[0 EBB.X?S^A8\_?'.YIF,0
M)1O^D.E/'R\VWQC1$@M3MBS1OO"9J:LWM_'=08,5: O[),9("Z6YE'S<0>$A
M+3WXSO;%=775.4C\6ZIC,R[DH/^:/\LD342Q8DZ>J43BW"T5#8UUTJ,<O.";
M=<Z Z+?+L28KK\,-# 2_:@,$LXG.XU!''/ =U(D#*F>#Z-VH^2O1Z?<UQWW;
M9ISEQ(2J0"<;'$9R394"+S_Q)]]-R+G#PV?9_[GNN@%G;O8\S+KOEHJHNP*1
M.,UK'HL>0IE)!?M#?,$@7@>AAXW:H6>7%Z _E66#7ANMJ6)8)Q$+:!7X8HKE
M);1S2:LG[ HZZ*>LUM*'5M$9?(%_SOIH,:28_R5[G4B9P [L^\Q1.3)S6RG;
MV4B.*>V4%9]\?U:M-Z[%%TZ+9^1GSW5.[95==4N3W:R]YVJH-F>B3B(>1\6L
M2JL]_3 QL<G4QRPK7U><:X#$T]^%/@)%CI +1>:WBVW.\TQ4PZC6CP;IGEO]
M-.)S<2;4Y.QB\F,*MQBY>Z.WV]B(:A$TH[F4V0FC=&;)>+=,0?\8>5@ZCBUE
M_XI@KNYW#GBWG5N?)G&2$];K(C'YB'Z<G(\K[>=M6=VH?7 X#JBEZH#&9-RL
M'X)((\YI=<>7&M*F68UW]+Z.$3TT&^0^Z@##@U6]+NWK\:5V/^_RM_W7^\3_
M''\J\,E_>=CVV\-,8+Z+[X%7G)&P<Z@F#LBM,E+^\YV')(J9SP+Y'&EWJ/*$
M_K+MKR'A=JAU((XW$U;]4R@.L+P%7>>L^X0#]!>4C,%DT)4T!_#A,B,VY 9A
MUO_BOR,1_F=K;?2?">9?V8]*''U\)F>&\1MK!C/D7;_]0:AL>I7ZS8>8VE7.
M1$:28P_EZ[WTI\6<"5_H,\^D(2PHJG8W"G:09;K*I AVT..8@[.NCJ&.)6Q_
M86Y6M%I)FN9>'_JRO,]KRIO.$P595&]6\94<XNQ/F93;D86.5JV+ Y$))Q4:
M6QA?VG8]O'9$EW@$OGDW_P/%IQZCV+&;45HQ;1U-'5;EX"B9.TM-';:(6%Y-
M%)'@J$-=N6EU=)[::?+Y6*@#3;& V4]:A60#YB=M1@2JX_H/20;!Y. GKUKH
M,$$1G89&$[%9&WO-1WQ]\\K,Y5&]@NEDDHK1H+?,>;8\UAP/;:Y,[G?@LXX"
M1&1$CAH'M.FY'GR@$">J2FJ?#MR,GM/=U$D=2-%\"9V?[>5^\7R8D.CAS:+/
M.*!( VN)[W/_W"M<V@JR'_(?5EC+"MW,1'.+8.A2>K"7ZE!55A/B,,IYW^B.
M%L%1VOOPN#X;S7[%1+^$?GR-3$9ZD%UI(+G3%XRO%2&MT#;UI_BE<^%L!^SV
MRLCMA0B(])*L^,$FT><$[N9&$3X_GB2WOG<G\LI"P93J0CV]OE^R]IQ7C AM
M-L$XP.1SYIF1"*_X7.E&@.6T50![IF7IEEPIU/N81>[0*Y-<QLL1N=NY633K
MN%T@VYAPX1*D@C5#TE.VZF120-7IS%SX^B>.$F<]_YZ6?+;$Q-4 CDS4\^6Y
M^*Y8 A>0<N+$VASFB_V9O$OF/%./DN6C'RD]I70<RFYO[<0K:@)K FUKMETB
M\Q_<C!?TEA[\WH0(BD5J+Q/'(TJ=.TH1T8&4;C4S4^1M3TN?U=^2OJ7Z186U
M(DZ-_H!JVQ9?]26'X,Z@T+H@1CC:_7G^G-\KK_R?X!EG >-O^;LN>\2KMK,E
M#<P4VU;7KF@1XAG'I)5X]!?DV_?ZMY+UGD>T[QR<,.FWC13J&"0>I[0N'\=:
M,+9KTZ[/7T+'YVRR',7R1E:7"F^XYH\R+)I%#S07B26[O:D5O?6%:==\/<O&
M!_8@3UR7\LKW=4\-?HVOV-?PQ0QX)2P"O)AK51'Q0D[4MUAS:$=&#$%A,?&C
MG:4EH_$-U8J3MIW"ZS=Z38\?05HDG[2,XYWG#VT3QI#@>XO]Z&Z6B(BG!_WQ
M#+ZGYV6''W3[->,UZO9H9J>_FYFJ=$L)+<;6_C_<?6=0DUO;;A05I0B"="$J
M3:G2D180 1$Q(-)+1)0B0D2Z!*(@("!=14 (2%-I2I5B0@=!1#J$$A*:-$D0
MXP-I)[S[.]_WOGOO,W-FSLSYSGM^A&&>259[UKJOZ[KO=:_U\(B'S]?U+SC%
M 131-W6 REV*UZ#%P#&_3N=B+LG&GOE\K\%'P^SPJYLSV"9DIN9=>:UCB\4U
MYU%/P4>9:BD&6Q)S:_17^%&<W1/':>>51)Z94,G8;.&:)ZNO+W(*W6B*;.*3
M:;4+@:Z?9S9H:!!Y Q6UNQE%Y2+X("]]&'?8O?#B@E3]\'+64NBIIGJS_'MK
M?B>4C8[@Q#M/U=MZUJLLK_3*CFEQ,5G/320@.1 -<4V.UU,F:3RN+0\ZK^/U
M;@#Y!IO9W!,H$9)WA%RIV=.O=26#]\B-<RSD8F-C:WV,Q=_8L?_?3>C__.Q#
MKU0NP^A'%6B1=.4(+(YH S\VC3@#A%6&K((Y 8AA@I6/1B_$S0L]YL;U:7SS
M\/13CQ]9]/C#/97M4$ .3N5W)-A2>?SI; WS:Y!8+%=48!%I_''S>;6?WBE.
MEUS5,?#KQW:NY8%V-EXMYW6=S].%?H$#?K8;CQ@@8P9H?H"RE^6WM\WKJ SM
M/>0[CAK* "'V,B2QNP-T<2Y:(>:["< T%P\U<-1T$ZKQ*8HI\ELR$<D @>"8
M':F""P%Z5QB@6+Z("? VG*[# *'W\@@WP$1"Y10+G2F[NU&_]_(K12O+&"""
M$A?6C/X8R1Q6@"5\C^(B.VZ":S)H3,W'7 S$0Y0]G7HH]C/J+S\OH)^PIMQ
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M9]/@WXQ#9?$5 .)7_?V,@! DL'KZ@05KKP>=[4B91N*A(@:(8XIB'HJ\25'
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MDQ*VQ<\SL<F3 7IB@O16W-D%F!V-YNMF@$Z/IR([+B'KZFG\?2BJU'8RW:B
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MN*C5 W%SX1H.M6'!"1;1M_4N)DIXSHA:9UY_;\.AP><TKRDJ^Z"1M['QO*2
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MJANVK73I0;K0S-JXV\5X,_5($1_?L]0$=C]A*.<(3U?4W0R.:U U.QH#1!C
M_L9#'NG)8@$!!R!SCE.Z*R/YN(6G;2.M3.M9I8).(;=*[(R4<6<73(<%RH2N
M#6?B.-ZV8PIR$(CMFA4=1$##7!7*&L-'L9T207X2:;I?2GZT<]O=UEZ0X7H&
M2'MU6Q+ .1AV-"]0T,E<0I9(EI"J>7S0V[G^^_ G]%-UI-KBYT2LMZAN@%<
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MM8KX..]&^L!D/1:(!+BW%OF@<B)N->O*4#?GW5.4![$1MUK$97[SD'.>\FW
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MS)_&11&:&G;:(@_2"WZ)XBH^"?!KUP88SC2DVU_4>@MYZX%8?(MDLB>_;M7
MWX9PL6IW4&1>N2M>D)*2\=BN+VMPX=A\0O#JG9*WC8DW=[ZM\>->FK]QLEX"
M90".,YNC7Q+O-4([V$ZTFCL4!8N >MP1TA5?BPH-"FR="VWX[J.2U\2NO;Q1
M6[@@/?8()A'1Y-2ER0(R=B_45D4BG.#Q.1*XHL24J'9^D(A]'2HR5E$GT#)H
M<#W!:LI7X5YY2/2E'+\XASLY]YVM[HT'?[67<7L-UB\:<8=.0XCV_F,?-7G
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MF7(#<XZ,W%5#HC7[L"\20J@ TTTDIB7E1'?G(^FD%WO&<YH.??(!S_2BA_[
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MF<]2VUTHTN;MK:IW)XGO3M-P!0TDA?>'#B 9J,!B#O1HL @6E:QY9+C5 +/
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M'I-?,9:5?SPT.+OT,^WY6+V7-Y?W 5\:!:("2N!K:*CC+?BA']972 5V=)Q
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MG)PZCZKA".(=1,=EFH^G_6.MGA)I4:SC\A )_>>.<CS<GILVN9DE>.1F!]$
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M/[OZP!)C7_8VG7_GV-61W38>XW9W^>\V[4V32H6C/F3EKSS)&MOR'6K<3L^
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M>NI0$_Y9?N["AS6::II: %=?7$-9 A1?N>8Q2#[O#!(W))='H$9(P5H:CT*
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M'=:D8G,T*5R1F#[JJ3^-K-X&6^"0%4D6!L$W@_R =GAFM&7[<Y;VM?S@[FZ
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M,D#;]_&3%#I09;JK<1D.#7SXGR-%.3]4!4S;9.-3/WX0_^5R^<Z:NR\P=SS
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M87!U'<1)?%%L*/*Q=,S,&-$P22(0TW=B>I+9EWAT(;[9??.2 (]UITJ?: I
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M%"C*TN.1M[1,.]F?R];_?F5]RAJR9=YCH,TPZ]K]A]@G225?EM7G\Z6KU>B
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MWSQIDE)\[=R^_>\'U)Z]^P9 GD^#/B DM$X'"V-:NO8(60Y=C?.M<7K#G1F
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M\TY#]IO3]E!-PVD'&A=7UO_+F^Y;.4^#I:$<6\""?]W?4/=?IQ]5E/VKMD<
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M0UL?7,WB(FE/9@DGRQ?]H,73MI?/6OL];:K2:VYO)[WQO@&B6[=O@/0)L8,
M%'FR;ZD>B<.>B.U4I^^YGA%?EPR<)4=!^+$/RO?7KRFN<0<]R4\=FB]( ">Y
MT%_F_'T(Y C!@ 1:0:3=SAK*C;'H3F0TY@7Q^R,X161!;$SR$SII!B9;5<^K
M0 _=E9O;]&"ZJF$BP<?WG?V)?2!)@<*1M>B2@%#+7_F%9$9([PN=JDQZQ]7*
MXK[/U?)ZV(O3@\W<TNEE!EQS9SK[_F0TY1)/1Q=)Q8@439%)9@&>@][\-GNW
MFBN1?U0L:H3R E$(%XT33YQATA$US/?@I-LU>H[V@"1RVXD2^Q+J$]W;#S+"
M$;JDQ@?D.RB.&N)&]1K;S*P;IB"Q;<U.('U7WM@RKR5 1D![Z:T,8!P;@6R$
M]0P9Z))%"4-!UL339;@<C/"L>7I?5[KUK89?=FQ!P2*_[C?T#&?W;KM9O?;4
MTGF=?J/_HP7TE\),&O5L%7%W'T9"51#H/JQ>/P8D*T'8R1'=4+Q,O%R&>9'Y
M>&65W;7Q3Q=;O>:8D*I^K;&\7^EF;9%AQP"'JN=H%I3H6K;<-Y0PV?T.B;6Z
M4=H[@*L:YVGC^SGQ[ SP[304D9OMP.<Q3K=3U'X,F!7=CZ6AH,YWCA:M9&]"
MHA$AH]/#II>?.\+A_="'C@)W;C]E"^5O2E\RGKTY_W9^XP5J-.']R]+OYG\.
MX.]HR"*NDPU+H9CQS,A?/8D&ML2E6&!T/2R:Y8,]W/W0-"@F<U7$X]:LFWE/
MQ5+<7,$ _?53J>:?JQKK@3.ZN*\E.$,.S6:B2M26CSV+JX4&[VAY?JU.>)=!
M<[A:4+R85GO4[4=)RG<3BNE6+36XCT)#6,A:.&P,1=*%2.B2[*(J6.9-EF]M
M#BV.ITK,,PZ,UBK*&N[J-'>[O&)TI>?9!Y+S2(Y]V5PD,W2/$7"-_\&!?'GZ
M@7!!,=3OP'"I\?'^R&V[H-ORE8YQMY>@'P;ZHV_I8O)?J),MZ(E:^VY$HXV)
MW(55U&GB?%*82\F#X$KBS6&QQC2/^T#95$5P I>9IO,U,\!#9@N$%."OKF01
MR/[G"%JT^$AO=PP8\_FY_E?+5]CO2\F)QX#]\^[8 \_LT.OV,]%4PS+<\E'\
M=1@UM<]VZ"FV%DC)LN@:/N3VP1Z))WW*_.N<B&B/F<(7Q;6R$+ ,JR%"QX#G
MI0:V!G<GE9C6D2S3T%^9"?AQZX @=N+S\P'#KXS>Q1K356Q''@,X$9IXV$PE
MMCLS<2IZVY</+"=<VGCPA/J$X^NWVX>M;4UFOXV)W9?E 70!/V4JA"?Q!P)]
M]8VI.Q.V%][V@J?-]K<9IP>B,,WTE2/9X35[L*@#UC#UC?1 Y1Q7WS/<F!\B
M8::J>>:OPE_1>S(92H.?/7[R,Q?X!GSJT!BA3P2%[PEY=_/;M>%E0-R85;],
M__V*Q/KRH9*Y/K%13OY _:4)A\2LI>>?[1\E;#UJN_ON\!D\N4=QNC)Y4>!<
MX_"I0B4AQ*P>UWC+$TS4:(GG,:#E?M@87.UUJ\O#4W&'"_6+'CS=*%YJSWA=
ML(+QR("8<^?2J*J'?B&C0GI[)6=86-*ERZ.IP^W7N7,$I6$?5B_)H;K8^USX
M8_9O.=@V"7K$O.Z]?D%F+ [P.X/&&<+#W3!&4;Y5[/9PO[[[(YY58K;<O$I*
M20<2_.*HXFI#WIC2GOJ">ZK/M%H=G:=8;)=B#ZW6,Z,3HV*]<,'<"]!ZIGE&
M'MN +/[$@AS,TB[G;(10B?% [3E+ZL;K<?W+:]S'@-.M(&BQ40!/)%A%:&*B
MNB;S\=AY*_'04R<D/)HOX\YY@!'Q?2>R\$81*!Z:GRWQ#L#-\[O//QN?=N-!
M.B8\F)]]P=F]$RJ4!F#FF XT9L@)&46> VOCT+QDV%WB5[0+K-SM2>&LEK+)
MERF<2XR1^I=*;Y:WQNG,G[D&/X=9O2Y_DL,+UB941=K7(I-]8Y6&Y"A:'LM&
M>78"E[Y-]_8JQ>AQ\_A-ROJ]?9$O[7^^>0_&@1 G5B75NQOJ/B!^#2M?XQ;U
MJ)^@OF/IGEQ4)K+-ZYDTG6Y7UPF<G"S)MW9/9\<L8&87K+\J]S.38D5?^':8
MGH$D A IE2&3*&62;C<?6.5A9GI&!;2E,B-OW5HG!>JB_![Z;#^P>[=<+B F
M4]7\ZZ3K_.<OK/D.KXLC"%.]VVQPFOLS(LE8HT9\<[CMW19 )(DW4C5)7R=W
M]1JXIXK%QT4"\I)4'[*5/M ]ZV]UA5WYN\5DXN*1^,^&\5F#L;OY7Y(\AVH"
M?J0(G=ONW2@U$(G(/IG$P.S] ]EH'NGX@=H)$:3VN;A#]]$GUW\I_KXL&^)3
M4634HM/^^_6B4[(D)QW%W(K9YOS7$),_G0[,RK<<#2QWUC1,L-/WT4_BJ8$*
MRU:IV\_TCZ*. 1'V2"?DF87"CR2,0?,6ZCQ9S2)#>P1G$/[1E63HW"\[JJ-Q
M:"@X^B%C($R 2R#*@C2UF8(<UJ:L;V^3E15Z>$9H#O01E7_ETII%R0=R^)2E
M[3TC@V@;6[U'HYX_8IUCA%)/IIA-P=4L3URZH42B^*8L6:&,[M&_Q&?SUV76
M36R53TQFKM5]6VN?C.0?\'7\\@G4;,]_#%@L1W*',%)T6XE;L8?G*6[D@L(9
M;7I=O#UK/G(&$PM_-3LPET\IB,LVNNC^\A@0/4]Y>@S(HSO*1V_'H,EQ1URU
M]0;:9P7=^<]W1CX J)?J.#%DU^]9R7.C>.AT66*+U^ZRQ;W,WH%:H;/&OY:_
M+/S!Y31-F9U"+C;9"\I=#2J)WN YO#E==UDM/NOS^*P-3@\K_WGPM_M$0_@T
M R#SP'$?>O3>=YL7 4ON;,R^1E3H'E(P)1:35/8;(\NI0]PITMG74L\JS]VM
M$.K4'V9BKXK7\T87'ZBY[I5C6<F*NL3P>?FT_-46ZX4OGO*G"DHUEP<"/VW2
M>PM_W[5+>5/PGU-4_Z?E"R3_ HZFIU!Q!\8,0YGVE()#RV- C:K#,:"H#'-@
MDL0Y-13X7[\UI!*"I>CCR,TD^67<4<7;%U9,.76JIE]NF_5YJF5/3+A:1[AE
M*K5UZ7RK&XF6P@9<48SSF1RQS6772;WX-G3P!8LAZWAT#4%UO^I=^X_F2-E)
ME#Q*-#MA_+[T3L'GR:W#3[\W/"Z^\!F_[VN#6EXVG.HQXD/('KV'P32NDS_M
M)Y%]U> _<2/U;?Q?OV[C*KZF213]@)JGOGZ?M;&N]$F3>=A/Y*6A:(K4J3/K
M&N>HLUB>5AFB-Z$J >P?1$P7 G4< \XIY;"2_=8M)K?E;O9SES943W^NME2\
M$C/[Q,YT$#SZQ#"T0;?:B$:P)HAV'_%IOF7P''Q1#%CEJ DE(LPQT>KH'X3;
MA3>>6+KB,9?N*OI:IJ)6-933?AZG+9F 7'QS# !2'%02&MVRP:.;"*=*;?P;
MV3TLF^$I5$J%KA?7Y_$-BXJVCDPNY_,O']E+[Z)"8KI_=_6BB28*L?;\5&'X
M(ZSN-T=B8S>$B>)!I$78[8U,POT1'^PYF_GIX(\GP_<'!%8\9B2-5\5+9!UD
MLQ_59&Y*'M6!O0@YL5AF'Q [!D-6Z%Y@(L]Z+:)Y,2O\;QLSS>L]P:!B-Q+8
MD]0GVMXO5_;Z^XU!689B1J,2/=H^F\C!WKAWI@,>[GCMWHI2\H>^W@Q^RH),
M<Y8E=:*VWL8F*/)=;9WL;9X!^H'.L&J%05O),,C#*@!%HX&XG'$,.,O]L13N
MWU-+WJSWL#!/73L&F$^*5V?=#2IK!AY@]_0P%WCIV$1CS<P<C0%@QWT%6I2K
M=K>O=^D%GEI=;A\$/@\1MWY@!^7QXSXHS[!F]II5^B)IFNHN50'(%#]_E:/)
MRNI<0%AC4MY^^4>22D\56<J^"QFU#V%K#5Y48%T# 5NU\#(Y9.VJA_792SN3
MQP#=<&Z_=#ZMBP5S6&GCLP_O>D6L0$X@'9#,U*]4A;%ML"(>%LN-88VKE7B%
M4T7<\U:)WGOY2O_UAWK)UR] \]JBX*>)*.O"D7C[.OL-,UPR!H+7B<"O;P;U
M+?"1>*)]!MOX,<> 3I18TTA1D%K)^717H??G:VHQ[?.:IR]'9 )^+^.F-LT(
M,"!"YR/9%[_-YBXL.P[F(TT"HT?(J4.+8R"[FIPNP[).&"&)@[/FEL2Y@1?E
M%[<%31%OI.]K@) =KE4_R"XDCEZ[R\2IB+W+B^]8#<V-3O25V_40$N6]?;G*
MN:<F5;B](BW2'YLW/>_G5P2 VP?Z5A680CK1+ @@+N?T:J!Y<H ';!')@4ZH
MD S6@6XKL3@L9O/!8)YBSNE;4.XETVW%RXZ-;Z7Z%)UH&C!(]@XX^@"V+8;O
MXN\'1D7XXN \O1HB.68>BD8M\._94F)/]&O4.N@#MH:OO'84T:PS9G@-UZ4R
MOL<')=,A=#*Z^4'A/K9&G>:!3EMO*N:5/SGBVFX:S);(167;+1LF;6[GN>Z(
M-(;?4\@!&)?W6$A@J8R_\$M'.:W:Y7,4]=HQBA[.2$ASL<V9NH.UJ?_F R\<
MNS#^84+^0X:1H;Z GTW,0[K-&[M.6DMG7NO9C10C.ZZ!9?#)=/8K&N=)?;T*
M[&<K?0[G::S$G)38T[,=O?5$8K?"4S8G,LG'>U??+/\E\^VO35R0:,CBNP5^
M8G2T4IDML!?+X_/.L3O[0G+W026:(4$>=!_=9B!5KOGJ^URJUG=-_A@A9GT3
M_0^;MKG"BB1Z*N-R.30=Q332JN1 '.L.D9H"*RK$*_R44S"?4*IB42IN31\]
M4R$O*RN1J?L&]R(]76H2)/=R^XE<L/\AF&*31NAK1Y\FCWH [Q._+,B,>"A!
M?8+U)>)V]0,^6/$O.#F9 _D>%5V\8G&-BT"B!>'+(4(KF2I1[XF3>83ADVL+
M/ VHNF2[;PAM]<JR8JU@OU^-\?[2<_*(V6:QMV\X7Z;,O'@OT89M1_%%M]NQ
MC]99*B@9K <+?Y41:QG?+D"U-;$5&^\:24/%7Q#D1#\ZBZ5-ABJO%/XN.UIC
M7H/$A0K9:1T#3IT^!J2=(6./ 8].MQT#"E?7I\ 3HML6*;3E:"8A'_YO$0:I
M*A5R-.G*=@=:N)6I8+C8>GKE^H^D\JF0D'$KE^?6K8Q"+9=TFCQR=[B2+K4^
MI'"3T7@0;\@7-G*624MUFG%:5V*I]M.WAJ(U7U=%NZHO]IH\>GS^'<&?GOZ\
M\) V(G81B='%NX2VLN".@JP_DI0_%L$[9PT^?M00239,,ANO%$V%2L1 <W-J
M F[?L++X<J5./_]$3Z"<Y/XTR25!8JPW&0=A[1/^\,V:/KA2U;72:71I7.]H
M7+[BC('_#4WFGF\X@,,-T)T1>Y%5--%8#GF'N-",ETF4T9VH*QM\ ZF1O7?O
M;+%5SH9:L(GC.W/U,L <Z8V>',H295MY>?Y/9\Z<F"JP[U&$[WNR,V;-8'">
MV<7R97 V]>O@YK.A2Y>6U"2Z+@Z&3[M:5FU?R@7=,+%S)TWUTMA]$GI18A2V
M\62OS:@[_<"O3+ !Y=$S;EJV>7NZVK)74[SZRU/ ;'\Y)"&S+RF$C?J%"IX0
M(RF5HT2BO^;HC6NT1ZFK"G[HY;\"2'/D?J(,O^"OK'(.Z/R_NE1W2QY%:*CH
MS&"H=%/W%Q<75\>FDM9!];"D5EO2!8H,DSN_9W/!6HM=8@64G]/\Q(%,1LVD
MIX3RJ'VR5-<5C+61@%Y_9+5R\T,92B!Y!%_%0=,.::J$V]1UG8_X]2.MFR3Y
M-[Z"IE;6:_Q"I;,+N<':?/B8!S:ELMY] $>T&EO[$"#D+%F1RFIYE$N17#R2
MU*LC8CNXZT?+<VLC"XB/6A-2>HL+DK,&'S)GJ^Y5*)!CL?OQQX#W[HLP*IO!
MG\J#W>PA0$."B_]GU9_X@FF9*P$I!Y+' #8UZ@AR3P[QIZ^*-)*\:3V*7%Q5
MP-C<&!=M^?B-RCACJ_TN37.1)!C[0K-+MCTA(KG0?3?^8<G>IS,_6?07SE::
M?^4KO/W]7:_Y*5DZ[XV\G,["9S_B,Q[E54:O_KF0H![M[@L*POE3.9XA20='
MYVE?/:,!V^IC "_MHQC-1I6&(CEM.I%.Q*BLHGE+I..JA_/L4KI3\(_\X"ZV
M2@;>JK=H6 Y9I'%CF6A#/=M/ ++#D88YNE-@'MS4Q-XV>W]I_]66MD[=EJLO
M.7[<EN<]:1R7RW=Z%- 1066IICFM8X#S]LP!*&Z!C5SR?AW"KB$*S^SKXI_J
M<K$4:TGM]Z4[LY-B:2NV>G)T(2"7M[7IZT],A0C%_@1IGSZ...$5@'#A'<N*
M6$Z6+VLX4*SE"RN)@MYO*#T H>Z;TL59'^8E_.>$$)E_.!VWT/T'W!IZ7>P/
M0+W]Y\3\7UYC?D+M7QV(>]C^/7YUI0_\V_);&CHU'?US7 [X74O3@)=H=]"^
MKBQD[V>0O=YM18%@F:4V]3\W4=C]C#@&W/>F(;>Q^1_!@F.(/$C/MNX+$"/M
M;X_1;L D^]I7VZ%3B]^OY\>6B:].L%2&*QF]053)J.K._,H14K2W#AG\X]<]
M#E7A($O2S<\HD8FK!C;O;NLQO,#C/IC^3J9WF#,:#(O;!+_TU##O/SG^[06#
M9ZN%.!C\WL[LP:QIPSNNY""^MR85Z<;MNL S=[/27FF3OAY*!\A'_^#98#L$
MP[-Z4")$;#>0 0$6/I'3B65'0$O)97A1=^.S8*\BW9+U<Y6O]J\]AKK<D[&A
M3+GS/K=: J=;[QT#(B%U/'W#7!3NHZRM>FP\OQRJX/"N$%B^PFEQW09.X8_]
M,+^6VL<X*!;KY>OWK><,-./1N8T7"3'KVU7,",@W&BA8'O4)!AF,^I1(-#4%
MJ1D\CIK/S]9-]Y?*E8:*I>H^T[%Z%]LOT4Q3YY"A8P K]3SE0B,YJ *NT'E0
M%"Z+BUJ8U<RY&[LA9RIXYM93PI,0NY'JXE-^"8Y<DW#);BK741U*"J%+FHJD
MLL\C]+\AQ(N3><GH&^,:(GUYF+K,#7Y^*S#4PT-YW;)2[-!;K(BUU&<],>83
MV@_!?%0<<HTZ5D.Y0*R,)-WKLE;?CK^Z+3RWAI*P9YQ=.T%5Y^GF;@E^._DM
MUEQJ!O=:V5OL\>5KC\RB1^SK7#;X<A%69"X<.AK%E=RAP4"<BH)I3U1FJ(35
MM?D;F$3_-AU=4Q2\*WP3?ZO+4^QMU,/ [9F\_3M$V,8GXEBG]>D<=Q@2B3.P
M&52S=:,NT!7KPSPUI@*U1"[V2KZ[E2BH>>_[#9XS38#?1HN03?O#FQ08N1^&
MEU/1'\]J;T"SPR@\Y5 +:=RAK7#?W?JV+*-4YY?SQP WI.M6HKQRP$V577!=
M3(F>#<W -QT.=37SR66:)-8"]<;>(?<._X/ER-;+I:XMMT*XQB62=B;%FT=^
MN@>%2R2RKXE;PN:%+9HB7_>^+]N4T]I7(>N6(3SB\=K#7?8GYN!4/E,?$OU*
MPV9QK,G-?)3G?*^9,>?MN\1<P U\#47NK[1LKL5$R6[KD!0B$E?YSA&_[NU2
M/JN)F[T?;=(H#_J<HNQQ&4;7#<?PGNX-R 6F(20/#=:SY4G^72!6<M[]*; 6
M?A-(,$M*++4D$SI:_+(JX [R8-5B6^T?]6EMY0F'3 5?&-2$OBVGNORYT, ;
M[PT/V;W1U#CV,SD&!$"HX2M<\!,5;:^3#W6"E54=1A83;XA@#XUYM\><]7O.
M:KY-U>@G>Q^*4Q3(6K@V&H'NHQ%5AI5 S_B2=YZ]3.H7>2<QE.YO1Q5/FW<I
MA:X4++IZ\^NURJQ;9"<<FIE<:S=5MTFO73T%OO_0P]VXL29)K>)!!^C5V::4
M&U!$$U5[X>[$XD.O&R")/TD$J"L4.#F-)*"%(LVI8(JZMOG@HE1V7E^;/>)1
M34_QF_(O)JL?5QO3AN2>OW@P,%NI!78^TZC?:RRC0+#?V"4N[\?1PF8=/',*
M[Q)=9QND]PW%XOK+K\;-\$>B]/?)>K-4U_RY"J97VL*/JA]R/E,[NDR,H#TP
MPT,(?/ >B2<,)0 7[;R^]5&@*P"9[_K-:LY0H.4S:3M1DZVVM%DS4O9]C)AS
M,BW"?:SJA& X>I1;EI-#>.'TO9B>Q.K:QM:I.B9;'=>'S%]%S-_P/F?^,AOH
M%+M^ W22.I0C1+F/R>ETK<L:DNS-=,JN)5WOPVW'MMZ3Q%0J"0EWGK^Z>C?W
M>_]W[M/<3?W0]Y%";VJ;ADJ0'9K4*Q0.LB*^ M*3V1C'0^!)P[GF?Z-HXA*Y
M1V=O\#>4MOBTO(K\43\UO57>77@KTM/9G%U,QX)Q*'G$PWMQZCG"B#M+N "'
M!+JQK4RFK>Z?]2K2OFAE8W0NRE74W)1=5>2$LF:DD\!MT;CO5.&0;B1#" =9
MS8ZX'47E@3/H?D/<#Y=SN=OPK2)]ZG["8]E[?;5/4HJ=&1,8BQU#K[C2?Y^W
MV$\F_UR$G,;"=7M2R>MZ))<8BH-#'OG$DA"DL]%.:LHQS:BI]5-#4Y1:7L%L
M3&1!5T5W)),.@*TVH5%ML6H6N)]$KCV$K(Q"O=9^\2SPD!IC6U4(3,< )BA&
MZ!@0NS!EF.)8ERTCO<QM2AF].'?T^M/I^SLO8&HAZ CJV5FB\!3.;#F,0(80
M-\&2)7:ZQ?/0B)N-._*>>9^3_ 6>C8JDEG[?,A/79.HQPAM-TR_"XEMY"LG>
MQF0MX@)!<V1;'/UQK"_:PQ3S-< O]G$B%T#KO!DP5"62KC;L!HB+1HX;JWJW
M,3RF3=5DR1)W89'D+GN6.@BWY5IZBWRD(S#>LPK?[.5=K%EJIR57D;[NP"%>
M:"LX<"?/[<(A_?[(1)72,8 LT=@3OWGSJ[H&]1<N^Z/Z4+EW1:>-/N;!%U)Y
M_$Z3N=AI.P$^0?X5E#3UC_RO6;LJ4R^1;8A_FE!2>1IMU"7D=#4;F@ROS]PX
ML2#^^()#._T Z ( T<HX=(3:%*&!FG DPBW\#"&*-T1X/:5/T(W+T:3P*P#P
M%"#XT)CAWO^K/!=>JB11(X/@H5K^LT+%<%(V/O94V\_2![=X71C<PZ\H3J8#
M3T'W,R-_S"FGC\S9V_2Y*\;T;8LD(S/XA)057E/H*#KU_3T"Q?0*YL20G,J5
MQ,(%R^EYZ)?BJ-$@W_03I9K&)F$/F)F]>AERBS1Q:DP.O$F]/2=M_#P:-6O=
M>'NO;?)=5.=,&8L;6;@\;KK%21<![+(]S30C[SARU7)+LI$[=2#],D,J6R,;
M1Z.XAMEO(Y 4(<[Y$[&QBRH1;%BU9WMQS=#MVS1V8']P:>&&#O/=1<_'[?0G
M"6&KMJQ0E623&UR55XLKNT-\O+X\\A+A,9[E]7'(?A[X<RE_7/;"A.S" E[*
M)>JNL*KQ]>I?#'%9O@*1 )>JJ/)C0%W(]&1#HO\K1]5(Q*B9U?WTWF=<<_39
M])>VO'] &NT23[\Z9$0\O=3%+$%HQ^R-OB:<7;KML[JS&38HR)R6UE[E_%7F
M3_&S"6VJ:ECO].PK&& ]-VS%9W6%GORV=KR"4)_ ]^'K",5QM( ZT?CO-66H
M R*2(CAX: _7[;QNGN9(,&+4=2R8Z7+Q3,3)<#^.NS9QCOV>)&.N<QT:+P6;
M%:5&)Y\Y!N NT)YMM_GCE1#:TW6;/08,NR*W/]Y<(P*0HR(=:RIQ1\S'@)CW
MZ"?)!\)_BJR?1]+0*ILN19OE\#'R&PD'HHC)0LAQIXJ\<>\<"=MQ%+U%=PC3
MFO!5TNGWN+:K476CGDH!!1_K'3I?1K[^0&A@X#ID.P:<MHT/UB)D],6&-J;B
MA3CT[C_-K7/SE+]"[PO8Y*./"%NUET\F7Q?8_TRC!X1.>[+N-)+$=0BE_>-Z
MR!R6#;V8BZW.KB!4Q5TOS"J#)XWU\K3<\IZ!?K34D2.$3XSHWSJ1RF_Q^V.V
MFY1)D9Z2_D7IM8T*_QV9-XUES;]^<)K8_'\!$-OTJ 0VY-#(NQ[)J3?,T:5D
M_06%LR:(R:!DJ%5%D<5Y[P,XS.91>KM<1,*>TD6$_5$Y,X+"0S8?N XB&TD0
MC@%B:T?A6S1[;W.GIQ9OT68J^C1P "Z67.IQL,[*'G4?[7L?WJ?+FJ,D=?<8
M,!2LL2JZV[6/(A\##LU7INR$(\%T.%N&+Y\:YKE?X:T4WK\\J@1*-5^ZR85Q
M%'0 ;[]S>FH<:AN".7K[,]'>GJR>N^">L./&T<ZO)Y:2">V]._7BZJ57*2TU
M 09UI-GL3ORH0%.ZJJB>J#FP?OS22<&(X:=/-3?<NDU^>&\%\@\"(U]=3RU>
M^A&2_'[V]?+]CY;6<+@#SK"CS1$9>+2UL%#T_3?9'I<3B23>0?,C$*,_/=P[
MD0)U:%YR)8S%W:]E:-Q?^/R$*$GY/5?4*_'FESW^7/U),O?H14]$AS*&JV<?
M[O<=?="0HGY#78]NUV ?5[B*CK*[6DTLF(SE2D\YR@H&ICDIOU>:W^RA^+\8
M_&';+R9\1]AN&C?\;NFR?>$?ZGERC\Q#',.79ZM^"^& ,QB07C9ZVPLY"PFS
M!39RJ(%KRB/]96H5+SMUB"=7N")TCZ)10(H]N<R%D,R)4"4F->/73S?"ZVV&
MU,6:Y#P/-P<;(/!'B"L\_3?I'E@XX$!2J^A&E>Y-H_U:HD=O6(E;M@A9A8"-
M"2P*?8\:!RL50C'!Y9/?UBZ&](@L-+P'OYB?!GN(-0PROQ>3J?TAV4OEA&*Y
MP0:'S-0OC1EH3OQ$_5 0X>I3UU\'V<]=/+CRD.=T90SB0Z<>;YXRF^%2EOH=
MVA,2Z4KS+RX=2"#".0LOGMP%.FU-QGMH_G2>)(PY\L3[K0WLEA&D1:,\-IH4
MTCXI!7728H)_)_(4O,QTZFIR-)5[S-?#YH$1A^W<['0I&),9, MCO<8!K#/:
M31#\LES&#R! 'BK$AUPA1^<C;A-_)?MZ0+JSSY.="$'#--[F@8%V&5&GPCPJ
M/#]DWN9Z(_I"[EMB@U#1X!Q@3CN8WA+%14:^A_/O6C6-['T24D:>PS:4E?3#
MSB56569>C1F^  KXXJ7S*?F:ME"9NR^ TR13Y5$HH]200"TM,G'$J1C3:?/E
M/>VS#P3\Y4NQ.PX@@6/ QHTI]-Z\>B!1]>_>H._1C5*_0'8\[(&0#:LQY%[Z
M]2WWJ*/7R.\8E#!RNK;P&+ JZSOW5S4]PTOJS)1U7S32Q8C+'0.*\46RKH4(
MCRV/G\\RVO%6S'<Y>SY=E>[.;B@=H<+=;L%-^"11)69CRHXZV?1MSZ4E?&O'
M]?MX:V?:I8#1J[>8=HH-2Q4_UHY^&BR[7561S9>7Y/I8P%9(2R;Y)M"Z%,57
M;7AW;<^Z:__3BND"W@,-'BD\BNMK$L""MOD!OR4[T$(H280<.0B'97?G1HE-
MU&%Y;%:M@XM)LAB?T:[B.=%!\<[@YZ$-A5<Q[!:LH_WLH1%B>]:@S5<$(T&-
M-T<IN!PF3%>)4EO1@6>1;$+:8(%1<<9ISHLCIQJE+CU;>)23<1)44 ]DG78[
M,%C]Y>?7:,Y^/G&S,-:.QR1!^J;RBTO7>MA6E+T\9MT]/YV1:5#B[=SD)=10
M\F:37M+M:*0<(N!I=XA+C57]12N!0P6;W:G0%HO9 7MH[HH?)C,VO/!4M3,\
MX;6L,-Q(!Z,V)+E?/=67[/3MIQRD4_E9GW]07K/[;U%WF2P#4%W;W-K@CI7J
M7.DQ '[V@J2& ]-6"EE&-^KW5H;!6#K^MG:MOMP+M5N7;CTFB-,!-L%/I3.'
M0WWLSU4< V;K*C16UM)[OY+RPPSF.I$_LAJN]&_<E:+_C*:%E9@I*C^-X>Z]
MX^DUR"/'W[^X;ZUZ>-6O5J>1+6#*HN8.$Y.OUH\8PL6M'0>])YS-))0]+T+J
MZ$UK<+%"W"_WP:7A K>;(V?'S&;8(2DH"XR!,A"DO!#>=L^*J).,ERGV5&)1
MN(MNHH5J,[FATCLD[YR7U6+>PUSOO:%"W^4$1\I3T L6Q@-(^AL@07+T_@MR
M! $8JPB_BSVT[NOFOUM6X'J >I775I^/=G47<L-;-&2O\H'?3$Y^]5%(^_'B
MC<7<27NA$!EREPU-ITT1^N/BHUL(^W);5SNQ,27>[ZT-]6W?Y-(Q/P4V(]/%
M4O'3%\7BV5DVGF5E+$,>-<2[_8I_.DFL[WQQJ_ R^OPY5B\:4-F?"S8,@&PN
M%VDZ')ZEP%P?)2FHM;?LI7(9@WNO^RS6!F8S2&9+T9.+:P'6O0SGI9:%X.MQ
M&5QN?9W6758W!_/6F2OX7VB_?<X61ATR. :<B:H]!MSP<#D& ![_Z;Q^17:
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M'N@KS_U62=5^5YS6Q_FL=!%P)X+W 0#HQL-H#U-='<VO2FP5)>7@,SJ&HS1
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M0I\>_>KP/$LOZ732YRRG>'($NDKDX_X\BAQ[<WH,U6(^NCWOH_!:[#S3TRY
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MJQ+/Y7ON[+%?O7X,,,NR3^RK.[CBE@)SU:BU]#6?$";Z7.!/Q)QD6WO#X&,
M6T67H"OPZ>Y4Q2#;RN</S6-HN++.2>#2-&_MW/@<G#XSML*H$SM9+JUI7BZE
MM%>:>* #DR<@N+2-^5SIGF;NT4[)2G#,[*B$)26="?J2:'DX'7>;S>XR6EXF
MRU63P4--FST!)QN*,7MO;*Q?Q$$*:O@G&-V@P/7EC[.*\#5!+X.H)^I/%)A[
M\.>/IO)P70BRICWUYKLS$!M=4&/3,&8O/]9JXP%N1&6]:D-6"";MW(#00RER
M]U=RBQ>G^7S;1O"T_WP_*TU%UL AZ!C=FA$40B PCF=(B!X?2TXE1_#:ANY8
M\&<CN?HX)SK?@#350U\D9 SK&W=LLM,?$NT@(B'(& .O"I. !FZ/J94?76'\
MS0HW$GSNG)>Y<^?VDY]GF(4 COB+=&?*G'! %CBO/7%7W-FFJ>G 9RP7Q7W/
M1'ER,._K-T<\?-I$KPCX)C*#KH@J1]/?[8!R*8>E6;%A<KDL*=Y5D%KRM.=A
MPXYMG6:OLE.6JS)7;]Q[6[EY^.WNXO<2?HY4!(-O>8&HO]=6U1._^UM%:^;Z
MH-FX;"*1Y:[KQIHS?M@[ZV;J5/54$)'&8^WG][05-<V%#1%_7)UZDFGF$N.,
MZO+F[*F>2+)!19_H5*%<IX+KWI_E=$CDZT_/E .W++:-'!.8A3!(X^<20KB1
MB)2OK=J4B<T8XV#:5=6?X!]_FWU$H_[>UIDFYEN)WGZ:KIZNP+S$=PR(+X70
MC#F/ 0V10&2S36K)K:$8$P.S>=&*/G$UJY$_T(V%QB98!*T1*#FQ9"4@"K8S
M['HH]V4IUH &/JP/,3XA&FEQTM1#W#-Y4JOF!SPZ!(+);T!@;=%S%]^6;6$M
MBZS[AV]X9]K.E'KV*7^*?>A&5Z$8\TQVA)3#G GZ.6W568L]D:4FEPB+2)<H
MY'56E'C\P@92REL. T9P1(B+=@O.2F%_[+JY1]NGFD67FWKS1>=:;5,\;K=,
MQ%00>(SL5JZ)LD,Q&LZ%55PK#;2!"^E""^#T7PK%H$*'=/2:@YJUPBGUH"+$
MWF^!K\;(#^^?"-UWL%09D2BX9=MV4C-(8\BN_^?_IO\_ CR>_"]02P,$%
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MSL6Z]+I@ZXYKLQB]G& Y[E;E$\RXNAO==O/;:O84U^4?[/*0B]*2/78DG/\
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MWK_AL_=OP/ZQPL/ "='[2?66.K$6;=HR=B-,GX\PIR5MVS4W.FZ4]\XQHNF
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M421[N<>FJ15DTZ@^["I(D8P+R[5ZPW^2V#R3H7]MDQV3.=NQ#3=?!TWB*M>
MUGC*V<Q*8[!,$!9_=O' >ZZ'Z<^N'-PD.G[X@A\7N\:<1.!M*S/=-@RELH<-
M'+I#QZ+ 90T*J'ETZ=O5RGH6-Q&YE]XS7T+49FE&^Z3C$*""UU<,Q1U6% 1
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M[5LWYQ;$#ZC%:]6\,^6)/;^2<[79IPB*?OG[U;<21)I/%Q62K(_328_7VB.
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M;V+CE-DQB\R4@\=UN7Q)7O%J1M4-"6G,,Q*&?,.WK+S>IYL_T[2/*>[<8(,
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M6:.M+W7J *ZE@HPT#<F^R1N:"A2QS)GK?5&LVOP?'CIN]>&LDF!;=P"\L3K
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M\16R&S@"''Z- +L<UPC5@,@:$4KS-Y>B=1<T=#@,VGC+7.*[=[@"#3ZRIYZ
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MI$^57OIXJ*7R:H37Q<7KS>[3AV71T!XY.^C!&C(!27[@A%SA*J/E@"?I1FW
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M%*WEM2NJ5.6H&4HO'*X?XN!/FGS>MENCP3)LGX%^ Z<L"1_H7/D+,K3OK<N
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MA(*X_R_E1Q#B9[^<OS10YLX_U/OQ&F2;!E)=H9X.^N?E9\<RJ7SQM320)A(
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M*1)"1RG@DNJ&*1[,ZKI1!"#O>'$*6YLUIN*ZGHZ:Z?W][>23^B30(1;G#4V
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MO#]/UH!6I1GQD=V<+ N0ETHT$"\<^K!^0DG45'!#_NRU>#^SB_H'"HF Z;P
M'&-(Y(I *6?YF%2/^&9I*BJ/_Y[)O^@QY.?DA./RT1)Z]$ BYK+TI9ERA1-_
M+K\.N3SJ2%+*N#QO55?!^67NQONW@=_8K]X_9]=L>$QQ]'RHTO_,&@*P4]E[
MJ<U[QC30EWW\T9&L_0T$,PW$O$#G1K(4#3091!RDQKN1]_YCV(=_?"BD?YM0
M2QFH W,BVZTA[@RRL>;9,+A)'/#7N["XOC7$F4#E8HW&V^AP^/G=RGS6,F.S
MX=J-\K_>W*J!\JX8?'Z41<IJ KG#7$M)^\=;T0JZ[:-E#?V&[,#$0,;%^&B@
MO%](8G:)'J^._SRQMIP&6F:'_94_VLS#;C5(#:W#)-&O J\FL-% 0UL0P/C1
MR7^DL8)9TK_S8[>@Q (J?VW.(8,'\L+1V]Y_-OE)Q(AO&MDQ44T#Y<JB?F'P
M>A19&.3@V!35D'H:6:HA30-I?ST*^6&BED%UQ^":()^1/:A8"/'A_!N[LT14
M1PX8'JF-SIZ9AJX<2.SS[X.T0E/\'IP\(4Y$+:?M#=!))H]RZ6@W/D*IFH3L
MEK8>4+PY)I]F%&'-J3;WU=G1&90?^S)< SMP%=D^DU-5R!V>8$<JO;QC2NS"
ML5%CB(J=%!5;JT JHU#5Z5+=1^,E?4(E.O6;ZBLP=\G!Q7FJZ"NR+G*8ZRBB
MV.M9+-T3TZ.HL^S%TD#Y8)(A#<3:C**>QQ2B@)BR/57ZF%_UT*W*NS/TB>/V
M"Z&7=Z[ Y^FU,J.I[R2H'DC\3TB-\^$I&B@:"AC-(DFGD9V?D2Z#!W2;^32&
MF-E$ Q&D#^[00%%-& ?DP1D-+_I=![K!) 'S=7I1FR6.!B*F-^1R+6+_+SMF
MOBRU/D[6AGOM?08X\5YOQ$YEK"(Y@(YV9=GKAN\Y>#7D/_!K]V5?%P)19?Y;
M;_GLR%36$O(M5S1T2I.-<C?RA_?I(,J-Y\T_=^YO^>VA_EQO,(Z/-9-GQR72
M%7':ZS C%!)C#/AS;0C20+<AA#0J;P"4HH.\"28Z%Z]O+V FI_?N M7% )W&
MSQ.#=^E88=]0]\K\<](/PZCN#VZVIFT7;C(]#4!A5_]MCD!&U1[HUD4WS.Z2
M*C44AL\!5*JI]Z%T.OS97TD#K72XD3/_0P40'HE;\XJG*AUF(W'I_DW[+Q$/
M47 ]*R_^G]:9&Y*D#>>K7_HL5?-87-N^;D93Z08P?HT&JND]%$B(S@'NS]!
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M=A<C] Q0N=1M)TJ2W^ D]G8+V56(%1-C<%F]D3N'5O ,E]U9F576"^$C:,V
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M2/::7\7:7:'/4N]-;E=^?RK;2,M]OWP@H?-+NG&ZC[-[V2_HW^FA+U\-CBF
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M(XN9'@*;3,% 0M^Y4&/UA0/E/:%'S+?U+ ^^\" &^,2J'.O6YA@?0GN7X41
ME[:=PFD1LO!#XJBVS0OW.[$_:SX)7TU85H4H&3W Z(D JCX*&) ["!N.F$W-
M5AF@RR!3NJPD$20];'0=-]N27FW&+R3M@,/!X?U'7>Z5CF^O""V%'>P26%/N
M]QP #S#]3^EKT*YXRC,]+:;6>@U'<RE$EAJKMJ>+#M7*.RW_].>;&!<MY&N>
MZ$EJOWMAVYVUEH2E"<ZUM<+(J=@CJ,/D"-RC$",B.ZDR?DYSA> @=_53JG[4
M+V&7W"P\^ 9O(MM43P*?X"S,[F>#Z"X&P-LL7=0WBY9T3V=/J/.J8-4C']^M
M/?1RVI-7N_0Z1_5S_0V!E;L9XB(?O9Z3-&@" HXD7!1-E3"!BQJ<H0F3$+'B
M7;;"D?BJCN G5JC[:7PZBFO/="<ZU:K/FO%7O=\_:^7,3A-8/=L,(6$,? 4N
MSY!*FYWE8@\[56/!9\*IWTUEXF>.0MV[5E%K)NZLPZW*]*%TX;<SXJ"NWNBQ
MUCADSYI4?4N\X,1$2UV-O<H'P_W">M=?L\NXQ)"M\;,ECGQ@!$D%QH=$#7<T
M&G\O(JRX.%QK&>9;57.O71>:)K)*K7\K.-'4ZBRUKNJ(H?K3WW-2/4*.#M/4
M6H\VD2HHSRO&E@Z/%Y5+&>:OR_1VL4A_2U9Y'YK>S "N,@5T?:$!R@=774IM
ME6MNJ -+"$](4PG9WNVZA$_*I1_)&QO;%4<4=+JTJRX<J</3!(VZQK>B6A7<
MZ^&<GV\-TZ1GC:"\"]FRUBMS#3%V64I>>0IDT5AOI=@ZP3.GWU+4:YBJ9@#,
MQR1.T@?.R;4Q "YPHHWIL6;BM/UF,]#\UHN!%)*!"U'J58=/]H$$?22I_[5"
MS..2_;=PD^AW<.VK^2!N;QW# R);CBLA1Q0I.?QN^OCPFIJNG]]=[]N%M9'?
MQYU5MN5NQ]G8V$LJ)]0-A"CL/BP />:@#VVKP62C&I)5FP#23/I,'KIN?RI9
M]X= TU?I#Q^G@S=S>6(IT;O54J  &:9'\LF:18N &YWPH\-*_G9&W!QG-2.G
MGMZ<D1G2CT+YQ66;LF;+1Y+6:$)7VQ"\>,(^3)LD+WDKUA\2)6;\O<+-[>7"
MPG?KBJSQ<0>#NPZ?;R"_WW@IQ^[Q3OM6VHHW297X XOWSF$!8PD);XI ?46-
MMO2LB-6ZDOF7EG4&J>Z7];X=RI<R?5)=3X3;\^KYHGYS(IEDR5$<R&EAF^?E
M.H1'R:!6^[E4S+FIBZVW7MY#AZ2-"M]^2S!\!N?E MZZ)5S0S(E$D\PG'+S:
M^ R\"L T(GN<.DYHZ9SDT]R%^L,CPO&2V>W]BM_[OQTD[F>5/[<F ^1F6F8Q
MNV/79CZ-9#<>;(;.]?.!&*)@\+/:P9]4D?3%ME#-^BF[R<A$!9_XKKO72/<>
M<=]+%Z;Q;]B#9I(9."1G-^6<$[86(;C4N)):5#+_8KUOQ=^-V\]5@?/480X+
M40=[W@]GNX4&:/Q[=0W:21AB-U/_(CW$'G]CI[<#2\.>E;<?ZSJV?GYN^R#.
M!VY> ISBHN7IW^L!EM"S>= C>V\S*4+DEQU0MA[7?#"C?>=F<";?8CW"*QY^
M?X8KJ0QW]L8;[G<22Q_S=O/A"B'NNP4K= AHL+>Y9C6/X,1FC<SHA,LU#?3-
M-KUNEM'U]O;Z<4*OK4E5-?,ZP/T LC),U5R"UN&6:XAXC"TLJIPF?X]8S#_D
MH/_#5*.72^MSX3Z$,OQ&65C@'9,[7GTA-E0.<.,R>0M#ET:R$V4QA)R8*^!=
M*">8L+K1WA=4@$P8D6Z4]3([IVW>-7:J]R0AZF@,L(1P1H_K=D+%A(ER$<WW
MO(M>QK4*@>FF/(O"Z9YJ <&UMT1^/%H\^R5%$OS*DIA2]V1=7[ZG69X9?YQ;
M23EAK9K(&B)[.TY@@2X,&A$G^GCD5\XK?J?:F]55&_!B/TX/I^;XO>6LQ6F^
MQ_GO)N!=11B :\Y!)E;S&:ULMIF#B'OQ@YB.G652+'I%?D&(=_M.B=0),SX^
MZ?VS,'-#G-#>DNG];\ER'>=9YS0>.X/QKFZD+>)T;:OL8>X\WT]J%1=;:B[K
M=6<*$9QOO]85.9JR$9#+T]_M1#(W@NYKS7DY&7*._):L7W#@8W[Z@?8O8XX&
M+]\N1I)_V\@_57.6(Z.Y[>X9\C44$X"_NT:3(RT1Y")I:%\"FF\I^]#HS]01
MF<_77U<WT/NC[0NCR*;GC&2B+*JKY'.>S*FC*1V[X3@4G&8_T'H4:7>-Y)-!
MK) SRM!]'=OI*(3ML/7^EIFL4+!E+.-]I$3JD813XJ6CX8[&Y!KZ(4XB-GJG
MHZ$>P1LB['JF:;:#%%E#Z=^GZR^17':Y*_043-.\,Z/O:#$/SV?MI'3@)Y;I
MHM[IJD,.HX8DSPRLT 0J/)T@M5#.!4FY:K)$7I@!Q:O7*S9Y7?X#E*OJQ 7A
MHY$?SY;',Q$8P87H<+4]&)5#>D!L^5@TU\+=K$/0<O%V$T<^^BPD:5Y4"3S.
M;\R9$9R$]&;&C)!&:0);'3,\-#//$,VY)7$TCV?VOF$:A&C'V2?8?R97P=NU
MH:&QX=GE5MT;;I-%]I+G)+UR28AE46@X_&@(WRA[U-?7"#::M!_AYN/Q"/HP
M_T0G)--D+472TJ_?L98E=J\:H3G)IV#6B<TS^P@3OD0U&Y8AAXW??,X=/)8\
M]''UP_2XB^^=8?6.P0Y16;;S>3VWH$IZ5T<9P&RYI*A[[5/F@*.AY\JRKK8E
M@YVS0Q4K@^7ESIGO$.G#EV-D$O2<7_';>4QDRV-;F 9]T1[IUC:]/Z-M6HZ4
M.:U <J@L>V'H1\0=TJOT:'R:1<D[3M;U&9(VD+E[+B()FEC(J],9C'F(=^;$
M0L"I$+UB9(I)QI4,PO(TVYM8XT&7X?(MHSNW-/@NQ%FJBXY+BRYD?@_31$?F
MD,S/&\W)K002G#A JW?GNEI(U"[)_=7DT!=U!R-/*NIUMG6W6B1;.(O).S^]
M]LHG+&9GJ-48A#$']0\R;/G''.)Q<$,X_:AU1S8;Z0G\$'F_6&24#UO+R^X[
M-9$1J:Y4[8DG\1V73J,6<.7%?[2L_K]JK+,P$ ;=61M#T'MG(O=.CINI(PG3
MA+&[@<O,',MUK1VQHUFV-OYGTQ/-5RD%9-FZ\I!?P7ND+:,17+.JUYQ1[)@_
M]^7WI5,'%9WY@_A4]PD5*JE\>7_M=O  >]V@DP832I(UWN:,G]L@T./+%K,U
MJT:U88@HM=?^$[/]+R??:=^IE25<:4B32S\X*?(H/N&L.)1T94;",YME]QD#
MJ%58\V]1(AI[&=:_2=%C,R)P-;PJ[#D(I 98N@)<F3]S(<C\UN,DW(HP+N3
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M#LZ@9W490#Q:9X9TTZ?(KQB$S%6]?IU^MS$R ZORRY?=R=8Z&GGTIR(#8+O
M -Y'D.?H;6*^]-C4ED1$4/'>'&HXN$(O8V(IBD0] Q@K:ZZ$S#7LX)C9WI>
M"09P*Y=G_:\43>6:$46_SRME *.9,SLLN$CT['C_MAXJG &X*#4Q@)>'RE9]
M_\8=Q:QK>T<:BZTK&+UY;A%JV'FNU6"O?K-CB'VL2166\.E,LFZ]JF:0*U_U
M=C$BF",H"-)P"QIP+U'O0<YRA3_1J/_1N!U8C8#9]D:W-U<H7^^&NSV+TO7I
M![R[3E_"P;,U3844-.3M2[?F=R&5W7<R7XT)<:TQ<X81$^WH:;\&&Z6T\X=C
M3N N;/.W5I7;@NC+;UI;7T=^_/!1-CWH^YVDMAB5WSI( )!L?!?!B?= 8!B
M.$RF@82)UU8E&D5=_0U9NZ(O'RV$:*DS/+NU8+^V0F1"H!N^L9ZY-="#GF&
M)F*^VNK=SC#(VHG@1+LT^897@2C?^#.-^$C'[S_:>;M@Y3_]&YQ63!NTI:4^
M=2;VP@Y09F^%(<Q/5G]X=?'C<FD4IZI &+#JM;Y&\6<"4U7:A=W<96V;4F3O
MQ:&;F&[;A*Q*T(<!=!9\#%41E;.HJA^"_R9B+S*7<&FB[W@LOR$[*Q:4IYJ!
M5*+5BL6LEC&LR[8C&P 'B\#2:6\I:N?@DM@G(^XGU3H*];&WHU\VGAW/.X[Z
MT*X]P+[XHHSLVRYV? VSLEJWHG2HV4++SGU^E#/+Q,+\F]2/'\=TSDI$W+<
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MWR>%YD./EF+&>57.4&YG'HD!OJ,)4SFU[+N2F XL[?C]G+W#1K1J*&$,H&
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M?\?IRO_$C<.E:&^'*&/LWP!02P,$%     @ R8B(5#N-B+6VN0  D<@  !0
M  !N8G@M,C R,3$R,S%?9S(W+FIP9\R[!U04Z[HM6DB4())$@C02!"4I64%:
M1/)"!"4+J$@6R5&@%90<) LH+0*"1,D2FYR1*#GG3#>Q@0ZOVN5RK;WW&>^>
M<\=X][Z"&J.Z^Z^_OC3G-S\"?@0_ YQ54U)5 HB(B( Z\ O SP)<BA[6%@"@
MH0%< 0"  OR,'B &KXC KY\'?AQ0 $X1$1&^?QW$I,2$@XR$A)B4G(R<G'!2
MG*8Z34%!24%.3DE#24E%#1[DI\_0TE"?(5P3-B'<3K@+_*:F(*>@_A\?^#J
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M#B@^D 01:9P'FWTQ)X*[FW9/;@[77XP'X*$_RS[AY&X/%(4BV$2.'FXT1='
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M'I0;I!8M)7!*AA5%"RHEI!I\M&>V-;P$<=;JF'%H+,7_Q87%V/"YJJ,HGK
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MM3?RH_YU\];ME?O7XQ#QK3W+HP<*H9D4BR,0,YZMZ1*GRLULJ"!BCJOB4=7
MU/J,:>-XYR9%ZX6,R>X1OS7B,[J7*"YR\=V36V._V/:06D\%CG1Q#TF(1#\
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M\U!#-_9+^=,!0R=3'3O*\#^R1;4WUWN[T)'@DP91[LU"Y/6U')'UOEQ(G<"
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M78(8-('W1C;#HHZ-0)K$ W)E(/?SLVK\M7OI43I(.RE7"./5;]_!5_5$W@_
M$7#\5T-1/GC^NY_(E083_IHJ!)RS]A)=JBZ^X#L62I@T/;)(V;\Z( A;'NL$
MJ\#7FA;-:1D2WBB"$:;RSB+'R3L?]F"E#C+L">WK'>CNWVF/W)BHPOE#=U1A
M[VI+0Q!(*!-.&0PJ6);'HWA@NB3M1+@5YY.+V![36XH";00(O\77Y_SK]A@<
M^\\@7X7]AZDPP]_N/_RSX@GN"]"VID@@RQN%+MB7MKN<R%CSZ-_#PKO<S4:U
MF!*_BC:]>J-C(7U/!;,%!OL4&BS^WS7P:JX ?4FN](0&W=@@)_?#]_*$B;6;
M5V+ @KZ!2H+HY>"%:W;6[.+"A5]CH][<TI\YU?GA&8*8]?D#E'?/I\5H1%>E
M?MB=#&NMHFT7WY"'WAY(RO5=:]WR<UZ?,RES0HWEVO-37+F=SW=<-I 49FDX
MQY];]5+PXQ%D,\ U,JPLA:88;>HJ-6[GFBALLM:QOB'I?L?@85!O]U)34="2
ME8G*8$='=M?%=TUMLLQU<.J"6DG<D"\#BBS&9Z[[2NL,=K'WQ]X%FFCIL$YG
MQ^=%M_  ?_SU3+^YTT'4D@J<'33-6.C!!O8-1NO$>7V*X;4M:\*K_&JIY9*5
M(K9NNOG8"T5WLLWL2P-D3K><8I%AFESLS;SK>I%E<#%T<G1U9WU'QL;DVO-K
M52M5*5@D]RP14F@Z3$2"8AK'-[9WJ.MV?TUTNM7<ZM7CT,=QXY;)BR6+#$1_
MG#A(#MO+Q9EAB^UQH9:15^X69K)G^#Z'-;Z2O5\%17X#A\$_"_JS^D\-I3VE
M3/AQCEV_P%7[C78TL3U6ZK# [$3J=[%[(@R:87]F^Y%X)^3H\"<*U5PZ:8_V
MP<M:>H3X.(Z"9J[LG]4#SJ9G3J&T0.PWDN.H^ C_W_H/PNDX'N+#>?OR8X5N
MF <1( ,E -)2_S<@!\ 6(T(0#_YX@#0&#Z".K<$*)4(3(/H;X_]$I$C>$\1R
MSQRB#2N,ZP+E ?Q/C%O\W#(!BXP[2OMI$4C";+](>!4V6V=RA1NG3@WYDT7Z
M_N9@ 0(%[_ZBX W8,B@2T6I0PM4O&,(:7WKK1!X1T%$$HD/U'YLS]1 8'O>]
M$[$BA@=X$HY"?V^F6B!>=:$7]@G$7QYDI_TFC3[KSRY!@&-!-^'W#:0>GRXD
MHFN>NTN;N/Q-F'=A"U_EP4\K".] 1BO<L62PA6@\<%7_/9C$!$@(5%WI3QHR
M)="0.0'B/SL/W=\4#.K*I9]I  N!P$$_]T.@L="-:I F8#L&L'>XPK\IZ)MU
M&3FHDQ';K[/=RRN%H[)6D:J7$FS=OSQDLV5T9E5U%FWF:>:^8-#DJ()FWPR/
M5)0XJ@*#0(K2Q@/=CUZ"NDH4C,O='R#3^4V)HYB;H(&5BX>M0E:-R"V<S(C@
MAGEMH;$J25#X<Q.!ET-'I;;?7O?Y(K&9)+$/.63=:$^K)=RDUI2M,BCHFJ;5
M+5GNU$ZXLNV\MWGW@?;PZ1G[UY7_#V7O&=;$UKT/1Q%1JB*]*EVJ4J5(L-!$
MJO06I8=012! ($@5I @(2!%$FG3IG= 1:4KO$*KTA!("A.0-YSSG*;__I_=#
MK@OG&F?V7GNM>]WWS%I[PD-:Q*!IG=I+.WYZPYY]$ T_D<NK'28.\X^=[,*Q
ME7=./F6\UK:<FX.&N^E[9Z*WQWA5?8@<?4")!M1H:7MF"O-WG2I:W%F/G-"P
ML-ZN["";BII7<[W?ONY%\WP]U_?U^?0R7@9'_PL/A-+"J;"1\A&2?1'6*>/,
MS[5,6%_C.FJ4W>UTRA0DE\,J/G\NJSZ]]2(M<7_71VS;Z,R9<WI9'TTG@IP\
M%-MF>OGA7J/$R?PK]_/?44[GD"RLS]EK+'=WJD%B]Q<IT'7-@B=@'XAS<0=G
MBDCN<+;97%)MO$,\F>@WBSDOX,\S=9TW!( ]8HJDC0"HE-HMD FU:@FM#HF1
MCW-_8T]YH]S</G]>\OP61@SK\<5XTFSFC[CSB)>PB&BNIU"5&M?U*U'##/&D
M^[=G*!)83M0>1QF)JJHR:U]G6I[VE&HT<\U?M \WH&.LQH;6G%<JLFX&Z'LI
M"GP?%1.M\CF:,7OPY/KNSAT3Y@PIMR\KRG=TU&9O?K)]Q.5  $#VPB%+% \Y
MMKI8G&.J_5ZY%E I(B.'*"4$)?W0B89W1E;Y@>*8V\E0;8PZBC'(U;7TS1Q]
MR=J82%X5PMK?G7]F.3''_J!6#=;3/XR<$<[Z<85:4)YS\@"YDY3@;_7&KZC(
MXMDP*VM5PYCHKN)O-EY*L_<_U6WVEPU@NQ0LI5Z!0A/2K$BQZ:%6 N"F@I\K
M<H%JB^'TZ*"I?#9->K9&.(X9X#8)E)ZB<Q[DD'D19D@B2#/SGFA 5/81#9NE
MZC=P47Z'9$F6N;K#]&Q4FE*(68\\:6+*LD[,ST=QWMMD4E-8LT7&4 7FI>O5
MFC(:#+4)%K,@&_-GO[NDNI_OL#!,<7XRF0H"4,A+BWOHQ$XAVCR@VOJ_]MZP
M6A"9Q@K8DW0LY8C9U2+QQ9OX08O)T*>Z22>/!9A:OU#S=\%K74.;;LG@--_
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MXKHK$]3/L/$[ BN#;)0_8\Z87YL'T3[GN*Z3^,;U,"#K+=F& >*B:)Z(#,-
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MW 2![>)$TUT<B(?^?>"$ V$ 1 *P5F2X0!P)T>.)L4?4 M?(.CA/+V')" #
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MO<-]QK50_AQ.*O9M#7AXDXAH7P@ DSH-?"CPQ-1^]:*8+KOIF38N7IO\7^'
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M+DF$XS5R@"A(QG?X6C48CGU&3(N\$_/AF*T/\/Z&_"TH$)NJC76IC\7U11
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MLYH) PE5M_>A=C8D+H^_QK_6]-^&NZ0 _UC$+IP324AY7NW.V&W@OD@9GI0
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MAO7 O!FM8F4794A3CBL6S:KCO?.*E<EY*?BCH(9/BZ[=23(8AD>5JI$53)F
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MTL"1X3GRJ@Y^U/([[_CFPL/=#;G6UO>!3CMB)[5040_:YO:PG^T?D]SS',<
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M]8>B"S$!);YR,*/?0.0HMC?7F6P?FR+-I$&)6X*/R*/4SD]L%W9&09JAJN[
M#Z)HDDI3F0OM?WK0^.:A/>-1[F9MN.B4E@"$.=L]@+XVX5, 2G)$;E;8QX!7
M&DOM@X/0,-V"VO8'CA7&YY0<S:Q?V8=[@]7%<#H;'P3W#.CY]%'&>6.YW0P%
MMD'LF\W<#189.WHN-.N3F!DID*S;Y3H4\4%3]%1EN%C>[199Z+B !NX!6O7Q
M.P$HLJ[1P4.AKI+AVH#->)K=G*(D7IANKO)D&RR-AT8;1R[8%HNM5'AT[6Z
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M-4W$%",)?S+Y@,1?-#[]4?1=C4Z9("OXSK(R8:31!0.[A@_KV;JWHX_6;C7
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M1QUY8BCVR-)1AC_KGU]_'EIK9EPM\JO3=SY*_&/W^]UT/&4WQ;4>D5C8=J#
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M(2O_.AQMPD57QX(2U4*>1"^TP*8TL\W!$TS3\N5=T!MS*NB@NNCR-S:R_4I
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M?9NTKV#-"]LKRPD%^RNM1:S-CQM.K?"TD=^[_.J#W E<\=^4X$(.^'A>4#>
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MND<+UJ<I=&!CL#QP\E3CF2O_J 7Q,R#N):.(K1V=R#;JY)H>,K26)(I8JWN
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MI%S_6P+6;/ Y24XS9X:&V\YPO%4='=$QV?LW>&UF,/P;L6B_,'SP_I)&?S,
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MRGC^"7'/UE@HC"+^D#/ /&NK@\XD:CZJUFH80/2IS&.%HCXJ["&W1/WV(40
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MZK[;#0#X7T\<Z?%@YULXB4!>Y>;(JX)K7I,F1OB\2?7LU172Y 9P=Q/#Q-Z
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M=6D&"DJV\RLEEKF5\E#+/E%DYJ?]4GV8Q-<YNC.(:M+Y1_@:,FA(R+)QS$%
M5#"X=)%#?KC!Z4[4$(O[FK>?G97\=:X$*63)AB+=OYAK::N818&\3GO4/+K<
M_I%6_V&?Y[!I((,:8AO6&=.F@G@\DF_C,1MO]-R.(:G"8/<1E:O>A.FD,J<>
M;3>W.%U@Y,X5(]Q]3QFIB>!XCAXVL*L$JT]M1 HE?$AF&XC>R/Y(L^^K@ICL
M7L:;J8]2(S'B^BBD@F,]7JYX//A4O Q'7551-DX?%-$!]-3IO@'<.Y#PHIL5
MRPX_+(RDRNK#]2)08D\-:G^N/<!TRA0)N-SM7C6) %6Z7MM.=E.B&:9/EV@5
MZK_4"_?SJMT[.(\^>/]L891(GM #C"-%A^R60;:7VF:QTGS+$F[3XXD>>@_*
M2U096W5@_6B4\TZ'2M*N!DYYP .+H_"L-88?;';MB!5E^TBV.:E2:UNO1;!:
M<<J3-U2S\<>3S=K!;P!K_6%2['*>:(:I&=1^(DZ:$)D%].D/%C;=6[*N MUC
M^QC:;1[Z3UQK'_WGD;Z1+BCFE_*Q)?G_'#B!:+RB6$?+\X2&HS,AX-/'>_O_
M3"*S@"9PN@&P4'9!?YVWWP#&\JNN%/XX9MO.KVO7NXR*Y'U^7JC%Z4E=A9WS
M2B,2_/$&L 1,9D]9J*[;WI$F[*5OWW%/F*)Q[CL8I[J^#> G>UV3$"]/G%NH
M:Q0FDQ0)<'C<RWVG3_YQ#DXOF<]$6>I.X)D X*-IT0J=U08MRB+\.-]9,=]Q
M'IV?FW/'&EM0?+XFQU%K]CIK13_*QF%)- =WK7WA&V/-079D&S9LY;YM]@,)
M'AAUFXRED;#*#,V;1#.Z++WAI\GJ!MBL%Q""8^BZB;RAIY4L,@.N Y-,0*R$
M70&E0NE/]9,[2IT')6XIQ\.";K-U:,3?!G@VQF!^W&#8#2!:$'C/3LRU>O>7
M:\<;Q-<B+<EN#N[GK^\P7>!^N?UY_^N=1VP1^!*U*2PE=,YR?K7"O4>WD!D]
MQDS3E1)J+B ["Y^BA87Y07_7AK:&AH"'S3:W!!)O?47_I#LF>M*X\D# 7ED)
MV0C9F=50[;@_[2!H0KCT-=S,KX.7:-I47'0E&(J;W&^V:1(*) !)<7@FJO 1
M*JB-VW/9+Q^BWDRS':_6!4J=5._Z!0P*+BFAGNZF9),\>-&*, X$P1HG9@U,
MJ*@_[?0-QDXE,3D,@E(=^-.W.W"0E-W^(H@N/61W3T,'S5A.:!4W6VOVD+"%
MERYYRZWMH/Z<08CY;'T!@J)P70U_3^H1O"C3?HV>>692+ENEA:=HQVE!I9G+
M:-K_]9#2H@)[TLRGN&PTJZ_@E/\#Y#J*0*.YOO/R77/#%*>)7_OB_7?Y*?P_
MY<"*0(+.C72D#OJ;^^]#Z\OMWP%"A"PZ"%"8P!*ENI'I9/<OKI387]$O7^@\
MD =Z#L;???49.];)9*R_"RU%Y_D&//5T]K<QH3-'5*PA1_8F /.%M=:RLG_$
M74 VCPQ2D=J2M#W1B]WE<...D9 3BO6&&%Y4$&.CA_@]37K=EYDZ$/R[E G+
M?@UR%,5$*Q:>O,T;9N.-5E-O\7\]RL^2"Z-F-:O74'X0O8KULM>%?]O'9,YX
MJ_>PD@GQ!-T[A1[X5=DZ]R3=LM'=_+A@!?7%XUXTPV=M*PRD6QY1&'O: ^M]
M7\T3Y=HSY!)ETB?7@.I0+Q;2TJ5O &VWI;$/$Y*66W&19^4\ ?4\Y(UA;^LF
M?9=:9)=M-8H74EV><$5_!'V$>3VJJ;L!S!?UZTV>KN,FN!&B:T'V0JD$BJU5
M%-IN\<&3%^]CLKL*\BZZ@7/M5]AKA 2Z&4;V\GZ"9]34MSO&69:2V6]G?K)?
M6/R\5>/0:7'WC!YG1Z?CL0U+V.#^^\VP0?6>3EM*TE3:T6,J@+>YM[95^ W
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M4@T.''G^2&KM7NSV,N1IC0Q5XB00RP^ODK<2/8J[B2N_30@ENU-F_^HEC6R
M-X^W=QM+7.T&V+-Z1+]^_!!B<)<L9J_7-5VG>V&XO7#6VB$ '["E3=C*0/*#
M_;;!E:WGJ=Z1U1SH 2][J#KXZ5DF.ZQ"NR+&^;E1&_M953JMCZ3D"W>$? "=
M;YFPGS7VH&MVF%CAB?\YKT,3(S\XU'4&C&MF5&3W'9%4CW5@-&RB<)?=ARY;
M-=FHOH0E_GC5/8?(02WXEXO9]5,9Z8&AX,C)I&\7^5T*W?%[$]RQLXRV0O[Z
MH5[27RU94OK?>FM/9Q4DDK]=X:#S72K;3H$;)B4GL8C[\?_$=,S306UL??%(
M*^X@/O#BHQ4#LL+/H/O"O3S#_(34WU+<&Q7O,SM&L7OW=3?>6.Q3+N7N>?]"
MTOMR)\)&;8Q?Q_"^#R<W13  <.&>#&N=A6",ZCQ6_9U"[$\#!OF@_$K\B7.<
M57V^L:XB?[0'9 4<QM$(@X9>U[6^NP'$ST#VHTHG_^L8U*[$_*T7CFFFXHKK
M&%Z* DH"^5Q@H5+T74?LJ%URBZZFQF<"&VR*:R@4]47YOLRJL^UH-ISCFQA7
M?SB(:8+%()MH0<6B:(1U]!7I*[ GGQKKQK&SO">$#9$=)V%5A#'#O\TX2.CX
M%>ZDB,V-UY43BJL&+OF_<#Q@[>1A34ATQ*-+/SZB]=5!0'J(PUO$;+WW?M:,
M6!09W@ L>HLWSR)HSEX4/*.6*<L75\5C16A:&HV?KGP 6F43[*9+Y>)FQ14O
M+5K7_%0225=B,7 ?)9 W(!I0>JK&=%$)"0<2"'2&>9-,5$(>-=?YB/O@Q'H1
M34<^?O'V,?3V%]T+UO3+SI[?OA1VL&NAQZ[7VD!"*GN0&X$BN-9WLF*)K?NI
M7JR488#4T7</JYP2-VO?=VMJ]Q=^Q%'8TK@W.JT;V*105\YH%G:S)?'^*'!N
M9B6<H],HL7%9QHBY)4]X@Y"'T+B-!T"%3J,@#BRN;$?WWH@"C_N5-"\[OH+^
M;,:J20C$?COLO,M>]D"(<6Y2V<N-LT: X5T\X?Y",)YXL!53X(Z)9';T"GE5
MF]YJ.]^RLLB;N6]L4Q??N-:G"H0)Z5:>R":2.I/CQ_=+$NK,H/F0%W)P^A2(
MWUJ,M)U^R,4L1;I?5?*M'I8@]8@';9]820>QN9T=GSVN)1\_A82@"9$ZWR8-
M1HI^ .??I1L$NC@YL1X/LGX@S5)PY]RVQMYBIRK/(D0:85@;8,E8*5?6R8I\
MLC;#S(UC(=>2T[=I+K)(B7T3N](7:H7PZ$<_19PW%]ID<7Y8(33=4VB _[+Y
MJ=+&/%ZH7.0L.L<]/D6T9#=_ [#*_D#3V$M(^QIQ^ZI[W]A<2'WATN"5#NF+
MO#WVSJ,H2,.0$5[N/IF&G-X?B5'_Z4[S?_  U_[3 SP4%.K]KT1@3YK^=2^/
M=:(6"-XXE;##" 5TY[:GPA4Y!:EP5!L.$7B];Z_XVO7E!?CO_!QC+R"?3.XC
MP@.@UR*+-X"?/7_Q\ZW"VC.K+DH:^O9U4DXEH?&+3*^=/=U:)+$RZ"RE'1Q>
M4C404^7%ZJ.9L<WI%.>]*J8FTH$T*E[D#[6I[ .&P#EH0$$E;VC]I$^N3[?:
MO14I-Q<7+WIQ?QS"GJ\%2&AU$.UJ'[1P?#)_]V/#LHJ]"S48+S%RITG]UK[(
MB/?LW'=/5H>CAIS$-4&<&N%-:09-)_C,9;>7HT&Y65B?TXB5&KS3(('4P(%R
M[/RTUX>D78FUBX5$3;^6L&\&%+\-[,'HFCIHL'WFK Y^/ZJ,R*ZP%JEE9L-
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M'\\3;>AU6"7&"$E70[H!]_?Z?'W*LE'1"S< A #6Y7.GM789TWNI$WRQ4N=
MFJS^?OV4[&2#4EJ63:@(9!J,=./9W[L!R!YB6@C. *$?Q2'=U/9W.T^ MBM(
ML<;?(5ZDEX;^3+8_^A?,L9O)9-=C5!R[#C*R"'1VPZ_$(.<N1^O7.C< /.T;
MP)7*TQO -PZ@%89HI:&T@!<T?]2GOG1?(164UV9>!V$VY6X9)0/?M,.;GHM8
MDEB9AMO^9>#N<HR!)X-1\R$HK;_F@F%Y.)77GU'(&X 6IM'ISC\"_)(2=FL@
MHY9^-X#E1:]RCK41F67IU^=:&E>LL[LK5V+=YRY?&>'9NVT8A3]@N_([O N$
M9 /O;QTDK5]C &#QCV<YQ,-XB.52INY=/GL6*N.G(5E,S4GNW%;]52<FY?GH
MNWHHT1O V V@[ :PNON[0B&F$=#^#F:5T)B1!I>#T8\"@&RLTT5^H9L)B$D7
M=5!!<D8)U<9VO7\],9+-9'\;4_2\1.%?4_&X$FL\=S.YS*[7N $X_5F;)68_
ML!'PS&<MWEAD=&O4[JP?36^"$K/'_&H$V%J8[W>_RR6AZ750HEE9P.G W\$G
MC7^L08+S(C\3=7^I(&/:X,:7?N]K;Y/?P]NF8D)BUMSHSVG? ,*U_4>CP1O^
MTV"X&^B/R+@-?GY'1\4CC42 B,/G:[NS,_!J<F=MMAI2[<SDBM[@]W[)AN_&
MS4$A5^PMI1B0_5>'\3,]UWGW_=^W(+*=3";9,3KEDIV! C,@HT9TI#Y2'?R-
M VRE.*<GX5=V>.\9L*&R>?MZ_AH 7TX%Y?X4<\BT8U&VL[&G(Q4GZ4U^ U"B
M]R0[*@Q:4A%[0DN_MP6*8ZS#[81#UBB:\=) C.$/Q[#"K*(>K6C$JX[Q-WC)
M'[]<GV6H9_(3E/.=O $0:KG VI6[O8TK"^9-P+8V0#N#*/%-?NJ9V0,B!CK?
M#X[2K-O%5*689;>!/A@8MQ%F).YMC#Q[8B\?5Y2I<L^E5\)9D4%/NL="FYWU
MWOFMJ-C^"3*=$4W_Z?2I(&"U)Y7JN1#(J^IP:ESN4^3JPE U C5!K435IU!H
MA% XT%XFG;[2LW'*G3=6*/BA!+;E=&-+4>H:*'G]/&ZI>N6S.6K<L?I4CLWW
M6X6O.^*ZH[E*?U>?,"RF6&_'VV_+'B*!^F2>9=_JA65H1BW9O*=OS(3<7,NT
MZYK?*BWX&9'_4VB^O2/S7?FP:XVR:]<!<X8KDP59D*.+7%?_>'W7E2Y2H<#7
M8.)]Q9E$CSTWA>?6\Q, \?=L&8X>]NN&M'H>TF\6JPOE>UR25D*S":W[4F^Z
M'O'[=C(?&[!X &8K[8#D#G4K(0W^3QN"%=M:FV*%WHB5%291'-8FG!!WLT_4
M%6N[%A6KS.6+3L8H-JD8\4]4'.15UX<MD^G"(FXQEWS%QP64EF\A@79*W *Z
M;CWP6J%0$&P:053L=MZ[]#YZ@BF&DK'-=-Q1@4JT<B7L!E 7LBR!-%OKI "&
M;=9ER,9L4>1I-NR\8-:Z<U@.%5>CPF&HSUQYO=_"L"WG>V:%DD/6(!P$S.%D
M3]:3.PW,)VBUU![F/?-:TY1Z)B4MO^A644Z\H*S2-,GEL W?'"E7\@+A) BL
M?H*Y)[!GB&R:>A;@T3L2>^O0QQ650&BG.B2,9.'0;O^'-7"4L9T46ZN!"OM+
MGT"2^-;&C]"'5%J/<Z&SY'V+_M,,K&&KNNP!6O624LMVE;;\9>RIE@FJ"5)]
M_4=W[S\Q]!,I=M+]I1V)@$:LW&]3AMT :#P57HV]KW 0&-'O0V\=KFV]KNEZ
M&.Y-1O5M]R[]WO<ZX/R>-ORH>])CG8?H4NQK75VV6J)X+O/N+:][MH<D_GO)
MK+&>>>O59S'_O#UN!06!']"NS08<^,K\>O-+H$:9];[^(G8\HOKUD"*U;'1P
MK)P3\.^@M_?G#8)H^?_L1@4#(CG#DDJ-?5WAG\\37L&K/FBE\TGCC0A>6/T=
MYWQW?A/>2>8V9"5L^Z,YV"(A#F5MUTK>!NZ*?GR  35%0[^&D?-7#@]!"I;D
MI"V?;@##7N"C6A-ENRS*FK:8%!^W)MG^I0V?V1C/2=AB!_T[)]L1R7(Z$O]C
MJU\Z=YO[KO- EP?LU^?6J%<K)_-JJ/W)C9AW(NPN1$T[*O=]FWX4P[<"B.M&
M;@"2FS> CI&'3:EH'Z4;@%^Z4[0B5C3]RI*DK63E(N-0 /VV,J:0"?J70)9K
MTPW @/WZU.85=ULRD]^3CX ;@)C)Y>X-X&*\@%_I7\68#T5&5!OXA+7F)0TB
M :'FR1FW%*"HON(8@]&[K(GWQ<JJUQ&EFLH)@1;OD[<#;!63S8;4< (:#1VM
ML:+<'"I3O'ZX=C477XY)W5)Q3-MKCZ@<$?XJ+)9%(V(5HR9>@"7/X3T+,R#Q
M&*X%+ON#DP&.E0Z+5$<>VTAG[4 KMT8NIU"HFO - &(<MH)O%0IV'_N^Y'CH
M=%5.^QK>T5Q\56I!4Z5*0SZ88\7:H)/H.V"^<'@#N/8^7<%&#P,IT,Q(6V)2
M3[LNL3!(_G=#63><J C\S HR*];@7J_"4^$(Q]=NR8;KF[YQ$QW)TU+T2%1?
MYVU_'&"00*4QVLY\BK3*=0S&%+\45+CH6!SD[/>8],2]VLPO?_?!#]M'!BHR
M\_)AGNR+<0^"@RJ(90@MK_-TEVHY@L2NMCJ?2ZC!.HGW5L@D--<XVH$*LPY)
MZI,"RJV-DP73-#[?'#IM".Z]+VO]1#<T,D6G0UGI*P$72NF0FC*%+T6R=]M;
MGAM$B>+*'=2-@_/Z5K-DAJ2I).\4.M7YIJU";B/#UX0_5-;QW+.Y\.ZK=DJB
M+VS0^T2D=(X]-2L'@O.OO5HA+8"3^=-,XT6-WZLLI(O >6O>:6C?[Y^L \,+
MN=)9!]TW_N$IKX=;>BYJF3XZL[=_O/15-)$*BK@/#,_.A91?^< .3-Z,G4G2
MJDY"*JX\2CR)^CC4B*B_SYX+P0VS^1XYA;F[/OPB+;).=DK OY[ITNU]%.2K
M)Q2Z1D!;R:%;F\F2-;/]%/$YMC,4_'*%Z/=_!<-7P,B4WSP9\M5DWG_H>*5?
MBNC+U.+@&B&P.]VBH;*]6S&I[#@6W(:+->)_=25^ TC ZS8YO]?P.^F\UKG<
M=":V._F 9RTL/+0-1%2-VU@@6]);,<^6?.IRZ\58/C^3U"?.'E*HX*R4^$GD
MY>1:8Q\/F:?.FFISP4ZJXY)T.GEO7[:9W9U$Q:K\#QU6KX7M)>PY^CPE9MX7
M>#_P!<!I=QU-&J*HT\GG2$ZR3;<863-;JY,8AS];5B"#5S&L14(+E7$@QA$!
M4V36#G./M7YAT%9944&-'_8N7D$?0<AX'H 0[B&4&9KM3I_^TM@\)>!#.<5<
M>_+"WZVNQC P2QA/6I*RT.G8LUL/J6"!(- )?M/LYZ&-,%IJ\U"Q ; ]#. K
M;UW%D01L(/KU\8IE5ZRNTWP9/=9:C5[:>0@)N3\Q(\JJ:8'<3U-N)DP3YATD
MCE=[U$!Y#H;3)>VZW !,\S-?*#;B6SB'B(?'WUX*'7[,3K75IM9E4L<>*?CS
M3'EOR7M6;:;B] -WA2_[.1W8NG:>LTA]XY#%RX&R:)&F$\88O2RI%NS/BY \
M+\Y%!FV-TMI4;$PV&OI]$KG>22;7"=VEA. ]BI&57<"0TU &XMGZ@FDW<0$[
M:*V"57NQN4Z,+A_'XX>Z0;AW!\GQKIZ ;^LK5QC&"+XU>NG:W!H'=<+[7$6G
M^,!]VG[UOC0U)-NU\[Y=)[FO#8S KM)+0A;6SM\KQ^7F^3Z9:?J-/O5=UTVU
ME!O XW=[NQP*YWEM4[#9-I?B1XV.\<N>,M3O75.H8[8,I@B9B0I*OHE($C*U
MU$-=38+0#S[L/N*P^X";,\(Z"/(1L&F.7=/0"I!1$S5T*Z=<N=/&Y@&C)294
M+LS[.>\;Q57Q=#^,&DO$\>OA4J(75!22(7@48_+ 5]P!S1"L/LG27#==. F-
M$'S<,4+1VZC$+'^I)[]ERK_(4^F=VJL6R< ,AP1=W;H0JPP/OP$T5+U>T460
MMSTRL'NX2;$8V(3UZ2W%^DF^^M@I%P^,,L0U1LA>:D$Q1%_E;8MAM:)R^<(3
M2]+/6?)&<1(GFC]7B*Y$,=A(9&1-,0X\-]H5>&VP:-C6.E8UD=-Z'U<<__+H
M-7)G+=-D;;HSY$JPDC8Y37_ T%!?/D$@V\PFT5QEV>S64*<PP0D)Q_V]M8L(
M-*M"SBX'53WJE7YER/N4BD?U3<%JWRMB?EPN8'")4"JW,*[@2@YNU67\.''7
MX%JDOK>G&LK6\Z"-'_3B>"I<'L<W!((7KZ+5AL1;%8=A973/%-J?;D^8:MV6
M60 N2V/M>FU#V+/L>ESC8EN.PHKA\A]_G=*,AE?9.*X4?WCT@9%9W-'X2E&!
M^@> (20=@XK6D#BQ\,!W\!-/V]WGW+D.;G<^! &9/8.YL07")<(8GQ+V"^"F
M2+H8PXG#)/1@PR!B$_UN[DS[+P8&O0]C<JR_SIM9/$SX:):+HT7/L]H??!HE
M'$3_2.#^G&1(Q3&_1#5_!!W_@Q2V -8LNZT?5TH52&%CQ.P' ;N[//4<] I&
M6<O++SSDF3D,??-+Z#X3-552H8&>4+5QD!N]N&$]PCC*SL?&-+W'_2&%4M7:
M6\I-$69JWQJGN2_6#;EN9CO ^[Y ^$HD1""BWOI%[4[5BJE%6I[Y8@:U_VOA
M6VTDGA6HHR#TO<X: SW7#Z^4[.C32?:IF6.B<EX3/=?>(!WQO2[R?8L 1;F!
M[D%+GH,$O/W+7,OC[74?^!!65$H$9^%N&A)]$I35O\Z18O(4[BKU*K/]8C12
M^N/'<K_3.5EH1=NE'FN,\#/- "Q:Z$P\HY$G2*8&8Q>0AV5O^:7S)FP-352S
M)RKSLJ(%-_Y!;_8[<.S$.CKAG7*=L_7*?F8Z3=&#DM.YLM3#=(_GCC?N6=&?
M&(+^0:">_9G^SO8&\%\A\V9O_\\A\W UY!,R3,'[5V)J.#8QH^"=0I^5?U A
M%(8*L6*,VM!BV/HTN&84KS/MKT3%\\85R(,D3I?@I/G:,WL^@@4]LT3>ZK[)
M?D%O.=T"5O//DV$S7]];07";5(/[W4Q"*^FG^@C<K >' J1[S:#PE=?:S@VV
MSS<>+R08'U<7!*^4E*#[']RG>AM\48*]'16'O:MM^RJEEGLR4?O9CU_:[V?0
M:L-L4^.,\N&$)HJ+.WSVCQYM-WB;?G&3?#2I:9\Z\X1)XZ(5388%N[7\>('0
M$<IO9NT&%<3_9D7[+E%I82$P_5RI@^:G!Q'KFQ1V]D+#<-AA,EGPD+R525H&
MW1A>3'\AE$D[=F5 6X3P8:^##9IBBBVZS;WFN],H)4'VMG$O;H0-?D"*4U(6
M]:6@O[@-Y2%IK)36@32#TKM5>F.$S.+ 3'6L8YM__3S2YYOZ0A[D8^-]B-*C
M;="V ;^%.5/#E@F,O5+_RQ3-L*.NMLQ5<@Z^=UB49,3R-MUI'X>D>M?7CXL&
M'2[&466&"F#3<0%FTQ+J9-4[.&YX\\VZIQ.=CY_J?,&^3 <,^"A1I43S0CO)
MBF0IA[JI-R)G:-Z/K=8ZJE&59\-C!\4?!.A MJ7IEOI2;4J?"LSL\(YZ.W/(
MS\IHU0NE3!K.+QQT]>) :8*\X42WW7X! _4/=^3JB.2E[(LE?NETVJS4 ",H
MNX5:%FQ.,FSBE6+:;P-\/3OO%C;8$&64F.C>5;70M6 2/1/I ]/X'495V702
MNYG@+^C/X4T?FF5H3!, YR'W^3^MF:K>*@7 18^,4976SIZ@U^FCBHPCT6:T
M=KA[^Y3WM/I3F>C*HTFE&5E'5I<4GD^1]-Z>TM'(3E@35[RXQZ$]VXUF0CV?
M%EZ\;G?6"/G.*MGLNW'-\9->]F7CHOLQ9;P=Q;H:5T+3@<-'K!/MJHO*JO[S
MVH<?AUJCHY5Y%_F4).U^Z?Q.E,M,'-:Y3_NO/!B"V3CSMJ_+OW>V16WK42Y\
MUCDRZ>Z\)/'%D-&W"^!KBGJPN9%JR+9@:)7MO%2@8^VN.-?P<Y;Z887XZIS%
MS6PZ@*0*2.>CKR/\4?YZ,Q<7%[.>O8G*E+W5?:5Z8642W6 ,+1*R$](7]Z-8
ME^VHKFN9)"Q(N7A:^XT3/]=<<^!=G*G711F%U"/X]@?!3!_%&-.4/;DL@?98
MSR]1+#ENHBPX!X<<VVK!V0179C P+?+^-IJD:+S"7J!DWXVGT;"74RA/P(W'
M0:NF:E_6#(?$Y1LY:$VA*YM<&8'=T[+NJ0JB0#KOZ89MGAKX3 <>F5%8LODK
MXK"&T%<H0&RSF:O\N+_LV#M1'U?VH)RHYULQ+*S&>ZVZ'DKI:??UV$8H5<J0
MJV*9@,"U(>19HFGAEP5Y/, 9Y/,5)3RU7XH,8<B_ET4&(E,2RKQOD]K_ID>?
MU$3@$]V#YB\,@HO-2PW-& 5Q18M,<H'HKNP:4QE1S$B:CL+G^OD^K,^!^%[M
M"E=OIOF_WVSYK$XIU3G!<^K3JJST?H;*U()/EE9ADR]VVP80&:4SVR9NX5<L
M6[*D5SB:^Z2^5L\]2>#3H@8XBV-S$VF_'HIP3^*%<\X*ZP/#S8,FW]A-D1@N
M*U*19]]CM(4, >@-)+0IP]!XR#V4K,SL61P.Y_DOJ\AW4\SCVIYCO=@&E\Y*
M-*D61C7O/BPE17*55/F%VGCEV\WP#E7WP1<SAQI)#CB'G!(KQ!#:6T92Q_PX
MY81=@<$$@%6? TBBV__7SG<&-;7UZP>I4D247L6@J*$( H*4($@[@A0Q("U4
MJ2$BTJ0$I4H5$% ZTKM( (% Z#V M"A%""!(#SV2D%R\9^ZYY]QY_W._W/E_
M>C_LF?W,['GV7FNO]2MK_=:3'0(^[YX_,A_("5/[L2D</F!DJ:HIPS/Y<T!D
MJ.'7D2@/CZC\JJ5C^VE@:07$9W=B;G6:0,;*4\U2/DWE;WI\5D;%%6)!61ER
M "$))UZ5"*)*6HW?JD CAKLMX9'Z-7ZJK GS1Q,REO0:#>.5S%+?S+1$MD5<
M6/MS:M[0/XQ9$7!=4JP* 5\,T%O</J_G@SO\@G3]2=O<^@GU36 @^N?2!>IE
M3O@LB-1Y?2D&DMH)#?XN4N]:Q@)L]_0-Z1!\DD>7G:]5P@ 9TEF,[V_H$#2^
MF12SY#YO:-VP_R3W@^^M+E N=';5$*J%<,,_+E/U9G" 2KVTBN*^-!0H96F<
MX.RIEN4&&=5R!UCV%SRDKB_P<WRMQ+7 %\] X&SO/ZLR462FQS':(R%7_3'Q
M2M\P&.5 ]EI,#*#=@8<'*,)A14X^O'6)XOO^F?H:Y-&IJ9@O(*;\[SW;CC8*
MN+J#G#O9YK>_<KVY_.L3 1#0>@".K]" ":8*H%-YS<L5ZVD?&>03S[T_<5W1
M9P_@V-&*1*(%YYPF+SC=P6PE%7U;/:]\N$CCQ#^C&MMK].W1;)QOY6T+@OX.
M"TH@W_E8-+0R3<']:D9EG@?KU/-O][OJK;6,C84MMOC>"<Y\L;$@,@O<49XV
MXKAQ_R/@J7_UOLI!?X!^-=YA)<3=7>F1*TMW@KW1_*=7 HQO.-Z4]%[*FM@[
M>MW"1E)#";%5("ONK,E[\97Y?]Z2J%P@:A >/RJH?TW4-. 7B[KIVT?W4>D1
M7JC;)TWEO5L6YSA*'>91V%Q;T7Q8P&[DE$KWP_[[VCNU)BIJ=X_1K-SG@6'S
M:.:?+6SXD\K,G,=:-H6EOQ(ZSK?^:A +U!D6V;,R_$?YCM,HSDE,/,\CPC3A
M<2"# :B+_,]=/>R?NWJ>)G^M^'ORT?[+%?]@1)MV/M..?D=.!NO&[\0L>9O\
M#S7';!+[I\4^0BVN;3SS6@9B6OUO?O^7]#HA*N[K\83()4$%91?(^)V2V(^L
MD^D_>*1"NYYF4M>?GSE^WJ5=X.,S;!;@?0%S^96*9RNS:D69T+GI$DW4>(7X
M17G%; ^AX!SF=[!)3>H<46S:=@LOB1K;(F4U^Y@0U&DY !=Z+RR)I%I-ZM:S
MJ^@)W?<OG[&8=1G@LQ<#W/OD;[]GZ5"TJ5#Q\["LD&![#25>:+<2UVF3?^2M
ME*3*3GI$E"6@6SUZO:"L:W*K/&WI_;/<1S/RE;SZS+/%@2DK3\GXKL ^(CCH
M6YH>-N*AVLYP=O&M1-JEKPF,"*^WQR95OG#<41L%$#5Y'#91$9=Z"ZX@5VYK
M3]] <W!L0/_CRE"VYSF(L? P$ [.-$Q9V=@PV"-/@K9BU0]=\$6Q02)M.03(
M\B[(Y )7X^?(L'AG!4'RQ"*4#6R[S4MP-!X/&B[Y.6K:H5AN-+C$:3AVZ;E,
M> !.!'/Y^8J20<MS'\.\RXG?)S9\Y@ F'=OY%("S;\3]MQ:5J[RC%K^TY"^%
M6'*DOB0+$GPZH2[C7F%9[5=5J[L+!J-)6LHED;N9=$/.$L8:; G3X1HTB: O
ME60Z0N/0Y.@&P?L !F>[4I]@.\.C#Z^J#:3Z0+(F2.%8D1:K6;R-S;Z''[-=
M  VKGU^V8EYP)A&#?+4VQ 6Z0T3TF>TV=C3;WGX$^V1E^.2P)@;<PE_L:KF$
M%1Y+[<"RR0RJ[K7J[B3%'%6IX=$;-0N/L)8'BHB-=5=OJ1Z.3OM?%9EY":/-
M5D0R(TL>4]X=PEV'K*N#<)E^N1,&CDS_4_\AB*AYSQJZ\<?1XR?P]N"1 VA(
M=DTP?CM:$MK):UG: ^>'N7^4L'VS4B**KO4_Z)J80+5S/]^3C<H,E0!0?_7A
MP >ND-@]+5O>U!9F%SX.;N:I#U)*VX.R40!MZDH0[(/%3A 5/=\EH6ND$I=;
MF_"8N9J@[!V=O'%D+Z+&2\7'W;+48]T*Y$&\2(@VB'J>Z9;WAC5%RR.\ZAWJ
M[NG7G=EY4EA:M5 6QNA!S(B?_*QW_Q ]Z>7,/[S =]BZ]@2>?E (G%21"AI0
MD2)XMSN+T7:5,9>G&+VF7[B58,5Q,^5;S+,R4,BKRAO-1YL*7MZLZ:5SO;,*
MR:_)7MFLG43PA5Z@SRQHA]BV=_$@AT7AG8RTM2<R"?H9^GNI11T_=Q)R&L/\
M%A/.KV<<J1O+.N>/W?K/X 6E\%?P8K<L4?ZS));["4U4( <U</?X&'%CD>2U
M ^T08C&;(U]@6D;>"K??S?6+U.@^L@Y.UN@=X*=*VP3UD24"6.(7]"/W,QV@
M#Q)=[SN7%]1.5+!T2C+'Q'0".LXQLAJ^>G:=PW/(2W+J!P+I98K$G*TJ7\1N
MHL"%@\!L6&<B3!S$QD-U<\8Z@RR[FN;8$W^NOU&\F;2LK Y)6^#S]Y=W^/S+
M-O.#Q&#)KL0\G3FUK!%V_O*WJ6GSCM+(W)#.$<)+8)Q *:>,QGD *_59;)U+
M53B9>JV%&8O$Z&ON\$M)=WBX%HL=^I.^VC>ZANVVP!/&ZV8R0K \']I;"B>P
MF[3ST>R3:2O&:;/(P&SG<//KB9K?B>>["VY=>L)W5_69RQ*83TG8@PD]O12;
M7)&<FS9I^H/EJ0?#-1-OTY#I&$\KJ#/QABOGBY:22D2[;>)ZHLR%*2N])_8J
M]K?I[)WKI<08%+4MF*EB(-^K\7#3'=%N!"TA&H**\Y6I4)XS\G?J-+2< 26=
MV5S"W99:.C:ZMN:5/47=QBL4"=]7.+@N,B'6^4H[IS9YO#?2,O<"[;=E&,WF
MD.L;_-SF71O1MEF^'K+P*%RL_"#ZH*:NOKHNQ9G#LK][J.GN,/]BO.Y$ ]JQ
MZ1=*XP48!XPGL_G'FL&\W/1RN,[ZB.@+*HWXQ<!%N8<?N)H8$$2?!3$3$&W>
M+Q;:BIW0#OXP3>W;(!WJ<*.^K(C/&  $G[TICE.V/8*,'2C6%$!-+:&:Y.?2
MD:&0H4?I@S>XO&>D#)[=&FT2.AM@C!^.>VZ^^5"G67K*5$Y"=P0ESMHO)%:9
M$VP<3L\-+'@:=/GD/6[')Z1P1%;9.=2$:RIY8W2ZE0KS?4&5A@(XZWZB6C%'
M%7 QNIU,-1F@X#WU0J=4;7)OUEDN?.[%NU";KYP* :Q%M5(6PB=Y*"9P>%R#
MP,%,FN<#<1RHR()'@K\$,7L5,RHQ\N 'C;57Z>VY6F@'BXK3!?T+8M$R3P<_
M=3C+O*XS:E<>+%9+<7!H6P$*N#"TG",,B;-VK)^^W3O[:BUNY7K13-T[&G&J
MT,Y[D7Q7ZNJ>Y3._[ ;1JY\DBI/ .6N\#BUHD3X_CZ)95(UY['>'YH$9;5]E
M@7PW5EP^UYW#DP\!G(TR+WZ.)RC)B*TT9AUK+YE$]"=?=G#J=^=V!*PDK.H$
M$G4#E,9(<HT_NJNEOR)WI\,X'_(<=>?F7Q5/;R]]X\,6(U@[Z)+]J7=<1L!?
M_PYY>%,!7B#-]S0 C;3H4I'*QNU6$[!,1%42XT[8452Y+)SEL62D>&%+UMK"
MH$5M-9VV720P^1+RWE7SK(@"P3R5XE$O$ RNAVRN%3O$&HI]4;Q.4P;HUU:6
M9K%B>YD%$NV0FNG*<Q[P8Y8[NG]&Y./42E_LJYA2Q\0<_*VI.B>UE%?7JEC^
MUZK!FC^K!I?_]Y,8,>CYBA;Y[ XPOY(XG/_ZY;H8J*>7$.IR"^;O3[T"S]=(
M<Q!^X3BH%4;BR;&RLU&$/#*[C9;SBYHE+T*#@EMM,9"8&UF&)UE$]J34)] 3
MQ3%^FH?DU1YLFKY,>(]LN_N+L0!3I(-(V[7A0-+XA0#3Z(%!B'^\)] 6];%W
ML"?.F4G)T6=%53!!M,M_5?5F&[/I/!U/:76 [D1H_W0K=YNN->_>ML*OMJYK
M"3T**V@9J@U>:#=,$TN]I"4PV61)?9B$E7FWQ#8CSZRRX6Z00##!K$O]TER@
M+] [_%"JG51O,4(_*8>NDXR"/7F]..X.?,['EFC+<%CI SDI5M(KM=#=]A/6
M.2MF9N1SNZ0J@_RE56)E?83,(3H5/CD@)3_DH2I84!Y@,R$!%!.YQ]/WU4^E
M-MECYY9Q0PP-ZJD6?FM]T\KG2M_#I-US[>\//S1S@=5U63^![2B 6(@5CZ!D
M:F>-V3!GL=N^DPV:<2T6I")R[46QXC-_:BO]G;Q.#V<HFR3L.9$/S6PYI6U$
MO.]\NXVEOW[06CF@#A>L4KN@\]36R/-5C\A*PK95\\Z+BXN29WRU%LPL0#/?
MJP[E:CAQ*"OS8J;K MJ)RD4J#?FWHM.[T\)S/;Q$]M@451:J$[FR0AE=?=/V
M!IS(7X"<Y#T341',,L_=-BLPH\O-]2S]%X Y\N2[=@\0=5:02P31,/W&EO:1
M2[]\HJXC(SB:_Z&YM1TRXRB'"5,L$Z42X,_XRG6S7Y'X"#:[JR? )3\\&BPF
M_D5C=<];H:BK5)_FY6)"GM>2] %=">< LZ"_D4RZZ=+2\0CP"Q+ZNBLWCFD"
M?O--BXM@@_R2R;X^?CL>0( +@&O^](Q[HK P5!WPC3WTA,%D?QJ_3;XGQ$(!
M?)7[2^TC]T^U#PT >\S3LP7Y.:SGL& GF/L0!=!5_94@>W5LGV^LL#+7KR3_
MK,\S#M,/$I-N,/C09Z%(:*UF[0(KE;DE :SZ&2E]U\:SV.6"Y>6ZC*N-VNTT
M0&E[NC[N5MFMXY6V>$;?\!X#9--'^ T*P( \GM$% O)E4"V?N<,/D"]71'^+
MP,TNW=&5=@I5+U1[8]Y9TUC9F811G1=*=]V]-?KF2ZL>46^&X*CSI'ZD*L#@
MT,/2I;%\5)^?Q=&.O5O.:_'";9K2&/YS#UR9S DG.W3K#^N3]$82_>&$^WEC
M2**_?RUD7#SK6_[9Z\ C1+O.<G.JQ4D&B78!:',XR^=;X\QX0[=?P/*H485U
M**QARA?C0@&TO\<7D40<+7C]N"@ EZA]-B#-X[R8[LJR$8$BP7WFW8.3BKQT
M8_QL;%7HMD112^VK=:/PZTS*$>G"KXUM&)*8BT1O 'B*[4_*9:_@T8=XO*VZ
M+?8VTP4+E\@:/1BU6XI]C+#(UA!7S&)QU8/X><=0V(&X!'FJVURQ0H'94+FY
MHZ>!*76* )9GU@$<3P@\//3 <U;;%9E9.#,+?WR<R,:_%6&/:306$7R4GLAR
M1MZ\:JK,B/QUPN837ASS_;USH$?!W<##)18//X&&3"";W27I$KZ:MLO-(%Q\
MEW:+:*;:<GO7A]'-Q3HIRYJ0Y3X1-8BN]S6!NT=7&[)IR9@6?CPBMC:;_6;:
M$:1IW %=YV@+K)_CCG?2W11C9VNJY,;JX%UQEO7MK/1U8;"GV""''YC]>MHS
M6WX%S@S4'PW4XAW8*WOL?3KMV72=U*V7=HP,'[1_[EUD.Q)=U_\09?M_I_PQ
M'T\0:Z4 HD]P@K<H@ M "B!/+W#['[K\U(BV)Y_0I_972V@'*$\!H N;/*#L
M_[57'013D'=Y5A6P%Z4YX&7$6B$*&I:O!'KF$7SL:(\ZA1C-9D/3)A<AM5%.
M^6!0]]@EZ\!($9/1ELL$49PDO^MQ[5'X_H^0>^.R'51CFQ)V.LBC,)$]''-/
MY!!'VQ8KQYYR40<%P&'I9$!X-:8V?F54<-Z\"\&L9:>706ND,.1[C%6'XQ$+
M@?61(F,Y^"$T716_VL&',$N'J6<T#?25SVYA:X6KU"=1=J?Y&K!=KGY=KJ!4
M>7.P6T#!+D4N3HB06O%]]32E[W'D<-0^25&Z7KQF9/:>I II9PI_6_36'.*T
M:>9QY=WP3#],@;Q[5,70B.>*KT1.*T,6M2<+:UH:Y#Y:]#6'U@1B\D057]/Z
MK<>8/,2!Z4C6^.Z*H+0'+RL#&X?:[^LDYSFK8.#2-ZTS2$UOY1B/>:F77@@F
M$&\ZF=4E+3 M3!5$J</%,6]3N0SI7J=,..[:QSRSX)QZX0_!I+9E Z9[Y*(+
MS=8>NLBE_6BNZ*[V_=(;5>4@4B[G&#8;?&O&)&9-B*'EZFI*OVWUI'L%O.+2
MN(/_8XL\L0ZI]RKNIOLK::ED=FAG.@M3YYW,Y=12YYW5-VV>/OR?;OI!M+[&
MW QRXS]>I(M_#P5^$3M-Y5SF#**ZY0_,[;QLQ%%I<<B$DX39'!/S=!_Z#RE*
M@E]E*Q%/6*E[%HM&PNN+>U5Z@%IG>G,&I >!- ,Q-SY>"0^4LN+QP!.[WA"B
M'^"WZL\5%,P.G"4JW7ZEU6DJRA"<G1H7LE-<BV8D4  =%YR.IC+K&@IB=2!S
M^JC/*??V#*O#-&<SSFL)2-T% [^0:4BB(P=5/&MG*Z>A+J+W)U+:W,32%,X$
MDC *HG3"R#,F#95-9)Z(=A,(F>=][7I*\Z0[1"N\$P04R7*6N@<.&[/F/\#X
M^<2 ';<CA9CW^6)=%B:W%+VRS.]CJR68^;SWA!_V5]O$U287_*0 S@?0+Z"9
MN@YAZCKC$H4FHYO;]7YNHZ3TB;.M8+ RBV#(M&:\:<CA,SP2N[-% 82&J@>(
M+\;UW#PITI'DL9.=D]]M$VAZ$@W_1@&HU7PA215_6S,Q2?&QQ<&?I#F1T+*P
M_#>PT%T%7;HE.XXELZ,.M-!/E:OC^\0F\<<'"@(+F7E^W#-A239]PT--D?S+
M21""R0Y0!UG+=4R'=H6Q]SF[)T9,)6JKF(XXQG;$*?_DTHNWG6AA(L"[A)!<
MD4@^%HGCC@YO.;DC)G83J:[8=>[OY=_Z$WN*9$L0Q!L$NN'N"P1U\@4!(W%K
MS-.^XMZ=P 3AJ /KMI64:YY9[ZMH47BN3G%&HK%KK*3E1]1H17*5O;, +X-Y
MV,QTRVI;*SV_\7%$.YH7T7XVWW>([_ZF^KUQVV<2%0/HQ'O=RG&>)%WZY6N_
MDN?4/YWD*/'D$A3;$:Q<ZJ-P9$IC.&&FLJQ^TTC:@@,2B+*CCK>S$MV3CMFD
M.7#9I@!PAB0MK)*&<[ZEK[_9YPG1Z*%8]Y!>B%B89.(#=GYJB^%HE*SG//KB
M6J/ =)?X9+KGE8Q/6D?W@><]LKZQ]]W\(_EG:[P93V-P=\;MZT.^2O-&2(65
M7!F&2%)%1EJ N- .\]B,A%91X76B"34(0\UW)B3078L:8P6>5T,75D4@=B\1
M7,EM=?]Y1/]]C5Z]03+]B>TA!>!DLH_YT\\CODK_Y>8_G+IYP'^==/G[I?<A
MR6EQ*O,?DI/_-X6S;7/XQTQ,Z57Q61=]W;8D.)Y+,ZDSR=-C5%ZU[.!%P741
ML=73NJ?/?4DULTS>?[GEMKG%STR7<L66ONARDX=Y#PFT>_.W=@7IU(S:K2DC
MIS<H &P-!1!V^6=C@@4%X&CU M'S&R,>(/!QJ]!]YE/0^IP"8 3C!$;1/WD<
M*8#@53)'1\F77!+!%[H()/BTJP@B3R? ;4@#%@DQS45Q/=1RP9]%#<I^MN!1
MN*3BNQXS6==$5+.HC:U+Q@TSN#8^2(5[<DQ%EWVK=,^ZZ[&BS6L9_%84(.EF
MOX3=[B$!&PU6"Q_'$WWT\7EDMED0^64*@G N&Z<J]!)&5)=>2[.JIW_E5;!#
M6['Q# .RPAR:O.3I+U7_D?Q8KH%OR(^GYVJ%ZQSRL*'8Y?#A5P*B\ZR#8_'7
MN<M6NE9&=<M&MD_B1&@N2FUV@X[*_LZN=?I>DQ-J,0H +P!N#QXA48<LS@[>
M+Q#&6Y7)&%B9SEIUCNF6/!,/"0ZAOL%@0XA:11D2#=&12I$;*-KRJ2Y79WZY
M:)F-I?L"(Y^UDMQ4I5=NF BPFIU@3WO&YP\*(,<AFTQ=1#"D !C(J12 ZC28
MB/_=IN#O,H2#<D+9 CQ"Z4$++Y87JZ$3ZNVS],>/'WT!TO>")?0!KUPO+DAV
M!?KW?.?3NZ%_SL60X8 )]/.[1J)JED9]0K6F//VV!W2DZO#<^U/>=7TB'HW3
M.CSW[H[S9 CYJR3!0"4%3",K&6<V/EDX]P<^O)H%G?I<UT1?I'A,[X? $FR)
MFHMZ9$(HYM2OH@QW/*WP6\59'%CQ<ZE>AZO"#2HN[P= MY,_7;F1+:DY$[A^
M1"2RZITV)[#JY!<4GT=D?? 7R%%QQ#VJ[P9%^]JDS.$JD8V9J-' E,/[)7QN
MK$\E>'B\GTVW4=6,<:3GDZQV*F*BQ@@/(>/&7322_'LZO7&/+2/E%4W+\^GX
M7U%5?4=L*"N27QZBCWX@VN/_=O]2Z"6431;CV1W$C6!U5N&:>![(PSFIZ!'H
M=:6K53L-8B.6KGF"D6K]">!HFH?RK:O0XQ$1&^(D87_)R.?WG&!5RPVI&["+
MEDSAK+ :5SE5P#+:&_QQ?_N8?HH"F$O^/<[_@:B7@T"N0MQP)8TRT)H@UP[M
M]WARTP:LF'O9/%[A*@M_0OOG^&LY)7V75A2JF DOYY6A/8+R6)3JY$,S%J-C
M\^%+=X'OCJIA#3WR&(1Z]M<7\!/J3<1V_^D$$_H[H-H#9_2VL'S?ZDR8O=;M
M6QN$^",%'')$2W;:UMXD1Y&",K#[EB<1A13 B J63*HB&/XWD"08%CLA%._C
M _9=_1=.IV\3ZRHD%2=C\_;D%:&8^U+GJ56%CLP="J:?#@\BE+C[>WC\#6CF
MYI+VM? MW'Z\#LO&X33M)W>/3?;I\9M_$%@[7#09QF!M--840)G9.+EC3+MM
M;%.; J@$D3F\C&\$TP'FJ1X%B@D[?8A2_;O$[K^Z_I4-1)S:0+IAV'$$.;*R
M'/S_5M[O(3D2I0C^W5;2C3MWL2B]W#7L_4^/9?3NF85;7&MKMX]_XU,^1[ _
MN4V.$NV$DZ[-40"15<\^-$*NENI<=[/^^3"I22O\-,00747O&ZH $3A-"H"D
M(83O.X:?L.M'SA$,T10 F]4/#7 %A&P3:)6ZF\5' 3!GG_;QEWN$V-,_= IW
MV!'_@\ _F3W0I7Z/?F(5<1V'_A]L6B3IH-->UKBX<)O,_KL.W*3!4&NR#''S
MW_3_IO\W_?\W>HX\'/A;O!J^*@99=1'\&O6X<HW7\?VA_>0!M/9>.M;5FKUW
M<23JD/>ZDAZD?$E6+=''D/$T0X[]G2&S4K[]!U!+ P04    " #)B(A46:S&
ML#U# 0!S90$ $P   &YB>"TR,#(Q,3(S,5]G,RYJ<&?LNW=84U^W+KIHHA21
M+BI$!4% 0*4I(!&1)B(J(@A"1)0J1 0D0$@4E0X1$% 00A.0%J5*#1T4D4ZD
MDU"E)M0%:2>_[^SRW&^?^SS?M__8>S_WGIF,?[)6QIICS#'?\;XK*\S?S"G@
MT#5#$T. C8T-:&"] .8HH ]PL+/_]68-3M:;:S\7%R<G%P\W][[]?#Q\?+P\
MO+S\!X4.\1\4/,C+>TCLD*"PB*BH*)^ ^&$QD<-"(J(B?SEAXV!]AY/K !?7
M 1%^7GZ1?WHP&P#!_>RW.>LXV$X"[()L'()LS!8  @!L7&Q_&\"_##9VUASW
M<>\_P,/+.J'\$,#.QL'!SLGQUZQ91X-8QP%.02ZA$^?T]@G?<N ^Z25R_F5L
MQG[I*U\;16_WDF54'SX+/L C)GY8XL@I6;G3\@IJZAJ:%RYJZ5\U,#0R-KEF
M<<?RKI7U/1O'1X^=G%U<W;Q]?)_[(?P#7KU^$Q(:%AX1%_\N(3'I_8?DS*SL
M3SFY>9_S2TK+RBLJOU55-S6WM+:U=WS_T=<_,#A$^#T\0B1-S\S.S2_\6:2L
M;VQN;>^ NWM_Q<4&<+#]Z_@_QB7(BHN=DY.#D_NON-C8_?XZ09"3Z\2Y?4)Z
MM[@=O(1/GG^Y7^1*;,;7Q@/2JK?)H@^?]?*(R:@13U'^"NUOD?UC@07_IR+[
MM\#^/:X1@(^#C;5X'(( %*!;9$:<!OZO_;<9>Z'6I]36_E$#/\Y*03IXVT 9
M?^MCQ+-%L1*[\ORQ)L*U\SWA;$\O7=O"M:7JD\9W&M#@:?&(6OB1ZSZ1:.&N
MQY^7N=UM?[3:F3^9/J,Z[KZ(?:-Y<Q+=>%L'[0M7Z(9#0TF)\HX7K0Q#3A8*
M/-7;]_(W-;K6)/M,B&K^/6YN5XNG'[C[)0K\Q"NV$QG(C5:^8ZAU(Y[:S1D*
M+ ;*5<]#4P&+IN$8<;Q@K9%*R*/><O=A'^JWM:%)]Z/A):W&/]\??ZJX /W]
MBCCWF7H#]4-7A6S4(FE^KYH<MW1%"7+KO&B:\<U]VI*-IS09]Z3+.;[N, ':
MJ2.:=*Y"-/D4M"W'SMW</R,<OI)\[X5+S_6:CU)O#/UIBNLJC9-?,<&U^E0O
M1,K4;.MV<;U$OP^A-@2Q"E0I<UYE_]T&100&6.$9H[!2(YH"]#7^8&T@&1R3
MA!&]@B%EQGY=2G'?%'X9:CY!U?\:?\/^=:=U*-?94<9K;+P1+H/U>AQ[I[)'
MN,O B\2OW.<4$G2M3^(=,2O.]R[DIAG*"\D[H,P$X)A1"93,8J*0+>)HH]A;
M]=0H)G">-\I)[5+X>?A;ZLE7(R7%*#90<3N$"02'TMQ[:KV]_#QRAN\U!_(E
M^F4.MM3;E3QK.19=B*"Y2&+Z%YQB2.IQ<O>D'1)\+G(ON&OMM![12$%4) 74
M11?U^P2[OS."DH6\8?M0#2-M!41L-/:HKK"+E,(W"N35YH6H:N4,?_G4$TD(
MO;*9*'9_CF"+DU]H]ZB<H'"C%$#QBZC71NH?28I9J^_U=R\P0CI8/O@4>TMF
M]^/JM-1[#I']]).<9SF/O;HY ;-U)>]66@G:&J36S#V-Q%Y/WBUE'.@DF0LB
MLK;-R763X9[*<.6L1-+$"&E-UD3I]NVO0N9RLX<YM]F_84#%"^-4Y6&!O0]G
MF,#F_4UNB^4/ZKS63UI'QYH2O_'/E[V0%="OR54_HVKD)?1=N##VRX_J8\&7
M]'#?,0)()VP;EFP&B] %AE+[6Z3X K5]0U R&IC  U&'T-\:XW]SX8K5T"..
MS=!2R+(?&6M#X=2T>3.4D3U\[\^>7=@^]\]1QU<D+@ 'YP<">L1T2S+K'<%3
M5$\;FAE8R@1X1ELF. GU4F"%^]W:LK(A]EB=!YXK'=IZTCK'CK0.XJ<RDB_A
MHI#^1#-5XEJ$^MHAA+V1>:GKU^S,60OZHY27+2Y9<;:X)\GL[4,#5MUH :B'
M^3YP=-MK@''6WM9N(5DWL:_5_[&&S(?'5P"#T69/&<>E+G_L"_14SA%(N(X#
M<5RU!2U ,YA:.=KB?>;(W<H\+I=33B<L+BR;<$A?Z&)S7.%1G!>(A%148,BX
M:9E)?LRK<B8@Z-Y^PW9)K;?WE*9GLR*/\K.#YTVE@'UE4&?S4=YF)B!5"YWF
M[2R2W6@<P;S.5BQTW<N2=_=ABUDWRDV<BDDO @+IHN2M=IKH44-;?9(I.D17
MX1OXK!+OH'NFY2'[;MN5^9Y791\9ZDM8*;2'"@]M7V2#G]_(W8S"/RAE<ZV1
M]7;/DV'Y7YX;:J><: /F7GS=5')TKU?M0:KX.;@7+(G9/.ZBI5EF:UH4>FC/
M\.<=V(TQG@H@S*NL6%#]W:OG7I+GF$!3XH0"&"0-!OO557ZK7)]8;1.S;/Q!
MG_]UY:"7?3.E<CJT"2YIC^2BR(4CN0J7O)=&OASAC,>6F.;\/&6P<2KZO9"F
MQX7&/Y>MJ=>2?W[]['3"TM!4^ 47DD@U0HU40QLP1US3>/J1*@6(^3;-'GHN
M5<68XVS[[ZI+'9Q3!S_VZTJ@!NVEZ#D,5NX]M&_4]ZB/"S7-35KTEA_G'%KN
M^5Y&&1 JO*1WFQ\(.NJ,]LB[^JC\6\3<V>=);YJC]A[Y?5Z:PH&RW)%E>(#1
M@5*C2%5Z;YO)F1+6BE=SI;6E30.?W=!.T[*R(*Z!\C=B_3^[^"7O-*-%$(X-
M>RN$8;5)4?O,HZ[6J>EO#UZ6Z[^0?B;H@P%RB7H9-:SEW(B5=)7BZJV5*T10
MVZH3\"/])KW!J\;^S4(!\^X/!*X3;*F:C+XT"#V;IH+^_$=,?$\C(V<LY9*1
MR4#6J'IA%FAR[.R."-M2^6U^^[;%/T49=96)1._JP[-WO6*J@+E\1&7+6811
M4_6O*F]6H>QY?"3$>6,2U931>K 86,GS@B)0?!L#.E*,+!-"8J=7G!@-UX>E
M7/W.'3*G^R"ZB9>MZ5F9M:K;$?3",LAP3<L$3Y]OE_B= 4)+7]<Q[S_Y)8=U
M2@]?Q*Q=U'W08(_ G>U'3V4.:46O1?BH@)83*IBV/5-%6_"^;<'X_:M67K%D
MKT.6S9+M67R/6%NS*;/>NX\)>*#YER EXVMM-78"-U-N?%42_?56DJOI6K'H
MVW/:YA/<NB'?C-%3GZ0@3.#UJ\;,#2(3"-_$'T D6Z\4(4V#A(P\^R\"K^_/
M#EI/Q6Y)B'!A<-D#12>J8X9,\V[/F5?Q&G-4]CC+EDY3$M^HA,^02>YB9KAV
M\8][+JFHGJ]3DJVJ'Q_$!"T15494&;>#R)J,;RJ,5^H!)> &,3&!^AQ1_!TI
MFJ?2$@CAHU>LM7S]>42^Z.[AE._6E<[/Q[-R+5F+:21;F6OT6?;CSO;G/./S
MB='GPZT=+Q[XF'8I?P5E0F,#2XEP,=0(]E"]S)*67-A6EZ<\#EY[SD/D>A&/
M$=],J^ZJM.RI_1EA$A=P99OXT=*F:NPR/I_F=D0L2RPEUXX>8B>9'37VH;;E
M<OJK2NPY6]PU]O:>(Y5194K<5OUE1:;6)5\'RF6'G5V]M+(K^=^>C;AA/1.3
M5EX*DT3>!''DR99)<;S3N$4K6L!7$2<*)G76D+>&JPT8'>=UKO.EGQW?>4L6
MN+:"4D2-!@@T8:+C:.>KR#GXHB6/G/8@9WJLT"_/F:#1XU>YGSJ6T=IYM%G0
MUR=BU07C8 *>*OPTZUYDD'^1BPWFY6JM2([=[6X+A=78%_Z[Z#!1Q4K")__Z
M%"; =;5'\DEYJBT1%ZF&X7!3K2O"A$O)Q%V<@1'W'WR&F'*68&6QQN 9EI?F
M[DL1;MB#AZFH\:[QF0<4,H'A@+?L)-&Q*VL<46_9:.Y$? RVXFX&>7Y[K7=S
M(X@$!?4VW37*!GT4M6^35HE924]BTR5\N:8O<H,"GP#4J^(,-T*T2^79E$\2
M9P_L([,(4H'H+JX0:?6*B*6)8-HF3IAQ6U-.#0Z]A$LF8K)&)92+'P4BK&6U
M5("92@[131:1&K5J8@(2NA!PLO5(8I+_U SY451U5WVF992":,IQG,7ZV?;[
M43?%=",RZQ7[6$B?K-0Z%)OOQ@3X:;<RD-#!-=W6QZ3.;'W/E8^>"@>]-K]#
MW@1EP+TD!P2[> O?=F3T#LR<CWUK1+PL6KQ5!#5/^E&-KZB(EQA6^Q$J]4T6
M^SA_V,V@]=-L7:]YW<P/7-3F+WZ4.X. YJ>I4MP9//Q$/"_8?#M(^G)MS[MN
M7\FFACOY-:<GQOC><@7NBR7G$BN7+Y%-24;1-/Y"=ZD3&,L26VGUVJ4 QP]7
M(X55$B_P],UB'ISFA3R\MU3M^4F]12/Y3=' $!-8R@KQ?1Y)GQ* 1&N;#971
M'1ZY\RZYSX97&'ODW&/7S&B\H ZND,5)2:\9XHSODR)K16>0AKHG$!&:?<6^
M+@ZQ12_>&3LZ'(<HL]?/_=)S@.DS6IB >+THZA<3*,&$U3Y*U)K].-1GR^]:
MG"%-O;+;O'^(<($O]T+'E*_:P?8%7]%U>-,:>/I@RK1 F)04&1>)Y" )A)8B
M/N@O6"5_L^!?@%>S2:K^WIRY6[ER@.KU!\;%D-:;DA1OW.O&Z-AXO!EO38S;
MIS0M+>VE$W>YFR-FDZ>]_YU5.^,T_5L9!(+Z;J].(800A]3,G!HJXM7?1OI.
MI"*:9Y2BHK->U50&5#(!SD5ZIG*]*E+.#G*_:DC=7-0E-ER=W^K6B[#BJR7?
M2SOC 5WVJ>E<%N 4N>#.TS/JH0B_;3CH"XU$&I:.Z<\K%94GY+'HR&^AK\6(
M8XK'T@#1:2P7&KXB1W)N"=)NU)4FZ]9,23K>?=W]J:(PJ[,&$.,1X!1B:S\L
M%U/&MB4Y5)EK/:'GZHUVA_M=;+EI>KXP#EV=/<,0??HV/>ZIXGJD 1A+%(B"
MD6\;$I FN6#(XJ^)]8G^YNTECH(1.\-;ECG7'Y\<G]- 0,ZJ[V%Q3*"#^S83
MP+E"-X4O\\&$7 ]2Q>^4./_2B'S]"ZW5AVN'#AMM.X-!E"SB9"M.&*RY5]]3
M#A=85"UZ,UL$5AHWA'5(O,.DS.U()6QV+RM1;W03L<,<K?9G0$R!'<RE_A ^
M;FCRUL</<M]"W40NFW1*=I<]HHQ16!W[5P1(:&0"Y-O\VM84S==%- ,RH67B
M$'D^4LY:S0/%!#I=E'D/B7[)79U-BOWH?$FQ%MRE.KNR<(,A[P(5\.GF=K?7
MHMSX!-0$2HJ<0&3*3+-A?OZ^^^0Y1SR+,2T8;YE>E$E3JWDY\\+ISCVV<TR@
M5K5]^@Y2=9I?H"U1Q3]]<2B@-?O9X61W^<0[5I)W$BZY3V%_^[5LH\[0\Z N
MJ?Y/5E>6UZ15RU.7#>5[_$-]/'-7O\Q8Y3/:\>+U@BZ04EQD[6.B.;\=\A+9
M'A/DI9'!OTER4@[[E,UY;O$LL)4N4.R"B]@T!^738OWS$9Y+5J [*9J#M;ZU
M8C;.X<4M3@?>5_0TZGV_G^;505-D=5*\>Y<%$;[R8<I.H_\6A5-*N->C>:G:
M++K*=\ T]/&Y8E59MOLKFRQ,G%6)+#/6,1![*5O@E#S6*Y'5/_)8N.1@H?!%
MZ8GRI3DE_3;801S:P_R =1>1]X_N<7N$5_$R[4H_5\31VP?.J066UN#<?H!=
MK$RR]=4?I5T;K!4FXCC<)Z"#:G<VU%U]$F *A*B2^3CCCN[#W!' WH\(,K_<
M=B<Y*0SOE&HUK1SO$!28X^K6M&;RX]2 A?S-7J$;8[1%[X^'#/R??V)Y52>O
M1./?^*)!JS0%*<&AV9C!6CTU><E:/_[H7EGS-1[ON L7+OQB@8O+K>L1=Y+5
MXC0.QG H'GPM%8*]'!QQ.IW]?YPI:$>&%:[,I/G?/BQ]>TTF2M3R\G>9M!<W
MN>?$7Z'X1I%!8"O5%M1Z9%X^]L/IRX?0O8+L]V5FFV. ;@M!B849/P?*4_6W
MOPQ,$T8,!Y^H2:C]N>NPD1O7>=APYV8->NID/1D,9!&88 @?Z@2BLBU9/,K'
MI;Q;Q&1NT5PS[$2<AL=H_1V5-_-]>:!I Q:@"5#B[X.I68A<_3+*C9+"RB?J
MX'7^FJ-AD2BV4\^,5\V+N.Z#JBS0$62I!:L6: R.HK&E]GNSRXE2N':$[I%\
M;.SZO1?0P,.0&4(?EGP-'V:S%E8/ 3N;=OP\\A'PYB.YPVJV;9>_O:P\]-'W
M<+. V:"S#3V""3R:/.1.V*O;"2O,J:FO25Q_ A9I2,@\6WF)?UF%$=T4;[ZD
M/U79.,G32)SD7F((]ZJ]#T?+\M_EJTDK_@D[TS[0P_UCD@\ZJR2EPP2^B.#W
M^.L"_&@BD=-J$^R@JGAP&6P2S&U713\:M6W3A+XU%CXK14W@ILY+*I;UUIX@
MJ^B!LY]I-F64F+?UYP8\DOO\4UK.ENT[?^B0].0+E,%<%B4I&,6)O S6I2--
M"$B'[$D0<V6_VA9:4'_;^KG0#V0JU63,U)D@LG\W=/MH]1#^$7[$% 8*3LMG
M";H/D2=="8HM\*?28QKQ ^=783M9[%5H851W!:0,O4*D4)L)?CLCON-I[RJK
MD146AS>\9T8S#W!3Y+I^$'[CQ73XR9!IN6BD*FD<W7;DJOU)\A+W%WQ_K8%H
M;63HP8P(_$\.OJC-L2"WG3<T*%F_"2*A8T:!WJ#$1*4I4D1X/=!GTHZ_R7AD
M]WY4 BE/']G<2??3A;,*PA;,O4SV:X:$VZA/A"7:JY''QTH7)Z[-S2V*\+&_
MG'24+N:6.%F##XLD*V[O@*?3- ?+[Y6]W[3V9'3)[+A[>#T^;G\]-KYCZIC?
MBGTX$0K0N,C0-B4_DGTT:>5D9TL J1J6"49 2GX>/5IZD%YGN/99MA;?R@2^
M8I>SI@6$)]QO(S#F?2/K%NI=,1](B/2*V/#ONM:>YY\AMM*U4D-IPN9M(^W1
M4"?)"V[]0<67%!CSUTNJUYO\*WHKI*?8>KQ *U46(#@Q@7B[$I;7N$XF8- -
MTT.(MT+W,R1 BQMD0@C2C&@G9_ %TUE9_LJRDB?KL]S\3'R<R4S\_?EV?NVI
MRA7^J0Z:RC1$PJ7RR'4_KTD%&W=R \-M'X^?XOQA[U;V110"W7A%5V22=GI(
M;?+PPHDBI#:%0[^R?- Q"AFR>$(D2B!GXQA\T3A@#]H&.T8$3:E*-+8^GS4>
M5UUY2F6X&M74[)#[+6G;>]]BSO8+-0?SY@#2NK56]2P66\]-<P.]!8)U+$EU
M[&OZKYMZPLI_.R9K1#G<NZ^KUZ:WQ4F0ITA/K2UO4$R)W6^0$H5@Y34[S6;!
M0AO+5EP8,6:1RY(7HXJZ<5FB.SW=^=<1J112D1R#QY*\#CF":".TH4YYB,[4
MI+5QADST1EQ'=1_Y+*.PCO)$!?R!/H;O7H2.-.R,:C*Z[2O):]M!].1Z<<2&
M(27Q)2GH/.20JY>:B2\TO,_BX@-]$^4_!W>.3\OU!%C=F\)Q(WG(W)&U<)*9
M=-L1G8#<*'U^RT\4/F7,Q_F'2;M::>_8R-QO'!+AX*G)%@ZA4DZ*GO/H,++U
MN^ZX8C^K#7E?'X(ZPX<SNV\,**FH)&^W=X9,6/I#!UNT.&)_<1,B]G(;H >9
M@'-W*(S7%QN:[!>VR8OG<1<R49I-R\+I0]_#CM8_W)5DDWJ/TP7AU%.,3A@?
MTL.1%*W=4NU!W\:JI#X^^)GD4GR\\NDSB9N5-_TE%EQX/U:4^HIB:*(6S2$D
MQ$HC^=?/'T0V1\\Q[\F1+TS@\:28J]1AD$*%@3D,]0$=S5QS+[_GL7FQLM&G
M4M^S]59RP1V3F\!F.'F)1*")//S5V6+3EA!$U,8<7([;NV0F'7/QJE)9X>*T
M>TC;6>_D/3A1@$7?A]>F<"]I!D0[WI9JT;84TJ'O^;J?</HZ!.,."\>+Z&H.
M#6ZJX0M=!7!W&GN4]H@>[8N3M)M$H!NP!U?+]V?U(GDS;0U+[-F>YC_Z ,X:
MJY1?GCV/*%[:CKLE@_Z:^84O1_M,B 1D<0IWHX(>@7X$^J2L:,!%;.U'[Q]R
M%)=2-J3*=<7/T, K <)1;[WL/Y$F0V$ [8DN)-J\=<^4"33Q21_13")=B'=J
MR/ C,E"" 3W<,4R@T5+&NI"Q7_O+59AXV\^?3P&>*IF].S#RS8(\>/TY5%>2
MV(:1%V>:])62EL:$T%2!XS'\@81V'#^-GYZMH^B1#G:W)HNVEK-4E&M%&L$N
M6"(CGE.H$/+M@G3=,R@YB[6PGY%0\I)Q%:4H>D"*_1OU1K1,FFR85CV91:).
M,+P2CAT!-@P&E,I@H*)AKNXG;_XH8=!.Z(#RH_W%$U>1\I= > >A$.%.$F]2
M.0)#^I6!09\*=4_WKRC'M]B\TPBYL#JK>);OU'>AQPF_#+2G=YJ@P_/;;^O[
MMP3$$+D&&*NOY@K\IF843HV-Y5_/5;EW7\C$8FWZ0/TIE1=0#MJ! M"BJ5ZV
MQZ-0W=<7_RW%/L0T)?J'Q=S;>@3G=+\:&P6WO'0L#MVHS% +Z_U8_#G@IS@U
M4_$VFL\I_SX24C^(=T*'[B5A\"[X92; !E-/L78Y;RWSG>\'RCCIP<2UJ:CX
M]@"J-U'@%8.#)@SZYX/2S1/R/4[DN<]>ZJWCQ:SR\)XKR\M;-(6.*[QP7+*'
M$?'# MM6Y.[(,^4=M68.B$1-B%M9'Z[6XMC069./LP]5HCAB+N7Q?H"4)35A
M#[+Z4S?17U>*=K.2#&_O$C?&+ _U>]X*?/(Y02#VC8Q8^TV]XS&*>/IKM$NT
MX[1LTC0_1VN !C8';&\69P). YZ;[P<?U#\T/D^KA?_X.+716(3&0/C0SFLC
M)^=OU%.,(LJLU:,O7;-U&[$*.U%>?55G>0(75[7L#I]Z_HJLLNU'_KDG]TK'
MG+ADK/QX8[78T[=#]EM5?,X?&97$XUZ7JP]CR;<$(.@F-JH<V'0UZ7OUX-U+
M"MS=E&N3FHP+.%@J5%C=/%(+NKQ!GK\^B#HX#II>)BO]M-JV5WRVZ_><OVJ
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M(:,O("%U?MF;JC+:Z,M'"+U3MC^V0^(E!W?&-.=+^QJJ(0@G:C9B?WNWI_&
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M&5J<*#40LNT/#Y\LQ;6I'/M#$,>/UHL1N/>.W<:>=+\/3SJ'J9U^KK<L5K\
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M;Y5GWYR E:@/='QSC2@>/!-(1.".TXOP,UB$-Z-M18 )F&;B/-(=_D6V<,2
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MV.J6>-Z:R_@S_TJ<0SV/"LEM9L!3X*'*+.ZMXO:NB&J4$5:S#A*C>! *S[
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MLUM<[*;3L'P7]HJV36 J&+N/<Q!2QH.1S,#VNC<0IVZA<TVU;9B)[F]V/%D
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M7 MCRPRI\XO1K%:W)!J'W>S/M9X&;W#Q*?A;/9UBKWWX.?F&E$),7NE5 <=
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MB>60WL\ ,9V^ZE8L9_NI10B:8/OAMBI"/.LE2XB$8.*(2X$!).N1K4/\N=4
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MT$46&U5[5%A.?ET\LS%Y[VYLK.2DV;>-ZWEQ4SUD*;P7$LP&U2.E*O#Z!E]
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MJ,9=6*9R8WG66*K?0=2?P(8/='$L_Z@/C'^,^*.OB^HW(2HU[S$%(5\2V2D
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M,J[J3%.ZV\?_$_K*RQ]+;A8H$#"Z:@N![#?#(\56+@+%H"W0L,UQW6V\9;?
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MZ05Y4KJ?B)%IXO/H%DO_X@#'"5A"=XR-"<6._K""E\%S"K9=*DVR+2,^YJ^
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M,0[KK -@A<\C^\GU3 7CM1ZP4U)D1N^[E7_Y/M2PV$+XGK"ESOFBX$5%7NU
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MILFU+/7R6T>]!0+,#("*$>5=:S0$SUJR0W#SXLJ\S)].)QJW@]WU^04P'(X
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M/+](B)BP;%5%S7N*Z_[25-O[!N#/ =".<NS9&Y:%](<HX1';%KAJ(T-&!6@
MJGQN+Q3-.VUYSTZ7ORE90+%?[SE6)3;A,> 0%'D%ENN]>U<?O*U<*%!4YLDG
MJ-,/2)NUB*I%=V5$;1/%EP6G1*/Q24(8Y4>1*+S\3AY>HJ^#0\4?;2C8GW.#
M8-X.[$CN[S'"^[;FNZL72$4<& _(LU!R!Z-G*SV@# 1I+/ VU FW!K\*'U,W
MF$I%XH=[YIE;+U%[99;*F[:&1L[[QJUK9+/)U\T)>[A1#'V42C"F$>J+X](F
MP(L70:1G9\<?,=V8FS^[M+MHF[Z]]K9)2 _[I Y\ ;V%IXQ5,<7UZ$ZI^#L5
MSA$R'X%<.&4G%JP'1W__^ZW7Q?/+R^X<BB5>A]+AP9W #SA"4#\3XKS4*U1V
M_V^?Q+<&TT:3>XN3H >"W-!EZS.ECYK_L^+#/.?E(&=:OF-O JB,D&*R7^5[
MZRO2)?/]YS>[JUU4WW8IGVW30KF(TG,$V#&0D(J68(7J3%:*DL3PFLL#3:UZ
M#3SW5A<&N3W/._UIPOKIB;)GOAB)Z_]XQ=UT9F5L:%\@01F>QUOOO__VW!-'
MO8-L"H,9"!8Z^(CL8UJ?Q[4SHOZ41-5#:F$/'CIVAJ0M]=V00*@Q08L2X4EX
M(!A-N@++6SHUZ%C(TYE-Y7/RG=RL),X/U ^N%0]G^7<67R#\.,&=U<A/_4#Z
M"_ZYT3*H*5&Z(093OC4HF/*LMA_-'.)P:IE[[46R7U*_R"'C9%<S;7S3>:UG
M@657^2FUV_&_G2G#52&R9R'2=0"%45=#W:[ &]55<VX6S6+A2S6O^^I),_\F
M>P9!?$E)4X>J_ZAAB3"F5L=<PN2Q+]ZONM :JH03R/ J'TB[8*FO=8/=-I1:
M$-_@1(\X7B-?CWW!L-2>1-B0)PFU.:(H=^C=:=)9Y9JUVR.KOX=^&[S6L-R<
M>(;UV0_Z7/T+2V##[:I:F$ZE=W'2SQ^Q//!7G,2(/13DE^<9AA3O:!-52'J$
MC?-LE!BE)>X2$*G&T&Q]WKZ K+6G8 YOT$[X*LX"X%WZ2H<%H7)R*-HF+A@V
M[4&S?(BH]CN;/F[PMW,+]YP\[RON?/RCFF4Q=:2K.>ZN(I^W<6;X69.+BQJR
M\R(VE,8Y[WD(@*I-X^Y_NV>LM_Q^8D)^488,R]:2MK_N=6KP$Y3MU./"+06-
MJG,2J'3U;-A$I<"6Y ]DB#(NDCFZ@8#*@ HK%WO+-!.>D8?3PUO(UK/\;T_*
M5^0-VTY+25ZO/29$YP83X(5>:5L^ >]9Y=PS^@"^:7)I,[@2G2''2OTU?E&.
M7Z%T]=93-V^+>_]^Z"+X;9=&A])+G7'IS[((8BD_PC<>HZ@GWKD:66G1^&T@
M*G85(E!<&Y7IO"#7-48<NUX)-K%[NL]!?OKXD_- GZAKV_SJ1F;T:WVX@+=/
M+'$B&/;[N>9\]/[2(6#^R^]8B3]U_4E&PU52RL_G(]9 /?'3U[3<7I5E9?]%
M;*C?]D@M$H24NZP%W,TZVC"1+I-V\#;F0U8B K@3;_[UB1<B%RM.HSUX3S&3
MX<AQ0"UOXC/*XGH_\F7[3B/W='"Y/PV^=YZG"W!F<HW)#1FT**/O5V3B]='-
M:/&SW[ZD\H*X#O) 5;K+.O)X,L.GYI5"2,!:&VB[J%=Z[Z8<JKB:F<R\G^%^
MQ<C<]019&8/C1\*1[W::\YHS*K?[Z2@.^AX]'V1WO'O-A'S!&L'_NKL<MF6*
M<.5WI!MN/"R/XM?63&@->OYGO(_#6S.G*9<62+? )7C[R=SGG$IDL]N7'0$D
MG^\+':],U*M&J7M?58UM)Y=>EN6]?IU>2Z'.$YOIBOK5K\Z]+IL9R_!7/'":
M!]0WZCKD^;["K''!>,N&BV'*@.&WO P9^\C.7+&T1\ET/!9F[5\(\ ?37@*F
MED);.WZW/,9<<(>6MET" D)3_;[2_,]**[/ ,+1&=FQ:'1T?^['/<I"4:<HB
M)C2U/Z]]ML4G0TANFM$ TE;]>134BZCOW,&@Q@<UE>?E):27#5[QC[:$[/V-
M![<6&;-XXS[D]/CXNM;C4[HN 9SMJB%#O-?&H=HH.W7(GB;^?LF4X\O/=O/]
M/X)+N%$?%1RV8-;G5/EA"P3L<=5YAN^Y1*\:+Z$#IV688$P(S].+\B_<V/RI
M6S;/=, GU)T&2 S64/O8Y)F0PT7(P!K'VC/C!=IP!WV\\@3/T+S^.-2BH*G<
MQQY3OG6B"5W>K,JK%(3Q8V)W-/EZS_(OIVULE7/'334Y C7B@C6FVYSWWM1:
MD%XK6JQ,BY^JQ!%*ZI8S\0X6N1+&'UTA(#!^-*$>R$'(- UU1!D^A,AK-E)Z
M/[2X_SN':.$\< G(B6A?)[3A$C0(BZ@Y%4F,3KN=E'ZRW\5(2Y"+@?@[^=(1
M146>S=!P,!54&F?396[/@DO+:O9(<+5*4^U;7(RW6DP0[=W7SQ7W/335)O_O
M__6N5,_+^R2<.2^/-"-7)*2/M_[+(TV^IDP6(L-%\XOSAIXJ(K+UW:F9<J91
M9.P]@9> LS((^F,_DAUK]O%FTDOM40   "P4#8I<Q,XT>;*#5=)OSWD\"#]@
MOP0(UV2>K972Y=34OO[ G_B#UVO#WM<K0*V\I+56<T!]H3VGNWK1]785C.U;
MD<TODN+N X=+0$)DDLE=$X!RA_"M98VMBRB.II25VWG^;]>I*/EG4R5VR IM
MFM+V)VR&;)H*(AZPI%J*QG?=6,K%4@I.M$4;%"9+4G,G4J7M:G!GXNB9H6+C
M*K(N&%J_8".;-KG>P=*>EP-4VN]8XO6Y$Q7X-IY.NBM_7#B*4=7\W6^6\Z)F
M /P[6F@%T,+0R7L>*ER(,?0TQE4E^)>#:QH^RI'-: TLO .<Y8 X"<;=S8@O
MLH9J>XC,R!CVPHA"VCQXVI,R6\#CWS=1+[PFVX(EY6.JK[*]W/$VZY1GYF+E
M^H&:?3PH$%$DEV0+"5!4@L-D?UQ8BX' WU8:G&HA%KUIL^G#UT1G?OU1LPFP
ME*8C6T2\!4Y401*L(PWJTVR&D_H+7!A+7K\^J6;_U3CM(4LK9XFU,=1!ISU@
MEIOAOC$ -*JO)CXB1(=2DR2:TGZO5/W8XQ81WZG:[O6P/;L$A'M/>L?12'G'
M^C7;@'PW> XW6]/0+4Z%U#&J!E9ZK3LSXW.5G7(]5.PU7.K;N61@$9=+  /_
M!$D_J,+>=735UDV HR!3\^+5B^Q\F6VO#_1:?08X"6Q(I4=ZP]DV7*FP52GA
MV-MV('>(L[F$4N7=+8'ZNM /)S-JPBV->-XHIQLQ!7WWAXL*W24#JF]H%>Q<
ML%*F[-EG&AENU9[+2<&UEO*?B4TH_:Y*II?VVXY\-J"P[66Q(R&VL_+=MS59
M"\X>ZY1)\$0O]R:P(DFVC=\O&+F^%34V1U/6)#\<#W_)_(&^B#:X#]7Q14Y-
M?**XK3[.'8E<W?&H7 $J-6<W430*9B*^GQ>G?]_>.5@^E%D=Z\931J=H-4Y4
M[,KKJQXN6=];89A-DS7N"V5IO8\"A>,)/?;3=R?NOIO0I?G,%?5-TI3SSNJW
MI'E\16@4JSSO@[&*MZ*[5&!$B>P?-F']O]Z=3,MA&TOM"H0N(A_4H;F]9B9_
M2C<Z;1@Z4+=E3BV;G";(T+\LPC2+7VMZ6']?.$XIVOIM^DEAU?S[HR=^NG/
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MK2!.3;]=5H;'FW/\I.T?)PC[:<>^=M'X$9>7K5/;AW9JR^?NPZN_U8MGT_E
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MH]N:/2QO=S!G_Y.DT_MY>I+GL@)-^RF'U[OVOO-W1(2H85JS %G<-XTS^ZA
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MJ6;/)J\V:/?,I&WB0!H6L4QXKAEIP7@<7F5-$-I9]^Q$,U7.:O$2O[4=?0_
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M9!";4-N2]CG8L++$=&CPFZL](.T-ZC5N-$CHD2"Y;CK8T:?(YIMDW@<6C>R
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ME%NV]-?\((/?(2<1J+S6TMU2NS&!=/R&\[QVXD'.7WF=!XDT(?A $S06"/(
M'3_;Y/%LJ(X>/UD]D1Y>LAZ"(]Q_KN/TXA]50-OOZ(Z",E:'30A0U2YT;*>Y
M81H,+RX>#F0%?R/U>=4HFSE$T5^8G(E_\#P.?^'N6>'>H84M69BDE>MEJ%D)
M'U<CN&[&2<=)>'U9Y"777,'I9KTQ>_+(.NXWCW.TA=02X;%R3!"W_,9L158=
M0D=E1D<^,JR)XJ<0O@>3759$?D#&SC[7MPT-1D=E:-/R6?&^>+^7J""AP."+
MN'4NZ[ 15_QLL5TJ)WX_GP[6</%[ +&8)F4Y>@?V[LOQ=-?[[HVDBH\<ET^;
M_ WUCZ51YA%=:)*YX:+;\'4$C%B1#:FR15((_=.HKC&.'%'!WG9_!#NA6;C)
MS_"^G'_Q"RWCR6H]>^#/*HY)[9J!/ );H6Z%_TCP5^1,6,=?ZK:RF/135MN^
MZ.OK&_%E#O.Q?-C*W5&!H=6?$@NE*=U)$A1W^-RQJ;-%]QG<B^?*TW9L]^<6
M?]4"ZL+2E!?U,4RF[U.\ E-6FY_?NCZS;ON#4?DQSQMEH_W]3U0*+JSL'"=F
M]P"*7@^SR<K)HL$LHI'I*_.VX<HF.Q5$@F_B-/+@;[J"&\NR1,%TKX5AK8UC
M^F8FRLBIPLOT/*2"<3!$T_M<;C*+:IJ]N6G28LG+-,!=]Y^*(DGKH;X37?3H
M?-+*WS*QK!6UGC[95U79JVR@A!=(OA4]RDS#RV=4WV AH-@T\6E7 JNR62M
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M(R;6U8<@&A)V>TUOR->($B3/&75,-R9)Y,X>^7M9\F+MM/;!Z0/JK5B6EQ;
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MITD5B35,X+5!X'@>XF_]S1=J;Z)9-I9[0(18CG!J<PULZ"HVV^F@1<[R=,_
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MKNL0>.GBF^14$UQ5)R?&#Y)WWK[R%3\BS069>HQJG!4SB,*3<12C(30ZP]I
MN,XW]L+*^'4E%'MZWO+'5_ I!QZ$DBS#"NT50NP[RE .28MB\A&]*V^E 2WM
MZ?Q!^XG2#]?#:MC7ONH[9G]H\_V)!/BR[%;>"L84@_;.LU<9*16,' ;*QTYW
M-RSV9*?E9C1UXFY9[B"WM"AP]Z4?=76$YJB/I /ES]VYR9RZI#]X\=G7!/)G
M6PW+S_WFEIZ,.K@R(7E&B,%U0K9#F$O%A=8.;/D?(?@WP]\).^OSXBTTRG:8
MB;<4^*"CR,NS0QT1.^_,.QG'RRRJ9EK(+4?H&BFB,A:M;_4$9<05.Y+Y^,D>
MZ&44;/N>Z*ZF&7,MB\BZ472HO&&UGU=VWL05:HUT</BJ*E'NL0U7UQT;<#K/
M$1S/>YOC<C8+G2[9GQ',;<Q$R7AL]Q#.E78L/[VU8PP^[^/EGT@>LA\_<+NW
M2G'C0WRC21'</0"S:-U5-Q-EZZ*-CS2KIFK1/I)V;$/50]8WW9H6AER6@E_J
MU9=?UT'B+;1,<&)SWD*.=UNC=I<_=&4*&UZ&L_3Z4=]/BN&C$]:HAQ[C^H)D
MIJ$KX*1QUXBW\#2/"7LQ79&$:*==8^5CW(NR";&7/FXH]J22>3#7;N/W?KN\
MN;L?^5Y?V=<^K@/I^6DRZ\M_.-Z;,.DD[M;?,!7SW/ 7-)W[A45D"GEF&5=S
MF7Y-&J%_G0X2O__=^OIXLCP"1:]6BZ*#^9N80E4N+^E>S95::3:81P;ZNPG>
M!FM%7"#1S@QKVC4H$OT7JAOLS=<&=S_JG'[=<5[?:*K2(P9:% 5LOA;W@V%D
M<)WYMN0#P<GRD=RB"FYT\8V4A^HJ/B3XB#?5(DL5A8<05AKD)20NTG+@C+ET
M;$?IBA'?E8L0K1W]X&LE-/!UD)^HJ+F@Y+431>8UMC.0+@X_Q<:FF683@0"U
M8Z9>R:J0V5_LU/J[JY_*7C0@-37&=.+5:2<;C0T&GP2]>YTD'N45T['HI6S:
M,6JP(';3(CJ4_SU3'M3H3Q0ST#S0J!H$EQU!>&W&R!]"UQOI#@C&KW4.Z&C6
M"U0I#9XL-PF<<N@^ -+\ WK#8AKSO4E)U$%_L#/^O<4Y_PU1E\IL]+[C$G2T
M)<"SV0F74^JKM%(*H/=8V9X$]+R#@6B+_Y17W6 P,FCJ&Q"(>K$P@>+46L"R
M::S3I((U#?YXS(3!H='4$F+B&$./$#NQ#*^!V"1?0UA]0FE,12:J91H(G?3&
MK9WD9SOTA-]GX^.K=/!2:T>[?@H(]OG*\J-^/$NIF4B1FU F]C&FJYM7T#P\
MP;UA@H8%JC]1-JX),V>F%6"6TP=LN.*_]69*ML >1" '!%YGZ_WL;:#(.<#4
MFSCBJ)UI[7><AYI1?+P 3#(Y0,>W%O*C$Q^QE:5O?+K,<D>Y[NK,+6TMNLO_
MQ._KZ^%:7$N-E^_0$TJFCYP:+G5P=H) !Q4+3-631D3" 3WUD?U8!YI>IL^'
M D9,=>CGWT2\I?;_ A8;EK3_3;&R]8U'=I>V_VIYM%$[K9*L^^>C%9^9LKX9
M]K=+@-<P]O+Y@Z( H>B)1W$OR?$&\M\2>%#<OANJ(N-=4!#O4C%X5YYO0O<\
M6IXG\Z-BQYLGRO-CWQA#[9H_($5.G&1.Z:7R'C&<TUK#5;*:HJBQ<T:\&(.;
M1]Y'L@M1818!ELW;KZA%6AB3;EJZ0^-"!0NERG6+!?%LA'_MQT,">M@4_[A$
M-N4]"DV-=/32*N7%Z5/BIO$=<\0WF]D=Q^U)%-.)!TL6R,?RY-1D)4(YR<J2
ME*<4F<\W,OZ,LJ:R#&Y#^8;@",U-4-&U9C$7<V3.XC+)(V-A_E.XV?J.S69D
M/RQ7\ZH?<:087&&N]\3PP%R@L)=(9H&+6M2*#%)P2W_3F(UXOX]&&8<9.Q]_
MXT\JYG9.!FT:1TET_F=R/>IOKL3'+3><Z G]8#,Z2<I0:E%OM=HFY=3Z6,2!
M-YE R8\*4T^S^]<J[UZ%".!!B:_\3(_L\HXX]U0WU;N89GO%SKEB9=W]2$WI
M]"ZVG7JS"RNYZ>7B,1Z+V;]S1T6?S0&V3?^X\IS2DXM]Q'YY(-)6\%5'/PD1
M4_03[H"W4)%-NDN5M)'L]N)C1'/)V:W,U^FE%W53.>1DGYX1RRZ8=@QDKO.\
ML+/7A#?5IVE@C08J)=NWGH,TB/>T/W$*^"XSJ2^5M*8[Y^P] +[\^I[Y]9!=
M>+U <3J$+\C>!.^VAB:P%L,7SUOYZ[I,;)<WP]+?[6O)RFV0?!E61-]7_K%<
M#)2U"?HX6B9-4&"_1:-"^!MP-!.^,G<]-JU]/V1!UAA9$1SJKW6>'31*'W\S
M0(XOU)ZIG\?"A_%Y^Z6OC+5N%=F2A=KB*TRLVUC.87&J=1YE;5U[OUZ7'$K'
M3@65%;E"EGR#I+!"I1^_^UF^OQ5/L6:\<I8@JS@7)/M3; YLUAU\E# =)[4X
M\CI;]C&IA;;.YSR,Z8D)SID:[@R*M<^S%O=T*L]N.56:JHA9/\G8#]#//8T]
M;MC(>@ 88>JEV$4=S6%VR5<AOK"6-CL*NYX7;8'KDF;-0$L^$?47"(_"!<.G
MIH#<8GR8PK;C1=$KN].0Z)6H7C$##BE,3.-U=4L#KBU9^900QF^J?N\<V%^%
M"'YT5F"A+WF[A=\G^-*/A)/\1;ZLUCLX^/7)4UJY*E[KO! *;>";U%]]1A!@
MS-59-HBLFV@I(CTJ5J@LJY.TR1VK?$[.D[;LQTD*\+WVR&^!(4L%L /A;,'S
M6OSZL!=N2G5"J!W_7WI5&4:*-R!O(>#2MI4QEJPXX53 UZKDN@K'$U8V^AZJ
MYT!*P5[5 J/: 'W.C87?]Y\P0MKQ@_IX5=;6=)?[8>D#S$  S7:DY7%)!+4T
MEX%(JV%UMK&_L:A"=K7+1.L?N+H"F+BZE*M-.$94=#\C5$BE@$:5,8ED0(_[
MEBUMATJU.H';+I3H.^M5_S8E74.YMV95<WW5.^K' 7#LS_R96T'LA7-&_//S
M7-7\BRNH7MZ\_#UE@BJ 88D0<OTJ;>N5'D,-K%$ZAHT+.?W[0&Y5_YJ!?5J]
M&15'S734-Z*(^_&L9ZE,P3:H#V(O!B-MMA#04K5//2NY3.D<DA;&_'C2"\.D
MF0YW#9Q+=)2+-[TB\,)BO&5AUD#)[\TK4*YD$M9?ENMHHE-7EM&*'"^;4!:A
M%MKKX/RY1*;]Z)S$.LGKJ:.P5B:/1\@O5B+@58@' FO1>%GD ="^@R$!$JR#
M\TT3*&X[6IQ!LYZ"E#S72C\Q5)O)7DEY[!J;/ !PR=MS@AX G::KQ[^;).^G
M_WY'E.^O^H?S$!)[9+R-*=]M;(Z5U1M#G C./J+HG^O%V%<X4&41#0]G*AOX
MGSJO9A"BA@N>:UGJQ!AC)HRM18K#\<F8-_EQ,1,-I3!]Q N;Z>3\S_.+0T2W
M-)-I]R(C>4P6,P5L=_D/@+-";Y[[)Z3M/CZH[F7\>T)T7K?;M:%7]Q1?4_*P
MR_(+XHZOZXV1&W<L;87*>.[/FS_)5O>\3O+84!MH/W]"!]LTV9-*LM(LIK,J
M3#<P8BQI2\V;N>U%KZ^'^5@> SLOJ;*Z9WA;9-<\+.D(1P_BEP:58\!FC46K
M?V+S,F@1+2GKO1$\0$R_:=!3UR';L#-A<<)>A@1;KN^@9<S$;\\ZXRDR9X9\
M0:;'\(XT\Y;)%D@PC[<5^XQHM]-L-G'ECD$T6 6$LY-"3G9)O$O&-?)WD:_&
MRY.F"53*]C XUC.8+K5)9)&84$>:RAJ&:6FK<([E*JGHYD/M#N87?WKS+U>=
M8%Z&UX*BENL> -]A,8^'[JH@NU1@6AU-6%2@4' "LP(@(^19PD2=L,ZO_KO@
MU5!49NEQ[QKRJ N-M-\"MV&CDS$H4WO?2#V69O^*M:+L^P!8;</:H<,/T:VE
M)>N5C;98?#W37N4@!J&U288=#W;<,TRDJ$\V<^3;Z ?&RDP.Y8JDTA+(E^V@
M^.@B)P7&4ZHCZ9^D1Y;GSE\FYJX=N8,-4K*%[*ZSR'SLIT7T4 87TFBG=7R0
M[+N[K#)?B&;XV,*'>(, V-N3]G8-7RSAJ1BD$2JAPY^VE0;-W7$/:##R[N%W
MGT):8N;CT?5(K10SX#>O0X#LX$,^6#!4N4::VH#DY/<;K*%ZQ&(+)U+7B["K
M#0>M?6^ I.Y*,T[Q9ERNKX5]<$8'Z)F@$W 5QHM9A34*!(?3(J% WZ6Q,20'
MBY$5OS+2=R2%UTA\\*Y-!!_L1]_04'=\QKPE07T9X1"X;+B=5G%CY!&A<.R
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M>L*B'%IP2,&]&\OL?59 'N,UXGK<*K>59H)%9W6>XIY1+^ !P,9JCH\F"A^
MM@4?^Y:N?1B9&U?M?P $U(D7^(6VJR?6#-BY1%9<&IQ:;77[XUTT,N6V0519
M_SV7PO\;WE$?INDS873"F#;B[YUJUW\[;-G04WY\##FI<+UA9=CNCQ$_#%>M
M_NOABY@^ %HQV60]3&0_O^?^I'0/%4M"MID&W7O(/0!\<,1ZL6^/8^[1)-T>
M+JG"$K0>$&C#R7R0\>*%@/CV=__+]H(;5O%3A/C-AAKV=VIQ7H+-VQZ-&[:M
MS'GD8DR^'4C*-YGP:AUX=_).K!_[%O6/)+PKA*@33"$8ABRR_=7"(KN]BBQ
M%B<SF%E0XK L/0!JD,Y9-=)91H'Y9"B"N.P'P+?P)SX0U_Q%*[@234X*8^2U
M=F@J0\1FJ&5,X_0XAZD#(X?#"^!%+)4D9*Y"R4KN%J"&/11>5D4R(VL#FTR5
M=T<*E^XN5\[[CS2#+MNS9^;YL9;H'P" OXK8+V9MCF"/U598I)KT&<^,%/B^
MNDNW?@"(_7D +%>IW.!7[3N0WQTS$9T:U2Q0DAR(@_2]$#5?58^$@D#R=R'S
M][YK_XS>RW&DG))5Z+]U?*(_ ,=M1E+TK94O2)7GQ"8S?-;YDV4"?P!D>;0=
M!<C-V+5M+W'<K*AA#W-N"30CUH%=X68%Z3NJBSV^]!?4IE/__-3P#?QOL@$^
M$\=#FZ4O13(TD8T4ZGH$U,67%7GW70Y_M43Y+S\.,K5=M%L3/WXD 13IZ^I_
MXHS65/M@UO4Y<=@OZ0STWWMCM9L.<'@./,0!7%W5;#$;W)[ 'SE]<#N1;NY[
MV@N"^CYFM9NL?AD)- I,G&WWZJ#\.^HX@!6QYPU6O,^]N1X S&?ZT4STH6*&
M8#HO)$ S\3^7()&)WE<@'ZO)#4Y28%XZW]$*\ GC&2OUZ66DFU0GVTZW%GM'
MQAD!/N+^+7U9E?9W*7Q/5SDYO<C'#/&:2$DSQ%J!=C/?A/";7D_*^W! 6(@V
M[?M7PT2T@AA!Q+KPQ">MULY159%QYU#-E&';'"Q6,QW*(@\MGGJ_<5SNVJ_D
MIKN[5SK2.399<VI\$DO9C^6 T4S$MI-F"XX2+ NN99_LY]BKJ"6"#G2B8-/5
M_=/T8W6F(II"P?5-T:3WO*DTP,^>V7EIJ(OD\?D>=Q*93(ZDN@N*?</)LB6[
MLAC'XY*NWB-JRB$OEXM])I=7=94=Z^7@(=ZC)T:[)]0_3,$1:L_H1[TWU)2
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MQU_B"[8/%_Q)T78<\W[W/?"8RO^"<H52DO9>?SHW:08Z<=KBO,J\IX,X&7L
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MXU/#TF87NK: [OCCFX^R/PDK"OVX49$2>0];4E=-#8XTR1G9(CP+GB%4SG@
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MJ1K&P"C%N'OI"Q::OVH9JH2M@EY(>[(] ,)<!H>TL9H\"NM@L?89,CAR#BP
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M$ZTLK!JX>2AO!H\@5N88D%A0ZDN]('ET,$M7JQ.ZY/%"[R\?MIE=ZLWCF78
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M50F->"A,1OR\EV<C5"_]3B?D7('P[NO?-3FJJ4-X'12W=%O] &A/!>D6^3P
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M_#QGP;E>+JJEU\02^=Y7_P;1$YC1*5&$IPSQ"AWW],.\>=D9&!Z^G)'[SCS
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MUP I.6J,Y1@)0%<\)83V2H#P<32BO="T0.VZ9EW4*V^5P%81T]11\L3?_!M
M%JU5Z3= 7I#[74EU45Q"=Z;#M;KQ??_RT&M.> $OP=<?YLS\5;)"GB4F%S>3
M (PP_^GV  ^\\A(T'R6YV:LFW1]"=[+14.H1)#M;.,,DX72'=KN+6OEFB&(
M"<""<++$C6'D5QOKJG,^W@$QV7K4X'R,:Q#^MY!ULR*9;$\J.IV^]D:^-90U
MP94@P7T[25HKEG&.R.E(E)I63[;DTL<*:)C/YZ8&78%'JXG]'=8O*$*_47/U
M QYB; =GP@$X<60"XBK!8AJFA:33ZOLRW^?(:#18:K\5Z!+^))K%\^N3\C8/
M\>:\YK)."4Q3@JHX7I1@BF&(#9?N7=V3HF[RH</%3S_PTAOAMLJT\N8R$[\K
M^.T1-76JP^<*&X)#"YHONA1GV\,M'*D8IF21=DG[*3K6I#TJK&J]Q#<+H4E#
M*K&\EA0K,VF>E^F<!.@#LL-4< <OB=QCJL)E.)P'Y@\4K-]N$2%=]SUZ,U.C
M+$*7RJ_>>9UW!"#])EP4.H-UP[C%^Q_@'@=(O\EV(MQMQR0:09;LLKC#%EO,
M@>T/[?J%#EI#F/H=)@(<XT!7%8&O'42F.@4]\Q2;<)%E<Q[WEE)+-:_/#9Q:
MC,KI/V?23!@63W3;X!P)*0@?)%Z=(#+C9GKFJ+(5["W[YWBVE,[[)H8#?&/>
M?.5[ECA2H_MK[/4RV^8Y0T]*(IQ1T2=R3CJY7I*Z-P^(\_VJ63I<YC$7UQ)F
M 7'GYJ0P]J)2>++6N)JO![C,:I$(/E5X"7&\4V6< $:I=.CWW-LHJG*?HPBB
M>#YQ4!'QHZ9T$*.]";CLL\]--W#(52K<-32/T26/.O&A@;KUR=E7Q\.\7+R%
M6J)3\W<Q\KM/F;]KT^9 YRC]U24NWA'\R@D"N%C**/; 3B7'-QSJ,NBZG.BY
M'_,<D#OJ!IBS>)V. #XJ' 23@W3L=HP.Y);,3"]?=']K-X?+ZF[*$KW!':&W
M^QVSP/9<U>T32)Q*^:\(>1JN=+6:$R>--4^WB$3M(>(D-C#F&8T?5[WXK*;7
M/%X:E@VKO*X;>2C!]6IO5'$/5#</=;6WM4KO7>8Z<8Q/_J9=9[/L^7:QZ+W$
MHQ?\#^=L2]0TJJ].(5Q\WE@"J53=;JC?^+U[,LH$G1[N^PU5 K>;U]1%<-S'
MQ%V/7KQI8DN3F">^)1T9I"Z2;C+%8H\S+H(I-S(..#5/!%R5HIOP5M9FNKTB
MLBD\_4K-$]0L.OF'N%+R__IGYO_-? >H-WX(8#5Y%C+6[,:U\8H]7L\&(%)8
M\$*-#B#):JQ!^9_SVNLM[;$M_8< H;'_NJ NXN3U_>\K@IQ\[^J-KCP),7[]
M7P+_6O#B>_<DQ&1,XUI]B'']ORXNE5$72;("<G2*_KVG_C]%KLNHB;I_HN@Z
M+G _+BJ6V7E$[:L]]E<\!Y/<X8O<40FN7-4)2G]Z)#]!@3VW%$$PGTB?G380
M<@B03<R'#19RRS_3(=G:.9E?CR\*QA,9](Z ..OL?$BHXQ!B(.6?R]#0IY<E
MSP=3)7U2(+5/1'6\2P%_:>\ELKL6D0"JD@@A$H ;C+,.R2?@;<,-B J(Z41$
M&SYR]M')=?&?(*2K)_SHP(L$@#7A+E,FC;PI"9 /\<&O7VH_*9$BNIU2UZ9N
M'5N^A_?\G )MSLT3SWPP!9?*2T@ ]6E$.CP)]*_'KF!-U-3CCQC^073Y(/BR
M)%'A?VRY<!]N0S2K_1M<Z3_[ET^'X4E =)TB^ S;2 )TVA(NJZ:-W/[!/H,+
M_\3?:AD2(/I#&7RTH^GB<'E5AR Q B:&52(.,B]M DTGMIWE+_ -Z)2,.3S]
M%_0#+Z\SI?\PP^1?9ESZ*.M\(NL4_B)4E"]?-_M?SLOZ3T? >X8G$9?P#O\#
M'?Z_H[MTG3J6!/@''C],[U)LZ1^QPN82Z8ZJ_[ ULU95OE2W_"_V].67PC3R
M#(=<YKN$<FO(MOMT$E0L=7;[V53TEWAQW_]ZX;A:,]8RCRAU!BSO]IO9FS@/
M$.&+K'ONP,9;>W7GV3]:4I]&:*>!A509GZTX'WVB4;IWC!;UNU?X!.YO1MX_
M9CL_*'"*1F8I_SAR"$#1A04HTWTL]!&L" X,ODI6&^)\/L/OC7B:L1;Z5Q>0
ML; @0@*<&%$W::WNV+X9ZY_N]Y:__4H= 0X9;YIV:4Z\9U@K;%=%!Y6P'!L*
MOLHA:_?VD=4@=1YT-7N\;89_?$][1S]15VAYX:7R"C/'IQT-7CA!4G^8UV3/
MAU_<L]9+LYZWHRW@I'(>Q&7GR<%2U-#'8?&'[@9FA2GW11=1=2;>T5&H\D5F
MYL^Q:'7WF"=F,?O:D-*(;HN%VL:A.\A&9][#L-:0H$\,3YNF7#)E>ER>7JSW
M,H0_!&,O64%'?I=EAA4N_L" Z9>C5YOZ@1C;P_LJ>9%<)^>6YCZ5V_?ZWM<T
MZ;M?B3F2&DM&A0$4R*8O:AT/PB-*1RKL>DMMYRLKQK5NURE./@V\KZ.Q>#;*
M>:S(VZ9+R]7L_C.^Q9G[;<=9=Y77Y=L2%=MWYS158LC#YWNV5M(?(BMO8!J9
M<*<(>;WM4!OBKPAD*%;[@M+%H]73H_*E"20N?$S^\8-#CFNYL/*+*2Q?@V_V
M*R&O^^;;),"G2G%EVNGO:VOYF(IKR4L0G\LZF<+9&7N6#6CXW\MA1F0&!X;%
M<'9/JQMN?0=G5'/P&9^+=S,_X0UN Y*6*QR[%Y6XS?O?)DYX;2:,Z^J3)8T%
MH(%Z?<IBR5%Y5,K5)>HB\.]W)HAM\-WB3K'+[CM19S-\H%/0<--V G3L;+EI
M7FI:V7==T2F[;OGW3KPW-Q"8CQ,7[G^X2F0"7_*7%=YE$D#@-P)MX1,?2W0!
M_7MI9H"#787.XM JL+K..IR2!!C^>O'=M,0DITY]\;+9_P8SFV^&FG;S$Q>E
M2( SH2^7:W4$,Q+@,[@;A*,.(@&&%#%&)F6>DB7CT9DKB,W)<)3@STKGO7Q<
MJ%(_^)R5P$("O J"$](U+D'7P?Y/.]4GVNX66?V,?6U^D1-Q&=W&^#B[O3]X
M1R+?*,:4&"W];YB7\<_@AKO,+_>S(N!H^@,2( V"FFI074W?,I7*6Q9]8J:D
M-5>"!UUI*@(V=^HN^^V.XD)!_P. #D$M'U5R<=WA&@G0I8(@ZE8G%M;03"8W
M%Z8;0E<9FL1S?75=<,"S$V"S()>6Q6@= KF[S ;Z:X(&$\DN?7%HH Q?J4"P
M\91$M?^73D<.M>KT%!FO4;V7 SGD,=]'E+*>M!JG+)@D[/#OD9$ E$ZX\O^.
MV0..W,UG@_\U_;=.F-/3N4^IW5S%%>+"X6J>\#HT_&@;Y%M;$O8!&WSILAJ8
M^1[R?QW7.+SW3Z>86_XUJ# ) -C_YT@Z%?%BVBV+Z>;>-YY1WOA=2V#-1SN?
M4FS=\VUSFUM&8QGB\X]%<9?B9/\ZP11<*$>_XW_SBR-;3]N,0II, 5Z%&KXR
MN"^<I;^ '^X"HLVDXSK%,)LQ]?H(&JB<BCW8M*'VP^?Z5GIF77/.4B5J:EK?
M[NH)E>\62]@-07S-]Q_RNWUP/0(U3F$9 VV_]/+3'88+D60$7%$SR0)/;!NZ
M/'MNG)1$S^]>[80"2EZ'[V:G;J50#A Z<3:,Y])-BK]G0"N@,_;GG4G_B/Z%
M'!R.GMX##]U(P[TW?LBVS<SZ3QMP.9TAUVVV#.4/X4G!)0DGVI/5ZH-DMSD-
M421 3U\ YS';+.%1:]J,=C,T^T'ZDUZ=W.2P,/%A+]BB[JW<XFDY0E<>:.G<
MB%JM\C&LNV0>\2% I)?OU?7LWIX[C=_ZA!)@L2ER6AD@QRU+?UMH<7O'A\F4
M>R9EG*O1:F^V?D\?UPA_Y--_[-<!4.W4V4H,.OY$RU4?[?5E^V[@P%7[>&T=
MH Q_QN9XZ5#A\I^%^K1+QD6K0<<@F?PI0PU2;F1KE)B4=2L&5:%!GAQU(>KT
M.H#B&24;:QW5OLS=N]A/]/=<0I.<:'J9%P3BS02<J^X.J(GM##,U9:0IWQ34
M9LM)><SP'%6YS7TW[;%MCPO,)_/&WH+&@"4O#Z)3UHYZ4)K' ::$IB4*3D@Z
M(9+9'\&&,CYX_8YL;W?&-0\ZR(\ @GQW8L3=PR>WE1XV%+QU1G"NYGO.C\$L
M@PO[K["%)MAE7K7=&'S1^:7==B5E0-PG.9P'X5?"8WLA=+=]DJ955.X%%^<S
M0 B;0.Z3F2\Z_(7./R7,R80X!T4C0'J XV6.'3JA!%J+XD?>TJ^ZW\0\XZ1(
MSEUS\813-5;>D-/\*C;(JL<N*!YS<5?5DKQHFT7+?\;"4>6^#/O#(?XQS2UB
MR,SGK3RANK:FHV?-MAY7R3Z_?1U!??>7O 8OHX^GG%B[7V%J\%?DZGRSW*&L
MP43UWHF^>4NC*_0]NE]O\VA/@_F1DL6O?_BV;!C#444P!R#[SP1\=4#Z,]'U
ME:0I]_T6M9KL +-VIT:_](M>0MFSW;OE]8E)2BBJUQ7+NBXE.^Q*3;XQTG3M
MV_N?#:_=Y!OX(-SG2/^PY**E84_Q>5^G9NY"U:@,[;M?X5@5RSY'AOV<;J+4
M1+OA!RO!Z6J%MA)5NNH?F\L;H PMZ-=EJKW'WS[,$%F4%J^?^'Y;UYGTQ<W\
MDIB&53972H5U&/)&N7!<:^)P:;+W[K107VO")2';VI3WD3/^6Y)>9]DN+28U
MF\F&T+(Q@A4ZL?8YF-G#$"?LWF;8J]YP./H:IH*L9H,]KQO_A*Y8XABK4IBU
M.-"=U!*>5TF4"@W8F6LB4A DT9TUJ_ XT8 BS=ONYP7S5NGYQ_[J3WJ.)OA:
MMFRU>"V*6DRF=TH';<5ZGYYU%!9] 9=8^FP/CA]"5[5B=1/,TRUK4AYG1 Q"
M9Z[?]DN3X;FK&GEF;CL:E\?QK1.BDL_HT7CZZ'Z[W.+MUO3?C&#>AS =9$[)
MM*(T+>[ZMH77]=&^EWOM\!-3$6]&8&\)/@"!"M/JMG$<2'FS.6!CNAU8E"JI
M^G4VT2386;*;\_L<F=J.8O:=JLIY!VQ+^7>UCV WH7G/[<5J%^)SO#J^;RXP
MIP3N;K]L,__G[=7F3*.:W.->?\4['ZIL('=*_9Q]Z1;K$BM^-[N [HNO2P-@
MX@G]^5?]D\!]:9Z6-H'IDOV+>:]YJ/!F#]993__*R-I+[T;*"2S)Q_!.LZ..
M56TD=@?T'RKCNXY'P3BZ@/&!7P&WN 0]Q',5:YM-"RP*W8*HW8KS9U;"1#=X
M6U"I&_,'=L!^AAO;#@RU35X@@^8V#^%H&_\'[I/RKXS68W_JZ.WXMVTI&JCS
M?/ 2K,V8$5IZH512T\U_4FWY\<[J)%K04$\LC"O#%P/J:0Q*LP&CZ.Z(?UT>
MACJLDY?3?TH\*3]O2JBOI!J2.N'5'A^8>WQUH_G=;5G^F\^R<>D6"+1V_BHB
MCK]_[G%K4E_6867"0.)C@\S1FZ^4!VT:JH-WT)O(.[$HT0<O[!P:^A#NX<PS
M+VC2_[*FJ25!07,I2[4V\(\-ZH,7CDDK+=D;A[8VIPZQL\8X?._AEG295%-)
M8W92355_S]F3X^[GJ\JE"C[<?SL%4M-UIYXW<!BG-4Z4IYYQXT)4YJ'J# 2=
ML4I>@;K&:?[,V0*O'[?E (4AQU4D@ 7:.P.]C*+NOM#I?0MW!9?KI3H$&P9^
MYS(-U%0[;=HR!\OF5NQ6SFSL?8Y^GIW!Y][2MC-<G"V^LQVF#UFENTU<VD;-
MF];E+4W]]!N^\6.8A?YS,I1_O'P>A]?LF/ .H/%R ^?]6'"%1#6;I)( [;.H
M3IYXCRH8OU_!AV?ZDEH#HVP_M/N"XUYW8XE?.O1-<)!/4!ULU#A,]JD3_V_%
MCV(/.B>&:^)],[?EM\O"O^3Z71NQE[QS]F%4N 2L<V<QQR'![R_$,7Z)I:/9
MZB:&/4MB]T5-Y3@S^-N(YSRN5[MUW&42.26Q/O%90#^P3C3NZD[F+TI8#;H:
MN1RSB2$!^J*S]**JX@*2U P/CI]3X=MG>)#@-S,ACEWV\%Y1Y(CV]M*V]6S#
MHW09G>;DDOD;DR2 AV%N<%G1#.18D=@;[7,:K';#)U0ZP;$++[6#LHR1L*!N
MGCG^P^Q_Y.0A972- S\\RK^43F1WBR9VS?3V<7O46<,RF_$FS^FU[Z?GNMU
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MIKR%T+5D<8T?)/,U"=J\^%Z'M8AG*#>IOV?A4<5*>FZH17]RMF"BG&T671?
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M_LLV2(3W$Y:O2<]DV^\ SY:2O+M"WLE1>>^)*P>.,$Y]("*EGV[X@E[=$$;
M9J]+DI:?B*^7HPC1G=,T5RI4/G> W;3CETUW@-)CZ+9T:]H=P(_F/P&0ZB\
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M1FIN\>B4^I*H7Y((1S(J<-9%5,0"I(9!;@N;TSH53L-$Q6N731SE7CY]@L6
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MK.5\3WXS'0WHLJNF4&](T5&EF^VJ$QNVWH??N5-.;R5"?QBU^;6WP2B0<;W
M%S:ZX?YG@RFF<F-524 *H-$<CN?T&5V-G/1> "9K>!6GP5>C K)<;?24(>\D
M+PL5-7Y6\V'>;1QC]<*Y-,_'AIC(P%A&DS8<KDHBL4)N.6-NOA@I+9"*(4?&
M&=YW+P[+E5$\7:OSY]SS>AA![!1.401RK+T8#%&>IN/5>QN>X7/@'D.B"D6%
M+BZ4CZ)@:36$,Y%"SO1XLY)49X0TJM2-\ULOY00/S9QC#_E,:!9"?V*[07&]
M=JS'^4#^M\Q+3@HUL1Y_<_,EX("X^X2(9?!)JMS/ F:FB9/6)2T1E3,#(N1M
MW('C6JA\#[!R9^Y3+1^?FJ$(XD/NO/*\ ^*[3)39<30VNLQ.T/CX&TC?NA;H
MG3MG((>MUR_RAN5#%R&9^:,"^@*R7KBA"P='B5]PC%)SL*KJGW(I095LHT)L
M;DI %L.,/3P-$-O=DU]'I;E\58O2V+BTH']7T"]G/?4].ZO>#][Z;&%OA(9:
MJO2+N2UZ0'@FW^J*K30<LC[_$=\S-:>YORBB)Z('GTA#W0C &?Q+:[]>4T&2
M+2QQM$A@@Y^6-"<[!Y;%_3?:2V*$_!US'P1>'?S?TQ[F[@ OQ==)P/>FM_5<
M#?02VBXKOCYX [RGIA+^.X"DS<WE':#_K[!\UE]A^8A8G!P9WE/0?B=2%2]@
MKBK@#D WO@*QN>QGX"RC+R\QGUJOTU:14$U;A)4/O8OL&7.RK!01&>3(2X!O
M!!14BO7?IK<(6XGQ(FZK V(^5W+A-)W@Q7NS]-PPPQNI[)_LJ-R,:$-=FF:K
M2<*E(W_Z=IG"Z*I%L(L';;MXA@G*X$6;5AM@C(!S)^K>_DY&]&B')Z5(C1 -
MF9OTLDQD%Q<+NUNW>W'G8$,'OT]N[1GL!=#;F4XX2F)74;5IHA@DS3IN@J!<
MFVLN9K!4>J-AV?@U9+O[;>G^UL'!I\J&VN%>'"$U=GZ95S^BU*GMQQ.>=\4F
M2+2+=X,D?49I*O=!Q!F-B<<'$ B<S/II_^AX0WE\@QNY;;5EQG)8K\J@=<,9
MJ,'KL)@V_L67Y[8]105Z@Y1F9._X9NR0$RM#K5A>FE=>(Q52$;MK#=1G[?)C
M)2=)3VB-'O>.E\;8N!7*5_-GO4VEBQ5*MN=)#:F'QR0.[ NUS!*=--;1-7?8
MS7'HCC<1+]'(M8>]EXM&C7B$S(PJ-R\V]WR9CS\M>63L_H7<9;Y*BYH%4X&0
M\6WAN<B"!4B!C/'M54XAO],PZ=[JYJ;F,3*VO_1DI;6S"$9EH[8S?=@(L!1N
ML#<T:3@=QHF-W7V(WT^T<$.+\G=&S&@KRBN9 M8QINO*)Y%X>+P*/H%I"6K=
M(JQ3F-:B8<MK)/N'7B3PF*ELR+'L[)MMEJUK;UZ&?F4NKB\LTV@6]-C,'>#%
M*[X*FE/C&XPP;D.@:7Y.HTC;PV+99]8;7WHF[H&]ZD;*;!)Y6M9Z$+[TY@?Q
MM(F2P)[.Q4RH,RW#ERRK F=LN,BXNZE-K4V67TU+%+[+9NS6M.I/5.J6.4+_
M#M -1S##SL\"T;]D0+^?E/04>-X!0 1_8__RO[#_W[,I_IE.NY5LB5 Y@V8L
MRQ3L^F#< 2(M!K>7K_!+ ^J/'MP!^BK-3^WNWY($6<;< >K'3Z4)_L>!-T<Q
MAL>P"%QD^"8X>K*)I^0SC0*VN2OU0Q[HV[/M]Z6U77V#[I1UC'P/>B>G/[D^
M]CA-QX'BN@7H#0;Q7/\AI_CS1&^L^427O%-7T9:^Z4>38O+-=_^+\^+O*6PB
MEL)# ZE. 'JGG3\S\B7U<C09Z7AOD$Q1J41@O48%F%"'@]M\HV4&)K+0(R S
MMKR=/C]J20IK@3J%.\2DF=T.3V?@Q.X#HG6$[0[P5;SPBE"?:#KFX=S^: S'
MT+CN")_?Y$TJ*AU#/LR O4>2]OHCMA_Y1W<-@2WQ\4J.656!0\V%KHH^70VV
M9.3OM-$<O9JFGE03.3*ZCW. GI76I:N)H<K%N9]&1O52E_&0/VY'J>]%?:H>
M='M)338IYMZ(-]@]TI$LV*.!2!F]MWQ1?IGP8+<S3)1;/V__=G648(^:L!%$
MW#A8-#>P3[S]-.>GHQD]\X4Z+NG9L'-#Z<]5\"BE56+LST+I)<I:[[@K3ZHL
M 4'3D.C34KRN.9?JK!O]).6)"!E+9X>:(MX>KX034E.RO=2UC/9N]S]#'\L6
M*N1W&JDW=;X&",])#0RS%"4']N(%S@4A>1%^6LX3O)Z.KJ(E7>$-@@_$K$<%
M<.LT,'+M#4%PFD>HVG9Q8AX0"<H7JXD;3J&7GM__)@J\_N>1_=/)*)(,9BJA
MF;%4KFIJ.E1!EM4J$XB+]#LR.KK2-?X.D/G ,&\5%HBF1,:$SU;KT2$[.9+P
MXN@_[BY8/O9P(J-Z6OJ)^:B<L&#,RD,GZJKF22CV86DOT,+\Y_6'U2\?B#A?
MK@6TTXP45Q],G88R#B?S/T^IG_\Z..'K:3I77+VBYZ0'=COY6EA'VK;R; &(
M#21.M#OCB37X2KJ_?ZQ3&>)C<%NT(/9Q\[21H[IR=B=VAWIZY,]O.K-C#Q_>
M>SN/5XN'N3.//J<1OYC7P@2O[(4S,NA,3ZUO9.F')JR[K@>?+N/.Y83]!-O1
M+(1^$>=^3\[S-YR+6@^/QP_(MA5OE5&SK>)=XMF(GRVVIACW9UF?\,Z+^A=5
MK_XX5/A0;*'\CNA8S.@!K:4 T39Y;>>M_(5Z8UV8[".'OI&,^/6'/C%::**:
MHCN Z/U8/,J] SR[$2>*WL3#%^Q(FDH94*G)2Y)#W $Z3JS/KSS=+&7 V)8G
MQM7@IR$J]2(5N0L8O7;R7FA,Q.+43G-2YYQZ;9*&V!CC+XL/A>\>0.K;*/&
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MA9HW0(*RB-;HF5 C0.6KR.^'NS2XEE.\A#QPD8"?UE+1*;=)Q_G[7O2K;-1
M)D&"\PE2:K.O0L&G?/$<K'RPB_@5#ZA0_WB30398-[8\[\]RN[-GUD"9S0OI
M2["E&6XA^GO6DRMR0&X#U=:%.G6K&Z6FY8\F"N\B:T<) JE-3E5^_#_KP0<Q
MM1!CW[H^P;/<R^W=;NT7V;YMB+J]-'G \>#H=P(#W7W_Q &+1^Y)G:;A2H'B
MTV7T*,75? YFV>'6V6BK #N!)[:"?:=$NZE4R.G0U44UT$158Y:C:X;!3XJS
MIS(QG*%FV-$S&^:"U-7U6SWE"=CY$A'#=9!'E$9I^K\Q0V00R]W@!T#V::XO
MKKWO'D7^7JU?_IF*,05'X&9XN[*5I/TALB.P_.55(>U0)Y:7?C4S!GP=3O'#
M8+C*[%N4)YZ:OEUWZSTO=_0CQ/+@&XW$T?IT%7(A_D9M(>$?I,6%-KND5;,8
MB5Q-:Q^K\B!?_%K,<G9=]QI$!%"$![<2.C>[]&>2<,YUDDO2[QL]O8S'^^3+
M,@^"PW[8FL8P:+?8\E]V7FH)7@NA1X72.EKQ07M"+1D0>X??26[P2A,5]0@%
M/D\$YS8W2**7-AHGWKQ'\DV?>*C]1M7N1'ISU>>CR]0:[Q\9(%)T"4L[HUW=
MR0%-FY8'VT;F_+Q><\W$5C\+!M/^%YDU \:>.%=*][!7PM&A21W(U'K>)Y%(
MELY4NH;R0+G))[EV# T!;TKHW.D(]/CZI[*QJY_5DII@T:X)\/*5K#532"&9
M ZLH!ELYU&="]O(Z"K4_&2L>.PB0@G3/@,G4/." !9_W#M(/5GR<JTVQYV>[
M*6XW2 4R;/%-+'%R2&AKX-_"LD3+U=XP2M _^4IU/]8?J@RSO00L5C5:6^48
M4=2$5NV^KGC0:#6OE/F3]O_;(]\X)._O_*)/#_^Y+_$P8?GEE272(AKCYS\<
M?Z7 BWL\6.1=6287(]@&48N1VH@]1A+U9%GG+"U*N,R0FY5G[XX1J#_<;O-+
M=8-Y_$>XX'A807OB5#LK3J6U>F(ULLOJ0HU58N%463LD>@<4OE57^.?3_)RR
MSX5D1:(2GV6?#!H+B/A6WMAER,>,;F43OZ2.1E,I(#S1 1P4]W;#/.\.0#_S
M1S<@RSI[MM\5ZOP\M-C4*8Z$@-4^_8Q5]F&1U1+=N)>419RN9H%YP;SP9YWB
M0U4SMI#(&.8TV^JNNI_\UH,)\[]AEACK4)0S1_OR%:G7/;U\BTV["9=O1<A#
M_;;;8#^:["(<Q"?^$M[2-^>6+8)S7MPZK3]J"VW'GNU"G8-0C.$=@O%Q2.;0
MT=L67>BQJ/;]0NYK=/.F2K7<+:YG]VG['>!3U;T)]+B"4\IF_"IZM=VVCJ]$
MPZ_D;2U&/V08!O)E_J.V6R7V,1"-!47D+@&YQ G<_H@YIM7\]36G.% 9WC<.
MGF^Y<JO+%-[A-$Z&NG< 9/ 5%\046!VU*UB-+6M6%:+@4*$4;"29+.SKHR%P
MW8M1HC7FI9:)2C"'T.A,5-L3BXR6&?2*#9V.=-BG>00GC)BJ3D0U-X4P^W:J
M6P]@5:Y?MJ[<>ZA/MTQ&5\4I*JGO )__;K+I':#];<N+/H =@=O*6M[5/U6.
M6E^G%D(JU";[$"D$.;Z&_43(R&>]+(Y$PFZ$DE;.Q==-D:WH)W\UGP:Q"_)K
M/7V'6KZWI7\KL;]]S2]-GB\-W:QU-9S0G(>B:T[V2*. =A;XX)XC\>Z-.X)K
MXMZ1WA&'3[9B-J)^]MP!4&36]\[TV3E0)?$M=#ID$.WC\]1P1#0\M!4^"<6$
M;IL@:]&/Y_XECM/M7^(RP\^RN.X :6F^>);4O?<?^^N5Y?L6S=\!'A[<OQ+^
M5]\?79$VW1/E-Y?[O@>9J0!OK89:M[96_&:[+EDZQ1&?0-];B)!,T25SX"6N
MJ"/%QH#SEXF'DUDBME22)@N4!%D"O&=373VKJSKAS^E)Q)*3)]4SFX8L(,%#
M[AKNAMW2;X6IZ_^7Q>LZ50N]I3!&R?4_H@-N6MW0IVY9DJ@=."@(3?,;"F>O
M+A\KK5(X8*+X'K#+&/4QDMG/_=E"Z;2J1,_3'4,2),>*:_=1$#43E'@8+DHC
MVW!,[E:5PHXDT,3*GU]@59/K:.[L)8R%-B;C>5QG6?$DD>2^QE@!$:%'Q?&]
M#%:!I&YQ*@CSZ46005WKQ.E,2VV3;.3^6I#(M:OY!^Q7EV.=O5%:O+K 69G5
MYRFE#6,H2<7JQI;I*HCN&<_\KU3A00'((U=-:+/1^*K=$B2FID6086:;NONT
MN)4(!#5U,]6:5'-HSDF>* AYV%9(O"9B&7:CC-DYQ[QOMV:@Y*VDUT=]/UG@
MA%-L-T(S<>FAA*J)R.S:/Y&<ZG.!]&18==\TG%IG75=9A;@&&AY-SXEP6V/J
M(GR7)""X+;$;+;\!H0.Q@C3"D9M?^9^=<F#Y+)"HH7S&T4?MM;4-C+\:1&/S
M8,-0'(<@V!C.YYKM>$A.S\I3#!&+9KUN$#6O)\V/Q'O_H8EM12&-N#70I#).
MIT[Q XLDWIPDZ?1+^^OQE[9V">\IS5)?8W0YC<Z.]A!X/4?MP:_%G\$"0-US
M^ZZ)3*'$Z?7!,Y ZEF9<>EKZF_05IR?Y;I7GULC8GVLP@CDK:MSR9I2Y?<G.
MS'FBF4-V %NB=;!KV.RZ=I!UW^+F(4W/R\1M,5J?A;G &UINX,K1T^C51K#P
MSQ+-"=4&Y43^:*]8?\8'4+=Q04BZZ;?4F/D%GVDM(<C40??%MSP@KK70(BS@
M+-202HZ!K^'[DK)Y&-W700*>/IP$5<>(O)</3I;BKFENI"=;:,![)5;/EMY6
M(@S"(M-'V7,K>$@0R\ W4<R83S_:D>*UM[6M!<_,B %N),>=!N<;FPGWT6\J
MIYS9P.JH[XD1+LT3NDOZNNY&1R82LC<5#V%Q=5H::Z/S/PW"5S9J?\ 13FA"
M(.$<J!=>HJN @N'-'?@E*SZ5*-<Q<2B)GHC@8BG^>3ZF)TXTNTV(DE;4R;W6
M*.8G-\QY/CS</=R<4.=L]8(H?&ANH-!L.=G\B15&NQ<C@J77YS7*=.46V)[Z
ML/9W"0,BIKFT)LXC@;Z+2<XX0JPK4J$AL^\.T&3>;\>ZX6B0UW$TJ]4UDX9?
M]6J-XQD=BKK78)I7O2QU]Q6!I#W8MJ8/LBI,0O!Q/?U2HGVKQ ,W]!H,0@4H
MD@#'T32]GJ6[<]]=B,_?H0*HRKGUFE!IG$%TYNJO8K)Z?'9L=M X/E-<-^I(
MF<"J^>5'"VX.\UW$<1,[,ZHV^ O<HLF9+#_6I50JHX^34]J<[G4^U;L?C:0;
M_*A(WRE$U!K(7K*%Y-9?U@4Q8.5WNXIPZ?;6BQG'QZPNR/1'SU5[0:YY4%O=
M$SSH!P@>T+.(.9L7>KVWU<U1.JS?/P#9L&1=R][$7PHN_.&]B(O-JWX5JD=&
MEH[WK>0.8'X'(.4+%XE"F2I7C:,7C5FLB"MT+IED39RBUF>).96PC'(,)EOQ
M.I]==9Z[(@Y;5^X ?BT48UXR>;K6Y-7)JC*,*;]&>51@\=T 2PO: WJ6.O^1
M!VU$.X:Z5\KT&MNO'UA;_3_>AV_GX<P73?8_KKZ8N):5RZ7YWM"=FP-7&"5/
MZKX6+0TW_7S<S[IUR+>!.?#,G<L^1&M\^:7X^E^&W^ .<*YF^'F"06"9KK=N
MQ?9+8W/]'BC4_C'0-,E3P7#:16AGCX)&&&R(,?.7?>ALP S+GKI1*-)9F!UT
MM,_LJB4A%F98".MKN\UY18I3-_AMJ>GHFD-SJLD^#_PF;UDN1\\M43 ;R1>8
MO;"S/$=6&?FQ0G<E0J4C(U+]S<AS[\!"L*;N\XRF2;OTLAJUJE''UQ\?G9(Q
M%76N#I.#2>TRIXO-*A)5[*@&#%Z%KHL\PL'%)DS&K>Z7Y$TVN0.X^EC< ?#K
M]K+$3!#GK6O+C]Q [8DMS?ENM6IIVHC#]!FDHLU)DV[:P[E7!$S;(P]ZX+Z.
MPYJ(D8RU18?N Q&-0K=Y()*JBSC26M,#$LEW00S[++*5'#-7;,9*V8@)BK/:
M;"F+UJP*!M?-73U*G&-,A'_Z2IHE^.J/I3\M-9!2%6JK71/E+'[P%#>N<I0_
M]<N[2^]Y'_MPK]6L:Q5#="]TQPD7Q+T&Q46%]Z3A^1#-[=18KU8G-#TY/^?[
MF;>@R*H[OBAVJE+Y=I!,%>M2_I2IQG2RY94.RG9&>>H,CP3KJ/KRP$)31W5I
M>EK@!)_N=:)RZ2(9)K/O>UCA*93 .I4N3,ZI67=457:$ 2SL'V>7+@PD@MHS
M1\GM:(F,O[F>9#VZ_;L!=H&Q+3Q(+5^?U\MNX7)3N3-V32140>!&++K833.P
M_],'*LTUOW:2USTFT4Q)RIY03' :G@@]S'H.%NCT9D*WL6J<?$!G*D-V>O%C
ML,@,@?D5WT/"Z99.UF%?[>CY1.Q*!^THT2M5]%P5;!^M-3Y==NE!0XF2T4;]
M7 VGU$$YK*DA/XI1Q*FYMU:QP1O"^9:-+"YMF8+TK%/>;V$R8_B^"2J]T?@M
MPIV^N*"/ZE1-TT7 DS28%@XK&A1.0V4?BG1?AW;[^G:9?V5.O&:H?+<1'UY"
M,9\6CW9.KOSAR**B:2"&6#\18_^-ID6-G?7SC+[<76(I1U3QDT?/+EK'QM%8
M)Q=;3:=7]FZ*B-0_CBO%,#*I;*%"[:TN!WV^$707*RKF'1[R<$HT6S:+U8:]
M8D-'F:D#V8(Z,=EWE8V^@O?M7J*8)9!5+CLP:\VK_%I68_YG<N%?.@$2?8^^
MR$CJUO!]L8Y]IZ/32963TO TH];_@PSY@Z^%65\!IR5YR?!+T3GY?4$:!TU!
MTUX:_3&%H\EQK;[^Q87)UYG!$7]/8I6EJ%^NA6$K'EO_RT&%4\V_&8;:Z7^<
M5/B[:$Z>HG@A?(<]N^)\<[O, =HGH7UM 321O!;!@&,P:#8./AP8:%LE(")$
MHE!?5]$0NSP"351XG[E8F7R301*&VBQUFSGW1FAUX1%2>>J,F\6I1AH';W<Z
MLW(N92LV$-5]-&)4-XT@M3^%*69^%2%L;ZVH";+FZ,:&$>?$-KLB'YXQ3:Z5
MUX!E"4CO %/2?I[O7E7LS]>;IMDLTU32=(ZB9"'5[D[6.?4!;ASD9':,GIX_
MX]59M0BE]3Y'Y:L$&J<^$.3=^Z6,.7P'> XUH<% J;4UN 2MRIHA#<ZJJZ<J
M]8=Y^I_=9DI;&Y(J5'0-/5752L7[-"._7,'1L35)O(+R,=<NM6@.F.7(TZ9-
M-#=/67O_1XW6M"ZL_L!P1@K@SA$(M8 "W"R[IJGI:\=MV:NOF4-7ICA@C*G.
M6!3=Y+:F YFR*V_0R))E[!M"!/2[W:EP,X<L<2TYG4&.WV7QDG(#E&O%P7VA
M4P1-M#3V+ZW_OQ:^E$]GV6UK?]U,RO7/FTF-;O.9$,7BF,[VJX,LS=*8'7_F
MK0M[D##QC<BO^0-UMJY.&(*P//2_[C)M:CE1K9P@YF]NJJF4HZ3C'1HDM1 E
M4J &EFVV4H[N>K+.I\Y4UPB_N<$<7F(=%[EW-' Z5]R:/+'!0F>EM=D+NYP2
MMI81>@SP'S'OA1=-K]=Q97>&OZ01B5$R=P.IAYD#1<0+K.X >&>*>C+5]6ZL
MJ<.6#9K)_<XO&26 ;#H/HJT>K;C JNPXC">,HS9W5UD$Z"E2K=?Q,\-5N[YB
M3J>/GPT^=YBRK5J4GE&MB=[0.6 G5C?=J9<C.X>)A5EJ^N]*QVGMP&XXO?)1
M'>?+J[89I5[O$349&?H&J$!=1>9.8 '[]@$,8D204.JU\")CM2.USI)W=J<!
M[X<3S>S,&F9GT1'>J"53M*7#G&@Q >^<:$I' GV H LL7OE(_T%JS)GT9L\#
M@=.LS358?D&LXYOL%)YJX*9__Z:7WQK+7LRDDSB!%Q=BI#J/+Q*^ W$>/.#_
MQ,?&(B0=2:L53B!B2ZTXKV?U*"0ZN 0.Q/>216J%8 ;FS#1I@--E'%WIEMZ;
M$<@]K<![<;(>POTFGI(28SX#5G[!*<@0);K-Q>UL B7/27G=,Q)U>4@9M^ME
MN\2*RH(?X,DG'JDB+3)YO9^-[*DF66F6U_/KF9D;$Y)J#<!]B]Y1AKD7E]"O
MNH;K77O,=U._0AJ&YUJ[-&1?B8ZD823]3,#_5LO-+=.\]M0A9_(AWI #R\$H
M9^^K'Z*.B5M>.HBC3FJ1V"4@OI6+1U?L[E@WXSA!7^A%-*VO^H5:>\D;2W6[
MZP%==ZSV4\N!I:?(K>YF1^W?[.R\BEH'))CR4>TZ#&#//>9OY*MR]ZM,5[E7
MHU#,JR^<,_LUUSU).')@.ZJFM^42Y-]ELT@UE-^]Q&W#Y50P9#(.#>-R#7FI
MRA-<\TWJI=8O916IEX#_*JIAI[^RF@4.OYZ-_OM.K?[%O]LXV'83['8D+E-D
MQ^O3O3D\P_I_@J#_/\6R1"QA3_4?D^^_K@6VN,W)'L/KH+*8UT-,;?WTG_O!
M>EJ$[1IKS0Z\JM%\_TD/*&9)>LNRD_;O2=4<3=-L/,ZAAT?IY3IZ@])U"::X
MO2@)YNA]%N0(;<%^I;GJ3'5*V(!'V^6>(<*P,0\]@*8<\Z%5+ (G-C=W)\=I
M"4DU+"I:UBCVC?= UU8% HAZL(SPB+8XYY:6W985IR 06[IQMB8@910JKM,#
M,AQ:DZD[(D5 H4IAK/G,?_*S<)D[K(J=X]7$E%FJVT&G4+JUV3-L_@<.GM%M
M5+O&+ 4TPA@AN/;A-B?YF^.9V3GR%Y!+\#%;QU;WB=O/U9KHE:-'"[OW@XR6
MO"=0]&!Q$B'4CYM/\UESGOY;_/-X8PH :70LU=N9&^9E O@T+VEI=;/[F;51
MBLYGIR"7/]"LAZ73H<33[]=>K464FX8VF;3TG,3S2?)IHYW<0ZN\#@X^C+R9
MUQ?:N_W,#N+N$;=8)@![H--@4D4+-EK(N4& [_F)9SO?]C<HDQQ]V <,[PWS
M2^T5 I;9-T-#RVZ'HI6*IU<6392*4H9%!:0.>6/$51)2;+SQ;Z.47CK(G9Z5
M&FIY:IN,?0JP*C71,8XT#PK06#-J#\RG+U&?Y#W@EDU\"CMC$7[#? =0CR,L
MM@!>2(C\'];>.ZK)KVD4C:*@(J!(;T'ITA&D$P$! 2'2.ZB1$D*1W@F"@'01
M 0$A M*D2>]-FH+T)ITD= @DE!!:N/%]?]^Y[SGW6_>L==;Y8U96\NS9LV=F
M/].RRU@L#]^KD!:UFRI%?.'L%M^_Z<$:7V%U)/V3/[__D:/YRFR\Q,'_ 1M6
M1@&A1<>-5Q49,3P8@.E.YOI)8E0FSV\ATR=MWPL<R/ !XRS7ZK-_Z'D[7(Z.
MV-Q;Z&%(0?DNQ=Z2?H)4UVQG5BK(T]'LT;3Z0IIL7R]_]/F:Q[[1ZTE1YDM#
M5,L0S86OJS>RK#537 #N#:2.M!UP65'!U?Z] W%-&_6"]!(5/OG/E^@O3+.I
MAT?=H."N:*=+[*LL?&7K^>)]GSN5R40UH<999+,O\%CZMB2X>@D9(2.U5]<)
M?&<^U+X(= R^CA,:G??UEIUPWK5[N6AO FH*O "\/L!+7CK,HZ=[X%=17"Q8
M###ZN'S+_Q8TR489EJ#DBQH"B_^X ,@!*M34*Z\SNDM49KUEBP[ZGRX+^#\&
M"80.R>VA_L.)M;XZS\\?IN@XMUOLX@ VXIZ::"^;0[W%J\#"ORX QGH?[20*
M,L\C)ULS_FLG\K_*G/N",5L!0*&Y>65';N=H^V3(S84POB3,WY1%0UO:0 M?
M,0U>4G*?"A1$*_+A70D^>;Y9*"O7+GPKY\AR@\/[IFZ6N5#Z/T%HEJ4'B*?I
MRR6'X.@Z:]:*MGI<9/3 X528%Y6_I]CCRYMBNL;7'NW5&S^2R+0H#0IU;YTP
M>3;A5%V88K&U9<$T_;W<2ZZK9#Y$2%W'KWK?G@Z]G=3DZK*R=XP0<FCL[5J\
MLYGN/+$6=:99H%'HF^;9@'%>BI?Y4O'PI?HK<@GE_4N7?LD,"C+J$'[A1+6Q
M0^\PAP$8I\U]LS^]7[Z/1?E9N7+(IY%S]01^SXAQBU<+BN-9%LM12!7[ZOX"
MXI.LTJ!(KRG#C6??9*Z)80U8+\EKJXDX>=$H;R9RV]9M;$7%/4C.IQ140U?7
MF=\B?YOD^#+<T#2Q<N#(YU.2 V#+2:D!=;1U+8O._#?)6]RL \7WKNBSQH:"
M!SY[=,NMH:1CT>.ESM6(.[X9S[!T8]"H$M_XS2[*+>97^TIC=,!&9GT5^VL]
M$ETFDR;IR65I+E.,=>_-'M63P]*,N3D0#]B,:6(8.XC"8_"J9C6_W,49!NWP
M"!11ZGY_WY-8-C'%3C)S_=^Y@AXO)IJ^LK7:__1N8PSF<30Q7VDICSJ<#@1!
MBQQ3&HW+A90L]P88/W)&//LN[D3.K6ZDG:)PXDWKFX"JW#@Z6<@NWA(.HGFW
M79TZ JFQ^9YA5GJIWCE<^A;WKSEPGZ_40?G;ZD5J@JN.CFBG*KBF>IZ[W]7V
M=27C2_?MX)>#[G[<6;E2N5[EI-C]ZY1<:7*SR"IW.JQPA#G2Z,IG6ODWI SJ
M?D&#LL4P74#5BF@$AP0N2[+8YI8C\>YP>;:.E*054&?D_<QB^Q;Q_>B71[EK
MR-97>^T4;/NCOID*#[+/GA(*+P"T"HH>)9DO9<C?+K[XL&TY_2[T/&4^-/-#
ME+NNF'L['KV^-6 \!@ZW:VJMJPK'&EO$A,>Q*EZSXV3YP/IIYXNF\VJ\KZ7M
MJ_#.XIO>7-&HK%>S'H8E6>G0J8:<!-5E S0PRKM5D$7QJWGM&_KFVI03W3!_
M<\\D7;$$2>U:KE697^2J]S#WR17]%B.#F2<P1/) 2%W0_1/!F(1K4)PRW7LQ
M/TONI6^ALEQ<;\:D\+LS=P9NI3WKZ[RGB/:X%/O9B]/^L&#7*2SIO;L@U%ZA
MXIGAAUDLX]T]FAB177BUY !\J?:-&^S;!@=#HX[QZJ)V@"G?QUZFZ'NQT;QI
M%@'E%$R[Z:&@J&"E^$D9[LF:K;C+NWH14A.Y0MPAQU?SXK63G.OO!M5?9[[;
M:CGU)R_&)]=#G(\[_=W:;4T!?=WYPY>>BQ[[>W8X1()D4_&Y_WX78G8F)2[O
MQT]\R3N[&,-[JE7]/<OO-/@FHM:^G&PM80;;J//0 ZSFXU)4QE,:D\2!_,5-
M+87CTM_7^83H59%I(9PF.9U>['W7[V;)O^O@5- M:UA75[X7Q?/$P/.#D*/,
MW#9@&2M[*,7T>P %/674% PFBW4NW/FHI_/! :FS]S.QW#LQ] T!X7_\->//
ML!?_KAJ]IOR;K:S_GS5I([+_^LO4;_1_J3K_!:D,Q]4OM8W1&SZ=]_O2>I:=
M8N-SM_1UKJ7+<O%=>D/!@6I]0H"@@B!+B)AF;5AA\U0K:Z2>PRZZP[Z*VH.]
MG7TX+.S@"TW9;)ZO">82<HN5W:,SB[^IQB).<97X:P+B] *3+W/E M X?VI2
M#95+SJ^"4&'BNGR,J_@]4WCG2I1JUFRJ\R9B012'?T3RC+*0#(*F^_O-W1'#
MN0T#  __A+! >^Q8YU'I5]^]29H;LX]?T3JFK)J5ONQY'2MW:C_3/-1Y ;BB
MH(>SFSJUAC4(;9=5XC;-NP:/'A2M;[&\O\71/E5XYGSZ=/'Z&4^!S>68('C!
MK'5\&%2PP6)KM*7V6FY=^+TX%?60^X5+ )G+(0JI2XL=019(G8D.1'>J?_?G
MD6T&#X&]D:K,3CZNMC7KYC9/O6[;+>+=L6;1?'"18UV%Z9\?#[C'Q #P*#S=
MI6(U/]=.U_@3DVX:1D<Y]:3\16X&O>MQ!QLU3'="Q,?M"X=>6.?]?_T1CU1C
M-)8F>F8M:I<HX\!Q9^1,32D<&O1R+R64VZ-%<XV*%&GX3R0SY4^<L'^RE*PP
M>*T[J7/>.VQH,N@OVL-N@43$UI#2*L*N88))5<5WXDC=>&X(=QS'HYF^9A?>
M1BI!?/*H2WZZL.KC\>JHUJZCR2+/9^??I/2[!(QEG*@CZ=^ZC=M^S42DC2G4
MW6%_P6';,@69Y2^G&KX 0#%\QFVCD*;A0RLNW8G;"V/ZC89[MG^N/Q?31+.[
M6=HGD)I0&9B/25H@J* G97$%5HX5J@S%<GS)/AS;$N7Z#W;D6?1[AZ/;Q WW
MFHTT^?=FSJU[QZM-WL! U?J.Z:Y1I9)!#TPKD[0U1YU?/(]_4CHMQR;>>6<:
MC#8UM^D%T\[[-BJ*_FQ. CM?L<K(KWNGV08#UM!3L,J0.>R(CT9!BC3LW2$I
M+[DS:DKG3AQ)0J0FCMR>)< ?U<3W&^,0[UR=!N8J9CKH]$M>O%M88H\9"Z&1
M6MRX #!(6NQ&5A+ZU.NK1E%Q60X[7()"3@57'UX  OC(IN[5QO-^QMLK/F5W
MU%'76X0,\Y?3C5X ',Y%H'4P.8929+^FT,S)S"I13-_WHST75(;ONZ)C2P+F
M+J3LML.);G:.-APJV>@\L/JC*EFE\Y+F3 #R&X=$Z*EZ8C].W^29?8/^U&_0
ME58^WX)N#E%L<DINL:8/U53DP@Z2W= OZ;HIA0S[:\ !ONRH%\CQ!:M44&1>
M%W$8I[*HJ\PS?^!8\2B-^5@[L8U(EGXWMD#&HX7QTZ;M(=+D3Y[/<@ 5/<H_
M%<.3+_2#G?'Q1+,6I%I[MG9LQ-!"?9/9QT7A,]O2JRDI/LRE$L?%6UEC.M_;
M8CKWH+RK#\7X/L6%G9Z)GX;ET[@9"#DSS0P>B3"[\/HT.SM[*27F-$LC$;TQ
M5EJ+.F->T)W5QE3MH*>./N*]-^9RJLA_9/_XWLMIJ$<<FTQ-]Y1NA(=+%:]S
M1Y51.C\9>4EQJ:YB1I.X+HO_=K+"*AK@ =H^ S^(#A_RR6EUO@!$Q(X?[@(=
MGJVG!RUG <<E\9^+'V=!I+E^7\FZS'$-7RIZG3BLZ8K,9+C#48 &WG:4L&3"
M+(7RVPFPQ5)*A%480MC]NI^ZC;^:S^JIZL-)CKK(7P#,2>\&G4FDSBG8P6V#
M@5$/*O?YR,>DM*#V<Z$"P5XO,_;ZF4Q9)]*G.P84!3&*5E3:?S(N^>NMM+%T
MDT]/%ZVLOO*ZOW%%M_[G!HBPKO\G-C5^CT$JKF&'?&&EQOA;^08;]?]$CW^+
M)A> ?U5-"I:QHV<<$TB<R!LOE.\.(+I7IR(\:V4GX:0V[N,=9HK,,X"BO\G8
MXAU2TLD*^Z]:MV<9;KE8(JFCHSM8MHL^*,(9X^Q9,MCGB*W8WTW#L2*/MF>1
M3VH&]/T"-=GGDULK"J<[URS-3!4^)=93!";F3XB&S:%CIZ[S%D#YXLNDRAGG
MP2@X=7_.@"TR"-)M+A0'6RO!K)8DWENNZC'DSC"L9WO9VJQO5-E ,:Z_ QE/
M.L1O6!L)3:BFU3O.SNKT+^\KW6)QC0F6]N7K)#*-! (#7C@CY6']Z]GI*)AA
MZ.Z ;84M+*SA1[CW7@>W"UGTZ$2SLC,*-J#13;MN(BU'K%+*4" R3$FFZ>^A
M''X(I.HT):R&ZX6ML+X)?=)17I>N$4AN]USNU1H=,WMCU9T=6,&I1TY>?DO
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MS8,0A3;2"UD&XZ>7AFD<,6<3A^>"0V?TN.).)<E/9I01HS5O.C?\0X\?1!P
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MZAG-^3M"4(T[&"X^(GR#>./:E(S]6(DZGW70DW"+*#^C5"?CWK'KO3MV7CV
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M#,_D6799WD]LYW@,E-<K_)HT$UN]:N3+T>U'P =U\]A1*:,?MS##J=O1G4D
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MB2$%&79!:TNS2\L8X+G,2-3<,8K[M'B]N=YCY.A&0"X\V\_*=;;0BT-2H!]
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MU0W"K)C6O.6K7IWC^,:N]J%HG7N^"2*P<4B%TH"7K(@F!QTIW=" >WV>?<Q
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MGL&?HIMK'QS/K$'/!7TGP<M51]_(K1B=MU?P572C>DNNCX^@-$CS$7LM@QC
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M=(L-@:5\Z,(V%I0U.A;%C %HL4T'1$:"=!"7>D+=RM(+N4)CL]<.1)]8R].
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M?JN=JM6EN:Z5D*A6N67T;<AX52W:VHO(;FH]G3_.ALBV7:+GJD@F@1Z^U%!
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MN.>:HI;*E_J9WZ[GG[);&_,!M1V8+T?)JAXDC0T$'UP5BM&:(=\OH*4,X<]
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M6"(VU>*9X&R3=<S*>G1HOCV2)\XE\KB+N47U\\N1D^(?WI,.\KZP'^]:S,]
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M;I.-^D?*@H@_;5$U(8A8G8$,@$#\VGWWCZ:#^_=%\V?MTG@Z?QGJS+?#/OJ
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M>U+=6;[%\T@TC3Z-!)C4=BKGM*&=E0I>H3Q>"A"Z1*K8++LIW5&_[F7N=G6
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M?"- <IQP>IXO8UU*R,P\Q7>O6SAN+J NT?1G?USN<JQ7LJKCNCF( ?H4=#I
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M9/F9"7,]$ZT#=9,,2V49HRS^;!FY*Q;@LT=N,<:ZND/B*P_.4P>F..N\\F'
MELGS!&0"NGPXPI*0F^HG'*<6; "1#H<]KVL4%'BP4M71_NXX(?Y-,:)O"BO]
MF"I^BR3=4L]"@#[V[;H\=:#;JB9M6C54K-"OPJGGV1X8Q1L0& N0;Q"Y5^/9
MI3HZU8G<JISC7MVLG [QQ?EGF)C67OO#S$/'C=O!B![J$8IL<G'>GT\Q<\4:
M=!E/E?C!K/MOW-'CL6H(_3US/\CJ7?LN_Y)LYR\FB:PEV5T4ZTXKG9WC#AZ\
M7($802A+?QH0C VXWTY*^W=_RQR7#B3<A3NI4_#Z@]!?\>5JCJ>X35,5K_V%
MJ7UA*RA4W8J4^!U4&D'(6HK6Q!('? _2<BJ3E]]>7F4[9OWU40,@:(2;,-7,
M#[KVIGCU&6I-Y\9+;?/3;-[.#.>"@:87L4N2HA-G&L?[<PQ;52)DW!Z:A7"H
M$T"H?))B*R0\=+B2:RF)V]O9MZ3$H$/P3%?L<:8%\%BQN^T@ULZ]3=Z[".9E
M]:&_Z-X==T?V0H&O3T(WVKO2G>,Y&'-]UG),A'T&+3]5?O@\BT;3 (=;9RB3
M>O**2!*3Q Q.9,(]*-&Z8^:#N4GL.R_0 E=)L98S[Q?%"4$!E2FY(*?T"[Q/
M4Y/;KXKCB[Z8]>D9WOG'^M1<9PP>49S-4&Y)?>+R$!9LC^U]4S[XMFKH2%=D
M]8%C8F%@\HHQA_S+%UIM!N,#J2L&^;FQ1CFW/)F>H$QSI.=4X/-XFQX@;'-?
MD1O&M/.8$!XWC79L"=*IHPI''WQV;-*4:K:33KT:O1CVL?N<=VKWL+8[?FJT
M>,N$J-_6DY I5DUXFJB#V_' /1D;6UB_'.$2V:I2*IK'=KD-)C(M,M)%U20H
M-H"?HLK56]=D9]7"[F23'GIP==1QN'N[*X^UNSD\F\B)O!HY?V"L-%9K(/\"
MP&T!XB1;AB'$J1T[P!-^X0-DO>DU"8C8*:&=):"Q]9M;WR2K \_EW[L29?%R
M+@60GFZA.TE"HH%X]&:5J7[Q%*%]B:[ P@/I$B+*GG> ;#@3!QFQ[<7,;LEC
MT$#?AVS/0AH/G[@Y_?C824Z;@\)Y#$EZHB5@ZC@<&9+7*3(I7$?<J0;%R#&=
MTWE5M7?UUO0;I/)A;^B-V._9.S6;ISP'EL9$C0TT;URZW/=OY/W?(N^)&WJ\
MSZO^(([RNXZ,9>'A%)4VSY CIYFZ4#SURN1+1&1KG,-,7B.&#>9P<Z1.^0AV
MIPS/(61R?GD,GG36Y:3!M+E<8NE1CX;0K!%M*X)7*P??BCTH9GIJC6$:Q]SU
MCI1T-77+%-<KN+YM9W_!0'E<FU_V@QWOB_?C+Q[-"@BFM.%8ZT_#Y4A3>$S4
M%,LVFK]-+5.N')M@1ZC'Y*NA-*JQNB+<D)Z27D>!<'W O4,<VLH-2';J*?AE
M$O''",7QW=\&,AN_7MZUS!0A9";E"R_W&X>^70B.^O2V]O#U-PZ' 0\-VB7E
MWR("<%GT<;T?G=,/K[<D*X3POR8AKQ+:DEQS7,8\<I-R(">C)S^U\88?N^Y[
M4X_A9C #!##]T)4_K'%ULNY@-J(MCG_:]#&J1;/KP_Q!EP][."K7M2]* <O:
M87-?C?!.0J%]Y/7AG5QR6XI#;ZGRE0N8I#K% P]WUQRR51UQJHFNG++8DK53
M3#5ST_)6>MU\T!\^O1+SE\E_&7].TO&*0^R^U6 -".U<O*P&>?%TU<\AD,76
MIAOE;S"A*\MQ]YB*JH=>R'W[M\_,>O_>-4G&Q+^P4;W[ ^Q5+U:\*:W[+)L]
M/V;/TCX+9;&)4H+<V:!^/:V9G)B,"Y+\DQI'4/QA=P\!_X?=';JU;U6 Z$5N
M*B_3 -_I1QDV$$(#H/KK\YC( BA!^KR /?_.WP3=DTY5I_AX4=@+,<6ZOYY!
M74-4R0^F16_(9_9/OHV6E7CP#R9@OR)C'*HM< N23R!15K=RH*C.%:_(:,S>
M4*5.%4P]D_?LB./FEPZ1T#<3Z;=%\A=J$=M/1?H=0'*DSAD4,[7'GR\%? +I
M;AHU*6)3% -S'/0X7?7R.*NDDK5*+)/@[6RVV%3<@0I,<<:YM0?H"N0BJQ)[
M6J$"JHIL>MY'T!4? H_?!_5GVM2.4U(%K1Z^8[GE<4'26>02, XN3S#>F2.E
M%)$M!^7JM.LE^WU;"0F1JLF<XZRW'!QKL?'^PN)>&B]&6=G6S7MX:J"Q<&5B
MWLXW0D0DE6\*XEYA#R10*)4Q<+UL]IW$=K6>DK'R%;5/>#W70^$7 /O>-]-J
MMG"=^C0 FXD)]QY\!_3QVU%O^[,'EG"1$80\#-R\"^*NPD:TUG./%)&-LYL1
MK1[%N97R+Z5N'Q_R]1=^_^!!B$FP_;DJ4=E%TW$?/%_MM.EAV/DIPQ$I0DX\
M#K^FKC=$UO5LE!PH<G0Z;U!\14*RH'BKX7@POLQMS7T(X9(SM ?^N#>IR$#M
M18"(T'8;1=)-X^DJJJQ^WJBMVU@QSMG;(\NFW<5C741.SGXFTND+K[XDGX0
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M6#,?#O6.?701^. &%(!L7J$>0_:BB8PTP)%A,/F5/AF$F8Z@L$R= !/L'&B
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M_SO##617,"2I'C(*V@P^B*)76;I>;X$IP$VG@#=#D&PTP+HT#9#;60.@4/\
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MLSFA*RZ32NG$7UY\-=6DP3L5X/>C(>)6TYWH#7IZ9M5P@<.VE]Y*ZV+E7CR
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M/<^)%VI>FL]:DI":,P;*DZ;NDE)B&SQPC2(#1@T0AO4HDW$>"1Z0DU1CL6W
M88;=4]Y3WB5W9,YU(-H.45#+TI92(;@Q7K3UEW63C#,/[Z1U9R+4V?5"5G87
M7?_E]B]GCP%Q+TT\8693W?C&-7( ,268*GJHX$B"JSU6G8T/R&GZ?# :YCF9
MU-YCE[IHI'=%YW5[4/<AIBVR*VW_T>=EC.@::5<JKR\+NTW#T/4UJ!T#SH@,
M 4TS+=<L=9J/ 3&I&2&O,^S\*M'!'/[FT1S\[1%N)E]:OO,O0[' FZ2IYB99
MBI9H^QH+<AHN531+-GCTJO-KYP<.1GI[B_/?DCI?WX"P('N/ =4VB<2;9#!1
M+KV(>I62Z>/TW(5L.K&A>+8SSETFA74A?#/#WHCIUD-"*9_2GN1Z(#'-@BC?
M;)Q-(>A45HSN;6@^'BNMX)%R9RFP?K3-]'*N\#D?PT:"ELNM[5I?KV/ FQ<Y
MGP,.^#*$CP%O ^&,%A.[4>HZ;2)JQ(R0HFD=:#:ENATIG#R@/2J1>/0X\G4[
M[N#M:I;01_,1JS<#GTI#,,Y8(0JVTYWU+ ),<3U!=!K,K&Q3LMBX2Z.?QJB4
M2W5FU5?.1C:F/NSE4ZA!R</I[>8#>C"K*;T@.>S[H,X;:\:"KSU\:5'47C]P
M4B'J89K;P(FZ_@3*0?HAAU$<38).)U-$.T/AJ(1JCV-ELWK89C"(X*IF?^+D
M7*#<YB7<<//<//.Y@,WLH)B"6R6%!D?9R(N(.T>)R+/ZN6O7G9"JE/C"+MPO
MJHYPG<HO0Q&4QN:MR T%1>\EIC>G$*0W4MK;80K;$/A,8OD.E;7&AR[#8[:V
M41Y_(:B8,@4A)J6OI-D,XBIK1F4?/J*7<A-J]8FOK/8%MR9&>T1';K.&@LI3
M8C18*8>/1A4QT4URI+R0$B.["46TB$W, Z-#E-?ECYE<K:8'F3U)DC7<>-0I
ME(-'#FT*S7/E&!#R@<1!A+MXJF'EUB [G"8[N%K8E5U?VQ^1P!=*!$?9[WEY
M!F&E$FCC=<C9-9K$N!*:8PJ:P7,,"/;K;-V]FP-!.>IX'!7"RIX,E#$\:^.Q
MCAOHS=@;8^"C TY\%Y#1N$[)SZ.-V0B,4$V+?ZZ2#W!5@W*9HR]C=E<8T# 9
M/2:&/L,/OA?=+I#7$A_#!PCCI208V9YBRABJ))C.VPGBE'^U:UXSL@"7\US4
MGLGOCLY6X$MF"ND6>ZOUT!M"WB*4R6ZA0,T'O^,RN<&6X[**+%?VC9L2OW\K
M#]F43#Q3U1EI$<LH"1!)(D$VO BPL%36]I"1IHO($9H<Q<GIS$?IY[C2T]\5
M51Y_KTA)W7:\E*&G$I.C&0RX<#/A$>\;!#B?-BKZ%=NN&4 2;#>/I]@:CKFL
M TT_/YIT62QW@)V#LW3?F,^.N!1F].FK8<9K9[NC[WJ>QX!067F_&P'6&":T
M!T6G(Q42VR"514F\7WOH&E/XJP-E[[Y0@7RE\ D^!07T)CUSNP/<EK9:Z)X7
MBJ1(MR+%ZH_>G:CG]'$1X C0JG0M-:/L\_+VI"B73=J:-8?^/[AP)L<QA7?W
M)60N_2Y?"+21#SBTA-/AF+TU%(CF&_J$TH@FN=#-7Y5@)DKJC_45O^+Z!Y\7
M9/$)0QS];Y,]GRT)GMY)Q2;O"8G/=NHU/8)].&BL$=BY2/I'94,(>_X8\$UC
M*Y2W'3UY#'!>2\N"S?M:J5?#L!O5C?#]SH@&4U(;^?TWRNUL^-)3BB_.1:5-
M'V]@<PQHW6%R,2+-IV>&GET2^ZU;S\1QL_Z6>"8?^GP#:S[UUE%#VKU1A%4A
M_(<T*C125DG6-WZ+BMX0WP9?NQ;QS_57MQ^[F0B]>[+$ZJ>WZT/E/#(T<M(V
M<"VF5![<7,;&8#E96S#!&3*D[A%4%>JKYV_YD#CT_.]#!N^MR2F/M8HC%J_4
M"T5*Z:S@T0>^IU=G)+?W7:=J[W;Z$]2A72!79M%?HO@N%"5O4_L&&E?*2<DG
MIN!96_^0'2$"GN"8INLI'1JB0R-F*6W[QETG]O \L8//5]:HPWC^S"G3U^MS
M<\F2J2&7?3U<\E:-H_:-UE"#A_YN^!2W3>@BZCQ5>^P5R G%-#/CS-O5*LI%
MO<R]F9(W\_2[A+)J>L$YNU@)B2*D?<-4^&,5OG/SBY7' (<X#N=C )>&%,*2
M5'&0OIO!$V8*85Y6]7@*^G7/0LHJ[7V<FH^>V[8<U8$M,-'28G9@@.A-:XC^
M7;%H[4(I1-_9I'_<QYO@QEB,^'5HY2PB>;)%LPTA;N#KM\[I%U.2_=4*"WDE
M/2'/TV.7O_^Z*.AS]9U"V/D.*SX@I@O&NHP^K7%A.94U$N,$XH>KW$DQ3/4_
M>GVPLY$A/IH4JM58V:K3=%G[&LJ'B:U&].K:>7/P.#8^IW$-98WJ/M@(7_4S
M>=6J)"EVL$-#?2\-1MF*QM4]RB?5=S2=(Z(ZT&S4YQ1_**ZLY&X!O.QEP(/.
MC2O;"T$_DJ]FW+_639 .;!;M2"_]=0S [<<= QRWSCJA!?<@T;3K1')I4:_Z
M8B*ND6=1:;#()=E!]UE-A>/ )!S\(4I::$XH9G0^-4YA@^9-C0![8HHYU3&X
MN*YB#_S2^A24)-]FPWCHW>@/<[^,#D%5#H-4=9?@#9A*/8&"I><N?5G\78U^
MY#3UCLYTJ.S,E_+Z!"4GE^! :J[X^^E;KX2B8VM*@VF\:W5YH:BYA/W4JJ1\
M:R?+RHS  OTS>\$#](/=\I)MG:M3[X,&@U(W&^Q]"*QQ$%Y%^>!46&PEYA0<
M:D ,*0WWZK=J\[DD:T9SFN[BNC&MD,@1)SOS\?23C^P_M),X3.W/;IQ -)HF
M<K-T8$=_3Z-1XC68KMA#@X,2\HFRNM:N/"F[TI!R9Q2M.VK22OJMHB^@^WWG
MZLQV3YATTE*^V,0/#4 Y2>=DTL;4Q347.^!Y(Q"V. P[Q8Q@-E0Y\V(%\G3D
MLA[]36W7MS%4W6_B23W?"/$3\4=O:8PGBU.>Q(E?K#T&,-%UJ6+(DM&5PGQ.
M=;F52[^P+Y@\R(7_4,L6GU)_[BC<8NKB_NARY=#R&.#Q57_&QJ<:Y[&"?G,,
MX!WHQ##,KG7IT3H.-<J^.$%>'H+1]>O5\HP?ZE\0?%+J^0BWOG>"LUWI@B!H
MS&G::7@<_F0QL*U6B?(VV,YICS08X!F&7R&D/9.]FQPQ__Q."8(J=<LP=EMP
M76WFE^D\Z1;FE3S;\C&@3+)5GL>YZ7)8J^5^3$GFL!*(1S;JZ<FBT6[RF90;
MIM=LNO?5[=,SQ0]SY\6)DA/@=HTI?>MC -V60F]\HG[\&N0#A 7C##Z%4*>T
M$<E=N*X-=@(LFJ?IROC<D!>&%3XIG=\'O24E/%.Q8W7_XO;"C2 ^23>4\WXI
M+]RA W0"HZ'RX1EGH_"P* 0W#HIB7N&%L8:6!O.>UDZ81R[J7/C*,,GT3<Q[
M,L@-\'9FUWJ+(AV&DI\ ]QVL?]TZL:8FVD0K(5$:(A1PEUFJ?#MH,JT3Q;I1
M5'$(?^4IRM K8]XKIMF$/W"\^&'!B6&83L:VAO%V$>8,-8"D$H>:0XOR[:VA
M!"#0%)I@BLGP+HK/ZIQ,*4SV\_GQ?=DW10GOW]GAK )/]AG?QN_@SRP?7QRL
M4"#4 8P"XW"B6R<4#XX294**(]0H^@&DM@<4 D&ZE&<Y]<&:N8#P7KL+;NV?
MK&B]RU^_G54.->B1</ 9Z'M2K;2LH4")*7#$<C6=0=R/>MQ4372(+L;@1$=W
M4VH]7%@ZIO7=GZLDI6<X_!,J?N5F!.#'K<(UF!HJ!5LF-"GE"]FLI,T'*'49
M=SC @VQ&J/*9V#6!XFEO5>M@CJ<SU@]^ZF9IR6QV#0+ .!MQG"@'5)0= XWC
M"X@S:8QK::(?%ANV^2$89@4M-EN.6/"YX]T]=*_LZO2%$6G;Q,>T:7,&\%NR
M)1.C,E*<)!?UV<87M;.F3KUD+SGTCDNC/W;OPK:>K%!1T[X]S;Y02FWW&"#[
M8/;:4:6B?"B(B2I%P(K /4R(Y#!\HX6,9V6U-)!DI5M$G)G)\D7J.@[6:S?9
M7A5#=(GY\[;#PB?-VR"A=?NQ\N/^,[PZ(SEC5ZR!TKTR5T,&4FJ3GKR[U7MJ
MRT;PT,[1#UF+CWNCJI'IP#+[P9=@7YDQK,5P^Y*+QH;%^0,V=QLMO+7_8XKM
MH2K"GT*'A];*P1"R.+6U+69(WR\7G;OPF>?\F^2-PV2R25?Q[0>D%+F#J?EW
M.OA(I/GOZJ. KNE9=I)2:72#=-8:V4G&S"_GH\K7[%4>+3TVU5# .SX&_A:0
ML65[B)%>:3SU.<FX$\-$8T (:%P@A;6"SC4NAIRM@T6F?B3KW=+W#\#8;__R
MX9Z>VAGQ1%8.()2.<IKDX5%XQC#/8BM\WGIC_DIU"K'%W0&'9ILUR!\0O'5&
M-C[[8H[8NT]$/>XL2JHU<_[W.O>TU1)_A\Z!R8%6]!FJL0/NY1#0F(#BG;$*
MJ(%[M*3J.ZL,3;E*+]4MF!J+"U4%%)K/P38NXT!Q[U9)CE^=)^4:/]=I%5!@
M[<JR]OE/>.GS/K!+AM*)Y8MC@>8A5'V26>,<Z 1K0,::V"AZ-!EXT];=B@H2
M.#1DTNE[[J5RI2(L+&5?=UOZ^G4VB[>%;HRJF&^;.5[XTDE1O$,XU3]')9 F
M;;TR;K8UEW?)M'(8[\#^]/)P>HK__ O^04"(Z=GE1^Z/]"$@"H\BNFYW^V3/
M1[;7^5"Y-!],R$ZN:5$$2>7M K T"<-52YW@A,7QU[&&T:^+._E<C6YNK%E[
MAQW:6% &YF(F.@SH6C3$3E"OO_[HY:JQ=:_W5@;:X[,,4Q[N0E?M.?Z)7>]J
MU-N>YY_.?(#P'"M"V1\#?G6Z<.(6HBQ6#X*/ 3\S>$>&'9*FC!H_5'$KW+"M
MG$\P3G!CFWOVHE%T[D1#I\OC0*VB%^ <8T:KO0]'AH<M^'4.].,_V+E/=R_\
M/$A6E-RLJD.B)A9O6ZYXHE+V?@MGQ!5:K$UJ)>?D/>WRS9N]E\*S?[UJ/EGY
M<?>JSN.[] '.B]"E@9\V!Q8@AT8U?5OQNYG.=251SL-"Z/(IR "7-%HKQA U
MI[0KL+M8:##>:OYK,\32\H$EP_]?893_EX+C^4&9WZK#\[RRB/G.J\UNA);]
M_J',8T!3."W)0X<X-A.:P[Q=\5+IAW>9>OAN23D7DOLW33#P6[3<);Y4=P3)
MJ=@O[W6)K^2&&C'%G#)$;(##[M>45S;2QD=@U-Y]NZC>ZH90'WX3VYJB5X!.
M!6U=H:%#?00;*A;%O*F8KOK;$\;]\T$=.JPRL:4,$W=%1>*TM]![]Z D[SF2
M385CUR/IK6F3K-XE5"\U.#VG#Q'D=7@53A;]"6T#G=V=T6G#$-.61RRF9<=&
M=XX!+RO>.3-YO6V5OYYOVC4M=.#UA0HA[I.;*<6X&..6V2OC&LS+(D(3LECP
M:*4HZ]1J(E;+Y=+[Q.]ZQP#O)YG/=]@GO@ G?CX], PRP]YTV?.Y(ATO42>T
M'XC@M2?N-]>QAGB62Y*]HYXSI+]ZZ3*PH"706:O^@\OC*>]Z*3'.@G*1"-8E
M(NO=[7WR?\U !B0F$;'$I RRT^#IU9AW"5] \O1"=L_0-EV5?)FSYK OA,T.
MK5=P5"ODK>KF!Y+MR0;-B4!YY*UJ7!N;.E31#7L4OU ][.EY.Y;>X?X5/;Z4
M]X0S9;'2H+FE9@@[E6<<*4;Q>5 _<IEB4?3@(#DPC]_.JEAD\9E!1XU!FD;?
MTZV'UZ_IL^3=+OUT-FL\*^613?)7+TSZ,:"TFR@?A"F_,W@,L',1G^N*2^XR
MU1JY,E(IGE</E&_2>39T\W.5^>NOE^\RGQ*^:40!X5C;!R@O%XB,X0C?HT2"
M-/WA%32!E;4L^64H+\.D18+=TUI3TR0%318LJ$]W/Z;"I3 %TX<U>E%[VV@9
MX8\_!IQ@FPI45SHWE8FDWPEBK<"&)?:?&W4%BMK['Q46: I%TO1_]XF'(8=J
MWWWT;&,.VEMHK+.<RC:\&L-^KR"VV=V8G6+XZ,#JTT "E>401'6CW"6 V9TT
MSI'D VTI,#S+ZR7+FE$E*-,'KT-CM\-YW5;NT'O9[THOWNKNOM62@P/_G.CT
M1@%>:8@ZBT@->S8ZM"#%71R:9R6&GR4X732-GX\I?9%X_L?LJR_+Z"OC?#\N
M(%M:LKLJM1IG(>"VYXU6.QK^%(<YV"2G!6DSL8AJ1DH)KCABU=JQQ&H2F57T
M1/+%.PTM]S8?>7^Z'.S4\HH#^5BJ"G46*4DQ)U>06.,0ZOZXV]13^*D #>'7
M6&->3=.@]7<]X;+>R.7Y[G-R?NZ!T=6#AP'Y[J;^JP*_2I;BJ?P4_2*$&FF@
M(]W!J.9;ZD1'ZH%SE9[SYK .6T6H\+?-QW2N,;%<7UN$8H-^(#EI/7Y_A]AQ
M ]91%YN?.PL_W^.BO=_J]U!F<;%SR=#19B_[S.EKF[%WTIZ0I!WX.P(T@[35
M\[5>5TQHP=ZEUI5O>2Q8>\R!.N, 5#=27C228TV#+D"R<\?JJ?,*05JMUG7=
MYFJRZ.[+P)0^H\)ZVV]OX"*56<0NL@L)$^0)B6GB'$/<S7+.$"3E=,QFY3KK
M,4=]N3PS?]DUI@_.3L_,]KG3(^:7.N# @>L?C21@?HEYN=EO[@#C'4S?;_]F
M4#DJ#JAW* <F1N'',W%?)+Y65H[LJINWY"[,SJJ9A$\]?>!Z>C/=/L)JX90N
M'^%*$1S6@JI\E%.RD@J+I**(QX"'Q,:D=B-P$1RJEUX9\^#63TZA^($T.*+Y
M>M^;C8'33:F3CEV5UEB5&SP-ON",IEN("Z2CI?8C27Q>JS!*<Q@(@^961?CG
MP3/X[4:4],4E4Z,NANV'DVI?,F=)>BLPW,TG5L^%M1^!R*''@) L$B.$N%GH
MX87C'I*L&,Q,/NOB>@:7]NJ<F,P0_3$@.>[BZS[LM1+ @::+T(%17#T498[Y
M'6NS#<6L0)$ZJ;2A8P#+GGP4]C359:Y? *KO8FXU<J6\*O7HUS.=YV^>%I2?
M.9 Z, ^E3)%11Y^:+L(]$=?'@#YS4Y 0%9XA"X@SV8R7KMV<)_-.PO1;Y,#.
MJ:_=F7I"&T+% 7#D^S3'V-BC8\#=Z=^VY(V3Q8UC/DKWQ++!+9]48#C@O,8C
MFU3%>J9-=)^5?96IT->$VQ^4#Z-WN\F@7_LX3Q2#!C-<L^4+XOMNX5E"71K-
M_VGU !!-E++1ICK- H_0#70DE2X-/E)8!%7E0CF>E;DV4:\NP_?>5-FS7]M!
MX=.AIF)U']G.=OAQ! U&NKO>\%G=-*@T6XZ[3/E.3'M""2&<;.MUBVGJ[Y4S
M."?L1[<25G4X]#@M#<X^>7./R37^$=^79N!2Y +&<2!P5I7D$]? 0A+%)>?A
MIE "<#.UWB=%"&OF8:?RMM=L:IRL6^+QWLP*7HP,3<$M6=P\M"8SZ6*:3I\&
M]PG4>#M%V ^A25)2;(C>A5Y>G_H_P;/ Y56UH4Q0F&+_^96Y9 >-Y[\GO><Y
M0_A/O6X2H9ZB;!%?SL$%6T24B"CJM8M>BLD^ ATA?77D>)AT>9J_6Y%8HM/+
MR>TE_@5=0>B:7,#5EBGS8>SX_H6M@W5$-0[["]KA!UH7#B ^LM;73>PP=E*I
M8D*4ZY/E%9P6XI]@4C""3^FVO7Z<<48\.$(C4 [X 1;J?8IAZ;*E3KNPVCTP
MZZJRAGBH146QY9"NEP7SDWB!VRH*=='O?MX2,A\&#@U8&C7D]$\<' .NSUC\
M 7%QIRC21/TN,S3['FND**_2!N\3TEAGJB)4FI6Y1<;R98K#HF]L&3_X@W@W
M[DG]]NDWMPK0]$A6*IAB3,K"2^S,4A[MX^(BO=)*V;H6CKY #6<>O/L2_188
MS\8N$EPVM]]\(,XX'&(\&UQ<L '#0/JLMD9))TAK:HY63DS$Y1;C-EXL]BP>
M;%F.>?'-E\7/WA#N'RW7SJZ3FN;NU#[+>$NRV+<K#&5G[3=!?D+QG[N-T()^
M1MPA&O2LIFIC\J2?3K8$"'W[QA'[Q2XF*RG+Z]DMVPFA(^-^T1"#?S7NWN(>
M%9Q!$Z) R(EC0/O<6<0#4EB@9]P%IV^*,;D407!-@K7551/9]A3?;1,.07;F
MA!OQ+259;:AS7@&BY&127KM4B4R:UGB%K(I^5>AMH>GLJBTU-=7WDUP1YO0W
M@$*!-K440XJIZ\BZ' U%7.I)76I&1=-.47 $$!_BRCB"X0 <DUM5,T8@):5/
MIWC+<^FS'JC=Z5V4,ITI^W4'R&IY C0B1<]0[8GF9.C1%UFE8@?="81\J:9O
MZ<K^N^SX50,OMS<S3,'-$<:O2UI$X#_\)F:LH'1=-F>&FB0H.N9$3'@1IL)3
MUG*F&.8"G(CJCP@]OZ7-C#$5&ZTY+)8;EU),GYVHW>X*;SI'15)JY^I!  A\
MK94'?4Y)6A NKP1U4?4B29!#N!KK\Z],R6AH7MKHGK^Z !W%0%GI'+>1/1D*
M(V:.%6K6C#JTP1'7?SAD7GX[#?7A^_[;AFOYG+CX1WSCM]9.6>7.V>$98(U8
MS(L8A4?<VH#OMX$7]MH0UA3&.5 <CY]Z7AQ0G3>\6#&M!>5$O],K(-',GGQV
M5>A9?.6WO)H"=*,GII3RPJG$+&WE""G)><A#D38F8IK3;YJ3SA\#.BSP:Q$-
MIL4:,[5U#3 5UYN=W7UZL5/2>4?930)8A!D%5.KH!XQ@##?11&4;7&S-V:O(
M5Z^5_/8[_JI&'W3$-EA3X-*ESV*MGZ,!JL^,DF[G@7RQ!]O<(&_L1/Y.:";T
M9*=WPC "(9G?G7+ . AGC YDV$M*6.[5R]A)N&3%Y!=LD]YE(>5!$U?&,Z^W
MILS)EIBC;*1P%V^(E[0!8Q</>S_L>;[U30D%RVG))"^7F]?4?%]K>[1^5+BX
MI[3[LI5O#BE>?,MUJGLQ5T^M]!_"9F]:3U?*"@I E2Y&J!#-PQ#^.! +I7.I
M;=*.1]?+6EGPY^?X%S$2C@WSES7YNI[I&F8D*<<?*B(N$3?SH?DKH/-4SEQG
M[]<RY(EDI'!YJ*.=<9*G5S3W,]_N>?-<CXXK+%8NU7)%AI'1)CR]FHN@<-%3
M-!D*B* 2@;R,X"")AM@VD.QX!M>:1$F-C6T6>K)UONY/M61K=[BK$/4W8K,3
MFZTA@<> 4PBO7*KYN(8,X@F))Z:(LGFH%W>OJHPX5O1NI<X^M7?QF_9PHD0(
MFMFB+%9'G._@4B)#CE.^T7XUT*$3Q>@U((H<LCE'>EGH98=@Q3$)ID6QW'[I
MX2Y7K++9/GRE/TT\S+NM)OT'7!B:2QDCW1,-IM'5CQG-5+*XOI;9=;G$^:%2
M^K?"UZE.M637O,]?7MXZK[O+C/0<M_ZUG^_>8**YX2'B<:A&5:BA:!(=VD3X
MFM+E*JV@WFC#FKC-?G_%&*7>.%N9!/:-R-V0PYI/=-6,J390[<U-B5K30+\_
ME]%J_I^\_/R_G*28SJS^]W,!:2&"?WAO:2%7<']/$&2YK?R]0%MX>5K=<>?/
MO_T,,?_I>$#\W_NU+_^M\X&+Y_1)CBNN2]U)D^[/60/'O\<$_I7X+Y/N#UE/
M/W VIGE7$; JQ71J=-@WZ,]A!Y63AOYE\K5,*-8'?CKSOS&LR/_A9-#FK3;(
MV(,E[L)^1=$B'6B/E< T[9)"'&QCC2A)T(G='6"@J'2!ID0D1ANPWRQ0=I"6
M15]W8.E.[^E/K=I+R?R=C!+G:5X'_\] %0!D-_(GA*]!AR@Y%YN''S@WY>3C
MMZZ2;)9,@K)WD_,&:F,YGFHO3S-*AFY@<WQ%8YIDD6.HT]0;_@2TR#+D'%5G
MKE](YJ 8'>PP^GDTI&E.1#=F8'/[T^8UOS?NUKQ4KL(-V4/I-8@MVU'IH97>
M=M,@.*7^\!Y+/>G']%[7K7[X,:!+5I,<0]+.Q$&",;Q>J# 13J)YNW[HL"1)
M,LA%/B^)#X#O2\L[G_"(Z[-PMM>2&-WU,:?&C85OG-5*.95- >!:&#  -R/:
M>H."-AU_Y6EPZE/LW*I >JO578%;9_35WA5^C,UK!+5J (G8=A:)U0P>TH4D
MO/5-W[B-5/5U<[=-87/$*VV=7.B2_&3)3DL=,I,XT2Q%C*$IP//-\&MWB!]3
MXJ>>='&QR[S6?STB*O'%_!2B':G7J8J6.?J'$T*LWH@A"/(WL?ZBLAWZ!'(^
M1IU=4:TLWLN9+IOE(]2>_F5VZV>HYU0U\ ;M&G?VY$HI[HOSY[1MZBN,\8:Z
M)CXER!/+8T4Q6^N8Y"Z-+ $X*NI57C4B/];6_LD$NPW8%8Z!\S8? R)L9"F9
MAQ(4QH[4K?8U449X[#' R- 7SW0HJ"D\64R-C[HKZ.M>^*"@['20FP0;D_G%
M0YX3" <EZ9-A0PAW//;<BH@D*2]BL7ZT$L6V:K:B1*E746"X\4.;<MX%</:7
M=]+ T]0=R'D\B'+E&-#R*2^.HK_;YZJ.PONA5(>G\_-A</G&&(Q[Y=+OF[OB
M'2(W!A%,GWL+X2E6(PA0SOT["8<F];&3])*?%&Z?9R4\=J1I$+LB@#<DPW?C
MV%=42\,,173&BDI?I Z9,EA'%W1<_\3Q"-[2CQ@B@,\LBPJ 7"N)F#C/0P@[
M'-66<2[.;(@**KA_N3QAT;\ZTC\WHLF"WU0\;I&>Y5>G[Q>$RAPK"T+VJ,H5
MP3^WP00>IHKC,70#J%*XZP]Z?59EZ:1(*=H/AG:Y. D[ />;>3NS!QM.XR=6
MRC&@6[1NYL"*5/T[(X4H3RXAPKI G/ VS>&]_C.5PJ)/,EI;9P<L0A==C,9O
M?495Z?!=C+;/]NK9A+Q+GPD#'0)I0V1>R 6[4>05RIK6B)=^*2=4P#H(RNM=
MYP\6;MR-U^&";C->"^2:XP%R)G@\1:_?)7:UU/%&T52<4WV"=V5!1B,(5+[3
MN$IRW:L;!E HV?^%6,387=UO7?-/Y24C%X\!+T&_!G#H#M:W38H8$BQ($<7N
M;(Z\1#I3BQG=2/:/@G<<-3/1QS+=8=!';L'Z.NH2'!<-*^I>Y_VF3RX&+58O
M!M0J3?.02]UEACI@ OPBYL^X39B3)3_Q;3W%!B&OP:7Q-ZU+@ZF03'AFT8^I
MI*'*JZY]$F24;"RV$P.D:N%!G%#(5Y7UJ<RV'&OXN"C;6O+DH\S,=%/%G<*[
M[+77?ZF/1&N7/(_P[;SGL@K-'48*4A^+\FGPK<WR'"560-YZ. E,2Q>L^8E&
M5N19I<O=,5KE=YEC_X#47*3;N7Z#> %J8Y8[=Z#&@:[EURA8FJY+Z4#3+1>[
MI89%5S#Q5C<9*+A[%=SEC]P85;"J6N1+2GH?#+I!SR:%@)*,6R LR)Y9.1(R
M"/?<\\%4.M0XM.^ASN,,6[EU.\^]TM0F.JHXT3Q.0QV!'&\PP,5(MON%H@E\
M6M&IE076LIF'+(6P"#OFLMIG&-4W7<[SU"RAK4Y9XWND_:XXOK:Y$Q@?.4)8
MBMC5W5"<\3$C\10Z0!U>=H(4KLHF$W5KF2[*+A2\UKL-'%<9UG "-><4#WR#
M :TSG3+X$]M5_,;14!QE[M DM6A?-[GPPLU%?KU)3J'-'])RHE$V9VM(=C:\
M49TVHHGMPYV7X[0,C.C\ELW=GE_8F.?^71[[<;?T#4U4#P4[!M!O'&5[1LU<
M;%!,U2XM?3)%\9R-:A\6%^2;E"C<KLNJ?]/;<EN\V"]L@_U0A2I]8LK:HMDH
MW]I:4S42\>F2=VC3WT@&V?H\>>3Y:'VA8E]:E;;3C?0?/JY;'4^+TIK&P5NC
MAN.]_:4UAQP#'0(:^<7.JNH9Q;8^A4Z?;P8\/],*)'^^8WE3YMGFG3F.^C?=
M])$72=IQ[GBFF//J9CT&KK/T=6D&^L$J-^[-%^@.+;EI7VN^P2<AY%F:8F[>
M1)3O@@1!V"L?N[C0Q.&N(.:UA=!NPB@'IZ^#..L6)_E+6"[.6G[=7Y"RT701
M\:+&>H-0['X,*)=X->^D;#=E><&/84JF 34 Z2S EBY!D4W!.]97ZJ9(M%3U
MG?;9:T,(WJQIYUFQL75/V6M8!NC1@P79N2A).L_8>[&ZJ_YCL+.4M38(FV=Y
M 1S2K@J)\.SOT/B5;=/E=0$W"HL)'R! -) _1<2(C=@((!U.L#2$XV1.5?:E
M^,7&X'QAXE5EIA'<5U(7<C4>G>X^_3N<FACMI6%X>'5J34/XJ!)HF#=+%?]&
MX67(FONG-(]8DEAH93/Y5#>EZ:D/9+FGK/.G@T'-0 ^89**#K=NC@G!1Z)K:
M1A O;/1 FJQ/B<*S1J!9O-2MVJN7C#!A[9:-;_7G=7A^BC4F7TUD+XA+XM;6
M_=XED;HU\:]+$'?]&!"L3^.$7$!S;TYZ7BQH(6_\_ &,.=R)<_ZMCP-%[*$8
M:*T8/J69\SIAEB.E#18>4!E;6:$('T_3YBY3<1^<&>'H/?)\Z;ISW6>*^7WH
M%D4+5*43C7@O$%]SJ((FM_C2*I1)BP'KWIVSU[@V1)P\]4D0XNG9G<C5!0J(
M(CE>-Q';H(*;&BL?:]#,6?%Q@<I2WI+)MYY.Z<0INQ0U_W:J]0'=K;&+'D%<
M) PP4^\-8RJ!LGA9R?:ZESNB4Y[^/TMPTZHEE)\E)WLJ'GQVY3K"CU)\J*1/
M$M6/@J0\IMA[H5 .^702*J\WRY_M="(M3MU*M'U;_]4]B=Y/M!5S:AET#N6*
MY5\681YV02CACLQ;>%0K?\3GWA<K5]'WE;ED&G+'1(U!X_&I[^IZQ3RI(%#K
M,6!>1Z5NONZ/:D=KP=OP78$TD:<6+7@,W[(&?\8^3?WSN-<M%Q&D^_8Y?GV/
M+NY1346/^W&<1?$US$5Y8D'=8A.+X+?K5 AA2_C$1A#&KA=G4;T;T1UUL:FS
M8B3&B-UE@7%!7V9#BPX7#T%%::'GOGRR]=Y@[CV'=7D<2 3.BKN0_XE":&.9
M^_EJ;VI@79C#P%+XX2^G5V:ZGW8(WK/B/LDW/@J)S3$;QS4*4GO0]5>:=)X?
MWD7HCE/E14.!XG/D"* +07HGSZF:XU.\S*7["M8VWT3X--DDI.;JM<^V*"T@
M58^*E+#!HI7:(43"TXHJ# 5^H!Y&#HN4C+)?*-X;+=>D3_S&'?'")UAJBB/$
MZ50WG_$XO-$>-I6"JZV;(M^8VX"NI]7]/@8XE>W<V"J'/7)/)2 ,B?M:E++#
M9PA38EBX"VWL\QJ(I6)*/[RE#3"1\L1>_<,C/I%V.F.F$G/H[(&?M16Q1M_)
MLQ+#@^G;8YUD(HB4$_/:1<^M*T9!F<(15OC>@/._2\6]X1NS4M89ETKJ(3=B
MGUR?)]GT%%V_.8ZYC;A+.'J]9DD1)@YT[GQ H.;D(\9571;:HH4?=4]."ZKM
M[7&T VPG_#3<X"5AY"Q&&B\2<PR0=-]WP<PGH[KI:.J$8T <"K5U EP-=@^<
M2C"?.6R.T/<QR@';1]U"^*:[0S0UY)"HD%SEA@^.,51#] F%5W]TT[/>AY0T
MAL.,"<QJ"B7<%VN]G_/^"X='?&(7-_J0O_LBB5PM+CH)<5YY"*;*H7\SS.F)
M'L0=P%9H/P[F:4Q4$"6?--*JNM4N'XSE(E#$Y]#<SBK5WAG<83IA%E?N2G?(
MMO5*2U4FF&N_C&2OU/NASZF7YU]<3)G.*8+D;S:Q'WU5+-8GVXQKR%."[M4-
MIMWE-3LH"?\F\TW+ESZ7YZW*G/**<H@K8__ @[D]4"RZ M.&9=(CW>Q$LU+/
M(H6GFJL/0@,_KZJ \2RJ@QL*:KIS5CVD*Q9)WIN3=RZE$T$M&OQ'F2 [E !5
M/.T!A#E&T@A#K"J\'+WE(^C,UB<!_9F3N/A>,3H1L73[LAY!L@_DV'T,<"P]
M1V6OI_@34#P4<:NX]GS14$5NXDQZSUK=[C9:QI?FQ-8:>"[!3,OUU&-S[U6_
M':?B#5?LR*!B5>,,#3*BD4[)(>D;4_P+X))=59/_C&GP03FMG%*+L[3XK"YZ
M]E351;\^<\&\#SY\_Z7XJ\#W4L;UTRF;$_V@2MZ0%T3Y=4[\%@L_CV$VW$Q=
M@Q?4):$GH%,ABI<IC$.8#])$#\%D$32Y^<S2+\).U2ZVPK6+ #8P6NZ.V>"5
MQ:X< RXXG;=\8,GT?]W$_5])MG3U@>#/;S0 QX"P:U1V=80IB0Y$9B\[T6"J
M6TUT)]!;GL9#^W$,X%$$A6L(3E A_L6.--2ON3&8BUTU3/F<F,MJ<G<7DS1[
MJ%#@J)WH5\=/K"#*!!&J3=F8LZ!*EC[%6JP,SUA9?_"<N/\>R"GQY92G^]NA
M-TB;X+G(1()\RP83(>6-//4RGM.+)6E$1\8G%?%6NO VP8T$I@]Y])W]/=M/
M]19Z#NGZ2XE<#9C2M;M>M004'^8E*RO5>82JZ&6-:I]4B0"J%M6AHH#J7Z)8
M+-57"^6W#)61.XXRIVU!GK(OX6"R!C'O+=4+!^+["8_KY(0G:E:ECJ\9-8[/
MXEV\;X/"'OO0]W$WV3]^+,44& +PK[6\<6]HAC4G+EV0S$N\C(G=JCRZ:4W*
M",IV-G<)R(>KZ$PL5 YZG<,>V1J\RI*X<=C-=U'(I8N[-H_V78-]1.,LQ0'W
M2C6V JB..WK 8C1,^!%LK?AU)BW'_#E/:SU%[*H:O!LX48V/#;BZ ELS",S0
M)[61G8C57=[#,"_I&6@;\O*P2HQ*.XUG5*#-J)SUS6K"&^UQNJ1G.I)\BEMO
M0>6P$-J9JD+?W-DU&PD23XFX0$H$POB+<F;^[#6[2\ BQIY/'Z^]D1Z_VI+U
M;)J$.8WL\Y-O0T?;7*8$9<&S.LI$V0R49K9")<8T'7,7'P=NGJGJ^XVI%[UA
M&_WN5K.P3NM T &X5?2<#<5?I[:I]EL]IF'4+N'@OA-]RDW@,,"4RX5Y_FKG
MG4Z]K9F=%1W%6M/*#=B[:J#_HZ,D*A.4>+IM[FBO<;$6)\W74&-)<Y,;"\XU
M2;*/,'X5OG2MAY?O8 E-@1WR4*R:-11&$.!\2GW7"5*SOCQI($[C1+-I9/$D
MK^=8S,4Y?W') WQ]H<;F6_JI[ Y#P>9&4^9P%_N<:' =N W- 9^R''&%.=21
M7'/KBK>MNZ/C>[YVG7WR]LM%[\X\YB?S&?[F'Q'WCF(0\@1,!&^&8CG)(1;(
MDK]J8TYN$+E HD]U:2I=*!D]?/!Y(?QN]343 C9U?]W?L"JI&,I,62.''V4
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M>[N.F->&O3#3]NFGQ@=[A\N]LVU\"=O/9=L52@:'B^XK7.^S>YLM1%25W+#
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MW!4M-1XI6CBWKK%9 BD&V_EX(K;W;3.NY]\:4+YRR5^[_URC.1,UB S+B'Q
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M"2E,Z26)U*B$1G/D=#<A4$06&[;OH6^3W*T>/122$;CW4&>I;TG<\-HJ4I1
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M$YCL>\*1#T:A-+GUIJE*A)@(+SDO"\;]V=GUTF:4$Z1?@+DHK-9Y)HF'?Y/
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MBG6%+[(N+88CV.3?\I@*DOVC[-U:XZ?O-9-7=A16LNZ?=ZFT^]OLF$RWS21
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M)P)LS+UCUEW/4;9[:AKAG6-XZVN7DD[F.,OP<U =Z-,RWZN"NQ^YP3A,PLC
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M&04,_;KK!R-<'1LO7&6<,N92]%%R-9IO_8S&ZYY)^J.67WYZ_N9,H>A+GW[
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MP(?[!+=6V+-N/HDO93;SNWA9(ZUTMM*D0PE-!IB7V0E/W%W@FGXJZRG]+1_
M_O8/)[:_)<M$(I1 YR733'B#?V:RP!6P): 35F[FL,RN>NO20,C>G1CVE.SW
M+3A_=1U3YJJ-*2T9>Q!J<FX7Z1Z=>4KYWJ&8^4"1Y#M_ZQ[F;&F^;G7JRYR!
MR=TNU"TQ1V>(4K@5 LPU@\<(1-#?=:TMDVKW.9>N^:)R(8KD*>J1HW@\H^&7
M1^@[$B'*$'8Q3!X^W<("/&G-YX_?5LAYWJ]+@BEE2I@+L"RON=L@034]'62
M%W;:&I_Z&JMUP8MEJ=G-O\K D=N9K[.X[4*2!O7%=7L/''9O%#?;B8C-4!HL
M56$1(8&6A 7KQUO1$ML_%1LKS_;R J%!!Q0VT3-;.=L!C3H,#G4J)IA)>=1H
M0M8FI79^SM=,/@B<5$M%^NHWO5O,-+?AR:PV09;T7S'[I"T4S3,"5F\YG:8N
MYH(E?3-/J;]-STA?N%!#XH+[XWBZ)Y\>P$]C;(R?KLF6^ AJIAK4,Q?=ORO@
MSGK%D;[VP3*D9AS)XH-1Z0F5!3L63,/R&<3"UQP?0)ICN9/.$U!6.N*O!&-]
M= 07XR%.; QN]JPM=;B93.ZW&%XPG]]<O_!>P'V7=0]Q/<;8QGFZ,XME]X*_
MDX%*2&@P\U*:W*^-!*]"PA<A%E_W53*@[2KWY=7D^0BU>Z)6D"A *7G%O0E'
MOZZ+J\;$?RY<:N'!YZ>7K*2R:W6._:BF4Q1!]KZE"0QKETF\I3P[23/WO1+]
MWJ23&\JN;!,G>CU"ND+>S#&*6U^:UR%VXX$9]:[ZL@Y?6N2:"2Z:0DK3%"+H
M(Q]4#^\8+C8,_:H>D8Q8Z/SF<T[W0LNNWI*Y^E[9T>9/?W39WOLY=U7<_JL,
MAE?&6?TL(WTJ;Z=X0\\$?2O5Z;UW*;_OZ Y<(@;=; _V$G1%X&*,_/8X/[-V
MUO:N @D"Q/;C*>?/\B5'M^'B@W U].8I>]BF88PNGOH[RFGI58V__;4%TP90
MP.,+!>_>.2I379O=TR/8.>-U"(>3.DG#]N[#154VLR9"'YJU/(V;&F)[G]9=
M+.\Q(UQ"&T,QMX2UFH?&$*>1>8;999.:CFOQOU 7WJ(NB6W';MM6/"<#[EYA
M) T\=_@'%WOM(14Y&]NH_@(44GI:G>]+_'G0+Z]7Z ;P[0%&TG K$]P#3XUM
MYY>,W9DD YR7M_1\"1,1_@G:]W).<7VY.R^MW@7<FPKN@3!Z:@M8$GA([.,Q
MR$._G;3X=Q]GKB>[;C>*I\V83F)78/2".Q5:A,0CAB5[*3Q/AXV<D$,U3N'Y
M@Q'QUN$-^0WK#73Y+3A^H!46-%?I,6W"M:8-.<ZCL!UYO%-F!/PFYHA%U+;I
M9)^S](/[%AZ%0URT9QS;Y&)'TBK6^7#8JU5XE>G]&%F/]6:5(-;T$H-?E:X^
MTM3JD_&E!MU:+C3O&H_C6CBFX(I#Q!.4#-,6>65HP_KPBX&\4_P&4^KW@[%'
MD_MU-VX$$$^X+T&JZ9%0IJ]S <J9+%?NS3 ]?:$,/:=_W)E<=%K39[MZ_E>Z
M9-JV <33A!'FCHWLA)Z '9D/@27S77BX3[GZ#W\[VC3NU)UHZ.:4GE![I.U@
ME]F=,'D:G="VT% ]5CM0[S[8+KB<O>SBW/C20"?*>RM_"S;SA<T:B#$[CB%Q
MKMB?KL(M#<JO/7Q8L>$GXRJK(A,3@$F;6W@LIL\2N:1_W9QH?,1+%,7K1S:K
MY1BB$6NK4-;)VHQTB11_E=P?;3T*[$FJS+T]XF&GDTS*O'X&#\VRRH/O9IQJ
MP!O'O\>R3;_P96JDGN[8I,^L?5W /I_\CMFO6%O@N(S"[5H&.OVM(0G*)02P
MEMO^8;*^R'%_E;,O4G0Q]I3>K]XLMFNX@8B=67J8O_&/FJ<.SGFN/\3+RAJ>
M. BZG"])%7M'-37V/F"+&$R C]]1179QZSU=9V@V\GS[L"^_>$---*&Q/M/Z
M&\'_R PN3:C$N! A: 6!Y<"9:KF*2<?J>I\6@\JDKR_5'!L$XW>H5E[=U 4X
M_R+PX:.'2X'A>044S(RZ<T>-_WU%*-C*O7CE25WE6_$CIC#.H6S B).Y+$3C
M_EYAL%3P]\"Q''RR(>$7;N#6QQ:\8GW$#-8 +Q8<E-+_]IR1S46!,B?4!3YU
M\+.+*CO30NJ"C #>!%7=9MW:R19Y>"O0) 0.P7,LFHR*M"9?'=_(F+H@=;>;
M@7/.:/NNU\&C&^Y]"&?0SWO['20:0BG<>TY(>%8??R=;14L-75O;,64]$87M
M./,R)$;THV %=4MW=@A$J_DVI4#2J<3)QY6@7.XT5;Q0L8DI E]"3[/=(GV+
M&!+UQ"^GCFW%/F!2<WK<>##I\]A]-EB*2(VWZ/2:0$VV:;3D"%?B69'7JM/D
M#.?/5:VD?A+3G]'3<3U]XC/O^. K4_KV)XBJA,YU_7;[$Z-^)0(,8+\@O 9(
M )9WK\GTY>6RVML"A#V]8D"X-KDD>  ":C;!^U_&Z[7F(XO(0(<<%E\^61K8
M?,K2=GF- *V>++V4=/M*(TI/O,EGK/5R819;_['CGB$!66(#*VE;G5MGE6/K
MS&0G VAI87D/0^U!)Y>D'!_NZ:ZW%K_:L6*"SBJ?\ )[:H1TC+$"]D:RH\?]
MHA(8ZFMWD]!\8$C,>H>V\"C)S.'11=;'%^C'6G66LMA26Q^0@9"F[\GHS.C7
MJ+W0(H)FI[:Z\/7-(EB4.\^%>_1Q#Q)3N+C:GQQ]UK'=J5 G>!UI$BT_$4"%
M<)YQ.!L:P3QA"3/;UPGK.34CNV\Q;& 8U5W\(4EB8)-&,.-GQ2>I++;O4#I2
M-^04_-(<A-LU;3^\7-F$LR!D'A>16>IF+\.SM\^R!23J)(9R@J1E/HD;;MJ-
M)1^I$_4R,3S/P;HE,'VCYF%/;6ZC.0]GP\S;J+I]1JO7\B6OXZ^?^Q5@-[^W
MN,$H1;-=T2;,1,BAG*9!2$%@Y"1-AXC<,WRDCA_-HMZ%^F4S_44&_.IC*(,<
MYH\<<R<>&_!)Y@5:Q$,>*/!!@Y&MS,%\RW=^3!/2=1L'/;T<DKSY)5/.?55G
M#EP7#]GM"DK2T=)S=:&94XB!5)*!3C8>&'0OZ1GRZO"#$:(KYK.2^8]?J9CS
MFQ[,B<K/&_D2J&P2\!4^QU4M+(0"S "2C5$7;:S]]<XX7!,CIVE+&OC\UH''
MT/,H0T2$5MHKF"6(BQ)GFGCS/7O\;$*ST9'^ZDV"OXD^OO5YS;3FU7BC-]-#
M*^JWC(0QVCJ\CO[ '#^6)!7<,\O^"Y_R/<<#O9K O30CA0M.01\;71\F7FLR
M0PUX,':O/KJF]IY*)C.97N50G-)!ZY%>\ #_9IPV#UP05Q&AO.0YARMOS9F:
MGIRUBV1P?DC=8M>S:4 C&%L;P!;?>A\2A6J&<I\=]DWGBK$GI.3#DF_$>0YR
ME7Z06;@(ZI@*FLEO(5'"2Q3L@Z=!DO@(7_%,T%'?]-93A+/CF),C\S^4O4Y/
MHM)CEN['*[^;N-;JFJ2#%9-GK^P1'&]<F:TRZ61Q; ^&*+I8/W5#+78UP!WN
M;YGP]_H.7C!,O7>A%(!(CK7,9:(WPSUK?XU+X,82Y&M*>=U,'-@;:'TIX/Z3
MZ)Z5Q380Y+.GBJ]I%0 [NA<2GAQUV9_$Z\=FXZ^YJ;:<XP_ZG!9A!E_UDOW4
M+RS@8![6]71V+1TG>8=@CE&(L>Z)VGG*Y*'?J2W_>:14P4%:;,BJ]Y+.=SJ+
MXZGQP1I3^OD[H7@!'5Q%UX-Q/[NSF_8XO];.%[5V:E<'P<:>+UBSQB4XF_C=
M*U!O(\6*S@C.>T,-85Y[7H0RW.:>)R&G@&!^;?!AL-AJQKG/(V7E[RZ)U7-S
MV):$<VBD6$RP_CA@#%I=4R$\1;L0=?Q&<6,OFWYZ])AQ*S*]GVEY,/V[<_U'
M%1-?,>,OP*+XKR8-PZD,Q(?*05XW@ARMC?I0"_T11S(%5TV[(F[@5./I/[O
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M$=YH$RZ[@2=Z%5Y"K^K\:0M3OZ#4(U^Q>S=K<OM /_B:TB-G:]76CO!&G61
M2!YLCOMTV0-D,5+VL,PD>GUW8F@BRE9);C>V\F/BK:!9A>3N0 L!_.L]*\)
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M_[,\;3J\\6T?M8CDY;9X_8?1:X5 =A7Q4JEJI#LM1BQ1&"-EVR<5>_93^/2
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MH*K775[QH)I'>)YG<+Y"=]3Y(;DRTCAU2,:]S:GFC)]<AZ.ZP<FO?M54P;G
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M S>:R<'/T[K\2]\L-\GVJ(IO7;[)/7/_\:A&^/B>!VUQ="1.W =K48,.=S+
MR2FC'-7DM_P%U,-&#T]*<5Y6@Q<A>E02CMI*!8<T7M0DW!,KCGQ.BQ=61,IB
M .H6F:I<IN\6V-'P@D0:G#]YD.^P]$#XB^"K!P4F?3QB7:XLO92Q>H#%=A_
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MV?.SL[WYOK8[AF]CA$<6X"Z&NW!G4L,^Y:]J<][(AL)%6D5B)#.\+(X+'ML
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M20N*+!L-K'A&811RZV%],$%[B1%6*XX!YG?,$,%6$^T%1EI1M!^V7%,W@=
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M/&M,P"<M+M85<(L?_U!&()&![VEJ)MXQ>=> J::HT!@T)[&9FO?9NX39.D*
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MK_9EVFQF;S?YT^Y"UXQ MR :<)AGUQLJKB9QOGDD(TQ'?6C>RX(]GYNR3")
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MP>//5=/DCBE1H_)2X<(JLD2,%&>,B"/\O<UWU% '"VGP5\*V5N;>*SE6'_2
MB"=QY:31F-T4@@A=K$#TSQ61HO[/OA_P_P"('U&SFNA;>6C)I\DC-!]H6223
MSG&?G.^3=M/ (R*]1HH X71OA+IFD>!='\,BXG>'3B6^T X>4L'64'KPRR.O
M7(!'/ I^F_!?P?I=[=W4.CHTUU%:Q3>:[.&^SQF.)L$X#!6P6')P,YQ7;T4
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MUN444 %%%% !1110 4444 ?_V5!+ P04    " #)B(A4:) \ $NJ 0!PS $
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M$L)K/!!X3K =+_G:RQITN6DMFN/U ^&3QF7/Y@%NAW6,CS!Z,!N@?V  KQA
M')AUV4@5VG.A%FA5F!Z$H!FM@% .R*^-NHNMM>U5&<_6T#&:W718-GW:S=/I
MMV#+ ,*AT]F82G2+TJ@1R/+B"-]G]+ZLXX3L-C&;2U<4=03=QZ&1UH%O/S\\
M17OQC;WKSDEJ][U6.TE;KJ(!IFZDM[F%O?SN@*/5+C>JUT7?NUR4CQ,_-_".
MCUF@Z0"?JGG?>7,#?N!O.],62+L[Q[?MU0,#TJ2/N$",&<&/A$VT'25?'C%.
M-C5_.3E*2R\(Z#_2TU">^OE@PJJ3J%^[&;*( ;1JP<LQ-+YC4,++8>BF;*,
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MS8+_IA+<_U-]"__EP\ V T&.2ASV7UXW_T].I,3$R LYM6#^Z?B<?VMU:4.
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M?R>*'?0=G'=LZ:I?9O-(X[ZWG[XA3N2=[J^HV+2*\/5Q<>"M7SUIFJ.$BF4
M.&MR-CT<LP<U78&B'TH@7VZ48@#/W5HA9/EL,,K/> 8_H%R5QH1($>0FRFF$
M?DTD+C)8QZO,K_[C:G,MAD_G8 #:A2<GKX'7SG9\@<0 WMAL.L7[DSKS,C_&
MG5D_: <;CZ2S:Q.,\$K+3!37I0S+>/G5*FP,=I<:AI-L[Y4WV:H>=U+NIHG"
MD(A\1W64<&!Q+QNS^B;H._:15A V"N1(!L *!IG(CVJN(NJAOM@0V>@<T@P
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M:B^.X"J)&PD^/8+K^@/6XS<##66D:EVN&!<ZV!6+/M%^J>WW00+JBVGO#6<
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M>D>C*UF98DK5)T8N._H0,BV(.Y_*9[%A/J%_V%EY3%\FLL:4& X,\5JZGHE
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MHND[#8Q H^@27:@Q=9$#PNLR(N+16C-[NK]#S4-419#5%^@09G$J7]"'R"$
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M[..)#@6L.LGQ;,K3H"-]#* 47I@_".:R-<;<HI89ET#6[**;O9F1IJ5B!1G
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M*_X&SS2JF30HZN\:G)!C90!7L$\E-.8^KA;HRLWUDET2_GKHP'8L_HI:]K:
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MTG%YO/;Y1CO68>FB#@SOH=UDO[]Q6/W!4J#FF<$# <5OWD1K&'CP<75_@QD
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MREF!?^6LY3G_MK3KO_.4ZK_LL/#OKDB9C2&]:6KKCZ@ 7#Y)]\ND<QF.KI[
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M+0!/U?%@U-[86U[$=2=7LDA.MHM)Y5]B&%?7UKCNI)_*%"$\G\0W'3T8 \;
MPQ15LL'VNR1@[WK9X?V9U92*2G;_^_4^(.#7>+8[M<2"S:L"LYPX$;=(N3>L
M2 Z""V;]U))\R%S<NX4:M<E"K/;BBJ-59<)VBZ:]"2.+8F*RP,<\!S* O@QX
M7GK3@9T_+A"=\V5T,CU=<$[VE9#5YW837<) Z?FB5S0,U-(E:IR=YP[(@#/V
MOH65<9ZYB[MZ^6@:FHJT4<X),UI"T"V-'N ZWQZ=T;RSG%R6':ZT43XP1B:=
M.I0(HLMP9;RG;<^=?K9>U-6=X=I)]$/0RPLAJY&3%/I=\S>:%J-O3>YM+%Y
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M*21JX"9]P2#):)=+C*D+UC"-ZSD\539U0!+\QU!2Q1/X%AO%WZGB]L(&E\@
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MVZ H6%%K>EOV;"]=X_0$Y'9-PKB>!)-J30VW+;VP+0EO0A,LOLA U+?^,SW
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M70',36=)OB9$?\!-N+*NDMW@>G+>U<]JH^F:5T)-D^8.=ROKV5( C\B/XXG
M[^*S0'IJ5;CK G>8.1'61P9JX^+9+(C8YD::&_C>:*\)\[8? 4N<[I+Y(?K&
MIGR72EF>JK5%%.''3(*VGR"FB\@\69U;[FPP$P.\^Q9?"J[6VT,MA[8?ZYS%
MDRQ;X%3P4;&SYPC2,>KR95@?V4CT@YHQ%]"46M:A&RQ/[*BU2QURB12P7Y>Q
MA=C/"N*!=5GB(_HW(1$CBL8TNL.5'^6+> \OXCY9H,3V;C\[>7NZY:YAQ5KZ
M]<^'W@N$$@^VY7R$=V]$8&G(C)?TKE7O78OW?;60)3"%"U3DU=*M'V*>F(D:
MT7,"[:N?TRGR33>];*1]7$\^-RHZ*?39YC:)88,EVY,$R8.GH<B39'Z"/28R
M=X#$A).F)WHV40!GO*;"^XAQEW3T,BN+J@B\KU,N:+D*NG6Y=2A+"]!Z1+(>
MNUMF/-\((8IN8EJI? QCM?A@OGJP."!N8G,K<UJ/K:/ HH>OU@-*V]-A5LP2
MZ<H6$*#ZYJZ#9*WMH99;G4^^!M ^VT#_2Q40T5[JC(SZ5M3H8-+MS#"!%D,+
M8ON,Y%IK:&E%IDA-9745N7?B_K7/G/%C@VDP(]/,B'9=1!RRLC<BG,2\CM-J
MDSY5]2@'BC5YLFEEH5G?[QT-.>,4@Q?849(9OX8V:G%P=+EP^F$>;.X$4(>&
M/!!TQ^[B3KS:$![1""2*,K0@.$GWB4;38"9+TX5)F?X-::Z%*:8*XG+.CU4%
M5S%>/E>U7683V49/UZ!J1\;0>_7TZK(S?A"B2/C*(P)DJV00+CUSR0*7'R7I
MKG86+C9 LMNO+(313VG4#2AX2KZI";_.SN8QMIB<95ER[YE=FBT#$W,"E>L?
MAI_?58@+VOXN*OYHF^H$9-"A_6RT NS,UCD"77NL)VZH-WH:SQ"]>7$3P3#U
M744S%/WFU4+ZT##2F^5"\Y&')T8E[9A;:$C;LEJ,',^COI'/4?&LKL9O1I(D
M F==H3CCXFGD29*3'@NQ3!LD.?T%;N0]TR/,?3&_?[G[-G:\8O+FO4N#&>K,
MH,Y[L4PW7KR5"'I.^W&O_4?>*+F/5+2^OA6Z7Z*F  .3CR_@UW"5O5&5>B>(
M2W?PCX8RKN,QC[0BY'EO$'<N:"KF%QS).J7XH6FQ7TZ/_F7"?;.ISL/H[/W7
M8.<%L /X$9J'8)\?#L'1;D=N%K.KOQO8N'2-PPY=.Y@?=RR+\QN_'-O.H9/=
MAPQ.:YEGR'S>XJ\!PLAW@AV(F!O4/+E%+48?8 ^EL1HWB)Z%1+>V=GUW1B?R
MZ6%F:?:%$?9=GUIOGILV8<T/QR?,FB7ZFH6PKX+W.ML^QLP^KZ1^-!T*+ <N
MV^01E]K,;UK+Q"RI207L[6NTIEM'/]C"^M0BF,U'FQ\L;E=#H<P1,YI&-HQ'
M;W>_1-_^JC61 <;NGP=/(UZBHE#49N)-^GQS? 0%P*< 9H=IZ0*/DSDMOGM^
MWRU^7<RB-.)>J.Z^==%>>^NLTH5QD4]K7!8QX1*';%#3#$1QM12"TH=N-!_>
M)8B?0$++A#<JJK#%XHK!!OV;XATNW/IGM I;;@I/2 HDY;IFV8(D@<FW^EM3
MS8 0I@-@Z)3OHSZ;] !+E>+A@7NW@[KYE#.,":=KIY%L2" QXWIEG<P7R"3L
M(;>5K>.K2D!N<KF??OO<ZKE&H(S@]$A/'7)%FH!I!)<9-\Q&3\5DB0U+M[<Y
MH3FO)EN?Z)<J<95PK3<2?CZB./P9ZY:UJN.(&'JZ:/5ID(Y#^<K'?=%/X CR
M'9EV@M)7")#D3HW'+.H0N2V+:0 D3: SCL:A6MT9*8"[,,\6""-(SC7;<N&L
MWXB2$KM*@,81F[OE%36B?+(-6<!Z*PT_]QCP]"NT K&/;GG ;V:*&;;>6(=H
M0=' HDT("IC')";V*(6+E9F*\]H5R5,? Z!A<1QN4M+Z:7=.1C2"HN#9G4&1
MRS_U@PMX$IQT!S]XQIP8U"8>W15[!2?NV ]],V-J7_?@I7Q<5&%!]\,;A<''
MSP(N%@TA9?B@MK7[*.^#I_%J*8":T G_"^?%M^-YO%"J9;-;F"'PLL[!)=>]
MN@UJDQJ]I'%7^"\1\Z[G0#$$UU)1:30'KHYOE6:'<^ZG;*XQP<0F9RJC+8J.
M"=>'Z 0:6W&U0;^<:Q@T[KLP<@KJLGY+ ##?.<=X#$1'.N.^A1Q2 RTAV$%*
M!;"Z61Q?!GZ[)=G'7SIJ5=Z^__6PA-M&E\40<\NS5FYMEH3.K'L>KSJ SXD[
M94[.C]L''I5YU!-6+E,[OTB,&%'ZSGX.6=J:FNU"WFMQ?&<(61EY2^D9T"!Y
M/V^KBXO%=ODG.F*S,N_%+/'<U>"131,T TP(')'X@,HF#R$Y@L1@T;.^+;TG
MX$J$I/C']X@:>%Q7VQ)/G2XU7TA"[",)B[;<9MV=-XTCZ@S%4WVNZTY>C?X:
M;!YA!C3[I=^R('NZ.R:AL*59<*R:.*(1_#9(  [&],&!!QM[*3*PM*N]R:_*
MY\O@J4-@1^V>@&R^6H8:"KC0)1NW#>"0W!CGWIA)#B(K'MR.-9HU)R)NXS7#
M(TEFA531,M:5K^,%T4GX*CUG+_QI8/G"HF%XN!WGN3M7>LHX@>(G@ _X3BLI
M?;U, 01LH"*]$=CW+1 ."L!.#TO3FBX2ARD+XH?9MBVUFH-#S\HV>T]W65U\
MCQVU!BAI2[8DR[7[TZAHB8]CB^Z/EP=&3X/9QTB7\;<B4=BV/O.E*K;=&-%V
M22Y=KH\O]X*_O'GN\OCC"!91/Y4D_+?:1:D0+;G)[)A6]U]KQ$SQ^JM?5)@'
MGP#/U9.,_MU*?4CRJC]?TT'^_'+;KIA?^+V_Y?+) Z8MP&I191'26F,OD&0\
MHD9+;H&PPYUF,EH&2)HS8+I%_ZJTAWBAIK'Q9I<U[M1Q5K@,'?0P@S];26/V
MDI7>I'OG+S493FT+*("Q7AQ="PK+/8UJ[F6S7-AUB'S93[)X3=(>F*V,M:L=
MK/BRX>?BGFVKI$7;6KF&O7V>WGCN#5T7QWNJ<M[?1]?K[5T)&E 3[B?IOOU>
M/<E,C,P=AS7/Q+!Y:/ ,<UEEY2@\&5Y_+C2I?=;U HE3S9O]AS![9ZN)Y.-V
M;  8"T[B/GA1YA;7,>RF4414(,1^O@2R>-(^_9E%F<Q A2"[[7!G<R_PDLFB
MJ,$@0QAX>HH/<;\W!K-E\7OOP%=H^O_U5%TV;T3 P=(V M-KQ+-:I+3_K!LJ
M#7%KYW^R!,F"X*_&QZHH4172J&';L-*4RSH%,.,,*X-,:-4 O-D%&@+#P,YZ
MIW:=@<33X#:,0C?IYHP+FQCLIK7*"S%UK/[#(;7NM?S@EEN@OI#R2W+=$'-0
MZR9*#EPI'7Y)@8%$!YR]?O#Y.&PXF2:>4")-C 91VU$-+@B167I/B944LS$E
M&^BXSCY<WTOFRFA&;E+9\8,'61[1;$!T)[\"$D^"V^+_^!##\KC)#[D!ZB Y
MU+'6P41GR"D*8%"# C@4_O.RKX)T& 6P2"WMP<TD*CU%E#=2$2=[<&?T67)/
M*T+@/S92 &&O\?/[5\%X'D0L$#\XR4,!%/PT,X?,WTM' 7QN2R$?"?EIY2!Q
M" _4(*YX3-<JO/'FZ'T$UW/"]:@N)TH$K$DFW(FU[ZSZ'I'V(^<(X>-W&!(;
MOL6!'UDQP[T_Y7F'P!X+4B@R^\X5'_JUYK/TRT<HKZ[UX[553W5/9FOX'0^/
MOQ?R%'BT3OK/F1 /=HG6F<'L1B"F90ZN[:'8:BXANG_9(T>U9QUQL)*D-)QV
M5E>N)=V=),BGTK\!X2#R=7TP_Y9A7V!Q(M#@4R>G365-X-8J;E$^[8.7O6'H
M>.PCJ^1'>[P+Z%/$GD)8<S-9AC ?[NJ]X@32+((];%K\[(A-PC^^R.=@)IGN
MO6XL&A/-\K%DH2:F/'F8ZJT\_-2!MS@0A#L_PS-P^U>LJ 9*/0C?/^F$F+X.
M+O> ?/QT<*7W,0)&=UDOO+1HJ?HI21Y-H"6GL+9B+UA654B%XBQM9:QD?44O
MY]V(K96,\PN4)A]_-%.@Q@93^I >W^(>S7<6#WZ,*#<>4!]2X#[NZF8W4,)?
M4Q9G;*&0>BR=8\3+0$N ?\77>9.!ZK73B)].:_\OIW$A".P7-<AA\AB\('"T
M!C5GAW "C^HT(2KOH.D36R%8]7HZG([[F86V3@^&#)!J^#-%H^JQCAIW]8JJ
MH9TP\4@\M0P9SJ":I4],.NYJ$TXJ^F*8[A+3OZ[I3RAPB$0YNG[>04B^N"^H
M^>1DX=S1#N'W\?__P/CS\B?__#'$'ZCZ"CJS!R#J?$"#*H>+2>JS.M&NTNU*
M2,:*'C[<CXF*%7'#^O#;4=^O% $2.YXO^C*S.'&$'[M3<++8"7-WZC!XN7P6
M%3*@B/&8 48HI?=L%?3XLQ'LAZ2^OJ_YD7OGT)4N.1=:BT.774GSV;^B]YKZ
M,WCV("W^.')"M%@<;,;*0:7F#T\1]W&89R_ CZD"[D46$SX_!C,C@"9HQ</U
M<.=!AJ^)=8$:QNC*"Y;6IF:Z=BZAYZJC%$+OIKZYJMEAI/S)LPV.H ;^[G<@
MXP;X-,SW>F2)O*[&+ N2!62HE@^_VB?1!4KQ&<;)<[^J\='Q/,-S[/7S<ED
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M<'.?@6^3'\;27OW(F^;A[7BV3A/W!32".F#/ V2]#G(GL^1L&8]0 /-[.A0
M&DD!1.9%XF=;ZJ_FB!']^SUTA;_Z/$_*3?PV6CS<+1#_H=5,&P@ZN @("2%=
M*EID3S;FBJU;?+S>6VYEN[X'XBYKFTGXW#5WK9_-]@;_=#G38VUE__QE*'[*
M>,@%)8)?SK)_8N[B^&PQQ:-99J J^HR$CFC<_6#^)TZLJ;0\+TX&*E  )U$X
MAI]$L99/ > .+AR9$.C^0_T*?7PTA!L7YF/%MOWA[O8#./:1=\">,_/0J='X
M1I7'L.S[_?=_D&P"^=X47DN/'?3H\./.*>Z^47;(76WCV@6-TFC^!$\C;^2H
MTH<@_O^'M?>,:F+MWH>C@H@(J#0!)4H5*4&D*"TVNH" ="$JW5!46I"0* A(
M5Q!0$*+21*3W&CJ*(M)[29#>$D (I/"?6,[QG.?\/KQKO1_&Q>PUY;[WOO:U
MKQUGYNXJ)NM=TN_-PQ8)5R#<'/M+F*J;ZPQ5#.[.^.8=>'A0[DK+F6)DM5D7
M4'ZV?](]YA=#_+E[< +,:>MF:=*+Q7Y+I8P6KW]5JWBP((Q0[:_#,,,HW+"0
MF%E"6:"9@9Z49[?P0]-1T+XP7'6=V6U<H!O#;C;?]WJ7-M1)Z'>D^'[SRLX5
MZ;PETVZ_CO?C6@E+MR^4^95_;I9.D=TK<&=I-2+V 5-7($!6!3^*S<_:#(R&
M=OQOX!<TDGSP;L=TY)S,HL^X#GE7^94YWQXW;3"G[!G36F4UKM]V*\'7B%VO
M+%OS<CTD?;C%0VB/FYB)A<:N^I%#FL<GC]J*EN>(;5P@>;PAE;K>!K,YS#OT
M\+?%T^;A9VO'CMCL6TJY= "NL"%]B/.P1\\!?W%ZQ/)F:-!B[,]4,R#9^],S
MKZ-]!]20R@3DW7/SU9OYWU_EP,4M+)>&M5U]%=?\6R51>ZT^@D\[80O<&ZWW
MZ/2]7Z*H*E_ LQY%H"@C\V4)1@8WV$R'D85%DG#*":VALT=RI/@W+ B0$)JP
M)OZ3*K>3UP<OB9Q;/'QQG:5EU14:NJ&39;)'#DVQ#8>]^@BPFO\1J+V_'YA(
M3J>)T(=%IZG%'5#K<L(6EK[*J>P$E/-;1KI.3<9[*K4W)Z\F-_&^$R3OAG+J
M#)@-U3:VAY"2[NYE^ZI0/IFZG GG+.OG&!YJ1\2(="0<B)&[FQ8N5Q%Y3=0Z
MZNOMA!"HK4$PC:-37DJAHW&-&FU2$'XE43G9='6EK2CJPBFKB_9Q$3(A)JY/
MN6!Q]]CVJB6!"TMKH5-_95PJC1?6!/Z;Z'O1;VO%U]-A5OYEW28;5:6-"X-H
M1(KB&Q*3)F$SDG(!+Z$L'VA!-"Q1ROGP--S:_P7?65GFH2JN >0K1Y5O:]<!
M3$(=5O:2A)KNS _9Q$J5C-;FW,VU"O2_0Q@:[3C:V2YL*!=\=O/]FIO)U;2*
MLQ\8_/>A@9@!<N$'(6#^">\[W81/3<\][MW,EO9,A?@ATNTP->]T+U<YF6T$
M,VT]7;,;+U1\8*75O3C1E5<\4%QP/[[+N;)]Z=%L0FQ)^V=72=G4:O<SO IG
MN%@_["XK@3P<X^I;5#&!^Z75^[I.^ITMIKJ=L_.Q(@D]JGL\Z'::GZMM(B4M
MMMTOGQI7\D>\=(!H(M&?-A)V0/Y08-_*A+#6-%^Z\0Q>Y>J[E8567!.F&OG%
M?E_</:2UQ=,RGI\00+GTZE+F','&LM$+SPHQ[Q.I[(7D29<(%XP)1>BOO4BU
M9P_RO&.VY]A>"&ER0YZ ?5S+3_*IWW9-SHD.61_GMD)D&T:MM&/+>]+"-)/7
M)'._='V"Q MH.HC*+(SLW\ZF!VT/#?8;]NR+.7F.24L0NAZM\6H8DY#7TPDR
M6QR.J3(PS?'QR;:&E%V"OI\:%2Y1Z7Q>Q WURQ*K82#:/*.C]'>V)-!%''1U
M*X/F3N,B&A$,(K\MKV[1P-.>Z-LWH<D"/&!*/+F#S).S UI_AZ]\-D=BG[+R
MQA8Y #6AV.9U)C7/@$,3YZ<;H.U?I3?5MNUG=@,(+ +]Z9<3;4I=)SIX>ZY=
MD^'PSN3<&(7I?0QV#M+.]:J8KFCFS^Z*7LS+VP%U;/P\6OM'9M/W7VQA26;1
M0-W1C,3.PJ"-E#9:3P-:2:4'0"\L_:XBM*CU41[M>"/>+YQ_H<9HC'3[CDA+
MMH_\,YZ;WE)-WCGB91:@V0:92\A&UG;_7?^XK-$.""A&,W_[<5U&[3 I,/ >
MXOHQ<P\)-=.X?D?'_/07-]*)>F=FL&%@!ASIZ60',SP2T=>%\(0-VJB78/'V
MF6/#1QQ+1][G\,I*'F8R?G)KD\$$J!;VZ#US0Z+86W*C%^=4]!P%DK-&;. \
M90FQPY?-6_>5QYO&RQDM7DP]^8FC/W%;&8CH'PHB$)!?)'J+ 2% @*3L3S=H
M'#^,"PGF3N%[?Y/1[DU7]XN/-AU6VJ.P6VHU#[%G8BK6\L*P]H# )4WB#Z#$
M>N6@)?!#->^CU+^W68VJ9HVZK VG!?"F0'#.AQ[7S3P,WQZO0[.0PL;-K#[Q
MAXKVRY^5#Z]ZN^(8O+)TE<%<.,IIU"ZZ[=K5A[P7(QO!9QS' -55LO*GZ/I;
M@O&$H,2D3=^:;1KIC@U*R"74O-&3XK$? (9%<Z*V?D&S0QUSE'&M3>1(5//K
ML(;A1DN?1^M22B<5,J)OWN[ZT!DBG""K-:M]]FS0/?,UFY H>%<(@(3)OSD=
MN!WEP@\)\[/F^&YE/J(=GY:/0SKL3TN+B1R76HQ+L(9Y?W<WRS+\?.>J:43G
M=+%;GLZ_B[?<;Y$&M&V$/$7:\6A^]-=:=,A6'#7K$<W3]S54)M>Q ;IJB 3\
M: VD__I3B1'-Q>P\\!:R&TT7!/LG*4QD!;C9#HA;[;AE^G2*<&%%=V,,C+6R
M3>'(9%=-1%%]U)E,S4.\$Z(O7]N7YJ6P8^UH>+$7.*OHVC(J>.MY^/B"KDT\
MVMX:X5G[6V0X_WM^"&"L#(AQ6M :!?H9NW1%;"VUW<=H3T'9W:46>-<_]:\A
M61(^#F@I>LX: BF+WXK?#<PH9".#9ZMS;>4!UA&VCR)'/-OG677L0HG6DD #
M2Q+5<L40KNSMY1,&+M;!<SI<%M;@4>84 .U.J2*K69!"\'F/Y1?"/T4OCG,[
M*52J9676"\=W:4OE-'YROQ/;M"#LDBW\V/N)P8=[,A>VSZ)^TS7ZMSC9_$,N
MK7-2E(G2\BDG<._:[D5+#>NMCLK%C<4[RP_.1XPI[X%[2"TCUU)I[;6L7SW]
MPD]Z5F58U5@.7Z],F32N+*^NJBZSD_DHTA3#:\<\]6K?EVN[(FX\U2/T+S9/
MH)DHVK'-E6X1A 57U=X>M_Y-6:LA/4\/#TF%Q>DC=L]BK%/5I2HJMI*@E_^2
MYD1'NJ2#%OXA@#4IESHX$A,])<CS79N;>L(K*]ZF@(*B0Q=S;GZ\L/_!]Q6V
MV6V3Z;!^;B7^*X3C->4:"1U/[5]>:9L88;8S\3F<P%9WF#F'_1%FOQ4N>25\
M11J"+?8RX$4$S%A7O;AYZ-1><UP %Z^*NOL!\1B4PX$1QSUC_X@@WMD,D%1_
M2N W92$H$;-& V8K5M.K*?-Z:M5#UG,^#ETE0V:#3/WYXEGB0NU!7'.P?RHO
MH.5 'T1W_%6B8,H_&','](,RVZ$E,I@UH@#\I?$2>G(>NAFREJ?Y(S_VHB?)
MNA1>@/_32JAQ7BLEFK07&53<*& H3IW \(MGK&ZM3-%N4K."REJB.?[KQZD)
M"$G1X3.0JH5ES=G>I]K=B0G-APXK'2YLR 3'^9-A\RUF^M<(GEGM%F^;H59"
M:_-1:ZX^^T^^J7JL1O_P.4,TJ;&#'SWXZ[,#$Q=J]LZ3 FG[#NV 1'TGW<D2
M M([H.[P_F$B.IMKIH<4^=<"WQ8/QG\OE U2_&T\S_IK<>^>JWM^K\3-"?K_
M<J XKXFFCK^"VG5VLV:^!P_$:>"6A%O;9M\,%JUR*3ZD;/+=CCR28Q.4WUT.
M=H!B3S0)B9*''D*DZ&)VM>*>BS[3M&=,6U. '"I][[#OZV60Y!U$)A%+8SE-
M+&H9WXN2=$8=Z54[EEW60#5HI?$3$T**I3STPL;&VK8EX$'%_A?.8VV/5@0O
MRVE=>>PC;L3HO#A^!WHC["%%Y3X^,GP.%DM3I7_-E7*5&HDZ0]$B)C3I@AE(
MW<U*['5+[#9=&83O8P7.&==SEDLEEYI[WY>=N51C%Y<>@[AEP2OS:IUK-@%#
MN#8^Q-(PQE1<UEO+,^M-$^VM/36K!OKJ%0EOO+\2Y&EP:&B>,+)O^?#0NG\A
MK]2RH'H2]78<5%I7G*GH!BK*!::CD(.Z-@LE7$4/>4RZ+_D2C!LV+$,:\EC&
MS2GJQ,S&%0Y+]6-DIS&ABLZE+FW'DU\<S"DAGYFQ=\JMO^@H-&_#-XY2*RE^
MQ+6-MZ2'A!6\Z5/<#F@7W.:H;O8HM,$@[;8,?(]^%'F1<%L"+522\AHNZS%M
M]1YEA?/.WWJX.+1GH3U\3H]V="GO,^38#JC>5\6*8+815$9@CU"!X,XZ$**;
MDJT:QP^NN+ZI")*#L@H/(2U-<_B*<_)'T,YUNN?L1<>N<N[F1:(W'@&>#$#>
M)N8U+.GBXY/=4TE[6H>PBSCT9+FTE'N)O![DBMIQ%K?CQ?"04C+<HEA:+$9R
MY1;SOMV&BP/@HK:JD-')?LXJGBZL"$T%U0DMUJSK&%I&"PR,(L7Z59QQ[(-1
M:RT"PL$^/2T/_>SAV=KW6KYPH65&/QZ^F/3MQNO$2Q^&2C;$EB3(=Q=L]E*C
M:WE(:XT^-H<(*Z&UIW33-#/-%Q)MLO)\NVP&2SI+2HJZC9<4?4#BH#U\C\R\
MA9R,E%S8LQ0@Z?S _:4H0CL@QC>D.6)JG0TWF@FAB-.+?@RI!2-26Y0Z-E8V
M8H8:I8/>J;[\Q.#4</W*X_W-)TPC7RY[#Y9LT!> KW=!"2*,]3N77"D\. A)
MNU86J4IP#U<[;%Y>&2.E:]B;>Z,(V[T\HI5A["K2H%-[]?$6U"_%:<.%O6LI
M7*-Y/>\)>B(54P9M,ACH:!W;%=:J2QA+(FR:!6@0>:*^Y_ 8]7K6G%K4X[QJ
M\3D>,FTA/#7LVC-V2[QAR>6T %R,PA6.+PO%NF(/DC0;P"SC31AV))AX" 5>
MT'7&U3C,&!5%: 18W]+3D5?RE&F6>QA9_3SAHS4Y&%?\[08J<(F__/K#_B%Z
MADYAZW= PX'XUB5-=[( 18,4_1K!KM^M=A)Y40:!ZF_8SBB 2Z49.B?&C&K[
M@E-./*_>F.V\C+]V^1:_AX=!-W2B%'KD)@$2@!*^;<-&L@7*Z\RD2$C8>'VB
M?USSMZ&-2(6G< \52)9]DU&KV.#C9Q</M@C#G@L<N>/$WF,=/D=W1$=2'ND4
MMKD&I>P'8:2H$CJBJO7\R.><=D \.>NZ3,EN;O))PQ]P,9W0^\VOM*ZW/7G@
M\.2MR3UK^"C4;F4XMQOO3O\Z6;B-9#_E7)8527(^,E<W;39AFV^ GQ,B7](<
MMZ:RL6DXD=IBW;+(=8OM)!""M'V&P^OO[L\\!L0#&XMIC_M[X(^RD59[%S='
M<U2W\C=A[?+(+@4V3KN7=UA14K06<-EXTS[:(=17/B#$)Q'#ED2>9O8 R_'F
M8_OAY$B-,0/&A8.-]_OY')*%<=Z25_4<9?EM"Y!OKD4XU 1NW*?&JTFANM#Y
M8L&0C$XU,? A&[@ )]'@!3XORBSQ4<KQXH AB_3*[N6G&4D:,<9W]'M8Q$:^
M^=X('-S<\UWKN-ARYU1>NN_*8@+],7IEZ@LDTVODQ;Z$)INS77+*5GH>1APE
MK</273+"[O(/G/41LC*,'R0UM/,NO[WA6_-D!Q112W\_N_#G^]G7SOOXP[\L
M_F-M56XH?OMK'4#PJ;>VC;,*#T1/M1_G T$;=1]&5Z)/4=J C.^$URI0DU$*
M" @^_BD>$U'+0;#!X-W9(:$JQC<G]6B\A-$7Y:<[')#*+,QNB5ZGJZI:MF3?
MLCXLS PT)?8OTC].<;VDIU;:&NF4U #CJA4>=0:SY<EUA$'NXN+,"EE8X_H>
MY'JWY"8<@"VG/FMCK8I*^3(_R]XU ?"%F]*$9UH+J&U2[4VM(/55-$6:G225
MT(C>.\^7\3I]KI:!I(QGYS'7=3YU223EM9\7]W.W24=3F(*$=RQ<Y@2+XQ%)
M]@^T0U74-YZ08Z@>-!,2C(=$"O"1$GPG]%B:U/83$L(HB-J3O6Y2'%?#6(V-
M2GJ'-,M*4IR2WVC%]6S%!%O7F@_T2#,MYO) O9\%@1NWS>I@!$UTI( @.AQ;
MK!E 4?<EGFJMI[$0N8/@N$\&H:@3T>;]G@M5PX<W3=E]9SX?33"WUT+VV?$<
MOV.UYU.M"#@,O'<'-/%^C(?P'1.E=AHA=IF4=1/??N9"+])@$D;2+H;RS.?<
M7KHE53RKJYFA[BB<?6HYDMD\;M^GTUZ+W_/!60.\+5T&KSBK[M1QG7,+/ 8G
M9M9C@)8R$NNP<C"OL2/"1H;T\!T"4F\CJ+0#"K,G;(9"D 9O1ZWG$KEREC8B
M*I,;FR4&SV]L6J:OW_YL*)WSOE-7Y6FT>2E)$X\9@EE3*VC[*1)$6X3W&-!(
M*8E%K"N/KK6ZM.<XGQZUL2J(C-WTD<3*W=L;S5&DI*"5^H2]>^*=>62Y4!\@
M#22:L1,I0&E"WB2?0;6I\1#<HZJU:D\116/YMS:S);L$A11L'R);;V0?QNUN
M+139OULPE]'/^M*N6LMMLV2*))B(0IW: ?6/ :(L@[30&6VYA@G"K-K\89R?
MS(^^_%N'F-KR \G!SW-,O!"9*;_5/6G AD@"M&O 5X2R'LF0&()O?>Q H%([
M'J.DG(="0FW<]Y$\=!./Q]]7,;W-P.PA9)=V\\IK]/TERL54_H?;DM<@!$Q;
M!+*J]%AMR58[601YI.<]>B*?)OH5X%>_26PHZAAR/Z$+$B9%,28R7>V7+($=
MG+^+?>IP*_$2ATC):^?H-IW/MAVG]JDH9]P&%T<O99$]8<,=]$<7<-<(V(!U
M?GH+"6%? -L%[ZV)^=*W?9&[Y_I(D?L3I0+3X[)/TLR.@U.%#TRZR[WCP@9C
MN=&.*U'H@RH^KTAB$Y"P6E&D)>%]X@YHB?T=PK9I[BZ^*I2BCM.3/B9ME7T,
M! \C+ZMLW>*-%SO'\&I(AG\>,]"X44+T"89./-T!<2*U??&?L'R(*MSG,:5"
M0FY.]JC4V.N\H=E-'FUG#Z'3HYZ&1JJK]\Q/CFB?$RO:LU*W5VU)'(1F/T;-
M)JY,+(<2PYMLA AEC>,A6+Y:043;)+ZLKH.=8@ TC,(VYZJ<6?$+W,$;RA+?
M1Z6?EYE&>X%6%8*&TF[D3LVC;Q@,IVS5GJ5(==.D$-VM?,NQN-D;A)D@B(N;
M&Z0XYS[9M$?ZO:M7I/Y<LDAUF,4)?[46S:BKM"ME;D(<+3BR M/\5UB2LW7.
MBCX0^-IS0'PA\SEI2&%2,X$&/D-FQT%:(%P(LPM&:N9RWZK)EZ]F^QPJ7BX_
M>G+7_5TP.U/W\W24J#'LMI\L3_NY_&S,"'L0D(3CD"T%@"(QO]Z</]T_UDLP
MH_!/ 4+ZS\?-^VI.+EX)"#OY3IBD3-MW$#W)KD)_+]2V>7S[[GTRZLPCKJVB
M'1##+=+&."O4@9W?^6-:> >ITD8BX;.B#6RL!U;:"+O./KSK&?I#+90 ]# E
M_?BM\<@1_GC;^2G2"$Q*QSU>-\:MW2TW+MHHQ20LB_%LJV;IVPWJ8'H[ D'-
M?[D#^EP+Y1^G]0,M#^N#\75('@W@D(W*5: =ND'BH 6B5[5W0*LB.R#;26@L
M4;-L.O9.'M .!->Y;_, O=(>--E:C*( -"-?@58N%D/-C28]5V/8 ;T:I\2@
M*8]W0 4%F(^DU.'-_8IFC]&--S[N@"[N@&CZ])M <?DP6A!Q!_00^^,\Z;_/
M0]O:0A.(FN4.$?WTLQ2I+ N_#W/92__ (OK';('&/31PPF ;:%X^BNV /H23
MP;P43)AJE??)$8DF]J6 29K]#JAM#3B4_BH!(#+7(3N@;RL[(#C0[W,PU6'6
M^7= ,08[H*?@#84S6VA./Q1.-Y&P R*Y\ "W0=/7Y2-;0R@*>]!?:[$DX."A
MV?_CGE@YMV9$R+^.#*Z_NP.2)>V Z@ ?:U*N@'>CO[K3M*&TR] "X@_'E.U7
MW$]D)[F(0V<!?OGXX[!_^5/Z7_[\1$H=.:,!;P+\QT\+^O[[XG_<>0[=5$\0
MHP*>^A8+;.K4Z B:0;/ ^$OCN]&5OE_@35A<_A'TY]]' Q>R^S5;*-E:?OW1
M'].+)O/_F!X[#ET/V8_DZO+R8]\_J\ GDH+-MEZHC)#9;;J\/5<VHH\+_:1\
MS\_/+([^\6E;LBI%QO]F,?@1C;> -M:Y3%%%0OU/M6>,RC@OUOF<N.%P]3(\
MR#CF]3V/]#\",P,$)AU<R@+>2O@%+C/*%<@?/J.#Z;4*<"C#!(E_HH-EU*D2
MW0AFS8CSQ\5.#"<YQ^@^*N]B_5RFT4YI<6F=:1=^ 95QF"#(K.P&I/4Y%#-%
M@;"!29\=9_=,LCHFUJ1@(U&D[28MS<=J].&0\ST!;=ZRB\S[F(=VS6G_,Q_^
MY>HKBG^-"39 ZOA&,10+1T\DCS-0/)]&PG"M(2L'U*3*B4.GUTSZK<I/.=8<
MR&7;4LB=^M(R)%MMFE>W QI(PADLCD_6>#0+[".8)@!=UT& OXO&89=7/TD^
MV0IV%U%IO<FIH2%M&WT[_ERK3C. I0;T-@#*59]_H9GNM%2:*,=#&*7E5\ U
MJ9$1-%@SCYH@,&TH[0#2FJ@859+'@3Q'V"C*1E[)+^FB&'LI05_D#%O)Z3$8
M/6E\)'/QPG7PJ*AV\VWX>$%TPSCGF6.7ZE+ E18JQ\=VG20>PPP(!WA27TU<
MBC,"\3)J[&OVF-RHMZ6#F^+^7RD2- '[(T5^8$B$D$GA:)TH"U"15XA.IRA_
M72H>CMXWBMAO[G.%YA;D)=%^]T;SRX(H;6'O<\J%K4^M,%QHV[Q@*'_MP5F!
M/42SP/4:6 .*R\]"SE5U2*LEOJ_SR TG.PV+@VGJL2<*31Z?8PB;P?X9*'H0
M \6H+#N@+>6?6=%PY^^LN/1S5%((#AKS$L$8EQR94_N0,--8J5>3$OJ6=&_?
M4M_Y N>A1V/^2_G\).UTD>=>'R?"II!^ /HF"7D14"?88']SO%3F+(V'FK3H
MQ6+-U/C4G)=;(V6(!>X^7OQ":RD>U)9D'K]?]ZXU$T7A .8O\GF%&F 'B/ G
M+S1@Z!@',OXGH- # QU3%,,2XLR&,,F8;$ J4^]7\9](AC3SQ0<<DOQ6Y>O-
MH'VY+48C][#=81!.V-1Z!)]%"MG80SJ'CXZ.)%XDURFIU*K$X/D_>IGXOH&'
MXO;GMTLZX<6%S[_C&F4YP'8[X=\D]0>9&_R9;[^P78/##G3@? (IIPF;ZMTJ
M'*D6<]#]$)@A(;*0:?#5B%);CO YEV4)N=1I8>1TO@I 7@QX$A=A!N^6,WF,
M!^<>)(E4SU7W99WZ^C#9 G)FHT3K1<1=YH>"!E)F".&C 4Y_0]OC%[3_"-H\
M%G\3P?.[$ G16EK0$'P$= ^Z7A3J" X>DB[*G(7MHYQ)'R(%UWO67#[?'2J]
M%(^72(O$?!Y_E+C/>M_QUZ$7G^R5*.Z$W@('J1VEOBR!/O*V8>["D3QRF+'%
MQ=:KS[]SR*78M:L$408M-:8&1^)GM8^:0BD*P!B^_JJK0*7Y9QEZ[L;X%RMC
M?Q:Y+%(.691RCH3S>MV.'V=RVOZ6PMO]G55,Q[DS8=$T82/XRRK#D.;R5)DM
MO_B'UBL'61UIGP%"9VJ #?1ZO29@ZQ+% K XP8.LNF35Z_[O+TS[6I6=\>]0
MN&(+1O9!*?)D^G"P)%XZE-F7'A[? ;WX1=E U,3^BAIZH!R(FH$KX_ETH @"
MS)7V-[>#"0-& +G^[6H.QC]J(/NBB^,J[>2\9!0:OF1,:ZJ"4"%5>1K1D>.6
M6V[=&VEVU'1Y8'#L+U0DX*Y3U+R'X9_BOWC[];M@2\AO@?-_5>5^#:'67*;T
M3QT19;)Z?K&#WP<PBTBK(7"8:J.W>"9\/Y&#?",?&#P2Q?.SHHO]/4!@6/\H
M73H_ QY:>QQ=KTQCIEPC+;$WC1^B*!*FBR:?9Y14*J6W5<D569U*KRY4KVJ+
MT8HS,4QFO@K:FP'H+8Z5B=;&E6A%&*<<.N0^*R9:.@\BSY%-6]46K*CV]LO"
M:WH<-?K\96I,WF@XRD T"XCQ3>@/Y)W[01= D:0+I)^)0@=B^5] %*2/2PP?
MC+Q+?2QG$ G,FCT )3(Z+FF &V=?$#C<[_G"I6EC[%3G]R//5%^VWAG(.O7^
M :X,V:9Y/$QM/R T+6D=6+9:,"FU81O2@&4=F$V1"QX;MGPDUR&RKK#*+(4_
M(Q=\32O9Y*GA,W&3XP?V P ,QKH 9/J[:/]4-[_44\+_4 B0MSX-Z'QH/78/
MY4PGDC\=J4R@8H*1JOB32.N;=F\7!?M.W"&.%Q7QQ'C=4/-Q$ :QG=_]FF0&
M)"^1)$+0G%3M;S+8CP3\'#ZIF^66X6HDXA/#*VU>T]B4VWS"V>)Y1>2U4CP[
M0R_Z[_BA?P!,]B? Z&6J^U^%(.2GR-++ \J2JAH+*1LG$#OA;XQ;#G]+@JG7
M5/4LN4H+.-[U\)E.JK"QIKE$0C&*B78.:PP1_,=[HP<3-G2+J,E(7Z)5,_M[
M[3PXEEO%@%KCJSS,XE50&K9OZ?VBT-7VYQ/!,J]#&<-/-T3L,J#Q[P(\)+A-
M4P2D5"(4WL=$4_^SBO_ELE]4MS0),BPW>_S/9(^E\3/3?[T')M%!ZS?^+^$(
M!83C/?B76FXP"0OEPBZL 'JZ:]]"'*!E@!9)\+?BQ5?O(AMI9U*L24&^U)"J
MI4U+7_&-:I=A>[[O@^V>-RG(B;""EZ\CNO:OC*3TZY9YA]):FW,F2:GSUZ<C
M^D.BAW?KT\ P"N#-)4\L88"5OCP1T&RX Q4EU_W?NONGO-0R\K!A 30H0PT5
MXT8[I]A4H<9%LJY&# V1(A:L[,D7>BZ_N>F)\J^]\63O7$14G,<_YOI/*9KE
M?^(L%_KS/\K4+'A_+0,".A$Q)AK;@ )WKY]#VN=<1T1;Q8R<]C>XBA%P_?R^
M*=Y[*#47='27#10?31+-?$@[3KE/*L&[<VJZX@WV41R[/<VK+^&4/UW:\.GQ
M+(,Z]ARVO]-&5BFI P6'FBO<DW@%N!%#!Y4R,*8+U+QO8M'LXCN@,J!V D1L
MPX EK_P*X@_<\](_+8_<!]Z%Q9E'!]& W4='YP.ME7P21"??KJH-SRROU78&
MF+6/8YV%SN(KV9EIS6!FY $D#_4I@=RH=(^BU)VWCF%M9<T5ZG)U+]CX\!0U
MQS$)J3Y]RSPV7ACW1Q@63_Y/[>)@J</^DU!1)Z-Q@/"QG8#5YS$A&B\0,(VN
M3(WW8=$N^@FY&1CAK]K^#I?VN(BP3VNR?]D!547&:4RVRG?-CQ>4-;1[X-D#
M@4R>@+)_S$7L'1KZU+C)?"C"^:H5CT)G*]^3I)NRYR)D,9(%$@$>US?_$:V'
MY)OGH*M_MCM_CNQ7N^.$:MH!%?IC%WT( 9N-V.$$@9-]\DMH8Z)^58Z>B]2X
M20]DV<;7;K51H6Z75MT(RKQ%6WZ1-^_@/T3#_G^H8WI^,/^1'SP;:C_RPWO1
M&'<N#O6F6HXV( V=AE'R +I7&]^H?9H931,G?F)##0,#O3[7.L=8%YG^_1_]
M8PJ@EO9NH3^6(8$^I7 8/TX5CZK]GO<  /\HN>@MZA.4.U=AB:S9XL[97G9N
MN-+)BI<"7VFC]K.;RCMKI"G$Z-V7]_@8'T5_7WL@=I6'QNRD0&$BYE&?=7#N
M@.;JL^>LW]2ZT%D9_9&9F/FW^4+7_[RPW8=YE<3(SRC%M97SI5XA3*4Z*J4G
M,W&K8V/M:W^SP%F24*8VSA_:DC^&R/UNUPE9-AKKH[#RD7"CG3V,+<O75E./
M3O1WWXFZ=&#F3.:#+./!+'%%J6,5MZ9ZT[N&BA-,;1]G+4Y,/UTWSHQ'V0L=
M/;J1>M0?CL<"GN"HMB4?H1PN(K1CPE]4&TY@6*\C4E9TS25S/4DY-ML76(L3
M?%9;5?(%G]X.OYV!?G)Z_K$%T:"))O8UG33W3C'J6\_Q3A5;7.@;0E]FAO-F
MO#O<1S0B>_7CH1BYR$QE/MF*&!&/%\QBZR/@@!(B=]Z!ZZH1F KAM)$$I3#O
MTM",1)^[:[K&41;/;%/#L3"AI7M0C,"ZZ\PRIJW6GF0+L"S>IPD:S<.T^(D]
M^";1H0"WL*0TM_X\M:"D:*U+_);@#/G"<G@S?^''?1&MXB>NG?1>@QZF($A9
M>:@O"NBA,46K[/%0S#XO+%>]Z(LW%VP50CP<W1G>Y5=.);5'W<IMC4,G0B'[
M4^,3 BIBFR15KZN?Q/IDNX]-N]M77[,:%2UUPU'36:S%J%:4CHJH7D[;/3W]
M[??%6L <B#.M:-8E><A1=,.%B='[';KYX<8%95V9*>1K53%Z^>.7DQS"Q"[M
M5Y<O=&44=GY^KS>=;(GT)I8UP/@BF1HV^?SF42I?^S[5/[6VS!:VQ-LT<B9]
MZ;)F+>E(+G@(LJQH8;']@ DJ!RCYE(7]J?QG[UJ,PC=C;DNW*^?P:7_,#86F
MA/,;#%9&NOCOZ7H3OS$VMLSO*QHD+:WH:W@FR-<[HK1W_LZYL[,24QU!.Z#B
MX"RRS@)M%U$DK8][C+^_VF-O8+I<I1W'=><BL6!YYI4,C:=LPE9=M^;/<^=6
MOX^L"J)BWJO83V+84!UWARGZ%4E-BF=(Z:*]D.)AJX4<<2$+H1C0\UUI(NSM
M=ZLSM%JXSF_?1NTW">)1<9"6B3&:-KVGG:[HT%7Z,CZA72J.Z)N&^NR&Q467
M+>?>+"B-<?X6=>2$T:JV4-#EJ[+:8@] ,Z(I$84MO/L+\T?>LUW:\S6,I-B*
M*4&'U:J@VL:$:3U$GQ *UU$T<^[W[&_Q#2.9H<MVF*OY,6<_MS^/I7*=-]<G
MBK0=>+);L7 .S4713D5TM,1>)S7T-]+VD& 34D*6*9V>9_/2XF;RJV.TK5=%
M3K=NW*!=L[?X,%QQX?C6\W&F@H$K4-7[7TVDNVW63*NON?183XGK"<>/6B_'
M/_U\0FPYTYWD,3LA,VQ@LW[P3>T% GH)/<G*27JS9MYO=96P&>".5'Q_V\=L
M(]%R[!B_D?.M"O8-9N$@E??-=S(E!-_)8IGDDW!YPW"\8BCE#%Y7.Z/;$\N!
MT&Q,.4XL3>/^:&&FXZK$G\QZWK,%O_G<XX%V]Q1K\L@"9,]:B;AECIIY<=+T
M[7[M^42L^?J8%F9)2?7%Q@->>=-/E@4])2Q5RG[#RN$U*F\K \1[OY5*RK[N
M.9HE]/3)&1MYPAX\)!(VV9(U@>9&A'4T14,"UK'<];[N:<V9U "KI/ D7]>G
M!TM)SQHB@O6^J-WX7!>!2%B<0+KC5IB<-O@@4:FEO2K^1,>F2OW7V:-.W&8\
MAX:'U;+.Q&WMW3HV<:#VIGU$\BN7-C-IGH;$F'C12.0U(:7;;%(>9S_JR\8-
ME_2F,G6;7BOX:/&V2IF&F?8OUV2:HCH-G8&=QB[QX[\1EYJ[2*DZ"60(WBOO
M 12W'\Y_UR?+4O4S]PI2^$.RXVF=S5>YQP\V!Y1_BG /'N= G49>K"+P[8 :
M6KLD;Y)"G?$L\>(X*V>P1K1>A3EN5=M%6_@A\<0S69#:-=.M=[B),;LYLL4M
M<0W5X7A*KAY253"IML-NF'V)S\\"8[FT Q(-.#U,S&/OHLF0AO'@12@N[XB3
M^YMATG 3G]>C10$M*=NX,:WFAF%J^B,690V1TY+M4RM#;.J^'<&T4PMJ:J2E
M"=A!9^AA^97%&@/<1HD7-P:=86ZU [H]9C&OS5"@HI-^X'6=$8'C*?<M=^E+
M*9()#=5N:ESO=(IO9'VY@^;8?)77Z912BM(;>/=\H#Y;J@OM^SW_:,HIX>H
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M-6(@QC^R)N0/QODA#OXTS/P[QM#?Q$'VXL]^^%.C[X#6K6M_-^.S_VW[YU7
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M)J#5BVS9!-I=.W#0YCU$:#J!)VC*_<B%MU9PY47#X'0N<JO(JM;IMA$5P^K
MU,+@<^?D;5O!A?V-V-##N@H5$Z-,5U-<+^J93/O=*9+_'#_G*ES5SUHQ$75V
M^*6L8-:'W0_4O(E0"I>$*7HO:7M2D^3AY>SWQDE-IK=:43HOJR4?SHJK&EA<
M09(FC:7*1U6DWXZ?P5]3LS!QG$,[&0S!\#XA:L<IAPACX6F1D*NDD(SYQ. 2
MUPSG.3QS\48I-_]NE5C+S!BU'O*WXRD'&6<P=N@'8%9TD9TLPJ !8XOP@I]3
M'%*?.E)R+EY/1^AI9)GLF^)W".\+Y78F_N@-?=+-R0X6DJ-N3S4/;LE8C_#(
M52 @UBIT;V($ITQ0Y;O\RU_8V#I?3EQEZE <)YA*+/ G94>3KMU?WY8JV_@^
M,XPG,L;/=!>KVCDK1?8_&[C18'$#\69!L/C5\S;(BYS):-*IEVJ'#$)YGB!E
MB1E9KTEL>CI=K!J,@VQ9OIGCC9D=;O9VW 2YV#::QMSS#_DZUR^>9QK';-B2
M_*13^C+K44<5<N!O+>0T/BH\ARS'KVZHV"YWW N5#"0E7U#IM=;<N$)R?;=@
M<[Q'6H4#-[A<;5)%AOGGGYX_T,%1I(6Y4R1W^HR"XNE(;3'.76O8Q^B)]YL"
MK$18>'&-,:ZD&_+P=?PQY^)1+XAH2<]A/:5]2P&^^U6JPB-UA(--[:5+-UT+
MKHCPS41 )]YMVNSNLJWL17&0<KO)D$N]2&V\?'D%M^.5[N+A 2DW::FNZ;/I
M5686?>8H+4JS4<Y4&=>P,YJ@!P[IP_!66TQ:&^EI-H$)+Q3>>$E)7 W^/&@M
M0GAL<&#QB>2F3%Y,RC6/3X+JO>=/Z&QN&RRV$LJ:! Z8NU+$<,G&ZKV>?I&2
MYR+=_A]?Y]G61-=^_2@J(B#2FQ"EJA!0I"A@4)!F1(I20U'IA( (2(! D"I=
MBJ!PT7MO"9T@742DMU 3$*4GU)&$^'#_/\#S8E[N8_;>Y]KG^JT<DYD\_%B5
MF/GJAV\PWX2GZW%O=9"E_I= I$ ^^G1S+IH9J* PD!0C"E"VFH!C&6*87_Y$
MLXIU/O.+]/>?WT<J9R[U-#A)^K\]NP)![RQA@)M*W:?NA[Y/5DQPEP@K0:MG
M]38$"E!@*%,=*XL[_"/YDY"TGTQN.8(F-Z^'ZPJK,\]:;O'S@9VS9OJ^.@QT
MIQ1U^O'C*._RA"LJOB*U/Y7,Y^5'RY<<F3?DUHBAN^U^2\H'2M#[U5@#[VZ,
MKF=*D97"#[:>N=?MM+34F6;@?S8P,RU.K<!;/C'>/^LHQ KR!#.U(XPI0[%X
M413&9'2JJV'QLG&:&4ZEPS&@&-X[FM-^6R<JP?S'*\=PKQ2S+TQS(\VJB%6U
M2Z?>7ZQDPTN70'EV--MTS11.XC*>(>!?EB>_CB$A(F/R6P8+VM+5VM)_)@DQ
M+CFO! N?2O&96;+EM-X\=1[1#H&4!M\"%%P3UTP14W,8_T6]]ZXUPK,AD5I'
MK1W]W@-=<[ZZ+*T["+RBBM+N G>*"0LHTZ\+@L/NTBLI3C(0)+=#9$$XG]AU
M^N%31;+VU+9Z],A#D+ M5?74*;7WLV(QYU7-*9POR/%1K8)+_T"L0* L+WQ=
M^5/+29;A:$&X\TB*>E26L\[2O-@=;'&F*]S^HYJP$-$=N-G>S<9+'U1VG=Q%
M>1H 2>#N!VJ=QZV!0F-Q^<%#!EBD^MPLO%_U48%.!G(F4Z\0#@MFU 2_= +7
M1G2Y7P3@)L/[.^=1@4./I])D&YPILVRU<Q=7Y+0R3><O5O[HX#H_('Q? 4%2
MV^PA'RUSSQ_T1:$%B2=^R\]Y$-Z07VG]8O] MKX+XRD;GRU6EW+6\9[+)=EL
M2L &]=5Z>]U0N*HL0C+,6Y87E;C7Z9<:HV"6MCJKK=@<F"J4-9N%:(T^S#BJ
MOO6PW%8,OY;PXJXO;Y<-<',J2KJB];E'.<#;+2P[MMT*(\%DF73S+B[0_\K3
M](3*9K3"[8T;;*G#8LE8.09V"5'9,?J#DV2Z(.T9N3 B!XCH@ I-8K-8OB*Q
M+? !S125&T^DD1R.=/-:D3+)^9>E?%<O#8%KW#OC 9CWH)]:!)TOPH(B^9^W
M%% ^J1)=_V7DU]N-8"'"C8%[76"(7*!A$-LM<BJ-"S_59\-)@Q#;V#J5JZ*N
M32"Q)0<!-EV>NF5FSHY&:23F=[&C9U:[KJ:,\J^D;_;R_7S7(E8B;-K1#MQ*
MHVF3IT)V%# 1A-3PJD Q,V>!OE"OP\EK+8V3KE62J&T'E1?2#C^YE(RRI=&I
M\7DUL0&S3T^2\ * O^6PMQ3X'!#XG=KUCC*S5@<G?$A;N+'BFZ>?*A@\()8H
MLTE<<03?Y?#RDIW9^4H7PC J1(2BU9P6+V^)5Y.[-.VBO"Z*1[Y*5+&-GY?2
MB@J5D<N^G'QF3RE";:GLJ)U#5:APD'A*N/0[]'%*J!J27+OXI/Z=WZ=H,RL;
MW\)U+YW L:N*L?B+/XJ%_3&+?"O.M@3<21--EY@UW;<4B#N)]%C6CP1SJW)?
MKN9AJM@'!%!8XW%9&6;=#^,'N\L@*972) $W[WT \[H]V*_PBR^QA\P;(B.]
MY2;:TCBFV:Q,N!]GIS_O>/1D9% Y](QQBO.%BPX_=R(QCO%A_T \JNQ%*"4C
M<E68=P5CAY8*\P/QBN5$(5YD<>Q+L[[C;*2#\2YPX>;#:V4L0>A?1#;@5A9-
M)*LV)9JTR(D*_ >RF"AWS:T?_]V0IN(]+I-'E@^42B/)SX9J&PV?9PB_3VTU
MR1BB<6GT"MCT#HIV#)%7=W=ZA&4:1I[K#6/JMVRCGZ4<#G2;4G^W7GK4+7"#
MHU0J5/+(VH="5:RC<M'XVR:WMJOP0JA;L,FQGQ%NHVL4.T*Z9*WB'S8^17OB
M-9;/X8O-MY7[Z>=1RAAA,Z"@5397*5)^47(S+0%G@YW]>\5JM@M'2:@5W/@V
M->)F#^YV8O@]-#-&O_3)EFI,LR8'ABPM7E@W%5"+Q*9#K+?INR<BS2,OFT>O
M3X@FPLU&GW8:K3)C[@X:N/%E\UT:C*5$'!* AFS:X\91+PSCGQ+A5$I4U]?)
M.QIE>6H?RE='Q/ )#LZO>TI,4&)R$JNS3=SF24=M.^\Q2^GMEP.9:*AZ(#97
MSY<([#^_.IEFA54T:0[,X%(V6HL&?;H&SZHIP!HFN.[QF>ATOW][[P"&"<IB
M.VCG[5^^B+Y+I%;8FK1A)].?Z[ OK*\NS"_5MRS<<^9@LE;XZ%E3DWCGH3 ;
M&4Z_E%%$\Z=,A>XOLJ$?4'"3Z97PM8I2FSZWL7^@ET,!7$,"WZKS<L)%+XM_
M68F130OC>2BVNT/S.V6[Y"ZR9+?U7>=6]C*70'ZR\=9DF'>91O'71%A95XZ0
MYS>X*R_/%@*GNNO#!/_<FFU?947>V4PBCW5:BX_@8J4ZH. Q;S:V66W'5PH5
MU:&S&H)/*+UGE[BU,QT,OF[)-?&)C0O+G*1!N5!'I,"<D@UK-G)<"6G0]ED*
M<[\,\G7B]O:H#NM_,>N^]DY\LZFB$HJ[>PU1H"4H.WWQ#DV_;0HK-70!"'E$
MZ?WDZ^YXX6._3 %"-=4"K708[+^A8Q\^+N^9VP(+U397Q);FI _0!3 =9F@-
M7[*S*HRT& YQ/TDB[W4M*$TZCAQ@TR23+)Q)-?7UD</WG<6"4N9F7YM2=^6"
M%BW6 EG)19WI)\]-<=4C6";<WTU2>XLQS#/@5OF[E-*MWM5+(F%G5FA1*I=^
MHV]2P309LGZ( H;-61A$KH@+JUJCK G$AEKX,?L/W$MSB)H?X[MSO3'+Q<M&
MH?H\"-4>A5DJTEMR9_HC$(<CGT:RT>TJV5]U$UXM7U8;VG&1WLRP\VW8<)B]
M?[I)XJXDYQ/(1QE3J+-9/+_W:2IPHNAWM5^8=[&6 6"')=C/JKH5ZQH/*5QR
MXI5)>1NPPB=_9'C4Y%;J:#7;QI@;-:BN,)M\;_WI,B*TS3'/8A%@Z/(+#13V
M2>S:,EGPA-<-"G6A!Q-GTF[D=W%&Q J6!DOK4Z_1I&=(C*E? WGL*.HV,E7-
M/9<6Q3=KAE!B0^<=4FZL?/1RM.I+U .ALOZWDBDH6UWU6"6>"V@^ZNVDFC5,
MJ*KE/U6X#WDU.IC3B/ )5D1\L8-1-5@<[DU\F;?6B0JF_0/%8I9*Z=<BN@@M
M* PQJ;(0;I3:U6<ZF1>W:-XP2M-TSEEG$^DMA#GLN5]S^M0AS7^$W#W=*>V-
MK#I,EVSTNY3FC*FP5H4*31]/B;KS^X92OKN6/0+]RM\CI"5B15F#C2=,[X->
M'%=MEI!GK4;%:UK)2F';TK^QXZ["O-7QSB$&S7&[QZJV89FK-PK?0/=Z*\89
M'@I[4HWHLWY%FV,5?YK=:=>4K,7PC>1W=<L!KUP/&B%YHZY>2;:'/5I?3(<^
MGN!,;I^]8"\8\Z1G+'BJ?:G\, 4J3/G95H2^2ZDO(2Y>BB[>5 "%+T!,2%.&
M#6.K[U<2SO%L[UER7G3^_"UEC_?*ITL!_LMLF[KD =)47*LH29_O3[U 06K0
MOM06P[,QV5&EL>O!ZW!)1SN/C._2MC'V]<DIFB]GPY69AV9DB94YY0A"Z (3
M>7]*^(:M1$7S.%>[IYA1W;<LKQ;=<]*#L3]&;HI]O,'PM4)M*3_PVH@,33=O
M#L6#].PA:)54#4!3A>L0"$31VK%"YI<'2W%KX[Z[[N/99B%:Z0,U"<3'\T:
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MN@Q)C9.?1U@#)46 %9JYLHN(\*V$N%8I")8H"*E+G6_SUEM=WK1QO,:1)9:
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MC;@,_!-U&KEF[*:Z0J.49"86FUU?UJ%C/^,V3TNYV "Y.L[3/9'O;4%L*\<
M/C?RW#ZA/K!H50W(_K41!U5R&6OP'5]N:LND-:2-VNE]*^CVE#+:%N)WBY)]
MRE9*YS@4I-^E04B;HC9D1K1? <@]**0JXQ4JLW?/?[P+REUK$[W90S :ZK^R
M<WU0XVZIV+F_%H+S7 C7S@MT)XIQ8CDMRZ1ELDI%X"SUAD'97-$G9:8D<R>/
MNB@1%\Y!E$5<RQ8QXIR6U03]*J5UH:1G9B2:(3U)=Z@$:[#%B35AY3?\:M4R
M HA1<.9+! -(<6 >?!JNS77V@6ANVY:.Y6__T'+&I3-%=,B)"NMDFJ5?(V_'
M5.SK8I;;<PQ-./2<U.*#7&IAT*VOC-'&Q@PUYH^_2)M\/YS9&[-:WMY[O$@]
M17LNAK$699U=/=!034@O >,R0QM++0FKY%74@3_6D+5'N7",?Z&S+:KN-IB3
MI/.QZ7;I?BY-IK'[GH]NHE%*=S6D6(\X!9>DJ@FV'X47$=)9E+M8&\A=&I*D
M:UMN9F#MEL /Y6?>@X1F:38GBGBDE.Z0]5T=P5.Y=94"C/.-0EK1G5BL7U$I
M\SHBN9 2&T/O%BS,]O&COFN8H1B=6_IUNN^K*)T;AX>/\;0=(U$#;(>XWH*=
M4H_&$"ST'\X^]OG$Y@)B(^.5HJ)@B/G85IX% _M >#;]4L$EZE:Q]%.V*LU3
MAXKNHLP=LL"H!J%X0\/:0]59[Y4;=OHMM@'JZ1PC 0&_T^26]4=[WP+,M'RN
ML6H6M=_PK8X-%:7E+O)UC<RPV>-.N @AI/Z6;A#@D[>*APOBU[ 'C?7K3RM3
M)RXJT(=9P"5'Q<M0%-6[5_ 6=VH2_U&AQM/3-WOATPO;M.M\86T!Q,/XAR-H
M+<W&Q VW9YCTI\AZ#,X::?.[)@TFG;-TU2R&I#\9M_-(/\GJ3/D9T&.1U)WY
MKER:E PZ-Q+$^LH7:K]^0L18>4F#EU@AJW9D9A?F68BNLFOL'=ZWMK=J.=BO
MY&^=!0#.1:*K:=?3T: 8K>ODK=PB*UC7?T<Z.Y+.6O]LL4PT1N:^: 1OB*7&
M9?4D;\ 8CUST+@FGV@G4R'<N5.:<H9C'YZV9FVM)CLKO&^P--:3;C\<Y[CYN
M2UM60CT43TJ83!YWN?L=>.UE7$("(78AD293THV(U##/<BJ@A2X3Y@TZQE7E
M7$+,U\QMXF4O63:[?DS;F?@2IH\@S3VS_N]Q;@8[?H;F/\_@B,@495ZE6IOG
M<K?$_TPJ0A9B3,YZ5E[E!!QPN84:GN\: #QE@IC0KH'"GZ,S[0N^P=SZ<X0C
M;<=5[1#&B::8_ 3($*O6.&'',/Q%1DTUS\]@GIK#R4FLFJU%(NP]XU)7(%'(
MA,_#%/8,.6,GO6L-E3/&8 ;;VNOJ,'L09+*55/I0?"2U(.,RVX_W'DO&VR[8
MSH4ON2SP$P<SU!TP1FM9U\>8PQ28:?7/#XV0%=A8%X5,DS]_8SVH*Z4.K#6;
M++K'@,P*#Q#9N/-#)C(ASPL8Z<D25(0J GO7OVC1=>YLJ*]O0<N_+7-_I6!V
M:R$O]LW'GSUO'6AN5#KF? \-+E$%"[;':.J4PW(0;*MXI\HO/C87%'S_+H&7
MU(W.5C'1/3GQ!E+N!SQ1?TU3IXZ^=BY\M6<YRH '2[\GE0L'"9S+#BA%^W@J
MN!I6UX,;6[XD2=K#FD:F&];K)-W3."E1].\;W_Q4.Z<"_E//$A'W'L_;=33:
MN>)ZU&^85!$TK;./ZJ:C%!7-!J.S6</+3T__38K^=3"G1QJA<^T2W?HZHS+3
MH^D&!6OJ03FU+!\)%4'#<^V5&(-B.["T><0=7J"*)6'V>W7CFXH/<3=8 #=]
M1VBR2N_]1BXW8 F"%'KF+N2INSE#D#%HLAG;7(*Q>1$]#E0?XD"&&0!'Q)LX
MZG@X2<I_ZA!=AOO5E^ 21]ETAPJ8,=1ZA%3ROAIN0F*&7AI<:L$P1DIL",KW
MDW_F.3V3+/H0]_/AMRK;<"]7"MN&''F^1SV=SZC$ \N'$XS/*57R/?+<^;'&
MG&5WIV$@1]8QR1ZX)Y/,>^F^B_\O@V%;T5H3]+N%W/,TF'L]J\SW("9<A,IM
MHZ.^=2.MY6D%URC4T3AOA(K=EE7$K<L&*J=Z:3C&I??DSN\M?%&J%[-ZU&MI
M_D)9@WD--9Q&WD[GPE0Q",YTH<K,T6]R7[CN1D6Q?KEUP+@$)3*?0KC)O&=(
M(;J-"F*SXDW0N5.UQP /,%:-BL69SNMW!*3_CO+<C#)+*G+-&K+\&;/2#.(#
M+GS.X:&%!RRN-AP]:+BC^8+\GL%-_6P^-8MPLN+P%5Q(^RCP6TZ>.4(L'-6W
MV+98W/K?P_5PV8D] ZCG*_HSU4F,;>RP4=OS,@1X'NT-\0+?:\,]1-S9)!"P
MTRPZJ'>GV<^P3ISZ.7/2@,_;I)SR:+F6D_2;)*BZ(:;M!90(8IL5D ^#H:SV
M**4%WW>,D[KSIS1[9ML,ZU^R."-D_;2N(+I,.P3I+R@ZV6DIX,7S&%6A#[4-
MV-]CT[Z'68VCB[CDL0M.LE]6M\9?[=#<[2ZR.+%-KLW71**S3;>H1'F_>"U(
MI>-(#[L0J^?6!#@SO#*I)H8T9GH?M0&]&-[S4KX,'<'C97@4RQ!=Q5$/:BW7
MDD$VL'=PL_2Z=?4WMJABE6=Y1Z4_G.5'J ")WXL!VS>7X1.GEAG_'>;.I>GU
M2L^;OS?&9FE/:MYUJE@UK[5!^Y6NU1$\WALA8R28>CYN9?HGW!2J4WEB\^LF
M]'6]+:++(E1X"K):/+<2JMG0U,!Q#/!4R31S!3*G33J/6]K7_;@O%RB"^?TW
M+PEK-B_RQS[6Z.1+$+H$!M$H;<=GEOZ,<C7&3N]YNFT;Y#"#U)9 %:H&#A,:
M+_JPF,I_TS[#N?O.7/R_H!FX3*3NI/S\_8X6.X])!;^+GJJQ@U5*W6O):S-+
MJ86*XZI[XS]^&2^V>OH#OIX1I0X?M?!1W[29L*UH2!=4PVJ,\HW\S7\.E;A3
M,Q.J17*Y&XTE=4$W*D<37X94LM]B>LCL##X&D"U,/F@4QY/DUB&5UNX-=Z".
M*+NT-3P.[R59]^ZKP@W+U)+X=X=6C==:G5_6U@3M=<:!:JO?=MR#D69Z[,5K
M)YTG\A+Z9$,'*^RFT/ TBUQHO6%47I*I2\3OAJ@K5W@]OR99H?[GXK-,F.9A
M_D((]MZ\V7F;-?,T Q+S9.RCYK#-:O'DGHN(L<>_>B-3&YQ^'^8J %X'@,@6
M;!'+\\:YQJ,=8A!L(]XUH\Q0*Z.@J,?__+.)JKURFT#]3ZYN$_)%C3W!$_5R
M$3<]DWP;3&C7$6AAI_X<'C*FGW0/:$U1H5@908(AW+=6TDWG9\%C,[9YZ<'Z
M.%1*MU'+SZBG=^OZ!B4"+.9K$6_]8C.J5)GO/3=K:VD<4_!4K/:++8^-_3"N
M*K!_EW5KG/-)0 #G@ GEW(5IG4M")[ XU?F]XS(M5O3$/D A^EA!L'0+1,%S
MB]^/\^# .D+1T4KM2;E/\)LU?O:S15K+O&]O@Z8;J600/GB1T%RX(B(ZF4<V
MZ@Q3&>%=:<2A0*XME-/V=O9]*5TM#XOQEI4D]YZP.V>4O2Y^%T"P 1>^A0I1
MV- A?/:X-M;%D<LA57W"%I;:$*8)+:&:',I&Y;:G<\+SSRZ9LF\YY'[D$RQ@
M6-7+(7<7V#:<%MBF<WO4!=/?[QV9_EHSDIY!4RJQM0'!K&G9$,DZF^F9?I6X
M&C27B?3$?0!K@JY<=B3C8BTYYY3K>T.<47O>"[5ADMRNE]_9@ BJG$'!+FH(
MRC,8*!'>]6A7\JE:JRP@C^)&710]@X"P/N]JH;XOFX7IF9 [PBN&*E:QH0'4
M)RT192$E]7.U'QT!HS90CH(!]2>_^1==C2.I;D?MFDR'5K16ZS&ZA.I>H^"]
M%I!D2H6A2)X[9OCTK"[']-B3CTW3&KV*6-T=:DOM.*W\D)=V?A'8"T$(PL+Z
MS9JP1&1M[4?M"KL9J_D'+K #U)BMC9XX^E;_FTVQRR4R[U,'-/X+0G$]!K P
M1F[:V]!L#CU&C)IE?F"J5"%9Y<)WGM0]-L4+"">?G9>#EP+.>,1=+P6(*!2=
M !VH@W<-3$QOP<!="FUH]<Y84P\U?^K?^N3-5\E[>;G!#W%2'R],+HFKIPSM
M>%_-_8X@F]JI&Y+=PCTUO0OMK.=AK;T:D1%0M_'A)J15>H^/>]JSOV]FF2,#
M77B[\-=^Z_^<^7U3;Y?MP2C0H3,RE*6)'(<7+D;FC2RTW_.-US "VK:ADFVN
MOE9D:EAR/@?K*7AMI>[D<PI]X_;PB9G?I&F7KP==KN1-+)7'W]NS+JI%XKPX
MF<L<L""[#S]CKUF-WS/ $U^@K\GPXT^_O2R#_J_/@6=7CP',<(%J&!J=(TT.
M^1/GV-)FI+&TL93\JX] NAOH997V6N2JY-B[*\%;0G_DF*\K6QB1#:F42&KD
M41E?=X[PF-\UNI!,N)??D)WCOX&NHP;JOSCSAX:ZNQ?<+RJ?EGSTD2>^AF.B
MT:" T85@@ZNKQ2I^RKDV7@77/.A\F3/2TT@>/LN7TNOM[7[%L&E&I>81B=/_
M*NB3HK$77/ H1DL4?H9RU!_=IE2RYA_T*>WYZL<*?/OD9&5\(0X$26:&2285
MA+/\[N#0LPT9!0!V$R\ANHP;8JLCS/%;M>1MDG16F;T=+#I%IQ&)ZFBU4W_4
MS'N 3^'.>AFCELQ]<VLWTT+NRIO2RUZ,$Q1N )[2#"![;02I:(F1@3T%]["5
M57K^8VKA)8EUDA9=EXA$3OMN%WF+H=C@'>X8/$6=SC5$-.XL%E9;&[&/$"H?
M]B"ION_!47>^>6S5K?DGU3T1@"I*QCL'^VE9NK#PZ \'=*@=9;7Q43C7#5,L
M1S>]),8:@C=/C\^V%K58$GJO6-S@_Q3N#"/&!YX'>,=E OX"B5YTGM@>4?:V
MP(5[:NO=&I<SG!;YZ<"S53@+2V3SY*;B4MS1UQZ%[D(4I:=6?U5RV5:OQ2BI
M(S$6L5!(N$V3(!_V$S0H\^%T"9DP!B]MLDV4=&Y,25'HZ4OL*'_5@D%8^1F?
M (B0KK&YLGS&7;5<1[(2G0M"%$5[T?2>&XRI0H*!EV96J%1_I6J0H?.B_B#&
M'F;MF#+H.>4;J"V\DF#@;*H!Z9R:(1**RFWMYE8>[F[F7&VAO!A&]D[46]MY
MJ*N!7J:!K[I>.P:L].07G(XQ>'GFA&2)6NPG1!9)(YG@,6C@);^1<[27D* /
M+7XYY>>R2FU_8!.]"PQ*9VW1=V('DID#'G"8#DE$$@KR<PZI3X]J]Q/C!1M[
M#86#]<;3%HG9/1P-F>KX@F",5*LQA1DRE9=[,W6J/I7]ET]-F0&'AM>ET*Y<
M%CI7"1CU+S0)(3"VK=)Z>#=:-;A9$;J,@78,N@_)Z8.64 K,+/25C>JFF\.=
MEQD#H6?)$>](E5K+]R"VB?V9SD'GD'XDUJ#=YZT3\CS2"7>!6B3S),=G/J]?
M<$2.>$OL;%F^#=Q#D%^(GK:GA8XOH]$=M[&J<I6NVP\8@^.;%=M;CLTHC/BD
M\\^:662]S-1RPOU59184.OK4 ^%$.G> #BV;,D_TBF@[4[P6]"<2#JG.5GI*
MD<3[]!?G-T9X[@\0PQZND7[WR5M&)CHD@,VX)#VYD&31C8OD$>)O5+WE:@NR
M=[(JSZ>L:)B!# RXV93[)/9Q4JS!5<F0&/[\%\#K9YGN:TZ(7D8LY""80SEI
M&+3@0>1>MG7W>M<F=\N+1NK2^M3,B$BRBE^3VK!L]!^-H(ISNJ8]+'^\Y>_?
M 4;E(M/C&F9$$P1'(C?IS+R1Y$BK2/U O_6L+,1MO0)TZ9R6HZZ"Q% @Q$L0
M #BM]S/.7'I%2R04BT^&I?>STS#:_QUA!;+2)/0H:U-B"B$N4#^F>7RE"^O;
M76UOI]NS:N<XKV\R&0K G0Z98,])P#A-F\!J#\$]/"A:TZ@$]DN(]:YI\WB6
M"59^P[3']F)ED6Z2]6WH%XG?\C71YRQEC;99&3\R7Z3'P$,"RSVL$UK=%J&7
MT-V;3+/C*BB\2P57_Y(J^JZA2IU!0(#$DY_\?Z,TBI<!.STG-5A&4S?7$.[1
M\(IN</<4M!E:%P89[E3/FV@P;=5[^5RP>GQ]B.?3NT>1KV^VW"IX.8&/I/,L
M$D-CB<]#$"6P?J,):_>S&JK[V>U%1[UM6)FG,2N!]15R0M81KZNO#S7#.Y6&
MQ97Q$!#99/Y#0.8']?3,LQV^YNSN8\H>Z=<TH_9FVJ6O]6_?,)E6VG(:,75F
M/9C4SS+[WX^O6Q/(TGUWWTVGQ]BOO(ZLAD;8;04EA?"B3VGL'Y(DF?2FBY/5
MA$7%4%9F;UE!G*%3#([1-BORB%ZCG:%Y+JFWN7W4!:6?%V'XC/H&<[,I6?QU
MXS-@*G\@]2*_KKFZW++@>3K/'Z)7W!YS^3& ;8K6V2/I(6@7D0LIL7J@\*M&
M5?9/8UTF]VY_6K*!E[3Y EH>@OP=SY&:6 ]_?)2EJ41Y8\+,QJY8&0)=.%PW
M>MP]NM8H]^K / 7M U6A1/:,ZZBV&5=*+Z;>&7 ]GTU&;"B3=[_CSV45KE*#
M1JB*X=^F(8*Z65K- ?=R$N]]21[R1(VU?=#A5*D^1/Y]_,%4+?_ZV]<M%G3N
MD>X69_R$!BJ=9/![5-5F2K6L85,)+B)0%VN6;A2SO-?0+#;,\@V>J%K+4EWK
M)%1N8W6R=AGPVZ-TOJ-V'[XH;/\AYZ$]:$]E) G\3:=H@#]#[:JZLK3 M)/E
M@?ZV8#E'03FB2TN+DY;5DYX^#N8;\O-#W-LJ$T8U!K!8%PS#_:1CME0^R8\Q
MEPF^B+G_ MX/8/)_[G/_**Q#F*;=V]+77JA#@BJ98Z%;KWY2.R0Z$C?8;4'Q
M#]TK+8:G/1-]F5/CKEV-X:A? G#1P4<-;4 RWX)B.H7+?FR_=W1?#H0:NJ(\
M)5#AR#ORYN<&3HZ[4$_( ?H[M? V1_0MUL" 'C;:=;7$0KH]1M[WWGG09)N
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MG2!$'NY=MW=_/>A?-RMOR'K4%J $D1_;\/<UR[BTF>WHSY+P;:"K/)7VX!C
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MG]7,2^)/-CH+>#'T*DT<U_VO+[;<'N:!#3'>NG=M/;W<O5'C0V/RG.TKSF-
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MVKK1Z?\-)V%,$_*LN^1;8-ND0))CZX3W;<[W37]9L?U4B[V7?5PYEC#HB*T
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M<?+TX,5H-\7<6U[$B"->F<% !EO']!X$NIYD*6)^[@E#(&9M8V/Z7KN637F
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MW;P$,.%-=S@N2X3?M&#ER'(5=M _XV4*@WALN*B2<;+Z'Y?M&O1T :F5X0-
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M6I@B6FAQ^^]&K-LJK9RI&O*>=PCB][>:AR&\CYY4Q"^61]L/CPYVJ!O=*$T
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MW8Z='@C)*O@VM(CR6U,[P&H[4OQ^Y/V$INX?)U^-J_L:UJ58*?_GLGV58K"
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MM7D]U1Z17.5W_X[Z:O5M=:;/V.'&.Z,9%]/7"09$:LHP:"!6'C:J>!E8-!O
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M(_IFI-&<D"2S5=;WN#G! QWD-YF>J.4QU[Z>>W&KDHSY5Q:X/6(GF*/-X"1
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MX=LQ8;\.E[]0<[G]91N1P2 J7N;%M3&6:7WKW=\1QG,U!$9;N,U[=CW2=&_
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M126IOLIXL/#);N:5=ITOH.O[ Y,"N-)1D(.*^X99>9DU5+$Q1<XXGT8G6]M
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MLYIL-ZS<?O:MS%R!7#7YY9A J0$*\^QV<J&+#0?663\+1LG6)+[\=I+$!M)
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MJJMH)(1$QA=SW,68&VGOBZ:32HVK0+2*!#\5JZ#4NI1_-N><"T8HEBS# H:
MHX0#R.(04(0SP,(TYGD(<XJ$>>$_/V/D9U>W'Z5U%<SZHL,TO.CZ@7YJAY-6
M(FB0OY%!K4>P4R1XOPHJ50#5N@2-,D%'&R_#8;Z"^QD63RO[E,-CM>Q?CFJ/
M.7!!X][,A,L!Z)H/([3FZGI\K<^GM$=S=_CQ?E5N-]77W%;"@RCE!#$$\K2J
M$2\R@'.<@"QC5'".21H;7=:PZG5N1L/^H*_8BVI\OG<!^J;>JY$Q]79NZ@*G
M@Y_* IZIW5,FHGCV2EF@<^R,LGG9(19!;#^LR_+=>O/E3M2;J69FT#BF-%,;
M&TDE5+N;$ /,! ,9DHJRD$ARRHW##L[U,C<>4H(&2R5IE<]G>R>L74SG\1PV
M<D=!:6)FT0!I(0,E9:#$;/P=+F$ 9Y&RN/$_!F*^+O>?1FZD6_Q#0/1=V#_[
MKK^[^4/B'US#'WS8G@:/RAON$JF]7['U?5L3H_Q"Z%)\$3^VKW1ZKT5$$\K"
M- $DE9&^79(HCB010!%)<D1)(A-C#Y";"',CT,^/]_=D\[2O_[G>9:0K*C6"
MGYK,=!:N!<?1&6;<Z3&?F(X[-2S4CK6.C]OG 'S?(-ZJ\>?@:Z5)H%4)7O5G
MJ!MK%,S9?/K1\$3UEJ,RSA)P&7H]ZX-CP]X6C\L4[ZXL%[;DD.&O#B?;6?:=
M9 MM,@2,$\&C%"0\) #2/ 8X1@)@#*F@*4XB86R%#_8VM\6D$;B3(ZB3L,0B
MG]P@RL,KQ:C83;PHM+#MO0 ?NA6-K"WU8?PL\N^-B:.O?'M]>(Z45<\4EKXL
M>H-M^,N:9ZK.098\XY>F2C%]M@AO-]UQF"0RC$*H;/XL!C#6-<=CG@*40!)'
M<1IAAL?-.FTBUMRH^V-?->NQ<U(;C9NII]?W:$R]0S#)7#U0>_R%$EK;(/W2
M.:Z-9)U9VFL;?.TS85NU/D:-T<;UH'XH;E=5(C/5[Z%<Q6'F>H8EDEQ((&.!
M 8RH!(1&&% <8RI$&.?0,I'"1?+,C<-?KU>EDI(WERTWA5J6'Y9-JL![L;U;
M<_O$J!<-F#&'^QH&?^X=Q=WE7H$C'B^F+#PP!IH^RY?:"_F"%4V=$>TO<NK>
MK"L7-_<GRAM9%4'HF.^OF]22.DU.8]ZO;J_9MOA6_7F!XYBC+,4@I4P R"*J
M*)@*$(6"X1QE$<>94P9J9Y&,.,!_/NKVRI$B@ZK8B+T_9(SA,F7A:='WP\"M
M#B<A;VY45(KHQ'.R5471<ZO+F$1\,:!3D["[@)X)^&(DC\GW\B8=<NBNZFS;
MS[)N=^*7_D8VA?96OU\IBU&4V\:%K9[8/!ZX6*XW1:G$>J? .DG1"+-(8@DB
M"G.@2VL!DB8AB% >)C).89@8F<I>I9Z;0=V-)?S6J*AC:"L==S6Q2:VE159;
M;U_!L)]\EF,[\1K1ZAS\U&K]YZ#1.^@.>:MYT*H>-+H'C?)7!X[Z1O]  Q#L
M$ BNAY>6%_Q"+!(IS_%+\969>6Y?C%WN9]\CUY=,VILL_K)3^X;W(-VU]\[M
MK9YKM85]4RP?55/BLV"Z!&FUE67+1RZX[N\U63(M;>6;?$LV*]5U^5%LJLO^
MBQA'$H4D 9+%"8!0[31SF2,@:1I*GI*,(..@Z@MEF9N%\G&]5>Q7)=SBO"K:
MHGY4XZ+&;_/4Q(0%VSNR#=1/.G%.6>AZ/FKWH][B#0YN\6.7CNJP;>)QK":V
M.+0FH%4EV.L2M,K42T!''7T1J55(WSRM(YG\C8ZY7>!QE#RM]I./EM7J/1*^
M/6ORI3UX6VE'@J*[?H[5I*L3]OGZ_7[U^WKSA^KB-7DHMF2Y@)!D(2<Q2 6$
M -((@AR%*4"())#S,".<['RM.G+.U-<ZU+.+2W77_X2'7'<ZVJ]4V_#.5>7O
MM>0!JT6W=:T.#H*I!W443'UO@OEN2Z,P-472P1MJ"L[43L]!.3S[-DUQ.79A
M&K]Y<3QL179-J[LR-PC%(B(@B5,.("(Z5P,+08B8D%!(2A++>U4]O<W-[JXD
M;"?)Y0&O)^ UI9R10)N8;2SQNB2B]3P.WB)93XCP4A&LY]'HB5SM><F52?Y:
M"O6_'PHI?E5,];C19RMU+-B-_%+<B[.WCQ:,<!KR4-D^,<H 9'D,\D290BD-
MB>0ZOR<V*B\X@BQS8Z%NLKLF\K4Z^.R]'FA+4NXC9TIA7L9C8H*K=0B62HG@
MOM%"'S'7HU+E^%2:7#D.C0,?7@SJU&SI+J!G+KT8R6.FO;Q)9XMN724C8)HR
MWJ]4/[=J%NQ2FT!,<P0E2$,J 4PE!SG.,A!GE-.82,$ILC3I>KJ;&YM^.4S"
MJW=##XW UH9='\K&EMU(V$W,?%TQNYA-8^498#*YF=<G@V\[SP"/$X:>R5M3
M!>T\=Z%U[PM'4!!)>0HXC73ZW"@!>1:JC66:H9CF,DHRH^C)4:29&S]5R2C4
MLE ?U8P=D],W+*:,Y0GLB0G-* )'M-[^W8"\6-B- :HO'6W3)^+,@FP,T+2/
MK3%IU/D$H2P?!6\]U9*EL<0B5@P:IP#B* (8QS%@'$,>\PA!LWM_9]J?&R<>
M^)6LW?X'R!G[^%WQF-JA7\DUB>/^E,:3>^D/.O7MDC^E\0G_^\G'QHB-^VV]
M%:7:^%59+3IL\7ZE%I_[RN'37:!A+E">,0["4!  \S@'.9+*C J3-(Q0)E-D
M&^/L+,S<*.+U^OZ!K)[4UF0G[25!<)8C8VPZ><%[:LOI(/QMI=6H'%QU9BFQ
ME[D[&%["X-P@]1D#9RGA"P; N6'9'_WFV*8KU;Z54K#MC7S[@U77"3Z1K6@N
M%MRL7I/R3HFB_T?[W;Z1I0X369 L3G 49P#SA %(, :Y1!F(F! XA0PFB=$M
MQ(NDF!NYUBI4-<L;)8(-T=.>-=<TU/QF2@5;QG49(%.JG1CVB3GV#.+/ :]X
MM_I![-48DUTO0'%J6G41S3.?7H#>,9%>TICS.4*=_*=S?7R14A[G(8< RPP"
M"&$(<AQQ($-)I<1Y@B*U];2YHG;<B17_>;B-5M<@8$W"J0NB>T_@:7Q.<!%*
M4Y\.6$#C<AYP5O?)3P&.>_;M^S^K^PF/__EG1ZHKO\!)&K$\1H @K*:_CCTE
M@B(@!.(P@[D4W'(/^JR'N=D^]=S?YSITJ]WY'$;367\!.!-/^>=%X"<L\^YK
MLC_O]F6+N)^?YN<>',,E]49L2;'4)5AV6[)KNG[<OEIO-NOOVKO=]7O@# G!
MDP1(S'( $8P!R7*H_HDEPX@@SJ&[1\I*EKGQQJ&7A#>J'+A$B%9&AVOM8KH(
M_Z9&5EP%E*S^")9K4A>TU3^4@?YF@MOU-[%95>E&]%\>'NFR8 %YW-ZM-TXF
MB?O@NSB])AM2KSZOGM&D.T6\>+R<\/3I\+(3\ 7]74Y(]KN[W)J\K$S"EPWA
MXB-YTK' .U?;L5WXH5B)]UMQ7RYXI+YXE.8@HB'2J:PQR&%:7<N@ L$DCB+C
M%"*7"#)O_JZT"5IU*NJM$\BW.Y^#7,Y:J:#2RC&1O_4H]G.QS['Q2L1S'Q:W
M*@M3#H__6@N6PS1^V057. V++U@W_R(E&%Q!.%>(P;D]N^6-BV+Q08WT\N/=
M>B7J<I$+0:F(82R!B&*UZTC5:D4ER4"*4LBBE*5<"),EZU3C<UN&*OF"2L"F
M"*H9=9T$KG^5N!2.B9G? @ECJNA3>6\EEZV97 KV%[4!^UF]5AG(_X#Z1U#_
M6)'#R0:]3/@^5=I)W/N,0\87_O?'<ENEUWNWWNS#4]O_K3CADV"B^%;1Q()$
M,>(PX4"G#P502@@(SG7QPC!)&0H)#(TB#UPZG]O$WD5FZQ#W:C'<[(6UR !B
M.P;#EN*4R$[,$1W1JX)^K?#!3ZWX?];UHFOCXY,7O"U2K$R(NZ^<*F/C;Y=#
MQ1' OJ0IMDWZRY+BJ.Q!6A37-AQ\% -WI_]:*J/R_SSRNL1W^;;<%O>DOBUT
M79:/]]6;9?WXOHH=BB.14R% +)"R!$66 ARE2!F&:4+S,,UBS(R=%U-(.+=5
M1RFA-V1_;]6X"D2K1[4M(WM-++;(DXRM@4OCI4=L:E]')T3E1@9[#8-:YHIB
M]8BJ/^[5O IVBEX%2M6@HVOPM7G3K=3D).-LX2-YZ?'VY3P9?=Q'<JI,B7^?
MMV62?OVY8::$[< _,VE']FM^;XV+:UIN-X0-Y8\P;F=&O-V1]VCR5H[H5F8+
M[C7#TIQ+1\?4$S>.@*T5YUGAU,-A9NUXXR0KM;H<8_>B'6>4FVUSA8T]7?\H
MR@5E"16,QD 2KJ^7A#'(.=-E=I.$12Q"PBSYV/.&YV:5M[*IKU=)9\@*1VCU
M$^DE&$S,EZ;J&T_<<[J><.E*4M)*4O5.Y=/]62RWI?X7J.\W1*"9Q4>->IFL
MYU1IY^39OX]Q&>Q4T=?]X68<PU D&0(LX1Q !B7(,WTIE.4RRT*L-M_4_?)7
M;]]SF\"'I>7;Y*7O5^>*/7^P/8EV&9]^/I@8=:_7 $Y6(@^^+C7*13_*%]Z_
M,L++YWVK?H%>\'Z5$5+]]ZG,FG EOO\03[^2%:DW1Q\5::Q7*['4<<5B5596
M;96&@))2\*:JU"(4(B(ICM682%U_20T0P2@&+$^8Q'E(1&YT$GV1%',CPTI
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MD_JU&-350K6EL'Y<J0^E_'^"[Y6'08=L[7_2#<J-$+5'0ID6CRUF;KF*IO_
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M%^-P[<;+.$Y]:6=:)3Q?^?$R(L<7AOQT:W_=Z+>UKL*AI/C\=$_7RW=+<KN
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M+*OCAN68Q:(=P)F:W8<%\4SUQL@<\[[YJ\Y1_TM]HE3>R$ZC5> Y1)2C,,H
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MP#(*191CD*(P!I!PM4,75 *1YR+A,*0H%J9VG$/_<^-+K0)H=0@:):Z"1HU
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M%$^,IDD2)\J"2W744L8B0+C$((X%RR.>\3 WVA+U]C(WGOU-;*N4G@X7DHX
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M!@"8@C-Y4,"@(+X#!4R1.1$\8/SJ&!4;7B_UIU+>R,K1TH3.-!498(YP1"+
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M3%\N4#EP4S\.4_//F=X]<TP_!L<\,O"\_8VB+QMEG]V)+]_7S5<<Y3$*(>8
M(J+^(],(D(2D "&U \T3(00TOD#TO/'9<4(M7[#]OC:_UG*$6/^\OQ2'J>=Z
M X&2S2%TX0@+\QL]EV#BZ0)/!YMQKNF<T[GG5L[1*]XNX9P3MGOGYNPS8SCV
M?UNO"/_[8U5C[WR*\K<_=*H7#?K3@HLX2EB. &)2<5<2)8#0A((4,PX305#$
M+O#W6\LS-[IS+*LQUNBX' !,BKG7<X'5>@5VJC3X!Z2JN+#955QX:"IH;'7I
M#-I?.N/"\P)G9'T>(]@+^8*G"\Z(]A\ZN#<[!@GOW/$?]I4SZ_,\"4F6Y%("
M&.KBHYE4&\F8(B!@2E@2LTQDEK>=C/J=&ZEV9OF-#%Y7"1#*X/TJV!]D=%0(
MOGZY^(SU_)"X,.PH0'METOV!QK(+[+3'JX,P^:3%\\*\(/T-(M1/<\.OVT?@
MO6GV"=I,+0N]6:A9<Q%EL4[VEH,LYAC 5/TGU_5G4ACA#%.,,AF9QMV=ZV1V
M1-7(&>P%;6H]F0?8G06TGWG&@FEJFK%'R"I^;@@"YZBYLPU[BY4;4JT;(3?X
MK%-<7.4/>R1+'7E7;'7[Y:_%4I3;]4I\)$_Z%W]]T%TQ43QL]5V.8E4PLOR\
M?>1/M0#E(I-Q!..8@#1.=#RN)("0. 1YE-(XI5E*I5%!]1%EFAN-[!30-=6K
MV?*H5%![F$J'^@94K450:C6:W8U%"<>Q!G/8+_<"0S0QA74T"CHJ707[86NT
M"K1:0:-79;JVPU:IUA#?"PR;55"@[^'S%SKH:1AMPPS'!+P_&'&4GGR&+(X)
MS;/ QE&;'L,M\)9L='B)CJRL[D)V_7P$Z2"<E((H4>LG3'66&(0%B-4B&L5Q
ME"?<\H39L.>Y+94Z_DR[].J+P)=L^?O@=MGTCP2BUVV_:&3>(^K%3VH E<^M
M?Y\X+[CY-T"I?_MOTH![Y&9=1N6-J/_WR]UF_7A[]YO8MAE+WQ12BHU0BI?#
M@5<TDWDHD@1D.4\!A$P"]?U2$%,L>9)&,8R-3LBG$G!N-%A7"F5/P59O^);$
M/$'Z9$-HRIDO-S 34VNK6/ 3;U3[L[ZJJ)73%9OV&9?Y7K^KH/ ?GC<%_M/'
M\HTJM?? ORDP/Q4E.$D_KHM$U>+'S?I;42I^*A=9BE":\0Q$--;EB!.HK%B&
M 8%8(@YSBF'L$F;^K!\;3O 75%X)&3SLI!PIIOPYQCC-LBS),C6+2 9@#B'(
M<YH RJ3$.><<APX1Y!<C/'V\^"E\+PH7?XZLZ0)W 583KU#/(1IS63FC]=3K
MPO-N/1/[&:V/F?G<@_9^^;^)ZMK"]8^B7""9Q%&$0X S*8 F4$ Y2@#C)(L3
M%F6&;H%G[<[-VFU$"[YJX2RN4G:A&O9<.P(P\9P=0W=S]Z\C!IY<N(UTXSA>
M3ZC:XSSM/NW- 7I"Q*X3\]2?[0_TWS.YN7[DA4+J>KM535:#^&Y);A=I$J=,
MHDSQ29(#*',!2)A!(.($21X+C"/C(_WSW<R-;=Z_?O<I:$0-.K(&6ECS<_T>
M7(=/]L=!:^H-KQ-05L?[PS@X'_#W-.WMB']8O>XAO\'3SI7&]%'(IB!+M15\
MO*^JE]U([4O42;MU[:%RD48(9C 4:O;GL=J\L1@0Q#G@B,1A$E,49MBRXMA@
MIW.CAE8XMTICPQB;;C'&16YBFM@)JQU<C;1Z5\:[8(ZZ%S&'9_)29,.2^"Y)
M9HS-B=)DYN]>D!%2J(]O^Y$\5==O24+#F& *4%VI/HM!CE,$\C!#D1"Q%%!:
MYW_L]C WBFG%TU>!M'P.2>X. #1WRSO#,KE?W1 1MUQUI[3VD)GNH%O_>>A.
M:7TRZ]S)!YVO.XB'C6!%9;>\K3/G+ A!.!4Q!1%.0@!S96'0A#$ U1:#<DY8
M&B5.B9E.=&;T5?O/SW1]K\-._KLVGIN,0GJ%O##OZRFT3>G %3Q/MQ@ZTK6
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ME#LADQ\*J=[HE-^MPHMNJ@/!)FU.EF BU?\!FB$=]<\8H(+F($JC"$4(\9#
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M/;(8";Z)%UYGY!Q.*@P0F?J0HD\$S^<3!F@<'TV8O#2KXC*[(]P%X1DC(6&
MIS#4%WHC0'A$ ,2,Y!R)%.=B!@5FCLZ<Y\)Q+U]CY&6^&U.^G<_7,#%E>_@0
MEM-?IIENB/Y'5IWY,(?K.].-B:?J,\?]CG;'>W>CO+D$T(V;2,,XI@0C '.L
M;.\T9X F$ $.(:9I1" GE][U[NE^;@O53M3VMLM%N:P&P7=9'\:$U"O;/\]_
MWM9-]A*]8@B:]^O??3*]]#5P [P,KH.;M&)_;ME$R[]Z^J+>;:\DB1AE"''
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MC-2+LKBMT$)(%J,D!CE*)7'05'5DY!"D21Q*!F$IBD*CZ+S]T'/CB3IX*LI
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M/%L:.GB<&AM:3XTH)U?5CFBR#Y8;=K?YSO_YS,O=E^<U*Q>48$Q9@D"$\@1
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M5E"+A,8^N/3WFXE@\[1W7()O&MK7P**'PON>]D;'&BITJ57GX[9G,77+NX6
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M[OR&]?6\OB]2+^A]YK[TTB='N;)7[+^?RSH&[,MF^X<4&Y</=8,\3& ..8H
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M0;'J]DMA# $4" .<LT("S3."$XBB0JOYK_Z4<R.>XZO=)GAZ+W+P8V=PV6X
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M?SBT8#Z+ZL]FO.GM$_?I:+6[^E;1Y'N-V]:J;=>_0&D=5&I/W !PQ!=@VN:
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M$ SEAOU'ST\TMW=<%:[ 0LX4/&ZV/-A)>8,HEO]8[QZ,W_@+V.J^^>,1<\P
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M4R<SM/OITAF&_FCQ1@0',#MB!S^4X$$EN4$8@,'W6#L>P G"G@(#-)">)CS
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M6GU0K3]7N"R78JG..;YM-V*YN]E^E<ZT=+-OQ!W^M8@S&H>TR$$&PQS .,L
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M>HH+)\DQ3WR[>_DFEWMWM6:?V^+3W1L/EN<D2HL(Y$PU9!%5=33, 28LH53
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M.6WP]F5[&LGV1D:H#7Z7K5&KT:;(/6VRW_&O;FXC#S-&8H0!9)  6$0QP(E
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MS(TV.O+7H;RU!G614J6#JKFW4UH$HE'#LKJK\6+I^E NE\"U^30]^C9Q198
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M%_OP]H<BS@22#.91KIRM5)DE>1@0&& >"X[3-#/O[#P+14LS31JFND>(-^#
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M8CBX?4?F-RU<"\K0 '%&QE7,%->@7C)FG*\[]MBG6N;M]O%I)[Z*35E\$_6
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M0LY-<PGB/,L9"V&>\P0B1AC,HR2&L8B#.,IQ)HEE,H<]$4M3VD=B)TV]-A.
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M',4T#G0R1$C,\Q[\",M/(D2GD+RIOUB"O R.]+S(P/7Q7Y7$UXA ;6TU'^#
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M.M5SXC[L9<\ZDKG;K1Y^_W6]9ZK\Q:VH,JK?XP-O/6\HY$=%I.<M> Q@DN:
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MTI?(]YK*&*N>197Y,VRI3+IC3WQ_^*'.W@\W6Z9VM9ZJPN@%HI2%,08TJ]L
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M09][>K0%?X'SGYX1'$QN?1A.GKW.'KJPZ:E/8?/YI_<IMJ>8U8*6]"]HVQ)
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MLXXB;P+<4:5JJW1,UPEXHXW)1I*!C72V^V:&W-=V7A?@KN!5R?FCZ&W!>5<
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MWDCCU?HX\;!F0-:U0S9%1,_^VPQH7KI[<SS4EJ+K"+YCO^Z()@+#5( $9@F
M2#7XBV A_<2(AHC$)*2&M=S.!U@:D5;9XU]W&PE9^9=_07&4_[6)QS=ER1=
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M)B[/K3.KSSD!0_==4,Q%\]X5Q1J]OBXI]@_SW%[Q5TGNGP[\L5R)+(UX@5*
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M(M3G=WBL/=TKZGG)Z?Y+++I!-^&HO_$_?U6KA&/@_2JB&<64AD#ZTJK)$1,
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M'9^]/%*J^CBD(/Z):);C[$-,AY*L<7!.2"T$@<3 NJO1"0S39D96H/CM8=2
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M$G(!2 9S$<F_LAQ.R=\^#;6T^5JCJHHIF-I[-3- Y'JGYD4FMD8!I,GYUY=
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MC]GK9!:[, S"4 ##E3O]13$,BWX6RC!RZ;2$.)4-<DP-:5Y#R"E#E,> "R@
M+'(!,$UR$').XSR*&45: 0L:8RV-_.9/B.L#>)P+9X3-,2>>(Z9D?=--Y9J6
M$=<'GEU&W$00?6?$]8(Y?TK< "J:*7%]3WB5E+@!5:ZEQ W=8KM^:E=G[WG]
M[_W7_>[YX:OJAUT*26#'B@ERS<8/Y8K%&:4BP:#("5*=,0J 0R( )3B'(0\1
MIH79@:JA!$MCX%9.TV,14^!UU[(.X73.S,T6TD^LD?UGU?1"21\<6O'?=*JR
MX$J#.=>\EN"Y7@:;BN5Y96R)VN5BV?9!%C65=_O][L_U]N%O^/"\7Q]^W//]
MXY=G4O)_/,MI\X[OUSOVEN.]O*2EX%6:D32D20(HSV, :08!*40(*,H91"3/
MXE2K<I^M $NCOJ,.;X+R*'GP5(D>D%KV8-T(;U##V,8VXRZJ:\0=LV,'[%:!
M0&GP)CCI$-1*!(T6P2<_V!N4F79L U_5J%W8PJR"]00@API=VSS67SWL"4J?
ME<V>\AR;$(/A<HIO<;DN;\6[W;:4OV+5NUO_\9Y_/[Q5A3=7J"@*DL0Q8$*%
M%>," ZQBD[*8AG&61I3FVONZ,\BSN)E(B5R=BG2%-CE)GFXBG3  K\ [/_T_
MU9*]%<%)GZ"6N:H44!M&_OE,J>"/YA*E5_!VN+2L$V.9G/9[-9JW0WYKX\UU
MDC\;K(,'^--'\7AN/QLDY\?U\SW6OK#O?O]##GKSJ$9O-D;3/(-1KF+D(I:K
MLTH,$ P+D.*$H#S#(M([JQP>9FE352MC@"LAK8MA]D*JNTDT%2C'4XLQ1E9%
M=Z]#X+[(;L_8WHOJ7M>_KXCNP-76K-!$\3_C35-,_-WN\7%=UVM8<9Q3&$8(
MB#!B "91"G 8$H 2%&5Y*#U>IM5W1G.\Q?'$2=AC*7YZ$M>8+@:QUN:-N1!T
M32"6X-GPB XDS@EE4 C?S**#2 _%:-TVL1K"W_'FF=\PQMD]_OZ94[[^IC(0
MRU6(XHBF7+5X#S& 45JH*MT(1#F1*^\\+'BB5<-%>\2E\<W?;^Z#_5$\R_H%
M5^'5)ICY0'--,4VM@6]*U  K60/Y+7<P=%%R8 P83Y4%KHKQ.@4$QE"Y6B=@
M]$:+W;YU23>[\GG/ZXC/FRU3_WSXQ[-\]D9Q69WWSC"-:%$(D.&4 NGH2,]&
MY#&(:)*(O(!91D/M'3V],9=&.2>QU=:=DK@*NJM^Z,AN5F' Q 8:6W;S(^MZ
M6^ZU03786IL?7%_;9WH@S[159@;3T':8YI/\;7F9J7:VK65XJSF3UP5J;\4=
M5E-%6[%B5>11$6=YHN*>8@!%2 &.N2HN@01)"Q3S7)NX^X=8&D^?:G8_57(&
MO!%4GSRN8#E.P-,1<LRWIS+&M8C!A[G T2?2Z2!YXDUSL(R8<AB' 6*\<J,W
M'AP6O$M[(U?:=)>_>_<A#J/\CN_%;O_8B5PN8)ZG:4X *=),\EN* 2&( I9*
M._,P)+PP:#5_;9BEL5TEJ6HVG@<=64U:L%\%=)SNYH'),>7U(V35K?XJ5":M
MZ^> S%L?>Z.7R["K_1@0@RWNK][LL=_]F )G43SC5\]3!_X7O-[^NBO+VZWT
M.9]V)=ZHLD-/?'_X<2>->Y">I_(ZG]3U*Q4+BM2A)H-$)6#R!! A<L!"E..0
MI6F(T+%JD'W!>!.9M#Z#%_6%//"L$C_8;55-CUJ!:07FC:RDNQWI&/37*5+_
M(-4(?I)KI_+G,_S?J'IGE3;R)Z5/M:;EK4;N*MK;X.JWYKV1A*]:%=\&R[&Z
M^5;/M/=$L[:L?DYQQ'$,$&4,P)@B@$E" $*X$)07D.OGLK]X]F)]SLS<><J,
MG4L+$'QYE-D$+S*S=ATM /'M+UY_,:Q\Q,S8,<Q>RQO,QEW EY?8^GWMXKIJ
M1'1;MW/]\)WOZ;K$526;Z@^DOT/1"N<"(HPS@ 2/51JZY*L\"4$2\TSD@L",
M:O5EG4F>I7'<:1>Q5%*7P;HLGY4:P4_2'ZE_][.I#SC-8KINH#<[^-FK;$T0
M[)K6TORD2]#: E3J!$]->S=\4FA.1W 69%W[@M.$].P.SH+HI4<XSV-MB?E7
MN2C=WW_%VWMI:ZZ:I)32Z?QM=SC^X>/Z6_W[MB9(GL"(1ZED7TBD\RA7Y 44
M&"2Y]!M1*&(81F9D;"S#T@CX+3_\R?DV2*IU7?J7?XFR\*\_E+RFK&MN#EVF
M=0JR8W:M1 P.4D:5MLYY4&%;@;W='8+-Z<]"ZM#\U45HLS6(KHG47##/Y&F-
MW"5AVC_*EB3_@Z\?OAXXN_G&]_B!5X1<KL(T1"2E":!Q(KU2S%0W)T@!"B$J
MB'*><T,B[!UG:637"AG@6LI@^]+]G.!U]B.MRW&3\7/,8P/0R1=RO<7['RV&
MSV75ABF@>$.?-W5%=.D#K&D@W^NM_*]2E0.HKYZ3X08A=,UB_8-[9JI!!"[9
M:/AR6\:YYX]/N[U\']ZOA>![+F7_?:O>B7O\76T8<D5YQ]^\VW.V/I0WW]?E
MBL&(2?[A((]Q B##JGEF&@%"DR@L!"6A,"PC9"W+TICKJ$C CIJ\"9XKR:L(
MXTVE3>57='Y+:XV"/[#4R3B;S-Z2NJSGQ3Z.F=&M:2QX<#*HKKG27D#/?#H9
MR4O.G?Y(\S,4\\;J?Y,OY>/SXYU<RJOM[ ?>K.HY6_$DHC0)(2"82)).DA"0
MI&  TR++!,L(BI'N <R<@BV-L1O=@GU'N3?!8RV_<H :!=I]-L[T#S=F->CX
M$=%KF<DQ<;<6ZNI5E3BH- .5:D&C6]!13M7WJ:UXTB_X\,I6U#_?>BUK>CH<
M\VQ5HX,V%] /G-+-.IRW(SX7('7/!YT\W[Q#[,VSG-EW^X_K_>,GMLJ2_[^Z
M:^N-%,?"[_,KK'V:D6+)@(W-RTCIVVRDWNE6NF?WH1]*!DQ2F@2BJDI?]M>O
M#505Z5"4;6R'G8>>=!KP=S[#N?GXF$N[BJ2_A-3&KZ)*(,L2 3&+TTH@DD>)
M5EG#LR<OS2SVX(!"!Z[>Z!\0^Y2O::,UBP7/5D>7 */S84>%M3X?]NG3@IT/
M.RK$\'S8\0ML\Q2J@&G;N=P?ZK??BUOUN1^]<OG+ML7H76NOKD71W-3JD[^J
M/VX:=<3-1MV[HD61L;BB$$>L4)G4%#*6E)"D5!#.BI26V"QGX037TCY[J6'%
M^J:6SFXG3Q\4FV8DW,R9;G8B^$QX5CW/)F%0].DR >&4-]_)"#=@ R<FG#+\
M/$GA]O'F"8MAUX]CNX]_K>^DZ];4HO?0_GIHZD]R\+J\%C=JH:'9_+A\4,<S
M\[M5G""*<R(@SQ*U#3/CD!$:04ICQJN254FF??S'?#A+4\<'[(=2GD>)'FQ;
M^&!SP ]X+X!^5.M@[LYG),+.B&>U/.Q+-)!&!J2'6=K'JTHBT(D$CC*!RY>8
M)?V,0]C9"I1G"#!K1KD%=R1/9!0<#!(LC^".D&'VP.%3S>WBAP=1?^;?57W(
MF^9>&NE57!!,<Q+#-,&JD -QR!'#L$J%_"\B)"^HKIE[]O2E62T%$$B$0$$$
M7SJ0!GL"GM-WWM+,(L6SX7#/A[Y.G\5+(!7]A!\W6O:DV!-*\_D]P73@2;A#
ME7;Z(OL>GO</CU(C?&JJW3>^V6_?3BC-LSPM8(&%:J?'2^F=QQ1BM3TV)5F!
M<F[:O'-LH*7IK3TZ\_:<HS3JIB_FD^/=\>T @FV/T$]/WTD:_#?A'!T]>/?-
M*0[&VFY.7F_AN7QJ3_U$^$-?+-B_RU'%*<M9"6FA3ND4N8 LKDJ(8L+3@A;2
MK=&N)C@QQM*T@80)NM<%@P\&QOH$@QHNS'Q>?#LR0TKVU:3F>SY/463@U<RG
M*I1O,T*9(Q=GFH,I1^?$G>'<G6GH3YR>,Y?:NC[##G16M5[OU[6XVHG[[:J*
M&,I4FQ">9=)=0CF!#)<59&E%D2JWHMBP^[ [<$M3JD][+^YFEF1*D *LE9S&
M-;,.YU_7SWN96?5L$L)/J(5KZ9YYW^ZH0\2!75CW7#]W>SV,86M'?AJK]V0X
M0:DTN@)F:93)N#G'TB30!&9Y%%=8X B;1M"CXRQ-N__U\X=NJI7'V=15L+,Y
M\JPKG]'C)8Z>9,&WWAH?/+ *FF3@N3:9OMP\AE9K[L6MV&?^XYBD/,608K7
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MWV#;5'\:SX"NXO3):[#%H?*P.+'KX(/=$[KE7X\27/3+V2[UI2V+OA6E,:[
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M ;+TR=..TMF(H^'Q9-F^#Y]F=#EK2K ]H^+%]6(\)>I?SD@)Z=8$<L>\<TE
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M9.=5_?D1MT:[>C^=?*YVGK@.QFOP@2<3HTBQ].0K[L-&WT^2^@%M:XKN?]C
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ML^F**4$Q!*;C:N/:>C>7(.2"J*+D2786P!S$0=_ONSN%<OLZ'I1QON/U7:V
MN%>$\QS'6AHO$35DZ<F'EM)#T(Y^%Y)QF*/1NK/A"0=ST?>C\5Y\BW9U/21T
MOYV2]<?%\D,8Y^=X+!0!9A(D9%X?720KZ3!*Y&V)++(,T0G;X>BEG>GN^WEX
MIPAN2Y]#PNQN AT9)=&8(L%IHT YSR$88< F&8)RMEY1#"LKVO<K\4Z1VH(6
M!Y&[?UW(7U^>E]LA]!\)_C<OA\^GE>FS::Z_U)ODKV&RZB)6G[[[0LZ0*R71
MZ:$]N.A(DM;JC$D7G3JKB#F _KX#N1:S^&UK<Q!!V],JWRV<Q9RSBBR"-W)5
M2&G!>Y;!ZJ)\L,F'T-EUZ*Y$]QV:M0C.5O0V"".ZA0]7H@P\)(A(AXU"X< Q
MI\#H0J>!#2*6SB*J(]#6T4B;%BXTC]3)D0-)B+GYLEV$&1ET#F2V16!(@D'R
M:4H1P 19<%.*Q]Q9$]8C$-;1I)MN$+:/3H8[\N;E[/(J3+^/IV4VOUQ]UD.:
M=YIQL^%#&AAJ\QQI1TZQJ;>&K\:+-)DMKN>K&N*[=6X&L%W,+K[@#15W6/(B
M)TL*JF/8ZN-[P2 RJ2'$(#GY4CRJ_(RX#EOY>.-R?\WWLR4N;I]DO_YV-0G3
M^N^_WZ/EWG='*&J67UC0OC RIU[2#E(>9##9LIQBE)WU.SV<C7ZJ*3H VE.C
MU9&N&PL46C9JKW 9QI-%([;M]K-:,7$;">W'TF%BC)0OP5&<2*>F0\*!S) <
MBFA53N;Q]5?/EFZ_U2Y6O:449XXKID'(I(C)DB&D*, (S*B#S+&D1IF\V+WC
MUT ,T3XXN%^2TZ8J>B[N>CF;T'=FZSY\9Y_GN'(]S[Z-%R,1LDC&,N 6"RB%
M&;RF+Z:0$)4*GCTN+]P(J.TKG )V#E#HK''I#A(CKV:783P=I>+)GL<"SJN:
MI,X:HG,6F-,4L"HL.IN#4;)>HS^<-*6_9R%Q@#![!L4%SB_'TQ47Y^7#ET!;
MZ/7T\WB*[\:ISBNJ<>9&5M^_N/C/C_(WK(-[1R5DQ,Q]K;JAT--( 0Z#!\N,
MCI+;HG8J'6V$F*'![!!,S/I44,^(?#<.TQ?CV0/RF3,B\B) .E-'VS,% >F+
MR3J)D JCK;H#OC9\=#_5R*VAY5CA]:C[Q7PY^EAOC%9V6:-E/O@$Q4L/*HH
M7@@!Z.N$BXPIQ0VE;HO; +^$15Q12)^ZBNU_Q<ER4?\$ZS">PPTN'BS;'QJZ
M<&4.E_ 08'&#9FF#)/A&"$)H4,YI\)8E\"4J3$H)P3=4UQP#C#Z/E2-4]ECI
M!\BO9[7_%KZ-+Z\O;PCGWF9)J ;-T=?&^*9.=#>0A$83>?0E-V<1'BS=L^H/
M4=RL"2GV[ CL;A+?D3NT'IS !<HH.$(1@<[-^HXU\I3!V3IUDXRFEV4'1^&
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M-D)_<9_9Q)#%' 58K2D.<"I#<'0XH0@B)$91<'=S\8[@8S<<_V5O"IO2\$G
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MU'<"I$V('"_:(0'E3;B.L^OYYT]A7$_OY6P\O<WT8"HQV=6]9TAT<J,'3^Q
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M?X%Z[/<Z7S-@_)'VTX]?<+O3E_TBV*""*AF\3ZT@)!IV%U4"CSF64C#+.%M
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MO,V^5"4\79/PHZ<T0Q?Q:<6V_(V?5]F[&%J\$!N5AID.Z+2!I&K*9+-UI%^
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MA/80A _1U)/'MT^.\!@I=8*PVV=V5T49V9"(&$OK@NCY>/$"B/^*3$X2ZD,
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M9,?(IPMDOWAR.J*(/H(P4H,IL;&3SZL4E:3 4U=EB,%\?]3E;J:F0G:4?'I
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M8A\ZZ7/.UAAO6IT8W"YH.Z1DB2^^BE96QJ)INSP%B,0.D@@QU!S0D9_MW7W
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MR?;!B-O'"A&UT=X&<(7-7F-]!.0E\\39L,G9I:R&Q#3=&W2Y<-_QF#P&=H2
M^D#VE_5GVZ3D;(H3$%W3=AE;D)]A"3AA,A4AS*";HH?C+H[O&&@> SQ.3GU@
M_/9_-_O^IM65W%J76$R9O1->0"JA14LY)6**6M<X'.//XRYS#3@YQN/DU G&
M#->>H:RQ@F!'HX4,\$F5O0(L2!!S2M9H$ZP><IWS>.1ESN_I<1XIJSZ0_FES
MO=VWDK!"H-$98O6YI<Q92,$:B,)*4S5B%D.N;QX-O,S]W>0XCY14'S!?WLJ
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M1\'3X=*%:GW4(T(;Z7VJ!03QGC$JL954<@:?<HF":@E.S*4QO\VF'L<IPJ,
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ML!W-G,'&G8^>\/.J[.RG>^FLP^;W/+O$2.D\W8\U??8."H<QLV5BBZ]@2 ;
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M>ZK;6^2E52ZJ1AIB(]2T@A5MVR0"5W4)5FF<+!3]Q![G?@>' <$C; W!D45
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M[WSS8!=HE(W'[]."\VX>@%0HLO7 ^B%K!2+R ;76(!V3.(>D_'3.A!?>=?H
M)!W==?H0MLX?JSNZ?S'5UCK9!(C6&]9.9 !D$K!(\$)[YU)V70R&OV#7Z8.
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M); IWQ82*0^%%19?;$)2LQ#P+U(M<0A^1ZV6. 0'B] _#DO%*:K&F+$VETL
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M,PL?0%7!CSK_+?K)0EYS2\^;!@MM1F)=;S[?B*"TOK[:,GAW.7>7]9=_?;G
M5?ORURUGOUW1[*.S(68H,9D6&E 052W@<Q .I<]:=ZD5&GYG)RMI#P'I4Y)V
M!N;.;.D\=>(GWIBGSUQ-*=DZ#58VGWTF 2GS$Y2D=L&;S/9 )T /M)^Y7=O3
MPW@.1BX4O#_?;N77%;^_[=[^M%YMJ?LP0OOMU*$-:!2%[55=FWGI6PF\9,M5
MB"PQE:A$.0*^A^]H;I_V8@ \,C-/6O^]WRQJ^Y_@@S>J?^>LH7<PG0[=CRCS
M:]G9A$HY$@0I,AC'J@,*ZX *54<J)5LG2VB86LO^MO)WJM;MN[5CW(?U]F__
MN/[RY>*<K]]9T#[F$!%<(98U?+,AN%(@U6B*=24;G&PV[2$;/UDE^Q",/HY/
MCL;;183?]YWJK#HA4LH.2FBN&"L2H*T6T&21K [5^\D0NF^#)ZLG'X?$HWFU
M",0]=Y_.I-6L<14+VA@FD) .$O%I0E756_YMEI/EA3ZWT9-5=,>3A0?QKC\2
MUU=X,;,"^ZJ4\[807MQ3^T=76I]==3I%M?OAYU=.C8N5(@D([4DVROK6V:)"
MM0$3RNJ*G*P,9VX7<-=XS#8'/%0;G0\1$E;79MU%?D^< 2$K5I-)%=ME[D[?
M]4]6TSP$<,<&S@YFU,Q^KY_6%_PGZ\T-'W>]'K;UUCZB<L9+L#Y+,+(&B*:-
M5FR96A39&'[XZN^%V],KS .HZ3B['IS,BP3+S^O/>+XZB\)5ESWK&+X9698R
M8&7Z%!4M7SGE@NC2W_*Y->8#S%#\^R$D>A!S[KZ&/[W[[?U%WA5GFNQ4$Z[)
M6]Y]00VI)6MEE8R5IJ(/H0,*OOOHTMC>AT?K(0@V,Z=9&JY>GZ]_>_WAOW[7
MNVK)FE51.8,H,H )4D(2JN6'5&%5%L7Y'VG:3WQZ'G?":%P_EGASQ\<.?S'?
MWF5P!JE$M"E E3:QB"0#J:C":'>RLG4KO57C**YOYQUY/8NN,1FK%N&XVNOT
MB"45,A@AAZ3Y%"UE&"/?L\2OL5!5H9DL1[.WHVHIFF]/<'1SE!["J;D5G0>3
M]'Y=[4[Q;O7'NJ6O_T'Y-L^]?,!_\9^W$[<> S<!9_ZSV^.?\0U.:()C0Y0?
M$%.K@$:)%NCVHJ:D W7)$1AP2R<E((^#Y)S,7-+HN,-/?&:$"CFK -8FVYIC
MM X$K*U&JRGJ8(U,DQ5X'K[]>>(#,XO=D;F\""7@EGK?Y_?PCQ?7I8TXO?G;
M/<D^_/P$);0M4"0J,)$<!&-8FQ?9:ID+ICI9Y\^^AYBGL'1F5$_"\1>3T/4$
M,R9-Z?K!'N9)ZCJ$,/-'SI+VGGQ*8+$U]@Z>($86)4XP=(/1EL1DTFJ^M*Y;
M=O%#=6^EG2Y&QE/RF$!XV;IW:0)TR@/*PM0KD?D7)Q;H>S=ZLL&T0S#XI-@^
MGG=+4CMZ:%@NDS.A9$A65S J-[-7\E$M*64,:523.2AZG^)D$[X&P?#(7)_9
MV;'=_=_YI:2+"US1^OKR\2MY5HI,413%BEMAQ4T'#]%1@)B*<RYHE4J70ITN
M:YUL:E<?K(W"@$5(S"?TK3.&?C7*6$C2M10-7R$2;:LND"@+525-)0^?V./<
M_7MFDG9#<.RD\PKOFPO?FYNXMX!H4J/JD W-8V'U)MG\YE:L(B<1 B"UKGU!
M&N _(A#69L2LR,@7V^EC $]+M386Z2I0<@2FMC8[Z!&\4XI8(CDY71!N5-_:
M$LVT0[ [H'?M$)XOT[MVUXOJ?,6DO&Z9'Y?GVY,3GYWEW26OL$T(6=>Z^[=?
MUI<WZ=>KPH*>:;)>G6]IUN,5&'@# TC],4DRF)2_[XN^V_"OWS;\[68$5E!4
M%)"ULV!0\,W01*"TE^@TJ\T"IQ)+73<];)/X?2O=*^(_LTJ7;4I:5D&!R4D"
M>B-:[74N"BUF%$NAT+U]SRVK1T'@\[W<A^3D7T$<]V[R-,HV%B>:1VT9U?EZ
MD$Q2YZ"!%1B^'JPX,%ZM >.]E\)ZH^)D]4$S"^@;5>_^C=81T616JX3F'PRJ
M#)'I 91K3BV0&?TL(SJ>WO+)B.5#<-=1+!_'OT5X[/:>:W_WGS,O249; U@M
M6?O/IGFZ"?F$0@91$+WPLX)S_[[GCF/,B= !.#G[]/$G6ZU]HE]JI7SUKO[T
M"5<?Z?+7U9OUALX_KG[Y5][^R>_\.CYL^6.EB5300Q(R\16UL55D\#W54;)*
M$)1271HS#[NKN>,?HV)T9B;^%33?^R[9W]:K6Q?.@X>*_ZM]@J&_1WMY9UB<
MSCTX8Z97V)5)%JU)0-1FDTFK(9'VX)V0U4IDJW:RM*3E>%1NBG@\H;8:6RJM
M\:U<+$&2D6W]0BU F[RTBS%F%E'E/PKJ#O>B',Z]16CK/['D^;C>L&QX9(5L
MBY5==DZ;5J><:INVPC9(%#5!S:2<#*XD-YF&_H.]+AV(/1#R.,XR(+L6@;\'
MA[@]W]?;>E=E*%K#9H2+V)0RSU>630G0H<J:42$];& R'OJ>W>G<V!L4%X]0
M-QR3EHBY5U=O\'SS'WAQ31\^;=;7'S^]WZSK^=6[S=OUY</#HE/*>SZ=,$ZW
MTH/ A[6"#UN,18PBZ<E4ER/.,3=>!T34C] Z&GN7B>57G]>;J_-+*C^M+Z\>
MT55$&Y( 15L#6Q:(A74A+8./-0D3G9H-O,]L?&Y_VZ1H'8J!BX#G3RT7Y:E'
M*;#&;63UD$MT8)S4$$+K:R&M#QEUM7HR.#ZWT;GA-XEB.12C%@&[!X>XO3V.
M^(8ZZ<#Q:< (50 #99#"2BE4HA@F,ZWW[G#N5WDX$/Q(S/7@R,SU#4^ZVG::
M0W 4C"B\]Y1:WW\+@50$9XL(Z)65G8( /UAF;H0,P,;U.#1=A-S9ICO_3IG.
M_]QF1MR>(Q)E1'ZLA<H63-4*HF75LM9L790DJYO,:-B_Q;F?N.%P-2@SYFZ?
MB)>?VM 1_JGEZ_Z)%^VYW_4"DUJJK%GY(S;D#?^VC;2-8)72(NH@7*?FKL^M
M,7<,<5AI,Q@U%R%J'K_5]Q.\VX,=?0GD*X%7E>E48@*V$22HE')D:[:X.-E,
MCQ_N=FZHS:-C'\.R1:!PWTEN;Y1W.;),%1"395KQ@PTI&R98(89)*13K9(7U
M3V]S;H5J8$P\K7<?QZ#E*=][SA-DKBXYT":Q6:*B@4ALKT2LWH;"9HOLJ8$O
M#C5#<?5Y7?PX$L^M._WP,!B3TVU\AC84P01^_)'W#^1LS$H26=.E$^TP8)E"
MMQX.+,,2=V:D[!VPNFNV[#QBQ S"B6WS7H)4F50R>&U$PX&+'3#RS!)S*SXC
MH&,H@BY"P]D;67WX1H>4D(0OH&UIC6CXM8XB*="A#8.D4*.5DZG:'38\=VN"
MV5(ECF'<(N"X[R0/@D0NJ<JREX]3VRBQ&K8=<BTXGT-!K$;3]$D33VYW;E5J
M>)ATTL&/X-EB<?A\[+)JBTE+MEZP^=UD8,F?T(.+@:21468U62'2P;N?&Z5#
M0Z@31H?CYR(@^Z-'Y^U=IU%E6[5M4>"$SK<SG$FPR<W*D$&I,Z7%Y">_/6A@
M@3WM-WT<%BX"G0]\W6>9;W'2N@"KW04,*]X0-1\@JNR5$5K3=$6M#_8VMS <
M"04_BED?Q)(E8NI>)MP9JJQJ*FVPG0A@?-" %A7?0Y5"9=W&U,GZISV]S;E=
M)S,AK2^CYG:DM.9K^Q2)NT9 >WM^WXWV:.TE')\69'"RO0T5$O$K4:S!$$.0
M2G5QR!VYC;D=,N-B;FH^G38D[U_$R#?.B38$/C8E._([D#2:-G(YH29GHNP2
M;Q]N1TMWXLP.U+[<^ZN5]]Z42Z]WY=+GW]=)+[&8M]N.%UVZVX/HTQ?JAIP,
M)EE!Q"Q8^6AJB+<1A!'"5>M*F<Z5N+1"W=:8I; Q"]6XE@7K6ZLLY9A 55O)
M?TG+:0MW6H6ZAZ"N;Z'N(=Q;A"WW@?_EY;OZ^_GE/V]\TADS5J44&Z*!7S3O
M$(+5K94WRJ"=T4RGR9)*'VQNZ5#K@8''Z:7',&1QD+IUZH8H5#8I\LZ3:,FQ
M""AJ!%V#0Q&#2&DRH?9X>W/#ZCB6/XN@'O1?!(9N,D'RUW:(VS-D(ALM!=:M
M/=T2100#*<=,56B#>;)NH(^WMR0,]6'Z$ZV7>W-@1A1=;J[N=G]3I4Y6I$($
MM5C'^X[\\!NO@624S.)@(^Y)&;W<0:?B9=INDC^\1<W_HHNKR_8[N &(A%O+
MY.'*2_<S]G^OCJ+QC-C(MWL^>W5Q<;O_UK_H9J0Z16F-$PFP9<,:BQY"4019
MY1*M8#L_[ADJ>H>32\K_S\?UG_]KM\8-5G:_VV)EBY+G]C"/&#F.F^N!2;L$
M>/SCCY_/O),V>,J0+3$1JI&01,V@?4B62%84>V(9_>' :\[#_N$X]Q *AY)Q
M$;I'=P>DT5A"T:V9 [;\G9:W'-BV#!*%,4$@+:>IUMN# OJSE\0<9T2-P\*9
M@PY_T*HY /_<SG;#BZ^7YY=OUIM;Q>_ON/DG735E[?%$\=_HZF9RQL_7]&']
M@5;O:9.9#+M_^>MW3L(SOIRJ4E5@=1/^?-OY[@<)RIMB;2I5Z@>HWAN1F&B[
M<RO>(T%MO6R^O[2K\.U??$>22.0Q! TZJ-IZL 0((3J(L992LY'YH:-ZFJNP
M?[M+-S<6>!4&X/NI7H7MJ*:OW42#DT7$8C4XE@3\&F=WHP0FF2-:K,IE.>8]
M.&"O2U=O9KP$8W'\1=V )R2"3(J?Q8"LCZ;:<@W8BDG&@DA)HE48$W9)(IIB
MKZ>3P+&,&S  Q_\*J1VO2KGYBXM[K?&7DL7Q[.86E[#1G933YV98[;21+/,3
MMLF)+A.@C=B&=IGBK1+!3U9S.$]NQE,3(%ZO-YOU_YRO/MZZ*/B)I)9&"\([
M#\8GQ=++:1#\/DK!UE),LWA_.NY_Z89S+T0^[PH:@[.+<%E^.\#KK[\A"YBM
M$S^X:K,VD"WK<28)IINL!*R]1:,=)3[)5/C<M\$E 7 49#S"XM%L6B38=B7X
MB*2-0Y!6;L>[%XBD'.0:0HHVL=6\)WHV#=R6$:,_GOT_1%0/7LQLO?URO5E_
M(5S]NOJ3E:@F^5_CZI]OU[AZ]7%#6Y5JUV$OY:!\M2!%X7= B@31FA92HEJ+
M*R6YU,$$Z[S@TN#2A[?KL0F]"(GT>S/:MK?)ZJ0<5@>><FNT+BM$8S1(DI:<
M%4K(R;J#W>UJ27[9:1ZZ?@Q9#I9V*5268M)H Q3;;D(*&H+,!11YZ4(1M?K)
M5/S[&YM;-/7D[WZ<]"'V(J#R8?WE7=T>X?8$J=A$,D;0404P&BN@,0324,W9
M&97\9%.-'FYN$9#IQ>K'":['T'T1R#E,(G]SF.;"%B^J OP$,]UL;&DY:%L!
M7+#!E)RG,^EZGF%)\9EI'L,IF+T(5/^VOG%JOOJ\OEY=G9$C%Z3V$&IFY;%H
MOI56%$@JVAB$L36YJ<#Z_=;FEH63(.(1#H]@S]Q]6J^;F']7/VQPE3_1Y3?:
MG$41M'":@$)+3PPHX688(XJ*E23_KU-WUB=7."WE_3BL#$CKA2'FIE\_E7NG
M4=HI;Z1G4=Y*MVV2$$1I8SQ545*AM27T0,[CE4[KQ1L>04?2?IFQU=_I3UI=
M4YN(O&[- 6X">SWBH$]\:("899<M#A9?O%WL+FA3339"V-P\1RPKE&N##ZB"
M-5K7H*H,:C)3Z,'>AE7?;S_^R[^^7."J_9=?V1QQ(F9E@,U?5A<E!0BV]:;-
M69)RU58]60GM\UN=6Q$Z!C7/*]I'LN64A,Z'F_Y"0XF>#_?:%8TA@/9M=S0Q
M5)0B'T,%E?S6T<#ZK749"DJ+$5G/Q<F*1@<20^V)O4,ZO^CGE_CQXX8^;MES
M!_R[KC6_?B/Z!R;S:_[$/\^21C2B\/OK4^%[UFY<S@@FHA/8)AF9TD'W.7(;
M2Y,^AX#EOL(S)3=.23 -G#'68Y'1A-@,&5P/T4I&,C@]RYK4RC6V4^PR%JC5
M%M1HI!.3:1FC:EA/W*DW?*-_6J^V"U[^Y_G5IY^N+Z^8-9M;IUVVPH? UJJT
MJ;7FXH<_*H\0HQ=%^5I%F2P4>/QQEB8K#T'?#URBX[-W[IDQZPO^D_7FAEV[
M8/LV?.8]%8>ZY=7;UJ.A\BE8#P57^==L9%-Y.*MX_["8)U>8&S=3<WH].-D7
M"9[;XNQ@E3+%)<BQ-A\N7T7TEB DMIB"C)X-G-[PF;,CP9#\^R$D>A!S9E"\
M_X2L<_RR^GB^HM]>?_C/W_6NYXNLWF.10+[U.!/209!.@=16Z]8[7YHN@'CJ
M^TL#0Q_.K0<FX\Q0>'N.J]?G:][^?]UMG[R..;5Q#2F&=CTRI-8(R)F$V5C-
M6^B"@CV?GB<:,AH CB7>W)5O;*_4\[_1BCZP98)?OKY?;Z[J^N)\?6]<6FCS
M9EL7>3 Y:T"M$,AN$^<Q5_(=@/"C=>:)<(R&BD').G,CK&^96EG*%K81X%/S
M+:!JW;L8YB%I@Z4DX?<-RNG9!6N9N8_3Z9_]2;\$O.Q>P1:BDRH"2=&&+4H)
MR;L*JJ3L0TF:[,"(F5/+.()E#YG>@WXSL_WO^*_SS]>?;S>N^*0A4N'MZLJ(
MEQ%25;QQC]ZX;$L4:C#&?[?TS*SOP[CU$%2<F?U_[*I7_T;KC_SB?3K/>+&]
M!T)(8V0I[>7D0Q@7(08OH$@?JV]AL[#'R]@3"D]N8U$I%-.^(L.P9FY\T<>'
M1[C5T7P2J3;'H4-?6^HNM:$?&5!:4[3UB2@/AZ^GMC&?V!F(O>NA:3UG$\:6
MGKCY>O;F][,:8JR4+'AI6-$N@5_AF/D5%F2"J:C*L]+GK@7CS1=O.S#>_.9>
M \:[]6:$P3!,6Q]%P44D$>\MDO26']*,%C(FUL;:^1._H!#XD28*AH*=+(S?
MNY1YHI8K$[Y/ W)MD=C;];TNU4HM*UA2&4RR$4(5#BKF7%.L3+8]ZO!?OK+Y
M(/9WK6P^A!=SYR"O5S^?7UQ?G?])M_TM5A_O7%2OW__ZIN7'[L[%%H'13A@0
MMAD+JK+)44L )RFR_"^.KV:7;.0#UEP::/IP>#T!N1<AFEATMUY5-X[.VT;_
M-S/$7:I:\@,?%>EF91I 5SWD3,CF9HXQ3C;_^JE-+FF&\"S/XR#<6RP.;^^4
M3.A,51ID-A9,:).[8R[ !R0O14XD)JOW>GJ;<TN]8:#0"6$]^#+SDWE[&5]_
M;;W\=FXT:9)R@G=.-C2ZL$6L4@)5HTB.0AM&TN%EW//I)4*A#\_6PQ%P$3+F
M*'']]JY^B522W@4%59C6FD!KB)E5"HVR4-(UI3Q90Z)ACM0)L.X%OZ,S(&.1
MZ5__^,+L65V]QZ_M=[L"NS,M$K\=A0_"L@^,TY:E!B&(:D(UDJQ^^ (?D ZV
M?\VY9>@<B/AA0MD [%DD['YF@EZLOVS3\%;EI_5G)F+KVOCW\PMBDJ[H\O;(
M=S6?9T534-80>-%JAFM"0$NLVF@V\I)7T6.7*MNA]G/2Z0ACP75DMLX,Y;^?
MKUI0]@.CZ_+3^J)\6+_?K/\\+_=J./[?U?I__O?Z?SZL/WPZWY3WN+GZ^H\5
M0V$_N<[0D"DU(*@V$\ TQWJR+4V,G-,N(%G2'3 ]^,9..DIZ/+CG9?0B!?;[
M]17_N/<J?UB_IKOKK#Q)OK()9&IUMZ46B)YMSQ#9(A62C+.UMY3NN(F3CJ&,
M)9K'8. BD?KM?*^84TSN[>EI<[XN9\YZF<@FUI9<!2,27\/$MK$F#,CF:WMQ
M>J/SF85/VFTY%B*'8M3LGJ9+XL4_?<!__<0KGU_]X^K\XOS_;,]Z>YHFWHW+
M"'X[ $*I D$55G2R,RD*7XWOHKK^>*63-NN/Q]G K%B$"^N'9#OS**MS(8#V
MVQ8X64 J)D)E:@5*MD3S0(D<O7SWZ=UV0JA_D0@=BZ>SO\+W?,_-\7P[# <_
MMMF;.5NO%$136.T5+- Q^ 16..-<R5G4+@,@GUFB$Y["B\33D,1?FJC[V_I/
MVJRVB6P;9!7U+),QAA1"=JVY?4D)HA,*L.:J*E:E/<X@Y![NLQ,<XXN$X_!\
MG+LT]NXJO:N_?/YRL?Y*=/D;7?TG_\F=_ZH=\DT;4?WIVU'_XQR;0X!MK7^L
M:/L?WK3$Q\:7LYB#$E(X(*4SF%@\( ;+]E:IU6,T\6'GW?V%M:/LKIL37KQ(
M "^$YXL0Q0\ZO/(5==KX#)5:.:L0 H)M^V>:ZD(N>SV9BMFG >_+#!L-PJY3
M:@/U1_Y$Y?J"UO7>W]_KAC5T1ZBNZXW6'*K7@<=K@5=4;H.]02>K6(HQHE)-
M%OC1II0UN3JYH;FH/E$Q&2U]->!\Y3N<V7*+,1:P)'RH6KN0:"KZO+P^48>@
M;Y0^48>P=Q&/^/O-NESS65ZMRA^T^?,\T^4V/S F+S-2@I1":,Y5UD:$3$Q8
M3RC8.C1BLGYF3^QQ;O!-#9='>!V"=TL%X6[62I51,C! AU);$DMF4S"V0632
M&2%),J%FA.$R,CL'P4$7=/5@RMP]:[[?><#LO3($E%IRJMD68O@(HC*AO)#>
MYRY#_1;/_CZ,6@]"M9GYO=5[_\"+N[TC22<=L4A%9\&TV6&!3(":2$BG2?E.
M<Q<>?G?NS*[A>7X4Y1;QB@QD91=1?(E&@63,\[FEA2CXB?9>D##!NFPF>W(F
M3.1>:AKB$(K2#,A8Q(WX<0PQ)VN=<0FH$!M,Y!S$+%L*FO :@_713E:U,$Q<
M>*D*?T\8]8@+'\+3A>3%\#-V+RWX+C7C3/N:$WH%V&*4QF)JW1%;>3<)BI:4
M%%UR7W^PS$G+Q^-P-303EB;V'L461?"Z.%9H9$VJ3143$(1!<,ZQ0L.J4W&3
M^=^.C1$O/[EZ,%%W%!\7 <J_,T7IX@)7M+Z^W"K;[[Y0R\E8?;SQTY\)8Y5V
MQD,)-O+MXGL6E8[@E$V80XB.)FO\\</=OI#\Z>, .BQ/%P'3>X&CLZS87G2M
MJ9EPN?F/(C\!FJ]<X:M72>N<)Y.5]_;U0A*ECX->7S[U!]GZ"B^&?:#/DB 4
MR1(X+4KK;)P@4!)@^"#%E2 RUHD?XQ>2'3W(PWL0?P8#UJ Y G?RF/[UA5:7
MO0;7/?[& +'\'VQLL/C\JQ5>?+T\OWQ7;X0%*_F_W*SX;0RB3,9)5NV)F<*J
ME&552N8 MMB82T%CZF0.KQ]O=U@_X?>/]NU2]\<X.ELCE5A!NM!FI!D-J((#
MFS7_S_'U").UF3EDXW/[2@;&W?,^O4&YN,QDIT?RHO<<SJ>^-(90&W7Z9@>(
M&=(RMLX'P2C11FRP^AU$@)Q"3JG%1>1D[LWQ1-MW4R&?&;N]W]'S^+H\&!A9
M(D7C)=\64UM_<B9BJJD-MDB4%"JI<Y>"R/%V> *R[A @[AWV.2];9W83=Z'"
M'VR(L^1I<U0V>,&T>%4^GZ_.+[=U+W_2+3DNGZ:']K54YQ!RY$?(4&T>I5"@
M:&9<*98H=*E*GV*O<SNL9P;\I*P^ >COBA!>,T'J^=4S!Y<R1T?$O! M.2!Z
M YA:S]Q8;<G9N%K-0!COO*FY7=TS@WD<YIT :G\FWED^O_F#S^O-U6T1-M-_
MVTGEDG_]RWT]\ALE^*365ZE!6&KJ/ 6(DA7[2,+HHI0E-Y2H[K_+N3WD,^-Z
M(O8N".C[ @!/G#"3+")C $K2@)&5 '444 1Z1&F$C5U:Y_5;?6[_^43 '(D=
M)^(>^./Z\V?<?&U%03?6 >ZS#B[[5T,=N^(8[H9C#CVE6R(K0V@$O]^1GW/C
M9(&HJP3,5:$5(CZZ_J?JEGC6-OWC.NWB&*U[_FW5VHY+K3<!"E0:C&E:NDL)
M0E &JFF1_D*.5:#>R3^=MG "CH5#H/3CI)_A&7.XN(PWEWO5PEY4/HR89W9[
MH/?XE5>\^&E]>75Y5OGE"2SWP17!2G8F#QBD $5*$5N-)'.7ROO."YZ *3\*
MQ'H3_00 =8#J>X9&2>%4;1TN6-?5Q0&ZE$%$)*TP1NW[9S@>OI\3,,9'@>-8
M+)L?K?>C^L\0X,Q9U#9@@60E@6&]EY5O64$72LXJC4),F!CYS$Y/P*[N ]$Q
M^'0T^B9-S=BOM']KIWO/PS"@V=)CU3%,EV,//Z7YDFJ.6(P$K[4#0RH"2B_
MU=:.Q%67Q9XYF:=HOGSG3WB07W!;F615E:6RLE)3J[)3P?!=W]9=U&IBP.@Z
MM9S_\4HG8(P< HPGW3;'DWD1B;2OKJXVY^GZ)G-O=Y8V>NZ*C]E:@M/YYLWU
M*F\9V*JU;754G2YL1I$!8]M$)NDC))&TQ52)SSS9K3IP\_-@<PSH/'J-1^7C
M(I#Z=I<U^OKK[B"[X8B$'HTF(&7Y*$41'T4EL#K4%'30@B;3"9_<Y>QR<52
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MW^$@8BJLE(IHM9'5B.F<9D_O\P0*((X#VU \6A+N^JD+3EE994+PME5WH(^
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M-7AH8T)D'<>/$_'TW?>'C5T<V'FM,3R _0XZI3?04YLH&A"<<*&U+=,0H[9
M(5MB@16#%),])Q-X _>$@4) *86!Y&HSH5ANQY@4*PQFZWZ2)2T\E#NO/_ 0
M!'4*YA[ CQ,(YOI03")E;^QR8XN %$T A54:1;$4VZ6+\5#!W'G=>7VP,@:A
M%Z%Z_3"?#[50ILH$5/QV1(%D':"-*(C%*&=1UNDJ]0;)O9S7/W><H!J46XO
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MG6^:S9"RNA>5EL+AG0AR,3K2A=6/DCT;3%%!E)0A&8I1>N^+2H=P^!!)/<I
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MU[*]BI4,+A2^[5X4! HI<+;0\=,NM75/FF[?)CIB6!<[[B;*9D^:R0\B:XQ
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M_H^_/ *:Q/C/[6]M?Z?^K8]8_GO]]>\?W]Z.OPS+55RL+A9__%M:?;D:_$Y
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M2P$"% ,4    " #)B(A4_N?U?%XL  !B&0( $               @ 'P8@D
M;F)X+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( ,F(B%3Z?F?P 2$  )-) 0 4
M              "  7R/"0!N8G@M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( ,F(B%2D.K?=-]P  !/4"0 4              "  :^P"0!N8G@M,C R
M,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,F(B%1*VOD_ %X" #<& P 3
M          "  1B-"@!N8G@M,C R,3$R,S%?9S$N:G!G4$L! A0#%     @
MR8B(5.V-D<Q=#P$ 8$<! !0              ( !2>L, &YB>"TR,#(Q,3(S
M,5]G,3 N:G!G4$L! A0#%     @ R8B(5 NXU=Z5E@  59@  !0
M     ( !V/H- &YB>"TR,#(Q,3(S,5]G,3$N:G!G4$L! A0#%     @ R8B(
M5(F:Q;'YZ0  Q/D  !0              ( !GY$. &YB>"TR,#(Q,3(S,5]G
M,3(N:G!G4$L! A0#%     @ R8B(5.(66L$!LP  <=(  !0
M ( !RGL/ &YB>"TR,#(Q,3(S,5]G,3,N:G!G4$L! A0#%     @ R8B(5* (
MM*.:"P$ G*$! !0              ( !_2X0 &YB>"TR,#(Q,3(S,5]G,30N
M:G!G4$L! A0#%     @ R8B(5 =1VYPH=0  =GX  !0              ( !
MR3H1 &YB>"TR,#(Q,3(S,5]G,34N:G!G4$L! A0#%     @ R8B(5 @=JM#Y
M>P  U8<  !0              ( !([ 1 &YB>"TR,#(Q,3(S,5]G,38N:G!G
M4$L! A0#%     @ R8B(5.A_4R-TE   :9T  !0              ( !3BP2
M &YB>"TR,#(Q,3(S,5]G,3<N:G!G4$L! A0#%     @ R8B(5!/M,II@U0
MI-P  !0              ( !], 2 &YB>"TR,#(Q,3(S,5]G,3@N:G!G4$L!
M A0#%     @ R8B(5&/W%20KSP  @=@  !0              ( !AI83 &YB
M>"TR,#(Q,3(S,5]G,3DN:G!G4$L! A0#%     @ R8B(5 <XF32X=   ,WD
M !,              ( !XV44 &YB>"TR,#(Q,3(S,5]G,BYJ<&=02P$"% ,4
M    " #)B(A4;S8]7/13 0"Z8@$ %               @ ',VA0 ;F)X+3(P
M,C$Q,C,Q7V<R,"YJ<&=02P$"% ,4    " #)B(A41]J!02N,  #IEP  %
M            @ 'R+A8 ;F)X+3(P,C$Q,C,Q7V<R,2YJ<&=02P$"% ,4
M" #)B(A47C/U+ :3  "$JP  %               @ %/NQ8 ;F)X+3(P,C$Q
M,C,Q7V<R,BYJ<&=02P$"% ,4    " #)B(A4A*/-Y2B&   >E0  %
M        @ &'3A< ;F)X+3(P,C$Q,C,Q7V<R,RYJ<&=02P$"% ,4    " #)
MB(A4'Q;[D_:4  #)K@  %               @ 'AU!< ;F)X+3(P,C$Q,C,Q
M7V<R-"YJ<&=02P$"% ,4    " #)B(A4O!(^-$[=  #[]@  %
M    @ $):A@ ;F)X+3(P,C$Q,C,Q7V<R-2YJ<&=02P$"% ,4    " #)B(A4
MS&Q'V6_N  "N2@$ %               @ &)1QD ;F)X+3(P,C$Q,C,Q7V<R
M-BYJ<&=02P$"% ,4    " #)B(A4.XV(M;:Y  "1R   %
M@ $J-AH ;F)X+3(P,C$Q,C,Q7V<R-RYJ<&=02P$"% ,4    " #)B(A4E>PW
M94R>  "RL   %               @ $2\!H ;F)X+3(P,C$Q,C,Q7V<R."YJ
M<&=02P$"% ,4    " #)B(A46:S&L#U# 0!S90$ $P              @ &0
MCAL ;F)X+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( ,F(B%2U=J_>>\8
M &[/   3              "  ?[1' !N8G@M,C R,3$R,S%?9S0N:G!G4$L!
M A0#%     @ R8B(5 ;7K4.H=P$ ' 0" !,              ( !JI@= &YB
M>"TR,#(Q,3(S,5]G-2YJ<&=02P$"% ,4    " #)B(A4W..E#8)#  "G30
M$P              @ &#$!\ ;F)X+3(P,C$Q,C,Q7V<V+FIP9U!+ 0(4 Q0
M   ( ,F(B%0^BSQP#T<  &!+   3              "  394'P!N8G@M,C R
M,3$R,S%?9S<N:G!G4$L! A0#%     @ R8B(5&B0/ !+J@$ <,P! !,
M         ( !=IL? &YB>"TR,#(Q,3(S,5]G."YJ<&=02P$"% ,4    " #)
MB(A4#HQ.GB1(  #'20  $P              @ 'R12$ ;F)X+3(P,C$Q,C,Q
M7V<Y+FIP9U!+ 0(4 Q0    ( ,F(B%0&)+O"GH@! (#.$  4
M  "  4>.(0!N8G@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,F(B%13
M*S01HB ! #J/#0 4              "  1<7(P!N8G@M,C R,3$R,S%?<')E
:+GAM;%!+!08     (P C /\(  #K-R0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
